id,canonicalSmiles,inchiKey,drugType,blackBoxWarning,name,yearOfFirstApproval,maximumClinicalTrialPhase,parentId,hasBeenWithdrawn,isApproved,tradeNames,synonyms,crossReferences,childChemblIds,linkedDiseases,linkedTargets,description
CHEMBL1195,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,CAJIGINSTLKQMM-UHFFFAOYSA-N,Small molecule,False,PROPOXYCAINE,1982.0,4.0,,False,True,[],['Propoxycaine'],"[('PubChem', array(['11112410'], dtype=object)), ('Wikipedia', array(['Propoxycaine'], dtype=object)), ('drugbank', array(['DB09342'], dtype=object)), ('chEBI', array(['8496'], dtype=object))]",['CHEMBL1769'],,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1231,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,XIQVNETUBQGFHX-UHFFFAOYSA-N,Small molecule,False,OXYBUTYNIN,1975.0,4.0,,False,True,"['Anturol' 'Contimin 2.5' 'Contimin 5' 'Cystrin' 'Ditropan' 'Ditropan xl'
 'Kentera' 'Kentera (previously oxybutynin nicobrand)' 'Lyrinel xl'
 'Oxybutynin' 'Oxytrol' 'Oxytrol for women' 'Promictuline' 'Urimin']",['Ditropan' 'Oxybutynin'],"[('DailyMed', array(['oxybutynin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand'],
      dtype=object)), ('PubChem', array(['174006905', '50105262', '90341037'], dtype=object)), ('Wikipedia', array(['Oxybutynin'], dtype=object)), ('drugbank', array(['DB01062'], dtype=object)), ('chEBI', array(['7856'], dtype=object))]",['CHEMBL1133'],"{'rows': array(['EFO_0006865', 'EFO_1000781', 'HP_0000103', 'MONDO_0024290',
       'EFO_0006865', 'EFO_0003956', 'EFO_0003918', 'HP_0000975',
       'EFO_0000512', 'HP_0002307', 'EFO_0009562', 'HP_0000020',
       'EFO_0001663', 'HP_0000011', 'HP_0000020', 'EFO_1000781',
       'EFO_0003877'], dtype=object), 'count': 17}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 11 investigational indications.
CHEMBL1637,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,OKKDEIYWILRZIA-OSZBKLCCSA-N,Small molecule,False,GEMCITABINE HYDROCHLORIDE,1996.0,4.0,CHEMBL888,False,True,['Gemcitabine hydrochloride' 'Gemzar' 'Infugem'],"['Gemcitabine (as hydrochloride)' 'Gemcitabine hcl'
 'Gemcitabine hydrochloride' 'Gemzar' 'LY-188011'
 'LY-188011 HYDROCHLORIDE' 'LY188011 HYDROCHLORIDE']","[('DailyMed', array(['gemcitabine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206197', '170465129'], dtype=object)), ('chEBI', array(['31647'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'MONDO_0008627', 'EFO_0006859', 'EFO_0000183',
       'Orphanet_145', 'EFO_0000574', 'EFO_0006475', 'EFO_0000681',
       'EFO_1000613', 'MONDO_0005184', 'EFO_0008528', 'EFO_0000616',
       'EFO_1000359', 'EFO_1000043', 'EFO_0000313', 'EFO_0001075',
       'EFO_0000096', 'EFO_0000565', 'MONDO_0011962', 'EFO_0000691',
       'MONDO_0002087', 'EFO_1000251', 'EFO_1001961', 'EFO_0007532',
       'MONDO_0004192', 'MONDO_0016537', 'EFO_0006861', 'EFO_0006738',
       'EFO_0000588', 'MONDO_0002158', 'MONDO_0015760', 'MONDO_0001056',
       'EFO_0000305', 'MONDO_0005411', 'EFO_0005537', 'MONDO_0004986',
       'EFO_1001951', 'MONDO_0007254', 'MONDO_0002974', 'MONDO_0002367',
       'MONDO_0004992', 'EFO_0001416', 'HP_0001907', 'EFO_0000466',
       'EFO_0004252', 'EFO_1001469', 'EFO_1001051', 'EFO_1001959',
       'MONDO_0008315', 'EFO_0001378', 'EFO_0003060', 'MONDO_0008903',
       'MONDO_0001187', 'EFO_0002618', 'MONDO_0002691'], dtype=object), 'count': 55}","[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229,ENSG00000167325,ENSG00000048392,ENSG00000171848]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 48 investigational indications.
CHEMBL1743017,,,Antibody,False,FEZAKINUMAB,,2.0,,False,False,[],['Fezakinumab' 'ILV-094'],,,"{'rows': array(['EFO_0000676', 'EFO_0000274', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000127318],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2104927,CN(CCc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)[C@H](c1ccccc1)N1CCN(CC2CC2)CC1,HUTHJVYJUPXHDF-DEOSSOPVSA-N,Small molecule,False,FIGOPITANT,,2.0,,False,False,[],"['BIIF 1149 BS' 'BIIF 1149 CL' 'BIIF-1149 BS' 'BIIF-1149-BS' 'Biif 1149'
 'Figopitant']","[('drugbank', array(['DB12122'], dtype=object))]",['CHEMBL3542235'],,[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2105675,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1,DQJDBUPLRMRBAB-WZTVWXICSA-N,Small molecule,False,TAFAMIDIS MEGLUMINE,2011.0,4.0,CHEMBL2103837,False,True,['Vyndaqel'],['FX-1006A' 'Tafamidis meglumine'],"[('DailyMed', array(['tafamidis%20meglumine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel'],
      dtype=object)), ('chEBI', array(['79345'], dtype=object))]",,"{'rows': array(['EFO_1001875', 'EFO_0009562', 'EFO_0000318', 'MONDO_0019438',
       'EFO_0004129'], dtype=object), 'count': 5}",[ENSG00000118271],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 2 investigational indications.
CHEMBL2107826,O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21,DJXRIQMCROIRCZ-XOEOCAAJSA-N,Small molecule,False,VIBEGRON,2018.0,4.0,,False,True,['Gemtesa'],['KRP-114V' 'Mk4618' 'Vibegron'],"[('drugbank', array(['DB14895'], dtype=object))]",,"{'rows': array(['EFO_0006865', 'HP_0000020', 'EFO_0000555', 'EFO_0000537',
       'EFO_1000781'], dtype=object), 'count': 5}",[ENSG00000188778],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications.
CHEMBL2109177,,,Antibody,False,ODULIMOMAB,,3.0,,False,False,[],['Afolimomab' 'Odulimomab' 'anti-LFA1'],,,,[ENSG00000005844],Antibody drug with a maximum clinical trial phase of III.
CHEMBL2346976,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,JMEYDSHPKCSIJC-UHFFFAOYSA-N,Small molecule,False,AZD3514,,1.0,,False,False,[],['AZD-3514' 'Azd 3514' 'Azd3514' 'CS-1443'],,,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545096,COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1.O=C(O)/C=C\C(=O)O,YUXMAKUNSXIEKN-BTJKTKAUSA-N,Small molecule,False,BGT-226,,2.0,CHEMBL3218578,False,False,[],['BGT226' 'Bgt-226' 'NVP-BGT-226' 'NVP-BGT226'],"[('chEBI', array(['71953'], dtype=object))]",,"{'rows': array(['MONDO_0016063', 'MONDO_0004992', 'MONDO_0007254'], dtype=object), 'count': 3}","[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545103,,,Small molecule,False,AZD3199,,2.0,,False,False,[],['Azd3199'],,,"{'rows': array(['HP_0006536', 'EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 3}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545145,,,Small molecule,False,WX-554,,1.0,,False,False,[],['Wx-554'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545238,,,Small molecule,False,CS-8080,,1.0,,False,False,[],['Cs-8080'],,,,"[ENSG00000025434,ENSG00000131408]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545340,CNC(=O)COc1cccc(Nc2ncc(F)c(Nc3ccc4c(c3)NC(=O)C(F)(F)O4)n2)c1.O=C(O)c1ccc2ccccc2c1O,ILIHENOWEIBEQV-UHFFFAOYSA-N,Small molecule,False,R-343,,2.0,CHEMBL2170582,False,False,[],['R-343' 'R-940343' 'R940343'],,,,[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL363648,CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1,HEKAIDKUDLCBRU-UHFFFAOYSA-N,Small molecule,False,TAK-715,,2.0,,False,False,[],['TAK 715' 'TAK-715' 'Tak-715'],"[('PubChem', array(['103905024', '174006984'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707249,,,Small molecule,False,ASM-024,,2.0,,False,False,[],['Asm-024'],,,"{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}","[ENSG00000175344,ENSG00000181072,ENSG00000168539,ENSG00000133019,ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3910075,COc1ccc(C(=O)c2cn(C(C)C)c3ncnc(N)c23)cc1NC(=O)Nc1ccc(Cl)cc1Cl,VFCRSIORGUNNGT-UHFFFAOYSA-N,Small molecule,False,CE-245677,,1.0,,False,False,[],['Ce 245677' 'Ce-245677'],,,,[ENSG00000120156],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989990,,,Antibody,False,ISTIRATUMAB,,2.0,,False,False,[],['Istiratumab' 'MM-005' 'MM-141'],,,"{'rows': array(['EFO_0000182', 'EFO_0002618'], dtype=object), 'count': 2}","[ENSG00000065361,ENSG00000140443]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297785,,,Antibody,False,VIBOSTOLIMAB,,3.0,,False,False,[],"['MK-7684' 'MK7684' 'Mk-7684' 'TIGIT INHIBITOR MK-7684'
 'TIGIT-TARGETING AGENT MK-7684' 'Vibostolimab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VIBOSTOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000756', 'EFO_0000702', 'MONDO_0001187',
       'EFO_0003060', 'EFO_0000681', 'EFO_0001642', 'EFO_1001951',
       'EFO_0008528', 'EFO_0000616'], dtype=object), 'count': 10}",[ENSG00000181847],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL466659,O=[N+]([O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],TZRXHJWUDPFEEY-UHFFFAOYSA-N,Small molecule,False,PENTAERYTHRITOL TETRANITRATE,,4.0,,False,True,['Cardiacap' 'Mycardol' 'Peritrate' 'Peritrate sa'],"['Pentaerithritol tetranitrate' 'Pentaerithrityl tetranitrate'
 'Pentaerythritol tetranitrate' 'Pentaerythrityl tetranitrate' 'Pentalong'
 'Pentanitrol']","[('PubChem', array(['144205177', '144212064', '29215318'], dtype=object)), ('Wikipedia', array(['Pentaerythritol_tetranitrate'], dtype=object)), ('drugbank', array(['DB06154'], dtype=object)), ('chEBI', array(['25879'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease.
CHEMBL471737,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,ACRHBAYQBXXRTO-OAQYLSRUSA-N,Small molecule,False,IVABRADINE,2015.0,4.0,,False,True,['Corlanor' 'Procoralan'],['Ivabradine' 'S-16257'],"[('DailyMed', array(['ivabradine'], dtype=object)), ('PubChem', array(['50125937'], dtype=object)), ('Wikipedia', array(['Ivabradine'], dtype=object)), ('drugbank', array(['DB09083'], dtype=object)), ('chEBI', array(['85966'], dtype=object))]",['CHEMBL2145077'],"{'rows': array(['EFO_1001207', 'EFO_0003144', 'EFO_0006834', 'EFO_0007372',
       'EFO_1000645', 'EFO_0003144', 'EFO_1000899', 'EFO_1001373',
       'EFO_0000574', 'EFO_0003913', 'EFO_0005252', 'HP_0001649',
       'EFO_0000401', 'EFO_0008586', 'EFO_0000373', 'EFO_0001645',
       'EFO_0000319', 'EFO_0000275', 'EFO_0005251', 'EFO_0000373',
       'EFO_0003913', 'MONDO_0004992'], dtype=object), 'count': 22}",[ENSG00000138622],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 18 investigational indications.
CHEMBL521851,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,LHNIIDJUOCFXAP-UHFFFAOYSA-N,Small molecule,False,PICTILISIB,,2.0,,False,False,[],['CDC-0941' 'GDC 0941' 'GDC-0941' 'Pictilisib' 'Pictrelisib' 'Rg-7321'],"[('PubChem', array(['103905592'], dtype=object)), ('drugbank', array(['DB11663'], dtype=object)), ('chEBI', array(['65326'], dtype=object))]",['CHEMBL4097197' 'CHEMBL1922096'],"{'rows': array(['MONDO_0007254', 'EFO_0005952', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000616'], dtype=object), 'count': 5}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL524,COc1ccc(OC)c(C(O)C(C)N)c1,WJAJPNHVVFWKKL-UHFFFAOYSA-N,Small molecule,False,METHOXAMINE,1982.0,4.0,,False,True,[],['Methoxamine' 'NRL-001' 'NRL001' 'Nrl001' 'Vasoxyl'],"[('PubChem', array(['90341132'], dtype=object)), ('Wikipedia', array(['Methoxamine'], dtype=object)), ('drugbank', array(['DB00723'], dtype=object)), ('chEBI', array(['6839'], dtype=object))]",['CHEMBL1201103'],"{'rows': array(['EFO_0009523', 'EFO_0000319', 'EFO_0009523', 'HP_0000020'],
      dtype=object), 'count': 4}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 3 investigational indications.
CHEMBL5314392,C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOc1ccc(-c2c(C#N)c(SCc3csc(-c4ccc(Cl)cc4)n3)nc(N3CCCC3)c2C#N)cc1,WESNEIGKOAXSGX-VXKWHMMOSA-N,Small molecule,False,BAY1067197,,2.0,,False,False,[],"['BAY-10-67197' 'BAY-1067197' 'BAY10-67197' 'BAY1067197' 'Bay1067197'
 'Neladenoson bialanate' 'Neladenoson dalanate']",,,"{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL5314401,Cc1ncccc1C(=O)N1CCN(S(=O)(=O)c2ccc(C(F)(F)F)cc2)C[C@@H]1C,BLFJGFDZMABYMY-ZDUSSCGKSA-N,Small molecule,False,CNV2197944,,2.0,,False,False,[],['CNV2197944' 'Cnv-2197944' 'Cnv2197944'],,,"{'rows': array(['EFO_1000783', 'MONDO_0041052'], dtype=object), 'count': 2}",[ENSG00000148408],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1090090,NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F,FYSRKRZDBHOFAY-UHFFFAOYSA-N,Small molecule,False,VX-702,,2.0,,False,False,[],['VX-702' 'Vx-702'],"[('PubChem', array(['103905258', '137275870'], dtype=object)), ('drugbank', array(['DB05470'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1200469,CN(C)CCCN1c2ccccc2Sc2ccccc21.Cl,JIVSXRLRGOICGA-UHFFFAOYSA-N,Small molecule,False,PROMAZINE HYDROCHLORIDE,1956.0,4.0,CHEMBL564,False,True,"['Prazine' 'Promazine Granules' 'Promazine hydrochloride' 'Protactyl'
 'Sparine' 'Tranquazine' 'Verophene']","['NSC-17468' 'Promazine chloride' 'Promazine hcl'
 'Promazine hydrochloride']","[('PubChem', array(['144203786', '170464766', '26747628', '26747629', '50106839',
       '50106840', '50106841', '56422376', '57288080', '855749'],
      dtype=object)), ('chEBI', array(['8460'], dtype=object))]",,,"[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL1200879,CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[Na+],KYITYFHKDODNCQ-UHFFFAOYSA-M,Small molecule,True,WARFARIN SODIUM,1954.0,4.0,CHEMBL1464,False,True,['Athrombin' 'Coumadin' 'Jantoven' 'Marevan' 'Panwarfin' 'Warfarin sodium'],"['Aldocumar' 'Apo-warfarin' 'Prothromadin' 'Sodium warfarin'
 'Warfarin sodium' 'Warfarin sodium salt' 'Warfarinum natricum'
 'Zoocoumarin sodium salt']","[('DailyMed', array(['warfarin%20sodium'], dtype=object)), ('PubChem', array(['144211862', '50085469'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'HP_0004936', 'EFO_0003907', 'EFO_0000275',
       'EFO_0000612', 'EFO_0000685', 'EFO_0003827', 'HP_0001907',
       'EFO_0004239'], dtype=object), 'count': 9}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 7 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201746,C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,OGSBUKJUDHAQEA-WMCAAGNKSA-N,Small molecule,False,PRALATREXATE,2009.0,4.0,,False,True,['Folotyn'],['NSC-754230' 'PDX' 'Pralatrexate'],"[('DailyMed', array(['pralatrexate'], dtype=object)), ('PubChem', array(['144206459'], dtype=object)), ('Wikipedia', array(['Pralatrexate'], dtype=object)), ('drugbank', array(['DB06813'], dtype=object)), ('chEBI', array(['71223'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0002913', 'MONDO_0000430', 'EFO_1000785',
       'MONDO_0015760', 'MONDO_0002158', 'MONDO_0008903', 'MONDO_0002087',
       'EFO_0000574', 'EFO_0000305', 'EFO_0003060', 'EFO_0000616',
       'MONDO_0008170', 'EFO_0003032', 'EFO_0006859', 'MONDO_0019471',
       'EFO_0000211', 'MONDO_0004992', 'EFO_1001051'], dtype=object), 'count': 19}",[ENSG00000228716],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 14 investigational indications.
CHEMBL1721885,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1,CTNPALGJUAXMMC-PMFHANACSA-N,Small molecule,False,SU-014813,,2.0,,False,False,[],['SU-14813' 'Su-014813' 'Su-14813'],"[('PubChem', array(['50100117'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003869'], dtype=object), 'count': 2}","[ENSG00000157404,ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1761322,CCS(=O)(=O)CCCC12CCC(c3nnc(-c4ccccc4C(F)(F)F)n3C)(CC1)CC2,ORQZQBUNAMJFCY-UHFFFAOYSA-N,Small molecule,False,MK-0736,,2.0,,False,False,[],['MK0736' 'Mk-0736' 'Mk0736'],"[('drugbank', array(['DB15209'], dtype=object))]",,"{'rows': array(['EFO_0003875', 'EFO_0000537'], dtype=object), 'count': 2}",[ENSG00000117594],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL197672,C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F,SCVHJVCATBPIHN-SJCJKPOMSA-N,Small molecule,False,EMRICASAN,,2.0,,False,False,[],"['Emricasan' 'IDN 6556' 'IDN-6556' 'PF 03491390' 'PF-03491390' 'VAY-785'
 'VAY785']","[('drugbank', array(['DB05408'], dtype=object))]",,"{'rows': array(['EFO_0010282', 'EFO_0000400', 'MONDO_0100096', 'EFO_1001249',
       'EFO_0001422', 'EFO_0004220', 'EFO_1001345', 'EFO_0001421'],
      dtype=object), 'count': 8}","[ENSG00000196954,ENSG00000132906,ENSG00000164305,ENSG00000137757,ENSG00000138794,ENSG00000165806,ENSG00000064012,ENSG00000137752,ENSG00000106144,ENSG00000003400,ENSG00000105141,ENSG00000204403]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL2103840,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12,PIMQWRZWLQKKBJ-SFHVURJKSA-N,Small molecule,False,DINACICLIB,,3.0,,False,False,[],['Dinaciclib' 'Mk-7965' 'SCH 727965' 'SCH-727965' 'SCH727965'],"[('drugbank', array(['DB12021'], dtype=object))]",,"{'rows': array(['EFO_0006861', 'EFO_0000756', 'EFO_0000222', 'EFO_0000616',
       'EFO_0000095', 'MONDO_0001023', 'MONDO_0007254', 'EFO_0001378',
       'EFO_0000220'], dtype=object), 'count': 9}","[ENSG00000123374,ENSG00000170312,ENSG00000136807,ENSG00000164885]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL2108660,,,Antibody drug conjugate,False,TUCOTUZUMAB CELMOLEUKIN,,2.0,,False,False,[],"['EMD 273066' 'EMD-273066' 'HUKS-IL2' 'KSA-INTERLEUKIN-2'
 'Tucotuzumab celmoleukin']",,,"{'rows': array(['MONDO_0008170'], dtype=object), 'count': 1}",[ENSG00000119888],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108887,,,Antibody,False,AFELIMOMAB,,2.0,,False,False,['Segard'],['Afelimomab' 'LU-54107' 'LU54107' 'MAK-195F'],,,"{'rows': array(['EFO_0000540'], dtype=object), 'count': 1}",[ENSG00000232810],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL229430,CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1,YUTIXVXZQIQWGY-UHFFFAOYSA-N,Small molecule,False,AMG-517,,1.0,,False,False,[],['AMG-517' 'Amg-517'],,,,[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3039521,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@H](NC(=O)c5ccc(NCc6cnc7[nH]c(N)nc(=O)c7n6)cc5)C(=O)O)C(=O)O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,KUZYSQSABONDME-QRLOMCMNSA-N,Unknown,False,VINTAFOLIDE,,3.0,,False,False,[],['EC-145' 'EC145' 'Vintafolide'],"[('drugbank', array(['DB05168'], dtype=object))]",,"{'rows': array(['EFO_0000571', 'EFO_0000616', 'EFO_0003869', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0008170'], dtype=object), 'count': 6}",[ENSG00000110195],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3545185,O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,DEVSOMFAQLZNKR-RJRFIUFISA-N,Small molecule,False,SELINEXOR,2019.0,4.0,,False,True,['Nexpovio' 'Xpovio'],['KPT-330' 'Selinexor'],"[('DailyMed', array(['selinexor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio'],
      dtype=object)), ('drugbank', array(['DB11942'], dtype=object))]",,"{'rows': array(['MONDO_0044903', 'EFO_0000574', 'EFO_0000702', 'MONDO_0008315',
       'EFO_0000182', 'EFO_1000581', 'EFO_0005537', 'EFO_0000681',
       'EFO_0000708', 'EFO_0000616', 'EFO_0003085', 'MONDO_0011962',
       'EFO_0007143', 'EFO_0001642', 'EFO_1000251', 'EFO_0000519',
       'EFO_0003060', 'EFO_0000339', 'EFO_0000096', 'EFO_0001075',
       'EFO_0000389', 'MONDO_0019460', 'MONDO_0007254', 'EFO_0001378',
       'MONDO_0100096', 'EFO_1001968', 'EFO_0000198', 'EFO_0004142',
       'EFO_0000220', 'MONDO_0004992', 'EFO_0002617', 'EFO_0000211',
       'EFO_1000657', 'EFO_0000691', 'MONDO_0000430', 'EFO_0000756',
       'MONDO_0019438', 'EFO_0008528', 'EFO_1001459', 'EFO_1001465',
       'EFO_0000707', 'EFO_0000222', 'EFO_0000403'], dtype=object), 'count': 43}",[ENSG00000082898],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 39 investigational indications.
CHEMBL3545415,,,Protein,False,SMC021,,3.0,,False,False,[],['Smc021'],,,"{'rows': array(['EFO_0003882', 'GO_0042697', 'MONDO_0005178', 'EFO_0003854'],
      dtype=object), 'count': 4}",[ENSG00000004948],Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL356359,CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1,KVCSJPATKXABRQ-UHFFFAOYSA-N,Small molecule,False,PIBOSEROD,,2.0,,False,False,[],['Piboserod' 'SB-207266'],"[('PubChem', array(['137275879'], dtype=object)), ('Wikipedia', array(['Piboserod'], dtype=object)), ('drugbank', array(['DB04873'], dtype=object))]",['CHEMBL2106927'],"{'rows': array(['EFO_0000373', 'EFO_0000275'], dtype=object), 'count': 2}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297774,,,Antibody,False,AMIVANTAMAB,2021.0,4.0,,False,True,['Rybrevant'],"['Amivantamab' 'Amivantamab vmjw' 'CNTO-4424' 'CNTO4424' 'JNJ 61186372'
 'JNJ-611' 'JNJ-61186372' 'JNJ-6372' 'Jnj 61186372' 'Jnj-61186372']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMIVANTAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000182', 'MONDO_0001056', 'EFO_0003060', 'MONDO_0004669',
       'EFO_0000616'], dtype=object), 'count': 5}","[ENSG00000105976,ENSG00000146648]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 3 investigational indications.
CHEMBL4297880,,,Protein,False,EVORPACEPT,,2.0,,False,False,[],"['ALX-148' 'ALX148' 'Alx 148' 'Alx-148' 'Alx148' 'Evorpacept'
 'Lggl-alx-148' 'Sirpa variant alx148']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EVORPACEPT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0008170', 'MONDO_0004992', 'EFO_0000181', 'EFO_0000616',
       'EFO_0000198', 'EFO_1001931', 'EFO_0005952', 'EFO_0000222'],
      dtype=object), 'count': 8}",[ENSG00000196776],Protein drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL468,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,UEJJHQNACJXSKW-UHFFFAOYSA-N,Small molecule,True,THALIDOMIDE,1998.0,4.0,,False,True,['Talidex' 'Thalidomide lipomed' 'Thalomid'],"['.alpha.-phthalimidoglutarimide' 'Celgene' 'Contergan' 'Distaval' 'K-17'
 'Myrin' 'N-phthalylglutamic acid imide' 'NSC-527179' 'NSC-66847'
 'Neurosedyn' 'Pantosediv' 'Pharmion' 'Softenon' 'Thaled' 'Thalidomide'
 'Thalidomide ']","[('DailyMed', array(['thalidomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-lipomed'],
      dtype=object)), ('PubChem', array(['111716', '11532929', '124881523', '144210897', '170465323',
       '174007312', '26747126', '26751823', '50104514', '90341724'],
      dtype=object)), ('Wikipedia', array(['Thalidomide'], dtype=object)), ('drugbank', array(['DB01041'], dtype=object)), ('chEBI', array(['74947'], dtype=object))]",,"{'rows': array(['EFO_0000519', 'EFO_0005543', 'EFO_1000158', 'EFO_0000403',
       'EFO_1000613', 'EFO_0004142', 'EFO_0000191', 'EFO_0003060',
       'MONDO_0044903', 'MONDO_0002158', 'EFO_0003843', 'EFO_0001065',
       'MONDO_0008170', 'EFO_0006888', 'EFO_0000676', 'MONDO_0002087',
       'MONDO_0018364', 'EFO_0000389', 'MONDO_0019472', 'MONDO_0004975',
       'EFO_0000182', 'EFO_0000096', 'MONDO_0015564', 'MONDO_0017816',
       'EFO_0004268', 'EFO_0000474', 'EFO_0000681', 'EFO_0002430',
       'MONDO_0003196', 'EFO_0002939', 'EFO_1001767', 'MONDO_0019438',
       'HP_0003073', 'EFO_0000717', 'EFO_0006859', 'MONDO_0002367',
       'EFO_0000095', 'EFO_0000765', 'EFO_0005628', 'EFO_0009441',
       'EFO_0000756', 'EFO_1001875', 'MONDO_0004992', 'HP_0012735',
       'EFO_0000621', 'EFO_0000673', 'MONDO_0018906', 'EFO_1001951',
       'EFO_1001996', 'EFO_1001968', 'EFO_0000729', 'EFO_0000384',
       'EFO_0000574', 'MONDO_0008903', 'EFO_0000691', 'EFO_0000764',
       'MONDO_0019338', 'EFO_0000540', 'EFO_0005952', 'MONDO_0021063',
       'MONDO_0100096', 'MONDO_0001056', 'EFO_0000198', 'MONDO_0007254',
       'EFO_0005570', 'EFO_0000565', 'EFO_0003898', 'EFO_0001378',
       'Orphanet_848', 'EFO_0000183', 'EFO_0000616', 'EFO_0007160',
       'EFO_1001901', 'EFO_0007312', 'EFO_0000365', 'MONDO_0004976',
       'EFO_0000342', 'EFO_1000045', 'EFO_1000318', 'EFO_0003865',
       'EFO_0000768', 'MONDO_0019558', 'MONDO_0002691', 'MONDO_0007576',
       'EFO_1001469', 'EFO_0003047', 'MONDO_0008315'], dtype=object), 'count': 87}","[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for immune system disease and multiple myeloma and has 85 investigational indications. This drug has a black box warning from the FDA.
CHEMBL5314382,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,HSXBEUMRBMAVDP-QKXVGOHISA-N,Protein,False,PASIREOTIDE PAMOATE,2014.0,4.0,CHEMBL3349607,False,True,['Signifor lar' 'Signifor lar kit'],['Pasireotide embonate'],,,"{'rows': array(['EFO_1001485'], dtype=object), 'count': 1}","[ENSG00000139874,ENSG00000278195,ENSG00000180616,ENSG00000162009]",Protein drug with a maximum clinical trial phase of IV that was first approved in 2014 and is indicated for acromegaly.
CHEMBL888,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,SDUQYLNIPVEERB-QPPQHZFASA-N,Small molecule,False,GEMCITABINE,1996.0,4.0,,False,True,['Gemzar'],['Gemcitabine' 'Gemzar' 'LY-188011' 'LY188011' 'NSC-613327'],"[('PubChem', array(['124893555', '50113286'], dtype=object)), ('Wikipedia', array(['Gemcitabine'], dtype=object)), ('drugbank', array(['DB00441'], dtype=object)), ('chEBI', array(['175901'], dtype=object))]",['CHEMBL1637'],"{'rows': array(['EFO_0000182', 'MONDO_0001657', 'EFO_0000255', 'EFO_0000574',
       'EFO_0000707', 'EFO_0000681', 'EFO_0006859', 'MONDO_0005184',
       'EFO_0008528', 'MONDO_0002367', 'MONDO_0015760', 'EFO_0001075',
       'EFO_1001961', 'MONDO_0005575', 'MONDO_0004192', 'EFO_0006861',
       'EFO_0006738', 'MONDO_0021117', 'EFO_0001061', 'EFO_0000183',
       'MONDO_0005411', 'MONDO_0018906', 'MONDO_0002158', 'EFO_0005537',
       'MONDO_0004986', 'EFO_0009708', 'MONDO_0007254', 'MONDO_0002974',
       'MONDO_0019472', 'MONDO_0002367', 'MONDO_0004992', 'EFO_0000565',
       'EFO_0004252', 'MONDO_0000430', 'EFO_1000359', 'MONDO_0004986',
       'MONDO_0001187', 'EFO_0002618', 'MONDO_0007576', 'EFO_0001075',
       'EFO_1001469', 'MONDO_0008627', 'EFO_0002913', 'EFO_0003060',
       'EFO_0000222', 'EFO_0000616', 'EFO_1000613', 'EFO_0009534',
       'MONDO_0002087', 'EFO_0000681', 'EFO_1000043', 'MONDO_0011719',
       'EFO_0000096', 'EFO_0003869', 'EFO_0003893', 'MONDO_0008315',
       'EFO_0001376', 'MONDO_0002087', 'MONDO_0011962', 'EFO_1001956',
       'EFO_0005230', 'EFO_0007532', 'MONDO_0016537', 'MONDO_0021054',
       'EFO_0002618', 'EFO_0000403', 'EFO_0000756', 'MONDO_0001056',
       'EFO_0000637', 'MONDO_0004192', 'EFO_0000564', 'MONDO_0009348',
       'EFO_0000181', 'MONDO_0002691', 'EFO_1001959', 'MONDO_0004992',
       'EFO_0005088', 'EFO_0010282', 'MONDO_0008170', 'EFO_0001378',
       'EFO_0000294', 'EFO_0006859', 'EFO_0000571', 'EFO_1000026',
       'MONDO_0001187', 'EFO_0006475', 'EFO_0000691', 'EFO_0000220',
       'EFO_0001416', 'MONDO_0007254', 'MONDO_0005411', 'EFO_0003050',
       'EFO_0000096', 'EFO_0003891', 'EFO_0000228', 'EFO_0000174',
       'MONDO_0011962', 'EFO_0000770', 'EFO_0003860', 'EFO_1000251',
       'EFO_1001951', 'MONDO_0002108', 'EFO_1000292', 'MONDO_0003059',
       'EFO_0003863', 'EFO_0000588', 'MONDO_0008627', 'EFO_0005952',
       'MONDO_0021063', 'MONDO_0015760', 'EFO_0000305', 'MONDO_0018364',
       'MONDO_0003060', 'EFO_0004252', 'EFO_0000305', 'MONDO_0008903',
       'EFO_0005537', 'EFO_0002939', 'MONDO_0001056', 'HP_0001907',
       'EFO_0000466', 'EFO_1001051', 'EFO_1000657', 'EFO_0000365',
       'EFO_0004606', 'EFO_0000313', 'EFO_1000251', 'MONDO_0008315',
       'EFO_0003060', 'EFO_1001100', 'EFO_1001968', 'MONDO_0008170',
       'EFO_0000183', 'EFO_0000574', 'Orphanet_145', 'EFO_0003032',
       'EFO_0008528', 'EFO_0000616', 'EFO_1000359', 'EFO_0000313',
       'EFO_0000565', 'EFO_0000211', 'EFO_0000691', 'EFO_1001961',
       'MONDO_0019471', 'EFO_0005221', 'EFO_0000702', 'MONDO_0002158',
       'EFO_0000514', 'EFO_1001951', 'EFO_0001416', 'EFO_1001469',
       'MONDO_0005184', 'EFO_0000708', 'EFO_0000588', 'MONDO_0002974',
       'EFO_0001378', 'MONDO_0008903', 'MONDO_0002691'], dtype=object), 'count': 159}","[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229,ENSG00000167325,ENSG00000048392,ENSG00000171848]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 9 approved and 132 investigational indications.
CHEMBL900,Cc1ccccc1C(OCCN(C)C)c1ccccc1,QVYRGXJJSLMXQH-UHFFFAOYSA-N,Small molecule,False,ORPHENADRINE,1957.0,4.0,,False,True,[],"['Disipal' 'Invagesic' 'Mefenamine' 'Mialgin' 'Norflex' 'Norgesic'
 'Orphenadrin' 'Orphenadrine' 'Orphengesic']","[('PubChem', array(['124880989', '174006927', '90341796'], dtype=object)), ('Wikipedia', array(['Orphenadrine'], dtype=object)), ('drugbank', array(['DB01173'], dtype=object)), ('chEBI', array(['7789'], dtype=object))]",['CHEMBL1201023' 'CHEMBL1200395'],"{'rows': array(['MONDO_0005180', 'EFO_0003843', 'HP_0003419'], dtype=object), 'count': 3}","[ENSG00000196639,ENSG00000103546,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for parkinson disease and pain and has 1 investigational indication.
CHEMBL1091,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,ALEXXDVDDISNDU-JZYPGELDSA-N,Small molecule,False,HYDROCORTISONE ACETATE,1951.0,4.0,,False,True,"['Barquinol hc' 'Chloromycetin hydrocort' 'Colifoam' 'Cortef acetate'
 'Cortifoam' 'Cortril' 'Cortucid' 'Dricort' 'Epifoam' 'Framycort'
 'Fucidin h' 'Genticin hc' 'Gentisone hc' 'Gppe ear susp' 'Gppe eye crm'
 'Gppe foam aero' 'Hc45 hydrocort' 'Hemsol-hc' 'Hepacort plus' 'Hydrocal'
 'Hydrocortisone acetate' 'Hydrocortone' 'Lanacort' 'Micort-hc'
 'Neo-cortef' 'Orabase hca']","['Cortisol 21-acetate' 'Hydrocortisone 21-acetate'
 'Hydrocortisone Acetate' 'Hydrocortisone acetate' 'Hydrocortisoni acetas'
 'NSC-741']","[('DailyMed', array(['hydrocortisone%20acetate'], dtype=object)), ('PubChem', array(['56422202', '855532'], dtype=object)), ('drugbank', array(['DB14539'], dtype=object)), ('chEBI', array(['17609'], dtype=object))]",,"{'rows': array(['EFO_0009552', 'EFO_0004208', 'EFO_0000274', 'HP_0000989',
       'MP_0001845', 'EFO_0000701', 'MONDO_0002050'], dtype=object), 'count': 7}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 3 approved and 4 investigational indications.
CHEMBL1200950,C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2.[Br-],GKEGFOKQMZHVOW-UHFFFAOYSA-M,Small molecule,False,CLIDINIUM BROMIDE,1982.0,4.0,CHEMBL620,False,True,['Quarzan'],['Clidinium bromide' 'NSC-756686' 'RO 2-3773' 'RO-2-3773' 'RO-23773'],"[('DailyMed', array(['clidinium%20bromide'], dtype=object)), ('PubChem', array(['144204086', '170464768', '56423127', '855678'], dtype=object)), ('Wikipedia', array(['Clidinium_bromide'], dtype=object))]",,"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease.
CHEMBL1201827,,,Antibody,True,PANITUMUMAB,2006.0,4.0,,False,True,['Vectibix'],['ABX-EGF' 'Abenix' 'E7.6.3' 'L01xc08' 'Panitumumab'],"[('DailyMed', array(['panitumumab'], dtype=object)), ('DrugCentral', array(['4955'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix'],
      dtype=object)), ('Wikipedia', array(['Panitumumab'], dtype=object))]",,"{'rows': array(['EFO_0000707', 'MONDO_0007576', 'EFO_1000657', 'EFO_0001075',
       'EFO_0006859', 'MONDO_0008170', 'EFO_1000852', 'EFO_0000503',
       'EFO_0000681', 'EFO_0000365', 'MONDO_0021063', 'MONDO_0008903',
       'EFO_0000313', 'EFO_0005922', 'EFO_1000251', 'EFO_0002618',
       'MONDO_0005575', 'EFO_0005221', 'MONDO_0002158', 'MONDO_0002974',
       'EFO_0000616', 'MONDO_0008315', 'MONDO_0002367', 'EFO_0005537',
       'MONDO_0004992', 'MONDO_0001187', 'EFO_0004142', 'EFO_1001951',
       'EFO_0000181', 'EFO_1001512', 'MONDO_0007254', 'EFO_0002916',
       'EFO_0003060'], dtype=object), 'count': 33}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 27 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1336,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,MLDQJTXFUGDVEO-UHFFFAOYSA-N,Small molecule,False,SORAFENIB,2005.0,4.0,,False,True,['Nexavar'],['BAY 43-9006' 'BAY-43-9006' 'Sorafenib'],"[('PubChem', array(['103904444', '124893321', '124893323', '50100118', '50112741'],
      dtype=object)), ('Wikipedia', array(['Sorafenib'], dtype=object)), ('drugbank', array(['DB00398'], dtype=object)), ('chEBI', array(['50924'], dtype=object))]",['CHEMBL1200485' 'CHEMBL4297490' 'CHEMBL1760433'],"{'rows': array(['MONDO_0004192', 'EFO_0000691', 'EFO_0000673', 'EFO_0001061',
       'EFO_0000198', 'EFO_1001968', 'EFO_0000756', 'MONDO_0018531',
       'EFO_0000641', 'EFO_0004212', 'MONDO_0008170', 'EFO_0000365',
       'MONDO_0008903', 'EFO_0008524', 'EFO_0000756', 'MONDO_0008170',
       'EFO_0000691', 'EFO_0003060', 'EFO_0001361', 'EFO_1001968',
       'EFO_1001465', 'EFO_0003833', 'EFO_0000574', 'MONDO_0000831',
       'EFO_1000657', 'EFO_0002499', 'MONDO_0002108', 'EFO_0000588',
       'EFO_1001469', 'EFO_0000501', 'EFO_0000313', 'EFO_1000796',
       'EFO_0000702', 'MONDO_0002691', 'EFO_1001052', 'MONDO_0044937',
       'EFO_0003891', 'EFO_0000666', 'EFO_0000095', 'EFO_0001378',
       'EFO_0000224', 'EFO_0000196', 'MONDO_0008315', 'EFO_0002618',
       'MONDO_0004992', 'EFO_0003833', 'EFO_0000519', 'EFO_0002499',
       'EFO_0000640', 'EFO_0000565', 'EFO_0000221', 'MONDO_0007576',
       'MONDO_0011719', 'EFO_0009907', 'EFO_0000558', 'EFO_1001465',
       'EFO_0000621', 'EFO_0000702', 'EFO_1000158', 'EFO_0000681',
       'EFO_0000095', 'MONDO_0001187', 'EFO_1001901', 'MONDO_0002087',
       'EFO_1001346', 'EFO_0000222', 'EFO_1000657', 'EFO_0000501',
       'EFO_0003865', 'EFO_0003893', 'MONDO_0015277', 'MONDO_0001187',
       'EFO_0000403', 'MONDO_0002691', 'EFO_0003841', 'EFO_0000335',
       'EFO_0000637', 'MONDO_0011719', 'EFO_0000349', 'EFO_0006352',
       'EFO_0006861', 'EFO_0000389', 'EFO_0002501', 'MONDO_0007254',
       'MONDO_0002367', 'MONDO_0004992', 'EFO_0004142', 'EFO_0002918',
       'EFO_0000224', 'EFO_0007535', 'EFO_1000292', 'MONDO_0008315',
       'EFO_0000220', 'EFO_0000228', 'EFO_0000222', 'MONDO_0008903',
       'EFO_0002618', 'EFO_0000616', 'MONDO_0001056', 'EFO_1000613',
       'EFO_0003860', 'EFO_0000616', 'EFO_1000359', 'MONDO_0021063',
       'EFO_0005221', 'EFO_0002938', 'MONDO_0044926', 'EFO_0000707',
       'EFO_0002618', 'EFO_0000673', 'MONDO_0001056', 'EFO_0000339',
       'MONDO_0004986', 'EFO_0000641', 'EFO_0003060', 'EFO_0004284',
       'EFO_0001421', 'EFO_0000182', 'MONDO_0007254', 'EFO_0002501',
       'MONDO_0002108', 'EFO_0000222', 'EFO_1001951', 'MONDO_0002108',
       'EFO_0000182', 'EFO_0000588', 'EFO_0000519', 'MONDO_0002367',
       'EFO_0003086', 'EFO_0002892', 'EFO_0003060', 'EFO_0004252',
       'EFO_0000616', 'EFO_0000681', 'EFO_0005088', 'EFO_1001513',
       'EFO_0000637', 'EFO_0001378', 'EFO_0003871', 'EFO_0002892',
       'EFO_0004252', 'EFO_0003032', 'EFO_0000220', 'EFO_0000182',
       'MONDO_0002158'], dtype=object), 'count': 145}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025,ENSG00000132155,ENSG00000165731,ENSG00000157404,ENSG00000157764,ENSG00000113721]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 7 approved and 112 investigational indications.
CHEMBL1371200,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)[O-].[K+],JTZQCHFUGHIPDF-RYVBEKKQSA-M,Small molecule,False,CANRENOATE POTASSIUM,,4.0,CHEMBL1616951,False,True,['Soldactone' 'Spiroctan-m'],"['Canrenoate potassium' 'Canrenone free acid potassium salt' 'Kanrenol'
 'NSC-757789' 'Potassium canrenoate' 'SC-14266']","[('PubChem', array(['144204351', '56463334'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0008585'], dtype=object), 'count': 2}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.
CHEMBL1544,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,AUYYCJSJGJYCDS-LBPRGKRZSA-N,Small molecule,True,LIOTHYRONINE,1956.0,4.0,,False,True,['Cytomel' 'Tertroxin'],"[""3,5,3'-triiodothyronine, l-"" 'Cyronine' 'Euthroid-0.5' 'Euthroid-1'
 'Euthroid-2' 'Euthroid-3'
 'Levothyroxine sodium related compound liothyronine' 'Liothyronine'
 'NSC-80203' 'Rathyronine' 'Rathyronine, (s)-' 'Thyrolar-0.25'
 'Thyrolar-0.5' 'Thyrolar-1' 'Thyrolar-2' 'Thyrolar-3' 'Thyrolar-5'
 'Triiodothyronine (T3 Or Liothyronine, Active) (6-11%)' 'Triostat']","[('PubChem', array(['11532858', '124877498', '144203580', '144212260', '26753840',
       '4253003'], dtype=object)), ('Wikipedia', array(['Triiodothyronine'], dtype=object)), ('drugbank', array(['DB00279'], dtype=object)), ('chEBI', array(['18258'], dtype=object))]",['CHEMBL2106622' 'CHEMBL2107398' 'CHEMBL1356342' 'CHEMBL1201119'],"{'rows': array(['EFO_0003144', 'MONDO_0002050', 'EFO_1000931', 'EFO_0006859',
       'EFO_0004705', 'MONDO_0008315', 'EFO_0004705', 'EFO_0003929',
       'MONDO_0002009', 'EFO_0003840', 'MONDO_0007254', 'EFO_0000275',
       'HP_0030680', 'EFO_0003841', 'EFO_0005207', 'EFO_0006834',
       'EFO_1001465', 'HP_0030680', 'EFO_1002017', 'MONDO_0004985',
       'EFO_1001055', 'MONDO_0005301'], dtype=object), 'count': 22}","[ENSG00000126351,ENSG00000151090]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 4 approved and 18 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1628569,NC(=O)c1ccc(F)c2c1C[C@@H](N(C1CCC1)C1CCC1)CO2,MQTUXRKNJYPMCG-CYBMUJFWSA-N,Small molecule,False,ROBALZOTAN,,2.0,,False,False,[],['Azd-7371' 'NAD-299' 'Robalzotan'],"[('drugbank', array(['DB06538'], dtype=object))]",,,[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1963249,C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1,WGYPAJVJMXQXTR-ABNZCKJZSA-N,Small molecule,False,ULIMORELIN,,3.0,,False,False,[],['TZP-101 FREE BASE' 'Ulimorelin'],"[('drugbank', array(['DB12128'], dtype=object))]",['CHEMBL1923502' 'CHEMBL3926779'],"{'rows': array(['EFO_0010282', 'EFO_1000948', 'MONDO_0004567'], dtype=object), 'count': 3}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2108345,,,Oligonucleotide,False,TRABEDERSEN,,3.0,,False,False,[],['A-12009 FREE ACID' 'Trabedersen'],,,"{'rows': array(['EFO_0000519', 'EFO_0002499'], dtype=object), 'count': 2}",[ENSG00000092969],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109341,,,Antibody,False,CCR5MAB004,,1.0,,False,False,[],['CCR5MAB004' 'Ccr5mab004'],,,"{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}",[ENSG00000160791],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109366,,,Antibody,False,ANTI-TAC 90 Y-HAT,,1.0,,False,False,[],['ANTI-TAC 90 Y-HAT' 'Anti-tac 90 y-hat'],,,"{'rows': array(['EFO_0005952', 'EFO_0000183'], dtype=object), 'count': 2}",[ENSG00000134460],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2109595,,,Antibody,False,AMG-157,,2.0,,False,False,[],['AMG-157' 'Amg-157' 'MEDI-9929'],,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000145777],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL217899,CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2,DHCOPPHTVOXDKU-UHFFFAOYSA-N,Small molecule,False,TOFIMILAST,,2.0,,False,False,[],"['CP-325,366' 'CP-325366' 'Tofimilast']","[('drugbank', array(['DB11681'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2331680,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1,RGJOJUGRHPQXGF-INIZCTEOSA-N,Small molecule,False,RG-7603,,1.0,,False,False,[],['GDC-0349' 'Rg-7603'],"[('drugbank', array(['DB13072'], dtype=object))]",['CHEMBL2331681'],"{'rows': array(['EFO_0005952'], dtype=object), 'count': 1}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2346738,Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1,LZXMUJCJAWVHPZ-UHFFFAOYSA-N,Small molecule,False,DIPRAGLURANT,,2.0,,False,False,[],['ADX-48621' 'ADX48621' 'Adx48621' 'Dipraglurant'],"[('drugbank', array(['DB12733'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'MONDO_0011728'], dtype=object), 'count': 2}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL272980,Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1,HRNLUBSXIHFDHP-UHFFFAOYSA-N,Small molecule,False,MOCETINOSTAT,,2.0,,False,False,[],['MGCD-0103' 'MGCD0103' 'Mocetinostat'],"[('PubChem', array(['137276026'], dtype=object)), ('Wikipedia', array(['Mocetinostat'], dtype=object)), ('drugbank', array(['DB11830'], dtype=object))]",['CHEMBL481122'],"{'rows': array(['EFO_0000574', 'EFO_0000183', 'EFO_0003060', 'MONDO_0018906',
       'EFO_0008528', 'EFO_0000222', 'EFO_0000565', 'EFO_0000095',
       'EFO_0000616', 'EFO_0000198', 'EFO_0002918', 'EFO_0000199',
       'EFO_0000564', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0008903'],
      dtype=object), 'count': 16}","[ENSG00000196591,ENSG00000171720,ENSG00000147099,ENSG00000163517,ENSG00000116478]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications.
CHEMBL307429,OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,LXBIFEVIBLOUGU-JGWLITMVSA-N,Small molecule,False,DUVOGLUSTAT,,2.0,,False,False,[],"['1 deoxynojirimycin' '1,5-dideoxy-1,5-imino-'
 '1,5-dideoxy-1,5-imino-d-glucitol' '1-deoxynojirimycin' 'Bay-h-5595'
 'D-1-deoxynojirimycin' 'Deoxynojirimycin' 'Duvoglustat' 'Moranolin'
 'Moranoline' 'Nojirimycin, 1-deoxy-']","[('PubChem', array(['26752140'], dtype=object)), ('drugbank', array(['DB03206'], dtype=object)), ('chEBI', array(['44369'], dtype=object))]",['CHEMBL460785'],"{'rows': array(['Orphanet_365'], dtype=object), 'count': 1}",[ENSG00000171298],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3137320,Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,HWGQMRYQVZSGDQ-HZPDHXFCSA-N,Small molecule,False,TALAZOPARIB,2018.0,4.0,,False,True,[],['BMN 673' 'BMN-673' 'LT-673' 'Talazoparib'],"[('drugbank', array(['DB11760'], dtype=object))]",['CHEMBL3137318'],"{'rows': array(['EFO_0000196', 'EFO_0008528', 'EFO_0005537', 'EFO_0003869',
       'EFO_0005537', 'Orphanet_145', 'EFO_0003869', 'MONDO_0008170',
       'EFO_0003060', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000519',
       'EFO_0000326', 'MONDO_0004992', 'EFO_0000708', 'EFO_1001901',
       'EFO_0000616', 'EFO_0003060', 'EFO_0000305', 'EFO_0000681',
       'EFO_0000239', 'EFO_0000616', 'EFO_0000565', 'MONDO_0007254',
       'EFO_1001951', 'EFO_0000702', 'EFO_0000673', 'MONDO_0008315',
       'EFO_0002618', 'EFO_0000222', 'MONDO_0002334', 'MONDO_0011962',
       'EFO_0003968'], dtype=object), 'count': 33}","[ENSG00000143799,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 27 investigational indications.
CHEMBL3989478,CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,RVBRTNPNFYFDMZ-SPIKMXEPSA-N,Small molecule,False,THIETHYLPERAZINE MALEATE,1961.0,4.0,CHEMBL1378,False,True,['Torecan'],"['GS-95' 'NSC-130044' 'Thiethylperazine dimaleate'
 'Thiethylperazine maleate' 'Thietylperazine maleate']",,,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.
CHEMBL4650441,,,Antibody,False,IMSIDOLIMAB,,3.0,,False,False,[],['ANB-019' 'ANB019' 'Anb019' 'Imsidolimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IMSIDOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003894', 'MONDO_0019269', 'EFO_0000676', 'EFO_1000710',
       'EFO_1000662', 'MONDO_0015597'], dtype=object), 'count': 6}","[ENSG00000115598,ENSG00000196083]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL5314374,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],MVPQUSQUURLQKF-MCPDASDXSA-E,Oligosaccharide,False,IDRAPARINUX SODIUM,,3.0,CHEMBL5314801,False,False,[],"['Idraparinux nonasodium salt' 'Idraparinux sodium' 'ORG-34006'
 'SANORG-34006' 'SANORG34006']",,,"{'rows': array(['EFO_0003907', 'EFO_0003827', 'EFO_0000275'], dtype=object), 'count': 3}",[ENSG00000126218],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL762,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,WYWIFABBXFUGLM-UHFFFAOYSA-N,Small molecule,False,OXYMETAZOLINE,1986.0,4.0,,False,True,[],['Nasacon' 'Ocuclear' 'Operil' 'Oxymetazoline'],"[('PubChem', array(['104171207', '11111570', '11111571', '11113337', '124880976',
       '124880979', '144203768', '170464916', '26751491', '26751492',
       '50100299', '50104031', '90341671'], dtype=object)), ('Wikipedia', array(['Oxymetazoline'], dtype=object)), ('drugbank', array(['DB00935'], dtype=object)), ('chEBI', array(['7862'], dtype=object))]",['CHEMBL1200791'],"{'rows': array(['EFO_0009523', 'MONDO_0000728', 'EFO_0003956', 'MONDO_0001330',
       'HP_0010783', 'HP_0001742', 'EFO_0007141', 'HP_0010783',
       'EFO_0007214', 'EFO_0005854', 'EFO_1000760', 'EFO_0005252',
       'HP_0001742', 'EFO_0005751', 'EFO_0005854', 'MONDO_0001330',
       'EFO_0007486', 'EFO_0007214', 'EFO_0003956', 'EFO_1000760'],
      dtype=object), 'count': 20}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 8 approved and 10 investigational indications.
CHEMBL76222,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,GTXSRFUZSLTDFX-HRCADAONSA-N,Small molecule,False,REBIMASTAT,,2.0,,False,False,[],"['BMS 275291-01' 'BMS-275291' 'BMS-275291-01' 'D-2163' 'D2163'
 'Rebimastat']","[('drugbank', array(['DB06573'], dtype=object))]",,"{'rows': array(['MONDO_0008903', 'MONDO_0007254', 'EFO_0000673', 'EFO_0000691'],
      dtype=object), 'count': 4}","[ENSG00000137745,ENSG00000118113,ENSG00000157227,ENSG00000100985,ENSG00000087245,ENSG00000196611]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL117287,COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,ZPMNHBXQOOVQJL-UHFFFAOYSA-N,Small molecule,False,PRUCALOPRIDE,2009.0,4.0,,False,True,['Resolor'],['Prucalopride' 'R-093877' 'R093877'],"[('PubChem', array(['170466188', '174006285'], dtype=object)), ('drugbank', array(['DB06480'], dtype=object))]",['CHEMBL2105748' 'CHEMBL4757628' 'CHEMBL5199178'],"{'rows': array(['EFO_0000555', 'MONDO_0004567', 'MONDO_0002203', 'EFO_0001421',
       'HP_0002019', 'EFO_0008533', 'HP_0002019', 'HP_0002590',
       'MONDO_0002050', 'HP_0002015'], dtype=object), 'count': 10}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for constipation disorder and constipation and has 7 investigational indications.
CHEMBL1200585,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,ICMWWNHDUZJFDW-DHODBPELSA-N,Small molecule,True,OXYMETHOLONE,1972.0,4.0,,False,True,['Anadrol-50' 'Anapolon 50'],"['Anadrol' 'Anapolon' 'Anasteron' 'CI-406' 'HMD' 'NSC-26,198' 'NSC-26198'
 'Oximetholone' 'Oxymetholone' 'Oxymetholone ciii' 'Pardroyd']","[('PubChem', array(['144204682', '144207269', '170465403', '17388810'], dtype=object)), ('Wikipedia', array(['Oxymetholone'], dtype=object)), ('drugbank', array(['DB06412'], dtype=object))]",,,[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972. This drug has a black box warning from the FDA.
CHEMBL1201242,CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21,UCEWGESNIULAGX-UHFFFAOYSA-N,Small molecule,False,INDECAINIDE,1989.0,4.0,,False,True,[],['Indecainide'],"[('PubChem', array(['170465192'], dtype=object)), ('Wikipedia', array(['Indecainide'], dtype=object)), ('drugbank', array(['DB00192'], dtype=object))]",['CHEMBL1200341'],,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989.
CHEMBL1251,CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,GJNXBNATEDXMAK-PFLSVRRQSA-N,Protein,False,GANIRELIX,1999.0,4.0,,False,True,['Ganirelix Acetate Injection'],[],"[('Wikipedia', array(['Ganirelix'], dtype=object)), ('drugbank', array(['DB06785'], dtype=object))]",['CHEMBL5314377'],"{'rows': array(['EFO_1000859', 'EFO_0000660', 'EFO_1000645', 'EFO_0000545'],
      dtype=object), 'count': 4}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 investigational indications.
CHEMBL1276138,O=C(c1ccc2nonc2c1)N1CCCCC1,XFVRBYKKGGDPAJ-UHFFFAOYSA-N,Small molecule,False,FARAMPATOR,,2.0,,False,False,[],"['CX 691' 'CX-691' 'CX691' 'Farampator' 'ORG 24448' 'ORG-24448'
 'SCH-900460']","[('drugbank', array(['DB15012'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'MONDO_0005090', 'MONDO_0002050'], dtype=object), 'count': 3}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1921847,Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1,ZHPMYDSXGRRERG-DEOSSOPVSA-N,Small molecule,False,ATICAPRANT,,3.0,,False,False,[],"['Aticaprant' 'CERC-501' 'Cerc-501' 'JNJ-67953964-AAA' 'JSPA-0658'
 'JSPA0658' 'Jnj-67953964' 'LY-2456302' 'LY2456302' 'Ly2456302']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ATICAPRANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12341'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'MONDO_0002009', 'MONDO_0002009', 'EFO_0003768',
       'EFO_0009854'], dtype=object), 'count': 5}",[ENSG00000082556],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2103792,Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O,OKYYOKGIPDRZJA-CPSXWDTOSA-N,Oligonucleotide,False,AGATOLIMOD,,3.0,,False,False,[],['Agatolimod' 'Cpg-10104' 'PF-3512676' 'Pf-3512676 free acid'],,['CHEMBL2103793'],"{'rows': array(['EFO_0005952', 'EFO_0009441', 'EFO_0002913', 'EFO_0003869',
       'EFO_0000764', 'EFO_0000403', 'EFO_0001068', 'EFO_0000756',
       'EFO_0000574', 'EFO_0000681', 'EFO_1001051', 'HP_0100806',
       'EFO_0000096', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0007576',
       'EFO_0000313', 'EFO_0001068', 'MONDO_0008315', 'EFO_0000191',
       'EFO_0003060', 'EFO_1001469'], dtype=object), 'count': 22}",[ENSG00000239732],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.
CHEMBL2108475,,,Antibody,False,PRILIXIMAB,,2.0,,False,False,[],"['CEN 000029' 'CEN-000029' 'CEN000029' 'CM-MT412' 'CMT-412' 'MT-412'
 'Priliximab']",,,,[ENSG00000010610],Antibody drug with a maximum clinical trial phase of II.
CHEMBL219586,Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)NCc1ccc(OC(C)(C)C(=O)O)cc1,ILUPZUOBHCUBKB-UHFFFAOYSA-N,Small molecule,False,GW590735,,2.0,,False,False,[],['GW590735' 'Gw590735'],"[('drugbank', array(['DB07215'], dtype=object))]",,"{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL258940,CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,FTFRZXFNZVCRSK-UHFFFAOYSA-N,Small molecule,False,FALNIDAMOL,,2.0,,False,False,[],['BIBX 1382' 'BIBX-1382' 'Bibx 1382' 'Bibx-1382' 'Bibx1382' 'Falnidamol'],"[('PubChem', array(['124892343', '26755049'], dtype=object)), ('drugbank', array(['DB12966'], dtype=object))]",['CHEMBL2136050'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL267936,CNC1(C)C2CCC(C2)C1(C)C,IMYZQPCYWPFTAG-UHFFFAOYSA-N,Small molecule,False,MECAMYLAMINE,1956.0,4.0,,False,True,[],['Mecamylamine'],"[('PubChem', array(['104171190', '144203749', '170465225', '26755706', '50111169',
       '90341710'], dtype=object)), ('drugbank', array(['DB00657'], dtype=object)), ('chEBI', array(['6706'], dtype=object))]",['CHEMBL1237082'],"{'rows': array(['MONDO_0002009', 'MONDO_0007079', 'EFO_0003758', 'EFO_0000537',
       'MONDO_0002050', 'EFO_0003768', 'EFO_0009606', 'EFO_0001365',
       'HP_0001268'], dtype=object), 'count': 9}","[ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and is indicated for hypertension and has 8 investigational indications.
CHEMBL274070,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(N)cccc3nc2-1,FUXVKZWTXQUGMW-FQEVSTJZSA-N,Small molecule,False,9-AMINOCAMPTOTHECIN,,2.0,,False,False,[],"['9-amino-20(s)-camptothecin' '9-aminocamptothecin' 'Aminocamptothecin'
 'NSC-603071']","[('PubChem', array(['26725257', '483848'], dtype=object)), ('drugbank', array(['DB12515'], dtype=object)), ('chEBI', array(['80755'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'MONDO_0001056', 'EFO_0000574', 'EFO_0003893',
       'MONDO_0002367', 'MONDO_0004992', 'MONDO_0007576', 'MONDO_0008903',
       'EFO_0000222', 'EFO_0000220', 'MONDO_0002087'], dtype=object), 'count': 11}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.
CHEMBL3544932,CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1,WKDACQVEJIVHMZ-UHFFFAOYSA-N,Small molecule,False,TAK-901,,1.0,,False,False,[],['Tak-901'],"[('drugbank', array(['DB12756'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_0000222', 'EFO_0000095', 'EFO_0000198',
       'EFO_0001378', 'EFO_0002430', 'EFO_0009441', 'MONDO_0044903'],
      dtype=object), 'count': 8}",[ENSG00000178999],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications.
CHEMBL3545073,,,Small molecule,False,AMA0076,,2.0,,False,False,[],['AMA-0076' 'Ama0076' 'PHP-201' 'PHP201' 'Sovesudil'],,,"{'rows': array(['EFO_1001069', 'MONDO_0005041'], dtype=object), 'count': 2}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545209,,,Small molecule,False,NKTR-171,,1.0,,False,False,[],['Nktr-171'],,,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545263,,,Small molecule,False,LGX-806,,1.0,,False,False,[],['Lgx-806' 'NVP-LGX806'],,,,"[ENSG00000157764,ENSG00000132155]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3622533,COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1,JOWXJLIFIIOYMS-UHFFFAOYSA-N,Small molecule,False,FIMEPINOSTAT,,2.0,,False,False,[],['CUDC-907' 'CUDC907' 'Cudc 907' 'Cudc-907' 'Fimepinostat'],"[('drugbank', array(['DB11891'], dtype=object))]",,"{'rows': array(['MONDO_0002108', 'EFO_0000574'], dtype=object), 'count': 2}","[ENSG00000171608,ENSG00000051382,ENSG00000121879,ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3833384,,,Protein,False,EFLAPEGRASTIM,2022.0,4.0,,False,True,['Rolvedon'],"['Eflapegrastim' 'HM-10460A' 'HM10460A' 'HNK-460' 'HNK460' 'SPI-2012'
 'SPL-2012']",,,"{'rows': array(['MONDO_0001475', 'MONDO_0007254', 'EFO_0000574', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for neoplasm and has 3 investigational indications.
CHEMBL4297218,CCOC(=O)Cn1nc(C(F)(F)F)cc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1,ZUMNJDGBYXHASJ-UHFFFAOYSA-N,Small molecule,False,ROVAZOLAC,,2.0,,False,False,[],['ALX-101' 'Rovazolac'],,,"{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}","[ENSG00000025434,ENSG00000131408]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298128,Cc1nn(C)cc1S(=O)(=O)NC(=O)c1ccc(-n2ccc(OCC(C)(C)C(F)(F)F)n2)nc1N1C[C@@H](C)CC1(C)C,MVRHVFSOIWFBTE-INIZCTEOSA-N,Small molecule,False,ELEXACAFTOR,2019.0,4.0,,False,True,[],"['3-PYRIDINECARBOXAMIDE, N-((1,3-DIMETHYL-1H-PYRAZOL-4-YL)SULFONYL)-6-(3-(3,3,3-TRIFLUORO-2,2-DIMETHYLPROPOXY)-1H-PYRAZOL-1-YL)-2-((4S)-2,2,4-TRIMETHYL-1-PYRROLIDINYL)-'
 'Elexacaftor' 'VX-445' 'Vx-445']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELEXACAFTOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15444'], dtype=object))]",,"{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and has 1 investigational indication.
CHEMBL4594242,,,Protein,False,CALCITONIN,,4.0,,True,True,['Calcitare' 'Calsynar' 'Cibacalcin' 'Forcaltonin' 'Miacalcic'],"['Calcitonin' 'Calcitonin, unspecified' 'Throcalcitonin']",,,"{'rows': array(['EFO_1000950', 'EFO_0003854', 'MONDO_0002123'], dtype=object), 'count': 3}",[ENSG00000004948],Protein drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications. It was withdrawn in at least one region.
CHEMBL460785,Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O,ZJIHMALTJRDNQI-VFQQELCFSA-N,Small molecule,False,DUVOGLUSTAT HYDROCHLORIDE,,2.0,CHEMBL307429,False,False,[],"['1 deoxynojirimycin hydrochloride' '1-deoxynojirimycin hydrochloride'
 'AT-2220' 'AT2220' 'Duvoglustat hcl' 'Duvoglustat hydrochloride'
 'Moranoline hydrochloride']",,,"{'rows': array(['Orphanet_365'], dtype=object), 'count': 1}",[ENSG00000171298],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650288,,,Antibody,False,FLYSYN,,1.0,,False,False,[],['FLYSYN' 'Flysyn'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000122025],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL553,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,AAKJLRGGTJKAMG-UHFFFAOYSA-N,Small molecule,False,ERLOTINIB,2004.0,4.0,,False,True,['Tarceva'],"['CP-358,774' 'CP-358774' 'CP-35877401' 'Erlotinib' 'OSI-774' 'R-1415'
 'RG-1415' 'Ro-508231']","[('PubChem', array(['103905339', '124893165', '124893166', '144205755', '170465434',
       '26757996', '50100099', '85267493'], dtype=object)), ('Wikipedia', array(['Erlotinib'], dtype=object)), ('drugbank', array(['DB00530'], dtype=object)), ('chEBI', array(['114785'], dtype=object))]",['CHEMBL5220042' 'CHEMBL1079742'],"{'rows': array(['EFO_0005537', 'EFO_0000632', 'EFO_0002501', 'MONDO_0007576',
       'MONDO_0002974', 'MONDO_0004992', 'EFO_0001422', 'MONDO_0044881',
       'EFO_0000616', 'EFO_0002429', 'EFO_0000588', 'MONDO_0021117',
       'EFO_0000514', 'EFO_0000305', 'EFO_0000519', 'MONDO_0000521',
       'EFO_0000681', 'MONDO_0008903', 'EFO_0000182', 'EFO_0004252',
       'EFO_0000198', 'EFO_0006859', 'MONDO_0008315', 'MONDO_0002898',
       'EFO_0000222', 'EFO_1000657', 'EFO_0003050', 'EFO_0000308',
       'EFO_0000676', 'EFO_0003893', 'EFO_0003868', 'EFO_1001951',
       'MONDO_0008170', 'MONDO_0018531', 'MONDO_0008903', 'MONDO_0016693',
       'MONDO_0002087', 'MONDO_0002691', 'MONDO_0016691', 'EFO_0003060',
       'EFO_0000708', 'MONDO_0002158', 'MONDO_0003060', 'EFO_0002618',
       'MONDO_0002158', 'EFO_0002501', 'EFO_0005577', 'EFO_1000581',
       'MONDO_0002898', 'EFO_0000313', 'MONDO_0003060', 'EFO_0003860',
       'EFO_1000026', 'EFO_1000158', 'EFO_0000571', 'EFO_1001465',
       'MONDO_0021063', 'MONDO_0003478', 'EFO_0000756', 'EFO_0003833',
       'MONDO_0007254', 'EFO_0002499', 'EFO_0009708', 'EFO_0000588',
       'EFO_0000571', 'MONDO_0021063', 'EFO_0000365', 'MONDO_0007254',
       'Orphanet_733', 'EFO_0000691', 'EFO_0001378', 'EFO_0000519',
       'EFO_0002916', 'EFO_0000182', 'EFO_0005221', 'EFO_1001901',
       'MONDO_0001187', 'EFO_0000707', 'EFO_1000657', 'EFO_1000028',
       'MONDO_0004986', 'MONDO_0011962', 'EFO_1001951', 'MONDO_0020634',
       'EFO_0010282', 'MONDO_0005411', 'MONDO_0003268', 'EFO_0000565',
       'EFO_0002618', 'EFO_0006859', 'EFO_0004220', 'MONDO_0002367',
       'EFO_0005567', 'EFO_0000181', 'EFO_1001465', 'EFO_0000616',
       'MONDO_0002367', 'EFO_1000359', 'MONDO_0003268', 'EFO_0007243',
       'MONDO_0001657', 'EFO_0002499', 'MONDO_0002691', 'MONDO_0044926',
       'EFO_0000756', 'EFO_1000158', 'EFO_0000181', 'Orphanet_733',
       'EFO_0003060', 'EFO_0000681', 'EFO_0003050', 'MONDO_0008315',
       'MONDO_0008170', 'MONDO_0001187', 'EFO_0000349', 'EFO_0000308',
       'MONDO_0004992', 'EFO_0000640', 'MONDO_0007576'], dtype=object), 'count': 119}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 105 investigational indications.
CHEMBL586702,FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1,HGVNLRPZOWWDKD-UHFFFAOYSA-N,Small molecule,False,ZSTK-474,,2.0,,False,False,[],['TCMDC-137004' 'Zstk-474' 'Zstk474'],"[('drugbank', array(['DB12904'], dtype=object)), ('chEBI', array(['90545'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL87493,CCNC(C)Cc1cccc(C(F)(F)F)c1,DBGIVFWFUFKIQN-UHFFFAOYSA-N,Small molecule,True,FENFLURAMINE,2020.0,4.0,,True,True,[],"['Acino' 'Brabafen' 'Fenfluramin' 'Fenfluramine' 'J5.760F' 'Obedrex'
 'Pesos' 'Phenfluramine' 'Ponderax pa' 'Rotondin' 'S-768' 'Z-008' 'Z008'
 'ZX-008' 'ZX008']","[('PubChem', array(['144205250', '29215428'], dtype=object)), ('Wikipedia', array(['Fenfluramine'], dtype=object)), ('drugbank', array(['DB00574'], dtype=object)), ('chEBI', array(['5000'], dtype=object))]",['CHEMBL2106217'],"{'rows': array(['MONDO_0015643', 'EFO_0002610', 'MONDO_0100062', 'EFO_0000474',
       'HP_0001250', 'EFO_0001073'], dtype=object), 'count': 6}","[ENSG00000179546,ENSG00000147246,ENSG00000147955]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL940,NCC1(CC(=O)O)CCCCC1,UGJMXCAKCUNAIE-UHFFFAOYSA-N,Small molecule,False,GABAPENTIN,1993.0,4.0,,False,True,['Gabapentin' 'Gralise' 'Neurontin'],"['CI-945' 'DM-1796' 'GOE 3450' 'GOE-3450' 'Gabapentin' 'NSC-742194'
 'NSC-759254']","[('DailyMed', array(['gabapentin'], dtype=object)), ('PubChem', array(['104171164', '11112806', '11113327', '124880194', '144203708',
       '170464715', '50103936', '855579', '90340599'], dtype=object)), ('Wikipedia', array(['Gabapentin'], dtype=object)), ('drugbank', array(['DB00996'], dtype=object)), ('chEBI', array(['42797'], dtype=object))]",['CHEMBL542620'],"{'rows': array(['EFO_0005687', 'EFO_1002028', 'HP_0000989', 'EFO_0000512',
       'MONDO_0041052', 'MONDO_0011382', 'HP_0003419', 'EFO_0005611',
       'HP_0002013', 'EFO_0003756', 'EFO_0007191', 'EFO_0003917',
       'EFO_0001422', 'HP_0008419', 'EFO_0005230', 'EFO_1001931',
       'MONDO_0002050', 'EFO_0004777', 'EFO_0005762', 'EFO_0008507',
       'EFO_0000546', 'HP_0012532', 'HP_0001250', 'EFO_0005323',
       'MONDO_0007079', 'EFO_0004710', 'EFO_0003890', 'EFO_0009267',
       'EFO_0003843', 'HP_0031217', 'MONDO_0007254', 'HP_0001337',
       'EFO_0000764', 'EFO_1001800', 'EFO_0004329', 'MONDO_0043510',
       'EFO_0006859', 'EFO_0006510', 'EFO_0003768', 'EFO_0004698',
       'EFO_0004143', 'MONDO_0004986', 'EFO_0004263', 'EFO_1001250',
       'HP_0000726', 'HP_0000360', 'EFO_0009430', 'EFO_0000474',
       'EFO_1000783', 'EFO_0005407', 'EFO_0004888', 'MONDO_0004992',
       'EFO_0008568', 'EFO_1001255', 'MONDO_0005090', 'MONDO_0005301',
       'EFO_1000971', 'MONDO_0008315', 'MONDO_0002038', 'EFO_0000279',
       'EFO_0008533', 'EFO_0004270', 'EFO_0003818', 'EFO_0004273',
       'EFO_1001898', 'EFO_0000519'], dtype=object), 'count': 66}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 61 investigational indications.
CHEMBL979,CCCC(C)(COC(N)=O)COC(N)=O,NPPQSCRMBWNHMW-UHFFFAOYSA-N,Small molecule,False,MEPROBAMATE,1955.0,4.0,,True,True,"['Amosene' 'Bamate' 'Equanil' 'Mepriam' 'Meprobamate' 'Meprospan'
 'Miltown' 'Neuramate' 'Tenavoid' 'Tranmep']",['Meprobamate' 'Meprobamate civ' 'NSC-30418'],"[('DailyMed', array(['meprobamate'], dtype=object)), ('PubChem', array(['144204614', '144207530', '17389535'], dtype=object)), ('Wikipedia', array(['Meprobamate'], dtype=object)), ('drugbank', array(['DB00371'], dtype=object))]",,"{'rows': array(['EFO_0006788', 'EFO_0005230'], dtype=object), 'count': 2}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for anxiety disorder and anxiety. It was withdrawn in at least one region.
CHEMBL107367,Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1,ZZCHHVUQYRMYLW-HKBQPEDESA-N,Small molecule,False,FARGLITAZAR,,2.0,,False,False,[],['Farglitazar' 'G1-262570' 'GI-262570' 'GI-262570X' 'GI262570X' 'Gi262570'],"[('PubChem', array(['144210538'], dtype=object)), ('Wikipedia', array(['Farglitazar'], dtype=object))]",,"{'rows': array(['EFO_0001422'], dtype=object), 'count': 1}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL111659,C#Cc1cncc([C@@H]2CCCN2C)c1,NUPUDYKEEJNZRG-LBPRGKRZSA-N,Small molecule,False,ALTINICLINE,,2.0,,False,False,[],['(-)-5-ethynylnicotine' 'Altinicline' 'SIB-1508Y' 'SIB-1765F'],"[('Wikipedia', array(['Altinicline'], dtype=object))]",['CHEMBL2146093'],,"[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL112,CC(=O)Nc1ccc(O)cc1,RZVAJINKPMORJF-UHFFFAOYSA-N,Small molecule,True,ACETAMINOPHEN,1968.0,4.0,,False,True,"['Abdine' 'Acephen' 'Acetaminophen' 'Alvedon' 'Angiers' 'Calpol'
 'Calpol six plus' 'Calpol six plus fastmelts' 'Child lemsip' 'Cupanol'
 'Dafalgan' 'Datril' 'Disprol' 'Disprol infant' 'Disprol jnr'
 'Disprol paed' 'Fennings' 'Galpamol' 'Hedex' 'Infadrops'
 ""Infants' feverall"" 'Injectapap' 'Junior parapaed' 'Mandanol' 'Medinol'
 'Medinol for children' 'Medinol over 6' 'Medinol under 6' 'Medised plain'
 'Miradol' 'Neopap' 'Ofirmev' 'Paldesic' 'Panadol' 'Panadol actifast'
 'Panadol actifast solb' 'Panadol advan' 'Panadol jnr' 'Panadol oa'
 'Panaleve' 'Panaleve 6 plus' 'Paracetamol' 'Paramin' 'Parapaed jnr'
 'Parapaed six plus' 'Paravict' 'Perfalgan' 'Phenaphen' 'Placidex'
 'Rimadol' 'Salzone' 'Tixymol' 'Tramil 500' 'Tylenol']","['Acetaminophen' 'Apap' 'Biocetamol' 'Doliprane' 'Efferalgan'
 'N-acetyl-p-aminophenol' 'NSC-109028' 'NSC-3991' 'P-hydroxy-acetanilid'
 'Paracetamol' 'Paracetamolum' 'Vermidon']","[('DailyMed', array(['acetaminophen'], dtype=object)), ('PubChem', array(['104171293', '11112253', '11114188', '124882135', '144209128',
       '144210420', '170466797', '17390068', '174007306', '26747171',
       '56422763'], dtype=object)), ('TG-GATEs', array(['1'], dtype=object)), ('Wikipedia', array(['Paracetamol'], dtype=object)), ('drugbank', array(['DB00316'], dtype=object)), ('chEBI', array(['46195'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'HP_0002315', 'HP_0002013', 'MONDO_0007915',
       'EFO_0000685', 'EFO_0000220', 'EFO_0002460', 'EFO_0005592',
       'EFO_1001139', 'MONDO_0005147', 'HP_0012076', 'HP_0011110',
       'EFO_0000384', 'EFO_0009615', 'Orphanet_365', 'EFO_0000540',
       'EFO_0000389', 'EFO_1000783', 'EFO_0010282', 'EFO_0003086',
       'MONDO_0005148', 'MONDO_0043510', 'HP_0002018', 'EFO_0003843',
       'HP_0000175', 'EFO_0000574', 'HP_0000989', 'HP_0002027',
       'MONDO_0005180', 'HP_0012115', 'EFO_0000095', 'EFO_0000544',
       'EFO_0000339', 'EFO_1001412', 'EFO_0000537', 'EFO_0000403',
       'EFO_0000222', 'MONDO_0007254', 'HP_0003419', 'HP_0001945',
       'EFO_0004599', 'EFO_0001378', 'EFO_0001068', 'EFO_0004209',
       'EFO_0004253', 'EFO_1000831', 'MONDO_0005301', 'EFO_0000618',
       'MONDO_0005041', 'EFO_0001073', 'EFO_0005230', 'MONDO_0002367',
       'HP_0100806', 'EFO_0004616', 'HP_0000545', 'EFO_0003060',
       'EFO_0004255', 'EFO_0000198', 'EFO_0000546', 'EFO_0004197',
       'EFO_1000249', 'EFO_1001216', 'EFO_0003931', 'EFO_0004888',
       'EFO_0009846', 'HP_0001643', 'EFO_0010072', 'EFO_0000616',
       'EFO_0007160', 'EFO_1001250', 'EFO_1000749', 'HP_0003418',
       'MONDO_0005277', 'EFO_1001476', 'EFO_0000668', 'EFO_0001074',
       'EFO_0000096', 'HP_0012228', 'EFO_0005856', 'EFO_0004269',
       'MONDO_0004992', 'HP_0012532', 'MONDO_0005178', 'EFO_0007486',
       'HP_0030833', 'EFO_0004273', 'HP_0100607', 'EFO_0000764',
       'EFO_0005762', 'HP_0008419', 'EFO_0005761', 'MP_0001914',
       'MONDO_0044917', 'EFO_0011023', 'EFO_0007359', 'MONDO_0100342',
       'MONDO_0009291', 'EFO_0005952', 'MONDO_0002258', 'MONDO_0017287',
       'EFO_0009267', 'EFO_1000786', 'MONDO_0024355', 'EFO_0801084',
       'EFO_0007214', 'EFO_0007328', 'EFO_1001898', 'EFO_0007444'],
      dtype=object), 'count': 108}","[ENSG00000196689,ENSG00000117480,ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 12 approved and 96 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1162175,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21,NXHAXEBZOXCDKD-XIXRRVGJSA-N,Small molecule,False,REGRELOR,,2.0,,False,False,[],['Regrelor'],"[('drugbank', array(['DB05553'], dtype=object))]",['CHEMBL261244'],"{'rows': array(['EFO_0001645', 'EFO_0000319'], dtype=object), 'count': 2}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1200541,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl.[Cl-].[Cl-],DXUUXWKFVDVHIK-UHFFFAOYSA-N,Small molecule,False,AMBENONIUM CHLORIDE,1956.0,4.0,CHEMBL1652,False,True,['Mytelase'],['Ambenonium chloride'],"[('PubChem', array(['144205583', '170465386'], dtype=object)), ('chEBI', array(['2628'], dtype=object))]",,,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL1200724,CN[C@@H](C)[C@@H](O)c1ccccc1.Cl,BALXUFOVQVENIU-KXNXZCPBSA-N,Small molecule,False,PSEUDOEPHEDRINE HYDROCHLORIDE,1975.0,4.0,CHEMBL1590,False,True,"['Actifed' 'Contac' 'Dimotane plus' 'Dimotane plus l.a.' 'Galpseud'
 'Galpseud plus' 'Novafed' 'Otrivine mu-cron'
 'Pseudoephedrine hydrochloride' 'Pseudophed' 'Sinutab' 'Sudafed'
 'Sudafed 12 hour' 'Sudafed 12 hr decongest' 'Sudafed 24 hour'
 'Sudafed plus' 'Sudafed-sa']","['Efidac 24' 'Galsud' 'NSC-106567' 'NSC-33634' 'Otrinol'
 'Pseudoephedrine hcl' 'Pseudoephedrine hydrochloride' 'Rhinalair']","[('DailyMed', array(['pseudoephedrine%20hydrochloride'], dtype=object)), ('PubChem', array(['50086711', '544025'], dtype=object)), ('chEBI', array(['8604'], dtype=object))]",,"{'rows': array(['EFO_0003956', 'EFO_0007214', 'EFO_0005854', 'EFO_0003843',
       'HP_0001742', 'MONDO_0005271', 'EFO_0007486', 'EFO_0007328',
       'MONDO_0005277', 'MONDO_0024290', 'HP_0012735'], dtype=object), 'count': 11}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 10 approved and 1 investigational indication.
CHEMBL1200745,C=CCOc1ccccc1OCC(O)CNC(C)C.Cl,COAJXCLTPGGDAJ-UHFFFAOYSA-N,Small molecule,False,OXPRENOLOL HYDROCHLORIDE,1983.0,4.0,CHEMBL546,False,True,"['Apsolox' 'Laracor' 'Oxyprenix excel 160' 'Paritane' 'Slow-pren'
 'Slow-trasicor' 'Trasicor' 'Trasicor ret']","['BA-39,089' 'BA-39089' 'Oxprenolol hcl' 'Oxprenolol hydrochloride']","[('PubChem', array(['144204107', '170464995', '56463641'], dtype=object))]",,,"[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983.
CHEMBL1201486,,,Small molecule,True,QUINIDINE POLYGALACTURONATE,1982.0,4.0,,False,True,['Cardioquin'],['Galactoquin' 'Naticardina' 'Quinidine polygalacturonate'],,,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982. This drug has a black box warning from the FDA.
CHEMBL1201489,,,Protein,False,SERACTIDE ACETATE,1978.0,4.0,,False,True,['Acthar gel-synthetic'],['Seractide acetate' 'Seractide acetate hydrate'],,,,[ENSG00000185231],Protein drug with a maximum clinical trial phase of IV that was first approved in 1978.
CHEMBL1614710,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12,FGTCROZDHDSNIO-UHFFFAOYSA-N,Small molecule,False,OSI-930,,1.0,,False,False,[],['OSI-930' 'Osi 930' 'Osi-930'],"[('PubChem', array(['137276003'], dtype=object)), ('drugbank', array(['DB05913'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1743004,,,Antibody,False,CRENEZUMAB,,3.0,,False,False,[],['Crenezumab' 'MABT-5102A' 'MABT5102A' 'RG-7412' 'RG7412'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1743019,,,Antibody,False,FIGITUMUMAB,,3.0,,False,False,[],"['871' 'CP-751' 'CP-751,871' 'CP-751871' 'Figitumumab']",,,"{'rows': array(['EFO_0006859', 'EFO_0000673', 'EFO_0000691', 'EFO_0003869',
       'EFO_0003050', 'EFO_0001378', 'EFO_0004142', 'EFO_0000702',
       'MONDO_0004992', 'MONDO_0021117', 'MONDO_0007254', 'EFO_0000707',
       'EFO_0000174', 'EFO_0003060'], dtype=object), 'count': 14}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.
CHEMBL1922673,CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1.[Na+],NOJNFULGOQGBKB-UHFFFAOYSA-M,Small molecule,False,FIBOFLAPON SODIUM,,3.0,CHEMBL1922660,False,False,[],"['AM-803 SODIUM' 'Am803 sodium' 'Fiboflapon sodium' 'GSK-2190915A'
 'GSK2190915A' 'SODIUM SALT']",,,"{'rows': array(['MONDO_0004979', 'EFO_1001348', 'MONDO_0009061'], dtype=object), 'count': 3}",[ENSG00000132965],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1951575,CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1,PFWVGKROPKKEDW-UHFFFAOYSA-N,Small molecule,False,VIDUPIPRANT,,2.0,,False,False,[],['AMG 853' 'AMG-853' 'AMG853' 'Vidupiprant'],"[('drugbank', array(['DB12272'], dtype=object))]",,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}","[ENSG00000183134,ENSG00000168229]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2068724,CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2],BUVGWDNTAWHSKI-UHFFFAOYSA-L,Small molecule,False,ACAMPROSATE CALCIUM,2004.0,4.0,CHEMBL1201293,False,True,['Acamprosate calcium' 'Campral' 'Campral ec'],['Acamprosate calcium' 'NSC-759186' 'SN-102'],"[('DailyMed', array(['acamprosate%20calcium'], dtype=object)), ('PubChem', array(['144206019', '144212923'], dtype=object)), ('chEBI', array(['51042'], dtype=object))]",,"{'rows': array(['MONDO_0007079'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2004 and is indicated for alcohol dependence.
CHEMBL2108350,,,Protein,False,CONESTAT ALFA,2010.0,4.0,,False,True,['Ruconest'],"['C1 esterase inhibitor' 'Complement c1 esterase inhibitor'
 'Conestat alfa' 'Recombinant human c1 inhibitor'
 'Recombinant human c1-inhibitor' 'Rhucin' 'Ruconest']","[('DrugCentral', array(['5152'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ruconest'],
      dtype=object))]",,"{'rows': array(['EFO_0000508', 'MONDO_0100096', 'HP_0001919', 'EFO_0007224',
       'MONDO_0019623', 'EFO_0004599', 'EFO_0008586'], dtype=object), 'count': 7}",[ENSG00000149131],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for hereditary angioedema and has 6 investigational indications.
CHEMBL30,CN/C(=N\CCSCc1nc[nH]c1C)NC#N,AQIXAKUUQRKLND-UHFFFAOYSA-N,Small molecule,False,CIMETIDINE,1977.0,4.0,,False,True,"['Acid-eze' 'Acitak 200' 'Acitak 400' 'Acitak 800' 'Brumetadina'
 'Cimetidine' 'Dyspamet' 'Galenamet' 'Kentamet' 'Peptimax 200'
 'Peptimax 400' 'Peptimax 800' 'Tagadine' 'Tagamet' 'Tagamet 100'
 'Tagamet hb' 'Tagamet hb 200' 'Ultec' 'Valmagen' 'Zita']","['Aciloc' 'Acinil' 'Brumetidina' 'Cimal' 'Cimetidine' 'Cimetidinum'
 'Gastromet' 'NSC-335308' 'SKF-92334' 'Stomedine' 'Ulcedin' 'Ulcimet'
 'Ulcomedina']","[('DailyMed', array(['cimetidine'], dtype=object)), ('PubChem', array(['104171130', '11113773', '11533056', '144203657', '144208358',
       '170464651', '17389962', '26747359', '26751957', '460110',
       '50104629', '56462993', '90341189'], dtype=object)), ('TG-GATEs', array(['35'], dtype=object)), ('Wikipedia', array(['Cimetidine'], dtype=object)), ('drugbank', array(['DB00501'], dtype=object)), ('chEBI', array(['3699'], dtype=object))]",['CHEMBL1201051'],"{'rows': array(['MP_0001914', 'MONDO_0004976', 'EFO_0000341', 'MONDO_0011962',
       'EFO_0000544', 'HP_0002239', 'EFO_0000274', 'EFO_0004607',
       'EFO_1001892', 'HP_0004398', 'EFO_0003948', 'MONDO_0001676',
       'MONDO_0004658', 'MONDO_0043839'], dtype=object), 'count': 14}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 3 approved and 11 investigational indications.
CHEMBL3260567,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,FJCDSQATIJKQKA-UHFFFAOYSA-N,Small molecule,False,VACTOSERTIB,,2.0,,False,False,[],['Ew-7197' 'TEW-7197' 'Tew 7197' 'Tew-7197' 'Vactosertib'],"[('drugbank', array(['DB15310'], dtype=object))]",['CHEMBL3260908'],"{'rows': array(['EFO_0000637', 'EFO_0003060', 'EFO_0002618', 'EFO_0009907',
       'EFO_0004251', 'EFO_0008528', 'EFO_0000198', 'EFO_0000616',
       'EFO_0003897', 'EFO_0001378', 'MONDO_0001056'], dtype=object), 'count': 11}",[ENSG00000106799],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.
CHEMBL3544906,C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1.Cl,ANFSNXAXVLRZCG-RSAXXLAASA-N,Small molecule,False,BENZPHETAMINE HYDROCHLORIDE,1960.0,4.0,CHEMBL3545985,False,True,['Benzphetamine hydrochloride' 'Didrex'],"['Benzfetamine hydrochloride' 'Benzphetamine chloride' 'Benzphetamine hcl'
 'Benzphetamine hydrochloride' 'Benzphetamine hydrochloride ciii'
 'NSC-10937' 'U-0441']","[('DailyMed', array(['benzphetamine%20hydrochloride'], dtype=object)), ('chEBI', array(['59169'], dtype=object))]",,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000165646]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for obesity.
CHEMBL3545131,,,Antibody,False,ISATUXIMAB,2020.0,4.0,,False,True,['Sarclisa'],['Isatuximab' 'Isatuximab irfc' 'SAR-650984' 'SAR650984'],"[('DailyMed', array(['isatuximab-irfc'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa'],
      dtype=object))]",,"{'rows': array(['EFO_1001951', 'MONDO_0019438', 'EFO_0000220', 'EFO_0001642',
       'EFO_0000616', 'EFO_0001378', 'EFO_0005592', 'EFO_0000203',
       'EFO_0000222', 'EFO_1001264', 'EFO_0000540', 'EFO_0003073',
       'MONDO_0044881', 'MONDO_0044917', 'MONDO_0001705', 'EFO_0000403',
       'EFO_0000574'], dtype=object), 'count': 17}",[ENSG00000004468],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and multiple myeloma and has 15 investigational indications.
CHEMBL3894860,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1,PDGKHKMBHVFCMG-UHFFFAOYSA-N,Small molecule,False,TRILACICLIB,2021.0,4.0,,False,True,[],['G1T28' 'G1t28-1' 'Trilaciclib'],"[('drugbank', array(['DB15442'], dtype=object))]",['CHEMBL4650272'],"{'rows': array(['EFO_0003060', 'MONDO_0007254', 'EFO_0003869', 'EFO_0000702',
       'EFO_0003968', 'EFO_0005537', 'EFO_0000702'], dtype=object), 'count': 7}","[ENSG00000105810,ENSG00000135446]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for small cell lung carcinoma and has 6 investigational indications.
CHEMBL3989676,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O,CNDQSXOVEQXJOE-UHFFFAOYSA-N,Small molecule,False,OXYPHENBUTAZONE,1960.0,4.0,CHEMBL1228,True,True,['Oxyphenbutazone' 'Tandearil' 'Tanderil' 'Tanderil chloramphen'],"['NSC-757261' 'Oxiphenbutazone' 'Oxyphenbutazone'
 'Oxyphenbutazone hydrate' 'Oxyphenbutazone monohydrate' 'Phlogase'
 'Phlogistol' 'Phlogont']",,,"{'rows': array(['EFO_0005755', 'EFO_0005752', 'HP_0002829', 'HP_0003326'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 approved indications. It was withdrawn in at least one region.
CHEMBL4297456,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O,MMHDBUJXLOFTLC-WOYTXXSLSA-N,Protein,False,ATN-161,,2.0,,False,False,[],['ATN 161' 'ATN-161' 'Ac-phscn-nh2' 'Atn-161'],,,"{'rows': array(['EFO_1000158', 'EFO_0000681'], dtype=object), 'count': 2}","[ENSG00000150093,ENSG00000161638,ENSG00000259207,ENSG00000138448]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297530,CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(=O)O,MRWFZSLZNUJVQW-DEOSSOPVSA-N,Small molecule,False,SAROGLITAZAR,,3.0,,False,False,[],['Saroglitazar'],"[('drugbank', array(['DB13115'], dtype=object))]",,"{'rows': array(['HP_0001397', 'Orphanet_309005', 'EFO_0003095', 'EFO_1001486',
       'EFO_0001422', 'EFO_0001421', 'EFO_1001249', 'EFO_0003086'],
      dtype=object), 'count': 8}","[ENSG00000132170,ENSG00000186951]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL4297533,CC(=O)O.CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O,MAYUSRUHXFWITM-GBRHMYBBSA-N,Protein,False,BREMELANOTIDE ACETATE,2019.0,4.0,CHEMBL2070241,False,True,['Vyleesi (autoinjector)'],['Bremelanotide acetate' 'PT 141' 'PT-141' 'Vyleesi'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BREMELANOTIDE%20ACETATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000677', 'EFO_0004714'], dtype=object), 'count': 2}",[ENSG00000166603],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for mental or behavioural disorder and sexual dysfunction.
CHEMBL4298037,,,Antibody,False,RETIFANLIMAB,2023.0,4.0,,False,True,['Zynyz'],"['AEX-1188' 'AEX1188' 'INCMGA-00012' 'INCMGA-0012' 'INCMGA00012'
 'Incmga00012' 'MGA-012' 'MGA012' 'Mga012' 'Retifanlimab'
 'Retifanlimab-dlwr' 'Zynyz']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RETIFANLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000181', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000519',
       'EFO_0008528', 'MONDO_0005184', 'EFO_1001471', 'EFO_0005537',
       'EFO_0000756', 'EFO_0002618', 'MONDO_0008315', 'EFO_0000707',
       'MONDO_0007576', 'EFO_1000852', 'MONDO_0007254', 'EFO_0000691',
       'EFO_1001901', 'EFO_0006859', 'EFO_1001968', 'MONDO_0011962',
       'EFO_0000616'], dtype=object), 'count': 21}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 18 investigational indications.
CHEMBL507361,O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,SUDAHWBOROXANE-SECBINFHSA-N,Small molecule,False,MIRDAMETINIB,,2.0,,False,False,[],"['Mirdametinib' 'PD-0325901' 'Pd 0325901' 'Pd 03525901' 'Pd 901'
 'Pd-0325901']","[('PubChem', array(['144206915'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIRDAMETINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB07101'], dtype=object)), ('chEBI', array(['88249'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0018975', 'EFO_1001951',
       'EFO_0003060'], dtype=object), 'count': 5}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL919,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+],GQPXYJNXTAFDLT-UHFFFAOYSA-L,Small molecule,True,FOSPHENYTOIN SODIUM,1996.0,4.0,CHEMBL1201336,False,True,['Cerebyx' 'Fosphenytoin sodium' 'Pro-epanutin' 'Sesquient'],"['ACC-9653-010' 'ACC-9653-010 (SODIUM SALT)' 'CI 982' 'CI-982'
 'Fosphenytoin disodium salt' 'Fosphenytoin sodium']","[('DailyMed', array(['fosphenytoin%20sodium'], dtype=object)), ('Wikipedia', array(['Fosphenytoin'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996. This drug has a black box warning from the FDA.
CHEMBL1088752,Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1,KKYABQBFGDZVNQ-UHFFFAOYSA-N,Small molecule,False,LOSMAPIMOD,,3.0,,False,False,[],"['FTX-1821' 'FTX1821' 'GSK-AHAB' 'GSKAHAB' 'GW-856553X' 'GW856553'
 'GW856553X' 'Gw-856553' 'Gw856553' 'Losmapimod']","[('Wikipedia', array(['Losmapimod'], dtype=object)), ('drugbank', array(['DB12270'], dtype=object))]",,"{'rows': array(['EFO_0004236', 'Orphanet_269', 'EFO_0000319', 'MONDO_0100096',
       'EFO_0005762', 'EFO_0005672', 'EFO_0000685', 'EFO_0000341',
       'EFO_0003914', 'MONDO_0002009', 'Orphanet_309005'], dtype=object), 'count': 11}","[ENSG00000185386,ENSG00000112062]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL1200542,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,VPGRYOFKCNULNK-ACXQXYJUSA-N,Small molecule,False,DESOXYCORTICOSTERONE ACETATE,1939.0,4.0,,False,True,['Doca' 'Percorten'],"['11-deoxycorticosterone' '11-deoxycorticosterone acetate'
 '21-hydroxyprogesterone' 'Deoxycorticosterone'
 'Deoxycorticosterone acetate' 'Deoxycortone' 'Desoxycorticosterone'
 'Desoxycorticosterone acetate' 'Desoxycortone' 'Desoxycortone acetate'
 'NSC-11319' 'NSC-9567']","[('PubChem', array(['144204427', '170465334', '29215003', '56422097', '855662'],
      dtype=object)), ('drugbank', array(['DB06780'], dtype=object)), ('chEBI', array(['34671'], dtype=object))]",,,[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939.
CHEMBL1201057,CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)[O-].[Na+],QXPBTTUOVWMPJN-QBNHLFMHSA-M,Small molecule,False,CILASTATIN SODIUM,1985.0,4.0,CHEMBL766,False,True,[],['Cilastatin sodium' 'Cilastatin sodium salt' 'MK-791'],"[('DailyMed', array(['cilastatin%20sodium'], dtype=object)), ('PubChem', array(['144206357', '49732002'], dtype=object)), ('chEBI', array(['59511'], dtype=object))]",,"{'rows': array(['HP_0100806', 'EFO_0000544', 'EFO_0003103', 'EFO_0003106',
       'EFO_0000465'], dtype=object), 'count': 5}",[ENSG00000015413],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved indications.
CHEMBL1742997,,,Antibody drug conjugate,False,CANTUZUMAB MERTANSINE,,2.0,,False,False,[],['Cantuzumab mertansine' 'HUC-242-DM1' 'HUC242-DM1' 'SB-408075'],,,,"[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000185499]",Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2103862,O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1,BGBVSGSIXIIREO-UHFFFAOYSA-N,Small molecule,False,BAVISANT,,2.0,,False,False,[],['Bavisant' 'JNJ-31001074'],"[('drugbank', array(['DB12299'], dtype=object))]",['CHEMBL3577957' 'CHEMBL2105715'],"{'rows': array(['EFO_0003888', 'MONDO_0007079'], dtype=object), 'count': 2}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109137,,,Protein,False,MOROCTOCOG ALFA,1999.0,4.0,,False,True,['Refacto af'],['Moroctocog alfa' 'Refacto' 'Refacto-af' 'Xyntha'],"[('DrugCentral', array(['5166'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/refacto-af'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Protein drug with a maximum clinical trial phase of IV that was first approved in 1999 and is indicated for hemophilia a.
CHEMBL2109634,,,Antibody,False,ONCOLYSIN S,,2.0,,False,False,[],['ONCOLYSIN S'],,,,[ENSG00000149294],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2111083,CN(C)C(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2,OANCEOSLKSTLTA-REWPJTCUSA-N,Small molecule,False,BEDORADRINE,,2.0,,False,False,[],['Bedoradrine'],"[('drugbank', array(['DB05590'], dtype=object))]",['CHEMBL2218893'],"{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0008590'], dtype=object), 'count': 3}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL21731,CNCCCC12CCC(c3ccccc31)c1ccccc12,QSLMDECMDJKHMQ-UHFFFAOYSA-N,Small molecule,True,MAPROTILINE,1980.0,4.0,,False,True,[],"['BA-34,276 FREE BASE' 'BA-34,276 [AS HYDROCHLORIDE]' 'BA-34276 FREE BASE'
 'Maprotiline']","[('PubChem', array(['104171192', '11111502', '11112599', '11113802', '124880790',
       '124880792', '144203751', '170464778', '26751977', '50085871',
       '50104649', '90341780'], dtype=object)), ('Wikipedia', array(['Maprotiline'], dtype=object)), ('drugbank', array(['DB00934'], dtype=object)), ('chEBI', array(['6690'], dtype=object))]",['CHEMBL1237135'],"{'rows': array(['EFO_0005230', 'MONDO_0002009', 'HP_0000726', 'MONDO_0002009',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0003833', 'EFO_0000519'],
      dtype=object), 'count': 8}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for major depressive disorder and depressive disorder and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL259571,CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O,ZISJNXNHJRQYJO-CMDGGOBGSA-N,Small molecule,False,TAPINAROF,2022.0,4.0,,False,True,['Vtama'],"['Benvitimod' 'GSK-2894512' 'GSK2894512' 'Tapinarof' 'Vtama' 'WBI-1001'
 'Wbi-1001']","[('drugbank', array(['DB06083'], dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_0000274'], dtype=object), 'count': 2}",[ENSG00000106546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 1 investigational indication.
CHEMBL301829,O=C(O)c1ccc(C(F)(F)F)cc1-c1ccc2c(c1)OC[C@H](Cc1ccccc1)[C@H]2O,NZQDWKCNBOELAI-KSFYIVLOSA-N,Small molecule,False,CP-195543,,2.0,,False,False,[],"['CP-195,543' 'Cp-195,543' 'Cp-195543']","[('drugbank', array(['DB13053'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}","[ENSG00000213906,ENSG00000213903]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3334824,CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(c2ccc(Cl)cc2)C(C)(C)C1,GTDPZONCGOCXOD-JPYJTQIMSA-N,Small molecule,False,BMS-817399,,2.0,,False,False,[],['BMS-817399' 'Bms-817399'],"[('drugbank', array(['DB14941'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000163823],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545413,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1,BJCJYEYYYGBROF-UHFFFAOYSA-N,Small molecule,False,FLUMATINIB,,3.0,,False,False,[],['Flumatinib' 'Flumbatinib' 'HH-GV678' 'Hhgv-678'],"[('drugbank', array(['DB11904'], dtype=object))]",['CHEMBL3901539'],"{'rows': array(['EFO_0000220', 'EFO_0000339'], dtype=object), 'count': 2}",[ENSG00000097007],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3989909,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1.O=P(O)(O)O,XXEDEGOAYSGNPS-ZOWNYOTGSA-N,Small molecule,False,LENIOLISIB PHOSPHATE,2023.0,4.0,CHEMBL3643413,False,True,['Joenja'],"['CDZ-173' 'CDZ-173-AZ' 'CDZ173' 'CDZ173-AZ' 'Cdz173' 'Joenja'
 'Leniolisib monophosphate' 'Leniolisib phosphate']",,,"{'rows': array(['MONDO_0015517', 'EFO_0000699', 'MONDO_0003778'], dtype=object), 'count': 3}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for inborn error of immunity and has 2 investigational indications.
CHEMBL3989910,O=C(O)c1ccc(-c2ccc3cc(O)ccc3n2)c(Cl)c1,BXSZILNGNMDGSL-UHFFFAOYSA-N,Small molecule,False,CAVOSONSTAT,,2.0,,False,False,[],['Cavosonstat' 'N-91115' 'N91115'],"[('drugbank', array(['DB14775'], dtype=object))]",,"{'rows': array(['MONDO_0009061', 'MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 3}",[ENSG00000197894],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL412262,CN/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1,AXJQVVLKUYCICH-OAQYLSRUSA-N,Small molecule,False,IBIPINABANT,,2.0,,False,False,[],['BMS-646256' 'Ibipinabant' 'SLV-319' 'Slv319'],"[('drugbank', array(['DB12649'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 2}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297244,,,Oligonucleotide,False,DANVATIRSEN SODIUM,,-1.0,,False,False,[],['AZD9150 sodium' 'Danvatirsen pentadecasodium' 'Danvatirsen sodium'],,,,[ENSG00000168610],Oligonucleotide drug.
CHEMBL4444976,COc1cc(N2CCN(C(=O)Cn3nc(-c4ncc[nH]4)c4cccnc43)CC2)ccc1Cl,ZIMLRKWQDLVPEK-UHFFFAOYSA-N,Small molecule,False,CCX354,,2.0,,False,False,[],['CCX354' 'CCX354-C' 'Ccx-354' 'Ccx354' 'GSK-2941266' 'GSK2941266'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000163823],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650485,COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1,FWZAWAUZXYCBKZ-NSHDSACASA-N,Small molecule,False,PIRTOBRUTINIB,2023.0,4.0,,False,True,['Jaypirca'],"['Jaypirca' 'LOXO-305' 'LY-3527727' 'LY3527727' 'Loxo-305' 'Pirtobrutinib'
 'RXC-005']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PIRTOBRUTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001469', 'EFO_0000616', 'EFO_0000095', 'EFO_0000565',
       'EFO_0009441'], dtype=object), 'count': 5}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for mantle cell lymphoma and has 4 investigational indications.
CHEMBL567,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,RGCVKNLCSQQDEP-UHFFFAOYSA-N,Small molecule,True,PERPHENAZINE,1957.0,4.0,,False,True,"['Chlorpiprazine' 'Decentan' 'Fentazin' 'Perphenazine'
 'Perphenazine Fendizoate' 'Trilafon' 'Trilafon-La']","['Etaperazine' 'NSC-150866' 'Perphenazine' 'Perphenazine fendizoate'
 'Perphenazine maleate']","[('DailyMed', array(['perphenazine'], dtype=object)), ('PubChem', array(['11111645', '11111646', '124881147', '144203784', '170464834',
       '26747080', '26747081', '50100322', '50104233', '50104234',
       '56422427', '57287811', '85231190', '856006', '90340948'],
      dtype=object)), ('Wikipedia', array(['Perphenazine'], dtype=object)), ('drugbank', array(['DB00850'], dtype=object)), ('chEBI', array(['8028'], dtype=object))]",,"{'rows': array(['HP_0002017', 'HP_0000713', 'EFO_0005230', 'MONDO_0005090',
       'EFO_0002610', 'MONDO_0002050', 'HP_0002140', 'HP_0000726',
       'EFO_0005407'], dtype=object), 'count': 9}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL570,CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21,XSCGXQMFQXDFCW-UHFFFAOYSA-N,Small molecule,False,TRIFLUPROMAZINE,1957.0,4.0,,False,True,['Fluopromazine' 'Nivoman' 'Vesprin' 'Vetame'],['Fluopromazine' 'Triflupromazine'],"[('PubChem', array(['11111873', '11111874', '124881619', '50100355', '50104262',
       '90341005'], dtype=object)), ('Wikipedia', array(['Triflupromazine'], dtype=object)), ('drugbank', array(['DB00508'], dtype=object)), ('chEBI', array(['9711'], dtype=object))]",['CHEMBL1201102'],"{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for psychosis.
CHEMBL1201460,,,Oligosaccharide,True,DALTEPARIN SODIUM,1994.0,4.0,,False,True,['Fragmin' 'Low liquemine'],"['.alpha.-heparin' 'B01AB04' 'Boxol' 'Dalteparin' 'Dalteparin sodium'
 'FR-860' 'Fragmine' 'HEPARIN FRAGMENT KABI 2165' 'KABI-2165'
 'Low-liquemine']","[('DailyMed', array(['dalteparin%20sodium'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_0002618', 'EFO_0001378', 'HP_0001907',
       'EFO_1000954', 'MONDO_0043510', 'EFO_0004286', 'HP_0004419',
       'MONDO_0011382', 'MONDO_0008903', 'EFO_0000681', 'MONDO_0007254',
       'EFO_1001951', 'MONDO_0008315', 'HP_0004936', 'MONDO_0008170',
       'EFO_0009315', 'EFO_0002950', 'EFO_1000158', 'MONDO_0019514',
       'EFO_0003884', 'MONDO_0100096', 'EFO_0006834', 'EFO_1001459',
       'EFO_0003907'], dtype=object), 'count': 25}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201609,,,Protein,False,CORTICOTROPIN ZINC HYDROXIDE,1955.0,4.0,,False,True,['Cortrophin-zinc'],"['Corticotrophin zinc hydroxide' 'Corticotropin zinc hydroxide'
 'Corticotropin-zinc hydroxide']",,,,[ENSG00000185231],Protein drug with a maximum clinical trial phase of IV that was first approved in 1955.
CHEMBL1201692,,,Protein,False,FOLLITROPIN ALFA,2014.0,4.0,,False,True,['Bemfola' 'Gonal-f' 'Gonal-f rff' 'Gonal-f rff redi-ject' 'Ovaleap'],"['Follitropin .alpha.' 'Follitropin alfa' 'Follitropin alpha' 'Gonal f'
 'Human FSH']","[('DrugCentral', array(['4928'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bemfola'],
      dtype=object))]",,"{'rows': array(['MONDO_0002775'], dtype=object), 'count': 1}",[ENSG00000170820],Protein drug with a maximum clinical trial phase of IV that was first approved in 2014 and is indicated for anovulation.
CHEMBL1201749,CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,WYQPLTPSGFELIB-JTQPXKBDSA-N,Small molecule,False,DIFLUPREDNATE,2008.0,4.0,,False,True,['Durezol'],['Difluprednate' 'W 6309' 'W-6309'],"[('DailyMed', array(['difluprednate'], dtype=object)), ('PubChem', array(['144206181', '56422387', '856020'], dtype=object)), ('Wikipedia', array(['Difluprednate'], dtype=object)), ('drugbank', array(['DB06781'], dtype=object)), ('chEBI', array(['31485'], dtype=object))]",,"{'rows': array(['EFO_1000811', 'EFO_1000906', 'EFO_1001231', 'EFO_1001082',
       'MP_0001845', 'MONDO_0005129'], dtype=object), 'count': 6}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for anterior uveitis and inflammation and has 4 investigational indications.
CHEMBL1215661,N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12,AQRLDDAFYYAIJP-UHFFFAOYSA-N,Small molecule,False,PRUVANSERIN,,2.0,,False,False,[],"['EMD 390920' 'EMD-281014' 'EMD-390920' 'EMD390920' 'LSN-2422347'
 'LSN2422347' 'LY-2420586' 'LY-2422347' 'LY-2422347 FREE BASE' 'LY2420586'
 'LY2422347' 'Ly2422347' 'Pruvanserin']","[('Wikipedia', array(['Pruvanserin'], dtype=object)), ('drugbank', array(['DB13094'], dtype=object))]",['CHEMBL2104980'],"{'rows': array(['EFO_0008568'], dtype=object), 'count': 1}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1255582,CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1,KXSUAWAUCNFBQJ-UHFFFAOYSA-N,Small molecule,False,FIPAMEZOLE,,2.0,,False,False,[],['Fipamezole'],"[('drugbank', array(['DB06585'], dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1257,FC(F)OC(F)(F)C(F)Cl,JPGQOUSTVILISH-UHFFFAOYSA-N,Small molecule,False,ENFLURANE,1972.0,4.0,,False,True,['Enflurane' 'Ethrane'],"['ANESTHETIC COMPOUND NO. 347' 'Alyrane' 'Anesthetic Compound No. 347'
 'Compound 347' 'Efrane' 'Enflurane' 'Methylflurether' 'NSC-115944'
 'Ohio 347' 'R-E-235CA2']","[('PubChem', array(['144207364', '50112675'], dtype=object)), ('Wikipedia', array(['Enflurane'], dtype=object)), ('drugbank', array(['DB00228'], dtype=object)), ('chEBI', array(['4792'], dtype=object))]",,,"[ENSG00000186795,ENSG00000100433,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000082482,ENSG00000145888,ENSG00000109738,ENSG00000169427,ENSG00000171303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972.
CHEMBL1484,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,ZBBHBTPTTSWHBA-UHFFFAOYSA-N,Small molecule,False,NICARDIPINE,1988.0,4.0,,False,True,[],['Nicardipine' 'Nicardipine (stn)' 'Perpidine'],"[('PubChem', array(['104171201', '124880905', '144203762', '170465173', '26755701',
       '26755702', '50111158', '50111159', '90340664'], dtype=object)), ('Wikipedia', array(['Nicardipine'], dtype=object)), ('drugbank', array(['DB00622'], dtype=object)), ('chEBI', array(['7550'], dtype=object))]",['CHEMBL1200326'],"{'rows': array(['EFO_1000994', 'EFO_0000713', 'EFO_0000319', 'EFO_0009846',
       'EFO_0001645', 'EFO_0000668', 'EFO_0005669', 'EFO_0003833',
       'EFO_0000319', 'EFO_0000712', 'EFO_0000537', 'EFO_0000537',
       'EFO_0004282', 'EFO_0003843'], dtype=object), 'count': 14}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for cardiovascular disease and hypertension and has 12 investigational indications.
CHEMBL1504,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,YNDXUCZADRHECN-JNQJZLCISA-N,Small molecule,False,TRIAMCINOLONE ACETONIDE,1960.0,4.0,,False,True,"['Adcortyl' 'Adcortyl in orabase' 'Allernaze' 'Aristocort' 'Aristocort a'
 'Aristogel' 'Audicort' 'Aureocort' 'Azmacort' 'Flutex' 'Gppe ear dps cap'
 'Gppe ear oint' 'Kenacort' 'Kenalog' 'Kenalog in orabase' 'Kenalog-10'
 'Kenalog-40' 'Kenalog-80' 'Kenalog-h' 'Nasacort'
 'Nasacort allergy 24 hour' 'Nasacort aq' 'Nasacort hfa' 'Nystadermal'
 'Oracort' 'Oralone' 'Pevaryl t.c.' 'Remiderm' 'Remotic' 'Silderm'
 'Tri-Nasal' 'Tri-adcortyl' 'Triacet' 'Triacort' 'Triamcinolone acetonide'
 'Triamcinolone acetonide in absorbase' 'Triatex' 'Triderm' 'Triesence'
 'Trivaris' 'Trymex' 'Vetalog' 'Xipere' 'Zilretta']","['FX-006' 'FX006' 'Kenacourt' 'NSC-21916' 'Triamcinolone Acetonide'
 'Triamcinolone acetonide']","[('DailyMed', array(['triamcinolone%20acetonide'], dtype=object)), ('PubChem', array(['144204436', '144208993', '144213331', '170464660', '29215012',
       '56423119', '855857'], dtype=object)), ('Wikipedia', array(['Triamcinolone_acetonide'], dtype=object)), ('chEBI', array(['71418'], dtype=object))]",,"{'rows': array(['EFO_0004719', 'EFO_0003943', 'EFO_0003956', 'EFO_1000809',
       'EFO_0007363', 'EFO_0000497', 'MONDO_0004037', 'EFO_1001898',
       'EFO_1001494', 'EFO_0004229', 'MONDO_0002406', 'EFO_1000706',
       'MONDO_0002041', 'EFO_0003843', 'EFO_0009606', 'EFO_1001896',
       'EFO_0004208', 'EFO_1000680', 'MONDO_0005129', 'EFO_0010822',
       'EFO_1000941', 'EFO_1001250', 'EFO_1001222', 'MONDO_0007935',
       'EFO_0000685', 'EFO_0004683', 'EFO_1001157', 'MONDO_0004979',
       'EFO_0004616', 'EFO_0000701', 'HP_0001742', 'EFO_0008521',
       'EFO_1001231', 'HP_0030834', 'EFO_0004212', 'EFO_1000726',
       'EFO_1001129', 'MONDO_0003005', 'EFO_1001887', 'EFO_0008507',
       'EFO_0003770', 'MONDO_0018092', 'MONDO_0005041', 'HP_0012735',
       'EFO_1000786', 'MONDO_0002471', 'MONDO_0005301', 'MONDO_0002959',
       'EFO_0004238', 'EFO_1001435', 'EFO_0001365', 'EFO_0009485',
       'EFO_0007415', 'EFO_0008517', 'MONDO_0007254', 'MONDO_0002280',
       'MONDO_0004857', 'EFO_0004274', 'MONDO_0005178', 'EFO_0004192',
       'HP_0009588', 'EFO_1000049', 'EFO_0000274', 'EFO_0000546',
       'EFO_0005854', 'EFO_1001224'], dtype=object), 'count': 66}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 21 approved and 45 investigational indications.
CHEMBL150894,CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCO)Cc1ccccc1-4)C(=O)NC3,MLIFNJABMANKEU-UHFFFAOYSA-N,Small molecule,False,CEP-5214,,1.0,,False,False,[],['CEP-5214' 'CEP5214' 'Cep-5214'],,,,"[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1643895,Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21,NTHPAPBPFQJABD-LLVKDONJSA-N,Small molecule,False,RAMOSETRON,,3.0,,False,False,[],['Ramosetron'],"[('PubChem', array(['50112691'], dtype=object)), ('Wikipedia', array(['Ramosetron'], dtype=object)), ('drugbank', array(['DB09290'], dtype=object))]",['CHEMBL3181841'],"{'rows': array(['EFO_0004888', 'MONDO_0004992', 'HP_0002018', 'EFO_0006912',
       'MONDO_0001056', 'EFO_0000555', 'HP_0002013'], dtype=object), 'count': 7}","[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL1659,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,DBAKFASWICGISY-BTJKTKAUSA-N,Small molecule,False,CHLORPHENIRAMINE MALEATE,1950.0,4.0,CHEMBL505,False,True,"['Allercalm allergy relief' 'Allerief' 'Alunex' 'Antagonate' 'Calimal'
 'Chlor-trimeton' 'Chlorphenamine' 'Chlorpheniramine maleate'
 'Efidac 24 chlorpheniramine maleate' 'Hayleve' 'Kloromin' 'Phenetron'
 'Piriject' 'Piriton' 'Piriton allergy' 'Pyridamal 100'
 'Rhino-syrup allergy' 'Rimarin' 'Teldrin']","['(+)-Chlorpheniramine Maleate' 'Chlorphenamine hydrogen maleate'
 'Chlorphenamine maleate' 'Chlorphenamini hydrogenomaleas'
 'Chlorpheniramine Maleate' 'Chlorpheniramine maleate'
 'Chlorprophenpyridamine maleate' 'Efidac' 'Histaspan' 'NSC-756684'
 'Neorestamin' 'Pyridamal' 'Synistamin']","[('DailyMed', array(['chlorpheniramine%20maleate'], dtype=object)), ('PubChem', array(['144209290', '144213766', '17389966', '26719778', '50106014',
       '50106015', '56422503'], dtype=object)), ('chEBI', array(['3645'], dtype=object))]",,"{'rows': array(['HP_0012735', 'HP_0002315', 'EFO_0007214', 'HP_0001742',
       'HP_0001945', 'EFO_0003956', 'MONDO_0002258', 'EFO_0005854',
       'HP_0003418', 'EFO_0003958', 'MONDO_0005271', 'EFO_0007486',
       'EFO_0003843'], dtype=object), 'count': 13}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 12 approved and 1 investigational indication.
CHEMBL1829433,Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1,SMFXSYMLJDHGIE-UHFFFAOYSA-N,Small molecule,False,AZD-4877,,2.0,,False,False,[],['AZD-4877' 'AZD4877' 'Azd 4877' 'Azd-4877'],"[('drugbank', array(['DB11671'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_0005952', 'EFO_0000616', 'EFO_0000574',
       'EFO_0000313'], dtype=object), 'count': 5}",[ENSG00000138160],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL193482,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O,PROQIPRRNZUXQM-ZXXIGWHRSA-N,Small molecule,False,ESTRIOL,2000.0,4.0,,False,True,['Gynest' 'Incurin' 'Ortho-gynest' 'Ovestin'],"['16.ALPHA.-HYDROXYESTRADIOL' '16.alpha.,17.beta.-estriol' 'Aacifemine'
 'Colpogyn' 'Estriol' 'Estriol acetate benzoate' 'Estriol propionate'
 'Estriol succinate' 'Incurin' 'NSC-12169' 'Oestriol' 'Trihydroxyestrin']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/incurin'],
      dtype=object)), ('PubChem', array(['11532998', '144205873', '144211921', '170465807'], dtype=object)), ('Wikipedia', array(['Estriol'], dtype=object)), ('drugbank', array(['DB04573'], dtype=object)), ('chEBI', array(['27974'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'EFO_0002950', 'GO_0042697', 'EFO_0008520',
       'EFO_1001271', 'EFO_0008522'], dtype=object), 'count': 6}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 investigational indications.
CHEMBL1976040,C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1,BKWJAKQVGHWELA-UHFFFAOYSA-N,Small molecule,False,ADAVOSERTIB,,2.0,,False,False,[],"['AZD 1775' 'AZD-1775' 'AZD1775' 'Adavosertib' 'Azd-1775' 'MK-1775'
 'MK1775']","[('PubChem', array(['103905025', '137276027'], dtype=object)), ('drugbank', array(['DB11740'], dtype=object))]",,"{'rows': array(['EFO_0000181', 'EFO_0003060', 'EFO_0001075', 'MONDO_0007254',
       'EFO_0000702', 'MONDO_0001187', 'EFO_1000131', 'MONDO_0044704',
       'EFO_1000043', 'EFO_0000349', 'EFO_0002939', 'MONDO_0002715',
       'EFO_0000616', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0006352',
       'EFO_0000503', 'EFO_0005537', 'EFO_1001960', 'EFO_0000519',
       'MONDO_0008903', 'EFO_0001378', 'EFO_1000251', 'EFO_0002618',
       'EFO_0000466', 'MONDO_0008315', 'EFO_0000707', 'MONDO_0002087',
       'MONDO_0008170'], dtype=object), 'count': 29}",[ENSG00000166483],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 29 investigational indications.
CHEMBL201960,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1,SWUVZKWCOBGPTH-UHFFFAOYSA-N,Small molecule,False,PYROVALERONE,,4.0,,True,True,[],['J8.659B' 'Pyrovalerone'],"[('Wikipedia', array(['Pyrovalerone'], dtype=object))]",['CHEMBL2104793'],,"[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL2028852,CC(=O)O.N=C(N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C[C@@H]2CCCC[C@@H]21,HKMZRZUEADSZDQ-DZJWSCHMSA-N,Protein,False,ICATIBANT ACETATE,2008.0,4.0,CHEMBL2028850,False,True,['Firazyr'],['HOE 140' 'HOE-140' 'Icatibant acetate'],"[('DailyMed', array(['icatibant%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr'],
      dtype=object))]",,"{'rows': array(['MONDO_0100096', 'MONDO_0019623', 'MP_0001845', 'EFO_0005532'],
      dtype=object), 'count': 4}",[ENSG00000168398],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for hereditary angioedema and angioedema and has 2 investigational indications.
CHEMBL2103852,COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC,JXONINOYTKKXQQ-CQSZACIVSA-N,Small molecule,False,CROLIBULIN,,2.0,,False,False,[],['Crolibulin' 'EPC 2407' 'EPC-2407' 'EPC2407'],"[('drugbank', array(['DB12925'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'MONDO_0002108'], dtype=object), 'count': 2}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2105692,CC(C)OC(=O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1,NVPXUFQLKWKBHK-UHFFFAOYSA-N,Small molecule,False,TAPRENEPAG ISOPROPYL,,2.0,,False,False,[],['PF-04217329' 'Taprenepag isopropyl'],,,,[ENSG00000125384],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108222,,,Unknown,False,ALOXIPRIN,,4.0,,False,True,['Palaprin fte'],"['Alaprin' 'Aloxiprin' 'Paloxin' 'Polyoxyaluminium acetylsalicylate'
 'Polyoxyaluminum acetylsalicylate' 'Superpyrin']","[('DrugCentral', array(['4760'], dtype=object))]",,"{'rows': array(['HP_0001945', 'HP_0004419', 'EFO_0003843'], dtype=object), 'count': 3}","[ENSG00000073756,ENSG00000095303]",Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved indications.
CHEMBL2108767,,,Antibody,False,RUPLIZUMAB,,3.0,,False,False,['Antova'],['BG-9588' 'BG9588' 'HU-5C8' 'Ruplizumab' 'hu5c8'],,,"{'rows': array(['EFO_0005761'], dtype=object), 'count': 1}",[ENSG00000102245],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109435,,,Antibody,False,HUA33,,1.0,,False,False,[],['HUA33' 'Hua33'],,,"{'rows': array(['EFO_1001951', 'EFO_0004142'], dtype=object), 'count': 2}",[ENSG00000143167],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2110756,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC,BELMMAAWNYFCGF-PZXAHSFZSA-N,Small molecule,False,MITEMCINAL,,2.0,,False,False,[],['Mitemcinal'],"[('drugbank', array(['DB06587'], dtype=object))]",['CHEMBL2105890'],"{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}",[ENSG00000102539],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2165191,Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1,IRTDIKMSKMREGO-OAHLLOKOSA-N,Small molecule,False,AZD-6482,,2.0,,False,False,[],['AZD-6482' 'AZD6482' 'Azd 6482' 'Azd-6482'],"[('drugbank', array(['DB14980'], dtype=object))]",,"{'rows': array(['HP_0002140'], dtype=object), 'count': 1}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2397751,CCOC(=O)c1c(C)cc2nc(COC(=O)NCCO)n(-c3ccccc3S(=O)(=O)NC)c(=O)c2c1C,PMBUDILHPXTDNY-UHFFFAOYSA-N,Small molecule,False,SAD448,,1.0,,False,False,[],['Sad448'],,,"{'rows': array(['EFO_1001069'], dtype=object), 'count': 1}","[ENSG00000118432,ENSG00000188822]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3286830,C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,IIXWYSCJSQVBQM-LLVKDONJSA-N,Small molecule,False,LORLATINIB,2018.0,4.0,,False,True,['Lorbrena' 'Lorviqua'],['Lorlatinib' 'PF-06463922'],"[('DailyMed', array(['lorlatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua'],
      dtype=object)), ('drugbank', array(['DB12130'], dtype=object))]",['CHEMBL4539157'],"{'rows': array(['EFO_0000621', 'EFO_0003032', 'EFO_0003060', 'EFO_0003086',
       'EFO_0001421', 'EFO_0000502', 'EFO_0000574', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 9}","[ENSG00000171094,ENSG00000143924]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 5 investigational indications.
CHEMBL3301587,,,Antibody,False,DURVALUMAB,2017.0,4.0,,False,True,['Imfinzi'],['Durvalumab' 'MEDI-4736' 'MEDI4736'],"[('DailyMed', array(['durvalumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0001071', 'EFO_0000403', 'EFO_0000514',
       'MONDO_0008315', 'MONDO_0021117', 'EFO_0000198', 'EFO_0000181',
       'EFO_0000501', 'MONDO_0007254', 'EFO_0000588', 'EFO_0003869',
       'EFO_0000503', 'EFO_0003897', 'MONDO_0004986', 'EFO_0005537',
       'EFO_0000702', 'EFO_0000228', 'EFO_0000640', 'MONDO_0008903',
       'EFO_0002618', 'MONDO_0018906', 'EFO_0003060', 'EFO_0000707',
       'EFO_0001378', 'EFO_0000681', 'EFO_0001075', 'EFO_0000708',
       'EFO_0001642', 'EFO_0000313', 'EFO_0002430', 'EFO_0000691',
       'EFO_0003868', 'EFO_0005922', 'EFO_1000984', 'EFO_0009709',
       'EFO_1001931', 'MONDO_0005184', 'EFO_0000294', 'MONDO_0002974',
       'EFO_0003968', 'EFO_0000365', 'EFO_0000770', 'MONDO_0001056',
       'MONDO_0003001', 'EFO_0002913', 'EFO_0000222', 'EFO_0003863',
       'EFO_0000673', 'EFO_0000199', 'MONDO_0002898', 'MONDO_0003199',
       'EFO_0004230', 'EFO_0000182', 'EFO_0000519', 'EFO_1000251',
       'MONDO_0008170', 'EFO_1001961', 'EFO_1001951', 'EFO_0005221',
       'MONDO_0044903', 'EFO_0003891', 'EFO_0006859', 'MONDO_0021148',
       'EFO_0000571', 'MONDO_0021063', 'EFO_0000641', 'MONDO_0003059',
       'MONDO_0044704', 'EFO_0000095', 'EFO_0004284', 'MONDO_0005575',
       'EFO_0000348', 'MONDO_0011962', 'EFO_0002429', 'EFO_0008528',
       'EFO_1000657', 'MONDO_0003060', 'MONDO_0007576', 'EFO_0003050',
       'EFO_0005952', 'EFO_0000756', 'EFO_0000305', 'EFO_0000349',
       'MONDO_0004992', 'MONDO_0001187', 'EFO_0006738', 'EFO_0005220',
       'MONDO_0003002', 'EFO_0000574', 'MONDO_0002108', 'EFO_1001968'],
      dtype=object), 'count': 92}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 11 approved and 81 investigational indications.
CHEMBL3545039,Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O,DXDVSYALLVVBOV-UHFFFAOYSA-N,Small molecule,False,AZD1386,,2.0,,False,False,[],['AZD1386' 'Azd 1386' 'Azd-1386' 'Azd1386'],,,"{'rows': array(['EFO_0003843', 'HP_0012532', 'EFO_0005762'], dtype=object), 'count': 3}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3833386,,,Cell,False,GALINPEPIMUT-S,,3.0,,False,False,[],['Galinpepimut-s' 'SLS-001'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000184937],Cell drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4594568,,,Unknown,False,KN-026,,3.0,,False,False,[],"['Anbenitamab' 'Anti-her2 bsab kn026' 'KN-026' 'KN026' 'Kn 026' 'Kn-026'
 'Kn026']",,,"{'rows': array(['MONDO_0001056', 'MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000141736],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4650338,CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1,DNPOFZXZJJDQLB-MRXNPFEDSA-N,Small molecule,False,EDRALBRUTINIB,,2.0,,False,False,[],"['Edralbrutinib' 'SHR-1459' 'SHR1459' 'Shr1459' 'TG-1701' 'TG1701'
 'Tg 1701' 'Tg-1701']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EDRALBRUTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000096', 'EFO_0004256', 'EFO_0004289', 'EFO_0003086',
       'EFO_0000616', 'EFO_0000095', 'EFO_0005809'], dtype=object), 'count': 7}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4802198,,,Antibody,False,QUISOVALIMAB,,2.0,,False,False,[],"['AEVI-002' 'AEVI002' 'AVTX-002' 'AVTX002' 'Avtx-002' 'CERC-002' 'CERC002'
 'Cerc 002' 'Cerc-002' 'F-19' 'KHK-252067' 'MDGN-002' 'MDGN002' 'Mdgn-002'
 'Quisovalimab' 'SAR-252067' 'SAR252067']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/QUISOVALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1000637', 'EFO_0000384', 'MONDO_0004979', 'MONDO_0100096',
       'EFO_0000729'], dtype=object), 'count': 5}",[ENSG00000125735],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL485629,O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,JJWKQXNHYDJXKF-UHFFFAOYSA-N,Small molecule,False,MK-0873,,2.0,,False,False,[],['MK-0873' 'MK0873' 'Mk-0873'],"[('drugbank', array(['DB13029'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_0000676', 'EFO_0000341'], dtype=object), 'count': 3}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL70,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,BQJCRHHNABKAKU-KBQPJGBKSA-N,Small molecule,True,MORPHINE,1984.0,4.0,,False,True,[],"['Anhydrous morphine' 'Avinza' 'Depodur'
 'Hydromorphone hydrochloride impurity, morphine-' 'IDS-NM-009'
 'Infumorph' 'Kadian' 'Morphia' 'Morphine' 'Morphine (anhydrous)'
 'Morphine anhydrous' 'Morphine extended release' 'Morphine polistirex'
 'Morphium' 'N02AA01' 'Nepenthe' 'Ospalivina']","[('Wikipedia', array(['Morphine'], dtype=object)), ('drugbank', array(['DB00295'], dtype=object)), ('chEBI', array(['17303'], dtype=object))]",['CHEMBL2096625' 'CHEMBL4068407' 'CHEMBL2103744' 'CHEMBL556578'],"{'rows': array(['EFO_0801084', 'HP_0012532', 'EFO_0000768', 'EFO_0009688',
       'HP_0011110', 'HP_0003418', 'EFO_0000616', 'EFO_0000768',
       'EFO_0004240', 'EFO_0005611', 'EFO_0003890', 'EFO_0003931',
       'EFO_0000341', 'EFO_0005323', 'EFO_0004270', 'EFO_0003918',
       'EFO_0010702', 'EFO_0009513', 'EFO_0000222', 'HP_0000989',
       'HP_0002019', 'EFO_0020911', 'HP_0000989', 'EFO_1001412',
       'EFO_0009842', 'EFO_0003843', 'EFO_0003917', 'EFO_0003918',
       'EFO_0005611', 'MONDO_0004992', 'EFO_0009727', 'MONDO_0011382',
       'EFO_0008583', 'EFO_1001250', 'HP_0012532', 'EFO_0005799',
       'EFO_0003843', 'EFO_0004273', 'EFO_0000546', 'EFO_0002950',
       'EFO_0801084', 'EFO_0000612', 'EFO_0009492', 'EFO_0009314',
       'MONDO_0004992', 'EFO_0004253', 'EFO_0004616', 'EFO_0003843',
       'HP_0001822', 'HP_0003419', 'EFO_0010702', 'EFO_0005799',
       'EFO_0000341', 'MP_0001914', 'EFO_0009620', 'EFO_0005762',
       'MONDO_0008315', 'EFO_0001073', 'EFO_0005755', 'MONDO_0011382',
       'EFO_0001361', 'EFO_1001898', 'EFO_0005611'], dtype=object), 'count': 63}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 5 approved and 50 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1076903,c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,JQSHBVHOMNKWFT-DTORHVGOSA-N,Small molecule,False,VARENICLINE,2006.0,4.0,,False,True,[],"['CP-526,555' 'CP-526555' 'Varenicline']","[('Wikipedia', array(['Varenicline'], dtype=object)), ('chEBI', array(['84500'], dtype=object))]",['CHEMBL5303393' 'CHEMBL5316216'],"{'rows': array(['MONDO_0007079', 'EFO_0002610', 'EFO_0004319', 'MONDO_0008903',
       'EFO_0005672', 'MONDO_0002491', 'Orphanet_98757', 'EFO_1000906',
       'EFO_0004329', 'EFO_0007191', 'MONDO_0004992', 'EFO_0003768',
       'MONDO_0007079', 'EFO_0001071', 'MONDO_0100339', 'EFO_0003890',
       'EFO_0004319', 'EFO_0004701', 'EFO_0003966', 'EFO_0003768',
       'MONDO_0005180', 'MONDO_0005090', 'EFO_0005411', 'EFO_1000906',
       'MONDO_0004975'], dtype=object), 'count': 25}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for nicotine dependence and eye disease and has 21 investigational indications.
CHEMBL1200501,CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,IKDXDQDKCZPQSZ-JHYYTBFNSA-N,Protein,False,GOSERELIN ACETATE,1989.0,4.0,CHEMBL1201247,False,True,['Novgos' 'Zoladex' 'Zoladex la'],['Fertilan' 'Goserelin Acetate' 'Goserelin acetate'],"[('DailyMed', array(['goserelin%20acetate'], dtype=object))]",,"{'rows': array(['EFO_0006861', 'EFO_0000305', 'MONDO_0002087', 'MONDO_0008315',
       'GO_0042697', 'EFO_0001663', 'MONDO_0007254', 'MONDO_0008170',
       'EFO_0000313', 'MONDO_0002158', 'EFO_0000673', 'EFO_0000545',
       'MONDO_0000521', 'EFO_0000195'], dtype=object), 'count': 14}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 11 investigational indications.
CHEMBL1201284,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,VDHAWDNDOKGFTD-MRXNPFEDSA-N,Small molecule,False,CINACALCET,2004.0,4.0,,False,True,[],['AMG 073' 'AMG-073' 'AMG073' 'Cinacalcet' 'KRN-1493' 'KRN1493'],"[('PubChem', array(['124893630', '50125742'], dtype=object)), ('Wikipedia', array(['Cinacalcet'], dtype=object)), ('drugbank', array(['DB01012'], dtype=object)), ('chEBI', array(['48390'], dtype=object))]",['CHEMBL1200776'],"{'rows': array(['EFO_1001173', 'EFO_1001152', 'HP_0003072', 'EFO_0003884',
       'EFO_0000673', 'EFO_0003884', 'EFO_0008506', 'EFO_0005754',
       'EFO_0001072', 'MONDO_0024300', 'EFO_1001173', 'EFO_0008519',
       'EFO_0000313', 'EFO_1000456', 'EFO_0008506'], dtype=object), 'count': 15}",[ENSG00000036828],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 8 investigational indications.
CHEMBL1201294,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1,HYPPXZBJBPSRLK-UHFFFAOYSA-N,Small molecule,False,DIPHENOXYLATE,1960.0,4.0,,False,True,[],['Diphenoxylate' 'IDS-ND-016'],"[('PubChem', array(['50113007'], dtype=object)), ('Wikipedia', array(['Diphenoxylate'], dtype=object)), ('drugbank', array(['DB01081'], dtype=object)), ('chEBI', array(['4639'], dtype=object))]",['CHEMBL1200665'],,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1201666,,,Protein,False,LEPIRUDIN,1997.0,4.0,,False,True,['Refludan'],"['Hirudin lepirudin' 'Lepirudin' 'Lepirudin Recombinant'
 'Lepirudin recombinant']","[('DrugCentral', array(['2995'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/refludan'],
      dtype=object)), ('Wikipedia', array(['Lepirudin'], dtype=object))]",,"{'rows': array(['HP_0001873', 'HP_0004419', 'MONDO_0000831', 'HP_0001907',
       'MONDO_0008903'], dtype=object), 'count': 5}",[ENSG00000180210],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 1 investigational indication.
CHEMBL1237132,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,KPBZROQVTHLCDU-UHFFFAOYSA-N,Small molecule,False,CLEVIDIPINE,2008.0,4.0,,False,True,['Cleviprex'],['Clevidepine' 'Clevidepine butyrate' 'Clevidipine'],"[('DailyMed', array(['clevidipine'], dtype=object)), ('PubChem', array(['170466066'], dtype=object)), ('drugbank', array(['DB04920'], dtype=object))]",,"{'rows': array(['EFO_1001031', 'EFO_0000319', 'EFO_0004264', 'EFO_0000537',
       'EFO_0004273', 'EFO_0000712'], dtype=object), 'count': 6}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for cardiovascular disease and has 5 investigational indications.
CHEMBL1580,OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,FPVKHBSQESCIEP-JQCXWYLXSA-N,Small molecule,True,PENTOSTATIN,1991.0,4.0,,False,True,['Nipent' 'Pentostatin'],"['CI-825' 'Deoxycoformycin' 'NSC-218321' 'Nipent' 'PD 81565' 'PD-81565'
 'Pentostatin' 'YK-176']","[('DailyMed', array(['pentostatin'], dtype=object)), ('PubChem', array(['124893765', '144206967'], dtype=object)), ('Wikipedia', array(['Pentostatin'], dtype=object)), ('drugbank', array(['DB00552'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000574', 'MONDO_0013730', 'EFO_0000565',
       'MONDO_0002367', 'MONDO_0004992', 'EFO_0004599', 'MONDO_0011382',
       'EFO_0000095', 'EFO_1000956', 'EFO_0006927', 'MONDO_0002280',
       'MONDO_0020547'], dtype=object), 'count': 13}",[ENSG00000196839],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1581,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,IPVQLZZIHOAWMC-QXKUPLGCSA-N,Small molecule,True,PERINDOPRIL,1993.0,4.0,,False,True,[],['MCN-A-2833' 'Perindopril' 'S-9490'],"[('PubChem', array(['144206638', '170464836', '56463760'], dtype=object)), ('Wikipedia', array(['Perindopril'], dtype=object)), ('drugbank', array(['DB00790'], dtype=object)), ('chEBI', array(['8024'], dtype=object))]",['CHEMBL3544986' 'CHEMBL1200343'],"{'rows': array(['EFO_0001358', 'MONDO_0001134', 'EFO_0004701', 'EFO_0000537',
       'MONDO_0004975', 'EFO_0000319', 'MONDO_0007947', 'EFO_1000654',
       'EFO_0000612', 'MONDO_0005148', 'EFO_0000407', 'EFO_0001645',
       'EFO_0000537', 'MONDO_0007254', 'MONDO_0002491', 'EFO_0004214',
       'EFO_0000537'], dtype=object), 'count': 17}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1652,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl,OMHBPUNFVFNHJK-UHFFFAOYSA-P,Small molecule,False,AMBENONIUM,1956.0,4.0,,False,True,[],['Ambenonium' 'Ambenonium cation' 'Ambenonium ion'],"[('PubChem', array(['11113478', '26756578'], dtype=object)), ('Wikipedia', array(['Ambenonium_chloride'], dtype=object)), ('drugbank', array(['DB01122'], dtype=object)), ('chEBI', array(['2627'], dtype=object))]",['CHEMBL1200541'],,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL17,NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1,GJQPMPFPNINLKP-UHFFFAOYSA-N,Small molecule,False,DICHLORPHENAMIDE,1958.0,4.0,,False,True,['Daranide' 'Keveyis' 'Oratrol'],['Dichlorphenamide' 'Diclofenamide'],"[('DailyMed', array(['dichlorphenamide'], dtype=object)), ('PubChem', array(['11112264', '144203952', '56463645'], dtype=object)), ('Wikipedia', array(['Diclofenamide'], dtype=object)), ('drugbank', array(['DB01144'], dtype=object)), ('chEBI', array(['101085'], dtype=object))]",,"{'rows': array(['MONDO_0008223', 'MONDO_0008195', 'MONDO_0008224', 'MONDO_0005041'],
      dtype=object), 'count': 4}","[ENSG00000133742,ENSG00000074410,ENSG00000104267,ENSG00000167434]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and is indicated for glaucoma and has 3 investigational indications.
CHEMBL1742996,,,Antibody,True,BRODALUMAB,2017.0,4.0,,False,True,['Kyntheum' 'Siliq'],['AMG 827' 'AMG-827' 'Brodalumab' 'KHK-4827' 'KHK4827'],"[('DailyMed', array(['brodalumab'], dtype=object)), ('DrugCentral', array(['5179'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum'],
      dtype=object))]",,"{'rows': array(['EFO_0000540', 'EFO_0003778', 'EFO_0000384', 'MONDO_0004979',
       'MONDO_0015597', 'EFO_0000676', 'EFO_1000710', 'EFO_0003898',
       'EFO_0000717', 'EFO_1001494', 'EFO_0000685'], dtype=object), 'count': 11}",[ENSG00000177663],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2087337,CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@@H](O)CN(C)S(C)(=O)=O)cc2ccccc21,HXLOHDZQBKCUCR-WOZUAGRISA-N,Small molecule,False,VELUSETRAG,,2.0,,False,False,[],['TD-5108' 'Velusetrag'],"[('drugbank', array(['DB12702'], dtype=object))]",['CHEMBL2105660'],"{'rows': array(['EFO_1000988', 'EFO_1000948', 'MONDO_0004975'], dtype=object), 'count': 3}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2105648,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,YTFHCXIPDIHOIA-DHZHZOJOSA-N,Small molecule,True,PALOVAROTENE,2023.0,4.0,,False,True,['Sohonos'],"['CLM-001' 'IPN-60120' 'IPN60120' 'Palovarotene' 'R-667' 'RG-667'
 'RO-3300074' 'RO3300074']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PALOVAROTENE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12320'], dtype=object))]",,"{'rows': array(['MONDO_0008153', 'EFO_1000906', 'MONDO_0007606'], dtype=object), 'count': 3}",[ENSG00000172819],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for fibrodysplasia ossificans progressiva and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108669,,,Antibody drug conjugate,False,YTTRIUM Y 90 TACATUZUMAB TETRAXETAN,,2.0,,False,False,['Afp-cide'],"['HAFP-31' 'Yttrium (90y) tacatuzumab tetraxetan'
 'Yttrium y 90 tacatuzumab tetraxetan']",,,,[ENSG00000081051],Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2109413,,,Antibody,False,AS-1409,,1.0,,False,False,[],['AS-1409' 'As-1409' 'HUBC1-HUIL12'],,,"{'rows': array(['EFO_0000756', 'EFO_0000681'], dtype=object), 'count': 2}",[ENSG00000115414],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2219416,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O,MNYIRXLCPODKLG-VUTNLTPYSA-N,Small molecule,False,NALOXEGOL OXALATE,2014.0,4.0,CHEMBL2219418,False,True,['Movantik' 'Moventig'],['AZ13337019 oxalate' 'NKTR-118 oxalate' 'Naloxegol oxalate'],"[('DailyMed', array(['naloxegol%20oxalate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/moventig'],
      dtype=object))]",,"{'rows': array(['MONDO_0002203', 'EFO_0005611', 'HP_0002019', 'EFO_0003843'],
      dtype=object), 'count': 4}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved indications.
CHEMBL2336071,CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1,KIHYPELVXPAIDH-HNSNBQBZSA-N,Small molecule,False,SIPONIMOD,2019.0,4.0,,False,True,['Mayzent'],['BAF-312' 'BAF312' 'Baf312' 'NVP-BAF312-NX' 'Siponimod'],"[('DailyMed', array(['siponimod'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIPONIMOD/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12371'], dtype=object))]",['CHEMBL4298150'],"{'rows': array(['EFO_0008522', 'EFO_0008522', 'EFO_0003840', 'EFO_0003929',
       'MONDO_0005301', 'EFO_0000398', 'EFO_0003929', 'EFO_0001421',
       'EFO_0003086', 'EFO_0000540', 'EFO_0003063', 'MONDO_0005301'],
      dtype=object), 'count': 12}",[ENSG00000170989],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 6 investigational indications.
CHEMBL2369989,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)[N+](C)(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCC(=O)[O-])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)O,DUQRILZXKXSRIY-RUBJUKRASA-N,Protein,False,ATILMOTIN,,2.0,,False,False,[],['Atilmotin' 'BAX-ACC-1638' 'MOT-288' 'OHM-11638'],,,,[ENSG00000102539],Protein drug with a maximum clinical trial phase of II.
CHEMBL3039522,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12,PKWRMUKBEYJEIX-DXXQBUJASA-N,Small molecule,False,BIRINAPANT,,2.0,,False,False,[],['Birinapant' 'TL-32711' 'TL32711'],"[('drugbank', array(['DB11782'], dtype=object))]",,"{'rows': array(['EFO_0004197', 'EFO_0000222', 'MONDO_0004992', 'EFO_1001100',
       'EFO_0000181', 'EFO_1000251', 'MONDO_0002158', 'EFO_0000198',
       'MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 10}","[ENSG00000023445,ENSG00000110330]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL3142541,CCCCOC(=O)c1ccc(N)cc1.CCCCOC(=O)c1ccc(N)cc1.O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1,ATAGSVCDFKGYPE-UHFFFAOYSA-N,Small molecule,False,BUTAMBEN PICRATE,,4.0,CHEMBL127516,True,True,[],['ABBOTT-34842' 'Butamben picrate'],"[('chEBI', array(['86300'], dtype=object))]",,,"[ENSG00000111199,ENSG00000104321]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL3544998,,,Small molecule,False,LY-3007113,,1.0,,False,False,[],['Ly-3007113'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545097,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21,GYLDXIAOMVERTK-UHFFFAOYSA-N,Small molecule,False,SAPANISERTIB,,2.0,,False,False,[],"['CB-228' 'INK-128' 'INK128' 'Ink-128' 'MLN-0128' 'MLN0128' 'Mln-0128'
 'Sapanisertib' 'TAK-228']","[('drugbank', array(['DB11836'], dtype=object))]",['CHEMBL3943182'],"{'rows': array(['MONDO_0008315', 'EFO_0000616', 'EFO_0007416', 'EFO_1001968',
       'EFO_0004230', 'EFO_0000182', 'EFO_0000681', 'EFO_1000251',
       'MONDO_0007254', 'EFO_0000519', 'EFO_1001471', 'EFO_0001378',
       'EFO_0000708', 'EFO_1000045', 'MONDO_0004992', 'EFO_1000043',
       'EFO_0003060', 'EFO_0000209', 'EFO_0000466', 'EFO_0007532',
       'MONDO_0002108', 'EFO_0000574', 'EFO_0009441', 'EFO_1001465',
       'EFO_0003869'], dtype=object), 'count': 25}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 25 investigational indications.
CHEMBL3545125,CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O,FTBQORVNHOIASH-CKYFFXLPSA-N,Small molecule,False,MIROGABALIN,,3.0,,False,False,[],['A-200-0700' 'A200-0700' 'Mirogabalin'],"[('drugbank', array(['DB11825'], dtype=object))]",['CHEMBL3545257'],"{'rows': array(['EFO_1000783', 'EFO_0005687', 'MONDO_0041052', 'EFO_0005762'],
      dtype=object), 'count': 4}","[ENSG00000153956,ENSG00000007402]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3707293,,,Small molecule,False,XEN-D0501,,2.0,,False,False,[],['Xen-d0501'],,,"{'rows': array(['EFO_0000341', 'HP_0012735', 'MONDO_0005148'], dtype=object), 'count': 3}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL392149,OC[C@H]1O[C@@H](n2cnc3c(N[C@@H]4CCOC4)ncnc32)[C@H](O)[C@@H]1O,OESBDSFYJMDRJY-BAYCTPFLSA-N,Small molecule,False,TECADENOSON,,2.0,,False,False,[],['CVT-510' 'Tecadenoson'],"[('drugbank', array(['DB04954'], dtype=object))]",,"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298004,,,Antibody,False,VOPRATELIMAB,,2.0,,False,False,[],"['Anti-icos agonist mab jtx-2011' 'JTX-2011' 'Jtx 2011' 'Jtx-2011'
 'Vopratelimab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VOPRATELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000163600],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL482967,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1,GPSZYOIFQZPWEJ-UHFFFAOYSA-N,Small molecule,False,CYC-116,,1.0,,False,False,[],['CYC-116' 'Cyc 116' 'Cyc-116'],"[('PubChem', array(['103904403', '137276048'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000178999,ENSG00000105146,ENSG00000087586,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL521686,O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,FDLYAMZZIXQODN-UHFFFAOYSA-N,Small molecule,False,OLAPARIB,2014.0,4.0,,False,True,['Lynparza'],"['AZ-2281' 'AZ2281' 'AZD-2281' 'AZD2281' 'KEYLYNK-010 COMPONENT OLAPARIB'
 'KU-0059436' 'KU-59436' 'NSC-747856' 'OLAPARIB COMPONENT OF KEYLYNK-010'
 'Olaparib']","[('DailyMed', array(['olaparib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza'],
      dtype=object)), ('PubChem', array(['124947876', '164339421', '174007124'], dtype=object)), ('Wikipedia', array(['Olaparib'], dtype=object)), ('drugbank', array(['DB09074'], dtype=object)), ('chEBI', array(['83766'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0100342', 'EFO_0000707', 'MONDO_0001056',
       'EFO_0005537', 'EFO_0000519', 'EFO_0003869', 'EFO_0000216',
       'EFO_0000702', 'EFO_0005221', 'MONDO_0008315', 'EFO_0006859',
       'EFO_1001951', 'EFO_0002618', 'EFO_0000294', 'EFO_0003825',
       'MONDO_0008903', 'EFO_1000251', 'EFO_0000174', 'EFO_0003860',
       'MONDO_0005184', 'EFO_0002617', 'EFO_0000389', 'EFO_0000514',
       'MONDO_0001187', 'EFO_0003060', 'EFO_0000574', 'MONDO_0003060',
       'MONDO_0007254', 'MONDO_0004986', 'EFO_0000095', 'MONDO_0004992',
       'EFO_0000503', 'EFO_0003968', 'EFO_1000984', 'EFO_0002918',
       'EFO_1001901', 'EFO_1001512', 'EFO_0003893', 'Orphanet_145',
       'EFO_0000305', 'EFO_0004230', 'MONDO_0002087', 'MONDO_0002715',
       'EFO_1000158', 'EFO_0001663', 'MONDO_0002158', 'EFO_0007532',
       'MONDO_0008170', 'MONDO_0003059', 'EFO_0001075', 'EFO_0009708',
       'MONDO_0011962', 'EFO_0000313', 'EFO_1001100', 'EFO_0000196',
       'EFO_0001061', 'EFO_0000673', 'EFO_0000588', 'EFO_0000637',
       'EFO_1001968', 'MONDO_0002974', 'EFO_0000181', 'MONDO_0002928',
       'EFO_0000691', 'MONDO_0018364', 'EFO_0000681', 'EFO_0001361'],
      dtype=object), 'count': 68}","[ENSG00000143799,ENSG00000041880,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 63 investigational indications.
CHEMBL5315050,CC(=O)O.CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1,SVDWBHHCPXTODI-QIWYXCRTSA-N,Protein,False,ATOSIBAN ACETATE,2000.0,4.0,CHEMBL382301,False,True,['Tractocile'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tractocile'],
      dtype=object))]",,"{'rows': array(['EFO_0003917'], dtype=object), 'count': 1}",[ENSG00000180914],Protein drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for premature birth.
CHEMBL68055,CC1=C(c2ccc(O)cc2)[C@H](c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21,DUYNJNWVGIWJRI-LJAQVGFWSA-N,Small molecule,False,ACOLBIFENE,,3.0,,False,False,[],['Acolbifene' 'Em-652' 'SCH-57068' 'SCH57068'],,['CHEMBL2105965'],"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1200586,CCCNC(C)C(=O)Nc1ccccc1C.Cl,BJPJNTKRKALCPP-UHFFFAOYSA-N,Small molecule,False,PRILOCAINE HYDROCHLORIDE,1965.0,4.0,CHEMBL1194,False,True,"['Citanest' 'Citanest plain' 'Citanest plain dental'
 'Prilocaine hydrochloride']","['ASTRA 1512' 'Citanest hydrochloride' 'L-67' 'NSC-758432'
 'Prilocaine hcl' 'Prilocaine hydrochloride' 'Propitocaine hydrochloride'
 'Xylonest']","[('DailyMed', array(['prilocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['11532855', '144204064', '170464697', '50106902'], dtype=object)), ('chEBI', array(['32053'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965.
CHEMBL1201476,,,Oligosaccharide,True,ENOXAPARIN SODIUM,1993.0,4.0,,False,True,"['Clexane' 'Enoxaparin sodium' 'Enoxaparin sodium (preservative free)'
 'Inhixa' 'Lovenox' 'Lovenox (preservative free)']","['Enoxaparin' 'Enoxaparin sodium' 'Enoxaparin sodium salt' 'Klexane'
 'PK 10169' 'PK-10169' 'RP 54563' 'RP-54563']","[('DailyMed', array(['enoxaparin%20sodium'], dtype=object)), ('DrugCentral', array(['4879'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa'],
      dtype=object))]",,"{'rows': array(['EFO_0000275', 'EFO_0000616', 'EFO_0003964', 'MONDO_0008170',
       'EFO_0005681', 'EFO_0000495', 'EFO_0005672', 'EFO_0000702',
       'HP_0004936', 'HP_0004419', 'MP_0001914', 'EFO_0009314',
       'EFO_1001375', 'EFO_0004255', 'EFO_0003827', 'MONDO_0000831',
       'EFO_0000712', 'EFO_0000612', 'MONDO_0100096', 'EFO_1000954',
       'HP_0001907', 'MONDO_0021148', 'EFO_0003086', 'EFO_0003907',
       'EFO_0003060', 'EFO_0002916', 'EFO_0001422', 'EFO_0002618',
       'EFO_0001073', 'EFO_0008583', 'MONDO_0004992', 'EFO_0004286',
       'EFO_1000985', 'EFO_0008585', 'EFO_0000574', 'EFO_0000544'],
      dtype=object), 'count': 36}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 28 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1286,CC[C@@H](C(N)=O)N1CCCC1=O,HPHUVLMMVZITSG-LURJTMIESA-N,Small molecule,False,LEVETIRACETAM,1999.0,4.0,,False,True,"['Desitrend' 'Elepsia xr' 'Keppra' 'Keppra xr' 'Levetiracetam'
 'Levetiracetam in sodium chloride' 'Levetiracetam teva' 'Matever'
 'Spritam']","['AGB-101' 'Elepsia' 'Levetiracetam' 'Levetiracetam accord'
 'Levetiracetam actavis' 'Levetiracetam hospira' 'Levetiracetam sun'
 'Levetiracetam teva' 'Levetiracetame' 'N03AX14' 'NSC-760119' 'UCB 22059'
 'UCB L059' 'UCB-22059' 'UCB-L059']","[('DailyMed', array(['levetiracetam'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-teva'],
      dtype=object)), ('PubChem', array(['26719810', '90341134'], dtype=object)), ('Wikipedia', array(['Levetiracetam'], dtype=object)), ('drugbank', array(['DB01202'], dtype=object)), ('chEBI', array(['6437'], dtype=object))]",,"{'rows': array(['HP_0000473', 'EFO_0004270', 'EFO_0003833', 'MONDO_0005180',
       'MONDO_0007079', 'MONDO_0002046', 'EFO_0004777', 'MONDO_0010079',
       'EFO_0003108', 'EFO_0009562', 'MONDO_0005090', 'EFO_0000621',
       'EFO_1000904', 'EFO_0000712', 'HP_0001250', 'EFO_0002610',
       'EFO_0005543', 'HP_0000726', 'HP_0002069', 'EFO_0001358',
       'EFO_0004263', 'MONDO_0002050', 'MONDO_0015643', 'EFO_0005407',
       'EFO_0005230', 'EFO_0000326', 'EFO_0004280', 'EFO_0004262',
       'EFO_0004242', 'HP_0100543', 'MONDO_0004975', 'HP_0002121',
       'MONDO_0041052', 'HP_0007359', 'EFO_0007262', 'MONDO_0011382',
       'EFO_0005611', 'EFO_0000222', 'EFO_0000713', 'HP_0002381',
       'EFO_0008526', 'EFO_0000474', 'MONDO_0004985', 'EFO_0000519'],
      dtype=object), 'count': 44}","[ENSG00000159164,ENSG00000148408]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 39 investigational indications.
CHEMBL1433,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,JBIWCJUYHHGXTC-AKNGSSGZSA-N,Small molecule,True,DOXYCYCLINE ANHYDROUS,1967.0,4.0,,False,True,[],['Anhydrous doxycycline' 'Doxycycline (anhydrous)'],"[('PubChem', array(['26755247', '90340791'], dtype=object)), ('Wikipedia', array(['Doxycycline'], dtype=object)), ('drugbank', array(['DB00254'], dtype=object)), ('chEBI', array(['50845'], dtype=object))]","['CHEMBL1200699' 'CHEMBL2364574' 'CHEMBL1256723' 'CHEMBL1200567'
 'CHEMBL2106418' 'CHEMBL3989740']","{'rows': array(['EFO_0008510', 'EFO_0002618', 'EFO_1001466', 'EFO_1000906',
       'EFO_0009536', 'EFO_1001896', 'EFO_0000341', 'EFO_0004214',
       'MONDO_0007039', 'EFO_0009659', 'EFO_0003102', 'MONDO_0018076',
       'EFO_0007470', 'EFO_0000662', 'EFO_0001068', 'EFO_0009425',
       'MONDO_0007947', 'EFO_0000778', 'EFO_0000574', 'EFO_1002047',
       'EFO_0007460', 'HP_0001250', 'EFO_1001466', 'MONDO_0004992',
       'EFO_0000729', 'EFO_1001898', 'EFO_0007205', 'EFO_1001788',
       'MONDO_0100096', 'MONDO_0009061', 'MONDO_0019438', 'MP_0001914',
       'EFO_0007430', 'EFO_0000612', 'EFO_1001051', 'MONDO_0004975',
       'MONDO_0005178', 'EFO_0002913', 'MONDO_0019180', 'EFO_0003770',
       'EFO_0007185', 'EFO_0000384', 'EFO_1001235', 'EFO_0000464',
       'EFO_0000199', 'EFO_0003894', 'EFO_0000756', 'EFO_0007205',
       'EFO_1001951', 'EFO_1001388', 'EFO_0000649', 'EFO_1000760',
       'EFO_0000274', 'EFO_0000544', 'MONDO_0002635', 'EFO_0000365',
       'EFO_0000771', 'MONDO_0005180', 'MONDO_0017816', 'EFO_0003878',
       'EFO_0005952', 'EFO_1000760', 'EFO_0009117', 'EFO_0008517',
       'HP_0000964', 'EFO_0007272', 'EFO_0007480', 'EFO_0000096',
       'EFO_0003106', 'EFO_0000649', 'EFO_0000544', 'EFO_1001459',
       'EFO_0000694', 'EFO_0001365', 'EFO_1001875', 'EFO_0007410',
       'DOID_7551', 'EFO_0003843', 'EFO_0003060', 'EFO_0005044',
       'EFO_0007504', 'EFO_1000785', 'EFO_0003894', 'MONDO_0100096',
       'EFO_0000768', 'EFO_0007357', 'EFO_0009637', 'EFO_1001444',
       'EFO_0002687'], dtype=object), 'count': 89}","[ENSG00000137745,ENSG00000118113,ENSG00000196611,ENSG00000137673]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 15 approved and 71 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1456,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,RTGDFNSFWBGLEC-SYZQJQIISA-N,Small molecule,True,MYCOPHENOLATE MOFETIL,1995.0,4.0,,False,True,['Arzip' 'Cellcept' 'Myclausen' 'Mycophenolate mofetil' 'Myfenax'],"['Myclausen' 'Mycophenolate mofetil'
 'Mycophenolic acid 2-(4-morpholinyl)ethyl ester' 'Mycophenylate mofetil'
 'NSC-724229' 'NSC-758905' 'RS-61443']","[('DailyMed', array(['mycophenolate%20mofetil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/myclausen'],
      dtype=object)), ('PubChem', array(['144205239', '170464859', '29215409'], dtype=object)), ('Wikipedia', array(['Mycophenolate_mofetil'], dtype=object)), ('drugbank', array(['DB00688'], dtype=object)), ('chEBI', array(['8764'], dtype=object))]",['CHEMBL1200955'],"{'rows': array(['EFO_0000404', 'EFO_0000519', 'EFO_1000784', 'EFO_0004719',
       'EFO_1000309', 'EFO_0000220', 'MONDO_0019469', 'EFO_1000965',
       'EFO_0004826', 'MONDO_0002334', 'EFO_0000681', 'EFO_0000616',
       'EFO_0002618', 'EFO_0003777', 'MONDO_0002367', 'EFO_0000565',
       'MONDO_0044881', 'EFO_1001779', 'EFO_0000255', 'EFO_0000211',
       'MONDO_0021193', 'EFO_0003032', 'EFO_0004228', 'EFO_0004236',
       'EFO_1000560', 'MONDO_0000870', 'MONDO_0010518', 'Orphanet_79292',
       'EFO_0000676', 'EFO_0006803', 'EFO_0000319', 'MONDO_0015253',
       'EFO_0000389', 'EFO_1002048', 'EFO_0000339', 'EFO_1001857',
       'EFO_0006927', 'EFO_0004251', 'MONDO_0007915', 'MONDO_0001705',
       'EFO_0004256', 'HP_0001915', 'MONDO_0018906', 'MONDO_0019391',
       'EFO_0000574', 'HP_0001871', 'EFO_0004991', 'EFO_0000699',
       'EFO_0007196', 'EFO_0000764', 'EFO_0002428', 'EFO_0000318',
       'EFO_1001469', 'EFO_1001051', 'MONDO_0004976', 'DOID_13406',
       'Orphanet_848', 'EFO_0000621', 'MONDO_0019471', 'EFO_0003047',
       'MONDO_0013730', 'EFO_0000191', 'EFO_0004244', 'EFO_0005952',
       'EFO_0001365', 'HP_0002721', 'EFO_0000401', 'EFO_0003086',
       'EFO_1000785', 'MONDO_0005147', 'EFO_0004274', 'EFO_0000685',
       'MONDO_0044903', 'EFO_1001231', 'EFO_1001017', 'EFO_0000096',
       'EFO_1000680', 'MONDO_0015760', 'EFO_0000309', 'EFO_0000384',
       'EFO_0000198', 'EFO_0000537', 'EFO_0000182', 'EFO_0004255',
       'MONDO_0005301', 'EFO_0005297', 'MONDO_0009387', 'EFO_0001062',
       'EFO_0002430', 'EFO_0000095', 'EFO_0002429', 'MONDO_0000873',
       'EFO_0004194', 'EFO_0001378', 'MONDO_0015974', 'EFO_1000956',
       'MONDO_0009833', 'EFO_0003884', 'EFO_1000690', 'EFO_0001642',
       'EFO_1000318', 'MONDO_0100244', 'MONDO_0011382', 'EFO_0000222',
       'MONDO_0019472', 'EFO_0005140', 'EFO_0000717', 'EFO_1001345',
       'MONDO_0018923', 'EFO_0000702', 'EFO_0000403', 'EFO_0004599',
       'EFO_0009441', 'MONDO_0020547', 'EFO_0004254', 'EFO_0007187',
       'EFO_0007160', 'EFO_0000183', 'EFO_0007359', 'EFO_0005761',
       'EFO_0001421', 'EFO_1000102', 'EFO_0008507', 'MONDO_0019262',
       'EFO_1001465', 'MONDO_0004992'], dtype=object), 'count': 126}","[ENSG00000106348,ENSG00000178035]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 126 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1534525,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C.Cl.Cl,MTJLQTFHJIHXIX-GDUXWEAWSA-N,Small molecule,False,MIBEFRADIL DIHYDROCHLORIDE,1997.0,4.0,CHEMBL45816,True,True,[],['Mibefradil dihydrochloride' 'Mibefradil hydrochloride' 'RO 40-5967/001'],"[('PubChem', array(['144204795', '170466110', '50106572'], dtype=object))]",,,"[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997. It was withdrawn in at least one region.
CHEMBL1615439,C[C@H]1[C@H](c2ccccc2)OCCN1C,MFOCDFTXLCYLKU-CMPLNLGQSA-N,Small molecule,False,PHENDIMETRAZINE,1976.0,4.0,,False,True,[],['NSC-169187' 'Phendimetrazine'],"[('drugbank', array(['DB01579'], dtype=object)), ('chEBI', array(['8059'], dtype=object))]",['CHEMBL2062163'],"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for obesity.
CHEMBL1743031,,,Antibody drug conjugate,False,INDATUXIMAB RAVTANSINE,,2.0,,False,False,[],['BT-062' 'Indatuximab ravtansine'],,,"{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}",[ENSG00000115884],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1952329,CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,MHXGEROHKGDZGO-UHFFFAOYSA-N,Small molecule,False,SGI-1776,,1.0,,False,False,[],['SGI-1776' 'Sgi-1776'],"[('PubChem', array(['137276030'], dtype=object)), ('drugbank', array(['DB12494'], dtype=object))]",['CHEMBL1952141'],"{'rows': array(['MONDO_0008315', 'EFO_0000565', 'EFO_0005952'], dtype=object), 'count': 3}","[ENSG00000137193,ENSG00000102096,ENSG00000198355]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL2103863,CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12,MAUCONCHVWBMHK-UHFFFAOYSA-N,Small molecule,False,ABEXINOSTAT,,3.0,,False,False,[],"['Abexinostat' 'CRA 024781' 'CRA 24781' 'CRA-024781' 'PCI 24781'
 'PCI-24781' 'PZP-115891' 'PZP115891' 'S-78454' 'S78454']","[('drugbank', array(['DB12565'], dtype=object))]",['CHEMBL2105727'],"{'rows': array(['MONDO_0018906', 'EFO_0005952', 'EFO_0000616', 'EFO_0000691',
       'EFO_0000681', 'EFO_0000183', 'EFO_0000403'], dtype=object), 'count': 7}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2107725,Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)c4ccc(C(=N)N)cc4)c3Cl)c2n1,XUHBBTKJWIBQMY-MHZLTWQESA-N,Small molecule,False,ANATIBANT,,2.0,,False,False,[],['Anatibant' 'Lf16-0687' 'XY-2405' 'XY2405'],"[('drugbank', array(['DB05038'], dtype=object))]",,,[ENSG00000168398],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL284838,O=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O,ULGNGSQNNMKROG-WOJBJXKFSA-N,Small molecule,False,K-134,,2.0,,False,False,[],['K-134' 'OPC-33509'],"[('drugbank', array(['DB12685'], dtype=object))]",,"{'rows': array(['EFO_0003876'], dtype=object), 'count': 1}","[ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3137353,,,Antibody,False,BIMAGRUMAB,,3.0,,False,False,[],['BYM-338' 'BYM338' 'Bimagrumab' 'O81t794r34'],,,"{'rows': array(['EFO_1000653', 'HP_0004326', 'EFO_0009851', 'EFO_0007323',
       'EFO_0000341', 'MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 7}",[ENSG00000114739],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL3544958,,,Small molecule,False,CER-002,,1.0,,False,False,[],['Cer-002'],,,,[ENSG00000112033],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545235,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(CC2)C2(C1)OCCO2,OXWUWXCJDBRCCG-UHFFFAOYSA-N,Small molecule,False,SIMOTINIB,,3.0,,False,False,[],['Sim-6802' 'Simotinib'],,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3746388,Cn1cc(C(=O)O)c2ccc(N3CCC(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)CC3)cc21,RPVDFHPBGBMWID-UHFFFAOYSA-N,Small molecule,False,TERN-101,,2.0,,False,False,[],['LY-2562175' 'LY2562175' 'TERN-101' 'Tern-101'],,,"{'rows': array(['EFO_1001249'], dtype=object), 'count': 1}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989716,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1,GBKONKCASNNUQD-VGHSCWAPSA-N,Small molecule,True,PROPOXYPHENE NAPSYLATE,1971.0,4.0,CHEMBL1213351,True,True,['Darvon-n'],"['D-propoxyphene napsylate hydrate' 'Dextropropoxyphene napsilate'
 'Propoxyphene napsylate' 'Propoxyphene napsylate cii'
 'Propoxyphene napsylate monohydrate']","[('DailyMed', array(['propoxyphene%20napsylate'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1971 and is indicated for pain. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL404108,Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,KHPKQFYUPIUARC-UHFFFAOYSA-N,Small molecule,False,LUMIRACOXIB,2005.0,4.0,,True,True,['Prexige'],['COX-189' 'Lumiracoxib'],"[('PubChem', array(['144207115', '170465597'], dtype=object)), ('Wikipedia', array(['Lumiracoxib'], dtype=object)), ('drugbank', array(['DB01283'], dtype=object)), ('chEBI', array(['73044'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'MONDO_0005178', 'EFO_0005755', 'EFO_0004616',
       'EFO_1000786'], dtype=object), 'count': 5}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for rheumatic disease and has 4 investigational indications. It was withdrawn in at least one region.
CHEMBL4297700,,,Antibody,False,BIMEKIZUMAB,2021.0,4.0,,False,True,['Bimzelx'],['Bimekizumab' 'UCB-4940' 'UCB4940' 'Ucb4940'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx'],
      dtype=object))]",,"{'rows': array(['EFO_0003898', 'EFO_0000540', 'EFO_1000747', 'EFO_0000676',
       'EFO_0000685', 'EFO_1000710', 'EFO_0003778'], dtype=object), 'count': 7}","[ENSG00000112116,ENSG00000112115]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 4 investigational indications.
CHEMBL434394,OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,KOHIRBRYDXPAMZ-UHFFFAOYSA-N,Small molecule,False,NEBIVOLOL,2007.0,4.0,,False,True,['Hypoloc' 'Nebilet'],"['Narbivolol' 'Nebivolol' 'R-65824' 'R65,824']","[('Wikipedia', array(['Nebivolol'], dtype=object)), ('drugbank', array(['DB04861'], dtype=object)), ('chEBI', array(['64019'], dtype=object))]",['CHEMBL1201731'],"{'rows': array(['MONDO_0100096', 'EFO_0000537', 'EFO_0003882', 'MONDO_0001134',
       'EFO_0000537', 'MONDO_0007947', 'EFO_0000712', 'EFO_0000712',
       'EFO_0000768', 'EFO_0000319'], dtype=object), 'count': 10}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 7 investigational indications.
CHEMBL4650326,C(=C/c1cccs1)\c1cc[nH]n1,FOHWAQGURRYJFK-ONEGZZNKSA-N,Small molecule,False,TEREVALEFIM,,3.0,,False,False,[],['ANG-3777' 'Ang-3777' 'BB3' 'Refanalin' 'SNV-003' 'Terevalefim'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEREVALEFIM/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0001919', 'MONDO_0002492'], dtype=object), 'count': 2}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL5315115,,,Small molecule,False,LASOFOXIFENE TARTRATE,2009.0,4.0,,False,True,['Fablyn'],"['CB-336156EB' 'CP-336,156-CB' 'CP-336156' 'CP-336156-CB' 'Fablyn'
 'Lasofoxifene d-tartrate' 'Lasofoxifene tartrate' 'Oporia']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fablyn'],
      dtype=object))]",,"{'rows': array(['EFO_0003854'], dtype=object), 'count': 1}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for postmenopausal osteoporosis.
CHEMBL539770,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl,RNGHAJVBYQPLAZ-UHFFFAOYSA-N,Small molecule,False,TERODILINE HYDROCHLORIDE,1986.0,4.0,CHEMBL363295,True,True,['Micturin 12.5' 'Micturin 25'],['Terodiline hydrochloride'],"[('PubChem', array(['144206962'], dtype=object))]",,,"[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984,ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. It was withdrawn in at least one region.
CHEMBL57242,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,KGSXMPPBFPAXLY-UHFFFAOYSA-N,Small molecule,False,AZILSARTAN,,3.0,,False,False,[],['Azilsartan' 'TAK-536'],"[('chEBI', array(['68850'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'MONDO_0005148', 'EFO_0000694', 'EFO_0000400',
       'MONDO_0001134', 'EFO_0000537'], dtype=object), 'count': 6}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL589586,COC(=O)/C=C/C(=O)O,NKHAVTQWNUWKEO-NSCUHMNNSA-N,Small molecule,False,MONOMETHYL FUMARATE,2020.0,4.0,,False,True,['Bafiertam'],"['Fumaric acid monomethyl ester' 'Methyl Fumarate' 'Monomethyl fumarate'
 'NSC-523835']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MONOMETHYL%20FUMARATE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14219'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 2}",[ENSG00000079999],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for multiple sclerosis and has 1 investigational indication.
CHEMBL7413,C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O,NZXKDOXHBHYTKP-UHFFFAOYSA-N,Small molecule,True,METHOHEXITAL,1960.0,4.0,,False,True,[],['Methohexital' 'Methohexital civ' 'Methohexitone'],"[('Wikipedia', array(['Methohexital'], dtype=object)), ('drugbank', array(['DB00474'], dtype=object)), ('chEBI', array(['102216'], dtype=object))]",['CHEMBL30219'],,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA.
CHEMBL750,NS(=O)(=O)Cc1noc2ccccc12,UBQNRHZMVUUOMG-UHFFFAOYSA-N,Small molecule,False,ZONISAMIDE,2000.0,4.0,,False,True,['Zonegran' 'Zonisade' 'Zonisamide'],"['AD-810' 'CI-912' 'Excegran' 'N03AX15' 'PD-110843' 'Zonisade'
 'Zonisamide']","[('DailyMed', array(['zonisamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zonegran'],
      dtype=object)), ('PubChem', array(['144205122', '49666067', '90341782'], dtype=object)), ('Wikipedia', array(['Zonisamide'], dtype=object)), ('drugbank', array(['DB00909'], dtype=object)), ('chEBI', array(['10127'], dtype=object))]",['CHEMBL1514931' 'CHEMBL1596271'],"{'rows': array(['EFO_0004238', 'HP_0001250', 'EFO_0003768', 'EFO_0004319',
       'MONDO_0002046', 'EFO_0001073', 'MONDO_0005090', 'EFO_0003108',
       'EFO_0000474', 'EFO_0004566', 'HP_0007359', 'MONDO_0005180',
       'MONDO_0007079', 'EFO_0005203', 'EFO_0004263', 'EFO_1001254',
       'MONDO_0005277', 'EFO_0005411', 'EFO_0002610', 'EFO_1000877'],
      dtype=object), 'count': 20}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 16 investigational indications.
CHEMBL917,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,Small molecule,True,FLOXURIDINE,1970.0,4.0,,False,True,['F.u.d.r.' 'Floxuridine' 'Fudr'],"['5-Fluoro-2-deoxyuridine' '5-fudr' 'FUDR' 'Floxuridine'
 'Fluoruridine deoxyribose' 'NSC-27640']","[('DailyMed', array(['floxuridine'], dtype=object)), ('PubChem', array(['124886843', '144204443', '170465247', '29215018', '29215019',
       '50104188', '855946', '93576919'], dtype=object)), ('Wikipedia', array(['Floxuridine'], dtype=object)), ('drugbank', array(['DB00322'], dtype=object)), ('chEBI', array(['60761'], dtype=object))]",,"{'rows': array(['EFO_0005221', 'EFO_0000365', 'MONDO_0001056', 'EFO_1001951',
       'EFO_0000503', 'MONDO_0021063', 'EFO_0000182', 'EFO_0004142',
       'MONDO_0002158', 'MONDO_0007576', 'MONDO_0002691', 'MONDO_0008170',
       'MONDO_0004992', 'MONDO_0002087', 'EFO_1001961', 'EFO_0004243',
       'EFO_1000657', 'EFO_0000616', 'MONDO_0011719'], dtype=object), 'count': 19}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for cancer and neoplasm and has 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL10188,CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,BIAVGWDGIJKWRM-FQEVSTJZSA-N,Small molecule,False,TALNETANT,,2.0,,False,False,[],['SB-2234' 'SB-223412' 'Sb-223412' 'Talnetant'],,['CHEMBL2146089'],"{'rows': array(['EFO_0000555', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000169836],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1051,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O,GGXICVAJURFBLW-CEYXHVGTSA-N,Small molecule,False,LATANOPROST,1996.0,4.0,,False,True,['Latanoprost' 'Monopost' 'Xalatan' 'Xelpros'],"['Iyuzeh' 'Latanoprost' 'Latanoprost (isopropyl ester)' 'PHXA-41' 'PHXA41'
 'T-2345' 'T2345' 'XA-41' 'XA41']","[('DailyMed', array(['latanoprost'], dtype=object)), ('PubChem', array(['26719861'], dtype=object)), ('Wikipedia', array(['Latanoprost'], dtype=object)), ('drugbank', array(['DB00654'], dtype=object)), ('chEBI', array(['6384'], dtype=object))]",,"{'rows': array(['MONDO_0005041', 'EFO_0004190', 'EFO_1001069', 'EFO_0004208',
       'EFO_0006862', 'EFO_0000537'], dtype=object), 'count': 6}",[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 2 investigational indications.
CHEMBL1088750,CC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(C(=O)NCCN(C)C)cc21,IFGWYHGYNVGVRB-UHFFFAOYSA-N,Small molecule,False,ARRY-797,,3.0,,False,False,[],['ARRY-371797' 'ARRY-797' 'Arry-797'],,,"{'rows': array(['EFO_0000407', 'EFO_0003898', 'EFO_0010072', 'EFO_0000685',
       'EFO_0004616'], dtype=object), 'count': 5}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL1200326,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1.Cl,AIKVCUNQWYTVTO-UHFFFAOYSA-N,Small molecule,False,NICARDIPINE HYDROCHLORIDE,1988.0,4.0,CHEMBL1484,False,True,['Cardene' 'Cardene sr' 'Nicardipine hydrochloride'],"['Barizin' 'Cardepine' 'Dacarel' 'Lecibra' 'Lecibral' 'Lescodil' 'Loxen'
 'NSC-757855' 'Nerdipina' 'Nicant' 'Nicapress' 'Nicardal'
 'Nicardipine hcl' 'Nicardipine hydrochloride' 'Nicarpin' 'Nicodel'
 'Nimicor' 'Perdipina' 'Perdipine' 'RS-69216' 'RS-69216-XX-07-0'
 'RS-69216XX07-0' 'Ranvil' 'Ridene' 'Rycarden' 'Rydene' 'Vasodin'
 'Vasonase' 'YC-93']","[('DailyMed', array(['nicardipine%20hydrochloride'], dtype=object)), ('PubChem', array(['144212149', '26747578', '26747579', '50106640', '50106641',
       '50106642'], dtype=object))]",,"{'rows': array(['EFO_1000994', 'EFO_0000319', 'EFO_0000537', 'EFO_0005669'],
      dtype=object), 'count': 4}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for hypertension and has 3 investigational indications.
CHEMBL1200383,CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2.CS(=O)(=O)O,CPFJLLXFNPCTDW-BWSPSPBFSA-N,Small molecule,False,BENZTROPINE MESYLATE,1954.0,4.0,CHEMBL1201203,False,True,['Benztropine mesylate' 'Cogentin'],"['Benzatropine mesilate' 'Benztropine mesilate' 'Benztropine mesylate'
 'Benztropine methanesulfonate' 'NSC-169913']","[('DailyMed', array(['benztropine%20mesylate'], dtype=object)), ('PubChem', array(['144203579'], dtype=object)), ('chEBI', array(['3049'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'HP_0003418', 'EFO_0009387'], dtype=object), 'count': 3}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for parkinson disease and has 2 investigational indications.
CHEMBL1201044,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl,ZIODNPFQZIHCOE-UHFFFAOYSA-N,Small molecule,False,DAPIPRAZOLE HYDROCHLORIDE,1990.0,4.0,CHEMBL1201216,False,True,['Dapiprazole hydrochloride'],"['AF 2139' 'AF-2139' 'Dapiprazole hcl' 'Dapiprazole hydrochloride'
 'Dapiprazole monohydrochloride']","[('PubChem', array(['144206586', '170466549'], dtype=object))]",,"{'rows': array(['HP_0011499', 'EFO_0004190'], dtype=object), 'count': 2}",[ENSG00000120907],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for mydriasis and open-angle glaucoma.
CHEMBL1201185,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O,PUDHBTGHUJUUFI-SCTWWAJVSA-N,Protein,False,LANREOTIDE,2007.0,4.0,,False,True,['Somatuline autogel' 'Somatuline la'],['Angiopeptin' 'Lanreotide'],"[('Wikipedia', array(['Lanreotide'], dtype=object))]",['CHEMBL1201184'],"{'rows': array(['EFO_1001485', 'EFO_0004243', 'EFO_1001901', 'EFO_0000182',
       'EFO_1000852', 'HP_0002014', 'EFO_1001466', 'EFO_1001471',
       'EFO_1001769', 'EFO_1001307', 'EFO_1001095', 'EFO_1000852',
       'EFO_0009431', 'EFO_1000478', 'MONDO_0008315', 'MONDO_0024503',
       'EFO_1001496', 'MONDO_0004565', 'MONDO_0044937', 'HP_0003074',
       'EFO_1001485', 'EFO_0000616', 'EFO_0003769'], dtype=object), 'count': 23}","[ENSG00000180616,ENSG00000162009]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for acromegaly and carcinoid syndrome and has 21 investigational indications.
CHEMBL1214827,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,IFRGXKKQHBVPCQ-UHFFFAOYSA-N,Small molecule,False,ONALESPIB,,2.0,,False,False,[],['ATI-13387X' 'ATI13387X' 'At-13387' 'At13387' 'Onalespib'],"[('drugbank', array(['DB06306'], dtype=object))]",['CHEMBL3301599'],"{'rows': array(['MONDO_0007254', 'EFO_0003060', 'EFO_0003060', 'EFO_0000616',
       'EFO_0005537', 'MONDO_0008315'], dtype=object), 'count': 6}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1371,O=c1[nH]c2cc(Cl)ccc2o1,TZFWDZFKRBELIQ-UHFFFAOYSA-N,Small molecule,False,CHLORZOXAZONE,1958.0,4.0,,False,True,"['Chlorzoxazone' 'Paraflex' 'Parafon Forte' 'Parafon forte dsc'
 'Parafon-Forte' 'Strifon forte dsc']",['Chlorzoxazone' 'NSC-26189'],"[('DailyMed', array(['chlorzoxazone'], dtype=object)), ('PubChem', array(['11110945', '11110946', '144203656', '170464957', '50106005',
       '8139927', '85230968', '90340987'], dtype=object)), ('Wikipedia', array(['Chlorzoxazone'], dtype=object)), ('drugbank', array(['DB00356'], dtype=object)), ('chEBI', array(['3655'], dtype=object))]",,,[ENSG00000104783],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958.
CHEMBL1706,Cl.c1ccc2c(CC3=NCCN3)cccc2c1,DJDFFEBSKJCGHC-UHFFFAOYSA-N,Small molecule,False,NAPHAZOLINE HYDROCHLORIDE,1971.0,4.0,CHEMBL761,False,True,"['Albalon' 'Antistin-privine' 'Gppe nsl soln' 'Nafazair' 'Naphaz hcl'
 'Naphazoline hydrochloride' 'Naphcon forte' 'Opcon' 'Vasocon']","['NSC-35711' 'Naphazoline HCl' 'Naphazoline hcl'
 'Naphazoline hydrochloride' 'Naphazoline nitrate']","[('DailyMed', array(['naphazoline%20hydrochloride'], dtype=object)), ('PubChem', array(['56422379', '855777'], dtype=object)), ('chEBI', array(['7470'], dtype=object))]",,"{'rows': array(['EFO_0000678', 'MP_0001845', 'HP_0001742', 'EFO_0007328',
       'EFO_0003956', 'EFO_0007214', 'EFO_0007486'], dtype=object), 'count': 7}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 4 approved and 3 investigational indications.
CHEMBL2037511,CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C,UWHCWRQFNKUYCG-QUZACWSFSA-N,Small molecule,False,EPELSIBAN,,2.0,,False,False,[],['Epelsiban' 'GSK-557296' 'GSK557296' 'GSK557296B' 'Gsk557296'],"[('drugbank', array(['DB11934'], dtype=object))]",['CHEMBL2105736'],"{'rows': array(['EFO_1001757', 'EFO_0803321'], dtype=object), 'count': 2}",[ENSG00000180914],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108147,,,Enzyme,False,STREPTOKINASE,1997.0,4.0,,False,True,['Kabikinase'],['Streptokinase' 'Streptokinase c'],,,"{'rows': array(['EFO_1000652', 'EFO_1001375', 'HP_0004419', 'EFO_0000612',
       'HP_0002140', 'EFO_0008583', 'HP_0004936'], dtype=object), 'count': 7}",[ENSG00000122194],Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for recurrent thrombophlebitis and has 6 investigational indications.
CHEMBL2109321,,,Antibody,False,CAROTUXIMAB,,3.0,,False,False,[],['Carotuximab' 'DE-122' 'TRC-105' 'Trc105' 'c-SN6j'],,,"{'rows': array(['MONDO_0007254', 'EFO_0000349', 'MONDO_0004992', 'EFO_1001968',
       'EFO_0000640', 'EFO_0002499', 'MONDO_0003268', 'EFO_0003968',
       'EFO_1001111', 'MONDO_0008903', 'EFO_0003060', 'EFO_1001465',
       'MONDO_0008315', 'EFO_0009708', 'EFO_0000681', 'EFO_0000519',
       'EFO_0002893', 'EFO_0001365', 'EFO_0000616', 'EFO_0002501',
       'EFO_0000182'], dtype=object), 'count': 21}",[ENSG00000106991],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.
CHEMBL2109643,,,Antibody,False,F19 131I,,3.0,,False,False,[],['BIBH-1' 'F19' 'F19 131i'],,,"{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}",[ENSG00000078098],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2110580,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1,FIGNGSHKNAHTSH-JJMFXPFOSA-N,Small molecule,False,BERUBICIN,,2.0,,False,False,[],['Berubicin'],,['CHEMBL2103796'],"{'rows': array(['EFO_0000519', 'MONDO_0100342', 'EFO_0000519', 'EFO_0005543',
       'EFO_0000313'], dtype=object), 'count': 5}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL218490,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,IAVUPMFITXYVAF-XPUUQOCRSA-N,Small molecule,False,DORZOLAMIDE,1994.0,4.0,,False,True,['Dorzant' 'Trusopt'],"['Dorzolamide' 'Dorzolamide, trans-(-)-' 'MK-507' 'Trusopt']","[('Wikipedia', array(['Dorzolamide'], dtype=object)), ('drugbank', array(['DB00869'], dtype=object)), ('chEBI', array(['4702'], dtype=object))]",['CHEMBL1201162'],"{'rows': array(['EFO_0004190', 'EFO_1001069', 'MONDO_0005041', 'MONDO_0005041',
       'EFO_0004190', 'EFO_0004683', 'EFO_1001069'], dtype=object), 'count': 7}",[ENSG00000104267],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 3 investigational indications.
CHEMBL259209,CCN(CC)C(=O)C1(c2ccccc2)CC1CN,GJJFMKBJSRMPLA-UHFFFAOYSA-N,Small molecule,True,MILNACIPRAN,2009.0,4.0,,False,True,[],['Impulsor' 'Midalcipran' 'Milnacipran'],"[('drugbank', array(['DB04896'], dtype=object))]",['CHEMBL4297064' 'CHEMBL3527085'],"{'rows': array(['EFO_0005762', 'HP_0003419', 'EFO_0005687', 'MONDO_0002050',
       'EFO_0000555', 'HP_0003418', 'EFO_0003100', 'EFO_0005687',
       'MONDO_0002009'], dtype=object), 'count': 9}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL301742,NC[C@H](CC(=O)O)c1ccc(Cl)cc1,KPYSYYIEGFHWSV-QMMMGPOBSA-N,Small molecule,False,ARBACLOFEN,,3.0,,False,False,[],"['(r)-baclofen' 'Arbaclofen' 'Baclofen (r)-form' 'Baclofen, (r)-'
 'Baclofen, r(-)-' 'Baclofen, r-' 'D-baclofen' 'R-(-)-baclofen' 'STX-209'
 'STX209']","[('PubChem', array(['11113710'], dtype=object)), ('drugbank', array(['DB08891'], dtype=object))]",,"{'rows': array(['EFO_0003756', 'MONDO_0010383', 'HP_0001257'], dtype=object), 'count': 3}","[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3545168,,,Small molecule,False,IMD-1041,,2.0,,False,False,[],['Imd-1041'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000104365],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545374,,,Antibody,False,TREVOGRUMAB,,2.0,,False,False,[],"['Human igg4 anti-myostatin mab' 'REGN-1033' 'REGN1033' 'SAR-391786'
 'SAR391786' 'Trevogrumab']",,,"{'rows': array(['EFO_1000653', 'EFO_0007323'], dtype=object), 'count': 2}",[ENSG00000138379],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297884,,,Antibody,False,PEPINEMAB,,2.0,,False,False,[],"['Anti-sema4d monoclonal antibody vx15/2503' 'Pepinemab' 'VX-15'
 'VX-152503' 'VX15' 'VX15/2503' 'Vx15/2503']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEPINEMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0000616', 'EFO_0000181', 'EFO_0003060',
       'EFO_0000389', 'MONDO_0007254', 'EFO_0000637', 'MONDO_0007739',
       'MONDO_0005301'], dtype=object), 'count': 9}",[ENSG00000187764],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL450,CCC1(CC)C(=O)NC(=O)N(C)C1=O,FWJKNZONDWOGMI-UHFFFAOYSA-N,Small molecule,False,METHARBITAL,1982.0,4.0,,False,True,['Gemonil'],['Endiemal' 'Metharbital' 'Metharbital ciii' 'Metharbitone' 'NSC-27156'],"[('PubChem', array(['144206305'], dtype=object)), ('Wikipedia', array(['Metharbital'], dtype=object)), ('drugbank', array(['DB00463'], dtype=object))]",,"{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for epilepsy.
CHEMBL4585668,CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F,LOMMPXLFBTZENJ-ZACQAIPSSA-N,Small molecule,True,BELZUTIFAN,2021.0,4.0,,False,True,['Welireg'],"['Belzutifan' 'MK-6482' 'MK6482' 'Mk-6482' 'PT-2977' 'PT2977' 'Pt 2977'
 'Pt2977']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELZUTIFAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1000045', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000681',
       'EFO_0003884', 'EFO_0001421', 'EFO_0000349', 'MONDO_0016748',
       'MONDO_0008667'], dtype=object), 'count': 9}",[ENSG00000116016],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL464,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C,HQMNCQVAMBCHCO-DJRRULDNSA-N,Small molecule,False,ETRETINATE,1986.0,4.0,,True,True,['Tegison' 'Tigason'],"['Acitretin related compound b' 'Ethyl etrinoate' 'Etretinate'
 'NSC-297936' 'RO 10-9359' 'RO-10-9359' 'RO-109359']","[('PubChem', array(['144206054', '170465372', '50112753'], dtype=object)), ('Wikipedia', array(['Etretinate'], dtype=object)), ('chEBI', array(['4913'], dtype=object))]",,"{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}","[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for psoriasis. It was withdrawn in at least one region.
CHEMBL4650437,,,Antibody,False,EBDAROKIMAB,,3.0,,False,False,[],['AK-101' 'AK101' 'Ak101' 'Ebdarokimab'],,,"{'rows': array(['EFO_1001494', 'EFO_0000676'], dtype=object), 'count': 2}","[ENSG00000113302,ENSG00000110944,ENSG00000168811]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL582857,COc1ccc(S(=O)(=O)N2C(=O)[C@@](c3ccccc3OC)(N3C[C@H](O)C[C@H]3C(=O)N(C)C)c3cc(Cl)ccc32)c(OC)c1,NJXZWIIMWNEOGJ-WEWKHQNJSA-N,Small molecule,False,NELIVAPTAN,,2.0,,False,False,[],"['Nelivaptan' 'SR-149415' 'SSR-149,415' 'SSR-149415' 'SSR149415'
 'Ssr149415']","[('PubChem', array(['144210560'], dtype=object)), ('Wikipedia', array(['Nelivaptan'], dtype=object)), ('drugbank', array(['DB12643'], dtype=object))]",['CHEMBL1098000'],"{'rows': array(['MONDO_0002050', 'EFO_0005230'], dtype=object), 'count': 2}",[ENSG00000198049],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL981,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,MQOBSOSZFYZQOK-UHFFFAOYSA-N,Small molecule,False,FENOFIBRIC ACID,2009.0,4.0,,False,True,"['Fenocor-67' 'Fenogal' 'Fibricor' 'Lipanthyl' 'Lipofen' 'Lofibra'
 'Supralip' 'Trilipix']","['Fenofibrate free acid' 'Fenofibrate related compound b'
 'Fenofibric acid' 'LF-153' 'NSC-281318' 'Procetofenic acid']","[('DailyMed', array(['fenofibric%20acid'], dtype=object)), ('drugbank', array(['DB13873'], dtype=object)), ('chEBI', array(['83469'], dtype=object))]",['CHEMBL1201745'],"{'rows': array(['EFO_0000319', 'EFO_0004211', 'MONDO_0001751', 'HP_0003124',
       'EFO_0001645', 'MONDO_0007079', 'HP_0003124', 'Orphanet_309005',
       'EFO_0002939', 'Orphanet_79211', 'MONDO_0005148'], dtype=object), 'count': 11}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 8 investigational indications.
CHEMBL1200426,CN1CCCC(CC2c3ccccc3Sc3ccccc32)C1.Cl.O,RAOHHYUBMJLHNC-UHFFFAOYSA-N,Small molecule,False,METHIXENE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201342,False,True,['Metixen' 'Tremaril' 'Tremarit' 'Tremonil' 'Trest'],"['Anhydrous metixene hydrochloride' 'Methixene hcl'
 'Methixene hydrochloride' 'Methixene hydrochloride anhydrous'
 'Metixene hydrochloride' 'Metixene hydrochloride anhydrous' 'NSC-78194'
 'SJ 1977' 'SJ-1977']","[('PubChem', array(['56463218'], dtype=object)), ('chEBI', array(['51025'], dtype=object))]",,,"[ENSG00000168539,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200759,Cl.O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1,TVWRQCIPWUCNMI-UHFFFAOYSA-N,Small molecule,False,ANAGRELIDE HYDROCHLORIDE,1997.0,4.0,CHEMBL760,False,True,"['Agrelin' 'Agrylin' 'Anagrelide hydrochloride' 'Anagrelide mylan'
 'Xagrid']","['Anagrelide hcl' 'Anagrelide hydrochloride'
 'Anagrelide hydrochloride hydrate' 'Anagrelide hydrochloride monohydrate'
 'BL-4162A' 'BMY-26538-01' 'NSC-724577' 'NSC-759170' 'Thromboreductin']","[('DailyMed', array(['anagrelide%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/anagrelide-mylan'],
      dtype=object)), ('PubChem', array(['49681599'], dtype=object)), ('chEBI', array(['55345'], dtype=object))]",,"{'rows': array(['MONDO_0000831', 'EFO_0000479', 'EFO_0004251', 'HP_0004419'],
      dtype=object), 'count': 4}","[ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved indications.
CHEMBL1200895,NNCCc1ccccc1.O=S(=O)(O)O,RXBKMJIPNDOHFR-UHFFFAOYSA-N,Small molecule,True,PHENELZINE SULFATE,1961.0,4.0,CHEMBL1089,False,True,['Nardil' 'Phenelzine sulfate'],"['NSC-170957' 'Phenelzine acid sulfate' 'Phenelzine sulfate'
 'Phenelzine sulphate']","[('DailyMed', array(['phenelzine%20sulfate'], dtype=object)), ('PubChem', array(['11533068', '144203787', '144207332', '170465229', '26747636',
       '26747637', '49681616', '50106853'], dtype=object)), ('chEBI', array(['8061'], dtype=object))]",,"{'rows': array(['EFO_0000673', 'MONDO_0007254'], dtype=object), 'count': 2}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200984,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=C(O)/C=C\C(=O)O,TZNOWAJJWCGILX-BTJKTKAUSA-N,Small molecule,False,AMLODIPINE MALEATE,2003.0,4.0,CHEMBL1491,False,True,['Amvaz'],"['Amlodipine maleate' 'UK-48,340-11' 'UK-48340-11']",,,,"[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003.
CHEMBL1206245,COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(OP(=O)(O)O)c2)c(OC)c1,LXENKEWVEVKKGV-BQYQJAHWSA-N,Small molecule,False,BRICICLIB,,2.0,,False,False,[],['Briciclib' 'ON 014185' 'ON-014185' 'ON014185' 'On-013105'],"[('drugbank', array(['DB12004'], dtype=object))]",['CHEMBL3137303' 'CHEMBL1627071'],"{'rows': array(['EFO_0000220', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000110092],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1316,CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12,PUXBGTOOZJQSKH-UHFFFAOYSA-N,Small molecule,False,CARPROFEN,1987.0,4.0,,False,True,['Rimadyl'],"['Carprofen' 'Carprofen for veterinary use' 'NSC-297935' 'RO 20-5720/000'
 'Ro-205720000']","[('PubChem', array(['144204916', '170464799', '26748565', '50085988'], dtype=object)), ('Wikipedia', array(['Carprofen'], dtype=object)), ('drugbank', array(['DB00821'], dtype=object)), ('chEBI', array(['364453'], dtype=object))]",,,[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL1513,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,YOSHYTLCDANDAN-UHFFFAOYSA-N,Small molecule,True,IRBESARTAN,1997.0,4.0,,False,True,['Aprovel' 'Avapro' 'Ifirmasta' 'Irbesartan' 'Karvea' 'Sabervel'],"['BMS-186295' 'Irbesartan' 'Irbesartan bms' 'Irbesartan teva'
 'Irbesartan zentiva' 'NSC-758696' 'SR 47436' 'SR-47436' 'Sarbevel']","[('DailyMed', array(['irbesartan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/karvea'],
      dtype=object)), ('PubChem', array(['144204986', '170464670', '26719813', '26748950'], dtype=object)), ('Wikipedia', array(['Irbesartan'], dtype=object)), ('drugbank', array(['DB01029'], dtype=object)), ('chEBI', array(['5959'], dtype=object))]",,"{'rows': array(['MONDO_0007947', 'EFO_0003884', 'EFO_0004220', 'EFO_0004194',
       'EFO_0000373', 'MONDO_0100096', 'MONDO_0005148', 'EFO_0000694',
       'EFO_0000275', 'EFO_0000401', 'HP_0001919', 'EFO_0000319',
       'EFO_0003884', 'EFO_0004236', 'EFO_1001375', 'MONDO_0017314',
       'EFO_0000537', 'HP_0100806', 'EFO_0007243', 'HP_0003124',
       'MONDO_0001134'], dtype=object), 'count': 21}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1536,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12,MECHNRXZTMCUDQ-RKHKHRCZSA-N,Small molecule,False,ERGOCALCIFEROL,1941.0,4.0,,False,True,"['Calciferol' 'Calciferol in arach oil' 'Caltrate' 'D-forte' 'Deltalin'
 'Drisdol' 'Eciferol d2' 'Ergo-d2' 'Ergocalciferol' 'Ergoral d2' 'Lanes'
 'Oleovitamin D' 'Osto-d2' 'Sterogyl' 'Sterogyl 15h' 'Sterogyl-15'
 'Uvesterol d' 'Vitamin D 2' 'Vitamin d']","['Calciferol' 'Ergocalciferol' 'Ergocalciferolum' 'Ergorone' 'NSC-62792'
 'Oleovitamin d, synthetic' 'Ostelin' 'Viosterol' 'Viosterol in oil'
 'Vitamin d (ergocalciferol)' 'Vitamin d2']","[('DailyMed', array(['ergocalciferol'], dtype=object)), ('PubChem', array(['144205957', '144209546', '144213069', '57264355'], dtype=object)), ('Wikipedia', array(['Ergocalciferol'], dtype=object)), ('drugbank', array(['DB00153'], dtype=object)), ('chEBI', array(['28934'], dtype=object))]",,"{'rows': array(['EFO_0007319', 'EFO_0000574', 'EFO_0003854', 'HP_0002901',
       'EFO_0007176', 'EFO_0004278', 'EFO_0008519', 'EFO_0000676',
       'EFO_0004593', 'EFO_0004288', 'EFO_0003917', 'MONDO_0002171',
       'EFO_0001378', 'EFO_0003834', 'EFO_0003882', 'HP_0002148',
       'MONDO_0005148', 'MONDO_0100096', 'Orphanet_309005', 'EFO_0004261',
       'EFO_0003762', 'HP_0000938', 'EFO_0000389', 'GO_0042697',
       'EFO_0009706', 'EFO_1001375', 'MONDO_0011962', 'MONDO_0024300',
       'HP_0003549', 'EFO_0004270', 'EFO_0009451', 'MONDO_0019019',
       'EFO_0009314', 'EFO_0003869', 'EFO_0003095', 'MONDO_0008315',
       'MONDO_0008903', 'EFO_0003843', 'EFO_0000673', 'MONDO_0007254',
       'EFO_0003767', 'EFO_0003144', 'EFO_0008572', 'EFO_0004247',
       'EFO_0005952', 'MONDO_0021063', 'MONDO_0004975', 'MONDO_0005277',
       'HP_0005521', 'EFO_1000049', 'EFO_0000764', 'EFO_1000783',
       'EFO_0004616', 'MONDO_0018076', 'EFO_0009516', 'EFO_1001951',
       'EFO_0005762', 'MONDO_0002974', 'EFO_0002614', 'EFO_0000660',
       'EFO_0003964', 'MONDO_0005147', 'EFO_1000653', 'EFO_1001494',
       'EFO_0003931', 'MONDO_0004992', 'EFO_0003047', 'EFO_1001792',
       'EFO_0007405', 'EFO_0003884', 'EFO_1001919', 'Orphanet_89936',
       'EFO_0001073', 'EFO_0000729', 'MONDO_0005301', 'MONDO_0004979',
       'MONDO_0011382', 'EFO_0000565', 'EFO_0004220', 'EFO_0002950',
       'EFO_0000384', 'EFO_0004192', 'EFO_0000400'], dtype=object), 'count': 83}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1941 and has 3 approved and 80 investigational indications.
CHEMBL2103758,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,TZIRZGBAFTZREM-MKAGXXMWSA-N,Protein,True,PRAMLINTIDE,2005.0,4.0,,False,True,[],['AC-0137' 'AC-137' 'AC0137' 'AC137' 'Pramlintide' 'Tripro-amylin'],"[('drugbank', array(['DB01278'], dtype=object))]",['CHEMBL3833353'],"{'rows': array(['EFO_0001073', 'EFO_0001073', 'MONDO_0005148', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0005147', 'MONDO_0005147'], dtype=object), 'count': 7}","[ENSG00000004948,ENSG00000132329,ENSG00000131477,ENSG00000122679]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for diabetes mellitus and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2104964,Cc1ccc(S(=O)(=O)O)cc1.Clc1ccc(OC[C@H]2CCN2)cn1,JCPWIGCGJUGLJQ-OGFXRTJISA-N,Small molecule,False,TEBANICLINE TOSYLATE,,2.0,CHEMBL430497,False,False,[],"['A-165594' 'A-166594.47' 'A-16659447' 'ABT-165594' 'ABT-594'
 'Ebanicline tosylate' 'Tebanicline tosilate' 'Tebanicline tosylate']",,,,"[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2107779,C/C(=N\NC(=N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(/C(C)=N/NC(=N)N)cc(/C(C)=N/NC(=N)N)c2)cc(/C(C)=N/NC(=N)N)c1,PWDYHMBTPGXCSN-VCBMUGGBSA-N,Small molecule,False,SEMAPIMOD,,2.0,,False,False,[],"['AXD-455' 'CNI-1493' 'CPSI-2364 FREE BASE' 'Cni-1493' 'Semapimod'
 'Semapimod hydrochloride' 'Semapimod tetrahydrochloride']","[('drugbank', array(['DB12094'], dtype=object))]",,"{'rows': array(['EFO_0000384'], dtype=object), 'count': 1}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107831,CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC,NOZIJMHMKORZBA-KJCUYJGMSA-N,Small molecule,False,LUSUTROMBOPAG,2018.0,4.0,,False,True,['Mulpleo (previously lusutrombopag shionogi)' 'Mulpleta' 'S-888711'],['Lusutrombopag' 'RSC888711' 'S-888711'],"[('DailyMed', array(['lusutrombopag'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo'],
      dtype=object)), ('drugbank', array(['DB13125'], dtype=object))]",,"{'rows': array(['HP_0001873', 'EFO_0007160', 'MP_0001914'], dtype=object), 'count': 3}",[ENSG00000117400],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for thrombocytopenia and hemorrhage and has 1 investigational indication.
CHEMBL2108252,,,Antibody,False,APOLIZUMAB,,2.0,,False,False,['Remitogen smart1d10'],['Apolizumab' 'HU-1D10' 'HU1D10' 'Remitogen'],,,"{'rows': array(['EFO_0000403', 'EFO_0000095', 'EFO_0000574', 'MONDO_0018906',
       'EFO_1001469'], dtype=object), 'count': 5}","[ENSG00000231679,ENSG00000198502,ENSG00000196126,ENSG00000227357]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2109410,,,Antibody,False,TB-402,,2.0,,False,False,[],['TB-402' 'Tb-402'],,,"{'rows': array(['EFO_0004286'], dtype=object), 'count': 1}",[ENSG00000185010],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2181927,CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2,BTBHLEZXCOBLCY-QGZVFWFLSA-N,Small molecule,False,FINERENONE,2021.0,4.0,,False,True,['Kerendia'],['BAY 94-8862' 'BAY-94-8862' 'Bay94-8862' 'Finerenone'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia'],
      dtype=object))]",,"{'rows': array(['EFO_0000401', 'EFO_0003884', 'MONDO_0005148', 'EFO_0000319',
       'EFO_0003144'], dtype=object), 'count': 5}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications.
CHEMBL313971,COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O,YKPUWZUDDOIDPM-VURMDHGXSA-N,Small molecule,False,ZUCAPSAICIN,,3.0,,False,False,[],['Civamide' 'Zucapsaicin'],"[('PubChem', array(['11112338', '11113255', '11113512', '11113513', '124882262',
       '124882263', '26719735'], dtype=object)), ('drugbank', array(['DB09120'], dtype=object))]",,"{'rows': array(['EFO_1000906', 'HP_0002829', 'EFO_0004616', 'HP_0003326',
       'EFO_0003843', 'MONDO_0041052'], dtype=object), 'count': 6}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3545414,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,FYJROXRIVQPKRY-UHFFFAOYSA-N,Small molecule,False,RIVOCERANIB MESYLATE,,3.0,CHEMBL3186534,False,False,['Aitan'],"['Apatinib (registered name in China)' 'Apatinib mesylate'
 'Rivoceranib mesylate' 'YN-968D1' 'Yn-968d1']",,,"{'rows': array(['EFO_1000359', 'EFO_0004252', 'EFO_0000231', 'MONDO_0007254',
       'EFO_0001061', 'EFO_0000756', 'EFO_0000702', 'MONDO_0008170',
       'EFO_0000178', 'EFO_0006859', 'EFO_1001968', 'EFO_0005221',
       'MONDO_0003060', 'MONDO_0002120', 'EFO_0004142', 'MONDO_0001056',
       'EFO_0003868', 'EFO_1001951', 'MONDO_0004992', 'EFO_0000182',
       'EFO_0000313', 'EFO_0000571', 'MONDO_0008903', 'EFO_1001961',
       'MONDO_0021063', 'EFO_1001956', 'EFO_0002939', 'EFO_0001071',
       'EFO_0005537', 'MONDO_0100342', 'EFO_0000199', 'MONDO_0002108',
       'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869',
       'HP_0001541', 'MONDO_0002974', 'EFO_0003891', 'EFO_0000637',
       'EFO_0002916', 'EFO_0005543', 'EFO_0003897', 'EFO_0000181',
       'EFO_0000616', 'EFO_0005922', 'EFO_0000691', 'EFO_0000621',
       'EFO_0003893', 'MONDO_0018944', 'EFO_0000707', 'EFO_0000211',
       'MONDO_0007576', 'EFO_0002618', 'EFO_1002017', 'EFO_0009708',
       'EFO_0000365', 'EFO_0000574', 'EFO_0000503', 'EFO_0003860',
       'EFO_0000681', 'MONDO_0008315'], dtype=object), 'count': 62}",[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 62 investigational indications.
CHEMBL3707398,,,Small molecule,False,PAC-14028,,3.0,,False,False,[],['Asivatrep' 'Pac-14028'],,,"{'rows': array(['HP_0000989', 'EFO_0000274', 'EFO_1000764', 'EFO_1000760'],
      dtype=object), 'count': 4}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL375611,N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21,AVDUGNCTZRCAHH-MDASVERJSA-N,Small molecule,False,LY404039,,1.0,,False,False,[],"['LY-404039' 'LY-404039, (-)-' 'LY404039' 'Ly 404039' 'Ly-404039'
 'Ly404039' 'Pomaglumetad']",,,,"[ENSG00000164082,ENSG00000198822]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL38434,Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O,PHEZJEYUWHETKO-UHFFFAOYSA-N,Small molecule,False,BREQUINAR,,2.0,,False,False,[],['Brequinar'],"[('drugbank', array(['DB03523'], dtype=object))]",['CHEMBL300058'],"{'rows': array(['MONDO_0100096', 'MONDO_0100096', 'EFO_0000222'], dtype=object), 'count': 3}",[ENSG00000102967],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3900554,Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,ZRYMMWAJAFUANM-INIZCTEOSA-N,Small molecule,False,BMS-986142,,2.0,,False,False,[],['Bms-986142'],"[('drugbank', array(['DB15291'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'MONDO_0005178'], dtype=object), 'count': 2}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594442,Cc1cc(-c2nnc(N)nc2-c2ccc(F)cc2)cc(Cl)n1,NCWQLHHDGDXIJN-UHFFFAOYSA-N,Small molecule,False,IMARADENANT,,2.0,,False,False,[],"['AZD-4635' 'AZD4635' 'Azd 4635' 'Azd4635' 'HTL-1071' 'HTL1071'
 'Imaradenant']",,,"{'rows': array(['MONDO_0008315', 'EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 3}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL507282,Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1,FPNPSEMJLALQSA-MIYUEGBISA-N,Small molecule,False,DENUFOSOL,,3.0,,False,False,[],['Denufosol'],"[('drugbank', array(['DB04983'], dtype=object))]",['CHEMBL1767407'],"{'rows': array(['EFO_0005773', 'MONDO_0009061', 'MONDO_0003005', 'EFO_1001417'],
      dtype=object), 'count': 4}",[ENSG00000175591],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL5095022,CC(C)S(=O)(=O)N[C@H]1COC[C@H]1Oc1ccc(-c2ccc(C#N)s2)cc1,TTYKUKSFWHEBLI-DLBZAZTESA-N,Small molecule,False,PESAMPATOR,,2.0,,False,False,[],"['BIIB-104' 'BIIB104' 'PF-04958242' 'PF-4958242' 'Pesampator'
 'Pf-04958242']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PESAMPATOR/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001176', 'EFO_0000677', 'MONDO_0005090', 'HP_0001268'],
      dtype=object), 'count': 4}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL514201,C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl,ZMELOYOKMZBMRB-DLBZAZTESA-N,Small molecule,False,TALMAPIMOD,,2.0,,False,False,[],['SCIO 469' 'SCIO-469' 'Scio-469' 'Talmapimod'],"[('drugbank', array(['DB05412'], dtype=object)), ('chEBI', array(['90683'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_0001378'], dtype=object), 'count': 2}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL818,N=C(N)NCc1cccc(I)c1,PDWUPXJEEYOOTR-UHFFFAOYSA-N,Small molecule,False,IOBENGUANE,1994.0,4.0,,False,True,[],['Iobenguane' 'Iobenguane (127-i)'],"[('PubChem', array(['11111341', '90341658'], dtype=object)), ('Wikipedia', array(['Iobenguane'], dtype=object)), ('drugbank', array(['DB06704'], dtype=object))]","['CHEMBL1374843' 'CHEMBL1615777' 'CHEMBL3989511' 'CHEMBL4584538'
 'CHEMBL1615779' 'CHEMBL3989523' 'CHEMBL1255738']","{'rows': array(['MONDO_0024503', 'EFO_1000453', 'EFO_0000621', 'EFO_0003144',
       'EFO_0000621', 'EFO_0000373', 'EFO_1001901', 'EFO_0000239'],
      dtype=object), 'count': 8}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 5 investigational indications.
CHEMBL832,O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,MBGGBVCUIVRRBF-UHFFFAOYSA-N,Small molecule,False,SULFINPYRAZONE,1959.0,4.0,,False,True,['Anturan' 'Anturane' 'Sulfinpyrazone'],['NSC-75925' 'Sulfinpyrazone' 'Sulphinpyrazone'],"[('PubChem', array(['11112139', '124881954', '144203882', '170464677', '26747070',
       '46500625', '855982'], dtype=object)), ('Wikipedia', array(['Sulfinpyrazone'], dtype=object)), ('drugbank', array(['DB01138'], dtype=object)), ('chEBI', array(['9342'], dtype=object))]",,"{'rows': array(['EFO_0004274'], dtype=object), 'count': 1}",[ENSG00000197891],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for gout.
CHEMBL957,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,GJPICJJJRGTNOD-UHFFFAOYSA-N,Small molecule,True,BOSENTAN,2001.0,4.0,,False,True,['Stayveer' 'Tracleer'],"['Anhydrous bosentan' 'Bosentan' 'Bosentan anhydrous' 'Bosentan hydrate'
 'Bosentan monohydrate' 'RO 47-0203/029' 'RO-47-0203-029' 'RO-470203029']","[('DailyMed', array(['bosentan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/stayveer',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer'],
      dtype=object)), ('PubChem', array(['144205997', '170465245'], dtype=object)), ('Wikipedia', array(['Bosentan'], dtype=object)), ('drugbank', array(['DB00559'], dtype=object)), ('chEBI', array(['51450'], dtype=object))]",['CHEMBL175616'],"{'rows': array(['EFO_0000768', 'EFO_0000537', 'EFO_0000373', 'EFO_1001103',
       'EFO_0003877', 'HP_0001945', 'EFO_0000616', 'EFO_1000809',
       'EFO_1001346', 'EFO_0001361', 'EFO_0009200', 'EFO_0001422',
       'EFO_0000717', 'MONDO_0004979', 'EFO_0002618', 'MONDO_0004933',
       'EFO_0000400', 'MONDO_0007172', 'MONDO_0005148', 'MONDO_0005149',
       'EFO_0005207', 'EFO_0005207', 'MONDO_0043839', 'EFO_0000341',
       'EFO_0000756', 'MONDO_0005041', 'EFO_0007372'], dtype=object), 'count': 27}","[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1037,N=C(N)NCC1COC2(CCCCC2)O1,HPBNRIOWIXYZFK-UHFFFAOYSA-N,Small molecule,False,GUANADREL,1982.0,4.0,,False,True,[],['Guanadrel' 'Hylorel'],"[('Wikipedia', array(['Guanadrel'], dtype=object)), ('drugbank', array(['DB00226'], dtype=object)), ('chEBI', array(['5555'], dtype=object))]",['CHEMBL3184143'],,[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200878,CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,TZIZWYVVGLXXFV-FLRHRWPCSA-N,Small molecule,False,TRIAMCINOLONE HEXACETONIDE,1969.0,4.0,,False,True,['Aristospan' 'Lederspan'],['CL 34433' 'CL-34433' 'TATBA' 'Triamcinolone hexacetonide'],"[('PubChem', array(['144206532'], dtype=object)), ('chEBI', array(['9670'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'MONDO_0005178', 'EFO_0000685', 'EFO_0004616',
       'EFO_1000999'], dtype=object), 'count': 5}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and is indicated for osteoarthritis and has 4 investigational indications.
CHEMBL1201139,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,Small molecule,False,MEGESTROL ACETATE,1971.0,4.0,,False,True,['Megace' 'Megace es' 'Megestrol acetate' 'Ovaban'],"['5071' 'BDH 1298' 'BDH-1298' 'Chronopil' 'Megesterol acetate' 'Megestrol'
 'Megestrol 17.alpha.-acetate' 'Megestrol acetate' 'NSC-71423' 'SC 10363'
 'SC-10363']","[('DailyMed', array(['megestrol%20acetate'], dtype=object)), ('PubChem', array(['144204020', '144212677', '170465406', '26719675', '56422102',
       '856018'], dtype=object)), ('drugbank', array(['DB00351'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0002715', 'MONDO_0002691', 'HP_0031217',
       'EFO_0004230', 'HP_0002039', 'EFO_1001512', 'HP_0004326',
       'EFO_0000765', 'MONDO_0004992', 'EFO_0007312', 'EFO_0006859',
       'MONDO_0011962', 'MONDO_0003778', 'MONDO_0007254', 'EFO_0000616',
       'EFO_0007532', 'MONDO_0024474', 'EFO_0003869', 'HP_0000726',
       'EFO_1000796'], dtype=object), 'count': 21}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 6 approved and 15 investigational indications.
CHEMBL1201173,CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C,GZENKSODFLBBHQ-ILSZZQPISA-N,Small molecule,False,MEDRYSONE,1969.0,4.0,,False,True,[],['Hydroxymesterone' 'Medrysone' 'NSC-63278' 'U-8471'],"[('PubChem', array(['11533031', '144204077', '170465194', '56423131'], dtype=object)), ('Wikipedia', array(['Medrysone'], dtype=object)), ('drugbank', array(['DB00253'], dtype=object)), ('chEBI', array(['34829'], dtype=object))]",,"{'rows': array(['EFO_0005752'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969 and is indicated for eye inflammation.
CHEMBL1201250,CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O,JSZILQVIPPROJI-UHFFFAOYSA-N,Small molecule,False,BENZQUINAMIDE,1974.0,4.0,,False,True,[],"['Benzchinamide' 'Benzquinamide' 'NSC-108159' 'NSC-169193' 'NSC-64375'
 'P-2647' 'Promecon']","[('PubChem', array(['170465138'], dtype=object)), ('Wikipedia', array(['Benzquinamide'], dtype=object)), ('drugbank', array(['DB00767'], dtype=object)), ('chEBI', array(['27662'], dtype=object))]",['CHEMBL1200707'],,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974.
CHEMBL1201733,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl,MQHIQUBXFFAOMK-UHFFFAOYSA-N,Small molecule,True,PAZOPANIB HYDROCHLORIDE,2009.0,4.0,CHEMBL477772,False,True,['Votrient'],"['GW-786034B' 'GW786034B' 'Pazopanib (as hydrochloride)' 'Pazopanib hcl'
 'Pazopanib hydrochloride' 'Pazopanib monohydrochloride']","[('DailyMed', array(['pazopanib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/votrient'],
      dtype=object)), ('chEBI', array(['71217'], dtype=object))]",,"{'rows': array(['MONDO_0002087', 'EFO_0003016', 'EFO_0000681', 'EFO_0000501',
       'MONDO_0001187', 'MONDO_0015277', 'EFO_1001465', 'MONDO_0008903',
       'EFO_1000613', 'MONDO_0004192', 'EFO_0000349', 'MONDO_0002158',
       'EFO_0003968', 'MONDO_0004986', 'EFO_0000588', 'EFO_0001663',
       'EFO_0000691', 'EFO_0000641', 'MONDO_0008315', 'EFO_0000640',
       'MONDO_0008667', 'MONDO_0007254', 'EFO_1001968', 'EFO_0000616',
       'EFO_0006861', 'EFO_0000335', 'EFO_0000389', 'MONDO_0008170'],
      dtype=object), 'count': 28}","[ENSG00000077782,ENSG00000113263,ENSG00000182866,ENSG00000068078,ENSG00000157404,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201833,,,Antibody,True,GOLIMUMAB,2009.0,4.0,,False,True,['Simponi'],['CNTO 148' 'CNTO-148' 'Golimumab'],"[('DailyMed', array(['golimumab'], dtype=object)), ('DrugCentral', array(['4967'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/simponi'],
      dtype=object)), ('Wikipedia', array(['Golimumab'], dtype=object))]",,"{'rows': array(['EFO_0000384', 'EFO_0002609', 'EFO_0000706', 'EFO_0009672',
       'EFO_0000540', 'MONDO_0004979', 'EFO_0000729', 'MONDO_0019338',
       'EFO_0003898', 'MONDO_0005147', 'EFO_0003778', 'MONDO_0005178',
       'EFO_0000685', 'MONDO_0003937'], dtype=object), 'count': 14}",[ENSG00000232810],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1518,CCCc1cc(=O)[nH]c(=S)[nH]1,KNAHARQHSZJURB-UHFFFAOYSA-N,Small molecule,True,PROPYLTHIOURACIL,1947.0,4.0,,False,True,['Propacil' 'Propylthiouracil' 'Prothyran' 'Thyreostat'],['NSC-6498' 'NSC-70461' 'Propylthiouracil' 'Thyreostat ii'],"[('DailyMed', array(['propylthiouracil'], dtype=object)), ('PubChem', array(['11112111', '144204433', '144208939', '144210600', '170464965',
       '17389748', '174006773', '26751509', '855783'], dtype=object)), ('TG-GATEs', array(['29'], dtype=object)), ('Wikipedia', array(['Propylthiouracil'], dtype=object)), ('drugbank', array(['DB00550'], dtype=object)), ('chEBI', array(['8502'], dtype=object))]",,"{'rows': array(['EFO_0009190', 'EFO_1001466', 'EFO_0009189', 'HP_0002140',
       'HP_0000820'], dtype=object), 'count': 5}","[ENSG00000115705,ENSG00000211452]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and is indicated for hyperthyroidism and abnormality of the thyroid gland and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1615438,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1,ZCGOMHNNNFPNMX-KYTRFIICSA-N,Small molecule,False,LEVOCABASTINE,1993.0,4.0,,False,True,['Livostin direct'],['Levocabastine' 'R-50547'],"[('drugbank', array(['DB01106'], dtype=object))]",['CHEMBL1237102'],"{'rows': array(['EFO_1001417', 'EFO_0003956', 'HP_0001742', 'EFO_0005751',
       'EFO_1001417'], dtype=object), 'count': 5}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for nasal congestion and eye allergy and has 3 investigational indications.
CHEMBL1650595,NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1,YULUCECVQOCQFQ-UHFFFAOYSA-N,Small molecule,False,AR-12,,1.0,,False,False,[],['AR-12' 'Ar-12' 'OSU-03012' 'Pdk1 inhibitor ar-12'],"[('PubChem', array(['172131582'], dtype=object))]",,"{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}",[ENSG00000140992],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1743076,,,Antibody,False,TADOCIZUMAB,,2.0,,False,False,[],['C4G1' 'Tadocizumab' 'YM-337' 'YM337'],,,,"[ENSG00000259207,ENSG00000005961]",Antibody drug with a maximum clinical trial phase of II.
CHEMBL189475,C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,DDLPYOCJHQSVSZ-SSDOTTSWSA-N,Small molecule,False,LADARIXIN,,3.0,,False,False,[],['Df2156a' 'Ladarixin'],,['CHEMBL4442431'],"{'rows': array(['EFO_0003060', 'MONDO_0005147', 'EFO_0007187'], dtype=object), 'count': 3}","[ENSG00000163464,ENSG00000180871]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1909283,CC(NN)c1ccccc1,HHRZAEJMHSGZNP-UHFFFAOYSA-N,Small molecule,False,MEBANAZINE,,4.0,,True,True,[],['Actamol' 'Mebanazine'],"[('Wikipedia', array(['Mebanazine'], dtype=object)), ('drugbank', array(['DB09248'], dtype=object))]",['CHEMBL3186515'],,"[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2107801,COc1cccc(-c2nccc3[nH]c(=O)c(-c4noc(C)n4)cc23)c1,JQOFKKWHXGQABB-UHFFFAOYSA-N,Small molecule,False,RESEQUINIL,,2.0,,False,False,[],['AVE-3933' 'Ac-3933' 'Radequinil' 'Resequinil' 'SX-3933'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108702,,,Oligonucleotide,False,IMETELSTAT SODIUM,,2.0,,False,False,[],"['GRN-163L TRIDECASODIUM SALT' 'GRN163L' 'GRN163L TRIDECASODIUM SALT'
 'Imetelstat sodium']",,,"{'rows': array(['EFO_0001378', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0008903'],
      dtype=object), 'count': 4}",[ENSG00000164362],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2109047,,,Protein,False,INTERFERON ALFA-N3,1989.0,4.0,,False,True,[],"['.alpha.-interferons' 'Alferon' 'Alferon n' 'Interferon alfa-n3'
 'Interferon alpha-n3' 'Leukocyte interferon']",,,"{'rows': array(['EFO_0000694', 'EFO_0000764'], dtype=object), 'count': 2}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 2 investigational indications.
CHEMBL2109574,,,Antibody drug conjugate,False,ASG-5ME,,1.0,,False,False,[],['ASG-5ME' 'Asg-5me'],,,"{'rows': array(['EFO_0001663'], dtype=object), 'count': 1}","[ENSG00000204385,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545365,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1,GNNDEPIMDAZHRQ-UHFFFAOYSA-N,Small molecule,False,ALTIRATINIB,,2.0,,False,False,[],['Altiratinib' 'DCC-2701' 'DP-5164'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000120156,ENSG00000198400,ENSG00000148053,ENSG00000140538,ENSG00000128052,ENSG00000105976]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL377300,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,WCWUXEGQKLTGDX-LLVKDONJSA-N,Small molecule,False,BRIVANIB,,3.0,,False,False,[],['BMS-540215' 'Brivanib'],"[('drugbank', array(['DB11958'], dtype=object))]",,"{'rows': array(['EFO_0000313', 'EFO_1001951', 'EFO_0000616', 'EFO_0009708',
       'EFO_0000365', 'MONDO_0002974', 'EFO_0000182', 'MONDO_0002691',
       'MONDO_0004992', 'MONDO_0008170'], dtype=object), 'count': 10}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL3916243,C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1,VLLFGVHGKLDDLW-SFHVURJKSA-N,Small molecule,False,ATABECESTAT,,2.0,,False,False,[],"['Atabecestat' 'JNJ-54861911' 'JNJ-54861911-AAA' 'Jnj-54861911'
 'RSC- 385896' 'RSC-385896']","[('drugbank', array(['DB15307'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000186318],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297188,Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1,HNFMVVHMKGFCMB-UHFFFAOYSA-N,Small molecule,False,MIRANSERTIB,,2.0,,False,False,[],['ARQ 092' 'ARQ 092 FREE BASE' 'ARQ-092' 'ARQ092' 'Arq-092' 'Miransertib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIRANSERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14982'], dtype=object))]",['CHEMBL4298151' 'CHEMBL4523032'],"{'rows': array(['MONDO_0011962', 'EFO_0000616', 'EFO_0000616', 'MONDO_0008318',
       'EFO_0000574', 'MONDO_0008170'], dtype=object), 'count': 6}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4297661,Cn1cnc([N+](=O)[O-])c1C[N+](C)(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Cl)c(Br)c3)ncnc2cn1,MUJMYVFVAWFUJL-SNAWJCMRSA-O,Small molecule,False,TARLOXOTINIB,,2.0,,False,False,[],['Tarloxotinib' 'Tarloxotinib cation' 'Tarloxotinib ion'],"[('drugbank', array(['DB14944'], dtype=object))]",['CHEMBL4297662'],"{'rows': array(['EFO_0000181', 'EFO_0003060', 'EFO_0003060'], dtype=object), 'count': 3}","[ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297866,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O,QITOONQVTOGMOJ-IUJXYRIYSA-N,Small molecule,False,ABIVERTINIB MALEATE,,3.0,CHEMBL4297865,False,False,[],"['A-610MA' 'A610MA' 'AC-0010MA' 'AC0010MA' 'ACEA-100610MA' 'ACEA100610MA'
 'Abivertinib maleate' 'Abivertinib maleate dihydrate'
 'Ac0010 maleate dihydrate' 'Ac0010ma' 'EX-ACEA-0010MA' 'EX-ACEA0010MA'
 'Sti-5656']",,,"{'rows': array(['EFO_0000096', 'EFO_0003060', 'MONDO_0100096'], dtype=object), 'count': 3}","[ENSG00000146648,ENSG00000010671]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4298213,,,Antibody,False,VOLAGIDEMAB,,2.0,,False,False,[],['AMG 477' 'AMG-477' 'REMD-477' 'Volagidemab'],,,"{'rows': array(['HP_0003074', 'MONDO_0005148', 'MONDO_0005147'], dtype=object), 'count': 3}",[ENSG00000215644],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL449,CCC(C)C1(CC)C(=O)NC(=O)NC1=O,ZRIHAIZYIMGOAB-UHFFFAOYSA-N,Small molecule,False,BUTABARBITAL,1939.0,4.0,,False,True,[],"['Butabarbital' 'Butabarbital ciii' 'Butatab' 'Medarsed' 'Nilox'
 'Sec-butobarbitone' 'Secbutabarbital' 'Secbutobarbitone' 'Unicelles']","[('Wikipedia', array(['Butabarbital'], dtype=object)), ('drugbank', array(['DB00237'], dtype=object)), ('chEBI', array(['3228'], dtype=object))]",['CHEMBL1200982'],,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939.
CHEMBL4594471,,,Protein,False,EFEPOETIN ALFA,,3.0,,False,False,[],['Efepoetin alfa'],,,,[ENSG00000187266],Protein drug with a maximum clinical trial phase of III.
CHEMBL5314387,C[C@H](N)c1ccc([C@H](O)CNC(C)(C)C)cc1,KUHBBYPXWKYKKR-GXFFZTMASA-N,Small molecule,False,MK-1496,,1.0,,False,False,[],['Mk-1496'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL728,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,WIKYUJGCLQQFNW-UHFFFAOYSA-N,Small molecule,True,PROCHLORPERAZINE,1956.0,4.0,,False,True,['Compazine' 'Compro' 'Prochlorperazine' 'Stemetil eff'],"['Prochlorperazine' 'Prochlorperazine mesilate'
 'Prochlorperazine mesylate']","[('DailyMed', array(['prochlorperazine'], dtype=object)), ('PubChem', array(['11111685', '11111686', '50100332', '50104093', '855827',
       '90341442'], dtype=object)), ('Wikipedia', array(['Prochlorperazine'], dtype=object)), ('drugbank', array(['DB00433'], dtype=object)), ('chEBI', array(['8435'], dtype=object))]",['CHEMBL1200587' 'CHEMBL1201154' 'CHEMBL1314751'],"{'rows': array(['EFO_0006788', 'HP_0002018', 'EFO_0001378', 'EFO_0006911',
       'HP_0002017', 'MONDO_0005277', 'MONDO_0005090', 'EFO_0005407',
       'MONDO_0021148', 'HP_0002315', 'EFO_1001482'], dtype=object), 'count': 11}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL782,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,JLRGJRBPOGGCBT-UHFFFAOYSA-N,Small molecule,False,TOLBUTAMIDE,1961.0,4.0,,False,True,['Glyconon' 'Orinase' 'Pramidex' 'Rastinon' 'Tolbutamide'],"['1-butyl-3-(p-tolylsulfonyl)urea' 'Arkozal' 'Butamide' 'Diabetamid'
 'Ipoglicone' 'NSC-23813' 'NSC-87833' 'Tolbutamide' 'Tolbutamidum'
 'Willbutamide']","[('PubChem', array(['11111858', '144203830', '144208810', '144213112', '170465238',
       '17389707', '26751511', '26751513', '50104069', '56436662',
       '855782'], dtype=object)), ('TG-GATEs', array(['114'], dtype=object)), ('Wikipedia', array(['Tolbutamide'], dtype=object)), ('drugbank', array(['DB01124'], dtype=object)), ('chEBI', array(['27999'], dtype=object))]",['CHEMBL1200874'],"{'rows': array(['EFO_0000616', 'EFO_0600064', 'MONDO_0005148', 'EFO_0000574',
       'HP_0012532', 'MONDO_0004992', 'EFO_0000400', 'EFO_0004220'],
      dtype=object), 'count': 8}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 6 investigational indications.
CHEMBL82301,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,CNPVJJQCETWNEU-CYFREDJKSA-N,Small molecule,False,VICRIVIROC,,3.0,,False,False,[],['MK-7690' 'SCH-351125' 'SCH-417690 FREE BASE' 'SCH-D' 'Vicriviroc'],"[('Wikipedia', array(['Vicriviroc'], dtype=object)), ('drugbank', array(['DB06652'], dtype=object))]",['CHEMBL2107384'],"{'rows': array(['EFO_0004142', 'EFO_0000765', 'EFO_0000764', 'EFO_0000764'],
      dtype=object), 'count': 4}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1089636,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,GBVKRUOMSUTVPW-AHNVSIPUSA-N,Protein,False,ANG1005,,3.0,,False,False,[],['ANG-1005' 'ANG1005' 'Ang1005' 'Paclitaxel trevatide'],,,"{'rows': array(['MONDO_0100342', 'EFO_0000616', 'EFO_0000519', 'EFO_0003833'],
      dtype=object), 'count': 4}","[ENSG00000123384,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL1200638,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,SRGKFVAASLQVBO-DASCVMRKSA-N,Small molecule,False,DEXBROMPHENIRAMINE MALEATE,1963.0,4.0,CHEMBL1201287,False,True,['Disomer'],"['Brompheniramine d-form maleate' 'Dexbrompheniramine fumarate'
 'Dexbrompheniramine maleate']","[('PubChem', array(['144205553', '170465028', '49681545', '50105972'], dtype=object)), ('chEBI', array(['59273'], dtype=object))]",,"{'rows': array(['EFO_0003956'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1963 and is indicated for seasonal allergic rhinitis.
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,VIQCGTZFEYDQMR-UHFFFAOYSA-N,Small molecule,True,FLUPHENAZINE DECANOATE,1972.0,4.0,,False,True,"['Decazate' 'Fluphenazine decanoate' 'Modecate' 'Modecate conc'
 'Prolixin decanoate']","['Dapotum d' 'Fluphenazine decanoate' 'Fluphenazini decanoas' 'Lyogen'
 'Moditen depot' 'NSC-169510' 'QD-10733' 'SQ-10733']","[('DailyMed', array(['fluphenazine%20decanoate'], dtype=object))]",,"{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972 and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1200969,C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)Nc3cc(C(F)(F)F)ccc3C(F)(F)F)CC[C@@H]12,JWJOTENAMICLJG-QWBYCMEYSA-N,Small molecule,False,DUTASTERIDE,2001.0,4.0,,False,True,['Avodart' 'Dutasteride'],"['Avolve' 'Duastride' 'Dutasteride' 'GG-745' 'GI 198745' 'GI-198745'
 'NSC-740477' 'NSC-759880']","[('DailyMed', array(['dutasteride'], dtype=object)), ('PubChem', array(['144205752'], dtype=object)), ('Wikipedia', array(['Dutasteride'], dtype=object)), ('drugbank', array(['DB01126'], dtype=object)), ('chEBI', array(['521033'], dtype=object))]",,"{'rows': array(['EFO_0001663', 'MONDO_0002146', 'MONDO_0004976', 'EFO_0000284',
       'EFO_0003830', 'MONDO_0010735', 'MONDO_0004907', 'EFO_0004191',
       'MONDO_0100096', 'EFO_0000673', 'MONDO_0008315'], dtype=object), 'count': 11}","[ENSG00000145545,ENSG00000277893,ENSG00000128039]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 8 investigational indications.
CHEMBL1201101,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,HPFVBGJFAYZEBE-ZLQWOROUSA-N,Small molecule,False,TESTOSTERONE CYPIONATE,1978.0,4.0,,False,True,"['Andro-Cyp' 'Depandro' 'Depo-testosterone' 'Depotest'
 'Testosterone cypionate']","['Depo-Testadiol' 'NSC-9157'
 'Testosterone 17.beta.-cyclopentanepropionate' 'Testosterone cipionate'
 'Testosterone cyclopentylpropionate' 'Testosterone cypionate'
 'Testosterone cypionate ciii']","[('DailyMed', array(['testosterone%20cypionate'], dtype=object)), ('drugbank', array(['DB13943'], dtype=object)), ('chEBI', array(['9463'], dtype=object))]",,"{'rows': array(['EFO_0000673', 'EFO_0000616', 'EFO_0004714', 'MONDO_0002146',
       'MONDO_0008315', 'EFO_1001078', 'EFO_1000783', 'EFO_0000196'],
      dtype=object), 'count': 8}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 3 approved and 5 investigational indications.
CHEMBL1201740,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O,YCBPQSYLYYBPDW-UHFFFAOYSA-N,Small molecule,True,NILOTINIB HYDROCHLORIDE MONOHYDRATE,2007.0,4.0,CHEMBL255863,False,True,['Tasigna'],"['Nilotinib (as hydrochloride)' 'Nilotinib Hydrochloride Monohydrate'
 'Nilotinib hydrochloride' 'Nilotinib hydrochloride anhydrous'
 'Nilotinib hydrochloride hydrate' 'Nilotinib hydrochloride monohydrate']","[('DailyMed', array(['nilotinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna'],
      dtype=object))]",,"{'rows': array(['MONDO_0005180', 'EFO_0001075', 'EFO_1001512', 'EFO_0000616',
       'EFO_1000251', 'MONDO_0007254', 'EFO_0000339', 'EFO_0000717'],
      dtype=object), 'count': 8}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic myelogenous leukemia and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL123292,C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1,YPHMISFOHDHNIV-FSZOTQKASA-N,Small molecule,False,CYCLOHEXIMIDE,,2.0,,False,False,[],"['Cicloheximide' 'Cycloheximide' 'GNF-Pf-5118' 'NSC-171' 'NSC-185'
 'TCMDC-125838' 'U-4527']","[('PubChem', array(['103076162', '124883128', '124883129', '144207129', '144208356',
       '144213954', '170466349', '17389082', '17389083', '26752000',
       '50104677', '56463698', '67121'], dtype=object)), ('Wikipedia', array(['Cycloheximide'], dtype=object)), ('chEBI', array(['27641'], dtype=object))]",,,"[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1236107,Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1,BCZUAADEACICHN-UHFFFAOYSA-N,Small molecule,False,SGX-523,,1.0,,False,False,[],['SGX-523' 'SGX523' 'Sgx-523'],"[('PubChem', array(['137276007', '174006581'], dtype=object)), ('drugbank', array(['DB06314'], dtype=object)), ('chEBI', array(['90624'], dtype=object))]",,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1743025,,,Antibody,False,GANTENERUMAB,,3.0,,False,False,[],"['Gantenerumab' 'R-04909832' 'R-1450' 'R04909832' 'R1450' 'RG-1450'
 'RO-4909832 R-1450' 'Ro-4909832']",,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1951071,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)C(O)C(O)C(=O)O,FCSXYHUNDAXDRH-QVRIGTRMSA-N,Small molecule,False,ARFORMOTEROL TARTRATE,2006.0,4.0,CHEMBL1363,False,True,['Brovana'],"['Arformoterol tartrate' 'Formoterol r,r-form l-tartrate']",,,"{'rows': array(['EFO_0009661', 'EFO_0000341', 'EFO_0006505', 'EFO_0000464'],
      dtype=object), 'count': 4}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 1 investigational indication.
CHEMBL2105729,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O,YKGMKSIHIVVYKY-UHFFFAOYSA-N,Small molecule,False,DABRAFENIB MESYLATE,2013.0,4.0,CHEMBL2028663,False,True,['Tafinlar'],"['Dabrafenib mesilate' 'Dabrafenib mesylate'
 'GSK-2118436 METHANESULFONATE SALT' 'GSK-2118436B'
 'GSK-2118436B MESYLATE' 'GSK-2118436B METHANESULFONATE SALT'
 'GSK2118436B' 'GSK2118436B, METHANE SULFONATE SALT'
 'METHANE SULFONATE SALT']","[('DailyMed', array(['dabrafenib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar'],
      dtype=object)), ('chEBI', array(['75048'], dtype=object))]",,"{'rows': array(['EFO_1000926', 'EFO_0002892', 'MONDO_0002108', 'EFO_0001378',
       'EFO_0000389', 'EFO_0000756', 'EFO_0002617'], dtype=object), 'count': 7}",[ENSG00000157764],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 2 investigational indications.
CHEMBL2109562,,,Antibody,False,CAL,,2.0,,False,False,[],['CAL' 'Cal'],,,"{'rows': array(['EFO_0000764', 'MONDO_0007254'], dtype=object), 'count': 2}",[ENSG00000087494],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2151197,CCNC(=O)[C@H]1C[C@@](F)(c2ccc(CN3CCCC3)c(F)c2)C1,SXMBKHYDZOCBMT-PPUGGXLSSA-N,Small molecule,False,PF-03654746,,2.0,,False,False,[],['PF 03654746' 'Pf-03654746'],"[('drugbank', array(['DB12201'], dtype=object))]",,"{'rows': array(['EFO_0005854', 'EFO_0003888', 'MONDO_0004975', 'MONDO_0005090',
       'EFO_0004895'], dtype=object), 'count': 5}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2219776,,,Oligonucleotide,False,CENERSEN SODIUM,,2.0,,False,False,[],['Cenersen sodium' 'EL-625' 'EL625' 'OL(1)P53'],,,"{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}",[ENSG00000141510],Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL25202,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,MUTNCGKQJGXKEM-UHFFFAOYSA-N,Small molecule,False,TAMIBAROTENE,2005.0,4.0,,False,True,[],"['AM-80' 'Am80' 'Amnoid' 'INNO-507' 'NSC-608000' 'OP-01' 'RR-110'
 'SY-1425' 'Sy-1425' 'TM-411' 'TOS-80T' 'Tamibarotene']","[('PubChem', array(['144206278', '170465883', '485050', '50125822'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAMIBAROTENE/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Tamibarotene'], dtype=object)), ('drugbank', array(['DB04942'], dtype=object)), ('chEBI', array(['32181'], dtype=object))]",,"{'rows': array(['EFO_0000224', 'MONDO_0004975', 'EFO_0007527', 'EFO_0002618',
       'EFO_0000198', 'EFO_0005761', 'EFO_0000222', 'EFO_0000384'],
      dtype=object), 'count': 8}","[ENSG00000077092,ENSG00000131759]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 8 investigational indications.
CHEMBL3188386,Cc1cc(-c2ncc(CC(=O)Nc3ccc(-c4cnccn4)cn3)cc2C)ccn1,XXYGTCZJJLTAGH-UHFFFAOYSA-N,Small molecule,False,WNT-974,,2.0,,False,False,[],['LGK-974' 'LGK974' 'Lgk974' 'WNT-974' 'WNT974' 'Wnt-974' 'Wnt974'],"[('PubChem', array(['174006720'], dtype=object)), ('drugbank', array(['DB12561'], dtype=object)), ('chEBI', array(['78030'], dtype=object))]",,"{'rows': array(['EFO_0000707'], dtype=object), 'count': 1}",[ENSG00000102312],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545407,O=[N+]([O-])OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O,AQLVRTWKJDTWQQ-SDBHATRESA-N,Small molecule,False,TRABODENOSON,,3.0,,False,False,[],['INNO-8875' 'Ino-8875' 'PJ-875' 'Trabodenoson'],"[('drugbank', array(['DB13122'], dtype=object))]",,"{'rows': array(['EFO_1001069', 'EFO_0004190'], dtype=object), 'count': 2}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3707227,,,Antibody,False,ATEZOLIZUMAB,2016.0,4.0,,False,True,['Tecentriq'],"['0ine2sfd9e' 'Anti-PD-L1' 'Anti-PDL1' 'Atezolizumab' 'MPDL-3280A'
 'MPDL3280A' 'RG-7446' 'RG7446']","[('DailyMed', array(['atezolizumab'], dtype=object)), ('DrugCentral', array(['5151'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq'],
      dtype=object))]",,"{'rows': array(['EFO_0000707', 'EFO_0003869', 'MONDO_0004992', 'EFO_1001465',
       'EFO_0007143', 'MONDO_0008315', 'EFO_0002617', 'EFO_0002918',
       'EFO_0000768', 'EFO_0001378', 'EFO_0004288', 'EFO_0000339',
       'MONDO_0005184', 'EFO_0006859', 'EFO_0005221', 'EFO_0000096',
       'EFO_1001951', 'EFO_0000199', 'EFO_0001061', 'EFO_0005922',
       'MONDO_0001187', 'EFO_1001100', 'EFO_0000640', 'MONDO_0021063',
       'MONDO_0044881', 'EFO_1000251', 'MONDO_0011962', 'EFO_0000503',
       'MONDO_0008170', 'MONDO_0003060', 'MONDO_0007576', 'EFO_0000196',
       'EFO_1001956', 'EFO_0008528', 'EFO_0000673', 'EFO_0000403',
       'MONDO_0002367', 'EFO_0000313', 'EFO_0000702', 'EFO_0005567',
       'EFO_0000691', 'EFO_1000657', 'EFO_0002618', 'EFO_1001961',
       'MONDO_0011719', 'EFO_0007532', 'EFO_0001075', 'EFO_1000613',
       'EFO_0000616', 'MONDO_0002158', 'EFO_0000095', 'EFO_0000588',
       'MONDO_0001056', 'MONDO_0007254', 'EFO_0000183', 'MONDO_0002898',
       'MONDO_0002691', 'EFO_0000770', 'EFO_0002892', 'EFO_1000601',
       'EFO_1001512', 'EFO_0009708', 'EFO_0003893', 'EFO_0000182',
       'EFO_0003863', 'EFO_0000181', 'MONDO_0001879', 'EFO_1001513',
       'EFO_0005537', 'EFO_0000305', 'MONDO_0100342', 'EFO_0000637',
       'EFO_0002916', 'EFO_0004142', 'EFO_1001051', 'EFO_0008528',
       'MONDO_0002974', 'EFO_0000756', 'EFO_0001642', 'EFO_0004284',
       'MONDO_0008903', 'MONDO_0002120', 'MONDO_0018906', 'MONDO_0004180',
       'EFO_0000198', 'EFO_0003060', 'EFO_0000574', 'EFO_0000389',
       'EFO_1000785', 'EFO_0000519', 'EFO_0000222', 'EFO_0000681',
       'EFO_0005952'], dtype=object), 'count': 93}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 11 approved and 82 investigational indications.
CHEMBL4297527,O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12,IXQHNBONEVULTL-UHFFFAOYSA-N,Small molecule,False,REVAMILAST,,2.0,,False,False,[],['Revamilast'],"[('drugbank', array(['DB11838'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0000685'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297600,NC(=O)c1ccn(-c2cnc(NC[C@]3(c4ncccc4F)C[C@H](F)C3)nc2)c1,MQXWPWOCXGARRK-HJGJAMNPSA-N,Small molecule,False,RELDESEMTIV,,3.0,,False,False,[],['CK-2127107' 'Ck-2127107' 'Reldesemtiv'],"[('drugbank', array(['DB15256'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004976', 'EFO_0008525'], dtype=object), 'count': 3}","[ENSG00000130598,ENSG00000130595,ENSG00000101470]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297843,,,Antibody,False,TORIPALIMAB,2023.0,4.0,,False,True,['Loqtorzi'],"['Anti-pd-i mab-shanghai junshi' 'CHS-007' 'JS-001' 'JS001' 'Js-001'
 'Js001' 'TAB-001' 'TAB001' 'Teriprizumab' 'Toripalimab' 'Treprizumab'
 'Tripleitriumab' 'Triprizumab' 'Tuoyi']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TORIPALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000569', 'EFO_0000178', 'EFO_0000691', 'EFO_0003897',
       'EFO_0000199', 'EFO_0008528', 'EFO_0003060', 'MONDO_0004986',
       'MONDO_0002974', 'EFO_0000707', 'EFO_0006859', 'EFO_1001972',
       'MONDO_0002691', 'MONDO_0001056', 'MONDO_0008903', 'MONDO_0007254',
       'EFO_0001416', 'EFO_1001968', 'EFO_0000503', 'EFO_0000702',
       'EFO_0005922', 'EFO_0004252', 'EFO_0002617', 'EFO_0003826',
       'MONDO_0005575', 'MONDO_0002108', 'MONDO_0011871', 'EFO_0000616',
       'EFO_0003891', 'MONDO_0021358', 'EFO_1001513', 'MONDO_0003060',
       'EFO_0000181', 'EFO_0000769', 'EFO_0000681', 'MONDO_0001187',
       'MONDO_0002120', 'EFO_0005221', 'EFO_0000756', 'EFO_1000657',
       'EFO_0002916', 'EFO_0000389', 'MONDO_0019472', 'MONDO_0007576',
       'EFO_0000182', 'MONDO_0000831', 'EFO_1000359', 'EFO_0000770',
       'MONDO_0004992', 'EFO_0003868', 'EFO_0005537', 'EFO_0000574',
       'EFO_1001961', 'EFO_0004288', 'EFO_1001951'], dtype=object), 'count': 55}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for niemann-pick disease type b and has 54 investigational indications.
CHEMBL4298113,,,Oligonucleotide,False,BAMOSIRAN,,2.0,,False,False,[],['Bamosiran' 'SYL-040012' 'SYL040012' 'Syl040012'],,,,[ENSG00000169252],Oligonucleotide drug with a maximum clinical trial phase of II.
CHEMBL5316167,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1,GBXJAPBXPROFPY-GOSISDBHSA-N,Small molecule,False,ARQ-736 FREE ACID,,1.0,,False,False,[],[],,['CHEMBL5314407'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000132155,ENSG00000157764]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL53366,Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1,SQKXYSGRELMAAU-UHFFFAOYSA-N,Small molecule,False,IMIDAFENACIN,,3.0,,False,False,[],['Imidafenacin' 'KRP-197' 'ONO-8025' 'Staybla' 'Uritos'],"[('drugbank', array(['DB09262'], dtype=object))]",,"{'rows': array(['HP_0000020', 'EFO_1000781', 'HP_0000103'], dtype=object), 'count': 3}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL551978,CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC,OMFNSKIUKYOYRG-MOSHPQCFSA-N,Small molecule,False,DROTAVERINE,,3.0,,False,False,[],"['Dihydroethaverine' 'Dihydroisoperparine' 'Drotaverin' 'Drotaverine'
 'Drotin']","[('Wikipedia', array(['Drotaverine'], dtype=object)), ('drugbank', array(['DB06751'], dtype=object))]",,"{'rows': array(['EFO_0010282', 'MONDO_0002887'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL848,Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,GOTYRUGSSMKFNF-UHFFFAOYSA-N,Small molecule,True,LENALIDOMIDE,2005.0,4.0,,False,True,['Revlimid'],['CC-5013' 'CDC-501' 'Lenalidomide' 'NSC-747972' 'SYP-1512'],"[('DailyMed', array(['lenalidomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid'],
      dtype=object)), ('PubChem', array(['124893327', '124893328', '144206045', '170465201'], dtype=object)), ('Wikipedia', array(['Lenalidomide'], dtype=object)), ('drugbank', array(['DB00480'], dtype=object)), ('chEBI', array(['63791'], dtype=object))]",,"{'rows': array(['MONDO_0018906', 'MONDO_0100342', 'EFO_1000657', 'EFO_0000180',
       'EFO_1001779', 'MONDO_0002280', 'MONDO_0002158', 'EFO_0003758',
       'EFO_1001951', 'MONDO_0044903', 'MONDO_0004992', 'EFO_1001469',
       'MONDO_0002367', 'EFO_0000681', 'EFO_0000621', 'EFO_0000095',
       'EFO_0006475', 'HP_0004326', 'EFO_0000673', 'MONDO_0004095',
       'EFO_1001115', 'EFO_0000479', 'EFO_0000182', 'MONDO_0001187',
       'EFO_0000616', 'MONDO_0008170', 'EFO_1001465', 'EFO_0000384',
       'MONDO_0021063', 'EFO_0004142', 'EFO_0000403', 'EFO_0000209',
       'MONDO_0002087', 'EFO_0000183', 'EFO_0002892', 'EFO_1000630',
       'MONDO_0005184', 'EFO_0000222', 'EFO_1001938', 'MONDO_0019471',
       'EFO_1001998', 'EFO_0000191', 'EFO_0004272', 'MONDO_0008315',
       'EFO_0003060', 'MONDO_0017816', 'EFO_0000294', 'EFO_0002499',
       'MONDO_0001023', 'EFO_0000540', 'EFO_0000339', 'EFO_0000756',
       'EFO_0002430', 'EFO_0000574', 'EFO_0003841', 'MONDO_0044881',
       'EFO_1000026', 'EFO_0000707', 'EFO_0009708', 'EFO_0002618',
       'MONDO_0019438', 'EFO_0000196', 'EFO_0002913', 'MONDO_0015760',
       'EFO_0000096', 'EFO_0006738', 'MONDO_0002691', 'EFO_0000764',
       'MONDO_0004192', 'MONDO_0013730', 'EFO_0003073', 'EFO_1000158',
       'EFO_0000558', 'EFO_0000769', 'EFO_0000198', 'EFO_0004251',
       'EFO_0000211', 'MONDO_0002959', 'EFO_0001378', 'EFO_0009441',
       'EFO_0005952', 'EFO_0000309', 'MONDO_0006412', 'EFO_0002429',
       'EFO_0000565', 'EFO_0000220', 'MONDO_0000430', 'HP_0001871'],
      dtype=object), 'count': 88}","[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 6 approved and 82 investigational indications. This drug has a black box warning from the FDA.
CHEMBL88055,Oc1ccc(C(O)C2CCCCN2)cc1O,IYMMESGOJVNCKV-UHFFFAOYSA-N,Small molecule,False,RIMITEROL,,4.0,,False,True,[],['Rimiterol'],,['CHEMBL2000813'],"{'rows': array(['HP_0006536'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV and is indicated for airway obstruction.
CHEMBL1094785,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1,IHOXNOQMRZISPV-YJYMSZOUSA-N,Small molecule,False,CARMOTEROL,,2.0,,False,False,[],['CHF-4226' 'Carmoterol' 'Chf 4226' 'Quinoterol' 'TA-2005'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1117,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,XDXDZDZNSLXDNA-TZNDIEGXSA-N,Small molecule,True,IDARUBICIN,1990.0,4.0,,False,True,[],['Idamycin' 'Idarubicin'],"[('PubChem', array(['124891657', '50106402', '50106403', '50106404', '90340569'],
      dtype=object)), ('Wikipedia', array(['Idarubicin'], dtype=object)), ('drugbank', array(['DB01177'], dtype=object)), ('chEBI', array(['42068'], dtype=object))]",['CHEMBL1200976'],"{'rows': array(['EFO_0002428', 'EFO_0000222', 'EFO_1001968', 'EFO_0000182',
       'EFO_0003025', 'EFO_0000339', 'MONDO_0004643', 'EFO_0000223',
       'EFO_0003027', 'EFO_0003811', 'EFO_0000616', 'MONDO_0001475',
       'EFO_0004251', 'EFO_0000220', 'EFO_0005952', 'EFO_0000565',
       'EFO_1001257', 'EFO_1000131', 'EFO_0000182', 'EFO_0000218',
       'EFO_0001378', 'MONDO_0002691', 'EFO_0000574', 'EFO_0003802',
       'EFO_0000221', 'EFO_0000224', 'EFO_0000222', 'MONDO_0000873',
       'EFO_1001779', 'EFO_0000198'], dtype=object), 'count': 30}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for acute myeloid leukemia and neoplasm and has 27 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200986,CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,GUTXTARXLVFHDK-UHFFFAOYSA-N,Small molecule,True,HALOPERIDOL DECANOATE,1986.0,4.0,,False,True,['Haldol' 'Haldol Dec' 'Haloperidol decanoate'],"['Halomonth' 'Haloperidol decanoate' 'R-13,672' 'R-13672']","[('DailyMed', array(['haloperidol%20decanoate'], dtype=object))]",,"{'rows': array(['MONDO_0005090', 'EFO_0009267'], dtype=object), 'count': 2}","[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for schizophrenia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201616,,,Protein,False,SECRETIN SYNTHETIC PORCINE,2002.0,4.0,,False,True,['Secreflo'],"['Porcine secretin acetate salt' 'RG-1068'
 'Secretin (swine), acetate (salt)' 'Secretin porcine pentaacetate'
 'Secretin synthetic porcine']",,,"{'rows': array(['EFO_0003758'], dtype=object), 'count': 1}",[ENSG00000080293],Protein drug with a maximum clinical trial phase of IV that was first approved in 2002 and has 1 investigational indication.
CHEMBL1653,CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O,SSOXZAQUVINQSA-BTJKTKAUSA-N,Small molecule,False,PHENIRAMINE MALEATE,1994.0,4.0,CHEMBL1193,False,True,['Avil ret' 'Daneral-sa'],"['Antolozine' 'Daneral' 'Fervex' 'Inhiston' 'NSC-757270' 'Naphcon a'
 'PM-241' 'Pheniramine Maleate' 'Pheniramine hydrogen maleate'
 'Pheniramine maleate' 'Prophenpyridamine maleate' 'Trimeton' 'Trimetose']","[('DailyMed', array(['pheniramine%20maleate'], dtype=object)), ('PubChem', array(['144204739', '144208272', '170464902', '26747641', '50106867',
       '56422488', '93576675'], dtype=object)), ('chEBI', array(['31990'], dtype=object))]",,"{'rows': array(['EFO_0007214', 'MONDO_0024355', 'EFO_0007328'], dtype=object), 'count': 3}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 investigational indications.
CHEMBL1709,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21.Cl,BLFQGGGGFNSJKA-XHXSRVRCSA-N,Small molecule,True,SERTRALINE HYDROCHLORIDE,1991.0,4.0,CHEMBL809,False,True,['Aremis' 'Besitron' 'Lustral' 'Sertraline hydrochloride' 'Zoloft'],"['CP-51,974-1' 'CP-51974-1' 'NSC-746308' 'NSC-758948'
 'Sertraline (as hydrochloride)' 'Sertraline hcl'
 'Sertraline hydrochloride']","[('DailyMed', array(['sertraline%20hydrochloride'], dtype=object)), ('PubChem', array(['144204750', '170465121', '26719805', '26753298', '26753614',
       '49681568'], dtype=object)), ('chEBI', array(['9124'], dtype=object))]",,"{'rows': array(['MONDO_0002050', 'EFO_1001917', 'EFO_0001358', 'EFO_0004262',
       'MONDO_0007739', 'MONDO_0002009', 'MONDO_0002009', 'HP_0002315',
       'EFO_0004242', 'HP_0001249'], dtype=object), 'count': 10}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1742420,CCOC(=O)NC(=N)c1ccc(OCc2cccc(COc3ccc(C(C)(C)c4ccc(O)cc4)cc3)c2)cc1,SBVYURPQULDJTI-UHFFFAOYSA-N,Small molecule,False,AMELUBANT,,2.0,,False,False,[],"['Amelubant' 'BIIL 284' 'BIIL 284 BS' 'BIIL-284' 'BIIL-284BS' 'BIIL284 BS'
 'Biil 284 bs' 'LS-49968']","[('drugbank', array(['DB06248'], dtype=object))]",,"{'rows': array(['MONDO_0009061', 'EFO_0000685', 'EFO_0000341', 'MONDO_0004979'],
      dtype=object), 'count': 4}",[ENSG00000213903],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL20,CC(=O)Nc1nnc(S(N)(=O)=O)s1,BZKPWHYZMXOIDC-UHFFFAOYSA-N,Small molecule,True,ACETAZOLAMIDE,1953.0,4.0,,False,True,['Acetazolamide' 'Diamox' 'Diamox sr' 'Eytazox'],"['Acetamox' 'Acetazolamide' 'Acetazolamidum' 'Atenezo' 'Defiltran' 'Didoc'
 'Diuriwas' 'Donmox' 'Edemox' 'Glaupax' 'L 579486' 'NSC-145177'
 'Nephramide' 'Phonurit']","[('DailyMed', array(['acetazolamide'], dtype=object)), ('PubChem', array(['11110757', '144208757', '144213090', '170464692', '26747033',
       '26751551', '50104152', '855900'], dtype=object)), ('TG-GATEs', array(['108'], dtype=object)), ('Wikipedia', array(['Acetazolamide'], dtype=object)), ('drugbank', array(['DB00819'], dtype=object)), ('chEBI', array(['27690'], dtype=object))]",['CHEMBL1200814' 'CHEMBL542496'],"{'rows': array(['MONDO_0005301', 'EFO_0002617', 'MONDO_0005147', 'EFO_0003086',
       'Orphanet_37553', 'EFO_1000961', 'MONDO_0005041', 'EFO_1001065',
       'HP_0012532', 'HP_0002104', 'MONDO_0008315', 'EFO_0009373',
       'MONDO_0005090', 'EFO_0008526', 'EFO_0005252', 'MONDO_0003005',
       'EFO_1001132', 'EFO_0000182', 'EFO_1000782', 'EFO_0001361',
       'MONDO_0005041', 'EFO_0007231', 'EFO_0003144', 'EFO_0000702',
       'MONDO_0001744', 'EFO_0000712', 'EFO_0003918', 'EFO_0000373',
       'HP_0001250', 'MONDO_0001744', 'HP_0001250', 'EFO_0000474',
       'EFO_0009373', 'EFO_1001010'], dtype=object), 'count': 34}","[ENSG00000074410,ENSG00000167434,ENSG00000133742,ENSG00000104267]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 8 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103846,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,HKDLNTKNLJPAIY-WKWWZUSTSA-N,Small molecule,False,ULIPRISTAL,,4.0,,False,True,[],['Uliprisnil' 'Ulipristal' 'Ulipristal acetate ulipristal'],"[('drugbank', array(['DB08867'], dtype=object))]",,"{'rows': array(['MONDO_0001572', 'MONDO_0003061'], dtype=object), 'count': 2}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.
CHEMBL2104793,CCCC(C(=O)c1ccc(C)cc1)N1CCCC1.Cl,MWRACNBZNVAJHE-UHFFFAOYSA-N,Small molecule,False,PYROVALERONE HYDROCHLORIDE,,4.0,CHEMBL201960,True,True,[],"['Centroton' 'F 1983' 'F-1983' 'Pyrovalerone hcl'
 'Pyrovalerone hydrochloride' 'SP-1059' 'Thymergix']",,,,"[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2105233,C=CCC1(CC(C)O)C(=O)NC(=O)NC1=O,VNLMRPAWAMPLNZ-UHFFFAOYSA-N,Small molecule,False,PROXIBARBAL,,4.0,,True,True,[],['Axeen' 'Centralgol' 'HH-184' 'Hydroxydial' 'Ipronal' 'Proxibarbal'],"[('drugbank', array(['DB13253'], dtype=object))]",,,"[ENSG00000002726,ENSG00000189221]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2107860,,,Protein,False,TASPOGLUTIDE,,3.0,,False,False,[],"['BIM-51077' 'BIM51077' 'R-1583' 'R1583' 'RO-5073031' 'RO5073031'
 'Taspoglutide']",,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL354541,O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1,MBBCVAKAJPKAKM-UHFFFAOYSA-N,Small molecule,True,LOMITAPIDE,2012.0,4.0,,False,True,['Lojuxta'],['AEGR-733' 'BMS-201038' 'BMS-201038-01' 'Lomitapide'],"[('drugbank', array(['DB08827'], dtype=object)), ('chEBI', array(['72297'], dtype=object))]",['CHEMBL2105662'],"{'rows': array(['MONDO_0018328', 'MONDO_0018328', 'HP_0003124', 'MONDO_0021187',
       'EFO_0004911', 'EFO_0004911', 'EFO_0000319'], dtype=object), 'count': 7}","[ENSG00000138823,ENSG00000185624]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3674570,CC1(C)CC=C(c2nc(C3CC(C)(C)OC(C)(C)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1,BNVPFDRNGHMRJS-UHFFFAOYSA-N,Small molecule,False,EDICOTINIB,,2.0,,False,False,[],['Edicotinib' 'JNJ-40346527' 'Jnj-40346527'],"[('drugbank', array(['DB12504'], dtype=object))]",['CHEMBL4297225'],"{'rows': array(['EFO_0000222', 'EFO_0000673', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000182578],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297320,CCCCCCC(=O)N[C@@H]1CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2C[C@H](C(N)=O)NC(=O)[C@@H]2CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](CCCC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O,HSHVZRILAMZYHY-WXSGKXQHSA-N,Protein,False,PL-3994,,2.0,,False,False,[],['Pl-3994'],,,"{'rows': array(['EFO_0003144', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000169418],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297845,,,Unknown,False,TRU-015,,2.0,,False,False,[],['Pf-5212374' 'Tru-015'],,,"{'rows': array(['MONDO_0007915', 'EFO_0000574', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000156738],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4298002,,,Antibody,False,ICHORCUMAB,,2.0,,False,False,[],['Ichorcumab' 'JNJ-375' 'JNJ-64179375' 'JNJ-9375' 'Jnj-64179375'],,,,[ENSG00000180210],Antibody drug with a maximum clinical trial phase of II.
CHEMBL4751394,NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1,JBGYKRAZYDNCNV-UHFFFAOYSA-N,Small molecule,False,BAY-1125976,,1.0,,False,False,[],['BAY-1125976' 'BAY1125976' 'Bay 1125976' 'Bay-1125976'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000142208,ENSG00000105221]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4802223,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1.CS(=O)(=O)O,MBIDSOMXPLCOHS-XNHQSDQCSA-N,Protein,False,LEUPROLIDE MESYLATE,2021.0,4.0,CHEMBL1201199,False,True,['Camcevi' 'Camcevi kit'],['Camcevi' 'Leuprorelin mesilate' 'Leuprorelin mesylate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/camcevi'],
      dtype=object))]",,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for prostate cancer.
CHEMBL5315093,,,Unknown,False,AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA CDNA SEQUENCE,2016.0,4.0,,False,True,['Strimvelis'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis'],
      dtype=object))]",,"{'rows': array(['MONDO_0015974'], dtype=object), 'count': 1}",[ENSG00000196839],Unknown drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for severe combined immunodeficiency.
CHEMBL53463,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,AOJJSUZBOXZQNB-TZSSRYMLSA-N,Small molecule,False,DOXORUBICIN,,4.0,,False,True,[],"['Adriablastin' 'Adriamycin' 'Doxil' 'Doxorubicin'
 'Epirubicin hydrochloride impurity, doxorubicin-' 'Hydroxydaunorubicin'
 'NSC-123127' 'NSC-759155' 'Rubex' 'Valrubicin impurity, doxorubicin']","[('PubChem', array(['124886887', '124886893', '164339434'], dtype=object)), ('TG-GATEs', array(['149'], dtype=object)), ('Wikipedia', array(['Doxorubicin'], dtype=object)), ('drugbank', array(['DB00997'], dtype=object)), ('chEBI', array(['28748'], dtype=object))]",['CHEMBL359744' 'CHEMBL272706' 'CHEMBL216371'],"{'rows': array(['MONDO_0002928', 'MONDO_0002974', 'EFO_0002618', 'EFO_0001378',
       'EFO_0004289', 'EFO_0000309', 'MONDO_0003175', 'EFO_0002918',
       'EFO_1001951', 'EFO_0005561', 'MONDO_0000873', 'EFO_0002617',
       'EFO_0000183', 'EFO_1000350', 'EFO_1000292', 'MONDO_0015760',
       'MONDO_0018531', 'EFO_0009708', 'EFO_0003060', 'MONDO_0004192',
       'MONDO_0004986', 'EFO_0007143', 'EFO_1000796', 'EFO_0005537',
       'MONDO_0018364', 'MONDO_0000870', 'EFO_0000096', 'EFO_0000095',
       'EFO_0003893', 'EFO_0000691', 'EFO_0000239', 'EFO_0000702',
       'EFO_0000094', 'MONDO_0017387', 'EFO_0000637', 'MONDO_0017816',
       'MONDO_0008170', 'MONDO_0000870', 'MONDO_0004986', 'MONDO_0005184',
       'EFO_0002913', 'EFO_0000313', 'EFO_0000220', 'EFO_0000403',
       'EFO_0000565', 'EFO_0000432', 'EFO_0000558', 'EFO_0000621',
       'EFO_0003032', 'EFO_0000760', 'EFO_1000131', 'Orphanet_145',
       'MONDO_0002367', 'EFO_0000569', 'EFO_0000702', 'MONDO_0100342',
       'EFO_0003833', 'EFO_0000220', 'EFO_0003869', 'EFO_0000502',
       'MONDO_0000873', 'MONDO_0019460', 'EFO_0000565', 'EFO_0000182',
       'EFO_0000222', 'EFO_1000984', 'EFO_1002017', 'EFO_1000158',
       'EFO_0005537', 'EFO_0000389', 'MONDO_0001187', 'EFO_0000502',
       'EFO_0000632', 'EFO_0000255', 'EFO_0004252', 'MONDO_0004992',
       'MONDO_0020077', 'EFO_0000248', 'HP_0001871', 'EFO_0003968',
       'EFO_0000209', 'EFO_0000630', 'MONDO_0002087', 'EFO_0000211',
       'EFO_0009708', 'EFO_0001378', 'MONDO_0008380', 'EFO_0006861',
       'EFO_0005952', 'EFO_0000574', 'EFO_1001100', 'EFO_0000503',
       'MONDO_0007576', 'MONDO_0015540', 'MONDO_0019004', 'MONDO_0018906',
       'EFO_1000251', 'MONDO_0008315', 'MONDO_0002691', 'EFO_0008528',
       'EFO_1001365', 'MONDO_0018906', 'MONDO_0018364', 'MONDO_0001056',
       'EFO_0000313', 'EFO_0000616', 'EFO_0006475', 'EFO_0003868',
       'MONDO_0016691', 'EFO_0000621', 'EFO_1000796', 'EFO_1001042',
       'MONDO_0011934', 'MONDO_0011962', 'EFO_0003060', 'EFO_1000292',
       'MONDO_0021117', 'EFO_0000223', 'EFO_0000681', 'EFO_0001376',
       'EFO_1000294', 'MONDO_0044917', 'MONDO_0021054', 'MONDO_0002974',
       'MONDO_0016717', 'EFO_0003869', 'MONDO_0000432', 'EFO_0006861',
       'EFO_0000198', 'EFO_0003085', 'EFO_0000305', 'EFO_0000437',
       'EFO_0000558', 'EFO_0003144', 'EFO_0000198', 'MONDO_0005094',
       'EFO_1000984', 'EFO_1000251', 'HP_0002017', 'EFO_0000309',
       'MONDO_0002730', 'MONDO_0002367', 'MONDO_0002158', 'MONDO_0008315',
       'MONDO_0004095', 'EFO_0000588', 'EFO_0000588', 'EFO_1000576',
       'MONDO_0002108', 'EFO_1001469', 'EFO_0000211', 'MONDO_0001475',
       'EFO_0000403', 'EFO_1001365', 'MONDO_0008903', 'EFO_0005952',
       'EFO_0000095', 'MONDO_0015540', 'EFO_0000519', 'MONDO_0008380',
       'EFO_0000174', 'EFO_0003032', 'EFO_0007160', 'EFO_0004230',
       'EFO_0000637', 'MONDO_0019004', 'MONDO_0007254', 'MONDO_0019472',
       'EFO_0003893', 'MONDO_0004992', 'MONDO_0002087', 'MONDO_0001187',
       'MONDO_0009348', 'EFO_0000673', 'EFO_0006475', 'MONDO_0044881',
       'MONDO_0001657', 'EFO_0000182', 'MONDO_0000430', 'EFO_1001968',
       'MONDO_0002158', 'MONDO_0007254', 'EFO_0009254', 'EFO_0000691',
       'EFO_0003968', 'MONDO_0004192', 'MONDO_0001056', 'MONDO_0004986',
       'EFO_0000183', 'EFO_1001469', 'MONDO_0015564', 'EFO_0005221',
       'EFO_0000096', 'MONDO_0002678', 'EFO_0000222', 'EFO_0000305',
       'MONDO_0004669', 'EFO_0000770', 'EFO_0001075', 'EFO_0000231',
       'EFO_0006859', 'EFO_0009907', 'EFO_0000174', 'EFO_1000581',
       'MONDO_0008170', 'MONDO_0002691', 'EFO_0000681', 'EFO_1001968',
       'MONDO_0009348', 'EFO_0002918', 'EFO_0000616', 'EFO_0002499',
       'MONDO_0011962', 'EFO_0000209', 'EFO_0000564', 'EFO_1001901',
       'EFO_1000595', 'EFO_0007532', 'MONDO_0019471', 'EFO_0001075',
       'EFO_1001100', 'EFO_0000564', 'EFO_0000094', 'EFO_0000765',
       'MONDO_0004658', 'EFO_0000574', 'MONDO_0044917'], dtype=object), 'count': 227}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 24 approved and 173 investigational indications.
CHEMBL558,Cc1cccc(C)c1OCC(C)N,VLPIATFUUWWMKC-UHFFFAOYSA-N,Small molecule,True,MEXILETINE,1985.0,4.0,,False,True,[],['(rs)-mexiletine' 'Dl-mexiletine' 'Mexiletine'],"[('PubChem', array(['90341048'], dtype=object)), ('TG-GATEs', array(['103'], dtype=object)), ('Wikipedia', array(['Mexiletine'], dtype=object)), ('drugbank', array(['DB00379'], dtype=object)), ('chEBI', array(['6916'], dtype=object))]",['CHEMBL1200606'],"{'rows': array(['MONDO_0016107', 'MONDO_0016120', 'EFO_0004278', 'EFO_0000612',
       'MONDO_0015626', 'HP_0004308', 'EFO_0004287', 'MONDO_0011728',
       'EFO_0004269', 'HP_0012532', 'Orphanet_273', 'EFO_0009387',
       'EFO_0000555'], dtype=object), 'count': 13}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL636,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,XSVMFMHYUFZWBK-NSHDSACASA-N,Small molecule,False,RIVASTIGMINE,1998.0,4.0,,False,True,"['Alzest' 'Eluden' 'Erastig' 'Exelon' 'Kerstipon' 'Nimvastid' 'Prometax'
 'Rivastigmine' 'Somniton' 'Voleze']","['ENA-713' 'ENA-713D' 'ONO-2540' 'Rivastigmine' 'Rivastigmine hexal'
 'Rivastigmine sandoz' 'Rivastigmine teva' 'SDZ-212-713' 'SDZ-212713'
 'SDZ-ENA-713']","[('DailyMed', array(['rivastigmine'], dtype=object)), ('Wikipedia', array(['Rivastigmine'], dtype=object)), ('drugbank', array(['DB00989'], dtype=object)), ('chEBI', array(['8874'], dtype=object))]",['CHEMBL215645' 'CHEMBL1201092' 'CHEMBL3187096'],"{'rows': array(['EFO_0003890', 'EFO_0004718', 'EFO_0005230', 'EFO_0004701',
       'MONDO_0004975', 'MONDO_0002050', 'EFO_0002610', 'MONDO_0005090',
       'MONDO_0043510', 'MONDO_0005180', 'EFO_0005252', 'EFO_0001064',
       'HP_0000726', 'MONDO_0002491', 'EFO_0004364', 'HP_0000726',
       'MONDO_0005180', 'HP_0100543', 'MONDO_0019037', 'EFO_0009267'],
      dtype=object), 'count': 20}","[ENSG00000114200,ENSG00000087085]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 15 investigational indications.
CHEMBL1095607,Cn1c(=O)c2c(ncn2CCCNCC(O)c2cc(O)cc(O)c2)n(C)c1=O,WVLAAKXASPCBGT-UHFFFAOYSA-N,Small molecule,False,REPROTEROL,,4.0,,False,True,[],['D-1959' 'Reproterol'],"[('drugbank', array(['DB12846'], dtype=object))]",['CHEMBL2104771'],"{'rows': array(['HP_0006536', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 1 investigational indication.
CHEMBL1201155,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.O=C(O)CCC(=O)O,YQZBAXDVDZTKEQ-UHFFFAOYSA-N,Small molecule,True,LOXAPINE SUCCINATE,1975.0,4.0,CHEMBL831,False,True,['Loxapac' 'Loxapine succinate' 'Loxitane'],['CL 71563' 'CL-71563' 'Loxapine succinate' 'NSC-759578'],"[('PubChem', array(['11112040', '11112041', '124881879', '144203862', '170465094',
       '26719661', '26747560', '26747561', '49731997', '50106540',
       '85231309', '855705'], dtype=object)), ('chEBI', array(['6549'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}","[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975 and is indicated for schizophrenia. This drug has a black box warning from the FDA.
CHEMBL1201191,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,ZKLPARSLTMPFCP-OAQYLSRUSA-N,Small molecule,False,LEVOCETIRIZINE,2007.0,4.0,,False,True,['Xyzal'],"['(-)-cetirizine' '(r)-cetirizine' 'Cetirizine (r)-form'
 'Cetirizine, (-)-' 'Cetirizine, (r)-' 'Levocetirizine' 'Xazal']","[('PubChem', array(['26719822', '49681558'], dtype=object)), ('Wikipedia', array(['Levocetirizine'], dtype=object)), ('drugbank', array(['DB06282'], dtype=object))]",['CHEMBL1201190'],"{'rows': array(['EFO_0000274', 'EFO_1001417', 'EFO_0007533', 'EFO_0008521',
       'EFO_0000701', 'EFO_0005531', 'EFO_0005531', 'EFO_0003956',
       'EFO_0003956', 'Orphanet_79292', 'EFO_0005854', 'MONDO_0005271',
       'EFO_0008521', 'EFO_1001417', 'MONDO_0004979', 'EFO_0000401',
       'HP_0012735', 'HP_0000964', 'MONDO_0002406', 'EFO_0004142'],
      dtype=object), 'count': 20}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 14 investigational indications.
CHEMBL1201356,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1,UNBRKDKAWYKMIV-QWQRMKEZSA-N,Small molecule,False,METHYLERGONOVINE,1946.0,4.0,,False,True,[],['Ergotyl' 'Methylergometrine' 'Methylergonovine'],"[('PubChem', array(['104171343', '144204360', '170465383', '26751766', '50104453',
       '90341291'], dtype=object)), ('Wikipedia', array(['Methylergometrine'], dtype=object)), ('drugbank', array(['DB00353'], dtype=object))]",['CHEMBL1200843'],"{'rows': array(['MP_0001914'], dtype=object), 'count': 1}","[ENSG00000135914,ENSG00000184845]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for hemorrhage.
CHEMBL1201463,,,Small molecule,False,CODEINE POLISTIREX,1985.0,4.0,CHEMBL485,False,True,[],['Codeine polistirex'],,,,"[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985.
CHEMBL1201497,,,Protein,False,INSULIN GLARGINE,2000.0,4.0,,False,True,"['Abasaglar' 'Abasaglar kwikpen' 'Basaglar' 'Ins lantus'
 'Ins lantus opticlik' 'Ins lantus optiset' 'Ins lantus solostar' 'Lantus'
 'Lantus solostar' 'Toujeo' 'Toujeo (previously optisulin)'
 'Toujeo max solostar' 'Toujeo solostar']","['Basalin' 'Basalog' 'Galactus' 'Glargin' 'Glargine' 'Glaricon' 'HOE 71GT'
 'HOE 901' 'HOE-71GT' 'HOE-901' 'Insulin Glargine Recombinant'
 'Insulin glargine' 'Insulin glargine (lantus)'
 'Insulin glargine (sanofi)' 'Insulin glargine aglr'
 'Insulin glargine recombinant' 'Insulin glargine yfgn'
 'Insulin glargine-aglr' 'Insulin glargine-yfgn' 'LY-2963016' 'LY2963016'
 'Lantus r' 'Lusduna' 'MK-1293' 'MYL-1501D' 'Myl-1501d' 'Rezvoglar'
 'Rezvoglar kwikpen' 'Semglee']","[('DailyMed', array(['insulin%20glargine', 'insulin%20glargine%20recombinant'],
      dtype=object)), ('DrugCentral', array(['4901'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/toujeo-previously-optisulin'],
      dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_0000565', 'EFO_0000400', 'MONDO_0005148',
       'EFO_0003770', 'EFO_0008583', 'EFO_1000897', 'MONDO_0009061',
       'EFO_0001645', 'EFO_1001121', 'HP_0003124', 'MONDO_0005147',
       'EFO_0003914', 'HP_0003074', 'EFO_0000537'], dtype=object), 'count': 15}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 12 investigational indications.
CHEMBL1201639,,,Protein,False,INSULIN ZINC SUSP BEEF,1982.0,4.0,,False,True,['Lente insulin'],['Insulin zinc susp beef'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1701,CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl,WCNLCIJMFAJCPX-UHFFFAOYSA-N,Small molecule,True,MEPERIDINE HYDROCHLORIDE,1942.0,4.0,CHEMBL607,False,True,"['Demerol' 'Meperidine hydrochloride'
 'Meperidine hydrochloride preservative free' 'Pamergan' 'Pethidine'
 'Pethilorfan' 'Spasmodlin']","['Meperidine hcl' 'Meperidine hydrochloride'
 'Meperidine hydrochloride cii' 'NIH 10522' 'NSC-400479'
 'Pethidine hydrochloride' 'Pethidini hydrochloridum']","[('DailyMed', array(['meperidine%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0003890', 'EFO_0005251'], dtype=object), 'count': 3}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and is indicated for pain and drug dependence and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2031465,Cc1ccc(C(=O)NC2CC2)cc1-n1cnc2ccc(N3CCN(C)CC3)cc2c1=O,ZMAZXHICVRYLQN-UHFFFAOYSA-N,Small molecule,False,AZD-6703,,1.0,,False,False,[],['AZ-12012199' 'AZ12012199' 'AZD-6703' 'Azd 6703' 'Azd-6703' 'Azd6703'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2108078,,,Protein,True,PARATHYROID HORMONE,2006.0,4.0,,False,True,['Natpar' 'Preotact'],"['ALX-1-11' 'ALX-111' 'ALX1-11' 'NPSP-558' 'NPSP558' 'Natpar' 'Natpara'
 'Parathormone (human recombinant)' 'Parathormonum' 'Parathyroid'
 'Parathyroid hormone' 'Parathyroid hormone (rdna)' 'Pth (1-84)'
 'Pth (1-84) human' 'Pth(1-84)']","[('DrugCentral', array(['4936'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/natpar',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/preotact'],
      dtype=object))]",,"{'rows': array(['EFO_0008506', 'HP_0002901', 'EFO_0009451', 'EFO_0000676',
       'EFO_0003854', 'EFO_0003882'], dtype=object), 'count': 6}",[ENSG00000160801],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109552,,,Antibody drug conjugate,False,YTTRIUM Y 90 CAPROMAB PENDETIDE,,2.0,,False,False,['Oncoltad'],"['90Y-CYT-356' 'CYT-356-90Y' 'CYT-356-Y-90' 'Cyt-356 90y'
 'Yttrium y 90 capromab pendetide']",,,,[ENSG00000086205],Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2111101,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,RKEWSXXUOLRFBX-UHFFFAOYSA-N,Small molecule,True,PIMAVANSERIN,2016.0,4.0,,False,True,[],['Pimavanserin'],"[('drugbank', array(['DB05316'], dtype=object))]",['CHEMBL2448613' 'CHEMBL5177911'],"{'rows': array(['EFO_0005772', 'EFO_0005407', 'EFO_0004895', 'MONDO_0005180',
       'EFO_0005407', 'MONDO_0002009', 'HP_0000738', 'MONDO_0004975',
       'MONDO_0005090', 'MONDO_0005090', 'MONDO_0005180'], dtype=object), 'count': 11}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3990012,,,Protein,False,PEGAPAMODUTIDE,,2.0,,False,False,[],['LY-2944876' 'LY2944876' 'Pegapamodutide'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL422872,O=C(O)CSC(CCCc1ccccc1)c1ccc(OCc2ccc3ccccc3n2)cc1,JOIXGLLMSDPZDN-UHFFFAOYSA-N,Small molecule,False,AZD-4769,,1.0,,False,False,[],"['AZ-12096971' 'AZD-4769' 'AZD4769' 'Azd 4769' 'Azd-4769' 'L-674573'
 'L674573']",,,,[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4297348,CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(=O)O)C(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)O)[C@H](C)O)[C@H](C)O,HRMVIAFZYCCHGF-BMCUWHFPSA-N,Protein,False,"BRIMAPITIDE, C-TERMINAL ACID",,3.0,,False,False,[],"['AM-111' 'Am-111' 'Brimapitide, c-terminal acid' 'D-jnki-1'
 'Xg-102 c-terminal acid']",,,"{'rows': array(['EFO_0004238'], dtype=object), 'count': 1}",[ENSG00000109339],Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297507,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2,LOWWYYZBZNSPDT-ZBEGNZNMSA-N,Small molecule,False,DELGOCITINIB,,3.0,,False,False,[],"['Delgocitinib' 'JTE-052' 'JTE-052A' 'LEO 124249' 'LEO 124249A'
 'LEO-124249' 'LEO-124249A']",,,"{'rows': array(['EFO_0000274', 'HP_0000964', 'EFO_0000676', 'EFO_0004192',
       'MONDO_0019558'], dtype=object), 'count': 5}","[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297718,,,Unknown,False,CD40 LIGAND,,2.0,,False,False,[],"['AMG-950' 'Cd40 ligand' 'Cd40 ligand recombinant'
 'Recombinant cd40-ligand' 'Recombinant human cd40 ligand'
 'Soluble cd154 recombinant']",,,"{'rows': array(['EFO_0000616', 'EFO_0000389'], dtype=object), 'count': 2}",[ENSG00000101017],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297888,,,Antibody,False,SOTIGALIMAB,,2.0,,False,False,[],['APX-005' 'APX-005M' 'APX005M' 'Apx005m' 'EPI-0050' 'Sotigalimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOTIGALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007576', 'MONDO_0008170', 'EFO_0000616', 'EFO_0002617',
       'EFO_1000657', 'EFO_1001968', 'EFO_0000756'], dtype=object), 'count': 7}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL440115,O=C(/C=C/c1c(-c2ccccc2)nn2ccccc12)N1CCCC[C@@H]1CCO,OPLOPFHUHFGKMJ-JXOMPUQVSA-N,Small molecule,False,FK453,,1.0,,False,False,[],['FK-453' 'Fk453'],,,,[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4594573,,,Antibody,False,FEPIXNEBART,,2.0,,False,False,[],['Fepixnebart' 'LY-3016859' 'LY3016859' 'Ly-3016859' 'Ly3016859'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FEPIXNEBART/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000401', 'HP_0003419', 'EFO_0005762', 'HP_0012532',
       'MONDO_0005178'], dtype=object), 'count': 5}","[ENSG00000163235,ENSG00000124882]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL462018,CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23,URLYINUFLXOMHP-HTVVRFAVSA-N,Small molecule,False,TRICIRIBINE PHOSPHATE,,2.0,,False,False,[],"['NSC-154020' 'NSC-280594' 'Phosphate salt of tricyclic nucleoside'
 'Triciribine' 'Triciribine phosphate' 'Vqd-002']","[('drugbank', array(['DB14636'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000565', 'MONDO_0008170'], dtype=object), 'count': 3}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650518,,,Antibody,False,PLONMARLIMAB,,2.0,,False,False,[],['Plonmarlimab' 'TJ-003234' 'TJ003234' 'TJM-2' 'Tj 003234' 'Tj003234'],,,"{'rows': array(['MONDO_0100096', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000164400],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5095028,CC(C)N1C[C@@H]2C[C@H]1CN2c1ccc(Nc2ncc(-c3coc(C(N)=O)c3)n3ncnc23)cc1,YBFGSJUVEOYPIS-OALUTQOASA-N,Small molecule,False,GLPG-0259,,2.0,,False,False,[],['GLPG-0259' 'GLPG0259' 'Glpg-0259'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000089022],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL809,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,VGKDLMBJGBXTGI-SJCJKPOMSA-N,Small molecule,True,SERTRALINE,1991.0,4.0,,False,True,[],['Sertraline'],"[('PubChem', array(['26753299', '29215139', '49665783', '50105682', '50105683',
       '50105684', '50105685', '90341218'], dtype=object)), ('Wikipedia', array(['Sertraline'], dtype=object)), ('drugbank', array(['DB01104'], dtype=object)), ('chEBI', array(['9123'], dtype=object))]",['CHEMBL1709'],"{'rows': array(['MONDO_0002009', 'EFO_0003756', 'EFO_0003047', 'EFO_0004262',
       'EFO_0002610', 'EFO_0007453', 'EFO_0001073', 'HP_0000989',
       'EFO_0001358', 'EFO_0000519', 'MONDO_0010383', 'MONDO_0002050',
       'EFO_1001917', 'MONDO_0002046', 'EFO_1001917', 'MONDO_0043510',
       'EFO_1001892', 'EFO_0005230', 'HP_0002315', 'EFO_0004262',
       'EFO_0003890', 'EFO_0001358', 'EFO_0007211', 'EFO_0003758',
       'MONDO_0004985', 'MONDO_0007739', 'MONDO_0007079', 'MONDO_0002009',
       'MONDO_0005090', 'EFO_0004242', 'EFO_0004242', 'EFO_0000222',
       'HP_0001249', 'EFO_0004247', 'EFO_0004698', 'EFO_0000198',
       'MONDO_0002050', 'EFO_0007228', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0002009'], dtype=object), 'count': 41}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1007,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,XLXSAKCOAKORKW-AQJXLSMYSA-N,Protein,False,GONADORELIN,1982.0,4.0,,False,True,['Fertiral lh-rh' 'Relefact lh-rh'],"['Gonadorelin' 'Gonadorelin decapeptide' 'Gonadotropin-releasing hormone'
 'Human gonadoliberin-i']","[('chEBI', array(['5520'], dtype=object))]",['CHEMBL1200516' 'CHEMBL1200511'],"{'rows': array(['MONDO_0018555', 'EFO_0000673', 'EFO_0003882', 'EFO_0001663',
       'MONDO_0007254', 'EFO_0002610', 'MONDO_0018800', 'MONDO_0007254',
       'MONDO_0008315', 'MONDO_0008315', 'EFO_0000545', 'EFO_0000196',
       'EFO_0000512', 'MONDO_0002146'], dtype=object), 'count': 14}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 13 investigational indications.
CHEMBL1115,CN(C)C(=O)Oc1ccc[n+](C)c1,RVOLLAQWKVFTGE-UHFFFAOYSA-N,Small molecule,True,PYRIDOSTIGMINE,1955.0,4.0,,False,True,[],"['Mestinon' 'Pyridostigmine' 'Pyridostigmine cation' 'Pyridostigmine ion'
 'Regonol']","[('PubChem', array(['11111694', '90340824'], dtype=object)), ('Wikipedia', array(['Pyridostigmine'], dtype=object)), ('drugbank', array(['DB00545'], dtype=object)), ('chEBI', array(['8665'], dtype=object))]",['CHEMBL812' 'CHEMBL4303667'],"{'rows': array(['EFO_0003144', 'EFO_0000764', 'MONDO_0100096', 'EFO_0005251',
       'MONDO_0004567', 'EFO_0004991', 'Orphanet_365', 'MONDO_0005180',
       'EFO_0004991', 'EFO_0005252', 'EFO_0005252', 'EFO_0000400',
       'MONDO_0009672', 'EFO_0005687', 'Orphanet_83419'], dtype=object), 'count': 15}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for myasthenia gravis and has 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200534,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl,JXRAXHBVZQZSIC-JKVLGAQCSA-N,Small molecule,True,MOEXIPRIL HYDROCHLORIDE,1995.0,4.0,CHEMBL1165,False,True,['Moexipril hydrochloride' 'Perdix' 'Univasc'],"['CI 925' 'CI-925' 'Moexipril hcl' 'Moexipril hydrochloride'
 'RS-10085-197' 'SPM 925' 'SPM-925']","[('DailyMed', array(['moexipril%20hydrochloride'], dtype=object)), ('PubChem', array(['144206143', '170465131'], dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for hypertension. This drug has a black box warning from the FDA.
CHEMBL1201210,CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2,UVOIBTBFPOZKGP-UHFFFAOYSA-N,Small molecule,False,PROPIOMAZINE,1960.0,4.0,,False,True,[],"['CB 1678' 'CB-1678' 'Dorevan' 'Dorevane' 'Indorm' 'Largon' 'Propavan'
 'Propiomazine' 'WY-1359']","[('Wikipedia', array(['Propiomazine'], dtype=object)), ('drugbank', array(['DB00777'], dtype=object)), ('chEBI', array(['8491'], dtype=object))]",['CHEMBL1201068'],,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1201556,,,Protein,False,BECAPLERMIN,1997.0,4.0,,False,True,['Regranex'],"['Becaplermin' 'GEM 21S' 'GEM-21S' 'Gemesis' 'Pdgf-2' 'Pdgf-bb' 'Pdgfb'
 'Platelet derived growth factor-bb'
 'Platelet-derived growth factor becaplermin' 'RWJ 60235' 'RWJ-60235'
 'Sh-polypeptide-59']","[('DailyMed', array(['becaplermin'], dtype=object)), ('DrugCentral', array(['4925'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/regranex'],
      dtype=object)), ('Wikipedia', array(['Becaplermin'], dtype=object))]",,"{'rows': array(['EFO_1001459', 'GO_0042060', 'HP_0200042', 'MONDO_0043839'],
      dtype=object), 'count': 4}","[ENSG00000113721,ENSG00000134853]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for wound healing and skin ulcer and has 2 investigational indications.
CHEMBL1237080,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2.Cl,QYZRTBKYBJRGJB-UHFFFAOYSA-N,Small molecule,False,GRANISETRON HYDROCHLORIDE,1993.0,4.0,CHEMBL289469,False,True,"['Granisetron hydrochloride' 'Granisetron hydrochloride preservative free'
 'Granisol' 'Granisteron HCl' 'Kytril']","['BRL 43694A' 'BRL-43694A' 'Bema granisetron'
 'Granisetron (as hydrochloride)' 'Granisetron hcl'
 'Granisetron hydrochloride' 'NSC-759839']","[('DailyMed', array(['granisetron%20hydrochloride'], dtype=object)), ('PubChem', array(['124894588'], dtype=object))]",,"{'rows': array(['HP_0002017', 'MONDO_0004992', 'HP_0002018', 'EFO_0006911',
       'EFO_0000616', 'HP_0100806'], dtype=object), 'count': 6}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 1 investigational indication.
CHEMBL1495,CN1CCCN=C1COC(=O)C(O)(c1ccccc1)C1CCCCC1,DUDKAZCAISNGQN-UHFFFAOYSA-N,Small molecule,False,OXYPHENCYCLIMINE,1982.0,4.0,,False,True,[],['Oxyphencyclimine'],"[('drugbank', array(['DB00383'], dtype=object)), ('chEBI', array(['7868'], dtype=object))]",['CHEMBL1200891'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease.
CHEMBL2103829,CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1,JIRYWFYYBBRJAN-ZFWWWQNUSA-N,Small molecule,False,FAXELADOL,,2.0,,False,False,[],"['EM-906' 'EM906' 'Faxeladol' 'GCR-9905' 'GCR9905' 'GRT-TA300'
 'GRTA-0009906' 'GRTA-9906' 'GRTA0009906' 'GRTA9906' 'Grt9906']",,['CHEMBL3893776'],"{'rows': array(['HP_0012532', 'EFO_0005762', 'EFO_0005687'], dtype=object), 'count': 3}","[ENSG00000108576,ENSG00000112038,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109295,,,Antibody,False,ASCRINVACUMAB,,2.0,,False,False,[],['Ascrinvacumab' 'PF-03446962'],,,"{'rows': array(['EFO_0000182', 'EFO_1001951', 'EFO_0000616', 'EFO_0000770'],
      dtype=object), 'count': 4}",[ENSG00000139567],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2109360,,,Antibody,False,AS-1403,,1.0,,False,False,['Therafab'],['AS-1403'],,,,[ENSG00000185499],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2364638,C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,DDOOFTLHJSMHLN-ZQHRPCGSSA-N,Small molecule,False,UBROGEPANT,2019.0,4.0,,False,True,['Ubrelvy'],['MK-1602' 'Ubrogepant' 'Ubrogepant anhydrous'],"[('DailyMed', array(['ubrogepant'], dtype=object)), ('drugbank', array(['DB15328'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for migraine disorder.
CHEMBL3137321,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341,VPMRSLWWUXNYRY-NDOYXKHWSA-N,Small molecule,False,BENZHYDROCODONE,2018.0,4.0,,False,True,[],['Benzhydrocodone'],"[('drugbank', array(['DB15465'], dtype=object))]",['CHEMBL3137310'],"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for pain.
CHEMBL3264610,CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1,ZBRAJOQFSNYJMF-SFHVURJKSA-N,Small molecule,False,SEVITERONEL,,2.0,,False,False,[],['Seviteronel' 'Vt-464'],"[('drugbank', array(['DB12275'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0008315'],
      dtype=object), 'count': 4}","[ENSG00000148795,ENSG00000169083]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3545211,CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1,OHCPNHFLPCVWRG-YQOGLFJVSA-N,Small molecule,False,SR16234,,2.0,,False,False,[],[],,['CHEMBL3545210'],"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL384467,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,UREBDLICKHMUKA-CXSFZGCWSA-N,Small molecule,False,DEXAMETHASONE,1958.0,4.0,,False,True,"['Aeroseb-dex' 'Dalalone' 'Decaderm' 'Decadron' 'Decadron-75' 'Decaspray'
 'Dexacortisyl' 'Dexafree' 'Dexamethasone' 'Dexamethasone intensol'
 'Dexone' 'Dexone 0.5' 'Dexone 0.75' 'Dexone 1.5' 'Dexone 4' 'Dexsol'
 'Dextenza' 'Dexycu kit' 'Dropodex' 'Gppe ear spy' 'Hemady' 'Hexadrol'
 'Kortico Injection' 'Martapan' 'Maxidex' 'Maxitrol' 'Oradexon' 'Otomize'
 'Ozurdex' 'Sofradex' 'Spersadex comp' 'Tobradex']","['Decadron-LA' 'Dexacen-4' 'Dexacort' 'Dexair' 'Dexamethasone'
 'Dexamethasone metasulfobenzoate sodium' 'Dexamethasone palmitate'
 'Dexamethasone valerate' 'Dexycu' 'Fluormethylprednisolone' 'ISV-305'
 'Mymethasone' 'NSC-34521' 'Neodecadron' 'OTO-104']","[('DailyMed', array(['dexamethasone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex'],
      dtype=object)), ('PubChem', array(['144207320', '17389945', '26752876', '26752877', '26752878',
       '56314873', '56320685', '92119'], dtype=object)), ('Wikipedia', array(['Dexamethasone'], dtype=object)), ('drugbank', array(['DB01234'], dtype=object)), ('chEBI', array(['41879'], dtype=object))]",,"{'rows': array(['EFO_0001663', 'EFO_0000546', 'EFO_0000224', 'EFO_0009449',
       'EFO_0003811', 'MONDO_0002331', 'EFO_1000657', 'MONDO_0019438',
       'EFO_1001267', 'EFO_1000941', 'EFO_1000694', 'EFO_0009456',
       'EFO_1000764', 'MONDO_0013730', 'EFO_0004237', 'EFO_1001231',
       'EFO_0000095', 'HP_0000265', 'EFO_0003932', 'MONDO_0004565',
       'EFO_0009491', 'MONDO_0002334', 'EFO_0002913', 'MONDO_0019460',
       'HP_0009926', 'EFO_0004888', 'MONDO_0044917', 'EFO_0000588',
       'EFO_1001469', 'EFO_0003025', 'HP_0011950', 'EFO_0000729',
       'EFO_0000673', 'EFO_0007405', 'EFO_1001012', 'EFO_0001642',
       'HP_0002901', 'EFO_0000373', 'EFO_0003917', 'EFO_1000879',
       'MONDO_0004658', 'HP_0002017', 'EFO_1001205', 'MONDO_0009348',
       'EFO_0006911', 'EFO_0009515', 'EFO_0000681', 'EFO_0001068',
       'MONDO_0018479', 'EFO_0003956', 'HP_0002013', 'EFO_0000309',
       'EFO_0003769', 'EFO_0004276', 'EFO_0007520', 'EFO_0006912',
       'MONDO_0015564', 'EFO_0004238', 'EFO_1000684', 'EFO_0003802',
       'EFO_0009536', 'EFO_0006862', 'EFO_0004255', 'EFO_0000565',
       'EFO_0006859', 'EFO_0007297', 'EFO_0000183', 'MONDO_0011962',
       'HP_0000486', 'EFO_0000616', 'EFO_0003106', 'EFO_0000223',
       'EFO_0003770', 'HP_0001094', 'HP_0030833', 'EFO_0000708',
       'MONDO_0004567', 'HP_0003072', 'EFO_0000384', 'EFO_0003918',
       'EFO_0008997', 'MONDO_0001280', 'EFO_0003103', 'MONDO_0015128',
       'MONDO_0002471', 'EFO_1001115', 'EFO_0009609', 'EFO_1001250',
       'HP_0002094', 'EFO_1000049', 'EFO_0004236', 'EFO_0009560',
       'EFO_1000965', 'MONDO_0001056', 'EFO_0007541', 'EFO_0009552',
       'EFO_0007537', 'EFO_0005752', 'EFO_0000182', 'EFO_0003893',
       'EFO_1001129', 'EFO_0003778', 'MONDO_0019472', 'HP_0000559',
       'EFO_1001417', 'MONDO_0007254', 'HP_0012378', 'EFO_0008517',
       'MONDO_0019338', 'EFO_0005221', 'MONDO_0017816', 'EFO_1001896',
       'MONDO_0002959', 'MONDO_0005301', 'EFO_0005319', 'MONDO_0008315',
       'MONDO_0005041', 'HP_0001742', 'EFO_0009430', 'EFO_0000274',
       'MONDO_0008170', 'MONDO_0007935', 'EFO_1000726', 'HP_0001873',
       'EFO_0004274', 'MONDO_0018076', 'EFO_0003032', 'EFO_1001494',
       'EFO_0000218', 'EFO_0003894', 'EFO_0005539', 'EFO_1001194',
       'EFO_0000676', 'MONDO_0006412', 'EFO_0005755', 'MONDO_0001572',
       'EFO_0000222', 'MONDO_0015540', 'EFO_0008520', 'MONDO_0004992',
       'EFO_0003073', 'EFO_0009441', 'EFO_0000221', 'EFO_0000613',
       'EFO_0009869', 'EFO_1001968', 'MONDO_0007576', 'EFO_1001435',
       'EFO_0007200', 'HP_0003418', 'EFO_0003027', 'MONDO_0000873',
       'MONDO_0002691', 'EFO_1000997', 'MONDO_0004979', 'MONDO_0008903',
       'EFO_0009507', 'EFO_1001801', 'EFO_0001422', 'EFO_0000540',
       'EFO_0007328', 'EFO_1001961', 'EFO_0000694', 'EFO_0000574',
       'EFO_0001063', 'HP_0011868', 'EFO_0007228', 'EFO_0003884',
       'EFO_0000209', 'EFO_0003966', 'MONDO_0001657', 'EFO_0000094',
       'EFO_0007231', 'EFO_0009104', 'MONDO_0005271', 'EFO_1000131',
       'EFO_0006475', 'EFO_0007257', 'EFO_0001378', 'MONDO_0002406',
       'MONDO_0001718', 'EFO_1001119', 'EFO_1002022', 'EFO_1000845',
       'EFO_0004616', 'EFO_0003869', 'EFO_0000544', 'EFO_0003843',
       'MONDO_0007079', 'EFO_0005207', 'Orphanet_1930', 'HP_0012532',
       'EFO_0005952', 'MONDO_0018896', 'MONDO_0018906', 'EFO_0000618',
       'EFO_1001909', 'EFO_0003060', 'HP_0001915', 'MONDO_0005178',
       'EFO_1001830', 'EFO_1001051', 'EFO_0000198', 'EFO_0007403',
       'MONDO_0100096', 'MONDO_0008728', 'EFO_0009448', 'EFO_0004208',
       'EFO_0004992', 'MONDO_0011382', 'EFO_0000365', 'MONDO_0005129',
       'EFO_0005570', 'EFO_0009708', 'EFO_0006738', 'EFO_1001951',
       'MONDO_0000465', 'MONDO_0000870', 'EFO_0000519', 'MONDO_0019091',
       'EFO_0007486', 'HP_0002015', 'EFO_0002618', 'EFO_1000811',
       'EFO_0004289', 'EFO_0002950', 'MP_0001845', 'EFO_0000220',
       'EFO_1001222', 'EFO_0005592', 'HP_0011110', 'EFO_0005558',
       'MONDO_0100130', 'EFO_1000986', 'MONDO_0044881', 'EFO_0000713',
       'EFO_0007149', 'EFO_0004272', 'EFO_0004274', 'MONDO_0002462',
       'EFO_0000211', 'EFO_1000039', 'EFO_1001176', 'MONDO_0100053',
       'MONDO_0003005', 'EFO_0000181', 'EFO_0000756', 'MONDO_0021148',
       'HP_0012424', 'EFO_1001157', 'EFO_0003898', 'EFO_0004252',
       'EFO_0007160', 'EFO_0004719', 'HP_0006536', 'EFO_0001365',
       'EFO_0004710', 'MONDO_0001705', 'EFO_0003144', 'HP_0100806',
       'MP_0001914', 'EFO_0007344', 'EFO_1000637', 'EFO_1001779',
       'EFO_0000691', 'EFO_0007141', 'EFO_1000797', 'EFO_0000305',
       'EFO_0000685', 'MONDO_0016226', 'EFO_0007355', 'MONDO_0011972',
       'EFO_1001216', 'EFO_0008528', 'EFO_1000749', 'MONDO_0005277',
       'EFO_0000537', 'HP_0004398', 'MONDO_0021108', 'MONDO_0020547',
       'EFO_0000403', 'EFO_0008571', 'EFO_0001075', 'EFO_0003957',
       'EFO_1001139', 'MONDO_0007915', 'MONDO_0019471', 'EFO_1000906',
       'HP_0002018', 'EFO_0004683', 'EFO_1000992', 'EFO_0002609',
       'EFO_0000096', 'EFO_1001875', 'EFO_0005854', 'MONDO_0001187',
       'EFO_1000318', 'EFO_0000702', 'HP_0002315', 'EFO_1001158'],
      dtype=object), 'count': 300}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 79 approved and 221 investigational indications.
CHEMBL4297383,Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1,WIEDUMBCZQRGSY-UHFFFAOYSA-N,Small molecule,False,GSK-1521498,,2.0,,False,False,[],['GSK1521498' 'Gsk-1521498' 'Gsk1521498'],"[('drugbank', array(['DB12886'], dtype=object))]",,"{'rows': array(['MONDO_0007079', 'EFO_0001073'], dtype=object), 'count': 2}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297942,,,Antibody,False,QUETMOLIMAB,,2.0,,False,False,[],['E-6011' 'E6011' 'Quetmolimab'],,,"{'rows': array(['EFO_0000685', 'EFO_1001486', 'EFO_0000384'], dtype=object), 'count': 3}",[ENSG00000006210],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL45305,Cc1ccc(CNCC2(F)CCN(C(=O)c3ccc(F)c(Cl)c3)CC2)nc1,PKZXLMVXBZICTF-UHFFFAOYSA-N,Small molecule,False,BEFIRADOL,,2.0,,False,False,[],['Befiradol' 'F-13640' 'F13640' 'NLX-112'],"[('Wikipedia', array(['Befiradol'], dtype=object))]",,"{'rows': array(['EFO_0004280'], dtype=object), 'count': 1}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594444,C[C@H](O)c1nc(Cn2nc(-c3ccc(Cl)cc3)n(C[C@H](O)C(F)(F)F)c2=O)nn1-c1cccc(Cl)c1,AZXOTZCWQDJCLY-SJCJKPOMSA-N,Small molecule,False,PECAVAPTAN,,2.0,,False,False,[],['BAY 1753011' 'BAY-1753011' 'Bay 1753011' 'Pecavaptan'],,,"{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}","[ENSG00000166148,ENSG00000126895]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL49,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,QWCRAEMEVRGPNT-UHFFFAOYSA-N,Small molecule,False,BUSPIRONE,1986.0,4.0,,False,True,[],['BCI-024' 'Buspar' 'Buspirone' 'Gen-buspirone'],"[('PubChem', array(['104171117', '11110857', '11112732', '11113821', '144203643',
       '144212688', '170464909', '26751994', '90340780'], dtype=object)), ('Wikipedia', array(['Buspirone'], dtype=object)), ('drugbank', array(['DB00490'], dtype=object)), ('chEBI', array(['3223'], dtype=object))]",['CHEMBL1200399'],"{'rows': array(['EFO_0003756', 'EFO_0000717', 'EFO_0004714', 'MONDO_0005090',
       'MONDO_0002050', 'HP_0002104', 'EFO_0005230', 'MONDO_0005090',
       'EFO_1001919', 'MONDO_0002050', 'EFO_0007191', 'EFO_0008533',
       'EFO_1001892', 'EFO_1000948', 'EFO_0004888', 'EFO_0006788',
       'EFO_0002610', 'HP_0000726', 'EFO_0003758', 'EFO_0003888',
       'EFO_0004714', 'MONDO_0002009', 'MONDO_0005180', 'EFO_0005411',
       'HP_0002140', 'EFO_1001919'], dtype=object), 'count': 26}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 4 approved and 19 investigational indications.
CHEMBL536151,O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O,CHILCFMQWMQVAL-UHFFFAOYSA-N,Small molecule,False,IMD-0354,,1.0,,False,False,[],['IMD-0354' 'Imd-0354' 'TCMDC-125465'],"[('PubChem', array(['103904747', '29217569', '50111708'], dtype=object))]",,,[ENSG00000104365],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1199324,C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,BARDROPHSZEBKC-OITMNORJSA-N,Small molecule,False,FOSAPREPITANT,2008.0,4.0,,False,True,['Ivemend'],['Fosaprepitant' 'L-758298'],"[('Wikipedia', array(['Fosaprepitant'], dtype=object)), ('drugbank', array(['DB06717'], dtype=object)), ('chEBI', array(['64321'], dtype=object))]",['CHEMBL1201782' 'CHEMBL1159797'],"{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_0001378', 'EFO_0006911',
       'EFO_0004888', 'HP_0002017', 'MONDO_0043510', 'MONDO_0021148',
       'MONDO_0004992', 'EFO_0006911', 'EFO_0000691', 'HP_0002017',
       'EFO_0004252'], dtype=object), 'count': 13}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 9 investigational indications.
CHEMBL1200791,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl,BEEDODBODQVSIM-UHFFFAOYSA-N,Small molecule,False,OXYMETAZOLINE HYDROCHLORIDE,1986.0,4.0,CHEMBL762,False,True,['Afrazine' 'Ocuclear' 'Rhofade' 'Upneeq' 'Visine l.r.'],"['Agn-199201' 'NSC-757254' 'Oximetazoline hydrochloride'
 'Oxymetazoline hcl' 'Oxymetazoline hydrochloride' 'SCH 9384' 'SCH-9384']","[('DailyMed', array(['oxymetazoline%20hydrochloride'], dtype=object)), ('PubChem', array(['26747607', '26747608', '50106757', '50106758', '50106759',
       '856146'], dtype=object)), ('chEBI', array(['7863'], dtype=object))]",,"{'rows': array(['EFO_0005854', 'HP_0001742', 'MONDO_0000728', 'MONDO_0001330',
       'HP_0010783', 'EFO_0007486', 'EFO_0007214', 'EFO_0007141',
       'EFO_0003956', 'EFO_1000760'], dtype=object), 'count': 10}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 approved and 3 investigational indications.
CHEMBL1201206,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1,OWWLUIWOFHMHOQ-XGHATYIMSA-N,Small molecule,False,PIPECURONIUM,1990.0,4.0,,False,True,[],['Pipecuronium'],"[('drugbank', array(['DB01338'], dtype=object)), ('chEBI', array(['8230'], dtype=object))]",['CHEMBL1200722'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990.
CHEMBL1266,c1ccc2c(c1)CCCC2C1=NCCN1,BYJAVTDNIXVSPW-UHFFFAOYSA-N,Small molecule,False,TETRAHYDROZOLINE,1979.0,4.0,,False,True,[],['Caltheon' 'Tetrahydrozoline' 'Tetryzoline' 'Tyzine'],"[('PubChem', array(['90341828'], dtype=object)), ('Wikipedia', array(['Tetrahydrozoline'], dtype=object)), ('drugbank', array(['DB06764'], dtype=object)), ('chEBI', array(['28674'], dtype=object))]",['CHEMBL1200413'],"{'rows': array(['HP_0001742', 'EFO_1000906', 'EFO_0000678', 'MP_0001845',
       'EFO_0005751'], dtype=object), 'count': 5}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for nasal congestion and eye allergy and has 3 investigational indications.
CHEMBL1743067,,,Antibody,False,SAMALIZUMAB,,2.0,,False,False,[],['ALXN-6000' 'ALXN6000' 'Samalizumab'],,,"{'rows': array(['EFO_0000222', 'EFO_0000095', 'EFO_0001378', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000091972],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1900528,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12,LERNTVKEWCAPOY-DZZGSBJMSA-N,Small molecule,False,TIOTROPIUM,2004.0,4.0,,False,True,['Braltus' 'Spiriva' 'Spiriva respimat'],['Tiotropium' 'Tiotropium cation' 'Tiotropium ion'],"[('PubChem', array(['50113015'], dtype=object)), ('drugbank', array(['DB01409'], dtype=object))]",['CHEMBL4440620' 'CHEMBL3545181'],"{'rows': array(['EFO_1001919', 'HP_0006536', 'HP_0000083', 'MONDO_0009061',
       'EFO_0000616', 'EFO_0000341', 'MONDO_0004979', 'EFO_0006505',
       'EFO_0000341', 'EFO_0000464'], dtype=object), 'count': 10}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 5 investigational indications.
CHEMBL2105864,COc1ccc(C[C@@H](CN[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](Cc2cccs2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCNC(=N)N)cc1,IDXCXSCCZNCXCL-XMADEQCMSA-N,Protein,False,LABRADIMIL,,2.0,,False,False,[],['Labradimil' 'Lobradimil' 'RMP-7'],"[('drugbank', array(['DB06549'], dtype=object))]",,"{'rows': array(['EFO_0005543', 'EFO_1000158', 'EFO_0007228', 'EFO_0002939'],
      dtype=object), 'count': 4}",[ENSG00000168398],Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2107355,Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,ZJIHMALTJRDNQI-OLALXQGDSA-N,Small molecule,False,MIGALASTAT HYDROCHLORIDE,2016.0,4.0,CHEMBL110458,False,True,['Galafold'],"['AT-1001 (MIGALASTAT HYDROCHLORIDE)' 'Migalastat hcl'
 'Migalastat hydrochloride']","[('DailyMed', array(['migalastat%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/galafold'],
      dtype=object))]",,"{'rows': array(['MONDO_0010526'], dtype=object), 'count': 1}",[ENSG00000102393],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for fabry disease.
CHEMBL2107877,,,Protein,False,BLISIBIMOD,,3.0,,False,False,[],['A-623' 'AMG 623' 'AMG-623' 'Blisibimod'],,,"{'rows': array(['EFO_0007160', 'EFO_0005297', 'EFO_0004194', 'MONDO_0007915',
       'EFO_1000784'], dtype=object), 'count': 5}",[ENSG00000102524],Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2108045,,,Antibody,False,PRITUMUMAB,,2.0,,False,False,[],['Pritumumab'],,,,[ENSG00000026025],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108572,,,Protein,False,BALUGRASTIM,,2.0,,False,False,[],['Balugrastim' 'CG-10639' 'CG10639'],,,"{'rows': array(['MONDO_0001475', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109224,,,Antibody,False,ROVELIZUMAB,,2.0,,False,False,['Leukarrest'],['HU-23F2G' 'HU23F2G' 'Rovelizumab'],,,,"[ENSG00000005844,ENSG00000160255,ENSG00000169896]",Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109286,,,Antibody drug conjugate,False,COLTUXIMAB RAVTANSINE,,2.0,,False,False,[],['Coltuximab ravtansine' 'SAR-3419' 'SAR3419'],,,"{'rows': array(['EFO_0005952', 'EFO_0000403', 'EFO_0000220'], dtype=object), 'count': 3}",[ENSG00000177455],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109544,,,Antibody,False,CDP-860,,2.0,,False,False,[],['CDP-860'],,,,[ENSG00000113721],Antibody drug with a maximum clinical trial phase of II.
CHEMBL24778,C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,PNCPYILNMDWPEY-QGZVFWFLSA-N,Small molecule,False,SILODOSIN,2008.0,4.0,,False,True,['Rapaflo' 'Silodyx'],"['KAD-3213' 'KMD-3213' 'Kso-0400' 'Rapilif' 'Silodal' 'Silodosin'
 'Silodyx' 'Urief' 'Urorec']","[('DailyMed', array(['silodosin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/silodyx'],
      dtype=object)), ('Wikipedia', array(['Silodosin'], dtype=object)), ('drugbank', array(['DB06207'], dtype=object))]",,"{'rows': array(['EFO_0000284', 'EFO_0803321', 'MONDO_0008315', 'MONDO_0024647',
       'EFO_0004253', 'EFO_0003830'], dtype=object), 'count': 6}",[ENSG00000120907],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for benign prostatic hyperplasia and has 5 investigational indications.
CHEMBL260933,CCCn1c(=O)c2[nH]c(-c3cnn(Cc4cccc(C(F)(F)F)c4)c3)nc2n(CC)c1=O,KOYXXLLNCXWUNF-UHFFFAOYSA-N,Small molecule,False,GS 6201,,1.0,,False,False,[],['CVT-6883' 'GS-6201' 'Gs 6201'],"[('PubChem', array(['103905523', '174007167'], dtype=object)), ('drugbank', array(['DB05936'], dtype=object))]",,,[ENSG00000170425],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL325041,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,GXJABQQUPOEUTA-RDJZCZTQSA-N,Small molecule,False,BORTEZOMIB,2003.0,4.0,,False,True,['Bortezomib accord' 'Velcade'],"['Bortezomib' 'Bortezomib accord' 'Bortezomib hydrate' 'LDP-341'
 'NSC-681239' 'PS-341' 'Velcade']","[('DailyMed', array(['bortezomib'], dtype=object)), ('PubChem', array(['124950705', '144206183', '144206225', '170465087', '518755'],
      dtype=object)), ('Wikipedia', array(['Bortezomib'], dtype=object)), ('drugbank', array(['DB00188'], dtype=object)), ('chEBI', array(['52717'], dtype=object))]",,"{'rows': array(['EFO_1001961', 'EFO_1000158', 'MONDO_0004192', 'MONDO_0002367',
       'MONDO_0003175', 'EFO_0000574', 'EFO_0000519', 'EFO_1001226',
       'MONDO_0008170', 'MONDO_0017816', 'EFO_0000588', 'EFO_0000096',
       'EFO_0000095', 'MONDO_0044917', 'MONDO_0016537', 'MONDO_0008627',
       'EFO_0000183', 'EFO_0001378', 'EFO_0003060', 'EFO_0000094',
       'EFO_0006859', 'EFO_0005952', 'EFO_0009441', 'EFO_0000339',
       'EFO_0000220', 'EFO_0000182', 'MONDO_0018922', 'EFO_0000681',
       'EFO_0003811', 'EFO_0000616', 'EFO_0004599', 'MONDO_0020547',
       'EFO_0000571', 'MONDO_0019460', 'EFO_0005543', 'EFO_0001642',
       'EFO_0003884', 'MONDO_0019471', 'MONDO_0001705', 'EFO_1001365',
       'EFO_0007183', 'EFO_1001968', 'EFO_0000209', 'EFO_0000198',
       'MONDO_0002974', 'MONDO_0007254', 'EFO_1001052', 'EFO_0000224',
       'MONDO_0015277', 'EFO_0000309', 'MONDO_0007576', 'EFO_1001875',
       'MONDO_0001056', 'EFO_0000641', 'EFO_0000501', 'MONDO_0019438',
       'EFO_0000621', 'MONDO_0004986', 'EFO_0002618', 'MONDO_0004992',
       'EFO_0003032', 'MONDO_0044881', 'MONDO_0009348', 'EFO_0000222',
       'EFO_0004252', 'EFO_0000191', 'EFO_1001051', 'EFO_1000785',
       'MONDO_0001187', 'EFO_0007160', 'EFO_0000255', 'EFO_0007332',
       'EFO_0000305', 'EFO_0000403', 'EFO_0003073', 'EFO_0000231',
       'EFO_0004289', 'EFO_0001663', 'MONDO_0008315', 'EFO_0006475',
       'EFO_1001469', 'EFO_0004256', 'EFO_0002428', 'EFO_0000211',
       'MONDO_0018906', 'EFO_0000565', 'MONDO_0002087', 'EFO_0002501',
       'EFO_1001465', 'EFO_0000756', 'MONDO_0002158', 'EFO_0000540',
       'EFO_0000707', 'EFO_0000691', 'MONDO_0015564', 'EFO_0006738',
       'MONDO_0013730', 'MONDO_0016145', 'MONDO_0008903', 'EFO_0002499',
       'EFO_0000673', 'EFO_1001951', 'MONDO_0000873', 'MONDO_0005184',
       'EFO_0000308'], dtype=object), 'count': 105}","[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 4 approved and 101 investigational indications.
CHEMBL3301582,,,Antibody drug conjugate,False,POLATUZUMAB VEDOTIN,2019.0,4.0,,False,True,['Polivy'],"['ACD-79B-VCMMAE' 'ACD-79BVCMMAE' 'ACD79B-VCMMAE' 'Anti-cd79b adc'
 'DCDS-4501A' 'DCDS4501A' 'FCU-2711' 'FCU2711' 'Polatuzumab vedotin'
 'Polatuzumab vedotin piiq' 'RG-7596' 'RG7596' 'RO-5541077-000'
 'RO-5541077000' 'RO5541077-000']","[('DailyMed', array(['polatuzumab%20vedotin-piiq'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/polivy'],
      dtype=object))]",,"{'rows': array(['MONDO_0018906', 'EFO_0000574', 'EFO_0000096', 'EFO_1001469',
       'EFO_0005952', 'EFO_0000403', 'EFO_0000095', 'MONDO_0004095',
       'EFO_0000616'], dtype=object), 'count': 9}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000007312]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 6 investigational indications.
CHEMBL3544911,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1,DOTGPNHGTYJDEP-UHFFFAOYSA-N,Small molecule,False,PREXASERTIB,,2.0,,False,False,[],['LY-2606368' 'LY2606368' 'Ly-2606368' 'Prexasertib'],"[('drugbank', array(['DB12008'], dtype=object))]",['CHEMBL5305850'],"{'rows': array(['EFO_0000616', 'MONDO_0001657', 'EFO_0009708', 'EFO_1001779',
       'MONDO_0004992', 'EFO_0000198', 'EFO_0000222', 'EFO_0004284',
       'EFO_1000158', 'MONDO_0008170', 'EFO_0004142', 'EFO_0000702',
       'EFO_0000708', 'EFO_0002939', 'MONDO_0007254', 'EFO_0003060'],
      dtype=object), 'count': 16}","[ENSG00000149554,ENSG00000183765]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications.
CHEMBL3545080,,,Small molecule,False,RG-7256,,1.0,,False,False,[],['PLX-3603' 'Rg-7256' 'Ro-5212054'],,,,[ENSG00000157764],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989408,CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+],VTGPMVCGAVZLQI-UHFFFAOYSA-M,Small molecule,False,IBUPROFEN SODIUM,2012.0,4.0,CHEMBL521,False,True,['Advil' 'Ibuprofen sodium'],"['Ibuprofen sodium' 'Ibuprofen sodium dihydrate'
 'Sodium ibuprofen dihydrate']","[('DailyMed', array(['ibuprofen%20sodium'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2012 and has 1 investigational indication.
CHEMBL3989927,O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,IXZOHGPZAQLIBH-NRFANRHFSA-N,Small molecule,False,IBERDOMIDE,,3.0,,False,False,[],['CC-220' 'Iberdomide'],"[('drugbank', array(['DB12101'], dtype=object))]",['CHEMBL3989912'],"{'rows': array(['EFO_0001378', 'EFO_0003073', 'EFO_0000574', 'MONDO_0018906',
       'HP_0000083', 'MONDO_0019338', 'EFO_0005952', 'EFO_0000403',
       'EFO_0001378', 'MONDO_0007915', 'EFO_0001421'], dtype=object), 'count': 11}","[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL3989937,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.O,COWBUPJEEDYWKD-UHFFFAOYSA-N,Small molecule,False,CAPMATINIB HYDROCHLORIDE,2020.0,4.0,CHEMBL3188267,False,True,['Tabrecta'],"['Capmatinib hydrochloride' 'Capmatinib hydrochloride hydrate'
 'NVP-INC280-AAA']","[('DailyMed', array(['capmatinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta'],
      dtype=object))]",,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for non-small cell lung carcinoma.
CHEMBL4297458,Cc1nnn(C)c1-c1cnc2c3ccc(C(C)(C)O)cc3n([C@H](c3ccccc3)C3CCOCC3)c2c1,KGERZPVQIRYWRK-GDLZYMKVSA-N,Small molecule,False,EZOBRESIB,,1.0,,False,False,[],['BMS-986158' 'Bet inhibitor bms-986158' 'Bms-986158' 'Ezobresib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EZOBRESIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15435'], dtype=object))]",['CHEMBL5185824'],"{'rows': array(['EFO_0000574', 'EFO_0000616', 'EFO_0001378', 'MONDO_0044903'],
      dtype=object), 'count': 4}","[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL4298055,,,Protein,False,ALDAFERMIN,,2.0,,False,False,[],['Aldafermin' 'NGM-282' 'NGM282' 'Ngm282'],,,"{'rows': array(['EFO_1001249', 'EFO_0004268', 'EFO_0000400', 'HP_0002019',
       'EFO_0003086', 'EFO_1001486', 'EFO_0001421'], dtype=object), 'count': 7}","[ENSG00000113578,ENSG00000134962,ENSG00000160867]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL436774,CC(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1,HUDQLWBKJOMXSZ-UHFFFAOYSA-N,Small molecule,False,AR9281,,2.0,,False,False,[],['Ar9281'],"[('drugbank', array(['DB06345'], dtype=object))]",,,[ENSG00000120915],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4594518,,,Antibody,False,LUTIKIZUMAB,,2.0,,False,False,[],['A-1234138' 'ABT-981' 'Abt-981' 'Lutikizumab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUTIKIZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0005178', 'EFO_0000616', 'EFO_1000710', 'EFO_0004616'],
      dtype=object), 'count': 4}","[ENSG00000125538,ENSG00000115008]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL460291,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C,GKQPCPXONLDCMU-CCEZHUSRSA-N,Small molecule,False,LACIDIPINE,,4.0,,False,True,['Caldine' 'Molap' 'Motens'],"[""3,3'-iminobispropylamine"" ""3,3'-iminodipropylamine""
 '4-azaheptamethylenediamine' ""Dipropylamine, 3,3'-diamino-""
 'Dipropylenetriamine' 'GR 43659X' 'GR-43659X' 'Lacidipine' 'NSC-7773']","[('PubChem', array(['144205727', '170465580'], dtype=object)), ('drugbank', array(['DB09236'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0003913', 'EFO_0000537'], dtype=object), 'count': 3}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL4650220,Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12.Cl,VQDUWCSSPSOSNA-RYWNGCACSA-N,Small molecule,False,ZAVEGEPANT HYDROCHLORIDE,2023.0,4.0,CHEMBL2397415,False,True,['Zavzpret'],"['BHV-3500 hydrochloride' 'BMS-742413 hydrochloride' 'BMS-742413-03'
 'Zavegepant hydrochloride' 'Zavzpret']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZAVEGEPANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for migraine disorder.
CHEMBL483465,Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3,FARXPFGGGGLENU-UHFFFAOYSA-N,Small molecule,False,ELRAGLUSIB,,2.0,,False,False,[],['9 ing 41' '9-ING-41' '9-ing-41' 'Elraglusib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELRAGLUSIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000691', 'EFO_0009708', 'MONDO_0100342', 'MONDO_0021117',
       'EFO_0003869', 'EFO_0000616', 'EFO_1000350', 'MONDO_0002367',
       'MONDO_0044903'], dtype=object), 'count': 9}",[ENSG00000082701],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL1201120,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1.Cl,WFBMIPUMYUHANP-UHFFFAOYSA-N,Small molecule,True,REMIFENTANIL HYDROCHLORIDE,1996.0,4.0,CHEMBL1005,False,True,['Ultiva'],['GI 87084B' 'GI-87084B' 'Remifentanil hcl' 'Remifentanil hydrochloride'],"[('DailyMed', array(['remifentanil%20hydrochloride'], dtype=object)), ('chEBI', array(['32091'], dtype=object))]",,,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996. This drug has a black box warning from the FDA.
CHEMBL1201538,,,Protein,False,INSULIN LISPRO,1996.0,4.0,,False,True,"['Admelog' 'Admelog solostar' 'Humalog' 'Humalog kwikpen' 'Humalog pen'
 'Humalog tempo pen' 'Ins humalog' 'Insulin lispro sanofi']","['Insulin Lispro Recombinant' 'Insulin lispro'
 'Insulin lispro recombinant' 'Lyumjev']","[('DailyMed', array(['insulin%20lispro', 'insulin%20lispro%20recombinant',
       'insulin%20lispro-aabc'], dtype=object)), ('DrugCentral', array(['5002'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-lispro-sanofi'],
      dtype=object))]",,"{'rows': array(['HP_0003074', 'MONDO_0005147', 'EFO_0000400', 'MONDO_0005148'],
      dtype=object), 'count': 4}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for diabetes mellitus and has 3 investigational indications.
CHEMBL146095,O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12,GWOFUCIGLDBNKM-UHFFFAOYSA-N,Small molecule,False,GLAFENINE,,4.0,,True,True,[],"['Glafenin' 'Glafenine' 'Glaphenine' 'Glycerylaminophenaquine'
 'NSC-757808' 'R 1707' 'R-1707']","[('PubChem', array(['26748455'], dtype=object)), ('chEBI', array(['31653'], dtype=object))]",['CHEMBL1572751'],"{'rows': array(['HP_0001945', 'EFO_0003843'], dtype=object), 'count': 2}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for fever and pain. It was withdrawn in at least one region.
CHEMBL1643880,O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O,AFUWQWYPPZFWCO-LBPRGKRZSA-N,Small molecule,False,PUMOSETRAG,,2.0,,False,False,[],['DDP733' 'Pumosetrag'],"[('drugbank', array(['DB12402'], dtype=object))]",,"{'rows': array(['EFO_0003948', 'EFO_0000555'], dtype=object), 'count': 2}","[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2103799,CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1,SDDSJMXGJNWMJY-BRHAQHMBSA-N,Small molecule,False,COBIPROSTONE,,2.0,,False,False,[],['Cobiprostone' 'RU-8811' 'SPI-8811'],"[('drugbank', array(['DB05514'], dtype=object))]",,"{'rows': array(['EFO_0004607', 'EFO_0000666', 'EFO_1001904'], dtype=object), 'count': 3}",[ENSG00000114859],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2103847,CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO,FWFGIHPGRQZWIW-SQNIBIBYSA-N,Small molecule,False,TOSEDOSTAT,,2.0,,False,False,[],['CHR 2797' 'CHR-2797' 'CHR2797' 'Tosedostat'],"[('drugbank', array(['DB11781'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000222', 'EFO_0000198', 'EFO_0003060',
       'EFO_0002618'], dtype=object), 'count': 5}","[ENSG00000166825,ENSG00000141279,ENSG00000176393,ENSG00000164024,ENSG00000113441,ENSG00000123992,ENSG00000138792,ENSG00000108039,ENSG00000002549,ENSG00000111142,ENSG00000122121,ENSG00000164308,ENSG00000164307,ENSG00000172901,ENSG00000148120,ENSG00000172878,ENSG00000215440,ENSG00000142327,ENSG00000196236]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2103858,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)C[C@@H]1OC,VGDDOIZXGFJDRC-VJTSUQJLSA-N,Small molecule,False,NARONAPRIDE,,2.0,,False,False,[],['ATI-7505' 'ATI7505' 'Naronapride'],"[('drugbank', array(['DB05542'], dtype=object))]",['CHEMBL2105706'],"{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108025,,,Protein,False,DEPELESTAT,,2.0,,False,False,[],['DX-890' 'Depelestat'],,,,[ENSG00000197561],Protein drug with a maximum clinical trial phase of II.
CHEMBL2108287,,,Oligonucleotide,False,APRINOCARSEN,,3.0,,False,False,[],['Aprinocarsen' 'LY-900003' 'LY900003' 'Ly900003' 'Pkc-alpha'],,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000154229],Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108305,,,Protein,False,INSULIN TREGOPIL,,2.0,,False,False,[],['IN-105' 'Insulin tregopil'],,,"{'rows': array(['MONDO_0005147', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109332,,,Antibody,False,MLNM-2201,,2.0,,False,False,[],['LDP-01' 'MLNM-2201'],,,,[ENSG00000160255],Antibody drug with a maximum clinical trial phase of II.
CHEMBL22108,CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1,MVMQESMQSYOVGV-UHFFFAOYSA-N,Small molecule,False,DIMETHINDENE,,4.0,,False,True,[],['Dimethpyrindene' 'Dimetindene' 'Feniallerg' 'Forhistal'],"[('Wikipedia', array(['Dimetindene'], dtype=object)), ('drugbank', array(['DB08801'], dtype=object))]",['CHEMBL1870768'],"{'rows': array(['EFO_0004269', 'MONDO_0005271', 'HP_0000989'], dtype=object), 'count': 3}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for allergic disease and pruritus and has 1 investigational indication.
CHEMBL24,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,METKIMKYRPQLGS-UHFFFAOYSA-N,Small molecule,True,ATENOLOL,1981.0,4.0,,False,True,"['Antipressan' 'Atenamin' 'Atenix-100' 'Atenix-25' 'Atenix-50' 'Atenolol'
 'Ibinolo' 'Kentol' 'Tenormin' 'Tenormin 25' 'Tenormin l.s.' 'Totamol'
 'Unibloc' 'Vasaten']","['Atenolol' 'Atenololum' 'Betacard' 'C07AB03' 'Corotenol' 'Duraatenolol'
 'Esatenolol' 'ICI 66,082' 'ICI 66082' 'ICI-66082' 'Juvental' 'Myocord'
 'NSC-757832' 'Novaten' 'Prenormine' 'Urosin']","[('DailyMed', array(['atenolol'], dtype=object)), ('PubChem', array(['144212743', '26751696', '50085956', '50104387', '855957',
       '90340978'], dtype=object)), ('Wikipedia', array(['Atenolol'], dtype=object)), ('drugbank', array(['DB00335'], dtype=object)), ('chEBI', array(['2904'], dtype=object))]",,"{'rows': array(['MONDO_0007947', 'EFO_0007372', 'EFO_0003882', 'EFO_0003896',
       'EFO_0000400', 'EFO_0003763', 'EFO_0003777', 'EFO_0000537',
       'EFO_1001375', 'EFO_0000319', 'EFO_0000612', 'EFO_1000645',
       'EFO_0000712', 'EFO_1000635', 'MONDO_0021661', 'EFO_0003144',
       'EFO_0000275', 'MONDO_0001134', 'EFO_0003913', 'EFO_0001358'],
      dtype=object), 'count': 20}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3186011,COCC1(CO)C(=O)C2CCN1CC2,BGBNULCRKBVAKL-UHFFFAOYSA-N,Small molecule,False,EPRENETAPOPT,,3.0,,False,False,[],['APR-246' 'Apr 246' 'Apr-246' 'Eprenetapopt' 'PRIMA-1Met'],"[('PubChem', array(['174007096'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EPRENETAPOPT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11684'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'EFO_0000198', 'EFO_1001469', 'MONDO_0008170',
       'EFO_0002916', 'EFO_0000616'], dtype=object), 'count': 6}",[ENSG00000141510],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3707348,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,WDENQIQQYWYTPO-IBGZPJMESA-N,Small molecule,False,ACALABRUTINIB,2017.0,4.0,,False,True,['Calquence'],['ACP-196' 'Acalabrutinib' 'Acp-196'],"[('DailyMed', array(['acalabrutinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/calquence'],
      dtype=object)), ('drugbank', array(['DB11703'], dtype=object))]",['CHEMBL4594293'],"{'rows': array(['MONDO_0001023', 'MONDO_0018906', 'EFO_0000565', 'EFO_0000095',
       'EFO_0000519', 'EFO_0000181', 'EFO_0001378', 'EFO_1001469',
       'EFO_0009441', 'EFO_0003060', 'MONDO_0020547', 'EFO_1001469',
       'MONDO_0100096', 'MONDO_0044881', 'EFO_1001890', 'EFO_0000616',
       'MONDO_0004992', 'EFO_0000096', 'EFO_0000095', 'EFO_0000574',
       'EFO_0000685', 'MONDO_0008170', 'EFO_0002618', 'EFO_0005741',
       'EFO_0005952', 'EFO_0000403'], dtype=object), 'count': 26}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 20 investigational indications.
CHEMBL4297214,OC(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)(C(F)(F)F)C(F)(F)F,CYSJNTQNMDWAJV-UHFFFAOYSA-N,Small molecule,False,PRALICIGUAT,,2.0,,False,False,[],['IW-1973' 'Praliciguat'],,,"{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297778,,,Antibody drug conjugate,False,LONCASTUXIMAB TESIRINE,2021.0,4.0,,False,True,['Zynlonta'],"['ADCT-402' 'ADCT-402 TESIRINE' 'Adct-402 tesirine'
 'Loncastuximab tesirine']",,,"{'rows': array(['EFO_1001938', 'EFO_0000309', 'EFO_1001469', 'EFO_0009441',
       'EFO_0000096', 'EFO_0000616', 'EFO_0000220', 'MONDO_0018906',
       'EFO_0005952', 'EFO_0000403'], dtype=object), 'count': 10}",[ENSG00000177455],Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 7 investigational indications.
CHEMBL4303241,COc1cc(S(C)(=O)=O)ccc1Nc1nc2ccc(-c3ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc3)cn2n1,NRJKIOCCERLIDG-GOSISDBHSA-N,Small molecule,False,BAY-1161909,,2.0,,False,False,[],"['(-)-BAY-1161909' 'BAY 1161909' 'BAY1161909' 'Bay-1161909' 'Empesertib'
 'MPS1-IN-5']",,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000112742],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL445,CNCCC=C1c2ccccc2CCc2ccccc21,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,Small molecule,True,NORTRIPTYLINE,1964.0,4.0,,False,True,['Allegron' 'Aventyl' 'Motipress' 'Motival'],"['Desitriptilina' 'Lumbeck' 'NCI-169453' 'NSC-757234' 'Noramitriptyline'
 'Nortrilen' 'Nortriptyline' 'Pamelor' 'Sesaval']","[('PubChem', array(['11110653', '11110654', '124878449', '152146160', '26747092',
       '26747093', '4253930', '50100156', '50104257', '50104258',
       '90340759'], dtype=object)), ('Wikipedia', array(['Nortriptyline'], dtype=object)), ('drugbank', array(['DB00540'], dtype=object)), ('chEBI', array(['7640'], dtype=object))]",['CHEMBL1201156'],"{'rows': array(['MONDO_0002009', 'EFO_0005230', 'EFO_1000948', 'EFO_0003948',
       'EFO_0000676', 'MONDO_0005090', 'MONDO_0002009', 'EFO_0008533',
       'EFO_0005279', 'EFO_0008524', 'HP_0000726', 'EFO_0000676',
       'EFO_0000555', 'MONDO_0002009', 'MONDO_0002050', 'EFO_0003768',
       'EFO_0000274'], dtype=object), 'count': 17}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and depressive disorder and has 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4650373,,,Unknown,False,APELIN,,2.0,,False,False,[],['Apelin'],,,"{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}",[ENSG00000134817],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL501259,CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)(O)O)[C@@H]1OCC[C@@H](CCCCCCC)OC,BPSMYQFMCXXNPC-MFCPCZTFSA-N,Small molecule,False,ERITORAN,,3.0,,False,False,[],['E5564' 'Eritoran'],"[('Wikipedia', array(['Eritoran'], dtype=object)), ('drugbank', array(['DB04933'], dtype=object)), ('chEBI', array(['68609'], dtype=object))]",['CHEMBL3301672'],"{'rows': array(['HP_0100806', 'EFO_0007328', 'EFO_0000565', 'EFO_0002614',
       'MONDO_0100096', 'EFO_0003106'], dtype=object), 'count': 6}","[ENSG00000136869,ENSG00000154589]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL5095035,CNC(=O)c1cc(F)c(-c2nc3cc(C)ccn3c2C[C@H]2CN(C(=O)OC)CCO2)c(F)c1,SEHLMRJSQFAPCJ-HNNXBMFYSA-N,Small molecule,False,CAMLIPIXANT,,3.0,,False,False,[],['BLU-5937' 'Blu-5937' 'Camlipixant'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['HP_0012735'], dtype=object), 'count': 1}",[ENSG00000109991],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL898,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,HUPFGZXOMWLGNK-UHFFFAOYSA-N,Small molecule,True,DIFLUNISAL,1982.0,4.0,,False,True,['Diflunisal' 'Dolobid' 'Dolobid 500'],['Diflunisal' 'NSC-756728'],"[('DailyMed', array(['diflunisal'], dtype=object)), ('PubChem', array(['11112675', '124882514', '144204149', '170464956', '26746997',
       '855794'], dtype=object)), ('Wikipedia', array(['Diflunisal'], dtype=object)), ('drugbank', array(['DB00861'], dtype=object)), ('chEBI', array(['39669'], dtype=object))]",['CHEMBL4745456'],"{'rows': array(['MONDO_0005148', 'EFO_0003843', 'HP_0001945', 'MONDO_0005178',
       'EFO_0000685', 'EFO_0004129'], dtype=object), 'count': 6}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL946,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1,SEBMTIQKRHYNIT-UHFFFAOYSA-N,Small molecule,False,AZATADINE,1977.0,4.0,,False,True,[],['Azatadine' 'Optimine' 'Trinalin'],"[('PubChem', array(['144206535', '170464865'], dtype=object)), ('Wikipedia', array(['Azatadine'], dtype=object)), ('drugbank', array(['DB00719'], dtype=object)), ('chEBI', array(['2946'], dtype=object))]",['CHEMBL3544908'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977 and is indicated for allergic disease.
CHEMBL1200813,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1.Cl,KTUFKADDDORSSI-UHFFFAOYSA-N,Small molecule,False,ACEBUTOLOL HYDROCHLORIDE,1984.0,4.0,CHEMBL642,False,True,"['Acebut hcl' 'Acebutolol hydrochloride' 'Sectral' 'Sectral 200'
 'Sectral 400']","['Acebutolol hcl' 'Acebutolol hydrochloride' 'Acetanol' 'B 17803A'
 'B-17803A' 'IL-17803A' 'M&B 17803A' 'M&B-17803A' 'NSC-757412' 'Neptal'
 'Prent']","[('DailyMed', array(['acebutolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204184', '170465309', '56424136', '855517'], dtype=object)), ('chEBI', array(['2380'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'HP_0004308'], dtype=object), 'count': 2}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for hypertension and ventricular arrhythmia.
CHEMBL1200822,CC(=O)O.O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,RKXNZRPQSOPPRN-UHFFFAOYSA-N,Small molecule,True,FLECAINIDE ACETATE,1985.0,4.0,CHEMBL652,False,True,['Flecainide acetate' 'Tambocor'],['Flecainide acetate' 'Flecainide monoacetate'],"[('DailyMed', array(['flecainide%20acetate'], dtype=object)), ('PubChem', array(['144207406', '50106340', '56422486', '855927'], dtype=object)), ('chEBI', array(['5091'], dtype=object))]",,"{'rows': array(['HP_0004308', 'EFO_0003843', 'EFO_0000275'], dtype=object), 'count': 3}",[ENSG00000183873],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for ventricular arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200948,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21.O=C(O)/C=C\C(=O)O,YDGHCKHAXOUQOS-BTJKTKAUSA-N,Small molecule,True,TRIMIPRAMINE MALEATE,1979.0,4.0,CHEMBL644,False,True,['Surmontil' 'Trimipramine maleate'],['NSC-758386' 'Stangyl' 'Trimipramine maleate'],"[('DailyMed', array(['trimipramine%20maleate'], dtype=object)), ('PubChem', array(['144204000', '170465260', '26732627', '26747677', '26747678',
       '50107079', '50107080', '50107081'], dtype=object)), ('chEBI', array(['35030'], dtype=object))]",,,"[ENSG00000103546,ENSG00000196639,ENSG00000149295,ENSG00000102468,ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979. This drug has a black box warning from the FDA.
CHEMBL1200973,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,UOACKFBJUYNSLK-XRKIENNPSA-N,Small molecule,True,ESTRADIOL CYPIONATE,1979.0,4.0,,False,True,['Depo-estradiol' 'Estradiol cypionate'],"['Estradiol 17.beta.-cyclopentanepropanoate' 'Estradiol cipionate'
 'Estradiol cypionate' 'NSC-3354']","[('DailyMed', array(['estradiol%20cypionate'], dtype=object)), ('PubChem', array(['144203554', '144205884', '144212135', '170464789', '46500620',
       '69855'], dtype=object)), ('drugbank', array(['DB13954'], dtype=object)), ('chEBI', array(['34745'], dtype=object))]",,,[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979. This drug has a black box warning from the FDA.
CHEMBL1201089,CN(C)CCOC(c1ccccc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,SPCKHVPPRJWQRZ-UHFFFAOYSA-N,Small molecule,False,DIPHENHYDRAMINE CITRATE,2005.0,4.0,CHEMBL657,False,True,[],"['Diphenhydramine' 'Diphenhydramine citrate'
 'Diphenhydramine laurylsulfate' 'Diphenhydramine tannate']","[('DailyMed', array(['diphenhydramine%20citrate'], dtype=object))]",,"{'rows': array(['MONDO_0005277', 'EFO_0003938'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 2 investigational indications.
CHEMBL1201321,N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1,UFIVBRCCIRTJTN-UHFFFAOYSA-N,Small molecule,False,DIFENOXIN,1978.0,4.0,,False,True,[],"['Acscn-9168' 'Difenoxin' 'Diphenoxylate related compound a'
 'Diphenoxylic acid' 'IDS-ND-007' 'Lyspafen' 'MCN-JR-15,403-11'
 'Mcn-jr 15403-11' 'R 15,403 [AS HYDROCHLORIDE]' 'R-15403']","[('Wikipedia', array(['Difenoxin'], dtype=object)), ('drugbank', array(['DB01501'], dtype=object)), ('chEBI', array(['4534'], dtype=object))]",['CHEMBL1200599'],,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978.
CHEMBL134,Clc1cccc(Cl)c1NC1=NCCN1,GJSURZIOUXUGAL-UHFFFAOYSA-N,Small molecule,True,CLONIDINE,1974.0,4.0,,False,True,"['Catapres' 'Catapres-tts-1' 'Catapres-tts-2' 'Catapres-tts-3' 'Clonidine'
 'Nexiclon xr']","['Catapres' 'Catarpres-tts' 'Clonidine' 'Clonidine extended release'
 'Clorpres' 'Combipres' 'Duraclon' 'ST-155-BS' 'ST-155BS']","[('DailyMed', array(['clonidine'], dtype=object)), ('PubChem', array(['104171138', '11110984', '11110985', '11113648', '144203669',
       '170464900', '26751841', '90341662'], dtype=object)), ('Wikipedia', array(['Clonidine'], dtype=object)), ('drugbank', array(['DB00575'], dtype=object)), ('chEBI', array(['3757'], dtype=object))]",['CHEMBL1705'],"{'rows': array(['EFO_0005762', 'MONDO_0005041', 'EFO_0002950', 'MONDO_0005299',
       'MONDO_0002959', 'EFO_0005230', 'MONDO_0005277', 'EFO_0007355',
       'EFO_0000274', 'HP_0002307', 'EFO_0002610', 'EFO_0001358',
       'MONDO_0043510', 'EFO_0005252', 'EFO_0003888', 'EFO_0003756',
       'EFO_0004240', 'EFO_0009676', 'MONDO_0004992', 'EFO_0005611',
       'EFO_0003843', 'EFO_0004273', 'EFO_1000783', 'MP_0001914',
       'EFO_0007191', 'EFO_0000537', 'EFO_0009267', 'EFO_0000537',
       'EFO_0003890', 'EFO_1000971', 'EFO_0003888', 'EFO_0005323',
       'EFO_1000645', 'EFO_0005799', 'HP_0003419', 'MONDO_0007254',
       'EFO_0009523', 'EFO_0003843', 'EFO_1001904', 'EFO_0000319'],
      dtype=object), 'count': 40}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1944698,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1,VXBAJLGYBMTJCY-NSCUHMNNSA-N,Small molecule,False,ZOTIRACICLIB,,2.0,,False,False,[],"['EX45' 'Ex 45' 'SB-1317' 'SB1317' 'Sb-1317 free base' 'TG02' 'Tg-02'
 'Tg02' 'Zotiraciclib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZOTIRACICLIB/relevant/1/'],
      dtype=object))]",['CHEMBL4298173'],"{'rows': array(['EFO_0000182', 'MONDO_0002334', 'EFO_0000616', 'EFO_0000095',
       'EFO_0000616', 'EFO_1001465', 'MONDO_0002334', 'EFO_0000519',
       'EFO_1000657'], dtype=object), 'count': 9}","[ENSG00000136807,ENSG00000170312,ENSG00000122025,ENSG00000096968,ENSG00000123374,ENSG00000134058]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL2107572,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1.Cl,YJXUXANREVNZLH-PFEQFJNWSA-N,Small molecule,False,TECALCET HYDROCHLORIDE,,2.0,CHEMBL292376,False,False,['Norcalin'],"['KRN-568' 'NPS R-568' 'NPS-R-568' 'NPSR-568' 'R-568' 'Tecalcet hcl'
 'Tecalcet hydrochloride']",,,,[ENSG00000036828],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2107829,Cl.NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1,BPZWRYOUJMDQSY-PKLMIRHRSA-N,Small molecule,False,EMIXUSTAT HYDROCHLORIDE,,2.0,CHEMBL2107821,False,False,['Acu-4429 hcl'],['ACU-4429 HCL' 'ACU-4429 HYDROCHLORIDE' 'Emixustat hydrochloride'],,,,[ENSG00000116745],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2109377,,,Antibody,False,PAMREVLUMAB,,3.0,,False,False,[],['FG-3019' 'Pamrevlumab'],,,"{'rows': array(['EFO_0004239', 'EFO_0000400', 'EFO_0002618', 'EFO_0004236',
       'EFO_0000768', 'MONDO_0010679', 'MONDO_0100096'], dtype=object), 'count': 7}",[ENSG00000118523],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2109623,,,Antibody,False,STX-100,,2.0,,False,False,[],['STX-100' 'Stx-100'],,,"{'rows': array(['EFO_0000768'], dtype=object), 'count': 1}","[ENSG00000138448,ENSG00000115221]",Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3544949,CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)C(N)=O,VUYRSKROGTWHDC-HZGLMRDYSA-N,Protein,False,CTCE-9908,,2.0,,False,False,[],['CTCE 9908' 'Ctce-9908'],,,,[ENSG00000121966],Protein drug with a maximum clinical trial phase of II.
CHEMBL3545394,,,Small molecule,False,DRF-10945,,2.0,,False,False,[],['Drf-10945'],,,,[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3668014,COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F,BMAAMIIYNNPHAB-UHFFFAOYSA-N,Small molecule,False,LINZAGOLIX,2022.0,4.0,,False,True,[],['KLH-2109' 'Klh-2109' 'Linzagolix' 'OBE-2109' 'OBE2109'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINZAGOLIX/relevant/1/'],
      dtype=object))]",['CHEMBL4298171'],"{'rows': array(['HP_0000131', 'HP_0000131', 'EFO_0001421', 'EFO_0000731',
       'EFO_0003086', 'EFO_0001065', 'EFO_0001065'], dtype=object), 'count': 7}",[ENSG00000109163],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for uterine leiomyoma and has 6 investigational indications.
CHEMBL3989986,,,Antibody,True,RAVULIZUMAB,2018.0,4.0,,False,True,['Ultomiris'],['ALXN-1210' 'ALXN1210' 'Ravulizumab' 'Ravulizumab cwvz'],"[('DailyMed', array(['ravulizumab-cwvz'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris'],
      dtype=object))]",,"{'rows': array(['EFO_0007541', 'EFO_0000398', 'MONDO_0016244', 'MONDO_0004976',
       'EFO_0004610', 'MONDO_0001549', 'EFO_0000540', 'EFO_1000637',
       'MONDO_0019737', 'MONDO_0100244', 'EFO_0004991', 'EFO_0004256'],
      dtype=object), 'count': 12}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL493,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,OZVBMTJYIDMWIL-AYFBDAFISA-N,Small molecule,False,BROMOCRIPTINE,1978.0,4.0,,False,True,['Parlodel'],"['2-bromo-.alpha.-ergocryptine' 'Bromergocryptine' 'Bromocriptine'
 'CB-154' 'Ergocryptine, 2-bromo-' 'SANDOZ 15-754']","[('PubChem', array(['144204458', '26751716', '26755307', '90340796'], dtype=object)), ('Wikipedia', array(['Bromocriptine'], dtype=object)), ('drugbank', array(['DB01200'], dtype=object)), ('chEBI', array(['3181'], dtype=object))]",['CHEMBL1255752' 'CHEMBL1200503'],"{'rows': array(['EFO_0000232', 'MONDO_0005351', 'MONDO_0002146', 'EFO_0000545',
       'EFO_1001757', 'MONDO_0005180', 'MONDO_0005180', 'HP_0001249',
       'MONDO_0005148', 'MONDO_0004975', 'MONDO_0011972', 'MONDO_0005147',
       'EFO_0001073', 'EFO_1001485', 'EFO_0007319'], dtype=object), 'count': 15}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 7 investigational indications.
CHEMBL549344,CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O,YZOQZEXYFLXNKA-UHFFFAOYSA-N,Small molecule,False,CPG-52852,,2.0,,False,False,[],['Cpg-52852' 'PF-4878691'],"[('drugbank', array(['DB12476'], dtype=object))]",,"{'rows': array(['EFO_0000389', 'EFO_0000616', 'EFO_0000756'], dtype=object), 'count': 3}",[ENSG00000196664],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL608,CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,FYPMFJGVHOHGLL-UHFFFAOYSA-N,Small molecule,False,PROBUCOL,1977.0,4.0,,True,True,['Bisbid' 'Lorelco' 'Lurselle' 'Probucol' 'Sinlestal'],['DH-581' 'NSC-652160' 'NSC-86225' 'Probucol'],"[('PubChem', array(['11112687', '123183', '124882521', '144204156', '170464772',
       '26748484', '50107410', '8139943'], dtype=object)), ('Wikipedia', array(['Probucol'], dtype=object)), ('drugbank', array(['DB01599'], dtype=object)), ('chEBI', array(['8427'], dtype=object))]",,"{'rows': array(['EFO_0000401', 'MONDO_0021187', 'EFO_0004265', 'EFO_0000319'],
      dtype=object), 'count': 4}",[ENSG00000165029],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for cardiovascular disease and has 3 investigational indications. It was withdrawn in at least one region.
CHEMBL75133,CC(/C=C/[C@@H]1C[C@]1(C)c1ccc2c(c1)C(C)(C)CCC2(C)C)=C\C(=O)O,BOOOLEGQBVUTKC-NVQSDHBMSA-N,Small molecule,False,IRX-4204,,2.0,,False,False,[],"['AGN-194204' 'AGN194204' 'Irx-4204' 'KB-145960' 'NRX-194204' 'NRX194204'
 'VTP-194204']","[('drugbank', array(['DB11806'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0005180'],
      dtype=object), 'count': 4}","[ENSG00000204231,ENSG00000143171,ENSG00000186350]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL91829,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1,ZCBUQCWBWNUWSU-SFHVURJKSA-N,Small molecule,False,RUBOXISTAURIN,,3.0,,False,False,['Arxxant'],['LY-333531' 'Ly-333531' 'Ruboxistaurin'],"[('PubChem', array(['50100106'], dtype=object)), ('Wikipedia', array(['Ruboxistaurin'], dtype=object)), ('drugbank', array(['DB11829'], dtype=object))]",['CHEMBL5307356' 'CHEMBL432130'],"{'rows': array(['EFO_0003770', 'MONDO_0005147', 'EFO_1000783', 'EFO_0003144',
       'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 6}",[ENSG00000166501],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL1201562,,,Protein,False,INTERFERON BETA-1A,1996.0,4.0,,False,True,['Avonex' 'Rebif'],['Interferon beta-1a' 'SNG-001' 'SNG001' 'Sng001'],"[('DailyMed', array(['interferon%20beta-1a'], dtype=object)), ('DrugCentral', array(['5139'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/avonex'],
      dtype=object)), ('Wikipedia', array(['Interferon_beta-1a'], dtype=object))]",,"{'rows': array(['EFO_0000384', 'MONDO_0100130', 'EFO_1001373', 'EFO_0003929',
       'EFO_0000616', 'EFO_0000729', 'EFO_0000712', 'EFO_0003047',
       'EFO_0003106', 'MONDO_0004979', 'MONDO_0004975', 'EFO_1000868',
       'EFO_0007328', 'MONDO_0005301', 'MONDO_0100096', 'EFO_0000341'],
      dtype=object), 'count': 16}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for neoplasm and multiple sclerosis and has 14 investigational indications.
CHEMBL1201774,C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)[nH]c(=O)c2N1,FNKQXYHWGSIFBK-RPDRRWSUSA-N,Small molecule,False,SAPROPTERIN,2007.0,4.0,,False,True,[],"['6r-bh4' 'Dapropterin' 'Daproterin' 'R-thbp' 'Sapropterin'
 'Tetrahydrobiopterin']","[('Wikipedia', array(['Tetrahydrobiopterin'], dtype=object)), ('drugbank', array(['DB00360'], dtype=object)), ('chEBI', array(['59560'], dtype=object))]",['CHEMBL1201775' 'CHEMBL1515624'],"{'rows': array(['MONDO_0010298', 'MONDO_0005090', 'MONDO_0043771', 'EFO_0000537',
       'Orphanet_238583', 'EFO_0000181', 'EFO_0003884', 'EFO_0003144',
       'EFO_0001645', 'EFO_0003876', 'EFO_0003884', 'EFO_0000341',
       'EFO_0001361', 'EFO_0003758', 'MONDO_0004975', 'EFO_0005411',
       'MONDO_0043579', 'MONDO_0011382', 'MONDO_0009861', 'EFO_0000666',
       'MONDO_0009861', 'EFO_0001422', 'EFO_0000537'], dtype=object), 'count': 23}",[ENSG00000171759],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hyperphenylalaninemia and phenylketonuria and has 20 investigational indications.
CHEMBL1624,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,XUIIKFGFIJCVMT-LBPRGKRZSA-N,Small molecule,True,LEVOTHYROXINE,2000.0,4.0,,False,True,[],"['L-thyroxine' 'Levothyroxin' 'Levothyroxine' 'NSC-36397'
 'Synthetic levothyroxine' 'Thyroxine, l-']","[('PubChem', array(['144205654', '144212473', '170465450', '26757755', '8139892'],
      dtype=object)), ('Wikipedia', array(['Levothyroxine'], dtype=object)), ('drugbank', array(['DB00451'], dtype=object)), ('chEBI', array(['18332'], dtype=object))]",['CHEMBL3989492' 'CHEMBL2103741' 'CHEMBL3989736'],"{'rows': array(['Orphanet_309005', 'EFO_0000400', 'MONDO_0018612', 'EFO_0004705',
       'EFO_0002892', 'EFO_0004705', 'EFO_0004237', 'MONDO_0018612',
       'EFO_0003843', 'EFO_1002017', 'MONDO_0004985', 'EFO_0002950',
       'MONDO_0002108'], dtype=object), 'count': 13}","[ENSG00000126351,ENSG00000151090]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2107846,,,Protein,False,DULANERMIN,,2.0,,False,False,[],['AMG-951' 'APO2L/TRAIL' 'B lymphocyte stimulator (human)' 'Dulanermin'],,,"{'rows': array(['EFO_1001951', 'EFO_0005952', 'EFO_0003060'], dtype=object), 'count': 3}","[ENSG00000104689,ENSG00000120889]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109036,,,Antibody,False,IGOVOMAB,1996.0,4.0,,False,True,['Inadmacis-125' 'Indimacis 125'],['Igovomab' 'OC-125'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125'],
      dtype=object))]",,"{'rows': array(['EFO_0003893', 'EFO_0006887'], dtype=object), 'count': 2}",[ENSG00000181143],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for ovarian neoplasm and radiologic finding.
CHEMBL2109281,,,Antibody drug conjugate,False,RG-7600,,1.0,,False,False,[],['DMOT4039A' 'RG-7600'],,,,"[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000102854]",Antibody drug conjugate drug with a maximum clinical trial phase of I.
CHEMBL2109381,,,Antibody,False,BHQ-880,,2.0,,False,False,[],['BHQ-880' 'BHQ880' 'Bhq-880'],,,"{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}",[ENSG00000107984],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109450,,,Antibody,False,AMG-811,,1.0,,False,False,[],['AMG-811' 'Amg-811'],,,"{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}",[ENSG00000111537],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL226267,COc1ccc(-c2sc3cc(O)ccc3c2Oc2ccc(OCCN3CCCCC3)cc2)cc1,MCGDSOGUHLTADD-UHFFFAOYSA-N,Small molecule,False,ARZOXIFENE,,3.0,,False,False,[],['Arzoxifene' 'LY-353381' 'LY353381'],"[('Wikipedia', array(['Arzoxifene'], dtype=object)), ('drugbank', array(['DB06249'], dtype=object))]",['CHEMBL2105949'],"{'rows': array(['MONDO_0008170', 'MONDO_0007254', 'MONDO_0011962', 'EFO_0003854',
       'EFO_0003869', 'Orphanet_145', 'MONDO_0002087', 'EFO_0003882',
       'MONDO_0007254'], dtype=object), 'count': 9}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL2364655,,,Antibody,False,EVOLOCUMAB,2015.0,4.0,,False,True,['Repatha' 'Repatha sureclick'],['AMG-145' 'Evolocumab'],"[('DailyMed', array(['evolocumab'], dtype=object)), ('DrugCentral', array(['5000'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/repatha'],
      dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_0000319', 'EFO_0003144', 'MONDO_0018328',
       'HP_0003124', 'EFO_0000519', 'EFO_0003060', 'EFO_0008585',
       'EFO_0001645', 'HP_0003119', 'MONDO_0008903', 'Orphanet_79211',
       'MONDO_0100096', 'Orphanet_309005', 'EFO_0005672', 'EFO_0000612',
       'MONDO_0021187', 'HP_0100806', 'EFO_0004911'], dtype=object), 'count': 19}",[ENSG00000169174],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 8 approved and 11 investigational indications.
CHEMBL2442750,Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,YOPFAMROKXHVCQ-UHFFFAOYSA-N,Small molecule,False,QAV680,,2.0,,False,False,[],"['NVP-QAV680' 'Nvp-qav-680' 'QAV680' 'QAV690 FREE ACID' 'Qav-680'
 'Qav-690 free acid' 'Qav680']","[('drugbank', array(['DB11658'], dtype=object))]",,"{'rows': array(['EFO_0003956', 'EFO_0005854', 'MONDO_0004979'], dtype=object), 'count': 3}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3408947,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)n[nH]c3c1)C(=O)N2,DADASRPKWOGKCU-FVTQAUBDSA-N,Small molecule,False,OCIFISERTIB,,2.0,,False,False,[],['Ocifisertib'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",['CHEMBL4297462'],"{'rows': array(['EFO_0000616', 'MONDO_0008315', 'MONDO_0004992', 'MONDO_0007254'],
      dtype=object), 'count': 4}",[ENSG00000142731],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3545063,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.CS(=O)(=O)O,FUKSNUHSJBTCFJ-UHFFFAOYSA-N,Small molecule,False,OSIMERTINIB MESYLATE,2015.0,4.0,CHEMBL3353410,False,True,['Tagrisso'],"['AZD-9291 MESYLATE' 'AZD9291 mesylate' 'Mereletinib mesilate'
 'Mereletinib mesylate' 'Osimertinib mesilate' 'Osimertinib mesylate']","[('DailyMed', array(['osimertinib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0008903'], dtype=object), 'count': 2}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.
CHEMBL3545166,CS(=O)(=O)N(c1cc(F)cc(F)c1)C1CN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)C1,IQQBRKLVEALROM-UHFFFAOYSA-N,Small molecule,False,DRINABANT,,3.0,,False,False,[],['Ave1625' 'Drinabant'],,,"{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3833346,,,Oligonucleotide,False,TOFERSEN,2023.0,4.0,,False,True,['Qalsody'],['BIIB-067' 'BIIB067' 'ISIS-SOD1Rx' 'Tofersen'],,,"{'rows': array(['MONDO_0004976'], dtype=object), 'count': 1}",[ENSG00000142168],Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for amyotrophic lateral sclerosis.
CHEMBL3942498,C#CCNc1nc(-n2cncn2)nc(N)c1Br,OQCWNHHZPYJHQR-UHFFFAOYSA-N,Small molecule,False,PBF-999,,1.0,,False,False,[],['PBF999' 'Pbf 999' 'Pbf-999'],,,"{'rows': array(['MONDO_0007739', 'MONDO_0004992'], dtype=object), 'count': 2}","[ENSG00000128271,ENSG00000112541]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3989509,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C.CC(O)C(=O)O,QNLDTXPVZPRSAM-UHFFFAOYSA-N,Small molecule,True,PENTAZOCINE LACTATE,1967.0,4.0,CHEMBL100116,False,True,['Talwin'],['Pentazocine lactate' 'Talwin (lactate)'],,,,[ENSG00000147955],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967. This drug has a black box warning from the FDA.
CHEMBL3989724,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl,ZIIJJOPLRSCQNX-UHFFFAOYSA-N,Small molecule,True,FLURAZEPAM HYDROCHLORIDE,1970.0,4.0,CHEMBL968,False,True,['Dalmane' 'Flurazepam hydrochloride'],"['Flurazepam' 'Flurazepam dihydrochloride' 'Flurazepam hydrochloride'
 'Flurazepam hydrochloride civ' 'NSC-78559' 'RO 5-6901' 'RO-5-6901']","[('DailyMed', array(['flurazepam%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970 and is indicated for insomnia. This drug has a black box warning from the FDA.
CHEMBL3989845,CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,BPQZYOJIXDMZSX-UHFFFAOYSA-N,Small molecule,True,IMIPRAMINE PAMOATE,1973.0,4.0,CHEMBL11,False,True,['Imipramine pamoate' 'Tofranil-pm'],['Imipramine embonate'],"[('DailyMed', array(['imipramine%20pamoate'], dtype=object))]",,,"[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973. This drug has a black box warning from the FDA.
CHEMBL419213,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,CZRQXSDBMCMPNJ-ZUIPZQNBSA-N,Small molecule,True,LISINOPRIL,1987.0,4.0,CHEMBL1237,False,True,['Acemin' 'Carace' 'Lisinopril' 'Lisopress' 'Prinivil' 'Qbrelis' 'Zestril'],"['Lisinopril' 'Lisinopril dihydrate' 'Lisinopril hydrate' 'MK-521'
 'NSC-751176' 'NSC-758151' 'Ranolip']","[('DailyMed', array(['lisinopril'], dtype=object)), ('PubChem', array(['11113057', '170464907'], dtype=object)), ('chEBI', array(['6503'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000373', 'EFO_0000612', 'EFO_0000712',
       'EFO_0000400', 'EFO_0003144', 'EFO_0000319'], dtype=object), 'count': 7}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 7 approved indications. This drug has a black box warning from the FDA.
CHEMBL4297768,,,Oligosaccharide,False,IDRABIOTAPARINUX SODIUM,,3.0,,False,False,[],['Idrabiotaparinux sodium'],,,"{'rows': array(['EFO_0003907', 'MONDO_0000831', 'EFO_0000275'], dtype=object), 'count': 3}",[ENSG00000126218],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4302409,,,Protein,False,LUTETIUM OXODOTREOTIDE,2018.0,4.0,,False,True,[],[],,['CHEMBL4297545'],"{'rows': array(['EFO_1000045', 'MONDO_0002120', 'EFO_0000305', 'MONDO_0020634',
       'EFO_0000621', 'MONDO_0016642', 'MONDO_0024503', 'EFO_1001901',
       'EFO_1001471', 'EFO_0007416'], dtype=object), 'count': 10}","[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for pancreatic neuroendocrine tumor and neuroendocrine neoplasm and has 8 investigational indications.
CHEMBL448343,NC[C@@H](F)C[PH](=O)O,LJNUIEQATDYXJH-GSVOUGTGSA-N,Small molecule,False,LESOGABERAN,,2.0,,False,False,[],['AZD-3355' 'AZD3355' 'Azd3355' 'Lesogaberan'],"[('Wikipedia', array(['Lesogaberan'], dtype=object)), ('drugbank', array(['DB11920'], dtype=object))]",,"{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}","[ENSG00000136928,ENSG00000204681]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650332,O=C([C@H](CO)c1ccccc1)N1CC2=C(C1)CN(S(=O)(=O)c1cnc3c(c1)OCCO3)C2,KZFFYEPYCVDOGE-LJQANCHMSA-N,Small molecule,False,ETAVOPIVAT,,2.0,,False,False,[],['Etavopivat' 'FT-4202' 'Ft-4202'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETAVOPIVAT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000198', 'MONDO_0011382'], dtype=object), 'count': 2}",[ENSG00000143627],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL495727,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1,LOLPPWBBNUVNQZ-UHFFFAOYSA-N,Small molecule,False,AT-9283,,2.0,,False,False,[],['AT-9283' 'AT9283' 'At 9283' 'At-9283'],,['CHEMBL496311'],"{'rows': array(['EFO_0001378', 'EFO_0000616', 'EFO_0005952', 'EFO_0000565'],
      dtype=object), 'count': 4}","[ENSG00000096968,ENSG00000087586,ENSG00000105639,ENSG00000097007,ENSG00000178999,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL5314357,,,Antibody,False,ETARACIZUMAB,,2.0,,False,False,['Abegrin' 'Abegrin vitaxin'],['ETARATUZUMAB' 'Etaracizumab' 'HLM60' 'MEDI-522' 'Vitaxin'],,,"{'rows': array(['EFO_0000676', 'MONDO_0008315', 'EFO_1001951', 'EFO_0002617',
       'EFO_0000685', 'EFO_0000756', 'MONDO_0004992', 'EFO_0000681'],
      dtype=object), 'count': 8}","[ENSG00000259207,ENSG00000138448]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL611,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,VCKUSRYTPJJLNI-UHFFFAOYSA-N,Small molecule,False,TERAZOSIN,1987.0,4.0,,False,True,[],['Hytrin' 'Terazosabb' 'Terazosin'],"[('PubChem', array(['174007477', '50085853', '855611', '90340975'], dtype=object)), ('Wikipedia', array(['Terazosin'], dtype=object)), ('drugbank', array(['DB01162'], dtype=object)), ('chEBI', array(['9445'], dtype=object))]",['CHEMBL1201091' 'CHEMBL3989562' 'CHEMBL1256665'],"{'rows': array(['EFO_0003914', 'EFO_0000284', 'MONDO_0005180', 'HP_0000726',
       'MONDO_0005148', 'EFO_0000284', 'EFO_0000537', 'EFO_0001645',
       'EFO_0002615', 'HP_0003124'], dtype=object), 'count': 10}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for benign prostatic hyperplasia and has 8 investigational indications.
CHEMBL1090488,C[C@@H]1CN(C(=O)[C@@H]2CN(C(C)(C)C)C[C@H]2c2ccc(F)cc2F)C[C@H](C)[C@@]1(O)c1ccccc1,WHPJOAUPIZDJNX-AGGGUQDCSA-N,Small molecule,False,PF-00446687,,2.0,,False,False,[],['(-)-PF-00446687' 'Pf-00446687'],"[('drugbank', array(['DB12517'], dtype=object))]",['CHEMBL1204059'],"{'rows': array(['EFO_0004234', 'EFO_0004714'], dtype=object), 'count': 2}",[ENSG00000166603],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1200671,CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,FUCZIEGYURIPAY-CFWZQLQRSA-N,Protein,False,NAFARELIN ACETATE,1990.0,4.0,CHEMBL1201309,False,True,['Synarel'],"['Nafarelin acetate' 'Nafarelin acetate anhydrous'
 'Nafarelin acetate hydrate' 'Nasanyl' 'RS-94991' 'RS-94991-298']","[('DailyMed', array(['nafarelin%20acetate'], dtype=object))]",,"{'rows': array(['EFO_0001065'], dtype=object), 'count': 1}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for endometriosis.
CHEMBL1201265,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12,IMBXEJJVJRTNOW-XYMSELFBSA-N,Small molecule,False,METHYLPREDNISOLONE HEMISUCCINATE,1959.0,4.0,,False,True,[],['Methylprednisolone hemisuccinate' 'Methylprednisolone succinate'],"[('PubChem', array(['124896649'], dtype=object)), ('drugbank', array(['DB14644'], dtype=object))]",['CHEMBL1201081'],"{'rows': array(['EFO_0003929', 'EFO_0000694', 'EFO_0000768', 'EFO_0008522',
       'MONDO_0007915', 'MONDO_0002280', 'EFO_0000095', 'EFO_0000685',
       'EFO_1001222', 'EFO_0000540', 'MONDO_0002135', 'MONDO_0002406',
       'MONDO_0005301', 'MONDO_0100096', 'MONDO_0013730', 'MONDO_0005301',
       'EFO_0000220', 'EFO_0003106', 'EFO_0003843', 'MONDO_0002462',
       'EFO_0003840', 'EFO_0000198', 'EFO_0004194', 'EFO_1001272',
       'EFO_0000574', 'MONDO_0004979', 'EFO_0004599', 'EFO_0000565',
       'EFO_0005952', 'EFO_0007359', 'EFO_0007332', 'EFO_0007537',
       'EFO_0004228', 'EFO_0001378', 'EFO_0000222', 'EFO_0000474',
       'EFO_0001063'], dtype=object), 'count': 37}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 8 approved and 29 investigational indications.
CHEMBL1201419,,,Protein,False,LUTROPIN ALFA,2000.0,4.0,,False,True,['Luveris'],"['ATC G03 GA GONADOTROPINS' 'Luteinising hormone'
 'Luteinising hormone (human)' 'Lutropin alfa']","[('DrugCentral', array(['4929'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/luveris'],
      dtype=object))]",,"{'rows': array(['EFO_0000545', 'EFO_0008560', 'GO_0060279', 'MONDO_0002146'],
      dtype=object), 'count': 4}",[ENSG00000138039],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for female infertility and positive regulation of ovulation and has 2 investigational indications.
CHEMBL1201717,,,Protein,False,MECASERMIN RINFABATE,2005.0,4.0,,False,True,['Iplex'],"['Mecasermin Rinfabate Recombinant' 'Mecasermin rinfabate'
 'Mecasermin rinfabate recombinant' 'RHIGF-I/RHIGFBP-3']","[('DrugCentral', array(['5197'], dtype=object))]",,"{'rows': array(['Orphanet_273', 'MONDO_0016107', 'MONDO_0009877', 'EFO_1001158'],
      dtype=object), 'count': 4}",[ENSG00000140443],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 investigational indications.
CHEMBL1230065,CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C,GDTQLZHHDRRBEB-UHFFFAOYSA-N,Small molecule,False,BMS-582949,,2.0,,False,False,[],['BMS-582949' 'Bms 582949' 'Bms-582949' 'PS-540446' 'Ps-540446'],"[('drugbank', array(['DB12696'], dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_0004264', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1237102,C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl,OICFWWJHIMKBCD-VALQNVSPSA-N,Small molecule,False,LEVOCABASTINE HYDROCHLORIDE,1993.0,4.0,CHEMBL1615438,False,True,['Livostin'],"['Levocabastine hcl' 'Levocabastine hydrochloride' 'R 50,547' 'R-50547']","[('PubChem', array(['144204246', '170465061', '56463149'], dtype=object))]",,"{'rows': array(['EFO_1001417'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993 and has 1 investigational indication.
CHEMBL1364144,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,PLBHSZGDDKCEHR-LFYFAGGJSA-N,Small molecule,False,METHYLPREDNISOLONE ACETATE,1959.0,4.0,,False,True,"['Depmedalone' 'Depo-medrol' 'Depo-medrone' 'M-predrol' 'Medrol acetate'
 'Methylprednisolone acetate' 'Neo-medrone']","['Methyl prednisolone acetate' 'Methylprednisolone 21-acetate'
 'Methylprednisolone acetate' 'NSC-48985']","[('DailyMed', array(['methylprednisolone%20acetate'], dtype=object)), ('PubChem', array(['144205275', '50085428'], dtype=object)), ('chEBI', array(['6889'], dtype=object))]",,"{'rows': array(['EFO_1000941', 'EFO_1001222', 'EFO_0000565', 'EFO_1001896',
       'EFO_0003833', 'EFO_0004255', 'EFO_0003843', 'HP_0003419',
       'EFO_0005762', 'EFO_0004274', 'MONDO_0004979', 'EFO_1001178',
       'MONDO_0002041', 'MONDO_0002406', 'MONDO_0002280', 'EFO_0007405',
       'EFO_0000685', 'MONDO_0005178', 'EFO_1001231', 'HP_0012532',
       'EFO_0000574'], dtype=object), 'count': 21}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 13 approved and 8 investigational indications.
CHEMBL1764,COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2,VRQVVMDWGGWHTJ-CQSZACIVSA-N,Small molecule,False,LEVOMEPROMAZINE,1982.0,4.0,,False,True,['Levomepromazine' 'Levoprome' 'Nirvan' 'Tisercin'],"['CL 36467' 'CL 39743' 'CL-36467' 'CL-39743' 'Levomepromazine'
 'Methotrimeprazine' 'N05AA02' 'NSC-226516' 'Neozine' 'Nirvan' 'RP 7044'
 'RP-7044' 'SK&F 5116' 'SK&F-5116' 'XP-03' 'XP03']","[('Wikipedia', array(['Levomepromazine'], dtype=object)), ('drugbank', array(['DB01403'], dtype=object)), ('chEBI', array(['6838'], dtype=object))]",['CHEMBL2104973' 'CHEMBL1725730'],"{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0005407', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for psychosis and has 4 investigational indications.
CHEMBL1922235,COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1,IJNIQYINMSGIPS-UHFFFAOYSA-N,Small molecule,False,DAREXABAN,,3.0,,False,False,[],['Darexaban' 'Tanexaban' 'YM-150' 'YM150'],"[('drugbank', array(['DB12289'], dtype=object))]",['CHEMBL1922345' 'CHEMBL3527359'],"{'rows': array(['EFO_0004286', 'EFO_0000275', 'HP_0001907', 'EFO_0005672'],
      dtype=object), 'count': 4}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2019090,CCc1c(C)cc(C(=O)NC2(C(=O)O)CCCCC2)c(=O)n1Cc1ccc(F)cc1,JIYXOJFSPOFZPY-UHFFFAOYSA-N,Small molecule,False,S-777469,,2.0,,False,False,[],['S-777469'],,,"{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}",[ENSG00000188822],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2104449,CC(=O)N(O)CC1=C(n2ccccc2=O)c2cc(C(F)(F)F)ccc2OC1(C)C,FXRJKZVWFJSKGI-UHFFFAOYSA-N,Small molecule,False,SARAKALIM,,2.0,,False,False,[],['RS-91309' 'Sarakalim'],,,,"[ENSG00000187486,ENSG00000069431,ENSG00000006071,ENSG00000121361]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108658,,,Antibody,False,TREMELIMUMAB,2022.0,4.0,,False,True,['Imjudo'],"['CP-675,206' 'CP-675206' 'PF-06753388' 'TICILIMUMAB' 'Tremelimumab'
 'Tremelimumab (genetical recombination)' 'Tremelimumab actl']",,,"{'rows': array(['EFO_0002617', 'EFO_0000514', 'EFO_0000501', 'MONDO_0008315',
       'EFO_0000691', 'EFO_0000181', 'EFO_0000349', 'MONDO_0004992',
       'EFO_0003863', 'MONDO_0008903', 'EFO_0000503', 'EFO_0001075',
       'MONDO_0001187', 'EFO_0000681', 'EFO_0001378', 'MONDO_0002158',
       'EFO_0000702', 'EFO_0000764', 'EFO_0005221', 'EFO_0001642',
       'EFO_0000305', 'EFO_0003060', 'MONDO_0007576', 'EFO_1001100',
       'EFO_0005537', 'EFO_0000403', 'MONDO_0008170', 'MONDO_0003060',
       'EFO_0000365', 'MONDO_0003001', 'EFO_0000182', 'EFO_0003891',
       'MONDO_0002108', 'EFO_0000198', 'EFO_0000756', 'EFO_0008528',
       'EFO_0004142', 'MONDO_0044704', 'EFO_0000199', 'EFO_0000673',
       'EFO_0000574', 'EFO_1000251', 'EFO_0000616', 'EFO_0000389',
       'MONDO_0021148', 'EFO_0000641', 'MONDO_0005184', 'MONDO_0007254',
       'EFO_0000708', 'EFO_1001961', 'EFO_0004284', 'EFO_0000519',
       'EFO_0002618', 'EFO_0000588', 'MONDO_0001056', 'EFO_1001951',
       'EFO_1001968', 'EFO_0005220', 'MONDO_0003002'], dtype=object), 'count': 59}",[ENSG00000163599],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 56 investigational indications.
CHEMBL2109171,,,Protein,False,DIBOTERMIN ALFA,2002.0,4.0,,False,True,['Inductos'],['Dibotermin' 'Dibotermin alfa' 'Inductos' 'Nebotermin' 'Rhbmp-2'],"[('DrugCentral', array(['5024'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inductos'],
      dtype=object))]",,"{'rows': array(['EFO_0004260', 'HP_0000689', 'EFO_0003931', 'EFO_0003957',
       'EFO_0003944', 'MONDO_0005178'], dtype=object), 'count': 6}","[ENSG00000107779,ENSG00000115170,ENSG00000121989,ENSG00000114739,ENSG00000138696,ENSG00000204217]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for bone disease and tibia fracture and has 4 investigational indications.
CHEMBL2109322,,,Antibody,False,AMG-820,,1.0,,False,False,[],['AMG-820' 'AMG820' 'Amg 820' 'Amg-820'],,,"{'rows': array(['EFO_0002618', 'EFO_1001951', 'EFO_0003060', 'MONDO_0004992'],
      dtype=object), 'count': 4}",[ENSG00000182578],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL2220486,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,CUDVHEFYRIWYQD-UHFFFAOYSA-N,Small molecule,False,LUCITANIB,,2.0,,False,False,[],['AL-3810' 'Al-3810' 'CO-3810' 'E-3810' 'Lucitanib' 'S 80881' 'S-80881'],"[('drugbank', array(['DB11845'], dtype=object)), ('chEBI', array(['65209'], dtype=object))]",['CHEMBL2180605'],"{'rows': array(['EFO_0000702', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254',
       'MONDO_0021148', 'EFO_0003060'], dtype=object), 'count': 6}","[ENSG00000077782,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL235191,CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1,VAZAPHZUAVEOMC-UHFFFAOYSA-N,Small molecule,False,TACEDINALINE,,3.0,,False,False,[],['CI-994' 'GOE 5549' 'GOE-5549' 'PD 123654' 'PD-123654' 'Tacedinaline'],"[('drugbank', array(['DB12291'], dtype=object)), ('chEBI', array(['90195'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'MONDO_0008903', 'EFO_0002618'], dtype=object), 'count': 3}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL294199,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,YKPUWZUDDOIDPM-SOFGYWHQSA-N,Small molecule,False,CAPSAICIN,2009.0,4.0,,False,True,['Qutenza' 'Zacin' 'Zostrix' 'Zostrix hp'],"['ALGRX 4975' 'ALGRX-4975' 'Ausanil' 'Axsain' 'Capsaicin' 'Capzasin-hp'
 'Cntx-4975' 'Dolenon' 'FEMA NO. 3404' 'Mioton' 'NGX-1998' 'NGX-4010'
 'NSC-56353' 'Ngx-1998' 'Ovocap' 'Ratden pe 40' 'Togarashi orenji'
 'Trans-capsaicin']","[('DailyMed', array(['capsaicin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza'],
      dtype=object)), ('PubChem', array(['104171351', '124883045', '124883047', '124883049', '124883050',
       '124890089', '144204368', '144207513', '17389996', '26747263',
       '26752818', '26752819', '26752820', '50105473', '56463572'],
      dtype=object)), ('Wikipedia', array(['Capsaicin'], dtype=object)), ('drugbank', array(['DB06774'], dtype=object)), ('chEBI', array(['3374'], dtype=object))]",,"{'rows': array(['HP_0000989', 'EFO_0001361', 'EFO_0000764', 'EFO_0003843',
       'EFO_0009364', 'MONDO_0043510', 'EFO_0006859', 'EFO_0009430',
       'EFO_0009387', 'EFO_0005762', 'HP_0002829', 'EFO_1000941',
       'MONDO_0041052', 'MONDO_0001583', 'EFO_1001434', 'HP_0003394',
       'HP_0002013', 'EFO_0003100', 'EFO_0006911', 'EFO_1001896',
       'EFO_1000783', 'EFO_0009619', 'EFO_0009625', 'EFO_0004616',
       'EFO_1001054', 'EFO_0003913', 'EFO_0000712', 'EFO_0006510',
       'MONDO_0005178', 'HP_0003418', 'MONDO_0005277', 'MONDO_0007254',
       'HP_0012735', 'EFO_0000319', 'EFO_0005856', 'EFO_0010582',
       'EFO_0009582', 'HP_0003326', 'MONDO_0004976'], dtype=object), 'count': 39}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 12 approved and 27 investigational indications.
CHEMBL3,CN1CCC[C@H]1c1cccnc1,SNICXCGAKADSCV-JTQLQIEISA-N,Small molecule,False,NICOTINE,1984.0,4.0,,False,True,"['Habitrol' 'Nicabate' 'Nicoderm cq' 'Nicopass' 'Nicopatch'
 'Nicorette invisi' 'Nicotine' 'Nicotinell classic' 'Nicotinell support'
 'Nicotinell tts 10' 'Nicotinell tts 20' 'Nicotinell tts 30' 'Nicotrol'
 'Nicotrol Inhaler' 'Nicotrol NS' 'Niquitin' 'Niquitin clr'
 'Niquitin minis cherry' 'Niquitin minis mint' 'Niquitin minis orange'
 'Niquitin mint' 'Niquitin pre-quit' 'Niquitin strips mint' 'Prostep'
 'Stoppers' 'Stubit']",['Nicotine'],"[('DailyMed', array(['nicotine'], dtype=object)), ('PubChem', array(['144209012', '144210494', '17389805', '26752744', '26752745',
       '26752746', '50105392', '50105393', '56314824', '90341453'],
      dtype=object)), ('Wikipedia', array(['Nicotine'], dtype=object)), ('drugbank', array(['DB00184'], dtype=object)), ('chEBI', array(['17688'], dtype=object))]","['CHEMBL3137669' 'CHEMBL1448280' 'CHEMBL3989563' 'CHEMBL151515'
 'CHEMBL3182465' 'CHEMBL225057' 'CHEMBL1201536']","{'rows': array(['HP_0100543', 'MONDO_0002050', 'MONDO_0005180', 'EFO_0003768',
       'EFO_0004329', 'EFO_0002610', 'MONDO_0004647', 'MONDO_0019338',
       'MONDO_0004938', 'EFO_0003888', 'EFO_0000691', 'EFO_0003144',
       'MONDO_0005090', 'EFO_0000341', 'MONDO_0008903', 'MONDO_0100096',
       'EFO_0000313', 'EFO_0001072', 'MONDO_0002050', 'EFO_0004319',
       'EFO_0000694', 'MONDO_0018076', 'DOID_13406', 'EFO_0004888',
       'EFO_0000546', 'EFO_0004318', 'EFO_0004318', 'MONDO_0002974',
       'EFO_0003768', 'EFO_0007191', 'EFO_0003768'], dtype=object), 'count': 31}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for nicotine dependence and has 30 investigational indications.
CHEMBL3133037,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C,POERAARDVFVDLO-QGZVFWFLSA-N,Small molecule,False,LEQ506,,1.0,,False,False,[],['LEQ-506' 'LEQ506' 'Leq 506' 'Leq506' 'NVP-LEQ506' 'Nvp-leq-506'],"[('drugbank', array(['DB12857'], dtype=object))]",,"{'rows': array(['EFO_0004193', 'EFO_0002939'], dtype=object), 'count': 2}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3301624,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O,HDHDTKMUACZDAA-PHNIDTBTSA-N,Protein,False,SETMELANOTIDE,2020.0,4.0,,False,True,['Imcivree'],['BIM-22493' 'RM-493' 'Setmelanotide'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree'],
      dtype=object)), ('drugbank', array(['DB11700'], dtype=object))]",['CHEMBL4650273'],"{'rows': array(['EFO_0001073', 'MONDO_0008300', 'EFO_0001073', 'HP_0000083',
       'EFO_0001074', 'MONDO_0015229'], dtype=object), 'count': 6}",[ENSG00000166603],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for obesity and has 4 investigational indications.
CHEMBL3545215,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21,JCINBYQJBYJGDM-UHFFFAOYSA-N,Small molecule,False,BMS-911543,,2.0,,False,False,[],['Bms-911543' 'JAK2 INHIBITOR BMS-911543'],"[('drugbank', array(['DB12591'], dtype=object))]",,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000096968],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707377,C=C1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O,CKFBRGLGTWAVLG-GOMYTPFNSA-N,Small molecule,False,SEGESTERONE ACETATE,2018.0,4.0,,False,True,['Nestorone'],['Elcometrine' 'ST-1435' 'Segesterone acetate'],"[('DailyMed', array(['segesterone%20acetate'], dtype=object)), ('drugbank', array(['DB14583'], dtype=object))]",,,[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018.
CHEMBL423,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,NWIUTZDMDHAVTP-UHFFFAOYSA-N,Small molecule,False,BETAXOLOL,1985.0,4.0,,False,True,['Betoptic' 'Betoptic susp'],"['ALO-140102 FREE BASE' 'Betaxolol' 'Betoptic' 'Kerledex' 'Kerlone'
 'SL-7521210 FREE BASE']","[('PubChem', array(['144203642', '170465448', '90341580'], dtype=object)), ('Wikipedia', array(['Betaxolol'], dtype=object)), ('drugbank', array(['DB00195'], dtype=object)), ('chEBI', array(['3082'], dtype=object))]",['CHEMBL1691'],"{'rows': array(['EFO_0004190', 'EFO_0000537', 'EFO_0004190', 'EFO_0000319',
       'EFO_1001069', 'EFO_1001069', 'MONDO_0005041'], dtype=object), 'count': 7}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 2 investigational indications.
CHEMBL4297183,CN1Cc2cc(Cl)ccc2-n2c(nnc2[C@H]2CC[C@H](Oc3ccccn3)CC2)C1,GMPZPHGHNDMRKL-RZDIXWSQSA-N,Small molecule,False,BALOVAPTAN,,3.0,,False,False,[],['Balovaptan' 'RG-7314' 'RG7314' 'RO-5285119' 'RO5285119' 'Rg7314'],"[('drugbank', array(['DB14823'], dtype=object))]",,"{'rows': array(['HP_0002140', 'EFO_0003756', 'EFO_0001358'], dtype=object), 'count': 3}",[ENSG00000166148],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297293,Clc1ccc(-c2nn(Cc3ccccc3)c3c2CCNCC3)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,DIQZMBPDLFAJLK-UHFFFAOYSA-N,Small molecule,False,JNJ-18038683,,2.0,CHEMBL4205783,False,False,[],['Jnj-18038683'],,,"{'rows': array(['MONDO_0002009', 'MONDO_0004985'], dtype=object), 'count': 2}",[ENSG00000148680],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297416,Cn1nccc1-c1ccc(Sc2cccc(C3(C(N)=O)CCOCC3)c2)cc1,DVNQWYLVSNPCJZ-UHFFFAOYSA-N,Small molecule,False,PF-4191834,,2.0,,False,False,[],['Pf-04191834' 'Pf-4191834'],"[('drugbank', array(['DB11645'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0004616'], dtype=object), 'count': 2}",[ENSG00000012779],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297555,,,Unknown,False,RESIMMUNE,,2.0,,False,False,[],['A-dmdt390-bisfv(ucht1)' 'LAX-699' 'Resimmune'],,,"{'rows': array(['EFO_1001051', 'EFO_0005592', 'EFO_1000785', 'EFO_0000756'],
      dtype=object), 'count': 4}","[ENSG00000167658,ENSG00000198851]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4650516,,,Antibody,False,FINOTONLIMAB,,3.0,,False,False,[],['Finotonlimab' 'SCT-I10A' 'Sct i10a' 'Sct-i10a'],,,"{'rows': array(['EFO_0000182', 'EFO_0000707', 'EFO_0000181', 'EFO_0000574'],
      dtype=object), 'count': 4}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL5315120,CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1.CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1.O.O.O,UIYFGCAQGONAMU-ZHQCGWDOSA-N,Small molecule,False,ODEVIXIBAT SESQUIHYDRATE,2021.0,4.0,CHEMBL4297588,False,True,['Bylvay'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay'],
      dtype=object))]",,"{'rows': array(['HP_0000989', 'MONDO_0017290'], dtype=object), 'count': 2}",[ENSG00000125255],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pruritus and familial intrahepatic cholestasis.
CHEMBL705,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,SHGAZHPCJJPHSC-ZVCIMWCZSA-N,Small molecule,False,ALITRETINOIN,1999.0,4.0,,False,True,['Panretin' 'Toctino'],"['9-cis retinoic acid' '9-cis-retinoic acid' 'AGN 192013' 'AGN-192013'
 'AGN192013' 'ALRT-1057' 'ALRT1057' 'Alitretinoin' 'BAL-4079' 'LG-100057'
 'LG100057' 'LGD-1057' 'LGD1057' 'NSC-659772' 'Panretin'
 'Retinoic acid 9-cis-form']","[('DailyMed', array(['alitretinoin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/panretin'],
      dtype=object)), ('PubChem', array(['144212512', '26755228', '26755229', '26755230'], dtype=object)), ('Wikipedia', array(['Alitretinoin'], dtype=object)), ('drugbank', array(['DB00523'], dtype=object)), ('chEBI', array(['50648'], dtype=object))]",,"{'rows': array(['HP_0000964', 'EFO_1000706', 'EFO_0003834', 'EFO_0000676',
       'EFO_1000726', 'EFO_0000558', 'MONDO_0007254', 'EFO_0000616'],
      dtype=object), 'count': 8}","[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 5 investigational indications.
CHEMBL1200715,CC(CNC1CCCCC1)OC(=O)c1ccccc1.Cl,MTFCPNHRBINLRQ-UHFFFAOYSA-N,Small molecule,False,HEXYLCAINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1197,False,True,['Cyclaine'],['Hexylcaine HCl' 'Hexylcaine hcl' 'Hexylcaine hydrochloride'],"[('PubChem', array(['144204007', '170465088', '56463225'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200769,CN(C)CCN(Cc1ccccc1)c1ccccn1.O=C(O)CC(O)(CC(=O)O)C(=O)O,GGRBYIUPUOYRLQ-UHFFFAOYSA-N,Small molecule,False,TRIPELENNAMINE CITRATE,1948.0,4.0,CHEMBL1241,False,True,[],['NSC-757360' 'Tripelennamine citrate'],"[('PubChem', array(['144205071', '170465118', '26749792'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1948.
CHEMBL1200963,CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O,AQOKCDNYWBIDND-FTOWTWDKSA-N,Small molecule,False,BIMATOPROST,2001.0,4.0,,False,True,['Bimatoprost' 'Durysta' 'Latisse' 'Lumigan'],['AGN 192024' 'AGN-192024' 'Bimatoprost' 'Prostamide'],"[('DailyMed', array(['bimatoprost'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lumigan'],
      dtype=object)), ('Wikipedia', array(['Bimatoprost'], dtype=object)), ('drugbank', array(['DB00905'], dtype=object)), ('chEBI', array(['51230'], dtype=object))]",,"{'rows': array(['EFO_0004208', 'EFO_0004191', 'EFO_0004192', 'MONDO_0005041',
       'EFO_1001069', 'MONDO_0003037', 'MONDO_0004907', 'MONDO_0018914',
       'EFO_0004190', 'EFO_1001466'], dtype=object), 'count': 10}",[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 5 investigational indications.
CHEMBL1201659,,,Small molecule,False,CHLORPHENIRAMINE POLISTIREX,1984.0,4.0,CHEMBL505,False,True,[],['Chlorpheniramine polistirex'],"[('DailyMed', array(['chlorpheniramine%20polistirex'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984.
CHEMBL1650443,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O,IWYJYHUNXVAVAA-OAHLLOKOSA-N,Small molecule,False,TRELAGLIPTIN,2015.0,4.0,,False,True,[],['SYR-472' 'Trelagliptin'],"[('drugbank', array(['DB15323'], dtype=object))]",['CHEMBL1650457' 'CHEMBL2105754' 'CHEMBL1650456'],"{'rows': array(['MONDO_0005148', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications.
CHEMBL1908397,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,YYLKKYCXAOBSRM-JXMROGBWSA-N,Small molecule,False,KW-2449,,1.0,,False,False,[],['KW-2449' 'Kw 2449' 'Kw-2449'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}","[ENSG00000097007,ENSG00000178999,ENSG00000122025,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2103794,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1.Cl,VFYAEUWJFGTGGO-GHTUPXNNSA-N,Small molecule,False,ANAMORELIN HYDROCHLORIDE,,3.0,CHEMBL2110579,False,False,[],['Anamorelin hcl' 'Anamorelin hydrochloride' 'Ono-7643' 'RC-1291 HCl'],,,"{'rows': array(['HP_0004326', 'HP_0012378', 'EFO_0002618'], dtype=object), 'count': 3}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2107386,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1.O=S(=O)(O)O,NQRYCIGCIAWEIC-CKLVGUEFSA-N,Small molecule,True,VORAPAXAR SULFATE,2014.0,4.0,CHEMBL493982,False,True,['Zontivity'],['SCH 530348' 'SCH-530348' 'Vorapaxar sulfate'],"[('DailyMed', array(['vorapaxar%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zontivity'],
      dtype=object)), ('chEBI', array(['83314'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_0005672', 'EFO_0004265', 'EFO_0000612'],
      dtype=object), 'count': 4}",[ENSG00000181104],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2109458,,,Antibody,False,AMG-108,,2.0,,False,False,[],['AMG-108' 'Amg-108'],,,"{'rows': array(['MONDO_0005178', 'EFO_0000400', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000115594],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2111112,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,VBHQKCBVWWUUKN-KZNAEPCWSA-N,Small molecule,False,VERNAKALANT,2010.0,4.0,,False,True,[],['Vernakalant'],"[('drugbank', array(['DB06217'], dtype=object))]",['CHEMBL2107383'],"{'rows': array(['EFO_0000275', 'EFO_0003911', 'EFO_0004269', 'EFO_0000275',
       'EFO_0003911'], dtype=object), 'count': 5}","[ENSG00000171385,ENSG00000130037,ENSG00000162989,ENSG00000120457,ENSG00000183873,ENSG00000055118]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for cardiac arrhythmia and atrial fibrillation and has 3 investigational indications.
CHEMBL2165615,Cc1cnc(NC(=O)c2cc(Oc3cnc(C(=O)N(C)C)nc3)c3cc(C)oc3c2)cn1,MASKQITXHVYVFL-UHFFFAOYSA-N,Small molecule,False,NERIGLIATIN,,2.0,,False,False,[],['Nerigliatin' 'PF-04937319' 'Pf-04937319'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object)), ('drugbank', array(['DB15009'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000106633],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL225071,Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1,IVTVGDXNLFLDRM-HNNXBMFYSA-N,Small molecule,False,RALTITREXED,1996.0,4.0,,False,True,['Tomudex'],['Raltitrexed' 'ZD-16' 'ZD-1694' 'ZD1694'],"[('PubChem', array(['144205790', '144207198', '49681782', '499545'], dtype=object)), ('Wikipedia', array(['Raltitrexed'], dtype=object)), ('drugbank', array(['DB00293'], dtype=object)), ('chEBI', array(['5847'], dtype=object))]",,"{'rows': array(['EFO_0005922', 'EFO_0000707', 'EFO_0002618', 'EFO_0000588',
       'MONDO_0002691', 'EFO_1001951', 'EFO_0000182', 'MONDO_0005575',
       'EFO_0004252', 'EFO_0000365', 'EFO_1000657', 'MONDO_0007576',
       'EFO_0004142', 'EFO_0000616', 'EFO_1000123', 'MONDO_0000870',
       'MONDO_0001056'], dtype=object), 'count': 17}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for neoplasm and has 16 investigational indications.
CHEMBL2396661,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,STUWGJZDJHPWGZ-LBPRGKRZSA-N,Small molecule,False,ALPELISIB,2019.0,4.0,,False,True,['Piqray' 'Vijoice'],['Alpelisib' 'BYL-719' 'BYL719' 'Byl-719' 'NVP-BYL719' 'Vijoice'],"[('DailyMed', array(['alpelisib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/piqray'],
      dtype=object)), ('drugbank', array(['DB12015'], dtype=object))]",,"{'rows': array(['MONDO_0011962', 'EFO_0001421', 'EFO_0000181', 'EFO_1001951',
       'MONDO_0004992', 'MONDO_0007254', 'EFO_0001378', 'EFO_0005922',
       'EFO_1001931', 'EFO_0004284', 'EFO_0002618', 'EFO_1000657',
       'EFO_0000707', 'EFO_0005537', 'MONDO_0011719', 'MONDO_0044704',
       'EFO_0000305', 'MONDO_0001056', 'MONDO_0016642', 'EFO_0000616',
       'EFO_0003869', 'MONDO_0008170'], dtype=object), 'count': 22}",[ENSG00000121879],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 17 investigational indications.
CHEMBL244243,C[C@@H](NC(=O)[C@@H](CC(=O)N1CCC(N2CCCCC2)CC1)N1C(=O)[C@@H](N2C(=O)OC[C@@H]2c2ccccc2)[C@H]1/C=C/c1ccccc1)c1cccc(C(F)(F)F)c1,ZPKHVQNRKMCYGL-AFAPVMNMSA-N,Small molecule,False,SRX246,,2.0,,False,False,[],['Srx246'],,,"{'rows': array(['EFO_0001358', 'EFO_0004247', 'EFO_0005230', 'MONDO_0007739'],
      dtype=object), 'count': 4}",[ENSG00000166148],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3301601,CN1C(N)=N[C@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS1(=O)=O,YHYKUSGACIYRML-KRWDZBQOSA-N,Small molecule,False,VERUBECESTAT,,3.0,,False,False,[],['MK-8931' 'SCH 900931' 'SCH-900931' 'SCH900931' 'Verubecestat'],"[('drugbank', array(['DB12285'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000186318],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3301622,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,GYQYAJJFPNQOOW-UHFFFAOYSA-N,Small molecule,True,GILTERITINIB,2018.0,4.0,,False,True,[],['ASP-2215' 'ASP2215' 'Asp-2215' 'Gilteritinib'],"[('drugbank', array(['DB12141'], dtype=object))]",['CHEMBL3301603' 'CHEMBL4524472'],"{'rows': array(['EFO_1000131', 'EFO_0000198', 'EFO_0001421', 'EFO_0003060',
       'MONDO_0004643', 'EFO_0003086', 'EFO_0000222', 'EFO_0000616',
       'EFO_0000222'], dtype=object), 'count': 9}","[ENSG00000167601,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545163,CCNC(=O)[C@H]1CC(n2ccc3c(NC(CC)Cc4sccc4Cl)ncnc32)[C@H](O)[C@@H]1O,CKQOOYMMAAPDKH-NXKGBEFYSA-N,Small molecule,False,AMP579,,2.0,,False,False,[],['Amp579' 'RPR-100579'],,,,"[ENSG00000128271,ENSG00000163485]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545295,,,Small molecule,False,AVE0847,,1.0,,False,False,[],['Ave0847'],,,,"[ENSG00000132170,ENSG00000112033]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4297457,CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12.Cl,MQBBSMNIRWXALO-UHFFFAOYSA-N,Small molecule,False,BMS-823778,,2.0,CHEMBL4301600,False,False,[],['BMS-823778' 'Bms-823778'],,,"{'rows': array(['EFO_0000319', 'MONDO_0005148', 'EFO_0000537', 'Orphanet_309005'],
      dtype=object), 'count': 4}",[ENSG00000117594],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297722,,,Oligonucleotide,False,CEMDISIRAN,,3.0,,False,False,[],"['AD-62643' 'AD-62643 FREE ACID' 'ALN-62643' 'ALN-62643 FREE ACID'
 'Cemdisiran' 'Cemdisiran sodium']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CEMDISIRAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004991', 'MONDO_0100244', 'MONDO_0100244', 'MONDO_0016244',
       'EFO_0004194'], dtype=object), 'count': 5}",[ENSG00000106804],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL688,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,IVLVTNPOHDFFCJ-UHFFFAOYSA-N,Small molecule,True,FENTANYL CITRATE,1968.0,4.0,CHEMBL596,False,True,"['Abstral' 'Actiq' 'Fentanyl' 'Fentanyl citrate'
 'Fentanyl citrate preservative free' 'Fentora' 'Instanyl' 'Lazanda'
 'Onsolis' 'Sublimaze' 'Sublimaze preservative free' 'Thalamonal']","['Fentanyl buccal' 'Fentanyl citrate' 'Fentanyl citrate cii' 'Instanyl'
 'Kw-2246' 'Leptanal' 'MCN-JR-4263-49' 'R-4263']","[('DailyMed', array(['fentanyl%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/instanyl'],
      dtype=object)), ('chEBI', array(['31602'], dtype=object))]",,"{'rows': array(['HP_0003419', 'MONDO_0005277', 'EFO_0003843', 'EFO_0005762',
       'EFO_0801084', 'EFO_0004244', 'HP_0002094', 'HP_0012532',
       'EFO_1001139', 'EFO_0009727', 'MONDO_0004992', 'EFO_0000546'],
      dtype=object), 'count': 12}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 4 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL7492,COc1ccc(OC)c(Cc2cnc3nc(N)nc(N)c3c2C)c1,VJXSSYDSOJBUAV-UHFFFAOYSA-N,Small molecule,False,PIRITREXIM,,2.0,,False,False,[],['BW-301U' 'Bw 301u' 'Bw-301u' 'Piritrexim' 'TCMDC-137235'],"[('drugbank', array(['DB03695'], dtype=object))]",['CHEMBL1712863'],"{'rows': array(['MONDO_0001187', 'MONDO_0004192'], dtype=object), 'count': 2}",[ENSG00000228716],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1201728,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O=C(O)CCC(=O)O,ORUUBRMVQCKYHB-UHFFFAOYSA-N,Small molecule,True,DESVENLAFAXINE SUCCINATE,2008.0,4.0,CHEMBL1118,False,True,['Desvenlafaxine succinate' 'Pristiq'],"['DVS-233' 'Desvenlafaxine succinate' 'Desvenlafaxine succinate anhydrous'
 'Desvenlafaxine succinate hydrate' 'Desvenlafaxine succinate monohydrate'
 'Dvs anhydrous' 'O-desmethyl venlafaxine succinate'
 'O-desmethylvenlafaxine succinate' 'WY-45233' 'WY45233']","[('DailyMed', array(['desvenlafaxine%20succinate'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0005687', 'HP_0031217', 'MONDO_0002009',
       'GO_0042697', 'EFO_1000783', 'MONDO_0002050'], dtype=object), 'count': 7}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for major depressive disorder and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL15770,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1,MLKXDPUZXIRXEP-MFOYZWKCSA-N,Small molecule,True,SULINDAC,1978.0,4.0,,False,True,['Clinoril' 'Sulindac'],['Arthrocine' 'Artribid' 'MK-231' 'NSC-757344' 'Sulindac'],"[('DailyMed', array(['sulindac'], dtype=object)), ('PubChem', array(['11111823', '11111824', '11114189', '124881496', '144203821',
       '144211735', '170464648', '26732639', '50106970', '85231236',
       '90341400'], dtype=object)), ('TG-GATEs', array(['100'], dtype=object)), ('Wikipedia', array(['Sulindac'], dtype=object)), ('drugbank', array(['DB00605'], dtype=object)), ('chEBI', array(['9352'], dtype=object))]",,"{'rows': array(['EFO_0000389', 'MONDO_0021074', 'EFO_0004142', 'EFO_1001951',
       'MONDO_0007254', 'Orphanet_733', 'EFO_0000222', 'EFO_0009907',
       'EFO_0000181', 'MONDO_0005178', 'EFO_0005755', 'EFO_0000685',
       'MONDO_0010383', 'MONDO_0003937'], dtype=object), 'count': 14}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1688243,CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,ZMCJFJZOSKEMOM-DNKZPPIMSA-N,Small molecule,False,INCB-9471,,2.0,,False,False,[],['INCB-009471' 'INCB009471' 'INCB9471' 'Incb-9471'],"[('drugbank', array(['DB12960'], dtype=object))]",,"{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1743016,,,Antibody,False,FARLETUZUMAB,,3.0,,False,False,[],['Farletuzumab' 'M3' 'MORAb-003'],,,"{'rows': array(['MONDO_0002158', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000571',
       'EFO_1001100'], dtype=object), 'count': 5}",[ENSG00000110195],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL1817709,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O,JCVQBJTWWDYUFQ-MRUTUVJXSA-N,Protein,False,SELEPRESSIN,,2.0,,False,False,[],['FE 202158' 'FE-202158' 'FE202158' 'Fe-202158' 'Selepressin'],"[('drugbank', array(['DB12495'], dtype=object))]",,"{'rows': array(['EFO_0006834'], dtype=object), 'count': 1}",[ENSG00000166148],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107771,C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O,BHJIBOFHEFDSAU-LBPRGKRZSA-N,Small molecule,False,RALFINAMIDE,,3.0,,False,False,[],"['FCE-26742A' 'NW1029' 'Nw-1029' 'PNU-0154339E' 'Priralfinamide'
 'Ralfinamide']","[('drugbank', array(['DB06649'], dtype=object))]",,"{'rows': array(['EFO_0005762', 'EFO_0003843'], dtype=object), 'count': 2}","[ENSG00000069535,ENSG00000148408,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL237500,CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,LTXREWYXXSTFRX-QGZVFWFLSA-N,Small molecule,False,LINAGLIPTIN,2011.0,4.0,,False,True,['Tradjenta' 'Trajenta'],"['BI 1356' 'BI 1356 BS' 'BI-1356' 'BI-1356-BS' 'BI-1356BS' 'BS 1356 BS'
 'BS-1356-BS' 'Linagliptin' 'Trazenta']","[('DailyMed', array(['linagliptin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta'],
      dtype=object)), ('Wikipedia', array(['Linagliptin'], dtype=object)), ('drugbank', array(['DB08882'], dtype=object)), ('chEBI', array(['68610'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0100096', 'EFO_0000537', 'EFO_0000503',
       'MONDO_0005090', 'MONDO_0005148', 'EFO_0002916', 'HP_0000083',
       'EFO_0000400', 'EFO_0000684'], dtype=object), 'count': 10}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 8 investigational indications.
CHEMBL2393130,COc1cc(OC)c2c(=O)[nH]c(-c3cc(C)c(OCCO)c(C)c3)nc2c1,NETXMUIMUZJUTB-UHFFFAOYSA-N,Small molecule,False,APABETALONE,,3.0,,False,False,[],['Apabetalone' 'RVX-000222' 'RVX-208' 'RVX000222'],"[('drugbank', array(['DB12000'], dtype=object))]",,"{'rows': array(['EFO_0001645', 'MONDO_0010526', 'MONDO_0100096', 'EFO_0001361',
       'EFO_0000400', 'EFO_0003884'], dtype=object), 'count': 6}","[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL290194,C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC,KSEYRUGYKHXGFW-UHFFFAOYSA-N,Small molecule,False,ALIZAPRIDE,,3.0,,False,False,[],['Alizapride' 'Litican' 'Plitican' 'Superan' 'Vergentan'],"[('Wikipedia', array(['Alizapride'], dtype=object)), ('drugbank', array(['DB01425'], dtype=object))]",['CHEMBL1896987'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3301600,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1,ABSXPNGWJFAPRT-UHFFFAOYSA-N,Small molecule,False,SPEBRUTINIB BESYLATE,,2.0,CHEMBL3301625,False,False,[],"['AVL-292' 'AVL-292 BESYLATE' 'CC-292' 'CC-292 BESYLATE' 'Spebrutinib'
 'Spebrutinib besilate' 'Spebrutinib besylate']",,,"{'rows': array(['EFO_0000403', 'EFO_0000685', 'EFO_0000565'], dtype=object), 'count': 3}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL33986,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,IFKLAQQSCNILHL-QHAWAJNXSA-N,Small molecule,True,BUTORPHANOL,1978.0,4.0,,False,True,[],['Butorphanol' 'LEVO-BC-2627'],"[('Wikipedia', array(['Butorphanol'], dtype=object)), ('chEBI', array(['3242'], dtype=object))]",['CHEMBL299400'],"{'rows': array(['EFO_0003890', 'EFO_0003843', 'EFO_0005230'], dtype=object), 'count': 3}","[ENSG00000112038,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for drug dependence and pain and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL3639788,O=C(Cc1cccc(OC(F)(F)F)c1)Nc1ccc(CCCCc2nnc(NC(=O)Cc3ccccn3)s2)nn1,PRAAPINBUWJLGA-UHFFFAOYSA-N,Small molecule,False,TELAGLENASTAT,,2.0,,False,False,[],['CB-839' 'Telaglenastat'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TELAGLENASTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15232'], dtype=object))]",['CHEMBL4594286'],"{'rows': array(['EFO_0001061', 'EFO_0000349', 'EFO_0003060', 'EFO_0000681',
       'EFO_0000222', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000220',
       'EFO_0000272', 'EFO_0000198', 'EFO_0005537', 'EFO_0000616',
       'EFO_1001779', 'EFO_0001378', 'EFO_0000760'], dtype=object), 'count': 15}",[ENSG00000115419],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 14 investigational indications.
CHEMBL3833306,,,Antibody drug conjugate,False,VANDORTUZUMAB VEDOTIN,,2.0,,False,False,[],['DSTP3086S' 'MSTP2109A' 'RG-7450' 'RG7450' 'Vandortuzumab vedotin'],,,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}","[ENSG00000164647,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989826,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1,BTEYIHUKHHAVAN-KDKWOIFOSA-N,Small molecule,False,OXYCODONE TEREPHTHALATE,1950.0,4.0,CHEMBL656,False,True,[],['Oxycodone terephthalate'],"[('DailyMed', array(['oxycodone%20terephthalate'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950 and is indicated for pain.
CHEMBL4297864,,,Antibody,False,CENDAKIMAB,,3.0,,False,False,[],['ABT-308' 'Abt-308' 'CC-93538' 'Cendakimab' 'RPC-4046'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CENDAKIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0004232', 'EFO_1001463'], dtype=object), 'count': 3}",[ENSG00000169194],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4650316,C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO,GQCXHIKRWBIQMD-AKJBCIBTSA-N,Small molecule,False,GIREDESTRANT,,3.0,,False,False,[],['GDC-9545' 'Gdc-9545' 'Giredestrant' 'RO-7197597' 'RO7197597'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GIREDESTRANT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0011962', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL971,CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+],QGMRQYFBGABWDR-UHFFFAOYSA-M,Small molecule,False,PENTOBARBITAL SODIUM,1973.0,4.0,CHEMBL448,True,True,"['Beuthanasia' 'Euthanase' 'Euthatal' 'Nembutal' 'Nembutal sodium'
 'Pentobarbital sodium' 'Pentobarbitone Sodium' 'Sagatal'
 'Sodium pentobarbital']","['Auropan' 'Barpental' 'Biosedan' 'Diabutal' 'Embutal' 'Entobar'
 'Etaminal sodium' 'Ethaminal sodium' 'Euthanyl' 'Euthatal' 'Isobarb'
 'Mebubarbital sodium' 'Mebumal sodium' 'NSC-10816' 'Napental' 'Narcoren'
 'Pacifan' 'Pental' 'Pentobarbital sodium' 'Pentobarbital sodium salt'
 'Pentobarbitone sodium' 'Pentonal' 'Pentone' 'Praecicalm'
 'Rs-pentobarbital sodium' 'Sagatal' 'Sodium ethaminal' 'Sodium nembutal'
 'Sodium pental' 'Sodium pentobarbitone' 'Sodium pentobarbiturate'
 'Sodium-pent' 'Soluble pentobarbital' 'Somnopentyl' 'Somnotol' 'Sopental'
 'Sotyl' 'V-pento' 'Vetbutal']","[('DailyMed', array(['pentobarbital%20sodium'], dtype=object)), ('chEBI', array(['7984'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973. It was withdrawn in at least one region.
CHEMBL1094,NC(=O)OCC(COC(N)=O)c1ccccc1,WKGXYQFOCVYPAC-UHFFFAOYSA-N,Small molecule,True,FELBAMATE,1993.0,4.0,,False,True,['Felbamate' 'Felbatol' 'Taloxa'],['ADD-03055' 'Felbamate' 'NSC-759866' 'W-554'],"[('DailyMed', array(['felbamate'], dtype=object)), ('PubChem', array(['104171154', '11113343', '144203696', '144212685', '170465178',
       '50104096', '56422162', '855835', '90340922'], dtype=object)), ('Wikipedia', array(['Felbamate'], dtype=object)), ('drugbank', array(['DB00949'], dtype=object)), ('chEBI', array(['4995'], dtype=object))]",['CHEMBL2130858'],"{'rows': array(['MONDO_0002280', 'MONDO_0004985', 'EFO_0000474', 'HP_0001250'],
      dtype=object), 'count': 4}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1200480,CC(=O)O.C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,XQEJFZYLWPSJOV-XJQYZYIXSA-N,Protein,False,OCTREOTIDE ACETATE,1988.0,4.0,CHEMBL1680,False,True,"['Bynfezia pen' 'Mycapssa' 'Octreotide acetate'
 'Octreotide acetate (preservative free)'
 'Octreotide acetate preservative free' 'Sandostatin' 'Sandostatin lar']","['Octreolin' 'Octreotide (as acetate)' 'Octreotide acetate'
 'SMS 201-995 AC' 'SMS-201-995 AC' 'SMS-201995-AC']","[('DailyMed', array(['octreotide%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mycapssa'],
      dtype=object))]",,"{'rows': array(['MONDO_0008300', 'EFO_1000852', 'EFO_1002048', 'EFO_1001901',
       'MONDO_0043579', 'EFO_0009708', 'EFO_0000616', 'HP_0002019',
       'MONDO_0004565', 'EFO_0003770', 'EFO_1001951', 'MONDO_0017611',
       'EFO_1001485', 'EFO_0002626', 'HP_0002014', 'EFO_0004243',
       'EFO_0001073', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0002691',
       'MONDO_0017182', 'EFO_0000574'], dtype=object), 'count': 22}","[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 18 investigational indications.
CHEMBL1200870,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O,WLRMANUAADYWEA-NWASOUNVSA-N,Small molecule,False,TIMOLOL MALEATE,1978.0,4.0,CHEMBL499,False,True,"['Blocadren' 'Istalol' 'Timolol maleate' 'Timoptic' 'Timoptic Xe'
 'Timoptic in ocudose' 'Timoptic-xe']","['Aquanil' 'NSC-757351' 'Ophtamolol' 'Timolol (as maleate)'
 'Timolol hydrogen maleate salt' 'Timolol maleate'
 'Timolol maleate, s-enantiomer' 'Timololi maleas' 'WP-934']","[('DailyMed', array(['timolol%20maleate'], dtype=object)), ('PubChem', array(['144212785', '56423148', '855659', '93576681'], dtype=object)), ('chEBI', array(['9600'], dtype=object))]",,"{'rows': array(['EFO_1000879', 'MONDO_0005041', 'EFO_0000666', 'EFO_1001022',
       'EFO_0004190', 'EFO_1000809', 'EFO_1000635', 'EFO_1001069'],
      dtype=object), 'count': 8}","[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 3 approved and 5 investigational indications.
CHEMBL1201748,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,BMQGVNUXMIRLCK-OAGWZNDDSA-N,Small molecule,True,CABAZITAXEL,2010.0,4.0,,False,True,['Cabazitaxel accord' 'Jevtana' 'Jevtana kit'],"['Cabazitaxel' 'Cabazitaxel acetonate' 'Jevtana' 'NSC-761432' 'TXD 258'
 'TXD-258' 'TXD258' 'XRP 6258' 'XRP-6258' 'XRP6258']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord'],
      dtype=object)), ('Wikipedia', array(['Cabazitaxel'], dtype=object)), ('drugbank', array(['DB06772'], dtype=object)), ('chEBI', array(['63584'], dtype=object))]",,"{'rows': array(['EFO_0003085', 'MONDO_0007254', 'EFO_0001663', 'EFO_0005088',
       'MONDO_0008315', 'EFO_0003060', 'EFO_0000326', 'EFO_1001094',
       'EFO_1000796', 'EFO_0006859', 'EFO_1000601', 'MONDO_0001657',
       'EFO_0000519', 'MONDO_0008170', 'EFO_0000702', 'EFO_0000181',
       'EFO_0000196', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0021259',
       'MONDO_0001056', 'MONDO_0004986', 'EFO_0000673', 'EFO_0000616',
       'EFO_0008528'], dtype=object), 'count': 25}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 7 approved and 18 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1237061,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2],RHGYHLPFVJEAOC-FFNUKLMVSA-L,Small molecule,False,PITAVASTATIN CALCIUM,2009.0,4.0,CHEMBL1201753,False,True,['Livalo' 'Pitavastatin calcium'],"['Itavastatin calcium' 'NK-104' 'Pitavastatin Calcium'
 'Pitavastatin calcium' 'Pitavastatin calcium salt']","[('DailyMed', array(['pitavastatin%20calcium'], dtype=object)), ('PubChem', array(['49681579'], dtype=object)), ('chEBI', array(['71258'], dtype=object))]",,"{'rows': array(['Orphanet_309005', 'EFO_0004911', 'HP_0003124', 'MONDO_0021187',
       'HP_0003119'], dtype=object), 'count': 5}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 1 investigational indication.
CHEMBL1493,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O,SPIUTQOUKAMGCX-UHFFFAOYSA-N,Small molecule,False,FLAVOXATE,1970.0,4.0,,False,True,[],['Bladuril' 'Flavoxate'],"[('PubChem', array(['11112543'], dtype=object)), ('Wikipedia', array(['Flavoxate'], dtype=object)), ('drugbank', array(['DB01148'], dtype=object)), ('chEBI', array(['5088'], dtype=object))]",['CHEMBL1200875'],"{'rows': array(['HP_0000020', 'EFO_0003830', 'EFO_0003901', 'EFO_0003878',
       'EFO_0003103', 'HP_0000103'], dtype=object), 'count': 6}","[ENSG00000205268,ENSG00000171408,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000113231,ENSG00000073417]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 6 approved indications.
CHEMBL1508,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,WSEQXVZVJXJVFP-FQEVSTJZSA-N,Small molecule,True,ESCITALOPRAM,2002.0,4.0,,False,True,['Cipralex'],['Escitalopram' 'Esertia' 'Esitol' 'LU-26-054'],"[('PubChem', array(['11110983', '11114081', '124879737', '50100207'], dtype=object)), ('Wikipedia', array(['Escitalopram'], dtype=object)), ('drugbank', array(['DB01175'], dtype=object)), ('chEBI', array(['36791'], dtype=object))]",['CHEMBL1200322'],"{'rows': array(['MONDO_0005184', 'EFO_0000712', 'MONDO_0004992', 'EFO_0004262',
       'EFO_0003047', 'EFO_0001358', 'MONDO_0004985', 'EFO_1001892',
       'EFO_0000313', 'EFO_0003890', 'EFO_0009963', 'EFO_0002610',
       'HP_0002381', 'EFO_0004242', 'MONDO_0002009', 'EFO_1001908',
       'EFO_0005230', 'MONDO_0002009', 'EFO_0803321', 'MONDO_0004975',
       'MONDO_0002050', 'EFO_1001892', 'EFO_0003884', 'MONDO_0005149',
       'MONDO_0002491', 'MONDO_0002009', 'MONDO_0002050', 'HP_0012076',
       'EFO_0005687', 'EFO_1001917', 'HP_0000726', 'EFO_0010282',
       'EFO_1001919', 'MONDO_0002009', 'MONDO_0005090', 'EFO_0006788',
       'EFO_0000685', 'EFO_0000555'], dtype=object), 'count': 38}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 4 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1569,Cl.NC12CC3CC(CC(C3)C1)C2,WOLHOYHSEKDWQH-UHFFFAOYSA-N,Small molecule,False,AMANTADINE HYDROCHLORIDE,1968.0,4.0,CHEMBL660,False,True,"['Amantadine hydrochloride' 'Gocovri' 'Lysovir' 'Mantadine' 'Osmolex er'
 'Symadine' 'Symmetrel']","['Adamantanamine hydrochloride' 'Amantadine hcl'
 'Amantadine hydrochloride' 'EXP-105-1' 'Mantadix' 'NSC-83653' 'Osmolex']","[('DailyMed', array(['amantadine%20hydrochloride'], dtype=object)), ('PubChem', array(['26747411', '26747412', '50105719', '50105720'], dtype=object)), ('chEBI', array(['2619'], dtype=object))]",,"{'rows': array(['EFO_1001175', 'EFO_0004247', 'HP_0001300', 'EFO_0007328',
       'EFO_0003047', 'MONDO_0004976', 'MONDO_0005301', 'MONDO_0005090',
       'EFO_0000544', 'EFO_1001402', 'EFO_1000860', 'MONDO_0043510',
       'MONDO_0100096', 'MONDO_0005180', 'EFO_0005411'], dtype=object), 'count': 15}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 8 investigational indications.
CHEMBL159226,CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C,VRYMTAVOXVTQEF-UHFFFAOYSA-N,Small molecule,False,MOXISYLYTE,,4.0,,False,True,['Erecnos' 'Moxivig'],"['Acetoxythymoxamine' 'Carlytene' 'Moxisylyte' 'Moxisylyte hcl'
 'Moxisylyte hydrochloride' 'NSC-170448' 'Thymoxamine' 'Thymoxamine hcl'
 'Thymoxamine hydrochloride']","[('PubChem', array(['11111464', '11111465', '90340735'], dtype=object)), ('TG-GATEs', array(['61'], dtype=object)), ('drugbank', array(['DB09205'], dtype=object))]",['CHEMBL1256739'],"{'rows': array(['EFO_0000319', 'EFO_0004234'], dtype=object), 'count': 2}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and erectile dysfunction.
CHEMBL1698,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,HEYVINCGKDONRU-UHFFFAOYSA-N,Small molecule,True,BUPROPION HYDROCHLORIDE,1985.0,4.0,CHEMBL894,False,True,"['Bupropion hydrochloride' 'Forfivo xl' 'Wellbutrin' 'Wellbutrin 100'
 'Wellbutrin 75' 'Wellbutrin sr' 'Wellbutrin xl' 'Zyban']","['Amfebutamone hydrochloride' 'BW 323' 'BW-323' 'BW323' 'Bupropion HCl'
 'Bupropion hcl' 'Bupropion hydrochloride' 'Mysimba' 'NSC-315851']","[('DailyMed', array(['bupropion%20hydrochloride'], dtype=object)), ('PubChem', array(['144204172', '144212161', '170464747', '26747451', '49681824',
       '50105906', '573995', '855813'], dtype=object))]",,"{'rows': array(['EFO_0005203', 'MONDO_0002009', 'MONDO_0002009', 'MONDO_0008903',
       'EFO_0003768', 'MONDO_0002050', 'EFO_0004319', 'MONDO_0007079',
       'EFO_0009963', 'EFO_0004318', 'EFO_0001073', 'MONDO_0010200',
       'MONDO_0007254', 'MONDO_0004985', 'EFO_0004247'], dtype=object), 'count': 15}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743260,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CC[Si](C)(C)C)cccc3nc2-1,SYXGVIWFCCQOEK-VWLOTQADSA-N,Small molecule,False,KARENITECIN,,3.0,,False,False,[],['Karenitecin'],,,"{'rows': array(['EFO_0003833', 'EFO_1000158', 'EFO_0000756', 'MONDO_0008170',
       'MONDO_0008903', 'EFO_0003060'], dtype=object), 'count': 6}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL1808388,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,BTCRKOKVYTVOLU-SJSRKZJXSA-N,Small molecule,False,BEXAGLIFLOZIN,2023.0,4.0,,False,True,['Brenzavvy'],"['Bexagliflozin' 'Brenzavvy' 'EGT-0001442' 'EGT-1442' 'EGT0001442'
 'EGT1442' 'THR-1442' 'THR1442']","[('drugbank', array(['DB12236'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'MONDO_0001134', 'EFO_0000400'], dtype=object), 'count': 3}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for type 2 diabetes mellitus and has 2 investigational indications.
CHEMBL2105581,C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC,RYJXBGGBZJGVQF-UHFFFAOYSA-N,Small molecule,False,VERALIPRIDE,1979.0,4.0,,True,True,['Agreal'],['Agradil' 'Veralipride'],"[('PubChem', array(['144205502'], dtype=object)), ('drugbank', array(['DB13523'], dtype=object))]",,"{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for psychosis. It was withdrawn in at least one region.
CHEMBL2107387,Br.Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,VNGRUFUIHGGOOM-UHFFFAOYSA-N,Small molecule,True,VORTIOXETINE HYDROBROMIDE,2013.0,4.0,CHEMBL2104993,False,True,['Brintellix' 'Trintellix'],"['Lu AA21004 (HBr)' 'Lu aa21004 hbr' 'Lu-aa21004 hydrobromide'
 'Vortioxetine hydrobromide']","[('DailyMed', array(['vortioxetine%20hydrobromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix'],
      dtype=object)), ('chEBI', array(['76015'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'MONDO_0002009'], dtype=object), 'count': 2}","[ENSG00000178394,ENSG00000108576,ENSG00000166736]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder. This drug has a black box warning from the FDA.
CHEMBL2107861,,,Antibody,False,ZALUTUMUMAB,,3.0,,False,False,[],"['2F8' 'HUMAX-EGFR, 2F8' 'HUMAX-EGFR-2F8' 'HuMax-EGFr' 'Zalutumumab']",,,"{'rows': array(['EFO_0000707', 'EFO_0004284', 'EFO_0003060', 'EFO_0006859',
       'EFO_1001951'], dtype=object), 'count': 5}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2108354,,,Antibody,False,UBLITUXIMAB,2022.0,4.0,,False,True,['Briumvi'],['Briumvi' 'TG-1101' 'Ublituximab' 'Ublituximab xiiy' 'Ublituximab-xiiy'],,,"{'rows': array(['MONDO_0005301', 'EFO_0009441', 'EFO_0004256', 'EFO_1001469',
       'MONDO_0018906', 'EFO_0000403', 'EFO_0003840', 'EFO_0003929',
       'EFO_0000095', 'EFO_0000096', 'EFO_0000540'], dtype=object), 'count': 11}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 8 investigational indications.
CHEMBL2108592,,,Antibody drug conjugate,False,EPITUMOMAB CITUXETAN,,2.0,,False,False,[],['Epitumomab cituxetan' 'Hmfg 1'],,,,[ENSG00000185499],Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL29741,CN(C)CCOc1ccccc1-c1nc(-c2ccccc2)no1,QZULPCPLWGCGSL-UHFFFAOYSA-N,Small molecule,False,IRAMPANEL,,2.0,,False,False,[],['BIIR 561' 'BIIR-561' 'BIIR-561 CL' 'Irampanel'],,,,"[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3301626,Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1,UPZWINBEAHDTLA-UHFFFAOYSA-N,Small molecule,False,BASIMGLURANT,,2.0,,False,False,[],['Basimglurant' 'NOE-101' 'RG-7090' 'RO-4917523' 'RO4917523' 'Rg7090'],"[('drugbank', array(['DB11833'], dtype=object))]",,"{'rows': array(['MONDO_0001734', 'EFO_1001219', 'MONDO_0002050', 'MONDO_0002009',
       'MONDO_0010383'], dtype=object), 'count': 5}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4297363,CCOC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C12CCCCC2,QCYAXXZCQKMTMO-QFIPXVFZSA-N,Small molecule,False,UCB-1184197,,2.0,,False,False,[],['CDP-323' 'CDP323' 'Cdp323' 'Ucb-1184197' 'Zaurategrast ethyl ester'],,,"{'rows': array(['MONDO_0005301'], dtype=object), 'count': 1}",[ENSG00000115232],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297648,[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1,LNLJHGXOFYUARS-OAQYLSRUSA-N,Small molecule,False,SELETALISIB,,2.0,,False,False,[],['Seletalisib' 'UCB-5857' 'UCB5857' 'Ucb5857'],"[('drugbank', array(['DB12706'], dtype=object))]",,"{'rows': array(['EFO_0000699', 'EFO_0000676'], dtype=object), 'count': 2}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL460,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,KLPWJLBORRMFGK-UHFFFAOYSA-N,Small molecule,True,MOLINDONE,1974.0,4.0,,False,True,[],['Moban' 'Molindone' 'Spn-810'],"[('PubChem', array(['26755691', '50111112', '90341242'], dtype=object)), ('Wikipedia', array(['Molindone'], dtype=object)), ('drugbank', array(['DB01618'], dtype=object)), ('chEBI', array(['6965'], dtype=object))]",['CHEMBL1200419'],"{'rows': array(['MONDO_0005090', 'EFO_0005407', 'EFO_0003888'], dtype=object), 'count': 3}","[ENSG00000149295,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for schizophrenia and psychosis and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL4802176,,,Unknown,False,ONO-5334,,2.0,,False,False,[],['ONO-5334' 'Ono-5334'],,,,[ENSG00000143387],Unknown drug with a maximum clinical trial phase of II.
CHEMBL481611,CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1,FWIVDMJALNEADT-SFTDATJTSA-N,Small molecule,False,ODANACATIB,,3.0,,False,False,[],['MK-0822' 'MK0822' 'Odanacatib'],"[('Wikipedia', array(['Odanacatib'], dtype=object)), ('drugbank', array(['DB06670'], dtype=object))]",,"{'rows': array(['EFO_0003854', 'MONDO_0005178', 'MONDO_0008315', 'MONDO_0007254',
       'EFO_0003882', 'HP_0000083'], dtype=object), 'count': 6}",[ENSG00000143387],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL956,CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1,MDKGKXOCJGEUJW-UHFFFAOYSA-N,Small molecule,False,SUPROFEN,1985.0,4.0,,True,True,['Profenal'],"['NSC-303611' 'P-(2-thenoyl)hydratropic acid'
 'P-2-thenoylhydratropic acid' 'R-25,061' 'R-25061' 'Racemic suprofen'
 'Srendam' 'Sulproltin' 'Suprofen' 'Sutoprofen' 'TN-762' 'Topalgic']","[('PubChem', array(['144204194', '170465412', '26748525', '56463227'], dtype=object)), ('Wikipedia', array(['Suprofen'], dtype=object)), ('drugbank', array(['DB00870'], dtype=object)), ('chEBI', array(['9362'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for rheumatic disease. It was withdrawn in at least one region.
CHEMBL1200531,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl,AQORHZJDCHLLJN-UHFFFAOYSA-N,Small molecule,True,ALFENTANIL HYDROCHLORIDE,1986.0,4.0,CHEMBL634,False,True,"['Alfenta' 'Alfentanil' 'Rapifen' 'Rapifen conc' 'Rapifen dilute'
 'Rapifen intensive care']","['Alfentanil hydrochloride' 'Alfentanil hydrochloride cii'
 'Alfentanil hydrochloride monohydrate' 'R 39,209' 'R 39209' 'R-39,209'
 'R-39209']","[('PubChem', array(['144206431', '85273815'], dtype=object))]",,,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. This drug has a black box warning from the FDA.
CHEMBL148674,CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1,BHLXTPHDSZUFHR-UHFFFAOYSA-N,Small molecule,False,VARESPLADIB,,2.0,,False,False,[],['LY-315920' 'LY315920' 'Varepladib' 'Varespladib' 'Varespladib sodium'],"[('PubChem', array(['174006184'], dtype=object)), ('Wikipedia', array(['Varespladib'], dtype=object)), ('drugbank', array(['DB11909'], dtype=object))]",['CHEMBL2107809'],"{'rows': array(['EFO_0001645', 'MONDO_0100096', 'MONDO_0011382'], dtype=object), 'count': 3}",[ENSG00000188257],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1678,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl,XWAIAVWHZJNZQQ-UHFFFAOYSA-N,Small molecule,False,DONEPEZIL HYDROCHLORIDE,1996.0,4.0,CHEMBL502,False,True,"['Adlarity' 'Aricept' 'Aricept evess' 'Aricept odt'
 'Donepezil hydrochloride']","['Adlarity' 'BNAG' 'Donepezil hcl' 'Donepezil hydrochloride' 'E-2020'
 'E2020' 'NSC-737535' 'NSC-758882']","[('DailyMed', array(['donepezil%20hydrochloride'], dtype=object)), ('PubChem', array(['144206087', '170464858', '26719734', '49732006'], dtype=object)), ('chEBI', array(['4696'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0003758', 'EFO_1000158', 'EFO_0005762',
       'EFO_0009267', 'HP_0100543', 'MONDO_0002050', 'MONDO_0010726',
       'MONDO_0005277', 'EFO_0001064', 'HP_0000726', 'EFO_0004718'],
      dtype=object), 'count': 12}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for alzheimer disease and dementia and has 10 investigational indications.
CHEMBL1767408,O=c1ccn([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1.[Na+].[Na+].[Na+].[Na+],OWTGMPPCCUSXIP-FNXFGIETSA-J,Small molecule,False,DIQUAFOSOL TETRASODIUM,,3.0,CHEMBL221326,False,False,[],"['DE-089' 'Diquafosol sodium' 'Diquafosol tetrasodium'
 'Diquafosol tetrasodium salt' 'INS 365' 'INS365' 'KPY-998']","[('Wikipedia', array(['Diquafosol'], dtype=object))]",,"{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}","[ENSG00000171631,ENSG00000186912,ENSG00000175591,ENSG00000169860]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1946170,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,FNHKPVJBJVTLMP-UHFFFAOYSA-N,Small molecule,True,REGORAFENIB,2012.0,4.0,,False,True,['Stivarga'],"['BAY 73-4506' 'BAY 73-4506 monohydrate' 'BAY-73-4506' 'BAY-734506'
 'Regorafenib' 'Regorafenib anhydrous' 'Regorafenib hydrate'
 'Regorafenib monohydrate']","[('DailyMed', array(['regorafenib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga'],
      dtype=object)), ('PubChem', array(['137275982'], dtype=object)), ('Wikipedia', array(['Regorafenib'], dtype=object)), ('drugbank', array(['DB08896'], dtype=object)), ('chEBI', array(['68647'], dtype=object))]",,"{'rows': array(['EFO_0004142', 'EFO_1001961', 'MONDO_0021063', 'EFO_0000569',
       'EFO_0000616', 'EFO_0000222', 'EFO_0005540', 'EFO_0000691',
       'MONDO_0004992', 'MONDO_0007576', 'EFO_0002918', 'EFO_0000365',
       'EFO_0000637', 'EFO_0003893', 'EFO_0000756', 'EFO_1001949',
       'MONDO_0003060', 'MONDO_0002158', 'EFO_0000182', 'EFO_0000702',
       'MONDO_0008170', 'EFO_1000350', 'EFO_0000681', 'EFO_0000519',
       'EFO_0005221', 'EFO_1001951', 'MONDO_0011719', 'MONDO_0001056',
       'EFO_0000389', 'MONDO_0002108', 'EFO_0002618', 'EFO_0009606',
       'EFO_0000231', 'EFO_0003968', 'EFO_1001968', 'EFO_1000657',
       'EFO_0001075', 'MONDO_0005575'], dtype=object), 'count': 38}","[ENSG00000165731,ENSG00000120156,ENSG00000077782,ENSG00000142627,ENSG00000185386,ENSG00000113721,ENSG00000134853,ENSG00000162733,ENSG00000157764,ENSG00000066468,ENSG00000132155,ENSG00000111816,ENSG00000157404,ENSG00000097007,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000198400]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1969664,N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1,BLTVBQXJFVRPFK-UHFFFAOYSA-N,Small molecule,False,AZD-1080,,1.0,,False,False,[],['AZ-11548415' 'AZD-1080' 'Azd-1080'],"[('PubChem', array(['103905163'], dtype=object))]",,,"[ENSG00000105723,ENSG00000082701]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL198362,O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,KGFYHTZWPPHNLQ-AWEZNQCLSA-N,Small molecule,True,RIVAROXABAN,2008.0,4.0,,False,True,['Xarelto'],['BAY 59-7939' 'BAY-59-7939' 'JNJ-39039039' 'JNJ39039039' 'Rivaroxaban'],"[('DailyMed', array(['rivaroxaban'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto'],
      dtype=object)), ('Wikipedia', array(['Rivaroxaban'], dtype=object)), ('drugbank', array(['DB06228'], dtype=object)), ('chEBI', array(['68579'], dtype=object))]",,"{'rows': array(['HP_0002140', 'EFO_0003964', 'HP_0004419', 'EFO_0009314',
       'MONDO_0000831', 'EFO_0000612', 'EFO_0004265', 'EFO_0001378',
       'HP_0001907', 'EFO_0001645', 'MONDO_0100096', 'MP_0001914',
       'EFO_1000985', 'EFO_0003884', 'EFO_0003777', 'EFO_0009531',
       'EFO_0004286', 'HP_0004936', 'EFO_1001161', 'EFO_0003907',
       'HP_0000083', 'EFO_0001074', 'EFO_0000712', 'MONDO_0004992',
       'HP_0001873', 'EFO_0005672', 'EFO_0000694', 'EFO_0001422',
       'MONDO_0005148', 'EFO_0002689', 'EFO_0010680', 'EFO_0000275',
       'MONDO_0011382', 'EFO_0000616', 'EFO_0000266', 'EFO_0010726',
       'EFO_0000556', 'EFO_0003827'], dtype=object), 'count': 38}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 8 approved and 30 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2364609,CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl,VCMGMSHEPQENPE-ZOWNYOTGSA-N,Small molecule,True,ESKETAMINE HYDROCHLORIDE,2019.0,4.0,CHEMBL395091,False,True,['Spravato'],"['AM-101' 'Esketamine hydrochloride' 'Ketamine hydrochloride, (s)-'
 'Ketamine hydrochloride, s-' 'Ketanest s']","[('DailyMed', array(['esketamine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/spravato'],
      dtype=object)), ('chEBI', array(['60800'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'MONDO_0002050', 'EFO_0003843', 'HP_0000360',
       'MONDO_0002009'], dtype=object), 'count': 5}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for major depressive disorder and depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2364611,Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1,IVRXNBXKWIJUQB-UHFFFAOYSA-N,Small molecule,False,GALUNISERTIB,,2.0,,False,False,[],['Galunisertib' 'LY-2157299' 'LY2157299' 'Ly-2157299'],"[('drugbank', array(['DB11911'], dtype=object))]",,"{'rows': array(['EFO_0009708', 'EFO_0005537', 'EFO_0000519', 'EFO_0005543',
       'EFO_0000616', 'EFO_0004252', 'EFO_0002618', 'EFO_0000182',
       'EFO_1000657', 'EFO_0000198', 'MONDO_0008315', 'EFO_0003860'],
      dtype=object), 'count': 12}",[ENSG00000106799],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.
CHEMBL296468,CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1,OUSFTKFNBAZUKL-UHFFFAOYSA-N,Small molecule,False,BMS-387032,,1.0,,False,False,[],['BMS-387032' 'Bms-387032' 'Bms387032' 'SNS-032' 'Sns 032'],"[('PubChem', array(['103905658', '137276011', '50100091'], dtype=object)), ('drugbank', array(['DB05969'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0000616', 'EFO_0000095', 'EFO_1001469'],
      dtype=object), 'count': 4}","[ENSG00000134058,ENSG00000136807,ENSG00000123374]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL324547,CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1,YDZYKNJZCVIKPP-VWLOTQADSA-N,Protein,False,NETAZEPIDE,,2.0,,False,False,[],['Netazepide' 'Sograzepide' 'YF-476' 'Yf476'],"[('drugbank', array(['DB12355'], dtype=object))]",,"{'rows': array(['EFO_1001095', 'EFO_0004243', 'EFO_0000280', 'EFO_0007549',
       'EFO_0008533'], dtype=object), 'count': 5}",[ENSG00000110148],Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3287735,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21,FKSFKBQGSFSOSM-QFIPXVFZSA-N,Small molecule,False,GSK2816126,,1.0,,False,False,[],['Gsk2816126'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000106462],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3360975,CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1,JLPURTXCSILYLW-UHFFFAOYSA-N,Small molecule,False,BMS-779788,,1.0,,False,False,[],"['BMS 788' 'Bms-779788' 'EXEL 04286652' 'EXEL-04286652' 'XL 652' 'XL-014'
 'XL-652']",,,"{'rows': array(['EFO_0003914'], dtype=object), 'count': 1}",[ENSG00000131408],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3544966,O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1,QDITZBLZQQZVEE-YBEGLDIGSA-N,Small molecule,False,GSK-1059615,,1.0,,False,False,[],['GSK-615' 'GSK1059615' 'GSK615' 'Gsk-1059615'],"[('drugbank', array(['DB11962'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545192,,,Antibody,False,MIRVETUXIMAB,,2.0,,False,False,[],['M-9346A' 'M9346A' 'Mirvetuximab'],,,,[ENSG00000110195],Antibody drug with a maximum clinical trial phase of II.
CHEMBL3707226,,,Oligonucleotide,False,DEFIBROTIDE SODIUM,2013.0,4.0,,False,True,['Defitelio'],['Defibrotide sodium' 'JZP-381'],"[('DailyMed', array(['defibrotide%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio'],
      dtype=object))]",,"{'rows': array(['MONDO_0019514'], dtype=object), 'count': 1}",[ENSG00000122194],Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for hepatic veno-occlusive disease.
CHEMBL3986824,Nc1cncc(-c2cn3ccnc3c(Nc3ccc(N4CCN(C5COC5)CC4)cc3)n2)n1,XCIGZBVOUQVIPI-UHFFFAOYSA-N,Small molecule,False,LANRAPLENIB,,2.0,,False,False,[],['GS-SYK' 'Lanraplenib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LANRAPLENIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14770'], dtype=object))]",['CHEMBL4298174'],"{'rows': array(['EFO_0003834', 'EFO_0000699', 'MONDO_0007915', 'EFO_0000222',
       'MP_0001845', 'MP_0001845'], dtype=object), 'count': 6}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4079239,C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl,CWFVVQFVGMFTBD-SECBINFHSA-N,Small molecule,False,JNJ-54175446,,2.0,,False,False,[],['Jnj-54175446'],"[('drugbank', array(['DB15358'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}",[ENSG00000089041],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4279455,CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,DXOJIXGRFSHVKA-BZVZGCBYSA-N,Small molecule,False,LAROTAXEL,,3.0,,False,False,[],['Larotaxel' 'XRP-9881' 'XRP9881' 'Xrp9881'],"[('drugbank', array(['DB12984'], dtype=object))]",,"{'rows': array(['EFO_0000294', 'EFO_0003860', 'EFO_0003869', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297794,,,Antibody,False,NEMOLIZUMAB,,3.0,,False,False,[],['CD14152' 'CIM-331' 'CIM331' 'Nemolizumab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NEMOLIZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003884', 'EFO_0000717', 'MONDO_0021739', 'EFO_0000274'],
      dtype=object), 'count': 4}",[ENSG00000164509],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297935,,,Unknown,False,RG-7841,,1.0,,False,False,[],"['Anti-ly6e-vcmmae' 'DLYE-5953A' 'DLYE5953A' 'Dlye5953a' 'RG-7841'
 'RG7841' 'Rg 7841' 'Rg-7841']",,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000160932]",Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4298021,,,Antibody,False,ZAGOTENEMAB,,2.0,,False,False,[],['LY-3303560' 'LY3303560' 'Ly3303560' 'Zagotenemab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZAGOTENEMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005815', 'MONDO_0004975'], dtype=object), 'count': 2}",[ENSG00000186868],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4298210,,,Antibody,False,ISCALIMAB,,2.0,,False,False,[],['CFZ-533' 'CFZ533' 'Iscalimab' 'NVP-CFZ533'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ISCALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1000710', 'EFO_0000699', 'EFO_0004991', 'EFO_0005761',
       'MONDO_0005147', 'EFO_0004237', 'EFO_0004599', 'EFO_0000685',
       'EFO_0010134', 'MONDO_0007915'], dtype=object), 'count': 10}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL45816,COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C,HBNPJJILLOYFJU-VMPREFPWSA-N,Small molecule,False,MIBEFRADIL,1997.0,4.0,,True,True,['Posicor 100' 'Posicor 50'],['Mibefradil' 'Posicor'],"[('PubChem', array(['11111472', '26755047', '50110875', '90340964'], dtype=object)), ('Wikipedia', array(['Mibefradil'], dtype=object)), ('drugbank', array(['DB01388'], dtype=object)), ('chEBI', array(['6920'], dtype=object))]",['CHEMBL1256688' 'CHEMBL1534525' 'CHEMBL1421212'],"{'rows': array(['EFO_0000519', 'EFO_1000158', 'EFO_0000319'], dtype=object), 'count': 3}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for cardiovascular disease and has 2 investigational indications. It was withdrawn in at least one region.
CHEMBL595573,O=C1O[C@]2(CC[C@H](C(=O)Nc3ccn(-c4ccccc4F)n3)CC2)c2cnccc21,RMYZIRFUCOMQRH-CAJLXGCNSA-N,Small molecule,False,MK-0557,,3.0,,False,False,[],['MK-0557' 'MK0557' 'Mk-0557' 'Mk0557'],"[('drugbank', array(['DB12168'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000164129],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1084172,O=C(O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,KLOLZALDXGTNQE-JIDHJSLPSA-N,Small molecule,False,VILANTEROL TRIFENATATE,2013.0,4.0,CHEMBL1198857,False,True,[],"['GW-642444M' 'GW642444M' 'Vilanterol (as trifenatate)'
 'Vilanterol trifenatate']","[('DailyMed', array(['vilanterol%20trifenatate'], dtype=object)), ('chEBI', array(['75040'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'EFO_0000464', 'MONDO_0004979', 'EFO_0006505'],
      dtype=object), 'count': 4}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved indications.
CHEMBL11,CN(C)CCCN1c2ccccc2CCc2ccccc21,BCGWQEUPMDMJNV-UHFFFAOYSA-N,Small molecule,True,IMIPRAMINE,1959.0,4.0,,False,True,[],"['Antideprin' 'Berkomine' 'Cristalia' 'Imipramine' 'Janimine'
 'Melipramine' 'NSC-169866' 'ORG-2463' 'Pramine' 'Presamine' 'Sermonil'
 'Tofranil' 'Tofranil-PM' 'Trimipramine maleate impurity, imipramine-']","[('PubChem', array(['104171178', '11111330', '11111331', '124880469', '144203725',
       '170464777', '26751600', '50100256', '50104254', '90341377'],
      dtype=object)), ('TG-GATEs', array(['69'], dtype=object)), ('Wikipedia', array(['Imipramine'], dtype=object)), ('drugbank', array(['DB00458'], dtype=object)), ('chEBI', array(['47499'], dtype=object))]",['CHEMBL1692' 'CHEMBL3989845'],"{'rows': array(['MONDO_0002050', 'HP_0100749', 'EFO_0000519', 'EFO_0005230',
       'EFO_0009687', 'EFO_0004278', 'MONDO_0024290', 'EFO_0003948',
       'EFO_0004287', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0008623',
       'HP_0010992', 'MONDO_0007254', 'EFO_0000612', 'HP_0000726',
       'MONDO_0002009', 'EFO_0002496', 'HP_0003419', 'EFO_0010282'],
      dtype=object), 'count': 20}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1171754,O=C(c1ccc(Oc2ccc(F)cc2)nc1)N1CCCN(C2CCC2)CC1,IQOWHZHNGJXGHG-UHFFFAOYSA-N,Small molecule,False,JNJ-39220675,,2.0,,False,False,[],['Jnj 39220675' 'Jnj-39220675'],"[('drugbank', array(['DB12929'], dtype=object))]",,"{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1200776,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl,QANQWUQOEJZMLL-PKLMIRHRSA-N,Small molecule,False,CINACALCET HYDROCHLORIDE,2004.0,4.0,CHEMBL1201284,False,True,['Mimpara' 'Sensipar'],"['AMG-073' 'AMG-073 HCL' 'AMG073 HCL' 'AMG073 HYDROCHLORIDE'
 'Cinacalcet hcl' 'Cinacalcet hydrochloride']","[('DailyMed', array(['cinacalcet%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara'],
      dtype=object)), ('PubChem', array(['144206207', '170465336'], dtype=object)), ('chEBI', array(['48391'], dtype=object))]",,"{'rows': array(['EFO_1001173', 'HP_0003072', 'EFO_0000673', 'EFO_0000313',
       'EFO_0003884', 'EFO_1000456', 'EFO_0008506'], dtype=object), 'count': 7}",[ENSG00000036828],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 1 investigational indication.
CHEMBL1201262,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,OCUJLLGVOUDECM-UHFFFAOYSA-N,Small molecule,False,DIPIVEFRIN,1980.0,4.0,,False,True,[],['DPE' 'Dipivalyl epinephrine' 'Dipivefrin' 'Dipivefrine'],"[('Wikipedia', array(['Dipivefrine'], dtype=object)), ('drugbank', array(['DB00449'], dtype=object)), ('chEBI', array(['4646'], dtype=object))]",['CHEMBL1200833'],"{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for glaucoma.
CHEMBL1201513,,,Oligosaccharide,False,HEPARIN CALCIUM,1982.0,4.0,,False,True,['Calciparine' 'Uniparin ca'],['Ecasolv' 'Heparin calcium' 'Heparin calcium salt' 'Heparinum calcicum'],,,"{'rows': array(['EFO_1000954', 'EFO_1000965'], dtype=object), 'count': 2}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 2 investigational indications.
CHEMBL1201828,,,Antibody,True,ECULIZUMAB,2007.0,4.0,,False,True,['Soliris'],"['5G1.1' 'ABP-959' 'Alexion' 'Eculizumab' 'Elizaria' 'H5G1-1' 'H5G1.1'
 'H5G1.1VHC+H5G1.1VLC' 'H5G11']","[('DailyMed', array(['eculizumab'], dtype=object)), ('DrugCentral', array(['4969'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/soliris'],
      dtype=object)), ('Wikipedia', array(['Eculizumab'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'EFO_0001365', 'EFO_0004826', 'EFO_0007292',
       'MONDO_0100096', 'MONDO_0001549', 'EFO_0009473', 'EFO_1001311',
       'EFO_0004256', 'EFO_0004599', 'MONDO_0016244', 'EFO_0000668',
       'MONDO_0018922', 'MONDO_0019736', 'MONDO_0100244', 'EFO_0004991',
       'HP_0001873', 'EFO_0003884', 'MONDO_0018904', 'EFO_0000565',
       'EFO_0000398', 'EFO_0000540'], dtype=object), 'count': 22}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1722,COC(=O)C(c1ccccc1)C1CCCCN1.Cl,JUMYIBMBTDDLNG-UHFFFAOYSA-N,Small molecule,True,METHYLPHENIDATE HYDROCHLORIDE,1955.0,4.0,CHEMBL796,False,True,"['Adhansia xr' 'Aptensio xr' 'Concerta' 'Delmosart' 'Equasym' 'Equasym xl'
 'Jornay pm' 'Matoride xl' 'Medikinet' 'Medikinet xl' 'Metadate cd'
 'Metadate er' 'Methylin' 'Methylin er' 'Methylphenidate hydrochloride'
 'Quillichew er' 'Quillivant xr' 'Relexxii' 'Ritalin' 'Ritalin la'
 'Ritalin sr' 'Ritalin-sr' 'Tranquilyn' 'Xenidate xl']","['Aptensio' 'Aptensio xr' 'Foquest' 'Metadate' 'Methylphenidate HCl'
 'Methylphenidate hcl' 'Methylphenidate hydrochloride'
 'Methylphenidate hydrochloride cii' 'NSC-169868' 'Oros mph' 'Quillichew'
 'Quillivant' 'SPD-544' 'SPD544']","[('DailyMed', array(['methylphenidate%20hydrochloride'], dtype=object)), ('PubChem', array(['144204737', '144207507', '17389819'], dtype=object)), ('chEBI', array(['31836'], dtype=object))]",,"{'rows': array(['EFO_0003888', 'MONDO_0005090', 'EFO_0004216', 'MONDO_0004992',
       'EFO_0008568', 'HP_0012378', 'EFO_0003840', 'MONDO_0011184',
       'EFO_0003929', 'EFO_0003768', 'MONDO_0002050'], dtype=object), 'count': 11}","[ENSG00000103546,ENSG00000142319]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743048,,,Antibody,True,OBINUTUZUMAB,2013.0,4.0,,False,True,['Gazyvaro'],"['AFUTUZUMAB' 'Afutuzumab' 'GA-101' 'GA101' 'Gazyva' 'HUMAB CD20'
 'HUMAB<CD20>' 'HUMABCD20' 'Obinutuzumab' 'R-7159' 'RG-7159' 'RO 5072759'
 'RO 5072759 HUMAB<CD20>' 'RO-5072759' 'RO-5072759 HUMAB<CD20>'
 'Ro5072759']","[('DailyMed', array(['obinutuzumab'], dtype=object)), ('DrugCentral', array(['4983'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro'],
      dtype=object))]",,"{'rows': array(['MONDO_0001023', 'EFO_0005761', 'EFO_0000220', 'EFO_0004255',
       'EFO_1001469', 'EFO_0005952', 'EFO_1001951', 'EFO_0008528',
       'MONDO_0004992', 'EFO_0000574', 'MONDO_0018906', 'EFO_0009441',
       'EFO_0000565', 'EFO_0000403', 'MONDO_0007915', 'EFO_0003060',
       'MONDO_0013730', 'EFO_0004236', 'EFO_1001051', 'EFO_0003086',
       'EFO_0003884', 'EFO_0000309', 'EFO_0000095', 'EFO_0000096',
       'EFO_0000183', 'EFO_0000616', 'EFO_1000956'], dtype=object), 'count': 27}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2016681,CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)Nc2ccc(C(F)(F)F)cn2)CC1,WGEWUYACXPEFPO-AULYBMBSSA-N,Small molecule,False,VELNEPERIT,,2.0,,False,False,[],['S-2367' 'Velneperit'],"[('drugbank', array(['DB12889'], dtype=object))]",,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}",[ENSG00000164129],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108027,,,Protein,True,DULAGLUTIDE,2014.0,4.0,,False,True,['Trulicity'],['Dulaglutide' 'LY-2189265' 'LY2189265'],"[('DailyMed', array(['dulaglutide'], dtype=object)), ('DrugCentral', array(['4885'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity'],
      dtype=object))]",,"{'rows': array(['EFO_0004319', 'MONDO_0005147', 'MONDO_0005148', 'EFO_0000400',
       'EFO_0003884', 'HP_0001959'], dtype=object), 'count': 6}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109664,,,Antibody,False,ELDELUMAB,,2.0,,False,False,[],['BMS-936557' 'Eldelumab' 'MDX-1100'],,,"{'rows': array(['EFO_0000729', 'EFO_0000384', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000169245],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2397415,Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12,JJVAPHYEOZSKJZ-JGCGQSQUSA-N,Small molecule,False,ZAVEGEPANT,2023.0,4.0,,False,True,[],['BHV-3500' 'BMS-742413' 'BMS-742413-01' 'Vazegepant' 'Zavegepant'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZAVEGEPANT/relevant/1/'],
      dtype=object))]",['CHEMBL4650220'],"{'rows': array(['MONDO_0005277', 'MONDO_0004979', 'MONDO_0005277', 'MONDO_0100096'],
      dtype=object), 'count': 4}","[ENSG00000064989,ENSG00000132329]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for migraine disorder and has 3 investigational indications.
CHEMBL313972,C[C@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1,HCZKYJDFEPMADG-TXEJJXNPSA-N,Small molecule,False,MASOPROCOL,1992.0,4.0,,False,True,['Actinex'],"['CHX-100' 'Dihydronorguaiaretic acid' 'Dinorguaiaretic acid, dihydro-'
 'INSM-18' 'Insm-18' 'Insm18' 'MESO-NDGA' 'Masoprocol'
 'Meso-nordihydroguaiaretic acid' 'NSC-4291' 'NSC-682984'
 'Nordihydroguaiaretate' 'Nordihydroguaiaretic acid'
 'Nordihydroguiaretic acid' 'Oristar nhga']","[('PubChem', array(['11111540', '11111541', '124891671', '144203761', '50100292',
       '50106727', '50106728', '90341429'], dtype=object)), ('Wikipedia', array(['Masoprocol'], dtype=object)), ('drugbank', array(['DB00179'], dtype=object)), ('chEBI', array(['73468'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 2}","[ENSG00000140443,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for neoplasm and has 1 investigational indication.
CHEMBL346631,CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCOC(=O)CN(C)C)Cc1ccccc1-4)C(=O)NC3,UHEBDUAFKQHUBV-UHFFFAOYSA-N,Small molecule,False,CEP-7055,,1.0,,False,False,[],['CEP-7055' 'Cep-7055'],,,,"[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545010,CCN1CCC(c2cccc(S(C)(=O)=O)c2F)CC1,UKUPJASJNQDHPH-UHFFFAOYSA-N,Small molecule,False,ORDOPIDINE,,2.0,,False,False,[],['ACR-325' 'ACR325' 'Acr325' 'Ordopidine'],,,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545159,,,Small molecule,False,R-333,,2.0,,False,False,[],['R-333'],,,"{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}","[ENSG00000165025,ENSG00000105639]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545369,NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,FBKMWOJEPMPVTQ-UHFFFAOYSA-N,Small molecule,False,EPACADOSTAT,,3.0,,False,False,[],['Epacadostat' 'INCB-024360' 'INCB024360'],"[('drugbank', array(['DB11717'], dtype=object))]",,"{'rows': array(['EFO_0000691', 'EFO_0000702', 'MONDO_0005184', 'MONDO_0002158',
       'EFO_0000196', 'Orphanet_145', 'MONDO_0008903', 'MONDO_0044881',
       'EFO_0000222', 'EFO_1000251', 'EFO_0003863', 'MONDO_0001187',
       'MONDO_0002087', 'EFO_0000181', 'EFO_0008528', 'EFO_0000616',
       'EFO_0006859', 'EFO_1000657', 'EFO_1001512', 'EFO_0003060',
       'EFO_0000756', 'EFO_0000574', 'MONDO_0011719', 'EFO_0000519',
       'EFO_0000681', 'EFO_1000576', 'MONDO_0008170', 'EFO_0000389',
       'EFO_0001075', 'EFO_0000198', 'MONDO_0011962'], dtype=object), 'count': 31}",[ENSG00000131203],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 31 investigational indications.
CHEMBL3545391,CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C,DFELGYQKEOCHOA-RBXNTRDFSA-N,Small molecule,False,ORG-34517,,2.0,,False,False,[],"['ORG 34517' 'ORG-34517' 'ORG34517' 'Org-34517' 'PT-150' 'PT150' 'Pt150'
 'SCH 900636' 'SCH-900636']",,,"{'rows': array(['MONDO_0002050', 'MONDO_0007079', 'MONDO_0002009'], dtype=object), 'count': 3}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3682589,O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc3ccccc3c2C2CC2)cc1,CWEFDWIKLABKBX-UHFFFAOYSA-N,Small molecule,False,ELISMETREP,,2.0,,False,False,[],['Elismetrep' 'MT-8554' 'Mt-8554'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELISMETREP/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15287'], dtype=object))]",,"{'rows': array(['EFO_1000783', 'HP_0031217'], dtype=object), 'count': 2}",[ENSG00000144481],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3990033,,,Oligonucleotide,False,INCLISIRAN,,3.0,,False,False,[],['ALN-60212' 'ALN-PCSSC' 'ALN-PSCsc' 'Inclisiran' 'Leqvio'],,,"{'rows': array(['HP_0003124', 'EFO_0005672', 'EFO_0003086', 'EFO_0004911',
       'EFO_0000319', 'EFO_0003914', 'EFO_0001645', 'MONDO_0021187',
       'MONDO_0018328'], dtype=object), 'count': 9}",[ENSG00000169174],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL4210847,CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21,ZUHZNKJIJDAJFD-UHFFFAOYSA-N,Small molecule,False,PF-00489791,,2.0,,False,False,[],"['PF-489,791' 'Pf-00489791' 'UK-489,791']","[('drugbank', array(['DB11736'], dtype=object))]",,"{'rows': array(['EFO_0001361', 'EFO_0000401', 'EFO_1001145', 'EFO_0000537'],
      dtype=object), 'count': 4}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297184,Cc1ccc(-c2nc(N)nc3c2nnn3Cc2cccc(CO[C@H]3CCOC3)n2)o1,KURQKNMKCGYWRJ-HNNXBMFYSA-N,Small molecule,False,CIFORADENANT,,2.0,,False,False,[],['CPI-444' 'Ciforadenant' 'V-81444' 'V81444'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CIFORADENANT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000681', 'EFO_0000616', 'EFO_0001378',
       'EFO_0003888', 'MONDO_0005180'], dtype=object), 'count': 6}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4297228,,,Unknown,False,BRIVOLIGIDE,,2.0,,False,False,[],['AYX-1' 'AYX1' 'Brivoligide'],,,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000120738],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297345,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1.Cl,XROFSGVHHSJMMG-UHFFFAOYSA-N,Small molecule,False,ADL-5747,,2.0,CHEMBL561339,False,False,[],['ADL5747' 'Adl-5747' 'Adl5747'],,,"{'rows': array(['MONDO_0041052', 'EFO_0004616'], dtype=object), 'count': 2}",[ENSG00000116329],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297750,,,Antibody,False,FARICIMAB,2022.0,4.0,,False,True,['Vabysmo'],"['Faricimab' 'Faricimab svoa' 'Faricimab-svoa' 'RG7716' 'RG77161'
 'RO-6867461' 'RO6867461' 'Rg-7716' 'Ro6867461' 'Vabysmo' 'Y8ha1i28d3']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FARICIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0000478', 'EFO_0009606', 'MONDO_0007935', 'EFO_0010977',
       'EFO_0001365', 'EFO_0005753', 'MONDO_0003005', 'EFO_0004683'],
      dtype=object), 'count': 8}","[ENSG00000112715,ENSG00000091879]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 5 approved and 3 investigational indications.
CHEMBL4303404,Cc1noc2c1-c1ccccc1C(c1ccc(Cl)cc1)=N[C@H]2CC(N)=O,GCWIQUVXWZWCLE-INIZCTEOSA-N,Small molecule,False,PELABRESIB,,3.0,,False,False,[],"['CPI-0610' 'CPI-232' 'CPI-267232' 'Cpi 0610' 'Cpi-0610'
 'Cpi-0610 anhydrous' 'Pelabresib' 'Pelabresib anhydrous'
 'Pelabresib monohydrate']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PELABRESIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0044903', 'EFO_0002430', 'EFO_0002431', 'EFO_0000574',
       'EFO_0001378'], dtype=object), 'count': 5}","[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL482950,CC[C@@H](C)Nc1nc(C)nc2c(-c3ccc(OC)nc3C)c(C)nn12,LBWQSAZEYIZZCE-SNVBAGLBSA-N,Small molecule,False,PEXACERFONT,,3.0,,False,False,[],['BMS-562086' 'Bms562086' 'CRF1 ANTAGONIST' 'Dpc-a69448' 'Pexacerfont'],"[('drugbank', array(['DB12572'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0000555', 'EFO_1001892'], dtype=object), 'count': 3}",[ENSG00000120088],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL483321,COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1,LLVZBTWPGQVVLW-SNAWJCMRSA-N,Small molecule,False,CP-724714,,2.0,,False,False,[],"['CP-724,714' 'CP-724714' 'Cp-724714']","[('PubChem', array(['50100096'], dtype=object)), ('drugbank', array(['DB12302'], dtype=object))]",,"{'rows': array(['EFO_0003869', 'MONDO_0007254', 'EFO_0009708'], dtype=object), 'count': 3}",[ENSG00000141736],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL517427,COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,FAIIFDPAEUKBEP-UHFFFAOYSA-N,Small molecule,False,NILVADIPINE,,3.0,,False,False,[],"['CL 287,389' 'CL-287,389' 'CL-287389' 'Dl-nilvadipine' 'Escor' 'FK 235'
 'FK-235' 'FR-34235' 'Nilvadipine' 'Nivadil' 'Nivadip' 'Nivadipine'
 'SK&F 102,362' 'SKF-102362']","[('PubChem', array(['144205992', '50112689'], dtype=object)), ('Wikipedia', array(['Nilvadipine'], dtype=object)), ('drugbank', array(['DB06712'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0000319'], dtype=object), 'count': 2}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL960,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,VHOGYURTWQBHIL-UHFFFAOYSA-N,Small molecule,True,LEFLUNOMIDE,1998.0,4.0,,False,True,"['Arava' 'Leflunomide'
 'Leflunomide zentiva (previously leflunomide winthrop)']","['HWA-486' 'L04AA13' 'Leflunomide' 'Leflunomide medac'
 'Leflunomide ratiopharm' 'Leflunomide teva' 'Leflunomide winthrop'
 'NSC-677411' 'NSC-759864' 'Repso' 'SU-101' 'SU101' 'SULOL']","[('DailyMed', array(['leflunomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-zentiva'],
      dtype=object)), ('PubChem', array(['11111382', '11111383', '124880563', '124880568', '144203733',
       '144212190', '170464823', '174006674', '26746985', '26746986',
       '26746987', '50100264', '50104054', '50104055', '50104056',
       '56422128', '85231115', '855764', '90341277'], dtype=object)), ('Wikipedia', array(['Leflunomide'], dtype=object)), ('drugbank', array(['DB01097'], dtype=object)), ('chEBI', array(['6402'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'MONDO_0007915', 'EFO_0003778', 'EFO_0000764',
       'EFO_0005761', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000616',
       'EFO_0000540', 'EFO_0003073', 'MONDO_0100096', 'EFO_0004991',
       'EFO_1000965', 'MONDO_0016537', 'EFO_0008518', 'EFO_1000158',
       'EFO_1001231', 'EFO_0000685', 'MONDO_0020547', 'MONDO_0007254',
       'EFO_0007187', 'EFO_0000699'], dtype=object), 'count': 22}",[ENSG00000102967],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1133,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl,SWIJYDAEGSIQPZ-UHFFFAOYSA-N,Small molecule,False,OXYBUTYNIN CHLORIDE,1975.0,4.0,CHEMBL1231,False,True,['Ditropan' 'Ditropan xl' 'Gelnique' 'Oxybutynin chloride'],"['5058' 'MJ 4309-1' 'MJ-4309-1' 'NSC-759108' 'Oxybutynin chloride'
 'Oxybutynin hydrochloride' 'Pollakisu' 'Tropax']","[('DailyMed', array(['oxybutynin%20chloride'], dtype=object)), ('PubChem', array(['144204058', '50106787', '50106788', '56422498', '855604'],
      dtype=object)), ('chEBI', array(['7857'], dtype=object))]",,"{'rows': array(['EFO_0006865', 'HP_0000020', 'EFO_0001663', 'EFO_1000781'],
      dtype=object), 'count': 4}","[ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and is indicated for urgency urinary incontinence and overactive bladder and has 2 investigational indications.
CHEMBL1201064,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,YRFXGQHBPBMFHW-SBTZIJSASA-N,Small molecule,False,FLUOROMETHOLONE ACETATE,1986.0,4.0,,False,True,['Flarex'],"['Fluorometholone 17-acetate' 'Fluorometholone acetate' 'NSC-47438'
 'U-17,323' 'U-17323']","[('DailyMed', array(['fluorometholone%20acetate'], dtype=object)), ('PubChem', array(['100431'], dtype=object)), ('chEBI', array(['78354'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986.
CHEMBL1289494,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,SPMVMDHWKHCIDT-UHFFFAOYSA-N,Small molecule,False,TIVOZANIB,2017.0,4.0,,False,True,['Fotivda'],['ASP-4130' 'AV-951' 'KIL8951' 'KRN-951' 'Kil-8951' 'Krn-951' 'Tivozanib'],"[('PubChem', array(['124955473'], dtype=object)), ('Wikipedia', array(['Tivozanib'], dtype=object)), ('drugbank', array(['DB11800'], dtype=object))]",['CHEMBL2105756' 'CHEMBL3426917' 'CHEMBL4784300'],"{'rows': array(['EFO_0005221', 'MONDO_0002158', 'EFO_0000681', 'EFO_0001421',
       'EFO_1001951', 'EFO_0000519', 'MONDO_0008315', 'EFO_0000182',
       'EFO_0000616', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001968',
       'MONDO_0007254', 'EFO_0000681', 'EFO_0003060'], dtype=object), 'count': 15}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157404,ENSG00000113721]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for renal cell carcinoma and has 14 investigational indications.
CHEMBL1477,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,SEERZIQQUAZTOL-ANMDKAQQSA-N,Small molecule,False,CERIVASTATIN,1997.0,4.0,,True,True,['Lipobay'],['Baycol' 'Cerivastatin' 'Lipobay'],"[('PubChem', array(['50111694'], dtype=object)), ('Wikipedia', array(['Cerivastatin'], dtype=object)), ('drugbank', array(['DB00439'], dtype=object)), ('chEBI', array(['3558'], dtype=object))]",['CHEMBL1200563'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for cardiovascular disease. It was withdrawn in at least one region.
CHEMBL1715,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,GHUUBYQTCDQWRA-UHFFFAOYSA-N,Small molecule,True,PIOGLITAZONE HYDROCHLORIDE,1999.0,4.0,CHEMBL595,False,True,"['Actos' 'Diabiom' 'Glidipion'
 'Glidipion (previously pioglitazone actavis group)' 'Glizofar'
 'Pioglitazone hydrochloride']","['Actos' 'NSC-758876' 'Pioglitazone (as hydrochloride)' 'Pioglitazone hcl'
 'Pioglitazone hydrochloride' 'Piomed' 'STR-001' 'U-72107A']","[('DailyMed', array(['pioglitazone%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion'],
      dtype=object)), ('PubChem', array(['144204993', '144210901', '170465116', '26748968', '49681546'],
      dtype=object))]",,"{'rows': array(['HP_0002745', 'MONDO_0004976', 'EFO_0002618', 'MONDO_0005148',
       'EFO_0003095', 'EFO_0001421', 'EFO_0003884', 'MONDO_0002009',
       'EFO_0003060'], dtype=object), 'count': 9}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for type 2 diabetes mellitus and liver disease and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743041,,,Antibody,False,MOGAMULIZUMAB,2018.0,4.0,,False,True,['Poteligeo'],"['AMG-761' 'KM-8761' 'KM8761' 'KW-0761' 'Mogamulizumab'
 'Mogamulizumab (genetical recombination)' 'Mogamulizumab kpkc']","[('DailyMed', array(['mogamulizumab-kpkc'], dtype=object)), ('DrugCentral', array(['5031'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/poteligeo'],
      dtype=object))]",,"{'rows': array(['EFO_0000313', 'EFO_0000616', 'EFO_0002913', 'EFO_0007527',
       'EFO_1001051', 'MONDO_0004979', 'EFO_0003060', 'EFO_0000182',
       'MONDO_0019471', 'EFO_0000211', 'EFO_1000785'], dtype=object), 'count': 11}",[ENSG00000183813],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 8 investigational indications.
CHEMBL1774080,O=C1CCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)nc2N1,QGNOXTFZOLDODX-UHFFFAOYSA-N,Small molecule,False,PF-00217830,,2.0,,False,False,[],['J2.975.999E' 'PF-00217830' 'PF-217830' 'Pf-00217830'],"[('drugbank', array(['DB12998'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL178,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,STQGQHZAVUOBTE-VGBVRHCVSA-N,Small molecule,True,DAUNORUBICIN,1979.0,4.0,,False,True,['Daunoxome'],"['Cerubidine' 'Daunomycin' 'Daunorubicin' 'Daunoxome'
 'Epirubicin hydrochloride impurity, daunorubicin-' 'FI 6339' 'FI-6339'
 'NSC-83142' 'RP 13057' 'RP-13057' 'Valrubicin impurity, daunorubicin']","[('DailyMed', array(['daunorubicin'], dtype=object)), ('PubChem', array(['11114094', '144204447', '170465048', '29215022'], dtype=object)), ('Wikipedia', array(['Daunorubicin'], dtype=object)), ('drugbank', array(['DB00694'], dtype=object)), ('chEBI', array(['41977'], dtype=object))]",['CHEMBL1563' 'CHEMBL1200475'],"{'rows': array(['MONDO_0044881', 'EFO_0000220', 'MONDO_0000873', 'EFO_0000558',
       'MONDO_0004643', 'EFO_0000565', 'EFO_0003028', 'EFO_0003811',
       'EFO_0004289', 'EFO_0004251', 'EFO_0000218', 'EFO_0000198',
       'EFO_0000209', 'MONDO_0044917', 'EFO_0003802', 'MONDO_0000870',
       'EFO_0000565', 'EFO_0000224', 'EFO_0003025', 'EFO_0000221',
       'MONDO_0000870', 'MONDO_0007254', 'EFO_0000691', 'EFO_0000094',
       'EFO_0003884', 'EFO_0000094', 'MONDO_0044917', 'MONDO_0044903',
       'EFO_0000222', 'EFO_0000574', 'EFO_0000616', 'EFO_0000565',
       'EFO_0000223', 'EFO_0004239', 'EFO_0004289', 'EFO_0000198',
       'EFO_0000479', 'EFO_0000220', 'EFO_0005952', 'EFO_0000222',
       'EFO_0000339', 'EFO_0003029', 'EFO_0000691', 'EFO_0002429',
       'EFO_0003027', 'EFO_0003802', 'EFO_1001779', 'EFO_1001052'],
      dtype=object), 'count': 48}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 3 approved and 41 investigational indications. This drug has a black box warning from the FDA.
CHEMBL178803,CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1,XVGOZDAJGBALKS-UHFFFAOYSA-N,Small molecule,False,BLONANSERIN,2008.0,4.0,,False,True,[],['AD-5423' 'Blonanserin' 'DSP-5423'],"[('PubChem', array(['144206818'], dtype=object)), ('drugbank', array(['DB09223'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}","[ENSG00000102468,ENSG00000149295,ENSG00000151577]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and has 1 investigational indication.
CHEMBL2106227,CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1,IBYCYJFUEJQSMK-UHFFFAOYSA-N,Small molecule,False,ETIFOXINE,,3.0,,False,False,[],['36-801' 'Etifoxine' 'HOE 36801' 'HOE-36801'],"[('drugbank', array(['DB08986'], dtype=object))]",,"{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108282,,,Protein,False,CATRIDECACOG,2012.0,4.0,,False,True,['Novothirteen'],['Catridecacog' 'Novothirteen' 'Tretten'],"[('DrugCentral', array(['5134'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/novothirteen'],
      dtype=object))]",,"{'rows': array(['Orphanet_183654', 'MP_0001914', 'MONDO_0018029', 'MONDO_0002243'],
      dtype=object), 'count': 4}",[ENSG00000124491],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for rare genetic coagulation disorder and hemorrhage and has 2 investigational indications.
CHEMBL2109662,,,Protein,False,DALANTERCEPT,,3.0,,False,False,[],['ACE-041' 'Dalantercept' 'Delantercept'],,,"{'rows': array(['EFO_0000681', 'EFO_0000182', 'EFO_0004142', 'EFO_0000181',
       'EFO_0001378'], dtype=object), 'count': 5}","[ENSG00000163217,ENSG00000263761]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2336325,CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,JUSFANSTBFGBAF-IRXDYDNUSA-N,Small molecule,False,VISTUSERTIB,,2.0,,False,False,[],['AZD-2014' 'AZD2014' 'Azd-2014' 'Vistusertib'],"[('drugbank', array(['DB11925'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000707', 'MONDO_0004992', 'MONDO_0007254',
       'EFO_0005537', 'EFO_0000702', 'EFO_0003897', 'EFO_1000251',
       'MONDO_0016642', 'MONDO_0001187', 'EFO_0000708', 'MONDO_0008315',
       'EFO_0000519', 'EFO_0000349', 'EFO_0000228', 'EFO_0000503',
       'EFO_0003060', 'EFO_1001512', 'EFO_0000403', 'EFO_0007532',
       'Orphanet_145'], dtype=object), 'count': 21}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 21 investigational indications.
CHEMBL256147,CNC(=N)NCCC[C@H](N)C(=O)O,NTNWOCRCBQPEKQ-YFKPBYRVSA-N,Small molecule,False,TILARGININE,,3.0,,False,False,[],"['.omega.-n-methylarginine' 'L-NMMA' 'Ng-methylarginine'
 'Ng-monomethyl-l-arginine' 'Omega-n-methylarginine'
 'Omega-n-methylated arginine' 'Targinine' 'Tilarginine']","[('PubChem', array(['11111490', '11113694', '90340995'], dtype=object)), ('Wikipedia', array(['Methylarginine'], dtype=object)), ('drugbank', array(['DB11815'], dtype=object)), ('chEBI', array(['28229'], dtype=object))]",['CHEMBL3217190' 'CHEMBL1256175' 'CHEMBL1744478'],"{'rows': array(['MONDO_0007254', 'EFO_0004272', 'EFO_1000859', 'EFO_0600064',
       'EFO_0000764', 'EFO_1000653', 'MONDO_0011382', 'MONDO_0021187',
       'HP_0031273', 'EFO_0009444'], dtype=object), 'count': 10}","[ENSG00000089250,ENSG00000007171,ENSG00000164867]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL3337527,CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O,HYOGJHCDLQSAHX-UHFFFAOYSA-N,Small molecule,False,JNJ-40411813,,2.0,,False,False,[],['ADX-71149' 'Jnj-40411813'],"[('drugbank', array(['DB12059'], dtype=object))]",,"{'rows': array(['HP_0001250', 'MONDO_0002009', 'MONDO_0005090', 'MONDO_0024417'],
      dtype=object), 'count': 4}",[ENSG00000164082],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL360328,C[C@H]1CNCCc2ccc(Cl)cc21,XTTZERNUQAFMOF-QMMMGPOBSA-N,Small molecule,False,LORCASERIN,2012.0,4.0,,True,True,[],['Lorcaserin'],"[('PubChem', array(['144206569', '170466882'], dtype=object)), ('Wikipedia', array(['Lorcaserin'], dtype=object)), ('drugbank', array(['DB04871'], dtype=object)), ('chEBI', array(['65353'], dtype=object))]",['CHEMBL3527027' 'CHEMBL2095211'],"{'rows': array(['EFO_0003100', 'EFO_0005611', 'EFO_0003768', 'EFO_0007191',
       'EFO_0003086', 'EFO_0003890', 'EFO_0001421', 'EFO_0004319',
       'EFO_0001073', 'EFO_0010702', 'EFO_0002610', 'EFO_0000319',
       'EFO_0001073'], dtype=object), 'count': 13}",[ENSG00000147246],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for obesity and has 12 investigational indications. It was withdrawn in at least one region.
CHEMBL37744,CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1,OYPPVKRFBIWMSX-SXGWCWSVSA-N,Small molecule,False,ZIMELDINE,,4.0,,True,True,[],['Cis-zimelidine' 'Normud' 'Zelmid' 'Zimeldine' 'Zimelidine'],"[('PubChem', array(['50104953', '90340829'], dtype=object)), ('Wikipedia', array(['Zimelidine'], dtype=object)), ('drugbank', array(['DB04832'], dtype=object))]",['CHEMBL2355333' 'CHEMBL1257002' 'CHEMBL1257115'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder.
CHEMBL3889654,O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1,NYNZQNWKBKUAII-KBXCAEBGSA-N,Small molecule,False,LAROTRECTINIB,2018.0,4.0,,False,True,[],"['ARRY-470' 'BAY-2757556' 'BAY2757556' 'LOXO-101' 'Larotrectinib'
 'Loxo-101']","[('drugbank', array(['DB14723'], dtype=object))]",['CHEMBL3989939'],"{'rows': array(['EFO_0009708', 'MONDO_0002108', 'EFO_1000026', 'EFO_0000616',
       'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 6}","[ENSG00000198400,ENSG00000148053,ENSG00000140538]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications.
CHEMBL4298095,,,Antibody,False,NIMACIMAB,,2.0,,False,False,[],['JNJ-2463' 'JNJ2463' 'Nimacimab' 'RYI-018' 'RYI018' 'Ryi-018'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NIMACIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1000948', 'EFO_0003095'], dtype=object), 'count': 2}",[ENSG00000118432],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4559134,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1,XIIOFHFUYBLOLW-UHFFFAOYSA-N,Small molecule,False,SELPERCATINIB,2020.0,4.0,,False,True,['Retevmo' 'Retsevmo'],"['LOXO-292' 'LY-3527723' 'LY3527723' 'Loxo-292' 'Ret inhibitor loxo-292'
 'Selpercatinib']","[('DailyMed', array(['selpercatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SELPERCATINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000501', 'EFO_0001421', 'MONDO_0015277',
       'EFO_0000616', 'EFO_0003841', 'MONDO_0004992', 'HP_0000083',
       'EFO_0000641', 'MONDO_0002108'], dtype=object), 'count': 10}","[ENSG00000165731,ENSG00000170759,ENSG00000108091]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 7 approved and 3 investigational indications.
CHEMBL46516,O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2,QOYHHIBFXOOADH-UHFFFAOYSA-N,Small molecule,False,FLUSPIRILENE,,4.0,,False,True,['Imap' 'Redeptin'],['Fluspirilene' 'Imap' 'MCN-JR-6218' 'R 6218' 'R-6218' 'Redeptin'],"[('PubChem', array(['104171151', '11111163', '11112501', '11532937', '124880064',
       '124880066', '144203693', '170466307', '174006661', '26753577',
       '26753578', '50106303', '50106304', '56422781', '85231040',
       '90341058'], dtype=object)), ('Wikipedia', array(['Fluspirilene'], dtype=object)), ('drugbank', array(['DB04842'], dtype=object))]",,"{'rows': array(['EFO_0005407', 'EFO_0005230', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications.
CHEMBL5095030,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(N)=O)C(=O)N1)C(N)=O,JJVZSYKFCOBILL-DPNRMINZSA-N,Protein,False,MOTIXAFORTIDE,,3.0,,False,False,[],"['4F-BENZOYL-TN-14003' '4F-benzoyl-TN14003' 'BKT-140' 'BKT140' 'BL-8040'
 'Bkt140' 'Bl 8040' 'Motixafortide' 'T140' 'TF 14016' 'TF-14016' 'TF14016']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOTIXAFORTIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000198', 'EFO_0000616', 'EFO_0000220', 'EFO_0000503',
       'MONDO_0011382', 'EFO_0000339', 'EFO_0002916', 'HP_0001915',
       'EFO_0000222', 'EFO_0001378', 'EFO_0000183', 'MONDO_0000873'],
      dtype=object), 'count': 12}",[ENSG00000121966],Protein drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL5314395,CC(C)(C)c1nnc([C@H]2O[C@@H](n3cnc4c(Nc5ccc(Cl)cc5F)ncnc43)[C@H](O)[C@@H]2O)o1,ZQYJPMPXQLNTPQ-QCUYGVNKSA-N,Small molecule,False,GW493838,,2.0,,False,False,[],['GW-493838 X' 'GW-493838X' 'GW493838' 'Gw-493838' 'Gw493838'],,,"{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL679,CNC[C@H](O)c1ccc(O)c(O)c1,UCTWMZQNUQWSLP-VIFPVBQESA-N,Small molecule,False,EPINEPHRINE,1976.0,4.0,,False,True,"['Adren co' 'Adrenaclick' 'Adrenalin' 'Ana-Kit' 'Ana-guard' 'Anapen'
 'Anaphylactic shock drug kit' 'Asma-vydrin' 'Asthmahaler' 'Auvi-q'
 'Bronkaid mist' 'Brovon' 'Emerade' 'Epi e z pen jr' 'Epinephrine'
 'Epinephrine (copackaged)' 'Epipen' 'Epipen e z pen' 'Epipen jr'
 'Epipen jr.' 'Eppy' 'Gppe inh soln' 'Jext' 'Medihaler-epi' 'Primatene'
 'Primatene mist' 'Riddobron' 'Riddofan' 'Rybarvin' 'Simplene'
 'Soln made to rybarvin for' 'Sus-Phrine' 'Sus-Phrine Sulfite-Free'
 'Sus-phrine sulfite free' 'Symjepi' 'Twinject 0.15' 'Twinject 0.3']","['(-)-(r)-epinephrine' '(-)-epinephrine' 'Adrenaline' 'Adrenalinum'
 'Epinephrine' 'Epinephrine hcl' 'Epinephrine hydrochloride'
 'Epinephrinum' 'Glauposine' 'L-epinephrine hydrochloride'
 'Levo-methylaminoethanolcatechol' 'NSC-62786' 'Nephridine'
 'Racepinefrine hydrochloride, (r)-' 'Racepinefrine, (r)-'
 'Sus-phrine sulphite-free' 'Susphrine' 'Tonogen' 'Twinject']","[('DailyMed', array(['epinephrine'], dtype=object)), ('PubChem', array(['11111154', '144205115', '170464973', '26754418', '26754419',
       '26754420', '29215202', '90341589'], dtype=object)), ('Wikipedia', array(['Epinephrine'], dtype=object)), ('drugbank', array(['DB00668'], dtype=object)), ('chEBI', array(['28918'], dtype=object))]",['CHEMBL3183376' 'CHEMBL1256958' 'CHEMBL1200818' 'CHEMBL227634'],"{'rows': array(['MONDO_0001056', 'MONDO_0003061', 'EFO_0000319', 'EFO_0005532',
       'HP_0002105', 'EFO_0003060', 'EFO_0007355', 'EFO_1001250',
       'MONDO_0007254', 'EFO_0004198', 'EFO_0000544', 'EFO_0003895',
       'EFO_0000400', 'HP_0002239', 'EFO_0003956', 'EFO_0004278',
       'EFO_0006834', 'EFO_0004209', 'MONDO_0004979', 'HP_0001742',
       'HP_0011950', 'EFO_0003843', 'EFO_0007149', 'EFO_1001087',
       'EFO_0005251', 'HP_0100543', 'EFO_0009676', 'EFO_0004287',
       'MONDO_0100053', 'HP_0011499', 'HP_0006536', 'EFO_0000546',
       'EFO_0004610', 'MP_0001914', 'EFO_0005854', 'HP_0012532',
       'EFO_0003843', 'EFO_0009492', 'EFO_1001139', 'MONDO_0005041',
       'MONDO_0005271', 'EFO_0003144', 'HP_0031273', 'EFO_0009840',
       'EFO_0009846', 'EFO_0005306', 'EFO_1001417', 'EFO_0005531',
       'EFO_0007486', 'EFO_0004278', 'MONDO_0002050', 'EFO_1001222',
       'EFO_0004616'], dtype=object), 'count': 53}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 19 approved and 34 investigational indications.
CHEMBL1090479,CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1,QTBWCSQGBMPECM-UHFFFAOYSA-N,Small molecule,False,GSK-1070916,,1.0,,False,False,[],['GSK 1070916A' 'GSK1070916' 'Gsk-1070916' 'Gsk-1070916a'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000178999,ENSG00000105146]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1095292,CC[N+](C)(C)Cc1ccccc1Br.Cc1ccc(S(=O)(=O)[O-])cc1,KVWNWTZZBKCOPM-UHFFFAOYSA-M,Small molecule,False,BRETYLIUM TOSYLATE,1986.0,4.0,CHEMBL1199080,False,True,['Bretylium tosylate' 'Bretylol'],['ASL-603' 'Bretylium tosilate' 'Bretylium tosylate' 'NSC-62164'],"[('PubChem', array(['11111997', '11111998', '50104303', '85231294', '855621'],
      dtype=object)), ('chEBI', array(['3173'], dtype=object))]",,"{'rows': array(['EFO_0004287', 'HP_0004308', 'EFO_0004269'], dtype=object), 'count': 3}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications.
CHEMBL1200951,CCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,LRWSFOSWNAQHHW-UHFFFAOYSA-N,Small molecule,False,FLUPHENAZINE ENANTHATE,1967.0,4.0,,False,True,['Moditen enant' 'Prolixin enanthate'],"['Flufenan' 'Fluphenazine enantate' 'Fluphenazine enanthate'
 'Fluphenazine maleate' 'Fluphenazini enantas' 'SQ 16,114' 'SQ 16144']","[('chEBI', array(['5125'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'EFO_0000676', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 5 investigational indications.
CHEMBL1201167,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O,XCPXNPBILMXKNX-UHFFFAOYSA-N,Small molecule,False,CARVEDILOL PHOSPHATE,2006.0,4.0,CHEMBL723,False,True,['Coreg cr'],"['Carvedilol phosphate' 'Carvedilol phosphate hemihydrate'
 'Carvedilol phosphate hydrate' 'SK&F-105517-D' 'SKF 105517D'
 'SKF-105517D']","[('DailyMed', array(['carvedilol%20phosphate'], dtype=object))]",,"{'rows': array(['EFO_0000373', 'EFO_0000612', 'EFO_0000537'], dtype=object), 'count': 3}","[ENSG00000043591,ENSG00000169252,ENSG00000188778,ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for myocardial infarction and hypertension and has 1 investigational indication.
CHEMBL1201863,Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1,MJIHNNLFOKEZEW-RUZDIDTESA-N,Small molecule,False,DEXLANSOPRAZOLE,2009.0,4.0,,False,True,['Dexilant' 'Dexilant solutab' 'Kapidex'],"['(r)-lansoprazole' 'Dexlansoprazole' 'Kapidex' 'Lansoprazole r-form'
 'Lansoprazole, (r)-' 'NSC-758710' 'T-168390' 'TAK-390']","[('DailyMed', array(['dexlansoprazole'], dtype=object)), ('Wikipedia', array(['Dexlansoprazole'], dtype=object)), ('drugbank', array(['DB05351'], dtype=object))]",,"{'rows': array(['EFO_0000280', 'EFO_0003948', 'EFO_1001095', 'HP_0004398',
       'HP_0100633'], dtype=object), 'count': 5}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 2 investigational indications.
CHEMBL250270,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1,ZDXUKAKRHYTAKV-UHFFFAOYSA-N,Small molecule,False,LERCANIDIPINE,,4.0,,False,True,[],['Lercanidipine' 'Lercanil'],"[('PubChem', array(['50112745', '90340703'], dtype=object)), ('Wikipedia', array(['Lercanidipine'], dtype=object)), ('drugbank', array(['DB00528'], dtype=object))]",['CHEMBL2106419'],"{'rows': array(['EFO_0000537', 'MONDO_0001134', 'EFO_0000319'], dtype=object), 'count': 3}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL3188267,CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F,LIOLIMKSCNQPLV-UHFFFAOYSA-N,Small molecule,False,CAPMATINIB,2020.0,4.0,,False,True,[],"['Capmatinib' 'INC-280' 'INC280' 'INCB-28060' 'INCB-28060 FREE BASE'
 'Incb-28060' 'NVP-INC280' 'NVP-INC280-NX' 'NYP-INC280-NX']","[('PubChem', array(['174006562'], dtype=object)), ('drugbank', array(['DB11791'], dtype=object))]",['CHEMBL3989937'],"{'rows': array(['MONDO_0008903', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0002367',
       'EFO_0003060', 'MONDO_0004992', 'EFO_0000756', 'EFO_1001968',
       'EFO_0000519', 'EFO_0000389', 'EFO_0000616', 'EFO_0001421',
       'EFO_0003060'], dtype=object), 'count': 13}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 10 investigational indications.
CHEMBL3716057,COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O,HLWURFKMDLAKOD-UHFFFAOYSA-N,Small molecule,False,GEFAPIXANT,,3.0,,False,False,[],"['AF-219' 'Af-219' 'Gefapixant' 'R-1646' 'R1646' 'RG-1646' 'RG1646'
 'RO-4926219' 'RO4926219']","[('drugbank', array(['DB15097'], dtype=object))]",['CHEMBL4594278'],"{'rows': array(['MONDO_0004979', 'EFO_0004616', 'HP_0012735', 'EFO_0000768',
       'HP_0000083', 'EFO_0008507', 'EFO_0003918'], dtype=object), 'count': 7}",[ENSG00000109991],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4094894,CC(C)c1cccc([C@H](C)C2CC2)c1O,BMEARIQHWSVDBS-SNVBAGLBSA-N,Small molecule,False,CIPEPOFOL,,3.0,,False,False,[],"['Cipepofol' 'Ciprofol' 'HSK-3486' 'HSK-3486, (R)-' 'HSK3486' 'Hsk-3486'
 'Hsk3486']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",,"{'rows': array(['MONDO_0002050', 'EFO_0003086'], dtype=object), 'count': 2}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4297837,,,Antibody,False,TALACOTUZUMAB,,2.0,,False,False,[],['CSL-362' 'CSL362' 'Csl362' 'JNJ-56022473' 'Jnj-56022473' 'Talacotuzumab'],,,"{'rows': array(['EFO_0000198', 'MONDO_0007915', 'EFO_0000222'], dtype=object), 'count': 3}","[ENSG00000292332,ENSG00000185291]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4790100,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1,JLRIJKVMMZEKDF-UHFFFAOYSA-N,Small molecule,False,AKN-028,,2.0,,False,False,[],['Akn-028'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000122025],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL622,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,NNYBQONXHNTVIJ-UHFFFAOYSA-N,Small molecule,True,ETODOLAC,1991.0,4.0,,False,True,"['Ebretin' 'Etodolac' 'Etolyn' 'Etopan xl' 'Lodine' 'Lodine sr'
 'Lodine xl' 'Ramodar']","['(rs)-etodolic acid' 'AY-24,236' 'AY-24-236' 'AY-24236' 'Eccoxolac'
 'Edolan' 'Etodolac' 'Etodolic acid' 'Flancox' 'Lodin xl' 'NIH-9918'
 'NSC-282126' 'Napilac' 'Tedolan' 'Ultradol' 'Zedolac']","[('DailyMed', array(['etodolac'], dtype=object)), ('PubChem', array(['144209416', '170464915', '174007213', '50105240', '56422166',
       '85231029', '855612', '90340662'], dtype=object)), ('Wikipedia', array(['Etodolac'], dtype=object)), ('drugbank', array(['DB00749'], dtype=object)), ('chEBI', array(['4909'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0003843', 'EFO_0000685', 'EFO_0002609',
       'EFO_0004142', 'EFO_0002970', 'EFO_0009582', 'EFO_0005755',
       'EFO_0000182', 'Orphanet_79292', 'MONDO_0005178', 'EFO_0003860'],
      dtype=object), 'count': 12}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL643,CC(CN1c2ccccc2Sc2ccccc21)N(C)C,PWWVAXIEGOYWEE-UHFFFAOYSA-N,Small molecule,True,PROMETHAZINE,1951.0,4.0,,False,True,[],"['Dimapp' 'Diphergan' 'Fargan' 'NSC-30321' 'Phenergan' 'Proazamine'
 'Procit' 'Prometazin' 'Promethacon' 'Promethazine' 'Promethegan'
 'Protazine' 'Prothazin' 'RP-3277' 'Remsed' 'Vallergine' 'Zipan-25'
 'Zipan-50']","[('PubChem', array(['104171211', '124881100', '124881103', '144203778', '170465107',
       '26752304', '50105224', '90341785'], dtype=object)), ('TG-GATEs', array(['110'], dtype=object)), ('Wikipedia', array(['Promethazine'], dtype=object)), ('drugbank', array(['DB01069'], dtype=object)), ('chEBI', array(['8461'], dtype=object))]",['CHEMBL1200750'],"{'rows': array(['EFO_0005230', 'HP_0002013', 'EFO_0003843', 'MONDO_0002050',
       'MONDO_0004900', 'MONDO_0005090', 'EFO_0005531', 'MONDO_0005271',
       'HP_0002017', 'EFO_1000971', 'EFO_0003843', 'HP_0000726',
       'EFO_0006928', 'EFO_0003956', 'MONDO_0005475', 'EFO_0004698',
       'MONDO_0100431', 'EFO_0000384', 'EFO_0000274', 'HP_0000989',
       'HP_0002018', 'MONDO_0005271', 'EFO_0006928', 'EFO_1000948',
       'EFO_0007141'], dtype=object), 'count': 25}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 9 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL75880,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1,CYXKNKQEMFBLER-UHFFFAOYSA-N,Small molecule,False,PERHEXILINE,1974.0,4.0,,True,True,[],['Perhexiline'],"[('PubChem', array(['174006795'], dtype=object)), ('TG-GATEs', array(['45'], dtype=object)), ('Wikipedia', array(['Perhexiline'], dtype=object)), ('drugbank', array(['DB01074'], dtype=object)), ('chEBI', array(['35553'], dtype=object))]",['CHEMBL1334033'],"{'rows': array(['EFO_1000899', 'EFO_0003144', 'EFO_0000538', 'EFO_0000319',
       'EFO_1001458'], dtype=object), 'count': 5}","[ENSG00000157184,ENSG00000205560,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for cardiovascular disease and has 4 investigational indications.
CHEMBL1181731,COCCOCCOCCOCCOC(=O)OC[n+]1ccc(N/C(=N/CCCCCCOc2ccc(Cl)cc2)NC#N)cc1,RXXJCNMVVRGOJB-UHFFFAOYSA-O,Small molecule,False,TEGLARINAD,,2.0,,False,False,[],['Teglarinad cation' 'Teglarinad ion'],,['CHEMBL190412'],"{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}",[ENSG00000105835],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1190,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C,MTCUAOILFDZKCO-UHFFFAOYSA-N,Small molecule,False,DECAMETHONIUM,1982.0,4.0,,False,True,[],['Decamethonium' 'Decamethonium cation' 'Decamethonium ion' 'Syncurine'],"[('PubChem', array(['11111046', '11111047', '26756594', '90341654'], dtype=object)), ('drugbank', array(['DB01245'], dtype=object)), ('chEBI', array(['41934'], dtype=object))]",['CHEMBL1134'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200374,C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,BFYIZQONLCFLEV-DAELLWKTSA-N,Small molecule,False,EXEMESTANE,1999.0,4.0,,False,True,['Aromasin' 'Exemestane'],['Exemestane' 'FCE-24304' 'FCE24304' 'NSC-758907' 'PNU-155971'],"[('DailyMed', array(['exemestane'], dtype=object)), ('PubChem', array(['144205052', '170464628', '26719821', '49681613'], dtype=object)), ('Wikipedia', array(['Exemestane'], dtype=object)), ('drugbank', array(['DB00990'], dtype=object)), ('chEBI', array(['4953'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'MONDO_0011962', 'MONDO_0004658', 'EFO_0006861',
       'EFO_0005537', 'EFO_0000432', 'MONDO_0008315', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000305', 'EFO_1000098', 'MONDO_0008170',
       'EFO_0000574', 'EFO_0003869', 'MONDO_0004992'], dtype=object), 'count': 15}",[ENSG00000137869],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 10 investigational indications.
CHEMBL1200561,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O,VJECBOKJABCYMF-UHFFFAOYSA-N,Small molecule,False,DOXAZOSIN MESYLATE,1990.0,4.0,CHEMBL707,False,True,"['Cardozin xl' 'Cardura' 'Cardura xl' 'Cascor' 'Colixil xl' 'Doxadura'
 'Doxazosin mesylate' 'Doxzogen xl' 'Larbex xl' 'Oxandosin xl'
 'Raporsin xl' 'Slocinx xl']","['Alfadil' 'Doxazosin (as mesilate)' 'Doxazosin mesilate'
 'Doxazosin mesylate' 'Doxazosin methanesulfonate' 'NSC-759284'
 'UK-33,274-27' 'UK-33274-27']","[('DailyMed', array(['doxazosin%20mesylate'], dtype=object)), ('PubChem', array(['144204347', '170465395', '50106256', '56422468', '85231302',
       '855527'], dtype=object)), ('chEBI', array(['4709'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000612', 'EFO_0000284'], dtype=object), 'count': 3}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved indications.
CHEMBL1213583,C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,SIGSPDASOTUPFS-XUDSTZEESA-N,Small molecule,False,GESTODENE,,3.0,,False,False,[],['Gestodene' 'SH B 331' 'SH-B-331'],"[('PubChem', array(['144205785', '170466131'], dtype=object)), ('Wikipedia', array(['Gestodene'], dtype=object)), ('drugbank', array(['DB06730'], dtype=object))]",,,[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL1577,CN1C(CCl)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,CESYKOGBSMNBPD-UHFFFAOYSA-N,Small molecule,False,METHYCLOTHIAZIDE,1960.0,4.0,,False,True,['Aquatensen' 'Enduron' 'Methyclothiazide'],['Methyclothiazide' 'NSC-110431'],"[('PubChem', array(['144206003', '170465243', '92764517'], dtype=object)), ('Wikipedia', array(['Methyclothiazide'], dtype=object)), ('drugbank', array(['DB00232'], dtype=object)), ('chEBI', array(['6847'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for cardiovascular disease.
CHEMBL1697,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl,HDRXZJPWHTXQRI-BHDTVMLSSA-N,Small molecule,False,DILTIAZEM HYDROCHLORIDE,1982.0,4.0,CHEMBL23,False,True,"['Adizem-60' 'Adizem-sr' 'Adizem-xl' 'Angiozem 60' 'Angiozem cr 120'
 'Angiozem cr 90' 'Angitil sr 120' 'Angitil sr 180' 'Angitil sr 90'
 'Angitil xl 240' 'Angitil xl 300' 'Anoheal' 'Bi-carzem sr' 'Bi-carzem xl'
 'Britiazim' 'Calazem' 'Calcicard' 'Calcicard cr' 'Cardizem' 'Cardizem cd'
 'Cardizem la' 'Cardizem sr' 'Cartia xt' 'Dilacor xr' 'Dilcardia sr'
 'Dilcardia xl' 'Dilt-cd' 'Diltiazem hydrochloride'
 'Diltiazem hydrochloride in dextrose 5%' 'Diltzac' 'Dilzem sr 120'
 'Dilzem sr 60' 'Dilzem sr 90' 'Dilzem xl 120' 'Dilzem xl 180'
 'Dilzem xl 240' 'Disogram sr' 'Horizem sr 120' 'Horizem sr 60'
 'Horizem sr 90' 'Kentiazem' 'Kenzem sr' 'Optil' 'Optil sr 120'
 'Optil sr 180' 'Optil sr 90' 'Optil xl 240' 'Optil xl 300' 'Retalzem 60'
 'Slozem' 'Slozem 120' 'Slozem 180' 'Slozem 240' 'Taztia xt' 'Tiamex'
 'Tiazac' 'Tildiem' 'Tildiem la 200' 'Tildiem la 300' 'Tildiem ret 120'
 'Tildiem ret 90' 'Uard 120xl' 'Uard 180xl' 'Uard 240xl' 'Uard 300xl'
 'Viazem xl' 'Zemret 180 xl' 'Zemret 240 xl' 'Zemret 300 xl'
 'Zemtard 120 xl' 'Zemtard 180 xl' 'Zemtard 240 xl' 'Zemtard 300 xl'
 'Zildil sr']","['Adizem' 'Altiazem' 'CRD-401' 'Cartia' 'Deltazen' 'Diladel' 'Dilpral'
 'Dilrene' 'Diltiazem hcl' 'Diltiazem hydrochloride' 'Dilzem' 'Dilzene'
 'Masdil' 'NSC-759576' 'RG 83606' 'RG-83606' 'Taztia' 'Zilden']","[('DailyMed', array(['diltiazem%20hydrochloride'], dtype=object)), ('PubChem', array(['50106088', '56422509', '855699'], dtype=object)), ('chEBI', array(['645509'], dtype=object))]",,"{'rows': array(['HP_0012390', 'EFO_0000537', 'EFO_0003144', 'EFO_1001951',
       'EFO_0000701', 'EFO_0000275', 'EFO_0000764', 'EFO_0003913',
       'EFO_0004225', 'HP_0002019'], dtype=object), 'count': 10}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 6 investigational indications.
CHEMBL2108407,,,Antibody,False,FARALIMOMAB,,2.0,,False,False,[],['64G12' 'Faralimomab'],,,,"[ENSG00000197919,ENSG00000233816]",Antibody drug with a maximum clinical trial phase of II.
CHEMBL3039530,O=c1ccc2c([C@@H](O)CNCCCCCCOCC(F)(F)c3ccccc3)ccc(O)c2[nH]1,SFYAXIFVXBKRPK-QFIPXVFZSA-N,Small molecule,False,ABEDITEROL,,2.0,,False,False,[],['Abediterol' 'LAS-100977' 'LAS100977'],"[('drugbank', array(['DB12100'], dtype=object))]",['CHEMBL3039510'],"{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3182444,O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1,LCVIRAZGMYMNNT-UHFFFAOYSA-N,Small molecule,False,MK-5108,,1.0,,False,False,[],['MK 5108' 'MK5108' 'Mk-5108' 'VX-689'],"[('PubChem', array(['174006374'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000087586],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL429736,CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1,PLVGDGRBPMVYPB-FDUHJNRSSA-N,Small molecule,False,RETOSIBAN,,3.0,,False,False,[],['GSK-221149' 'GSK-221149A' 'GSK221149' 'GSK221149A' 'Retosiban'],"[('drugbank', array(['DB11818'], dtype=object))]",,"{'rows': array(['EFO_0003917'], dtype=object), 'count': 1}",[ENSG00000180914],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4298097,,,Antibody,False,ROMILKIMAB,,2.0,,False,False,[],['Hutbti3_2_1' 'Romilkimab' 'SAR-156597' 'SAR156597' 'Sar156597'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROMILKIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000717', 'EFO_0000768'], dtype=object), 'count': 2}","[ENSG00000169194,ENSG00000113520]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL472,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,Small molecule,False,GLYBURIDE,1984.0,4.0,,False,True,"['Amglidia' 'Calabren' 'Daonil' 'Diabeta' 'Diabetamide 2.5'
 'Diabetamide 5' 'Euglucon' 'Gliken' 'Glyburide' 'Glyburide (micronized)'
 'Glynase' 'Glynase Prestab' 'Lederglib' 'Libanil' 'Malix' 'Micronase'
 'Semi-daonil']","['Cirara' 'Glibenclamide' 'Glibenclamidum' 'Glybenclamide' 'Glyburide'
 'HB 419' 'HB-419' 'NSC-759618' 'U-26,45' 'U-26,452' 'U-26452']","[('Wikipedia', array(['Glibenclamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia'],
      dtype=object)), ('TG-GATEs', array(['42'], dtype=object)), ('PubChem', array(['11111219', '11112597', '11113353', '144203709', '144211075',
       '170464964', '26747031', '26747032', '26751550', '50100249',
       '50104148', '50104149', '50104150', '50126365', '56422139',
       '85231061', '855894'], dtype=object)), ('DailyMed', array(['glyburide'], dtype=object)), ('drugbank', array(['DB01016'], dtype=object)), ('chEBI', array(['5441'], dtype=object))]",,"{'rows': array(['EFO_1001919', 'HP_0002140', 'MONDO_0005148', 'EFO_0000712',
       'MONDO_0005147', 'EFO_0004593', 'MONDO_0043510', 'EFO_0000400',
       'EFO_0003913'], dtype=object), 'count': 9}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 7 investigational indications.
CHEMBL4802160,COC[C@H]1CN(C(=O)[C@]2(F)CN(C3CCCC3)C[C@H]2c2ccc(OC)cc2)C[C@@H]1c1ccc(C(F)(F)F)cc1N1CCC(C(=O)O)CC1,MUNWOYRHJPWQNE-GMFUQMJFSA-N,Small molecule,False,DERSIMELAGON,,3.0,,False,False,[],['Dersimelagon' 'MT-7117' 'Mt-7117'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DERSIMELAGON/relevant/1/'],
      dtype=object))]",['CHEMBL4802244'],"{'rows': array(['EFO_1000753', 'MONDO_0001676', 'EFO_0000404', 'EFO_1000753',
       'EFO_0001421', 'MONDO_0001676', 'EFO_0003086'], dtype=object), 'count': 7}",[ENSG00000258839],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL5314366,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.O.O.O.[Mg+2],ARGAGMTUBUKMOG-OXLUMUBXSA-N,Small molecule,False,ESOMEPRAZOLE MAGNESIUM,2001.0,4.0,CHEMBL1201320,False,True,"['Emozul' 'Esomeprazole magnesium' 'Nexium' 'Nexium 24hr' 'Nexium control'
 'Nexium i.v.' 'Ventra']","['Esomeprazole (as magnesium)' 'Esomeprazole magnesium'
 'Esomeprazole magnesium hydrate' 'Esomeprazole magnesium trihydrate'
 'H199/18 MAGNESIUM TRIHYDRATE']","[('DailyMed', array(['esomeprazole%20magnesium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nexium-control'],
      dtype=object))]",,"{'rows': array(['EFO_0009454', 'EFO_0010282', 'MONDO_0005178', 'EFO_0003948',
       'EFO_0007549', 'EFO_0004607', 'EFO_0000342', 'MONDO_0004247',
       'EFO_0003898', 'HP_0100633', 'MONDO_0005148', 'EFO_0008533',
       'EFO_0000685'], dtype=object), 'count': 13}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 8 approved and 5 investigational indications.
CHEMBL1743046,,,Antibody,False,NARNATUMAB,,2.0,,False,False,[],['IMC RON-8' 'IMC-RON-8' 'IMC-RON8' 'Narnatumab' 'RON-8' 'RON8'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000164078],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1743056,,,Antibody,False,PATECLIZUMAB,,2.0,,False,False,[],"['MLTA-3698A' 'MLTA3698A' 'PRO-283698' 'PRO283698' 'Pateclizumab'
 'RG-7416' 'RG7415']",,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000226979],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107067,CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,UDSFVOAUHKGBEK-CNQKSJKFSA-N,Small molecule,True,TESTOSTERONE UNDECANOATE,2014.0,4.0,,False,True,"['Aveed' 'Jatenzo' 'Kyzatrex' 'Nebido' 'Restandol' 'Restandol testocap'
 'Tlando' 'Undestor']","['Kyzatrex' 'MK-3033' 'ORG 538' 'ORG-538' 'TSX-011'
 'Testosterone 17.beta.-undecylate' 'Testosterone undecanoate'
 'Testosterone undecylate' 'Testosterone, undecanoate (ester)' 'Tlando']","[('DailyMed', array(['testosterone%20undecanoate'], dtype=object)), ('drugbank', array(['DB13946'], dtype=object))]",,"{'rows': array(['EFO_1001919', 'EFO_0000681', 'EFO_1001078', 'EFO_0001645',
       'EFO_0008572', 'EFO_0000616', 'EFO_1001006', 'EFO_0009686',
       'MONDO_0002146', 'MONDO_0018555', 'MONDO_0008315', 'EFO_0004714'],
      dtype=object), 'count': 12}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2107872,,,Protein,False,DELCASERTIB,,2.0,,False,False,[],['BMS-875944' 'Delcasertib' 'KAI-9803' 'Kai-9803'],,,"{'rows': array(['EFO_0000612'], dtype=object), 'count': 1}",[ENSG00000163932],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109464,,,Antibody,False,CNTO-5825,,1.0,,False,False,[],['CNTO-5825' 'Cnto-5825'],,,,[ENSG00000169194],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2364617,CC(=O)O.CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O,WVDSKQXKCDZXLH-OHIDFYLOSA-N,Small molecule,False,MACIMORELIN ACETATE,2017.0,4.0,CHEMBL278623,False,True,['Ghryvelin (previously macimorelin aeterna zentaris)' 'Macrilen'],['ARD 07' 'D-87575' 'EP 1572' 'Macimorelin acetate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ghryvelin-previously-macimorelin-aeterna-zentaris'],
      dtype=object))]",,,[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017.
CHEMBL3545257,CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O.O=S(=O)(O)c1ccccc1,OKJXJRVWXYRSAN-TXULWXBWSA-N,Small molecule,False,MIROGABALIN BESYLATE,,-1.0,CHEMBL3545125,False,False,[],"['DS-5565' 'DS5565' 'Ds-5565' 'Mirogabalin' 'Mirogabalin besilate'
 'Mirogabalin besylate']",,,,"[ENSG00000007402,ENSG00000153956]",Small molecule drug.
CHEMBL3707316,,,Small molecule,False,ND0801,,2.0,,False,False,[],['Nd0801'],,,"{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4065122,C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,WNEODWDFDXWOLU-QHCPKHFHSA-N,Small molecule,False,FENEBRUTINIB,,3.0,,False,False,[],"['Fenebrutinib' 'G-02599853' 'G02599853' 'GDC-0853' 'Gdc-0853' 'RG-7845'
 'RG7845' 'RO-7010939' 'RO7010939']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FENEBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14785'], dtype=object))]",,"{'rows': array(['MONDO_0005301', 'EFO_0003840', 'EFO_0005531', 'EFO_0005809',
       'MONDO_0007915', 'EFO_0000685'], dtype=object), 'count': 6}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4650406,,,Antibody,False,LEVILIMAB,,3.0,,False,False,[],['BCD-089' 'Bcd-089' 'Levilimab'],,,"{'rows': array(['EFO_0000685', 'MONDO_0100096'], dtype=object), 'count': 2}",[ENSG00000160712],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL491473,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,XXJWYDDUDKYVKI-UHFFFAOYSA-N,Small molecule,False,CEDIRANIB,,3.0,,False,False,['Recentin'],['AZD-2171' 'AZD2171' 'Azd-2171' 'Cediranib' 'ZD-2171'],"[('PubChem', array(['103905340', '137275941'], dtype=object)), ('drugbank', array(['DB04849'], dtype=object))]",['CHEMBL2103798'],"{'rows': array(['EFO_1000657', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004992',
       'EFO_1001951', 'EFO_0000702', 'EFO_0006861', 'EFO_1001465',
       'EFO_0000681', 'EFO_0000222', 'EFO_0003893', 'MONDO_0002974',
       'EFO_0003060', 'EFO_0000770', 'MONDO_0002974', 'MONDO_0008903',
       'EFO_0000681', 'EFO_0000305', 'EFO_0000673', 'MONDO_0008903',
       'EFO_1001951', 'EFO_0003891', 'EFO_0000196', 'EFO_0000588',
       'EFO_0000673', 'EFO_0000616', 'EFO_0007143', 'MONDO_0002158',
       'EFO_0003833', 'EFO_0000389', 'EFO_0000519', 'EFO_0000349',
       'EFO_0003060', 'MONDO_0001056', 'MONDO_0011962', 'EFO_0002892',
       'EFO_0000182', 'EFO_0002617', 'MONDO_0007254', 'EFO_0000095',
       'MONDO_0008315', 'EFO_0000565', 'EFO_0000519', 'EFO_0009709',
       'MONDO_0002087'], dtype=object), 'count': 45}","[ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 39 investigational indications.
CHEMBL498,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,RKWGIWYCVPQPMF-UHFFFAOYSA-N,Small molecule,False,CHLORPROPAMIDE,1958.0,4.0,,False,True,['Chlorpropamide' 'Diabemide' 'Diabinese' 'Glucamide' 'Glymese' 'Melitase'],['Chlorpropamide' 'NSC-44634' 'NSC-626720'],"[('PubChem', array(['11110918', '11110919', '144203653', '144208589', '144213106',
       '170464898', '17389965', '50103916', '56423142', '855559'],
      dtype=object)), ('TG-GATEs', array(['80'], dtype=object)), ('Wikipedia', array(['Chlorpropamide'], dtype=object)), ('drugbank', array(['DB00672'], dtype=object)), ('chEBI', array(['3650'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and is indicated for type 2 diabetes mellitus and diabetes mellitus.
CHEMBL5315123,CC(=O)O.CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1,MZWHRPKAHCWTOI-KGURMGBCSA-N,Protein,False,DIFELIKEFALIN ACETATE,2021.0,4.0,CHEMBL3989915,False,True,['Kapruvia' 'Korsuva'],['Cr-845 acetate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia'],
      dtype=object))]",,"{'rows': array(['EFO_0003884', 'HP_0000989'], dtype=object), 'count': 2}",[ENSG00000082556],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for chronic kidney disease and pruritus.
CHEMBL539697,CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,KSGXQBZTULBEEQ-UHFFFAOYSA-N,Small molecule,True,DABIGATRAN ETEXILATE,2008.0,4.0,,False,True,['Pradaxa'],"['BIBR 1048' 'BIBR 1048 BS RS1' 'BIBR-1048' 'BIBR-1048-BS-RS1'
 'Dabigatran etexilate' 'Dabigatran etexilate methanesulfonate']","[('PubChem', array(['170466107'], dtype=object)), ('Wikipedia', array(['Dabigatran'], dtype=object)), ('drugbank', array(['DB06695'], dtype=object)), ('chEBI', array(['70746'], dtype=object))]",['CHEMBL1615369'],"{'rows': array(['EFO_0001645', 'HP_0000083', 'EFO_0000275', 'EFO_0010726',
       'HP_0001907', 'EFO_0003095', 'EFO_0000712', 'EFO_0003884',
       'EFO_0000275', 'EFO_0003827', 'EFO_0000712', 'EFO_1000652',
       'EFO_0003907', 'EFO_0004286', 'EFO_0004286', 'HP_0004936',
       'HP_0004419', 'HP_0001871', 'MONDO_0000831', 'EFO_0000673'],
      dtype=object), 'count': 20}",[ENSG00000180210],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 8 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL93,CC(c1cc2ccccc2s1)N(O)C(N)=O,MWLSOWXNZPKENC-UHFFFAOYSA-N,Small molecule,False,ZILEUTON,1996.0,4.0,,False,True,['Zyflo' 'Zyflo cr'],['A-64077' 'ABBOTT-64077' 'NSC-730712' 'NSC-759277' 'Zileuton'],"[('DailyMed', array(['zileuton'], dtype=object)), ('PubChem', array(['144205233', '144211465', '170465222', '174007276', '26719885',
       '29215400'], dtype=object)), ('Wikipedia', array(['Zileuton'], dtype=object)), ('drugbank', array(['DB00744'], dtype=object)), ('chEBI', array(['10112'], dtype=object))]",,"{'rows': array(['EFO_0003768', 'MONDO_0008903', 'EFO_0000341', 'EFO_0000768',
       'EFO_0000339', 'MONDO_0011382', 'MONDO_0004979', 'EFO_0003894',
       'MP_0001845'], dtype=object), 'count': 9}",[ENSG00000012779],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for asthma and has 8 investigational indications.
CHEMBL1200497,CC(O)C(=O)O.CN1CCN(C(c2ccccc2)c2ccccc2)CC1,JOROEVAWQLGPFQ-UHFFFAOYSA-N,Small molecule,False,CYCLIZINE LACTATE,1982.0,4.0,CHEMBL648,False,True,['Marezine'],['Cyclizine lactate'],,,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200578,Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCC(=O)[O-].[Na+],AIJQWRAOMFRHTQ-UHFFFAOYSA-M,Small molecule,False,THEOPHYLLINE SODIUM GLYCINATE,1982.0,4.0,CHEMBL1208646,False,True,['Asbron' 'Synophylate'],"['Bronchoparat' 'Englate' 'Glycin theophyllinate' 'Glytheonate'
 'Panophylline' 'Theonate sodium' 'Theophylline sodium glycinate']",,,,"[ENSG00000172572,ENSG00000152270,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201583,,,Antibody,False,BEVACIZUMAB,2004.0,4.0,,False,True,['Avastin' 'Mvasi'],"['12-IGG1' 'AVA-1' 'Abp-215' 'Alymsys' 'BAT-1706' 'BEVZ-92' 'BEVZ92'
 'BI 695502' 'BI695502' 'BS-503A' 'Bat 1706' 'Bat1706' 'Bevacizumab'
 'Bevacizumab (avastin)' 'Bevacizumab adcd' 'Bevacizumab awwb'
 'Bevacizumab beta' 'Bevacizumab biosimilar (abp-215)'
 'Bevacizumab biosimilar (amgen)' 'Bevacizumab biosimilar (fkb-238)'
 'Bevacizumab biosimilar (pfizer)' 'Bevacizumab bvzr' 'Bevacizumab maly'
 'Bevacizumab-adcd' 'Bevacizumab-awwb' 'Bevacizumab-bvzr'
 'Bevacizumab-maly' 'Bevax' 'Bi-695502' 'Bs-503' 'Byvasda' 'CHS-5217'
 'CT-16' 'CT-P16' 'CT-P16 (BIOSIMILAR OF BEVACIZUMAB)' 'Ct p16' 'Ct-16'
 'Ct-p16' 'FKB-238' 'Fkb 238' 'Fkb238' 'HLX-04' 'HLX04' 'Hlx 04' 'Ibi-305'
 'Ibi305' 'LY 01008' 'LY-01008' 'MB-02' 'Mvasi' 'Oyavas' 'PF-06439535'
 'Pf-06439535' 'Q-1101' 'Q1101' 'R-435' 'RG-435' 'RHUMAB-' 'RHUMAB-VEGF'
 'RO-4876646' 'Usp mab 002, monoclonal igg1' 'Vegzelma' 'Zirabev']","[('DailyMed', array(['bevacizumab', 'bevacizumab-awwb', 'bevacizumab-bvzr'],
      dtype=object)), ('DrugCentral', array(['4956'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mvasi'],
      dtype=object)), ('Wikipedia', array(['Bevacizumab'], dtype=object))]",,"{'rows': array(['EFO_0000326', 'EFO_0003050', 'MONDO_0005184', 'EFO_1000613',
       'EFO_0000174', 'EFO_1000796', 'EFO_0006859', 'EFO_0003828',
       'MONDO_0002158', 'MONDO_0008903', 'HP_0009588', 'MONDO_0004992',
       'EFO_0003016', 'EFO_1000052', 'MONDO_0002363', 'EFO_0007224',
       'MONDO_0018364', 'EFO_0001061', 'EFO_0002893', 'MONDO_0100342',
       'EFO_0002618', 'EFO_1000783', 'EFO_1001100', 'EFO_0003869',
       'EFO_0009708', 'EFO_0003106', 'EFO_0003884', 'EFO_0009637',
       'EFO_0000182', 'EFO_0008528', 'EFO_0004243', 'MONDO_0003060',
       'EFO_1001187', 'EFO_0003060', 'MONDO_0001187', 'EFO_0000756',
       'EFO_0000698', 'EFO_1000158', 'EFO_0000349', 'MONDO_0001280',
       'MONDO_0003005', 'EFO_1000657', 'MONDO_0011719', 'EFO_0009606',
       'EFO_0000770', 'MONDO_0020634', 'EFO_0000630', 'EFO_1001231',
       'EFO_0000571', 'EFO_0005537', 'HP_0001541', 'EFO_1001465',
       'EFO_0000678', 'EFO_0000095', 'EFO_1000895', 'EFO_1000984',
       'MONDO_0024677', 'EFO_0005577', 'EFO_0000305', 'EFO_0002087',
       'EFO_0000632', 'EFO_0001416', 'EFO_1000581', 'MONDO_0001576',
       'EFO_0000198', 'EFO_0002892', 'EFO_0000694', 'EFO_0000673',
       'EFO_0000564', 'MONDO_0018906', 'MONDO_0009937', 'EFO_0000588',
       'MONDO_0011962', 'EFO_1001951', 'MONDO_0044903', 'EFO_0000707',
       'MONDO_0008315', 'EFO_0000365', 'EFO_1001949', 'EFO_0009448',
       'MONDO_0002087', 'MONDO_0003268', 'MONDO_0002691', 'EFO_0003833',
       'EFO_0005543', 'EFO_0002499', 'EFO_0000503', 'EFO_0004212',
       'EFO_0004284', 'EFO_0002617', 'EFO_1001111', 'EFO_0005753',
       'EFO_0004264', 'MONDO_0044937', 'MP_0001914', 'EFO_0000335',
       'MONDO_0005575', 'EFO_0000640', 'MONDO_0002989', 'MONDO_0002108',
       'EFO_0007532', 'MONDO_0019472', 'EFO_0000519', 'EFO_1001961',
       'MONDO_0007254', 'EFO_0001376', 'EFO_0000574', 'EFO_0000248',
       'EFO_0001365', 'EFO_0000621', 'EFO_1000043', 'EFO_0001642',
       'EFO_0001065', 'MONDO_0002120', 'EFO_0000183', 'EFO_0004683',
       'EFO_0000348', 'EFO_0002916', 'EFO_0002918', 'EFO_0006772',
       'EFO_0000339', 'MONDO_0016700', 'EFO_0000569', 'EFO_1001471',
       'EFO_0005773', 'EFO_0002939', 'EFO_0000313', 'EFO_0005952',
       'EFO_1000809', 'EFO_0000096', 'EFO_0007143', 'MP_0001845',
       'EFO_0005221', 'EFO_1001158', 'EFO_0000272', 'EFO_0007416',
       'EFO_0001075', 'EFO_1001157', 'EFO_0009784', 'EFO_1001469',
       'EFO_1000026', 'EFO_1000475', 'EFO_1001968', 'MONDO_0008170',
       'EFO_0004252', 'EFO_0000232', 'EFO_0000514', 'EFO_0003839',
       'MONDO_0001657', 'EFO_0005567', 'MONDO_0021632', 'MONDO_0016642',
       'EFO_0000389', 'EFO_0000681', 'MONDO_0005041', 'EFO_1000028',
       'EFO_0000558', 'EFO_0000228', 'EFO_0000403', 'EFO_0004251',
       'EFO_1000823', 'MONDO_0018271', 'EFO_0010282', 'MONDO_0100096',
       'EFO_0000466', 'MONDO_0018092', 'MONDO_0008667', 'EFO_0001378',
       'EFO_0006861', 'EFO_1001901', 'EFO_0003893', 'EFO_0003770',
       'EFO_1001512', 'EFO_1001513', 'EFO_0000691', 'EFO_1000251',
       'EFO_0000565', 'EFO_0004142', 'MONDO_0007576', 'EFO_0000178',
       'MONDO_0005835', 'MONDO_0019297', 'EFO_0003860', 'MONDO_0007935',
       'EFO_0004256', 'MONDO_0021063', 'HP_0000545', 'EFO_0003968',
       'EFO_0000196', 'MONDO_0002974', 'EFO_0000760', 'MONDO_0019180',
       'EFO_0000702', 'EFO_0008626', 'MONDO_0002367', 'EFO_0002501',
       'EFO_0004288', 'MONDO_0005411', 'EFO_0000181', 'EFO_0000616',
       'MONDO_0043510', 'EFO_1000880', 'MONDO_0001056'], dtype=object), 'count': 203}",[ENSG00000112715],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 29 approved and 174 investigational indications.
CHEMBL1201620,,,Protein,False,SOMATREM,1985.0,4.0,,False,True,['Protropin'],['Protropin (genentech)' 'Somatrem'],"[('DrugCentral', array(['5042'], dtype=object)), ('Wikipedia', array(['Somatrem'], dtype=object))]",,,[ENSG00000112964],Protein drug with a maximum clinical trial phase of IV that was first approved in 1985.
CHEMBL1428,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,Small molecule,True,NIMODIPINE,1988.0,4.0,,False,True,['Nimodipine' 'Nimotop' 'Nymalize'],"['Admon' 'BAY E 9736' 'BAY-E-9736' 'NSC-758476' 'Nemotan' 'Nimodipine'
 'Nimodipine ap' 'Periplum']","[('DailyMed', array(['nimodipine'], dtype=object)), ('PubChem', array(['104171194', '124880812', '124880816', '144203753', '170466561',
       '26747118', '26747119', '26747120', '26751792', '26751793',
       '50104485', '50104486', '50104487', '85231145', '90340912'],
      dtype=object)), ('Wikipedia', array(['Nimodipine'], dtype=object)), ('drugbank', array(['DB00393'], dtype=object)), ('chEBI', array(['7575'], dtype=object))]",,"{'rows': array(['EFO_0002610', 'EFO_0003763', 'EFO_0000712', 'EFO_0008546',
       'HP_0009588', 'EFO_0000319', 'EFO_0003870', 'MONDO_0005090',
       'EFO_0009846', 'EFO_0000545', 'EFO_0000713'], dtype=object), 'count': 11}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000151623]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for cardiovascular disease and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1535,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,Small molecule,False,HYDROXYCHLOROQUINE,1955.0,4.0,,False,True,[],['Hydroxychloroquine' 'Polirreumin'],"[('PubChem', array(['29215442'], dtype=object)), ('Wikipedia', array(['Hydroxychloroquine'], dtype=object)), ('drugbank', array(['DB01611'], dtype=object)), ('chEBI', array(['5801'], dtype=object))]",['CHEMBL1690'],"{'rows': array(['DOID_13406', 'EFO_0000616', 'EFO_0002618', 'EFO_0009001',
       'EFO_0001068', 'EFO_0004244', 'MONDO_0005178', 'EFO_0007427',
       'MONDO_0004992', 'EFO_0007448', 'MONDO_0100096', 'EFO_0003840',
       'EFO_0000519', 'MONDO_0100130', 'EFO_1000158', 'EFO_0002689',
       'EFO_0000389', 'MONDO_0011705', 'EFO_0007328', 'EFO_1001951',
       'EFO_0000565', 'EFO_0003818', 'EFO_0004616', 'EFO_0000729',
       'MONDO_0005147', 'EFO_0007224', 'EFO_0001378', 'MONDO_0100096',
       'EFO_0003834', 'EFO_0000198', 'MONDO_0007915', 'EFO_0002614',
       'EFO_0001068', 'MONDO_0008315', 'EFO_0001663', 'EFO_0000694',
       'MONDO_0005148', 'EFO_0000228', 'EFO_0005221', 'MONDO_0010520',
       'EFO_0009686', 'MONDO_0007254', 'EFO_0000756', 'EFO_0002950',
       'MONDO_0013730', 'EFO_0004220', 'EFO_0000681', 'EFO_1000710',
       'EFO_0000095', 'EFO_0000685', 'EFO_0000389', 'MONDO_0007915',
       'EFO_0000637', 'EFO_0000384', 'EFO_0005221', 'Orphanet_912',
       'EFO_0000702', 'EFO_0007224', 'EFO_0005755', 'EFO_0000349',
       'EFO_0000685', 'EFO_0000691', 'EFO_1001209', 'MONDO_0015104',
       'EFO_0003047', 'EFO_0004244', 'EFO_0002618', 'HP_0001873',
       'EFO_0000668', 'EFO_0000222', 'EFO_0007541', 'EFO_0003106',
       'MONDO_0009061', 'MONDO_0008170', 'EFO_0004142', 'EFO_0000182',
       'EFO_0000699', 'EFO_0000764', 'EFO_1000954', 'EFO_1000726',
       'MONDO_0008903', 'MONDO_0019200', 'EFO_0000544', 'MONDO_0021117',
       'MONDO_0100342', 'EFO_1000637', 'EFO_0003060', 'EFO_0002689'],
      dtype=object), 'count': 88}","[ENSG00000239732,ENSG00000196664]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for malaria and rheumatoid arthritis and has 80 investigational indications.
CHEMBL169901,N=C(N)N1CCc2ccccc2C1,JWPGJSVJDAJRLW-UHFFFAOYSA-N,Small molecule,False,DEBRISOQUIN,,4.0,,False,True,[],['Debrisoquine'],"[('PubChem', array(['11112418'], dtype=object)), ('Wikipedia', array(['Debrisoquine'], dtype=object)), ('drugbank', array(['DB04840'], dtype=object)), ('chEBI', array(['34665'], dtype=object))]",['CHEMBL3527581' 'CHEMBL1593558' 'CHEMBL1255735'],"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV and is indicated for hypertension.
CHEMBL207433,O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1,JYILLRHXRVTRSH-GFCCVEGCSA-N,Small molecule,False,SB-705498,,2.0,,False,False,[],['GSK705498' 'SB-705498' 'Sb-705498'],"[('drugbank', array(['DB11883'], dtype=object))]",,"{'rows': array(['MONDO_0005277', 'EFO_0000555', 'EFO_0008521', 'EFO_0010072',
       'EFO_0000274'], dtype=object), 'count': 5}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2103857,COc1ccc(F)cc1C[C@@](O)(C1CCOCC1)[C@@H]1CNCCO1,CPBHSHYQQLFAPW-ZWKOTPCHSA-N,Small molecule,False,EDIVOXETINE,,3.0,,False,False,[],['Edivoxetine' 'LY-2216684' 'LY-2216684 HYDROCHLORIDE' 'LY2216684'],"[('drugbank', array(['DB09184'], dtype=object))]",['CHEMBL2105702'],"{'rows': array(['EFO_0003888', 'MONDO_0002009'], dtype=object), 'count': 2}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2103869,O=C(O)[C@@H]1C[C@H]2C[C@@H](Oc3cccc(Cl)c3-c3nnn[nH]3)CC[C@H]2CN1,LAKQPSQCICNZII-NOHGZBONSA-N,Small molecule,False,DASOLAMPANEL,,2.0,,False,False,[],['Dasolampanel' 'NGX426'],,['CHEMBL3088054'],,"[ENSG00000171189,ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2103884,COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1,SWZXEVABPLUDIO-WSZYKNRRSA-N,Small molecule,False,OPROZOMIB,,2.0,,False,False,[],['ONX 0912' 'ONX-0912' 'Oprozomib' 'Pr-047'],"[('drugbank', array(['DB11991'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000182', 'MONDO_0004992', 'EFO_0009441',
       'EFO_0001378'], dtype=object), 'count': 5}","[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2106468,CCN(CC)C(=O)CNC(=O)c1cc(OC)c(OC)c(OC)c1,NLRFFZRHTICQBO-UHFFFAOYSA-N,Small molecule,False,TRICETAMIDE,,1.0,,False,False,[],['R-548' 'Tricetamide'],,,,"[ENSG00000162434,ENSG00000105639]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2108470,,,Unknown,False,MURELETECAN,,2.0,,False,False,[],['Mag-camptothecin' 'Mag-cpt' 'Mureletecan' 'PNU-166148'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000198900],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109388,,,Antibody,False,FUTUXIMAB,,3.0,,False,False,[],['992 DS' '992-DS' 'Futuximab' 'SYM-004' 'Sym004'],,,"{'rows': array(['MONDO_0100342', 'EFO_0000616', 'EFO_0000707', 'EFO_0003060'],
      dtype=object), 'count': 4}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2110725,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,NMDYYWFGPIMTKO-KLCPSUAYSA-N,Small molecule,False,VINFLUNINE,2009.0,4.0,,False,True,[],['Vinflunine'],"[('drugbank', array(['DB11641'], dtype=object)), ('chEBI', array(['90241'], dtype=object))]",['CHEMBL2105629'],"{'rows': array(['MONDO_0001056', 'EFO_0008528', 'MONDO_0004992', 'EFO_0000702',
       'EFO_1001094', 'MONDO_0007254', 'EFO_0000616', 'EFO_0003060',
       'MONDO_0002038', 'MONDO_0008903', 'EFO_1000601', 'MONDO_0001187',
       'MONDO_0004986', 'EFO_0003863', 'MONDO_0008315'], dtype=object), 'count': 15}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 15 investigational indications.
CHEMBL240597,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,RUDATBOHQWOJDD-BSWAIDMHSA-N,Small molecule,True,CHENODIOL,1983.0,4.0,,False,True,"['Chendol 125' 'Chendol 250' 'Chenix' 'Chenocedon'
 'Chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau)'
 'Chenodiol' 'Chenofalk' 'Combidol' 'Lithofalk' 'Xenbilox']","['Anthropodeoxycholic acid' 'Anthropodesoxycholic acid'
 'Anthropododesoxycholic acid' 'Chendol' 'Chenic acid' 'Chenocol'
 'Chenodeoxycholate' 'Chenodeoxycholic acid' 'Chenodesoxycholic acid'
 'Chenodiol' 'Chenossil' 'Cholanorm' 'Fluibil' 'Gallodesoxycholic acid'
 'NSC-657949' 'NSC-757798']","[('DailyMed', array(['chenodiol'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/chenodeoxycholic-acid-leadiant'],
      dtype=object)), ('PubChem', array(['144203963', '144207689', '26754178', '56463362'], dtype=object)), ('Wikipedia', array(['Chenodeoxycholic_acid'], dtype=object)), ('drugbank', array(['DB06777'], dtype=object)), ('chEBI', array(['16755'], dtype=object))]",,"{'rows': array(['HP_0001258', 'MONDO_0019052', 'EFO_0000555', 'MONDO_0008948'],
      dtype=object), 'count': 4}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for inborn errors of metabolism and cerebrotendinous xanthomatosis and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL240624,COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1,DTYWJKSSUANMHD-UHFFFAOYSA-N,Small molecule,False,PRELADENANT,,3.0,,False,False,[],['MK-3814' 'Preladenant' 'SCH 420814' 'SCH-420814' 'Sch-420814'],"[('drugbank', array(['DB11864'], dtype=object))]",['CHEMBL540115'],"{'rows': array(['EFO_0000616', 'MONDO_0005180', 'EFO_0001421'], dtype=object), 'count': 3}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL281398,CC(C)(C)N/C(=N\C#N)Nc1cccc(/C(=C\CCCC(=O)O)c2cccnc2)c1,XUTLOCQNGLJNSA-RGVLZGJSSA-N,Small molecule,False,TERBOGREL,,2.0,,False,False,[],['BIBV 308 SE' 'BIBV-308-SE' 'BIBV-308SE' 'Terbogrel'],"[('Wikipedia', array(['Terbogrel'], dtype=object)), ('drugbank', array(['DB12204'], dtype=object))]",,"{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}","[ENSG00000006638,ENSG00000059377]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL301265,CCCN[C@H]1CCc2nc(N)sc2C1,FASDKYOPVNHBLU-ZETCQYMHSA-N,Small molecule,False,PRAMIPEXOLE,1997.0,4.0,,False,True,['Mirapexin' 'Neliprax' 'Oprymea' 'Pipexus'],"['Ctc-501' 'NSC-760426' 'Pramipexole' 'SUD-919CL2Y' 'SUD919CL2Y'
 'U-98528E']","[('PubChem', array(['144205998', '170465264', '50112695'], dtype=object)), ('Wikipedia', array(['Pramipexole'], dtype=object)), ('drugbank', array(['DB00413'], dtype=object)), ('chEBI', array(['8356'], dtype=object))]",['CHEMBL3143955' 'CHEMBL542257' 'CHEMBL3182733'],"{'rows': array(['HP_0012532', 'EFO_0004270', 'EFO_0005411', 'MONDO_0004985',
       'EFO_0005203', 'EFO_0002610', 'MONDO_0005090', 'EFO_0003108',
       'MONDO_0002050', 'EFO_0005687', 'MONDO_0005180', 'MONDO_0002491',
       'EFO_1001412', 'EFO_0004270', 'EFO_0004895', 'MONDO_0002009',
       'EFO_0004242', 'MONDO_0004975', 'MONDO_0004976', 'MONDO_0005180',
       'MONDO_0004985'], dtype=object), 'count': 21}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for parkinson disease and restless legs syndrome and has 17 investigational indications.
CHEMBL3707356,,,Oligonucleotide,False,TIVANISIRAN,,3.0,,False,False,[],['SYL 1001' 'SYL-1001' 'SYL1001' 'Syl-1001' 'Tivanisiran'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIVANISIRAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1000906', 'HP_0200026'], dtype=object), 'count': 2}",[ENSG00000196689],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3787344,Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1,IOMMMLWIABWRKL-WUTDNEBXSA-N,Small molecule,False,NAZARTINIB,,2.0,,False,False,[],['EGF-816' 'EGF816' 'Egf816' 'NVP-EGF816-NX' 'Nazartinib'],,['CHEMBL4297222' 'CHEMBL3984979'],"{'rows': array(['EFO_0000616', 'MONDO_0008903', 'EFO_1000849', 'EFO_0003060'],
      dtype=object), 'count': 4}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3989844,C[C@H](N)Cc1ccccc1.O=C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O,VHKVKWTWHZUFIA-DGOKBZBKSA-N,Small molecule,False,DEXTROAMPHETAMINE SACCHARATE,1996.0,4.0,CHEMBL612,False,True,[],"['D-amphetamine saccharate' 'Dexamfetamine hemisaccharate'
 'Dexamfetamine saccharate' 'Dexamfetaphine saccharate']","[('DailyMed', array(['dextroamphetamine%20saccharate'], dtype=object))]",,"{'rows': array(['EFO_0003888', 'MONDO_0016158'], dtype=object), 'count': 2}","[ENSG00000142319,ENSG00000103546,ENSG00000165646]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome.
CHEMBL4297615,CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,ZQPDJCIXJHUERQ-QWRGUYRKSA-N,Small molecule,False,PARSACLISIB,,3.0,,False,False,[],['INCB-050465' 'INCB050465' 'Incb050465' 'Parsaclisib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PARSACLISIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14867'], dtype=object))]",['CHEMBL4298155'],"{'rows': array(['EFO_0000574', 'EFO_0000211', 'MONDO_0000430', 'EFO_0004719',
       'MONDO_0007254', 'EFO_0000616', 'EFO_1001264', 'EFO_0000756',
       'MONDO_0011962', 'EFO_0000403', 'EFO_0000095', 'EFO_0004251',
       'EFO_0000616', 'MONDO_0018906', 'MONDO_0004992', 'EFO_1001469',
       'EFO_0000096', 'EFO_0000699'], dtype=object), 'count': 18}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.
CHEMBL4802263,,,Gene,False,CILTACABTAGENE AUTOLEUCEL,2022.0,4.0,,False,True,['Carvykti'],"['Ciltacabtagene autoleucel' 'JNJ-68284528'
 'JNJ-68284528(LCAR-B38M CAR-T cells)']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CILTACABTAGENE%20AUTOLEUCEL/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}",[ENSG00000048462],Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for multiple myeloma.
CHEMBL514270,COc1ccc(N2CCc3c(-n4ccc(N5CCNC5=O)n4)cc(C)nc32)c(C)c1,JFHJGXQFESYQGY-UHFFFAOYSA-N,Small molecule,False,EMICERFONT,,2.0,,False,False,[],['Emicerfont' 'GW-876008' 'GW-876008X' 'GW876008' 'GW876008X' 'Gw876008'],"[('drugbank', array(['DB12910'], dtype=object))]",,"{'rows': array(['EFO_0000555', 'EFO_1001917'], dtype=object), 'count': 2}",[ENSG00000120088],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL599,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,Small molecule,True,MELOXICAM,2000.0,4.0,,False,True,['Anjeso' 'Loxicom' 'Meloxicam' 'Mobic' 'Qmiiz odt' 'Vivlodex'],"['Acticam' 'Contacera' 'Coxicam' 'Emdocam' 'Flexicam' 'Inflacam' 'Loxicom'
 'Melfax' 'Melosus' 'Melovem' 'Meloxicam' 'Meloxidolor' 'Meloxidyl'
 'Meloxivet' 'Meloxoral' 'Metacam' 'Movatec' 'N-1539' 'N1539' 'Recocam'
 'Revitacam' 'Rheumocam' 'UH-AC 62XX' 'UH-AC-62 XX' 'UHAC-62XX']","[('Wikipedia', array(['Meloxicam'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/loxicom'],
      dtype=object)), ('TG-GATEs', array(['124'], dtype=object)), ('PubChem', array(['144205287', '144206743', '144208887', '144213073', '170464857',
       '26747003', '50085983', '855815'], dtype=object)), ('DailyMed', array(['meloxicam'], dtype=object)), ('drugbank', array(['DB00814'], dtype=object)), ('chEBI', array(['6741'], dtype=object))]",['CHEMBL1898907' 'CHEMBL1256873'],"{'rows': array(['HP_0030834', 'EFO_0003843', 'EFO_0000685', 'EFO_0002609',
       'EFO_0004616', 'MONDO_0005277', 'MONDO_0018076', 'MONDO_0002258',
       'MONDO_0005178', 'EFO_0000673', 'EFO_0010072', 'MONDO_0007915',
       'HP_0003419', 'EFO_0002950', 'EFO_0003898', 'HP_0100607',
       'EFO_0005755'], dtype=object), 'count': 17}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL965,C[N+](C)(C)CCOC(N)=O,VPJXQGSRWJZDOB-UHFFFAOYSA-O,Small molecule,False,CARBAMOYLCHOLINE,1972.0,4.0,,False,True,[],['Carbachol' 'Carbastat' 'Miostat'],"[('PubChem', array(['11110943', '11110944', '26756576', '90341139'], dtype=object)), ('drugbank', array(['DB00411'], dtype=object))]",['CHEMBL14'],"{'rows': array(['MONDO_0005129', 'HP_0000616', 'MONDO_0001330', 'MONDO_0005041'],
      dtype=object), 'count': 4}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 3 approved and 1 investigational indication.
CHEMBL1200904,C#CCN(C)[C@H](C)Cc1ccccc1.Cl,IYETZZCWLLUHIJ-UTONKHPSSA-N,Small molecule,False,SELEGILINE HYDROCHLORIDE,1989.0,4.0,CHEMBL972,False,True,"['Centrapryl 10' 'Centrapryl 5' 'Eldepryl' 'Selegiline hydrochloride'
 'Stilline 10' 'Stilline 5' 'Vivapryl' 'Zelapar']",['L-deprenyl' 'NSC-759259' 'Selegiline hcl' 'Selegiline hydrochloride'],"[('DailyMed', array(['selegiline%20hydrochloride'], dtype=object)), ('PubChem', array(['144204123', '144212163', '170464993', '26719766', '56463000'],
      dtype=object)), ('chEBI', array(['9087'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0007191'], dtype=object), 'count': 2}",[ENSG00000069535],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 2 investigational indications.
CHEMBL1201309,CC(C)C[C@H](NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,PPXLVGBVOZLEIW-ITQXDASVSA-N,Protein,False,NAFARELIN,1990.0,4.0,,False,True,[],"['Lhrh, 6(d-nal(2))' 'Nafarelin']","[('Wikipedia', array(['Nafarelin'], dtype=object))]",['CHEMBL1200671'],"{'rows': array(['EFO_0001065', 'EFO_0001065', 'EFO_0003843', 'EFO_0000545'],
      dtype=object), 'count': 4}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for endometriosis and has 3 investigational indications.
CHEMBL1201336,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O,XWLUWCNOOVRFPX-UHFFFAOYSA-N,Small molecule,True,FOSPHENYTOIN,1996.0,4.0,,False,True,[],['Fosphenytoin' 'Np-06'],"[('PubChem', array(['170465016'], dtype=object)), ('drugbank', array(['DB01320'], dtype=object)), ('chEBI', array(['5165'], dtype=object))]",['CHEMBL5205794' 'CHEMBL919'],"{'rows': array(['EFO_0000474', 'EFO_0008526'], dtype=object), 'count': 2}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for epilepsy and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201542,,,Protein,False,INSULIN ZINC SUSP EXTENDED PURIFIED BEEF,1982.0,4.0,,False,True,['Ultralente'],['Insulin zinc susp extended purified beef'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1411979,CN(C)CCN(Cc1cccs1)c1ccccn1,HNJJXZKZRAWDPF-UHFFFAOYSA-N,Small molecule,False,METHAPYRILENE,,4.0,,True,True,[],"['A 3322' 'A-3322' 'Metapyrilene' 'Methapyrilene' 'Pyrinistol' 'Restryl'
 'Semikon' 'Sleepwell' 'Tenalin' 'Thionylan']","[('PubChem', array(['11111497', '11111498', '90341056'], dtype=object)), ('TG-GATEs', array(['25'], dtype=object)), ('drugbank', array(['DB04819'], dtype=object)), ('chEBI', array(['6820'], dtype=object))]",['CHEMBL1255739' 'CHEMBL3187246'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV and is indicated for allergic disease.
CHEMBL1667969,O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,IPEXHQGMTHOKQV-UHFFFAOYSA-N,Small molecule,False,SAR-407899,,2.0,,False,False,[],['SAR-407899'],,['CHEMBL3545341'],"{'rows': array(['EFO_0003884', 'EFO_0004234', 'EFO_0001645'], dtype=object), 'count': 3}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1742982,,,Protein,False,AFLIBERCEPT,2011.0,4.0,,False,True,['Eylea' 'Zaltrap'],"['ABP-938' 'AVE-0005' 'AVE0005' 'Aflibercept'
 'Aflibercept (genetical recombination)' 'Aflibercept beta'
 'Aflibercept biosimilar (amgen)' 'Aflibercept recombinant' 'BAY-86-5321'
 'BAY-865321' 'BAY86-5321' 'VEGF TRAP' 'Vegf trap-eye']","[('DailyMed', array(['aflibercept', 'ziv-aflibercept'], dtype=object)), ('DrugCentral', array(['4916'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eylea'],
      dtype=object))]",,"{'rows': array(['EFO_0007310', 'EFO_0005753', 'EFO_1001951', 'EFO_1000657',
       'MONDO_0005041', 'MONDO_0004992', 'MONDO_0005575', 'EFO_1001060',
       'EFO_0004207', 'EFO_0004142', 'EFO_0000616', 'EFO_0000565',
       'EFO_0010977', 'EFO_1001158', 'EFO_0009606', 'EFO_0004243',
       'MONDO_0004986', 'MONDO_0003005', 'EFO_0000365', 'EFO_0000681',
       'EFO_0000702', 'EFO_0002617', 'EFO_0002499', 'EFO_0003770',
       'EFO_0000641', 'MONDO_0003268', 'EFO_0001365', 'EFO_0000574',
       'EFO_0003839', 'EFO_0008626', 'MONDO_0004192', 'EFO_0000756',
       'EFO_0002501', 'EFO_0000501', 'EFO_1001465', 'EFO_0003060',
       'EFO_0009784', 'EFO_1000880', 'EFO_0005952', 'EFO_1001512',
       'EFO_1001466', 'Orphanet_758', 'MONDO_0001576', 'EFO_0004683',
       'EFO_0000389', 'MONDO_0021063', 'EFO_1001157', 'EFO_0001378',
       'MONDO_0007254'], dtype=object), 'count': 49}","[ENSG00000119630,ENSG00000112715]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 13 approved and 36 investigational indications.
CHEMBL1743006,,,Antibody,False,DALOTUZUMAB,,2.0,,False,False,[],['Dalotuzumab' 'MK 0646' 'MK-0646' 'MK0646'],,,"{'rows': array(['MONDO_0007254', 'EFO_1000657', 'EFO_0003060', 'EFO_1001901',
       'MONDO_0008903', 'EFO_0003869', 'EFO_0001378', 'EFO_0000616',
       'EFO_1001951'], dtype=object), 'count': 9}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL182066,O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,GKGRZLGAQZPEHO-UHFFFAOYSA-N,Small molecule,False,RADIPRODIL,,2.0,,False,False,[],['RGH-896' 'Radiprodil' 'Rgh-896'],"[('drugbank', array(['DB12260'], dtype=object))]",['CHEMBL1802037'],"{'rows': array(['MONDO_0018097', 'EFO_0005762'], dtype=object), 'count': 2}","[ENSG00000176884,ENSG00000273079]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2105720,O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,FGQFOYHRJSUHMR-UHFFFAOYSA-N,Small molecule,True,LESINURAD,2015.0,4.0,,False,True,['Zurampic'],['Lesinurad' 'RDEA 594' 'RDEA-594' 'RDEA594'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic'],
      dtype=object)), ('drugbank', array(['DB11560'], dtype=object))]",['CHEMBL2105716'],"{'rows': array(['EFO_0009104', 'EFO_0004274'], dtype=object), 'count': 2}",[ENSG00000197891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hyperuricemia and gout. This drug has a black box warning from the FDA.
CHEMBL2178573,Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1,LUUMLYXKTPBTQR-UHFFFAOYSA-N,Small molecule,False,ILACIRNON,,2.0,,False,False,[],['CCX-140' 'CCX140' 'CCX140-B' 'Ccx140' 'Ilacirnon'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ILACIRNON/relevant/1/'],
      dtype=object))]",['CHEMBL4650229'],"{'rows': array(['HP_0000077', 'EFO_0000401', 'EFO_0004236', 'MONDO_0005148',
       'EFO_0004236', 'EFO_0000401', 'HP_0000077'], dtype=object), 'count': 7}",[ENSG00000121807],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3039508,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1,WCYDLROFMZJJLE-RTMHEQJQSA-N,Small molecule,False,NALDEMEDINE TOSYLATE,2017.0,4.0,CHEMBL2105755,False,True,['Rizmoic' 'Symproic'],['Naldemedine tosilate' 'Naldemedine tosylate'],"[('DailyMed', array(['naldemedine%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic'],
      dtype=object))]",,"{'rows': array(['EFO_0003843', 'HP_0002019', 'MONDO_0002203'], dtype=object), 'count': 3}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications.
CHEMBL3990025,,,Antibody,False,OLENDALIZUMAB,,2.0,,False,False,[],"['ALXN-1007' 'ALXN1007' 'ALXN1007 antibody' 'Alxn1007' 'Lendalizumab'
 'Olendalizumab']",,,"{'rows': array(['EFO_0004599', 'EFO_0002689'], dtype=object), 'count': 2}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297594,CC(C)OCCn1c(=S)[nH]c(=O)c2[nH]ccc21,FVJCUZCRPIMVLB-UHFFFAOYSA-N,Small molecule,False,VERDIPERSTAT,,3.0,,False,False,[],"['AZD-3241' 'AZD3241' 'Azd 3241' 'Azd3241' 'BHV-3241' 'BHV-3421'
 'Verdiperstat']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VERDIPERSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12440'], dtype=object))]",['CHEMBL5191541'],"{'rows': array(['EFO_1001050', 'MONDO_0010857', 'MONDO_0004976', 'MONDO_0005180'],
      dtype=object), 'count': 4}",[ENSG00000005381],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4594352,CC[C@@]1(OC(=O)C(C)ON=C2c3cc([N+](=O)[O-])cc([N+](=O)[O-])c3-c3c2cc([N+](=O)[O-])cc3[N+](=O)[O-])C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,JCCCLGDYMMTBPM-HXDHBHDHSA-N,Small molecule,False,TLC-388,,2.0,,False,False,[],['Lipotecan' 'Lipothecan free base' 'Tlc-388'],,,"{'rows': array(['EFO_0000616', 'EFO_0000182', 'EFO_0000681'], dtype=object), 'count': 3}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650299,,,Oligosaccharide,False,HEPARIN,2023.0,4.0,,False,True,[],"['B01AB10' 'Heparin' 'Heparin porcine' 'Heparin porcine intestinal mucosa'
 'Heparin, porcine']",,,"{'rows': array(['MONDO_0005148', 'MONDO_0100096'], dtype=object), 'count': 2}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 2 investigational indications.
CHEMBL4650452,,,Unknown,False,BNC-210,,2.0,,False,False,[],['BNC-210' 'BNC210' 'Bnc-210' 'Bnc210' 'Iw-2143'],,,"{'rows': array(['EFO_0001358', 'HP_0000713', 'EFO_1001917'], dtype=object), 'count': 3}",[ENSG00000175344],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL594,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21,KBUZBQVCBVDWKX-UHFFFAOYSA-N,Small molecule,False,EMEDASTINE,1997.0,4.0,,False,True,[],['Emadine' 'Emedastine'],"[('PubChem', array(['50125935'], dtype=object)), ('Wikipedia', array(['Emedastine'], dtype=object)), ('drugbank', array(['DB01084'], dtype=object)), ('chEBI', array(['4779'], dtype=object))]",['CHEMBL2103739'],"{'rows': array(['EFO_0007141', 'EFO_0005751'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for allergic conjunctivitis and eye allergy.
CHEMBL6622,O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],MOYKHGMNXAOIAT-JGWLITMVSA-N,Small molecule,False,ISOSORBIDE DINITRATE,1986.0,4.0,,False,True,"['Angitak' 'Carvasin' 'Cedocard' 'Cedocard ret' 'Cedocard-10'
 'Cedocard-20' 'Cedocard-40' 'Cedocard-5' 'Dilatrate-sr' 'Imtack'
 'Iso mack' 'Isocard' 'Isoket 10' 'Isoket 20' 'Isoket 5' 'Isoket ret 20'
 'Isoket ret 40' 'Isordil' 'Isordil tembids' 'Isosorbide dinitrate'
 'Jeridin' 'Soni-slo' 'Sorbichew' 'Sorbid sa' 'Sorbid-20 sa'
 'Sorbid-40 sa' 'Sorbidilat' 'Sorbitrate' 'Vascardin']","['C01DA08' 'Diluted isosorbide dinitrate'
 'Diluted isosorbide dinitrate rs' 'Diluted-isosorbide dinitrate'
 'Isomannide dinitrate' 'Isomannide-dinitrate' 'Isosorbide dinitrate'
 'Isosorbide dinitrate, diluted' 'Isosorbide dinitrate, diluted-'
 'Isosorbidi dinitras dilutes' 'Isosorbidi dinitras dilutus' 'NSC-80038'
 'Sorbide nitrate']","[('DailyMed', array(['isosorbide%20dinitrate'], dtype=object)), ('PubChem', array(['144204870', '170464980', '57260297'], dtype=object)), ('drugbank', array(['DB00883'], dtype=object)), ('chEBI', array(['6061'], dtype=object))]",,"{'rows': array(['MONDO_0010679', 'EFO_0001645', 'EFO_1001459', 'EFO_0000373',
       'EFO_0009552', 'EFO_1001375', 'EFO_0000319', 'EFO_0003913'],
      dtype=object), 'count': 8}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 4 approved and 4 investigational indications.
CHEMBL79261,O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2cc(Cl)cc3c2OCCO3)CC1,LYXKFNHUJJDTIA-UHFFFAOYSA-N,Small molecule,False,DU 125530,,2.0,,False,False,[],['DU-125530' 'Du 125530' 'Du125530'],,,"{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL836,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,DRHKJLXJIQTDTD-OAHLLOKOSA-N,Small molecule,False,TAMSULOSIN,1997.0,4.0,,False,True,[],['HGP-0412' 'HIP-1402' 'HIP1402' 'Tamsulon' 'Tamsulosin'],"[('Wikipedia', array(['Tamsulosin'], dtype=object)), ('drugbank', array(['DB00706'], dtype=object)), ('chEBI', array(['9398'], dtype=object))]",['CHEMBL1200914'],"{'rows': array(['HP_0000016', 'EFO_0005323', 'EFO_0005323', 'EFO_0004253',
       'EFO_0803321', 'EFO_1001228', 'EFO_0004234', 'MONDO_0024647',
       'EFO_0000284', 'HP_0000016', 'EFO_0000537', 'EFO_0000536',
       'EFO_0003830', 'HP_0000011', 'EFO_0001663', 'EFO_0000284',
       'MONDO_0008315'], dtype=object), 'count': 17}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for benign prostatic hyperplasia and prostate carcinoma and has 13 investigational indications.
CHEMBL1200961,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,SRGKFVAASLQVBO-BTJKTKAUSA-N,Small molecule,False,BROMPHENIRAMINE MALEATE,1957.0,4.0,CHEMBL811,False,True,"['Brompheniramine maleate' 'Dimegan' 'Dimetane' 'Dimetane-ten' 'Dimotane'
 'Dimotane l.a.']","['(+)-Brompheniramine Maleate' 'Brompheniramine fumarate'
 'Brompheniramine maleate' 'NSC-758652' 'Parabromdylamine maleate']","[('DailyMed', array(['brompheniramine%20maleate'], dtype=object)), ('PubChem', array(['26747454', '50105943', '56422493', '855910', '93576630'],
      dtype=object)), ('chEBI', array(['3184'], dtype=object))]",,"{'rows': array(['EFO_0007214', 'HP_0001742', 'MONDO_0005271', 'EFO_0003956',
       'EFO_0007486', 'HP_0012735'], dtype=object), 'count': 6}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved indications.
CHEMBL1200967,CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1.Cl,ZQDJSWUEGOYDGT-UHFFFAOYSA-N,Small molecule,False,BROMODIPHENHYDRAMINE HYDROCHLORIDE,1954.0,4.0,CHEMBL1201245,False,True,['Ambodryl'],"['Bromazine' 'Bromodiphenhydramine hcl'
 'Bromodiphenhydramine hydrochloride' 'NSC-36113']","[('chEBI', array(['59178'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954.
CHEMBL1201022,Cl.Nc1ccc(/N=N/c2ccccc2)c(N)n1,QQBPIHBUCMDKFG-GEEYTBSJSA-N,Small molecule,False,PHENAZOPYRIDINE HYDROCHLORIDE,1987.0,4.0,CHEMBL1242,False,True,['Pyridium' 'Uropyrine'],"['NC 150' 'NC-150' 'NSC-1879' 'Phenazopyridine hcl'
 'Phenazopyridine hydrochloride' 'W 1655' 'W-1655']","[('PubChem', array(['17389769', '26748196', '26752976'], dtype=object))]",,"{'rows': array(['EFO_0003103'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and has 1 investigational indication.
CHEMBL1429,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,NFLWUMRGJYTJIN-PNIOQBSNSA-N,Protein,True,DESMOPRESSIN,1978.0,4.0,,False,True,[],['Desmopressin' 'H01BA02' 'Ser-120' 'Ser120'],"[('drugbank', array(['DB00035'], dtype=object)), ('chEBI', array(['4450'], dtype=object))]",['CHEMBL1200556'],"{'rows': array(['EFO_0005669', 'MONDO_0004782', 'EFO_1000781', 'MP_0001914',
       'EFO_1001412', 'MONDO_0024290', 'MONDO_0004782', 'MONDO_0007254',
       'HP_0001742', 'MONDO_0024574', 'HP_0031364', 'MP_0001914',
       'MONDO_0024290', 'EFO_0009505', 'HP_0000863', 'MONDO_0008315',
       'EFO_0000537', 'EFO_0007344'], dtype=object), 'count': 18}","[ENSG00000126895,ENSG00000166148,ENSG00000198049]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743040,,,Antibody,False,MILATUZUMAB,,2.0,,False,False,[],['HLL1' 'IMMU-115' 'Milatuzumab'],,,"{'rows': array(['EFO_0000095', 'EFO_0001378', 'EFO_0000574', 'EFO_0006738'],
      dtype=object), 'count': 4}",[ENSG00000019582],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1946618,CN(CCO)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1,ZJKUETLEJYCOBO-UHFFFAOYSA-N,Small molecule,False,AZD-7268,,2.0,,False,False,[],['AZ-12488024' 'AZ12488024' 'AZD7268' 'Azd 7268' 'Azd-7268' 'Azd7268'],,,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}",[ENSG00000116329],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2035874,CC(C)c1cc(Oc2c(Br)cc(NC(=O)CC(=O)O)cc2Br)ccc1O,VPCSYAVXDAUHLT-UHFFFAOYSA-N,Small molecule,False,EPROTIROME,,3.0,,False,False,[],['Bms-356384' 'Eprotirome' 'Kb-2115' 'Kb2115'],"[('drugbank', array(['DB05035'], dtype=object))]",,"{'rows': array(['Orphanet_309005', 'EFO_0004911', 'HP_0003124'], dtype=object), 'count': 3}",[ENSG00000151090],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2108061,,,Antibody,False,VOLOCIXIMAB,,3.0,,False,False,[],['M-200' 'M200' 'Volociximab'],,,"{'rows': array(['MONDO_0008903', 'EFO_0003060', 'EFO_0000756', 'EFO_0002618',
       'MONDO_0008170', 'EFO_0001365', 'EFO_1001100'], dtype=object), 'count': 7}","[ENSG00000150093,ENSG00000161638]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2109374,,,Antibody,False,TRC-093,,1.0,,False,False,[],['MT-293' 'TRC-093' 'TRC093' 'Trc-093'],,,"{'rows': array(['MONDO_0004992', 'EFO_0009708'], dtype=object), 'count': 2}",[ENSG00000081052],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2109539,,,Antibody,False,RG-7652,,2.0,,False,False,[],['RG-7652'],,,,[ENSG00000169174],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109636,,,Antibody,False,VILOBELIMAB,,2.0,,False,False,[],['CACP 29' 'CACP29' 'IFX-1' 'Vilobelimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VILOBELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1000710', 'EFO_1000784', 'HP_0000999', 'EFO_0006835',
       'MONDO_0100096', 'EFO_0005297', 'MONDO_0015492', 'EFO_0006834',
       'MP_0001845', 'HP_0100806', 'EFO_0000717'], dtype=object), 'count': 11}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.
CHEMBL2110659,O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CO3)N1,DYJIKHYBKVODAC-ZDUSSCGKSA-N,Small molecule,False,APLINDORE,,2.0,,False,False,[],['Aplindore'],"[('drugbank', array(['DB06620'], dtype=object))]",['CHEMBL2104864'],"{'rows': array(['MONDO_0005180', 'EFO_0004270'], dtype=object), 'count': 2}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL223360,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1,MPVGZUGXCQEXTM-UHFFFAOYSA-N,Small molecule,False,LINIFANIB,,3.0,,False,False,[],['A-741439' 'ABT-869' 'AL-39324' 'Linifanib' 'RG-3635'],"[('PubChem', array(['103904340', '137275904', '50100086'], dtype=object))]",,"{'rows': array(['EFO_0000681', 'EFO_1000657', 'EFO_0000365', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000182', 'MONDO_0021063', 'EFO_0001065',
       'EFO_0001365', 'MONDO_0007254'], dtype=object), 'count': 10}","[ENSG00000182578,ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL300138,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,AXRCEOKUDYDWLF-UHFFFAOYSA-N,Small molecule,False,ENZASTAURIN,,3.0,,False,False,['Kinenza'],['DB-102' 'DB102' 'Enzastaurin' 'LY-317615' 'LY317615' 'Ly-317615'],"[('PubChem', array(['137275839', '144206918', '170465609'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENZASTAURIN/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Enzastaurin'], dtype=object)), ('drugbank', array(['DB06486'], dtype=object))]",['CHEMBL2107337'],"{'rows': array(['MONDO_0008315', 'EFO_0004288', 'EFO_1001465', 'EFO_0001378',
       'EFO_0002913', 'EFO_1001469', 'EFO_0009441', 'EFO_1001951',
       'EFO_0000096', 'EFO_1000158', 'MONDO_0018906', 'MONDO_0008315',
       'EFO_0003060', 'EFO_0000403', 'EFO_0000403', 'MONDO_0002087',
       'EFO_0004289', 'EFO_0000365', 'MONDO_0008170', 'MONDO_0020066',
       'MONDO_0004992', 'EFO_0003860', 'EFO_0005543', 'EFO_0000681',
       'EFO_1001100', 'EFO_0000519', 'MONDO_0100342', 'EFO_0000702',
       'MONDO_0008903', 'EFO_0005952', 'MONDO_0008903', 'EFO_0003869',
       'EFO_1000251', 'EFO_0000616', 'EFO_0003060', 'EFO_0000621',
       'EFO_0000519', 'EFO_0000574', 'EFO_0000326', 'MONDO_0008170',
       'EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 42}",[ENSG00000166501],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 37 investigational indications.
CHEMBL3544971,C[C@H](N)Cc1ccccc1.C[C@H](N)Cc1ccccc1.O=S(=O)(O)O,PYHRZPFZZDCOPH-QXGOIDDHSA-N,Small molecule,True,DEXTROAMPHETAMINE SULFATE,1960.0,4.0,CHEMBL612,False,True,['Dexampex' 'Dexedrine' 'Dextroamphetamine sulfate' 'Dextrostat' 'Ferndex'],"['Amphetamine sulfate, dextro' 'D-amphetamine hemisulfate salt'
 'Dexamfetamine sulfate' 'Dexamphetamine sulfate'
 'Dexamphetamine sulphate' 'Dextroamphetamine sulfate'
 'Dextroamphetamine sulfate cii' 'Dextroamphetamine sulphate' 'NSC-27104']","[('DailyMed', array(['dextroamphetamine%20sulfate'], dtype=object)), ('chEBI', array(['51064'], dtype=object))]",,"{'rows': array(['EFO_0003888', 'MONDO_0016158'], dtype=object), 'count': 2}","[ENSG00000165646,ENSG00000103546,ENSG00000142319]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome. This drug has a black box warning from the FDA.
CHEMBL3545236,,,Small molecule,False,BPI-9016,,1.0,,False,False,[],['BPI-9016M' 'Bpi-9016'],,,"{'rows': array(['EFO_0003060', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000105976,ENSG00000167601]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL4297517,CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O,RLCLASQCAPXVLM-NSHDSACASA-N,Small molecule,True,MAVACAMTEN,2022.0,4.0,,False,True,['Camzyos'],['Camzyos' 'MYK-461' 'Mavacamten' 'Myk-461' 'SAR-439152'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MAVACAMTEN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14921'], dtype=object))]",,"{'rows': array(['EFO_0000538', 'EFO_0003144', 'EFO_0000319'], dtype=object), 'count': 3}","[ENSG00000092054,ENSG00000197616,ENSG00000078814,ENSG00000160808,ENSG00000111245,ENSG00000106631,ENSG00000198336]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hypertrophic cardiomyopathy and cardiovascular disease and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL4298012,,,Antibody,False,TESIDOLUMAB,,2.0,,False,False,[],['LFG-316' 'LFG316' 'Lfg316' 'NOV-4' 'Tesidolumab'],,,"{'rows': array(['EFO_0001365', 'EFO_0004683', 'EFO_1001492', 'EFO_1000986'],
      dtype=object), 'count': 4}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4650296,,,Unknown,False,BOS-589,,2.0,,False,False,[],['BOS-589' 'Bos-589' 'GSK3352589'],,,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}",[ENSG00000165731],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL473,CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,IXTMWRCNAAVVAI-UHFFFAOYSA-N,Small molecule,True,DOFETILIDE,1999.0,4.0,,False,True,['Dofetilide' 'Tikosyn'],"['Dofetilide' 'UK-68,798' 'UK-68798']","[('DailyMed', array(['dofetilide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn'],
      dtype=object)), ('PubChem', array(['144205731', '170465418', '26757968'], dtype=object)), ('Wikipedia', array(['Dofetilide'], dtype=object)), ('drugbank', array(['DB00204'], dtype=object)), ('chEBI', array(['4681'], dtype=object))]",,"{'rows': array(['EFO_0003911', 'EFO_0004269', 'EFO_0003144', 'HP_0001657',
       'HP_0004308', 'EFO_0000275'], dtype=object), 'count': 6}",[ENSG00000055118],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL592374,Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl,BSMNRYCSBFHEMQ-KCJUWKMLSA-N,Small molecule,False,AMITIFADINE,,2.0,,False,False,[],"['Amitifadine' 'DOV 21947' 'DOV-21,947' 'DOV-21947' 'EB1010']","[('Wikipedia', array(['Amitifadine'], dtype=object)), ('drugbank', array(['DB05964'], dtype=object))]",['CHEMBL1818442'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL595,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,HYAFETHFCAUJAY-UHFFFAOYSA-N,Small molecule,True,PIOGLITAZONE,1999.0,4.0,,False,True,[],['AD-4833' 'Actos' 'Duetact' 'Glustin' 'Pioglitazone' 'U-72107' 'Zactos'],"[('PubChem', array(['137275816', '174007207', '26756476'], dtype=object)), ('Wikipedia', array(['Pioglitazone'], dtype=object)), ('drugbank', array(['DB01132'], dtype=object)), ('chEBI', array(['8228'], dtype=object))]",['CHEMBL1715'],"{'rows': array(['EFO_0000756', 'EFO_0004265', 'EFO_0000712', 'EFO_0000400',
       'EFO_0000384', 'MONDO_0002108', 'MONDO_0008903', 'HP_0012115',
       'HP_0003124', 'EFO_0002546', 'EFO_0000544', 'HP_0002745',
       'EFO_0000339', 'MONDO_0005148', 'EFO_0003095', 'MONDO_0004975',
       'EFO_0003929', 'EFO_0001421', 'EFO_0000616', 'MONDO_0018305',
       'MONDO_0005148', 'EFO_0001361', 'MP_0001845', 'EFO_0001421',
       'MONDO_0004976', 'EFO_0003085', 'MONDO_0015339', 'MONDO_0100339',
       'EFO_0000707', 'EFO_1001249', 'EFO_0001073', 'EFO_0003884',
       'Orphanet_43', 'EFO_0000708', 'HP_0002745', 'EFO_0001645',
       'EFO_0003914', 'MONDO_0005301', 'MONDO_0008315', 'EFO_0002618',
       'MONDO_0007915', 'EFO_0000613', 'EFO_0000519', 'EFO_0003095',
       'EFO_0003047', 'EFO_1000948', 'EFO_0000537', 'EFO_0000685',
       'MONDO_0002009', 'EFO_0004272', 'HP_0100543', 'EFO_0002618',
       'EFO_0002499', 'EFO_0003756', 'MONDO_0001437', 'EFO_0005611',
       'EFO_0002614', 'EFO_0003060', 'MONDO_0009061', 'MONDO_0007079',
       'EFO_1001348', 'EFO_0000676', 'EFO_0005669', 'EFO_0000673',
       'EFO_0008620', 'EFO_0003060', 'MONDO_0004976', 'MONDO_0004979',
       'EFO_0000319', 'EFO_0000660', 'EFO_0000195', 'EFO_0003884',
       'HP_0001397', 'MONDO_0005180', 'EFO_0001378', 'MONDO_0016642',
       'EFO_0004220', 'MONDO_0005147', 'EFO_0000222', 'MONDO_0001657'],
      dtype=object), 'count': 80}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 74 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1173655,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,ULXXDDBFHOBEHA-CWDCEQMOSA-N,Small molecule,False,AFATINIB,2013.0,4.0,,False,True,['Gilotrif' 'Giotrif'],"['Afatinib' 'BIBW-2992' 'BIBW2992' 'Bibw 2992' 'NSC-750691' 'Tomtovok'
 'Tovok']","[('Wikipedia', array(['Afatinib'], dtype=object)), ('drugbank', array(['DB08916'], dtype=object)), ('chEBI', array(['61390'], dtype=object))]",['CHEMBL2105712'],"{'rows': array(['EFO_0003869', 'MONDO_0021117', 'EFO_0000616', 'EFO_0000673',
       'MONDO_0001657', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001378',
       'EFO_0004142', 'HP_0000083', 'EFO_0000707', 'EFO_0003859',
       'EFO_0006859', 'EFO_0000702', 'MONDO_0008978', 'MONDO_0007254',
       'EFO_0002618', 'EFO_0003863', 'EFO_0009709', 'MONDO_0004992',
       'EFO_0004284', 'EFO_0005543', 'EFO_1001956', 'EFO_0000181',
       'EFO_0000519', 'EFO_0001421', 'EFO_0005922', 'EFO_0001065',
       'EFO_0003060'], dtype=object), 'count': 29}","[ENSG00000146648,ENSG00000141736,ENSG00000178568]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for non-small cell lung carcinoma and has 28 investigational indications.
CHEMBL1200618,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl,RRJFVPUCXDGFJB-UHFFFAOYSA-N,Small molecule,False,FEXOFENADINE HYDROCHLORIDE,1996.0,4.0,CHEMBL914,False,True,"['Allegra' 'Allegra allergy' 'Allegra hives' ""Children's allegra allergy""
 ""Children's allegra hives""
 ""Children's fexofenadine hydrochloride allergy""
 ""Children's fexofenadine hydrochloride hives""
 'Fexofenadine hydrochloride' 'Fexofenadine hydrochloride allergy'
 'Fexofenadine hydrochloride hives' 'Telfast 120' 'Telfast 180'
 'Telfast 30']","['Fexofenadine hcl' 'Fexofenadine hydrochloride' 'MDL 16,455A'
 'MDL-16455A']","[('DailyMed', array(['fexofenadine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206676', '170464669', '26749923', '26753303', '50085984'],
      dtype=object))]",,"{'rows': array(['MONDO_0005271', 'EFO_0004253', 'EFO_1001417', 'EFO_0005854',
       'EFO_0003956', 'EFO_0005531'], dtype=object), 'count': 6}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 2 investigational indications.
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,AFCGFAGUEYAMAO-UHFFFAOYSA-N,Small molecule,False,ACAMPROSATE,2004.0,4.0,,False,True,[],['Acamprosate'],"[('PubChem', array(['50112716'], dtype=object)), ('Wikipedia', array(['Acamprosate'], dtype=object)), ('drugbank', array(['DB00659'], dtype=object)), ('chEBI', array(['51041'], dtype=object))]",['CHEMBL2068724'],"{'rows': array(['EFO_0003758', 'HP_0000360', 'MONDO_0007079', 'EFO_0005230',
       'EFO_0002610', 'HP_0000726', 'EFO_0003756', 'EFO_0005203',
       'MONDO_0002050', 'MONDO_0005090', 'MONDO_0010383', 'MONDO_0007079',
       'EFO_0004701'], dtype=object), 'count': 13}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for alcohol dependence and has 11 investigational indications.
CHEMBL1201664,,,Protein,False,INSULIN ASPART PROTAMINE RECOMBINANT,2001.0,4.0,,False,True,[],['Insulin aspart protamine recombinant'],"[('DailyMed', array(['insulin%20aspart%20protamine%20recombinant'], dtype=object))]",,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 2001.
CHEMBL1236682,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,RDSACQWTXKSHJT-NSHDSACASA-N,Small molecule,False,REFAMETINIB,,2.0,,False,False,[],"['BAY 869766' 'BAY 8697661' 'BAY-86-9766' 'BAY-869766' 'BAY-8697661'
 'BAY86-9766' 'BAY869766' 'BAY8697661' 'Bay-86-9766' 'RDEA 119' 'RDEA-119'
 'Rdea119' 'Refametinib']","[('drugbank', array(['DB06309'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'MONDO_0003060', 'MONDO_0004992', 'EFO_0000616'],
      dtype=object), 'count': 4}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1743073,,,Protein,False,SOTATERCEPT,,3.0,,False,False,[],['ACE-001' 'ACE-011' 'ACE011' 'Sotatercept'],,,"{'rows': array(['HP_0012410', 'EFO_0001378', 'MONDO_0044903', 'EFO_0004272',
       'EFO_0001361', 'MONDO_0016486', 'MONDO_0016487'], dtype=object), 'count': 7}",[ENSG00000122641],Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2105711,CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O,ZXOCGDDVNPDRIW-NHFZGCSJSA-N,Small molecule,False,TOFOGLIFLOZIN,2014.0,4.0,CHEMBL2110731,False,True,[],"['CSG452' 'Tofogliflozin' 'Tofogliflozin hydrate'
 'Tofogliflozin monohydrate']","[('Wikipedia', array(['Tofogliflozin'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_1001249'], dtype=object), 'count': 2}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 2 investigational indications.
CHEMBL2109193,,,Antibody,False,GAVILIMOMAB,,3.0,,False,False,[],['ABX-CBL' 'Gavilimomab'],,,"{'rows': array(['MONDO_0013730'], dtype=object), 'count': 1}",[ENSG00000172270],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109328,,,Antibody,False,IMC-EB10,,1.0,,False,False,[],['IMC-EB10' 'Imc-eb10'],,,"{'rows': array(['MONDO_0004643'], dtype=object), 'count': 1}",[ENSG00000122025],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109338,,,Antibody,False,AMG-729,,1.0,,False,False,[],['AMG-729'],,,,[ENSG00000177455],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2178422,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F,KRNAOFGYEFKHPB-ANJVHQHFSA-N,Small molecule,False,RIMEGEPANT,2020.0,4.0,,False,True,[],['BMS-927711' 'Bhv-3000' 'Rimegepant'],"[('drugbank', array(['DB12457'], dtype=object))]",['CHEMBL2364629'],"{'rows': array(['MONDO_0005277', 'EFO_0003843', 'EFO_0000676', 'EFO_0007486',
       'EFO_0005279', 'MONDO_0005277', 'EFO_1001219'], dtype=object), 'count': 7}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 6 investigational indications.
CHEMBL2361370,CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1.CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1.O=S(=O)(O)O,FEDSNBHHWZEYTP-ZFQYHYQMSA-N,Small molecule,False,PENBUTOLOL SULFATE,1987.0,4.0,CHEMBL1290,False,True,['Betapressin' 'Levatol'],"['HOE 39-893D' 'HOE 893D' 'HOE-39-893D' 'HOE-893D' 'NSC-760043'
 'Penbutolol sulfate' 'Penbutolol sulphate']","[('PubChem', array(['144204192'], dtype=object))]",,,"[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL3039544,,,Protein,False,TECEMOTIDE,,3.0,,False,False,['Stimuvax'],"['BLP-25' 'BLP25' 'BP-1-148' 'Blp 25' 'Blp-25 lipopeptide' 'EMD 531444'
 'Emepepimut-s' 'LIPOPEPTIDE BLP-25' 'Tecemotide']",,,"{'rows': array(['EFO_0003060', 'EFO_0001378', 'MONDO_0008315', 'MONDO_0008903',
       'MONDO_0044937', 'EFO_1000657', 'MONDO_0007254', 'EFO_1001950'],
      dtype=object), 'count': 8}",[ENSG00000185499],Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL3187365,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1,VSWBSWWIRNCQIJ-UHFFFAOYSA-N,Small molecule,True,ASENAPINE,2009.0,4.0,,False,True,['Secuado' 'Sycrest'],['Asenapine'],"[('DailyMed', array(['asenapine'], dtype=object)), ('PubChem', array(['124899263'], dtype=object)), ('chEBI', array(['71255'], dtype=object))]",['CHEMBL3544974'],"{'rows': array(['MONDO_0005090', 'EFO_0009963', 'HP_0025268', 'EFO_0005407',
       'EFO_0005411', 'EFO_0009963', 'MONDO_0004985', 'MONDO_0005090',
       'EFO_0005407'], dtype=object), 'count': 9}","[ENSG00000149295,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3301576,,,Unknown,False,PEGPLERANIB SODIUM,,3.0,,False,False,['Fovista'],['E-01AJ' 'E-10030' 'E01AJ' 'E10030' 'Pegpleranib sodium' 'X-01E' 'X01E'],,,"{'rows': array(['MONDO_0008667', 'EFO_0001365'], dtype=object), 'count': 2}",[ENSG00000100311],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3301672,CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)([O-])[O-])[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)([O-])[O-])[C@@H]1OCC[C@@H](CCCCCCC)OC.[Na+].[Na+].[Na+].[Na+],FEMINZOAAWPBPP-RHMAUSBNSA-J,Small molecule,False,ERITORAN TETRASODIUM,,3.0,CHEMBL501259,False,False,[],"['B-1287' 'B1287' 'E-5564' 'E5564' 'Eritoran sodium'
 'Eritoran tetrasodium' 'Eritoran tetrasodium salt']","[('chEBI', array(['46692'], dtype=object))]",,"{'rows': array(['HP_0100806', 'EFO_0000565'], dtype=object), 'count': 2}","[ENSG00000136869,ENSG00000154589]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3348963,CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1.O=C(O)CNC(=O)c1ccccc1,XSFPZBUIBYMVEA-CELUQASASA-N,Small molecule,False,TELOTRISTAT ETIPRATE,2017.0,4.0,CHEMBL2105695,False,True,['Xermelo'],"['LX1032 HIPPURATE' 'LX1606 HIPPURATE' 'Telotristat ethyl hippurate'
 'Telotristat etiprate']","[('DailyMed', array(['telotristat%20etiprate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xermelo'],
      dtype=object))]",,"{'rows': array(['EFO_1001901', 'HP_0002014', 'EFO_0004243'], dtype=object), 'count': 3}","[ENSG00000139287,ENSG00000129167]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications.
CHEMBL3707275,,,Gene,False,VORETIGENE NEPARVOVEC,2018.0,4.0,,False,True,['Luxturna'],"['AAV-2-HRPE65V2' 'AAV2-hRPE65v2' 'Luxturna' 'SPK-RPE65'
 'Voretigene neparvovec' 'Voretigene neparvovec rzyl'
 'Voretigene neparvovec-rzyl']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna'],
      dtype=object))]",,"{'rows': array(['EFO_0003966', 'HP_0000580', 'MONDO_0018998'], dtype=object), 'count': 3}",[ENSG00000116745],Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications.
CHEMBL4073443,Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,HKTBYUWLRDZAJK-UHFFFAOYSA-N,Small molecule,False,TOMIVOSERTIB,,2.0,,False,False,[],['EFT-508' 'Eft 508' 'Eft508' 'Tomivosertib' 'eFT508'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOMIVOSERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15219'], dtype=object))]",['CHEMBL4298140'],"{'rows': array(['EFO_0000574', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0004992',
       'EFO_0000616', 'EFO_0003060', 'EFO_0000222', 'MONDO_0007254',
       'EFO_0000616'], dtype=object), 'count': 9}","[ENSG00000099875,ENSG00000079277]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL412309,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[Si](C)(C)C(C)(C)C,XUSKJHCMMWAAHV-SANMLTNESA-N,Small molecule,False,AR-67,,2.0,,False,False,[],['AR67' 'Ar-67' 'DB 67' 'DB-67' 'NSC-708298' 'Silatecan'],"[('PubChem', array(['582483'], dtype=object)), ('drugbank', array(['DB12384'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000198', 'MONDO_0004992', 'EFO_1001465'],
      dtype=object), 'count': 4}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL414157,CCCn1c(=O)c2[nH]c(C34CCC(CCC(=O)O)(CC3)CC4)nc2n(CCC)c1=O,ZWTVVWUOTJRXKM-UHFFFAOYSA-N,Small molecule,False,TONAPOFYLLINE,,3.0,,False,False,[],['BG-9928' 'BG9928' 'Tonapofylline'],"[('drugbank', array(['DB12569'], dtype=object))]",['CHEMBL535165'],"{'rows': array(['EFO_0003144', 'HP_0000083', 'EFO_0000373', 'EFO_0001421'],
      dtype=object), 'count': 4}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4594419,CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O,CMVHFGNTABZQJU-HCXYKTFWSA-N,Small molecule,False,BMS-813160,,2.0,,False,False,[],['BMS-813160' 'Bms 813160' 'Bms-813160'],,,"{'rows': array(['MONDO_0004992', 'MONDO_0005184', 'EFO_0000536', 'EFO_0000401'],
      dtype=object), 'count': 4}","[ENSG00000160791,ENSG00000121807]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4650275,,,Oligonucleotide,False,LUMASIRAN SODIUM,2020.0,4.0,,False,True,['Oxlumo'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oxlumo'],
      dtype=object))]",,"{'rows': array(['MONDO_0009823', 'MONDO_0002474'], dtype=object), 'count': 2}",[ENSG00000101323],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for primary hyperoxaluria type 1 and primary hyperoxaluria.
CHEMBL5314388,CCN1CCC(Oc2c(C#N)ncc3[nH]c4ncccc4c23)CC1,XEZLBMHDUXSICI-UHFFFAOYSA-N,Small molecule,False,RG-7602,,1.0,,False,False,[],['GDC-0425' 'RG-7602' 'Rg-7602'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000149554],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL5315119,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O,GJMQTRCDSIQEFK-SCDRJROZSA-N,Small molecule,True,UPADACITINIB HEMIHYDRATE,2019.0,4.0,CHEMBL3622821,False,True,['Rinvoq'],['Upadacitinib hydrate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq'],
      dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}","[ENSG00000105639,ENSG00000096968,ENSG00000162434,ENSG00000105397]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for rheumatoid arthritis. This drug has a black box warning from the FDA.
CHEMBL712,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1,XRCFXMGQEVUZFC-UHFFFAOYSA-N,Small molecule,False,ANISINDIONE,1957.0,4.0,,False,True,['Miradon'],['Anisindione' 'NSC-759629'],"[('PubChem', array(['144204923', '14729672', '170465379', '26748631', '50086377'],
      dtype=object)), ('Wikipedia', array(['Anisindione'], dtype=object)), ('drugbank', array(['DB01125'], dtype=object)), ('chEBI', array(['133809'], dtype=object))]",,,[ENSG00000115486],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957.
CHEMBL856,CCC1(c2ccccc2)C(=O)NCNC1=O,DQMZLTXERSFNPB-UHFFFAOYSA-N,Small molecule,False,PRIMIDONE,1954.0,4.0,,False,True,['Lepsiral' 'Liskantin' 'Mysoline' 'Neurosyn' 'Primidone'],['Lepimidin' 'NSC-41701' 'Primaclone' 'Primidone' 'Resimatil'],"[('DailyMed', array(['primidone'], dtype=object)), ('PubChem', array(['104171217', '11111659', '11112270', '11113350', '144203789',
       '144209146', '144213511', '170464846', '17389534', '50104129',
       '50126364', '56324597', '855864', '90340844'], dtype=object)), ('Wikipedia', array(['Primidone'], dtype=object)), ('drugbank', array(['DB00794'], dtype=object)), ('chEBI', array(['8412'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_0000474'], dtype=object), 'count': 2}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for epilepsy and has 1 investigational indication.
CHEMBL1097279,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(Cl)(Cl)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Na+].[Na+].[Na+].[Na+],COWWROCHWNGJHQ-OPKBHZIBSA-J,Small molecule,False,CANGRELOR TETRASODIUM,2015.0,4.0,CHEMBL334966,False,True,['Kengreal' 'Kengrexal'],"['AR-C69931MX' 'Cangrelor tetrasodium' 'Cangrelor tetrasodium salt'
 'Kengrexal']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal'],
      dtype=object))]",,"{'rows': array(['EFO_0000612', 'HP_0004419'], dtype=object), 'count': 2}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for myocardial infarction and recurrent thrombophlebitis.
CHEMBL1200338,CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C.O,AFJCNBBHEVLGCZ-UHFFFAOYSA-N,Small molecule,False,PINACIDIL,1989.0,4.0,CHEMBL1159,False,True,['Pindac'],['NSC-759588' 'Pinacidil' 'Pinacidil hydrate' 'Pinacidil monohydrate'],"[('PubChem', array(['144204505', '170465261', '56462991'], dtype=object)), ('Wikipedia', array(['Pinacidil'], dtype=object)), ('chEBI', array(['34923'], dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000187486,ENSG00000069431]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for hypertension.
CHEMBL1201346,O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1,IPOKCKJONYRRHP-FMQUCBEESA-N,Small molecule,False,BALSALAZIDE,2000.0,4.0,,False,True,[],['Balsalazide'],"[('PubChem', array(['144205805', '170465305', '26758056'], dtype=object)), ('drugbank', array(['DB01014'], dtype=object)), ('chEBI', array(['267413'], dtype=object))]",['CHEMBL1200760'],"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}","[ENSG00000132170,ENSG00000073756,ENSG00000095303,ENSG00000012779]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for ulcerative colitis.
CHEMBL1201577,,,Antibody,True,CETUXIMAB,2004.0,4.0,,False,True,['Erbitux'],"['ABP-494' 'C-225' 'C225' 'CMAB-009' 'CMAB009' 'Cetuximab'
 'Cetuximab (genetical recombination)' 'Cetuximab biosimilar (abp-494)'
 'IMC-225' 'IMC-C225' 'MOAB C225']","[('DailyMed', array(['cetuximab'], dtype=object)), ('DrugCentral', array(['4954'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux'],
      dtype=object)), ('Wikipedia', array(['Cetuximab'], dtype=object))]",,"{'rows': array(['MONDO_0001056', 'EFO_0007535', 'EFO_0005950', 'EFO_0000571',
       'MONDO_0002974', 'EFO_0000519', 'EFO_0000616', 'EFO_0009430',
       'MONDO_0007576', 'EFO_0004284', 'EFO_0004252', 'EFO_1001931',
       'MONDO_0002358', 'MONDO_0008315', 'EFO_0002916', 'EFO_1001949',
       'EFO_0000231', 'MONDO_0021074', 'EFO_0001061', 'EFO_0002938',
       'EFO_1001951', 'EFO_0000503', 'EFO_0003897', 'MONDO_0021355',
       'EFO_0004142', 'EFO_0005922', 'EFO_0003817', 'EFO_1000657',
       'MONDO_0004992', 'MONDO_0001187', 'EFO_0001378', 'MONDO_0021364',
       'EFO_0000182', 'MONDO_0002691', 'EFO_0003871', 'MONDO_0007254',
       'EFO_0003835', 'EFO_0000673', 'MONDO_0044926', 'EFO_0003060',
       'MONDO_0005575', 'MONDO_0008978', 'MONDO_0001879', 'EFO_0006352',
       'MONDO_0044704', 'EFO_0004198', 'EFO_0000181', 'MONDO_0021310',
       'EFO_0009708', 'EFO_0000365', 'MONDO_0100342', 'MONDO_0002087',
       'EFO_0003869', 'EFO_0002618', 'EFO_1001100', 'EFO_0000707',
       'MONDO_0005184', 'MONDO_0008903', 'MONDO_0011962', 'EFO_1000251',
       'EFO_0006859', 'MONDO_0001657', 'EFO_0002499', 'MONDO_0008170',
       'MONDO_0002038', 'MONDO_0021063', 'EFO_0000313', 'EFO_0000691',
       'EFO_0003891', 'EFO_0000228', 'EFO_1001998', 'EFO_0003868',
       'EFO_0005221', 'EFO_1001950'], dtype=object), 'count': 74}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 13 approved and 61 investigational indications. This drug has a black box warning from the FDA.
CHEMBL13,COCCc1ccc(OCC(O)CNC(C)C)cc1,IUBSYMUCCVWXPE-UHFFFAOYSA-N,Small molecule,True,METOPROLOL,1978.0,4.0,,False,True,[],"['(rs)-metoprolol' 'Beatrolol' 'CGP-2175' 'Dl-metoprolol' 'Lopressidone'
 'Metoprolol' 'Metoprolol slow release' 'Seroken' 'Toprol-XL']","[('PubChem', array(['251919670'], dtype=object)), ('Wikipedia', array(['Metoprolol'], dtype=object)), ('drugbank', array(['DB00264'], dtype=object)), ('chEBI', array(['6904'], dtype=object))]","['CHEMBL1200337' 'CHEMBL1200840' 'CHEMBL2062335' 'CHEMBL545787'
 'CHEMBL3186768' 'CHEMBL2356097' 'CHEMBL3989566' 'CHEMBL1868892']","{'rows': array(['HP_0004308', 'EFO_0008585', 'EFO_0003913', 'EFO_0003144',
       'EFO_0001073', 'EFO_0008586', 'HP_0003124', 'EFO_0000712',
       'EFO_0003917', 'EFO_0000537', 'EFO_0000676', 'EFO_0000319',
       'EFO_0000275', 'EFO_0000612', 'EFO_0003777', 'EFO_0003913',
       'EFO_0000373', 'EFO_0000538', 'MONDO_0005148', 'EFO_0000266',
       'EFO_0003777', 'MONDO_0010679', 'EFO_0004287', 'Orphanet_79292',
       'EFO_0000712', 'EFO_0001068', 'EFO_0000275', 'EFO_0000764',
       'HP_0001653', 'Orphanet_848', 'EFO_0000275', 'EFO_0001645',
       'EFO_0000612', 'EFO_1002000', 'EFO_0000616', 'EFO_0003914',
       'EFO_0000537', 'EFO_0000341', 'EFO_0000274', 'EFO_0008583',
       'EFO_0000373', 'MONDO_0008300', 'EFO_0005306', 'EFO_0004278',
       'EFO_0000612', 'EFO_0003144', 'EFO_1000637', 'MONDO_0007254',
       'EFO_0003144', 'EFO_0000537', 'EFO_1000645'], dtype=object), 'count': 51}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 37 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1611,O=C1N=C([O-])NC1(c1ccccc1)c1ccccc1.[Na+],FJPYVLNWWICYDW-UHFFFAOYSA-M,Small molecule,True,PHENYTOIN SODIUM,1956.0,4.0,CHEMBL16,False,True,"['Dilantin' 'Diphenylan sodium' 'Extended phenytoin sodium' 'Pentran'
 'Phenytek' 'Phenytex' 'Phenytoin sodium' 'Prompt phenytoin sodium']","['5,5-diphenylhydantoin sodium salt' 'Antisacer'
 'Diphenylhydantoin sodium' 'NSC-757274' 'Phenytoin Sodium'
 'Phenytoin sodium' 'Phenytoin sodium extended'
 'Phenytoin sodium for injection' 'Phenytoin sodium salt'
 'Phenytoin sodium, extended' 'Phenytoin sodium, prompt'
 'Phenytoin sodium,extended' 'Phenytoin sodium,prompt'
 'Phenytoinum natricum' 'Tacosal']","[('DailyMed', array(['phenytoin%20sodium'], dtype=object)), ('PubChem', array(['11112021', '144212655', '14742085', '26757853', '50106089',
       '85231301', '855788'], dtype=object))]",,"{'rows': array(['HP_0001250', 'EFO_0000474'], dtype=object), 'count': 2}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and is indicated for seizure and epilepsy. This drug has a black box warning from the FDA.
CHEMBL1655,CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,XFCLJVABOIYOMF-QPLCGJKRSA-N,Small molecule,True,TOREMIFENE,1996.0,4.0,,False,True,[],"['Acapodene' 'Chlortamoxifen' 'Farestone' 'GTX-006' 'J33.157K'
 'Toremifene' 'Toremiphene']","[('PubChem', array(['29216214'], dtype=object)), ('Wikipedia', array(['Toremifene'], dtype=object)), ('drugbank', array(['DB00539'], dtype=object)), ('chEBI', array(['9635'], dtype=object))]",['CHEMBL1200675'],"{'rows': array(['EFO_0009907', 'MONDO_0008315', 'EFO_0000616', 'EFO_0003931',
       'MONDO_0100096', 'EFO_0003869', 'EFO_0003882', 'EFO_1001366',
       'MONDO_0007254', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0003869',
       'EFO_0000305', 'EFO_0002621', 'EFO_0003931'], dtype=object), 'count': 15}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1742994,,,Antibody drug conjugate,True,BRENTUXIMAB VEDOTIN,2011.0,4.0,,False,True,['Adcetris'],"['Brentuximab vedotin' 'Brentuximab vedotin brentuximab' 'CAC-10' 'CAC10'
 'CAC10-VCMMAE' 'Cac10-1006(4)' 'Cac10-vcmmae(4)'
 'Monoclonal antibody sgn-30' 'SGN-35' 'Sgn 30']","[('DailyMed', array(['brentuximab%20vedotin'], dtype=object)), ('DrugCentral', array(['4964'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris'],
      dtype=object))]",,"{'rows': array(['EFO_0000404', 'MONDO_0019473', 'EFO_0002913', 'EFO_0000095',
       'EFO_0000616', 'MONDO_0009348', 'EFO_0001642', 'EFO_0000565',
       'EFO_1000785', 'MONDO_0013730', 'EFO_0000096', 'EFO_0000764',
       'EFO_1001051', 'MONDO_0019471', 'MONDO_0018906', 'EFO_0000211',
       'EFO_0000514', 'EFO_0000222', 'EFO_0003032', 'EFO_0000574',
       'MONDO_0007915', 'EFO_0000183', 'EFO_0000403', 'EFO_0000588',
       'EFO_0007359', 'EFO_0005952'], dtype=object), 'count': 26}","[ENSG00000120949,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2107384,COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O,GXINKQQWHLIBJA-UCIBKFKQSA-N,Small molecule,False,VICRIVIROC MALEATE,,3.0,CHEMBL82301,False,False,[],['MK-4176' 'SCH 417690' 'SCH-417690' 'Sch417690' 'Vicriviroc maleate'],,,"{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108707,,,Antibody,False,GLEMBATUMUMAB,,2.0,,False,False,[],['CR-011' 'CR011' 'CR011-VCMMAE' 'Glembatumumab'],,,"{'rows': array(['EFO_0000756', 'MONDO_0007254'], dtype=object), 'count': 2}",[ENSG00000136235],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109128,,,Protein,False,LENOGRASTIM,,4.0,,False,True,['Granocyte-13' 'Granocyte-34'],"['G-csf (cho cell derived)' 'Glycosylated recombinant g-csf' 'Granocyte'
 'Granulocyte colony-stimulating factor lenograstim' 'Lenograstim'
 'Lenograstim (genetical recombination)' 'Lenograstim rdna' 'Neutrogin'
 'RG-CSF']","[('DrugCentral', array(['5167'], dtype=object))]",,"{'rows': array(['EFO_0008583', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000403',
       'EFO_0001378', 'EFO_0000222'], dtype=object), 'count': 6}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 5 investigational indications.
CHEMBL2109455,,,Antibody,False,AL-901,,2.0,,False,False,[],['AL-901'],,,,[ENSG00000211891],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109553,,,Antibody,False,CYT-500 177LU,,1.0,,False,False,[],['CYT-500' 'Cyt-500 177lu'],,,"{'rows': array(['EFO_0000196'], dtype=object), 'count': 1}",[ENSG00000086205],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL235668,N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,QQHMKNYGKVVGCZ-UHFFFAOYSA-N,Small molecule,False,TIPIRACIL,2015.0,4.0,,False,True,[],['MA-1' 'TPI (freebase)' 'Tipiracil'],"[('drugbank', array(['DB09343'], dtype=object))]",['CHEMBL65375'],"{'rows': array(['EFO_0004252', 'EFO_0000365', 'MONDO_0001187', 'MONDO_0044937',
       'EFO_1001951', 'EFO_0003869', 'EFO_1001949', 'EFO_0005221',
       'EFO_1000657', 'EFO_0000616', 'EFO_0000365', 'MONDO_0021063',
       'EFO_0002618', 'EFO_0000708', 'MONDO_0001056', 'MONDO_0005575',
       'EFO_0003860', 'EFO_0004142', 'MONDO_0007254', 'EFO_1000657',
       'EFO_0000702'], dtype=object), 'count': 21}",[ENSG00000025708],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 20 investigational indications.
CHEMBL29919,Nc1cnc(-c2cc(Cl)cc(Cl)c2Cl)c(N)n1,NNXUYJFHOVCRSM-UHFFFAOYSA-N,Small molecule,False,ELPETRIGINE,,2.0,,False,False,[],['Elpetrigine' 'JZP-4'],,,,"[ENSG00000141837,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000136531,ENSG00000153253,ENSG00000148408]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3544944,O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12,JJWLXRKVUJDJKG-UHFFFAOYSA-N,Small molecule,False,BMS-863233,,2.0,,False,False,[],[],,['CHEMBL3544943'],,[ENSG00000097046],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545305,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O,WZTIQQBMSJTRBR-WYKNNRPVSA-N,Protein,False,CIBINETIDE,,2.0,,False,False,[],"['ARA 290' 'ARA-290' 'ARA290' 'Ara 290' 'Ara290' 'Cibinetide' 'Ph-bsp'
 'Phbsp']","[('drugbank', array(['DB13006'], dtype=object))]",,"{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}","[ENSG00000187266,ENSG00000100368]",Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545328,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1,ISOCDPQFIXDIMS-UHFFFAOYSA-N,Small molecule,False,XL-019,,1.0,,False,False,[],['XL019' 'Xl-019'],,,"{'rows': array(['EFO_0002429', 'MONDO_0044903', 'EFO_0000479'], dtype=object), 'count': 3}",[ENSG00000096968],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3989406,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,MZYVOFLIPYDBGD-MLZQUWKJSA-N,Small molecule,True,ENALAPRILAT,1988.0,4.0,CHEMBL577,False,True,['Enalaprilat'],"['Enalapril diacid dihydrate' 'Enalapril diacid dihydrate anhydrous'
 'Enalaprilat' 'Enalaprilat dihydrate' 'MK-422' 'NSC-760053'
 'Vasotec i.v.']","[('DailyMed', array(['enalaprilat'], dtype=object))]",,"{'rows': array(['EFO_0000407', 'EFO_0006346', 'EFO_0000537'], dtype=object), 'count': 3}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3989933,N=C(N)NCCC[C@@H](N)C(=O)O.O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,GVPVVOSNDUAUKM-YMQOIHNTSA-N,Small molecule,False,ETRASIMOD ARGININE,2023.0,4.0,CHEMBL3358920,False,True,['Velsipity'],['APD334 L-Arginine' 'Etrasimod arginine'],,,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}","[ENSG00000170989,ENSG00000125910,ENSG00000180739]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for ulcerative colitis.
CHEMBL4163691,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1,LZMJNVRJMFMYQS-UHFFFAOYSA-N,Small molecule,False,POSELTINIB,,2.0,,False,False,[],['HM71224' 'Hm-71224' 'LY3337641' 'Ly3337641' 'Poseltinib'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297849,C[C@@H]1CN(c2nc(-n3ccc(OCCC4(C(F)(F)F)CC4)n3)ccc2C(=O)NS(=O)(=O)c2ccccc2)C(C)(C)C1,IGEOJNMYRZUKIK-IBGZPJMESA-N,Small molecule,False,BAMOCAFTOR,,3.0,,False,False,[],['Bamocaftor' 'VX-659' 'VX659' 'Vx-659'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BAMOCAFTOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15177'], dtype=object))]",['CHEMBL4298159'],"{'rows': array(['MONDO_0009061', 'MONDO_0009061'], dtype=object), 'count': 2}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL461101,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,XDXWLKQMMKQXPV-QYQHSDTDSA-N,Small molecule,True,ELTROMBOPAG,2008.0,4.0,,False,True,['Revolade'],['Eltrombopag' 'SB497115'],"[('Wikipedia', array(['Eltrombopag'], dtype=object)), ('drugbank', array(['DB06210'], dtype=object)), ('chEBI', array(['85010'], dtype=object))]",['CHEMBL461805' 'CHEMBL461806' 'CHEMBL3989691'],"{'rows': array(['EFO_0000198', 'MONDO_0010518', 'EFO_0001421', 'HP_0001915',
       'EFO_0006927', 'EFO_0000637', 'EFO_0001422', 'EFO_0006927',
       'EFO_0000565', 'EFO_0007160', 'EFO_0007160', 'HP_0001873',
       'EFO_0004599', 'EFO_0001378', 'EFO_0000095', 'MONDO_0002245',
       'EFO_0000616', 'EFO_0003047', 'EFO_0004220', 'EFO_0000198',
       'MONDO_0019391', 'EFO_0000574', 'EFO_0004220', 'EFO_0000222',
       'EFO_0004272', 'MP_0001914', 'HP_0001873'], dtype=object), 'count': 27}",[ENSG00000117400],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL477,Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,OIRDTQYFTABQOQ-KQYNXXCUSA-N,Small molecule,False,ADENOSINE,1989.0,4.0,,False,True,['Adenocard' 'Adenocor' 'Adenoscan' 'Adenosine'],"['9-.beta.-d-ribofuranosyladenine' 'Adenosine' 'NSC-7652' 'SR 96225'
 'SR-96225']","[('DailyMed', array(['adenosine'], dtype=object)), ('PubChem', array(['144204442', '170465447', '26751564', '50104175', '855932',
       '90341699'], dtype=object)), ('Wikipedia', array(['Adenosine'], dtype=object)), ('drugbank', array(['DB00640'], dtype=object)), ('chEBI', array(['16335'], dtype=object))]",,"{'rows': array(['EFO_0000556', 'EFO_1001375', 'EFO_1001450', 'EFO_0008583',
       'EFO_1000637', 'EFO_0008585', 'MONDO_0006715', 'EFO_0003843',
       'EFO_0000318', 'EFO_0000612', 'EFO_0000275', 'EFO_0000095',
       'EFO_0009493', 'EFO_0001645', 'MONDO_0004992', 'EFO_0000319',
       'EFO_1002000', 'EFO_0003913', 'EFO_0000616', 'MP_0001845',
       'EFO_0005306'], dtype=object), 'count': 21}","[ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 18 investigational indications.
CHEMBL5095049,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O,BAHHBHSHSRTKNK-BJILWQEISA-N,Small molecule,False,PACRITINIB CITRATE,2022.0,4.0,CHEMBL2035187,False,True,['Vonjo'],[],,,"{'rows': array(['EFO_0002429', 'EFO_0002430'], dtype=object), 'count': 2}","[ENSG00000122025,ENSG00000096968]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for polycythemia vera and primary myelofibrosis.
CHEMBL5314394,COc1cc2c(cc1S(=O)(=O)c1ccc(OCc3ccc(Cl)cc3)cc1)CCN(C)CC2,HIBWHHQXUSKNOV-UHFFFAOYSA-N,Small molecule,False,SB-773812,,2.0,,False,False,[],['GW773812' 'SB-737050-A' 'SB-773812' 'Sb-773812'],,,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}","[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL967,CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,SEQDDYPDSLOBDC-UHFFFAOYSA-N,Small molecule,True,TEMAZEPAM,1981.0,4.0,,False,True,['Kentepam' 'Normison' 'Restoril' 'Temaz' 'Temazepam'],['(rs)-temazepam' 'NSC-246303' 'Temazepam' 'Temazepam civ' 'WY-3917'],"[('DailyMed', array(['temazepam'], dtype=object)), ('PubChem', array(['144205223', '144207242', '29215382'], dtype=object)), ('Wikipedia', array(['Temazepam'], dtype=object)), ('drugbank', array(['DB00231'], dtype=object)), ('chEBI', array(['9435'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'EFO_0005230', 'EFO_0000341', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090'], dtype=object), 'count': 6}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for insomnia and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL113313,CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O,KVLLHLWBPNCVNR-SKCUWOTOSA-N,Small molecule,False,CAPROMORELIN,,2.0,,False,False,[],"['CP-424,391' 'CP-424391-18' 'Capimorelin' 'Capromorelin' 'Cp-424,391'
 'Cp-424391']","[('Wikipedia', array(['Capromorelin'], dtype=object)), ('drugbank', array(['DB15205'], dtype=object))]",,,[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1200604,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1,BGDKAVGWHJFAGW-UHFFFAOYSA-N,Small molecule,False,TROPICAMIDE,1960.0,4.0,,False,True,['Mydriacyl' 'Mydriafair' 'Nods' 'Tropicacyl' 'Tropicamide'],"['Bistropamide' 'NSC-757372' 'RO-1-7683' 'Tropicamide' 'Tropicamidum'
 'Visumidriatic']","[('DailyMed', array(['tropicamide'], dtype=object)), ('PubChem', array(['104171259', '144203848', '170464754', '26747134', '50086517',
       '50104635', '85231280', '90341160'], dtype=object)), ('Wikipedia', array(['Tropicamide'], dtype=object)), ('drugbank', array(['DB00809'], dtype=object))]",,"{'rows': array(['EFO_1001069', 'EFO_0003966', 'MONDO_0001330', 'MONDO_0005180',
       'HP_0011499', 'HP_0002307'], dtype=object), 'count': 6}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for mydriasis and has 5 investigational indications.
CHEMBL1201103,COc1ccc(OC)c(C(O)C(C)N)c1.Cl,YGRFXPCHZBRUKP-UHFFFAOYSA-N,Small molecule,False,METHOXAMINE HYDROCHLORIDE,1982.0,4.0,CHEMBL524,False,True,['Vasoxine' 'Vasoxyl'],['Methoxamine hcl' 'Methoxamine hydrochloride' 'NSC-757102'],"[('PubChem', array(['144204799', '26747569', '50106595', '56422119', '855753'],
      dtype=object))]",,"{'rows': array(['EFO_0009523'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.
CHEMBL1201201,CN[C@@H](C)Cc1ccccc1,MYWUZJCMWCOHBA-VIFPVBQESA-N,Small molecule,True,METHAMPHETAMINE,1943.0,4.0,,False,True,[],"['(s)-phenylmethylaminopropane' 'J6.362B' 'Metamfetamine'
 'Methamphetamine' 'NSC-25115']","[('Wikipedia', array(['Methamphetamine'], dtype=object)), ('drugbank', array(['DB01577'], dtype=object)), ('chEBI', array(['6809'], dtype=object))]",['CHEMBL1200952'],"{'rows': array(['EFO_0003888', 'EFO_0004701', 'EFO_0004242', 'EFO_0003888'],
      dtype=object), 'count': 4}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and is indicated for attention deficit hyperactivity disorder and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1232583,COc1ccc(S(=O)(=O)n2cc(CCC(=O)O)c3cc(OC)ccc32)cc1,YMPALHOKRBVHOJ-UHFFFAOYSA-N,Small molecule,False,INDEGLITAZAR,,2.0,,False,False,[],['Indeglitazar' 'PPM-204'],"[('drugbank', array(['DB07724'], dtype=object))]",,"{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}","[ENSG00000132170,ENSG00000186951,ENSG00000112033]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1561,OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,IBAQFPQHRJAVAV-ULAWRXDQSA-N,Small molecule,False,MIGLITOL,1996.0,4.0,,False,True,['Diastabol' 'Glyset' 'Miglitol'],['BAY M 1099' 'BAY-M-1099' 'Miglitol' 'NSC-758702'],"[('DailyMed', array(['miglitol'], dtype=object)), ('PubChem', array(['144204989', '170465326', '26719889', '49681630'], dtype=object)), ('Wikipedia', array(['Miglitol'], dtype=object)), ('drugbank', array(['DB00491'], dtype=object)), ('chEBI', array(['6935'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'EFO_0000400'], dtype=object), 'count': 3}","[ENSG00000171298,ENSG00000257335]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 1 investigational indication.
CHEMBL160038,O=C(Cc1ccccc1)c1cc(O)c(O)c([N+](=O)[O-])c1,MRFOLGFFTUGAEB-UHFFFAOYSA-N,Small molecule,False,NEBICAPONE,,2.0,,False,False,[],['Nebicapone'],"[('drugbank', array(['DB14849'], dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000093010],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1950289,O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,IBGLGMOPHJQDJB-IHRRRGAJSA-N,Small molecule,False,TANZISERTIB,,2.0,,False,False,[],['CC-930' 'JNK 930' 'JNK-930' 'JNK930' 'Tanzisertib'],"[('drugbank', array(['DB11798'], dtype=object))]",,"{'rows': array(['EFO_0000768'], dtype=object), 'count': 1}","[ENSG00000107643,ENSG00000050748,ENSG00000109339]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2105618,C=CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCCC4[C@H]3CC[C@@]21C,ATXHVCQZZJYMCF-XZCODKSBSA-N,Small molecule,False,ALLYLESTRENOL,,4.0,,False,True,['Gestanin'],['Allylestrenol' 'Allyloestrenol' 'NSC-37723' 'Perselin'],,,,"[ENSG00000140009,ENSG00000091831,ENSG00000082175]",Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL2105664,CC(OC(=O)c1ccc(Cc2c(O)c3ccccc3oc2=O)cc1)(C(F)(F)F)C(F)(F)F,QFLNTQDOVCLQKW-UHFFFAOYSA-N,Small molecule,False,TECARFARIN,,3.0,,False,False,[],['ATI-5923' 'Tecarfarin'],"[('drugbank', array(['DB12823'], dtype=object))]",['CHEMBL2105676'],"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3545330,c1cnc(NCc2ccc(CNc3ncccn3)cc2)nc1,PXZXYRKDDXKDTK-UHFFFAOYSA-N,Small molecule,False,MSX-122,,1.0,,False,False,[],['Msx 122' 'Msx-122'],"[('drugbank', array(['DB12715'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000121966],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545427,,,Small molecule,False,CM-082,,3.0,,False,False,[],['Cm-082'],,,"{'rows': array(['EFO_0001365', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000681', 'EFO_0000702'], dtype=object), 'count': 7}","[ENSG00000157404,ENSG00000122025,ENSG00000113721,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL3707400,,,Small molecule,False,INDANTADOL,,2.0,,False,False,[],['Chf-3381 free base' 'Chf3381' 'Indantadol' 'V3381'],,,"{'rows': array(['EFO_1000783', 'EFO_0005762', 'HP_0012735', 'EFO_0003843'],
      dtype=object), 'count': 4}","[ENSG00000189221,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3989887,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,NWJQLQGQZSIBAF-MLAUYUEBSA-N,Small molecule,True,TACROLIMUS,1994.0,4.0,CHEMBL269732,False,True,"['Adoport' 'Advagraf' 'Astagraf xl' 'Capexion' 'Envarsus' 'Envarsus xr'
 'Modigraf' 'Perixis' 'Prograf' 'Protopic' 'Tacni' 'Tacrolimus' 'Vivadex']","['FK 506' 'FK-506' 'FK506' 'FR-900506' 'FR900506' 'NSC-758659'
 'Tacrolimus' 'Tacrolimus hydrate' 'Tacrolimus monohydrate']","[('DailyMed', array(['tacrolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/protopic'],
      dtype=object))]",,"{'rows': array(['EFO_0000274', 'EFO_0000540', 'HP_0000964'], dtype=object), 'count': 3}",[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL3989967,CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1,BBTFKAOFCSOZMB-UHFFFAOYSA-N,Small molecule,False,LOTAMILAST,,2.0,,False,False,[],['E-6005' 'E6005' 'Lotamilast' 'RVT-501'],"[('drugbank', array(['DB12776'], dtype=object))]",,"{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650393,,,Antibody,False,EPCORITAMAB,2023.0,4.0,,False,True,['Epkinly'],['Epcoritamab' 'Epcoritamab-bysp' 'Epkinly' 'GEN-3013' 'GEN3013'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EPCORITAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000095', 'EFO_0000403', 'MONDO_0018906', 'EFO_0005952',
       'EFO_1001469', 'EFO_0000096', 'EFO_0000616'], dtype=object), 'count': 7}","[ENSG00000156738,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for diffuse large b-cell lymphoma and has 6 investigational indications.
CHEMBL471,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1,ZBMZVLHSJCTVON-UHFFFAOYSA-N,Small molecule,True,SOTALOL,1992.0,4.0,,False,True,[],"['Betapace' 'C07AA07' 'Darob mite' 'Dl-sotalol' 'MJ-1999' 'Sorine'
 'Sotalol']","[('PubChem', array(['144203812', '26751989'], dtype=object)), ('Wikipedia', array(['Sotalol'], dtype=object)), ('drugbank', array(['DB00489'], dtype=object)), ('chEBI', array(['63622'], dtype=object))]",['CHEMBL1700'],"{'rows': array(['HP_0004308', 'EFO_0004278', 'EFO_0000319', 'EFO_0000275',
       'EFO_0000612', 'EFO_0004287', 'EFO_0003144', 'EFO_0000275',
       'EFO_0005306'], dtype=object), 'count': 9}","[ENSG00000043591,ENSG00000055118,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for ventricular arrhythmia and cardiovascular disease and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200710,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21.Cl,WIMWMKZEIBHDTH-UHFFFAOYSA-N,Small molecule,True,CLOMIPRAMINE HYDROCHLORIDE,1989.0,4.0,CHEMBL415,False,True,"['Anafranil' 'Anafranil sr' 'Chlorimipramine' 'Clomicalm'
 'Clomipramine hydrochloride' 'Tranquax']","['Clomipramine hcl' 'Clomipramine hydrochloride' 'G 34586' 'G-34586'
 'NSC-759323']","[('DailyMed', array(['clomipramine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/clomicalm'],
      dtype=object)), ('PubChem', array(['144212136', '26747483', '50106071', '56422907', '855785'],
      dtype=object)), ('chEBI', array(['3755'], dtype=object))]",,"{'rows': array(['MONDO_0002050', 'EFO_0004242'], dtype=object), 'count': 2}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for obsessive-compulsive disorder and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201027,C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],VPNYRYCIDCJBOM-UHFFFAOYSA-M,Small molecule,False,GLYCOPYRROLATE,1961.0,4.0,CHEMBL1201335,False,True,"['Cuvposa' 'Dartisla odt' 'Glycopyrrolate' 'Glyrx-pf'
 'Lonhala magnair kit' 'Robinul' 'Robinul forte' 'Robinul fte' 'Seebri'
 'Seebri breezhaler' 'Sialanar']","['AD-237' 'AHR-504' 'CHF-5259' 'CHF5259' 'Glycopyrrolate'
 'Glycopyrrolate, erythro-' 'Glycopyrrone bromide'
 'Glycopyrronium (as bromide)' 'Glycopyrronium bromide' 'NSC-250836'
 'NSC-251251' 'NSC-251252' 'NVA-237' 'NVA237' 'Nodapton' 'ORG-NC-45'
 'PT-001' 'PT001' 'Robanul' 'Tarodyl' 'Tarodyn']","[('DailyMed', array(['glycopyrrolate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar'],
      dtype=object)), ('PubChem', array(['144206695', '144206696', '170465427', '85273808'], dtype=object))]",,"{'rows': array(['EFO_0006505', 'MONDO_0004979', 'HP_0000975', 'HP_0002307',
       'EFO_0010282', 'MONDO_0002050', 'EFO_0000341', 'EFO_0009516',
       'EFO_0003086', 'HP_0006536'], dtype=object), 'count': 10}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 5 approved and 5 investigational indications.
CHEMBL1201032,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1,JPRXYLQNJJVCMZ-UHFFFAOYSA-N,Small molecule,False,RIZATRIPTAN BENZOATE,1998.0,4.0,CHEMBL905,False,True,['Maxalt' 'Maxalt-mlt' 'Rizatriptan benzoate'],['MK-0462' 'NSC-758919' 'Rizafilm' 'Rizatriptan benzoate'],"[('DailyMed', array(['rizatriptan%20benzoate'], dtype=object))]",,"{'rows': array(['MONDO_0100431', 'MONDO_0005277', 'MONDO_0005475'], dtype=object), 'count': 3}","[ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 2 investigational indications.
CHEMBL1201587,,,Antibody,True,ALEMTUZUMAB,2001.0,4.0,,False,True,"['Campath' 'Campath Mabcampath, Lemtrada' 'Campath mabcampath' 'Lemtrada'
 'Mabcampath']","['Alemtuzumab' 'Alemtuzumab (genetical recombination)' 'Allo 647'
 'CAMPATH-1H' 'GZ-402673' 'GZ402673' 'LDP-03']","[('DailyMed', array(['alemtuzumab'], dtype=object)), ('DrugCentral', array(['4909'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada'],
      dtype=object)), ('Wikipedia', array(['Alemtuzumab'], dtype=object))]",,"{'rows': array(['MONDO_0019469', 'EFO_1001996', 'EFO_0000183', 'EFO_0000211',
       'EFO_0000094', 'EFO_0000621', 'EFO_0003086', 'EFO_0000095',
       'EFO_0000403', 'EFO_0002428', 'EFO_1000785', 'EFO_0005952',
       'EFO_0003884', 'MONDO_0011382', 'EFO_0000685', 'MONDO_0015974',
       'EFO_1002048', 'EFO_0000384', 'MONDO_0008170', 'EFO_1001264',
       'EFO_0001378', 'EFO_1001257', 'MONDO_0005301', 'EFO_0004272',
       'EFO_0000220', 'MONDO_0000870', 'MONDO_0044348', 'EFO_0000222',
       'MONDO_0001023', 'MONDO_0021193', 'EFO_0007160', 'EFO_0000540',
       'MONDO_0019472', 'EFO_1000560', 'EFO_1000690', 'MONDO_0002087',
       'MONDO_0013730', 'MONDO_0015540', 'MONDO_0004992', 'MONDO_0017198',
       'EFO_0000209', 'HP_0001915', 'EFO_0000616', 'MONDO_0005147',
       'MONDO_0002158', 'EFO_0001642', 'MONDO_0019391', 'HP_0100727',
       'EFO_0000565', 'EFO_0006803', 'Orphanet_848', 'EFO_0000574',
       'EFO_0004289', 'MONDO_0044881', 'EFO_0003929', 'EFO_1001051',
       'EFO_0006927', 'EFO_0009441', 'MONDO_0018305', 'EFO_0000096',
       'EFO_0001421', 'EFO_0000198', 'EFO_0007323', 'EFO_0004599',
       'EFO_0000255', 'MONDO_0002367'], dtype=object), 'count': 66}",[ENSG00000169442],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 63 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1277001,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1,ULRDYYKSPCRXAJ-KRWDZBQOSA-N,Small molecule,False,MIBAMPATOR,,2.0,,False,False,[],['LY 451395' 'LY-451395' 'LY451395' 'Mibampator'],"[('drugbank', array(['DB12717'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1566,C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,XUFXOAAUWZOOIT-SXARVLRPSA-N,Oligosaccharide,False,ACARBOSE,1995.0,4.0,,False,True,['Acarbose' 'Glucobay' 'Precose'],['Acarbose' 'BAY G 5421' 'BAY-G-5421' 'NSC-758915'],"[('DailyMed', array(['acarbose'], dtype=object)), ('PubChem', array(['144205150', '170464784'], dtype=object)), ('TG-GATEs', array(['116'], dtype=object)), ('Wikipedia', array(['Acarbose'], dtype=object))]",,"{'rows': array(['EFO_0007318', 'EFO_0000400', 'EFO_0000589', 'EFO_0004593',
       'EFO_0001645', 'HP_0003124', 'EFO_0005252', 'MONDO_0002367',
       'EFO_0003914', 'EFO_0001073', 'EFO_0000195', 'MONDO_0005148',
       'EFO_0000537', 'EFO_0003095'], dtype=object), 'count': 14}","[ENSG00000257335,ENSG00000243480]",Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 12 investigational indications.
CHEMBL2103830,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,GKDRMWXFWHEQQT-UHFFFAOYSA-N,Small molecule,False,FOSTAMATINIB,2018.0,4.0,,False,True,[],"['Fostamatinib' 'R-788' 'R-788 FREE ACID' 'R-935788' 'R-935788 FREE ACID'
 'R788 FREE ACID' 'R935788 FREE ACID']","[('PubChem', array(['174006453'], dtype=object)), ('drugbank', array(['DB12010'], dtype=object))]",['CHEMBL3989516'],"{'rows': array(['EFO_0000574', 'MONDO_0007915', 'MONDO_0100096', 'EFO_0004194',
       'EFO_0000685', 'MP_0001914', 'MONDO_0008170', 'EFO_0007160',
       'EFO_0000403', 'EFO_0003106', 'EFO_0001642', 'EFO_0007160',
       'MONDO_0044903', 'EFO_1000710', 'EFO_0000574', 'EFO_0000685',
       'EFO_0004194', 'EFO_1001264', 'EFO_1001264', 'HP_0001873'],
      dtype=object), 'count': 20}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 16 investigational indications.
CHEMBL2103870,Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,UFSKUSARDNFIRC-UHFFFAOYSA-N,Small molecule,False,LUMACAFTOR,2015.0,4.0,,False,True,[],"['Lumacaftor' 'VRT 826809' 'VRT-826809' 'VRT826809' 'VX 809' 'VX-809'
 'VX809']","[('DailyMed', array(['lumacaftor'], dtype=object)), ('drugbank', array(['DB09280'], dtype=object))]",,"{'rows': array(['MONDO_0009061', 'EFO_0001421'], dtype=object), 'count': 2}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for cystic fibrosis and has 1 investigational indication.
CHEMBL2107457,COc1ccc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc1OC,QQQIECGTIMUVDS-UHFFFAOYSA-N,Small molecule,False,ITOPRIDE,,3.0,,False,False,[],['Itopride' 'NSC-759643'],"[('drugbank', array(['DB04924'], dtype=object))]",['CHEMBL2139257'],"{'rows': array(['EFO_0008533', 'EFO_0010282', 'HP_0002019', 'EFO_0008588',
       'EFO_1000948', 'EFO_0000555'], dtype=object), 'count': 6}","[ENSG00000087085,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2108248,,,Antibody drug conjugate,False,ANATUMOMAB MAFENATOX,,2.0,,False,False,['Anyara'],['ABR-214936' 'Anatumomab mafenatox' 'PNU-214936'],,,,[ENSG00000146242],Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2108566,,,Antibody,False,NERELIMOMAB,,3.0,,False,False,['Humicade'],"['BAY X 1351' 'BAY-103356' 'BAY-X 1351' 'BAY-X-1351' 'BAYX-1351' 'CDP-571'
 'Nerelimomab' 'TNF MAB' 'TNF-MAB']",,,,[ENSG00000232810],Antibody drug with a maximum clinical trial phase of III.
CHEMBL284092,CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1,QOIGKGMMAGJZNZ-UHFFFAOYSA-N,Small molecule,True,GEPIRONE,2023.0,4.0,,False,True,[],['Ariza' 'BMY-13805' 'Gepirone' 'ORG-13011' 'Variza'],"[('Wikipedia', array(['Gepirone'], dtype=object)), ('drugbank', array(['DB12184'], dtype=object))]",['CHEMBL1204187'],"{'rows': array(['MONDO_0002009', 'EFO_0002610', 'MONDO_0002009'], dtype=object), 'count': 3}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545174,,,Small molecule,False,GSK2881078,,2.0,,False,False,[],['Gsk2881078'],,,"{'rows': array(['HP_0004326'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297352,C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(Cl)cn3)CC2)NC(=O)NC1=O,SFJFBTPHDHUUPU-OAHLLOKOSA-N,Small molecule,False,AZD-1236,,2.0,,False,False,[],['AZD1236' 'Azd 1236' 'Azd-1236' 'Azd1236'],"[('drugbank', array(['DB11961'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0009061'], dtype=object), 'count': 2}","[ENSG00000100985,ENSG00000262406]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL429910,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,JVHXJTBJCFBINQ-ADAARDCZSA-N,Small molecule,False,DAPAGLIFLOZIN,2012.0,4.0,,False,True,[],['BMS-512148' 'Dapagliflozin' 'LYN-045'],"[('DailyMed', array(['dapagliflozin'], dtype=object)), ('Wikipedia', array(['Dapagliflozin'], dtype=object)), ('drugbank', array(['DB06292'], dtype=object)), ('chEBI', array(['85078'], dtype=object))]","['CHEMBL3125457' 'CHEMBL3125455' 'CHEMBL3125318' 'CHEMBL3125316'
 'CHEMBL3125317' 'CHEMBL2103802' 'CHEMBL3125456' 'CHEMBL3125458']","{'rows': array(['EFO_0001645', 'EFO_0000660', 'HP_0001919', 'EFO_1001375',
       'EFO_1000783', 'EFO_0000195', 'EFO_0000400', 'MONDO_0005148',
       'EFO_0001073', 'EFO_0000275', 'EFO_0002614', 'EFO_0004194',
       'EFO_0000612', 'MONDO_0007254', 'EFO_1002048', 'MONDO_0010526',
       'EFO_0002687', 'EFO_1000899', 'EFO_0009104', 'EFO_1001249',
       'EFO_0001663', 'MONDO_0100096', 'EFO_0003884', 'MONDO_0005147',
       'MONDO_0009067', 'HP_0001397', 'EFO_0003144', 'MONDO_0005147',
       'EFO_0001361', 'EFO_0000401', 'EFO_0002618', 'EFO_0003770',
       'EFO_0003940', 'EFO_0004285', 'MONDO_0005148', 'MONDO_0004975',
       'EFO_0001422', 'MONDO_0002050', 'HP_0001824', 'EFO_0003833',
       'EFO_0003144'], dtype=object), 'count': 41}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 37 investigational indications.
CHEMBL4650486,,,Antibody,False,ZANSECIMAB,,2.0,,False,False,[],['LY-3127804' 'LY3127804' 'Ly3127804' 'Zansecimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANSECIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0100096', 'MONDO_0100096', 'EFO_0003106', 'EFO_0000616',
       'EFO_1000637'], dtype=object), 'count': 5}",[ENSG00000091879],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL541758,Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)NC4(C(=O)N5CCN(C(=O)[C@@H](N)CCC[N+](C)(C)C)CC5)CCOCC4)c3Cl)c2n1.[Cl-],ZNHJDJYKDVGQSH-JMAPEOGHSA-M,Small molecule,False,FASITIBANT CHLORIDE,,2.0,CHEMBL218427,False,False,[],['Fasitibant chloride' 'Men16132'],,,,[ENSG00000168398],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL815,CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O,PXGPLTODNUVGFL-YNNPMVKQSA-N,Small molecule,False,DINOPROST,1982.0,4.0,,False,True,[],"['Dinoprost' 'Pgf2a' 'Pgf2alpha' 'Prosmon' 'Prostaglandin f2-alpha'
 'Prostaglandin f2.alpha.' 'Prostaglandin f2alpha' 'U-14,583' 'U-14583']","[('PubChem', array(['144205330', '29216066'], dtype=object)), ('Wikipedia', array(['Prostaglandin_F2alpha'], dtype=object)), ('drugbank', array(['DB12789'], dtype=object)), ('chEBI', array(['15553'], dtype=object))]",['CHEMBL1200896'],,[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200495,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+],HHZQLQREDATOBM-CODXZCKSSA-M,Small molecule,False,HYDROCORTISONE SODIUM SUCCINATE,1955.0,4.0,CHEMBL977,False,True,['A-hydrocort' 'Hcss' 'Hydrocortisone sodium succinate' 'Solu-cortef'],"['Cortisol 21-(sodium succinate)' 'Hydrocortisone 21-sodium succinate'
 'Hydrocortisone sodium succinate' 'Hydrocortisoni natrii succinas'
 'NSC-9152' 'SOLU-CORTEF']","[('DailyMed', array(['hydrocortisone%20sodium%20succinate'], dtype=object)), ('PubChem', array(['144207050', '170465053', '50106430', '855547'], dtype=object)), ('chEBI', array(['5782'], dtype=object))]",,"{'rows': array(['EFO_0003032', 'EFO_0000403', 'EFO_0006834', 'EFO_0000565',
       'MONDO_0000870', 'EFO_0000220', 'EFO_0000309', 'MONDO_0004979'],
      dtype=object), 'count': 8}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for asthma and has 7 investigational indications.
CHEMBL1200906,CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.[Br-],UKLQXHUGTKWPSR-UHFFFAOYSA-M,Small molecule,False,OXYPHENONIUM BROMIDE,1982.0,4.0,CHEMBL1201286,False,True,['Antrenyl'],"['Antrenil' 'BA-5473' 'C-5473' 'NSC-759248' 'Oxifenon' 'Oxyfenon'
 'Oxyphenon' 'Oxyphenonium bromide' 'Spasmodin' 'Spasmophen']","[('PubChem', array(['144204402', '170465282', '56422900', '855750'], dtype=object)), ('Wikipedia', array(['Oxyphenonium_bromide'], dtype=object))]",,,"[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201219,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,BGSZAXLLHYERSY-XQIGCQGXSA-N,Small molecule,True,VECURONIUM,1984.0,4.0,,False,True,[],['Vecuronium' 'Vecuronium cation' 'Vecuronium ion'],"[('PubChem', array(['50112721'], dtype=object)), ('Wikipedia', array(['Vecuronium_bromide'], dtype=object)), ('drugbank', array(['DB01339'], dtype=object)), ('chEBI', array(['9939'], dtype=object))]",['CHEMBL1200629'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA.
CHEMBL1201342,CN1CCCC(CC2c3ccccc3Sc3ccccc32)C1,MJFJKKXQDNNUJF-UHFFFAOYSA-N,Small molecule,False,METHIXENE,1982.0,4.0,,False,True,[],['Atosil' 'Methixene' 'Metixene'],"[('Wikipedia', array(['Metixene'], dtype=object)), ('drugbank', array(['DB00340'], dtype=object)), ('chEBI', array(['51024'], dtype=object))]",['CHEMBL2359044' 'CHEMBL1200426'],"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for parkinson disease.
CHEMBL1491,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,HTIQEAQVCYTUBX-UHFFFAOYSA-N,Small molecule,True,AMLODIPINE,1992.0,4.0,,False,True,['Astudal 5' 'Istin' 'Norvas' 'Norvasc'],['Amlodipine' 'CKD-330 COMPONENT AMLODIPINE' 'HGP-0904' 'HGP0904'],"[('PubChem', array(['124893198', '225144262', '29217715', '50111725'], dtype=object)), ('Wikipedia', array(['Amlodipine'], dtype=object)), ('drugbank', array(['DB00381'], dtype=object)), ('chEBI', array(['2668'], dtype=object))]",['CHEMBL1200402' 'CHEMBL4594262' 'CHEMBL1200984'],"{'rows': array(['EFO_0000319', 'EFO_0000612', 'MONDO_0016486', 'HP_0000093',
       'EFO_0001421', 'EFO_1001145', 'HP_0003124', 'EFO_0004911',
       'EFO_0003144', 'MONDO_0000477', 'EFO_0000537', 'EFO_0000278',
       'MONDO_0021187', 'HP_0003124', 'EFO_0000373', 'Orphanet_79292',
       'EFO_0007148', 'EFO_0003086', 'EFO_0000612', 'MONDO_0001422',
       'MONDO_0002050', 'EFO_0000764', 'EFO_0003913', 'EFO_0000400',
       'EFO_0000537', 'EFO_0003144', 'EFO_1000013', 'EFO_0000537',
       'EFO_0000400', 'MONDO_0021187', 'EFO_0000373', 'MONDO_0005178',
       'MONDO_0005148', 'EFO_0004234', 'EFO_0001645', 'EFO_0000712',
       'MONDO_0001134', 'EFO_0003914', 'MONDO_0007254', 'EFO_1001375',
       'EFO_1001996', 'MONDO_0001134', 'EFO_0003777', 'EFO_0000538',
       'EFO_0001645', 'EFO_0004214'], dtype=object), 'count': 46}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 14 approved and 30 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1742408,c1ccc2c(c1)OC[C@H](CNCCCOc1ccc3c(c1)OCO3)O2,MEEQBDCQPIZMLY-HNNXBMFYSA-N,Small molecule,False,OSEMOZOTAN,,3.0,,False,False,[],['MN-305' 'Mkc-242' 'Osemozotan'],,,,[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL1743062,,,Antibody,False,RAMUCIRUMAB,2014.0,4.0,,False,True,['Cyramza'],['1121B' 'IMC-1121B' 'LY3009806' 'Ramucirumab'],"[('DailyMed', array(['ramucirumab'], dtype=object)), ('DrugCentral', array(['4917'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000588', 'EFO_0000756', 'MONDO_0004992',
       'EFO_0000519', 'EFO_0004243', 'EFO_0000681', 'EFO_0008528',
       'EFO_0000708', 'EFO_1000895', 'MONDO_0003060', 'EFO_0000228',
       'EFO_0001376', 'EFO_1000657', 'EFO_0002916', 'EFO_0000503',
       'EFO_0003060', 'EFO_1001961', 'EFO_1001951', 'MONDO_0007254',
       'EFO_0000181', 'MONDO_0007576', 'MONDO_0021063', 'EFO_0000182',
       'MONDO_0008315', 'EFO_0000389', 'EFO_0000326', 'EFO_0003897',
       'EFO_1000576', 'MONDO_0005411', 'EFO_0005922', 'MONDO_0001056',
       'EFO_1001469', 'EFO_1000581', 'EFO_0005952', 'EFO_0000178',
       'EFO_0002618'], dtype=object), 'count': 37}",[ENSG00000128052],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 7 approved and 30 investigational indications.
CHEMBL181,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1,GDLBFKVLRPITMI-UHFFFAOYSA-N,Small molecule,False,DIAZOXIDE,1973.0,4.0,,False,True,['Diazoxide' 'Eudemine' 'Eudimine' 'Hyperstat' 'Mutabase' 'Proglycem'],"['Diazoxide' 'Diazoxidum' 'Eudemine injection' 'Hypertonalum' 'NSC-64198'
 'NSC-76130' 'SCH 6783' 'SCH-6783' 'SRG 95213' 'SRG-95213']","[('DailyMed', array(['diazoxide'], dtype=object)), ('PubChem', array(['11111111', '11113823', '124879964', '144203683', '170465328',
       '26747146', '26751995', '50104671', '56422090', '855807'],
      dtype=object)), ('Wikipedia', array(['Diazoxide'], dtype=object)), ('drugbank', array(['DB01119'], dtype=object)), ('chEBI', array(['4495'], dtype=object))]",['CHEMBL4297276'],"{'rows': array(['MONDO_0002177', 'EFO_0001073', 'MONDO_0002050', 'EFO_0004211',
       'HP_0001943', 'MONDO_0008300', 'EFO_0000537', 'MONDO_0005148',
       'MONDO_0024677', 'EFO_0001073'], dtype=object), 'count': 10}","[ENSG00000121361,ENSG00000187486]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved and 6 investigational indications.
CHEMBL1928262,CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1,YPFZMBHKIVDSNR-UHFFFAOYSA-N,Small molecule,False,GISADENAFIL,,2.0,,False,False,[],"['Gisadenafil' 'UK-369,003' 'UK-369003']","[('drugbank', array(['DB11902'], dtype=object))]",['CHEMBL2103843'],"{'rows': array(['EFO_0000341', 'EFO_0000284', 'HP_0000802', 'EFO_1000781'],
      dtype=object), 'count': 4}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1980297,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12,WPHKIQPVPYJNAX-UHFFFAOYSA-N,Small molecule,False,ILORASERTIB,,2.0,,False,False,"['Abt-348, a-968660']",['A-968660' 'A-968660.0' 'ABBOTT-968660' 'ABT-348' 'Abt-348' 'Ilorasertib'],"[('PubChem', array(['103904272'], dtype=object)), ('drugbank', array(['DB11694'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000178999,ENSG00000105146,ENSG00000087586,ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2095212,Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,PBAPPPCECJKMCM-IBGZPJMESA-N,Small molecule,False,MIRABEGRON,2012.0,4.0,,False,True,['Betmiga' 'Myrbetriq' 'Myrbetriq granules'],['Betanis' 'Mirabegron' 'YM-178' 'YM178'],"[('DailyMed', array(['mirabegron'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga'],
      dtype=object)), ('drugbank', array(['DB08893'], dtype=object)), ('chEBI', array(['65349'], dtype=object))]",['CHEMBL3542362'],"{'rows': array(['EFO_0003086', 'EFO_0006865', 'EFO_0001421', 'EFO_0005669',
       'HP_0002571', 'HP_0000103', 'EFO_0004253', 'EFO_0000660',
       'EFO_1000781', 'EFO_0003896', 'EFO_1001121', 'EFO_1000869',
       'HP_0000020', 'HP_0000011', 'EFO_0003144', 'EFO_0003843'],
      dtype=object), 'count': 16}",[ENSG00000188778],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 4 approved and 12 investigational indications.
CHEMBL2104991,Cl.c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2,PYPPENBDXAWXJC-QNTKWALQSA-N,Small molecule,False,VABICASERIN HYDROCHLORIDE,,2.0,CHEMBL2110670,False,False,[],['SCA-136' 'Vabicaserin hydrochloride'],,,,"[ENSG00000147246,ENSG00000135914,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108666,,,Antibody drug conjugate,False,YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN,,2.0,,False,False,[],"['(sup 90)y-dota-hll2' '2F35K89X9W' '90Y-DOTA-HLL2' '90y-epratuzumab'
 'S9S0Y-DOTA-HLL2' 'Y-90-dota-hll2' 'Yttrium y 90 epratuzumab tetraxetan']",,,"{'rows': array(['EFO_0000094', 'MONDO_0018906', 'EFO_0000403', 'EFO_0000096'],
      dtype=object), 'count': 4}",[ENSG00000012124],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2145077,COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2.Cl,HLUKNZUABFFNQS-ZMBIFBSDSA-N,Small molecule,False,IVABRADINE HYDROCHLORIDE,2015.0,4.0,CHEMBL471737,False,True,['Corlanor' 'Ivabradine zentiva' 'Procoralan'],"['AMG 998' 'AMG-998' 'Corlentor' 'Ivabradine hcl'
 'Ivabradine hydrochloride' 'S 16257' 'S-16257-2']","[('DailyMed', array(['ivabradine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-zentiva'],
      dtype=object)), ('PubChem', array(['144206355'], dtype=object)), ('chEBI', array(['85969'], dtype=object))]",,"{'rows': array(['EFO_0003144', 'EFO_0000373', 'EFO_0003913'], dtype=object), 'count': 3}",[ENSG00000138622],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved indications.
CHEMBL2218894,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+],ZGGHKIMDNBDHJB-CALJPSDSSA-M,Small molecule,False,FLUVASTATIN SODIUM,1993.0,4.0,CHEMBL2220442,False,True,"['Dorisin xl' 'Fluvastatin sodium' 'Lescol' 'Lescol xl' 'Luvinsta xl'
 'Nandovar xl' 'Pinmactil' 'Stefluvin xl']","['Almastatin' 'Canef' 'Cranoc' 'Fluindostatin' 'Fluvastatin sodium'
 'Fluvastatin sodium salt' 'Fractal' 'Lipaxan' 'Lochol' 'Locol' 'Primexin'
 'Vastin' 'XU 62-320' 'XU-62-320']","[('DailyMed', array(['fluvastatin%20sodium'], dtype=object))]",,"{'rows': array(['EFO_0004911', 'HP_0003124', 'MONDO_0007254'], dtype=object), 'count': 3}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for familial hypercholesterolemia and hypercholesterolemia and has 1 investigational indication.
CHEMBL2387408,CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(=O)O)CC(=O)O)c(OC)cc2[C@@H](c2ccccc2)N1,CZGVOBIGEBDYTP-VSGBNLITSA-N,Small molecule,False,LINERIXIBAT,,3.0,,False,False,[],['GSK2330672' 'Gsk-2330672' 'Gsk2330672' 'Linerixibat'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINERIXIBAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11729'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'HP_0000989', 'MONDO_0019072', 'MONDO_0001751'],
      dtype=object), 'count': 4}",[ENSG00000125255],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3181947,Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+],PPOSVVJOVKVBPW-UHFFFAOYSA-L,Small molecule,False,BROMFENAC SODIUM,1997.0,4.0,CHEMBL1077,True,True,['Bromday' 'Bromfenac sodium' 'Bromsite' 'Prolensa' 'Xibrom' 'Yellox'],"['AHR-10282B' 'Bromfenac monosodium salt'
 'Bromfenac monosodium salt sesquihydrate' 'Bromfenac sodium'
 'Bromfenac sodium hydrate' 'Bromfenac sodium sesquihydrate']","[('DailyMed', array(['bromfenac%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yellox'],
      dtype=object)), ('PubChem', array(['144205734', '170465189'], dtype=object)), ('chEBI', array(['59176'], dtype=object))]",,"{'rows': array(['MONDO_0005129', 'HP_0200026', 'EFO_0003843', 'MP_0001845'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved indications. It was withdrawn in at least one region.
CHEMBL3989943,CS(=O)(=O)CCC#N,LQFRYKBDZNPJSW-UHFFFAOYSA-N,Small molecule,False,DAPANSUTRILE,,2.0,,False,False,[],['Dapansutrile' 'OLT-1177' 'OLT1177'],,,"{'rows': array(['MONDO_0100096', 'EFO_0000756', 'EFO_1001165', 'EFO_0000612',
       'EFO_1001207'], dtype=object), 'count': 5}",[ENSG00000162711],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3989962,NC(CO)(CO)CO.NC(CO)(CO)CO.Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1.O.O,DUORKVZYABUEHW-AHJYMZSGSA-N,Small molecule,False,PEMETREXED TROMETHAMINE,2022.0,4.0,CHEMBL225072,False,True,[],"['Pemetrexed ditrometamol' 'Pemetrexed tromethamine'
 'Pemetrexed tromethamine anhydrous']",,,"{'rows': array(['EFO_0003050', 'EFO_0000228'], dtype=object), 'count': 2}","[ENSG00000159131,ENSG00000228716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for large cell lung carcinoma and adenocarcinoma.
CHEMBL408,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2,GXPHKUHSUJUWKP-UHFFFAOYSA-N,Small molecule,False,TROGLITAZONE,1997.0,4.0,,True,True,['Prelay' 'Rezulin' 'Romozin'],['CI-991' 'CS-045' 'GR-92132X' 'GR92132X' 'Rezulin' 'Troglitazone'],"[('PubChem', array(['137275811', '144205672', '144210788', '170465091', '174007238',
       '26755242', '26755243', '26757864', '29216382'], dtype=object)), ('Wikipedia', array(['Troglitazone'], dtype=object)), ('drugbank', array(['DB00197'], dtype=object)), ('chEBI', array(['9753'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'EFO_0000691'], dtype=object), 'count': 2}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for diabetes mellitus and has 1 investigational indication. It was withdrawn in at least one region.
CHEMBL4297928,,,Unknown,False,NOMACOPAN,,3.0,,False,False,[],['Coversin' 'Nomacopan' 'REV-576' 'REV-675' 'REV675' 'rEV576'],,,"{'rows': array(['MONDO_0100244', 'EFO_0007187'], dtype=object), 'count': 2}","[ENSG00000213906,ENSG00000213903,ENSG00000106804]",Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL49429,Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1,PPHTXRNHTVLQED-UHFFFAOYSA-N,Small molecule,False,LIXIVAPTAN,,3.0,,False,False,['Lixar'],"['CRTX 080' 'CRTX-080' 'CRTX080' 'Lixivaptan' 'VPA 985' 'VPA-985' 'VPA985'
 'Vpa-985' 'WAY-VPA-985']","[('Wikipedia', array(['Lixivaptan'], dtype=object)), ('drugbank', array(['DB06666'], dtype=object))]",['CHEMBL3526685'],"{'rows': array(['EFO_0000373', 'HP_0002902', 'EFO_0008620', 'EFO_1001496'],
      dtype=object), 'count': 4}",[ENSG00000126895],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL5316170,CO[C@]1(COC(=O)CCNC(=O)C(N)CCCCN)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,GFNQJZFJGAULCC-BWENMZSBSA-N,Small molecule,False,CEP-2563,,1.0,,False,False,[],[],,['CHEMBL5314390'],,"[ENSG00000122025,ENSG00000165731,ENSG00000113721,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675,ENSG00000198400,ENSG00000148053,ENSG00000140538]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL779,CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O,WOXKDUGGOYFFRN-IIBYNOLFSA-N,Small molecule,False,TADALAFIL,2003.0,4.0,,False,True,['Adcirca' 'Adcirca (previously tadalafil lilly)' 'Cialis' 'Tadliq'],"['IC-351' 'IC351' 'LY-450190' 'LY450190' 'NSC-750236' 'NSC-759172'
 'Tadalafil' 'Tadalafil mylan' 'Trans-tadalafil']","[('DailyMed', array(['tadalafil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adcirca'],
      dtype=object)), ('PubChem', array(['144206195', '170464819', '26719828', '49666420'], dtype=object)), ('Wikipedia', array(['Tadalafil'], dtype=object)), ('drugbank', array(['DB00820'], dtype=object)), ('chEBI', array(['71940'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0009200', 'EFO_0000284', 'EFO_0000616',
       'EFO_0004714', 'EFO_0004244', 'EFO_0001361', 'EFO_0002614',
       'MONDO_0000153', 'MONDO_0005148', 'EFO_0002499', 'EFO_0803321',
       'HP_0030680', 'HP_0000802', 'MONDO_0005149', 'EFO_0000373',
       'HP_0001952', 'EFO_0004284', 'EFO_1000948', 'EFO_0000181',
       'EFO_0004718', 'EFO_0003099', 'EFO_0004234', 'EFO_0002618',
       'EFO_0001073', 'MONDO_0010679', 'EFO_0000537', 'MONDO_0020121',
       'MONDO_0002009', 'EFO_0000712', 'EFO_0001378', 'EFO_0000717',
       'MONDO_0001134', 'HP_0200023', 'MONDO_0004992', 'EFO_0000519',
       'EFO_1001145'], dtype=object), 'count': 37}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 5 approved and 32 investigational indications.
CHEMBL1084617,COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1,ZEOQUKRCASTCFR-UHFFFAOYSA-N,Small molecule,False,TEMANOGREL,,2.0,,False,False,[],['APD-791' 'APD791' 'Apd791' 'Temanogrel'],,['CHEMBL2105696'],"{'rows': array(['EFO_0005672'], dtype=object), 'count': 1}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1200425,C#CCN(C)Cc1ccccc1.Cl,BCXCABRDBBWWGY-UHFFFAOYSA-N,Small molecule,False,PARGYLINE HYDROCHLORIDE,1982.0,4.0,CHEMBL673,False,True,['Eutonyl'],['A-19120' 'MO-911' 'NSC-43798' 'Pargyline hcl' 'Pargyline hydrochloride'],"[('PubChem', array(['144203792', '144212995', '170465066', '50106924', '56422872',
       '855526'], dtype=object))]",,,"[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200781,Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,WIHMBLDNRMIGDW-UHFFFAOYSA-N,Small molecule,True,CITALOPRAM HYDROBROMIDE,1998.0,4.0,CHEMBL549,False,True,['Celexa' 'Cipramil' 'Citalopram hydrobromide' 'Paxoran'],"['Citalopram (as hydrobromide)' 'Citalopram hbr' 'Citalopram hydrobromide'
 'LU 10-171-B' 'LU-10-171-B' 'NSC-758684']","[('DailyMed', array(['citalopram%20hydrobromide'], dtype=object)), ('PubChem', array(['26719710', '29215151', '46500388', '50106010', '50106011'],
      dtype=object))]",,"{'rows': array(['HP_0031217', 'MONDO_0002009', 'EFO_0004262', 'EFO_0003758',
       'MONDO_0002009'], dtype=object), 'count': 5}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for major depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201061,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.Cl,OWNWYCOLFIFTLK-YDALLXLXSA-N,Small molecule,False,LEVALBUTEROL HYDROCHLORIDE,1999.0,4.0,CHEMBL1002,False,True,['Levalbuterol hydrochloride' 'Xopenex'],"['Albuterol (r)-form hydrochloride' 'Albuterol hydrochloride, r-'
 'Levalbuterol hcl' 'Levalbuterol hydrochloride'
 'Levosalbutamol hydrochloride' 'NSC-759255']","[('DailyMed', array(['levalbuterol%20hydrochloride'], dtype=object))]",,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999 and is indicated for asthma.
CHEMBL1201505,,,Unknown,False,"FIBRINOLYSIN, HUMAN",1964.0,4.0,,False,True,[],"['Fibrinolysin' 'Fibrinolysin (human)' 'Fibrinolysin human'
 'Fibrinolysin, human' 'Plasmin' 'Plasmin (bos taurus)' 'Plasmin (bovine)'
 'Plasmin (human)' 'Plasmin bovine' 'Thrombolysin.']","[('Wikipedia', array(['Fibrinolysin'], dtype=object))]",,"{'rows': array(['HP_0004419', 'MONDO_0020673', 'HP_0002140'], dtype=object), 'count': 3}","[ENSG00000171560,ENSG00000171564,ENSG00000171557]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for recurrent thrombophlebitis and has 2 investigational indications.
CHEMBL1711,CC(C)NCC(O)c1ccc(O)c(O)c1.Cl,IROWCYIEJAOFOW-UHFFFAOYSA-N,Small molecule,False,ISOPROTERENOL HYDROCHLORIDE,1956.0,4.0,CHEMBL434,False,True,"['Aerolone' 'Imuprel' 'Isoprenaline' 'Isoproterenol hydrochloride'
 'Isuprel' 'Norisodrine aerotrol' 'Oriconazole' 'Vapo-iso']","['Aerotrol' 'Dl-isoprenaline hydrochloride' 'Euspiran' 'Isomenyl'
 'Isoprenaline hydrochloride' 'Isoprenaline hydrochloride, dl-'
 'Isopropylarterenol hydrochloride' 'Isoproterenol HCl'
 'Isoproterenol hcl' 'Isoproterenol hydrochloride' 'Isovon'
 'L-isoprenaline hydrochloride' 'Medihaler-Iso' 'Mistarel' 'NSC-37745'
 'NSC-89747' 'Suscardia']","[('DailyMed', array(['isoproterenol%20hydrochloride'], dtype=object)), ('PubChem', array(['144208470', '144210628', '17388957', '26747558', '26747559',
       '26752241', '50085961', '50106483', '50106527', '50106528',
       '56320927', '56320928'], dtype=object))]",,"{'rows': array(['EFO_0000373'], dtype=object), 'count': 1}","[ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for congestive heart failure.
CHEMBL1717,Cl.Clc1ccccc1CN1CCc2sccc2C1,MTKNGOHFNXIVOS-UHFFFAOYSA-N,Small molecule,True,TICLOPIDINE HYDROCHLORIDE,1991.0,4.0,CHEMBL833,False,True,['Ticlid' 'Ticlopidine hydrochloride' 'Tiklid'],"['4-C-32' '53-32C' 'Ipaton' 'NSC-759165' 'Ticlopidine hcl'
 'Ticlopidine hydrochloride']","[('DailyMed', array(['ticlopidine%20hydrochloride'], dtype=object)), ('PubChem', array(['865815'], dtype=object)), ('chEBI', array(['9589'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'MONDO_0000831'], dtype=object), 'count': 2}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for stroke and thrombotic disease. This drug has a black box warning from the FDA.
CHEMBL180101,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,CBQGYUDMJHNJBX-OALUTQOASA-N,Small molecule,False,ESREBOXETINE,,3.0,,False,False,[],"['(s,s)-reboxetine' 'Esreboxetine' 'REBOXETINE' 'S,s-reboxetine']","[('PubChem', array(['11114256'], dtype=object)), ('drugbank', array(['DB12395'], dtype=object))]",['CHEMBL2103809'],"{'rows': array(['EFO_0003843', 'EFO_0005687', 'EFO_1000783'], dtype=object), 'count': 3}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1983268,CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1,HAYYBYPASCDWEQ-UHFFFAOYSA-N,Small molecule,False,ENTRECTINIB,2019.0,4.0,,False,True,['Rozlytrek'],['Entrectinib' 'NMS-E628' 'RXDX-101' 'Rxdx-101'],"[('DailyMed', array(['entrectinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek'],
      dtype=object)), ('PubChem', array(['103905026'], dtype=object)), ('drugbank', array(['DB11986'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0001642', 'EFO_0000326', 'EFO_0003060',
       'EFO_0000389', 'EFO_0000616', 'EFO_0000222', 'EFO_0000553'],
      dtype=object), 'count': 8}","[ENSG00000047936,ENSG00000171094,ENSG00000198400,ENSG00000148053,ENSG00000140538]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 5 investigational indications.
CHEMBL2041933,NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1,IAYGCINLNONXHY-LBPRGKRZSA-N,Small molecule,False,AZD-7762,,1.0,,False,False,[],['AZD-7762' 'AZD7762' 'Azd 7762' 'Azd-7762'],"[('PubChem', array(['124950686'], dtype=object)), ('drugbank', array(['DB12242'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000149554],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL206253,Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,WAXQNWCZJDTGBU-UHFFFAOYSA-N,Small molecule,False,NETUPITANT,2014.0,4.0,,False,True,[],['Netupitant' 'RO 67-3189/000' 'RO-67-3189' 'RO-673189000'],"[('DailyMed', array(['netupitant'], dtype=object)), ('drugbank', array(['DB09048'], dtype=object)), ('chEBI', array(['85155'], dtype=object))]",,"{'rows': array(['EFO_0006911', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for chemotherapy-induced nausea and vomiting and has 1 investigational indication.
CHEMBL2097081,,,Small molecule,True,NITROPRUSSIDE,1981.0,4.0,,False,True,[],['Nitroprusside'],"[('DrugCentral', array(['4631'], dtype=object)), ('PubChem', array(['29217813'], dtype=object)), ('chEBI', array(['7596'], dtype=object))]",['CHEMBL3183086' 'CHEMBL136478'],"{'rows': array(['EFO_0001358', 'EFO_0000537', 'MP_0001914', 'EFO_0005251',
       'MONDO_0005090', 'EFO_1000653', 'MONDO_0002050', 'EFO_0008585',
       'EFO_0000373', 'EFO_0000612', 'EFO_1000645', 'EFO_0004272',
       'EFO_0005252', 'EFO_0000319', 'MP_0001845', 'EFO_0000537'],
      dtype=object), 'count': 16}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103795,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+],IHWFKDWIUSZLCJ-UHFFFAOYSA-M,Small molecule,True,AZILSARTAN KAMEDOXOMIL,2011.0,4.0,CHEMBL2028661,False,True,['Edarbi'],['Azilsartan kamedoxomil' 'Azilsartan medoxomil potassium' 'TAK-491'],"[('DailyMed', array(['azilsartan%20kamedoxomil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi'],
      dtype=object)), ('chEBI', array(['68847'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000712'], dtype=object), 'count': 2}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hypertension and stroke. This drug has a black box warning from the FDA.
CHEMBL2109342,,,Antibody,False,HGS-1025,,1.0,,False,False,[],['HGS-1025' 'Hgs-1025'],,,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}",[ENSG00000160791],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3414621,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,NSQSAUGJQHDYNO-UHFFFAOYSA-N,Small molecule,False,TAZEMETOSTAT,2020.0,4.0,,False,True,[],['E-7438' 'E7438' 'EPZ-6438' 'EPZ6438' 'Tazemetostat'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAZEMETOSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12887'], dtype=object))]",['CHEMBL4594260'],"{'rows': array(['EFO_0005952', 'EFO_0000222', 'MONDO_0001187', 'EFO_0000181',
       'EFO_0000702', 'EFO_0000616', 'MONDO_0018906', 'EFO_0000196',
       'MONDO_0015760', 'MONDO_0018906', 'EFO_0002913', 'EFO_0000574',
       'EFO_0000096', 'EFO_0000403', 'EFO_0000691', 'EFO_0008528',
       'EFO_0001378', 'MONDO_0008315', 'MONDO_0017387', 'EFO_0000588',
       'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 22}",[ENSG00000106462],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 19 investigational indications.
CHEMBL3545057,CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O,HPMZBILYSWLILX-UMDUKNJSSA-N,Small molecule,False,ACETYLDIGITOXIN,1982.0,4.0,,False,True,['Acylanid'],['Acetyldigitoxin' 'Acetyldigitoxins .alpha.-form'],"[('drugbank', array(['DB00511'], dtype=object)), ('chEBI', array(['53773'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease.
CHEMBL3545068,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21.Cl.Cl,STGQPVQAAFJJFX-UHFFFAOYSA-N,Small molecule,False,COPANLISIB HYDROCHLORIDE,2017.0,4.0,CHEMBL3218576,False,True,['Aliqopa'],"['BAY 80-6946 DIHYDROCHLORIDE' 'BAY 84-1236' 'BAY-80-6946 DIHYDROCHLORIDE'
 'BAY-84-1236' 'Copanlisib hydrochloride'
 'Copanlisib hydrochloride hydrate']","[('DailyMed', array(['copanlisib%20dihydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0005537', 'MONDO_0018906', 'EFO_0000305', 'EFO_1001051',
       'EFO_1001469', 'EFO_0000616', 'EFO_0000096', 'EFO_0000403',
       'EFO_0001378', 'EFO_0000183'], dtype=object), 'count': 10}","[ENSG00000121879,ENSG00000171608]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for follicular lymphoma and neoplasm of mature b-cells and has 8 investigational indications.
CHEMBL3545138,,,Small molecule,False,PRT-2607,,1.0,,False,False,[],['BIIB-057' 'P505-15' 'PRT-062607' 'Prt-2607'],,,,[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545367,Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1,MUGXRYIUWFITCP-PGRDOPGGSA-N,Small molecule,False,LEMBOREXANT,2020.0,4.0,,False,True,['Dayvigo'],['E-2006' 'E2006' 'Lemborexant'],"[('DailyMed', array(['lemborexant'], dtype=object)), ('drugbank', array(['DB11951'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'EFO_0003918', 'MONDO_0007079', 'MONDO_0004975',
       'MONDO_0024361', 'EFO_0001421', 'EFO_0003086', 'EFO_0008568'],
      dtype=object), 'count': 8}","[ENSG00000121764,ENSG00000137252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for insomnia and has 7 investigational indications.
CHEMBL4297584,CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,HDXDQPRPFRKGKZ-INIZCTEOSA-N,Small molecule,False,TENALISIB,,2.0,,False,False,[],['Tenalisib'],"[('drugbank', array(['DB15295'], dtype=object))]",,"{'rows': array(['EFO_0000211', 'EFO_0000574', 'MONDO_0007254', 'EFO_0001642',
       'EFO_0000095', 'MONDO_0009348', 'EFO_0005952'], dtype=object), 'count': 7}","[ENSG00000105851,ENSG00000171608]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4297611,CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(-c2ccc(F)cc2)n1,YFHRCLAKZBDRHN-MRXNPFEDSA-N,Small molecule,False,VENGLUSTAT,,3.0,,False,False,[],"['GENZ-682452' 'GZ-402671' 'GZ/SAR402671' 'GZ402671' 'Genz-682452'
 'Genz-682452-AA' 'Gz402671' 'Ibiglustat' 'SAR-402671' 'SAR402671'
 'Venglustat']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VENGLUSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14966'], dtype=object))]",['CHEMBL4594270'],"{'rows': array(['Orphanet_77259', 'MONDO_0018150', 'HP_0001300', 'HP_0001300',
       'EFO_1001496', 'EFO_1001496', 'EFO_0008615', 'MONDO_0010526',
       'MONDO_0005180', 'Orphanet_77261', 'MONDO_0018150',
       'MONDO_0010526'], dtype=object), 'count': 12}",[ENSG00000148154],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL4297638,Cn1cc(-c2ccc(S(=O)(=O)[C@@H]3C[C@@H](C(=O)NC4(C#N)CC4)N(C(=O)C4(C(F)(F)F)CC4)C3)c(C(F)(F)F)c2)cn1,KXAAIORSMACJSI-AEFFLSMTSA-N,Small molecule,False,PETESICATIB,,2.0,,False,False,[],"['Petesicatib' 'RG-7625' 'RG7625' 'RO-5459072' 'RO5459072' 'Rg7625'
 'Ro5459072']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PETESICATIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15297'], dtype=object))]",,"{'rows': array(['EFO_0001060', 'EFO_0000699', 'EFO_0005809'], dtype=object), 'count': 3}",[ENSG00000163131],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297886,,,Protein,False,ASUNERCEPT,,3.0,,False,False,[],['APG-101' 'APG101' 'Apg101' 'Apocept' 'Asinercept' 'Asunercept' 'CAN-008'],,,"{'rows': array(['EFO_0000519', 'MONDO_0100096', 'EFO_0000198'], dtype=object), 'count': 3}",[ENSG00000117560],Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4298098,,,Antibody drug conjugate,False,TUSAMITAMAB RAVTANSINE,,3.0,,False,False,[],"['Maytansin-loaded anti-ceacam5 mab' 'SAR-408701' 'SAR408701' 'Sar 408701'
 'Sar-408701' 'Sar408701' 'Tusamitamab ravtansine']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TUSAMITAMAB%20RAVTANSINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000105388,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL866,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2,HPNSFSBZBAHARI-RUDMXATFSA-N,Small molecule,True,MYCOPHENOLIC ACID,2004.0,4.0,,False,True,['Mycophenolic acid' 'Myfortic'],"['68618' 'Mycophenolate'
 'Mycophenolate mofetil impurity, mycophenolic acid-' 'Mycophenolic acid'
 'NSC-129185' 'RS-61443 [AS MOFETIL]']","[('PubChem', array(['11112696', '11112697', '11114111', '124882524', '124882525',
       '124882528', '124882529', '124882530', '144204161', '170465182',
       '26747168', '26752207', '26752208', '420202', '47193743',
       '50104875', '85148364'], dtype=object)), ('Wikipedia', array(['Mycophenolic_acid'], dtype=object)), ('drugbank', array(['DB01024'], dtype=object)), ('chEBI', array(['168396'], dtype=object))]",['CHEMBL2106643'],"{'rows': array(['EFO_0004255', 'EFO_0005761', 'EFO_0005140', 'HP_0001871',
       'MONDO_0007915', 'EFO_0000717', 'EFO_0000384', 'EFO_1002048',
       'EFO_0003884', 'MONDO_0005147', 'EFO_0000540', 'EFO_0004599',
       'EFO_1000906', 'EFO_0000699', 'EFO_0003086', 'EFO_1000986',
       'MONDO_0005301', 'EFO_0000222', 'EFO_0003884', 'EFO_0004599',
       'MONDO_0013730', 'EFO_0005761'], dtype=object), 'count': 22}","[ENSG00000106348,ENSG00000178035]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for immune system disease and multiple sclerosis and has 18 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1108,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,RMEDXOLNCUSCGS-UHFFFAOYSA-N,Small molecule,True,DROPERIDOL,1970.0,4.0,,False,True,['Dridol' 'Droleptan' 'Droperidol' 'Inapsine'],['Droperidol' 'MCN-JR-4749' 'NSC-169874' 'R-4749'],"[('DailyMed', array(['droperidol'], dtype=object)), ('PubChem', array(['11112409', '124882342', '144204012', '170464722', '26719691',
       '26748461', '56463295', '855921'], dtype=object)), ('Wikipedia', array(['Droperidol'], dtype=object)), ('drugbank', array(['DB00450'], dtype=object)), ('chEBI', array(['4717'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'HP_0002017', 'EFO_0005407', 'EFO_0004888'],
      dtype=object), 'count': 4}","[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1164729,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,BQSJTQLCZDPROO-UHFFFAOYSA-N,Small molecule,True,FEBUXOSTAT,2009.0,4.0,,False,True,['Adenuric' 'Febuxostat mylan' 'Uloric'],['Febuxostat' 'NSC-758874' 'TMX-67'],"[('DailyMed', array(['febuxostat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-mylan'],
      dtype=object)), ('PubChem', array(['124893781', '144206555', '170465220'], dtype=object)), ('Wikipedia', array(['Febuxostat'], dtype=object)), ('drugbank', array(['DB04854'], dtype=object))]",,"{'rows': array(['EFO_0004253', 'EFO_0000537', 'EFO_1001479', 'EFO_0000319',
       'EFO_0004274', 'EFO_0003095', 'EFO_0003086', 'EFO_0003913',
       'EFO_0009104'], dtype=object), 'count': 9}",[ENSG00000158125],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for gout and hyperuricemia and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200377,CC(N)Cc1ccccc1.NC(CC(=O)O)C(=O)O,DYOBNLAYPQSBLB-UHFFFAOYSA-N,Small molecule,False,AMPHETAMINE ASPARTATE,1996.0,4.0,CHEMBL405,False,True,[],['Amfetamine aspartate' 'Amphetamine aspartate'],"[('DailyMed', array(['amphetamine%20aspartate'], dtype=object))]",,"{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996 and has 1 investigational indication.
CHEMBL1201653,,,Protein,False,INSULIN ZINC SUSP PURIFIED PORK,1979.0,4.0,,False,True,['Lente' 'Lente iletin ii (pork)'],['Insulin zinc susp purified pork'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1979.
CHEMBL1589,CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,VGZSUPCWNCWDAN-UHFFFAOYSA-N,Small molecule,False,ACETOHEXAMIDE,1964.0,4.0,,False,True,['Acetohexamide' 'Dimelor' 'Dymelor'],['33006' 'Acetohexamide' 'NSC-759128'],"[('PubChem', array(['11110689', '11112460', '144203618', '144209220', '144213052',
       '170465411', '17390067', '50105548', '56463352'], dtype=object)), ('Wikipedia', array(['Acetohexamide'], dtype=object)), ('drugbank', array(['DB00414'], dtype=object)), ('chEBI', array(['28052'], dtype=object))]",,"{'rows': array(['MONDO_0005129', 'EFO_0000400'], dtype=object), 'count': 2}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for diabetes mellitus and has 1 investigational indication.
CHEMBL1723,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl,YTNKWDJILNVLGX-UHFFFAOYSA-N,Small molecule,False,ALFUZOSIN HYDROCHLORIDE,2003.0,4.0,CHEMBL709,False,True,"['Alfutral sr' 'Alfuzosin hydrochloride' 'Benestan' 'Benestan ret'
 'Besavar xl' 'Fuzatal xl' 'Kelanu xl' 'Urion s' 'Uroxatral' 'Vasran xl'
 'Xatral' 'Xatral sr' 'Zufal xl']","['Alfuzosin hcl' 'Alfuzosin hydrochloride' 'SL 77 499-10' 'SL-77-499-10'
 'SL-77499-10']","[('DailyMed', array(['alfuzosin%20hydrochloride'], dtype=object)), ('PubChem', array(['144204252', '170465022'], dtype=object)), ('chEBI', array(['32286'], dtype=object))]",,"{'rows': array(['EFO_0000284', 'EFO_1001228', 'EFO_0004253'], dtype=object), 'count': 3}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for benign prostatic hyperplasia and has 2 investigational indications.
CHEMBL1742423,CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,ACCMWZWAEFYUGZ-UHFFFAOYSA-N,Small molecule,False,BILASTINE,,4.0,,False,True,['Ilaxten'],['Bilastine'],"[('PubChem', array(['170466329'], dtype=object)), ('drugbank', array(['DB11591'], dtype=object))]",,"{'rows': array(['EFO_0005751', 'MONDO_0005271', 'EFO_1001417', 'EFO_0003956',
       'EFO_0007141', 'EFO_1001881', 'EFO_0005531'], dtype=object), 'count': 7}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for eye allergy and allergic disease and has 5 investigational indications.
CHEMBL1743063,,,Antibody,False,RILOTUMUMAB,,3.0,,False,False,[],['AMG 102' 'AMG-102' 'Rilotumumab'],,,"{'rows': array(['EFO_0000702', 'MONDO_0100342', 'EFO_0000681', 'EFO_0000708',
       'EFO_0000588', 'MONDO_0001056', 'MONDO_0008315', 'EFO_1001465'],
      dtype=object), 'count': 8}",[ENSG00000019991],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL1822792,CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1,JGEBLDKNWBUGRZ-HXUWFJFHSA-N,Small molecule,False,MK-2461,,2.0,,False,False,[],['MK-2461' 'Mk-2461'],,,"{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1852688,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1,QADPYRIHXKWUSV-UHFFFAOYSA-N,Small molecule,False,INFIGRATINIB,2021.0,4.0,,False,True,[],['BGJ-398' 'BGJ398' 'Bgj-398' 'Infigratinib' 'MVP-BGJ398' 'NVP-BGJ398'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/INFIGRATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11886'], dtype=object)), ('chEBI', array(['63451'], dtype=object))]",['CHEMBL1834657'],"{'rows': array(['EFO_0001668', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0044704',
       'MONDO_0004992', 'MONDO_0007037', 'EFO_0005221', 'EFO_1002027',
       'EFO_0000519', 'EFO_0005221', 'EFO_0000616', 'EFO_1001961',
       'MONDO_0001187', 'MONDO_0011719', 'EFO_0000756', 'EFO_0001061'],
      dtype=object), 'count': 16}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 12 investigational indications.
CHEMBL2028019,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,KPWSJANDNDDRMB-QAQDUYKDSA-N,Small molecule,True,CARIPRAZINE,2015.0,4.0,,False,True,['Reagila'],['Cariprazine' 'Fri-7000188' 'GED-129' 'MP-214' 'RGH-188'],"[('drugbank', array(['DB06016'], dtype=object))]",['CHEMBL2024517'],"{'rows': array(['MONDO_0004985', 'EFO_0009963', 'MONDO_0004985', 'EFO_1001892',
       'EFO_0003756', 'MONDO_0002009', 'EFO_0009963', 'EFO_0005407',
       'MONDO_0005090', 'MONDO_0005090', 'MONDO_0002050'], dtype=object), 'count': 11}","[ENSG00000151577,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2043437,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1,SFNSLLSYNZWZQG-VQIMIIECSA-N,Small molecule,True,GLASDEGIB,2018.0,4.0,,False,True,[],['Glasdegib' 'PF-04449913' 'PF-4449913'],"[('drugbank', array(['DB11978'], dtype=object))]",['CHEMBL4297534' 'CHEMBL2043440'],"{'rows': array(['EFO_0000519', 'MONDO_0020547', 'MONDO_0004992', 'EFO_0000198',
       'EFO_0000222', 'EFO_1001968', 'EFO_0000616', 'EFO_0000222'],
      dtype=object), 'count': 8}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2110670,c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2,NPTIPEQJIDTVKR-STQMWFEESA-N,Small molecule,False,VABICASERIN,,2.0,,False,False,[],['Vabicaserin'],"[('drugbank', array(['DB12071'], dtype=object))]",['CHEMBL2104991' 'CHEMBL3126691'],"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}","[ENSG00000135914,ENSG00000102468,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL232202,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,BJRNKVDFDLYUGJ-RMPHRYRLSA-N,Small molecule,False,ARBUTIN,,2.0,,False,False,[],['Arbutin' 'Arbutinum' 'Arbutoside' 'NSC-4036' 'Ursin'],"[('PubChem', array(['144205062', '144212745', '170465722', '93576640'], dtype=object)), ('Wikipedia', array(['Arbutin'], dtype=object)), ('drugbank', array(['DB11217'], dtype=object)), ('chEBI', array(['18305'], dtype=object))]",,"{'rows': array(['EFO_0003963'], dtype=object), 'count': 1}",[ENSG00000077498],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545029,CN1CC2CCN(c3ccc(-c4ccc(-n5ncccc5=O)cc4)cc3)C2C1,GNIRITULTPTAQW-UHFFFAOYSA-N,Small molecule,False,ABT-288,,2.0,,False,False,[],['Abt-288'],,,"{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3678076,CCCCOc1cccc(CCNCC(=O)N(C)C)c1,GRHBODILPPXVKN-UHFFFAOYSA-N,Small molecule,False,EVENAMIDE,,2.0,,False,False,[],['Evenamide' 'Nw-3509'],,['CHEMBL4286909'],"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707320,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl,GYABBVHSRIHYJR-UHFFFAOYSA-N,Small molecule,False,ALECTINIB HYDROCHLORIDE,2015.0,4.0,CHEMBL1738797,False,True,['Alecensa'],[],"[('DailyMed', array(['alectinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa'],
      dtype=object))]",,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}","[ENSG00000171094,ENSG00000165731,ENSG00000143924]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for non-small cell lung carcinoma.
CHEMBL3833372,,,Antibody,False,BRAZIKUMAB,,3.0,,False,False,[],['AMG-139' 'Brazikumab' 'MEDI-2070' 'MEDI2070'],,,"{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}","[ENSG00000113302,ENSG00000110944]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3907479,Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1,BEMNJULZEQTDJY-UHFFFAOYSA-N,Small molecule,False,FGFR INHIBITOR DEBIO 1347,,2.0,,False,False,[],['Fgfr inhibitor debio 1347'],"[('drugbank', array(['DB12903'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000068078,ENSG00000066468,ENSG00000077782]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3989562,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O,NZMOFYDMGFQZLS-UHFFFAOYSA-N,Small molecule,False,TERAZOSIN HYDROCHLORIDE,1987.0,4.0,CHEMBL611,False,True,['Benph' 'Hytrin' 'Hytrin bph' 'Terazosin hydrochloride'],"['ABBOTT-45975' 'ABBOTT-45975 ANHYDROUS' 'Heitrin' 'Hytracin' 'Itrin'
 'NSC-759168' 'Terazosin (as hydrochloride)' 'Terazosin hcl'
 'Terazosin hcl 2h20' 'Terazosin hydrochloride'
 'Terazosin hydrochloride anhydrous' 'Terazosin hydrochloride dihydrate'
 'Terazosin hydrochloride hydrate' 'Urodie']","[('DailyMed', array(['terazosin%20hydrochloride'], dtype=object))]",,"{'rows': array(['HP_0000726', 'EFO_0000284'], dtype=object), 'count': 2}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for benign prostatic hyperplasia and has 1 investigational indication.
CHEMBL4228124,COc1ccc2c(c1)CC[C@H](CN(C)CC(=O)O)[C@@H]2c1ccccc1,UEBBYLJZCHTLEG-UTKZUKDTSA-N,Small molecule,False,ORG-25935,,2.0,,False,False,[],"['ORG 25935' 'Org 25935' 'Org-25935' 'Org-25935 free base' 'SCH 900435'
 'SCH-900435' 'Sch 900435']","[('drugbank', array(['DB12220'], dtype=object))]",,"{'rows': array(['EFO_0004262', 'MONDO_0005090', 'MONDO_0007079'], dtype=object), 'count': 3}",[ENSG00000196517],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297909,,,Antibody,False,FAZPILODEMAB,,2.0,,False,False,[],"['BFKB-8488A' 'BFKB8488A' 'Bfkb-8488a' 'Bfkb8488a' 'Fazpilodemab'
 'RG-7992' 'RG7992' 'RO-7040551' 'RO7040551']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FAZPILODEMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003095', 'EFO_0002614', 'MONDO_0005148'], dtype=object), 'count': 3}","[ENSG00000113578,ENSG00000134962]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297945,,,Unknown,False,EFMOROCTOCOG ALFA,2015.0,4.0,,False,True,['Elocta'],['Efmoroctocog alfa' 'Efraloctocog alfa' 'Elocta' 'Eloctate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/elocta'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602', 'MONDO_0018660'], dtype=object), 'count': 2}",[ENSG00000185010],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hemophilia a and hemophilia.
CHEMBL4303201,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,KSMZEXLVHXZPEF-UHFFFAOYSA-N,Small molecule,False,CATEQUENTINIB,,3.0,,False,False,[],['AL 3818' 'AL-3818' 'AL3818' 'Al-3818' 'Anlotinib' 'Catequentinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CATEQUENTINIB/relevant/1/'],
      dtype=object))]",['CHEMBL5314570'],"{'rows': array(['MONDO_0021117', 'EFO_0003108', 'EFO_0002618', 'EFO_0003860',
       'MONDO_0004992', 'EFO_0004252', 'EFO_0000564', 'EFO_0000756',
       'MONDO_0011962', 'EFO_0000333', 'MONDO_0005575', 'EFO_0001378',
       'EFO_1001512', 'EFO_0003869', 'EFO_1001951', 'EFO_0000174',
       'EFO_1000657', 'EFO_0000616', 'EFO_0005221', 'EFO_0000616',
       'MONDO_0002367', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0024503',
       'MONDO_0008170', 'MONDO_0020547', 'EFO_0007143', 'EFO_0003818',
       'EFO_0000707', 'MONDO_0015277', 'EFO_0003060', 'EFO_0000403',
       'EFO_1001968', 'EFO_0000691', 'EFO_0003820', 'MONDO_0008903',
       'EFO_1000359', 'EFO_0000313', 'EFO_1001972', 'MONDO_0002108',
       'MONDO_0003060', 'EFO_0000574', 'MONDO_0011719', 'EFO_0001376',
       'MONDO_0002912', 'EFO_0002916', 'HP_0001410', 'MONDO_0100342',
       'EFO_0005537', 'MONDO_0007576', 'EFO_0000681', 'EFO_0001071',
       'EFO_0000702', 'MONDO_0002974', 'MONDO_0001056', 'EFO_0000621',
       'EFO_0005922', 'EFO_0000588', 'EFO_0000519', 'EFO_0000181'],
      dtype=object), 'count': 60}","[ENSG00000157404,ENSG00000113721,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 60 investigational indications.
CHEMBL52333,CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O,PJBFVWGQFLYWCB-UHFFFAOYSA-N,Small molecule,False,ROLOFYLLINE,,3.0,,False,False,[],['KW 3902' 'KW-3902' 'KW3902' 'MK-7418' 'Rolofylline'],"[('PubChem', array(['137275983'], dtype=object))]",,"{'rows': array(['EFO_0000373', 'EFO_0003144'], dtype=object), 'count': 2}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL592054,Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1,ULVDFHLHKNJICZ-QCWLDUFUSA-N,Small molecule,False,IMIGLITAZAR,,3.0,,False,False,[],['Imiglitazar' 'TAK-559' 'Tak-559'],"[('drugbank', array(['DB12511'], dtype=object))]",,"{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}","[ENSG00000186951,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL92,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,ZDZOTLJHXYCWBA-VCVYQWHSSA-N,Small molecule,True,DOCETAXEL ANHYDROUS,1996.0,4.0,,False,True,[],"['Bind 014' 'CKD-810' 'Cabazitaxel metabolite (rp56976)'
 'Docetaxel accord' 'Docetaxel kabi' 'Docetaxel mylan' 'Docetaxel teva'
 'Docetaxel teva pharma' 'Docetaxel winthrop' 'Docetaxel, anhydrous'
 'NSC-628503' 'RP-56976' 'Rp56976' 'Taxotere']","[('PubChem', array(['124950708', '144206334', '144206639', '170464919', '494081'],
      dtype=object)), ('Wikipedia', array(['Docetaxel'], dtype=object)), ('drugbank', array(['DB01248'], dtype=object)), ('chEBI', array(['4672'], dtype=object))]",['CHEMBL3545252'],"{'rows': array(['MONDO_0011719', 'HP_0002039', 'EFO_0000313', 'MONDO_0008315',
       'MONDO_0001187', 'EFO_0004281', 'MONDO_0021117', 'EFO_0007355',
       'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'EFO_0000181',
       'MONDO_0004986', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000673',
       'MONDO_0001528', 'EFO_0000432', 'HP_0004326', 'EFO_0001416',
       'MONDO_0003060', 'EFO_0009708', 'EFO_0006859', 'EFO_0004230',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0005271',
       'MONDO_0000521', 'MONDO_0002038', 'EFO_0003869', 'MONDO_0021310',
       'EFO_1000043', 'MONDO_0005575', 'EFO_0003891', 'MONDO_0004192',
       'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'Orphanet_145',
       'EFO_0001376', 'EFO_1000984', 'EFO_0005537', 'EFO_0003817',
       'EFO_0000616', 'MONDO_0001325', 'MONDO_0002120', 'EFO_0000174',
       'EFO_0000565', 'EFO_0000574', 'EFO_0000178', 'EFO_0003860',
       'EFO_0007362', 'EFO_0005570', 'EFO_0002916', 'EFO_0005088',
       'MONDO_0021063', 'EFO_0000503', 'EFO_0000571', 'EFO_0002938',
       'EFO_0006352', 'EFO_0000707', 'MONDO_0002158', 'EFO_0003897',
       'EFO_0000466', 'EFO_0003060', 'EFO_0002428', 'EFO_0000756',
       'EFO_0000198', 'EFO_0000199', 'MONDO_0004992', 'MONDO_0002974',
       'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0003865',
       'EFO_0000702', 'MONDO_0002367', 'EFO_0001663', 'EFO_0000637',
       'EFO_0002618', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0018364',
       'EFO_0008528', 'EFO_0000305', 'EFO_0003893', 'EFO_0006911',
       'EFO_0004284', 'HP_0012378', 'MONDO_0007254', 'MONDO_0001056',
       'EFO_0000228', 'MONDO_0011962', 'EFO_0000691', 'EFO_0000196',
       'MONDO_0007576', 'EFO_0000564', 'EFO_0005950', 'MONDO_0001475',
       'EFO_1000601', 'MONDO_0021355', 'MONDO_0004669', 'EFO_0000182',
       'EFO_0000708', 'EFO_0001075', 'EFO_0005577', 'EFO_1001931',
       'EFO_1001100', 'MONDO_0003199', 'EFO_1001214', 'EFO_0004252',
       'EFO_1000595', 'EFO_0003859', 'EFO_0001378', 'MONDO_0001402'],
      dtype=object), 'count': 116}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 20 approved and 96 investigational indications. This drug has a black box warning from the FDA.
CHEMBL103667,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,MVCOAUNKQVWQHZ-UHFFFAOYSA-N,Small molecule,False,DORAMAPIMOD,,2.0,,False,False,[],['BIRB 796 BS' 'BIRB-796' 'BIRB-796 BS' 'Birb-796' 'Doramapimod'],"[('PubChem', array(['103904828', '124950164', '144206937', '170466618', '50100090'],
      dtype=object)), ('drugbank', array(['DB03044'], dtype=object)), ('chEBI', array(['40953'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_0000676'], dtype=object), 'count': 2}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1201011,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.Cl,IBBLRJGOOANPTQ-JKVLGAQCSA-N,Small molecule,True,QUINAPRIL HYDROCHLORIDE,1991.0,4.0,CHEMBL1592,False,True,['Accupril' 'Accupro' 'Quinapril hydrochloride' 'Quinil'],['CI 906' 'CI-906' 'NSC-758222' 'Quinapril hcl' 'Quinapril hydrochloride'],"[('DailyMed', array(['quinapril%20hydrochloride'], dtype=object)), ('PubChem', array(['144204934', '144207588', '170465312', '49648461'], dtype=object)), ('chEBI', array(['8714'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_1002048', 'EFO_0000712', 'EFO_0003144',
       'EFO_0000400'], dtype=object), 'count': 5}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved indications. This drug has a black box warning from the FDA.
CHEMBL1201130,C[N+](C)(C)CC(=O)O.[Cl-],HOPSCVCBEOCPJZ-UHFFFAOYSA-N,Small molecule,False,BETAINE HYDROCHLORIDE,,4.0,CHEMBL95889,False,True,['Acidol pepsin' 'Cystadane'],"['Betaine HCl' 'Betaine hcl' 'Betaine hydrochloride' 'Betainum muriaticum'
 'Lycine hydrochloride' 'NSC-32191' 'NSC-3976']","[('PubChem', array(['144204926', '144212459', '170464844', '26748661', '50105912',
       '56462965'], dtype=object))]",,,"[ENSG00000145692,ENSG00000132840]",Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL1201643,,,Protein,False,INSULIN ZINC SUSP PROMPT PURIFIED PORK,1982.0,4.0,,False,True,['Semilente'],['Insulin zinc susp prompt purified pork'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1237082,CNC1(C)C2CCC(C2)C1(C)C.Cl,PKVZBNCYEICAQP-UHFFFAOYSA-N,Small molecule,False,MECAMYLAMINE HYDROCHLORIDE,1956.0,4.0,CHEMBL267936,False,True,['Inversine' 'Mecamylamine hydrochloride'],"['Mecamylamine chloride' 'Mecamylamine hcl' 'Mecamylamine hydrochloride'
 'NSC-757086']","[('DailyMed', array(['mecamylamine%20hydrochloride'], dtype=object)), ('PubChem', array(['50106687', '50106688', '50106689'], dtype=object))]",,"{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}","[ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and has 1 investigational indication.
CHEMBL1951914,CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1,QOSMEMHKXNNIGG-SSEXGKCCSA-N,Small molecule,False,AZD5672,,2.0,,False,False,[],['AZD-5672' 'AZD5672' 'Azd 5672' 'Azd-5672' 'Azd5672'],,,"{'rows': array(['EFO_0000685', 'EFO_0003086'], dtype=object), 'count': 2}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108678,,,Antibody,False,NESVACUMAB,,2.0,,False,False,['Regn910'],['Nesvacumab' 'REGN-910' 'REGN910'],,,"{'rows': array(['EFO_0000616', 'EFO_0001365'], dtype=object), 'count': 2}",[ENSG00000091879],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108709,,,Enzyme,False,COLLAGENASE CLOSTRIDIUM HISTOLYTICUM,2010.0,4.0,,False,True,['Santyl' 'Xiaflex' 'Xiapex'],"['AA-4500' 'AA4500' 'Clostridial collagenase'
 'Clostridium histolyticum enzymes' 'Collagenase'
 'Collagenase (clostridium histolyticum)'
 'Collagenase clostridium histolyticum' 'Cordase' 'Iruxol' 'MZ-004'
 'Plaquase']","[('DailyMed', array(['collagenase%20clostridium%20histolyticum'], dtype=object)), ('DrugCentral', array(['5051'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex'],
      dtype=object))]",,"{'rows': array(['HP_0012227', 'HP_0200042', 'EFO_1000941', 'EFO_1001459',
       'EFO_0004229', 'EFO_1000466', 'EFO_0000759', 'EFO_1000438',
       'MONDO_0043839', 'EFO_1001434', 'EFO_0007067', 'HP_0003549',
       'EFO_0003899'], dtype=object), 'count': 13}","[ENSG00000164692,ENSG00000108821,ENSG00000139219,ENSG00000168542,ENSG00000187498,ENSG00000130635,ENSG00000142156,ENSG00000060718,ENSG00000204291,ENSG00000182871,ENSG00000171502,ENSG00000196739,ENSG00000215018,ENSG00000134871,ENSG00000204262,ENSG00000142173,ENSG00000204248,ENSG00000169031,ENSG00000080573,ENSG00000163359,ENSG00000081052,ENSG00000188153,ENSG00000172752,ENSG00000197565,ENSG00000206384]",Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 7 investigational indications.
CHEMBL3334624,Cc1cc(C[C@@H](OC(=O)N2CCC(N3CCc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCOCC3)CC2)cc(C)c1O,HTLWMOKBJQKDIJ-WJOKGBTCSA-N,Small molecule,False,BI-44370,,2.0,,False,False,[],"['BI 44370 TA' 'BI-44370-BS' 'BI44370' 'Bi 44370 ta' 'Bi-44370'
 'J3.353.239C']",,,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545403,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1,KLRRGBHZCJLIEL-UHFFFAOYSA-N,Small molecule,False,BMS-833923,,2.0,,False,False,[],"['BMS-833923' 'BMS-833923 DIMESYLATE MONOHYDRATE' 'Bms-833923' 'XL-139'
 'XL139']",,,"{'rows': array(['EFO_0000702', 'EFO_0002916', 'EFO_0003897', 'MONDO_0007187',
       'EFO_0000565', 'EFO_0004193', 'MONDO_0004992'], dtype=object), 'count': 7}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL377559,C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2.Cl,OIRUWDYJGMHDHJ-AFXVCOSJSA-N,Small molecule,False,RETASPIMYCIN HYDROCHLORIDE,,3.0,CHEMBL1184904,False,False,[],"['IPI-504' 'IPI-504 HYDROCHLORIDE' 'Retaspimycin hcl'
 'Retaspimycin hydrochloride']","[('chEBI', array(['71956'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0002617', 'MONDO_0008903', 'EFO_0000305',
       'EFO_0001378', 'MONDO_0011719', 'MONDO_0004992', 'MONDO_0007254',
       'EFO_0003085', 'EFO_0000673'], dtype=object), 'count': 10}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL3989686,CN1CCCC[C@H]1CCc1ccccc1NC(=O)/C=C/c1ccccc1,UXIPFQUBOVWAQW-UEBLJOKOSA-N,Small molecule,False,IFERANSERIN,,3.0,,False,False,[],['Iferanserin' 'Ven-309'],"[('drugbank', array(['DB11686'], dtype=object))]",,"{'rows': array(['EFO_0009552'], dtype=object), 'count': 1}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297588,CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1,XULSCZPZVQIMFM-IPZQJPLYSA-N,Small molecule,False,ODEVIXIBAT,2021.0,4.0,,False,True,[],['A-4250' 'A4250' 'AR-H064974' 'AZD-8294' 'AZD8294' 'Odevixibat'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ODEVIXIBAT/relevant/1/'],
      dtype=object))]",['CHEMBL5315120'],"{'rows': array(['MONDO_0007318', 'EFO_0004267', 'HP_0000989', 'MONDO_0017290',
       'MONDO_0001751', 'MONDO_0008867', 'EFO_1001249', 'MONDO_0019072'],
      dtype=object), 'count': 8}",[ENSG00000125255],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pruritus and familial intrahepatic cholestasis and has 6 investigational indications.
CHEMBL4297828,,,Unknown,False,SHR-1316,,3.0,,False,False,[],['Adebrelimab' 'HTI-1088' 'SHR-1316' 'Shr-1316'],,,"{'rows': array(['EFO_0000707', 'EFO_0003893', 'MONDO_0007254', 'EFO_0003060',
       'MONDO_0004992', 'EFO_0000616', 'EFO_0000702', 'EFO_0000182'],
      dtype=object), 'count': 8}",[ENSG00000120217],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL4298077,,,Antibody,False,PRASINEZUMAB,,2.0,,False,False,[],"['PRX002' 'Prasinezumab' 'Prx-002' 'Prx002' 'RG-7935' 'RG7935'
 'RO-7046015' 'RO7046015' 'Ro7046015']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PRASINEZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000145335],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL430497,Clc1ccc(OC[C@H]2CCN2)cn1,MKTAGSRKQIGEBH-SSDOTTSWSA-N,Small molecule,False,TEBANICLINE,,2.0,,False,False,[],['Tebanicline'],,['CHEMBL2104964' 'CHEMBL5303486'],,"[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4594550,,,Antibody,False,SERPLULIMAB,,3.0,,False,False,[],['HLX-10' 'HLX10' 'Hlx10' 'Serplulimab'],,,"{'rows': array(['EFO_0000616', 'HP_0001541', 'MONDO_0007254', 'MONDO_0002974',
       'EFO_0000503', 'MONDO_0021063', 'EFO_0003060', 'MONDO_0001056',
       'EFO_1001951', 'EFO_0000571', 'EFO_0000681', 'EFO_0000182',
       'MONDO_0002120', 'EFO_0005922', 'EFO_0004252', 'EFO_0000181',
       'EFO_0000702'], dtype=object), 'count': 17}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.
CHEMBL493982,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1,ZBGXUVOIWDMMJE-QHNZEKIYSA-N,Small molecule,True,VORAPAXAR,2014.0,4.0,,False,True,[],['SCH-530348' 'Vorapaxar'],"[('Wikipedia', array(['Vorapaxar'], dtype=object)), ('drugbank', array(['DB09030'], dtype=object)), ('chEBI', array(['82702'], dtype=object))]",['CHEMBL3542336' 'CHEMBL2107386'],"{'rows': array(['EFO_0000712', 'HP_0004419', 'EFO_0000764', 'EFO_0005672',
       'EFO_0000612', 'EFO_0004265', 'MONDO_0002679'], dtype=object), 'count': 7}",[ENSG00000181104],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL516,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,JJCFRYNCJDLXIK-UHFFFAOYSA-N,Small molecule,False,CYPROHEPTADINE,1961.0,4.0,,False,True,[],['Ciprovit' 'Cyproheptadine'],"[('PubChem', array(['104171133', '11110964', '11110965', '11113362', '124879679',
       '144203663', '170465127', '174007288', '26751603', '50100203',
       '50104260', '90341656'], dtype=object)), ('Wikipedia', array(['Cyproheptadine'], dtype=object)), ('drugbank', array(['DB00434'], dtype=object)), ('chEBI', array(['4046'], dtype=object))]",['CHEMBL1716'],"{'rows': array(['MONDO_0004992', 'MONDO_0100096', 'HP_0002027', 'MONDO_0005271',
       'EFO_0005531', 'EFO_0007141', 'EFO_0000712', 'EFO_0003956',
       'HP_0001653', 'MONDO_0007079'], dtype=object), 'count': 10}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 4 approved and 6 investigational indications.
CHEMBL5314384,C#CCOc1ccc(Nc2nc(Nc3ccc(C)c(S(=O)(=O)NC(=O)CC)c3)ncc2F)cc1,IGLNXKVGKIFNBQ-UHFFFAOYSA-N,Small molecule,False,R-348,,2.0,,False,False,[],['R-348'],,,"{'rows': array(['MONDO_0020547', 'EFO_1000906'], dtype=object), 'count': 2}","[ENSG00000105639,ENSG00000165025]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL575448,C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1,LQVXSNNAFNGRAH-QHCPKHFHSA-N,Small molecule,False,BMS-754807,,2.0,,False,False,[],['BMS-754807' 'BMS754807' 'Bms 754807' 'Bms-754807'],"[('PubChem', array(['164339435'], dtype=object)), ('drugbank', array(['DB15399'], dtype=object)), ('chEBI', array(['88339'], dtype=object))]",['CHEMBL2401777'],"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000140443,ENSG00000171105]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL596802,CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1,YGKUEOZJFIXDGI-UHFFFAOYSA-N,Small molecule,False,PRIDOPIDINE,,3.0,,False,False,['Huntexil'],['ACR-16' 'ACR16' 'FR-310826' 'FR310826' 'Pridopidine'],"[('drugbank', array(['DB11947'], dtype=object))]",['CHEMBL2105691'],"{'rows': array(['MONDO_0007739', 'MONDO_0005180', 'MONDO_0004976'], dtype=object), 'count': 3}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL621,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,PHLBKPHSAVXXEF-UHFFFAOYSA-N,Small molecule,True,TRAZODONE,1981.0,4.0,,False,True,[],['Desyrel' 'J10.767K' 'Trazodone' 'Trialodine' 'Trittico'],"[('PubChem', array(['11111900', '11111901', '174007449', '90341328'], dtype=object)), ('Wikipedia', array(['Trazodone'], dtype=object)), ('drugbank', array(['DB00656'], dtype=object)), ('chEBI', array(['9654'], dtype=object))]",['CHEMBL1200798'],"{'rows': array(['EFO_0007453', 'MONDO_0002009', 'EFO_0005230', 'MONDO_0002009',
       'EFO_0003918', 'MONDO_0005090', 'EFO_1000783', 'EFO_0008568',
       'MONDO_0004976', 'MONDO_0002050', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0007079', 'MONDO_0002050', 'MONDO_0004975', 'MONDO_0002009',
       'EFO_0004698'], dtype=object), 'count': 17}","[ENSG00000102468,ENSG00000147246,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for major depressive disorder and depressive disorder and has 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL923,O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O,IIDJRNMFWXDHID-UHFFFAOYSA-N,Small molecule,False,RISEDRONIC ACID,1998.0,4.0,,False,True,[],['Actonel' 'M05BA07' 'NE-58095' 'Ridron' 'Risedronate' 'Risedronic acid'],"[('PubChem', array(['29216086'], dtype=object)), ('Wikipedia', array(['Risedronic_acid'], dtype=object)), ('drugbank', array(['DB00884'], dtype=object)), ('chEBI', array(['8869'], dtype=object))]",['CHEMBL4303174' 'CHEMBL3560765' 'CHEMBL1654'],"{'rows': array(['MONDO_0005351', 'EFO_0003854', 'EFO_0000574', 'HP_0000938',
       'GO_0042697', 'EFO_1001919', 'EFO_0004260', 'EFO_0000196',
       'HP_0003418', 'MONDO_0021165', 'MONDO_0019019', 'MONDO_0000845',
       'EFO_0004261', 'EFO_0000565', 'EFO_0003854', 'EFO_0003882',
       'EFO_1001152', 'MONDO_0008315', 'EFO_0003882', 'MONDO_0021117'],
      dtype=object), 'count': 20}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 16 investigational indications.
CHEMBL1200413,Cl.c1ccc2c(c1)CCCC2C1=NCCN1,BJORNXNYWNIWEY-UHFFFAOYSA-N,Small molecule,False,TETRAHYDROZOLINE HYDROCHLORIDE,1979.0,4.0,CHEMBL1266,False,True,['Tyzine'],"['NSC-757339' 'Tetrahydrozoline hydrochloride' 'Tetrahydrozoline nitrate'
 'Tetryzoline' 'Tetryzoline hydrochloride']","[('PubChem', array(['170464943', '26747671', '50107052', '56424102', '855698'],
      dtype=object))]",,"{'rows': array(['EFO_0000678', 'MP_0001845'], dtype=object), 'count': 2}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 2 investigational indications.
CHEMBL1200760,O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+],CKMOQBVBEGCJGW-LLIZZRELSA-L,Small molecule,False,BALSALAZIDE DISODIUM,2000.0,4.0,CHEMBL1201346,False,True,['Balsalazide disodium' 'Colazal' 'Colazide' 'Giazo'],"['BX-661A' 'BX661A' 'Balsalazide disodium'
 'Balsalazide disodium anhydrous' 'Balsalazide disodium dihydrate'
 'Balsalazide disodium salt dihydrate' 'Balsalazide sodium' 'Balsalazine'
 'NSC-760046']","[('DailyMed', array(['balsalazide%20disodium'], dtype=object))]",,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}","[ENSG00000132170,ENSG00000073756,ENSG00000095303,ENSG00000012779]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for ulcerative colitis.
CHEMBL1471,C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,ATALOFNDEOCMKK-OITMNORJSA-N,Small molecule,False,APREPITANT,2003.0,4.0,,False,True,['Aprepitant' 'Cinvanti' 'Emend'],"['Aprepitant' 'L-754,030' 'MK-0869' 'MK-869' 'NSC-748825']","[('DailyMed', array(['aprepitant'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emend'],
      dtype=object)), ('Wikipedia', array(['Aprepitant'], dtype=object)), ('drugbank', array(['DB00673'], dtype=object)), ('chEBI', array(['499361'], dtype=object))]",,"{'rows': array(['EFO_0006911', 'EFO_0005611', 'EFO_0002610', 'HP_0002017',
       'EFO_0000514', 'MONDO_0100096', 'HP_0000989', 'EFO_0000519',
       'HP_0002018', 'EFO_0004240', 'EFO_0003060', 'EFO_0007191',
       'EFO_0000182', 'EFO_0000764', 'EFO_0000222', 'EFO_1000948',
       'EFO_0001378', 'MONDO_0004992', 'HP_0002013', 'EFO_0003843',
       'MONDO_0007079', 'MONDO_0002009', 'EFO_0004888'], dtype=object), 'count': 23}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved and 17 investigational indications.
CHEMBL1823872,C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,NHXLMOGPVYXJNR-ATOGVRKGSA-N,Protein,False,SOMATOSTATIN,,3.0,,False,False,[],['SRIF-14' 'Somatostatin' 'Somatostatin-14'],"[('drugbank', array(['DB09099'], dtype=object)), ('chEBI', array(['64628'], dtype=object))]",,"{'rows': array(['MONDO_0005147', 'EFO_0004606', 'HP_0001399', 'EFO_0000666',
       'HP_0004398', 'EFO_1001496', 'EFO_1000045', 'EFO_1000652',
       'EFO_0004243', 'EFO_0000182', 'HP_0001943', 'EFO_0000673'],
      dtype=object), 'count': 12}","[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL2062335,COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)C(O)C(O)C(=O)O,YGULWPYYGQCFMP-UHFFFAOYSA-N,Small molecule,True,METOPROLOL TARTRATE,1978.0,4.0,CHEMBL13,False,True,"['Arbralene' 'Beloc cor' 'Betaloc' 'Betaloc s.a.' 'Lopresor' 'Lopresor sr'
 'Lopressor' 'Mepranix 100' 'Mepranix 50' 'Metoprolol tartrate' 'Tensomex'
 'Toprol xl']","['Beloc' 'CGP-2175E' 'Metoprolol hemitartrate' 'Metoprolol tartrate'
 'Metropress' 'NSC-757105' 'Prelis' 'Seloken' 'Selopral']","[('DailyMed', array(['metoprolol%20tartrate'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0003144', 'EFO_0000275', 'EFO_0003777',
       'EFO_0003913', 'EFO_0000612', 'EFO_0000712'], dtype=object), 'count': 7}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2105695,CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1,MDSQOJYHHZBZKA-GBXCKJPGSA-N,Small molecule,False,TELOTRISTAT ETHYL,2017.0,4.0,,False,True,['Xermelo'],"['LX 1032' 'LX 1606' 'LX-1032' 'LX-1606' 'LX1032' 'LX1606'
 'Telotristat ethyl']","[('drugbank', array(['DB12095'], dtype=object))]",['CHEMBL3348963'],"{'rows': array(['EFO_0001421', 'EFO_1001901', 'EFO_1001901', 'EFO_1001769',
       'MONDO_0003060', 'HP_0002014', 'EFO_0004243', 'EFO_1000852'],
      dtype=object), 'count': 8}","[ENSG00000139287,ENSG00000129167]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 5 investigational indications.
CHEMBL2105759,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,XUZMWHLSFXCVMG-UHFFFAOYSA-N,Small molecule,True,BARICITINIB,2017.0,4.0,,False,True,['Olumiant'],"['Baricitinib' 'Baricitinib phosphate' 'Baricitinib phosphate salt'
 'INCB-028050' 'INCB028050' 'Incb-28050' 'LY-3009104' 'LY3009104']","[('DailyMed', array(['baricitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant'],
      dtype=object)), ('drugbank', array(['DB11817'], dtype=object))]",,"{'rows': array(['EFO_0000699', 'EFO_1001486', 'EFO_0000783', 'EFO_0000694',
       'EFO_0004256', 'MONDO_0005147', 'EFO_1001231', 'EFO_0007160',
       'EFO_0000764', 'EFO_0000676', 'EFO_1001209', 'EFO_0000398',
       'EFO_0000401', 'MONDO_0007915', 'EFO_0000685', 'MONDO_0020547',
       'MONDO_0013730', 'EFO_0000540', 'EFO_1000726', 'EFO_0004192',
       'EFO_0003884', 'EFO_0000274', 'EFO_0004208', 'EFO_1001034',
       'EFO_1000668', 'EFO_0000557', 'EFO_0003106', 'EFO_0002609',
       'MONDO_0100096'], dtype=object), 'count': 29}","[ENSG00000096968,ENSG00000162434]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for rheumatoid arthritis and immune system disease and has 27 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108955,,,Antibody,False,EDRECOLOMAB,,3.0,,False,False,['Panorex'],['17-1A' 'C-1' 'Edrecolomab' 'MAB-17-1A' 'Mab17-1a'],,,"{'rows': array(['EFO_1001951', 'EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 3}",[ENSG00000119888],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2181753,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)NCc1ccccc1,OPXIRFWNLBDKQB-UHFFFAOYSA-N,Small molecule,False,AM-211,,1.0,,False,False,[],['AM211' 'Am-211'],,,,[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2220442,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,FJLGEFLZQAZZCD-VAWYXSNFSA-N,Small molecule,False,FLUVASTATIN,1993.0,4.0,,False,True,[],['Fluvas' 'Fluvastatin' 'NSC-758896'],"[('chEBI', array(['38562'], dtype=object))]",['CHEMBL2218894'],"{'rows': array(['HP_0003124', 'EFO_0004911', 'Orphanet_309005', 'EFO_0003047',
       'EFO_0004220', 'HP_0003124', 'EFO_0002689', 'HP_0000802',
       'EFO_0005543', 'MONDO_0008315', 'EFO_0000266', 'EFO_0000756',
       'MONDO_0007254', 'MONDO_0018965', 'EFO_0000319'], dtype=object), 'count': 15}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 12 investigational indications.
CHEMBL25263,O=C(O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)O,HZLAWYIBLZNRFZ-VXGBXAGGSA-N,Small molecule,False,MIRIDESAP,,2.0,,False,False,[],"['CPHPC' 'Cphpc' 'GSK-2315698' 'GSK2315698' 'Gsk2315698' 'Miridesap'
 'RO-638695' 'Ro 63-8695']","[('Wikipedia', array(['CPHPC'], dtype=object)), ('drugbank', array(['DB13087'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'EFO_1001875', 'MONDO_0017816'], dtype=object), 'count': 3}",[ENSG00000132703],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3039517,Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1,SYYBDNPGDKKJDU-ZDUSSCGKSA-N,Small molecule,False,RABUSERTIB,,2.0,,False,False,[],['IC-83' 'LY-2603618' 'LY2603618' 'Ly-2603618' 'Rabusertib'],"[('drugbank', array(['DB11662'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003060', 'MONDO_0004992', 'EFO_0003860'],
      dtype=object), 'count': 4}",[ENSG00000149554],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3137313,NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1,ATLYLVPZNWDJBW-KIHHCIJBSA-N,Small molecule,False,AXELOPRAN,,2.0,,False,False,[],['Axelopran' 'TD-1211'],"[('drugbank', array(['DB12013'], dtype=object))]",['CHEMBL3137319' 'CHEMBL3895543'],"{'rows': array(['HP_0002019'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3301625,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1,KXBDTLQSDKGAEB-UHFFFAOYSA-N,Small molecule,False,SPEBRUTINIB,,2.0,,False,False,[],['AVL-292' 'Btk inhibitor cc-292' 'CC-292' 'Spebrutinib'],"[('drugbank', array(['DB11764'], dtype=object))]",['CHEMBL3301600'],"{'rows': array(['EFO_0000095', 'EFO_0000403', 'EFO_0009441', 'EFO_0000685',
       'EFO_0000565'], dtype=object), 'count': 5}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3545030,,,Small molecule,False,JNJ-17216498,,2.0,,False,False,[],['Jnj-17216498'],,,"{'rows': array(['MONDO_0021107'], dtype=object), 'count': 1}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3915620,CC#C[C@@H](CC(=O)O)c1ccc(OCc2ccc(CN3CCC4(C=Cc5ccccc54)CC3)cc2)cc1,FHRWHNJJQGSCQC-LJAQVGFWSA-N,Small molecule,False,LY2881835,,1.0,,False,False,[],['LY-2881835' 'LY2881835' 'Ly2881835'],"[('drugbank', array(['DB15046'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000126266],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989680,COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1,LQJLLAOISDVBJM-UHFFFAOYSA-N,Small molecule,False,AXOMADOL,,2.0,,False,False,[],"['Axomadol' 'BN-110 FREE BASE' 'BN110 BASE' 'BN110 FREE BASE' 'En3324'
 'GRT-151 FREE BASE' 'GRT0151Y' 'GRT151 Base' 'GRT151 FREE BASE']",,['CHEMBL3976339'],"{'rows': array(['HP_0003419', 'HP_0012532', 'EFO_0003843'], dtype=object), 'count': 3}","[ENSG00000112038,ENSG00000116329,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL419667,COc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3[C@](O)(c3ccccc3Cl)[C@@H]2C(=O)N2CCC[C@H]2C(N)=O)cc1OC,CEBYCSRFKCEUSW-NAYZPBBASA-N,Small molecule,False,RELCOVAPTAN,,2.0,,False,False,[],['Relcovaptan' 'SR 49059' 'SR49059' 'Sr-49059' 'TDI 0134' 'TDI-0134'],"[('PubChem', array(['26753276'], dtype=object)), ('Wikipedia', array(['Relcovaptan'], dtype=object)), ('drugbank', array(['DB13929'], dtype=object))]",,,"[ENSG00000166148,ENSG00000180914]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297502,C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC,TUWMKPVJGGWGNL-UHFFFAOYSA-N,Small molecule,False,AVORALSTAT,,3.0,,False,False,[],['Avoralstat' 'BCX-4161'],"[('drugbank', array(['DB12120'], dtype=object))]",,"{'rows': array(['MONDO_0019623'], dtype=object), 'count': 1}",[ENSG00000164344],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4650487,,,Antibody,False,TORUDOKIMAB,,2.0,,False,False,[],['LY-3375880' 'LY3375880' 'Ly3375880' 'Torudokimab'],,,"{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}",[ENSG00000137033],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL473159,Oc1cc(O)cc(O)c1,QCDYQQDYXPDABM-UHFFFAOYSA-N,Small molecule,False,PHLOROGLUCINOL,,4.0,,False,True,['Spasfon' 'Spasfon-lyoc'],"['Benezene-1,3,5-triol' 'Dilospan s' 'NSC-1572' 'Phloroglucin'
 'Phloroglucinol' 'Sym-trihydroxybenzene']","[('PubChem', array(['29218028'], dtype=object)), ('Wikipedia', array(['Phloroglucinol'], dtype=object)), ('drugbank', array(['DB12944'], dtype=object)), ('chEBI', array(['16204'], dtype=object))]",,"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for gastrointestinal disease.
CHEMBL539843,Cl.Cl.NC(=O)c1cnc2n1CCc1ccccc1C21CCNCC1,BOYLPLUVCXUHDJ-UHFFFAOYSA-N,Small molecule,False,VAPITADINE DIHYDROCHLORIDE,,2.0,CHEMBL369075,False,False,['Hivenyl'],['R-129160' 'R129160' 'Vapitadine dihydrochloride'],,,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL565612,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,OAVGBZOFDPFGPJ-UHFFFAOYSA-N,Small molecule,False,SOTRASTAURIN,,2.0,,False,False,[],['AEB-071' 'AEB071' 'Aeb-071' 'NVP-AEB071' 'Sotrastaurin'],"[('PubChem', array(['103905056'], dtype=object)), ('drugbank', array(['DB12369'], dtype=object)), ('chEBI', array(['90531'], dtype=object))]",['CHEMBL2105655'],"{'rows': array(['EFO_0000403', 'EFO_0000729', 'EFO_0000574', 'EFO_0000676',
       'EFO_1001119'], dtype=object), 'count': 5}","[ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL669,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,JURKNVYFZMSNLP-UHFFFAOYSA-N,Small molecule,False,CYCLOBENZAPRINE,1977.0,4.0,,False,True,[],['Cyclobenzaprine' 'Flexeril' 'MK-130 (AS THE BASE)' 'TNX-102'],"[('PubChem', array(['11110649', '11110650', '174007219', '4253288', '50108641',
       '50111010', '90340629'], dtype=object)), ('Wikipedia', array(['Cyclobenzaprine'], dtype=object)), ('drugbank', array(['DB00924'], dtype=object)), ('chEBI', array(['3996'], dtype=object))]",['CHEMBL1200636'],"{'rows': array(['MONDO_0005277', 'EFO_0005687', 'HP_0003394', 'EFO_1000632',
       'EFO_0001422', 'EFO_0009488', 'HP_0003326', 'HP_0001257',
       'EFO_0003843', 'EFO_0001358', 'MONDO_0002050'], dtype=object), 'count': 11}","[ENSG00000102468,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 6 investigational indications.
CHEMBL84,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,UCFGDBYHRUNTLO-QHCPKHFHSA-N,Small molecule,True,TOPOTECAN,1996.0,4.0,,False,True,[],"['Ff-10850 (liposomal topotecan)' 'Hycamptin' 'Hycamtin' 'NSC-609699'
 'NSC-641007' 'SKF-104864' 'Topotecan']","[('PubChem', array(['164339428'], dtype=object)), ('Wikipedia', array(['Topotecan'], dtype=object)), ('drugbank', array(['DB01030'], dtype=object)), ('chEBI', array(['63632'], dtype=object))]",['CHEMBL1607'],"{'rows': array(['EFO_0003833', 'EFO_0008498', 'MONDO_0002158', 'EFO_0002087',
       'MONDO_0100342', 'MONDO_0008903', 'EFO_0002918', 'EFO_0002617',
       'EFO_0000613', 'EFO_1000158', 'EFO_0000466', 'MONDO_0004992',
       'EFO_0000519', 'MONDO_0008380', 'EFO_0000621', 'MONDO_0037745',
       'EFO_0002939', 'MONDO_0100096', 'EFO_0000630', 'EFO_0000702',
       'EFO_1001465', 'EFO_0001416', 'EFO_0003893', 'MONDO_0004992',
       'MONDO_0008170', 'EFO_0005543', 'MONDO_0002974', 'EFO_0001378',
       'EFO_0000502', 'EFO_1001042', 'EFO_0000565', 'EFO_1000251',
       'EFO_0000681', 'EFO_0003833', 'EFO_0000220', 'EFO_0000691',
       'EFO_0008524', 'MONDO_0019004', 'EFO_0000198', 'EFO_1001100',
       'EFO_0002501', 'MONDO_0007576', 'EFO_1000823', 'EFO_0005561',
       'EFO_0005537', 'EFO_0002428', 'EFO_0002499', 'MONDO_0007254',
       'EFO_0000174', 'EFO_1000657', 'EFO_0000326', 'EFO_0001061',
       'EFO_0001075', 'EFO_0000616', 'EFO_0005952', 'EFO_0000389',
       'EFO_0000313', 'EFO_0003060', 'EFO_0003851', 'EFO_0003060',
       'EFO_0000616', 'MONDO_0021063', 'EFO_0003869', 'EFO_0000574',
       'MONDO_0011962', 'EFO_0000702', 'MONDO_0006058', 'EFO_0000222',
       'EFO_1001331', 'EFO_0000621', 'MONDO_0018271', 'EFO_0003893',
       'MONDO_0002974', 'EFO_0007362', 'EFO_0003859', 'MONDO_0018364',
       'MONDO_0018364', 'EFO_1000895', 'MONDO_0008315', 'MONDO_0008170',
       'MONDO_0002380', 'MONDO_0002087', 'EFO_1000043'], dtype=object), 'count': 83}",[ENSG00000184428],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 75 investigational indications. This drug has a black box warning from the FDA.
CHEMBL895,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,NETZHAKZCGBWSS-CEDHKZHLSA-N,Small molecule,False,NALBUPHINE,,4.0,,False,True,[],['Intapan' 'Nalbuphine' 'Nubain'],"[('PubChem', array(['144205561'], dtype=object)), ('Wikipedia', array(['Nalbuphine'], dtype=object)), ('drugbank', array(['DB00844'], dtype=object)), ('chEBI', array(['7454'], dtype=object))]",['CHEMBL1396398' 'CHEMBL1201132'],"{'rows': array(['HP_0000175', 'EFO_0005611', 'EFO_0000222', 'EFO_0003843',
       'EFO_1001250', 'EFO_0005323', 'HP_0000989', 'EFO_0009267',
       'EFO_0001421', 'EFO_0003843'], dtype=object), 'count': 10}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and has 8 investigational indications.
CHEMBL1200880,COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1,BREMLQBSKCSNNH-UHFFFAOYSA-M,Small molecule,False,DIPHEMANIL METHYLSULFATE,1982.0,4.0,CHEMBL1201340,False,True,['Prantal'],"['Diphemanil methylsulfate' 'Diphemanil methylsulphate'
 'Diphemanil metilsulfate' 'NSC-41725']","[('PubChem', array(['144203900', '170464876', '56463612'], dtype=object)), ('Wikipedia', array(['Diphemanil_metilsulfate'], dtype=object)), ('chEBI', array(['59782'], dtype=object))]",,,"[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201420,,,Enzyme,False,UROKINASE,2007.0,4.0,,False,True,['Abbokinase' 'Kinlytic' 'Ukidan'],"['Kinase (enzyme-activating), uro-' 'Urinary plasminogen activator'
 'Urokinase']","[('DrugCentral', array(['5109'], dtype=object)), ('Wikipedia', array(['Urokinase'], dtype=object))]",,"{'rows': array(['EFO_0008585', 'EFO_0000712', 'EFO_0003827', 'EFO_0003097',
       'EFO_0009680', 'EFO_0000544', 'HP_0004419'], dtype=object), 'count': 7}",[ENSG00000122861],Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for recurrent thrombophlebitis and has 6 investigational indications.
CHEMBL1201454,,,Unknown,False,ALSEROXYLON,1982.0,4.0,,False,True,['Rautensin' 'Rauwiloid'],['Alseroxylon'],"[('Wikipedia', array(['Alseroxylon'], dtype=object))]",,,"[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Unknown drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1213351,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,XLMALTXPSGQGBX-GCJKJVERSA-N,Small molecule,True,PROPOXYPHENE,1957.0,4.0,,True,True,[],"['Algafan' 'D-propoxyphene' 'Depromic' 'Dextropropoxyphen'
 'Dextropropoxyphene' 'J5.928E' 'Levopropoxyphene' 'Propoxyphene'
 'Propoxyphene, d-' 'SK-65']","[('Wikipedia', array(['Dextropropoxyphene', 'Levopropoxyphene'], dtype=object)), ('drugbank', array(['DB00647'], dtype=object)), ('chEBI', array(['51173'], dtype=object))]",['CHEMBL3989716' 'CHEMBL1237104'],"{'rows': array(['EFO_0003843', 'EFO_0003843', 'EFO_0003843'], dtype=object), 'count': 3}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for pain. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL13280,CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21,PPTYJKAXVCCBDU-UHFFFAOYSA-N,Small molecule,False,FLUNITRAZEPAM,,4.0,,True,True,['Rohypnol'],['Flunitrazepam' 'N05CD03' 'RO 5-4200' 'RO-5-4200' 'RO-54200'],"[('Wikipedia', array(['Flunitrazepam'], dtype=object)), ('drugbank', array(['DB01544'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL13817,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12,UMUPQWIGCOZEOY-JOCHJYFZSA-N,Small molecule,False,IBUTAMOREN,,2.0,,False,False,[],"['Ibutamoren' 'L-163,191' 'MK-677']",,['CHEMBL542653' 'CHEMBL2105872'],"{'rows': array(['EFO_0005687'], dtype=object), 'count': 1}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1702,CNCC[C@@H](Oc1ccccc1C)c1ccccc1.Cl,LUCXVPAZUDVVBT-UNTBIKODSA-N,Small molecule,True,ATOMOXETINE HYDROCHLORIDE,2002.0,4.0,CHEMBL641,False,True,['Atomoxetine hydrochloride' 'Strattera'],"['Atomoxetine (as hydrochloride)' 'Atomoxetine hcl'
 'Atomoxetine hydrochloride' 'LY-139603' 'NSC-759104' 'Tomoxetine'
 'Tomoxetine hydrochloride']","[('DailyMed', array(['atomoxetine%20hydrochloride'], dtype=object)), ('PubChem', array(['144203843', '170465067', '49681605'], dtype=object)), ('chEBI', array(['331697'], dtype=object))]",,"{'rows': array(['HP_0010865', 'EFO_0003918', 'EFO_0004701', 'EFO_0003888',
       'MONDO_0004975'], dtype=object), 'count': 5}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for attention deficit hyperactivity disorder and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743044,,,Antibody,False,NAMILUMAB,,2.0,,False,False,[],['Anti-hgm-csf igg1' 'MT-203' 'MT203' 'Namilumab'],,,"{'rows': array(['MONDO_0019338', 'EFO_0003898', 'EFO_0000676', 'EFO_0000685'],
      dtype=object), 'count': 4}",[ENSG00000164400],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1743079,,,Antibody,False,TEPROTUMUMAB,2020.0,4.0,,False,True,['Tepezza'],"['Onilcamotide' 'R-1507' 'RG-1507' 'RG1507' 'RO-4858696' 'RO-4858696-000'
 'RO-4858696000' 'RO4858696' 'RO4858696-000' 'RV-001' 'RV-001 MONOCLONAL'
 'RV001' 'RV001 MONOCLONAL' 'Rhoc peptide vaccine rv001v' 'Tepezza'
 'Teprotumumab' 'Teprotumumab trbw']","[('DailyMed', array(['teprotumumab-trbw'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000616', 'EFO_0000540', 'MONDO_0007254',
       'EFO_1001466', 'EFO_0000404', 'EFO_0000691'], dtype=object), 'count': 7}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for immune system disease and graves ophthalmopathy and has 5 investigational indications.
CHEMBL2103851,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1,FOFDIMHVKGYHRU-UHFFFAOYSA-N,Small molecule,False,AMUVATINIB,,2.0,,False,False,[],['Amuvatinib' 'HPK 56' 'HPK-56' 'HPK56' 'MP 470' 'MP-470' 'MP470'],"[('PubChem', array(['137276002'], dtype=object)), ('drugbank', array(['DB12742'], dtype=object))]","['CHEMBL4071984' 'CHEMBL4061772' 'CHEMBL4092757' 'CHEMBL2105685'
 'CHEMBL4063359' 'CHEMBL4099995' 'CHEMBL4085000']","{'rows': array(['EFO_0000616', 'EFO_0000702'], dtype=object), 'count': 2}","[ENSG00000105976,ENSG00000157404,ENSG00000122025,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2106615,CC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,OMZAMQFQZMUNTP-UHFFFAOYSA-N,Small molecule,False,BAZEDOXIFENE ACETATE,2009.0,4.0,CHEMBL46740,False,True,['Conbriza'],"['Bazedoxifen acetate' 'Bazedoxifene acetate' 'Conbriza' 'Duavive'
 'WAY-140424']","[('DailyMed', array(['bazedoxifene%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza'],
      dtype=object)), ('PubChem', array(['144206564', '170466793'], dtype=object))]",,"{'rows': array(['GO_0042697', 'EFO_0003929', 'EFO_0003882', 'EFO_0003854'],
      dtype=object), 'count': 4}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for postmenopausal osteoporosis and has 3 investigational indications.
CHEMBL2109477,,,Antibody,False,SELICRELUMAB,,2.0,,False,False,[],"['CP 870,893' 'CP-870,893' 'CP-870893' 'RG-7876' 'RG7876' 'RO-7009789'
 'Selicrelumab']",,,"{'rows': array(['EFO_0000616', 'EFO_1001951', 'EFO_0000096', 'EFO_0003860',
       'EFO_0000756', 'MONDO_0007254'], dtype=object), 'count': 6}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL2109534,,,Antibody,False,PF-03732010,,1.0,,False,False,[],"['P-cadherin antagonist pf-03732010' 'PF-03732010' 'PF03732010'
 'Pf-03732010']",,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000062038],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2151570,c1cc2cc(-c3ccc(O[C@H]4CN5CCC4CC5)nn3)ccc2[nH]1,LUKNJAQKVPBDSC-SFHVURJKSA-N,Small molecule,False,ABT-107,,1.0,,False,False,[],['ABT-PR1' 'Abt-107' 'Abt-107 free base'],,,,[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545087,,,Small molecule,False,GSK159802,,1.0,,False,False,[],['Gsk159802'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545395,,,Small molecule,False,BI-811283,,2.0,,False,False,[],['Bi-811283'],,,"{'rows': array(['EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000178999],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL37676,Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2,SEBPXHSZHLFWRL-UHFFFAOYSA-N,Small molecule,False,APC-100,,1.0,,False,False,[],"['2,2,5,7,9-pentamethyl-6-chromanol' 'APC-100' 'Apc-100' 'Chromane c1'
 'NSC-226236']","[('drugbank', array(['DB13111'], dtype=object))]",,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989855,CN[C@@H](C)[C@@H](O)c1ccccc1.CN[C@@H](C)[C@@H](O)c1ccccc1.O=S(=O)(O)O,CAVQBDOACNULDN-NRCOEFLKSA-N,Small molecule,False,PSEUDOEPHEDRINE SULFATE,1963.0,4.0,CHEMBL1590,False,True,['Afrinol'],"['D-pseudoephedrine sulfate' 'Pseudoephedrine sulfate'
 'Pseudoephedrine sulphate' 'SCH 4855' 'SCH-4855']","[('DailyMed', array(['pseudoephedrine%20sulfate'], dtype=object))]",,"{'rows': array(['EFO_0003956', 'EFO_0005854'], dtype=object), 'count': 2}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for seasonal allergic rhinitis and allergic rhinitis.
CHEMBL4297583,Cc1nc2cc(C(=O)N(C)C)cc(O[C@H]3CCOc4cc(F)cc(F)c43)c2[nH]1,CLIQCDHNPDMGSL-HNNXBMFYSA-N,Small molecule,False,TEGOPRAZAN,,3.0,,False,False,[],['Cj-12420' 'LXI-15028' 'Lxi-15028' 'Tegoprazan'],,,"{'rows': array(['HP_0004398', 'EFO_0004607', 'EFO_1001355', 'EFO_1000961',
       'EFO_0003948', 'EFO_0001421'], dtype=object), 'count': 6}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4297804,,,Unknown,False,PF-06263507,,1.0,,False,False,[],['Pf-06263507'],,,,"[ENSG00000146242,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Unknown drug with a maximum clinical trial phase of I.
CHEMBL4297949,,,Protein,False,AVEXITIDE,,3.0,,False,False,[],"['Avexitide' 'Exendin (9-39)' 'Exendin (9-39) amide' 'Exendin 9-39'
 'Exendin(9-39)amide' 'Exendin-3 (9-39) amide']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AVEXITIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0007318', 'MONDO_0017182', 'EFO_0001069', 'HP_0001943',
       'EFO_0001073', 'MONDO_0005148'], dtype=object), 'count': 6}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4298092,,,Antibody,False,GLOFITAMAB,2023.0,4.0,,False,True,['Columvi'],"['Columvi' 'Glofitamab' 'Glofitamab-gxbm' 'RG-6026' 'RG6026' 'RO-7082859'
 'RO7082859' 'Ro7082859']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GLOFITAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000403', 'EFO_1001469', 'EFO_0000096', 'EFO_0000574',
       'EFO_0005952', 'EFO_0000616', 'MONDO_0018906'], dtype=object), 'count': 7}","[ENSG00000156738,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for diffuse large b-cell lymphoma and has 6 investigational indications.
CHEMBL4298138,C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1,FIKPXCOQUIZNHB-WDEREUQCSA-N,Small molecule,False,REPOTRECTINIB,2023.0,4.0,,False,True,['Augtyro'],['Repotrectinib' 'TPX-0005' 'TRX-0005'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/REPOTRECTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}","[ENSG00000047936,ENSG00000124145,ENSG00000140538,ENSG00000148053,ENSG00000019582,ENSG00000198400]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 investigational indications.
CHEMBL4594497,,,Oligonucleotide,False,SEPOFARSEN,,2.0,,False,False,[],['EW9I3PJC3R' 'QR-110' 'QR-110 FREE ACID' 'Qr-110' 'Sepofarsen'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SEPOFARSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0018998', 'EFO_0003966'], dtype=object), 'count': 2}",[ENSG00000198707],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4650495,,,Protein,False,PEGSEBRENATIDE,,2.0,,False,False,[],['NLY-01' 'NLY01' 'Nly-01' 'Nly01' 'Pegsebrenatide'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'MONDO_0005180'], dtype=object), 'count': 2}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL554,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,BCFGMOOMADDAQU-UHFFFAOYSA-N,Small molecule,True,LAPATINIB,2007.0,4.0,,False,True,['Tyverb'],['GSK-572016' 'GW-2016' 'GW-572016' 'GW-572016X' 'GW572016' 'Lapatinib'],"[('PubChem', array(['103905567', '103905568', '144206058', '170465125', '50100107'],
      dtype=object)), ('Wikipedia', array(['Lapatinib'], dtype=object)), ('drugbank', array(['DB01259'], dtype=object)), ('chEBI', array(['49603'], dtype=object))]",['CHEMBL1201179' 'CHEMBL3526325' 'CHEMBL1076241' 'CHEMBL1201183'],"{'rows': array(['EFO_0000228', 'MONDO_0008315', 'EFO_0006859', 'EFO_0005543',
       'MONDO_0044926', 'EFO_0005774', 'EFO_1000478', 'EFO_1001465',
       'MONDO_0004986', 'EFO_0000707', 'MONDO_0004986', 'EFO_1001951',
       'EFO_1000294', 'EFO_1000158', 'EFO_1001512', 'MONDO_0004992',
       'MONDO_0007254', 'EFO_0005922', 'MONDO_0007576', 'EFO_0002618',
       'EFO_0005950', 'EFO_0003869', 'EFO_0000181', 'EFO_0003884',
       'MONDO_0011962', 'MONDO_0001056', 'EFO_1001968', 'EFO_0000365',
       'EFO_0006352', 'EFO_0002892', 'EFO_0002938', 'EFO_0003869',
       'EFO_0000616', 'EFO_1000294', 'EFO_0002618', 'EFO_0000305',
       'MONDO_0002974', 'MONDO_0002087', 'EFO_0000305', 'MONDO_0001187',
       'EFO_0000616', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0008170',
       'EFO_0000574', 'EFO_0006859', 'EFO_0006318', 'EFO_0000756',
       'MONDO_0007254', 'EFO_0006861', 'EFO_0000681', 'MONDO_0001657'],
      dtype=object), 'count': 52}","[ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 47 investigational indications. This drug has a black box warning from the FDA.
CHEMBL572284,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO,IXWNTLSTOZFSCM-YVACAVLKSA-N,Small molecule,False,OMBRABULIN,,3.0,,False,False,[],['AC7700' 'AVE-8062' 'AVE8062' 'Ave8062' 'Ombrabulin'],"[('drugbank', array(['DB12882'], dtype=object))]",['CHEMBL585539'],"{'rows': array(['EFO_0000691', 'EFO_0000616', 'EFO_0003060', 'MONDO_0008170'],
      dtype=object), 'count': 4}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL766,CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O,DHSUYTOATWAVLW-WFVMDLQDSA-N,Small molecule,False,CILASTATIN,1985.0,4.0,,False,True,[],['Cilastatin' 'Primaxin'],"[('PubChem', array(['50125939'], dtype=object)), ('Wikipedia', array(['Cilastatin'], dtype=object)), ('drugbank', array(['DB01597'], dtype=object)), ('chEBI', array(['3697'], dtype=object))]",['CHEMBL1201057'],"{'rows': array(['HP_0100806', 'EFO_0000544', 'EFO_0003103', 'EFO_1001141',
       'EFO_0003106', 'EFO_0000465', 'EFO_0000771', 'HP_0100806',
       'EFO_0003103', 'MONDO_0044881', 'EFO_1001865', 'EFO_0000544',
       'EFO_1001272', 'EFO_0003102'], dtype=object), 'count': 14}",[ENSG00000015413],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 9 investigational indications.
CHEMBL9298,N#Cc1ccc(C2CCCc3cncn32)cc1,CLPFFLWZZBQMAO-UHFFFAOYSA-N,Small molecule,False,FADROZOLE,,-1.0,,False,False,[],['CGS-16949A' 'Fadrozole'],"[('Wikipedia', array(['Fadrozole'], dtype=object))]",['CHEMBL468419'],,[ENSG00000137869],Small molecule drug.
CHEMBL1120,,,Small molecule,False,BISMUTH SUBSALICYLATE,1996.0,4.0,,False,True,['Bismukote' 'Corrective Suspension' 'Gastro-Cote' 'Pepto-Bismol'],['Bismuth salicylate' 'Bismuth subsalicylate' 'NSC-759117'],"[('PubChem', array(['144205951', '225144280', '29218057'], dtype=object)), ('Wikipedia', array(['Bismuth_subsalicylate'], dtype=object)), ('chEBI', array(['261649'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'HP_0002018', 'EFO_1000961', 'HP_0002014'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for nausea and diarrhea and has 2 investigational indications.
CHEMBL1201464,,,Protein,False,CHORIOGONADOTROPIN ALFA,2000.0,4.0,,False,True,['Ovidrel' 'Ovitrelle'],"['ATC CODE G03 GA GONADOTROPINS' 'Choriogonadotropin alfa'
 'Choriogonadotropin alpha' 'Choriongonadotropin alfa'
 'Chorionic gonadotrophin alfa' 'Fe-999302']","[('DailyMed', array(['choriogonadotropin%20alfa'], dtype=object)), ('DrugCentral', array(['5149'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ovitrelle'],
      dtype=object))]",,"{'rows': array(['MONDO_0011972', 'MONDO_0002146', 'EFO_0008560', 'EFO_0004266',
       'EFO_0001073', 'EFO_0000660', 'EFO_0000545', 'MONDO_0002775'],
      dtype=object), 'count': 8}",[ENSG00000138039],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 approved and 2 investigational indications.
CHEMBL1568698,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,PGTVWKLGGCQMBR-FLBATMFCSA-N,Small molecule,False,GANAXOLONE,2022.0,4.0,,False,True,['Ztalmy'],['CCD 1042' 'CCD-1042' 'DEA NO. 2401' 'Ganaxolone' 'Ztalmy'],"[('PubChem', array(['144205817', '170466317', '29217560', '50111707', '90341411'],
      dtype=object)), ('drugbank', array(['DB05087'], dtype=object))]",,"{'rows': array(['HP_0001250', 'EFO_0004263', 'MONDO_0010383', 'EFO_0001358',
       'MONDO_0018097', 'EFO_0000474', 'MONDO_0001734', 'EFO_0008526',
       'EFO_1000877', 'EFO_0004319'], dtype=object), 'count': 10}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 7 investigational indications.
CHEMBL1767164,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1,YANGEESWIGIKOP-UUWRZZSWSA-N,Small molecule,False,GSK-1004723,,2.0,,False,False,[],['GSK1004723' 'Gsk-1004723' 'Gsk1004723'],"[('drugbank', array(['DB12806'], dtype=object))]",['CHEMBL3215857' 'CHEMBL1767170'],"{'rows': array(['EFO_0003956', 'EFO_0005854'], dtype=object), 'count': 2}","[ENSG00000196639,ENSG00000101180]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2103791,CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12,UAMAIHOEGLEXSV-UHFFFAOYSA-N,Small molecule,False,ADIPIPLON,,2.0,,False,False,[],['Adipiplon' 'NG2-73'],"[('drugbank', array(['DB06579'], dtype=object))]",,"{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108681,,,Antibody,False,TILDRAKIZUMAB,2018.0,4.0,,False,True,['Ilumetri' 'Ilumya'],['MK-3222' 'SCH-900222' 'Tildrakizumab' 'Tildrakizumab asmn'],"[('DailyMed', array(['tildrakizumab-asmn'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri'],
      dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_0000540', 'EFO_1001494', 'MONDO_0008315',
       'MONDO_0004992'], dtype=object), 'count': 5}","[ENSG00000113302,ENSG00000110944]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications.
CHEMBL2109480,,,Antibody,False,AHN-12,,1.0,,False,False,[],['AHN-12' 'Ahn-12'],,,"{'rows': array(['EFO_0000339', 'EFO_0000565', 'EFO_0000220', 'EFO_0000222',
       'EFO_0000198'], dtype=object), 'count': 5}",[ENSG00000081237],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.
CHEMBL2109491,,,Antibody,False,COL-1,,-1.0,,False,False,[],['COL-1'],,,,[ENSG00000105388],Antibody drug.
CHEMBL2165326,NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,DKULOVKANLVDEA-UHFFFAOYSA-N,Small molecule,False,APROCITENTAN,,3.0,,False,False,[],['ACT-132577' 'Act-132577' 'Aprocitentan' 'Macitentan metabolite m6'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/APROCITENTAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15059'], dtype=object)), ('chEBI', array(['76609'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0003086', 'EFO_0001421', 'MONDO_0001134'],
      dtype=object), 'count': 4}","[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL243712,CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC,NTJOBXMMWNYJFB-UHFFFAOYSA-N,Small molecule,False,AMISULPRIDE,1986.0,4.0,,False,True,['Barhemsys' 'Solian' 'Solian 100' 'Solian 200' 'Solian 400' 'Solian 50'],"['APD-421' 'APD421' 'Aminosultopride' 'Amisulpride' 'DAN-2163' 'Deniban'
 'NSC-760085' 'Socian' 'Sulamid']","[('DailyMed', array(['amisulpride'], dtype=object)), ('PubChem', array(['124891581', '144206943', '170466480', '26719747', '26719748',
       '26753203'], dtype=object)), ('Wikipedia', array(['Amisulpride'], dtype=object)), ('drugbank', array(['DB06288'], dtype=object)), ('chEBI', array(['64045'], dtype=object))]",,"{'rows': array(['EFO_0004888', 'MONDO_0005351', 'MONDO_0004985', 'EFO_0003884',
       'EFO_0006911', 'EFO_0005230', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0005407', 'HP_0002017',
       'EFO_0004242'], dtype=object), 'count': 13}","[ENSG00000149295,ENSG00000151577,ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 10 investigational indications.
CHEMBL3402762,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1,AHYMHWXQRWRBKT-UHFFFAOYSA-N,Small molecule,False,TEPOTINIB,2020.0,4.0,,False,True,[],"['EMD 1214063' 'EMD-1214063' 'EMD1214063' 'Emd-1214063' 'MSC-2156119'
 'MSC-2156119J' 'MSC2156119' 'Tepotinib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPOTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15133'], dtype=object))]",['CHEMBL4594292'],"{'rows': array(['EFO_0003833', 'EFO_0000616', 'EFO_0000571', 'EFO_0000616',
       'EFO_0001421', 'EFO_0000182', 'EFO_0003060', 'EFO_0004142',
       'EFO_0003060'], dtype=object), 'count': 9}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and non-small cell lung carcinoma and has 7 investigational indications.
CHEMBL3545000,,,Small molecule,False,MK-2201,,1.0,,False,False,[],['Mk-2201'],,,,"[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545346,,,Small molecule,False,AZD2516,,2.0,,False,False,[],['Azd2516'],,,"{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297779,,,Oligonucleotide,False,LUMASIRAN,,4.0,,False,True,[],['AD-65585' 'ALN-65585' 'ALN-G01' 'ALN-GO1' 'Lumasiran'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUMASIRAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0009823', 'EFO_0004253', 'MONDO_0002474'], dtype=object), 'count': 3}",[ENSG00000101323],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.
CHEMBL4297784,,,Antibody,False,FAVEZELIMAB,,3.0,,False,False,[],['Favezelimab' 'MK-4280' 'MK4280' 'Mavezelimab' 'Mk-4280'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FAVEZELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005952', 'MONDO_0001187', 'EFO_1001951', 'EFO_0000616',
       'EFO_0000756', 'EFO_0000183', 'EFO_0005922', 'EFO_0000702',
       'EFO_0008528', 'EFO_0003060', 'EFO_0000681'], dtype=object), 'count': 11}",[ENSG00000089692],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL4297950,,,Protein,False,BENEGRASTIM,2023.0,4.0,,False,True,['Ryzneuta'],"['Benegrastim' 'Efbemalenograstim alfa' 'F-627'
 'Rh g-csf fc fusion protein f-627']",,,"{'rows': array(['MONDO_0007254', 'EFO_0000616', 'MONDO_0001475'], dtype=object), 'count': 3}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for neoplasm and has 2 investigational indications.
CHEMBL4298111,,,Unknown,False,APILIMOD MESYLATE,,2.0,,False,False,[],"['Apilimod bis-mesylate' 'Apilimod dimesylate' 'Apilimod mesilate'
 'Apilimod mesylate' 'STA 5326 MESYLATE' 'STA-5326 MESYLATE'
 'Sta 5326 mesilate' 'Sta 5326 mesylate' 'Sta-5326 mesilate'
 'Sta-5326 mesylate']",,,"{'rows': array(['EFO_0000685', 'EFO_0000384'], dtype=object), 'count': 2}",[ENSG00000115020],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4650292,,,Antibody,False,CDX-3379,,2.0,,False,False,[],['CDX-3379' 'Cdx 3379' 'Cdx-3379' 'Cdx3379' 'KTN-3379' 'MEDI-3379'],,,"{'rows': array(['EFO_0000181', 'EFO_0000756'], dtype=object), 'count': 2}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL49080,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,STJMRWALKKWQGH-UHFFFAOYSA-N,Small molecule,False,CLENBUTEROL,,4.0,,False,True,['Spiropent' 'Spiropent mite'],"['Clenbuterol' 'Clenbuterol hydrochloride' 'Contraspasmin' 'NAB 365'
 'NSC-758633' 'Planipart']","[('PubChem', array(['144205569', '170465955', '26756514', '29216418'], dtype=object)), ('Wikipedia', array(['Clenbuterol'], dtype=object)), ('drugbank', array(['DB01407'], dtype=object)), ('chEBI', array(['174690'], dtype=object))]",['CHEMBL1330729'],"{'rows': array(['Orphanet_365', 'MONDO_0004976', 'MONDO_0005180', 'MONDO_0005148',
       'HP_0006536'], dtype=object), 'count': 5}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 4 investigational indications.
CHEMBL511,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,YECBIJXISLIIDS-UHFFFAOYSA-N,Small molecule,False,PYRILAMINE,1973.0,4.0,,False,True,[],['Mepyramine' 'NSC-13136' 'Pyrilamine'],"[('PubChem', array(['104171213', '11111639', '11111640', '11113355', '144203781',
       '144208176', '170464656', '17389532', '26751558', '50100317',
       '50104164', '90341279'], dtype=object)), ('Wikipedia', array(['Mepyramine'], dtype=object)), ('drugbank', array(['DB06691'], dtype=object)), ('chEBI', array(['6762'], dtype=object))]",['CHEMBL1201006'],"{'rows': array(['HP_0000989', 'MONDO_0005271', 'EFO_0003956'], dtype=object), 'count': 3}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved indications.
CHEMBL926,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,JRWZLRBJNMZMFE-UHFFFAOYSA-N,Small molecule,False,DOBUTAMINE,1978.0,4.0,,False,True,[],"['COMPOUND 81929' 'COMPOUND-81929' 'Dl-dobutamine' 'Dobutamine' 'Dobutrex'
 'Racemic dobutamine']","[('PubChem', array(['104171143', '144203677', '170465050', '26751752', '50104446',
       '90341592'], dtype=object)), ('Wikipedia', array(['Dobutamine'], dtype=object)), ('drugbank', array(['DB00841'], dtype=object)), ('chEBI', array(['4670'], dtype=object))]",['CHEMBL1200418' 'CHEMBL4297079'],"{'rows': array(['EFO_0000373', 'EFO_0000319', 'MONDO_0043510', 'EFO_0004610',
       'EFO_0006834', 'EFO_0000319', 'EFO_0009516', 'EFO_0003144',
       'HP_0031273'], dtype=object), 'count': 9}","[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for congestive heart failure and cardiovascular disease and has 7 investigational indications.
CHEMBL997,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,MPBVHIBUJCELCL-UHFFFAOYSA-N,Small molecule,False,IBANDRONIC ACID,2003.0,4.0,,False,True,['Bondronat' 'Bonviva' 'Iasibon' 'Quodixor'],"['Bondenza' 'Boniva' 'Ibandronate' 'Ibandronic Acid' 'Ibandronic acid'
 'Ibandronic acid accord' 'Ibandronic acid sandoz' 'Ibandronic acid teva'
 'NSC-722623']","[('PubChem', array(['90340689'], dtype=object)), ('Wikipedia', array(['Ibandronic_acid'], dtype=object)), ('drugbank', array(['DB00710'], dtype=object))]",['CHEMBL1201008' 'CHEMBL3989569'],"{'rows': array(['HP_0002027', 'EFO_0003854', 'EFO_0003820', 'EFO_0003854',
       'MONDO_0007254', 'EFO_0003882', 'EFO_0001642', 'EFO_0001378',
       'MONDO_0007254', 'EFO_0009708', 'EFO_0003843', 'EFO_0003843',
       'EFO_0004259', 'EFO_0003882', 'HP_0000938', 'EFO_0004260'],
      dtype=object), 'count': 16}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for postmenopausal osteoporosis and osteoporosis and has 12 investigational indications.
CHEMBL1005,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,ZTVQQQVZCWLTDF-UHFFFAOYSA-N,Small molecule,True,REMIFENTANIL,1996.0,4.0,,False,True,[],"['GI 87084X' 'IDS-NR-005' 'Ramifentanyl' 'Remifentanil' 'Remifentanyl'
 'Ultiva' 'Ultiva-']","[('Wikipedia', array(['Remifentanil'], dtype=object)), ('drugbank', array(['DB00899'], dtype=object)), ('chEBI', array(['8802'], dtype=object))]",['CHEMBL1201120'],"{'rows': array(['EFO_0000616', 'EFO_0004337', 'EFO_0000712', 'EFO_0003918',
       'EFO_0001074', 'MONDO_0021233', 'MONDO_0041052', 'EFO_0003833',
       'EFO_0003877', 'EFO_0005611', 'EFO_0010702', 'EFO_0009483',
       'HP_0002093', 'EFO_0003777', 'EFO_0003843', 'EFO_0009842',
       'EFO_0003917', 'EFO_0006834'], dtype=object), 'count': 18}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 18 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200613,Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+],QGUALMNFRILWRA-UHFFFAOYSA-M,Small molecule,True,TOLMETIN SODIUM,1976.0,4.0,CHEMBL1020,False,True,['Tolectin' 'Tolectin 600' 'Tolectin ds' 'Tolmetin sodium'],"['MCN-2559-21-98' 'NSC-757341' 'Sodium tolmetin' 'Tolmetin sodium'
 'Tolmetin sodium anhydrous' 'Tolmetin sodium dihydrate'
 'Tolmetin sodium salt dihydrate']","[('DailyMed', array(['tolmetin%20sodium'], dtype=object)), ('PubChem', array(['26748279'], dtype=object)), ('chEBI', array(['9619'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'MONDO_0005178'], dtype=object), 'count': 2}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for rheumatoid arthritis and osteoarthritis. This drug has a black box warning from the FDA.
CHEMBL1201010,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,SYWHXTATXSMDSB-GSLJADNHSA-N,Small molecule,False,FLUDROCORTISONE ACETATE,1955.0,4.0,,False,True,['Astonin' 'Florinef' 'Fludrocortisone acetate' 'Fludrocortone' 'Panotile'],"['Fludrocortisone 21-acetate' 'Fludrocortisone acetate'
 'Fludrocortisoni acetas' 'Fluorhydrocortisone acetate'
 'Fluorocortisol acetate' 'NSC-15186' 'Scherofluron']","[('DailyMed', array(['fludrocortisone%20acetate'], dtype=object)), ('chEBI', array(['5102'], dtype=object))]",,"{'rows': array(['MONDO_0002050', 'EFO_1001176', 'MONDO_0015128', 'MONDO_0015898',
       'MONDO_0100096', 'EFO_0000694', 'MONDO_0005180', 'MONDO_0015129',
       'EFO_0006834', 'EFO_0000756', 'MONDO_0011972', 'MONDO_0018479'],
      dtype=object), 'count': 12}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 3 approved and 9 investigational indications.
CHEMBL1282,CC(C)Cn1cnc2c(N)nc3ccccc3c21,DOUYETYNHWVLEO-UHFFFAOYSA-N,Small molecule,True,IMIQUIMOD,1997.0,4.0,,False,True,['Aldara' 'Imiquimod' 'Zyclara'],"['Aldara' 'Imiquimod' 'NSC-369100' 'NSC-759651' 'R-837' 'S-26308' 'S26308'
 'Tmx-101']","[('DailyMed', array(['imiquimod'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aldara'],
      dtype=object)), ('PubChem', array(['144204536', '170464691', '174006731', '26752301', '865810'],
      dtype=object)), ('Wikipedia', array(['Imiquimod'], dtype=object)), ('drugbank', array(['DB00724'], dtype=object)), ('chEBI', array(['36704'], dtype=object))]",,"{'rows': array(['MONDO_0024475', 'EFO_0000565', 'EFO_0000389', 'EFO_0002627',
       'EFO_0001061', 'EFO_0004197', 'EFO_1001968', 'EFO_0002913',
       'MONDO_0008094', 'EFO_0000707', 'EFO_0002499', 'EFO_0003868',
       'MONDO_0100342', 'EFO_1000026', 'EFO_0000220', 'EFO_0000095',
       'EFO_1000249', 'EFO_0007147', 'MONDO_0022394', 'MONDO_0002102',
       'EFO_0004193', 'EFO_0007444', 'EFO_0007328', 'MONDO_0002974',
       'EFO_0005222', 'MONDO_0021054', 'MONDO_0008315', 'EFO_0000756',
       'EFO_0002496', 'EFO_0000673', 'MONDO_0004992', 'MONDO_0008170',
       'EFO_1001361', 'EFO_0002939', 'MONDO_0002158', 'EFO_0001422',
       'MONDO_0005341', 'EFO_1000028', 'EFO_1002048', 'MONDO_0024474',
       'EFO_1001951', 'EFO_0000519', 'MONDO_0001657', 'EFO_1000635',
       'EFO_0001668', 'EFO_0000763', 'EFO_0003835', 'EFO_0005046',
       'EFO_0003060', 'EFO_0004212', 'MONDO_0007254', 'EFO_1000720',
       'EFO_1001051'], dtype=object), 'count': 53}",[ENSG00000196664],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 6 approved and 47 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1465,CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O,DQDAYGNAKTZFIW-UHFFFAOYSA-N,Small molecule,False,PHENPROCOUMON,1957.0,4.0,,False,True,['Liquamar' 'Marcoumar'],"['BS-7565' 'Fencumar' 'Marcumar' 'Phenprocoumarol' 'Phenprocoumarole'
 'Phenprocoumon' 'Phenprocumone' 'RO-1-4849']","[('Wikipedia', array(['Phenprocoumon'], dtype=object)), ('drugbank', array(['DB00946'], dtype=object)), ('chEBI', array(['50438'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'HP_0004419', 'HP_0004936', 'EFO_0003907'],
      dtype=object), 'count': 4}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for recurrent thrombophlebitis and has 3 investigational indications.
CHEMBL2108332,,,Gene,False,BEPERMINOGENE PERPLASMID,,2.0,,False,False,[],['Beperminogene perplasmid'],,,,[ENSG00000105976],Gene drug with a maximum clinical trial phase of II.
CHEMBL2108481,,,Unknown,False,ANCROD,,3.0,,False,False,[],"['Acc-c' 'Ancrod' 'Arvin' 'Arwin' 'Ec 3.4.21.74' 'Protein c activator'
 'Proteinase, agkistrodon serine' 'Venombin-a' 'Viprinex']",,,"{'rows': array(['HP_0004419'], dtype=object), 'count': 1}","[ENSG00000171560,ENSG00000171564,ENSG00000171557]",Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109330,,,Antibody,False,IC14,,2.0,,False,False,[],['Atibuclimab' 'IC-14' 'IC14' 'Ic14'],,,"{'rows': array(['EFO_1000637', 'MONDO_0004976', 'MONDO_0100130', 'MONDO_0100096',
       'EFO_0005547'], dtype=object), 'count': 5}",[ENSG00000170458],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2109361,,,Antibody,False,PEMTUMOMAB,,3.0,,False,False,['Theragyn'],['Pemtumomab' 'RG-1549'],,,,[ENSG00000185499],Antibody drug with a maximum clinical trial phase of III.
CHEMBL2109389,,,Antibody,False,IMGATUZUMAB,,2.0,,False,False,[],"['GA-201' 'GA201' 'HUMA-B' 'HUMAB' 'HuMAB<EGFR>' 'Imgatuzumab' 'RG7160'
 'RO-5083945' 'RO5083945']",,,"{'rows': array(['EFO_1001951', 'EFO_0000616', 'EFO_0003060', 'EFO_0006859'],
      dtype=object), 'count': 4}","[ENSG00000146648,ENSG00000203747]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2109492,,,Antibody,False,MDX-1411,,1.0,,False,False,[],['MDX-1411' 'Mdx-1411'],,,"{'rows': array(['EFO_1001469'], dtype=object), 'count': 1}",[ENSG00000125726],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2178578,CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1,JRWROCIMSDXGOZ-UHFFFAOYSA-N,Small molecule,False,VERCIRNON,,3.0,,False,False,[],['CCX-282-B' 'CCX282' 'GSK-1605786' 'GSK1605786' 'Vercirnon' 'Verecimon'],"[('drugbank', array(['DB15250'], dtype=object))]",['CHEMBL3039505'],"{'rows': array(['EFO_0000729', 'EFO_0001060', 'EFO_0000384', 'EFO_0000384'],
      dtype=object), 'count': 4}",[ENSG00000173585],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2392545,COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2c(n1)N(C1CCCC1)CC(F)(F)C(=O)N2C,GWRSATNRNFYMDI-UHFFFAOYSA-N,Small molecule,False,TAK-960,,1.0,,False,False,[],['TAK-960' 'TAK960' 'Tak-960'],,['CHEMBL5307337'],"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3039539,,,Antibody,False,OTLERTUZUMAB,,2.0,,False,False,[],['Otlertuzumab' 'TRU-016'],,,"{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}",[ENSG00000104894],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3219124,COC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1,FJEJHJINOKKDCW-INIZCTEOSA-N,Small molecule,False,AZD-1656,,2.0,,False,False,[],['AZD1656' 'Azd 1656' 'Azd-1656' 'Azd1656'],"[('drugbank', array(['DB14810'], dtype=object))]",,"{'rows': array(['MONDO_0005147', 'MONDO_0005148', 'MONDO_0100096'], dtype=object), 'count': 3}",[ENSG00000106633],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545169,CC(C)(C)OC(=O)NCCN1CC2CN(CCOc3ccc(C#N)cc3F)CC(C1)O2,BLLNYXOLLAVTRF-UHFFFAOYSA-N,Small molecule,False,AZD1305,,2.0,,False,False,[],['Azd 1305' 'Azd-1305' 'Azd1305'],,,"{'rows': array(['EFO_0003911', 'EFO_0000275'], dtype=object), 'count': 2}","[ENSG00000055118,ENSG00000183873,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545300,,,Small molecule,False,CP-459632,,1.0,,False,False,[],['Cp-459632'],,,,"[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000066056,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545378,Cc1cc(Nc2cc(N3CC(F)(C4CC4)C3)nc(O[C@H]3CCN(C(=O)c4cc(Cl)ccc4F)C3)n2)n[nH]1,SLUHYAXFRJQTGB-KRWDZBQOSA-N,Small molecule,False,MK-6592,,1.0,,False,False,[],['Mk-6592' 'VX-667'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000178999,ENSG00000105146,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL355200,C#Cc1c[nH]c(=O)[nH]c1=O,JOZGNYDSEBIJDH-UHFFFAOYSA-N,Small molecule,False,ENILURACIL,,3.0,,False,False,[],['776-C-85' '776C85' 'Eniluracil'],"[('drugbank', array(['DB03516'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_1001951', 'EFO_0000365', 'EFO_0006859',
       'EFO_1000657', 'MONDO_0007254', 'MONDO_0021063', 'MONDO_0004992'],
      dtype=object), 'count': 8}",[ENSG00000188641],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL3644587,O=c1[nH]nc2c3c(cccc13)N=C(CN1Cc3ccccc3C1)N2,JLFSBHQQXIAQEC-UHFFFAOYSA-N,Small molecule,False,2X-121,,2.0,,False,False,[],['2X-121' '2x-121' 'E-7449' 'E7449' 'Parp inhibitor 2x-121' 'Stenoparib'],,,"{'rows': array(['MONDO_0008170', 'EFO_0000305', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000107854,ENSG00000173273,ENSG00000143799,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3655081,CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1,IUEWXNHSKRWHDY-PHIMTYICSA-N,Small molecule,True,ABROCITINIB,2021.0,4.0,,False,True,['Cibinqo'],['Abrocitinib' 'Cibinqo' 'PF-04965842' 'Pf-04965842'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo'],
      dtype=object)), ('drugbank', array(['DB14973'], dtype=object))]",,"{'rows': array(['MONDO_0019338', 'EFO_1001890', 'MONDO_0005147', 'EFO_1000704',
       'HP_0000964', 'EFO_0000676', 'EFO_0000274', 'EFO_0001421',
       'EFO_0003086'], dtype=object), 'count': 9}",[ENSG00000162434],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for eczematoid dermatitis and atopic eczema and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3707225,,,Small molecule,False,GSK2798745,,2.0,,False,False,[],['Gsk-2798745' 'Gsk2798745'],,,"{'rows': array(['HP_0012735', 'MONDO_0003005', 'EFO_0000373', 'EFO_0003144',
       'EFO_1001134'], dtype=object), 'count': 5}",[ENSG00000111199],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3989698,N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1.O=S(=O)(O)O,BKPRVQDIOGQWTG-ICOOEGOYSA-N,Small molecule,True,TRANYLCYPROMINE SULFATE,1961.0,4.0,CHEMBL3989843,False,True,['Parnate' 'Parstelin' 'Tranylcypromine sulfate'],['NSC-757342' 'Tranylcypromine sulfate' 'Tranylcypromine sulphate'],"[('DailyMed', array(['tranylcypromine%20sulfate'], dtype=object))]",,"{'rows': array(['EFO_1002014', 'MONDO_0002009'], dtype=object), 'count': 2}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for melancholia and major depressive disorder. This drug has a black box warning from the FDA.
CHEMBL3989947,CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N(C)CC(=O)OCC)o1,FYJLDICZGDFWKP-UHFFFAOYSA-N,Small molecule,False,OLUMACOSTAT GLASARETIL,,3.0,,False,False,[],['DRM-01B' 'DRM01B' 'DRMO1B' 'Olumacostat glasaretil'],"[('drugbank', array(['DB12642'], dtype=object))]",,"{'rows': array(['EFO_0003894'], dtype=object), 'count': 1}","[ENSG00000278540,ENSG00000076555]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3990042,,,Antibody,False,GOSURANEMAB,,2.0,,False,False,[],['BIIB092' 'BMS-986168' 'BMS-986168-01' 'Biib-092' 'Gosuranemab' 'IPN-007'],,,"{'rows': array(['MONDO_0004975', 'Orphanet_240071', 'MONDO_0019037'], dtype=object), 'count': 3}",[ENSG00000186868],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4296719,O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,DVJAMEIQRSHVKC-BDAKNGLRSA-N,Small molecule,False,DUTOGLIPTIN,,3.0,,False,False,[],['Dutogliptin' 'PHX1149' 'Phx1149'],"[('drugbank', array(['DB11723'], dtype=object))]",['CHEMBL4297203'],"{'rows': array(['MONDO_0005148', 'MONDO_0005148', 'EFO_0008585'], dtype=object), 'count': 3}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4297711,,,Protein,False,BULEVIRTIDE,,4.0,,False,True,['Hepcludextm' 'Myrcludex'],['915207G' 'Bulevirtide' 'Hepcludex'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BULEVIRTIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000763', 'EFO_0008496', 'EFO_0007304', 'HP_0001392',
       'EFO_0004197'], dtype=object), 'count': 5}",[ENSG00000100652],Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for viral disease and has 4 investigational indications.
CHEMBL4442620,C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,UELYDGOOJPRWGF-MFOHZAOFSA-N,Small molecule,False,RONICICLIB,,2.0,,False,False,[],['BAY10-00394' 'BAY1000394' 'Bay 1000394' 'Bay-1000394' 'Roniciclib'],,,"{'rows': array(['EFO_0003060', 'EFO_0000616', 'EFO_0000702'], dtype=object), 'count': 3}","[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4456085,COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F,WNEILUNVMHVMPH-UHFFFAOYSA-N,Small molecule,False,BAY-1217389,,1.0,,False,False,[],['BAY-1217389' 'Bay-1217389'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000112742],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4518483,N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1,HYBAKUMPISVZQP-DEOSSOPVSA-N,Small molecule,False,DANUGLIPRON,,2.0,,False,False,[],['Danuglipron' 'PF-06882961' 'Pf-06882961'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANUGLIPRON/relevant/1/'],
      dtype=object))]",['CHEMBL4650218'],"{'rows': array(['MONDO_0005148', 'EFO_0003095', 'EFO_0003095', 'EFO_0001421',
       'EFO_0001073', 'MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 7}",[ENSG00000112164],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4650482,,,Antibody,False,PIMIVALIMAB,,2.0,,False,False,[],['JTX-4014' 'Jtx 4014' 'Jtx-4014' 'Pimivalimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PIMIVALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 3}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4802165,,,Antibody,False,BEMARITUZUMAB,,3.0,,False,False,[],['Bemarituzumab' 'FPA-144' 'FPA144' 'Fpa144'],,,"{'rows': array(['MONDO_0001056', 'EFO_0000616', 'EFO_0003060', 'EFO_0000228',
       'MONDO_0007576'], dtype=object), 'count': 5}",[ENSG00000066468],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL521606,CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2,VWPOSFSPZNDTMJ-UHFFFAOYSA-N,Small molecule,True,NADOLOL,1979.0,4.0,,False,True,['Corgard' 'Nadolol' 'Solgol'],['NSC-758430' 'Nadolol' 'SQ 11725' 'SQ-11725'],"[('DailyMed', array(['nadolol'], dtype=object)), ('PubChem', array(['56463045'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_1000635', 'EFO_0000612', 'EFO_0003913',
       'EFO_0000319', 'EFO_0004319', 'EFO_0000537', 'EFO_0000712'],
      dtype=object), 'count': 8}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL714,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,NDAUXUAQIAJITI-UHFFFAOYSA-N,Small molecule,True,ALBUTEROL,1981.0,4.0,,False,True,"['Aerolin' 'Aerolin 400' 'Aerolin auto' 'Airomir' 'Airsalb' 'Albuterol'
 'Asmasal clickhaler' 'Asmasal spacehaler' 'Asmaven' 'Asmavent'
 'Cobutolin' 'Combivent' 'Combivent udvs' 'Ipramol steri-neb' 'Kentamol'
 'Libetist' 'Maxivent' 'Proair Hfa' 'Proventil' 'Proventil Hfa' 'Rimasal'
 'Salamol e-breathe' 'Salapin' 'Salbulin novolizer' 'Salbuvent'
 'Salipraneb' 'Steri-neb salamol' 'Ventmax sr' 'Ventodisks' 'Ventolin'
 'Ventolin Hfa' 'Ventolin cr' 'Ventolin e-breathe' 'Volmax']","['Accuneb' 'Albuterol' 'Combivent' 'Duoneb' 'Etinoline' 'NSC-757417'
 'PROVENTIL-HFA' 'SCH 13949W' 'SCH-13949W' 'Salbutamol' 'Salbutamolum'
 'Ventoline' 'Volmax']","[('DailyMed', array(['albuterol'], dtype=object)), ('PubChem', array(['104171238', '144203817', '170465034', '50104505', '90340718',
       '90341530'], dtype=object)), ('Wikipedia', array(['Salbutamol'], dtype=object)), ('drugbank', array(['DB01001'], dtype=object)), ('chEBI', array(['2549'], dtype=object))]",['CHEMBL1437301' 'CHEMBL1201026' 'CHEMBL1441059'],"{'rows': array(['EFO_1001919', 'EFO_0010581', 'EFO_0003818', 'MONDO_0005149',
       'MONDO_0004979', 'EFO_0001072', 'EFO_0008590', 'MONDO_0004979',
       'HP_0006536', 'MONDO_0002009', 'EFO_0003818', 'Orphanet_1764',
       'Orphanet_590', 'EFO_0000319', 'MONDO_0100130', 'EFO_0001361',
       'MONDO_0017147', 'HP_0011950', 'MONDO_0016575', 'EFO_0009686',
       'MONDO_0011705', 'EFO_0000373', 'HP_0012735', 'EFO_0008590',
       'MONDO_0004976', 'MONDO_0005271', 'Orphanet_365', 'EFO_0000400',
       'EFO_1001134', 'EFO_0009840', 'EFO_0003956', 'EFO_0000341',
       'EFO_0000768', 'EFO_0000341', 'HP_0002027'], dtype=object), 'count': 35}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 30 investigational indications. This drug has a black box warning from the FDA.
CHEMBL72,CNCCCN1c2ccccc2CCc2ccccc21,HCYAFALTSJYZDH-UHFFFAOYSA-N,Small molecule,True,DESIPRAMINE,1964.0,4.0,,False,True,[],"['Desipramine' 'Imipramine, demethyl-' 'Monodemethylimipramine'
 'N-desmethylimipramine' 'Norimipramine']","[('PubChem', array(['11111066', '11111067', '174316136', '50100220', '50104283',
       '90341801'], dtype=object)), ('Wikipedia', array(['Desipramine'], dtype=object)), ('drugbank', array(['DB01151'], dtype=object)), ('chEBI', array(['47781'], dtype=object))]",['CHEMBL227644' 'CHEMBL1696'],"{'rows': array(['MONDO_0002009', 'MONDO_0002009', 'EFO_0004234', 'EFO_0003918',
       'EFO_0002610', 'EFO_0001358', 'MONDO_0002050', 'MONDO_0007079',
       'HP_0011868', 'EFO_0000702', 'MONDO_0004992', 'MONDO_0010726',
       'MONDO_0002009', 'EFO_0003948', 'HP_0003418', 'MONDO_0002050'],
      dtype=object), 'count': 16}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and depressive disorder and has 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1004,CN(C)CCOC(C)(c1ccccc1)c1ccccn1,HCFDWZZGGLSKEP-UHFFFAOYSA-N,Small molecule,False,DOXYLAMINE,1948.0,4.0,,False,True,[],['Decapryn' 'Doxy-Sleep-Aid' 'Doxylamine' 'Unisom'],"[('PubChem', array(['90340822'], dtype=object)), ('Wikipedia', array(['Doxylamine'], dtype=object)), ('drugbank', array(['DB00366'], dtype=object)), ('chEBI', array(['51380'], dtype=object))]",['CHEMBL1200392'],"{'rows': array(['MONDO_0005271', 'EFO_0005854', 'HP_0002017', 'EFO_0000544'],
      dtype=object), 'count': 4}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for allergic disease and has 3 investigational indications.
CHEMBL1118,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,KYYIDSXMWOZKMP-UHFFFAOYSA-N,Small molecule,True,DESVENLAFAXINE,2008.0,4.0,,False,True,['Desvenlafaxine' 'Khedezla' 'Pristiq'],"['D-veniz' 'Desvenlafaxine' 'Mdd-xr' 'Newven' 'O-desmethylvenlafaxine'
 'ODV']","[('DailyMed', array(['desvenlafaxine'], dtype=object)), ('Wikipedia', array(['Desvenlafaxine'], dtype=object)), ('drugbank', array(['DB06700'], dtype=object)), ('chEBI', array(['83527'], dtype=object))]",['CHEMBL3989861' 'CHEMBL1201728'],"{'rows': array(['MONDO_0002009', 'EFO_0005687', 'MONDO_0002009', 'HP_0031217',
       'EFO_0004220', 'MONDO_0002009', 'MONDO_0002009', 'GO_0042697',
       'MONDO_0002050', 'EFO_1000783', 'EFO_0005687', 'MONDO_0002050',
       'MONDO_0002009'], dtype=object), 'count': 13}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for major depressive disorder and depressive disorder and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL12,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,AAOVKJBEBIDNHE-UHFFFAOYSA-N,Small molecule,True,DIAZEPAM,1963.0,4.0,,False,True,"['Alupram 10' 'Alupram 2' 'Alupram 5' 'Apozepam' 'Atensine' 'Dialar'
 'Dialar fte' 'Diastat' 'Diastat acudial' 'Diazepam' 'Diazepam intensol'
 'Dizac' 'E-Pam' 'Paxel' 'Q-pam' 'Relanium' 'Scriptopam' 'Serenack'
 'Solis' 'Stesolid' 'Tensium' 'Tranimul' 'Valclair' 'Valium' 'Valrelease'
 'Valtoco' 'Vivol']","['Ansiolisina' 'Centrazepam' 'Diacepin' 'Diazepam' 'Diazepam civ' 'LA III'
 'LA-III' 'NRL-1' 'NSC-169897' 'NSC-77518' 'Nrl-1' 'RO 5-2807' 'RO-5-2807'
 'RO-52807' 'Servizepam' 'Tranquase' 'WY-3467']","[('DailyMed', array(['diazepam'], dtype=object)), ('PubChem', array(['124893574', '144206622', '144209656', '170464626'], dtype=object)), ('TG-GATEs', array(['23'], dtype=object)), ('Wikipedia', array(['Diazepam'], dtype=object)), ('drugbank', array(['DB00829'], dtype=object)), ('chEBI', array(['49575'], dtype=object))]",['CHEMBL543191'],"{'rows': array(['HP_0001250', 'HP_0003419', 'EFO_0005230', 'EFO_0000474',
       'EFO_0008526', 'MONDO_0002050', 'EFO_0003843', 'MONDO_0005090',
       'EFO_0006788', 'EFO_0000546', 'EFO_1001250', 'EFO_1000632',
       'HP_0000713', 'HP_0000726', 'EFO_0007498', 'EFO_1001010',
       'EFO_1000877'], dtype=object), 'count': 17}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200707,CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O.Cl,KZLNXGBVFTWMPS-UHFFFAOYSA-N,Small molecule,False,BENZQUINAMIDE HYDROCHLORIDE,1974.0,4.0,CHEMBL1201250,False,True,['Emete-con'],['Benzquinamide hcl'],,,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974.
CHEMBL1200790,CCC1(CC)C(=O)NCC(C)C1=O,SIDLZWOQUZRBRU-UHFFFAOYSA-N,Small molecule,False,METHYPRYLON,1982.0,4.0,,False,True,['Noludar'],['Methyprylon' 'NSC-30442'],"[('Wikipedia', array(['Methyprylon'], dtype=object)), ('drugbank', array(['DB01107'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200908,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,BDSYKGHYMJNPAB-LICBFIPMSA-N,Small molecule,False,HALOBETASOL PROPIONATE,1990.0,4.0,,False,True,['Bryhali' 'Halobetasol propionate' 'Lexette' 'Ultravate'],"['21-chloro diflorasone' 'BMY-30056' 'CGP-14,458' 'CGP-14458'
 'Halobetasol' 'Halobetasol propionate' 'IDP-122' 'Jemdel' 'Ulobetasol'
 'Ulobetasol propionate']","[('DailyMed', array(['halobetasol%20propionate'], dtype=object)), ('PubChem', array(['144206008'], dtype=object))]",,"{'rows': array(['EFO_0000701', 'EFO_0000274', 'EFO_1001494', 'EFO_0000676'],
      dtype=object), 'count': 4}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved and 1 investigational indication.
CHEMBL1201237,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,Small molecule,False,LEVOBUNOLOL,1985.0,4.0,,False,True,[],"['Bunolol, (-)-' 'Bunolol, (s)-' 'Levobunolol']","[('PubChem', array(['11112712', '11112713'], dtype=object)), ('Wikipedia', array(['Levobunolol'], dtype=object)), ('drugbank', array(['DB01210'], dtype=object)), ('chEBI', array(['6438'], dtype=object))]",['CHEMBL1201177'],"{'rows': array(['MONDO_0005041', 'MONDO_0005041'], dtype=object), 'count': 2}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for glaucoma.
CHEMBL1315867,CC(C)(C)NCC(O)c1cc(O)cc(O)c1.CC(C)(C)NCC(O)c1cc(O)cc(O)c1.O=S(=O)(O)O,KFVSLSTULZVNPG-UHFFFAOYSA-N,Small molecule,True,TERBUTALINE SULFATE,1974.0,4.0,CHEMBL1760,False,True,"['Brethaire' 'Brethine' 'Bricanyl' 'Bricanyl sa' 'Monovent' 'Monovent sa'
 'Terbasmin' 'Terbutaline sulfate']","['KWD 2019' 'KWD-2019' 'NSC-757336' 'Terbutaline sulfate'
 'Terbutaline sulphate']","[('DailyMed', array(['terbutaline%20sulfate'], dtype=object)), ('PubChem', array(['144204153', '170464990', '50107039'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0009661'], dtype=object), 'count': 3}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for asthma and bronchitis and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL175,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,HEFNNWSXXWATRW-JTQLQIEISA-N,Small molecule,False,DEXIBUPROFEN,1994.0,4.0,,False,True,['Seractil'],"['(s)-ibuprofen' 'Dexibuprofen' 'IBU-TAB' 'NSC-759814' 'Neoprofen' 'Rufen'
 'S-ibuprofen']","[('PubChem', array(['11111293', '11111294', '11112775', '144206692', '47193724',
       '50100253', '50106464', '85231335', '90340840'], dtype=object)), ('Wikipedia', array(['Dexibuprofen'], dtype=object)), ('drugbank', array(['DB09213'], dtype=object)), ('chEBI', array(['43415'], dtype=object))]",['CHEMBL1778537'],"{'rows': array(['EFO_0005755', 'HP_0001945', 'EFO_0003843'], dtype=object), 'count': 3}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for rheumatic disease and has 2 investigational indications.
CHEMBL1779710,CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,LCDDAGSJHKEABN-MLGOLLRUSA-N,Small molecule,False,EVOGLIPTIN,2015.0,4.0,,False,True,[],['DA-1229' 'DA1229' 'Da-1229' 'Evogliptin'],"[('drugbank', array(['DB12625'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'MONDO_0005148', 'HP_0001410', 'EFO_0003086',
       'EFO_0009531'], dtype=object), 'count': 5}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 investigational indications.
CHEMBL1800955,COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,RFUBTTPMWSKEIW-UHFFFAOYSA-N,Small molecule,False,OMECAMTIV MECARBIL,,3.0,,False,False,[],['CK-1827452' 'Omecamtiv mecarbil'],"[('PubChem', array(['174007336'], dtype=object)), ('drugbank', array(['DB11816'], dtype=object))]",,"{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}","[ENSG00000092054,ENSG00000197616,ENSG00000078814,ENSG00000160808,ENSG00000111245,ENSG00000106631,ENSG00000198336]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2107354,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+],SARBMGXGWXCXFW-GJHVZSAVSA-M,Small molecule,False,MIFAMURTIDE,2009.0,4.0,CHEMBL2111100,False,True,['Mepact'],"['L-MTP-PE' 'Mifamurtide' 'Mifamurtide sodium hydrate'
 'Mifamurtide sodium salt monohydrate' 'Sodium mifamurtide']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mepact'],
      dtype=object))]",,"{'rows': array(['MONDO_0002629', 'EFO_0000637', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000167207],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications.
CHEMBL2109365,,,Antibody,False,HUPAM4,,1.0,,False,False,[],['HUPAM4'],,,,[ENSG00000185499],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109593,,,Antibody,False,FGI-101-1A6,,1.0,,False,False,[],['FGI-101-1A6' 'Fgi-101-1a6'],,,"{'rows': array(['EFO_0007328'], dtype=object), 'count': 1}",[ENSG00000074319],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL276711,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,WUWDLXZGHZSWQZ-WQLSENKSSA-N,Small molecule,False,SEMAXANIB,,3.0,,False,False,[],"['NSC-696819' 'SU-5416' 'SU005416' 'SU5416' 'Semaxanib' 'Semaxinib'
 'Su-5416']","[('PubChem', array(['124891688', '49674962', '50107014', '50107016', '525180',
       '56322916', '90341564'], dtype=object)), ('Wikipedia', array(['Semaxanib'], dtype=object)), ('drugbank', array(['DB06436'], dtype=object))]",,"{'rows': array(['EFO_1000158', 'EFO_1000657', 'EFO_1001951', 'MONDO_0002974',
       'EFO_0001378', 'EFO_0000588', 'EFO_0000616', 'EFO_0006859',
       'MONDO_0007254', 'MONDO_0021063', 'EFO_0000389', 'EFO_0000681',
       'MONDO_0002367', 'EFO_0000756', 'EFO_0000365', 'EFO_0000691',
       'MONDO_0008315'], dtype=object), 'count': 17}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157404]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.
CHEMBL3716365,O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2,IRBAWVGZNJIROV-SFHVURJKSA-N,Small molecule,False,GLPG-1205,,2.0,,False,False,[],['Glpg-1205' 'Glpg1205'],"[('drugbank', array(['DB15346'], dtype=object))]",,"{'rows': array(['EFO_0000729', 'EFO_0000768'], dtype=object), 'count': 2}",[ENSG00000139572],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3833393,,,Antibody,True,EMICIZUMAB,2017.0,4.0,,False,True,['Hemlibra'],['ACE-910' 'ACE910' 'Emicizumab' 'Emicizumab kxwh' 'Emicizumab-kxwh'],"[('DailyMed', array(['emicizumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra'],
      dtype=object))]",,"{'rows': array(['MP_0001914', 'MONDO_0010602'], dtype=object), 'count': 2}","[ENSG00000101981,ENSG00000126218]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for hemorrhage and hemophilia a. This drug has a black box warning from the FDA.
CHEMBL4091801,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2,YJCZPJQGFSSFOL-MNZPCBJKSA-N,Small molecule,False,APG115,,2.0,,False,False,[],['Apg115'],,,"{'rows': array(['EFO_0000569', 'EFO_1001779', 'MONDO_0004669', 'EFO_0004289',
       'EFO_0000574', 'EFO_0000621', 'EFO_0000222', 'EFO_0000198'],
      dtype=object), 'count': 8}","[ENSG00000141510,ENSG00000135679]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL4297538,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](CN2CCc3ncc(C(F)(F)F)cc3C2)(C(C)C)C1,UNVWTBOGMHPKJM-CWKRKGSWSA-N,Small molecule,False,MK-0812,,2.0,,False,False,[],['Mk-0812' 'Mk0812'],"[('drugbank', array(['DB11990'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000121807],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594402,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,LEQOVFCHMOTJKU-WJVXOHEGSA-N,Small molecule,False,ORP-101,,2.0,,False,False,[],['Buprenorphine dimer' 'Orp-101'],,,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594579,,,Antibody,False,FELZARTAMAB,,3.0,,False,False,[],"['Felzartamab' 'MOR-03087' 'MOR-202' 'MOR03087' 'Mor03087' 'Mor202'
 'TJ-202' 'TJ202']",,,"{'rows': array(['EFO_0001378', 'MONDO_0002462', 'MONDO_0007915', 'EFO_0004194',
       'EFO_0003086', 'EFO_0004254'], dtype=object), 'count': 6}",[ENSG00000004468],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL5314397,Cc1ccc(C(=O)NC2CC2)cc1-n1ncc(C(=O)c2cccc(C#N)c2)c1N,VGUSQKZDZHAAEE-UHFFFAOYSA-N,Small molecule,False,ACUMAPIMOD,,2.0,,False,False,[],['Acumapimod' 'Bct-197'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL566757,O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1,KPBNHDGDUADAGP-VAWYXSNFSA-N,Small molecule,False,DAPORINAD,,2.0,,False,False,[],"['APO 866' 'APO-866' 'APO866' 'Daporinad' 'FK 866' 'FK-866' 'FK866'
 'K 22.175']","[('drugbank', array(['DB12731'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'EFO_0000095', 'EFO_0002913'], dtype=object), 'count': 3}",[ENSG00000105835],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL589,CCCN(CCC)CCc1cccc2c1CC(=O)N2,UHSKFQJFRQCDBE-UHFFFAOYSA-N,Small molecule,True,ROPINIROLE,1997.0,4.0,,False,True,['Requip'],['NSC-758917' 'Requip' 'Ropinirole' 'SK&F 101468'],"[('PubChem', array(['104171231', '11111741', '144203807', '170465139', '26750081',
       '90341563'], dtype=object)), ('Wikipedia', array(['Ropinirole'], dtype=object)), ('drugbank', array(['DB00268'], dtype=object)), ('chEBI', array(['8888'], dtype=object))]",['CHEMBL1200411'],"{'rows': array(['EFO_0007319', 'MONDO_0005180', 'EFO_0005687', 'EFO_0002610',
       'MONDO_0009698', 'EFO_0000712', 'MONDO_0005180', 'EFO_0004270',
       'EFO_0004270'], dtype=object), 'count': 9}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for parkinson disease and restless legs syndrome and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL607,CCOC(=O)C1(c2ccccc2)CCN(C)CC1,XADCESSVHJOZHK-UHFFFAOYSA-N,Small molecule,True,MEPERIDINE,1942.0,4.0,,False,True,[],"['IDS-NP-001' 'Isonipecaine' 'Meperidine' 'Meperidol' 'Pethanol'
 'Pethidine' 'Pethidine dbl' 'Pethidineter' 'Renaudin']","[('Wikipedia', array(['Pethidine'], dtype=object)), ('drugbank', array(['DB00454'], dtype=object)), ('chEBI', array(['6754'], dtype=object))]",['CHEMBL429713' 'CHEMBL1701'],"{'rows': array(['EFO_0004273', 'HP_0011868', 'EFO_0003843', 'EFO_0003843',
       'EFO_0003890', 'EFO_0005251', 'HP_0002140'], dtype=object), 'count': 7}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and is indicated for pain and drug dependence and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL887,C#CCN[C@@H]1CCc2ccccc21,RUOKEQAAGRXIBM-GFCCVEGCSA-N,Small molecule,False,RASAGILINE,2006.0,4.0,,False,True,[],['AGN-1135' 'Azilect' 'NSC-759639' 'Rasagiline' 'TV-1030'],"[('Wikipedia', array(['Rasagiline'], dtype=object)), ('drugbank', array(['DB01367'], dtype=object)), ('chEBI', array(['63620'], dtype=object))]",['CHEMBL5315052' 'CHEMBL1201142'],"{'rows': array(['MONDO_0019037', 'EFO_1001050', 'MONDO_0005180', 'EFO_0004270',
       'MONDO_0005180', 'MONDO_0005180', 'MONDO_0004976', 'MONDO_0004975'],
      dtype=object), 'count': 8}",[ENSG00000069535],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for parkinson disease and has 5 investigational indications.
CHEMBL101253,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,YCOYDOIWSSHVCK-UHFFFAOYSA-N,Small molecule,False,VATALANIB,,3.0,,False,False,[],"['BAY-86-5127' 'CGP-79787' 'K-222584' 'NVP-PTK787' 'PTK-787' 'PTK787'
 'Ptk-787' 'Vatalanib' 'Vatalanib succinate' 'ZK-222584' 'ZK222584']","[('PubChem', array(['103905548', '104171421', '144206361', '170466113', '50100112'],
      dtype=object)), ('Wikipedia', array(['Vatalanib'], dtype=object)), ('drugbank', array(['DB04879'], dtype=object)), ('chEBI', array(['90620'], dtype=object))]",['CHEMBL75232' 'CHEMBL2142861'],"{'rows': array(['MONDO_0008667', 'EFO_0002618', 'MONDO_0002087', 'EFO_1000158',
       'EFO_0001378', 'EFO_0000588', 'EFO_1000657', 'MONDO_0002367',
       'MONDO_0011962', 'EFO_0002430', 'EFO_0004288', 'EFO_0000691',
       'EFO_0000519', 'EFO_0000339', 'EFO_0000222', 'MONDO_0002974',
       'EFO_0000403', 'EFO_0000389', 'EFO_0000756', 'MONDO_0007254',
       'MONDO_0008170', 'EFO_0009708', 'EFO_0003869', 'EFO_0000616',
       'MONDO_0008315', 'EFO_0003060', 'MONDO_0002158', 'EFO_0001365',
       'EFO_1001901', 'MONDO_0004992'], dtype=object), 'count': 30}","[ENSG00000157404,ENSG00000113721,ENSG00000134853,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications.
CHEMBL1101,OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2,YSXKPIUOCJLQIE-UHFFFAOYSA-N,Small molecule,False,BIPERIDEN,1959.0,4.0,,False,True,[],['Akineton' 'Akineton-' 'Biperiden' 'Biperidenum' 'KL 373' 'NSC-759145'],"[('PubChem', array(['124894170', '174006780', '90341640'], dtype=object)), ('Wikipedia', array(['Biperiden'], dtype=object)), ('drugbank', array(['DB00810'], dtype=object)), ('chEBI', array(['3112'], dtype=object))]",['CHEMBL1201035' 'CHEMBL1201067'],"{'rows': array(['MONDO_0005180', 'EFO_0005230', 'EFO_0002610', 'HP_0000726',
       'MONDO_0043510', 'MONDO_0002050', 'MONDO_0005090'], dtype=object), 'count': 7}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for parkinson disease and has 6 investigational indications.
CHEMBL113051,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2/C=N/OC(C)(C)C,UIVFUQKYVFCEKJ-OPTOVBNMSA-N,Small molecule,False,GIMATECAN,,2.0,,False,False,[],['Gimatecan'],"[('PubChem', array(['170465615'], dtype=object)), ('drugbank', array(['DB06721'], dtype=object))]",,"{'rows': array(['EFO_0000702', 'EFO_1000158', 'EFO_0000198', 'EFO_0002618',
       'EFO_0000616'], dtype=object), 'count': 5}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1181829,CN(c1ccc(Cl)cc1)c1cc[n+](Cc2ccc(-c3ccc(C[n+]4ccc(N(C)c5ccc(Cl)cc5)c5ccccc54)cc3)cc2)c2ccccc12,QGYGTMZEJNOHNU-UHFFFAOYSA-N,Small molecule,False,RSM-932A CATION,,1.0,,False,False,[],[],,['CHEMBL192986'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000110721],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1200475,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O,VNTHYLVDGVBPOU-QQYBVWGSSA-N,Small molecule,True,DAUNORUBICIN CITRATE,1996.0,4.0,CHEMBL178,False,True,['Daunoxome'],"['Daunorubicin citrate' 'Daunorubicin citrate liposome'
 'Daunorubicin liposomal']",,,"{'rows': array(['MONDO_0007254', 'EFO_0000691', 'EFO_0000565'], dtype=object), 'count': 3}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200560,CC(=O)O.N=C(N)N/N=C/c1c(Cl)cccc1Cl,MCSPBPXATWBACD-GAYQJXMFSA-N,Small molecule,False,GUANABENZ ACETATE,1982.0,4.0,CHEMBL420,False,True,['Guanabenz acetate' 'Wytensin'],"['Guanabenz acetate' 'Guanabenz monoacetate' 'NSC-757044' 'WY-8678'
 'WY-8678 ACETATE']","[('PubChem', array(['50106405'], dtype=object))]",,,"[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1237,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,RLAWWYSOJDYHDC-BZSNNMDCSA-N,Small molecule,True,LISINOPRIL ANHYDROUS,1987.0,4.0,,False,True,[],['Lisinopril anhydrous'],"[('PubChem', array(['50085996'], dtype=object)), ('Wikipedia', array(['Lisinopril'], dtype=object)), ('drugbank', array(['DB00722'], dtype=object)), ('chEBI', array(['43755'], dtype=object))]",['CHEMBL419213' 'CHEMBL1729579'],"{'rows': array(['EFO_0003144', 'EFO_0000319', 'EFO_0000279', 'EFO_0003896',
       'HP_0003124', 'EFO_0004264', 'EFO_0000537', 'EFO_0000400',
       'EFO_1000948', 'EFO_0000373', 'MONDO_0007915', 'EFO_0000612',
       'MONDO_0002474', 'EFO_0004236', 'EFO_0000712', 'MONDO_0001134',
       'EFO_0000537', 'EFO_0000612', 'MONDO_0002462', 'Orphanet_79292',
       'EFO_0000712', 'EFO_0000401', 'EFO_0000400', 'EFO_0008620',
       'EFO_0000318', 'MONDO_0007254', 'EFO_0000319', 'EFO_0000182',
       'EFO_0001645', 'EFO_0003914', 'EFO_1001375', 'EFO_1001249',
       'MONDO_0005148', 'EFO_0000373', 'EFO_0003144'], dtype=object), 'count': 35}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 7 approved and 28 investigational indications. This drug has a black box warning from the FDA.
CHEMBL12610,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,CNBGNNVCVSKAQZ-UHFFFAOYSA-N,Small molecule,False,BENZYDAMINE,,4.0,,False,True,[],['Apo-benzydamine' 'Benzindamine' 'Benzydamine'],"[('PubChem', array(['11112291', '160657813'], dtype=object)), ('Wikipedia', array(['Benzydamine'], dtype=object)), ('drugbank', array(['DB09084'], dtype=object))]",['CHEMBL1528134'],"{'rows': array(['EFO_1001904', 'HP_0003326', 'EFO_0009688', 'EFO_1001904',
       'EFO_0005755', 'HP_0002829', 'EFO_0005757'], dtype=object), 'count': 7}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 2 investigational indications.
CHEMBL141305,CC(=O)Oc1ccc(C(=C2CCCCC2)c2ccc(OC(C)=O)cc2)cc1,GVOUFPWUYJWQSK-UHFFFAOYSA-N,Small molecule,False,CYCLOFENIL,,4.0,,True,True,['Neoclym' 'Rehibin'],"['Cyclofenil' 'F 6066' 'F-6066' 'ICI 48213' 'ICI-48213' 'NSC-86464'
 'Sexovid']","[('PubChem', array(['144205812', '170465970', '29217524'], dtype=object)), ('drugbank', array(['DB13472'], dtype=object))]",,,"[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1529,Cl.OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,AVZIYZHXZAYGJS-UHFFFAOYSA-N,Small molecule,False,DIPHENIDOL HYDROCHLORIDE,1967.0,4.0,CHEMBL936,False,True,['Vontrol'],"['Cephadol' 'Diphenidol hcl' 'Diphenidol hydrochloride' 'NSC-23012'
 'SK&F 478-A' 'SK-478-A']","[('PubChem', array(['11533019', '85273789'], dtype=object))]",,,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967.
CHEMBL1738697,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12,LGXVKMDGSIWEHL-UHFFFAOYSA-N,Small molecule,False,PF-00337210,,1.0,,False,False,[],['Pf-00337210' 'Pf-337210'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1743043,,,Antibody drug conjugate,True,MOXETUMOMAB PASUDOTOX,2018.0,4.0,,False,True,['Lumoxiti'],"['CAT-8015' 'HA-22' 'HA22' 'Moxetumomab pasudotox'
 'Moxetumomab pasudotox tdfk']","[('DailyMed', array(['moxetumomab%20pasudotox-tdfk'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lumoxiti'],
      dtype=object))]",,"{'rows': array(['EFO_0000565', 'EFO_0000574', 'MONDO_0000870', 'EFO_0000616',
       'EFO_1000956', 'EFO_0005952', 'EFO_0000220', 'EFO_0000095'],
      dtype=object), 'count': 8}","[ENSG00000167658,ENSG00000012124]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for neoplasm and hairy cell leukemia and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103761,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,VXMOONUMYLCFJD-DHLKQENFSA-N,Small molecule,False,BARNIDIPINE,,2.0,,False,False,[],['Barnidipine' 'Barnidipine hydrochloride' 'Mepirodipine' 'Vasexten'],"[('drugbank', array(['DB09227'], dtype=object))]",['CHEMBL2356712'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108667,,,Antibody drug conjugate,True,YTTRIUM Y 90 IBRITUMOMAB TIUXETAN,2002.0,4.0,,False,True,[],"['(90)y-ibritumomab tiuxetan' '90y ibritumomab tiuxetan' '90y-ibritumomab'
 'Ibritumomab tiuxetan y-90' 'Ibritumomab tiuxetan yttrium y-90'
 'Yttrium y 90 ibritumomab tiuxetan' 'Yttrium y-90 ibritumomab tiuxetan']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin'],
      dtype=object))]",,"{'rows': array(['MONDO_0013730', 'EFO_0000183', 'EFO_0001378', 'EFO_0003032',
       'EFO_0000191', 'EFO_1001365', 'EFO_0009441', 'EFO_0000565',
       'EFO_0000403', 'EFO_0000309', 'EFO_1001469', 'MONDO_0000873',
       'EFO_0000574', 'EFO_0000095', 'EFO_0005952', 'EFO_0000096',
       'MONDO_0018906'], dtype=object), 'count': 17}",[ENSG00000156738],Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109265,,,Antibody,False,MOC31-PE,,1.0,,False,False,[],['MOC31-PE' 'Moc31-pe'],,,"{'rows': array(['EFO_0000313'], dtype=object), 'count': 1}",[ENSG00000119888],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109401,,,Antibody,False,AV-203,,1.0,,False,False,[],['AV-203' 'AV203' 'Av 203' 'Av-203' 'CAN-017'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109592,,,Antibody,False,MEDI-500,,3.0,,False,False,[],['MEDI-500' 'Medi-500' 'T10B9'],,,,"[ENSG00000211810,ENSG00000277734,ENSG00000278030,ENSG00000211699]",Antibody drug with a maximum clinical trial phase of III.
CHEMBL2143592,Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl,PDYXPCKITKHFOZ-UHFFFAOYSA-N,Small molecule,False,BMS-794833,,1.0,,False,False,[],['Bms-794833'],"[('PubChem', array(['137276020'], dtype=object))]",,,"[ENSG00000105976,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL230011,Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1,UJIAQDJKSXQLIT-UHFFFAOYSA-N,Small molecule,False,TG100-115,,2.0,,False,False,[],['TG100-115' 'Tg100-115'],"[('drugbank', array(['DB05552'], dtype=object))]",,"{'rows': array(['EFO_0000612'], dtype=object), 'count': 1}","[ENSG00000171608,ENSG00000105851]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL25336,C(=N/NC1=NCCN1)\c1c2ccccc2c(/C=N/NC2=NCCN2)c2ccccc12,NJSMWLQOCQIOPE-OCHFTUDZSA-N,Small molecule,False,BISANTRENE,,3.0,,False,False,[],['Bisantrene' 'NSC-337766'],,['CHEMBL3989424'],"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000140718],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3137301,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,PYNXFZCZUAOOQC-UTKZUKDTSA-N,Small molecule,False,SACUBITRIL,2015.0,4.0,,False,True,[],['AHU-377' 'AHU377' 'Sacubitril'],"[('DailyMed', array(['sacubitril'], dtype=object)), ('drugbank', array(['DB09292'], dtype=object))]",,"{'rows': array(['EFO_0003144', 'EFO_0007148', 'EFO_0000612', 'EFO_0008583',
       'MONDO_0001134', 'EFO_0004265', 'MONDO_0005149', 'EFO_0000538',
       'EFO_0000537', 'MONDO_0100096', 'EFO_0000373', 'EFO_0008585',
       'EFO_0005529'], dtype=object), 'count': 13}",[ENSG00000196549],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for heart failure and congestive heart failure and has 11 investigational indications.
CHEMBL3545408,O=C1c2ccccc2C(=O)N1[C@@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)C1O5,DHAITNWJDOSRBU-RCSSWNHXSA-N,Small molecule,False,NALTALIMIDE,,2.0,,False,False,[],['Naltalimide' 'TAK-363' 'TAK363' 'Trk-130'],,,,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3989920,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+],NBDQGOCGYHMDSJ-NRFPMOEYSA-M,Small molecule,False,PITAVASTATIN SODIUM,2017.0,4.0,CHEMBL1201753,False,True,['Nikita'],[],,,"{'rows': array(['HP_0003119', 'MONDO_0021187'], dtype=object), 'count': 2}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for abnormal circulating lipid concentration and hyperlipidemia.
CHEMBL3989969,C[C@@H](O)C(=N)NS(=O)(=O)c1cc(C(=O)C(C(=O)c2cc(F)ccc2F)=C2Nc3ccccc3N2)ccc1F,CWNLBPBIFALUQD-GFCCVEGCSA-N,Small molecule,False,OPIGOLIX,,2.0,,False,False,[],['ASP-1707' 'ASP1707' 'Opigolix' 'Opigolixum'],,,"{'rows': array(['EFO_0001065', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000109163],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL415606,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,MEUCPCLKGZSHTA-XYAYPHGZSA-N,Protein,False,DEGARELIX,2008.0,4.0,,False,True,['Firmagon'],['Degarelix' 'FE200486 (AS ACETATE SALT)'],"[('drugbank', array(['DB06699'], dtype=object))]",['CHEMBL2028987'],"{'rows': array(['MONDO_0008315', 'EFO_0006861', 'MONDO_0021259', 'MONDO_0008315',
       'EFO_0001663', 'EFO_0000196', 'MONDO_0008315', 'EFO_0000228',
       'EFO_0000673', 'EFO_0000284', 'EFO_0001065', 'MONDO_0100096',
       'EFO_0008528', 'EFO_0001663', 'EFO_0000616', 'EFO_0000673',
       'MONDO_0007254', 'EFO_0000545'], dtype=object), 'count': 18}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 15 investigational indications.
CHEMBL4297258,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C,GHKOONMJXNWOIW-UHFFFAOYSA-N,Small molecule,False,FIRMONERTINIB,,3.0,,False,False,[],['AST-2818' 'AST2818' 'Alflutinib' 'Firmonertinib' 'Furmonertinib'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0008903', 'EFO_0000571', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297891,,,Antibody,False,CUSATUZUMAB,,2.0,,False,False,[],['Argx-110' 'Cusatuzumab'],,,"{'rows': array(['EFO_0000616', 'EFO_0000198', 'MONDO_0004992', 'EFO_0000222'],
      dtype=object), 'count': 4}",[ENSG00000125726],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL441,CCCC(C)C1(CC)C(=O)NC(=S)NC1=O,IUJDSEJGGMCXSG-UHFFFAOYSA-N,Small molecule,False,THIOPENTAL,1982.0,4.0,,False,True,[],['Thiopental' 'Thiopental ciii'],"[('PubChem', array(['29215503'], dtype=object)), ('drugbank', array(['DB00599'], dtype=object)), ('chEBI', array(['102166'], dtype=object))]",['CHEMBL738'],"{'rows': array(['EFO_0006834', 'EFO_0008526', 'HP_0000486', 'EFO_1001454',
       'MONDO_0043510'], dtype=object), 'count': 5}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 5 investigational indications.
CHEMBL4457723,CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1,PJTGSIKANITYOO-RCOXNQKVSA-N,Small molecule,False,BMS-741672,,2.0,,False,False,[],['BMS 741672' 'Bms-741672' 'Bms741672'],,,"{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}",[ENSG00000121807],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL452,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,DGBIGWXXNGSACT-UHFFFAOYSA-N,Small molecule,True,CLONAZEPAM,1975.0,4.0,,False,True,['Clonazepam' 'Klonopin' 'Klonopin rapidly disintegrating' 'Rivotril'],"['Clonazepam' 'Clonazepam civ' 'NSC-179913' 'RO 5-4023' 'RO-5-4023'
 'RO-54023' 'Ravotril' 'Rivatril']","[('DailyMed', array(['clonazepam'], dtype=object)), ('Wikipedia', array(['Clonazepam'], dtype=object)), ('drugbank', array(['DB01068'], dtype=object)), ('chEBI', array(['3756'], dtype=object))]",,"{'rows': array(['EFO_0000474', 'EFO_0003843', 'EFO_0004262', 'HP_0001250',
       'EFO_0005230', 'EFO_0008526', 'EFO_1000850', 'EFO_0007262',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_0007191', 'HP_0000726',
       'EFO_0007462', 'EFO_0005762', 'EFO_1000924'], dtype=object), 'count': 15}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL672,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,YMTINGFKWWXKFG-UHFFFAOYSA-N,Small molecule,False,FENOFIBRATE,1993.0,4.0,,False,True,"['Antara (micronized)' 'Fenofibrate' 'Fenofibrate (micronized)' 'Fenogal'
 'Fenoglide' 'Lipantil' 'Lipantil micro 200' 'Lipantil micro 267'
 'Lipantil micro 67' 'Lipidil' 'Lipofen' 'Supralip 160' 'Tricor'
 'Tricor (micronized)' 'Triglide']","['Fenofibrate' 'Fenofibrate delayed release' 'Fenofibrate micronized'
 'NSC-281319']","[('DailyMed', array(['fenofibrate'], dtype=object)), ('PubChem', array(['104171156', '11111181', '11111182', '124880099', '144203698',
       '144210471', '170464718', '174007303', '26746914', '26751450',
       '50103926', '56422492', '85231046', '855565', '90340778'],
      dtype=object)), ('TG-GATEs', array(['79'], dtype=object)), ('Wikipedia', array(['Fenofibrate'], dtype=object)), ('drugbank', array(['DB01039'], dtype=object)), ('chEBI', array(['5001'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'MONDO_0018473', 'EFO_0004268', 'HP_0003124',
       'EFO_1001486', 'MONDO_0007739', 'MONDO_0005148', 'MONDO_0007079',
       'EFO_0000195', 'EFO_0000319', 'MONDO_0021187', 'Orphanet_309005',
       'EFO_1000727', 'Orphanet_79211', 'EFO_0000589', 'EFO_0004211',
       'EFO_0000401', 'EFO_0001645', 'EFO_0000180', 'EFO_0001073',
       'EFO_0003914', 'EFO_0001378', 'MONDO_0037748', 'EFO_1001249',
       'EFO_0003767', 'HP_0003119', 'EFO_0009516', 'EFO_0004705',
       'EFO_0000537', 'EFO_0003770'], dtype=object), 'count': 30}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 24 investigational indications.
CHEMBL797,CN1C(=O)CC(c2ccccc2)C1=O,WLWFNJKHKGIJNW-UHFFFAOYSA-N,Small molecule,False,PHENSUXIMIDE,1982.0,4.0,,False,True,['Milontin'],"['1-methyl-3-phenylsuccinimide' 'Epimid' 'Lifene' 'Milonton' 'Mirontin'
 'N-methyl-3-phenylpyrrolidinedione' 'NSC-760079' 'PM-334' 'Phensuximid'
 'Phensuximide' 'Racemic phensuximide' 'Succitimal']","[('PubChem', array(['144203933', '170465315', '56463169'], dtype=object)), ('Wikipedia', array(['Phensuximide'], dtype=object)), ('drugbank', array(['DB00832'], dtype=object)), ('chEBI', array(['8079'], dtype=object))]",,"{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for epilepsy.
CHEMBL83063,CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1,IOVGROKTTNBUGK-UHFFFAOYSA-N,Small molecule,False,RITODRINE,1991.0,4.0,,False,True,[],['DU-21220' 'Ritodrine'],"[('PubChem', array(['174007152'], dtype=object))]",['CHEMBL1367605'],,[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991.
CHEMBL962,CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)[O-])O[C@H]2C[C@H]1O.[Na+],LMHIPJMTZHDKEW-XQYLJSSYSA-M,Small molecule,False,EPOPROSTENOL SODIUM,1995.0,4.0,CHEMBL1139,False,True,['Epoprostenol sodium' 'Flolan' 'Veletri'],"['Epoprostenol sodium' 'Epoprostenolsodium' 'Prostacyclin sodium salt'
 'Sodium prostacyclin' 'U-53,217A' 'U-53217A']","[('DailyMed', array(['epoprostenol%20sodium'], dtype=object)), ('PubChem', array(['144205984'], dtype=object)), ('Wikipedia', array(['Prostacyclin'], dtype=object))]",,"{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for pulmonary arterial hypertension.
CHEMBL1200467,O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,ASDOKGIIKXGMNB-UHFFFAOYSA-N,Small molecule,False,HYDROXYZINE PAMOATE,1959.0,4.0,CHEMBL896,False,True,"['""hy-pam """"25""""""' 'Hy-Pam ""25""' 'Hydroxyzine pamoate' 'Vistaril']",['Hydroxyzine embonate' 'Hydroxyzine pamoate' 'NSC-757063'],"[('DailyMed', array(['hydroxyzine%20pamoate'], dtype=object)), ('PubChem', array(['124886739', '26748082', '855631'], dtype=object)), ('chEBI', array(['31680'], dtype=object))]",,"{'rows': array(['EFO_0004257', 'HP_0000989', 'EFO_0006788', 'EFO_0005531',
       'EFO_0000701'], dtype=object), 'count': 5}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 5 approved indications.
CHEMBL1201066,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.Cl,QYRYFNHXARDNFZ-UHFFFAOYSA-N,Small molecule,True,VENLAFAXINE HYDROCHLORIDE,1993.0,4.0,CHEMBL637,False,True,['Effexor' 'Effexor xr' 'Venlafaxine hydrochloride'],"['NSC-745751' 'Venlafaxine (as hydrochloride)' 'Venlafaxine hcl'
 'Venlafaxine hydrochloride' 'WY-45,030' 'WY-45030']","[('DailyMed', array(['venlafaxine%20hydrochloride'], dtype=object)), ('PubChem', array(['144212825', '49681556'], dtype=object)), ('chEBI', array(['9944'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'MONDO_0002009', 'EFO_0006862', 'MONDO_0004985',
       'EFO_0009854', 'HP_0000726', 'HP_0031217', 'EFO_0005687',
       'MONDO_0004975', 'EFO_0006788', 'EFO_1001892', 'EFO_1001917',
       'EFO_0004242', 'EFO_0004262', 'EFO_0000673', 'MONDO_0007254',
       'MONDO_0005090', 'EFO_0003843', 'EFO_1001919', 'EFO_1002014',
       'MONDO_0002050', 'HP_0030833', 'EFO_0002610', 'EFO_0005230',
       'MONDO_0008315', 'EFO_0003918', 'EFO_0005762', 'MONDO_0002009'],
      dtype=object), 'count': 28}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL129857,COc1cccc2nc(-c3cccs3)nc(NN3C(=O)C=C(C)C3=O)c12,GZGLPBNOIFLLRE-UHFFFAOYSA-N,Small molecule,False,AS-602868,,1.0,,False,False,[],['As-602868' 'SPC-839'],"[('PubChem', array(['137275813', '26755375'], dtype=object))]",,,"[ENSG00000122025,ENSG00000104365]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1382,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1,OOGJQPCLVADCPB-HXUWFJFHSA-N,Small molecule,False,TOLTERODINE,1998.0,4.0,,False,True,"['Blerone xl' 'Detrusitol' 'Detrusitol xl' 'Efflosomyl xl' 'Inconex xl'
 'Mariosea xl' 'Neditol xl' 'Preblacon xl' 'Santizor xl']",['KABI 2234' 'KABI-2234' 'Tolterodine'],"[('PubChem', array(['144205290', '170465337', '29215497', '49666284'], dtype=object)), ('Wikipedia', array(['Tolterodine'], dtype=object)), ('drugbank', array(['DB01036'], dtype=object)), ('chEBI', array(['9622'], dtype=object))]",['CHEMBL1200871' 'CHEMBL1722209'],"{'rows': array(['EFO_0003843', 'HP_0000103', 'HP_0000020', 'EFO_0004253',
       'EFO_0006865', 'EFO_0005762', 'EFO_1000781', 'HP_0003419',
       'EFO_1000781', 'EFO_0004710'], dtype=object), 'count': 10}","[ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 6 investigational indications.
CHEMBL15677,O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl,IDKAXRLETRCXKS-UHFFFAOYSA-N,Small molecule,False,FENCLOFENAC,1978.0,4.0,,True,True,[],['Fenclofenac' 'R 67408' 'R-67408' 'RX 67408' 'RX-67408'],"[('PubChem', array(['144206863'], dtype=object)), ('Wikipedia', array(['Fenclofenac'], dtype=object))]",,,"[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978. It was withdrawn in at least one region.
CHEMBL1614,C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1,OBATZBGFDSVCJD-LALPQLPRSA-N,Small molecule,False,DESLANOSIDE,1982.0,4.0,,False,True,['Cedilanid-d'],['Deacetylanatoside c' 'Desacetyl-lanatoside c' 'Deslanoside'],"[('PubChem', array(['144205224', '170465236'], dtype=object)), ('Wikipedia', array(['Deslanoside'], dtype=object)), ('drugbank', array(['DB01078'], dtype=object)), ('chEBI', array(['31468'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease.
CHEMBL1685,C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N,VTMVHDZWSFQSQP-VBNZEHGJSA-N,Small molecule,False,DEZOCINE,1989.0,4.0,,False,True,['Dalgan'],"['Dezocine' 'Docozine' 'Dozocine' 'WY-16,225' 'WY-16225']","[('Wikipedia', array(['Dezocine'], dtype=object)), ('drugbank', array(['DB01209'], dtype=object)), ('chEBI', array(['4474'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for pain.
CHEMBL1742428,N#Cc1ccc(N2CCN(C(=O)COc3ccc4[nH]cc(CCN)c4c3)CC2)cc1,SOHCKWZVTCTQBG-UHFFFAOYSA-N,Small molecule,False,DONITRIPTAN,,2.0,,False,False,[],['Donitriptan' 'Donitriptan hydrochloride' 'F-11356'],,,,"[ENSG00000183134,ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1742466,CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1,WMDSZGFJQKSLLH-RBBKRZOGSA-N,Small molecule,False,LANDIOLOL,,3.0,,False,False,[],['AOP-200704' 'AOP200704' 'LDLL-600' 'LDLL600' 'Landiolol' 'ONO-1101'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LANDIOLOL/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12212'], dtype=object))]",['CHEMBL2362410'],"{'rows': array(['EFO_0004269', 'HP_0004755', 'EFO_0000319', 'EFO_0000275',
       'EFO_0009492', 'EFO_0003911', 'HP_0004755', 'EFO_0006834',
       'EFO_0000275', 'EFO_0003911'], dtype=object), 'count': 10}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL1743060,,,Antibody,False,RADRETUMAB,,2.0,,False,False,[],['Radretumab'],,,,[ENSG00000115414],Antibody drug with a maximum clinical trial phase of II.
CHEMBL1743085,,,Antibody,False,URELUMAB,,2.0,,False,False,[],['BMS-663513' 'Urelumab'],,,"{'rows': array(['EFO_0001378', 'EFO_0005952', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0000756', 'EFO_0002618', 'EFO_0000096', 'EFO_1001465',
       'EFO_0003060', 'EFO_0000565'], dtype=object), 'count': 10}",[ENSG00000049249],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL1829335,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1,XUKROCVZGZNGSI-CQSZACIVSA-N,Small molecule,False,IRDABISANT,,2.0,,False,False,[],['CEP-26401' 'CEP26401' 'Cep 26401' 'Irdabisant'],"[('drugbank', array(['DB12900'], dtype=object))]",['CHEMBL1813067'],"{'rows': array(['HP_0100543'], dtype=object), 'count': 1}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108739,,,Antibody,False,PLACULUMAB,,2.0,,False,False,[],"['ART-621' 'ART-621 ( ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY)'
 'ART621' 'CEP-37247' 'PN-0621' 'PN0621' 'Placulumab']",,,"{'rows': array(['HP_0011868', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000232810],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109150,,,Antibody,False,LINTUZUMAB,,3.0,,False,False,['Zamyl'],['HUM-195' 'HUM195' 'Huma-195-Gelonin' 'Lintuzumab' 'SGN-33'],,,"{'rows': array(['EFO_1001779', 'EFO_0000565', 'EFO_0000222', 'EFO_0001378',
       'EFO_0000198', 'MONDO_0001475'], dtype=object), 'count': 6}",[ENSG00000105383],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2218898,CC[C@@H](C)[C@@H]1NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)CCSCC[C@@H](C(=O)N(C)[C@H](CO)CCCN)NC(=O)[C@H](CC(N)=O)NC1=O,UGNGRKKDUVKQDF-IHOMMZCZSA-N,Protein,False,BARUSIBAN,,2.0,,False,False,[],['Barusiban' 'Fe-200440'],"[('drugbank', array(['DB12292'], dtype=object))]",,"{'rows': array(['EFO_0000545'], dtype=object), 'count': 1}",[ENSG00000180914],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL320775,Cc1ccc2nc(N)[nH]c(=O)c2c1Sc1ccncc1,XHWRWCSCBDLOLM-UHFFFAOYSA-N,Small molecule,False,NOLATREXED,,3.0,,False,False,[],['Nolatrexed'],"[('PubChem', array(['50125758'], dtype=object)), ('drugbank', array(['DB12912'], dtype=object))]",['CHEMBL1983788' 'CHEMBL2356692'],"{'rows': array(['MONDO_0002691'], dtype=object), 'count': 1}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL334966,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O,PAEBIVWUMLRPSK-IDTAVKCVSA-N,Small molecule,False,CANGRELOR,2015.0,4.0,,False,True,[],['AR-C69931XX' 'Cangrelor'],"[('DailyMed', array(['cangrelor'], dtype=object)), ('drugbank', array(['DB06441'], dtype=object))]",['CHEMBL1097279'],"{'rows': array(['EFO_0005672', 'HP_0004419', 'HP_0002140', 'EFO_0000556',
       'EFO_0008585', 'EFO_0001645', 'EFO_0000612', 'HP_0004419'],
      dtype=object), 'count': 8}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for myocardial infarction and recurrent thrombophlebitis and has 6 investigational indications.
CHEMBL3545092,,,Small molecule,False,CR 1447,,2.0,,False,False,[],['Cr 1447'],,,,"[ENSG00000169083,ENSG00000140009]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545420,CCNCc1cncc(-c2ccc3c(c2)/C(=C2/N=c4cc(F)cc(F)c4=N2)NN3)c1C,RBOKLZGCVRXGEP-XTQSDGFTSA-N,Small molecule,False,AG-24322,,1.0,,False,False,[],['AG-024322' 'Ag 024322' 'Ag-24322'],,,"{'rows': array(['EFO_0005952'], dtype=object), 'count': 1}","[ENSG00000123374,ENSG00000170312,ENSG00000135446]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989694,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,ZIMCQJVMPKQQPB-UHFFFAOYSA-N,Small molecule,True,OLANZAPINE PAMOATE,2009.0,4.0,CHEMBL715,False,True,['Zyprexa relprevv'],"['Olanzapine (as embonate)' 'Olanzapine embonate' 'Olanzapine pamoate'
 'Olanzapine pamoate anhydrous' 'Olanzapine pamoate monohydrate'
 'Zypadhera']","[('DailyMed', array(['olanzapine%20pamoate'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}","[ENSG00000147246,ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for schizophrenia. This drug has a black box warning from the FDA.
CHEMBL3990034,,,Gene,False,FIDANACOGENE ELAPARVOVEC,,3.0,,False,False,[],"['Aav8 hfix19' 'Fidanacogene elaparvovec' 'PF-06838435'
 'Raav-spark100-hfix-padua' 'SPK 101' 'SPK-1001' 'SPK-9001'
 'SPK-FIX Padua' 'Spark 101']",,,"{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}",[ENSG00000101981],Gene drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4071161,CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,SEJLPXCPMNSRAM-GOSISDBHSA-N,Small molecule,False,TIRABRUTINIB,2020.0,4.0,,False,True,['Velexbru'],"['GS-4059' 'Gs-4059' 'ONO-4059' 'ONO-4059(FREE BASE)' 'Ono-4059'
 'Tirabrutinib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIRABRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15227'], dtype=object))]",['CHEMBL5314600'],"{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_0000685', 'EFO_0000699',
       'EFO_0000095', 'EFO_0005531', 'MONDO_0004992'], dtype=object), 'count': 7}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 6 investigational indications.
CHEMBL4297558,,,Antibody,False,INOTUZUMAB,,4.0,,False,True,['Besponsa'],['G544' 'Inotuzumab'],,,"{'rows': array(['EFO_0000220'], dtype=object), 'count': 1}",[ENSG00000012124],Antibody drug with a maximum clinical trial phase of IV and has 1 investigational indication.
CHEMBL4297715,,,Antibody,False,CAMRELIZUMAB,,3.0,,False,False,[],['Camrelizumab' 'Carilizumab' 'Carrelizumab' 'SHR-1210' 'Shr-1210'],,,"{'rows': array(['EFO_0000637', 'MONDO_0008170', 'EFO_0005537', 'MONDO_0007254',
       'MONDO_0003060', 'MONDO_0021355', 'EFO_0004252', 'EFO_0000519',
       'EFO_1001012', 'MONDO_0001187', 'EFO_0002916', 'MONDO_0021117',
       'EFO_0000365', 'MONDO_0002120', 'EFO_0000708', 'EFO_0000707',
       'MONDO_0001056', 'EFO_1001961', 'MONDO_0009348', 'EFO_1000657',
       'EFO_1001951', 'MONDO_0008903', 'EFO_0000178', 'EFO_1001968',
       'MONDO_0005184', 'EFO_0003868', 'EFO_0005952', 'MONDO_0007576',
       'EFO_0000403', 'EFO_0000199', 'MONDO_0020669', 'EFO_0002618',
       'EFO_0004142', 'EFO_0003060', 'MONDO_0021063', 'MONDO_0005575',
       'EFO_0009637', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0019472',
       'EFO_0002938', 'EFO_0001061', 'EFO_0000182', 'EFO_0005221',
       'EFO_0000349', 'EFO_0001071', 'EFO_0000222', 'EFO_0000702',
       'MONDO_0002108', 'MONDO_0002974', 'MONDO_0011962', 'MONDO_0018944',
       'EFO_0000616', 'EFO_0000181', 'EFO_0000574', 'EFO_0003897',
       'EFO_0000211', 'EFO_0000294', 'EFO_1000796', 'EFO_0000503',
       'EFO_0000183', 'EFO_0000691', 'EFO_0000571', 'EFO_0005922'],
      dtype=object), 'count': 64}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 64 investigational indications.
CHEMBL4594271,N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1,UXNXMBYCBRBRFD-UHFFFAOYSA-N,Small molecule,False,BEROTRALSTAT,2020.0,4.0,,False,True,[],['BCX-7353' 'BCX7353' 'Bcx7353' 'Berotralstat'],,['CHEMBL4594272'],"{'rows': array(['EFO_0005532', 'MONDO_0019623', 'MONDO_0019623'], dtype=object), 'count': 3}",[ENSG00000164344],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hereditary angioedema and has 1 investigational indication.
CHEMBL4594602,,,Antibody,False,LOMVASTOMIG,,2.0,,False,False,[],['Lomvastomig' 'RO-7121661' 'RO7121661' 'Ro-7121661' 'Ro7121661'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0005922'], dtype=object), 'count': 2}","[ENSG00000135077,ENSG00000188389]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL631,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,JWHAUXFOSRPERK-UHFFFAOYSA-N,Small molecule,True,PROPAFENONE,1989.0,4.0,,False,True,[],['GNF-Pf-4594' 'Propafenon hexal' 'Propafenone' 'Rythmol'],"[('PubChem', array(['104171212', '124881115', '144203779', '170464755', '26752315',
       '26752316', '50105251', '50105252', '90341088'], dtype=object)), ('Wikipedia', array(['Propafenone'], dtype=object)), ('drugbank', array(['DB01182'], dtype=object)), ('chEBI', array(['63619'], dtype=object))]",['CHEMBL1201063'],"{'rows': array(['HP_0004308', 'EFO_0000275', 'EFO_0004278', 'EFO_0000612',
       'EFO_0003144', 'EFO_0004287', 'EFO_0004269', 'EFO_0000275'],
      dtype=object), 'count': 8}","[ENSG00000043591,ENSG00000169252,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL100116,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C,VOKSWYLNZZRQPF-UHFFFAOYSA-N,Small molecule,True,PENTAZOCINE,1967.0,4.0,,False,True,[],"['Dl-pentazocine' 'NIH-7958' 'NSC-107430' 'Pentazocine' 'Pentazocine civ'
 'WIN 20,228' 'WIN-20228']",,['CHEMBL3989509' 'CHEMBL3989510'],"{'rows': array(['MONDO_0004985', 'EFO_0003843', 'EFO_0003843'], dtype=object), 'count': 3}",[ENSG00000147955],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for pain and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1200485,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,IVDHYUQIDRJSTI-UHFFFAOYSA-N,Small molecule,False,SORAFENIB TOSYLATE,2005.0,4.0,CHEMBL1336,False,True,['Nexavar'],['BAY 54-9085' 'BAY-54-9085' 'Sorafenib tosilate' 'Sorafenib tosylate'],"[('DailyMed', array(['sorafenib%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar'],
      dtype=object)), ('PubChem', array(['144206042', '170465175', '85147444'], dtype=object)), ('chEBI', array(['50928'], dtype=object))]",,"{'rows': array(['MONDO_0004192', 'MONDO_0011719', 'EFO_0000691', 'EFO_0000349',
       'EFO_0006352', 'EFO_1001968', 'EFO_0006861', 'EFO_0000756',
       'EFO_0000389', 'EFO_0002501', 'EFO_0000641', 'MONDO_0002367',
       'MONDO_0004992', 'MONDO_0008170', 'EFO_0000365', 'MONDO_0008903',
       'EFO_0007535', 'EFO_0000220', 'EFO_0002618', 'EFO_0000616',
       'EFO_1000613', 'EFO_1001465', 'EFO_1000657', 'MONDO_0021063',
       'EFO_0002938', 'MONDO_0044926', 'EFO_0002499', 'EFO_0000588',
       'EFO_1001469', 'EFO_0000501', 'EFO_0000673', 'MONDO_0002691',
       'EFO_1001052', 'MONDO_0044937', 'MONDO_0004986', 'EFO_0003060',
       'EFO_0001378', 'EFO_0000224', 'MONDO_0007254', 'MONDO_0008315',
       'MONDO_0002108', 'EFO_0003833', 'EFO_1001951', 'EFO_0000640',
       'EFO_0000182', 'EFO_0000519', 'EFO_0009907', 'EFO_0000702',
       'EFO_1000158', 'EFO_0000095', 'MONDO_0002087', 'EFO_0000681',
       'EFO_0000222', 'MONDO_0001187', 'EFO_0000403', 'EFO_0000637',
       'EFO_0003871', 'EFO_0000335', 'EFO_0002892', 'EFO_0003032',
       'MONDO_0002158'], dtype=object), 'count': 61}","[ENSG00000122025,ENSG00000132155,ENSG00000165731,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157764,ENSG00000113721]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 7 approved and 54 investigational indications.
CHEMBL1201035,Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2,RDNLAULGBSQZMP-UHFFFAOYSA-N,Small molecule,False,BIPERIDEN HYDROCHLORIDE,1959.0,4.0,CHEMBL1101,False,True,['Akineton' 'Akineton ret'],"['Akinophyl' 'Biperiden hcl' 'Biperiden hydrochloride'
 'Biperideni hydrochloridum' 'NSC-170950' 'NSC-84989' 'Tasmolin']","[('PubChem', array(['144206338', '144206615', '170465324'], dtype=object)), ('chEBI', array(['59171'], dtype=object))]",,,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959.
CHEMBL1201177,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O.Cl,DNTDOBSIBZKFCP-YDALLXLXSA-N,Small molecule,False,LEVOBUNOLOL HYDROCHLORIDE,1985.0,4.0,CHEMBL1201237,False,True,['Akbeta' 'Betagan' 'Levobunolol hydrochloride'],"['Levobunolol hcl' 'Levobunolol hydrochloride' 'NSC-759158' 'W 7000A'
 'W-7000A']","[('DailyMed', array(['levobunolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204168', '170464743', '56463666'], dtype=object)), ('chEBI', array(['6439'], dtype=object))]",,"{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for glaucoma.
CHEMBL1201347,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1,LKYQLAWMNBFNJT-UHFFFAOYSA-N,Small molecule,False,ANILERIDINE,1982.0,4.0,,False,True,[],"['Adopol' 'Alidine' 'Anileridine' 'Apidol' 'IDS-NA-012' 'Leritin'
 'Nipecotan']","[('PubChem', array(['170465266'], dtype=object)), ('Wikipedia', array(['Anileridine'], dtype=object)), ('drugbank', array(['DB00913'], dtype=object)), ('chEBI', array(['61203'], dtype=object))]",['CHEMBL1200543' 'CHEMBL1201047'],,"[ENSG00000082556,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1509,C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12,METQSPRSQINEEU-HXCATZOESA-N,Small molecule,False,DROSPIRENONE,2001.0,4.0,,False,True,['Angeliq' 'Slynd'],['Drospirenone' 'NSC-760103' 'ZK 30595' 'ZK-30595'],"[('DailyMed', array(['drospirenone'], dtype=object)), ('PubChem', array(['144205769', '170464870'], dtype=object)), ('Wikipedia', array(['Drospirenone'], dtype=object)), ('drugbank', array(['DB01395'], dtype=object)), ('chEBI', array(['50838'], dtype=object))]",,"{'rows': array(['EFO_1000710', 'EFO_0000660', 'EFO_0003894', 'EFO_0005204',
       'MONDO_0004169', 'EFO_0005924', 'HP_0100607', 'MONDO_0002050'],
      dtype=object), 'count': 8}","[ENSG00000151623,ENSG00000082175]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for acne and has 7 investigational indications.
CHEMBL1650,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C,ITRJWOMZKQRYTA-RFZYENFJSA-N,Small molecule,False,CORTISONE ACETATE,1950.0,4.0,,False,True,['Cortate' 'Cortelan' 'Cortisone acetate' 'Cortistab' 'Cortisyl' 'Cortone'],"['Cortisone' 'Cortisone 21-acetate' 'Cortisone Acetate'
 'Cortisone acetate' 'Cortisone aceticum' 'NSC-49420']","[('PubChem', array(['144207031', '170464685', '29214995', '50103888', '855514',
       '90341460'], dtype=object)), ('drugbank', array(['DB01380'], dtype=object)), ('chEBI', array(['3897'], dtype=object))]",,"{'rows': array(['EFO_1001896', 'HP_0004398', 'EFO_1001435', 'EFO_0004276',
       'EFO_1001205', 'EFO_0008997', 'EFO_1001119', 'EFO_1000764',
       'EFO_0007403', 'EFO_0000274', 'EFO_0007160', 'EFO_0000398',
       'EFO_1000694', 'EFO_0004255', 'EFO_0005752', 'EFO_1000039',
       'HP_0001094', 'HP_0003072', 'EFO_0000685', 'EFO_0003778',
       'MONDO_0008728', 'EFO_1000049', 'MONDO_0043579', 'MONDO_0007915',
       'MONDO_0005178', 'EFO_1001194', 'EFO_0003106', 'EFO_1000941',
       'EFO_0000565', 'EFO_0005319', 'HP_0001873', 'MONDO_0018479',
       'MONDO_0015128', 'EFO_0005558', 'EFO_1001250', 'EFO_0002609',
       'EFO_0004274', 'EFO_1000684', 'EFO_0005532', 'EFO_0009456',
       'EFO_0000574', 'EFO_0003063', 'HP_0001915', 'EFO_1000997',
       'MONDO_0004979', 'MONDO_0005271'], dtype=object), 'count': 46}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 44 approved and 2 investigational indications.
CHEMBL185,O=c1[nH]cc(F)c(=O)[nH]1,GHASVSINZRGABV-UHFFFAOYSA-N,Small molecule,False,FLUOROURACIL,1962.0,4.0,,False,True,"['5.f.u.' 'Accusite' 'Actikerall' 'Adrucil' 'Carac' 'Efudex' 'Efudix'
 'Fluoro-uracil roche' 'Fluoroplex' 'Fluorouracil' 'Tolak']","['5 FU' '5-FU' '5-Fluorouracil' '5-fluoruracil' 'Fluorouracil'
 'Fluorouracilum' 'Fluorouricil' 'Fluracil' 'NSC-19893' 'Phthoruracil'
 'Queroplex' 'RO 2-9757' 'RO-2-9757' 'RO-29757']","[('DailyMed', array(['fluorouracil'], dtype=object)), ('PubChem', array(['104171158', '11111190', '124880118', '124880121', '144203701',
       '144209533', '144210432', '170464762', '17389875', '174007005',
       '26747342', '26752979', '50105574', '8139872', '82653', '85231050',
       '90341469'], dtype=object)), ('Wikipedia', array(['Fluorouracil'], dtype=object)), ('drugbank', array(['DB00544'], dtype=object)), ('chEBI', array(['46345'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'MONDO_0002691', 'EFO_1001959', 'EFO_1000720',
       'EFO_1001471', 'EFO_0000198', 'EFO_0004208', 'EFO_0007363',
       'EFO_0002617', 'EFO_1001365', 'EFO_0004252', 'EFO_0003060',
       'EFO_0005952', 'EFO_1000910', 'EFO_0005577', 'EFO_0000365',
       'EFO_1000657', 'EFO_0005221', 'EFO_1000251', 'EFO_1001951',
       'MONDO_0021063', 'EFO_0008528', 'EFO_0003866', 'MONDO_0002358',
       'EFO_0002938', 'EFO_0005950', 'EFO_0002618', 'MONDO_0002974',
       'MONDO_0002038', 'EFO_0004284', 'EFO_0000294', 'MONDO_0000831',
       'MONDO_0005184', 'MONDO_0004992', 'EFO_0000503', 'EFO_0003897',
       'EFO_0003869', 'EFO_0000698', 'EFO_0003859', 'EFO_1000292',
       'MONDO_0044937', 'EFO_0000199', 'EFO_0004288', 'MONDO_0004192',
       'EFO_1001512', 'EFO_0010282', 'MONDO_0001879', 'MONDO_0004986',
       'EFO_0000707', 'EFO_1001129', 'EFO_1001961', 'MONDO_0008170',
       'MONDO_0002087', 'EFO_1001949', 'EFO_0009259', 'EFO_1000028',
       'MONDO_0024475', 'EFO_0000178', 'EFO_0009708', 'EFO_0002496',
       'EFO_0003835', 'EFO_0000228', 'MONDO_0007254', 'MONDO_0003199',
       'EFO_0005537', 'EFO_0002428', 'MONDO_0003060', 'MONDO_0002367',
       'EFO_0000181', 'EFO_0000326', 'MONDO_0044704', 'EFO_0003100',
       'EFO_0000574', 'MONDO_0011719', 'EFO_1001901', 'MONDO_0007576',
       'EFO_0000389', 'MONDO_0002516', 'MONDO_0005575', 'EFO_0000197',
       'MONDO_0001187', 'MONDO_0002120', 'MONDO_0021355', 'EFO_1000359',
       'EFO_0003860', 'HP_0002745', 'MONDO_0005041', 'MONDO_0005835',
       'EFO_1001956', 'MONDO_0001056', 'EFO_0000616', 'EFO_0000565',
       'EFO_0003817', 'EFO_0001075', 'EFO_0002916', 'MONDO_0003059',
       'EFO_0008549', 'EFO_0001378', 'EFO_0000313', 'EFO_0000756',
       'EFO_1000984', 'EFO_0005570', 'EFO_0006859', 'EFO_1001100',
       'EFO_0000681', 'EFO_0003891', 'EFO_0004606', 'EFO_0005922',
       'EFO_0004193', 'EFO_0007416', 'EFO_0004142'], dtype=object), 'count': 111}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 6 approved and 105 investigational indications.
CHEMBL1967878,Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1,KSOVGRCOLZZTPF-UHFFFAOYSA-N,Small molecule,False,CENISERTIB,,2.0,,False,False,[],"['AS 703569' 'AS-703569' 'AS703569' 'As-703569' 'As703569'
 'Aurora kinase inhibitor as703569' 'Cenisertib' 'R 763' 'R-763']","[('PubChem', array(['103904402', '103904437'], dtype=object))]",,"{'rows': array(['EFO_0001642', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000178999,ENSG00000105146,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108673,,,Antibody,False,VORSETUZUMAB,,2.0,,False,False,"['Sgn-70, h1f6']",['H-1F6' 'SGN-70' 'Vorsetuzumab'],,,,[ENSG00000125726],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109364,,,Antibody,False,AR-20.5,,2.0,,False,False,[],['AR-20.5'],,,,[ENSG00000185499],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109598,,,Antibody,False,BIIB-023,,2.0,,False,False,[],['BIIB-023' 'Biib-023'],,,"{'rows': array(['EFO_0005761', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000239697],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL25,CC(=O)Oc1ccccc1C(=O)O,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,Small molecule,False,ASPIRIN,1950.0,4.0,,False,True,"['8-hour bayer' 'Acetosalic Acid' 'Acetylsalic acid'
 'Acetylsalicylic Acid' 'Alka rapid' 'Anadin all night' 'Angettes 75'
 'Aspirin' 'Aspro clr' 'Bayer extra strength aspirin for migraine pain'
 'Danamep' 'Disprin cv' 'Disprin direct' 'Durlaza' 'Ecotrin' 'Enprin'
 'Equi-Prin' 'Gencardia' 'Levius' 'Max strgh aspro clr' 'Measurin'
 'Micropirin ec' 'Nu-seals 300' 'Nu-seals 600' 'Nu-seals 75'
 'Nu-seals cardio 75' 'Paynocil' 'Platet' 'Platet 300' 'Postmi 300'
 'Postmi 75' 'Salicylic Acid Acetate' 'Vazalore']","['Acetyl salicylate' 'Acetylsalicylic Acid' 'Acetylsalicylic acid'
 'Acetylsalicylic acid (who-ip)' 'Acetylsalicylicum acidum'
 'Acidum acetylsalicylicum' 'Acidum acetylsalicylicum (who-ip)' 'Aspirin'
 'BAY1019036' 'Benzoic acid, 2-(acetyloxy)-' 'NSC-27223' 'NSC-406186']","[('DailyMed', array(['aspirin'], dtype=object)), ('PubChem', array(['144203627', '144209315', '144210466', '170465039', '17389202',
       '17390036', '174007205', '26747283', '26752858', '47193676',
       '50105490', '85230910', '87798', '90340586'], dtype=object)), ('TG-GATEs', array(['14'], dtype=object)), ('Wikipedia', array(['Aspirin'], dtype=object)), ('drugbank', array(['DB00945'], dtype=object)), ('chEBI', array(['15365'], dtype=object))]",['CHEMBL1697753' 'CHEMBL2296002'],"{'rows': array(['EFO_0000495', 'MONDO_0007576', 'EFO_0000180', 'EFO_0001645',
       'Orphanet_733', 'EFO_0002615', 'EFO_0008586', 'EFO_0004607',
       'HP_0012042', 'EFO_0007328', 'MONDO_0002009', 'EFO_0003843',
       'MONDO_0004247', 'EFO_0000266', 'EFO_0003144', 'EFO_0000275',
       'EFO_0009364', 'HP_0012378', 'EFO_0003770', 'EFO_0000519',
       'MONDO_0005277', 'EFO_0003868', 'EFO_0000339', 'MONDO_0011962',
       'EFO_0004698', 'EFO_1001157', 'EFO_0003106', 'EFO_0005411',
       'EFO_1001161', 'MP_0001845', 'EFO_0003914', 'EFO_0003060',
       'EFO_0000571', 'MONDO_0005178', 'EFO_0004277', 'MONDO_0008170',
       'EFO_0009315', 'EFO_0008573', 'EFO_0000389', 'MONDO_0005090',
       'EFO_0010282', 'EFO_1000637', 'EFO_0003964', 'EFO_0000764',
       'EFO_1001951', 'HP_0002140', 'MONDO_0043839', 'MONDO_0005835',
       'MONDO_0010888', 'EFO_0005406', 'EFO_0003870', 'MONDO_0004979',
       'HP_0005521', 'EFO_0000319', 'EFO_0000195', 'MONDO_0007254',
       'MONDO_0021108', 'EFO_0001378', 'MONDO_0005129', 'EFO_0000673',
       'EFO_0000712', 'MP_0001914', 'EFO_0007443', 'EFO_0000266',
       'EFO_0003931', 'EFO_0009606', 'EFO_0001361', 'EFO_0000545',
       'HP_0100806', 'EFO_0000668', 'MONDO_0041052', 'EFO_0005856',
       'EFO_0007541', 'HP_0002239', 'MONDO_0018896', 'MONDO_0100096',
       'MONDO_0018076', 'EFO_0004610', 'MONDO_0001056', 'EFO_0004286',
       'HP_0002315', 'EFO_1000860', 'EFO_0000182', 'HP_0004398',
       'EFO_0000537', 'MONDO_0004985', 'EFO_0003893', 'EFO_0008585',
       'HP_0003326', 'EFO_0003764', 'EFO_0004259', 'EFO_0003913',
       'EFO_0000280', 'EFO_0009454', 'EFO_0000341', 'EFO_1001375',
       'HP_0003394', 'EFO_0007129', 'EFO_0000616', 'EFO_0003763',
       'EFO_0000707', 'EFO_0003875', 'EFO_0001663', 'EFO_0006859',
       'EFO_0003869', 'EFO_0002429', 'EFO_0003884', 'EFO_0004264',
       'EFO_1001154', 'EFO_0003777', 'EFO_0000400', 'EFO_0002950',
       'EFO_0000649', 'EFO_1000954', 'HP_0100607', 'EFO_0009854',
       'EFO_0000479', 'EFO_0000729', 'EFO_0009314', 'MONDO_0005301',
       'Orphanet_309005', 'EFO_0000556', 'EFO_0000684', 'EFO_1000657',
       'MONDO_0011382', 'EFO_1002022', 'EFO_0000538', 'EFO_0002618',
       'HP_0002745', 'EFO_0003762', 'EFO_0005407', 'EFO_0003768',
       'EFO_0000694', 'HP_0003418', 'EFO_0004252', 'EFO_0008583',
       'EFO_0009846', 'EFO_0000546', 'MONDO_0002679', 'HP_0000618',
       'EFO_0009686', 'HP_0004936', 'MONDO_0002974', 'MONDO_0021063',
       'MONDO_0007915', 'MONDO_0004992', 'HP_0001945', 'HP_0004419',
       'MONDO_0002258', 'EFO_0004265', 'MONDO_0008315', 'HP_0003419',
       'EFO_0010072', 'EFO_0000612', 'EFO_0005672', 'HP_0012228',
       'EFO_1001923', 'HP_0003124', 'MONDO_0005148', 'MONDO_0000831',
       'EFO_0004246', 'EFO_0007214', 'EFO_0004211'], dtype=object), 'count': 163}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 19 approved and 143 investigational indications.
CHEMBL264374,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,IIBYAHWJQTYFKB-UHFFFAOYSA-N,Small molecule,False,BEZAFIBRATE,,4.0,,False,True,"['Bezagen xl' 'Bezalip' 'Bezalip-mono' 'Fibrazate xl' 'Liparol xl'
 'Zimbacol xl']","['BM 15.075' 'BM-15.075' 'BM-15075' 'Bezafibrate' 'Bezatol sr'
 'NSC-758174']","[('PubChem', array(['11112764', '144204196', '144212162', '170465743', '26751546',
       '26751547', '56422496', '855877', '90341401'], dtype=object)), ('Wikipedia', array(['Bezafibrate'], dtype=object)), ('drugbank', array(['DB01393'], dtype=object)), ('chEBI', array(['47612'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'MONDO_0004985', 'EFO_0004268', 'EFO_0000198',
       'Orphanet_79211', 'MONDO_0044970', 'EFO_1001486', 'EFO_0000319'],
      dtype=object), 'count': 8}","[ENSG00000132170,ENSG00000186951,ENSG00000112033]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 7 investigational indications.
CHEMBL3402567,COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O.Cl,ICIJBYYMEBOTQP-UHFFFAOYSA-N,Small molecule,False,ITX-5061,,2.0,CHEMBL1208829,False,False,[],['ITX 5061' 'Itx 5061' 'Itx-5061' 'KC-706' 'KC706' 'Kc-706'],,,"{'rows': array(['EFO_0004719', 'EFO_0003047'], dtype=object), 'count': 2}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545157,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,PMJIHLSCWIDGMD-UHFFFAOYSA-N,Small molecule,False,TIDEGLUSIB,,2.0,,False,False,['Zentylor nypta'],['NP-031112' 'NP-12' 'NP031112' 'Np-031112' 'Tideglusib'],"[('drugbank', array(['DB12129'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'Orphanet_273', 'MONDO_0016107', 'EFO_0003756',
       'MONDO_0004976'], dtype=object), 'count': 5}",[ENSG00000082701],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3545311,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,AILRADAXUVEEIR-UHFFFAOYSA-N,Small molecule,False,BRIGATINIB,2017.0,4.0,,False,True,['Alunbrig'],['AP-26113' 'AP26113' 'Ap-26113' 'Brigatinib'],"[('DailyMed', array(['brigatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig'],
      dtype=object)), ('drugbank', array(['DB12267'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003060', 'EFO_0003032'], dtype=object), 'count': 3}","[ENSG00000171094,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for neoplasm and non-small cell lung carcinoma and has 1 investigational indication.
CHEMBL3786673,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)c1ccccc1O,JQLBBYLGWHUHRW-KUBAVDMBSA-N,Small molecule,False,EDASALONEXENT,,3.0,,False,False,[],['CAT 1004' 'CAT-1004' 'CAT1004' 'Cat 1004' 'Cat-1004' 'Edasalonexent'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EDASALONEXENT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15010'], dtype=object))]",,"{'rows': array(['MONDO_0010679', 'MONDO_0005148'], dtype=object), 'count': 2}","[ENSG00000077150,ENSG00000109320,ENSG00000173039]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL402548,CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1,XKFTZKGMDDZMJI-HSZRJFAPSA-N,Small molecule,False,DANUSERTIB,,2.0,,False,False,[],['Danusertib' 'PHA-739358' 'Pha-739358'],"[('drugbank', array(['DB11778'], dtype=object))]",['CHEMBL534499'],"{'rows': array(['EFO_0001378', 'MONDO_0008315', 'EFO_0000565'], dtype=object), 'count': 3}","[ENSG00000178999,ENSG00000105146,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL405,CC(N)Cc1ccccc1,KWTSXDURSIMDCE-UHFFFAOYSA-N,Small molecule,True,AMPHETAMINE,1955.0,4.0,,False,True,['Adzenys er' 'Adzenys xr-odt' 'Dyanavel xr'],"['Amfetamin' 'Amfetamine' 'Amphetamine' 'Amphetamine, dl-' 'Dyanavel'
 'NSC-27159' 'Norephedrane']","[('DailyMed', array(['amphetamine'], dtype=object)), ('Wikipedia', array(['Adderall', 'Amphetamine'], dtype=object)), ('drugbank', array(['DB00182'], dtype=object)), ('chEBI', array(['2679'], dtype=object))]","['CHEMBL3250774' 'CHEMBL1200377' 'CHEMBL3250773' 'CHEMBL3250775'
 'CHEMBL554211' 'CHEMBL1200387' 'CHEMBL3250772' 'CHEMBL3250770'
 'CHEMBL3250771' 'CHEMBL501']","{'rows': array(['EFO_0003888', 'EFO_0001073', 'MONDO_0016158', 'EFO_0003925',
       'EFO_0003888', 'EFO_0003888', 'EFO_0002610', 'EFO_0002610'],
      dtype=object), 'count': 8}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297524,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1,DUPWHXBITIZIKZ-UHFFFAOYSA-N,Small molecule,False,RADOTINIB,,3.0,,False,False,[],['IY5511' 'Radotinib'],"[('drugbank', array(['DB12323'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'EFO_0000339'], dtype=object), 'count': 2}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4297787,,,Antibody,False,MONALIZUMAB,,3.0,,False,False,[],"['IPH-2201 (ANTI-NKG2A)' 'IPH2201' 'Iph-2201' 'Iph2201' 'Monalizumab'
 'NN-8765' 'NN8765' 'NN8765-3658']",,,"{'rows': array(['MONDO_0004992', 'EFO_0000095', 'MONDO_0007254', 'EFO_0004284',
       'EFO_0000616', 'EFO_0003060', 'EFO_0000707', 'EFO_0000702',
       'EFO_0000181', 'MONDO_0100096', 'MONDO_0021148', 'EFO_0000199'],
      dtype=object), 'count': 12}",[ENSG00000134545],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL4297926,,,Unknown,False,CJM-112,,2.0,,False,False,[],['CJM-112' 'CJM112' 'Cjm 112' 'Cjm-112' 'Cjm112'],,,"{'rows': array(['EFO_0001378', 'EFO_0003894', 'EFO_1000710', 'MONDO_0004979',
       'EFO_0000676'], dtype=object), 'count': 5}",[ENSG00000112115],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL475534,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1,PVHUJELLJLJGLN-UHFFFAOYSA-N,Small molecule,False,NITRENDIPINE,,4.0,,False,True,['Baypress'],"['BAY E 5009' 'BAY-E-5009' 'Bayotensin' 'Deiten' 'NSC-758466' 'Nidrel'
 'Nitrendipine' 'Nitrepin']","[('PubChem', array(['104171193', '124880808', '144203752', '170465897', '26751794',
       '26751795', '50104488', '85231144', '90341570'], dtype=object)), ('Wikipedia', array(['Nitrendipine'], dtype=object)), ('drugbank', array(['DB01054'], dtype=object)), ('chEBI', array(['7582'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 2}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.
CHEMBL483158,COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,ZLHFILGSQDJULK-UHFFFAOYSA-N,Small molecule,False,ALISERTIB,,3.0,,False,False,[],['Alisertib' 'MLN 8237' 'MLN-8237' 'MLN8237' 'Mln-8237'],"[('PubChem', array(['103905632', '137276087', '174006392'], dtype=object)), ('drugbank', array(['DB05220'], dtype=object))]",['CHEMBL2103871' 'CHEMBL3586471'],"{'rows': array(['EFO_0001378', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000222',
       'EFO_1001469', 'MONDO_0008903', 'EFO_0006859', 'MONDO_0007254',
       'EFO_0000198', 'MONDO_0002158', 'EFO_0000574', 'EFO_0000211',
       'EFO_0000621', 'MONDO_0018906', 'EFO_0000181', 'MONDO_0002087',
       'EFO_0000702', 'EFO_0000305', 'EFO_0001075', 'EFO_0000673',
       'EFO_0000616', 'EFO_0000309', 'MONDO_0002516', 'EFO_0000403'],
      dtype=object), 'count': 24}",[ENSG00000087586],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.
CHEMBL494,CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,HIFJCPQKFCZDDL-ACWOEMLNSA-N,Small molecule,False,ILOPROST,2003.0,4.0,,False,True,['Ventavis'],"['Ciloprost' 'Endoprost' 'Ilomedin' 'Iloprost' 'ZK 00036374' 'ZK-00036374'
 'ZK-36374']","[('DailyMed', array(['iloprost'], dtype=object)), ('drugbank', array(['DB01088'], dtype=object)), ('chEBI', array(['63916'], dtype=object))]",['CHEMBL5315118'],"{'rows': array(['EFO_0000341', 'EFO_0001071', 'MONDO_0005149', 'MONDO_0008903',
       'EFO_0006834', 'EFO_0000717', 'MONDO_0100130', 'EFO_0003943',
       'HP_0004419', 'MONDO_0004979', 'EFO_0009492', 'EFO_1001373',
       'EFO_0003884', 'EFO_0000612', 'EFO_0001361', 'EFO_1001145'],
      dtype=object), 'count': 16}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 13 investigational indications.
CHEMBL1193,CN(C)CCC(c1ccccc1)c1ccccn1,IJHNSHDBIRRJRN-UHFFFAOYSA-N,Small molecule,False,PHENIRAMINE,1994.0,4.0,,False,True,[],"['NSC-47965' 'Pheniramine' 'Propheniramine' 'Prophenpyridamine' 'Pyriton'
 'Tripoton']","[('PubChem', array(['90341510'], dtype=object)), ('Wikipedia', array(['Pheniramine'], dtype=object)), ('drugbank', array(['DB01620'], dtype=object))]",['CHEMBL1596440' 'CHEMBL1580221' 'CHEMBL1653'],"{'rows': array(['EFO_0007214', 'MONDO_0024355', 'MONDO_0005271', 'EFO_0007328',
       'EFO_0007214', 'HP_0000989'], dtype=object), 'count': 6}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for allergic disease and pruritus and has 3 investigational indications.
CHEMBL1200774,C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,MYYIMZRZXIQBGI-HVIRSNARSA-N,Small molecule,False,FLUPREDNISOLONE,1982.0,4.0,,False,True,['Alphadrol'],['Fluprednisolone' 'NSC-47439' 'U-7800'],"[('PubChem', array(['144205251', '144206694', '170465086'], dtype=object)), ('Wikipedia', array(['Fluprednisolone'], dtype=object)), ('drugbank', array(['DB09378'], dtype=object)), ('chEBI', array(['34474'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200795,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O,PMGQWSIVQFOFOQ-YKVZVUFRSA-N,Small molecule,False,CLEMASTINE FUMARATE,1977.0,4.0,CHEMBL1626,False,True,['Clemastine fumarate' 'Tavegil' 'Tavist' 'Tavist-1'],['Clemastine fumarate' 'Clemastine hydrogen fumarate'],"[('DailyMed', array(['clemastine%20fumarate'], dtype=object)), ('PubChem', array(['144204125', '170465318', '93576607'], dtype=object)), ('chEBI', array(['3739'], dtype=object))]",,"{'rows': array(['EFO_0003840', 'MONDO_0005271', 'EFO_0005854', 'EFO_0005531',
       'EFO_0007214', 'EFO_0003956', 'EFO_0003929', 'MONDO_0005301'],
      dtype=object), 'count': 8}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 4 approved and 4 investigational indications.
CHEMBL1201764,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1,DCCSDBARQIPTGU-HSZRJFAPSA-N,Small molecule,False,FESOTERODINE,2007.0,4.0,,False,True,[],['Fesoterodine'],"[('Wikipedia', array(['Fesoterodine'], dtype=object)), ('drugbank', array(['DB06702'], dtype=object))]",['CHEMBL1201765'],"{'rows': array(['HP_0000103', 'HP_0000020', 'EFO_1000781', 'EFO_1001762',
       'HP_0000020', 'HP_0000011', 'EFO_1000781', 'EFO_0006865',
       'HP_0010992'], dtype=object), 'count': 9}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 5 investigational indications.
CHEMBL1743029,,,Antibody,False,IBALIZUMAB,2018.0,4.0,,False,True,['Trogarzo'],['HU5A8' 'Ibalizumab' 'Ibalizumab-uiyk' 'TNX-355'],"[('DailyMed', array(['ibalizumab-uiyk'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trogarzo'],
      dtype=object))]",,"{'rows': array(['EFO_0000763', 'EFO_0000764', 'EFO_0000544', 'EFO_0000180'],
      dtype=object), 'count': 4}",[ENSG00000010610],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 1 investigational indication.
CHEMBL2103778,Cc1nccn1C[C@H]1CCc2c(c3cccc4c3n2CCC4)C1=O,NCNFDKWULDWJDS-OAHLLOKOSA-N,Small molecule,False,CILANSETRON,,2.0,,False,False,[],['Cilansetron' 'KC-9946'],"[('drugbank', array(['DB04885'], dtype=object))]",['CHEMBL2107807'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000166736,ENSG00000149305]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2105890,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC.O=C(O)/C=C/C(=O)O,IDLXWTNPDREJQZ-HSOMBQIOSA-N,Small molecule,False,MITEMCINAL FUMARATE,,2.0,CHEMBL2110756,False,False,[],"['115-8543 JAPAN' '115-8543-JAPAN' '5-1 UKIMA 5 CHOME' '5-1-UKIMA-5-CHOME'
 'GM-611' 'KITA-KU TOYKO' 'Mitemcinal fumarate']",,,"{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}",[ENSG00000102539],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107383,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC.Cl,JMHYCBFEEFHTMK-IIUXMCBISA-N,Small molecule,False,VERNAKALANT HYDROCHLORIDE,2010.0,4.0,CHEMBL2111112,False,True,['Brinavess'],"['Brinavess' 'Kynapid' 'RSD-1235' 'RSD1235' 'Vernakalant hcl'
 'Vernakalant hydrochloride']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess'],
      dtype=object))]",,"{'rows': array(['EFO_0000275', 'EFO_0003911'], dtype=object), 'count': 2}","[ENSG00000055118,ENSG00000183873,ENSG00000171385,ENSG00000130037,ENSG00000162989,ENSG00000120457]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for atrial fibrillation and has 1 investigational indication.
CHEMBL2109522,,,Antibody,False,PF-03446879,,-1.0,,False,False,[],['PF-03446879'],,,,[ENSG00000138379],Antibody drug.
CHEMBL220492,CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1,KJADKKWYZYXHBB-XBWDGYHZSA-N,Small molecule,False,TOPIRAMATE,1996.0,4.0,,False,True,"['Epitomax' 'Eprontia' 'Qudexy xr' 'Topamax' 'Topamax sprinkle'
 'Topiramate' 'Trokendi xr']","['(-)-topiramate' 'Epitoma' 'Eprontia' 'MCN-4853' 'Qudexy' 'RWJ-17021'
 'RWJ-17021-000' 'Sincronil' 'Topamac' 'Topimax' 'Topina' 'Topiramate'
 'Topomax' 'USL-255' 'USL255']","[('DailyMed', array(['topiramate'], dtype=object)), ('PubChem', array(['144205025', '144212718', '170464746'], dtype=object)), ('Wikipedia', array(['Topiramate'], dtype=object)), ('drugbank', array(['DB00273'], dtype=object)), ('chEBI', array(['63631'], dtype=object))]",,"{'rows': array(['HP_0011868', 'EFO_0007191', 'MONDO_0002046', 'EFO_0005203',
       'MONDO_0005180', 'EFO_0001073', 'EFO_1001176', 'MONDO_0021187',
       'EFO_0007262', 'EFO_0004211', 'EFO_0004895', 'EFO_0001063',
       'MONDO_0005299', 'HP_0000726', 'MONDO_0008300', 'HP_0002315',
       'EFO_0005204', 'MONDO_0005148', 'MONDO_0005277', 'EFO_0004263',
       'EFO_0000400', 'EFO_0004701', 'EFO_0004242', 'EFO_0001358',
       'EFO_0004329', 'EFO_0005230', 'EFO_0003768', 'HP_0100543',
       'EFO_0003843', 'EFO_0005207', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0004319', 'EFO_0001421', 'EFO_0004699', 'EFO_0000474',
       'EFO_0003108', 'EFO_0000195', 'MONDO_0016532', 'MONDO_0005301',
       'MONDO_0004985', 'EFO_0000537', 'HP_0001250', 'EFO_0005924',
       'EFO_0002610', 'MONDO_0007079'], dtype=object), 'count': 46}","[ENSG00000104267,ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000167434,ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 42 investigational indications.
CHEMBL3544964,Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1,RZUOCXOYPYGSKL-GOSISDBHSA-N,Small molecule,False,RAVOXERTINIB,,2.0,,False,False,[],['GDC-0994' 'GDC0994' 'Gdc-0994' 'RG-7842' 'Ravoxertinib'],"[('drugbank', array(['DB15281'], dtype=object))]",['CHEMBL4581802'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000100030,ENSG00000102882]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4069704,CCOC(=O)[C@@H]1CC2(CCN(c3cc(O[C@H](c4ccc(Cl)cc4-c4ccccc4)C(F)(F)F)nc(N)n3)CC2)CN1,TZSZZENYCISATO-WIOPSUGQSA-N,Small molecule,False,RODATRISTAT ETHYL,,2.0,,False,False,[],['KAR-5585' 'KAR5585' 'Rodatristat ethyl'],,,"{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}",[ENSG00000129167],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL408513,O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,NCNRHFGMJRPRSK-MDZDMXLPSA-N,Small molecule,False,BELINOSTAT,2014.0,4.0,,False,True,['Beleodaq'],['Belinostat' 'NSC-726630' 'NSC726630' 'PX-105684' 'PXD-101' 'PXD101'],"[('DailyMed', array(['belinostat'], dtype=object)), ('Wikipedia', array(['Belinostat'], dtype=object)), ('drugbank', array(['DB05015'], dtype=object)), ('chEBI', array(['61076'], dtype=object))]",,"{'rows': array(['EFO_0000309', 'EFO_0000403', 'EFO_1000131', 'MONDO_0015760',
       'EFO_0000616', 'EFO_0000588', 'MONDO_0002158', 'EFO_0003060',
       'EFO_0002913', 'MONDO_0000430', 'EFO_0000222', 'EFO_0005952',
       'EFO_0003032', 'EFO_1001469', 'EFO_0000183', 'EFO_0000228',
       'EFO_0000466', 'EFO_0001642', 'MONDO_0019471', 'MONDO_0004992',
       'EFO_1001968', 'EFO_0000313', 'EFO_0000198', 'MONDO_0002087',
       'EFO_0000211', 'EFO_1001051', 'EFO_1000581', 'EFO_0008528',
       'EFO_0000702', 'EFO_0001378', 'EFO_0000519', 'EFO_0000574',
       'EFO_0000182', 'EFO_1000576', 'MONDO_0018906', 'EFO_1000043'],
      dtype=object), 'count': 36}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 31 investigational indications.
CHEMBL4298084,,,Antibody,False,ODRONEXTAMAB,,2.0,,False,False,[],['Odronextamab' 'REGN-1979' 'REGN1979' 'Regn1979'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ODRONEXTAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004289', 'EFO_1001938', 'EFO_0000095', 'EFO_0000096'],
      dtype=object), 'count': 4}","[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000156738]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL433,CCCC(CCC)C(=O)[O-].[Na+],AEQFSUDEHCCHBT-UHFFFAOYSA-M,Small molecule,True,VALPROATE SODIUM,1996.0,4.0,CHEMBL109,False,True,"['Delepsine' 'Depacon' 'Depakine' 'Depakote' 'Depakote CP' 'Depakote ER'
 'Epilim' 'Epilim 200' 'Epilim 500' 'Epilim chrono 200'
 'Epilim chrono 300' 'Epilim chrono 500' 'Epilim chronosphere' 'Epilim iv'
 'Episenta' 'Kentilim' 'Orfiril' 'Orlept' 'Valproate sodium']","['A-44090' 'ABBOTT 44090' 'ABBOTT-44090' 'KW-6066N' 'NSC-732626'
 'NSC-757376' 'Natrii valproas' 'Selenica' 'Sodium 2-propylpentanoate'
 'Sodium valproate' 'Valproate sodium' 'Valproic acid sodium salt (1:1)'
 'Valproic acid, sodium' 'Valproic acid, sodium salt']","[('DailyMed', array(['valproate%20sodium'], dtype=object)), ('PubChem', array(['11112073', '144212940', '50106736', '50112990', '57264447',
       '85231324'], dtype=object)), ('Wikipedia', array(['Sodium_valproate'], dtype=object)), ('chEBI', array(['9925'], dtype=object))]",,"{'rows': array(['MONDO_0007079', 'EFO_0000474', 'EFO_0009963', 'EFO_0009430',
       'EFO_0003758', 'EFO_0000198', 'MONDO_0019188', 'MONDO_0005277',
       'HP_0001250', 'MONDO_0003478', 'EFO_0008526', 'MONDO_0043510',
       'EFO_0000519', 'MONDO_0010604', 'EFO_0004192', 'MONDO_0004976',
       'EFO_0008525', 'MONDO_0009293', 'EFO_0005762', 'EFO_0009267',
       'EFO_0000095', 'MONDO_0018105', 'HP_0000713', 'EFO_0000403',
       'MONDO_0004975', 'MONDO_0004985'], dtype=object), 'count': 26}",[ENSG00000112294],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for epilepsy and has 25 investigational indications. This drug has a black box warning from the FDA.
CHEMBL5314341,,,Protein,False,GLUCAGON,1998.0,4.0,,False,True,['Glucagon' 'Gvoke hypopen' 'Ogluo'],"['Baqsimi' 'Glucagen' 'Glucagon' 'Glucagon (recombinant dna origin)'
 'Glucagon recombinant' 'Glucagon, human' 'Glucagon, pig'
 'Glucagon, porcine']","[('DailyMed', array(['glucagon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ogluo'],
      dtype=object))]",,"{'rows': array(['EFO_0000400', 'HP_0001943', 'EFO_0001073', 'MONDO_0005148',
       'MONDO_0017182', 'EFO_0007214', 'EFO_0007318', 'MONDO_0005147'],
      dtype=object), 'count': 8}",[ENSG00000215644],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for diabetes mellitus and hypoglycemia and has 6 investigational indications.
CHEMBL5314399,Cc1ccc(N2c3cccc(C(=O)Nc4ccc(OCC(F)(F)F)nc4)c3OC[C@@H]2CO)nc1,QZUCKCLSVBFSOS-INIZCTEOSA-N,Small molecule,False,JTS-653,,2.0,,False,False,[],['JTS653' 'Jts-653'],,,,[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL690,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+],VWBQYTRBTXKKOG-IYNICTALSA-M,Small molecule,False,PRAVASTATIN SODIUM,1991.0,4.0,CHEMBL1144,False,True,['Elisor' 'Lipemol' 'Liplat' 'Lipostat' 'Pravachol' 'Pravastatin sodium'],"['CS-514' 'Dehypotin protect' 'Eptastatin sodium' 'NSC-759253'
 'Pravastatin sodium' 'SQ-31,000' 'SQ-31000']","[('DailyMed', array(['pravastatin%20sodium'], dtype=object)), ('PubChem', array(['144205027', '144210590', '26753280'], dtype=object)), ('chEBI', array(['8361'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0000400', 'MONDO_0005147', 'EFO_1000727',
       'EFO_0004255', 'EFO_0001645', 'EFO_0004911', 'EFO_0003914',
       'HP_0003124', 'Orphanet_79211', 'MONDO_0008903', 'EFO_0000565',
       'EFO_0000612', 'EFO_0000764', 'MONDO_0002691', 'EFO_0000180',
       'EFO_0004705', 'MONDO_0021661'], dtype=object), 'count': 18}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 8 investigational indications.
CHEMBL1179047,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,VDANGULDQQJODZ-UHFFFAOYSA-N,Small molecule,False,CHLOROPROCAINE,1955.0,4.0,,False,True,[],['2-chloroprocaine' 'Chloroprocaine'],"[('Wikipedia', array(['Chloroprocaine'], dtype=object)), ('drugbank', array(['DB01161'], dtype=object)), ('chEBI', array(['3636'], dtype=object))]",['CHEMBL944'],"{'rows': array(['EFO_0003843', 'EFO_0003843', 'EFO_0002950', 'MONDO_0005129'],
      dtype=object), 'count': 4}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 4 investigational indications.
CHEMBL1200803,O=C(O)CCC(=O)O.O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,RXZMMZZRUPYENV-VROPFNGYSA-N,Small molecule,False,SOLIFENACIN SUCCINATE,2004.0,4.0,CHEMBL1734,False,True,['Solifenacin succinate' 'Vesicare' 'Vesicare ls'],['Solifenacin succinate' 'YM-67905' 'YM-905' 'YM67905' 'YM905'],"[('DailyMed', array(['solifenacin%20succinate'], dtype=object))]",,"{'rows': array(['EFO_1000781', 'EFO_0000284', 'EFO_0006865'], dtype=object), 'count': 3}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for overactive bladder and urgency urinary incontinence and has 1 investigational indication.
CHEMBL1201150,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O,PORMUFZNYQJOEI-UHFFFAOYSA-N,Small molecule,False,SUMATRIPTAN SUCCINATE,1992.0,4.0,CHEMBL128,False,True,"['Alsuma' 'Imigran' 'Imigran 50' 'Imigran radis' 'Imigran recovery'
 'Imigran subject' 'Imitrex' 'Imitrex statdose' 'Migraitan'
 'Migraleve ultra' 'Onzetra xsail' 'Sumatriptan succinate'
 'Sumavel dosepro' 'Zecuity' 'Zembrace symtouch']","['GR 43175C' 'GR-43175C' 'NSC-760362' 'Sumatriptan (as succinate)'
 'Sumatriptan galpharm' 'Sumatriptan succinate' 'Treximet']","[('DailyMed', array(['sumatriptan%20succinate'], dtype=object)), ('PubChem', array(['49681638'], dtype=object)), ('chEBI', array(['64359'], dtype=object))]",,"{'rows': array(['MONDO_0005475', 'MONDO_0005277', 'MONDO_0100431'], dtype=object), 'count': 3}","[ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for migraine disorder and has 2 investigational indications.
CHEMBL1738889,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,JNGVJMBLXIUVRD-SFHVURJKSA-N,Small molecule,False,ENOBOSARM,,3.0,,False,False,['Ostarine'],['Enobosarm' 'GTX-024' 'Gtx-024' 'MK-2866'],"[('drugbank', array(['DB12078'], dtype=object))]",,"{'rows': array(['EFO_0009851', 'HP_0004326', 'HP_0010992', 'MONDO_0007254',
       'EFO_0003060', 'EFO_0005537'], dtype=object), 'count': 6}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL1910936,O=C(CN1C(=O)C2(CCCC2)NC[C@H]1c1cc(F)cc(F)c1)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2ncccc21,AZAANWYREOQRFB-SETSBSEESA-N,Small molecule,False,MK3207,,2.0,,False,False,[],['MK 3207' 'MK-3207' 'Mk-3207' 'Mk3207'],"[('drugbank', array(['DB12424'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2007641,,,Antibody,True,PERTUZUMAB,2012.0,4.0,,False,True,['Omnitarg' 'Omnitarg Perjeta' 'Perjeta'],['Pertuzumab' 'Pertuzumab-zzxf' 'RG-1273' 'RHUMAB 2C4' 'RHUMAB-2C4'],"[('DailyMed', array(['pertuzumab'], dtype=object)), ('DrugCentral', array(['4957'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta'],
      dtype=object)), ('Wikipedia', array(['Pertuzumab'], dtype=object))]",,"{'rows': array(['EFO_1000294', 'EFO_0001642', 'EFO_1000657', 'MONDO_0007254',
       'MONDO_0002120', 'EFO_0000305', 'EFO_0001663', 'MONDO_0021063',
       'EFO_0006861', 'EFO_0002916', 'MONDO_0008170', 'EFO_0002618',
       'EFO_0009708', 'EFO_0000365', 'MONDO_0001056', 'MONDO_0008315',
       'MONDO_0004992', 'MONDO_0002158', 'EFO_0003869', 'MONDO_0002087',
       'EFO_1001951', 'EFO_0003968', 'EFO_0003060', 'EFO_1000984',
       'EFO_0000616', 'EFO_0005537'], dtype=object), 'count': 26}",[ENSG00000141736],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2104987,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC,CILIXQOJUNDIDU-ASQIGDHWSA-N,Protein,False,TEDUGLUTIDE,2012.0,4.0,,False,True,['Gattex kit' 'Revestive'],"['ALX 0600' 'ALX-0600' 'Gattex' 'Revestive' 'Teduglutide'
 'Teduglutide (rdna origin)']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revestive'],
      dtype=object)), ('chEBI', array(['72305'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'MONDO_0021187', 'EFO_0001421', 'MONDO_0013730',
       'EFO_0000384', 'EFO_0003086', 'MONDO_0015183', 'EFO_0700081',
       'EFO_0008572', 'EFO_0009554'], dtype=object), 'count': 10}",[ENSG00000065325],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 7 investigational indications.
CHEMBL2107841,,,Protein,True,ALBIGLUTIDE,2014.0,4.0,,False,True,['Eperzan'],"['Albiglutide' 'Albiglutide (genetical recombination)' 'GSK-716155'
 'GSK716155' 'Tanzeum']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eperzan'],
      dtype=object))]",,"{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'EFO_0000400', 'EFO_0000373'],
      dtype=object), 'count': 4}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108742,,,Antibody,False,SIPLIZUMAB,,2.0,,False,False,[],['MEDI-507' 'Siplizumab'],,,"{'rows': array(['MONDO_0013730', 'EFO_0000676', 'MONDO_0004992', 'EFO_0003086',
       'EFO_0000565', 'EFO_1002048', 'EFO_0000574', 'EFO_0003884',
       'MONDO_0005147', 'MONDO_0016537'], dtype=object), 'count': 10}",[ENSG00000116824],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL2110372,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl,GGWBHVILAJZWKJ-UHFFFAOYSA-N,Small molecule,False,RANITIDINE HYDROCHLORIDE,1983.0,4.0,CHEMBL1790041,False,True,"['Azantac' 'Dumoran' 'Gavilast' 'Gavilast-p' 'Histac' 'Raciran 150'
 'Raciran 300' 'Ranicalm' 'Raniplex' 'Ranitic' 'Ranitidine hydrochloride'
 'Ranitil' 'Rantec' 'Ranzac' 'Vivatak' 'Zaedoc 150' 'Zaedoc 300' 'Zantac'
 'Zantac 150' 'Zantac 25' 'Zantac 300' 'Zantac 75' 'Zantac 75 dissolve'
 'Zantac 75 relief' 'Zantac 75 relief dissolve']","['AH 19065' 'AH-19065' 'Ranitidine hcl' 'Ranitidine hydrochloride'
 'Taladine']","[('DailyMed', array(['ranitidine%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0004607', 'MONDO_0043839', 'EFO_0009454', 'EFO_0000764'],
      dtype=object), 'count': 4}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 3 approved and 1 investigational indication.
CHEMBL3707253,,,Antibody,False,BEVACIZUMAB 111IN,,-1.0,,False,False,[],['Bevacizumab 111in' 'Bevacizumab in111'],,,,[ENSG00000112715],Antibody drug.
CHEMBL3979920,Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1,MJHOMTRKVMKCNE-NWDGAFQWSA-N,Small molecule,False,MIVAVOTINIB,,2.0,,False,False,[],['CB-659' 'Mivavotinib' 'TAK-659F'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIVAVOTINIB/relevant/1/'],
      dtype=object))]",['CHEMBL4594253'],"{'rows': array(['EFO_0000616', 'MONDO_0002334', 'EFO_0000616', 'MONDO_0002334',
       'EFO_0005952', 'EFO_0000222', 'EFO_0000403', 'EFO_0000574',
       'EFO_0000403', 'MONDO_0018906', 'EFO_0001075'], dtype=object), 'count': 11}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL4298006,,,Antibody,False,ENVAFOLIMAB,,3.0,,False,False,[],['ASC-22' 'ASC22' 'Asc22' 'Envafolimab' 'KN-035' 'KN035' 'Kn 035' 'Kn035'],,,"{'rows': array(['EFO_0004142', 'MONDO_0021117', 'EFO_0004252', 'MONDO_0011962',
       'EFO_0000616', 'EFO_0005922', 'MONDO_0007576', 'EFO_1001968',
       'EFO_0003060', 'EFO_0000182', 'EFO_0004288', 'MONDO_0004992',
       'MONDO_0021063', 'MONDO_0008170', 'MONDO_0002974', 'EFO_1000359',
       'EFO_0003891', 'MONDO_0007254', 'EFO_1001012', 'EFO_1000657',
       'EFO_0000180', 'EFO_0000503', 'MONDO_0003060', 'EFO_0004239',
       'EFO_1001951', 'EFO_0000764'], dtype=object), 'count': 26}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.
CHEMBL4298117,,,Antibody,False,ORILANOLIMAB,,2.0,,False,False,[],"['ALXN-1830' 'ALXN1830' 'Alxn1830' 'Orilanolimab' 'SYNT-001' 'SYNT001'
 'SYNT1001' 'Synt001']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ORILANOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004719', 'MONDO_0017287', 'EFO_0005809', 'EFO_0008601',
       'EFO_0004991', 'EFO_1001264'], dtype=object), 'count': 6}",[ENSG00000104870],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4594554,,,Antibody,False,TAFOLECIMAB,,3.0,,False,False,[],['IBI-306' 'IBI306' 'Ibi306' 'Tafolecimab'],,,"{'rows': array(['MONDO_0018328', 'EFO_0004911', 'HP_0003124'], dtype=object), 'count': 3}",[ENSG00000169174],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL5315125,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1.O,FQLHRUBTGKTKPZ-ZOWNYOTGSA-N,Small molecule,True,DUVELISIB MONOHYDRATE,2018.0,4.0,CHEMBL3039502,False,True,['Copiktra'],['Duvelisib hydrate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra'],
      dtype=object))]",,"{'rows': array(['MONDO_0018906', 'EFO_0000095', 'EFO_0000574', 'EFO_0000096'],
      dtype=object), 'count': 4}","[ENSG00000105851,ENSG00000171608]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved indications. This drug has a black box warning from the FDA.
CHEMBL629,CN(C)CCC=C1c2ccccc2CCc2ccccc21,KRMDCWKBEZIMAB-UHFFFAOYSA-N,Small molecule,True,AMITRIPTYLINE,1961.0,4.0,,False,True,[],"['Amitid' 'Amitril' 'Amitriptyline' 'Damitriptyline' 'Elavil' 'Endep'
 'Etrafon-A' 'Etrafon-Forte' 'Flavyl' 'Laroxyl' 'Limbitrol'
 'Proheptadiene' 'Seroten' 'Triptanol']","[('PubChem', array(['11110782', '11110783', '124879280', '90340850'], dtype=object)), ('TG-GATEs', array(['70'], dtype=object)), ('Wikipedia', array(['Amitriptyline'], dtype=object)), ('drugbank', array(['DB00321'], dtype=object)), ('chEBI', array(['2666'], dtype=object))]",['CHEMBL1200964'],"{'rows': array(['EFO_0007169', 'EFO_1000941', 'EFO_0003843', 'EFO_0005230',
       'EFO_1001800', 'EFO_0004698', 'EFO_0000400', 'MONDO_0005090',
       'EFO_0004244', 'HP_0002315', 'MONDO_0005277', 'EFO_0000512',
       'EFO_0004149', 'EFO_0009387', 'MONDO_0002050', 'EFO_0005762',
       'EFO_0005687', 'EFO_0010282', 'HP_0000989', 'EFO_0008507',
       'HP_0000726', 'MONDO_0016028', 'MONDO_0002009', 'MONDO_0002009',
       'MONDO_0002009'], dtype=object), 'count': 25}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for depressive disorder and major depressive disorder and has 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL864,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1,OJFSXZCBGQGRNV-UHFFFAOYSA-N,Small molecule,False,CARBINOXAMINE,2003.0,4.0,,True,True,[],['Carbinoxamine' 'Clistin' 'Palgic'],"[('PubChem', array(['29217899'], dtype=object)), ('Wikipedia', array(['Carbinoxamine'], dtype=object)), ('drugbank', array(['DB00748'], dtype=object)), ('chEBI', array(['3398'], dtype=object))]",['CHEMBL1200974' 'CHEMBL1519829'],"{'rows': array(['EFO_0007533', 'EFO_1001417', 'EFO_0003956', 'EFO_0005532',
       'EFO_0007141', 'MONDO_0005271', 'EFO_0005531'], dtype=object), 'count': 7}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved indications. It was withdrawn in at least one region.
CHEMBL894,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,SNPPWIUOZRMYNY-UHFFFAOYSA-N,Small molecule,True,BUPROPION,1985.0,4.0,,False,True,[],"['Amfebutamone' 'Bupropion' 'Bupropion extended release'
 'Bupropion slow release' 'NSC-758686']","[('PubChem', array(['174006913', '90340803'], dtype=object)), ('Wikipedia', array(['Bupropion'], dtype=object)), ('drugbank', array(['DB01156'], dtype=object)), ('chEBI', array(['3219'], dtype=object))]",['CHEMBL1698' 'CHEMBL1201735'],"{'rows': array(['EFO_0005203', 'MONDO_0002009', 'EFO_0003768', 'EFO_0004714',
       'MONDO_0002009', 'EFO_0006859', 'EFO_0001073', 'MONDO_0004975',
       'MONDO_0002491', 'MONDO_0008315', 'EFO_0009963', 'EFO_0000616',
       'EFO_0001073', 'MONDO_0002009', 'HP_0000726', 'MONDO_0004985',
       'MONDO_0007254', 'EFO_0009854', 'MONDO_0004985', 'EFO_0002610',
       'MONDO_0007739', 'MONDO_0005148', 'EFO_0003890', 'EFO_0000384',
       'EFO_0002617', 'EFO_0007191', 'EFO_0003060', 'EFO_0005230',
       'MONDO_0008903', 'EFO_0004319', 'MONDO_0002009', 'MONDO_0044970',
       'EFO_0004701', 'EFO_0003888', 'MONDO_0002050', 'EFO_0004319',
       'MONDO_0005090', 'MONDO_0002046', 'MONDO_0007079', 'EFO_0004318',
       'EFO_0000095', 'MONDO_0010200', 'MONDO_0002050', 'MONDO_0002009',
       'EFO_0003768', 'EFO_0004247', 'EFO_0004270'], dtype=object), 'count': 47}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 38 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1073,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,Small molecule,False,GLIPIZIDE,1984.0,4.0,,False,True,"['Glibenese' 'Glipizide' 'Glucotrol' 'Glucotrol xl' 'Minodiab 2.5'
 'Minodiab 5']","['CP-28,720' 'CP-28720' 'Glipizide' 'Glipizide slow release' 'K 4024'
 'K-4024' 'NSC-759120']","[('DailyMed', array(['glipizide'], dtype=object)), ('PubChem', array(['11111214', '11112714', '144203707', '144212151', '170465089',
       '50104189', '56422485', '855947'], dtype=object)), ('Wikipedia', array(['Glipizide'], dtype=object)), ('drugbank', array(['DB01067'], dtype=object)), ('chEBI', array(['5384'], dtype=object))]",,"{'rows': array(['EFO_0003914', 'MONDO_0005148', 'EFO_0003884', 'EFO_0000400'],
      dtype=object), 'count': 4}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 2 investigational indications.
CHEMBL1194666,CCN(CC)C(C)C(=O)c1ccccc1,XXEPPPIWZFICOJ-UHFFFAOYSA-N,Small molecule,False,DIETHYLPROPION,1959.0,4.0,,False,True,[],"['.alpha.-benzoyltriethylamine' 'Amfepramone' 'Anfepramone' 'Anferpramon'
 'C06954' 'D07444' 'Diethylcathinone' 'Diethylpropion' 'J4.327C']","[('Wikipedia', array(['Amfepramone'], dtype=object)), ('drugbank', array(['DB00937'], dtype=object)), ('chEBI', array(['4530'], dtype=object))]",['CHEMBL1693'],"{'rows': array(['EFO_0001073', 'EFO_0001073'], dtype=object), 'count': 2}","[ENSG00000103546,ENSG00000142319]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for obesity.
CHEMBL1466,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,Small molecule,False,DICUMAROL,1944.0,4.0,,False,True,['Dicumarol'],"['Bishydroxycoumarin' 'Dicoumarol' 'Dicoumarolum' 'Dicumarol' 'NSC-17860'
 'NSC-221570' 'NSC-41834']","[('PubChem', array(['11112184', '144203908', '170465275'], dtype=object)), ('Wikipedia', array(['Dicoumarol'], dtype=object)), ('drugbank', array(['DB00266'], dtype=object)), ('chEBI', array(['4513'], dtype=object))]",,"{'rows': array(['HP_0004419'], dtype=object), 'count': 1}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1944 and is indicated for recurrent thrombophlebitis.
CHEMBL1555,Br.COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,QORVDGQLPPAFRS-XPSHAMGMSA-N,Small molecule,False,GALANTAMINE HYDROBROMIDE,2001.0,4.0,CHEMBL659,False,True,['Galantamine hydrobromide' 'Razadyne' 'Razadyne er'],"['(-)-galantamine hydrobromide' 'Galantamine hydrobromide'
 'Galanthamine hydrobromide' 'Jilkon hydrobromide'
 'Lycoremine hydrobromide' 'Nivalin' 'Nivaline' 'Tamilin']","[('DailyMed', array(['galantamine%20hydrobromide'], dtype=object)), ('PubChem', array(['26719770', '49681569'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0004718', 'HP_0000726', 'MONDO_0005090',
       'MONDO_0017276', 'HP_0100543', 'EFO_0000677'], dtype=object), 'count': 7}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for alzheimer disease and dementia and has 5 investigational indications.
CHEMBL181954,CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O,OKJHGOPITGTTIM-DEOSSOPVSA-N,Small molecule,False,NAVEGLITAZAR,,2.0,,False,False,[],['LY-519818' 'LY-9818' 'LY519818' 'LY9818' 'Ly519818' 'Naveglitazar'],"[('drugbank', array(['DB12662'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}","[ENSG00000186951,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108575,,,Antibody,False,ASELIZUMAB,,2.0,,False,False,[],['Aselizumab'],,,,[ENSG00000188404],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108895,,,Oligonucleotide,False,ALICAFORSEN SODIUM,,-1.0,,False,False,[],"['Alicaforsen' 'Alicaforsen nonadecasodium salt' 'Alicaforsen sodium'
 'ISIS 2302' 'ISIS-2302']",,,,[ENSG00000090339],Oligonucleotide drug.
CHEMBL2109540,,,Antibody,False,ALIROCUMAB,2015.0,4.0,,False,True,['Praluent'],['Alirocumab' 'REGN-727' 'REGN727' 'SAR-236553' 'SAR236553'],"[('DailyMed', array(['alirocumab'], dtype=object)), ('DrugCentral', array(['5016'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/praluent'],
      dtype=object))]",,"{'rows': array(['EFO_0003914', 'HP_0100806', 'EFO_0000319', 'EFO_0004911',
       'HP_0003124', 'HP_0003119', 'Orphanet_309005', 'EFO_0004255',
       'MONDO_0018328', 'EFO_0000400', 'EFO_0001645'], dtype=object), 'count': 11}",[ENSG00000169174],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 6 investigational indications.
CHEMBL3544936,,,Small molecule,False,XL-844,,1.0,,False,False,[],['Xl-844'],,,"{'rows': array(['EFO_0000574', 'EFO_0000095', 'MONDO_0004992'], dtype=object), 'count': 3}","[ENSG00000149554,ENSG00000183765]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3545122,CC(C)C[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](CC(C)C)C(=O)O)CSSC[C@@H](C(=O)N[C@H](C(=O)O)C(C)C)NC1=O,WGEWYYPHYMGJNT-HLHYUOOASA-N,Protein,False,DOLCANATIDE,,2.0,,False,False,[],['Dolcanatide' 'SP-333'],,,"{'rows': array(['HP_0002019', 'EFO_1001951'], dtype=object), 'count': 2}",[ENSG00000070019],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545167,,,Protein,False,FE 202767,,2.0,,False,False,[],['Fe 202767'],,,"{'rows': array(['EFO_0003917'], dtype=object), 'count': 1}",[ENSG00000180914],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3716552,COc1cc(OCc2csc(-c3ccc(C(=O)N(C)C)cc3)n2)c2cc(-c3cn4nc(OC)sc4n3)oc2c1,KEEBLYWBELVGPQ-UHFFFAOYSA-N,Small molecule,False,BMS-986141,,2.0,,False,False,[],['BMS-986141' 'Bms-986141' 'UDM-003183'],"[('drugbank', array(['DB14942'], dtype=object))]",,"{'rows': array(['EFO_0001645', 'HP_0002140', 'EFO_0001421', 'MONDO_0000831'],
      dtype=object), 'count': 4}",[ENSG00000127533],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL372205,C[C@H](CN(C(=O)c1ccc(C#N)cc1)c1ccccn1)N1CCN(c2cccc3c2OCCO3)CC1,NRPQELCNMADTOZ-OAQYLSRUSA-N,Small molecule,False,LECOZOTAN,,3.0,,False,False,[],['Lecozotan'],"[('drugbank', array(['DB12540'], dtype=object))]",['CHEMBL2107349'],"{'rows': array(['MONDO_0004975', 'MONDO_0004975'], dtype=object), 'count': 2}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication.
CHEMBL3989481,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,GTPHQORJKFJIRB-JTQLPTLWSA-N,Protein,False,FRAKEFAMIDE,,2.0,,False,False,[],['Bch-3963' 'Frakefamide' 'LEF-576' 'SPD-759' 'SPD759'],,,,[ENSG00000112038],Protein drug with a maximum clinical trial phase of II.
CHEMBL4091374,O=C(O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1,OQDQIFQRNZIEEJ-UHFFFAOYSA-N,Small molecule,False,LANIFIBRANOR,,3.0,,False,False,[],['IVA-337' 'IVA337' 'Iva337' 'Lanifibranor'],"[('drugbank', array(['DB14801'], dtype=object))]",,"{'rows': array(['EFO_0000404', 'EFO_0003095', 'EFO_1001249'], dtype=object), 'count': 3}","[ENSG00000132170,ENSG00000186951,ENSG00000112033]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297859,,,Antibody drug conjugate,False,AZINTUXIZUMAB VEDOTIN,,2.0,,False,False,[],['Abbv-838' 'Azintuxizumab vedotin'],,,"{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}","[ENSG00000026751,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298176,,,Antibody,False,GARETOSMAB,,3.0,,False,False,[],['Garetosmab' 'REGN-2477' 'REGN2477'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GARETOSMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007606', 'EFO_0007323'], dtype=object), 'count': 2}",[ENSG00000122641],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4466233,CC(=O)N1CCC(Nc2cc(C(=O)NC[C@H](O)CN3CCc4ccccc4C3)ncn2)CC1,JLCCNYVTIWRPIZ-NRFANRHFSA-N,Small molecule,False,PEMRAMETOSTAT,,2.0,,False,False,[],"['EPZ-015938' 'EPZ015938' 'GSK-3326595A' 'GSK3326595' 'Gsk 3326595'
 'Gsk-3326595' 'Gsk3326595' 'Pemrametostat']",,,"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000100462],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594348,C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1,UNHZLHSLZZWMNP-LLVKDONJSA-N,Small molecule,False,ELSUBRUTINIB,,2.0,,False,False,[],['ABBV-105' 'ABBV105' 'Elsubrutinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELSUBRUTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007915', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4650421,,,Unknown,False,RECOMBINANT HUMAN INTERLEUKIN-15,,2.0,,False,False,[],['Recombinant human il-15' 'Recombinant human interleukin-15' 'Rhil-15'],,,"{'rows': array(['EFO_0000681', 'EFO_0000565', 'MONDO_0004992'], dtype=object), 'count': 3}","[ENSG00000147168,ENSG00000100385,ENSG00000134470]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL707,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,Small molecule,False,DOXAZOSIN,1990.0,4.0,,False,True,[],['C02CA04' 'Cardura' 'Doxazosin' 'UK-33274'],"[('PubChem', array(['124883384', '50105246', '90341261'], dtype=object)), ('Wikipedia', array(['Doxazosin'], dtype=object)), ('drugbank', array(['DB00590'], dtype=object)), ('chEBI', array(['4708'], dtype=object))]",['CHEMBL1200561'],"{'rows': array(['EFO_0002610', 'EFO_0000537', 'EFO_0000284', 'HP_0003124',
       'EFO_0000400', 'EFO_0004234', 'EFO_0000537', 'EFO_0004253',
       'MONDO_0002491', 'EFO_0003144', 'EFO_1001375', 'EFO_0000612',
       'EFO_0001358', 'MONDO_0007079', 'EFO_0000612', 'EFO_0003777',
       'EFO_0003890', 'EFO_0000284', 'EFO_0003768'], dtype=object), 'count': 19}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved and 15 investigational indications.
CHEMBL94454,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1,PVLJETXTTWAYEW-UHFFFAOYSA-N,Small molecule,False,MIZOLASTINE,1998.0,4.0,,False,True,['Mizollen'],['Mizolastine'],"[('PubChem', array(['144206216', '170465604', '50125752'], dtype=object)), ('Wikipedia', array(['Mizolastine'], dtype=object)), ('drugbank', array(['DB12523'], dtype=object))]",,"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998 and is indicated for allergic disease.
CHEMBL1078178,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,ZVHNDZWQTBEVRY-UHFFFAOYSA-N,Small molecule,False,MOMELOTINIB,2023.0,4.0,,False,True,[],"['CYT-0387' 'CYT-11387' 'CYT-387' 'CYT387' 'Cyt-387' 'GS-0387'
 'Momelotinib']","[('PubChem', array(['137275866'], dtype=object)), ('drugbank', array(['DB11763'], dtype=object))]",['CHEMBL2219411'],"{'rows': array(['EFO_0000479', 'EFO_0002429', 'EFO_0000479', 'EFO_0002429',
       'EFO_0002430', 'EFO_0003060', 'MONDO_0044903', 'EFO_0002430',
       'MONDO_0005184'], dtype=object), 'count': 9}","[ENSG00000162434,ENSG00000096968]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 6 investigational indications.
CHEMBL1086,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,PUFQVTATUTYEAL-UHFFFAOYSA-N,Small molecule,False,DIBUCAINE,1982.0,4.0,,False,True,[],['Cinchocaine' 'Dibucaine' 'NSC-159055'],"[('PubChem', array(['11112228', '144203932', '170464829', '50100394', '50100395',
       '56424123', '855529'], dtype=object)), ('Wikipedia', array(['Cinchocaine'], dtype=object)), ('drugbank', array(['DB00527'], dtype=object)), ('chEBI', array(['247956'], dtype=object))]",['CHEMBL1200612'],"{'rows': array(['EFO_0003958', 'EFO_0009552', 'HP_0000989'], dtype=object), 'count': 3}","[ENSG00000185313,ENSG00000183873]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved indications.
CHEMBL1200597,CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C.Cl,LMWQQUMMGGIGJQ-UHFFFAOYSA-N,Small molecule,False,ETIDOCAINE HYDROCHLORIDE,1976.0,4.0,CHEMBL492,False,True,['Duranest'],['Duranest hydrochloride' 'Etidocaine hcl' 'W-19053'],,,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976.
CHEMBL1201151,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C,IMSSROKUHAOUJS-MJCUULBUSA-N,Small molecule,False,MESTRANOL,1961.0,4.0,,False,True,[],"['33355' 'EE-3ME' 'EE3 ME' 'EE3-ME' 'EE3ME' 'EEI3ME' 'Mestranol'
 'NSC-84032']","[('PubChem', array(['144204751', '144212154', '170465357', '29215140', '56422167',
       '8139980'], dtype=object)), ('Wikipedia', array(['Mestranol'], dtype=object)), ('drugbank', array(['DB01357'], dtype=object)), ('chEBI', array(['6784'], dtype=object))]",,,[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.
CHEMBL1201323,NCCc1cc[nH]n1,JXDFEQONERDKSS-UHFFFAOYSA-N,Small molecule,False,BETAZOLE,1982.0,4.0,,False,True,[],['Betazole'],"[('PubChem', array(['11112911'], dtype=object)), ('Wikipedia', array(['Betazole'], dtype=object)), ('drugbank', array(['DB00272'], dtype=object)), ('chEBI', array(['59170'], dtype=object))]",['CHEMBL1200949' 'CHEMBL4303510'],,[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201697,,,Protein,False,LH (MENOTROPINS),1975.0,4.0,,False,True,[],['Human lh' 'Lh (menotropins)'],,,"{'rows': array(['EFO_0000545'], dtype=object), 'count': 1}",[ENSG00000138039],Protein drug with a maximum clinical trial phase of IV that was first approved in 1975 and has 1 investigational indication.
CHEMBL1256175,CC(=O)O.CNC(=N)NCCC[C@H](N)C(=O)O,IKPNWIGTWUZCKM-JEDNCBNOSA-N,Small molecule,False,TILARGININE ACETATE,,3.0,CHEMBL256147,False,False,[],"['ANO-1020' 'L-nmma acetate' 'Ng-methyl-l-arginine acetate salt'
 'Ng-methylarginine acetate' 'Ng-monomethyl-l-arginine acetate'
 'Targinine acetate' 'Tilarginine acetate']","[('PubChem', array(['144204797', '144207069', '144207127', '56463670'], dtype=object))]",,"{'rows': array(['HP_0031273'], dtype=object), 'count': 1}","[ENSG00000089250,ENSG00000007171,ENSG00000164867]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1308,Cc1cn[nH]c1,RIKMMFOAQPJVMX-UHFFFAOYSA-N,Small molecule,False,FOMEPIZOLE,1997.0,4.0,,False,True,['Antizol' 'Fomepizole'],['4-MP' '4-methylpyrazole' 'Fomepizole' 'NSC-760365'],"[('DailyMed', array(['fomepizole'], dtype=object)), ('PubChem', array(['11111426', '50111124', '90341211'], dtype=object)), ('Wikipedia', array(['Fomepizole'], dtype=object)), ('drugbank', array(['DB01213'], dtype=object)), ('chEBI', array(['5141'], dtype=object))]",['CHEMBL1256285'],"{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}","[ENSG00000187758,ENSG00000196616,ENSG00000248144]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and has 1 investigational indication.
CHEMBL1542,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2[nH]cnc12,LMEKQMALGUDUQG-UHFFFAOYSA-N,Small molecule,True,AZATHIOPRINE,1968.0,4.0,,False,True,"['Azamune' 'Azapress' 'Azasan' 'Azathioprine' 'Berkaprine' 'Immunoprin 50'
 'Imuran' 'Jayempi' 'Kentaprine' 'Oprisine 50']",['Azathioprine' 'Azathioprinum' 'BW-57-322' 'NSC-39084'],"[('Wikipedia', array(['Azathioprine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi'],
      dtype=object)), ('TG-GATEs', array(['46'], dtype=object)), ('PubChem', array(['104171105', '11110740', '11110741', '124879189', '144203625',
       '144213985', '170464989', '17390031', '174006316', '26670994',
       '26747870', '26747871', '26747872', '26752814', '50105466',
       '50105467', '50105468', '85230906', '90340846'], dtype=object)), ('DailyMed', array(['azathioprine'], dtype=object)), ('drugbank', array(['DB00993'], dtype=object)), ('chEBI', array(['2948'], dtype=object))]",['CHEMBL1200400' 'CHEMBL3785814' 'CHEMBL3785780'],"{'rows': array(['EFO_0000318', 'EFO_0005297', 'EFO_0003818', 'EFO_0003884',
       'EFO_0000729', 'EFO_0000222', 'MONDO_0007915', 'EFO_0005761',
       'EFO_0004826', 'EFO_0000384', 'HP_0001873', 'MONDO_0011382',
       'EFO_0000685', 'EFO_1001857', 'EFO_0004719', 'EFO_0000182',
       'EFO_0007208', 'EFO_0004274', 'EFO_0004244', 'EFO_0009448',
       'MONDO_0019249', 'EFO_0006803', 'EFO_0005676', 'EFO_0004256',
       'EFO_0007187', 'EFO_0003767', 'EFO_0000545', 'EFO_1000784',
       'EFO_0001423', 'EFO_0004991', 'EFO_1000749', 'HP_0000964',
       'EFO_0000768', 'EFO_0000540', 'EFO_0004194', 'EFO_0005531',
       'EFO_0000198', 'EFO_0000220'], dtype=object), 'count': 38}",[ENSG00000128059],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and is indicated for rheumatoid arthritis and immune system disease and has 36 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743080,,,Antibody,False,TIGATUZUMAB,,3.0,,False,False,[],['Anti-dr5 moab' 'Anti-trail-r2 moab' 'CS-1008' 'TRA-8' 'Tigatuzumab'],,,"{'rows': array(['MONDO_0004992', 'MONDO_0008170', 'EFO_0000574', 'EFO_0003060',
       'EFO_0004142', 'EFO_0002618', 'EFO_0000182'], dtype=object), 'count': 7}",[ENSG00000120889],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL175247,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,AHLBNYSZXLDEJQ-FWEHEUNISA-N,Small molecule,False,ORLISTAT,1999.0,4.0,,False,True,['Alli' 'Alli (previously orlistat gsk)' 'Beacita' 'Xenical'],"['Lipstatin' 'NSC-758881' 'Orlipastat' 'Orlistat' 'RO 18-0647/002'
 'RO-180647-002' 'RO-180647002' 'Tetrahydrolipstatin']","[('DailyMed', array(['orlistat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alli'],
      dtype=object)), ('PubChem', array(['26719846', '29217614', '49681644', '93576635'], dtype=object)), ('Wikipedia', array(['Orlistat'], dtype=object)), ('drugbank', array(['DB01083'], dtype=object))]",,"{'rows': array(['EFO_0000660', 'EFO_0000545', 'Orphanet_411', 'EFO_0000195',
       'EFO_0001073'], dtype=object), 'count': 5}","[ENSG00000175535,ENSG00000182333]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for obesity and has 4 investigational indications.
CHEMBL2108738,,,Antibody,False,NIVOLUMAB,2015.0,4.0,,False,True,['Opdivo'],['BMS-936558' 'BMS-986298' 'MDX-1106' 'MDX1106' 'Nivolumab' 'ONO-4538'],"[('DailyMed', array(['nivolumab'], dtype=object)), ('DrugCentral', array(['4923'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo'],
      dtype=object))]",,"{'rows': array(['MONDO_0001657', 'EFO_0005221', 'MONDO_0002691', 'EFO_0000588',
       'EFO_1001972', 'EFO_1001949', 'EFO_0000183', 'EFO_0009709',
       'EFO_0005537', 'EFO_0000691', 'EFO_0001642', 'EFO_0003968',
       'EFO_1000657', 'MONDO_0007187', 'MONDO_0002158', 'EFO_0004243',
       'EFO_0004197', 'MONDO_0021148', 'EFO_0000096', 'EFO_0000365',
       'EFO_0000565', 'EFO_0000403', 'EFO_0000519', 'EFO_0006859',
       'EFO_0003891', 'MONDO_0002108', 'MONDO_0008170', 'EFO_0000198',
       'EFO_0000621', 'EFO_0000211', 'EFO_0000637', 'EFO_0000180',
       'EFO_0000305', 'EFO_1001469', 'MONDO_0021117', 'EFO_0003047',
       'MONDO_0007254', 'EFO_0001061', 'EFO_1001931', 'MONDO_0002928',
       'EFO_1001465', 'MONDO_0100342', 'EFO_1000613', 'EFO_0002617',
       'HP_0100806', 'EFO_0004252', 'EFO_0004142', 'EFO_0000708',
       'MONDO_0016642', 'EFO_0000616', 'MONDO_0002547', 'EFO_0000681',
       'MONDO_0015760', 'EFO_0000294', 'MONDO_0008315', 'MONDO_0000521',
       'MONDO_0002367', 'EFO_1001051', 'EFO_0000632', 'EFO_1000601',
       'MONDO_0100096', 'EFO_0009259', 'MONDO_0017582', 'EFO_0000389',
       'EFO_0000339', 'EFO_0005543', 'MONDO_0004992', 'EFO_0000770',
       'MONDO_0001187', 'EFO_0000220', 'EFO_0000571', 'MONDO_0024503',
       'EFO_0007532', 'HP_0002745', 'EFO_0008524', 'EFO_0007466',
       'EFO_0007541', 'EFO_1000984', 'EFO_1001950', 'EFO_0001416',
       'MONDO_0007576', 'EFO_0003833', 'EFO_0000181', 'MONDO_0044704',
       'EFO_0003032', 'EFO_0001376', 'EFO_1000251', 'EFO_0000228',
       'MONDO_0002087', 'MONDO_0005184', 'EFO_0000196', 'MONDO_0018906',
       'EFO_0002892', 'EFO_0003085', 'EFO_0000181', 'EFO_0000174',
       'EFO_1001951', 'EFO_0000564', 'MONDO_0011719', 'EFO_1001512',
       'MONDO_0002038', 'EFO_0000707', 'EFO_0003050', 'MONDO_0001056',
       'EFO_0005922', 'EFO_0004239', 'EFO_0000756', 'EFO_0001075',
       'EFO_0000199', 'EFO_1001471', 'EFO_0002916', 'EFO_0000182',
       'EFO_1000359', 'MONDO_0008903', 'MONDO_0002898', 'EFO_0000503',
       'EFO_0000326', 'EFO_0002918', 'EFO_0000514', 'MONDO_0002120',
       'EFO_0000349', 'EFO_1001968', 'EFO_0001378', 'MONDO_0003060',
       'EFO_0005952', 'EFO_0000702', 'MONDO_0020634', 'EFO_0003016',
       'EFO_0008528', 'MONDO_0004669', 'EFO_0000558', 'MONDO_0004986',
       'EFO_0000574', 'EFO_0000640', 'EFO_1000796', 'EFO_1000209',
       'EFO_0004193', 'EFO_0004284', 'MONDO_0000870', 'EFO_0000095',
       'EFO_0000673', 'EFO_0008585', 'EFO_0007304', 'MONDO_0004180',
       'EFO_0000313', 'MONDO_0021063', 'EFO_1000785', 'MONDO_0044881',
       'EFO_0003060', 'EFO_0003863', 'MONDO_0008978', 'EFO_0000335',
       'EFO_0000222', 'EFO_0002618', 'EFO_1000026', 'MONDO_0002974',
       'MONDO_0009348'], dtype=object), 'count': 157}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 23 approved and 134 investigational indications.
CHEMBL266125,Cc1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1,YQYSVMKCMIUCHY-WJOKGBTCSA-N,Small molecule,False,IBODUTANT,,3.0,,False,False,[],['Ibodutant' 'Men15596'],"[('drugbank', array(['DB12042'], dtype=object))]",,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}",[ENSG00000075073],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL282724,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,PHWXUGHIIBDVKD-UHFFFAOYSA-N,Small molecule,False,SITAXENTAN,2006.0,4.0,,True,True,[],['IPI-1040' 'Sitaxentan' 'Sitaxsentan' 'TBC-11251'],"[('PubChem', array(['170465720'], dtype=object)), ('Wikipedia', array(['Sitaxentan'], dtype=object)), ('drugbank', array(['DB06268'], dtype=object))]",['CHEMBL2105740'],"{'rows': array(['MONDO_0005149', 'EFO_0000537', 'HP_0000093', 'EFO_1000899',
       'EFO_0001361', 'MONDO_0004979', 'EFO_0003884', 'MONDO_0005149'],
      dtype=object), 'count': 8}","[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for hypertension and pulmonary hypertension and has 6 investigational indications. It was withdrawn in at least one region.
CHEMBL297302,O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,FEBOTPHFXYHVPL-UHFFFAOYSA-N,Small molecule,False,BENPERIDOL,,4.0,,False,True,['Anquil' 'Benquil'],['Benperidol' 'MCN-JR-4584' 'NSC-170982' 'R-4584'],"[('PubChem', array(['11112508', '144204068', '170466409', '56463215'], dtype=object)), ('Wikipedia', array(['Benperidol'], dtype=object)), ('drugbank', array(['DB12867'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0005407'], dtype=object), 'count': 5}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications.
CHEMBL299400,O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,GMTYREVWZXJPLF-SXWPHCFWSA-N,Small molecule,True,BUTORPHANOL TARTRATE,1978.0,4.0,CHEMBL33986,False,True,"['Butorphanol tartrate' 'Butorphanol tartrate preservative free' 'Stadol'
 'Stadol ns' 'Stadol preservative free' 'Torbugesic' 'Torbutrol']","['Butorphanol tartrate' 'Butorphanol tartrate civ' 'Dolorex'
 'LEVO-BC-2627 TARTRATE' 'Torbugesic' 'Torbutrol']","[('DailyMed', array(['butorphanol%20tartrate'], dtype=object))]",,"{'rows': array(['EFO_0003890'], dtype=object), 'count': 1}","[ENSG00000112038,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978 and is indicated for drug dependence. This drug has a black box warning from the FDA.
CHEMBL3623290,COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C,MXDSJQHFFDGFDK-CYBMUJFWSA-N,Small molecule,False,AZD-3759,,2.0,,False,False,[],['AZD3759' 'Azd 3759' 'Azd-3759' 'Azd3759' 'Zorifertinib'],"[('drugbank', array(['DB14795'], dtype=object))]",,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989958,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1,WIJZXSAJMHAVGX-DHLKQENFSA-N,Small molecule,True,IVOSIDENIB,2018.0,4.0,,False,True,['Tibsovo'],['AG-120' 'Ivosidenib'],"[('DailyMed', array(['ivosidenib'], dtype=object)), ('drugbank', array(['DB14568'], dtype=object))]",,"{'rows': array(['MONDO_0005184', 'EFO_0000333', 'EFO_0000616', 'EFO_0000198',
       'EFO_0005221', 'EFO_0001421', 'EFO_0003891', 'EFO_0005543',
       'EFO_0000222', 'MONDO_0004992'], dtype=object), 'count': 10}",[ENSG00000138413],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4164059,Cl.Clc1ccc(CCCOCCCN2CCCCC2)cc1,XLFKECRRMPOAQS-UHFFFAOYSA-N,Small molecule,False,PITOLISANT HYDROCHLORIDE,2019.0,4.0,CHEMBL462605,False,True,['Ozawade' 'Wakix'],['Ciproxidine' 'Pitolisant hydrochloride'],"[('DailyMed', array(['pitolisant%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PITOLISANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005246', 'MONDO_0016158'], dtype=object), 'count': 2}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for hypersomnia and narcolepsy-cataplexy syndrome.
CHEMBL4297596,Cn1c(=O)oc2cc(-n3cc(C(=O)O)c(=O)n([C@@H]4CCc5c4cccc5C(F)(F)F)c3=O)ccc21,JDARDSVOVYVQST-MRXNPFEDSA-N,Small molecule,False,FULACIMSTAT,,2.0,,False,False,[],['BAY-1142524' 'BAY1142524' 'Bay1142524' 'Fulacimstat'],"[('drugbank', array(['DB15085'], dtype=object))]",,"{'rows': array(['EFO_0000612', 'EFO_0000401', 'EFO_0003144'], dtype=object), 'count': 3}",[ENSG00000092009],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL435,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,JZUFKLXOESDKRF-UHFFFAOYSA-N,Small molecule,False,HYDROCHLOROTHIAZIDE,1959.0,4.0,,False,True,"['Apo-hydro' 'Esidrex' 'Esidrix' 'Hydro-d' 'Hydrochlorothiazide'
 'Hydrochlorothiazide intensol' 'Hydrodiuril' 'Hydrosaluric' 'Microzide'
 'Oretic' 'Zide']","['Apresazide' 'Carozide' 'Chlorosulthiadil' 'Copalia-hct' 'Dafiro-hct'
 'Dihydrochlorurite' 'Exforge-hct' 'Hctz' 'Hidrotiazida'
 'Hydrochlorothiaizide' 'Hydrochlorothiazide' 'Hydrochlorothiazidum'
 'Idrotiazide' 'Imprida-hct' 'Lotensin hct' 'Megadiuril' 'NSC-53477'
 'Newtolide' 'Pantemon' 'Rasilez-hct' 'SU-5879' 'Servithiazid' 'Unipres'
 'Vetidrex']","[('DailyMed', array(['hydrochlorothiazide'], dtype=object)), ('PubChem', array(['103995', '11111269', '11111270', '144208763', '144210612',
       '170465005', '17389854', '26746944', '50103978', '85231074',
       '855646'], dtype=object)), ('Wikipedia', array(['Hydrochlorothiazide'], dtype=object)), ('drugbank', array(['DB00999'], dtype=object)), ('chEBI', array(['5778'], dtype=object))]",,"{'rows': array(['EFO_0001422', 'EFO_0003913', 'EFO_0000537', 'EFO_0000319',
       'EFO_0000400', 'Orphanet_79292', 'MONDO_0005148', 'EFO_0003884',
       'EFO_0000668', 'EFO_0004278', 'EFO_0009373', 'EFO_0001645',
       'EFO_0000612', 'HP_0003124', 'EFO_0004255', 'EFO_0003914',
       'EFO_0003144', 'EFO_0004253', 'EFO_0000195', 'MONDO_0001134',
       'EFO_1001496', 'EFO_0003086', 'EFO_0000668', 'EFO_0000373',
       'MONDO_0002462'], dtype=object), 'count': 25}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 12 approved and 13 investigational indications.
CHEMBL4650333,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC,JHJNPOSPVGRIAN-SFHVURJKSA-N,Small molecule,False,SERALUTINIB,,2.0,,False,False,[],['GB-002' 'GB002' 'Gb002' 'PK-10571' 'Seralutinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SERALUTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001361', 'MONDO_0005149'], dtype=object), 'count': 2}","[ENSG00000157404,ENSG00000182578,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4650472,,,Antibody,False,PUCOTENLIMAB,,3.0,,False,False,[],['HX-008' 'HX008' 'Hx 008' 'Hx008' 'Pucotenlimab'],,,"{'rows': array(['EFO_0000756', 'EFO_0000182', 'MONDO_0001056', 'EFO_0000616',
       'MONDO_0001187', 'MONDO_0002108', 'EFO_0003060'], dtype=object), 'count': 7}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL708,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,MVWVFYHBGMAFLY-UHFFFAOYSA-N,Small molecule,True,ZIPRASIDONE,2001.0,4.0,,False,True,[],['CP-88059' 'Geodon' 'Zipradon' 'Ziprasidone'],"[('PubChem', array(['144205747', '144207074', '170465342', '26719835'], dtype=object)), ('Wikipedia', array(['Ziprasidone'], dtype=object)), ('drugbank', array(['DB00246'], dtype=object)), ('chEBI', array(['10119'], dtype=object))]",['CHEMBL1712' 'CHEMBL1200997' 'CHEMBL3989833' 'CHEMBL1375743'],"{'rows': array(['EFO_1001917', 'EFO_0005411', 'MONDO_0005090', 'EFO_0005230',
       'EFO_0009963', 'MONDO_0004985', 'MONDO_0004985', 'MONDO_0005090',
       'HP_0012076', 'MONDO_0004985', 'EFO_0004247', 'EFO_0005306',
       'HP_0000713', 'EFO_1001141', 'HP_0000726', 'EFO_0003890',
       'EFO_0005407', 'MONDO_0002050', 'EFO_0004269', 'EFO_0003758',
       'EFO_0005611', 'EFO_0000319', 'MONDO_0005090', 'MONDO_0002009'],
      dtype=object), 'count': 24}","[ENSG00000147246,ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 8 approved and 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL93747,O=C1NC(=O)C(Cc2ccc3cc(OCc4ccccc4F)ccc3c2)S1,PKWDZWYVIHVNKS-UHFFFAOYSA-N,Small molecule,False,NETOGLITAZONE,,2.0,,False,False,[],['MCC 555' 'MCC555' 'Mcc-555' 'Netoglitazone' 'PGX-510' 'RWJ-241947'],"[('drugbank', array(['DB09199'], dtype=object))]",,,[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1200396,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,SIEYLFHKZGLBNX-UHFFFAOYSA-N,Small molecule,True,BUPIVACAINE HYDROCHLORIDE,1972.0,4.0,CHEMBL1098,False,True,"['Bupivac hcl' 'Bupivacaine hydrochloride' 'Bupivacaine hydrochloride kit'
 'Bupivacaine hydrochloride preservative free' 'Marcain' 'Marcaine'
 'Marcaine hydrochloride' 'Marcaine hydrochloride preservative free'
 'Sensorcaine' 'Xaracoll']","['AH-2250' 'Bupivacaine hcl' 'Bupivacaine hydrochloride'
 'Bupivacaine hydrochloride hydrate'
 'Bupivacaine hydrochloride monohydrate' 'Bupivacaine hydrochloride rs'
 'Bupivacaini hydrochloridum' 'Carbostesin' 'LAC-43' 'NSC-758631'
 'WIN 11,318' 'WIN-11318' 'Xaracoll']","[('DailyMed', array(['bupivacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['26748842', '56463371'], dtype=object)), ('chEBI', array(['31322'], dtype=object))]",,"{'rows': array(['HP_0031217', 'MONDO_0002087', 'EFO_0004616', 'MONDO_0005277',
       'MONDO_0007254', 'HP_0000023', 'MONDO_0041052', 'HP_0012532',
       'EFO_0009552', 'HP_0000175', 'EFO_1001087', 'EFO_0000546',
       'EFO_0003843', 'EFO_0000764', 'MONDO_0004992', 'MONDO_0002959',
       'HP_0001822'], dtype=object), 'count': 17}",[ENSG00000007314],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for pain and has 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200624,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C,ONKUMRGIYFNPJW-KIEAKMPYSA-N,Small molecule,False,ETHYNODIOL DIACETATE,1966.0,4.0,,False,True,['Femulen'],"['Ethynodiol diacetate' 'Etynodiol' 'Etynodiol acetate'
 'Etynodiol diacetate' 'NSC-759288' 'SC 11800' 'SC-11800']","[('DailyMed', array(['ethynodiol%20diacetate'], dtype=object)), ('PubChem', array(['144205886', '144206477', '170464933', '29217896'], dtype=object)), ('drugbank', array(['DB00823'], dtype=object)), ('chEBI', array(['31580'], dtype=object))]",,,[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1966.
CHEMBL1200675,CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,IWEQQRMGNVVKQW-OQKDUQJOSA-N,Small molecule,True,TOREMIFENE CITRATE,1996.0,4.0,CHEMBL1655,False,True,['Fareston'],['FC-1157A' 'NSC-613680' 'Toremifene citrate'],"[('DailyMed', array(['toremifene%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fareston'],
      dtype=object)), ('PubChem', array(['144205430', '144212057', '486747', '49681796', '50085986'],
      dtype=object))]",,"{'rows': array(['EFO_0003931', 'EFO_0003869', 'EFO_0000305', 'EFO_0003882',
       'MONDO_0007254'], dtype=object), 'count': 5}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200695,CC(N)C(O)c1ccccc1.Cl,DYWNLSQWJMTVGJ-UHFFFAOYSA-N,Small molecule,False,PHENYLPROPANOLAMINE HYDROCHLORIDE,1958.0,4.0,CHEMBL61006,True,True,"['Dexatrim' 'Dimotapp' 'Dimotapp l.a.' 'Eskornade' 'Procol' 'Propagest'
 'Sine-off' 'Triogesic' 'Triominic']","['NSC-23798' 'Norephedrine hydrochloride' 'Phenylpropanolamine chloride'
 'Phenylpropanolamine hcl' 'Phenylpropanolamine hydrochloride'
 'Propadrine hydrochloride']",,,,"[ENSG00000120907,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958. It was withdrawn in at least one region.
CHEMBL1200833,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1.Cl,VKFAUCPBMAGVRG-UHFFFAOYSA-N,Small molecule,False,DIPIVEFRIN HYDROCHLORIDE,1980.0,4.0,CHEMBL1201262,False,True,['Akpro' 'Dipivefrin hydrochloride' 'Propine'],['Dipivefrin hcl' 'Dipivefrin hydrochloride' 'Dipivefrine hydrochloride'],"[('PubChem', array(['144204226', '56463529'], dtype=object)), ('chEBI', array(['4647'], dtype=object))]",,,"[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980.
CHEMBL1201635,,,Protein,False,INSULIN SUSP ISOPHANE BEEF/PORK,1966.0,4.0,,False,True,['Nph iletin i (beef-pork)'],['Insulin susp isophane beef/pork'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1966.
CHEMBL1230609,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,CXQHYVUVSFXTMY-UHFFFAOYSA-N,Small molecule,False,FORETINIB,,2.0,,False,False,[],"['EXEL-2880' 'Foretinib' 'GSK-089' 'GSK-1363089' 'GSK-1363089G' 'GSK089'
 'GSK1363089G' 'Gsk-1363089' 'Gsk1363089' 'XL-880' 'XL880']","[('PubChem', array(['137275948'], dtype=object)), ('drugbank', array(['DB12307'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000182', 'EFO_0005950', 'MONDO_0008903',
       'EFO_0000616', 'EFO_0000681', 'MONDO_0004992'], dtype=object), 'count': 7}","[ENSG00000113721,ENSG00000134853,ENSG00000120156,ENSG00000122025,ENSG00000105976,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL1743052,,,Antibody drug conjugate,False,OPORTUZUMAB MONATOX,,3.0,,False,False,"['Proxinium' 'Proxinium, Vicinium' 'Vicineum' 'Vicinium']",['4D5MOCB-ETA' 'Oportuzumab monatox' 'VB4-845' 'XD60E5X7FI'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OPORTUZUMAB%20MONATOX/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000294', 'MONDO_0001187', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000119888],Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1769,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC.Cl,GITPCGSPKUQZTE-UHFFFAOYSA-N,Small molecule,False,PROPOXYCAINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1195,False,True,[],"['NSC-760044' 'Propoxycaine HCl' 'Propoxycaine hcl'
 'Propoxycaine hydrochloride']","[('PubChem', array(['144204013', '56463554'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1773,CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,GAGWJHPBXLXJQN-UORFTKCHSA-N,Small molecule,True,CAPECITABINE,1998.0,4.0,,False,True,['Capecitabine' 'Xeloda'],"['Capecitabine' 'Capecitabine accord' 'Capecitabine medac'
 'Capecitabine sun' 'Capecitabine teva' 'Capecitibine' 'Capecytabine'
 'Capiibine' 'Captabin' 'Ecansya' 'NSC-759853' 'RO 09-1978/000'
 'RO-09-1978000' 'RO-091978000' 'Xeloda']","[('DailyMed', array(['capecitabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda'],
      dtype=object)), ('PubChem', array(['144205751', '170464779'], dtype=object)), ('Wikipedia', array(['Capecitabine'], dtype=object)), ('drugbank', array(['DB01101'], dtype=object)), ('chEBI', array(['31348'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'EFO_0001075', 'EFO_0007456', 'EFO_0002938',
       'EFO_1001893', 'EFO_1001901', 'EFO_0005774', 'EFO_0000181',
       'EFO_0002617', 'EFO_0003897', 'MONDO_0005575', 'EFO_0005540',
       'EFO_0004252', 'EFO_0006352', 'EFO_0005922', 'MONDO_0002691',
       'MONDO_0002165', 'MONDO_0001056', 'MONDO_0002158', 'EFO_1001471',
       'EFO_0003860', 'MONDO_0001657', 'EFO_0003869', 'EFO_1001949',
       'EFO_1000158', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0005221',
       'EFO_0004288', 'MONDO_0005184', 'EFO_0006859', 'EFO_0005543',
       'MONDO_0002974', 'EFO_0000588', 'MONDO_0100342', 'EFO_1000251',
       'EFO_1000657', 'MONDO_0001879', 'MONDO_0002087', 'EFO_0003891',
       'EFO_0000681', 'MONDO_0002367', 'EFO_0009259', 'EFO_1000984',
       'EFO_0000178', 'EFO_0008528', 'EFO_0004142', 'EFO_0005537',
       'EFO_0003060', 'EFO_0002618', 'MONDO_0008315', 'EFO_1001956',
       'MONDO_0004992', 'EFO_0000616', 'MONDO_0002108', 'MONDO_0044926',
       'MONDO_0007576', 'EFO_1000294', 'EFO_0000228', 'EFO_0007416',
       'EFO_0000389', 'EFO_0000365', 'EFO_0000707', 'EFO_1000045',
       'EFO_0000305', 'MONDO_0021063', 'EFO_0000503', 'EFO_0000519',
       'EFO_0004284', 'EFO_0009708', 'MONDO_0005411', 'EFO_1001951',
       'EFO_1001961', 'MONDO_0003060', 'EFO_0005952', 'EFO_0002916',
       'EFO_0000313', 'EFO_0006861', 'EFO_0000756', 'MONDO_0008170',
       'EFO_0003865', 'MONDO_0002898', 'MONDO_0002120', 'MONDO_0044937'],
      dtype=object), 'count': 84}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 16 approved and 68 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108429,,,Antibody,False,MEPOLIZUMAB,2015.0,4.0,,False,True,['Bosatria' 'Nucala'],['Mepolizumab' 'SB-240563'],"[('DailyMed', array(['mepolizumab'], dtype=object)), ('DrugCentral', array(['5061'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nucala'],
      dtype=object))]",,"{'rows': array(['EFO_0004232', 'EFO_0005297', 'EFO_0005531', 'EFO_0000341',
       'MONDO_0004979', 'EFO_0007208', 'EFO_0000274', 'EFO_1000024',
       'HP_0001880', 'HP_0006536', 'EFO_1001467', 'EFO_0006803',
       'EFO_1000391'], dtype=object), 'count': 13}",[ENSG00000113525],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 8 investigational indications.
CHEMBL2109356,,,Antibody,False,BIIB-022,,1.0,,False,False,[],['BIIB-022' 'Biib 022' 'Biib-022'],,,"{'rows': array(['EFO_0000616', 'EFO_0003060', 'EFO_0000182'], dtype=object), 'count': 3}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL215645,CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1.O=C(O)C(O)C(O)C(=O)O,GWHQHAUAXRMMOT-MERQFXBCSA-N,Small molecule,False,RIVASTIGMINE TARTRATE,1998.0,4.0,CHEMBL636,False,True,['Exelon' 'Rivastigmine tartrate'],"['ENA 713' 'Rivastigmine Tartrate' 'Rivastigmine actavis'
 'Rivastigmine bitartrate' 'Rivastigmine hydrogen tartrate'
 'Rivastigmine hydrogentartrate' 'Rivastigmine tartrate' 'Sdz-ena 713']","[('DailyMed', array(['rivastigmine%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/exelon'],
      dtype=object))]",,"{'rows': array(['HP_0000726', 'MONDO_0005180', 'EFO_0005252'], dtype=object), 'count': 3}","[ENSG00000114200,ENSG00000087085]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for dementia and parkinson disease and has 1 investigational indication.
CHEMBL3039556,,,Oligonucleotide,False,APATORSEN,,2.0,,False,False,[],['Apatorsen' 'OGX-427'],,,"{'rows': array(['EFO_0000708', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0002618',
       'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 6}",[ENSG00000106211],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3301580,,,Antibody,False,FLETIKUMAB,,2.0,,False,False,[],['Anti-IL-20' 'Fletikumab' 'NNC-0109-0012' 'NNC01 09-0012' 'NNC0109-0012'],,,"{'rows': array(['MP_0001845', 'EFO_0000685', 'EFO_0000676'], dtype=object), 'count': 3}",[ENSG00000162891],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL389621,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,JYGXADMDTFJGBT-VWUMJDOOSA-N,Small molecule,False,HYDROCORTISONE,1952.0,4.0,,False,True,"['Acetasol hc' 'Acticort' 'Aeroseb-hc' 'Ala-cort' 'Ala-scalp'
 'Alkindi sprinkle' 'Alphaderm' 'Anflam' 'Anucort-Hc' 'Anugesic hc'
 'Anusol hc' 'Anusol plus hc' 'Anusol soothing relief' 'Anusol-Hc'
 'Balneol-hc' 'Beta-hc' 'Calmurid hc' 'Canesten hc' 'Cetacort' 'Cipro hc'
 'Cobadex' 'Colocort' 'Corlan' 'Cort-dome' 'Cortef' 'Cortenem' 'Cortenema'
 'Cortril' 'Daktacort' 'Daktacort hydrocort' 'Derma care hydrocort'
 'Dermacort' 'Dermaspray demang' 'Dioderm' 'Dome-cort' 'Econacort'
 'Efcortelan p' 'Eldecort' 'Epicort' 'Eurax-hc' 'Eurax-hydrocort'
 'Evacort' 'Exe-cort' 'Flexicort' 'Germoloids hc' 'Glycort' 'Gregoderm'
 'H-cort' 'Hc #1' 'Hc #4' 'Hc (hydrocortisone)' 'Hi-cor' 'Hydro-rx'
 'Hydrocort in calamine oily' 'Hydrocort in cetomacrogol for a'
 'Hydrocort in wte soft paraf' 'Hydrocortisone'
 'Hydrocortisone in absorbase' 'Hydrocortone' 'Hydroderm' 'Hydroderm hc'
 'Hytone' 'Jungle for' 'Locoid' 'Medicort' 'Mildison lipocream'
 'Nogenic hc' 'Nutracort' 'Nybadex' 'Nystaform-hc' 'Otoseptil' 'Otosporin'
 'Penecort' 'Perinal' 'Plenadren' 'Proctocort' 'Proctocream hc'
 'Proctofoam hc' 'Proctosedyl' 'Quinocort' 'Sential hc' 'Stie-cort'
 'Synacort' 'Terra-cortril nystatin' 'Texacort' 'Timocort' 'Timodine'
 'Topisone' 'Tri-cicatrin' 'Uniroid' 'Uniroid hc' 'Xyloproct' 'Zenoxone']","['Cor-Oticin' 'Cortifoam' 'Cortisol' 'FLEXICORT' 'Hydrocortisone'
 'Micort-HC' 'NSC-10483' 'Neo-Cortef' 'Ophthocort' 'Terra-Cortril'
 'U-Cort']","[('DailyMed', array(['hydrocortisone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren'],
      dtype=object)), ('PubChem', array(['144204434', '144208013', '170464635', '26751519', '26751520',
       '29215010', '56422453', '75748', '85148352', '855803', '90341326'],
      dtype=object)), ('Wikipedia', array(['Cortisol'], dtype=object)), ('drugbank', array(['DB00741'], dtype=object)), ('chEBI', array(['17650'], dtype=object))]",,"{'rows': array(['EFO_0004251', 'EFO_1001222', 'MONDO_0019460', 'EFO_0000221',
       'MONDO_0100096', 'MONDO_0004979', 'MONDO_0000873', 'EFO_0005251',
       'EFO_0000574', 'MONDO_0022096', 'EFO_0003843', 'MONDO_0018479',
       'EFO_0000278', 'EFO_0000223', 'EFO_0003027', 'EFO_0003811',
       'EFO_0000673', 'EFO_0000094', 'EFO_0000565', 'EFO_0000274',
       'EFO_1000796', 'EFO_1001435', 'EFO_0000403', 'EFO_0000764',
       'MONDO_0015540', 'EFO_0007541', 'EFO_0009492', 'HP_0012076',
       'EFO_1000764', 'EFO_0001379', 'EFO_0001072', 'EFO_0003032',
       'EFO_0000546', 'MONDO_0000870', 'EFO_0000198', 'MONDO_0003937',
       'EFO_0000384', 'EFO_0009444', 'EFO_0000685', 'EFO_0000220',
       'HP_0000964', 'EFO_0005687', 'MONDO_0008728', 'EFO_1001779',
       'EFO_0000612', 'EFO_0000756', 'MONDO_0015129', 'EFO_0001378',
       'MONDO_0005178', 'MONDO_0005147', 'MONDO_0002471', 'EFO_0001073',
       'MONDO_0002406', 'EFO_0003768', 'EFO_0003025', 'MONDO_0007079',
       'HP_0001742', 'HP_0100806', 'EFO_0000544', 'EFO_0005752',
       'EFO_0000209', 'EFO_0005611', 'EFO_1000158', 'MP_0001845',
       'EFO_0007141', 'EFO_0000676', 'MONDO_0015128', 'HP_0000989',
       'EFO_0003106', 'EFO_0009560', 'EFO_0000701', 'EFO_0006834',
       'MONDO_0004992', 'MONDO_0019091', 'EFO_0009552', 'EFO_0000275',
       'EFO_0002609', 'EFO_0001422', 'EFO_0000218', 'EFO_1001494',
       'EFO_0003778', 'EFO_0009491', 'EFO_0004192', 'EFO_0005539',
       'EFO_1001818', 'EFO_0003144', 'EFO_0007359', 'MONDO_0008315',
       'EFO_0010702', 'EFO_1001908', 'EFO_0007328', 'EFO_1001347',
       'EFO_0002614', 'EFO_0000729', 'EFO_1000697', 'EFO_0003802',
       'EFO_0000222'], dtype=object), 'count': 97}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 35 approved and 62 investigational indications.
CHEMBL408194,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,RFTSSZJZXOSICM-GRSHGNNSSA-N,Small molecule,False,OBATOCLAX,,3.0,,False,False,[],['GX15-070' 'Obatoclax'],"[('drugbank', array(['DB12191'], dtype=object))]",['CHEMBL2107358'],"{'rows': array(['EFO_1001469', 'EFO_0000702', 'MONDO_0001023', 'EFO_0000702',
       'EFO_0000222', 'EFO_0000183', 'EFO_0000095', 'MONDO_0044903',
       'EFO_0000198', 'EFO_0001378', 'EFO_0001642', 'MONDO_0008903',
       'EFO_0002617', 'EFO_0000403', 'MONDO_0018906'], dtype=object), 'count': 15}","[ENSG00000143384,ENSG00000171552,ENSG00000258643,ENSG00000129473,ENSG00000140379,ENSG00000137875,ENSG00000171791]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.
CHEMBL4303214,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,BALLNEJQLSTPIO-UHFFFAOYSA-N,Small molecule,False,FRUQUINTINIB,2023.0,4.0,,False,True,['Fruzaqla'],['Fruquintinib' 'HMPL-013' 'HMPL013' 'Hmpl-013'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FRUQUINTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_1001968', 'EFO_0002618', 'EFO_1001951',
       'EFO_1000657', 'MONDO_0001056', 'EFO_0003897', 'MONDO_0007254',
       'MONDO_0011962', 'EFO_0001421', 'EFO_0003060', 'MONDO_0021063',
       'EFO_0000365', 'MONDO_0008903', 'EFO_0003086', 'EFO_0005922',
       'MONDO_0004992', 'EFO_0000681', 'EFO_0004142'], dtype=object), 'count': 19}","[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 16 investigational indications.
CHEMBL4650827,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C,FRVSRBKUQZKTOW-YOCNBXQISA-N,Small molecule,False,REVUMENIB,,2.0,,False,False,[],['Revumenib'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",['CHEMBL4650278'],"{'rows': array(['EFO_0000565', 'EFO_0000222', 'EFO_0000220', 'EFO_1001951',
       'EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 6}","[ENSG00000133895,ENSG00000118058]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL776,CC(C)NCC(O)c1cc(O)cc(O)c1,LMOINURANNBYCM-UHFFFAOYSA-N,Small molecule,False,METAPROTERENOL,1973.0,4.0,,True,True,[],['Metaproterenol' 'Orciprenaline'],"[('PubChem', array(['26748125', '90340962'], dtype=object)), ('Wikipedia', array(['Orciprenaline'], dtype=object)), ('drugbank', array(['DB00816'], dtype=object)), ('chEBI', array(['6792'], dtype=object))]",['CHEMBL1200812' 'CHEMBL1568057' 'CHEMBL2164775' 'CHEMBL1628446'],"{'rows': array(['HP_0006536', 'EFO_0003890', 'MONDO_0004979'], dtype=object), 'count': 3}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for airway obstruction and asthma and has 1 investigational indication.
CHEMBL1200343,CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,IYNMDWMQHSMDDE-MHXJNQAMSA-N,Small molecule,True,PERINDOPRIL ERBUMINE,1993.0,4.0,CHEMBL1581,False,True,['Aceon' 'Coversyl' 'Perindopril erbumine'],"['MCN-A-2833-109' 'NSC-758929' 'Perindopril erbumine'
 'Perindopril tert-butylamine' 'S-9490-3']","[('DailyMed', array(['perindopril%20erbumine'], dtype=object)), ('chEBI', array(['8025'], dtype=object))]",,"{'rows': array(['EFO_0000612', 'MONDO_0001134', 'EFO_0001645', 'EFO_0000537'],
      dtype=object), 'count': 4}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201162,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl,OSRUSFPMRGDLAG-QMGYSKNISA-N,Small molecule,False,DORZOLAMIDE HYDROCHLORIDE,1994.0,4.0,CHEMBL218490,False,True,['Cosopt Pf' 'Dorzolamide hydrochloride' 'Trusopt'],"['Dorzolamide (as hydrochloride)' 'Dorzolamide hcl'
 'Dorzolamide hydrochloride' 'MK-507']","[('DailyMed', array(['dorzolamide%20hydrochloride'], dtype=object)), ('PubChem', array(['170465119', '56463558'], dtype=object)), ('chEBI', array(['4703'], dtype=object))]",,"{'rows': array(['EFO_0004190', 'MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 3}",[ENSG00000104267],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved indications.
CHEMBL1201286,CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,GFRUPHOKLBPHTQ-UHFFFAOYSA-N,Small molecule,False,OXYPHENONIUM,1982.0,4.0,,False,True,[],['Oxyphenonium' 'Oxyphenonium cation' 'Oxyphenonium ion'],"[('drugbank', array(['DB00219'], dtype=object))]",['CHEMBL1200906'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease.
CHEMBL1230607,CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C,HUXYBQXJVXOMKX-UHFFFAOYSA-N,Small molecule,False,PHA-793887,,1.0,,False,False,[],['PHA-793887' 'Pha-793887'],"[('PubChem', array(['137276012'], dtype=object)), ('drugbank', array(['DB12686'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1237023,,,Antibody,False,DENOSUMAB,2010.0,4.0,,False,True,"['Prolia' 'Prolia, Ranmark Xgeva' 'Prolia, xgeva' 'Xgeva']","['AMG 162' 'AMG-162' 'Denosumab' 'Denosumab biosimilar (ql-1206)'
 'Denosumab biosimilar tk-006' 'QL-1206' 'QL1206' 'Ql1206' 'TK-006'
 'TK006']","[('DailyMed', array(['denosumab'], dtype=object)), ('DrugCentral', array(['4965'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/prolia'],
      dtype=object)), ('Wikipedia', array(['Denosumab'], dtype=object))]",,"{'rows': array(['EFO_0000305', 'MONDO_0000837', 'MONDO_0005271', 'EFO_0000400',
       'EFO_0007176', 'EFO_0000685', 'EFO_1000318', 'EFO_0000756',
       'MONDO_0002171', 'EFO_0009870', 'EFO_0000616', 'EFO_1000984',
       'EFO_1000786', 'EFO_0000681', 'EFO_0001378', 'MONDO_0005351',
       'EFO_0004248', 'EFO_0009708', 'MONDO_0002108', 'EFO_0003060',
       'EFO_0000637', 'EFO_0004274', 'MONDO_0008903', 'EFO_0003882',
       'EFO_0000389', 'EFO_0003854', 'EFO_0003931', 'MONDO_0007254',
       'MONDO_0019019', 'HP_0003072', 'EFO_0000384', 'MONDO_0000845',
       'EFO_1001951', 'EFO_0004260', 'EFO_0000313', 'EFO_0000266',
       'EFO_0003086', 'MONDO_0008315', 'EFO_0001075', 'EFO_0003869',
       'HP_0000938'], dtype=object), 'count': 41}",[ENSG00000120659],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 11 approved and 30 investigational indications.
CHEMBL1334033,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1.O=C(O)/C=C\C(=O)O,JDZOTSLZMQDFLG-BTJKTKAUSA-N,Small molecule,False,PERHEXILINE MALEATE,1974.0,4.0,CHEMBL75880,True,True,['Pexid' 'Pexsig'],['NSC-758409' 'Perhexiline maleate' 'Perhexilinum'],"[('PubChem', array(['144204948', '170466435', '26748746', '56422147', '855892'],
      dtype=object))]",,,"[ENSG00000205560,ENSG00000198793,ENSG00000157184]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974. It was withdrawn in at least one region.
CHEMBL1795071,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,JFMWPOCYMYGEDM-XFULWGLBSA-N,Small molecule,True,RUXOLITINIB PHOSPHATE,2011.0,4.0,CHEMBL1789941,False,True,['Jakafi' 'Jakavi' 'Opzelura'],"['INCB-018424 PHOSPHATE' 'INCB-018424 SALT' 'INCB-18424 PHOSPHATE'
 'INCB018424 PHOSPHATE' 'INCB018424 SALT' 'Opzelura'
 'Ruxolitinib (as phosphate)' 'Ruxolitinib monophosphate'
 'Ruxolitinib phosphate']","[('DailyMed', array(['ruxolitinib%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi'],
      dtype=object)), ('chEBI', array(['66917'], dtype=object))]",,"{'rows': array(['EFO_0001068', 'EFO_0000222', 'EFO_0004192', 'HP_0011974',
       'EFO_0004251', 'EFO_0002430', 'EFO_0000220', 'EFO_0000676',
       'EFO_0000095', 'MONDO_0013730', 'MONDO_0002158', 'EFO_0000466',
       'EFO_0005537', 'EFO_0000274', 'EFO_0002429'], dtype=object), 'count': 15}","[ENSG00000162434,ENSG00000096968]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1915540,CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1,ISBHYKVAFKTATD-SNVBAGLBSA-N,Small molecule,False,ADRIFORANT,,2.0,,False,False,[],"['Adriforant' 'NVP-ZPL389-NX' 'PF-03893787' 'PF-3893787' 'Pf-03893787'
 'ZPL-389' 'ZPL-389-NX' 'ZPL-3893787' 'ZPL389-NX']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ADRIFORANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15027'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'HP_0011123', 'EFO_0000274', 'EFO_0000676'],
      dtype=object), 'count': 4}",[ENSG00000134489],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2108375,,,Enzyme,False,DUTEPLASE,,2.0,,False,False,[],['Duteplase'],,,,[ENSG00000104368],Enzyme drug with a maximum clinical trial phase of II.
CHEMBL2109452,,,Antibody,False,MEDI-4212,,1.0,,False,False,[],['MEDI-4212' 'MEDI4212' 'Medi-4212'],,,"{'rows': array(['EFO_0005854', 'EFO_0000274'], dtype=object), 'count': 2}",[ENSG00000211891],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2109586,,,Antibody,False,AMG-780,,1.0,,False,False,[],['AMG-780' 'Amg 780' 'Amg-780'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000154188,ENSG00000091879]",Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL284348,Nc1ccncc1,NUKYPUAOHBNCPY-UHFFFAOYSA-N,Small molecule,False,DALFAMPRIDINE,2010.0,4.0,,False,True,['Ampyra' 'Ampyra Extended Release' 'Fampridine accord' 'Fampyra'],"['Dalfampridine' 'EL-970' 'Fampridine' 'Fampridine (4-aminopyridine)'
 'NSC-15041']","[('DailyMed', array(['dalfampridine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord'],
      dtype=object)), ('PubChem', array(['104171097', '11110683', '11113806', '124879040', '124879042',
       '136964060', '144203616', '144207991', '170466526', '26747141',
       '26751980', '26751983', '50104658', '8139900', '90341267'],
      dtype=object)), ('Wikipedia', array(['4-Aminopyridine'], dtype=object)), ('drugbank', array(['DB06637'], dtype=object)), ('chEBI', array(['34385'], dtype=object))]",,"{'rows': array(['EFO_1000632', 'HP_0000083', 'HP_0002140', 'MONDO_0005301',
       'EFO_0003918', 'EFO_0008522', 'EFO_0009602', 'EFO_0000712',
       'EFO_0003782', 'EFO_0007292', 'EFO_0009490', 'Orphanet_83419',
       'EFO_1001919', 'EFO_0004335', 'EFO_0007405', 'EFO_0003929',
       'HP_0001257'], dtype=object), 'count': 17}","[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for multiple sclerosis and has 16 investigational indications.
CHEMBL3137326,[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2,MKJIEFSOBYUXJB-LIJFRPJRSA-N,Small molecule,True,DEUTETRABENAZINE,2017.0,4.0,CHEMBL117785,False,True,['Austedo'],['Deutetrabenazine' 'Dutetrabenazine' 'SD-809'],"[('DailyMed', array(['deutetrabenazine'], dtype=object))]",,"{'rows': array(['EFO_1000632', 'MONDO_0007739', 'EFO_0004895', 'MONDO_0003441',
       'EFO_0004280', 'EFO_0004152'], dtype=object), 'count': 6}",[ENSG00000165646],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for huntington disease and chorea and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3244648,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1.[Na+].[Na+],DASQOOZCTWOQPA-GXKRWWSZSA-L,Small molecule,True,METHOTREXATE SODIUM,1953.0,4.0,CHEMBL34259,False,True,"['Abitrexate' 'Folex' 'Folex pfs' 'Methotrexate lpf'
 'Methotrexate preservative free' 'Methotrexate sodium'
 'Methotrexate sodium preservative free' 'Mexate' 'Mexate-aq'
 'Mexate-aq preserved' 'Trexall' 'Xatmep']","['ADX-2191 SODIUM' 'Disodium methotrexate' 'Methotrexate (as disodium)'
 'Methotrexate disodium' 'Methotrexate disodium salt'
 'Methotrexate sodium' 'Methotrexate sodium salt'
 'Methotrexate, sodium salt']","[('DailyMed', array(['methotrexate%20sodium'], dtype=object)), ('chEBI', array(['50679'], dtype=object))]",,"{'rows': array(['EFO_0005856', 'MONDO_0002041', 'EFO_0000676', 'EFO_0000220',
       'EFO_0000685', 'EFO_1001012', 'EFO_0002609', 'MONDO_0008903',
       'MONDO_0007254', 'EFO_0000232', 'EFO_0005952', 'EFO_0002893'],
      dtype=object), 'count': 12}",[ENSG00000228716],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 11 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL3544945,,,Small molecule,False,SAR-113945,,2.0,,False,False,[],['Sar-113945'],,,"{'rows': array(['MONDO_0005178', 'EFO_0004616'], dtype=object), 'count': 2}",[ENSG00000104365],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545176,,,Small molecule,False,DB959,,2.0,,False,False,[],['Db959' 'T3D-959'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000112033,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3813842,CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,LGWACEZVCMBSKW-UHFFFAOYSA-N,Small molecule,False,PAXALISIB,,2.0,,False,False,[],['G-02441729' 'G02441729' 'GDC-0084' 'GDC0084' 'Paxalisib' 'Rg-7666'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PAXALISIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15186'], dtype=object))]",,"{'rows': array(['EFO_0000519', 'EFO_1000158', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL416146,Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,MNJVRJDLRVPLFE-UHFFFAOYSA-N,Small molecule,False,ETORICOXIB,2002.0,4.0,,False,True,['Arcoxia'],['Etoricoxib' 'L-791456' 'MK-0663'],"[('PubChem', array(['144205759', '170465621', '26758000'], dtype=object)), ('Wikipedia', array(['Etoricoxib'], dtype=object)), ('drugbank', array(['DB01628'], dtype=object)), ('chEBI', array(['6339'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'HP_0003419', 'EFO_0003820', 'EFO_0003898',
       'MONDO_0005178', 'EFO_0003843', 'MONDO_0008315', 'EFO_0000546',
       'EFO_0000685', 'EFO_0005755', 'MONDO_0018076', 'EFO_0010072',
       'EFO_0004616', 'EFO_0000764', 'HP_0100607'], dtype=object), 'count': 15}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for rheumatic disease and has 14 investigational indications.
CHEMBL429,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1,SGUAFYQXFOLMHL-UHFFFAOYSA-N,Small molecule,False,LABETALOL,1984.0,4.0,,False,True,[],"['AH-5158A FREE BASE' 'Ibidomide' 'Labetalol' 'Normodyne' 'Normozide'
 'SCH-15719W FREE BASE' 'Trandate']","[('PubChem', array(['90341718'], dtype=object)), ('TG-GATEs', array(['40'], dtype=object)), ('Wikipedia', array(['Labetalol'], dtype=object)), ('drugbank', array(['DB00598'], dtype=object)), ('chEBI', array(['6343'], dtype=object))]",['CHEMBL1200323'],"{'rows': array(['EFO_0000319', 'EFO_0003843', 'EFO_0000668', 'EFO_0005251',
       'EFO_0002610', 'EFO_0000537', 'EFO_0000537', 'EFO_0005669',
       'EFO_0000712', 'EFO_0007486', 'EFO_0000668', 'EFO_0003768'],
      dtype=object), 'count': 12}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and hypertension and has 10 investigational indications.
CHEMBL4297423,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCCN1CCN(C)CC1)c1nnc(C)n1-2,PKQXLRYFPSZKDU-QFIPXVFZSA-N,Small molecule,False,RO-6870810,,1.0,,False,False,[],"['(S)-JQ35' 'BET INHIBITOR TEN-010' 'Bet inhibitor ro6870810'
 'Jq-35, (s)-' 'RO6870810' 'Rg 6146' 'Ro-6870810' 'Ro6870810']","[('drugbank', array(['DB15151'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0000616', 'EFO_0000222', 'EFO_0000198'],
      dtype=object), 'count': 4}","[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL4298009,,,Antibody,False,IERAMILIMAB,,2.0,,False,False,[],"['Humanised imp-701' 'Ieramilimab' 'LAG-525' 'LAG525' 'Lag 525' 'Lag525'
 'NVP-LAG525']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IERAMILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0005537', 'EFO_0000616', 'EFO_0000756'],
      dtype=object), 'count': 4}",[ENSG00000089692],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4298198,,,Oligonucleotide,False,VUPANORSEN SODIUM,,1.0,,False,False,[],['AKCEA-ANGPTL3-LRx salt' 'ISIS 703802 salt' 'Vupanorsen sodium'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VUPANORSEN%20SODIUM/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0021187'], dtype=object), 'count': 1}","[ENSG00000141505,ENSG00000132855]",Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4594350,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,PEMUGDMSUDYLHU-ZEQRLZLVSA-N,Small molecule,False,ADAGRASIB,2022.0,4.0,,False,True,['Krazati'],"['Adagrasib' 'Kras g12c inhibitor mrtx849' 'Krazati' 'MRTX-849' 'MRTX849'
 'Mrtx-849' 'Mrtx849']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ADAGRASIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003060', 'EFO_1001951', 'MONDO_0008903',
       'EFO_0009709', 'MONDO_0021063', 'EFO_0002618'], dtype=object), 'count': 7}",[ENSG00000133703],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for neoplasm and non-small cell lung carcinoma and has 5 investigational indications.
CHEMBL462605,Clc1ccc(CCCOCCCN2CCCCC2)cc1,NNACHAUCXXVJSP-UHFFFAOYSA-N,Small molecule,False,PITOLISANT,2019.0,4.0,,False,True,"['Wakix' 'Wakix, europe']","['BF-2.649' 'BF-2649' 'BF2.649' 'Bf2.649' 'HBS-101' 'Pitolisant'
 'Tiprolisant']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PITOLISANT/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Pitolisant'], dtype=object)), ('drugbank', array(['DB11642'], dtype=object))]",['CHEMBL4164059'],"{'rows': array(['EFO_0003890', 'MONDO_0018044', 'MONDO_0008300', 'MONDO_0005090',
       'EFO_0003086', 'EFO_0005246', 'MONDO_0016158', 'MONDO_0016158',
       'MONDO_0021107', 'MONDO_0005180', 'MONDO_0007079'], dtype=object), 'count': 11}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for hypersomnia and narcolepsy-cataplexy syndrome and has 9 investigational indications.
CHEMBL545437,CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2.Cl,NQIZCDQCNYCVAS-RQBPZYBGSA-N,Small molecule,False,AMIBEGRON HYDROCHLORIDE,,3.0,CHEMBL1193948,False,False,[],"['Amibegron hcl' 'Amibegron hydrochloride' 'SR-58611A' 'SR58611A'
 'Sr-58611a']","[('Wikipedia', array(['Amibegron'], dtype=object))]",,,[ENSG00000188778],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL651,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,USSIQXCVUWKGNF-UHFFFAOYSA-N,Small molecule,True,METHADONE,1947.0,4.0,,False,True,[],"['Amidone' 'Diaminon' 'Dl-methadone' 'Dolophin' 'Dolophine' 'Heptadon'
 'Heptadone' 'IDS-NM-002' 'Metasedin' 'Methadone' 'Methadose' 'Phenadone'
 'Phy' 'Physeptone' 'Symoron' 'Westadone']","[('Wikipedia', array(['Methadone'], dtype=object)), ('drugbank', array(['DB00333'], dtype=object)), ('chEBI', array(['6807'], dtype=object))]",['CHEMBL1200825'],"{'rows': array(['EFO_0005611', 'MONDO_0041052', 'EFO_0003843', 'EFO_0003843',
       'EFO_0004240', 'EFO_0010702', 'EFO_0801084', 'EFO_0000764',
       'EFO_0003890', 'HP_0012532', 'EFO_0003917', 'HP_0008419',
       'EFO_0004273', 'EFO_0005611', 'EFO_0003047', 'EFO_0003884',
       'EFO_0005799', 'EFO_0000180', 'EFO_0003890', 'MONDO_0004992',
       'EFO_0000764', 'EFO_0004270', 'EFO_0005762', 'EFO_0002610',
       'EFO_0003100'], dtype=object), 'count': 25}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and has 3 approved and 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL92401,CC(C)NNC(=O)c1ccncc1,NYMGNSNKLVNMIA-UHFFFAOYSA-N,Small molecule,False,IPRONIAZID,,4.0,,False,True,['Marsilid'],['Iproniazid' 'Iproniazide'],"[('PubChem', array(['11111333', '11111334', '50111104', '90341605'], dtype=object)), ('TG-GATEs', array(['62'], dtype=object)), ('Wikipedia', array(['Iproniazid'], dtype=object)), ('drugbank', array(['DB04818'], dtype=object)), ('chEBI', array(['5958'], dtype=object))]",['CHEMBL1256361' 'CHEMBL1534878'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder.
CHEMBL977,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O,VWQWXZAWFPZJDA-CGVGKPPMSA-N,Small molecule,False,HYDROCORTISONE HEMISUCCINATE ANHYDROUS,1955.0,4.0,,False,True,[],"['Hydrocortisone Hemisuccinate' 'Hydrocortisone hemisuccinate anhydrous'
 'Hydrocortisone succinate' 'NSC-7576' 'Oristar hcshs']","[('PubChem', array(['56422426', '855704'], dtype=object)), ('drugbank', array(['DB14545'], dtype=object)), ('chEBI', array(['31677'], dtype=object))]",['CHEMBL3989663' 'CHEMBL1200495'],"{'rows': array(['EFO_0000403', 'EFO_0003032', 'EFO_0006834', 'EFO_0000565',
       'MONDO_0000870', 'EFO_0000220', 'EFO_0000309', 'MONDO_0004979'],
      dtype=object), 'count': 8}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for asthma and has 7 investigational indications.
CHEMBL1198855,CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F,FQJISUPNMFRIFZ-HXUWFJFHSA-N,Small molecule,False,RONACALERET,,2.0,,False,False,[],['Ronacaleret' 'Sb-751689'],"[('drugbank', array(['DB05255'], dtype=object))]",['CHEMBL1083998'],"{'rows': array(['EFO_0003931', 'EFO_0003882'], dtype=object), 'count': 2}",[ENSG00000036828],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1200,CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N,CMHHMUWAYWTMGS-UHFFFAOYSA-N,Small molecule,False,BENOXINATE,1982.0,4.0,,False,True,[],"['Benoxinate' 'Conjucain' 'Dorsacain' 'Monofree oxybuprocaine'
 'Oxybucaine' 'Oxybuprocaine']","[('PubChem', array(['11112575', '56320722'], dtype=object)), ('Wikipedia', array(['Oxybuprocaine'], dtype=object)), ('drugbank', array(['DB00892'], dtype=object)), ('chEBI', array(['309594'], dtype=object))]",['CHEMBL1200654'],"{'rows': array(['HP_0000989'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for pruritus.
CHEMBL1201002,CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2.Cl,FYBXRCFPOTXTJF-UHFFFAOYSA-N,Small molecule,False,CARTEOLOL HYDROCHLORIDE,1988.0,4.0,CHEMBL839,False,True,['Carteolol hydrochloride' 'Cartrol' 'Ocupress' 'Teoptic'],"['ABBOTT-43326' 'Carteolol hcl' 'Carteolol hydrochloride' 'NSC-300906'
 'OPC-1085']","[('DailyMed', array(['carteolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204205', '170465122', '56463040'], dtype=object)), ('chEBI', array(['3438'], dtype=object))]",,"{'rows': array(['EFO_0004190'], dtype=object), 'count': 1}","[ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and is indicated for open-angle glaucoma.
CHEMBL1201202,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,KANJSNBRCNMZMV-ABRZTLGGSA-N,Oligosaccharide,True,FONDAPARINUX,2001.0,4.0,,False,True,[],['Fondaparinux'],"[('Wikipedia', array(['Fondaparinux'], dtype=object)), ('drugbank', array(['DB00569'], dtype=object)), ('chEBI', array(['61033'], dtype=object))]",['CHEMBL1200644'],"{'rows': array(['HP_0001907', 'EFO_0000275', 'EFO_0003907', 'EFO_0000612',
       'EFO_0004286', 'EFO_0007541', 'EFO_0001074', 'EFO_0005672',
       'HP_0004419', 'HP_0004936', 'EFO_0004286', 'HP_0001873',
       'EFO_0003827', 'MONDO_0100096', 'HP_0000083', 'EFO_1000985',
       'EFO_0009686', 'HP_0001907', 'EFO_0001075', 'HP_0004936'],
      dtype=object), 'count': 20}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201821,,,Protein,False,PALIFERMIN,2005.0,4.0,,False,True,['Kepivance'],['Palifermin'],"[('DailyMed', array(['palifermin'], dtype=object)), ('DrugCentral', array(['4804'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kepivance'],
      dtype=object)), ('Wikipedia', array(['Palifermin'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0000574', 'MONDO_0004992', 'MONDO_0005301',
       'EFO_0000707', 'EFO_0000764', 'EFO_0004276', 'MONDO_0015760',
       'EFO_0005555', 'EFO_0006475', 'EFO_1001904', 'EFO_0000198',
       'EFO_0005952', 'EFO_0009688', 'EFO_0000222', 'MONDO_0013730',
       'EFO_1001898', 'MONDO_0044881', 'EFO_0000565', 'EFO_0000183',
       'EFO_0004599', 'EFO_1001451', 'MONDO_0021193', 'EFO_0001378',
       'EFO_0006859', 'EFO_1000690', 'MONDO_0004907', 'MONDO_0021063'],
      dtype=object), 'count': 28}",[ENSG00000066468],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 25 investigational indications.
CHEMBL1237119,CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,PAJMKGZZBBTTOY-ZFORQUDYSA-N,Small molecule,False,TREPROSTINIL,2002.0,4.0,,False,True,['Remodulin' 'Tyvaso' 'Tyvaso dpi'],"['15-AU-81' '15AU81' 'L-606' 'LRX -15' 'LRX-15' 'Rumodolin' 'Treprostinil'
 'UT-15' 'Uniprost']","[('DailyMed', array(['treprostinil'], dtype=object)), ('drugbank', array(['DB00374'], dtype=object)), ('chEBI', array(['50861'], dtype=object))]",['CHEMBL561157' 'CHEMBL2107815'],"{'rows': array(['MONDO_0005149', 'MONDO_0005149', 'MONDO_0005147', 'EFO_0000768',
       'EFO_0000717', 'EFO_0000341', 'MONDO_0001999', 'MONDO_0100130',
       'EFO_1001145', 'EFO_0000556', 'EFO_1001103', 'EFO_0003875',
       'EFO_0002687', 'EFO_0001361', 'EFO_0001361', 'EFO_0005207',
       'EFO_1001459', 'HP_0004419', 'EFO_0000717'], dtype=object), 'count': 19}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 3 approved and 15 investigational indications.
CHEMBL1409,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O,LFMYNZPAVPMEGP-PIDGMYBPSA-N,Small molecule,True,FLUVOXAMINE MALEATE,1994.0,4.0,CHEMBL814,False,True,"['Faverin 100' 'Faverin 50' 'Floxyfral' 'Fluvoxamine maleate' 'Luvox'
 'Luvox cr']","['DU-23000' 'DU23000' 'Faverin' 'Fevarin' 'Fluvoxamine hydrogenmaleate'
 'Fluvoxamine maleate' 'NSC-759602']","[('DailyMed', array(['fluvoxamine%20maleate'], dtype=object)), ('PubChem', array(['50106274', '50106275', '93576625'], dtype=object))]",,"{'rows': array(['EFO_0000694', 'EFO_0004262', 'MONDO_0100096', 'EFO_0004242'],
      dtype=object), 'count': 4}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for obsessive-compulsive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1476022,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,IIVBFTNIGYRNQY-YQLZSBIMSA-N,Small molecule,False,NOMEGESTROL ACETATE,,3.0,,False,False,[],"['Nomac' 'Nomegestrol acetate' 'ORG 10486-0' 'ORG-10486-0' 'TX 066'
 'TX-066' 'Zoely']","[('PubChem', array(['56463139'], dtype=object)), ('drugbank', array(['DB13981'], dtype=object))]",,"{'rows': array(['MONDO_0005301', 'EFO_0000660', 'HP_0100607'], dtype=object), 'count': 3}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1628227,CN(C)CCC=C1c2ccccc2COc2ccccc21,ODQWQRRAPPTVAG-UHFFFAOYSA-N,Small molecule,True,DOXEPIN,1969.0,4.0,,False,True,['Sinepin' 'Sinequan'],['Doxepin' 'P-3693A' 'Zonalon'],"[('PubChem', array(['174006603'], dtype=object)), ('TG-GATEs', array(['39'], dtype=object)), ('drugbank', array(['DB01142'], dtype=object)), ('chEBI', array(['4710'], dtype=object))]",['CHEMBL1628234'],"{'rows': array(['MONDO_0007079', 'EFO_0005230', 'EFO_0005531', 'EFO_0004698',
       'EFO_1001904', 'MONDO_0005090', 'MONDO_0004985', 'HP_0000989',
       'EFO_0008568', 'EFO_0003843', 'HP_0000726', 'MONDO_0002009',
       'MONDO_0002009', 'EFO_0000555', 'MONDO_0007254', 'MONDO_0002050',
       'EFO_0000274'], dtype=object), 'count': 17}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 7 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1921976,CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,OZPFIJIOIVJZMN-SFHVURJKSA-N,Small molecule,False,ORTERONEL,,3.0,,False,False,[],['Orteronel' 'TAK-700'],"[('Wikipedia', array(['Orteronel'], dtype=object)), ('drugbank', array(['DB12066'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000673'],
      dtype=object), 'count': 4}",[ENSG00000148795],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2107888,,,Antibody,False,TALIZUMAB,,2.0,,False,False,[],['C21/AL-90' 'HU-901' 'TNX-901' 'Talizumab'],,,,[ENSG00000211891],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108427,,,Protein,False,MENOTROPINS,1975.0,4.0,,False,True,['Humegon' 'Menopur' 'Merional' 'Normegon' 'Pergonal' 'Pergonal low lh'],"['FSH' 'Follotropin' 'HMG' 'Human follicle stimulating hormone'
 'Menotrophin' 'Menotropins']","[('DailyMed', array(['menotropins%20(fsh;lh)'], dtype=object))]",,"{'rows': array(['EFO_0002950', 'MONDO_0002146', 'EFO_0008560', 'EFO_0000279',
       'MONDO_0002259', 'MONDO_0018800', 'EFO_0000660', 'EFO_0000545'],
      dtype=object), 'count': 8}","[ENSG00000170820,ENSG00000138039]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 8 investigational indications.
CHEMBL211471,CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1.COS(=O)(=O)[O-],OSZNNLWOYWAHSS-UHFFFAOYSA-M,Small molecule,False,NEOSTIGMINE METHYLSULFATE,2013.0,4.0,CHEMBL278020,False,True,['Bloxiverz' 'Neostigmine methylsulfate' 'Robinul-neostig'],"['Intrastigmina' 'NSC-93753' 'Neostigmine methyl sulfate'
 'Neostigmine methylsulfate' 'Neostigmine methylsulphate'
 'Neostigmine metilsulfate' 'Neostigmini metilsulfas' 'Syntostigmin']","[('DailyMed', array(['neostigmine%20methylsulfate'], dtype=object)), ('PubChem', array(['56422780', '855838'], dtype=object)), ('chEBI', array(['7516'], dtype=object))]",,"{'rows': array(['EFO_0004991', 'HP_0025267'], dtype=object), 'count': 2}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for myasthenia gravis and has 1 investigational indication.
CHEMBL303960,COCc1cccc(C[C@H](O)/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(=O)OC)c1,FBQUXLIJKPWCAO-AZIFJQEOSA-N,Small molecule,False,RIVENPROST,,2.0,,False,False,[],['(-)-ono-4819' 'ONO-4819' 'Rivenprost'],,,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}",[ENSG00000171522],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3187812,CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C,FXKFFTMLFPWYFH-RDGPPVDQSA-N,Small molecule,False,ILEPATRIL,,2.0,,False,False,[],['AVE-7688' 'AVE7688' 'Ave7688' 'Ilepatril'],"[('PubChem', array(['144210558'], dtype=object)), ('drugbank', array(['DB06604'], dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000196549,ENSG00000159640]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545038,,,Small molecule,False,S-237648,,2.0,,False,False,[],['S-237648'],,,,[ENSG00000164129],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545201,,,Small molecule,False,TA-5493,,1.0,,False,False,[],['Ta-5493'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989409,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](COP(=O)(O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O,XTAUIEMSNCLHEG-GGVFYUGVSA-N,Protein,False,FORIGERIMOD,,3.0,,False,False,['Lupuzor'],['Forigerimod' 'IPP 201101' 'IPP-201101' 'IPP201101' 'Rigerimod'],,['CHEMBL3989801'],"{'rows': array(['MONDO_0007915', 'MONDO_0007915'], dtype=object), 'count': 2}",[ENSG00000109971],Protein drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication.
CHEMBL3989923,O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2],MPAZKXHCZWDZDY-FFNUKLMVSA-L,Small molecule,False,PITAVASTATIN MAGNESIUM,2017.0,4.0,CHEMBL1201753,False,True,['Zypitamag'],[],"[('DailyMed', array(['pitavastatin%20magnesium'], dtype=object))]",,"{'rows': array(['HP_0003119', 'MONDO_0021187', 'HP_0003124'], dtype=object), 'count': 3}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications.
CHEMBL3991927,COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1,OCKHRKSTDPOHEN-BQYQJAHWSA-N,Small molecule,False,HMN-214,,1.0,,False,False,[],['Hmn-214' 'IVX-214'],,,,[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4650336,COc1ccc([C@H]2c3[nH]c4ccc(Cl)cc4c3CCN2C(=O)Oc2ccc(Cl)cc2)cc1,SRSHBZRURUNOSM-DEOSSOPVSA-N,Small molecule,False,EMVODODSTAT,,2.0,,False,False,[],['Emvododstat' 'PTC299' 'Ptc-299' 'Ptc299'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EMVODODSTAT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004992', 'MONDO_0100096', 'MONDO_0007254', 'EFO_0000222',
       'MONDO_0007039'], dtype=object), 'count': 5}",[ENSG00000102967],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4650342,CCCN1C[C@H](CSCC(=O)NCCCC[C@@H](NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(CCC)C2)C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c[nH]c4ccccc34)NC(=O)[C@H](Cc3ccc(O)cc3)NC2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,WLBJBODHTIKYSL-JFPOTJHNSA-N,Unknown,False,ONZIGOLIDE,,2.0,,False,False,[],['BIM-23A760' 'Dopastatin' 'Onzigolide' 'TBR-760' 'Tbr-760'],,,"{'rows': array(['EFO_1000478'], dtype=object), 'count': 1}","[ENSG00000149295,ENSG00000180616,ENSG00000162009]",Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650476,,,Oligonucleotide,False,COFIRASERSEN,,2.0,,False,False,[],['Cofirasersen' 'ION-827359' 'IONIS-ENACRX' 'Ion-827359' 'Ionis-enacrx'],,,"{'rows': array(['EFO_0006505', 'MONDO_0009061'], dtype=object), 'count': 2}","[ENSG00000166828,ENSG00000111319,ENSG00000168447]",Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5303393,O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1,TWYFGYXQSYOKLK-UFIFRZAQSA-N,Small molecule,False,VARENICLINE TARTRATE,2006.0,4.0,CHEMBL1076903,False,True,['Champix' 'Chantix' 'Tyrvaya'],"['CP-526,555-18' 'CP-526555-18' 'Tyrvaya' 'Varenicline tartrate']","[('DailyMed', array(['varenicline%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/champix'],
      dtype=object))]",,"{'rows': array(['EFO_0004319', 'EFO_0003768', 'EFO_1000906', 'MONDO_0007079'],
      dtype=object), 'count': 4}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 investigational indications.
CHEMBL5314385,CCc1ccc(CSc2ccc(NS(=O)(=O)c3ccc(C)c(C(=O)O)c3)cc2)cc1,VRAPCAZHERPDQO-UHFFFAOYSA-N,Small molecule,False,CP-778875,,2.0,,False,False,[],"['CP-778,875' 'CP-778875' 'Cp-778875']",,,"{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL778,Cc1cccc([C@H](C)c2c[nH]cn2)c1C,CUHVIMMYOGQXCV-NSHDSACASA-N,Small molecule,False,DEXMEDETOMIDINE,1999.0,4.0,,False,True,[],"['Dexmedetomidine' 'MPV-1440' 'Medetomidine, (s)-']","[('PubChem', array(['11114268'], dtype=object)), ('Wikipedia', array(['Dexmedetomidine'], dtype=object)), ('drugbank', array(['DB00633'], dtype=object)), ('chEBI', array(['4466'], dtype=object))]",['CHEMBL2106195'],"{'rows': array(['EFO_0003843', 'EFO_0003918', 'EFO_0002460', 'EFO_1002048',
       'MONDO_0007172', 'MONDO_0005129', 'HP_0030834', 'EFO_0006834',
       'EFO_0005774', 'EFO_0004698', 'EFO_0003777', 'EFO_0009516',
       'EFO_0001074', 'EFO_0005279', 'MONDO_0004976', 'EFO_0005251',
       'HP_0000713', 'MP_0001845', 'EFO_0003957', 'EFO_0001645',
       'EFO_0000275', 'EFO_0001073', 'EFO_0003843', 'EFO_0004888',
       'EFO_1000391', 'MONDO_0007254', 'HP_0012532', 'EFO_0000668',
       'MONDO_0005090', 'EFO_0005207', 'MONDO_0001056', 'HP_0012735',
       'HP_0001919', 'EFO_0005762', 'EFO_0005323', 'HP_0002093',
       'EFO_0003833', 'EFO_0005411', 'EFO_0002950', 'EFO_0000474',
       'EFO_0005230', 'EFO_0009267', 'EFO_0000239', 'EFO_0002610',
       'MONDO_0002258', 'EFO_0000546', 'MONDO_0005149', 'MONDO_0003544',
       'EFO_0004273', 'EFO_1001210', 'HP_0000713', 'HP_0100543',
       'MONDO_0004975', 'EFO_0000537', 'EFO_0009267', 'EFO_0000677',
       'EFO_0009620', 'EFO_0009686', 'MONDO_0005299', 'MONDO_0043510',
       'MONDO_0004992', 'HP_0000175', 'EFO_0005611', 'EFO_0003756',
       'EFO_0010282', 'EFO_0003931', 'EFO_0000713', 'MONDO_0043510',
       'EFO_1001884', 'EFO_0004264', 'EFO_1001454', 'HP_0001337',
       'HP_0002315', 'HP_0000023'], dtype=object), 'count': 74}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 73 investigational indications.
CHEMBL1186579,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,JVLBPIPGETUEET-GAAHOAFPSA-O,Small molecule,False,METHYLNALTREXONE,2008.0,4.0,,False,True,[],"['MRZ-2663' 'Methylnaltrexone' 'Methylnaltrexone cation'
 'Methylnaltrexone ion']","[('Wikipedia', array(['Methylnaltrexone'], dtype=object))]",['CHEMBL470617' 'CHEMBL1201770'],"{'rows': array(['EFO_0002618', 'MONDO_0004565', 'EFO_1000948', 'EFO_0003086',
       'HP_0002019', 'EFO_0005611', 'EFO_0005611', 'HP_0001410',
       'MONDO_0004567', 'HP_0033454', 'EFO_1000652', 'MONDO_0004567',
       'HP_0002019'], dtype=object), 'count': 13}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and opioid dependence and has 10 investigational indications.
CHEMBL1231124,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1,PDOQBOJDRPLBQU-QMMMGPOBSA-N,Small molecule,False,AZD-1480,,2.0,,False,False,[],['AZD-1480' 'AZD1480' 'Azd 1480' 'Azd-1480'],"[('drugbank', array(['DB12588'], dtype=object))]",,"{'rows': array(['MONDO_0001056', 'EFO_0000479', 'EFO_0003060', 'EFO_0002430',
       'MONDO_0004992', 'EFO_0000182'], dtype=object), 'count': 6}",[ENSG00000096968],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL2103831,COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1,AKFJWRDCWYYTIG-ZDUSSCGKSA-N,Small molecule,False,NAPROXCINOD,,3.0,,False,False,[],"['AR-P900758XX' 'AZD-3582' 'AZD3582' 'HCT 3012' 'HCT-3012' 'HCT3012'
 'Naproxcinod' 'Naproxen-n-butyl nitrate' 'Nitronaproxen']","[('drugbank', array(['DB06682'], dtype=object)), ('chEBI', array(['76254'], dtype=object))]",,"{'rows': array(['MONDO_0005178', 'EFO_1002048', 'EFO_1000786', 'EFO_0001421',
       'EFO_0005755'], dtype=object), 'count': 5}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2103882,O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12,UCEQXRCJXIVODC-PMACEKPBSA-N,Small molecule,False,TIVANTINIB,,3.0,,False,False,[],['ARQ 197' 'ARQ-197' 'Arq-197' 'Tivantinib'],"[('drugbank', array(['DB12200'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0005537', 'EFO_0000182', 'MONDO_0004992',
       'EFO_0000770', 'EFO_0000514', 'MONDO_0002691', 'EFO_0000616',
       'EFO_0003860', 'EFO_0000702', 'MONDO_0007576', 'EFO_0000640',
       'EFO_0000673', 'MONDO_0001056', 'EFO_0001378', 'EFO_0000181'],
      dtype=object), 'count': 16}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications.
CHEMBL2107339,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O,RPUBHMMISKEXSR-MLCLTIQSSA-N,Small molecule,False,ESMIRTAZAPINE MALEATE,,3.0,CHEMBL1366933,False,False,[],"['Esmirtazapine maleate' 'Mirtazapine maleate, (s)-' 'ORG 50081'
 'ORG-50081' 'Org-50081']",,,"{'rows': array(['EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 2}","[ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000196639,ENSG00000147246,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2107777,CCOc1ccc2c(c1)[C@]1(CC[C@H](CCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC,CDSBFDCCJJDFCV-CKZSCMLPSA-N,Small molecule,False,SATAVAPTAN,,3.0,,False,False,['Aquilda'],"['SR 121463' 'SR 121463A' 'SR 121463B' 'SR-121463' 'SR-121463A'
 'SR-121463B' 'SR121463B' 'SR121463F' 'Satavaptan'
 'Satavaptan monophosphate' 'Satavaptan phosphate' 'Sr121463']",,,"{'rows': array(['HP_0001541', 'HP_0002902', 'EFO_0001422', 'EFO_1000982'],
      dtype=object), 'count': 4}",[ENSG00000126895],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL274654,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,NHFDRBXTEDBWCZ-ZROIWOOFSA-N,Small molecule,False,ORANTINIB,,3.0,,False,False,[],['NSC-702827' 'Orantinib' 'SU-6668' 'Su-6668' 'TSU-68'],"[('PubChem', array(['527809'], dtype=object)), ('drugbank', array(['DB12072'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_1001951', 'EFO_0000182', 'MONDO_0008903',
       'MONDO_0008315', 'EFO_0000616', 'EFO_0002618', 'MONDO_0007254',
       'MONDO_0001056', 'MONDO_0002367'], dtype=object), 'count': 10}","[ENSG00000113721,ENSG00000134853,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL3813873,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,JGWRKYUXBBNENE-UHFFFAOYSA-N,Small molecule,True,PEXIDARTINIB,2019.0,4.0,,False,True,[],['CML-261' 'PLX-3397' 'PLX3397' 'Pexidartinib' 'Plx-3397'],"[('drugbank', array(['DB12978'], dtype=object))]",['CHEMBL3989973'],"{'rows': array(['EFO_0000183', 'MONDO_0008315', 'MONDO_0011719', 'EFO_0000519',
       'EFO_0001421', 'EFO_0000222', 'MONDO_0002171', 'EFO_1000562',
       'EFO_0002617', 'EFO_1001106', 'EFO_0003968', 'EFO_0000685',
       'EFO_0000760', 'EFO_0000756', 'EFO_0000616', 'EFO_0005537',
       'EFO_0000673', 'MONDO_0007254'], dtype=object), 'count': 18}","[ENSG00000182578,ENSG00000157404,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for tenosynovial giant cell tumor and neoplasm and has 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3989496,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1.O,XPYQFIISZQCINN-QVXDJYSKSA-N,Small molecule,False,TEZACITABINE,,2.0,CHEMBL2105467,False,False,[],"['Anhydrous' 'FMDC' 'MDL 101,731' 'Tezacitabine'
 'Tezacitabine monohydrate']",,,,"[ENSG00000167325,ENSG00000048392,ENSG00000171848]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3989794,CCOC(=O)[C@H](CCCc1ccccc1)C1(C(=O)N[C@H]2CCc3ccccc3N(CC(=O)O)C2=O)CCCC1,FVWPYVZWVOLAOP-DQEYMECFSA-N,Small molecule,False,DAGLUTRIL,,2.0,,False,False,[],['Daglutril' 'SLV-306' 'SLV306'],,,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000117298,ENSG00000196549]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989819,CCCn1c(=O)c2nc([C@H]3C[C@H]4C[C@@H]3[C@@H]3O[C@H]43)[nH]c2n(CCC)c1=O,OQCJPFYWFGUHIN-GJKBLCTNSA-N,Small molecule,False,NAXIFYLLINE,,2.0,,False,False,[],['BG-9719' 'BG9719' 'CVT-124' 'Naxifylline'],,,,[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL404849,CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1,BFCDFTHTSVTWOG-UHFFFAOYSA-N,Small molecule,False,SULOCTIDIL,1979.0,4.0,,True,True,[],"['Bemperil' 'CP-556S' 'Cerebro' 'Circleton' 'Dulasi' 'Duloctil' 'Euvasal'
 'Fluversin' 'Fluvisco' 'Hemoantin' 'Iangene' 'Loctidon' 'Locton'
 'MJF 12637' 'MJF-12637' 'Octamet' 'Polivasal' 'Sudil' 'Suloctidil'
 'Sulocton' 'Sulodene']","[('PubChem', array(['104171389', '144204409', '170466521', '26748521'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for cardiovascular disease. It was withdrawn in at least one region.
CHEMBL4594301,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21.O=S(=O)(O)c1ccccc1,QMTKNJZIWGTNTE-LMOVPXPDSA-N,Small molecule,True,REMIMAZOLAM BESYLATE,2020.0,4.0,CHEMBL4297526,False,True,['Byfavo'],"['BIPRAZINE PF' 'CNS 7056 besylate' 'CNS 7056B' 'CNS-7056 BESYLATE'
 'CNS-7056B' 'GW-502056X' 'GW502056X' 'ONO-2745BS' 'ONO-IN-251' 'RF-10007'
 'RF10007' 'Remimazolam besilate' 'Remimazolam besylate' 'SP148.5']","[('DailyMed', array(['remimazolam%20besylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/byfavo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/REMIMAZOLAM%20BESYLATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0009868', 'EFO_0003843'], dtype=object), 'count': 2}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sedation and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL479527,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC,CMSGWTNRGKRWGS-NQIIRXRSSA-N,Small molecule,False,TORCETRAPIB,,3.0,,False,False,[],"['CP-529,414' 'CP-529414' 'Torcetrapib']","[('Wikipedia', array(['Torcetrapib'], dtype=object)), ('drugbank', array(['DB06281'], dtype=object)), ('chEBI', array(['49203'], dtype=object))]",,"{'rows': array(['MONDO_0021187', 'MONDO_0018473', 'EFO_0001645', 'HP_0003124',
       'Orphanet_413', 'EFO_0004211', 'Orphanet_79211', 'EFO_0004911',
       'Orphanet_309005'], dtype=object), 'count': 9}",[ENSG00000087237],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL5314377,CC(=O)O.CC(=O)O.CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,OVBICQMTCPFEBS-SATRDZAXSA-N,Protein,False,GANIRELIX ACETATE,1999.0,4.0,CHEMBL1251,False,True,['Ganirelix acetate' 'Orgalutran'],['Ganirelix' 'Ganirelix acetate' 'Ganirest' 'RS-26306' 'RS-26306-298'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ganirelix-gedeon-richter'],
      dtype=object))]",,"{'rows': array(['EFO_1000859', 'EFO_0000660', 'EFO_1000645', 'EFO_0000545'],
      dtype=object), 'count': 4}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 investigational indications.
CHEMBL53292,Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1,YYUAYBYLJSNDCX-UHFFFAOYSA-N,Small molecule,False,ISOXICAM,,4.0,,True,True,[],['Isoxicam' 'NSC-758436' 'W 8495' 'W-8495'],"[('PubChem', array(['11112741', '144204185', '170466334', '26747065', '855966'],
      dtype=object)), ('drugbank', array(['DB08942'], dtype=object)), ('chEBI', array(['76163'], dtype=object))]",,,"[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1025,CC(C)OP(=O)(F)OC(C)C,MUCZHBLJLSDCSD-UHFFFAOYSA-N,Small molecule,False,ISOFLUROPHATE,1957.0,4.0,,False,True,['Floropryl'],['Dyflos' 'Fluostigmine' 'Isoflurophate' 'NSC-727370'],"[('PubChem', array(['144206196', '50113285'], dtype=object)), ('Wikipedia', array(['Diisopropyl_fluorophosphate'], dtype=object)), ('drugbank', array(['DB00677'], dtype=object)), ('chEBI', array(['17941'], dtype=object))]",,"{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for glaucoma.
CHEMBL1174,N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O,CZKPOZZJODAYPZ-LROMGURASA-N,Protein,False,EPTIFIBATIDE,1998.0,4.0,,False,True,['Eptifibatide' 'Eptifibatide accord' 'Integrilin'],['Eptifibatide' 'Integrelin'],"[('DailyMed', array(['eptifibatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord'],
      dtype=object)), ('PubChem', array(['144206056', '170465043'], dtype=object)), ('Wikipedia', array(['Eptifibatide'], dtype=object)), ('chEBI', array(['291902'], dtype=object))]",['CHEMBL4068311'],"{'rows': array(['MONDO_0011382', 'EFO_0000612', 'EFO_0000319', 'EFO_0001645',
       'EFO_0000712', 'HP_0002140', 'EFO_0005672', 'EFO_0008583',
       'EFO_0006834', 'EFO_0003106', 'HP_0004419', 'EFO_0008585',
       'EFO_0004277'], dtype=object), 'count': 13}","[ENSG00000259207,ENSG00000005961]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 9 investigational indications.
CHEMBL1201515,,,Protein,False,PEGVISOMANT,2002.0,4.0,,False,True,['Somavert'],['B-2036-PEG' 'B2036-PEG' 'Pegvisomant' 'Pegwisomant' 'Somavent' 'Trovert'],"[('DailyMed', array(['pegvisomant'], dtype=object)), ('DrugCentral', array(['5015'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/somavert'],
      dtype=object)), ('Wikipedia', array(['Pegvisomant'], dtype=object))]",,"{'rows': array(['EFO_0000691', 'EFO_0003869', 'MONDO_0018919', 'MONDO_0021117',
       'EFO_1001485', 'EFO_0009607', 'EFO_0000673', 'EFO_0004142',
       'MONDO_0008274'], dtype=object), 'count': 9}",[ENSG00000112964],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for acromegaly and has 8 investigational indications.
CHEMBL1201735,Br.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,WSTCENNATOVXKQ-UHFFFAOYSA-N,Small molecule,True,BUPROPION HYDROBROMIDE,2008.0,4.0,CHEMBL894,False,True,['Aplenzin'],['BVF-033' 'Bupropion hbr' 'Bupropion hydrobromide'],"[('DailyMed', array(['bupropion%20hydrobromide'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and is indicated for major depressive disorder. This drug has a black box warning from the FDA.
CHEMBL1215923,O=C(O)Cc1cccc(-c2cc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(-c4cccc(CC(=O)O)c4)c3)ccc2O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c1,RYWCQJDEHXJHRI-XJMXIVSISA-N,Small molecule,False,BIMOSIAMOSE,,2.0,,False,False,[],['Bimosiamose' 'TBC-1269'],"[('PubChem', array(['124894548', '144206811'], dtype=object)), ('drugbank', array(['DB06197'], dtype=object))]",['CHEMBL2146099'],"{'rows': array(['EFO_0000341', 'EFO_0000676'], dtype=object), 'count': 2}","[ENSG00000188404,ENSG00000007908,ENSG00000174175]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1278146,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,GKEYKDOLBLYGRB-LGMDPLHJSA-N,Small molecule,False,FAMITINIB,,3.0,,False,False,[],['Famitinib' 'SHR-1020' 'SHR1020' 'Shr-1020'],"[('drugbank', array(['DB11741'], dtype=object))]",,"{'rows': array(['MONDO_0024503', 'EFO_0003869', 'EFO_0003060', 'EFO_0000756',
       'EFO_0004252', 'EFO_0005537', 'EFO_0002618', 'EFO_0000681',
       'EFO_0001071', 'EFO_0005922', 'EFO_1001961', 'MONDO_0002974',
       'MONDO_0011719', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0000365'], dtype=object), 'count': 17}","[ENSG00000128052,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000037280,ENSG00000102755,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.
CHEMBL1387,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C,ICTXHFFSOAJUMG-SLHNCBLASA-N,Small molecule,False,NORETHYNODREL,1961.0,4.0,,False,True,[],['Enidrel' 'NSC-15432' 'Norethynodrel' 'Noretynodrel' 'SC-4642'],"[('PubChem', array(['11533052', '144203910'], dtype=object)), ('Wikipedia', array(['Norethynodrel'], dtype=object)), ('drugbank', array(['DB09371'], dtype=object)), ('chEBI', array(['34895'], dtype=object))]",,,[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.
CHEMBL166863,CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O,IJWPAFMIFNSIGD-UHFFFAOYSA-N,Small molecule,False,POLMACOXIB,,3.0,,False,False,[],['CG-100649' 'CG100649' 'Polmacoxib'],"[('drugbank', array(['DB12399'], dtype=object))]",,"{'rows': array(['EFO_1000786', 'MONDO_0005178', 'EFO_0005755', 'EFO_0004616'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000133742,ENSG00000104267]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL1672054,CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,XGGTZCKQRWXCHW-WMTVXVAQSA-N,Small molecule,False,CASOPITANT,,3.0,,False,False,['Rezonic' 'Zunrisa'],['Casopitant' 'GW-679769' 'GW679769' 'Gw679769'],"[('drugbank', array(['DB06634'], dtype=object))]",['CHEMBL3542382' 'CHEMBL2107320'],"{'rows': array(['HP_0002017', 'EFO_0006911', 'HP_0002018', 'HP_0002013',
       'EFO_0004888', 'MONDO_0002009', 'EFO_1000781', 'EFO_0008533',
       'EFO_0004698'], dtype=object), 'count': 9}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL1712842,CC(=O)O.CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1,COBIOCPXKOZHSU-UHFFFAOYSA-N,Small molecule,False,MEPAZINE ACETATE,,4.0,CHEMBL395110,True,True,[],['Mepazine acetate' 'NND 1964' 'Pecazine acetate'],"[('PubChem', array(['49645132'], dtype=object))]",,,[ENSG00000172175],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1743089,,,Antibody,False,VESENCUMAB,,2.0,,False,False,[],['MNRP-1685A' 'MNRP1685A' 'RG-7347' 'Vesencumab'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000099250],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107371,CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O,GWVQGVCXFNYGFP-PFHKOEEOSA-N,Small molecule,False,SELODENOSON,,2.0,,False,False,[],['DTI-0009' 'GR-56072' 'GR56072' 'RG-14202' 'Selodenoson'],,,"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108250,,,Enzyme,False,ANISTREPLASE,,4.0,,False,True,['Eminase'],['APSAC' 'Anistreplase' 'BRL 26921' 'BRL-26921'],,,"{'rows': array(['HP_0004419'], dtype=object), 'count': 1}",[ENSG00000122194],Enzyme drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis.
CHEMBL2108319,,,Protein,False,SIMOCTOCOG ALFA,2017.0,4.0,,False,True,['Vihuma'],['Human-cl rh fviii' 'Nuwiq' 'Simoctocog alfa'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vihuma'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Protein drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia a.
CHEMBL2108403,,,Antibody,False,EPITUMOMAB,,2.0,,False,False,[],['Epitumomab'],,,,[ENSG00000185499],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109268,,,Antibody drug conjugate,False,NARATUXIMAB EMTANSINE,,2.0,,False,False,[],"['DEBIO-1562' 'IMGN-529' 'IMGN529' 'Imgn 529' 'Imgn529' 'K7153a-smcc-dm1'
 'Naratuximab emtansine']",,,"{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}",[ENSG00000104894],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109310,,,Antibody,False,8H9 131I,,2.0,,False,False,[],['8H9' '8h9 131i'],,,"{'rows': array(['EFO_1001012', 'MONDO_0002087', 'EFO_0000621', 'EFO_1000026'],
      dtype=object), 'count': 4}",[ENSG00000103855],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3544910,,,Small molecule,False,MOTEXAFIN GADOLINIUM,,3.0,,False,False,['Xcytrin'],"['API-GP3' 'FP-GP1' 'GD-TEXAPHYRIN' 'Gd texaphyrin' 'Gd-Tex'
 'Motexafin gadolinium' 'Motexafin gadolinium anhydrous'
 'Motexafin gadolinium hydrate' 'NSC-695238' 'PCI-0120'
 'gadolinium texaphyrin']","[('chEBI', array(['50161'], dtype=object))]",,"{'rows': array(['EFO_0009708', 'EFO_0000095', 'EFO_1000158', 'EFO_0000681',
       'EFO_0000632', 'EFO_0000228', 'EFO_0005952', 'EFO_0000519',
       'EFO_0002618', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001378',
       'EFO_0003863', 'MONDO_0005411', 'MONDO_0002367', 'EFO_1001465',
       'EFO_0003833'], dtype=object), 'count': 17}","[ENSG00000167325,ENSG00000048392,ENSG00000171848,ENSG00000198431]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.
CHEMBL3828074,CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1,REQQVBGILUTQNN-UHFFFAOYSA-N,Small molecule,False,ZIRITAXESTAT,,3.0,,False,False,[],"['G-451990' 'G451990' 'GLPG-1690' 'GLPG1690' 'Glpg1690' 'Ziritaxestat'
 'Ziritaxestatn']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZIRITAXESTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15403'], dtype=object))]",,"{'rows': array(['EFO_0000768', 'EFO_0006890', 'EFO_0000717'], dtype=object), 'count': 3}",[ENSG00000136960],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL395110,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1,CBHCDHNUZWWAPP-UHFFFAOYSA-N,Small molecule,False,MEPAZINE,,4.0,,True,True,[],"['III-2318' 'Lacumin' 'Mepasin' 'Mepazin' 'Mepazine base' 'Meprazine'
 'Mesapin' 'Nothiazine' 'P-391' 'Pacatal' 'Pacatal base' 'Pacatol'
 'Pakatal' 'Paxital' 'Pecatal' 'Pecazine']","[('PubChem', array(['144205395', '29216162'], dtype=object))]",['CHEMBL1712842'],,[ENSG00000172175],Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL426559,CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3,NXFFJDQHYLNEJK-CYBMUJFWSA-N,Small molecule,False,LAROPIPRANT,,4.0,,True,True,[],['Cordaptive' 'Laropiprant' 'MK-0524'],"[('Wikipedia', array(['Laropiprant'], dtype=object)), ('drugbank', array(['DB11629'], dtype=object))]",['CHEMBL218415' 'CHEMBL375527'],"{'rows': array(['Orphanet_309005', 'EFO_0004911', 'Orphanet_79211', 'HP_0003124',
       'EFO_1000760', 'MONDO_0005148', 'HP_0031284', 'MONDO_0021187'],
      dtype=object), 'count': 8}",[ENSG00000168229],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications. It was withdrawn in at least one region.
CHEMBL4297270,Cc1noc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1,GQBRZBHEPUQRPL-LJQANCHMSA-N,Small molecule,False,BMS-986020,,2.0,,False,False,[],['AP-3152 FREE ACID' 'Bms-986020'],"[('drugbank', array(['DB14948'], dtype=object))]",,"{'rows': array(['EFO_1001993', 'EFO_0000768'], dtype=object), 'count': 2}",[ENSG00000198121],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4298192,,,Oligonucleotide,False,SUVODIRSEN,,2.0,,False,False,[],['BMTR0139' 'Suvodirsen' 'WLS-4176' 'WV-3473' 'WVE-210201' 'Wve-210201'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SUVODIRSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}",[ENSG00000198947],Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4535757,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,NXQKSXLFSAEQCZ-SFHVURJKSA-N,Small molecule,False,SOTORASIB,2021.0,4.0,,False,True,['Lumakras' 'Lumykras'],"['AMG-510' 'AMG510' 'Kras g12c inhibitor 9'
 'Kras mutant-targeting amg 510' 'Sotorasib']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOTORASIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000571', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001075',
       'EFO_1001512', 'EFO_0001421', 'EFO_1000251', 'EFO_0002618',
       'EFO_0000365', 'EFO_0000616'], dtype=object), 'count': 10}",[ENSG00000133703],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 8 investigational indications.
CHEMBL494089,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21,KGPGFQWBCSZGEL-ZDUSSCGKSA-N,Small molecule,False,GSK-690693,,1.0,,False,False,[],['GSK 690693' 'GSK690693' 'Gsk-690693'],"[('drugbank', array(['DB12745'], dtype=object)), ('chEBI', array(['90677'], dtype=object))]",,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000142875,ENSG00000072062,ENSG00000165059,ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL632,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,UREBDLICKHMUKA-DVTGEIKXSA-N,Small molecule,False,BETAMETHASONE,1961.0,4.0,,False,True,"['Alphatrex' 'Betasolan' 'Betatrex' 'Betnelan' 'Celestone' 'Dermabet'
 'Uticort']","['BETA-VAL' 'Betamethasone' 'Betatrex' 'Dermabet' 'Flubenisolone'
 'Lotrisone' 'NSC-39470' 'SCH 4831' 'SCH-4831' 'Taclonex' 'Uticort'
 'VISUBETA']","[('PubChem', array(['144205668', '144211772', '170465027', '26757820', '46500420',
       '56320847'], dtype=object)), ('Wikipedia', array(['Betamethasone'], dtype=object)), ('drugbank', array(['DB00443'], dtype=object)), ('chEBI', array(['3077'], dtype=object))]",,"{'rows': array(['MONDO_0005271', 'MONDO_0009971', 'EFO_1000644', 'HP_0011868',
       'EFO_0008517', 'HP_0030833', 'EFO_0004209', 'EFO_1000637',
       'EFO_1000906', 'HP_0012735', 'EFO_0009840', 'HP_0000964',
       'EFO_0004143', 'MONDO_0003005', 'EFO_0002950', 'EFO_0000232',
       'EFO_0005854', 'EFO_0003917', 'MONDO_0005041', 'HP_0006536',
       'EFO_0000676', 'EFO_0000274', 'EFO_0004274', 'HP_0001742',
       'MONDO_0002258', 'EFO_1001157', 'EFO_0005752', 'EFO_0009552',
       'EFO_1001077', 'EFO_1001494', 'EFO_0000756', 'HP_0011950'],
      dtype=object), 'count': 32}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 4 approved and 28 investigational indications.
CHEMBL1116,Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,BKXVVCILCIUCLG-UHFFFAOYSA-N,Small molecule,True,RALOXIFENE HYDROCHLORIDE,1997.0,4.0,CHEMBL81,False,True,"['Evirex' 'Evista' 'Optruma' 'Ostiral' 'Raloxifene hydrochloride'
 'Razylan']","['Keoxifene hydrochloride' 'LY-156758' 'LY156758' 'NSC-706725'
 'Raloxifene hcl' 'Raloxifene hydrochloride' 'Raloxifene teva']","[('DailyMed', array(['raloxifene%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evista'],
      dtype=object)), ('PubChem', array(['144203806', '144212686', '170465341', '26753259', '26753260',
       '50106949', '50106950', '56320710', '56324093'], dtype=object)), ('chEBI', array(['50740'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000673', 'EFO_0003854', 'EFO_0003882'],
      dtype=object), 'count': 4}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1200411,CCCN(CCC)CCc1cccc2c1CC(=O)N2.Cl,XDXHAEQXIBQUEZ-UHFFFAOYSA-N,Small molecule,True,ROPINIROLE HYDROCHLORIDE,1997.0,4.0,CHEMBL589,False,True,"['Adartrel' 'Aimpart xl' 'Clevor' 'Ipinnia xl' 'Ralnea xl' 'Raponer xl'
 'Repinex xl' 'Requip' 'Requip xl' 'Ropilynz xl'
 'Ropinirole hydrochloride' 'Spiroco xl']","['Ropinirole (as hydrochloride)' 'Ropinirole hcl'
 'Ropinirole hydrochloride' 'SK&F 101468-A' 'SK&F-101468-A']","[('DailyMed', array(['ropinirole%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/clevor'],
      dtype=object)), ('PubChem', array(['50107005'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'EFO_0004270'], dtype=object), 'count': 2}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for parkinson disease and restless legs syndrome. This drug has a black box warning from the FDA.
CHEMBL1201212,COc1ccc(OC)c(C(O)CNC(=O)CN)c1,PTKSEFOSCHHMPD-UHFFFAOYSA-N,Small molecule,True,MIDODRINE,1996.0,4.0,,False,True,[],['Midodrine' 'ST 1085' 'ST-1085'],"[('drugbank', array(['DB00211'], dtype=object)), ('chEBI', array(['6933'], dtype=object))]",['CHEMBL1200461'],"{'rows': array(['EFO_1001346', 'EFO_1001919', 'EFO_0005251', 'EFO_0000319',
       'EFO_0006834', 'EFO_0000712', 'HP_0002140', 'EFO_0005252',
       'HP_0001541', 'EFO_0006834', 'HP_0100806', 'EFO_0005252'],
      dtype=object), 'count': 12}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for cardiovascular disease and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL131,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,OIGNJSKKLXVSLS-VWUMJDOOSA-N,Small molecule,False,PREDNISOLONE,1955.0,4.0,,False,True,"['Cortalone' 'Dekotil' 'Delta-cortef' 'Deltacortril' 'Deltalone'
 'Dilacort' 'Equisolon' 'Fernisolone-p' 'Hydeltra' 'Meti-derm'
 'Meticortelone' 'Pevanti' 'Precortisyl' 'Precortisyl fte' 'Prednisolone'
 'Prelone' 'Scheriproct' 'Servisone' 'Sterane']","['Desowen' 'Hydeltra-Tba' 'Meticortelone' 'NSC-9120' 'NSC-9900'
 'Neo-Delta-Cortef' 'Poly-Pred' 'Pred-G' 'Prednisolone' 'Servisone'
 'Tridesilon' 'Verdeso']","[('DailyMed', array(['prednisolone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/equisolon'],
      dtype=object)), ('PubChem', array(['144204880', '144208871', '144213304', '170464732', '50085972'],
      dtype=object)), ('Wikipedia', array(['Prednisolone'], dtype=object)), ('drugbank', array(['DB00860'], dtype=object)), ('chEBI', array(['8378'], dtype=object))]",,"{'rows': array(['MONDO_0000873', 'MONDO_0015128', 'EFO_0005319', 'EFO_0007486',
       'HP_0001742', 'EFO_0005558', 'EFO_0008997', 'EFO_1001345',
       'EFO_0004254', 'EFO_1001321', 'HP_0002315', 'EFO_0000341',
       'EFO_1001205', 'EFO_0004190', 'MONDO_0018906', 'EFO_1001968',
       'EFO_0000768', 'EFO_0000565', 'EFO_0005297', 'HP_0001915',
       'EFO_0000222', 'EFO_0003872', 'EFO_0000182', 'EFO_1001139',
       'EFO_0000183', 'EFO_0001663', 'EFO_0007257', 'EFO_0009609',
       'EFO_0000685', 'EFO_0005854', 'HP_0003072', 'EFO_0000545',
       'EFO_1001896', 'EFO_1001231', 'EFO_1001069', 'MONDO_0005090',
       'EFO_0007537', 'MONDO_0009348', 'MONDO_0005129', 'EFO_0003938',
       'EFO_1000684', 'EFO_0007427', 'EFO_0000699', 'EFO_0004236',
       'EFO_0004194', 'MONDO_0015540', 'EFO_0009456', 'EFO_0000274',
       'MONDO_0004992', 'EFO_0004274', 'EFO_0000196', 'EFO_0000384',
       'EFO_0004237', 'EFO_0003106', 'HP_0002140', 'EFO_1001857',
       'EFO_0000209', 'EFO_0003884', 'EFO_1000941', 'MONDO_0004750',
       'MONDO_0019338', 'EFO_0007520', 'EFO_0000764', 'MONDO_0002462',
       'EFO_0004246', 'MONDO_0001705', 'EFO_0001378', 'MP_0001845',
       'EFO_0000255', 'EFO_1001194', 'EFO_0003778', 'EFO_1000764',
       'HP_0004398', 'EFO_0000211', 'EFO_0003898', 'EFO_1001110',
       'EFO_0000318', 'EFO_1001467', 'EFO_0000096', 'EFO_1000694',
       'HP_0001873', 'EFO_0002609', 'MONDO_0013730', 'EFO_0007227',
       'EFO_1001176', 'EFO_0009491', 'EFO_0000676', 'MONDO_0005178',
       'MONDO_0007254', 'EFO_0000398', 'EFO_0004826', 'MONDO_0005148',
       'EFO_1000726', 'EFO_1000680', 'MONDO_0007915', 'EFO_0000220',
       'EFO_0003086', 'EFO_0004616', 'EFO_0000717', 'EFO_1001051',
       'MONDO_0010679', 'EFO_1000997', 'EFO_0007141', 'EFO_0000673',
       'MONDO_0018097', 'EFO_0001054', 'EFO_0001365', 'EFO_1000954',
       'MONDO_0004979', 'EFO_0000756', 'EFO_0005761', 'MONDO_0008315',
       'MONDO_0005271', 'EFO_1001222', 'EFO_0003032', 'MONDO_0100096',
       'HP_0012424', 'EFO_0007160', 'EFO_1000784', 'EFO_0007208',
       'HP_0001094', 'EFO_0009449', 'EFO_1001209', 'EFO_1000749',
       'HP_0000964', 'EFO_0001060', 'MONDO_0008867', 'EFO_0005752',
       'EFO_1001887', 'EFO_0004255', 'EFO_1000049', 'EFO_0005952',
       'EFO_1000635', 'EFO_0000712', 'EFO_1001435', 'EFO_1001264',
       'MONDO_0018896', 'MONDO_0005301', 'MONDO_0005041', 'EFO_1001119',
       'EFO_0000574', 'EFO_0000729', 'MONDO_0008728', 'EFO_0007405',
       'MONDO_0020290', 'EFO_0007403', 'EFO_1001888', 'EFO_0007140',
       'MONDO_0001280', 'EFO_0000759', 'EFO_0009552', 'EFO_0000403',
       'EFO_1001077', 'EFO_0008518', 'EFO_0007167', 'MONDO_0009387',
       'EFO_1000039'], dtype=object), 'count': 157}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 58 approved and 99 investigational indications.
CHEMBL1434513,NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O,LNBCGLZYLJMGKP-JZGIKJSDSA-N,Small molecule,True,NOREPINEPHRINE BITARTRATE,1950.0,4.0,CHEMBL1437,False,True,"['Adrenor' 'Aktamin' 'Levarterenol Bitartrate' 'Levophed' 'Noradrenaline'
 'Norepinephrine bitartrate' 'Norepinephrine bitartrate in 5% dextrose']","['Aktamin' 'Arterenol, tartrate, monohydrate' 'Binodrenal'
 'Levarterenol bitartrate' 'NSC-169106' 'Noradrenaline'
 'Noradrenaline (as tartrate)' 'Noradrenaline bitartrate'
 'Noradrenaline tartrate' 'Norepinephrine' 'Norepinephrine bitartrate'
 'Norepinephrine bitartrate monohydrate' 'Norepinephrine d-bitartrate'
 'Norepinephrine hydrochloride']","[('DailyMed', array(['norepinephrine%20bitartrate'], dtype=object)), ('PubChem', array(['56463315'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'HP_0100806', 'MONDO_0001382', 'EFO_0005251',
       'EFO_0004610', 'HP_0002140', 'EFO_0007450', 'EFO_0002497',
       'MONDO_0008867'], dtype=object), 'count': 9}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1742995,,,Antibody,False,BRIAKINUMAB,,3.0,,False,False,['Ozespa'],"['A-796874.0' 'ABT-874' 'BSF 415977' 'BSF-415977' 'Briakinumab' 'J-695'
 'J-695 BSF-415977 LU-415977 WAY-165772 A-796874.0' 'J695' 'LU 415977'
 'LU-415977' 'WAY-165772']",,,"{'rows': array(['EFO_0000676', 'EFO_0000384', 'EFO_0000540', 'MONDO_0005301'],
      dtype=object), 'count': 4}","[ENSG00000113302,ENSG00000110944,ENSG00000168811]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2062262,C[C@H](N)[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O,VENXSELNXQXCNT-YDYUUSCQSA-N,Small molecule,False,METARAMINOL BITARTRATE,1954.0,4.0,CHEMBL1201319,False,True,['Aramine' 'Metaraminol bitartrate'],"['Metaradrine bitartrate' 'Metaraminol bitartrate'
 'Metaraminol hydrochloride' 'Metaraminol hydrochloride, (-)-'
 'Metaraminol tartrate' 'NSC-758425']",,,,"[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954.
CHEMBL2105721,CC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1,VYFGDLGHHBUDTQ-ZLGUVYLKSA-N,Small molecule,False,NIVOCASAN,,2.0,,False,False,[],['GS-9450' 'LB-84451' 'LB84451' 'Nivocasan'],"[('drugbank', array(['DB12720'], dtype=object))]",,"{'rows': array(['EFO_0003047', 'EFO_1001249'], dtype=object), 'count': 2}","[ENSG00000137752,ENSG00000064012,ENSG00000132906]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108316,,,Oligonucleotide,False,EDIFOLIGIDE,,2.0,,False,False,[],['Edifoligide'],,,,"[ENSG00000101412,ENSG00000007968,ENSG00000112242,ENSG00000205250,ENSG00000133740,ENSG00000169016,ENSG00000165891,ENSG00000129173]",Oligonucleotide drug with a maximum clinical trial phase of II.
CHEMBL2108348,,,Protein,False,NONACOG BETA PEGOL,2017.0,4.0,,False,True,['Refixia'],['Nonacog beta pegol' 'Rebinyn' 'Refixia'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/refixia'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}",[ENSG00000101981],Protein drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia b.
CHEMBL2108357,,,Antibody,False,EPRATUZUMAB 90Y,,3.0,,False,False,['Lymphocide'],['AMG-412' 'Epratuzumab 90y' 'HLL2'],,,"{'rows': array(['EFO_1001938'], dtype=object), 'count': 1}",[ENSG00000012124],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2147777,Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1,WGRQANOPCQRCME-PMACEKPBSA-N,Small molecule,False,TENELIGLIPTIN,2012.0,4.0,,False,True,[],['MP-513' 'Teneligliptin'],"[('drugbank', array(['DB11950'], dtype=object))]",['CHEMBL2147708'],"{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 2 investigational indications.
CHEMBL221692,Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1,IUVSEUFHPNITEQ-UHFFFAOYSA-N,Small molecule,False,ADOPRAZINE,,2.0,,False,False,[],['Adoprazine' 'SLV-313'],,['CHEMBL4751170'],,"[ENSG00000151577,ENSG00000178394,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3185463,CN1CCN(c2ccccc2/C=C2\SCCN(c3ccc(Cl)c(Cl)c3)C2=O)CC1,LHYMPSWMHXUWSK-STZFKDTASA-N,Small molecule,False,ELZASONAN,,2.0,,False,False,[],['Elzasonan'],"[('PubChem', array(['144210759'], dtype=object))]",['CHEMBL3989903' 'CHEMBL3989805'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000135312,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3286580,Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1,YBAWYTYNMZWMMJ-UHFFFAOYSA-N,Small molecule,False,IDALOPIRDINE,,3.0,,False,False,[],"['Idalopirdine' 'LU AE-58054' 'LU-AE-58054' 'LU-AE58054' 'LY-483518'
 'LY483518' 'Lu AE58054' 'Lu-ae58054' 'SGS-518' 'SGS518']","[('drugbank', array(['DB11957'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'HP_0100543', 'MONDO_0005090'], dtype=object), 'count': 3}",[ENSG00000158748],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3590106,CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1,KSERXGMCDHOLSS-LJQANCHMSA-N,Small molecule,False,ULIXERTINIB,,2.0,,False,False,[],['BVD-ERK' 'Bvd-523' 'Ulixertinib' 'VRT-752271'],"[('drugbank', array(['DB13930'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_0000616', 'EFO_0002618', 'EFO_0000198',
       'EFO_0000326'], dtype=object), 'count': 5}","[ENSG00000102882,ENSG00000100030]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4279047,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F,QCZAWDGAVJMPTA-RNFRBKRXSA-N,Small molecule,False,VORASIDENIB,,3.0,,False,False,[],['AG-881' 'Ag-881' 'Vorasidenib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VORASIDENIB/relevant/1/'],
      dtype=object))]",['CHEMBL4594378'],"{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_0001421', 'EFO_0000272',
       'EFO_0000326'], dtype=object), 'count': 5}","[ENSG00000138413,ENSG00000182054]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297770,,,Oligonucleotide,False,INOTERSEN,,4.0,,False,True,[],['GSK-2998728' 'ISIS 420915' 'ISIS-420915' 'Inotersen'],,,"{'rows': array(['EFO_1001875', 'EFO_0004129'], dtype=object), 'count': 2}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.
CHEMBL4297777,,,Unknown,False,LMB-100,,2.0,,False,False,[],"['Anti-msln-pe24 cfp lmb-100' 'LMB-100' 'Lmb 100' 'Lmb-100' 'RG-7787'
 'RG7787' 'RO-6927005' 'RO6927005' 'Ro6927005']",,,"{'rows': array(['MONDO_0004992', 'EFO_0000571', 'EFO_0000588', 'EFO_0003860'],
      dtype=object), 'count': 4}","[ENSG00000102854,ENSG00000167658]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297939,,,Antibody drug conjugate,False,DATOPOTAMAB DERUXTECAN,,3.0,,False,False,[],"['ADC DS-1062A' 'DS-1062' 'DS-1062a' 'DS1062' 'Dato-DXd'
 'Datopotamab deruxtecan' 'Ds-1062' 'Ds-1062a']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DATOPOTAMAB%20DERUXTECAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0008903', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000616',
       'EFO_0003869', 'EFO_0003968', 'EFO_0005537'], dtype=object), 'count': 7}","[ENSG00000198900,ENSG00000184292]",Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4298178,,,Antibody drug conjugate,False,TRASTUZUMAB DUOCARMAZINE,,3.0,,False,False,[],['SYD-985' 'SYD985' 'Trastuzumab duocarmazine'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRASTUZUMAB%20DUOCARMAZINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'MONDO_0001056', 'EFO_0004243', 'EFO_0001075',
       'EFO_0000616', 'EFO_0003968', 'MONDO_0011962', 'MONDO_0001187',
       'MONDO_0021251', 'EFO_0005537'], dtype=object), 'count': 10}",[ENSG00000141736],Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL4298209,,,Antibody drug conjugate,True,BELANTAMAB MAFODOTIN,2020.0,4.0,,False,True,['Blenrep'],"['Belantamab mafodotin' 'Belantamab mafodotin blmf' 'GSK-2857916'
 'GSK2857916']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELANTAMAB%20MAFODOTIN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0019438', 'EFO_0000403', 'EFO_0000616', 'EFO_0001378'],
      dtype=object), 'count': 4}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000048462]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and multiple myeloma and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4802129,C[C@@H]1NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2,MKXOUIKTXREBLX-NDKBASPVSA-N,Protein,False,BALIXAFORTIDE,,3.0,,False,False,[],['Balixafortide' 'POL-6326' 'POL6326' 'Pol6326'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BALIXAFORTIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005809', 'EFO_0000616', 'EFO_0000339', 'EFO_0000612',
       'EFO_0000198', 'EFO_0000222', 'MONDO_0007254', 'EFO_0001378',
       'EFO_0000095'], dtype=object), 'count': 9}",[ENSG00000121966],Protein drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL48582,CS(=O)(=O)O.C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,YKOCHIUQOBQIAC-YDALLXLXSA-N,Small molecule,False,SAFINAMIDE MESYLATE,2015.0,4.0,CHEMBL396778,False,True,['Xadago'],"['EMD 1195686' 'NW 1015' 'NW-1015' 'PNU 151774E' 'PNU-151774E'
 'Safinamide mesilate' 'Safinamide mesylate' 'Safinamide methanesulfonate'
 'Safinamide methansulfonate']","[('DailyMed', array(['safinamide%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xadago'],
      dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000069535],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for parkinson disease.
CHEMBL521589,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1,ANZXOIAKUNOVQU-UHFFFAOYSA-N,Small molecule,False,BAMBUTEROL,,3.0,,False,False,[],['Bambuterol'],"[('PubChem', array(['56463628'], dtype=object)), ('Wikipedia', array(['Bambuterol'], dtype=object)), ('drugbank', array(['DB01408'], dtype=object)), ('chEBI', array(['553827'], dtype=object))]",['CHEMBL1603534'],"{'rows': array(['HP_0006536', 'EFO_0001361'], dtype=object), 'count': 2}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL897,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,DBABZHXKTCFAPX-UHFFFAOYSA-N,Small molecule,False,PROBENECID,1951.0,4.0,,False,True,['Benemid' 'Benuryl' 'Probalan' 'Probampicin' 'Probecid' 'Probenecid'],"['HC 5006' 'NSC-18786' 'P-(dipropylsulfamoyl)benzoic acid' 'Probenate'
 'Probenecid' 'Probenecidum']","[('DailyMed', array(['probenecid'], dtype=object)), ('PubChem', array(['11112135', '144203879', '144209308', '144213245', '170464839',
       '17389752', '26747055', '26747056', '26751571', '50100375',
       '56424104', '855953'], dtype=object)), ('Wikipedia', array(['Probenecid'], dtype=object)), ('drugbank', array(['DB01032'], dtype=object)), ('chEBI', array(['8426'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'EFO_0004248', 'EFO_0004274', 'EFO_0000544',
       'MONDO_0007079', 'MONDO_0001314', 'EFO_0003144', 'MONDO_0043510',
       'MONDO_0005148', 'EFO_0003103', 'EFO_1001207', 'EFO_0005222',
       'EFO_1000025', 'EFO_0000616', 'EFO_0001073', 'EFO_0003035'],
      dtype=object), 'count': 16}","[ENSG00000149452,ENSG00000197901,ENSG00000168065]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for gout and has 15 investigational indications.
CHEMBL1200787,CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl,VBCPVIWPDJVHAN-UHFFFAOYSA-N,Small molecule,False,PHENOXYBENZAMINE HYDROCHLORIDE,1953.0,4.0,CHEMBL753,False,True,['Dibenyline' 'Dibenzyline' 'Phenoxybenzamine hydrochloride'],"['Bensylyte hydrochloride' 'Dibenzylin' 'Dibenzyline chloride'
 'Dibenzyline hydrochloride' 'Dibenzyran' 'NSC-37448'
 'Phenoxybenzamine chloride' 'Phenoxybenzamine hcl'
 'Phenoxybenzamine hydrochloride']","[('DailyMed', array(['phenoxybenzamine%20hydrochloride'], dtype=object)), ('PubChem', array(['144208786', '144213295', '17389764', '26747462', '26752311',
       '50105976', '855636'], dtype=object)), ('chEBI', array(['8078'], dtype=object))]",,"{'rows': array(['EFO_0000239'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and is indicated for adrenal gland pheochromocytoma.
CHEMBL1201037,Cl.NCCCC(N)(C(=O)O)C(F)F.O,FJPAMFNRCFEGSD-UHFFFAOYSA-N,Small molecule,False,EFLORNITHINE HYDROCHLORIDE,1990.0,4.0,CHEMBL830,False,True,['Ornidyl' 'Vaniqa'],"['Dfmo hcl' 'Difluromethylornithine' 'Eflornithine hcl'
 'Eflornithine hydrochloride' 'Eflornithine hydrochloride monohydrate'
 'MDL 71,782 A' 'MDL-71782-A' 'MDL-71782A' 'NSC-270295' 'NSC-337250'
 'RMI-71782-A']","[('DailyMed', array(['eflornithine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa'],
      dtype=object))]",,"{'rows': array(['Orphanet_733', 'EFO_0000621'], dtype=object), 'count': 2}",[ENSG00000115758],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 2 investigational indications.
CHEMBL1201168,Cc1cc(C(=O)NNCc2ccccc2)no1,XKFPYPQQHFEXRZ-UHFFFAOYSA-N,Small molecule,True,ISOCARBOXAZID,1959.0,4.0,,False,True,['Marplan'],['Enerzer' 'Isocarboxazid' 'NSC-169893' 'RO 5-0831' 'RO-5-0831'],"[('DailyMed', array(['isocarboxazid'], dtype=object)), ('PubChem', array(['11112152', '144203887', '56463226'], dtype=object)), ('Wikipedia', array(['Isocarboxazid'], dtype=object)), ('drugbank', array(['DB01247'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'MONDO_0002009', 'MONDO_0004975'], dtype=object), 'count': 3}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for major depressive disorder and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201630,,,Protein,False,INSULIN PURIFIED PORK,1979.0,4.0,,False,True,"['Iletin ii' 'Regular iletin ii (pork)' 'Regular purified pork insulin'
 'Velosulin']",['Insulin (pork)' 'Insulin purified pork'],,,"{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for diabetes mellitus.
CHEMBL1201640,,,Protein,False,INSULIN ZINC SUSP EXTENDED BEEF,1982.0,4.0,,False,True,['Ultralente insulin'],['Insulin zinc susp extended beef'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1256958,CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O,YLXIPWWIOISBDD-FVGYRXGTSA-N,Small molecule,False,EPINEPHRINE BITARTRATE,1965.0,4.0,CHEMBL679,False,True,['Bronitin mist' 'Medihaler-epi'],"['(-)-Epinephrine Bitartrate' 'Adrenalin tartrate'
 'Adrenaline (as tartrate)' 'Adrenaline acid tartrate'
 'Adrenaline bitartate' 'Adrenaline bitartrate' 'Epinephrine bitartrate'
 'Epinephrine d-bitartrate' 'Epinephrine hydrogen tartrate'
 'Epinephrine tartrate' 'Epinephrini hydrogenotartras'
 'L-epinephrine hydrogen tartrate' 'NSC-756755']","[('DailyMed', array(['epinephrine%20bitartrate'], dtype=object)), ('PubChem', array(['11532860', '50106283'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965 and is indicated for pain.
CHEMBL1431,CN(C)C(=N)NC(=N)N,XZWYZXLIPXDOLR-UHFFFAOYSA-N,Small molecule,True,METFORMIN,1995.0,4.0,,False,True,[],['LA-6023' 'Metformin' 'Metformin extended release'],"[('PubChem', array(['11112469', '137275802', '144212687', '174006543'], dtype=object)), ('TG-GATEs', array(['53'], dtype=object)), ('Wikipedia', array(['Metformin'], dtype=object)), ('drugbank', array(['DB00331'], dtype=object)), ('chEBI', array(['6801'], dtype=object))]",['CHEMBL3094198' 'CHEMBL1703'],"{'rows': array(['EFO_0000685', 'EFO_0002617', 'MONDO_0044704', 'EFO_0005537',
       'MONDO_0007254', 'EFO_0002618', 'HP_0000842', 'MONDO_0005090',
       'EFO_0004214', 'HP_0003124', 'MONDO_0100096', 'MONDO_0010383',
       'MONDO_0018906', 'MONDO_0005299', 'EFO_0008522', 'EFO_0000571',
       'MONDO_0001941', 'EFO_0001378', 'EFO_0003095', 'MONDO_0010679',
       'EFO_0000403', 'EFO_0000182', 'MONDO_0007254', 'EFO_0000673',
       'EFO_1001951', 'MP_0001845', 'EFO_0005687', 'MONDO_0018875',
       'EFO_1001496', 'HP_0002745', 'EFO_0000432', 'EFO_0000660',
       'EFO_0000275', 'EFO_0003914', 'MONDO_0011382', 'MONDO_0021063',
       'HP_0003419', 'MONDO_0019391', 'EFO_0001071', 'MONDO_0019353',
       'EFO_0004593', 'EFO_0000305', 'EFO_0005411', 'EFO_0003968',
       'MONDO_0005148', 'MONDO_0004782', 'EFO_0000673', 'EFO_0000676',
       'EFO_0002687', 'EFO_0003884', 'EFO_0000341', 'EFO_0003770',
       'EFO_0003060', 'EFO_0009516', 'EFO_1001121', 'EFO_0000537',
       'EFO_0000702', 'EFO_0000199', 'EFO_0004208', 'EFO_0004616',
       'MONDO_0002158', 'MONDO_0008315', 'Orphanet_309005', 'EFO_0002950',
       'EFO_0000756', 'EFO_1001892', 'EFO_0000365', 'MONDO_0021350',
       'EFO_1001512', 'EFO_0004265', 'EFO_0009637', 'HP_0100543',
       'EFO_0000181', 'EFO_0003767', 'EFO_0000095', 'MONDO_0002108',
       'EFO_0000400', 'EFO_0000280', 'EFO_1000043', 'EFO_0004566',
       'EFO_0005672', 'MONDO_0004658', 'EFO_0000694', 'MONDO_0011962',
       'EFO_1000359', 'EFO_1001492', 'HP_0002910', 'EFO_0008520',
       'MONDO_0002009', 'EFO_0004364', 'EFO_0000729', 'EFO_1001459',
       'EFO_1000710', 'EFO_0008520', 'EFO_0003144', 'EFO_0001663',
       'EFO_0000474', 'EFO_0004142', 'EFO_0006859', 'EFO_0000519',
       'EFO_0000196', 'MONDO_0008903', 'MONDO_0019338', 'MONDO_0005180',
       'EFO_0000228', 'HP_0001268', 'MONDO_0004992', 'MONDO_0005178',
       'EFO_0000195', 'EFO_0001416', 'EFO_0003884', 'EFO_0006859',
       'EFO_0001645', 'EFO_0000466', 'EFO_0000313', 'EFO_0003060',
       'EFO_0005922', 'EFO_0001054', 'EFO_0001361', 'EFO_0004593',
       'EFO_0000308', 'Orphanet_733', 'MONDO_0005301', 'EFO_0000707',
       'MONDO_0005277', 'EFO_1001249', 'EFO_0000616', 'EFO_0003963',
       'HP_0001541', 'MONDO_0020121', 'EFO_0002618', 'MONDO_0008170',
       'MONDO_0002974', 'HP_0001397', 'EFO_0005762', 'MONDO_0008315',
       'EFO_0003050', 'EFO_0000571', 'EFO_0001068', 'EFO_0003863',
       'EFO_0000649', 'MONDO_0002691', 'MONDO_0005147', 'EFO_0000545',
       'EFO_0001378', 'EFO_1001207', 'MONDO_0005184', 'EFO_0000348',
       'EFO_1000045', 'EFO_0003940', 'EFO_0003144', 'MONDO_0017975',
       'EFO_0003918', 'EFO_0002546', 'EFO_0000195', 'EFO_1001901',
       'EFO_0003868', 'EFO_0003876', 'MONDO_0001187', 'EFO_0000199',
       'HP_0012115', 'EFO_1000783', 'MONDO_0015229', 'MONDO_0007739',
       'EFO_1000657', 'MONDO_0005041', 'EFO_0001663', 'EFO_0000220',
       'EFO_1000286', 'EFO_0000400', 'EFO_0000589', 'EFO_0001075',
       'MONDO_0018076', 'MONDO_0021063', 'MONDO_0002087', 'EFO_0001073',
       'MONDO_0017276', 'MONDO_0004985', 'EFO_0000660', 'EFO_0008522',
       'EFO_0000764', 'EFO_0003833', 'EFO_1000632', 'EFO_0001073',
       'EFO_0003100', 'HP_0001249', 'EFO_1001465', 'EFO_0000319',
       'EFO_0000616', 'EFO_1001348', 'MONDO_0005148', 'EFO_0002614'],
      dtype=object), 'count': 192}","[ENSG00000115159,ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 181 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1703,CN(C)C(=N)NC(=N)N.Cl,OETHQSJEHLVLGH-UHFFFAOYSA-N,Small molecule,True,METFORMIN HYDROCHLORIDE,1995.0,4.0,CHEMBL1431,False,True,"['Bolamyn sr' 'Diagemet xl' 'Fortamet' 'Glucamet 500' 'Glucamet 850'
 'Glucient sr' 'Glucophage' 'Glucophage sr' 'Glucophage xr' 'Glumetza'
 'Glyformin' 'Janumet' 'Ledermetin' 'Metabet sr' 'Metformin hydrochloride'
 'Metsol' 'Milform' 'Orabet' 'Riomet' 'Riomet er' 'Sukkarto sr']","['Apophage' 'Benofomin' 'Diabefagos' 'Diabex' 'EX-404' 'EX404'
 'Glucaminol' 'LA-6023' 'Metformin hcl' 'Metformin hydrochloride'
 'NSC-91485' 'Neodipa' 'Siamformet' 'Walaphage']","[('DailyMed', array(['metformin%20hydrochloride'], dtype=object)), ('PubChem', array(['11532867', '144204049', '170464804', '26749076', '85273756'],
      dtype=object)), ('chEBI', array(['6802'], dtype=object))]",,"{'rows': array(['EFO_0003884', 'EFO_0000571', 'EFO_0008520', 'MONDO_0007254',
       'EFO_0002618', 'HP_0000842', 'EFO_0000199', 'MONDO_0005184',
       'EFO_0000348', 'EFO_0004208', 'EFO_1001459', 'EFO_0004616',
       'EFO_0003144', 'MONDO_0005299', 'MONDO_0002158', 'EFO_0000195',
       'EFO_0001663', 'EFO_0003868', 'EFO_0006859', 'MONDO_0008315',
       'EFO_1000783', 'EFO_0001378', 'EFO_0000400', 'EFO_1001512',
       'MONDO_0002087', 'MP_0001845', 'EFO_0009637', 'EFO_0000432',
       'EFO_0000660', 'EFO_0008522', 'EFO_0000466', 'EFO_0003060',
       'MONDO_0021063', 'EFO_0001073', 'EFO_0004593', 'EFO_0001071',
       'MONDO_0019391', 'EFO_1000043', 'MONDO_0019353', 'EFO_1001465',
       'EFO_0000616', 'MONDO_0005148', 'HP_0001541', 'EFO_0000673'],
      dtype=object), 'count': 44}","[ENSG00000115159,ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 42 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2105738,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,PAFKTGFSEFKSQG-PAASFTFBSA-N,Small molecule,False,GALETERONE,,3.0,,False,False,[],['Galeterone' 'TOK 001' 'TOK-001' 'VN 124' 'VN-124' 'VN/124' 'VN/124-1'],"[('drugbank', array(['DB12415'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_1000359'], dtype=object), 'count': 2}","[ENSG00000169083,ENSG00000148795]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2424780,CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2,VFOKSTCIRGDTBR-UHFFFAOYSA-N,Small molecule,False,VESATOLIMOD,,2.0,,False,False,[],['GS-9620' 'Vesatolimod'],"[('drugbank', array(['DB12687'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'EFO_0003047', 'EFO_0000180', 'EFO_0004239',
       'EFO_0000765', 'EFO_0004197'], dtype=object), 'count': 6}",[ENSG00000196664],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3039502,C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,SJVQHLPISAIATJ-ZDUSSCGKSA-N,Small molecule,True,DUVELISIB,2018.0,4.0,,False,True,[],['Duvelisib' 'INK-1197' 'IPI-145'],"[('DailyMed', array(['duvelisib'], dtype=object)), ('drugbank', array(['DB11952'], dtype=object))]",['CHEMBL5315125'],"{'rows': array(['EFO_0000574', 'MONDO_0004979', 'EFO_0000095', 'EFO_0000685',
       'EFO_0000181', 'EFO_0000574', 'EFO_0000095', 'MONDO_0100096',
       'EFO_0000403', 'EFO_1001051', 'MONDO_0018906', 'EFO_0000220',
       'EFO_0001421', 'EFO_1000785', 'MONDO_0004992', 'MONDO_0044881',
       'EFO_0000096', 'EFO_0000756', 'EFO_0000211', 'EFO_0000616',
       'EFO_0000565', 'MONDO_0018906', 'EFO_0005952'], dtype=object), 'count': 23}","[ENSG00000171608,ENSG00000105851]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3039526,CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1.CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1.O=C(O)CCC(=O)O,MSOIHUHNGPOCTH-UHFFFAOYSA-N,Small molecule,False,LASMIDITAN SUCCINATE,2020.0,4.0,CHEMBL3039520,False,True,['Rayvow' 'Reyvow'],"['LY-573144' 'LY-683974' 'LY683974' 'Lasmiditan hemisuccinate'
 'Lasmiditan succinate']","[('DailyMed', array(['lasmiditan%20succinate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rayvow'],
      dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000179097],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for migraine disorder.
CHEMBL3301581,,,Protein,True,ABALOPARATIDE,2017.0,4.0,,False,True,['Eladynos' 'Tymlos'],['Abaloparatide' 'BA-058' 'BA058' 'BIM-44058'],"[('DailyMed', array(['abaloparatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos'],
      dtype=object))]",,"{'rows': array(['EFO_0003931', 'EFO_0003882', 'EFO_0003854'], dtype=object), 'count': 3}",[ENSG00000160801],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for osteoporosis and postmenopausal osteoporosis and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL3545070,,,Enzyme,False,VONAPANITASE,,3.0,,False,False,[],['PRT-201' 'PRT201' 'Pancreatic elastase 1' 'Vonapanitase'],,,"{'rows': array(['EFO_0003884', 'EFO_0004265'], dtype=object), 'count': 2}",[ENSG00000049540],Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3545072,,,Antibody,False,LANDOGROZUMAB,,2.0,,False,False,[],['Anti-myostatin antibody' 'LY-2495655' 'LY2495655' 'Landogrozumab'],,,"{'rows': array(['HP_0003202', 'EFO_0002970', 'MONDO_0004992', 'EFO_0002618'],
      dtype=object), 'count': 4}",[ENSG00000138379],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3545270,,,Small molecule,False,LY2969822,,1.0,,False,False,[],['Ly2969822'],,,,"[ENSG00000164082,ENSG00000198822]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707328,,,Antibody,False,GALCANEZUMAB,2018.0,4.0,,False,True,['Emgality'],['Galcanezumab' 'Galcanezumab gnlm' 'LY-2951742' 'LY2951742'],"[('DailyMed', array(['galcanezumab-gnlm'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emgality'],
      dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0004616', 'MONDO_0005277'], dtype=object), 'count': 3}","[ENSG00000110680,ENSG00000175868]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 2 investigational indications.
CHEMBL3900409,Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21,AEXFXNFMSAAELR-RXVVDRJESA-N,Small molecule,False,BRENSOCATIB,,3.0,,False,False,[],"['AZD 7986' 'AZD-7986' 'AZD7986' 'Azd-7986' 'Azd7986' 'Brensocatib'
 'INS-1007' 'INS1007']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BRENSOCATIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15638'], dtype=object))]",,"{'rows': array(['MONDO_0009061', 'EFO_0003086', 'HP_0002110', 'MONDO_0100096',
       'MONDO_0004822', 'EFO_0001421'], dtype=object), 'count': 6}",[ENSG00000109861],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL3989559,COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[n-]2)c1OC.O.[Na+],CGJRLPRCWSHOFU-UHFFFAOYSA-N,Small molecule,False,PANTOPRAZOLE SODIUM,2000.0,4.0,CHEMBL1502,False,True,['Pantoprazole sodium' 'Pantozol control' 'Protonix' 'Protonix iv'],"['Controloc control' 'Pantoprazole (as sodium)' 'Pantoprazole sodium'
 'Pantoprazole sodium hydrate' 'Pantoprazole sodium sesquihydrate'
 'Pantozol control' 'Somac control']","[('DailyMed', array(['pantoprazole%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pantozol-control'],
      dtype=object))]",,"{'rows': array(['EFO_0003948', 'EFO_0007549', 'HP_0100633', 'Orphanet_79292',
       'EFO_0000616'], dtype=object), 'count': 5}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 2 investigational indications.
CHEMBL4297721,,,Unknown,False,CDX-1140,,2.0,,False,False,[],['CDX-1140' 'CDX1140' 'Cdx 1140' 'Cdx-1140'],,,"{'rows': array(['EFO_0005221', 'EFO_0000756', 'EFO_0006859', 'EFO_0003060',
       'MONDO_0001056', 'EFO_0000182', 'EFO_0005540', 'EFO_0000305',
       'EFO_0000681', 'EFO_0002618', 'EFO_1001951', 'EFO_0000616',
       'EFO_0002617', 'MONDO_0007576', 'MONDO_0008170', 'MONDO_0007254',
       'MONDO_0002158', 'EFO_0000403', 'EFO_1001469'], dtype=object), 'count': 19}",[ENSG00000101017],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 19 investigational indications.
CHEMBL4297754,,,Oligonucleotide,False,FITUSIRAN,,3.0,,False,False,[],['ALN-57213' 'ALN-AT3SC' 'Aln-at3sc' 'Fitusiran'],,,"{'rows': array(['MONDO_0018660', 'MONDO_0010602', 'MONDO_0010604'], dtype=object), 'count': 3}",[ENSG00000117601],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4298023,,,Unknown,False,M-1095,,2.0,,False,False,[],['ALX-0761' 'ALX0761' 'M-1095' 'M1095' 'Sonelokimab'],,,"{'rows': array(['EFO_0003778', 'EFO_0000676', 'EFO_1000710'], dtype=object), 'count': 3}","[ENSG00000112116,ENSG00000112115]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4594292,CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1.Cl.O,KZVOMLRKFJUTLK-UHFFFAOYSA-N,Small molecule,False,TEPOTINIB HYDROCHLORIDE,2021.0,4.0,CHEMBL3402762,False,True,['Tepmetko'],"['MSC2156119J' 'Msc2156119j' 'Tepotinib hydrochloride'
 'Tepotinib hydrochloride hydrate']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPOTINIB%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.
CHEMBL488436,Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C,WJRRGYBTGDJBFX-UHFFFAOYSA-N,Small molecule,False,AZD-5438,,1.0,,False,False,[],['AZD-5438' 'Azd 5438' 'Azd-5438'],,['CHEMBL454649'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL730,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],SNIOPGDIGTZGOP-UHFFFAOYSA-N,Small molecule,True,NITROGLYCERIN,1981.0,4.0,,False,True,"['Coro-nitro' 'Deponit 10' 'Deponit 5' 'Glytrin' 'Gonitro' 'Lenitral 7.5'
 'Minitran' 'Minitran 10' 'Minitran 15' 'Minitran 5' 'Natirose'
 'Nitriderm tts' 'Nitro iv' 'Nitro-bid' 'Nitro-dur' 'Nitro-mack ret'
 'Nitrocine' 'Nitrocontin continus' 'Nitroglycerin' 'Nitrol'
 'Nitrolingual' 'Nitrolingual pumpspray' 'Nitromin' 'Nitromist' 'Nitronal'
 'Nitrostat' 'Percutol' 'Rectiv' 'Rectogesic' 'Suscard buccal' 'Sustac'
 'Transderm-nitro' 'Transiderm-nitro 10' 'Transiderm-nitro 5' 'Tridil'
 'Trintek 10' 'Trintek 15' 'Trintek 5']","['C01DA02' 'Chlormethine oxide hydrochloride' 'Diluted nitroglycerin'
 'Glonoinum' 'Glyceryl Trinitrate' 'Glyceryl trinitrate'
 'Glyceryl trinitrate solution' 'Imx-150' 'Mechlorethamine oxide hcl'
 'Mitomen' 'Mustron' 'Nitora' 'Nitroglycerin' 'Nitroglycerin tablets'
 'Nitromin hydrochloride' 'Transderm-Nitro' 'Trinitrin'
 'Trinitrin tablets' 'Trinitrine']","[('DailyMed', array(['nitroglycerin'], dtype=object)), ('Wikipedia', array(['Nitroglycerin'], dtype=object)), ('drugbank', array(['DB00727'], dtype=object)), ('chEBI', array(['28787'], dtype=object))]",,"{'rows': array(['EFO_1001993', 'EFO_1000783', 'EFO_1000657', 'EFO_0004234',
       'EFO_0000537', 'EFO_1001375', 'MONDO_0005149', 'EFO_0003913',
       'EFO_0009660', 'EFO_0000319', 'EFO_0000685', 'EFO_0000373',
       'HP_0031273', 'MP_0001845', 'EFO_1001951', 'EFO_0000612',
       'HP_0031217', 'EFO_0003882', 'EFO_1001395', 'EFO_0009552',
       'MONDO_0004857', 'EFO_1001145', 'EFO_0002687', 'EFO_0004265',
       'MONDO_0008903', 'HP_0000938', 'EFO_0000546', 'EFO_0001645',
       'EFO_0000544', 'EFO_0003144', 'EFO_0009846', 'EFO_0003843',
       'EFO_0000712', 'EFO_0005251', 'EFO_0003060'], dtype=object), 'count': 35}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 26 investigational indications. This drug has a black box warning from the FDA.
CHEMBL772,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,QEVHRUUCFGRFIF-MDEJGZGSSA-N,Small molecule,False,RESERPINE,1960.0,4.0,,True,True,"['Hiserpia' 'Rau-sed' 'Reserpine' 'Sandril' 'Serpalan' 'Serpanray'
 'Serpasil' 'Serpate' 'Serpivite']",['Apoplon' 'ENT-50146' 'NSC-237659' 'NSC-59272' 'Reserpine' 'Reserpinum'],"[('PubChem', array(['107574', '144204658', '144209593', '144210855', '170465405',
       '17389743', '26752948', '50105550', '50105551', '50105552',
       '50105553', '56463068', '90341213'], dtype=object)), ('Wikipedia', array(['Reserpine'], dtype=object)), ('drugbank', array(['DB00206'], dtype=object)), ('chEBI', array(['28487'], dtype=object))]",,"{'rows': array(['EFO_0002610', 'EFO_0003914', 'EFO_0001361', 'MONDO_0005148',
       'EFO_0000537', 'EFO_0003777', 'EFO_0003763', 'EFO_0001645',
       'EFO_0004701', 'HP_0003124'], dtype=object), 'count': 10}",[ENSG00000165646],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for hypertension and has 9 investigational indications. It was withdrawn in at least one region.
CHEMBL995,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+],OXCMYAYHXIHQOA-UHFFFAOYSA-N,Small molecule,True,LOSARTAN POTASSIUM,1995.0,4.0,CHEMBL191,False,True,['Cozaar' 'Losaprex' 'Losartan potassium'],"['Aradois' 'Cozaar' 'DU PONT-753' 'DUP 753' 'DUP-753' 'DUP753' 'E-3340'
 'Hyzaar' 'L-158086' 'Losacar' 'Losartan monopotassium salt'
 'Losartan potassium' 'Losata' 'MK-0954' 'MK0954' 'Nu-lotan'
 'Presartan-50' 'Tancin' 'Zaart']","[('DailyMed', array(['losartan%20potassium'], dtype=object)), ('PubChem', array(['49665951', '49681581'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'HP_0000093', 'EFO_0004232', 'MONDO_0005184',
       'EFO_0002618', 'EFO_0000537', 'MONDO_0001134', 'EFO_0000668',
       'EFO_0003095', 'EFO_0003896', 'MONDO_0007947', 'EFO_0000712',
       'EFO_0003884'], dtype=object), 'count': 13}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1068,NC(=O)N1c2ccccc2CC(=O)c2ccccc21,CTRLABGOLIVAIY-UHFFFAOYSA-N,Small molecule,False,OXCARBAZEPINE,2000.0,4.0,,False,True,['Oxcarbazepine' 'Oxtellar xr' 'Trileptal'],"['GP-47680' 'KIN-493' 'NSC-758693' 'Oxcarbamazepine' 'Oxcarbazepine'
 'SPN-804']","[('DailyMed', array(['oxcarbazepine'], dtype=object)), ('PubChem', array(['144204534', '170464811', '174006287', '26719673', '26747194',
       '50085868', '866068'], dtype=object)), ('Wikipedia', array(['Oxcarbazepine'], dtype=object)), ('drugbank', array(['DB00776'], dtype=object)), ('chEBI', array(['7824'], dtype=object))]",,"{'rows': array(['MONDO_0005090', 'HP_0000713', 'EFO_0005230', 'HP_0000726',
       'MONDO_0004992', 'EFO_0005762', 'MONDO_0002050', 'EFO_0000474',
       'MONDO_0005301', 'EFO_0003015', 'HP_0001250', 'EFO_0004263'],
      dtype=object), 'count': 12}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for epilepsy and seizure and has 10 investigational indications.
CHEMBL1200562,CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,FZCHYNWYXKICIO-FZNHGJLXSA-N,Small molecule,False,HYDROCORTISONE VALERATE,1978.0,4.0,,False,True,['Hydrocortisone valerate' 'Westcort'],"['Cortisol 17-valerate' 'Hydrocortisone 17-valerate'
 'Hydrocortisone valerate' 'NSC-759133']","[('DailyMed', array(['hydrocortisone%20valerate'], dtype=object)), ('PubChem', array(['144204404', '170464775', '56422095', '855996'], dtype=object)), ('drugbank', array(['DB14544'], dtype=object)), ('chEBI', array(['50865'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978.
CHEMBL1201153,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1.CS(=O)(=O)O,SOYAGMVKMXZVNZ-UHFFFAOYSA-N,Small molecule,False,ISOETHARINE MESYLATE,1984.0,4.0,CHEMBL1201213,False,True,['Bronchilator' 'Bronkometer' 'Isoetharine mesylate'],"['Isoetarine mesilate' 'Isoetharine mesilate' 'Isoetharine mesylate'
 'NSC-759286']","[('PubChem', array(['144204319', '50106482', '56422893', '85231307', '856022'],
      dtype=object))]",,,[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984.
CHEMBL1265,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,LZCDAPDGXCYOEH-UHFFFAOYSA-N,Small molecule,False,ADAPALENE,1996.0,4.0,,False,True,['Adapalene' 'Differin'],['Adapalene' 'CD 271' 'CD-271' 'Differin'],"[('DailyMed', array(['adapalene'], dtype=object)), ('PubChem', array(['144205789', '170464674', '174006867', '26758039'], dtype=object)), ('Wikipedia', array(['Adapalene'], dtype=object)), ('drugbank', array(['DB00210'], dtype=object)), ('chEBI', array(['31174'], dtype=object))]",,"{'rows': array(['EFO_0007375', 'EFO_0000701', 'EFO_0003894'], dtype=object), 'count': 3}","[ENSG00000172819,ENSG00000077092,ENSG00000131759]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for acne and has 2 investigational indications.
CHEMBL1294,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,LOUPRKONTZGTKE-LHHVKLHASA-N,Small molecule,True,QUINIDINE,1950.0,4.0,,False,True,[],"['(8r,9s)-quinidine' '.beta.-quinidine' 'Conquinine' 'Kinidin' 'Pitayine'
 'Quinidine']","[('PubChem', array(['17389531', '56320931', '56320932'], dtype=object)), ('drugbank', array(['DB00908'], dtype=object)), ('chEBI', array(['28593'], dtype=object))]","['CHEMBL2068675' 'CHEMBL3707183' 'CHEMBL1435413' 'CHEMBL1200437'
 'CHEMBL2165709']","{'rows': array(['EFO_0001068', 'EFO_0004278', 'HP_0004308', 'EFO_0004287',
       'HP_0002019', 'EFO_0000275', 'MONDO_0100096', 'EFO_0004269',
       'MONDO_0004976', 'EFO_1001413', 'MONDO_0002050', 'EFO_0000612',
       'MONDO_0004976', 'MONDO_0005277', 'MONDO_0002009', 'MONDO_0005301',
       'EFO_1001249', 'EFO_0003758', 'EFO_0004197'], dtype=object), 'count': 19}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1546,CC(N)Cc1ccc(O)cc1,GIKNHHRFLCDOEU-UHFFFAOYSA-N,Small molecule,False,HYDROXYAMPHETAMINE,1969.0,4.0,,False,True,[],"['Dl-4-hydroxyamphetamine' 'Dl-p-hydroxyamphetamine' 'Hydroxyamfetamine'
 'Hydroxyamphetamine' 'NSC-170995' 'Norveritol' 'P-hydroxyamphetamine'
 'Phenol, p-(2-aminopropyl)-' 'Pulsoton' 'Racemic p-hydroxyamphetamine']","[('Wikipedia', array(['Hydroxyamfetamine'], dtype=object)), ('drugbank', array(['DB09352'], dtype=object))]",['CHEMBL1200705'],,"[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969.
CHEMBL1563,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,GUGHGUXZJWAIAS-QQYBVWGSSA-N,Small molecule,True,DAUNORUBICIN HYDROCHLORIDE,1979.0,4.0,CHEMBL178,False,True,['Cerubidine' 'Daunorubicin hydrochloride'],"['Daunorubicin (as hydrochloride)' 'Daunorubicin hcl'
 'Daunorubicin hydrochloride' 'FI 6339 HYDROCHLORIDE'
 'FI 6339 [AS THE BASE]' 'FI-6339' 'FI-6339 HYDROCHLORIDE' 'NDC 0082-4155'
 'NDC-0082-4155' 'NSC-82151' 'RP 13057 HYDROCHLORIDE'
 'RP 13057 [AS THE BASE)' 'RP-13057' 'RP-13057 HYDROCHLORIDE']","[('DailyMed', array(['daunorubicin%20hydrochloride'], dtype=object)), ('PubChem', array(['144208357', '17389073', '85273781', '855543'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_0000220', 'EFO_0000565', 'EFO_0000223',
       'EFO_0003028', 'EFO_0000209', 'EFO_0003811', 'EFO_0004251',
       'EFO_0000218', 'EFO_0000198', 'EFO_0004289', 'MONDO_0000870',
       'EFO_0000224', 'EFO_0003025', 'EFO_0000222', 'EFO_0000221',
       'EFO_0003029', 'EFO_0000691', 'EFO_0003027', 'EFO_0003802',
       'EFO_1001052', 'EFO_1001779', 'EFO_0000094', 'MONDO_0044917'],
      dtype=object), 'count': 24}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for lymphoid leukemia and has 23 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1614702,COc1cc2c(cc1C(=O)N1CCC(Cc3ccc(F)cc3)CC1)c(C(=O)C(=O)N(C)C)cn2C,JBNWDYGOTHQHOZ-UHFFFAOYSA-N,Small molecule,False,SCIO-323,,1.0,,False,False,[],['SCIO-323' 'Scio-323'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1676,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,XTULMSXFIHGYFS-VLSRWLAYSA-N,Small molecule,False,FLUTICASONE FUROATE,2007.0,4.0,,False,True,"['Arnuity ellipta' 'Avamys' 'Flonase sensimist allergy relief'
 'Relvar ellipta' 'Trelegy ellipta' 'Veramyst']","['Allermist' 'Ennhale' 'Fluticasone furoate' 'Furamist' 'GSK 685 698'
 'GSK-685968' 'GSK685968' 'GW-685698X' 'GW685698X']","[('DailyMed', array(['fluticasone%20furoate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/avamys'],
      dtype=object)), ('Wikipedia', array(['Fluticasone_furoate'], dtype=object)), ('drugbank', array(['DB08906'], dtype=object)), ('chEBI', array(['74899'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'EFO_0008521', 'MONDO_0004979', 'EFO_0007533',
       'HP_0001742', 'HP_0006536', 'EFO_1001417', 'EFO_0005854',
       'EFO_0003956'], dtype=object), 'count': 9}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 7 approved and 2 investigational indications.
CHEMBL1724,C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1.[Br-],JRRNZNSGDSFFIR-UHFFFAOYSA-M,Small molecule,False,MEPENZOLATE BROMIDE,1956.0,4.0,CHEMBL524004,False,True,['Cantil'],"['AN-6437' 'FT-0671006' 'Glycophenylate' 'HY-17585' 'Mepenzolate'
 'Mepenzolate Bromide' 'Mepenzolate bromide' 'Mepenzolate methylbromide'
 'Mepenzolone bromide' 'NSC-4358']","[('PubChem', array(['144203918', '170465214', '26748120', '49648464'], dtype=object))]",,,"[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL1742999,,,Antibody,False,CARLUMAB,,2.0,,False,False,[],['CNTO 888' 'CNTO-888' 'Carlumab'],,,"{'rows': array(['EFO_0009448', 'MONDO_0008315', 'MONDO_0004992'], dtype=object), 'count': 3}",[ENSG00000108691],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1908360,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,HKVAMNSJSFKALM-GKUWKFKPSA-N,Small molecule,True,EVEROLIMUS,2009.0,4.0,,False,True,['Afinitor' 'Afinitor disperz' 'Certican' 'Votubia' 'Zortress'],"['40-o-(2-hydroxyethyl)-rapamycin' 'Everolimus' 'RAD 666' 'RAD-001'
 'RAD-666' 'RAD001' 'SDZ-RAD' 'Sdz rad']","[('DailyMed', array(['everolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/votubia'],
      dtype=object)), ('PubChem', array(['144206063'], dtype=object)), ('drugbank', array(['DB01590'], dtype=object)), ('chEBI', array(['68478'], dtype=object))]",,"{'rows': array(['HP_0001871', 'EFO_0004224', 'EFO_0002618', 'EFO_0000339',
       'EFO_0000519', 'EFO_0000349', 'MONDO_0001422', 'EFO_0000691',
       'MONDO_0017623', 'EFO_0000770', 'EFO_0002499', 'EFO_0000326',
       'EFO_1000312', 'MONDO_0015277', 'MONDO_0007576', 'EFO_0000365',
       'EFO_0002916', 'EFO_0005220', 'EFO_0003060', 'MONDO_0018975',
       'EFO_1000630', 'MONDO_0100342', 'EFO_0003897', 'MONDO_0002898',
       'EFO_1000634', 'EFO_0003833', 'MONDO_0011962', 'MONDO_0002120',
       'MONDO_0018076', 'MONDO_0007039', 'EFO_0000231', 'EFO_0002913',
       'EFO_0000574', 'EFO_0003047', 'EFO_0000272', 'MONDO_0000873',
       'EFO_0000474', 'MONDO_0002367', 'EFO_0009708', 'EFO_0005672',
       'MONDO_0001056', 'EFO_0000632', 'EFO_0000222', 'EFO_0001365',
       'EFO_0008620', 'MONDO_0008280', 'EFO_0004243', 'MONDO_0008170',
       'MONDO_0024503', 'EFO_1002048', 'EFO_0001071', 'MONDO_0021054',
       'EFO_1001496', 'EFO_1000852', 'MONDO_0009348', 'MONDO_0002087',
       'MONDO_0003268', 'EFO_0000702', 'EFO_0004599', 'MONDO_0013730',
       'EFO_0002617', 'EFO_0000403', 'EFO_1000601', 'MONDO_0008903',
       'EFO_1001469', 'EFO_0000183', 'EFO_0003884', 'EFO_0000565',
       'EFO_0005537', 'EFO_0007331', 'EFO_0000630', 'MONDO_0007254',
       'MONDO_0003478', 'EFO_0005952', 'EFO_0000637', 'MONDO_0002974',
       'EFO_0009441', 'EFO_0000182', 'HP_0009720', 'MONDO_0020732',
       'EFO_0000544', 'EFO_1001231', 'EFO_1001901', 'EFO_0003860',
       'EFO_0006861', 'MONDO_0018364', 'EFO_0000228', 'EFO_0000558',
       'MONDO_0001187', 'EFO_1001968', 'MONDO_0021063', 'EFO_0004289',
       'EFO_0005221', 'MONDO_0004992', 'EFO_0004252', 'EFO_0001378',
       'MONDO_0011719', 'EFO_1000045', 'MONDO_0016586', 'EFO_0000313',
       'MONDO_0011705', 'EFO_0006859', 'MONDO_0002715', 'EFO_0001376',
       'EFO_0003086', 'EFO_0000333', 'MONDO_0002108', 'MONDO_0002158',
       'EFO_0005543', 'EFO_0001062', 'EFO_0002626', 'EFO_0000181',
       'MONDO_0002603', 'MONDO_0001734', 'MONDO_0002691', 'MONDO_0008315',
       'EFO_0000514', 'EFO_0000305', 'EFO_1000158', 'MONDO_0020290',
       'EFO_0000760', 'EFO_1000026', 'EFO_0000540', 'MONDO_0016642',
       'EFO_1001951', 'MONDO_0016693', 'EFO_0000616', 'EFO_0003869',
       'EFO_0000681', 'EFO_0000220', 'EFO_0000198', 'MONDO_0005411',
       'EFO_0000389', 'EFO_0000588'], dtype=object), 'count': 134}",[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 19 approved and 115 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103879,CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,RVAQIUULWULRNW-UHFFFAOYSA-N,Small molecule,False,GANETESPIB,,3.0,,False,False,[],['Ganetespib' 'STA 9090' 'STA-9090'],"[('drugbank', array(['DB12047'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0001056', 'EFO_0000702', 'MONDO_0008903',
       'EFO_0000673', 'EFO_0006861', 'MONDO_0021063', 'MONDO_0011719',
       'EFO_0002916', 'EFO_0003060', 'EFO_0001378', 'MONDO_0007254',
       'EFO_1000657', 'MONDO_0002158', 'EFO_0000182', 'EFO_0000198',
       'MONDO_0008170', 'EFO_0000756', 'EFO_0000222', 'EFO_0000571',
       'EFO_0000760', 'EFO_0003968', 'EFO_0000770', 'EFO_0005537'],
      dtype=object), 'count': 24}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.
CHEMBL2108568,,,Protein,False,TREBANANIB,,3.0,,False,False,[],['AMG 386' 'AMG-386' 'Trebananib'],,,"{'rows': array(['MONDO_0008170', 'EFO_0000673', 'EFO_1001465', 'EFO_0000632',
       'MONDO_0002158', 'EFO_0008528', 'EFO_0000616', 'EFO_0003060',
       'EFO_0000182', 'MONDO_0007254', 'MONDO_0002087', 'EFO_1000158',
       'EFO_0000681', 'EFO_0003968'], dtype=object), 'count': 14}","[ENSG00000091879,ENSG00000154188]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.
CHEMBL2109354,,,Antibody,False,MONO-DGA-RFB4,,1.0,,False,False,[],['MONO-DGA-RFB4' 'Mono-dga-rfb4'],,,"{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}",[ENSG00000012124],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109481,,,Antibody,False,ICM3,,2.0,,False,False,[],['ICM3'],,,,[ENSG00000076662],Antibody drug with a maximum clinical trial phase of II.
CHEMBL24828,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1,UHTHHESEBZOYNR-UHFFFAOYSA-N,Small molecule,True,VANDETANIB,2011.0,4.0,,False,True,['Caprelsa' 'Zactima'],"['GNF-PF-2188' 'NSC-744325' 'NSC-760766' 'Vandetanib' 'ZD-64' 'ZD-6474'
 'ZD6474']","[('DailyMed', array(['vandetanib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa'],
      dtype=object)), ('PubChem', array(['103905338', '124893338', '144206064', '170465617', '50100123',
       '50112766'], dtype=object)), ('Wikipedia', array(['Vandetanib'], dtype=object)), ('drugbank', array(['DB05294'], dtype=object)), ('chEBI', array(['49960'], dtype=object))]",['CHEMBL533849'],"{'rows': array(['EFO_0000588', 'MONDO_0008627', 'EFO_1001951', 'MONDO_0100342',
       'EFO_0009708', 'EFO_0000349', 'EFO_0000641', 'MONDO_0008315',
       'MONDO_0007254', 'EFO_0001663', 'EFO_0000182', 'EFO_0007535',
       'MONDO_0002367', 'EFO_0000702', 'MONDO_0008903', 'EFO_1000026',
       'EFO_0003060', 'EFO_0003869', 'EFO_0002501', 'EFO_1000657',
       'EFO_0002916', 'MONDO_0011719', 'EFO_0000519', 'EFO_0003897',
       'MONDO_0001187', 'MONDO_0008170', 'EFO_0001378', 'MONDO_0002108',
       'EFO_0006859', 'EFO_1000158', 'EFO_0002499', 'MONDO_0004992',
       'MONDO_0015277', 'EFO_0000501', 'MONDO_0002087', 'EFO_0000222',
       'EFO_0000630', 'MONDO_0004192', 'MONDO_0001056', 'EFO_0002618',
       'MONDO_0002158', 'EFO_0000616', 'EFO_0000181', 'EFO_1001465',
       'EFO_0000621', 'EFO_0002892', 'EFO_0003841', 'EFO_0000365'],
      dtype=object), 'count': 48}","[ENSG00000197122,ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361,ENSG00000142627,ENSG00000133216,ENSG00000145242,ENSG00000116106,ENSG00000070886,ENSG00000080224,ENSG00000135333,ENSG00000182580,ENSG00000044524,ENSG00000154928,ENSG00000196411,ENSG00000146904,ENSG00000106123,ENSG00000183317,ENSG00000120156,ENSG00000165731,ENSG00000101213,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 7 approved and 41 investigational indications. This drug has a black box warning from the FDA.
CHEMBL267044,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,BGRJTUBHPOOWDU-NSHDSACASA-N,Small molecule,False,LEVOSULPIRIDE,,2.0,,False,False,[],"['(-)-sulpiride' 'L-sulpiride' 'Lesuride' 'Levobren' 'Levopraid'
 'Levopride' 'Levosulpiride' 'S-(-)-sulpiride' 'Sulpiride l-form'
 'Sulpiride, (-)-' 'Sulpiride, (s)-']","[('PubChem', array(['11112626', '11113767', '170465834', '26719874', '50104627'],
      dtype=object)), ('Wikipedia', array(['Levosulpiride'], dtype=object)), ('chEBI', array(['64119'], dtype=object))]",,"{'rows': array(['EFO_0005407', 'EFO_0008533', 'HP_0000713'], dtype=object), 'count': 3}","[ENSG00000164270,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3707378,,,Small molecule,False,CB-189625,,-1.0,,False,False,[],['CB-625' 'Cb-189625'],,,,[ENSG00000104321],Small molecule drug.
CHEMBL3989917,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,HZIYEEMJNBKMJH-UHFFFAOYSA-N,Small molecule,False,FOSNETUPITANT,2018.0,4.0,,False,True,[],['07-PNET' 'Fosnetupitant'],"[('drugbank', array(['DB14019'], dtype=object))]",['CHEMBL3989919'],"{'rows': array(['EFO_0006911', 'HP_0002013'], dtype=object), 'count': 2}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chemotherapy-induced nausea and vomiting and vomiting.
CHEMBL4297477,Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1,BUWBRTXGQRBBHG-MJBXVCDLSA-N,Small molecule,False,BREPOCITINIB,,3.0,,False,False,[],['Brepocitinib' 'PF-06700841' 'Pf-06700841'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BREPOCITINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15003'], dtype=object))]",['CHEMBL4298160'],"{'rows': array(['EFO_0000384', 'EFO_0000540', 'EFO_1000710', 'EFO_0003778',
       'EFO_0000540', 'EFO_0000274', 'EFO_0000398', 'EFO_0000676',
       'EFO_0000729', 'MONDO_0007915', 'EFO_0004192', 'EFO_0003086',
       'EFO_1002028'], dtype=object), 'count': 13}","[ENSG00000105397,ENSG00000162434]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL4303389,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1,UQTPDWDAYHAZNT-AWEZNQCLSA-N,Small molecule,False,NS-018,,2.0,,False,False,[],['Ilginatinib' 'NS-018' 'Ns-018'],,,"{'rows': array(['EFO_0002430', 'MONDO_0044903'], dtype=object), 'count': 2}",[ENSG00000096968],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL440498,O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1,ROSNVSQTEGHUKU-UHFFFAOYSA-N,Small molecule,False,CTS-1027,,2.0,,False,False,[],['Cts-1027' 'RO-1130830' 'RS-130830'],"[('drugbank', array(['DB08490'], dtype=object))]",,"{'rows': array(['EFO_0004220', 'EFO_0003047'], dtype=object), 'count': 2}","[ENSG00000149968,ENSG00000157227,ENSG00000087245,ENSG00000100985,ENSG00000137745,ENSG00000262406,ENSG00000118113]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594248,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O)C(C)C,LDVRMNJZLWXJPL-JKQNMTHDSA-N,Protein,False,CALCITONIN HUMAN,1986.0,4.0,,False,True,['Cibacalcin'],['Calcitonin (human synthetic)'],,,"{'rows': array(['EFO_0005754'], dtype=object), 'count': 1}",[ENSG00000004948],Protein drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for parathyroid disease.
CHEMBL4594611,,,Antibody drug conjugate,False,PATRITUMAB DERUXTECAN,,3.0,,False,False,[],['Patritumab deruxtecan' 'U3 1402' 'U3-1402' 'U3-1402A' 'U31402'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PATRITUMAB%20DERUXTECAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}","[ENSG00000065361,ENSG00000198900]",Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4650387,,,Protein,False,CDX-301,,2.0,,False,False,[],['Amg-949' 'CDX-301' 'Cdx 301' 'Cdx-301'],,,"{'rows': array(['EFO_0005221', 'MONDO_0008315', 'EFO_0006859', 'EFO_0002617',
       'MONDO_0007254', 'MONDO_0001056', 'EFO_0000182', 'EFO_0003060',
       'EFO_0000681', 'EFO_0000574', 'EFO_0002618', 'MONDO_0007576',
       'EFO_1001951', 'MONDO_0008170', 'EFO_0000756', 'MONDO_0002158',
       'EFO_1001469', 'EFO_0000403'], dtype=object), 'count': 18}",[ENSG00000122025],Protein drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications.
CHEMBL896,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,ZQDWXGKKHFNSQK-UHFFFAOYSA-N,Small molecule,False,HYDROXYZINE,1956.0,4.0,,False,True,[],"['Atarax' 'Ataraxoid' 'Hydroxyzine' 'Marex' 'NSC-169188' 'Orgatrax'
 'Tran-q' 'Tranquizine' 'U.c.b-4492']","[('PubChem', array(['144207118', '170464958'], dtype=object)), ('TG-GATEs', array(['71'], dtype=object)), ('Wikipedia', array(['Hydroxyzine'], dtype=object)), ('drugbank', array(['DB00557'], dtype=object)), ('chEBI', array(['5818'], dtype=object))]",['CHEMBL1201007' 'CHEMBL3186993' 'CHEMBL1200467'],"{'rows': array(['EFO_0004257', 'HP_0000989', 'HP_0000726', 'EFO_0006788',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_0005531', 'EFO_0005230',
       'EFO_0000701'], dtype=object), 'count': 9}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 6 approved and 3 investigational indications.
CHEMBL998,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,JCCNYMKQOSZNPW-UHFFFAOYSA-N,Small molecule,False,LORATADINE,1993.0,4.0,,False,True,"['Alavert' ""Children's claritin"" 'Claritin' 'Claritin hives relief'
 'Claritin hives relief reditab' 'Claritin reditabs' 'Clarityn'
 'Clarityn rapide' 'Clarityne' 'Hay-rite' 'Loratadine'
 'Loratadine redidose' 'Roletra']","['BAY76-2211' 'Claritin-D' 'Loratadine' 'NSC-758628' 'SCH 29851'
 'SCH-29851']","[('DailyMed', array(['loratadine'], dtype=object)), ('PubChem', array(['104171183', '11111394', '11113345', '124880597', '124880599',
       '144203736', '144211849', '170464867', '26719690', '26747010',
       '26751528', '50104102', '535878', '56424146', '85231118', '855843',
       '90340694'], dtype=object)), ('Wikipedia', array(['Loratadine'], dtype=object)), ('drugbank', array(['DB00455'], dtype=object))]",['CHEMBL4092143'],"{'rows': array(['EFO_0004232', 'HP_0003418', 'EFO_0001378', 'EFO_0005531',
       'MONDO_0004979', 'EFO_0000685', 'MONDO_0005271', 'EFO_0003956',
       'MONDO_0011705', 'MONDO_0005301', 'MONDO_0007254', 'HP_0000989',
       'EFO_1001417', 'MONDO_0100096', 'EFO_0005854', 'EFO_0000574',
       'EFO_0000274'], dtype=object), 'count': 17}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 11 investigational indications.
CHEMBL1200644,CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],XEKSTYNIJLDDAZ-JASSWCPGSA-D,Oligosaccharide,True,FONDAPARINUX SODIUM,2001.0,4.0,CHEMBL1201202,False,True,['Arixtra' 'Fondaparinux sodium'],"['Fondaparin sodium' 'Fondaparinux sodium' 'Fondaparinux sodium for assay'
 'Fondaparinux sodium identification' 'IC-851589' 'ORG 31540' 'ORG-31540'
 'Quixidar' 'SR 90107A' 'SR-90107A']","[('DailyMed', array(['fondaparinux%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra'],
      dtype=object))]",,"{'rows': array(['HP_0001907', 'HP_0000083', 'EFO_0000612', 'EFO_0003907',
       'EFO_0004286', 'EFO_1000985', 'EFO_0003827', 'HP_0004936'],
      dtype=object), 'count': 8}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201244,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,YXRDKMPIGHSVRX-OOJCLDBCSA-N,Small molecule,False,ROCURONIUM,1994.0,4.0,,False,True,[],['Rocuronium' 'Rocuronium cation' 'Rocuronium ion'],"[('PubChem', array(['50112687'], dtype=object)), ('Wikipedia', array(['Rocuronium_bromide'], dtype=object)), ('drugbank', array(['DB00728'], dtype=object)), ('chEBI', array(['8884'], dtype=object))]",['CHEMBL1200648'],"{'rows': array(['EFO_0007490', 'EFO_0009492', 'EFO_0003843', 'EFO_0010581',
       'EFO_0003931', 'EFO_0009492', 'HP_0003326', 'EFO_0003086',
       'HP_0003418', 'MONDO_0008315', 'EFO_0002618', 'MONDO_0021117'],
      dtype=object), 'count': 12}","[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 11 investigational indications.
CHEMBL1714,CNC1(c2ccccc2Cl)CCCCC1=O.Cl,VCMGMSHEPQENPE-UHFFFAOYSA-N,Small molecule,False,KETAMINE HYDROCHLORIDE,1970.0,4.0,CHEMBL742,False,True,"['Anaket-V' 'Ketalar' 'Ketamine hydrochloride' 'Ketanest' 'Ketavet'
 'Vetalar']","['CI-581' 'CL 369' 'CL-369' 'CN-52,372-2' 'CN-52372-2' 'CN-523722'
 'Ketamine (as hydrochloride)' 'Ketamine hcl' 'Ketamine hydrochloride'
 'Ketamine hydrochloride ciii' 'Ketamini hydrochloridum' 'Special k'
 'Vetalar']","[('DailyMed', array(['ketamine%20hydrochloride'], dtype=object)), ('chEBI', array(['650657'], dtype=object))]",,"{'rows': array(['EFO_0000546', 'EFO_0003931', 'EFO_0000713', 'MONDO_0007079',
       'EFO_0007430', 'MONDO_0002009', 'EFO_0009854', 'EFO_0005611',
       'EFO_0002610', 'HP_0000360', 'MONDO_0004992', 'EFO_1000391',
       'EFO_0004321', 'HP_0000989', 'EFO_0000474', 'HP_0000713',
       'MONDO_0002050', 'HP_0100543', 'MONDO_0005351', 'EFO_0004320',
       'EFO_0009963', 'EFO_0003015', 'MONDO_0004985', 'EFO_1001884'],
      dtype=object), 'count': 24}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 24 investigational indications.
CHEMBL1743000,,,Antibody drug conjugate,False,CITATUZUMAB BOGATOX,,2.0,,False,False,[],['Citatuzumab bogatox' 'VB6-845'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000119888],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL203567,Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1,IJDQETGUEUJVTB-HNNXBMFYSA-N,Small molecule,False,RO-3201195,,1.0,,False,False,[],['Ro-3201195' 'SYD003' 'Syd-003'],"[('drugbank', array(['DB08424'], dtype=object)), ('chEBI', array(['45116'], dtype=object))]",,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2103802,CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1.C[C@H](O)CO.O,GOADIQFWSVMMRJ-UPGAGZFNSA-N,Small molecule,False,DAPAGLIFLOZIN PROPANEDIOL,2012.0,4.0,CHEMBL429910,False,True,['Farxiga' 'Forxiga'],['BMS-512148-05'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga'],
      dtype=object)), ('chEBI', array(['85079'], dtype=object))]",,"{'rows': array(['EFO_0003144', 'MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 3}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for heart failure and type 2 diabetes mellitus and has 1 investigational indication.
CHEMBL2103815,CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,NYGCNONRVCGHAT-UFIKZEAMSA-N,Protein,False,LARAZOTIDE ACETATE,,3.0,CHEMBL2105646,False,False,[],['AT-1001' 'AT-1001 (LARAZOTIDE ACETATE)' 'Larazotide acetate'],,,"{'rows': array(['EFO_0001060'], dtype=object), 'count': 1}","[ENSG00000117971,ENSG00000080644]",Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109249,,,Antibody,False,AMG-557,,2.0,,False,False,[],['AMG-557' 'Amg-557' 'MEDI-5872' 'Medi 5872' 'Prezalumab'],,,"{'rows': array(['MONDO_0007915', 'EFO_0000699', 'EFO_0003834', 'EFO_0000676'],
      dtype=object), 'count': 4}",[ENSG00000160223],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2109621,,,Antibody,False,ABITUZUMAB,,2.0,,False,False,[],"['ALD403' 'Abituzumab' 'DI 17E6' 'DI-17E6' 'DI17E6' 'EMD 525797'
 'EMD-525797']",,,"{'rows': array(['MONDO_0008170', 'EFO_0004244', 'EFO_0000717', 'MONDO_0008315',
       'EFO_1001951'], dtype=object), 'count': 5}","[ENSG00000150093,ENSG00000138448,ENSG00000115221,ENSG00000259207,ENSG00000105855,ENSG00000082781]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2110579,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1,VQPFSIRUEPQQPP-MXBOTTGLSA-N,Small molecule,False,ANAMORELIN,,3.0,,False,False,[],['Anamorelin' 'RC-1291' 'ST-1291'],"[('drugbank', array(['DB06645'], dtype=object))]",['CHEMBL2103794'],"{'rows': array(['HP_0004326', 'HP_0012378', 'EFO_0002618', 'HP_0004326',
       'EFO_0003060'], dtype=object), 'count': 5}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL232201,CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1,CZCHIEJNWPNBDE-UHFFFAOYSA-N,Small molecule,False,BENZIODARONE,,4.0,,True,True,[],['Amplivix' 'Benziodarone' 'L 2329' 'L-2329' 'NSC-82133'],"[('PubChem', array(['144205346', '170465852', '29216089'], dtype=object)), ('TG-GATEs', array(['130'], dtype=object)), ('Wikipedia', array(['Benziodarone'], dtype=object)), ('drugbank', array(['DB13277'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000198668],Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region.
CHEMBL2326966,N=C(N)NCCC[C@H](NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)[O-],SVNJBEMPMKWDCO-KCHLEUMXSA-N,Small molecule,False,SF-1126,,2.0,,False,False,[],['SF 1126' 'SF-1126' 'SF-1126 INNER SALT' 'Sf-1126'],,,"{'rows': array(['EFO_0000181', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000621'],
      dtype=object), 'count': 4}","[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3545117,,,Small molecule,False,AVE-9940,,1.0,,False,False,[],['Ave-9940'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545237,C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C,CKAXZOYFIHQCBN-UQOAMHMYSA-N,Small molecule,False,HE3235,,1.0,,False,False,['Apotone'],['Apoptone' 'HE-3235' 'He 3235' 'He3235'],,,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3707247,CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N,XRVDGNKRPOAQTN-FQEVSTJZSA-N,Small molecule,False,OZANIMOD,2020.0,4.0,,False,True,[],['Ozanimod' 'RPC-1063' 'RPC1063'],"[('drugbank', array(['DB12612'], dtype=object))]",['CHEMBL3707246'],"{'rows': array(['EFO_0000729', 'MONDO_0100096', 'EFO_0001421', 'EFO_0000384',
       'MONDO_0005301', 'MONDO_0005301', 'EFO_0000729', 'EFO_0000540',
       'EFO_0003929'], dtype=object), 'count': 9}",[ENSG00000170989],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 5 investigational indications.
CHEMBL4297873,,,Protein,False,"ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT",2004.0,4.0,,False,True,['Advate'],"['Advate' 'Antihemophilic factor, human recombinant' 'BAY 14-2222'
 'BAY 81-8973' 'BAY W 6240' 'BAY-14-2222' 'BAY-81-8973' 'BAY-W-6240'
 'BAY81-8973' 'Bay81-8973' 'Factor viii (rdna)' 'Factor viii octocog alfa'
 'Factor viii, recombinant' 'Octocog alfa']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/advate'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602', 'Orphanet_903'], dtype=object), 'count': 2}",[ENSG00000185010],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for hemophilia a and has 1 investigational indication.
CHEMBL435191,O=C1c2c(c3c4ccc(O)cc4n([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c3[nH]c4cc(O)ccc4c23)C(=O)N1NC(CO)CO,QMVPQBFHUJZJCS-NTKFZFFISA-N,Small molecule,False,EDOTECARIN,,3.0,,False,False,[],['Edotecarin' 'J-107088' 'PF-804950'],"[('drugbank', array(['DB04882'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000519', 'EFO_0003897'], dtype=object), 'count': 3}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4435170,[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,BZZKEPGENYLQSC-FIBGUPNXSA-N,Small molecule,False,DEUCRAVACITINIB,2022.0,4.0,CHEMBL4596392,False,True,['Sotyktu'],['BMS-986165' 'Bms-986165' 'Deucravacitinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DEUCRAVACITINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003778', 'EFO_0003834', 'EFO_0000729', 'EFO_0000540',
       'HP_0000999', 'EFO_0003086', 'EFO_0000676', 'MONDO_0007915',
       'EFO_0004192', 'EFO_0005761', 'HP_0001410', 'MP_0001845'],
      dtype=object), 'count': 12}",[ENSG00000105397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 11 investigational indications.
CHEMBL4594547,,,Antibody,False,TEMELIMAB,,2.0,,False,False,[],['GNBAC1' 'Gnbac1' 'Temelimab'],,,"{'rows': array(['MONDO_0005147', 'EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 3}",[ENSG00000242950],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650321,C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1,MZPVEMOYADUARK-UHFFFAOYSA-N,Small molecule,False,ORELABRUTINIB,,3.0,,False,False,['Innobruka'],['ICP-022' 'ICP022' 'Icp-022' 'Orelabrutinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ORELABRUTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000096', 'MONDO_0018906', 'EFO_1001469', 'EFO_0007160',
       'MONDO_0007915', 'EFO_0000616', 'EFO_0000403', 'EFO_0003929',
       'EFO_0009441', 'EFO_0000095', 'EFO_0000183', 'EFO_0001421',
       'MONDO_0004992'], dtype=object), 'count': 13}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL4650365,C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F,WDHOIABIERMLGY-CMJOXMDJSA-N,Small molecule,False,CAMIZESTRANT,,3.0,,False,False,[],['AZ-14066724' 'AZ14066724' 'AZD-9833' 'AZD9833' 'Azd9833' 'Camizestrant'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CAMIZESTRANT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001421', 'MONDO_0007254', 'EFO_0003869'], dtype=object), 'count': 3}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4802239,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.O=C(O)CCC(=O)O,YXYAEUMTJQGKHS-UHFFFAOYSA-N,Small molecule,True,MOBOCERTINIB SUCCINATE,2021.0,4.0,CHEMBL4650319,False,True,['Exkivity'],[],,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for non-small cell lung carcinoma. This drug has a black box warning from the FDA.
CHEMBL1175,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,ZEUITGRIYCTCEM-KRWDZBQOSA-N,Small molecule,True,DULOXETINE,2004.0,4.0,,False,True,[],['Cymbalta' 'Duloxetine' 'LY-248686' 'LY248686'],"[('PubChem', array(['124893161', '26719725', '26757978', '49681583'], dtype=object)), ('Wikipedia', array(['Duloxetine'], dtype=object)), ('drugbank', array(['DB00476'], dtype=object)), ('chEBI', array(['36795'], dtype=object))]",['CHEMBL1200328'],"{'rows': array(['MONDO_0005301', 'HP_0012532', 'EFO_0005762', 'HP_0000020',
       'EFO_0001358', 'EFO_0001358', 'EFO_0005687', 'MONDO_0002009',
       'EFO_0000400', 'EFO_0005762', 'MONDO_0005180', 'MONDO_0005178',
       'EFO_0003888', 'HP_0010992', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0002009', 'MONDO_0002050', 'HP_0003418', 'EFO_0006788',
       'EFO_1000783', 'EFO_0004701', 'EFO_0005687', 'EFO_0005230',
       'EFO_0000712', 'EFO_0007169', 'HP_0030834', 'EFO_0005230',
       'EFO_1001951', 'MONDO_0001583', 'MONDO_0002009', 'MONDO_0005090',
       'EFO_0004244', 'EFO_0004540', 'HP_0000020', 'HP_0003326',
       'EFO_1001951', 'HP_0003419', 'HP_0100543', 'MONDO_0005301',
       'EFO_0003843', 'EFO_0003843', 'EFO_0003100', 'EFO_0004616',
       'MONDO_0007079', 'EFO_1001892', 'MONDO_0005178', 'MONDO_0002050',
       'EFO_1000783', 'EFO_0000401', 'EFO_0002970'], dtype=object), 'count': 51}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 38 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200819,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC.Cl,GDWDBGSWGNEMGJ-UHFFFAOYSA-N,Small molecule,False,ARTICAINE HYDROCHLORIDE,2000.0,4.0,CHEMBL1093,False,True,[],"['40 045' 'Articaine hcl' 'Articaine hydrochloride'
 'Carticaine hydrochloride' 'HOE 045' 'HOE-045' 'HOE-40045' 'Ubistesine'
 'Ultracain']","[('DailyMed', array(['articaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204160', '170464825', '56463593'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000.
CHEMBL1200875,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl,XOEVKNFZUQEERE-UHFFFAOYSA-N,Small molecule,False,FLAVOXATE HYDROCHLORIDE,1970.0,4.0,CHEMBL1493,False,True,['Flavoxate hydrochloride' 'Urispas' 'Urispas 200'],"['DW-61' 'Flavoxate' 'Flavoxate hcl' 'Flavoxate hydrochloride'
 'NSC-114649']","[('DailyMed', array(['flavoxate%20hydrochloride'], dtype=object)), ('PubChem', array(['144204088', '170466285'], dtype=object)), ('chEBI', array(['5089'], dtype=object))]",,"{'rows': array(['EFO_0003830', 'EFO_0003901', 'EFO_0003878', 'EFO_0003103'],
      dtype=object), 'count': 4}","[ENSG00000205268,ENSG00000171408,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000113231,ENSG00000073417]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 4 approved indications.
CHEMBL1201099,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O=P(O)(O)O,JPGKFBXFEQWCAI-CCLYOLAMSA-N,Small molecule,False,CODEINE PHOSPHATE,1952.0,4.0,CHEMBL485,False,True,['Bepro' 'Evacode' 'Galcodine'],"['Codeine phosphate' 'Codeine phosphate anhydrous' 'Codeine phosphate bp'
 'Codeine phosphate cii' 'Codeine phosphate hemihydrate'
 'Codeine phosphate hydrate' 'Codeini phosphas' 'Methylmorphine']","[('DailyMed', array(['codeine%20phosphate'], dtype=object))]",,"{'rows': array(['MONDO_0005277', 'HP_0012735', 'EFO_0003890', 'HP_0003394',
       'EFO_0003843', 'EFO_0000764', 'HP_0011868'], dtype=object), 'count': 7}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 4 approved and 3 investigational indications.
CHEMBL1201132,Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,YZLZPSJXMWGIFH-BCXQGASESA-N,Small molecule,True,NALBUPHINE HYDROCHLORIDE,1979.0,4.0,CHEMBL895,False,True,['Nalbuphine' 'Nalbuphine hydrochloride' 'Nubain'],"['EN-2234A' 'NSC-757829' 'Nalbufine hydrochloride' 'Nalbuphine hcl'
 'Nalbuphine hydrochloride']","[('DailyMed', array(['nalbuphine%20hydrochloride'], dtype=object)), ('PubChem', array(['56463337'], dtype=object)), ('chEBI', array(['7455'], dtype=object))]",,"{'rows': array(['HP_0000175', 'EFO_0005611', 'EFO_0000222', 'EFO_0003843',
       'EFO_1001250', 'EFO_0005323', 'HP_0000989', 'EFO_0009267',
       'EFO_0001421'], dtype=object), 'count': 9}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for pain and has 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1437,NC[C@H](O)c1ccc(O)c(O)c1,SFLSHLFXELFNJZ-QMMMGPOBSA-N,Small molecule,False,NOREPINEPHRINE,,4.0,,False,True,[],"['(-)-noradrenaline' 'Levarterenol' 'Levophed' 'NSC-757246'
 'Nor adrenalin' 'Norepinephrine' 'R-norepinephrine']","[('PubChem', array(['144212261', '26754493', '26754494', '29215339', '50109852',
       '50109853', '57288371', '90341660'], dtype=object)), ('Wikipedia', array(['Norepinephrine'], dtype=object)), ('drugbank', array(['DB00368'], dtype=object)), ('chEBI', array(['18357'], dtype=object))]","['CHEMBL1356607' 'CHEMBL5087452' 'CHEMBL3273169' 'CHEMBL2311152'
 'CHEMBL3248963' 'CHEMBL2130595' 'CHEMBL1434513']","{'rows': array(['EFO_0005207', 'EFO_0000319', 'MONDO_0043771', 'HP_0031273',
       'EFO_0005251', 'EFO_0005252', 'HP_0002140', 'EFO_0004610',
       'MONDO_0002050', 'HP_0002140', 'EFO_0002497', 'EFO_0001073',
       'MONDO_0008867', 'EFO_0003777', 'HP_0100806', 'HP_0100806',
       'MONDO_0001382', 'MONDO_0043510', 'EFO_0005251', 'MP_0001845',
       'EFO_0000319', 'EFO_0007450', 'HP_0100543', 'EFO_0006834'],
      dtype=object), 'count': 24}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 approved and 19 investigational indications.
CHEMBL160,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,PMATZTZNYRCHOR-CGLBZJNRSA-N,Protein,True,CYCLOSPORINE,1983.0,4.0,,False,True,"['Capimune' 'Capsorin' 'Cequa' 'Cyclosporine' 'Deximune' 'Gengraf'
 'Ikervis' 'Neoral' 'Optimmune' 'Restasis' 'Restasis multidose'
 'Sandimmun' 'Sandimmune' 'Sangcya' 'Vanquoral' 'Verkazia']","['27-400' 'ANTIBIOTIC S-7481F1' 'Atopica' 'Ciclosporin' 'Ciclosporin a'
 'Ciclosporinum' 'Cyclosporin' 'Cyclosporin a' 'Cyclosporine'
 'Cyclosporine a' 'Cyclosporine microemulsion' 'Cyclosporine, modified'
 'Equoral' 'Mitogard' 'NSC-290193' 'Neoplanta' 'Neurostat' 'OL-27-400'
 'Ramihyphin a' 'SANG-35' 'SDZ-OXL-400' 'Vevye' 'Zinograf me']","[('Wikipedia', array(['Ciclosporin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis'],
      dtype=object)), ('TG-GATEs', array(['142'], dtype=object)), ('PubChem', array(['11532934', '144204218', '144212166', '170466812', '26757675',
       '56422786'], dtype=object)), ('DailyMed', array(['cyclosporine'], dtype=object)), ('drugbank', array(['DB00091'], dtype=object)), ('chEBI', array(['4031'], dtype=object))]",,"{'rows': array(['EFO_0000389', 'MP_0001845', 'EFO_1001478', 'EFO_0000565',
       'EFO_0000685', 'EFO_0000274', 'EFO_0000681', 'EFO_0000783',
       'EFO_0000183', 'HP_0009926', 'EFO_0003777', 'MONDO_0019469',
       'EFO_0004599', 'EFO_0000400', 'EFO_0000365', 'EFO_1000785',
       'EFO_0004254', 'EFO_0003884', 'EFO_1001365', 'MONDO_0001475',
       'EFO_0000574', 'MONDO_0013730', 'EFO_1001231', 'MONDO_0018906',
       'MONDO_0021193', 'EFO_1001264', 'MONDO_0007254', 'EFO_0008507',
       'EFO_0009464', 'HP_0000964', 'EFO_0009492', 'EFO_1000560',
       'EFO_0000220', 'MONDO_0020547', 'EFO_0002687', 'EFO_0007141',
       'EFO_1001051', 'EFO_0004236', 'EFO_0005676', 'EFO_0009609',
       'EFO_0003966', 'EFO_0001054', 'EFO_0000694', 'MONDO_0005041',
       'MONDO_0019249', 'MONDO_0001705', 'EFO_0007160', 'MONDO_0018305',
       'EFO_0003780', 'MONDO_0008315', 'EFO_0004220', 'EFO_0000649',
       'EFO_0000222', 'MONDO_0004992', 'EFO_0005761', 'EFO_0000616',
       'MONDO_0008380', 'MONDO_0018896', 'EFO_0007527', 'EFO_0000341',
       'EFO_0003047', 'Orphanet_848', 'EFO_0000198', 'EFO_0000621',
       'EFO_0000540', 'EFO_0006927', 'EFO_0003818', 'MONDO_0019019',
       'EFO_0004214', 'EFO_1001413', 'EFO_1000690', 'EFO_0008583',
       'EFO_0000557', 'MONDO_0015540', 'EFO_0000544', 'EFO_0002428',
       'EFO_0001642', 'EFO_0000691', 'EFO_0009708', 'MONDO_0011382',
       'MONDO_0002898', 'EFO_0003833', 'EFO_0000612', 'MONDO_0009387',
       'EFO_0007157', 'MONDO_0002158', 'MONDO_0005148', 'EFO_0000403',
       'EFO_0000764', 'EFO_0000339', 'MONDO_0019623', 'EFO_1000906',
       'HP_0001915', 'EFO_0003086', 'EFO_0004276', 'MONDO_0044881',
       'EFO_1001951', 'EFO_0005952', 'MONDO_0100096', 'EFO_1002048',
       'EFO_0000678', 'MONDO_0018904', 'MONDO_0008170', 'EFO_0000182',
       'EFO_0001378', 'EFO_0000095', 'EFO_1001469', 'MONDO_0043510',
       'MONDO_0004768', 'MONDO_0002367', 'MONDO_0020077', 'MONDO_0018923',
       'EFO_0000309', 'MONDO_0000870', 'EFO_1001156', 'MONDO_0005147',
       'MONDO_0010788', 'EFO_0000676', 'MONDO_0020290', 'EFO_0007359',
       'MONDO_0000873', 'EFO_0001421', 'EFO_0007183', 'EFO_0004286',
       'EFO_1000102', 'EFO_0005531', 'MONDO_0019391', 'EFO_0009441',
       'HP_0001919'], dtype=object), 'count': 129}",[ENSG00000196262],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 7 approved and 122 investigational indications. This drug has a black box warning from the FDA.
CHEMBL180022,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,JWNPDZNEKVCWMY-VQHVLOKHSA-N,Small molecule,False,NERATINIB,2017.0,4.0,,False,True,[],['CDP-820' 'HKI-272' 'Neratinib' 'WAY-179272'],"[('PubChem', array(['124950160'], dtype=object)), ('Wikipedia', array(['Neratinib'], dtype=object)), ('drugbank', array(['DB11828'], dtype=object))]",['CHEMBL3989921'],"{'rows': array(['EFO_0000339', 'MONDO_0007254', 'EFO_0000313', 'EFO_0003869',
       'EFO_1001951', 'EFO_0000305', 'EFO_0000673', 'EFO_0003060',
       'EFO_1000294', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0007254',
       'EFO_0000182', 'EFO_0000519', 'EFO_0003891', 'EFO_0003968',
       'EFO_0000616', 'MONDO_0008170', 'EFO_0000553', 'EFO_0005537',
       'EFO_0000305'], dtype=object), 'count': 21}","[ENSG00000178568,ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for breast cancer and breast carcinoma and has 19 investigational indications.
CHEMBL1829174,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,BZCALJIHZVNMGJ-HSZRJFAPSA-N,Small molecule,False,FASIGLIFAM,,3.0,,False,False,[],"['Fasiglifam' 'Fasiglifam hemihydrate' 'Fasiglifam hydrate' 'TAK-875'
 'TAK875' 'Tak-875 anhydrous']","[('drugbank', array(['DB12491'], dtype=object))]",['CHEMBL2047171' 'CHEMBL2047159'],"{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000126266],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108081,,,Protein,False,TRAFERMIN,,3.0,,False,False,[],['CAB-2001' 'Trafermin'],,,"{'rows': array(['EFO_0000649', 'EFO_0009472', 'EFO_1001459', 'HP_0200042'],
      dtype=object), 'count': 4}",[ENSG00000066468],Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2109482,,,Antibody,False,BI-505,,2.0,,False,False,[],['BI-505' 'Bi-505'],,,"{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}",[ENSG00000090339],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109513,,,Antibody,False,PD-360324,,2.0,,False,False,[],['PD-360324' 'Pd-360324'],,,"{'rows': array(['EFO_0001075', 'MONDO_0004992', 'EFO_1000251', 'EFO_0000685',
       'EFO_0003834', 'DOID_13406'], dtype=object), 'count': 6}",[ENSG00000184371],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL2109607,,,Antibody,False,MEDI-8968,,2.0,,False,False,[],['MEDI-8968' 'Medi-8968'],,,"{'rows': array(['EFO_1000710', 'EFO_0000341'], dtype=object), 'count': 2}",[ENSG00000115594],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2325014,Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl,ZYSCOUXLBXGGIM-UHFFFAOYSA-N,Small molecule,False,PF-05089771,,2.0,,False,False,[],['Pf-05089771'],"[('drugbank', array(['DB14856'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0010072', 'EFO_1000783', 'MONDO_0016028'],
      dtype=object), 'count': 4}",[ENSG00000169432],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL236593,O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1,CGDZXLJGHVKVIE-DNVCBOLYSA-N,Small molecule,False,TELCAGEPANT,,3.0,,False,False,[],['MK-0974' 'MK0974' 'Mk-0974' 'Telcagepant'],"[('Wikipedia', array(['Telcagepant'], dtype=object)), ('drugbank', array(['DB12228'], dtype=object))]",['CHEMBL2105656'],"{'rows': array(['MONDO_0005277', 'MONDO_0005277'], dtype=object), 'count': 2}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication.
CHEMBL3544941,,,Small molecule,False,RG7185,,1.0,,False,False,[],['RO5271983' 'Rg7185'],,,,[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545396,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1,CSGQVNMSRKWUSH-IAGOWNOFSA-N,Small molecule,False,BMS-690514,,2.0,,False,False,[],['Bms 6690514' 'Bms 690514' 'Bms-690514'],"[('drugbank', array(['DB11665'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0003060', 'MONDO_0007254'], dtype=object), 'count': 3}","[ENSG00000141736,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000178568,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3707383,,,Oligonucleotide,False,MONGERSEN SODIUM,,3.0,,False,False,[],['GED-0301' 'GED-0301 SODIUM' 'Mongersen sodium'],,,"{'rows': array(['EFO_0000729', 'EFO_0000384'], dtype=object), 'count': 2}",[ENSG00000101665],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL382277,NC(=O)C1CCCC2c3cc(Cl)ccc3NC12,NYORQUCSPQVLTE-UHFFFAOYSA-N,Small molecule,False,EX-527,,2.0,,False,False,[],['Ex-527'],,,,[ENSG00000096717],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3908979,COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)ncc1C#N,BHKDKKZMPODMIQ-UHFFFAOYSA-N,Small molecule,False,FGF401,,2.0,,False,False,[],['FGF-401' 'Fgf401' 'Roblitinib'],,,"{'rows': array(['EFO_0000182'], dtype=object), 'count': 1}",[ENSG00000160867],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4175981,CC(C)(C)[C@@H](CO)NC(=O)c1nn(-c2c[n+]([O-])ccn2)c2c1C[C@@H]1C[C@H]21,ACSQLTBPYZSGBA-GMXVVIOVSA-N,Small molecule,False,OLORINAB,,2.0,,False,False,[],['APD-371' 'APD371' 'Apd371' 'Olorinab'],"[('drugbank', array(['DB14998'], dtype=object))]",,"{'rows': array(['HP_0002027', 'EFO_0000384', 'EFO_0000555'], dtype=object), 'count': 3}",[ENSG00000188822],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL428647,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,RCINICONZNJXQF-MZXODVADSA-N,Small molecule,True,PACLITAXEL,1992.0,4.0,,False,True,"['Abraxane' 'Apealea' 'Pacitaxel' 'Paclitaxel' 'Paxene' 'Taxol'
 'Taxol 100']","['(-)-paclitaxel' 'ABI-007' 'ABI-007 COMPONENT PACLITAXEL' 'BMS 181339-01'
 'BMS-181339-01' 'Capxol' 'Cyclopax' 'DHP 107' 'DHP-107' 'Ebetaxel'
 'Empac' 'Endotag 1' 'Genaxol' 'Genetaxyl' 'Genexol' 'Genexol-pm'
 'Intaxel' 'Lep-etu' 'MBT 0206' 'MBT-0206' 'Mitotax' 'NK 105' 'NK-105'
 'NSC-125973' 'Oncogel' 'Onxal' 'Onxol' 'Pacliex' 'Paclitaxel'
 'Paclitaxel (taxus canadensis)' 'Paclitaxol' 'Plaxicel' 'QW-8184'
 'Taxalbin' 'Taxol' 'Taxol a' 'Taxus' 'Taxus liberte' 'Taxus stent'
 'Tocosol paclitaxel' 'Yewtaxan']","[('DailyMed', array(['paclitaxel'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/apealea'],
      dtype=object)), ('PubChem', array(['124893045', '144205660', '418145', '56463361'], dtype=object)), ('drugbank', array(['DB01229'], dtype=object)), ('chEBI', array(['45863'], dtype=object))]",,"{'rows': array(['EFO_0003869', 'EFO_1000984', 'EFO_0000616', 'EFO_1000350',
       'MONDO_0021043', 'EFO_1000043', 'MONDO_0008315', 'EFO_0002938',
       'EFO_0004243', 'EFO_1001931', 'MONDO_0002158', 'MONDO_0003060',
       'EFO_0006818', 'EFO_0002892', 'MONDO_0001187', 'EFO_0006352',
       'EFO_0007535', 'EFO_0000685', 'EFO_0003860', 'EFO_0006859',
       'MONDO_0018364', 'EFO_0003893', 'MONDO_0004658', 'EFO_0001061',
       'EFO_0002916', 'EFO_0000308', 'EFO_0000305', 'EFO_0005952',
       'EFO_0003859', 'EFO_0009708', 'MONDO_0004669', 'EFO_0000702',
       'MONDO_0044704', 'MONDO_0021148', 'MONDO_0021657', 'EFO_0000514',
       'EFO_0000519', 'MONDO_0005184', 'EFO_0000180', 'EFO_0000294',
       'EFO_0004272', 'EFO_1000796', 'EFO_0000466', 'MONDO_0005271',
       'MONDO_0003751', 'EFO_1000576', 'EFO_1001100', 'MONDO_0021251',
       'EFO_1000158', 'EFO_1000294', 'EFO_0000503', 'MONDO_0004192',
       'MONDO_0011719', 'EFO_0000558', 'EFO_0003868', 'EFO_0005567',
       'EFO_1001951', 'EFO_0006772', 'EFO_1000251', 'EFO_0004224',
       'EFO_1000613', 'EFO_0003826', 'EFO_0000182', 'EFO_0000588',
       'MONDO_0001879', 'EFO_0004149', 'EFO_1001968', 'MONDO_0007576',
       'MONDO_0002108', 'MONDO_0004992', 'EFO_0000707', 'EFO_0000691',
       'EFO_0005537', 'EFO_0003863', 'EFO_0000556', 'EFO_0001075',
       'MONDO_0001402', 'EFO_1001961', 'MONDO_0008170', 'MONDO_0002367',
       'EFO_0000574', 'MONDO_0002715', 'MONDO_0002120', 'EFO_1001512',
       'EFO_0000183', 'EFO_1001331', 'EFO_0001378', 'EFO_0005088',
       'EFO_0003060', 'MONDO_0022394', 'EFO_0003050', 'EFO_0001642',
       'MONDO_0002691', 'MONDO_0021355', 'EFO_0006861', 'EFO_0003875',
       'EFO_1001471', 'EFO_0000199', 'EFO_0004265', 'MONDO_0005411',
       'EFO_0000181', 'MONDO_0002974', 'EFO_0003968', 'EFO_0004284',
       'EFO_0001416', 'EFO_0002617', 'MONDO_0001528', 'EFO_0005221',
       'EFO_0000565', 'EFO_0010282', 'EFO_0004281', 'MONDO_0008903',
       'EFO_0004142', 'EFO_0000389', 'EFO_0008524', 'EFO_1000052',
       'EFO_0000228', 'EFO_0003833', 'EFO_1000657', 'EFO_0000764',
       'MONDO_0002601', 'EFO_0000681', 'MONDO_0004986', 'MONDO_0001056',
       'EFO_0007532', 'EFO_0000178', 'MONDO_0044926', 'MONDO_0011962',
       'EFO_0000313', 'Orphanet_145', 'EFO_0000432', 'MONDO_0018944',
       'EFO_0000284', 'EFO_1001465', 'MONDO_0001325', 'EFO_0000676',
       'EFO_0002496', 'EFO_0000708', 'EFO_0005922', 'EFO_0004230',
       'EFO_0008528', 'MONDO_0021117', 'EFO_1000359', 'EFO_0000673',
       'EFO_0003843', 'EFO_0000095', 'MONDO_0007254', 'MONDO_0002087',
       'EFO_0002618', 'EFO_0006318', 'EFO_0004252', 'EFO_0000756',
       'EFO_0003100', 'EFO_1000581', 'MONDO_0100342', 'EFO_0003897',
       'EFO_0000571', 'EFO_0000365'], dtype=object), 'count': 158}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 12 approved and 146 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4298062,,,Oligonucleotide,False,VILTOLARSEN,2020.0,4.0,,False,True,['Viltepso'],['NCNP-01' 'NS-065' 'NS-065/NCNP-01' 'Ns-065/ncnp-01' 'Viltolarsen'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VILTOLARSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0020121', 'MONDO_0010679'], dtype=object), 'count': 2}",[ENSG00000198947],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for muscular dystrophy and duchenne muscular dystrophy.
CHEMBL4298179,,,Oligonucleotide,False,TEPRASIRAN SODIUM,,1.0,,False,False,[],['Teprasiran sodium'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPRASIRAN%20SODIUM/relevant/1/'],
      dtype=object))]",,,[ENSG00000141510],Oligonucleotide drug with a maximum clinical trial phase of I.
CHEMBL4594394,O=C([O-])CCCO.O=C([O-])CCCO.[Mg+2],QWZIZKOBUUSCLO-UHFFFAOYSA-L,Small molecule,False,MAGNESIUM OXYBATE,2020.0,4.0,CHEMBL1342,False,True,[],['Oxybate magnesium'],"[('DailyMed', array(['magnesium%20oxybate'], dtype=object))]",,,"[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020.
CHEMBL4650438,,,Oligonucleotide,False,OLEZARSEN,,3.0,,False,False,[],"['AKCEA-APOCIII-LRx' 'Akcea-apociii-lrx' 'IONIS- APOCIII-LRx'
 'IONIS-APOCIII-LRX' 'ISIS 678354' 'ISIS-678354' 'ISIS-APOCIII-LRX'
 'Olezarsen']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLEZARSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004211', 'EFO_0000319'], dtype=object), 'count': 2}",[ENSG00000110245],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL494753,C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O,JKKFKPJIXZFSSB-CBZIJGRNSA-N,Small molecule,True,ESTRONE SULFURIC ACID,1977.0,4.0,,False,True,[],['Estrone Sulphate'],"[('PubChem', array(['11112590'], dtype=object)), ('Wikipedia', array(['Estrone_sulfate'], dtype=object)), ('drugbank', array(['DB04574'], dtype=object)), ('chEBI', array(['17474'], dtype=object))]",['CHEMBL1200980' 'CHEMBL1546237' 'CHEMBL2106240'],"{'rows': array(['EFO_1000096', 'GO_0042697', 'EFO_0004266', 'MONDO_0002146',
       'EFO_0003882'], dtype=object), 'count': 5}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved indications. This drug has a black box warning from the FDA.
CHEMBL634,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1,IDBPHNDTYPBSNI-UHFFFAOYSA-N,Small molecule,True,ALFENTANIL,1986.0,4.0,,False,True,[],['Afentanyl' 'Alfentanil' 'Alfentanyl' 'IDS-NA-014' 'R-39209' 'R-39209-'],"[('Wikipedia', array(['Alfentanil'], dtype=object)), ('drugbank', array(['DB00802'], dtype=object)), ('chEBI', array(['2569'], dtype=object))]",['CHEMBL1200531'],,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. This drug has a black box warning from the FDA.
CHEMBL1096979,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,BNQDCRGUHNALGH-UHFFFAOYSA-N,Small molecule,False,BENSERAZIDE,,4.0,,False,True,[],"['Benserazide' 'Benserazide (as hydrochloride)' 'Benserazide hcl'
 'Benserazide hydrochloride' 'NSC-755907' 'RO 4-4602' 'RO-4-4602'
 'Serazide']","[('PubChem', array(['174006784', '90341370'], dtype=object)), ('Wikipedia', array(['Benserazide'], dtype=object)), ('drugbank', array(['DB12783'], dtype=object)), ('chEBI', array(['64187'], dtype=object))]",['CHEMBL1255778'],"{'rows': array(['EFO_0004270', 'MONDO_0005180'], dtype=object), 'count': 2}",[ENSG00000132437],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.
CHEMBL1200692,CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,UQGKUQLKSCSZGY-UHFFFAOYSA-N,Small molecule,True,OLMESARTAN MEDOXOMIL,2002.0,4.0,,False,True,['Benicar' 'Olmesartan medoxomil' 'Olmetec'],['CS-866' 'NSC-758924' 'Olmesartan medoxomil'],"[('DailyMed', array(['olmesartan%20medoxomil'], dtype=object)), ('PubChem', array(['144204998', '26748978'], dtype=object))]",,"{'rows': array(['MONDO_0002462', 'EFO_0000401', 'EFO_0000712', 'EFO_0000400',
       'EFO_0000319', 'EFO_0003086', 'EFO_0000537', 'MONDO_0001134',
       'EFO_0000612', 'EFO_0003144', 'EFO_0003914', 'HP_0000093'],
      dtype=object), 'count': 12}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743083,,,Antibody,False,TREGALIZUMAB,,2.0,,False,False,[],['BT-061' 'Tregalizumab'],,,"{'rows': array(['EFO_1001494', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000010610],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1763,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O,DMDGGSIALPNSEE-UHFFFAOYSA-N,Small molecule,False,HYDROFLUMETHIAZIDE,1959.0,4.0,,False,True,['Diucardin' 'Hydrenox' 'Hydroflumethiazide' 'Saluron'],['Hydroflumethiazide' 'NSC-44627'],"[('PubChem', array(['11112295', '144203973', '170465082', '26747027', '56422879',
       '855883'], dtype=object)), ('Wikipedia', array(['Hydroflumethiazide'], dtype=object)), ('drugbank', array(['DB00774'], dtype=object)), ('chEBI', array(['5784'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for cardiovascular disease.
CHEMBL207538,CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,AURFZBICLPNKBZ-SYBPFIFISA-N,Small molecule,True,BREXANOLONE,2019.0,4.0,,False,True,['Zulresso'],"['Allopregnan-3.alpha.-ol-20-one' 'Allopregnanolone'
 'Allotetrahydroprogesterone' 'Brexanolone' 'SAGE-547' 'SGE-102']","[('DailyMed', array(['brexanolone'], dtype=object)), ('PubChem', array(['144205595', '26756639'], dtype=object)), ('drugbank', array(['DB11859'], dtype=object)), ('chEBI', array(['50169'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0007453', 'MONDO_0002050', 'MONDO_0043510',
       'HP_0000360', 'EFO_0008526', 'EFO_0005407', 'EFO_0003108',
       'EFO_0001358', 'MONDO_0007079', 'MONDO_0002009'], dtype=object), 'count': 11}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2106829,Cc1ccccc1-n1c(C)nc2ccccc2c1=O.Cl,KJUHIXIWKSVBKB-UHFFFAOYSA-N,Small molecule,False,METHAQUALONE HYDROCHLORIDE,,4.0,CHEMBL282052,True,True,[],['Methaqualone hcl' 'Methaqualone hydrochloride' 'NSC-75892'],,,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2108326,,,Oligonucleotide,False,ALICAFORSEN,,3.0,,False,False,[],['Alicaforsen'],,,"{'rows': array(['EFO_0003767', 'EFO_0000729', 'EFO_0000384', 'EFO_0003921'],
      dtype=object), 'count': 4}",[ENSG00000090339],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2218893,CN(C)C(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2.CN(C)C(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2.O=S(=O)(O)O,VPCOODFYDJWLHD-YMZXMBPUSA-N,Small molecule,False,BEDORADRINE SULFATE,,2.0,CHEMBL2111083,False,False,[],['Bedoradrine sulfate' 'Bedoradrine sulphate' 'KUR-1246' 'MN-221'],,,"{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0008590'], dtype=object), 'count': 3}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2368861,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl,UAIXRPCCYXNJMQ-HPRIMLMLSA-N,Small molecule,True,BUPRENORPHINE HYDROCHLORIDE,1981.0,4.0,CHEMBL511142,False,True,"['Belbuca' 'Buprenex' 'Buprenorphine hydrochloride' 'Espranor' 'Gabup'
 'Natzon' 'Prefibin' 'Probuphine' 'Sixmo' 'Subutex']","['Anorfin' 'Buprederm' 'Buprenorphine hcl' 'Buprenorphine hydrochloride'
 'Buprenorphine hydrochloride ciii' 'Buprex' 'CL 112,302' 'CL-112302'
 'Finibron' 'Lepetan' 'M-6029' 'NIH 8805' 'NIH-8805' 'Nopan'
 'RX 6029-M HCL' 'RX-6029-M HCL' 'SCH-028444' 'UM 952' 'UM-952'
 'Vetergesic']","[('DailyMed', array(['buprenorphine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo'],
      dtype=object))]",,"{'rows': array(['EFO_0005611', 'EFO_0003890'], dtype=object), 'count': 2}","[ENSG00000082556,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for opioid dependence and drug dependence. This drug has a black box warning from the FDA.
CHEMBL3542265,CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1,IHIWYQYVBNODSV-KRWDZBQOSA-N,Small molecule,False,LY2452473,,2.0,,False,False,[],['LY-2452473' 'LY2452473' 'Ly2452473' 'OPK-88004' 'TT-701'],"[('drugbank', array(['DB12573'], dtype=object))]",['CHEMBL3542296'],"{'rows': array(['MONDO_0008315', 'EFO_0004234', 'EFO_0000284'], dtype=object), 'count': 3}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL376897,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12,LZCOQTDXKCNBEE-IKIFYQGPSA-N,Small molecule,False,METHSCOPOLAMINE,1953.0,4.0,,False,True,[],"['(-)-n-methylscopolamine' 'Methscopolamine cation' 'Methscopolamine ion'
 'Methylscopolamine' 'N-methylhyoscine' 'N-methylscopolamine']","[('Wikipedia', array(['Methylscopolamine_bromide'], dtype=object)), ('drugbank', array(['DB11315'], dtype=object))]",['CHEMBL1506225' 'CHEMBL1354199'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and is indicated for gastrointestinal disease.
CHEMBL4298195,,,Antibody,False,NARSOPLIMAB,,3.0,,False,False,[],"['Masp-2 antibody' 'Narsoplimab' 'OMS-721' 'OMS00620646' 'OMS620646'
 'OMS721']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NARSOPLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0016244', 'EFO_0005761', 'MONDO_0100096', 'EFO_0004194'],
      dtype=object), 'count': 4}",[ENSG00000009724],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL504652,c1cncc(N2CCC3(CCCN3)C2)c1,NXIPMBQVNTWEEX-UHFFFAOYSA-N,Small molecule,False,TC-2216,,1.0,,False,False,[],['TC-2216' 'Tc-2216'],,,"{'rows': array(['MONDO_0002050', 'EFO_0005230'], dtype=object), 'count': 2}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL598172,COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C,COSPVUFTLGQDQL-UHFFFAOYSA-N,Small molecule,False,NELOTANSERIN,,2.0,,False,False,[],['APD-125' 'APD125' 'Apd-125' 'Nelotanserin'],"[('drugbank', array(['DB12555'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'HP_0000738', 'EFO_0006792'], dtype=object), 'count': 3}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL95,Nc1c2c(nc3ccccc13)CCCC2,YLJREFDVOIBQDA-UHFFFAOYSA-N,Small molecule,False,TACRINE,1993.0,4.0,,False,True,[],['Tacrinal' 'Tacrine'],"[('PubChem', array(['104171104', '11110734', '11113824', '124879172', '124879174',
       '144203624', '144212594', '170465420', '26755281', '90341647'],
      dtype=object)), ('TG-GATEs', array(['60'], dtype=object)), ('Wikipedia', array(['Tacrine'], dtype=object)), ('drugbank', array(['DB00382'], dtype=object)), ('chEBI', array(['45980'], dtype=object))]",['CHEMBL1677' 'CHEMBL1337960'],"{'rows': array(['EFO_0002610', 'HP_0000726'], dtype=object), 'count': 2}","[ENSG00000114200,ENSG00000087085]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for dementia and has 1 investigational indication.
CHEMBL1200379,Cl.Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1,OTQYGBJVDRBCHC-UHFFFAOYSA-N,Small molecule,False,APRACLONIDINE HYDROCHLORIDE,1987.0,4.0,CHEMBL647,False,True,['Apraclonidine hydrochloride' 'Iopidine'],"['AL-02145' 'AL02145' 'Aplonidine hydrochloride' 'Apraclonidine hcl'
 'Apraclonidine hydrochloride']","[('DailyMed', array(['apraclonidine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204758', '50105753'], dtype=object)), ('chEBI', array(['2789'], dtype=object))]",,,"[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL1201203,CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2,GIJXKZJWITVLHI-PMOLBWCYSA-N,Small molecule,False,BENZTROPINE,1954.0,4.0,,False,True,[],['Benzatropine' 'Benztropine' 'Cobrentin' 'NK-02'],"[('PubChem', array(['144204856', '144205248', '29215426'], dtype=object)), ('Wikipedia', array(['Benzatropine'], dtype=object)), ('drugbank', array(['DB00245'], dtype=object)), ('chEBI', array(['3048'], dtype=object))]",['CHEMBL1200383'],"{'rows': array(['EFO_0005279', 'EFO_0002610', 'HP_0003418', 'MONDO_0005180',
       'MONDO_0005180', 'HP_0011868', 'EFO_0009387'], dtype=object), 'count': 7}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for parkinson disease and has 5 investigational indications.
CHEMBL1233528,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,SXNJFOWDRLKDSF-STROYTFGSA-N,Small molecule,False,VOLASERTIB,,3.0,,False,False,[],['BI 6727' 'BI-6727' 'BI6727' 'Bi-6727' 'Volasertib'],"[('drugbank', array(['DB12062'], dtype=object))]",['CHEMBL2105742'],"{'rows': array(['EFO_0000221', 'EFO_1001257', 'EFO_0003060', 'EFO_0002913',
       'EFO_0000198', 'EFO_0000574', 'EFO_0000616', 'EFO_0003893',
       'EFO_0000565', 'EFO_0000222', 'MONDO_0000430'], dtype=object), 'count': 11}",[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL1451,C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F,GFNANZIMVAIWHM-OBYCQNJPSA-N,Small molecule,False,TRIAMCINOLONE,1957.0,4.0,,False,True,"['Aristocort' 'Aristocort A' 'Delphicort' 'Kenacort' 'Kenalog'
 'Triamcinolone' 'Volon']",['Fluoxiprednisolone' 'NSC-13397' 'Triamcinolone'],"[('PubChem', array(['144204885', '144210498', '170465188', '26751455', '47193900',
       '50103941', '50103942', '77851', '855586', '90341396'],
      dtype=object)), ('Wikipedia', array(['Triamcinolone'], dtype=object)), ('drugbank', array(['DB00620'], dtype=object)), ('chEBI', array(['9667'], dtype=object))]",,"{'rows': array(['EFO_0005762', 'EFO_0000274', 'EFO_0007486', 'EFO_1000391',
       'EFO_0005752', 'HP_0002027', 'EFO_0005854', 'MONDO_0005178',
       'EFO_1000786', 'HP_0001742', 'HP_0006536', 'EFO_1000662',
       'EFO_1001157', 'EFO_1001492', 'EFO_1000879', 'MONDO_0003005',
       'MONDO_0002959', 'EFO_0000701', 'EFO_0004683', 'EFO_0003843',
       'EFO_0001365', 'EFO_0004208', 'EFO_1001250', 'EFO_0004212',
       'EFO_0004264', 'EFO_0003963', 'HP_0030834', 'EFO_0009552',
       'EFO_0004616', 'EFO_1001417', 'EFO_0000342', 'EFO_1001077',
       'EFO_0000341', 'EFO_1000809', 'EFO_0000676', 'EFO_0008517',
       'EFO_0003770', 'EFO_0000756', 'EFO_0004192'], dtype=object), 'count': 39}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 5 approved and 34 investigational indications.
CHEMBL1516474,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12.O=C(O)/C=C\C(=O)O,CPDDZSSEAVLMRY-FEQFWAPWSA-N,Small molecule,False,TEGASEROD MALEATE,2002.0,4.0,CHEMBL76370,True,True,['Zelmac' 'Zelnorm'],['HTF 919' 'HTF-919' 'NSC-760425' 'Tegaserod maleate'],"[('DailyMed', array(['tegaserod%20maleate'], dtype=object)), ('PubChem', array(['26748994'], dtype=object)), ('chEBI', array(['51044'], dtype=object))]",,"{'rows': array(['EFO_0000555', 'MONDO_0002203'], dtype=object), 'count': 2}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for irritable bowel syndrome and constipation disorder. It was withdrawn in at least one region.
CHEMBL1574,CC(C)(N)Cc1ccccc1,DHHVAGZRUROJKS-UHFFFAOYSA-N,Small molecule,False,PHENTERMINE,1959.0,4.0,,False,True,['Duromine' 'Ionamin' 'Phentermine resin 30' 'Phentermine resin complex'],['NSC-759163' 'Phentermine' 'Phentermine resin' 'Qsiva'],"[('Wikipedia', array(['Phentermine'], dtype=object)), ('drugbank', array(['DB00191'], dtype=object)), ('chEBI', array(['8080'], dtype=object))]",['CHEMBL1200912'],"{'rows': array(['EFO_0001074', 'EFO_0003890', 'EFO_0001073', 'EFO_0005204',
       'EFO_0001421', 'EFO_0003086', 'EFO_0000400', 'EFO_0001073'],
      dtype=object), 'count': 8}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for obesity and has 6 investigational indications.
CHEMBL1873475,C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,XYFPWWZEPKGCCK-GOSISDBHSA-N,Small molecule,False,IBRUTINIB,2013.0,4.0,,False,True,['Imbruvica'],"['CRA-032765' 'Ibrutinib' 'PC-32765' 'PCI 32765' 'PCI-32765'
 'PCI-32765-00']","[('DailyMed', array(['ibrutinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica'],
      dtype=object)), ('PubChem', array(['124898784'], dtype=object)), ('drugbank', array(['DB09053'], dtype=object)), ('chEBI', array(['76612'], dtype=object))]",,"{'rows': array(['EFO_1001469', 'MONDO_0100096', 'EFO_0000183', 'EFO_0007359',
       'EFO_0001421', 'EFO_1000560', 'EFO_0000403', 'MONDO_0007576',
       'MONDO_0021063', 'EFO_0000220', 'EFO_0000096', 'EFO_1001890',
       'EFO_0000222', 'EFO_0001642', 'EFO_0005952', 'EFO_0003060',
       'MONDO_0007254', 'EFO_1001264', 'EFO_0001378', 'MONDO_0044881',
       'EFO_0000181', 'EFO_1000630', 'EFO_0000574', 'EFO_0000616',
       'EFO_0000389', 'EFO_0000198', 'EFO_0009441', 'EFO_0004243',
       'MONDO_0008903', 'MONDO_0001023', 'MONDO_0100053', 'EFO_0000309',
       'MONDO_0009348', 'EFO_0004289', 'EFO_0000519', 'MONDO_0008315',
       'EFO_0002617', 'EFO_0000095', 'MONDO_0020547', 'EFO_0002616',
       'MONDO_0018906', 'EFO_1001875', 'MONDO_0004992', 'MONDO_0013730',
       'EFO_0000565', 'EFO_1001951', 'EFO_1000956', 'EFO_0000681'],
      dtype=object), 'count': 48}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 42 investigational indications.
CHEMBL2105667,Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,XWNBGDJPEXZSQM-VZOBGQTKSA-N,Small molecule,False,ORVEPITANT,,2.0,,False,False,[],['GW-823296X' 'GW823296X' 'Gw-823296' 'Gw823296' 'Orvepitant'],"[('drugbank', array(['DB12427'], dtype=object))]",['CHEMBL2105668'],"{'rows': array(['MONDO_0002009', 'HP_0012735', 'MONDO_0002050', 'EFO_0001358'],
      dtype=object), 'count': 4}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2109084,,,Enzyme,False,DESMOTEPLASE,,3.0,,False,False,[],['Desmoteplase' 'Dspa desmoteplase' 'RDSPA ALPHA 1'],,,"{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}",[ENSG00000122194],Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2146146,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O=S(=O)(O)O,VJFQPODMEGSXHC-RIMUKSHESA-N,Small molecule,False,ATROPINE SULFATE,1960.0,4.0,CHEMBL517712,False,True,"['Atropine' 'Atropine sulfate' 'Atropine sulfate ansyr plastic syringe'
 'Atropine sulfate lifeshield abboject syringe' 'Isopto atropine']","['Atropine sulfate' 'Atropine sulfate anhydrous'
 'Atropine sulfate hydrate' 'Atropine sulfate monohydrate'
 'Atropine sulphate' 'Atropini sulfas' 'Atropinum sulphuricum' 'Atropt'
 'NSC-26671' 'NSC-755889' 'SYD-101']","[('DailyMed', array(['atropine%20sulfate'], dtype=object))]",,"{'rows': array(['HP_0000545', 'HP_0004398', 'EFO_0005854', 'EFO_0003956',
       'MONDO_0005180', 'EFO_0010581', 'EFO_0005323', 'HP_0011499'],
      dtype=object), 'count': 8}","[ENSG00000168539,ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 5 approved and 3 investigational indications.
CHEMBL245030,CCOC(=O)c1ccc2[nH]c3c(OC)c4[nH]c5ccc(C(=O)OCC)cc5c4cc3c2c1,BMTPVPNVQOYGAP-UHFFFAOYSA-N,Small molecule,False,SR-13668,,1.0,,False,False,[],['SR-13668' 'SR13668' 'Sr-13668'],,,,[ENSG00000142208],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL259972,COc1ccc(-c2noc(CC(=O)O)c2-c2ccc(OC)cc2)cc1,DJEIHHYCDCTAAH-UHFFFAOYSA-N,Small molecule,False,MOFEZOLAC,1994.0,4.0,,False,True,[],['Mofezolac'],"[('PubChem', array(['144206111', '50112817'], dtype=object))]",,,[ENSG00000095303],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994.
CHEMBL286738,NS(=O)(=O)Oc1ccc2c3c(c(=O)oc2c1)CCCCC3,DSLPMJSGSBLWRE-UHFFFAOYSA-N,Small molecule,False,IROSUSTAT,,2.0,,False,False,[],"['667 COUMATE' '667-COUMATE' 'BN 83495' 'BN-83495' 'BN83495' 'Irosustat'
 'STX 64' 'STX-64' 'STX64']","[('drugbank', array(['DB02292'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0008315'],
      dtype=object), 'count': 4}",[ENSG00000101846],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3544986,CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC.N=C(N)NCCC[C@H](N)C(=O)O,RYCSJJXKEWBUTI-YDYAIEMNSA-N,Small molecule,False,PERINDOPRIL ARGININE,2015.0,4.0,CHEMBL1581,False,True,[],['Perindopril arginine'],"[('DailyMed', array(['perindopril%20arginine'], dtype=object)), ('chEBI', array(['77655'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0004214'], dtype=object), 'count': 2}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hypertension and has 1 investigational indication.
CHEMBL3545307,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,QHADVLVFMKEIIP-UHFFFAOYSA-N,Small molecule,False,MERESTINIB,,2.0,,False,False,[],['LY-2801653' 'LY2801653' 'Ly-2801653' 'Merestinib'],"[('drugbank', array(['DB12381'], dtype=object))]",,"{'rows': array(['EFO_0000389', 'MONDO_0003060', 'EFO_0003060', 'EFO_1001469',
       'EFO_0002618', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0007254'],
      dtype=object), 'count': 8}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL3545412,,,Small molecule,False,K-877,,3.0,,False,False,[],['K-877'],,,"{'rows': array(['EFO_0004211', 'EFO_0003095', 'MONDO_0021187', 'HP_0003124',
       'Orphanet_309005', 'EFO_1001249'], dtype=object), 'count': 6}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3697617,Cc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C,AKQXQLUNFKDZBN-UHFFFAOYSA-N,Small molecule,False,TAVAPADON,,3.0,,False,False,[],['CVL-751' 'Cvl-751' 'PF-06649751' 'Pf-06649751' 'Tavapadon'],"[('drugbank', array(['DB14899'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'EFO_0001421', 'EFO_0003086'], dtype=object), 'count': 3}","[ENSG00000184845,ENSG00000169676]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3989693,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.O=C(O)C(O)C(O)C(=O)O,VNVNZKCCDVFGAP-NMFAMCKASA-N,Small molecule,False,LEVALBUTEROL TARTRATE,2005.0,4.0,CHEMBL1002,False,True,['Xopenex hfa'],['Levalbuterol tartrate' 'Levosalbutamol tartrate'],"[('DailyMed', array(['levalbuterol%20tartrate'], dtype=object))]",,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2005 and has 1 investigational indication.
CHEMBL3989908,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,DYLUUSLLRIQKOE-UHFFFAOYSA-N,Small molecule,True,ENASIDENIB,2017.0,4.0,,False,True,[],['AG-221' 'Ag 221' 'CC-90007 Free Base' 'Enasidenib'],"[('drugbank', array(['DB13874'], dtype=object))]",['CHEMBL3989931'],"{'rows': array(['EFO_0000222', 'EFO_0000565', 'MONDO_0044881', 'EFO_0000616',
       'EFO_1001779', 'EFO_0001378', 'MONDO_0004992', 'EFO_0001421',
       'EFO_0000198', 'EFO_0000222'], dtype=object), 'count': 10}",[ENSG00000182054],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297436,Cc1nc(-c2cccnc2)sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1,LAMQVIQMVKWXOC-UHFFFAOYSA-N,Small molecule,False,SRT-2104,,2.0,,False,False,[],['SRT2104' 'Srt-2104' 'Srt2104'],"[('drugbank', array(['DB12186'], dtype=object))]",,"{'rows': array(['EFO_1000096', 'EFO_0000341', 'EFO_0000676', 'EFO_0009851',
       'HP_0100806', 'EFO_0000729', 'MONDO_0005148'], dtype=object), 'count': 7}",[ENSG00000096717],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4297452,C[N+](C)(C)CCO.[O-]c1ccc(Cc2cc3cccccc-3c2)cc1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,UKOOBSDARBTSHN-NGOMLPPMSA-M,Small molecule,False,YM-543,,2.0,CHEMBL2397450,False,False,[],['ASP-543' 'YM 543' 'YM543' 'Ym-543' 'Ym543'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297549,,,Protein,False,HUMAN C1-ESTERASE INHIBITOR,2011.0,4.0,,False,True,['Cinryze'],"['Berinert' 'C1 inhibitor human' 'C1-inhibitor, plasma derived' 'Cinryze'
 'Human c1-esterase inhibitor' 'RVG-19303']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze'],
      dtype=object))]",,"{'rows': array(['EFO_1002048', 'EFO_0005532', 'EFO_0003884', 'MONDO_0100096',
       'MONDO_0019623', 'EFO_0004256'], dtype=object), 'count': 6}","[ENSG00000088926,ENSG00000182326,ENSG00000131187,ENSG00000164344]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hereditary angioedema and has 5 investigational indications.
CHEMBL4650293,,,Antibody drug conjugate,False,APRUTUMAB IXADOTIN,,1.0,,False,False,[],['Aprutumab ixadotin' 'BAY 1187982' 'BAY-1187982' 'BAY1187982'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000066468,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL513922,CCN(Cc1ccccc1)C(=O)Cn1c(=O)n(C)c2cnc(-c3ccccc3)nc21,NBMBIEOUVBHEBM-UHFFFAOYSA-N,Small molecule,False,EMAPUNIL,,2.0,,False,False,[],['AC-5216' 'Emapunil' 'XBD-173' 'XBD173'],"[('drugbank', array(['DB12666'], dtype=object))]",['CHEMBL2206281'],"{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}",[ENSG00000100300],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL527,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,QYSPLQLAKJAUJT-UHFFFAOYSA-N,Small molecule,True,PIROXICAM,1982.0,4.0,,False,True,"['Brexidol' 'Feldene' 'Feldene 20' 'Feldene p' 'Flamatrol' 'Kentene'
 'Larapam' 'Piroflam 10' 'Piroflam 20' 'Piroxicam' 'Pirozip 10'
 'Pirozip 20']","['CP-16,171' 'CP-16171' 'NSC-666076' 'Piroxicam']","[('DailyMed', array(['piroxicam'], dtype=object)), ('PubChem', array(['11111641', '11111642', '11113322', '124881135', '144203782',
       '144207349', '170464817', '26746904', '26751443', '50085963',
       '50103896', '511550', '856007', '859011'], dtype=object)), ('Wikipedia', array(['Piroxicam'], dtype=object)), ('drugbank', array(['DB00554'], dtype=object)), ('chEBI', array(['8249'], dtype=object))]",['CHEMBL2106953' 'CHEMBL1418195'],"{'rows': array(['EFO_0000685', 'EFO_0005752', 'HP_0002829', 'EFO_1001896',
       'MONDO_0005178', 'EFO_1001412', 'EFO_0004616', 'EFO_0003843',
       'EFO_0005755', 'HP_0003326'], dtype=object), 'count': 10}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200989,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl,DJHCCTTVDRAMEH-DUUJBDRPSA-N,Small molecule,False,ALCLOMETASONE DIPROPIONATE,1982.0,4.0,,False,True,['Aclovate' 'Alclometasone dipropionate' 'Modrasone'],"['Alclometasone' 'Alclometasone 17,21-dipropionate'
 'Alclometasone dipropionate' 'NSC-758914' 'SCH 22219' 'SCH-22219']","[('DailyMed', array(['alclometasone%20dipropionate'], dtype=object)), ('PubChem', array(['144204277'], dtype=object)), ('chEBI', array(['31184'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000701', 'EFO_0005752'], dtype=object), 'count': 3}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for skin disease and eye inflammation and has 1 investigational indication.
CHEMBL1201572,,,Protein,True,ETANERCEPT,1998.0,4.0,,False,True,['Benepali' 'Enbrel'],"['Chs-0214' 'Davictrel' 'Dwp-422' 'Enia-11' 'Erelzi' 'Etanercept'
 'Etanercept (enbrel)' 'Etanercept biosimilar (gp-2015)'
 'Etanercept biosimilar (sandoz)' 'Etanercept biosimilar (sb-4)'
 'Etanercept szzs' 'Etanercept ykro' 'Etanercept-szzs' 'Etanercept-ykro'
 'Eticovo' 'GP-2015' 'GP2015' 'GP2015C' 'HD203' 'Hd-203' 'L04ab01'
 'LBEC0101' 'Lbec-0101' 'RHU TNFR:FC' 'RHU-TNFR:FC' 'TNFR-IMMUNOADHESIN'
 'Tunex']","[('DailyMed', array(['etanercept'], dtype=object)), ('DrugCentral', array(['4978'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/benepali'],
      dtype=object)), ('Wikipedia', array(['Etanercept'], dtype=object))]",,"{'rows': array(['HP_0002039', 'MONDO_0004979', 'MONDO_0003937', 'EFO_0009688',
       'MONDO_0013730', 'EFO_0003884', 'EFO_0003778', 'EFO_0005279',
       'EFO_0004208', 'EFO_0005297', 'MONDO_0019391', 'EFO_0007323',
       'EFO_0000616', 'EFO_1000726', 'HP_0100727', 'EFO_0004719',
       'MONDO_0005147', 'EFO_0005761', 'EFO_0000713', 'EFO_0004246',
       'MONDO_0024280', 'HP_0000360', 'EFO_0000341', 'HP_0011868',
       'HP_0004326', 'EFO_0000398', 'MONDO_0017816', 'EFO_0002609',
       'EFO_1001494', 'EFO_0009448', 'EFO_0003898', 'EFO_0000565',
       'EFO_0000685', 'EFO_0000699', 'EFO_0002687', 'EFO_0007430',
       'EFO_0003106', 'EFO_0000764', 'EFO_0000095', 'MONDO_0008315',
       'MONDO_0004975', 'EFO_0000540', 'EFO_0000198', 'MP_0001845',
       'EFO_0003834', 'EFO_0000195', 'EFO_0004599', 'EFO_0008997',
       'EFO_1000710', 'EFO_0008518', 'EFO_0000676', 'MONDO_0002959',
       'EFO_0004276'], dtype=object), 'count': 53}",[ENSG00000232810],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 8 approved and 45 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1237022,,,Antibody,True,TOCILIZUMAB,2005.0,4.0,,False,True,['Actemra' 'Actemra roactemra' 'Roactemra'],"['ATLIZUMAB' 'Actemra' 'BAT-1806' 'BAT1806' 'Bat1806' 'MRA' 'MSB-11456'
 'MSB11456' 'R-1569' 'RG-1569' 'RHPM-1' 'RO-4877533' 'Tocilizumab'
 'Tocilizumab biosimilar (bat-1806)' 'Tocilizumab biosimilar (msb11456)']","[('DailyMed', array(['tocilizumab'], dtype=object)), ('DrugCentral', array(['4933'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra'],
      dtype=object)), ('Wikipedia', array(['Tocilizumab'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_1001513', 'EFO_0000565', 'MONDO_0000845',
       'EFO_0000540', 'EFO_0000095', 'EFO_1000926', 'EFO_0000222',
       'EFO_0000702', 'EFO_0007328', 'EFO_0000094', 'EFO_0003818',
       'EFO_0008586', 'EFO_0003780', 'EFO_0000685', 'EFO_1000986',
       'EFO_1001469', 'EFO_0000474', 'EFO_0004256', 'HP_0001945',
       'EFO_0008518', 'EFO_0007135', 'EFO_0004991', 'EFO_0008528',
       'EFO_1000637', 'EFO_1001165', 'MONDO_0007915', 'EFO_0007541',
       'EFO_0000519', 'EFO_0003106', 'MONDO_0005147', 'EFO_1001119',
       'MONDO_0015564', 'EFO_0001378', 'MONDO_0007254', 'EFO_1001231',
       'EFO_0000717', 'EFO_0000673', 'EFO_1001951', 'EFO_1001148',
       'EFO_0000403', 'EFO_0000764', 'EFO_0000694', 'EFO_1001806',
       'MONDO_0013730', 'EFO_0002609', 'EFO_0003060', 'MONDO_0002009',
       'EFO_0000756', 'MONDO_0004976', 'EFO_0000220', 'EFO_0003898',
       'EFO_0000398', 'EFO_1001209', 'EFO_0000182', 'MONDO_0008170',
       'MONDO_0044881', 'EFO_1001857', 'MONDO_0005090', 'MONDO_0018088',
       'EFO_0002618', 'EFO_0000574', 'EFO_1001466', 'EFO_0001361',
       'EFO_0004599', 'EFO_0000096', 'MONDO_0001187', 'EFO_0005952',
       'MONDO_0018906', 'EFO_0003884', 'MONDO_0100096', 'EFO_0009730',
       'MONDO_0015540'], dtype=object), 'count': 73}",[ENSG00000160712],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 6 approved and 67 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1571,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)OC(=O)CC[C@@H]12,BPEWUONYVDABNZ-DZBHQSCQSA-N,Small molecule,False,TESTOLACTONE,1969.0,4.0,,False,True,['Fludestrin' 'Teslac'],"['NSC-23759' 'SQ 9538' 'SQ-9538' 'Teolit' 'Testolactone'
 'Testolactone ciii']","[('PubChem', array(['144205129', '85554'], dtype=object)), ('Wikipedia', array(['Testolactone'], dtype=object)), ('drugbank', array(['DB00894'], dtype=object)), ('chEBI', array(['9460'], dtype=object))]",,"{'rows': array(['MONDO_0000088'], dtype=object), 'count': 1}",[ENSG00000137869],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969 and has 1 investigational indication.
CHEMBL1743070,,,Antibody,False,SILTUXIMAB,2014.0,4.0,,False,True,['Sylvant'],['CLLB8' 'CNTO-328' 'Siltuximab'],"[('DailyMed', array(['siltuximab'], dtype=object)), ('DrugCentral', array(['4977'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant'],
      dtype=object))]",,"{'rows': array(['EFO_0000565', 'EFO_0000673', 'EFO_0005952', 'EFO_0001663',
       'MONDO_0100096', 'MONDO_0005147', 'EFO_0000540', 'EFO_0000222',
       'EFO_0000198', 'EFO_0000203', 'EFO_0000681', 'MONDO_0015564',
       'MONDO_0008315', 'MONDO_0005090', 'EFO_1001332', 'EFO_0001378',
       'MONDO_0002367'], dtype=object), 'count': 17}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 14 investigational indications.
CHEMBL17976,C=C(C)[C@]12C[C@@H](C)[C@@]34O[C@](Cc5ccccc5)(O[C@@H]1[C@@H]3C=C(COC(=O)Cc1ccc(O)c(OC)c1)C[C@]1(O)C(=O)C(C)=C[C@@H]41)O2,DSDNAKHZNJAGHN-MXTYGGKSSA-N,Small molecule,False,RESINIFERATOXIN,,3.0,,False,False,['Neuroclastin'],['Lopain' 'MTX-71' 'Mtx-071' 'RTX' 'Resiniferatoxin'],"[('PubChem', array(['26755740'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RESINIFERATOXIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06515'], dtype=object))]",,"{'rows': array(['EFO_0010582', 'EFO_0003843', 'EFO_0801084', 'EFO_0004616'],
      dtype=object), 'count': 4}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL1923502,C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1.Cl.O,ZWIXEQBDJMFCMN-DHHNQDMHSA-N,Small molecule,False,ULIMORELIN HYDROCHLORIDE,,3.0,CHEMBL1963249,False,False,[],"['TZP-101' 'Ulimorelin hydrochloride'
 'Ulimorelin hydrochloride monohydrate']",,,"{'rows': array(['EFO_1000948', 'MONDO_0004567'], dtype=object), 'count': 2}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2104967,CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(=O)O)cc2)c(OC)c1,YLFZHHDVRSYTKT-NRFANRHFSA-N,Small molecule,False,FIRATEGRAST,,2.0,,False,False,[],['Firategrast' 'SB-683699'],"[('drugbank', array(['DB12732'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 2}","[ENSG00000150093,ENSG00000115232,ENSG00000139626]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2107341,OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,NKZTZAQIKKGTDB-QPLCGJKRSA-N,Small molecule,False,FISPEMIFENE,,2.0,,False,False,[],['Fispemifene' 'HM-101' 'HM-101a'],"[('drugbank', array(['DB06640'], dtype=object))]",,"{'rows': array(['EFO_0004234', 'MONDO_0002146', 'EFO_0004714', 'MONDO_0018555'],
      dtype=object), 'count': 4}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2108752,,,Unknown,False,PEGAPTANIB OCTASODIUM,,3.0,,False,False,[],['Pegaptanib octasodium'],"[('DrugCentral', array(['4905'], dtype=object))]",,"{'rows': array(['EFO_0004683'], dtype=object), 'count': 1}",[ENSG00000112715],Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109205,,,Protein,False,COAGULATION FACTOR IX RECOMBINANT HUMAN,1997.0,4.0,,False,True,['Benefix' 'Rixubis'],"['Coagulation factor ix recombinant human' 'Factor ix,recombinant'
 'Nonacog alfa' 'Nonacog gamma' 'Recombinant factor ix']","[('DrugCentral', array(['5163'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/benefix',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/rixubis'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}",[ENSG00000101981],Protein drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for hemophilia b.
CHEMBL2109390,,,Antibody,False,MAB-425,,2.0,,False,False,[],['MAB-425' 'Mab-425'],,,"{'rows': array(['EFO_0000326'], dtype=object), 'count': 1}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109399,,,Antibody drug conjugate,False,T-DM1,,3.0,,False,False,[],['T-DM1' 'T-dm1'],,,"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}",[ENSG00000141736],Antibody drug conjugate drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109449,,,Antibody,False,MEDI-570,,1.0,,False,False,[],['MEDI-570' 'Medi 570' 'Medi-570'],,,"{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}",[ENSG00000163600],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL257704,CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F,VAIOZOCLKVMIMN-PRJWTAEASA-N,Small molecule,False,EPLIVANSERIN,,3.0,,False,False,[],['Eplivanserin' 'SR-46349' 'SR46349'],"[('drugbank', array(['DB12177'], dtype=object))]",['CHEMBL2103845'],"{'rows': array(['EFO_0008568', 'EFO_0004698'], dtype=object), 'count': 2}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3329435,Cc1nc2c(N3CCNCC3)cccc2n1S(=O)(=O)c1ccccc1,MAYQIFVKVAUMPD-UHFFFAOYSA-N,Small molecule,False,PF-05212377,,2.0,,False,False,[],['PF-05212377' 'PF-5212377' 'Pf-05212377' 'SAM-760' 'WYE-103760'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000158748],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545036,Cc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1,MEDCLNYIYBERKO-UHFFFAOYSA-N,Small molecule,False,RASEGLURANT,,2.0,,False,False,[],['ADX-10059' 'ADX10059' 'Adx-10059' 'Adx10059' 'Raseglurant'],,['CHEMBL3894333'],"{'rows': array(['EFO_0003948', 'MONDO_0005277'], dtype=object), 'count': 2}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545104,,,Protein,False,MODIMELANOTIDE,,2.0,,False,False,[],['ABT-719' 'Ap-214' 'Ap214' 'Modimelanotide' 'ZP-1480' 'ZP1480'],,,"{'rows': array(['EFO_0001666', 'HP_0001919'], dtype=object), 'count': 2}","[ENSG00000258839,ENSG00000124089]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545147,,,Small molecule,False,IMD-2560,,1.0,,False,False,[],['Imd-2560'],,,,[ENSG00000104365],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545268,,,Small molecule,False,MLN3126,,1.0,,False,False,[],['Mln3126'],,,,[ENSG00000173585],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545359,,,Small molecule,False,ARRY-300,,1.0,,False,False,[],['Arry-300' 'MET-300'],,,,[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707266,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1.O=C(O)CCC(=O)O,NHANOMFABJQAAH-UHFFFAOYSA-N,Small molecule,False,RIBOCICLIB SUCCINATE,2017.0,4.0,CHEMBL3545110,False,True,['Kisqali'],['Birociclib' 'LEE-011-BBA' 'LEE011-BBA' 'Ribociclib succinate'],"[('DailyMed', array(['ribociclib%20succinate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali'],
      dtype=object))]",,"{'rows': array(['EFO_0000305', 'EFO_0003869', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000105810,ENSG00000135446]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved indications.
CHEMBL3989988,,,Antibody,False,MODOTUXIMAB,,3.0,,False,False,[],['1024 DS' '1024-DS' 'Modotuximab' 'Zatuximab'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL406381,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,VPBYZLCHOKSGRX-UHFFFAOYSA-N,Small molecule,False,KRN-633,,1.0,,False,False,[],['K00589A' 'KRN-633' 'KRN633' 'Krn-633'],"[('PubChem', array(['174006598'], dtype=object))]",,,"[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4594330,,,Antibody,False,DAXDILIMAB,,2.0,,False,False,[],"['Daxdilimab' 'HZN-7734' 'MEDI-7734' 'MEDI7734' 'Medi 7734' 'Medi7734'
 'VIB7734' 'Vib-7734' 'Vib7734']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DAXDILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004610', 'MONDO_0019558', 'MONDO_0020122', 'EFO_0005809',
       'EFO_0005761', 'EFO_0004192', 'MONDO_0007915'], dtype=object), 'count': 7}",[ENSG00000239961],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4594393,O=C([O-])CCCO.O=C([O-])CCCO.[Ca+2],AZRRVLSHRWGNRS-UHFFFAOYSA-L,Small molecule,False,CALCIUM OXYBATE,2020.0,4.0,CHEMBL1342,False,True,[],['Oxybate calcium'],"[('DailyMed', array(['calcium%20oxybate'], dtype=object))]",,,"[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020.
CHEMBL4802159,N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12,BJXYHBKEQFQVES-NWDGAFQWSA-N,Small molecule,False,ENPATORAN,,2.0,,False,False,[],['Enpatoran' 'M-5049' 'M5049'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENPATORAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007915', 'MONDO_0100096', 'EFO_0000398', 'MONDO_0100096',
       'EFO_0003834'], dtype=object), 'count': 5}","[ENSG00000101916,ENSG00000196664]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL53418,O=C1c2cccc(O)c2C(=O)c2c(O)cccc21,QBPFLULOKWLNNW-UHFFFAOYSA-N,Small molecule,False,DANTHRON,,4.0,,True,True,[],"['Chrysazin' 'Danthron' 'Dantron' 'NSC-38626' 'NSC-646568'
 'Pilules vinchy n.f.']","[('PubChem', array(['144204673', '144208184', '170465532', '17389963', '26747347',
       '73151', '8139970'], dtype=object)), ('Wikipedia', array(['Dantron'], dtype=object)), ('drugbank', array(['DB04816'], dtype=object)), ('chEBI', array(['3682'], dtype=object))]",,"{'rows': array(['HP_0002019'], dtype=object), 'count': 1}",[ENSG00000186350],Small molecule drug with a maximum clinical trial phase of IV and is indicated for constipation. It was withdrawn in at least one region.
CHEMBL1000,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,ZKLPARSLTMPFCP-UHFFFAOYSA-N,Small molecule,False,CETIRIZINE,1995.0,4.0,,False,True,[],['AC-170' 'Cetiderm' 'Cetirizine'],"[('PubChem', array(['174007233', '90341832'], dtype=object)), ('Wikipedia', array(['Cetirizine'], dtype=object)), ('drugbank', array(['DB00341'], dtype=object)), ('chEBI', array(['3561'], dtype=object))]",['CHEMBL1201113' 'CHEMBL1607273'],"{'rows': array(['EFO_0008521', 'HP_0000989', 'EFO_0004256', 'EFO_1001417',
       'MONDO_0005271', 'EFO_1001417', 'EFO_0005854', 'HP_0001742',
       'HP_0000989', 'MONDO_0005277', 'EFO_1000749', 'EFO_0007141',
       'MONDO_0005271', 'EFO_0004191', 'MONDO_0009291', 'EFO_0007141',
       'EFO_0005751', 'MONDO_0005301', 'EFO_0003956', 'HP_0000964',
       'MONDO_0002406', 'EFO_0005531', 'EFO_0000274', 'EFO_0005854',
       'EFO_0003956', 'EFO_0003830'], dtype=object), 'count': 26}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 9 approved and 17 investigational indications.
CHEMBL1922660,CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,DFQGDHBGRSTTHX-UHFFFAOYSA-N,Small molecule,False,FIBOFLAPON,,3.0,,False,False,[],['AM-803' 'Am803' 'Fiboflapon' 'GSK-2190915' 'GSK2190915' 'GSK2190915B'],"[('drugbank', array(['DB06346'], dtype=object))]",['CHEMBL1922673'],"{'rows': array(['MONDO_0004979', 'EFO_1001348', 'MONDO_0009061', 'MONDO_0004979'],
      dtype=object), 'count': 4}",[ENSG00000132965],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1951143,CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,AMEROGPZOLAFBN-UHFFFAOYSA-N,Small molecule,False,FIMASARTAN,,3.0,,False,False,[],['Fimasartan'],"[('drugbank', array(['DB09279'], dtype=object))]",['CHEMBL1951146'],"{'rows': array(['MONDO_0001134', 'EFO_0000537', 'EFO_0003086', 'MONDO_0021187',
       'EFO_0000319'], dtype=object), 'count': 5}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2105756,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O,RQXMKRRBJITKRN-UHFFFAOYSA-N,Small molecule,False,TIVOZANIB HYDROCHLORIDE,2017.0,4.0,CHEMBL1289494,False,True,['Fotivda'],"['(tivozanib hydrochloride hydrate' 'AV-951' 'Tivozanib hydrochloride'
 'Tivozanib hydrochloride monohydrate']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fotivda'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0001421', 'EFO_0000681'], dtype=object), 'count': 3}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157404,ENSG00000113721]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for renal cell carcinoma and has 2 investigational indications.
CHEMBL289469,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,Small molecule,False,GRANISETRON,1993.0,4.0,,False,True,['Kytril' 'Sancuso' 'Sustol'],['APF-530' 'APF530' 'BRL 43694' 'BRL-43694' 'Granisetron' 'LY-278584'],"[('DailyMed', array(['granisetron'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso'],
      dtype=object)), ('PubChem', array(['90340785'], dtype=object))]",['CHEMBL1237080'],"{'rows': array(['MONDO_0004992', 'HP_0000989', 'HP_0002018', 'HP_0002018',
       'EFO_0001061', 'MONDO_0100342', 'EFO_0000616', 'EFO_0007359',
       'HP_0002017', 'EFO_0000182', 'EFO_0006911', 'HP_0002013',
       'MONDO_0004992', 'EFO_0000574', 'HP_0002017', 'EFO_0006911',
       'EFO_0000616', 'EFO_0004888', 'HP_0100806', 'EFO_1000948'],
      dtype=object), 'count': 20}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 8 investigational indications.
CHEMBL3039525,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,UQRCJCNVNUFYDX-UHFFFAOYSA-N,Small molecule,False,GOLVATINIB,,2.0,,False,False,[],['E-7050' 'E7050' 'Golvatinib'],"[('drugbank', array(['DB11977'], dtype=object))]",['CHEMBL3039500'],"{'rows': array(['MONDO_0004992', 'EFO_0000181', 'MONDO_0001056', 'EFO_0000616'],
      dtype=object), 'count': 4}","[ENSG00000128052,ENSG00000105976]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3039598,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,BIDNLKIUORFRQP-XYGFDPSESA-N,Small molecule,True,FOSINOPRIL,1991.0,4.0,,False,True,['Monopril'],['C09AA09' 'Fosenopril' 'Fosinopril' 'SQ-28555'],"[('drugbank', array(['DB00492'], dtype=object))]",['CHEMBL3039596'],"{'rows': array(['EFO_0000319', 'EFO_0000537', 'EFO_0003144', 'EFO_0003777',
       'EFO_0000401', 'EFO_0000537'], dtype=object), 'count': 6}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3833344,,,Antibody,False,GANCOTAMAB,,2.0,,False,False,[],['Gancotamab' 'MM-302'],,,"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}","[ENSG00000141736,ENSG00000131747]",Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297302,CCS(=O)(=O)c1ccc(Oc2cc(O[C@@H](C)CO)cc(C(=O)Nc3ccn(C)n3)c2)cn1.CS(=O)(=O)O,PIDNRTWDGDJKSQ-UQKRIMTDSA-N,Small molecule,False,MK-0941,,2.0,CHEMBL3580737,False,False,[],['MK0941' 'Mk-0941' 'Mk0941'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000106633],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297713,,,Antibody,False,CABIRALIZUMAB,,2.0,,False,False,[],['Cabiralizumab' 'Fpa-008' 'Fpa008'],,,"{'rows': array(['EFO_0000685', 'EFO_1000359', 'EFO_0000211', 'EFO_0000181',
       'EFO_0002618', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000182'],
      dtype=object), 'count': 8}",[ENSG00000182578],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL4297732,,,Antibody,False,ZILTIVEKIMAB,,3.0,,False,False,[],['COR-001' 'COR001' 'Cor-001' 'Ziltivekimab'],,,"{'rows': array(['EFO_0003884', 'EFO_0003144', 'EFO_0004272'], dtype=object), 'count': 3}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4301162,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1,UBZPNQRBUOBBLN-PWRODBHTSA-O,Small molecule,False,SERDEXMETHYLPHENIDATE,2021.0,4.0,,False,True,[],['Serdexmethylphenidate'],,['CHEMBL4298139'],"{'rows': array(['EFO_0003888', 'MONDO_0018044'], dtype=object), 'count': 2}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder and has 1 investigational indication.
CHEMBL4594457,,,Unknown,False,AL-78898A,,2.0,,False,False,[],"['(trp(me)4)-ac-compstatin' '4(1mew)' 'AL-78898A' 'Al-78898a'
 'Compstatin analog 4(1mew)' 'POT-4' 'Pot-4']",,,"{'rows': array(['EFO_0001365', 'EFO_1001492'], dtype=object), 'count': 2}",[ENSG00000125730],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5095032,Cl.O=C(N[C@@H]1CN2CCC1CC2)c1n[nH]c2ccccc12,CMRLNEYJEPELSM-BTQNPOSSSA-N,Small molecule,False,FACINICLINE HYDROCHLORIDE,,2.0,CHEMBL2151439,False,False,[],"['Facinicline hydrochloride' 'MEM 3454' 'MEM-3454' 'MEM3454' 'RG-3487'
 'RG3487' 'Rg3487']",,,"{'rows': array(['MONDO_0005090', 'MONDO_0004975'], dtype=object), 'count': 2}","[ENSG00000175344,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL52885,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21,OVSKGTONMLKNPZ-UHFFFAOYSA-N,Small molecule,False,ENMD-981693,,2.0,,False,False,[],"['ENMD 981693' 'ENMD-2076' 'ENMD-981693' 'Enmd-2076 free base'
 'Enmd-981693' 'MKC-1' 'Mkc 1' 'R-440' 'RO 31-7453' 'RO-31-7453'
 'Ro-317453']","[('drugbank', array(['DB05608'], dtype=object))]",,"{'rows': array(['EFO_1001951', 'EFO_0003060', 'EFO_0002618', 'MONDO_0007254',
       'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 6}","[ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000113721,ENSG00000134853,ENSG00000087586,ENSG00000122025,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL916,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,COKMIXFXJJXBQG-NRFANRHFSA-N,Small molecule,False,TIROFIBAN,1998.0,4.0,,False,True,[],['Aggrastat' 'Agrastat' 'L-700462' 'MK-383' 'Tirofiban'],"[('Wikipedia', array(['Tirofiban'], dtype=object)), ('drugbank', array(['DB00775'], dtype=object)), ('chEBI', array(['9605'], dtype=object))]",['CHEMBL3189072' 'CHEMBL1704'],"{'rows': array(['MONDO_0100096', 'EFO_0004286', 'EFO_0000612', 'HP_0004419',
       'EFO_0007541', 'EFO_0001645', 'EFO_0000712', 'EFO_0005672',
       'EFO_0009686', 'HP_0002140', 'EFO_0008583', 'EFO_0000612',
       'HP_0000083'], dtype=object), 'count': 13}","[ENSG00000259207,ENSG00000005961]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for myocardial infarction and recurrent thrombophlebitis and has 11 investigational indications.
CHEMBL1170,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,PDMMFKSKQVNJMI-BLQWBTBKSA-N,Small molecule,False,TESTOSTERONE PROPIONATE,1974.0,4.0,,False,True,['Testosterone propionate'],"['NRB-03689' 'NSC-9166' 'Orchisterone' 'Testosteron 17-propionate'
 'Testosterone 17.beta.-propionate' 'Testosterone Propionate'
 'Testosterone propionate' 'Testosterone propionate ciii'
 'Testosteroni propionas' 'Virormone']","[('PubChem', array(['11112138', '144203881', '144212587', '170464835', '56463044'],
      dtype=object)), ('drugbank', array(['DB01420'], dtype=object)), ('chEBI', array(['9466'], dtype=object))]",,"{'rows': array(['EFO_1001271'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and has 1 investigational indication.
CHEMBL1200367,CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-],OVXQHPWHMXOFRD-UHFFFAOYSA-M,Small molecule,False,ECHOTHIOPHATE IODIDE,1960.0,4.0,CHEMBL1201341,False,True,['Phospholine iodide'],"['217-MI' 'Echodide' 'Echothiophate iodide' 'Ecostigmine iodide'
 'Ecothiopate iodide']","[('chEBI', array(['59849'], dtype=object))]",,,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1201178,CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,CETWSOHVEGTIBR-FORAGAHYSA-N,Small molecule,True,LISDEXAMFETAMINE DIMESYLATE,2007.0,4.0,CHEMBL1201222,False,True,['Elvanse' 'Elvanse adult' 'Vyvanse'],"['Lisdexamfetamine dimesilate' 'Lisdexamfetamine dimesylate'
 'Lisdexamfetamine dimethanesulfonate' 'Lisdexamfetamine mesilate'
 'Lisdexamphetamine dimesilate' 'NRP-104' 'NRP104' 'SPD-489' 'SPD489'
 'Tyvense']","[('DailyMed', array(['lisdexamfetamine%20dimesylate'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'MONDO_0002009', 'EFO_0005203', 'MONDO_0002277',
       'MONDO_0005090', 'EFO_0005924', 'EFO_0004698', 'EFO_0003890',
       'EFO_0005204', 'MONDO_0005041', 'EFO_0003888'], dtype=object), 'count': 11}","[ENSG00000103546,ENSG00000165646,ENSG00000142319]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201260,C/N=C(\NC)NCc1ccccc1,NIVZHWNOUVJHKV-UHFFFAOYSA-N,Small molecule,False,BETHANIDINE,1982.0,4.0,,False,True,[],['Betanidine' 'Bethanidine'],"[('Wikipedia', array(['Bethanidine'], dtype=object)), ('drugbank', array(['DB00217'], dtype=object)), ('chEBI', array(['37937'], dtype=object))]",['CHEMBL2110368'],"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for hypertension.
CHEMBL1201340,C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1,LCTZPQRFOZKZNK-UHFFFAOYSA-N,Small molecule,False,DIPHEMANIL,1982.0,4.0,,False,True,[],['Diphemanil' 'Diphemanil cation' 'Diphemanil ion'],"[('PubChem', array(['11112168'], dtype=object)), ('drugbank', array(['DB13720'], dtype=object))]",['CHEMBL1200880'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease.
CHEMBL1255794,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2,GWNOTCOIYUNTQP-FQLXRVMXSA-N,Small molecule,False,APLAVIROC,,3.0,,False,False,[],['AK-602' 'Aplaviroc' 'GSK-873140' 'GW-873140' 'GW873140'],"[('drugbank', array(['DB06497'], dtype=object))]",['CHEMBL1668019'],"{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1425,Sc1ncnc2nc[nH]c12,GLVAUDGFNGKCSF-UHFFFAOYSA-N,Small molecule,False,MERCAPTOPURINE ANHYDROUS,1953.0,4.0,,False,True,[],['Mercaptopurine anhydrous'],"[('PubChem', array(['124891196', '144204709', '144209789', '170464985', '174006957',
       '26748122', '49675007', '50086850', '538245'], dtype=object)), ('Wikipedia', array(['Mercaptopurine'], dtype=object)), ('drugbank', array(['DB01033'], dtype=object)), ('chEBI', array(['2208'], dtype=object))]",['CHEMBL1200751'],"{'rows': array(['MONDO_0000873', 'EFO_0000309', 'EFO_0000565', 'EFO_0000574',
       'MONDO_0044917', 'MONDO_0019460', 'EFO_0000224', 'EFO_0003833',
       'EFO_0004289', 'MONDO_0003268', 'EFO_0002501', 'EFO_0000729',
       'MONDO_0000870', 'EFO_0000209', 'EFO_0000616', 'EFO_0000222',
       'EFO_0000094', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872',
       'EFO_0002499', 'EFO_1000318', 'EFO_0000220'], dtype=object), 'count': 23}",[ENSG00000128059],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 5 approved and 18 investigational indications.
CHEMBL14370,CCOc1ccccc1OC(c1ccccc1)C1CNCCO1,CBQGYUDMJHNJBX-UHFFFAOYSA-N,Small molecule,False,REBOXETINE,1997.0,4.0,,False,True,['Edronax'],['Reboxetine'],"[('Wikipedia', array(['Reboxetine'], dtype=object))]",['CHEMBL2146087'],"{'rows': array(['MONDO_0002009', 'EFO_0003888', 'EFO_0005230', 'EFO_0005687',
       'HP_0000726', 'EFO_0003843', 'HP_0012378', 'EFO_0001358',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_1000783', 'MONDO_0002009'],
      dtype=object), 'count': 12}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for major depressive disorder and depressive disorder and has 10 investigational indications.
CHEMBL1514,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1,XBMIVRRWGCYBTQ-AVRDEDQJSA-N,Small molecule,False,LEVOMETHADYL ACETATE,1993.0,4.0,,False,True,['Orlaam'],"['LAA-M' 'LAAM' 'Levacetylmethadol' 'Levo-alphacetylmethadol'
 'Levoacetyl methadol' 'Levomethadyl acetate']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orlaam'],
      dtype=object)), ('Wikipedia', array(['Levacetylmethadol'], dtype=object)), ('drugbank', array(['DB01227'], dtype=object)), ('chEBI', array(['6441'], dtype=object))]",['CHEMBL1200817'],"{'rows': array(['EFO_0005611', 'EFO_0003890'], dtype=object), 'count': 2}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for opioid dependence and drug dependence.
CHEMBL1742981,,,Antibody,False,ABAGOVOMAB,,3.0,,False,False,[],['ACA-125' 'Abagovomab' 'MEN-2234'],,,"{'rows': array(['MONDO_0008170', 'MONDO_0002158', 'MONDO_0002087'], dtype=object), 'count': 3}",[ENSG00000181143],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1800159,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1,AOMXMOCNKJTRQP-UHFFFAOYSA-N,Small molecule,False,RELUGOLIX,2019.0,4.0,,False,True,['Orgovyx'],['Relugolix' 'TAK-385' 'Tak-385'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orgovyx'],
      dtype=object)), ('drugbank', array(['DB11853'], dtype=object))]",,"{'rows': array(['EFO_0000731', 'EFO_0000196', 'EFO_0000673', 'MONDO_0008315',
       'EFO_0001065', 'EFO_0003843', 'MONDO_0008315', 'EFO_0000616'],
      dtype=object), 'count': 8}",[ENSG00000109163],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 4 investigational indications.
CHEMBL2105872,CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12.CS(=O)(=O)O,DUGMCDWNXXFHDE-VZYDHVRKSA-N,Small molecule,False,IBUTAMOREN MESYLATE,,2.0,CHEMBL13817,False,False,[],['Ibutamoren mesilate' 'Ibutamoren mesylate' 'MK-0677' 'MK-677'],,,"{'rows': array(['EFO_0005687'], dtype=object), 'count': 1}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107786,Cc1ccc2c(c1CCC(=O)O)CC[C@@H](NS(=O)(=O)c1ccc(Cl)cc1)C2,HWEOXFSBSQIWSY-MRXNPFEDSA-N,Small molecule,False,TERUTROBAN,,3.0,,False,False,['Triplion'],['S18886' 'Terutroban'],,,,[ENSG00000006638],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL2108029,,,Antibody,False,ERTUMAXOMAB,,2.0,,False,False,['Rexomun'],['Ertumaxomab'],,,"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000141736,ENSG00000198851]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109124,,,Antibody drug conjugate,False,DORLIMOMAB ARITOX,,2.0,,False,False,[],['Dorlimomab aritox' 'MDX-RA' 'ST-1 4197X-RA'],,,,"[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]",Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2364648,,,Antibody,False,GUSELKUMAB,2017.0,4.0,,False,True,['Tremfya'],['CNTO 1959' 'CNTO-1959' 'Guselkumab'],"[('DailyMed', array(['guselkumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya'],
      dtype=object))]",,"{'rows': array(['EFO_0008573', 'EFO_0000676', 'EFO_0000540', 'MONDO_0015597',
       'EFO_0000685', 'EFO_0005761', 'MONDO_0100017', 'EFO_1001494',
       'EFO_1001209', 'Orphanet_733', 'EFO_1000710', 'EFO_0000384',
       'EFO_0000717', 'EFO_0001060', 'EFO_0003778', 'EFO_0000729',
       'EFO_0002609'], dtype=object), 'count': 17}","[ENSG00000113302,ENSG00000110944]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 12 investigational indications.
CHEMBL277062,O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1,VMIYHDSEFNYJSL-UHFFFAOYSA-N,Small molecule,False,BROMAZEPAM,,4.0,,False,True,['Lexotan'],"['Bromazepam' 'Bromazepam civ' 'Lexatin' 'Lexotanil' 'NSC-140669'
 'RO 5-3350' 'RO-5-3350']","[('Wikipedia', array(['Bromazepam'], dtype=object)), ('drugbank', array(['DB01558'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090'],
      dtype=object), 'count': 4}",[ENSG00000151834],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for anxiety and has 3 investigational indications.
CHEMBL3092650,O=C1CCCN1c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1,YFRBKEVUUCQYOW-UHFFFAOYSA-N,Small molecule,False,GSK239512,,2.0,,False,False,[],['GSK-239512A' 'GSK239512' 'Gsk-239512' 'Gsk239512'],"[('drugbank', array(['DB15120'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0003929', 'MONDO_0005301', 'MONDO_0005090',
       'HP_0000726'], dtype=object), 'count': 5}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3188034,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1.Cl.O,CUZMOIXUFHOLLN-UMVVUDSKSA-N,Small molecule,False,TRIPROLIDINE HYDROCHLORIDE,1983.0,4.0,CHEMBL855,False,True,['Actidil' 'Myidyl' 'Pro-actidil' 'Triprolidine hydrochloride'],['NSC-757361' 'Triprolidine hcl' 'Triprolidine hydrochloride'],"[('DailyMed', array(['triprolidine%20hydrochloride'], dtype=object)), ('PubChem', array(['144208046'], dtype=object)), ('chEBI', array(['32265'], dtype=object))]",,"{'rows': array(['HP_0001742', 'EFO_0005854', 'EFO_0007214', 'EFO_0003956'],
      dtype=object), 'count': 4}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 4 approved indications.
CHEMBL3707277,,,Antibody drug conjugate,False,DEPATUXIZUMAB MAFODOTIN,,3.0,,False,False,[],['ABT-414' 'Abt-414' 'Depatuxizumab mafodotin'],,,"{'rows': array(['EFO_0000519', 'EFO_1001465', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000146648],Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3786343,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,FDMQDKQUTRLUBU-UHFFFAOYSA-N,Small molecule,False,OLMUTINIB,2016.0,4.0,,False,True,[],['BI 1482694' 'BI-1482694' 'HM-61713' 'HM61713' 'Hm-61713' 'Olmutinib'],"[('drugbank', array(['DB13164'], dtype=object))]",['CHEMBL3989930'],"{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 2 investigational indications.
CHEMBL4297521,COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(C(F)(F)F)nc2s1,DCXFIOLWWRXEQH-SSDOTTSWSA-N,Small molecule,False,PADSEVONIL,,3.0,,False,False,[],"['Padsevonil' 'UCB-0942' 'UCB-1415943-000' 'UCB0942' 'UCB1415943-000'
 'Ucb0942']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PADSEVONIL/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14977'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'HP_0001250', 'EFO_0000474', 'EFO_0004263'],
      dtype=object), 'count': 4}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000159164,ENSG00000185518,ENSG00000122012]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL5314405,COC(=O)/C(=C/c1cc(OC)cc(OC)c1)c1ccc(Oc2ccc(CC3SC(=O)NC3=O)cc2)cc1,IVAQJHSXBVHUQT-ZVHZXABRSA-N,Small molecule,False,CLX-0921,,1.0,,False,False,[],['Clx-0921' 'THR-0921'],,,,[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1040,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12,JWUBBDSIWDLEOM-DTOXIADCSA-N,Small molecule,False,CALCIFEDIOL ANHYDROUS,1980.0,4.0,,False,True,[],"['Calcifediol' 'Calcifediol, anhydrous' 'Calcifediol,anhydrous']","[('PubChem', array(['144205540', '26754888', '50110817'], dtype=object)), ('drugbank', array(['DB00146'], dtype=object)), ('chEBI', array(['17933'], dtype=object))]",['CHEMBL3544909' 'CHEMBL4594399'],"{'rows': array(['EFO_0003884', 'MONDO_0100096', 'HP_0001919', 'EFO_0005754',
       'EFO_0003918', 'EFO_0000612', 'EFO_1001173', 'EFO_0003762'],
      dtype=object), 'count': 8}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved and 5 investigational indications.
CHEMBL1201129,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,XAUDJQYHKZQPEU-KVQBGUIXSA-N,Small molecule,False,DECITABINE,2006.0,4.0,,False,True,['Dacogen' 'Decitabine'],"[""2'-deoxy-5-azacytidine"" 'DAC' 'Decitabine' 'NSC-127716']","[('DailyMed', array(['decitabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen'],
      dtype=object)), ('PubChem', array(['144205864', '170465126', '47211573', '56324652', '57260149'],
      dtype=object)), ('Wikipedia', array(['Decitabine'], dtype=object)), ('drugbank', array(['DB01262'], dtype=object)), ('chEBI', array(['50131'], dtype=object))]",,"{'rows': array(['EFO_0000096', 'EFO_0000224', 'EFO_0000403', 'EFO_0000326',
       'EFO_0000220', 'MONDO_0011382', 'MONDO_0003660', 'MONDO_0007254',
       'EFO_0000198', 'EFO_0002913', 'EFO_1000131', 'MONDO_0000870',
       'EFO_0003869', 'EFO_0000621', 'MONDO_0004643', 'EFO_1001996',
       'EFO_0003811', 'EFO_1001830', 'MONDO_0003659', 'EFO_0000756',
       'EFO_0007160', 'MONDO_0019472', 'EFO_0000183', 'EFO_0000641',
       'EFO_0002428', 'EFO_0004251', 'EFO_0003060', 'EFO_0004599',
       'MONDO_0008170', 'EFO_0002617', 'EFO_0005537', 'MONDO_0013730',
       'EFO_0000681', 'EFO_0000501', 'EFO_0001663', 'HP_0001915',
       'MONDO_0002158', 'EFO_0000196', 'EFO_0000180', 'EFO_0000211',
       'MONDO_0002280', 'EFO_0005952', 'EFO_0000565', 'EFO_0006859',
       'EFO_0000616', 'EFO_1001779', 'EFO_0000339', 'EFO_0001642',
       'HP_0001873', 'EFO_0000222', 'MONDO_0004992', 'EFO_0002939',
       'EFO_0000389', 'MONDO_0002087', 'MONDO_0000430', 'EFO_0001378',
       'EFO_0000574', 'EFO_0005922', 'EFO_0000309', 'EFO_1001469',
       'MONDO_0100096'], dtype=object), 'count': 61}","[ENSG00000130816,ENSG00000119772]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 7 approved and 54 investigational indications.
CHEMBL1201179,CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O,XNRVGTHNYCNCFF-UHFFFAOYSA-N,Small molecule,True,LAPATINIB DITOSYLATE,2007.0,4.0,CHEMBL554,False,True,['Tykerb' 'Tyverb'],"['GW-572016F' 'GW572016F' 'Lapatinib'
 'Lapatinib ditoluenesulfonate monohydrate' 'Lapatinib ditosylate'
 'Lapatinib ditosylate anhydrous' 'Lapatinib ditosylate monohydrate'
 'Lapatinib tosilate' 'Lapatinib tosilate hydrate' 'Tycerb']","[('DailyMed', array(['lapatinib%20ditosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb'],
      dtype=object))]",,"{'rows': array(['EFO_0002892', 'MONDO_0008315', 'EFO_0002938', 'MONDO_0044926',
       'EFO_0000616', 'EFO_1001465', 'EFO_0000305', 'MONDO_0004986',
       'MONDO_0001187', 'EFO_1000294', 'EFO_1000158', 'EFO_1001512',
       'EFO_0000574', 'EFO_0006859', 'MONDO_0007254', 'EFO_0002618',
       'EFO_0006861', 'EFO_0003869', 'EFO_0006352'], dtype=object), 'count': 19}","[ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 15 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201320,COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,SUBDBMMJDZJVOS-DEOSSOPVSA-N,Small molecule,False,ESOMEPRAZOLE,2001.0,4.0,,False,True,[],"['A02BC05' 'Esomeprazole' 'Inexium paranova' 'Omeprazole s-form'
 'Omeprazole, (s)-']","[('Wikipedia', array(['Esomeprazole'], dtype=object)), ('drugbank', array(['DB00736'], dtype=object)), ('chEBI', array(['50275'], dtype=object))]","['CHEMBL1200470' 'CHEMBL2146140' 'CHEMBL5279304' 'CHEMBL2105642'
 'CHEMBL5314366']","{'rows': array(['EFO_0008533', 'EFO_0000342', 'EFO_0004607', 'EFO_0000337',
       'EFO_0003948', 'EFO_1001095', 'EFO_0009454', 'MONDO_0005178',
       'HP_0004398', 'EFO_0000574', 'EFO_0004607', 'HP_0002239',
       'EFO_0007549', 'EFO_0009454', 'EFO_0003948', 'MONDO_0004247',
       'EFO_0004232', 'EFO_0002609', 'MONDO_0004247', 'EFO_0008533',
       'EFO_0003869', 'MONDO_0009061', 'MONDO_0007576', 'MP_0001914',
       'EFO_0000217', 'MONDO_0004979', 'EFO_0000668', 'EFO_0005762',
       'EFO_0000616', 'EFO_0003948', 'EFO_0001361', 'MONDO_0005148',
       'EFO_0007549', 'EFO_0010282', 'MONDO_0005178', 'EFO_0003948',
       'EFO_0010282', 'EFO_0004239', 'EFO_0004607', 'MONDO_0043839',
       'EFO_0003758', 'HP_0002018', 'EFO_0003898', 'HP_0100633',
       'EFO_0009454', 'EFO_0000685', 'EFO_0004607', 'EFO_0003756',
       'EFO_1000961'], dtype=object), 'count': 49}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 8 approved and 34 investigational indications.
CHEMBL1201574,,,Unknown,True,ONABOTULINUMTOXINA,1991.0,4.0,,False,True,['Botox' 'Botox Cosmetic' 'Botox/botox cosmetic'],"['Bontoxilysin' 'Botulin' 'Botulinum neurotoxin' 'Botulinum toxin'
 'Botulinum toxin type a purified neurotoxin complex' 'Onabotulinumtoxina'
 'RTI-150' 'RTI150']","[('DailyMed', array(['onabotulinumtoxina'], dtype=object))]",,"{'rows': array(['EFO_0005279', 'EFO_1001896', 'EFO_1001887', 'HP_0030834',
       'EFO_0003897', 'EFO_1001434', 'EFO_1001466', 'MONDO_0011728',
       'EFO_0009550', 'EFO_0005422', 'EFO_1001993', 'Orphanet_93955',
       'EFO_0008521', 'MONDO_0005180', 'HP_0012532', 'HP_0000565',
       'EFO_0001073', 'HP_0002307', 'EFO_0003899', 'MONDO_0043839',
       'EFO_0000618', 'HP_0003419', 'HP_0000020', 'HP_0001347',
       'HP_0012390', 'HP_0000016', 'EFO_1000781', 'EFO_1000999',
       'EFO_0004212', 'EFO_0009523', 'HP_0000473', 'EFO_1000657',
       'EFO_1000391', 'EFO_0005762', 'EFO_1000948', 'HP_0000726',
       'EFO_1001054', 'EFO_0003877', 'EFO_0004234', 'MONDO_0005178',
       'MONDO_0005301', 'MONDO_0043510', 'EFO_0009453', 'HP_0001257',
       'EFO_0004270', 'EFO_0009619', 'HP_0002315', 'HP_0000989',
       'EFO_0003894', 'HP_0010992', 'EFO_0004616', 'MONDO_0004001',
       'EFO_0000275', 'EFO_0007159', 'EFO_1001250', 'EFO_0002618',
       'MONDO_0000485', 'HP_0000486', 'EFO_1000632', 'EFO_1001092',
       'MONDO_0002050', 'EFO_0002970', 'EFO_0000284', 'EFO_0004143',
       'EFO_0004273', 'HP_0001337', 'EFO_0002916', 'MONDO_0002471',
       'HP_0009926', 'EFO_0004269', 'EFO_1001866', 'EFO_1001219',
       'HP_0012228', 'EFO_0005306', 'EFO_0009846', 'EFO_0009625',
       'EFO_0000546', 'EFO_1000850', 'EFO_0004191', 'HP_0000975',
       'MONDO_0041052', 'EFO_0003911', 'EFO_0006865', 'EFO_0009430',
       'EFO_0003830', 'MONDO_0005277', 'HP_0003549', 'EFO_0003108',
       'HP_0000011', 'EFO_0000712', 'EFO_0007507', 'EFO_0006346',
       'EFO_1001919', 'HP_0001605', 'MONDO_0002009', 'EFO_0008507',
       'EFO_0803321', 'EFO_1001909', 'EFO_1001494', 'EFO_1001145',
       'HP_0032252', 'EFO_0001074', 'EFO_0003843', 'EFO_1000906',
       'MONDO_0002507'], dtype=object), 'count': 105}",[ENSG00000132639],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 104 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201628,,,Protein,False,INSULIN SUSP PROTAMINE ZINC BEEF/PORK,1966.0,4.0,,False,True,['Protamine zinc & iletin i (beef-pork)'],['Insulin susp protamine zinc beef/pork'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1966.
CHEMBL1214124,N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O,PRMWGUBFXWROHD-UHFFFAOYSA-N,Small molecule,True,PERAMPANEL,2012.0,4.0,,False,True,['Fycompa'],['E-2007' 'E2007' 'ER-155055-90' 'Perampanel'],"[('DailyMed', array(['perampanel'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa'],
      dtype=object)), ('Wikipedia', array(['Perampanel'], dtype=object)), ('drugbank', array(['DB08883'], dtype=object)), ('chEBI', array(['71013'], dtype=object))]",,"{'rows': array(['EFO_0001358', 'HP_0002069', 'EFO_0004263', 'EFO_0003108',
       'MONDO_0004985', 'EFO_0007262', 'EFO_0009430', 'HP_0001250',
       'MONDO_0004976', 'MONDO_0800207', 'MONDO_0002009', 'MONDO_0005277',
       'MONDO_0005180', 'EFO_0000474', 'MONDO_0007079', 'HP_0000473',
       'EFO_1000783', 'MONDO_0016532'], dtype=object), 'count': 18}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1241,CN(C)CCN(Cc1ccccc1)c1ccccn1,UFLGIAIHIAPJJC-UHFFFAOYSA-N,Small molecule,False,TRIPELENNAMINE,1948.0,4.0,,False,True,[],['NSC-118946' 'PBZ' 'PBZ-SR' 'Tripelennamine'],"[('Wikipedia', array(['Tripelennamine'], dtype=object)), ('drugbank', array(['DB00792'], dtype=object)), ('chEBI', array(['9741'], dtype=object))]",['CHEMBL1200769' 'CHEMBL1200446'],"{'rows': array(['MONDO_0005271', 'HP_0000989'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for allergic disease and pruritus.
CHEMBL1258006,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2o1,OXKRFEWMSWPKKV-GHTZIAJQSA-N,Small molecule,False,BRADANICLINE,,2.0,,False,False,[],['ATA-101' 'Bradanicline' 'TC 5619' 'TC-5619'],"[('drugbank', array(['DB06090'], dtype=object))]",['CHEMBL3137311'],"{'rows': array(['MONDO_0005090', 'EFO_0003888', 'HP_0012735'], dtype=object), 'count': 3}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2016893,Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1,IKBSEBRGSVFUHM-UHFFFAOYSA-N,Small molecule,False,XL-418,,1.0,,False,False,[],['XL418' 'Xl-418'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000175634,ENSG00000108443]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2104993,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1,YQNWZWMKLDQSAC-UHFFFAOYSA-N,Small molecule,True,VORTIOXETINE,2013.0,4.0,,False,True,['Brintellix'],['LU AA21004' 'LU-AA21004' 'LUAA21004' 'Vortioxetine'],"[('drugbank', array(['DB09068'], dtype=object)), ('chEBI', array(['76016'], dtype=object))]",['CHEMBL5314578' 'CHEMBL2107387' 'CHEMBL3260563' 'CHEMBL2204360'],"{'rows': array(['MONDO_0004985', 'MONDO_0002009', 'MONDO_0002009', 'MONDO_0002050',
       'MONDO_0002009', 'EFO_0005203', 'EFO_0003888', 'EFO_0001421',
       'EFO_0006788', 'EFO_1001892', 'MONDO_0002009', 'MONDO_0002009'],
      dtype=object), 'count': 12}","[ENSG00000178394,ENSG00000108576,ENSG00000166736]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder and has 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109590,,,Antibody,False,GSK-1995057,,1.0,,False,False,[],['GSK-1995057' 'Gsk-1995057'],,,"{'rows': array(['EFO_0000684'], dtype=object), 'count': 1}",[ENSG00000067182],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3218578,COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1,BMMXYEBLEBULND-UHFFFAOYSA-N,Small molecule,False,BGT-226,,2.0,,False,False,[],['BGT-226' 'NVP-BGT226'],"[('chEBI', array(['71967'], dtype=object))]",['CHEMBL3545096'],"{'rows': array(['MONDO_0016063', 'MONDO_0007254', 'MONDO_0004992'], dtype=object), 'count': 3}","[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3544922,,,Antibody,False,OPICINUMAB,,2.0,,False,False,[],['Anti-LINGO' 'BIIB-033' 'BIIB033' 'Opicinumab'],,,"{'rows': array(['EFO_0003929', 'MONDO_0005301', 'EFO_0007405'], dtype=object), 'count': 3}",[ENSG00000169783],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545252,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O,XCDIRYDKECHIPE-QHEQPUDQSA-N,Small molecule,True,DOCETAXEL,1996.0,4.0,CHEMBL92,False,True,"['Docefrez' 'Docetaxel'
 'Docetaxel zentiva (previously docetaxel winthrop)' 'Taxceus' 'Taxotere']","['Docetaxel' 'Docetaxel (as trihydrate)' 'Docetaxel hydrate'
 'Docetaxel trihydrate' 'RP 56976' 'RP-56976' 'XRP6976']","[('DailyMed', array(['docetaxel'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop'],
      dtype=object)), ('chEBI', array(['59809'], dtype=object))]",,"{'rows': array(['MONDO_0011719', 'HP_0002039', 'EFO_0000313', 'MONDO_0008315',
       'MONDO_0001187', 'EFO_0004281', 'MONDO_0021117', 'EFO_0007355',
       'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'EFO_0000181',
       'MONDO_0004986', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000673',
       'MONDO_0001528', 'EFO_0000432', 'HP_0004326', 'EFO_0001416',
       'MONDO_0003060', 'EFO_0009708', 'EFO_0006859', 'EFO_0004230',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0005271',
       'MONDO_0002038', 'MONDO_0000521', 'EFO_0003869', 'MONDO_0021310',
       'EFO_1000043', 'MONDO_0005575', 'EFO_0003891', 'MONDO_0004192',
       'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'Orphanet_145',
       'EFO_0001376', 'EFO_1000984', 'EFO_0005537', 'EFO_0003817',
       'EFO_0000616', 'MONDO_0001325', 'MONDO_0002120', 'EFO_0000174',
       'EFO_0000565', 'EFO_0000574', 'EFO_0000178', 'EFO_0003860',
       'EFO_0007362', 'EFO_0005570', 'EFO_0002916', 'EFO_0005088',
       'MONDO_0021063', 'EFO_0000503', 'EFO_0002938', 'EFO_0000571',
       'EFO_0006352', 'EFO_0000707', 'EFO_0003897', 'MONDO_0002158',
       'EFO_0000466', 'EFO_0003060', 'EFO_0002428', 'EFO_0000756',
       'EFO_0000198', 'EFO_0000199', 'MONDO_0002974', 'MONDO_0004992',
       'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0003865',
       'EFO_0000702', 'MONDO_0002367', 'EFO_0001663', 'EFO_0000637',
       'EFO_0002618', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0018364',
       'EFO_0008528', 'EFO_0000305', 'EFO_0003893', 'EFO_0006911',
       'EFO_0004284', 'HP_0012378', 'MONDO_0007254', 'MONDO_0001056',
       'MONDO_0011962', 'EFO_0000228', 'EFO_0000691', 'EFO_0000196',
       'MONDO_0007576', 'EFO_0000564', 'EFO_0005950', 'MONDO_0001475',
       'EFO_1000601', 'MONDO_0021355', 'MONDO_0004669', 'EFO_0000182',
       'EFO_0000708', 'EFO_0001075', 'MONDO_0003199', 'EFO_1001931',
       'EFO_0005577', 'EFO_1001100', 'EFO_1001214', 'EFO_0004252',
       'EFO_0003859', 'EFO_1000595', 'EFO_0001378', 'MONDO_0001402'],
      dtype=object), 'count': 116}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 20 approved and 96 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3989520,NCCc1c[nH]cn1.O=P(O)(O)O.O=P(O)(O)O,ZHIBQGJKHVBLJJ-UHFFFAOYSA-N,Small molecule,True,HISTAMINE PHOSPHATE,1939.0,4.0,CHEMBL90,False,True,['Histamine phosphate'],['Histamine phosphate'],,,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939. This drug has a black box warning from the FDA.
CHEMBL405130,COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC,HOZUXBLMYUPGPZ-UHFFFAOYSA-N,Small molecule,False,WHI-P131,,1.0,,False,False,[],['JANEX-1' 'Janex 1' 'WHI-P131' 'Whi-p131'],,['CHEMBL555201'],,[ENSG00000105639],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL411907,C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C,QIUASFSNWYMDFS-NILGECQDSA-N,Small molecule,False,SONOLISIB,,2.0,,False,False,[],['PX-866' 'Px-866' 'Sonolisib'],"[('drugbank', array(['DB12601'], dtype=object)), ('chEBI', array(['65345'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000519'],
      dtype=object), 'count': 4}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL41306,CSc1cccc(N(C)C(=N)Nc2cc(SC)ccc2Cl)c1,JHVHEDNLONERHY-UHFFFAOYSA-N,Small molecule,False,CNS-5161,,-1.0,,False,False,[],['Cns 5161' 'Cns-5161'],"[('drugbank', array(['DB05824'], dtype=object))]",['CHEMBL1079972'],,"[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug.
CHEMBL4297666,CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1,VIQCWEGEHRBLAC-UHFFFAOYSA-N,Small molecule,False,OMIDENEPAG ISOPROPYL,2022.0,4.0,,False,True,['Omlonti'],['DE-117' 'De-117' 'Omidenepag isopropyl'],"[('drugbank', array(['DB15071'], dtype=object))]",,"{'rows': array(['EFO_1001069', 'EFO_0004190', 'MONDO_0005041'], dtype=object), 'count': 3}",[ENSG00000125384],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for ocular hypertension and open-angle glaucoma and has 1 investigational indication.
CHEMBL4594357,,,Antibody,False,IANALUMAB,,3.0,,False,False,[],['Ianalumab' 'NVP-VAY736' 'VAY-736' 'VAY736' 'Vay736'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IANALUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000768', 'EFO_0005809', 'EFO_0000699', 'EFO_0005676',
       'EFO_1001264', 'EFO_0000685', 'MONDO_0018906', 'MONDO_0005301',
       'EFO_1001469', 'EFO_1000630', 'EFO_0000616', 'EFO_0007160',
       'MONDO_0007915', 'EFO_0000095', 'EFO_0000403', 'EFO_0004719',
       'EFO_0005761'], dtype=object), 'count': 17}",[ENSG00000159958],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.
CHEMBL4650392,,,Antibody,False,DOMVANALIMAB,,3.0,,False,False,[],['AB-154' 'AB154' 'Ab154' 'Domvanalimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DOMVANALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000756', 'EFO_0000616', 'EFO_0000228', 'MONDO_0002691',
       'EFO_0003060', 'MONDO_0004992', 'EFO_0000519'], dtype=object), 'count': 7}",[ENSG00000181847],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4650469,,,Antibody,False,DEPEMOKIMAB,,3.0,,False,False,[],"['AQ-82742999' 'AQ82742999' 'Depemokimab' 'GSK-3511294' 'GSK3511294'
 'Gsk3511294']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DEPEMOKIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005297', 'EFO_1001467', 'EFO_1000391', 'MONDO_0004979'],
      dtype=object), 'count': 4}",[ENSG00000113525],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL61780,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO,TUYWTLTWNJOZNY-UHFFFAOYSA-N,Small molecule,False,TEZOSENTAN,,3.0,,False,False,['Veletri'],['ACT-050089' 'Ro 61-0612' 'Ro-610612' 'Tezosentan'],"[('Wikipedia', array(['Tezosentan'], dtype=object)), ('drugbank', array(['DB06558'], dtype=object))]",,"{'rows': array(['EFO_0001361', 'EFO_0003144'], dtype=object), 'count': 2}","[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL655,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,DDLIGBOFAVUZHB-UHFFFAOYSA-N,Small molecule,True,MIDAZOLAM,1985.0,4.0,,False,True,"['Midazolam in 0.8% sodium chloride' 'Midazolam in 0.9% sodium chloride'
 'Nayzilam']",['Midazolam' 'Midazolam civ' 'USL-261' 'USL261'],"[('DailyMed', array(['midazolam'], dtype=object)), ('PubChem', array(['50113067'], dtype=object)), ('Wikipedia', array(['Midazolam'], dtype=object)), ('drugbank', array(['DB00683'], dtype=object)), ('chEBI', array(['6931'], dtype=object))]",['CHEMBL2106922' 'CHEMBL1200420'],"{'rows': array(['EFO_0009686', 'EFO_0005741', 'MONDO_0043510', 'HP_0000083',
       'EFO_1001413', 'EFO_1001884', 'EFO_0000685', 'EFO_0003929',
       'EFO_0001073', 'MONDO_0002050', 'MONDO_0004992', 'EFO_0009854',
       'EFO_0000544', 'EFO_0000384', 'EFO_0007157', 'EFO_0006834',
       'EFO_0004272', 'EFO_0008525', 'MONDO_0002009', 'EFO_1002048',
       'EFO_0007328', 'HP_0000989', 'EFO_0003869', 'MONDO_0002009',
       'EFO_0003914', 'EFO_0009708', 'EFO_0003103', 'EFO_0003890',
       'MONDO_0004985', 'EFO_1000049', 'MONDO_0005148', 'EFO_0000616',
       'MONDO_0005148', 'EFO_0005251', 'EFO_1001494', 'EFO_1001454',
       'EFO_0003144', 'HP_0030833', 'EFO_0003060', 'EFO_0003854',
       'EFO_0000701', 'EFO_0000545', 'EFO_0004242', 'EFO_0000546',
       'EFO_0006911', 'EFO_0009267', 'EFO_0005230', 'EFO_0001422',
       'EFO_0000756', 'MONDO_0044970', 'MONDO_0011719', 'EFO_0000537',
       'HP_0002140', 'EFO_0000095', 'HP_0001250', 'HP_0012532',
       'EFO_0004888', 'EFO_0003015', 'MONDO_0011382', 'MONDO_0018076',
       'EFO_1001884', 'EFO_0003768', 'EFO_0000676', 'HP_0001623',
       'EFO_0000662', 'EFO_1001328', 'HP_0011110', 'MONDO_0002050',
       'EFO_1001249', 'MONDO_0005129', 'EFO_0001378', 'EFO_0004320',
       'MONDO_0007606', 'EFO_1001454', 'EFO_0002617', 'EFO_0003931',
       'EFO_0009513', 'EFO_0003047', 'EFO_0000588', 'MONDO_0007254',
       'HP_0100806', 'EFO_0004220', 'MONDO_0004975', 'MONDO_0005180',
       'EFO_0002610', 'MONDO_0004976', 'EFO_0000274', 'HP_0012076',
       'EFO_0000274', 'EFO_0003758', 'MONDO_0100096', 'EFO_0003863',
       'EFO_0000713', 'HP_0003419', 'EFO_0001068', 'EFO_0000764',
       'EFO_0000616', 'EFO_0000319', 'EFO_0008526', 'HP_0000726',
       'EFO_0004239', 'EFO_0003843', 'EFO_0000222', 'EFO_0005411',
       'EFO_0000618', 'EFO_0000474', 'EFO_0008526', 'MONDO_0005090',
       'MONDO_0004985', 'EFO_0005952', 'EFO_0005762', 'EFO_0000729',
       'MP_0001914', 'MONDO_0018076', 'EFO_0001065', 'MONDO_0008315',
       'EFO_0001358', 'EFO_0000673', 'HP_0000023', 'HP_0012735'],
      dtype=object), 'count': 120}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 112 investigational indications. This drug has a black box warning from the FDA.
CHEMBL787,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,UCHDWCPVSPXUMX-TZIWLTJVSA-N,Small molecule,True,MONTELUKAST,1998.0,4.0,,False,True,['Singulair'],['Brondilat' 'MK-476' 'Montelukast'],"[('Wikipedia', array(['Montelukast'], dtype=object)), ('drugbank', array(['DB00471'], dtype=object)), ('chEBI', array(['50730'], dtype=object))]",['CHEMBL1200681'],"{'rows': array(['HP_0040187', 'EFO_0007183', 'EFO_1001417', 'EFO_0003918',
       'MONDO_0011382', 'EFO_0003917', 'EFO_0000694', 'HP_0012735',
       'EFO_0000540', 'HP_0011950', 'EFO_0003843', 'EFO_0004227',
       'EFO_0003877', 'EFO_0000684', 'EFO_0000222', 'EFO_0003956',
       'MONDO_0100096', 'MONDO_0004979', 'EFO_0008521', 'EFO_0001378',
       'EFO_0000220', 'EFO_0003060', 'EFO_0004232', 'EFO_0000341',
       'EFO_1001417', 'EFO_0000764', 'EFO_1001249', 'EFO_0008590',
       'EFO_0000685', 'EFO_0000401', 'HP_0100806', 'EFO_0003956',
       'MONDO_0004979', 'EFO_0005854', 'EFO_0005854', 'MONDO_0004975',
       'MONDO_0019091', 'EFO_0004232', 'HP_0006536', 'EFO_0009715'],
      dtype=object), 'count': 40}",[ENSG00000173198],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL821,N=C(N)N,ZRALSGWEFCBTJO-UHFFFAOYSA-N,Small molecule,False,GUANIDINE,1939.0,4.0,,False,True,[],['Guanidine'],"[('Wikipedia', array(['Guanidine'], dtype=object)), ('drugbank', array(['DB00536'], dtype=object)), ('chEBI', array(['42820'], dtype=object))]",['CHEMBL1200728' 'CHEMBL3187576'],"{'rows': array(['EFO_0009708', 'EFO_0008524', 'EFO_1001901', 'HP_0001324',
       'EFO_0004991'], dtype=object), 'count': 5}","[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 3 approved and 2 investigational indications.
CHEMBL91397,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,WUZYKBABMWJHDL-UHFFFAOYSA-N,Small molecule,False,RUPATADINE,2001.0,4.0,,False,True,[],['Rupatadine' 'UR-12592'],"[('Wikipedia', array(['Rupatadine'], dtype=object)), ('drugbank', array(['DB11614'], dtype=object))]",,"{'rows': array(['MONDO_0005271', 'EFO_0000685', 'EFO_0005531', 'EFO_0009001',
       'EFO_1001881'], dtype=object), 'count': 5}","[ENSG00000196639,ENSG00000169403]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 investigational indications.
CHEMBL944,CCN(CC)CCOC(=O)c1ccc(N)cc1Cl.Cl,SZKQYDBPUCZLRX-UHFFFAOYSA-N,Small molecule,False,CHLOROPROCAINE HYDROCHLORIDE,1955.0,4.0,CHEMBL1179047,False,True,"['Ampres' 'Chloroprocaine hydrochloride' 'Clorotekal' 'Nesacaine'
 'Nesacaine-mpf']","['Chloroprocaine HCl' 'Chloroprocaine hcl' 'Chloroprocaine hydrochloride'
 'Chlorprocaine chloride' 'Iheezo']","[('DailyMed', array(['chloroprocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206478'], dtype=object)), ('chEBI', array(['3637'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and has 1 investigational indication.
CHEMBL1082462,CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N,VQKSCYBKUIDZEI-STQMWFEESA-N,Small molecule,False,DBPR-108,,3.0,,False,False,[],['DBPR-108' 'Dbpr-108' 'Prusogliptin'],,,"{'rows': array(['EFO_0001421', 'EFO_0003086', 'MONDO_0005148'], dtype=object), 'count': 3}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1200959,CN1CCC(CN2c3ccccc3Sc3ccccc32)C1,HTMIBDQKFHUPSX-UHFFFAOYSA-N,Small molecule,False,METHDILAZINE,1982.0,4.0,,False,True,['Tacaryl'],['Methdilazine'],"[('Wikipedia', array(['Methdilazine'], dtype=object)), ('drugbank', array(['DB00902'], dtype=object)), ('chEBI', array(['6823'], dtype=object))]",['CHEMBL1200532'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease.
CHEMBL1341,COC(F)(F)C(Cl)Cl,RFKMCNOHBTXSMU-UHFFFAOYSA-N,Small molecule,False,METHOXYFLURANE,,4.0,,True,True,['Metofane' 'Penthrane' 'Pentrane'],"['Analgizer' 'Anecotan' 'DA-759' 'Inhalan' 'Methoxiflurane'
 'Methoxy flurane' 'Methoxyflurane' 'NSC-110432' 'Penthrox']","[('Wikipedia', array(['Methoxyflurane'], dtype=object)), ('drugbank', array(['DB01028'], dtype=object)), ('chEBI', array(['6843'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'MONDO_0004992', 'HP_0001945', 'EFO_0000546'],
      dtype=object), 'count': 4}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000145888,ENSG00000109738]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 2 investigational indications. It was withdrawn in at least one region.
CHEMBL2051955,C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,WHXMKTBCFHIYNQ-SECBINFHSA-N,Small molecule,False,LEVOSIMENDAN,,3.0,,False,False,[],"['(-)-OR-1259' '(r)-simendan' 'Levosimendan' 'NSC-759644' 'OR-1259'
 'Simendan, (r)-']","[('PubChem', array(['144205744', '170466128', '170466129'], dtype=object)), ('drugbank', array(['DB00922'], dtype=object)), ('chEBI', array(['50567'], dtype=object))]",,"{'rows': array(['EFO_0000373', 'MP_0001914', 'HP_0001919', 'EFO_0000712',
       'EFO_0003764', 'EFO_0008585', 'EFO_0005207', 'EFO_0001645',
       'EFO_0000319', 'EFO_0000694', 'EFO_0003144', 'EFO_0002970',
       'MONDO_0004976', 'HP_0031273', 'EFO_0006834'], dtype=object), 'count': 15}","[ENSG00000114854,ENSG00000129991,ENSG00000118194,ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.
CHEMBL2105635,CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@H](C)O)[C@H](C)O,SLYFITHISHUGLZ-LWZDQURMSA-N,Protein,False,DAVALINTIDE,,2.0,,False,False,[],['AC-2307' 'AC2307' 'Ac2307' 'Davalintide'],,['CHEMBL2105636'],"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000064989,ENSG00000004948,ENSG00000132329]",Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107328,CCC(CC)COC(=O)[C@@H]1C[C@H]2C[C@@H](Oc3cccc(Cl)c3-c3nnn[nH]3)CC[C@H]2CN1,HPBRMCFZIGUGTK-ZMMAXQRCSA-N,Small molecule,False,DASOLAMPANEL ETIBUTIL,,2.0,,False,False,[],['Dasolampanel etibutil' 'LY-545694' 'Ly545694'],"[('drugbank', array(['DB12049'], dtype=object))]",['CHEMBL2107327'],"{'rows': array(['EFO_1000783'], dtype=object), 'count': 1}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108413,,,Antibody,False,BIVATUZUMAB,,2.0,,False,False,[],['Bivatuzumab'],,,"{'rows': array(['EFO_0003869', 'EFO_0000707', 'EFO_0004284'], dtype=object), 'count': 3}",[ENSG00000026508],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109363,,,Antibody,False,BRE-3 90Y,,1.0,,False,False,[],['BRE-3' 'Bre-3 90y'],,,,[ENSG00000140545],Antibody drug with a maximum clinical trial phase of I.
CHEMBL247951,CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O,ZHKNLJLMDFQVHJ-RUZDIDTESA-N,Small molecule,False,PEMAFIBRATE,2017.0,4.0,,False,True,[],"['(R)-K-13675' 'K-13675, (r)-' 'Pemafibrate']","[('drugbank', array(['DB15212'], dtype=object))]",,,[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017.
CHEMBL3545398,,,Small molecule,False,PG-760564,,2.0,,False,False,[],['Pg-760564'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707357,,,Antibody,False,BROLUCIZUMAB,2019.0,4.0,,False,True,['Beovu'],"['Brolucizumab' 'Brolucizumab dbll' 'ESBA-1008' 'ESBA1008' 'RTH-258'
 'RTH258']","[('DailyMed', array(['brolucizumab-dbll'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/beovu'],
      dtype=object))]",,"{'rows': array(['EFO_1001157', 'EFO_0004683', 'MONDO_0003005', 'EFO_0001365',
       'EFO_0005753'], dtype=object), 'count': 5}",[ENSG00000112715],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for wet macular degeneration and ocular vascular disease and has 3 investigational indications.
CHEMBL3989824,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O,MEUAAEMCZUPORO-LRSHZYOCSA-N,Small molecule,True,THIOTHIXENE HYDROCHLORIDE,1970.0,4.0,CHEMBL1201,False,True,['Navane' 'Thiothixene hydrochloride' 'Thiothixene hydrochloride intensol'],"['CP-12,252-1' 'CP-122521' 'Thiothixene dihydrochloride'
 'Thiothixene hcl h20' 'Thiothixene hydrochloride'
 'Tiotixene hydrochloride']",,,,"[ENSG00000149295,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970. This drug has a black box warning from the FDA.
CHEMBL4080062,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12,JNLSTLQFDDAULK-UHFFFAOYSA-N,Small molecule,False,BFH-772,,2.0,,False,False,[],['BFH-722' 'BFH-772' 'BFH722' 'BFH772' 'Bfh-772' 'Bfh772'],,,"{'rows': array(['EFO_1000760'], dtype=object), 'count': 1}",[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297323,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,VZRIKWNVDCTBTF-BKGFHLQYSA-N,Protein,False,PZ-128,,2.0,,False,False,[],['Palmitate-kksralf-nh2' 'Pz-128'],"[('drugbank', array(['DB11839'], dtype=object))]",,"{'rows': array(['EFO_0001645'], dtype=object), 'count': 1}",[ENSG00000181104],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297563,,,Antibody,False,PACMILIMAB,,2.0,,False,False,[],['CX-072' 'CX-072 PROBODY' 'CX072' 'Cx 072' 'Cx-072' 'Pacmilimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PACMILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0002617', 'EFO_0000574', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL5314410,C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)N4C[C@H]5CCN(C)[C@H]5C4)cc23)c1,FSXCKIBROURMFT-VGSWGCGISA-N,Small molecule,False,THELIATINIB,,2.0,,False,False,[],['HMPL-309' 'Hmpl-309' 'Theliatinib' 'Xiliertinib'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1084546,CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O,MZDKLVOWGIOKTN-UHFFFAOYSA-N,Small molecule,False,PF-00562271,,1.0,,False,False,[],['PF 562271' 'PF-562271' 'Pf-00562271' 'Pf-562271 besilate'],"[('PubChem', array(['103905684'], dtype=object))]",['CHEMBL2430359'],,[ENSG00000169398],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL11662,O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1,SHZKQBHERIJWAO-AATRIKPKSA-N,Small molecule,False,OZAGREL,1988.0,4.0,,False,True,[],['KCT-0809' 'Ozagrel' 'Ozagrel sodium'],"[('Wikipedia', array(['Ozagrel'], dtype=object)), ('drugbank', array(['DB12017'], dtype=object))]",['CHEMBL1715705' 'CHEMBL542549'],"{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}",[ENSG00000059377],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and has 1 investigational indication.
CHEMBL1200334,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2.Cl,GAQAKFHSULJNAK-UHFFFAOYSA-N,Small molecule,True,MORICIZINE HYDROCHLORIDE,1990.0,4.0,CHEMBL1075,False,True,['Ethmozine'],['Moracizine hydrochloride' 'Moricizine hcl' 'Moricizine hydrochloride'],"[('PubChem', array(['144204173', '170465141', '24840971', '856698'], dtype=object)), ('chEBI', array(['60937'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. This drug has a black box warning from the FDA.
CHEMBL1201573,,,Protein,True,OPRELVEKIN,1997.0,4.0,,False,True,['Neumega'],['Interleukin-11 (2-178)' 'Oprelvekin'],"[('DrugCentral', array(['5026'], dtype=object)), ('Wikipedia', array(['Oprelvekin'], dtype=object))]",,"{'rows': array(['Orphanet_903', 'EFO_0000191', 'EFO_0000095', 'EFO_0000339',
       'MONDO_0018906', 'MONDO_0010602', 'EFO_0009441', 'HP_0001873',
       'EFO_0000616'], dtype=object), 'count': 9}",[ENSG00000137070],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for thrombocytopenia and neoplasm and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1395,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,GCKMFJBGXUYNAG-HLXURNFRSA-N,Small molecule,False,METHYLTESTOSTERONE,1973.0,4.0,,False,True,"['Android 10' 'Android 25' 'Android 5' 'Metandren' 'Methitest'
 'Methyltestosterone' 'Oreton' 'Oreton methyl' 'Perandren' 'Plex hormone'
 'Potensan fte' 'Testovis' 'Testred' 'Virilon']","['17-methyltestosterone' 'CDB-110' 'L 589.372' 'L-589.372' 'L-589372'
 'Methyltestosterone' 'Methyltestosterone ciii' 'NSC-139965' 'NSC-9701'
 'Oxandrolone impurity, methyltestosterone-' 'RU 24400' 'RU-24400'
 'U-2842']","[('DailyMed', array(['methyltestosterone'], dtype=object)), ('PubChem', array(['144206712', '144206713', '144214019', '170464631', '17388912',
       '26719668', '56463771'], dtype=object)), ('TG-GATEs', array(['41'], dtype=object)), ('Wikipedia', array(['Methyltestosterone'], dtype=object)), ('drugbank', array(['DB06710'], dtype=object)), ('chEBI', array(['27436'], dtype=object))]",,"{'rows': array(['GO_0042697', 'MONDO_0007254', 'MONDO_0002146', 'EFO_1001078'],
      dtype=object), 'count': 4}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 1 investigational indication.
CHEMBL1743036,,,Antibody,False,LEXATUMUMAB,,2.0,,False,False,[],['ETR2-ST01' 'HGS-1018' 'HGS-ETR2' 'HGS1018' 'Lexatumumab'],,,"{'rows': array(['EFO_0000174', 'EFO_0002918', 'EFO_0000637', 'EFO_0000621'],
      dtype=object), 'count': 4}",[ENSG00000120889],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL197194,COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1,XPRDUGXOWVXZLL-UHFFFAOYSA-N,Small molecule,False,VIDOFLUDIMUS,,3.0,,False,False,[],"['4SC-101' 'IMU-838' 'Imu-838' 'NSC-717824' 'SC-12267' 'SC12267'
 'Vidofludimus']","[('PubChem', array(['174007069'], dtype=object)), ('drugbank', array(['DB15446'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0004268',
       'EFO_0003767', 'EFO_0003929', 'EFO_0000729'], dtype=object), 'count': 7}",[ENSG00000102967],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2108034,,,Protein,False,IBOCTADEKIN,,2.0,,False,False,[],"['Iboctadekin' 'Ifn-gamma-inducing factor' 'Il-1 gamma' 'Il-18'
 'Interferon gamma-inducing factor' 'Interleukin-1 gamma' 'Interleukin-18'
 'SB-485232']",,,"{'rows': array(['EFO_0005952', 'EFO_0000756', 'EFO_0000574', 'MONDO_0004992'],
      dtype=object), 'count': 4}","[ENSG00000115607,ENSG00000115604]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2108184,,,Small molecule,False,CROFELEMER,2012.0,4.0,,False,True,['Fulyzaq' 'Mytesi'],['Crofelemer' 'NP-303' 'SP-303' 'TRN-002'],"[('DailyMed', array(['crofelemer'], dtype=object)), ('DrugCentral', array(['4744'], dtype=object))]",,"{'rows': array(['HP_0002014', 'EFO_0000555', 'MONDO_0007254', 'EFO_0000765'],
      dtype=object), 'count': 4}","[ENSG00000001626,ENSG00000131620]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for diarrhea and aids and has 2 investigational indications.
CHEMBL2219422,Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,AFJRDFWMXUECEW-LBPRGKRZSA-N,Small molecule,False,AFURESERTIB,,2.0,,False,False,[],"['ASB-183' 'ASB183' 'Afuresertib' 'GSK-2110183' 'GSK-2110183C'
 'GSK2110183' 'GSK2110183C' 'Gsk-2110183']","[('drugbank', array(['DB11648'], dtype=object))]",['CHEMBL2219423'],"{'rows': array(['MONDO_0008170', 'MONDO_0008315', 'EFO_0001378', 'MONDO_0007254',
       'EFO_0000616', 'MONDO_0004992', 'EFO_1000318'], dtype=object), 'count': 7}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL2219773,,,Oligonucleotide,False,CUSTIRSEN SODIUM,,3.0,,False,False,[],['Custirsen sodium' 'ISIS 112989' 'ISIS-112989' 'OGX-011' 'Ogx 011'],,,"{'rows': array(['MONDO_0008315', 'MONDO_0007254', 'EFO_0003060'], dtype=object), 'count': 3}",[ENSG00000120885],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3137318,Cc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,QUQKKHBYEFLEHK-QNBGGDODSA-N,Small molecule,False,TALAZOPARIB TOSYLATE,2018.0,4.0,CHEMBL3137320,False,True,['Talzenna'],['BMN 673ts' 'BMN-673TS' 'Talazoparib tosilate' 'Talazoparib tosylate'],"[('DailyMed', array(['talazoparib%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0003060', 'EFO_0000222',
       'EFO_0000305', 'EFO_0003869', 'EFO_0005537'], dtype=object), 'count': 7}","[ENSG00000129484,ENSG00000143799]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 4 investigational indications.
CHEMBL32800,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,LSLYOANBFKQKPT-UHFFFAOYSA-N,Small molecule,False,FENOTEROL,,4.0,,True,True,['Berodual' 'Berodual n' 'Berotec' 'Berotec 100' 'Berotec 200' 'Duovent'],"['Airum' 'Dosberotec' 'Fenoterol' 'Fenoterol hbr' 'Fenoterol hydrobromide'
 'NSC-757811' 'Partusisten' 'TH 1165A' 'TH 1165A FREE BASE'
 'TH 1165A [AS HYDROBROMIDE SALT]' 'TH-1165' 'TH-1165A'
 'TH-1165A FREE BASE']","[('PubChem', array(['90340690'], dtype=object)), ('Wikipedia', array(['Fenoterol'], dtype=object)), ('drugbank', array(['DB01288'], dtype=object)), ('chEBI', array(['149226'], dtype=object))]",['CHEMBL537445'],"{'rows': array(['EFO_0000373', 'HP_0006536', 'MONDO_0004979', 'EFO_0000341'],
      dtype=object), 'count': 4}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 3 investigational indications. It was withdrawn in at least one region.
CHEMBL3545043,CC(C)Oc1ccc(S(=O)(=O)N2CCN(c3ccc(-c4ncco4)c(OCC(=O)O)c3)CC2)cc1,ZMZNWNTZRWXTJU-UHFFFAOYSA-N,Small molecule,False,ASAPIPRANT,,3.0,,False,False,[],['Asapiprant' 'BGE175' 'Bge 175' 'Bge-175' 'S-555739'],,,"{'rows': array(['EFO_0003956', 'MONDO_0100096'], dtype=object), 'count': 2}",[ENSG00000168229],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3545203,,,Small molecule,False,RG7342,,1.0,,False,False,[],['RO6806127' 'Rg7342'],,,,[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL397420,CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,VABCILAOYCMVPS-UHFFFAOYSA-N,Small molecule,False,ACENOCOUMAROL,,4.0,,False,True,['Sinthrome'],['Acenocoumarin' 'Acenocoumarol' 'Mini-sintrom' 'NSC-760052' 'Nicoumalone'],"[('PubChem', array(['144203981', '170465636'], dtype=object)), ('Wikipedia', array(['Acenocoumarol'], dtype=object)), ('drugbank', array(['DB01418'], dtype=object)), ('chEBI', array(['53766'], dtype=object))]",,"{'rows': array(['EFO_0003827', 'EFO_0000275', 'EFO_0000756', 'HP_0004419'],
      dtype=object), 'count': 4}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 3 investigational indications.
CHEMBL3989569,CCCCCN(C)CCC(O)(P(=O)([O-])O)P(=O)(O)O.O.[Na+],VBDRTGFACFYFCT-UHFFFAOYSA-M,Small molecule,False,IBANDRONATE SODIUM,2003.0,4.0,CHEMBL997,False,True,['Boniva' 'Ibandronate sodium' 'Ibandronic acid accord'],"['BM 21.0955 NA H20' 'BM-21.0955' 'BM-210955'
 'Ibandronate monosodium monohydrate' 'Ibandronate sodium'
 'Ibandronate sodium hydrate' 'Ibandronate sodium monohydrate'
 'Ibandronic acid sodium salt' 'Ibandronic acid sodium salt monohydrate'
 'Ibandronic sodium monohydrate' 'NSC-759815']","[('DailyMed', array(['ibandronate%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-accord'],
      dtype=object))]",,"{'rows': array(['EFO_0003854', 'MONDO_0007254', 'EFO_0003843', 'EFO_0003882',
       'HP_0000938'], dtype=object), 'count': 5}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for postmenopausal osteoporosis and osteoporosis and has 3 investigational indications.
CHEMBL4297856,,,Antibody,False,ZIMBERELIMAB,,3.0,,False,False,[],"['AB-122' 'AB122' 'Ab-122' 'Ab122' 'GLS-010' 'Gls-010' 'WBP-3055'
 'WBP3055' 'Zimberelimab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZIMBERELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000228', 'MONDO_0002691', 'EFO_1000657', 'MONDO_0007254',
       'EFO_0000181', 'MONDO_0005184', 'MONDO_0009348', 'EFO_0000196',
       'EFO_0000348', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0000616',
       'EFO_0000756', 'EFO_0001061', 'EFO_0003085', 'MONDO_0002974',
       'EFO_0000673', 'EFO_1000359', 'EFO_0003060', 'EFO_0000519'],
      dtype=object), 'count': 20}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.
CHEMBL4303729,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12,YYACLQUDUDXAPA-MRXNPFEDSA-N,Small molecule,False,PLIXORAFENIB,,2.0,,False,False,[],['FORE-8394' 'FORE8394' 'PLX8394' 'Plixorafenib' 'Plx 8394' 'Plx-8394'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000756', 'MONDO_0004992', 'HP_0100727',
       'EFO_0005221', 'EFO_1000956', 'MONDO_0002108', 'EFO_1001951',
       'EFO_0000616'], dtype=object), 'count': 9}",[ENSG00000157764],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL4567446,COc1cc(C(=O)N2CCC3(CC2)CC(=O)c2c(cnn2C(C)C)C3)cc(-c2ccc(C(=O)O)cc2)n1,LXZMHBHEXAELHH-UHFFFAOYSA-N,Small molecule,False,CLESACOSTAT,,2.0,,False,False,[],['Clesacostat' 'PF-05221304' 'PF05221304' 'Pf-05221304'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CLESACOSTAT/relevant/1/'],
      dtype=object))]",['CHEMBL4650217'],"{'rows': array(['EFO_0003095', 'EFO_0003095', 'EFO_0001421', 'EFO_1001249'],
      dtype=object), 'count': 4}","[ENSG00000278540,ENSG00000076555]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4594511,,,Oligonucleotide,False,VUTRISIRAN,2022.0,4.0,,False,True,['Amvuttra'],['ALN-65492' 'ALN-TTRSC02' 'Votrisiran' 'Vutrisiran'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VUTRISIRAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001875', 'EFO_0004129', 'EFO_0009562'], dtype=object), 'count': 3}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for familial amyloid neuropathy and polyneuropathy and has 1 investigational indication.
CHEMBL4594569,,,Antibody,False,AMLITELIMAB,,2.0,,False,False,[],"['Amlitelimab' 'KY-1005' 'KY-1005-2D10' 'KY1005' 'KY1005-2D10' 'Ky-1005'
 'Ky1005' 'SAR-445229' 'SAR445229']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMLITELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0000964', 'MONDO_0004979', 'EFO_0000274', 'EFO_0005809',
       'EFO_0000540'], dtype=object), 'count': 5}",[ENSG00000117586],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4650411,,,Antibody,False,OCIPERLIMAB,,3.0,,False,False,[],['BGB-A1217' 'Bgb-a1217' 'Ociperlimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OCIPERLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000182', 'EFO_0000403', 'EFO_0000702',
       'EFO_0005922', 'MONDO_0004992', 'MONDO_0002974', 'MONDO_0007254',
       'EFO_0003060'], dtype=object), 'count': 9}",[ENSG00000181847],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL1200837,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1.Cl,CHDPSNLJFOQTRK-LMOVPXPDSA-N,Small molecule,False,LEVOBETAXOLOL HYDROCHLORIDE,2000.0,4.0,CHEMBL1201274,False,True,['Betaxon'],['AL-1577A' 'AL1577A' 'Levobetaxolol hcl' 'Levobetaxolol hydrochloride'],"[('chEBI', array(['59256'], dtype=object))]",,"{'rows': array(['MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 2}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 2 investigational indications.
CHEMBL1201743,Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,TUAZNHHHYVBVBR-NHKADLRUSA-N,Small molecule,False,SAXAGLIPTIN HYDROCHLORIDE,2009.0,4.0,CHEMBL385517,False,True,['Onglyza'],['Saxagliptin HCl' 'Saxagliptin hcl' 'Saxagliptin hydrochloride'],"[('DailyMed', array(['saxagliptin%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onglyza'],
      dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for type 2 diabetes mellitus.
CHEMBL1668019,CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl,QNNBMSGFNQRUEH-PQQSRXGVSA-N,Small molecule,False,APLAVIROC HYDROCHLORIDE,,3.0,CHEMBL1255794,False,False,[],['Aplaviroc hcl' 'Aplaviroc hydrochloride' 'GW-873140A' 'GW873140A'],"[('PubChem', array(['144210531'], dtype=object))]",,"{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108612,,,Antibody,False,IRATUMUMAB,,2.0,,False,False,[],['Iratumumab' 'MDX-060'],,,"{'rows': array(['EFO_0000574', 'EFO_0000183', 'EFO_0001642'], dtype=object), 'count': 3}",[ENSG00000120949],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109271,,,Antibody,False,MDX-210,,2.0,,False,False,[],['520C9XH22' 'MDX-210'],,,,"[ENSG00000150337,ENSG00000141736]",Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109468,,,Antibody,False,HUMAX-IL15,,2.0,,False,False,[],['HUMAX-IL15'],,,,[ENSG00000004468],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2178579,O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(F)c1Cl,YQYFEGTYCUQBEI-UHFFFAOYSA-N,Small molecule,False,ELUBRIXIN,,2.0,,False,False,[],['Elubrixin' 'SB-656933' 'SB-656933-AAF' 'SB656933' 'Sb-656933'],"[('drugbank', array(['DB12135'], dtype=object))]",['CHEMBL3039524'],"{'rows': array(['EFO_0000341', 'EFO_0000729', 'EFO_0000341', 'MONDO_0009061'],
      dtype=object), 'count': 4}",[ENSG00000180871],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545402,,,Small molecule,False,XL-820,,2.0,,False,False,[],['Xl-820'],,,"{'rows': array(['MONDO_0011719', 'MONDO_0004992'], dtype=object), 'count': 2}","[ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3707235,N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,ZWPRRQZNBDYKLH-VIFPVBQESA-N,Small molecule,False,GEMIGLIPTIN,,3.0,,False,False,[],['Gemigliptin' 'LC-15-0444' 'LC-150444' 'LC15-0444'],"[('drugbank', array(['DB12412'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'EFO_0000400', 'MONDO_0005148', 'EFO_0001421',
       'MONDO_0004992'], dtype=object), 'count': 5}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297624,CCOC(=O)C12CCC(NCC(=O)N3C[C@@H](F)C[C@H]3C#N)(CC1)CC2,AKFNKZFJBFQFAA-DIOPXHOYSA-N,Small molecule,False,BISEGLIPTIN,,2.0,,False,False,[],['Bisegliptin' 'KRP-104' 'Krp-104'],"[('drugbank', array(['DB06127'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297797,,,Unknown,False,NNC0114-0006,,2.0,,False,False,[],['NN-8828' 'NN-9828' 'Nnc0114-0006'],,,"{'rows': array(['MONDO_0005147'], dtype=object), 'count': 1}",[ENSG00000138684],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297833,,,Antibody,False,MEZAGITAMAB,,2.0,,False,False,[],['Mezagitamab' 'TAK-079' 'TAK079' 'Tak-079'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MEZAGITAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0004991', 'MONDO_0002462', 'EFO_0000616',
       'EFO_0005809', 'EFO_0007160', 'EFO_0005140', 'MONDO_0007915'],
      dtype=object), 'count': 8}",[ENSG00000004468],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL4303596,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1,KWRYMZHCQIOOEB-LBPRGKRZSA-N,Small molecule,False,AMG-319,,2.0,,False,False,[],['AMG319' 'Amg-319' 'J3.391.906I'],,,"{'rows': array(['EFO_0000095', 'EFO_0000181', 'EFO_1001469', 'EFO_0000403',
       'MONDO_0004992'], dtype=object), 'count': 5}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4594492,,,Oligonucleotide,False,REVUSIRAN,,3.0,,False,False,[],['AD-51547' 'Revusiran'],,,"{'rows': array(['EFO_0004129'], dtype=object), 'count': 1}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL5315055,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O,XOBQQQVDLSMXCE-JVRGSUDVSA-N,Small molecule,False,NALMEFENE HYDROCHLORIDE DIHYDRATE,2013.0,4.0,CHEMBL982,False,True,['Selincro'],['Nalmefene hydrochloride hydrate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/selincro'],
      dtype=object))]",,"{'rows': array(['MONDO_0007079'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for alcohol dependence.
CHEMBL593430,C[C@H]1CC(CN)(CC(=O)O)C[C@@H]1C,IUVMAUQEZFTTFB-YUMQZZPRSA-N,Small molecule,False,ATAGABALIN,,2.0,,False,False,[],"['Atagabalin' 'PD 0200390' 'PD-0200,390' 'PD-0200390' 'PD0200390']","[('Wikipedia', array(['Atagabalin'], dtype=object)), ('drugbank', array(['DB12032'], dtype=object))]",,"{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL635,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,Small molecule,False,PREDNISONE,1955.0,4.0,,False,True,"['Cortan' 'Cortancyl' 'Decortisyl' 'Delta-dome' 'Deltasone' 'Fernisone'
 'Liquid pred' 'Lodotra' 'Meticorten' 'Orasone' 'Paracort' 'Prednicen-m'
 'Prednisone' 'Prednisone intensol' 'Rayos' 'Servisone' 'Sterapred']","['3en3hg4wsw' 'Decortin' 'Dehydrocortisone' 'Metacortandracin' 'NSC-10023'
 'Prednisone' 'Prednisone anhydrous' 'Prednisone tablets' 'Supercortil']","[('DailyMed', array(['prednisone'], dtype=object)), ('PubChem', array(['144204565', '144208762', '144210516', '170464847', '17389753',
       '50085971', '56314869', '75351'], dtype=object)), ('Wikipedia', array(['Prednisone'], dtype=object)), ('drugbank', array(['DB00635'], dtype=object)), ('chEBI', array(['8382'], dtype=object))]",,"{'rows': array(['DOID_13406', 'EFO_0000318', 'Orphanet_77260', 'MP_0001845',
       'MONDO_0019391', 'EFO_0005319', 'EFO_1001194', 'EFO_0005531',
       'EFO_0003898', 'EFO_0005854', 'MONDO_0015760', 'MONDO_0019338',
       'EFO_1001435', 'EFO_0000616', 'EFO_1001968', 'EFO_0003956',
       'EFO_0004826', 'EFO_0008997', 'EFO_1001896', 'MONDO_0003937',
       'EFO_0007403', 'EFO_0002609', 'MONDO_0008315', 'EFO_0003777',
       'EFO_0003778', 'EFO_1000318', 'EFO_0005761', 'MONDO_0009061',
       'EFO_0000764', 'MONDO_0018896', 'EFO_1001264', 'EFO_0000565',
       'EFO_0000196', 'EFO_0004274', 'EFO_0001378', 'EFO_1000997',
       'EFO_1000965', 'EFO_1000131', 'EFO_0000403', 'EFO_0007405',
       'MONDO_0008903', 'EFO_0004991', 'HP_0001094', 'EFO_0002428',
       'EFO_0000222', 'EFO_1001205', 'HP_0012424', 'EFO_0000309',
       'EFO_0004228', 'MONDO_0016537', 'EFO_0007427', 'EFO_0005856',
       'EFO_0007187', 'MONDO_0018906', 'EFO_0008518', 'MONDO_0044903',
       'HP_0001952', 'EFO_0004256', 'EFO_0009456', 'EFO_0000691',
       'EFO_0009448', 'MONDO_0004979', 'EFO_0007141', 'MONDO_0015540',
       'EFO_1000784', 'MONDO_0017719', 'EFO_0005952', 'HP_0001871',
       'EFO_0000198', 'MONDO_0004992', 'EFO_0005801', 'EFO_0000209',
       'EFO_0004236', 'EFO_0007313', 'EFO_0000211', 'EFO_0007537',
       'EFO_0002430', 'EFO_0000183', 'MONDO_0018998', 'MONDO_0013730',
       'EFO_0007486', 'EFO_1001383', 'MONDO_0015564', 'MONDO_0000873',
       'EFO_0000557', 'EFO_1001051', 'EFO_0004254', 'MONDO_0004976',
       'EFO_0007160', 'HP_0012410', 'EFO_0003833', 'EFO_1001467',
       'EFO_0003032', 'MONDO_0005301', 'EFO_0009491', 'EFO_0007167',
       'MONDO_0001085', 'EFO_0000398', 'EFO_0000096', 'EFO_0008590',
       'EFO_0003818', 'EFO_0007541', 'HP_0003072', 'EFO_0009609',
       'EFO_1001417', 'EFO_1000684', 'EFO_0004719', 'MONDO_0002280',
       'EFO_0001663', 'MONDO_0000870', 'EFO_1001413', 'EFO_0003086',
       'MONDO_0000432', 'EFO_0001379', 'EFO_0002626', 'EFO_0004599',
       'EFO_1001345', 'EFO_0000729', 'EFO_0000094', 'EFO_0007498',
       'EFO_0003144', 'EFO_1001466', 'EFO_1001469', 'EFO_0004238',
       'EFO_0007168', 'EFO_0007520', 'MONDO_0017287', 'EFO_0000220',
       'MONDO_0004095', 'EFO_1000635', 'EFO_0000479', 'EFO_1001176',
       'MONDO_0018150', 'EFO_0005558', 'EFO_1000049', 'EFO_0000768',
       'MONDO_0005271', 'EFO_0000255', 'EFO_0006803', 'MONDO_0001280',
       'MONDO_0008728', 'EFO_0000574', 'MONDO_0005178', 'EFO_1000694',
       'EFO_1000391', 'EFO_1000986', 'EFO_1000158', 'EFO_0003047',
       'EFO_0009538', 'EFO_0003063', 'HP_0002043', 'EFO_1001857',
       'MONDO_0010602', 'EFO_1000749', 'EFO_0003884', 'MONDO_0004975',
       'EFO_0002429', 'EFO_0001063', 'EFO_0000756', 'MONDO_0044881',
       'HP_0001915', 'EFO_0003106', 'MONDO_0002471', 'HP_0001873',
       'EFO_0004289', 'MONDO_0000430', 'MONDO_0002367', 'EFO_0004194',
       'MONDO_0010079', 'EFO_1001209', 'HP_0004398', 'MONDO_0007915',
       'EFO_0003929', 'EFO_0000673', 'EFO_1001119', 'MONDO_0015128',
       'EFO_0005539', 'MONDO_0009348', 'MONDO_0017276', 'EFO_1000764',
       'HP_0011868', 'EFO_0005297', 'EFO_1001492', 'EFO_0005140',
       'MONDO_0010679', 'MONDO_0007254', 'EFO_0000274', 'EFO_0000676',
       'EFO_1000941', 'EFO_0000373', 'EFO_0004276', 'EFO_0000384',
       'MONDO_0018076', 'EFO_0003843', 'EFO_1001365', 'MONDO_0005148',
       'EFO_0004255', 'EFO_0000095', 'MONDO_0100096', 'EFO_0000182',
       'EFO_0008517', 'EFO_1001231', 'EFO_0004251', 'MONDO_0018848',
       'EFO_1001222', 'EFO_0007208', 'EFO_0009449', 'MONDO_0019471',
       'EFO_0000621', 'EFO_0003060', 'MONDO_0044917', 'EFO_0000685',
       'EFO_0000341', 'MONDO_0020547', 'MONDO_0011719', 'EFO_1000039',
       'EFO_0000765', 'EFO_0007257', 'EFO_0005676'], dtype=object), 'count': 219}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 72 approved and 147 investigational indications.
CHEMBL1200437,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,XHKUDCCTVQUHJQ-LCYSNFERSA-N,Small molecule,True,QUINIDINE GLUCONATE,1950.0,4.0,CHEMBL1294,False,True,"['Duraquin' 'Quinact' 'Quinaglute' 'Quinalan' 'Quinatime'
 'Quinidine gluconate']","['Dura-tab' 'Gluconic acid quinidine salt' 'Gluquinate' 'NSC-757297'
 'Quinidine gluconate' 'Quinidine mono-d-gluconate'
 'Quinidine monogluconate, d-']","[('DailyMed', array(['quinidine%20gluconate'], dtype=object)), ('chEBI', array(['27502'], dtype=object))]",,"{'rows': array(['EFO_0001068', 'HP_0004308'], dtype=object), 'count': 2}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for malaria and ventricular arrhythmia. This drug has a black box warning from the FDA.
CHEMBL1200980,C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O,HZEQBCVBILBTEP-ZFINNJDLSA-N,Small molecule,True,ESTROPIPATE,1977.0,4.0,CHEMBL494753,False,True,"['Estropipate' 'Harmogen' 'Ogen' 'Ogen .625' 'Ogen 1.25' 'Ogen 2.5'
 'Ogen 5' 'Ortho-est']","['Estrone sulfate piperazine salt' 'Estropipate' 'NSC-758912'
 'Piperazine estrone sulfate' 'Piperazine estrone sulphate'
 'Sulestrex piperazine']","[('DailyMed', array(['estropipate'], dtype=object)), ('PubChem', array(['144206901', '26750028', '56463533'], dtype=object)), ('Wikipedia', array(['Estropipate'], dtype=object))]",,"{'rows': array(['EFO_1000096', 'GO_0042697', 'EFO_0004266', 'MONDO_0002146',
       'EFO_0003882'], dtype=object), 'count': 5}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved indications. This drug has a black box warning from the FDA.
CHEMBL1201124,NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,BWHLPLXXIDYSNW-UHFFFAOYSA-N,Small molecule,True,KETOROLAC TROMETHAMINE,1989.0,4.0,CHEMBL469,False,True,"['Acular' 'Acular ls' 'Acular preservative free' 'Acuvail'
 'Ketorolac tromethamine' 'Sprix' 'Toradol']","['Dolac' 'Ketorolac trometamol' 'Ketorolac tromethamine' 'Lixidol'
 'NSC-758637' 'Tarasyn']","[('DailyMed', array(['ketorolac%20tromethamine'], dtype=object)), ('PubChem', array(['124881877', '26747544', '49681816', '50106489', '8139924'],
      dtype=object)), ('chEBI', array(['6130'], dtype=object))]",,"{'rows': array(['EFO_0003777', 'MONDO_0005129', 'EFO_1000859', 'MONDO_0005184',
       'EFO_1001139', 'MONDO_0005277', 'EFO_1001412', 'MP_0001845',
       'EFO_0003843', 'EFO_1001178', 'HP_0003418', 'EFO_0005854',
       'EFO_0004253', 'MONDO_0003005', 'HP_0200026'], dtype=object), 'count': 15}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201247,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,BLCLNMBMMGCOAS-URPVMXJPSA-N,Protein,False,GOSERELIN,1989.0,4.0,,False,True,[],"['Goserelin' 'Goserelin acetate' 'ICI 118,630' 'ICI-118630']","[('Wikipedia', array(['Goserelin'], dtype=object)), ('drugbank', array(['DB00014'], dtype=object))]",['CHEMBL1200501'],"{'rows': array(['EFO_0006861', 'MONDO_0002087', 'MONDO_0008315', 'EFO_0001663',
       'EFO_0001663', 'MONDO_0008170', 'EFO_0000313', 'EFO_0000195',
       'MONDO_0007254', 'MONDO_0002158', 'EFO_0000545', 'MONDO_0000521',
       'EFO_0000305', 'EFO_0000196', 'GO_0042697', 'MONDO_0007254',
       'MONDO_0008170', 'MONDO_0008315', 'EFO_0001065', 'EFO_0000616',
       'EFO_1001757', 'EFO_0000305', 'EFO_0000731', 'EFO_0000673',
       'EFO_0000545', 'HP_0008209', 'EFO_0000673', 'EFO_0003869',
       'EFO_0000183', 'EFO_0000195', 'EFO_0000553', 'MONDO_0004669'],
      dtype=object), 'count': 32}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 4 approved and 23 investigational indications.
CHEMBL1201341,CCOP(=O)(OCC)SCC[N+](C)(C)C,BJOLKYGKSZKIGU-UHFFFAOYSA-N,Small molecule,False,ECHOTHIOPHATE,1960.0,4.0,,False,True,[],"['Echothiophate' 'Echothiophate cation' 'Echothiophate ion' 'Ecothiopate'
 'Ecothiopate cation']","[('Wikipedia', array(['Echothiophate'], dtype=object)), ('drugbank', array(['DB01057'], dtype=object)), ('chEBI', array(['4753'], dtype=object))]",['CHEMBL1200367'],"{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for glaucoma.
CHEMBL1255901,C/C=C1\[C@H]2C=C(C)C[C@@]1(N)c1ccc(=O)[nH]c1C2,ZRJBHWIHUMBLCN-HZRLMBICSA-N,Small molecule,False,HUPERZINE A,,2.0,,False,False,[],['(-)-huperzine a' '(-)-selagine' 'Huperzine a' 'L-huperzine a' 'Selagine'],,,"{'rows': array(['MONDO_0002491', 'MONDO_0004975', 'EFO_0002610', 'MONDO_0043510'],
      dtype=object), 'count': 4}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1291,CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C,BQIPXWYNLPYNHW-UHFFFAOYSA-N,Small molecule,False,METIPRANOLOL,1989.0,4.0,,True,True,['Glauline'],"['BM-01.004' 'BM-01004' 'BM01.004' 'D,l-metipranolol' 'Metipranolol'
 'Optipranolol' 'VUAB-6453' 'VUAB6453' 'VUAB6453 (SPOFA)']","[('PubChem', array(['144205272', '29215465'], dtype=object)), ('Wikipedia', array(['Metipranolol'], dtype=object)), ('drugbank', array(['DB01214'], dtype=object)), ('chEBI', array(['6897'], dtype=object))]",['CHEMBL1200947'],"{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for glaucoma.
CHEMBL1520,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,SECKRCOLJRRGGV-UHFFFAOYSA-N,Small molecule,False,VARDENAFIL,2003.0,4.0,,False,True,['Levitra'],['BAY-389456' 'BAY38-9456' 'Vardenafil' 'Vivanza'],"[('Wikipedia', array(['Vardenafil'], dtype=object)), ('drugbank', array(['DB00862'], dtype=object)), ('chEBI', array(['46295'], dtype=object))]",['CHEMBL2106480' 'CHEMBL1874590' 'CHEMBL1339'],"{'rows': array(['HP_0000360', 'EFO_0002687', 'EFO_0004234', 'HP_0000802',
       'MONDO_0009061', 'EFO_1001145', 'EFO_0004234', 'EFO_1000781',
       'EFO_0000284', 'MONDO_0005149'], dtype=object), 'count': 10}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for erectile dysfunction and impotence and has 7 investigational indications.
CHEMBL1626570,COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1,NSILVESQCSUIAJ-UHFFFAOYSA-M,Small molecule,False,HEXOCYCLIUM METHYLSULFATE,1982.0,4.0,CHEMBL1201325,False,True,['Tral'],"['Hexocyclium methyl sulfate' 'Hexocyclium methylsulfate'
 'Hexocyclium methylsulphate' 'Hexocyclium metilsulfate'
 'Hexocyclium metilsulphate' 'NSC-30256']","[('PubChem', array(['144206775'], dtype=object))]",,,"[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL2068839,Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,RECBFDWSXWAXHY-IAGOWNOFSA-N,Small molecule,False,RISLENEMDAZ,,2.0,,False,False,[],"['CERC-301' 'Cerc-301' 'MK-0657' 'MK-0657, (-)-' 'Rislenemdaz'
 'Rislenemdaz, (-)-']","[('drugbank', array(['DB12063'], dtype=object))]",['CHEMBL2036513'],"{'rows': array(['MONDO_0002050', 'MONDO_0002009'], dtype=object), 'count': 2}","[ENSG00000176884,ENSG00000273079]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3112866,C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1,UAXHPOBBKRWJGA-ZDUSSCGKSA-N,Small molecule,False,SAR-260301,,1.0,,False,False,[],['SAR-260301' 'SAR260301' 'Sar-260301'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000051382],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL319144,O=P(O)(O)C(O)(Cc1cnc2ccccn12)P(=O)(O)O,VMMKGHQPQIEGSQ-UHFFFAOYSA-N,Small molecule,False,MINODRONIC ACID,2009.0,4.0,,False,True,[],"['Minodronate' 'Minodronic acid' 'NSC-725590' 'ONO-5920' 'YM 529' 'YM-529'
 'YM529']","[('PubChem', array(['144206806'], dtype=object)), ('Wikipedia', array(['Minodronic_acid'], dtype=object)), ('drugbank', array(['DB06548'], dtype=object))]",,"{'rows': array(['EFO_0003854', 'EFO_0003882'], dtype=object), 'count': 2}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 2 investigational indications.
CHEMBL3545231,c1ccc(-c2nnc(O[C@@H]3C4CC5C[C@H]3CN(C5)C4)s2)cc1,QZDCYUCETTWCMO-CDFKWJNJSA-N,Small molecule,False,ABT-126,,2.0,,False,False,[],['ABT-126' 'Abt-126' 'Nelonicline'],,,"{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545411,,,Unknown,False,MF101,,3.0,,False,False,[],['Mf101'],,,"{'rows': array(['GO_0042697', 'HP_0031217'], dtype=object), 'count': 2}",[ENSG00000140009],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4206033,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1,RNMAUIMMNAHKQR-QFBILLFUSA-N,Small molecule,False,BAY1436032,,1.0,,False,False,[],['Bay1436032'],,,"{'rows': array(['EFO_0000616', 'EFO_0000222'], dtype=object), 'count': 2}",[ENSG00000138413],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL445813,O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl,OVPNQJVDAFNBDN-UHFFFAOYSA-N,Small molecule,False,AT-7519,,2.0,,False,False,[],['AT 7519' 'AT-7519' 'AT7519' 'At-7519' 'Cdki at7519'],"[('PubChem', array(['137275934', '137275935'], dtype=object)), ('drugbank', array(['DB08142'], dtype=object))]",['CHEMBL497478'],"{'rows': array(['EFO_0000616', 'EFO_0001378', 'EFO_1001469', 'EFO_0000095',
       'EFO_0000574'], dtype=object), 'count': 5}","[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4594275,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1,NLFLXLJXEIUQDL-UHFFFAOYSA-N,Small molecule,False,GUSACITINIB,,2.0,,False,False,[],['ASN-002' 'ASN002' 'Asn-002' 'Asn002' 'EN-3351' 'EN3351' 'Gusacitinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GUSACITINIB/relevant/1/'],
      dtype=object))]",['CHEMBL4594276'],"{'rows': array(['EFO_0005809', 'MONDO_0002334', 'EFO_0005809', 'MONDO_0002406',
       'MONDO_0002334', 'MONDO_0018906', 'EFO_1001469', 'EFO_0000403',
       'EFO_0000274'], dtype=object), 'count': 9}","[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397,ENSG00000165025]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL568,O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,ADIMAYPTOBDMTL-UHFFFAOYSA-N,Small molecule,True,OXAZEPAM,1965.0,4.0,,False,True,['Lederpam' 'Oxazepam' 'Serax' 'Serenid fte' 'Zaxopam'],"['J3.308A' 'NSC-169448' 'Oxazepam' 'Oxazepam civ' 'Oxozepam'
 'Temazepam impurity, oxazepam-' 'WY-3498']","[('DailyMed', array(['oxazepam'], dtype=object)), ('PubChem', array(['144205125', '144206372', '144207898', '144213809', '29215230'],
      dtype=object)), ('Wikipedia', array(['Oxazepam'], dtype=object)), ('drugbank', array(['DB00842'], dtype=object)), ('chEBI', array(['7823'], dtype=object))]",['CHEMBL3251468'],"{'rows': array(['HP_0000713', 'EFO_0003768', 'HP_0000726', 'EFO_0006788',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_0000764', 'EFO_0005230'],
      dtype=object), 'count': 8}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL577,C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,LZFZMUMEGBBDTC-QEJZJMRPSA-N,Small molecule,False,ENALAPRILAT ANHYDROUS,,-1.0,,False,False,[],['Enalaprilat anhydrous' 'MK-421'],"[('Wikipedia', array(['Enalaprilat'], dtype=object)), ('drugbank', array(['DB09477'], dtype=object)), ('chEBI', array(['4786'], dtype=object))]",['CHEMBL3989406'],"{'rows': array(['EFO_0000407', 'EFO_0006346', 'EFO_0000537'], dtype=object), 'count': 3}",[ENSG00000159640],Small molecule drug and has 3 investigational indications.
CHEMBL1171837,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,PHXJVRSECIGDHY-UHFFFAOYSA-N,Small molecule,True,PONATINIB,2012.0,4.0,,False,True,['Iclusig'],['AP-24534' 'AP24534' 'Ponatinib'],"[('PubChem', array(['137275996'], dtype=object)), ('Wikipedia', array(['Ponatinib'], dtype=object)), ('drugbank', array(['DB08901'], dtype=object)), ('chEBI', array(['78543'], dtype=object))]",['CHEMBL2105708'],"{'rows': array(['EFO_0000222', 'EFO_0000571', 'EFO_0000198', 'EFO_0003841',
       'MONDO_0015277', 'EFO_0000339', 'EFO_0000519', 'EFO_0000222',
       'EFO_0000339', 'EFO_0000702', 'EFO_0000565', 'EFO_1000131',
       'EFO_0000616', 'EFO_0000220', 'EFO_0003060', 'MONDO_0004992',
       'EFO_1000131', 'MONDO_0011719', 'EFO_0000220'], dtype=object), 'count': 19}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for chronic myelogenous leukemia and acute lymphoblastic leukemia and has 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200907,C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C#N)C[C@]35C)[C@@H]1CC[C@@H]2O,KVJXBPDAXMEYOA-CXANFOAXSA-N,Small molecule,False,TRILOSTANE,1984.0,4.0,,False,True,['Modrastane' 'Modrenal'],"['Desopan' 'NSC-758904' 'Trilostane' 'WIN 24,540' 'WIN-24540']","[('PubChem', array(['144206007', '144212723', '170465836'], dtype=object)), ('Wikipedia', array(['Trilostane'], dtype=object)), ('drugbank', array(['DB01108'], dtype=object)), ('chEBI', array(['32260'], dtype=object))]",,"{'rows': array(['EFO_0005539', 'EFO_0000673'], dtype=object), 'count': 2}",[ENSG00000203859],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for adrenal gland disease and has 1 investigational indication.
CHEMBL1201837,,,Protein,True,ECALLANTIDE,2009.0,4.0,,False,True,[],['DX-88' 'Ecallantide' 'Escallantide'],"[('DailyMed', array(['ecallantide'], dtype=object)), ('DrugCentral', array(['4846'], dtype=object)), ('Wikipedia', array(['Ecallantide'], dtype=object))]",,"{'rows': array(['EFO_0005532', 'MONDO_0019623'], dtype=object), 'count': 2}",[ENSG00000164344],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for hereditary angioedema and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1908318,CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CNC(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2,NGCNKEZHGRXHNL-WVWQGFTISA-N,Protein,False,NEPADUTANT,,2.0,,False,False,[],['Nepadutant'],"[('drugbank', array(['DB12538'], dtype=object))]",,"{'rows': array(['HP_0002027'], dtype=object), 'count': 1}",[ENSG00000075073],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2103836,CCC[C@@H](C)C[C@H](N)CC(=O)O,JXEHXYFSIOYTAH-SFYZADRCSA-N,Small molecule,False,IMAGABALIN,,3.0,,False,False,[],['Imagabalin' 'PD 0332334' 'PD-0332334' 'PD0332334' 'PF-00195889'],"[('drugbank', array(['DB12105'], dtype=object))]",['CHEMBL2105673'],"{'rows': array(['EFO_1001892', 'HP_0000083', 'EFO_0005230'], dtype=object), 'count': 3}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2108312,,,Protein,False,OZARELIX,,3.0,,False,False,[],['D-63153' 'D63153' 'Ozarelix'],,,"{'rows': array(['MONDO_0008315', 'EFO_0000284'], dtype=object), 'count': 2}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108675,,,Antibody,False,DUPILUMAB,2017.0,4.0,,False,True,"['Dupixent' 'Regn668, sar231893']",['Dupilumab' 'REGN-668' 'REGN668' 'SAR-231893' 'SAR231893'],"[('DailyMed', array(['dupilumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent'],
      dtype=object))]",,"{'rows': array(['EFO_0007425', 'EFO_0007141', 'EFO_0007140', 'EFO_0007187',
       'EFO_0000729', 'HP_0000964', 'EFO_0003060', 'EFO_0000274',
       'EFO_0000341', 'EFO_1000391', 'EFO_0004212', 'EFO_1001881',
       'MONDO_0004979', 'MONDO_0100096', 'MONDO_0002406', 'EFO_0005531',
       'EFO_0004192', 'HP_0000989', 'EFO_0000684', 'EFO_0005532',
       'HP_0100582', 'EFO_0004232', 'MONDO_0009735', 'EFO_1001361',
       'EFO_0007486', 'EFO_0005854', 'MONDO_0008315', 'EFO_1000740',
       'EFO_0000701'], dtype=object), 'count': 29}",[ENSG00000077238],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 25 investigational indications.
CHEMBL2108806,,,Oligosaccharide,False,BEMIPARIN SODIUM,,4.0,,False,True,['Zibor'],['Badyket' 'Bemiparin sodium' 'Hibor' 'Zivor'],,,"{'rows': array(['EFO_0003907', 'MONDO_0100096'], dtype=object), 'count': 2}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.
CHEMBL214268,O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1,IPKZCLGGYKRDES-ZDUSSCGKSA-N,Small molecule,False,PHA-543613,,1.0,,False,False,[],"['J3.179.420J' 'PHA-543,613' 'PHA-543613' 'Pha-00543613' 'Pha-543613']","[('PubChem', array(['144210766'], dtype=object)), ('Wikipedia', array(['PHA-543,613'], dtype=object))]",,,[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2356097,COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)CCC(=O)O,RGHAZVBIOOEVQX-UHFFFAOYSA-N,Small molecule,True,METOPROLOL SUCCINATE,1992.0,4.0,CHEMBL13,False,True,['Kapspargo sprinkle' 'Metoprolol succinate' 'Toprol Xl' 'Toprol-xl'],"['H 93/26 SUCCINATE' 'Metoprolol hemisuccinate' 'Metoprolol succinate'
 'Seloken-zok' 'Selozok']","[('DailyMed', array(['metoprolol%20succinate'], dtype=object)), ('PubChem', array(['144206706'], dtype=object))]",,"{'rows': array(['MONDO_0010679', 'EFO_0000341', 'EFO_0000537', 'EFO_0003913',
       'EFO_0000712', 'EFO_0000612', 'HP_0001653', 'EFO_0000275',
       'EFO_0000266', 'EFO_0003144', 'EFO_0000538', 'EFO_0000373',
       'Orphanet_79292'], dtype=object), 'count': 13}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL315795,Cc1ncsc1CCCl,PCLITLDOTJTVDJ-UHFFFAOYSA-N,Small molecule,False,CLOMETHIAZOLE,,4.0,,False,True,['Heminevrin'],['Chlormethiazole' 'Clomethiazole' 'Distraneurine' 'SCTZ [AS EDISYLATE]'],"[('PubChem', array(['11113756', '144204482', '170466516', '26751938', '90341262'],
      dtype=object)), ('Wikipedia', array(['Clomethiazole'], dtype=object)), ('drugbank', array(['DB06470'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090'],
      dtype=object), 'count': 4}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications.
CHEMBL3545419,,,Antibody,False,TELISOTUZUMAB,,2.0,,False,False,[],['ABT-700' 'Abt-700' 'Telisotuzumab'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000105976],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989862,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,SVCSMAZYWOQCBW-NVJMFHFGSA-N,Small molecule,False,PEFCALCITOL,,3.0,,False,False,[],['M-5181' 'M-518101' 'M5181' 'M518101' 'Pefcalcitol'],"[('drugbank', array(['DB11786'], dtype=object))]",,"{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4303323,C[C@H](Nc1ncnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1,DOCINCLJNAXZQF-LBPRGKRZSA-N,Small molecule,False,ACALISIB,,2.0,,False,False,[],['Acalisib' 'CAL-120' 'CAL120' 'GS-9820' 'GS9820' 'Gs-9820'],,,"{'rows': array(['EFO_0001642'], dtype=object), 'count': 1}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594403,CC1=CN2CCS(=O)(=O)N=C2C(c2ccc(OC3CCCCC3)cc2)=N1,PXJBHEHFVQVDDS-UHFFFAOYSA-N,Small molecule,False,OSAVAMPATOR,,2.0,,False,False,[],['Osavampator' 'Tak-653'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object))]",,"{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650369,,,Antibody,False,ABELACIMAB,,3.0,,False,False,[],['Abelacimab'],,,"{'rows': array(['EFO_0000275', 'EFO_0004286'], dtype=object), 'count': 2}",[ENSG00000088926],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL515387,O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1,QWEWGXUTRTXFRF-KBPBESRZSA-N,Small molecule,False,GOSOGLIPTIN,2016.0,4.0,,False,True,[],"['Gosogliptin' 'PF-00734200' 'PF-734,200' 'PF-734200']","[('drugbank', array(['DB08382'], dtype=object))]",['CHEMBL3526419'],"{'rows': array(['EFO_0003884', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 2 investigational indications.
CHEMBL5314381,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.O=S(=O)(O)OC[C@H]1O[C@@](COS(=O)(=O)O)(O[C@H]2O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H]1OS(=O)(=O)O,BCPSLKYBXGKPIW-RTXWKGGWSA-N,Small molecule,False,IRINOTECAN SUCROSOFATE,,3.0,,False,False,[],['Irinotecan sucrosofate' 'MM-398' 'PEP-02'],,,"{'rows': array(['EFO_1001951', 'MONDO_0004992', 'EFO_1000657', 'EFO_0000616',
       'EFO_0002618'], dtype=object), 'count': 5}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL563251,CN1C[C@@H]2[C@H](C1)[C@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,KYLOBHXXQOZRKK-FICVDOATSA-N,Small molecule,False,PF-03463275,,2.0,,False,False,[],['Pf-03463275' 'Pf-3463275'],"[('drugbank', array(['DB11993'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}",[ENSG00000196517],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL61006,CC(N)C(O)c1ccccc1,DLNKOYKMWOXYQA-UHFFFAOYSA-N,Small molecule,False,PHENYLPROPANOLAMINE,1958.0,4.0,,True,True,[],"['Fansia' 'NSC-9920' 'Norephedrine' 'Phenylfenesin' 'Phenylpropanolamine'
 'Propadrine' 'Rinexin']",,['CHEMBL1200695' 'CHEMBL2146104' 'CHEMBL1201535'],"{'rows': array(['HP_0001742'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958 and is indicated for nasal congestion. It was withdrawn in at least one region.
CHEMBL1200342,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,HYRKAAMZBDSJFJ-LFDBJOOHSA-N,Small molecule,False,PARAMETHASONE ACETATE,1982.0,4.0,,False,True,['Haldrone'],"['Dillar' 'Paramethasone' 'Paramethasone 21-acetate'
 'Paramethasone acetate']","[('PubChem', array(['144206683'], dtype=object)), ('drugbank', array(['DB14657'], dtype=object)), ('chEBI', array(['31963'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200479,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl,GUBNMFJOJGDCEL-UHFFFAOYSA-N,Small molecule,False,DICYCLOMINE HYDROCHLORIDE,1950.0,4.0,CHEMBL1123,False,True,"['Bentyl' 'Bentyl preservative free'
 'Dicyclomine Hydrochloride (Preservative-Free)'
 'Dicyclomine hydrochloride'
 'Dicyclomine hydrochloride (preservative free)' 'Merbentyl'
 'Merbentyl 20']","['Bentylol' 'Dicyclomine hcl' 'Dicyclomine hydrochloride'
 'Dicycloverine hydrochloride' 'Kolantyl hydrochloride' 'NSC-404381'
 'Wyovin']","[('DailyMed', array(['dicyclomine%20hydrochloride'], dtype=object)), ('PubChem', array(['26747501', '26747502', '50106212', '50106213', '50106214',
       '56423126', '855865'], dtype=object)), ('chEBI', array(['4515'], dtype=object))]",,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950 and is indicated for irritable bowel syndrome.
CHEMBL1200807,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC,ISHXLNHNDMZNMC-VTKCIJPMSA-N,Small molecule,False,NORELGESTROMIN,2001.0,4.0,,False,True,[],['Deacetylnorgestimate' 'Norelgestromin' 'RWJ-10553'],"[('DailyMed', array(['norelgestromin'], dtype=object)), ('PubChem', array(['144206200'], dtype=object)), ('Wikipedia', array(['Norelgestromin'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'HP_0100608', 'EFO_0002950'], dtype=object), 'count': 3}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 investigational indications.
CHEMBL1201629,,,Protein,False,INSULIN PURIFIED BEEF,1980.0,4.0,,False,True,['Regular iletin ii'],"['(beef) insulin' 'Bovine insulin highly purified' 'Bovine insulinum'
 'Insulin (beef)' 'Insulin (bison bonasus)' 'Insulin beef'
 'Insulin bovine' 'Insulin purified beef' 'Insulin, regular, beef'
 'Insulin,lente,beef' 'Insulin,nph,beef' 'Insulin,semilente,beef'
 'Insulin,ultralente,beef']","[('DrugCentral', array(['5192'], dtype=object))]",,"{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for diabetes mellitus.
CHEMBL1237024,,,Cell,False,SIPULEUCEL-T,,4.0,,False,True,[],['APC-8015' 'APC8015' 'Sipuleucel-t'],"[('Wikipedia', array(['Sipuleucel-T'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0008315', 'EFO_0000673', 'EFO_0000196'],
      dtype=object), 'count': 4}",[ENSG00000014257],Cell drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and prostate cancer and has 2 investigational indications.
CHEMBL1303,CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,KFQYTPMOWPVWEJ-INIZCTEOSA-N,Small molecule,False,ROTIGOTINE,2007.0,4.0,,False,True,['Leganto' 'Neupro'],['Leganto' 'Rotigotine' 'SPM 962' 'SPM-962'],"[('DailyMed', array(['rotigotine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/leganto'],
      dtype=object)), ('PubChem', array(['144206180', '170465204', '50113269'], dtype=object)), ('Wikipedia', array(['Rotigotine'], dtype=object)), ('drugbank', array(['DB05271'], dtype=object))]",,"{'rows': array(['EFO_0003890', 'MONDO_0004975', 'MONDO_0005180', 'EFO_0004270',
       'EFO_0005687', 'EFO_0000712'], dtype=object), 'count': 6}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for parkinson disease and restless legs syndrome and has 4 investigational indications.
CHEMBL2027925,Nc1c(Cl)cc(-c2nn(C3CCN(CCc4ccccc4)CC3)c(=O)o2)c2c1OCCO2,MDBNTXARNGRHEV-UHFFFAOYSA-N,Small molecule,False,CAPESEROD,,2.0,,False,False,[],['Capeserod' 'SL650155' 'Sl65.0155'],,['CHEMBL2022742'],,[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108185,,,Protein,False,CORIFOLLITROPIN ALFA,2010.0,4.0,,False,True,['Elonva'],"['Corifollitropin alfa' 'MK-8962' 'ORG 36286' 'ORG-36286' 'SCH 900962'
 'SCH-900962']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/elonva'],
      dtype=object))]",,"{'rows': array(['MONDO_0018555', 'GO_0060279', 'EFO_0000545'], dtype=object), 'count': 3}",[ENSG00000170820],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for positive regulation of ovulation and has 2 investigational indications.
CHEMBL2108492,,,Protein,False,"INSULIN ZINC, EXTENDED",,4.0,,False,True,['Ins humulin zn' 'Ins ultrat' 'Ins ultrat mc'],"['Crystalline (aqueous suspension)' 'Insulin zinc injection'
 'Insulin zinc injection, crystalline (aqueous suspension)'
 'Insulin zinc suspension ' 'Insulin zinc suspension (crystalline)'
 'Insulin zinc, extended']",,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV.
CHEMBL2108591,,,Antibody,False,ELSILIMOMAB,,2.0,,False,False,['B-e8'],['Anti-il-6 mab b-e8' 'Antibody b-e8' 'Elsilimomab' 'Mab b-e8'],,,,[ENSG00000136244],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109284,,,Antibody,False,CMB-401,,1.0,,False,False,[],['CMB-401' 'HCTMO1-CALICHEAMICIN'],,,,[ENSG00000185499],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109642,,,Antibody,False,A33 131I,,2.0,,False,False,[],['A33' 'A33 131i'],,,"{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}",[ENSG00000143167],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL21333,O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1,NBQKINXMPLXUET-UHFFFAOYSA-N,Small molecule,False,PRANLUKAST,1995.0,4.0,,False,True,[],"['Azlaire' 'CCN 00401' 'CCN-00401' 'ONO 1078' 'ONO-1078' 'Pranlukast'
 'RS 411' 'RS-411' 'SB 205312' 'SB-205312']","[('PubChem', array(['144206505'], dtype=object)), ('Wikipedia', array(['Pranlukast'], dtype=object)), ('drugbank', array(['DB01411'], dtype=object))]",['CHEMBL3810125'],"{'rows': array(['EFO_0003956', 'HP_0006536', 'EFO_0007486'], dtype=object), 'count': 3}",[ENSG00000173198],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 investigational indications.
CHEMBL2364612,O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-],LOVMMUBRQUFEAH-UIEAZXIASA-N,Small molecule,False,LATANOPROSTENE BUNOD,2017.0,4.0,,False,True,['Vesneo' 'Vyzulta'],"['BOL-303259-X' 'Bol-303259-x' 'Latanoprostene bunod' 'NCX 116' 'NCX-116'
 'NCX116' 'PF-3187207']","[('DailyMed', array(['latanoprostene%20bunod'], dtype=object)), ('drugbank', array(['DB11660'], dtype=object))]",,"{'rows': array(['MONDO_0005041', 'EFO_0004190', 'EFO_1001069'], dtype=object), 'count': 3}",[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications.
CHEMBL3218576,COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,PZBCKZWLPGJMAO-UHFFFAOYSA-N,Small molecule,False,COPANLISIB,2017.0,4.0,,False,True,[],['BAY 80-6946' 'BAY-80-6946' 'BAY80-6946' 'Bay-80-6946' 'Copanlisib'],"[('drugbank', array(['DB12483'], dtype=object))]",['CHEMBL3545068'],"{'rows': array(['EFO_0000403', 'EFO_0000616', 'EFO_0000403', 'MONDO_0018906',
       'EFO_0001378', 'EFO_0005537', 'EFO_0000574', 'MONDO_0018906',
       'EFO_0000305', 'EFO_0000305', 'MONDO_0007254', 'EFO_1001469',
       'EFO_0000220', 'EFO_0005221', 'EFO_0000183', 'EFO_0003060',
       'EFO_0000096', 'EFO_0008528', 'HP_0000083', 'EFO_0000616',
       'EFO_0000096', 'EFO_0005952', 'EFO_0000707', 'MONDO_0021063',
       'EFO_0004606', 'EFO_0007532', 'MONDO_0008315', 'EFO_1001051',
       'EFO_1001469', 'EFO_0000095'], dtype=object), 'count': 30}","[ENSG00000171608,ENSG00000121879]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 26 investigational indications.
CHEMBL3785197,CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ncc(OCCCC(=O)O)cn2)C[C@H]1CC,NRWORBQAOQVYBJ-GJZUVCINSA-N,Small molecule,False,OBICETRAPIB,,3.0,,False,False,[],['AMG-899' 'DEZ-001' 'Obicetrapib' 'TA-8995' 'Ta-8995'],"[('drugbank', array(['DB14890'], dtype=object))]",,"{'rows': array(['Orphanet_309005', 'EFO_0000319', 'MONDO_0004975'], dtype=object), 'count': 3}",[ENSG00000087237],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3990038,,,Antibody,False,FLOTETUZUMAB,,2.0,,False,False,[],['Flotetuzumab' 'MGD-006' 'MGD006' 'RES-234' 'RES234' 'S-80880' 'S80880'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}","[ENSG00000292332,ENSG00000185291,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4101807,CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,FWCVZAQENIZVMY-UHFFFAOYSA-N,Small molecule,False,VOXELOTOR,2019.0,4.0,,False,True,['Oxbryta'],['GBT-440' 'GBT440' 'GTX-011' 'Gbt440' 'Voxelotor'],"[('DailyMed', array(['voxelotor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta'],
      dtype=object)), ('drugbank', array(['DB14975'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'MONDO_0002280', 'EFO_0004272', 'EFO_0001421',
       'EFO_0000768', 'EFO_0004610', 'MONDO_0011382'], dtype=object), 'count': 7}","[ENSG00000206172,ENSG00000188536,ENSG00000244734]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 4 investigational indications.
CHEMBL4297181,CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,ACCFLVVUVBJNGT-AWEZNQCLSA-N,Small molecule,False,SAMOTOLISIB,,2.0,,False,False,[],['LY 3023414' 'LY-3023414' 'LY3023414' 'Ly-3023414' 'Samotolisib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SAMOTOLISIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12167'], dtype=object))]",,"{'rows': array(['EFO_0003869', 'MONDO_0008315', 'EFO_0005952', 'EFO_0009708',
       'EFO_0004142', 'EFO_0000616', 'MONDO_0005184', 'MONDO_0007254',
       'EFO_0000588', 'MONDO_0011962', 'EFO_0003060'], dtype=object), 'count': 11}","[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.
CHEMBL4297572,,,Unknown,False,ABBV-3373,,2.0,,False,False,[],['ABBV-3373' 'Abbv-3373'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}","[ENSG00000113580,ENSG00000232810]",Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297580,,,Antibody,False,ETOKIMAB,,2.0,,False,False,[],['ANB-020' 'ANB020' 'Anb020' 'Etokimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETOKIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0000274', 'EFO_0007425', 'EFO_0007486',
       'HP_0011123'], dtype=object), 'count': 5}",[ENSG00000137033],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4297729,,,Antibody,False,COSIBELIMAB,,3.0,,False,False,[],['CK-301' 'Ck-301' 'Cosibelimab' 'TG-1501' 'Tg-1501'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/COSIBELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000095', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4298197,,,Oligonucleotide,False,VUPANORSEN,,2.0,,False,False,[],['AKCEA-ANGPTL3-LRx' 'ISIS 703802' 'ISIS-703802' 'Vupanorsen'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VUPANORSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0020088', 'MONDO_0018328', 'MONDO_0021187'], dtype=object), 'count': 3}","[ENSG00000132855,ENSG00000141505]",Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL448,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,WEXRUCMBJFQVBZ-UHFFFAOYSA-N,Small molecule,False,PENTOBARBITAL,1973.0,4.0,,True,True,['Nembutal'],"['Mebubarbital' 'Mebumal' 'NSC-28708' 'Pentobarbital'
 'Pentobarbital calcium' 'Pentobarbital cii' 'Pentobarbitone']","[('PubChem', array(['144205108', '26750091'], dtype=object)), ('Wikipedia', array(['Pentobarbital'], dtype=object)), ('drugbank', array(['DB00312'], dtype=object)), ('chEBI', array(['7983'], dtype=object))]",['CHEMBL971'],"{'rows': array(['EFO_0003890', 'EFO_0008526', 'EFO_0004698', 'EFO_0003777',
       'MONDO_0043510'], dtype=object), 'count': 5}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for insomnia and has 4 investigational indications. It was withdrawn in at least one region.
CHEMBL4594584,,,Unknown,False,"ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT",2018.0,4.0,,False,True,['Adynovi'],"['Adynovate' 'Adynovi'
 'Antihemophilic factor, pegylated (mw 20000) human sequence recombinant'
 'Pegylated recombinant factor viii' 'Pegylated rfviii'
 'Rurioctocog alfa pegol']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Unknown drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for hemophilia a.
CHEMBL4650434,,,Antibody,False,ENIBARCIMAB,,2.0,,False,False,[],['Adrecizumab' 'Enibarcimab' 'HAM-8101' 'HAM8101'],,,"{'rows': array(['MONDO_0100096', 'EFO_0003144', 'EFO_0006834'], dtype=object), 'count': 3}",[ENSG00000148926],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL5267842,N#Cc1cccc(-c2ccc3ncc(-c4cc(F)cc(F)c4)c(N4CCC(N)CC4)c3c2)c1O,GHILNKWBALQPDP-UHFFFAOYSA-N,Small molecule,False,PALTUSOTINE,,3.0,,False,False,[],['CRN-00808' 'CRN00808' 'Crn00808' 'Paltusotine'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PALTUSOTINE/relevant/1/'],
      dtype=object))]",['CHEMBL5314560'],"{'rows': array(['EFO_1001485', 'EFO_1000852', 'EFO_1001485', 'EFO_1001901',
       'EFO_1000852', 'EFO_1001901'], dtype=object), 'count': 6}",[ENSG00000180616],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL553025,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,GBABOYUKABKIAF-IELIFDKJSA-N,Small molecule,True,VINORELBINE,1994.0,4.0,,False,True,[],['NSC-760087' 'Navelbin' 'Vinorelbine' 'Vinorelbine Base'],"[('PubChem', array(['124893200', '29217724', '50111727'], dtype=object)), ('drugbank', array(['DB00361'], dtype=object)), ('chEBI', array(['480999'], dtype=object))]",['CHEMBL538943'],"{'rows': array(['EFO_0000437', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0021063', 'EFO_0004284', 'EFO_0002918',
       'MONDO_0004992', 'EFO_1000895', 'EFO_0003869', 'EFO_0000313',
       'EFO_0000770', 'EFO_0003050', 'EFO_1000026', 'EFO_0003032',
       'EFO_0000437', 'EFO_0000571', 'MONDO_0007254', 'EFO_0000313',
       'MONDO_0002367', 'MONDO_0021117', 'MONDO_0008315', 'EFO_0000616',
       'EFO_0000621', 'EFO_0000616', 'EFO_0005537', 'EFO_0005952',
       'EFO_0000248', 'EFO_1000158', 'EFO_0003869', 'EFO_0000403',
       'EFO_0001071', 'MONDO_0008903', 'MONDO_0002158', 'EFO_0000389',
       'EFO_0000248', 'EFO_0002617', 'EFO_0000571', 'EFO_0003060',
       'EFO_0000211', 'EFO_0000691', 'EFO_0001378', 'EFO_0000691',
       'EFO_0006861', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0009348',
       'EFO_0000183', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0008903',
       'EFO_0000183', 'EFO_0000702', 'MONDO_0001187', 'EFO_0005922',
       'EFO_0000565', 'EFO_1000294', 'EFO_0001416', 'MONDO_0001402',
       'MONDO_0011962', 'EFO_0005952', 'EFO_0000574', 'MONDO_0007254'],
      dtype=object), 'count': 64}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for cancer and neoplasm and has 52 investigational indications. This drug has a black box warning from the FDA.
CHEMBL565,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1,KNHUKKLJHYUCFP-UHFFFAOYSA-N,Small molecule,False,CLOFIBRATE,1967.0,4.0,,False,True,['Atromid-s' 'Clofibrate'],"['AY-61123' 'Chlorfenisate' 'Clofibrate'
 'Ethyl p-chlorophenoxyisobutyrate' 'ICI 28257' 'ICI-28257' 'NSC-79389']","[('PubChem', array(['11110971', '119396', '124879709', '144203667', '144209612',
       '170465329', '50106069', '57260455', '85230976', '90341380'],
      dtype=object)), ('TG-GATEs', array(['6'], dtype=object)), ('Wikipedia', array(['Clofibrate'], dtype=object)), ('drugbank', array(['DB00636'], dtype=object)), ('chEBI', array(['3750'], dtype=object))]",,"{'rows': array(['EFO_1001375', 'EFO_0000612', 'EFO_0000319'], dtype=object), 'count': 3}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL592435,OC1CCC(Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1,RBZNJGHIKXAKQE-UHFFFAOYSA-N,Small molecule,False,DERENOFYLLINE,,2.0,,False,False,[],['Derenofylline' 'SLV-320' 'SLV320' 'Slv320'],,,"{'rows': array(['EFO_0000373'], dtype=object), 'count': 1}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL74355,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,HXTGXYRHXAGCFP-OAQYLSRUSA-N,Small molecule,False,VOLINANSERIN,,3.0,,False,False,[],"['M-100907' 'M100907' 'MDL-100.907' 'MDL-100907' 'MDL100.907' 'Mdl-100907'
 'Volinanserin']","[('PubChem', array(['144210564'], dtype=object)), ('Wikipedia', array(['Volinanserin'], dtype=object))]",['CHEMBL5173614' 'CHEMBL5189294'],"{'rows': array(['MONDO_0002050', 'EFO_0008568'], dtype=object), 'count': 2}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL744,Nc1nc2ccc(OC(F)(F)F)cc2s1,FTALBRSUTCGOEG-UHFFFAOYSA-N,Small molecule,False,RILUZOLE,1995.0,4.0,,False,True,"['Exservan' 'Rilutek' 'Riluzole' 'Riluzole zentiva' 'Teglutik'
 'Tiglutik kit']","['BHV-0223' 'NSC-753433' 'NSC-759823' 'RP 54274' 'RP-54274' 'Riluzole'
 'Tiglutik']","[('DailyMed', array(['riluzole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/riluzole-zentiva'],
      dtype=object)), ('PubChem', array(['104171227', '11111723', '11113346', '124881305', '144203803',
       '170464928', '26751529', '50104104', '85231207', '855844',
       '90341557'], dtype=object)), ('Wikipedia', array(['Riluzole'], dtype=object)), ('drugbank', array(['DB00740'], dtype=object)), ('chEBI', array(['8863'], dtype=object))]",['CHEMBL1531817'],"{'rows': array(['EFO_0001358', 'EFO_0003100', 'MONDO_0004976', 'MONDO_0007739',
       'MONDO_0005301', 'MONDO_0004985', 'HP_0002196', 'MONDO_0002050',
       'EFO_0000275', 'MONDO_0007254', 'MONDO_0019037', 'MONDO_0008458',
       'EFO_1001919', 'MONDO_0002009', 'EFO_1001050', 'EFO_0003756',
       'EFO_0008522', 'EFO_0008525', 'EFO_0000389', 'MONDO_0016163',
       'MONDO_0000437', 'MONDO_0004975', 'EFO_0004242'], dtype=object), 'count': 23}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for amyotrophic lateral sclerosis and has 22 investigational indications.
CHEMBL817,Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1,OUDSBRTVNLOZBN-UHFFFAOYSA-N,Small molecule,False,TOLAZAMIDE,1966.0,4.0,,False,True,['Tolazamide' 'Tolinase'],['NSC-70762' 'Tolazamide' 'U-17835'],"[('PubChem', array(['11111870', '124881598', '144203832', '144208705', '144210734',
       '170465136', '26747047', '26751566', '50104182', '56422126',
       '85231252', '855941'], dtype=object)), ('Wikipedia', array(['Tolazamide'], dtype=object)), ('drugbank', array(['DB00839'], dtype=object)), ('chEBI', array(['9613'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and is indicated for diabetes mellitus and type 2 diabetes mellitus.
CHEMBL1200843,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1.O=C(O)/C=C\C(=O)O,NOFOWWRHEPHDCY-DAUURJMHSA-N,Small molecule,False,METHYLERGONOVINE MALEATE,1946.0,4.0,CHEMBL1201356,False,True,['Methergine' 'Methylergonovine maleate'],"['Methylergometrine maleate' 'Methylergonovine maleate'
 'Methylergonovinium bimaleate' 'NSC-757104']","[('DailyMed', array(['methylergonovine%20maleate'], dtype=object)), ('PubChem', array(['93576602'], dtype=object))]",,"{'rows': array(['MP_0001914'], dtype=object), 'count': 1}","[ENSG00000135914,ENSG00000184845]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for hemorrhage.
CHEMBL1201319,C[C@H](N)[C@H](O)c1cccc(O)c1,WXFIGDLSSYIKKV-RCOVLWMOSA-N,Small molecule,False,METARAMINOL,1954.0,4.0,,False,True,[],['Metaraminol'],"[('Wikipedia', array(['Metaraminol'], dtype=object)), ('drugbank', array(['DB00610'], dtype=object)), ('chEBI', array(['6794'], dtype=object))]",['CHEMBL4303541' 'CHEMBL2062262' 'CHEMBL3184244' 'CHEMBL2062343'],"{'rows': array(['EFO_0000668', 'EFO_0005251', 'EFO_0000319'], dtype=object), 'count': 3}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL1201752,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,FABUFPQFXZVHFB-PVYNADRNSA-N,Small molecule,True,IXABEPILONE,2007.0,4.0,,False,True,['Ixempra' 'Ixempra kit'],"['Azaepothilone b' 'BMS 247550-01' 'BMS-247550' 'BMS-247550-01'
 'Ixabepilone' 'Ixempra' 'NSC-747973']","[('Wikipedia', array(['Ixabepilone'], dtype=object)), ('drugbank', array(['DB04845'], dtype=object)), ('chEBI', array(['63605'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'MONDO_0004992', 'MONDO_0004192', 'EFO_1001968',
       'EFO_0000182', 'EFO_0003897', 'EFO_1001465', 'EFO_0005221',
       'EFO_1000613', 'MONDO_0005411', 'MONDO_0007254', 'EFO_0006861',
       'MONDO_0044926', 'EFO_0000305', 'EFO_0007532', 'EFO_1001469',
       'MONDO_0011962', 'MONDO_0004986', 'EFO_0000403', 'EFO_0000349',
       'EFO_0000565', 'EFO_0000309', 'MONDO_0008903', 'EFO_0002499',
       'EFO_0000681', 'EFO_0003869', 'MONDO_0018906', 'EFO_0000673',
       'EFO_0000616', 'MONDO_0002158', 'EFO_0002938', 'EFO_0003871',
       'EFO_0002618', 'EFO_0003032', 'EFO_0000574', 'EFO_0003060',
       'EFO_0006859', 'MONDO_0002087', 'MONDO_0008170', 'EFO_0006352',
       'EFO_0007535', 'EFO_1001951', 'MONDO_0008315'], dtype=object), 'count': 43}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 38 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1345,N=C(N)NCCN1CCCCCCC1.O=S(=O)(O)O,YUFWAVFNITUSHI-UHFFFAOYSA-N,Small molecule,False,GUANETHIDINE MONOSULFATE,1960.0,4.0,CHEMBL765,False,True,['Ganda' 'Guanethidine monosulfate' 'Ismelin' 'Ismeline' 'Lotens'],['Guanethidine monosulfate' 'Guanethidine monosulphate'],"[('PubChem', array(['26748068'], dtype=object)), ('chEBI', array(['51016'], dtype=object))]",,,[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1595,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341,RBOXVHNMENFORY-DNJOTXNNSA-N,Small molecule,False,DIHYDROCODEINE,1983.0,4.0,,False,True,[],"['.alpha.-hydrocodol' '8,14-dihydroneopine' 'Codhydrine' 'Dehacodin'
 'Dh-codeine' 'Dihydrocodeine' 'IDS-ND-008(SECT.2)' 'NSC-231319'
 'Novicondin' 'Rapacodin' 'Remedacen']","[('Wikipedia', array(['Dihydrocodeine'], dtype=object)), ('drugbank', array(['DB01551'], dtype=object))]",['CHEMBL2062266'],"{'rows': array(['EFO_0003843', 'EFO_0003843'], dtype=object), 'count': 2}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for pain.
CHEMBL1614650,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](N)CC3,ZVYVPGLRVWUPMP-FYSMJZIKSA-N,Small molecule,False,EXATECAN,,3.0,,False,False,[],['DX-8951' 'Exatecan'],"[('Wikipedia', array(['Exatecan'], dtype=object)), ('drugbank', array(['DB12185'], dtype=object))]",['CHEMBL3989759'],"{'rows': array(['MONDO_0008315', 'EFO_0000565', 'MONDO_0002158', 'EFO_0002618',
       'MONDO_0008170', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0002691',
       'EFO_1000158', 'MONDO_0002974', 'EFO_0000691', 'EFO_0000616',
       'EFO_0000198', 'MONDO_0007254', 'EFO_0000574'], dtype=object), 'count': 15}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.
CHEMBL1693,CCN(CC)C(C)C(=O)c1ccccc1.Cl,ICFXZZFWRWNZMA-UHFFFAOYSA-N,Small molecule,False,DIETHYLPROPION HYDROCHLORIDE,1959.0,4.0,CHEMBL1194666,False,True,"['Apisate' 'Diethylpropion hydrochloride' 'Tenuate' 'Tenuate dospan'
 'Tepanil' 'Tepanil ten-tab']","['Amfepramone hydrochloride' 'Anorex' 'D03801' 'Diethylpropion HCl'
 'Diethylpropion hcl' 'Diethylpropion hydrochloride'
 'Diethylpropion hydrochloride civ' 'Dobesin' 'Moderatan' 'Prefamone'
 'Regenon']","[('DailyMed', array(['diethylpropion%20hydrochloride'], dtype=object)), ('PubChem', array(['170464650'], dtype=object)), ('chEBI', array(['643703'], dtype=object))]",,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000142319]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for obesity.
CHEMBL1742984,,,Antibody,False,AMATUXIMAB,,2.0,,False,False,[],['Amatuximab' 'MORAb-009'],,,"{'rows': array(['EFO_0000588', 'MONDO_0004992', 'EFO_0000770', 'EFO_0002618'],
      dtype=object), 'count': 4}",[ENSG00000102854],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1743012,,,Antibody,False,ENOKIZUMAB,,2.0,,False,False,[],['7F3COM-2H2' '7f3com2h2' 'Enokizumab' 'MEDI 528' 'MEDI-528'],,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000145839],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL19236,COc1nc(C)nc(Cl)c1NC1=NCCN1,WPNJAUFVNXKLIM-UHFFFAOYSA-N,Small molecule,False,MOXONIDINE,1991.0,4.0,,False,True,['Fisiotens' 'Normatens' 'Physiotens'],"['BDF-5896' 'BDF5896' 'BE-5895' 'BE5895' 'LY-326869' 'LY326869'
 'Moxonidine']","[('PubChem', array(['11111430', '11111431', '144203741', '170466534', '85148350',
       '90341434'], dtype=object)), ('Wikipedia', array(['Moxonidine'], dtype=object)), ('drugbank', array(['DB09242'], dtype=object)), ('chEBI', array(['7009'], dtype=object))]",['CHEMBL1256287'],"{'rows': array(['EFO_0000537', 'EFO_0005252', 'EFO_0003777'], dtype=object), 'count': 3}",[ENSG00000010322],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for hypertension and has 2 investigational indications.
CHEMBL1950649,CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)nc(C#CC[C@H]4CC[C@H](C(=O)OC)CC4)nc32)[C@H](O)[C@@H]1O,FLEVIENZILQUKB-XTWQNQIISA-N,Small molecule,False,APADENOSON,,3.0,,False,False,['Stedivaze'],['Apadenoson' 'BMS-068645' 'BMS068645' 'Bms-068645' 'DWH-146E'],"[('drugbank', array(['DB05009'], dtype=object))]",,,[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL2108041,,,Antibody,False,OCRELIZUMAB,2017.0,4.0,,False,True,['Ocrevus'],['2H7' 'Ocrelizumab' 'PR-070769' 'PR070769' 'R-1594' 'RG-1594'],"[('DailyMed', array(['ocrelizumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus'],
      dtype=object))]",,"{'rows': array(['MONDO_0005301', 'EFO_0003929', 'EFO_0005952', 'EFO_0003840',
       'EFO_0000540', 'MONDO_0007915', 'EFO_0008520', 'EFO_0000685',
       'EFO_0007332'], dtype=object), 'count': 9}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 4 investigational indications.
CHEMBL2110618,CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(C(=O)OC[C@H](COC(=O)N(Cc2cccc[n+]2CC)C(=O)c2ccccc2OC)OC)CC1,HGOAIWZFTWACBD-RRHRGVEJSA-O,Small molecule,False,MINOPAFANT,,2.0,,False,False,[],['E-5880' 'Minopafant'],,['CHEMBL2104419'],,[ENSG00000169403],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL216981,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,RXIUEIPPLAFSDF-CYBMUJFWSA-N,Small molecule,False,NAVARIXIN,,2.0,,False,False,[],['Mk-7123' 'Navarixin' 'PS-291822' 'PS291822' 'SCH-527123' 'SCH527123'],,['CHEMBL2103864'],"{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0000676'], dtype=object), 'count': 3}","[ENSG00000180871,ENSG00000163464]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL266497,O=C1NC(=O)[C@@]2(CCOc3ccc(F)cc32)N1,LXANPKRCLVQAOG-NSHDSACASA-N,Small molecule,False,SORBINIL,,3.0,,False,False,[],"['CP-45,634' 'CP-45634' 'NSC-355082' 'Sorbinil']","[('PubChem', array(['144205232', '170466611', '29215399'], dtype=object)), ('drugbank', array(['DB02712'], dtype=object)), ('chEBI', array(['102029'], dtype=object))]",,"{'rows': array(['EFO_0003770'], dtype=object), 'count': 1}",[ENSG00000085662],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL271227,CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(c4cccnc4)=CC[C@@H]32)C1,UVIQSJCZCSLXRZ-UBUQANBQSA-N,Small molecule,False,ABIRATERONE ACETATE,2011.0,4.0,,False,True,['Abiraterone krka' 'Yonsa' 'Zytiga'],['Abiraterone acetate' 'CB-7630' 'CB7630' 'NSC-748121' 'NSC-749227'],"[('DailyMed', array(['abiraterone%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-krka',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga'],
      dtype=object)), ('PubChem', array(['144207138'], dtype=object)), ('chEBI', array(['68639'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'MONDO_0018479', 'EFO_0003826', 'MONDO_0007254',
       'MONDO_0008728', 'EFO_0001663', 'HP_0000083', 'EFO_0003060',
       'EFO_0000196', 'EFO_0000673', 'EFO_0001421', 'MONDO_0008315'],
      dtype=object), 'count': 12}",[ENSG00000148795],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 8 investigational indications.
CHEMBL3184143,N=C(N)NCC1COC2(CCCCC2)O1.N=C(N)NCC1COC2(CCCCC2)O1.O=S(=O)(O)O,RTEVGQJRTFFMLL-UHFFFAOYSA-N,Small molecule,False,GUANADREL SULFATE,1982.0,4.0,CHEMBL1037,False,True,['Hylorel'],"['CL-1388R' 'Guanadrel sulfate' 'Guanadrel sulphate' 'NSC-760062'
 'U-28,288D' 'U-28288D']","[('PubChem', array(['144204146'], dtype=object)), ('chEBI', array(['5556'], dtype=object))]",,,[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL3359265,Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1,BDXXSFOJPYSYOC-UHFFFAOYSA-N,Small molecule,False,PF-05175157,,2.0,,False,False,[],['Pf-05175157'],"[('drugbank', array(['DB12096'], dtype=object))]",,"{'rows': array(['EFO_0003894', 'MONDO_0005148'], dtype=object), 'count': 2}","[ENSG00000278540,ENSG00000076555]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL362558,O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2,HRJWTAWVFDCTGO-UHFFFAOYSA-N,Small molecule,False,LY-2090314,,2.0,,False,False,[],['LY-2090314' 'LY2090314' 'Ly 2090314' 'Ly-2090314'],"[('PubChem', array(['103905564'], dtype=object)), ('drugbank', array(['DB11913'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000565', 'EFO_0002618'], dtype=object), 'count': 3}","[ENSG00000082701,ENSG00000105723]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3707278,,,Antibody,False,CROTEDUMAB,,2.0,,False,False,[],['Crotedumab' 'REGN-1193' 'REGN1193'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000215644],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL405821,NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1,SCTZUZTYRMOMKT-UHFFFAOYSA-N,Small molecule,False,SENICAPOC,,3.0,,False,False,[],['ICA-17043' 'PF-05416266' 'Senicapoc'],"[('drugbank', array(['DB06280'], dtype=object))]",,"{'rows': array(['EFO_0000694', 'MONDO_0100096', 'MONDO_0004979', 'MONDO_0011382'],
      dtype=object), 'count': 4}",[ENSG00000104783],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297182,COCCN1C(=O)O[C@@]2(C[C@H]3O[C@]2(C)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)C1=O,SHWPFRVVBIKGAT-LYWBODIJSA-N,Small molecule,False,PEGCANTRATINIB,,2.0,,False,False,[],['CT-327' 'CT327' 'Ct-327' 'Pegcantratinib' 'SNA-120' 'Sna-120'],,,"{'rows': array(['EFO_0000274', 'EFO_0000676', 'EFO_0005762', 'EFO_1001494'],
      dtype=object), 'count': 4}",[ENSG00000198400],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297427,O[C@]1(c2ncccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl,MQWMHMZNBGQNMT-XHNJZIHCSA-N,Small molecule,False,SCH-486757,,2.0,,False,False,[],['SCH 486757' 'SCH486757' 'Sch 486757' 'Sch-486757'],"[('drugbank', array(['DB12782'], dtype=object))]",,"{'rows': array(['HP_0012735'], dtype=object), 'count': 1}",[ENSG00000125510],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4740383,Cc1c(C#N)cccc1-c1cc(-c2cn(Cc3cccc(C(C)(C)O)n3)nn2)nc(N)n1,BUXIAWLTBSXYSW-UHFFFAOYSA-N,Small molecule,False,ETRUMADENANT,,2.0,,False,False,[],['AB-928' 'AB928' 'Ab928' 'Etrumadenant'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETRUMADENANT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001951', 'EFO_0000616', 'EFO_1000657', 'EFO_0000673',
       'EFO_0003085', 'EFO_0000196', 'EFO_0003060', 'MONDO_0008315'],
      dtype=object), 'count': 8}","[ENSG00000170425,ENSG00000128271]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL522038,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N\O)cc1)C1CCCCC1,ZXIBCJHYVWYIKI-PZJWPPBQSA-N,Small molecule,False,XIMELAGATRAN,,4.0,,True,True,[],['Exanta' 'H 376/95' 'Ximelagatran'],"[('PubChem', array(['144207182'], dtype=object)), ('Wikipedia', array(['Ximelagatran'], dtype=object)), ('drugbank', array(['DB04898'], dtype=object)), ('chEBI', array(['65172'], dtype=object))]",,"{'rows': array(['HP_0001907', 'HP_0004419', 'EFO_0000275'], dtype=object), 'count': 3}",[ENSG00000180210],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 2 investigational indications. It was withdrawn in at least one region.
CHEMBL796,COC(=O)C(c1ccccc1)C1CCCCN1,DUGOZIWVEXMGBE-UHFFFAOYSA-N,Small molecule,True,METHYLPHENIDATE,1955.0,4.0,,False,True,['Concerta' 'Cotempla xr-odt' 'Daytrana'],"['Concerta' 'Methylin' 'Methylphenidate'
 'Methylphenidate extended release' 'Prc-063' 'Threo-dl-methylphenidate']","[('DailyMed', array(['methylphenidate'], dtype=object)), ('Wikipedia', array(['Methylphenidate'], dtype=object)), ('drugbank', array(['DB00422'], dtype=object)), ('chEBI', array(['84276'], dtype=object))]",['CHEMBL1722'],"{'rows': array(['HP_0000726', 'EFO_0009267', 'MONDO_0005180', 'EFO_0001642',
       'MONDO_0004992', 'EFO_0008568', 'MONDO_0008315', 'EFO_0003768',
       'MONDO_0007079', 'EFO_0003840', 'MONDO_0011184', 'MONDO_0011382',
       'MONDO_0002050', 'EFO_0001663', 'EFO_0005252', 'MONDO_0004992',
       'EFO_0005203', 'EFO_0007625', 'EFO_0003890', 'MONDO_0005090',
       'HP_0012378', 'MONDO_0043510', 'EFO_0001358', 'MONDO_0004985',
       'EFO_0003833', 'EFO_0004701', 'EFO_0002610', 'MONDO_0002050',
       'HP_0012378', 'EFO_0003888', 'MONDO_0004975', 'EFO_0005323',
       'EFO_0003888', 'EFO_0004216', 'HP_0012532', 'MONDO_0016158',
       'MONDO_0005301', 'EFO_0005611', 'EFO_0003768', 'EFO_0003929',
       'MONDO_0002009', 'EFO_0003843'], dtype=object), 'count': 42}","[ENSG00000103546,ENSG00000142319]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome and has 36 investigational indications. This drug has a black box warning from the FDA.
CHEMBL98,O=C(CCCCCCC(=O)Nc1ccccc1)NO,WAEXFXRVDQXREF-UHFFFAOYSA-N,Small molecule,False,VORINOSTAT,2006.0,4.0,,False,True,['Zolinza'],"['MK-0683' 'MK0683' 'NSC-701852' 'NSC-748799' 'NSC-759852'
 'Suberoylanilide hydroxamic acid' 'Vorinostat']","[('DailyMed', array(['vorinostat'], dtype=object)), ('PubChem', array(['104171411', '124893442', '144206158', '144207172', '170465180',
       '49645508', '50113029'], dtype=object)), ('Wikipedia', array(['Vorinostat'], dtype=object)), ('drugbank', array(['DB02546'], dtype=object)), ('chEBI', array(['45716'], dtype=object))]",,"{'rows': array(['EFO_1001951', 'MONDO_0004992', 'EFO_0002913', 'EFO_0000096',
       'EFO_0000691', 'MONDO_0008903', 'EFO_0000220', 'EFO_0000191',
       'EFO_0003828', 'EFO_0006352', 'EFO_1000026', 'MONDO_0004975',
       'MONDO_0015760', 'EFO_0000616', 'EFO_1001830', 'EFO_0004198',
       'EFO_0000574', 'EFO_0000621', 'EFO_1001110', 'MONDO_0002158',
       'EFO_0000641', 'EFO_0003833', 'MONDO_0003268', 'EFO_0007535',
       'MONDO_0007254', 'MONDO_0005090', 'EFO_0000309', 'MONDO_0011382',
       'EFO_0000365', 'EFO_0000565', 'EFO_0000222', 'MONDO_0019460',
       'EFO_0000764', 'EFO_0000224', 'EFO_1001380', 'MONDO_0008315',
       'EFO_0003060', 'MONDO_0001657', 'EFO_0005774', 'EFO_0000349',
       'EFO_0002429', 'EFO_0000180', 'EFO_0002939', 'EFO_0000211',
       'MONDO_0007576', 'EFO_0000198', 'EFO_0000519', 'EFO_1000785',
       'EFO_0003893', 'EFO_0000479', 'EFO_0000339', 'MONDO_0015277',
       'EFO_1001968', 'MONDO_0018364', 'EFO_0002618', 'EFO_0003869',
       'MONDO_0044926', 'EFO_1000657', 'EFO_0000183', 'EFO_0000702',
       'EFO_1001465', 'EFO_0002938', 'EFO_1001469', 'EFO_0004289',
       'MONDO_0018906', 'EFO_1000309', 'MONDO_0001879', 'EFO_0000756',
       'MONDO_0002087', 'EFO_0001378', 'EFO_0000588', 'EFO_0000681',
       'MONDO_0021063', 'MONDO_0008170', 'MONDO_0000873', 'EFO_0000095',
       'MONDO_0002691', 'EFO_0002501', 'EFO_0000673', 'MONDO_0001056',
       'EFO_0000384', 'EFO_0000770', 'EFO_0000403', 'EFO_0002499',
       'MONDO_0004986', 'EFO_0005952', 'EFO_1001051', 'EFO_0006861',
       'MONDO_0000870'], dtype=object), 'count': 89}","[ENSG00000094631,ENSG00000116478,ENSG00000196591,ENSG00000171720]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 85 investigational indications.
CHEMBL1113,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2,QWGDMFLQWFTERH-UHFFFAOYSA-N,Small molecule,True,AMOXAPINE,1980.0,4.0,,False,True,['Amoxapine' 'Asendin' 'Asendis' 'Defanyl'],"['Amoxapine' 'CL 67,772' 'CL 67772' 'CL-67,772' 'CL-67772' 'NSC-759559']","[('DailyMed', array(['amoxapine'], dtype=object)), ('PubChem', array(['104171096', '11110675', '11110676', '124879022', '124879024',
       '144203615', '144212669', '170465376', '26747067', '26751577',
       '50100159', '50104205', '50104206', '85230879', '855963',
       '90341240'], dtype=object)), ('Wikipedia', array(['Amoxapine'], dtype=object)), ('drugbank', array(['DB00543'], dtype=object)), ('chEBI', array(['2675'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000108576,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for major depressive disorder. This drug has a black box warning from the FDA.
CHEMBL1201570,,,Protein,False,ANAKINRA,2001.0,4.0,,False,True,['Kineret'],"['AMG-719' 'Alta-2530' 'Alta2530' 'Anakinra'
 'Interleukin-1 receptor antagonist anakinra' 'Osp-101']","[('DailyMed', array(['anakinra'], dtype=object)), ('DrugCentral', array(['5017'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kineret'],
      dtype=object)), ('Wikipedia', array(['Anakinra'], dtype=object))]",,"{'rows': array(['EFO_0009672', 'EFO_0000540', 'EFO_0004274', 'MONDO_0005301',
       'EFO_0004227', 'EFO_0009609', 'EFO_0000398', 'MONDO_0004979',
       'EFO_0000685', 'EFO_0004246', 'MONDO_0007254', 'EFO_0001378',
       'EFO_0002609', 'EFO_0007328', 'EFO_0003073', 'EFO_0007427',
       'EFO_1001806', 'EFO_0000694', 'EFO_0000764', 'EFO_0009507',
       'EFO_0000096', 'MONDO_0008315', 'EFO_1000637', 'MONDO_0019338',
       'EFO_0000660', 'MONDO_0043510', 'EFO_0001065', 'EFO_0003884',
       'EFO_0007135', 'MONDO_0100096', 'MONDO_0005178', 'EFO_0003843',
       'EFO_0000095', 'MONDO_0005147', 'EFO_1000657', 'MONDO_0011776',
       'EFO_0004238', 'EFO_1001209', 'EFO_1000668', 'EFO_0009536',
       'MONDO_0005149', 'EFO_0004540', 'EFO_0005669', 'EFO_0007323',
       'Orphanet_47045', 'EFO_0003144', 'EFO_0000400', 'HP_0001943',
       'MONDO_0004976', 'EFO_0000195', 'EFO_1000710', 'EFO_1001345',
       'EFO_0000544', 'MONDO_0018088', 'EFO_0008583', 'EFO_1001231',
       'EFO_0000616', 'MONDO_0018305', 'EFO_0001361', 'EFO_0002618',
       'EFO_0003106'], dtype=object), 'count': 61}",[ENSG00000115594],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 57 investigational indications.
CHEMBL1684,NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O,HDWIHXWEUNVBIY-UHFFFAOYSA-N,Small molecule,False,BENDROFLUMETHIAZIDE,1959.0,4.0,,False,True,"['Aprinox' 'Berkozide' 'Centyl' 'Naturetin-10' 'Naturetin-2.5'
 'Naturetin-5' 'Neo-bendromax 2.5' 'Neo-bendromax 5' 'Neo-naclex'
 'Urizide']","['Bendrofluazide' 'Bendroflumethiazide' 'Benzydroflumethiazide'
 'NSC-758229']","[('DailyMed', array(['bendroflumethiazide'], dtype=object)), ('PubChem', array(['124883448', '144203916', '170465156', '26747201', '56422088',
       '855628'], dtype=object)), ('Wikipedia', array(['Bendroflumethiazide'], dtype=object)), ('drugbank', array(['DB00436'], dtype=object)), ('chEBI', array(['3013'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0000537', 'EFO_0003144'], dtype=object), 'count': 3}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for cardiovascular disease and hypertension and has 1 investigational indication.
CHEMBL1743035,,,Antibody,False,LEBRIKIZUMAB,,3.0,,False,False,[],"['Lebrikizumab' 'MILR-1444A' 'MILR1444A' 'PRO-301444' 'PRO-301444 RG-3637'
 'PRO301444' 'RG-3637']",,,"{'rows': array(['EFO_0000768', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000274'],
      dtype=object), 'count': 4}",[ENSG00000169194],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL189,Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,PZRHRDRVRGEVNW-UHFFFAOYSA-N,Small molecule,False,MILRINONE,1987.0,4.0,,False,True,[],"['Milrila' 'Milrinone' 'NSC-760072' 'WIN 47,203-2' 'WIN-47203-2']","[('PubChem', array(['11111460', '11111461', '11114110', '11532967', '124880718',
       '144205666', '144214030', '170465221', '26757809', '49681694',
       '50104873', '90341667'], dtype=object)), ('Wikipedia', array(['Milrinone'], dtype=object)), ('drugbank', array(['DB00235'], dtype=object)), ('chEBI', array(['50693'], dtype=object))]",['CHEMBL1200977'],"{'rows': array(['MONDO_0005149', 'EFO_0002687', 'EFO_0000319', 'EFO_0000713',
       'EFO_0005207', 'EFO_0003144', 'EFO_0006834', 'EFO_1000994',
       'EFO_0003144', 'EFO_0009846', 'HP_0004308', 'HP_0030680'],
      dtype=object), 'count': 12}",[ENSG00000172572],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 3 approved and 9 investigational indications.
CHEMBL2103796,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1.Cl,GPMIHHFZKBVWAZ-LMMKTYIZSA-N,Small molecule,False,BERUBICIN HYDROCHLORIDE,,2.0,CHEMBL2110580,False,False,[],"['Berubicin hcl' 'Berubicin hydrochloride' 'RTA 744' 'RTA-744' 'WP-744'
 'WP744']",,,"{'rows': array(['EFO_0000519', 'MONDO_0100342', 'EFO_0005543', 'EFO_0000313'],
      dtype=object), 'count': 4}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL258805,COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2,QNUKRWAIZMBVCU-WCIBSUBMSA-N,Small molecule,False,SU-9516,,1.0,,False,False,[],['SU-9516' 'Su-9516' 'Su9516'],"[('PubChem', array(['124891674', '124891675', '26753623', '26753624', '29215168',
       '49674687', '90341527'], dtype=object)), ('drugbank', array(['DB03428'], dtype=object))]",,,[ENSG00000123374],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL279260,C[C@H](Cc1c[nH]c2c(OCC(=O)O)cccc12)NC[C@H](O)c1cccc(Cl)c1,FHEYFIGWYQJVDR-ACJLOTCBSA-N,Small molecule,False,RAFABEGRON,,2.0,,False,False,[],['AD-9677' 'Aj-9677' 'Rafabegron' 'TAK-677'],,,,[ENSG00000188778],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL304902,CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1,KAAZGXDPUNNEFN-UHFFFAOYSA-N,Small molecule,False,CLOTHIAPINE,,4.0,,False,True,[],['Clothiapine' 'Clotiapine' 'Entumin' 'HF-2159'],"[('PubChem', array(['144205332', '170465938', '26754613', '29216068'], dtype=object)), ('Wikipedia', array(['Clotiapine'], dtype=object)), ('drugbank', array(['DB13256'], dtype=object))]",,"{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}","[ENSG00000069696,ENSG00000135914,ENSG00000102468,ENSG00000147246,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for psychosis.
CHEMBL3137304,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](O)(C(F)(F)F)CC[C@@]21Cc1ccccc1,QJJBNCHSWFGXML-KEKPKEOLSA-N,Small molecule,False,DAGROCORAT,,2.0,,False,False,[],['Dagrocorat' 'PF-00251802' 'PF-0251802' 'PF-802'],"[('drugbank', array(['DB14676'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3183740,NC(=O)Cn1c(=O)cc(CCN2CCN(c3nccc4sccc34)CC2)c2ccc(F)cc21,JDLYOFUDIKMYBL-UHFFFAOYSA-N,Small molecule,False,TRELANSERIN,,2.0,,False,False,[],['SL-650472' 'SL65.0472' 'Sl650472' 'Trelanserin'],"[('PubChem', array(['144210557'], dtype=object))]",,,"[ENSG00000135312,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3617964,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1,QNQZWEGMKJBHEM-UHFFFAOYSA-N,Small molecule,False,ALVELESTAT,,2.0,,False,False,[],['AZD-9668' 'AZD9668' 'Alvelestat' 'Azd9668' 'MPH-966' 'MPH966' 'Mph966'],"[('drugbank', array(['DB11863'], dtype=object))]",,"{'rows': array(['MONDO_0044881', 'HP_0002110', 'EFO_0000341', 'MONDO_0009061',
       'MONDO_0100096'], dtype=object), 'count': 5}",[ENSG00000197561],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3833353,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,DTPWZYSUQQHRKD-VIUAGAKSSA-N,Protein,True,PRAMLINTIDE ACETATE,2005.0,4.0,CHEMBL2103758,False,True,['Symlin' 'Symlinpen'],"['AC0-137' 'AC0137' 'Pramlintide acetate' 'Pramlintide acetate anhydrous'
 'Pramlintide acetate hydrate' 'Tripro-amylin acetate'
 'Tripro-amylin acetate hydrate']",,,"{'rows': array(['EFO_0001073', 'MONDO_0005148', 'MONDO_0005147'], dtype=object), 'count': 3}","[ENSG00000004948,ENSG00000132329,ENSG00000131477,ENSG00000122679]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3989740,CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O,HALQELOKLVRWRI-VDBOFHIQSA-N,Small molecule,True,DOXYCYCLINE HYCLATE,1967.0,4.0,CHEMBL1433,False,True,"['Acticlate' 'Acticlate cap' 'Alodox' 'Atridox' 'Cyclodox' 'Demix 100'
 'Demix 50' 'Doryx' 'Doryx mpc' 'Doxatet' 'Doxy 100' 'Doxy 200'
 'Doxy-Caps' 'Doxy-lemmon' 'Doxychel hyclate' 'Doxycycline hyclate'
 'Doxylar' 'Lymepak' 'Nordox' 'Periostat' 'Ramysis' 'Vibra-tabs'
 'Vibramycin' 'Vibramycin 50' 'Vibramycin Hyclate' 'Vibramycin acne pack'
 'Vibramycin-d' 'Vibrox']","['Azudoxat' 'Clinofug' 'Diocimex' 'Doxicrisol' 'Doxycycline hyclate'
 'Doxycycline hydrochloride hemiethanolate hemihydrate'
 'Doxycycline hydrochloride hydrate' 'Doxycyclini hyclas' 'Doxyprex'
 'Duradoxal' 'Granudoxy' 'Mespafin' 'Monodoks' 'NSC-741421' 'Retens'
 'Ronaxan' 'Spanor' 'Tetraclean' 'Tetradox' 'Unacil' 'Vibraveineuse'
 'Vibravenos' 'Zadorin']","[('DailyMed', array(['doxycycline%20hyclate'], dtype=object))]",,"{'rows': array(['EFO_0001365', 'EFO_1001896', 'EFO_1000760', 'MONDO_0019180',
       'EFO_0000649', 'EFO_0003894', 'EFO_1001466', 'EFO_0007205',
       'EFO_1001898'], dtype=object), 'count': 9}","[ENSG00000196611,ENSG00000118113,ENSG00000137673,ENSG00000137745]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for acne and has 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL399510,CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,GIYAQDDTCWHPPL-UHFFFAOYSA-N,Small molecule,False,BROMOPRIDE,,3.0,,False,False,[],['Bromopride' 'Movipride' 'NSC-758391'],"[('PubChem', array(['104171315', '11112553', '144204094', '170466299', '56463076'],
      dtype=object)), ('Wikipedia', array(['Bromopride'], dtype=object)), ('drugbank', array(['DB09018'], dtype=object))]",,"{'rows': array(['EFO_0008533', 'EFO_0010282'], dtype=object), 'count': 2}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL406,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1,NDDAHWYSQHTHNT-UHFFFAOYSA-N,Small molecule,False,INDAPAMIDE,1983.0,4.0,,False,True,"['Cardide sr' 'Ethibide xl' 'Indapamide' 'Indaxa 2.5' 'Indipam xl' 'Lozol'
 'Mapemid xl' 'Natrilix' 'Natrilix sr' 'Nindaxa 2.5' 'Opumide 2.5'
 'Rawel xl' 'Tensaid xl' 'Varbim xl']","['Arifon' 'Bajaten' 'Damide' 'Flubest' 'Fludex' 'Fludin' 'Flupamid'
 'Indaflex' 'Indamide' 'Indamol' 'Indapamide' 'Ipamix' 'KYD-041' 'Lorvas'
 'NSC-757075' 'Natrix' 'Noranat' 'S-1520' 'SE-1520' 'Tandix' 'Tertensif'
 'Veroxil']","[('DailyMed', array(['indapamide'], dtype=object)), ('PubChem', array(['124883405', '144204326', '144206733', '144213004', '170465366',
       '26747199', '56422467', '855885'], dtype=object)), ('Wikipedia', array(['Indapamide'], dtype=object)), ('drugbank', array(['DB00808'], dtype=object)), ('chEBI', array(['5893'], dtype=object))]",,"{'rows': array(['EFO_0000668', 'MONDO_0005148', 'EFO_0000537', 'MONDO_0001134',
       'EFO_0003840', 'EFO_0000373', 'EFO_0000319'], dtype=object), 'count': 7}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 4 approved and 3 investigational indications.
CHEMBL426161,COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,WPOXAFXHRJYEIC-UHFFFAOYSA-N,Small molecule,False,AZM-475271,,2.0,,False,False,[],['Azm 475271' 'Azm-475271' 'M-475271'],,,,"[ENSG00000097007,ENSG00000197122]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297658,O=C(O)[C@@H]1CCCN1.OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,TUVGWWULBZIUBS-FVYIYGEMSA-N,Small molecule,False,IPRAGLIFLOZIN L-PROLINE,,3.0,,False,False,[],['Ipragliflozin l-proline'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4594304,Cn1cc(S(=O)(=O)[C@@](C)(F)C2CCN(C(=O)Nc3ccon3)CC2)c(C(F)F)n1,NREKKBAMVWQRES-MRXNPFEDSA-N,Small molecule,False,DANICAMTIV,,2.0,,False,False,[],['Danicamtiv' 'MYK-491' 'MYK491' 'Myk-491' 'SAR-440181' 'SAR440181'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANICAMTIV/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003144', 'EFO_0000407'], dtype=object), 'count': 2}","[ENSG00000092054,ENSG00000197616,ENSG00000078814,ENSG00000160808,ENSG00000111245,ENSG00000106631,ENSG00000198336]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL475251,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC,NHHQJBCNYHBUSI-UHFFFAOYSA-N,Small molecule,False,R-406,,2.0,,False,False,[],['R-406' 'R940406' 'Tamatinib'],"[('PubChem', array(['103904600', '137275829', '99460878'], dtype=object)), ('drugbank', array(['DB07159'], dtype=object))]",,,[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL525610,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,OGBMKVWORPGQRR-UMXFMPSGSA-N,Protein,True,TERIPARATIDE,2002.0,4.0,,False,True,['Bonsity' 'Forsteo' 'Forteo' 'Teriparatide sun'],"['(1-34)-human parathyroid hormone' '1-34-human pth'
 'Human parathyroid hormone 1-34' 'LY 333334' 'LY-333334' 'LY333334'
 'Pth (1-34)' 'Teriparatide' 'Teriparatide rdna' 'ZT-034']","[('DailyMed', array(['teriparatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/teriparatide-sun'],
      dtype=object))]",,"{'rows': array(['EFO_0003854', 'EFO_0003964', 'EFO_0003957', 'HP_0000938',
       'EFO_0009451', 'MONDO_0019019', 'EFO_0003931', 'EFO_0004616',
       'EFO_1001378', 'HP_0002901', 'HP_0003418', 'EFO_0003882'],
      dtype=object), 'count': 12}",[ENSG00000160801],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for postmenopausal osteoporosis and osteoporosis and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL61593,NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O,BOCUKUHCLICSIY-UHFFFAOYSA-N,Small molecule,False,CYCLOTHIAZIDE,1982.0,4.0,,False,True,['Anhydron' 'Fluidil'],['35483' 'Cyclothiazide' 'NSC-758431'],"[('PubChem', array(['144203675', '170465274', '26751850', '50104549', '50104550',
       '56424127', '85230990'], dtype=object)), ('Wikipedia', array(['Cyclothiazide'], dtype=object)), ('drugbank', array(['DB00606'], dtype=object)), ('chEBI', array(['31448'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease.
CHEMBL1200891,CN1CCCN=C1COC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl,WXAYTPABEADAAB-UHFFFAOYSA-N,Small molecule,False,OXYPHENCYCLIMINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1495,False,True,['Daricon'],"['NSC-528449' 'Oxiphencyclimine chloride' 'Oxyphencyclimine hcl'
 'Oxyphencyclimine hydrochloride']","[('PubChem', array(['144204969', '170465276', '26748867', '56422213', '855685'],
      dtype=object)), ('Wikipedia', array(['Oxyphencyclimine'], dtype=object))]",,,"[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201174,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O,GQPYTJVDPQTBQC-KLQYNRQASA-N,Small molecule,False,SITAGLIPTIN PHOSPHATE,2006.0,4.0,CHEMBL1422,False,True,['Janumet Xr' 'Januvia' 'Xelevia'],"['Glactiv' 'MK-0431' 'MK0431' 'ONO-5435' 'Sitagliptin monophosphate'
 'Sitagliptin monophosphate anhydrous'
 'Sitagliptin monophosphate monohydrate' 'Sitagliptin phosphate'
 'Sitagliptin phosphate anhydrous' 'Sitagliptin phosphate hydrate'
 'Sitagliptin phosphate monohydrate']","[('DailyMed', array(['sitagliptin%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xelevia'],
      dtype=object))]",,"{'rows': array(['EFO_0000612', 'MONDO_0005148', 'EFO_0000400', 'HP_0000083',
       'MONDO_0021187', 'EFO_0000712'], dtype=object), 'count': 6}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 2 investigational indications.
CHEMBL1201207,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,VQODGRNSFPNSQE-DVTGEIKXSA-N,Small molecule,False,BETAMETHASONE PHOSPHORIC ACID,1965.0,4.0,,False,True,[],['Betamethasone phosphate' 'Betamethasone phosphoric acid'],"[('drugbank', array(['DB14669'], dtype=object)), ('chEBI', array(['68603'], dtype=object))]",['CHEMBL1200762'],"{'rows': array(['MONDO_0005178', 'EFO_1000906', 'EFO_1001434', 'EFO_0000729',
       'EFO_1001097', 'EFO_1001909', 'EFO_0002950', 'HP_0003419'],
      dtype=object), 'count': 8}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for ulcerative colitis and has 7 investigational indications.
CHEMBL1201770,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-],IFGIYSGOEZJNBE-KNLJMPJLSA-N,Small molecule,False,METHYLNALTREXONE BROMIDE,2008.0,4.0,CHEMBL1186579,False,True,['Relistor'],"['MOA728' 'MRZ 2663BR' 'MRZ-2663BR' 'MRZ2663BR' 'Methylnaltrexone bromide'
 'Moa-728' 'N-methylnaltrexone bromide' 'Naltrexone methobromide'
 'Naltrexone methylbromide']","[('DailyMed', array(['methylnaltrexone%20bromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/relistor'],
      dtype=object))]",,"{'rows': array(['EFO_0002618', 'HP_0002019', 'EFO_0005611', 'MONDO_0004567'],
      dtype=object), 'count': 4}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and opioid dependence and has 2 investigational indications.
CHEMBL2062264,CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O,NHKOTKKHHYKARN-FVGYRXGTSA-N,Small molecule,False,PHENYLEPHRINE BITARTRATE,1973.0,4.0,CHEMBL1215,False,True,[],"['Phenylephrine acid tartrate' 'Phenylephrine bitartrate'
 'Phenylephrine hydrogen tartrate']",,,"{'rows': array(['HP_0012735', 'HP_0001742', 'EFO_0007214', 'HP_0002315'],
      dtype=object), 'count': 4}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved indications.
CHEMBL22242,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC,GUJRSXAPGDDABA-NSHDSACASA-N,Small molecule,False,REMOXIPRIDE,1990.0,4.0,,True,True,[],['A 33547' 'A-33547' 'FLA 731' 'FLA-731(-)' 'Remoxipride' 'Roxiam'],"[('PubChem', array(['11112836', '11113786', '144204485', '170466425', '26751966'],
      dtype=object)), ('Wikipedia', array(['Remoxipride'], dtype=object)), ('drugbank', array(['DB00409'], dtype=object))]",['CHEMBL1899328' 'CHEMBL3989556'],"{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for psychosis. It was withdrawn in at least one region.
CHEMBL3544963,,,Small molecule,False,DS-3078A,,1.0,,False,False,[],['Ds-3078a'],,,"{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545065,CN(C)C(C(=O)Nc1ccc2c(=O)[nH]ccc2c1)c1ccsc1,VDYRZXYYQMMFJW-UHFFFAOYSA-N,Small molecule,False,VEROSUDIL,,2.0,,False,False,[],['AR-12286' 'AR-12286 FREE BASE' 'Ar-12286' 'Verosudil'],,['CHEMBL3545124'],"{'rows': array(['MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 2}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3989971,CC[C@H]1C[C@@H](C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2NC(C)=O)[C@@H]1O[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O,LYSYOXNOOPBOSC-NGSKMYNLSA-N,Small molecule,False,UPROLESELAN,,3.0,,False,False,[],['GMI-1271' 'GMI-1271 FREE ACID' 'Uproleselan'],"[('drugbank', array(['DB14829'], dtype=object))]",['CHEMBL3989975'],"{'rows': array(['EFO_0003907', 'EFO_0001378', 'EFO_0000222', 'MONDO_0100096'],
      dtype=object), 'count': 4}",[ENSG00000007908],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL418995,O=C(O)CCCCCCNC1c2ccccc2CCc2ccccc21,ONNOFKFOZAJDHT-UHFFFAOYSA-N,Small molecule,False,AMINEPTINE,,4.0,,True,True,[],['Amineptin' 'Amineptine' 'Dea no. 1219'],"[('PubChem', array(['144206864'], dtype=object)), ('Wikipedia', array(['Amineptine'], dtype=object)), ('drugbank', array(['DB04836'], dtype=object)), ('chEBI', array(['32499'], dtype=object))]",['CHEMBL1697712'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000149295,ENSG00000184845]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder. It was withdrawn in at least one region.
CHEMBL4297564,,,Oligonucleotide,False,COBITOLIMOD,,3.0,,False,False,[],['Cobitolimod'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/COBITOLIMOD/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}",[ENSG00000239732],Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297911,,,Antibody,False,SPESOLIMAB,2022.0,4.0,,False,True,['Spevigo'],"['BI 655130' 'BI-655130' 'BI655130' 'Bi655130' 'Spesolimab'
 'Spesolimab sbzo']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SPESOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0015597', 'MP_0001845', 'EFO_0000274', 'EFO_1000710',
       'MONDO_0009735', 'EFO_0000540', 'EFO_0000676', 'EFO_0000729',
       'EFO_0000384'], dtype=object), 'count': 9}","[ENSG00000115598,ENSG00000196083]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 6 investigational indications.
CHEMBL451887,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,BLMPQMFVWMYDKT-NZTKNTHTSA-N,Protein,False,CARFILZOMIB,2009.0,4.0,,False,True,['Kyprolis'],['Carfilzomib' 'NSC-758252' 'PR-171'],"[('DailyMed', array(['carfilzomib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis'],
      dtype=object)), ('PubChem', array(['124955654', '144206630', '170466878'], dtype=object)), ('drugbank', array(['DB08889'], dtype=object)), ('chEBI', array(['65347'], dtype=object))]",,"{'rows': array(['EFO_0009441', 'MONDO_0004992', 'MONDO_0002120', 'EFO_1000785',
       'MONDO_0018906', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000574',
       'EFO_0000616', 'EFO_0000095', 'MONDO_0002367', 'EFO_0000220',
       'EFO_0000702', 'EFO_0000096', 'EFO_0005952', 'EFO_1001469',
       'EFO_0000183', 'EFO_0000222', 'EFO_0006475', 'EFO_0006738',
       'EFO_0000211', 'MONDO_0001023', 'MONDO_0017816', 'EFO_0000565',
       'MONDO_0020547', 'EFO_0000403', 'EFO_1001875', 'EFO_1001051'],
      dtype=object), 'count': 28}","[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 25 investigational indications.
CHEMBL4594446,O=C(c1cc(Cl)c(O)c(Cl)c1)N1CS(=O)(=O)c2ccccc21,VOFLAIHEELWYGO-UHFFFAOYSA-N,Small molecule,False,DOTINURAD,,3.0,,False,False,[],['Dotinurad' 'FYU-981' 'Fyu-981'],,,"{'rows': array(['EFO_0009104', 'HP_0000083', 'EFO_0004274'], dtype=object), 'count': 3}",[ENSG00000197891],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4594603,,,Unknown,False,LONOCTOCOG ALFA,2017.0,4.0,,False,True,['Afstyla'],['Afstyla' 'CSL-627' 'CSL627' 'Lonoctocog alfa' 'Rviii-singlechain'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/afstyla'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Unknown drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia a.
CHEMBL4594608,,,Antibody,False,AXATILIMAB,,2.0,,False,False,[],['Axatilimab' 'SNDX-6352' 'Sndx-6352' 'UCB-6352' 'UCB6352'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AXATILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005221', 'MONDO_0020547', 'EFO_0009709', 'EFO_0009448',
       'EFO_0005537', 'EFO_0000183', 'EFO_0000616'], dtype=object), 'count': 7}",[ENSG00000182578],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL5095025,Cn1/c(=N\C#N)n(-c2ccc(C(C)(C)C#N)nc2)c2c3cc(-c4cnc(N)c(C(F)(F)F)c4)ccc3ncc21,VJLRLTSXTLICIR-AUGOTPMTSA-N,Small molecule,False,PANULISIB,,2.0,,False,False,[],['P-7170' 'P7170' 'Panulisib'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000139567,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL515271,Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1,TVKGTSHBQZEFEE-UHFFFAOYSA-N,Small molecule,False,R-112,,2.0,,False,False,[],['R-112' 'R-921218'],,,,[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1201048,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)[C@H](C)C[C@]4(C)[C@H]3CC[C@]12C,NOTIQUSPUUHHEH-UXOVVSIBSA-N,Small molecule,False,DROMOSTANOLONE PROPIONATE,1982.0,4.0,,False,True,['Drolban' 'Masteril'],"['32379' 'Dromostanolone propionate' 'Drostanolone propionate' 'Masterid'
 'Masteron' 'NSC-12198' 'NSC-1298' 'Permastril']","[('drugbank', array(['DB14655'], dtype=object)), ('chEBI', array(['31523'], dtype=object))]",,,[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201217,CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1,BZEWSEKUUPWQDQ-UHFFFAOYSA-N,Small molecule,False,DYCLONINE,1982.0,4.0,,False,True,[],['Dyclonine'],"[('PubChem', array(['11112403', '50100427'], dtype=object)), ('Wikipedia', array(['Dyclonine'], dtype=object)), ('drugbank', array(['DB00645'], dtype=object)), ('chEBI', array(['4724'], dtype=object))]",['CHEMBL1200478'],,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1482,CC(C[N+](C)(C)C)OC(N)=O,NZUPCNDJBJXXRF-UHFFFAOYSA-O,Small molecule,False,BETHANECHOL,1948.0,4.0,,False,True,[],['Bethanechol'],"[('PubChem', array(['124879661', '26756574', '90341349'], dtype=object)), ('Wikipedia', array(['Bethanechol'], dtype=object)), ('drugbank', array(['DB01019'], dtype=object)), ('chEBI', array(['3084'], dtype=object))]",['CHEMBL1768'],"{'rows': array(['EFO_0004232', 'HP_0000016', 'EFO_0002618', 'MONDO_0005148'],
      dtype=object), 'count': 4}","[ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for urinary retention and has 3 investigational indications.
CHEMBL207197,NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(N2Cc3ccccc3NC2=O)CC1)C(=O)N1CCN(c2ccncc2)CC1,ITIXDWVDFFXNEG-JHOUSYSJSA-N,Small molecule,False,OLCEGEPANT,,2.0,,False,False,[],"['BIBN 4096 BS' 'BIBN-4096 BS' 'BIBN-4096BS' 'Bibn 4096 bs' 'Bibn-4096bs'
 'Olcegepant']","[('drugbank', array(['DB04869'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107815,CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O.OCCNCCO,RHWRWEUCEXUUAV-ZSESPEEFSA-N,Small molecule,False,TREPROSTINIL DIOLAMINE,2013.0,4.0,CHEMBL1237119,False,True,['Orenitram' 'Ut-15c'],"['Treprostinil diethanolamine' 'Treprostinil diolamin'
 'Treprostinil diolamine' 'UT-15C']","[('DailyMed', array(['treprostinil%20diolamine'], dtype=object))]",,"{'rows': array(['EFO_0000717', 'EFO_0001361'], dtype=object), 'count': 2}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 2 investigational indications.
CHEMBL2403108,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,VERWOWGGCGHDQE-UHFFFAOYSA-N,Small molecule,False,CERITINIB,2014.0,4.0,,False,True,['Zykadia'],"['Ceritinib' 'Ceritinib[mi]' 'LDK-378' 'LDK378' 'NVP-LDK-378-NX'
 'NVP-LDK378-NX']","[('DailyMed', array(['ceritinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia'],
      dtype=object)), ('drugbank', array(['DB09063'], dtype=object)), ('chEBI', array(['78432'], dtype=object))]",['CHEMBL4476089' 'CHEMBL4468931' 'CHEMBL4542506'],"{'rows': array(['EFO_0000756', 'EFO_0003032', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000519', 'EFO_0000389', 'EFO_1001968', 'EFO_0001421',
       'MONDO_0015798', 'EFO_0000621', 'EFO_0005221', 'MONDO_0002108',
       'EFO_0000616'], dtype=object), 'count': 13}","[ENSG00000171094,ENSG00000181163,ENSG00000143924]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 10 investigational indications.
CHEMBL253969,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1,HXHAJRMTJXHJJZ-UHFFFAOYSA-N,Small molecule,False,OSI-632,,2.0,,False,False,[],"['CP-547,632' 'CP-547632' 'CP-632' 'Cp-547,632' 'OSI-632' 'Osi-632'
 'PAN 90806' 'PAN-90806' 'PAN90806']","[('PubChem', array(['103905622', '137275944'], dtype=object)), ('drugbank', array(['DB12962'], dtype=object))]",,"{'rows': array(['MONDO_0021117', 'MONDO_0002158', 'EFO_0003770', 'EFO_0001365',
       'MONDO_0008170', 'MONDO_0002087'], dtype=object), 'count': 6}",[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL306280,CC[C@@]1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(F)c(F)cc3nc2-1,LFQCJSBXBZRMTN-OAQYLSRUSA-N,Small molecule,False,DIFLOMOTECAN,,2.0,,False,False,[],['Diflomotecan'],,,"{'rows': array(['EFO_0000702'], dtype=object), 'count': 1}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3137336,Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl,AXTAPYRUEKNRBA-JTQLQIEISA-N,Small molecule,False,UPROSERTIB,,2.0,,False,False,[],"['Akt inhibitor gsk-2141795' 'Akt inhibitor gsk2141795' 'GSK-2141795C'
 'GSK2141795' 'GSK2141795C' 'Gsk-2141795' 'Uprosertib']","[('drugbank', array(['DB11969'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_0001378', 'EFO_0000756', 'EFO_0000616',
       'MONDO_0002974', 'MONDO_0004992', 'EFO_0005537'], dtype=object), 'count': 7}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL3545243,,,Small molecule,False,AS-703988,,1.0,,False,False,[],['As-703988' 'MSC-2015103B'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3589904,COc1ccc(Cl)c(-c2ccc(NC(=O)c3ccnn3C)nc2N)c1,ZRJGMDIPCQOGNI-UHFFFAOYSA-N,Small molecule,False,PF-04531083,,2.0,,False,False,[],['PF-4531083' 'Pf-04531083'],"[('drugbank', array(['DB12468'], dtype=object))]",,"{'rows': array(['HP_0012532', 'EFO_0010072'], dtype=object), 'count': 2}",[ENSG00000185313],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3707250,,,Small molecule,False,CP-601927,,2.0,,False,False,[],"['CP-601,927' 'Cp-601927']",,,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707324,,,Antibody,False,UTOMILUMAB,,3.0,,False,False,[],['PF-05082566' 'PF-5082566' 'Utomilumab'],,,"{'rows': array(['EFO_0000403', 'MONDO_0018906', 'EFO_0000616', 'MONDO_0004992',
       'EFO_1000294', 'EFO_0001075', 'EFO_0000096', 'EFO_0005537',
       'EFO_0000365', 'EFO_0000196', 'MONDO_0007254'], dtype=object), 'count': 11}",[ENSG00000049249],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL3990044,,,Antibody,False,RELATLIMAB,2022.0,4.0,,False,True,[],['BMS-986016' 'Relatlimab' 'Relatlimab rmbw' 'Relatlimab-rmbw'],,,"{'rows': array(['MONDO_0008978', 'MONDO_0007576', 'EFO_1001950', 'EFO_0000756',
       'EFO_0000403', 'EFO_1001465', 'EFO_0000181', 'MONDO_0001056',
       'EFO_0000574', 'MONDO_0018906', 'EFO_0003060', 'MONDO_0004992',
       'EFO_1001951', 'EFO_0000222', 'EFO_1001968', 'MONDO_0044881',
       'EFO_0000519', 'EFO_0004142', 'EFO_0000616', 'EFO_0000681',
       'EFO_0000707', 'EFO_0002617', 'EFO_0000365', 'EFO_0003016',
       'EFO_0001378', 'EFO_0000182', 'EFO_0000389', 'EFO_0004193'],
      dtype=object), 'count': 28}",[ENSG00000089692],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 28 investigational indications.
CHEMBL476323,Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1,DDDZBLNULGDPGA-UHFFFAOYSA-N,Small molecule,False,MK-0249,,2.0,,False,False,[],['MK-0249' 'MK0249' 'Mk-0249'],"[('drugbank', array(['DB11910'], dtype=object))]",,"{'rows': array(['EFO_0003888', 'HP_0000726', 'EFO_0003918', 'MONDO_0005090',
       'MONDO_0004975'], dtype=object), 'count': 5}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4871106,NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(Cl)c(C(F)(F)F)c3)ncnc12,HXAUJHZZPCBFPN-QGZVFWFLSA-N,Small molecule,False,MSC-2363318A,,1.0,,False,False,[],['M-2698' 'M2698' 'MSC-2363318A' 'MSC2363318A' 'Msc-2363318a'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000175634,ENSG00000108443,ENSG00000142208,ENSG00000117020]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL6995,CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1,DURULFYMVIFBIR-UHFFFAOYSA-N,Small molecule,False,PRACTOLOL,,4.0,,False,True,['Eraldin'],"['AY-21,011' 'AY-21011' 'Dalzic' 'I.C.I. 50,172' 'I.C.I.-50,172'
 'ICI-50172' 'Practolol'
 '[3-(4-Acetylamino-Phenoxy)-2-Hydroxy-Propyl]-Isopropyl-Ammonium']","[('PubChem', array(['144204479', '170466619', '56463034'], dtype=object)), ('Wikipedia', array(['Practolol'], dtype=object)), ('drugbank', array(['DB01297'], dtype=object)), ('chEBI', array(['258351'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease.
CHEMBL1193948,CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2,RDJQCOBTKKAQAH-FPOVZHCZSA-N,Small molecule,False,AMIBEGRON,,3.0,,False,False,[],['Amibegron' 'SR-58611' 'SR58611'],"[('drugbank', array(['DB05395'], dtype=object))]",['CHEMBL545437'],"{'rows': array(['EFO_0005230', 'MONDO_0002050', 'MONDO_0002009'], dtype=object), 'count': 3}",[ENSG00000188778],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1200681,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],LBFBRXGCXUHRJY-HKHDRNBDSA-M,Small molecule,True,MONTELUKAST SODIUM,1998.0,4.0,CHEMBL787,False,True,['Montelukast sodium' 'Singulair'],"['MK-476' 'Montelukast (as sodium)' 'Montelukast monosodium salt'
 'Montelukast sodium' 'NSC-759107']","[('DailyMed', array(['montelukast%20sodium'], dtype=object)), ('PubChem', array(['144205750', '170465230', '56320471'], dtype=object)), ('chEBI', array(['6993'], dtype=object))]",,"{'rows': array(['HP_0040187', 'EFO_0005854', 'EFO_0007183', 'EFO_0003956',
       'HP_0011950', 'EFO_1001417', 'EFO_0000341', 'EFO_0004232',
       'EFO_0008521', 'MONDO_0004979', 'HP_0100806'], dtype=object), 'count': 11}",[ENSG00000173198],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1287935,CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1,VKHVAUKFLBBZFJ-SFHVURJKSA-N,Small molecule,False,VERUCERFONT,,2.0,,False,False,[],"['GSK-561,679' 'GSK-561679' 'GSK-561679A' 'GSK561679' 'GSK561679A'
 'NBI-77860' 'Verucerfont']","[('drugbank', array(['DB12512'], dtype=object))]",,"{'rows': array(['MONDO_0007079', 'MONDO_0018479', 'EFO_0000555', 'EFO_0001358',
       'EFO_1001917', 'MONDO_0002009'], dtype=object), 'count': 6}",[ENSG00000120088],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL1393,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12,LXMSZDCAJNLERA-ZHYRCANASA-N,Small molecule,True,SPIRONOLACTONE,1960.0,4.0,,False,True,"['Abbolactone' 'Aldactone' 'Carospir' 'Diatensec' 'Gx spironol'
 'Laractone' 'Spiretic' 'Spiroctan 100' 'Spiroctan 25' 'Spiroctan 50'
 'Spironolactone' 'Spironolactone ceva' 'Spirospare 100' 'Spirospare 25']","['NSC-150399' 'SC-9420' 'Spironolactone' 'Spironolactone ceva'
 'Spironolactonum' 'Verospirone']","[('DailyMed', array(['spironolactone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/spironolactone-ceva'],
      dtype=object)), ('PubChem', array(['144206598', '144212471', '26757816', '47193741'], dtype=object)), ('Wikipedia', array(['Spironolactone'], dtype=object)), ('drugbank', array(['DB00421'], dtype=object)), ('chEBI', array(['9241'], dtype=object))]",,"{'rows': array(['HP_0001397', 'EFO_0000401', 'EFO_0000537', 'MONDO_0010679',
       'EFO_0003894', 'EFO_0000400', 'EFO_0000275', 'EFO_1000899',
       'EFO_0008586', 'EFO_0000319', 'EFO_0001422', 'EFO_0000373',
       'EFO_0001361', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000266',
       'HP_0001919', 'EFO_0000668', 'EFO_0001365', 'EFO_1001249',
       'MONDO_0007079', 'EFO_0000612', 'EFO_0000621', 'EFO_0000222',
       'EFO_0004255', 'EFO_0000685', 'EFO_0008585', 'EFO_0003144',
       'Orphanet_247', 'EFO_0000318', 'MONDO_0001134', 'EFO_0003884',
       'MONDO_0000088', 'EFO_0000694', 'MONDO_0100096', 'EFO_0003963',
       'HP_0012424', 'EFO_0005669', 'EFO_0000660', 'EFO_1001496'],
      dtype=object), 'count': 40}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 8 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1510,CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,PWVXXGRKLHYWKM-LJQANCHMSA-N,Small molecule,False,ELETRIPTAN,2002.0,4.0,,False,True,['Relpax'],"['Eletriptan' 'UK-116,044' 'UK-116,044-04 FREE BASE'
 'UK-116,044-04 [AS HYDROBROMIDE)' 'UK-116044' 'UK-116044-04'
 'UK-116044-04 FREE BASE']","[('PubChem', array(['144206290', '170465317', '50125841'], dtype=object)), ('Wikipedia', array(['Eletriptan'], dtype=object)), ('drugbank', array(['DB00216'], dtype=object)), ('chEBI', array(['50922'], dtype=object))]",['CHEMBL1201003'],"{'rows': array(['MONDO_0005475', 'MONDO_0100431', 'MONDO_0005277', 'MONDO_0005277'],
      dtype=object), 'count': 4}","[ENSG00000135312,ENSG00000179546,ENSG00000179097]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for migraine disorder and has 2 investigational indications.
CHEMBL1767407,Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1.[Na+].[Na+].[Na+].[Na+],PASYJVRFGUDDEW-WMUGRWSXSA-J,Small molecule,False,DENUFOSOL TETRASODIUM,,3.0,CHEMBL507282,False,False,[],"['Denufosol tetrasodium' 'Denufosol tetrasodium salt' 'INS-37217'
 'INS37217']",,,"{'rows': array(['EFO_0005773', 'MONDO_0009061', 'MONDO_0003005', 'EFO_1001417'],
      dtype=object), 'count': 4}",[ENSG00000175591],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL189963,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,AHJRHEGDXFFMBM-UHFFFAOYSA-N,Small molecule,False,PALBOCICLIB,2015.0,4.0,,False,True,['Ibrance'],['PD-0332991' 'Palbociclib'],"[('DailyMed', array(['palbociclib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance'],
      dtype=object)), ('PubChem', array(['103905660', '103905661', '137275973'], dtype=object)), ('drugbank', array(['DB09073'], dtype=object)), ('chEBI', array(['85993'], dtype=object))]",['CHEMBL2364621' 'CHEMBL3962672'],"{'rows': array(['EFO_0008528', 'MONDO_0008170', 'EFO_0003060', 'EFO_1001950',
       'EFO_0006318', 'EFO_0001378', 'EFO_0001075', 'EFO_0000349',
       'EFO_0000569', 'EFO_0000616', 'EFO_0000182', 'MONDO_0007254',
       'EFO_0005952', 'MONDO_0008978', 'EFO_0000574', 'EFO_1000294',
       'MONDO_0008315', 'EFO_0000228', 'EFO_0000632', 'EFO_0002626',
       'EFO_1000251', 'EFO_0004252', 'MONDO_0005184', 'EFO_0002618',
       'EFO_1001469', 'EFO_0000707', 'EFO_0000305', 'EFO_0000220',
       'EFO_0000222', 'EFO_0000174', 'EFO_0003085', 'MONDO_0004992',
       'EFO_1000045', 'EFO_0000630', 'Orphanet_145', 'EFO_0000637',
       'EFO_0000181', 'MONDO_0011962', 'EFO_0003869', 'EFO_0000616',
       'MONDO_0100096', 'EFO_0000708', 'EFO_0005922', 'EFO_0003086',
       'EFO_0000519', 'EFO_1001512', 'EFO_0006859', 'EFO_0000681',
       'EFO_1001968', 'MONDO_0008903', 'EFO_0000756'], dtype=object), 'count': 51}","[ENSG00000110092,ENSG00000105810,ENSG00000135446]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 45 investigational indications.
CHEMBL2029988,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC,DKNUPRMJNUQNHR-UHFFFAOYSA-N,Small molecule,False,CEP-32496,,2.0,,False,False,[],"['AB-024' 'AC-013773' 'Agerafenib' 'CEP-32496' 'Cep-32496' 'RXDX-105'
 'Rxdx 105']","[('drugbank', array(['DB15068'], dtype=object))]",['CHEMBL3309923'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000165731,ENSG00000157764,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2105748,COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1.O=C(O)CCC(=O)O,QZRSNVSQLGRAID-UHFFFAOYSA-N,Small molecule,False,PRUCALOPRIDE SUCCINATE,2009.0,4.0,CHEMBL117287,False,True,['Motegrity' 'Resolor'],['Prucalopride (as succinate)' 'Prucalopride succinate' 'R-108512'],"[('DailyMed', array(['prucalopride%20succinate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/resolor'],
      dtype=object))]",,"{'rows': array(['MONDO_0002203', 'HP_0002019'], dtype=object), 'count': 2}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for constipation disorder and constipation.
CHEMBL2108583,,,Protein,False,CINTREDEKIN BESUDOTOX,,3.0,,False,False,[],['Cintredekin besudotox' 'IL-13-PE38' 'IL13-PE38' 'IL13-PE38QQR'],,,"{'rows': array(['EFO_0003833', 'EFO_0002501', 'EFO_1000158', 'EFO_0000519',
       'EFO_0000630', 'EFO_0002499', 'MONDO_0100342', 'EFO_0005543'],
      dtype=object), 'count': 8}","[ENSG00000077238,ENSG00000131724,ENSG00000123496]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL2109573,,,Antibody,False,GSK-249320,,2.0,,False,False,[],['GSK-249320' 'Gsk-249320'],,,"{'rows': array(['EFO_0000712'], dtype=object), 'count': 1}",[ENSG00000105695],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL227529,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O.O=C(O)c1ccccc1,KEJICOXJTRHYAK-XFULWGLBSA-N,Small molecule,False,ALOGLIPTIN BENZOATE,2013.0,4.0,CHEMBL376359,False,True,['Nesina' 'Vipidia'],['Alogliptin (as benzoate)' 'Alogliptin benzoate' 'SYR 322' 'SYR-322'],"[('DailyMed', array(['alogliptin%20benzoate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia'],
      dtype=object)), ('chEBI', array(['72324'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for type 2 diabetes mellitus.
CHEMBL257978,Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O,FOYWMEJSRSBQGB-UHFFFAOYSA-N,Small molecule,False,DABUZALGRON,,2.0,,False,False,[],['Dabuzalgron' 'Ro 115-1240' 'Ro-115-1240'],,['CHEMBL2107325'],,[ENSG00000120907],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL314437,CCC1(c2cccc(O)c2)CCCCN(C)C1,JLICHNCFTLFZJN-UHFFFAOYSA-N,Small molecule,False,MEPTAZINOL,,4.0,,False,True,[],['IL-22811' 'Meptazinol'],"[('Wikipedia', array(['Meptazinol'], dtype=object)), ('drugbank', array(['DB13478'], dtype=object))]",['CHEMBL1477274'],"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV and is indicated for pain.
CHEMBL3707446,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](NC(=O)c3cc(=O)[nH]c(=O)[nH]3)C[C@@H](C(=O)NCCNC(=O)COCCOCC(=O)Nc3cc(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(S(=O)(=O)O)c34)C[C@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2OC(=O)c2ccccc2)[C@@H](O)[C@H](O)[C@@H]1O,VXBNTHRZPJLRSS-PTCSXESPSA-N,Small molecule,False,RIVIPANSEL,,3.0,,False,False,[],['GMI-1070' 'PF-06460031' 'Rivipansel'],"[('drugbank', array(['DB12778'], dtype=object))]",['CHEMBL3833316'],"{'rows': array(['EFO_0001421', 'MONDO_0011382', 'MONDO_0011382', 'EFO_0003086'],
      dtype=object), 'count': 4}","[ENSG00000007908,ENSG00000188404,ENSG00000174175]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3989677,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O,IUAXSWPNEQYKDR-GXTZACRKSA-N,Small molecule,True,HYDROCODONE BITARTRATE,1943.0,4.0,CHEMBL1457,False,True,['Hysingla' 'Hysingla er' 'Vantrela er' 'Zohydro er'],"['CEP-33237' 'Dihydrocodeinone bitartrate' 'Hycodan'
 'Hydrocodone bitartrate' 'Hydrocodone bitartrate cii'
 'Hydrocodone bitartrate hemipentahydrate' 'Hydrocodone tartrate'
 'Vantrela' 'Zohydro']","[('DailyMed', array(['hydrocodone%20bitartrate'], dtype=object))]",,"{'rows': array(['EFO_1001250', 'EFO_0003843', 'EFO_0001421', 'EFO_0003890',
       'EFO_0005762', 'EFO_0003086', 'HP_0012532', 'MONDO_0005178',
       'EFO_0000546', 'HP_0003419'], dtype=object), 'count': 10}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and is indicated for pain and drug dependence and has 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3989873,CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4ccc(I)cc4)ncnc32)[C@H](O)[C@@H]1O,JTZRECOPNKCRTE-MOROJQBDSA-N,Small molecule,False,PICLIDENOSON,,3.0,,False,False,[],['ALB-7208' 'CF-101' 'CF101' 'Cf101' 'IB-MECA' 'Piclidenoson'],,,"{'rows': array(['EFO_0004616', 'EFO_1000906', 'EFO_0000685', 'EFO_1000986',
       'EFO_0000676', 'MONDO_0005041', 'MONDO_0100096', 'EFO_1001069',
       'EFO_1001119'], dtype=object), 'count': 9}",[ENSG00000282608],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL41194,CCCc1nc2c(n1Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CCCC2,KCTFTBCZZUBAKN-UHFFFAOYSA-N,Small molecule,False,PRATOSARTAN,,2.0,,False,False,[],['DA-727' 'DA727' 'KT3-671' 'Kt-3671' 'Pratosartan'],"[('chEBI', array(['32041'], dtype=object))]",,,"[ENSG00000197901,ENSG00000144891,ENSG00000197891,ENSG00000149452]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4298185,,,Protein,False,LONAPEGSOMATROPIN,2021.0,4.0,,False,True,"['Skytrofa' 'Skytrofa (previously lonapegsomatropin ascendis pharma)'
 'Stem-stat ortho']","['ACP-011' 'Lonapegsomatropin' 'Lonapegsomatropin tcgd' 'TRANSCONPEG-HGH'
 'TransConPEG hGh' 'rhGH-PEG']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa-previously-lonapegsomatropin-ascendis-pharma'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LONAPEGSOMATROPIN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0019499', 'EFO_1001109', 'MONDO_0005178'], dtype=object), 'count': 3}",[ENSG00000112964],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pituitary dwarfism and has 2 investigational indications.
CHEMBL444929,CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O,UIRKNQLZZXALBI-MSVGPLKSSA-N,Small molecule,False,SQUALAMINE,,3.0,,False,False,[],['Squalamine'],"[('Wikipedia', array(['Squalamine'], dtype=object)), ('drugbank', array(['DB06461'], dtype=object)), ('chEBI', array(['80765'], dtype=object))]",['CHEMBL3989689' 'CHEMBL2386601'],"{'rows': array(['MONDO_0008315', 'MONDO_0008170', 'EFO_0009606', 'EFO_0001365',
       'EFO_0003770'], dtype=object), 'count': 5}",[ENSG00000066230],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4594549,,,Antibody,False,PIMURUTAMAB,,2.0,,False,False,[],['HLX-07' 'HLX07' 'Hlx07' 'Pimurutamab'],,,"{'rows': array(['EFO_1001951', 'EFO_0005922', 'EFO_0003060', 'EFO_0000182',
       'EFO_0004252', 'EFO_0000616', 'EFO_0000702', 'EFO_0000181'],
      dtype=object), 'count': 8}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL4650473,,,Unknown,False,IBI-939,,1.0,,False,False,[],['IBI-939' 'IBI939' 'Ibi 939' 'Ibi-939' 'Ibi939' 'Tamgiblimab'],,,"{'rows': array(['MONDO_0008903', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000181847],Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL48361,Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,YBSJFWOBGCMAKL-UHFFFAOYSA-N,Small molecule,False,DABIGATRAN,,3.0,,False,False,['Pradaxa'],"['BIBR 953 ZW' 'BIBR-953' 'BIBR-953-ZW' 'Dabigatran'
 'Pradaxa (dabigatran)']","[('PubChem', array(['174006835'], dtype=object)), ('Wikipedia', array(['Dabigatran'], dtype=object)), ('drugbank', array(['DB14726'], dtype=object)), ('chEBI', array(['70752'], dtype=object))]",,"{'rows': array(['EFO_0000275', 'EFO_0000712', 'Orphanet_136', 'EFO_0000546',
       'EFO_1001413', 'EFO_0010680', 'HP_0002140', 'HP_0001907',
       'EFO_0004286', 'HP_0000083', 'MP_0001914'], dtype=object), 'count': 11}",[ENSG00000180210],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL514800,CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,IMOZEMNVLZVGJZ-QGZVFWFLSA-N,Small molecule,False,APREMILAST,2014.0,4.0,,False,True,['Otezla'],['Apremilast' 'CC-10004' 'CC10004'],"[('DailyMed', array(['apremilast'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/otezla'],
      dtype=object)), ('drugbank', array(['DB05676'], dtype=object)), ('chEBI', array(['78540'], dtype=object))]",,"{'rows': array(['MONDO_0015597', 'EFO_0003894', 'EFO_1000710', 'MONDO_0002406',
       'HP_0000964', 'MONDO_0019558', 'MONDO_0007079', 'EFO_0000729',
       'EFO_0000685', 'EFO_0003106', 'MONDO_0100096', 'EFO_0003898',
       'EFO_1000760', 'EFO_0003778', 'EFO_0007328', 'EFO_1000726',
       'EFO_0003830', 'EFO_1000668', 'HP_0000155', 'EFO_1000694',
       'EFO_0000676', 'EFO_0003780', 'EFO_1001231', 'EFO_0008517',
       'EFO_0004208', 'EFO_0000540', 'EFO_0000274', 'EFO_0000398',
       'EFO_0004274'], dtype=object), 'count': 29}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 24 investigational indications.
CHEMBL559180,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl,QVPSGVSNYPRFAS-UHFFFAOYSA-N,Small molecule,False,ISOXSUPRINE HYDROCHLORIDE,,4.0,CHEMBL1197051,False,True,['Defencin' 'Duvadilan' 'Duvadilan ret'],"['Dilavase' 'Duviculine' 'Isoxsuprine hcl' 'Isoxsuprine hydrochloride'
 'NSC-757067' 'Navilox' 'Suprilent' 'Vadosilan' 'Vasotran']","[('PubChem', array(['144204018', '170465968', '26748094', '56422878', '855622'],
      dtype=object))]",,"{'rows': array(['MONDO_0005301'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication.
CHEMBL1161,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,WOFMFGQZHJDGCX-ZULDAHANSA-N,Small molecule,False,MOMETASONE FUROATE,1987.0,4.0,,False,True,"['Asmanex hfa' 'Asmanex twisthaler' 'Elocon' 'Mometasone furoate'
 'Nasonex' 'Nasonex 24hr allergy' 'Sinuva']","['LAS-41002' 'LAS41002' 'LYR-210' 'LYR210' 'Lyr-210' 'Mometasone furoate'
 'Mometasone furoate anhydrous' 'Mometasone furoate hydrate'
 'Mometasone furoate monohydrate' 'Monovo' 'NSC-746171' 'NSC-760077'
 'Nasonex' 'SCH 32088' 'SCH-32088']","[('DailyMed', array(['mometasone%20furoate'], dtype=object)), ('PubChem', array(['144204256', '170464666', '56463118'], dtype=object)), ('Wikipedia', array(['Mometasone_furoate'], dtype=object)), ('drugbank', array(['DB14512'], dtype=object)), ('chEBI', array(['47564'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'HP_0001742', 'EFO_0000676', 'EFO_0004232',
       'HP_0100582', 'EFO_0007486', 'MONDO_0004979', 'EFO_0007415',
       'EFO_1000391', 'HP_0006536', 'EFO_1001919', 'EFO_0000274',
       'MONDO_0011382', 'EFO_0003918', 'MONDO_0005271', 'MONDO_0043771',
       'EFO_1001417', 'EFO_0003956', 'EFO_0002460', 'EFO_0004192',
       'MONDO_0007254', 'EFO_0007187', 'MONDO_0100096', 'EFO_0005854',
       'EFO_0000701', 'EFO_1001494'], dtype=object), 'count': 26}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 8 approved and 18 investigational indications.
CHEMBL1200690,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,BJFIDCADFRDPIO-DZCXQCEKSA-N,Protein,False,LYPRESSIN,1982.0,4.0,,False,True,['Diapid'],"['8-l-lysinevasopressin' 'L-8' 'Lypressin' 'Lysine vasopressin'
 'Vasopressin pig' 'Vasopressin, 8-l-lysine']","[('PubChem', array(['144206455', '144206977'], dtype=object)), ('drugbank', array(['DB14642'], dtype=object))]",,,"[ENSG00000126895,ENSG00000166148,ENSG00000198049]",Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201470,,,Small molecule,False,HYDROCODONE POLISTIREX,1987.0,4.0,CHEMBL1457,False,True,[],['Hydrocodone polistirex'],"[('DailyMed', array(['hydrocodone%20polistirex'], dtype=object))]",,,"[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL1201483,,,Small molecule,False,PSEUDOEPHEDRINE POLISTIREX,1987.0,4.0,CHEMBL1590,False,True,['Pseudo-12'],['Pseudoephedrine polistirex'],,,,[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL1272,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,FAEKWTJYAYMJKF-QHCPKHFHSA-N,Small molecule,False,REPAGLINIDE,1997.0,4.0,,False,True,['Enyglid' 'Novonorm' 'Prandin' 'Repaglinide' 'Repaglinide krka'],"['A10BX02' 'AG-EE 623 ZW' 'AG-EE-623-ZW' 'AG-EE-623ZW' 'AGEE-623ZW'
 'NSC-759893' 'Prandin' 'Repaglinide']","[('DailyMed', array(['repaglinide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-krka'],
      dtype=object)), ('PubChem', array(['11112894', '144204272', '26719812', '49648522'], dtype=object)), ('Wikipedia', array(['Repaglinide'], dtype=object)), ('drugbank', array(['DB00912'], dtype=object)), ('chEBI', array(['8805'], dtype=object))]",,"{'rows': array(['MONDO_0044970', 'EFO_0001068', 'EFO_0000616', 'EFO_0000400',
       'EFO_0001645', 'MONDO_0005148', 'HP_0003124', 'MONDO_0011719',
       'MONDO_0009061', 'MONDO_0008315', 'EFO_0003914', 'MONDO_0005180',
       'EFO_0000685', 'EFO_0000537'], dtype=object), 'count': 14}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 12 investigational indications.
CHEMBL1628234,CN(C)CCC=C1c2ccccc2COc2ccccc21.Cl,MHNSPTUQQIYJOT-UHFFFAOYSA-N,Small molecule,True,DOXEPIN HYDROCHLORIDE,1969.0,4.0,CHEMBL1628227,False,True,"['Adapin' 'Doxepin hydrochloride' 'Quitaxon' 'Silenor' 'Sinequan' 'Xepin'
 'Zonalon']",['Doxepin hcl' 'Doxepin hydrochloride' 'NSC-108160' 'P-3693A'],"[('DailyMed', array(['doxepin%20hydrochloride'], dtype=object)), ('PubChem', array(['26719773', '26748009'], dtype=object))]",,"{'rows': array(['MONDO_0007079', 'EFO_0003843', 'EFO_0004698', 'MONDO_0002009',
       'EFO_1001904', 'EFO_0000274', 'MONDO_0004985'], dtype=object), 'count': 7}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL168815,CC1OC2(CS1)CN1CCC2CC1,WUTYZMFRCNBCHQ-UHFFFAOYSA-N,Small molecule,False,CEVIMELINE,2000.0,4.0,,False,True,[],['Cevimeline'],,['CHEMBL2218917'],"{'rows': array(['EFO_0009869', 'EFO_0009869'], dtype=object), 'count': 2}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for xerostomia and has 1 investigational indication.
CHEMBL1743047,,,Antibody,True,NECITUMUMAB,2015.0,4.0,,False,True,['Portrazza'],['11F8' 'IMC-11F8' 'Necitumumab' 'Portrazza'],"[('DailyMed', array(['necitumumab'], dtype=object)), ('DrugCentral', array(['5071'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/portrazza'],
      dtype=object))]",,"{'rows': array(['EFO_0000708', 'EFO_0000616', 'EFO_0000707', 'EFO_0003060',
       'EFO_0009708'], dtype=object), 'count': 5}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and non-small cell lung carcinoma and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1751,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,LTMHDMANZUZIPE-PUGKRICDSA-N,Small molecule,False,DIGOXIN,1975.0,4.0,,False,True,"['Digamex' 'Digoxin' 'Digoxin pediatric' 'Lanoxicaps' 'Lanoxin'
 'Lanoxin pediatric' 'Lanoxin-125' 'Lanoxin-pg' 'Vanoxin']","['Digoxin' 'Digoxinum' 'Dynamos' 'Fargoxin' 'Lanocardin' 'Mapluxin'
 'NSC-95100' 'Natigoxin' 'Rougoxin' 'Stillacor-' 'Toloxin' 'Vanoxin']","[('DailyMed', array(['digoxin'], dtype=object)), ('PubChem', array(['11533002', '144204576', '144208876', '144213367', '17389540',
       '26752810', '49718191', '50105460', '56422204'], dtype=object)), ('Wikipedia', array(['Digoxin'], dtype=object)), ('drugbank', array(['DB00390'], dtype=object)), ('chEBI', array(['4551'], dtype=object))]",,"{'rows': array(['EFO_1000359', 'EFO_1001249', 'EFO_0006911', 'MONDO_0002009',
       'EFO_0000616', 'EFO_0003047', 'EFO_0000400', 'EFO_0000222',
       'MP_0001845', 'EFO_0001062', 'MONDO_0008667', 'EFO_0000764',
       'EFO_0003890', 'MONDO_0001134', 'EFO_0000474', 'EFO_0000373',
       'EFO_0000685', 'EFO_0001073', 'EFO_0000558', 'EFO_0006859',
       'EFO_0003869', 'MONDO_0002050', 'EFO_0003060', 'EFO_0007328',
       'HP_0004755', 'EFO_0000198', 'EFO_0000544', 'EFO_0000275',
       'EFO_0003144', 'EFO_0000756', 'MONDO_0008315', 'MONDO_0019623',
       'EFO_0000319', 'EFO_0002496', 'MONDO_0005148', 'EFO_0003843',
       'MONDO_0007254', 'EFO_0004239'], dtype=object), 'count': 38}","[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 34 investigational indications.
CHEMBL2108054,,,Protein,False,TADEKINIG ALFA,,3.0,,False,False,[],['Tadekinig alfa'],,,"{'rows': array(['EFO_0007135', 'MONDO_0015540'], dtype=object), 'count': 2}",[ENSG00000150782],Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108266,,,Antibody,False,CEDELIZUMAB,,2.0,,False,False,[],['Cedelizumab' 'ORTHOCLONE OKT4 A' 'RWJ 49004' 'RWJ-49004'],,,,[ENSG00000010610],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109065,,,Protein,False,DROTRECOGIN ALFA (ACTIVATED),2001.0,4.0,,True,True,['Xigris'],"['Activated protein c' 'Drotrecogin alfa' 'Drotrecogin alfa (activated)'
 'Drotrecogin alfa activated' 'Drotrecogin alfa, activated'
 'Drotrecogin-alfa' 'LY-203638' 'LY203638']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xigris'],
      dtype=object))]",,"{'rows': array(['EFO_0005251', 'EFO_0006834', 'HP_0100806', 'EFO_0003827',
       'HP_0002140', 'EFO_0000712', 'EFO_0003884', 'MONDO_0100130',
       'EFO_1001373', 'HP_0004419'], dtype=object), 'count': 10}","[ENSG00000185010,ENSG00000198734]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 7 investigational indications. It was withdrawn in at least one region.
CHEMBL2109402,,,Antibody,False,MM-121,,2.0,,False,False,[],['MM-121' 'Mm-121' 'SAR-256212'],,,"{'rows': array(['MONDO_0007254', 'MONDO_0008170', 'MONDO_0002087', 'EFO_0000616',
       'EFO_0003060', 'MONDO_0004992', 'MONDO_0002158'], dtype=object), 'count': 7}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL2109630,,,Antibody,False,BC8 131I,,2.0,,False,False,[],['BC8' 'Bc8 131i'],,,,[ENSG00000081237],Antibody drug with a maximum clinical trial phase of II.
CHEMBL3039596,CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C.[Na+],TVTJZMHAIQQZTL-WATAJHSMSA-M,Small molecule,True,FOSINOPRIL SODIUM,1991.0,4.0,CHEMBL3039598,False,True,['Fosinopril sodium' 'Fositens' 'Fozitec' 'Monopril' 'Staril'],"['Fosenopril sodium' 'Fosinopril sodium' 'Fosinopril sodium salt'
 'SQ 28555' 'SQ-28555']","[('DailyMed', array(['fosinopril%20sodium'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0003144'], dtype=object), 'count': 2}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for hypertension and heart failure. This drug has a black box warning from the FDA.
CHEMBL3137316,Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1,BVXLAHSJXXSWFF-KEKPKEOLSA-N,Small molecule,False,FOSDAGROCORAT,,2.0,,False,False,[],['Fosdagrocorat' 'PF-04171327'],"[('drugbank', array(['DB12198'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3234035,CCCCCCC(C)(C)c1cc(O)c([C@H]2CC(=O)[C@H]3C[C@@H]2C3(C)C)c(OC(=O)/C=C/C(=O)O)c1,GSTZHANFXAKPSE-MXTREEOPSA-N,Small molecule,False,PRS-211375,,2.0,,False,False,[],"['Cannabinor' 'Cannabinor, (-)-' 'PRS-211,375' 'Prs-211375']","[('drugbank', array(['DB05048'], dtype=object))]",,,[ENSG00000188822],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3989949,NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl,GFHAXPJGXSQLPT-VIFPVBQESA-N,Small molecule,False,CENOBAMATE,2020.0,4.0,,False,True,['Ontozry' 'Xcopri'],['Cenobamate' 'YKP-3089' 'YKP3089'],"[('DailyMed', array(['cenobamate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry'],
      dtype=object)), ('drugbank', array(['DB06119'], dtype=object))]",,"{'rows': array(['EFO_0000474', 'HP_0001250', 'EFO_0001421', 'EFO_0004263',
       'HP_0007359'], dtype=object), 'count': 5}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 2 investigational indications.
CHEMBL413,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,QFJCIRLUMZQUOT-HPLJOQBZSA-N,Small molecule,True,SIROLIMUS,1999.0,4.0,,False,True,['Fyarro' 'Hyftor' 'Rapamune' 'Sirolimus'],"['AY-22989' 'Fyarro' 'Hyftor' 'L04AA10' 'NSC-226080' 'Npc-12g' 'Rapalimus'
 'Rapamycin' 'SM-88 COMPONENT SIROLIMUS' 'Sirolimus' 'WY-090217']","[('DailyMed', array(['sirolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune'],
      dtype=object)), ('PubChem', array(['124886754', '144204421', '144206303', '50103901'], dtype=object)), ('Wikipedia', array(['Sirolimus'], dtype=object)), ('drugbank', array(['DB00877'], dtype=object)), ('chEBI', array(['9168'], dtype=object))]",,"{'rows': array(['EFO_1002048', 'Orphanet_77260', 'EFO_0007323', 'EFO_0000760',
       'MONDO_0004976', 'EFO_1001465', 'MONDO_0002898', 'MONDO_0018848',
       'Orphanet_365', 'MONDO_0002280', 'EFO_1000749', 'EFO_1000475',
       'EFO_0000519', 'EFO_0000514', 'EFO_1000637', 'EFO_1001968',
       'EFO_0000182', 'MONDO_0007079', 'HP_0001915', 'EFO_0008620',
       'Orphanet_122', 'Orphanet_733', 'EFO_0000637', 'MONDO_0011705',
       'EFO_0000180', 'EFO_1000986', 'MONDO_0000873', 'MONDO_0007915',
       'HP_0003124', 'EFO_0000681', 'EFO_1000906', 'EFO_0000565',
       'EFO_0008514', 'MONDO_0005147', 'EFO_0001421', 'EFO_0001365',
       'EFO_0000220', 'EFO_0003086', 'EFO_0004610', 'EFO_0000699',
       'EFO_0008517', 'EFO_0003144', 'MONDO_0018975', 'Orphanet_848',
       'EFO_0001378', 'EFO_0000183', 'HP_0002721', 'EFO_0002913',
       'MONDO_0021121', 'EFO_0000095', 'EFO_0001075', 'EFO_0000717',
       'EFO_1001119', 'MONDO_0017719', 'EFO_0006475', 'EFO_1001492',
       'EFO_0004236', 'MONDO_0011382', 'EFO_0003060', 'EFO_1001469',
       'MONDO_0002691', 'MONDO_0100096', 'EFO_1000811', 'EFO_0003929',
       'EFO_0000198', 'MONDO_0044881', 'EFO_0000196', 'HP_0001871',
       'EFO_0004194', 'EFO_0000222', 'MONDO_0019313', 'EFO_0007328',
       'MONDO_0001718', 'MONDO_0016471', 'EFO_1001466', 'EFO_0000574',
       'EFO_0003870', 'EFO_1001050', 'MONDO_0007254', 'MONDO_0002177',
       'MONDO_0015974', 'EFO_0000571', 'EFO_0000401', 'EFO_0000174',
       'EFO_1001996', 'EFO_0002618', 'EFO_0000540', 'EFO_0003966',
       'EFO_0009661', 'EFO_0003770', 'EFO_0005952', 'MONDO_0004986',
       'EFO_1000251', 'EFO_0000708', 'EFO_0000339', 'EFO_1001496',
       'EFO_0002424', 'MONDO_0018150', 'MONDO_0008501', 'MONDO_0019338',
       'EFO_0006927', 'MONDO_0001187', 'Orphanet_46724', 'EFO_0000621',
       'EFO_1000312', 'EFO_0000702', 'EFO_0004208', 'EFO_1000464',
       'MONDO_0018531', 'EFO_0004599', 'EFO_0010134', 'EFO_0009708',
       'MONDO_0002108', 'EFO_0000616', 'EFO_0009259', 'EFO_1000657',
       'EFO_0005761', 'MONDO_0004992', 'MONDO_0013730', 'MONDO_0005180',
       'MONDO_0008094', 'EFO_1001264', 'EFO_1000158', 'MONDO_0020547',
       'EFO_0004683', 'MONDO_0017276', 'EFO_0003884', 'HP_0001626',
       'MONDO_0002050', 'EFO_0000537', 'MONDO_0018305', 'EFO_1000653',
       'EFO_1001761', 'MONDO_0008903', 'EFO_0000691', 'MONDO_0005149',
       'EFO_0000403', 'MONDO_0001734', 'EFO_0006888', 'MONDO_0019391',
       'MONDO_0008315', 'MONDO_0015564', 'EFO_0009907'], dtype=object), 'count': 143}",[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 138 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297229,,,Unknown,True,PRABOTULINUMTOXIN A,2019.0,4.0,,False,True,['Jeuveau'],"['ABP 450' 'ABP-450' 'ABP450' 'Botulinum toxin type a complex' 'DWP-450'
 'DWP450' 'Prabotulinumtoxin a' 'Prabotulinumtoxina'
 'Prabotulinumtoxina xvfs']","[('DailyMed', array(['prabotulinumtoxina-xvfs'], dtype=object))]",,"{'rows': array(['EFO_0005422', 'MONDO_0005277', 'HP_0000473'], dtype=object), 'count': 3}",[ENSG00000132639],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for skin aging and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297536,,,Oligonucleotide,False,PATISIRAN SODIUM,2018.0,4.0,,False,True,['Onpattro'],[],"[('DailyMed', array(['patisiran%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onpattro'],
      dtype=object))]",,"{'rows': array(['MONDO_0018634', 'EFO_0004129', 'EFO_0009562', 'EFO_1001875'],
      dtype=object), 'count': 4}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved indications.
CHEMBL4594214,CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC3=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O,BPKIMPVREBSLAJ-QTBYCLKRSA-N,Protein,False,ZICONOTIDE,2004.0,4.0,,False,True,[],['.omega.-conotoxin m viia' 'SNX-111' 'Ziconotide'],,,"{'rows': array(['EFO_0003843', 'HP_0001945'], dtype=object), 'count': 2}",[ENSG00000148408],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 2 investigational indications.
CHEMBL506871,C[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1,JNAHVYVRKWKWKQ-CYBMUJFWSA-N,Small molecule,False,VELIPARIB,,3.0,,False,False,[],['ABT-888' 'PARP-1 INHIBITOR ABT-888' 'Veliparib'],"[('drugbank', array(['DB07232'], dtype=object)), ('chEBI', array(['62880'], dtype=object))]",,"{'rows': array(['EFO_0002617', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0008170',
       'EFO_0000616', 'EFO_0006861', 'EFO_0000708', 'EFO_0005537',
       'Orphanet_145', 'MONDO_0002898', 'MONDO_0015760', 'EFO_0001075',
       'EFO_0000305', 'MONDO_0001056', 'EFO_1000158', 'EFO_0000182',
       'EFO_0000519', 'EFO_0002618', 'EFO_0005088', 'EFO_1000657',
       'EFO_1001951', 'MONDO_0004992', 'EFO_0000466', 'EFO_0005952',
       'EFO_0000702', 'EFO_1001465', 'EFO_0002499', 'MONDO_0002158',
       'EFO_1001469', 'EFO_0001663', 'EFO_0003060', 'EFO_0000574',
       'EFO_0006772', 'EFO_0003968'], dtype=object), 'count': 34}","[ENSG00000143799,ENSG00000041880,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 34 investigational indications.
CHEMBL5315078,,,Unknown,False,EPTACOG BETA (ACTIVATED),2022.0,4.0,,False,True,['Cevenfacta'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cevenfacta'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604', 'MONDO_0010602'], dtype=object), 'count': 2}",[ENSG00000057593],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hemophilia b and hemophilia a.
CHEMBL941,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,KTUFNOKKBVMGRW-UHFFFAOYSA-N,Small molecule,False,IMATINIB,2001.0,4.0,,False,True,[],['Glamox' 'Gleevec' 'Imatinib' 'NSC-743414' 'NSC-759854' 'STI-571'],"[('PubChem', array(['103905596', '124892207', '124892208', '124892209', '26755316',
       '29215405', '50100104'], dtype=object)), ('Wikipedia', array(['Imatinib'], dtype=object)), ('drugbank', array(['DB00619'], dtype=object)), ('chEBI', array(['45783'], dtype=object))]",['CHEMBL2386595' 'CHEMBL1642'],"{'rows': array(['EFO_0004288', 'EFO_0006861', 'MONDO_0002108', 'EFO_0000717',
       'EFO_0000760', 'EFO_1001361', 'MONDO_0005575', 'EFO_0003032',
       'EFO_0003106', 'EFO_0001361', 'MONDO_0011934', 'EFO_0000756',
       'MONDO_0004979', 'MONDO_0004643', 'EFO_0007328', 'EFO_0000181',
       'EFO_0000685', 'MONDO_0008978', 'EFO_0004198', 'EFO_0000717',
       'EFO_0000220', 'MONDO_0005301', 'MONDO_0018975', 'MONDO_0005147',
       'EFO_1001465', 'MONDO_0002108', 'EFO_0000702', 'EFO_0002429',
       'HP_0001880', 'MONDO_0013730', 'EFO_0000588', 'EFO_0009907',
       'EFO_1000729', 'MONDO_0100096', 'EFO_0000339', 'MONDO_0004992',
       'EFO_0002617', 'MONDO_0021063', 'MONDO_0005149', 'MONDO_0011962',
       'MONDO_0009937', 'EFO_0000691', 'MONDO_0008170', 'EFO_1000657',
       'EFO_1000895', 'MONDO_0008903', 'MONDO_0007254', 'EFO_0000641',
       'MONDO_0100096', 'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715',
       'EFO_0000313', 'EFO_0009907', 'EFO_0000209', 'MONDO_0007254',
       'EFO_1000613', 'MONDO_0001056', 'EFO_0000756', 'MONDO_0018076',
       'EFO_1001471', 'EFO_1000359', 'EFO_0000389', 'MONDO_0008903',
       'EFO_0000333', 'EFO_0000768', 'EFO_0003060', 'EFO_0004683',
       'EFO_0001361', 'MONDO_0000870', 'EFO_0006859', 'EFO_0000519',
       'EFO_0000497', 'EFO_0000094', 'EFO_0005952', 'EFO_0001422',
       'EFO_0000616', 'MONDO_0011719', 'MONDO_0011382', 'EFO_0007444',
       'MONDO_0008315', 'EFO_0000339', 'EFO_0002087', 'MONDO_0004992',
       'MONDO_0002367', 'MONDO_0002087', 'EFO_1000158', 'EFO_1001951',
       'EFO_0000519', 'MONDO_0005149', 'MONDO_0000873', 'MONDO_0013730',
       'MONDO_0044881', 'MONDO_0011719', 'MONDO_0011705', 'MONDO_0002158',
       'EFO_0000503', 'EFO_1001467', 'EFO_0000712', 'EFO_1001814',
       'EFO_1001467', 'EFO_0000673', 'EFO_0000658', 'EFO_1000576',
       'EFO_0000691', 'EFO_1001993', 'EFO_0002430', 'EFO_0000365',
       'EFO_0000222', 'EFO_0004610', 'EFO_0001376', 'EFO_0003956',
       'MONDO_0044917', 'EFO_0002428', 'EFO_0000616', 'MONDO_0020547',
       'EFO_0000565', 'EFO_0005952', 'EFO_1001919', 'EFO_0004289',
       'EFO_0000220', 'EFO_0000349', 'MONDO_0000873', 'EFO_0000565',
       'EFO_0000574', 'EFO_0003897', 'EFO_0000222'], dtype=object), 'count': 127}","[ENSG00000157404,ENSG00000097007,ENSG00000186716,ENSG00000113721]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for chronic myelogenous leukemia and has 110 investigational indications.
CHEMBL112797,CCCCP(=O)(O)CCCN,ONNMDRQRSGKZCN-UHFFFAOYSA-N,Small molecule,False,SGS-742,,2.0,,False,False,[],['CGP-36742' 'LU-AE-58479' 'SGS742' 'Sgs 742' 'Sgs-742' 'Sgs742'],"[('drugbank', array(['DB05010'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1200778,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl,BIFMNMPSIYHKDN-FJXQXJEOSA-N,Small molecule,False,DEXRAZOXANE HYDROCHLORIDE,1995.0,4.0,CHEMBL1738,False,True,['Dexrazoxane hydrochloride' 'Savene' 'Totect' 'Zinecard'],"['ADR-529 HYDROCHLORIDE' 'Cardioxan' 'Dexrazoxane hcl'
 'Dexrazoxane hydrochloride' 'ICRF-187 HYDROCHLORIDE'
 'Razoxane hydrochloride, (s)-' 'Savene']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/savene'],
      dtype=object)), ('chEBI', array(['50224'], dtype=object))]",,"{'rows': array(['EFO_0000318', 'EFO_0000691', 'MONDO_0000870', 'EFO_1000984',
       'EFO_0000621', 'EFO_0000574', 'EFO_0000502', 'EFO_0000565',
       'MONDO_0007254', 'EFO_0000222', 'EFO_0000209', 'EFO_0000616',
       'EFO_1000158'], dtype=object), 'count': 13}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 11 investigational indications.
CHEMBL1200935,Br.NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1,UQAVIASOPREUIT-VQIWEWKSSA-N,Small molecule,False,DARIFENACIN HYDROBROMIDE,2004.0,4.0,CHEMBL1346,False,True,['Darifenacin hydrobromide' 'Emselex' 'Enablex'],"['Darifenacin hbr' 'Darifenacin hydrobromide' 'UK-88525-04 (HYDROBROMIDE)'
 'Uk-88525-04 (hbr)']","[('DailyMed', array(['darifenacin%20hydrobromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emselex'],
      dtype=object)), ('PubChem', array(['144206189', '170465079'], dtype=object)), ('chEBI', array(['31455'], dtype=object))]",,"{'rows': array(['EFO_0006865', 'EFO_1000781'], dtype=object), 'count': 2}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for urgency urinary incontinence and overactive bladder.
CHEMBL1201229,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1,RWZVPVOZTJJMNU-UHFFFAOYSA-N,Small molecule,False,DEMECARIUM,1959.0,4.0,,False,True,[],['Demecarium' 'Demecarium cation' 'Demecarium ion'],"[('drugbank', array(['DB00944'], dtype=object)), ('chEBI', array(['59719'], dtype=object))]",['CHEMBL1200514'],"{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for glaucoma.
CHEMBL1207366,O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1,XDKRVNKVAKCFGW-FOCLMDBBSA-N,Small molecule,False,GW468816,,2.0,,False,False,[],['GW468816' 'Gw-468816' 'Gw468816'],,['CHEMBL400007'],"{'rows': array(['EFO_0003768'], dtype=object), 'count': 1}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1224,Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1,PWACSDKDOHSSQD-IUTFFREVSA-N,Small molecule,False,ACRIVASTINE,1994.0,4.0,,False,True,['Benadryl allgy relief plus decongest' 'Semprex'],['Acrivastine' 'BW 825C' 'BW-825C'],"[('PubChem', array(['144206566'], dtype=object)), ('Wikipedia', array(['Acrivastine'], dtype=object)), ('drugbank', array(['DB09488'], dtype=object)), ('chEBI', array(['83168'], dtype=object))]",,"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994 and is indicated for allergic disease.
CHEMBL1980391,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2,UOVCGJXDGOGOCZ-UHFFFAOYSA-N,Small molecule,False,RG-1530,,1.0,,False,False,[],['R-1530' 'RG-1530' 'Rg-1530'],"[('PubChem', array(['103905607'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000122025,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000087586,ENSG00000142731,ENSG00000077782,ENSG00000113721,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2104386,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O,NSQLIUXCMFBZME-MPVJKSABSA-N,Protein,False,CARPERITIDE,,3.0,,False,False,[],"['Atrial natriuretic peptide' 'Atrial natriuretic peptide carperitide'
 'Carperitide' 'SUN 4936' 'SUN-4936']",,,,"[ENSG00000159899,ENSG00000169418,ENSG00000113389]",Protein drug with a maximum clinical trial phase of III.
CHEMBL2106841,CCCCCC(C)C(C)c1cc(O)c2c(c1)OC(C)(C)C=C2c1ccncc1,YHUDSHIRWOVVCV-UHFFFAOYSA-N,Small molecule,False,NONABINE,,2.0,,False,False,[],['BRL 4664' 'Brl-4664' 'Nonabine'],,,,"[ENSG00000118432,ENSG00000188822]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108080,,,Oligosaccharide,False,PARNAPARIN SODIUM,,3.0,,False,False,[],"['Fluxum' 'Lowepa' 'Minidalton' 'OP 21-23' 'OP-21-23' 'OP-2123'
 'Parnaparin sodium' 'Tromboparin']",,,"{'rows': array(['HP_0004418', 'EFO_0000545'], dtype=object), 'count': 2}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108489,,,Antibody,False,KELIXIMAB,,2.0,,False,False,[],['IDEC CE-9.1' 'IDEC-CE9.1' 'Keliximab' 'SB-210396'],,,,[ENSG00000010610],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108581,,,Antibody,False,CATUMAXOMAB,2009.0,4.0,,False,True,['Removab'],['Catumaxomab'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/removab'],
      dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_1000251', 'HP_0001541', 'MONDO_0004992',
       'MONDO_0001187', 'EFO_1001100', 'EFO_0003897', 'EFO_0000294',
       'EFO_0000503', 'EFO_0000616'], dtype=object), 'count': 10}","[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000119888]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 7 investigational indications.
CHEMBL3137347,,,Antibody,False,VARLILUMAB,,2.0,,False,False,[],['CDX-1127' 'Varlilumab'],,,"{'rows': array(['EFO_0000574', 'EFO_0000756', 'EFO_0003060', 'EFO_1001956',
       'EFO_0000632', 'EFO_0000519', 'EFO_0003863', 'EFO_0000272',
       'EFO_0000681', 'EFO_0000630'], dtype=object), 'count': 10}",[ENSG00000139193],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL3545239,,,Small molecule,False,PF-05019702,,1.0,,False,False,[],['PRA-027' 'Pf-05019702' 'WAY-257027'],,,"{'rows': array(['EFO_0000731'], dtype=object), 'count': 1}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL427216,Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,BOVGTQGAOIONJV-UHFFFAOYSA-N,Small molecule,False,GLICLAZIDE,,4.0,,False,True,"['Bilxona' 'Dacadis mr' 'Diaglyk' 'Diamicron' 'Diamicron mr' 'Edicil'
 'Glimil' 'Nazdol mr' 'Vamju' 'Vitile xl' 'Ziclaseg' 'Zicron' 'Zicron pr']","['Gliclazide' 'Glimicron' 'J3.151H' 'NSC-758673' 'S-1702' 'S-852'
 'SE 1702' 'SE-1702']","[('PubChem', array(['144204141', '170465698', '26748918', '26748919', '26748920',
       '49646130'], dtype=object)), ('Wikipedia', array(['Gliclazide'], dtype=object)), ('drugbank', array(['DB01120'], dtype=object)), ('chEBI', array(['31654'], dtype=object))]",,"{'rows': array(['EFO_0000474', 'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 3}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 2 investigational indications.
CHEMBL429317,Cc1cc(/C(=C/Nc2ccc(Cl)cc2)C(=O)Nc2ccc(Cl)cc2)on1,VMAKIACTLSBBIY-BOPFTXTBSA-N,Small molecule,False,AVL-3288,,1.0,,False,False,[],['Anvylic-3288' 'Avl-3288' 'CCMI' 'UCI-4083' 'XY-4083'],,,"{'rows': array(['EFO_0005411', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL4583691,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1,UEPXBTCUIIGYCY-UHFFFAOYSA-N,Small molecule,False,LXH254,,2.0,,False,False,[],"['LXH-254' 'LXH254' 'Lxh 254' 'Lxh254' 'Naporafenib'
 'PAN-RAF INHIBITOR LXH254']",,,"{'rows': array(['EFO_0003060', 'EFO_0000756'], dtype=object), 'count': 2}","[ENSG00000132155,ENSG00000157764]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594355,,,Unknown,False,APL-501,,2.0,,False,False,[],"['APL-501' 'Apl-501' 'CBT-501' 'GB-226' 'GB226' 'Gb226' 'Genolimzumab'
 'Geptanolimab']",,,"{'rows': array(['EFO_1001938', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0000211',
       'EFO_0007143', 'EFO_0003060'], dtype=object), 'count': 6}",[ENSG00000188389],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4802221,,,Antibody,False,SOCAZOLIMAB,,3.0,,False,False,[],"['Anti-PD-L1 SH1E2' 'SH1E2' 'STI-A1014' 'Socazolimab' 'ZKAB-001' 'ZKAB001'
 'Zkab001']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOCAZOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000702', 'EFO_0000637', 'MONDO_0002974', 'EFO_0002617',
       'EFO_0000616', 'EFO_0008528', 'MONDO_0003060'], dtype=object), 'count': 7}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL508102,CCOC(=O)n1ccn(C)c1=S,CFOYWRHIYXMDOT-UHFFFAOYSA-N,Small molecule,False,CARBIMAZOLE,,4.0,,False,True,['Neo-mercazole 20' 'Neo-mercazole 5'],['Athyromazole' 'Carbimazol henning' 'Carbimazole' 'NSC-758966'],"[('PubChem', array(['11112670', '144204147', '144212637', '170465583', '26749040'],
      dtype=object)), ('Wikipedia', array(['Carbimazole'], dtype=object)), ('drugbank', array(['DB00389'], dtype=object)), ('chEBI', array(['617099'], dtype=object))]",,"{'rows': array(['EFO_0009190', 'HP_0000820'], dtype=object), 'count': 2}",[ENSG00000115705],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for abnormality of the thyroid gland and has 1 investigational indication.
CHEMBL5315069,,,Protein,False,DAMOCTOCOG ALFA PEGOL,2018.0,4.0,,False,True,['Jivi'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jivi'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Protein drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for hemophilia a.
CHEMBL597,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,MRBDMNSDAVCSSF-UHFFFAOYSA-N,Small molecule,False,PHENTOLAMINE,1952.0,4.0,,False,True,[],['Phentolamin' 'Phentolamine'],"[('PubChem', array(['104171285', '11112200', '124882050', '124882053', '144203915',
       '170464866', '26751465', '26751466', '26751467', '50085867',
       '50100389', '50100390', '50103967', '860967', '90341742'],
      dtype=object)), ('Wikipedia', array(['Phentolamine'], dtype=object)), ('drugbank', array(['DB00692'], dtype=object)), ('chEBI', array(['8081'], dtype=object))]",['CHEMBL1204146' 'CHEMBL1200873'],"{'rows': array(['MONDO_0008315', 'EFO_0000239', 'EFO_0000319', 'EFO_0001073',
       'EFO_0001073', 'HP_0001943', 'HP_0011499', 'EFO_0000319',
       'MONDO_0001330'], dtype=object), 'count': 9}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and is indicated for adrenal gland pheochromocytoma and cardiovascular disease and has 6 investigational indications.
CHEMBL1089318,Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1,ASOADIZOVZTJSR-UHFFFAOYSA-N,Small molecule,False,OPICAPONE,2020.0,4.0,,False,True,['Ongentys' 'Ontilyv'],['BIA 9-1067' 'BIA-9-1067' 'BIA-91067' 'Ongentys' 'Opicapone'],"[('DailyMed', array(['opicapone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv'],
      dtype=object)), ('drugbank', array(['DB11632'], dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000093010],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for parkinson disease.
CHEMBL1201631,,,Protein,True,INSULIN HUMAN,1982.0,4.0,,False,True,"['Actrapid' 'Afrezza' 'Exubera' 'Humulin br' 'Humulin r'
 'Humulin r kwikpen' 'Humulin r pen' 'Inpremzia' 'Ins humulin r' 'Insuman'
 'Insuman infusat' 'Myxredlin' 'Novolin r' 'Velosulin Br Human'
 'Velosulin br']","['Biosulin r' 'Capsulin' 'Exubera (inhaled insulin human)'
 'High molecular weight insulin human' 'Human insulin' 'Humulin' 'Insulin'
 'Insulin (human)' 'Insulin Recombinant Human' 'Insulin human'
 'Insulin human (biosynthesis)' 'Insulin human (synthesis)'
 'Insulin human lente' 'Insulin human nph' 'Insulin human rdna'
 'Insulin human regular' 'Insulin human regular (rdna)'
 'Insulin human semisynthetic' 'Insulin human, rdna origin'
 'Insulin recombinant human' 'Insulin recombinant purified human'
 'Insulin reconbinanet human' 'Insulin semi synthetic human'
 'Insulin semisynthetic human' 'Insulin, human'
 'Insulin,regular,human buffered' 'Insulin,ultralente,human'
 'Regular insulin, human' 'Viatab']","[('DailyMed', array(['insulin%20human', 'insulin%20recombinant%20human'], dtype=object)), ('DrugCentral', array(['5003'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/actrapid',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/inpremzia',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/insuman'],
      dtype=object))]",,"{'rows': array(['MONDO_0021187', 'HP_0003074', 'EFO_1000783', 'EFO_0000401',
       'HP_0000842', 'EFO_1001050', 'EFO_0009492', 'EFO_0007430',
       'MONDO_0005148', 'HP_0003124', 'MONDO_0005041', 'HP_0001919',
       'EFO_0003840', 'EFO_0001358', 'EFO_0009267', 'EFO_0002614',
       'EFO_0000400', 'HP_0002140', 'EFO_0000373', 'EFO_0000712',
       'EFO_1000906', 'EFO_0001645', 'HP_0100543', 'MONDO_0002009',
       'EFO_0003768', 'EFO_0003917', 'EFO_1000653', 'EFO_0005672',
       'EFO_0008583', 'EFO_0003929', 'MONDO_0005180', 'EFO_0003914',
       'EFO_0003843', 'MONDO_0005147', 'EFO_1000985', 'EFO_0001073',
       'MONDO_0100096', 'EFO_0004143', 'MONDO_0002146', 'EFO_0000612',
       'EFO_0000546', 'MONDO_0018555', 'EFO_0006834', 'MONDO_0005090',
       'EFO_0003095', 'EFO_0004593', 'EFO_0009516', 'EFO_0000537',
       'HP_0001943', 'MONDO_0004985', 'HP_0002153'], dtype=object), 'count': 51}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 49 investigational indications. This drug has a black box warning from the FDA.
CHEMBL139835,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,UWFYSQMTEOIJJG-FDTZYFLXSA-N,Small molecule,False,CYPROTERONE ACETATE,,4.0,,False,True,['Androcur' 'Androcur 10' 'Cyprostat' 'Diane'],"['Cyproterone' 'Cyproterone 17.alpha.-acetate' 'Cyproterone acetate'
 'NSC-81430' 'SH 714' 'SH-714' 'SH714']","[('PubChem', array(['144204615', '144208884', '144213258', '170465682', '17389953',
       '26752883', '46500455', '49737417', '90340797'], dtype=object)), ('drugbank', array(['DB04839'], dtype=object)), ('chEBI', array(['50743'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0003894', 'EFO_0001065', 'EFO_0000673',
       'EFO_0000536', 'GO_0042697', 'HP_0031217', 'EFO_0000660'],
      dtype=object), 'count': 8}","[ENSG00000082175,ENSG00000113580,ENSG00000169083]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications.
CHEMBL1689,Cl.c1ccc(CC2=NCCN2)cc1,RHTNTTODYGNRSP-UHFFFAOYSA-N,Small molecule,False,TOLAZOLINE HYDROCHLORIDE,1985.0,4.0,CHEMBL770,False,True,['Benzidazol' 'Priscol' 'Priscoline'],"['Benzazoline hydrochloride' 'NSC-757353' 'TCMDC-125842' 'Tolazoline HCl'
 'Tolazoline hcl' 'Tolazoline hydrochloride']","[('PubChem', array(['144203890', '14742771', '170465219', '26748277'], dtype=object))]",,,"[ENSG00000196639,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000113749]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985.
CHEMBL1742993,,,Antibody,False,BLOSOZUMAB,,2.0,,False,False,[],['Blosozumab' 'LY-2541546' 'LY2541546'],,,"{'rows': array(['EFO_0003854', 'EFO_0003882'], dtype=object), 'count': 2}",[ENSG00000167941],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2103793,Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],QUWFSKKBMDKAHK-SBOJBMMISA-A,Oligonucleotide,False,AGATOLIMOD SODIUM,,3.0,CHEMBL2103792,False,False,[],"['Agatolimod sodium' 'Agatolimod tricosasodium salt' 'CPG 7909' 'CPG-7909'
 'PF-03512676' 'PF-3512676' 'Vaximmune']",,,"{'rows': array(['EFO_0005952', 'EFO_0009441', 'EFO_0002913', 'EFO_0003869',
       'EFO_0000764', 'EFO_0000403', 'EFO_0001068', 'EFO_0000756',
       'EFO_0000574', 'EFO_0000681', 'EFO_1001051', 'HP_0100806',
       'EFO_0000096', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0007576',
       'EFO_0000313', 'MONDO_0008315', 'EFO_0000191', 'EFO_0003060',
       'EFO_1001469'], dtype=object), 'count': 21}",[ENSG00000239732],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications.
CHEMBL2105712,CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,USNRYVNRPYXCSP-JUGPPOIOSA-N,Small molecule,False,AFATINIB DIMALEATE,2013.0,4.0,CHEMBL1173655,False,True,['Gilotrif' 'Giotrif'],"['Afatinib dimaleate' 'Afatinib maleate' 'BIBW-2992 MA2' 'BIBW-2992-MA2'
 'BIBW-2992MA2' 'BIBW2992 MA2' 'BIBW2992-MA2']","[('DailyMed', array(['afatinib%20dimaleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif'],
      dtype=object)), ('chEBI', array(['76003'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0001378'], dtype=object), 'count': 2}","[ENSG00000141736,ENSG00000178568,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for non-small cell lung carcinoma and has 1 investigational indication.
CHEMBL2106643,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)[O-])C(=O)OC2.[Na+],DOZYTHNHLLSNIK-JOKMOOFLSA-M,Small molecule,True,MYCOPHENOLATE SODIUM,2004.0,4.0,CHEMBL866,False,True,['Ceptava' 'Myfortic'],"['ERL 080' 'ERL-080' 'Mycophenolate sodium'
 'Mycophenolic acid sodium salt' 'Mycophenolic sod' 'NSC-116072'
 'Sodium mycophenalate']","[('DailyMed', array(['mycophenolic%20sodium'], dtype=object)), ('chEBI', array(['67155'], dtype=object))]",,"{'rows': array(['EFO_0000699', 'EFO_0005140', 'EFO_0005761', 'HP_0001871',
       'MONDO_0005301', 'EFO_1002048', 'EFO_0003884', 'EFO_0004599',
       'EFO_0003086'], dtype=object), 'count': 9}","[ENSG00000106348,ENSG00000178035]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for multiple sclerosis and has 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108680,,,Antibody,False,PIDILIZUMAB,,2.0,,False,False,['Ct-011'],['CT-011' 'Pidilizumab'],,,"{'rows': array(['EFO_0000673', 'EFO_0004220', 'EFO_0000681', 'EFO_0000574',
       'EFO_0000403', 'EFO_0000182', 'EFO_0001378', 'EFO_0000756',
       'EFO_0002618'], dtype=object), 'count': 9}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL2109520,,,Antibody,False,ONCOLYSIN M,,2.0,,False,False,[],['ONCOLYSIN M'],,,,[ENSG00000105383],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2360580,CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1.Cl.Cl,SDBHDSZKNVDKNU-UHFFFAOYSA-N,Small molecule,False,BUCLIZINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201271,False,True,['Bucladin-s' 'Equivert'],"['Aphilan' 'Buclina' 'Buclizine dihydrochloride' 'Buclizine hcl'
 'Buclizine hydrochloride' 'Buclodin' 'Longifene' 'NSC-25141' 'Softran'
 'UCB 4445' 'UCB-4445']","[('PubChem', array(['144203574'], dtype=object)), ('chEBI', array(['61193'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL3407547,COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1,ZZWWXIBKLBMSCS-FQEVSTJZSA-N,Small molecule,False,FIRSOCOSTAT,,2.0,,False,False,[],['Firsocostat' 'GS-0976' 'GS-ACC' 'Gs-0976' 'ND-630' 'Ndi-010976'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FIRSOCOSTAT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001249', 'MONDO_0019052'], dtype=object), 'count': 2}","[ENSG00000278540,ENSG00000076555]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545264,CC(Oc1ccc2[nH]nc(/C=C/c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl,GKJCVYLDJWTWQU-DUXPYHPUSA-N,Small molecule,False,LY-2874455,,1.0,,False,False,[],['LY2874455' 'Ly-2874455'],,,,"[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3833304,,,Antibody,False,TOSITUMOMAB 131I,,3.0,,False,False,['Bexxar'],"['Tositumomab (131I)' 'Tositumomab 131i'
 'Tositumomab/iodine (131i) tositumomab']",,,"{'rows': array(['EFO_0000403', 'EFO_0001378', 'MONDO_0000873', 'EFO_0000574',
       'EFO_0009441', 'EFO_0000096', 'EFO_0005952', 'EFO_0000191',
       'MONDO_0018906', 'EFO_1001469', 'EFO_0003032', 'EFO_0000183',
       'EFO_0000309', 'EFO_0000095'], dtype=object), 'count': 14}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.
CHEMBL4297255,COC(=O)C1(OC(=O)c2cncn2[C@H](C)c2ccccc2)CC1,DRAFVCKNYNQOKR-GFCCVEGCSA-N,Small molecule,False,ABP-700,,2.0,,False,False,[],['Abp-700'],"[('drugbank', array(['DB15411'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297504,CO[C@@H]1[C@H](OC(=O)/C=C/c2ccc(OCCN(C)C)cc2)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C,ZEZFKUBILQRZCK-MJSCXXSSSA-N,Small molecule,False,BELORANIB,,3.0,,False,False,[],['Beloranib' 'ZGN-433' 'ZGN-440' 'Zgn-433' 'Zgn-440'],"[('drugbank', array(['DB12671'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'MONDO_0008300'], dtype=object), 'count': 2}",[ENSG00000111142],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL452461,O=c1c2c(c1=O)N(CCP(=O)(O)O)CCCN2,BDABGOLMYNHHTR-UHFFFAOYSA-N,Small molecule,False,PERZINFOTEL,,2.0,,False,False,[],['EAA-090' 'Perzinfotel'],"[('drugbank', array(['DB12365'], dtype=object))]",,,"[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4594395,O=C([O-])CCCO.[K+],TXSIWDVUJVMMKM-UHFFFAOYSA-M,Small molecule,False,POTASSIUM OXYBATE,2020.0,4.0,CHEMBL1342,False,True,[],['Oxybate potassium'],"[('DailyMed', array(['potassium%20oxybate'], dtype=object))]",,,"[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020.
CHEMBL4650483,,,Antibody,False,ERFONRILIMAB,,3.0,,False,False,[],['Erfonrilimab' 'KN-046' 'KN046' 'Kn 046' 'Kn046'],,,"{'rows': array(['MONDO_0005184', 'EFO_0000574', 'EFO_0000616', 'EFO_0003060',
       'EFO_0005922', 'EFO_0005537', 'EFO_1000576', 'EFO_0002618',
       'EFO_0000182'], dtype=object), 'count': 9}","[ENSG00000120217,ENSG00000163599]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL5315049,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=C(O)/C=C\C(=O)O,YRKLLQIZVVYDQY-YLGLLLDBSA-N,Small molecule,False,SITAGLIPTIN FUMARATE,2021.0,4.0,CHEMBL1422,False,True,['Sitagliptin sun'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-sun'],
      dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for type 2 diabetes mellitus.
CHEMBL562668,CCNC1(C(N)=O)CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1,UNAZAADNBYXMIV-UHFFFAOYSA-N,Small molecule,False,OTENABANT,,3.0,,False,False,[],"['CP-945,598' 'CP-945598' 'CP-945598-01' 'Cp-945598' 'Otenabant'
 'Otenabant hydrochloride']","[('Wikipedia', array(['Otenabant'], dtype=object)), ('drugbank', array(['DB11745'], dtype=object))]",['CHEMBL2103817' 'CHEMBL3526399'],"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL58,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,KKZJGLLVHKMTCM-UHFFFAOYSA-N,Small molecule,True,MITOXANTRONE,1987.0,4.0,,False,True,['Mitoxantrone HCl' 'Novantrone'],['Misostol' 'Mitoxantrone' 'NSC-279836' 'Novantrone'],"[('PubChem', array(['11111482', '11111483', '142727', '162108252', '50111146',
       '85856281', '90341083', '92763439'], dtype=object)), ('Wikipedia', array(['Mitoxantrone'], dtype=object)), ('drugbank', array(['DB01204'], dtype=object)), ('chEBI', array(['50729'], dtype=object))]",['CHEMBL1200827' 'CHEMBL1417019'],"{'rows': array(['MONDO_0019472', 'EFO_0000182', 'MONDO_0005301', 'EFO_1001469',
       'EFO_0000403', 'EFO_1000359', 'MONDO_0008170', 'EFO_0003843',
       'EFO_0000220', 'EFO_0004289', 'EFO_0000198', 'EFO_0001378',
       'EFO_0000616', 'EFO_0004289', 'EFO_0003929', 'EFO_0000222',
       'EFO_1001830', 'EFO_0008522', 'EFO_0000565', 'EFO_0000224',
       'EFO_0000339', 'MONDO_0008315', 'EFO_1001968', 'MONDO_0007254',
       'EFO_0000574', 'EFO_0006859', 'MONDO_0007254', 'EFO_0004256',
       'EFO_0004252', 'EFO_0000326', 'MONDO_0019472', 'EFO_0000222',
       'MONDO_0001023', 'MONDO_0005301', 'MONDO_0019460', 'EFO_1001052',
       'EFO_0000574', 'MONDO_0015760', 'EFO_0000211', 'MONDO_0018906',
       'EFO_0004251', 'EFO_0000673', 'EFO_0000196', 'EFO_0000221',
       'EFO_1001469', 'EFO_0005952', 'MONDO_0004992', 'EFO_0000095',
       'MONDO_0008315', 'EFO_0001378', 'EFO_0000178', 'EFO_0000403',
       'EFO_1000286', 'EFO_0000211', 'EFO_0000616', 'MONDO_0000873',
       'EFO_0001663'], dtype=object), 'count': 57}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 6 approved and 48 investigational indications. This drug has a black box warning from the FDA.
CHEMBL9960,CC[C@H](NC(=O)c1cc(-c2ccccc2)nc2ccccc12)c1ccccc1,MXNGYQJJYRVGGJ-QFIPXVFZSA-N,Small molecule,False,AZD-7624,,2.0,,False,False,[],['AZD-7624' 'Azd 7624' 'Azd-7624'],,,"{'rows': array(['MONDO_0004979', 'EFO_0000341', 'MP_0001845'], dtype=object), 'count': 3}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1014,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,GHOSNRCGJFBJIB-UHFFFAOYSA-N,Small molecule,True,CANDESARTAN CILEXETIL,1998.0,4.0,,False,True,['Amias' 'Atacand' 'Candesartan cilexetil' 'Ratacand'],"['Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester'
 'Candesartan cilexetil' 'NSC-758697' 'TCV-116']","[('DailyMed', array(['candesartan%20cilexetil'], dtype=object)), ('PubChem', array(['144212519', '26748952'], dtype=object)), ('drugbank', array(['DB00796'], dtype=object)), ('chEBI', array(['3348'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0000319', 'EFO_0003913', 'MONDO_0005147',
       'EFO_0000612', 'EFO_0000537', 'MONDO_0043510', 'EFO_0003144',
       'EFO_0001645', 'HP_0000093', 'EFO_1001150', 'HP_0003124',
       'MONDO_0007254', 'EFO_0000373', 'EFO_0000400', 'EFO_0003914',
       'MONDO_0001134', 'MONDO_0005148', 'EFO_1001153', 'MONDO_0100096',
       'EFO_0000712'], dtype=object), 'count': 21}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 7 approved and 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1123,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,CURUTKGFNZGFSE-UHFFFAOYSA-N,Small molecule,False,DICYCLOMINE,1950.0,4.0,,False,True,[],['Bentyl' 'Dicyclomine' 'Dicycloverine' 'Dicymine' 'Kolantyl'],"[('PubChem', array(['11111098', '11112188', '144207120', '170464896', '50100226',
       '50104289', '90341021'], dtype=object)), ('Wikipedia', array(['Dicycloverine'], dtype=object)), ('drugbank', array(['DB00804'], dtype=object)), ('chEBI', array(['4514'], dtype=object))]",['CHEMBL1200479'],"{'rows': array(['EFO_0010282', 'EFO_0000555'], dtype=object), 'count': 2}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for gastrointestinal disease and irritable bowel syndrome.
CHEMBL1139,CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)O[C@H]2C[C@H]1O,KAQKFAOMNZTLHT-OZUDYXHBSA-N,Small molecule,False,EPOPROSTENOL,1995.0,4.0,,False,True,[],"['ACT-385781A' 'Epoprostenol' 'Flolan' 'PG-I2' 'Pgi2' 'Pgx' 'Prostacyclin'
 'Prostaglandin i2' 'Prostaglandin x' 'U-53,217' 'U-53217']","[('PubChem', array(['26754811', '50112680'], dtype=object)), ('drugbank', array(['DB01240'], dtype=object)), ('chEBI', array(['15552'], dtype=object))]",['CHEMBL962'],"{'rows': array(['EFO_0002687', 'HP_0004419', 'MONDO_0005149', 'EFO_0001361',
       'EFO_0000713', 'MONDO_0043510', 'MONDO_0100096', 'EFO_0001361'],
      dtype=object), 'count': 8}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for recurrent thrombophlebitis and pulmonary arterial hypertension and has 6 investigational indications.
CHEMBL1187833,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,FVTWTVQXNAJTQP-UHFFFAOYSA-N,Small molecule,False,UMECLIDINIUM,2013.0,4.0,,False,True,[],"['GSK-573719' 'GSK573719' 'Umeclidinium' 'Umeclidinium cation'
 'Umeclidinium ion']","[('drugbank', array(['DB09076'], dtype=object))]",['CHEMBL523299'],"{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0000464', 'HP_0006536',
       'EFO_0000341', 'MONDO_0004979', 'HP_0000975', 'EFO_0006505'],
      dtype=object), 'count': 8}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 4 investigational indications.
CHEMBL1200402,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=S(=O)(O)c1ccccc1,ZPBWCRDSRKPIDG-UHFFFAOYSA-N,Small molecule,True,AMLODIPINE BESYLATE,1992.0,4.0,CHEMBL1491,False,True,['Amlodipine besylate' 'Norliqva' 'Norvasc'],"['Amlodipine (as besilate)' 'Amlodipine benzenesulfonate'
 'Amlodipine besilate' 'Amlodipine besylate' 'Amlor' 'Antacal'
 'Lodipressin' 'Monopina' 'NSC-758922' 'Norliqva' 'UK-48,340-26'
 'UK-48340-26']","[('DailyMed', array(['amlodipine%20besylate'], dtype=object)), ('PubChem', array(['144205078', '144207025', '26749852'], dtype=object)), ('chEBI', array(['2669'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'EFO_0003144', 'EFO_0000612', 'HP_0000093',
       'EFO_0004911', 'EFO_1000013', 'MONDO_0005178', 'MONDO_0021187',
       'EFO_0000373', 'EFO_0000537', 'EFO_0000712', 'MONDO_0001134',
       'HP_0003124', 'Orphanet_79292', 'EFO_0003913', 'EFO_0001645'],
      dtype=object), 'count': 16}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 13 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200789,O=P([O-])(O)OCC(Cl)(Cl)Cl.[Na+],WFKJEZKHPGDCRK-UHFFFAOYSA-M,Small molecule,False,TRICLOFOS SODIUM,1982.0,4.0,CHEMBL1201317,False,True,['Triclos'],"['SCH 10159' 'SCH-10159' 'Trichloroethyl phosphate sodium'
 'Triclofos monosodium salt' 'Triclofos sodium' 'Tricloryl']",,,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201014,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],VJZLQIPZNBPASX-OJJGEMKLSA-L,Small molecule,False,PREDNISOLONE SODIUM PHOSPHATE,1973.0,4.0,CHEMBL1201231,False,True,"['Codelsol' 'Cortisate' 'Hydeltrasol' 'Inflamase' 'Inflamase forte'
 'Inflamase mild' 'Metreton' 'Orapred' 'Orapred odt' 'Pediapred' 'Predair'
 'Predair forte' 'Prednisolone sodium phosphate' 'Predsol' 'Predsol-n']","['NSC-759187' 'Prednisolone 21-disodium phosphate'
 'Prednisolone sodium phosphate' 'Prednisoloni natrii phosphas']","[('DailyMed', array(['prednisolone%20sodium%20phosphate'], dtype=object))]",,"{'rows': array(['MONDO_0005301', 'MONDO_0002280', 'EFO_1001231', 'EFO_0007126',
       'MP_0001845', 'EFO_0003929', 'MONDO_0004979', 'EFO_0000768',
       'EFO_1001226', 'EFO_0000341', 'HP_0000559', 'EFO_0009448',
       'EFO_0000565', 'EFO_0005854', 'EFO_0007141', 'EFO_0004255',
       'EFO_0007415'], dtype=object), 'count': 17}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 14 approved and 3 investigational indications.
CHEMBL1201063,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1.Cl,XWIHRGFIPXWGEF-UHFFFAOYSA-N,Small molecule,True,PROPAFENONE HYDROCHLORIDE,1989.0,4.0,CHEMBL631,False,True,['Arythmol' 'Propafenone hydrochloride' 'Rythmol' 'Rythmol sr' 'Rytmonorm'],['NSC-758640' 'Propafenone hcl' 'Propafenone hydrochloride'],"[('DailyMed', array(['propafenone%20hydrochloride'], dtype=object)), ('PubChem', array(['26747617', '26747618', '50106779', '50106780', '50106781',
       '56422489', '855997'], dtype=object)), ('chEBI', array(['8466'], dtype=object))]",,"{'rows': array(['HP_0004308', 'EFO_0000275', 'EFO_0003144'], dtype=object), 'count': 3}","[ENSG00000043591,ENSG00000169252,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for ventricular arrhythmia and atrial fibrillation and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1398126,Cl.N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.O.O,LTKVFMLMEYCWMK-UHFFFAOYSA-N,Small molecule,True,AMILORIDE HYDROCHLORIDE,1981.0,4.0,CHEMBL945,False,True,"['Amilamont' 'Amiloride hydrochloride' 'Amilospare 5' 'Amoride' 'Berkamil'
 'Midamor']","['Amiloride hcl' 'Amiloride hydrochloride'
 'Amiloride hydrochloride anhydrous' 'Amiloride hydrochloride dehydrate'
 'Amiloride hydrochloride dihydrate' 'Amiloridi hydrochloridum'
 'Amipramidine' 'Anhydrous amiloride hydrochloride' 'NSC-755847']","[('DailyMed', array(['amiloride%20hydrochloride'], dtype=object)), ('PubChem', array(['11113002'], dtype=object)), ('chEBI', array(['2640'], dtype=object))]",,"{'rows': array(['EFO_0004269', 'MONDO_0009061', 'EFO_0000537', 'EFO_0000373'],
      dtype=object), 'count': 4}","[ENSG00000111319,ENSG00000168447,ENSG00000166828]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1684950,CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1,IQIKXZMPPBEWAD-CQSZACIVSA-N,Small molecule,False,SUVECALTAMIDE,,2.0,,False,False,[],"['CX-8998' 'Cx-8998' 'JZP-385' 'JZP385' 'MK-8998' 'Mk-8998'
 'Suvecaltamide']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SUVECALTAMIDE/relevant/1/'],
      dtype=object))]",['CHEMBL4802242'],"{'rows': array(['MONDO_0005090', 'EFO_0003108', 'EFO_0000474', 'EFO_0003108'],
      dtype=object), 'count': 4}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1743057,,,Protein,False,PEGSUNERCEPT,,2.0,,False,False,[],['Pegsunercept' 'STNF-RI'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000232810],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1755,Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2,IKENVDNFQMCRTR-UHFFFAOYSA-N,Small molecule,False,CONIVAPTAN,2005.0,4.0,,False,True,[],['Conivaptan'],"[('Wikipedia', array(['Conivaptan'], dtype=object)), ('drugbank', array(['DB00872'], dtype=object)), ('chEBI', array(['681850'], dtype=object))]",['CHEMBL1201108'],"{'rows': array(['HP_0002902', 'MONDO_0043510', 'HP_0002902', 'EFO_0003144',
       'EFO_0001422', 'EFO_0001421', 'EFO_0003144', 'EFO_0000319'],
      dtype=object), 'count': 8}","[ENSG00000126895,ENSG00000166148]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for heart failure and cardiovascular disease and has 5 investigational indications.
CHEMBL2108628,,,Small molecule,False,PACLITAXEL POLIGLUMEX,,3.0,,False,False,[],"['CT-2103' 'L-polyglutamic paclitaxel' 'Opaxio' 'PG-TXL'
 'Paclitaxel conjugate with poly-l-glutamic acid' 'Paclitaxel poliglumex']",,,"{'rows': array(['EFO_0006772', 'MONDO_0008170', 'MONDO_0002158', 'MONDO_0008315',
       'EFO_0000466', 'MONDO_0005575', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0003060', 'MONDO_0002087', 'EFO_0003833', 'EFO_0000673',
       'MONDO_0008903', 'EFO_0000707'], dtype=object), 'count': 14}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.
CHEMBL2109298,,,Antibody,False,MEDI-3617,,1.0,,False,False,[],['MEDI-3617' 'MEDI3617' 'Medi 3617' 'Medi-3617'],,,"{'rows': array(['EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000091879],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2109653,,,Antibody,False,BERMEKIMAB,,3.0,,False,False,['Xilonix'],['Bermekimab' 'CA-18C3' 'CV-18C3' 'MaBp1' 'RA-18C3' 'T2-18C3'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BERMEKIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_1000710', 'EFO_0000676',
       'EFO_0003894', 'EFO_0000717', 'EFO_0000274', 'MP_0001845',
       'MONDO_0005148', 'EFO_0000365', 'HP_0000999'], dtype=object), 'count': 11}",[ENSG00000115008],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL3139186,Cc1nc(N2CCN(C)CC2)c2nc(-c3ccccc3Cl)n(C3CCOCC3)c2n1,UCMNDPDJRSEZPL-UHFFFAOYSA-N,Small molecule,False,LY2828360,,2.0,,False,False,[],['LY-2828360' 'LY2828360' 'Ly2828360'],,['CHEMBL3092901'],"{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}",[ENSG00000188822],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3234237,Fc1ccc(CN2CCC(Nc3ccc(C(F)(F)F)nn3)CC2)cc1F,UVUYWJWYRLJHEN-UHFFFAOYSA-N,Small molecule,False,JNJ-37822681,,2.0,,False,False,[],['JNJ-37822681' 'Jnj-37822681'],"[('drugbank', array(['DB12579'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL34124,COc1ccc2c(c1OCc1ccccc1)C[C@@H](C(=O)O)N(C(=O)C(c1ccccc1)c1ccccc1)C2,GHBCIXGRCZIPNQ-MHZLTWQESA-N,Small molecule,False,OLODANRIGAN,,2.0,,False,False,[],['EMA-401' 'EMA401' 'Ema401' 'Olodanrigan' 'PD-126055'],,['CHEMBL157510'],"{'rows': array(['EFO_1000783', 'MONDO_0041052'], dtype=object), 'count': 2}",[ENSG00000180772],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3544994,,,Oligonucleotide,False,VOLANESORSEN,,4.0,,False,True,[],"['ISIS 304801' 'ISIS 304801 FREE ACID' 'ISIS-304801' 'Volanesorsen'
 'free acid']",,,"{'rows': array(['EFO_0004211', 'MONDO_0020088', 'EFO_0000319'], dtype=object), 'count': 3}",[ENSG00000110245],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL3586404,CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1,UFKLYTOEMRFKAD-SHTZXODSSA-N,Small molecule,False,ONATASERTIB,,2.0,,False,False,[],['ATG-008' 'ATG008' 'CC-223' 'CC223' 'Cc-223' 'Onatasertib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ONATASERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12570'], dtype=object))]",,"{'rows': array(['EFO_1001901', 'EFO_0001378', 'EFO_0003060', 'EFO_0000519',
       'EFO_0000182', 'EFO_0000616', 'EFO_0000403', 'MONDO_0007254'],
      dtype=object), 'count': 8}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL3916929,CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2,MBKYLPOPYYLTNW-ZDUSSCGKSA-N,Small molecule,False,BALCINRENONE,,2.0,,False,False,[],['AZD-9977' 'AZD9977' 'Azd 9977' 'Azd-9977' 'Azd9977' 'Balcinrenone'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('drugbank', array(['DB15418'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0003086', 'EFO_0003144'], dtype=object), 'count': 3}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4066936,COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N,QZFHIXARHDBPBY-UHFFFAOYSA-N,Small molecule,True,VERICIGUAT,2021.0,4.0,,False,True,['Verquvo'],['BAY 1021189' 'BAY-1021189' 'MK-1242' 'Vericiguat'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/verquvo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VERICIGUAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15456'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0000195', 'EFO_0003144', 'EFO_0001645'],
      dtype=object), 'count': 4}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cardiovascular disease and heart failure and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL419792,CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1,RKZSNTNMEFVBDT-MRVPVSSYSA-N,Small molecule,False,SUMANIROLE,,3.0,,False,False,[],['PNU-95666E' 'Pnu-95666' 'Sumanirole'],"[('Wikipedia', array(['Sumanirole'], dtype=object)), ('drugbank', array(['DB06477'], dtype=object))]",['CHEMBL5071215'],"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297865,C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1,UOFYSRZSLXWIQB-UHFFFAOYSA-N,Small molecule,False,ABIVERTINIB,,3.0,,False,False,[],"['A610' 'AC-0010' 'AC0010' 'ACEA100610' 'Abivertinib' 'Ac0010' 'Avitinib'
 'EX-ACEA0010']","[('drugbank', array(['DB15327'], dtype=object))]",['CHEMBL4297866' 'CHEMBL5307684'],"{'rows': array(['EFO_0000096', 'MONDO_0100096', 'EFO_0003060', 'MONDO_0100096',
       'EFO_0003060', 'MONDO_0008315'], dtype=object), 'count': 6}","[ENSG00000010671,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4298127,,,Unknown,False,VRC-01LS,,2.0,,False,False,[],['VRC-01LS' 'VRC01LS' 'Vrc-01ls' 'Vrc-hivmab080-00-ab' 'Vrc01ls'],,,"{'rows': array(['EFO_0000180', 'EFO_0000764'], dtype=object), 'count': 2}",[ENSG00000010610],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4298134,,,Antibody,False,OBEXELIMAB,,3.0,,False,False,[],['Obexelimab' 'XMAB-5871' 'XMAB5871' 'Xmab5871'],,,"{'rows': array(['MONDO_0007915', 'EFO_1001264', 'MONDO_0017287'], dtype=object), 'count': 3}","[ENSG00000072694,ENSG00000177455]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL452231,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,NRUKOCRGYNPUPR-QBPJDGROSA-N,Small molecule,True,TENIPOSIDE,1992.0,4.0,,False,True,['Vumon'],['NSC-122819' 'Teniposide' 'VM-26' 'VM26'],"[('drugbank', array(['DB00444'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000220', 'EFO_0000574', 'EFO_0000565'],
      dtype=object), 'count': 4}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for neoplasm and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL5316169,O=C(N[C@@H](Cc1ccc(OCc2ccc3ccc(F)cc3n2)cc1)C(=O)O)c1ccc2ccccc2n1,XBKBJNOSNDZQGN-MHZLTWQESA-N,Small molecule,False,CR-3465 FREE ACID,,1.0,,False,False,[],[],,['CHEMBL5314389'],,[ENSG00000173198],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL715,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,KVWDHTXUZHCGIO-UHFFFAOYSA-N,Small molecule,True,OLANZAPINE,1996.0,4.0,,False,True,"['Arkolamyl' 'Olanzapine' 'Olanzapine mylan' 'Zalasta' 'Zyprexa'
 'Zyprexa zydis']","['LY-170053' 'LY170053' 'Olansek' 'Olanzapine' 'Olanzapine apotex'
 'Olanzapine cipla' 'Olanzapine glenmark' 'Olanzapine mylan'
 'Olanzapine teva' 'Olazax' 'Olazax disperzi' 'Zyprexa velotab']","[('DailyMed', array(['olanzapine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-mylan'],
      dtype=object)), ('PubChem', array(['144205109', '170465009', '174006883', '26719852', '26750094',
       '29215187', '49666419'], dtype=object)), ('Wikipedia', array(['Olanzapine'], dtype=object)), ('drugbank', array(['DB00334'], dtype=object)), ('chEBI', array(['7735'], dtype=object))]",['CHEMBL3989694'],"{'rows': array(['Orphanet_79292', 'EFO_0005088', 'HP_0012076', 'HP_0001249',
       'MONDO_0002009', 'EFO_0004699', 'EFO_0000616', 'MONDO_0002009',
       'EFO_0010702', 'MONDO_0005351', 'HP_0000726', 'HP_0002039',
       'EFO_0009963', 'MONDO_0007079', 'MONDO_0002009', 'EFO_0005407',
       'MONDO_0044881', 'HP_0002013', 'EFO_0004888', 'EFO_0003758',
       'EFO_0005230', 'EFO_0004247', 'MONDO_0004985', 'HP_0001824',
       'HP_0002018', 'EFO_0006911', 'MONDO_0021148', 'EFO_0004566',
       'MONDO_0002050', 'EFO_0005411', 'HP_0000713', 'EFO_0009854',
       'EFO_0005203', 'EFO_1000904', 'EFO_0003852', 'EFO_0009267',
       'HP_0002017', 'MONDO_0004976', 'MONDO_0005090', 'MONDO_0005090',
       'MONDO_0007739'], dtype=object), 'count': 41}","[ENSG00000102468,ENSG00000147246,ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL90,NCCc1c[nH]cn1,NTYJJOPFIAHURM-UHFFFAOYSA-N,Small molecule,True,HISTAMINE,1939.0,4.0,,False,True,[],"['.beta.-aminoethylglyoxaline' 'Ergamine' 'Ergotidine' 'Histamine'
 'NSC-33792']","[('PubChem', array(['104171171', '11111275', '124880328', '144203717', '170465001',
       '26753351', '26753352', '8139979', '90341171'], dtype=object)), ('Wikipedia', array(['Histamine'], dtype=object)), ('drugbank', array(['DB05381'], dtype=object)), ('chEBI', array(['18295'], dtype=object))]",['CHEMBL1533310' 'CHEMBL544208' 'CHEMBL3989520' 'CHEMBL535166'],"{'rows': array(['MONDO_0005271', 'MONDO_0004979', 'EFO_0000678', 'MONDO_0002367',
       'MP_0001845', 'EFO_0005854', 'EFO_0000389', 'EFO_0000565',
       'EFO_0000222', 'EFO_0004616', 'EFO_0000616', 'EFO_0005952',
       'EFO_0003956', 'MONDO_0005301'], dtype=object), 'count': 14}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and is indicated for acute myeloid leukemia and neoplasm and has 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1042,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12,QYSXJUFSXHHAJI-YRZJJWOYSA-N,Small molecule,False,CHOLECALCIFEROL,1999.0,4.0,,False,True,"['Accrete d3' 'Aciferol d3' 'Adcal-d3' 'Aviticol' 'Bio-vitamin d3'
 'Biolife vitamin d3' 'Cacit d3' 'Calceos' 'Calci-d' 'Calcichew d3'
 'Calcichew d3 fte' 'Calcichew d3 once daily' 'Caldrink d3' 'Calfovit d3'
 'Colecal d3' 'Colecalciferol' 'Colekal-d3' 'Colevit d3' 'Cubicole d3'
 'D-max' 'D-tracetten' 'D-vit3' 'D3 lemon melts' 'D3-50' 'Dekristol'
 'Desunin' 'Dihydrocholesterol' 'Dlux 400' 'E-d3' 'Evacal d3'
 'Fultium daily d3' 'Fultium-d3' 'Hux d3' 'Invita d3' 'Iso d3'
 'Kora liquid' 'Natecal d3' ""Nature's remedy vitamin d3"" 'Neo-d' 'Nphd3'
 'Osteocaps d3' 'Plenachol' 'Pro d3' 'Pro d3 folic' 'Pro d3 forte'
 'Royalvit d3' 'Stexerol-d3' 'Stivit-d3' 'Sunvit-d3 1,000'
 'Sunvit-d3 10,000' 'Sunvit-d3 2,000' 'Sunvit-d3 20,000' 'Sunvit-d3 3,000'
 'Sunvit-d3 400' 'Sunvit-d3 5,000' 'Sunvit-d3 50,000' 'Sunvit-d3 800'
 'Synervit-d3' 'Theical d-3' 'Thorens' 'Vigantol' 'Vigantoletten'
 'Vigantoletten 500' 'Vit d3 streuli' 'Vita-d3' 'Vitamin D 3' 'Zymad']","['7-dehydrocholesterol, activated' 'AK R215 COMPONENT COLECALCIFEROL'
 'AK-R215 COMPONENT COLECALCIFEROL' 'Cholecalciferol' 'Colecalciferol'
 'Colecalciferolum' 'Delsterol' 'Delta-d' 'Deparal' 'Ebivit' 'NSC-375571'
 'Provitina' 'Ricketon' 'Vitamin d' 'Vitamin d (cholecalciferol)'
 'Vitamin d assay system suitability' 'Vitamin d-3' 'Vitamin d3'
 'Vitamin d3 (as cholecalciferol)']","[('DailyMed', array(['cholecalciferol'], dtype=object)), ('PubChem', array(['144205131', '144209744', '17388665', '26754459', '29215239'],
      dtype=object)), ('Wikipedia', array(['Cholecalciferol'], dtype=object)), ('drugbank', array(['DB00169'], dtype=object)), ('chEBI', array(['28940'], dtype=object))]",,"{'rows': array(['MONDO_0002508', 'EFO_0003929', 'MONDO_0003778', 'EFO_0003917',
       'EFO_0005406', 'MONDO_0008315', 'EFO_0000365', 'MONDO_0005301',
       'MONDO_0004979', 'MONDO_0008170', 'MONDO_0007915', 'EFO_0000765',
       'EFO_0000616', 'EFO_0003047', 'EFO_0000660', 'MONDO_0005271',
       'EFO_0001073', 'MONDO_0007254', 'EFO_0003767', 'EFO_0009516',
       'EFO_0003884', 'EFO_0007141', 'EFO_0002950', 'EFO_0005531',
       'HP_0100543', 'EFO_0000432', 'EFO_0007328', 'MONDO_0002898',
       'EFO_0003854', 'EFO_0000274', 'EFO_0000694', 'EFO_0000676',
       'MONDO_0004647', 'MONDO_0021063', 'EFO_0005681', 'Orphanet_145',
       'EFO_0004272', 'EFO_0002609', 'EFO_0000400', 'MONDO_0004992',
       'EFO_0008572', 'Orphanet_309005', 'EFO_0000222', 'MONDO_0011382',
       'EFO_0000474', 'EFO_0007405', 'EFO_0000764', 'MONDO_0005148',
       'EFO_0000729', 'EFO_1000049', 'MONDO_0002050', 'EFO_0000544',
       'EFO_0000095', 'EFO_0009686', 'EFO_0003762', 'EFO_0003106',
       'MONDO_0005180', 'EFO_0000756', 'HP_0001891', 'EFO_0000180',
       'EFO_1000961', 'MONDO_0002363', 'HP_0000938', 'EFO_0000319',
       'EFO_0004593', 'EFO_0003931', 'HP_0001742', 'MONDO_0005090',
       'MONDO_0002146', 'MONDO_0018975', 'EFO_0000341', 'EFO_0004261',
       'EFO_1001951', 'MONDO_0100096', 'EFO_0000403', 'EFO_0007214',
       'EFO_0003964', 'EFO_1000653', 'EFO_0002546', 'EFO_0000555',
       'EFO_0000519', 'MONDO_0044881', 'EFO_0003944', 'EFO_0003758',
       'MONDO_0018076', 'EFO_0002496', 'EFO_0008506', 'MONDO_0021187',
       'HP_0011950', 'EFO_1001121', 'EFO_0004248', 'EFO_0003095',
       'MONDO_0005147', 'EFO_0000384', 'EFO_0000196', 'EFO_1000657',
       'EFO_0000280', 'EFO_0003882', 'EFO_0005411', 'EFO_0000195',
       'EFO_0003144', 'EFO_0000673', 'Orphanet_43', 'EFO_0003103'],
      dtype=object), 'count': 104}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 101 investigational indications.
CHEMBL1079175,NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1,ULDXWLCXEDXJGE-UHFFFAOYSA-N,Small molecule,False,MK-2206,,2.0,,False,False,[],['MK-2206' 'MK2206' 'Mk-2206'],"[('PubChem', array(['124897541', '124897542', '144206919', '170466896'], dtype=object)), ('chEBI', array(['67271'], dtype=object))]",['CHEMBL4635254'],"{'rows': array(['MONDO_0008903', 'EFO_0000756', 'EFO_0005221', 'MONDO_0011962',
       'EFO_0001663', 'EFO_0000308', 'EFO_0000403', 'MONDO_0005411',
       'MONDO_0021063', 'MONDO_0004992', 'EFO_0000681', 'MONDO_0007254',
       'EFO_0004252', 'EFO_0000095', 'EFO_0000305', 'EFO_0003060',
       'EFO_0000181', 'EFO_0006861', 'EFO_1000657', 'EFO_0000182',
       'MONDO_0100342', 'EFO_0000616', 'EFO_0003050', 'EFO_0005537'],
      dtype=object), 'count': 24}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 24 investigational indications.
CHEMBL1112,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,CEUORZQYGODEFX-UHFFFAOYSA-N,Small molecule,True,ARIPIPRAZOLE,2002.0,4.0,,False,True,"['Abilify' 'Abilify maintena' 'Abilify maintena kit' 'Abilify mycite kit'
 'Aripiprazole'
 'Aripiprazole mylan pharma (previously aripiprazole pharmathen)']","['Abilify mycite' 'Aripiprazole' 'Aripiprex' 'NSC-759266' 'OPC-14597'
 'OPC-31']","[('DailyMed', array(['aripiprazole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma'],
      dtype=object)), ('PubChem', array(['144205281', '170465392', '174006897', '26719891', '29215485',
       '49666418'], dtype=object)), ('Wikipedia', array(['Aripiprazole'], dtype=object)), ('drugbank', array(['DB01238'], dtype=object)), ('chEBI', array(['31236'], dtype=object))]",,"{'rows': array(['HP_0000726', 'EFO_0004895', 'MONDO_0000594', 'MONDO_0010383',
       'MONDO_0004985', 'EFO_0003756', 'EFO_0004242', 'MONDO_0002009',
       'EFO_0005407', 'EFO_0003757', 'MONDO_0005090', 'HP_0012167',
       'EFO_0009963', 'EFO_0002610', 'EFO_0003758', 'MONDO_0004975',
       'EFO_0005230', 'EFO_0004701', 'MONDO_0002050', 'MONDO_0007079',
       'EFO_0007453', 'EFO_0003888', 'EFO_0005411', 'MONDO_0002009',
       'MONDO_0005351', 'EFO_0003015', 'EFO_0001358', 'HP_0000713'],
      dtype=object), 'count': 28}","[ENSG00000149295,ENSG00000102468,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 11 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1166,CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,KXNPVXPOPUZYGB-IOVMHBDKSA-N,Small molecule,False,ARGATROBAN,2000.0,4.0,,False,True,"['Acova' 'Argatroban' 'Argatroban in dextrose'
 'Argatroban in sodium chloride']","['Argatroban' 'Argatroban anhydrous' 'Argatroban hydrate'
 'Argatroban monohydrate' 'Argipidine' 'DK-7419' 'GN-1600' 'GN1600'
 'MCI-9038' 'MD-805']","[('DailyMed', array(['argatroban'], dtype=object)), ('Wikipedia', array(['Argatroban'], dtype=object)), ('drugbank', array(['DB00278'], dtype=object))]",,"{'rows': array(['HP_0004419', 'HP_0002140', 'HP_0001873', 'EFO_1000985',
       'MONDO_0002243', 'MONDO_0000831'], dtype=object), 'count': 6}",[ENSG00000180210],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 3 investigational indications.
CHEMBL1200802,C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O,BJVVMKUXKQHWJK-UHFFFAOYSA-N,Small molecule,False,TALBUTAL,1982.0,4.0,,False,True,['Lotusate'],['Talbutal'],"[('PubChem', array(['170465408'], dtype=object)), ('Wikipedia', array(['Talbutal'], dtype=object)), ('drugbank', array(['DB00306'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1,GFBKORZTTCHDGY-UWVJOHFNSA-N,Small molecule,True,THIOTHIXENE,1967.0,4.0,,False,True,['Navane' 'Orbinamon' 'Thiothixene'],"['(z)-thiothixene' 'CP-12252-1' 'Cis-thiothixene' 'NSC-108165' 'P-4657 B'
 'P-4657B' 'Thiothixene' 'Thiothixene cis-isomer' 'Tiotixene']","[('DailyMed', array(['thiothixene'], dtype=object)), ('PubChem', array(['11532885', '50111253'], dtype=object)), ('Wikipedia', array(['Thiothixene'], dtype=object)), ('drugbank', array(['DB01623'], dtype=object))]",['CHEMBL1200902' 'CHEMBL3989824'],"{'rows': array(['EFO_0005407', 'MONDO_0005090'], dtype=object), 'count': 2}","[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for psychosis and schizophrenia. This drug has a black box warning from the FDA.
CHEMBL1201184,CC(=O)O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O,DEXPIBGCLCPUHE-UISHROKMSA-N,Protein,False,LANREOTIDE ACETATE,2007.0,4.0,CHEMBL1201185,False,True,['Somatuline depot'],['BIM-23014C' 'Lanreotide acetate' 'Somatuline' 'Somatuline lp'],"[('DailyMed', array(['lanreotide%20acetate'], dtype=object))]",,"{'rows': array(['EFO_1001485', 'EFO_1000852'], dtype=object), 'count': 2}","[ENSG00000180616,ENSG00000162009]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for acromegaly and carcinoid syndrome.
CHEMBL1201439,,,Antibody,True,BASILIXIMAB,1998.0,4.0,,False,True,['Simulect'],['Basiliximab' 'CHI-621' 'SDZ-CHI-621'],"[('DailyMed', array(['basiliximab'], dtype=object)), ('DrugCentral', array(['4940'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/simulect'],
      dtype=object)), ('Wikipedia', array(['Basiliximab'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'MONDO_0013730', 'EFO_0000183', 'EFO_1000794',
       'EFO_0004236', 'EFO_0000616', 'EFO_0003884', 'MONDO_0018923',
       'MONDO_0019472', 'EFO_0010134', 'EFO_1001226', 'EFO_1001231',
       'EFO_0002687', 'EFO_0000544', 'EFO_0000464', 'EFO_0004599',
       'EFO_0000729', 'EFO_0001378', 'EFO_0000540', 'MONDO_0005147',
       'MONDO_0004976', 'EFO_0003086', 'EFO_0000519'], dtype=object), 'count': 23}","[ENSG00000134460,ENSG00000147168,ENSG00000100385]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for kidney transplant and immune system disease and has 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1254682,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13,OZYUPQUCAUTOBP-QXAKKESOSA-N,Small molecule,False,LEVALLORPHAN,1982.0,4.0,,False,True,[],['Levallorphan' 'Lorfan' 'Naloxiphan'],"[('PubChem', array(['144205558', '170465778'], dtype=object)), ('Wikipedia', array(['Levallorphan'], dtype=object)), ('drugbank', array(['DB00504'], dtype=object)), ('chEBI', array(['6431'], dtype=object))]",['CHEMBL2062276'],,"[ENSG00000112038,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1533,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC,RPLCPCMSCLEKRS-BPIQYHPVSA-N,Small molecule,False,DESOGESTREL,1992.0,4.0,,False,True,['Aizea' 'Cerazette' 'Cerelle' 'Desomono' 'Feanolla' 'Nacrez' 'Zelleta'],['Desogestrel' 'Mircette' 'ORG 2969' 'ORG-2969'],"[('DailyMed', array(['desogestrel'], dtype=object)), ('PubChem', array(['144206006', '50112703'], dtype=object)), ('Wikipedia', array(['Desogestrel'], dtype=object)), ('drugbank', array(['DB00304'], dtype=object)), ('chEBI', array(['4453'], dtype=object))]",,"{'rows': array(['EFO_0000660', 'EFO_0010269', 'Orphanet_661', 'MP_0001914'],
      dtype=object), 'count': 4}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 4 investigational indications.
CHEMBL1614713,c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1,XDJCLCLBSGGNKS-UHFFFAOYSA-N,Small molecule,False,CC-401,,2.0,,False,False,[],['CC-401' 'Cc-401'],"[('drugbank', array(['DB12432'], dtype=object))]",,"{'rows': array(['MONDO_0004643'], dtype=object), 'count': 1}","[ENSG00000107643,ENSG00000050748,ENSG00000109339]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1614766,O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F,FIMYFEGKMOCQKT-UHFFFAOYSA-N,Small molecule,False,RO-4987655,,1.0,,False,False,[],['CH-4987655' 'RO4987655' 'Ro 4987655' 'Ro-4987655'],"[('drugbank', array(['DB12933'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL17157,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,GUGOEEXESWIERI-UHFFFAOYSA-N,Small molecule,False,TERFENADINE,1985.0,4.0,,True,True,"['Antihistamine' 'Histafen' 'Histafen 120' 'Seldane' 'Terfenor'
 'Terfenor fte' 'Terfex' 'Terfinax 120' 'Terfinax 60' 'Triludan'
 'Triludan fte']",['NSC-665802' 'NSC-758627' 'RMI 9918' 'RMI-9918' 'Terfenadine'],"[('PubChem', array(['104171258', '144203846', '144203847', '170465598', '26752308',
       '50105228', '56422373', '85231279', '855647', '90341346'],
      dtype=object)), ('Wikipedia', array(['Terfenadine'], dtype=object)), ('drugbank', array(['DB00342'], dtype=object)), ('chEBI', array(['9453'], dtype=object))]",,"{'rows': array(['EFO_0007425', 'MONDO_0005271', 'EFO_0003869', 'MONDO_0004979',
       'EFO_0007304', 'EFO_0004197', 'EFO_0000403', 'EFO_0003840',
       'MONDO_0005301'], dtype=object), 'count': 9}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for allergic disease and has 8 investigational indications. It was withdrawn in at least one region.
CHEMBL1743024,,,Antibody,False,GANITUMAB,,3.0,,False,False,[],['AMG 479' 'AMG-479' 'AMG479' 'Ganitumab'],,,"{'rows': array(['EFO_0000702', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000174', 'EFO_0003893', 'EFO_0002918', 'EFO_0000691',
       'EFO_0002618', 'EFO_0003968', 'EFO_0000616', 'EFO_0005537'],
      dtype=object), 'count': 12}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL1743030,,,Antibody,False,ICRUCUMAB,,2.0,,False,False,[],['IMC 18F1' 'IMC-18F1' 'IMC18F1' 'Icrucumab'],,,"{'rows': array(['MONDO_0007254', 'MONDO_0021063', 'EFO_0000616', 'EFO_1000657'],
      dtype=object), 'count': 4}",[ENSG00000102755],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1743038,,,Antibody,False,LUCATUMUMAB,,2.0,,False,False,[],['CHIR-12.12' 'HCD-122' 'HCD122' 'Lucatumumab'],,,"{'rows': array(['EFO_0005952', 'EFO_0001378', 'MONDO_0018906', 'EFO_0000183',
       'EFO_0000095'], dtype=object), 'count': 5}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1752,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O,KSCFJBIXMNOVSH-UHFFFAOYSA-N,Small molecule,False,DYPHYLLINE,1951.0,4.0,,False,True,['Dilor' 'Dilor-400' 'Lufyllin' 'Neothylline'],['Diprophylline' 'Dyphilline' 'Dyphylline' 'Glyphylline' 'NSC-14305'],"[('PubChem', array(['144203995', '170465316', '174006928', '56422180', '855557'],
      dtype=object)), ('Wikipedia', array(['Dyphylline'], dtype=object)), ('drugbank', array(['DB00651'], dtype=object)), ('chEBI', array(['4728'], dtype=object))]",,"{'rows': array(['HP_0006536'], dtype=object), 'count': 1}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000172572]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for airway obstruction.
CHEMBL2106370,COc1ccnc(C[S+]([O-])c2nc3cc(-n4cccc4)ccc3[nH]2)c1C,HRRXCXABAPSOCP-UHFFFAOYSA-N,Small molecule,False,ILAPRAZOLE,,3.0,,False,False,[],['Ilaprazole' 'Noltec'],"[('drugbank', array(['DB11964'], dtype=object))]",,"{'rows': array(['EFO_0003948', 'MP_0001914', 'HP_0004398', 'EFO_0004607'],
      dtype=object), 'count': 4}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2107823,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1,SQSZANZGUXWJEA-UHFFFAOYSA-N,Small molecule,False,GANDOTINIB,,2.0,,False,False,[],['Gandotinib' 'LY-2784544' 'LY2784544' 'Ly-2784544' 'Ly2784544'],"[('drugbank', array(['DB13040'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000096968],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2146140,COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.O.O.O.O.[Sr+2],NCGHIAKEJNQSMS-QLGOZJDFSA-N,Small molecule,False,ESOMEPRAZOLE STRONTIUM,2013.0,4.0,CHEMBL1201320,False,True,['Esomeprazole strontium'],"['Esomeprazole strontium' 'FM-0F67' 'FM0F67' 'HIP-1601' 'Hip1601'
 'S-omeprazole strontium hydrate']","[('DailyMed', array(['esomeprazole%20strontium'], dtype=object))]",,"{'rows': array(['EFO_0009454', 'EFO_0004607', 'EFO_0003948', 'EFO_0007549'],
      dtype=object), 'count': 4}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved indications.
CHEMBL2216859,CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1,MCIDWGZGWVSZMK-UHFFFAOYSA-N,Small molecule,False,NEMIRALISIB,,2.0,,False,False,[],"['GSK-2269557' 'GSK-2269557 FREE BASE' 'GSK-2269557A' 'GSK2269557A'
 'Nemiralisib']",,['CHEMBL5314409' 'CHEMBL4297193'],"{'rows': array(['EFO_0000341', 'EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 3}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545141,,,Small molecule,False,RP-6530,,1.0,,False,False,[],['Rp-6530'],,,"{'rows': array(['EFO_0000574', 'EFO_0002913'], dtype=object), 'count': 2}","[ENSG00000105851,ENSG00000171608]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3545354,,,Small molecule,False,CAFUSERTIB,,1.0,,False,False,[],['Cafusertib'],,,"{'rows': array(['EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL4297520,CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1,OKFDRAHPFKMAJH-UHFFFAOYSA-N,Small molecule,False,OGLEMILAST,,2.0,,False,False,[],['GRC 3845' 'Oglemilast'],"[('drugbank', array(['DB12375'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297651,CO[C@@H]1[C@H](OC(=O)N2CC(CCN3CCOCC3)C2)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C,QJWJPMLDQYEPPW-AUKZVGPFSA-N,Small molecule,False,ACLIMOSTAT,,2.0,,False,False,[],['Aclimostat' 'ZGN-1061' 'Zgn-1061'],,,,[ENSG00000111142],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4298101,,,Antibody drug conjugate,False,LADIRATUZUMAB VEDOTIN,,2.0,,False,False,[],['Ladiratuzumab vedotin' 'SGN-LIV1A' 'Sgn-liv1a'],,,"{'rows': array(['EFO_0003968', 'EFO_0003869', 'EFO_0005537', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000141424,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4298189,,,Gene,False,ELADOCAGENE EXUPARVOVEC,2022.0,4.0,,False,True,['Upstaza'],['AGIL-AADC' 'Eladocagene exuparvovec'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELADOCAGENE%20EXUPARVOVEC/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004736'], dtype=object), 'count': 1}",[ENSG00000132437],Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for inborn disorder of amino acid metabolism.
CHEMBL4594460,,,Antibody,False,TEGOPRUBART,,2.0,,False,False,[],['AT-1501' 'At-1501' 'Tegoprubart'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]",,"{'rows': array(['MONDO_0004976', 'EFO_0004194', 'EFO_0005809', 'MONDO_0005147'],
      dtype=object), 'count': 4}",[ENSG00000102245],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4802163,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1,VQIIUJSNIKEMCK-MHZLTWQESA-N,Small molecule,False,NEZULCITINIB,,2.0,,False,False,[],['Nezulcitinib' 'TD-0903' 'THRX-136377' 'Td-0903'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NEZULCITINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0004610'], dtype=object), 'count': 2}","[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5315324,Cc1ccsc1C(=O)Nc1cc(CN2CCN(C(=O)CO)CC2)ccc1/C=C/c1n[nH]c2ccccc12,HHCSNTXVZDWIGT-CMDGGOBGSA-N,Small molecule,False,KW-2450 FREE BASE,,2.0,,False,False,[],[],,['CHEMBL5283463'],"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000171105,ENSG00000140443]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1072,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,MAEIEVLCKWDQJH-UHFFFAOYSA-N,Small molecule,True,BUMETANIDE,1983.0,4.0,,False,True,['Betinex' 'Bumetanide' 'Bumex' 'Burinex' 'Lixil'],['Bumetanide' 'RO 10-6338' 'RO-10-6338' 'RO-106338' 'S-95008.' 'S95008.'],"[('DailyMed', array(['bumetanide'], dtype=object)), ('PubChem', array(['11110843', '11110844', '144203639', '170464735', '26746951',
       '26751481', '50103991', '56424138', '855675'], dtype=object)), ('Wikipedia', array(['Bumetanide'], dtype=object)), ('drugbank', array(['DB00887'], dtype=object)), ('chEBI', array(['3213'], dtype=object))]",,"{'rows': array(['HP_0001250', 'EFO_0003086', 'MONDO_0005148', 'EFO_0003758',
       'EFO_0003756', 'EFO_0000373', 'EFO_0004255', 'EFO_0003144',
       'MONDO_0008223', 'EFO_0000319', 'EFO_0000182', 'EFO_0003884'],
      dtype=object), 'count': 12}",[ENSG00000074803],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL109480,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,AYUNIORJHRXIBJ-TXHRRWQRSA-N,Small molecule,False,TANESPIMYCIN,,3.0,,False,False,[],"['17-AAG' '17aag' 'BMS-722782' 'CNF-1010' 'CNF1010' 'KOS-953' 'NSC-330507'
 'Tanespimycin']","[('PubChem', array(['144205607', '26756800', '26756801', '574817'], dtype=object)), ('Wikipedia', array(['Tanespimycin'], dtype=object)), ('drugbank', array(['DB05134'], dtype=object)), ('chEBI', array(['64153'], dtype=object))]",,"{'rows': array(['EFO_0000565', 'MONDO_0001187', 'MONDO_0002367', 'EFO_0002428',
       'MONDO_0008903', 'EFO_1000785', 'EFO_0000333', 'EFO_0000616',
       'EFO_0009441', 'EFO_0000403', 'EFO_0001378', 'EFO_0000183',
       'MONDO_0015277', 'EFO_0000637', 'MONDO_0018906', 'MONDO_0001056',
       'MONDO_0019471', 'MONDO_0000873', 'EFO_1001365', 'EFO_0000255',
       'EFO_0000191', 'EFO_0000309', 'EFO_0000574', 'EFO_0006859',
       'EFO_0000641', 'EFO_0000673', 'MONDO_0004992', 'EFO_1001951',
       'EFO_0000756', 'EFO_0000095', 'EFO_0003032', 'MONDO_0001023',
       'EFO_1001051', 'EFO_0000389', 'MONDO_0007254', 'MONDO_0008315',
       'MONDO_0008170', 'EFO_1001469'], dtype=object), 'count': 38}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 38 investigational indications.
CHEMBL1190199,CN(C(=O)C(c1ccccc1)c1ccccc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1,JHLHNYVMZCADTC-LOSJGSFVSA-N,Small molecule,False,ASIMADOLINE,,3.0,,False,False,[],['Asimadoline' 'EMD-61753'],"[('Wikipedia', array(['Asimadoline'], dtype=object)), ('drugbank', array(['DB05104'], dtype=object))]",['CHEMBL540342'],"{'rows': array(['EFO_0000555', 'MONDO_0004567'], dtype=object), 'count': 2}",[ENSG00000082556],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1201533,,,Protein,False,THYROTROPIN ALFA,1998.0,4.0,,False,True,['Thyrogen'],['GX-30' 'Thyrotropin alfa' 'Thyrotropin alpha'],"[('DailyMed', array(['thyrotropin%20alfa'], dtype=object)), ('DrugCentral', array(['4930'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen'],
      dtype=object))]",,"{'rows': array(['EFO_0000501', 'MONDO_0002108', 'EFO_1001062', 'EFO_0002892',
       'EFO_0003841', 'EFO_0000641', 'EFO_0004237'], dtype=object), 'count': 7}",[ENSG00000165409],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 3 investigational indications.
CHEMBL1201584,,,Antibody,False,ABCIXIMAB,1993.0,4.0,,False,True,['Reopro'],['Abciximab' 'Abciximab (genetical recombination)' 'C7E3'],"[('DrugCentral', array(['4950'], dtype=object)), ('Wikipedia', array(['Abciximab'], dtype=object))]",,"{'rows': array(['EFO_0008583', 'EFO_0003913', 'MONDO_0005299', 'EFO_0000712',
       'EFO_0002615', 'HP_0004419', 'EFO_0008585', 'EFO_0000612',
       'EFO_1000985'], dtype=object), 'count': 9}","[ENSG00000259207,ENSG00000005961,ENSG00000138448]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for recurrent thrombophlebitis and intermediate coronary syndrome and has 7 investigational indications.
CHEMBL1208646,Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCC(=O)O,HXSKWEQQPCKYIF-UHFFFAOYSA-N,Small molecule,False,THEOPHYLLINE GLYCINATE,1982.0,4.0,,False,True,[],[],,['CHEMBL1200578'],,"[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1256842,CN1Cc2c(N)cccc2C(c2ccccc2)C1.O=C(O)/C=C\C(=O)O,GEOCVSMCLVIOEV-BTJKTKAUSA-N,Small molecule,False,NOMIFENSINE MALEATE,1984.0,4.0,CHEMBL273575,True,True,[],"['HOE 984' 'HOE-984' 'Hostalival' 'NSC-289114'
 'Nomifensine hydrogen maleate' 'Nomifensine maleate' 'Psicronizer']","[('PubChem', array(['170466450', '26747597', '26747598', '50106723', '50106724',
       '50106725', '855660', '93576623'], dtype=object))]",,,"[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. It was withdrawn in at least one region.
CHEMBL1742983,,,Antibody,False,ALACIZUMAB PEGOL,,2.0,,False,False,[],['Alacizumab pegol' 'CDP-791' 'g165 DFM-PEG'],,,,[ENSG00000128052],Antibody drug with a maximum clinical trial phase of II.
CHEMBL190083,C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,SYTBZMRGLBWNTM-SNVBAGLBSA-N,Small molecule,False,TARENFLURBIL,,3.0,,False,False,[],"['E-7869' 'Flurbiprofen, (r)-' 'MPC-7869' 'R-flurbiprofen' 'Tarenflurbil']","[('PubChem', array(['11112562', '11114208', '520769', '520770'], dtype=object)), ('drugbank', array(['DB05289'], dtype=object)), ('chEBI', array(['38666'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'HP_0000726', 'MONDO_0004975'], dtype=object), 'count': 3}","[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1908394,C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F,ZHJGWYRLJUCMRT-QGZVFWFLSA-N,Small molecule,False,GSK-461364,,1.0,,False,False,[],['GSK-461364A' 'GSK461364' 'Gsk 461364' 'Gsk-461364'],,,"{'rows': array(['EFO_0005952'], dtype=object), 'count': 1}",[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2107857,,,Protein,True,METRELEPTIN,2014.0,4.0,,False,True,['Myalepta'],"['Leptin (human), n-methionyl-' 'Metreleptin' 'Myalept'
 'N-methionylleptin (human)' 'R-METHULEPTIN']","[('DailyMed', array(['metreleptin'], dtype=object)), ('DrugCentral', array(['4826'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta'],
      dtype=object))]",,"{'rows': array(['EFO_0001073', 'EFO_0003095', 'EFO_0002614', 'EFO_0001421',
       'MONDO_0020088', 'EFO_1000728', 'MONDO_0005147', 'EFO_0002756',
       'EFO_0000195', 'EFO_1001348', 'EFO_0010269', 'EFO_1000727'],
      dtype=object), 'count': 12}",[ENSG00000116678],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109151,,,Antibody,False,LUMILIXIMAB,,2.0,,False,False,[],"['Gomiliximab' 'IDEC-152' 'Lumiliximab' 'P5E8 SI-3401 GOMILIXIMAB'
 'Primatized anti-cd23' 'ST-152']",,,"{'rows': array(['EFO_0000574', 'EFO_0000095', 'EFO_0000565'], dtype=object), 'count': 3}",[ENSG00000104921],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2140408,Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1,IVUGFMLRJOCGAS-UHFFFAOYSA-N,Small molecule,False,AMG-900,,1.0,,False,False,[],['AMG-900' 'AMG900' 'Amg 900' 'Amg-900'],"[('PubChem', array(['137275938'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'MONDO_0004643'], dtype=object), 'count': 2}","[ENSG00000178999,ENSG00000105146,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL296913,CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+],HQPVVKXJNZEAFW-UHFFFAOYSA-M,Small molecule,False,PARECOXIB SODIUM,2002.0,4.0,CHEMBL1206690,False,True,['Dynastat'],['Parecoxib sodium' 'Parecoxib sodium salt' 'SC-69124A'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dynastat'],
      dtype=object)), ('PubChem', array(['144206591'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'MONDO_0005178'], dtype=object), 'count': 2}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for pain and has 1 investigational indication.
CHEMBL3183075,CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1,SGXXNSQHWDMGGP-UHFFFAOYSA-N,Small molecule,False,NIZATIDINE,1988.0,4.0,,False,True,['Axid' 'Axid ar' 'Nizatidine' 'Zinga 150' 'Zinga 300'],['Acinon' 'LY 139037' 'LY-139037' 'NSC-759289' 'Nizatidine'],"[('DailyMed', array(['nizatidine'], dtype=object)), ('PubChem', array(['144204242', '144211911', '170464780'], dtype=object)), ('drugbank', array(['DB00585'], dtype=object)), ('chEBI', array(['7601'], dtype=object))]",,"{'rows': array(['EFO_1000948', 'EFO_0000217', 'HP_0004398', 'EFO_0003948',
       'HP_0100633', 'EFO_0004607'], dtype=object), 'count': 6}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 2 investigational indications.
CHEMBL3301595,N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,SRPXSILJHWNFMK-MEDUHNTESA-N,Small molecule,False,DASOTRALINE,,3.0,,False,False,[],"['(1r,4s)-trans-norsertraline' 'Dasotraline'
 'Norsertraline, (1r,4s)-trans-' 'SEP-225289']","[('drugbank', array(['DB12305'], dtype=object))]",['CHEMBL3301596'],"{'rows': array(['MONDO_0002009', 'EFO_0005203', 'EFO_0003888'], dtype=object), 'count': 3}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL35,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,Small molecule,True,FUROSEMIDE,1966.0,4.0,,False,True,"['Aluzine 20' 'Aluzine 40' 'Aluzine 500' 'Aquamed' 'Disal' 'Diuresal'
 'Dryptal' 'Froop' 'Frumax' 'Frumil' 'Frusemide' 'Frusetic' 'Frusid'
 'Frusol' 'Furosemide' 'Hydroled' 'Lasix' 'Lasix ret' 'Rusyde'
 'Tenkofruse']","['Frusemide' 'Furoscix' 'Furosemide' 'Furosemidum' 'LB-502' 'Logirene'
 'Marsemide' 'Mirfat' 'NSC-269420' 'Oedemex']","[('DailyMed', array(['furosemide'], dtype=object)), ('PubChem', array(['11112125', '144203873', '144209411', '144213288', '170464879',
       '17389872', '47193739'], dtype=object)), ('TG-GATEs', array(['78'], dtype=object)), ('Wikipedia', array(['Furosemide'], dtype=object)), ('drugbank', array(['DB00695'], dtype=object)), ('chEBI', array(['47426'], dtype=object))]",['CHEMBL1788133'],"{'rows': array(['EFO_0002617', 'MONDO_0019091', 'MONDO_0005090', 'EFO_0001422',
       'EFO_0000400', 'EFO_0009373', 'EFO_0000319', 'HP_0003124',
       'HP_0011950', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000341',
       'EFO_1000391', 'EFO_0009840', 'EFO_0000373', 'EFO_0003086',
       'EFO_0008583', 'MONDO_0001134', 'EFO_0009662', 'EFO_1001134',
       'EFO_0000668', 'HP_0002094', 'EFO_1002048', 'EFO_0003827',
       'EFO_0003144', 'EFO_0004610', 'EFO_0003917', 'EFO_0001645',
       'EFO_0000222', 'EFO_0003914', 'MONDO_0005148', 'MONDO_0024664',
       'EFO_0000537', 'EFO_0004255', 'EFO_0003818', 'HP_0001919',
       'EFO_0002496', 'EFO_0003884', 'EFO_0004253'], dtype=object), 'count': 39}",[ENSG00000074803],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 7 approved and 32 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3544988,O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,RUEYEZADQJCKGV-UHFFFAOYSA-N,Small molecule,True,DAPRODUSTAT,2023.0,4.0,,False,True,['Jesduvroq'],['Daprodustat' 'GSK-1278863' 'GSK1278863' 'Jesduvroq'],"[('drugbank', array(['DB11682'], dtype=object))]",,"{'rows': array(['EFO_0003884', 'EFO_0003875', 'EFO_0000546', 'MONDO_0002280',
       'EFO_0004272'], dtype=object), 'count': 5}","[ENSG00000269858,ENSG00000178467,ENSG00000135766,ENSG00000129521]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545386,,,Small molecule,False,BI113823,,1.0,,False,False,[],['Bi113823'],,,"{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}",[ENSG00000100739],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3646118,O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1,IJMBOKOTALXLKS-UHFFFAOYSA-N,Small molecule,False,MOLIDUSTAT,,2.0,,False,False,[],['BAY 85-3934' 'BAY-85-3934' 'Molidustat'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOLIDUSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15642'], dtype=object))]",['CHEMBL3931782'],"{'rows': array(['EFO_0004272', 'EFO_0004272'], dtype=object), 'count': 2}","[ENSG00000269858,ENSG00000129521,ENSG00000135766]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication.
CHEMBL3702854,CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1,LCFFREMLXLZNHE-GBOLQPHISA-N,Small molecule,False,RILZABRUTINIB,,3.0,,False,False,[],['PRN1008' 'Prn-1008' 'Prn1008' 'Rilzabrutinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RILZABRUTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000274', 'EFO_1001264', 'MP_0001845', 'MONDO_0004979',
       'EFO_0005531', 'MONDO_0017287', 'EFO_1000749', 'EFO_0007160',
       'EFO_0005809', 'EFO_0004719'], dtype=object), 'count': 10}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL3991065,C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,QIVUCLWGARAQIO-OLIXTKCUSA-N,Small molecule,False,ATOGEPANT,2021.0,4.0,,False,True,['Qulipta'],['AGN-241689' 'Atogepant' 'MK-8031'],,['CHEMBL3981883'],"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for migraine disorder.
CHEMBL4297646,Fc1cc(F)c(OCc2ccccc2C2CCNCC2)c(F)c1,TZIALEBTHQWNAO-UHFFFAOYSA-N,Small molecule,False,AMPRELOXETINE,,3.0,,False,False,[],['Ampreloxetine' 'TD-9855' 'Td-9855'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMPRELOXETINE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15348'], dtype=object))]",['CHEMBL4594277'],"{'rows': array(['MONDO_0005180', 'EFO_0003888', 'EFO_0005252', 'EFO_1001050',
       'EFO_0005252', 'EFO_0005687'], dtype=object), 'count': 6}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4297838,,,Unknown,False,TILSOTOLIMOD,,3.0,,False,False,[],['IMO-2125' 'Tilsotolimod'],,,"{'rows': array(['EFO_0002617', 'EFO_0000616', 'EFO_0000756', 'MONDO_0004992'],
      dtype=object), 'count': 4}",[ENSG00000239732],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL450044,CCOC(=O)OC[C@H]1O[C@@H](Oc2ccccc2Cc2ccc(OC)cc2)[C@H](O)[C@@H](O)[C@@H]1O,QLXKHBNJTPICNF-QMCAAQAGSA-N,Small molecule,False,SERGLIFLOZIN ETABONATE,,2.0,,False,False,[],"['GW-869682X' 'GW-869683X' 'GW869682X' 'Sergliflozin' 'Sergliflozin a'
 'Sergliflozin etabonate']",,,,[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4582651,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1,GBLBJPZSROAGMF-RWYJCYHVSA-N,Small molecule,False,PRALSETINIB,2020.0,4.0,,False,True,['Gavreto'],"['BLU-123244' 'BLU-667' 'BLU123244' 'Blu-667' 'Pralsetinib' 'X-581238'
 'X581238']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PRALSETINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0015277', 'EFO_0000616', 'MONDO_0004992', 'EFO_0003060'],
      dtype=object), 'count': 4}","[ENSG00000165731,ENSG00000108091,ENSG00000170759]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved indications.
CHEMBL4651002,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12,BOOMBLZEOHXPPX-BQYQJAHWSA-N,Small molecule,False,SAFUSIDENIB,,2.0,,False,False,[],['Safusidenib'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",['CHEMBL4650282'],"{'rows': array(['EFO_0000616', 'EFO_0005543'], dtype=object), 'count': 2}",[ENSG00000138413],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL488,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O,ROBVIMPUHSLWNV-UHFFFAOYSA-N,Small molecule,False,AMINOGLUTETHIMIDE,1980.0,4.0,,False,True,['Cytadren' 'Orimeten'],['Aminoglutethimide' 'Cytadren' 'NSC-330915'],"[('PubChem', array(['144203957', '144213805', '170465259', '174007456', '26747446',
       '459146', '46500462', '50105852', '85230926', '90340970'],
      dtype=object)), ('Wikipedia', array(['Aminoglutethimide'], dtype=object)), ('drugbank', array(['DB00357'], dtype=object)), ('chEBI', array(['2654'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 3}","[ENSG00000137869,ENSG00000140459]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for neoplasm and has 2 investigational indications.
CHEMBL1121,CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,IZTQOLKUZKXIRV-YRVFCXMDSA-N,Protein,False,SINCALIDE,1976.0,4.0,,False,True,['Kinevac'],"['Cck c-terminal octapeptide' 'Cck-8' 'Cholecystokinin'
 'Cholecystokinin c-terminal octapeptide' 'Pancreozymin' 'SQ 19844'
 'SQ-19844' 'Sincalide']","[('DailyMed', array(['sincalide'], dtype=object)), ('PubChem', array(['144206508', '144207030'], dtype=object)), ('Wikipedia', array(['Sincalide'], dtype=object)), ('drugbank', array(['DB09142'], dtype=object))]",,,[ENSG00000163394],Protein drug with a maximum clinical trial phase of IV that was first approved in 1976.
CHEMBL1200862,C[C@](N)(Cc1ccc(O)cc1)C(=O)O,NHTGHBARYWONDQ-JTQLQIEISA-N,Small molecule,False,METYROSINE,1979.0,4.0,,False,True,['Demser'],"['L-588357-0' 'MK-781' 'Metirosine' 'Metyrosine' 'Racemetirosine, (s)-']","[('DailyMed', array(['metyrosine'], dtype=object)), ('PubChem', array(['170465112', '29215162', '50106644', '50106645', '50106646',
       '90341393'], dtype=object)), ('Wikipedia', array(['Metirosine'], dtype=object)), ('drugbank', array(['DB00765'], dtype=object)), ('chEBI', array(['6912'], dtype=object))]",,"{'rows': array(['EFO_0000239', 'EFO_0000537', 'EFO_0005407', 'EFO_0000174'],
      dtype=object), 'count': 4}",[ENSG00000180176],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for adrenal gland pheochromocytoma and hypertension and has 2 investigational indications.
CHEMBL1354199,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-],CXYRUNPLKGGUJF-RAFJPFSSSA-M,Small molecule,False,METHSCOPOLAMINE BROMIDE,1953.0,4.0,CHEMBL376897,False,True,['Methscopolamine bromide' 'Pamine' 'Pamine forte'],"['(-)-Scopolamine Methyl Bromide' 'Epoxytropine tropate methylbromide'
 'Holopon' 'Hyoscine methobromide' 'Methscopolamine bromide'
 'Methylscopolamine bromide' 'N-methylscopolamine bromide'
 'N-methylscopolamine methylsulfate' 'NSC-120606'
 'Scopolamine methyl bromide' 'Scopolamine methylbromide']","[('DailyMed', array(['methscopolamine%20bromide'], dtype=object)), ('PubChem', array(['11532979', '144203588', '170464623'], dtype=object)), ('chEBI', array(['61276'], dtype=object))]",,,"[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953.
CHEMBL1739,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3.[I-].[I-],DIGFQJFCDPKEPF-OIUSMDOTSA-L,Small molecule,False,METOCURINE IODIDE,1982.0,4.0,CHEMBL1259,False,True,['Metubine iodide'],"['Dimethyl tubocurarine iodide' 'Dimethylchondrocurarine iodide'
 'Dimethyltubocurarinium iodide' 'Metocurine iodide' 'NSC-36388']","[('PubChem', array(['144206308', '170465111'], dtype=object)), ('drugbank', array(['DB00416'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1773683,CCS(=O)(=O)c1ccc2oc(-c3ccc4ccccc4c3)nc2c1,KSGCNXAZROJSNW-UHFFFAOYSA-N,Small molecule,False,EZUTROMID,,2.0,,False,False,[],"['BMN 195' 'BMN-195' 'BMN195' 'Ezutromid' 'SMT-C1100' 'SMTC-1100'
 'Smt c1100']","[('drugbank', array(['DB12888'], dtype=object))]",,"{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}",[ENSG00000152818],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1908376,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,LVLLALCJVJNGQQ-SEODYNFXSA-N,Small molecule,False,SEOCALCITOL,,3.0,,False,False,[],['CB-1089' 'Eb-1089' 'Seocalcitol'],"[('drugbank', array(['DB04258'], dtype=object))]",,"{'rows': array(['EFO_0000182'], dtype=object), 'count': 1}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL19299,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,YMBXTVYHTMGZDW-UHFFFAOYSA-N,Small molecule,False,LOXOPROFEN,1986.0,4.0,,False,True,[],['Loxoprofen' 'Loxoprofen acid' 'Loxoprofen sodium'],"[('PubChem', array(['144203729', '170465808', '50106490', '85231106', '90341428'],
      dtype=object)), ('Wikipedia', array(['Loxoprofen'], dtype=object)), ('drugbank', array(['DB09212'], dtype=object)), ('chEBI', array(['76172'], dtype=object))]",['CHEMBL66552'],"{'rows': array(['HP_0002829', 'HP_0003326', 'EFO_0000685', 'EFO_0002970',
       'EFO_0003843', 'HP_0030833', 'HP_0003419'], dtype=object), 'count': 7}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 investigational indications.
CHEMBL2018096,OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,AHFWIQIYAXSLBA-RQXATKFSSA-N,Small molecule,False,IPRAGLIFLOZIN,2014.0,4.0,,False,True,[],['ASP-1941' 'Ipragliflozin'],"[('drugbank', array(['DB11698'], dtype=object))]",,"{'rows': array(['MONDO_0005147', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 investigational indications.
CHEMBL2109093,,,Protein,False,EPOETIN DELTA,2002.0,4.0,,False,True,['Dynepo'],['Epoetin delta' 'GA-EPO' 'HMR-4396' 'HMR4396'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dynepo'],
      dtype=object))]",,"{'rows': array(['EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 2}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for chronic kidney disease and anemia (phenotype).
CHEMBL2109406,,,Antibody,False,PATRITUMAB,,3.0,,False,False,[],['AMG 888' 'Patritumab' 'U3-1287'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PATRITUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000181', 'EFO_0003060', 'EFO_0004284', 'EFO_0003968',
       'EFO_0000616', 'EFO_0005537'], dtype=object), 'count': 6}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2178570,CC(=O)Nc1ccc(O)cc1OC[C@@](C)(O)CNC1CCN(Cc2ccc(Cl)cc2)CC1,RKWKLTLIBREDHD-DEOSSOPVSA-N,Small molecule,False,AZD4818,,2.0,,False,False,[],['AZD-4818' 'AZD4818' 'Azd 4818' 'Azd-4818' 'Azd4818'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000163823],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2218896,CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)C1CCC(=O)CC21,GECBBEABIDMGGL-UHFFFAOYSA-N,Small molecule,False,NABILONE,1985.0,4.0,,False,True,['Cesamet'],['CPD 109514' 'CPD-109514' 'Nabilone'],"[('DailyMed', array(['nabilone'], dtype=object))]",,"{'rows': array(['EFO_0005687', 'EFO_0004320', 'EFO_0005762', 'EFO_0004242',
       'HP_0002018', 'EFO_0007191', 'EFO_1000783', 'HP_0001257',
       'EFO_0001073', 'MONDO_0004992', 'EFO_0004888', 'HP_0002017',
       'MONDO_0005180'], dtype=object), 'count': 13}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 9 investigational indications.
CHEMBL284121,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,JKFZMIQMKFWJAY-RQJQXFIZSA-N,Small molecule,False,ILX23-7553,,1.0,,False,False,[],"['BXL 353' 'BXL-353' 'ILEX-23-7553' 'ILX-23-7553' 'ILX-237553' 'ILX7553'
 'Ilx 237553' 'Ilx23-7553' 'Ro-23-7553']",,,,[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545050,,,Small molecule,False,BMS-817378,,1.0,,False,False,[],['Bms-817378'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000105976,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545200,,,Small molecule,False,S-222611,,1.0,,False,False,[],['S-222611'],,,,"[ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545259,,,Antibody,False,VANUCIZUMAB,,2.0,,False,False,[],['C0u97738ae' 'RG-7221' 'RG7221' 'RO-5520985' 'RO5520985' 'Vanucizumab'],,,"{'rows': array(['EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 2}","[ENSG00000091879,ENSG00000112715]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3707315,,,Small molecule,False,D-3263,,1.0,,False,False,[],['D 3263' 'D-3263' 'D-3263 (FREE BASE)'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000144481],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3936761,C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,RNOAOAWBMHREKO-QFIPXVFZSA-N,Small molecule,False,ZANUBRUTINIB,2019.0,4.0,,False,True,['Brukinsa'],['BGB-3111' 'Bgb-3111' 'Zanubrutinib'],"[('DailyMed', array(['zanubrutinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANUBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15035'], dtype=object))]",,"{'rows': array(['MONDO_0015540', 'EFO_0004256', 'EFO_0000096', 'MONDO_0004992',
       'EFO_0003086', 'EFO_0005761', 'EFO_1001469', 'EFO_0009441',
       'EFO_1000630', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0017287',
       'EFO_0000403', 'EFO_1001264', 'EFO_0000616', 'MONDO_0015564',
       'MONDO_0100096', 'EFO_0007160', 'EFO_0000565', 'EFO_0000574'],
      dtype=object), 'count': 20}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 16 investigational indications.
CHEMBL409,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,LKJPYSCBVHEWIU-UHFFFAOYSA-N,Small molecule,False,BICALUTAMIDE,1995.0,4.0,,False,True,['Bicalutamide' 'Calutide' 'Casodex' 'Cosudex' 'Kalumid'],"['Bicalutamide' 'Casodex' 'ICI 176,334' 'ICI-176334' 'ICI176,334-1'
 'NSC-759816']","[('DailyMed', array(['bicalutamide'], dtype=object)), ('PubChem', array(['26719836'], dtype=object)), ('drugbank', array(['DB01128'], dtype=object))]",,"{'rows': array(['EFO_0000196', 'MONDO_0002087', 'MONDO_0001187', 'EFO_0000313',
       'EFO_0000673', 'EFO_0003869', 'MONDO_0008315', 'MONDO_0000088',
       'MONDO_0002158', 'EFO_0000694', 'MONDO_0008170', 'EFO_0000305',
       'MONDO_0100096', 'EFO_0001663', 'HP_0000771', 'EFO_0000616',
       'MONDO_0004669', 'MONDO_0007254'], dtype=object), 'count': 18}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for carcinoma and neoplasm and has 16 investigational indications.
CHEMBL4650501,,,Unknown,False,PF-4136309,,2.0,,False,False,[],"['INCB-8761' 'INCB8761' 'PF-04136309' 'PF-4136309' 'Pf-04136309'
 'Pf-4136309']",,,"{'rows': array(['MONDO_0005184', 'EFO_0004220', 'EFO_0003860', 'EFO_0004616'],
      dtype=object), 'count': 4}",[ENSG00000121807],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL480,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,MJIHNNLFOKEZEW-UHFFFAOYSA-N,Small molecule,False,LANSOPRAZOLE,1995.0,4.0,,False,True,"['Lansoprazole' 'Opiren' 'Prevacid' 'Prevacid 24 hr'
 'Prevacid Delayed Release' 'Prevacid Solutab' 'Prevacid iv' 'Zoton']","['A-65006' 'AG-1749' 'Agopton' 'Lansoprazole' 'Lansox' 'Lanzoprazole'
 'Lanzor' 'Limpidex' 'NSC-758638' 'Ogast' 'Ogastoro' 'Prevonco' 'Takepron']","[('DailyMed', array(['lansoprazole'], dtype=object)), ('PubChem', array(['11111389', '11111390', '124880589', '124880592', '144203735',
       '144211340', '170464649', '174007196', '26719660', '26747053',
       '50104195', '50104197', '56422192', '57287635', '85231117',
       '855954', '90341606'], dtype=object)), ('Wikipedia', array(['Lansoprazole'], dtype=object)), ('drugbank', array(['DB00448'], dtype=object)), ('chEBI', array(['6375'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0009454', 'MONDO_0011962', 'EFO_0000768',
       'EFO_0000095', 'EFO_1001355', 'EFO_0003843', 'EFO_0000574',
       'EFO_0000616', 'EFO_0003917', 'EFO_0004274', 'EFO_1001095',
       'MONDO_0005178', 'EFO_0007456', 'EFO_0003948', 'MONDO_0005147',
       'EFO_1000657', 'EFO_0004607', 'HP_0004398', 'EFO_1000961',
       'MONDO_0002974', 'MONDO_0009061', 'EFO_0000217', 'EFO_0004232'],
      dtype=object), 'count': 24}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 4 approved and 20 investigational indications.
CHEMBL639,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,MBUVEWMHONZEQD-UHFFFAOYSA-N,Small molecule,False,AZELASTINE,1996.0,4.0,,False,True,[],['Azelastine' 'NSC-758971'],"[('Wikipedia', array(['Azelastine'], dtype=object)), ('drugbank', array(['DB00972'], dtype=object)), ('chEBI', array(['2950'], dtype=object))]",['CHEMBL1200809'],"{'rows': array(['HP_0001742', 'MONDO_0005271', 'EFO_0005854', 'EFO_0005751',
       'EFO_0005854', 'EFO_0009364', 'EFO_0003956', 'HP_0001742',
       'EFO_1001417', 'EFO_1001417', 'EFO_0003956', 'EFO_0007533',
       'EFO_0007141'], dtype=object), 'count': 13}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 4 investigational indications.
CHEMBL717,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,PSGAAPLEWMOORI-PEINSRQWSA-N,Small molecule,True,MEDROXYPROGESTERONE ACETATE,1959.0,4.0,,False,True,"['Adgyn medro' 'Amen' 'Climanor' 'Curretab' 'Cycrin' 'Depo-progevera'
 'Depo-provera' 'Depo-provera oncology' 'Depo-subq provera 104' 'Farlutal'
 'Farlutal 100' 'Farlutal 200' 'Farlutal 250' 'Farlutal 500' 'Lunelle'
 'Medroxyprogesterone acetate' 'Provera' 'Sayana press']","['Amen' 'Depot-medroxyprogesterone acetate' 'Farlutal inyectable'
 'G03AC06' 'Medroxiprogesterone acetate' 'Medroxyprogesterone'
 'Medroxyprogesterone 17-acetate' 'Medroxyprogesterone Acetate'
 'Medroxyprogesterone acetate' 'Medroxyprogesteroni acetas' 'NSC-21171'
 'NSC-26386' 'NSC-27408' 'Prempro' 'Provera' 'TV-46046']","[('DailyMed', array(['medroxyprogesterone%20acetate'], dtype=object)), ('PubChem', array(['144204872', '144207339', '170464622', '17388931', '26751478',
       '56422500', '855664'], dtype=object)), ('Wikipedia', array(['Medroxyprogesterone_acetate'], dtype=object)), ('drugbank', array(['DB00603'], dtype=object)), ('chEBI', array(['6716'], dtype=object))]",,"{'rows': array(['MONDO_0011962', 'EFO_0000536', 'MONDO_0007915', 'EFO_0000198',
       'EFO_0000537', 'EFO_0000545', 'EFO_0000400', 'EFO_0000616',
       'HP_0031217', 'GO_0042697', 'HP_0000132', 'EFO_0001065',
       'EFO_1001375', 'EFO_0000764', 'EFO_0000180', 'HP_0008209',
       'EFO_0003843', 'EFO_0000681', 'EFO_0003882', 'MONDO_0019499',
       'EFO_0002890', 'MP_0001914', 'MONDO_0002367', 'EFO_0000673',
       'MONDO_0000831', 'EFO_0001645', 'HP_0003124', 'EFO_0004230',
       'EFO_0003877', 'EFO_0003777', 'MONDO_0004975', 'EFO_0002950'],
      dtype=object), 'count': 32}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 6 approved and 26 investigational indications. This drug has a black box warning from the FDA.
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],YOEWQQVKRJEPAE-UHFFFAOYSA-L,Small molecule,True,SUCCINYLCHOLINE CHLORIDE,1952.0,4.0,CHEMBL703,False,True,"['Anectine' 'Quelicin' 'Quelicin preservative free' 'Scoline'
 'Succinylcholine chloride' 'Sucostrin' 'Suxamethonium Chloride']","['Choline chloride succinate (2:1)' 'NSC-49132' 'Succinylcholine chloride'
 'Suxamethone' 'Suxamethonii chloridum' 'Suxamethonium chloride'
 'Suxamethonium chloride dihydrate' 'Suxamethonium chloride hydrate']","[('DailyMed', array(['succinylcholine%20chloride'], dtype=object)), ('PubChem', array(['144204820', '170464625', '50106980'], dtype=object)), ('Wikipedia', array(['Suxamethonium_chloride'], dtype=object)), ('chEBI', array(['61219'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1952. This drug has a black box warning from the FDA.
CHEMBL1180725,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C,VVWYOYDLCMFIEM-UHFFFAOYSA-N,Small molecule,False,PROPANTHELINE,1953.0,4.0,,False,True,[],['Propantheline' 'Propantheline cation' 'Propantheline ion'],"[('PubChem', array(['11111683', '11112101', '90340675'], dtype=object)), ('drugbank', array(['DB00782'], dtype=object)), ('chEBI', array(['8481'], dtype=object))]",['CHEMBL1240'],"{'rows': array(['MONDO_0004247', 'EFO_0010282', 'EFO_1000781'], dtype=object), 'count': 3}","[ENSG00000133019,ENSG00000168539,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for peptic ulcer disease and gastrointestinal disease and has 1 investigational indication.
CHEMBL1200686,CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,KASDHRXLYQOAKZ-XDSKOBMDSA-N,Small molecule,True,PIMECROLIMUS,2001.0,4.0,,False,True,['Elidel'],"['(-)-pimecrolimus' 'Pimecrolimus' 'SDZ ASM 981' 'SDZ ASM-981'
 'SDZ-ASM 981' 'SDZ-ASM-981']","[('DailyMed', array(['pimecrolimus'], dtype=object)), ('Wikipedia', array(['Pimecrolimus'], dtype=object)), ('drugbank', array(['DB00337'], dtype=object))]",,"{'rows': array(['EFO_1000906', 'MONDO_0009735', 'EFO_0000274', 'EFO_1000726',
       'EFO_1000764', 'HP_0000964', 'MONDO_0002406', 'EFO_1000724',
       'EFO_1001305', 'EFO_0004208', 'EFO_0008517'], dtype=object), 'count': 11}",[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for atopic eczema and eczematoid dermatitis and has 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200953,CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,FOGXJPFPZOHSQS-AYVLZSQQSA-N,Small molecule,False,HYDROCORTISONE PROBUTATE,1997.0,4.0,,False,True,['Pandel'],"['Hydrocortisone buteprate' 'Hydrocortisone butyrate propionate'
 'Hydrocortisone probutat' 'Hydrocortisone probutate' 'TS 408' 'TS-408']","[('PubChem', array(['144206491'], dtype=object)), ('drugbank', array(['DB14543'], dtype=object)), ('chEBI', array(['31675'], dtype=object))]",,"{'rows': array(['EFO_0000701'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for skin disease.
CHEMBL1549,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,DLVOSEUFIRPIRM-KAQKJVHQSA-N,Small molecule,False,HYDROCORTISONE CYPIONATE,1955.0,4.0,,False,True,['Cortef'],"['Hydrocortisone Cypionate' 'Hydrocortisone cipionate'
 'Hydrocortisone cyclopentylpropionate' 'Hydrocortisone cypionate'
 'NSC-10721']","[('PubChem', array(['75847'], dtype=object)), ('drugbank', array(['DB14541'], dtype=object)), ('chEBI', array(['5783'], dtype=object))]",,"{'rows': array(['MONDO_0015129'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and has 1 investigational indication.
CHEMBL1587,CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O,CYLWJCABXYDINA-UHFFFAOYSA-N,Small molecule,False,POLYTHIAZIDE,1961.0,4.0,,False,True,['Nephril' 'Renese'],['NSC-108161' 'P-2525' 'Polythiazide'],"[('PubChem', array(['144206688', '170465068'], dtype=object)), ('Wikipedia', array(['Polythiazide'], dtype=object)), ('drugbank', array(['DB01324'], dtype=object)), ('chEBI', array(['8327'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961 and is indicated for cardiovascular disease.
CHEMBL1639,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,UXOWGYHJODZGMF-QORCZRPOSA-N,Small molecule,True,ALISKIREN,2007.0,4.0,,False,True,['Rasilez'],['Aliskiren' 'SPP-100' 'SPP100'],"[('Wikipedia', array(['Aliskiren'], dtype=object)), ('drugbank', array(['DB09026'], dtype=object)), ('chEBI', array(['601027'], dtype=object))]",['CHEMBL559358' 'CHEMBL1667' 'CHEMBL3545059' 'CHEMBL3508698'],"{'rows': array(['EFO_0000537', 'EFO_0000275', 'EFO_0000537', 'EFO_0000400',
       'EFO_0003884', 'MONDO_0001134', 'MONDO_0005148', 'EFO_0000712',
       'EFO_0000319', 'MONDO_0007947', 'EFO_0000401', 'EFO_0004194',
       'EFO_0003144', 'EFO_0000373', 'EFO_0003086', 'EFO_0005672',
       'MONDO_0021661', 'EFO_0003914', 'EFO_0003896', 'EFO_0000612'],
      dtype=object), 'count': 20}",[ENSG00000143839],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743003,,,Antibody,False,CONATUMUMAB,,2.0,,False,False,[],"['AMG 655' 'AMG-655' 'Conatumumab' 'TRAIL-R2 MAB' 'TRAIL-R2-MAB'
 'TRAIL-R2MAB XG1-048' 'XG1-048']",,,"{'rows': array(['EFO_0000183', 'EFO_0003060', 'EFO_0002618', 'EFO_1001469',
       'EFO_0000403', 'EFO_1001968', 'MONDO_0008170', 'MONDO_0002158'],
      dtype=object), 'count': 8}",[ENSG00000120889],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL1940832,O=CNc1cc([C@@H](O)CNCCc2ccc(NC[C@H](O)c3ccccc3)cc2)ccc1O,BMKINZUHKYLSKI-DQEYMECFSA-N,Small molecule,False,MILVETEROL,,2.0,,False,False,[],['GSK-159797' 'GSK159797' 'Gsk159797' 'Milveterol' 'TD3327'],,['CHEMBL2107356'],"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108280,,,Oligonucleotide,False,CENERSEN,,2.0,,False,False,[],['Cenersen'],,,"{'rows': array(['EFO_0000222', 'EFO_0000198'], dtype=object), 'count': 2}",[ENSG00000141510],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545106,,,Protein,False,TM30339,,2.0,,False,False,[],['Tm30339'],,,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}",[ENSG00000204174],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3833321,,,Antibody,False,LECANEMAB,2023.0,4.0,,False,True,['Leqembi'],"['BAN-2401' 'BAN2401' 'Ban 2401' 'Lecanemab' 'Lecanemab irmb'
 'Lecanemab-irmb' 'Leqembi']",,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for alzheimer disease.
CHEMBL3989754,CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1.O.O.[Na+],GNMBMOULKUXEQF-UHFFFAOYSA-M,Small molecule,False,FLURBIPROFEN SODIUM,1986.0,4.0,CHEMBL563,False,True,['Ansaid' 'Flurbiprofen sodium' 'Occufen' 'Ocufen' 'Zepolas'],"['Flurbiprofen sodium' 'Flurbiprofen sodium anhydrous'
 'Flurbiprofen sodium dihydrate']","[('DailyMed', array(['flurbiprofen%20sodium'], dtype=object))]",,,"[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986.
CHEMBL4297846,,,Antibody,False,SEMZUVOLIMAB,,3.0,,False,False,[],"['Db4c7 mab' 'Mab db4c7' 'Semzuvolimab' 'Semzuvolimab ' 'UB-421'
 'UB-421 (DB4C7 MAB)' 'UB421' 'Ub-421']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",,"{'rows': array(['EFO_0000180', 'EFO_0000544', 'EFO_0005809'], dtype=object), 'count': 3}",[ENSG00000010610],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4301600,CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12,PTIFVLOBVCIMKL-UHFFFAOYSA-N,Small molecule,False,BMS-823778,,2.0,,False,False,[],[],,['CHEMBL4297457'],"{'rows': array(['EFO_0000319', 'MONDO_0005148', 'Orphanet_309005', 'EFO_0000537'],
      dtype=object), 'count': 4}",[ENSG00000117594],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL434,CC(C)NCC(O)c1ccc(O)c(O)c1,JWZZKOKVBUJMES-UHFFFAOYSA-N,Small molecule,False,ISOPROTERENOL,1956.0,4.0,,False,True,[],"['A-21' 'Aleudrin' 'Aludrine' 'Asiprenol' 'Asmalar' 'Assiprenol'
 'Bellasthman' 'Isonorin' 'Isoprenaline' 'Isopropydrin' 'Isoproterenol'
 'Isoproterenol dl-form' 'Isorenin' 'Isupren' 'NSC-33791' 'NSC-9975'
 'Neo-epinine' 'Neodrenal' 'Novodrin' 'Proternol' 'Respifral' 'Saventrine'
 'Vapo-n-iso']","[('PubChem', array(['104171176', '144203723', '170464679', '26752240', '50104946',
       '50111114', '90340610'], dtype=object)), ('Wikipedia', array(['Isoprenaline'], dtype=object)), ('drugbank', array(['DB01064'], dtype=object)), ('chEBI', array(['64317'], dtype=object))]",['CHEMBL3989521' 'CHEMBL1711'],"{'rows': array(['EFO_0000319', 'EFO_0000373', 'EFO_1000645', 'EFO_0000275',
       'EFO_0000759', 'EFO_0001073', 'EFO_0005252', 'EFO_0004253',
       'HP_0006536'], dtype=object), 'count': 9}","[ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 3 approved and 6 investigational indications.
CHEMBL4594254,C(=C/[C@H]1CCNC1)\c1cncnc1,FNEHSHNEXMPCLJ-VWCDRPFISA-N,Small molecule,False,SIMPINICLINE,,2.0,,False,False,[],['OC-02' 'Oc-02' 'Simpinicline' 'TC-6499' 'TC-6499-12' 'TC6499' 'Tc-6499'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMPINICLINE/relevant/1/'],
      dtype=object))]",['CHEMBL4594377'],"{'rows': array(['EFO_1000906', 'EFO_1000948', 'EFO_0000555', 'EFO_1000906'],
      dtype=object), 'count': 4}","[ENSG00000160716,ENSG00000101204,ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4596972,c1cnc2ccc(Nc3nc(NC4CC4)c4nc[nH]c4n3)cc2c1,QUTFBURLXCODBH-UHFFFAOYSA-N,Small molecule,False,PUQUITINIB MESYLATE DIHYDRATE,,1.0,,False,False,[],"['Puquitinib dimesylate dihydrate' 'Puquitinib mesylate dihydrate'
 'Xc-302']",,['CHEMBL4545915'],,"[ENSG00000128052,ENSG00000113721,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL587723,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1,OONFNUWBHFSNBT-HXUWFJFHSA-N,Small molecule,False,AEE-788,,2.0,,False,False,[],"['AEE-788' 'AEE788' 'Aee 788' 'Aee-788' 'GNF-PF-5343' 'NVP-AEE-788'
 'NVP-AEE788']","[('Wikipedia', array(['AEE788'], dtype=object)), ('drugbank', array(['DB12558'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000519', 'EFO_1000158'], dtype=object), 'count': 3}","[ENSG00000102755,ENSG00000146648,ENSG00000141736,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1071,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1,OFPXSFXSNFPTHF-UHFFFAOYSA-N,Small molecule,True,OXAPROZIN,1992.0,4.0,,False,True,['Daypro' 'Oxaprozin'],"['NSC-310839' 'Oxaprozin' 'WY-21,743' 'WY-21743']","[('DailyMed', array(['oxaprozin'], dtype=object)), ('PubChem', array(['11110656', '11110657', '144203610', '170464987', '26719634',
       '26747622', '4254158', '455291', '50106813', '50106814',
       '85230870', '90340983'], dtype=object)), ('Wikipedia', array(['Oxaprozin'], dtype=object)), ('drugbank', array(['DB00991'], dtype=object)), ('chEBI', array(['7822'], dtype=object))]",['CHEMBL1200463'],"{'rows': array(['EFO_0000685', 'MONDO_0005178', 'EFO_0002609', 'EFO_0005755'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 4 approved indications. This drug has a black box warning from the FDA.
CHEMBL1201170,O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+],WJSIUCDMWSDDCE-UHFFFAOYSA-K,Small molecule,True,LITHIUM CITRATE ANHYDROUS,1980.0,4.0,,False,True,[],['Citric acid trilithium salt'],"[('Wikipedia', array(['Lithium_citrate'], dtype=object)), ('drugbank', array(['DB14507'], dtype=object)), ('chEBI', array(['64735'], dtype=object))]",['CHEMBL2103738'],"{'rows': array(['EFO_0009963'], dtype=object), 'count': 1}","[ENSG00000133731,ENSG00000105723,ENSG00000082701]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for bipolar i disorder. This drug has a black box warning from the FDA.
CHEMBL1201716,,,Protein,False,MECASERMIN,2005.0,4.0,,False,True,['Increlex'],"['CEP-151' 'Cg-gf2' 'Cg-igf-1' 'Igf-1-ec' 'Igf-1ec'
 'Insulin-like growth factor 1' 'Insulin-like growth factor i'
 'Mecasermin' 'Mechano growth factor' 'Pv-802' 'Pv802' 'Rh-oligopeptide-2'
 'Sh-oligopeptide-2' 'Somatomedin c' 'Somatomedin c, human' 'Vexxon-igf-1']","[('DailyMed', array(['mecasermin%20recombinant'], dtype=object)), ('DrugCentral', array(['5009'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/increlex'],
      dtype=object)), ('Wikipedia', array(['Mecasermin'], dtype=object))]",,"{'rows': array(['EFO_0004260', 'EFO_1001348', 'EFO_0000400', 'MONDO_0002177',
       'MONDO_0010726', 'EFO_1001158', 'EFO_0000384', 'EFO_0004705',
       'MONDO_0005301', 'MONDO_0005351', 'EFO_1001434', 'MONDO_0015892',
       'MONDO_0004976', 'MONDO_0018997', 'MONDO_0009877', 'HP_0001510'],
      dtype=object), 'count': 16}",[ENSG00000140443],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 approved and 12 investigational indications.
CHEMBL163,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,NCDNCNXCDXHOMX-XGKFQTDJSA-N,Small molecule,True,RITONAVIR,1996.0,4.0,,False,True,['Norvir' 'Ritonavir'],"['A-84538' 'ABBOTT-84538' 'ABT-538' 'Empetus' 'NSC-693184' 'Norvir'
 'Ritomune' 'Ritonavir' 'Ritonavir related compounds mixture'
 'Ritonavirum' 'Ritovir' 'Viekirax' 'Viriton']","[('DailyMed', array(['ritonavir'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/norvir'],
      dtype=object)), ('PubChem', array(['144206522', '144206981', '170464891', '26719904', '29215414'],
      dtype=object)), ('Wikipedia', array(['Ritonavir'], dtype=object)), ('drugbank', array(['DB00503'], dtype=object)), ('chEBI', array(['45409'], dtype=object))]",,"{'rows': array(['EFO_0000558', 'EFO_0000691', 'EFO_0002950', 'EFO_0004234',
       'EFO_0003106', 'EFO_0000765', 'EFO_0001068', 'EFO_0000519',
       'EFO_0004220', 'EFO_0009708', 'EFO_0007328', 'MONDO_0004976',
       'EFO_0000764', 'EFO_0003086', 'EFO_0001361', 'EFO_0000694',
       'MONDO_0100116', 'EFO_0003047', 'EFO_0000763', 'EFO_0003835',
       'MONDO_0100096', 'EFO_0000180', 'EFO_0007224', 'MONDO_0018076',
       'EFO_0007386', 'EFO_0001421', 'EFO_0004197', 'EFO_0000537',
       'MONDO_0004992', 'EFO_0000544', 'EFO_1000637', 'EFO_0002614',
       'EFO_0007304', 'EFO_0000673'], dtype=object), 'count': 34}","[ENSG00000160868,ENSG00000106258,ENSG00000021461,ENSG00000160870]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 29 investigational indications. This drug has a black box warning from the FDA.
CHEMBL191413,CC(C)Cc1ccc([C@@H](C)C(=O)NS(C)(=O)=O)cc1,KQDRVXQXKZXMHP-LLVKDONJSA-N,Small molecule,False,REPARIXIN,,3.0,,False,False,[],['DF 1681Y' 'DF-1681Y' 'DF1681Y' 'Df-1681y' 'Reparixin' 'Repertaxin'],"[('PubChem', array(['144205825'], dtype=object)), ('drugbank', array(['DB12614'], dtype=object))]",['CHEMBL1527147'],"{'rows': array(['MONDO_0005147', 'MONDO_0100096', 'EFO_0002687', 'MONDO_0007254',
       'EFO_0000342', 'EFO_0007541', 'EFO_0003106', 'MONDO_0100130'],
      dtype=object), 'count': 8}","[ENSG00000180871,ENSG00000163464]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL2103975,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(N)=O)NC1=O,SWXOGPJRIDTIRL-KTJGOPLGSA-N,Protein,False,VAPREOTIDE,,3.0,,False,False,['Sanvar'],"['BMY-41606' 'Bmy-41606' 'DP-05-094' 'RC-160' 'Vapreotide'
 'Vapreotide acetate']",,['CHEMBL2218872'],"{'rows': array(['EFO_0005323'], dtype=object), 'count': 1}","[ENSG00000162009,ENSG00000180616,ENSG00000278195]",Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108187,,,Antibody,False,CLENOLIXIMAB,,2.0,,False,False,[],['CE9.GAMMA.4PE' 'CE9?4PE' 'Clenoliximab' 'IDEC-151' 'IDEC151'],,,,[ENSG00000010610],Antibody drug with a maximum clinical trial phase of II.
CHEMBL220808,Fc1ccc(-c2cncc(CNC[C@H]3CCc4ccccc4O3)c2)cc1,HKFMQJUJWSFOLY-OAQYLSRUSA-N,Small molecule,False,SARIZOTAN,,3.0,,False,False,[],['EMD-77697' 'Sarizotan'],"[('drugbank', array(['DB06454'], dtype=object))]",['CHEMBL2146110'],"{'rows': array(['MONDO_0010726', 'EFO_0004280', 'MONDO_0005180', 'EFO_0004280'],
      dtype=object), 'count': 4}","[ENSG00000149295,ENSG00000069696,ENSG00000151577,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2364659,,,Antibody,False,ONTUXIZUMAB,,2.0,,False,False,[],['MORAB-004' 'Ontecizumab' 'Ontuxizumab'],,,"{'rows': array(['EFO_1001968', 'EFO_0000616', 'EFO_0002617'], dtype=object), 'count': 3}",[ENSG00000174807],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL306823,O=C([O-])C(Cl)Cl.[Na+],LUPNKHXLFSSUGS-UHFFFAOYSA-M,Small molecule,False,SODIUM DICHLOROACETATE,,4.0,,False,True,[],"['CMI X-11S' 'CPC-211' 'DCA' 'Dca sodium' 'NSC-744479'
 'Sodium dichloroacetate']","[('PubChem', array(['144207122', '144211711', '50112986'], dtype=object))]",,"{'rows': array(['MONDO_0019169', 'EFO_0003777', 'EFO_1000036', 'EFO_0001361',
       'EFO_0000519', 'EFO_0000181', 'MONDO_0007254', 'MONDO_0008903'],
      dtype=object), 'count': 8}","[ENSG00000005882,ENSG00000067992,ENSG00000004799,ENSG00000152256]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications.
CHEMBL3237547,O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F,VUDZSIYXZUYWSC-DBRKOABJSA-N,Small molecule,False,CEDAZURIDINE,2020.0,4.0,,False,True,[],"['ASTX-727 COMPONENT CEDAZURIDINE' 'ASTX727 COMPONENT CEDAZURIDINE'
 'Cedazuridine' 'E-7727' 'E7727']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CEDAZURIDINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005537', 'EFO_0000198', 'EFO_0001663', 'EFO_0000222',
       'EFO_0000211', 'EFO_0000616', 'EFO_0000339', 'EFO_1001779'],
      dtype=object), 'count': 8}",[ENSG00000158825],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for myelodysplastic syndrome and has 7 investigational indications.
CHEMBL3264002,CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F,LMMJFBMMJUMSJS-UHFFFAOYSA-N,Small molecule,False,AVUTOMETINIB,,2.0,,False,False,[],"['Avutometinib' 'CH-5126766' 'CH5126766' 'CKI-27' 'R-7304' 'RG-7304'
 'Rg-7304' 'Ro 5126766' 'Ro-5126766' 'VS-6766']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AVUTOMETINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15254'], dtype=object)), ('chEBI', array(['78825'], dtype=object))]",['CHEMBL3264004'],"{'rows': array(['MONDO_0008170', 'EFO_0000466', 'EFO_0002618', 'EFO_0000616',
       'EFO_0000616', 'MONDO_0007254', 'MONDO_0021148', 'EFO_0003060',
       'EFO_0001378', 'EFO_0000519'], dtype=object), 'count': 10}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL3545317,,,Antibody,False,REFANEZUMAB,,2.0,,False,False,[],['GSK249320' 'Refanezumab'],,,,[ENSG00000105695],Antibody drug with a maximum clinical trial phase of II.
CHEMBL3989691,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O.NCCO.NCCO,PLILLUUXAVKBPY-SBIAVEDLSA-N,Small molecule,True,ELTROMBOPAG OLAMINE,2008.0,4.0,CHEMBL461101,False,True,['Promacta' 'Promacta kit' 'Revolade'],"['Eltrombopag (as olamine)' 'Eltrombopag compd with 2-aminoethanol (1:2)'
 'Eltrombopag olamine' 'SB-497115-GR']","[('DailyMed', array(['eltrombopag%20olamine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revolade'],
      dtype=object))]",,"{'rows': array(['EFO_0000198', 'EFO_0006927', 'EFO_0004220', 'EFO_0007160',
       'HP_0001873'], dtype=object), 'count': 5}",[ENSG00000117400],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL4297674,CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1,VJPPLCNBDLZIFG-ZDUSSCGKSA-N,Small molecule,False,BRANEBRUTINIB,,2.0,,False,False,[],['BMS-986195' 'Bms-986195' 'Branebrutinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BRANEBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15347'], dtype=object))]",['CHEMBL4639484'],"{'rows': array(['MONDO_0002334', 'EFO_0005809', 'EFO_0000274', 'EFO_0000685'],
      dtype=object), 'count': 4}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297748,,,Protein,False,ONVITRELIN UCALONTIDE,,2.0,,False,False,[],"['EP-100' 'EP-100 (PEPTIDE)' 'EP100' 'Ep 100' 'Ep-100'
 'Onvitrelin ucalontide']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297879,,,Protein,False,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,2015.0,4.0,,False,True,['Respreeza'],"['.alpha.-1 protease inhibitor' '.alpha.1-antitrypsin'
 '.alpha.1-proteinase inhibitor human' 'Alfa1 antitrypsin'
 'Alpha 1-antitrypsin' 'Alpha-1 protease inhibitor'
 'Alpha-1 proteinase inhibitor (human)' 'Alpha-1-antiproteinase'
 'Alpha-1-antitrypsin' 'Alpha1-proteinase inhibitor'
 'Alpha1-proteinase inhibitor (human)' 'Aralast' 'Atc-b02ab02' 'Glassia'
 'Human alpha1-proteinase inhibitor' 'Prolastin' 'Prolastin-c' 'Zemaira']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza'],
      dtype=object))]",,"{'rows': array(['MP_0001845', 'MONDO_0020547', 'EFO_0000342', 'EFO_0000341',
       'EFO_0008583', 'EFO_0003818', 'MP_0001914', 'MONDO_0100096',
       'Orphanet_60', 'MONDO_0009061', 'MONDO_0013730', 'EFO_0000508',
       'MONDO_0005147'], dtype=object), 'count': 13}",[ENSG00000197561],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 10 investigational indications.
CHEMBL431,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2,HRWCVUIFMSZDJS-SZMVWBNQSA-N,Small molecule,False,SPIRAPRIL,1994.0,4.0,,False,True,[],['Spirapril'],"[('Wikipedia', array(['Spirapril'], dtype=object)), ('drugbank', array(['DB01348'], dtype=object))]",['CHEMBL1200831'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994 and is indicated for cardiovascular disease.
CHEMBL431733,CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O,IPSYPUKKXMNCNQ-PFHKOEEOSA-N,Small molecule,False,NAMODENOSON,,3.0,,False,False,[],"['CF-102' 'CF102' 'CI-IB-MECA' 'CL-IB-MECA' 'Cf102' 'Chloro-ib-meca'
 'Namodenoson']","[('PubChem', array(['26752072', '56463287'], dtype=object)), ('drugbank', array(['DB12885'], dtype=object))]",,"{'rows': array(['EFO_0004220', 'EFO_0000182', 'EFO_0003095', 'EFO_1001249'],
      dtype=object), 'count': 4}",[ENSG00000282608],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4594575,,,Antibody,False,SABATOLIMAB,,3.0,,False,False,[],['MBG-453' 'MBG453' 'Mbg 453' 'Mbg453' 'NVP-MBG453' 'Sabatolimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SABATOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000519', 'MONDO_0044903', 'EFO_0000616', 'EFO_0005809',
       'EFO_0000198', 'EFO_0000222', 'EFO_1001779', 'MONDO_0004992'],
      dtype=object), 'count': 8}",[ENSG00000135077],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL4650423,,,Antibody,False,DANBURSTOTUG,,2.0,,False,False,[],['Danburstotug' 'IMC-001' 'Imc-001' 'STI-3031' 'Sti-3031'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANBURSTOTUG/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0019472', 'MONDO_0004992'], dtype=object), 'count': 3}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL591501,CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21,MNLNAGRCHNMKKJ-UHFFFAOYSA-N,Small molecule,False,PF-03049423,,2.0,,False,False,[],['Pf-03049423'],,,"{'rows': array(['HP_0002140'], dtype=object), 'count': 1}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1083390,O=S(=O)(c1ccccc1)c1cnc2c(N3CCNCC3)cccc2c1,JJZFWROHYSMCMU-UHFFFAOYSA-N,Small molecule,False,INTEPIRDINE,,3.0,,False,False,[],['GSK-742457' 'GSK742457' 'Intepirdine' 'RVT-101' 'SB-742457' 'Sb-742457'],"[('Wikipedia', array(['SB-742,457'], dtype=object)), ('drugbank', array(['DB12680'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'HP_0000726'], dtype=object), 'count': 2}",[ENSG00000158748],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1200622,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C,BPKAHTKRCLCHEA-UBFJEZKGSA-N,Small molecule,False,PARICALCITOL,1998.0,4.0,,False,True,['Paricalcitol' 'Zemplar'],['COMPOUND 49510' 'COMPOUND-49510' 'Paricalcitol'],"[('DailyMed', array(['paricalcitol'], dtype=object)), ('PubChem', array(['144206540'], dtype=object)), ('Wikipedia', array(['Paricalcitol'], dtype=object)), ('drugbank', array(['DB00910'], dtype=object)), ('chEBI', array(['7931'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000342', 'MONDO_0005184', 'EFO_0003086',
       'MONDO_0007254', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000401',
       'MONDO_0005148', 'HP_0002901', 'EFO_0004194', 'EFO_0003896',
       'EFO_1000657', 'EFO_0002618', 'HP_0000093', 'EFO_1001173',
       'EFO_1000359', 'EFO_0005754', 'EFO_0008506', 'EFO_0004285',
       'EFO_0003884'], dtype=object), 'count': 21}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 18 investigational indications.
CHEMBL1505,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,WKEMJKQOLOHJLZ-UHFFFAOYSA-N,Small molecule,False,ALMOTRIPTAN,2001.0,4.0,,False,True,[],['Almotriptan' 'LAS 31416' 'LAS-31416' 'NSC-760092'],"[('PubChem', array(['170465288', '174006290', '26748976'], dtype=object)), ('Wikipedia', array(['Almotriptan'], dtype=object)), ('drugbank', array(['DB00918'], dtype=object)), ('chEBI', array(['520985'], dtype=object))]",['CHEMBL1200521'],"{'rows': array(['MONDO_0005277', 'MONDO_0005277'], dtype=object), 'count': 2}","[ENSG00000179097,ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for migraine disorder.
CHEMBL1713,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl,FBSMERQALIEGJT-UHFFFAOYSA-N,Small molecule,True,CHLORPROMAZINE HYDROCHLORIDE,1957.0,4.0,CHEMBL71,False,True,"['Chloractil' 'Chlorazine' 'Chlorpromazine hydrochloride'
 'Chlorpromazine hydrochloride intensol' 'Largactil' 'Largactil fte'
 'Promapar' 'Rimazine' 'Sonazine' 'Thorazine']","['Chlorpromazine HCl' 'Chlorpromazine hcl' 'Chlorpromazine hydrochloride'
 'Chlorpromazini hydrochloridum' 'Klorproman' 'Marazine' 'NSC-17479'
 'Nci-c05210' 'Norcozine']","[('DailyMed', array(['chlorpromazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144210835', '14743551', '26751622', '50106001', '50125717',
       '56422870', '855926'], dtype=object)), ('chEBI', array(['3649'], dtype=object))]",,,"[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957. This drug has a black box warning from the FDA.
CHEMBL1750,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,WDDPHFBMKLOVOX-AYQXTPAHSA-N,Small molecule,False,CLOFARABINE,2004.0,4.0,,False,True,['Clolar' 'Evoltra'],['Clofarabine' 'Clolar' 'NSC-759857'],"[('DailyMed', array(['clofarabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra'],
      dtype=object)), ('PubChem', array(['144205735', '170465145'], dtype=object)), ('Wikipedia', array(['Clofarabine'], dtype=object)), ('drugbank', array(['DB00631'], dtype=object)), ('chEBI', array(['681569'], dtype=object))]",,"{'rows': array(['MONDO_0017198', 'EFO_0000574', 'MONDO_0000873', 'EFO_0000220',
       'EFO_1001779', 'MONDO_0015760', 'EFO_0000222', 'MONDO_0013730',
       'EFO_1000318', 'EFO_0000095', 'EFO_0005803', 'EFO_0000183',
       'EFO_0001378', 'EFO_0005952', 'EFO_0000198', 'EFO_0000096',
       'EFO_0000339', 'EFO_0004289', 'MONDO_0004992', 'EFO_0000565',
       'EFO_0000616', 'EFO_0000224'], dtype=object), 'count': 22}","[ENSG00000167325,ENSG00000048392,ENSG00000171848,ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 17 investigational indications.
CHEMBL1779046,O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1,UXZDMXYRRQJIBJ-IBGZPJMESA-N,Small molecule,False,TARAFENACIN,,2.0,,False,False,[],['Svt-40776' 'Tarafenacin'],,,"{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1812161,CC(C)=CCC/C(C)=C/CC/C(C)=C/CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O,LNOVHERIIMJMDG-XZXLULOTSA-N,Small molecule,False,VATIQUINONE,,3.0,,False,False,[],"['(R)-Alpha-Tocotrienol Quinone' '.alpha.-tocotrienol quinone'
 'Alpha tocotrienol quinone' 'Alpha-tocotrienol quinone' 'EPI-743'
 'PTC-743' 'PTC743' 'Vatiquinone']","[('drugbank', array(['DB11917'], dtype=object))]",,"{'rows': array(['EFO_0004895', 'MONDO_0005180', 'EFO_0004145', 'EFO_0003756',
       'MONDO_0009723', 'MONDO_0044970', 'MONDO_0100339', 'MONDO_0010726',
       'EFO_1001254'], dtype=object), 'count': 9}",[ENSG00000181019],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL2105107,C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C,HHGRMHMXKPQNGF-WNSNRMDMSA-N,Small molecule,False,INECALCITOL,,2.0,,False,False,[],['Inecalcitol' 'TX-522' 'Tx-522'],"[('drugbank', array(['DB04796'], dtype=object))]",,"{'rows': array(['EFO_0000339', 'EFO_0000222'], dtype=object), 'count': 2}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109637,,,Antibody,False,HUHMFG1,,2.0,,False,False,[],"['AS-1402' 'AS1402' 'HUHMFG1' 'Huhmfg1' 'MOAB HuHMFG1' 'R1550' 'Therex'
 'humanized IgG1 monoclonal antibody'
 'humanized human milk fat globule-1 monoclonal antibody']",,,"{'rows': array(['EFO_0000305', 'MONDO_0007254'], dtype=object), 'count': 2}",[ENSG00000185499],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2365940,C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c1ccccc1)c1ccccc1)C2,BKLAJZNVMHLXAP-AGYIDARRSA-N,Small molecule,False,DAROTROPIUM,,2.0,,False,False,[],['Darotropium cation' 'Darotropium ion'],,['CHEMBL2308782'],"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL308148,CC(=O)NC1(c2ccccc2)CCN(CC[C@H](CN(C)C(=O)c2ccccc2)c2ccc(Cl)c(Cl)c2)CC1,PGKXDIMONUAMFR-AREMUKBSSA-N,Small molecule,False,SAREDUTANT,,3.0,,False,False,[],['Saredutant' 'Sr-48968'],"[('Wikipedia', array(['Saredutant'], dtype=object)), ('drugbank', array(['DB06660'], dtype=object))]",,"{'rows': array(['MONDO_0002050', 'MONDO_0002009', 'EFO_0005230'], dtype=object), 'count': 3}",[ENSG00000075073],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3181841,Cl.Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21,XIXYTCLDXQRHJO-RFVHGSKJSA-N,Small molecule,False,RAMOSETRON HYDROCHLORIDE,,3.0,CHEMBL1643895,False,False,[],"['(r)-(-)-ramosetron hydrochloride' 'Irribow' 'Ramosetron hydrochloride'
 'YM-060' 'YM060' 'Ym060']","[('PubChem', array(['144205994', '170465928'], dtype=object))]",,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}","[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3301589,,,Antibody drug conjugate,True,ENFORTUMAB VEDOTIN,2019.0,4.0,,False,True,['Padcev'],"['AGS-22CE' 'AGS-22M6E' 'AGS-22ME' 'AGS-22MSE' 'ASG-22ME' 'Asg-22ce'
 'Enfortumab vedotin' 'Enfortumab vedotin ejfv']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/padcev'],
      dtype=object))]",,"{'rows': array(['EFO_1000601', 'MONDO_0004180', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0003863', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0008528',
       'MONDO_0005184'], dtype=object), 'count': 9}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000143217]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL339427,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C,JFJZZMVDLULRGK-URLMMPGGSA-O,Small molecule,False,TUBOCURARINE,1945.0,4.0,,False,True,[],['D-tubocurarine' 'Tubocurarine' 'Tubocurarine cation' 'Tubocurarine ion'],"[('PubChem', array(['26756599'], dtype=object)), ('drugbank', array(['DB01199'], dtype=object)), ('chEBI', array(['9774'], dtype=object))]",['CHEMBL292280' 'CHEMBL3989821' 'CHEMBL1687'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1945.
CHEMBL34259,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,FBOZXECLQNJBKD-ZDUSSCGKSA-N,Small molecule,True,METHOTREXATE,1953.0,4.0,,False,True,"['Amethopterin' 'Ebetrex' 'Emtexate high-pot' 'Emtexate pf' 'Folex'
 'Maxtrex' 'Methotrexate' 'Metoject' 'Nordimet' 'Otrexup' 'Otrexup pfs'
 'Rasuvo' 'Reditrex' 'Rheumatrex' 'Trexall' 'Zlatal']","['(r)-methotrexate' 'ADX-2191' 'Abitrexate' 'Amethopterin' 'CL 14377'
 'CL-14377' 'D-amethopterin' 'D-methotrexate' 'EMT-25299' 'Folex'
 'Jylamvo' 'Methotrexate' 'Methotrexate, (r)-' 'Methotrexate, d-'
 'Methotrexatum' 'Methylaminopterin' 'Mexate' 'Mexate-AQ' 'NSC-740'
 'R-9985' 'R-methotrexate' 'TCMDC-123832' 'TCMDC-125488' 'TCMDC-125858'
 'Trexall']","[('DailyMed', array(['methotrexate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet'],
      dtype=object)), ('PubChem', array(['11113978', '124886991', '144204495', '144210589', '170464688',
       '26752120', '26752121', '26752122', '50104777', '50104778',
       '56463665', '67627', '90340825'], dtype=object)), ('Wikipedia', array(['Methotrexate'], dtype=object)), ('drugbank', array(['DB00563'], dtype=object)), ('chEBI', array(['44185'], dtype=object))]",['CHEMBL4572304' 'CHEMBL3244648' 'CHEMBL1376974'],"{'rows': array(['MONDO_0019460', 'EFO_0000221', 'EFO_1000785', 'EFO_0000717',
       'EFO_0000339', 'MONDO_0019338', 'EFO_0002609', 'EFO_0004192',
       'EFO_0000224', 'MONDO_0019469', 'EFO_0003027', 'EFO_0003811',
       'EFO_0006859', 'EFO_1001469', 'MONDO_0021054', 'EFO_0000232',
       'MONDO_0004979', 'EFO_0000574', 'MONDO_0015540', 'EFO_0000220',
       'EFO_0000384', 'EFO_0004208', 'EFO_0000389', 'EFO_0002609',
       'MONDO_0004192', 'EFO_0000255', 'EFO_0000096', 'EFO_0000612',
       'MONDO_0005178', 'EFO_1001486', 'EFO_1000131', 'EFO_0006475',
       'MONDO_0011382', 'EFO_1001471', 'EFO_0009784', 'EFO_1001365',
       'MONDO_0004986', 'HP_0012410', 'EFO_0000274', 'EFO_1000309',
       'MONDO_0010518', 'EFO_0000094', 'EFO_1001012', 'EFO_0000095',
       'EFO_0003025', 'MONDO_0005090', 'EFO_0007187', 'MONDO_0100096',
       'EFO_0000209', 'EFO_0000198', 'EFO_0000676', 'MONDO_0015253',
       'EFO_0001642', 'EFO_0000729', 'HP_0001915', 'MONDO_0009833',
       'EFO_0009441', 'MONDO_0007254', 'EFO_0005531', 'EFO_0004284',
       'EFO_0000616', 'EFO_0000305', 'MONDO_0002041', 'MONDO_0000873',
       'EFO_0001068', 'EFO_0000540', 'MONDO_0018848', 'MP_0001845',
       'EFO_0003060', 'MONDO_0018944', 'MONDO_0008903', 'MONDO_0008170',
       'EFO_0003032', 'EFO_0002893', 'MONDO_0005575', 'EFO_0000181',
       'EFO_1001779', 'EFO_0005297', 'EFO_0008528', 'MONDO_0017198',
       'MONDO_0003005', 'MONDO_0019200', 'EFO_0003898', 'EFO_1001209',
       'EFO_0005952', 'EFO_0000770', 'EFO_1000318', 'EFO_0003802',
       'EFO_0002939', 'MONDO_0001187', 'MONDO_0044917', 'EFO_0002428',
       'MONDO_0019471', 'EFO_0000685', 'EFO_0000191', 'EFO_0000707',
       'EFO_0000565', 'EFO_1001494', 'EFO_0000637', 'EFO_0000223',
       'MONDO_0016717', 'MONDO_0100244', 'MONDO_0044881', 'EFO_1000298',
       'MONDO_0005301', 'EFO_0002430', 'EFO_0000557', 'EFO_0000691',
       'MONDO_0007254', 'EFO_0003869', 'EFO_0000403', 'MONDO_0024280',
       'MONDO_0002367', 'EFO_0000588', 'EFO_1001951', 'EFO_0005856',
       'EFO_0004599', 'EFO_0009708', 'MONDO_0002038', 'MONDO_0013730',
       'EFO_0006803', 'EFO_0000676', 'EFO_0000764', 'EFO_0002429',
       'EFO_0006927', 'MONDO_0002974', 'EFO_1001012', 'EFO_0000309',
       'EFO_0001075', 'EFO_0004289', 'MONDO_0001657', 'MONDO_0000159',
       'EFO_0000685', 'MONDO_0015974', 'MONDO_0018975', 'MONDO_0004992',
       'EFO_1000956', 'EFO_0003833', 'MONDO_0020077', 'EFO_1001231',
       'EFO_0000183', 'EFO_0005952', 'MONDO_0019391', 'EFO_0000211',
       'MONDO_0000870', 'EFO_0006818', 'EFO_0004991', 'EFO_0003778',
       'EFO_1000158', 'EFO_1001176', 'EFO_1000986', 'EFO_1001051',
       'EFO_0005235', 'EFO_0001645', 'EFO_0000319', 'EFO_1001129',
       'EFO_0000220', 'EFO_0004251', 'EFO_1001830', 'EFO_0000218',
       'EFO_0002893', 'EFO_0000222', 'MONDO_0007915', 'MONDO_0003478',
       'EFO_0009907', 'MONDO_0044903', 'MONDO_0019472', 'EFO_0000621',
       'EFO_0001378', 'MONDO_0018906', 'EFO_0000398'], dtype=object), 'count': 171}",[ENSG00000228716],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 22 approved and 143 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3544992,,,Antibody,False,DENINTUZUMAB,,-1.0,,False,False,[],['Denintuzumab' 'HBU-12' 'hBU12'],,,,[ENSG00000177455],Antibody drug.
CHEMBL3545101,,,Small molecule,False,KRP203,,2.0,,False,False,[],['Krp203'],,,"{'rows': array(['EFO_0001642', 'EFO_0000729', 'EFO_0003834'], dtype=object), 'count': 3}",[ENSG00000170989],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545164,C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1,SXWHYTICXCLKDG-GFCCVEGCSA-N,Small molecule,False,AZD2066,,2.0,,False,False,[],['Azd 2066' 'Azd-2066' 'Azd2066'],"[('drugbank', array(['DB12644'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0003948', 'EFO_1000783', 'HP_0012532',
       'EFO_0005762', 'EFO_0003843'], dtype=object), 'count': 6}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3545366,CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21,RGHYDLZMTYDBDT-UHFFFAOYSA-N,Small molecule,False,VOXTALISIB,,2.0,,False,False,[],['SAR-245409' 'SAR245409' 'Voxtalisib' 'XL-765' 'XL765'],"[('drugbank', array(['DB12400'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0003268',
       'EFO_0000756', 'EFO_0000095', 'EFO_0000574', 'EFO_1001469',
       'EFO_1001951', 'EFO_0000519', 'MONDO_0004992', 'MONDO_0008170'],
      dtype=object), 'count': 12}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.
CHEMBL3590187,CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,GPNHMOZDMYNCPO-PDUMRIMRSA-N,Small molecule,False,CLASCOTERONE,2020.0,4.0,,False,True,['Breezula' 'Winlevi'],"['CB-03-01' 'Cb-03-01' 'Clascoterone' 'Cortexolone 17.alpha.-propionate'
 'Cortodoxone 17.alpha.-propionate']","[('drugbank', array(['DB12499'], dtype=object))]",,"{'rows': array(['EFO_0004191', 'EFO_0003894'], dtype=object), 'count': 2}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for acne and has 1 investigational indication.
CHEMBL3818875,CNc1nc(C)nc(N[C@H]2CCC[C@@H](C(=O)NCc3ccc(C#N)cc3C(F)(F)F)C2)n1,LQHDJQIMETZMPH-ZBFHGGJFSA-N,Small molecule,False,GSK2256294,,2.0,,False,False,[],['GSK-2256294' 'GSK-2256294A' 'Gsk2256294'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000120915],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3833374,,,Antibody,False,ANDECALIXIMAB,,3.0,,False,False,[],['Andecaliximab' 'GS-5745' 'GS5745'],,,"{'rows': array(['EFO_0000341', 'EFO_0000685', 'EFO_0000384', 'EFO_0000729',
       'MONDO_0009061', 'EFO_0000503'], dtype=object), 'count': 6}",[ENSG00000100985],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3989558,CCC(CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1.O=C(O)/C=C\C(=O)O,LWYXFDXUMVEZKS-TZTNOGQLSA-N,Small molecule,False,METHYSERGIDE MALEATE,1962.0,4.0,CHEMBL485253,False,True,['Sansert'],['Methysergide hydrogen maleate' 'Methysergide maleate' 'NSC-759143'],,,,"[ENSG00000178394,ENSG00000147246,ENSG00000135914]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962.
CHEMBL3989830,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1.Cl.O,KFNNPQDSPLWLCX-UHFFFAOYSA-N,Small molecule,False,SIBUTRAMINE HYDROCHLORIDE,1997.0,4.0,CHEMBL1419,True,True,['Meridia'],"['BTS 54524' 'BTS-54524' 'NSC-758928' 'Sibutramine hcl'
 'Sibutramine hydrochloride' 'Sibutramine hydrochloride civ'
 'Sibutramine hydrochloride hydrate'
 'Sibutramine hydrochloride monohydrate']",,,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and has 1 investigational indication. It was withdrawn in at least one region.
CHEMBL420,N=C(N)N/N=C/c1c(Cl)cccc1Cl,WDZVGELJXXEGPV-YIXHJXPBSA-N,Small molecule,False,GUANABENZ,1982.0,4.0,,False,True,[],['Guanabenz' 'NSC-68982' 'WY-8678'],"[('PubChem', array(['26751943', '50104618', '50104619', '90341577'], dtype=object)), ('Wikipedia', array(['Guanabenz'], dtype=object)), ('chEBI', array(['5553'], dtype=object))]",['CHEMBL1200560'],"{'rows': array(['EFO_0003929'], dtype=object), 'count': 1}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.
CHEMBL4297223,O.O.O.O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1.O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1.O=S(=O)(O)O,DMRIPASJCJRBMV-UHFFFAOYSA-N,Small molecule,False,MITAPIVAT SULFATE,2022.0,4.0,CHEMBL4299940,False,True,['Pyrukynd'],"['AG-348 HEMISULFATE SESQUIHYDRATE' 'AG-348 sulfate hydrate'
 'Mitapivat sulfate' 'Pyrukynd']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd'],
      dtype=object))]",,"{'rows': array(['MONDO_0003689', 'MONDO_0002280', 'EFO_0000508'], dtype=object), 'count': 3}",[ENSG00000143627],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved indications.
CHEMBL4297256,CC(C)(C(=O)NC1C2CC3CC1CC(C(N)=O)(C3)C2)N1CCN(c2ccc(C(F)(F)F)cn2)CC1,CLHMYBJIOZXCEX-QIGVQZHLSA-N,Small molecule,False,ABT-384,,2.0,,False,False,[],['Abt-384'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000117594],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297993,,,Unknown,False,EMD-1201081,,2.0,,False,False,[],['Emd-1201081' 'HYB-2055' 'IMO-2055' 'Imo-2055' 'Imoxine'],,,"{'rows': array(['EFO_0000681', 'EFO_0003060', 'EFO_1001951'], dtype=object), 'count': 3}",[ENSG00000239732],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL461522,Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,LVWZTYCIRDMTEY-UHFFFAOYSA-N,Small molecule,False,METAMIZOLE,,4.0,,True,True,[],['Metamizole' 'Methamizole-'],"[('drugbank', array(['DB04817'], dtype=object)), ('chEBI', array(['62088'], dtype=object))]",['CHEMBL487894' 'CHEMBL3989803'],"{'rows': array(['HP_0100806', 'MONDO_0005277', 'EFO_0003843', 'HP_0001945',
       'EFO_1001463', 'HP_0012532'], dtype=object), 'count': 6}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 4 investigational indications.
CHEMBL4802209,,,Unknown,False,INCB-086550,,2.0,,False,False,[],['INCB-086550' 'INCB086550' 'Incb 086550' 'Incb-086550' 'Incb086550'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000120217],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL571209,Cn1cc(C[C@@H](N)C(=O)O)c2ccccc21,ZADWXFSZEAPBJS-SNVBAGLBSA-N,Small molecule,False,INDOXIMOD,,2.0,,False,False,[],"['1-methyltryptophan, d-' 'D-1-methyltryptophan' 'D-1MT' 'Indoximod'
 'N-1-methyl-d-tryptophan' 'NLG-8189' 'NSC-721782']","[('PubChem', array(['536240'], dtype=object)), ('drugbank', array(['DB12827'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'EFO_1000028', 'MONDO_0007254', 'EFO_0002617',
       'EFO_0002939', 'EFO_0003060', 'EFO_0000616', 'EFO_0000222',
       'EFO_1001465', 'EFO_0000196'], dtype=object), 'count': 10}","[ENSG00000198793,ENSG00000141564,ENSG00000167965]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL807,CC12CC3CC(C)(C1)CC(N)(C3)C2,BUGYDGFZZOZRHP-UHFFFAOYSA-N,Small molecule,False,MEMANTINE,2003.0,4.0,,False,True,[],['D-145' 'DRG-0267' 'Memantine' 'NSC-757843' 'Namenda'],"[('PubChem', array(['104171191', '144203750', '170464999', '26751885', '50104569',
       '90341818'], dtype=object)), ('Wikipedia', array(['Memantine'], dtype=object)), ('drugbank', array(['DB01043'], dtype=object)), ('chEBI', array(['64312'], dtype=object))]",['CHEMBL1882685' 'CHEMBL1699'],"{'rows': array(['EFO_0000326', 'HP_0012167', 'MONDO_0005180', 'MONDO_0004985',
       'MONDO_0004975', 'EFO_0009386', 'MONDO_0004992', 'EFO_0005611',
       'EFO_0003890', 'EFO_0003758', 'MONDO_0004976', 'MONDO_0007079',
       'HP_0100543', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0007328',
       'MONDO_0017276', 'MONDO_0002009', 'EFO_0003757', 'EFO_0000519',
       'HP_0002140', 'MONDO_0005277', 'EFO_0003833', 'MONDO_0011382',
       'HP_0001268', 'EFO_0005411', 'MONDO_0002046', 'EFO_0001073',
       'EFO_0004699', 'MONDO_0002491', 'EFO_1001801', 'EFO_0004240',
       'MONDO_0004681', 'MONDO_0007739', 'MONDO_0007915', 'EFO_0005407',
       'EFO_0005230', 'EFO_0003768', 'EFO_0003758', 'EFO_0004329',
       'HP_0000726', 'EFO_0003843', 'MONDO_0004976', 'MONDO_0010383',
       'HP_0000726', 'MONDO_0004975', 'EFO_0004242', 'HP_0012228',
       'MONDO_0005301', 'EFO_0004190', 'EFO_1001465', 'EFO_0005762',
       'EFO_0003756', 'EFO_0002610', 'EFO_0005687'], dtype=object), 'count': 55}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and dementia and has 51 investigational indications.
CHEMBL1034,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],KPHWPUGNDIVLNH-UHFFFAOYSA-M,Small molecule,True,DICLOFENAC SODIUM,1988.0,4.0,CHEMBL139,False,True,"['Acoflam' 'Acoflam ret' 'Acoflam sr' 'Arthronac' 'Arthrotec 50'
 'Arthrotec 75' 'Closteril 100' 'Defanac' 'Defanac retard' 'Defanac sr'
 'Dexomon ret' 'Dexomon sr' 'Diclofenac sodium' 'Dicloflex'
 'Dicloflex ret' 'Dicloflex sr' 'Diclomax ret' 'Diclomax sr'
 'Diclotard 100 mr' 'Diclotard 75 mr' 'Diclovol' 'Diclovol ret'
 'Diclovol sr' 'Diclozip 25' 'Diclozip 50' 'Difenor xl' 'Digenac xl 100'
 'Dyloject' 'Econac' 'Econac sr' 'Econac xl' 'Enstar sr' 'Enstar xl'
 'Enzed' 'Fenactol' 'Fenactol ret' 'Fenactol sr' 'Flamatak mr' 'Flamrase'
 'Flamrase sr' 'Flexotard mr' 'Isclofen' 'Lofensaid 25' 'Lofensaid 50'
 'Lofensaid ret 100' 'Lofensaid ret 75' 'Masidemen' 'Misofen' 'Mobigel'
 'Mobigel paineze' 'Motifene' 'Pennsaid' 'Rheumatac ret 75' 'Rhumalgan'
 'Rhumalgan cr 100' 'Rhumalgan cr 75' 'Rhumalgan sr' 'Rhumalgan xl'
 'Slofenac' 'Solaraze' 'Valdic 100 ret' 'Valdic 75 ret' 'Valenac'
 'Volraman' 'Volsaid ret 100' 'Volsaid ret 75' 'Voltaren'
 'Voltaren arthritis pain' 'Voltaren emulgel' 'Voltaren ret' 'Voltaren-xr'
 'Voltarene' 'Voltarene emulgel' 'Voltarene l.p.' 'Voltarene ret'
 'Voltarol' 'Voltarol 12 hour emulgel p' 'Voltarol active'
 'Voltarol emulgel' 'Voltarol emulgel p' 'Voltarol gel patch'
 'Voltarol ophtha' 'Voltarol pain-eze emulgel' 'Voltarol ret'
 'Voltarol sr']","['Abitren' 'Benfofen' 'Dealgic' 'Deflamat' 'Delphinac'
 'Diclofenac diethylamine' 'Diclofenac diethylamine salt'
 'Diclofenac diethylammonium' 'Diclofenac diethylammonium salt'
 'Diclofenac sod' 'Diclofenac sodium' 'Diclofenac sodium salt' 'Diclomax'
 'Diclophenac sodium' 'Diclophlogont' 'Dicloreum' 'Duravolten' 'Ecofenac'
 'Effekton' 'GP 45840' 'GP-45840' 'Lexobene' 'NSC-756725' 'Neriodin'
 'Novapirina' 'Primofenac' 'Prophenatin' 'Rewodina' 'Sodium diclofenac'
 'Voldal' 'Xenid']","[('DailyMed', array(['diclofenac%20sodium'], dtype=object)), ('PubChem', array(['11111091', '11112998', '144204321', '144210585', '170464642',
       '26747983', '50106220', '56422389', '85231008', '855544',
       '90341049'], dtype=object)), ('chEBI', array(['4509'], dtype=object))]",,"{'rows': array(['EFO_0009560', 'EFO_0010072', 'EFO_0002970', 'EFO_0004616',
       'EFO_0000685', 'MONDO_0001187', 'EFO_0000649', 'MP_0001914',
       'MONDO_0005178', 'MONDO_0002959', 'EFO_0009582', 'HP_0003419',
       'EFO_0004272', 'EFO_0004607', 'MP_0001845', 'EFO_0003958',
       'EFO_0003843', 'HP_0012532', 'EFO_0004274', 'EFO_0002496',
       'HP_0011868'], dtype=object), 'count': 21}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 5 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200654,CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N.Cl,PRGUDWLMFLCODA-UHFFFAOYSA-N,Small molecule,False,BENOXINATE HYDROCHLORIDE,1982.0,4.0,CHEMBL1200,False,True,['Benoxinate hydrochloride'],"['Benoxinate hcl' 'Benoxinate hydrochloride' 'NSC-759847'
 'Oxibuprocaine chloride' 'Oxybuprocaine hcl'
 'Oxybuprocaine hydrochloride']","[('DailyMed', array(['benoxinate%20hydrochloride'], dtype=object)), ('PubChem', array(['144204104', '170464771', '56463336'], dtype=object)), ('chEBI', array(['31260'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201012,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,POPFMWWJOGLOIF-XWCQMRHXSA-N,Small molecule,False,FLURANDRENOLIDE,1965.0,4.0,,False,True,['Cordran' 'Cordran sp' 'Flurandrenolide' 'Haelan' 'Haelan-c' 'Haelan-x'],"['33379' 'Fludroxicortide' 'Fludroxycortide' 'Flurandrenolide'
 'Flurandrenolone' 'NSC-757869']","[('DailyMed', array(['flurandrenolide'], dtype=object)), ('PubChem', array(['144204060', '144212928', '170465298', '56424122', '855862'],
      dtype=object)), ('Wikipedia', array(['Fludroxycortide'], dtype=object)), ('drugbank', array(['DB00846'], dtype=object))]",,"{'rows': array(['EFO_0000701', 'EFO_0003884'], dtype=object), 'count': 2}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for skin disease and has 1 investigational indication.
CHEMBL1201634,,,Protein,False,INSULIN ZINC SUSP PURIFIED BEEF/PORK,1982.0,4.0,,False,True,['Lentard'],['Insulin zinc susp purified beef/pork'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201662,,,Protein,False,DESIRUDIN,1997.0,4.0,,False,True,['Iprivask' 'Revasc'],"['63-desulfohirudin' '63-desulfohirudin (recombinant)' 'CGP 39393'
 'CGP-39393' 'Desirudin' 'Desirudin recombinant' 'Hirudin desirudin'
 'Revasc']","[('DrugCentral', array(['2990'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revasc'],
      dtype=object))]",,"{'rows': array(['EFO_0003907', 'HP_0004936', 'HP_0004419'], dtype=object), 'count': 3}",[ENSG00000180210],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved indications.
CHEMBL1201773,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl,JALHGCPDPSNJNY-UHFFFAOYSA-N,Small molecule,True,PRASUGREL HYDROCHLORIDE,2009.0,4.0,CHEMBL1201772,False,True,['Effient' 'Efient'],['LY640315' 'Prasu doc' 'Prasugrel hcl' 'Prasugrel hydrochloride'],"[('DailyMed', array(['prasugrel%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/efient'],
      dtype=object)), ('PubChem', array(['144207170', '170465441'], dtype=object))]",,"{'rows': array(['EFO_0000612', 'EFO_0005672', 'MP_0001914'], dtype=object), 'count': 3}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL1201825,,,Antibody,True,RANIBIZUMAB,2006.0,4.0,,False,True,['Lucentis'],"['BCD-300' 'Byooviz' 'Cimerli' 'FAB-12 VARIANT Y0317' 'FYB-201' 'FYB201'
 'PF-582' 'Pf-582 (ranibizumab biosimilar)' 'Pf582' 'QL-1205' 'QL1205'
 'RG-3645' 'RHUFAB' 'Ranibizumab' 'Ranibizumab biosimilar pf582'
 'Ranibizumab eqrn' 'Ranibizumab nuna' 'Ranibizumab-eqrn'
 'Ranibizumab-nuna' 'SB-11' 'SB11 (RANIBIZUMAB BIOSIMILAR)' 'Susvimo']","[('DailyMed', array(['ranibizumab'], dtype=object)), ('DrugCentral', array(['4971'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis'],
      dtype=object)), ('Wikipedia', array(['Ranibizumab'], dtype=object))]",,"{'rows': array(['EFO_1001158', 'MONDO_0008380', 'EFO_0004190', 'EFO_0004207',
       'EFO_0009606', 'EFO_1000880', 'EFO_1001157', 'EFO_0003770',
       'HP_0000545', 'MONDO_0001576', 'EFO_1001060', 'EFO_0010977',
       'EFO_0000400', 'EFO_0005753', 'HP_0000573', 'EFO_0001365',
       'MONDO_0001941', 'EFO_0003839', 'MONDO_0007935', 'EFO_0000678',
       'HP_0000545', 'MONDO_0005041', 'EFO_1000805', 'MONDO_0020204',
       'EFO_1000809', 'EFO_0007310', 'MONDO_0008667', 'EFO_0004683',
       'EFO_0009784', 'EFO_0005773', 'MONDO_0003005'], dtype=object), 'count': 31}",[ENSG00000112715],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 8 approved and 23 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1237026,,,Protein,False,TESAMORELIN,2010.0,4.0,,False,True,[],['TH-9507' 'TH9507' 'Tesamorelin'],"[('DrugCentral', array(['4170'], dtype=object))]",['CHEMBL2111290'],"{'rows': array(['EFO_0000341', 'EFO_1001348', 'EFO_1001348', 'EFO_0000764',
       'MONDO_0005148', 'HP_0100543'], dtype=object), 'count': 6}",[ENSG00000106128],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for hiv-associated lipodystrophy syndrome and has 5 investigational indications.
CHEMBL1254025,CO/N=C1/C[C@@H](CO)N(C(=O)c2ccc(-c3ccccc3C)cc2)C1,OLUJSZLBWZWGJT-HGBKYHTQSA-N,Small molecule,False,NOLASIBAN,,3.0,,False,False,[],['Erlosiban' 'Nolasiban' 'OBE-001' 'Obe001'],,,"{'rows': array(['EFO_0003917', 'EFO_0000545'], dtype=object), 'count': 2}",[ENSG00000180914],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1269258,CC(C)N(Cc1ccccc1)C(=O)CN1C(=O)[C@@H](Cc2c[nH]c3ccccc23)c2nnc(-c3ccccc3)n2-c2ccccc21,UBNMGTSDHSQBEL-PMERELPUSA-N,Small molecule,False,CE-326597,,2.0,,False,False,[],"['CE-326,597' 'Ce-326,597' 'Ce-326597']","[('drugbank', array(['DB12694'], dtype=object))]",,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}",[ENSG00000163394],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1311,O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,YWXYYJSYQOXTPL-SLPGGIOYSA-N,Small molecule,False,ISOSORBIDE MONONITRATE,1991.0,4.0,,False,True,"['Angeze 10' 'Angeze 20' 'Angeze 40' 'Angeze sr 40' 'Angeze sr 60'
 'Angitate' 'Astrodur mr' 'Carmil xl' 'Chemydur 60 xl' 'Cibral 10'
 'Cibral 20' 'Cibral 40' 'Cibral xl 60' 'Dynamin' 'Dynamin xl 25'
 'Dynamin xl 50' 'Elantan 10' 'Elantan 20' 'Elantan 40' 'Elantan la 25'
 'Elantan la 50' 'Eumon 40 xl' 'Eumon 60 xl' 'Imdur' 'Imo la' 'Isib 20'
 'Isib 40' 'Isib 50 xl' 'Isib 60 xl' 'Ismo' 'Ismo 10' 'Ismo 20' 'Ismo 40'
 'Ismo ret' 'Isodur' 'Isodur 25 xl' 'Isodur 50 xl'
 'Isosorbide mononitrate' 'Isotard 25 xl' 'Isotard 40 xl' 'Isotard 50 xl'
 'Isotard 60 xl' 'Isotrate' 'Ketanodur' 'Mcr 50' 'Modisal 40 xl'
 'Modisal 60 xl' 'Modisal la 25' 'Modisal la 50' 'Monigen xl 60' 'Monit'
 'Monit ls' 'Monit sr' 'Monit xl 60' 'Mono-cedocard 10' 'Mono-cedocard 20'
 'Mono-cedocard 40' 'Monodur' 'Monoket' 'Monomax sr 40' 'Monomax sr 60'
 'Monomax xl' 'Monomil xl' 'Monosorb xl 60' 'Pertil ret' 'Phasonit la 50'
 'Relosorb xl' 'Slomon xl 60' 'Tardisc xl' 'Tenkosorb' 'Trangina xl'
 'Vasotrate 60 sr' 'Xismox xl 60' 'Zemon 40 xl' 'Zemon 60 xl' 'Ziotan xl']","['1,1-diureidisobutane' 'AHR-4698' 'BM 22.145' 'BM 22.145IS 5-MNAHR-4698'
 'BM-22-145' 'BM-22.145' 'BM-22145' 'Corangin'
 'Diluted isosorbide mononitrate' 'IS 5-MN' 'IS-5-MN' 'IS-5MN'
 'Iso-5-mononitrate' 'Isobutyldiurea' 'Isobutylenediurea'
 'Isosorbide 5-mononitrate' 'Isosorbide 5-nitrate'
 'Isosorbide dinitrate isosorbide-5-mononitrate' 'Isosorbide mononitrate'
 'Isosorbide-5-mononitrate' 'Monocord' 'NSC-758619']","[('DailyMed', array(['isosorbide%20mononitrate'], dtype=object)), ('PubChem', array(['144205134'], dtype=object)), ('Wikipedia', array(['Isosorbide_mononitrate'], dtype=object)), ('drugbank', array(['DB01020'], dtype=object)), ('chEBI', array(['6062'], dtype=object))]",,"{'rows': array(['EFO_0003913', 'EFO_0000537', 'EFO_0002950', 'EFO_0001645',
       'HP_0001788', 'EFO_0004264', 'EFO_0000319', 'EFO_0007401',
       'EFO_0000712', 'EFO_0003144', 'HP_0012390'], dtype=object), 'count': 11}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 8 investigational indications.
CHEMBL2108334,,,Protein,False,EPTACOG ALFA (ACTIVATED),1996.0,4.0,,False,True,['Novoseven'],"['Activated recombinant human factor vii'
 'Coagulation factor viia (recombinant)'
 'Coagulation factor viia recombinant human' 'Eptacog alfa'
 'Eptacog alfa (activated)' 'Recombinant activated factor vii']","[('DrugCentral', array(['5159'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven'],
      dtype=object))]",,"{'rows': array(['MONDO_0002243', 'MP_0001914', 'MONDO_0010604', 'EFO_1000025',
       'EFO_0005669', 'MONDO_0010602', 'MONDO_0100326', 'MONDO_0002244',
       'MONDO_0018660', 'EFO_0000551'], dtype=object), 'count': 10}",[ENSG00000057593],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 5 investigational indications.
CHEMBL2109393,,,Antibody,False,RG-7160,,2.0,,False,False,[],['RG-7160'],,,,[ENSG00000146648],Antibody drug with a maximum clinical trial phase of II.
CHEMBL321582,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N,FBMYKMYQHCBIGU-UHFFFAOYSA-N,Small molecule,False,BUCINDOLOL,,2.0,,False,False,[],['Bucindolol'],"[('PubChem', array(['144206141', '170466320', '50112957'], dtype=object)), ('drugbank', array(['DB12752'], dtype=object))]",['CHEMBL2107546'],"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545093,,,Small molecule,False,ZYH7,,2.0,,False,False,[],['Zyh7'],,,"{'rows': array(['EFO_0004211', 'Orphanet_309005'], dtype=object), 'count': 2}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545334,,,Small molecule,False,AVE8134,,2.0,,False,False,[],['Ave8134'],,,,[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3746329,O=C(O)C1(Sc2ccnc3ccc(Br)cc23)CCC1,QGBWIYLNOBYNDL-UHFFFAOYSA-N,Small molecule,False,SHR-4640,,3.0,,False,False,[],['Ruzinurad' 'SHR-4640' 'SHR4640' 'Shr-4640' 'Shr4640'],,,"{'rows': array(['EFO_0009104', 'EFO_0001421', 'EFO_0004274'], dtype=object), 'count': 3}",[ENSG00000197891],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4650340,O=C(O)c1cccc(CN2CN(C3CCCCC3)C3(CCN(CCCC(=O)c4ccccc4)CC3)C2=O)c1,BDXJYAAYLZTLEK-UHFFFAOYSA-N,Small molecule,False,TRAZPIROBEN,,2.0,,False,False,[],['TAK-906' 'TAK906' 'Tak-906' 'Trazpiroben'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRAZPIROBEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0011024', 'EFO_1000948'], dtype=object), 'count': 2}","[ENSG00000149295,ENSG00000151577]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5095029,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1,MCRWZBYTLVCCJJ-DKALBXGISA-N,Small molecule,False,PF-04634817,,2.0,,False,False,[],['Pf-04634817'],,,"{'rows': array(['EFO_0000401', 'HP_0000083'], dtype=object), 'count': 2}","[ENSG00000160791,ENSG00000121807]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL770,c1ccc(CC2=NCCN2)cc1,JIVZKJJQOZQXQB-UHFFFAOYSA-N,Small molecule,False,TOLAZOLINE,1985.0,4.0,,False,True,[],['NSC-35110' 'Priscoline' 'Tolazine' 'Tolazoline'],"[('PubChem', array(['11112156'], dtype=object)), ('Wikipedia', array(['Tolazoline'], dtype=object)), ('drugbank', array(['DB00797'], dtype=object)), ('chEBI', array(['28502'], dtype=object))]",['CHEMBL1689'],"{'rows': array(['HP_0003326', 'HP_0002829', 'EFO_0000319'], dtype=object), 'count': 3}","[ENSG00000196639,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000113749]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved indications.
CHEMBL829,CC(CN(C)C)CN1c2ccccc2Sc2ccccc21,ZZHLYYDVIOPZBE-UHFFFAOYSA-N,Small molecule,False,METHYLPROMAZINE,1982.0,4.0,,False,True,[],"['Alimemazine' 'BAYER-1219' 'Dl-trimeprazine' 'Methylpromazine' 'RP-6549'
 'Temaril' 'Trimeprazine']","[('Wikipedia', array(['Alimemazine'], dtype=object)), ('drugbank', array(['DB01246'], dtype=object)), ('chEBI', array(['9725'], dtype=object))]",['CHEMBL3989885' 'CHEMBL4785767' 'CHEMBL1713082'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease.
CHEMBL84158,CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC,JTVPZMFULRWINT-UHFFFAOYSA-N,Small molecule,False,TIAPRIDE,,3.0,,False,False,[],['NSC-758225' 'Tiapride'],"[('PubChem', array(['11111853', '11111854'], dtype=object)), ('Wikipedia', array(['Tiapride'], dtype=object)), ('drugbank', array(['DB13025'], dtype=object))]",['CHEMBL1256772'],"{'rows': array(['EFO_0005407', 'EFO_0004895', 'EFO_0005230', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090', 'MONDO_0007739'], dtype=object), 'count': 7}","[ENSG00000149295,ENSG00000151577]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL89598,C=CC(N)CCC(=O)O,PJDFLNIOAUIZSL-UHFFFAOYSA-N,Small molecule,True,VIGABATRIN,2009.0,4.0,,False,True,['Kigabeq' 'Sabril'],"['5-hexenoic acid, 4-amino-' 'CPP-109' 'Gamma vinyl gaba'
 'Gamma-vinyl gaba' 'MDL 71,754' 'MDL-71754' 'RMI-71754' 'Vigabatrin'
 'Vinyl gamma-aminobutyric acid']","[('DailyMed', array(['vigabatrin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq'],
      dtype=object)), ('PubChem', array(['104171263', '144203852', '26747129', '26751903', '50104581',
       '50104582', '50104583', '85231284', '90340732'], dtype=object)), ('Wikipedia', array(['Vigabatrin'], dtype=object)), ('drugbank', array(['DB01080'], dtype=object)), ('chEBI', array(['63638'], dtype=object))]",['CHEMBL4303352'],"{'rows': array(['MONDO_0001734', 'EFO_1000877', 'EFO_0004263', 'EFO_0004701',
       'HP_0011097', 'EFO_0001073', 'MONDO_0007079', 'EFO_0004895',
       'MONDO_0100062', 'MONDO_0018097', 'EFO_0000474', 'EFO_0002610'],
      dtype=object), 'count': 12}",[ENSG00000183044],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1089221,O=C(O)COc1nn(Cc2ccccc2)c2ccccc12,BYFMCKSPFYVMOU-UHFFFAOYSA-N,Small molecule,False,BENDAZAC,1984.0,4.0,,True,True,[],['AF 1934 [LYSINE]' 'Bendazac' 'Bindazac' 'Iwazac'],"[('PubChem', array(['50112715'], dtype=object)), ('TG-GATEs', array(['129'], dtype=object)), ('Wikipedia', array(['Bendazac'], dtype=object)), ('drugbank', array(['DB13501'], dtype=object)), ('chEBI', array(['31257'], dtype=object))]",['CHEMBL3189046' 'CHEMBL1089222'],"{'rows': array(['EFO_0005752', 'HP_0003326', 'HP_0002829'], dtype=object), 'count': 3}",[ENSG00000158125],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved indications. It was withdrawn in at least one region.
CHEMBL1199307,CN(CCCCCCN(C)C(=O)Oc1ccc[n+](C)c1)C(=O)Oc1ccc[n+](C)c1,AHZBEVXBKNYXPU-UHFFFAOYSA-N,Small molecule,False,DISTIGMINE,,4.0,,False,True,[],['Distigmine' 'Distigmine cation' 'Distigmine ion'],"[('drugbank', array(['DB13694'], dtype=object)), ('chEBI', array(['80756'], dtype=object))]",['CHEMBL1098285'],,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL1200418,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1.Cl,BQKADKWNRWCIJL-UHFFFAOYSA-N,Small molecule,False,DOBUTAMINE HYDROCHLORIDE,1978.0,4.0,CHEMBL926,False,True,['Dobutamine hydrochloride' 'Dobutrex' 'Posiject'],"['46236' 'Dl-dobutamine hydrochloride' 'Dobutamine hcl'
 'Dobutamine hydrochloride' 'NSC-299583']","[('PubChem', array(['46500392', '50106131', '50106132', '56320684'], dtype=object)), ('chEBI', array(['4671'], dtype=object))]",,"{'rows': array(['EFO_0000373', 'EFO_0000319'], dtype=object), 'count': 2}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for congestive heart failure and has 1 investigational indication.
CHEMBL1200703,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1.Cl,DMLFJMQTNDSRFU-UHFFFAOYSA-N,Small molecule,True,CHLORDIAZEPOXIDE HYDROCHLORIDE,1960.0,4.0,CHEMBL451,False,True,"['A-poxide' 'Chlordiazachel' 'Chlordiazepoxide hydrochloride' 'Librium'
 'Lygen' 'Tropium']","['Chlordiazepoxide hcl' 'Chlordiazepoxide hydrochloride'
 'Clopoxide chloride' 'NSC-115748' 'RO 5-0690' 'RO-5-0690']","[('DailyMed', array(['chlordiazepoxide%20hydrochloride'], dtype=object)), ('chEBI', array(['3612'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA.
CHEMBL1201146,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,IMONTRJLAWHYGT-ZCPXKWAGSA-N,Small molecule,False,NORETHINDRONE ACETATE,1973.0,4.0,,False,True,['Aygestin' 'Norethidrone Acetate' 'Norethindrone acetate' 'Norlutate'],"['NSC-22844' 'Norethindrone acetate' 'Norethisteron acetate'
 'Norethisterone 17-acetate' 'Norethisterone acetate'
 'Norethisteroni acetas' 'Norethynyltestosterone' 'Norlutin acetate'
 'SH-420']","[('DailyMed', array(['norethindrone%20acetate'], dtype=object)), ('PubChem', array(['144206922', '29215468'], dtype=object)), ('Wikipedia', array(['Norethisterone_acetate'], dtype=object)), ('chEBI', array(['7628'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000574', 'EFO_0002950', 'EFO_0001065',
       'MP_0001914', 'EFO_0003894', 'MONDO_0002146', 'EFO_0000731',
       'MONDO_0009061', 'EFO_0003843', 'GO_0042697'], dtype=object), 'count': 11}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 8 investigational indications.
CHEMBL1255739,CN(C)CCN(Cc1cccs1)c1ccccn1.Cl,BONORRGKLJBGRV-UHFFFAOYSA-N,Small molecule,False,METHAPYRILENE HYDROCHLORIDE,,4.0,CHEMBL1411979,True,True,[],"['Methapyrilene hcl' 'Methapyrilene hydrochloride' 'NSC-758410'
 'Thenylpyramine hydrochloride']","[('PubChem', array(['11533035', '144204808', '144208332', '170465531', '26747593',
       '50106697', '56422381'], dtype=object)), ('chEBI', array(['38213'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1389,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,WWYNJERNGUHSAO-XUDSTZEESA-N,Small molecule,False,LEVONORGESTREL,1982.0,4.0,,False,True,"['Athentia next' 'Emerres' 'Emerres una' 'Ezinelle' 'Fallback solo'
 'Her style' 'Isteranda' 'Jadelle' 'Jaydess' 'Kyleena' 'Levonelle'
 'Levonelle one step' 'Levonelle-2' 'Levonorgestrel' 'Levosert' 'Liletta'
 'Microval' 'Mirena' 'Norgeston' 'Norplant' 'Norplant Ii'
 'Norplant System' 'Opcicon one-step' 'Ovrette' 'Plan B' 'Plan b one-step'
 'Postinor-2' 'Skyla' 'Upostelle']","['BAY86-5028' 'Levonorgestrel' 'Levonorgestrelum' 'NSC-744007'
 'Norgestrel (-)-form' 'Norgestrel, (-)-' 'WY-5104']","[('DailyMed', array(['levonorgestrel'], dtype=object)), ('PubChem', array(['11532896', '144205146', '144210070', '144213960', '170465033',
       '26719646', '29215264', '56422866'], dtype=object)), ('Wikipedia', array(['Levonorgestrel', 'Norgestrel'], dtype=object)), ('drugbank', array(['DB00367'], dtype=object)), ('chEBI', array(['6443'], dtype=object))]",,"{'rows': array(['HP_0000132', 'MP_0001914', 'EFO_0000180', 'MONDO_0005351',
       'EFO_0001065', 'MONDO_0005148', 'MONDO_0005277', 'EFO_0000764',
       'EFO_0001075', 'EFO_1001757', 'MONDO_0004992', 'HP_0100607',
       'EFO_0004220', 'EFO_0000095', 'EFO_0004239', 'EFO_0002950',
       'EFO_1001249', 'EFO_0003843', 'HP_0000938'], dtype=object), 'count': 19}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for menorrhagia and has 18 investigational indications.
CHEMBL1800807,COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C,MZZLGJHLQGUVPN-HAWMADMCSA-N,Small molecule,False,ANACETRAPIB,,3.0,,False,False,[],['Anacetrapib' 'MK-0859' 'MK0859'],"[('Wikipedia', array(['Anacetrapib'], dtype=object)), ('drugbank', array(['DB06630'], dtype=object))]",,"{'rows': array(['Orphanet_309005', 'MONDO_0018328', 'EFO_0004911', 'EFO_0001645',
       'HP_0003124', 'EFO_0000319', 'MONDO_0021187'], dtype=object), 'count': 7}",[ENSG00000087237],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2107361,Cc1cc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)sc1CC[C@@H]1CNc2nc(N)[nH]c(=O)c2C1,QXOPTIPQEVJERB-JQWIXIFHSA-N,Small molecule,False,PELITREXOL,,2.0,,False,False,[],['AG-2037' 'AG2037' 'Pelitrexol'],"[('drugbank', array(['DB12757'], dtype=object))]",,"{'rows': array(['EFO_0004142', 'MONDO_0021117', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000159131],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2108040,,,Protein,False,MIROCOCEPT,,2.0,,False,False,[],['APT 070' 'APT-070' 'Mirococept'],,,,[ENSG00000203710],Protein drug with a maximum clinical trial phase of II.
CHEMBL2109469,,,Antibody,False,AFASEVIKUMAB,,2.0,,False,False,[],"['Afasevikumab' 'MCAF-5352A' 'MCAF5352A' 'NI-1401' 'RG-7624' 'RG7624'
 'RO-5553110' 'RO5553110']",,,,[ENSG00000112115],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2111084,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C,LNHWXBUNXOXMRL-VWLOTQADSA-N,Small molecule,False,BELOTECAN,,3.0,,False,False,[],['Belotecan'],"[('drugbank', array(['DB12459'], dtype=object))]",['CHEMBL2107315'],"{'rows': array(['MONDO_0008903', 'EFO_0000616', 'EFO_0000702', 'EFO_0003060',
       'MONDO_0008170', 'MONDO_0002974'], dtype=object), 'count': 6}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL248702,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1,DBGIVFWFUFKIQN-VIFPVBQESA-N,Small molecule,False,DEXFENFLURAMINE,,4.0,,True,True,[],"['D-fenfluramine' 'Dexfenfluramine' 'Fenfluramine d-form' 'Isolipan'
 'J13.711A' 'S 5614']","[('Wikipedia', array(['Dexfenfluramine'], dtype=object)), ('drugbank', array(['DB01191'], dtype=object)), ('chEBI', array(['439329'], dtype=object))]",['CHEMBL1887891'],"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for obesity.
CHEMBL266510,COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(C(F)(F)F)ccc21,ULYONBAOIMCNEH-HNNXBMFYSA-N,Small molecule,False,FLINDOKALNER,,3.0,,False,False,[],['BMS-204352' 'BMS-204352-01' 'Flindokalner'],,,,"[ENSG00000075043,ENSG00000184156,ENSG00000185760,ENSG00000156113,ENSG00000117013]",Small molecule drug with a maximum clinical trial phase of III.
CHEMBL3544953,,,Small molecule,False,SAF312,,2.0,,False,False,[],['Saf312'],,,"{'rows': array(['HP_0200026', 'EFO_0003843', 'HP_0000011'], dtype=object), 'count': 3}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545385,,,Small molecule,False,WX-037,,1.0,,False,False,[],['Wx-037'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989911,CC(O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)CCCNC(=O)CCCN(CC(N)=O)C(=O)[C@H](Cc2ccccc2)NC1=O,ABFNTRQPWNXUHA-NNIYEDDKSA-N,Protein,False,VELDOREOTIDE,,2.0,,False,False,[],"['COR-005' 'DG-3173' 'DG3173' 'Dg3173' 'PTR 3173' 'PTR-3173' 'Somatoprim'
 'Veldoreotide']",,,"{'rows': array(['EFO_1001485'], dtype=object), 'count': 1}","[ENSG00000162009,ENSG00000132671,ENSG00000180616]",Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989929,CCCCc1nc(-c2ccc(OCCCN(CC)CC)cc2)cn1-c1ccc(Oc2ccc(Cl)cc2)cc1,KJNNWYBAOPXVJY-UHFFFAOYSA-N,Small molecule,False,AZELIRAGON,,3.0,,False,False,[],['Azeliragon' 'PF-04494700' 'TTP-488' 'TTP448' 'TTP488'],"[('drugbank', array(['DB12689'], dtype=object))]",,"{'rows': array(['EFO_0000519', 'EFO_0002618', 'MONDO_0100096', 'MONDO_0002158',
       'EFO_0000401', 'MONDO_0008170', 'MONDO_0004975'], dtype=object), 'count': 7}",[ENSG00000204305],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4297534,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O,VJCVKWFBWAVYOC-UIXXXISESA-N,Small molecule,True,GLASDEGIB MALEATE,2018.0,4.0,CHEMBL2043437,False,True,['Daurismo'],['Glasdegib maleate' 'PF-04449913 MALEATE'],"[('DailyMed', array(['glasdegib%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo'],
      dtype=object))]",,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA.
CHEMBL4297730,,,Antibody,False,CONCIZUMAB,,3.0,,False,False,[],"['Anti-TFPI' 'Concizumab' 'MAB-2021' 'NN-7415' 'NN7415'
 'NNC 0172-0000-2021' 'NNC-0172-0000-2021' 'mAb2021']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CONCIZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604', 'MONDO_0010602'], dtype=object), 'count': 2}",[ENSG00000003436],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4594273,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1.Cl.Cl,XGFHYCAZOCBCRQ-FBHGDYMESA-N,Small molecule,False,ELACESTRANT HYDROCHLORIDE,2023.0,4.0,CHEMBL4297509,False,True,['Orserdu'],"['Elacestrant dihydrochloride' 'Elacestrant hydrochloride' 'Orserdu'
 'RAD1901 hydrochloride']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELACESTRANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0006861', 'EFO_0003869'], dtype=object), 'count': 2}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for male breast carcinoma and breast neoplasm.
CHEMBL4650273,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O.CC(=O)O.CC(=O)O,GOOYENKUPOAYOV-KMKYJKQVSA-N,Protein,False,SETMELANOTIDE ACETATE,2020.0,4.0,CHEMBL3301624,False,True,['Imcivree'],[],,,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}",[ENSG00000166603],Protein drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for obesity.
CHEMBL517,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C,UVTNFZQICZKOEM-UHFFFAOYSA-N,Small molecule,True,DISOPYRAMIDE,1977.0,4.0,,False,True,[],"['(rs)-disopyramide' 'Dicorantil' 'Disopyramide' 'Dl-disopyramide'
 'H-3292' 'Isorythm' 'Lispine' 'Norpace' 'Ritmilen' 'Rythmodan p'
 'SC-7031' 'Searle-703']","[('PubChem', array(['144204278', '170464947', '174006632', '50106174', '85148360',
       '85231006', '90340571', '90341382'], dtype=object)), ('TG-GATEs', array(['102'], dtype=object)), ('Wikipedia', array(['Disopyramide'], dtype=object)), ('drugbank', array(['DB00280'], dtype=object)), ('chEBI', array(['4657'], dtype=object))]",['CHEMBL1201020'],"{'rows': array(['HP_0004308', 'EFO_0004269', 'EFO_0000275', 'EFO_0004269',
       'EFO_0003144', 'EFO_0000275'], dtype=object), 'count': 6}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL570015,COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1,JFHROPTYMMSOLG-UHFFFAOYSA-N,Small molecule,False,GSK-256066,,2.0,,False,False,[],['GSK256066' 'Gsk-256066'],"[('drugbank', array(['DB12137'], dtype=object))]",['CHEMBL5307584'],"{'rows': array(['EFO_0003956', 'EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 3}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL572878,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1,GCIKSSRWRFVXBI-UHFFFAOYSA-N,Small molecule,False,TOZASERTIB,,2.0,,False,False,[],['MK-045' 'MK-0457' 'Tozasertib' 'VX-68' 'VX-680'],"[('PubChem', array(['103905648', '137275826', '162108261', '164339430', '49645761',
       '50100121'], dtype=object))]",['CHEMBL2105657'],"{'rows': array(['EFO_1001951', 'EFO_0003060', 'MONDO_0004992', 'EFO_0004289',
       'EFO_0000339', 'EFO_0000220', 'EFO_0000198', 'EFO_0000565'],
      dtype=object), 'count': 8}","[ENSG00000178999,ENSG00000105146,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL1095777,CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,QZZUEBNBZAPZLX-QFIPXVFZSA-N,Small molecule,False,INDACATEROL,2009.0,4.0,,False,True,[],['Indacaterol' 'Indacterol' 'Onbrez' 'QAB-149' 'QAB149' 'QABI49'],"[('Wikipedia', array(['Indacaterol'], dtype=object)), ('drugbank', array(['DB05039'], dtype=object)), ('chEBI', array(['68575'], dtype=object))]",['CHEMBL1789842' 'CHEMBL3527369' 'CHEMBL4297657'],"{'rows': array(['HP_0006536', 'EFO_0006505', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0000464', 'MONDO_0004979', 'EFO_0000341', 'EFO_0003144',
       'MONDO_0004979'], dtype=object), 'count': 9}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 4 investigational indications.
CHEMBL1195136,CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1,AVDSOVJPJZVBTC-CTYIDZIISA-N,Small molecule,False,SNX 5422,,2.0,,False,False,[],['Pf-04929113' 'Pf-4929113' 'Snx 5422' 'Snx-5422'],"[('drugbank', array(['DB06070'], dtype=object))]",['CHEMBL553939'],"{'rows': array(['EFO_0000574', 'MONDO_0004992', 'MONDO_0044881', 'EFO_0000565'],
      dtype=object), 'count': 4}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1200689,[N]=O,MWUXSHHQAYIFBG-UHFFFAOYSA-N,Small molecule,False,NITRIC OXIDE,1999.0,4.0,,False,True,['Genosyl' 'Inomax'],"['Amidogen, oxo-' 'Inovent' 'Nitric oxide' 'Nitric oxide trimer'
 'Nitrogen oxide (no)' 'Nitrosyl radical' 'OHM-11771']","[('DailyMed', array(['nitric%20oxide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inomax'],
      dtype=object)), ('Wikipedia', array(['Nitric_oxide', 'Nitroxyl'], dtype=object)), ('drugbank', array(['DB00435'], dtype=object)), ('chEBI', array(['16480'], dtype=object))]",,"{'rows': array(['MONDO_0011382', 'EFO_0000341', 'EFO_1001375', 'EFO_0000373',
       'EFO_0004272', 'EFO_1001923', 'MONDO_0005299', 'MONDO_0005149',
       'EFO_0000544', 'MONDO_0100096', 'EFO_0004278', 'EFO_0009444',
       'EFO_0000694', 'EFO_0007512', 'MONDO_0019091', 'EFO_0009447',
       'EFO_0007486', 'EFO_0005762', 'EFO_0005611', 'HP_0100806',
       'EFO_0008585', 'EFO_0005046', 'MONDO_0043510', 'EFO_1001399',
       'EFO_1000644', 'EFO_1001951', 'MONDO_0009061', 'EFO_1000637',
       'EFO_0003827', 'HP_0011950', 'EFO_1001459', 'EFO_0003917',
       'EFO_0007067', 'MONDO_0004992', 'EFO_0009492', 'EFO_0000684',
       'EFO_0009686', 'EFO_0008583', 'EFO_0005207', 'EFO_0003106',
       'HP_0001919', 'EFO_0001068', 'MP_0001845', 'EFO_0003818',
       'EFO_0007541', 'EFO_0002687', 'HP_0002093', 'EFO_1001103',
       'EFO_0000712', 'HP_0002094', 'HP_0200042', 'EFO_0000768',
       'EFO_0001361', 'EFO_0007224'], dtype=object), 'count': 54}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 49 investigational indications.
CHEMBL1200797,,,Small molecule,False,TECHNETIUM TC 99M SUCCIMER,1982.0,4.0,CHEMBL2110572,False,True,['Mpi dmsa kidney reagent' 'Nephroscan'],"['99mtc-dmsa' 'Nephroscan' 'Tc-99m dmsa' 'Technetium (99Mtc) Succimer'
 'Technetium (99mtc) dimercaptosuccinic acid for injection'
 'Technetium (99mtc) succimer' 'Technetium tc 99m succimer'
 'Technetium tc-99m succimer' 'Technetium-99 dimercaptosuccinate'
 'Technetium-99-dmsa']",,,,[ENSG00000175899],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201554,,,Protein,False,ANTITHROMBIN ALFA,2006.0,4.0,,False,True,['Atryn'],"['Antithrombin (recombinant)' 'Antithrombin alfa'
 'Antithrombin iii,recombinant' 'Human anti-thrombin-iii' 'KW-3357']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/atryn'],
      dtype=object))]",,"{'rows': array(['EFO_0000668', 'HP_0001976', 'HP_0005521'], dtype=object), 'count': 3}","[ENSG00000180210,ENSG00000126218]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for reduced antithrombin iii activity and has 2 investigational indications.
CHEMBL1620,CN(C)CCOC(c1ccccc1)c1ccccc1.Cl,PCHPORCSPXIHLZ-UHFFFAOYSA-N,Small molecule,False,DIPHENHYDRAMINE HYDROCHLORIDE,1946.0,4.0,CHEMBL657,False,True,"['Alledryl' 'Antitussive' 'Beldin' 'Belix' 'Benadryl'
 'Benadryl preservative free' 'Benylin' 'Caladryl' 'Coltex' 'Dibenil'
 'Diphen' 'Diphenhydramine hydrochloride'
 'Diphenhydramine hydrochloride preservative free' 'Dreemon' 'Dytuss'
 'Fedril' 'Gppe cough expect paed' 'Gppe oral soln' 'Histergan'
 'Hydramine' 'Medinex' 'Nightcalm' 'Nytol' 'Nytol one-a-night' 'Paxidorm'
 'Silphen' 'Sleepia' 'Syntedril' 'Tixylix catarrh' 'Vicks formula 44']","['Dimedrol' 'Diphenhydramine HCl' 'Diphenhydramine hcl'
 'Diphenhydramine hydrochloride' 'NSC-33299']","[('DailyMed', array(['diphenhydramine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206544', '144208670', '144210928', '26719640', '26747495',
       '26747496', '26751624', '50106145', '50106146', '50106147',
       '543925', '56422455', '855936'], dtype=object)), ('chEBI', array(['4637'], dtype=object))]",,"{'rows': array(['MONDO_0005271', 'EFO_0006928', 'EFO_0004255', 'EFO_0009516',
       'MONDO_0007915', 'EFO_0005252', 'EFO_1000783', 'HP_0002017',
       'HP_0002018', 'HP_0002315', 'EFO_0000701', 'EFO_0005761',
       'EFO_0009847', 'MONDO_0002258', 'EFO_0000403', 'MONDO_0002367',
       'HP_0002013', 'HP_0000989', 'EFO_0003958', 'EFO_0004698',
       'EFO_0000095', 'EFO_0003843', 'HP_0001742', 'EFO_1000657',
       'HP_0001945', 'EFO_0005854', 'EFO_0007214', 'MONDO_0007254',
       'EFO_0003956', 'HP_0012735'], dtype=object), 'count': 30}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 18 approved and 12 investigational indications.
CHEMBL2105749,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O,RARHXUAUPNYAJF-QSYGGRRVSA-N,Small molecule,False,SAMIDORPHAN L-MALATE,2021.0,4.0,CHEMBL426084,False,True,[],['RDC-0313-02' 'Samidorphan l-malate' 'Samidorphan malate'],,,"{'rows': array(['EFO_0009963', 'MONDO_0005090'], dtype=object), 'count': 2}","[ENSG00000082556,ENSG00000112038,ENSG00000116329]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for bipolar i disorder and schizophrenia.
CHEMBL2105842,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,RKHQGWMMUURILY-UHRZLXHJSA-N,Small molecule,False,CORTIVAZOL,,4.0,,False,True,['Altim'],['Cortivazol' 'NSC-80998'],"[('drugbank', array(['DB13003'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication.
CHEMBL2109369,,,Antibody,False,90Y-CT84.66,,1.0,,False,False,[],['90Y-CT84.66'],,,,[ENSG00000105388],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109459,,,Antibody,False,CDP-484,,1.0,,False,False,[],['CDP-484'],,,,[ENSG00000125538],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109479,,,Antibody,False,PF-03475952,,-1.0,,False,False,[],['PF-03475952'],,,,[ENSG00000026508],Antibody drug.
CHEMBL2359670,CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)CC(O)C(=O)O.O=C(O)CC(O)C(=O)O,GTHHLZDYRHLACN-UHFFFAOYSA-N,Small molecule,False,THIETHYLPERAZINE MALATE,1961.0,4.0,CHEMBL1378,False,True,['Torecan'],"['Thiethylperazine dimalate' 'Thiethylperazine malate'
 'Thietylperazine malate']","[('PubChem', array(['144204335'], dtype=object))]",,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.
CHEMBL3189072,CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O.Cl.O,HWAAPJPFZPHHBC-FGJQBABTSA-N,Small molecule,False,TIROFIBAN HYDROCHLORIDE,1998.0,4.0,CHEMBL916,False,True,['Aggrastat'],"['L-700,462' 'L-700462' 'MK-383' 'Tirofiban hcl' 'Tirofiban hydrochloride'
 'Tirofiban hydrochloride anhydrous']","[('DailyMed', array(['tirofiban%20hydrochloride'], dtype=object)), ('PubChem', array(['144206533', '170465092'], dtype=object)), ('chEBI', array(['9606'], dtype=object))]",,"{'rows': array(['EFO_0000612'], dtype=object), 'count': 1}","[ENSG00000259207,ENSG00000005961]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998 and is indicated for myocardial infarction.
CHEMBL3349001,CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1,GYCPCOJTCINIFZ-OXJNMPFZSA-N,Small molecule,False,AVN-944,,2.0,,False,False,[],['AVN 944' 'AVN944' 'Avn-944' 'Avn944'],,,"{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}","[ENSG00000106348,ENSG00000178035]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL338975,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C.O=C(O)c1ccccc1O,HZOTZTANVBDFOF-PBCQUBLHSA-N,Small molecule,False,PHYSOSTIGMINE SALICYLATE,,4.0,CHEMBL94,False,True,[],"['Eserine salicylate' 'NSC-757275' 'Physostigmine monosalicylate'
 'Physostigmine salicylate' 'Physostigmini salicylas']","[('PubChem', array(['855875'], dtype=object)), ('chEBI', array(['48883'], dtype=object))]",,,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL3544954,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,OOUACICUAVTCEC-LZHWUUGESA-N,Protein,False,ZOPTARELIN DOXORUBICIN,,3.0,,False,False,[],['AN-152' 'Aezs-108' 'Zoptarelin doxorubicin'],,['CHEMBL3989956'],"{'rows': array(['MONDO_0007254', 'MONDO_0011962', 'EFO_0008528'], dtype=object), 'count': 3}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3545278,CCCCCS(=O)(=O)NC(=O)c1ccc2nc(C)n(Cc3ccc(Cl)cc3Cl)c2c1,UYGZODVVDUIDDQ-UHFFFAOYSA-N,Small molecule,False,ATX08-001,,2.0,,False,False,[],['Atx08-001' 'FK-614' 'FK614'],"[('drugbank', array(['DB12557'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'MONDO_0041052'], dtype=object), 'count': 2}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545347,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,PVHLMTREZMEJCG-GDTLVBQBSA-N,Protein,False,TXA127,,2.0,,False,False,[],"['5-ile-angiotensin-(1-7)' 'Angiotensin (1-7)' 'Angiotensin 1-7'
 'Angiotensin fragment 1-7' 'Angiotensin peptide (1-7)'
 'Angiotensin-(1-7)' 'Asp-arg-val-tyr-ile-his-pro' 'Bf-angiotensin 1-7'
 'Human angiotensin ii (1-7)' 'Sh-heptapeptide-13' 'TXA-127' 'TXA127'
 'Txa127']","[('drugbank', array(['DB11720'], dtype=object)), ('chEBI', array(['55438'], dtype=object))]",,"{'rows': array(['EFO_0000198', 'EFO_0000616', 'EFO_0003144', 'MONDO_0004992',
       'EFO_0000537', 'EFO_0001073', 'EFO_0000764', 'MONDO_0100096',
       'EFO_0004265', 'EFO_0009686'], dtype=object), 'count': 10}",[ENSG00000130368],Protein drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL3545350,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1,BOVUHBFXPNLTKF-UHFFFAOYSA-N,Small molecule,False,EVT-101,,2.0,,False,False,[],['Evt-101'],,['CHEMBL3545349'],"{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}","[ENSG00000176884,ENSG00000273079]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3833389,C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1,XHKXWINHANRSNT-NRFANRHFSA-N,Small molecule,False,DEXTROMORAMIDE,,4.0,,False,True,[],"['Acscn-9613' 'Alcoid' 'Dextromoramide' 'IDS-ND-003' 'Jetrium' 'Linfadol'
 'MCP-875' 'Moramide' 'Narcolo' 'Palfadonna' 'R-875' 'Racemoramide, (s)-'
 'SKF-5137' 'Troxilan' 'Yetrium']",,['CHEMBL3833311'],"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for pain.
CHEMBL4297650,CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(=O)O)C(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(N)=O)[C@H](C)O)[C@H](C)O,BAAXVYBAMNDCIB-BMCUWHFPSA-N,Protein,False,BRIMAPITIDE,,3.0,,False,False,[],['Brimapitide' 'Xg-102'],"[('drugbank', array(['DB15231'], dtype=object))]",,"{'rows': array(['MP_0001845'], dtype=object), 'count': 1}",[ENSG00000109339],Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297680,,,Unknown,False,1018 ISS,,3.0,,False,False,[],"['1018 ISS' '1018 iss' 'CPG-1018' 'Cpg 1018'
 'Cpg oligonucleotide 1018 iss' 'Iss 1018'
 'Iss 1018 cpg oligodeoxynucleotide' 'Iss-1018']",,,"{'rows': array(['EFO_0004197', 'EFO_0005952', 'EFO_0000764', 'MONDO_0100096',
       'EFO_0004142'], dtype=object), 'count': 5}",[ENSG00000239732],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4594594,,,Antibody,False,ITEPEKIMAB,,3.0,,False,False,[],"['Itepekimab' 'REGN-3500' 'REGN3500' 'Regn3500' 'SAR-440340' 'SAR440340'
 'Sar440340']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ITEPEKIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0000274'], dtype=object), 'count': 3}",[ENSG00000137033],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL5315075,,,Protein,False,SUSOCTOCOG ALFA,2015.0,4.0,,False,True,['Obizur'],['BAX-802' 'BAX802' 'Susoctocog alfa'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/obizur'],
      dtype=object))]",,"{'rows': array(['MP_0001914', 'MONDO_0010602'], dtype=object), 'count': 2}",[ENSG00000185010],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hemorrhage and hemophilia a.
CHEMBL644,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21,ZSCDBOWYZJWBIY-UHFFFAOYSA-N,Small molecule,True,TRIMIPRAMINE,1979.0,4.0,,False,True,[],"['7162 RP' '7162-RP' 'IL 6001' 'IL-6001' 'Surmontil' 'Trimeproprimine'
 'Trimipramine']","[('PubChem', array(['50111256', '90341093'], dtype=object)), ('Wikipedia', array(['Trimipramine'], dtype=object)), ('drugbank', array(['DB00726'], dtype=object)), ('chEBI', array(['9738'], dtype=object))]",['CHEMBL1200948'],"{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002009', 'MONDO_0005090',
       'MONDO_0002050'], dtype=object), 'count': 5}","[ENSG00000196639,ENSG00000149295,ENSG00000102468,ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000147246,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for major depressive disorder and depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL742,CNC1(c2ccccc2Cl)CCCCC1=O,YQEZLKZALYSWHR-UHFFFAOYSA-N,Small molecule,False,KETAMINE,1970.0,4.0,,False,True,['Ketalar'],"['Anaket v' 'Calypsol' 'Clorketam 1000' 'Dl-ketamine' 'Imalgene 1000'
 'Ketamine' 'Ketasol 100' 'NSC-70151' 'Narketan' 'PMI-150' 'Tekam'
 'Ursotamin' 'Vetaket']","[('PubChem', array(['144205256', '29215438', '56424156'], dtype=object)), ('Wikipedia', array(['Esketamine', 'Ketamine'], dtype=object)), ('drugbank', array(['DB01221'], dtype=object)), ('chEBI', array(['6121'], dtype=object))]",['CHEMBL1714'],"{'rows': array(['EFO_0001358', 'EFO_1001998', 'HP_0012532', 'EFO_0003768',
       'EFO_0007224', 'EFO_0000713', 'EFO_0003756', 'MONDO_0002009',
       'MONDO_0007079', 'EFO_0001074', 'EFO_0002460', 'MONDO_0002009',
       'EFO_0009854', 'EFO_1001412', 'EFO_0000512', 'EFO_0000546',
       'EFO_0004320', 'EFO_1001898', 'EFO_0003890', 'MONDO_0005129',
       'HP_0002315', 'EFO_0005279', 'EFO_0009963', 'EFO_0000712',
       'EFO_0008526', 'MONDO_0002009', 'EFO_0007191', 'MONDO_0010726',
       'EFO_0009513', 'HP_0012378', 'EFO_0003957', 'MONDO_0007079',
       'EFO_0000713', 'MONDO_0011382', 'EFO_0007430', 'EFO_0005762',
       'HP_0000486', 'EFO_0009552', 'EFO_0004242', 'EFO_1000391',
       'EFO_0000474', 'EFO_1001917', 'EFO_0004321', 'EFO_0005323',
       'MONDO_0008903', 'EFO_1000637', 'EFO_0007453', 'MONDO_0004992',
       'MONDO_0005351', 'EFO_0009267', 'EFO_0004320', 'EFO_0801084',
       'MONDO_0004985', 'HP_0012076', 'EFO_0000677', 'MONDO_0002050',
       'MONDO_0002038', 'MONDO_0002070', 'HP_0100806', 'EFO_0009854',
       'EFO_0005611', 'EFO_0002610', 'HP_0000360', 'EFO_0003843',
       'HP_0100543', 'HP_0000989', 'MONDO_0002050', 'EFO_0007149',
       'EFO_0008590', 'MONDO_0007254', 'MONDO_0043510', 'EFO_0009686',
       'EFO_0009492', 'EFO_1001210', 'MONDO_0100096', 'EFO_0006834',
       'EFO_0002610', 'EFO_0000546', 'EFO_0005611', 'EFO_0003931',
       'MONDO_0002258', 'EFO_0009620', 'EFO_0003931', 'HP_0002140',
       'MONDO_0004992', 'MONDO_0005090', 'EFO_0000474', 'HP_0000713',
       'HP_0100543', 'MONDO_0004985', 'EFO_0003015', 'MONDO_0024417',
       'EFO_0000694', 'EFO_1001884'], dtype=object), 'count': 94}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 83 investigational indications.
CHEMBL1096882,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,GIUYCYHIANZCFB-FJFJXFQQSA-N,Small molecule,True,FLUDARABINE PHOSPHATE,1991.0,4.0,,False,True,['Fludara' 'Fludarabine phosphate' 'Oforta'],"['2-f-ara-amp' '2-f-araa' '2-fluoro ara-a' '2-fluorovidarabine'
 'Fludarabine' ""Fludarabine 5'-monophosphate"" 'Fludarabine monophosphate'
 'Fludarabine phosphate' 'Fluradosa' 'NSC-118218' 'NSC-118218H'
 'NSC-312887' 'NSC-328002']","[('DailyMed', array(['fludarabine%20phosphate'], dtype=object)), ('chEBI', array(['63599'], dtype=object))]",,"{'rows': array(['EFO_0000691', 'EFO_0000403', 'EFO_0000221', 'HP_0001871',
       'EFO_0009709', 'EFO_0000209', 'EFO_0003027', 'EFO_0003811',
       'EFO_0004599', 'EFO_0004256', 'EFO_1000292', 'MONDO_0008170',
       'EFO_0009441', 'EFO_0003778', 'MONDO_0021063', 'EFO_0004251',
       'EFO_0000309', 'MONDO_0002334', 'MONDO_0015760', 'EFO_0001642',
       'EFO_0005952', 'EFO_1000690', 'EFO_0000389', 'EFO_0000220',
       'MONDO_0001023', 'EFO_0003802', 'EFO_0000255', 'EFO_0000621',
       'MONDO_0004992', 'EFO_0000196', 'HP_0001915', 'Orphanet_848',
       'MONDO_0019391', 'EFO_0000339', 'MONDO_0009348', 'MONDO_0021193',
       'EFO_0003032', 'HP_0012410', 'EFO_0006927', 'EFO_0005761',
       'MONDO_0007576', 'EFO_1001257', 'MONDO_0015277', 'EFO_1000560',
       'EFO_0003025', 'MONDO_0002691', 'EFO_0004272', 'EFO_0000222',
       'EFO_0000095', 'EFO_1001779', 'EFO_0000349', 'EFO_0000182',
       'EFO_0000096', 'MONDO_0018906', 'MONDO_0015253', 'MONDO_0009833',
       'MONDO_0019469', 'EFO_0006803', 'EFO_0002617', 'EFO_0001075',
       'MONDO_0011382', 'EFO_0000565', 'MONDO_0015974', 'EFO_0000540',
       'EFO_0000708', 'EFO_0009708', 'MONDO_0019460', 'MONDO_0002158',
       'MONDO_0017198', 'EFO_1001051', 'EFO_0000519', 'EFO_0001378',
       'MONDO_0008903', 'EFO_0000384', 'MONDO_0000159', 'EFO_1001465',
       'EFO_0000574', 'EFO_1000131', 'EFO_0003869', 'EFO_1001996',
       'MONDO_0044881', 'MONDO_0008315', 'EFO_0000223', 'EFO_0000174',
       'MONDO_0100244', 'MONDO_0002898', 'EFO_1000309', 'EFO_0004252',
       'EFO_0000183', 'EFO_0000685', 'EFO_0000616', 'EFO_0003865',
       'MONDO_0000870', 'EFO_0000637', 'EFO_1002048', 'MONDO_0020077',
       'EFO_0000211', 'EFO_0006475', 'EFO_0002429', 'EFO_1001469',
       'EFO_0006859', 'EFO_0000588', 'EFO_0000094', 'MONDO_0002108',
       'EFO_0000218', 'EFO_0000198', 'MONDO_0002087', 'EFO_0002428',
       'MONDO_0010518', 'MONDO_0013730', 'MONDO_0018922', 'EFO_1000956',
       'EFO_0003060', 'MONDO_0044903', 'EFO_0000717', 'EFO_0001061',
       'EFO_0000681', 'EFO_0000756', 'MONDO_0005184', 'EFO_1000318',
       'HP_0100727', 'MONDO_0019472', 'MONDO_0018305', 'MONDO_0002367',
       'HP_0002721', 'EFO_0002430', 'EFO_1001938', 'EFO_0005803',
       'EFO_0000571', 'EFO_0004289', 'MONDO_0005301', 'EFO_0000676',
       'EFO_1000785', 'MONDO_0000873', 'MONDO_0019471', 'MONDO_0007915',
       'EFO_1000102', 'EFO_0000326', 'EFO_0000191', 'MONDO_0007254',
       'MONDO_0001657'], dtype=object), 'count': 141}","[ENSG00000167325,ENSG00000048392,ENSG00000171848,ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 138 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200694,FCOC(C(F)(F)F)C(F)(F)F,DFEYYRMXOJXZRJ-UHFFFAOYSA-N,Small molecule,False,SEVOFLURANE,1995.0,4.0,,False,True,"['Sevoflurane' 'Sevohale (previously known as sevocalm)' 'Sojourn'
 'Ultane']","['MR-6S4' 'MR6S4' 'NSC-760367' 'Sevocalm' 'Sevoflo' 'Sevoflurane'
 'Sevorane']","[('DailyMed', array(['sevoflurane'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/sevohale-previously-known-sevocalm'],
      dtype=object)), ('PubChem', array(['144205978', '50112674'], dtype=object)), ('Wikipedia', array(['Sevoflurane'], dtype=object)), ('drugbank', array(['DB01236'], dtype=object)), ('chEBI', array(['9130'], dtype=object))]",,"{'rows': array(['EFO_0009267', 'EFO_0003870', 'EFO_0000713', 'EFO_0001074',
       'MONDO_0021698', 'EFO_0005207', 'EFO_1001328', 'EFO_0009686',
       'HP_0011110', 'HP_0003418', 'EFO_0003884', 'EFO_0001073',
       'EFO_0003843', 'EFO_0002687', 'MONDO_0007254', 'MONDO_0007576',
       'EFO_0003777', 'EFO_0005323', 'HP_0001919', 'MONDO_0100096',
       'EFO_0001645', 'EFO_0008583', 'MONDO_0004992', 'EFO_0005611',
       'EFO_1002048', 'EFO_0000694', 'MONDO_0043510', 'MP_0001845',
       'EFO_0006834', 'EFO_1000637', 'EFO_1001951', 'MONDO_0021117',
       'EFO_1001884'], dtype=object), 'count': 33}","[ENSG00000145888,ENSG00000109738,ENSG00000100433,ENSG00000186795,ENSG00000082482,ENSG00000169427,ENSG00000171303,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 33 investigational indications.
CHEMBL1200920,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1.Cl,MUFDLGGSOCHQOC-UHFFFAOYSA-N,Small molecule,False,ISOETHARINE HYDROCHLORIDE,1979.0,4.0,CHEMBL1201213,False,True,"['Beta-2' 'Bronkosol' 'Isoetharine hydrochloride'
 'Isoetharine hydrochloride s/f' 'Numotac']","['Asthmalitan' 'Dl-isoetharine hydrochloride' 'Isoetarine hydrochloride'
 'Isoetharine hcl' 'Isoetharine hydrochloride']",,,,[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979.
CHEMBL1201192,NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,YFGHCGITMMYXAQ-LJQANCHMSA-N,Small molecule,False,ARMODAFINIL,2007.0,4.0,,False,True,['Armodafinil' 'Nuvigil'],"['Armodafinil' 'CEP-10952' 'CEP-10953' 'CRL-40982' 'Modafinil, (r)-'
 'NSC-751850' 'NSC-758711' 'R-(-)-modafinil']","[('DailyMed', array(['armodafinil'], dtype=object)), ('Wikipedia', array(['Armodafinil'], dtype=object)), ('drugbank', array(['DB06413'], dtype=object)), ('chEBI', array(['77590'], dtype=object))]",,"{'rows': array(['MONDO_0100342', 'HP_0012378', 'EFO_0003060', 'MONDO_0021107',
       'EFO_0003888', 'MONDO_0007576', 'MONDO_0005090', 'EFO_0006859',
       'MONDO_0016158', 'EFO_0001073', 'EFO_0008568', 'MONDO_0002050',
       'EFO_0004698', 'MONDO_0043510', 'EFO_0003918', 'EFO_0005246',
       'EFO_0000712', 'EFO_0000616', 'MONDO_0005301'], dtype=object), 'count': 19}",[ENSG00000142319],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 14 investigational indications.
CHEMBL1201448,,,Oligosaccharide,False,ARDEPARIN SODIUM,1997.0,4.0,,False,True,['Normiflo'],"['Ardeparin sodium' 'Ardeparin sodium salt' 'RD-11885' 'WY-90493 RD'
 'WY-90493-RD']","[('Wikipedia', array(['Ardeparin_sodium'], dtype=object))]",,,[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV that was first approved in 1997.
CHEMBL1237105,CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO,UMMADZJLZAPZAW-XOWPVRJPSA-N,Small molecule,True,CARBOPROST TROMETHAMINE,1979.0,4.0,CHEMBL1237122,False,True,['Hemabate'],"['Carboprost trometamol' 'Carboprost trometanol' 'Carboprost tromethamine'
 'Carboprost tromethamine salt' 'U-32,921E' 'U-32921E']","[('DailyMed', array(['carboprost%20tromethamine'], dtype=object))]",,"{'rows': array(['EFO_0000731', 'EFO_0009579', 'MP_0001914'], dtype=object), 'count': 3}",[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for postpartum hemorrhage and hemorrhage and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1276308,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,VKHAHZOOUSRJNA-GCNJZUOMSA-N,Small molecule,True,MIFEPRISTONE,2000.0,4.0,,False,True,['Korlym' 'Mifegyne' 'Mifeprex'],"['Mifepristone' 'NSC-759862' 'RU 38486' 'RU 486' 'RU-38486' 'RU-486'
 'RU486']","[('DailyMed', array(['mifepristone'], dtype=object)), ('PubChem', array(['11533034', '144204503', '144212158', '170465151', '26752198',
       '26752199', '50104862', '50104863', '50124354', '56424093',
       '90341299'], dtype=object)), ('drugbank', array(['DB00834'], dtype=object)), ('chEBI', array(['50692'], dtype=object))]",,"{'rows': array(['EFO_1001110', 'MONDO_0002050', 'MONDO_0001572', 'EFO_0000764',
       'MONDO_0007254', 'EFO_0006861', 'EFO_0003060', 'MONDO_0004975',
       'EFO_1001757', 'EFO_0000400', 'MONDO_0002158', 'HP_0012076',
       'EFO_0001358', 'MONDO_0007079', 'MONDO_0011962', 'EFO_1001255',
       'MONDO_0002046', 'MONDO_0016642', 'EFO_0009784', 'MONDO_0002087',
       'EFO_0000432', 'EFO_0000673', 'EFO_0003047', 'EFO_0003099',
       'EFO_0001065', 'MONDO_0008170', 'MONDO_0008315', 'EFO_0007430',
       'MONDO_0002009', 'EFO_0002610', 'EFO_0002950', 'EFO_0000731',
       'MONDO_0004985', 'HP_0005268', 'EFO_0003768', 'EFO_0005230'],
      dtype=object), 'count': 36}","[ENSG00000082175,ENSG00000113580]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for cushing syndrome and has 35 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2048028,CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1,JFOZKMSJYSPYLN-QHCPKHFHSA-N,Small molecule,False,LIFITEGRAST,2016.0,4.0,,False,True,['Xiidra'],['Lifitegrast' 'SAR 1118' 'SAR-1118' 'SHP-606' 'SHP606'],"[('DailyMed', array(['lifitegrast'], dtype=object)), ('drugbank', array(['DB11611'], dtype=object))]",['CHEMBL2048409' 'CHEMBL2048410'],"{'rows': array(['EFO_0003966', 'EFO_0007141', 'MONDO_0013730', 'EFO_1000906'],
      dtype=object), 'count': 4}","[ENSG00000005844,ENSG00000160255]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for eye disease and dry eye syndrome and has 2 investigational indications.
CHEMBL2107863,,,Unknown,False,RINDOPEPIMUT,,3.0,,False,False,[],['CDX-110' 'PF-04948568' 'PF-04948568 (FORMERLY CDX-110)' 'Rindopepimut'],,,"{'rows': array(['EFO_1001465', 'MONDO_0100342', 'MONDO_0001657'], dtype=object), 'count': 3}",[ENSG00000146648],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2108339,,,Protein,False,EGAPTIVON PEGOL,,2.0,,False,False,[],['ARC-1779' 'ARC1779' 'Arc1779' 'Egaptivon pegol'],,,"{'rows': array(['MONDO_0018896', 'Orphanet_903', 'MONDO_0000831'], dtype=object), 'count': 3}",[ENSG00000110799],Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2177390,CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1,GRZXWCHAXNAUHY-NSISKUIASA-N,Small molecule,False,IPATASERTIB,,3.0,,False,False,[],['GDC-0068' 'Ipatasertib' 'RG-7440' 'RG7440' 'Rg-7440'],"[('drugbank', array(['DB11743'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0001075',
       'MONDO_0001056', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0003893',
       'EFO_0003869', 'MONDO_0011962', 'EFO_0000616', 'EFO_0005537',
       'EFO_0000503', 'EFO_0003060', 'EFO_1001512', 'EFO_1000251'],
      dtype=object), 'count': 16}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications.
CHEMBL2368924,CS(=O)(=O)O.O.O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,QTFFGPOXNNGTGZ-LIFGOUTFSA-N,Small molecule,False,DOLASETRON MESYLATE,1997.0,4.0,CHEMBL2368925,False,True,['Anzemet'],"['Dolasetron mesilate' 'Dolasetron mesilate monohydrate'
 'Dolasetron mesylate' 'Dolasetron mesylate anhydrous'
 'Dolasetron mesylate monohydrate' 'Dolasetron methanesulfonate'
 'MDL 73,147EF' 'MDL-73147EF']",,,"{'rows': array(['MONDO_0004992', 'EFO_0004888', 'HP_0002017'], dtype=object), 'count': 3}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved indications.
CHEMBL27,CC(C)NCC(O)COc1cccc2ccccc12,AQHHHDLHHXJYJD-UHFFFAOYSA-N,Small molecule,True,PROPRANOLOL,1967.0,4.0,,False,True,[],"['.beta.-propranolol' 'AY-64043-' 'Betalong' 'Dl-propranolol' 'Euprovasin'
 'Inderal' 'Inderide-40/25' 'Inderide-80/25' 'Propranolol' 'Proprasylyt'
 'Reducor']","[('PubChem', array(['124881056', '26751802', '26755283', '50104497', '90341556'],
      dtype=object)), ('Wikipedia', array(['Propranolol'], dtype=object)), ('drugbank', array(['DB00571'], dtype=object)), ('chEBI', array(['8499'], dtype=object))]",['CHEMBL1671'],"{'rows': array(['EFO_0000712', 'EFO_0001663', 'EFO_0000341', 'EFO_0005230',
       'EFO_0005687', 'EFO_0009516', 'EFO_0000612', 'MONDO_0004938',
       'EFO_0000389', 'EFO_0004319', 'EFO_0009545', 'EFO_1000911',
       'HP_0001943', 'EFO_0005252', 'EFO_0001358', 'EFO_0005537',
       'EFO_0000712', 'EFO_0001422', 'MONDO_0043510', 'EFO_0003756',
       'MONDO_0001187', 'EFO_0003913', 'EFO_0001365', 'EFO_1001375',
       'MONDO_0021661', 'EFO_0004329', 'EFO_0001073', 'EFO_0000182',
       'MONDO_0018089', 'HP_0004755', 'EFO_0005223', 'HP_0001279',
       'EFO_0001072', 'MONDO_0005475', 'MONDO_0001056', 'EFO_1001450',
       'HP_0030834', 'EFO_1000645', 'EFO_0002610', 'EFO_1001158',
       'MONDO_0019297', 'EFO_0000666', 'MONDO_0005147', 'EFO_0005251',
       'EFO_0003968', 'EFO_0004280', 'EFO_0000681', 'EFO_0001422',
       'EFO_1001968', 'EFO_0003882', 'MONDO_0005277', 'EFO_0004269',
       'MONDO_0100431', 'MONDO_0002363', 'EFO_0003918', 'MONDO_0004979',
       'MONDO_0005277', 'MONDO_0005148', 'MONDO_0002009', 'EFO_0001378',
       'EFO_0004262', 'EFO_0004142', 'EFO_0000546', 'EFO_0009444',
       'EFO_1001884', 'HP_0002315', 'EFO_0001358', 'HP_0001541',
       'EFO_0000558', 'MONDO_0031037', 'MONDO_0008315', 'EFO_0000537',
       'EFO_0003843', 'EFO_0003086', 'HP_0001636', 'MONDO_0011382',
       'EFO_0002610', 'EFO_0000537', 'EFO_1000635', 'EFO_0004287',
       'HP_0003419', 'MONDO_0007254', 'MONDO_0007947', 'EFO_0004278',
       'EFO_1000635', 'MONDO_0019180', 'EFO_0000756', 'EFO_0000319',
       'EFO_0003860'], dtype=object), 'count': 89}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 9 approved and 77 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545090,,,Small molecule,False,RXDX-103,,1.0,,False,False,[],['Rxdx-103'],,,,[ENSG00000097046],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545186,Cc1cc2c(CCc3sc(-c4ccc(C(F)(F)F)cc4)nc3C(C)C)noc2cc1OCC(=O)O,WWKYLBGQYALEDL-UHFFFAOYSA-N,Small molecule,False,FONADELPAR,,3.0,,False,False,[],['Fonadelpar' 'NPS-005' 'SJP-0035'],,,"{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}",[ENSG00000112033],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL420762,Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(N(C)C)c3ccccc32)cc1,WRNXUQJJCIZICJ-UHFFFAOYSA-N,Small molecule,False,MOZAVAPTAN,2006.0,4.0,,False,True,[],['Mozavaptan' 'Mozavaptane'],"[('PubChem', array(['170466304'], dtype=object)), ('Wikipedia', array(['Mozavaptan'], dtype=object))]",['CHEMBL5087555'],,[ENSG00000126895],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006.
CHEMBL4297511,N[C@@H](CCS(=O)(=O)O)CSSC[C@@H](N)CCS(=O)(=O)O,HJPXZXVKLGEMGP-YUMQZZPRSA-N,Small molecule,False,FIRIBASTAT,,3.0,,False,False,[],['Firibastat' 'QGC001' 'Qgc-001' 'Qgc001' 'RB-150'],"[('drugbank', array(['DB13107'], dtype=object))]",,"{'rows': array(['MONDO_0001134', 'EFO_0003144', 'EFO_1002048', 'EFO_0000537',
       'EFO_0000612'], dtype=object), 'count': 5}",[ENSG00000138792],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4594440,Fc1cc(F)c2c(c1)C[C@@H](n1c(CCNCc3ccccc3)c[nH]c1=S)CO2,ZSSLCFLHEFXANG-GOSISDBHSA-N,Small molecule,False,ZAMICASTAT,,2.0,,False,False,[],['Zamicastat'],,,"{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}",[ENSG00000123454],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594517,,,Antibody,False,GILORALIMAB,,2.0,,False,False,[],['ABBV-927' 'Abbv-927' 'Giloralimab' 'PR-1614645'],,,"{'rows': array(['MONDO_0004992', 'EFO_0002618', 'MONDO_0007254', 'EFO_0006859'],
      dtype=object), 'count': 4}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL5095024,C=CC(=O)Nc1cc(C#CC(C)(C)N2CCN(C)CC2)cc2ncnc(Nc3ccc(F)c(Cl)c3)c12.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1,BRZCZOWSDKKGGK-UHFFFAOYSA-N,Small molecule,False,MP-412,,1.0,CHEMBL5095492,False,False,[],['AV-412' 'Mp 412' 'Mp-412'],,,"{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL73234,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,CFJMRBQWBDQYMK-UHFFFAOYSA-N,Small molecule,False,CARBETAPENTANE,,4.0,,True,True,[],['Pentoxyverine'],"[('PubChem', array(['11113506', '144204460', '170465562', '26751724', '50104415',
       '50104416', '90340636'], dtype=object)), ('Wikipedia', array(['Pentoxyverine'], dtype=object)), ('drugbank', array(['DB11186'], dtype=object))]",['CHEMBL1256696'],"{'rows': array(['EFO_0007486', 'HP_0012735'], dtype=object), 'count': 2}",[ENSG00000147955],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for sinusitis and cough.
CHEMBL1200464,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N.Cl,BFUUJUGQJUTPAF-UHFFFAOYSA-N,Small molecule,False,PROPARACAINE HYDROCHLORIDE,1953.0,4.0,CHEMBL1196,False,True,"['Alcaine' 'Kainair' 'Ophthaine' 'Ophthetic' 'Paracaine'
 'Proparacaine hydrochloride']","['Ak-taine' 'NSC-759896' 'Proparacaine hcl' 'Proparacaine hydrochloride'
 'Proxymetacaine' 'Proxymetacaine hydrochloride']","[('DailyMed', array(['proparacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144207096', '170465400', '56320661'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953.
CHEMBL1200645,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,LIQODXNTTZAGID-OCBXBXKTSA-N,Small molecule,False,ETOPOSIDE PHOSPHATE,1996.0,4.0,,False,True,['Etopophos' 'Etopophos preservative free'],['BMY 40481' 'BMY-40481' 'Etoposide phosphate' 'VP-16' 'VP16' 'Vepeside'],,,"{'rows': array(['EFO_0000621', 'EFO_0000183', 'MONDO_0002158', 'EFO_0000502',
       'EFO_0000094', 'EFO_0000574', 'EFO_0002939', 'EFO_1000158',
       'EFO_0000096', 'MONDO_0000873', 'EFO_0005952', 'EFO_0000222',
       'EFO_0000220', 'MONDO_0009348', 'EFO_0000565', 'EFO_0000313',
       'EFO_0002918', 'MONDO_0002087', 'MONDO_0100342', 'EFO_0002501',
       'MONDO_0008170', 'EFO_0001378', 'MONDO_0008903'], dtype=object), 'count': 23}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 23 investigational indications.
CHEMBL1200705,Br.CC(N)Cc1ccc(O)cc1,RZCJLMTXBMNRAD-UHFFFAOYSA-N,Small molecule,False,HYDROXYAMPHETAMINE HYDROBROMIDE,1969.0,4.0,CHEMBL1546,False,True,['Paredrine'],"['Hydroxyamfetamine hbr' 'Hydroxyamfetamine hydrobromide'
 'Hydroxyamphetamine hbr' 'Hydroxyamphetamine hydrobromide'
 'Hyroxyamfetamine hydrobromide' 'NSC-61065' 'Oxamphetamine hydrobromide'
 'Phenol, 4-(2-aminopropyl)-, hbr']","[('DailyMed', array(['hydroxyamphetamine%20hydrobromide'], dtype=object)), ('PubChem', array(['124752968', '124752971', '144205040', '26749172'], dtype=object))]",,,"[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969.
CHEMBL1200841,CCN(CC)CCOC(=O)c1ccc(N)cc1.Cl,HCBIBCJNVBAKAB-UHFFFAOYSA-N,Small molecule,False,PROCAINE HYDROCHLORIDE,1954.0,4.0,CHEMBL569,False,True,['Novocain' 'Pasconeural n' 'Procaine hydrochloride'],"['Anestil' 'Enpro' 'Jenacaine' 'Medaject' 'NSC-757280' 'Naucaine'
 'Neocaine' 'Omnicain' 'Planocaine' 'Procaine hcl'
 'Procaine hydrochloride' 'Procaini hydrochloridum' 'Rocain' 'SP-01A'
 'SP01A' 'Sp01a' 'Syntocain']","[('PubChem', array(['144203799', '144212431', '170464937', '50085977', '50106847'],
      dtype=object)), ('chEBI', array(['8431'], dtype=object))]",,"{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954 and has 1 investigational indication.
CHEMBL1201199,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,GFIJNRVAKGFPGQ-LIJARHBVSA-N,Protein,False,LEUPROLIDE,1985.0,4.0,,False,True,[],"['(-)-leuprolide' 'ABBOTT-43818 FREE BASE' 'CKD-841' 'Leuporelin'
 'Leuprolide' 'Leuprorelin' 'Leuprorelin slow release' 'NSC-377526'
 'TAP-144 FREE BASE']","[('Wikipedia', array(['Leuprorelin'], dtype=object)), ('drugbank', array(['DB00007'], dtype=object)), ('chEBI', array(['6427'], dtype=object))]",['CHEMBL1200775' 'CHEMBL4802223'],"{'rows': array(['EFO_0009029', 'EFO_0000731', 'MONDO_0004975', 'EFO_0004248',
       'EFO_0000616', 'MONDO_0000521', 'EFO_0005204', 'MONDO_0008170',
       'EFO_0000731', 'MONDO_0000088', 'EFO_0003869', 'EFO_0000756',
       'EFO_0000764', 'MONDO_0008315', 'EFO_0000673', 'MONDO_0004992',
       'EFO_0003843', 'EFO_0001065', 'EFO_0001065', 'EFO_0000545',
       'MONDO_0008315', 'HP_0100543', 'EFO_0001378', 'MONDO_0008315',
       'EFO_0000537', 'MONDO_0003061', 'MONDO_0007254', 'GO_0042697',
       'EFO_0009006', 'MONDO_0000521', 'EFO_0001073', 'EFO_1001469',
       'MONDO_0007254', 'EFO_0000673', 'EFO_0000196', 'EFO_0001073',
       'EFO_0000183', 'EFO_0001663', 'EFO_0001663', 'EFO_0000196',
       'MONDO_0002146', 'EFO_0007453'], dtype=object), 'count': 42}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 7 approved and 30 investigational indications.
CHEMBL1201561,,,Protein,True,PEGINTERFERON ALFA-2B,2000.0,4.0,,False,True,['Peg-Intron' 'Pegintron'],"['Peg-interferon alfa-2b' 'Pegifn alfa-2b' 'Peginterferon alfa-2b'
 'Peginterferon-alfa-2b' 'Pegylated interferon alpha 2b' 'Sylatron']","[('DrugCentral', array(['5164'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pegintron'],
      dtype=object)), ('Wikipedia', array(['Peginterferon_alfa-2b'], dtype=object))]",,"{'rows': array(['EFO_0006859', 'EFO_0002430', 'EFO_0005221', 'EFO_0000681',
       'EFO_0000565', 'EFO_0005543', 'EFO_0000756', 'EFO_1001469',
       'EFO_0000182', 'MONDO_0002974', 'EFO_0001378', 'MONDO_0018975',
       'HP_0012115', 'EFO_0004239', 'EFO_0002617', 'EFO_0004220',
       'EFO_0000765', 'EFO_0009708', 'EFO_0000479', 'MONDO_0008170',
       'EFO_0000707', 'EFO_0000637', 'MONDO_0005301', 'MONDO_0002367',
       'EFO_1000209', 'MONDO_0002158', 'EFO_0000658', 'MONDO_0019471',
       'EFO_0000616', 'MONDO_0016691', 'MONDO_0002087', 'EFO_0004243',
       'EFO_0001642', 'EFO_0001422', 'MONDO_0004992', 'EFO_0003047',
       'EFO_0000764', 'EFO_0007304', 'EFO_0002429', 'EFO_0000389',
       'EFO_0000180', 'EFO_0000339', 'EFO_0009259'], dtype=object), 'count': 43}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 approved and 37 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201593,,,Enzyme,False,ALTEPLASE,1996.0,4.0,,False,True,['Actilyse' 'Actilyse cathflo' 'Activase' 'Cathflo activase'],"['Alteplase' 'Alteplase (genetical recombination)'
 'Alteplase for injection' 'Alteplase, recombinant'
 'Alteplase,recombinant' 'Ec 3.4.21.68' 'RT-PA'
 'Tissue plasminogen activator alteplase']","[('DailyMed', array(['alteplase'], dtype=object)), ('DrugCentral', array(['5141'], dtype=object))]",,"{'rows': array(['EFO_0009680', 'EFO_1000637', 'EFO_0001365', 'EFO_0003966',
       'MONDO_0000831', 'EFO_0003907', 'EFO_0000616', 'MONDO_0005299',
       'EFO_0000712', 'MONDO_0100096', 'HP_0004418', 'EFO_0000618',
       'EFO_0003827', 'MONDO_0002679', 'EFO_0000713', 'EFO_0003913',
       'EFO_1001375', 'HP_0000573', 'HP_0004419', 'EFO_0003144',
       'EFO_1001753', 'EFO_1001154', 'EFO_1001157', 'HP_0002140',
       'EFO_0009661', 'EFO_0000694', 'MP_0001914', 'EFO_0000612',
       'EFO_0000544', 'EFO_0003030', 'EFO_0005669', 'MONDO_0020673',
       'EFO_0003097', 'EFO_0000373', 'MONDO_0004992', 'HP_0000016'],
      dtype=object), 'count': 36}",[ENSG00000104368],Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 28 investigational indications.
CHEMBL1222883,CN1C(=O)CC[C@H]1C(=O)NCc1cccc(C(F)(F)F)c1Cl,BJEMSIVBBUBXMZ-JTQLQIEISA-N,Small molecule,False,GSK1482160,,1.0,,False,False,[],['GSK1482160' 'Gsk-1482160' 'Gsk1482160'],,['CHEMBL5204842'],"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000089041],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1240967,CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,YPHDIMUXXABSSO-YTTGMZPUSA-N,Small molecule,False,PF-00610355,,2.0,,False,False,[],['PF - 00610355' 'PF-610355' 'Pf-00610355'],"[('drugbank', array(['DB11871'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0003818'], dtype=object), 'count': 3}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1272307,Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(-c2ccc(F)cc2)s1,ZJXIUGNEAIHSBI-IBGZPJMESA-N,Small molecule,False,SB-649868,,2.0,,False,False,[],['GSK649868' 'SB-649868' 'Sb-649868'],"[('Wikipedia', array(['SB-649,868'], dtype=object)), ('drugbank', array(['DB14822'], dtype=object))]",['CHEMBL3527302'],"{'rows': array(['EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 2}","[ENSG00000121764,ENSG00000137252]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1819077,CCC(CC)Nc1c2c(nc3c(-c4ccc(OC)cc4Cl)c(C)nn13)CCC2,LDIOUQIXNSSOGU-UHFFFAOYSA-N,Small molecule,False,ONO-2333MS,,2.0,,False,False,[],['Ono-2333ms'],,,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}",[ENSG00000120088],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2106068,CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1.Cl,IJFUJIFSUKPWCZ-SQMFDTLJSA-N,Small molecule,False,ATRASENTAN HYDROCHLORIDE,,3.0,CHEMBL9194,False,False,[],"['A-127722' 'A-147627.1' 'ABBOT-147627' 'ABT-627' 'Atrasentan hcl'
 'Atrasentan hydrochloride']",,,"{'rows': array(['MONDO_0002367', 'MONDO_0008315', 'EFO_1000158', 'MONDO_0002087',
       'MONDO_0002158', 'MONDO_0008170'], dtype=object), 'count': 6}",[ENSG00000151617],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2107358,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,ZFKXDVMHNXPEIY-PEZBNFGJSA-N,Small molecule,False,OBATOCLAX MESYLATE,,3.0,CHEMBL408194,False,False,[],"['GX-15-070MS' 'GX15-070MS' 'Obatoclax' 'Obatoclax mesilate'
 'Obatoclax mesylate']",,,"{'rows': array(['EFO_0000198', 'EFO_0001378', 'EFO_0001642', 'EFO_1001469',
       'EFO_0000702', 'MONDO_0008903', 'MONDO_0001023', 'EFO_0002617',
       'EFO_0000403', 'EFO_0000183', 'EFO_0000095', 'MONDO_0018906',
       'MONDO_0044903'], dtype=object), 'count': 13}","[ENSG00000171791,ENSG00000140379,ENSG00000137875,ENSG00000258643,ENSG00000129473,ENSG00000143384,ENSG00000171552]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL2109103,,,Antibody,False,BERTILIMUMAB,,2.0,,False,False,[],['Bertilimumab' 'CAT-213' 'ICO-008'],,,"{'rows': array(['EFO_0000729', 'EFO_0007187'], dtype=object), 'count': 2}",[ENSG00000172156],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109264,,,Antibody,False,SOLITOMAB,,2.0,,False,False,[],['MT110' 'Solitomab'],,,,"[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000119888]",Antibody drug with a maximum clinical trial phase of II.
CHEMBL2355051,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,GKIRPKYJQBWNGO-UHFFFAOYSA-N,Small molecule,False,CLOMIPHENE,1967.0,4.0,,False,True,[],['Clomifene' 'Clomiphene'],"[('PubChem', array(['144206661', '170464951'], dtype=object)), ('drugbank', array(['DB00882'], dtype=object)), ('chEBI', array(['3752'], dtype=object))]",['CHEMBL3185958'],"{'rows': array(['MONDO_0002775', 'EFO_0000660', 'EFO_0000279', 'EFO_0000731',
       'EFO_0000512', 'EFO_0001073', 'EFO_1001485', 'EFO_0008560',
       'EFO_0000660', 'EFO_0000545', 'MONDO_0002146', 'MONDO_0018555',
       'EFO_0000545', 'MP_0001914', 'EFO_0008560'], dtype=object), 'count': 15}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 3 approved and 12 investigational indications.
CHEMBL3545135,,,Small molecule,False,NV-128,,1.0,,False,False,[],['Nv-128'],,,,"[ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545355,COc1ccc(C2=C(Cc3ccc(OCCN4CCCCC4)cc3)c3ccc(O)cc3OC2)cc1,ZUDXUNPSRMREOJ-UHFFFAOYSA-N,Small molecule,False,CHF4227,,1.0,,False,False,[],['Chf4227'],,,,"[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3984441,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C,VQYYQSZNRVQLIS-UHFFFAOYSA-N,Small molecule,False,NINGETINIB,,2.0,,False,False,[],"['CT-053 FREE BASE' 'CT-053-PTSA FREE BASE' 'CT053PTSA FREE BASE'
 'Ningetinib']",,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}","[ENSG00000153208,ENSG00000128052,ENSG00000167601,ENSG00000122025,ENSG00000105976]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989954,C=C1CC[C@H]2[C@H](CN)[C@@H]([C@@]3(C)CC[C@H](O)C[C@@H]3CO)CC[C@]12C,MDEJTPWQNNMAQF-BVMLLJBZSA-N,Small molecule,False,ROSIPTOR,,3.0,,False,False,[],['AQX-1125' 'AQX-1125 free base' 'Aqx-1125' 'Rosiptor'],"[('drugbank', array(['DB13012'], dtype=object))]",['CHEMBL3989953'],"{'rows': array(['EFO_0000341', 'EFO_1000869', 'EFO_0000274', 'EFO_0008507'],
      dtype=object), 'count': 4}",[ENSG00000168918],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297619,O=C(O)CNC(=O)c1c(O)cc(CCc2ccccc2)n2ncnc12,NALAUGMPMIVAOW-UHFFFAOYSA-N,Small molecule,False,ENARODUSTAT,,3.0,,False,False,[],['Enarodustat' 'JTZ-951' 'Jtz-951'],"[('drugbank', array(['DB14985'], dtype=object))]",['CHEMBL4166742'],"{'rows': array(['EFO_0003884'], dtype=object), 'count': 1}",[ENSG00000135766],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297633,CC(C)OC(=O)CCC[C@H]1CC[C@@H]2[C@@H](/C=C/[C@@H](O)COc3cc(F)ccc3F)[C@H](O)C[C@@H]2OC1,BKVUSNOUTQMSBE-XCMGCKIWSA-N,Small molecule,False,SEPETAPROST,,3.0,,False,False,[],['DE-126' 'ONO-9054' 'Ono-9054' 'STN-1012600' 'STN1012600' 'Sepetaprost'],"[('drugbank', array(['DB12043'], dtype=object))]",,,"[ENSG00000050628,ENSG00000122420]",Small molecule drug with a maximum clinical trial phase of III.
CHEMBL4297636,C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O,IEKGSKLKBICCHQ-BDOJOPHNSA-N,Small molecule,False,PLOCABULIN,,2.0,,False,False,[],['J3.348.355D' 'PM-060184' 'PM060184' 'Plocabulin' 'Pm 060184' 'Pm060184'],"[('drugbank', array(['DB13137'], dtype=object))]",,"{'rows': array(['MONDO_0005575', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297878,,,Antibody,False,LIRENTELIMAB,,3.0,,False,False,[],"['AK-002' 'AK002' 'Ak002' 'Antolimab' 'Lirentelimab'
 'Monoclonal antibody ak002']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LIRENTELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0011024', 'EFO_0004232', 'EFO_0007141', 'EFO_0005531',
       'EFO_0005531', 'MONDO_0016586', 'EFO_0000274', 'MONDO_0004627',
       'EFO_1000886', 'EFO_0009450'], dtype=object), 'count': 10}",[ENSG00000105366],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL431770,CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O,IQVRBWUUXZMOPW-PKNBQFBNSA-N,Small molecule,False,ISTRADEFYLLINE,2013.0,4.0,,False,True,['Nourianz'],['Istradefylline' 'KW-6002' 'Nouriast'],"[('DailyMed', array(['istradefylline'], dtype=object)), ('PubChem', array(['170466116'], dtype=object)), ('Wikipedia', array(['Istradefylline'], dtype=object)), ('drugbank', array(['DB11757'], dtype=object))]",,"{'rows': array(['MONDO_0004976', 'EFO_0003890', 'MONDO_0005180', 'EFO_0001421'],
      dtype=object), 'count': 4}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for parkinson disease and has 3 investigational indications.
CHEMBL4459585,Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1,XPLZTJWZDBFWDE-OYOVHJISSA-N,Small molecule,False,ROPSACITINIB,,2.0,,False,False,[],['PF-06826647' 'Pf-06826647' 'Ropsacitinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROPSACITINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1000710', 'EFO_0000729', 'EFO_0003767', 'EFO_0000676'],
      dtype=object), 'count': 4}",[ENSG00000105397],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4594310,,,Antibody,False,NIPOCALIMAB,,3.0,,False,False,[],['JNJ-80202135' 'M-281' 'M281' 'Nipocalimab'],,,"{'rows': array(['EFO_1001264', 'EFO_0004991', 'EFO_0000699', 'EFO_1000937',
       'MONDO_0007915', 'EFO_1000868', 'EFO_0005761', 'EFO_0000783',
       'EFO_0000685'], dtype=object), 'count': 9}",[ENSG00000104870],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL4594539,,,Protein,False,TRENIBOTULINUMTOXINE,,3.0,,False,False,[],"['AGN-151586' 'BoNT/E' 'Bontoxilysin-e' 'Botulinum neurotoxin type e'
 'Botulinum toxin type e' 'EB-001' 'Eb-001' 'Trenibotulinumtoxine']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRENIBOTULINUMTOXINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000132639],Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL506569,CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,JAYAGJDXJIDEKI-PTGWOZRBSA-N,Small molecule,False,LANATOSIDE C,,4.0,,False,True,['Cedilanid'],"['Allocor' 'Celadigal' 'Cetosanol' 'Digilanogen c' 'Isolanid' 'Isolanide'
 'Lanatigen c' 'Lanatoside c' 'Lanatoside c jp 17' 'Lanimerck'
 'NSC-119991' 'NSC-7533']","[('PubChem', array(['144204914'], dtype=object)), ('Wikipedia', array(['Lanatoside_C'], dtype=object)), ('drugbank', array(['DB13467'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease.
CHEMBL5095021,COc1ccc(CC(=O)O)cc1Oc1ccc(NC(=O)C(C)(C)C)cc1CSC(C)(C)C,SDHFXINHZHARIB-UHFFFAOYSA-N,Small molecule,False,AM-461,,1.0,,False,False,[],['AM461' 'Am-461'],,,,[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL71,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,Small molecule,True,CHLORPROMAZINE,1957.0,4.0,,False,True,['Elmarin' 'Largactil' 'Megaphen' 'Thorazine'],"['Aminazine' 'Chlorpromazine' 'Chlorpromazine hibenzate'
 'Chlorpromazine phenolphthalinate' 'Chlorpromazine tannate'
 'Chlorpromazinum' 'Esmind' 'Fenactil' 'J2.794D' 'Largactilothiazine'
 'NSC-167745' 'NSC-226514' 'Novomazina' 'Propaphenin' 'SKF-2601A'
 'Sanopron' 'Sonazine' 'Wintermin']","[('PubChem', array(['104171139', '11110990', '11110991', '124879752', '124879754',
       '124879757', '144203671', '152146164', '170465371', '26747094',
       '26747095', '26751620', '26751621', '50100209', '50104291',
       '57287810', '90340916'], dtype=object)), ('TG-GATEs', array(['16'], dtype=object)), ('Wikipedia', array(['Chlorpromazine'], dtype=object)), ('drugbank', array(['DB00477'], dtype=object)), ('chEBI', array(['3647'], dtype=object))]",['CHEMBL1713'],"{'rows': array(['EFO_0009267', 'HP_0002017', 'MONDO_0021063', 'EFO_0000519',
       'EFO_0004216', 'EFO_0005407', 'MONDO_0005090', 'MONDO_0100096',
       'MONDO_0037939', 'EFO_0000677', 'EFO_0005799'], dtype=object), 'count': 11}","[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1059,CC(C)C[C@H](CN)CC(=O)O,AYXYPKUFHZROOJ-ZETCQYMHSA-N,Small molecule,False,PREGABALIN,2004.0,4.0,,False,True,"['Alzain' 'Axalid' 'Lecaent' 'Lyrica' 'Lyrica cr' 'Pregabalin'
 'Pregabalin mylan' 'Rewisca']","['CI-1008' 'NSC-759256' 'PD-144723' 'Pregabalin' 'Pregabalin mylan'
 'Pregabalin sandoz' 'Pregabalin sandoz gmbh' 'Pregabalin zentiva'
 'Vronogabic' 'YNP-1807']","[('DailyMed', array(['pregabalin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-mylan'],
      dtype=object)), ('PubChem', array(['144205028'], dtype=object)), ('Wikipedia', array(['Pregabalin'], dtype=object)), ('drugbank', array(['DB00230'], dtype=object)), ('chEBI', array(['64356'], dtype=object))]",,"{'rows': array(['EFO_1000783', 'HP_0002018', 'EFO_0006510', 'MONDO_0005277',
       'HP_0002069', 'EFO_1000877', 'EFO_0000400', 'MONDO_0007079',
       'EFO_0009558', 'EFO_0006788', 'EFO_0002950', 'EFO_1001892',
       'EFO_0000474', 'HP_0012532', 'EFO_1000906', 'EFO_0000342',
       'HP_0012735', 'HP_0000726', 'EFO_0003108', 'EFO_1001998',
       'EFO_0003931', 'EFO_0009846', 'EFO_0009430', 'EFO_0004270',
       'HP_0000989', 'EFO_0005230', 'HP_0008419', 'EFO_0005762',
       'EFO_0005687', 'HP_0007359', 'EFO_0003100', 'MONDO_0004892',
       'EFO_0004149', 'MONDO_0002959', 'MONDO_0005090', 'MONDO_0002050',
       'HP_0001250', 'EFO_1000781', 'EFO_0000707', 'EFO_0003830',
       'MONDO_0007254', 'MONDO_0005178', 'EFO_0007191', 'EFO_0004257',
       'EFO_1001919', 'EFO_1001884', 'EFO_0004698', 'EFO_1001931',
       'EFO_0003768', 'EFO_0005611', 'MONDO_0041052', 'EFO_0000555',
       'EFO_0003843', 'EFO_0004263'], dtype=object), 'count': 54}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 9 approved and 45 investigational indications.
CHEMBL1095,CCN1C(=O)NC(c2ccccc2)C1=O,SZQIFWWUIBRPBZ-UHFFFAOYSA-N,Small molecule,False,ETHOTOIN,1957.0,4.0,,False,True,['Peganone'],['Accenon' 'Ethotoin' 'NSC-760074'],"[('PubChem', array(['144203934', '56463534'], dtype=object)), ('Wikipedia', array(['Ethotoin'], dtype=object)), ('drugbank', array(['DB00754'], dtype=object)), ('chEBI', array(['4888'], dtype=object))]",,"{'rows': array(['HP_0001250', 'EFO_0000474'], dtype=object), 'count': 2}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for seizure and epilepsy.
CHEMBL1200556,CC(=O)O.N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,MLSVJHOYXJGGTR-IFHOVBQLSA-N,Protein,True,DESMOPRESSIN ACETATE,1978.0,4.0,CHEMBL1429,False,True,"['Concentraid' 'Ddavp' 'Ddavp (needs no refrigeration)' 'Desmomelt'
 'Desmopressin acetate' 'Desmopressin acetate (needs no refrigeration)'
 'Desmopressin acetate preservative free' 'Desmospray' 'Desmotabs'
 'Minirin' 'Nocdurna' 'Noctiva' 'Nocutil' 'Noqdirna' 'Octim' 'Octostim'
 'Presinex' 'Stimate' 'Stimate (needs no refrigeration)']","['Anhydrous desmopressin acetate' 'Desmopressin acetate'
 'Desmopressin acetate anhydrous' 'Desmopressin acetate hydrate'
 'Desmopressin acetate trihydrate']","[('DailyMed', array(['desmopressin%20acetate'], dtype=object))]",,"{'rows': array(['EFO_0009505', 'EFO_0005669', 'HP_0000863', 'MONDO_0024290',
       'EFO_0000537', 'MONDO_0004782', 'HP_0001742', 'MONDO_0024574',
       'HP_0031364', 'MP_0001914'], dtype=object), 'count': 10}","[ENSG00000126895,ENSG00000166148,ENSG00000198049]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201039,NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O,NDTSRXAMMQDVSW-UHFFFAOYSA-N,Small molecule,False,BENZTHIAZIDE,1960.0,4.0,,False,True,['Aquatag' 'Benzthiazide' 'Exna' 'Fovane' 'Urese'],['Benzothiazide' 'Benzthiazide' 'NSC-755902'],"[('PubChem', array(['11112238', '124882104', '144203938', '170465246', '26747882',
       '855918'], dtype=object)), ('Wikipedia', array(['Benzthiazide'], dtype=object)), ('drugbank', array(['DB00562'], dtype=object)), ('chEBI', array(['3047'], dtype=object))]",,,[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1201335,C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1,ANGKOCUUWGHLCE-UHFFFAOYSA-N,Small molecule,False,GLYCOPYRRONIUM,1961.0,4.0,,False,True,[],"['Glycopyrrolate cation' 'Glycopyrrolate ion' 'Glycopyrronium'
 'Glycopyrronium cation' 'Glycopyrronium ion' 'Glycopyrronium, erythro-']","[('Wikipedia', array(['Glycopyrronium_bromide'], dtype=object)), ('drugbank', array(['DB00986'], dtype=object))]",['CHEMBL3707243' 'CHEMBL1201027'],"{'rows': array(['MONDO_0004979', 'EFO_0010282', 'EFO_0004269', 'EFO_0000341',
       'MONDO_0004247', 'HP_0006536', 'EFO_0006505', 'MONDO_0004979',
       'EFO_1000632', 'HP_0000975', 'HP_0002307', 'MONDO_0002050',
       'EFO_0000341', 'HP_0000975', 'HP_0000975', 'EFO_0000341',
       'EFO_0009516', 'MONDO_0100096', 'EFO_0003086'], dtype=object), 'count': 19}","[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 9 approved and 8 investigational indications.
CHEMBL1201546,,,Protein,False,INSULIN ZINC SUSP PURIFIED BEEF,1980.0,4.0,,False,True,['Lente iletin ii'],['Insulin zinc susp purified beef'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1980.
CHEMBL1201610,,,Protein,False,CORTICOTROPIN,1950.0,4.0,,False,True,"['Acth' 'Acthar' 'Acthar gel' 'Adrenocorticotropic Hormone'
 'Adrenocorticotropin' 'Adrenomone' 'Corticotropin' 'H.p. acthar gel'
 'Purified cortrophin gel']","['Adrenocorticotrophin' 'Adrenocorticotropic hormone' 'Corticotrophin'
 'Corticotropin' 'Corticotropin (acth)' 'Corticotropin in gelatin matrix'
 'Corticotropin, repository' 'Cortigel' 'Cortrophin']",,,"{'rows': array(['EFO_0003929', 'EFO_0000685', 'EFO_0008520', 'EFO_1001129',
       'EFO_0000474', 'EFO_0008522', 'MONDO_0004976', 'MONDO_0005301',
       'MONDO_0018097', 'EFO_0000401', 'MONDO_0001718', 'EFO_1001231',
       'EFO_0000398', 'EFO_0007405', 'EFO_0000660', 'MONDO_0002462',
       'MONDO_0019338', 'EFO_0004254', 'EFO_0003884', 'EFO_0004255',
       'EFO_0003086', 'MONDO_0005277'], dtype=object), 'count': 22}",[ENSG00000185231],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for multiple sclerosis and west syndrome and has 20 investigational indications.
CHEMBL146032,CC(=O)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C(F)(F)C(F)(F)F)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,VHZPUDNSVGRVMB-RXDLHWJPSA-N,Small molecule,False,LONAPRISAN,,2.0,,False,False,[],['BAY86-5044' 'Lonaprisan' 'ZK 230211' 'ZK-230211' 'ZK230211' 'Zk-230211'],,,"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1743032,,,Antibody,False,INTETUMUMAB,,2.0,,False,False,[],['CNTO 095' 'CNTO 95' 'CNTO-095' 'CNTO-95' 'Intetumumab'],,,"{'rows': array(['EFO_0000756', 'EFO_0000673'], dtype=object), 'count': 2}","[ENSG00000138448,ENSG00000082781,ENSG00000259207]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1743068,,,Antibody,False,SECUKINUMAB,2015.0,4.0,,False,True,['Cosentyx'],['AIN-457' 'AIN457' 'AIN457A' 'Cosentyx' 'Secukinumab'],"[('DailyMed', array(['secukinumab'], dtype=object)), ('DrugCentral', array(['4934'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx'],
      dtype=object))]",,"{'rows': array(['EFO_0008518', 'MONDO_0100017', 'EFO_0005761', 'EFO_1000906',
       'EFO_0004192', 'EFO_1000738', 'EFO_1001209', 'EFO_0000685',
       'EFO_1001231', 'MONDO_0005301', 'MONDO_0005178', 'EFO_0003778',
       'MONDO_0019558', 'EFO_0009856', 'EFO_0000540', 'EFO_1000710',
       'MONDO_0005147', 'EFO_1001494', 'EFO_1001466', 'EFO_0000384',
       'HP_0000999', 'EFO_1001434', 'MONDO_0100096', 'EFO_0003929',
       'EFO_0003780', 'MONDO_0004979', 'EFO_1000760', 'EFO_0000274',
       'EFO_0000706', 'EFO_0000676', 'EFO_0003898'], dtype=object), 'count': 31}",[ENSG00000112115],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 25 investigational indications.
CHEMBL1834657,CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O,GUQNHCGYHLSITB-UHFFFAOYSA-N,Small molecule,False,INFIGRATINIB PHOSPHATE,2021.0,4.0,CHEMBL1852688,False,True,['Truseltiq'],['BGJ-398 phosphate' 'Infigratinib monophosphate' 'Infigratinib phosphate'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/INFIGRATINIB%20PHOSPHATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0005221', 'EFO_1001961'], dtype=object), 'count': 3}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cholangiocarcinoma and intrahepatic cholangiocarcinoma and has 1 investigational indication.
CHEMBL2107308,COc1cc(O)c(C(=O)Nc2nc(C(=O)NCCN(C(C)C)C(C)C)cs2)cc1OC.Cl.O.O.O,NPTDXIXCQCFGKC-UHFFFAOYSA-N,Small molecule,False,ACOTIAMIDE HYDROCHLORIDE,,3.0,CHEMBL2107723,False,False,[],"['Acotiamide hydrochloride' 'Acotiamide hydrochloride hydrate'
 'Acotiamide hydrochloride trihydrate' 'YM-443' 'YM443' 'Z-338']",,,"{'rows': array(['EFO_0008533'], dtype=object), 'count': 1}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108730,,,Antibody,True,SARILUMAB,2017.0,4.0,,False,True,['Kevzara'],['REG-N88' 'REGN-88' 'REGN88' 'SAR-153191' 'SAR153191' 'Sarilumab'],"[('DailyMed', array(['sarilumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara'],
      dtype=object))]",,"{'rows': array(['EFO_0000694', 'EFO_0000540', 'EFO_1001231', 'EFO_0000685',
       'EFO_0008518', 'MONDO_0100096', 'MONDO_0016586', 'EFO_0002609',
       'EFO_0003106', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0007328',
       'EFO_1001361', 'EFO_1001209', 'EFO_0003898', 'EFO_0000756'],
      dtype=object), 'count': 16}",[ENSG00000160712],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for immune system disease and rheumatoid arthritis and has 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109257,,,Antibody,False,IMC-1C11,,1.0,,False,False,[],['IMC-1C11'],,,,[ENSG00000128052],Antibody drug with a maximum clinical trial phase of I.
CHEMBL261244,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21.[Na+].[Na+],MKQKPLQMNCXTJE-VEZQGTPESA-L,Small molecule,False,REGRELOR DISODIUM,,2.0,CHEMBL1162175,False,False,[],['INS-50589' 'INS50589' 'Regrelor disodium'],,,"{'rows': array(['EFO_0001645', 'EFO_0000319'], dtype=object), 'count': 2}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3137310,COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl,VVCUIDHKAHHSAN-JJHQWJQCSA-N,Small molecule,False,BENZHYDROCODONE HYDROCHLORIDE,2018.0,4.0,CHEMBL3137321,False,True,[],['Benzhydrocodone hydrochloride' 'KP-201' 'KP201'],"[('DailyMed', array(['benzhydrocodone%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for pain.
CHEMBL3544917,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O,GIBQQARAXHVEGD-BSOLPCOYSA-N,Protein,False,RAPASTINEL,,3.0,,False,False,[],['GLYX-13' 'Rapastinel' 'Rapastinelum' 'Tppt-amide'],"[('drugbank', array(['DB11801'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0004242'], dtype=object), 'count': 2}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3644672,COc1c(OC[C@H](O)CN2CCOCC2)ccc2c1N=C(NC(=O)c1cccnc1C)N1CCN=C21,JGNRMIWLBBNSMU-QGZVFWFLSA-N,Small molecule,False,BAY-1082439,,1.0,,False,False,[],['BAY1082439' 'Bay 1082439' 'Bay-1082439'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000051382,ENSG00000121879]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989869,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1,KYJWUPZPSXZEPG-NTISSMGPSA-N,Small molecule,False,UMBRALISIB TOSYLATE,2021.0,4.0,CHEMBL3948730,False,True,['Ukoniq'],"['RP-5307' 'TGR-1202' 'TGR-1202 (4-METHYLBENZENESULFONATE)' 'Tgr-1202'
 'Umbralisib tosylate']",,,"{'rows': array(['MONDO_0044903', 'MONDO_0001056', 'EFO_0000095', 'EFO_1000630',
       'MONDO_0018906', 'MONDO_0007576', 'EFO_1001469', 'EFO_0002618',
       'EFO_1001951', 'MONDO_0011719', 'EFO_0000183', 'EFO_0000403',
       'EFO_1000657', 'EFO_0002429', 'EFO_0000211'], dtype=object), 'count': 15}","[ENSG00000097007,ENSG00000213923,ENSG00000171608]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for marginal zone b-cell lymphoma and follicular lymphoma and has 13 investigational indications.
CHEMBL3990014,,,Antibody,False,MIRIKIZUMAB,2023.0,4.0,,False,True,['Omvoh'],['LY-3074828' 'LY3074828' 'Mirikizumab'],,,"{'rows': array(['EFO_0000384', 'EFO_0000676', 'EFO_0000729'], dtype=object), 'count': 3}","[ENSG00000113302,ENSG00000110944]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for ulcerative colitis and has 2 investigational indications.
CHEMBL421,O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,NCEXYHBECQHGNR-QZQOTICOSA-N,Small molecule,False,SULFASALAZINE,1950.0,4.0,,False,True,"['Azulfidine' 'Azulfidine EN' 'Azulfidine en-tabs' 'Colizine' 'S.a.s.-500'
 'Salazopyrin' 'Salazopyrin e.c.' 'Salazopyrin-en' 'Salazosulfapyridine'
 'Salicylazosulfapyridine' 'Sulfasalazine' 'Ucine']","['Azulfidine' 'Benzosulfa' 'NSC-203730' 'NSC-667219' 'SAS-500'
 'Salazosulfapyridine' 'Salicylazosulfapyridine' 'Sulfasalazine'
 'Sulfasalazinum' 'Sulfasalazopyridine' 'Sulphasalazine']","[('DailyMed', array(['sulfasalazine'], dtype=object)), ('PubChem', array(['144204588', '144208437', '144210859', '170464716', '17389737',
       '26747277'], dtype=object)), ('TG-GATEs', array(['34'], dtype=object)), ('Wikipedia', array(['Sulfasalazine'], dtype=object)), ('drugbank', array(['DB00795'], dtype=object)), ('chEBI', array(['9334'], dtype=object))]",['CHEMBL3765414' 'CHEMBL2311115'],"{'rows': array(['EFO_0000222', 'EFO_0000685', 'EFO_0006911', 'MONDO_0004565',
       'EFO_0004268', 'EFO_0003917', 'EFO_0003898', 'EFO_0003778',
       'EFO_0000519', 'EFO_0002609', 'EFO_0001361', 'EFO_0003102',
       'EFO_0004149', 'EFO_0000729'], dtype=object), 'count': 14}","[ENSG00000073756,ENSG00000095303,ENSG00000012779]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 11 investigational indications.
CHEMBL4250860,CC(=O)c1nn(CC(=O)N2C[C@H](F)C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccc(-c3cnc(C)nc3)cc12,PIBARDGJJAGJAJ-NQIIRXRSSA-N,Small molecule,False,DANICOPAN,,3.0,,False,False,[],['ACH-0144471' 'ACH-4471' 'Ach-0144471' 'Danicopan'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANICOPAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15401'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0001421', 'MONDO_0100244', 'EFO_1001492',
       'MONDO_0019736', 'MONDO_0100244', 'EFO_0003086'], dtype=object), 'count': 7}",[ENSG00000197766],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4297861,,,Antibody,False,NEIHULIZUMAB,,2.0,,False,False,[],['Abgn-168h' 'Neihulizumab'],,,"{'rows': array(['EFO_0000729', 'EFO_0003778', 'EFO_0000676', 'EFO_0004599',
       'MONDO_0013730'], dtype=object), 'count': 5}",[ENSG00000110876],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4298169,O=C(O)c1cc(F)c2nc(N3[C@@H]4CC[C@H]3C[C@@H](OCc3c(-c5ccccc5OC(F)(F)F)noc3C3CC3)C4)sc2c1,VYLOOGHLKSNNEK-PIIMJCKOSA-N,Small molecule,False,TROPIFEXOR,,2.0,,False,False,[],['LJN-452' 'LJN452' 'NVP-LJN452-NXA' 'Tropifexor'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TROPIFEXOR/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001249', 'EFO_0003095', 'EFO_1001486'], dtype=object), 'count': 3}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL5314801,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O,AJBMORBNKXNZSF-COSHMZDQSA-N,Oligosaccharide,False,IDRAPARINUX,,3.0,,False,False,[],['SR 34006' 'SR-34006' 'Sr34006'],,['CHEMBL5314374'],"{'rows': array(['EFO_0003907', 'EFO_0003827', 'EFO_0003827', 'EFO_0000275'],
      dtype=object), 'count': 4}",[ENSG00000126218],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1102,CCC1(c2ccccc2)CCC(=O)NC1=O,JMBQKKAJIKAWKF-UHFFFAOYSA-N,Small molecule,False,GLUTETHIMIDE,1976.0,4.0,,False,True,['Doriden' 'Glutethimide'],['Elrodorm' 'Glutethimide' 'NSC-95239' 'Noxyron' 'Rigenox' 'Sarodormin'],"[('PubChem', array(['144205194', '170465223', '29215340'], dtype=object)), ('Wikipedia', array(['Glutethimide'], dtype=object)), ('drugbank', array(['DB01437'], dtype=object)), ('chEBI', array(['5439'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976.
CHEMBL1201317,O=P(O)(O)OCC(Cl)(Cl)Cl,YYQRGCZGSFRBAM-UHFFFAOYSA-N,Small molecule,False,TRICLOFOS,1982.0,4.0,,False,True,[],['Neguvon' 'Tri-beta-chloroethylphosphate' 'Triclofos'],"[('Wikipedia', array(['Triclofos'], dtype=object)), ('drugbank', array(['DB06753'], dtype=object)), ('chEBI', array(['9695'], dtype=object))]",['CHEMBL1200789'],,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1615025,Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21,RCLQNICOARASSR-SECBINFHSA-N,Small molecule,False,TAK-733,,1.0,,False,False,[],['Mek inhibitor tak-733' 'TAK-733' 'TAK733' 'Tak 733' 'Tak-733'],"[('drugbank', array(['DB12241'], dtype=object))]",,"{'rows': array(['EFO_0002617', 'MONDO_0004992'], dtype=object), 'count': 2}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2028850,N=C(N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C[C@@H]2CCCC[C@@H]21,QURWXBZNHXJZBE-SKXRKSCCSA-N,Protein,False,ICATIBANT,2008.0,4.0,,False,True,[],['HOE-140' 'Icatibant'],"[('drugbank', array(['DB06196'], dtype=object))]",['CHEMBL2028852'],"{'rows': array(['EFO_0000694', 'MONDO_0044970', 'EFO_1000999', 'EFO_0005251',
       'MONDO_0100096', 'MONDO_0100096', 'MONDO_0019623', 'MONDO_0019623',
       'EFO_0005532', 'MP_0001845', 'EFO_0003144', 'EFO_0005532'],
      dtype=object), 'count': 12}",[ENSG00000168398],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for hereditary angioedema and angioedema and has 9 investigational indications.
CHEMBL2105694,COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,JVBGZFRPTRKSBB-MJBQOYBXSA-N,Small molecule,False,TELAPRISTONE ACETATE,,3.0,,False,False,['Proellex' 'Proellextm' 'Progenta'],['CDB-4124' 'RU 44675' 'RU-44675' 'Telapristone acetate' 'ZPV-200'],"[('drugbank', array(['DB05253'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'MONDO_0007254', 'EFO_0001065', 'EFO_0003086',
       'EFO_0000731', 'EFO_0010269'], dtype=object), 'count': 6}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2105704,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O,HWLFIUUAYLEFCT-UHFFFAOYSA-N,Small molecule,False,LENVATINIB MESYLATE,2015.0,4.0,CHEMBL1289601,False,True,['Kisplyx' 'Lenvima'],"['E-7080 MESYLATE' 'E7080' 'E7080 MESYLATE' 'Lenvatinib mesilate'
 'Lenvatinib mesylate' 'Lenvatinib methanesulfonate']","[('DailyMed', array(['lenvatinib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx'],
      dtype=object)), ('chEBI', array(['85995'], dtype=object))]",,"{'rows': array(['MONDO_0003060', 'EFO_1001961', 'MONDO_0004992', 'EFO_0000681',
       'EFO_0003060', 'EFO_0002892', 'MONDO_0005184', 'MONDO_0002108',
       'EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 10}","[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 7 investigational indications.
CHEMBL2109529,,,Antibody,False,MU-BC-1,,1.0,,False,False,['Angiomab'],['MU-BC-1'],,,,[ENSG00000115414],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109585,,,Antibody,False,LY-2382770,,2.0,,False,False,[],['LY-2382770' 'LY2382770' 'Ly-2382770'],,,"{'rows': array(['EFO_0000401'], dtype=object), 'count': 1}",[ENSG00000105329],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3899477,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2,NPJCURIANJMFEO-UHFFFAOYSA-N,Small molecule,False,CONTELTINIB ,,1.0,,False,False,[],['Conteltinib '],,,"{'rows': array(['EFO_1000359', 'EFO_0003060'], dtype=object), 'count': 2}","[ENSG00000169398,ENSG00000140443,ENSG00000171094,ENSG00000120899]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3977543,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12,KVCQTKNUUQOELD-UHFFFAOYSA-N,Small molecule,False,BELVARAFENIB,,2.0,,False,False,[],['Belvarafenib'],,,"{'rows': array(['EFO_0000756', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}","[ENSG00000132155,ENSG00000157764,ENSG00000078061]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL398707,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,WVLOADHCBXTIJK-YNHQPCIGSA-N,Small molecule,False,HYDROMORPHONE,,4.0,,False,True,[],"['Dilaudid' 'Dilaudid-HP' 'Dimorphone' 'Hydromorphon' 'Hydromorphone'
 'IDS-NH-004' 'Jurnista' 'N02AA03' 'NSC-19046' 'Novolaudon' 'Palladone']","[('Wikipedia', array(['Hydromorphone'], dtype=object)), ('drugbank', array(['DB00327'], dtype=object)), ('chEBI', array(['5790'], dtype=object))]",['CHEMBL3989585' 'CHEMBL1237055'],"{'rows': array(['EFO_1000786', 'HP_0012532', 'EFO_0010702', 'EFO_0001421',
       'HP_0003419', 'EFO_0801084', 'EFO_0005611', 'EFO_0004616',
       'EFO_0003890', 'EFO_0003843', 'HP_0002019', 'EFO_0004616',
       'MONDO_0004567', 'HP_0003418', 'EFO_1000786', 'EFO_0000546',
       'EFO_0004240', 'MONDO_0002367', 'EFO_0801084', 'EFO_1001898',
       'EFO_0003843', 'MONDO_0011382', 'HP_0012532'], dtype=object), 'count': 23}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for drug dependence and pain and has 16 investigational indications.
CHEMBL4216467,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21,CEFJVGZHQAGLHS-UHFFFAOYSA-N,Small molecule,False,RIPRETINIB,2020.0,4.0,,False,True,['Qinlock'],['DCC-2618' 'Dcc-2618' 'Ripretinib'],"[('DailyMed', array(['ripretinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock'],
      dtype=object)), ('drugbank', array(['DB14840'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0011719'], dtype=object), 'count': 2}","[ENSG00000134853,ENSG00000157404]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and gastrointestinal stromal tumor.
CHEMBL465,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,CYQFCXCEBYINGO-IAGOWNOFSA-N,Small molecule,False,DRONABINOL,1985.0,4.0,,False,True,['Dronabinol' 'Marinol' 'Syndros'],"['.delta.-9-tetrahydrocannabinol' '.delta.1-thc'
 '.delta.9-tetrahydrocannabinol' '.delta.9-thc' 'ABBOTT 40566'
 'ABBOTT-40566' 'Delta-9-tetrahydrocannabinol' 'Delta-9-thc' 'Dronabinol'
 'J882F' 'NSC-134454' 'QCD 84924' 'QCD-84924' 'SP 104' 'SP-104'
 'Tetrahydrocannabinol' 'Tetrahydrocannabinols (-)-trans-.delta.9-form']","[('DailyMed', array(['dronabinol'], dtype=object)), ('PubChem', array(['144206169'], dtype=object)), ('Wikipedia', array(['Tetrahydrocannabinol'], dtype=object)), ('drugbank', array(['DB00470'], dtype=object)), ('chEBI', array(['66964'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'EFO_0003778', 'MONDO_0005301', 'EFO_0007191',
       'EFO_0001358', 'HP_0002018', 'MONDO_0005475', 'EFO_0006911',
       'HP_0100543', 'HP_0003040', 'EFO_0004895', 'HP_0002039',
       'EFO_0003890', 'EFO_0003918', 'EFO_0004329', 'MONDO_0004976',
       'MONDO_0004992', 'HP_0002017', 'MONDO_0011382', 'EFO_0000555',
       'EFO_0003756', 'HP_0012532', 'HP_0012167', 'HP_0000726',
       'HP_0000473', 'EFO_0003843', 'MONDO_0007079', 'MONDO_0004985',
       'MONDO_0005351', 'MONDO_0005090', 'EFO_0005762', 'MONDO_0005148',
       'EFO_0005611', 'EFO_0003108', 'EFO_0004616', 'MONDO_0100431'],
      dtype=object), 'count': 36}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 31 investigational indications.
CHEMBL569713,CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12,STECJAGHUSJQJN-FWXGHANASA-N,Small molecule,False,SCOPOLAMINE,1979.0,4.0,,False,True,['Isoptpo Hyoscine' 'Scopolamine' 'Transderm scop'],['Scopolamine'],"[('DailyMed', array(['scopolamine'], dtype=object)), ('drugbank', array(['DB00747'], dtype=object)), ('chEBI', array(['16794'], dtype=object))]",['CHEMBL2251240' 'CHEMBL3185877' 'CHEMBL1530287' 'CHEMBL1877254'],"{'rows': array(['HP_0002027', 'EFO_1001412', 'HP_0002018', 'EFO_0006928',
       'EFO_1001917', 'MONDO_0004985', 'EFO_0003843', 'EFO_0006928',
       'MONDO_0002009', 'HP_0002017', 'MONDO_0002050', 'MONDO_0002009',
       'HP_0002307', 'HP_0000726', 'EFO_0000544', 'MONDO_0004976',
       'EFO_0003843', 'EFO_0004888', 'MONDO_0004975'], dtype=object), 'count': 19}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 4 approved and 14 investigational indications.
CHEMBL1093,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,QTGIAADRBBLJGA-UHFFFAOYSA-N,Small molecule,False,ARTICAINE,2000.0,4.0,,False,True,[],"['40 045' '40-045' 'Articaine' 'Carticaine' 'HOE 045' 'HOE-045'
 'Septocaine']","[('Wikipedia', array(['Articaine'], dtype=object)), ('drugbank', array(['DB09009'], dtype=object))]",['CHEMBL1200819'],"{'rows': array(['EFO_1001139', 'EFO_1002048', 'EFO_0000649', 'EFO_0003843'],
      dtype=object), 'count': 4}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 investigational indications.
CHEMBL1200419,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl,GQWNECFJGBQMBO-UHFFFAOYSA-N,Small molecule,True,MOLINDONE HYDROCHLORIDE,1974.0,4.0,CHEMBL460,False,True,['Moban' 'Molindone hydrochloride'],['EN-1733A' 'Molindone hcl' 'Molindone hydrochloride'],"[('DailyMed', array(['molindone%20hydrochloride'], dtype=object)), ('PubChem', array(['144204130', '170465047', '26753596', '49648854'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}","[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for schizophrenia. This drug has a black box warning from the FDA.
CHEMBL1200444,CC(=O)O.CC(C)(C)NCC(O)c1ccc(O)c(CO)n1,QSXMZJGGEWYVCN-UHFFFAOYSA-N,Small molecule,False,PIRBUTEROL ACETATE,1986.0,4.0,CHEMBL1094966,False,True,['Maxair'],"['CP-24,314-14' 'CP-24314-14' 'Pirbuterol acetate'
 'Pirbuterol monoacetate' 'Spirolair']",,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for asthma.
CHEMBL1200487,C=C(CC)C(=O)c1ccc(OCC(=O)[O-])c(Cl)c1Cl.[Na+],CWCSCNSKBSCYCS-UHFFFAOYSA-M,Small molecule,False,ETHACRYNATE SODIUM,1967.0,4.0,CHEMBL456,False,True,['Edecrin' 'Ethacrynate sodium'],"['Etacrynate sodium' 'Ethacrynate sodium' 'Ethacrynic acid sodium salt'
 'Sodium etacrynate' 'Sodium ethacrynate']","[('DailyMed', array(['ethacrynate%20sodium'], dtype=object))]",,,[ENSG00000074803],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967.
CHEMBL1200699,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,XQTWDDCIUJNLTR-CVHRZJFOSA-N,Small molecule,False,DOXYCYCLINE,1967.0,4.0,CHEMBL1433,False,True,['Doxirobe' 'Doxychel' 'Doxycycline' 'Monodox' 'Oracea' 'Vibramycin'],"['Doxirobe' 'Doxycycline' 'Doxycycline monohydrate' 'Doxylin' 'GS-3065'
 'Supracyclin' 'Xyrosa']","[('DailyMed', array(['doxycycline'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/doxirobe'],
      dtype=object)), ('chEBI', array(['60648'], dtype=object))]",,"{'rows': array(['EFO_0008510', 'EFO_1001466', 'EFO_0002618', 'EFO_1000906',
       'EFO_0009536', 'EFO_0000341', 'EFO_0004214', 'MONDO_0007039',
       'EFO_0009659', 'EFO_0003102', 'MONDO_0018076', 'EFO_0001068',
       'EFO_0000662', 'EFO_0009425', 'EFO_0007470', 'MONDO_0007947',
       'EFO_0000778', 'EFO_0000574', 'EFO_1002047', 'EFO_0007460',
       'HP_0001250', 'MONDO_0004992', 'EFO_0000729', 'EFO_0007205',
       'EFO_1001788', 'MONDO_0100096', 'MONDO_0009061', 'MONDO_0019438',
       'MP_0001914', 'EFO_0007430', 'EFO_0000612', 'EFO_1001051',
       'MONDO_0004975', 'MONDO_0005178', 'EFO_0002913', 'EFO_0003770',
       'EFO_0007185', 'EFO_0000384', 'EFO_1001235', 'EFO_0000464',
       'EFO_0000199', 'EFO_0003894', 'EFO_0000756', 'EFO_1001951',
       'EFO_1001388', 'EFO_0000649', 'EFO_1000760', 'EFO_0000274',
       'MONDO_0002635', 'EFO_0000365', 'EFO_0000771', 'MONDO_0005180',
       'MONDO_0017816', 'EFO_0003878', 'EFO_0005952', 'EFO_0009117',
       'HP_0000964', 'EFO_0008517', 'EFO_0007272', 'EFO_0007480',
       'EFO_0000096', 'EFO_0003106', 'EFO_0000544', 'EFO_1001459',
       'EFO_1001875', 'EFO_0007410', 'EFO_0003843', 'DOID_7551',
       'EFO_0003060', 'EFO_0005044', 'EFO_0007504', 'EFO_1000785',
       'EFO_0000768', 'EFO_0007357', 'EFO_0009637', 'EFO_1001444',
       'EFO_0002687'], dtype=object), 'count': 77}","[ENSG00000137673,ENSG00000137745,ENSG00000118113,ENSG00000196611]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 15 approved and 62 investigational indications.
CHEMBL1200982,CCC(C)C1(CC)C(=O)[N-]C(=O)NC1=O.[Na+],QORQZMBCPRBCAB-UHFFFAOYSA-M,Small molecule,False,BUTABARBITAL SODIUM,1939.0,4.0,CHEMBL449,False,True,"['Butabarb' 'Butabarbital' 'Butabarbital sodium' 'Butalan' 'Buticaps'
 'Butisol sodium' 'Sarisol' 'Sarisol no. 1' 'Sarisol no. 2'
 'Sodium butabarbital']","['Astrudion' 'Butabarbital sodium' 'Butabarbital sodium salt' 'Loubarb'
 'Mebutal' 'NSC-11778' 'Secbutabarbital sodium']",,,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939.
CHEMBL1201149,Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,RHBRMCOKKKZVRY-ITLPAZOVSA-N,Small molecule,True,NALTREXONE HYDROCHLORIDE,1984.0,4.0,CHEMBL19019,False,True,['Adepend' 'Depade' 'Nalorex' 'Naltrexone hydrochloride' 'Opizone' 'Revia'],"['EN-1639A' 'EN-1639A (AS HYDROCHLORIDE)' 'Naltrexone hcl'
 'Naltrexone hydrochloride' 'Trexan']","[('DailyMed', array(['naltrexone%20hydrochloride'], dtype=object)), ('PubChem', array(['56422210', '855955'], dtype=object))]",,"{'rows': array(['EFO_0005203', 'HP_0100716', 'MONDO_0100096', 'MONDO_0015626',
       'EFO_0005611', 'HP_0012532', 'EFO_0010702', 'EFO_0003843',
       'EFO_0004701', 'EFO_0004329'], dtype=object), 'count': 10}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for pain and has 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201264,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21,GZHFODJQISUKAY-UHFFFAOYSA-N,Small molecule,False,METHANTHELINE,1951.0,4.0,,False,True,[],"['Methantheline' 'Methantheline cation' 'Methantheline ion'
 'Methanthelinium']","[('PubChem', array(['11112123'], dtype=object)), ('Wikipedia', array(['Methantheline'], dtype=object)), ('drugbank', array(['DB00940'], dtype=object)), ('chEBI', array(['6817'], dtype=object))]",['CHEMBL1200988'],"{'rows': array(['HP_0000011', 'EFO_0010282'], dtype=object), 'count': 2}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for gastrointestinal disease and has 1 investigational indication.
CHEMBL1269102,CC(C)C[C@@H]1NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O,VYCMAAOURFJIHD-AOYLRGCGSA-N,Protein,False,BQ-123,,2.0,,False,False,[],['BQ-123' 'BQ123' 'Bq-123' 'Cyclo(d-trp-d-asp-pro-d-val-leu)'],"[('Wikipedia', array(['BQ-123'], dtype=object))]",,"{'rows': array(['EFO_0001645', 'EFO_0000319', 'EFO_0002687', 'EFO_0003144',
       'EFO_0008585', 'MONDO_0005149'], dtype=object), 'count': 6}",[ENSG00000151617],Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL12856,Nc1cc(-c2ccncc2)c[nH]c1=O,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,Small molecule,False,INAMRINONE,1984.0,4.0,,False,True,[],"['Amcoral' 'Amrinone' 'C01CE01' 'Cartonic' 'Cordemcura' 'Inamrinone'
 'NSC-759805' 'Vesistol' 'WIN 40680' 'WIN-40680' 'Wincoram']","[('PubChem', array(['11112811', '11533005', '124882647', '144205663', '144212164',
       '170465367', '26750001', '26757798', '56424028'], dtype=object)), ('Wikipedia', array(['Amrinone'], dtype=object)), ('drugbank', array(['DB01427'], dtype=object))]",['CHEMBL2096642'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000172572],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for cardiovascular disease.
CHEMBL1519,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21,VXFJYXUZANRPDJ-WTNASJBWSA-N,Small molecule,True,TRANDOLAPRIL,1996.0,4.0,,False,True,['Gopten' 'Mavik' 'Odrik' 'Trandolapril'],['Indolapril' 'NSC-758939' 'RU 44570' 'RU-44570' 'Trandolapril'],"[('DailyMed', array(['trandolapril'], dtype=object)), ('PubChem', array(['144205006', '144206703', '90340949'], dtype=object)), ('Wikipedia', array(['Trandolapril'], dtype=object)), ('drugbank', array(['DB00519'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0003144', 'EFO_0000537', 'EFO_0000612'],
      dtype=object), 'count': 4}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved indications. This drug has a black box warning from the FDA.
CHEMBL1788132,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl,DWWHMKBNNNZGHF-UHFFFAOYSA-N,Small molecule,False,LOFEXIDINE HYDROCHLORIDE,2018.0,4.0,CHEMBL17860,False,True,['Britlofex' 'Lucemyra'],"['Lofexidine hcl' 'Lofexidine hydrochloride' 'MDL 14,042' 'MDL-14042'
 'NSC-759654']",,,"{'rows': array(['EFO_0005800', 'EFO_0005611'], dtype=object), 'count': 2}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for substance withdrawal syndrome and has 1 investigational indication.
CHEMBL2105395,OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,LUMKNAVTFCDUIE-VHXPQNKSSA-N,Small molecule,True,OSPEMIFENE,2013.0,4.0,,False,True,['Osphena' 'Senshio'],"['(deaminohydroxy) toremifene' 'FC-1271' 'FC-1271A' 'Ospemifene'
 'Tore iii']","[('DailyMed', array(['ospemifene'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/senshio'],
      dtype=object)), ('Wikipedia', array(['Ospemifene'], dtype=object)), ('drugbank', array(['DB04938'], dtype=object)), ('chEBI', array(['73275'], dtype=object))]",,"{'rows': array(['EFO_1001271', 'EFO_0000512', 'HP_0030016', 'GO_0042697',
       'EFO_1000096'], dtype=object), 'count': 5}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2105662,CS(=O)(=O)O.O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1,QKVKOFVWUHNEBX-UHFFFAOYSA-N,Small molecule,True,LOMITAPIDE MESYLATE,2012.0,4.0,CHEMBL354541,False,True,['Juxtapid' 'Lojuxta'],"['AEGR-733' 'AEGR-733 MESYLATE' 'Aegr-733 mesilate' 'BMS-201038'
 'BMS-201038-04' 'Lomitapide mesilate' 'Lomitapide mesylate']","[('DailyMed', array(['lomitapide%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta'],
      dtype=object)), ('chEBI', array(['72299'], dtype=object))]",,"{'rows': array(['MONDO_0018328', 'HP_0003124', 'MONDO_0021187', 'EFO_0004911'],
      dtype=object), 'count': 4}","[ENSG00000138823,ENSG00000185624]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2107832,O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F,VIUAUNHCRHHYNE-JTQLQIEISA-N,Small molecule,False,PIMASERTIB,,2.0,,False,False,['Msc1936369a; as703026; emd 1036239'],"['AS 703026' 'AS-703026' 'AS703026' 'As-703026' 'EMD 1036239'
 'EMD-1036239' 'G-02443714' 'MSC-1936369A' 'MSC-1936369B' 'MSC1936369A'
 'Msc-1936369' 'Pimasertib']","[('drugbank', array(['DB14904'], dtype=object))]",['CHEMBL4297676'],"{'rows': array(['EFO_0000389', 'EFO_0000756', 'EFO_0000641', 'EFO_0003060',
       'MONDO_0008170', 'EFO_1001951', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0000182', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0016691',
       'EFO_0000222', 'EFO_0002618'], dtype=object), 'count': 14}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 13 investigational indications.
CHEMBL2108718,,,Oligosaccharide,False,SEMULOPARIN SODIUM,,3.0,,False,False,[],['AVE-5026' 'Semuloparin sodium'],,,"{'rows': array(['HP_0004936', 'EFO_0004286'], dtype=object), 'count': 2}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109266,,,Antibody drug conjugate,False,AVE-9633,,1.0,,False,False,[],['AVE-9633' 'Ave-9633' 'HUMY9-6'],,,"{'rows': array(['MONDO_0004643'], dtype=object), 'count': 1}",[ENSG00000105383],Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109584,,,Antibody,False,F16SIP 131I,,2.0,,False,False,[],['F16SIP' 'F16sip 131i'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000041982],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2360079,CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,NUKVZKPNSKJGBK-SPIKMXEPSA-N,Small molecule,False,ACETOPHENAZINE MALEATE,1961.0,4.0,CHEMBL1085,False,True,['Tindal'],"['Acephenazine dimaleate' 'Acetophenazine dimaleate'
 'Acetophenazine maleate' 'NSC-169180' 'NSC-70600' 'SCH 6673' 'SCH-6673']","[('PubChem', array(['144206283'], dtype=object)), ('chEBI', array(['2402'], dtype=object))]",,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.
CHEMBL3186534,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,WPEWQEMJFLWMLV-UHFFFAOYSA-N,Small molecule,False,RIVOCERANIB,,3.0,,False,False,[],"['Apatinib' 'Apatinib free base' 'Rivoceranib' 'YN968D1'
 'YN968D1 FREE BASE']","[('PubChem', array(['124955476'], dtype=object)), ('drugbank', array(['DB14765'], dtype=object))]",['CHEMBL3545414'],"{'rows': array(['EFO_1000359', 'EFO_0004252', 'EFO_0000231', 'MONDO_0007254',
       'EFO_0000231', 'EFO_0001061', 'EFO_0000756', 'EFO_0000702',
       'EFO_0000178', 'MONDO_0008170', 'EFO_0006859', 'EFO_1001968',
       'EFO_0005221', 'MONDO_0003060', 'MONDO_0002120', 'EFO_0004142',
       'EFO_0000616', 'MONDO_0001056', 'EFO_0003868', 'EFO_1001951',
       'MONDO_0004992', 'MONDO_0011719', 'EFO_0000182', 'EFO_0000313',
       'EFO_0000571', 'MONDO_0008903', 'EFO_1001961', 'MONDO_0021063',
       'EFO_1001956', 'EFO_0002939', 'EFO_0001071', 'EFO_0005537',
       'MONDO_0100342', 'EFO_0000503', 'EFO_0000199', 'MONDO_0002108',
       'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869',
       'HP_0001541', 'MONDO_0002974', 'EFO_0003891', 'EFO_0000637',
       'EFO_0002916', 'EFO_0000182', 'EFO_0005543', 'EFO_0003897',
       'EFO_0000181', 'EFO_0000616', 'EFO_0005922', 'EFO_0000691',
       'EFO_0003893', 'EFO_0000621', 'MONDO_0018944', 'EFO_0000707',
       'EFO_0000211', 'MONDO_0007576', 'EFO_0002618', 'EFO_1002017',
       'EFO_0009708', 'EFO_0000365', 'EFO_0000574', 'EFO_0000503',
       'EFO_0003860', 'EFO_0000681', 'MONDO_0008315'], dtype=object), 'count': 67}",[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 64 investigational indications.
CHEMBL3545423,NC1CCCN(c2c(/C=C3/SC(=O)NC3=O)cccc2-c2ccccc2)C1,MCUJKPPARUPFJM-LDADJPATSA-N,Small molecule,False,AZD-1208,,1.0,,False,False,[],['Azd 1208' 'Azd-1208'],,,"{'rows': array(['EFO_0000574', 'MONDO_0004992', 'EFO_0000222'], dtype=object), 'count': 3}","[ENSG00000137193,ENSG00000102096,ENSG00000198355]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3786098,C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1,ODMXWZROLKITMS-RISCZKNCSA-N,Small molecule,False,PF-06459988,,2.0,,False,False,[],['PF-06459988' 'Pf-06459988'],"[('drugbank', array(['DB14768'], dtype=object))]",,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3822773,O=C(O)c1ccc([C@H]2C[C@@H]2c2ccc(OCc3c(-c4c(Cl)cccc4Cl)noc3C3CC3)cc2Cl)cc1,XBUXXJUEBFDQHD-NHCUHLMSSA-N,Small molecule,False,PX-102,,2.0,,False,False,[],['Px-102' 'Px-104'],"[('drugbank', array(['DB15416'], dtype=object))]",,"{'rows': array(['EFO_0003095'], dtype=object), 'count': 1}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3833343,,,Antibody,False,VOBARILIZUMAB,,2.0,,False,False,[],['ALX-0061' 'ALX0061' 'Vobarilizumab'],,,"{'rows': array(['EFO_0000685', 'MONDO_0007915'], dtype=object), 'count': 2}",[ENSG00000160712],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3916700,COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,SNXJYSXRLKUBSZ-WBXFWKJNSA-N,Small molecule,False,LAS190792,,1.0,,False,False,[],['Azd 8999' 'LAS-190792' 'Las190792'],,,"{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}","[ENSG00000169252,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3989556,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC.Cl.O,SPFVHFBNXPARTR-IDMXKUIJSA-N,Small molecule,False,REMOXIPRIDE HYDROCHLORIDE,1990.0,4.0,CHEMBL22242,True,True,['Roxiam' 'Roxiam ir'],"['(-)-FLA-731' 'A 33547.HCL.H20' 'FLA 731(-)' 'FLA-731' 'Remoxipride hcl'
 'Remoxipride hydrochloride']",,,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. It was withdrawn in at least one region.
CHEMBL4116008,CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,BGLPECHZZQDNCD-UHFFFAOYSA-N,Small molecule,False,CERDULATINIB,,2.0,,False,False,[],['Cerdulatinib' 'PRT-062070' 'Prt-2070' 'RVT-502'],"[('drugbank', array(['DB15499'], dtype=object))]",['CHEMBL3991929'],"{'rows': array(['EFO_0004208', 'EFO_0000095', 'MONDO_0019473', 'MONDO_0018906'],
      dtype=object), 'count': 4}","[ENSG00000162434,ENSG00000165025,ENSG00000105397,ENSG00000105639]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297329,C[C@]1(O)C[C@@](N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1,AIFGVDXMHWGOGJ-DIVCQZSQSA-N,Small molecule,False,PIFUSERTIB,,2.0,,False,False,[],['Pifusertib' 'TAS 117' 'Tas-117'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('drugbank', array(['DB15054'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297344,FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1,OZOGDCZJYVSUBR-UHFFFAOYSA-N,Small molecule,False,OBEFAZIMOD,,3.0,,False,False,[],['ABX-464' 'ABX464' 'Abx 464' 'Abx-464' 'Abx464' 'Obefazimod' 'SPL-464'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OBEFAZIMOD/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14828'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'EFO_0000685', 'MONDO_0100096', 'EFO_0000729',
       'EFO_0000384'], dtype=object), 'count': 5}","[ENSG00000114503,ENSG00000136937]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297775,,,Unknown,False,KAI-1678,,2.0,,False,False,[],['KP-1678' 'Kai-1678'],,,"{'rows': array(['EFO_0003843', 'EFO_1001919', 'MONDO_0041052'], dtype=object), 'count': 3}",[ENSG00000171132],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL435224,COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC,CMLUGNQVANVZHY-POURPWNDSA-N,Small molecule,False,LAPAQUISTAT ACETATE,,3.0,,False,False,[],['Lapaquistat acetate' 'TAK 475' 'TAK-475'],,,"{'rows': array(['MONDO_0021187', 'Orphanet_309005', 'HP_0003124', 'MONDO_0005148'],
      dtype=object), 'count': 4}",[ENSG00000079459],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4594447,CCCNCCOc1cc(F)cc(S(C)(=O)=O)c1,OSBPYFBXSLJHCR-UHFFFAOYSA-N,Small molecule,False,MESDOPETAM,,2.0,,False,False,[],['IRL-790' 'IRL790' 'Irl790' 'Mesdopetam'],,,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000151577],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650334,C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1,CMLVKUWQFZQPPS-YUNKPMOVSA-N,Small molecule,False,ALDUMASTAT,,2.0,,False,False,[],"['Aldumastat' 'G-504572' 'G504572' 'GLPG-1972' 'GLPG1972' 'Glpg1972'
 'S-201086' 'S201086']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ALDUMASTAT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}",[ENSG00000154736],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL513994,N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F,IENZFHBNCRQMNP-UHFFFAOYSA-N,Small molecule,False,PRX-08066,,2.0,,False,False,[],[],,['CHEMBL4297322'],,[ENSG00000135914],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL5314398,O=C(Nc1cccc2cnccc12)N[C@@H]1CC2(CCC2)Oc2ccc(F)cc21,JADKHWDNSKIILG-LJQANCHMSA-N,Small molecule,False,GRC-6211,,2.0,,False,False,[],['GRC6211' 'Grc-6211'],,,,[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL56564,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2,ZNRGQMMCGHDTEI-ITGUQSILSA-N,Small molecule,False,TROPISETRON,,4.0,,False,True,['Navoban'],"['ICS-205-930' 'NSC-759842' 'Novaban' 'SDZ-ICS-930' 'Tropisetron'
 'Tropisetron (as hydrochloride)' 'Tropisetron hcl'
 'Tropisetron hydrochloride' 'Tropisetron monohydrochloride']","[('PubChem', array(['26755041'], dtype=object)), ('drugbank', array(['DB11699'], dtype=object)), ('chEBI', array(['32269'], dtype=object))]",['CHEMBL3348564' 'CHEMBL2130744'],"{'rows': array(['EFO_0006911', 'HP_0002017', 'EFO_0003843', 'HP_0002018'],
      dtype=object), 'count': 4}","[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for chemotherapy-induced nausea and vomiting and nausea and has 2 investigational indications.
CHEMBL709,COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC,WNMJYKCGWZFFKR-UHFFFAOYSA-N,Small molecule,False,ALFUZOSIN,2003.0,4.0,,False,True,[],['Alfuzosin' 'NSC-760065' 'Uroxatral'],"[('PubChem', array(['174007387', '26719847', '26749009', '26749010', '50107503',
       '50107504', '90341616'], dtype=object)), ('Wikipedia', array(['Alfuzosin'], dtype=object)), ('drugbank', array(['DB00346'], dtype=object)), ('chEBI', array(['51141'], dtype=object))]",['CHEMBL1723'],"{'rows': array(['EFO_0000284', 'HP_0002019', 'EFO_0003830', 'EFO_0000284',
       'MONDO_0005301', 'EFO_1001228', 'EFO_0004253', 'HP_0000016',
       'HP_0000011', 'EFO_0004253'], dtype=object), 'count': 10}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for benign prostatic hyperplasia and has 7 investigational indications.
CHEMBL1087,Cc1cccc(C)c1NC(=O)C1CCCCN1C,INWLQCZOYSRPNW-UHFFFAOYSA-N,Small molecule,False,MEPIVACAINE,1960.0,4.0,,False,True,[],"[""1-methyl-2',6'-pipecoloxylidide"" ""2',6'-pipecoloxylidide, 1-methyl-""
 'APF-135' 'Carbocaine' 'Carboplyin dental' 'Dl-mepivacaine' 'Mepisv'
 'Mepivacaine' 'Polocaine' 'Polocaine-Mpf' 'Tevacaine']","[('Wikipedia', array(['Mepivacaine'], dtype=object)), ('drugbank', array(['DB00961'], dtype=object)), ('chEBI', array(['6759'], dtype=object))]",['CHEMBL1200440'],"{'rows': array(['MONDO_0004001', 'EFO_0004616', 'EFO_1000786', 'EFO_0003843'],
      dtype=object), 'count': 4}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 investigational indications.
CHEMBL1200648,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1.[Br-],OYTJKRAYGYRUJK-FMCCZJBLSA-M,Small molecule,False,ROCURONIUM BROMIDE,1994.0,4.0,CHEMBL1201244,False,True,['Esmeron' 'Rocuronium bromide' 'Zemuron'],['ORG 9426' 'ORG-9426' 'Rocuronium bromide'],"[('DailyMed', array(['rocuronium%20bromide'], dtype=object)), ('PubChem', array(['144205990'], dtype=object)), ('chEBI', array(['8885'], dtype=object))]",,"{'rows': array(['EFO_0007490', 'EFO_0009492', 'HP_0003418'], dtype=object), 'count': 3}","[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 investigational indications.
CHEMBL1201180,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1,DCERVXIINVUMKU-UHFFFAOYSA-N,Small molecule,True,DICLOFENAC EPOLAMINE,2007.0,4.0,CHEMBL139,False,True,['Flector' 'Flector Patch' 'Licart'],['Diclofenac epolamine' 'Diclofenac epolaminum'],"[('DailyMed', array(['diclofenac%20epolamine'], dtype=object)), ('chEBI', array(['48296'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0009582', 'EFO_0003843', 'EFO_1000652'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for sprain and pain and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743050,,,Antibody,False,OLOKIZUMAB,,3.0,,False,False,[],['CDP-6038' 'CDP6038' 'Olokizumab'],,,"{'rows': array(['MONDO_0100096', 'EFO_0000384', 'EFO_0000540', 'EFO_0000685',
       'MONDO_0005178'], dtype=object), 'count': 5}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL18,CCOc1ccc2nc(S(N)(=O)=O)sc2c1,OUZWUKMCLIBBOG-UHFFFAOYSA-N,Small molecule,False,ETHOXZOLAMIDE,1982.0,4.0,,False,True,['Cardrase' 'Ethamide'],['Ethoxzolamide' 'NSC-10679'],"[('PubChem', array(['144204399', '170465083', '56422188', '855751'], dtype=object)), ('Wikipedia', array(['Ethoxzolamide'], dtype=object)), ('drugbank', array(['DB00311'], dtype=object)), ('chEBI', array(['101096'], dtype=object))]",,,"[ENSG00000104267,ENSG00000168748,ENSG00000133742,ENSG00000164879,ENSG00000131686,ENSG00000074410,ENSG00000118298,ENSG00000107159,ENSG00000167434,ENSG00000185015,ENSG00000169239,ENSG00000174990]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1933350,CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12,FYRJJCYFYLLOSC-LXFBAYGMSA-N,Small molecule,False,MK-3577,,2.0,,False,False,[],['Mk-3577'],"[('drugbank', array(['DB14957'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000215644],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1947204,C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,MVZGYPSXNDCANY-UHFFFAOYSA-N,Small molecule,False,ALLITINIB,,2.0,,False,False,[],['ALL-3' 'AST-1306' 'Allitinib' 'Als 1306' 'Ast 1306' 'Ast-1306' 'Ast1306'],,['CHEMBL4779286'],"{'rows': array(['MONDO_0008903'], dtype=object), 'count': 1}","[ENSG00000141736,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2103736,CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2],LZPBLUATTGKZBH-UHFFFAOYSA-L,Small molecule,True,FENOPROFEN CALCIUM,1976.0,4.0,CHEMBL1297,False,True,['Fenoprofen calcium' 'Nalfon'],"['69323' 'Fenoprofen calcium' 'Fenoprofen calcium salt dihydrate'
 'Fenopron' 'Fepron' 'Feprona' 'Nalgesic']","[('DailyMed', array(['fenoprofen%20calcium'], dtype=object)), ('chEBI', array(['5005'], dtype=object))]",,"{'rows': array(['MONDO_0005178', 'EFO_0000685'], dtype=object), 'count': 2}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for osteoarthritis and rheumatoid arthritis. This drug has a black box warning from the FDA.
CHEMBL2109528,,,Antibody,False,FASINUMAB,,3.0,,False,False,[],['Fasinumab' 'REGN-475' 'REGN475' 'SAR-164877' 'SAR164877'],,,"{'rows': array(['HP_0003418', 'HP_0011868', 'EFO_1000786', 'EFO_0004616',
       'HP_0003419', 'MONDO_0005178', 'HP_0002027'], dtype=object), 'count': 7}",[ENSG00000134259],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2109589,,,Antibody,False,L19TNFA,,2.0,,False,False,[],['L19TNFA' 'L19tnfa'],,,"{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}",[ENSG00000115414],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2153191,CCCSc1nc(N2CCC[C@@H](CC(=O)O)C2)ccc1C(=O)NC1CCCCC1,NCDZABJPWMBMIQ-INIZCTEOSA-N,Small molecule,False,AZD-4017,,2.0,,False,False,[],['AZD-4017' 'AZD4017' 'Azd 4017' 'Azd-4017'],"[('drugbank', array(['DB14875'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_1001132', 'EFO_1001110', 'EFO_1001069',
       'EFO_0001073'], dtype=object), 'count': 5}",[ENSG00000117594],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3039498,CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1,HZVLFTCYCLXTGV-UHFFFAOYSA-N,Small molecule,False,GRAPIPRANT,2018.0,2.0,,False,False,['Galliprant'],"['423' 'AAT-007' 'CJ 023423' 'CJ-023' 'CJ-023423' 'Cj-023,423'
 'Grapiprant' 'MR-10A7' 'MR10A7' 'RQ-00000007' 'RQ-7']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/galliprant'],
      dtype=object)), ('drugbank', array(['DB12836'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0005178', 'EFO_0000305', 'EFO_1001951'],
      dtype=object), 'count': 4}",[ENSG00000171522],Small molecule drug with a maximum clinical trial phase of II (across all indications) that was first approved in 2018 and has 4 investigational indications.
CHEMBL3137331,CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1,FWLMVFUGMHIOAA-UHFFFAOYSA-N,Small molecule,False,DEFACTINIB,,2.0,,False,False,[],['Defactinib' 'PF-04554878' 'VS-6063' 'Vs-6063'],"[('drugbank', array(['DB12282'], dtype=object))]",['CHEMBL3137305'],"{'rows': array(['MONDO_0005184', 'EFO_0000466', 'EFO_0002618', 'EFO_0001378',
       'EFO_0000770', 'MONDO_0021148', 'EFO_0003060', 'MONDO_0004992',
       'MONDO_0008170', 'EFO_0000770', 'MONDO_0008170', 'EFO_0000519'],
      dtype=object), 'count': 12}","[ENSG00000120899,ENSG00000169398]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL3545165,O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1,IJUMFEAYOMCXAQ-UHFFFAOYSA-N,Small molecule,False,AFACIFENACIN,,2.0,,False,False,[],['Afacifenacin' 'NS-986' 'Smp-986'],,,"{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}","[ENSG00000185313,ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984,ENSG00000168356]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545279,Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N.Cl.Cl,WFIOHOJEIMQCEG-UHFFFAOYSA-N,Small molecule,False,EFATUTAZONE HYDROCHLORIDE,,2.0,CHEMBL3545280,False,False,[],"['CS-7017' 'Efatutazone dihydrochloride' 'Efatutazone hydrochloride'
 'Inolitazone dihydrochloride' 'RS5444']",,,,[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3931971,COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(=O)(=O)O)cc1)c1csc(-c2cccs2)n1,KWJDHELCGJFUHW-SFTDATJTSA-N,Small molecule,False,RAZUPROTAFIB,,2.0,,False,False,[],['AKB-9778' 'Razuprotafib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RAZUPROTAFIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001157', 'EFO_0003770', 'MONDO_0005041'], dtype=object), 'count': 3}",[ENSG00000127329],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297625,CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,XFJAMQQAAMJFGB-ZQGJOIPISA-N,Small molecule,False,LICOGLIFLOZIN,,2.0,,False,False,[],['LIK-066' 'LIK066' 'Licogliflozin' 'Lik066'],"[('drugbank', array(['DB15048'], dtype=object))]",['CHEMBL4762033'],"{'rows': array(['EFO_0003086', 'EFO_0000660', 'EFO_0001073', 'MONDO_0005148',
       'EFO_0003095'], dtype=object), 'count': 5}","[ENSG00000100170,ENSG00000140675]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL431651,CCCOc1ccc2c(c1)[C@@H](c1ccc(OC)cc1OCCO)[C@H](C(=O)O)[C@H]2c1ccc2c(c1)OCO2,GLCKXJLCYIJMRB-UPRLRBBYSA-N,Small molecule,False,ENRASENTAN,,2.0,,False,False,[],['Enrasentan' 'SB-217242' 'Sb-217242'],"[('drugbank', array(['DB06460'], dtype=object))]",,,"[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL432162,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,ADXGNEYLLLSOAR-UHFFFAOYSA-N,Small molecule,False,TASOSARTAN,,2.0,,False,False,[],['ANA-756' 'Tasosartan' 'WAY-ANA-756'],"[('drugbank', array(['DB01349'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594341,,,Antibody,False,VIXARELIMAB,,2.0,,False,False,[],"['30C6 [N73D) IgG4P.agly/IgG1' 'BIIB-069' 'BIIB069' 'KPL-716' 'Kpl-716'
 'Vixarelimab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VIXARELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0000989'], dtype=object), 'count': 1}",[ENSG00000145623],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594454,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12.Cl.O.O,CMDJNMACGABCKQ-XVSRHIFFSA-N,Small molecule,False,RIPASUDIL HYDROCHLORIDE DIHYDRATE,,2.0,CHEMBL3426621,False,False,[],"['Glanatec' 'K-115' 'K-115-R' 'Ripasudil hydrochloride dihydrate'
 'Ripasudil hydrochloride hydrate']",,,"{'rows': array(['MONDO_0005321'], dtype=object), 'count': 1}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650286,Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(C(=O)N2CCN(C3COC3)CC2)CC1,QAYHKBLKSXWOEO-UHFFFAOYSA-N,Small molecule,False,M4344,,1.0,,False,False,[],['Gartisertib' 'M 4344' 'M-4344' 'M4344' 'VX-803'],,,"{'rows': array(['MONDO_0007254', 'MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000175054],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL46618,COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1,PFGVNLZDWRZPJW-OPAMFIHVSA-N,Small molecule,False,OTAMIXABAN,,3.0,,False,False,[],"['FXV-673' 'Fxv673' 'Otamixaban' 'RPR-130673' 'RPR130673' 'XRP-0673'
 'XRP0673']","[('Wikipedia', array(['Otamixaban'], dtype=object)), ('drugbank', array(['DB06635'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'EFO_0001421', 'EFO_0001645', 'EFO_0005672'],
      dtype=object), 'count': 4}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL492,CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C,VTUSIVBDOCDNHS-UHFFFAOYSA-N,Small molecule,False,ETIDOCAINE,1976.0,4.0,,False,True,[],['Etidocaine' 'W-19053' 'W-19053 [AS HYDROCHLORIDE]'],"[('PubChem', array(['144206521'], dtype=object)), ('Wikipedia', array(['Etidocaine'], dtype=object)), ('drugbank', array(['DB08987'], dtype=object)), ('chEBI', array(['4904'], dtype=object))]",['CHEMBL1200597'],,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976.
CHEMBL526,CC(C)c1cccc(C(C)C)c1O,OLBCVFGFOZPWHH-UHFFFAOYSA-N,Small molecule,False,PROPOFOL,1989.0,4.0,,False,True,['Diprivan' 'Disoprivan' 'Propofol' 'Rapinovet'],"['Disoprofol' 'Fresofol' 'ICI 35,868' 'ICI 35-868' 'ICI-35868' 'ICI35,868'
 'Lipuro' 'NSC-5105' 'Phenol, 2,6-bis(1-methylethyl)' 'Propofol']","[('DailyMed', array(['propofol'], dtype=object)), ('PubChem', array(['104171149', '11111121', '11111122', '124879991', '144203685',
       '144208569', '144213542', '170464994', '17389856', '26747380',
       '47193694', '50105615', '90341256'], dtype=object)), ('Wikipedia', array(['Propofol'], dtype=object)), ('drugbank', array(['DB00818'], dtype=object)), ('chEBI', array(['44915'], dtype=object))]",['CHEMBL356637' 'CHEMBL154232'],"{'rows': array(['EFO_0004698', 'EFO_0000713', 'EFO_0003918', 'EFO_0003870',
       'EFO_0004259', 'EFO_0004888', 'HP_0000989', 'EFO_0001074',
       'EFO_0003855', 'EFO_0005251', 'EFO_0007355', 'MONDO_0002009',
       'EFO_0006834', 'HP_0011110', 'HP_0003418', 'EFO_0002618',
       'EFO_0003884', 'MONDO_0002050', 'EFO_0003917', 'EFO_0002687',
       'HP_0000713', 'EFO_0009267', 'EFO_0004273', 'MONDO_0007576',
       'EFO_1001210', 'EFO_0000662', 'MONDO_0043510', 'EFO_0001073',
       'EFO_0001422', 'HP_0100806', 'EFO_0000616', 'EFO_0009854',
       'EFO_0000537', 'EFO_0003869', 'EFO_0000712', 'HP_0031273',
       'HP_0002093', 'EFO_0007490', 'HP_0000486', 'EFO_0003843',
       'MONDO_0005277', 'EFO_0000546', 'EFO_0000565', 'EFO_1000644',
       'MP_0001845', 'MONDO_0004992', 'EFO_1002048', 'EFO_0000694',
       'EFO_0008526', 'EFO_1000637', 'EFO_1001951', 'EFO_0003777',
       'EFO_1001454', 'EFO_0001645', 'MONDO_0021117'], dtype=object), 'count': 55}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 55 investigational indications.
CHEMBL547,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,SHGAZHPCJJPHSC-XFYACQKRSA-N,Small molecule,True,ISOTRETINOIN,1982.0,4.0,,False,True,"['Absorica' 'Absorica ld' 'Accutane' 'Amnesteem' 'Claravis' 'Isotrex'
 'Myorisan' 'Roaccutane' 'Sotret' 'Zenatane']","['13 Cis-Retinoic Acid' '13-cis-retinoic acid' 'Isotretinoin' 'NSC-758156'
 'PAT-001' 'RO 4-3780' 'RO-4-3780' 'RO-43780' 'Retinoic acid 13-cis-form'
 'Retinoic acid, 13-cis-' 'Vitamin a acid, 13-cis']","[('DailyMed', array(['isotretinoin'], dtype=object)), ('PubChem', array(['144207291', '26747659', '26753641', '26753642', '26753643',
       '26753644', '47193696', '50106981', '90341473'], dtype=object)), ('Wikipedia', array(['Isotretinoin'], dtype=object)), ('drugbank', array(['DB00982'], dtype=object)), ('chEBI', array(['6067'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0000632', 'EFO_0000180', 'EFO_0000616',
       'EFO_0000565', 'EFO_1001051', 'EFO_0000544', 'MONDO_0008315',
       'EFO_0002501', 'EFO_0000464', 'EFO_0000339', 'EFO_0001378',
       'MONDO_0002974', 'EFO_1000309', 'MONDO_0008903', 'EFO_0004236',
       'EFO_1000760', 'MONDO_0003268', 'EFO_0000519', 'EFO_1001465',
       'EFO_0000403', 'EFO_0007512', 'EFO_0000198', 'MONDO_0002367',
       'EFO_0000309', 'EFO_0002499', 'EFO_0003833', 'EFO_0000183',
       'EFO_0000621', 'EFO_1000690', 'EFO_0002496', 'EFO_1001006',
       'EFO_1000158', 'MONDO_0000870', 'MONDO_0000873', 'EFO_0000502',
       'MONDO_0007254', 'EFO_0000681', 'EFO_0002939', 'EFO_0000222',
       'EFO_0006859', 'EFO_1000910', 'EFO_0000224', 'EFO_0000279',
       'EFO_0003894', 'MONDO_0006058', 'MONDO_0019269', 'MONDO_0004975'],
      dtype=object), 'count': 48}","[ENSG00000172819,ENSG00000077092,ENSG00000131759]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for acne and has 47 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200563,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c1-c1ccc(F)cc1.[Na+],GPUADMRJQVPIAS-QCVDVZFFSA-M,Small molecule,False,CERIVASTATIN SODIUM,1997.0,4.0,CHEMBL1477,True,True,['Baycol'],"['BAY W 6228' 'BAY-W-6228' 'Cerivastatin sodium'
 'Cerivastatin sodium salt']","[('PubChem', array(['144205797', '170465109', '251919809', '49681715'], dtype=object)), ('chEBI', array(['3559'], dtype=object))]",,,[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997. It was withdrawn in at least one region.
CHEMBL1200762,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],PLCQGRYPOISRTQ-LWCNAHDDSA-L,Small molecule,False,BETAMETHASONE SODIUM PHOSPHATE,1965.0,4.0,CHEMBL1201207,False,True,"['Betam-ophtal' 'Betamethasone sodium phosphate' 'Betnesol' 'Betnesol-n'
 'Celestone' 'Vistamethasone' 'Vistamethasone n']","['Betamethasone 21-phosphate disodium salt'
 'Betamethasone disodium phosphate' 'Betamethasone sodium phosphate'
 'NSC-90616']","[('PubChem', array(['144212784'], dtype=object)), ('chEBI', array(['3078'], dtype=object))]",,"{'rows': array(['EFO_1000906', 'MONDO_0005178', 'EFO_1001434', 'EFO_0000729',
       'EFO_1001097', 'HP_0003419'], dtype=object), 'count': 6}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for ulcerative colitis and has 5 investigational indications.
CHEMBL1200826,O=C([O-])[O-].[Li+].[Li+],XGZVUEUWXADBQD-UHFFFAOYSA-L,Small molecule,True,LITHIUM CARBONATE,1970.0,4.0,,False,True,"['Camcolit 250' 'Camcolit 400' 'Eskalith' 'Eskalith cr' 'Liskonum'
 'Lithane' 'Lithium carbonate' 'Lithobid' 'Lithonate' 'Lithotabs' 'Phasal']","['CP-15,467-61' 'CP-15467-61' 'CP-1546761' 'Carbonic acid, dilithium salt'
 'Lithii carbonas' 'Lithium carbonate' 'Lithium carbonicum' 'NSC-16895']","[('DailyMed', array(['lithium%20carbonate'], dtype=object)), ('DrugCentral', array(['4207'], dtype=object)), ('PubChem', array(['8139879'], dtype=object)), ('Wikipedia', array(['Lithium_carbonate'], dtype=object)), ('drugbank', array(['DB14509'], dtype=object)), ('chEBI', array(['6504'], dtype=object))]",,"{'rows': array(['MONDO_0007079', 'MONDO_0005090', 'EFO_0004216', 'EFO_0000712',
       'EFO_0009963', 'MONDO_0008315', 'EFO_1002017', 'MONDO_0015277',
       'EFO_0011023', 'EFO_1000158', 'MONDO_0001475', 'MONDO_0002050',
       'MONDO_0005301', 'MONDO_0018982', 'EFO_1001901', 'MONDO_0017276',
       'MONDO_0004976', 'HP_0000726', 'MONDO_0019037', 'MONDO_0002009',
       'MONDO_0007739', 'MONDO_0001657', 'EFO_0000702', 'Orphanet_733',
       'MONDO_0018696', 'EFO_0003931', 'MONDO_0005180', 'EFO_0002615',
       'EFO_1001919', 'MONDO_0008458', 'EFO_1001050', 'EFO_0009854',
       'MONDO_0004975', 'EFO_0003756', 'MONDO_0008119', 'EFO_0003015',
       'MONDO_0004985', 'Orphanet_98757', 'MONDO_0002009', 'EFO_0005230'],
      dtype=object), 'count': 40}","[ENSG00000133731,ENSG00000105723,ENSG00000082701]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 4 approved and 36 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1256841,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,NOIIUHRQUVNIDD-UHFFFAOYSA-N,Small molecule,False,NIALAMIDE,,4.0,,True,True,[],['NSC-124514' 'Nialamide' 'Niamid'],"[('PubChem', array(['11111522', '11111523', '144203759', '170466097', '50104074',
       '56422110', '85231151', '855800', '90341025'], dtype=object)), ('drugbank', array(['DB04820'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder. It was withdrawn in at least one region.
CHEMBL139,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,DCOPUUMXTXDBNB-UHFFFAOYSA-N,Small molecule,True,DICLOFENAC,1988.0,4.0,,False,True,"['Cambia' 'Voltaren' 'Voltaren Ophthalmic' 'Voltaren Xr' 'Zorvolex'
 'Zorvolex capsules']","['Arthrotec' 'Cataflam' 'Diclofenac' 'Diclofenac acid'
 'Diclofenac free acid' 'LAS-41007' 'LAS41007' 'Las41007' 'Solaraze'
 'Voltaren' 'Voltaren-XR']","[('DailyMed', array(['diclofenac'], dtype=object)), ('PubChem', array(['24424557'], dtype=object)), ('TG-GATEs', array(['19'], dtype=object)), ('Wikipedia', array(['Diclofenac'], dtype=object)), ('drugbank', array(['DB00586'], dtype=object)), ('chEBI', array(['47381'], dtype=object))]",['CHEMBL1201180' 'CHEMBL3350449' 'CHEMBL1034' 'CHEMBL1200804'],"{'rows': array(['MP_0001845', 'EFO_1000786', 'EFO_0000685', 'MONDO_0005277',
       'EFO_0009582', 'EFO_0003898', 'EFO_0004607', 'HP_0100607',
       'HP_0003326', 'EFO_0010072', 'EFO_0004616', 'MONDO_0001187',
       'EFO_1000652', 'EFO_0004616', 'EFO_1001139', 'EFO_0003843',
       'EFO_0000649', 'MONDO_0005178', 'MP_0001845', 'EFO_0003843',
       'EFO_0004274', 'EFO_0009582', 'EFO_1000720', 'MONDO_0007254',
       'EFO_0000685', 'EFO_1001412', 'EFO_0003843', 'MONDO_0005129',
       'EFO_0010072', 'MONDO_0005277', 'EFO_0003931', 'EFO_1001366',
       'EFO_0000545', 'MONDO_0005178', 'MONDO_0005178', 'HP_0003419',
       'EFO_0004272', 'EFO_0010072', 'EFO_0000685', 'EFO_0000546',
       'EFO_0003843', 'EFO_0002496', 'EFO_0002496', 'EFO_0009582',
       'MONDO_0002050', 'EFO_0009560', 'EFO_0000616', 'EFO_0002970',
       'EFO_0000649', 'EFO_0009454', 'MP_0001914', 'HP_0002829',
       'MONDO_0002959', 'MONDO_0002887', 'EFO_0004193', 'HP_0100607',
       'EFO_0005755', 'EFO_0003958', 'HP_0012532', 'EFO_0005752',
       'EFO_0000313', 'HP_0011868', 'EFO_0003827'], dtype=object), 'count': 63}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 16 approved and 35 investigational indications. This drug has a black box warning from the FDA.
CHEMBL149082,NCCCS(=O)(=O)O,SNKZJIOFVMKAOJ-UHFFFAOYSA-N,Small molecule,False,TRAMIPROSATE,,3.0,,False,False,[],"['3-aminopropane sulfonic acid' 'Acamprosate related compound a'
 'Homotaurine' 'NC-758' 'NSC-77071' 'Tramiprosate']","[('PubChem', array(['8139961', '90340792'], dtype=object)), ('Wikipedia', array(['Homotaurine'], dtype=object)), ('drugbank', array(['DB06527'], dtype=object)), ('chEBI', array(['1457'], dtype=object))]",['CHEMBL1256473' 'CHEMBL1256024'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1649931,CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1,QETUKYDWZIRTEI-QUMGSSFMSA-N,Small molecule,False,PF-232798,,2.0,,False,False,[],['PF-232798' 'Pf-00232798' 'Pf-232798'],"[('drugbank', array(['DB14813'], dtype=object))]",,"{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL197669,CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1,CYYQMAWUIRPCNW-UHFFFAOYSA-N,Small molecule,False,ST1535,,1.0,,False,False,[],['Ct-1500' 'ST-1535' 'St1535'],,,,[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2103824,CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,BJBCSGQLZQGGIQ-QGZVFWFLSA-N,Small molecule,False,ARHALOFENATE,,2.0,,False,False,[],['Arhalofenate' 'CB-102' 'CB102' 'JNJ-39659100' 'M-102' 'M102' 'MBX-102'],"[('drugbank', array(['DB11811'], dtype=object))]",,"{'rows': array(['EFO_0004274', 'MONDO_0005148'], dtype=object), 'count': 2}","[ENSG00000197891,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2105737,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,VZZJRYRQSPEMTK-CALCHBBNSA-N,Small molecule,True,SONIDEGIB,2015.0,4.0,,False,True,[],"['Erismodegib' 'LDE 225' 'LDE-225' 'LDE225' 'NVP-LDE 225' 'NVP-LDE-225'
 'NVP-LDE225' 'Sonidegib']","[('drugbank', array(['DB09143'], dtype=object))]",['CHEMBL3137317'],"{'rows': array(['EFO_0004193', 'EFO_0002618', 'EFO_0004193', 'MONDO_0008315',
       'EFO_0000616', 'EFO_0000182', 'EFO_0001378', 'MONDO_0007254',
       'EFO_0003869', 'MONDO_0007576', 'MONDO_0008170', 'EFO_0001421',
       'MONDO_0005341', 'EFO_0002939', 'MONDO_0013730', 'EFO_0000565'],
      dtype=object), 'count': 16}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for basal cell carcinoma and neoplasm and has 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109457,,,Antibody,False,LIGELIZUMAB,,3.0,,False,False,[],['Ligelizumab' 'QGE-031' 'QGE031'],,,"{'rows': array(['EFO_0007187', 'MONDO_0004979', 'EFO_1001890', 'EFO_0005531',
       'MONDO_0005271', 'EFO_0000274', 'EFO_1001881', 'EFO_0007425'],
      dtype=object), 'count': 8}",[ENSG00000211891],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL2205230,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1,ZADWXQMNNVICKB-UHFFFAOYSA-N,Small molecule,False,TAK-441,,1.0,,False,False,[],['Tak-441'],,,"{'rows': array(['EFO_0004193'], dtype=object), 'count': 1}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2448612,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O,CJMJLDQKTOJACI-SEUSHGJOSA-N,Small molecule,True,ERGOTAMINE TARTRATE,1948.0,4.0,CHEMBL442,False,True,"['Cafergot' 'Ergomar' 'Ergostat' 'Femergin' 'Gynergen' 'Lingraine'
 'Medihaler ergotamine' 'Migril' 'Wigrettes']","['Ergotamine bitartrate' 'Ergotamine d-tartrate' 'Ergotamine tartrate'
 'Ergotamini tartras' 'Gotamine tartrate' 'NSC-41869']","[('DailyMed', array(['ergotamine%20tartrate'], dtype=object))]",,"{'rows': array(['MONDO_0005277', 'HP_0002315'], dtype=object), 'count': 2}","[ENSG00000179546,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for migraine disorder and headache. This drug has a black box warning from the FDA.
CHEMBL3039553,,,Oligonucleotide,False,APATORSEN SODIUM,,-1.0,,False,False,[],['Apatorsen sodium' 'OGX-427'],,,,[ENSG00000106211],Oligonucleotide drug.
CHEMBL3306803,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12,HOIIHACBCFLJET-SFTDATJTSA-N,Small molecule,True,LUMATEPERONE,2019.0,4.0,,False,True,[],['ITI 007' 'ITI-007' 'ITI-722' 'ITI007' 'Lumateperone'],"[('drugbank', array(['DB06077'], dtype=object))]",['CHEMBL3233142'],"{'rows': array(['MONDO_0002009', 'MONDO_0005090', 'HP_0012076', 'EFO_0005407',
       'MONDO_0004975', 'MONDO_0004985', 'MONDO_0005090'], dtype=object), 'count': 7}","[ENSG00000102468,ENSG00000149295,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for schizophrenia and psychosis and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3663929,C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,QKDCLUARMDUUKN-XMMPIXPASA-N,Small molecule,False,NAQUOTINIB,,3.0,,False,False,[],['ASP-8273' 'ASP8273' 'Naquotinib'],"[('drugbank', array(['DB12036'], dtype=object))]",['CHEMBL3707350'],"{'rows': array(['EFO_0003060', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3833373,,,Antibody,False,AVELUMAB,2017.0,4.0,,False,True,['Bavencio'],['Avelumab' 'MSB-0010682' 'MSB0010682' 'MSB0010718C' 'Msb-0010718c'],"[('DailyMed', array(['avelumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio'],
      dtype=object))]",,"{'rows': array(['MONDO_0100342', 'EFO_0000574', 'EFO_0001668', 'MONDO_0008170',
       'EFO_0004142', 'EFO_1000158', 'MONDO_0011962', 'EFO_1001951',
       'EFO_0000349', 'EFO_0006859', 'MONDO_0008315', 'EFO_0000181',
       'MONDO_0016642', 'EFO_0000707', 'EFO_1001471', 'EFO_0000339',
       'EFO_0000637', 'MONDO_0005184', 'MONDO_0004992', 'MONDO_0002087',
       'EFO_0000222', 'MONDO_0021063', 'EFO_0000182', 'EFO_0002618',
       'EFO_0000403', 'EFO_0000365', 'EFO_0000616', 'EFO_0000231',
       'EFO_0000096', 'MONDO_0007254', 'MONDO_0018906', 'EFO_0005537',
       'EFO_0003968', 'MONDO_0002898', 'EFO_0003869', 'MONDO_0004986',
       'MONDO_0002120', 'EFO_0000588', 'EFO_0000228', 'EFO_0004252',
       'MONDO_0044903', 'EFO_0000519', 'EFO_0001378', 'MONDO_0002158',
       'EFO_1000581', 'EFO_0000503', 'MONDO_0001187', 'EFO_1000576',
       'EFO_0002890', 'EFO_0003863', 'EFO_0000564', 'EFO_0000681',
       'MONDO_0018944', 'EFO_0000756', 'EFO_0008528', 'EFO_1000657',
       'EFO_0005922', 'MONDO_0008978', 'EFO_0005952', 'EFO_0008528',
       'EFO_0000196', 'EFO_0000183', 'EFO_0003060', 'EFO_1001901',
       'EFO_0000702'], dtype=object), 'count': 65}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 60 investigational indications.
CHEMBL4204794,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1,DWYRIWUZIJHQKQ-SANMLTNESA-N,Small molecule,False,AVAPRITINIB,2020.0,4.0,,False,True,['Ayvakit' 'Ayvakyt'],['70C366' 'Avapritinib' 'BLU-285' 'C-366' 'X-720776' 'X720776'],"[('DailyMed', array(['avapritinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt'],
      dtype=object)), ('drugbank', array(['DB15233'], dtype=object))]",,"{'rows': array(['EFO_0000326', 'EFO_0007359', 'MONDO_0011719', 'EFO_0000616',
       'MONDO_0004992', 'MONDO_0016586'], dtype=object), 'count': 6}","[ENSG00000134853,ENSG00000157404]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 3 investigational indications.
CHEMBL4297813,,,Unknown,False,PRI-724,,2.0,,False,False,[],"['(S,S)-ICG-001' 'Foscenvivint' 'PRI-724' 'PRI724' 'Pri-724']",,,"{'rows': array(['EFO_0000616', 'EFO_0000365', 'EFO_0000222', 'EFO_0000339'],
      dtype=object), 'count': 4}","[ENSG00000005339,ENSG00000168036]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL580,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,DIWRORZWFLOCLC-UHFFFAOYSA-N,Small molecule,True,LORAZEPAM,1977.0,4.0,,False,True,"['Abbloraz' 'Ativan' 'Loraz' 'Lorazepam' 'Lorazepam intensol'
 'Lorazepam preservative free' 'Loreev xr' 'Temesta']",['Lorazepam' 'Lorazepam civ' 'NSC-289758' 'WY-4036'],"[('DailyMed', array(['lorazepam'], dtype=object)), ('PubChem', array(['144205222', '29215381'], dtype=object)), ('Wikipedia', array(['Lorazepam'], dtype=object)), ('drugbank', array(['DB00186'], dtype=object))]",,"{'rows': array(['EFO_0009267', 'EFO_0005411', 'EFO_0008526', 'MONDO_0002009',
       'HP_0000713', 'MONDO_0007079', 'HP_0000726', 'MONDO_0002009',
       'EFO_0002610', 'EFO_0009692', 'EFO_0004701', 'EFO_0000474',
       'EFO_0003890', 'EFO_0001064', 'EFO_0005230', 'MONDO_0005090',
       'MONDO_0004900', 'EFO_0004777', 'MONDO_0004975', 'EFO_0006788',
       'EFO_1000690', 'MONDO_0002050', 'EFO_0004242', 'HP_0001250',
       'EFO_1000924', 'EFO_0003843', 'EFO_1001146'], dtype=object), 'count': 27}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL659,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,ASUTZQLVASHGKV-JDFRZJQESA-N,Small molecule,False,GALANTAMINE,2001.0,4.0,,False,True,"['Acumor xl' 'Consion xl' 'Elmino xl' 'Galsya xl' 'Galzemic xl'
 'Gatalin xl' 'Gazylan xl' 'Lotprosin xl' 'Luventa xl' 'Reminyl'
 'Reminyl xl' 'Zeebral xl']","['(-)-galantamine' '(-)-galanthamine' 'Galantamine' 'Galanthamine'
 'NSC-100058' 'Razadyne']","[('PubChem', array(['104171341', '144204358', '26751839'], dtype=object)), ('Wikipedia', array(['Galantamine'], dtype=object)), ('drugbank', array(['DB00674'], dtype=object)), ('chEBI', array(['42944'], dtype=object))]",['CHEMBL4467191' 'CHEMBL1555' 'CHEMBL3099484'],"{'rows': array(['EFO_0001072', 'EFO_0005230', 'MONDO_0005090', 'EFO_0000713',
       'EFO_0006792', 'EFO_0004718', 'HP_0000726', 'EFO_0005252',
       'EFO_0003758', 'MONDO_0002050', 'Orphanet_79292', 'MONDO_0005090',
       'MONDO_0004975', 'EFO_0001073', 'MONDO_0004975', 'EFO_0003768',
       'EFO_0004718', 'HP_0000726', 'EFO_0000764', 'MONDO_0017276',
       'HP_0100543', 'EFO_0005411', 'EFO_0002610', 'EFO_0000677'],
      dtype=object), 'count': 24}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for dementia and alzheimer disease and has 19 investigational indications.
CHEMBL70972,CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O,ZBVKEHDGYSLCCC-UHFFFAOYSA-N,Small molecule,False,SERATRODAST,1995.0,4.0,,False,True,[],"['A-73001' 'AA-2414' 'ABBOTT 73001' 'ABBOTT-73001' 'ABT-001' 'Bronica'
 'NSC-759640' 'Seratrodast']","[('PubChem', array(['144206327', '170465940', '50125893'], dtype=object)), ('drugbank', array(['DB06739'], dtype=object))]",,"{'rows': array(['HP_0006536'], dtype=object), 'count': 1}",[ENSG00000006638],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication.
CHEMBL1079742,C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,GTTBEUCJPZQMDZ-UHFFFAOYSA-N,Small molecule,False,ERLOTINIB HYDROCHLORIDE,2004.0,4.0,CHEMBL553,False,True,['Erlotinib hydrochloride' 'Tarceva'],"['CP-358' 'CP-358,774-01' 'CP-358774-01' 'Erlotinib hcl'
 'Erlotinib hydrochloride' 'OSI-774']","[('DailyMed', array(['erlotinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva'],
      dtype=object)), ('PubChem', array(['534851'], dtype=object)), ('chEBI', array(['53509'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0005537', 'EFO_0002501', 'EFO_0000632',
       'MONDO_0003060', 'EFO_0002618', 'EFO_0000691', 'MONDO_0005411',
       'MONDO_0002158', 'MONDO_0007576', 'MONDO_0002974', 'EFO_0005567',
       'EFO_0000181', 'EFO_0005221', 'MONDO_0004992', 'MONDO_0002367',
       'MONDO_0001187', 'EFO_0001422', 'EFO_0000616', 'MONDO_0003268',
       'EFO_0000519', 'EFO_1001465', 'EFO_0000305', 'EFO_1000657',
       'MONDO_0021063', 'MONDO_0000521', 'MONDO_0004986', 'MONDO_0008903',
       'MONDO_0044926', 'EFO_0000182', 'EFO_1000158', 'EFO_0006859',
       'MONDO_0008315', 'MONDO_0002898', 'Orphanet_733', 'MONDO_0011962',
       'EFO_0000681', 'EFO_0003050', 'EFO_0000756', 'EFO_0003833',
       'MONDO_0007254', 'EFO_0002499', 'EFO_1001951', 'MONDO_0008170',
       'EFO_0000588', 'MONDO_0020634', 'EFO_0000308', 'EFO_0000571',
       'EFO_0000640', 'EFO_0000365', 'MONDO_0002087', 'MONDO_0002691',
       'EFO_0000708'], dtype=object), 'count': 53}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 52 investigational indications.
CHEMBL1083993,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1.Cl,ITPDYQOUSLNIHG-UHFFFAOYSA-N,Small molecule,True,AMIODARONE HYDROCHLORIDE,1985.0,4.0,CHEMBL633,False,True,"['Amidox' 'Amiodarone hydrochloride' 'Amyben' 'Cordarone' 'Cordarone x'
 'Cordarone x 100' 'Cordarone x 200' 'Darmil' 'Nexterone' 'Pacerone']","['Amiodar' 'Amiodarone' 'Amiodarone hcl' 'Amiodarone hydrochloride'
 'L-3428' 'Miodaron' 'NSC-343341' 'NSC-85442' 'Ortacrone' 'Ritmocardyl'
 'SK&F-33134-A' 'SKF 33134-A' 'SKF-33134-A' 'Trangorex' 'VF-236']","[('DailyMed', array(['amiodarone%20hydrochloride'], dtype=object)), ('PubChem', array(['144207027', '144210713', '26747445', '50105848', '50105849',
       '50105850', '552042', '56422901', '855533'], dtype=object))]",,"{'rows': array(['EFO_0000275', 'EFO_0004287', 'MONDO_0019438', 'EFO_0005529',
       'EFO_0003144', 'EFO_0005306', 'HP_0004308'], dtype=object), 'count': 7}",[ENSG00000055118],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL110458,OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O,LXBIFEVIBLOUGU-DPYQTVNSSA-N,Small molecule,False,MIGALASTAT,2016.0,4.0,,False,True,"['At-1001, gr-181314a' 'Galafold']",['Migalastat'],"[('PubChem', array(['11114003'], dtype=object)), ('drugbank', array(['DB05018'], dtype=object))]",['CHEMBL2107355'],"{'rows': array(['MONDO_0010526', 'MONDO_0010526'], dtype=object), 'count': 2}",[ENSG00000102393],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for fabry disease and has 1 investigational indication.
CHEMBL1200443,,,Small molecule,False,MERETHOXYLLINE PROCAINE,,4.0,,False,True,[],"['Merethoxyline procaine' 'Merethoxylline procaine'
 'Procaine merethoxylline']","[('DrugCentral', array(['4992'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL1200949,Cl.NCCc1cc[nH]n1,HLJRAERMLKNULP-UHFFFAOYSA-N,Small molecule,False,BETAZOLE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201323,False,True,['Histalog'],"['Ametazole' 'Betazole dihydrochloride' 'Betazole hcl'
 'Betazole hydrochloride' 'Betazolium chloride' 'NSC-759872']","[('PubChem', array(['144204280', '170465002', '56463652'], dtype=object))]",,,[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1560,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,FAKRSMQSSFJEIM-RQJHMYQMSA-N,Small molecule,True,CAPTOPRIL,1981.0,4.0,,False,True,"['Acepril' 'Capoten' 'Captomex' 'Captopril' 'Ecopace' 'Hyteneze 12.5'
 'Hyteneze 25' 'Hyteneze 50' 'Kaplon' 'Lopril' 'Noyada' 'Tensobon']","['Apopril' 'C09AA01' 'Capoten' 'Captomax' 'Captopril' 'Captoprilum'
 'Farcopril' 'Garranil' 'Hypopress' 'Mepha' 'NSC-757419' 'SA-333'
 'SQ -14225' 'SQ 14,225' 'SQ-14225' 'Tensiomin' 'Zapto']","[('DailyMed', array(['captopril'], dtype=object)), ('PubChem', array(['11110941', '144204441', '170464644', '26747043', '26751563',
       '50104171', '50104172', '50104173', '50104174', '56422201',
       '855925', '90340865'], dtype=object)), ('TG-GATEs', array(['94'], dtype=object)), ('Wikipedia', array(['Captopril'], dtype=object)), ('drugbank', array(['DB01197'], dtype=object)), ('chEBI', array(['3380'], dtype=object))]",,"{'rows': array(['EFO_0005755', 'EFO_0003106', 'EFO_0000537', 'EFO_0000373',
       'EFO_1002048', 'EFO_0002430', 'EFO_0001361', 'MONDO_0005148',
       'EFO_0000519', 'EFO_0003777', 'EFO_0000616', 'EFO_0000612',
       'MONDO_0100096', 'EFO_0000401', 'EFO_0000319', 'EFO_0003144',
       'EFO_0003770'], dtype=object), 'count': 17}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1691,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl,CHDPSNLJFOQTRK-UHFFFAOYSA-N,Small molecule,False,BETAXOLOL HYDROCHLORIDE,1985.0,4.0,CHEMBL423,False,True,['Betaxolol' 'Betaxolol hydrochloride' 'Betoptic' 'Betoptic s' 'Kerlone'],"['ALO 1401-02' 'ALO-1401-02' 'ALO-140102' 'Betaxolol hcl'
 'Betaxolol hydrochloride' 'NSC-760048' 'SL 75.212-10' 'SL-75.212-10'
 'SL-75212-10' 'SL-7521210']","[('DailyMed', array(['betaxolol%20hydrochloride'], dtype=object)), ('PubChem', array(['26663050', '50105931', '855778'], dtype=object)), ('chEBI', array(['643228'], dtype=object))]",,"{'rows': array(['EFO_0004190', 'EFO_0000537', 'EFO_1001069'], dtype=object), 'count': 3}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved indications.
CHEMBL1743013,,,Antibody,False,ENSITUXIMAB,,2.0,,False,False,[],['Ensituximab' 'NEO-101' 'NEO-102' 'NPC-1C'],,,"{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}",[ENSG00000215182],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1743020,,,Antibody,False,FORALUMAB,,2.0,,False,False,[],['Foralumab' 'NI-0401' 'TZLS-401'],,,"{'rows': array(['EFO_0000384', 'EFO_0008520', 'EFO_0008522', 'EFO_0004599',
       'MONDO_0100096'], dtype=object), 'count': 5}","[ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2104765,C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C,JUNDJWOLDSCTFK-MTZCLOFQSA-N,Small molecule,False,TRIMEGESTONE,,3.0,,False,False,[],['RU 27987' 'RU-27987' 'Trimegestone'],"[('drugbank', array(['DB13129'], dtype=object))]",,"{'rows': array(['EFO_0002950'], dtype=object), 'count': 1}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2104864,O=C(O)/C=C/C(=O)O.O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CO3)N1,GELJVTSEGKGLDF-QDSMGTAFSA-N,Small molecule,False,APLINDORE FUMARATE,,2.0,CHEMBL2110659,False,False,[],['Aplindore fumarate' 'DAB-452' 'Palindore' 'Palindore fumarate'],,,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108058,,,Protein,False,VANUTIDE CRIDIFICAR,,2.0,,False,False,[],['ACC-001' 'Vanutide cridificar'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108557,,,Protein,False,TELBERMIN,,2.0,,False,False,[],"['RH VEGF' 'RH-VEGF' 'RHVEG-F' 'RHVEGF' 'SNN0029' 'Telbermin' 'Vegf-a165'
 'Vegf165']",,,"{'rows': array(['EFO_1001459', 'MONDO_0004976'], dtype=object), 'count': 2}","[ENSG00000102755,ENSG00000128052]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2358147,CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,TVPJGGZLZLUPOB-SPIKMXEPSA-N,Small molecule,False,CARPHENAZINE MALEATE,1982.0,4.0,CHEMBL1201328,False,True,['Proketazine'],"['Carfenazine maleate' 'Carphenazine' 'Carphenazine dimaleate'
 'Carphenazine maleate' 'NSC-71755' 'WY-2445']","[('PubChem', array(['144206284'], dtype=object))]",,,"[ENSG00000149295,ENSG00000102468,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL3590674,O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1,AGPIHNZOZNKRGT-CYBMUJFWSA-N,Small molecule,False,ABT-639,,2.0,,False,False,[],['Abt-639' 'Abt-639 free base'],"[('drugbank', array(['DB15055'], dtype=object))]",['CHEMBL3589557'],"{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}",[ENSG00000196557],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4541964,O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1,LTSUMTMGJHPGFX-UHFFFAOYSA-N,Small molecule,False,ZATOLMILAST,,3.0,,False,False,[],['BPN-14770' 'BPN14770' 'Bpn14770' 'Zatolmilast'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZATOLMILAST/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0002039', 'MONDO_0004975', 'MONDO_0010383'], dtype=object), 'count': 3}",[ENSG00000113448],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4594401,CC1=NN(c2ccc3c(c2)CCCC3)C(=O)/C1=N\Nc1cccc(-c2ccc(C(=O)O)o2)c1O,BDGGFTDRPHKXFC-QYQHSDTDSA-N,Small molecule,False,RAFUTROMBOPAG,,3.0,,False,False,[],['Hetrombopag' 'Rafutrombopag' 'SHR-8735' 'SHR8735'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'EFO_0000198', 'HP_0001915', 'EFO_0007160',
       'HP_0001873', 'MONDO_0007254'], dtype=object), 'count': 6}",[ENSG00000117400],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4594448,CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@H](c2ccc(C(=O)O)cc2)C1,RENRQMCACQEWFC-UGKGYDQZSA-N,Small molecule,False,IPTACOPAN,,3.0,,False,False,[],['Iptacopan' 'LNP-023' 'LNP023' 'Lnp023' 'NVP-LNP023' 'NVP-LNP023-NX'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IPTACOPAN/relevant/1/'],
      dtype=object))]",['CHEMBL4643495' 'CHEMBL5095401'],"{'rows': array(['EFO_0004254', 'EFO_0005761', 'MONDO_0100244', 'HP_0000077',
       'MONDO_0002462', 'EFO_0001365', 'HP_0000077', 'EFO_0001421',
       'MONDO_0100244', 'MONDO_0018904', 'EFO_0004194', 'MONDO_0002462',
       'MONDO_0016244', 'MONDO_0100244'], dtype=object), 'count': 14}",[ENSG00000243649],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL5095451,,,Gene,False,ETRANACOGENE DEZAPARVOVEC,,1.0,,False,False,[],"['AAV5-hFIXco-Padua' 'AMT-061' 'Etranacogene dezaparvovec'
 'Etranacogene dezaparvovec-dlrb' 'Hemgenix']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETRANACOGENE%20DEZAPARVOVEC/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}",[ENSG00000101981],Gene drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL6,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,CGIGDMFJXJATDK-UHFFFAOYSA-N,Small molecule,True,INDOMETHACIN,1965.0,4.0,,False,True,"['Artracin' 'Artracin sr' 'Berlind 75 ret' 'Flexin-25 continus'
 'Flexin-50 continus' 'Flexin-75 continus' 'Imbrilon' 'Indo-lemmon'
 'Indo-paed' 'Indocid ret' 'Indocid-r' 'Indocin' 'Indocin sr' 'Indoderm'
 'Indoflex' 'Indolar' 'Indolar sr' 'Indomax-25' 'Indomax-75 sr'
 'Indomethacin' 'Indomod' 'Indoptol' 'Indotard mr 75' 'Ledmecin'
 'Maximet sr' 'Mobilan' 'Pardelprin mr' 'Rheumacin la' 'Rimacid'
 'Slo-indo' 'Tivorbex']","['Aconip' 'Durametacin' 'Indometacin' 'Indometacin farnesil'
 'Indometacinum' 'Indomethacin' 'NSC-757061' 'NSC-77541' 'Reumacide']","[('DailyMed', array(['indomethacin'], dtype=object)), ('PubChem', array(['11111328', '11111329', '11113361', '124880453', '124880455',
       '124880457', '124880458', '144206660', '144208989', '144210586',
       '170464705', '17389851', '174007200', '26747086', '26747087',
       '26751593', '50100255', '50104238', '50104239', '50126367',
       '56422212', '85231093', '856012', '90340917'], dtype=object)), ('TG-GATEs', array(['15'], dtype=object)), ('Wikipedia', array(['Indometacin'], dtype=object)), ('drugbank', array(['DB00328'], dtype=object)), ('chEBI', array(['49662'], dtype=object))]",['CHEMBL2028292' 'CHEMBL3989410' 'CHEMBL4590319'],"{'rows': array(['MONDO_0003937', 'EFO_0000278', 'EFO_0005755', 'MONDO_0004979',
       'EFO_1001412', 'EFO_0000199', 'EFO_0000685', 'EFO_1000652',
       'EFO_0010072', 'MONDO_0004975', 'MONDO_0100096', 'HP_0002829',
       'EFO_1000318', 'EFO_0005252', 'MONDO_0007254', 'EFO_0003843',
       'MP_0001914', 'Orphanet_79292', 'EFO_0003898', 'EFO_0003917',
       'MP_0001845', 'EFO_0000181', 'MONDO_0024475', 'EFO_0000196',
       'EFO_0000342', 'MONDO_0005178', 'HP_0001643', 'EFO_0000319',
       'HP_0003326', 'EFO_0004274', 'EFO_0005752', 'MP_0001845',
       'MONDO_0008315', 'EFO_0000389', 'EFO_0000673'], dtype=object), 'count': 35}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 12 approved and 23 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1173055,CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,HMABYWSNWIZPAG-UHFFFAOYSA-N,Small molecule,False,RUCAPARIB,2016.0,4.0,,False,True,[],['AG-014699' 'AG-14447' 'Rucaparib'],"[('PubChem', array(['103905261', '137276017', '174006354'], dtype=object)), ('drugbank', array(['DB12332'], dtype=object))]",['CHEMBL2105733' 'CHEMBL3833368'],"{'rows': array(['EFO_0003060', 'MONDO_0002087', 'MONDO_0002158', 'MONDO_0004992',
       'MONDO_0008170', 'EFO_0000616', 'MONDO_0007254', 'EFO_0003893',
       'MONDO_0008315', 'EFO_0000702', 'MONDO_0008170', 'MONDO_0001056',
       'MONDO_0003060', 'EFO_0000616', 'EFO_0000616', 'Orphanet_145',
       'MONDO_0002974', 'EFO_0002618', 'MONDO_0005184', 'EFO_1000613',
       'EFO_0000564', 'EFO_0000673', 'MONDO_0011962', 'EFO_0001075',
       'EFO_0000588'], dtype=object), 'count': 25}","[ENSG00000143799,ENSG00000041880,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 5 approved and 19 investigational indications.
CHEMBL1201248,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC,YXSLJKQTIDHPOT-LJCJQEJUSA-N,Small molecule,False,CISATRACURIUM,1995.0,4.0,,False,True,['Nimbex'],['Cisatracurium' 'Cisatracurium cation' 'Cisatracurium ion'],"[('Wikipedia', array(['Cisatracurium_besilate'], dtype=object)), ('drugbank', array(['DB00565'], dtype=object))]",['CHEMBL1200641'],"{'rows': array(['EFO_1000637'], dtype=object), 'count': 1}","[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication.
CHEMBL1201468,,,Unknown,True,"ESTROGENS, ESTERIFIED",1977.0,4.0,,False,True,['Amnestrogen' 'Esterified estrogens' 'Estratab' 'Evex' 'Femogen' 'Menest'],"['Esterified estrogens' 'Estrogens esterified' 'Estrogens, esterified'
 'Estrogens,esterified']","[('DailyMed', array(['estrogens,%20esterified'], dtype=object))]",,"{'rows': array(['EFO_1000096', 'GO_0042697', 'EFO_0004266', 'MONDO_0002146',
       'MONDO_0007254'], dtype=object), 'count': 5}","[ENSG00000140009,ENSG00000091831]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved indications. This drug has a black box warning from the FDA.
CHEMBL1201772,CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,DTGLZDAWLRGWQN-UHFFFAOYSA-N,Small molecule,True,PRASUGREL,2009.0,4.0,,False,True,['Efient'],['LY-640315' 'NSC-759625' 'Prasugrel'],"[('PubChem', array(['124899264', '174006898'], dtype=object)), ('Wikipedia', array(['Prasugrel'], dtype=object)), ('drugbank', array(['DB06209'], dtype=object)), ('chEBI', array(['87723'], dtype=object))]",['CHEMBL1201773'],"{'rows': array(['EFO_0003777', 'EFO_0000612', 'EFO_0000612', 'MONDO_0004979',
       'EFO_0008585', 'MP_0001914', 'EFO_0003884', 'EFO_0000275',
       'EFO_0000764', 'EFO_0003106', 'HP_0004419', 'MONDO_0011382',
       'EFO_0007328', 'EFO_0005672', 'EFO_0001645', 'MONDO_0100096',
       'EFO_0005672'], dtype=object), 'count': 17}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1234354,COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1,XDLYKKIQACFMJG-WKILWMFISA-N,Small molecule,False,PF-04691502,,2.0,,False,False,[],['PF-04691502' 'PF-4691502' 'Pf-04691502'],"[('drugbank', array(['DB11974'], dtype=object))]",,"{'rows': array(['EFO_0003869', 'MONDO_0007254', 'MONDO_0004992'], dtype=object), 'count': 3}","[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1423,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,YVUQSNJEYSNKRX-UHFFFAOYSA-N,Small molecule,False,PIMOZIDE,1984.0,4.0,,False,True,['Orap' 'Pimozide'],['MCN-JR-6238' 'NSC-170984' 'Pimozide' 'R 623' 'R 6238' 'R-623' 'R-6238'],"[('DailyMed', array(['pimozide'], dtype=object)), ('PubChem', array(['104171210', '11111615', '11112507', '11113804', '124881071',
       '124881072', '124881075', '124881079', '144116849', '144203775',
       '144211903', '170464864', '26747138', '26751488', '26751978',
       '26751979', '50104653', '563187', '56422165', '85231181', '855710',
       '90341263'], dtype=object)), ('Wikipedia', array(['Pimozide'], dtype=object)), ('drugbank', array(['DB01100'], dtype=object)), ('chEBI', array(['8212'], dtype=object))]",,"{'rows': array(['MONDO_0005090', 'EFO_0005230', 'HP_0000726', 'HP_0100033',
       'MONDO_0002050', 'EFO_0005407', 'MONDO_0004976', 'EFO_0004895'],
      dtype=object), 'count': 8}","[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 5 investigational indications.
CHEMBL1515,Cn1ccnc1S,PMRYVIKBURPHAH-UHFFFAOYSA-N,Small molecule,False,METHIMAZOLE,1950.0,4.0,,False,True,['Favistan' 'Methimazole' 'Tapazole'],['Mercaptizole' 'Methimazole' 'NSC-38608' 'Thiamazole'],"[('DailyMed', array(['methimazole'], dtype=object)), ('PubChem', array(['11112158', '144203892', '144208539', '144210850', '170464856',
       '57299280', '8139973'], dtype=object)), ('TG-GATEs', array(['57'], dtype=object)), ('Wikipedia', array(['Methimazole'], dtype=object)), ('drugbank', array(['DB00763'], dtype=object)), ('chEBI', array(['50673'], dtype=object))]",,"{'rows': array(['HP_0000820', 'EFO_0000519', 'EFO_1001466', 'EFO_1001465',
       'EFO_0000398', 'EFO_0009189'], dtype=object), 'count': 6}",[ENSG00000115705],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for abnormality of the thyroid gland and hyperthyroidism and has 4 investigational indications.
CHEMBL1683544,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O,QAMYWGZHLCQOOJ-WRNBYXCMSA-N,Small molecule,False,ERIBULIN MESYLATE,2010.0,4.0,CHEMBL1683590,False,True,['Halaven'],"['E-7389' 'E7389' 'Eribulin (as mesylate)' 'Eribulin mesilate'
 'Eribulin mesylate' 'Eribulin monomethanesulfonate' 'Halaven']","[('DailyMed', array(['eribulin%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/halaven'],
      dtype=object)), ('chEBI', array(['70710'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000616', 'MONDO_0001187', 'EFO_0000569',
       'EFO_0008528', 'MONDO_0004992', 'MONDO_0004669', 'EFO_0000574',
       'EFO_0006859', 'EFO_0000637', 'EFO_1001968', 'MONDO_0004192',
       'EFO_0000673', 'EFO_0006861', 'MONDO_0021632', 'EFO_1000613',
       'MONDO_0002974', 'EFO_0003869', 'EFO_0000305', 'MONDO_0007254',
       'EFO_0005537', 'MONDO_0008315'], dtype=object), 'count': 22}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 4 approved and 18 investigational indications.
CHEMBL1729,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC,DCSUBABJRXZOMT-UHFFFAOYSA-N,Small molecule,True,CISAPRIDE,1993.0,4.0,,True,True,"['Alimix' 'Prepulsid' 'Prepulsid quicklet' 'Propulsid'
 'Propulsid quicksolv']","['Cisapride' 'Cisapride monohydrate' 'Propulsid' 'R-51,619' 'R-51619']","[('PubChem', array(['144204250', '170465200'], dtype=object)), ('Wikipedia', array(['Cisapride'], dtype=object))]",['CHEMBL1200788'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993 and is indicated for gastrointestinal disease. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1743065,,,Antibody,False,ROLEDUMAB,,2.0,,False,False,[],['Roledumab'],,,,[ENSG00000187010],Antibody drug with a maximum clinical trial phase of II.
CHEMBL1789941,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,HFNKQEVNSGCOJV-OAHLLOKOSA-N,Small molecule,True,RUXOLITINIB,2011.0,4.0,,False,True,['Jakavi'],['INC-424' 'INC424' 'INCB-018424' 'INCB-18424' 'INCB018424' 'Ruxolitinib'],"[('Wikipedia', array(['Ruxolitinib'], dtype=object)), ('drugbank', array(['DB08877'], dtype=object)), ('chEBI', array(['66919'], dtype=object))]",['CHEMBL1795071' 'CHEMBL4594382' 'CHEMBL4594381'],"{'rows': array(['EFO_0004192', 'EFO_0003086', 'EFO_0000222', 'HP_0011974',
       'EFO_0000181', 'EFO_0000685', 'EFO_0000220', 'EFO_1000710',
       'HP_0004326', 'EFO_0000616', 'EFO_0003060', 'MONDO_0021739',
       'EFO_0000339', 'EFO_0000574', 'MONDO_0002158', 'MONDO_0019469',
       'EFO_0000305', 'MONDO_0002406', 'EFO_0002618', 'EFO_0000274',
       'EFO_0001068', 'EFO_1001951', 'EFO_0002430', 'EFO_0004208',
       'EFO_1000738', 'EFO_1000984', 'EFO_0004192', 'EFO_0000676',
       'EFO_0002429', 'MONDO_0044903', 'EFO_0003106', 'EFO_0000676',
       'HP_0000964', 'EFO_0000274', 'EFO_1000764', 'EFO_0004272',
       'EFO_0000222', 'EFO_1001467', 'MONDO_0008903', 'EFO_1001806',
       'EFO_1000724', 'EFO_1000726', 'EFO_0000095', 'EFO_0001378',
       'EFO_0000565', 'EFO_0000694', 'EFO_1001779', 'EFO_0000479',
       'MONDO_0009348', 'EFO_0004251', 'EFO_0001421', 'MONDO_0013730',
       'MONDO_0007254', 'EFO_0000220', 'EFO_0000466', 'EFO_0007183',
       'MONDO_0100096', 'EFO_0004256', 'EFO_0002430', 'MONDO_0020547',
       'EFO_0004192', 'MONDO_0004992', 'EFO_0000209', 'EFO_0004192',
       'EFO_0001642', 'EFO_0004251', 'EFO_0005952', 'EFO_0000764',
       'MONDO_0005184', 'EFO_0000519', 'MONDO_0019558', 'MONDO_0013730',
       'EFO_0000095', 'EFO_0004599', 'EFO_0000183', 'MONDO_0008315',
       'EFO_0005537', 'MONDO_0015540', 'MONDO_0016486', 'EFO_0002429'],
      dtype=object), 'count': 80}","[ENSG00000162434,ENSG00000096968]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 8 approved and 68 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1823817,COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O,FUCKCIVGBCBZNP-MRXNPFEDSA-N,Small molecule,False,CE-224535,,2.0,,False,False,[],"['CE 224,535' 'CE-224,535' 'CE224535' 'Ce 224535' 'Ce-224535']","[('drugbank', array(['DB12113'], dtype=object))]",,"{'rows': array(['MONDO_0005178', 'EFO_0000685'], dtype=object), 'count': 2}",[ENSG00000089041],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2104981,COCCN1CCC(N(Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C(=O)Cn2c(SCc3cccc(F)c3F)cc(=O)c3ccccc32)CC1,NNBGCSGCRSCFEA-UHFFFAOYSA-N,Small molecule,False,RILAPLADIB,,2.0,,False,False,[],['Rilapladib' 'SB-659032'],"[('drugbank', array(['DB05119'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0003914'], dtype=object), 'count': 2}",[ENSG00000146070],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2107333,COC(=O)/C=C/C(=O)OC,LDCRTTXIJACKKU-ONEGZZNKSA-N,Small molecule,False,DIMETHYL FUMARATE,2013.0,4.0,,False,True,['Dimethyl fumarate neuraxpharm' 'Tecfidera'],"['AZL 0 211089' 'AZL O 211089' 'AZL-0211089' 'AZL-O-211089' 'BG 00012'
 'BG 12' 'BG-00012' 'BG-12' 'BG00012' 'Dimethyl fumar' 'Dimethyl fumarate'
 'FAG-201' 'FP-187' 'FP187' 'Fumaric acid dimethyl ester' 'LAS-41008'
 'LAS41008' 'Las41008' 'NSC-167432' 'NSC-25942' 'Panaclar']","[('DailyMed', array(['dimethyl%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-neuraxpharm'],
      dtype=object)), ('drugbank', array(['DB08908'], dtype=object)), ('chEBI', array(['76004'], dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_0003778', 'EFO_0000540', 'EFO_1001465',
       'EFO_0005669', 'EFO_0003918', 'EFO_0000095', 'HP_0002140',
       'EFO_0002913', 'EFO_0000685', 'EFO_0003929', 'EFO_0003840',
       'EFO_0000694', 'MONDO_0005301', 'EFO_0008520'], dtype=object), 'count': 15}",[ENSG00000079999],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 12 investigational indications.
CHEMBL2107873,,,Protein,False,VONICOG ALFA,2018.0,4.0,,False,True,['Veyvondi'],"['BAX 111' 'BAX-111' 'Von willebrand factor (recombinant)' 'Vonicog alfa'
 'Vonvendi']","[('DrugCentral', array(['5173'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi'],
      dtype=object))]",,"{'rows': array(['Orphanet_903'], dtype=object), 'count': 1}",[ENSG00000110799],Protein drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for von willebrand disease.
CHEMBL2108278,,,Oligonucleotide,False,ETEPLIRSEN,2016.0,4.0,,False,True,['Exondys 51'],['AVI-4658' 'Eteplirsen'],"[('DailyMed', array(['eteplirsen'], dtype=object)), ('DrugCentral', array(['5182'], dtype=object))]",,"{'rows': array(['MONDO_0010679', 'MONDO_0020121'], dtype=object), 'count': 2}",[ENSG00000198947],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for duchenne muscular dystrophy and muscular dystrophy.
CHEMBL2109092,,,Protein,False,EPOETIN BETA,1997.0,4.0,,False,True,"['Neorecormon' 'Neorecormon 1000' 'Neorecormon 10000' 'Neorecormon 2000'
 'Neorecormon 20000' 'Neorecormon 3000' 'Neorecormon 30000'
 'Neorecormon 4000' 'Neorecormon 500' 'Neorecormon 5000'
 'Neorecormon 6000' 'Recormon 1000' 'Recormon 10000' 'Recormon 2000'
 'Recormon 5000' 'Recormon s 1000' 'Recormon s 10000' 'Recormon s 2000'
 'Recormon s 5000']","['BM 06.019' 'EPOCH' 'Epoetin' 'Epoetin beta' 'Erythropoietin'
 'Erythropoietin for bioassays']","[('DrugCentral', array(['5160'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon'],
      dtype=object))]",,"{'rows': array(['EFO_1001919', 'EFO_1002048', 'EFO_0000712', 'EFO_0001068',
       'MONDO_0043510', 'EFO_0000198', 'EFO_1001330', 'MP_0001914',
       'EFO_0004247', 'MONDO_0005180', 'EFO_0000183', 'MONDO_0004976',
       'EFO_1000632', 'MONDO_0002135', 'EFO_0004220', 'MONDO_0008170',
       'EFO_1001375', 'EFO_0004272', 'EFO_1001779', 'EFO_1000824',
       'EFO_0003964', 'EFO_0001061', 'HP_0002140', 'EFO_0000713',
       'MONDO_0005301', 'EFO_0008583', 'MONDO_0004992', 'EFO_1001100',
       'EFO_0003928', 'EFO_0000403', 'MONDO_0003608', 'EFO_0003884',
       'EFO_0000612', 'MONDO_0005299', 'EFO_0002687', 'EFO_0000574',
       'MONDO_0002158', 'EFO_0005676', 'EFO_0007405', 'HP_0001919',
       'EFO_0003917', 'EFO_0006859', 'EFO_0004273', 'EFO_1000809',
       'EFO_0000546', 'EFO_0004599'], dtype=object), 'count': 46}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for anemia (phenotype) and chronic kidney disease and has 44 investigational indications.
CHEMBL2109440,,,Antibody,False,LY-2787106,,1.0,,False,False,[],['LY-2787106' 'LY2787106' 'Ly-2787106'],,,"{'rows': array(['EFO_0004272'], dtype=object), 'count': 1}",[ENSG00000105697],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2110585,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,GWEJFLVSOGNLSS-WPFOTENUSA-N,Small molecule,False,EZATIOSTAT,,2.0,,False,False,[],['Ezatiostat' 'TLK-199'],"[('drugbank', array(['DB05460'], dtype=object))]",['CHEMBL2103810'],"{'rows': array(['MONDO_0001475', 'EFO_0000198', 'EFO_0000198'], dtype=object), 'count': 3}",[ENSG00000084207],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2110900,CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1,USRHYDPUVLEVMC-FQEVSTJZSA-N,Small molecule,False,DAPOXETINE,,4.0,,False,True,[],['Dapoxetine' 'Kutub' 'LY-210448'],"[('PubChem', array(['170466555'], dtype=object)), ('drugbank', array(['DB04884'], dtype=object))]",['CHEMBL2106574'],"{'rows': array(['EFO_0004714', 'EFO_0803321', 'EFO_0004234'], dtype=object), 'count': 3}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.
CHEMBL2304041,C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O,BFZKMNSQCNVFGM-UCEYFQQTSA-N,Small molecule,False,SAGOPILONE,,2.0,,False,False,[],"['BAY86-5302' 'DE-03757' 'Sagopilone' 'ZK 219477' 'ZK-219477' 'ZK-EPO'
 'Zk219477']","[('drugbank', array(['DB12391'], dtype=object))]",,"{'rows': array(['EFO_0000519', 'MONDO_0007254', 'EFO_0003893', 'EFO_1000158',
       'EFO_0003060', 'EFO_0000616', 'EFO_0000756', 'EFO_0003869',
       'EFO_0000702', 'MONDO_0008315'], dtype=object), 'count': 10}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL2364629,N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F.N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F.O.O.O.O=S(=O)(O)O,SOGUOEZRYKUOHR-CQZKMDJHSA-N,Small molecule,False,RIMEGEPANT SULFATE,2020.0,4.0,CHEMBL2178422,False,True,['Nurtec odt' 'Vydura'],['Rimegepant sulfate'],"[('DailyMed', array(['rimegepant%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vydura'],
      dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000064989],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for migraine disorder.
CHEMBL2402737,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,TVTXCJFHQKSQQM-LJQIRTBHSA-N,Small molecule,False,IDASANUTLIN,,3.0,,False,False,[],['Idasanutlin' 'RG-7388' 'RG7388' 'RO-5503781' 'RO5503781'],"[('drugbank', array(['DB12325'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0000403', 'EFO_1001951', 'MONDO_0018906',
       'MONDO_0007254', 'EFO_0000616', 'EFO_0002429', 'EFO_0000222',
       'EFO_0000519', 'EFO_0000479', 'EFO_0005952'], dtype=object), 'count': 11}","[ENSG00000141510,ENSG00000135679]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL265502,Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1,FIAFUQMPZJWCLV-UHFFFAOYSA-N,Small molecule,False,SURAMIN,,3.0,,False,False,[],"['FARMA-939' 'Farma' 'Fourneau' 'Metaret' 'NSC-34936' 'Naganol' 'Suramin'
 'Suramine']","[('PubChem', array(['11114098', '124887029', '144205598', '170466101', '26752197',
       '26756673', '50104860', '544513', '90341387'], dtype=object)), ('Wikipedia', array(['Suramin'], dtype=object)), ('drugbank', array(['DB04786'], dtype=object)), ('chEBI', array(['45906'], dtype=object))]",['CHEMBL413376'],"{'rows': array(['MONDO_0008315', 'EFO_0000681', 'MONDO_0007254', 'DOID_10113',
       'EFO_1000796', 'EFO_0003060', 'HP_0001919', 'EFO_0000673',
       'MONDO_0001187', 'EFO_0005044', 'EFO_0007294', 'EFO_0003756',
       'EFO_0001378', 'EFO_0003060', 'EFO_1000158', 'EFO_1001951'],
      dtype=object), 'count': 16}",[ENSG00000113578],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.
CHEMBL3039513,CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F,ASUGUQWIHMTFJL-QGZVFWFLSA-N,Small molecule,False,DECERNOTINIB,,2.0,,False,False,[],['Adelatinib' 'Decernotinib' 'VRT-831509' 'VX-509'],"[('drugbank', array(['DB12566'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000105639],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3187246,CN(C)CCN(Cc1cccs1)c1ccccn1.CN(C)CCN(Cc1cccs1)c1ccccn1.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O,OLGIEIJNOQGBSS-VQYXCCSOSA-N,Small molecule,False,METHAPYRILENE FUMARATE,,4.0,CHEMBL1411979,True,True,[],['Methapyrilene fumarate'],"[('PubChem', array(['144213936'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL345524,O=C(OCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1ccccc1Nc1ccnc2cc(C(F)(F)F)ccc12,NWGGKKGAFZIVBJ-UHFFFAOYSA-N,Small molecule,False,ANTRAFENINE,,4.0,,True,True,[],['Antrafenine'],"[('Wikipedia', array(['Antrafenine'], dtype=object)), ('drugbank', array(['DB01419'], dtype=object))]",,,[ENSG00000107317],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL3544913,NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1,JESCETIFNOFKEU-SJORKVTESA-N,Small molecule,False,VIXOTRIGINE,,3.0,,False,False,[],"['BIIB-074' 'BIIB074' 'CNV-1014802' 'CNV1014802' 'GSK-1014802'
 'GSK1014802' 'Raxatrigine' 'Vixotrigine']","[('drugbank', array(['DB11706'], dtype=object))]",['CHEMBL3544912'],"{'rows': array(['MONDO_0004985', 'MONDO_0016028', 'MONDO_0002959', 'EFO_1001219',
       'EFO_1000783', 'EFO_0005762'], dtype=object), 'count': 6}",[ENSG00000169432],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3545154,C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1,LPFWVDIFUFFKJU-UHFFFAOYSA-N,Small molecule,False,POZIOTINIB,,3.0,,False,False,[],"['HM 781-36' 'HM 781-36B' 'HM-781-36' 'HM-781-36B' 'HM781-36B'
 'Hm-781-36b' 'NOV-1201' 'NOV-120101' 'Poziotinib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/POZIOTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12114'], dtype=object))]",['CHEMBL5095402'],"{'rows': array(['EFO_0000616', 'MONDO_0001056', 'EFO_0004284', 'EFO_0005922',
       'MONDO_0007254', 'EFO_0003060', 'EFO_0000571', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 9}","[ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL3545199,,,Small molecule,False,RG-7741,,1.0,,False,False,[],['GDC-0575' 'Rg-7741'],,,"{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}",[ENSG00000149554],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3639728,COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1,NSMOZFXKTHCPTQ-UHFFFAOYSA-N,Small molecule,False,PLX-5622,,1.0,,False,False,[],['PLX-5622' 'PLX5622' 'Plx-5622'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000182578],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989510,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C.Cl,OQGYMIIFOSJQSF-UHFFFAOYSA-N,Small molecule,False,PENTAZOCINE HYDROCHLORIDE,1969.0,4.0,CHEMBL100116,False,True,['Sosegon' 'Talwin 50'],['Pentazocine hcl' 'Pentazocine hydrochloride'],,,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000147955],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969 and is indicated for pain.
CHEMBL4112930,C[C@]12CCCN1CC1=NNC(=O)c3cc(F)cc4[nH]c2c1c34,DENYZIUJOTUUNY-MRXNPFEDSA-N,Small molecule,False,PAMIPARIB,,3.0,,False,False,[],['BGB-290' 'Bgb-290' 'Pamiparib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PAMIPARIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14769'], dtype=object))]",,"{'rows': array(['EFO_0000181', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0001056',
       'EFO_0003060', 'EFO_1000158', 'MONDO_0004992', 'MONDO_0007254',
       'MONDO_0003060', 'EFO_0000702', 'EFO_0000616', 'EFO_0000519'],
      dtype=object), 'count': 12}","[ENSG00000143799,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL4297556,,,Unknown,False,MM-111,,2.0,,False,False,[],['Mm 111' 'Mm-111'],,,"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}","[ENSG00000141736,ENSG00000065361]",Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297831,,,Antibody,False,SPARTALIZUMAB,,3.0,,False,False,[],"['ANTI-PD1 MONOCLONAL ANTIBODY PDR001' 'NVP-LZV184' 'PDR-001' 'PDR001'
 'Pdr001' 'Spartalizumab']",,,"{'rows': array(['EFO_0000389', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000756',
       'MONDO_0005184', 'EFO_0005537', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0000681', 'MONDO_0011719', 'EFO_0000181', 'EFO_0003060',
       'MONDO_0001056', 'EFO_0005922', 'MONDO_0008903', 'EFO_0000182',
       'EFO_0004252', 'EFO_0000574', 'MONDO_0002120'], dtype=object), 'count': 19}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.
CHEMBL4297844,,,Antibody drug conjugate,True,TRASTUZUMAB DERUXTECAN,2019.0,4.0,,False,True,['Enhertu'],"['DS-8201' 'DS-8201a' 'Ds-8201a' 'Trastuzumab deruxtecan'
 'Trastuzumab deruxtecan nxki' 'Trastuzumab deruxtecan-nxki']","[('DailyMed', array(['fam-trastuzumab%20deruxtecan-nxki'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu'],
      dtype=object))]",,"{'rows': array(['EFO_0003869', 'EFO_0003060', 'EFO_0000616', 'EFO_0004142',
       'MONDO_0005575', 'EFO_0008549', 'EFO_1001951', 'EFO_0000503',
       'EFO_1000984', 'MONDO_0007254', 'EFO_0009708', 'EFO_0000637',
       'EFO_0000305', 'MONDO_0001056', 'MONDO_0004992'], dtype=object), 'count': 15}","[ENSG00000198900,ENSG00000141736]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297986,,,Unknown,False,COAGULATION FACTOR IX HUMAN,2001.0,4.0,,False,True,['Nonafact'],['Coagulation factor ix human' 'Human coagulation factor ix'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nonafact'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}",[ENSG00000101981],Unknown drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for hemophilia b.
CHEMBL4298024,,,Protein,False,BINTRAFUSP ALFA,,3.0,,False,False,[],"['8L9YQ2N6PA' 'Bintrafusp alfa' 'M-7824' 'M7824' 'MSB-0011359C'
 'MSB0011359C' 'Msb0011359c']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BINTRAFUSP%20ALFA/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0001879', 'MONDO_0001325', 'EFO_0003869', 'EFO_0000196',
       'EFO_0000588', 'EFO_0000702', 'MONDO_0007254', 'MONDO_0002974',
       'EFO_1001968', 'MONDO_0001528', 'EFO_0000181', 'MONDO_0008315',
       'EFO_0003863', 'MONDO_0008903', 'EFO_1000581', 'EFO_0000305',
       'EFO_0000365', 'EFO_1001961', 'MONDO_0008170', 'EFO_0001416',
       'EFO_0005537', 'MONDO_0001056', 'EFO_0002618', 'EFO_0005221',
       'EFO_0000616', 'EFO_0003060', 'EFO_0002916', 'EFO_0001663',
       'MONDO_0001402', 'MONDO_0021063', 'EFO_1001931', 'EFO_0000558'],
      dtype=object), 'count': 32}","[ENSG00000120217,ENSG00000105329,ENSG00000092969,ENSG00000119699]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 32 investigational indications.
CHEMBL521,CC(C)Cc1ccc(C(C)C(=O)O)cc1,HEFNNWSXXWATRW-UHFFFAOYSA-N,Small molecule,True,IBUPROFEN,1974.0,4.0,,False,True,"['Aches-n-pain' 'Advil' 'Advil liqui-gels' 'Advil migraine liqui-gels'
 'Anadin joint pain' 'Anadin liquifast' 'Anadin period pain relief'
 'Anadin ultra' 'Apsifen' 'Apsifen-f' 'Arthrofen 200' 'Arthrofen 400'
 'Arthrofen 600' 'Brufen ret' 'Caldolor' 'Cap-profen' ""Children's advil""
 ""Children's advil-flavored"" ""Children's elixsure"" ""Children's ibuprofen""
 ""Children's motrin"" 'Co-op' 'Codafen continus' 'Cuprofen for child'
 'Cuprofen plus' 'Deep relief' 'Ebufac' 'Femafen' 'Fenbid' 'Fenbid fte'
 'Fenpaed' 'Feverfen' 'Fleximex' 'Ibu-slo' 'Ibu-tab' 'Ibu-tab 200'
 'Ibucalm' 'Ibuderm' 'Ibufac' 'Ibugel' 'Ibugel fte' 'Ibular' 'Ibuleve'
 'Ibumed' 'Ibumetin' 'Ibumousse' 'Ibuprin' 'Ibuprofen' 'Ibuprohm'
 'Ibuspray' 'Ibutime' 'Inabrin' ""Infant's advil"" 'Inoven' 'Isisfen'
 'Junifen' 'Junior strength advil' 'Junior strength ibuprofen'
 'Junior strength motrin' 'Lidifen' 'Lidifen-f' 'Lobufen' 'Mandafen'
 'Manorfen' 'Maxa-gesic' 'Medipren' 'Midol' 'Midol liquid gels' 'Migrafen'
 'Motrin' 'Motrin ib' 'Motrin migraine pain' 'Novaprin' 'Nuprin'
 'Nurofen 400' 'Nurofen back pain sr' 'Nurofen child' 'Nurofen for child'
 'Nurofen plus' 'Nurofen recovery' 'Nurofen sinus' 'Nurofen solb'
 'Orbifen' 'Pacifene' 'Paxofen' 'Pedea' 'Pediatric advil' 'Phensic'
 'Phor pain' 'Phorpain' 'Phorpain max strgh' 'Profen' 'Proflex'
 'Proflex sr' 'Relcofen' 'Rimafen' 'Rufen' 'Seclodin' 'Suspren'
 'Tab-profen']","['Burana' 'IB-100' 'IP-82' 'Ibuprofen' 'Ibuprofenum' 'M01AE01'
 'NSC-256857' 'RD 13621' 'U-18,573' 'U-18573']","[('Wikipedia', array(['Ibuprofen'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pedea'],
      dtype=object)), ('TG-GATEs', array(['72'], dtype=object)), ('PubChem', array(['104171175', '124880372', '124880375', '138460', '144203721',
       '144208582', '144213146', '170464979', '174007269', '26747223',
       '26747224', '26752326', '50105276', '50105277', '50105278',
       '56422436', '85231082', '855602', '90341584'], dtype=object)), ('DailyMed', array(['ibuprofen'], dtype=object)), ('drugbank', array(['DB01050'], dtype=object)), ('chEBI', array(['5855'], dtype=object))]","['CHEMBL4594450' 'CHEMBL5201530' 'CHEMBL1201141' 'CHEMBL3989408'
 'CHEMBL1241153']","{'rows': array(['EFO_0002609', 'EFO_0007328', 'EFO_0009582', 'EFO_1000652',
       'EFO_0003931', 'HP_0003326', 'MONDO_0002009', 'EFO_0000546',
       'HP_0012228', 'EFO_0003869', 'HP_0004398', 'EFO_0009615',
       'EFO_0005252', 'HP_0003419', 'EFO_0002970', 'MONDO_0004975',
       'HP_0002315', 'EFO_1001158', 'EFO_0000685', 'EFO_0009516',
       'EFO_0009846', 'EFO_0001068', 'EFO_0003917', 'EFO_1000632',
       'EFO_0000537', 'EFO_0005854', 'EFO_0003843', 'MONDO_0024290',
       'EFO_0006803', 'EFO_0005279', 'EFO_0003938', 'EFO_0007214',
       'HP_0001643', 'EFO_0000649', 'EFO_0004263', 'EFO_0003918',
       'EFO_0003843', 'EFO_0004209', 'MONDO_0002367', 'EFO_0003958',
       'HP_0001945', 'HP_0100543', 'EFO_0010072', 'EFO_0003944',
       'EFO_0000706', 'EFO_0004616', 'EFO_0005856', 'MONDO_0007254',
       'EFO_1000843', 'EFO_0000464', 'MONDO_0019091', 'EFO_1000637',
       'EFO_1001139', 'MONDO_0005301', 'MP_0001914', 'HP_0012532',
       'EFO_0000544', 'MONDO_0005147', 'EFO_0006834', 'EFO_0000668',
       'MONDO_0005277', 'EFO_0003843', 'HP_0030833', 'MONDO_0010679',
       'HP_0003418', 'EFO_0005755', 'HP_0001643', 'EFO_1000782',
       'EFO_0007486', 'EFO_0000764', 'EFO_1000854', 'MONDO_0005178',
       'MONDO_0100342', 'EFO_0009610', 'MONDO_0009291', 'MONDO_0002258',
       'EFO_1001216', 'EFO_0000319', 'EFO_0005757', 'HP_0100607',
       'MONDO_0018076', 'MONDO_0018305', 'HP_0002829'], dtype=object), 'count': 83}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 21 approved and 61 investigational indications. This drug has a black box warning from the FDA.
CHEMBL578390,CCCCCCCCC/C(=C\C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(=O)O,AALSSIXXBDPENJ-FYWRMAATSA-N,Small molecule,False,APX-3330,,2.0,,False,False,[],['APX 3330' 'APX-3330' 'APX3330' 'Apx-3330' 'Apx3330' 'E 3330' 'E-3330'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000100823],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL603,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,YEEZWCHGZNKEEK-UHFFFAOYSA-N,Small molecule,False,ZAFIRLUKAST,1996.0,4.0,,False,True,['Accolate' 'Zafirlukast'],"['ICI 204,219' 'ICI-204219' 'Ici-204,219' 'Zafirlukast']","[('DailyMed', array(['zafirlukast'], dtype=object)), ('PubChem', array(['144205729', '170464673', '26719823', '26757966', '49681658'],
      dtype=object)), ('Wikipedia', array(['Zafirlukast'], dtype=object)), ('drugbank', array(['DB00549'], dtype=object)), ('chEBI', array(['10100'], dtype=object))]",,"{'rows': array(['HP_0006536', 'MONDO_0007254', 'MONDO_0004979', 'MONDO_0008170'],
      dtype=object), 'count': 4}",[ENSG00000173198],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for airway obstruction and asthma and has 2 investigational indications.
CHEMBL1194,CCCNC(C)C(=O)Nc1ccccc1C,MVFGUOIZUNYYSO-UHFFFAOYSA-N,Small molecule,False,PRILOCAINE,1965.0,4.0,,False,True,[],"['ASTRA-1512' 'ASTRA-1515' 'Citanest' 'NSC-40027' 'Prilocaine'
 'Propitocaine']","[('DailyMed', array(['prilocaine'], dtype=object)), ('PubChem', array(['90341069'], dtype=object)), ('Wikipedia', array(['Prilocaine'], dtype=object)), ('drugbank', array(['DB00750'], dtype=object)), ('chEBI', array(['8404'], dtype=object))]",['CHEMBL1200586'],"{'rows': array(['MONDO_0041052', 'EFO_0002950', 'EFO_0000707', 'EFO_0003843',
       'HP_0012532', 'EFO_0803321', 'EFO_0002496', 'EFO_0000701'],
      dtype=object), 'count': 8}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for pain and has 7 investigational indications.
CHEMBL1201236,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,TZFNLOMSOLWIDK-JTQLQIEISA-N,Small molecule,False,CARBIDOPA ANHYDROUS,1975.0,4.0,,False,True,[],"['Carbidopa, l- anhydrous']","[('PubChem', array(['11113507', '144204461', '26749935', '29215028', '50104417',
       '50104418', '8139862', '93576631'], dtype=object)), ('Wikipedia', array(['Carbidopa'], dtype=object)), ('drugbank', array(['DB00190'], dtype=object)), ('chEBI', array(['39585'], dtype=object))]",['CHEMBL1200748'],"{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0003770', 'EFO_1001402',
       'EFO_0002610', 'Orphanet_1764', 'EFO_0000546', 'EFO_0003768',
       'MONDO_0018910', 'MONDO_0005301', 'MONDO_0007113', 'HP_0002381',
       'EFO_0005252', 'EFO_0005687', 'MONDO_0004979', 'HP_0012532',
       'MONDO_0005180', 'HP_0003418', 'EFO_0000537', 'MONDO_0019200',
       'MONDO_0005090', 'EFO_0003888', 'MONDO_0001020', 'EFO_1001175',
       'EFO_0003843', 'MONDO_0004976', 'EFO_0001365'], dtype=object), 'count': 27}",[ENSG00000132437],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 23 investigational indications.
CHEMBL1201608,,,Antibody,True,MUROMONAB-CD3,1986.0,4.0,,False,True,['Orthoclone okt3'],"['Anticd3' 'L04AA02' 'Macs gmp cd3 pure' 'Muromomab' 'Muromonab'
 'Muromonab cd3' 'Muromonab-cd3' 'OKT-3' 'OKT3']","[('DrugCentral', array(['5177'], dtype=object)), ('Wikipedia', array(['Muromonab-CD3'], dtype=object))]",,"{'rows': array(['MONDO_0002367', 'MONDO_0004992', 'EFO_0000756', 'EFO_0000616',
       'EFO_0000389', 'EFO_0000540', 'EFO_1000158', 'EFO_1001249',
       'EFO_0003865', 'EFO_0000729'], dtype=object), 'count': 10}","[ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for immune system disease and has 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201759,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1,UDGHXQPQKQPSBB-BOXHHOBZSA-N,Small molecule,False,BEPOTASTINE BESYLATE,2009.0,4.0,CHEMBL1201758,False,True,['Bepreve'],"['BB' 'Bepotastine Besilate' 'Bepotastine benzenesulfonate salt'
 'Bepotastine besilate' 'Bepotastine besylate' 'TAU-284' 'Talion']","[('DailyMed', array(['bepotastine%20besilate'], dtype=object)), ('chEBI', array(['31281'], dtype=object))]",,"{'rows': array(['EFO_1001417', 'EFO_0007141', 'HP_0000989'], dtype=object), 'count': 3}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for allergic conjunctivitis and pruritus and has 1 investigational indication.
CHEMBL1770248,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,MCIACXAZCBVDEE-CUUWFGFTSA-N,Small molecule,False,ERTUGLIFLOZIN,2017.0,4.0,,False,True,['Steglatro'],"['Ertugliflozin' 'MK-8835' 'PF-04971729' 'PF-04971729-00' 'PF04971729'
 'Pf-04971729']","[('DailyMed', array(['ertugliflozin'], dtype=object)), ('drugbank', array(['DB11827'], dtype=object))]",['CHEMBL3526992' 'CHEMBL5315054'],"{'rows': array(['MONDO_0005148', 'MONDO_0005148', 'EFO_0000400', 'EFO_0003144'],
      dtype=object), 'count': 4}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 1 investigational indication.
CHEMBL2103825,CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1,MVCQKIKWYUURMU-UHFFFAOYSA-N,Small molecule,False,CETILISTAT,,2.0,,False,False,[],['ATL-962' 'Cetilistat'],"[('drugbank', array(['DB06586'], dtype=object))]",,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000182333,ENSG00000175535]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2105629,CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,YIHUEPHBPPAAHH-PEPODRRYSA-N,Small molecule,False,VINFLUNINE DITARTRATE,2009.0,4.0,CHEMBL2110725,False,True,['Javlor'],"['BMS-710485' 'F-12158' 'Vinflunine bitartrate' 'Vinflunine ditartrate'
 'Vinflunine tartrate']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/javlor'],
      dtype=object))]",,,"[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009.
CHEMBL2108720,,,Antibody,False,OXELUMAB,,2.0,,False,False,[],"['HUMAB OX-40L' 'HUMAB OX40L' 'Humab ox 40l' 'Oxelumab' 'R-4930'
 'R-4930 HUMAB OX40L' 'R-4930 HUMABOX40L' 'R4930' 'RO-49-89991'
 'RO-4989991' 'RO4989991']",,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000117586],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109485,,,Antibody,False,ONCOLYSIN CD6,,2.0,,False,False,[],['ONCOLYSIN CD6'],,,,[ENSG00000013725],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2386889,Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,GMIZZEXBPRLVIV-SECBINFHSA-N,Small molecule,False,SCH-900776,,2.0,,False,False,[],['MK-8776' 'Mk-8776' 'SCH 900776' 'SCH-900776' 'Sch-900776'],"[('drugbank', array(['DB11899'], dtype=object))]",,"{'rows': array(['EFO_0000183', 'EFO_0000220', 'EFO_0000222', 'EFO_0000339',
       'EFO_0005952'], dtype=object), 'count': 5}",[ENSG00000149554],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL332750,CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,XDBHURGONHZNJF-UHFFFAOYSA-N,Small molecule,False,TETOMILAST,,3.0,,False,False,[],['OPC-6535' 'Tetomilast'],"[('drugbank', array(['DB05298'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'EFO_0000729', 'EFO_0000384'], dtype=object), 'count': 3}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3544989,,,Oligonucleotide,False,VOLANESORSEN SODIUM,2019.0,4.0,,False,True,['Waylivra'],"['ISIS 304801' 'ISIS 304801 SODIUM SALT' 'ISIS-304801 SODIUM'
 'ISIS-304801 SODIUM SALT' 'Volanesorsen sodium' 'salt']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/waylivra'],
      dtype=object))]",,"{'rows': array(['EFO_1000727', 'MONDO_0009387'], dtype=object), 'count': 2}",[ENSG00000110245],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for familial lipoprotein lipase deficiency and has 1 investigational indication.
CHEMBL3642985,Cc1nc(C#Cc2ccc(-c3cc(F)cc(C#N)c3)nc2)cs1,SYOSUEIMOYEGKU-UHFFFAOYSA-N,Small molecule,False,STX107,,2.0,,False,False,[],['Stx107'],,,"{'rows': array(['MONDO_0010383'], dtype=object), 'count': 1}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL373742,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,KBZOIRJILGZLEJ-LGYYRGKSSA-N,Protein,False,VASOPRESSIN,2014.0,4.0,,False,True,['Beta-Hypophamine' 'Leiormone' 'Pitressin' 'Vasophysin' 'Vasostrict'],"['Arginine Vasopressin' 'Arginine vasopressin' 'Argipressin or lypressin'
 'Vasopressin' 'Vasopressin injection' 'Vasopressin, unspecified']","[('DailyMed', array(['vasopressin'], dtype=object)), ('PubChem', array(['144206588', '29218064'], dtype=object)), ('chEBI', array(['34543'], dtype=object))]",['CHEMBL2360839'],"{'rows': array(['MONDO_0003061', 'EFO_0003756', 'EFO_1001255', 'EFO_0003843',
       'EFO_0009637', 'MONDO_0001572', 'EFO_0004610', 'EFO_0003758',
       'MONDO_0002009', 'MONDO_0005149', 'EFO_0004278', 'EFO_0006834',
       'EFO_0003777', 'EFO_0005251', 'EFO_0009492', 'MONDO_0004782',
       'EFO_0005207', 'HP_0031273', 'HP_0100806'], dtype=object), 'count': 19}","[ENSG00000126895,ENSG00000166148,ENSG00000198049]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for diabetes insipidus and sepsis and has 17 investigational indications.
CHEMBL3989566,COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)/C=C/C(=O)O,BRIPGNJWPCKDQZ-WXXKFALUSA-N,Small molecule,False,METOPROLOL FUMARATE,1989.0,4.0,CHEMBL13,False,True,['Lopressor' 'Metoros' 'Metoros ls'],['CGP 2175C' 'CGP-2175C' 'Metoprolol fumarate'],,,,[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989.
CHEMBL3991932,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1,LNMRSSIMGCDUTP-UHFFFAOYSA-N,Small molecule,False,PEXMETINIB,,2.0,,False,False,[],['ARRY-614' 'Arry-614' 'Pexmetinib'],,,"{'rows': array(['EFO_0000198'], dtype=object), 'count': 1}","[ENSG00000112062,ENSG00000120156]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297830,,,Protein,False,SOMATROGON,2022.0,4.0,,False,True,['Ngenla'],"['Ctp-somatropin fusion protein' 'MOD-4023' 'MOD4023' 'Mod-4023'
 'Somatrogon' 'Somatropin-ctp fusion protein']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla'],
      dtype=object))]",,"{'rows': array(['EFO_1001109'], dtype=object), 'count': 1}",[ENSG00000112964],Protein drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for pituitary dwarfism.
CHEMBL4298088,,,Antibody drug conjugate,False,CETUXIMAB SAROTALOCAN,,2.0,,False,False,[],"['ASP-1929' 'Cetuximab sarotalocan' 'Cetuximab sarotalocan sodium'
 'Cetuximab-IRDye-700DX' 'Cetuximab-irdye 700dx conjugate' 'RM-1929']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CETUXIMAB%20SAROTALOCAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000146648],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298119,,,Antibody,False,OLINVACIMAB,,2.0,,False,False,[],['Olinvacimab' 'TTAC-0001' 'Tanibirumab' 'Ttac-0001'],,,"{'rows': array(['EFO_0005537', 'MONDO_0007254', 'EFO_0000519'], dtype=object), 'count': 3}",[ENSG00000128052],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL447955,C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,FLNYCRJBCNNHRH-OIYLJQICSA-N,Small molecule,False,SERLOPITANT,,3.0,,False,False,[],['MK-0594' 'Serlopitant' 'VPD-737' 'Vpd-737'],"[('drugbank', array(['DB12973'], dtype=object))]",,"{'rows': array(['HP_0000989', 'EFO_1000690'], dtype=object), 'count': 2}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4594565,,,Protein,False,PABINAFUSP ALFA,,3.0,,False,False,[],['JR-141' 'JR141' 'Jr-141' 'Pabinafusp alfa'],,,"{'rows': array(['MONDO_0010674'], dtype=object), 'count': 1}","[ENSG00000072274,ENSG00000106327]",Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4650298,,,Unknown,False,PLB1003,,1.0,,False,False,[],['PLB1003' 'Plb1003'],,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}","[ENSG00000171094,ENSG00000143924]",Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL59,NCCc1ccc(O)c(O)c1,VYFYYTLLBUKUHU-UHFFFAOYSA-N,Small molecule,False,DOPAMINE,,4.0,,False,True,[],"['A-dopamine' 'Dobutamine a' 'Dopamine' 'Intropin' 'Medopa' 'NSC-173182'
 'Oxytyramine']","[('PubChem', array(['104171172', '11111282', '124880336', '124880337', '124880340',
       '144203718', '170464942', '26750067', '26753786', '26753787',
       '50107800', '57288369', '90341661'], dtype=object)), ('Wikipedia', array(['Dopamine'], dtype=object)), ('drugbank', array(['DB00988'], dtype=object)), ('chEBI', array(['18243'], dtype=object))]",['CHEMBL3247442' 'CHEMBL1557'],"{'rows': array(['EFO_0000400', 'EFO_0005207', 'EFO_0003917', 'EFO_0006834',
       'MONDO_0002050', 'EFO_0003144', 'MONDO_0005180', 'EFO_0000612',
       'HP_0031273', 'MONDO_0005180', 'EFO_0000373', 'HP_0100543',
       'EFO_0000319', 'EFO_1002048'], dtype=object), 'count': 14}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 9 investigational indications.
CHEMBL657,CN(C)CCOC(c1ccccc1)c1ccccc1,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,Small molecule,False,DIPHENHYDRAMINE,1946.0,4.0,,False,True,[],"['Antitussive' 'Beldin' 'Belix' 'Benadryl' 'Benylin' 'Dibenil' 'Diphen'
 'Diphenhdyra' 'Diphenhydramine' 'Hydramine' 'Restamin' 'Silphen']","[('PubChem', array(['104171144', '11111059', '11111060', '124879862', '124879863',
       '144203678', '170466857', '26751623', '50100219', '50104292',
       '85148365', '90341811'], dtype=object)), ('Wikipedia', array(['Diphenhydramine'], dtype=object)), ('drugbank', array(['DB01075'], dtype=object)), ('chEBI', array(['4636'], dtype=object))]",['CHEMBL1620' 'CHEMBL1201089'],"{'rows': array(['MONDO_0005271', 'MONDO_0007915', 'EFO_0005592', 'EFO_0000220',
       'MONDO_0011962', 'EFO_0000384', 'MONDO_0005277', 'EFO_0005761',
       'MONDO_0002009', 'MONDO_0007915', 'Orphanet_365', 'EFO_0005252',
       'EFO_1000783', 'EFO_0004270', 'EFO_0000540', 'EFO_0000616',
       'MP_0001845', 'EFO_0005761', 'Orphanet_60', 'EFO_0003086',
       'EFO_0003758', 'MONDO_0002367', 'EFO_0000403', 'EFO_0000574',
       'HP_0002013', 'EFO_0005230', 'HP_0000989', 'EFO_0006890',
       'EFO_0003958', 'EFO_0004698', 'EFO_0009688', 'EFO_0000095',
       'EFO_0004239', 'EFO_0008521', 'HP_0001742', 'EFO_0000222',
       'EFO_0005531', 'EFO_1000657', 'HP_0001945', 'EFO_0003938',
       'EFO_0009104', 'MONDO_0008903', 'EFO_0005854', 'EFO_0004599',
       'EFO_0001378', 'MONDO_0001056', 'MONDO_0007254', 'HP_0012735',
       'MONDO_0005271', 'MONDO_0008315', 'EFO_0003060', 'EFO_0006928',
       'MONDO_0007079', 'EFO_0004255', 'EFO_0000198', 'MONDO_0002050',
       'EFO_0009516', 'EFO_1001904', 'HP_0002017', 'EFO_0007160',
       'HP_0002018', 'HP_0002315', 'EFO_0000701', 'HP_0000726',
       'EFO_0009847', 'MONDO_0002258', 'EFO_0002610', 'EFO_0000403',
       'EFO_0000096', 'EFO_0000681', 'MONDO_0004658', 'MONDO_0004992',
       'MONDO_0005090', 'EFO_0003843', 'HP_0000989', 'EFO_0007359',
       'MONDO_0044917', 'EFO_0005952', 'MONDO_0017287', 'EFO_0000274',
       'EFO_0007214', 'EFO_0003956', 'EFO_0008520', 'EFO_0003843',
       'HP_0012735'], dtype=object), 'count': 85}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 19 approved and 63 investigational indications.
CHEMBL1172,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,JAUOIFJMECXRGI-UHFFFAOYSA-N,Small molecule,False,DESLORATADINE,2001.0,4.0,,False,True,['Aerius' 'Clarinex' 'Desloratadine' 'Midetorin' 'Neoclarityn'],"['Allex' 'Azomyr' 'Dasselta' 'Denosin' 'Descarboethoxyloratadine'
 'Desloratadine' 'Desloratadine actavis' 'Desloratadine teva'
 'Loratadine related compound a' 'Loratadine related compound a rs'
 'NSC-759824' 'Opulis' 'SCH 34117' 'SCH-34117']","[('DailyMed', array(['desloratadine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn'],
      dtype=object)), ('PubChem', array(['144205127', '14742700', '170464781', '26719697', '26754458',
       '29215232', '50086379'], dtype=object)), ('Wikipedia', array(['Desloratadine'], dtype=object)), ('drugbank', array(['DB00967'], dtype=object)), ('chEBI', array(['291342'], dtype=object))]",,"{'rows': array(['EFO_0003956', 'EFO_0007214', 'EFO_0005854', 'MONDO_0002406',
       'EFO_0007141', 'HP_0000989', 'HP_0000964', 'MONDO_0005271',
       'EFO_0003060', 'EFO_1001417', 'EFO_0005531', 'EFO_0008520',
       'Orphanet_79292', 'EFO_0000274'], dtype=object), 'count': 14}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 9 investigational indications.
CHEMBL1200490,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,SBNPWPIBESPSIF-MHWMIDJBSA-N,Protein,False,CETRORELIX,1999.0,4.0,,False,True,['Cetrotide'],['Cetrorelix'],"[('Wikipedia', array(['Cetrorelix'], dtype=object)), ('drugbank', array(['DB00050'], dtype=object)), ('chEBI', array(['59224'], dtype=object))]",['CHEMBL2103735'],"{'rows': array(['EFO_0000545', 'MONDO_0011972', 'EFO_0000685', 'EFO_0001065',
       'EFO_0000284', 'EFO_0000545', 'EFO_0000660'], dtype=object), 'count': 7}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 7 investigational indications.
CHEMBL1200782,C[C@H](N)Cc1ccccc1.O=C(O)CCCCC(=O)O,OFCJKOOVFDGTLY-QRPNPIFTSA-N,Small molecule,False,DEXTROAMPHETAMINE ADIPATE,1975.0,4.0,CHEMBL612,False,True,[],['D-amphetamine adipate' 'Dextroamphetamine adipate'],,,,"[ENSG00000142319,ENSG00000103546,ENSG00000165646]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975.
CHEMBL1200978,O=[As]O[As]=O,IKWTVSLWAPBBKU-UHFFFAOYSA-N,Small molecule,True,ARSENIC TRIOXIDE,2000.0,4.0,,False,True,['Arsenic trioxide mylan' 'Trisenox'],"['Arseneous anhydride' 'Arseneous oxide' 'Arsenic oxide'
 'Arsenic oxide (as4o6)' 'Arsenic sesquioxide' 'Arsenic trioxide'
 'Arsenicum album' 'Arsenous oxide' 'Diarsenic trioxide' 'NSC-759274'
 'NSC-92859' 'Tetraarsenic hexaoxide' 'White arsenic']","[('DailyMed', array(['arsenic%20trioxide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-mylan'],
      dtype=object)), ('PubChem', array(['26758061'], dtype=object)), ('Wikipedia', array(['Arsenic_trioxide'], dtype=object)), ('drugbank', array(['DB01169'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'EFO_1001512', 'EFO_0003060', 'EFO_0000479',
       'MONDO_0002974', 'EFO_0000339', 'MONDO_0020547', 'EFO_0000222',
       'EFO_0002429', 'MONDO_0004992', 'EFO_1001951', 'EFO_1000158',
       'EFO_0000095', 'MONDO_0008627', 'MONDO_0007254', 'EFO_0000565',
       'EFO_0000616', 'EFO_0000765', 'EFO_0000224', 'EFO_1001465',
       'EFO_0000702', 'MONDO_0007915', 'EFO_0000574', 'MONDO_0002367',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_0000621', 'MONDO_0002691',
       'EFO_0001378', 'EFO_0002430', 'MONDO_0044903', 'EFO_0002617',
       'MONDO_0004192', 'MONDO_0004986', 'EFO_0002618', 'EFO_0000198',
       'MONDO_0005341', 'MONDO_0001657'], dtype=object), 'count': 38}",[ENSG00000198431],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 35 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201325,C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1,ZRYHPQCHHOKSMD-UHFFFAOYSA-N,Small molecule,False,HEXOCYCLIUM,1982.0,4.0,,False,True,[],['Hexocyclium' 'Hexocyclium cation' 'Hexocyclium ion'],"[('Wikipedia', array(['Hexocyclium'], dtype=object)), ('drugbank', array(['DB06787'], dtype=object)), ('chEBI', array(['5707'], dtype=object))]",['CHEMBL1626570'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease.
CHEMBL190412,COCCOCCOCCOCCOC(=O)OC[n+]1ccc(N/C(=N/C#N)NCCCCCCOc2ccc(Cl)cc2)cc1.[Cl-],DAHMXVAETAAQOZ-UHFFFAOYSA-N,Small molecule,False,TEGLARINAD CHLORIDE,,2.0,CHEMBL1181731,False,False,[],['EB-1627' 'EB1627' 'GMX-1777' 'GMX1777' 'Teglarinad chloride'],,,"{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}",[ENSG00000105835],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2017974,Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,CWHUFRVAEUJCEF-UHFFFAOYSA-N,Small molecule,False,BUPARLISIB,,3.0,,False,False,[],"['BKM-120' 'BKM-120NX' 'BKM120-NX' 'Bkm-120' 'Buparlisib' 'NVP-BKM-120'
 'NVP-BKM120']","[('PubChem', array(['137275918'], dtype=object)), ('drugbank', array(['DB11666'], dtype=object)), ('chEBI', array(['71954'], dtype=object))]",['CHEMBL2364604'],"{'rows': array(['EFO_1000581', 'MONDO_0044903', 'EFO_0000519', 'EFO_0000403',
       'EFO_0000565', 'EFO_0000702', 'EFO_0003060', 'EFO_0000095',
       'MONDO_0018906', 'MONDO_0008903', 'MONDO_0011719', 'MONDO_0007576',
       'MONDO_0007254', 'EFO_0006859', 'MONDO_0002108', 'EFO_0001421',
       'EFO_1001469', 'EFO_0003086', 'EFO_1001951', 'EFO_0000756',
       'EFO_0000616', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0002974',
       'EFO_0000181', 'MONDO_0008315'], dtype=object), 'count': 26}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.
CHEMBL2105741,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1.C[S+](C)[O-],OQUFJVRYDFIQBW-UHFFFAOYSA-N,Small molecule,False,TRAMETINIB DIMETHYL SULFOXIDE,2013.0,4.0,,False,True,['Mekinist'],['GSK-1120212B' 'GSK1120212B' 'Trametinib dimethyl sulfoxide'],"[('DailyMed', array(['trametinib%20dimethyl%20sulfoxide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist'],
      dtype=object)), ('chEBI', array(['75991'], dtype=object))]",,"{'rows': array(['EFO_0002617', 'MONDO_0004992', 'MONDO_0002108', 'EFO_1000926',
       'MONDO_0008903', 'EFO_0001378', 'EFO_0000389'], dtype=object), 'count': 7}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 3 investigational indications.
CHEMBL2108292,,,Protein,False,EPTACOG ALFA PEGOL (ACTIVATED),,2.0,,False,False,[],"['Activated recombinant human factor vii, long acting'
 'Eptacog alfa pegol (activated)']",,,"{'rows': array(['MONDO_0010604', 'MONDO_0010602'], dtype=object), 'count': 2}",[ENSG00000057593],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109467,,,Antibody,False,ORDESEKIMAB,,2.0,,False,False,[],"['AMG 714' 'AMG-714' 'AMG714' 'Amg 714' 'HuMax-IL-15' 'Humax il15'
 'Humax-il 15' 'MAb146B7' 'Ordesekimab' 'PRV-015' 'Prv-015']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ORDESEKIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_0004208', 'EFO_0001060', 'EFO_0000685',
       'EFO_0005809'], dtype=object), 'count': 5}",[ENSG00000164136],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2110731,CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1,VWVKUNOPTJGDOB-BDHVOXNPSA-N,Small molecule,False,TOFOGLIFLOZIN ANHYDROUS,2014.0,4.0,,False,True,[],['CSG-452' 'R-7201' 'RO-4998452' 'RO4998452'],"[('drugbank', array(['DB11824'], dtype=object))]",['CHEMBL2105711'],"{'rows': array(['MONDO_0005148', 'EFO_1001249'], dtype=object), 'count': 2}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 2 investigational indications.
CHEMBL289480,C1COC(NC(C2CC2)C2CC2)=N1,CQXADFVORZEARL-UHFFFAOYSA-N,Small molecule,False,RILMENIDINE,1987.0,4.0,,False,True,[],['Hyperium' 'Rilmenidine'],"[('PubChem', array(['104171229', '11111726', '11111727', '11113329', '124881316',
       '144203805', '170466278', '50103956', '510678', '85231209',
       '90340708'], dtype=object)), ('Wikipedia', array(['Rilmenidine'], dtype=object)), ('drugbank', array(['DB11738'], dtype=object)), ('chEBI', array(['8862'], dtype=object))]",['CHEMBL1256674'],"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}",[ENSG00000010322],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and has 1 investigational indication.
CHEMBL398338,CC(C)(C)c1ccc2c(c1)CC[C@H]2NC(=O)Nc1cccc2[nH]ncc12,TYOYXJNGINZFET-GOSISDBHSA-N,Small molecule,False,ABT-102,,1.0,,False,False,[],['ABT-102' 'Abt-102'],,,,[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4297460,CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC,QDZOBXFRIVOQBR-LJQANCHMSA-N,Small molecule,False,DOVRAMILAST,,2.0,,False,False,[],['CC-11050' 'CC11050' 'Cc-11050' 'Dovramilast'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['MONDO_0018076', 'EFO_0003834'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297537,,,Oligonucleotide,True,INOTERSEN SODIUM,2018.0,4.0,,False,True,['Tegsedi'],[],"[('DailyMed', array(['inotersen%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi'],
      dtype=object))]",,"{'rows': array(['EFO_0004129', 'EFO_1001875', 'EFO_0009562'], dtype=object), 'count': 3}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL4297862,,,Protein,True,BOTULINUM TOXIN TYPE A,2019.0,4.0,,False,True,['Nuceiva'],"['Agn-151607' 'Ant-1401' 'Ant-1403' 'Botulift' 'Botulinum a toxin'
 'Botulinum toxin type a' 'Btx-a' 'Cunox' 'Neuronox' 'RTI-150' 'RTI150']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nuceiva'],
      dtype=object))]",,"{'rows': array(['Orphanet_93955', 'EFO_0009846', 'HP_0000473', 'MONDO_0005277',
       'HP_0000975', 'EFO_1000781', 'EFO_0005422', 'EFO_0006865',
       'EFO_1000999'], dtype=object), 'count': 9}",[ENSG00000132639],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4298191,,,Antibody,False,SASANLIMAB,,3.0,,False,False,[],['PF-06801591' 'RN-888' 'Sasanlimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SASANLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0008528', 'MONDO_0001187', 'EFO_0000616',
       'EFO_0000673', 'EFO_0009708'], dtype=object), 'count': 6}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL53,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,VMWNQDUVQKEIOC-CYBMUJFWSA-N,Small molecule,False,APOMORPHINE,2001.0,4.0,,False,True,[],"['6a.beta.-aporphine-10,11-diol' 'APL-130277' 'Apomorphine' 'Apomorphinum'
 'VR-040' 'VR040']","[('PubChem', array(['11114270', '144204518', '170465297', '26752261'], dtype=object)), ('Wikipedia', array(['Apomorphine'], dtype=object)), ('drugbank', array(['DB00714'], dtype=object)), ('chEBI', array(['48538'], dtype=object))]",['CHEMBL3187985' 'CHEMBL1256708' 'CHEMBL1616' 'CHEMBL5314363'],"{'rows': array(['EFO_0004234', 'HP_0000802', 'MONDO_0005180', 'MONDO_0005180',
       'MONDO_0007079', 'EFO_0000616', 'MONDO_0043510', 'HP_0000738',
       'EFO_0003882'], dtype=object), 'count': 9}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 5 investigational indications.
CHEMBL1200430,CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,FHXBMXJMKMWVRG-SLHNCBLASA-N,Small molecule,True,ESTRADIOL ACETATE,2003.0,4.0,,False,True,['Femring' 'Femtrace'],['E3A' 'ESTRADIOL-3-ACETATE' 'Estradiol 3-acetate' 'Estradiol acetate'],"[('DailyMed', array(['estradiol%20acetate'], dtype=object)), ('PubChem', array(['144204912', '170465258'], dtype=object)), ('drugbank', array(['DB13952'], dtype=object))]",,"{'rows': array(['EFO_1000096', 'GO_0042697'], dtype=object), 'count': 2}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for atrophy and menopause. This drug has a black box warning from the FDA.
CHEMBL1200733,FC(F)OC(F)C(F)(F)F,DPYMFVXJLLWWEU-UHFFFAOYSA-N,Small molecule,False,DESFLURANE,1992.0,4.0,,False,True,['Suprane'],['Desflurane' 'I-653'],"[('DailyMed', array(['desflurane'], dtype=object)), ('Wikipedia', array(['Desflurane'], dtype=object)), ('drugbank', array(['DB01189'], dtype=object)), ('chEBI', array(['4445'], dtype=object))]",,"{'rows': array(['EFO_0005323', 'EFO_1002048'], dtype=object), 'count': 2}","[ENSG00000169427,ENSG00000186795,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000171303,ENSG00000145888,ENSG00000109738,ENSG00000082482,ENSG00000100433]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 2 investigational indications.
CHEMBL1237065,COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,PPKXEPBICJTCRU-UHFFFAOYSA-N,Small molecule,True,TRAMADOL HYDROCHLORIDE,1995.0,4.0,CHEMBL1237044,False,True,"['Aceon' 'Conzip' 'Dromadol sr' 'Dromadol xl' 'Invodol sr' 'Larapam sr'
 'Mabron' 'Maneo' 'Marol' 'Maxitram sr' 'Nobligan ret' 'Oldaram' 'Qdolo'
 'Rybix odt' 'Ryzolt' 'Tilodol sr' 'Tradorec xl' 'Tramacet'
 'Tramadol hydrochloride' 'Tramake' 'Tramake insts' 'Tramquel sr'
 'Tramulief sr' 'Ultram' 'Ultram er' 'Zamadol' 'Zamadol 24hr'
 'Zamadol melt' 'Zamadol sr' 'Zeridame sr' 'Zydol' 'Zydol sr' 'Zydol xl']","['Amadol' 'CG-315' 'CG-315E' 'Contramal' 'NIH-10969' 'NSC-759105'
 'Tradonal' 'Tramadol hcl' 'Tramadol hydrochloride'
 'Tramadol hydrochloride civ' 'Tramal' 'U-26,225A' 'U-26225A' 'Zamudol'
 'Zertane']","[('DailyMed', array(['tramadol%20hydrochloride'], dtype=object))]",,"{'rows': array(['HP_0012532', 'EFO_0010072', 'HP_0003419', 'EFO_0803321',
       'EFO_0003843', 'EFO_0003890', 'MONDO_0004992'], dtype=object), 'count': 7}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1642,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,YLMAHDNUQAMNNX-UHFFFAOYSA-N,Small molecule,False,IMATINIB MESYLATE,2001.0,4.0,CHEMBL941,False,True,['Gleevec' 'Glivec' 'Imatinib accord' 'Imatinib mesylate'],"['Gleevec' 'Imatinib (as mesilate)' 'Imatinib accord' 'Imatinib medac'
 'Imatinib mesilate' 'Imatinib mesylate' 'Imatinib methane sulfonate'
 'Imatinib methanesulfonate' 'NSC-716051' 'QTI-571' 'QTI571' 'Qti571'
 'STI 571' 'STI-571' 'STI571']","[('DailyMed', array(['imatinib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord'],
      dtype=object)), ('PubChem', array(['144205237', '170465393', '49681833'], dtype=object)), ('chEBI', array(['31690'], dtype=object))]",,"{'rows': array(['EFO_0006861', 'EFO_0000389', 'MONDO_0008903', 'EFO_0000333',
       'EFO_0000768', 'EFO_0003060', 'EFO_0000760', 'EFO_1001361',
       'EFO_0004683', 'EFO_0001361', 'MONDO_0011934', 'MONDO_0000870',
       'MONDO_0004979', 'EFO_0006859', 'EFO_0000094', 'EFO_0005952',
       'EFO_0000616', 'EFO_0004198', 'MONDO_0011382', 'MONDO_0011719',
       'MONDO_0008315', 'EFO_0000339', 'EFO_0000717', 'EFO_0000220',
       'MONDO_0004992', 'MONDO_0002367', 'MONDO_0002087', 'EFO_1000158',
       'MONDO_0005301', 'EFO_0000519', 'MONDO_0018975', 'MONDO_0005147',
       'EFO_1001951', 'EFO_1001465', 'MONDO_0002108', 'MONDO_0011705',
       'MONDO_0002158', 'EFO_0000702', 'EFO_0002429', 'HP_0001880',
       'MONDO_0013730', 'EFO_0000588', 'EFO_0009907', 'EFO_1000729',
       'EFO_0000503', 'EFO_1001467', 'EFO_1001814', 'EFO_0000673',
       'EFO_0000658', 'EFO_1001993', 'MONDO_0021063', 'MONDO_0005149',
       'EFO_0002430', 'MONDO_0011962', 'MONDO_0009937', 'EFO_0000222',
       'EFO_0000691', 'MONDO_0008170', 'EFO_0001376', 'EFO_1000657',
       'MONDO_0044917', 'EFO_0002428', 'MONDO_0020547', 'MONDO_0100096',
       'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715', 'EFO_0000313',
       'EFO_0004289', 'MONDO_0000873', 'EFO_0000209', 'MONDO_0007254',
       'EFO_0000565', 'EFO_1000613', 'EFO_0000574', 'MONDO_0001056',
       'EFO_0000756', 'EFO_1001471'], dtype=object), 'count': 78}","[ENSG00000097007,ENSG00000186716,ENSG00000113721,ENSG00000157404]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for chronic myelogenous leukemia and has 77 investigational indications.
CHEMBL1743001,,,Antibody,False,CIXUTUMUMAB,,2.0,,False,False,[],['Cixutumumab' 'IMC-A12' 'NSC-742460'],,,"{'rows': array(['EFO_0000702', 'EFO_0003050', 'EFO_0000756', 'EFO_0000571',
       'MONDO_0008903', 'MONDO_0021063', 'EFO_1001951', 'EFO_0003060',
       'EFO_0000588', 'EFO_1001968', 'EFO_0000181', 'EFO_1000796',
       'EFO_1000657', 'MONDO_0008315', 'EFO_0006859', 'EFO_0002618',
       'EFO_0006861', 'EFO_0000437', 'EFO_0000637', 'MONDO_0007254',
       'EFO_0000182', 'EFO_0000673', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0000248', 'EFO_1000294'], dtype=object), 'count': 26}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 26 investigational indications.
CHEMBL1743072,,,Antibody,False,SOLANEZUMAB,,3.0,,False,False,[],['LY-2062430' 'LY2062430' 'Solanezumab'],,,"{'rows': array(['HP_0100543', 'MONDO_0004975'], dtype=object), 'count': 2}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1743077,,,Antibody,False,TENATUMOMAB,,2.0,,False,False,[],['ST-2146' 'Tenatumomab'],,,,[ENSG00000041982],Antibody drug with a maximum clinical trial phase of II.
CHEMBL1950651,COC(=O)N1CCC(CC#Cc2nc(N)c3ncn([C@@H]4O[C@H](C(=O)NC5CC5)[C@@H](O)[C@H]4O)c3n2)CC1,SQJXTUJMBYVDBB-RQXXJAGISA-N,Small molecule,False,EVODENOSON,,2.0,,False,False,"['Atl313, de-112']",['ATL-313' 'ATL313' 'Atl313' 'DE-112' 'Evodenoson'],"[('drugbank', array(['DB12295'], dtype=object))]",,"{'rows': array(['EFO_0004190', 'EFO_1001069'], dtype=object), 'count': 2}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2103826,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O,DWLTUUXCVGVRAV-XWRHUKJGSA-N,Protein,False,DAVUNETIDE,,2.0,,False,False,[],['AL-108' 'AL-208' 'Davunetide'],"[('drugbank', array(['DB12613'], dtype=object))]",,"{'rows': array(['HP_0100543', 'MONDO_0019037', 'MONDO_0005090'], dtype=object), 'count': 3}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2105527,CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21,IQWYAQCHYZHJOS-UHFFFAOYSA-N,Small molecule,False,TETRAZEPAM,,4.0,,True,True,[],['CB 4261' 'CB-4261' 'Myolastan' 'Tetrazepam'],"[('drugbank', array(['DB13324'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2109337,,,Antibody,False,MDX-1342,,1.0,,False,False,[],['MDX-1342' 'Mdx-1342'],,,"{'rows': array(['EFO_0000685', 'EFO_0000095'], dtype=object), 'count': 2}",[ENSG00000177455],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL218291,O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,IWKXDMQDITUYRK-KUBHLMPHSA-N,Small molecule,False,FORODESINE,,2.0,,False,False,[],['BCX-1777' 'Forodesine' 'Immucillin h' 'Mundesine' 'NSC-717904'],"[('Wikipedia', array(['Forodesine'], dtype=object)), ('drugbank', array(['DB06185'], dtype=object)), ('chEBI', array(['43362'], dtype=object))]",['CHEMBL550755' 'CHEMBL1213652'],"{'rows': array(['EFO_0000574', 'EFO_0002913', 'EFO_0000095', 'MONDO_0000430',
       'EFO_0000094', 'EFO_0000095', 'EFO_0000565', 'EFO_0004289',
       'EFO_0000574', 'MONDO_0004992'], dtype=object), 'count': 10}",[ENSG00000198805],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL292376,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1,ZVQUCWXZCKWZBP-CQSZACIVSA-N,Small molecule,False,TECALCET,,2.0,,False,False,[],['Tecalcet'],,['CHEMBL2107572'],,[ENSG00000036828],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3137332,Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F,GFPPXZDRVCSVNR-UHFFFAOYSA-N,Small molecule,False,FEVIPIPRANT,,3.0,,False,False,[],['Fevipiprant' 'NVP-QAW039' 'QAW-039' 'QAW039'],"[('drugbank', array(['DB12011'], dtype=object))]",,"{'rows': array(['HP_0000083', 'EFO_0005854', 'HP_0001880', 'EFO_1000391',
       'EFO_0001421', 'EFO_0000274', 'MONDO_0004979', 'EFO_0000341'],
      dtype=object), 'count': 8}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL388590,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,WHQCHUCQKNIQEC-UHFFFAOYSA-N,Small molecule,False,BENZBROMARONE,,4.0,,True,True,['Desuric' 'Narcaricin mite'],"['Benzbromaron' 'Benzbromarone' 'Benzpromarone' 'L-2214' 'MJ 10061'
 'MJ-10061' 'NSC-85433' 'Uroleap']","[('PubChem', array(['11110651', '122758', '144203592', '170465792', '24424558',
       '26664708', '4253342', '50103990', '56422114', '855676'],
      dtype=object)), ('TG-GATEs', array(['21'], dtype=object)), ('Wikipedia', array(['Benzbromarone'], dtype=object)), ('drugbank', array(['DB12319'], dtype=object)), ('chEBI', array(['3023'], dtype=object))]",,"{'rows': array(['MONDO_0017147', 'EFO_0004274', 'EFO_0009104'], dtype=object), 'count': 3}",[ENSG00000197891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gout and has 2 investigational indications. It was withdrawn in at least one region.
CHEMBL4204869,C[C@H]1OC[C@]2(c3cc(NC(=O)c4cnc(C(F)F)cn4)ccc3F)N=C(N)SC[C@H]12,AACUJFVOHGRMTR-DPXNYUHVSA-N,Small molecule,False,ELENBECESTAT,,3.0,,False,False,[],['E-2609' 'E2609' 'Elenbecestat'],"[('drugbank', array(['DB15391'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000186318],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297788,,,Antibody,False,MOSUNETUZUMAB,2022.0,4.0,,False,True,['Lunsumio'],"['BTCT-4465A' 'BTCT4465A' 'Mosunetuzumab' 'Mosunetuzumab axgb'
 'Mosunetuzumab-axgb' 'RG-7828' 'RG7828' 'RO-7030816' 'RO7030816']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lunsumio'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOSUNETUZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005952', 'EFO_0000183', 'MONDO_0002334', 'MONDO_0007915',
       'EFO_0000403', 'MONDO_0018906', 'EFO_0000096', 'EFO_0000095'],
      dtype=object), 'count': 8}","[ENSG00000156738,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for follicular lymphoma and neoplasm of mature b-cells and has 6 investigational indications.
CHEMBL4298005,,,Unknown,False,MITIGLINIDE CALCIUM DIHYDRATE,,3.0,,False,False,[],"['Glufast' 'KAD-1229' 'Kad-1229' 'Mitiglinide calcium dihydrate'
 'Mitiglinide calcium hydrate' 'Mitiglinide calcium salt dihydrate'
 'S-21403']",,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}","[ENSG00000187486,ENSG00000006071]",Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4563522,CCCC[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(N)=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O,AVYLMJODKHVQHD-WFOXQDBGSA-N,Protein,False,FE 203799,,3.0,,False,False,[],['Fe 203799'],,,"{'rows': array(['MONDO_0015183', 'EFO_0001421', 'EFO_0003884', 'MONDO_0013730'],
      dtype=object), 'count': 4}",[ENSG00000065325],Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL49120,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1,IFPPYSWJNWHOLQ-UHFFFAOYSA-N,Small molecule,False,PD-0166285,,1.0,,False,False,[],['PD-0166285' 'TCMDC-140940'],"[('PubChem', array(['103905313', '137275855', '307078458'], dtype=object))]",['CHEMBL3545196'],,"[ENSG00000077782,ENSG00000197122,ENSG00000146648,ENSG00000113721]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL567303,Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1,WYJCYXOCHXWTHG-UHFFFAOYSA-N,Small molecule,False,PALOSURAN,,2.0,,False,False,[],['Act-058362' 'Palosuran'],,['CHEMBL1164032'],,[ENSG00000181408],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL591,C#CC(O)(/C=C/Cl)CC,ZEHYJZXQEQOSON-AATRIKPKSA-N,Small molecule,False,ETHCHLORVYNOL,1961.0,4.0,,False,True,['Ethchlorvynol' 'Placidyl'],"['Alvinol' 'Arvynol' 'Ethchlorvynol' 'Ethchlorvynol civ' 'NSC-30372'
 'Normoson' 'Nostel' 'Roeridorm' 'Serenesil' 'Serensil']","[('Wikipedia', array(['Ethchlorvynol'], dtype=object)), ('drugbank', array(['DB00189'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.
CHEMBL1201535,,,Small molecule,False,PHENYLPROPANOLAMINE POLISTIREX,1984.0,4.0,CHEMBL61006,True,True,[],['Phenylpropanolamine polistirex'],,,,"[ENSG00000120907,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. It was withdrawn in at least one region.
CHEMBL1229517,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,GPXBXXGIAQBQNI-UHFFFAOYSA-N,Small molecule,False,VEMURAFENIB,2011.0,4.0,,False,True,['Zelboraf'],"['PLX-4032' 'PLX4032' 'RG 7204' 'RG-7204' 'RO 5185426' 'RO-51-85426'
 'RO-5185426' 'Vemurafenib']","[('DailyMed', array(['vemurafenib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf'],
      dtype=object)), ('Wikipedia', array(['Vemurafenib'], dtype=object)), ('drugbank', array(['DB08881'], dtype=object)), ('chEBI', array(['63637'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000326', 'EFO_0001642', 'MONDO_0002108',
       'EFO_1000209', 'EFO_1000956', 'EFO_0000756', 'MONDO_0002898',
       'EFO_0000222', 'HP_0100727', 'EFO_0002892', 'EFO_0000365',
       'MONDO_0004992', 'EFO_0002618', 'EFO_0002617', 'EFO_0001378',
       'EFO_0003060', 'EFO_0000574', 'EFO_0000389', 'EFO_1000318',
       'EFO_1001951'], dtype=object), 'count': 21}",[ENSG00000157764],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 16 investigational indications.
CHEMBL1305,c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,REYFJDPCWQRWAA-UHFFFAOYSA-N,Small molecule,False,ANTAZOLINE,1994.0,4.0,,False,True,['Antaz sulf' 'Vasocon-a'],['Antazoline' 'Atazoline' 'Vasocon-A'],"[('PubChem', array(['11112519', '11113348', '124882433', '50100471', '50100472'],
      dtype=object)), ('Wikipedia', array(['Antazoline'], dtype=object)), ('drugbank', array(['DB08799'], dtype=object)), ('chEBI', array(['84115'], dtype=object))]",['CHEMBL1256819' 'CHEMBL1200550'],"{'rows': array(['EFO_0000678', 'MP_0001845', 'HP_0001742', 'MONDO_0005271'],
      dtype=object), 'count': 4}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for nasal congestion and allergic disease and has 2 investigational indications.
CHEMBL1722209,Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O,TWHNMSJGYKMTRB-VEIFNGETSA-N,Small molecule,False,TOLTERODINE TARTRATE,1998.0,4.0,CHEMBL1382,False,True,['Detrol' 'Detrol la' 'Tolterodine tartrate'],['PNU-200583E' 'Tolterodine l-tartrate' 'Tolterodine tartrate'],"[('DailyMed', array(['tolterodine%20tartrate'], dtype=object)), ('PubChem', array(['49681822'], dtype=object))]",,"{'rows': array(['EFO_0006865', 'EFO_1000781'], dtype=object), 'count': 2}","[ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for urgency urinary incontinence and overactive bladder.
CHEMBL2105467,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1,GFFXZLZWLOBBLO-ASKVSEFXSA-N,Small molecule,False,TEZACITABINE,,2.0,,False,False,[],['FMD-C' 'KW-2331' 'MDL-101731' 'Tezacitabine'],"[('drugbank', array(['DB06433'], dtype=object))]",['CHEMBL3989496'],"{'rows': array(['MONDO_0004992', 'EFO_0004142', 'EFO_0000228', 'EFO_0003897',
       'EFO_0002916'], dtype=object), 'count': 5}","[ENSG00000167325,ENSG00000048392,ENSG00000171848]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2109256,,,Antibody,False,SGN-30,,3.0,,False,False,[],['SGN-30' 'Sgn-30'],,,"{'rows': array(['EFO_0002913', 'EFO_0000558', 'EFO_0000183', 'EFO_0000574',
       'EFO_0003032', 'EFO_0001642'], dtype=object), 'count': 6}",[ENSG00000120949],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2109427,,,Antibody,False,ZOLBETUXIMAB,,3.0,,False,False,[],['Claudiximab' 'IMAB-362' 'IMAB362' 'Zolbetuximab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZOLBETUXIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000066405],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109484,,,Antibody,False,BB-10901,,2.0,,False,False,[],['BB-10901' 'Bb-10901' 'HUN901-DM1'],,,"{'rows': array(['EFO_0001378', 'EFO_0000702'], dtype=object), 'count': 2}",[ENSG00000149294],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3301603,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O,UJOUWHLYTQFUCU-WXXKFALUSA-N,Small molecule,True,GILTERITINIB FUMARATE,2018.0,4.0,CHEMBL3301622,False,True,['Xospata'],"['ASP-2215 HEMIFUMARATE' 'ASP2215 hemifumarate' 'Gilteritinib fumarate'
 'Gilteritinib hemifumarate']","[('DailyMed', array(['gilteritinib%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xospata'],
      dtype=object))]",,"{'rows': array(['MONDO_0004643', 'EFO_0000222'], dtype=object), 'count': 2}","[ENSG00000122025,ENSG00000167601]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for myeloid leukemia and acute myeloid leukemia. This drug has a black box warning from the FDA.
CHEMBL3545189,,,Antibody,False,LANADELUMAB,2018.0,4.0,,False,True,['Takhzyro'],"['DX-2930' 'Lanadelumab' 'Lanadelumab flyo' 'Lanadelumab-flyo' 'SHP-643'
 'Tak-743']","[('DailyMed', array(['landelumab-flyo'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro'],
      dtype=object))]",,"{'rows': array(['EFO_0000546', 'EFO_0005532', 'EFO_0005251', 'MONDO_0019623',
       'MONDO_0100096'], dtype=object), 'count': 5}",[ENSG00000164344],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for hereditary angioedema and has 4 investigational indications.
CHEMBL3707183,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O,ZHNFLHYOFXQIOW-AHSOWCEXSA-N,Small molecule,True,QUINIDINE SULFATE,1962.0,4.0,CHEMBL1294,False,True,['Cin-quin' 'Quinicardine' 'Quinidex' 'Quinidine sulfate' 'Quinora'],"['AVP-786 COMPONENT QUINIDINE SULFATE' 'NSC-10004'
 'QUINIDINE SULFATE COMPONENT OF AVP-786' 'Quinidex extentabs'
 'Quinidine sulfate' 'Quinidine sulfate anhydrous'
 'Quinidine sulfate dihydrate' 'Quinidine sulfate hydrate'
 'Quinidine sulphate' 'Quinidine sulphate anhydrous'
 'Quinidine sulphate dihydrate' 'Quinidine, sulfate (2:1) (salt)'
 'Quinidini sulfas']","[('DailyMed', array(['quinidine%20sulfate'], dtype=object))]",,"{'rows': array(['MONDO_0004976', 'EFO_0003758'], dtype=object), 'count': 2}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL408403,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,CZGUSIXMZVURDU-JZXHSEFVSA-N,Protein,False,ANGIOTENSIN II,2017.0,4.0,,False,True,[],"['5-l-isoleucineangiotensin ii' 'Angiotensin ii'
 'Angiotensin ii (human type)' 'Angiotensin ii human'
 'Asp-arg-val-tyr-ile-his-pro-phe' 'Delivert' 'LJPC-501']","[('PubChem', array(['50112427'], dtype=object)), ('drugbank', array(['DB11842'], dtype=object)), ('chEBI', array(['2719'], dtype=object))]",['CHEMBL4303682' 'CHEMBL3989932'],"{'rows': array(['EFO_1000645', 'EFO_0000319', 'MONDO_0001382', 'EFO_0005251',
       'EFO_0006834', 'EFO_0006834', 'EFO_0000537', 'HP_0031273'],
      dtype=object), 'count': 8}",[ENSG00000144891],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 4 investigational indications.
CHEMBL4297863,,,Antibody,False,REMTOLUMAB,,2.0,,False,False,[],['A-1230717' 'ABT-122' 'Abt-122' 'Remtolumab'],,,"{'rows': array(['EFO_0000685', 'EFO_0003778'], dtype=object), 'count': 2}","[ENSG00000232810,ENSG00000112115]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594470,,,Unknown,False,CVX-060,,2.0,,False,False,[],['CVX-060' 'CVX060' 'Cvx-060' 'PF-04856884' 'PF04856884' 'Pf-04856884'],,,"{'rows': array(['EFO_0000519', 'EFO_0000681', 'EFO_0000313'], dtype=object), 'count': 3}",[ENSG00000091879],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4594531,,,Unknown,False,BI-836826,,2.0,,False,False,[],['BI 836826' 'BI-836826' 'Bi 836826' 'Bi-836826' 'Mab 37.1'],,,"{'rows': array(['EFO_0000403', 'EFO_0000095', 'EFO_0005952'], dtype=object), 'count': 3}",[ENSG00000104894],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL482767,O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1,FAYAUAZLLLJJGH-UHFFFAOYSA-N,Small molecule,False,SNS-314,,1.0,,False,False,[],['SNS-314' 'Sns 314' 'Sns-314'],"[('PubChem', array(['103905586', '124950687'], dtype=object)), ('drugbank', array(['DB06134'], dtype=object))]",['CHEMBL518051'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000178999,ENSG00000105146,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL5314411,C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)N4CCN(CC)CC4)cc23)c1,DQAZPZIYEOGZAF-UHFFFAOYSA-N,Small molecule,False,EPITINIB,,1.0,,False,False,[],['Epitinib' 'HMPL-813' 'Hmpl-813'],,,"{'rows': array(['EFO_0000519', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL799,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,RRGUKTPIGVIEKM-UHFFFAOYSA-N,Small molecule,True,CILOSTAZOL,1999.0,4.0,,False,True,['Cilostazol' 'Pletal'],['Cilostazol' 'NSC-758936' 'OPC-13013' 'OPC-21'],"[('DailyMed', array(['cilostazol'], dtype=object)), ('PubChem', array(['104171123', '11110906', '11113335', '124879546', '144203649',
       '170465347', '174007041', '26719653', '26719654', '26746958',
       '26746959', '50100194', '50103999', '50104000', '56463107',
       '85230957', '855683', '90341176'], dtype=object)), ('Wikipedia', array(['Cilostazol'], dtype=object)), ('drugbank', array(['DB01166'], dtype=object)), ('chEBI', array(['31401'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_0003914', 'EFO_0003843', 'MONDO_0005178',
       'HP_0004419', 'EFO_0003144', 'EFO_0001645', 'EFO_0008493',
       'EFO_0000712', 'EFO_0004265', 'EFO_0003876', 'HP_0100543',
       'Orphanet_136', 'EFO_0003875', 'EFO_0000319', 'HP_0001397',
       'EFO_0003763', 'MONDO_0002679'], dtype=object), 'count': 18}",[ENSG00000172572],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for recurrent thrombophlebitis and has 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL8030,Cc1cccc(Oc2cnc(=O)[nH]c2)c1,HJQILFPVRNHTIG-UHFFFAOYSA-N,Small molecule,False,TOLIMIDONE,,2.0,,False,False,[],"['CP-26,154' 'CP-26154' 'MLR-1023' 'Mlr-1023' 'NSC-314335' 'Tolimidone']",,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000254087],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL841,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,RDOIQAHITMMDAJ-UHFFFAOYSA-N,Small molecule,False,LOPERAMIDE,,4.0,,False,True,[],['Imodium' 'Loperamide'],"[('PubChem', array(['104171181', '11111380', '11112740', '11113732', '124880549',
       '124880551', '124880553', '144203731', '170464852', '26751916',
       '26751917', '50104594', '50104595', '90340730'], dtype=object)), ('Wikipedia', array(['Loperamide'], dtype=object)), ('drugbank', array(['DB00836'], dtype=object)), ('chEBI', array(['6532'], dtype=object))]",['CHEMBL1707'],"{'rows': array(['EFO_0000305', 'MONDO_0004565', 'EFO_0009130', 'EFO_0003060',
       'MONDO_0004992', 'HP_0002014', 'EFO_0003869', 'HP_0002014',
       'EFO_0003843', 'EFO_0009523', 'MONDO_0007254', 'HP_0000964',
       'EFO_0000512'], dtype=object), 'count': 13}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diarrhea and has 12 investigational indications.
CHEMBL94081,C=CCOc1ccc(CC(=O)O)cc1Cl,ARHWPKZXBHOEEE-UHFFFAOYSA-N,Small molecule,False,ALCLOFENAC,,4.0,,True,True,[],['Alclofenac' 'W 7320'],"[('PubChem', array(['144205279', '29215481'], dtype=object)), ('Wikipedia', array(['Alclofenac'], dtype=object)), ('drugbank', array(['DB13167'], dtype=object)), ('chEBI', array(['31183'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}",[ENSG00000095303],Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease. It was withdrawn in at least one region.
CHEMBL953,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,JRURYQJSLYLRLN-BJMVGYQFSA-N,Small molecule,False,ENTACAPONE,1999.0,4.0,,False,True,['Comtan' 'Comtess' 'Entacapone' 'Entacapone orion'],['Entacapone' 'Entacapone orion' 'Entacapone teva' 'OR-611'],"[('DailyMed', array(['entacapone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-orion'],
      dtype=object)), ('PubChem', array(['144205737', '170464850', '26757974'], dtype=object)), ('Wikipedia', array(['Entacapone'], dtype=object)), ('drugbank', array(['DB00494'], dtype=object)), ('chEBI', array(['4798'], dtype=object))]",,"{'rows': array(['EFO_0002610', 'EFO_0000474', 'MONDO_0005180', 'MONDO_0011719',
       'EFO_0001073', 'EFO_0004701'], dtype=object), 'count': 6}",[ENSG00000093010],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for parkinson disease and has 5 investigational indications.
CHEMBL1023,C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,NAVMQTYZDKMPEU-UHFFFAOYSA-N,Small molecule,True,BEXAROTENE,1999.0,4.0,,False,True,['Bexarotene' 'Targretin' 'Targretine'],['Bexarotene' 'LG-100069' 'LG100069' 'LGD-1069' 'LGD1069' 'NSC-747528'],"[('DailyMed', array(['bexarotene'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/targretin'],
      dtype=object)), ('PubChem', array(['124893633', '144206219', '144212724', '170465308', '50125754'],
      dtype=object)), ('Wikipedia', array(['Bexarotene'], dtype=object)), ('drugbank', array(['DB00307'], dtype=object)), ('chEBI', array(['50859'], dtype=object))]",['CHEMBL5290401'],"{'rows': array(['EFO_0004192', 'EFO_0000676', 'EFO_0000565', 'MONDO_0005090',
       'EFO_0000574', 'EFO_1001051', 'EFO_0002913', 'HP_0100543',
       'EFO_0000222', 'MONDO_0020077', 'EFO_0003060', 'EFO_1001110',
       'MONDO_0004975', 'EFO_0000198', 'MONDO_0008903', 'EFO_1000785',
       'EFO_0005411', 'EFO_1000747', 'EFO_0005537', 'EFO_0000616',
       'MONDO_0002108', 'EFO_0001378', 'MONDO_0015760', 'EFO_0003032',
       'EFO_0000432', 'MONDO_0007254'], dtype=object), 'count': 26}","[ENSG00000204231,ENSG00000143171,ENSG00000186350]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 23 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200386,CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,FNPXMHRZILFCKX-KAJVQRHHSA-N,Small molecule,False,PREDNICARBATE,1991.0,4.0,,False,True,['Dermatop' 'Dermatop e emollient' 'Prednicarbate'],"['HOE 777' 'HOE-777' 'LAS-189961' 'LAS-41003 COMPONENT PREDNICARBATE'
 'LAS189961' 'NSC-760042' 'Prednicarbate' 'S 77 0777' 'S-77 0777'
 'S-77-0777' 'S-770777']","[('DailyMed', array(['prednicarbate'], dtype=object)), ('PubChem', array(['144204238', '56463553'], dtype=object)), ('Wikipedia', array(['Prednicarbate'], dtype=object)), ('drugbank', array(['DB01130'], dtype=object))]",,"{'rows': array(['MONDO_0002026', 'EFO_0000676', 'EFO_0000701', 'HP_0000964',
       'EFO_0007512'], dtype=object), 'count': 5}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for skin disease and has 4 investigational indications.
CHEMBL1200805,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.O=C(O)CC(O)C(=O)O,IUSFTUWHKCSCDY-BHDTVMLSSA-N,Small molecule,False,DILTIAZEM MALATE,1996.0,4.0,CHEMBL23,False,True,['Tiamate'],['Diltiazem malate' 'MK-793'],,,,"[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996.
CHEMBL1201193,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,LEBVLXFERQHONN-INIZCTEOSA-N,Small molecule,False,LEVOBUPIVACAINE,1999.0,4.0,,False,True,[],"['(-)-bupivacaine' '(s)-bupivacaine' 'Bupivacaine (-)-form'
 'Bupivacaine, (-)-' 'Bupivacaine, (s)-' 'L-bupivacaine' 'Levobupivacaine'
 'Novabupi']","[('PubChem', array(['11112642', '29215441'], dtype=object)), ('Wikipedia', array(['Levobupivacaine'], dtype=object)), ('drugbank', array(['DB01002'], dtype=object)), ('chEBI', array(['6149'], dtype=object))]",['CHEMBL1200749'],"{'rows': array(['HP_0002027', 'EFO_0005323', 'EFO_0002950', 'EFO_0000616',
       'EFO_0003843', 'EFO_0003843', 'HP_0000175', 'HP_0003418',
       'EFO_0002950'], dtype=object), 'count': 9}",[ENSG00000007314],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 7 investigational indications.
CHEMBL1201656,,,Protein,False,INSULIN SUSP ISOPHANE PURIFIED PORK,1979.0,4.0,,False,True,"['Insulin insulatard nph nordisk' 'Nph iletin ii (pork)'
 'Nph purified pork isophane insulin']",['Insulin susp isophane purified pork'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1979.
CHEMBL1201835,,,Antibody,False,USTEKINUMAB,2009.0,4.0,,False,True,['Stelara' 'Stelera'],['CNTO 1275' 'CNTO-1275' 'TT-20' 'Ustekinumab' 'Ustekinumab '],"[('DailyMed', array(['ustekinumab'], dtype=object)), ('DrugCentral', array(['4966'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/stelara'],
      dtype=object)), ('Wikipedia', array(['Ustekinumab'], dtype=object))]",,"{'rows': array(['EFO_0000540', 'EFO_1001486', 'MONDO_0007915', 'EFO_1001494',
       'MONDO_0019269', 'MONDO_0002334', 'EFO_0000685', 'EFO_1000710',
       'EFO_0000384', 'EFO_1001209', 'EFO_0007187', 'EFO_0000729',
       'EFO_0003780', 'MONDO_0013730', 'EFO_0003898', 'EFO_1001231',
       'MONDO_0019338', 'EFO_0003921', 'MONDO_0005147', 'MONDO_0005301',
       'EFO_0003872', 'EFO_0000676', 'EFO_0000398', 'EFO_0000274',
       'EFO_0002609', 'EFO_0003778', 'EFO_1001857'], dtype=object), 'count': 27}","[ENSG00000113302,ENSG00000110944,ENSG00000168811]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 21 investigational indications.
CHEMBL1370,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,VOVIALXJUBGFJZ-KWVAZRHASA-N,Small molecule,True,BUDESONIDE,1994.0,4.0,,False,True,"['Aircort' 'Budeflam aquanase' 'Budelin novolizer' 'Budenofalk'
 'Budesonide' 'Cortiment' 'Duoresp spiromax' 'Entocort' 'Entocort cr'
 'Entocort ec' 'Jorveza' 'Ortikos' 'Preferid' 'Pulmaxan' 'Pulmicort'
 'Pulmicort flexhaler' 'Pulmicort l.s.' 'Pulmicort respules' 'Rhinocort'
 'Rhinocort allergy' 'Rhinocort aqua' 'Rhinocort aqua 64' 'Symbicort'
 'Tarpeyo' 'Uceris']",['Budesonide' 'MAP-0010' 'MAP0010' 'NSC-757788' 'R01AD05' 'S-1320'],"[('DailyMed', array(['budesonide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jorveza'],
      dtype=object)), ('PubChem', array(['56422168', '855541', '90341081'], dtype=object)), ('Wikipedia', array(['Budesonide'], dtype=object)), ('drugbank', array(['DB01222'], dtype=object)), ('chEBI', array(['3207'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'HP_0025267', 'HP_0002014', 'EFO_1000391',
       'EFO_1001223', 'HP_0001742', 'EFO_0000464', 'EFO_0009544',
       'MONDO_0013730', 'EFO_0004194', 'EFO_1001486', 'EFO_0005854',
       'EFO_1001295', 'EFO_0004232', 'EFO_0003918', 'EFO_1000637',
       'EFO_1000782', 'EFO_0000684', 'EFO_0007140', 'MONDO_0100096',
       'EFO_1001294', 'EFO_0000384', 'EFO_0007183', 'EFO_0000341',
       'EFO_0000694', 'EFO_0000729', 'EFO_0007486', 'MONDO_0019091',
       'EFO_0004268', 'EFO_1001411', 'EFO_0008572', 'MONDO_0005271',
       'EFO_0000756', 'EFO_0005628', 'EFO_0003956', 'HP_0002043',
       'EFO_0004599', 'MONDO_0020547', 'MONDO_0008903', 'EFO_0006505',
       'EFO_1001417', 'EFO_0008590', 'EFO_0001378', 'HP_0006536',
       'MONDO_0004979', 'EFO_0005676', 'EFO_1001293'], dtype=object), 'count': 47}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 12 approved and 35 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1734,O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,FBOUYBDGKBSUES-VXKWHMMOSA-N,Small molecule,False,SOLIFENACIN,2004.0,4.0,,False,True,['Vesicare'],['NSC-759144' 'Solifenacin'],"[('PubChem', array(['50113280'], dtype=object)), ('Wikipedia', array(['Solifenacin'], dtype=object)), ('drugbank', array(['DB01591'], dtype=object))]",['CHEMBL1200803' 'CHEMBL2361425'],"{'rows': array(['EFO_0006865', 'EFO_0000284', 'EFO_1000781', 'EFO_1000781',
       'HP_0000020', 'EFO_0006865', 'HP_0000103', 'EFO_0000284'],
      dtype=object), 'count': 8}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 3 investigational indications.
CHEMBL2108318,,,Protein,False,ELSIGLUTIDE,,2.0,,False,False,[],['Elsiglutide' 'ZP-1846' 'ZP1846' 'Zp1846'],,,"{'rows': array(['HP_0002014'], dtype=object), 'count': 1}",[ENSG00000065325],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108811,,,Antibody,False,VISILIZUMAB,,3.0,,False,False,['Nuvion'],['HUM-291' 'Visilizumab' 'huM291'],,,"{'rows': array(['MONDO_0013730', 'EFO_0000384', 'EFO_0000729', 'EFO_0000222',
       'EFO_0000574'], dtype=object), 'count': 5}",[ENSG00000198851],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2141296,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,MXAYKZJJDUDWDS-LBPRGKRZSA-N,Small molecule,False,IXAZOMIB,,4.0,,False,True,['Ninlaro'],['Ixazomib' 'MLN-2238' 'MLN-9708 FREE BASE' 'MLN2238'],"[('PubChem', array(['124955652'], dtype=object)), ('drugbank', array(['DB09570'], dtype=object))]",['CHEMBL5171825'],"{'rows': array(['EFO_1001264', 'EFO_0000565', 'EFO_0000220', 'EFO_0009441',
       'MONDO_0019438', 'MONDO_0044881', 'EFO_0001378', 'EFO_0005537',
       'EFO_0005761', 'EFO_0000681', 'EFO_0006738', 'EFO_0000764',
       'MONDO_0004992', 'EFO_0000574', 'EFO_0000616', 'EFO_0007160',
       'EFO_1001469', 'EFO_0000222', 'MONDO_0000873', 'EFO_0003884',
       'MONDO_0018906'], dtype=object), 'count': 21}","[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 19 investigational indications.
CHEMBL21536,CCCCCCOc1nsnc1C1=CCCN(C)C1,JOLJIIDDOBNFHW-UHFFFAOYSA-N,Small molecule,False,XANOMELINE,,3.0,,False,False,[],['LY-246708' 'LY-246708 FREE BASE' 'LY246708' 'Xanomeline'],"[('Wikipedia', array(['Xanomeline'], dtype=object)), ('drugbank', array(['DB15357'], dtype=object)), ('chEBI', array(['10056'], dtype=object))]",['CHEMBL2336050' 'CHEMBL73149'],"{'rows': array(['MONDO_0005090', 'MONDO_0005090'], dtype=object), 'count': 2}","[ENSG00000168539,ENSG00000180720]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2179105,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1,IWXUVYOOUMLUTQ-CZUORRHYSA-N,Small molecule,False,EDELINONTRINE,,2.0,,False,False,[],['Edelinontrine' 'Pf-04447943'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object)), ('drugbank', array(['DB11953'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000160191],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3039511,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1,ZGCYVRNZWGUXNQ-UHFFFAOYSA-N,Small molecule,False,BEVENOPRAN,,3.0,,False,False,[],['ADL-5945' 'ADL5945' 'Bevenopran' 'CB-5945' 'CB5-945' 'CB5945'],"[('drugbank', array(['DB12464'], dtype=object))]",,"{'rows': array(['HP_0002019', 'EFO_0003086'], dtype=object), 'count': 2}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3187723,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,ACWZRVQXLIRSDF-UHFFFAOYSA-N,Small molecule,False,BINIMETINIB,2018.0,4.0,,False,True,['Mektovi'],"['ARRY 438162' 'ARRY-162' 'ARRY-438162' 'Binimetinib' 'MEK-162' 'MEK162'
 'Mek-162' 'NVP-MEK162']","[('DailyMed', array(['binimetinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi'],
      dtype=object)), ('PubChem', array(['174006430'], dtype=object)), ('drugbank', array(['DB11967'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'EFO_0003060', 'EFO_0000389', 'EFO_0002617',
       'EFO_1000251', 'EFO_1001959', 'MONDO_0004992', 'MONDO_0007254',
       'MONDO_0021063', 'EFO_1000956', 'MONDO_0008170', 'MONDO_0011719',
       'EFO_0002503', 'EFO_0003833', 'EFO_0005537', 'EFO_0002892',
       'EFO_0002618', 'EFO_1000657', 'EFO_0000565', 'EFO_0000305',
       'EFO_0009259', 'EFO_0000685', 'EFO_0001075', 'EFO_1001951',
       'MONDO_0002158', 'MONDO_0003060', 'EFO_1001512', 'EFO_0000756',
       'EFO_0003891', 'EFO_0000616', 'MONDO_0008903', 'EFO_0004606',
       'EFO_0001378', 'MONDO_0002087'], dtype=object), 'count': 34}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 29 investigational indications.
CHEMBL3545216,,,Small molecule,False,FX-005,,2.0,,False,False,[],['Fx-005'],,,"{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545283,CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO,QLUYMIVVAYRECT-UHFFFAOYSA-N,Small molecule,False,RIVICICLIB,,2.0,,False,False,[],['P 276-00 free base' 'P-276-00 free base' 'P276-00' 'Riviciclib'],,,,"[ENSG00000136807,ENSG00000135446,ENSG00000170312]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545349,Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1.Cl.Cl,OJBLXSPBJMGZDN-UHFFFAOYSA-N,Small molecule,False,EVT-101,,2.0,CHEMBL3545350,False,False,[],['Evt-101' 'Evt101'],"[('drugbank', array(['DB05956'], dtype=object))]",,,"[ENSG00000176884,ENSG00000273079]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3577124,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1,HHCBMISMPSAZBF-UHFFFAOYSA-N,Small molecule,False,LY-3009120,,1.0,,False,False,[],['DP-4978' 'LY3009120' 'Ly-3009120' 'Pan-raf inhibitor ly3009120'],,,"{'rows': array(['EFO_0004142', 'EFO_0009708', 'EFO_0003060', 'EFO_0000756'],
      dtype=object), 'count': 4}","[ENSG00000132155,ENSG00000157764,ENSG00000078061]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL3707330,C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.O,GZQWMYVDLCUBQX-WVZIYJGPSA-N,Small molecule,False,ROLAPITANT HYDROCHLORIDE,2015.0,4.0,CHEMBL3707331,False,True,['Varubi' 'Varuby'],"['Rolapitant hcl h20' 'Rolapitant hydrochloride'
 'Rolapitant hydrochloride monohydrate' 'SCH-619734' 'SCH619734']","[('DailyMed', array(['rolapitant%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/varuby'],
      dtype=object))]",,"{'rows': array(['EFO_0006911', 'EFO_0000691'], dtype=object), 'count': 2}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for chemotherapy-induced nausea and vomiting and has 1 investigational indication.
CHEMBL4289017,CC(=O)NCC(=O)N1[C@@H]2CC[C@H]1c1ccc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)cc12,RYYNGWLOYLRZLK-RBUKOAKNSA-N,Small molecule,False,PF-03814735,,1.0,,False,False,[],['PF 03814735' 'PF 3814735' 'PF-3814735' 'Pf-03814735'],"[('drugbank', array(['DB13059'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000087586,ENSG00000178999]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4650277,CC(C)(C)NCCNc1ccc(C2=NN=C(C(F)(F)F)C2)nc1C1CCN(c2ncnc3c2C(C)(C)C(=O)N3)CC1,UVKWCPOZHXNKAZ-UHFFFAOYSA-N,Small molecule,False,TAS0612,,1.0,,False,False,[],['TAS0612' 'Tas0612'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000175634,ENSG00000108443,ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000177189,ENSG00000071242,ENSG00000072133,ENSG00000117676]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL479,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2,KLBQZWRITKRQQV-UHFFFAOYSA-N,Small molecule,True,THIORIDAZINE,1962.0,4.0,,True,True,['Mellaril-s' 'Melleril' 'Rideril'],"['Dl-thioridazine' 'Mellaril' 'Mellerette' 'Novoridazine' 'Sonapax'
 'TP-21' 'Thioridazine' 'Thioridazine prolongatum' 'Thioril']","[('PubChem', array(['104171257', '124881748', '144203845', '170465080', '174006671',
       '26752322', '50105272', '90341630'], dtype=object)), ('TG-GATEs', array(['38'], dtype=object)), ('Wikipedia', array(['Thioridazine'], dtype=object)), ('drugbank', array(['DB00679'], dtype=object)), ('chEBI', array(['9566'], dtype=object))]",['CHEMBL1200916'],"{'rows': array(['EFO_0000222', 'EFO_0005230', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090', 'EFO_0005407'], dtype=object), 'count': 6}","[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and is indicated for psychosis and has 5 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL501867,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,AQTQHPDCURKLKT-JKDPCDLQSA-N,Small molecule,True,VINCRISTINE SULFATE,1963.0,4.0,CHEMBL90555,False,True,"['Kyocristine' 'Leurocristine Sulfate' 'Marqibo kit' 'Oncovin' 'Vincasar'
 'Vincasar pfs' 'Vincrex' 'Vincristine sulfate' 'Vincristine sulfate pfs']","['37231' 'Kyocristine' 'LILLY-37231' 'Marqibo' 'NSC-67574' 'Novopharm'
 'Vincristine sulfate' 'Vincristine sulfate liposome'
 'Vincristine sulphate' 'Vincristini sulfas' 'Vincrisul']","[('PubChem', array(['112141'], dtype=object)), ('chEBI', array(['79401'], dtype=object))]",,"{'rows': array(['EFO_0000174', 'EFO_0000272', 'EFO_0000094', 'MONDO_0009348',
       'EFO_0000248', 'EFO_0000220', 'MONDO_0008380', 'MONDO_0018975',
       'EFO_0006859', 'EFO_1001469', 'EFO_0000558', 'EFO_0000183',
       'EFO_0002939', 'EFO_0004289', 'EFO_0003032', 'EFO_0000502',
       'EFO_0000756', 'EFO_0000211', 'EFO_0000565', 'EFO_1001042',
       'EFO_0000096', 'MONDO_0008903', 'MONDO_0002367', 'EFO_1000131',
       'EFO_0000616', 'EFO_0001378', 'EFO_0005235', 'EFO_1000292',
       'EFO_0000621', 'MONDO_0000430', 'EFO_1001951', 'EFO_0000095',
       'MONDO_0000870', 'EFO_0000209', 'MONDO_0018906', 'MONDO_0015540',
       'EFO_0005952', 'EFO_0000313', 'EFO_0000691', 'MONDO_0002974',
       'EFO_1000158', 'HP_0001871', 'EFO_0000588', 'EFO_0000403',
       'MONDO_0000873', 'EFO_0000222', 'EFO_1001365', 'EFO_0000574',
       'MONDO_0018271', 'EFO_0009441', 'MONDO_0019004', 'EFO_0003833',
       'EFO_0000309', 'MONDO_0019471', 'EFO_0000765', 'EFO_0002918',
       'MONDO_0044917', 'EFO_0000437'], dtype=object), 'count': 58}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 58 investigational indications. This drug has a black box warning from the FDA.
CHEMBL839,CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2,LWAFSWPYPHEXKX-UHFFFAOYSA-N,Small molecule,False,CARTEOLOL,1988.0,4.0,,False,True,[],['Carteolol' 'Cartrol' 'Ocupress'],"[('Wikipedia', array(['Carteolol'], dtype=object)), ('drugbank', array(['DB00521'], dtype=object)), ('chEBI', array(['3437'], dtype=object))]",['CHEMBL1201002'],"{'rows': array(['EFO_0004190', 'MONDO_0005041', 'EFO_0000319'], dtype=object), 'count': 3}","[ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 3 approved indications.
CHEMBL1200511,CC(=O)O.CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,NGCGMRBZPXEPOZ-HBBGHHHDSA-N,Protein,False,GONADORELIN ACETATE,1989.0,4.0,CHEMBL1007,False,True,"['Cystorelin' 'Factrel' 'GnRH' 'Gonadotropin Releasing Hormone'
 'Lh Releasing Factor' 'Lutrelef' 'Lutrepulse kit']","['ABBOTT-41070' 'Fertagyl' 'Gonadorelin acetate'
 'Gonadorelin acetate anhydrous' 'Gonadorelin acetate mixture'
 'Gonadorelin diacetate' 'Hypocrine' 'Luteinizing'
 'Luteinizing hormone-releasing factor diacetate tetrahydrate']",,,"{'rows': array(['MONDO_0007254', 'MONDO_0018555', 'EFO_0000673', 'EFO_0001663',
       'MONDO_0008315', 'EFO_0000545', 'MONDO_0018800', 'EFO_0000196',
       'EFO_0000512', 'MONDO_0002146'], dtype=object), 'count': 10}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 10 investigational indications.
CHEMBL1200592,CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,VVOIQBFMTVCINR-WWMZEODYSA-N,Small molecule,False,DESOXYCORTICOSTERONE PIVALATE,1982.0,4.0,,False,True,['Percorten' 'Zycortal'],['Desoxycorticosterone pivalate' 'Desoxycorticosterone trimethylacetate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/zycortal'],
      dtype=object)), ('PubChem', array(['144205152'], dtype=object)), ('drugbank', array(['DB01134'], dtype=object)), ('chEBI', array(['50782'], dtype=object))]",,,[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200964,CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl,KFYRPLNVJVHZGT-UHFFFAOYSA-N,Small molecule,True,AMITRIPTYLINE HYDROCHLORIDE,1961.0,4.0,CHEMBL629,False,True,"['Amitid' 'Amitril' 'Amitriptyline hydrochloride' 'Cytriptyline' 'Domical'
 'Elavil' 'Endep' 'Lentizol' 'Limbitrol 5' 'Saroten' 'Saroten retard'
 'Triptafen' 'Triptafen-m' 'Tryptizol' 'Tryptizol-75']","['Amitriptyline hcl' 'Amitriptyline hydrochloride'
 'Amitriptylini hydrochloridum' 'Etravil' 'NIH 10794' 'NSC-104210'
 'Novoprotect' 'Syneudon']","[('DailyMed', array(['amitriptyline%20hydrochloride'], dtype=object)), ('PubChem', array(['144206673', '144208476', '144213917', '170464758', '17389180',
       '26747443', '26751626', '49816669', '50105841', '855970'],
      dtype=object))]",,"{'rows': array(['HP_0000989', 'MONDO_0016028', 'MONDO_0002009', 'EFO_0009387'],
      dtype=object), 'count': 4}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for major depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201108,Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2.Cl,BTYHAFSDANBVMJ-UHFFFAOYSA-N,Small molecule,False,CONIVAPTAN HYDROCHLORIDE,2005.0,4.0,CHEMBL1755,False,True,['Vaprisol'],['CI-1025' 'Conivaptan hcl' 'Conivaptan hydrochloride' 'YM-087' 'YM087'],"[('chEBI', array(['31430'], dtype=object))]",,"{'rows': array(['EFO_0003144', 'HP_0002902', 'EFO_0001421'], dtype=object), 'count': 3}","[ENSG00000166148,ENSG00000126895]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for heart failure and has 2 investigational indications.
CHEMBL1201534,,,Unknown,False,DANAPAROID SODIUM,1996.0,4.0,,False,True,['Orgaran'],"['Danaparoid' 'Danaparoid sodium' 'ORG 10172' 'ORG-10172'
 'Sodium danaparoid']",,,"{'rows': array(['HP_0004419', 'HP_0001873'], dtype=object), 'count': 2}",[ENSG00000117601],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for recurrent thrombophlebitis and has 1 investigational indication.
CHEMBL1201765,CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1.O=C(O)/C=C/C(=O)O,MWHXMIASLKXGBU-RNCYCKTQSA-N,Small molecule,False,FESOTERODINE FUMARATE,2007.0,4.0,CHEMBL1201764,False,True,['Fesoterodine fumarate' 'Toviaz'],['Fesoterodine fumarate' 'SPM 8272' 'SPM 907' 'SPM-8272' 'SPM-907'],"[('DailyMed', array(['fesoterodine%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/toviaz'],
      dtype=object))]",,"{'rows': array(['EFO_1000781', 'HP_0000020', 'EFO_0006865'], dtype=object), 'count': 3}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for overactive bladder and urgency urinary incontinence and has 1 investigational indication.
CHEMBL1204165,C[C@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1.Cl,WQVZLXWQESQGIF-WJKBNZMCSA-N,Small molecule,False,DILEVALOL HYDROCHLORIDE,1990.0,4.0,CHEMBL27193,True,True,[],['Dilevalol hcl' 'Dilevalol hydrochloride' 'SCH 19927' 'SCH-19927'],,,,"[ENSG00000169252,ENSG00000043591,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. It was withdrawn in at least one region.
CHEMBL1255840,CC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1,VCRGLZYPNNAVRP-JTQLQIEISA-N,Small molecule,False,NEBOGLAMINE,,2.0,,False,False,[],['Cr2249' 'Neboglamine' 'Nebostinel' 'XY-2401'],"[('PubChem', array(['144204806', '50106666', '90341776'], dtype=object))]",,,"[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1378,CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2,XCTYLCDETUVOIP-UHFFFAOYSA-N,Small molecule,False,THIETHYLPERAZINE,1961.0,4.0,,False,True,[],['Thiethylperazine' 'Torecan'],"[('Wikipedia', array(['Thiethylperazine'], dtype=object)), ('drugbank', array(['DB00372'], dtype=object)), ('chEBI', array(['9544'], dtype=object))]","['CHEMBL2359670' 'CHEMBL3989478' 'CHEMBL1326247' 'CHEMBL1201074'
 'CHEMBL1200856']","{'rows': array(['MONDO_0004975', 'MONDO_0005271', 'HP_0000023'], dtype=object), 'count': 3}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for allergic disease and has 2 investigational indications.
CHEMBL13828,O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1,BAINIUMDFURPJM-UHFFFAOYSA-N,Small molecule,False,OXATOMIDE,,4.0,,False,True,['Tinset'],"['Celtect' 'Cobiona' 'Dasten' 'NSC-309710' 'Oxatomide' 'R 35,443'
 'R-35443']","[('PubChem', array(['11111579', '144203770', '170466059', '50100302', '50106789',
       '50106790', '85231171', '855791'], dtype=object)), ('Wikipedia', array(['Oxatomide'], dtype=object)), ('drugbank', array(['DB12877'], dtype=object))]",,"{'rows': array(['MONDO_0005271', 'MONDO_0010679'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for allergic disease and has 1 investigational indication.
CHEMBL1567328,COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Mg+2],KWORUUGOSLYAGD-UHFFFAOYSA-N,Small molecule,False,OMEPRAZOLE MAGNESIUM,2003.0,4.0,CHEMBL1503,False,True,['Omeprazole magnesium' 'Prilosec' 'Prilosec otc'],"['H 168/68 MAGNESIUM' 'Omeprazole (as magnesium)' 'Omeprazole magnesium'
 'Omeprazole magnesium salt']","[('DailyMed', array(['omeprazole%20magnesium'], dtype=object)), ('PubChem', array(['49665950', '49681830'], dtype=object))]",,"{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003 and has 1 investigational indication.
CHEMBL2074972,COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1,QZVNQOLPLYWLHQ-UHFFFAOYSA-N,Small molecule,False,BENIDIPINE,,3.0,,False,False,[],['Benidipine' 'Benidipine hydrochloride'],,,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2107729,O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1,PQHLRGARXNPFCF-UHFFFAOYSA-N,Small molecule,False,ATACIGUAT,,2.0,,False,False,[],['Ataciguat'],"[('PubChem', array(['144206754', '170466340'], dtype=object)), ('drugbank', array(['DB12805'], dtype=object))]",['CHEMBL4079827'],"{'rows': array(['EFO_0003876', 'EFO_0000266', 'EFO_0003843'], dtype=object), 'count': 3}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2107821,NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1,WJIGGYYSZBWCGC-MRXNPFEDSA-N,Small molecule,False,EMIXUSTAT,,3.0,,False,False,['Acu-4429'],['ACU-4429' 'Emixustat'],"[('drugbank', array(['DB12608'], dtype=object))]",['CHEMBL2107829'],"{'rows': array(['EFO_1001492', 'MONDO_0019353'], dtype=object), 'count': 2}",[ENSG00000116745],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109247,,,Antibody,False,LBY-135,,1.0,,False,False,[],['LBY-135' 'LBY135' 'Lby 135'],,,,[ENSG00000120889],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109352,,,Antibody,False,BL22,,2.0,,False,False,[],['BL22' 'Bl22' 'CAT-3888'],,,"{'rows': array(['EFO_0000574', 'EFO_1000956', 'EFO_0000565'], dtype=object), 'count': 3}",[ENSG00000012124],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL278398,CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12,ISFHAYSTHMVOJR-UHFFFAOYSA-N,Small molecule,False,PHENINDAMINE,,4.0,,False,True,[],['NU-1504' 'Nolahist' 'Phenindamine' 'Thephorin'],"[('Wikipedia', array(['Phenindamine'], dtype=object)), ('drugbank', array(['DB01619'], dtype=object)), ('chEBI', array(['8065'], dtype=object))]",['CHEMBL2107213'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV and is indicated for allergic disease.
CHEMBL3358920,O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21,MVGWUTBTXDYMND-QGZVFWFLSA-N,Small molecule,False,ETRASIMOD,2023.0,4.0,,False,True,[],['APD-334' 'APD-334(FREE ACID)' 'APD334' 'Apd334' 'Etrasimod'],"[('drugbank', array(['DB14766'], dtype=object))]",['CHEMBL3989933'],"{'rows': array(['EFO_0004232', 'EFO_0003767', 'EFO_0000274', 'EFO_0000384',
       'EFO_1001486', 'EFO_0000729', 'HP_0000999', 'EFO_0000729',
       'EFO_0004192'], dtype=object), 'count': 9}","[ENSG00000170989,ENSG00000125910,ENSG00000180739]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for ulcerative colitis and has 8 investigational indications.
CHEMBL3989695,CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O,CDQVVPUXSPZONN-WPPLYIOHSA-N,Small molecule,False,REGADENOSON,2008.0,4.0,CHEMBL317052,False,True,['Lexiscan' 'Rapiscan'],"['CVT-3146' 'Rapiscan' 'Regadenoson' 'Regadenoson hydrate'
 'Regadenoson monohydrate']","[('DailyMed', array(['regadenoson'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan'],
      dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and is indicated for cardiovascular disease.
CHEMBL3990028,,,Antibody,False,BLESELUMAB,,2.0,,False,False,[],['ASKP-1240' 'ASKP1240' 'Bleselumab'],,,"{'rows': array(['EFO_0004236', 'EFO_0000676'], dtype=object), 'count': 2}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL424133,Cc1ccc(Cn2nc(CCCc3ccc(OC(C)(C)C(=O)O)cc3)nc2O)cc1,PNHFDVSKDSLUFH-UHFFFAOYSA-N,Small molecule,False,LY-518674,,2.0,,False,False,[],['KB-68984' 'LY-674' 'LY518674' 'Ly-518674'],"[('drugbank', array(['DB12988'], dtype=object))]",,"{'rows': array(['HP_0003124', 'EFO_0000537', 'EFO_0000195'], dtype=object), 'count': 3}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297526,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21,CYHWMBVXXDIZNZ-KRWDZBQOSA-N,Small molecule,True,REMIMAZOLAM,2020.0,4.0,,False,True,['Byfavo'],['CNS 7056' 'CNS-7056' 'Cns 7056' 'ONO-2745' 'Remimazolam'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/REMIMAZOLAM/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12404'], dtype=object))]",['CHEMBL4297324' 'CHEMBL4594301'],"{'rows': array(['EFO_0003890', 'EFO_0009868', 'MONDO_0000870', 'EFO_0001421',
       'EFO_0003843'], dtype=object), 'count': 5}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sedation and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL46423,CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(c2ccc(N(C)C)cc2)CCCC1,PKKNCEXEVUFFFI-UHFFFAOYSA-N,Small molecule,False,NEVANIMIBE,,2.0,,False,False,[],['Nevanimibe' 'PD 132301' 'PD-132301'],,['CHEMBL542103'],"{'rows': array(['EFO_1000796', 'MONDO_0018479', 'EFO_0003099'], dtype=object), 'count': 3}",[ENSG00000057252],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650278,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O,AXNUWYROYVRYIM-OQIJCFCCSA-N,Small molecule,False,SNDX-5613,,1.0,CHEMBL4650827,False,False,[],"['Revumenib sesquifumarate' 'SNDX-50613' 'SNDX-5613' 'SNDX50613'
 'SNDX5613' 'Sndx 5613' 'Sndx-5613']",,,"{'rows': array(['EFO_0000565', 'EFO_0000222', 'EFO_0000220', 'EFO_1001951'],
      dtype=object), 'count': 4}","[ENSG00000133895,ENSG00000118058]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL481958,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl,BHMLHEQFWVQAJS-IITOGVPQSA-N,Small molecule,False,AMRUBICIN HYDROCHLORIDE,,3.0,CHEMBL1186894,False,False,[],['Amrubicin hydrochloride' 'Calsed' 'SM 5887' 'SM-5887'],,,"{'rows': array(['MONDO_0008903', 'EFO_0000702'], dtype=object), 'count': 2}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL494480,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3cccc(O)c32)cc1,OPIKUXLJQFYMSC-UHFFFAOYSA-N,Small molecule,False,ADL-5859,,2.0,,False,False,[],['Adl-5859'],"[('PubChem', array(['174006844'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_0004616', 'EFO_0003843'], dtype=object), 'count': 3}",[ENSG00000116329],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1079,Clc1ccc2nsnc2c1NC1=NCCN1,XFYDIVBRZNQMJC-UHFFFAOYSA-N,Small molecule,False,TIZANIDINE,1996.0,4.0,,False,True,[],['Tizanidine' 'Zanaflex'],"[('PubChem', array(['144205429', '170465419', '26754628', '29216212', '29216213',
       '90340638'], dtype=object)), ('Wikipedia', array(['Tizanidine'], dtype=object)), ('drugbank', array(['DB00697'], dtype=object)), ('chEBI', array(['63629'], dtype=object))]",['CHEMBL1200329'],"{'rows': array(['EFO_0003843', 'HP_0001257', 'EFO_0000756', 'MONDO_0043510',
       'MONDO_0100431', 'HP_0001257', 'MONDO_0005475', 'MONDO_0002959'],
      dtype=object), 'count': 8}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for spasticity and has 7 investigational indications.
CHEMBL1200436,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,QSLJIVKCVHQPLV-PEMPUTJUSA-N,Small molecule,True,OXANDROLONE,1964.0,4.0,,False,True,['Anavar' 'Oxandrin' 'Oxandrolone'],"['Lonavar' 'NSC-67068' 'Oxandrolone' 'Oxandrolone ciii' 'Provitar'
 'SC 11585' 'SC-11585' 'Vasorome']","[('DailyMed', array(['oxandrolone'], dtype=object)), ('Wikipedia', array(['Oxandrolone'], dtype=object)), ('drugbank', array(['DB00621'], dtype=object)), ('chEBI', array(['7820'], dtype=object))]",,"{'rows': array(['EFO_1001006', 'MONDO_0019391', 'EFO_0007067', 'EFO_0000616',
       'EFO_0000546', 'EFO_0008572', 'EFO_1001250', 'EFO_0009516',
       'MONDO_0019499'], dtype=object), 'count': 9}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200817,CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1.Cl,UXBPQRGCVJOTNT-COBSGTNCSA-N,Small molecule,False,LEVOMETHADYL ACETATE HYDROCHLORIDE,1993.0,4.0,CHEMBL1514,False,True,['Orlaam'],"['LAAM' 'Levacetylmethadol hydrochloride' 'Levomethadyl acetate hcl'
 'Levomethadyl acetate hydrochloride' 'MK-790' 'MK790']","[('PubChem', array(['85273814'], dtype=object))]",,,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993.
CHEMBL1201134,CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1,WGFOBBZOWHGYQH-MXHNKVEKSA-N,Small molecule,False,LUBIPROSTONE,2006.0,4.0,,False,True,['Amitiza'],['Lubiprostone' 'RU-0211'],"[('DailyMed', array(['lubiprostone'], dtype=object)), ('PubChem', array(['144206539'], dtype=object)), ('Wikipedia', array(['Lubiprostone'], dtype=object)), ('drugbank', array(['DB01046'], dtype=object))]",,"{'rows': array(['MONDO_0002203', 'HP_0002019', 'EFO_0000555', 'EFO_0000764',
       'EFO_0003095', 'HP_0012532'], dtype=object), 'count': 6}",[ENSG00000114859],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 2 investigational indications.
CHEMBL1201668,,,Protein,False,NESIRITIDE,2001.0,4.0,,False,True,['Natrecor'],"['Bnp-32' 'Brain natriuretic peptide 32' 'C01DX19' 'Nesiritide'
 'Nesiritide Recombinant' 'Nesiritide recombinant']","[('Wikipedia', array(['Nesiritide'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'EFO_0000319', 'EFO_0000537', 'EFO_0000373',
       'EFO_0000701', 'EFO_0000756', 'EFO_0008583', 'EFO_0003086',
       'EFO_0000318', 'EFO_0000400', 'EFO_0003144', 'EFO_0005672',
       'EFO_0000612', 'HP_0000842', 'EFO_1002048', 'HP_0030680',
       'HP_0001919', 'HP_0002094'], dtype=object), 'count': 18}",[ENSG00000169418],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for cardiovascular disease and has 17 investigational indications.
CHEMBL1206232,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O,WDOGQTQEKVLZIJ-WAYWQWQTSA-N,Small molecule,False,FOSBRETABULIN,,3.0,,False,False,[],"['Combretastatin a-4 phosphate' 'Combretastatin a4 phosphate'
 'Fosbretabulin' 'Phosbretabulin']","[('drugbank', array(['DB12577'], dtype=object))]",['CHEMBL2105643' 'CHEMBL1972559' 'CHEMBL289351' 'CHEMBL263994'],"{'rows': array(['MONDO_0002108', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000616',
       'EFO_0004683', 'EFO_1001901', 'MONDO_0004992', 'MONDO_0008170',
       'EFO_1001901', 'EFO_0006859'], dtype=object), 'count': 10}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL1375743,Cl.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,ZCBZSCBNOOIHFP-UHFFFAOYSA-N,Small molecule,True,ZIPRASIDONE HYDROCHLORIDE,2001.0,4.0,CHEMBL708,False,True,['Geodon' 'Zeldox' 'Ziprasidone hydrochloride'],"['CP-88,059-1' 'CP-88059-1' 'CP-880591' 'Ziprasidone hydrochloride'
 'Ziprasidone hydrochloride hydrate'
 'Ziprasidone hydrochloride monohydrate']","[('DailyMed', array(['ziprasidone%20hydrochloride'], dtype=object)), ('PubChem', array(['90340940'], dtype=object)), ('chEBI', array(['32314'], dtype=object))]",,"{'rows': array(['EFO_0005306', 'MONDO_0005090', 'HP_0000713', 'EFO_0009963',
       'MONDO_0004985', 'EFO_0004269'], dtype=object), 'count': 6}","[ENSG00000147246,ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 approved indications. This drug has a black box warning from the FDA.
CHEMBL1521,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1,HUNXMJYCHXQEGX-UHFFFAOYSA-N,Small molecule,True,ZALEPLON,1999.0,4.0,,False,True,['Sonata' 'Zaleplon'],"['CL 284,846' 'CL-284846' 'L-846' 'L846' 'LJC 10846' 'LJC-10846'
 'LJC10846' 'SKP-1041' 'ZAL-846' 'Zaleplon' 'Zaleplon civ' 'Zerene']","[('DailyMed', array(['zaleplon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sonata'],
      dtype=object)), ('PubChem', array(['144205425', '170465168', '26719706', '29216208'], dtype=object)), ('Wikipedia', array(['Zaleplon'], dtype=object)), ('drugbank', array(['DB00962'], dtype=object)), ('chEBI', array(['10102'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'EFO_0005230', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}","[ENSG00000022355,ENSG00000113327,ENSG00000163288]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for insomnia and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1614701,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,CYOHGALHFOKKQC-UHFFFAOYSA-N,Small molecule,False,SELUMETINIB,2020.0,4.0,,False,True,[],['ARRY-142886' 'ARRY-886' 'AZD-6244' 'AZD6244' 'Azd-6244' 'Selumetinib'],"[('PubChem', array(['144206913', '170466898', '174006431'], dtype=object)), ('drugbank', array(['DB11689'], dtype=object)), ('chEBI', array(['90227'], dtype=object))]",['CHEMBL2105684'],"{'rows': array(['EFO_0000389', 'EFO_0003144', 'EFO_0000272', 'EFO_0000501',
       'EFO_0000403', 'EFO_0001075', 'EFO_0009254', 'EFO_0003060',
       'EFO_1001956', 'MONDO_0018975', 'EFO_0000756', 'MONDO_0001187',
       'EFO_0008514', 'EFO_0000365', 'MONDO_0018975', 'MONDO_0002367',
       'MONDO_0007254', 'MONDO_0003060', 'EFO_0000558', 'EFO_0002617',
       'EFO_1001951', 'EFO_0000339', 'EFO_0000228', 'EFO_1001950',
       'EFO_0000220', 'EFO_0001378', 'EFO_1000251', 'MONDO_0004992',
       'EFO_0002618', 'EFO_0000503', 'EFO_0005221', 'EFO_0002618',
       'MONDO_0016691', 'EFO_0000707', 'EFO_0005537', 'EFO_0000616',
       'EFO_0000182', 'EFO_1001968', 'EFO_0000641', 'EFO_0000708',
       'EFO_0000760', 'EFO_0004606', 'EFO_0000389', 'MONDO_0005411',
       'EFO_0004142', 'EFO_0000658', 'EFO_1000657', 'EFO_1001512',
       'EFO_0002617', 'MONDO_0021063', 'MONDO_0002108', 'MONDO_0018531',
       'MONDO_0008903'], dtype=object), 'count': 53}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 48 investigational indications.
CHEMBL17350,C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1,QEMSVZNTSXPFJA-HNAYVOBHSA-N,Small molecule,False,TRAXOPRODIL,,2.0,,False,False,[],"['CP-101,606' 'CP-101606' 'Cp-101,606' 'Traxoprodil']","[('Wikipedia', array(['Traxoprodil'], dtype=object))]",['CHEMBL3989673'],"{'rows': array(['MONDO_0005180', 'EFO_0000712', 'MONDO_0002009'], dtype=object), 'count': 3}","[ENSG00000176884,ENSG00000273079]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL20684,COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,URCVCIZFVQDVPM-UHFFFAOYSA-N,Small molecule,False,ABT-751,,2.0,,False,False,[],['Abt-751' 'E 7010' 'E-7010' 'NSC-742134'],"[('drugbank', array(['DB12254'], dtype=object))]",['CHEMBL1830238'],"{'rows': array(['EFO_0000681', 'EFO_0001642', 'EFO_1001951', 'EFO_0000621',
       'MONDO_0008315', 'MONDO_0007254', 'MONDO_0000870', 'EFO_0003060'],
      dtype=object), 'count': 8}","[ENSG00000188229,ENSG00000101162,ENSG00000258947,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000173213]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL2107773,Cc1cc(OCC(=O)O)c(C)cc1CCN[C@@H](C)[C@H](O)c1ccc(O)cc1,VMMYRRFPMAGXNP-BTYIYWSLSA-N,Small molecule,False,RITOBEGRON,,3.0,,False,False,[],['KUC-7483' 'Kuc-7483' 'Ritobegron'],"[('drugbank', array(['DB12080'], dtype=object))]",,"{'rows': array(['EFO_1000781', 'HP_0000011'], dtype=object), 'count': 2}",[ENSG00000188778],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108817,,,Antibody,False,YTTRIUM Y 90 EPRATUZUMAB,,1.0,,False,False,[],"['90Y-HLL2' '90Y_HLL2' 'Epratuzumab (y 90)' 'S9S0Y-HLL2'
 'Yttrium y 90 epratuzumab' 'Yttrium y-90 epratuzumab']",,,,[ENSG00000012124],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109494,,,Antibody,False,A27.15,,1.0,,False,False,[],['A27.15'],,,"{'rows': array(['EFO_0000198', 'EFO_0000565', 'EFO_0001378', 'EFO_0002428'],
      dtype=object), 'count': 4}",[ENSG00000072274],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL2110954,CC1(C)CC(C)(C)CC(C)(N)C1,OGZQTTHDGQBLBT-UHFFFAOYSA-N,Small molecule,False,NERAMEXANE,,3.0,,False,False,[],['Neramexane'],"[('drugbank', array(['DB04926'], dtype=object))]",['CHEMBL2106798'],"{'rows': array(['MONDO_0004975', 'HP_0000360', 'HP_0000360'], dtype=object), 'count': 3}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000174343,ENSG00000129749]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3186993,Cl.Cl.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,ANOMHKZSQFYSBR-UHFFFAOYSA-N,Small molecule,False,HYDROXYZINE HYDROCHLORIDE,1956.0,4.0,CHEMBL896,False,True,"['Atarax' 'Hydroxyzine' 'Hydroxyzine hydrochloride' 'Orgatrax' 'Ucerax'
 'Vistaril']","['Hydroxizine chloride' 'Hydroxyzine dihydrochloride'
 'Hydroxyzine hydrochloride']","[('DailyMed', array(['hydroxyzine%20hydrochloride'], dtype=object)), ('PubChem', array(['26752325'], dtype=object)), ('chEBI', array(['5819'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL3219616,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21,ZBVPUFSKFGYNLC-FIDNPTQWSA-N,Small molecule,False,CP-866087,,2.0,,False,False,[],"['CP-866,087' 'Cp-866,087' 'Cp-866087']","[('drugbank', array(['DB12196'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'EFO_0004714', 'MONDO_0007079'], dtype=object), 'count': 3}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545241,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1,DCRWIATZWHLIPN-UHFFFAOYSA-N,Small molecule,False,AC-430,,1.0,,False,False,[],['AC430' 'Ac-430'],"[('drugbank', array(['DB12535'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000096968],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3586573,CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21,GMYLVKUGJMYTFB-UHFFFAOYSA-N,Small molecule,False,CC-115,,2.0,,False,False,[],['Cc-115'],"[('drugbank', array(['DB12740'], dtype=object))]",,"{'rows': array(['EFO_0009708', 'EFO_0000095', 'EFO_0000181', 'EFO_0000519',
       'EFO_0000637', 'MONDO_0008315'], dtype=object), 'count': 6}","[ENSG00000253729,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4208229,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,VOVZXURTCKPRDQ-CQSZACIVSA-N,Small molecule,False,ASCIMINIB,2021.0,4.0,,False,True,[],['ABL-001' 'ABL001' 'ABL001-NX' 'Abl-001' 'Asciminib' 'NVP-ABL001'],"[('drugbank', array(['DB12597'], dtype=object))]",['CHEMBL4297220'],"{'rows': array(['EFO_1000131', 'EFO_0003086', 'EFO_0000616', 'MONDO_0003060',
       'EFO_0000220', 'EFO_0000339', 'EFO_0000339'], dtype=object), 'count': 7}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 4 investigational indications.
CHEMBL4297608,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O,FZEXGDDBXLBRTD-AYIMTCTASA-N,Small molecule,False,ELDECALCITOL,,3.0,,False,False,[],['Ed-71' 'Eldecalcitol'],"[('drugbank', array(['DB05295'], dtype=object))]",,"{'rows': array(['EFO_0003882'], dtype=object), 'count': 1}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL454,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,UZVHFVZFNXBMQJ-UHFFFAOYSA-N,Small molecule,False,BUTALBITAL,1983.0,4.0,,False,True,[],"['Alisobumal' 'Allylbarbituric acid' 'Butalbital' 'Butalbital ciii'
 'Itobarbital' 'Tetrallobarbital']","[('DailyMed', array(['butalbital'], dtype=object)), ('Wikipedia', array(['Butalbital'], dtype=object)), ('drugbank', array(['DB00241'], dtype=object)), ('chEBI', array(['102524'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and is indicated for migraine disorder.
CHEMBL4650436,,,Unknown,False,AGN-211745,,2.0,,False,False,[],['AGN 211745' 'AGN-211745' 'AGN-745' 'Agn 211745' 'Agn-211745' 'SIRNA-027'],,,"{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}",[ENSG00000102755],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL529437,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C.Cl,PIQVDUKEQYOJNR-VZXSFKIWSA-N,Small molecule,True,COCAINE HYDROCHLORIDE,2017.0,4.0,CHEMBL370805,False,True,['Goprelto' 'Numbrino'],"['Cocaine hcl' 'Cocaine hydrochloride' 'Cocaine hydrochloride cii'
 'Cocaine muriate' 'Cocainum muriaticum' 'MCV 4526' 'NIH 8211' 'NSC-25263'
 'RX-0041-002']","[('DailyMed', array(['cocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206436'], dtype=object)), ('chEBI', array(['613010'], dtype=object))]",,"{'rows': array(['EFO_0002610'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL569,CCN(CC)CCOC(=O)c1ccc(N)cc1,MFDFERRIHVXMIY-UHFFFAOYSA-N,Small molecule,False,PROCAINE,1954.0,4.0,,False,True,[],['NSC-169497' 'Novocain' 'Procaine'],"[('PubChem', array(['11111696', '11111697', '90341175'], dtype=object)), ('Wikipedia', array(['Procaine'], dtype=object)), ('drugbank', array(['DB00721'], dtype=object)), ('chEBI', array(['8430'], dtype=object))]",['CHEMBL1200841'],"{'rows': array(['EFO_0000764', 'EFO_0009552', 'EFO_0003102'], dtype=object), 'count': 3}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for hemorrhoid and has 2 investigational indications.
CHEMBL591118,COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2,GUYMHFIHHOEFOA-ZCPGHIKRSA-N,Small molecule,False,CARMEGLIPTIN,,2.0,,False,False,[],['Carmegliptin' 'R-1579' 'R1579' 'RO-4876904' 'RO4876904'],"[('drugbank', array(['DB12268'], dtype=object))]",['CHEMBL2105633'],"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1200509,CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,OWAUGAMNPZHEOJ-YKZVIGSYSA-N,Protein,False,HISTRELIN ACETATE,1991.0,4.0,CHEMBL1201255,False,True,['Supprelin' 'Supprelin la' 'Vantas'],['Histrelin acetate'],"[('DailyMed', array(['histrelin%20acetate'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000673'], dtype=object), 'count': 2}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for prostate cancer and prostate adenocarcinoma.
CHEMBL1201065,C=CCC1(C(C)CCC)C(=O)[N-]C(=S)NC1=O.[Na+],LYZGJWXNOGIVQA-UHFFFAOYSA-M,Small molecule,False,THIAMYLAL SODIUM,1982.0,4.0,CHEMBL440,False,True,['Surital'],"['NSC-759558' 'Sodium thiamylal' 'Thiamylal sodium'
 'Thiamylal sodium salt']","[('PubChem', array(['144205070', '26749789'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201068,CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2.Cl,UGVNGSMLNPWNNA-UHFFFAOYSA-N,Small molecule,False,PROPIOMAZINE HYDROCHLORIDE,1960.0,4.0,CHEMBL1201210,False,True,['Largon'],['Propiomazine hcl' 'Propiomazine hydrochloride'],"[('chEBI', array(['8492'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1201532,,,Unknown,False,THYROTROPIN,1953.0,4.0,,False,True,['Thytropar'],['Thyrotrophin' 'Thyrotropin' 'Thyrotropin (bovine)'],,,"{'rows': array(['EFO_0006859', 'EFO_0000641', 'EFO_0000501'], dtype=object), 'count': 3}",[ENSG00000165409],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 3 investigational indications.
CHEMBL1201836,,,Antibody,True,OFATUMUMAB,2009.0,4.0,,False,True,['Arzerra' 'Kesimpta'],"['2F2' 'GSK-1841157' 'GSK1841157' 'GSKI841157' 'HUMAX-CD20'
 'HUMAX-CD20 2F2' 'HUMAX-CD20, 2F2' 'HUMAX-CD20-2F2' 'Ofatumumab']","[('DailyMed', array(['ofatumumab'], dtype=object)), ('DrugCentral', array(['4951'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta'],
      dtype=object)), ('Wikipedia', array(['Ofatumumab'], dtype=object))]",,"{'rows': array(['EFO_0004255', 'MONDO_0005301', 'EFO_0000574', 'EFO_0004256',
       'MONDO_0020547', 'EFO_0003929', 'MONDO_0001023', 'EFO_0000183',
       'EFO_1000749', 'EFO_0000756', 'EFO_1001469', 'EFO_0000565',
       'EFO_0000685', 'EFO_0000540', 'EFO_0004289', 'EFO_0009441',
       'EFO_0000309', 'EFO_0000403', 'MONDO_0018906', 'MONDO_0004992',
       'MONDO_0000873', 'MONDO_0000870', 'EFO_0000765', 'EFO_0000616',
       'EFO_0000095', 'EFO_0004719', 'EFO_0005952', 'EFO_0000220'],
      dtype=object), 'count': 28}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1614707,FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1,ZTFBIUXIQYRUNT-MDWZMJQESA-N,Small molecule,False,MUBRITINIB,,2.0,,False,False,[],['Mubritinib' 'TAK-165'],"[('drugbank', array(['DB12682'], dtype=object))]",,"{'rows': array(['EFO_0003860', 'EFO_0003893', 'EFO_0003865', 'MONDO_0021117',
       'EFO_0003869'], dtype=object), 'count': 5}",[ENSG00000141736],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1716,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,ZPMVNZLARAEGHB-UHFFFAOYSA-N,Small molecule,False,CYPROHEPTADINE HYDROCHLORIDE,1961.0,4.0,CHEMBL516,False,True,['Cyproheptadine Hydrocloride' 'Cyproheptadine hydrochloride' 'Periactin'],"['Cyproheptadine HCl' 'Cyproheptadine hcl' 'Cyproheptadine hydrochloride'
 'Cyproheptadine hydrochloride hydrate'
 'Cyproheptadine hydrochloride sesquihydrate' 'NSC-169911' 'NSC-759282'
 'Periactine' 'Peritol']","[('DailyMed', array(['cyproheptadine%20hydrochloride'], dtype=object)), ('PubChem', array(['50105994', '50105995', '56422142', '855651'], dtype=object)), ('chEBI', array(['59695'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0005531', 'EFO_0007141', 'EFO_0003956'],
      dtype=object), 'count': 4}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 1 investigational indication.
CHEMBL1789842,CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\C(=O)O,IREJFXIHXRZFER-PCBAQXHCSA-N,Small molecule,False,INDACATEROL MALEATE,2009.0,4.0,CHEMBL1095777,False,True,['Arcapta neohaler' 'Onbrez breezhaler'],"['Indacaterol (as maleate)' 'Indacaterol maleate' 'Indacterol maleate'
 'QAB-149-AFA' 'QAB149-AFA']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler'],
      dtype=object)), ('chEBI', array(['68573'], dtype=object))]",,"{'rows': array(['EFO_0006505', 'EFO_0000341', 'MONDO_0004979', 'EFO_0000464'],
      dtype=object), 'count': 4}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 1 investigational indication.
CHEMBL2108051,,,Antibody,False,STAMULUMAB,,2.0,,False,False,[],['MYO-029' 'Stamulumab'],,,"{'rows': array(['MONDO_0016971', 'MONDO_0010311', 'Orphanet_269'], dtype=object), 'count': 3}",[ENSG00000138379],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109614,,,Antibody,False,MEDI-5117,,1.0,,False,False,[],['MEDI-5117' 'Medi 5117' 'Medi-5117'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2181929,CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(c2ccc(F)cc2)C1=O,AZNHWXAFPBYFGH-UHFFFAOYSA-N,Small molecule,False,MT-3995,,2.0,,False,False,[],['Apararenone' 'MT-3995' 'Mt-3995'],"[('drugbank', array(['DB15024'], dtype=object))]",,"{'rows': array(['EFO_0000401', 'EFO_1001249'], dtype=object), 'count': 2}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL220491,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,HCRKCZRJWPKOAR-JTQLQIEISA-N,Small molecule,False,BRINZOLAMIDE,1998.0,4.0,,False,True,['Azopt'],['AL-4862' 'Azopt' 'Brinzolamide' 'NSC-760050'],"[('DailyMed', array(['brinzolamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/azopt'],
      dtype=object)), ('PubChem', array(['170464926', '56463043'], dtype=object)), ('Wikipedia', array(['Brinzolamide'], dtype=object)), ('drugbank', array(['DB01194'], dtype=object)), ('chEBI', array(['3176'], dtype=object))]",,"{'rows': array(['EFO_0004190', 'EFO_0009784', 'MONDO_0005041', 'EFO_1001069'],
      dtype=object), 'count': 4}",[ENSG00000104267],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 1 investigational indication.
CHEMBL2206292,CC(C)CNC(=O)[C@H]1C[C@@](F)(c2ccc(CN3CCCC3)c(F)c2)C1,DJRDLCHHQYHQQK-UKIBZPOASA-N,Small molecule,False,PF-03654764,,2.0,,False,False,[],['Pf-03654764'],"[('drugbank', array(['DB12360'], dtype=object))]",,"{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2218861,CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21,GDFGTRDCCWFXTG-UHFFFAOYSA-N,Small molecule,False,QUINAGOLIDE,2004.0,4.0,,False,True,[],['Quinagolide'],,['CHEMBL5316219'],"{'rows': array(['MONDO_0011972'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2004 and has 1 investigational indication.
CHEMBL2364624,O=C(O)C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1,GXALXAKNHIROPE-QAQDUYKDSA-N,Small molecule,False,PRADIGASTAT,,3.0,,False,False,[],"['LCQ-908-NXA' 'LCQ-908NXA' 'LCQ908-NXA' 'Lcq-908'
 'Lcq908 - dgat-1-inhibitor' 'Pradigastat']","[('drugbank', array(['DB12866'], dtype=object))]",['CHEMBL2364625'],"{'rows': array(['EFO_0003095', 'EFO_0001421', 'MONDO_0037748', 'EFO_0003086',
       'HP_0002019', 'MONDO_0005148', 'EFO_0003047'], dtype=object), 'count': 7}",[ENSG00000185000],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL277474,Cc1cc(=O)n(-c2ccccc2)n1C,VEQOALNAAJBPNY-UHFFFAOYSA-N,Small molecule,False,ANTIPYRINE,,4.0,,False,True,[],['Antipyrin' 'Antipyrine' 'Antipyrinum' 'NSC-7945' 'Phenazon' 'Phenazone'],"[('PubChem', array(['104171279', '11112159', '144203893', '144208798', '144213343',
       '170465510', '26753718', '56320742'], dtype=object)), ('Wikipedia', array(['Phenazone'], dtype=object)), ('drugbank', array(['DB01435'], dtype=object)), ('chEBI', array(['31225'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'HP_0001945', 'HP_0100607', 'EFO_0004992',
       'EFO_0003843'], dtype=object), 'count': 5}",[ENSG00000095303],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for fever and pain and has 3 investigational indications.
CHEMBL3301611,Nc1ccncc1N.O=P(O)(O)O,KAICRBBQCRKMPO-UHFFFAOYSA-N,Small molecule,False,AMIFAMPRIDINE PHOSPHATE,2009.0,4.0,CHEMBL354077,False,True,['Firdapse' 'Firdapse (previously zenas)'],"['3,4-DAPP' 'Amifampridine phosphate' 'DAPP' 'Zenas']","[('DailyMed', array(['amifampridine%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse'],
      dtype=object))]",,"{'rows': array(['EFO_0008525', 'EFO_0004991', 'MONDO_0015263', 'EFO_0020094',
       'EFO_0004991', 'EFO_0009851'], dtype=object), 'count': 6}","[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for lambert-eaton myasthenic syndrome and myasthenia gravis and has 4 investigational indications.
CHEMBL3545046,,,Small molecule,False,GSK2849466,,1.0,,False,False,[],['Gsk2849466'],,,"{'rows': array(['HP_0004326'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3707325,,,Antibody,False,LENZILUMAB,,3.0,,False,False,[],['KB-003' 'KB003' 'Lenzilumab'],,,"{'rows': array(['EFO_0003106', 'EFO_0000096', 'EFO_1001779', 'MONDO_0004979',
       'EFO_0000685', 'MONDO_0100096'], dtype=object), 'count': 6}",[ENSG00000164400],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4297240,,,Gene,False,ONASEMNOGENE ABEPARVOVEC,2020.0,4.0,,False,True,['Zolgensma'],['AVXS-101' 'Onasemnogene abeparvovec' 'Zolgensma'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma'],
      dtype=object))]",,"{'rows': array(['Orphanet_83419', 'EFO_0008525', 'MONDO_0009669', 'MONDO_0009673'],
      dtype=object), 'count': 4}","[ENSG00000172062,ENSG00000205571]",Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for proximal spinal muscular atrophy type 3 and spinal muscular atrophy and has 2 investigational indications.
CHEMBL4297505,CCc1cc(-c2noc(-c3cc(OC)nc(C4CCCC4)c3)n2)cc(C)c1OC[C@@H](O)CO,KJKKMMMRWISKRF-FQEVSTJZSA-N,Small molecule,False,CENERIMOD,,3.0,,False,False,[],['ACT-334441' 'ACT334441' 'Act-334441' 'Cenerimod'],"[('drugbank', array(['DB12705'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'MONDO_0007915', 'EFO_0001421'], dtype=object), 'count': 3}",[ENSG00000170989],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297883,,,Antibody,False,IVUXOLIMAB,,3.0,,False,False,[],"['Anti-ox40 antibody pf-04518600' 'Ivuxolimab' 'PF-04518600' 'PF-8600'
 'PF04518600' 'Pf-04518600' 'Pf04518600']",,,"{'rows': array(['MONDO_0018906', 'EFO_0000349', 'MONDO_0004992', 'EFO_0000222',
       'EFO_0005537', 'EFO_0000616', 'EFO_0000196'], dtype=object), 'count': 7}",[ENSG00000186827],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4297919,,,Unknown,False,PAROXETINE HYDROCHLORIDE HEMIHYDRATE,,3.0,,False,False,[],"['BRL29060A' 'Brl29060a' 'Paroxetine hydrochloride'
 'Paroxetine hydrochloride hemihydrate' 'Paroxetine hydrochloride hydrate']",,,"{'rows': array(['EFO_1001917'], dtype=object), 'count': 1}",[ENSG00000108576],Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297938,,,Antibody drug conjugate,False,LIFASTUZUMAB VEDOTIN,,2.0,,False,False,[],"['DNIB-0600A' 'DNIB0600A' 'Dnib0600a' 'Lifastuzumab vedotin' 'NAPI3B'
 'RG-7599']",,,"{'rows': array(['EFO_0003060', 'MONDO_0008170'], dtype=object), 'count': 2}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000157765]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL450940,C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12,MQIMZDXIAHJKQP-UHFFFAOYSA-N,Small molecule,False,PRINABEREL,,2.0,,False,False,[],['ERB-041' 'PF-00913086' 'Prinaberel'],"[('drugbank', array(['DB06832'], dtype=object))]",,"{'rows': array(['HP_0001657', 'EFO_0001065', 'EFO_0000384'], dtype=object), 'count': 3}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650337,CNC[C@@H]1OCCc2ccsc21,ABDDQTDRAHXHOC-QMMMGPOBSA-N,Small molecule,False,ULOTARONT,,3.0,,False,False,[],['SEP-363856' 'SEP-856' 'Sep-363856' 'Ulotaront'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ULOTARONT/relevant/1/'],
      dtype=object))]",['CHEMBL5314561'],"{'rows': array(['MONDO_0005090', 'MONDO_0005090', 'MONDO_0005180', 'EFO_1001892',
       'MONDO_0005180', 'MONDO_0002009', 'MONDO_0002009', 'MONDO_0016158',
       'MONDO_0002009', 'MONDO_0016158'], dtype=object), 'count': 10}","[ENSG00000146399,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL467399,COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C,QULDDKSCVCJTPV-UHFFFAOYSA-N,Small molecule,False,BIIB021,,2.0,,False,False,[],['BIIB 021' 'BIIB-021' 'Biib021' 'CNF2024' 'Cnf-2024' 'Cnf2024'],"[('PubChem', array(['124954167'], dtype=object)), ('drugbank', array(['DB12359'], dtype=object)), ('chEBI', array(['90687'], dtype=object))]",['CHEMBL3526911' 'CHEMBL557165'],"{'rows': array(['EFO_0000616', 'EFO_0000574', 'MONDO_0011719', 'MONDO_0007254',
       'EFO_0000095'], dtype=object), 'count': 5}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL535,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,WINHZLLDWRZWRT-ATVHPVEESA-N,Small molecule,True,SUNITINIB,2006.0,4.0,,False,True,['Sunitinib accord' 'Sutent'],"['NSC-736511' 'NSC-750690' 'SU-011248' 'SU-11248' 'SU011248' 'Sunitinib'
 'Sutent']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord'],
      dtype=object)), ('PubChem', array(['124893176', '26758053', '50100120'], dtype=object)), ('Wikipedia', array(['Sunitinib'], dtype=object)), ('drugbank', array(['DB01268'], dtype=object)), ('chEBI', array(['38940'], dtype=object))]",['CHEMBL3109278' 'CHEMBL3542310' 'CHEMBL1567'],"{'rows': array(['EFO_0000222', 'EFO_0000313', 'MONDO_0003268', 'EFO_0000181',
       'EFO_0005221', 'EFO_0000228', 'EFO_1000251', 'MONDO_0002367',
       'EFO_0002499', 'EFO_0006861', 'EFO_0000349', 'EFO_1000045',
       'MONDO_0001056', 'MONDO_0044926', 'EFO_1000581', 'EFO_0000702',
       'MONDO_0004192', 'EFO_0000640', 'EFO_0000641', 'EFO_0003869',
       'EFO_0000514', 'EFO_0000673', 'EFO_0007331', 'EFO_0002617',
       'MONDO_0015277', 'EFO_0000294', 'EFO_0000095', 'EFO_0000673',
       'EFO_1001901', 'EFO_0000220', 'EFO_0000403', 'MONDO_0002367',
       'EFO_1000045', 'EFO_0003869', 'EFO_0003897', 'MONDO_0011719',
       'MONDO_0002691', 'EFO_0000702', 'EFO_0003833', 'EFO_0003897',
       'EFO_0003060', 'MONDO_0007254', 'EFO_0004142', 'EFO_0000519',
       'EFO_0008528', 'EFO_0006352', 'EFO_0001378', 'EFO_0000182',
       'EFO_0002618', 'MONDO_0008170', 'MONDO_0002087', 'EFO_0000756',
       'MONDO_0007254', 'EFO_0000239', 'MONDO_0008667', 'EFO_0000616',
       'EFO_0007416', 'EFO_0000558', 'MONDO_0008667', 'MONDO_0008903',
       'EFO_0000514', 'EFO_0000222', 'EFO_0000640', 'EFO_0000519',
       'EFO_0000349', 'MONDO_0002158', 'MONDO_0007576', 'EFO_0003060',
       'EFO_0004243', 'MONDO_0002158', 'EFO_1001951', 'EFO_1000984',
       'MONDO_0001187', 'EFO_1000796', 'MONDO_0008903', 'EFO_0000616',
       'EFO_1000576', 'EFO_0003863', 'EFO_1001465', 'EFO_0000501',
       'EFO_0000196', 'EFO_0002618', 'MONDO_0008315', 'EFO_1001951',
       'MONDO_0002087', 'EFO_0003865', 'EFO_0000632', 'EFO_0000681',
       'EFO_0000588', 'EFO_0007243', 'EFO_0004252', 'HP_0001541',
       'EFO_0000691', 'EFO_0000182', 'EFO_0000637', 'MONDO_0018364',
       'EFO_1001465', 'EFO_1001968', 'EFO_0007143', 'EFO_0002938',
       'EFO_1001968', 'MONDO_0008315', 'EFO_1001901', 'MONDO_0001187',
       'EFO_0007416', 'MONDO_0004992', 'EFO_0000681', 'MONDO_0011719',
       'MONDO_0004992', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0002892',
       'EFO_1000576', 'EFO_0002617'], dtype=object), 'count': 114}","[ENSG00000037280,ENSG00000128052,ENSG00000165731,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000182578,ENSG00000122025,ENSG00000102755]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 8 approved and 86 investigational indications. This drug has a black box warning from the FDA.
CHEMBL117785,COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2,MKJIEFSOBYUXJB-UHFFFAOYSA-N,Small molecule,True,TETRABENAZINE,2008.0,4.0,,False,True,['Nitoman' 'Revocon' 'Tetmodis' 'Tetrabenazine' 'Xenazine' 'Xenazine 25'],['NSC-169886' 'RO 1-9569' 'RO-1-9569' 'RO-19569' 'Tetrabenazine'],"[('DailyMed', array(['tetrabenazine'], dtype=object)), ('PubChem', array(['144205356', '170464675', '29216102', '50086515', '90341774'],
      dtype=object)), ('Wikipedia', array(['Tetrabenazine'], dtype=object)), ('drugbank', array(['DB04844'], dtype=object)), ('chEBI', array(['64028'], dtype=object))]",['CHEMBL3137326'],"{'rows': array(['EFO_1000632', 'MONDO_0007739', 'MONDO_0007739', 'EFO_0004895',
       'MONDO_0003441', 'EFO_0004280', 'EFO_0004152', 'EFO_0004895',
       'EFO_0004280', 'EFO_0004152'], dtype=object), 'count': 10}",[ENSG00000165646],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for huntington disease and chorea and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200392,CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O,KBAUFVUYFNWQFM-UHFFFAOYSA-N,Small molecule,False,DOXYLAMINE SUCCINATE,1948.0,4.0,CHEMBL1004,False,True,['Decapryn' 'Doxy-sleep-aid' 'Doxylamine succinate' 'Unisom'],"['Alsodorm' 'Donormil' 'Donormyl' 'Dormidina'
 'Doxylamine hydrogen succinate' 'Doxylamine succinate' 'Gittalun'
 'Hoggar n' 'Meraprina' 'NSC-74772']","[('DailyMed', array(['doxylamine%20succinate'], dtype=object)), ('PubChem', array(['144207064', '144209276', '144213178', '170465171', '26747491',
       '50106112', '56423151', '855569'], dtype=object)), ('chEBI', array(['82461'], dtype=object))]",,"{'rows': array(['EFO_0005854', 'HP_0002017', 'EFO_0000544'], dtype=object), 'count': 3}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 3 investigational indications.
CHEMBL1200477,O=c1[n-]cnc2[nH]ncc12.[Na+],PTJRZVJXXNYNLN-UHFFFAOYSA-M,Small molecule,False,ALLOPURINOL SODIUM,1996.0,4.0,CHEMBL1467,False,True,['Allopurinol sodium' 'Aloprim'],['Allopurinol sodium' 'Allopurinol sodium salt' 'NSC-108836'],"[('DailyMed', array(['allopurinol%20sodium'], dtype=object))]",,"{'rows': array(['EFO_1001793'], dtype=object), 'count': 1}",[ENSG00000158125],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996 and has 1 investigational indication.
CHEMBL1200521,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12.O=C(O)CC(O)C(=O)O,QHATUKWEVNMHRY-UHFFFAOYSA-N,Small molecule,False,ALMOTRIPTAN MALATE,2001.0,4.0,CHEMBL1505,False,True,['Almotriptan malate' 'Axert'],"['Almogran' 'Almotriptan d,l-hydrogenmalate' 'Almotriptan malate'
 'Almotriptan maleate' 'LAS 31416 D,L-MALATE ACID' 'LAS-31416'
 'LAS-31416 D,L-MALATE ACID' 'LAS-31416-D,L-MALATE-ACID' 'PNU-180638E']","[('DailyMed', array(['almotriptan%20malate'], dtype=object)), ('chEBI', array(['53781'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}","[ENSG00000179097,ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for migraine disorder.
CHEMBL1200755,CCNCC.CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,FHDKSYKZXIFRKJ-CBCFNHQSSA-N,Protein,False,CERULETIDE DIETHYLAMINE,1982.0,4.0,CHEMBL1201355,False,True,['Tymtran'],"['Caerulein diethylamine' 'Ceosunin' 'Ceruletide diethylamine'
 'Ceruletide diethylamine salt' 'Takus']","[('chEBI', array(['59223'], dtype=object))]",,,[ENSG00000163394],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201232,CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C,JTPUMZTWMWIVPA-UHFFFAOYSA-O,Small molecule,False,ISOPROPAMIDE,1957.0,4.0,,False,True,[],['Isopropamide' 'Isopropamide cation' 'Isopropamide ion'],"[('PubChem', array(['11112197', '144203913', '170465291'], dtype=object)), ('Wikipedia', array(['Isopropamide'], dtype=object)), ('drugbank', array(['DB01625'], dtype=object)), ('chEBI', array(['6043'], dtype=object))]",['CHEMBL1200347'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for gastrointestinal disease.
CHEMBL136478,,,Small molecule,True,SODIUM NITROPRUSSIDE,1981.0,4.0,CHEMBL2097081,False,True,['Nipride' 'Nitropress' 'Sodium nitroprusside'],"['NSC-755844' 'Nipruss' 'Nitroprusside sodium' 'Sodium nitroferricyanide'
 'Sodium nitroprusside' 'Sodium nitroprusside anhydrous'
 'Sodium nitroprusside dihydrate' 'Sodium nitroprusside hydrate']","[('DailyMed', array(['sodium%20nitroprusside'], dtype=object)), ('Wikipedia', array(['Sodium_nitroprusside'], dtype=object)), ('chEBI', array(['29321'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'MP_0001914', 'EFO_0004272', 'MONDO_0005090',
       'EFO_1000653', 'EFO_0000373', 'EFO_0008585', 'EFO_0000319',
       'MP_0001845', 'EFO_0001358'], dtype=object), 'count': 10}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for hemorrhage and congestive heart failure and has 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL193,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],HYIMSNHJOBLJNT-UHFFFAOYSA-N,Small molecule,False,NIFEDIPINE,1981.0,4.0,,False,True,"['Adalat' 'Adalat a.r.' 'Adalat cc' 'Adalat ic' 'Adalat la 20'
 'Adalat la 30' 'Adalat la 60' 'Adalat ret' 'Adalate lp' 'Adanif xl'
 'Adipine mr 10' 'Adipine mr 20' 'Adipine xl' 'Afeditab cr' 'Angiopine 10'
 'Angiopine 40 la' 'Angiopine 5' 'Angiopine mr 10' 'Angiopine mr 20'
 'Calanif' 'Calchan mr 10' 'Calchan mr 20' 'Calcilat' 'Cardilate mr'
 'Coracten sr' 'Coracten xl' 'Coroday mr' 'Fortipine la40'
 'Genalat 10 ret' 'Genalat 20 ret' 'Hypolar ret 10' 'Hypolar ret 20'
 'Hypolar xl 30' 'Kentipine' 'Kentipine mr 10' 'Kentipine mr 20'
 'Neozipine xl' 'Nife-wolff' 'Nifedipine' 'Nifedipress mr 10'
 'Nifedipress mr 20' 'Nifedotard 20 mr' 'Nifelease' 'Nifensar xl'
 'Nifopress mr' 'Nifopress ret' 'Nimodrel mr 10' 'Nimodrel mr 20'
 'Nimodrel xl' 'Nivaten ret' 'Procardia' 'Procardia xl'
 'Slofedipine xl 30' 'Slofedipine xl 60' 'Tensipine mr 10'
 'Tensipine mr 20' 'Unipine xl' 'Valni 20 ret' 'Valni xl' 'Vasad']","['BAY A 1040' 'BAY-A-1040' 'Coracten' 'NSC-757242' 'Nifedipine'
 'Nifedipine hydrochloride' 'Nifedipine slow release' 'Nifedipinum']","[('DailyMed', array(['nifedipine'], dtype=object)), ('PubChem', array(['104171202', '11111548', '11111549', '11113899', '124880908',
       '124880909', '124880910', '124880913', '144203763', '144207502',
       '170465006', '17388858', '26747150', '26747151', '26752059',
       '26752060', '50100293', '50104712', '50104713', '50104714',
       '85231157', '90341123'], dtype=object)), ('TG-GATEs', array(['91'], dtype=object)), ('Wikipedia', array(['Nifedipine'], dtype=object)), ('drugbank', array(['DB01115'], dtype=object)), ('chEBI', array(['7565'], dtype=object))]",,"{'rows': array(['MONDO_0018479', 'HP_0000093', 'EFO_1001145', 'EFO_0000401',
       'EFO_0003917', 'EFO_1001375', 'EFO_0003890', 'EFO_0004263',
       'EFO_0009660', 'EFO_0007442', 'HP_0012390', 'MONDO_0005149',
       'EFO_0000319', 'EFO_0003884', 'EFO_0004225', 'EFO_0000668',
       'EFO_0000537', 'EFO_0004253'], dtype=object), 'count': 18}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 15 investigational indications.
CHEMBL2021430,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],PLCQGRYPOISRTQ-FCJDYXGNSA-L,Small molecule,False,DEXAMETHASONE SODIUM PHOSPHATE,1959.0,4.0,CHEMBL1201302,False,True,"['Decadron' 'Dexacen-4' 'Dexacort' 'Dexair' 'Dexamethasone'
 'Dexamethasone sodium phosphate'
 'Dexamethasone sodium phosphate preservative free' 'Hexadrol' 'Maxidex']","['Dexamethasone 21-phosphate disodium salt'
 'Dexamethasone sodium phosphate' 'NSC-756722' 'TLC-399' 'TLC399' 'Tlc399']","[('DailyMed', array(['dexamethasone%20sodium%20phosphate'], dtype=object)), ('PubChem', array(['144206732', '144212903'], dtype=object)), ('chEBI', array(['4462'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_1000941', 'MONDO_0007915', 'EFO_0000556',
       'EFO_0007328', 'MONDO_0008728', 'EFO_0009609', 'EFO_0004719',
       'EFO_1000039', 'EFO_1000764', 'EFO_1000997', 'EFO_1001896',
       'EFO_0000574', 'HP_0001915', 'EFO_0001642', 'EFO_1001051',
       'HP_0012424', 'EFO_0005558', 'HP_0001873', 'EFO_0007257',
       'MONDO_0100096', 'EFO_1002022', 'EFO_0004276', 'EFO_1001250',
       'EFO_0006738', 'EFO_0005319', 'MP_0001845', 'EFO_0000729',
       'EFO_1000049', 'EFO_0007141', 'EFO_0009491', 'EFO_0001378',
       'EFO_0003929', 'EFO_0004265', 'EFO_0007490', 'EFO_0008997',
       'EFO_1000845', 'EFO_1001194', 'MONDO_0005178', 'EFO_0007403',
       'EFO_0007520', 'EFO_0004255', 'EFO_0004274', 'MONDO_0015128',
       'EFO_1000684', 'EFO_1001119', 'EFO_0003778', 'EFO_0003898',
       'EFO_0000694', 'EFO_0000565', 'MONDO_0019338', 'EFO_0003956',
       'EFO_0003106', 'EFO_0000685', 'EFO_1001222', 'EFO_0000384',
       'EFO_0009456', 'HP_0004398', 'HP_0003072', 'EFO_0002609',
       'EFO_0000676', 'EFO_0007405', 'EFO_0009449', 'EFO_0005854',
       'HP_0001094', 'EFO_1001205', 'MONDO_0001280', 'EFO_1000694',
       'HP_0003040', 'EFO_0007160', 'EFO_1001435', 'EFO_0000274'],
      dtype=object), 'count': 72}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 60 approved and 12 investigational indications.
CHEMBL2103735,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(=O)O,KFEFLCOCAHJBEA-ANRVCLKPSA-N,Protein,False,CETRORELIX ACETATE,1999.0,4.0,CHEMBL1200490,False,True,['Cetrotide'],"['Cetrorelix acetate' 'Cetrotide acetate' 'D-20761' 'NS-75A'
 'SB-075 ACETATE']","[('DailyMed', array(['cetrorelix%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cetrotide'],
      dtype=object)), ('chEBI', array(['31387'], dtype=object))]",,"{'rows': array(['EFO_0000545', 'EFO_0000660'], dtype=object), 'count': 2}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 2 investigational indications.
CHEMBL2103855,Cc1ccn(-c2cc(Cl)ccc2[C@@H](Oc2cc(-c3ccc(C[C@H](N)C(=O)O)cc3)nc(N)n2)C(F)(F)F)n1,NCLGDOBQAWBXRA-PGRDOPGGSA-N,Small molecule,False,TELOTRISTAT,,4.0,,False,True,[],['LP 778902' 'LP-778902' 'Telotristat'],"[('drugbank', array(['DB14218'], dtype=object))]",['CHEMBL4796268'],"{'rows': array(['EFO_1001901', 'EFO_0000729', 'EFO_1000852', 'EFO_0001421',
       'EFO_0003086'], dtype=object), 'count': 5}","[ENSG00000139287,ENSG00000129167]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 investigational indications.
CHEMBL2104986,Cc1ccc(Sc2ccccc2C2CCNCC2)cc1,CVASBKDYSQKLSO-UHFFFAOYSA-N,Small molecule,False,TEDATIOXETINE,,2.0,,False,False,[],['LU AA24530' 'LU-AA24530' 'LUAA24530' 'Lu aa24530' 'Tedatioxetine'],"[('drugbank', array(['DB12641'], dtype=object))]",['CHEMBL2107377'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000102468,ENSG00000142319,ENSG00000147246,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084,ENSG00000108576,ENSG00000120907]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2105728,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,DYNHJHQFHQTFTP-UHFFFAOYSA-N,Small molecule,False,CRENOLANIB,,3.0,,False,False,[],"['ARO 002' 'ARO-002' 'CP 868596' 'CP-868,596' 'CP-868596' 'Crenolanib']","[('drugbank', array(['DB11832'], dtype=object))]",['CHEMBL2146086'],"{'rows': array(['EFO_0005543', 'EFO_1000026', 'MONDO_0011719', 'EFO_0000616',
       'EFO_0000222', 'EFO_0000222', 'EFO_0000503', 'MONDO_0011719',
       'EFO_0000519'], dtype=object), 'count': 9}","[ENSG00000113721,ENSG00000134853,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL2105754,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O.O=C(O)CCC(=O)O,OGCNTTUPLQTBJI-XFULWGLBSA-N,Small molecule,False,TRELAGLIPTIN SUCCINATE,2015.0,4.0,CHEMBL1650443,False,True,[],"['SYR-111472 SUCCINATE' 'SYR-472' 'SYR111472 SUCCINATE'
 'Trelagliptin succinate' 'Zafatek']",,,"{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications.
CHEMBL2107866,,,Protein,False,PEGINESATIDE,,3.0,,False,False,['Hematide'],['AF-37702' 'AF37702' 'Peginesatide'],"[('DrugCentral', array(['4234'], dtype=object))]",,"{'rows': array(['EFO_0004272'], dtype=object), 'count': 1}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108072,,,Enzyme,False,PAMITEPLASE,,2.0,,False,False,[],['Pamiteplase' 'Solinase'],,,,[ENSG00000104368],Enzyme drug with a maximum clinical trial phase of II.
CHEMBL2108735,,,Oligonucleotide,False,DRISAPERSEN,,3.0,,False,False,[],"['Drisapersen' 'GSK-2402968' 'GSK-2402968A' 'GSK2402968' 'GSK2402968A'
 'Gsk 2402968a' 'H51AON23' 'PRO-051' 'PRO051']",,,"{'rows': array(['MONDO_0020121', 'MONDO_0010679'], dtype=object), 'count': 2}",[ENSG00000198947],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109379,,,Antibody,False,NI-0801,,2.0,,False,False,[],['NI-0801' 'Ni-0801'],,,"{'rows': array(['EFO_1000668', 'EFO_1001486'], dtype=object), 'count': 2}",[ENSG00000169245],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL222460,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO,QESHSZWKJULSAR-UHFFFAOYSA-N,Small molecule,False,BMS-223131,,2.0,,False,False,[],['Bms-223131'],,,,[ENSG00000156113],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL23,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,HSUGRBWQSSZJOP-RTWAWAEBSA-N,Small molecule,False,DILTIAZEM,1982.0,4.0,,False,True,[],"['Cardizem' 'Dilt-CD' 'Diltiazem' 'Diltiazem extended release' 'Diltzac'
 'Ditiaz' 'Surazem' 'Tiamate' 'Tiazac']","[('PubChem', array(['11113366', '144204449', '170464699', '26751609', '26751610',
       '50104266', '50104267', '50104268', '50104269', '90341257'],
      dtype=object)), ('TG-GATEs', array(['92'], dtype=object)), ('Wikipedia', array(['Diltiazem'], dtype=object)), ('drugbank', array(['DB00343'], dtype=object)), ('chEBI', array(['101278'], dtype=object))]",['CHEMBL1697' 'CHEMBL1200805'],"{'rows': array(['EFO_0004888', 'EFO_0002687', 'EFO_0000701', 'MONDO_0000831',
       'EFO_1001375', 'EFO_0000195', 'HP_0003124', 'EFO_0000537',
       'EFO_0003890', 'EFO_0000537', 'EFO_0009660', 'EFO_0000538',
       'EFO_0003144', 'EFO_0000275', 'EFO_1001951', 'EFO_0009552',
       'EFO_0007328', 'EFO_0004225', 'EFO_0001645', 'MONDO_0004992',
       'EFO_0003914', 'HP_0012390', 'EFO_0000319', 'EFO_0000275',
       'MONDO_0005148', 'EFO_0005251', 'HP_0012390', 'MONDO_0100096',
       'EFO_0000764', 'EFO_0003913', 'HP_0002019'], dtype=object), 'count': 31}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 approved and 25 investigational indications.
CHEMBL3137345,,,Antibody,False,DULIGOTUZUMAB,,2.0,,False,False,[],['Duligotumab' 'Duligotuzumab' 'MEHD-7945A' 'MEHD7945A' 'RG-7597' 'RG7597'],,,"{'rows': array(['EFO_0000616', 'EFO_1001951', 'EFO_0006859'], dtype=object), 'count': 3}","[ENSG00000065361,ENSG00000146648]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545110,CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,RHXHGRAEPCAFML-UHFFFAOYSA-N,Small molecule,False,RIBOCICLIB,2017.0,4.0,,False,True,[],"['LEE-011' 'LEE-011A' 'LEE011' 'LEE011A' 'Lee-011' 'NVP-LEE011'
 'Ribociclib']","[('drugbank', array(['DB11730'], dtype=object))]",['CHEMBL4468983' 'CHEMBL3707266'],"{'rows': array(['MONDO_0002158', 'MONDO_0007254', 'EFO_0003085', 'EFO_0000616',
       'MONDO_0044903', 'EFO_0000569', 'EFO_0000519', 'EFO_0002499',
       'EFO_0000182', 'EFO_0005701', 'EFO_1001968', 'EFO_0000220',
       'EFO_0000574', 'EFO_0000313', 'EFO_0000181', 'EFO_0001075',
       'EFO_0000305', 'EFO_0000196', 'EFO_1001901', 'MONDO_0004992',
       'EFO_0000305', 'EFO_0002626', 'EFO_0003869', 'EFO_1001100',
       'EFO_0000756', 'EFO_0000616', 'EFO_0003859', 'EFO_1000251',
       'EFO_0003869', 'MONDO_0002601', 'EFO_0003086', 'EFO_0005220',
       'EFO_1000026', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0008170',
       'MONDO_0007254', 'EFO_0000621'], dtype=object), 'count': 38}","[ENSG00000135446,ENSG00000105810]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 34 investigational indications.
CHEMBL3545985,C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1,YXKTVDFXDRQTKV-HNNXBMFYSA-N,Small molecule,False,BENZPHETAMINE,1960.0,4.0,,False,True,[],['Benzfetamine'],"[('drugbank', array(['DB00865'], dtype=object)), ('chEBI', array(['3044'], dtype=object))]",['CHEMBL3544906'],"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000165646]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for obesity.
CHEMBL3707229,,,Antibody,False,TEZEPELUMAB,2021.0,4.0,,False,True,['Tezspire'],['AMG 157' 'MEDI19929' 'Tezepelumab'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire'],
      dtype=object))]",,"{'rows': array(['EFO_0005531', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000274',
       'HP_0006536', 'EFO_0004232', 'MONDO_0005271'], dtype=object), 'count': 7}",[ENSG00000145777],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for asthma and airway obstruction and has 5 investigational indications.
CHEMBL4297560,,,Antibody,False,GATIPOTUZUMAB,,2.0,,False,False,[],['Gatipotuzumab'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000185499],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297581,,,Oligonucleotide,False,TOMINERSEN,,3.0,,False,False,[],"['ISIS-443139 FREE ACID' 'Ionis httrx' 'Isis 443139' 'RG-6042 FREE ACID'
 'RG6042' 'RG6042 FREE ACID' 'Rg6042' 'Ro7234292' 'Tominersen']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOMINERSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0006835', 'MP_0001845', 'MONDO_0015492', 'MONDO_0007739',
       'EFO_1000710'], dtype=object), 'count': 5}",[ENSG00000197386],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297616,NC(=O)[C@](O)(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)C(F)(F)F,YWQFJNWMWZMXRW-HXUWFJFHSA-N,Small molecule,False,OLINCIGUAT,,2.0,,False,False,[],['IW-1701' 'IW1701' 'Iw-1701' 'Olinciguat'],"[('drugbank', array(['DB15238'], dtype=object))]",,"{'rows': array(['HP_0002571', 'MONDO_0011382'], dtype=object), 'count': 2}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297832,,,Antibody,False,SUTIMLIMAB,2022.0,4.0,,False,True,['Enjaymo'],"['BIVV009' 'Bivv-009' 'Enjaymo' 'Sutimlimab' 'Sutimlimab jome'
 'Sutimlimab-jome' 'TNT-009' 'TNT009']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo'],
      dtype=object))]",,"{'rows': array(['EFO_0007160', 'EFO_0000540', 'EFO_1001264', 'MONDO_0018922',
       'EFO_0009473'], dtype=object), 'count': 5}",[ENSG00000182326],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 4 approved and 1 investigational indication.
CHEMBL4594605,,,Unknown,False,OMFILOCTOCOG ALFA,,3.0,,False,False,[],['Omfiloctocog alfa' 'SCT-800' 'SCT800' 'Sct800'],,,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4650461,,,Unknown,False,CSL-324,,2.0,,False,False,[],['Anumigilimab' 'CSL-324' 'CSL324' 'Csl 324' 'Csl-324' 'Csl324'],,,"{'rows': array(['MONDO_0100096'], dtype=object), 'count': 1}",[ENSG00000119535],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL5095492,C=CC(=O)Nc1cc(C#CC(C)(C)N2CCN(C)CC2)cc2ncnc(Nc3ccc(F)c(Cl)c3)c12,JZDDKMMYGMSSFH-UHFFFAOYSA-N,Small molecule,False,MP-412,,1.0,,False,False,[],[],,['CHEMBL5095024'],"{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL511142,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,RMRJXGBAOAMLHD-CTAPUXPBSA-N,Small molecule,True,BUPRENORPHINE,1981.0,4.0,,False,True,"['Bupeaze' 'Buplast' 'Butec' 'Butrans' 'Hapoctasin' 'Panitaz' 'Prenotrix'
 'Reletrans' 'Sevodyne' 'Sublocade' 'Temgesic' 'Tephine' 'Transtec']","['ALKS-5461 COMPONENT BUPRENORPHINE' 'Brixadi' 'Buprenorphin'
 'Buprenorphine' 'Suboxone']","[('DailyMed', array(['buprenorphine'], dtype=object))]",['CHEMBL2368861'],"{'rows': array(['EFO_0005799', 'EFO_0003047', 'EFO_0020911', 'MONDO_0002491',
       'HP_0003419', 'HP_0003418', 'EFO_0001358', 'EFO_0005611',
       'EFO_0000764', 'EFO_0010702', 'EFO_0010072', 'EFO_1001250',
       'EFO_0005611', 'EFO_0003843', 'EFO_0000181', 'MONDO_0002050',
       'EFO_0005762', 'HP_0012532', 'HP_0008419', 'EFO_0003890',
       'EFO_0002610', 'EFO_0004240', 'EFO_0004701', 'MONDO_0002009',
       'EFO_0003890', 'EFO_0005800', 'MONDO_0005090', 'MONDO_0011382',
       'MONDO_0005178', 'EFO_0005612'], dtype=object), 'count': 30}","[ENSG00000112038,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL604710,O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1,VCPMZDWBEWTGNW-UHFFFAOYSA-N,Small molecule,False,Z160,,2.0,,False,False,[],['MK-6721' 'MK6721' 'NMED-160' 'NP-118809' 'Z-160' 'Z160'],"[('drugbank', array(['DB12743'], dtype=object))]",,"{'rows': array(['MONDO_0002959', 'MONDO_0041052'], dtype=object), 'count': 2}",[ENSG00000148408],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL633,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,Small molecule,True,AMIODARONE,1985.0,4.0,,False,True,[],['Amiodarone' 'Cordarone' 'L-3428' 'Pacerone' 'SKF 33134-A'],"[('PubChem', array(['104171110', '11110784', '11110785', '124879287', '144203634',
       '170464920', '26751596', '26751597', '50100172', '90341282'],
      dtype=object)), ('TG-GATEs', array(['33'], dtype=object)), ('Wikipedia', array(['Amiodarone'], dtype=object)), ('drugbank', array(['DB01118'], dtype=object)), ('chEBI', array(['2663'], dtype=object))]",['CHEMBL1083993'],"{'rows': array(['EFO_0004269', 'EFO_0004287', 'EFO_0007243', 'EFO_0000373',
       'HP_0004755', 'EFO_0001645', 'MONDO_0100096', 'EFO_0000275',
       'EFO_0005529', 'MONDO_0019438', 'EFO_0003911', 'EFO_0005306',
       'EFO_0000612', 'EFO_0009492', 'EFO_0004287', 'EFO_0003144',
       'EFO_0004278', 'EFO_0005306', 'HP_0004308', 'EFO_0000275',
       'HP_0004308', 'EFO_0000318'], dtype=object), 'count': 22}",[ENSG00000055118],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL86,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,TTWJBBZEZQICBI-UHFFFAOYSA-N,Small molecule,True,METOCLOPRAMIDE,1979.0,4.0,,False,True,[],"['Clopra' 'Clopra-""Yellow""' 'Elieten' 'Maxolon' 'Methoxyclopramide'
 'Metoclopramide' 'Reglan' 'Terperan']","[('PubChem', array(['11111421', '11111422', '144203739', '170464848', '26751627',
       '90341551'], dtype=object)), ('Wikipedia', array(['Metoclopramide'], dtype=object)), ('drugbank', array(['DB01233'], dtype=object)), ('chEBI', array(['107736'], dtype=object))]",['CHEMBL1200940' 'CHEMBL1256771'],"{'rows': array(['HP_0002039', 'HP_0002239', 'EFO_1002048', 'HP_0002017',
       'EFO_1000948', 'HP_0002315', 'HP_0001943', 'HP_0002013',
       'MONDO_0004992', 'EFO_0004888', 'EFO_0003843', 'EFO_0005252',
       'HP_0100806', 'EFO_1000949', 'EFO_0000198', 'EFO_1000948',
       'HP_0002013', 'HP_0002017', 'EFO_1001463', 'EFO_0000764',
       'EFO_1000971', 'EFO_0006911', 'EFO_0000616', 'EFO_1000645',
       'MONDO_0005277', 'EFO_0010282', 'MONDO_0004565', 'EFO_0000546'],
      dtype=object), 'count': 28}","[ENSG00000149295,ENSG00000166736,ENSG00000164270]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 8 approved and 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200970,CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21.Cl,VXPCQISYVPFYRK-UHFFFAOYSA-N,Small molecule,False,ETHOPROPAZINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1206,False,True,['Parsidol'],"['Ethopropazine hcl' 'Ethopropazine hydrochloride' 'NSC-169467'
 'NSC-64074' 'Profenamine' 'Profenamine hibenzate'
 'Profenamine hydrochloride' 'Prophenamine hydrochloride']","[('PubChem', array(['144204047', '170465065', '26748043', '26748044'], dtype=object)), ('chEBI', array(['31568'], dtype=object))]",,,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201213,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1,HUYWAWARQUIQLE-UHFFFAOYSA-N,Small molecule,False,ISOETHARINE,1979.0,4.0,,False,True,[],"['Dilabron' 'Etyprenaline' 'Isoetarine' 'Isoetharine' 'Neoisuprel'
 'WIN 3406' 'WIN-3046' 'WIN-3406' 'WIN3406']","[('PubChem', array(['90341304'], dtype=object)), ('Wikipedia', array(['Isoetarine'], dtype=object)), ('drugbank', array(['DB00221'], dtype=object)), ('chEBI', array(['6005'], dtype=object))]",['CHEMBL1200920' 'CHEMBL1201153'],"{'rows': array(['HP_0006536'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for airway obstruction.
CHEMBL1201288,O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1,OZOMQRBLCMDCEG-VIZOYTHASA-N,Small molecule,True,DANTROLENE,1974.0,4.0,,False,True,[],"['2-methylbenzoic acid anilide' 'BAS-305' 'BAS-3050' 'BAS-3050F' 'Bebenil'
 'Dantrolene' 'F-368' 'Mebenil' 'NSC-227402' 'NSC-26404'
 'O-methylbenzanilide' 'O-toluanilide' 'SHA-458100']","[('PubChem', array(['26756482', '26756773'], dtype=object)), ('TG-GATEs', array(['119'], dtype=object)), ('Wikipedia', array(['Dantrolene'], dtype=object)), ('drugbank', array(['DB01219'], dtype=object))]",['CHEMBL2067986' 'CHEMBL928'],"{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0020003', 'MONDO_0005301',
       'EFO_1000632', 'HP_0001257', 'EFO_0000546', 'EFO_0005306',
       'HP_0001945', 'EFO_1001340', 'MONDO_0018105', 'MONDO_0005301',
       'HP_0001945'], dtype=object), 'count': 13}","[ENSG00000198838,ENSG00000196218]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201560,,,Protein,True,PEGINTERFERON ALFA-2A,2002.0,4.0,,False,True,['Pegasys' 'Roferon-A'],"['Peg-interferon alfa 2a' 'Peg-interferon alfa-2a'
 'Peginterferon .alpha.-2a' 'Peginterferon alfa' 'Peginterferon alfa-2a'
 'Peginterferon-alfa-2a' 'Pegyinterferon-alfa-2a'
 'Pegylated interferon alfa-2a' 'Pegylated interferon alpha 2a'
 'Pegylated-interferon alfa 2a' 'Pegylated-interferon-alfa-2a'
 'RO 25-8310/000' 'RO-258310000']","[('DailyMed', array(['peginterferon%20alfa-2a'], dtype=object)), ('DrugCentral', array(['5158'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys'],
      dtype=object)), ('Wikipedia', array(['Peginterferon_alfa-2a'], dtype=object))]",,"{'rows': array(['EFO_0002430', 'HP_0012115', 'HP_0001873', 'EFO_0004197',
       'EFO_0002429', 'EFO_0001378', 'MONDO_0002050', 'EFO_0000479',
       'MONDO_0021063', 'EFO_0004239', 'EFO_0000756', 'EFO_0001422',
       'MONDO_0007254', 'EFO_1000026', 'MONDO_0002367', 'MONDO_0044903',
       'EFO_0000544', 'EFO_0000182', 'EFO_0008496', 'EFO_0000095',
       'EFO_0000339', 'EFO_0007304', 'EFO_0000764', 'EFO_0004220',
       'EFO_0003047', 'MONDO_0004992', 'EFO_1000874', 'EFO_0000616'],
      dtype=object), 'count': 28}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 23 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1279,CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,XPSQPHWEGNHMSK-SECBINFHSA-N,Small molecule,False,FROVATRIPTAN,2001.0,4.0,,False,True,['Migard' 'Mylatrip'],['Allergo filmtabletten' 'Frova' 'Frovatriptan'],"[('Wikipedia', array(['Frovatriptan'], dtype=object)), ('drugbank', array(['DB00998'], dtype=object))]",['CHEMBL1200371' 'CHEMBL2138684'],"{'rows': array(['MONDO_0005277', 'MONDO_0005277', 'EFO_0003843'], dtype=object), 'count': 3}","[ENSG00000135312,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for migraine disorder and has 1 investigational indication.
CHEMBL1743078,,,Antibody,False,TEPLIZUMAB,2022.0,4.0,,False,True,['Tzield'],"['HOKT3-GAMMA-1 (ALA-ALA)' 'HUMANIZED OKT3' 'Humanzied OKT3' 'MGA-031'
 'MGA031' 'Teplizumab' 'Teplizumab mzwv' 'Teplizumab-mzwv' 'Tzield'
 'hOKT3 gamma 1 (Ala-Ala)']",,,"{'rows': array(['EFO_0002546', 'MONDO_0005147', 'EFO_0000676'], dtype=object), 'count': 3}",[ENSG00000198851],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for type 1 diabetes mellitus and has 2 investigational indications.
CHEMBL2103743,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,SYIKUFDOYJFGBQ-YLAFAASESA-N,Small molecule,True,TOFACITINIB CITRATE,2012.0,4.0,CHEMBL221959,False,True,['Xeljanz' 'Xeljanz xr'],"['CP-690,550-10' 'CP-690550-10' 'Cp-690550 citrate'
 'Tasocitinib monocitrate' 'Tofacitinib citrate' 'Tofacitinib monocitrate']","[('DailyMed', array(['tofacitinib%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz'],
      dtype=object)), ('chEBI', array(['71197'], dtype=object))]",,"{'rows': array(['MONDO_0019558', 'EFO_0003898', 'EFO_0003778', 'MONDO_0007915',
       'EFO_0000274', 'EFO_0000685'], dtype=object), 'count': 6}","[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for psoriatic arthritis and rheumatoid arthritis and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2107312,CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C,JXTAALBWJQJLGN-KSSFIOAISA-N,Small molecule,False,ARBACLOFEN PLACARBIL,,3.0,,False,False,[],['Arbaclofen placarbil' 'XP-19986' 'XP19986'],"[('drugbank', array(['DB08892'], dtype=object))]",,"{'rows': array(['HP_0003418', 'MONDO_0005301', 'HP_0001257', 'MONDO_0007079',
       'EFO_0003948'], dtype=object), 'count': 5}","[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2109250,,,Antibody,False,TGN-1412,,2.0,,False,False,[],"['CD28-SUPERMAB' 'TAB-08' 'TGN-1412' 'Tab08' 'Tgn-1412' 'Tgn1412'
 'Theralizumab']",,,"{'rows': array(['EFO_0000616', 'MONDO_0007915', 'EFO_0000685', 'EFO_1001494'],
      dtype=object), 'count': 4}",[ENSG00000178562],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2109348,,,Antibody,False,LFB-R603,,1.0,,False,False,[],['LFB-R603' 'Lfb-r603'],,,"{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2311030,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O,PBKVEOSEPXMKDN-LZHUFOCISA-N,Unknown,False,ERGOLOID MESYLATES,1953.0,4.0,CHEMBL2364968,False,True,"['Alkergot' 'Circanol' 'Deapril-st' 'Ergoloid mesylates' 'Gerimal'
 'Hydergine' 'Hydergine lc' 'Hydrogenated ergot alkaloids']","['Co-dergocrine mesilate' 'Co-dergocrine mesylate' 'Codergocrine mesilate'
 'Dihydroergotoxine mesilate' 'Dihydroergotoxine mesylate'
 'Dihydroergotoxine methanesulfonate' 'Dihydrogenated ergot alkaloids'
 'Ergoloid mesilates' 'Ergoloid mesylates' 'Hydrogenated ergot alkaloids']","[('DailyMed', array(['ergoloid%20mesylates'], dtype=object)), ('DrugCentral', array(['5035'], dtype=object))]",,"{'rows': array(['EFO_0004718', 'EFO_0000319', 'MONDO_0010383'], dtype=object), 'count': 3}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845,ENSG00000135312,ENSG00000178394]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL3527000,O=c1[nH]nc2c3c(cccc13)Oc1ccc(CN3CCC(O)CC3)cc1-2,HAVFFEMDLROBGI-UHFFFAOYSA-N,Small molecule,False,E-7016,,2.0,,False,False,[],['E 7016' 'E-7016' 'E7016' 'GPI-21016'],,,"{'rows': array(['EFO_0000756', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000143799,ENSG00000041880,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545261,,,Antibody,False,BRONTICTUZUMAB,,2.0,,False,False,[],['Brontictuzumab' 'OMP-52M51'],,,"{'rows': array(['EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000148400],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3989801,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](COP(=O)(O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O,AAYJNPGTWYJOET-VURLEEIPSA-N,Protein,False,FORIGERIMOD ACETATE,,3.0,CHEMBL3989409,False,False,['Lupuzor'],['CEP-33457' 'Forigerimod acetate' 'IPP 201101' 'P-140' 'P140'],,,"{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}",[ENSG00000109971],Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL413376,Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)[O-])c3cc(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)[O-])c5cc(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c45)ccc3C)c2)c1.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],VAPNKLKDKUDFHK-UHFFFAOYSA-H,Small molecule,False,SURAMIN HEXASODIUM,,3.0,CHEMBL265502,False,False,[],"['BAY-205' 'BAYER-205' 'CI-1003' 'FOURNEAU 309' 'FOURNEAU-309' 'NF-060'
 'NSC-758165' 'Nagananinum' 'Naphuride' 'Suramin hexasodium'
 'Suramin sodium' 'Suraminum natricum']","[('PubChem', array(['11112082', '124881892', '26747683', '26753666', '85231329'],
      dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000681', 'MONDO_0007254', 'DOID_10113',
       'EFO_1000796', 'HP_0001919', 'EFO_0000673', 'MONDO_0001187',
       'EFO_0005044', 'EFO_0007294', 'EFO_0003756', 'EFO_0001378',
       'EFO_0003060', 'EFO_1000158', 'EFO_1001951'], dtype=object), 'count': 15}",[ENSG00000113578],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications.
CHEMBL4297599,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O,PVPJTBAEAQVTPN-HRAQMCAYSA-N,Small molecule,False,ASPACYTARABINE,,2.0,,False,False,[],['Aspacytarabine' 'Astarabine' 'BST-236' 'Bst-236'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ASPACYTARABINE/relevant/1/'],
      dtype=object))]",['CHEMBL4802250'],"{'rows': array(['EFO_0000198', 'EFO_0000222', 'EFO_0000198', 'EFO_0000220',
       'EFO_0000222'], dtype=object), 'count': 5}","[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297764,,,Unknown,False,HETROMBOPAG OLAMINE,,3.0,,False,False,[],"['Hetrombopag diolamine' 'Hetrombopag ethanolamine' 'Hetrombopag olamine'
 'Rafutrombopag olamine' 'SHR-8735 OLAMINE' 'SHR8735 OLAMINE']",,,"{'rows': array(['EFO_0007160', 'EFO_0006927', 'HP_0001915'], dtype=object), 'count': 3}",[ENSG00000117400],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4650374,,,Unknown,False,APG-2575,,2.0,,False,False,[],['APG-2575' 'APG2575' 'Apg-2575' 'Apg2575' 'Lisaftoclax'],,,"{'rows': array(['EFO_0001378', 'EFO_0000220', 'EFO_1001875', 'EFO_0009441',
       'EFO_0004289', 'EFO_0000095', 'EFO_0000621', 'MONDO_0004992',
       'EFO_0000222', 'MONDO_0007254'], dtype=object), 'count': 10}",[ENSG00000171791],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL4650509,,,Antibody,False,MIBAVADEMAB,,2.0,,False,False,[],['Mibavademab' 'REGN-4461' 'REGN4461' 'Regn4461'],,,"{'rows': array(['MONDO_0027766', 'MONDO_0020088'], dtype=object), 'count': 2}",[ENSG00000116678],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5314409,CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1.Cl,GECUEJGEJLAXQA-UHFFFAOYSA-N,Small molecule,False,GSK-2269557,,2.0,CHEMBL2216859,False,False,[],['GSK-2269557' 'GSK2269557' 'Gsk-2269557' 'Nemiralisib hydrochloride'],,,"{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL658,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,GGCSSNBKKAUURC-UHFFFAOYSA-N,Small molecule,True,SUFENTANIL,1984.0,4.0,,False,True,[],"['IDS-NS-001' 'R 30,730' 'R-30730' 'Sufentanil' 'Sufentanyl']","[('Wikipedia', array(['Sufentanil'], dtype=object)), ('drugbank', array(['DB00708'], dtype=object)), ('chEBI', array(['9316'], dtype=object))]",['CHEMBL1201163' 'CHEMBL4747678'],"{'rows': array(['EFO_1001139', 'EFO_0003843', 'EFO_0009267', 'HP_0012532',
       'EFO_0002950', 'HP_0003418', 'EFO_0003843', 'EFO_0000546'],
      dtype=object), 'count': 8}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for pain and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL76688,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1,BTGNGJJLZOIYID-UHFFFAOYSA-N,Small molecule,False,SIVELESTAT,,3.0,,False,False,[],['LY-544349' 'LY544349' 'ONO-5046' 'Sivelestat'],"[('Wikipedia', array(['Sivelestat'], dtype=object)), ('drugbank', array(['DB12863'], dtype=object))]",['CHEMBL3182314' 'CHEMBL2107493'],"{'rows': array(['EFO_0000694'], dtype=object), 'count': 1}",[ENSG00000197561],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1200405,CS(=O)(=O)O.Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1,HODFCFXCOMKRCG-UHFFFAOYSA-N,Small molecule,False,BITOLTEROL MESYLATE,1984.0,4.0,CHEMBL1201295,False,True,['Tornalate'],"['Bitolterol mesilate' 'Bitolterol mesylate' 'Bitolterol methanesulfonate'
 'WIN 32,784' 'WIN-32784']","[('chEBI', array(['3134'], dtype=object))]",,,[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984.
CHEMBL1201154,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1.O=S(=O)(O)CCS(=O)(=O)O,SWOUGRBFXFILIB-UHFFFAOYSA-N,Small molecule,True,PROCHLORPERAZINE EDISYLATE,1957.0,4.0,CHEMBL728,False,True,['Compazine' 'Prochlorperazine edisylate'],"['NSC-757299' 'Prochlorperazine edisilate' 'Prochlorperazine edisylate'
 'Prochlorperazine edisylate salt' 'Prochlorperazine ethanedisulfonate']","[('DailyMed', array(['prochlorperazine%20edisylate'], dtype=object)), ('PubChem', array(['26748222', '56422461'], dtype=object))]",,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957. This drug has a black box warning from the FDA.
CHEMBL1201187,Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,GSNHKUDZZFZSJB-QYOOZWMWSA-N,Small molecule,True,MARAVIROC,2007.0,4.0,,False,True,['Celsentri' 'Selzentry'],"['Maraviroc' 'Rel-Maraviroc' 'UK-427857' 'Uk-427,857']","[('DailyMed', array(['maraviroc'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/celsentri'],
      dtype=object)), ('Wikipedia', array(['Maraviroc'], dtype=object)), ('drugbank', array(['DB04835'], dtype=object)), ('chEBI', array(['63608'], dtype=object))]",['CHEMBL4476214' 'CHEMBL4586236'],"{'rows': array(['EFO_0000198', 'MONDO_0100096', 'EFO_0000685', 'EFO_0000403',
       'EFO_0000183', 'EFO_0000544', 'EFO_0000339', 'EFO_0002608',
       'MONDO_0018906', 'MONDO_0044881', 'EFO_0000095', 'EFO_0000765',
       'EFO_0000558', 'EFO_0000712', 'MONDO_0013730', 'EFO_0004211',
       'EFO_0000763', 'EFO_0000180', 'HP_0100543', 'EFO_0000764',
       'MONDO_0021094'], dtype=object), 'count': 21}",[ENSG00000160791],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1621597,CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2,OEXHQOGQTVQTAT-BHIXFJMTSA-N,Small molecule,False,IPRATROPIUM,1986.0,4.0,,False,True,[],['Ipratropium' 'Ipratropium cation' 'Ipratropium ion'],"[('drugbank', array(['DB00332'], dtype=object))]",['CHEMBL1464005' 'CHEMBL2134724' 'CHEMBL3085123'],"{'rows': array(['MONDO_0005180', 'EFO_0000341', 'HP_0002307', 'EFO_0008590',
       'EFO_0006505', 'MONDO_0004979', 'HP_0001742', 'EFO_0000464',
       'Orphanet_1764', 'EFO_0003956', 'EFO_0001361', 'EFO_0000341',
       'EFO_0007214', 'HP_0006536', 'EFO_0000274'], dtype=object), 'count': 15}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 9 approved and 6 investigational indications.
CHEMBL2107856,,,Oligonucleotide,False,IMETELSTAT,,3.0,,False,False,[],['GRN-163L' 'GRN163L' 'Imetelstat'],,,"{'rows': array(['MONDO_0044903', 'EFO_0000479', 'EFO_0000621', 'EFO_0001378',
       'EFO_0003060', 'MONDO_0007254', 'EFO_0000198', 'EFO_0000574',
       'EFO_0002429'], dtype=object), 'count': 9}",[ENSG00000164362],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL2108358,,,Protein,False,SERELAXIN,,3.0,,False,False,[],"['Human relaxin 2 (relaxin h2)' 'Human relaxin recombinant' 'RLX-030'
 'RLX030' 'Recombinant human relaxin' 'Serelaxin']",,,"{'rows': array(['EFO_0001421', 'EFO_0000668', 'EFO_0001645', 'EFO_0003144',
       'EFO_0000319', 'EFO_0003884'], dtype=object), 'count': 6}","[ENSG00000133105,ENSG00000171509]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2109384,,,Antibody,False,DEMCIZUMAB,,2.0,,False,False,[],['Demcizumab' 'OMP-21M18'],,,"{'rows': array(['EFO_0002618', 'EFO_1001951', 'EFO_0003060', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000128917],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL249856,CSc1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1,ZJKNESGOIKRXQY-UHFFFAOYSA-N,Small molecule,False,ENOXIMONE,,4.0,,False,True,['Perfan'],"['Enoximone' 'MDL 17,043' 'MDL-17043']","[('PubChem', array(['11111134', '144203688', '170466419', '50106183', '56320891',
       '56320892', '85231030', '90340640'], dtype=object)), ('Wikipedia', array(['Enoximone'], dtype=object)), ('drugbank', array(['DB04880'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0001645', 'EFO_0000373'], dtype=object), 'count': 3}","[ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL278703,Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,XIESSJVMWNJCGZ-VKJFTORMSA-N,Small molecule,False,ERTEBEREL,,2.0,,False,False,[],['Erteberel' 'LY-500307' 'LY500307' 'Serba-1'],"[('drugbank', array(['DB07933'], dtype=object))]",,"{'rows': array(['MONDO_0005090', 'EFO_0000284'], dtype=object), 'count': 2}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL289228,Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,PLHJCIYEEKOWNM-HHHXNRCGSA-N,Small molecule,False,TIPIFARNIB,,3.0,,False,False,[],['NSC-702818' 'R-11577' 'R-115777' 'R115777' 'Tipifarnib' 'Zarnestra'],"[('Wikipedia', array(['Tipifarnib'], dtype=object)), ('drugbank', array(['DB04960'], dtype=object))]",,"{'rows': array(['EFO_0005235', 'EFO_0000565', 'EFO_0002430', 'MONDO_0002108',
       'MONDO_0001187', 'EFO_0000305', 'EFO_0000218', 'EFO_1001951',
       'EFO_0002429', 'EFO_1000984', 'EFO_0003869', 'EFO_0001378',
       'EFO_1001779', 'MONDO_0008315', 'EFO_0000616', 'EFO_0002618',
       'EFO_0003028', 'EFO_1000309', 'MONDO_0004992', 'EFO_0000632',
       'MONDO_0008903', 'MONDO_0007254', 'EFO_0002428', 'EFO_0006861',
       'EFO_1000158', 'EFO_0000756', 'EFO_0003060', 'EFO_0000198',
       'EFO_0002939', 'EFO_0008528', 'EFO_0000479', 'EFO_0003027',
       'MONDO_0019469', 'MONDO_0021633', 'EFO_0000222', 'EFO_0000223',
       'EFO_0000095', 'EFO_1001465', 'EFO_0000181', 'EFO_1001469',
       'EFO_1001933', 'EFO_0000519', 'MONDO_0021310', 'EFO_0000339'],
      dtype=object), 'count': 44}","[ENSG00000168522,ENSG00000257365]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 44 investigational indications.
CHEMBL3301604,O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1,NPDKXVKJRHPDQT-IYARVYRRSA-N,Small molecule,False,RALINEPAG,,3.0,,False,False,[],['APD-811' 'APD811' 'Ralinepag'],"[('drugbank', array(['DB12462'], dtype=object))]",['CHEMBL3961431'],"{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3545139,,,Small molecule,False,PS-516895,,1.0,,False,False,[],['Ps-516895'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL38943,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O,YDBLKRPLXZNVNB-UHFFFAOYSA-N,Small molecule,False,GW501516,,2.0,,False,False,[],['Cardarine' 'GSK-516' 'GW-1516' 'GW501516' 'Gw-501516' 'Gw501516'],"[('PubChem', array(['137275846', '99460836'], dtype=object)), ('Wikipedia', array(['GW501516'], dtype=object)), ('drugbank', array(['DB05416'], dtype=object)), ('chEBI', array(['73726'], dtype=object))]",,"{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}",[ENSG00000112033],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297356,CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1,FEFIBEHSXLKJGI-UHFFFAOYSA-N,Small molecule,False,AZD-8848,,2.0,,False,False,[],['AZD8848' 'Azd 8848' 'Azd-8848' 'Azd8848' 'DSP-3025' 'Dsp-3025'],"[('drugbank', array(['DB14868'], dtype=object))]",,"{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}",[ENSG00000196664],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL442,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,XCGSFFUVFURLIX-VFGNJEKYSA-N,Small molecule,True,ERGOTAMINE,1948.0,4.0,,False,True,[],['Ergotamine' 'Ergotamine Tartrate' 'NSC-95090'],"[('Wikipedia', array(['Ergotamine'], dtype=object)), ('drugbank', array(['DB00696'], dtype=object)), ('chEBI', array(['64318'], dtype=object))]",['CHEMBL2448612' 'CHEMBL1743258' 'CHEMBL2131781'],"{'rows': array(['MONDO_0005277', 'MONDO_0005277', 'HP_0002315', 'EFO_0005252'],
      dtype=object), 'count': 4}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for migraine disorder and headache and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL4650281,C=CC(=O)N[C@H]1C=C(C)c2c(-c3cnc4ccccc4c3)c3c(N)ncnc3n2C1,MKCYPWYURWOKST-INIZCTEOSA-N,Small molecule,False,CLN-081,,1.0,,False,False,[],"['CLN-081' 'CLN081' 'Cln 081' 'Cln-081' 'TAS-6417' 'TAS6417' 'TPC-064'
 'TPC064' 'Zipalertinib']",,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4650318,COc1nc(C(=O)NC[C@](C)(O)C(F)(F)F)c(N)cc1C(F)(F)F,USHQRIKZLHNPQR-JTQLQIEISA-N,Small molecule,False,ICENTICAFTOR,,2.0,,False,False,[],['Icenticaftor' 'QBW-251' 'QBW251' 'Qbw251'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ICENTICAFTOR/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0001399', 'EFO_0000341', 'MONDO_0004822', 'MONDO_0009061'],
      dtype=object), 'count': 4}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4650413,,,Oligonucleotide,False,OLPASIRAN,,3.0,,False,False,[],['AMG 890' 'AMG-890' 'Amg 890' 'Olpasiran'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLPASIRAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003086', 'EFO_0003914', 'EFO_0001421', 'EFO_0000319'],
      dtype=object), 'count': 4}",[ENSG00000198670],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL57997,Nc1sc2c(c1C(=O)c1ccc(Cl)cc1)CCCC2,OTZVBZFYMFTYKH-UHFFFAOYSA-N,Small molecule,False,T-62,,2.0,,False,False,[],['T-62'],"[('PubChem', array(['29217669'], dtype=object)), ('drugbank', array(['DB12919'], dtype=object))]",['CHEMBL203347'],"{'rows': array(['MONDO_0041052'], dtype=object), 'count': 1}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL603469,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O,UIARLYUEJFELEN-LROUJFHJSA-N,Small molecule,False,LESTAURTINIB,,3.0,,False,False,[],"['A-154475' 'A-154475.0' 'CEP-701' 'Cep-701' 'KT-555' 'KT-5555' 'KT5555'
 'Lestaurtinib' 'SP-924' 'SP924' 'SPM-924']","[('PubChem', array(['144206186', '50113274'], dtype=object)), ('Wikipedia', array(['Lestaurtinib'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0002429', 'EFO_0000479', 'EFO_0000222',
       'EFO_0000621', 'MONDO_0008315', 'MONDO_0044903', 'EFO_0000676',
       'EFO_0000565'], dtype=object), 'count': 9}","[ENSG00000096968,ENSG00000165731,ENSG00000122025,ENSG00000140538,ENSG00000198400,ENSG00000148053]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL73451,c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2,HOKDBMAJZXIPGC-UHFFFAOYSA-N,Small molecule,False,MEQUITAZINE,,4.0,,False,True,['Primalan'],['Kitazemin' 'Mequitazine' 'NSC-303612'],"[('PubChem', array(['144207197', '170465794', '26665232', '453325', '56320321'],
      dtype=object)), ('drugbank', array(['DB01071'], dtype=object)), ('chEBI', array(['31821'], dtype=object))]",,"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV and is indicated for allergic disease.
CHEMBL94,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C,PIJVFDBKTWXHHD-HIFRSBDPSA-N,Small molecule,False,PHYSOSTIGMINE,,4.0,,False,True,[],"['(-)-physostigmine' 'Cogmine' 'Eserin' 'Eserine' 'Eserinum' 'MCV-4484'
 'NSC-30782' 'Physostigmine']","[('PubChem', array(['144204779', '144211908', '170465757', '26753571', '26753572',
       '50085948', '50106262', '50106263', '90340907'], dtype=object)), ('Wikipedia', array(['Physostigmine'], dtype=object)), ('drugbank', array(['DB00981'], dtype=object)), ('chEBI', array(['27953'], dtype=object))]",['CHEMBL338975' 'CHEMBL537674' 'CHEMBL2105891'],"{'rows': array(['EFO_0002614', 'EFO_0009267', 'EFO_0003843', 'MONDO_0005041'],
      dtype=object), 'count': 4}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for glaucoma and has 3 investigational indications.
CHEMBL95889,C[N+](C)(C)CC(=O)O,KWIUHFFTVRNATP-UHFFFAOYSA-O,Small molecule,False,BETAINE,1996.0,4.0,,False,True,['Amversio' 'Cystadane'],"['Abromine' 'Betaine' 'Betaine anhydrous' 'Betaine, anhydrous' 'Cystadane'
 'FEMA NO. 4223' 'NSC-166511']","[('DailyMed', array(['betaine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amversio'],
      dtype=object)), ('PubChem', array(['11110845', '174007375', '90341438'], dtype=object)), ('drugbank', array(['DB04455'], dtype=object)), ('chEBI', array(['41139'], dtype=object))]",['CHEMBL1201130'],"{'rows': array(['EFO_1001249', 'EFO_0004248', 'EFO_0009869', 'MONDO_0004737',
       'MONDO_0002009', 'EFO_0003047', 'EFO_0004220', 'EFO_0001073',
       'MONDO_0002474'], dtype=object), 'count': 9}","[ENSG00000145692,ENSG00000132840]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for homocystinuria and major depressive disorder and has 7 investigational indications.
CHEMBL1200623,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C,AOXRBFRFYPMWLR-XGXHKTLJSA-N,Small molecule,False,ETHYLESTRENOL,1964.0,4.0,,False,True,['Maxibolin'],"['Durabolin-o' 'Duraboral' 'Ethylestrenol' 'Ethylnandrol' 'Ethyloestrenol'
 'NSC-37726' 'Orabolin']","[('PubChem', array(['144206065', '170465211', '50112767'], dtype=object)), ('Wikipedia', array(['Ethylestrenol'], dtype=object)), ('drugbank', array(['DB01493'], dtype=object)), ('chEBI', array(['31578'], dtype=object))]",,,[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1964.
CHEMBL1200809,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,YEJAJYAHJQIWNU-UHFFFAOYSA-N,Small molecule,False,AZELASTINE HYDROCHLORIDE,1996.0,4.0,CHEMBL639,False,True,"['Astelin' 'Astepro' 'Astepro allergy' 'Azelastine hydrochloride'
 ""Children's astepro allergy"" 'Optilast' 'Optivar' 'Rhinolast'
 'Rhinolast allergy']",['A-5610' 'Azelastine hcl' 'Azelastine hydrochloride' 'E-0659' 'W-2979M'],"[('DailyMed', array(['azelastine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205022', '170465172', '26749052', '49681818'], dtype=object)), ('chEBI', array(['2951'], dtype=object))]",,"{'rows': array(['HP_0001742', 'EFO_0005854', 'EFO_0009364', 'EFO_1001417',
       'EFO_0003956', 'EFO_0007533', 'EFO_0007141'], dtype=object), 'count': 7}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 1 investigational indication.
CHEMBL1200873,CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1,OGIYDFVHFQEFKQ-UHFFFAOYSA-N,Small molecule,False,PHENTOLAMINE MESYLATE,1952.0,4.0,CHEMBL597,False,True,['Oraverse' 'Phentolamine mesylate' 'Regitine' 'Rogitine'],"['Mesylate phentolamine' 'NV-101' 'Phentolamine mesilate'
 'Phentolamine mesylate' 'Phentolamine methanesulfonate']","[('DailyMed', array(['phentolamine%20mesylate'], dtype=object)), ('PubChem', array(['11112076', '50106870', '56423107', '85231326', '855630'],
      dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000239', 'EFO_0000319', 'EFO_0001073'],
      dtype=object), 'count': 4}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and is indicated for adrenal gland pheochromocytoma and has 3 investigational indications.
CHEMBL1200874,CCCCNC(=O)[N-]S(=O)(=O)c1ccc(C)cc1.[Na+],QKHDBRQBSNZFAK-UHFFFAOYSA-M,Small molecule,False,"TOLBUTAMIDE SODIUM, STERILE",1961.0,4.0,CHEMBL782,False,True,['Orinase diagnostic'],"['Sodium tolbutamide' 'Tolbutamide sodium' 'Tolbutamide sodium salt'
 'Tolbutamide sodium, sterile']",,,,"[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961.
CHEMBL1200896,CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO,IYGXEHDCSOYNKY-RZHHZEQLSA-N,Small molecule,False,DINOPROST TROMETHAMINE,1982.0,4.0,CHEMBL815,False,True,"['Dinoprost Trometamol' 'Lutalyse' 'PGF2A' 'Prostaglandin F 2 Alpha'
 'Prostin f2 alpha']","['Dinoprost trometamol' 'Dinoprost tromethamine' 'NSC-196515' 'PGF2A THAM'
 'PGF2ALPHA THAM' 'U-14,583E' 'U-14-583E' 'U-14583E']","[('PubChem', array(['11532973'], dtype=object)), ('drugbank', array(['DB01160'], dtype=object)), ('chEBI', array(['31502'], dtype=object))]",,,[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201549,,,Protein,False,TERIPARATIDE ACETATE,1987.0,4.0,,False,True,['Parathar'],"['Ak-159' 'Ak159' 'HPTH 1-34' 'HPTH 1-34 (ACETATE SALT)' 'HPTH-1-34'
 'Teriparatide acetate' 'Teriparatide acetate hydrate']",,,"{'rows': array(['EFO_0003882', 'MONDO_0018923', 'EFO_1001494', 'EFO_0003854',
       'EFO_0009451'], dtype=object), 'count': 5}",[ENSG00000160801],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 5 investigational indications.
CHEMBL1219,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,YREYEVIYCVEVJK-UHFFFAOYSA-N,Small molecule,False,RABEPRAZOLE,1999.0,4.0,,False,True,[],"['Aciphex' 'E-3810 (PPI)' 'E3810' 'Eraloc' 'LY-307640' 'LY307640'
 'Ly-307640' 'Pariprazole' 'Rabeprazole']","[('Wikipedia', array(['Rabeprazole'], dtype=object)), ('drugbank', array(['DB01129'], dtype=object)), ('chEBI', array(['8768'], dtype=object))]",['CHEMBL4303515' 'CHEMBL1200930'],"{'rows': array(['MONDO_0004976', 'EFO_0008533', 'EFO_0004607', 'EFO_0000574',
       'EFO_1001355', 'EFO_0003763', 'EFO_0007549', 'MONDO_0004992',
       'EFO_1000961', 'HP_0002239', 'EFO_1001095', 'EFO_0004607',
       'EFO_1000961', 'EFO_0003948', 'EFO_0003948', 'EFO_0001642',
       'EFO_0005741', 'HP_0004398'], dtype=object), 'count': 18}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 12 investigational indications.
CHEMBL1405,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,DNXHEGUUPJUMQT-CBZIJGRNSA-N,Small molecule,False,ESTRONE,1979.0,4.0,,False,True,"['Estrogenic substance' 'Estrone' 'Natural estrogenic substance-estrone'
 'Oestrone' 'Theelin']","['1,3,5-estratrien-3-ol-17-one' 'Estradiol metabolite e1' 'Estrone'
 'Follicular hormone' 'Follicular-hormone' 'Folliculin' 'Folliculinum'
 'Ketohydroxyestrin' 'NSC-9699' 'Oestrone' 'Theelin' 'Thelykinin'
 'Tokokin' 'WAY 164397']","[('PubChem', array(['11111162', '11112119', '144207116', '144208573', '144213953',
       '170465020', '26751561', '26751562', '50104169', '56423156',
       '855919', '90340856'], dtype=object)), ('Wikipedia', array(['Estrone'], dtype=object)), ('drugbank', array(['DB00655'], dtype=object)), ('chEBI', array(['17263'], dtype=object))]",,"{'rows': array(['MONDO_0004169', 'EFO_0001073'], dtype=object), 'count': 2}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 2 investigational indications.
CHEMBL1422,N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,MFFMDFFZMYYVKS-SECBINFHSA-N,Small molecule,False,SITAGLIPTIN,2006.0,4.0,,False,True,['Januvia'],['LEZ-763' 'LEZ763' 'MK-0431' 'Sitagliptin'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SITAGLIPTIN/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Sitagliptin'], dtype=object)), ('drugbank', array(['DB01261'], dtype=object)), ('chEBI', array(['40237'], dtype=object))]",['CHEMBL1201174' 'CHEMBL539077' 'CHEMBL393336' 'CHEMBL5315049'],"{'rows': array(['EFO_1001459', 'EFO_1001121', 'EFO_0000400', 'MONDO_0005147',
       'EFO_0002546', 'EFO_0000712', 'EFO_0003884', 'MONDO_0005148',
       'HP_0000083', 'MONDO_0013730', 'EFO_0000180', 'EFO_0003095',
       'HP_0001952', 'EFO_0000612', 'EFO_0004599', 'EFO_0001073',
       'MONDO_0005148', 'MONDO_0009061', 'EFO_0000373', 'MONDO_0021187',
       'EFO_0000400', 'EFO_0003047', 'EFO_0000182', 'MONDO_0021187',
       'MONDO_0005148', 'MONDO_0100096', 'EFO_0000676', 'EFO_0008583'],
      dtype=object), 'count': 28}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 23 investigational indications.
CHEMBL1445,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,YLRFCQOZQXIBAB-RBZZARIASA-N,Small molecule,False,FLUOXYMESTERONE,1956.0,4.0,,False,True,['Android-f' 'Androxy' 'Fluoxymesterone' 'Halotestin' 'Ora-testryl'],"['Fluoximesterone' 'Fluoxymesterone' 'Fluoxymesterone ciii' 'NSC-10704'
 'NSC-12165']","[('PubChem', array(['144206709', '144208052', '17388998', '56422069'], dtype=object)), ('Wikipedia', array(['Fluoxymesterone'], dtype=object)), ('drugbank', array(['DB01185'], dtype=object)), ('chEBI', array(['5120'], dtype=object))]",,"{'rows': array(['EFO_1001078', 'MONDO_0007254', 'MONDO_0002146', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 3 approved and 1 investigational indication.
CHEMBL1528134,CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,HNNIWKQLJSNAEQ-UHFFFAOYSA-N,Small molecule,False,BENZYDAMINE HYDROCHLORIDE,,4.0,CHEMBL12610,False,True,['Difflam' 'Difflam-p' 'Lozamine'],"['AF-864' 'Benzidamine hydrochloride' 'Benzydamine hcl'
 'Benzydamine hydrochloride' 'NSC-759276']","[('PubChem', array(['144203971', '170465576', '49665028'], dtype=object))]",,"{'rows': array(['EFO_1001904', 'EFO_0009688'], dtype=object), 'count': 2}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.
CHEMBL1720,Cl.O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,OLDRWYVIKMSFFB-SSPJITILSA-N,Small molecule,False,PALONOSETRON HYDROCHLORIDE,2003.0,4.0,CHEMBL1189679,False,True,['Aloxi' 'Palonosetron hospira' 'Palonosetron hydrochloride'],"['Palonocetron hydrochloride' 'Palonosetron (as hydrochloride)'
 'Palonosetron hcl' 'Palonosetron hydrochloride' 'RS-25259-197']","[('DailyMed', array(['palonosetron%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/palonosetron-hospira'],
      dtype=object)), ('PubChem', array(['144205974', '170465300'], dtype=object)), ('chEBI', array(['85157'], dtype=object))]",,"{'rows': array(['EFO_0004888', 'HP_0002013', 'HP_0002018', 'EFO_0006911',
       'MONDO_0004992', 'HP_0002017'], dtype=object), 'count': 6}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved indications.
CHEMBL1743034,,,Antibody,False,IXEKIZUMAB,2016.0,4.0,,False,True,['Taltz'],['Ixekizumab' 'LY-2439821' 'LY2439821'],"[('DailyMed', array(['ixekizumab'], dtype=object)), ('DrugCentral', array(['5083'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/taltz'],
      dtype=object))]",,"{'rows': array(['EFO_0006818', 'MONDO_0002009', 'MONDO_0005147', 'EFO_0003898',
       'EFO_0007187', 'EFO_0003778', 'MONDO_0100096', 'EFO_0000540',
       'HP_0000999', 'EFO_0009856', 'EFO_0000676', 'EFO_1001494',
       'MONDO_0100017', 'EFO_0000685'], dtype=object), 'count': 14}",[ENSG00000112115],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 4 approved and 10 investigational indications.
CHEMBL2103868,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O,HFCFMRYTXDINDK-WNQIDUERSA-N,Small molecule,True,CABOZANTINIB S-MALATE,2012.0,4.0,CHEMBL2105717,False,True,['Cabometyx' 'Cometriq'],"['BMS-907351' 'Cabozantinib malate' 'Cabozantinib s-malate' 'XL-184'
 'XL184']","[('DailyMed', array(['cabozantinib%20s-malate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cabometyx'],
      dtype=object)), ('chEBI', array(['72319'], dtype=object))]",,"{'rows': array(['EFO_0000681', 'EFO_0000519', 'EFO_0001075', 'MONDO_0004992',
       'EFO_0000326', 'EFO_0000272', 'EFO_0000501', 'EFO_0000637',
       'EFO_0000673', 'EFO_1001465', 'EFO_0000641', 'EFO_0003968',
       'EFO_0000239', 'EFO_0002892', 'EFO_0000640', 'EFO_0000182',
       'MONDO_0002108', 'EFO_1000251', 'EFO_0000616', 'EFO_1001512',
       'EFO_0007532', 'EFO_0000305', 'EFO_0008524', 'EFO_0004252',
       'EFO_0000349', 'EFO_0003060'], dtype=object), 'count': 26}","[ENSG00000128052,ENSG00000105976]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 7 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108784,,,Antibody,False,ZIRALIMUMAB,,2.0,,False,False,[],['ABX-RB2' 'Ziralimumab'],,,,[ENSG00000172270],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108893,,,Enzyme,False,ALFIMEPRASE,,3.0,,False,False,[],['Alfimeprase'],,,"{'rows': array(['HP_0002140', 'HP_0004936', 'MONDO_0000831'], dtype=object), 'count': 3}","[ENSG00000171560,ENSG00000171564,ENSG00000171557]",Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2219774,,,Oligonucleotide,False,GATAPARSEN,,2.0,,False,False,[],['Gataparsen' 'LY-2181308' 'LY2181308'],,['CHEMBL2219775'],"{'rows': array(['EFO_0000182', 'MONDO_0008315', 'EFO_0000222', 'EFO_0003060'],
      dtype=object), 'count': 4}",[ENSG00000089685],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2381848,CCC[C@H](Oc1cc(C)c(-n2cc(C(F)(F)F)cn2)c(C)c1)c1ccc(C(=O)NCCC(=O)O)cc1,IBDYYOQKQCCSDP-QFIPXVFZSA-N,Small molecule,False,PF-06291874,,2.0,,False,False,[],['PF-06291874' 'Pf-06291874'],"[('drugbank', array(['DB15065'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000215644],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2386081,O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2,IHAXLPDVOWLUOS-UHFFFAOYSA-N,Small molecule,False,SETIPIPRANT,,3.0,,False,False,[],['ACT-129968' 'KYTH-105' 'Setipiprant'],"[('drugbank', array(['DB12562'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'MONDO_0004907', 'EFO_0003956'], dtype=object), 'count': 3}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL341812,CC(C)Cc1ccc(CC(=O)O)cc1,CYWFCPPBTWOZSF-UHFFFAOYSA-N,Small molecule,False,IBUFENAC,,4.0,,True,True,[],"['(p-isobutylphenyl)acetic acid' 'Ibufenac' 'NSC-99976' 'RD 11654'
 'RD-11654']","[('PubChem', array(['170465922', '29216132'], dtype=object)), ('chEBI', array(['76158'], dtype=object))]",,,"[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL3545220,,,Small molecule,False,LY2590443,,2.0,,False,False,[],['Ly2590443'],,,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000148680],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707290,C=C(CCCCCCCCCCCCCCCc1nnn[nH]1)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)N[C@@H](CCCCNC(=O)CSC[C@H](N)C(=O)O)C(N)=O)C(=O)O)C(=O)O,NAKSIOUBFDBTSW-ITMZJIMRSA-N,Small molecule,False,SOMAPACITAN,2020.0,4.0,,False,True,['Sogroya'],"['NN-8640' 'NN8640' 'NNC-0195-0092' 'NNC0195-0092' 'Somapacitan'
 'Somapacitan beco']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya'],
      dtype=object))]",,"{'rows': array(['EFO_1001109'], dtype=object), 'count': 1}",[ENSG00000112964],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for pituitary dwarfism.
CHEMBL4206492,O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1,BZTIJCSHNVZMES-UHFFFAOYSA-N,Small molecule,False,OSORESNONTRINE,,2.0,,False,False,[],['BI 409306' 'BI-409306' 'Bi 409306' 'Osoresnontrine' 'SUB 166499'],,,"{'rows': array(['MONDO_0004975', 'EFO_0000677', 'MONDO_0005090'], dtype=object), 'count': 3}",[ENSG00000160191],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297998,,,Antibody,False,LACUTAMAB,,2.0,,False,False,[],['IPH-4102' 'IPH4102' 'Iph4102' 'Lacutamab'],,,"{'rows': array(['EFO_0002913', 'EFO_0000211'], dtype=object), 'count': 2}",[ENSG00000240403],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594258,CCCC[C@](C)(CO)Nc1nc(N)nc2cc(F)cnc12,HTCJUBZBSJQWBW-CQSZACIVSA-N,Small molecule,False,SELGANTOLIMOD,,2.0,,False,False,[],['GS-9688' 'Gs-9688' 'Selgantolimod'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SELGANTOLIMOD/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004197', 'EFO_0004239'], dtype=object), 'count': 2}",[ENSG00000101916],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594445,CNCc1cn(S(=O)(=O)c2cccc(F)c2)c(-c2ccc(F)cc2F)c1OC,OUNXGNDVWVPCOL-UHFFFAOYSA-N,Small molecule,False,ABEPRAZAN,,3.0,,False,False,[],['Abeprazan' 'DWP-14012' 'DWP14012' 'Dwp14012' 'Fexuprazan'],,,"{'rows': array(['HP_0004398', 'EFO_0000337', 'EFO_1001095', 'EFO_0003948'],
      dtype=object), 'count': 4}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4594485,,,Oligonucleotide,False,OLAPTESED PEGOL,,2.0,,False,False,[],['NOX-A12 FREE ACID' 'Olaptesed pegol'],,,"{'rows': array(['EFO_0002618', 'EFO_0000519'], dtype=object), 'count': 2}",[ENSG00000107562],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5095027,CCP(=S)(Oc1ccc([N+](=O)[O-])cc1Cl)OC(C)C,QINWTFKFPMRNJP-UHFFFAOYSA-N,Small molecule,False,OMS405,,2.0,,False,False,[],['Oms405'],,,,[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL524004,C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1,GKNPSSNBBWDAGH-UHFFFAOYSA-N,Small molecule,False,MEPENZOLATE,1956.0,4.0,,False,True,[],"['Mepenzolate' 'Mepenzolate bromide free base' 'Mepenzolate cation'
 'Mepenzolate ion']","[('Wikipedia', array(['Mepenzolate'], dtype=object)), ('drugbank', array(['DB04843'], dtype=object))]",['CHEMBL1724'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for gastrointestinal disease.
CHEMBL546,C=CCOc1ccccc1OCC(O)CNC(C)C,CEMAWMOMDPGJMB-UHFFFAOYSA-N,Small molecule,False,OXPRENOLOL,1983.0,4.0,,False,True,[],['Oxprenolol'],"[('Wikipedia', array(['Oxprenolol'], dtype=object)), ('drugbank', array(['DB01580'], dtype=object))]",['CHEMBL1200745' 'CHEMBL3245937'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and is indicated for cardiovascular disease.
CHEMBL963,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,UQCNKQCJZOAFTQ-ISWURRPUSA-N,Small molecule,True,OXYMORPHONE,1959.0,4.0,,False,True,[],"['14-hydroxydihydromorphinone' '7,8-dihydro-14-hydroxymorphinone'
 'Dihydroxymorphinone' 'IDS-NO-003' 'NIH 10323' 'NSC-19045' 'Numorphan'
 'Opana' 'Oxycodone hydrochloride impurity, oxymorphone-' 'Oxymorphone'
 'Oxymorphone cii']","[('Wikipedia', array(['Oxymorphone'], dtype=object)), ('drugbank', array(['DB01192'], dtype=object)), ('chEBI', array(['7865'], dtype=object))]",['CHEMBL1200794'],"{'rows': array(['EFO_0003843', 'HP_0012532', 'HP_0012532', 'EFO_0003843'],
      dtype=object), 'count': 4}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for pain and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1096146,CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,LPAUOXUZGSBGDU-STDDISTJSA-N,Small molecule,False,PONESIMOD,2021.0,4.0,,False,True,['Ponvory'],['ACT-128800' 'Ponesimod'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory'],
      dtype=object)), ('drugbank', array(['DB12016'], dtype=object))]",,"{'rows': array(['MONDO_0005301', 'EFO_0000676', 'MONDO_0020547', 'EFO_0000540',
       'EFO_0003929'], dtype=object), 'count': 5}",[ENSG00000170989],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications.
CHEMBL1097999,CCNc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\[C@@H](C)[C@H](C)OC2=O,MWUFVYLAWAXDHQ-HMNLTAHHSA-N,Small molecule,False,E-6201,,2.0,,False,False,[],['E-6201' 'E6201' 'ER-806201'],"[('drugbank', array(['DB11687'], dtype=object))]",,"{'rows': array(['EFO_1001494', 'EFO_0000616', 'EFO_0000676'], dtype=object), 'count': 3}","[ENSG00000169032,ENSG00000095015]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1200988,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21.[Br-],PQMWYJDJHJQZDE-UHFFFAOYSA-M,Small molecule,False,METHANTHELINE BROMIDE,1951.0,4.0,CHEMBL1201264,False,True,['Banthine'],"['Dixamone bromide' 'Methantheline bromide' 'Methanthelinium bromide'
 'NSC-32145' 'Vagantin']","[('PubChem', array(['144203871', '170465350', '56463185'], dtype=object))]",,,[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951.
CHEMBL1201461,,,Small molecule,False,DEXTROMETHORPHAN POLISTIREX,1982.0,4.0,CHEMBL52440,False,True,['Delsym' 'Dextromethorphan polistirex'],['Dextromethorphan polistirex' 'NSC-751452'],"[('DailyMed', array(['dextromethorphan%20polistirex'], dtype=object))]",,"{'rows': array(['EFO_0003756'], dtype=object), 'count': 1}","[ENSG00000147955,ENSG00000183454]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.
CHEMBL1742998,,,Antibody drug conjugate,False,CANTUZUMAB RAVTANSINE,,2.0,,False,False,[],['Cantuzumab ravtansine' 'HUC242-DM4' 'IMGN-242' 'IMGN242'],,,"{'rows': array(['EFO_0002618', 'MONDO_0001056', 'EFO_0000365'], dtype=object), 'count': 3}",[ENSG00000185499],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL19019,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,DQCKKXVULJGBQN-XFWGSAIBSA-N,Small molecule,True,NALTREXONE,1984.0,4.0,,False,True,['Celupan' 'Trexal' 'Trexan' 'Vivitrol'],"['EN-1639A' 'EN-1639A FREE BASE' 'EN-1639A [AS HYDROCHLORIDE]'
 'NSC-758439' 'Naltrexone' 'Revia']","[('DailyMed', array(['naltrexone'], dtype=object)), ('PubChem', array(['144205560', '170465207'], dtype=object)), ('drugbank', array(['DB00704'], dtype=object)), ('chEBI', array(['7465'], dtype=object))]",['CHEMBL1201149' 'CHEMBL4303313'],"{'rows': array(['EFO_0005203', 'EFO_0007224', 'MONDO_0002009', 'EFO_1000906',
       'MONDO_0002050', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0001358',
       'EFO_0000274', 'MONDO_0000594', 'EFO_0003843', 'EFO_0004329',
       'EFO_0000764', 'EFO_0005687', 'MONDO_0015626', 'EFO_0005611',
       'EFO_0002610', 'EFO_0005924', 'MONDO_0100096', 'EFO_0010702',
       'MONDO_0005351', 'EFO_1000783', 'EFO_0003843', 'EFO_1000637',
       'MONDO_0005277', 'EFO_0004701', 'EFO_0000676', 'HP_0012076',
       'EFO_0003768', 'EFO_0004242', 'MONDO_0002009', 'MONDO_0007254',
       'HP_0100716', 'MONDO_0021698', 'HP_0012532', 'HP_0012532',
       'HP_0012167', 'EFO_0003890', 'EFO_0005204', 'EFO_0004699',
       'EFO_0004329', 'HP_0012378', 'EFO_0004240', 'EFO_0001065',
       'EFO_0008507', 'EFO_0007191', 'EFO_0005611', 'EFO_0000729',
       'MONDO_0007079', 'EFO_0010702', 'EFO_0001073', 'EFO_0004701',
       'MONDO_0005090', 'MONDO_0002046', 'HP_0003419', 'EFO_0000694',
       'EFO_0000384'], dtype=object), 'count': 57}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 52 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1914489,CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O,JWYIGNODXSRKGP-UHFFFAOYSA-N,Small molecule,False,AZD1981,,2.0,,False,False,[],['AZD-1981' 'Azd 1981' 'Azd-1981' 'Azd1981'],"[('drugbank', array(['DB11946'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0000545'], dtype=object), 'count': 3}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2107881,,,Protein,False,REGRAMOSTIM,,3.0,,False,False,[],"['GM-CSF' 'GM-CSF (CHO CELL)' 'GMC 89-107' 'GMC-89-107'
 'Leucotropin glycoform gmc 89-107' 'RHGM-C' 'RHGM-CSF' 'Regramostim']",,,"{'rows': array(['MONDO_0008170', 'EFO_0000403', 'MONDO_0100342', 'MONDO_0002367',
       'MONDO_0004992', 'EFO_0000519', 'EFO_0000180', 'EFO_0003060',
       'EFO_0001378', 'EFO_0000764', 'EFO_0000574', 'EFO_1001951',
       'EFO_0000770', 'EFO_0007149', 'EFO_0000365', 'EFO_0000389',
       'EFO_0004265', 'EFO_0000681', 'EFO_0000756', 'MONDO_0021063',
       'MONDO_0008315', 'MONDO_0007254', 'EFO_1001923', 'EFO_0000309',
       'EFO_0004252', 'MONDO_0001437', 'MONDO_0008903', 'EFO_0000621'],
      dtype=object), 'count': 28}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications.
CHEMBL2108493,,,Protein,False,"INSULIN ZINC, PROMPT",,4.0,,False,True,['Ins semit mc'],"['Amorphous (aqueous suspension)' 'Insulin zinc injection'
 'Insulin zinc injection, amorphous (aqueous suspension)'
 'Insulin zinc suspension ' 'Insulin zinc suspension (amorphous)'
 'Insulin zinc, prompt']",,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV.
CHEMBL2108967,,,Antibody,False,LERDELIMUMAB,,3.0,,False,False,['Trabio'],['CAT-152' 'Lerdelimumab' 'TRABIO'],,,,[ENSG00000092969],Antibody drug with a maximum clinical trial phase of III.
CHEMBL2109555,,,Antibody,False,MDX-070,,2.0,,False,False,[],['MDX-070'],,,,[ENSG00000086205],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109615,,,Antibody,False,MRA 003 US,,1.0,,False,False,[],['MRA 003 US' 'Mra 003 us'],,,"{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL271220,CCOC[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2,SLKURXRZHJOZOD-RUZDIDTESA-N,Small molecule,False,CORT 108297,,1.0,,False,False,[],['ADS-108297' 'CORT-108297' 'Cort 108297'],,,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL312443,Oc1noc2c1CCNC2,ZXRVKCBLGJOCEE-UHFFFAOYSA-N,Small molecule,False,GABOXADOL,,3.0,,False,False,[],['Gaboxadol' 'LU 02-030' 'LU-02-030' 'LU-02030' 'MK-0928' 'NSC-759585'],"[('PubChem', array(['104171241', '11111836', '11111837', '11113715', '170466512',
       '90341079'], dtype=object)), ('Wikipedia', array(['Gaboxadol'], dtype=object)), ('drugbank', array(['DB06554'], dtype=object)), ('chEBI', array(['34373'], dtype=object))]",['CHEMBL1255746'],"{'rows': array(['MONDO_0010383', 'MONDO_0007113', 'EFO_0004698', 'MONDO_0002009'],
      dtype=object), 'count': 4}","[ENSG00000022355,ENSG00000145864,ENSG00000166206,ENSG00000109158,ENSG00000011677,ENSG00000163288,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3301612,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1,CMJCXYNUCSMDBY-ZDUSSCGKSA-N,Small molecule,False,ENCORAFENIB,2018.0,4.0,,False,True,['Braftovi'],"['Encorafenib' 'Lgx-818' 'Lgx818' 'NVP-LGX-818-NXA' 'NVP-LGX818'
 'NVP-LGX818-NXA']","[('DailyMed', array(['encorafenib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi'],
      dtype=object)), ('drugbank', array(['DB11718'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_1001951', 'EFO_0000365', 'EFO_0000756',
       'EFO_0002617', 'EFO_0009259', 'EFO_0002618', 'EFO_1000657',
       'EFO_1000956', 'EFO_0000389', 'EFO_0001378', 'EFO_0004142',
       'EFO_0003060', 'EFO_0002892', 'EFO_0003891', 'EFO_1001949',
       'MONDO_0005184', 'EFO_0000616'], dtype=object), 'count': 18}",[ENSG00000157764],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 8 approved and 10 investigational indications.
CHEMBL3545333,CN1C(=O)C(F)=C[C@]2(C)C3CC[C@@]4(C)C(CC[C@@H]4C(=O)NCc4nc5ncccc5[nH]4)C3CCC12,GBEUKTWTUSPHEE-PAWGCEJPSA-N,Small molecule,False,MK-0773,,2.0,,False,False,[],['Mk-0773' 'PF-05314882'],,,"{'rows': array(['EFO_1000653'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3833357,,,Antibody,False,BEGELOMAB,,3.0,,False,False,['Begedina'],['BT 5/9' 'Begelomab' 'SAND-26'],,,"{'rows': array(['EFO_0000540', 'MONDO_0013730'], dtype=object), 'count': 2}",[ENSG00000197635],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3990000,,,Antibody,False,TIBULIZUMAB,,2.0,,False,False,[],['LY-3090106' 'LY3090106' 'Tibulizumab'],,,"{'rows': array(['EFO_0000685', 'EFO_0000699'], dtype=object), 'count': 2}","[ENSG00000112115,ENSG00000102524]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4078588,Cc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1,JUVQLZBJFOGEEO-GOTSBHOMSA-N,Small molecule,False,MK-7622,,2.0,,False,False,[],['MK7622' 'Mk-7622'],"[('drugbank', array(['DB12897'], dtype=object))]",['CHEMBL4216833'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297236,,,Gene,False,LISOCABTAGENE MARALEUCEL,,3.0,,False,False,[],['Breyanzi' 'JCAR-017' 'JCAR017' 'Lisocabtagene maraleucel'],,,"{'rows': array(['MONDO_0018906', 'EFO_0000095', 'EFO_1001469', 'EFO_0000220',
       'EFO_0005952', 'EFO_0000403'], dtype=object), 'count': 6}",[ENSG00000177455],Gene drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4297523,COc1ccc2[nH]cc(CCNC(=O)c3cc(=O)cco3)c2c1,PNTNBIHOAPJYDB-UHFFFAOYSA-N,Small molecule,False,PIROMELATINE,,2.0,,False,False,[],['NEU-P-11' 'NEU-P11' 'Neu-p11' 'Piromelatine'],"[('drugbank', array(['DB12288'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0004698'], dtype=object), 'count': 2}","[ENSG00000168412,ENSG00000134640]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4298193,,,Oligonucleotide,False,SUVODIRSEN SODIUM,,1.0,,False,False,[],['BMTR0139 SODIUM' 'Suvodirsen sodium' 'WLS-4176 SODIUM' 'WV3473'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SUVODIRSEN%20SODIUM/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}",[ENSG00000198947],Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4650256,,,Antibody,False,ZANIDATAMAB,,3.0,,False,False,[],['ZW-25' 'Zanidatamab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANIDATAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0003060',
       'EFO_0003891', 'EFO_0003968', 'MONDO_0007254', 'EFO_0005537'],
      dtype=object), 'count': 8}",[ENSG00000141736],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL59356,C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O,MMSNEKOTSJRTRI-LLVKDONJSA-N,Small molecule,False,ATRELEUTON,,2.0,,False,False,[],['A-85761' 'A-85761.0' 'ABBOTT-85761' 'ABT-761' 'Atreleuton' 'VIA-2291'],"[('drugbank', array(['DB12758'], dtype=object))]",,"{'rows': array(['EFO_0005672', 'EFO_0003914', 'EFO_0001645'], dtype=object), 'count': 3}",[ENSG00000012779],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL701,NCC(CC(=O)O)c1ccc(Cl)cc1,KPYSYYIEGFHWSV-UHFFFAOYSA-N,Small molecule,True,BACLOFEN,1977.0,4.0,,False,True,"['Baclofen' 'Baclospas-10' 'Fleqsuvy' 'Gablofen' 'Kemstro' 'Lioresal'
 'Lioresal intrath' 'Lyflex' 'Lyvispah' 'Ozobax']","['(rs)-baclofen' 'BA-34,647' 'BA-34647' 'Baclofen' 'Fleqsuvy' 'Lyvispah'
 'NSC-755906']","[('DailyMed', array(['baclofen'], dtype=object)), ('PubChem', array(['104171115', '124879423', '124879424', '170465099', '26751712',
       '50104402', '85230940', '855960', '90341690'], dtype=object)), ('Wikipedia', array(['Baclofen'], dtype=object)), ('drugbank', array(['DB00181'], dtype=object)), ('chEBI', array(['2972'], dtype=object))]",['CHEMBL1897150'],"{'rows': array(['MONDO_0015626', 'EFO_0001073', 'EFO_0009488', 'MONDO_0043510',
       'EFO_0007191', 'EFO_0003768', 'EFO_0000512', 'MONDO_0008840',
       'EFO_1001919', 'MONDO_0010383', 'EFO_0004777', 'EFO_0003758',
       'MONDO_0005301', 'HP_0001257', 'EFO_0000182', 'EFO_1000632',
       'HP_0002063', 'EFO_1000802', 'EFO_0003948', 'EFO_0003890',
       'EFO_0003843', 'EFO_0002610', 'MONDO_0007079'], dtype=object), 'count': 23}","[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1086218,C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,YJDYDFNKCBANTM-QCWCSKBGSA-N,Protein,False,VALSPODAR,,3.0,,False,False,[],['PSC 833' 'SDZ PSC 833' 'SDZ-PSC 833' 'Valspodar'],"[('drugbank', array(['DB11869'], dtype=object)), ('chEBI', array(['8985'], dtype=object))]",,"{'rows': array(['EFO_0000218', 'EFO_0000223', 'EFO_0003027', 'EFO_0003025',
       'EFO_0000691', 'EFO_0000565', 'EFO_0003028', 'EFO_0003029',
       'EFO_0000681', 'EFO_0009708', 'MONDO_0007254', 'EFO_0004251',
       'EFO_0000198', 'MONDO_0008170', 'EFO_0001378', 'EFO_0000574',
       'EFO_0003865', 'EFO_0000221'], dtype=object), 'count': 18}",[ENSG00000085563],Protein drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.
CHEMBL1090173,O=C(CO)N1CCC(c2n[nH]c(-c3ccc(Cl)cc3)c2-c2ccncn2)CC1,CATQHDWESBRRQA-UHFFFAOYSA-N,Small molecule,False,SD-0006,,1.0,,False,False,[],['SD-0006' 'SD-06' 'SD0006' 'Sd-0006'],"[('PubChem', array(['174007108'], dtype=object)), ('drugbank', array(['DB07943'], dtype=object)), ('chEBI', array(['82712'], dtype=object))]",,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1200463,O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+],QTAQWNSMRSLSCG-UHFFFAOYSA-M,Small molecule,True,OXAPROZIN POTASSIUM,2002.0,4.0,CHEMBL1071,False,True,['Daypro alta'],['Oxaprozin potassium'],,,,"[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2002. This drug has a black box warning from the FDA.
CHEMBL1200761,COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1,BFPSDSIWYFKGBC-UHFFFAOYSA-N,Small molecule,False,CHLOROTRIANISENE,1982.0,4.0,,False,True,['Chlorotrianisene' 'Tace'],['Chlorotrianisene' 'Chlortrianisestrol' 'NSC-10108' 'Trianisestrol'],"[('PubChem', array(['104171308', '11112416', '11532856', '124882352', '144204017',
       '144209559', '144213214', '170465394', '17389725', '26747338'],
      dtype=object)), ('Wikipedia', array(['Chlorotrianisene'], dtype=object)), ('drugbank', array(['DB00269'], dtype=object)), ('chEBI', array(['3641'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'MONDO_0002691'], dtype=object), 'count': 2}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 2 investigational indications.
CHEMBL1200983,,,Small molecule,True,GALLIUM NITRATE,1991.0,4.0,,False,True,['Ganite'],"['Gallium nitrate' 'Gallium nitrate (anhydrous)'
 'Gallium nitrate anhydrous' 'Gallium nitrate nonahydrate' 'NSC-15200'
 'Nitric acid, gallium salt']","[('DailyMed', array(['gallium%20nitrate'], dtype=object)), ('DrugCentral', array(['5115'], dtype=object)), ('Wikipedia', array(['Gallium_nitrate'], dtype=object))]",['CHEMBL1697699'],"{'rows': array(['EFO_0009429', 'EFO_0000574', 'EFO_0000691', 'EFO_0000621',
       'EFO_1000158', 'MONDO_0009061', 'EFO_0005952'], dtype=object), 'count': 7}","[ENSG00000167325,ENSG00000048392,ENSG00000171848]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201052,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21.O=S(=O)(O)c1ccccc1,CRJHBCPQHRVYBS-UHFFFAOYSA-N,Small molecule,True,MESORIDAZINE BESYLATE,1970.0,4.0,CHEMBL1088,False,True,['Serentil'],"['Mesoridazine benzenesulfonate' 'Mesoridazine besilate'
 'Mesoridazine besylate' 'NSC-760073']","[('PubChem', array(['26719781', '85273786'], dtype=object)), ('chEBI', array(['6781'], dtype=object))]",,,"[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970. This drug has a black box warning from the FDA.
CHEMBL1201353,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,SOYKEARSMXGVTM-HNNXBMFYSA-N,Small molecule,False,DEXCHLORPHENIRAMINE,1981.0,4.0,,False,True,[],"['Chlorphenamine, (s)-' 'Chlorpheniramine d-form' 'Chlorpheniramine, (s)-'
 'Chlorpheniramine, d-' 'Dapriton' 'Dexchlorpheniramine']","[('PubChem', array(['29216403', '90340867'], dtype=object)), ('Wikipedia', array(['Dexchlorpheniramine'], dtype=object)), ('drugbank', array(['DB13679'], dtype=object)), ('chEBI', array(['4464'], dtype=object))]",['CHEMBL1200927' 'CHEMBL3183101'],"{'rows': array(['EFO_0005531', 'EFO_1001417', 'EFO_0007141', 'MONDO_0005271',
       'EFO_0005854', 'EFO_0003958', 'MONDO_0005301', 'MONDO_0005271',
       'EFO_0003956', 'EFO_0005532', 'EFO_0007533'], dtype=object), 'count': 11}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 8 approved and 3 investigational indications.
CHEMBL1201509,,,Protein,False,"GONADOTROPIN, CHORIONIC",1973.0,4.0,,False,True,"['A.p.l.' 'Choragon' 'Chorionic gonadotropin'
 'Equine Chorionic Gonadotropin' 'Follutein' 'Gonadotraphon lh'
 'Human Chorionic Gonadotropin' 'Pregnyl' 'Profasi' 'Profast' 'Progestyl']","['Choriogonadotropin beta' 'Chorionic gonadotrophin'
 'Gonadotropin, chorionic']","[('DailyMed', array(['gonadotropin,%20chorionic'], dtype=object)), ('DrugCentral', array(['5196'], dtype=object))]",,"{'rows': array(['MONDO_0018555', 'MONDO_0002259', 'EFO_0000545', 'EFO_0002950',
       'MONDO_0007254', 'MONDO_0002146', 'MONDO_0002775', 'EFO_1001006',
       'EFO_0004599', 'EFO_0000279', 'EFO_0000660'], dtype=object), 'count': 11}",[ENSG00000138039],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 11 investigational indications.
CHEMBL1201541,,,Protein,False,INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF,1980.0,4.0,,False,True,['Protamine zinc and iletin ii' 'Protamine zinc insulin'],['Insulin susp protamine zinc purified beef'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1980.
CHEMBL1201823,,,Protein,False,ABATACEPT,2006.0,4.0,,False,True,['Orencia' 'Orencia clickject'],"['Abatacept' 'Abatacept (genetical recombination)' 'Abatacept recombinant'
 'BMS-188667' 'CTLA4-IGG4M' 'RG-1046' 'RG-2077']","[('DailyMed', array(['abatacept'], dtype=object)), ('DrugCentral', array(['5089'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orencia'],
      dtype=object)), ('Wikipedia', array(['Abatacept'], dtype=object))]",,"{'rows': array(['EFO_1001148', 'MONDO_0100096', 'EFO_0004192', 'EFO_0009609',
       'EFO_0004255', 'EFO_1001494', 'MONDO_0013730', 'EFO_0004599',
       'EFO_0000699', 'MONDO_0020547', 'EFO_0000729', 'EFO_0000384',
       'MONDO_0019338', 'EFO_1001996', 'MONDO_0017287', 'EFO_0003780',
       'EFO_1001231', 'EFO_0005297', 'EFO_1001209', 'EFO_0004991',
       'EFO_0004208', 'EFO_0000685', 'EFO_0003929', 'MONDO_0005301',
       'EFO_0000404', 'MONDO_0019080', 'EFO_0000537', 'EFO_0000540',
       'MONDO_0005147', 'MONDO_0007915', 'EFO_0008518', 'EFO_0007425',
       'EFO_0009730', 'EFO_0003898', 'EFO_0003778', 'EFO_1001857',
       'EFO_0000398', 'EFO_0005761', 'EFO_0001378', 'EFO_0000676',
       'EFO_0004826', 'EFO_0002609'], dtype=object), 'count': 42}","[ENSG00000121594,ENSG00000114013]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 5 approved and 37 investigational indications.
CHEMBL1399,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,YBBLVLTVTVSKRW-UHFFFAOYSA-N,Small molecule,False,ANASTROZOLE,1995.0,4.0,,False,True,['Anastrozole' 'Arimidex' 'Nastrosa'],"['Anastrozole' 'Arimidex' 'ICI D1033' 'ICI-D1033' 'NSC-719344'
 'NSC-759855' 'Rvg-106400' 'ZD-1033' 'ZD1033']","[('DailyMed', array(['anastrozole'], dtype=object)), ('PubChem', array(['144205791', '144213873', '170464923', '174007355', '26719808'],
      dtype=object)), ('Wikipedia', array(['Anastrozole'], dtype=object)), ('drugbank', array(['DB01217'], dtype=object)), ('chEBI', array(['2704'], dtype=object))]",,"{'rows': array(['MONDO_0011962', 'EFO_0005537', 'EFO_0001361', 'EFO_0000195',
       'EFO_0000313', 'EFO_0003869', 'EFO_0000553', 'EFO_1001006',
       'MONDO_0002775', 'EFO_0000432', 'MONDO_0004992', 'EFO_0000537',
       'MONDO_0018800', 'EFO_0001065', 'MONDO_0000088', 'EFO_0000616',
       'EFO_0001380', 'MONDO_0008170', 'EFO_0006861', 'MONDO_0018919',
       'EFO_1001512', 'MONDO_0002146', 'HP_0000771', 'EFO_1001100',
       'EFO_0000305', 'MONDO_0007254'], dtype=object), 'count': 26}",[ENSG00000137869],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 21 investigational indications.
CHEMBL14935,O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,ZXFRFPSZAKNPQQ-YTWAJWBKSA-N,Small molecule,False,TEZAMPANEL ANHYDROUS,,2.0,,False,False,[],"['LY-293,558' 'LY-293558' 'NGX-424' 'NGX424' 'Tezampanel anhydrous']","[('drugbank', array(['DB06354'], dtype=object))]",['CHEMBL3989703'],"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}","[ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873,ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1621,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O,PMXMIIMHBWHSKN-UHFFFAOYSA-N,Small molecule,True,PALIPERIDONE,2006.0,4.0,,False,True,['Invega' 'Paliperidone' 'Trevicta' 'Xeplion'],"['9-hydroxyrisperidone' 'NSC-759623' 'Paliperidone' 'R-76477' 'RO-76477'
 'RO76477' 'Risperidone impurity, 9-hydroxyrisperidone-']","[('DailyMed', array(['paliperidone'], dtype=object)), ('PubChem', array(['90341688'], dtype=object)), ('Wikipedia', array(['Paliperidone'], dtype=object)), ('drugbank', array(['DB01267'], dtype=object)), ('chEBI', array(['83804'], dtype=object))]",,"{'rows': array(['EFO_0004242', 'EFO_0005230', 'EFO_0003758', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090', 'MONDO_0004985', 'EFO_0005407',
       'EFO_0005411'], dtype=object), 'count': 9}","[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743049,,,Antibody,False,OLARATUMAB,2016.0,4.0,,False,True,['Lartruvo'],['IMC-3G3' 'IMC3G3' 'Olaratumab'],"[('DrugCentral', array(['5183'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lartruvo'],
      dtype=object))]",,"{'rows': array(['EFO_0000564', 'MONDO_0008315', 'EFO_1001968', 'EFO_0000691',
       'EFO_0000519', 'EFO_0003893', 'EFO_0003060', 'MONDO_0011719',
       'EFO_0000616', 'EFO_0002618', 'EFO_0009708'], dtype=object), 'count': 11}",[ENSG00000134853],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 8 investigational indications.
CHEMBL2079588,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1,QFCXANHHBCGMAS-UHFFFAOYSA-N,Small molecule,False,TELATINIB,,2.0,,False,False,[],['BAY 57-9352' 'BAY-579352' 'Bay-57-9352' 'Telatinib'],"[('PubChem', array(['124955475'], dtype=object)), ('drugbank', array(['DB15393'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0001056'], dtype=object), 'count': 2}","[ENSG00000113721,ENSG00000128052,ENSG00000157404,ENSG00000037280]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2103744,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O,GRVOTVYEFDAHCL-RTSZDRIGSA-N,Small molecule,True,MORPHINE SULFATE,1984.0,4.0,CHEMBL70,False,True,"['Arymo er' 'Astramorph pf' 'Avinza' 'Depodur' 'Duramorph pf' 'Duromorph'
 'Filnarine sr' 'Infumorph' 'Kadian' 'Moraxen' 'Morcap sr' 'Morphabond'
 'Morphabond er' 'Morphgesic sr' 'Morphine sulfate'
 'Morphine sulfate (autoinjector)' 'Ms contin' 'Mst continus' 'Oramorph'
 'Oramorph sr' 'Oramorph udv' 'Rhotard' 'Sevredol' 'Srm-rhotard' 'Zomorph']","['Arymo' 'Astramorph' 'Dolcontin' 'Kapanol' 'Morcap' 'Morphine sulfate'
 'Morphine sulfate anhydrous' 'Morphine sulfate cii'
 'Morphine sulfate hydrate' 'Morphine sulfate pentahydrate'
 'Morphine sulfate,anhydrous' 'Morphine sulphate'
 'Morphine sulphate anhydrous' 'Morphine sulphate pentahydrate'
 'Morphini sulfas' 'Moscontin' 'NSC-11441']","[('DailyMed', array(['morphine%20sulfate'], dtype=object)), ('PubChem', array(['144206414'], dtype=object)), ('chEBI', array(['50731'], dtype=object))]",,"{'rows': array(['EFO_0010702', 'EFO_0000768', 'EFO_0004616', 'HP_0001822',
       'HP_0003419', 'HP_0012532', 'EFO_0020911', 'EFO_0005799',
       'HP_0000989', 'EFO_0003843', 'EFO_0003918', 'EFO_0801084',
       'EFO_0000612', 'EFO_0001361', 'MONDO_0004992', 'EFO_0005611',
       'EFO_0003890', 'MONDO_0011382'], dtype=object), 'count': 18}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 5 approved and 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108589,,,Antibody,False,CLAZAKIZUMAB,,3.0,,False,False,[],['ALD-518' 'ALD518' 'BMS-945429' 'Clazakizumab'],,,"{'rows': array(['HP_0004326', 'HP_0012378', 'MONDO_0100096', 'EFO_1001904',
       'EFO_0000384', 'EFO_0000685', 'MONDO_0004979', 'EFO_0004599',
       'EFO_0003778', 'MP_0001845'], dtype=object), 'count': 10}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL2109046,,,Protein,False,"INSULIN, PROTAMINE ZINC",,4.0,,False,True,['Ins hypurin bov prot zn' 'Ins prot zn bp'],"['Insulin zinc protamine injection (aqueous suspension)'
 'Insulin, protamine zinc' 'Protamine zinc insulin'
 'Protamine zinc insulin injection']",,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV.
CHEMBL2109396,,,Antibody,False,AMG-888,,2.0,,False,False,[],['AMG-888' 'Amg-888' 'U3-1287'],,,"{'rows': array(['EFO_0000691', 'EFO_0003060', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0000574', 'EFO_0000313'], dtype=object), 'count': 6}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL2109608,,,Antibody,False,L19IL2,,3.0,,False,False,[],['L19IL2' 'L19il2'],,,"{'rows': array(['EFO_0002617', 'EFO_0000616', 'EFO_0002618', 'EFO_0000756'],
      dtype=object), 'count': 4}",[ENSG00000115414],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2110737,CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O,HTJGLYIJVSDQAE-VWNXEWBOSA-N,Small molecule,False,CELGOSIVIR,,2.0,,False,False,[],['Celgosivir'],"[('drugbank', array(['DB06580'], dtype=object))]",['CHEMBL2105801'],"{'rows': array(['EFO_0000764', 'EFO_0004220', 'EFO_0005547'], dtype=object), 'count': 3}","[ENSG00000257335,ENSG00000171298,ENSG00000090402,ENSG00000257743]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2146883,O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,BSMCAPRUBJMWDF-KRWDZBQOSA-N,Small molecule,False,COBIMETINIB,2015.0,4.0,,False,True,['Cotellic'],"['Cobimetinib' 'GDC-0973' 'Gdc 0623' 'Gdc 0973' 'Gdc-0623' 'RG 7420'
 'RG-7420' 'RG7420' 'Rg-7420' 'Rg-7421' 'XL-518' 'Xl 518' 'Xl518']","[('drugbank', array(['DB05239'], dtype=object))]",['CHEMBL2364607' 'CHEMBL3526209'],"{'rows': array(['MONDO_0008170', 'EFO_1001779', 'EFO_0001642', 'EFO_1001956',
       'EFO_1000209', 'EFO_0000756', 'EFO_0003060', 'EFO_0000756',
       'MONDO_0002898', 'Orphanet_46724', 'EFO_0002892', 'EFO_1001951',
       'EFO_0002916', 'EFO_0001378', 'EFO_0000305', 'MONDO_0005184',
       'EFO_0000222', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000616',
       'EFO_0000389', 'EFO_0000503', 'EFO_0002617', 'EFO_0000691',
       'EFO_0002617'], dtype=object), 'count': 25}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 21 investigational indications.
CHEMBL3120215,COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12,JROFGZPOBKIAEW-HAQNSBGRSA-N,Small molecule,False,OSI-027,,2.0,,False,False,[],"['AEVI-006' 'ASP 7486' 'ASP-7486' 'ASP7486' 'CERC 006' 'CERC-006'
 'CERC006' 'OSI-027' 'OSI027' 'Osi 027' 'Osi-027']","[('drugbank', array(['DB12387'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'MONDO_0019313'], dtype=object), 'count': 2}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3137349,,,Antibody,False,BOCOCIZUMAB,,3.0,,False,False,[],['Bococizumab' 'PF-04950615' 'RN-316' 'RN316'],,,"{'rows': array(['EFO_0000319', 'EFO_0004911', 'MONDO_0021187', 'HP_0003124'],
      dtype=object), 'count': 4}",[ENSG00000169174],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3235279,N#Cc1c(N)nc(SCc2csc(-c3ccc(Cl)cc3)n2)c(C#N)c1-c1ccc(OCCO)cc1,CITWCLNVRIKQAF-UHFFFAOYSA-N,Small molecule,False,CAPADENOSON,,2.0,,False,False,[],['BAY 68-4986' 'BAY-68-4986' 'Bay-684986' 'Capadenoson'],,,"{'rows': array(['EFO_0003913', 'EFO_0000275'], dtype=object), 'count': 2}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545054,,,Small molecule,False,INCB-40093,,2.0,,False,False,[],['INCB-040093' 'Incb-40093'],,,"{'rows': array(['MONDO_0004992', 'EFO_0000183'], dtype=object), 'count': 2}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545142,,,Small molecule,False,OLOCROLIMUS,,1.0,,False,False,[],['Sar-943'],,,,[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707353,,,Small molecule,False,RG7893,,1.0,,False,False,[],['GDC-0276' 'Rg7893'],,,,[ENSG00000169432],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989932,CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,VBTZKFAHKJXHBA-PIONDTTLSA-N,Protein,False,ANGIOTENSIN II ACETATE,2017.0,4.0,CHEMBL408403,False,True,['Giapreza'],"['Angiotensin ii acetate' 'Angiotensin ii acetate human'
 'Angiotensin ii triacetate' 'Human angiotensin ii acetate salt']","[('DailyMed', array(['angiotensin%20ii%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza'],
      dtype=object))]",,"{'rows': array(['EFO_0005251', 'EFO_0006834', 'HP_0031273'], dtype=object), 'count': 3}",[ENSG00000144891],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications.
CHEMBL41355,CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N,PCOBBVZJEWWZFR-UHFFFAOYSA-N,Small molecule,True,EZOGABINE,2011.0,4.0,,False,True,['Potiga' 'Trobalt'],"['AWD-21360' 'AWD21-360' 'D-23129' 'Ezogabine' 'GKE-841' 'GW-582892X'
 'GW582892X' 'Retigabine' 'WAY-143841']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt'],
      dtype=object)), ('PubChem', array(['174006313'], dtype=object)), ('Wikipedia', array(['Retigabine'], dtype=object)), ('drugbank', array(['DB04953'], dtype=object)), ('chEBI', array(['68584'], dtype=object))]",,"{'rows': array(['EFO_0000474', 'MONDO_0002009', 'MONDO_0004976', 'MONDO_0002050',
       'MONDO_0041052', 'HP_0001250'], dtype=object), 'count': 6}","[ENSG00000053918,ENSG00000075043,ENSG00000184156,ENSG00000185760,ENSG00000117013]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for epilepsy and seizure and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297091,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O,BOLDZXRCJAJADM-AAXBYHQXSA-N,Small molecule,True,CODEINE SULFATE,2009.0,4.0,CHEMBL485,False,True,['Codeine sulfate'],"['Codeine sulfate' 'Codeine sulfate anhydrous' 'Codeine sulfate cii'
 'Codeine sulfate trihydrate' 'Codeine sulphate']","[('DailyMed', array(['codeine%20sulfate'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0003890'], dtype=object), 'count': 2}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for pain and drug dependence. This drug has a black box warning from the FDA.
CHEMBL4297525,NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,KUBPNVYPKPWGRJ-LIVOIKKVSA-N,Small molecule,False,RELAMORELIN,,3.0,,False,False,[],['BIM-28131' 'BIM28131' 'Relamorelin'],"[('drugbank', array(['DB12678'], dtype=object))]",,,[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL4298205,,,Antibody,False,ETIGILIMAB,,2.0,,False,False,[],['Etigilimab' 'OMP-313M32'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETIGILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0008170'], dtype=object), 'count': 2}",[ENSG00000181847],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594472,,,Unknown,False,EMB-01,,2.0,,False,False,[],['Bafisontamab' 'EMB-01' 'Emb-01' 'Emb01' 'Fit-013a'],,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}","[ENSG00000105976,ENSG00000146648]",Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594578,,,Antibody,False,TEBOTELIMAB,,2.0,,False,False,[],['Mgd 013' 'Mgd-013' 'Mgd013' 'Mgd013 (pd-1 x lag-3)' 'Tebotelimab'],,,"{'rows': array(['MONDO_0003060', 'MONDO_0007254', 'EFO_1001512', 'EFO_0000182',
       'MONDO_0001056', 'EFO_0000181'], dtype=object), 'count': 6}","[ENSG00000089692,ENSG00000188389]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4594612,,,Antibody,False,BEPRANEMAB,,2.0,,False,False,[],['Bepranemab' 'UCB-0107' 'UCB0107' 'Ucb0107'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BEPRANEMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004975', 'MONDO_0019037'], dtype=object), 'count': 2}",[ENSG00000186868],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5314403,COc1cc(Cl)ccc1CCNC(=O)c1ccc(Oc2cc3c(cc2Cl)[C@@H](C(=O)O)CCO3)cc1,QIDYUNXQPQEJEC-IBGZPJMESA-N,Small molecule,False,ARRY-502,,2.0,,False,False,[],['ARRY-502' 'ARRY502' 'Arry-502'],,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL607707,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C,WVUNYSQLFKLYNI-AATRIKPKSA-N,Small molecule,False,PELITINIB,,2.0,,False,False,[],['EKB-569' 'Pelitinib' 'WAY-EKB-569'],"[('PubChem', array(['50100098'], dtype=object)), ('drugbank', array(['DB05524'], dtype=object)), ('chEBI', array(['38927'], dtype=object))]",,"{'rows': array(['EFO_1000657', 'EFO_0003060', 'EFO_0000616', 'EFO_0004288'],
      dtype=object), 'count': 4}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1197,CC(CNC1CCCCC1)OC(=O)c1ccccc1,DKLKMKYDWHYZTD-UHFFFAOYSA-N,Small molecule,False,HEXYLCAINE,1982.0,4.0,,False,True,[],['Cyclaine' 'Hexylcaine' 'Osmocaine'],"[('Wikipedia', array(['Hexylcaine'], dtype=object)), ('drugbank', array(['DB00473'], dtype=object)), ('chEBI', array(['34791'], dtype=object))]",['CHEMBL1200715'],,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200641,COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1,XXZSQOVSEBAPGS-DONVQRBFSA-L,Small molecule,False,CISATRACURIUM BESYLATE,1995.0,4.0,CHEMBL1201248,False,True,"['Cisatracurium besylate' 'Cisatracurium besylate preservative free'
 'Nimbex' 'Nimbex preservative free']","['51 W89' '51-W-89' '51-W89' '51W-89' '51W89'
 'Cisatracurium (as besilate)' 'Cisatracurium besilate'
 'Cisatracurium besylate']","[('DailyMed', array(['cisatracurium%20besylate'], dtype=object)), ('PubChem', array(['11113043'], dtype=object)), ('chEBI', array(['3721'], dtype=object))]",,"{'rows': array(['EFO_1000637'], dtype=object), 'count': 1}","[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication.
CHEMBL1201334,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,VXKHXGOKWPXYNA-PGBVPBMZSA-N,Protein,False,TRIPTORELIN,2000.0,4.0,,False,True,['Decapeptyl' 'Decapeptyl sr' 'Gonapeptyl depot'],"['AY-25650' 'Arvekap' 'CL 118,532' 'CL-118532' 'Triptodur' 'Triptorelin'
 'Tryptorelin' 'WY-42462']","[('PubChem', array(['50112597'], dtype=object)), ('Wikipedia', array(['Triptorelin'], dtype=object)), ('drugbank', array(['DB06825'], dtype=object)), ('chEBI', array(['63633'], dtype=object))]",['CHEMBL1200554'],"{'rows': array(['EFO_0000196', 'MONDO_0011972', 'MONDO_0000088', 'EFO_0000196',
       'EFO_0000574', 'MONDO_0008315', 'EFO_0001663', 'MONDO_0000088',
       'EFO_0001663', 'EFO_0000616', 'MONDO_0008170', 'EFO_0000180',
       'EFO_1001757', 'EFO_0009029', 'MONDO_0007254', 'EFO_0001065',
       'EFO_0009029', 'MONDO_0008315', 'EFO_0000545', 'EFO_0000673',
       'EFO_0000305', 'EFO_0000673', 'EFO_0001065', 'MONDO_0004669',
       'MONDO_0007254'], dtype=object), 'count': 25}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 approved and 17 investigational indications.
CHEMBL1201414,,,Oligosaccharide,True,TINZAPARIN SODIUM,2000.0,4.0,,False,True,['Innohep' 'Logiparin'],"['LNH-1' 'LNH1' 'Tinzaparin' 'Tinzaparin na' 'Tinzaparin sodium'
 'Tinzaparin sodium, porcine']","[('Wikipedia', array(['Tinzaparin_sodium'], dtype=object))]",,"{'rows': array(['EFO_0003907', 'EFO_0000365', 'EFO_0003106', 'HP_0002140',
       'MONDO_0002367', 'EFO_0001378', 'MONDO_0100096', 'EFO_0003060',
       'HP_0001907', 'HP_0004419', 'MONDO_0008170'], dtype=object), 'count': 11}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for deep vein thrombosis and recurrent thrombophlebitis and has 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201564,,,Protein,False,INTERFERON GAMMA-1B,1999.0,4.0,,False,True,['Actimmune' 'Immukin'],"['Ifn-.gamma.' 'Ifn-.gamma.1b' 'Imifn' 'Immune ifn'
 'Interferon .gamma.-1b' 'Interferon gama-1b' 'Interferon gamma'
 'Interferon gamma-1b' 'Interferon gamma-1b, recombinant'
 'Interferon gamma-1b,recomb.' 'Interferon gamma-2a' 'Interferon-.gamma.'
 'Interferon-.gamma. (human)']","[('DailyMed', array(['interferon%20gamma-1b'], dtype=object)), ('Wikipedia', array(['Interferon-gamma'], dtype=object))]",,"{'rows': array(['EFO_1001231', 'MONDO_0018305', 'EFO_0000588', 'EFO_0000574',
       'EFO_0002918', 'EFO_0009869', 'MONDO_0009061', 'EFO_0000676',
       'EFO_0000616', 'MONDO_0018364', 'MONDO_0007254', 'EFO_0007386',
       'EFO_0000174', 'MONDO_0002158', 'EFO_0007460', 'EFO_0000756',
       'EFO_0005952', 'MONDO_0017198', 'EFO_0009448', 'MONDO_0002087',
       'EFO_1001359', 'EFO_0000637', 'EFO_0000764', 'MONDO_0004580',
       'EFO_0000621', 'Orphanet_53', 'EFO_0000389', 'EFO_1001865',
       'EFO_1001051', 'EFO_0009429', 'EFO_0004220', 'EFO_0001422',
       'EFO_0003830', 'EFO_0001378', 'EFO_1000811', 'EFO_0000768',
       'EFO_0007228', 'EFO_1001282', 'EFO_0007183', 'EFO_0000565',
       'MONDO_0008315', 'EFO_0007147', 'EFO_0007157', 'MONDO_0100339',
       'MONDO_0008170'], dtype=object), 'count': 45}","[ENSG00000159128,ENSG00000027697]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 41 investigational indications.
CHEMBL1201606,,,Antibody drug conjugate,False,IBRITUMOMAB TIUXETAN,2002.0,4.0,,False,True,['Zevalin' 'Zevalin Kit-Indium-111'],"['IDEC-129' 'IDEC-IN2B8' 'IDEC-Y2B8' 'IDEC-Y2B8 IDEC-129'
 'Ibritumomab tiuxetan']","[('DailyMed', array(['ibritumomab%20tiuxetan'], dtype=object)), ('DrugCentral', array(['4984'], dtype=object)), ('Wikipedia', array(['Ibritumomab_tiuxetan'], dtype=object))]",,"{'rows': array(['MONDO_0013730', 'EFO_0000183', 'EFO_0000095', 'EFO_0000191',
       'EFO_0009441', 'EFO_0000565', 'EFO_0000096', 'EFO_0001378',
       'EFO_0000403', 'EFO_0000574', 'MONDO_0018906', 'EFO_1001365',
       'EFO_0000309', 'EFO_0005952', 'EFO_1001469', 'MONDO_0000873'],
      dtype=object), 'count': 16}",[ENSG00000156738],Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 16 investigational indications.
CHEMBL1201830,,,Protein,False,RILONACEPT,2008.0,4.0,,False,True,['Arcalyst' 'Rilonacept regeneron (previously arcalyst)'],"['IL-1 TRAP' 'IL-1-TRAP' 'INTERLEUKIN-1 TRAP' 'KPL-914' 'Kpl-914'
 'Rilonacept']","[('DrugCentral', array(['5105'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rilonacept-regeneron-previously-arcalyst'],
      dtype=object)), ('Wikipedia', array(['Rilonacept'], dtype=object))]",,"{'rows': array(['EFO_0000404', 'EFO_0000540', 'Orphanet_47045', 'EFO_1001881',
       'MONDO_0016168', 'EFO_0007427', 'EFO_0002609', 'EFO_0004274',
       'MONDO_0018088', 'EFO_0004238', 'MONDO_0008633', 'MONDO_0005147',
       'EFO_1001345'], dtype=object), 'count': 13}",[ENSG00000125538],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 approved and 8 investigational indications.
CHEMBL134713,COc1ccc(/C=C2\CCCN=C2c2cccnc2)c(OC)c1,RPYWXZCFYPVCNQ-RVDMUPIBSA-N,Small molecule,False,GTS-21,,2.0,,False,False,[],"['3-(2,4-Dimethoxybenzylidene)Anabaseine'
 'Dimethoxybenzylidene anabaseine' 'Dmxb-a' 'Gts-21']","[('drugbank', array(['DB05708'], dtype=object))]",,"{'rows': array(['EFO_0003768', 'EFO_0001073', 'EFO_0003758', 'EFO_0005411',
       'MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 6}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL1388,Oc1ccc(OCc2ccccc2)cc1,VYQNWZOUAUKGHI-UHFFFAOYSA-N,Small molecule,False,MONOBENZONE,1952.0,4.0,,False,True,['Benoquin'],"['Monobenzone' 'Monobenzyl ether of hydroquinone' 'NSC-2132'
 'P-(benzyloxy)phenol' 'P-benzyloxyphenol']","[('PubChem', array(['11112252', '144203947', '144208345', '170464724', '174006811'],
      dtype=object)), ('Wikipedia', array(['Monobenzone'], dtype=object)), ('drugbank', array(['DB00600'], dtype=object)), ('chEBI', array(['34380'], dtype=object))]",,,[ENSG00000077498],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1952.
CHEMBL1512580,FC(F)(F)c1cccc(C2=CCN(CCc3ccc4ccccc4c3)CC2)c1,WJJYZXPHLSLMGE-UHFFFAOYSA-N,Small molecule,False,XALIPRODEN,,3.0,,False,False,[],['SR 57746' 'SR-57746' 'Xaliproden'],"[('PubChem', array(['50112828', '50112829'], dtype=object)), ('drugbank', array(['DB06393'], dtype=object)), ('chEBI', array(['48520'], dtype=object))]",['CHEMBL3183486'],"{'rows': array(['MONDO_0004975', 'EFO_0004142'], dtype=object), 'count': 2}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2107869,,,Protein,False,INSULIN DEGLUDEC,2013.0,4.0,,False,True,['Ins tresiba' 'Tresiba'],['Insulin degludec' 'NN-1250' 'NN1250'],"[('DailyMed', array(['insulin%20degludec'], dtype=object)), ('DrugCentral', array(['4960'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba'],
      dtype=object))]",,"{'rows': array(['MONDO_0005147', 'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 3}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for diabetes mellitus and has 2 investigational indications.
CHEMBL2107911,,,Protein,False,ONERCEPT,,3.0,,False,False,[],['Onercept' 'R-HTBP-1'],,,"{'rows': array(['EFO_0003778'], dtype=object), 'count': 1}",[ENSG00000232810],Protein drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2107917,,,Antibody,False,OREGOVOMAB,,3.0,,False,False,['Ovarex'],['Oregovamab' 'Oregovomab' 'mAb-B43.13'],,,"{'rows': array(['MONDO_0002087', 'EFO_0003893', 'MONDO_0008170', 'EFO_0001075',
       'MONDO_0002158'], dtype=object), 'count': 5}",[ENSG00000181143],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2108286,,,Protein,False,TUROCTOCOG ALFA,2013.0,4.0,,False,True,['Novoeight'],['NN-7008' 'NN7008' 'Novoeight' 'Turoctocog alfa'],"[('DrugCentral', array(['5019'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/novoeight'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Protein drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for hemophilia a.
CHEMBL2109545,,,Antibody,False,TB-403,,2.0,,False,False,[],['RG-7334' 'RO-5323441' 'TB-403' 'TB403' 'THR-317' 'Tb-403' 'Thr 317'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000119630],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2141712,COc1ccc(COc2cc3oc(=O)c4cc(C(C)O)ccc4c3cc2OC)cc1,YEAHTLOYHVWAKW-UHFFFAOYSA-N,Small molecule,False,PALOMID-529,,1.0,,False,False,[],"['P-529' 'P529' 'PALOMID-529' 'Palomid 529' 'Palomid-529' 'SG 00529'
 'SG-00529']","[('PubChem', array(['137275969'], dtype=object)), ('drugbank', array(['DB12812'], dtype=object))]",,"{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2360464,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],NYDXNILOWQXUOF-GXKRWWSZSA-L,Small molecule,False,PEMETREXED DISODIUM,2004.0,4.0,CHEMBL225072,False,True,['Alimta'],"['LY-231514 DISODIUM SALT' 'LY231514 DISODIUM SALT' 'Pemetrexed disodium'
 'Pemetrexed disodium heptahydrate' 'Pemetrexed sodium hydrate'
 'Pemetrexed sodium salt']","[('DailyMed', array(['pemetrexed%20disodium'], dtype=object)), ('PubChem', array(['144206040'], dtype=object)), ('chEBI', array(['63722'], dtype=object))]",,"{'rows': array(['EFO_0003050', 'MONDO_0011962', 'MONDO_0002158', 'MONDO_0008315',
       'EFO_1001951', 'EFO_0000308', 'EFO_0000365', 'EFO_0008528',
       'EFO_0000571', 'EFO_0006859', 'EFO_0002618', 'MONDO_0021117',
       'MONDO_0004192', 'MONDO_0008903', 'EFO_0003060', 'EFO_0000708',
       'EFO_0000574', 'MONDO_0000521', 'MONDO_0004992', 'MONDO_0002087',
       'MONDO_0018944', 'MONDO_0007254', 'EFO_0003860', 'MONDO_0001187',
       'MONDO_0008170', 'MONDO_0002974', 'EFO_0000691', 'MONDO_0001056',
       'EFO_0009708', 'EFO_1000576', 'EFO_0000770', 'EFO_0000588',
       'EFO_0003863', 'EFO_1000581', 'EFO_0000616'], dtype=object), 'count': 35}","[ENSG00000176890,ENSG00000159131,ENSG00000228716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 34 investigational indications.
CHEMBL3544975,COc1cc(N)c(Cl)cc1C(=O)NCC1CCN(CC[C@H](OC(N)=O)c2ccc(F)cc2)CC1,KGMMSPVVHZGPHL-NRFANRHFSA-N,Small molecule,False,RELENOPRIDE,,2.0,,False,False,[],['Relenopride' 'YKP-10811' 'YKP10811'],"[('drugbank', array(['DB12798'], dtype=object))]",['CHEMBL3544976'],"{'rows': array(['HP_0002019'], dtype=object), 'count': 1}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545027,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1,MMNNTJYFHUDSKL-UHFFFAOYSA-N,Small molecule,False,XL-281,,2.0,,False,False,[],['BMS-908662' 'Bms-908662 free base' 'EXEL-2819' 'Xl 281' 'Xl-281'],"[('drugbank', array(['DB12854'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'EFO_0000641', 'EFO_1001951', 'EFO_0003060'],
      dtype=object), 'count': 4}","[ENSG00000132155,ENSG00000157764]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3545274,CC(C)(C)n1nnc2c3c(ccc21)C1=CC(=O)CC[C@@]1(CCOc1ccccc1)C3,LYLIIGQPIKTONH-RUZDIDTESA-N,Small molecule,False,MK-6913,,2.0,,False,False,[],['Mk-6913'],,,,"[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545360,COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1,MGGBYMDAPCCKCT-UHFFFAOYSA-N,Small molecule,False,ASP-3026,,1.0,,False,False,[],['ASP3026' 'Asp 3026' 'Asp-3026'],"[('drugbank', array(['DB12729'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000096', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000171094],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3989843,N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1,IGLYMJRIWWIQQE-QUOODJBBSA-N,Small molecule,True,TRANYLCYPROMINE,1961.0,4.0,,False,True,[],['NSC-80664' 'Tranylcypromine'],,['CHEMBL3989698'],"{'rows': array(['MONDO_0002009', 'EFO_0005230', 'MONDO_0002009', 'HP_0000726',
       'EFO_1002014', 'EFO_0000198', 'MONDO_0002009', 'EFO_0000222',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0005252'], dtype=object), 'count': 11}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3989870,CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1,JZCWLJDSIRUGIN-UHFFFAOYSA-N,Small molecule,False,BERZOSERTIB,,2.0,,False,False,[],['Berzosertib' 'M-6620' 'M6620' 'VE-822' 'VX-970' 'VX970' 'Vx-970'],"[('drugbank', array(['DB11794'], dtype=object))]",,"{'rows': array(['EFO_0001075', 'EFO_1000251', 'EFO_0000199', 'EFO_0003060',
       'EFO_0000702', 'EFO_0006352', 'EFO_0002618', 'EFO_0000564',
       'EFO_0000616', 'EFO_0000196', 'MONDO_0008170', 'EFO_0003893',
       'EFO_0001416', 'EFO_0000365', 'EFO_1001960', 'MONDO_0044704',
       'EFO_0005537'], dtype=object), 'count': 17}",[ENSG00000175054],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 17 investigational indications.
CHEMBL3989885,CC(CN(C)C)CN1c2ccccc2Sc2ccccc21.CC(CN(C)C)CN1c2ccccc2Sc2ccccc21.O=C(O)C(O)C(O)C(=O)O,AJZJIYUOOJLBAU-UHFFFAOYSA-N,Small molecule,False,TRIMEPRAZINE TARTRATE,1982.0,4.0,CHEMBL829,False,True,['Temaril' 'Trimeprazine tartrate' 'Vallergan' 'Vallergan fte'],"['Alimemazine hemitartrate' 'Alimemazine tartrate'
 'Methylpromazine tartrate' 'NSC-17475' 'NSC-757358' 'Panectyl' 'Repeltin'
 'Theralene' 'Trimeprazine hemitartrate' 'Trimeprazine tartrate']",,,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL4297315,N=C(N)c1ccc2nc(-c3cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc(-c4cc(S(N)(=O)=O)ccc4O)c3O)[nH]c2c1,WDJHHCAKBRKCLW-IBGZPJMESA-N,Small molecule,False,PCI-27483,,2.0,,False,False,[],['Cra-027483' 'Pci-27483'],"[('drugbank', array(['DB13000'], dtype=object))]",,"{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}",[ENSG00000057593],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297442,OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@H](n3cc(-c4cccc(F)c4)nn3)[C@H]2O)[C@H](O)[C@@H](n2cc(-c3cccc(F)c3)nn2)[C@H]1O,YGIDGBAHDZEYMT-MQFIMZJJSA-N,Small molecule,False,OLITIGALTIN,,2.0,,False,False,[],"['GB-0139' 'GB0139' 'Olitigaltin' 'TD-139' 'TD139' 'Td 139' 'Td-139'
 'Td139']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLITIGALTIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12895'], dtype=object))]",,"{'rows': array(['EFO_0000768', 'MONDO_0100096', 'EFO_0006890'], dtype=object), 'count': 3}",[ENSG00000131981],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297447,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O,XIEWFECSPPTVQN-KMIMAYJXSA-N,Protein,False,TRV-120027,,2.0,,False,False,[],"['Sar-val-tyr-ile-his-pro-d-ala-oh' 'TRV 027' 'TRV-027' 'TRV027'
 'Trv-120027' 'Trv027' 'Trv120027']","[('drugbank', array(['DB12199'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0003144'], dtype=object), 'count': 2}",[ENSG00000144891],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297522,CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21,HCDMJFOHIXMBOV-UHFFFAOYSA-N,Small molecule,False,PEMIGATINIB,2020.0,4.0,,False,True,['Pemazyre'],"['Fgfr inhibitor incb054828' 'INCB054828' 'Incb-054828' 'Incb054828'
 'Pemigatinib']","[('DailyMed', array(['pemigatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEMIGATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15102'], dtype=object))]",,"{'rows': array(['EFO_0003863', 'EFO_0000616', 'EFO_0003060', 'EFO_1001961',
       'EFO_0008528', 'EFO_0000519', 'EFO_0004251', 'MONDO_0004992',
       'MONDO_0007254', 'EFO_1001951', 'MONDO_0011962', 'EFO_0000222',
       'EFO_0002618', 'EFO_0005221', 'MONDO_0001187'], dtype=object), 'count': 15}","[ENSG00000077782,ENSG00000066468,ENSG00000068078]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 11 investigational indications.
CHEMBL4298167,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O,BFENHEAPFWQJFL-BTJKTKAUSA-N,Small molecule,False,FILGOTINIB MALEATE,2020.0,4.0,CHEMBL3301607,False,True,['Jyseleca'],['Filgotinib maleate' 'GS-6034'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca'],
      dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}","[ENSG00000162434,ENSG00000105397,ENSG00000096968,ENSG00000105639]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for rheumatoid arthritis.
CHEMBL4650294,,,Antibody,False,IMALUMAB,,2.0,,False,False,[],['BAX-069' 'BAX-69' 'BAX69' 'Imalumab'],,,,[ENSG00000240972],Antibody drug with a maximum clinical trial phase of II.
CHEMBL4650424,,,Protein,False,SVN53-67/M57-KLH PEPTIDE VACCINE,,2.0,,False,False,[],['Survaxm' 'Svn53-67/m57-klh peptide vaccine'],,,"{'rows': array(['EFO_0000519', 'EFO_1001465', 'EFO_0006475', 'EFO_0001378'],
      dtype=object), 'count': 4}",[ENSG00000089685],Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL485253,CCC(CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1,KPJZHOPZRAFDTN-NQUBZZJWSA-N,Small molecule,False,METHYSERGIDE,1962.0,4.0,,False,True,['Deseril'],['Methysergide'],"[('drugbank', array(['DB00247'], dtype=object)), ('chEBI', array(['584020'], dtype=object))]",['CHEMBL3989558'],"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}","[ENSG00000147246,ENSG00000135914,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962 and is indicated for migraine disorder.
CHEMBL502097,COCCO[C@@H]1[C@H](SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cnc4c(N)ncnc43)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2O)[C@@H](COP(=O)([O-])S[C@H]2[C@@H](OCCOC)[C@H](n3cc(C)c(N)nc3=O)O[C@@H]2COP(=O)([O-])S[C@H]2[C@@H](OCCOC)[C@H](n3cnc4c(=O)[nH]c(N)nc43)O[C@@H]2CO)O[C@H]1n1cc(C)c(N)nc1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],OSGPYAHSKOGBFY-KMHHXCEHSA-A,Oligonucleotide,True,MIPOMERSEN SODIUM,2013.0,4.0,CHEMBL2219536,False,True,['Kynamro'],['ISIS 301012' 'ISIS-301012' 'Mipomersen sodium' 'Mipomersen sodium salt'],"[('DailyMed', array(['mipomersen%20sodium'], dtype=object)), ('Wikipedia', array(['Mipomersen'], dtype=object))]",,"{'rows': array(['EFO_0004911', 'HP_0003124'], dtype=object), 'count': 2}",[ENSG00000084674],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for familial hypercholesterolemia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL93645,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,Small molecule,False,ACECLOFENAC,,4.0,,False,True,['Gerbin' 'Preservex'],['Aceclofenac' 'Aceclofenac betadex'],"[('PubChem', array(['11112873', '144204261', '170465979', '50085951'], dtype=object)), ('Wikipedia', array(['Aceclofenac'], dtype=object)), ('drugbank', array(['DB06736'], dtype=object)), ('chEBI', array(['31159'], dtype=object))]",,"{'rows': array(['HP_0003326', 'MONDO_0003937', 'EFO_0005755', 'MONDO_0005178',
       'EFO_0000685', 'EFO_1001139', 'HP_0002829'], dtype=object), 'count': 7}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 6 approved and 1 investigational indication.
CHEMBL938,CNCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C,PFGWGEPQIUAZME-NXSMLHPHSA-N,Protein,False,SARALASIN,1982.0,4.0,,False,True,[],"['1-sar-8-ala-angiotensin ii' 'Sar-arg-val-tyr-val-his-pro-ala'
 'Saralasin']","[('Wikipedia', array(['Saralasin'], dtype=object)), ('drugbank', array(['DB06763'], dtype=object))]",['CHEMBL1200670'],,[ENSG00000144891],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1002,CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,NDAUXUAQIAJITI-LBPRGKRZSA-N,Small molecule,False,LEVOSALBUTAMOL,1999.0,4.0,,False,True,[],"['ASF-1096' 'Albuterol (r)-form' 'Levalbuterol' 'Levosalbutamol'
 'R-salbutamol' 'Xopenex']","[('PubChem', array(['11111805', '11111806', '11112645', '11113612'], dtype=object)), ('Wikipedia', array(['Levosalbutamol'], dtype=object)), ('drugbank', array(['DB13139'], dtype=object)), ('chEBI', array(['8746'], dtype=object))]",['CHEMBL3989693' 'CHEMBL1201061' 'CHEMBL3989589'],"{'rows': array(['MONDO_0004979', 'MONDO_0004979', 'MONDO_0004979', 'EFO_0000341'],
      dtype=object), 'count': 4}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for asthma and has 2 investigational indications.
CHEMBL1095032,O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1,GEHAEMCVKDPMKO-HXUWFJFHSA-N,Small molecule,False,LETAXABAN,,2.0,,False,False,[],['Letaxaban' 'TAK 442' 'TAK-442' 'TAK442'],"[('drugbank', array(['DB11984'], dtype=object))]",,"{'rows': array(['EFO_0004286', 'EFO_0005672'], dtype=object), 'count': 2}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1255654,CCCCNc1ccc(C(=O)OCCN(C)C)cc1.Cl,PPWHTZKZQNXVAE-UHFFFAOYSA-N,Small molecule,False,TETRACAINE HYDROCHLORIDE,2016.0,4.0,CHEMBL698,False,True,['Anethaine' 'Locan' 'Tetracaine hydrochloride'],"['Amethocaine hydrochloride' 'Butethanol' 'Curtacain' 'Dicainum'
 'Menonasal' 'NSC-757337' 'Pantocaine' 'Tetocaine' 'Tetraca'
 'Tetracaine hcl' 'Tetracaine hydrochloride' 'Tetracaini hydrochloridum']","[('DailyMed', array(['tetracaine%20hydrochloride'], dtype=object)), ('PubChem', array(['11533049', '144203841', '170465190', '26747689', '26747690',
       '50107143', '50107144', '50107145', '85273695'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016.
CHEMBL1562610,Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+],QHJLLDJTVQAFAN-UHFFFAOYSA-M,Small molecule,True,MECLOFENAMATE SODIUM,1980.0,4.0,CHEMBL509,False,True,['Meclodium' 'Meclofenamate sodium' 'Meclomen'],"['CL-583.NA SALT' 'Meclofenamate sodium' 'Meclofenamate sodium anhydrous'
 'Meclofenamate sodium hydrate' 'Meclofenamic acid sodium' 'NSC-757088'
 'Sodium meclofenamate' 'Sodium meclofenamate monohydrate']","[('DailyMed', array(['meclofenamate%20sodium'], dtype=object)), ('PubChem', array(['11112978', '144204315', '170464886', '85273783'], dtype=object)), ('chEBI', array(['76232'], dtype=object))]",,"{'rows': array(['MONDO_0005178', 'HP_0001945', 'EFO_0000685', 'EFO_0002609',
       'HP_0100607'], dtype=object), 'count': 5}","[ENSG00000012779,ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 5 approved indications. This drug has a black box warning from the FDA.
CHEMBL1742461,O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,KMZQAVXSMUKBPD-DJWKRKHSSA-N,Small molecule,False,LAFUTIDINE,,3.0,,False,False,[],['Lafutidine'],"[('PubChem', array(['144205732', '170465978'], dtype=object)), ('drugbank', array(['DB12770'], dtype=object))]",,"{'rows': array(['HP_0004398', 'EFO_0003948', 'EFO_0000337', 'EFO_0009454'],
      dtype=object), 'count': 4}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL1760,CC(C)(C)NCC(O)c1cc(O)cc(O)c1,XWTYSIMOBUGWOL-UHFFFAOYSA-N,Small molecule,False,TERBUTALINE,,4.0,,False,True,[],['Asthmasian' 'Brethaire' 'Brethine' 'Bricanyl' 'Terbutalin' 'Terbutaline'],"[('PubChem', array(['90341646'], dtype=object)), ('Wikipedia', array(['Terbutaline'], dtype=object)), ('drugbank', array(['DB00871'], dtype=object)), ('chEBI', array(['9449'], dtype=object))]",['CHEMBL1315867' 'CHEMBL1160544'],"{'rows': array(['HP_0006536', 'EFO_0000341', 'MONDO_0004979', 'EFO_0000341',
       'EFO_0009661', 'EFO_0007160', 'EFO_0005762', 'MONDO_0004979',
       'MONDO_0005147'], dtype=object), 'count': 9}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 5 investigational indications.
CHEMBL1908373,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,IEXUMDBQLIVNHZ-YOUGDJEHSA-N,Small molecule,False,ONAPRISTONE,,4.0,,False,True,[],['Onapristone' 'ZK-299' 'ZK-98299' 'ZK299' 'Zk-98299' 'Zk98299'],"[('drugbank', array(['DB12637'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0007254', 'EFO_0000196'], dtype=object), 'count': 3}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.
CHEMBL2012520,CC(C)(Cc1ccc(Oc2ccc(C(N)=O)cn2)cc1)NC[C@H](O)COc1cccc2[nH]c3ccccc3c12,RBSGUQYXRDKPAE-QFIPXVFZSA-N,Small molecule,False,LY377604,,2.0,,False,False,[],['LY-377604' 'Ly-377604' 'Ly377604'],"[('drugbank', array(['DB12858'], dtype=object))]",['CHEMBL2012522' 'CHEMBL2012521'],"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2105345,CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1,KEJXLQUPYHWCNM-UHFFFAOYSA-N,Small molecule,False,PROPANIDID,,4.0,,True,True,[],"['BAYER 1420' 'BAYER-1420' 'FBA 1420' 'FBA-1420' 'Propanidid' 'TH-2180'
 'WH 5668' 'WH-5668']","[('PubChem', array(['144206858'], dtype=object)), ('drugbank', array(['DB13234'], dtype=object))]",,,"[ENSG00000114200,ENSG00000087085]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2105762,CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,MKMPWKUAHLTIBJ-ISTRZQFTSA-N,Small molecule,False,OMARIGLIPTIN,2015.0,4.0,,False,True,[],['MK-3102' 'Omarigliptin'],"[('drugbank', array(['DB11992'], dtype=object))]",['CHEMBL3234203'],"{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications.
CHEMBL2105763,Cn1cc(CNCC2CCN(c3ncc(C(=O)NO)cn3)CC2)c2ccccc21,PAWIYAYFNXQGAP-UHFFFAOYSA-N,Small molecule,False,QUISINOSTAT,,2.0,,False,False,[],['JNJ 26481585' 'JNJ-26481585' 'Quisinostat'],"[('drugbank', array(['DB12985'], dtype=object))]",['CHEMBL3039527'],"{'rows': array(['EFO_0002913', 'MONDO_0008170', 'EFO_0000574'], dtype=object), 'count': 3}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2108342,,,Antibody,False,GEMTUZUMAB,,3.0,,False,False,[],['Gemtuzumab' 'Hp 67.6'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000105383],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108576,,,Antibody,False,BAPINEUZUMAB,,3.0,,False,False,[],"['3D-6' 'AAB-001' 'AAB-001, Humanized 3D-6 Monoclonal Antibody'
 'Bapineuzumab' 'HUMANIZED 3D-6 MONOCLONAL ANTIBODY']",,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108683,,,Unknown,False,ENTOLIMOD,,2.0,,False,False,['Cblb502'],['CBLB-502' 'CBLB502' 'Entolimod'],,,"{'rows': array(['EFO_0000616', 'EFO_1001951', 'EFO_0003890'], dtype=object), 'count': 3}",[ENSG00000187554],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109583,,,Antibody,False,F16IL2,,2.0,,False,False,[],['F16IL2' 'F16il2'],,,"{'rows': array(['EFO_0000222', 'EFO_1001471', 'MONDO_0007254', 'EFO_0003060'],
      dtype=object), 'count': 4}",[ENSG00000041982],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2110727,CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1,PNDKCRDVVKJPKG-WHERJAGFSA-N,Small molecule,False,CENICRIVIROC,,3.0,,False,False,[],['Cenicriviroc' 'TAK-652' 'TBR-652'],"[('drugbank', array(['DB11758'], dtype=object))]",['CHEMBL2105686'],"{'rows': array(['EFO_1001249', 'MONDO_0100096', 'EFO_0003095', 'EFO_0000180',
       'EFO_0000180', 'EFO_0000544', 'EFO_0001421', 'EFO_0000764',
       'EFO_0004268'], dtype=object), 'count': 9}","[ENSG00000121807,ENSG00000160791]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL2216870,CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,IFSDAJWBUCMOAH-HNNXBMFYSA-N,Small molecule,True,IDELALISIB,2014.0,4.0,,False,True,['Zydelig'],['CAL-101' 'GS-1101' 'GS-11CAL-101' 'Idelalisib'],"[('DailyMed', array(['idelalisib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig'],
      dtype=object)), ('drugbank', array(['DB09054'], dtype=object)), ('chEBI', array(['82701'], dtype=object))]",,"{'rows': array(['EFO_0000183', 'EFO_1001469', 'MONDO_0005184', 'MONDO_0018906',
       'MONDO_0044903', 'EFO_0000095', 'EFO_0005854', 'EFO_0000616',
       'MONDO_0004992', 'EFO_0000574', 'EFO_0000403', 'EFO_0000222',
       'EFO_0001378', 'MONDO_0000432', 'EFO_0009441', 'EFO_1001875',
       'EFO_0000096', 'EFO_0005952', 'EFO_0000220'], dtype=object), 'count': 19}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL262075,CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,CBIAWPMZSFFRGN-UHFFFAOYSA-N,Small molecule,False,INDIPLON,,3.0,,False,False,[],['CL-285489' 'Calenthys' 'Indiplon' 'NBI-34060'],"[('PubChem', array(['174006212'], dtype=object)), ('Wikipedia', array(['Indiplon'], dtype=object)), ('drugbank', array(['DB12590'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'MONDO_0002050'], dtype=object), 'count': 2}",[ENSG00000022355],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3545373,,,Antibody,False,ENOBLITUZUMAB,,2.0,,False,False,[],['Enoblituzumab' 'MGA-271' 'MGA271'],,,"{'rows': array(['MONDO_0008315', 'EFO_0000756', 'EFO_0000181'], dtype=object), 'count': 3}",[ENSG00000103855],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL364804,CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1,NXMZBNYLCVTRGB-UHFFFAOYSA-N,Small molecule,False,GW-406381,,3.0,,False,False,[],['Gw 406381' 'Gw-406381' 'Gw406381'],"[('drugbank', array(['DB12009'], dtype=object))]",,"{'rows': array(['EFO_0010072', 'EFO_0004616', 'EFO_0000685', 'EFO_0003843'],
      dtype=object), 'count': 4}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3989798,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O.O=C(O)/C=C/C(=O)O,RATSWNOMCHFQGJ-XODSYJLDSA-N,Small molecule,False,FORMOTEROL FUMARATE,2001.0,4.0,CHEMBL1256786,False,True,"['Atimos modulite' 'Foradil' 'Foradil certihaler' 'Oxis 12' 'Oxis 6'
 'Perforomist']","['Atock' 'BD 40A' 'BD-40A' 'CGP 25827A' 'CGP-25827A' 'Eformoterol'
 'Fomoterol fumarate' 'Foraseq' 'Formoterol fumarate'
 'Formoterol fumarate (superceded)' 'Formoterol fumarate anhydrous'
 'Formoterol fumarate dihydrate' 'Formoterol fumarate hydrate'
 'Formoterol hemifumarate' 'NSC-299587' 'Oxeze' 'YM-08316']","[('DailyMed', array(['formoterol%20fumarate', 'formoterol%20fumarate%20dihydrate'],
      dtype=object))]",,"{'rows': array(['HP_0006536', 'EFO_0007183', 'EFO_0009661', 'MONDO_0100096',
       'EFO_1000637', 'HP_0002110', 'MONDO_0005271', 'MONDO_0008903',
       'EFO_0000341', 'EFO_0006505', 'EFO_0003768', 'EFO_0000464',
       'MONDO_0004979'], dtype=object), 'count': 13}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 9 investigational indications.
CHEMBL3989805,CN1CCN(c2ccccc2/C=C2\SCCN(c3ccc(Cl)c(Cl)c3)C2=O)CC1.Cl,NMTRXBJYASHMND-UXTSPRGOSA-N,Small molecule,False,ELZASONAN HYDROCHLORIDE,,2.0,CHEMBL3185463,False,False,[],"['CP-448,187-01' 'Cp-448187-01' 'Elzasonan hcl' 'Elzasonan hydrochloride']",,,,"[ENSG00000135312,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4089083,O/N=c1\cc(-c2cc3sccc3cn2)oc2ccc(CCCN3CCOCC3)cc12,ZTEDNASHAWNBKQ-NCELDCMTSA-N,Small molecule,False,FOLIGLURAX,,2.0,,False,False,[],['DT-1687' 'DT1687' 'Foliglurax' 'PXT-002331' 'PXT002331' 'Pxt002331'],"[('drugbank', array(['DB15292'], dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000124493],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4110551,COC(=O)NCCCn1nc([C@@H](C)N(C(=O)[C@H]2CNCCO2)C2CC2)c2ccc(C)nc21,GRTDDIZIUSADLD-CRAIPNDOSA-N,Small molecule,False,SPH-3127,,3.0,,False,False,[],['SPH-3127' 'SPH3127' 'Sph-3127' 'Sph3127'],,,"{'rows': array(['EFO_0000729', 'EFO_0000401', 'MONDO_0001134', 'EFO_0000537'],
      dtype=object), 'count': 4}",[ENSG00000143839],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297312,COC[C@@]1(C)CCCN2CCc3c(oc4ccccc34)[C@@H]21,OCUKPFWNSAAHRP-QZTJIDSGSA-N,Small molecule,False,ORM-12741,,2.0,,False,False,[],['DB-105' 'ORM-10921' 'Orm-12741'],"[('drugbank', array(['DB12057'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000184160],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298047,,,Antibody,False,TAFASITAMAB,2020.0,4.0,,False,True,['Minjuvi' 'Monjuvi' 'Monjuvi (tafasitamab-cxix) for injection'],"['MOR-00208' 'MOR00208' 'MOR208' 'Mor-208' 'Mor00208' 'Tafasitamab'
 'Tafasitamab cxix' 'XmAb5574' 'Xmab-5574' 'Xmab5574']","[('DailyMed', array(['tafasitamab-cxix'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/minjuvi'],
      dtype=object))]",,"{'rows': array(['EFO_0000095', 'EFO_1001469', 'MONDO_0001023', 'EFO_0000574',
       'EFO_0000096', 'MONDO_0018906', 'EFO_0000403', 'EFO_0005952',
       'EFO_0000616', 'EFO_0000220'], dtype=object), 'count': 10}",[ENSG00000177455],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 7 investigational indications.
CHEMBL4594566,,,Antibody,False,ONGERICIMAB,,3.0,,False,False,[],['JS 002' 'JS-002' 'Js002' 'Ongericimab'],,,"{'rows': array(['MONDO_0004992', 'EFO_0004911', 'Orphanet_79211', 'HP_0003124',
       'MONDO_0021187'], dtype=object), 'count': 5}",[ENSG00000169174],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL515966,COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1,XPNMCDYOYIKVGB-CONSDPRKSA-N,Small molecule,False,EZLOPITANT,,2.0,,False,False,[],"['CJ-11, 974' 'CJ-11,974' 'Cj-11974' 'Ezlopitant']","[('Wikipedia', array(['Ezlopitant'], dtype=object))]",,,[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL5315052,C#CCN[C@@H]1CCc2ccccc21.C#CCN[C@@H]1CCc2ccccc21.O=C(O)C(O)C(O)C(=O)O,YGKHOZXCTLKSLJ-IUWNWRFPSA-N,Small molecule,False,RASAGILINE TARTRATE,2016.0,4.0,CHEMBL887,False,True,['Rasagiline mylan'],['Rasagiline hemitartrate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-mylan'],
      dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000069535],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for parkinson disease.
CHEMBL561157,CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)[O-])c3C[C@H]2C[C@H]1O.[Na+],IQKAWAUTOKVMLE-ZSESPEEFSA-M,Small molecule,False,TREPROSTINIL SODIUM,2020.0,4.0,CHEMBL1237119,False,True,['Remodulin' 'Trepulmix' 'Tyvaso'],['Treprostinil Sodium' 'Treprostinil sodium' 'Treprostinil sodium salt'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trepulmix'],
      dtype=object)), ('chEBI', array(['50863'], dtype=object))]",,"{'rows': array(['MONDO_0005149'], dtype=object), 'count': 1}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for pulmonary hypertension.
CHEMBL578,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,GBXSMTUPTTWBMN-XIRDDKMYSA-N,Small molecule,True,ENALAPRIL,1985.0,4.0,,False,True,[],['C09AA02' 'Enalapril' 'Lexxel' 'Olinapril' 'Vaseretic' 'Vasotec'],"[('PubChem', array(['11112847', '144204423', '170464969', '29214998'], dtype=object)), ('TG-GATEs', array(['95'], dtype=object)), ('Wikipedia', array(['Enalapril'], dtype=object)), ('drugbank', array(['DB00584'], dtype=object)), ('chEBI', array(['4784'], dtype=object))]",['CHEMBL1200659'],"{'rows': array(['HP_0000093', 'EFO_0000537', 'EFO_1001482', 'EFO_0003144',
       'EFO_0001378', 'EFO_0000668', 'EFO_0003884', 'EFO_0003106',
       'EFO_1001375', 'EFO_0000280', 'MONDO_0005147', 'EFO_0007328',
       'EFO_0003144', 'EFO_0000756', 'EFO_0000373', 'MONDO_0004992',
       'EFO_0008585', 'EFO_0005529', 'MONDO_0100096', 'EFO_0005669',
       'EFO_0000318', 'EFO_0000222', 'MONDO_0018638', 'EFO_0004289',
       'EFO_0000712', 'EFO_0000537', 'EFO_0004194', 'MONDO_0001134',
       'EFO_0004234', 'EFO_0000319', 'EFO_0000556', 'EFO_0000373',
       'EFO_0000685', 'EFO_0003777'], dtype=object), 'count': 34}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 30 investigational indications. This drug has a black box warning from the FDA.
CHEMBL61872,CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3,JACAAXNEHGBPOQ-LLVKDONJSA-N,Small molecule,False,TALAMPANEL,,2.0,,False,False,[],['(-)-talampanel' 'GYKI-53773' 'LY-300164' 'Ly300164' 'Talampanel'],"[('Wikipedia', array(['Talampanel'], dtype=object)), ('drugbank', array(['DB04982'], dtype=object)), ('chEBI', array(['34992'], dtype=object))]",,"{'rows': array(['EFO_0002501', 'MONDO_0005180', 'MONDO_0004976', 'EFO_0000630',
       'EFO_1000158', 'EFO_0000474', 'EFO_0000519', 'EFO_0002499'],
      dtype=object), 'count': 8}","[ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL1162,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,VIKNJXKGJWUCNN-XGXHKTLJSA-N,Small molecule,True,NORETHINDRONE,1962.0,4.0,,False,True,"['Aygestin' 'Camila' 'Errin' 'Heather' 'Incassia' 'Jencycla' 'Menzol'
 'Micronor' 'Micronor hrt' 'Nor-qd' 'Norethidrone' 'Norethindrone'
 'Noriday' 'Norlutin' 'Primolut n' 'Utovlan']","['Activella' 'Anovule' 'Aygestin' 'Calluna vulgaris'
 'Calluna vulgaris whole' 'Combipatch' 'Femhrt' 'Gestest' 'Heather whole'
 'NSC-9564' 'Norethindrone' 'Norethisteron' 'Norethisterone'
 'Norethisteronum' 'Norlutate' 'SC-4640' 'Triella']","[('DailyMed', array(['norethindrone'], dtype=object)), ('PubChem', array(['144204875', '144212744', '170464683', '49647479'], dtype=object)), ('Wikipedia', array(['Norethisterone'], dtype=object)), ('drugbank', array(['DB00717'], dtype=object)), ('chEBI', array(['7627'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0002687', 'HP_0100607', 'EFO_0003929',
       'EFO_0008520', 'GO_0042697', 'EFO_0001065', 'EFO_0003843',
       'EFO_0004714', 'EFO_0000616', 'EFO_0008522', 'EFO_0009006',
       'EFO_0003047'], dtype=object), 'count': 13}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200470,COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+],RYXPMWYHEBGTRV-JIDHJSLPSA-N,Small molecule,False,ESOMEPRAZOLE SODIUM,2005.0,4.0,CHEMBL1201320,False,True,['Esomeprazole sodium' 'Nexium iv'],['Esomeprazole (as sodium)' 'Esomeprazole sodium' 'H199/18 SODIUM'],"[('DailyMed', array(['esomeprazole%20sodium'], dtype=object))]",,"{'rows': array(['MONDO_0004247', 'EFO_0003948', 'EFO_0004607'], dtype=object), 'count': 3}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for gastroesophageal reflux disease and duodenal ulcer and has 1 investigational indication.
CHEMBL1200599,Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1,VMIZTXDGZPTKIK-UHFFFAOYSA-N,Small molecule,False,DIFENOXIN HYDROCHLORIDE,1978.0,4.0,CHEMBL1201321,False,True,[],"['Difenoxin hcl' 'Difenoxine hydrochloride' 'R 15,403' 'R-15403']","[('DailyMed', array(['difenoxin%20hydrochloride'], dtype=object)), ('chEBI', array(['59790'], dtype=object))]",,,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978.
CHEMBL1200877,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C,JWRMHDSINXPDHB-OJAGFMMFSA-N,Small molecule,False,FLUMETHASONE PIVALATE,1982.0,4.0,,False,True,['Locorten' 'Locorten-vioform'],"['Flumetasone pivalate' 'Flumethasone 21-pivalate' 'Flumethasone pivalate'
 'NSC-107680']","[('PubChem', array(['56423133', '855730'], dtype=object)), ('chEBI', array(['31620'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201006,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1.O=C(O)/C=C\C(=O)O,JXYWFNAQESKDNC-BTJKTKAUSA-N,Small molecule,False,PYRILAMINE MALEATE,1973.0,4.0,CHEMBL511,False,True,['Pyrilamine maleate'],"['Antamine' 'Anthisan' 'Dorantamin' 'Enrumay' 'Histalon' 'Histan'
 'Histapyran' 'Histatex' 'Mepyramine maleate' 'NSC-3604' 'Neo-antergan'
 'Paraminyl' 'Parmal' 'Pyramal' 'Pyrilamine maleate' 'Stamine' 'Stangen'
 'Thylogen']","[('PubChem', array(['144207712', '26747601', '26747602', '50106737', '50106738',
       '50106739', '56422415', '855902', '93576628'], dtype=object))]",,"{'rows': array(['EFO_0003956'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973 and is indicated for seasonal allergic rhinitis.
CHEMBL1231160,NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O,MPUQHZXIXSTTDU-QXGSTGNESA-N,Small molecule,False,PEVONEDISTAT,,3.0,,False,False,[],['MLN 4924' 'MLN-4924' 'MLN-4924003' 'MLN4924' 'Pevonedistat'],"[('drugbank', array(['DB11759'], dtype=object))]",['CHEMBL2364622'],"{'rows': array(['EFO_0000403', 'EFO_0001378', 'EFO_0000182', 'EFO_0003060',
       'EFO_0000220', 'MONDO_0004992', 'EFO_0002617', 'EFO_0000588',
       'EFO_0000616', 'EFO_0000222', 'EFO_0000198', 'EFO_1001961',
       'EFO_1001779'], dtype=object), 'count': 13}","[ENSG00000144744,ENSG00000159593]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL1290,CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1,KQXKVJAGOJTNJS-HNNXBMFYSA-N,Small molecule,False,PENBUTOLOL,1987.0,4.0,,False,True,[],['Levatol' 'Penbutolol'],"[('Wikipedia', array(['Penbutolol'], dtype=object)), ('drugbank', array(['DB01359'], dtype=object)), ('chEBI', array(['7954'], dtype=object))]",['CHEMBL1200363' 'CHEMBL2361370'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and is indicated for cardiovascular disease.
CHEMBL16,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,CXOFVDLJLONNDW-UHFFFAOYSA-N,Small molecule,False,PHENYTOIN,1953.0,4.0,,False,True,"['Dilabid' 'Dilantin' 'Dilantin-125' 'Dilantin-30' 'Diphenylhydantoin'
 'Hydantol' 'Phentytoin' 'Phenytoin']","['Diphenylhydantoin' 'Epamin' 'Lepitoin' 'NSC-8722' 'Phenytek' 'Phenytex'
 'Phenytoin' 'Phenytoinum' 'SM-88 COMPONENT PHENYTOIN' 'Zentropil']","[('DailyMed', array(['phenytoin'], dtype=object)), ('PubChem', array(['11111069', '11532994', '124879886', '124886706', '144204412',
       '144209497', '144210601', '170464785', '17389903', '26753026',
       '26753027', '26753028', '50106148', '56423134', '85230999',
       '90340679', '90341165'], dtype=object)), ('TG-GATEs', array(['26'], dtype=object)), ('Wikipedia', array(['Phenytoin'], dtype=object)), ('drugbank', array(['DB00252'], dtype=object)), ('chEBI', array(['8107'], dtype=object))]","['CHEMBL3274483' 'CHEMBL553532' 'CHEMBL1611' 'CHEMBL3786353'
 'CHEMBL4764504']","{'rows': array(['EFO_0007405', 'EFO_0005230', 'EFO_0000565', 'EFO_0000474',
       'EFO_0002618', 'EFO_0004272', 'EFO_1001996', 'MONDO_0002050',
       'MONDO_0005090', 'HP_0001250', 'EFO_0000174', 'EFO_0000621',
       'EFO_0000546', 'EFO_0000474', 'HP_0001250', 'HP_0000726',
       'EFO_0009562', 'EFO_0000574', 'EFO_0000540', 'MONDO_0011382',
       'EFO_0002610'], dtype=object), 'count': 21}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for epilepsy and seizure and has 17 investigational indications.
CHEMBL1695,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C.Cl,YUKARLAABCGMCN-PKLMIRHRSA-N,Small molecule,False,TIAGABINE HYDROCHLORIDE,1997.0,4.0,CHEMBL1027,False,True,['Gabitril' 'Tiagabine hydrochloride'],"['ABBOTT-70569 HYDROCHLORIDE' 'ABBOTT-70569.1' 'ABBOTT-70569.HCL'
 'ABBOTT-705691' 'ABT-569' 'Abbott-70569' 'Abbott-70569.1' 'Gabatril'
 'NNC-05-0328' 'NNC-050328' 'NO-05-0328' 'NO-050328' 'Tiagabine hcl'
 'Tiagabine hydrochloride']","[('DailyMed', array(['tiagabine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205798', '170465153', '49681547'], dtype=object)), ('chEBI', array(['85388'], dtype=object))]",,"{'rows': array(['EFO_1001892', 'HP_0001250', 'EFO_0005230'], dtype=object), 'count': 3}",[ENSG00000157103],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for seizure and has 2 investigational indications.
CHEMBL1743058,,,Antibody,False,PONEZUMAB,,2.0,,False,False,[],['PF-04360365' 'Ponezumab' 'RN-1219'],,,"{'rows': array(['EFO_0006790', 'MONDO_0004975'], dtype=object), 'count': 2}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2103837,O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1,TXEIIPDJKFWEEC-UHFFFAOYSA-N,Small molecule,False,TAFAMIDIS,2011.0,4.0,,False,True,['Vyndamax' 'Vyndaqel'],['FX-1005' 'FX-1006' 'FX1006' 'Tafamidis'],"[('DailyMed', array(['tafamidis'], dtype=object)), ('drugbank', array(['DB11644'], dtype=object)), ('chEBI', array(['78538'], dtype=object))]",['CHEMBL2105675'],"{'rows': array(['EFO_1001875', 'EFO_0009562', 'EFO_0000318', 'EFO_0000318',
       'MONDO_0019438', 'EFO_0004129', 'EFO_0004129', 'EFO_1001875'],
      dtype=object), 'count': 8}",[ENSG00000118271],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 3 investigational indications.
CHEMBL2105722,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,KZUIYQJTUIACIG-YBZCJVABSA-N,Small molecule,False,NOMEGESTROL,,4.0,,False,True,[],['Nomegestrol'],"[('drugbank', array(['DB11636'], dtype=object))]",,,[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL2108567,,,Antibody,False,TANEZUMAB,,3.0,,False,False,[],['PF-04383119' 'PF-4383119' 'RN-624' 'RN624' 'Tanezumab'],,,"{'rows': array(['EFO_1000786', 'EFO_1000869', 'EFO_0000342', 'EFO_0004616',
       'MONDO_0041052', 'HP_0001945', 'HP_0003419', 'EFO_0003830',
       'EFO_1000783', 'MONDO_0005178', 'HP_0012532', 'EFO_0001065',
       'EFO_0003843'], dtype=object), 'count': 13}",[ENSG00000134259],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL2218917,CC1OC2(CS1)CN1CCC2CC1.Cl.O,JKJRNPOQQPBPOV-UHFFFAOYSA-N,Small molecule,False,CEVIMELINE HYDROCHLORIDE,2000.0,4.0,CHEMBL168815,False,True,['Cevimeline' 'Cevimeline hydrochloride' 'Evoxac'],"['AF-102B' 'AF102B' 'Cevimeline hcl' 'Cevimeline hydrochloride'
 'Cevimeline hydrochloride hemihydrate' 'Cevimeline hydrochloride hydrate'
 'FKS-508' 'SND-5008' 'SNI-2011' 'SNK-508' 'Saligren']","[('DailyMed', array(['cevimeline%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0009869'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for xerostomia.
CHEMBL23293,CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O,WUILNKCFCLNXOK-CFBAGHHKSA-N,Small molecule,False,SALIRASIB,,2.0,,False,False,[],['FTS' 'Salirasib'],"[('PubChem', array(['11111197', '50106301', '50106302', '520931', '85231054'],
      dtype=object)), ('drugbank', array(['DB12681'], dtype=object))]",,,"[ENSG00000174775,ENSG00000213281,ENSG00000133703]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL256997,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,OOUGLTULBSNHNF-UHFFFAOYSA-N,Small molecule,False,ATALUREN,2014.0,4.0,,False,True,['Translarna'],['Ataluren' 'PTC-124' 'PTC124' 'Translarna'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/translarna'],
      dtype=object)), ('PubChem', array(['144206184', '170466862', '85852879', '87334013', '99460885'],
      dtype=object)), ('Wikipedia', array(['Ataluren'], dtype=object)), ('drugbank', array(['DB05016'], dtype=object))]",,"{'rows': array(['MONDO_0009061', 'MONDO_0010602', 'MONDO_0010679', 'MONDO_0019172',
       'MONDO_0010311', 'MONDO_0010604', 'EFO_0000474'], dtype=object), 'count': 7}","[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for duchenne muscular dystrophy and becker muscular dystrophy and has 5 investigational indications.
CHEMBL3039515,CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)NCC(=O)O)c3ccccc3)cc2S(=O)(=O)C1,XFLQIRAKKLNXRQ-UUWRZZSWSA-N,Small molecule,False,ELOBIXIBAT,,3.0,,False,False,[],['A-3309' 'A3309' 'AZD-7806' 'AZD7806' 'Elobixibat'],"[('drugbank', array(['DB12486'], dtype=object))]",,"{'rows': array(['EFO_1001249', 'Orphanet_309005', 'HP_0002019'], dtype=object), 'count': 3}",[ENSG00000125255],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3137351,,,Antibody,False,ABRILUMAB,,2.0,,False,False,[],['AMG 181' 'AMG-181' 'Abrilumab' 'MEDI-7183' 'MEDI7183'],,,"{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}","[ENSG00000115232,ENSG00000139626]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3301607,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1,RIJLVEAXPNLDTC-UHFFFAOYSA-N,Small molecule,False,FILGOTINIB,2020.0,4.0,,False,True,[],"['Filgotinib' 'G-146034' 'G146034' 'GLPG0634' 'GS-6034 FREE BASE'
 'Glpg-0634']","[('drugbank', array(['DB14845'], dtype=object))]",['CHEMBL3301602' 'CHEMBL4298167'],"{'rows': array(['EFO_0003086', 'EFO_0003767', 'EFO_0003834', 'EFO_0000699',
       'MONDO_0007915', 'EFO_0003778', 'EFO_0000384', 'EFO_0000729',
       'EFO_0000685', 'EFO_1001231', 'EFO_0000685', 'EFO_0003898',
       'EFO_0000540'], dtype=object), 'count': 13}","[ENSG00000105397,ENSG00000096968,ENSG00000105639,ENSG00000162434]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for rheumatoid arthritis and immune system disease and has 11 investigational indications.
CHEMBL3707375,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F,JVCPIJKPAKAIIP-UHFFFAOYSA-N,Small molecule,False,AMISELIMOD,,2.0,,False,False,[],['2240442' 'Amiselimod'],,['CHEMBL3707374'],"{'rows': array(['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000729',
       'EFO_0000384', 'MONDO_0007915'], dtype=object), 'count': 6}","[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3990032,,,Antibody drug conjugate,False,TELISOTUZUMAB VEDOTIN,,3.0,,False,False,[],"['ABBV-399' 'ABT-399' 'Abbv 399' 'Abt-700-vcmmae' 'PR-1420682'
 'Telisotuzumab vedotin']",,,"{'rows': array(['EFO_0000708', 'EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 3}","[ENSG00000105976,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL414357,CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,HTQBXNHDCUEHJF-XWLPCZSASA-N,Protein,True,EXENATIDE,2005.0,4.0,,False,True,['Bydureon' 'Bydureon bcise' 'Bydureon pen' 'Byetta'],"['AC 2993' 'AC-002993' 'AC-2993' 'AC-2993A' 'AC-2993LAR' 'AC002993'
 'AC2993' 'AC2993A' 'DA-3091' 'EXENDIN-4' 'Exenatide'
 'Exenatide Synthetic' 'Exenatide synthetic' 'Exendin 4' 'ITCA-650'
 'LY-2148568' 'LY2148568']","[('DailyMed', array(['exenatide%20synthetic'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon'],
      dtype=object))]",,"{'rows': array(['EFO_0003095', 'EFO_0001645', 'MONDO_0005147', 'HP_0002140',
       'HP_0000083', 'EFO_0001073', 'EFO_1001050', 'EFO_0007318',
       'EFO_0004319', 'EFO_0001074', 'HP_0001824', 'EFO_0008493',
       'EFO_0000712', 'EFO_0008583', 'MONDO_0005148', 'MONDO_0007079',
       'EFO_0000400', 'EFO_1001121', 'EFO_0002610', 'EFO_0000612',
       'EFO_0000660', 'MONDO_0005180', 'HP_0003074'], dtype=object), 'count': 23}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,QZUDBNBUXVUHMW-UHFFFAOYSA-N,Small molecule,True,CLOZAPINE,1989.0,4.0,,False,True,['Clozapine' 'Clozaril' 'Fazaclo odt' 'Versacloz' 'Zaponex'],"['Clozapine' 'Clozapine (caraco)' 'Clozapine (clozaril)'
 'Clozapine (fazaclo)' 'Clozapine (ivax)' 'Clozapine (mylan)'
 'Clozapine (teva)' 'Clozapine (udl)' 'Clozapine (versacloz)'
 'Clozapine resolution mixture' 'HF 1854' 'HF-1854' 'Leponex' 'NSC-757429']","[('DailyMed', array(['clozapine'], dtype=object)), ('PubChem', array(['104171134', '11110967', '11110968', '11113341', '124879684',
       '124879686', '124879688', '124879690', '124879691', '144203664',
       '170464853', '26747001', '26751524', '50104084', '50104086',
       '56422144', '85230974', '855811', '90341777'], dtype=object)), ('Wikipedia', array(['Clozapine'], dtype=object)), ('drugbank', array(['DB00363'], dtype=object)), ('chEBI', array(['3766'], dtype=object))]",['CHEMBL538973'],"{'rows': array(['EFO_0005407', 'EFO_0005230', 'MONDO_0004985', 'HP_0000726',
       'EFO_0003852', 'MONDO_0005090', 'MONDO_0002050', 'HP_0001249',
       'EFO_0005411'], dtype=object), 'count': 9}","[ENSG00000149295,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297852,,,Protein,False,CENEGERMIN,2017.0,4.0,,False,True,['Oxervate'],['Cenegermin' 'Cenegermin bkbj'],"[('DailyMed', array(['cenegermin-bkbj'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oxervate'],
      dtype=object))]",,"{'rows': array(['EFO_1000906', 'EFO_0003966', 'EFO_0009449'], dtype=object), 'count': 3}","[ENSG00000198400,ENSG00000148053,ENSG00000140538]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for eye disease and keratitis and has 1 investigational indication.
CHEMBL4297877,,,Antibody,False,BALSTILIMAB,,3.0,,False,False,[],['AGEN-2034' 'AGEN2034' 'Agen2034' 'Balstilimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BALSTILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000294', 'EFO_1001931', 'EFO_0004142', 'EFO_0003968',
       'MONDO_0002974', 'EFO_0002618', 'MONDO_0008170', 'EFO_0001668',
       'MONDO_0011962', 'EFO_0000756', 'EFO_1001968', 'EFO_0000616',
       'EFO_1001951', 'EFO_1000026', 'MONDO_0005184', 'EFO_0003060',
       'EFO_0000574'], dtype=object), 'count': 17}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.
CHEMBL443684,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,JLYAXFNOILIKPP-KXQOOQHDSA-N,Small molecule,False,NAVITOCLAX,,3.0,,False,False,[],['A-855071.0' 'ABT-263' 'Navitoclax'],"[('drugbank', array(['DB12340'], dtype=object))]",['CHEMBL2105690'],"{'rows': array(['EFO_0000198', 'MONDO_0008315', 'MONDO_0000873', 'EFO_1001469',
       'MONDO_0008170', 'EFO_0000220', 'EFO_0004251', 'EFO_0000616',
       'EFO_0000095', 'EFO_0000702', 'EFO_0000403', 'EFO_0000222',
       'EFO_0001642', 'EFO_0003060', 'MONDO_0004992', 'EFO_0002430'],
      dtype=object), 'count': 16}","[ENSG00000171552,ENSG00000258643,ENSG00000129473,ENSG00000171791]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications.
CHEMBL456,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,AVOLMBLBETYQHX-UHFFFAOYSA-N,Small molecule,False,ETHACRYNIC ACID,1967.0,4.0,,False,True,['Edecrin' 'Ethacrynic acid' 'Hydromedin' 'Reomax'],"['Etacrynic acid' 'Ethacrynate' 'Ethacrynic acid' 'MK-595' 'NSC-624008'
 'NSC-85791']","[('DailyMed', array(['ethacrynic%20acid'], dtype=object)), ('PubChem', array(['104171276', '11112144', '122995', '124881977', '124881979',
       '144203886', '144208300', '170465426', '17389016', '26746983',
       '26746984', '50100377', '855762', '92763949'], dtype=object)), ('Wikipedia', array(['Etacrynic_acid'], dtype=object)), ('drugbank', array(['DB00903'], dtype=object)), ('chEBI', array(['4876'], dtype=object))]",['CHEMBL1200487'],"{'rows': array(['EFO_1001134', 'MONDO_0001187', 'EFO_0004255', 'EFO_0000319',
       'EFO_0009690', 'MONDO_0005041', 'EFO_0001422', 'EFO_0000373'],
      dtype=object), 'count': 8}",[ENSG00000074803],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 6 approved and 2 investigational indications.
CHEMBL4650522,,,Unknown,False,ORN-0829 HYDRATE,,3.0,,False,False,[],['ORN-0829 HYDRATE' 'ORN0829 HYDRATE' 'Orn-0829 hydrate' 'Ts-142'],,,"{'rows': array(['EFO_0003918', 'EFO_0001421', 'EFO_0004698'], dtype=object), 'count': 3}","[ENSG00000137252,ENSG00000121764]",Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL5314391,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1,DMQYDVBIPXAAJA-VHXPQNKSSA-N,Small molecule,False,XL-999,,2.0,,False,False,[],['XL-999' 'Xl 999' 'Xl-999'],,,"{'rows': array(['EFO_1001951', 'EFO_0000222', 'EFO_0000681', 'EFO_0003060',
       'MONDO_0008170', 'MONDO_0004992', 'EFO_0001378'], dtype=object), 'count': 7}","[ENSG00000122025,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL723,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,OGHNVEJMJSYVRP-UHFFFAOYSA-N,Small molecule,False,CARVEDILOL,1995.0,4.0,,False,True,"['Carvedilol' 'Coreg' 'Coreg CR' 'Eucardic 12.5' 'Eucardic 25'
 'Eucardic 3.125' 'Eucardic 6.25']","['BM 14.190' 'BM-14-190' 'BM-14.190' 'BM-14190' 'C07AG02' 'Carvedilol'
 'Coronis' 'DQ-2466' 'Dilatrend' 'Dimitone' 'Eucardic' 'Korvasan' 'Kredex'
 'NSC-758694' 'SKF-105517' 'Talliton']","[('DailyMed', array(['carvedilol'], dtype=object)), ('PubChem', array(['26719722', '26719723', '50112972', '50112973', '90341342'],
      dtype=object)), ('Wikipedia', array(['Carvedilol'], dtype=object)), ('drugbank', array(['DB01136'], dtype=object)), ('chEBI', array(['3441'], dtype=object))]",['CHEMBL1201167' 'CHEMBL1437006'],"{'rows': array(['MONDO_0001134', 'EFO_0002610', 'EFO_0003896', 'EFO_0000612',
       'EFO_0004264', 'EFO_0001378', 'EFO_0000537', 'EFO_0000373',
       'EFO_0000275', 'EFO_0000666', 'HP_0003124', 'EFO_0000612',
       'MONDO_0008315', 'EFO_0003913', 'EFO_0009545', 'EFO_0000537',
       'EFO_0000373', 'EFO_0001358', 'EFO_0003144', 'MONDO_0005149',
       'EFO_0003086', 'EFO_0000222', 'EFO_0004289', 'EFO_0000318',
       'EFO_0000319', 'EFO_0001645', 'EFO_0003914', 'EFO_0000474',
       'MONDO_0007254', 'MONDO_0004992', 'MONDO_0005148', 'EFO_0000519',
       'HP_0001943', 'EFO_0001361'], dtype=object), 'count': 34}","[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 27 investigational indications.
CHEMBL833,Clc1ccccc1CN1CCc2sccc2C1,PHWBOXQYWZNQIN-UHFFFAOYSA-N,Small molecule,True,TICLOPIDINE,1991.0,4.0,,False,True,[],['Ticlopidin-puren' 'Ticlopidine'],"[('PubChem', array(['104171328', '11112786', '124882626', '144204209', '170464698',
       '26751617', '50085878'], dtype=object)), ('TG-GATEs', array(['146'], dtype=object)), ('Wikipedia', array(['Ticlopidine'], dtype=object)), ('drugbank', array(['DB00208'], dtype=object)), ('chEBI', array(['9588'], dtype=object))]",['CHEMBL1717'],"{'rows': array(['HP_0004419', 'EFO_0000712', 'EFO_0004265', 'MONDO_0000831',
       'EFO_0002615'], dtype=object), 'count': 5}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1078685,N#Cc1cc(-c2n[nH]c(-c3ccncc3)n2)ccn1,UBVZQGOVTLIHLH-UHFFFAOYSA-N,Small molecule,False,TOPIROXOSTAT,,2.0,,False,False,[],['FYX-051' 'Topiroxostat'],"[('drugbank', array(['DB01685'], dtype=object))]",,"{'rows': array(['EFO_0000401', 'EFO_0009104'], dtype=object), 'count': 2}",[ENSG00000158125],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1200434,C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O,RLANKEDHRWMNRO-UHFFFAOYSA-M,Small molecule,False,OXTRIPHYLLINE,1981.0,4.0,CHEMBL190,False,True,"['Choledyl' 'Choledyl sa' 'Oxtriphylline' 'Oxtriphylline pediatric'
 'Sabidal']","['Choline theophyllinate' 'Choline theophylline' 'Cholinophyllin'
 'NSC-760431' 'Oxtriphylline' 'Theocolin']","[('DrugCentral', array(['4390'], dtype=object)), ('Wikipedia', array(['Choline_theophyllinate'], dtype=object)), ('drugbank', array(['DB01303'], dtype=object))]",,"{'rows': array(['HP_0006536'], dtype=object), 'count': 1}","[ENSG00000172572,ENSG00000152270,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and is indicated for airway obstruction.
CHEMBL1201227,OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1,SWRUZBWLEWHWRI-UHFFFAOYSA-N,Small molecule,False,CYCRIMINE,1982.0,4.0,,False,True,[],['Cycrimine'],"[('Wikipedia', array(['Cycrimine'], dtype=object)), ('drugbank', array(['DB00942'], dtype=object)), ('chEBI', array(['59692'], dtype=object))]",['CHEMBL1200828'],,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201355,CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,YRALAIOMGQZKOW-HYAOXDFASA-N,Protein,False,CERULETIDE,1982.0,4.0,,False,True,[],['Caerulein' 'Cerulein' 'Ceruletide'],"[('Wikipedia', array(['Ceruletide'], dtype=object)), ('drugbank', array(['DB00403'], dtype=object)), ('chEBI', array(['59219'], dtype=object))]",['CHEMBL1200755'],,[ENSG00000163394],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201580,,,Antibody,True,ADALIMUMAB,2002.0,4.0,,False,True,['Amgevita' 'Humira'],"['AVT-02' 'Abp-501' 'Abrilada' 'Adalimumab' 'Adalimumab (abbvie)'
 'Adalimumab (genetical recombination)' 'Adalimumab (humira)'
 'Adalimumab aacf' 'Adalimumab adaz' 'Adalimumab adbm' 'Adalimumab afzb'
 'Adalimumab aqvh' 'Adalimumab atto' 'Adalimumab beta'
 'Adalimumab biosimilar (alvotech)' 'Adalimumab biosimilar (amgen)'
 'Adalimumab biosimilar (avt02)' 'Adalimumab biosimilar (celltrion)'
 'Adalimumab biosimilar (ct-p17)' 'Adalimumab biosimilar (fkb-327)'
 'Adalimumab biosimilar (msb11022)' 'Adalimumab biosimilar (mylan)'
 'Adalimumab biosimilar (pfizer)' 'Adalimumab biosimilar (sandoz)'
 'Adalimumab biosimilar (yusimry)' 'Adalimumab biosimilar (zrc-3197)'
 'Adalimumab bwwd' 'Adalimumab fkjp' 'Adalimumab-aacf' 'Adalimumab-aaty'
 'Adalimumab-adaz' 'Adalimumab-adbm' 'Adalimumab-afzb' 'Adalimumab-aqvh'
 'Adalimumab-atto' 'Adalimumab-bwwd' 'Adalimumab-fkjp' 'Amjevita'
 'Amsparity' 'Avt02' 'BI695501' 'Bcd-057' 'Bi 695501' 'Bi-695501' 'CT-P17'
 'Chs-1420' 'Cyltezo' 'D2E7' 'Exemptia' 'FKB-327' 'FKB327' 'GP2017'
 'Gp-2017' 'HLX-03' 'HLX03' 'Hadlima' 'Hulio' 'Hyrimoz' 'Idacio'
 'LU-200134' 'LU200134' 'M-923' 'M923' 'MSB-11022' 'MSB11022' 'Ons-3010'
 'Pf-06410293' 'Trudexa' 'Yuflyma' 'Yusimry' 'ZRC-3197' 'ZRC3197']","[('DailyMed', array(['adalimumab'], dtype=object)), ('DrugCentral', array(['4904'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita'],
      dtype=object)), ('Wikipedia', array(['Adalimumab'], dtype=object))]",,"{'rows': array(['MP_0001845', 'EFO_0003780', 'EFO_0000685', 'EFO_0003898',
       'EFO_1001209', 'MONDO_0009735', 'MONDO_0002108', 'EFO_0008507',
       'MONDO_0100096', 'EFO_0003872', 'MONDO_0019338', 'MONDO_0009661',
       'HP_0011868', 'EFO_0000729', 'EFO_0004616', 'EFO_0002609',
       'HP_0000999', 'EFO_0004236', 'MONDO_0010674', 'MONDO_0004979',
       'EFO_0000540', 'MONDO_0005178', 'EFO_1001231', 'EFO_0000676',
       'EFO_0000384', 'EFO_0004229', 'EFO_1000710', 'EFO_0003767',
       'EFO_0003778', 'EFO_0004683', 'EFO_1000941', 'EFO_0005856'],
      dtype=object), 'count': 32}",[ENSG00000232810],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 9 approved and 23 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1277072,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2,MCTXSDCWFQAGFS-UEXNTNOUSA-N,Small molecule,False,HENATINIB,,1.0,,False,False,[],['Henatinib'],"[('drugbank', array(['DB13019'], dtype=object))]",,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1366933,CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1,RONZAEMNMFQXRA-MRXNPFEDSA-N,Small molecule,False,ESMIRTAZAPINE,,3.0,,False,False,[],"['(s)-6-azamianserin' '(s)-mirtazapine' '(s)-org 3770' 'Esmirtazapine'
 'Mirtazapine, (s)-' 'ORG-44-20']","[('PubChem', array(['11114267'], dtype=object)), ('drugbank', array(['DB06678'], dtype=object))]",['CHEMBL2107339'],"{'rows': array(['EFO_0004698', 'EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 3}","[ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000196639,ENSG00000147246,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1464,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,PJVWKTKQMONHTI-UHFFFAOYSA-N,Small molecule,True,WARFARIN,1954.0,4.0,,False,True,[],['NSC-59813' 'Warfarin'],"[('PubChem', array(['144206736', '144209380', '144210849', '174006926', '26748308',
       '26754489'], dtype=object)), ('Wikipedia', array(['Warfarin'], dtype=object)), ('drugbank', array(['DB00682'], dtype=object)), ('chEBI', array(['87732'], dtype=object))]",['CHEMBL1200879' 'CHEMBL1200772'],"{'rows': array(['EFO_0000275', 'HP_0004419', 'EFO_0003764', 'EFO_0006911',
       'EFO_0003875', 'EFO_0002950', 'HP_0004936', 'EFO_0000685',
       'EFO_0003929', 'EFO_0004286', 'EFO_0002689', 'EFO_0003827',
       'MONDO_0002009', 'EFO_0000275', 'EFO_0000319', 'EFO_1001161',
       'HP_0001907', 'EFO_0004616', 'EFO_0003911', 'EFO_0000274',
       'EFO_0000712', 'EFO_0003907', 'EFO_0000574', 'EFO_0004277',
       'EFO_0000612', 'EFO_0009708', 'EFO_1001249', 'HP_0002140',
       'EFO_0000612', 'EFO_0001073', 'HP_0001907', 'EFO_0004239',
       'HP_0004936', 'EFO_0003914', 'EFO_0000384', 'HP_0004936',
       'MONDO_0008315', 'EFO_0000616', 'EFO_0000712', 'HP_0004418',
       'EFO_0000685', 'EFO_0001422', 'MONDO_0001134', 'EFO_0004211',
       'MONDO_0004992', 'EFO_0001361', 'EFO_0003907', 'EFO_0000673',
       'EFO_0003777', 'EFO_0000275', 'MP_0001914', 'MONDO_0005149',
       'EFO_0000756', 'EFO_0000266', 'MONDO_0005180', 'EFO_0003144',
       'HP_0001907', 'EFO_0000474', 'EFO_0000400', 'EFO_0000768',
       'MONDO_0000831', 'MONDO_0004975', 'EFO_0000676', 'EFO_1000781',
       'HP_0001873', 'EFO_0000729', 'MONDO_0002679', 'EFO_1001375',
       'EFO_0001642', 'EFO_0002618', 'MONDO_0005148', 'EFO_0003827'],
      dtype=object), 'count': 72}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 9 approved and 60 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1643,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,IWUCXVSUMQZMFG-AFCXAGJDSA-N,Small molecule,True,RIBAVIRIN,1985.0,4.0,,False,True,"['Copegus' 'Rebetol' 'Ribapak' 'Ribasphere' 'Ribavarin' 'Ribavirin'
 'Ribofluranosyl Carboxamide' 'Tribavirin' 'Viramid' 'Virazid' 'Virazole']","['Cotronak' 'NSC-163039' 'Ribavirin' 'Ribavirin biopartners'
 'Ribavirin mylan' 'Ribavirin teva' 'SCH 18908' 'SCH-18908' 'Tribavirin']","[('DailyMed', array(['ribavirin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rebetol'],
      dtype=object)), ('PubChem', array(['144203810', '144208165', '170464657', '17389529', '50105410',
       '50105411', '50105412', '50105413', '8139972', '90341426'],
      dtype=object)), ('Wikipedia', array(['Ribavirin'], dtype=object)), ('drugbank', array(['DB00811'], dtype=object)), ('chEBI', array(['63580'], dtype=object))]",,"{'rows': array(['EFO_0001422', 'EFO_0000764', 'EFO_0006890', 'EFO_0000616',
       'EFO_0000222', 'MONDO_0100096', 'HP_0001873', 'HP_0012115',
       'EFO_0007299', 'EFO_0004220', 'EFO_0000694', 'EFO_0003047',
       'EFO_0007328', 'EFO_0007338', 'EFO_1001413', 'MONDO_0002050',
       'EFO_0004197', 'EFO_0007332', 'MONDO_0005147', 'MONDO_0007254',
       'EFO_0000544', 'EFO_0004239', 'EFO_0007304', 'EFO_0000763'],
      dtype=object), 'count': 24}",[ENSG00000106348],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1683,CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,BMCQMVFGOVHVNG-TUFAYURCSA-N,Small molecule,False,HYDROCORTISONE BUTYRATE,1982.0,4.0,,False,True,"['Hydrocortisone butyrate' 'Locoid' 'Locoid c' 'Locoid crelo'
 'Locoid lipocream']","['Cortisol 17-butyrate' 'Hydrocortisone 17-butyrate'
 'Hydrocortisone butyrate' 'Hydrocortisone-17-butyrate' 'NSC-758433']","[('DailyMed', array(['hydrocortisone%20butyrate'], dtype=object)), ('PubChem', array(['11533027', '144204950', '170465456', '56422894'], dtype=object)), ('Wikipedia', array(['Hydrocortisone_17-butyrate'], dtype=object)), ('drugbank', array(['DB14540'], dtype=object)), ('chEBI', array(['31674'], dtype=object))]",,"{'rows': array(['EFO_1000764', 'EFO_1001494', 'EFO_0000701', 'EFO_0000274'],
      dtype=object), 'count': 4}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved and 1 investigational indication.
CHEMBL187709,CCN(CC)CCOc1ccc(C(O)(Cc2ccc(Cl)cc2)c2ccc(C)cc2)cc1,SYHDSBBKRLVLFF-UHFFFAOYSA-N,Small molecule,False,TRIPARANOL,,4.0,,True,True,[],['NSC-65345' 'Triparanol'],"[('PubChem', array(['144205821', '170466640', '29217665', '50111719'], dtype=object))]",,,[ENSG00000116133],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2180604,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1,DZFZXPPHBWCXPQ-UHFFFAOYSA-N,Small molecule,False,TAK-593,,1.0,,False,False,[],['TAK 593' 'TAK-593' 'Tak-593'],"[('drugbank', array(['DB13093'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL230158,CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1,JWHYSEDOYMYMNM-QGZVFWFLSA-N,Small molecule,False,SELADELPAR,,3.0,,False,False,[],['MBX-8025' 'Mbx-8025' 'RWJ-800025' 'Seladelpar'],"[('drugbank', array(['DB12390'], dtype=object))]",['CHEMBL5303479' 'CHEMBL3989960'],"{'rows': array(['EFO_0004268', 'MONDO_0021187', 'MONDO_0018328', 'EFO_1001249',
       'EFO_0001421', 'EFO_1001486'], dtype=object), 'count': 6}",[ENSG00000112033],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3301627,CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1.Cl.Cl,VFRAXTZDILCRKY-OWRGXFNZSA-N,Small molecule,True,TENAPANOR HYDROCHLORIDE,2019.0,4.0,CHEMBL3304485,False,True,['Ibsrela'],"['AZD-1722 HYDROCHLORIDE' 'AZD1722' 'AZD1722 hydrochloride' 'RDX-5791'
 'RDX5791' 'Tenapanor dihydrochloride' 'Tenapanor hydrochloride']","[('DailyMed', array(['tenapanor%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0003884', 'MONDO_0002203', 'EFO_0000555', 'HP_0002905'],
      dtype=object), 'count': 4}",[ENSG00000066230],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for constipation disorder and irritable bowel syndrome and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545114,,,Small molecule,False,KD3010,,1.0,,False,False,[],['Kd3010'],,,,[ENSG00000112033],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545153,,,Small molecule,False,DE-104,,2.0,,False,False,[],['De-104'],,,"{'rows': array(['EFO_1001069', 'EFO_0004190'], dtype=object), 'count': 2}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3707355,,,Small molecule,False,AZD8108,,1.0,,False,False,[],['Azd8108'],,,,"[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707404,,,Antibody,False,LUMRETUZUMAB,,2.0,,False,False,[],['Lumretuzumab' 'RG-7116' 'RG7116' 'RO-5479599' 'RO5479599'],,,"{'rows': array(['MONDO_0007254', 'EFO_0003060', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL415049,CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O,GBJVVSCPOBPEIT-UHFFFAOYSA-N,Small molecule,False,BARASERTIB,,3.0,,False,False,[],"['AZD 1152' 'AZD-1152' 'AZD1152' 'Azd-1152' 'Barasertib'
 'Barasertib (who-dd)']","[('PubChem', array(['103905346'], dtype=object)), ('drugbank', array(['DB11747'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0004643', 'EFO_0000574', 'EFO_0000222'],
      dtype=object), 'count': 4}",[ENSG00000178999],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4205783,Clc1ccc(-c2nn(Cc3ccccc3)c3c2CCNCC3)cc1,UKJPMZGILXATGT-UHFFFAOYSA-N,Small molecule,False,JNJ-18038683,,2.0,,False,False,[],[],,['CHEMBL4297293'],"{'rows': array(['MONDO_0002009', 'MONDO_0004985'], dtype=object), 'count': 2}",[ENSG00000148680],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297245,,,Antibody,False,DONANEMAB,,3.0,,False,False,[],['Donanemab' 'LY 3002813' 'LY-3002813' 'LY3002813'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DONANEMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297399,O=C(Nc1ncc(SCCN2CCCC2)s1)[C@]1(c2ccc(S(=O)(=O)C3CC3)cc2)C[C@H]1C1CCCCC1,QIIVJLHCZUTGSD-CUBQBAPOSA-N,Small molecule,False,LY-2608204,,2.0,,False,False,[],['Globalagliatin' 'LY2608204' 'Ly-2608204' 'Ly2608204' 'Sy-004'],"[('drugbank', array(['DB12284'], dtype=object))]",['CHEMBL5095182'],"{'rows': array(['MONDO_0005148', 'HP_0003074'], dtype=object), 'count': 2}",[ENSG00000106633],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297918,,,Antibody,False,SETRUSUMAB,,3.0,,False,False,[],['BPS-804' 'BPS804' 'Bps804' 'MOR05813' 'Setrusumab'],,,"{'rows': array(['MONDO_0019019', 'EFO_0003086', 'MONDO_0018570'], dtype=object), 'count': 3}",[ENSG00000167941],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4594557,,,Unknown,False,EFTILAGIMOD ALFA,,2.0,,False,False,[],['Eftilagimod alfa' 'IMP321' 'Immufact' 'Imp321'],,,"{'rows': array(['EFO_0000681', 'MONDO_0007254', 'EFO_0000756', 'EFO_0000389'],
      dtype=object), 'count': 4}",[ENSG00000089692],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4802262,,,Gene,False,ATIDARSAGENE AUTOTEMCEL,2020.0,4.0,,False,True,['Libmeldy'],['Atidarsagene autotemcel' 'OTL-200'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ATIDARSAGENE%20AUTOTEMCEL/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0018868'], dtype=object), 'count': 1}",[ENSG00000100299],Gene drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for metachromatic leukodystrophy.
CHEMBL5095034,CS(=O)(=O)N1CCC(c2ccc(-c3ncc4nccnc4c3NC[C@@H]3CNCCO3)cc2)CC1,BRCHZKBUGSKTND-FQEVSTJZSA-N,Small molecule,False,SOVLEPLENIB,,3.0,,False,False,[],['HMPL523' 'Hmpl 523' 'Hmpl-523' 'Sovleplenib'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_0007160', 'EFO_0000685', 'EFO_0000222',
       'EFO_1001264', 'EFO_0000616', 'MONDO_0004992', 'EFO_0005952'],
      dtype=object), 'count': 8}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL550,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,QCHFTSOMWOSFHM-WPRPVWTQSA-N,Small molecule,False,PILOCARPINE,1974.0,4.0,,False,True,['Ocusert pilo-20' 'Ocusert pilo-40'],"['Ocucarpine' 'Pilocarpine' 'Pilocarpinum' 'Pilocarpol' 'Pilokarpin'
 'Spersacarpine' 'Syncarpine']","[('PubChem', array(['11113352', '170464845', '26751548', '50104139', '90340957',
       '90341610'], dtype=object)), ('Wikipedia', array(['Pilocarpine'], dtype=object)), ('drugbank', array(['DB01085'], dtype=object)), ('chEBI', array(['8207'], dtype=object))]",['CHEMBL2139597' 'CHEMBL1200330' 'CHEMBL1213136'],"{'rows': array(['EFO_1000906', 'MONDO_0001330', 'EFO_0006859', 'MONDO_0001330',
       'EFO_0004190', 'HP_0000545', 'HP_0000616', 'EFO_0000699',
       'EFO_1001069', 'HP_0000020', 'EFO_0009869', 'MONDO_0005041',
       'MONDO_0001744'], dtype=object), 'count': 13}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 7 approved and 5 investigational indications.
CHEMBL573352,C#C[C@@]1(O)[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@@H]1O,JFIWEPHGRUDAJN-DYUFWOLASA-N,Small molecule,False,TAS-106,,2.0,,False,False,[],"[""2'-C-Ethynylcytidine"" ""3'-C-Ethynylcytidine"" 'Tas 106' 'Tas-106']","[('drugbank', array(['DB06656'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0006859'], dtype=object), 'count': 2}","[ENSG00000068654,ENSG00000148606,ENSG00000181222]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1106,NC1=NCC2c3ccccc3Cc3ccccc3N12,WHWZLSFABNNENI-UHFFFAOYSA-N,Small molecule,False,EPINASTINE,2003.0,4.0,,False,True,[],['Elestat' 'Epinastine' 'Purivist' 'WAL-801'],"[('PubChem', array(['29217549', '50111706', '90340676'], dtype=object)), ('Wikipedia', array(['Epinastine'], dtype=object)), ('drugbank', array(['DB00751'], dtype=object)), ('chEBI', array(['51032'], dtype=object))]",['CHEMBL1200491'],"{'rows': array(['EFO_0003956', 'EFO_0005854', 'EFO_1001417', 'EFO_0005751',
       'EFO_0007141', 'MONDO_0005271'], dtype=object), 'count': 6}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 3 investigational indications.
CHEMBL1237104,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl,QMQBBUPJKANITL-MYXGOWFTSA-N,Small molecule,True,PROPOXYPHENE HYDROCHLORIDE,1957.0,4.0,CHEMBL1213351,True,True,"['Darvon' 'Dolene' 'Doloxene' 'Kesso-gesic' 'Prophene 65'
 'Propoxyphene hydrochloride' 'Propoxyphene hydrochloride 65']","['Algaphan' 'Deprancol' 'Dextro propoxyphene hydrochloride'
 'Dextropropoxiphene chloride' 'Dextropropoxyphene'
 'Dextropropoxyphene hydrochloride' 'Femadol' 'Harmar' 'Propoxyphene hcl'
 'Propoxyphene hydrochloride' 'Propoxyphene hydrochloride cii'
 'Proxagesic']","[('PubChem', array(['144206413'], dtype=object)), ('chEBI', array(['8498'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for pain. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL127071,Cc1ncccc1OC[C@@H]1CCCN1,YRVIKLBSVVNSHF-JTQLQIEISA-N,Small molecule,False,POZANICLINE,,2.0,,False,False,[],['A-87089.0' 'A-870890' 'ABT-089' 'Pozanicline'],"[('Wikipedia', array(['A-84,543'], dtype=object)), ('drugbank', array(['DB05458'], dtype=object))]",['CHEMBL2105650'],"{'rows': array(['EFO_0003768', 'EFO_0003888', 'MONDO_0004975'], dtype=object), 'count': 3}","[ENSG00000160716,ENSG00000101204,ENSG00000169684,ENSG00000147434]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1692,CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl,XZZXIYZZBJDEEP-UHFFFAOYSA-N,Small molecule,True,IMIPRAMINE HYDROCHLORIDE,1959.0,4.0,CHEMBL11,False,True,"['Imipramine hydrochloride' 'Janimine' 'Pramine' 'Praminil' 'Presamine'
 'Sarimp' 'Tofranil']","['G-22355' 'Imidobenzyle' 'Imipramine HCl' 'Imipramine hcl'
 'Imipramine hydrochloride' 'Imipramine hydrochloride rs'
 'Imipramini hydrochloridum' 'Imizine' 'NSC-114900' 'Pryleugan']","[('DailyMed', array(['imipramine%20hydrochloride'], dtype=object)), ('PubChem', array(['144211734', '26747552', '26747553', '26751601', '50106516',
       '50106517', '50106518', '56422890', '855555'], dtype=object)), ('chEBI', array(['5882'], dtype=object))]",,"{'rows': array(['EFO_0000519', 'MONDO_0024290', 'MONDO_0002050'], dtype=object), 'count': 3}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for enuresis and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL17860,CC(Oc1c(Cl)cccc1Cl)C1=NCCN1,KSMAGQUYOIHWFS-UHFFFAOYSA-N,Small molecule,False,LOFEXIDINE,2018.0,4.0,,False,True,[],['Lofexidine'],"[('PubChem', array(['170466275'], dtype=object)), ('Wikipedia', array(['Lofexidine'], dtype=object)), ('drugbank', array(['DB04948'], dtype=object)), ('chEBI', array(['51368'], dtype=object))]",['CHEMBL1788132'],"{'rows': array(['EFO_0005800', 'EFO_0003890', 'HP_0001399', 'EFO_0004240',
       'EFO_0010702', 'EFO_0005611', 'EFO_0002610', 'EFO_0007191',
       'EFO_0005611'], dtype=object), 'count': 9}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for substance withdrawal syndrome and drug dependence and has 6 investigational indications.
CHEMBL189171,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,FSQKKOOTNAMONP-UHFFFAOYSA-N,Small molecule,False,ACEMETACIN,,4.0,,False,True,['Emflex'],['Acemetacin' 'NSC-757413' 'Rantudil'],"[('PubChem', array(['11112782', '124882621', '144207022', '170466043', '174007220',
       '26746953', '855677'], dtype=object)), ('Wikipedia', array(['Acemetacin'], dtype=object)), ('drugbank', array(['DB13783'], dtype=object)), ('chEBI', array(['31162'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease.
CHEMBL1921904,C[C@@](C(=O)O[C@H]1C[N+]2(CCc3ccc(F)cc3)CCC1CC2)(c1ccccc1)N1CCCCC1,FNYFFCOCVNTJCD-NNMXADRKSA-N,Small molecule,False,AZD-9164,,2.0,,False,False,[],['AZD9164' 'Azd 9164' 'Azd-9164' 'Azd9164' 'J3.232.015E'],"[('drugbank', array(['DB12115'], dtype=object))]",,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2103828,CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,LGSDFTPAICUONK-UHFFFAOYSA-N,Small molecule,False,ELINOGREL,,2.0,,False,False,[],['Elinogrel' 'PRT 060128' 'PRT-060128' 'Prt060128'],"[('drugbank', array(['DB06350'], dtype=object))]",['CHEMBL2105641'],"{'rows': array(['EFO_0000612', 'EFO_0003086'], dtype=object), 'count': 2}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2105671,O=C(O)C(O)C(O)C(=O)O.OC[C@H]1CNC[C@@H](O)[C@@H]1O,ULBPPCHRAVUQMC-RWOHWRPJSA-N,Small molecule,False,AFEGOSTAT TARTRATE,,2.0,CHEMBL206468,False,False,[],"['AT-2101' 'AT2101' 'Afegostat tartrate' 'HGT-3410' 'Isofagomine tartrate'
 'Plicera']",,,"{'rows': array(['MONDO_0018150'], dtype=object), 'count': 1}",[ENSG00000177628],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108208,,,Protein,False,LENERCEPT,,3.0,,False,False,[],['Lenercept' 'RO 45-2081' 'RO-45-2081' 'Ro-452081'],,,,[ENSG00000232810],Protein drug with a maximum clinical trial phase of III.
CHEMBL2109343,,,Antibody,False,LERONLIMAB,,3.0,,False,False,[],['Leronlimab' 'PRO 140' 'PRO-140' 'PRO140'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LERONLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0013730', 'MONDO_0100096', 'EFO_0003869', 'EFO_1001951',
       'EFO_0000616', 'EFO_0000764', 'EFO_1001249', 'EFO_0000180'],
      dtype=object), 'count': 8}",[ENSG00000160791],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL3184679,COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1,VRQMAABPASPXMW-UHFFFAOYSA-N,Small molecule,False,AZD-4547,,2.0,,False,False,[],"['ABSK-091' 'ABSK091' 'AZD-4547' 'Azd 4547' 'Azd-4547' 'Azd4547'
 'KB-74810']","[('PubChem', array(['174006594'], dtype=object))]",,"{'rows': array(['EFO_0000228', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0000707',
       'EFO_0000708', 'MONDO_0007254', 'EFO_0003060', 'EFO_0008528',
       'EFO_0000326', 'EFO_0001378', 'MONDO_0001187'], dtype=object), 'count': 11}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.
CHEMBL3261331,CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O,FDBYIYFVSAHJLY-UHFFFAOYSA-N,Small molecule,False,RESMETIROM,,3.0,,False,False,[],['MGL-3196' 'Mgl-3196' 'Resmetirom' 'VIA-3196'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RESMETIROM/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12914'], dtype=object))]",,"{'rows': array(['HP_0003119', 'HP_0003124', 'EFO_1001249', 'EFO_0004911',
       'EFO_0003095'], dtype=object), 'count': 5}",[ENSG00000151090],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL3301609,Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1,FCRFVPZAXGJLPW-UHFFFAOYSA-N,Small molecule,False,TOREFORANT,,2.0,,False,False,[],['JNJ-38518168' 'Jnj-38518168' 'Toreforant'],"[('drugbank', array(['DB12522'], dtype=object))]",['CHEMBL3301614'],"{'rows': array(['EFO_0000685', 'EFO_0000685', 'EFO_0000676', 'MONDO_0004979',
       'EFO_0001421'], dtype=object), 'count': 5}",[ENSG00000134489],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL345237,O=C1c2ccccc2OC=C(Cl)N1CCCCN1CC=C(c2ccccn2)CC1,URMTUEWUIGOJBW-UHFFFAOYSA-N,Small molecule,False,PICLOZOTAN,,2.0,,False,False,[],['Piclozotan' 'SUN-N-4057' 'Sun-n4057'],"[('drugbank', array(['DB12361'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'EFO_0000712'], dtype=object), 'count': 2}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545233,CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(-c2ccccc2)nc2ccccc12)c1ccccc1,QYTBBBAHNIWFOD-NRFANRHFSA-N,Small molecule,False,PAVINETANT,,2.0,,False,False,[],"['AZ-12472520' 'AZ12472520' 'AZ124752520' 'AZ4901' 'AZD-4901' 'AZD2624'
 'AZD4901' 'Azd 2624' 'Azd 4901' 'Azd-2624' 'Azd2624' 'MLE-4901' 'MLE4901'
 'Pavinetant']","[('drugbank', array(['DB11692'], dtype=object))]",,"{'rows': array(['MONDO_0005090', 'HP_0031284', 'EFO_0000660'], dtype=object), 'count': 3}",[ENSG00000169836],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3649803,CCOc1cc(CN2CCOCC2)cc2[nH]c(=O)c3c(c12)NCCC3,WBBZUHMHBSXBDT-UHFFFAOYSA-N,Small molecule,False,AMELPARIB,,2.0,,False,False,[],[],,['CHEMBL5314421'],"{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}",[ENSG00000143799],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3951811,CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl,BCSHRERPHLTPEE-NRFANRHFSA-N,Small molecule,False,CEP-37440,,1.0,,False,False,[],['Alk-fak inhibitor cep-37440' 'Cep-37440'],"[('drugbank', array(['DB13060'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000169398,ENSG00000171094]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989977,,,Antibody,False,EMAPALUMAB,2018.0,4.0,,False,True,['Gamifant'],['Emapalumab' 'Emapalumab lzsg' 'NI-0501'],"[('DailyMed', array(['emapalumab-lzsg'], dtype=object))]",,"{'rows': array(['EFO_1001806', 'Orphanet_158038', 'MONDO_0100096', 'EFO_0000540',
       'EFO_0007135', 'MONDO_0007915', 'EFO_0004599', 'MONDO_0015540',
       'MONDO_0018305'], dtype=object), 'count': 9}",[ENSG00000111537],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications.
CHEMBL3989989,,,Gene,True,AXICABTAGENE CILOLEUCEL,2018.0,4.0,,False,True,['Yescarta'],['Axicabtagene ciloleucel' 'KTE-C19' 'Yescarta'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta'],
      dtype=object))]",,"{'rows': array(['EFO_0001642', 'MONDO_0018906', 'EFO_1001469', 'EFO_0000574',
       'EFO_0000403', 'EFO_0000096'], dtype=object), 'count': 6}",[ENSG00000177455],Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL459324,CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,GVGLGOZIDCSQPN-PVHGPHFFSA-N,Small molecule,False,DIACETYLMORPHINE,,4.0,,False,True,[],['Diacetylmorphine' 'IDS-NH-001' 'IDS-NH-001(SECT.3)' 'J6.494G'],"[('PubChem', array(['144206165'], dtype=object)), ('Wikipedia', array(['Heroin'], dtype=object)), ('drugbank', array(['DB01452'], dtype=object)), ('chEBI', array(['27808'], dtype=object))]",['CHEMBL2106627'],"{'rows': array(['EFO_0003890', 'EFO_0010702', 'EFO_0004240', 'EFO_0005611'],
      dtype=object), 'count': 4}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for drug dependence and has 3 investigational indications.
CHEMBL4594333,,,Gene,False,ELIVALDOGENE AUTOTEMCEL,2021.0,4.0,,False,True,['Skysona'],['Elivaldogene autotemcel' 'Lenti-D Drug substance'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/skysona'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELIVALDOGENE%20AUTOTEMCEL/relevant/1/'],
      dtype=object))]",,"{'rows': array(['Orphanet_43'], dtype=object), 'count': 1}",[ENSG00000101986],Gene drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for x-linked adrenoleukodystrophy.
CHEMBL4650272,CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1.Cl.Cl,BRCYOXKEDFAUSA-UHFFFAOYSA-N,Small molecule,False,TRILACICLIB DIHYDROCHLORIDE,2021.0,4.0,CHEMBL3894860,False,True,['Cosela'],[],,,"{'rows': array(['EFO_0000702'], dtype=object), 'count': 1}","[ENSG00000105810,ENSG00000135446]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for small cell lung carcinoma.
CHEMBL4802222,,,Unknown,False,OSTABOLIN-C,,2.0,,False,False,[],['Ostabolin-c' 'PTH-1-31 CYCLIC' 'ZT-031' 'Zt-031'],,,"{'rows': array(['EFO_0003964'], dtype=object), 'count': 1}",[ENSG00000160801],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL515606,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O,HHHKFGXWKKUNCY-FHWLQOOXSA-N,Small molecule,False,CILAZAPRIL,,4.0,,False,True,['Vascace'],"['Anhydrous cilazapril' 'Cilazapril' 'Cilazapril anhydrous'
 'Cilazapril hydrate' 'Cilazapril monohydrate' 'Cilazaprilum' 'Initiss'
 'Justor' 'RO 31-2848/006' 'RO-312848006']","[('PubChem', array(['144206524'], dtype=object)), ('Wikipedia', array(['Cilazapril'], dtype=object)), ('drugbank', array(['DB01340'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease.
CHEMBL566315,CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12,ZXERDUOLZKYMJM-ZWECCWDJSA-N,Small molecule,True,OBETICHOLIC ACID,2016.0,4.0,,False,True,['Ocaliva'],"['6-ecdca' '6-ethylchenodeoxycholic acid' 'DSP-1747' 'INT-747'
 'Obeticholic acid']","[('DailyMed', array(['obeticholic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva'],
      dtype=object)), ('drugbank', array(['DB05990'], dtype=object))]",,"{'rows': array(['EFO_1001486', 'MONDO_0020088', 'Orphanet_733', 'EFO_1001345',
       'EFO_0004268', 'HP_0002014', 'MONDO_0001751', 'EFO_0001421',
       'EFO_0000280', 'EFO_1001249', 'EFO_0003095', 'EFO_0004267',
       'HP_0030151', 'EFO_0001073', 'HP_0000989'], dtype=object), 'count': 15}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL711,O=C1c2ccccc2C(=O)C1c1ccccc1,NFBAXHOPROOJAW-UHFFFAOYSA-N,Small molecule,False,PHENINDIONE,1982.0,4.0,,False,True,['Dindevan' 'Hedulin'],['Danilone' 'NSC-41693' 'Phenindione' 'Phenylindanedione'],"[('PubChem', array(['11112218', '11532881', '144203926', '170465130', '26748198',
       '26748199', '50107356', '50107357', '56423141'], dtype=object)), ('Wikipedia', array(['Phenindione'], dtype=object)), ('drugbank', array(['DB00498'], dtype=object)), ('chEBI', array(['8066'], dtype=object))]",,"{'rows': array(['HP_0004419', 'EFO_0002950'], dtype=object), 'count': 2}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for recurrent thrombophlebitis and has 1 investigational indication.
CHEMBL85,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,RAPZEAPATHNIPO-UHFFFAOYSA-N,Small molecule,True,RISPERIDONE,1993.0,4.0,,False,True,"['Okedi' 'Perseris kit' 'Risperdal' 'Risperdal Consta Long Acting'
 'Risperdal M' 'Risperdal M-Tab' 'Risperdal consta' 'Risperdal quicklet'
 'Risperidone']","['LY-03004' 'LY03004' 'N05AX08' 'NSC-759895' 'Perseris' 'R 64 766'
 'R-64,766' 'R-64-766' 'R-64766' 'RCN-3028' 'RCN3028' 'Risperidone'
 'Rykindo' 'Uzedy']","[('DailyMed', array(['risperidone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/okedi'],
      dtype=object)), ('PubChem', array(['104171228', '11111724', '11111725', '124881313', '124881314',
       '144203804', '170464925', '26719830', '26753640', '49666400',
       '50106974', '50106975', '50123965', '85231208'], dtype=object)), ('Wikipedia', array(['Risperidone'], dtype=object)), ('drugbank', array(['DB00734'], dtype=object)), ('chEBI', array(['8871'], dtype=object))]",,"{'rows': array(['EFO_0004895', 'EFO_0003852', 'EFO_0003758', 'HP_0000726',
       'EFO_0005407', 'EFO_0003757', 'EFO_0002610', 'EFO_0003015',
       'HP_0001249', 'MONDO_0002009', 'MONDO_0005090', 'EFO_0009963',
       'HP_0010865', 'EFO_0003756', 'MONDO_0002009', 'MONDO_0002050',
       'MONDO_0004985', 'EFO_0004701', 'EFO_0005411', 'EFO_0005230',
       'EFO_0004718', 'EFO_0001358', 'MONDO_0007739', 'Orphanet_79292',
       'EFO_0004242', 'MONDO_0004975', 'EFO_1000904', 'EFO_0003890',
       'EFO_0004216', 'MONDO_0001087', 'EFO_0010642', 'MONDO_0010726',
       'EFO_0005611'], dtype=object), 'count': 33}","[ENSG00000102468,ENSG00000147246,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 25 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1016,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,HTQMVQVXFRQIKW-UHFFFAOYSA-N,Small molecule,False,CANDESARTAN,,3.0,,False,False,[],"['Blopress' 'CV-11974' 'Candemore' 'Candesartan'
 'Candesartan cilexetil related compound g' 'NSC-759858']","[('PubChem', array(['144206031', '170466386', '50112728'], dtype=object)), ('Wikipedia', array(['Candesartan'], dtype=object)), ('drugbank', array(['DB13919'], dtype=object)), ('chEBI', array(['3347'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0000373', 'MONDO_0005277', 'EFO_0003896',
       'EFO_0002610', 'EFO_0003100', 'MONDO_0100431', 'EFO_0000694',
       'MONDO_0004985', 'MONDO_0005147', 'EFO_0003047', 'MONDO_0005148',
       'EFO_0003144', 'MONDO_0005475', 'EFO_0000407', 'EFO_0000319',
       'EFO_0000275', 'EFO_0000280', 'EFO_0003777', 'MONDO_0001134',
       'EFO_0004701', 'MONDO_0002491', 'EFO_0008573', 'EFO_0000538',
       'HP_0100543', 'EFO_0000537', 'EFO_0000266'], dtype=object), 'count': 27}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 27 investigational indications.
CHEMBL1084173,O=C(O)/C(=C/c1ccccc1)c1ccccc1.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,KAMFDHLRBHTIMJ-AZDLLSQWSA-N,Small molecule,False,VILANTEROL .ALPHA.-PHENYL CINNAMATE,,2.0,,False,False,[],"['GW-642444H' 'GW642444H' 'Gw642444h'
 'Vilanterol .alpha.-phenyl cinnamate']",,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1200799,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(C(F)(F)F)c2)[C@H](O)C[C@@H]1O,MKPLKVHSHYCHOC-AHTXBMBWSA-N,Small molecule,False,TRAVOPROST,2001.0,4.0,,False,True,['Izba' 'Travatan' 'Travatan z' 'Travoprost'],['AL-6221' 'NSC-760366' 'Otx-tp' 'Travoprost'],"[('DailyMed', array(['travoprost'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/travatan'],
      dtype=object)), ('Wikipedia', array(['Travoprost'], dtype=object)), ('drugbank', array(['DB00287'], dtype=object)), ('chEBI', array(['746859'], dtype=object))]",,"{'rows': array(['EFO_1001069', 'EFO_0004190', 'EFO_0004235', 'MONDO_0005041'],
      dtype=object), 'count': 4}",[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 1 investigational indication.
CHEMBL1201642,,,Protein,False,INSULIN ZINC SUSP PROMPT BEEF,1982.0,4.0,,False,True,['Semilente insulin'],['Insulin zinc susp prompt beef'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201729,CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1.Cl,DWKVCQXJYURSIQ-UHFFFAOYSA-N,Small molecule,True,DRONEDARONE HYDROCHLORIDE,2009.0,4.0,CHEMBL184412,False,True,['Multaq'],['Dronedarone hcl' 'Dronedarone hydrochloride' 'SR-33598B' 'SR33598B'],"[('DailyMed', array(['dronedarone%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0'],
      dtype=object))]",,"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000138622,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000123700]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for atrial fibrillation. This drug has a black box warning from the FDA.
CHEMBL1628688,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1,FJHHZXWJVIEFGJ-UHFFFAOYSA-N,Small molecule,False,ZIBOTENTAN,,3.0,,False,False,[],['ZD-4054' 'ZD4054' 'Zibotentan'],"[('drugbank', array(['DB06629'], dtype=object))]",,"{'rows': array(['EFO_1001951', 'MONDO_0008315', 'EFO_0004265', 'EFO_0003876',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000673', 'MONDO_0008170',
       'EFO_0001422', 'MONDO_0007254', 'EFO_0003884', 'EFO_0001421',
       'EFO_0009708'], dtype=object), 'count': 13}",[ENSG00000151617],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL1672627,O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1,XUYURJQIMYCWBB-UHFFFAOYSA-N,Small molecule,False,LAS101057,,1.0,,False,False,[],['LAS-101057' 'Las101057'],,,,[ENSG00000170425],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1690,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,JCBIVZZPXRZKTI-UHFFFAOYSA-N,Small molecule,False,HYDROXYCHLOROQUINE SULFATE,1955.0,4.0,CHEMBL1535,False,True,"['Ercoquin' 'Hydroxychloroquine sulfate' 'Oxichlorochine' 'Plaquenil'
 'Quensyl' 'Quinoric']","['Ercoquin' 'Hydroxychloroquine Sulfate' 'Hydroxychloroquine sulfate'
 'Hydroxychloroquine sulphate' 'NSC-4375' 'Oxichlorochine sulfate'
 'Oxiklorin' 'Quensyl' 'TCMDC-123987']","[('DailyMed', array(['hydroxychloroquine%20sulfate'], dtype=object)), ('PubChem', array(['144205260', '170464696', '26748879'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_0007224', 'EFO_0002618', 'EFO_0001068',
       'EFO_0004244', 'EFO_0005221', 'EFO_0003834', 'MONDO_0007915',
       'EFO_0005755', 'MONDO_0100096', 'MONDO_0010520', 'EFO_0002689',
       'EFO_0000389', 'EFO_0003818'], dtype=object), 'count': 14}","[ENSG00000239732,ENSG00000196664]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for rheumatoid arthritis and malaria and has 12 investigational indications.
CHEMBL1887891,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1.Cl,ZXKXJHAOUFHNAS-FVGYRXGTSA-N,Small molecule,False,DEXFENFLURAMINE HYDROCHLORIDE,,4.0,CHEMBL248702,True,True,['Adifax'],"['Adipomin' 'D-fenfluramine hydrochloride' 'Dexfenfluramine hcl'
 'Dexfenfluramine hydrochloride' 'Fenfluramine d-form hydrochloride'
 'Glypolix' 'Isomeride' 'S 5614 HCL' 'S-5614 HCL']","[('PubChem', array(['144206417', '170465626', '85273812'], dtype=object)), ('chEBI', array(['59730'], dtype=object))]",,,"[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2062163,C[C@H]1[C@H](c2ccccc2)OCCN1C.O=C(O)C(O)C(O)C(=O)O,VEPOHXYIFQMVHW-XOZOLZJESA-N,Small molecule,False,PHENDIMETRAZINE TARTRATE,1976.0,4.0,CHEMBL1615439,False,True,"['Adphen' 'Alphazine' 'Bontril' 'Bontril pdm' 'Cam-metrazine' 'Di-metrex'
 'Melfiat' 'Melfiat-105' 'Metra' 'Phenazine' 'Phenazine-35'
 'Phendimetrazine tartrate' 'Plegine' 'Sprx-105' 'Sprx-3' 'Statobex'
 'Statobex-g' 'X-trozine' 'X-trozine l.a.']","['Adipost' 'Appecon' 'Azophenylene' 'NSC-13157'
 'Phendimetrazine bitartrate' 'Phendimetrazine hydrogen tartrate'
 'Phendimetrazine tartrate' 'Phendimetrazine tartrate ciii']","[('DailyMed', array(['phendimetrazine%20tartrate'], dtype=object))]",,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for obesity.
CHEMBL2103876,Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1,VJGFOYBQOIPQFY-XMMPIXPASA-N,Small molecule,False,MAPRACORAT,,3.0,,False,False,[],"['BOL-303242-X' 'BOL-303242X' 'Mapracorat' 'ZK 245186' 'ZK-245186'
 'ZK245186' 'Zk-245186']","[('drugbank', array(['DB12041'], dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_1000906', 'EFO_0003966', 'EFO_0007141',
       'EFO_0000274', 'MONDO_0005129'], dtype=object), 'count': 6}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2103878,NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1,QWNDOCKIKKQJNN-UHFFFAOYSA-N,Small molecule,False,ODELEPRAN,,2.0,,False,False,[],['LY-2196044' 'LY2196044' 'Ly2196044' 'Odelepran' 'Ondelopran'],"[('drugbank', array(['DB12585'], dtype=object))]",['CHEMBL2105746'],"{'rows': array(['MONDO_0007079'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2104969,O=C(O)c1ccc(CCCc2c(CCNS(=O)(=O)Cc3ccccc3C(F)(F)F)n(C(c3ccccc3)c3ccccc3)c3ccc(Cl)cc23)cc1,NHHBNHIPCSPSHQ-UHFFFAOYSA-N,Small molecule,False,GIRIPLADIB,,2.0,,False,False,[],['Giripladib' 'PLA-695'],"[('drugbank', array(['DB15426'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'MONDO_0005178'], dtype=object), 'count': 2}",[ENSG00000116711],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2106217,CCNC(C)Cc1cccc(C(F)(F)F)c1.Cl,ZXKXJHAOUFHNAS-UHFFFAOYSA-N,Small molecule,True,FENFLURAMINE HYDROCHLORIDE,2020.0,4.0,CHEMBL87493,True,True,['Fintepla' 'Ponderax' 'Ponderax pacaps'],"['AHR-3002' 'Dl-fenfluramine hydrochloride' 'Fenfluramine hcl'
 'Fenfluramine hydrochloride' 'Ganal' 'HHR-965']","[('DailyMed', array(['fenfluramine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fintepla'],
      dtype=object)), ('chEBI', array(['59729'], dtype=object))]",,"{'rows': array(['MONDO_0015643', 'HP_0001250'], dtype=object), 'count': 2}","[ENSG00000147955,ENSG00000179546,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for seizure and has 1 investigational indication. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL2109293,,,Antibody,False,KRN-330,,1.0,,False,False,[],['KRN-330' 'Krn 330' 'Krn-330' 'Krn330'],,,"{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}",[ENSG00000143167],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109411,,,Antibody,False,RG-7444,,1.0,,False,False,[],['RG-7444'],,,,[ENSG00000068078],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109466,,,Antibody,False,TNX-650,,2.0,,False,False,[],['TNX-650' 'Tnx-650'],,,"{'rows': array(['EFO_0000183'], dtype=object), 'count': 1}",[ENSG00000169194],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL211456,CN[C@@H](C)[C@H](O)c1ccccc1,KWGRBVOPPLSCSI-WPRPVWTQSA-N,Small molecule,False,EPHEDRINE,2016.0,4.0,,True,True,[],"['(-)-ephedrine' 'Ephedrine' 'Ephedrine, anhydrous'
 'Ephedrinum, anhydrous' 'L-ephedrine' 'NSC-170951' 'NSC-8971' 'Xenadrine']","[('PubChem', array(['124892369'], dtype=object)), ('Wikipedia', array(['Ephedrine'], dtype=object)), ('drugbank', array(['DB01364'], dtype=object)), ('chEBI', array(['15407'], dtype=object))]",['CHEMBL2146102' 'CHEMBL1523964' 'CHEMBL526872'],"{'rows': array(['EFO_0001073', 'HP_0001742', 'EFO_0007214', 'EFO_0003956',
       'EFO_0005251', 'EFO_0003843', 'MP_0001914', 'HP_0001742',
       'EFO_0005251', 'MONDO_0004979', 'EFO_0000319', 'EFO_0000668',
       'MONDO_0004979', 'EFO_0009314', 'EFO_0005251', 'HP_0100543'],
      dtype=object), 'count': 16}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 7 approved and 6 investigational indications. It was withdrawn in at least one region.
CHEMBL228814,Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,QJZRFPJCWMNVAV-HHHXNRCGSA-N,Small molecule,False,ISPINESIB,,2.0,,False,False,[],['Ispinesib'],"[('drugbank', array(['DB06188'], dtype=object))]",['CHEMBL2347651'],"{'rows': array(['MONDO_0004992', 'EFO_0003869', 'EFO_0000681', 'EFO_1000657',
       'MONDO_0008170', 'MONDO_0002691', 'EFO_0000673', 'MONDO_0021063',
       'EFO_0003060', 'EFO_0000389'], dtype=object), 'count': 10}",[ENSG00000138160],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL348475,COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2,LGGHDPFKSSRQNS-UHFFFAOYSA-N,Small molecule,False,TARIQUIDAR,,3.0,,False,False,[],['Tariquidar' 'XR-9576' 'XR9576'],"[('PubChem', array(['174006280'], dtype=object)), ('Wikipedia', array(['Tariquidar'], dtype=object)), ('drugbank', array(['DB06240'], dtype=object))]",['CHEMBL1214643'],"{'rows': array(['EFO_1000796', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0008903',
       'EFO_0005762', 'EFO_0003060'], dtype=object), 'count': 6}",[ENSG00000085563],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3545196,CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1.Cl.Cl,NADLBPWBFGTESN-UHFFFAOYSA-N,Small molecule,False,PD-0166285,,1.0,CHEMBL49120,False,False,[],['Pd-0166285'],,,,"[ENSG00000077782,ENSG00000197122,ENSG00000146648,ENSG00000113721]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545222,,,Small molecule,False,AZD8683,,2.0,,False,False,[],['Azd8683'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707245,O=C(O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1,YHGSTSNEOJUIRN-UHFFFAOYSA-N,Small molecule,False,OMIDENEPAG,,2.0,,False,False,[],['Omidenepag' 'UR-7276'],,,"{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}",[ENSG00000125384],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707280,,,Antibody,False,CG250 111IN,,3.0,,False,False,[],['CG250' 'Cg250 (111in)' 'Cg250 111in'],,,"{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}",[ENSG00000107159],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3969876,COCCCCn1c(C(=O)N(CC(C)C)[C@@H]2CNC[C@H](C(=O)N3CCOCC3)C2)nc2ccccc21.Cl,PUXOYQIZZIWCHH-NSLUPJTDSA-N,Small molecule,False,IMARIKIREN HYDROCHLORIDE,,2.0,CHEMBL3990145,False,False,[],['Imarikiren hydrochloride' 'TAK-272' 'Tak-272'],,,,[ENSG00000143839],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297969,,,Antibody,False,FELADILIMAB,,3.0,,False,False,[],"['3359609' 'Feladilimab' 'GSK-3359609' 'GSK-609' 'GSK3359609'
 'Gsk 3359609' 'Gsk3359609']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FELADILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0005950', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000163600],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297971,,,Protein,False,PEPTIDE YY HUMAN (3-36),,2.0,,False,False,[],"['Gt-001' 'Human peptide yy (3-36)' 'Peptide yy (3-36)'
 'Peptide yy human (3-36)' 'Pyy 3-36' 'Pyy(3-36)' 'Pyy3-36']",,,"{'rows': array(['EFO_0005203', 'EFO_0001073'], dtype=object), 'count': 2}",[ENSG00000185149],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL439338,CC(C)(C)c1nc(N2CCN(CCCSc3nccc(O)n3)CC2)cc(C(F)(F)F)n1,KXVAICSRMHXLJN-UHFFFAOYSA-N,Small molecule,False,ABT-925,,2.0,,False,False,[],['A-437203' 'Abt-925'],,,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}",[ENSG00000151577],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594316,,,Antibody,False,CROVALIMAB,,3.0,,False,False,[],"['Crovalimab' 'RG-6107' 'RG6107' 'RO-7112689' 'RO7112689' 'Ro7112689'
 'SKY-59' 'SKY59']",,,"{'rows': array(['MONDO_0016244', 'MONDO_0100244', 'MONDO_0011382', 'EFO_0007292'],
      dtype=object), 'count': 4}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL1017,CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,RMMXLENWKUUMAY-UHFFFAOYSA-N,Small molecule,True,TELMISARTAN,1998.0,4.0,,False,True,['Micardis' 'Telmisartan' 'Tolura'],"['BIBR 277 SE' 'BIBR-277' 'BIBR-277 SE' 'BIBR-277-SE' 'BIBR-277SE'
 'C09CA07' 'Kinzalmono' 'Pritor' 'Semintra' 'Telmisartan'
 'Telmisartan actavis' 'Telmisartan teva']","[('DailyMed', array(['telmisartan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/micardis'],
      dtype=object)), ('PubChem', array(['137275807', '144205005', '170464873', '26719833', '26749005',
       '49648460'], dtype=object)), ('Wikipedia', array(['Telmisartan'], dtype=object)), ('drugbank', array(['DB00966'], dtype=object)), ('chEBI', array(['9434'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'Orphanet_309005', 'EFO_0000612', 'EFO_0000764',
       'EFO_0000694', 'EFO_0008620', 'EFO_0000401', 'EFO_0005762',
       'EFO_0000712', 'MONDO_0100096', 'EFO_0004285', 'EFO_0003918',
       'EFO_0003777', 'EFO_0000537', 'EFO_0000319', 'MONDO_0005148',
       'MONDO_0001134', 'EFO_0003884', 'EFO_0000180', 'MONDO_0004975'],
      dtype=object), 'count': 20}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 15 investigational indications. This drug has a black box warning from the FDA.
CHEMBL111,Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1,JZCPYUJPEARBJL-UHFFFAOYSA-N,Small molecule,False,RIMONABANT,2006.0,4.0,,True,True,['Acomplia' 'Zimulti'],['Rimonabant' 'SR-14171' 'SR-141716' 'SR-141716A' 'SR141716' 'Zimulti'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zimulti'],
      dtype=object)), ('PubChem', array(['144205753', '170465599', '26757994'], dtype=object)), ('Wikipedia', array(['Rimonabant'], dtype=object)), ('drugbank', array(['DB06155'], dtype=object)), ('chEBI', array(['34967'], dtype=object))]",['CHEMBL558598'],"{'rows': array(['EFO_0001073', 'EFO_0004329', 'EFO_0003843', 'EFO_1001919',
       'HP_0001397', 'EFO_1001121', 'MONDO_0008300', 'EFO_0004319',
       'EFO_0009086', 'HP_0001824', 'EFO_0007191', 'MONDO_0021661',
       'MONDO_0005148', 'Orphanet_309005', 'EFO_0000319', 'EFO_0003768',
       'EFO_0000195'], dtype=object), 'count': 17}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for obesity and has 16 investigational indications. It was withdrawn in at least one region.
CHEMBL1111,COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,OUJTZYPIHDYQMC-LJQANCHMSA-N,Small molecule,True,AMBRISENTAN,2007.0,4.0,,False,True,['Ambrisentan mylan' 'Letairis' 'Volibris'],"['Ambrisentan' 'GSK-1325760' 'GSK-1325760A' 'GSK1325760' 'GSK1325760A'
 'LU-208075']","[('DailyMed', array(['ambrisentan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ambrisentan-mylan'],
      dtype=object)), ('PubChem', array(['144205520', '170465143'], dtype=object)), ('Wikipedia', array(['Ambrisentan'], dtype=object)), ('drugbank', array(['DB06403'], dtype=object))]",,"{'rows': array(['MONDO_0004933', 'EFO_0001361', 'EFO_0000768', 'EFO_0000537',
       'EFO_1000782', 'MONDO_0100096', 'EFO_0004264', 'MONDO_0011382',
       'MONDO_0004979', 'MONDO_0005149'], dtype=object), 'count': 10}","[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],JUGOREOARAHOCO-UHFFFAOYSA-M,Small molecule,False,ACETYLCHOLINE CHLORIDE,1973.0,4.0,CHEMBL667,False,True,['Miochol' 'Miochol-e' 'Miphtel'],"['Acetylcholine' 'Acetylcholine Chloride' 'Acetylcholine chloride'
 'Acetylcholine chloride for injection' 'Choline acetate (ester) chloride'
 'Miochol' 'Miochol-E' 'NSC-755845']","[('PubChem', array(['11532873', '170464783', '26747837'], dtype=object)), ('chEBI', array(['2417'], dtype=object))]",,"{'rows': array(['HP_0000616', 'MONDO_0005129'], dtype=object), 'count': 2}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for miosis and cataract.
CHEMBL1200977,CC(O)C(=O)O.Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,VWUPWEAFIOQCGF-UHFFFAOYSA-N,Small molecule,False,MILRINONE LACTATE,1987.0,4.0,CHEMBL189,False,True,['Milrinone lactate' 'Primacor'],['Milrinone lactate'],"[('DailyMed', array(['milrinone%20lactate'], dtype=object)), ('chEBI', array(['34850'], dtype=object))]",,"{'rows': array(['EFO_0003144', 'HP_0004308'], dtype=object), 'count': 2}",[ENSG00000172572],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for heart failure and ventricular arrhythmia.
CHEMBL1201013,O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+],ZJEFYLVGGFISGT-VRZXRVJBSA-L,Small molecule,False,OLSALAZINE SODIUM,1990.0,4.0,CHEMBL425,False,True,['Dipentum'],"['Ads' 'Azodisal sodium' 'CJ 91B' 'CJ-91B' 'Disodium azodisalicylate'
 'Olsalazine disodium salt' 'Olsalazine sodium' 'Sodium azodisalicylate'
 'Sodium olsalazine']","[('DailyMed', array(['olsalazine%20sodium'], dtype=object))]",,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}","[ENSG00000012779,ENSG00000132170,ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for ulcerative colitis.
CHEMBL1201159,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl,LHCBOXPPRUIAQT-UHFFFAOYSA-N,Small molecule,True,FENTANYL HYDROCHLORIDE,2006.0,4.0,CHEMBL596,False,True,['Ionsys'],['Fentanyl hcl' 'Fentanyl hydrochloride'],,,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006 and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1565476,CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O,MPHPHYZQRGLTBO-UHFFFAOYSA-N,Small molecule,False,APAZONE,,4.0,,False,True,['Rheumox' 'Rheumox 600'],"['AHR-3018' 'Apazone' 'Apazone dihydrate' 'Azapropazone'
 'Azapropazone dihydrate' 'Cinnopropazone' 'MI-85' 'MI-85DI' 'NSC-102824'
 'Prolixan']","[('PubChem', array(['144204120', '56463151'], dtype=object)), ('chEBI', array(['38010'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease.
CHEMBL1567,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,LBWFXVZLPYTWQI-IPOVEDGCSA-N,Small molecule,True,SUNITINIB MALATE,2006.0,4.0,CHEMBL535,False,True,['Sunitinib malate' 'Sutent'],"['PHA-290940AD' 'SU-010398' 'SU-011248 L-MALATE SALT' 'SU010398'
 'SU011248 L-MALATE SALT' 'Sunitinib l-malate' 'Sunitinib malate' 'Sutent']","[('DailyMed', array(['sunitinib%20malate'], dtype=object))]",,"{'rows': array(['EFO_0000514', 'EFO_0000222', 'MONDO_0003268', 'MONDO_0002158',
       'EFO_1000984', 'MONDO_0002367', 'EFO_0002499', 'EFO_1000576',
       'EFO_0006861', 'EFO_0000349', 'MONDO_0044926', 'EFO_0000641',
       'EFO_0002618', 'MONDO_0004192', 'EFO_0000501', 'EFO_0000640',
       'EFO_0007331', 'MONDO_0008315', 'EFO_1001951', 'EFO_0002617',
       'EFO_0003865', 'EFO_0000681', 'EFO_0000588', 'EFO_0000632',
       'MONDO_0015277', 'EFO_0000095', 'EFO_0000673', 'EFO_0000182',
       'EFO_1001465', 'MONDO_0018364', 'EFO_1001968', 'EFO_0000220',
       'EFO_1000045', 'EFO_0000403', 'EFO_0003869', 'EFO_0003897',
       'EFO_0002938', 'MONDO_0011719', 'MONDO_0002691', 'EFO_0000702',
       'EFO_1001901', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0003060',
       'MONDO_0007576', 'MONDO_0007254', 'MONDO_0004986', 'EFO_0000519',
       'EFO_0001378', 'EFO_0006352', 'MONDO_0002087', 'MONDO_0008667',
       'EFO_0000616', 'EFO_0007416', 'EFO_0000558', 'MONDO_0008903'],
      dtype=object), 'count': 56}","[ENSG00000122025,ENSG00000165731,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 50 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1615372,Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,NEKCRUIRPWNMLK-SCIYSFAVSA-N,Small molecule,True,LURASIDONE HYDROCHLORIDE,2010.0,4.0,CHEMBL1237021,False,True,['Latuda'],['Lurasidone hcl' 'Lurasidone hydrochloride' 'SM-13496'],"[('DailyMed', array(['lurasidone%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/latuda'],
      dtype=object)), ('chEBI', array(['70732'], dtype=object))]",,"{'rows': array(['EFO_0009963', 'MONDO_0005090', 'MONDO_0004985'], dtype=object), 'count': 3}","[ENSG00000149295,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL1696,CNCCCN1c2ccccc2CCc2ccccc21.Cl,XAEWZDYWZHIUCT-UHFFFAOYSA-N,Small molecule,True,DESIPRAMINE HYDROCHLORIDE,1964.0,4.0,CHEMBL72,False,True,['Desipramine hydrochloride' 'Norpramin' 'Pertofran' 'Pertofrane'],"['18-8181' 'DMI' 'Desipramine hcl' 'Desipramine hydrochloride' 'EX 4355'
 'EX-4355' 'G-35020' 'JB-8181' 'NSC-114901' 'RMI 9,384A' 'RMI-9384A']","[('DailyMed', array(['desipramine%20hydrochloride'], dtype=object)), ('PubChem', array(['144203680', '170465424', '26732610', '26747493', '26747494',
       '50106122', '50106123', '50106124', '855832', '858256'],
      dtype=object)), ('chEBI', array(['4449'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'HP_0003418', 'EFO_0000702', 'MONDO_0002050'],
      dtype=object), 'count': 4}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1718,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,RGPDIGOSVORSAK-STHHAXOLSA-N,Small molecule,False,NALOXONE HYDROCHLORIDE,1971.0,4.0,CHEMBL80,False,True,"['Evzio' 'Evzio (autoinjector)' 'Kloxxado' 'Nalone' 'Naloxone'
 'Naloxone hydrochloride' 'Naloxone hydrochloride (autoinjector)' 'Narcan'
 'Narcan neonatal' 'Narconil' 'Prenoxad' 'Zimhi']","['Anhydrous naloxone hydrochloride' 'EN-15304' 'NIH 7890' 'NSC-757109'
 'Naloxone hcl' 'Naloxone hydrochloride'
 'Naloxone hydrochloride anhydrous' 'Naloxoni hydrochloridum anhydrous'
 'Narcanti']","[('DailyMed', array(['naloxone%20hydrochloride'], dtype=object)), ('PubChem', array(['11532915'], dtype=object)), ('chEBI', array(['31892'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0006834', 'MONDO_0002009', 'EFO_0005611',
       'HP_0002019', 'MONDO_0004565', 'EFO_0004699'], dtype=object), 'count': 7}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 3 approved and 4 investigational indications.
CHEMBL283120,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC,YJGVMLPVUAXIQN-HAEOHBJNSA-N,Small molecule,False,AXL-1717,,2.0,,False,False,[],"['AXL-1717' 'Axl-1717' 'Axl1717' 'NSC-36407' 'Picropodophyllin'
 'Picropodophyllotoxin' 'Podophyllotoxin picropodophyllin']","[('PubChem', array(['29216394'], dtype=object)), ('drugbank', array(['DB12802'], dtype=object)), ('chEBI', array(['75251'], dtype=object))]",,"{'rows': array(['EFO_0002501', 'EFO_0000616', 'EFO_0002499', 'EFO_0000571',
       'EFO_1001465', 'EFO_0003060', 'EFO_0001642', 'EFO_0000707'],
      dtype=object), 'count': 8}",[ENSG00000140443],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL295698,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,Small molecule,True,LEVOKETOCONAZOLE,2021.0,4.0,,False,True,"['Extina' 'Ketosidin' 'Ketozole' 'Nizoral' 'Nizoral A-D' 'Panfungol'
 'Recorlev' 'Xolegel']","['(-)-(2s,4r)-ketoconazole' '2s,4r ketoconazole' '2s,4r-ketoconazole'
 'COR-003' 'COR003' 'DIO-902' 'Ketoconazole, (2s,4r)-' 'Levoketoconazole'
 'Nizoral' 'Normocort' 'R-41400']","[('PubChem', array(['11111347', '11112822', '124882653', '124882654'], dtype=object)), ('drugbank', array(['DB05667'], dtype=object)), ('chEBI', array(['47518'], dtype=object))]",,"{'rows': array(['EFO_0005539', 'MONDO_0005148', 'EFO_0003099', 'EFO_1000797',
       'EFO_1001110'], dtype=object), 'count': 5}","[ENSG00000179142,ENSG00000140459,ENSG00000160882,ENSG00000148795]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3137317,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O,RWIVSVMMGFFZIJ-VWDRLOGHSA-N,Small molecule,True,SONIDEGIB PHOSPHATE,2015.0,4.0,CHEMBL2105737,False,True,['Odomzo'],['Erismodegib phosphate' 'Sonidegib diphosphate' 'Sonidegib phosphate'],"[('DailyMed', array(['sonidegib%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/odomzo'],
      dtype=object))]",,"{'rows': array(['EFO_0004193'], dtype=object), 'count': 1}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for basal cell carcinoma. This drug has a black box warning from the FDA.
CHEMBL3545100,,,Small molecule,False,ASP7991,,2.0,,False,False,[],['Asp7991'],,,"{'rows': array(['EFO_1001173'], dtype=object), 'count': 1}",[ENSG00000036828],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545184,CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,ANIAZGVDEUQPRI-ZJQCGQFWSA-N,Protein,False,VELCALCETIDE,2016.0,4.0,,False,True,['Parsabiv'],"['AMG-416' 'Amg416' 'Etelcalcetide' 'KAI-4169' 'ONO-5163' 'Telcalcetide'
 'Velcalcetide']","[('DailyMed', array(['etelcalcetide'], dtype=object)), ('drugbank', array(['DB12865'], dtype=object))]",['CHEMBL3545183'],"{'rows': array(['EFO_1001173', 'EFO_0003884', 'EFO_0005754', 'EFO_1001173',
       'EFO_0003884'], dtype=object), 'count': 5}",[ENSG00000036828],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 1 investigational indication.
CHEMBL3653256,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1,AGBSXNCBIWWLHD-FQEVSTJZSA-N,Small molecule,False,SIREMADLIN,,2.0,,False,False,[],['HDM-201' 'HDM201' 'Hdm 201' 'NVP-HDM 201' 'Siremadlin'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIREMADLIN/relevant/1/'],
      dtype=object))]",['CHEMBL5095424'],"{'rows': array(['EFO_0001421', 'EFO_0000616', 'MONDO_0044903', 'EFO_0000616',
       'EFO_0000569', 'EFO_1001968', 'EFO_0000222'], dtype=object), 'count': 7}","[ENSG00000141510,ENSG00000135679]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4297528,Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1,ASKZRYGFUPSJPN-UHFFFAOYSA-N,Small molecule,False,RISDIPLAM,2020.0,4.0,,False,True,['Evrysdi'],['RG-7916' 'RG7916' 'RO-7034067' 'RO7034067' 'Risdiplam'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RISDIPLAM/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15305'], dtype=object))]",,"{'rows': array(['EFO_0008525', 'EFO_1000096'], dtype=object), 'count': 2}",[ENSG00000205571],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for spinal muscular atrophy and atrophy.
CHEMBL43,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,XCPGHVQEEXUHNC-UHFFFAOYSA-N,Small molecule,False,AMSACRINE,1987.0,4.0,,False,True,[],"['Acridinylanisidide' 'Amekrin' 'Amsacrine' 'Amsidil' 'Amsidine' 'CI-880'
 'Lamasine' 'M-AMSA' 'NCI-249992' 'NSC-156303' 'NSC-249992' 'SN-11841'
 'SN-21429']","[('PubChem', array(['11110803', '137181', '50110958'], dtype=object)), ('Wikipedia', array(['Amsacrine'], dtype=object)), ('drugbank', array(['DB00276'], dtype=object)), ('chEBI', array(['2687'], dtype=object))]",['CHEMBL1256655' 'CHEMBL3229103' 'CHEMBL540070'],"{'rows': array(['EFO_0000222', 'EFO_0000616', 'EFO_0000565', 'EFO_0000198'],
      dtype=object), 'count': 4}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for neoplasm and has 3 investigational indications.
CHEMBL496102,COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,HEAIZQNMNCHNFD-UHFFFAOYSA-N,Small molecule,False,AMG-208,,2.0,,False,False,[],['AMG-208' 'Amg 208' 'Amg-208' 'Amg208'],"[('PubChem', array(['174006590'], dtype=object)), ('drugbank', array(['DB08079'], dtype=object)), ('chEBI', array(['90626'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5314402,O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc(F)cc(F)c1,UAKZGMMGIMKFMV-RBUKOAKNSA-N,Small molecule,False,TC-6987,,2.0,,False,False,[],['TC-6987' 'Tc-6987'],,,"{'rows': array(['MONDO_0005148', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL110691,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,QMBJSIBWORFWQT-DFXBJWIESA-N,Small molecule,False,CHLORMADINONE ACETATE,,4.0,,True,True,[],"['Chlormadinone' 'Chlormadinone acetate' 'Lutoral' 'NSC-92338' 'Normenon'
 'RS-1280']","[('PubChem', array(['144204432', '144207863', '170465776', '29215009', '56422443',
       '855775'], dtype=object)), ('chEBI', array(['31394'], dtype=object))]",,,[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1200339,CNC[C@H](O)c1cccc(O)c1.Cl,OCYSGIYOVXAGKQ-FVGYRXGTSA-N,Small molecule,False,PHENYLEPHRINE HYDROCHLORIDE,1952.0,4.0,CHEMBL1215,False,True,"['Biorphen' 'Fenilfar' 'Fenox' 'Mydfrin' 'Nazex' 'Neosynephrine'
 'Nurofen sinus pain relief' 'Phenylephrine hydrochloride' 'Prefrin'
 'Vazculep']","['Metaoxedrine chloride' 'NSC-757273' 'Phenylephrine HCl'
 'Phenylephrine hydrochloride']","[('DailyMed', array(['phenylephrine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204448', '144208459', '144213163', '170465356', '26751602',
       '50106782', '855560'], dtype=object)), ('chEBI', array(['8094'], dtype=object))]",,"{'rows': array(['EFO_0007486', 'HP_0000989', 'EFO_0004269', 'HP_0001742',
       'EFO_0004610', 'EFO_0006834', 'EFO_0007214', 'EFO_0007533',
       'EFO_0008521', 'EFO_0000319', 'EFO_0000178', 'EFO_0000544',
       'EFO_0005251', 'MONDO_0024355', 'EFO_0003956', 'EFO_0009552',
       'MONDO_0005129', 'MONDO_0005271'], dtype=object), 'count': 18}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 9 approved and 9 investigational indications.
CHEMBL122,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,RZJQGNCSTQAWON-UHFFFAOYSA-N,Small molecule,True,ROFECOXIB,1999.0,4.0,,True,True,['Vioxx'],"['M01AH02' 'MK-0966' 'MK-966' 'MK0966' 'NSC-720256' 'NSC-758705'
 'Rofecoxib' 'TRM-201' 'TRM201']","[('PubChem', array(['144204983', '174007305', '26748942', '49665949', '535364'],
      dtype=object)), ('Wikipedia', array(['Rofecoxib'], dtype=object)), ('drugbank', array(['DB00533'], dtype=object)), ('chEBI', array(['8887'], dtype=object))]",['CHEMBL5171570' 'CHEMBL4465601'],"{'rows': array(['EFO_0005755', 'MONDO_0005178', 'EFO_0003833', 'MONDO_0008315',
       'EFO_0005406', 'EFO_0005543', 'EFO_0004616', 'EFO_0003843',
       'EFO_0003897', 'EFO_1001951', 'EFO_0003060', 'MONDO_0004975',
       'HP_0003040'], dtype=object), 'count': 13}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for rheumatic disease and has 12 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1743064,,,Antibody,False,ROBATUMUMAB,,2.0,,False,False,[],['19D12' 'Robatumumab' 'SCH 717454' 'SCH-717454'],,,"{'rows': array(['EFO_1001951', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1981592,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O,VBUWHHLIZKOSMS-RIWXPGAOSA-N,Protein,False,AVIPTADIL,,3.0,,False,False,['Samiairtm' 'Samiviptm' 'Samivirtm' 'Zyesami'],['Aviptadil' 'Aviptadil acetate' 'Vip human vip'],"[('PubChem', array(['124893751'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AVIPTADIL/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0004610', 'EFO_1000637', 'MONDO_0100096'],
      dtype=object), 'count': 4}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL206468,OC[C@H]1CNC[C@@H](O)[C@@H]1O,QPYJXFZUIJOGNX-HSUXUTPPSA-N,Small molecule,False,AFEGOSTAT,,2.0,,False,False,[],['Afegostat' 'Isofagomine'],"[('PubChem', array(['85267413'], dtype=object)), ('drugbank', array(['DB04545'], dtype=object))]",['CHEMBL2105671'],"{'rows': array(['MONDO_0018150'], dtype=object), 'count': 1}",[ENSG00000177628],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2105719,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1.O,BSPLGGCPNTZPIH-IPZCTEOASA-N,Small molecule,False,DACOMITINIB,2018.0,4.0,CHEMBL2110732,False,True,['Vizimpro'],"['Dacomitinib' 'Dacomitinib hydrate' 'Dacomitinib monohydrate'
 'PF-00299804-03']","[('DailyMed', array(['dacomitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro'],
      dtype=object))]",,"{'rows': array(['MONDO_0008903', 'EFO_0000616', 'EFO_1001951', 'MONDO_0001657',
       'EFO_1001094', 'MONDO_0004992', 'EFO_0001421', 'EFO_0000181',
       'EFO_0000707', 'EFO_0003060'], dtype=object), 'count': 10}","[ENSG00000141736,ENSG00000146648,ENSG00000178568]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 7 investigational indications.
CHEMBL2107760,COc1ccccc1Oc1c(NS(=O)(=O)/C=C/c2ccccc2)nc(-c2ncccn2)nc1OC,LONWRQOYFPYMQD-DTQAZKPQSA-N,Small molecule,False,NEBENTAN,,2.0,,False,False,[],['HE-11' 'Nebentan' 'Nebentan potassium' 'YM-598' 'Ym598'],,,"{'rows': array(['EFO_0000673', 'MONDO_0008315'], dtype=object), 'count': 2}",[ENSG00000151617],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2107762,CCCN(c1ccncc1F)n1cc(C)c2ccccc21,BTDHTARYCBHHPJ-UHFFFAOYSA-N,Small molecule,False,NERISPIRDINE,,2.0,,False,False,[],['HP-184' 'HP184' 'Nerispirdine' 'Nerispirdine hydrochloride'],"[('drugbank', array(['DB12714'], dtype=object))]",['CHEMBL3585642'],"{'rows': array(['MONDO_0005301', 'EFO_1001919'], dtype=object), 'count': 2}","[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109487,,,Antibody,False,RG-1512,,2.0,,False,False,[],['RG-1512'],,,,[ENSG00000174175],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109527,,,Antibody,False,MEDI-578,,1.0,,False,False,[],['MEDI-578' 'Medi-578'],,,"{'rows': array(['EFO_0003843', 'MONDO_0005178'], dtype=object), 'count': 2}",[ENSG00000134259],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2109587,,,Antibody,False,AZ9773,,2.0,,False,False,[],['AZ-9773' 'AZ9773'],,,,[ENSG00000232810],Antibody drug with a maximum clinical trial phase of II.
CHEMBL288441,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,UBPYILGKFZZVDX-UHFFFAOYSA-N,Small molecule,False,BOSUTINIB,2012.0,4.0,,False,True,['Bosulif'],['Bosutinib' 'SK-606' 'SKI-606'],"[('PubChem', array(['124950167'], dtype=object)), ('Wikipedia', array(['Bosutinib'], dtype=object)), ('drugbank', array(['DB06616'], dtype=object)), ('chEBI', array(['39112'], dtype=object))]",['CHEMBL2095206' 'CHEMBL2131134'],"{'rows': array(['EFO_0000222', 'MONDO_0002974', 'MONDO_0004643', 'EFO_1000131',
       'EFO_0002618', 'EFO_0000616', 'EFO_1001496', 'MONDO_0002087',
       'EFO_1000581', 'MONDO_0007254', 'EFO_0000519', 'EFO_0000339',
       'EFO_0000565', 'EFO_0003060', 'MONDO_0001187', 'MONDO_0002586',
       'HP_0000726', 'EFO_0000305', 'EFO_0000588', 'EFO_0000220',
       'MONDO_0004976', 'MONDO_0008170', 'EFO_0000339'], dtype=object), 'count': 23}","[ENSG00000197122,ENSG00000101336,ENSG00000097007,ENSG00000186716,ENSG00000254087]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for myeloid leukemia and chronic myelogenous leukemia and has 21 investigational indications.
CHEMBL3039538,,,Protein,False,TRENONACOG ALFA,,3.0,,False,False,['Ixinity[tm]'],['IB-1001' 'IB1001' 'Trenonacog alfa'],,,"{'rows': array(['MONDO_0008840', 'MONDO_0010006', 'MONDO_0018982', 'MONDO_0010604',
       'MONDO_0010100'], dtype=object), 'count': 5}",[ENSG00000101981],Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4298093,,,Antibody,False,SEMORINEMAB,,2.0,,False,False,[],"['MTAU-9937A' 'MTAU9937A' 'RO-7105705' 'RO7105705' 'Ro7105705'
 'Semorinemab']",,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000186868],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298102,,,Antibody,False,VUNAKIZUMAB,,3.0,,False,False,[],['SHR-1314' 'Shr-1314' 'Vunakizumab'],,,"{'rows': array(['EFO_1001466', 'EFO_0003778', 'EFO_0000676', 'EFO_0003898',
       'EFO_0005761'], dtype=object), 'count': 5}",[ENSG00000112115],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4650426,,,Protein,False,PEGENZILEUKIN,,2.0,,False,False,[],"['Il-2 variant thor-707' 'Pegenzileukin' 'SAR-444245' 'SAR444245'
 'THOR-707' 'THOR707' 'Thor 707' 'Thor-707']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEGENZILEUKIN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0009708', 'EFO_0001378', 'MONDO_0009348', 'EFO_0000181',
       'EFO_0000403', 'EFO_0000616'], dtype=object), 'count': 6}","[ENSG00000147168,ENSG00000100385]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL517712,CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2,RKUNBYITZUJHSG-SPUOUPEWSA-N,Small molecule,False,ATROPINE,1960.0,4.0,,False,True,"['Atroject' 'Atropen' 'Atrophate' 'Atropine' 'Atropine (autoinjector)'
 'Isopto Atropine']",['Atropine' 'Atropinum' 'Dl-hyoscyamine'],"[('DailyMed', array(['atropine'], dtype=object)), ('PubChem', array(['11533003', '144204367', '144205143', '144207685', '56422449'],
      dtype=object)), ('drugbank', array(['DB00572'], dtype=object)), ('chEBI', array(['16684'], dtype=object))]",['CHEMBL1200752' 'CHEMBL2146146' 'CHEMBL3185794' 'CHEMBL3182372'],"{'rows': array(['HP_0000545', 'HP_0002315', 'EFO_1001865', 'EFO_0008546',
       'EFO_0004209', 'HP_0001943', 'EFO_0002614', 'HP_0000545',
       'HP_0004398', 'MONDO_0007254', 'EFO_0004207', 'MONDO_0005180',
       'EFO_0005252', 'EFO_0003956', 'MONDO_0004976', 'EFO_0005323',
       'EFO_0009314', 'MONDO_0001020', 'EFO_0010282', 'EFO_0003843',
       'EFO_1001109', 'HP_0011499', 'EFO_0009492', 'HP_0012803',
       'MP_0001914', 'EFO_1000645', 'EFO_0005854', 'HP_0001662',
       'EFO_0003956', 'EFO_1001121', 'HP_0000486', 'EFO_0010581',
       'HP_0011499'], dtype=object), 'count': 33}","[ENSG00000181072,ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 7 approved and 24 investigational indications.
CHEMBL585902,Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O,RQVKVJIRFKVPBF-VWLOTQADSA-N,Small molecule,False,AMG-548,,1.0,,False,False,[],['AMG-548' 'Amg-548'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL68117,CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC,XZAFZXJXZHRNAQ-STQMWFEESA-N,Small molecule,False,VOSAROXIN,,3.0,,False,False,[],['AG-7352' 'SNS-595' 'SPC-595' 'Vosaroxin'],"[('drugbank', array(['DB11999'], dtype=object))]",['CHEMBL543336'],"{'rows': array(['EFO_0000565', 'EFO_0000220', 'EFO_0003060', 'EFO_0000702',
       'EFO_0000339', 'EFO_0000198', 'EFO_0000616', 'EFO_0000222'],
      dtype=object), 'count': 8}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL75753,O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1,DXPOSRCHIDYWHW-UHFFFAOYSA-N,Small molecule,False,XAMOTEROL,,4.0,,False,True,[],"['ICI-118,587' 'ICI-118587' 'Xamoterol']","[('PubChem', array(['104171266', '144203855'], dtype=object)), ('Wikipedia', array(['Xamoterol'], dtype=object)), ('drugbank', array(['DB13781'], dtype=object)), ('chEBI', array(['10055'], dtype=object))]",['CHEMBL1329567' 'CHEMBL1256945' 'CHEMBL2104466'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease.
CHEMBL945,N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,XSDQTOBWRPYKKA-UHFFFAOYSA-N,Small molecule,True,AMILORIDE,1981.0,4.0,,False,True,[],['Amiclaran' 'Amiloride' 'Hydro-Ride' 'Midamor'],"[('PubChem', array(['104171108', '11110775', '11113372', '124879259', '124879263',
       '144203631', '170465124', '26751628', '26751629', '49645530',
       '90341609'], dtype=object)), ('Wikipedia', array(['Amiloride'], dtype=object)), ('drugbank', array(['DB00594'], dtype=object)), ('chEBI', array(['2639'], dtype=object))]",['CHEMBL1398126' 'CHEMBL1201085' 'CHEMBL540851'],"{'rows': array(['EFO_0000537', 'EFO_0000319', 'MONDO_0009061', 'EFO_0003144',
       'EFO_0008519', 'EFO_0000373', 'EFO_0003888', 'EFO_0001645',
       'EFO_0007405', 'EFO_0004269', 'EFO_0008522', 'MONDO_0005475',
       'MONDO_0009061', 'EFO_0000537', 'HP_0011096'], dtype=object), 'count': 15}","[ENSG00000111319,ENSG00000168447,ENSG00000166828]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL984,COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2.[Cl-].[Cl-],WMSYWJSZGVOIJW-ONUALHDOSA-L,Small molecule,False,MIVACURIUM CHLORIDE,1992.0,4.0,CHEMBL1182833,False,True,['Mivacron' 'Mivacurium chloride'],"['BW B109OU DICHLORIDE' 'BW-1090U DICHLORIDE' 'BW-B109OU'
 'BW-B109OU DICHLORIDE' 'BWB109OU' 'MIVACURIUM CHLORIDE'
 'Mivacurium chloride' 'mivacurium']","[('PubChem', array(['144206026'], dtype=object)), ('Wikipedia', array(['Mivacurium_chloride'], dtype=object))]",,"{'rows': array(['HP_0001410'], dtype=object), 'count': 1}","[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and has 1 investigational indication.
CHEMBL1184904,C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2,OAKGNIRUXAZDQF-TXHRRWQRSA-N,Small molecule,False,RETASPIMYCIN,,3.0,,False,False,[],['IPI-504' 'Retaspimycin'],"[('drugbank', array(['DB05626'], dtype=object)), ('chEBI', array(['71975'], dtype=object))]",['CHEMBL377559'],"{'rows': array(['EFO_0003060', 'EFO_0002617', 'MONDO_0008903', 'EFO_0000305',
       'MONDO_0011719', 'EFO_0001378', 'MONDO_0004992', 'MONDO_0007254',
       'EFO_0003085', 'EFO_0000673'], dtype=object), 'count': 10}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL1186894,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O,VJZITPJGSQKZMX-XDPRQOKASA-N,Small molecule,False,AMRUBICIN,,3.0,,False,False,[],['Amrubicin'],"[('Wikipedia', array(['Amrubicin'], dtype=object)), ('drugbank', array(['DB06263'], dtype=object))]",['CHEMBL481958'],"{'rows': array(['EFO_0001378', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0000702',
       'EFO_1000576', 'EFO_0000616', 'EFO_1000581', 'EFO_0000702',
       'EFO_1001968', 'MONDO_0001187', 'MONDO_0008903'], dtype=object), 'count': 11}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL1200472,Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21,IKMPWMZBZSAONZ-UHFFFAOYSA-N,Small molecule,True,QUAZEPAM,1985.0,4.0,,False,True,['Doral'],['NSC-309702' 'Quazepam' 'Quazepam civ' 'SCH 16134' 'SCH-16134'],"[('DailyMed', array(['quazepam'], dtype=object)), ('Wikipedia', array(['Quazepam'], dtype=object)), ('drugbank', array(['DB01589'], dtype=object)), ('chEBI', array(['8694'], dtype=object))]",,"{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for insomnia. This drug has a black box warning from the FDA.
CHEMBL1201003,Br.CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12,UTINOWOSWSPFLJ-FSRHSHDFSA-N,Small molecule,False,ELETRIPTAN HYDROBROMIDE,2002.0,4.0,CHEMBL1510,False,True,['Relpax'],"['Eletriptan hbr' 'Eletriptan hydrobromide' 'NSC-759258' 'UK-116,044-04'
 'UK-116044-04']","[('DailyMed', array(['eletriptan%20hydrobromide'], dtype=object)), ('chEBI', array(['61176'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}","[ENSG00000135312,ENSG00000179546,ENSG00000179097]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2002 and is indicated for migraine disorder.
CHEMBL1201109,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,WBGKWQHBNHJJPZ-LECWWXJVSA-N,Small molecule,False,DESONIDE,1972.0,4.0,,False,True,['Desonate' 'Desonide' 'Desowen' 'Tridesilon' 'Verdeso'],['D-2083' 'D2083' 'Desonate' 'Desonide' 'NSC-759226'],"[('DailyMed', array(['desonide'], dtype=object)), ('PubChem', array(['144206156', '170464832'], dtype=object)), ('Wikipedia', array(['Desonide'], dtype=object)), ('drugbank', array(['DB01260'], dtype=object)), ('chEBI', array(['204734'], dtype=object))]",,"{'rows': array(['EFO_0000274', 'EFO_0005752', 'EFO_0000701'], dtype=object), 'count': 3}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 3 approved indications.
CHEMBL1201163,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,OJCZPLDERGDQRJ-UHFFFAOYSA-N,Small molecule,True,SUFENTANIL CITRATE,1984.0,4.0,CHEMBL658,False,True,"['Dsuvia' 'Dzuveo' 'Sufenta' 'Sufenta preservative free' 'Sufental'
 'Sufentanil citrate']",['R 33800' 'R-33800' 'Sufentanil citrate' 'Sufentanil citrate cii'],"[('DailyMed', array(['sufentanil%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo'],
      dtype=object)), ('PubChem', array(['144206432', '85273816'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for pain. This drug has a black box warning from the FDA.
CHEMBL124162,CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1,YCNIQYLWIPCLNY-QHCPKHFHSA-N,Small molecule,False,CAMPTOTHECIN-20-O-PROPIONATE,,2.0,,False,False,[],['Camptothecin-20-o-propionate'],,,"{'rows': array(['EFO_0000574', 'EFO_0000702', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1743011,,,Antibody,False,ENAVATUZUMAB,,2.0,,False,False,[],['Enavatuzumab' 'PDL 192' 'PDL-192'],,,,[ENSG00000006327],Antibody drug with a maximum clinical trial phase of II.
CHEMBL1823681,CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1,NULMGOSOSZBEQL-QMMMGPOBSA-N,Small molecule,False,ETILEVODOPA,,2.0,,False,False,[],['Etilevodopa' 'L-dopa ethyl ester' 'TV-1203'],"[('drugbank', array(['DB06535'], dtype=object))]",,,[ENSG00000151577],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL20883,O=c1[nH]c(=O)n(C2CCCO2)cc1F,WFWLQNSHRPWKFK-UHFFFAOYSA-N,Small molecule,False,TEGAFUR,,4.0,,False,True,['Citofur' 'Uftoral'],"['Atillon' 'BMS-200604' 'Coparogin' 'Exonal' 'FT-207' 'Fental' 'Franrose'
 'Ftorafur' 'Fulaid' 'Fulfeel' 'Furafluor' 'Furofutran' 'Futraful'
 'J356.722B' 'Lamar' 'Lifril' 'MJF-12264' 'NSC-148958' 'Neberk'
 'Nitobanil' 'Sinoflurol' 'Sunfural' 'Tefsiel c' 'Tegafur'
 'Tegafur-uracil' 'Youfuding']","[('PubChem', array(['144205202', '144212129', '170465809', '26754499', '29215356',
       '56422217', '8139878'], dtype=object)), ('Wikipedia', array(['Tegafur'], dtype=object)), ('drugbank', array(['DB09256'], dtype=object)), ('chEBI', array(['32188'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0007576', 'EFO_0000182', 'MONDO_0007254',
       'MONDO_0004992', 'EFO_0000199', 'MONDO_0001187', 'EFO_0003891',
       'MONDO_0003060', 'EFO_0000228', 'MONDO_0002974', 'MONDO_0021355',
       'EFO_0003860', 'EFO_0003086', 'MONDO_0002120', 'EFO_1001951',
       'MONDO_0005184', 'MONDO_0044937', 'EFO_0001421', 'EFO_1001901',
       'EFO_0000702', 'EFO_0003060', 'EFO_0000365', 'EFO_0005922',
       'EFO_0004142', 'EFO_0003897', 'EFO_0003869', 'EFO_0000503',
       'EFO_0000181', 'EFO_1000359', 'EFO_1000657', 'EFO_1000045',
       'MONDO_0005575', 'EFO_0005221', 'EFO_0000178', 'MONDO_0001056',
       'EFO_0004252', 'EFO_0002916', 'EFO_0006859', 'EFO_0002618',
       'EFO_1001956'], dtype=object), 'count': 41}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and cancer and has 39 investigational indications.
CHEMBL2103849,CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1,IYFNEFQTYQPVOC-UHFFFAOYSA-N,Small molecule,False,UDENAFIL,,3.0,,False,False,[],['DA-8159' 'Udenafil' 'Zydena'],"[('drugbank', array(['DB06267'], dtype=object))]",,"{'rows': array(['EFO_1000899', 'EFO_0003777', 'EFO_0001421', 'EFO_0001361',
       'EFO_1001145', 'MONDO_0004975', 'EFO_0004234', 'EFO_0004718',
       'EFO_1001207'], dtype=object), 'count': 9}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL2105684,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21.O=S(=O)(O)O,GRKFGZYYYYISDX-UHFFFAOYSA-N,Small molecule,False,SELUMETINIB SULFATE,2020.0,4.0,CHEMBL1614701,False,True,['Koselugo'],"['AZD-6244 HYD-SULFATE' 'AZD-6244 HYDROGEN SULFATE' 'AZD6244 HYD-SULFATE'
 'AZD6244 HYDROGEN SULFATE' 'Azd-6244 hydrogen sulphate'
 'Azd6244 hydrogen sulphate' 'Selumetinib sulfate' 'Selumetinib sulphate']","[('DailyMed', array(['selumetinib%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo'],
      dtype=object))]",,"{'rows': array(['EFO_0000272', 'EFO_0001075', 'EFO_1001512', 'EFO_0002617',
       'EFO_1000251', 'EFO_0008514', 'EFO_0002618', 'MONDO_0018975',
       'EFO_0000389'], dtype=object), 'count': 9}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neurofibromatosis and neurofibromatosis type 1 and has 7 investigational indications.
CHEMBL2107834,COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,WXXSNCNJFUAIDG-UHFFFAOYSA-N,Small molecule,True,RIOCIGUAT,2013.0,4.0,,False,True,['Adempas' 'Bay 63-2521'],['BAY 63-2521' 'BAY-63-2521' 'Riociguat'],"[('DailyMed', array(['riociguat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adempas'],
      dtype=object)), ('drugbank', array(['DB08931'], dtype=object)), ('chEBI', array(['76018'], dtype=object))]",,"{'rows': array(['EFO_0001361', 'EFO_1001993', 'EFO_0000764', 'EFO_1001145',
       'EFO_0000537', 'MONDO_0005149', 'EFO_0000717', 'MONDO_0011382',
       'MONDO_0043839', 'HP_0002140', 'MONDO_0009061', 'EFO_0001645'],
      dtype=object), 'count': 12}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109308,,,Antibody,False,ONCOLYSIN B,,2.0,,False,False,[],['ONCOLYSIN B'],,,,[ENSG00000177455],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2364618,CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1,ORDHXXHTBUZRCN-NTEUORMPSA-N,Small molecule,False,MAVATREP,,2.0,,False,False,[],['JNJ-39439335' 'Mavatrep'],"[('drugbank', array(['DB12875'], dtype=object))]",,"{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545321,,,Small molecule,False,NMS-1116354,,1.0,,False,False,[],['Nms-1116354'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000097046],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3581647,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2,GNMUEVRJHCWKTO-FQEVSTJZSA-N,Small molecule,False,BIRABRESIB,,2.0,,False,False,[],"['Birabresib' 'MK-8628' 'OTX-015' 'OTX-015 ANHYDROUS' 'OTX015'
 'OTX015 ANHYDROUS' 'Y-803 anhydrous']","[('drugbank', array(['DB15189'], dtype=object))]",,"{'rows': array(['EFO_0000519', 'EFO_0000222', 'MONDO_0008315', 'EFO_0000403',
       'MONDO_0005184', 'MONDO_0007254', 'EFO_0003060'], dtype=object), 'count': 7}","[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL3608680,Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1,PPSNFPASKFYPMN-SECBINFHSA-N,Small molecule,False,FEZOLINETANT,2023.0,4.0,,False,True,['Veozah'],"['A-2693' 'A2693' 'AS-3472693-00' 'AS3472693-00' 'ES-256364' 'ESN-364'
 'ESN364' 'Esn364' 'Fezolinetant' 'Veozah']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FEZOLINETANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15669'], dtype=object))]",,"{'rows': array(['HP_0031217', 'EFO_0003086', 'EFO_0001421'], dtype=object), 'count': 3}",[ENSG00000169836],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for hot flashes and has 2 investigational indications.
CHEMBL3989865,C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@H]([C@@H]1OC(=O)CCCCCCC)[C@@](C)(OC(C)=O)C[C@H](OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)[C@@]1(O)[C@H]2OC(=O)[C@@]1(C)O,UPYNTAIBQVNPIH-ODMLWHIESA-N,Small molecule,False,MIPSAGARGIN,,2.0,,False,False,[],['G-202' 'Mipsagargin'],"[('drugbank', array(['DB11813'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'EFO_0000519', 'EFO_0000673', 'MONDO_0008315',
       'EFO_0000616', 'EFO_0000349'], dtype=object), 'count': 6}","[ENSG00000074370,ENSG00000196296,ENSG00000174437]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3989939,O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1.O=S(=O)(O)O,PXHANKVTFWSDSG-QLOBERJESA-N,Small molecule,False,LAROTRECTINIB SULFATE,2018.0,4.0,CHEMBL3889654,False,True,['Vitrakvi'],['ARRY-470 SULFATE' 'LOXO-101 sulfate' 'Larotrectinib sulfate'],"[('DailyMed', array(['larotrectinib%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi'],
      dtype=object))]",,"{'rows': array(['EFO_0009708', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}","[ENSG00000198400,ENSG00000148053,ENSG00000140538]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications.
CHEMBL3990016,,,Antibody,False,OLECLUMAB,,3.0,,False,False,[],['MEDI-9447' 'MEDI9447' 'Oleclumab'],,,"{'rows': array(['MONDO_0008315', 'EFO_0003060', 'EFO_0003869', 'MONDO_0007254',
       'MONDO_0004992', 'EFO_0000616', 'MONDO_0001187'], dtype=object), 'count': 7}",[ENSG00000135318],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4297793,,,Protein,False,NANGIBOTIDE,,2.0,,False,False,[],['LR-12' 'Motrem' 'Nangibotide'],,,"{'rows': array(['EFO_0006834', 'MONDO_0100096'], dtype=object), 'count': 2}",[ENSG00000124731],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4298129,,,Unknown,False,HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX,2013.0,4.0,,False,True,['Voncento'],['Human coagulation factor viii/von willebrand factor complex' 'Wilate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/voncento'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602', 'Orphanet_903'], dtype=object), 'count': 2}","[ENSG00000110799,ENSG00000185010]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for hemophilia a and von willebrand disease.
CHEMBL4594567,,,Antibody,False,ROCATINLIMAB,,3.0,,False,False,[],"['AMG 451' 'AMG-451' 'AMG451' 'KHK-4083' 'KHK4083' 'KLK4083' 'Khk-4083'
 'Khk4083' 'Rocatinlimab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROCATINLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000729', 'EFO_0000274'], dtype=object), 'count': 2}",[ENSG00000186827],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL5095033,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1,BRKWREZNORONDU-UHFFFAOYSA-N,Small molecule,False,IBCASERTIB,,3.0,,False,False,[],['CS-2164' 'CS2164' 'Chiauranib' 'Cs-2164' 'Ibcasertib'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['EFO_0005537', 'EFO_0005952', 'EFO_0000182', 'EFO_0000702',
       'EFO_0000616', 'MONDO_0008170', 'EFO_1001968'], dtype=object), 'count': 7}","[ENSG00000178999,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL5314348,,,Protein,False,BIVALIRUDIN,2000.0,4.0,,False,True,"['Angiomax' 'Angiomax rtu' 'Angiox' 'Bivalirudin'
 'Bivalirudin in 0.9% sodium chloride']",['BG-8967' 'BG8967' 'Bivalirudin'],"[('DailyMed', array(['bivalirudin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/angiox'],
      dtype=object))]",['CHEMBL5314353'],"{'rows': array(['HP_0004419', 'EFO_0005672', 'HP_0001871', 'EFO_0008583',
       'EFO_0000266', 'HP_0001873', 'EFO_0000713', 'EFO_0001645',
       'EFO_0003777', 'MP_0001914', 'EFO_1000985', 'EFO_0003907',
       'EFO_0000612', 'EFO_0000319', 'MONDO_0000831'], dtype=object), 'count': 15}",[ENSG00000180210],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 10 investigational indications.
CHEMBL58323,COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1,VPPJLAIAVCUEMN-GFCCVEGCSA-N,Small molecule,False,LACOSAMIDE,2008.0,4.0,,False,True,['Lacosamide' 'Vimpat'],"['(r)-lacosamide 1' 'ADD 243037' 'ADD-243037' 'ADD243037' 'Erlosamide'
 'Lacosamide' 'Lacosamide cv' 'Motpoly' 'SPM 927' 'SPM-927' 'SPM927']","[('DailyMed', array(['lacosamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat'],
      dtype=object)), ('PubChem', array(['170466190'], dtype=object)), ('Wikipedia', array(['Lacosamide'], dtype=object)), ('drugbank', array(['DB06218'], dtype=object))]",['CHEMBL1213900'],"{'rows': array(['EFO_0005543', 'EFO_0003833', 'EFO_0000474', 'MONDO_0007571',
       'EFO_0005230', 'HP_0001250', 'EFO_0005762', 'MONDO_0002050',
       'EFO_0008526', 'EFO_0005687', 'MONDO_0005090', 'MONDO_0004976',
       'EFO_0000326', 'MONDO_0041052', 'MONDO_0005277', 'MONDO_0007079',
       'MONDO_0005178', 'HP_0000726', 'EFO_0004263', 'EFO_0003086',
       'HP_0011868', 'EFO_1000783'], dtype=object), 'count': 22}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for epilepsy and seizure and has 20 investigational indications.
CHEMBL83,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,NKANXQFJJICGDU-QPLCGJKRSA-N,Small molecule,True,TAMOXIFEN,1977.0,4.0,,False,True,[],"['ICI-46474' 'ICI-47699' 'Mammaton' 'NSC-727681' 'Nolvadex' 'Novaldex'
 'Soltamox' 'Tamoplex' 'Tamoxifen']","[('PubChem', array(['11113844', '144208441', '144210857', '26752017', '26752018',
       '50104683', '50104684', '50104685', '50104686', '56320712',
       '90340643'], dtype=object)), ('TG-GATEs', array(['54'], dtype=object)), ('Wikipedia', array(['Tamoxifen'], dtype=object)), ('drugbank', array(['DB00675'], dtype=object)), ('chEBI', array(['41774'], dtype=object))]",['CHEMBL786'],"{'rows': array(['MONDO_0007254', 'GO_0042697', 'MONDO_0001187', 'MONDO_0010679',
       'EFO_0003869', 'EFO_0009907', 'MONDO_0002158', 'EFO_0003843',
       'HP_0100543', 'EFO_0000305', 'EFO_0000616', 'EFO_1000294',
       'EFO_0000536', 'EFO_0000294', 'MONDO_0011962', 'EFO_0000545',
       'EFO_0004248', 'EFO_0000519', 'MONDO_0018364', 'HP_0000771',
       'EFO_0000305', 'EFO_0003833', 'EFO_0009708', 'EFO_1000158',
       'MONDO_0002087', 'EFO_1001512', 'EFO_0000389', 'MONDO_0002691',
       'EFO_0004220', 'MONDO_0004985', 'EFO_1001901', 'EFO_0000232',
       'MONDO_0008170', 'MONDO_0019180', 'MONDO_0018848', 'EFO_0000764',
       'EFO_0005543', 'EFO_0006861', 'EFO_0000637', 'EFO_0000616',
       'MONDO_0008315', 'EFO_0001075', 'EFO_1000251', 'MONDO_0007254',
       'EFO_1001375', 'EFO_0007532', 'MONDO_0100096', 'MONDO_0004992',
       'EFO_0000432', 'Orphanet_145', 'EFO_0000537', 'MONDO_0004976',
       'EFO_1000984', 'EFO_0001416'], dtype=object), 'count': 54}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 49 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1026,CS(=O)(=O)O.Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1,CVKUMNRCIJMVAR-UHFFFAOYSA-N,Small molecule,False,FENOLDOPAM MESYLATE,1997.0,4.0,CHEMBL588,False,True,['Corlopam' 'Fenoldopam mesylate'],"['Fendolopam mesylate' 'Fenoldopam mesilate' 'Fenoldopam mesylate'
 'Fenoldopam methanesulfonate' 'NSC-759860' 'SK&F 82526-J' 'SK&F-82526J'
 'SK-82526-J']","[('DailyMed', array(['fenoldopam%20mesylate'], dtype=object)), ('PubChem', array(['49681595'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'HP_0001919'], dtype=object), 'count': 2}",[ENSG00000184845],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hypertension and has 1 investigational indication.
CHEMBL1077896,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,ZKMNUMMKYBVTFN-HNNXBMFYSA-N,Small molecule,False,ROPIVACAINE,1996.0,4.0,,False,True,[],['Ropivacaine' 'Ropivicaine' 'TLC-590' 'TLC590' 'Tlc590'],"[('PubChem', array(['26758019'], dtype=object)), ('Wikipedia', array(['Ropivacaine'], dtype=object)), ('drugbank', array(['DB00296'], dtype=object)), ('chEBI', array(['8890'], dtype=object))]",['CHEMBL1889140'],"{'rows': array(['EFO_0003843', 'HP_0012532', 'EFO_0007355', 'MONDO_0005178',
       'EFO_0003869', 'MONDO_0001572', 'EFO_0003931', 'EFO_0009507',
       'EFO_0002950', 'EFO_0009620', 'MONDO_0001056', 'HP_0003040',
       'MONDO_0004992', 'HP_0003470', 'EFO_0009676', 'EFO_0001358',
       'MONDO_0008170', 'EFO_0005251', 'EFO_0006859', 'HP_0000138',
       'MONDO_0007254', 'HP_0030834', 'HP_0000023', 'HP_0000023',
       'EFO_0007149', 'EFO_0003843', 'HP_0002027', 'HP_0001822',
       'HP_0002017', 'MONDO_0005178', 'EFO_0007486', 'EFO_1001909',
       'HP_0001822', 'EFO_0004616', 'EFO_1001250'], dtype=object), 'count': 35}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for pain and has 32 investigational indications.
CHEMBL1200420,Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.Cl,PLYSCVSCYOQVRP-UHFFFAOYSA-N,Small molecule,True,MIDAZOLAM HYDROCHLORIDE,1985.0,4.0,CHEMBL655,False,True,"['Buccolam' 'Dormicum' 'Hypnovel' 'Midazolam hydrochloride'
 'Midazolam hydrochloride (autoinjector)'
 'Midazolam hydrochloride preservative free' 'Midozalam hydrochloride'
 'Rocam' 'Seizalam' 'Versed']","['Midazolam hcl' 'Midazolam hydrochloride' 'Midazolam hydrochloride civ'
 'NSC-751451' 'RO 21-3981/003' 'RO-213981001' 'Ro-213981-003' 'SHP-615'
 'SHP615']","[('DailyMed', array(['midazolam%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/buccolam'],
      dtype=object)), ('PubChem', array(['144206166', '170465015', '49731994'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0000274', 'EFO_0008526', 'MONDO_0005148',
       'EFO_0000618', 'EFO_0000662', 'EFO_0000616', 'MONDO_0002050',
       'MONDO_0018076', 'MONDO_0004985', 'EFO_1001454', 'EFO_1001884'],
      dtype=object), 'count': 12}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for amnesia and has 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201102,CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21.Cl,FTNWXGFYRHWUKG-UHFFFAOYSA-N,Small molecule,False,TRIFLUPROMAZINE HYDROCHLORIDE,1957.0,4.0,CHEMBL570,False,True,['Vesprin'],"['MC-4703' 'NSC-14959' 'NSC-17473' 'Triflupromazine hcl'
 'Triflupromazine hydrochloride']","[('PubChem', array(['144204828', '170465325', '26747673', '26747674', '50107065',
       '50107066', '50107067', '540840', '541291', '56422371', '57288079',
       '855673'], dtype=object)), ('chEBI', array(['9712'], dtype=object))]",,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957.
CHEMBL1201165,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC5CCCC5)ccc4[C@H]3CC[C@@]21C,PWZUUYSISTUNDW-VAFBSOEGSA-N,Small molecule,False,QUINESTROL,1982.0,4.0,,False,True,['Estrovis'],['NSC-759637' 'Quinestrol' 'W 3566' 'W-3566'],"[('PubChem', array(['11532988', '144205893', '170465054', '29217904', '56422146'],
      dtype=object)), ('Wikipedia', array(['Quinestrol'], dtype=object)), ('drugbank', array(['DB04575'], dtype=object)), ('chEBI', array(['8716'], dtype=object))]",,,"[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201349,C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21,HDZAQYPYABGTCL-UHFFFAOYSA-N,Small molecule,False,HEXAFLUORENIUM,1982.0,4.0,,False,True,[],"['Hexafluorenium' 'Hexafluorenium cation' 'Hexafluorenium ion'
 'Hexafluronium']","[('drugbank', array(['DB00941'], dtype=object))]",['CHEMBL1200933'],,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201776,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,KWTWDQCKEHXFFR-SMDDNHRTSA-N,Small molecule,True,TAPENTADOL,2008.0,4.0,,False,True,[],"['BN 200 (BASE)' 'BN-200' 'CG-5503' 'CG5503' 'CG5503 (BASE)' 'CG5503 IR'
 'NSC-759619' 'Tapentadol']","[('Wikipedia', array(['Tapentadol'], dtype=object)), ('drugbank', array(['DB06204'], dtype=object))]",['CHEMBL1201777'],"{'rows': array(['EFO_0003843', 'MONDO_0005178', 'MONDO_0001583', 'EFO_0005762',
       'HP_0001822', 'EFO_0003843', 'EFO_0004616', 'EFO_1000999',
       'HP_0003418', 'HP_0012532', 'EFO_0005762', 'EFO_1000786',
       'EFO_0000616', 'HP_0003419', 'HP_0003419', 'HP_0012532',
       'EFO_1000783'], dtype=object), 'count': 17}","[ENSG00000103546,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1346,NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1,HXGBXQDTNZMWGS-RUZDIDTESA-N,Small molecule,False,DARIFENACIN,2004.0,4.0,,False,True,[],['Darifenacin' 'Darifenacin extended release' 'Enablex' 'UK-88525'],"[('PubChem', array(['50113277'], dtype=object)), ('Wikipedia', array(['Darifenacin'], dtype=object)), ('drugbank', array(['DB00496'], dtype=object)), ('chEBI', array(['391960'], dtype=object))]",['CHEMBL1200935'],"{'rows': array(['HP_0000020', 'HP_0000103', 'EFO_1000781', 'EFO_0006865',
       'EFO_1000781'], dtype=object), 'count': 5}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 1 investigational indication.
CHEMBL1738,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,BMKDZUISNHGIBY-ZETCQYMHSA-N,Small molecule,False,DEXRAZOXANE,1995.0,4.0,,False,True,['Cardioxane'],"['ADR-529' 'Dexrazoxane' 'ICRF-187' 'NSC-169780' 'Razoxane, (s)-'
 'Razoxane, d-']","[('PubChem', array(['144205809', '170464709', '442425'], dtype=object)), ('Wikipedia', array(['Dexrazoxane'], dtype=object)), ('drugbank', array(['DB00380'], dtype=object)), ('chEBI', array(['50223'], dtype=object))]",['CHEMBL1200778'],"{'rows': array(['EFO_0000502', 'EFO_0000691', 'EFO_1001968', 'MONDO_0000870',
       'EFO_1000292', 'MONDO_0005301', 'EFO_0000502', 'EFO_0000565',
       'EFO_0000616', 'EFO_0000174', 'EFO_1000158', 'EFO_0000209',
       'EFO_0000318', 'HP_0030680', 'EFO_0000637', 'EFO_0000220',
       'EFO_1000984', 'EFO_0000621', 'EFO_0000621', 'EFO_0000574',
       'EFO_0000198', 'MONDO_0004992', 'EFO_0000222', 'MONDO_0007254',
       'EFO_0000222', 'EFO_0002918'], dtype=object), 'count': 26}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 24 investigational indications.
CHEMBL1743033,,,Antibody,False,ITOLIZUMAB,,3.0,,False,False,[],['BMAB-600' 'Bmab 600' 'EQ-001' 'EQ001' 'Itolizumab' 'T1h'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ITOLIZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004979', 'MP_0001845', 'EFO_0005809', 'MONDO_0100096',
       'MONDO_0013730', 'EFO_0004599'], dtype=object), 'count': 6}",[ENSG00000013725],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL188952,CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1,PIDSZXPFGCURGN-UHFFFAOYSA-N,Small molecule,False,PIRPROFEN,1987.0,4.0,,True,True,[],"['Pirprofen' 'Racemic pirprofen' 'Rangasil 400' 'Rengasil' 'SU 21524'
 'SU-21524' 'Seflenyl']","[('Wikipedia', array(['Pirprofen'], dtype=object)), ('drugbank', array(['DB13722'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and is indicated for rheumatic disease. It was withdrawn in at least one region.
CHEMBL2104954,COc1cc2c(Nc3ccc(Sc4nccn4C)c(Cl)c3)c(C#N)cnc2cc1N1CCC(N2CCCC2)CC1,CVAKNHIXTWLGJO-UHFFFAOYSA-N,Small molecule,False,BALAMAPIMOD,,2.0,,False,False,[],['Balamapimod' 'MKI-833'],,,,"[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2106419,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1.Cl,WMFYOYKPJLRMJI-UHFFFAOYSA-N,Small molecule,False,LERCANIDIPINE HYDROCHLORIDE,,4.0,CHEMBL250270,False,True,['Zanidip'],['Lercanidipine hcl' 'Lercanidipine hydrochloride' 'REC-15/2375'],"[('PubChem', array(['144206046', '170465587'], dtype=object))]",,,"[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL2108705,,,Unknown,False,ASTUPROTIMUT-R,,3.0,,False,False,[],"['Astuprotimut r' 'Astuprotimut-r' 'GSK-1572932A' 'GSK-249553'
 'GSK1572932A' 'Hp3tut3x8x' 'MAGE-A3' 'Mage a3 protein'
 'Mage a3 recombinant protein' 'Mage-a3 asci'
 'Mage-a3 recombinant protein' 'SB-249553' 'Zastumotide']",,,"{'rows': array(['EFO_0001378', 'EFO_0000389', 'EFO_0000181', 'EFO_0000756',
       'EFO_0003060', 'MONDO_0001187'], dtype=object), 'count': 6}",[ENSG00000221867],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3305985,C=CC[N@@+]12CC[C@@]34c5ccccc5N5/C=C6/[C@H]7C[C@H]8[C@@]9(CC[N@@+]8(CC=C)C/C7=C/CO)c7ccccc7N(/C=C(/[C@@H](C[C@@H]31)/C(=C\CO)C2)[C@H]54)[C@@H]69,MUQUYTSLDVKIOF-CHJKCJHBSA-N,Small molecule,False,ALCURONIUM,,4.0,,False,True,[],"['Alcuronium' 'Alcuronium cation' 'Alcuronium ion' 'Diallylnortoxiferine'
 ""N,n'-diallylnortoxiferinium""]","[('drugbank', array(['DB13648'], dtype=object)), ('chEBI', array(['55313'], dtype=object))]",['CHEMBL3188339'],,[ENSG00000181072],Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL3306918,CC(C)n1c(=O)c(C(=O)NCCCN2CCCCC2)c(O)c2ccsc21,SCHKZZSVELPJKU-UHFFFAOYSA-N,Small molecule,False,PRX-03140,,2.0,,False,False,[],['Prx-03140'],"[('drugbank', array(['DB05596'], dtype=object))]",['CHEMBL3291085'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3334567,C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,XYDNMOZJKOGZLS-NSHDSACASA-N,Small molecule,False,SAVOLITINIB,,3.0,,False,False,[],['AZD-6094' 'AZD6094' 'Azd-6094' 'HMPL-504' 'Savolitinib' 'Volitinib'],"[('drugbank', array(['DB12048'], dtype=object))]",,"{'rows': array(['EFO_0003863', 'EFO_0000313', 'EFO_1000657', 'EFO_0003060',
       'EFO_0000681', 'MONDO_0004992', 'MONDO_0001056', 'EFO_0000503',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_0000640', 'EFO_0000616',
       'EFO_1001951', 'EFO_1001949'], dtype=object), 'count': 14}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.
CHEMBL3545006,,,Small molecule,False,PWT-33587,,1.0,,False,False,[],['Pwt-33587'],,,,"[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545280,Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N,JCYNMRJCUYVDBC-UHFFFAOYSA-N,Small molecule,False,EFATUTAZONE,,2.0,,False,False,[],['Efatutazone' 'Inolitazone'],"[('drugbank', array(['DB11894'], dtype=object))]",['CHEMBL3545279'],"{'rows': array(['MONDO_0004992', 'EFO_1001951', 'EFO_0000616', 'EFO_0000569',
       'EFO_0003060', 'EFO_0001378', 'MONDO_0002108', 'EFO_0000365'],
      dtype=object), 'count': 8}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL3545393,,,Small molecule,False,XL550,,3.0,,False,False,[],['CS-3150' 'Esaxerenone' 'XL-550' 'Xl550'],,,"{'rows': array(['EFO_0000537', 'EFO_0000401', 'MONDO_0001422', 'MONDO_0001134'],
      dtype=object), 'count': 4}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3989516,COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)([O-])[O-])C(=O)C(C)(C)O4)n2)cc(OC)c1OC.O.O.O.O.O.O.[Na+].[Na+],ZQGJCHHKJNSPMS-UHFFFAOYSA-L,Small molecule,False,FOSTAMATINIB DISODIUM,2018.0,4.0,CHEMBL2103830,False,True,['Tavalisse' 'Tavlesse'],"['Fostamatinib disodium' 'Fostamatinib disodium hexahydrate'
 'Fostamatinib disodium salt hexahydrate' 'Fostamatinib sodium hydrate'
 'R-788 SODIUM' 'R-788 SODIUM HYDRATE' 'R-935788 SODIUM'
 'R-935788 SODIUM HYDRATE' 'R788 SODIUM' 'R788 SODIUM HYDRATE'
 'R935788 SODIUM' 'R935788 SODIUM HYDRATE']","[('DailyMed', array(['fostamatinib%20disodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tavlesse'],
      dtype=object))]",,"{'rows': array(['EFO_0007160', 'MONDO_0007915', 'EFO_0000574', 'EFO_0000685',
       'EFO_0004194', 'HP_0001873', 'EFO_1001264'], dtype=object), 'count': 7}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for autoimmune thrombocytopenic purpura and thrombocytopenia and has 5 investigational indications.
CHEMBL4217292,N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1,LSYANGLAZUZYFX-UHFFFAOYSA-N,Small molecule,False,APINOCALTAMIDE,,2.0,,False,False,[],['ACT-709478' 'Act-709478' 'Apinocaltamide'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",['CHEMBL4204434'],"{'rows': array(['MONDO_0015643', 'HP_0001250'], dtype=object), 'count': 2}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297723,,,Antibody,False,CEMIPLIMAB,2018.0,4.0,,False,True,['Libtayo'],['Cemiplimab' 'Cemiplimab rwlc' 'REGN-2810' 'REGN2810' 'Regn2810'],"[('DailyMed', array(['cemiplimab-rwlc'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo'],
      dtype=object))]",,"{'rows': array(['EFO_0000519', 'MONDO_0007254', 'EFO_0000096', 'MONDO_0002158',
       'EFO_1001951', 'EFO_1000026', 'MONDO_0002898', 'EFO_0001378',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000707', 'MONDO_0008903',
       'EFO_0004197', 'EFO_0000764', 'MONDO_0044926', 'MONDO_0002974',
       'EFO_0005537', 'EFO_0006859', 'MONDO_0001187', 'EFO_0004193',
       'EFO_0000616', 'EFO_0000681', 'EFO_0000181', 'EFO_0003085',
       'MONDO_0021063', 'EFO_0000756', 'EFO_0003863', 'EFO_0002618',
       'EFO_0000183', 'MONDO_0008170', 'EFO_1001051', 'MONDO_0008315',
       'EFO_1001471', 'EFO_0009709', 'EFO_0000574', 'EFO_0003968',
       'MONDO_0001056'], dtype=object), 'count': 37}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 31 investigational indications.
CHEMBL4297808,,,Antibody,False,DAZUKIBART,,3.0,,False,False,[],['Dazukibart' 'PF-06823859' 'PF06823859' 'Pf-06823859'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DAZUKIBART/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007915', 'EFO_0000783', 'EFO_0000398', 'EFO_0003834'],
      dtype=object), 'count': 4}",[ENSG00000171855],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4650301,CC(C)[C@H](N)C(=O)NCCCS(=O)(=O)O,NRZRFNYKMSAZBI-ZETCQYMHSA-N,Small molecule,False,VALILTRAMIPROSATE,,3.0,,False,False,[],"['ALZ-801' 'Alz-801' 'BLU-8499' 'BLU8499' 'NRM-8499' 'NRM8499'
 'Valiltramiprosate']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VALILTRAMIPROSATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL495,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,GMVPRGQOIOIIMI-DWKJAMRDSA-N,Small molecule,True,ALPROSTADIL,1981.0,4.0,,False,True,"['Alprostadil' 'Caverject' 'Caverject impulse' 'Edex' 'Prostin vr'
 'Prostin vr pediatric' 'Viridal 10' 'Viridal 20' 'Viridal 5'
 'Viridal duo' 'Vitaros']","['Alprostadil' 'NSC-165559' 'ONO-1608' 'Pge1' 'Prostaglandin e1'
 'U-10,136' 'U-10136']","[('DailyMed', array(['alprostadil'], dtype=object)), ('PubChem', array(['144204033', '49681576'], dtype=object)), ('Wikipedia', array(['Prostaglandin_E1'], dtype=object)), ('drugbank', array(['DB00770'], dtype=object)), ('chEBI', array(['15544'], dtype=object))]",,"{'rows': array(['HP_0001919', 'EFO_0000319', 'MONDO_0008315', 'EFO_0004714',
       'EFO_1000809', 'EFO_0004234', 'EFO_0009606', 'MONDO_0100096',
       'EFO_0003144', 'HP_0001643', 'EFO_0004265', 'EFO_0003875',
       'MONDO_0100130', 'EFO_1000820'], dtype=object), 'count': 14}","[ENSG00000160951,ENSG00000125384]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL502,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,ADEBPBSSDYVVLD-UHFFFAOYSA-N,Small molecule,False,DONEPEZIL,1996.0,4.0,,False,True,[],['Aricept' 'D-797' 'Donaz' 'Donepezil' 'E-2020'],"[('PubChem', array(['50112790'], dtype=object)), ('Wikipedia', array(['Donepezil'], dtype=object)), ('drugbank', array(['DB00843'], dtype=object)), ('chEBI', array(['53289'], dtype=object))]",['CHEMBL2171854' 'CHEMBL1678' 'CHEMBL2337271'],"{'rows': array(['EFO_0000546', 'EFO_0003756', 'HP_0002381', 'HP_0100543',
       'EFO_0009267', 'EFO_0009386', 'MONDO_0005180', 'EFO_0000712',
       'MONDO_0010726', 'EFO_0001064', 'EFO_0004718', 'MONDO_0001020',
       'MONDO_0004992', 'MONDO_0004975', 'EFO_1000158', 'EFO_0009267',
       'MONDO_0002050', 'EFO_0000701', 'MONDO_0004975', 'HP_0000016',
       'MONDO_0005301', 'EFO_0005230', 'MONDO_0005148', 'MONDO_0010383',
       'MONDO_0002050', 'Orphanet_240071', 'EFO_0005762', 'EFO_0003768',
       'HP_0100543', 'EFO_0003758', 'EFO_0005762', 'EFO_0004718',
       'HP_0000726', 'EFO_1001176', 'MONDO_0005090', 'HP_0002140',
       'MONDO_0005277', 'EFO_0002610', 'HP_0000726'], dtype=object), 'count': 39}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for alzheimer disease and dementia and has 33 investigational indications.
CHEMBL5315053,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1.O,NBNBOZLBWLNZHB-ZOWNYOTGSA-N,Small molecule,False,PEMETREXED MONOHYDRATE,2016.0,4.0,CHEMBL225072,False,True,['Armisarte (previously pemetrexed actavis)'],['Armisarte' 'Pemetrexed diacid monohydrate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/armisarte'],
      dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000588'], dtype=object), 'count': 2}","[ENSG00000176890,ENSG00000228716,ENSG00000159131]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for non-small cell lung carcinoma and mesothelioma.
CHEMBL54349,CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12,JRTIDHTUMYMPRU-UHFFFAOYSA-N,Small molecule,False,ALPIDEM,,4.0,,True,True,[],['Alpidem' 'SL 80.0342-00' 'SL-80.0342-00'],"[('PubChem', array(['144207142', '170466634'], dtype=object)), ('Wikipedia', array(['Alpidem'], dtype=object))]",,,[ENSG00000100300],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL564,CN(C)CCCN1c2ccccc2Sc2ccccc21,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,Small molecule,False,PROMAZINE,1956.0,4.0,,False,True,[],['Combelen' 'NSC-31447' 'Promazine'],"[('PubChem', array(['11111651', '11111652', '124881158', '50100325', '50104276',
       '90341344'], dtype=object)), ('Wikipedia', array(['Promazine'], dtype=object)), ('drugbank', array(['DB00420'], dtype=object)), ('chEBI', array(['8459'], dtype=object))]",['CHEMBL1200469'],"{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}","[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for psychosis.
CHEMBL831,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,XJGVXQDUIWGIRW-UHFFFAOYSA-N,Small molecule,True,LOXAPINE,1975.0,4.0,,False,True,['Adasuve'],"['CL 62,362' 'CL-62362' 'Loxapac' 'Loxapine' 'Loxitane' 'SUM 3170'
 'SUM-3170']","[('DailyMed', array(['loxapine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve'],
      dtype=object)), ('PubChem', array(['50103874', '50104024', '50104025', '50104026', '90341467'],
      dtype=object)), ('Wikipedia', array(['Loxapine'], dtype=object)), ('drugbank', array(['DB00408'], dtype=object)), ('chEBI', array(['50841'], dtype=object))]",['CHEMBL1201155' 'CHEMBL1201060'],"{'rows': array(['EFO_0000341', 'HP_0000713', 'MONDO_0005090', 'MONDO_0004979',
       'EFO_0009267', 'MONDO_0005090', 'EFO_0005407', 'EFO_0003768',
       'MONDO_0004985', 'MONDO_0005277', 'EFO_0005762', 'EFO_0009963',
       'EFO_0005230'], dtype=object), 'count': 13}","[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL982,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,WJBLNOPPDWQMCH-MBPVOVBZSA-N,Small molecule,False,NALMEFENE,1995.0,4.0,,False,True,['Selincro'],"['JF-1' 'JKB-121' 'Nalmefene' 'Nalmetrene' 'ORF 1167' 'ORF 11676'
 'ORF-1167' 'ORF-11676' 'Revex' 'SRD-174' 'SRD174']","[('PubChem', array(['144204424', '170465281', '50103951', '855608'], dtype=object)), ('Wikipedia', array(['Nalmefene'], dtype=object)), ('drugbank', array(['DB06230'], dtype=object)), ('chEBI', array(['7457'], dtype=object))]",['CHEMBL5315055' 'CHEMBL1201152'],"{'rows': array(['EFO_0004699', 'EFO_0000274', 'MONDO_0007079', 'MONDO_0007079',
       'EFO_0005611', 'EFO_0004319', 'EFO_1001249', 'MONDO_0007079',
       'EFO_0003890', 'EFO_0003086', 'EFO_0005611'], dtype=object), 'count': 11}","[ENSG00000116329,ENSG00000112038,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for alcohol dependence and has 8 investigational indications.
CHEMBL10878,COc1ccc2cccc(CCNC(C)=O)c2c1,YJYPHIXNFHFHND-UHFFFAOYSA-N,Small molecule,False,AGOMELATINE,2009.0,4.0,,False,True,['Thymanax' 'Valdoxan'],['Agomelatine' 'S-20098' 'S20098' 'Thymanax'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax'],
      dtype=object)), ('PubChem', array(['170466417', '174006904'], dtype=object)), ('Wikipedia', array(['Agomelatine'], dtype=object)), ('drugbank', array(['DB06594'], dtype=object))]",,"{'rows': array(['EFO_0004242', 'MONDO_0002050', 'EFO_0005230', 'MONDO_0002009',
       'HP_0000726', 'MONDO_0005090', 'MONDO_0002009'], dtype=object), 'count': 7}","[ENSG00000168412,ENSG00000134640,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for depressive disorder and major depressive disorder and has 4 investigational indications.
CHEMBL1200550,O=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,DUIGUKRYYAGJAF-UHFFFAOYSA-N,Small molecule,False,ANTAZOLINE PHOSPHATE,1994.0,4.0,CHEMBL1305,False,True,[],['Antazoline phosphate' 'NSC-755865'],"[('PubChem', array(['26747864', '26747865', '50107311', '56422487', '855846'],
      dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994.
CHEMBL1200606,Cc1cccc(C)c1OCC(C)N.Cl,NFEIBWMZVIVJLQ-UHFFFAOYSA-N,Small molecule,True,MEXILETINE HYDROCHLORIDE,1985.0,4.0,CHEMBL558,False,True,['Mexiletine hydrochloride' 'Mexitil' 'Mexitil p.l.' 'Namuscla'],"['KO 1173 CL' 'KO-1173' 'KO-1173 CL' 'KO-1173-CL' 'Katen' 'Mexiletine hcl'
 'Mexiletine hydrochloride' 'NSC-758639']","[('DailyMed', array(['mexiletine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/namuscla'],
      dtype=object)), ('PubChem', array(['144204800', '144204801', '170464740', '26732616', '26747574',
       '50106611'], dtype=object)), ('chEBI', array(['6917'], dtype=object))]",,"{'rows': array(['MONDO_0016120', 'HP_0004308', 'EFO_0009387'], dtype=object), 'count': 3}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for myotonic syndrome and ventricular arrhythmia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1200890,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,MUZQPDBAOYKNLO-RKXJKUSZSA-N,Small molecule,True,OXYCODONE HYDROCHLORIDE,1950.0,4.0,CHEMBL656,True,True,"['Abtard' 'Candox' 'Carexil' 'Dolocodon pr' 'Leveraxo' 'Longtec' 'Lynlor'
 'Oxaydo' 'Oxecta' 'Oxeltra' 'Oxycodone hydrochloride' 'Oxycontin'
 'Oxylan' 'Oxynorm' 'Reltebon' 'Roxicodone' 'Roxybond' 'Shortec'
 'Zomestine']","['Anhydrous oxycodone hydrochloride' 'Endocodone' 'Oxecta' 'Oxycodone hcl'
 'Oxycodone hydrochloride' 'Oxycodone hydrochloride cii']","[('DailyMed', array(['oxycodone%20hydrochloride'], dtype=object)), ('chEBI', array(['7859'], dtype=object))]",,"{'rows': array(['EFO_0003890', 'EFO_0004616', 'HP_0003419', 'EFO_1000786',
       'HP_0012532', 'EFO_0003843'], dtype=object), 'count': 6}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 3 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1201141,CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O,IHHXIUAEPKVVII-ZSCHJXSPSA-N,Small molecule,False,IBUPROFEN LYSINE,2006.0,4.0,CHEMBL521,False,True,"['Feminax express' 'Ibuprofen lysine' 'Neoprofen' 'Nurofen advance'
 'Nurofen max strgth mig pain' 'Nurofen migraine pain'
 'Nurofen tension headache']","['Arfen' 'Dolormin' 'Ibuprofen l-lysine' 'Ibuprofen lysinate'
 'Ibuprofen lysine' 'Imbun' 'Lisiprofen' 'Saren' 'Solufenum' 'Soluphene']","[('DailyMed', array(['ibuprofen%20lysine'], dtype=object))]",,"{'rows': array(['HP_0001643'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006 and is indicated for patent ductus arteriosus.
CHEMBL1201557,,,Protein,True,INTERFERON ALFACON-1,1997.0,4.0,,False,True,['Infergen'],['Interferon alfacon-1' 'Rsifn-co'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/infergen'],
      dtype=object))]",,"{'rows': array(['EFO_0007328', 'MONDO_0100096', 'EFO_0000616', 'EFO_0003047',
       'EFO_0004220'], dtype=object), 'count': 5}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for neoplasm and chronic hepatitis c virus infection and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201571,,,Protein,False,ALEFACEPT,2003.0,4.0,,False,True,['Amevive'],"['Alefacept' 'BG-9273' 'BG-9712' 'BG9273' 'BG9712'
 'Human lfa-3igg fusion protein' 'LFA-3CD2' 'LFA-3TIP' 'LFA3TIP']","[('DrugCentral', array(['5088'], dtype=object)), ('Wikipedia', array(['Alefacept'], dtype=object))]",,"{'rows': array(['EFO_0000540', 'EFO_1000726', 'EFO_0000676', 'MONDO_0020547',
       'MONDO_0005147', 'MONDO_0015597', 'EFO_0000574', 'HP_0001915',
       'EFO_1002048', 'EFO_0003778'], dtype=object), 'count': 10}",[ENSG00000116824],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for immune system disease and has 9 investigational indications.
CHEMBL1201619,,,Unknown,False,APROTININ,1993.0,4.0,,True,True,['Trasylol'],"['Aprotinin' 'Aprotinin (bovine)' 'Aprotinin (synthetic)'
 'Aprotinin biosynthetic' 'Aprotinin bovine'
 'Aprotinin concentrated solution' 'BAYER A 128' 'BAYER-A-128'
 'BAYERA-128' 'Bovine aprotinin' 'Fibrinolysis inhibitor' 'RIKER 52G'
 'RIKER-52G' 'RP 9921' 'RP-9921']","[('DrugCentral', array(['4839'], dtype=object)), ('Wikipedia', array(['Aprotinin'], dtype=object))]",,"{'rows': array(['EFO_0000278', 'MONDO_0007254', 'MP_0001914'], dtype=object), 'count': 3}","[ENSG00000122194,ENSG00000164344]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for hemorrhage and has 2 investigational indications. It was withdrawn in at least one region.
CHEMBL190461,C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,QHMBSVQNZZTUGM-ZWKOTPCHSA-N,Small molecule,False,CANNABIDIOL,2018.0,4.0,,False,True,['Epidiolex' 'Epidyolex'],"['(-)-cannabidiol' '(-)-cbd' '(-)-trans-cannabidiol'
 '.delta.1(2)-trans-cannabidiol' 'BTX-1204' 'BTX-1503' 'CBD' 'Cannabidiol'
 'Cannabidiol solution' 'Cardiolrx' 'GWP-42003' 'GWP-42003-P' 'GWP42003'
 'GWP42003-P']","[('DailyMed', array(['cannabidiol'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex'],
      dtype=object)), ('drugbank', array(['DB09061'], dtype=object)), ('chEBI', array(['69478'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'EFO_0005762', 'MONDO_0007739', 'EFO_1001917',
       'EFO_0000474', 'MONDO_0008300', 'EFO_0000519', 'HP_0002829',
       'EFO_0005230', 'MONDO_0004976', 'EFO_0004242', 'MONDO_0010726',
       'EFO_0005411', 'EFO_0008507', 'MONDO_0005351', 'EFO_0001358',
       'EFO_0010072', 'EFO_0003756', 'EFO_0010702', 'EFO_0000384',
       'EFO_0008526', 'EFO_0007427', 'HP_0001249', 'EFO_0004599',
       'HP_0001397', 'EFO_0005676', 'MONDO_0011728', 'EFO_0000764',
       'EFO_1000783', 'EFO_0002610', 'EFO_0003843', 'EFO_0007191',
       'MONDO_0013730', 'MONDO_0008501', 'MONDO_0005090', 'EFO_0003108',
       'MONDO_0002959', 'EFO_0005407', 'HP_0100543', 'EFO_0003778',
       'HP_0000938', 'EFO_0003890', 'MONDO_0016532', 'EFO_0000180',
       'MONDO_0010826', 'EFO_0003758', 'HP_0012532', 'MONDO_0100062',
       'HP_0012167', 'MONDO_0018097', 'Orphanet_93955', 'EFO_0000537',
       'MONDO_0005277', 'EFO_0000546', 'EFO_0000673', 'MONDO_0007079',
       'EFO_0008568', 'EFO_0000729', 'EFO_0004698', 'EFO_0004616',
       'EFO_0005611', 'EFO_0005687', 'EFO_0003086', 'MONDO_0010383',
       'EFO_1000634', 'MONDO_0008903', 'HP_0001250', 'MONDO_0007254',
       'EFO_0003100', 'EFO_0000616', 'EFO_0004895', 'MONDO_0004985',
       'EFO_0009609', 'EFO_0003768', 'MONDO_0100096', 'EFO_0003144'],
      dtype=object), 'count': 76}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 71 investigational indications.
CHEMBL2103875,CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,LIRYPHYGHXZJBZ-UHFFFAOYSA-N,Small molecule,False,TRAMETINIB,2013.0,4.0,,False,True,['Mekinist'],"['GSK-1120212' 'GSK1120212' 'JTP 74057' 'JTP-74057' 'TMT-212' 'TMT212'
 'Tmt212' 'Trametinib']","[('PubChem', array(['137276024'], dtype=object)), ('drugbank', array(['DB08911'], dtype=object)), ('chEBI', array(['75998'], dtype=object))]",,"{'rows': array(['MONDO_0011719', 'MONDO_0008315', 'EFO_0002618', 'EFO_1000926',
       'MONDO_0015523', 'EFO_0000196', 'EFO_1000657', 'EFO_0000182',
       'EFO_0000222', 'MONDO_0004976', 'MONDO_0100342', 'MONDO_0008903',
       'EFO_0000565', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000756',
       'EFO_0001378', 'MONDO_0017795', 'EFO_0002617', 'EFO_1001968',
       'EFO_0005221', 'EFO_1001951', 'MONDO_0021063', 'EFO_1000209',
       'HP_0100727', 'EFO_0003868', 'MONDO_0002974', 'MONDO_0005184',
       'EFO_1000849', 'EFO_1000760', 'MONDO_0007254', 'EFO_0000571',
       'MONDO_0001056', 'EFO_0005537', 'EFO_0000616', 'EFO_0000389',
       'EFO_0000501', 'EFO_0000641', 'MONDO_0002108', 'MONDO_0016642',
       'EFO_0000365', 'EFO_0006772'], dtype=object), 'count': 42}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 42 investigational indications.
CHEMBL2111097,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl,HTIQEAQVCYTUBX-KRWDZBQOSA-N,Small molecule,False,LEVAMLODIPINE,2019.0,4.0,,False,True,[],"['Amlodipine, (s)-' 'Levamlodipine' 'S-amlodipine']","[('drugbank', array(['DB09237'], dtype=object)), ('chEBI', array(['53796'], dtype=object))]",['CHEMBL2107350' 'CHEMBL4594288'],"{'rows': array(['EFO_0000537', 'EFO_0000537', 'EFO_0000319', 'EFO_0000537'],
      dtype=object), 'count': 4}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for cardiovascular disease and hypertension and has 2 investigational indications.
CHEMBL219916,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,FGXWKSZFVQUSTL-UHFFFAOYSA-N,Small molecule,False,DOMPERIDONE,,4.0,,False,True,"['Domilium' 'Evoxin' 'Motilium' 'Motilium 10' 'Motilium instants'
 'Vivadone']","['Domperidone' 'NSC-299589' 'NSC-759575' 'R 33,812' 'R-33812']","[('PubChem', array(['11111029', '124878657', '124878660', '124878661', '124878664',
       '144203607', '147912', '170465594', '174006911', '26746912',
       '26746913', '26751449', '4254117', '46500486', '50103922',
       '50103923', '50103924', '50103925', '50109475', '85230869',
       '855562', '90341791'], dtype=object)), ('Wikipedia', array(['Domperidone'], dtype=object)), ('drugbank', array(['DB01184'], dtype=object)), ('chEBI', array(['31515'], dtype=object))]",['CHEMBL4594380' 'CHEMBL3436365'],"{'rows': array(['EFO_0003948', 'MONDO_0005180', 'EFO_0003917', 'EFO_1000948',
       'EFO_0003929', 'EFO_0003840', 'EFO_1000948', 'EFO_0008533',
       'EFO_1001463', 'EFO_0010282'], dtype=object), 'count': 10}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and has 9 investigational indications.
CHEMBL22055,CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1,UCQSBGOFELXYIN-UHFFFAOYSA-N,Small molecule,False,SUFUGOLIX,,2.0,,False,False,[],['Sufugolix' 'TAK-013' 'Tak-013'],"[('drugbank', array(['DB06494'], dtype=object))]",,,[ENSG00000109163],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2387080,Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1,BEUQXVWXFDOSAQ-UHFFFAOYSA-N,Small molecule,False,TASELISIB,,3.0,,False,False,[],['GDC-0032' 'RG-7604' 'Taselisib'],"[('drugbank', array(['DB12108'], dtype=object))]",,"{'rows': array(['MONDO_0008903', 'EFO_0000708', 'EFO_0005952', 'MONDO_0007254',
       'EFO_0005537', 'EFO_0001378'], dtype=object), 'count': 6}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL313006,CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1,YZQLWPMZQVHJED-UHFFFAOYSA-N,Small molecule,False,DALCETRAPIB,,3.0,,False,False,[],['Dalcetrapib' 'JTT-705' 'RO-4607381' 'RO4607381'],"[('Wikipedia', array(['Dalcetrapib'], dtype=object)), ('drugbank', array(['DB12181'], dtype=object))]",,"{'rows': array(['EFO_0005672', 'MONDO_0100096', 'EFO_0000319', 'EFO_0001645',
       'MONDO_0021187', 'EFO_0004265', 'Orphanet_309005', 'HP_0003119'],
      dtype=object), 'count': 8}",[ENSG00000087237],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL3545249,,,Small molecule,False,GLPG-0555,,1.0,,False,False,[],['Glpg-0555'],,,,[ENSG00000162434],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3940890,Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F,WBFUHHBPNXWNCC-UHFFFAOYSA-N,Small molecule,False,ACORAMIDIS,,3.0,,False,False,[],['AG-10' 'AG10' 'Acoramidis'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ACORAMIDIS/relevant/1/'],
      dtype=object))]",['CHEMBL4650226'],"{'rows': array(['EFO_0004129', 'EFO_1001875', 'EFO_0004129'], dtype=object), 'count': 3}",[ENSG00000118271],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3989968,CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1,VFBILHPIHUPBPZ-UHFFFAOYSA-N,Small molecule,False,DIFAMILAST,,3.0,,False,False,[],['Difamilast' 'OPA-15406'],"[('drugbank', array(['DB14987'], dtype=object))]",,"{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297762,,,Oligonucleotide,False,GOLODIRSEN,2019.0,4.0,,False,True,['Vyondys 53'],['Golodirsen' 'NG-12-0163' 'SRP-4053'],"[('DailyMed', array(['golodirsen'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GOLODIRSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0020121', 'MONDO_0010679'], dtype=object), 'count': 2}",[ENSG00000198947],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for muscular dystrophy and duchenne muscular dystrophy.
CHEMBL451930,CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,UUSZLLQJYRSZIS-LXNNNBEUSA-N,Small molecule,False,PLITIDEPSIN,,3.0,,False,False,[],['Aplidine' 'Plitidepsin'],"[('drugbank', array(['DB04977'], dtype=object)), ('chEBI', array(['90205'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000616', 'MONDO_0044903', 'EFO_0001378',
       'EFO_0000574', 'EFO_0003085', 'MONDO_0100096'], dtype=object), 'count': 7}",[ENSG00000101210],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4650492,,,Antibody,False,UNASNEMAB,,2.0,,False,False,[],['MT-3921' 'MT3921' 'Mt-3921' 'Unasnemab' 'rH116A3'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/UNASNEMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001919'], dtype=object), 'count': 1}",[ENSG00000182175],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL490029,CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,STWITCBWQHTJFJ-XMMPIXPASA-N,Small molecule,False,MK-0533,,2.0,,False,False,[],['MK-0533' 'MK0533' 'Mk-0533'],"[('drugbank', array(['DB15242'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL531,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,YEHCICAEULNIGD-MZMPZRCHSA-N,Small molecule,False,PERGOLIDE,1988.0,4.0,,True,True,[],['Pergolide'],"[('PubChem', array(['104171354', '26754330', '26754331', '90341767'], dtype=object)), ('Wikipedia', array(['Pergolide'], dtype=object)), ('drugbank', array(['DB01186'], dtype=object)), ('chEBI', array(['63617'], dtype=object))]",['CHEMBL1275'],"{'rows': array(['MONDO_0005180', 'EFO_0002610'], dtype=object), 'count': 2}","[ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for parkinson disease and has 1 investigational indication. It was withdrawn in at least one region.
CHEMBL60889,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,YPELFRMCRYSPKZ-UHFFFAOYSA-N,Small molecule,False,MOSAPRIDE,,3.0,,False,False,[],['Mosapride' 'Mosart'],"[('PubChem', array(['174006284', '29216210', '50110109'], dtype=object)), ('Wikipedia', array(['Mosapride'], dtype=object)), ('drugbank', array(['DB11675'], dtype=object))]",['CHEMBL1733174'],"{'rows': array(['MONDO_0004567', 'EFO_0010282', 'EFO_0008533', 'HP_0002014',
       'EFO_0000555', 'EFO_0008533', 'EFO_0000217', 'HP_0002019'],
      dtype=object), 'count': 8}","[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084,ENSG00000164270]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL623,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1,VRBKIVRKKCLPHA-UHFFFAOYSA-N,Small molecule,True,NEFAZODONE,1994.0,4.0,,True,True,[],['Nefazodone'],"[('PubChem', array(['29217604', '49666410', '50111710'], dtype=object)), ('Wikipedia', array(['Nefazodone'], dtype=object)), ('drugbank', array(['DB01149'], dtype=object)), ('chEBI', array(['7494'], dtype=object))]",['CHEMBL1200492'],"{'rows': array(['EFO_0007191', 'EFO_0002610', 'MONDO_0002009', 'MONDO_0002009'],
      dtype=object), 'count': 4}","[ENSG00000108576,ENSG00000147246,ENSG00000103546,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL697,CN1C(=O)CC(C)(c2ccccc2)C1=O,AJXPJJZHWIXJCJ-UHFFFAOYSA-N,Small molecule,False,METHSUXIMIDE,1957.0,4.0,,False,True,['Celontin'],['Mesuximide' 'Methsuximide' 'NSC-760075'],"[('DailyMed', array(['methsuximide'], dtype=object)), ('PubChem', array(['144207162'], dtype=object)), ('Wikipedia', array(['Mesuximide'], dtype=object)), ('drugbank', array(['DB05246'], dtype=object))]",,"{'rows': array(['HP_0001250', 'EFO_0000474'], dtype=object), 'count': 2}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for seizure and epilepsy.
CHEMBL765,N=C(N)NCCN1CCCCCCC1,ACGDKVXYNVEAGU-UHFFFAOYSA-N,Small molecule,False,GUANETHIDINE,1960.0,4.0,,False,True,[],['Esimil' 'Guanethidine' 'Ismelin'],"[('PubChem', array(['11112157'], dtype=object)), ('Wikipedia', array(['Guanethidine'], dtype=object)), ('drugbank', array(['DB01170'], dtype=object)), ('chEBI', array(['5557'], dtype=object))]",['CHEMBL2051958' 'CHEMBL1345' 'CHEMBL3560112'],"{'rows': array(['EFO_0000537', 'MONDO_0005041'], dtype=object), 'count': 2}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for hypertension and glaucoma.
CHEMBL114551,CC(=N)NCCSCC[C@H](N)C(=O)O,MOLOJNHYNHBPCW-ZETCQYMHSA-N,Small molecule,False,GW-274150,,2.0,,False,False,[],['GW274150' 'Gw-274150'],"[('drugbank', array(['DB12237'], dtype=object))]",,"{'rows': array(['MONDO_0005277', 'EFO_0000685', 'MONDO_0004979'], dtype=object), 'count': 3}",[ENSG00000007171],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1200514,CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1.[Br-].[Br-],YHKBUDZECQDYBR-UHFFFAOYSA-L,Small molecule,False,DEMECARIUM BROMIDE,1959.0,4.0,CHEMBL1201229,False,True,['Humorsol' 'Tosmilen'],['BC-48' 'Demecarium bromide' 'Demekastigmine bromide'],"[('PubChem', array(['57265778'], dtype=object)), ('Wikipedia', array(['Demecarium_bromide'], dtype=object)), ('chEBI', array(['4391'], dtype=object))]",,,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959.
CHEMBL1201142,C#CCN[C@@H]1CCc2ccccc21.CS(=O)(=O)O,JDBJJCWRXSVHOQ-UTONKHPSSA-N,Small molecule,False,RASAGILINE MESYLATE,2006.0,4.0,CHEMBL887,False,True,['Azilect' 'Rasagiline mesylate'],"['Agilect' 'Azilect' 'Rasagiline (as mesilate)' 'Rasagiline mesilate'
 'Rasagiline mesylate' 'Rasagline ratiopharm' 'TVP-1012']","[('DailyMed', array(['rasagiline%20mesylate'], dtype=object)), ('PubChem', array(['144206188', '170465410'], dtype=object))]",,"{'rows': array(['EFO_1001050', 'MONDO_0005180'], dtype=object), 'count': 2}",[ENSG00000069535],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for parkinson disease and has 1 investigational indication.
CHEMBL1201657,,,Oligosaccharide,False,HEPARIN SODIUM,1939.0,4.0,,False,True,"['Heparin lock flush' 'Heparin sodium' 'Heparin sodium preservative free'
 'Lipo-hepin' 'Liquaemin lock flush' 'Liquaemin sodium'
 'Liquaemin sodium preservative free' 'Multiparin' 'Panheprin' 'Pump-hep'
 'Sodium heparin' 'Thrombophob' 'Unihep' 'Uniparin' 'Uniparin fte']","['Crude heparin' 'Crude heparin porcine' 'Heparin sodium'
 'Heparin sodium porcine' 'Heparin sodium unfractionated'
 'Heparin sodium, porcine' 'Heparinum natricum' 'Liquemin sodium'
 'S01XA14']","[('DailyMed', array(['heparin%20sodium'], dtype=object))]",,"{'rows': array(['MONDO_0005147', 'HP_0000083', 'EFO_0001645', 'HP_0004936',
       'EFO_0003964', 'EFO_0003106', 'EFO_0000668', 'HP_0001907',
       'EFO_1000985', 'MONDO_0004992', 'EFO_1001904', 'EFO_0003103',
       'EFO_0002950', 'EFO_0000712', 'EFO_0003033', 'EFO_0000365',
       'EFO_0004610', 'EFO_0003907', 'EFO_0008507', 'EFO_0000713',
       'EFO_0000612', 'MONDO_0002243', 'EFO_0003777', 'EFO_0001073',
       'HP_0001919', 'EFO_0000616', 'EFO_1000637', 'EFO_0008585',
       'MP_0001914', 'EFO_0006834', 'EFO_0000319', 'HP_0100806',
       'EFO_1001129', 'HP_0031273', 'EFO_0000275', 'HP_0004418',
       'EFO_0003913', 'EFO_1001375', 'EFO_0003884', 'EFO_0004286',
       'EFO_0003827', 'EFO_0000546', 'MONDO_0021148', 'MONDO_0100096',
       'EFO_1001951', 'EFO_0000544', 'EFO_0000266', 'EFO_0003060',
       'MONDO_0005148', 'EFO_0008583', 'EFO_0000771', 'EFO_1002048',
       'EFO_0009516', 'EFO_0000545', 'EFO_0000694', 'MONDO_0000831',
       'EFO_0005672'], dtype=object), 'count': 57}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 5 approved and 52 investigational indications.
CHEMBL1269025,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,HGVDHZBSSITLCT-JLJPHGGASA-N,Small molecule,True,EDOXABAN,2015.0,4.0,,False,True,['Lixiana'],['DU-176' 'Edoxaban'],"[('drugbank', array(['DB09075'], dtype=object)), ('chEBI', array(['85973'], dtype=object))]",['CHEMBL3542264' 'CHEMBL2105682'],"{'rows': array(['EFO_0004286', 'EFO_0004265', 'EFO_0003827', 'EFO_0000712',
       'EFO_0008583', 'EFO_0000266', 'EFO_0000694', 'EFO_0009314',
       'EFO_0000275', 'HP_0004419', 'MONDO_0100096', 'EFO_0001645',
       'MP_0001914', 'EFO_0003907', 'EFO_0000712', 'EFO_0003777',
       'MONDO_0000831', 'EFO_0001422', 'EFO_0004286', 'HP_0002140',
       'EFO_0000275'], dtype=object), 'count': 21}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 15 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1705,Cl.Clc1cccc(Cl)c1NC1=NCCN1,ZNIFSRGNXRYGHF-UHFFFAOYSA-N,Small molecule,True,CLONIDINE HYDROCHLORIDE,1974.0,4.0,CHEMBL134,False,True,"['Catapres' 'Catapres p.l.' 'Catapres tts 1' 'Catapres tts 2'
 'Catapres tts 3' 'Clonidine hydrochloride' 'Dixarit' 'Duraclon' 'Jenloga'
 'Kapvay']","['Clonidine hcl' 'Clonidine hydrochloride' 'Dichloranilino imidazolin'
 'NSC-756699' 'ST-155']","[('DailyMed', array(['clonidine%20hydrochloride'], dtype=object)), ('PubChem', array(['144211869', '26719783', '50106022'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0000537', 'EFO_0003888'], dtype=object), 'count': 3}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for hypertension and attention deficit hyperactivity disorder and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1742990,,,Protein,True,BELATACEPT,2011.0,4.0,,False,True,['Nujolix' 'Nulojix'],['BMS-224818' 'Belatacept' 'LEA29Y'],"[('DailyMed', array(['belatacept'], dtype=object)), ('DrugCentral', array(['5091'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix'],
      dtype=object))]",,"{'rows': array(['EFO_0010134', 'HP_0000093', 'EFO_0000540', 'EFO_0004599',
       'EFO_0000685', 'EFO_0003884', 'MONDO_0005147'], dtype=object), 'count': 7}","[ENSG00000121594,ENSG00000114013]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for kidney transplant and immune system disease and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL184999,CC(C)OC(=O)CCC/C=C\CC[C@H]1[C@@H](O)CO[C@@H]1/C=C/[C@@H](O)COc1cccc(Cl)c1,SGNMBLPAWMQIHK-LYTYUWFYSA-N,Small molecule,False,AL-12182,,2.0,,False,False,[],['AL-12182' 'Al-12182'],,,,[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL185073,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1,GVEAYVLWDAFXET-XGHATYIMSA-N,Small molecule,False,PANCURONIUM,1972.0,4.0,,False,True,[],['Pancuronium' 'Pavulon'],"[('PubChem', array(['50104094', '90341747'], dtype=object)), ('Wikipedia', array(['Pancuronium_bromide'], dtype=object)), ('drugbank', array(['DB01337'], dtype=object)), ('chEBI', array(['7907'], dtype=object))]",['CHEMBL1200757'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972.
CHEMBL2028665,CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O,UAOCLDQAQNNEAX-ABMICEGHSA-N,Small molecule,False,REMOGLIFLOZIN ETABONATE,,2.0,,False,False,[],"['BHV-091009' 'GSK-189075' 'GSK-189075A' 'GSK189075A' 'Gsk189075'
 'Remogliflozin etabonate']","[('drugbank', array(['DB12935'], dtype=object))]",,"{'rows': array(['MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2095206,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O,BXPOSPOKHGNMEP-UHFFFAOYSA-N,Small molecule,False,BOSUTINIB MONOHYDRATE,2012.0,4.0,CHEMBL288441,False,True,['Bosulif'],['Bosutinib (as monohydrate)' 'Bosutinib hydrate'],"[('DailyMed', array(['bosutinib%20monohydrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif'],
      dtype=object)), ('chEBI', array(['68533'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'MONDO_0004643', 'EFO_0000339'], dtype=object), 'count': 3}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for myeloid leukemia and chronic myelogenous leukemia and has 1 investigational indication.
CHEMBL2103864,CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1.O,AFTCWZSEWTXWTL-BTQNPOSSSA-N,Small molecule,False,NAVARIXIN,,2.0,CHEMBL216981,False,False,[],"['Mk-7123' 'Navarixin' 'Navarixin monohydrate' 'PS291822' 'SCH 527123'
 'SCH527123']",,,,"[ENSG00000180871,ENSG00000163464]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2111290,,,Protein,False,TESAMORELIN ACETATE,2010.0,4.0,CHEMBL1237026,False,True,['Egrifta'],['TH9507' 'Tesamorelin acetate'],,,"{'rows': array(['EFO_1001348'], dtype=object), 'count': 1}",[ENSG00000106128],Protein drug with a maximum clinical trial phase of IV that was first approved in 2010 and is indicated for hiv-associated lipodystrophy syndrome.
CHEMBL218166,O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1,CYGODHVAJQTCBG-UHFFFAOYSA-N,Small molecule,False,BIFEPRUNOX,,3.0,,False,False,[],['Bifeprunox'],"[('Wikipedia', array(['Bifeprunox'], dtype=object)), ('drugbank', array(['DB04888'], dtype=object))]",['CHEMBL2107317'],"{'rows': array(['MONDO_0004985', 'MONDO_0005090', 'EFO_0009963', 'MONDO_0004975',
       'MONDO_0002050', 'EFO_0005411'], dtype=object), 'count': 6}","[ENSG00000178394,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3544974,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,GMDCDXMAFMEDAG-BTJKTKAUSA-N,Small molecule,True,ASENAPINE MALEATE,2009.0,4.0,CHEMBL3187365,False,True,['Saphris' 'Sycrest'],['Asenapine (as maleate)' 'Asenapine maleate' 'ORG 5222' 'ORG-5222'],"[('DailyMed', array(['asenapine%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest'],
      dtype=object)), ('drugbank', array(['DB06216'], dtype=object))]",,"{'rows': array(['MONDO_0005090', 'HP_0025268', 'EFO_0005407', 'EFO_0005411',
       'EFO_0009963', 'MONDO_0004985'], dtype=object), 'count': 6}","[ENSG00000149295,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545004,,,Small molecule,False,PL-225B,,1.0,,False,False,[],['Pl-225b'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000140443],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545071,,,Antibody,False,SERIBANTUMAB,,2.0,,False,False,[],['MM121' 'SAR256212' 'Seribantumab'],,,"{'rows': array(['MONDO_0007254', 'EFO_0002618'], dtype=object), 'count': 2}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545085,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1,ALKJNCZNEOTEMP-UHFFFAOYSA-N,Small molecule,False,XL-228,,1.0,,False,False,[],['Exel-2280' 'XL228' 'Xl-228'],,,"{'rows': array(['MONDO_0004992', 'EFO_0000220', 'EFO_0000574', 'EFO_0000339'],
      dtype=object), 'count': 4}","[ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000140443,ENSG00000097007]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL3545298,,,Small molecule,False,AZD-6918,,1.0,,False,False,[],['Azd-6918'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000198400,ENSG00000148053,ENSG00000140538]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3707319,,,Small molecule,False,GRC-15300,,2.0,,False,False,[],['Grc-15300' 'SAR-292833'],,,"{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}",[ENSG00000167723],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3833308,,,Antibody,False,LITIFILIMAB,,3.0,,False,False,[],"['24F4A' 'BIIB-059' 'BIIB059' 'Biib 059' 'Biib059' 'Litifilimab'
 'anti-BDCA2']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LITIFILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003834', 'MONDO_0007915', 'EFO_0005809'], dtype=object), 'count': 3}",[ENSG00000198178],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3984425,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1,XUMALORDVCFWKV-IBGZPJMESA-N,Small molecule,False,EGANELISIB,,2.0,,False,False,[],['Eganelisib' 'IPI-549' 'Ipi-549' 'Pi3k-gamma inhibitor ipi-549'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EGANELISIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000105851],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297220,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1,HGCOOPLEWPBLOY-PFEQFJNWSA-N,Small molecule,False,ASCIMINIB HYDROCHLORIDE,2021.0,4.0,CHEMBL4208229,False,True,['Scemblix'],['ABL001-AAA' 'Asciminib hydrochloride' 'Scemblix'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix'],
      dtype=object))]",,"{'rows': array(['EFO_1000131', 'EFO_0000339'], dtype=object), 'count': 2}","[ENSG00000097007,ENSG00000186716]","Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for blast phase chronic myelogenous leukemia, bcr-abl1 positive and chronic myelogenous leukemia."
CHEMBL4297326,COc1cccc(C(=O)Nc2ccc3c(c2)CCN(C(=O)Oc2ccccc2)C3)c1-c1ccc(C(F)(F)F)cc1,AZUIUVJESCFSLJ-UHFFFAOYSA-N,Small molecule,False,SLX-4090,,2.0,,False,False,[],['KD-026' 'Slx-4090'],"[('drugbank', array(['DB05678'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'Orphanet_411', 'EFO_0004211', 'MONDO_0021187'],
      dtype=object), 'count': 4}","[ENSG00000138823,ENSG00000185624]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297741,,,Unknown,False,DASIGLUCAGON,,3.0,,False,False,[],['Dasiglucagon' 'ZP-4207' 'ZP-GA-1' 'ZP4207'],,,"{'rows': array(['MONDO_0005147', 'EFO_0007318', 'MONDO_0017182', 'HP_0001943'],
      dtype=object), 'count': 4}",[ENSG00000215644],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297820,,,Antibody,False,ROZANOLIXIZUMAB,2023.0,4.0,,False,True,['Rystiggo'],['Rozanolixizumab' 'UCB-7665' 'UCB7665' 'Ucb7665'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROZANOLIXIZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0007160', 'HP_0001873', 'EFO_1000868', 'EFO_0005687',
       'EFO_0004991'], dtype=object), 'count': 5}",[ENSG00000104870],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for myasthenia gravis and has 4 investigational indications.
CHEMBL4298050,,,Antibody,False,TIRAGOLUMAB,,3.0,,False,False,[],"['MTIG-7192A' 'MTIG7192A' 'Mtig 7192a' 'Mtig7192a' 'RG-6058' 'RG6058'
 'RO-7092284' 'RO7092284' 'Tiragolumab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIRAGOLUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0018906', 'MONDO_0004992', 'MONDO_0002974', 'EFO_1000657',
       'EFO_1001513', 'EFO_0000616', 'EFO_0000707', 'EFO_0000702',
       'EFO_0000756', 'EFO_0008528', 'EFO_0000181', 'EFO_0005537',
       'EFO_0003060', 'MONDO_0001187', 'EFO_0005922', 'EFO_0000199',
       'EFO_0000681', 'MONDO_0011962', 'EFO_0000503', 'EFO_0000182',
       'EFO_0002916', 'EFO_0000389', 'EFO_0003863', 'MONDO_0007576'],
      dtype=object), 'count': 24}",[ENSG00000181847],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.
CHEMBL4298089,,,Antibody,False,CODRITUZUMAB,,2.0,,False,False,[],['Codrituzumab' 'GC-33' 'GC33' 'RG-7686' 'RO5137382' 'Ro5137382'],,,"{'rows': array(['EFO_0000616', 'EFO_0000182'], dtype=object), 'count': 2}",[ENSG00000147257],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594385,,,Antibody,False,ASTEGOLIMAB,,3.0,,False,False,[],"['AMG-282' 'AMG282' 'Astegolimab' 'MSTT-1041A' 'MSTT1041A' 'Mstt1041a'
 'RG-6149' 'RG6149' 'RO-7187807']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ASTEGOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0000341', 'MONDO_0100096', 'EFO_0000274'],
      dtype=object), 'count': 4}","[ENSG00000196083,ENSG00000115602]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL5095303,,,Oligonucleotide,False,VUTRISIRAN SODIUM,2022.0,4.0,,False,True,['Amvuttra'],['ALN-TTRSC02' 'Amvuttra' 'Votrisiran sodium'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra'],
      dtype=object))]",,"{'rows': array(['EFO_0004129', 'EFO_0009562'], dtype=object), 'count': 2}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for familial amyloid neuropathy and polyneuropathy.
CHEMBL560993,Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O,FATGTHLOZSXOBC-UHFFFAOYSA-N,Small molecule,False,TIMAPIPRANT,,3.0,,False,False,[],"['CHF-6532' 'OC-000459' 'OC000459' 'OC459' 'Oc-459' 'Oc000459' 'Odc-9101'
 'Timapiprant']","[('drugbank', array(['DB11900'], dtype=object))]",,"{'rows': array(['EFO_0000274', 'EFO_0005854', 'EFO_0004232', 'MONDO_0004979'],
      dtype=object), 'count': 4}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL970,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F,WYCLKVQLVUQKNZ-UHFFFAOYSA-N,Small molecule,False,HALAZEPAM,1981.0,4.0,,False,True,['Paxipam'],['Halazepam' 'Halazepam civ' 'SCH 12041' 'SCH-12041'],"[('Wikipedia', array(['Halazepam'], dtype=object)), ('drugbank', array(['DB00801'], dtype=object))]",,"{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and is indicated for anxiety.
CHEMBL1096380,CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,UNRCMCRRFYFGFX-TYPNBTCFSA-N,Small molecule,False,PLINABULIN,,3.0,,False,False,[],['NPI-2358' 'Plinabulin'],"[('drugbank', array(['DB05992'], dtype=object))]",['CHEMBL4063810'],"{'rows': array(['EFO_0001378', 'MONDO_0001475', 'EFO_0003060', 'MONDO_0004992',
       'EFO_0000702'], dtype=object), 'count': 5}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL1198857,OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,DAFYYTQWSAWIGS-DEOSSOPVSA-N,Small molecule,False,VILANTEROL,2013.0,4.0,,False,True,[],['GW-642444' 'GW-642444X' 'GW642444' 'GW642444X' 'Vilanterol'],"[('drugbank', array(['DB09082'], dtype=object)), ('chEBI', array(['75037'], dtype=object))]",['CHEMBL1084172' 'CHEMBL1084647'],"{'rows': array(['EFO_0000341', 'EFO_0000464', 'MONDO_0004979', 'MONDO_0004979',
       'EFO_0000341', 'EFO_0006505'], dtype=object), 'count': 6}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 2 investigational indications.
CHEMBL1200322,CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,KTGRHKOEFSJQNS-BDQAORGHSA-N,Small molecule,True,ESCITALOPRAM OXALATE,2002.0,4.0,CHEMBL1508,False,True,['Escitalopram oxalate' 'Lexapro'],"['Citalopram oxalate, (s)-' 'Escitalopram (as oxalate)'
 'Escitalopram oxalate' 'LU 26-054-0' 'LU-26-054-0' 'LU-26-054-O'
 'NSC-758934']","[('DailyMed', array(['escitalopram%20oxalate'], dtype=object)), ('PubChem', array(['144205088', '170465453', '26749920', '49681820'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_1001919', 'EFO_0004262', 'EFO_0006788',
       'MONDO_0002009', 'EFO_0000555', 'EFO_1001892', 'MONDO_0002050'],
      dtype=object), 'count': 8}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200409,CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl.O,YECIFGHRMFEPJK-UHFFFAOYSA-N,Small molecule,True,LIDOCAINE HYDROCHLORIDE,1948.0,4.0,CHEMBL79,False,True,"['Akten' 'Alphacaine hydrochloride' 'Anestacon' 'Anodesyn' 'Bismodyne'
 'Bradosol plus' 'Calgel' 'Co-phenylcaine fte' 'Denela' 'Dequaspray'
 'Emla' 'Germoloids' 'Germoloids complete' 'Glydo' 'Hemocane' 'Iglu'
 'Instillagel' 'Laryng-o-jet kit' 'Laryngojet'
 'Laryngotracheal anesthesia kit' 'Lido hcl' 'Lidocaine hydrochloride'
 'Lidocaine hydrochloride preservative free'
 'Lidocaine hydrochloride viscous' 'Lidocaine viscous' 'Lidocaton'
 'Lidopen' 'Lignokent' 'Lignospan special' 'Lignostab' 'Lignostab a 100'
 'Lignostab n' 'Lignostab-a' 'Lta ii kit' 'Medijel' 'Oragard'
 'Pediatric lta kit' 'Preparation h' 'Rexocaine' 'Versatis' 'Xylocaine'
 'Xylocaine dental' 'Xylocaine preservative free' 'Xylocaine viscous'
 'Xylotox e80' 'Zingo']","['Anhydrous lidocaine hydrochloride' 'Lidocaine hcl'
 'Lidocaine hydrochloride' 'Lidocaine hydrochloride anhydrous'
 'Lidocaine hydrochloride monohydrate' 'Lidocaine hydrochloride usp'
 'Lidocaini hydrochloridum' 'Lignocaine (as hydrochloride)'
 'Lignocaine hydrochloride' 'NSC-757420' 'Xylocaine hydrochloride']","[('DailyMed', array(['lidocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['56422178'], dtype=object)), ('chEBI', array(['60791'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0003843', 'MONDO_0004992', 'MONDO_0005277',
       'MONDO_0002691', 'EFO_0007490', 'EFO_1001250', 'HP_0012532',
       'HP_0003418', 'HP_0000989', 'EFO_0002950', 'EFO_0001663',
       'EFO_0009552', 'EFO_0000546', 'EFO_0000400', 'EFO_0002618',
       'HP_0002315', 'EFO_1001898', 'EFO_1001996'], dtype=object), 'count': 19}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 3 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200598,CC/C(=C(/CC)c1ccc(OP(=O)(O)O)cc1)c1ccc(OP(=O)(O)O)cc1,NLORYLAYLIXTID-ISLYRVAYSA-N,Small molecule,False,DIETHYLSTILBESTROL DIPHOSPHATE,1982.0,4.0,,False,True,['Fosfestrol' 'Stilphostrol'],['Diethylstilbestrol diphosphate' 'Fosfestrol'],"[('PubChem', array(['144206347', '50125929'], dtype=object)), ('chEBI', array(['4532'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for neoplasm.
CHEMBL1200773,Cc1cccc(C)c1NC(=O)C(C)N.Cl,AMZACPWEJDQXGW-UHFFFAOYSA-N,Small molecule,True,TOCAINIDE HYDROCHLORIDE,1984.0,4.0,CHEMBL1762,False,True,['Tonocard' 'Xylotocan'],['Tocainide hcl' 'Tocainide hydrochloride' 'Tocainide monohydrochloride'],"[('PubChem', array(['144204283', '170465114'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA.
CHEMBL1442422,CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21,QPGGEKPRGVJKQB-UHFFFAOYSA-N,Small molecule,False,DIBENZEPIN,,4.0,,False,True,[],['Dibenzepin'],"[('PubChem', array(['26754618', '29216076'], dtype=object)), ('drugbank', array(['DB13225'], dtype=object))]",['CHEMBL2104287'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000196639,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder.
CHEMBL1489,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,NMUSYJAQQFHJEW-KVTDHHQDSA-N,Small molecule,False,AZACITIDINE,2004.0,4.0,,False,True,['Azacitidine' 'Azacitidine accord' 'Onureg' 'Vidaza'],"['5-azacitidine' 'Azacitidine' 'Ladakamycin' 'NSC-102816' 'U-18,496'
 'U-18496' 'Vidaza']","[('DailyMed', array(['azacitidine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord'],
      dtype=object)), ('PubChem', array(['124890084', '144204583', '144213302', '170465076', '17390033',
       '26752817', '50105470', '50105471', '50122846', '56320704',
       '56323580', '90341307'], dtype=object)), ('Wikipedia', array(['Azacitidine'], dtype=object)), ('drugbank', array(['DB00928'], dtype=object)), ('chEBI', array(['2038'], dtype=object))]",['CHEMBL3250420' 'CHEMBL3250421'],"{'rows': array(['MONDO_0007576', 'EFO_1001951', 'MONDO_0018906', 'EFO_0000221',
       'EFO_0000403', 'EFO_0006861', 'MONDO_0008170', 'EFO_0000389',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000339', 'EFO_0000569',
       'MONDO_0044903', 'EFO_0005952', 'MONDO_0018076', 'EFO_0006859',
       'MONDO_0003478', 'EFO_1001257', 'EFO_0003869', 'EFO_0003833',
       'EFO_1001779', 'EFO_0000681', 'MONDO_0009348', 'EFO_0000707',
       'Orphanet_848', 'EFO_0003811', 'EFO_0001642', 'MONDO_0020077',
       'EFO_0001378', 'EFO_0000209', 'MONDO_0044881', 'EFO_0000326',
       'EFO_1000028', 'MONDO_0021063', 'EFO_0000574', 'EFO_0002617',
       'EFO_0002618', 'EFO_0000220', 'MONDO_0007254', 'MONDO_0000430',
       'EFO_0000673', 'EFO_0004251', 'EFO_1000657', 'EFO_0000637',
       'EFO_0004252', 'EFO_0000181', 'EFO_0000222', 'EFO_0000183',
       'MONDO_0019469', 'EFO_0000198', 'MONDO_0013730', 'HP_0001873',
       'EFO_0004289', 'EFO_0000255', 'MONDO_0008315', 'MONDO_0002492',
       'MONDO_0002280', 'MONDO_0016586', 'EFO_0000565', 'EFO_0000095',
       'EFO_0000616', 'MONDO_0016486', 'EFO_0000211', 'MONDO_0005184'],
      dtype=object), 'count': 64}","[ENSG00000119772,ENSG00000130816]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 approved and 56 investigational indications.
CHEMBL1628502,CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C,TZDUHAJSIBHXDL-UHFFFAOYSA-N,Small molecule,False,GABAPENTIN ENACARBIL,2011.0,4.0,,False,True,['Horizant'],"['ASP-8825' 'ASP8825' 'GSK1838262' 'Gabapentin enacarbil'
 'Gabapentin encarbil' 'Gsk-1838262' 'XP 13512' 'XP-13512' 'XP13512']","[('DailyMed', array(['gabapentin%20enacarbil'], dtype=object)), ('drugbank', array(['DB08872'], dtype=object)), ('chEBI', array(['68840'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'EFO_0009430', 'EFO_1000783', 'MONDO_0007079',
       'EFO_0004270', 'MONDO_0005277'], dtype=object), 'count': 6}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for neuralgia and restless legs syndrome and has 4 investigational indications.
CHEMBL1737,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,DEIYFTQMQPDXOT-UHFFFAOYSA-N,Small molecule,False,SILDENAFIL CITRATE,1998.0,4.0,CHEMBL192,False,True,['Mysildecard' 'Revatio' 'Sildenafil citrate' 'Viagra'],"['Liqrev' 'NSC-744009' 'NSC-758669' 'Sildenafil (as citrate)'
 'Sildenafil citrate' 'UK-92,480-10' 'UK-92480-10']","[('DailyMed', array(['sildenafil%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mysildecard'],
      dtype=object)), ('PubChem', array(['144205270', '170465285'], dtype=object)), ('Wikipedia', array(['Sildenafil'], dtype=object)), ('chEBI', array(['58987'], dtype=object))]",,"{'rows': array(['MONDO_0006058', 'EFO_0000341', 'MONDO_0008315', 'EFO_1001893',
       'EFO_1001103', 'EFO_1001145', 'MONDO_0005149', 'EFO_0009441',
       'EFO_0003144', 'EFO_1001017', 'EFO_1001827', 'EFO_0003833',
       'EFO_0000404', 'MONDO_0043510', 'EFO_0000668', 'EFO_0000519',
       'EFO_0000545', 'MONDO_0100096', 'EFO_0000464', 'EFO_1001986',
       'EFO_0003047', 'HP_0100607', 'EFO_1000824', 'EFO_0000537',
       'EFO_0001365', 'EFO_0011023', 'EFO_0000616', 'EFO_0004234',
       'EFO_0000495', 'EFO_0000712', 'EFO_0001361', 'EFO_1001134'],
      dtype=object), 'count': 32}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 28 investigational indications.
CHEMBL190333,OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1,QSUSKMBNZQHHPA-UHFFFAOYSA-N,Small molecule,False,RWJ-67657,,1.0,,False,False,[],['JNJ-3026582' 'JNJ3026582' 'RWJ-67657' 'RWJ67657' 'Rwj-67657'],"[('PubChem', array(['137275843'], dtype=object))]",,,"[ENSG00000112062,ENSG00000185386]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2103784,CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C,ZOEFCCMDUURGSE-SQKVDDBVSA-N,Protein,False,COSYNTROPIN,1970.0,4.0,,False,True,['Cortrosyn' 'Cosyntropin' 'Synacthen' 'Synacthen depot'],"['Corticotropin tetracosapeptide' 'Cosyntropin' 'Cosyntropin acetate'
 'Cosyntropin hexaacetate' 'Tetracosactide' 'Tetracosactide acetate'
 'Tetracosactide hexaacetate' 'Tetracosactide hexacetate' 'Tetracosactrin'
 'Vicotrope']","[('DailyMed', array(['cosyntropin'], dtype=object)), ('drugbank', array(['DB01284'], dtype=object)), ('chEBI', array(['3901'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0004254', 'MONDO_0100062', 'EFO_0005539'],
      dtype=object), 'count': 4}",[ENSG00000185231],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 4 investigational indications.
CHEMBL2108038,,,Antibody,False,MATUZUMAB,,2.0,,False,False,[],['EMD-72000' 'Matuzumab'],,,"{'rows': array(['EFO_0003060', 'MONDO_0008170'], dtype=object), 'count': 2}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108426,,,Enzyme,False,MONTEPLASE,,3.0,,False,False,[],['Cleactor' 'Monteplase'],,,,[ENSG00000104368],Enzyme drug with a maximum clinical trial phase of III.
CHEMBL2109474,,,Antibody,False,TRX-1,,2.0,,False,False,[],['TRX-1'],,,,[ENSG00000010610],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2111286,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3],XAUTYMZTJWXZHZ-UHFFFAOYSA-K,Small molecule,False,RANITIDINE BISMUTH CITRATE,1996.0,4.0,CHEMBL1790041,False,True,['Pylorid' 'Tritec'],"['GR 122311X' 'GR-122311X' 'Ranitidine bismuth citrate'
 'Ranitidine bismutrex']",,,"{'rows': array(['EFO_1000961', 'EFO_0003948', 'HP_0004398'], dtype=object), 'count': 3}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for gastroesophageal reflux disease and peptic ulcer and has 1 investigational indication.
CHEMBL2367706,O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O,JTZPPHUZZDKEOC-RBQAPOGLSA-A,Unknown,False,SUCRALFATE,1981.0,4.0,,False,True,['Antepsin' 'Carafate' 'Sucralfate' 'Ulcerlmin'],['Sucralfate'],"[('DailyMed', array(['sucralfate'], dtype=object)), ('DrugCentral', array(['4106'], dtype=object))]",['CHEMBL3989780'],"{'rows': array(['MP_0001914', 'EFO_0003948', 'HP_0100633', 'EFO_0004607',
       'HP_0004398', 'EFO_0004232'], dtype=object), 'count': 6}",[ENSG00000256713],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 3 investigational indications.
CHEMBL30219,C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+],KDXZREBVGAGZHS-UHFFFAOYSA-M,Small molecule,True,METHOHEXITAL SODIUM,1960.0,4.0,CHEMBL7413,False,True,"['Brevimytal' 'Brevital' 'Brevital sodium' 'Brietal' 'Brietal sod'
 'Methohexitone']","['Enallynymal sodium' 'Methohexital sodium' 'Methohexital sodium salt'
 'Sodium methohexital']","[('DailyMed', array(['methohexital%20sodium'], dtype=object)), ('chEBI', array(['6834'], dtype=object))]",,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA.
CHEMBL3039520,CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,XEDHVZKDSYZQBF-UHFFFAOYSA-N,Small molecule,False,LASMIDITAN,2020.0,4.0,,False,True,[],['COL-144' 'LY573144' 'Lasmiditan'],"[('drugbank', array(['DB11732'], dtype=object))]",['CHEMBL3039526'],"{'rows': array(['MONDO_0005277', 'EFO_0003890', 'MONDO_0005277'], dtype=object), 'count': 3}",[ENSG00000179097],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 1 investigational indication.
CHEMBL306700,CCOc1ccccc1OCC1CNCCO1,YWPHCCPCQOJSGZ-UHFFFAOYSA-N,Small molecule,True,VILOXAZINE,2021.0,4.0,,False,True,[],['Viloxazin' 'Viloxazine'],"[('Wikipedia', array(['Viloxazine'], dtype=object)), ('drugbank', array(['DB09185'], dtype=object))]",['CHEMBL2106483'],"{'rows': array(['MONDO_0002009', 'EFO_0003888'], dtype=object), 'count': 2}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for major depressive disorder and attention deficit hyperactivity disorder. This drug has a black box warning from the FDA.
CHEMBL3137354,,,Antibody,False,LULIZUMAB PEGOL,,2.0,,False,False,[],['BMS-931699' 'Lulizumab pegol'],,,,[ENSG00000178562],Antibody drug with a maximum clinical trial phase of II.
CHEMBL3545155,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1,ZXBFYBLSJMEBEP-UHFFFAOYSA-N,Small molecule,False,JI-101,,2.0,,False,False,[],['Angiogenesis inhibitor ji-101' 'CGI-1842' 'JI-101' 'Ji-101'],"[('drugbank', array(['DB12744'], dtype=object))]",,"{'rows': array(['MONDO_0021063', 'MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 3}","[ENSG00000113721,ENSG00000128052,ENSG00000196411]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL383322,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,BXNMTOQRYBFHNZ-UHFFFAOYSA-N,Small molecule,False,RESIQUIMOD,,2.0,,False,False,[],['CD-11301' 'CD11301' 'R-848' 'Resiquimod' 'S-28463'],"[('Wikipedia', array(['Resiquimod'], dtype=object)), ('drugbank', array(['DB06530'], dtype=object)), ('chEBI', array(['36706'], dtype=object))]",,"{'rows': array(['EFO_0002913', 'EFO_0000756', 'EFO_0000632', 'EFO_0000519',
       'EFO_0002496', 'EFO_0007328', 'EFO_0004193', 'MONDO_0004992',
       'EFO_0000389', 'EFO_0002617', 'EFO_0002499', 'EFO_0004197'],
      dtype=object), 'count': 12}","[ENSG00000196664,ENSG00000101916]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.
CHEMBL3989992,,,Protein,False,PEGILODECAKIN,,3.0,,False,False,[],['AM-0010' 'AM0010' 'LY-3500518' 'LY3500518' 'Pegilodecakin'],,,"{'rows': array(['EFO_0003060', 'EFO_0002618'], dtype=object), 'count': 2}","[ENSG00000243646,ENSG00000110324]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4285417,C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1,OHUHVTCQTUDPIJ-JYCIKRDWSA-N,Small molecule,False,CERALASERTIB,,3.0,,False,False,[],"['AZD6738' 'Atr kinase inhibitor azd6738' 'Azd 6738' 'Azd-6738'
 'Ceralasertib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CERALASERTIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0003059', 'EFO_0000707', 'EFO_0000181', 'MONDO_0008170',
       'EFO_0000616', 'EFO_0000637', 'EFO_0000756', 'MONDO_0001023',
       'EFO_0005537', 'MONDO_0008315', 'EFO_0000228', 'MONDO_0004992',
       'EFO_0000313', 'EFO_0000403', 'EFO_0000702', 'EFO_0003869',
       'EFO_0000305', 'MONDO_0007254', 'EFO_0000095', 'EFO_0003060'],
      dtype=object), 'count': 20}",[ENSG00000175054],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.
CHEMBL4297551,,,Protein,False,EFGARTIGIMOD ALFA,2021.0,4.0,,False,True,['Vyvgart'],"['ARGX-113' 'Argx-113' 'Efgartigimod' 'Efgartigimod alfa'
 'Efgartigimod alfa fcab' 'Efgartigimod alfa-fcab'
 'Efgartigimod alfa-qvfc' 'Vyvgart']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EFGARTIGIMOD%20ALFA/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005809', 'EFO_0000699', 'MONDO_0017287', 'EFO_0004991',
       'EFO_1000645', 'EFO_0003086', 'EFO_0007187', 'EFO_0007160',
       'EFO_0007292', 'EFO_0009538', 'EFO_0000540', 'EFO_0005761'],
      dtype=object), 'count': 12}",[ENSG00000104870],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for myasthenia gravis and immune system disease and has 10 investigational indications.
CHEMBL4297635,CCCCCc1cccc(CC(=O)O)c1,PEGQOIGYZLJMIB-UHFFFAOYSA-N,Small molecule,False,SETOGEPRAM,,2.0,,False,False,[],['Fezagepras' 'Pbi-4050' 'Setogepram'],"[('drugbank', array(['DB15447'], dtype=object))]",['CHEMBL4799780'],"{'rows': array(['HP_0001987'], dtype=object), 'count': 1}","[ENSG00000126266,ENSG00000139572]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297841,,,Antibody drug conjugate,True,TISOTUMAB VEDOTIN,2021.0,4.0,,False,True,['Tivdak'],"['GCT1015-04' 'HuMax-TF-ADC' 'IGG1-1015-011-1006' 'TF-011-MMAE'
 'Tisotumab vedotin' 'Tisotumab vedotin tftv']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TISOTUMAB%20VEDOTIN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0002087', 'MONDO_0002158', 'MONDO_0002974', 'MONDO_0008170',
       'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 6}","[ENSG00000117525,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4298016,,,Antibody,False,FROVOCIMAB,,2.0,,False,False,[],['Frovocimab' 'LY-3015014' 'LY3015014' 'Ly3015014'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FROVOCIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0003124', 'MONDO_0021187'], dtype=object), 'count': 2}",[ENSG00000169174],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4298139,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1.[Cl-],GONQEUJYYMYNMN-HWAJWLCKSA-N,Small molecule,False,SERDEXMETHYLPHENIDATE CHLORIDE,2021.0,4.0,CHEMBL4301162,False,True,[],['KP415 Cl' 'Serdexmethylphenidate chloride'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SERDEXMETHYLPHENIDATE%20CHLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder.
CHEMBL1094636,NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,PCHKPVIQAHNQLW-CQSZACIVSA-N,Small molecule,False,NIRAPARIB,2017.0,4.0,,False,True,['Zejula'],['JNJ-64091742' 'MK-4827' 'MK4827' 'Niraparib' 'ZL-2306'],"[('drugbank', array(['DB11793'], dtype=object))]",['CHEMBL3989922'],"{'rows': array(['EFO_0004230', 'EFO_0003869', 'MONDO_0008315', 'EFO_0001075',
       'EFO_0003893', 'EFO_0001075', 'EFO_0000181', 'EFO_0000702',
       'EFO_0001663', 'EFO_0000174', 'EFO_1001512', 'MONDO_0004992',
       'MONDO_0011962', 'EFO_1000465', 'EFO_0006859', 'MONDO_0002158',
       'EFO_1000657', 'EFO_0000707', 'EFO_0000616', 'MONDO_0008903',
       'MONDO_0002974', 'EFO_0003060', 'MONDO_0003060', 'EFO_0003893',
       'EFO_1000251', 'EFO_0000196', 'EFO_0000564', 'MONDO_0007254',
       'EFO_0002617', 'EFO_0000574', 'EFO_0000095', 'MONDO_0002087',
       'EFO_1000294', 'EFO_0003863', 'MONDO_0001056', 'EFO_0002618',
       'EFO_1001100', 'MONDO_0005184', 'EFO_0000588', 'Orphanet_145',
       'EFO_0000673', 'MONDO_0008170', 'EFO_0000519', 'EFO_0008528',
       'EFO_0003891', 'EFO_0001061', 'EFO_0000365', 'MONDO_0001187'],
      dtype=object), 'count': 48}","[ENSG00000129484,ENSG00000143799]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 6 approved and 42 investigational indications.
CHEMBL1200665,CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl,SHTAFWKOISOCBI-UHFFFAOYSA-N,Small molecule,False,DIPHENOXYLATE HYDROCHLORIDE,1960.0,4.0,CHEMBL1201294,False,True,[],"['Diphenoxylate HCl' 'Diphenoxylate hcl' 'Diphenoxylate hydrochloride'
 'Diphenoxylate hydrochloride cii' 'Diphenoxylati hydrochloridum'
 'R-1132 (ANTIPERISTALTIC)']","[('DailyMed', array(['diphenoxylate%20hydrochloride'], dtype=object)), ('PubChem', array(['144206146', '144206378', '170465332', '49681550'], dtype=object)), ('chEBI', array(['59784'], dtype=object))]",,,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1564,CN1CCC(OC(c2ccccc2)c2ccccc2)CC1.Cl,LPRLDRXGWKXRMQ-UHFFFAOYSA-N,Small molecule,False,DIPHENYLPYRALINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1492,False,True,['Hispril' 'Histryl' 'Histryl paed' 'Lergoban'],"['Diaminophen' 'Diamiphen' 'Diamiphene' 'Diaphen' 'Diphenylpyraline HCl'
 'Diphenylpyraline hcl' 'Diphenylpyraline hydrochloride'
 'Diphenylpyraline teoclate' 'NSC-16338' 'NSC-61825']","[('PubChem', array(['11532996', '144203970', '170464816', '26748003', '26748004'],
      dtype=object)), ('chEBI', array(['31508'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL159,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,JXLYSJRDGCGARV-CFWMRBGOSA-N,Small molecule,False,VINBLASTINE,1965.0,4.0,,False,True,[],['NSC-47842' 'Velban' 'Vinblastine' '[3H]-Vinblastine'],"[('Wikipedia', array(['Vinblastine'], dtype=object)), ('drugbank', array(['DB00570'], dtype=object))]",['CHEMBL378544'],"{'rows': array(['EFO_0000588', 'MONDO_0018975', 'EFO_0000681', 'EFO_0000574',
       'EFO_0000691', 'MONDO_0002898', 'MONDO_0009348', 'EFO_0000220',
       'MONDO_0001187', 'MONDO_0008170', 'EFO_0000574', 'EFO_0000222',
       'MONDO_0004192', 'EFO_0004281', 'MONDO_0004986', 'EFO_0006818',
       'MONDO_0003751', 'MONDO_0008315', 'MONDO_0009348', 'EFO_0000183',
       'EFO_0000183', 'EFO_1000318', 'EFO_0000565', 'EFO_0002617',
       'EFO_0000389', 'EFO_0000616', 'EFO_0003833', 'EFO_0005543',
       'EFO_0000389', 'EFO_0000211', 'MONDO_0002041', 'MONDO_0008315',
       'MONDO_0008903', 'MONDO_0002367', 'MONDO_0004986', 'EFO_0000756',
       'MONDO_0001187', 'EFO_1000158', 'EFO_0000756', 'MONDO_0008903',
       'EFO_0009907', 'EFO_0004281', 'EFO_0001642', 'MONDO_0004192',
       'EFO_0008528', 'MONDO_0002974', 'EFO_0000403'], dtype=object), 'count': 47}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 6 approved and 36 investigational indications.
CHEMBL1743007,,,Antibody,False,DARATUMUMAB,2015.0,4.0,,False,True,['Darzalex'],"['3003-005' 'Daratumumab' 'Daratumumab-fihj' 'Darzalex' 'HUMAX-CD 38'
 'HuMax-CD38']","[('DailyMed', array(['daratumumab'], dtype=object)), ('DrugCentral', array(['5063'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex'],
      dtype=object))]",,"{'rows': array(['MONDO_0002462', 'EFO_0001378', 'EFO_0005952', 'EFO_0000574',
       'MONDO_0007915', 'EFO_0006475', 'EFO_0005761', 'MONDO_0018906',
       'EFO_0004256', 'EFO_0000198', 'EFO_0003060', 'EFO_1001875',
       'EFO_0000220', 'EFO_0007160', 'EFO_1001469', 'HP_0001915',
       'EFO_0000616', 'EFO_0000349', 'EFO_0003073', 'EFO_0000540',
       'MONDO_0018904', 'EFO_1001115', 'EFO_0009441', 'EFO_0000519',
       'EFO_0000203', 'EFO_0000209', 'MONDO_0019438', 'EFO_0004255',
       'EFO_0000183', 'EFO_1001051', 'EFO_0000673', 'MONDO_0004992',
       'EFO_1001951', 'EFO_0000403', 'EFO_0000095', 'EFO_0004599',
       'EFO_0000222', 'EFO_0006738', 'MONDO_0004975', 'EFO_0005558',
       'MONDO_0008315'], dtype=object), 'count': 41}",[ENSG00000004468],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 38 investigational indications.
CHEMBL2104391,CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,UGOZVNFCFYTPAZ-IOXYNQHNSA-N,Protein,False,INSULIN DETEMIR,2004.0,4.0,,False,True,"['Ins levemir' 'Levemir' 'Levemir flexpen' 'Levemir flextouch'
 'Levemir innolet' 'Levemir penfill']","['Detemir' 'Insulin detemir' 'Insulin,detemir,human' 'NN-304']","[('DailyMed', array(['insulin%20detemir%20recombinant'], dtype=object)), ('DrugCentral', array(['4985'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/levemir'],
      dtype=object))]",,"{'rows': array(['EFO_0003914', 'MONDO_0005148', 'MONDO_0005147', 'MONDO_0009061',
       'EFO_0000400', 'EFO_0000537', 'EFO_0001645', 'HP_0003124'],
      dtype=object), 'count': 8}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 3 approved and 5 investigational indications.
CHEMBL2108785,,,Antibody drug conjugate,False,ZOLIMOMAB ARITOX,,2.0,,False,False,[],"['H-65-RTA' 'H-65RTA' 'H65-RTA' 'Orthozyme cd 5 plus' 'Xoma zyme h 65'
 'ZX-CD5' 'Zolimomab aritox']",,,,[ENSG00000110448],Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2109191,,,Antibody,False,GALIXIMAB,,3.0,,False,False,[],['Galiximab' 'IDEC-114'],,,"{'rows': array(['EFO_0000574', 'EFO_0005952'], dtype=object), 'count': 2}",[ENSG00000121594],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2165620,O=C(O)c1ccc(NC(=O)[C@H](CC2CCCC2)n2cnc(C(F)(F)F)c2)nc1,GKMLFBRLRVQVJO-ZDUSSCGKSA-N,Small molecule,False,PF-04991532,,2.0,,False,False,[],['Pf-04991532'],"[('drugbank', array(['DB11765'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000106633],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL259084,O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,HHFBDROWDBDFBR-UHFFFAOYSA-N,Small molecule,False,MLN-8054,,1.0,,False,False,[],['MLN 8054' 'MLN-8054' 'Mln-8054' 'Mln8054'],"[('PubChem', array(['103904597', '174006403', '50100109'], dtype=object)), ('drugbank', array(['DB13061'], dtype=object))]",['CHEMBL3586469'],"{'rows': array(['EFO_0003869', 'EFO_0003860', 'MONDO_0004992', 'EFO_0004288'],
      dtype=object), 'count': 4}",[ENSG00000087586],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL282052,Cc1ccccc1-n1c(C)nc2ccccc2c1=O,JEYCTXHKTXCGPB-UHFFFAOYSA-N,Small molecule,False,METHAQUALONE,,4.0,,True,True,[],"['CI-705' 'CN 38703' 'CN-38703' 'Methaqualone' 'Methaqualoneinone'
 'Metolquizolone' 'NSC-111388' 'NSC-111388-' 'NSC-126877' 'NSC-631628'
 'QZ-2' 'R-148' 'TR-495']","[('PubChem', array(['144206055', '144206422', '24804237'], dtype=object)), ('Wikipedia', array(['Methaqualone'], dtype=object)), ('drugbank', array(['DB04833'], dtype=object)), ('chEBI', array(['6821'], dtype=object))]",['CHEMBL2106829'],,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL291657,C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1,IEAKXXNRGSLYTQ-DEOSSOPVSA-N,Small molecule,False,CRINECERFONT,,3.0,,False,False,[],"['06-RORI' 'Crinecerfont' 'NBI-74788' 'Nbi-74788' 'SSR125543' 'Ssr 125543'
 'Ssr-125543' 'Ssr125543']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CRINECERFONT/relevant/1/'],
      dtype=object)), ('chEBI', array(['34969'], dtype=object))]",['CHEMBL1628268'],"{'rows': array(['MONDO_0002050', 'MONDO_0018479'], dtype=object), 'count': 2}",[ENSG00000120088],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL296522,COc1cc(N)c(Cl)cc1C(=O)NC1CCN2CCCC1C2,GZSKEXSLDPEFPT-UHFFFAOYSA-N,Small molecule,False,RENZAPRIDE,,3.0,,False,False,[],['ATL-1251' 'Renzapride'],,,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}","[ENSG00000164270,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3039540,,,Antibody,True,ADUCANUMAB,2021.0,4.0,,False,True,['Aduhelm'],['Aducanumab' 'Aducanumab avwa' 'BIIB-037' 'BIIB037'],,,"{'rows': array(['MONDO_0004975', 'HP_0000726'], dtype=object), 'count': 2}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alzheimer disease and dementia. This drug has a black box warning from the FDA.
CHEMBL3039547,,,Gene,False,PEXASTIMOGENE DEVACIREPVEC,,3.0,,False,False,[],['JX-594' 'Pexastimogene devacirepvec'],,,"{'rows': array(['EFO_0009709', 'EFO_0002617', 'EFO_0000681', 'EFO_0000182',
       'MONDO_0008170', 'EFO_0000756', 'EFO_0000616', 'EFO_0000365',
       'EFO_1001951'], dtype=object), 'count': 9}",[ENSG00000164400],Gene drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL3301606,CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1,MPYACSQFXVMWNO-UHFFFAOYSA-N,Small molecule,False,SOLCITINIB,,2.0,,False,False,[],"['G-154578' 'G154578' 'GLPG-0778' 'GLPG-0788' 'GLPG0778' 'GSK-2586184'
 'GSK-2586184A' 'GSK2586184A' 'Glpg-0778' 'Gsk-2586184' 'Solcitinib']",,,"{'rows': array(['MONDO_0007915', 'EFO_0000676', 'EFO_0000729'], dtype=object), 'count': 3}",[ENSG00000162434],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545011,O[C@@H]1[C@H](O)[C@@H](CSc2ccccc2F)O[C@H]1n1cnc2c(N[C@@H]3CCC[C@H]3O)ncnc21,IZRXENCTXNMAMI-DIJFLQFKSA-N,Small molecule,False,GS-9667,,1.0,,False,False,[],['CVT 3619' 'CVT-3619' 'Gs-9667'],,,,[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545371,,,Antibody drug conjugate,False,DENINTUZUMAB MAFODOTIN,,2.0,,False,False,[],['Denintuzumab mafodotin' 'SGN-19A' 'SGN-CD19A'],,,"{'rows': array(['EFO_1001469', 'EFO_0000220', 'EFO_0000403', 'EFO_0000309',
       'MONDO_0018906'], dtype=object), 'count': 5}",[ENSG00000177455],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL360055,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,OZLPUNFFCJDMJD-UHFFFAOYSA-N,Small molecule,False,GALLAMINE,1982.0,4.0,,False,True,[],['Gallamine'],"[('PubChem', array(['11111237', '11111238', '124880248', '26756602', '90341095'],
      dtype=object))]",['CHEMBL1200993'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL396778,C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O,NEMGRZFTLSKBAP-LBPRGKRZSA-N,Small molecule,False,SAFINAMIDE,2015.0,4.0,,False,True,['Xadago'],['EMD 1195686' 'EMD-1195686' 'Safinamide'],"[('Wikipedia', array(['Safinamide'], dtype=object)), ('drugbank', array(['DB06654'], dtype=object))]",['CHEMBL48582'],"{'rows': array(['EFO_1001050', 'EFO_0001421', 'MONDO_0005180', 'EFO_0003086',
       'MONDO_0005180'], dtype=object), 'count': 5}",[ENSG00000069535],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for parkinson disease and has 3 investigational indications.
CHEMBL3989401,NCCC(O)(P(=O)([O-])O)P(=O)([O-])O.O.O.O.O.O.[Na+].[Na+],CZYWHNTUXNGDGR-UHFFFAOYSA-L,Small molecule,False,PAMIDRONATE DISODIUM,1991.0,4.0,CHEMBL834,False,True,['Aredia' 'Pamidronate disodium'],"['CGP 23339AE' 'CGP-23339AE' 'Disodium pamidronate' 'Pamidronate disodium'
 'Pamidronate disodium hydrate' 'Pamidronate disodium pentahydrate']","[('DailyMed', array(['pamidronate%20disodium'], dtype=object))]",,"{'rows': array(['EFO_1001164', 'EFO_0001378', 'MONDO_0007254', 'MONDO_0019019'],
      dtype=object), 'count': 4}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 investigational indications.
CHEMBL4167360,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1,DCGDPJCUIKLTDU-QWQRMKEZSA-N,Small molecule,False,IDH305,,2.0,,False,False,[],['Idh305'],,,"{'rows': array(['EFO_0005543', 'EFO_0000222', 'MONDO_0004992'], dtype=object), 'count': 3}",[ENSG00000138413],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL454138,CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,INASOKQDNHHMRE-UHFFFAOYSA-N,Small molecule,False,TUROFEXORATE ISOPROPYL,,2.0,,False,False,[],['FXR-450' 'Turofexorate isopropyl' 'WAY-362450' 'XL-335' 'XL335'],"[('PubChem', array(['137275949'], dtype=object)), ('drugbank', array(['DB12719'], dtype=object))]",,,[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL5095031,CCCCCCN(CCOc1ccc(CCCCNC(=N)NC(=O)c2nc(Cl)c(N)nc2N)cc1)C[C@H](O)C(O)[C@H](O)[C@H](O)CO,HBZAZSCNDMDWEU-GNZRQIOVSA-N,Small molecule,False,IDREVLORIDE,,2.0,,False,False,[],['GS-560876' 'GS-5737' 'Idrevloride' 'P-1037' 'VRT-1499138' 'VX-371'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IDREVLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000684', 'MONDO_0016575', 'MONDO_0009061'], dtype=object), 'count': 3}","[ENSG00000111319,ENSG00000168447,ENSG00000166828]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL572881,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,RAHBGWKEPAQNFF-UHFFFAOYSA-N,Small molecule,False,MOTESANIB,,3.0,,False,False,[],['AMG 706' 'AMG-706' 'Motesanib'],"[('PubChem', array(['137276049', '50100087'], dtype=object)), ('drugbank', array(['DB05575'], dtype=object)), ('chEBI', array(['51098'], dtype=object))]",['CHEMBL2107357'],"{'rows': array(['MONDO_0007254', 'MONDO_0021063', 'MONDO_0008903', 'MONDO_0007254',
       'EFO_1000657', 'MONDO_0007576', 'MONDO_0002087', 'EFO_0003060',
       'MONDO_0008170', 'MONDO_0011719', 'EFO_0002618', 'EFO_0000616',
       'EFO_0007331', 'EFO_0003060', 'MONDO_0002158', 'MONDO_0002108',
       'EFO_0004243', 'EFO_0000574', 'MONDO_0016537'], dtype=object), 'count': 19}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000165731]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.
CHEMBL10316,c1ccc2c(c1)OCC(C1=NCCN1)O2,HPMRFMKYPGXPEP-UHFFFAOYSA-N,Small molecule,False,IDAZOXAN,,3.0,,False,False,[],['Dl-idazoxan' 'Idazoxan' 'NSC-759867' 'RX-781094' 'Racemic idazoxan'],"[('PubChem', array(['104171177', '144203724', '170466595', '26751897', '90341761'],
      dtype=object)), ('Wikipedia', array(['Idazoxan'], dtype=object)), ('drugbank', array(['DB12551'], dtype=object)), ('chEBI', array(['5862'], dtype=object))]",['CHEMBL543467'],"{'rows': array(['MONDO_0002009', 'MONDO_0004975'], dtype=object), 'count': 2}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1200629,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1.[Br-],VEPSYABRBFXYIB-PWXDFCLTSA-M,Small molecule,True,VECURONIUM BROMIDE,1984.0,4.0,CHEMBL1201219,False,True,['Musculax' 'Norcuron' 'Vecuronium bromide'],"['NSC-759184' 'ORG NC 45' 'ORG-NC 45'
 'Pancuronium bromide impurity, vecuronium bromide -' 'Vecuronium bromide']","[('DailyMed', array(['vecuronium%20bromide'], dtype=object)), ('PubChem', array(['144206024', '170465295'], dtype=object)), ('chEBI', array(['9940'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA.
CHEMBL1201568,,,Protein,False,PEGFILGRASTIM,2002.0,4.0,,False,True,['Fulphila' 'Neulasta' 'Neulasta sureclick'],"['B-12019' 'B12019' 'Cegfila' 'Chs-1701' 'Fulphila' 'Fylnetra'
 'Granulocyte colony-stimulating factor pegfilgrastim' 'Hsp-130'
 'LA EP 2006' 'LA EP-2006' 'La-ep2006' 'Lupifil-p' 'MYL-1401H' 'Msb-11455'
 'Msb11455' 'Neupopeg' 'Nyvepria' 'Peg-filgrastim' 'Pegfilgrastim'
 'Pegfilgrastim (neulasta)' 'Pegfilgrastim apgf'
 'Pegfilgrastim biosimilar (lupin)' 'Pegfilgrastim biosimilar (pfizer)'
 'Pegfilgrastim biosimilar (sandoz)' 'Pegfilgrastim biosimilar - lupin'
 'Pegfilgrastim bmez' 'Pegfilgrastim cbqv' 'Pegfilgrastim for bioassay'
 'Pegfilgrastim fpgk' 'Pegfilgrastim jmdb' 'Pegfilgrastim pbbk'
 'Pegfilgrastim-apgf' 'Pegfilgrastim-bmez' 'Pegfilgrastim-cbqv'
 'Pegfilgrastim-fpgk' 'Pegfilgrastim-jmdb' 'Pegfilgrastim-ljfd'
 'Pegfilgrastim-pbbk' 'Pelmeg' 'Pf-06881894' 'Ql-0605' 'Ql0605'
 'Stimufend' 'TPI-120' 'Udenyca' 'Ziextenzo']","[('DailyMed', array(['pegfilgrastim', 'pegfilgrastim-bmez', 'pegfilgrastim-cbqv',
       'pegfilgrastim-jmdb'], dtype=object)), ('DrugCentral', array(['4986'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fulphila-0'],
      dtype=object)), ('Wikipedia', array(['Pegfilgrastim'], dtype=object))]",,"{'rows': array(['EFO_0007532', 'EFO_0000183', 'EFO_0000544', 'MONDO_0001657',
       'MONDO_0004192', 'EFO_0000756', 'EFO_0000621', 'EFO_0006861',
       'MONDO_0008315', 'MONDO_0004643', 'EFO_0000305', 'EFO_0000702',
       'EFO_0000096', 'EFO_0000181', 'EFO_1000796', 'MONDO_0018906',
       'EFO_0000222', 'EFO_0006859', 'EFO_0000198', 'MONDO_0002087',
       'MONDO_0001056', 'MONDO_0008380', 'EFO_0004252', 'EFO_1001469',
       'EFO_0003060', 'MONDO_0001187', 'EFO_1001951', 'MONDO_0007254',
       'EFO_1000657', 'EFO_0003869', 'EFO_0002913', 'EFO_0000211',
       'EFO_0000574', 'EFO_0008528', 'EFO_0001645', 'MONDO_0001475',
       'EFO_0000403', 'MONDO_0002158', 'EFO_0000514', 'MONDO_0005147',
       'MONDO_0009348', 'MONDO_0002974', 'EFO_0000196', 'MONDO_0008170',
       'EFO_0002939', 'EFO_0000691', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0002618', 'EFO_0007416', 'EFO_0000220', 'EFO_0005537',
       'MONDO_0008903', 'EFO_0001642', 'MONDO_0021063', 'MONDO_0006058',
       'EFO_0005952', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0000637',
       'EFO_0000571', 'EFO_0000681', 'EFO_0000565', 'HP_0001915',
       'EFO_0001378'], dtype=object), 'count': 65}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 4 approved and 61 investigational indications.
CHEMBL1201576,,,Antibody,True,RITUXIMAB,1997.0,4.0,,False,True,['Mabthera' 'Mabthera rituxan' 'Rituxan' 'Ruxience'],"['ABP-798' 'ABP798' 'BI695500' 'Bi 695500' 'Bi-695500' 'Blitzima' 'CT-P10'
 'Gp2013' 'HS-006' 'HS-006 (RITUXIMAB BIOSIMILAR)' 'HS006' 'IDEC-102'
 'IDEC-C2B8' 'Mk-8808' 'Pf-05280586' 'R-105 IDEC-102' 'RG-105'
 'RHCACD20MA' 'Riabni' 'Ritemvia' 'Rituximab'
 'Rituximab (genetical recombination)' 'Rituximab (rituxan)'
 'Rituximab abbs' 'Rituximab arrx' 'Rituximab biosimilar (amgen)'
 'Rituximab biosimilar (celltrion)' 'Rituximab biosimilar (pfizer)'
 'Rituximab biosimilar - celltrion' 'Rituximab biosimilar -merck'
 'Rituximab pvvr' 'Rituximab-abbs' 'Rituximab-arrx'
 'Rituximab-boehringer ingelheim' 'Rituximab-ct-p10' 'Rituximab-pfizer'
 'Rituximab-pvvr' 'Ruxience' 'SAIT-101' 'SAIT101' 'Truxima' 'Tuxella'
 'Usp mab 001, monoclonal igg1' 'Zuberitamab']","[('DailyMed', array(['rituximab', 'rituximab-abbs', 'rituximab-pvvr'], dtype=object)), ('DrugCentral', array(['4975'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ruxience'],
      dtype=object)), ('Wikipedia', array(['Rituximab'], dtype=object))]",,"{'rows': array(['MONDO_0002334', 'EFO_0008518', 'EFO_0000309', 'EFO_0003032',
       'EFO_0009441', 'Orphanet_365', 'EFO_0007187', 'MONDO_0007915',
       'EFO_0003840', 'EFO_0000191', 'EFO_1001938', 'EFO_0009538',
       'EFO_0000707', 'EFO_0004244', 'MONDO_0004095', 'EFO_0004540',
       'EFO_0002617', 'MONDO_0010602', 'EFO_1000783', 'MONDO_0011382',
       'EFO_1000868', 'MONDO_0002462', 'EFO_0000220', 'EFO_1001264',
       'MONDO_0001437', 'MONDO_0019391', 'EFO_0003884', 'EFO_0000198',
       'EFO_0003898', 'HP_0000093', 'EFO_0000339', 'EFO_0004288',
       'MONDO_0044881', 'EFO_0007316', 'EFO_0003144', 'MONDO_0000873',
       'MONDO_0019338', 'EFO_0008522', 'MONDO_0004992', 'EFO_0000621',
       'EFO_0004254', 'MONDO_0017719', 'EFO_0000209', 'EFO_0000772',
       'HP_0001871', 'EFO_1000956', 'EFO_0000729', 'EFO_0004255',
       'EFO_0004256', 'EFO_0003086', 'EFO_0000222', 'EFO_0007332',
       'EFO_0000095', 'EFO_0000540', 'EFO_0000183', 'EFO_0009562',
       'EFO_0004236', 'EFO_0003778', 'EFO_0005297', 'EFO_0000389',
       'EFO_0002689', 'MONDO_0021117', 'MONDO_0018906', 'EFO_1002048',
       'MONDO_0013730', 'EFO_0008610', 'EFO_0005761', 'EFO_0003780',
       'EFO_1000749', 'EFO_0005140', 'MONDO_0000432', 'EFO_0005952',
       'EFO_0004826', 'EFO_0000255', 'EFO_0006803', 'EFO_1001161',
       'EFO_0004719', 'MONDO_0001718', 'EFO_0004145', 'MONDO_0015760',
       'MONDO_0005090', 'EFO_0004289', 'EFO_0000616', 'EFO_1000131',
       'MONDO_0000870', 'EFO_0006803', 'HP_0001915', 'MONDO_0015564',
       'EFO_1001051', 'MONDO_0016537', 'EFO_0003100', 'MONDO_0005147',
       'EFO_0005531', 'EFO_0004599', 'MONDO_0018922', 'MONDO_0008315',
       'MONDO_0018904', 'EFO_1001486', 'MONDO_0009348', 'MONDO_0018896',
       'EFO_0007160', 'EFO_0000565', 'EFO_0001378', 'HP_0002196',
       'EFO_0007498', 'EFO_1000784', 'MONDO_0017276', 'EFO_0003860',
       'EFO_1000318', 'EFO_0000096', 'EFO_0000403', 'EFO_1001469',
       'EFO_1000630', 'EFO_0000574', 'EFO_0000717', 'MONDO_0044917',
       'EFO_0003897', 'MONDO_0020547', 'EFO_0000557', 'EFO_0000699',
       'MONDO_0001023', 'EFO_0000094', 'EFO_0004991', 'EFO_0000685',
       'EFO_0000384', 'EFO_0009606', 'EFO_0003869', 'EFO_0003929',
       'EFO_0001423', 'EFO_0007359', 'EFO_1001779', 'EFO_0007208',
       'EFO_0003818', 'EFO_1001383', 'EFO_0008520', 'EFO_0001642',
       'MONDO_0005301', 'MONDO_0001549', 'EFO_0000765', 'EFO_0000768',
       'EFO_1001466', 'EFO_1001365'], dtype=object), 'count': 142}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 13 approved and 129 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201745,CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)[O-].C[N+](C)(C)CCO,JWAZHODZSADEHB-UHFFFAOYSA-M,Small molecule,False,CHOLINE FENOFIBRATE,2008.0,4.0,CHEMBL981,False,True,['Trilipix'],['ABT-335' 'Choline fenofibrate' 'Fenofibric acid choline salt'],"[('DailyMed', array(['choline%20fenofibrate'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0001645', 'HP_0003124', 'Orphanet_309005',
       'Orphanet_79211'], dtype=object), 'count': 5}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for cardiovascular disease and has 4 investigational indications.
CHEMBL1324,Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1,MIQPIUSUKVNLNT-UHFFFAOYSA-N,Small molecule,True,TOLCAPONE,1997.0,4.0,,True,True,['Tasmar' 'Tolcapone'],['RO 40-7592' 'RO-40-7592' 'RO-407592' 'Tolcapone'],"[('DailyMed', array(['tolcapone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tasmar'],
      dtype=object)), ('PubChem', array(['144206516', '144212731', '170465081', '50126317'], dtype=object)), ('Wikipedia', array(['Tolcapone'], dtype=object)), ('drugbank', array(['DB00323'], dtype=object)), ('chEBI', array(['63630'], dtype=object))]",,"{'rows': array(['HP_0001399', 'EFO_0002610', 'EFO_0003768', 'MONDO_0043510',
       'MONDO_0005180', 'EFO_0007046', 'MONDO_0005090', 'MONDO_0007079',
       'EFO_0004242', 'EFO_0003096', 'EFO_0004699', 'MONDO_0002046',
       'EFO_0000621'], dtype=object), 'count': 13}",[ENSG00000093010],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hepatic failure and parkinson disease and has 11 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL2062266,COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O,ZGSZBVAEVPSPFM-FFHNEAJVSA-N,Small molecule,False,DIHYDROCODEINE BITARTRATE,1983.0,4.0,CHEMBL1595,False,True,[],"['Codeine, dihydro-, tartrate (1:1)' 'DF 118' 'DF-118'
 'Dihydrocodeine bitartrate' 'Dihydrocodeine bitartrate cii'
 'Dihydrocodeine hydrogen tartrate' 'Dihydrocodeine phosphate'
 'Dihydrocodeine tartrate' 'Dihydroneopine' 'Drocode' 'NSC-117857']","[('DailyMed', array(['dihydrocodeine%20bitartrate'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and is indicated for pain.
CHEMBL2093999,C[C@]12CCC(=NOCCN)C[C@@H]1C(=O)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12,MPYLDWFDPHRTEG-IFVNMTGRSA-N,Small molecule,False,ISTAROXIME,,2.0,,False,False,[],"['(E,Z)-Istaroxime' 'Istaroxime' 'PST-2744']",,,"{'rows': array(['HP_0031273', 'EFO_0003144', 'EFO_0000373'], dtype=object), 'count': 3}","[ENSG00000174437,ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2108459,,,Antibody,False,FONTOLIZUMAB,,2.0,,False,False,[],['Fontolizumab' 'HUZAF'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000111537],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109334,,,Antibody,False,INEBILIZUMAB,2020.0,4.0,,False,True,['Uplizna'],['Inebilizumab' 'Inebilizumab cdon' 'MEDI-551' 'MEDI551'],"[('DailyMed', array(['inebilizumab-cdon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/uplizna'],
      dtype=object))]",,"{'rows': array(['EFO_0004256', 'EFO_0000095', 'EFO_0000717', 'EFO_0000540',
       'EFO_1001993', 'MONDO_0005301', 'EFO_0001378', 'MONDO_0017287',
       'MONDO_0004992', 'EFO_0004991', 'EFO_0007332', 'EFO_0000574',
       'EFO_0001642', 'EFO_0000403'], dtype=object), 'count': 14}",[ENSG00000177455],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neuromyelitis optica and immune system disease and has 12 investigational indications.
CHEMBL2109488,,,Antibody,False,INCLACUMAB,,3.0,,False,False,[],['Inclacumab' 'LC-1004-002' 'LC1004-002' 'RG1512' 'RO-4905417' 'RO4905417'],,,"{'rows': array(['EFO_0000612', 'EFO_0004265', 'EFO_0001645'], dtype=object), 'count': 3}",[ENSG00000174175],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2109610,,,Antibody,False,HUMIK-BETA-1,,1.0,,False,False,[],['HUMIK-BETA-1' 'Humik-beta-1'],,,"{'rows': array(['MONDO_0019469', 'EFO_0001060', 'EFO_0007316'], dtype=object), 'count': 3}",[ENSG00000100385],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3545082,,,Small molecule,False,RG-7376,,1.0,,False,False,[],['PLX-5568' 'Rg-7376'],,,,[ENSG00000132155],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL660,NC12CC3CC(CC(C3)C1)C2,DKNWSYNQZKUICI-UHFFFAOYSA-N,Small molecule,False,AMANTADINE,1968.0,4.0,,False,True,[],"['Amantadine' 'Amantidine' 'NSC-341865' 'Symadine' 'Symmetrel'
 'TCMDC-125869']","[('PubChem', array(['104171100', '11110715', '124879107', '144203619', '170464860',
       '26755640', '26755641', '50110918', '50110919', '90340894'],
      dtype=object)), ('Wikipedia', array(['Amantadine'], dtype=object)), ('drugbank', array(['DB00915'], dtype=object)), ('chEBI', array(['2618'], dtype=object))]",['CHEMBL465617' 'CHEMBL1569' 'CHEMBL1445834'],"{'rows': array(['EFO_0003843', 'MONDO_0005090', 'EFO_0000712', 'EFO_0002610',
       'MONDO_0002679', 'EFO_0003047', 'MONDO_0004976', 'MONDO_0005301',
       'MONDO_0005090', 'EFO_0007328', 'EFO_0000544', 'EFO_1001402',
       'EFO_0003888', 'MONDO_0005180', 'MONDO_0043510', 'EFO_0005411',
       'MONDO_0005301', 'MONDO_0005148', 'EFO_0004220', 'EFO_0000544',
       'EFO_1001175', 'EFO_0004247', 'HP_0001300', 'EFO_0007328',
       'EFO_1000860', 'MONDO_0100096', 'MONDO_0043510', 'MONDO_0100096',
       'MONDO_0005180', 'EFO_0005411'], dtype=object), 'count': 30}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 20 investigational indications.
CHEMBL1200682,O=C([O-])CCCO.[Na+],XYGBKMMCQDZQOZ-UHFFFAOYSA-M,Small molecule,True,SODIUM OXYBATE,2002.0,4.0,CHEMBL1342,False,True,['Xyrem'],"['.gamma.-hydroxybutyrate sodium salt' 'Catabate' 'Lumryz' 'NSC-84223'
 'Oxybate sodium' 'Sodium oxybat' 'Sodium oxybate' 'Sodium oxybutyrate'
 'WY-3478']","[('Wikipedia', array(['Sodium_oxybate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem'],
      dtype=object)), ('DrugCentral', array(['4566'], dtype=object)), ('PubChem', array(['144206424'], dtype=object)), ('DailyMed', array(['sodium%20oxybate'], dtype=object)), ('drugbank', array(['DB09072'], dtype=object))]",,"{'rows': array(['MONDO_0018044', 'EFO_0003108', 'EFO_0008568', 'MONDO_0021107',
       'EFO_0005203', 'HP_0001337', 'MONDO_0005180', 'EFO_0003843',
       'MONDO_0000485', 'MONDO_0016241', 'EFO_0005687', 'MONDO_0016158'],
      dtype=object), 'count': 12}","[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for narcolepsy and narcolepsy-cataplexy syndrome and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201467,,,Small molecule,True,"SYNTHETIC CONJUGATED ESTROGENS, B",2004.0,4.0,,False,True,['Enjuvia'],"['CE-10' 'Estrogens, conjugated synthetic b'
 'Estrogens,conjugated synthetic b' 'Synthetic conjugated estrogens, b']","[('DailyMed', array(['estrogens,%20conjugated%20synthetic%20b'], dtype=object))]",,"{'rows': array(['EFO_1000096', 'GO_0042697'], dtype=object), 'count': 2}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for atrophy and menopause. This drug has a black box warning from the FDA.
CHEMBL1551,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,RUDATBOHQWOJDD-UZVSRGJWSA-N,Small molecule,False,URSODIOL,1987.0,4.0,,False,True,"['Actigall' 'Cholurso' 'Destolit' 'Urdox' 'Urso 250' 'Urso forte'
 'Ursodiol' 'Ursofalk' 'Ursogal']","['NSC-683769' 'Ursodeoxycholate' 'Ursodeoxycholic acid'
 'Ursodesoxycholic acid' 'Ursodiol' 'Ursonorm']","[('DailyMed', array(['ursodiol'], dtype=object)), ('PubChem', array(['11532904'], dtype=object)), ('Wikipedia', array(['Ursodiol'], dtype=object)), ('drugbank', array(['DB01586'], dtype=object)), ('chEBI', array(['9907'], dtype=object))]",['CHEMBL2028234'],"{'rows': array(['MONDO_0005148', 'MONDO_0007739', 'MONDO_0001751', 'EFO_0000400',
       'EFO_1001951', 'EFO_0004268', 'EFO_0003095', 'EFO_0000685',
       'HP_0002910', 'HP_0001952', 'EFO_1001068', 'Orphanet_733',
       'MONDO_0100096', 'MONDO_0005180', 'MONDO_0019072', 'EFO_0001422',
       'EFO_0004220', 'EFO_0007304', 'EFO_0004799', 'EFO_0000373',
       'EFO_0001073', 'EFO_1001486', 'EFO_0001421', 'MP_0001845',
       'EFO_0002950', 'EFO_0004228', 'EFO_0004267'], dtype=object), 'count': 27}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for primary biliary cirrhosis and biliary liver cirrhosis and has 25 investigational indications.
CHEMBL1790041,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,VMXUWOKSQNHOCA-UHFFFAOYSA-N,Small molecule,False,RANITIDINE,1983.0,4.0,,False,True,[],['NSC-757851' 'Ranitidine' 'Tritec' 'Zantac'],"[('PubChem', array(['170465134'], dtype=object)), ('TG-GATEs', array(['86'], dtype=object)), ('Wikipedia', array(['Ranitidine'], dtype=object)), ('drugbank', array(['DB00863'], dtype=object))]",['CHEMBL2110372' 'CHEMBL2111286'],"{'rows': array(['EFO_0003948', 'HP_0004398', 'EFO_0009454', 'MONDO_0015277',
       'Orphanet_2314', 'EFO_0003948', 'HP_0012735', 'MONDO_0005301',
       'EFO_0005592', 'HP_0004398', 'EFO_0009579', 'EFO_0000540',
       'EFO_0005252', 'EFO_1000961', 'EFO_0004607', 'MONDO_0004992',
       'MONDO_0044917', 'EFO_1001095', 'MONDO_0043839', 'MONDO_0007254',
       'EFO_0000280', 'EFO_0000681', 'MONDO_0004658', 'EFO_0009454',
       'EFO_0000764'], dtype=object), 'count': 25}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 18 investigational indications.
CHEMBL1963683,CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O,WSNODXPBBALQOF-VEJSHDCNSA-N,Small molecule,False,TAFLUPROST,2012.0,4.0,,False,True,['Saflutan' 'Zioptan'],['AFP-168' 'MK-2452' 'Tafluprost'],"[('DailyMed', array(['tafluprost'], dtype=object)), ('Wikipedia', array(['Tafluprost'], dtype=object)), ('drugbank', array(['DB08819'], dtype=object)), ('chEBI', array(['66899'], dtype=object))]",,"{'rows': array(['EFO_1001069', 'EFO_0004190', 'MONDO_0005041'], dtype=object), 'count': 3}",[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved indications.
CHEMBL2005186,CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1,GKHIVNAUVKXIIY-UHFFFAOYSA-N,Small molecule,False,BELUMOSUDIL,2021.0,4.0,,False,True,[],"['Belumosudil' 'KD-025' 'KD025' 'Rock2 inhibitor kd025' 'SLx-2119'
 'Slx-2119 free base']","[('PubChem', array(['103905007'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELUMOSUDIL/relevant/1/'],
      dtype=object))]",['CHEMBL4802130'],"{'rows': array(['EFO_0000404', 'MONDO_0013730', 'EFO_0005809', 'EFO_0001421',
       'EFO_1001494', 'EFO_0000768', 'EFO_0005809', 'MONDO_0020547',
       'EFO_0000540', 'EFO_0000676', 'MONDO_0013730', 'EFO_1001951'],
      dtype=object), 'count': 12}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for graft versus host disease and immune system disease and has 9 investigational indications.
CHEMBL206815,CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO,MAVDNGWEBZTACC-HNNXBMFYSA-N,Small molecule,False,APRATASTAT,,2.0,,False,False,[],['Apratastat' 'TMI-005' 'TMI-05'],"[('drugbank', array(['DB13020'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}","[ENSG00000137745,ENSG00000151694]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108380,,,Protein,False,LIATERMIN,,2.0,,False,False,[],['Gdnf liatermin' 'Liatermin' 'R-methugdnf'],,,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000151892],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109512,,,Antibody,False,MCS-110,,2.0,,False,False,[],['MCS-110' 'Mcs-110'],,,"{'rows': array(['MONDO_0001056', 'MONDO_0007254', 'EFO_0000756'], dtype=object), 'count': 3}",[ENSG00000184371],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2316582,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1,TZKBVRDEOITLRB-UHFFFAOYSA-N,Small molecule,False,OLVEREMBATINIB,,3.0,,False,False,[],"['D-824' 'D-824 DIMESYLATE' 'GZD-824' 'GZD-824 DIMESYLATE' 'HQP-1351'
 'HQP-1351 DIMESYLATE' 'HQP1351' 'HQP1351 DIMESYLATE' 'Hqp1351'
 'Olverembatinib' 'Olverembatinib dimesylate']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLVEREMBATINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000339', 'EFO_0000220', 'MONDO_0011719'],
      dtype=object), 'count': 4}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL267495,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,XGZZHZMWIXFATA-UEZBDDGYSA-N,Small molecule,False,NALFURAFINE,2009.0,4.0,,False,True,[],['MT-9938' 'Nalfurafine'],"[('drugbank', array(['DB13471'], dtype=object))]",['CHEMBL490665'],"{'rows': array(['EFO_0003884', 'EFO_0001421'], dtype=object), 'count': 2}",[ENSG00000082556],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 2 investigational indications.
CHEMBL3545059,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)/C=C/C(=O)O,KLRSDBSKUSSCGU-KRQUFFFQSA-N,Small molecule,True,ALISKIREN FUMARATE,2007.0,4.0,CHEMBL1639,False,True,['Rasilez' 'Tekturna'],"['Aliskiren fumarate' 'Aliskiren hemifumarate' 'NSC-759185' 'SPP-100B'
 'SPP100']","[('DailyMed', array(['aliskiren%20hemifumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez'],
      dtype=object)), ('chEBI', array(['53777'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000712'], dtype=object), 'count': 2}",[ENSG00000143839],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hypertension and stroke. This drug has a black box warning from the FDA.
CHEMBL359744,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,MWWSFMDVAYGXBV-RUELKSSGSA-N,Small molecule,True,DOXORUBICIN HYDROCHLORIDE,1974.0,4.0,CHEMBL53463,False,True,"['Adriamycin' 'Adriamycin Rdf' 'Adriamycin pfs' 'Caelyx'
 'Caelyx pegylated liposomal' 'Doxil' 'Doxil (liposomal)'
 'Doxorubicin hydrochloride' 'Doxorubicin hydrochloride (liposomal)'
 'Myocet' 'Rubex']","['Adriablastina cs' 'Adriamycin, hydrochloride' 'Doxorubicin HCl'
 'Doxorubicin citrate' 'Doxorubicin citric acid salt' 'Doxorubicin hcl'
 'Doxorubicin hydrochloride'
 'Doxorubicin liposomal complex of the hydrochloride'
 'Doxorubicini hydrochloridum' 'Hydroxydaunomycin hydrochloride'
 'Liposomal doxorubicin hydrochloride']","[('DailyMed', array(['doxorubicin%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/caelyx-pegylated-liposomal'],
      dtype=object)), ('PubChem', array(['144203601', '144205614', '144209681', '170465451', '17389199',
       '49681823', '49718188', '50126368', '855944'], dtype=object))]",,"{'rows': array(['EFO_1000796', 'MONDO_0002974', 'EFO_0001378', 'EFO_1001042',
       'MONDO_0011934', 'MONDO_0003175', 'EFO_1001951', 'EFO_1000292',
       'EFO_0005561', 'EFO_0003060', 'EFO_0000223', 'EFO_0000183',
       'EFO_1000294', 'EFO_0001376', 'MONDO_0021054', 'EFO_0003869',
       'EFO_0006861', 'MONDO_0004986', 'EFO_0007143', 'EFO_0000437',
       'MONDO_0018364', 'EFO_0003144', 'EFO_0000198', 'MONDO_0005094',
       'EFO_1000984', 'EFO_0000095', 'EFO_0003893', 'EFO_0000691',
       'EFO_0000239', 'EFO_0000702', 'EFO_0000309', 'MONDO_0002367',
       'EFO_0000094', 'MONDO_0008315', 'MONDO_0017387', 'MONDO_0008170',
       'MONDO_0000870', 'EFO_0000588', 'EFO_0000220', 'EFO_0000565',
       'EFO_0000211', 'EFO_0000558', 'EFO_0000403', 'EFO_1001365',
       'MONDO_0008903', 'EFO_0003032', 'EFO_0000760', 'EFO_1000131',
       'EFO_0000174', 'EFO_0000569', 'EFO_0007160', 'EFO_0000637',
       'MONDO_0004992', 'MONDO_0009348', 'MONDO_0000873', 'EFO_0006475',
       'MONDO_0007254', 'MONDO_0002158', 'EFO_0000182', 'EFO_0003968',
       'EFO_0000222', 'MONDO_0004192', 'EFO_1002017', 'EFO_1000158',
       'MONDO_0004986', 'EFO_1001469', 'EFO_0005537', 'MONDO_0001187',
       'EFO_0000096', 'EFO_0000502', 'MONDO_0002678', 'EFO_0000305',
       'MONDO_0020077', 'EFO_0000248', 'MONDO_0002087', 'EFO_0009708',
       'EFO_0006859', 'MONDO_0008380', 'EFO_0005952', 'EFO_1001100',
       'EFO_0000681', 'EFO_1001968', 'MONDO_0015540', 'MONDO_0007576',
       'EFO_0002918', 'EFO_0000616', 'MONDO_0018906', 'MONDO_0019004',
       'EFO_1000251', 'EFO_0000209', 'MONDO_0002691', 'MONDO_0011962',
       'EFO_1000595', 'EFO_0007532', 'EFO_0001075', 'MONDO_0001056',
       'EFO_0000313', 'EFO_0000564', 'EFO_0000765', 'EFO_0000574',
       'MONDO_0004658', 'EFO_0000621', 'MONDO_0044917'], dtype=object), 'count': 103}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 22 approved and 81 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3833319,CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1,FYDWDCIFZSGNBU-UHFFFAOYSA-N,Small molecule,False,REVEFENACIN,2018.0,4.0,,False,True,['Yupelri'],['GSK-1160724' 'GSK1160724' 'Revefenacin' 'TD-4208'],"[('DailyMed', array(['revefenacin'], dtype=object)), ('drugbank', array(['DB11855'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'EFO_0000341', 'HP_0006536', 'EFO_0003086'],
      dtype=object), 'count': 4}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chronic obstructive pulmonary disease and airway obstruction and has 2 investigational indications.
CHEMBL3989834,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccncc2)nc1OC,YBWLTKFZAOSWSM-UHFFFAOYSA-N,Small molecule,False,AVOSENTAN,,3.0,,False,False,[],['Avosentan' 'RO 67-0565' 'RO-67-0565' 'Ro670565' 'SPP-301' 'SPP301'],,,"{'rows': array(['EFO_0000401'], dtype=object), 'count': 1}",[ENSG00000151617],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297064,CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl,XNCDYJFPRPDERF-UHFFFAOYSA-N,Small molecule,True,MILNACIPRAN HYDROCHLORIDE,2009.0,4.0,CHEMBL259209,False,True,['Dalcipran' 'Ixel' 'Milnacipran hydrochloride' 'Savella' 'Toledomin'],['Milnacipran hcl' 'Milnacipran hydrochloride' 'NSC-759806'],"[('DailyMed', array(['milnacipran%20hydrochloride'], dtype=object))]",,"{'rows': array(['HP_0003418', 'EFO_0005687'], dtype=object), 'count': 2}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for fibromyalgia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL492399,COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1,SNHCRNMVYDHVDT-UHFFFAOYSA-N,Small molecule,False,VERUBULIN,,2.0,,False,False,['Azixa'],['MPC-6827' 'MX-128495' 'Verubulin'],"[('drugbank', array(['DB05585'], dtype=object))]",['CHEMBL3910844' 'CHEMBL2105697'],"{'rows': array(['EFO_0000616', 'EFO_0000519', 'EFO_0003833'], dtype=object), 'count': 3}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL5315087,,,Unknown,False,PROTEIN C CONCENTRATE (HUMAN),2001.0,4.0,,False,True,['Ceprotin'],"['Human protein c' 'Protein c' 'Protein c (coagulation inhibitor)'
 'Protein c (homo sapiens)' 'Protein c human' 'Protexel']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin'],
      dtype=object))]",,"{'rows': array(['EFO_0009316', 'EFO_1001913', 'HP_0004419'], dtype=object), 'count': 3}",[ENSG00000115718],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved indications.
CHEMBL558752,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21,YABJJWZLRMPFSI-UHFFFAOYSA-N,Small molecule,False,RAF-265,,2.0,,False,False,[],['CHIR-265' 'NVP-RAF265' 'RAF265' 'Raf 265' 'Raf-265'],"[('PubChem', array(['137275908', '50100093'], dtype=object)), ('drugbank', array(['DB05984'], dtype=object))]",,"{'rows': array(['EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000128052,ENSG00000157764]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL585,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1,FNYLWPVRPXGIIP-UHFFFAOYSA-N,Small molecule,True,TRIAMTERENE,1964.0,4.0,,False,True,['Dyrenium' 'Dytac'],['NSC-639359' 'NSC-77625' 'SK&F 8542' 'SK&F-8542' 'SK-8542' 'Triamterene'],"[('DailyMed', array(['triamterene'], dtype=object)), ('PubChem', array(['104171252', '11111878', '11111879', '124881638', '124881640',
       '144203834', '144209219', '144213150', '170464706', '17389703',
       '26747035', '26751552', '50100356', '50104154', '50104155',
       '85231255', '855896', '90341047'], dtype=object)), ('TG-GATEs', array(['101'], dtype=object)), ('Wikipedia', array(['Triamterene'], dtype=object)), ('drugbank', array(['DB00384'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0003914', 'EFO_0001422', 'EFO_0004255',
       'MONDO_0005148', 'EFO_0009452', 'EFO_0000668', 'EFO_0000373',
       'EFO_0004278', 'EFO_0009373', 'EFO_0001645', 'HP_0003124',
       'EFO_0000319'], dtype=object), 'count': 13}","[ENSG00000111319,ENSG00000168447,ENSG00000166828]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 8 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL76370,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,IKBKZGMPCYNSLU-RGVLZGJSSA-N,Small molecule,False,TEGASEROD,2002.0,4.0,,True,True,[],['HTF 919' 'SDZ-HTF-919' 'Tegaserod'],"[('PubChem', array(['144205034', '170466887', '26749090'], dtype=object)), ('Wikipedia', array(['Tegaserod'], dtype=object)), ('drugbank', array(['DB01079'], dtype=object)), ('chEBI', array(['51043'], dtype=object))]",['CHEMBL533819' 'CHEMBL1516474' 'CHEMBL4303321'],"{'rows': array(['EFO_0008533', 'HP_0002019', 'EFO_0000555', 'MONDO_0002203',
       'EFO_0003948'], dtype=object), 'count': 5}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 3 approved and 2 investigational indications. It was withdrawn in at least one region.
CHEMBL846,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,GMRQFYUYWCNGIN-NKMMMXOESA-N,Small molecule,False,CALCITRIOL,1978.0,4.0,,False,True,"['Calcijex' 'Calcitriol' 'Dihydroxycholecalciferol' 'Dihydroxyvitamin D 3'
 'Rocaltrol' 'Silkis' 'Topitriol' 'Vectical']","['1,25-dihydroxy vitamin d3' '1,25-dihydroxyvitamin d3'
 '1,25-hydroxylated vitamin d' '1alpha,25-dihydroxycholecalciferol'
 '1alpha,25-dihydroxyvitamin d3' 'Calcitriol' 'RO 21-5535' 'RO-21-5535'
 'RO-215535']","[('DailyMed', array(['calcitriol'], dtype=object)), ('PubChem', array(['144205541', '26719902', '50110818'], dtype=object)), ('Wikipedia', array(['Calcitriol'], dtype=object)), ('drugbank', array(['DB00136'], dtype=object)), ('chEBI', array(['17823'], dtype=object))]",['CHEMBL578780'],"{'rows': array(['EFO_1001121', 'EFO_0002424', 'EFO_1001152', 'EFO_0000537',
       'EFO_0003884', 'MONDO_0100096', 'EFO_0000401', 'EFO_0003888',
       'MONDO_0008315', 'Orphanet_733', 'HP_0002901', 'HP_0100806',
       'EFO_0003854', 'EFO_0003868', 'EFO_0005221', 'MONDO_0024300',
       'EFO_0002617', 'EFO_0003882', 'EFO_0009451', 'EFO_1001494',
       'MONDO_0005147', 'Orphanet_89936', 'EFO_0003869', 'EFO_1000158',
       'MONDO_0007915', 'HP_0001919', 'EFO_0000673', 'EFO_0000616',
       'EFO_0000676', 'EFO_0002618', 'EFO_1001006', 'EFO_0000384',
       'MONDO_0017198', 'EFO_0004193', 'MONDO_0007254', 'EFO_0003060',
       'EFO_0000198'], dtype=object), 'count': 37}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 5 approved and 32 investigational indications.
CHEMBL1064,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,RYMZZMVNJRMUDD-HGQWONQESA-N,Small molecule,False,SIMVASTATIN,1991.0,4.0,,False,True,"['Flolipid' 'Lacersa' 'Ranzolont' 'Simvador' 'Simvastatin' 'Zocor'
 'Zocor heart-pro']","['C10AA01' 'MK-0733' 'MK-733' 'NSC-758706' 'Simvastatin'
 'Simvastatin hydroxy acid' 'Synvinolin']","[('DailyMed', array(['simvastatin'], dtype=object)), ('PubChem', array(['144204247', '144210718', '164339438', '170464984', '496592',
       '50086525'], dtype=object)), ('TG-GATEs', array(['117'], dtype=object)), ('Wikipedia', array(['Simvastatin'], dtype=object)), ('drugbank', array(['DB00641'], dtype=object)), ('chEBI', array(['9150'], dtype=object))]",,"{'rows': array(['EFO_1000359', 'EFO_0000713', 'EFO_0009441', 'EFO_0003060',
       'EFO_0004264', 'EFO_0007405', 'EFO_0004319', 'HP_0012532',
       'HP_0002140', 'EFO_0002618', 'MONDO_0005147', 'EFO_0004911',
       'EFO_0008522', 'EFO_0006834', 'EFO_0000474', 'EFO_0007328',
       'EFO_0000685', 'MONDO_0100096', 'EFO_0004268', 'EFO_0003770',
       'EFO_0000764', 'EFO_0001645', 'EFO_0005669', 'MONDO_0008903',
       'EFO_0004208', 'EFO_0008583', 'EFO_0003884', 'EFO_1001898',
       'EFO_0009783', 'EFO_1001782', 'MONDO_0010035', 'EFO_1001343',
       'EFO_0000731', 'EFO_1001466', 'EFO_0000195', 'EFO_1001951',
       'MONDO_0018997', 'EFO_0005672', 'EFO_0000712', 'EFO_0000666',
       'MONDO_0004985', 'EFO_0008568', 'EFO_0001663', 'EFO_0000182',
       'MONDO_0007915', 'MONDO_0004992', 'EFO_0004192', 'HP_0003119',
       'EFO_0000649', 'MONDO_0010557', 'MONDO_0001187', 'MONDO_0005180',
       'EFO_0600064', 'EFO_0000341', 'EFO_0001378', 'EFO_0000660',
       'EFO_0003106', 'EFO_1001231', 'MONDO_0005277', 'HP_0003124',
       'EFO_0000266', 'EFO_0001361', 'MONDO_0021118', 'EFO_0000702',
       'MP_0001845', 'EFO_1001375', 'EFO_0000407', 'EFO_0000612',
       'EFO_0000537', 'MONDO_0002009', 'EFO_0007486', 'EFO_0000574',
       'EFO_0004211', 'MONDO_0005301', 'MONDO_0008170', 'EFO_0003144',
       'MONDO_0005149', 'MONDO_0008315', 'EFO_1000652', 'EFO_0000401',
       'MONDO_0004979', 'MONDO_0001056', 'EFO_0000095', 'MONDO_0007254',
       'MONDO_0009061', 'MONDO_0011382', 'EFO_0000275', 'EFO_0000342',
       'EFO_0000319', 'EFO_0003914', 'HP_0100806', 'MONDO_0005148',
       'MONDO_0001134', 'Orphanet_309005', 'EFO_0004265',
       'Orphanet_79211', 'EFO_0000305', 'EFO_1001121', 'EFO_1000657',
       'EFO_0003876', 'EFO_0004197', 'MONDO_0004975', 'MONDO_0021187',
       'EFO_0001422', 'EFO_0003929', 'EFO_0009854', 'EFO_0000400'],
      dtype=object), 'count': 107}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 97 investigational indications.
CHEMBL1199080,CC[N+](C)(C)Cc1ccccc1Br,AAQOQKQBGPPFNS-UHFFFAOYSA-N,Small molecule,False,BRETYLIUM,1986.0,4.0,,False,True,[],['Bretylium' 'Bretylium cation' 'Bretylium ion'],"[('PubChem', array(['50113154', '50113155'], dtype=object)), ('Wikipedia', array(['Bretylium'], dtype=object)), ('drugbank', array(['DB01158'], dtype=object)), ('chEBI', array(['3172'], dtype=object))]",['CHEMBL1095292'],"{'rows': array(['EFO_0004269', 'EFO_0004287', 'HP_0004308'], dtype=object), 'count': 3}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications.
CHEMBL1200387,CC(N)Cc1ccccc1.O=C(O)CCCCC(=O)O,OFCJKOOVFDGTLY-UHFFFAOYSA-N,Small molecule,False,AMPHETAMINE ADIPATE,1975.0,4.0,CHEMBL405,False,True,[],['Amphetamine adipate'],,,,"[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975.
CHEMBL1200412,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@H]2OC(=O)CCc1ccccc1,UBWXUGDQUBIEIZ-QNTYDACNSA-N,Small molecule,False,NANDROLONE PHENPROPIONATE,1959.0,4.0,,False,True,['Durabolin' 'Nandrolone phenpropionate'],"['Nandrolone phenpropionate' 'Nandrolone phenylpropionate'
 'Norandrostenolone phenylpropionate' 'Nortestosterone furanpropionate'
 'Nortestosterone phenylpropionate']","[('PubChem', array(['144206893', '170465193'], dtype=object)), ('drugbank', array(['DB00984'], dtype=object)), ('chEBI', array(['7468'], dtype=object))]",,,[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959.
CHEMBL1200483,CC1NCCOC1c1ccccc1.Cl,VJNXVAVKCZJOFQ-UHFFFAOYSA-N,Small molecule,False,PHENMETRAZINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201208,False,True,['Preludin'],"['NSC-405728' 'Phenmetraline hydrochloride' 'Phenmetrazine chloride'
 'Phenmetrazine hcl' 'Phenmetrazine hydrochloride']","[('PubChem', array(['144205719', '170465166'], dtype=object)), ('chEBI', array(['8068'], dtype=object))]",,,"[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200600,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,FAOZLTXFLGPHNG-KNAQIMQKSA-N,Small molecule,False,FLUOROMETHOLONE,1972.0,4.0,,False,True,['Fluaton' 'Fluor-op' 'Fml forte' 'Fml fte' 'Fml-neo' 'Oxylone'],['Fluorometholone' 'NSC-33001'],"[('DailyMed', array(['fluorometholone'], dtype=object)), ('PubChem', array(['144203991', '144212910', '170464629', '56422125', '855588',
       '91286'], dtype=object)), ('Wikipedia', array(['Fluorometholone'], dtype=object)), ('drugbank', array(['DB00324'], dtype=object)), ('chEBI', array(['31625'], dtype=object))]",,"{'rows': array(['MP_0001845', 'HP_0007957', 'EFO_0005752', 'EFO_1000906',
       'EFO_0009552', 'EFO_0003894'], dtype=object), 'count': 6}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 4 approved and 2 investigational indications.
CHEMBL1200810,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,HKXBNHCUPKIYDM-CGMHZMFXSA-N,Small molecule,False,DOXERCALCIFEROL,1999.0,4.0,,False,True,['Doxercalciferol' 'Hectorol'],"['1-.alpha.-hydroxyergocalciferol' '1-alpha-hydroxyergocalciferol'
 '1-hydroxyergocalciferol' '1.alpha.-hydroxyergocalciferol'
 '1.alpha.-hydroxyvitamin d2' 'Doxercalciferol' 'GZ427397' 'TSA-840']","[('DailyMed', array(['doxercalciferol'], dtype=object)), ('PubChem', array(['144206531'], dtype=object)), ('Wikipedia', array(['Doxercalciferol'], dtype=object)), ('drugbank', array(['DB06410'], dtype=object)), ('chEBI', array(['4712'], dtype=object))]",,"{'rows': array(['EFO_1001173', 'EFO_0003884', 'EFO_0000676', 'MONDO_0008315',
       'EFO_0000616', 'EFO_0005754'], dtype=object), 'count': 6}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 3 investigational indications.
CHEMBL1743088,,,Antibody,False,VELTUZUMAB,,2.0,,False,False,[],['HA20' 'IMMU-106' 'Veltuzumab'],,,"{'rows': array(['EFO_0005952', 'EFO_0000220', 'EFO_0000095', 'EFO_0007160',
       'EFO_0000685', 'EFO_0000403', 'EFO_0000574', 'MONDO_0018906',
       'MONDO_0000432'], dtype=object), 'count': 9}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL1766582,Cl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,RQHSAIGGUWVOBG-UHFFFAOYSA-N,Small molecule,False,R-1487,,1.0,CHEMBL1230122,False,False,[],['R 1487' 'R-1487'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2109090,,,Antibody,False,ENLIMOMAB,,2.0,,False,False,[],['BI-RR-0001' 'BIRR-0001' 'Enlimomab'],,,,[ENSG00000090339],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109408,,,Antibody,False,LAMPALIZUMAB,,3.0,,False,False,[],"['AFD' 'Anti-fD' 'FCFD-4514S' 'FCFD4514S' 'Lampalizumab' 'RG-7417'
 'RG7417' 'Sn578b8z9q' 'anti-FACTOR-D']",,,"{'rows': array(['EFO_1001492'], dtype=object), 'count': 1}",[ENSG00000197766],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109571,,,Antibody,False,AMG-167,,1.0,,False,False,[],['AMG-167' 'Amg-167'],,,"{'rows': array(['HP_0000938'], dtype=object), 'count': 1}",[ENSG00000167941],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2110572,,,Small molecule,False,TECHNETIUM SUCCIMER,1982.0,4.0,,False,True,[],[],,['CHEMBL1200797'],,[ENSG00000175899],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL2110588,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2,FJZZPCZKBUKGGU-AUSIDOKSSA-N,Small molecule,False,ELIGLUSTAT,2014.0,4.0,,False,True,[],['Eliglustat' 'GENZ 99067' 'GENZ-99067'],"[('drugbank', array(['DB09039'], dtype=object)), ('chEBI', array(['82752'], dtype=object))]",['CHEMBL4297066'],"{'rows': array(['MONDO_0044881', 'MONDO_0018150', 'MONDO_0018150',
       'Orphanet_77261', 'Orphanet_77259'], dtype=object), 'count': 5}",[ENSG00000148154],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 1 investigational indication.
CHEMBL3545183,CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O.Cl,KHQMSZGKHGQUHG-WZDHWKSBSA-N,Protein,False,ETELCALCETIDE HYDROCHLORIDE,2016.0,4.0,CHEMBL3545184,False,True,['Parsabiv'],"['AMG 416' 'Etelcalcetide hydrochloride' 'KAI-4169 HCl'
 'Telcalcetide hydrochloride' 'Velcalcetide hydrochloride']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv'],
      dtype=object))]",,"{'rows': array(['EFO_1001173', 'EFO_0003884'], dtype=object), 'count': 2}",[ENSG00000036828],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for secondary hyperparathyroidism and chronic kidney disease.
CHEMBL3622820,N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,KTBSXLIQKWEBRB-UHFFFAOYSA-N,Small molecule,False,ITACITINIB,,3.0,,False,False,[],['INCB-039110' 'INCB039110' 'Incb-039110' 'Incb-39110' 'Itacitinib'],"[('drugbank', array(['DB12154'], dtype=object))]",['CHEMBL3948879' 'CHEMBL3707409' 'CHEMBL3947131'],"{'rows': array(['MONDO_0009348', 'EFO_0000540', 'MONDO_0013730', 'MONDO_0015540',
       'MONDO_0044881', 'MONDO_0008903', 'EFO_0000183', 'EFO_0000403',
       'MONDO_0020547', 'EFO_0000717', 'MONDO_0011962', 'EFO_0002618',
       'EFO_0000182', 'EFO_0004251', 'EFO_0000616', 'EFO_0000756',
       'MONDO_0044903', 'EFO_0003060', 'EFO_0007183', 'EFO_0004599',
       'EFO_0000676', 'HP_0000989', 'EFO_0005803', 'EFO_0000729',
       'MONDO_0007254', 'EFO_0000574', 'MONDO_0004992', 'EFO_1000560',
       'EFO_0007183', 'EFO_0000685'], dtype=object), 'count': 30}",[ENSG00000162434],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 29 investigational indications.
CHEMBL393220,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],FQCKMBLVYCEXJB-MNSAWQCASA-L,Small molecule,False,ATORVASTATIN CALCIUM,1996.0,4.0,CHEMBL1487,False,True,['Atorvastatin calcium' 'Lipitor'],"['Atorvastatin calcium' 'Atorvastatin calcium (anhydrous)'
 'Atorvastatin calcium anhydrous' 'Atorvastatin calcium hydrate'
 'Atorvastatin calcium salt anhydrous'
 'Atorvastatin calcium salt trihydrate' 'Atorvastatin calcium trihydrate'
 'CI-981' 'NSC-758617']","[('DailyMed', array(['atorvastatin%20calcium'], dtype=object)), ('PubChem', array(['144205238', '144212690', '170465113'], dtype=object)), ('chEBI', array(['50686'], dtype=object))]",,"{'rows': array(['MONDO_0018473', 'EFO_0001422', 'EFO_0003767', 'EFO_0009426',
       'EFO_0000198', 'EFO_0007328', 'EFO_0007129', 'EFO_0008568',
       'EFO_0000612', 'MONDO_0019338', 'EFO_0003086', 'MONDO_0005301',
       'EFO_0005672', 'MONDO_0002679', 'EFO_1001771', 'EFO_0008586',
       'EFO_0000275', 'EFO_0000196', 'EFO_0001361', 'MONDO_0021661',
       'EFO_0003095', 'EFO_0000764', 'EFO_0000676', 'MONDO_0013730',
       'MONDO_0018076', 'MONDO_0018373', 'EFO_0003869', 'EFO_0006818',
       'EFO_0004616', 'HP_0003119', 'EFO_0000616', 'EFO_0000685',
       'EFO_0009783', 'MONDO_0002492', 'HP_0100543', 'MONDO_0001444',
       'EFO_0000319', 'MONDO_0005147', 'EFO_0000180', 'EFO_0000222',
       'EFO_0007160', 'EFO_0008583', 'EFO_0003884', 'MONDO_0007254',
       'EFO_0000712', 'MONDO_0008315', 'EFO_0000519', 'EFO_0004208',
       'HP_0003124', 'EFO_0004264', 'MONDO_0004782', 'EFO_0003913',
       'EFO_1000984', 'EFO_1001993', 'EFO_0000660', 'Orphanet_79211',
       'EFO_0000538', 'EFO_0001645', 'Orphanet_413', 'EFO_0005952',
       'EFO_0000373', 'MONDO_0043510', 'MONDO_0001134', 'EFO_0004211',
       'MONDO_0011962', 'EFO_0000537', 'EFO_0000673', 'EFO_0008585',
       'EFO_1001249', 'EFO_0000384', 'EFO_0003144', 'EFO_0000318',
       'MONDO_0004992', 'EFO_0004255', 'EFO_1001466', 'EFO_0003870',
       'MONDO_0005835', 'EFO_0004246', 'EFO_0000649', 'EFO_0000574',
       'EFO_0004252', 'EFO_0003929', 'EFO_0004236', 'EFO_0001073',
       'EFO_0000365', 'EFO_0000681', 'Orphanet_309005', 'EFO_0000400',
       'EFO_0001378', 'EFO_0004286', 'EFO_0003914', 'EFO_0003047',
       'HP_0100806', 'EFO_0001365', 'EFO_0000668', 'EFO_0004911',
       'EFO_1001801', 'EFO_0000474', 'EFO_0004194', 'EFO_0003918',
       'EFO_0000195', 'HP_0000083', 'MONDO_0004975', 'MONDO_0004979',
       'MONDO_0005148', 'MONDO_0100096', 'MONDO_0021187', 'EFO_0000565',
       'MONDO_0007915', 'MONDO_0002050', 'HP_0001647', 'MONDO_0011382'],
      dtype=object), 'count': 112}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 13 approved and 99 investigational indications.
CHEMBL3989410,COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+],UHYAQBLOGVNWNT-UHFFFAOYSA-M,Small molecule,False,INDOMETHACIN SODIUM,1985.0,4.0,CHEMBL6,False,True,['Indocin' 'Indomethacin sodium'],"['Indometacin sodium' 'Indometacin sodium hydrate'
 'Indometacin sodium trihydrate' 'Indomethacin sodium'
 'Indomethacin sodium anhydrous' 'Indomethacin sodium salt trihydrate'
 'Indomethacin sodium trihydrate' 'Sodium indomethacin'
 'Sodium indomethacin trihydrate']",,,"{'rows': array(['MP_0001845'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and has 1 investigational indication.
CHEMBL407,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2,OFBIFZUFASYYRE-UHFFFAOYSA-N,Small molecule,True,FLUMAZENIL,1991.0,4.0,,False,True,['Anexate' 'Flumazenil' 'Flumazepil' 'Mazicon' 'Romazicon'],"['Flumazenil' 'Flumazepil' 'Lanexat' 'Mazicon' 'NSC-759193'
 'RO 15-1788/000' 'RO-15-1788' 'RO-151788' 'RO-151788000' 'RO-1722'
 'RO-41-8157']","[('DailyMed', array(['flumazenil'], dtype=object)), ('PubChem', array(['104171157', '11111184', '11114035', '11532958', '170464960',
       '26719655', '26752172', '26752173', '50104818', '56422177',
       '85231047', '90341071'], dtype=object)), ('Wikipedia', array(['Flumazenil'], dtype=object)), ('drugbank', array(['DB01205'], dtype=object)), ('chEBI', array(['5103'], dtype=object))]",,"{'rows': array(['MONDO_0018044', 'MONDO_0021107', 'EFO_0003890', 'MONDO_0007079',
       'EFO_0004242', 'MONDO_0005180', 'MONDO_0010383', 'EFO_0004698',
       'EFO_1001884', 'EFO_0005230'], dtype=object), 'count': 10}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4081711,CC[C@@H]1[C@H](F)C(=O)N[C@@H]1COc1nccc2cc(C(N)=O)c(OC)cc12,JKDGKIBAOAFRPJ-ZBINZKHDSA-N,Small molecule,False,ZIMLOVISERTIB,,2.0,,False,False,[],['PF-06650833' 'Pf 06650833' 'Pf-06650833' 'Zimlovisertib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZIMLOVISERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15143'], dtype=object))]",,"{'rows': array(['MONDO_0007915', 'EFO_1000710', 'EFO_0000685', 'MONDO_0100096',
       'EFO_1000637'], dtype=object), 'count': 5}",[ENSG00000198001],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4117187,COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br,GWCYPEHWIZXYFZ-UHFFFAOYSA-N,Small molecule,False,MASUPIRDINE,,3.0,,False,False,[],['Masupirdine' 'SUVN-502' 'Suvn-502'],"[('drugbank', array(['DB06140'], dtype=object))]",['CHEMBL4082473'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000158748],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4297734,,,Antibody,False,CRIZANLIZUMAB,2019.0,4.0,,False,True,['Adakveo'],"['Crizanlizumab' 'Crizanlizumab tmca' 'NVP-LXI-262' 'NVP-LXI262' 'SEG-101'
 'SEG101' 'SEL-G1' 'SelG1' 'Selg1']","[('DailyMed', array(['crizanlizumab-tmca'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adakveo'],
      dtype=object))]",,"{'rows': array(['MONDO_0011382', 'MONDO_0100096', 'MONDO_0044903', 'HP_0200023'],
      dtype=object), 'count': 4}",[ENSG00000174175],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for sickle cell anemia and has 3 investigational indications.
CHEMBL4297743,,,Antibody,False,ELEZANUMAB,,2.0,,False,False,[],['ABT-555' 'AE12-1Y-QL' 'Abt-555' 'Elezanumab' 'PR-1432051'],,,"{'rows': array(['HP_0002140', 'MONDO_0005301', 'EFO_1001919'], dtype=object), 'count': 3}",[ENSG00000182175],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297985,,,Antibody,False,MAGROLIMAB,,3.0,,False,False,[],['Hu5F9-G4' 'Hu5f9 g4' 'Hu5f9-g4' 'Magrolimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MAGROLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005537', 'EFO_0000198', 'MONDO_0008170', 'EFO_1001951',
       'EFO_0008528', 'EFO_0001378', 'EFO_0000181', 'EFO_1001051',
       'EFO_0000616', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0005952',
       'EFO_0000403', 'MONDO_0001657', 'EFO_0001642', 'MONDO_0009348',
       'EFO_1000785', 'EFO_0000222'], dtype=object), 'count': 18}",[ENSG00000196776],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications.
CHEMBL4303379,C[C@H](N)C(=O)N[C@@]1(C(=O)O)C[C@@H](Sc2nnc[nH]2)[C@H]2[C@H](C(=O)O)[C@H]21,BBGHHIUQOKQCBW-LDZWZCGGSA-N,Small molecule,False,LY2979165,,1.0,,False,False,[],['HY-13239' 'LY-2979165' 'Ly2979165'],,,"{'rows': array(['MONDO_0004985'], dtype=object), 'count': 1}",[ENSG00000164082],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4650419,,,Antibody,False,QUAVONLIMAB,,3.0,,False,False,[],['MK-1308' 'MK-1308A COMPONENT QUAVONLIMAB' 'Quavonlimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/QUAVONLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000681', 'EFO_0000182', 'EFO_0000756',
       'EFO_1001951', 'EFO_0000702', 'EFO_0003060'], dtype=object), 'count': 7}",[ENSG00000163599],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL513,O=NN(CCCl)C(=O)NCCCl,DLGOEMSEDOSKAD-UHFFFAOYSA-N,Small molecule,False,CARMUSTINE,1977.0,4.0,,False,True,['Bicnu' 'Carmustine obvius' 'Gliadel'],"['BCNU' 'Becenun' 'Bischloroethyl nitrosourea' 'Camustine' 'Carmubris'
 'Carmustine' 'DTI-015' 'FDA-0345' 'NSC-409962' 'SK-27702' 'SRI-1720']","[('DailyMed', array(['carmustine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-obvius'],
      dtype=object)), ('PubChem', array(['11110902', '124879537', '144203648', '170464880', '174007319',
       '26747453', '26753530', '479311', '50105925', '57264377',
       '85230955', '90341293'], dtype=object)), ('Wikipedia', array(['Carmustine'], dtype=object)), ('drugbank', array(['DB00262'], dtype=object)), ('chEBI', array(['3423'], dtype=object))]",,"{'rows': array(['EFO_0002913', 'EFO_0005543', 'EFO_1001469', 'EFO_0000565',
       'EFO_0000756', 'MONDO_0005184', 'EFO_1001051', 'EFO_0004256',
       'Orphanet_145', 'EFO_0003929', 'EFO_0000216', 'EFO_0000621',
       'EFO_0000096', 'EFO_0000519', 'EFO_1001465', 'EFO_1000785',
       'EFO_0000305', 'EFO_0000095', 'MONDO_0008170', 'EFO_0007498',
       'EFO_1000028', 'EFO_0002939', 'EFO_0005952', 'MONDO_0008315',
       'EFO_0001378', 'EFO_0000211', 'MONDO_0100342', 'EFO_1000158',
       'EFO_0000616', 'MONDO_0018906', 'HP_0001871', 'MONDO_0007254',
       'EFO_0004991', 'EFO_0000574', 'EFO_0006475', 'EFO_0000389',
       'EFO_0000691', 'EFO_0000183', 'EFO_0002501', 'EFO_0009538',
       'MONDO_0001657', 'EFO_1001383', 'EFO_0002499', 'EFO_0000272',
       'EFO_0000403', 'MONDO_0003268', 'EFO_1001951', 'EFO_0004599',
       'EFO_0003833'], dtype=object), 'count': 49}",[ENSG00000104687],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 12 approved and 37 investigational indications.
CHEMBL5315054,CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1.O=C1CC[C@@H](C(=O)O)N1,YHIUPZFKHZTLSH-LXYIGGQGSA-N,Small molecule,False,ERTUGLIFLOZIN PIDOLATE,2018.0,4.0,CHEMBL1770248,False,True,['Steglatro'],['Ertugliflozin l-pyroglutamic acid'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/steglatro'],
      dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for type 2 diabetes mellitus.
CHEMBL606,CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,OJLOPKGSLYJEMD-URPKTTJQSA-N,Small molecule,True,MISOPROSTOL,1988.0,4.0,,False,True,['Cytotec' 'Misoprostol' 'Mysodelle' 'Topogyne'],['Misoprostol' 'SC-29333'],"[('DailyMed', array(['misoprostol'], dtype=object)), ('PubChem', array(['11532984', '144205563', '26755780', '26755781'], dtype=object)), ('Wikipedia', array(['Misoprostol'], dtype=object)), ('drugbank', array(['DB00929'], dtype=object))]",,"{'rows': array(['EFO_1001255', 'EFO_0000668', 'EFO_0004607', 'MONDO_0004247',
       'EFO_0009579', 'EFO_0000731', 'MONDO_0000931', 'HP_0000132',
       'EFO_0000544', 'EFO_0002950', 'EFO_0003843', 'EFO_1001249',
       'MONDO_0001572', 'EFO_0009454', 'MONDO_0005178', 'MONDO_0003061',
       'EFO_0009846', 'EFO_0003898', 'HP_0004398', 'EFO_0001073',
       'MP_0001914', 'EFO_1000874', 'EFO_0003948', 'EFO_1001799',
       'EFO_0003917'], dtype=object), 'count': 25}",[ENSG00000050628],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 7 approved and 18 investigational indications. This drug has a black box warning from the FDA.
CHEMBL628,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,Small molecule,False,PENTOXIFYLLINE,1984.0,4.0,,False,True,"['Neotren mr' 'Pentoxifylline' 'Pentoxil' 'Trental' 'Trental 100'
 'Trental 400']","['BL 191' 'BL-191' 'C04AD03' 'NSC-637086' 'NSC-758481' 'Oxpentifylline'
 'Oxypentifylline' 'Pentoxifylline' 'Pentoxiphyllin']","[('DailyMed', array(['pentoxifylline'], dtype=object)), ('PubChem', array(['11111613', '11111614', '124881066', '144203774', '170465384',
       '26719692', '26747196', '50085870', '50105176', '85231180',
       '857899', '90341235'], dtype=object)), ('Wikipedia', array(['Pentoxifylline'], dtype=object)), ('drugbank', array(['DB00806'], dtype=object)), ('chEBI', array(['7986'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'EFO_1001249', 'EFO_0000278', 'MONDO_0021681',
       'MONDO_0004985', 'MONDO_0100096', 'MONDO_0002050', 'MONDO_0010679',
       'EFO_0001065', 'EFO_0000545', 'EFO_0004272', 'EFO_1001346',
       'EFO_0003780', 'MONDO_0008867', 'EFO_1001345', 'EFO_0003767',
       'HP_0001919', 'EFO_0006890', 'EFO_0003928', 'EFO_1001486',
       'EFO_0000319', 'EFO_0005046', 'EFO_1000158', 'EFO_0003869',
       'EFO_0005774', 'MONDO_0018373', 'MONDO_0002462', 'EFO_0003060',
       'EFO_0004255', 'EFO_0000384', 'EFO_0003884', 'EFO_0005044',
       'EFO_0004284', 'HP_0001643', 'HP_0001397', 'MONDO_0005090',
       'EFO_1000844', 'MONDO_0002009', 'EFO_0007444', 'HP_0040187',
       'EFO_0001645', 'EFO_0004259', 'EFO_0005672', 'EFO_0000474',
       'HP_0001399', 'EFO_0000401', 'MONDO_0004992', 'EFO_0000546',
       'EFO_0001422', 'EFO_0000220', 'EFO_1000652', 'DOID_13406'],
      dtype=object), 'count': 52}","[ENSG00000170425,ENSG00000128271,ENSG00000138735,ENSG00000065989,ENSG00000172572,ENSG00000139053,ENSG00000185527,ENSG00000186642,ENSG00000205268,ENSG00000115252,ENSG00000160191,ENSG00000133256,ENSG00000113448,ENSG00000184588,ENSG00000156973,ENSG00000132915,ENSG00000152270,ENSG00000095464,ENSG00000113231,ENSG00000112541,ENSG00000123360,ENSG00000105650,ENSG00000154678,ENSG00000073417,ENSG00000171408]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and has 51 investigational indications.
CHEMBL748,C[n+]1ccccc1/C=N/O.[Cl-],HIGSLXSBYYMVKI-UHFFFAOYSA-N,Small molecule,False,PRALIDOXIME CHLORIDE,1964.0,4.0,CHEMBL1420,False,True,"['2-Pam' 'Contrathion' 'Duodote' 'Pralidoxime chloride'
 'Pralidoxime chloride (autoinjector)' 'Protopam' 'Protopam chloride']","['2-PAM' '2-PAM CHLORIDE' '2-PAM Chloride' 'NSC-164614'
 'Pralidoxime chloride' 'Protopam']","[('DailyMed', array(['pralidoxime%20chloride'], dtype=object)), ('PubChem', array(['11533058', '144203867', '170465059', '56422221'], dtype=object)), ('chEBI', array(['8355'], dtype=object))]",,"{'rows': array(['EFO_0008546', 'EFO_0004991'], dtype=object), 'count': 2}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for poisoning and myasthenia gravis.
CHEMBL1085,CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2,WNTYBHLDCKXEOT-UHFFFAOYSA-N,Small molecule,False,ACETOPHENAZINE,1961.0,4.0,,False,True,[],['Acetophenazine' 'Tindal'],"[('PubChem', array(['50125831'], dtype=object)), ('Wikipedia', array(['Acetophenazine'], dtype=object)), ('drugbank', array(['DB01063'], dtype=object)), ('chEBI', array(['2401'], dtype=object))]",['CHEMBL2360079'],"{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961 and is indicated for psychosis.
CHEMBL1200947,CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C.Cl,BLWNYSZZZWQCKO-UHFFFAOYSA-N,Small molecule,False,METIPRANOLOL HYDROCHLORIDE,1989.0,4.0,CHEMBL1291,True,True,['Metipranolol' 'Optipranolol'],['Betamann' 'Metipranolol hcl'],"[('chEBI', array(['34845'], dtype=object))]",,,"[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989. It was withdrawn in at least one region.
CHEMBL1201302,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O,VQODGRNSFPNSQE-CXSFZGCWSA-N,Small molecule,False,DEXAMETHASONE PHOSPHORIC ACID,1959.0,4.0,,False,True,[],['Dexamethasone phosphate' 'Dexamethasone phosphoric acid'],"[('chEBI', array(['68637'], dtype=object))]",['CHEMBL1200637' 'CHEMBL2021430'],"{'rows': array(['MONDO_0004979', 'EFO_1000941', 'MONDO_0007915', 'EFO_0000556',
       'EFO_0007328', 'MONDO_0008728', 'EFO_0009609', 'EFO_0004719',
       'EFO_1000039', 'EFO_1000764', 'MONDO_0005129', 'EFO_1000997',
       'EFO_1001896', 'EFO_0000574', 'HP_0001915', 'EFO_0001642',
       'EFO_1001051', 'HP_0012424', 'EFO_0005558', 'HP_0001873',
       'EFO_0007257', 'MONDO_0100096', 'EFO_1002022', 'EFO_0004276',
       'EFO_1001250', 'EFO_0006738', 'EFO_0005319', 'MP_0001845',
       'EFO_0000729', 'EFO_1000049', 'EFO_0007141', 'EFO_0009491',
       'EFO_0001378', 'MONDO_0003005', 'EFO_0003929', 'MONDO_0001718',
       'EFO_0004265', 'EFO_1000906', 'EFO_0007490', 'EFO_0008997',
       'EFO_1000845', 'EFO_1000811', 'MONDO_0005178', 'EFO_1001194',
       'EFO_0007403', 'EFO_0007520', 'EFO_0004255', 'EFO_0004274',
       'MONDO_0015128', 'EFO_1000684', 'EFO_1001119', 'EFO_0003778',
       'EFO_0003898', 'EFO_0000694', 'EFO_0000565', 'MONDO_0019338',
       'EFO_0003956', 'EFO_0003106', 'EFO_0000685', 'EFO_0009560',
       'EFO_0000384', 'EFO_1001222', 'EFO_0009456', 'HP_0004398',
       'HP_0003072', 'EFO_0002609', 'EFO_0000676', 'EFO_0007405',
       'EFO_0009449', 'EFO_0005854', 'HP_0001094', 'EFO_1001205',
       'MONDO_0001280', 'HP_0003040', 'EFO_1000694', 'EFO_0007160',
       'EFO_1001435', 'EFO_0000274'], dtype=object), 'count': 78}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 60 approved and 18 investigational indications.
CHEMBL1201891,CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,FBHSPRKOSMHSIF-GRMWVWQJSA-N,Small molecule,False,DEFLAZACORT,2017.0,4.0,,False,True,['Calcort' 'Emflaza' 'Zamene'],['Deflazacort' 'MDL 458' 'MDL-458' 'MDL458'],"[('DailyMed', array(['deflazacort'], dtype=object)), ('PubChem', array(['144206059', '144211732', '170466610'], dtype=object)), ('drugbank', array(['DB11921'], dtype=object))]",,"{'rows': array(['MONDO_0020121', 'EFO_0001421', 'MONDO_0016971', 'EFO_0003086',
       'EFO_0007140', 'MONDO_0010679'], dtype=object), 'count': 6}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for muscular dystrophy and duchenne muscular dystrophy and has 4 investigational indications.
CHEMBL1275868,CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1,ZKFQEACEUNWPMT-UHFFFAOYSA-N,Small molecule,False,AZELNIDIPINE,,3.0,,False,False,[],['Azelnidipine' 'Calblock'],"[('PubChem', array(['144205993', '170465756', '174006618', '50112690'], dtype=object)), ('drugbank', array(['DB09230'], dtype=object))]",,,"[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of III.
CHEMBL142703,N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,SYOKIDBDQMKNDQ-XWTIBIIYSA-N,Small molecule,False,VILDAGLIPTIN,2007.0,4.0,,False,True,['Galvus' 'Xiliarx'],"['LAF 237' 'LAF-237' 'LAF237' 'NVP-LAF 237' 'NVP-LAF237' 'Vildagliptin'
 'Vitagliptin']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xiliarx'],
      dtype=object)), ('Wikipedia', array(['Vildagliptin'], dtype=object)), ('drugbank', array(['DB04876'], dtype=object))]",,"{'rows': array(['EFO_0004593', 'MONDO_0005147', 'EFO_1001121', 'MONDO_0005148',
       'EFO_0000400', 'MONDO_0002009', 'EFO_0002546'], dtype=object), 'count': 7}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 5 investigational indications.
CHEMBL1742985,,,Antibody,False,ANRUKINZUMAB,,2.0,,False,False,[],['Anrukinzumab' 'IMA-638'],,,"{'rows': array(['MONDO_0004979', 'EFO_0000729'], dtype=object), 'count': 2}",[ENSG00000169194],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2035187,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2,HWXVIOGONBBTBY-ONEGZZNKSA-N,Small molecule,False,PACRITINIB,2022.0,4.0,,False,True,[],['ONX-0803' 'Pacritinib' 'SB-1518' 'SB1518' 'Sb-1518'],"[('drugbank', array(['DB11697'], dtype=object))]",['CHEMBL5095049'],"{'rows': array(['EFO_0000616', 'MONDO_0100096', 'EFO_0004251', 'EFO_0002429',
       'EFO_1001469', 'MONDO_0007254', 'EFO_0002430', 'EFO_0002430',
       'MONDO_0013730', 'EFO_1001951', 'EFO_0000222', 'EFO_0001421',
       'EFO_0003060', 'EFO_0000095', 'MONDO_0044903', 'EFO_0000183',
       'EFO_0000565', 'MONDO_0008315'], dtype=object), 'count': 18}","[ENSG00000122025,ENSG00000096968]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 15 investigational indications.
CHEMBL2108356,,,Protein,False,PEGDINETANIB,,2.0,,False,False,[],"['Angiocept' 'BMS-844203' 'CT-322' 'Ct-322' 'Pegdinetanib'
 'VEGFR-2 INHIBITOR PEPTIDE CT-322']",,,"{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000519',
       'EFO_0000365'], dtype=object), 'count': 5}",[ENSG00000128052],Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2108734,,,Antibody,False,FLANVOTUMAB,,2.0,,False,False,[],['20-D-7S' '20D7S' 'Flanvotumab' 'IMC-20D7S' 'IMC20D7S'],,,"{'rows': array(['EFO_0000756'], dtype=object), 'count': 1}",[ENSG00000107165],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109259,,,Antibody,False,IGN-101,,3.0,,False,False,[],['IGN-101'],,,,[ENSG00000119888],Antibody drug with a maximum clinical trial phase of III.
CHEMBL2109677,,,Antibody,False,HUJ591 111IN,,2.0,,False,False,[],['HUJ591' 'Huj591 (111in)' 'Huj591 111in'],,,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000086205],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2364653,,,Antibody,False,ANIFROLUMAB,2021.0,4.0,,False,True,['Saphnelo'],['Anifrolumab' 'Anifrolumab fnia' 'MEDI-546'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo'],
      dtype=object))]",,"{'rows': array(['EFO_1001993', 'MONDO_0007915', 'EFO_0000699', 'EFO_0000540',
       'EFO_0004208', 'EFO_0000717', 'EFO_0000685', 'EFO_0005761'],
      dtype=object), 'count': 8}",[ENSG00000142166],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for systemic lupus erythematosus and immune system disease and has 6 investigational indications.
CHEMBL260538,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,OOLLAFOLCSJHRE-ZHAKMVSLSA-N,Small molecule,False,ULIPRISTAL ACETATE,2009.0,4.0,,True,True,['Ella' 'Ellaone' 'Esmya'],"['CDB-2914' 'PGL-4001' 'RTI-3021-012' 'Ulipristal acet'
 'Ulipristal acetate' 'Ulipristal acetate ' 'VA-2914' 'VA2914']","[('DailyMed', array(['ulipristal%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ellaone',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/esmya'],
      dtype=object)), ('Wikipedia', array(['Ulipristal_acetate'], dtype=object)), ('chEBI', array(['71025'], dtype=object))]",,"{'rows': array(['GO_0042697', 'EFO_0009520', 'MONDO_0007309', 'HP_0000131',
       'MONDO_0004169', 'EFO_1001757', 'MONDO_0001572', 'MP_0001914',
       'MONDO_0007254', 'EFO_0000731', 'MONDO_0002050'], dtype=object), 'count': 11}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 7 investigational indications. It was withdrawn in at least one region.
CHEMBL270995,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1,LTEJRLHKIYCEOX-OCCSQVGLSA-N,Small molecule,False,BRIVANIB ALANINATE,,3.0,,False,False,[],"['BMS-582664' 'BMS-582664-02' 'Brivanib alaninate'
 'Brivanib l-alanine ester']","[('drugbank', array(['DB11865'], dtype=object))]",['CHEMBL3526472'],"{'rows': array(['EFO_0000182', 'MONDO_0004992', 'EFO_0000681', 'EFO_0000616',
       'EFO_1001951'], dtype=object), 'count': 5}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL28218,O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1,RKLNONIVDFXQRX-UHFFFAOYSA-N,Small molecule,False,BROMPERIDOL,,4.0,,False,True,['Impromen'],"['Bromperidol' 'NSC-759275' 'R 11,333' 'R-11333']","[('PubChem', array(['11112600', '144204116', '170465873', '56463221'], dtype=object)), ('Wikipedia', array(['Bromperidol'], dtype=object)), ('drugbank', array(['DB12401'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'EFO_0005407',
       'MONDO_0005090'], dtype=object), 'count': 5}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications.
CHEMBL3184799,CNC(C)(C)Cc1ccccc1.CNC(C)(C)Cc1ccccc1.O=S(=O)(O)O,DNKCFBJMFIUNRS-UHFFFAOYSA-N,Small molecule,False,MEPHENTERMINE SULFATE,1951.0,4.0,CHEMBL1201234,False,True,['Wyamine sulfate'],"['Mephentermine sulfate' 'Mephentermine sulfate dihydrate'
 'Mephentermine sulphate' 'Mephine' 'NSC-758424' 'Wyamine'
 'Wyamine sulphate']","[('PubChem', array(['144204052', '170465271'], dtype=object))]",,,"[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951.
CHEMBL3989833,CS(=O)(=O)O.O.O.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1,WLQZEFFFIUHSJB-UHFFFAOYSA-N,Small molecule,True,ZIPRASIDONE MESYLATE,2002.0,4.0,CHEMBL708,False,True,['Geodon'],"['CP-88, 059-27' 'CP-88,059-27' 'CP-88059-27' 'CP-8805927' 'NSC-760351'
 'Ziprasidone mesilate' 'Ziprasidone mesilate trihydrate'
 'Ziprasidone mesylate' 'Ziprasidone mesylate anhydrous']","[('DailyMed', array(['ziprasidone%20mesylate'], dtype=object))]",,"{'rows': array(['MONDO_0004985', 'MONDO_0005090'], dtype=object), 'count': 2}","[ENSG00000102468,ENSG00000149295,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for bipolar disorder and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL425,O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O,QQBDLJCYGRGAKP-FOCLMDBBSA-N,Small molecule,False,OLSALAZINE,1990.0,4.0,,False,True,[],['C. i. mordant yellow 5' 'Dipentum' 'Olsalazine'],"[('PubChem', array(['50125747'], dtype=object)), ('drugbank', array(['DB01250'], dtype=object))]",['CHEMBL1201013'],"{'rows': array(['EFO_0003898', 'EFO_0000729'], dtype=object), 'count': 2}","[ENSG00000012779,ENSG00000132170,ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for ulcerative colitis and has 1 investigational indication.
CHEMBL4297322,N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F.O=C(O)/C=C/C(=O)O,RPYIKXHIQXRXEM-WLHGVMLRSA-N,Small molecule,False,PRX-08066,,2.0,CHEMBL513994,False,False,[],['Prx-08066'],"[('drugbank', array(['DB05607'], dtype=object))]",,,[ENSG00000135914],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297800,,,Protein,False,PEGTEOGRASTIM,,2.0,,False,False,[],['Neulapeg' 'Pegteograstim'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297892,,,Antibody drug conjugate,False,ANVATABART OPADOTIN,,2.0,,False,False,[],"['ARX-788' 'ARX788' 'ARX788 ADC' 'Anvatabart opadotin'
 'Anvatabart opafidotin' 'Arx 788' 'Arx-788' 'Arx788']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ANVATABART%20OPADOTIN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0003968',
       'EFO_0003869', 'EFO_0005537'], dtype=object), 'count': 6}","[ENSG00000141736,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4594272,Cl.Cl.N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1,XFZLBLTUANGZBD-UHFFFAOYSA-N,Small molecule,False,BEROTRALSTAT HYDROCHLORIDE,2020.0,4.0,CHEMBL4594271,False,True,['Orladeyo'],"['BCX7353.2HCl' 'Berotralstat dihydrochloride'
 'Berotralstat hydrochloride']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BEROTRALSTAT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005532', 'MONDO_0019623'], dtype=object), 'count': 2}",[ENSG00000164344],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hereditary angioedema and has 1 investigational indication.
CHEMBL4650285,Cn1nccc1Nc1nccc(-c2cc3c(s2)C(C)(C)N(CCN2CCOCC2)C3=O)n1,JNPRPMBJODOFEC-UHFFFAOYSA-N,Small molecule,False,TEMUTERKIB,,2.0,,False,False,[],['LY-3214996' 'LY3214996' 'Ly 3214996' 'Ly3214996' 'Temuterkib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEMUTERKIB/relevant/1/'],
      dtype=object))]",['CHEMBL4802243'],"{'rows': array(['EFO_0000616', 'MONDO_0005184', 'EFO_0002618', 'EFO_0000616',
       'EFO_0000222', 'MONDO_0004992', 'EFO_0000519'], dtype=object), 'count': 7}","[ENSG00000102882,ENSG00000100030]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL468419,Cl.N#Cc1ccc(C2CCCc3cncn32)cc1,UKCVAQGKEOJTSR-UHFFFAOYSA-N,Small molecule,False,FADROZOLE HYDROCHLORIDE,,-1.0,CHEMBL9298,False,False,[],"['Afema' 'CGS 16949A' 'CGS-16949A' 'Fadrozole hcl'
 'Fadrozole hydrochloride']","[('PubChem', array(['144213918'], dtype=object))]",,,[ENSG00000137869],Small molecule drug.
CHEMBL481,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,UWKQSNNFCGGAFS-XIFFEERXSA-N,Small molecule,True,IRINOTECAN,1996.0,4.0,,False,True,[],['Biotecan' 'Camptosar' 'Irinotecan' 'NSC-728073'],"[('PubChem', array(['124893595'], dtype=object)), ('Wikipedia', array(['Irinotecan'], dtype=object)), ('drugbank', array(['DB00762'], dtype=object)), ('chEBI', array(['80630'], dtype=object))]",['CHEMBL541887' 'CHEMBL1200512' 'CHEMBL3989514'],"{'rows': array(['EFO_1000359', 'EFO_1001901', 'MONDO_0002120', 'EFO_1001013',
       'EFO_0002618', 'EFO_0001075', 'MONDO_0004669', 'EFO_0000681',
       'EFO_0002617', 'EFO_0000707', 'EFO_0005543', 'EFO_0000178',
       'EFO_1000350', 'EFO_1000292', 'MONDO_0008315', 'EFO_0003893',
       'EFO_0000309', 'EFO_0003833', 'MONDO_0002120', 'EFO_0002501',
       'EFO_0000565', 'EFO_1000475', 'MONDO_0018364', 'EFO_0003860',
       'EFO_1001051', 'MONDO_0008170', 'MONDO_0021063', 'EFO_0000702',
       'EFO_0000326', 'MONDO_0007576', 'MONDO_0008903', 'MONDO_0008903',
       'EFO_0000621', 'HP_0002014', 'MONDO_0004992', 'EFO_0006352',
       'MONDO_0003060', 'EFO_1000359', 'EFO_0002918', 'EFO_1000158',
       'MONDO_0002974', 'EFO_0000174', 'MONDO_0044937', 'EFO_0004243',
       'MONDO_0002367', 'EFO_0009708', 'EFO_1001961', 'MONDO_0001475',
       'EFO_1000251', 'MONDO_0005575', 'EFO_0003968', 'MONDO_0044937',
       'EFO_0002939', 'EFO_0000632', 'MONDO_0005411', 'MONDO_0002087',
       'MONDO_0024503', 'EFO_1000895', 'EFO_0005952', 'EFO_1000657',
       'EFO_0003869', 'MONDO_0001325', 'EFO_0001416', 'MONDO_0005184',
       'EFO_1001951', 'EFO_0003891', 'EFO_0002499', 'EFO_1000785',
       'EFO_1001469', 'EFO_0000502', 'MONDO_0001187', 'MONDO_0001879',
       'EFO_0000389', 'EFO_1001365', 'EFO_0002618', 'EFO_0000502',
       'EFO_0000637', 'EFO_1001471', 'EFO_0000691', 'EFO_0006859',
       'EFO_0002939', 'EFO_0000616', 'EFO_1001949', 'MONDO_0005184',
       'EFO_0000691', 'EFO_0000616', 'EFO_0000503', 'EFO_0000174',
       'EFO_0003032', 'EFO_0002499', 'EFO_0000365', 'EFO_0005221',
       'EFO_0004142', 'EFO_0000588', 'MONDO_0021633', 'MONDO_0018271',
       'EFO_0007416', 'EFO_0000255', 'MONDO_0021063', 'EFO_0001075',
       'EFO_1000657', 'MONDO_0002367', 'MONDO_0002158', 'EFO_1001512',
       'EFO_0000313', 'EFO_1000292', 'EFO_0000707', 'EFO_0000403',
       'EFO_0000228', 'MONDO_0100342', 'EFO_0000574', 'MONDO_0016717',
       'EFO_0000365', 'EFO_1000407', 'MONDO_0044926', 'MONDO_0000873',
       'EFO_0002938', 'MONDO_0001056', 'MONDO_0002165', 'MONDO_0002537',
       'EFO_0002918', 'EFO_0002501', 'EFO_0005537', 'MONDO_0002974',
       'EFO_0004193', 'MONDO_0002087', 'EFO_0008549', 'EFO_0000519',
       'EFO_0003860', 'EFO_0000437', 'EFO_1000475', 'EFO_0004288',
       'MONDO_0003060', 'MONDO_0008170', 'EFO_0000191', 'EFO_0001061',
       'MONDO_0007254', 'EFO_1001465', 'EFO_0003060', 'MONDO_0020634',
       'EFO_0000702', 'EFO_0002916', 'EFO_0000313', 'EFO_0000519',
       'MONDO_0007576', 'MONDO_0019004', 'EFO_0000621', 'EFO_1000026',
       'EFO_0005537', 'MONDO_0100342', 'MONDO_0001657', 'EFO_0000095',
       'MONDO_0002158', 'MONDO_0019471', 'EFO_0000503', 'MONDO_0016717',
       'EFO_0007535', 'MONDO_0011719', 'EFO_0000182', 'EFO_0000574',
       'MONDO_0003196', 'EFO_0000183', 'EFO_0003897', 'EFO_0000197',
       'EFO_0005922', 'EFO_0006859', 'MONDO_0002691', 'Orphanet_145',
       'EFO_1000158', 'EFO_0004142', 'MONDO_0006058', 'EFO_1001465',
       'MONDO_0021117', 'EFO_1001951', 'EFO_0001071', 'EFO_0000248',
       'EFO_0000178', 'MONDO_0018906', 'MONDO_0004192', 'MONDO_0004992',
       'EFO_1001512', 'MONDO_0007254', 'EFO_0000565', 'MONDO_0002691',
       'EFO_0003060', 'MONDO_0001056'], dtype=object), 'count': 186}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 148 investigational indications. This drug has a black box warning from the FDA.
CHEMBL592,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13,JAQUASYNZVUNQP-USXIJHARSA-N,Small molecule,True,LEVORPHANOL,1991.0,4.0,,False,True,[],['Aromarone' 'IDS-NL-007' 'Levorphan' 'Levorphanol' 'RO 1-5431'],"[('Wikipedia', array(['Levorphanol'], dtype=object)), ('drugbank', array(['DB00854'], dtype=object)), ('chEBI', array(['6444'], dtype=object))]",['CHEMBL1628243' 'CHEMBL2062261' 'CHEMBL3989768' 'CHEMBL3249801'],"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991 and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL760,O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1,OTBXOEAOVRKTNQ-UHFFFAOYSA-N,Small molecule,False,ANAGRELIDE,1997.0,4.0,,False,True,[],['Agrylin' 'Anagrelide' 'Xagrid'],"[('PubChem', array(['124892336', '26755034'], dtype=object)), ('Wikipedia', array(['Anagrelide'], dtype=object)), ('drugbank', array(['DB00261'], dtype=object)), ('chEBI', array(['142290'], dtype=object))]",['CHEMBL1200759'],"{'rows': array(['EFO_0004251', 'EFO_0000479', 'EFO_0002429', 'MONDO_0000831',
       'EFO_0000479', 'EFO_0004251', 'HP_0004419', 'EFO_0000616'],
      dtype=object), 'count': 8}","[ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 3 investigational indications.
CHEMBL1200399,Cl.O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,RICLFGYGYQXUFH-UHFFFAOYSA-N,Small molecule,False,BUSPIRONE HYDROCHLORIDE,1986.0,4.0,CHEMBL49,False,True,['Buspar' 'Buspirone hydrochloride'],"['APD-405' 'APD405' 'Buspirone hcl' 'Buspirone hydrochloride' 'MJ 9022-1'
 'MJ-9022-1' 'NSC-751138' 'NSC-759571']","[('DailyMed', array(['buspirone%20hydrochloride'], dtype=object)), ('PubChem', array(['11533010', '50105965', '56422091'], dtype=object)), ('chEBI', array(['3224'], dtype=object))]",,"{'rows': array(['EFO_0006788', 'MONDO_0005090', 'EFO_0004714', 'EFO_0005411',
       'MONDO_0002050', 'EFO_1001892', 'EFO_0004888', 'EFO_1001919'],
      dtype=object), 'count': 8}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 5 investigational indications.
CHEMBL1200515,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,CVBMAZKKCSYWQR-WCGOZPBSSA-N,Small molecule,False,DESERPIDINE,1957.0,4.0,,False,True,['Harmonyl'],"['Deserpidine' 'Deserpidine, (-)-' 'Halmonyl' 'NSC-72138' 'Recanescin']","[('PubChem', array(['144206199', '144206653', '50113288'], dtype=object)), ('Wikipedia', array(['Deserpidine'], dtype=object)), ('drugbank', array(['DB01089'], dtype=object)), ('chEBI', array(['27478'], dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}",[ENSG00000165646],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for hypertension.
CHEMBL1200993,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC.[I-].[I-].[I-],REEUVFCVXKWOFE-UHFFFAOYSA-K,Small molecule,False,GALLAMINE TRIETHIODIDE,1982.0,4.0,CHEMBL360055,False,True,['Benzcurine Iodide' 'Flaxedil' 'Gallomone Triethiodide' 'Relaxan'],"['Benzcurine iodide' 'Gallamine triethiodide' 'Gallamini triethiodidum'
 'Gallamone triethiodide' 'NSC-102690' 'Remyolan' 'Syncurarine']","[('PubChem', array(['144205593', '170465398', '50106346', '57264265'], dtype=object)), ('Wikipedia', array(['Gallamine_triethiodide'], dtype=object)), ('drugbank', array(['DB00483'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201023,Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl,UQZKYYIKWZOKKD-UHFFFAOYSA-N,Small molecule,False,ORPHENADRINE HYDROCHLORIDE,1957.0,4.0,CHEMBL900,False,True,['Biorphen' 'Disipal'],"['Mephenamin' 'NSC-82357' 'Orphenadrine (chloride)'
 'Orphenadrine Chloride' 'Orphenadrine hcl' 'Orphenadrine hydrochloride']","[('PubChem', array(['144212244', '26752324', '50106731', '56422385', '855661'],
      dtype=object)), ('chEBI', array(['60902'], dtype=object))]",,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000196639,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for parkinson disease.
CHEMBL1240,CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-],XLBIBBZXLMYSFF-UHFFFAOYSA-M,Small molecule,False,PROPANTHELINE BROMIDE,1953.0,4.0,CHEMBL1180725,False,True,['Pro-banthine' 'Propantheline bromide'],['NSC-757294' 'Propantheline Bromide' 'Propantheline bromide'],"[('PubChem', array(['144204817', '144212648', '170464881', '26747652', '50106913',
       '56422773', '855578'], dtype=object)), ('Wikipedia', array(['Propantheline_bromide'], dtype=object))]",,"{'rows': array(['MONDO_0004247', 'EFO_1000781'], dtype=object), 'count': 2}","[ENSG00000133019,ENSG00000168539,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for peptic ulcer disease and has 1 investigational indication.
CHEMBL14376,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1,XMXHEBAFVSFQEX-UHFFFAOYSA-N,Small molecule,True,ILOPERIDONE,2009.0,4.0,,False,True,['Fanapt' 'Iloperidone'],['HP 873' 'HP-873' 'Iloperidone'],"[('DailyMed', array(['iloperidone'], dtype=object)), ('PubChem', array(['124899318', '144207159', '170465198'], dtype=object)), ('Wikipedia', array(['Iloperidone'], dtype=object)), ('drugbank', array(['DB04946'], dtype=object)), ('chEBI', array(['65173'], dtype=object))]",,"{'rows': array(['EFO_0005407', 'EFO_0001421', 'EFO_0009963', 'EFO_0001358',
       'MONDO_0005090'], dtype=object), 'count': 5}","[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for psychosis and schizophrenia and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1645462,Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12,LUJZZYWHBDHDQX-QFIPXVFZSA-N,Small molecule,False,AC-480,,1.0,,False,False,[],['AC-480' 'AC480' 'Ac-480' 'BMS-599626' 'Bms 599626'],"[('drugbank', array(['DB12318'], dtype=object))]",['CHEMBL5307497'],"{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_0005543'], dtype=object), 'count': 3}","[ENSG00000146648,ENSG00000141736,ENSG00000178568]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL2103827,N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,QXWYKJLNLSIPIN-JGVFFNPUSA-N,Small molecule,True,DROXIDOPA,2014.0,4.0,,False,True,['Northera'],['DOPS' 'Droxidopa' 'L-DOPS' 'L-threo-dops'],"[('DailyMed', array(['droxidopa'], dtype=object)), ('drugbank', array(['DB06262'], dtype=object)), ('chEBI', array(['31524'], dtype=object))]",,"{'rows': array(['EFO_0005687', 'MONDO_0005180', 'EFO_1000645', 'EFO_1001050',
       'EFO_0005251', 'EFO_0005252', 'EFO_0003888', 'EFO_0000319'],
      dtype=object), 'count': 8}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103838,Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2c1ccc(=O)n2-c1c(F)cccc1F,ORVNHOYNEHYKJG-UHFFFAOYSA-N,Small molecule,False,DILMAPIMOD,,2.0,,False,False,[],['Dilmapimod' 'Gw-681323' 'SB-681323' 'SB681323'],"[('drugbank', array(['DB12140'], dtype=object))]",['CHEMBL2105674'],"{'rows': array(['EFO_0004610', 'EFO_0001645', 'EFO_0005762', 'EFO_0000341',
       'EFO_0000685'], dtype=object), 'count': 5}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2107979,,,Antibody,False,PEXELIZUMAB,,3.0,,False,False,[],['5G1.1-SC' 'H-5G1.1 SCFV' 'H5G1.1 SCFV' 'H5G1.1 SCFV (CDR)' 'Pexelizumab'],,,"{'rows': array(['EFO_0008583', 'EFO_0001645'], dtype=object), 'count': 2}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108370,,,Antibody,False,INOLIMOMAB,,3.0,,False,False,['Leucotac'],['BT-563' 'Inolimomab' 'Leukotac'],,,"{'rows': array(['MONDO_0013730'], dtype=object), 'count': 1}",[ENSG00000134460],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108501,,,Antibody,False,LABETUZUMAB,,2.0,,False,False,['Cea-Cide'],['HMN-14' 'Labetuzumab'],,,"{'rows': array(['EFO_1000657', 'EFO_1001951', 'MONDO_0007254', 'EFO_0000365',
       'EFO_0004142', 'MONDO_0021063', 'EFO_0003860'], dtype=object), 'count': 7}",[ENSG00000105388],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL2109665,,,Antibody,False,OCARATUZUMAB,,2.0,,False,False,[],['AME-133v' 'LY2469298' 'Ocaratuzumab'],,,"{'rows': array(['EFO_0005952', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2151439,O=C(N[C@@H]1CN2CCC1CC2)c1n[nH]c2ccccc12,TXCYUSKWBHUVEP-CYBMUJFWSA-N,Small molecule,False,FACINICLINE,,2.0,,False,False,[],"['MEM 3454 FREE BASE' 'MEM-3454 FREE BASE' 'MEM3454 FREE BASE'
 'RG-3487 FREE BASE' 'RG3487 FREE BASE' 'RO-5313534 FREE BASE']","[('drugbank', array(['DB05586'], dtype=object))]",['CHEMBL5095032'],"{'rows': array(['MONDO_0005090', 'MONDO_0004975'], dtype=object), 'count': 2}","[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084,ENSG00000175344]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL231779,COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,QNZCBYKSOIHPEH-UHFFFAOYSA-N,Small molecule,True,APIXABAN,2011.0,4.0,,False,True,['Eliquis'],['Apixaban' 'BMS-562247' 'BMS-562247-01'],"[('DailyMed', array(['apixaban'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis'],
      dtype=object)), ('PubChem', array(['174006823'], dtype=object)), ('Wikipedia', array(['Apixaban'], dtype=object)), ('drugbank', array(['DB06605'], dtype=object)), ('chEBI', array(['72296'], dtype=object))]",['CHEMBL3526474'],"{'rows': array(['EFO_0003884', 'EFO_0009314', 'EFO_0003144', 'EFO_0000266',
       'MONDO_0000831', 'EFO_1002000', 'MONDO_0004992', 'HP_0002140',
       'EFO_0000275', 'EFO_0004286', 'EFO_0003907', 'MP_0001914',
       'HP_0000083', 'EFO_0000556', 'EFO_0004255', 'EFO_0003827',
       'EFO_0001422', 'EFO_0003911', 'MONDO_0011382', 'EFO_0005672',
       'HP_0001907', 'EFO_0000220', 'EFO_0010680', 'HP_0004419',
       'HP_0004936', 'HP_0001655', 'EFO_0000712', 'MONDO_0100096'],
      dtype=object), 'count': 28}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 8 approved and 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2402904,COC(=O)N1CCC(CN2CCC(CNC(=O)c3cccc4[nH]c(C(C)C)nc34)CC2)CC1,MZOITCJKGUIQEI-UHFFFAOYSA-N,Small molecule,False,FELCISETRAG,,2.0,,False,False,[],['Felcisetrag' 'TAK-954' 'TD-8954' 'THRX-149699' 'Tak-954' 'Td-8954'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FELCISETRAG/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12725'], dtype=object))]",,"{'rows': array(['EFO_1000948', 'EFO_0001421', 'EFO_0003086', 'HP_0011024'],
      dtype=object), 'count': 4}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL252164,CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,NDAZATDQFDPQBD-UHFFFAOYSA-N,Small molecule,False,LUMINESPIB,,2.0,,False,False,[],['Luminespib' 'NVP-AUY-922' 'NVP-AUY922' 'NVP-AUY922-NX' 'VER-52296'],"[('PubChem', array(['124954168'], dtype=object)), ('Wikipedia', array(['NVP-AUY922'], dtype=object)), ('chEBI', array(['83656'], dtype=object))]",['CHEMBL3137334'],"{'rows': array(['EFO_0000574', 'EFO_0000571', 'EFO_0003060', 'EFO_0000708',
       'EFO_0000616', 'MONDO_0001056', 'EFO_0001378', 'EFO_0000365',
       'EFO_0004251', 'MONDO_0011719', 'MONDO_0021063', 'EFO_1000657',
       'MONDO_0007254'], dtype=object), 'count': 13}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 13 investigational indications.
CHEMBL273575,CN1Cc2c(N)cccc2C(c2ccccc2)C1,XXPANQJNYNUNES-UHFFFAOYSA-N,Small molecule,False,NOMIFENSINE,1984.0,4.0,,True,True,[],['Linamiphen' 'Nomifensin' 'Nomifensine'],"[('PubChem', array(['144212072', '50105261', '90340560'], dtype=object)), ('Wikipedia', array(['Nomifensine'], dtype=object)), ('drugbank', array(['DB04821'], dtype=object)), ('chEBI', array(['116225'], dtype=object))]",['CHEMBL1256842'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for major depressive disorder.
CHEMBL3188551,Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F,XTKLTGBKIDQGQL-UHFFFAOYSA-N,Small molecule,False,GSK-2636771,,2.0,,False,False,[],['GSK-2636771' 'GSK2636771' 'Gsk 2636771' 'Gsk-2636771'],"[('PubChem', array(['174006492'], dtype=object)), ('drugbank', array(['DB11795'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0000503', 'MONDO_0004992', 'EFO_0002617',
       'EFO_0000616'], dtype=object), 'count': 5}",[ENSG00000051382],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3348923,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,VWMJHAFYPMOMGF-ZCFIWIBFSA-N,Small molecule,False,TOVORAFENIB,,3.0,,False,False,[],"['BIIB-024' 'BIIB024' 'Biib-024' 'DAY-101' 'DAY101' 'MLN-2480' 'Mln-2480'
 'TAK-580' 'Tak 580' 'Tak-580' 'Tovorafenib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOVORAFENIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15266'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000756', 'EFO_0000616', 'EFO_0002617',
       'EFO_1001951', 'EFO_1000209', 'MONDO_0016691', 'EFO_1000318',
       'EFO_0000641', 'EFO_0002618', 'EFO_0003060'], dtype=object), 'count': 11}","[ENSG00000132155,ENSG00000157764,ENSG00000078061]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL3544908,CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,SGHXFFAHXTZRQM-SPIKMXEPSA-N,Small molecule,False,AZATADINE MALEATE,1977.0,4.0,CHEMBL946,False,True,['Lergocil' 'Optimine'],"['Azatadine dimaleate' 'Azatadine maleate' 'NSC-759874' 'SCH 10649'
 'SCH-10649']","[('chEBI', array(['2947'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977.
CHEMBL3545193,,,Small molecule,False,MSC-2364447,,1.0,,False,False,[],['Msc-2364447'],,,"{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989803,Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+],UNZIDPIPYUMVPA-UHFFFAOYSA-M,Small molecule,False,DIPYRONE,,4.0,CHEMBL461522,True,True,[],"['Analgin' 'Dipyrone' 'Dipyrone anhydrous' 'Metamizol'
 'Metamizol monohydrate' 'Metamizole sodium'
 'Metamizole sodium (anhydrous)' 'Metamizole sodium hydrate'
 'Metamizole sodium monohydrate' 'Metamizolum natricum anhydricum'
 'Methampyrone' 'NSC-73205' 'NSC-758445'
 'Noramidopyrine methanesulfonate sodium' 'Novalgin' 'Sulpyrine'
 'Sulpyrine hydrate']",,,"{'rows': array(['HP_0100806', 'MONDO_0005277', 'EFO_0003843', 'HP_0001945',
       'EFO_1001463', 'HP_0012532'], dtype=object), 'count': 6}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 4 investigational indications. It was withdrawn in at least one region.
CHEMBL4297300,CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1,JUQMLSGOTNKJKI-IZUQBHJASA-N,Small molecule,False,LB-100,,2.0,,False,False,[],['LB 100' 'Lb-100'],"[('drugbank', array(['DB15412'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000632', 'EFO_1001968', 'EFO_0000198',
       'EFO_0000702', 'EFO_0000519'], dtype=object), 'count': 6}","[ENSG00000113575,ENSG00000104695,ENSG00000011485]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL4297894,,,Unknown,False,ASP-8374,,1.0,,False,False,[],['ASP-8374' 'ASP8374' 'Asp 8374' 'Asp-8374' 'Asp8374' 'PTZ-201'],,,"{'rows': array(['EFO_0000519', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000181847],Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL4298013,,,Antibody,False,ELGEMTUMAB,,2.0,,False,False,[],['69745p00p9' 'Elgemtumab' 'LJM-716' 'LJM716' 'Ljm716' 'NOV-6'],,,"{'rows': array(['EFO_0000181', 'EFO_0005922', 'MONDO_0007254'], dtype=object), 'count': 3}",[ENSG00000065361],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4558324,C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1,RRMJMHOQSALEJJ-UHFFFAOYSA-N,Small molecule,False,LAZERTINIB,,3.0,,False,False,[],"['C-18112003-G' 'GNS-1480' 'GNS1480' 'JNJ-73841937-AAA' 'Lazertinib'
 'YH-25448' 'YH25448' 'Yh25448']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LAZERTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0021117', 'EFO_0003060', 'MONDO_0004992', 'EFO_0001421',
       'EFO_0000616', 'MONDO_0008903'], dtype=object), 'count': 6}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL459505,CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1,SNFYYXUGUBUECJ-UHFFFAOYSA-N,Small molecule,False,TALAROZOLE,,2.0,,False,False,['Rambazole'],['R-115866' 'R115866' 'Talarozole'],"[('drugbank', array(['DB13083'], dtype=object))]",,"{'rows': array(['MP_0001845', 'EFO_0000676', 'EFO_0003894'], dtype=object), 'count': 3}",[ENSG00000095596],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650297,,,Unknown,False,HMPL-453,,2.0,,False,False,[],['HMPL-453' 'Hmpl-453'],,,"{'rows': array(['EFO_0000616', 'EFO_0000588', 'MONDO_0003059'], dtype=object), 'count': 3}","[ENSG00000077782,ENSG00000068078,ENSG00000066468]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650313,Cc1cc(S(=O)(=O)Nc2cscn2)c(F)cc1N(C)[C@H]1CCN(Cc2ccccc2)C1,UCSHINHOAVARGQ-SFHVURJKSA-N,Small molecule,False,ZANDATRIGINE,,2.0,,False,False,[],['NBI-921352' 'Nbi-921352' 'XEN-901' 'XEN901' 'Xen901' 'Zandatrigine'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,,[ENSG00000196876],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL5314649,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1,YOZLVAFWYLSRRN-VZXYPILPSA-N,Small molecule,True,RITLECITINIB TOSYLATE,2023.0,4.0,CHEMBL4085457,False,True,['Litfulo'],['Pf-06651600 tosylate' 'Ritlecitinib tosilate' 'Ritlecitinib toslate'],,,"{'rows': array(['EFO_0004192'], dtype=object), 'count': 1}","[ENSG00000113263,ENSG00000102010,ENSG00000135605,ENSG00000074966,ENSG00000010671,ENSG00000105639]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for alopecia areata. This drug has a black box warning from the FDA.
CHEMBL5315080,,,Protein,False,BULEVIRTIDE ACETATE,2020.0,4.0,,False,True,['Hepcludex'],[],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex'],
      dtype=object))]",,"{'rows': array(['EFO_0007304'], dtype=object), 'count': 1}",[ENSG00000100652],Protein drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for hepatitis d virus infection.
CHEMBL563646,CC(C)(C)c1ccc(CN(Cc2cccc(OCC(=O)O)c2)S(=O)(=O)c2cccnc2)cc1,WOHRHWDYFNWPNG-UHFFFAOYSA-N,Small molecule,False,EVATANEPAG,,2.0,,False,False,[],"['CP-533,536' 'CP-533536' 'Evatanepag']","[('drugbank', array(['DB12022'], dtype=object))]",['CHEMBL2105672'],"{'rows': array(['EFO_0003944'], dtype=object), 'count': 1}",[ENSG00000125384],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL574738,CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1,ODPGGGTTYSGTGO-UHFFFAOYSA-N,Small molecule,False,AST-487,,1.0,,False,False,[],['AST-487' 'Ast-487' 'NVP-AST-487' 'NVP-AST487'],"[('PubChem', array(['103905682', '50100088'], dtype=object))]",,,"[ENSG00000165731,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL803,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,Small molecule,True,CYTARABINE,1969.0,4.0,,False,True,"['Alexan' 'Alexan 100' 'Cytarabine' 'Cytosar' 'Cytosar-u' 'Depocyt'
 'Depocyte' 'Tarabine Pfs']","['Ara-c' 'Ara-cytidine' 'Arabinocytosine' 'Arabinosyl cytosine'
 'Aracytidine' 'Aracytin' 'Aracytine' 'Cytarabine' 'Cytarabine liposome'
 'Cytarabinoside' 'Cytarabinum' 'NSC-287459' 'Spongocytidine' 'U 19920a'
 'U-19,920' 'U-19920']","[('DailyMed', array(['cytarabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/depocyte'],
      dtype=object)), ('PubChem', array(['131404637', '144204754', '144212288', '26719755', '29215144',
       '47193873', '90341066'], dtype=object)), ('Wikipedia', array(['Cytarabine'], dtype=object)), ('drugbank', array(['DB00987'], dtype=object)), ('chEBI', array(['28680'], dtype=object))]",['CHEMBL1256472'],"{'rows': array(['MONDO_0044881', 'MONDO_0044917', 'EFO_0000339', 'EFO_1001779',
       'EFO_0000220', 'EFO_0000309', 'MONDO_0019460', 'EFO_0003811',
       'EFO_1000781', 'MONDO_0001475', 'MONDO_0000831', 'EFO_0003028',
       'EFO_0000096', 'MONDO_0007915', 'EFO_0000095', 'EFO_0003025',
       'EFO_0000519', 'EFO_0007498', 'EFO_1001257', 'MONDO_0008315',
       'EFO_0003851', 'EFO_0000691', 'EFO_0000094', 'EFO_0000211',
       'MONDO_0044903', 'MONDO_0018906', 'EFO_0000223', 'EFO_0003802',
       'EFO_0002939', 'EFO_0000574', 'MONDO_0000870', 'EFO_0004991',
       'EFO_0003086', 'EFO_0006475', 'EFO_0003833', 'MONDO_0004992',
       'EFO_0003029', 'EFO_0004191', 'EFO_0001378', 'EFO_0002429',
       'EFO_0009538', 'EFO_1001052', 'MONDO_0013730', 'EFO_1001365',
       'EFO_0002428', 'EFO_1000131', 'EFO_1001012', 'EFO_1000823',
       'EFO_0000183', 'MONDO_0000873', 'MONDO_0009348', 'EFO_0004256',
       'EFO_0000616', 'EFO_0003929', 'EFO_0000198', 'EFO_1000318',
       'EFO_0000209', 'EFO_0000218', 'EFO_0000756', 'EFO_0000403',
       'EFO_0000221', 'EFO_1000158', 'EFO_0000222', 'EFO_1000309',
       'MONDO_0019471', 'EFO_0003884', 'EFO_0004289', 'EFO_0003027',
       'EFO_0000222', 'EFO_0001068', 'MONDO_0007254', 'EFO_0000224',
       'EFO_1001469', 'EFO_1000286', 'EFO_0003032', 'EFO_0000479',
       'EFO_0004251', 'EFO_0000565', 'EFO_0005952', 'EFO_1001383',
       'MONDO_0008170'], dtype=object), 'count': 81}","[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 11 approved and 70 investigational indications. This drug has a black box warning from the FDA.
CHEMBL978,CC(=O)OC(C)C[N+](C)(C)C,NZWOPGCLSHLLPA-UHFFFAOYSA-N,Small molecule,True,METHACHOLINE,1986.0,4.0,,False,True,[],['Methacholine' 'Methacholine cation' 'Methacholine ion' 'Provocholine'],"[('PubChem', array(['90340728'], dtype=object)), ('Wikipedia', array(['Methacholine'], dtype=object)), ('drugbank', array(['DB06709'], dtype=object)), ('chEBI', array(['6804'], dtype=object))]",['CHEMBL1200764' 'CHEMBL12137' 'CHEMBL2106885'],"{'rows': array(['MONDO_0004979', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for asthma and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1009,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,WTDRDQBEARUVNC-LURJTMIESA-N,Small molecule,False,LEVODOPA,1970.0,4.0,,False,True,['Bendopa' 'Brocadopa' 'Dopar' 'Inbrija' 'Larodopa'],"['Bendopa' 'Cvt-301' 'Levodopa' 'Levodopa component of carbilev'
 'Levodopa component of parcopa' 'Levodopa component of sinemet'
 'Levodopum' 'NSC-118381' 'V-1512']","[('DailyMed', array(['levodopa'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija'],
      dtype=object)), ('PubChem', array(['104171278', '11111115', '11112155', '11532916', '144203889',
       '26753566', '90341430'], dtype=object)), ('Wikipedia', array(['L-DOPA'], dtype=object)), ('drugbank', array(['DB01235'], dtype=object)), ('chEBI', array(['15765'], dtype=object))]",,"{'rows': array(['EFO_0004270', 'EFO_0003770', 'EFO_1001919', 'EFO_0003768',
       'MONDO_0043209', 'MONDO_0018910', 'MONDO_0005180', 'EFO_0000712',
       'EFO_0004895', 'HP_0002381', 'EFO_0005252', 'MONDO_0004979',
       'HP_0012532', 'EFO_0002610', 'HP_0003418', 'EFO_0001358',
       'MONDO_0043510', 'MONDO_0019200', 'MONDO_0005090', 'MONDO_0001020',
       'EFO_0003843', 'MONDO_0004976', 'EFO_0001365', 'EFO_0003756',
       'MONDO_0007113'], dtype=object), 'count': 25}",[ENSG00000151577],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for parkinson disease and has 24 investigational indications.
CHEMBL1082407,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,WXCXUHSOUPDCQV-UHFFFAOYSA-N,Small molecule,False,ENZALUTAMIDE,2012.0,4.0,,False,True,['Xtandi'],['Enzalutamide' 'MDV-3100' 'MDV3100' 'Mdv 3100'],"[('DailyMed', array(['enzalutamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi'],
      dtype=object)), ('PubChem', array(['137275964'], dtype=object)), ('drugbank', array(['DB08899'], dtype=object)), ('chEBI', array(['68534'], dtype=object))]",['CHEMBL4594421'],"{'rows': array(['EFO_1001469', 'EFO_0007532', 'EFO_0001421', 'MONDO_0008315',
       'EFO_0001663', 'MONDO_0008315', 'EFO_0000349', 'EFO_0003086',
       'MONDO_0004992', 'MONDO_0008315', 'MONDO_0008170', 'MONDO_0100096',
       'EFO_0000616', 'EFO_0000673', 'EFO_0000196', 'EFO_0002618',
       'EFO_0000182', 'EFO_0000616', 'MONDO_0100096', 'EFO_0005537',
       'MONDO_0001187', 'EFO_0000313', 'MONDO_0007254'], dtype=object), 'count': 23}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 17 investigational indications.
CHEMBL1200595,CC(C)(N)Cc1ccc(Cl)cc1.Cl,WEJDYJKJPUPMLH-UHFFFAOYSA-N,Small molecule,False,CHLORPHENTERMINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201269,True,True,['Pre-sate'],"['Chlorphentermine hcl' 'Chlorphentermine hydrochloride' 'NSC-76098'
 'S-62' 'W 2426' 'W-2426']","[('PubChem', array(['144205357', '170465307'], dtype=object))]",,,[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982. It was withdrawn in at least one region.
CHEMBL1200934,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC,KIQQMECNKUGGKA-NMYWJIRASA-N,Small molecule,False,NORGESTIMATE,1989.0,4.0,,False,True,[],"['Dexnorgestrel acetime' 'NSC-759159' 'Norgestimate' 'ORF 10131'
 'ORF-10131' 'RWJ 10131' 'RWJ-10131']","[('DailyMed', array(['norgestimate'], dtype=object)), ('PubChem', array(['144206364', '170464733', '50125945'], dtype=object)), ('Wikipedia', array(['Norgestimate'], dtype=object)), ('drugbank', array(['DB00957'], dtype=object)), ('chEBI', array(['50815'], dtype=object))]",,"{'rows': array(['MONDO_0018075', 'EFO_0003894', 'MONDO_0009061', 'HP_0100608',
       'EFO_0003882', 'EFO_0003047', 'EFO_0000764', 'MONDO_0005277'],
      dtype=object), 'count': 8}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for acne and has 7 investigational indications.
CHEMBL1201287,CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1,ZDIGNSYAACHWNL-HNNXBMFYSA-N,Small molecule,False,DEXBROMPHENIRAMINE,1963.0,4.0,,False,True,[],"['Brompheniramine d-form' 'Brompheniramine, (s)-' 'Dexbrompheniramine']","[('PubChem', array(['29216402', '90341837'], dtype=object)), ('Wikipedia', array(['Dexbrompheniramine'], dtype=object)), ('drugbank', array(['DB00405'], dtype=object)), ('chEBI', array(['59269'], dtype=object))]",['CHEMBL1200638'],"{'rows': array(['MONDO_0005271', 'EFO_0003956'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for allergic disease and seasonal allergic rhinitis.
CHEMBL1280,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC.Cl,DOQPXTMNIUCOSY-UHFFFAOYSA-N,Small molecule,False,VERAPAMIL HYDROCHLORIDE,1981.0,4.0,CHEMBL6966,False,True,"['Berkatens' 'Calan' 'Calan sr' 'Cordilox' 'Cordilox i.v.'
 'Cordilox mr 240' 'Covera-hs' 'Ethimil mr 240' 'Geangin'
 'Half securon sr' 'Isoptin' 'Isoptin Sr' 'Manidon sr' 'Ranvera mr'
 'Securon' 'Securon iv' 'Securon mid' 'Securon sr' 'Univer' 'Vera-til sr'
 'Verapamil hydrochloride' 'Verapress mr 240' 'Verelan' 'Verelan pm'
 'Vertab sr 240' 'Zolvera']","['CP-16533-1' 'LU-20175' 'NSC-272366' 'NSC-657799' 'Verapamil hcl'
 'Verapamil hydrochloride' 'Verapamili hydrochloridum']","[('DailyMed', array(['verapamil%20hydrochloride'], dtype=object)), ('PubChem', array(['144208378', '17388668', '26747697', '26747698', '49718106',
       '50107178', '50107179', '50107180', '507863', '856000'],
      dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0004269', 'EFO_0000400', 'EFO_0003144',
       'EFO_0000183', 'EFO_0000275', 'EFO_0000537'], dtype=object), 'count': 7}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 4 investigational indications.
CHEMBL15870,CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1,RJMIEHBSYVWVIN-UHFFFAOYSA-N,Small molecule,False,INDOPROFEN,1979.0,4.0,,True,True,[],"['Bor-ind' 'Flosin' 'Flosint' 'Indoprofen' 'Isindone' 'K 4277' 'K-4277'
 'NSC-757065' 'Praxis' 'Reumofene']","[('PubChem', array(['11532964', '144204869', '26748086'], dtype=object)), ('Wikipedia', array(['Indoprofen'], dtype=object)), ('drugbank', array(['DB08951'], dtype=object)), ('chEBI', array(['76162'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for rheumatic disease. It was withdrawn in at least one region.
CHEMBL1716091,CCc1cccc2c3c([nH]c12)[C@@](CC)(CC(=O)O)OCC3,NNYBQONXHNTVIJ-QGZVFWFLSA-N,Small molecule,False,SDX-101,,2.0,,False,False,[],"['(-)-(r)-etodolac' '(-)-etodolac' 'Etodolac, (-)-' 'Etodolac, (r)-'
 'KS-1056' 'R-etodolac' 'RAK-593' 'SDX-101' 'Sdx-101']","[('PubChem', array(['11112763'], dtype=object)), ('chEBI', array(['60370'], dtype=object))]",,"{'rows': array(['EFO_0000095', 'EFO_0001378'], dtype=object), 'count': 2}",[ENSG00000186350],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2096642,CC(O)C(=O)O.Nc1cc(-c2ccncc2)c[nH]c1=O,DOSIONJFGDSKCQ-UHFFFAOYSA-N,Small molecule,False,INAMRINONE LACTATE,1984.0,4.0,CHEMBL12856,False,True,['Amrinone lactate' 'Inocor'],['Inamrinone lactate'],,,,[ENSG00000172572],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984.
CHEMBL2107890,,,Antibody drug conjugate,False,TAPLITUMOMAB PAPTOX,,2.0,,False,False,[],['Taplitumomab paptox'],,,,[ENSG00000177455],Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2138684,CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1.O.O=C(O)CCC(=O)O,CUETXFMONOSVJA-KLQYNRQASA-N,Small molecule,False,FROVATRIPTAN SUCCINATE,2001.0,4.0,CHEMBL1279,False,True,['Frova' 'Frovatriptan succinate'],"['Frovatriptan succinate' 'Frovatriptan succinate hydrate' 'Frovelan'
 'Miguard' 'NSC-760422' 'SB 209509 AX' 'SB 209509-AX' 'SB-209509-AX'
 'SB-209509AX' 'VML 251' 'VML-251']","[('DailyMed', array(['frovatriptan%20succinate'], dtype=object)), ('PubChem', array(['124894597', '144207155'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}","[ENSG00000135312,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for migraine disorder.
CHEMBL23261,COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1,FEJVSJIALLTFRP-LJQANCHMSA-N,Small molecule,False,DARUSENTAN,,3.0,,False,False,[],['Darusentan' 'HMR-4005' 'LU-135252' 'Lu-135252'],"[('PubChem', array(['170466416'], dtype=object)), ('Wikipedia', array(['Darusentan'], dtype=object)), ('drugbank', array(['DB04883'], dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000151617,ENSG00000136160]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3039507,CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,QKDRXGFQVGOQKS-CRSSMBPESA-N,Small molecule,False,SOTAGLIFLOZIN,2019.0,4.0,,False,True,['Inpefa' 'Zynquista'],"['Inpefa' 'LP-802034' 'LX-4211' 'LX4211' 'Sar-439954' 'Sar439954'
 'Sotagliflozin']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista'],
      dtype=object)), ('drugbank', array(['DB12713'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'MONDO_0005148', 'EFO_0004252', 'MONDO_0005147',
       'EFO_0003144', 'EFO_0003884', 'EFO_0003086', 'EFO_0001421'],
      dtype=object), 'count': 8}","[ENSG00000100170,ENSG00000140675]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 6 approved and 2 investigational indications.
CHEMBL3137308,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2,DREIJXJRTLTGJC-ZLBJMMTISA-N,Small molecule,False,PEFICITINIB,2019.0,4.0,,False,True,[],['ASP-015K' 'ASP015K' 'Asp-015k' 'JNJ-54781532' 'Peficitinib'],,['CHEMBL3137329'],"{'rows': array(['EFO_0003086', 'EFO_0000676', 'EFO_0000540', 'EFO_0001421',
       'EFO_0000729', 'EFO_0000685'], dtype=object), 'count': 6}","[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 6 investigational indications.
CHEMBL3545058,N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+],ANMYAHDLKVNJJO-CURYUGHLSA-M,Small molecule,False,DEXTROTHYROXINE SODIUM,1967.0,4.0,CHEMBL559,False,True,['Choloxin'],"['Anhydrous dextrothyroxine sodium' 'D-thyroxine sodium salt'
 'Dextrothyroxine sodium' 'Dextrothyroxine sodium anhydrous'
 'Dextrothyroxine sodium hydrate' 'Monosodium d-thyroxine hydrate'
 'Sodium dextrothyroxine']",,,"{'rows': array(['EFO_1001375', 'EFO_0000612'], dtype=object), 'count': 2}","[ENSG00000126351,ENSG00000151090]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 2 investigational indications.
CHEMBL384304,COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N,JRNJNYBQQYBCLE-UHFFFAOYSA-N,Small molecule,False,RG-547,,2.0,,False,False,[],['R 547' 'R-547' 'RG-547' 'RO4584820' 'Rg-547' 'Ro 4584820' 'Ro-4584820'],"[('drugbank', array(['DB08094'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000123374,ENSG00000135446,ENSG00000170312]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989703,O.O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1,LNDYQNTTYXLTNH-RTBBDAMFSA-N,Small molecule,False,TEZAMPANEL,,2.0,CHEMBL14935,False,False,[],['LY293558' 'Tezampanel' 'Tezampanel hydrate'],,,,"[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3989919,Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)(O)O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.[Cl-],LBTQUZNIWCWBNN-UHFFFAOYSA-N,Small molecule,False,FOSNETUPITANT CHLORIDE HYDROCHLORIDE,2018.0,4.0,CHEMBL3989917,False,True,[],"['08-PNET' 'Fosnetupitant chloride' 'Fosnetupitant chloride hydrochloride'
 'Fosnetupitant dihydrochloride']","[('DailyMed', array(['fosnetupitant%20chloride%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0006911', 'HP_0002013'], dtype=object), 'count': 2}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chemotherapy-induced nausea and vomiting and vomiting.
CHEMBL3989973,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,CJLUYLRKLUYCEK-UHFFFAOYSA-N,Small molecule,True,PEXIDARTINIB HYDROCHLORIDE,2019.0,4.0,CHEMBL3813873,False,True,['Turalio'],['FP-113' 'PLX-3397 HCL' 'PLX3397 HCl' 'Pexidartinib hydrochloride'],,,"{'rows': array(['EFO_1000562'], dtype=object), 'count': 1}","[ENSG00000182578,ENSG00000122025,ENSG00000157404]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for tenosynovial giant cell tumor. This drug has a black box warning from the FDA.
CHEMBL4085457,C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C,CBRJPFGIXUFMTM-WDEREUQCSA-N,Small molecule,True,RITLECITINIB,2023.0,4.0,,False,True,[],['PF-06651600' 'Pf-06651600' 'Ritlecitinib'],"[('drugbank', array(['DB14924'], dtype=object))]",['CHEMBL5314649'],"{'rows': array(['EFO_1001051', 'EFO_0000384', 'EFO_0004192', 'EFO_1000785',
       'EFO_0001421', 'EFO_0001060', 'EFO_0000729', 'EFO_0003086',
       'EFO_0004208', 'MONDO_0005147', 'EFO_0004192', 'EFO_0000685',
       'EFO_1002028'], dtype=object), 'count': 13}","[ENSG00000113263,ENSG00000102010,ENSG00000135605,ENSG00000074966,ENSG00000010671,ENSG00000105639]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for alopecia areata and has 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4116649,NCc1cc(Oc2cccc(C(=O)N3C[C@@H](O)[C@H](F)C3)c2)nc(C(F)(F)F)c1,ODGXXYXJORZPHE-ZIAGYGMSSA-N,Small molecule,False,LENUMLOSTAT,,2.0,,False,False,[],['Lenumlostat' 'PAT-1251' 'Pat-1251'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]",['CHEMBL4528871' 'CHEMBL4543285' 'CHEMBL4079398'],"{'rows': array(['EFO_0006890'], dtype=object), 'count': 1}",[ENSG00000134013],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297260,CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@@H](C(=O)N(C)[C@H](C(N)=O)[C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O,MUSGYEMSJUFFHT-UWABRSFTSA-N,Protein,False,AMY-101,,2.0,,False,False,[],['Amy 101' 'Amy-101' 'Compstatin 40' 'Compstatin analog peptide cp40'],,,"{'rows': array(['MONDO_0002508'], dtype=object), 'count': 1}",[ENSG00000125730],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297571,,,Antibody,False,PENPULIMAB,,3.0,,False,False,[],['AK-105' 'AK105' 'Ak-105' 'Ak105' 'Penpulimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PENPULIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000702', 'EFO_0000182', 'MONDO_0004992', 'EFO_0005922',
       'EFO_0000181', 'EFO_0003060', 'EFO_0003108', 'MONDO_0002108',
       'EFO_0000183', 'EFO_0003860', 'EFO_1000359', 'EFO_0000616',
       'EFO_0003869', 'MONDO_0007254', 'EFO_0004252', 'EFO_0000708',
       'EFO_0000574', 'EFO_1000657', 'EFO_0000178', 'EFO_0000519',
       'MONDO_0002974', 'MONDO_0008903', 'EFO_0000403', 'MONDO_0001056',
       'EFO_1001951'], dtype=object), 'count': 25}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 25 investigational indications.
CHEMBL522302,COc1ccc(-n2nnnc2C(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1,XILNRORTJVDYRH-HKUYNNGSSA-N,Small molecule,False,VOFOPITANT,,2.0,,False,False,[],['GR-205171' 'GR205171' 'Gr-205171' 'Vofopitant'],"[('drugbank', array(['DB12436'], dtype=object))]",['CHEMBL557983'],"{'rows': array(['EFO_0008568', 'MONDO_0004985', 'EFO_0001358'], dtype=object), 'count': 3}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL562318,Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,AZEXWHKOMMASPA-UHFFFAOYSA-N,Small molecule,False,MARDEPODECT,,2.0,,False,False,[],['MP-10' 'Mardepodect' 'PF-02545920' 'PF-2545920'],"[('PubChem', array(['165222673', '174006264'], dtype=object)), ('drugbank', array(['DB08387'], dtype=object))]",['CHEMBL1684440' 'CHEMBL5306001'],"{'rows': array(['MONDO_0007739', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000112541],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1089,NNCCc1ccccc1,RMUCZJUITONUFY-UHFFFAOYSA-N,Small molecule,True,PHENELZINE,1961.0,4.0,,False,True,[],['Nardil' 'Phenelzine'],"[('PubChem', array(['11111653', '11111654', '174006798', '50111200', '90341694'],
      dtype=object)), ('Wikipedia', array(['Phenelzine'], dtype=object)), ('drugbank', array(['DB00780'], dtype=object)), ('chEBI', array(['8060'], dtype=object))]",['CHEMBL1200895'],"{'rows': array(['EFO_0000673', 'MONDO_0007254', 'MONDO_0002009'], dtype=object), 'count': 3}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1171829,C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F,YUUGYIUSCYNSQR-LBPRGKRZSA-N,Small molecule,False,BITOPERTIN,,3.0,,False,False,[],"['Bitopertin' 'DISC-1459' 'Paliflutine' 'R-1678' 'RG-1678' 'RO-4917838'
 'RO-4917939' 'RO4917838']","[('drugbank', array(['DB12426'], dtype=object))]",,"{'rows': array(['EFO_0004242', 'MONDO_0005090', 'MONDO_0015253', 'Orphanet_848',
       'MONDO_0001676'], dtype=object), 'count': 5}",[ENSG00000196517],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL1189679,O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,CPZBLNMUGSZIPR-NVXWUHKLSA-N,Small molecule,False,PALONOSETRON,2003.0,4.0,,False,True,[],"['(-)-palonosetron' 'Aurothioglucose' 'NSC-743769' 'Palonosetron'
 'Palonosetron, (3as, 3s)-']","[('Wikipedia', array(['Palonosetron'], dtype=object)), ('drugbank', array(['DB00377'], dtype=object)), ('chEBI', array(['85161'], dtype=object))]",['CHEMBL1720'],"{'rows': array(['EFO_0004888', 'MONDO_0004992', 'EFO_0003869', 'HP_0002013',
       'HP_0002018', 'EFO_0006911', 'EFO_0000756', 'MONDO_0004992',
       'HP_0002013', 'HP_0000486', 'EFO_0001378', 'MONDO_0001657',
       'EFO_0000616', 'HP_0002018', 'MONDO_0001056', 'EFO_0006911',
       'EFO_0004888', 'HP_0002017', 'HP_0002017', 'MONDO_0100342'],
      dtype=object), 'count': 20}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved and 12 investigational indications.
CHEMBL1200347,CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C.[I-],BFSMWENDZZIWPW-UHFFFAOYSA-N,Small molecule,False,ISOPROPAMIDE IODIDE,1957.0,4.0,CHEMBL1201232,False,True,['Darbid'],"['Dipramid' 'Dipramide' 'Isamid' 'Isopropamide (as iodide)'
 'Isopropamide iodide' 'Isoproponum iodide' 'Marygin-m' 'NSC-15521'
 'Piaccamide' 'Priamide' 'Priazimide' 'SKF-4740' 'Sanulcin' 'Tyrimide']","[('PubChem', array(['11532965', '56424103'], dtype=object))]",,,"[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957.
CHEMBL1259,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3,JFXBEKISTKFVAB-AJQTZOPKSA-N,Small molecule,False,METOCURINE,1982.0,4.0,,False,True,[],"['Dimethyl tubocurarine' 'Dimethyltubocurarine' 'Dimethyltubocurarinium'
 'Metocurine' 'Metocurine cation' 'Metocurine ion']","[('Wikipedia', array(['Metocurine'], dtype=object)), ('drugbank', array(['DB01336'], dtype=object)), ('chEBI', array(['6900'], dtype=object))]",['CHEMBL1739' 'CHEMBL2105841'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1511,CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,RSEPBGGWRJCQGY-RBRWEJTLSA-N,Small molecule,True,ESTRADIOL VALERATE,2010.0,4.0,,False,True,"['Climaval' 'Delestrogen' 'Estradiol valerate' 'Femtab' 'Progynon depot'
 'Progynon-depot-10' 'Progynova']","['.beta.-estradiol 17-valerate' 'Estradiol 17-valerate'
 'Estradiol Valerate' 'Estradiol valerate' 'NSC-17590'
 'Oestradiol valerate']","[('DailyMed', array(['estradiol%20valerate'], dtype=object)), ('PubChem', array(['144204865', '56422428', '855707'], dtype=object)), ('drugbank', array(['DB13956'], dtype=object)), ('chEBI', array(['31561'], dtype=object))]",,"{'rows': array(['HP_0100608', 'EFO_0000660', 'EFO_1001271', 'HP_0000132',
       'MONDO_0002146', 'EFO_1000096', 'EFO_0000545', 'HP_0100607',
       'GO_0042697', 'HP_0008209', 'EFO_0004266'], dtype=object), 'count': 11}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2105643,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO,FIDMEHCRMLKKPZ-YSMBQZINSA-N,Small molecule,False,FOSBRETABULIN TROMETHAMINE,,2.0,CHEMBL1206232,False,False,['Zybrestat'],['Fosbretabulin tromethamine'],,,"{'rows': array(['MONDO_0008170', 'EFO_1001901'], dtype=object), 'count': 2}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109253,,,Antibody,False,HOKT3,,3.0,,False,False,[],['HOKT3' 'Hokt3'],,,"{'rows': array(['EFO_0003778', 'MONDO_0005147'], dtype=object), 'count': 2}",[ENSG00000198851],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109572,,,Antibody,False,ANTI-SCLEROSTIN,,1.0,,False,False,[],['ANTI-SCLEROSTIN'],,,,[ENSG00000167941],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2133806,Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1,JRWCBEOAFGHNNU-UHFFFAOYSA-N,Small molecule,False,JNJ-38877605,,1.0,,False,False,[],['JNJ-38877605' 'Jnj-38877605'],"[('PubChem', array(['137276033'], dtype=object)), ('drugbank', array(['DB13113'], dtype=object))]",['CHEMBL5275126'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2263632,COc1cccc(-c2cc(F)c(Nc3ncccc3C(=O)O)c(F)c2)c1,OMPATGZMNFWVOH-UHFFFAOYSA-N,Small molecule,False,ASLAN-003,,2.0,,False,False,[],['ASLAN-003' 'ASLAN003' 'Aslan-003' 'Aslan003' 'Farudodstat'],,,"{'rows': array(['EFO_0004192', 'EFO_0000222'], dtype=object), 'count': 2}",[ENSG00000102967],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3039582,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C,OWMZNFCDEHGFEP-NFBCVYDUSA-N,Protein,False,SECRETIN,2002.0,4.0,,False,True,['Secretin-ferring'],"['Secretin' 'Secretin (human, porcine, etc.)' 'Secretin, unspecified']",,,"{'rows': array(['MONDO_0005090', 'EFO_0000278', 'EFO_0008533', 'EFO_0003758',
       'EFO_0000342', 'EFO_0001073'], dtype=object), 'count': 6}",[ENSG00000080293],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 investigational indications.
CHEMBL3301588,,,Antibody,False,TAREXTUMAB,,2.0,,False,False,[],['OMP-59R5' 'Tarextumab'],,,"{'rows': array(['EFO_0000702', 'EFO_0002618', 'EFO_0000616'], dtype=object), 'count': 3}","[ENSG00000074181,ENSG00000134250]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545040,CC(C)(C)OC(=O)NCCN1CC2CN(C[C@H](O)COc3ccc(C#N)cc3)CC(C1)O2,JRHUUZPSMQIWBQ-PELRDEGISA-N,Small molecule,False,AZD7009,,2.0,,False,False,[],['Azd7009'],,,"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}","[ENSG00000183873,ENSG00000055118]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545162,,,Small molecule,False,PBF-680,,2.0,,False,False,[],['Pbf-680'],,,"{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}",[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545432,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,MBOMYENWWXQSNW-AWEZNQCLSA-N,Small molecule,False,IXAZOMIB CITRATE,2015.0,4.0,,False,True,['Ninlaro'],['Ixazomib citrate' 'MLN-9708' 'MLN9708'],"[('DailyMed', array(['ixazomib%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro'],
      dtype=object))]",,"{'rows': array(['EFO_0000220', 'MONDO_0019438', 'EFO_0009441', 'EFO_0000222',
       'EFO_0000558', 'EFO_0000574', 'MONDO_0004992', 'EFO_0006738',
       'MONDO_0007254', 'EFO_0000519', 'MONDO_0000873', 'MONDO_0020547',
       'EFO_1001469', 'EFO_0001378', 'EFO_0006475'], dtype=object), 'count': 15}","[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for multiple myeloma and has 14 investigational indications.
CHEMBL3657311,COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1,ULMMVBPTWVRPSI-UHFFFAOYSA-N,Small molecule,False,IFEBEMTINIB,,2.0,,False,False,[],['BI853520' 'Bi 853520' 'Bi-853520' 'IN-10018' 'IN10018' 'Ifebemtinib'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0008170', 'EFO_0002618', 'MONDO_0001056',
       'EFO_0002617'], dtype=object), 'count': 5}",[ENSG00000169398],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3989915,CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1,FWMNVWWHGCHHJJ-SKKKGAJSSA-N,Protein,False,DIFELIKEFALIN,2021.0,4.0,,False,True,[],"['4-PIPERIDINECARBOXYLIC ACID, N1-(D-PHENYLALANYL-D-PHENYLALANYL-D-LEUCYL-D-LYSYL)-4-AMINO-'
 'CR-845' 'CR845' 'Difelikefalin' 'FE-202845' 'FE202845' 'MR-13A9'
 'MR13A9']","[('drugbank', array(['DB11938'], dtype=object))]",['CHEMBL5315123'],"{'rows': array(['HP_0000989', 'EFO_0003884', 'HP_0000989', 'EFO_0003843',
       'MONDO_0005178'], dtype=object), 'count': 5}",[ENSG00000082556],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for chronic kidney disease and pruritus and has 3 investigational indications.
CHEMBL3990011,,,Antibody drug conjugate,False,ROVALPITUZUMAB TESIRINE,,3.0,,False,False,[],['Rovalpituzumab tesirine' 'SC-002' 'SC-16LD6.5' 'SC0002' 'Sc 002'],,,"{'rows': array(['MONDO_0004992', 'EFO_0000616', 'EFO_0000702'], dtype=object), 'count': 3}",[ENSG00000090932],Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297289,CN1CCN(C(=O)[C@H](CCCN[C@@H]2C[C@H]2c2ccc(F)cc2)NC(=O)c2ccc(-n3ccnn3)cc2)CC1,KQKBMHGOHXOHTD-KKUQBAQOSA-N,Small molecule,False,BOMEDEMSTAT,,2.0,,False,False,[],['Bomedemstat' 'IMG-7289' 'Img-7289'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BOMEDEMSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15126'], dtype=object))]",['CHEMBL5095405'],"{'rows': array(['EFO_0000616', 'EFO_0000222', 'EFO_0000616', 'EFO_0000198',
       'EFO_0002429', 'EFO_0000702', 'EFO_0000479', 'MONDO_0044903'],
      dtype=object), 'count': 8}",[ENSG00000004487],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4297590,COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1,NBGABHGMJVIVBW-QHCPKHFHSA-N,Small molecule,False,DARIDOREXANT,2022.0,4.0,,False,True,[],['ACT-541468' 'Act-541468' 'DEA NO. 2410' 'Daridorexant' 'Nemorexant'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DARIDOREXANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15031'], dtype=object))]",['CHEMBL4650216'],"{'rows': array(['EFO_0001358', 'EFO_0004698', 'EFO_0001421', 'HP_0000083',
       'EFO_0000341', 'EFO_0004698', 'EFO_0003918'], dtype=object), 'count': 7}","[ENSG00000137252,ENSG00000121764]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for insomnia and has 6 investigational indications.
CHEMBL4297955,,,Protein,False,FOLLITROPIN,,4.0,,False,True,[],"['F.s.h.-p injectable' 'Follicle stimulating hormone' 'Follitropin'
 'Follitropin (pig)' 'Follitropin epsilon' 'Follitropin gamma'
 'Follitropin porcine' 'Follotropin recombinant' 'Folltropin-v'
 'Fsh (menotropins)' 'Menotropins (fsh)' 'Super-ov']",,,"{'rows': array(['MONDO_0018555', 'EFO_0008560', 'EFO_0000660', 'EFO_0004266',
       'MONDO_0002146', 'EFO_0004248', 'MONDO_0002775', 'EFO_0000545'],
      dtype=object), 'count': 8}",[ENSG00000170820],Protein drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 4 investigational indications.
CHEMBL4298090,,,Protein,False,SIMLUKAFUSP ALFA,,2.0,,False,False,[],"['FAP-IL-2V' 'FAP-IL2V FP RO6874281' 'FAP-IL2v' 'RG-7461' 'RG7461'
 'RO-6874281' 'RO6874281' 'Ro6874281' 'Simlukafusp alfa']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMLUKAFUSP%20ALFA/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000681', 'EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 3}","[ENSG00000078098,ENSG00000147168,ENSG00000100385]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL452076,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)C1c1cccc([N+](=O)[O-])c1,KJEBULYHNRNJTE-DHZHZOJOSA-N,Small molecule,False,CILNIDIPINE,,3.0,,False,False,[],['Atelec' 'Cilnidipine' 'Cinalong' 'FRC-8653' 'Siscard'],"[('PubChem', array(['144205554', '170465867', '26755677', '50111041', '90341030'],
      dtype=object)), ('drugbank', array(['DB09232'], dtype=object)), ('chEBI', array(['31399'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_1001496', 'EFO_0000537'], dtype=object), 'count': 3}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL511115,COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1,CFBUZOUXXHZCFB-OYOVHJISSA-N,Small molecule,False,CILOMILAST,,3.0,,False,False,[],['Ariflo' 'Cilomilast' 'SB 207499' 'SB-207499' 'SB207499'],"[('PubChem', array(['144206070'], dtype=object)), ('Wikipedia', array(['Cilomilast'], dtype=object)), ('drugbank', array(['DB03849'], dtype=object))]",,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL695,CN1C(=O)OC(C)(C)C1=O,IRYJRGCIQBGHIV-UHFFFAOYSA-N,Small molecule,False,TRIMETHADIONE,1946.0,4.0,,False,True,['Tridione'],"['A 2297' 'Absentol' 'Epidione' 'J2.519D' 'Minoaleviatin' 'NSC-15799'
 'NSC-169503' 'Tridone' 'Trimethadione' 'Trimethadionum' 'Troxidone']","[('PubChem', array(['11112276', '144203959', '144207429'], dtype=object)), ('TG-GATEs', array(['122'], dtype=object)), ('Wikipedia', array(['Trimethadione'], dtype=object)), ('drugbank', array(['DB00347'], dtype=object))]",,"{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for epilepsy.
CHEMBL99946,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN,GJJFMKBJSRMPLA-DZGCQCFKSA-N,Small molecule,True,LEVOMILNACIPRAN,2013.0,4.0,,False,True,['Fetzima'],"['(1s,2r)-milnacipran' 'F 2695' 'F-2695' 'F2695' 'Levomilnacipran'
 'Milnacipran, (1s,2r)-']","[('drugbank', array(['DB08918'], dtype=object))]",['CHEMBL2105732'],"{'rows': array(['MONDO_0002009', 'MONDO_0002009', 'EFO_0005687', 'EFO_0003768',
       'HP_0002140', 'MONDO_0002009', 'MONDO_0002009'], dtype=object), 'count': 7}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder and fibromyalgia and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL101,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O,VYMDGNCVAMGZFE-UHFFFAOYSA-N,Small molecule,False,PHENYLBUTAZONE,1980.0,4.0,,True,True,"['Antadol' 'Azolid' 'Butacote' 'Butaject' 'Butazolidin' 'Elmedal'
 'Equiphar' 'Phenylbutazone' 'Pro-Bute']","['Ambene' 'Artrizin' 'Bizolin' 'Butadion' 'Butadiona' 'Butapirazol'
 'Butatron' 'Butoz' 'Buzon' 'Diphebuzol' 'Diphenylbutazone' 'Ecobutazone'
 'Equipalazone' 'Exrheudon n' 'Fenibutazona' 'Fenibutol' 'Fenylbutazon'
 'Flexazone' 'G-13871' 'Intrabutazone' 'Intrazone' 'Mepha-butazon'
 'NSC-25134' 'Phebuzine' 'Phenylbutazone' 'Phenyzene' 'R-3-ZON'
 'Robizone-v' 'Shigrodin' 'Tevcodyne' 'Uzone' 'Zolaphen']","[('PubChem', array(['104171220', '104171221', '11111674', '144203793', '144203794',
       '144209007', '144213080', '170465040', '17389760', '26747057',
       '26751573', '50104199', '56436656', '85231197', '855958',
       '90341773'], dtype=object)), ('TG-GATEs', array(['11'], dtype=object)), ('Wikipedia', array(['Phenylbutazone'], dtype=object)), ('drugbank', array(['DB00812'], dtype=object)), ('chEBI', array(['48574'], dtype=object))]",['CHEMBL3137687'],"{'rows': array(['EFO_0005755', 'HP_0003326', 'HP_0002829'], dtype=object), 'count': 3}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved indications. It was withdrawn in at least one region.
CHEMBL1027,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,PBJUNZJWGZTSKL-MRXNPFEDSA-N,Small molecule,False,TIAGABINE,1997.0,4.0,,False,True,['Gabitril'],"['A-70569-1' 'ABBOTT-70569' 'ABBOTT-70569 FREE BASE' 'ABBOTT-70569-1'
 'ABBOTT-705691 FREE BASE' 'ABT-569' 'ABT-569 FREE BASE' 'Gabitril'
 'NNC-05-0328' 'NNC-050328 FREE BASE' 'NO-05-0328' 'NO-050328 FREE BASE'
 'Tiagabine']","[('PubChem', array(['26758048'], dtype=object)), ('Wikipedia', array(['Tiagabine'], dtype=object)), ('drugbank', array(['DB00906'], dtype=object)), ('chEBI', array(['9586'], dtype=object))]",['CHEMBL1695'],"{'rows': array(['EFO_1001892', 'MONDO_0005090', 'EFO_0000474', 'HP_0001250',
       'EFO_0002610', 'EFO_0003918', 'MONDO_0007079', 'EFO_0005230',
       'EFO_0005230'], dtype=object), 'count': 9}",[ENSG00000157103],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for epilepsy and seizure and has 6 investigational indications.
CHEMBL1054,NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O,LMJSLTNSBFUCMU-UHFFFAOYSA-N,Small molecule,False,TRICHLORMETHIAZIDE,1960.0,4.0,,False,True,['Metahydrin' 'Naqua' 'Trichlorex' 'Trichlormas' 'Trichlormethiazide'],['NSC-61560' 'Trichlormethiazide' 'Trichloromethiazide'],"[('PubChem', array(['144203972', '170464812', '56422224', '855703'], dtype=object)), ('Wikipedia', array(['Trichlormethiazide'], dtype=object)), ('drugbank', array(['DB01021'], dtype=object)), ('chEBI', array(['9683'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for cardiovascular disease.
CHEMBL1075,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,FUBVWMNBEHXPSU-UHFFFAOYSA-N,Small molecule,True,MORICIZINE,1990.0,4.0,,False,True,[],['EN-313' 'EN-313 FREE BASE' 'Ethmozine' 'Moracizine' 'Moricizine'],"[('PubChem', array(['11112721', '174006664', '50086819'], dtype=object)), ('Wikipedia', array(['Moracizine'], dtype=object)), ('drugbank', array(['DB00680'], dtype=object)), ('chEBI', array(['6997'], dtype=object))]",['CHEMBL1200334'],"{'rows': array(['EFO_0000275', 'EFO_0004269'], dtype=object), 'count': 2}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for cardiac arrhythmia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1138,O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,OLNTVTPDXPETLC-XPWALMASSA-N,Small molecule,False,EZETIMIBE,2002.0,4.0,,False,True,['Ezetimibe' 'Ezetrol' 'Zetia'],['Ezetimibe' 'MK0653' 'NSC-758923' 'SCH-58235' 'SCH58235'],"[('DailyMed', array(['ezetimibe'], dtype=object)), ('PubChem', array(['144204996', '170465013', '26719841'], dtype=object)), ('Wikipedia', array(['Ezetimibe'], dtype=object)), ('drugbank', array(['DB00973'], dtype=object)), ('chEBI', array(['49040'], dtype=object))]",,"{'rows': array(['MONDO_0021187', 'EFO_0007304', 'EFO_0000764', 'EFO_0000195',
       'MONDO_0019052', 'EFO_0000537', 'MONDO_0008315', 'EFO_0001645',
       'HP_0003124', 'EFO_0004220', 'EFO_0000266', 'Orphanet_309005',
       'EFO_0003914', 'EFO_0004211', 'EFO_0003095', 'EFO_0004911',
       'EFO_0000612', 'EFO_0000319', 'MONDO_0005148', 'MONDO_0018328',
       'EFO_0000400'], dtype=object), 'count': 21}",[ENSG00000015520],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 16 investigational indications.
CHEMBL1200750,CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl,XXPDBLUZJRXNNZ-UHFFFAOYSA-N,Small molecule,True,PROMETHAZINE HYDROCHLORIDE,1951.0,4.0,CHEMBL643,False,True,"['Mymethazine fortis' 'Phenergan' 'Phenergan nightime' 'Phenhalal'
 'Phensedyl' 'Prometh fortis' 'Prometh plain' 'Promethacon' 'Promethazine'
 'Promethazine hydrochloride' 'Promethazine hydrochloride plain'
 'Promethazine plain' 'Promethegan' 'Q-mazine' 'Remsed' 'Sarantihist'
 'Sominex' 'Zipan-25' 'Zipan-50']",['Promethazine hydrochloride'],"[('DailyMed', array(['promethazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144209462', '144213195', '26747605', '26747606', '26752305',
       '50106751', '50106752', '50106753', '56422196', '567521', '855711'],
      dtype=object)), ('chEBI', array(['8462'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0006928', 'EFO_0003956', 'MONDO_0005475',
       'EFO_0004698', 'MONDO_0100431', 'EFO_0000274', 'EFO_0005531',
       'MONDO_0005271', 'HP_0002017', 'EFO_1000971', 'EFO_0007141'],
      dtype=object), 'count': 12}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 7 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1215331,N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl,XNULRSOGWPFPBL-REWPJTCUSA-N,Small molecule,False,PF-03882845,,1.0,,False,False,[],['PF-3882845' 'Pf-03882845'],"[('drugbank', array(['DB11814'], dtype=object))]",,"{'rows': array(['EFO_0000401', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL1237055,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl,XHILEZUETWRSHC-NRGUFEMZSA-N,Small molecule,True,HYDROMORPHONE HYDROCHLORIDE,1984.0,4.0,CHEMBL398707,False,True,"['Dilaudid' 'Dilaudid-hp' 'Exalgo' 'Hydromorphone hydrochloride'
 'Palladone' 'Palladone-sr']","['Dihydromorphinone hydrochloride' 'Hydromorphone HCl' 'Hydromorphone hcl'
 'Hydromorphone hydrochloride' 'Hydromorphone hydrochloride cii'
 'NSC-117862']","[('DailyMed', array(['hydromorphone%20hydrochloride'], dtype=object)), ('chEBI', array(['5791'], dtype=object))]",,"{'rows': array(['HP_0003418', 'EFO_0001421', 'EFO_0801084', 'EFO_1000786',
       'EFO_0004616', 'EFO_0003890', 'EFO_0003843', 'HP_0012532'],
      dtype=object), 'count': 8}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for drug dependence and pain and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1256786,COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,BPZSYCZIITTYBL-UHFFFAOYSA-N,Small molecule,False,FORMOTEROL,2001.0,4.0,,False,True,[],['Foradil' 'Formoterol'],"[('PubChem', array(['50125837'], dtype=object)), ('drugbank', array(['DB00983'], dtype=object)), ('chEBI', array(['63082'], dtype=object))]",['CHEMBL2133469' 'CHEMBL1893395' 'CHEMBL3989798'],"{'rows': array(['HP_0006536', 'MONDO_0004979', 'EFO_0000341', 'EFO_1000637',
       'MONDO_0005271', 'HP_0002110', 'MONDO_0008903', 'EFO_0003768',
       'EFO_0009661', 'MONDO_0004975', 'MONDO_0100096', 'HP_0006536',
       'MONDO_0004979', 'EFO_0006505', 'EFO_0000341', 'EFO_0000464',
       'EFO_0007183'], dtype=object), 'count': 17}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 12 investigational indications.
CHEMBL1257015,COc1ccc(C(=O)NCc2cccnc2)cc1C(=O)NCc1cccnc1,KYWCWBXGRWWINE-UHFFFAOYSA-N,Small molecule,False,PICOTAMIDE,,4.0,,False,True,[],['G-137' 'NSC-304384' 'Picotamide'],"[('PubChem', array(['11111675', '50106897', '85231198', '90341089'], dtype=object)), ('drugbank', array(['DB13327'], dtype=object))]",['CHEMBL1317747'],"{'rows': array(['HP_0004419'], dtype=object), 'count': 1}","[ENSG00000059377,ENSG00000006638]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis.
CHEMBL1743066,,,Antibody,False,RONTALIZUMAB,,2.0,,False,False,[],['RG-7415' 'RHUMAB IFNALPHA' 'RHUMAB-IFNALPHA' 'Rontalizumab'],,,"{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}","[ENSG00000120235,ENSG00000120242,ENSG00000147873,ENSG00000186803,ENSG00000188379,ENSG00000197919,ENSG00000233816,ENSG00000214042,ENSG00000137080,ENSG00000147885,ENSG00000228083,ENSG00000234829,ENSG00000236637]",Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2040682,CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,LUKZNWIVRBCLON-GXOBDPJESA-N,Small molecule,False,CICLESONIDE,2006.0,4.0,,False,True,"['Alvesco' 'Alvesco 160' 'Alvesco 80' 'Aservo equihaler' 'Omnaris'
 'Zetonna']",['BI54903' 'Ciclesonide' 'RPR-251526' 'RPR251526'],"[('DailyMed', array(['ciclesonide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/aservo-equihaler'],
      dtype=object)), ('PubChem', array(['144206039'], dtype=object)), ('drugbank', array(['DB01410'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0003956', 'EFO_1000024', 'MONDO_0005271',
       'HP_0006536', 'HP_0001742', 'EFO_0005854', 'MONDO_0004979',
       'EFO_1001417', 'EFO_0000341'], dtype=object), 'count': 10}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 4 investigational indications.
CHEMBL2103832,CN1CCN(c2cccc3[nH]c(=O)oc23)CC1,YVPUUUDAZYFFQT-UHFFFAOYSA-N,Small molecule,False,PARDOPRUNOX,,3.0,,False,False,[],"['DU 126891' 'DU-126891' 'DU126891' 'Pardoprunox' 'SLV 308' 'SLV-308'
 'SLV308']","[('drugbank', array(['DB12061'], dtype=object))]",['CHEMBL2105649'],"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}","[ENSG00000178394,ENSG00000149295,ENSG00000151577]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2103842,C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1,UWXSAYUXVSFDBQ-CYBMUJFWSA-N,Small molecule,False,VARLITINIB,,2.0,,False,False,[],"['AR-00334543' 'ARRY-334543' 'ARRY-543' 'ASLAN-001' 'ASLAN001'
 'Varlitinib']","[('drugbank', array(['DB05944'], dtype=object))]",['CHEMBL2105679'],"{'rows': array(['EFO_0000182', 'MONDO_0001056', 'EFO_0000616', 'EFO_0005221',
       'MONDO_0003060', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0002618'],
      dtype=object), 'count': 8}","[ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL2108973,,,Protein,False,"INSULIN HUMAN, ISOPHANE",,3.0,,False,False,[],"['Insulin human, isophane']",,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of III.
CHEMBL2109460,,,Antibody,False,SCH-708980,,2.0,,False,False,[],['SCH-708980' 'Sch-708980'],,,"{'rows': array(['EFO_0005044'], dtype=object), 'count': 1}",[ENSG00000136634],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109470,,,Antibody,False,PERAKIZUMAB,,2.0,,False,False,[],['Perakizumab' 'RG-4934' 'RG4934' 'RO-5310074' 'RO5310074'],,,"{'rows': array(['EFO_0003778'], dtype=object), 'count': 1}",[ENSG00000112115],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2178100,CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@@]1(CO)c1ccccc1,VAJGULUVTFDTAS-GOSISDBHSA-N,Small molecule,False,GLPG0492,,1.0,,False,False,[],['(-)-GLPG-0492' 'DT-200' 'G 100192' 'GLPG0492' 'Glpg-0492' 'Glpg0492'],"[('drugbank', array(['DB12461'], dtype=object))]",,,[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3188993,O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,ZTHJULTYCAQOIJ-WXXKFALUSA-N,Small molecule,True,QUETIAPINE FUMARATE,1997.0,4.0,CHEMBL716,False,True,['Quetiapine fumarate' 'Seroquel' 'Seroquel xr'],"['FK-947E' 'FK947E' 'ICI 204,636' 'ICI-204636' 'Quetiapine (as fumarate)'
 'Quetiapine fumarate' 'Quetiapine hemifumarate' 'Utapine' 'ZD-5077'
 'ZD5077' 'ZM 204,636' 'ZM-204636']","[('DailyMed', array(['quetiapine%20fumarate'], dtype=object)), ('PubChem', array(['144212683'], dtype=object)), ('chEBI', array(['8708'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'MONDO_0005301', 'EFO_1001892', 'EFO_0005411',
       'EFO_0009963', 'EFO_1001917', 'MONDO_0002046', 'HP_0000713',
       'EFO_0004242', 'MONDO_0005090', 'EFO_0005407', 'EFO_0005230',
       'EFO_0009964', 'MONDO_0002050', 'HP_0000726', 'Orphanet_79292',
       'MONDO_0004985', 'HP_0012076', 'EFO_0004257', 'EFO_0001358',
       'MONDO_0002009', 'MONDO_0007079'], dtype=object), 'count': 22}","[ENSG00000102468,ENSG00000149295,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3544923,,,Antibody drug conjugate,False,LABETUZUMAB GOVITECAN,,2.0,,False,False,[],['Anti-ceacam5-sn 38' 'IMMU-130' 'Labetuzumab govitecan'],,,"{'rows': array(['MONDO_0021063', 'EFO_1000657'], dtype=object), 'count': 2}",[ENSG00000105388],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL356388,CCOC(=O)c1cnc2c(cnn2CC)c1NN=C(C)C,OPQRBXUBWHDHPQ-UHFFFAOYSA-N,Small molecule,False,ETAZOLATE,,2.0,,False,False,[],['EHT-0202' 'Etazolate' 'SQ-20009'],"[('PubChem', array(['11111137', '11113501', '124880016', '90341463'], dtype=object)), ('Wikipedia', array(['Etazolate'], dtype=object))]",['CHEMBL1256671'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000166206],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3905910,CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO,MRPGRAKIAJJGMM-OCCSQVGLSA-N,Small molecule,False,VORUCICLIB,,2.0,,False,False,[],['P-1446' 'P1446a-05' 'Voruciclib'],"[('drugbank', array(['DB15157'], dtype=object))]",,"{'rows': array(['EFO_0000756', 'EFO_0000095', 'MONDO_0044881', 'MONDO_0004992'],
      dtype=object), 'count': 4}",[ENSG00000135446],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL41,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,Small molecule,True,FLUOXETINE,1987.0,4.0,,False,True,[],"['Fluoxetin ratiopharm' 'Fluoxetine' 'Fluval' 'NSC-283480' 'NSC-758685'
 'Prozac' 'Sarafem' 'Symbyax']","[('PubChem', array(['104171153', '144203695', '170465374', '26751973', '26755310',
       '50104648', '90341619'], dtype=object)), ('Wikipedia', array(['Fluoxetine'], dtype=object)), ('drugbank', array(['DB00472'], dtype=object)), ('chEBI', array(['86990'], dtype=object))]",['CHEMBL1201082'],"{'rows': array(['HP_0002140', 'EFO_0004262', 'MONDO_0002050', 'EFO_0003768',
       'MONDO_0024290', 'HP_0011868', 'MONDO_0005147', 'EFO_1001917',
       'EFO_1001050', 'EFO_0001361', 'HP_0000726', 'HP_0100543',
       'EFO_0001073', 'MONDO_0021632', 'EFO_0000694', 'MONDO_0002009',
       'EFO_0000712', 'EFO_0003948', 'MONDO_0004985', 'MONDO_0002009',
       'EFO_0003758', 'MONDO_0005090', 'EFO_0002610', 'MONDO_0100096',
       'EFO_0005230', 'MONDO_0002009', 'EFO_0005687', 'MONDO_0004985',
       'EFO_0009854', 'EFO_0008623', 'EFO_0000546', 'EFO_0004242',
       'EFO_0007328', 'EFO_0009963', 'MONDO_0002009', 'EFO_0008522',
       'EFO_0001358', 'EFO_0000474', 'EFO_0005669', 'MONDO_0002050',
       'EFO_0007191', 'EFO_0004242'], dtype=object), 'count': 42}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 approved and 36 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297744,,,Unknown,False,ELX-02,,2.0,,False,False,[],['ELX-02' 'Elx-02' 'Exaluren' 'NB-124'],,,"{'rows': array(['EFO_0000508', 'MONDO_0009061', 'MONDO_0016239', 'EFO_0003086',
       'MONDO_0018965'], dtype=object), 'count': 5}","[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4297829,,,Antibody,False,SINTILIMAB,,3.0,,False,False,['Tyvyt'],"['ANTI-PD-1 MONOCLONAL ANTIBODY IBI308' 'IBI-308' 'IBI308' 'Ibi308'
 'Sintilimab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SINTILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003897', 'EFO_0000178', 'EFO_0000702', 'EFO_1000359',
       'EFO_0004252', 'EFO_1001951', 'MONDO_0011962', 'EFO_0000183',
       'EFO_0000707', 'EFO_0000211', 'EFO_0003060', 'EFO_0000621',
       'EFO_0000348', 'EFO_0000255', 'MONDO_0003060', 'EFO_0000616',
       'EFO_0002618', 'EFO_0000349', 'EFO_1001972', 'MONDO_0004669',
       'EFO_0000313', 'EFO_0002916', 'EFO_0000199', 'MONDO_0002974',
       'MONDO_0019472', 'MONDO_0008903', 'MONDO_0008170', 'EFO_0000519',
       'EFO_0000182', 'EFO_1001968', 'EFO_0003860', 'EFO_1001961',
       'EFO_1000657', 'MONDO_0004992', 'EFO_0002913', 'EFO_0000365',
       'EFO_1001901', 'EFO_0004142', 'EFO_0000574', 'MONDO_0001056',
       'MONDO_0007254', 'EFO_0005570', 'EFO_0003968', 'MONDO_0021117',
       'MONDO_0002120', 'EFO_0005221', 'EFO_0001416', 'EFO_0000588',
       'MONDO_0009348', 'EFO_0000691', 'EFO_0000181', 'EFO_0000503',
       'MONDO_0005411', 'EFO_0005922', 'MONDO_0044704', 'EFO_0000403',
       'EFO_0000681'], dtype=object), 'count': 57}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 57 investigational indications.
CHEMBL4297876,,,Antibody,False,ZALIFRELIMAB,,2.0,,False,False,[],['AGEN1884' 'Agen-1884' 'Agen1884' 'Ugn-301' 'Zalifrelimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZALIFRELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000294', 'MONDO_0004992', 'EFO_0003060', 'EFO_1000026',
       'EFO_0000616', 'EFO_0003968', 'EFO_1001968', 'MONDO_0005184',
       'MONDO_0002974'], dtype=object), 'count': 9}",[ENSG00000163599],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL4298150,CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.O=C(O)/C=C/C(=O)O,JNLIKIBISICTMS-PEJBKAKVSA-N,Small molecule,False,SIPONIMOD FUMARIC ACID,2019.0,4.0,CHEMBL2336071,False,True,['Mayzent'],"['NVP-BAF312-AEA' 'Siponimod fumarate' 'Siponimod hemifumarate'
 'Siponimod hemifumaric acid']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIPONIMOD%20FUMARIC%20ACID/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0008522', 'EFO_0003840', 'EFO_0003929', 'MONDO_0005301'],
      dtype=object), 'count': 4}",[ENSG00000170989],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved indications.
CHEMBL435381,COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F,KYXDNECMRLFQMZ-UHFFFAOYSA-N,Small molecule,False,CIMICOXIB,2011.0,2.0,,False,False,['Cimalgex'],['Cimalgex' 'Cimicoxib' 'Cimicoxib (ema epar: veterinary)'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/cimalgex'],
      dtype=object)), ('drugbank', array(['DB05095'], dtype=object)), ('chEBI', array(['76127'], dtype=object))]",,"{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of II that was first approved in 2011 and has 1 investigational indication.
CHEMBL451,CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1,ANTSCNMPPGJYLG-UHFFFAOYSA-N,Small molecule,True,CHLORDIAZEPOXIDE,1960.0,4.0,,False,True,"['Clopoxide' 'Librelease' 'Libritabs' 'Librium' 'Sarlib' 'Trakipeal'
 'Zeisin']","['A-Poxide' 'Chlordiazachel' 'Chlordiazepoxide' 'Chlordiazepoxide civ'
 'Clopoxide' 'Librium' 'Lygen']","[('DailyMed', array(['chlordiazepoxide'], dtype=object)), ('PubChem', array(['144205120', '144205121', '49648393'], dtype=object)), ('Wikipedia', array(['Chlordiazepoxide'], dtype=object)), ('drugbank', array(['DB00475'], dtype=object)), ('chEBI', array(['3611'], dtype=object))]",['CHEMBL1200703'],"{'rows': array(['EFO_0005230', 'EFO_0006788', 'MONDO_0007079', 'EFO_0004777',
       'MONDO_0002009'], dtype=object), 'count': 5}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL455136,CNC(=O)[C@@H](c1ccccc1)N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(C(F)(F)F)cc1,DKMACHNQISHMDN-RPLLCQBOSA-N,Small molecule,False,ALMOREXANT,,3.0,,False,False,[],['ACT-078573' 'Almorexant'],"[('Wikipedia', array(['Almorexant'], dtype=object)), ('drugbank', array(['DB06673'], dtype=object))]",['CHEMBL3542330'],"{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}","[ENSG00000137252,ENSG00000121764]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4594455,,,Unknown,False,AGS-16C3F,,2.0,,False,False,[],['ADC AGS-16C3F' 'AGS-16C3F' 'Ags-16c3f' 'Ags-16c3f (anti-enpp3 antibody)'],,,"{'rows': array(['EFO_0000349', 'EFO_0000681'], dtype=object), 'count': 2}","[ENSG00000154269,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL500,CC(C)NCC(O)COc1cccc2[nH]ccc12,JZQKKSLKJUAGIC-UHFFFAOYSA-N,Small molecule,False,PINDOLOL,1982.0,4.0,,False,True,['Betadren' 'Pindolol' 'Visken'],"['(rs)-pindolol' 'Apo-pindol' 'Betapindol' 'Blocklin-l' 'Calvisken'
 'Carvisken' 'Decreten' 'Dl-lb-46' 'Dl-pindolol' 'Durapindol'
 'Glauco-visken' 'LB-46' 'NSC-757276' 'Pectobloc' 'Pinbetol' 'Pindolol'
 'Prinodolol' 'Pynastin']","[('DailyMed', array(['pindolol'], dtype=object)), ('PubChem', array(['104171209', '144203772', '170464892', '26747148', '26747149',
       '26752014', '50104680', '50104681', '85231175', '855790',
       '90341348'], dtype=object)), ('Wikipedia', array(['Pindolol'], dtype=object)), ('drugbank', array(['DB00960'], dtype=object)), ('chEBI', array(['8214'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'MONDO_0002009', 'MONDO_0002009'], dtype=object), 'count': 3}","[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 1 investigational indication.
CHEMBL559,N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,XUIIKFGFIJCVMT-GFCCVEGCSA-N,Small molecule,False,DEXTROTHYROXINE,1967.0,4.0,,False,True,['Thyroxine'],['Choloxin' 'D-thyroxine' 'Dextrothyroxine' 'Liotrix'],"[('PubChem', array(['11112110'], dtype=object)), ('Wikipedia', array(['Dextrothyroxine'], dtype=object)), ('drugbank', array(['DB00509'], dtype=object)), ('chEBI', array(['30659'], dtype=object))]",['CHEMBL1200777' 'CHEMBL3545058'],"{'rows': array(['EFO_0000319', 'EFO_1001375', 'EFO_0000612', 'EFO_0001064'],
      dtype=object), 'count': 4}","[ENSG00000126351,ENSG00000151090]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for cardiovascular disease and has 3 investigational indications.
CHEMBL661,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,VREFGVBLTWBCJP-UHFFFAOYSA-N,Small molecule,True,ALPRAZOLAM,1981.0,4.0,,False,True,['Alprazolam' 'Niravam' 'Xanax' 'Xanax xr'],"['Alprazolam' 'Alprazolam civ' 'NSC-760140' 'U 31,889' 'U-31,889'
 'U-31889']","[('DailyMed', array(['alprazolam'], dtype=object)), ('PubChem', array(['144205245', '26719699', '29215419'], dtype=object)), ('Wikipedia', array(['Alprazolam'], dtype=object)), ('drugbank', array(['DB00404'], dtype=object)), ('chEBI', array(['2611'], dtype=object))]",,"{'rows': array(['EFO_0006788', 'MONDO_0005147', 'EFO_0003890', 'EFO_0000474',
       'EFO_1001917', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_1001892', 'HP_0001250', 'EFO_0004262', 'EFO_0001358',
       'HP_0000726', 'MONDO_0005277', 'EFO_1001884', 'MONDO_0004979'],
      dtype=object), 'count': 16}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL834,NCCC(O)(P(=O)(O)O)P(=O)(O)O,WRUUGTRCQOWXEG-UHFFFAOYSA-N,Small molecule,False,PAMIDRONIC ACID,1991.0,4.0,,False,True,[],"['CGP-23339AE' 'Pamidronate' 'Pamidronic Acid' 'Pamidronic acid'
 'Ribodroat']","[('PubChem', array(['144205217', '170464689', '29215372', '29217620'], dtype=object)), ('Wikipedia', array(['Pamidronic_acid'], dtype=object)), ('drugbank', array(['DB00282'], dtype=object))]",['CHEMBL676' 'CHEMBL3989401'],"{'rows': array(['EFO_1001164', 'EFO_0001378', 'MONDO_0007254', 'EFO_0003882',
       'MONDO_0007254', 'HP_0003419', 'EFO_0001378', 'MONDO_0019019',
       'EFO_0004260'], dtype=object), 'count': 9}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for bone disease and has 6 investigational indications.
CHEMBL855,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1,CBEQULMOCCWAQT-WOJGMQOQSA-N,Small molecule,False,TRIPROLIDINE,1983.0,4.0,,False,True,[],"['Actahist' 'Actidil' 'Actifed' 'Allerfed' 'Corphed' 'Histafed' 'Myfed'
 'Myidyl' 'Trilitron' 'Triphed' 'Triprolidine']","[('PubChem', array(['144204470', '170464931', '26751829', '50104523', '50104524',
       '50104525', '90341007'], dtype=object)), ('Wikipedia', array(['Triprolidine'], dtype=object)), ('drugbank', array(['DB00427'], dtype=object)), ('chEBI', array(['84116'], dtype=object))]",['CHEMBL1200450' 'CHEMBL3188034'],"{'rows': array(['HP_0001742', 'MONDO_0005271', 'EFO_0005854', 'EFO_0007214',
       'EFO_0003956'], dtype=object), 'count': 5}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved indications.
CHEMBL105442,O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl,GFMMXOIFOQCCGU-UHFFFAOYSA-N,Small molecule,False,CI-1040,,2.0,,False,False,[],['CI-1040' 'Ci 1040' 'Ci-1040' 'PD-18435' 'PD-184352'],"[('PubChem', array(['144206914', '170466835', '174006413'], dtype=object)), ('drugbank', array(['DB12429'], dtype=object))]",,"{'rows': array(['EFO_0002618', 'EFO_0003860', 'EFO_1001951', 'EFO_0004142',
       'MONDO_0007254', 'MONDO_0008903', 'EFO_0003060', 'EFO_0003869'],
      dtype=object), 'count': 8}","[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL1200748,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O,QTAOMKOIBXZKND-PPHPATTJSA-N,Small molecule,False,CARBIDOPA,1975.0,4.0,CHEMBL1201236,False,True,['Carbidopa' 'Lodosyn'],"['Carbidopa' 'Carbidopa component of carbilev'
 'Carbidopa component of parcopa' 'Carbidopa component of sinemet'
 'Carbidopa hydrate' 'Carbidopa monohydrate' 'Carbidopum monohydrate'
 'Lodosyn' 'MK-486' 'NSC-751137' 'NSC-758190']","[('DailyMed', array(['carbidopa'], dtype=object)), ('chEBI', array(['3395'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0003770', 'Orphanet_1764',
       'EFO_0002610', 'EFO_1001402', 'EFO_0000546', 'EFO_0003768',
       'MONDO_0018910', 'MONDO_0007113', 'MONDO_0005301', 'HP_0002381',
       'EFO_0005252', 'EFO_0005687', 'MONDO_0004979', 'HP_0012532',
       'MONDO_0005180', 'HP_0003418', 'EFO_0000537', 'MONDO_0019200',
       'MONDO_0005090', 'MONDO_0001020', 'EFO_1001175', 'EFO_0003888',
       'EFO_0003843', 'MONDO_0004976', 'EFO_0001365'], dtype=object), 'count': 27}",[ENSG00000132437],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 23 investigational indications.
CHEMBL1200831,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2.Cl,CLDOLNORSLLQDI-OOAIBONUSA-N,Small molecule,False,SPIRAPRIL HYDROCHLORIDE,1994.0,4.0,CHEMBL431,False,True,['Renormax'],['SCH 33844' 'SCH-33844' 'Spirapril hcl' 'Spirapril hydrochloride'],"[('PubChem', array(['144206534'], dtype=object))]",,,[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994.
CHEMBL1201329,O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1,CHQOEHPMXSHGCL-UHFFFAOYSA-N,Small molecule,False,TRIMETHAPHAN,1982.0,4.0,,False,True,[],['Trimetaphan' 'Trimethaphan' 'Trimethaphan cation' 'Trimethaphan ion'],"[('drugbank', array(['DB01116'], dtype=object)), ('chEBI', array(['9728'], dtype=object))]",['CHEMBL1245'],"{'rows': array(['EFO_0000537', 'EFO_0002614'], dtype=object), 'count': 2}","[ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for hypertension and has 1 investigational indication.
CHEMBL1318287,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1.O=C([O-])[C@H](O)[C@@H](O)C(=O)O.O=C([O-])[C@H](O)[C@@H](O)C(=O)O,HSMKTIKKPMTUQH-WBPXWQEISA-L,Small molecule,False,PENTOLINIUM TARTRATE,1982.0,4.0,CHEMBL1271,False,True,['Ansolysen'],"['NSC-759890' 'Pentolinium tartrate' 'Pentolonium tartrate'
 'Pentolonum bitartrate']","[('PubChem', array(['50106735', '90341731'], dtype=object)), ('chEBI', array(['55326'], dtype=object))]",,,"[ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1614652,O=C1c2ccccc2S(=O)(=O)N1CCCCNC[C@H]1CCc2ccccc2O1,YGYBFMRFXNDIPO-QGZVFWFLSA-N,Small molecule,False,REPINOTAN,,2.0,,False,False,[],['Repinotan'],"[('Wikipedia', array(['Repinotan'], dtype=object)), ('drugbank', array(['DB06506'], dtype=object))]",,,[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1743086,,,Antibody,False,VATELIZUMAB,,2.0,,False,False,[],['GBR 500' 'GBR-500' 'SAR-339658' 'SAR339658' 'Vatelizumab'],,,"{'rows': array(['EFO_0000729', 'EFO_0003929'], dtype=object), 'count': 2}",[ENSG00000164171],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1933349,COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1,DNTVJEMGHBIUMW-IBGZPJMESA-N,Small molecule,False,MK-0893,,2.0,,False,False,[],['MK-0893' 'Mk-0893' 'Mk0893'],"[('drugbank', array(['DB12044'], dtype=object))]",['CHEMBL2159354'],"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000215644],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109465,,,Antibody,False,QAX-576,,2.0,,False,False,[],['Dectrekumab' 'QAX-576' 'Qax-576' 'Qax576'],,,"{'rows': array(['EFO_0005854', 'EFO_0004212', 'EFO_0009448', 'EFO_0004232',
       'EFO_0000768', 'MONDO_0004979', 'EFO_0000384', 'EFO_0000717'],
      dtype=object), 'count': 8}",[ENSG00000169194],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL2109495,,,Antibody,False,E2.3,,1.0,,False,False,[],['E2.3'],,,"{'rows': array(['EFO_0000198', 'EFO_0000565', 'EFO_0001378', 'EFO_0002428'],
      dtype=object), 'count': 4}","[ENSG00000072274,ENSG00000106327]",Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications.
CHEMBL2111100,CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC,JMUHBNWAORSSBD-WKYWBUFDSA-N,Small molecule,False,MIFAMURTIDE ACID,2009.0,4.0,,False,True,[],['CGP-19835' 'Mifamurtide free acid anhydrous'],,['CHEMBL2107354'],"{'rows': array(['MONDO_0002629', 'EFO_0000637', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000167207],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications.
CHEMBL3545108,O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,HSQAARMBHJCUOK-UHFFFAOYSA-N,Small molecule,False,AZD9056,,2.0,,False,False,[],['AZD9056' 'Azd 9056' 'Azd-9056' 'Azd9056'],"[('drugbank', array(['DB12594'], dtype=object))]",['CHEMBL3415305'],"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000089041],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3686884,CNC(=O)n1ccc2cc(Oc3ccnc(NC(=O)c4ccc(C5CCN(CCO)CC5)cc4)c3)c(OCCOC)cc21,IBHOLSBDZMIPPT-UHFFFAOYSA-N,Small molecule,False,E-7090,,2.0,,False,False,[],['E 7090' 'E-7090' 'E7090' 'Tasurgratinib'],,,"{'rows': array(['EFO_0005221', 'EFO_0003869', 'EFO_0001421', 'EFO_0000616'],
      dtype=object), 'count': 4}","[ENSG00000077782,ENSG00000068078,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3707359,,,Unknown,False,DAXIBOTULINUMTOXINA,2022.0,4.0,,False,True,['Daxxify'],['Daxibotulinumtoxina' 'RTI-150' 'RTI150' 'RTT150'],,,"{'rows': array(['HP_0000473', 'EFO_0005422'], dtype=object), 'count': 2}",[ENSG00000132639],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for skin aging and has 1 investigational indication.
CHEMBL395091,CN[C@]1(c2ccccc2Cl)CCCCC1=O,YQEZLKZALYSWHR-ZDUSSCGKSA-N,Small molecule,True,ESKETAMINE,2019.0,4.0,,False,True,[],"['(-)-ketamine' 'Esketamine' 'Jnj-54135419' 'Keta-s' 'Ketamine, (s)-'
 'Ketamine, s-' 'Ketaved' 'L-ketamine' 'S-(-)-ketamine' 'S-ketamine']","[('PubChem', array(['144206757'], dtype=object)), ('drugbank', array(['DB11823'], dtype=object)), ('chEBI', array(['60799'], dtype=object))]",['CHEMBL2364609'],"{'rows': array(['MONDO_0002050', 'EFO_0003843', 'MONDO_0002050', 'MONDO_0002009',
       'EFO_0003086', 'MONDO_0002009', 'MONDO_0002009', 'EFO_0003890',
       'EFO_0801084', 'EFO_0005854', 'EFO_0003843', 'HP_0000360',
       'EFO_0009267', 'EFO_0001421', 'EFO_0006834', 'MONDO_0002009'],
      dtype=object), 'count': 16}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for depressive disorder and major depressive disorder and has 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297643,Cc1cccc(/C=N/Nc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1,HSKAZIJJKRAJAV-KOEQRZSOSA-N,Small molecule,False,APILIMOD,,2.0,,False,False,[],['Apilimod' 'STA 5326' 'STA-5326' 'Sta-5326'],"[('drugbank', array(['DB05611'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'MONDO_0015517', 'EFO_0000384'], dtype=object), 'count': 3}",[ENSG00000115020],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL642,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1,GOEMGAFJFRBGGG-UHFFFAOYSA-N,Small molecule,False,ACEBUTOLOL,1984.0,4.0,,False,True,[],['Acebutolol' 'C07AB04' 'Sectral'],"[('Wikipedia', array(['Acebutolol'], dtype=object)), ('drugbank', array(['DB01193'], dtype=object)), ('chEBI', array(['2379'], dtype=object))]",['CHEMBL1200813'],"{'rows': array(['HP_0004308', 'EFO_0003777', 'EFO_0000537', 'EFO_0000537',
       'EFO_0000319', 'EFO_1000635'], dtype=object), 'count': 6}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 3 investigational indications.
CHEMBL105060,CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1,BHCJHYIMNHXLOM-WVDRJWPYSA-N,Small molecule,False,DNK333,,2.0,,False,False,[],['Dnk333'],,,"{'rows': array(['EFO_0000341', 'EFO_0000274', 'EFO_0000555'], dtype=object), 'count': 3}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1069,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,ACWBQPMHZXGDFX-QFIPXVFZSA-N,Small molecule,True,VALSARTAN,1996.0,4.0,,False,True,['Diovan' 'Exforge' 'Prexxartan' 'Valsartan'],['CGP 48933' 'CGP-48933' 'NSC-758927' 'Valsartan'],"[('DailyMed', array(['valsartan'], dtype=object)), ('PubChem', array(['26719825'], dtype=object)), ('Wikipedia', array(['Valsartan'], dtype=object)), ('drugbank', array(['DB00177'], dtype=object)), ('chEBI', array(['9927'], dtype=object))]",,"{'rows': array(['EFO_0000275', 'EFO_0004265', 'EFO_0008583', 'HP_0003124',
       'EFO_0008586', 'EFO_0007148', 'EFO_0000195', 'EFO_0005672',
       'MONDO_0005149', 'EFO_0003086', 'EFO_0000538', 'EFO_0000373',
       'EFO_0005529', 'EFO_0000401', 'Orphanet_309005', 'MONDO_0100096',
       'EFO_0000694', 'EFO_0008585', 'EFO_0001645', 'EFO_0000319',
       'EFO_0000712', 'EFO_0003914', 'EFO_0000400', 'MONDO_0005148',
       'EFO_0000612', 'EFO_0003144', 'EFO_0003884', 'MONDO_0001134',
       'MONDO_0018965', 'EFO_0000537'], dtype=object), 'count': 30}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1088,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21,SLVMESMUVMCQIY-UHFFFAOYSA-N,Small molecule,True,MESORIDAZINE,1970.0,4.0,,False,True,[],"['Mesoridazine' 'NC-123' 'NSC-186066' 'Serentil' 'TPS-23'
 'Thioridazine-2-sulfoxide']","[('PubChem', array(['144203603', '144205571', '170465272', '26756521', '447728'],
      dtype=object)), ('Wikipedia', array(['Mesoridazine'], dtype=object)), ('drugbank', array(['DB00933'], dtype=object)), ('chEBI', array(['6780'], dtype=object))]",['CHEMBL1201052'],"{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}","[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970 and is indicated for psychosis. This drug has a black box warning from the FDA.
CHEMBL1200955,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2.Cl,OWLCGJBUTJXNOF-HDNKIUSMSA-N,Small molecule,True,MYCOPHENOLATE MOFETIL HYDROCHLORIDE,1998.0,4.0,CHEMBL1456,False,True,['Cellcept' 'Mycophenolate mofetil hydrochloride'],"['Mycophenolate mofetil hcl' 'Mycophenolate mofetil hydrochloride'
 'RS-61443-190']","[('DailyMed', array(['mycophenolate%20mofetil%20hydrochloride'], dtype=object))]",,,"[ENSG00000106348,ENSG00000178035]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998. This drug has a black box warning from the FDA.
CHEMBL1201566,,,Protein,True,DARBEPOETIN ALFA,2001.0,4.0,,False,True,['Aranesp' 'Aranesp sureclick'],"['Darbepoetin' 'Darbepoetin alfa' 'Darbepoetin alfa,recombinant' 'KRN-321'
 'KRN321' 'NESP' 'Nespo']","[('DailyMed', array(['darbepoetin%20alfa'], dtype=object)), ('DrugCentral', array(['5157'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aranesp'],
      dtype=object))]",,"{'rows': array(['HP_0001298', 'EFO_0000095', 'EFO_0004272', 'EFO_0000198',
       'EFO_0000574', 'EFO_0001642', 'MONDO_0002280', 'EFO_0000565',
       'MONDO_0007254', 'EFO_0000222', 'MONDO_0043510', 'EFO_0000702',
       'EFO_0003884', 'EFO_0003086', 'EFO_0000612', 'HP_0001919',
       'MONDO_0005299', 'MONDO_0003002', 'MONDO_0004992', 'EFO_0008583',
       'EFO_0000403'], dtype=object), 'count': 21}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743071,,,Antibody,False,SIRUKUMAB,,3.0,,False,False,[],['CNTO 136' 'CNTO-136' 'Sirukumab'],,,"{'rows': array(['MONDO_0007915', 'EFO_0000540', 'MONDO_0004979', 'EFO_1001209',
       'MONDO_0100096', 'EFO_0003834', 'EFO_0008518', 'EFO_0005761',
       'EFO_0000685', 'MONDO_0002009'], dtype=object), 'count': 10}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL188185,CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1,RHLJLALHBZGAFM-UHFFFAOYSA-N,Small molecule,False,BUNAZOSIN,,3.0,,False,False,[],['Bunazosin' 'Bunazosin hydrochloride'],"[('Wikipedia', array(['Bunazosin'], dtype=object)), ('drugbank', array(['DB12230'], dtype=object))]",['CHEMBL3182014'],,"[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of III.
CHEMBL2095208,CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,ZCIGNRJZKPOIKD-CQXVEOKZSA-N,Small molecule,False,COBICISTAT,2012.0,4.0,,False,True,['Tybost'],"['Cobicistat' 'Cobicistat on silicon dioxide' 'Cobicistat, (r,r,s)-'
 'GS-9350']","[('DailyMed', array(['cobicistat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tybost'],
      dtype=object)), ('drugbank', array(['DB09065'], dtype=object)), ('chEBI', array(['72291'], dtype=object))]",,"{'rows': array(['EFO_0000765', 'EFO_0007448', 'MONDO_0004992', 'EFO_0001068',
       'EFO_0000764', 'EFO_0000220', 'EFO_0000544', 'MONDO_0100096',
       'MONDO_0005184', 'EFO_0002614', 'EFO_0003060', 'EFO_0000180'],
      dtype=object), 'count': 12}","[ENSG00000160868,ENSG00000106258,ENSG00000021461,ENSG00000160870]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 9 investigational indications.
CHEMBL312448,Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,HUCJFAOMUPXHDK-UHFFFAOYSA-N,Small molecule,False,XYLOMETAZOLINE,,4.0,,False,True,[],['Balminil' 'Xylometazoline'],"[('PubChem', array(['11111974', '11111975', '174007471', '50100368', '50104259',
       '90340774'], dtype=object)), ('Wikipedia', array(['Xylometazoline'], dtype=object)), ('drugbank', array(['DB06694'], dtype=object)), ('chEBI', array(['10082'], dtype=object))]",['CHEMBL1256400'],"{'rows': array(['HP_0001742', 'EFO_0005751', 'EFO_0007214'], dtype=object), 'count': 3}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for nasal congestion and eye allergy and has 1 investigational indication.
CHEMBL3707326,,,Antibody,False,BUROSUMAB,2018.0,4.0,,False,True,['Crysvita'],['Burosumab' 'Burosumab twza' 'KRN-23' 'KRN23'],"[('DailyMed', array(['burosumab-twza'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita'],
      dtype=object))]",,"{'rows': array(['MONDO_0000845', 'EFO_1002027', 'Orphanet_89936', 'EFO_0004260',
       'MONDO_0024300', 'HP_0002148'], dtype=object), 'count': 6}",[ENSG00000118972],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 3 investigational indications.
CHEMBL398435,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,OEKWJQXRCDYSHL-FNOIDJSQSA-N,Small molecule,True,TICAGRELOR,2010.0,4.0,,False,True,['Brilinta' 'Brilique'],['AR-C126532XX' 'AZD-6140' 'AZD6140' 'Possia' 'Ticagrelor'],"[('DailyMed', array(['ticagrelor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brilique'],
      dtype=object)), ('Wikipedia', array(['Ticagrelor'], dtype=object)), ('drugbank', array(['DB08816'], dtype=object)), ('chEBI', array(['68558'], dtype=object))]",,"{'rows': array(['EFO_0008585', 'EFO_0003884', 'EFO_0003870', 'EFO_0002615',
       'EFO_0000341', 'EFO_0008586', 'EFO_0000266', 'EFO_0000612',
       'EFO_0008583', 'EFO_0007328', 'EFO_0003086', 'EFO_0005672',
       'MONDO_0011382', 'MONDO_0000831', 'EFO_0003106', 'EFO_0004214',
       'EFO_0000556', 'EFO_0003875', 'MONDO_0005148', 'EFO_0003913',
       'EFO_0000275', 'EFO_0004265', 'EFO_0000319', 'EFO_0000712',
       'HP_0004419', 'MONDO_0100096', 'HP_0002140', 'EFO_0001645'],
      dtype=object), 'count': 28}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 9 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4209157,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1,NGFFVZQXSRKHBM-FKBYEOEOSA-N,Small molecule,False,LIFIRAFENIB,,2.0,,False,False,[],['BGB-283' 'Beigene-283' 'Bgb 283' 'Bgb-283' 'Lifirafenib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LIFIRAFENIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14773'], dtype=object))]",['CHEMBL4298146'],"{'rows': array(['EFO_0000616', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000157764],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication.
CHEMBL4297566,,,Oligonucleotide,False,CASIMERSEN,2021.0,4.0,,False,True,['Amondys 45'],['Casimersen' 'EXON-45: NG-12-0064' 'SRP-4045'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CASIMERSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0010679', 'MONDO_0020121'], dtype=object), 'count': 2}",[ENSG00000198947],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for duchenne muscular dystrophy and muscular dystrophy.
CHEMBL4297694,,,Protein,False,ANFIBATIDE,,2.0,,False,False,[],['Agkisacucetin' 'Anfibatide'],,,"{'rows': array(['EFO_0000612', 'MONDO_0019740'], dtype=object), 'count': 2}",[ENSG00000185245],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297840,,,Antibody,False,TISLELIZUMAB,,4.0,,False,True,[],['BGB-A317' 'BGN-1' 'BGN1' 'Bgb-a317' 'JHL-2108' 'JHL2108' 'Tislelizumab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TISLELIZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0019472', 'EFO_0005952', 'EFO_0000294', 'MONDO_0002974',
       'EFO_0005922', 'EFO_0000616', 'EFO_0004142', 'EFO_0000199',
       'EFO_0005221', 'EFO_0000707', 'MONDO_0021063', 'EFO_0000365',
       'EFO_0000272', 'MONDO_0002367', 'EFO_0000574', 'EFO_0000182',
       'EFO_1000350', 'EFO_1000657', 'EFO_1001961', 'EFO_0002609',
       'EFO_0003860', 'MONDO_0008170', 'EFO_0000183', 'MONDO_0011962',
       'EFO_0000211', 'MONDO_0001056', 'EFO_0000403', 'MONDO_0007576',
       'MONDO_0007254', 'MONDO_0002691', 'EFO_0000681', 'EFO_0001416',
       'MONDO_0002108', 'EFO_0008528', 'EFO_0004252', 'EFO_0000708',
       'EFO_0003060', 'EFO_0005537', 'MONDO_0003060', 'MONDO_0015760',
       'MONDO_0001187', 'MONDO_0004986', 'EFO_0000756', 'MONDO_0009348',
       'EFO_0000313', 'EFO_0003891', 'HP_0001541', 'EFO_0000702',
       'EFO_0002618', 'MONDO_0008315', 'EFO_1001951', 'EFO_0006859',
       'MONDO_0008903', 'EFO_0004244', 'EFO_0000181', 'MONDO_0005184',
       'MONDO_0005575', 'EFO_0000519', 'EFO_0000503', 'MONDO_0004992',
       'EFO_0000632', 'EFO_0000565'], dtype=object), 'count': 62}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and cancer and has 60 investigational indications.
CHEMBL456237,Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1,KYWWJENKIMRJBI-UHFFFAOYSA-N,Small molecule,False,LXR-623,,1.0,,False,False,[],['Lx-623' 'Lx623' 'Lxr-623' 'WAY-252623' 'Way252623'],,,,"[ENSG00000131408,ENSG00000025434]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL5283463,Cc1ccc(S(=O)(=O)O)cc1.Cc1ccsc1C(=O)Nc1cc(CN2CCN(C(=O)CO)CC2)ccc1/C=C/c1n[nH]c2ccccc12,SIJKXSMUXNJNQM-HRNDJLQDSA-N,Small molecule,False,KW-2450,,2.0,CHEMBL5315324,False,False,[],['KW-2450' 'Kw-2450'],,,"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000171105,ENSG00000140443]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL911,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,ZAFYATHCZYHLPB-UHFFFAOYSA-N,Small molecule,True,ZOLPIDEM,1992.0,4.0,,False,True,[],['Ambien' 'Sanval' 'Zolpidem' 'Zolpidem civ'],"[('PubChem', array(['144205024', '170465242', '26749064'], dtype=object)), ('Wikipedia', array(['Zolpidem'], dtype=object)), ('drugbank', array(['DB00425'], dtype=object)), ('chEBI', array(['10125'], dtype=object))]",['CHEMBL3989820' 'CHEMBL1723343'],"{'rows': array(['MONDO_0005180', 'EFO_0004698', 'EFO_0003888', 'MONDO_0000477',
       'MONDO_0005090', 'EFO_0007191', 'EFO_0003758', 'EFO_0000673',
       'EFO_0001073', 'EFO_0003890', 'EFO_0008568', 'EFO_0005230',
       'HP_0000726', 'EFO_0008568', 'EFO_0004698', 'HP_0003419',
       'MONDO_0002050'], dtype=object), 'count': 17}","[ENSG00000022355,ENSG00000113327,ENSG00000163288]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for insomnia and has 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL928,O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)[N-]1.[Na+],KSRLIXGNPXAZHD-HAZZGOGXSA-M,Small molecule,True,DANTROLENE SODIUM,1974.0,4.0,CHEMBL1201288,False,True,['Dantrium' 'Dantrolene sodium' 'Revonto' 'Ryanodex'],"['Dantamacrin' 'Dantrolen' 'Dantrolene sodium'
 'Dantrolene sodium heptahydrate' 'Dantrolene sodium hydrate'
 'Dantrolene sodium salt hemiheptahydrate' 'F-440' 'NSC-758403']","[('DailyMed', array(['dantrolene%20sodium'], dtype=object)), ('PubChem', array(['50106202'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0020003', 'EFO_1000632',
       'HP_0001257', 'EFO_1001340', 'MONDO_0018105', 'MONDO_0005301',
       'HP_0001945'], dtype=object), 'count': 9}","[ENSG00000196218,ENSG00000198838]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1079593,O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1[C@@H]1CCOc2c(F)cccc21,DBXGGXLBTWZXBB-MRXNPFEDSA-N,Small molecule,False,VS-5584,,1.0,,False,False,[],['VS-5584' 'Vs 5584' 'Vs-5584'],,,"{'rows': array(['EFO_0000588', 'EFO_0000574'], dtype=object), 'count': 2}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL1100,CCC1(C)OC(=O)N(C)C1=O,VQASKUSHBVDKGU-UHFFFAOYSA-N,Small molecule,False,PARAMETHADIONE,1949.0,4.0,,False,True,['Paradione'],['Isoethadione' 'NSC-760129' 'Paramethadione'],"[('Wikipedia', array(['Paramethadione'], dtype=object)), ('drugbank', array(['DB00617'], dtype=object)), ('chEBI', array(['7921'], dtype=object))]",,"{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1949 and is indicated for epilepsy.
CHEMBL1200764,CC(=O)OC(C)C[N+](C)(C)C.[Cl-],JHPHVAVFUYTVCL-UHFFFAOYSA-M,Small molecule,True,METHACHOLINE CHLORIDE,1986.0,4.0,CHEMBL978,False,True,['Provocholine'],['Methacholine chloride' 'NSC-757090'],"[('DailyMed', array(['methacholine%20chloride'], dtype=object)), ('PubChem', array(['144203899', '170464971', '50105745', '56423647', '855729'],
      dtype=object)), ('chEBI', array(['50142'], dtype=object))]",,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for asthma. This drug has a black box warning from the FDA.
CHEMBL124660,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1,UXXQOJXBIDBUAC-UHFFFAOYSA-N,Small molecule,False,TANDUTINIB,,2.0,,False,False,[],"['CT 53518' 'CT-53518' 'CT53518' 'MLN-518' 'Mln-0518' 'NSC-759851'
 'Tandutinib']","[('PubChem', array(['103905342', '124950156', '144206917', '170466826', '50100108'],
      dtype=object)), ('drugbank', array(['DB05465'], dtype=object)), ('chEBI', array(['90237'], dtype=object))]",,"{'rows': array(['EFO_1001465', 'EFO_0002501', 'EFO_0002499', 'EFO_0000222',
       'EFO_0000349', 'EFO_0000630', 'EFO_0000198', 'EFO_0000519'],
      dtype=object), 'count': 8}","[ENSG00000157404,ENSG00000113721,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL1457,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,LLPOLZWFYMWNKH-CMKMFDCUSA-N,Small molecule,True,HYDROCODONE,1943.0,4.0,,False,True,[],['Hydrocodone'],"[('PubChem', array(['29215221'], dtype=object)), ('Wikipedia', array(['Hydrocodone'], dtype=object)), ('drugbank', array(['DB00956'], dtype=object)), ('chEBI', array(['5779'], dtype=object))]","['CHEMBL3989677' 'CHEMBL1201470' 'CHEMBL3182640' 'CHEMBL2062267'
 'CHEMBL2135756']","{'rows': array(['EFO_0003843', 'HP_0002013', 'EFO_0005762', 'EFO_0003086',
       'MONDO_0005178', 'EFO_0009615', 'MONDO_0005178', 'EFO_0000546',
       'HP_0003419', 'HP_0012532', 'EFO_1001250', 'EFO_0003843',
       'EFO_0001421', 'EFO_0003890', 'EFO_0003966', 'HP_0003419',
       'HP_0012532', 'HP_0012735', 'HP_0002018'], dtype=object), 'count': 19}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1463345,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]21CCC(=O)O1,UJVLDDZCTMKXJK-WNHSNXHDSA-N,Small molecule,False,CANRENONE,,4.0,,True,True,[],"['Canrenone' 'NSC-261713' 'SC-9376' 'Spironolactone metabolite m1'
 'Spironolactone related compound a']","[('PubChem', array(['144205004', '170466206', '49646110'], dtype=object)), ('drugbank', array(['DB12221'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region.
CHEMBL1480,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,RZTAMFZIAATZDJ-UHFFFAOYSA-N,Small molecule,False,FELODIPINE,1991.0,4.0,,False,True,"['Cabren' 'Cardioplen xl' 'Felodipine' 'Felogen xl' 'Felotens xl'
 'Folpik xl' 'Keloc sr' 'Neofel xl' 'Parmid xl' 'Pinefeld xl' 'Plendil'
 'Preslow' 'Vascalpha']",['C08CA02' 'Felodipine' 'H 154/82' 'H-154/82' 'NSC-760343'],"[('DailyMed', array(['felodipine'], dtype=object)), ('PubChem', array(['124880165', '144203706', '170464849', '17405071', '50106289',
       '50106290', '85231057', '90340828'], dtype=object)), ('Wikipedia', array(['Felodipine'], dtype=object)), ('drugbank', array(['DB01023'], dtype=object)), ('chEBI', array(['585948'], dtype=object))]",,"{'rows': array(['EFO_0003914', 'EFO_0000400', 'EFO_0000537', 'EFO_0000319',
       'MONDO_0005148', 'EFO_0001645', 'HP_0003124'], dtype=object), 'count': 7}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000151623]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 4 investigational indications.
CHEMBL154,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,CMWTZPSULFXXJA-VIFPVBQESA-N,Small molecule,True,NAPROXEN,1976.0,4.0,,False,True,"['Aleve' 'Anaprox' 'Arthrosin 250' 'Arthrosin 250 ec' 'Arthrosin 500'
 'Arthrosin 500 ec' 'Condrotec' 'Ec-naprosyn' 'Equiproxen' 'Feminax ultra'
 'Grenoxal' 'Kenosyn' 'Laraflex' 'Napratec op' 'Naprosyn' 'Naprosyn 375'
 'Naprosyn ec' 'Naproxen' 'Nycopren' 'Pranoxen continus' 'Prosaid'
 'Rheuflex 250' 'Rheuflex 500' 'Rimoxyn' 'Stirlescent' 'Timpron'
 'Timpron 250 ec' 'Timpron 500 ec' 'Valrox' 'Vimovo']","['Aleve' 'Anaprox' 'NSC-750183' 'NSC-757239' 'Naprelan' 'Naproxen'
 'PN400 COMPONENT NAPROXEN' 'RS-3540']","[('DailyMed', array(['naproxen'], dtype=object)), ('PubChem', array(['11112669', '144212270', '26755231', '90341518'], dtype=object)), ('TG-GATEs', array(['73'], dtype=object)), ('Wikipedia', array(['Naproxen'], dtype=object)), ('drugbank', array(['DB00788'], dtype=object)), ('chEBI', array(['7476'], dtype=object))]",['CHEMBL1200806'],"{'rows': array(['HP_0003418', 'MONDO_0005277', 'EFO_0005856', 'EFO_0010072',
       'EFO_0004616', 'MONDO_0007254', 'EFO_0002609', 'MONDO_0002471',
       'HP_0003418', 'MONDO_0005178', 'MONDO_0005301', 'EFO_0009637',
       'EFO_1000786', 'MONDO_0004975', 'EFO_0009454', 'EFO_0000673',
       'EFO_0007214', 'EFO_0005755', 'MONDO_0002471', 'EFO_0004607',
       'MONDO_0005835', 'HP_0002315', 'MONDO_0005277', 'EFO_1001434',
       'MONDO_0003937', 'MP_0001845', 'EFO_0000685', 'MONDO_0004857',
       'MONDO_0010870', 'HP_0003326', 'EFO_0004616', 'EFO_0003898',
       'MONDO_0100096', 'HP_0003419', 'MONDO_0002258', 'EFO_0000685',
       'EFO_0004274', 'MONDO_0005178', 'EFO_0003843', 'EFO_0003898',
       'EFO_0002609', 'MONDO_0004975', 'EFO_0000546', 'HP_0002315',
       'EFO_0005757', 'HP_0002829', 'EFO_1000941', 'HP_0100607',
       'EFO_0009454', 'EFO_0004274', 'HP_0001945', 'EFO_0005762',
       'EFO_0003843', 'EFO_0010072', 'HP_0100607', 'EFO_0009846',
       'HP_0004398', 'MONDO_0003937'], dtype=object), 'count': 58}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 25 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2035185,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1,NNXDIGHYPZHXTR-ONEGZZNKSA-N,Small molecule,False,CT-1578,,1.0,,False,False,[],['CT-1578' 'Ct-1578' 'ONX 0805' 'ONX-0805' 'SB-1578' 'SB1578' 'Sb1578'],"[('drugbank', array(['DB15294'], dtype=object))]",,,"[ENSG00000122025,ENSG00000096968,ENSG00000182578]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2109633,,,Antibody drug conjugate,False,IMGN-388,,1.0,,False,False,[],['IMGN-388' 'Imgn-388'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000138448],Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2364639,COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2,GEJDGVNQKABXKG-CFKGEZKQSA-N,Small molecule,True,VALBENAZINE,2017.0,4.0,,False,True,[],['Mt-5199' 'NBI-98854' 'Valbenazine'],"[('drugbank', array(['DB11915'], dtype=object))]",['CHEMBL3707248'],"{'rows': array(['MONDO_0007739', 'HP_0012167', 'EFO_0004895', 'EFO_0004280',
       'EFO_0004280', 'MONDO_0005090'], dtype=object), 'count': 6}",[ENSG00000165646],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for movement disorder and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3039504,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,MMMVNAGRWOJNMW-FJBFXRHMSA-N,Small molecule,False,NINTEDANIB ESYLATE,2014.0,4.0,CHEMBL502835,False,True,['Ofev'],['Nintedanib esilate' 'Nintedanib esylate' 'Nintedanib ethanesulfonate'],"[('DailyMed', array(['nintedanib%20esylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ofev'],
      dtype=object)), ('chEBI', array(['85170'], dtype=object))]",,"{'rows': array(['EFO_0000768', 'EFO_0000717'], dtype=object), 'count': 2}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for idiopathic pulmonary fibrosis and systemic scleroderma.
CHEMBL3544947,CC(C)(C(N)=O)C1CCN(CCC2(c3ccc(Cl)c(Cl)c3)CN(C(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CCO2)CC1,ZLNYUCXXSDDIFU-UHFFFAOYSA-N,Small molecule,False,BURAPITANT,,2.0,,False,False,[],['Burapitant' 'SSR-240600' 'SSR240600C' 'Ssr240600'],,,"{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545337,CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23.Cl.Cl.O,XJYNBZQTAZDMHZ-UHFFFAOYSA-N,Small molecule,False,C-1311,,2.0,CHEMBL338604,False,False,['Symadex'],['C 1311' 'C-1311' 'NSC-645809' 'Xls-002'],,,,"[ENSG00000131747,ENSG00000077097,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3707314,,,Protein,False,METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA,2007.0,4.0,,False,True,['Mircera'],"['Methoxy polyethylene glycol-epoetin beta' 'Pegzerepoetin alfa' 'R-744'
 'R744']","[('DailyMed', array(['methoxy%20polyethylene%20glycol-epoetin%20beta'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mircera'],
      dtype=object))]",,"{'rows': array(['EFO_0003884', 'MONDO_0002280', 'EFO_0004272', 'EFO_0003086'],
      dtype=object), 'count': 4}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 1 investigational indication.
CHEMBL3920982,O=C(O)c1ccc(C2(NC(=O)C3CC4(CCN3Cc3ccc(C(F)(F)F)cc3)CC4)CC2)cc1,CADWTPLFEZSAHM-UHFFFAOYSA-N,Small molecule,False,VORBIPIPRANT,,2.0,,False,False,[],['CR-6086' 'CR6086' 'Cr 6086' 'Cr-6086' 'Cr6086' 'Vorbipiprant'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object))]",,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000171522],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL426084,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3,RYIDHLJADOKWFM-MAODMQOUSA-N,Small molecule,False,SAMIDORPHAN,2021.0,4.0,,False,True,[],"['ALKS 33' 'ALKS-33' 'ALKS-5461 COMPONENT SAMIDORPHAN' 'Alks-33'
 'RDC-0313' 'RDC-0313-00' 'Samidorphan']","[('drugbank', array(['DB12543'], dtype=object))]",['CHEMBL2105749' 'CHEMBL471243'],"{'rows': array(['EFO_0009963', 'EFO_0002610', 'MONDO_0005090', 'MONDO_0005090',
       'EFO_0005203', 'MONDO_0007079'], dtype=object), 'count': 6}","[ENSG00000112038,ENSG00000116329,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for bipolar i disorder and schizophrenia and has 4 investigational indications.
CHEMBL4303669,O.O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,FUXFIVRTGHOMSO-UHFFFAOYSA-N,Small molecule,False,ZOLEDRONIC ACID,2001.0,4.0,CHEMBL924,False,True,['Aclasta' 'Reclast' 'Zerlinda' 'Zoledronic acid' 'Zometa'],"['AK-156' 'CGP 42446' 'CGP-42446' 'CGP-42446A' 'NSC-721517'
 'Zoladrona acid mylan' 'Zoledronate hydrate' 'Zoledronic'
 'Zoledronic acid' 'Zoledronic acid accord' 'Zoledronic acid hydrate'
 'Zoledronic acid medac' 'Zoledronic acid monohydrate'
 'Zoledronic acid teva']","[('DailyMed', array(['zoledronic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aclasta'],
      dtype=object))]",,"{'rows': array(['EFO_0000228', 'EFO_0000588', 'EFO_0003820', 'EFO_0000564',
       'EFO_0004259', 'EFO_0001416', 'MONDO_0008310', 'EFO_0003863',
       'EFO_0005952', 'EFO_0003843', 'EFO_1001998', 'MONDO_0011382',
       'EFO_1001147', 'EFO_0004252', 'EFO_1001919', 'GO_0042697',
       'EFO_0000691', 'EFO_0003060', 'EFO_0003882', 'EFO_0003869',
       'EFO_0000681', 'EFO_0003854', 'EFO_0000196', 'MONDO_0019019',
       'MONDO_0021165', 'MONDO_0044903', 'MONDO_0002974', 'EFO_0002430',
       'MONDO_0008315', 'MONDO_0002171', 'EFO_0003931', 'EFO_0000685',
       'EFO_0000673', 'EFO_0009708', 'EFO_0001365', 'MONDO_0008903',
       'HP_0000938', 'EFO_0000182', 'MONDO_0020732', 'EFO_0001663',
       'EFO_0009870', 'EFO_0000637', 'Orphanet_848', 'HP_0003419',
       'EFO_0001378', 'EFO_0006738', 'MONDO_0007254', 'EFO_0000333',
       'EFO_0000432', 'EFO_0000621', 'EFO_0004260', 'MONDO_0002367',
       'EFO_0000174', 'EFO_0004261', 'EFO_1000786'], dtype=object), 'count': 55}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 12 approved and 43 investigational indications.
CHEMBL43064,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1,DERZBLKQOCDDDZ-JLHYYAGUSA-N,Small molecule,False,CINNARIZINE,,4.0,,False,True,['Marzine r.f.' 'Mylan travel sickness' 'Stugeron' 'Stugeron fte'],"['516 MD' '516-MD' 'Aplactan' 'Aplexal' 'Artate' 'Carecin' 'Cerebolan'
 'Cerepar' 'Cinaperazine' 'Cinarizine' 'Cinazyn' 'Cinnacet' 'Cinnageron'
 'Cinnarizine' 'Cinnipirine' 'Corathiem' 'Denapol' 'Dimitron' 'Eglen'
 'Folcodal' 'Giganten' 'Glanil' 'Hilactan' 'Ixertol' 'Katoseran' 'Labyrin'
 'Midronal' 'Mitronal' 'NSC-758400' 'Olamin' 'Processine' 'R 1575' 'R 516'
 'R-1575' 'R-516' 'Sedatromin' 'Sepan' 'Siptazin' 'Spaderizine' 'Stugeron'
 'Stunarone' 'Stutgeron' 'Stutgin']","[('PubChem', array(['144203660', '170465920', '50103929', '56422441', '85231348',
       '855570', '90340734'], dtype=object)), ('Wikipedia', array(['Cinnarizine'], dtype=object)), ('chEBI', array(['31403'], dtype=object))]",,"{'rows': array(['HP_0002321'], dtype=object), 'count': 1}","[ENSG00000196639,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for vertigo.
CHEMBL561339,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1,ALGHKWSXJUQNJJ-UHFFFAOYSA-N,Small molecule,False,ADL-5747,,2.0,,False,False,[],[],,['CHEMBL4297345'],"{'rows': array(['MONDO_0041052', 'EFO_0004616'], dtype=object), 'count': 2}",[ENSG00000116329],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL905,CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,ULFRLSNUDGIQQP-UHFFFAOYSA-N,Small molecule,False,RIZATRIPTAN,1998.0,4.0,,False,True,['Maxalt'],"['L-705126' 'MK-462' 'MK-462 FREE BASE' 'Maxalt' 'Maxalt-Mlt'
 'Rizatriptan']","[('PubChem', array(['144205087', '174007052'], dtype=object)), ('Wikipedia', array(['Rizatriptan'], dtype=object)), ('drugbank', array(['DB00953'], dtype=object)), ('chEBI', array(['48273'], dtype=object))]",['CHEMBL1201032' 'CHEMBL3989629'],"{'rows': array(['MONDO_0005277', 'MONDO_0100431', 'MONDO_0005277', 'MONDO_0005475'],
      dtype=object), 'count': 4}","[ENSG00000135312,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 2 investigational indications.
CHEMBL1082607,O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,XTZNCVSCVHTPAI-UHFFFAOYSA-N,Small molecule,True,SALMETEROL XINAFOATE,1994.0,4.0,CHEMBL1263,False,True,['Serevent'],"['GR 33343 G' 'GR-33343 G' 'GR-33343X' 'LIPO-202'
 'Salmeterol 1-hydroxy-2-naphthoate' 'Salmeterol xinafoate']","[('DailyMed', array(['salmeterol%20xinafoate'], dtype=object)), ('PubChem', array(['144204822', '170465397', '26753648', '29215171', '50107004',
       '56320805', '56320806', '90341116'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'EFO_0006505', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0007183', 'EFO_0000464'], dtype=object), 'count': 6}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1088751,CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,KCAJXIDMCNPGHZ-UHFFFAOYSA-N,Small molecule,False,PH-797804,,2.0,,False,False,[],['PH-797804' 'PHA-797804' 'Ph-797804'],"[('PubChem', array(['103905624', '137276009'], dtype=object)), ('drugbank', array(['DB07941'], dtype=object)), ('chEBI', array(['82715'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0005178', 'MONDO_0041052', 'EFO_0003843',
       'EFO_0000685'], dtype=object), 'count': 5}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1339,CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl,XCMULUAPJXCOHI-UHFFFAOYSA-N,Small molecule,False,VARDENAFIL HYDROCHLORIDE,2003.0,4.0,CHEMBL1520,False,True,['Levitra' 'Staxyn' 'Vardenafil hydrochloride' 'Vivanza'],"['BAY 38-9456' 'BAY-38-9456' 'Nuviva' 'Vardenafil hcl'
 'Vardenafil hydrochloride' 'Vardenafil hydrochloride anhydrous'
 'Vardenafil hydrochloride hydrate' 'Vardenafil hydrochloride trihydrate'
 'Vardenafil monohydrochloride']","[('DailyMed', array(['vardenafil%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vivanza'],
      dtype=object))]",,"{'rows': array(['HP_0000802', 'EFO_0004234'], dtype=object), 'count': 2}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for impotence and erectile dysfunction.
CHEMBL1601669,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,OFHCOWSQAMBJIW-AVJTYSNKSA-N,Small molecule,False,ALFACALCIDOL,,4.0,,False,True,['Alfa d' 'Etalpha' 'One-alpha'],"['.alpha.-calcidol' '1-alpha-vitamin d' '1-hydroxycholecalciferol'
 '1-hydroxyvitamin d3' '1.alpha-hydroxycholecalciferol' '1.alpha.(oh)d3'
 '1.alpha.-hydroxycholecalciferol' '1.alpha.-hydroxyvitamin d3'
 'Alfacalcidol' 'Alfarol' 'Alpha d3' 'Alphacalcidol' 'Alpharol' 'Alsiodol'
 'Bondiol' 'Einsalpha' 'Oxydevit' 'Tevabone' 'Un alfa' 'Un alpha']","[('PubChem', array(['50125753'], dtype=object)), ('drugbank', array(['DB01436'], dtype=object)), ('chEBI', array(['31186'], dtype=object))]",,"{'rows': array(['EFO_0003882', 'EFO_0004273', 'EFO_0004278', 'EFO_0004710',
       'EFO_0003837', 'EFO_0003854', 'EFO_1002048', 'EFO_0000660',
       'EFO_0002970'], dtype=object), 'count': 9}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 9 investigational indications.
CHEMBL1743037,,,Antibody drug conjugate,False,LORVOTUZUMAB MERTANSINE,,2.0,,False,False,[],"['HUN901-DM1, BB-10901' 'IMGN-901' 'Lorvotuzumab mertansine']",,,"{'rows': array(['EFO_0000565', 'MONDO_0006058', 'EFO_0000702', 'EFO_0002918',
       'EFO_0001378', 'EFO_0000760', 'EFO_0001376', 'EFO_0000621'],
      dtype=object), 'count': 8}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000149294]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL190,Cn1c(=O)c2[nH]cnc2n(C)c1=O,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,Small molecule,False,THEOPHYLLINE,1940.0,4.0,,False,True,"['Accurbron' 'Aerolate' 'Aerolate iii' 'Aerolate jr' 'Aerolate sr'
 'Aquaphyllin' 'Bronkodyl' 'Duraphyl' 'Elixicon' 'Elixomin' 'Elixophyllin'
 'Elixophyllin sr' 'Labid' 'Lanophyllin' 'Lasma' 'Nuelin' 'Nuelin sa'
 'Nuelin sa-250' 'Pro-vent' 'Quibron' 'Quibron-t' 'Quibron-t/sr' 'Respbid'
 'Slo-bid' 'Slo-phyllin' 'Somophyllin-crt' 'Somophyllin-t' 'Sustaire'
 'T-phyl' 'Theo-24' 'Theo-dur' 'Theobid' 'Theobid jr.' 'Theochron'
 'Theocin' 'Theoclear l.a.-130' 'Theoclear l.a.-260' 'Theoclear-100'
 'Theoclear-200' 'Theoclear-80' 'Theograd' 'Theolair' 'Theolair-sr'
 'Theolixir' 'Theophyl' 'Theophyl-225' 'Theophyl-sr' 'Theophylline'
 'Theophylline-sr' 'Theovent' 'Uni-dur' 'Uniphyl' 'Uniphyllin continus']","['Dimethylxanthine' 'Doxophylline metabolite m3' 'NSC-2066' 'NSC-757346'
 'Theophylline' 'Theophylline anhydrous'
 'Theophylline melting point standard' 'Theophylline monohydrate'
 'Theophylline, anhydrous' 'Theophylline,anhydrous']","[('DailyMed', array(['theophylline'], dtype=object)), ('PubChem', array(['104171361', '144204378', '144209573', '144210348', '170466874',
       '17389715', '174007168', '50103998', '56463437', '68760', '855679',
       '90341676'], dtype=object)), ('TG-GATEs', array(['96'], dtype=object)), ('Wikipedia', array(['Theophylline'], dtype=object)), ('drugbank', array(['DB00277'], dtype=object)), ('chEBI', array(['28177'], dtype=object))]","['CHEMBL1355736' 'CHEMBL1200434' 'CHEMBL2104089' 'CHEMBL2107084'
 'CHEMBL1370561']","{'rows': array(['MONDO_0019992', 'HP_0001919', 'EFO_1000782', 'MONDO_0007078',
       'HP_0002104', 'Orphanet_665', 'EFO_0003060', 'EFO_0000222',
       'MONDO_0001187', 'HP_0002315', 'HP_0006536', 'EFO_0000565',
       'EFO_0009492', 'EFO_0001361', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0003917', 'MONDO_0002009', 'EFO_0001361', 'HP_0006536',
       'HP_0006536', 'EFO_0000763', 'EFO_0006505', 'EFO_0009686',
       'EFO_1000782', 'HP_0006536', 'MONDO_0002050', 'EFO_0003086',
       'EFO_0005207', 'MONDO_0004979', 'EFO_0003884', 'EFO_0001663'],
      dtype=object), 'count': 32}","[ENSG00000172572,ENSG00000152270,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1940 and has 3 approved and 25 investigational indications.
CHEMBL2107016,CN1C(=O)C[C@@H](C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N2CCC[C@H]2C(N)=O)NC1=O,LQZAIAZUDWIVPM-SRVKXCTJSA-N,Protein,False,TALTIRELIN,,2.0,,False,False,[],['TA-0910' 'Taltirelin'],"[('PubChem', array(['144206235'], dtype=object))]",,,[ENSG00000174417],Protein drug with a maximum clinical trial phase of II.
CHEMBL2107818,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,OBMJQRLIQQTJLR-USGQOSEYSA-N,Small molecule,False,ALDOXORUBICIN,,3.0,,False,False,['Inno-206'],['Aldoxorubicin' 'Doxo-emch' 'Doxorubicin-emch'],"[('drugbank', array(['DB06013'], dtype=object))]",['CHEMBL2107827'],"{'rows': array(['EFO_0000182', 'EFO_0000702', 'EFO_0003060', 'MONDO_0008978',
       'EFO_0000519', 'MONDO_0005184', 'EFO_0002618', 'EFO_0000616',
       'MONDO_0007254', 'EFO_0000707', 'EFO_1001968'], dtype=object), 'count': 11}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL2108790,,,Antibody drug conjugate,False,TELIMOMAB ARITOX,,2.0,,False,False,[],['T-101' 'T101' 'Telimomab aritox'],,,"{'rows': array(['EFO_0004197'], dtype=object), 'count': 1}",[ENSG00000110448],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707380,,,Small molecule,False,RG6029,,1.0,,False,False,[],['GDC-0310' 'Rg6029'],,,,[ENSG00000169432],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3945728,O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1,SQZJGTOZFRNWCX-UHFFFAOYSA-N,Small molecule,False,ELCUBRAGISTAT,,2.0,,False,False,[],['ABX-1431' 'ABX1431' 'Abx-1431' 'Elcubragistat'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",,"{'rows': array(['EFO_0004895', 'EFO_0008533', 'EFO_0003843'], dtype=object), 'count': 3}",[ENSG00000074416],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3989972,COc1cn(-c2ccc(-n3cccn3)cc2F)nc(-c2ccnn2-c2ccccc2)c1=O,KVHRYLNQDWXAGI-UHFFFAOYSA-N,Small molecule,False,BALIPODECT,,2.0,,False,False,[],['Balipodect' 'TAK-063'],"[('drugbank', array(['DB14774'], dtype=object))]",,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}",[ENSG00000112541],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297431,CCOc1ccc(Cc2cc([C@@]34OC[C@@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1F,HYTPDMFFHVZBOR-VNXMGFANSA-N,Small molecule,False,HENAGLIFLOZIN,,3.0,,False,False,[],['Henagliflozin' 'SHR-3824' 'SHR3824' 'Shr3824'],"[('drugbank', array(['DB11939'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0001421', 'EFO_0000275'], dtype=object), 'count': 3}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4594217,Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,RCCZPUWDQVUJAB-FVYJGOGTSA-N,Small molecule,True,CANAGLIFLOZIN,2011.0,4.0,CHEMBL2048484,False,True,['Invokana'],"['Canagliflozin' 'Canagliflozin hemihydrate' 'Canagliflozin hydrate'
 'JNJ-24831754-ZAE' 'JNJ-28431754-AAA']","[('DailyMed', array(['canagliflozin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/invokana'],
      dtype=object))]",,"{'rows': array(['MONDO_0005147', 'EFO_0000401', 'HP_0000083', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0007254', 'EFO_0003144', 'EFO_0001073',
       'EFO_0000660'], dtype=object), 'count': 9}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL476960,OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,FZNCGRZWXLXZSZ-CIQUZCHMSA-N,Small molecule,False,VOGLIBOSE,1994.0,4.0,,False,True,[],['A-71100' 'AO-128' 'Voglibose'],"[('PubChem', array(['144205773', '170465993'], dtype=object)), ('Wikipedia', array(['Voglibose'], dtype=object)), ('drugbank', array(['DB04878'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}","[ENSG00000257335,ENSG00000171298,ENSG00000090402,ENSG00000257743]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 2 investigational indications.
CHEMBL557555,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O,KPSRODZRAIWAKH-UHFFFAOYSA-N,Small molecule,False,CIPROFIBRATE,1985.0,4.0,,False,True,['Modalim'],['Ciprofibrate' 'NSC-759617' 'WIN 35833' 'WIN-35833'],"[('PubChem', array(['144205674', '144208557', '144213157', '170466356', '26757866',
       '50105908', '56463556', '85230953', '90340632'], dtype=object)), ('Wikipedia', array(['Ciprofibrate'], dtype=object)), ('drugbank', array(['DB09064'], dtype=object)), ('chEBI', array(['50867'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for cardiovascular disease.
CHEMBL641,CNCC[C@@H](Oc1ccccc1C)c1ccccc1,VHGCDTVCOLNTBX-QGZVFWFLSA-N,Small molecule,True,ATOMOXETINE,2002.0,4.0,,False,True,[],['Atomoxetine' 'Strattera'],"[('PubChem', array(['11114266'], dtype=object)), ('Wikipedia', array(['Atomoxetine'], dtype=object)), ('drugbank', array(['DB00289'], dtype=object)), ('chEBI', array(['127342'], dtype=object))]",['CHEMBL1702'],"{'rows': array(['EFO_1001917', 'HP_0010865', 'EFO_0004895', 'EFO_0003758',
       'MONDO_0007079', 'EFO_0003918', 'EFO_0003888', 'MONDO_0002491',
       'EFO_0003768', 'EFO_0005611', 'EFO_0004701', 'HP_0100543',
       'EFO_1000645', 'MONDO_0004992', 'EFO_0003918', 'EFO_0002610',
       'EFO_0005252', 'MONDO_0005147', 'MONDO_0005180', 'EFO_0004701',
       'EFO_0003888', 'MONDO_0004975', 'EFO_0003877', 'EFO_0007191',
       'MONDO_0005090'], dtype=object), 'count': 25}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for attention deficit hyperactivity disorder and has 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL677,C[C@H](N)[C@H](O)c1ccc(O)c(O)c1,GEFQWZLICWMTKF-CDUCUWFYSA-N,Small molecule,False,LEVONORDEFRIN,1960.0,4.0,,False,True,[],"['(-)-cobefrin' 'BA 2818' 'BA-2818' 'Corbadrine'
 'L-.alpha.-methylnoradrenaline' 'L-nordefrin'
 'L-norephedrine, 3,4-dihydroxy-' 'Levonordefrin' 'NSC-757084'
 'Neo-Cobefrin' 'Nordefrin' 'Nordefrin (-)-form' 'Nordefrin, l-']","[('PubChem', array(['11111073', '11112447', '144205604', '170464794'], dtype=object)), ('Wikipedia', array(['Levonordefrin'], dtype=object)), ('drugbank', array(['DB06707'], dtype=object)), ('chEBI', array(['10304'], dtype=object))]",,,"[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1096,CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1,SGRYPYWGNKJSDL-UHFFFAOYSA-N,Small molecule,False,AMLEXANOX,1996.0,4.0,,False,True,['Amlexanox' 'Aphthasol'],"['AA-673' 'Amlexanox' 'Amoxanox' 'Aphtheal' 'CHX 3673' 'CHX-3673' 'Elics'
 'Solfa']","[('PubChem', array(['124893315', '144206029', '170465365', '26719859', '50112726'],
      dtype=object)), ('Wikipedia', array(['Amlexanox'], dtype=object)), ('drugbank', array(['DB01025'], dtype=object)), ('chEBI', array(['31205'], dtype=object))]",,"{'rows': array(['EFO_1001904', 'HP_0006536'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for airway obstruction and has 1 investigational indication.
CHEMBL1200382,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1.Cl.O,UEECHQPWQHYEDE-UHFFFAOYSA-N,Small molecule,False,BEPRIDIL HYDROCHLORIDE,1990.0,4.0,CHEMBL1008,False,True,['Bepadin' 'Vascor'],"['Bepridil hydrochloride' 'Bepridil hydrochloride hydrate' 'CERM 1978'
 'CERM-1978' 'Cordium' 'NSC-758390' 'Unicordium']","[('chEBI', array(['52715'], dtype=object))]",,,"[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990.
CHEMBL1200670,CC(=O)O.CNCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C.O,YBZYNINTWCLDQA-UHKVWXOHSA-N,Protein,False,SARALASIN ACETATE,1982.0,4.0,CHEMBL938,False,True,['Sarenin'],['P-113' 'Saralasin acetate' 'Saralasin hydrated acetate'],"[('Wikipedia', array(['Saralasin'], dtype=object))]",,,[ENSG00000144891],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201234,CNC(C)(C)Cc1ccccc1,RXQCGGRTAILOIN-UHFFFAOYSA-N,Small molecule,False,MEPHENTERMINE,1951.0,4.0,,False,True,[],['Mephentermine'],"[('PubChem', array(['11112475'], dtype=object)), ('Wikipedia', array(['Mephentermine'], dtype=object)), ('drugbank', array(['DB01365'], dtype=object)), ('chEBI', array(['6755'], dtype=object))]",['CHEMBL1200996' 'CHEMBL3184799'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for cardiovascular disease.
CHEMBL1230314,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O,AJIPIJNNOJSSQC-NYLIRDPKSA-N,Small molecule,False,ESTETROL,2021.0,4.0,,False,True,[],"['15.alpha.-hydroxyestriol' 'E-4' 'E4' 'Estetrol' 'Estetrol (anhydrous)'
 'Estetrol (e4)' 'Estetrol (hydrous)' 'Estetrol anhydrous'
 'Estetrol hydrate' 'Estetrol monohydrate']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ESTETROL/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12235'], dtype=object))]",,"{'rows': array(['EFO_0000673', 'EFO_0009520', 'GO_0042697', 'MONDO_0100096',
       'EFO_1001240', 'EFO_0003869', 'EFO_0002950', 'MONDO_0007254',
       'HP_0031217'], dtype=object), 'count': 9}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pregnancy and has 8 investigational indications.
CHEMBL1700,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1.Cl,VIDRYROWYFWGSY-UHFFFAOYSA-N,Small molecule,True,SOTALOL HYDROCHLORIDE,1992.0,4.0,CHEMBL471,False,True,"['Beta-cardone' 'Betapace' 'Betapace af' 'Sorine' 'Sotacor' 'Sotalex'
 'Sotalol hydrochloride' 'Sotylize']","['DL-MJ-1999' 'Darob' 'MJ 1999' 'MJ-1999' 'NSC-337251' 'NSC-760358'
 'Sotalol hcl' 'Sotalol hydrochloride']","[('DailyMed', array(['sotalol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204819', '26719708', '46500431', '50106953'], dtype=object)), ('chEBI', array(['9207'], dtype=object))]",,"{'rows': array(['HP_0004308', 'EFO_0003144', 'EFO_0000275'], dtype=object), 'count': 3}","[ENSG00000055118,ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for ventricular arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL192986,CN(c1ccc(Cl)cc1)c1cc[n+](Cc2ccc(-c3ccc(C[n+]4ccc(N(C)c5ccc(Cl)cc5)c5ccccc54)cc3)cc2)c2ccccc12.[Br-].[Br-],DGBVSSXGHKAASQ-UHFFFAOYSA-L,Small molecule,False,RSM-932A,,1.0,CHEMBL1181829,False,False,[],['RSM 932A' 'Tcd-717'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000110721],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2105458,CN1CCC(N(Cc2cccs2)c2ccccc2)CC1,KLOHYVOVXOUKQI-UHFFFAOYSA-N,Small molecule,False,THENALIDINE,,4.0,,True,True,[],['Thenaldine' 'Thenalidine' 'Thenophenopiperidine'],"[('PubChem', array(['144206868'], dtype=object)), ('drugbank', array(['DB04826'], dtype=object))]",,"{'rows': array(['HP_0000989', 'MONDO_0005271'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pruritus and allergic disease. It was withdrawn in at least one region.
CHEMBL2108063,,,Antibody,False,ZANOLIMUMAB,,3.0,,False,False,['Humax-cd4'],['HuMax-CD4' 'MDX-016' 'Zanolimumab'],,,"{'rows': array(['EFO_1001051', 'EFO_0000574', 'EFO_0000685', 'EFO_1000785',
       'EFO_0002913'], dtype=object), 'count': 5}",[ENSG00000010610],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2108818,,,Antibody,False,YTTRIUM Y 90 LABETUZUMAB,,-1.0,,False,False,[],"['90Y-HMN-14' 'Labetuzumab 90y' 'S9S0Y-HMN-14' 'Yttrium y 90 labetuzumab'
 'Yttrium y-90 labetuzumab']",,,,[ENSG00000105388],Antibody drug.
CHEMBL3990004,,,Unknown,False,BIROPEPIMUT-S,,2.0,,False,False,[],"['Biropepimut s' 'Biropepimut-s' 'GL-0817'
 'MAGE-A3 Trojan Peptide Vaccine']",,,"{'rows': array(['EFO_0000199'], dtype=object), 'count': 1}",[ENSG00000221867],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297492,CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1,LFMPVTVPXHNXOT-HNNXBMFYSA-N,Small molecule,False,GSK-2245035,,2.0,,False,False,[],['GSK-2245035' 'GSK2245035' 'Gsk-2245035' 'Gsk2245035'],,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000196664],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297688,,,Unknown,False,ADU-S100,,2.0,,False,False,[],"['ADU-S100' 'Adu s100' 'Adu-s100' 'CDN AGONIST ADU-S100' 'MIW815' 'MW-815'
 'Miw815']",,,"{'rows': array(['EFO_0006859', 'EFO_0000574'], dtype=object), 'count': 2}",[ENSG00000184584],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297968,,,Unknown,False,GSK-3174998,,2.0,,False,False,[],['GSK-3174998' 'GSK3174998' 'Gsk 3174998' 'Gsk-3174998' 'Gsk3174998'],,,"{'rows': array(['EFO_0001378', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000186827],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594253,Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1.O=C(O)CC(O)(CC(=O)O)C(=O)O,ZVPYVZMKBQYKQG-ZVWHLABXSA-N,Small molecule,False,MIVAVOTINIB CITRATE,,2.0,CHEMBL3979920,False,False,[],['Mivavotinib citrate' 'TAK-659' 'Tak 659' 'Tak-659'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIVAVOTINIB%20CITRATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0002334', 'EFO_0000616', 'EFO_0000222', 'EFO_0005952',
       'EFO_0000574', 'EFO_0000403', 'MONDO_0018906'], dtype=object), 'count': 7}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4594546,,,Antibody,False,TELAZORLIMAB,,2.0,,False,False,[],['GBR 830' 'GBR-830' 'GBR830' 'Gbr 830' 'ISB 830' 'ISB-830' 'Telazorlimab'],,,"{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}",[ENSG00000186827],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL503,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,PCZOHLXUXFIOCF-BXMDZJJMSA-N,Small molecule,False,LOVASTATIN,1987.0,4.0,,False,True,"['Altoprev' 'Lovastatin' 'Mevacor' 'Mevinacor' 'Mevinacor 10'
 'Mevinacor 40']","['6.alpha.-methylcompactin' 'C10AA02' 'L-154803' 'Lovastatin' 'MK-803'
 'Mevinolin' 'Mevlor' 'Monacolin k' 'NSC-758662'
 'Simvastatin impurity, lovastatin-' 'Sivlor']","[('DailyMed', array(['lovastatin'], dtype=object)), ('PubChem', array(['144204439', '144208673', '144210588', '170464913', '17389841',
       '26751557', '496591', '49732779', '855905'], dtype=object)), ('Wikipedia', array(['Lovastatin'], dtype=object)), ('drugbank', array(['DB00227'], dtype=object)), ('chEBI', array(['40303'], dtype=object))]",,"{'rows': array(['MONDO_0021661', 'MONDO_0010726', 'MONDO_0004979', 'EFO_0003777',
       'EFO_0000319', 'EFO_1001375', 'EFO_0003914', 'EFO_1000757',
       'EFO_0000764', 'MONDO_0010383', 'EFO_0000222', 'Orphanet_309005',
       'Orphanet_46724', 'EFO_0000589', 'EFO_0001645', 'EFO_0004705',
       'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004681', 'MP_0001845',
       'MONDO_0005180', 'EFO_1000860', 'HP_0100543', 'EFO_0000756',
       'MONDO_0018975', 'MONDO_0008948', 'EFO_0000712', 'EFO_0002615',
       'EFO_0000341', 'HP_0003124', 'EFO_0000685', 'EFO_0003876',
       'MONDO_0007254'], dtype=object), 'count': 33}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 6 approved and 27 investigational indications.
CHEMBL551064,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1,USVCWSAJUAARAL-MEMLXQNLSA-N,Small molecule,False,AEW-541,,1.0,,False,False,[],['AEW 541' 'Aew-541' 'NVP-AEW 541' 'NVP-AEW541'],,,,[ENSG00000140443],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL620,C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2,HOOSGZJRQIVJSZ-UHFFFAOYSA-N,Small molecule,False,CLIDINIUM,1982.0,4.0,,False,True,[],['Clidinium' 'Clidinium cation' 'Clidinium ion'],,['CHEMBL1200950'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease.
CHEMBL88712,O=C(O)[C@@H](c1ccc(OCc2ccc3ccccc3n2)cc1)C1CCCC1,ZEYYDOLCHFETHQ-JOCHJYFZSA-N,Small molecule,False,VELIFLAPON,,3.0,,False,False,[],['BAY X 1005' 'BAY X-1005' 'BAY-X-005' 'BAY-X-1005' 'DG-031' 'Veliflapon'],,,"{'rows': array(['EFO_0005672'], dtype=object), 'count': 1}",[ENSG00000132965],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL908,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,Small molecule,False,CHLORPROTHIXENE,1967.0,4.0,,False,True,['Taractan' 'Truxal'],"['Chlorprothixene' 'N-714' 'N-714RO 4-0403' 'NSC-18720' 'RO 4-0403'
 'RO-4-0403' 'RO-40403']","[('PubChem', array(['26665646', '29217891'], dtype=object)), ('Wikipedia', array(['Chlorprothixene'], dtype=object)), ('drugbank', array(['DB01239'], dtype=object)), ('chEBI', array(['50931'], dtype=object))]",['CHEMBL1256658'],"{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0005407', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}","[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for psychosis and has 4 investigational indications.
CHEMBL96172,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1,XOZIUKBZLSUILX-GIQCAXHBSA-N,Small molecule,False,EPOTHILONE D,,2.0,,False,False,[],"['(-)-desoxyepothilone b' '12,13-desoxyepothilone b'
 '12,13-desoxyepothilone b, cis' 'Desoxyepothilone b' 'Epothilone d'
 'KOS-862' 'NSC-703147' 'R-1492' 'R1492']","[('PubChem', array(['527930'], dtype=object)), ('drugbank', array(['DB01873'], dtype=object)), ('chEBI', array(['29579'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_1001951', 'MONDO_0008903', 'MONDO_0008315',
       'MONDO_0007254'], dtype=object), 'count': 5}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1200794,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl,BCGJBQBWUGVESK-KCTCKCTRSA-N,Small molecule,True,OXYMORPHONE HYDROCHLORIDE,1959.0,4.0,CHEMBL963,False,True,['Numorphan' 'Opana' 'Opana er' 'Oxymorphone hydrochloride'],['Oxymorphone hcl' 'Oxymorphone hydrochloride'],"[('DailyMed', array(['oxymorphone%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'HP_0012532'], dtype=object), 'count': 2}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for pain and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1200933,C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21.[Br-].[Br-],WDEFPRUEZRUYNW-UHFFFAOYSA-L,Small molecule,False,HEXAFLUORENIUM BROMIDE,1982.0,4.0,CHEMBL1201349,False,True,['Mylaxen'],"['Hexafluorenium bromide' 'Hexaflurone bromide' 'Hexafluronium bromide'
 'NSC-19477']","[('PubChem', array(['144206765'], dtype=object))]",,,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200974,CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,GVNWHCVWDRNXAZ-BTJKTKAUSA-N,Small molecule,False,CARBINOXAMINE MALEATE,2003.0,4.0,CHEMBL864,False,True,['Carbinoxamine maleate' 'Clistin' 'Davenol' 'Karbinal er'],['Carbinoxamine maleate' 'NSC-62362'],"[('DailyMed', array(['carbinoxamine%20maleate'], dtype=object)), ('PubChem', array(['144205889', '170465237', '26749308', '93576626'], dtype=object)), ('chEBI', array(['31353'], dtype=object))]",,"{'rows': array(['EFO_0007533', 'EFO_1001417', 'EFO_0003956', 'EFO_0005532',
       'EFO_0007141', 'EFO_0005531'], dtype=object), 'count': 6}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved indications.
CHEMBL1201047,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.Cl,UDUQHZSAAWGSPJ-UHFFFAOYSA-N,Small molecule,False,ANILERIDINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201347,False,True,['Leritine'],"['Aldine' 'Anileridine dihydrochloride' 'Anileridine hcl'
 'Anileridine hydrochloride' 'Anileridine hydrochloride cii' 'Apodol'
 'Leritine dihydrochloride']",,,,"[ENSG00000082556,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201558,,,Protein,True,INTERFERON ALFA-2B,1986.0,4.0,,False,True,['Intron a' 'Intron-A' 'Introna' 'Viraferon'],['Interferon alfa-2b' 'SCH 30500' 'SCH-30500'],"[('DailyMed', array(['interferon%20alfa-2b'], dtype=object)), ('DrugCentral', array(['5205'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/introna'],
      dtype=object)), ('Wikipedia', array(['Interferon_alfa-2b'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_0000182', 'EFO_1000956', 'EFO_0001668',
       'MONDO_0024503', 'EFO_0000616', 'EFO_1000131', 'EFO_0000756',
       'MONDO_0100096', 'EFO_0000339', 'EFO_0000673', 'EFO_0000764',
       'EFO_0000681', 'EFO_0009708', 'EFO_0000349', 'EFO_0001378',
       'MONDO_0044881', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0002618',
       'MONDO_0019471', 'EFO_0007147', 'MONDO_0002367', 'EFO_0004220',
       'EFO_0004197', 'EFO_0004243', 'EFO_0001422', 'EFO_0003047',
       'MONDO_0018906', 'EFO_0003869', 'EFO_0000389', 'EFO_0000565',
       'EFO_0004239', 'MONDO_0007254', 'MONDO_0002691', 'MONDO_0004658',
       'EFO_0000558'], dtype=object), 'count': 37}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 16 approved and 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL14,C[N+](C)(C)CCOC(N)=O.[Cl-],AIXAANGOTKPUOY-UHFFFAOYSA-N,Small molecule,False,CARBACHOL,1972.0,4.0,CHEMBL965,False,True,['Carbachol' 'Carbastat' 'Doryl' 'Miostat'],"['Carbachol' 'Carbachol chloride' 'Carbacholine Chloride'
 'Carbacholine chloride' 'Carbamoylcholine chloride' 'NSC-32865']","[('DailyMed', array(['carbachol'], dtype=object)), ('PubChem', array(['144205582', '170464972', '26747465', '50105987', '56463323'],
      dtype=object)), ('Wikipedia', array(['Carbachol'], dtype=object)), ('chEBI', array(['3385'], dtype=object))]",,"{'rows': array(['MONDO_0005129', 'HP_0000616', 'MONDO_0001330', 'MONDO_0005041'],
      dtype=object), 'count': 4}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 3 approved and 1 investigational indication.
CHEMBL1421,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Small molecule,False,DASATINIB,2006.0,4.0,,False,True,['Dasatinib' 'Dasatinib accordpharma' 'Sprycel'],"['BMS-354825' 'BMS-354825 HYDRATE' 'BMS-354825-03' 'Dasatinib'
 'Dasatinib hydrate' 'Dasatinib monohydrate' 'NSC-759877']","[('DailyMed', array(['dasatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma'],
      dtype=object)), ('PubChem', array(['103905543', '124893650', '124893651', '124893652', '144206289',
       '164339436', '170465390', '50100097', '50125840'], dtype=object)), ('Wikipedia', array(['Dasatinib'], dtype=object)), ('drugbank', array(['DB01254'], dtype=object)), ('chEBI', array(['49375'], dtype=object))]",['CHEMBL5314601'],"{'rows': array(['EFO_0000768', 'EFO_0000616', 'EFO_1000956', 'EFO_0000255',
       'EFO_0003884', 'MONDO_0019469', 'MONDO_0011719', 'EFO_0000191',
       'EFO_0000588', 'MONDO_0019472', 'EFO_1001469', 'EFO_0002429',
       'EFO_1000475', 'MONDO_0004975', 'MONDO_0018906', 'EFO_0000770',
       'EFO_1001951', 'EFO_0000702', 'MONDO_0000870', 'EFO_0000095',
       'MONDO_0002087', 'EFO_0006859', 'MONDO_0004992', 'EFO_0005774',
       'EFO_0000708', 'MONDO_0000873', 'EFO_1000131', 'MONDO_0100096',
       'MONDO_0008903', 'EFO_0000309', 'EFO_1001465', 'EFO_0002617',
       'MONDO_0016586', 'EFO_0000183', 'EFO_0003869', 'EFO_0000220',
       'EFO_0000621', 'MONDO_0004643', 'MONDO_0021063', 'EFO_1000026',
       'EFO_0000565', 'EFO_0002618', 'MONDO_0011962', 'EFO_0000764',
       'EFO_0000339', 'EFO_0000707', 'EFO_0000181', 'EFO_0001073',
       'EFO_0000673', 'EFO_0002918', 'EFO_0000196', 'EFO_0003032',
       'EFO_0000180', 'EFO_1001993', 'EFO_0000389', 'EFO_0001378',
       'EFO_0000182', 'EFO_0000403', 'EFO_1000158', 'MONDO_0008315',
       'EFO_0009441', 'EFO_0000756', 'EFO_0000574', 'EFO_0004289',
       'MONDO_0100342', 'EFO_0000211', 'EFO_1001051', 'EFO_0000198',
       'EFO_0003833', 'EFO_0005952', 'EFO_1000657', 'EFO_0003060',
       'EFO_0000222', 'EFO_1000654', 'MONDO_0008170', 'EFO_1000785',
       'EFO_0000305', 'MONDO_0019471', 'EFO_0004289', 'EFO_0000519',
       'MONDO_0003175', 'EFO_0005221', 'EFO_0000616', 'MONDO_0007254',
       'MONDO_0002158'], dtype=object), 'count': 85}","[ENSG00000142627,ENSG00000113721,ENSG00000157404,ENSG00000097007,ENSG00000186716,ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 9 approved and 76 investigational indications.
CHEMBL1503,COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,SUBDBMMJDZJVOS-UHFFFAOYSA-N,Small molecule,False,OMEPRAZOLE,1989.0,4.0,,False,True,"['Antra' 'Losec' 'Losec mups' 'Mezzopram' 'Mopral' 'Omeprazole' 'Omeran'
 'Prilosec' 'Zanprol']",['H 168/68' 'H-168/68' 'NSC-751450' 'NSC-759192' 'Omeprazole'],"[('DailyMed', array(['omeprazole'], dtype=object)), ('PubChem', array(['104171331', '11112840', '124882676', '124882677', '144204237',
       '144207707', '170465443', '174007234', '26751452', '26751453',
       '50103932', '56422106', '855576'], dtype=object)), ('TG-GATEs', array(['12'], dtype=object)), ('Wikipedia', array(['Omeprazole'], dtype=object)), ('drugbank', array(['DB00338'], dtype=object)), ('chEBI', array(['77260'], dtype=object))]",['CHEMBL2105294' 'CHEMBL1567328'],"{'rows': array(['MONDO_0001056', 'MONDO_0015277', 'EFO_0000191', 'EFO_1001095',
       'EFO_0003948', 'HP_0001601', 'EFO_0005741', 'MONDO_0004247',
       'EFO_0000676', 'MONDO_0009061', 'EFO_0003929', 'MONDO_0007254',
       'EFO_0003843', 'EFO_0000280', 'EFO_0000217', 'MONDO_0043839',
       'EFO_0009130', 'EFO_1001951', 'EFO_0003756', 'EFO_0004272',
       'EFO_0002617', 'EFO_0008533', 'EFO_0009784', 'EFO_0000768',
       'EFO_0000181', 'EFO_0004607', 'EFO_0000616', 'EFO_0007231',
       'MONDO_0024475', 'MP_0001914', 'EFO_0003100', 'HP_0002239',
       'EFO_0000274', 'MONDO_0004975', 'EFO_0000199', 'EFO_0000546',
       'EFO_1000961', 'EFO_0004239', 'EFO_0008525', 'EFO_0000685',
       'EFO_0007549', 'EFO_0003948', 'HP_0012735', 'MONDO_0005041',
       'EFO_0000729', 'HP_0002239', 'MONDO_0001684', 'HP_0004398',
       'EFO_0000764', 'EFO_0003898', 'EFO_0000341', 'EFO_0006859',
       'HP_0100633', 'MONDO_0008315', 'EFO_0000384', 'EFO_0000180',
       'EFO_0000574', 'EFO_0009454', 'EFO_0000673', 'EFO_0000756',
       'MONDO_0044970', 'EFO_0004234', 'MONDO_0003523', 'EFO_0000305',
       'EFO_0000400', 'EFO_0002618', 'EFO_0004220', 'MONDO_0005148',
       'HP_0032252', 'MONDO_0005178', 'EFO_0000544', 'HP_0012532',
       'EFO_0003047', 'MONDO_0005147', 'MONDO_0004992'], dtype=object), 'count': 75}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 7 approved and 67 investigational indications.
CHEMBL1592,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O,JSDRRTOADPPCHY-HSQYWUDLSA-N,Small molecule,True,QUINAPRIL,1991.0,4.0,,False,True,[],['C09AA06' 'CI-906' 'Quinapril'],"[('Wikipedia', array(['Quinapril'], dtype=object)), ('drugbank', array(['DB00881'], dtype=object)), ('chEBI', array(['8713'], dtype=object))]",['CHEMBL1201011'],"{'rows': array(['EFO_0000319', 'MONDO_0005147', 'EFO_0000537', 'EFO_1002048',
       'EFO_0000712', 'EFO_0003144', 'EFO_0000400'], dtype=object), 'count': 7}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 6 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1699,CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl,LDDHMLJTFXJGPI-UHFFFAOYSA-N,Small molecule,False,MEMANTINE HYDROCHLORIDE,2003.0,4.0,CHEMBL807,False,True,"['Akatinol' 'Ebixa' 'Marixino' 'Memantine' 'Memantine hydrochloride'
 'Memantine merz' 'Memantine mylan' 'Namenda' 'Namenda xr' 'Nemdatine'
 'Valios']","['Acrescent' 'Auxura' 'Balaxur' 'FP-01' 'Memantine accord' 'Memantine hcl'
 'Memantine hydrochloride' 'Memantine lek' 'Memantine merz'
 'Memantine mylan' 'Memantine ratiopharm' 'Memary' 'NSC-102290'
 'SUN-Y7017']","[('DailyMed', array(['memantine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-merz',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-mylan'],
      dtype=object)), ('PubChem', array(['26747595', '50106707', '50106708', '57260151'], dtype=object)), ('chEBI', array(['64323'], dtype=object))]",,"{'rows': array(['EFO_0004699', 'EFO_0000326', 'EFO_1001801', 'MONDO_0004681',
       'MONDO_0004975', 'EFO_0003758', 'HP_0000726', 'MONDO_0004976',
       'EFO_0007328', 'MONDO_0017276', 'EFO_0003757', 'EFO_1001465',
       'EFO_0003833', 'MONDO_0011382'], dtype=object), 'count': 14}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and dementia and has 12 investigational indications.
CHEMBL1742992,,,Antibody,True,BLINATUMOMAB,2014.0,4.0,,False,True,['Blincyto'],['Blinatumomab' 'Blincyto' 'MEDI-538' 'MT-103'],"[('DailyMed', array(['blinatumomab'], dtype=object)), ('DrugCentral', array(['4915'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto'],
      dtype=object))]",,"{'rows': array(['EFO_0000095', 'EFO_0004289', 'EFO_0000565', 'EFO_0005952',
       'EFO_0001642', 'EFO_0000616', 'EFO_0004289', 'EFO_0000574',
       'EFO_0000403', 'EFO_0000094', 'EFO_0001378', 'MONDO_0000873',
       'EFO_0000220', 'EFO_0000209', 'EFO_0000309'], dtype=object), 'count': 15}","[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000177455]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2104992,CS(=O)(=O)O.Cc1cc(F)ccc1[C@H]1CNCCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,BHECXGHXWKHZOY-DXPOFMJKSA-N,Small molecule,False,VESTIPITANT MESYLATE,,2.0,CHEMBL522987,False,False,[],"['GW-597588B' 'GW-597599B' 'GW597588B' 'GW597599B' 'Vestipitant mesilate'
 'Vestipitant mesylate']",,,,[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108313,,,Protein,False,CONBERCEPT,,3.0,,False,False,[],['Conbercept' 'KH-902'],,,"{'rows': array(['EFO_0004683', 'MONDO_0008380', 'EFO_0001365', 'EFO_1001157',
       'EFO_1000880', 'EFO_0004207'], dtype=object), 'count': 6}","[ENSG00000119630,ENSG00000112715,ENSG00000173511,ENSG00000150630]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2109058,,,Oligonucleotide,False,EDIFOLIGIDE SODIUM,,3.0,,False,False,[],"['CG-T003' 'CGT-003' 'CGT003' 'E2f duplex decoy'
 'E2f duplex decoy (trivial name)' 'Edifoligide sodium']",,,"{'rows': array(['EFO_0001645'], dtype=object), 'count': 1}","[ENSG00000101412,ENSG00000007968,ENSG00000112242,ENSG00000205250,ENSG00000133740,ENSG00000169016,ENSG00000165891,ENSG00000129173]",Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL225072,Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,WBXPDJSOTKVWSJ-ZDUSSCGKSA-N,Small molecule,False,PEMETREXED,2004.0,4.0,,False,True,['Alimta' 'Pemfexy'],['LY-2315' 'LY-231514' 'LY231514' 'NSC-698037' 'Pemetrexed'],"[('PubChem', array(['124893263', '124950689', '525786'], dtype=object)), ('Wikipedia', array(['Pemetrexed'], dtype=object)), ('drugbank', array(['DB00642'], dtype=object)), ('chEBI', array(['63616'], dtype=object))]",['CHEMBL2360464' 'CHEMBL5315053' 'CHEMBL3989962'],"{'rows': array(['MONDO_0011962', 'MONDO_0007254', 'EFO_1001901', 'EFO_0000574',
       'EFO_0001075', 'EFO_0006859', 'EFO_1001951', 'MONDO_0001187',
       'EFO_1001951', 'EFO_0003863', 'MONDO_0002158', 'EFO_0000365',
       'EFO_0008528', 'MONDO_0008315', 'EFO_0002617', 'EFO_0006859',
       'EFO_0002618', 'EFO_0000708', 'MONDO_0021117', 'MONDO_0004192',
       'MONDO_0001056', 'EFO_0003060', 'EFO_0000708', 'EFO_0003897',
       'MONDO_0002586', 'MONDO_0007576', 'MONDO_0000521', 'EFO_0003060',
       'MONDO_0002087', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0000707',
       'MONDO_0008170', 'EFO_0005952', 'MONDO_0021117', 'EFO_0002618',
       'MONDO_0008170', 'MONDO_0001056', 'EFO_0009708', 'EFO_1000576',
       'MONDO_0002974', 'EFO_0000588', 'EFO_0000588', 'EFO_1000251',
       'EFO_0000616', 'EFO_0003863', 'EFO_0002916', 'EFO_0000228',
       'MONDO_0011962', 'EFO_0000637', 'EFO_0003050', 'MONDO_0002691',
       'MONDO_0100342', 'EFO_0000308', 'EFO_0000681', 'EFO_0005537',
       'EFO_0000228', 'MONDO_0008978', 'MONDO_0008903', 'EFO_1000657',
       'EFO_0000691', 'EFO_0000571', 'EFO_0003050', 'EFO_0008528',
       'EFO_1001012', 'EFO_0000313', 'MONDO_0008903', 'EFO_0005567',
       'EFO_0004252', 'EFO_0000403', 'EFO_1000581', 'EFO_0000574',
       'EFO_0000389', 'MONDO_0004992', 'EFO_0000702', 'MONDO_0044903',
       'MONDO_0002158', 'MONDO_0004992', 'MONDO_0018944', 'EFO_0003860',
       'EFO_0004142', 'MONDO_0007254', 'EFO_0000178', 'MONDO_0002108',
       'EFO_0003869', 'MONDO_0002087', 'EFO_0006861', 'EFO_0002939',
       'EFO_0000691', 'EFO_0000181', 'MONDO_0002974', 'EFO_0009708',
       'EFO_0000588', 'EFO_0003050', 'EFO_0000770', 'EFO_0004284',
       'EFO_0003060', 'MONDO_0003060', 'EFO_0001416', 'EFO_0000571',
       'EFO_0000770', 'EFO_1000581', 'EFO_0000616'], dtype=object), 'count': 103}","[ENSG00000159131,ENSG00000176890,ENSG00000228716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 approved and 82 investigational indications.
CHEMBL2408045,CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1,DFJSJLGUIXFDJP-UHFFFAOYSA-N,Small molecule,False,SAPITINIB,,2.0,,False,False,[],['AZD-8931' 'AZD8931' 'Azd-8931' 'Sapitinib'],"[('PubChem', array(['174006599'], dtype=object)), ('drugbank', array(['DB12183'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000365', 'MONDO_0007254', 'EFO_0003869',
       'MONDO_0004992'], dtype=object), 'count': 5}","[ENSG00000141736,ENSG00000065361,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3545248,,,Small molecule,False,DS-7423,,1.0,,False,False,[],['Ds-7423'],,,"{'rows': array(['MONDO_0011962', 'EFO_1001951'], dtype=object), 'count': 2}","[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3707224,CCOC(=O)C[N+]1(C)CC[C@@H](OC(=O)[C@](O)(c2ccccc2)C2CCCC2)C1,SEVCTUCCZYBJER-BSJAROSPSA-N,Small molecule,False,SOFPIRONIUM,,3.0,,False,False,[],['Bbi-4000 ion' 'Sofpironium cation'],,['CHEMBL3707223'],"{'rows': array(['HP_0000975'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3707347,CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(=O)O,YYBOLPLTQDKXPM-UHFFFAOYSA-N,Small molecule,False,VERINURAD,,2.0,,False,False,[],['RDEA-3170' 'RDEA3170' 'Verinurad'],"[('drugbank', array(['DB11873'], dtype=object))]",['CHEMBL5170470'],"{'rows': array(['EFO_0003884', 'EFO_0003144', 'EFO_0004274', 'EFO_0009104'],
      dtype=object), 'count': 4}",[ENSG00000197891],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4088896,C[C@H](CN1CCOCC1)n1/c(=N\C(N)=O)[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc21,YPCLDHGBEKZGEB-RUDKWAFVSA-N,Small molecule,False,LY2623091,,2.0,,False,False,[],['Ly-2623091' 'Ly2623091'],"[('drugbank', array(['DB15367'], dtype=object))]",,"{'rows': array(['EFO_0003884', 'MONDO_0001134'], dtype=object), 'count': 2}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594456,,,Antibody,False,CADONILIMAB,,3.0,,False,False,[],['AK-104' 'AK104' 'Ak-104' 'Ak104' 'Cadonilimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CADONILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_0000519', 'EFO_0001061', 'MONDO_0001056',
       'MONDO_0002974', 'MONDO_0004992', 'EFO_1001968', 'EFO_0004252',
       'EFO_0001416', 'EFO_1001951', 'EFO_0002618', 'EFO_0000681',
       'EFO_0000349', 'EFO_0000616', 'EFO_0003060', 'MONDO_0003060',
       'EFO_0000211', 'MONDO_0044937', 'MONDO_0008903', 'EFO_0005922',
       'EFO_0000756', 'EFO_0000182', 'EFO_1001961', 'EFO_1000657'],
      dtype=object), 'count': 24}","[ENSG00000163599,ENSG00000188389]",Antibody drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.
CHEMBL843,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,SUFUKZSWUHZXAV-BTJKTKAUSA-N,Small molecule,True,ROSIGLITAZONE MALEATE,1999.0,4.0,CHEMBL121,True,True,['Avandia' 'Rosiglitazone maleate'],"['Avandia' 'BRL-49653' 'BRL-49653-C' 'BRL-49653C' 'NSC-717764'
 'Rosiglitazone maleate' 'Rosiglitzazone maleate']","[('DailyMed', array(['rosiglitazone%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/avandia'],
      dtype=object)), ('PubChem', array(['144212684', '49681563'], dtype=object)), ('chEBI', array(['8892'], dtype=object))]",,"{'rows': array(['HP_0002745', 'EFO_0000691', 'EFO_0003914', 'EFO_0000400',
       'MONDO_0005148', 'EFO_1000158', 'EFO_0000764', 'EFO_1001110',
       'EFO_0006859', 'EFO_0002614', 'EFO_0000373', 'EFO_1001249'],
      dtype=object), 'count': 12}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 10 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1165,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O,UWWDHYUMIORJTA-HSQYWUDLSA-N,Small molecule,True,MOEXIPRIL,1995.0,4.0,,False,True,[],['Moexipril' 'RS-10085' 'Uniretic' 'Univasc'],"[('Wikipedia', array(['Moexipril'], dtype=object)), ('drugbank', array(['DB00691'], dtype=object)), ('chEBI', array(['6960'], dtype=object))]",['CHEMBL1200534'],"{'rows': array(['EFO_0000319', 'EFO_1001486', 'EFO_0000537'], dtype=object), 'count': 3}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiovascular disease and hypertension and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201255,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,HHXHVIJIIXKSOE-QILQGKCVSA-N,Protein,False,HISTRELIN,1991.0,4.0,,False,True,[],"['Histrelin' 'ORF 17070' 'ORF 17070RWJ 17070' 'ORF-17070' 'RWJ 17070'
 'RWJ-17070']","[('Wikipedia', array(['Histrelin'], dtype=object)), ('chEBI', array(['5739'], dtype=object))]",['CHEMBL1200509'],"{'rows': array(['EFO_0000196', 'MONDO_0008315', 'EFO_0000616', 'EFO_0009029',
       'EFO_0000673', 'EFO_0000673'], dtype=object), 'count': 6}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 3 investigational indications.
CHEMBL1237135,CNCCCC12CCC(c3ccccc31)c1ccccc12.Cl,NZDMFGKECODQRY-UHFFFAOYSA-N,Small molecule,True,MAPROTILINE HYDROCHLORIDE,1980.0,4.0,CHEMBL21731,False,True,['Ludiomil' 'Maprotiline hydrochloride'],"['BA-34,276' 'BA-34276' 'Maprotiline hcl' 'Maprotiline hydrochloride'
 'NSC-757085']","[('PubChem', array(['144211309', '14743087', '152146163', '26719700', '26747580',
       '26747581', '50106647', '50106648', '56422491', '855591'],
      dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for major depressive disorder. This drug has a black box warning from the FDA.
CHEMBL1242,Nc1ccc(/N=N/c2ccccc2)c(N)n1,QPFYXYFORQJZEC-FOCLMDBBSA-N,Small molecule,False,PHENAZOPYRIDINE,1987.0,4.0,,False,True,[],['NSC-145895' 'Phenazopyridine'],"[('PubChem', array(['104171363'], dtype=object)), ('Wikipedia', array(['Phenazopyridine'], dtype=object)), ('drugbank', array(['DB01438'], dtype=object))]",['CHEMBL1201022'],"{'rows': array(['EFO_0003103', 'HP_0000016', 'EFO_0003843', 'EFO_0003901'],
      dtype=object), 'count': 4}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 investigational indications.
CHEMBL1278,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,AMKVXSZCKVJAGH-UHFFFAOYSA-N,Small molecule,False,NARATRIPTAN,1998.0,4.0,,False,True,['Amerge' 'Naratriptan'],['Amerge' 'Naratriptan'],"[('Wikipedia', array(['Naratriptan'], dtype=object)), ('drugbank', array(['DB00952'], dtype=object)), ('chEBI', array(['7478'], dtype=object))]",['CHEMBL1200601'],"{'rows': array(['MONDO_0005277', 'HP_0002315', 'MONDO_0005277'], dtype=object), 'count': 3}","[ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 1 investigational indication.
CHEMBL1516,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,VTRAEEWXHOVJFV-UHFFFAOYSA-N,Small molecule,False,OLMESARTAN,,3.0,,False,False,[],"['NSC-759810' 'Olmesartan' 'Olmesartan medoxomil impurity, olmesartan-'
 'RNH-6270']","[('PubChem', array(['174007156', '26719844'], dtype=object)), ('Wikipedia', array(['Olmesartan'], dtype=object)), ('drugbank', array(['DB00275'], dtype=object)), ('chEBI', array(['48416'], dtype=object))]",,"{'rows': array(['EFO_0000275', 'MONDO_0001134', 'EFO_0000537', 'MONDO_0100096',
       'EFO_0000694', 'EFO_0000712'], dtype=object), 'count': 6}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL1742471,NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1,ZQHFZHPUZXNPMF-UHFFFAOYSA-N,Small molecule,False,EBROTIDINE,,4.0,,True,True,[],['Ebrotidine'],,,,[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1742986,,,Protein,False,ATACICEPT,,3.0,,False,False,[],['Atacicept' 'TACI-FC5' 'TACI-IG'],,,"{'rows': array(['MONDO_0007915', 'EFO_0005761', 'EFO_0004194', 'EFO_0007405',
       'EFO_0000685', 'MONDO_0005301'], dtype=object), 'count': 6}","[ENSG00000102524,ENSG00000161955]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL1783256,CCCNC(=O)c1nnc2c(-c3cc(OC)ccc3OC)cccc2c1N,NVWCZRPXYVDQEE-UHFFFAOYSA-N,Small molecule,False,AZD6280,,1.0,,False,False,[],['AZD6280' 'Azd-6280' 'Azd6280'],"[('drugbank', array(['DB12210'], dtype=object))]",,"{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}","[ENSG00000011677,ENSG00000151834]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1909286,CC(COc1ccccc1)NN,QNEXFJFTGQBXBJ-UHFFFAOYSA-N,Small molecule,False,PHENOXYPROPAZINE,,4.0,,True,True,[],['Fenoxypropazine' 'Phenoxypropazine'],"[('PubChem', array(['144206870'], dtype=object)), ('Wikipedia', array(['Phenoxypropazine'], dtype=object)), ('drugbank', array(['DB09251'], dtype=object))]",['CHEMBL4303424'],,"[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL2109412,,,Antibody,False,L19SIP 131I,,2.0,,False,False,[],['L19SIP' 'L19sip 131i'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000115414],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109433,,,Antibody,False,OTILIMAB,,3.0,,False,False,[],['GSK-3196165' 'GSK3196165' 'MOR-103' 'MOR103' 'Otilimab'],,,"{'rows': array(['EFO_0000694', 'MONDO_0005178', 'EFO_0000685', 'MONDO_0005301'],
      dtype=object), 'count': 4}",[ENSG00000164400],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2109635,,,Antibody drug conjugate,False,SAR-566658,,2.0,,False,False,[],['SAR-566658' 'SAR566658' 'Sar 566658' 'Sar-566658' 'huDS6-DM4'],,,"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000185499],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2204263,O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1,CFKBNYUHQSQBSX-CYWCHRQTSA-N,Small molecule,False,JNJ-41443532,,2.0,,False,False,[],['Jnj-41443532'],"[('drugbank', array(['DB12632'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000121807],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL267431,COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C,GJMNAFGEUJBOCE-MEQIQULJSA-N,Small molecule,False,ASOPRISNIL,,3.0,,False,False,[],['Asoprisnil' 'BAY86-5294' 'J-867' 'J867'],"[('Wikipedia', array(['Asoprisnil'], dtype=object)), ('drugbank', array(['DB06680'], dtype=object))]",,"{'rows': array(['MONDO_0001572', 'HP_0000132', 'GO_0042697', 'EFO_0000731',
       'EFO_0001065', 'HP_0100608'], dtype=object), 'count': 6}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3039543,,,Antibody,False,ULOCUPLUMAB,,2.0,,False,False,[],['BMS-936564' 'MDX-1338' 'Ulocuplumab'],,,"{'rows': array(['MONDO_0018906', 'EFO_0000222', 'EFO_0000565', 'EFO_0009441',
       'EFO_0000616', 'EFO_0001378', 'EFO_0000095'], dtype=object), 'count': 7}",[ENSG00000121966],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL3544983,COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,HVXKQKFEHMGHSL-QKDCVEJESA-N,Small molecule,False,TESEVATINIB,,3.0,,False,False,[],['EXEL-7647' 'KD-019' 'KD-020' 'KD019' 'Tesevatinib' 'XL647' 'Xl-647'],"[('drugbank', array(['DB11973'], dtype=object))]",['CHEMBL3544982'],"{'rows': array(['MONDO_0007254', 'MONDO_0009889', 'EFO_0003060', 'EFO_0000519',
       'EFO_1001496', 'EFO_0003833', 'MONDO_0004992'], dtype=object), 'count': 7}","[ENSG00000141736,ENSG00000146648,ENSG00000196411]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL3622821,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,WYQFJHHDOKWSHR-MNOVXSKESA-N,Small molecule,True,UPADACITINIB,2019.0,4.0,,False,True,[],['ABT-494' 'Upadacitinib' 'Upadacitinib anhydrous'],"[('DailyMed', array(['upadacitinib'], dtype=object)), ('drugbank', array(['DB15091'], dtype=object))]",['CHEMBL3707269' 'CHEMBL5315119'],"{'rows': array(['EFO_0000274', 'EFO_0003778', 'EFO_0000540', 'EFO_0000384',
       'EFO_1000710', 'EFO_0002609', 'EFO_0000685', 'EFO_1001209',
       'EFO_0000729', 'EFO_0004208', 'EFO_0000685', 'MONDO_0007915',
       'EFO_0003898'], dtype=object), 'count': 13}","[ENSG00000105397,ENSG00000105639,ENSG00000096968,ENSG00000162434]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for rheumatoid arthritis and has 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297216,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O,QAFZLTVOFJHYDF-UHFFFAOYSA-N,Small molecule,True,FEDRATINIB HYDROCHLORIDE,2019.0,4.0,CHEMBL1287853,False,True,['Inrebic'],['Fedratinib hydrochloride' 'SAR302503A'],"[('DailyMed', array(['fedratinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic'],
      dtype=object))]",,"{'rows': array(['EFO_0002430', 'HP_0011974', 'EFO_0004251'], dtype=object), 'count': 3}","[ENSG00000096968,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL4297574,,,Oligonucleotide,False,TEPRASIRAN,,3.0,,False,False,[],['I5-NP' 'I5NP' 'QPI-1002' 'Qpi-1002' 'Teprasiran'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPRASIRAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0001919'], dtype=object), 'count': 1}",[ENSG00000141510],Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL471498,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,WPGGHFDDFPHPOB-BBWFWOEESA-N,Small molecule,False,MITIGLINIDE,,3.0,,False,False,[],['Mitiglinide'],"[('Wikipedia', array(['Mitiglinide'], dtype=object)), ('drugbank', array(['DB01252'], dtype=object))]",['CHEMBL1603301'],"{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL574737,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,PBCZSGKMGDDXIJ-KRUBCLEUSA-N,Small molecule,False,UCN-01,,2.0,,False,False,[],"['7-hydroxystaurosporine' 'KRX-0601' 'KW-2401' 'NSC-638850' 'UCN-01'
 'UCN-02' 'Ucn 01' 'Ucn-01']",,,"{'rows': array(['MONDO_0002158', 'EFO_1001013', 'EFO_0000756', 'EFO_1001512',
       'EFO_0003025', 'MONDO_0007254', 'EFO_0000209', 'MONDO_0004669',
       'EFO_0003027', 'MONDO_0002087', 'EFO_0000198', 'MONDO_0002367',
       'EFO_0007535', 'EFO_0000224', 'MONDO_0011719', 'EFO_1000407',
       'MONDO_0008315', 'MONDO_0003196', 'MONDO_0044926', 'EFO_0003060',
       'EFO_0000339', 'EFO_0002938', 'MONDO_0002537', 'MONDO_0018364',
       'EFO_0005537', 'MONDO_0002974', 'EFO_0004193', 'MONDO_0001879',
       'EFO_0000616', 'EFO_0000221', 'EFO_0006352', 'MONDO_0001056',
       'MONDO_0007576', 'EFO_0003028', 'EFO_0000702', 'MONDO_0005411',
       'EFO_0000218', 'EFO_0000574', 'MONDO_0008170', 'EFO_0002618',
       'EFO_0000223', 'EFO_0000673', 'EFO_0000565'], dtype=object), 'count': 43}","[ENSG00000140992,ENSG00000123374,ENSG00000135446,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675,ENSG00000105810,ENSG00000149554]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 43 investigational indications.
CHEMBL726,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,PLDUPXSUYLZYBN-UHFFFAOYSA-N,Small molecule,False,FLUPHENAZINE,,4.0,,False,True,[],['Fluphenazine' 'NSC-62323' 'Permitil' 'Prolixin'],"[('PubChem', array(['104171155', '11111179', '11111180', '144203697', '170465375',
       '26751625', '50100242', '50104297', '57287813', '90341540'],
      dtype=object)), ('TG-GATEs', array(['37'], dtype=object)), ('Wikipedia', array(['Fluphenazine'], dtype=object)), ('drugbank', array(['DB00623'], dtype=object)), ('chEBI', array(['5123'], dtype=object))]",['CHEMBL1200792' 'CHEMBL1448187'],"{'rows': array(['MONDO_0005090', 'EFO_0000677', 'EFO_0005407', 'EFO_0001378'],
      dtype=object), 'count': 4}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for mental or behavioural disorder and psychosis and has 2 investigational indications.
CHEMBL814,COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1,CJOFXWAVKWHTFT-XSFVSMFZSA-N,Small molecule,True,FLUVOXAMINE,1994.0,4.0,,False,True,[],['Fluvoxamine' 'N06AB08'],"[('PubChem', array(['104171369', '144204388', '170464809', '26751469', '50103976',
       '90340960'], dtype=object)), ('Wikipedia', array(['Fluvoxamine'], dtype=object)), ('drugbank', array(['DB00176'], dtype=object)), ('chEBI', array(['5138'], dtype=object))]",['CHEMBL1409'],"{'rows': array(['EFO_1001916', 'EFO_1001917', 'EFO_0000694', 'MONDO_0100096',
       'EFO_0003758', 'EFO_0004262', 'MONDO_0002009', 'EFO_0005230',
       'MONDO_0005090', 'EFO_0004242', 'EFO_0000616', 'EFO_0004242',
       'MONDO_0002050', 'HP_0000726', 'MONDO_0100096', 'EFO_1001892',
       'EFO_0000694', 'EFO_1002014'], dtype=object), 'count': 18}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL87992,CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21,QIALRBLEEWJACW-INIZCTEOSA-N,Small molecule,False,ESLICARBAZEPINE ACETATE,2009.0,4.0,,False,True,['Aptiom' 'Erelib' 'Pazzul' 'Stedesa' 'Zebinix'],"['BIA 2-093' 'BIA-2-093' 'BIA-2093' 'Eslicarbazepine acetate'
 'SEP - 0002093' 'SEP-0002093']","[('DailyMed', array(['eslicarbazepine%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix'],
      dtype=object)), ('PubChem', array(['29217508', '90341297'], dtype=object)), ('drugbank', array(['DB09119'], dtype=object)), ('chEBI', array(['87016'], dtype=object))]",,"{'rows': array(['MONDO_0041052', 'EFO_0005762', 'EFO_1000877', 'EFO_0005687',
       'HP_0001250', 'EFO_0000474', 'EFO_0009963', 'EFO_0004263',
       'MONDO_0005277', 'EFO_1000783'], dtype=object), 'count': 10}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for seizure and epilepsy and has 8 investigational indications.
CHEMBL936,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1,OGAKLTJNUQRZJU-UHFFFAOYSA-N,Small molecule,False,DIPHENIDOL,1967.0,4.0,,False,True,['Vontrol'],"['Difenidol' 'Difenidol hydrochloride' 'Diphenidol' 'SK&F 478' 'SK&F-478'
 'SK-478' 'Vontrol']","[('PubChem', array(['11112531', '144206624', '170465280', '50100475'], dtype=object)), ('Wikipedia', array(['Diphenidol'], dtype=object)), ('drugbank', array(['DB01231'], dtype=object)), ('chEBI', array(['4638'], dtype=object))]",['CHEMBL2105784' 'CHEMBL1529'],,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967.
CHEMBL1201087,C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,KORNTPPJEAJQIU-KJXAQDMKSA-N,Small molecule,False,CABERGOLINE,1996.0,4.0,,False,True,['Cabaser' 'Cabergoline' 'Dostinex' 'Velactis'],['Cabergoline' 'FCE 21336' 'FCE-21336' 'Velactis'],"[('DailyMed', array(['cabergoline'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/velactis'],
      dtype=object)), ('PubChem', array(['144206142', '170464667'], dtype=object)), ('Wikipedia', array(['Cabergoline'], dtype=object)), ('drugbank', array(['DB00248'], dtype=object)), ('chEBI', array(['3286'], dtype=object))]",,"{'rows': array(['EFO_0000400', 'EFO_0000545', 'EFO_0000512', 'MONDO_0002491',
       'MONDO_0007254', 'EFO_1001110', 'MONDO_0005180', 'EFO_0001073',
       'EFO_0002610', 'MONDO_0011972', 'EFO_0004270', 'EFO_1000979',
       'EFO_0001065'], dtype=object), 'count': 13}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for parkinson disease and hypothalamic neoplasm and has 11 investigational indications.
CHEMBL1228,CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O,HFHZKZSRXITVMK-UHFFFAOYSA-N,Small molecule,False,OXYPHENBUTAZONE ANHYDROUS,1960.0,4.0,,True,True,['Oxyphenbutazone' 'Tandearil'],"['Californit' 'Crovaril' 'Flogitolo' 'Flogoril' 'Frabel' 'G-27202'
 'NSC-526053' 'Neo-farmadol' 'Oxalid' 'Oxyphenbutazone' 'RO-04-4410'
 'Rapostan' 'Reozon' 'Suganril' 'Visubutina']","[('PubChem', array(['144203965', '170465310', '26748182', '56463172'], dtype=object)), ('Wikipedia', array(['Oxyphenbutazone'], dtype=object)), ('drugbank', array(['DB03585'], dtype=object)), ('chEBI', array(['76258'], dtype=object))]",['CHEMBL3989676'],"{'rows': array(['EFO_0005755', 'EFO_0005752', 'HP_0002829', 'HP_0003326'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 approved indications.
CHEMBL1297,CC(C(=O)O)c1cccc(Oc2ccccc2)c1,RDJGLLICXDHJDY-UHFFFAOYSA-N,Small molecule,True,FENOPROFEN,1976.0,4.0,,False,True,['Progesic'],['53858' 'Fenoprofen' 'LILLY-53858' 'NSC-757813' 'Nalfon'],"[('Wikipedia', array(['Fenoprofen'], dtype=object)), ('drugbank', array(['DB00573'], dtype=object)), ('chEBI', array(['5004'], dtype=object))]",['CHEMBL2068720' 'CHEMBL2103736' 'CHEMBL138241'],"{'rows': array(['MONDO_0005178', 'EFO_0000685', 'EFO_0005755'], dtype=object), 'count': 3}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL1738797,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,KDGFLJKFZUIJMX-UHFFFAOYSA-N,Small molecule,False,ALECTINIB,2015.0,4.0,,False,True,['Alecensa'],"['AF-802' 'AF802' 'Alectinib' 'CH-5424802' 'CH5424802' 'RO-5424802'
 'RO5424802']","[('PubChem', array(['174006440'], dtype=object)), ('drugbank', array(['DB11363'], dtype=object))]",['CHEMBL3707320'],"{'rows': array(['EFO_0001421', 'EFO_0000756', 'EFO_0000641', 'MONDO_0004992',
       'EFO_0001642', 'EFO_0000691', 'EFO_0003032', 'EFO_0005221',
       'EFO_0003826', 'EFO_0003893', 'EFO_0004142', 'EFO_0000326',
       'MONDO_0021117', 'EFO_0003833', 'EFO_1000849', 'EFO_0000616',
       'EFO_0003860', 'EFO_1001901', 'EFO_0003060', 'EFO_0000519',
       'EFO_0003060', 'EFO_0004284'], dtype=object), 'count': 22}","[ENSG00000171094,ENSG00000143924,ENSG00000165731]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 19 investigational indications.
CHEMBL1835207,CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1,JTMITOKKUMVWRT-UHFFFAOYSA-N,Small molecule,False,APRICOXIB,,2.0,,False,False,[],['Apricoxib' 'CS-706' 'R-109339' 'TG-01' 'TG01'],"[('drugbank', array(['DB12378'], dtype=object))]",,"{'rows': array(['EFO_0002618', 'EFO_0003060', 'MONDO_0007254', 'EFO_0001378'],
      dtype=object), 'count': 4}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2107759,CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C,GJQWFXNJAXOCBV-XVGNUGADSA-N,Small molecule,False,MILATAXEL,,2.0,,False,False,[],['MAC-321' 'Milataxel'],,,"{'rows': array(['EFO_0003060', 'EFO_0004288', 'EFO_1000657', 'EFO_0000588'],
      dtype=object), 'count': 4}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2108508,,,Protein,True,INTERFERON ALFA-2A,1986.0,4.0,,False,True,[],"['INTERFERON ALFA-2A' 'Interferon alfa-2a'
 'Interferon alfa-2a (genetical recombination)' 'RO 22-8181' 'RO-22-8181'
 'RO-228181']",,,"{'rows': array(['EFO_0003047', 'MONDO_0004992', 'EFO_1000956', 'EFO_1001156',
       'MONDO_0002367', 'EFO_0003780', 'EFO_0000676', 'EFO_0000681',
       'EFO_0001378', 'EFO_0004220', 'EFO_0000756', 'EFO_0000220',
       'EFO_0000616', 'EFO_0000764', 'EFO_0002617', 'EFO_0000574'],
      dtype=object), 'count': 16}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for cancer and neoplasm and has 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108593,,,Protein,False,EPOETIN ZETA,2007.0,4.0,,False,True,['Retacrit'],['Epoetin' 'Epoetin zeta' 'Erythropoietin' 'Erythropoietin for bioassays'],"[('DrugCentral', array(['5170'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit'],
      dtype=object))]",,"{'rows': array(['EFO_1001459', 'EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 3}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic kidney disease and anemia (phenotype) and has 1 investigational indication.
CHEMBL2109511,,,Antibody,False,ONTAMALIMAB,,3.0,,False,False,[],['Ontamalimab' 'PF-00547659' 'SHP-647' 'SHP647' 'Shp647'],,,"{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}",[ENSG00000099866],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,DDINXHAORAAYAD-UHFFFAOYSA-N,Small molecule,True,ARIPIPRAZOLE LAUROXIL,2015.0,4.0,,False,True,['Aristada' 'Aristada initio kit'],"['ALKS 9072' 'ALKS-9070' 'ALKS-9072' 'Aripiprazole lauroxil'
 'Aristada initio' 'RDC-3317' 'RDC3317']","[('DailyMed', array(['aripiprazole%20lauroxil'], dtype=object)), ('drugbank', array(['DB14185'], dtype=object))]",,"{'rows': array(['EFO_0005411', 'MONDO_0005090'], dtype=object), 'count': 2}","[ENSG00000178394,ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for schizophrenia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL270190,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1,UPNUIXSCZBYVBB-JVFUWBCBSA-N,Small molecule,True,ALVIMOPAN,2008.0,4.0,,False,True,['Entereg'],"['ADL 8-2698' 'ADL-8-2698' 'Alvimopan' 'Alvimopan anhydrous'
 'Alvimopan dihydrate' 'Anhydrous alvimopan' 'LY-246736'
 'LY-246736 DIHYDRATE' 'LY246736']","[('DailyMed', array(['alvimopan'], dtype=object)), ('Wikipedia', array(['Alvimopan'], dtype=object)), ('drugbank', array(['DB06274'], dtype=object))]",,"{'rows': array(['MONDO_0004567', 'MONDO_0002087', 'MONDO_0008170', 'MONDO_0002158',
       'MONDO_0001187', 'HP_0002019'], dtype=object), 'count': 6}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3084748,O=C(O[C@H]1C[C@H]2CC[C@@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-],RVCSYOQWLPPAOA-QKYUOBHYSA-M,Small molecule,False,TROSPIUM CHLORIDE,2004.0,4.0,CHEMBL1888176,False,True,"['Flotros' 'Regurin' 'Regurin xl' 'Sanctura' 'Sanctura xr' 'Spasmo-lyt'
 'Trospium chloride' 'Uraplex']",['IP-631' 'IP631' 'Relaspium' 'Spasmex' 'Spasmolyt' 'Trospium chloride'],"[('DailyMed', array(['trospium%20chloride'], dtype=object)), ('PubChem', array(['144205995', '170464918'], dtype=object))]",,"{'rows': array(['EFO_0006865', 'EFO_0000341', 'EFO_1000781', 'MONDO_0005090'],
      dtype=object), 'count': 4}","[ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for urgency urinary incontinence and overactive bladder and has 2 investigational indications.
CHEMBL333021,c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1,VOYMOBPSYVKQGF-UHFFFAOYSA-N,Small molecule,False,L-21649,,1.0,,False,False,[],['L-21649'],,,,"[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL371405,C[C@@]12OC(=O)[C@]1([C@@H](O)[C@@H]1C=CCCC1)NC(=O)[C@@H]2CCCl,NGWSFRIPKNWYAO-SHTIJGAHSA-N,Small molecule,False,MARIZOMIB,,3.0,,False,False,[],['Marizomib' 'NPI-0052' 'Salinosporamide a'],"[('Wikipedia', array(['Salinosporamide_A'], dtype=object)), ('drugbank', array(['DB11762'], dtype=object)), ('chEBI', array(['48045'], dtype=object))]",,"{'rows': array(['EFO_1000028', 'EFO_0000519', 'MONDO_0016700', 'EFO_0001378',
       'MONDO_0004992', 'EFO_0000574'], dtype=object), 'count': 6}","[ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL406050,CCC(C)SSc1ncc[nH]1,BPBPYQWMFCTCNG-UHFFFAOYSA-N,Small molecule,False,PX-12,,2.0,,False,False,[],['Px-12'],"[('PubChem', array(['174006855'], dtype=object)), ('drugbank', array(['DB05448'], dtype=object))]",,"{'rows': array(['EFO_0003860'], dtype=object), 'count': 1}",[ENSG00000136810],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL411,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1,RGLYKWWBQGJZGM-ISLYRVAYSA-N,Small molecule,False,DIETHYLSTILBESTROL,1973.0,4.0,,False,True,"['Apstil' 'Diethylstilbestrol' 'Distilbene' 'Stilbestrol' 'Stilbetin'
 'Stilboesterol' 'Tampovagan']","['Cyren a' 'Diethylstilbestrol' 'Estrobene' 'Estrogenine' 'Estromenin'
 'Fonatol' 'NSC-3070' 'New-estranol 1' 'Palestrol' 'Stilbestro'
 'Stilbestroform' 'Stilbestrol' 'Stilboestrol' 'Synestrin' 'Synthestrin']","[('PubChem', array(['11532921', '144209605', '144210844', '17389919', '26747240',
       '26752777'], dtype=object)), ('Wikipedia', array(['Diethylstilbestrol'], dtype=object)), ('drugbank', array(['DB00255'], dtype=object)), ('chEBI', array(['41922'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 2}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for neoplasm and has 1 investigational indication.
CHEMBL4297789,,,Unknown,False,MT-3724,,2.0,,False,False,[],['Mt-3724'],,,"{'rows': array(['EFO_0005952', 'EFO_0000403', 'EFO_0004289', 'EFO_0000095'],
      dtype=object), 'count': 4}","[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818,ENSG00000156738]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4298025,,,Antibody,False,ZENOCUTUZUMAB,,2.0,,False,False,[],['MCLA-128' 'MCLA128' 'Mcla 128' 'Mcla-128' 'Zenocutuzumab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZENOCUTUZUMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 2}","[ENSG00000141736,ENSG00000065361]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594251,CS(=O)(=O)O.CS(=O)(=O)O.Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,QQDRLKRHJOAQDC-FBHGDYMESA-N,Small molecule,False,NETARSUDIL DIMESYLATE,2017.0,4.0,CHEMBL4594250,False,True,['Rhokiinsa' 'Rhopressa'],"['AR-13324' 'Netarsudil dimesylate' 'Netarsudil mesilate'
 'Netarsudil mesylate']","[('DailyMed', array(['netarsudil%20dimesylate', 'netarsudil%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa'],
      dtype=object))]",,"{'rows': array(['EFO_0004190', 'EFO_1001069'], dtype=object), 'count': 2}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for open-angle glaucoma and ocular hypertension.
CHEMBL4594334,,,Oligonucleotide,False,EPLONTERSEN,,3.0,,False,False,[],"['AKCEA-TTR-LRx' 'Akcea ttr lrx' 'Akcea-ttr-lrx' 'Eplontersen'
 'ION-682884' 'ION-682884 FREE ACID' 'IONIS-TTR-LRx'
 'ISIS-682884 FREE ACID' 'Ion-ttr-lrx']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EPLONTERSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004129', 'EFO_1001875'], dtype=object), 'count': 2}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL46,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,FELGMEQIXOGIFQ-UHFFFAOYSA-N,Small molecule,False,ONDANSETRON,1991.0,4.0,,False,True,['Ondansetron' 'Zofran' 'Zofran odt' 'Zuplenz'],"['A04AA01' 'Desmethylondansetron' 'EUR-1025' 'GR-38032' 'GR-38032F'
 'NSC-757870' 'Ondansetron' 'Zofran']","[('DailyMed', array(['ondansetron'], dtype=object)), ('PubChem', array(['124893606', '144206599', '170464701'], dtype=object)), ('Wikipedia', array(['Ondansetron'], dtype=object)), ('drugbank', array(['DB00904'], dtype=object)), ('chEBI', array(['7773'], dtype=object))]",['CHEMBL1487310' 'CHEMBL1201111' 'CHEMBL3186492'],"{'rows': array(['EFO_0006911', 'EFO_0004888', 'EFO_0003843', 'EFO_0004701',
       'HP_0002018', 'HP_0002094', 'MONDO_0005090', 'EFO_0003843',
       'MONDO_0004992', 'HP_0002013', 'HP_0002017', 'EFO_0002618',
       'HP_0011110', 'MONDO_0007079', 'HP_0002017', 'Orphanet_79292',
       'EFO_0002610', 'MONDO_0100342', 'EFO_0005611', 'EFO_0000096',
       'EFO_0006911', 'EFO_0003869', 'MONDO_0004992', 'EFO_1000948',
       'HP_0002013', 'MONDO_0002046', 'EFO_0001061', 'MONDO_0021148',
       'EFO_1001463', 'HP_0002018', 'EFO_0005762', 'EFO_0003768',
       'EFO_0005774', 'EFO_0000764', 'HP_0000726', 'HP_0001082',
       'EFO_0011023', 'EFO_0004242', 'EFO_0005952', 'MONDO_0007254',
       'EFO_0006912', 'EFO_0007386', 'EFO_0000555', 'MONDO_0043510',
       'EFO_0000691', 'HP_0000738', 'EFO_0005251', 'EFO_0004888'],
      dtype=object), 'count': 48}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 approved and 35 investigational indications.
CHEMBL4650514,,,Antibody,False,BATOCLIMAB,,3.0,,False,False,[],"['Batoclimab' 'HBM-9161' 'HBM9161' 'HL161BKN' 'RVT-1401' 'RVT1401'
 'Rvt-1401']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BATOCLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0005809', 'EFO_1001466', 'EFO_1000749', 'EFO_0004237',
       'EFO_1001264', 'EFO_0009538', 'EFO_0004256', 'EFO_0004991',
       'EFO_0007160'], dtype=object), 'count': 9}",[ENSG00000104870],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL489095,C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1,RZKDEGZIFSJVNA-IBGZPJMESA-N,Small molecule,False,CAMICINAL,,3.0,,False,False,[],"['Camicinal' 'GSK-962040' 'GSK-962040B' 'GSK962040' 'GSK962040B'
 'Gsk962040']","[('drugbank', array(['DB12567'], dtype=object))]",['CHEMBL489679'],"{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}",[ENSG00000102539],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL499,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,BLJRIMJGRPQVNF-JTQLQIEISA-N,Small molecule,False,TIMOLOL,1978.0,4.0,,False,True,"['Betim' 'Betimol' 'Blocadren' 'Glau-opt' 'Glaucol' 'Nyogel' 'Timolol'
 'Timoptic' 'Tiopex']","['Blocadren' 'Istalol' 'Timolol' 'Timolol anhydrous' 'Timolol hemihydrate'
 'Timoptic' 'Timoptic-XE']","[('DailyMed', array(['timolol'], dtype=object)), ('PubChem', array(['104171325', '11111904', '11112709', '11113334', '144204165',
       '170465062', '90341807'], dtype=object)), ('Wikipedia', array(['Timolol'], dtype=object)), ('drugbank', array(['DB00373'], dtype=object)), ('chEBI', array(['9599'], dtype=object))]",['CHEMBL1200870'],"{'rows': array(['EFO_0000319', 'MONDO_0005041', 'EFO_1001022', 'EFO_0000666',
       'EFO_1000809', 'EFO_1000635', 'EFO_0000756', 'MONDO_0005041',
       'EFO_1000635', 'EFO_1001069', 'EFO_1000879', 'EFO_0004190',
       'EFO_0000546', 'MONDO_0005277', 'EFO_0004190', 'EFO_0004235',
       'EFO_0004683', 'EFO_1001923', 'EFO_1001069', 'MONDO_0019180'],
      dtype=object), 'count': 20}","[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 13 investigational indications.
CHEMBL545315,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl,JZZFDCXSFTVOJY-UHFFFAOYSA-N,Small molecule,False,CANERTINIB DIHYDROCHLORIDE,,3.0,CHEMBL31965,False,False,[],"['CI-1033' 'Canertinib dihydrochloride' 'Canertinib hydrochloride'
 'PD-0183805' 'PD-0183805-002B' 'PD-183805' 'SN-26606']",,,"{'rows': array(['EFO_0003869', 'MONDO_0021117', 'EFO_0003060'], dtype=object), 'count': 3}","[ENSG00000141736,ENSG00000178568,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL650,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12,VHRSUDSXCMQTMA-PJHHCJLFSA-N,Small molecule,False,METHYLPREDNISOLONE,1957.0,4.0,,False,True,['Medrol' 'Medrone' 'Methylprednisolone'],"['6-methyl-prednisolone' '6-methylprednisolone' 'J3.872E'
 'Methylprednisolone' 'NSC-19987' 'U-67,590A']","[('DailyMed', array(['methylprednisolone'], dtype=object)), ('PubChem', array(['144203927', '144212335', '170465051', '56424125', '82706',
       '855789'], dtype=object)), ('Wikipedia', array(['Methylprednisolone'], dtype=object)), ('drugbank', array(['DB00959'], dtype=object)), ('chEBI', array(['6888'], dtype=object))]",['CHEMBL1200844'],"{'rows': array(['Orphanet_77260', 'EFO_1000905', 'EFO_0004143', 'EFO_0000768',
       'EFO_0003898', 'EFO_1000391', 'HP_0002027', 'MONDO_0007915',
       'EFO_0004256', 'EFO_1000965', 'EFO_0007224', 'MONDO_0011972',
       'EFO_0000684', 'HP_0002015', 'EFO_0000403', 'MONDO_0018896',
       'EFO_0003777', 'EFO_0000662', 'MONDO_0002135', 'EFO_0007160',
       'EFO_0004826', 'EFO_0007405', 'EFO_1001919', 'EFO_0000729',
       'EFO_0004194', 'MONDO_0019391', 'EFO_0007149', 'EFO_0003840',
       'EFO_1000784', 'EFO_0003914', 'EFO_0001379', 'EFO_0003060',
       'EFO_0009104', 'EFO_0003103', 'EFO_0009609', 'EFO_0007537',
       'MONDO_0013730', 'MP_0001845', 'MONDO_0016537', 'EFO_1000941',
       'EFO_0005761', 'EFO_1001806', 'EFO_0003884', 'EFO_0001378',
       'HP_0002140', 'HP_0001915', 'EFO_0004991', 'EFO_0000209',
       'EFO_1001435', 'MONDO_0004750', 'EFO_1001466', 'EFO_0003872',
       'EFO_0003843', 'EFO_0005297', 'HP_0001873', 'HP_0030834',
       'MONDO_0002471', 'EFO_0003929', 'MONDO_0017719', 'MONDO_0020077',
       'MONDO_0100096', 'EFO_0000255', 'EFO_0000211', 'EFO_0000685',
       'EFO_0009373', 'MONDO_0015540', 'MONDO_0019091', 'EFO_0003106',
       'EFO_0000546', 'MONDO_0017287', 'MONDO_0004979', 'EFO_0000565',
       'MONDO_0004976', 'MONDO_0004992', 'EFO_1001345', 'EFO_0005952',
       'MONDO_0005301', 'EFO_0000694', 'EFO_0002428', 'MONDO_0005277',
       'MONDO_0000870', 'EFO_0004254', 'EFO_0003778', 'EFO_0000540',
       'MONDO_0008315', 'EFO_0003032', 'EFO_1001119', 'EFO_0004251',
       'MONDO_0009348', 'EFO_0000717', 'EFO_0000557', 'EFO_0004599',
       'EFO_0002609', 'EFO_0000341', 'EFO_1001909', 'EFO_0000198',
       'EFO_0000706', 'EFO_0004145', 'EFO_1000637', 'MONDO_0100339',
       'MONDO_0018150', 'EFO_1002048', 'EFO_0000574', 'MONDO_0007254',
       'EFO_0007498', 'EFO_1000809', 'EFO_0000274', 'MONDO_0002158',
       'EFO_1001254', 'EFO_0000616', 'EFO_0000196', 'EFO_0009492',
       'HP_0002576', 'MONDO_0044881', 'EFO_0007295', 'EFO_0000756',
       'EFO_1001365', 'EFO_0003086', 'MONDO_0016226', 'MONDO_0005180',
       'EFO_0004255', 'MONDO_0100062', 'EFO_0000220', 'MONDO_0009387',
       'MONDO_0008170', 'EFO_0000095', 'MONDO_0020547', 'MONDO_0017276',
       'EFO_0003894', 'EFO_0004278', 'EFO_1001801', 'EFO_0007448',
       'MONDO_0005178', 'HP_0100543', 'EFO_0001642', 'EFO_0000712',
       'EFO_0000309', 'EFO_0006862', 'MONDO_0018923', 'EFO_0007167',
       'EFO_0000384', 'EFO_0003957', 'EFO_0004246', 'MONDO_0000873',
       'EFO_0007486', 'EFO_0008520', 'MONDO_0100130', 'EFO_1001139',
       'MONDO_0002959'], dtype=object), 'count': 149}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 17 approved and 132 investigational indications.
CHEMBL806,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,MKXKFYHWDHIYRV-UHFFFAOYSA-N,Small molecule,True,FLUTAMIDE,1989.0,4.0,,False,True,['Chimax' 'Drogenil' 'Eulexin' 'Flutamide'],['Flutamide' 'NSC-215876' 'SCH 13521' 'SCH-13521'],"[('DailyMed', array(['flutamide'], dtype=object)), ('PubChem', array(['104171162', '11111202', '11111203', '11532925', '124880151',
       '124880153', '144203705', '144209367', '144210854', '170464921',
       '17388997', '174007322', '26747365', '26747366', '26753014',
       '26753015', '49675006', '50105597', '50105598', '50105599',
       '50105600', '85231055', '90341271'], dtype=object)), ('TG-GATEs', array(['44'], dtype=object)), ('Wikipedia', array(['Flutamide'], dtype=object)), ('drugbank', array(['DB00499'], dtype=object)), ('chEBI', array(['5132'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000196', 'EFO_0000313', 'MONDO_0008170',
       'EFO_0000673', 'EFO_0000660', 'MONDO_0008315', 'EFO_0001663'],
      dtype=object), 'count': 8}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL842,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,JBMKAUGHUNFTOL-UHFFFAOYSA-N,Small molecule,False,CHLOROTHIAZIDE,1958.0,4.0,,False,True,['Chlorothiazide' 'Diuril' 'Saluric'],"['Chlorothiazide' 'Chlorthiazide'
 'Hydrochlorothiazide impurity, chlorothiazide-' 'NSC-25693']","[('DailyMed', array(['chlorothiazide'], dtype=object)), ('PubChem', array(['11110950', '11110951', '144203658', '144208170', '170465303',
       '17389544', '50105505', '855976'], dtype=object)), ('Wikipedia', array(['Chlorothiazide'], dtype=object)), ('drugbank', array(['DB00880'], dtype=object)), ('chEBI', array(['3640'], dtype=object))]",['CHEMBL1200616'],"{'rows': array(['EFO_0003777', 'EFO_0003914', 'MONDO_0002462', 'EFO_0004255',
       'EFO_0000319', 'EFO_0000537', 'MONDO_0005148', 'EFO_0009373',
       'EFO_0003884', 'EFO_0001645', 'EFO_0000373', 'EFO_0000668',
       'HP_0003124'], dtype=object), 'count': 13}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 8 approved and 5 investigational indications.
CHEMBL924,O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,XRASPMIURGNCCH-UHFFFAOYSA-N,Small molecule,False,ZOLEDRONIC ACID ANHYDROUS,2001.0,4.0,,False,True,['Reclast' 'Zometa'],['CGP-42446' 'Zometa'],"[('PubChem', array(['144205292', '174006914', '29215499'], dtype=object)), ('Wikipedia', array(['Zoledronic_acid'], dtype=object)), ('drugbank', array(['DB00399'], dtype=object)), ('chEBI', array(['46557'], dtype=object))]",['CHEMBL3989655' 'CHEMBL4303669' 'CHEMBL4746555' 'CHEMBL2103912'],"{'rows': array(['EFO_0000228', 'EFO_0000588', 'EFO_0003820', 'EFO_0000564',
       'EFO_0004259', 'MONDO_0008310', 'EFO_0001416', 'EFO_0003863',
       'EFO_0005952', 'EFO_0003843', 'EFO_1001998', 'MONDO_0011382',
       'EFO_1001147', 'EFO_0004252', 'EFO_1001919', 'GO_0042697',
       'EFO_0003060', 'EFO_0003882', 'EFO_0000691', 'EFO_0003869',
       'EFO_0000681', 'EFO_0000196', 'EFO_0003854', 'MONDO_0019019',
       'MONDO_0021165', 'MONDO_0008315', 'MONDO_0002974', 'EFO_0002430',
       'MONDO_0044903', 'MONDO_0002171', 'EFO_0003931', 'EFO_0000685',
       'EFO_0000673', 'EFO_0009708', 'EFO_0001365', 'MONDO_0008903',
       'HP_0000938', 'EFO_0000182', 'EFO_0001663', 'EFO_0000637',
       'EFO_0009870', 'EFO_0001378', 'Orphanet_848', 'MONDO_0020732',
       'HP_0003419', 'EFO_0006738', 'MONDO_0007254', 'EFO_0000333',
       'EFO_0000432', 'EFO_0004260', 'EFO_0000621', 'MONDO_0002367',
       'EFO_0000174', 'EFO_0004261', 'EFO_1000786'], dtype=object), 'count': 55}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 12 approved and 43 investigational indications.
CHEMBL972,C#CCN(C)[C@H](C)Cc1ccccc1,MEZLKOACVSPNER-GFCCVEGCSA-N,Small molecule,True,SELEGILINE,1989.0,4.0,,False,True,['Eldepryl' 'Emsam' 'Zelapar'],['Eldepryl' 'L-selegiline' 'Selegiline' 'Zelapar'],"[('DailyMed', array(['selegiline'], dtype=object)), ('PubChem', array(['11113910', '26752066'], dtype=object)), ('Wikipedia', array(['Selegiline'], dtype=object)), ('drugbank', array(['DB01037'], dtype=object)), ('chEBI', array(['9086'], dtype=object))]",['CHEMBL1200904' 'CHEMBL5194110'],"{'rows': array(['EFO_0002610', 'MONDO_0002009', 'EFO_0004701', 'EFO_0000673',
       'MONDO_0005180', 'MONDO_0005090', 'EFO_0003768', 'MONDO_0004975',
       'MONDO_0002050', 'EFO_0007191', 'MONDO_0002009', 'HP_0012076'],
      dtype=object), 'count': 12}",[ENSG00000069535],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for major depressive disorder and parkinson disease and has 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL107430,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl,PNAWUIKCVQSLFG-UHFFFAOYSA-N,Small molecule,False,NRX195183,,2.0,,False,False,[],"['AGN 195183' 'AGN-195183' 'IRX5183' 'Irx-5183' 'NRX-195183' 'NRX195183'
 'Nrx195183' 'VTP-195183' 'VTP-5183']","[('drugbank', array(['DB05653'], dtype=object))]",,"{'rows': array(['EFO_0000224'], dtype=object), 'count': 1}",[ENSG00000131759],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1148,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1,NGBFQHCMQULJNZ-UHFFFAOYSA-N,Small molecule,False,TORSEMIDE,1993.0,4.0,,False,True,['Demadex' 'Soaanz' 'Torem 10' 'Torem 2.5' 'Torem 5' 'Torsemide' 'Upcard'],"['AC-4464' 'AC4464' 'BM-02.015' 'BM-02015' 'BM02.015' 'Luprac'
 'Torasemide' 'Torasemide anhydrous' 'Torsemide' 'Upcard']","[('DailyMed', array(['torsemide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/upcard'],
      dtype=object)), ('PubChem', array(['11112793', '144204213', '170465279', '26719820', '26748988',
       '49665992', '49666477'], dtype=object)), ('Wikipedia', array(['Torasemide'], dtype=object)), ('drugbank', array(['DB00214'], dtype=object)), ('chEBI', array(['9637'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_0000612', 'EFO_0000373', 'EFO_0003144',
       'EFO_0000319', 'MONDO_0005148', 'EFO_0000668', 'EFO_0000537'],
      dtype=object), 'count': 8}",[ENSG00000074803],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 2 investigational indications.
CHEMBL1200554,CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,ZBVJFYPGLGEMIN-OYLNGHKZSA-N,Protein,False,TRIPTORELIN PAMOATE,2000.0,4.0,CHEMBL1201334,False,True,['Trelstar' 'Triptodur kit'],"['Salvacyl' 'Triptorelin (as embonate)' 'Triptorelin embonate'
 'Triptorelin pamoate']","[('DailyMed', array(['triptorelin%20pamoate'], dtype=object))]",,"{'rows': array(['EFO_0000196', 'EFO_0001065', 'MONDO_0008315', 'EFO_0001663',
       'MONDO_0000088', 'EFO_0000673', 'EFO_0009029', 'MONDO_0007254'],
      dtype=object), 'count': 8}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 3 investigational indications.
CHEMBL1201082,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl,GIYXAJPCNFJEHY-UHFFFAOYSA-N,Small molecule,True,FLUOXETINE HYDROCHLORIDE,1987.0,4.0,CHEMBL41,False,True,"['Felicium' 'Fluoxetine' 'Fluoxetine hydrochloride' 'Olena' 'Oxactin'
 'Prozac' 'Prozac 60' 'Prozac weekly' 'Prozep' 'Prozit' 'Ranflutin'
 'Reconcile' 'Sarafem' 'Selfemra']","['Adofen' 'Fluctin' 'Fluneurin' 'Fluox-puren' 'Fluoxeren'
 'Fluoxetine (as hydrochloride)' 'Fluoxetine hydrochloride' 'Flusol'
 'Fluxet' 'Fontex' 'Foxetin' 'LY-110140' 'LY110140' 'Lovan' 'Reconcile']","[('DailyMed', array(['fluoxetine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/reconcile'],
      dtype=object)), ('PubChem', array(['144207380', '26747522', '26747523', '50106352', '50106353',
       '50106354', '56422172', '855820'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0004242', 'EFO_0004262', 'EFO_0009963',
       'MONDO_0004985', 'MONDO_0002009', 'MONDO_0002050'], dtype=object), 'count': 7}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201488,,,Protein,False,SECRETIN SYNTHETIC HUMAN,2004.0,4.0,,False,True,['Chirhostim'],"['Human secretin' 'Secretin (human)' 'Secretin (human), acetate (salt)'
 'Secretin Synthetic Human' 'Secretin acetate human' 'Secretin human'
 'Secretin human acetate' 'Secretin human pentaacetate'
 'Secretin synthetic human' 'Synthetic human secretin']","[('DailyMed', array(['secretin%20synthetic%20human'], dtype=object))]",,"{'rows': array(['EFO_0004242', 'EFO_0003758'], dtype=object), 'count': 2}",[ENSG00000080293],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 2 investigational indications.
CHEMBL1201641,,,Protein,False,INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN,1987.0,4.0,,False,True,['Humulin u'],['Insulin zinc susp extended recombinant human'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL1337,O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-],OUBCNLGXQFSTLU-UHFFFAOYSA-N,Small molecule,False,NITISINONE,2002.0,4.0,,False,True,['Nityr' 'Orfadin'],['Nitisinone' 'SC-0735'],"[('DailyMed', array(['nitisinone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nityr'],
      dtype=object)), ('PubChem', array(['174007248'], dtype=object)), ('Wikipedia', array(['Nitisinone'], dtype=object)), ('drugbank', array(['DB00348'], dtype=object)), ('chEBI', array(['50378'], dtype=object))]",,"{'rows': array(['MONDO_0004741', 'MONDO_0008753', 'MONDO_0043209'], dtype=object), 'count': 3}",[ENSG00000158104],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for tyrosinemia and has 2 investigational indications.
CHEMBL1417019,Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,ZAHQPTJLOCWVPG-UHFFFAOYSA-N,Small molecule,True,MITOXANTRONE HYDROCHLORIDE,1987.0,4.0,CHEMBL58,False,True,['Mitoxantrone hydrochloride' 'Novantrone'],"['CL 232,315' 'CL-232315' 'Mitoxantrone Dihcl'
 'Mitoxantrone Dihydrochloride' 'Mitoxantrone dihydrochloride'
 'Mitoxantrone hcl' 'Mitoxantrone hydrochloride' 'Mitozantrone'
 'NSC-301739']","[('PubChem', array(['144203748', '170465183', '26747571', '26747572', '26747573',
       '50106605'], dtype=object)), ('chEBI', array(['50727'], dtype=object))]",,"{'rows': array(['MONDO_0015760', 'MONDO_0019472', 'EFO_0000182', 'MONDO_0005301',
       'EFO_0000211', 'MONDO_0008170', 'EFO_0003843', 'EFO_0000220',
       'MONDO_0018906', 'EFO_0000198', 'EFO_0000616', 'EFO_0004251',
       'EFO_0000673', 'EFO_0004289', 'EFO_0003929', 'EFO_0000196',
       'EFO_0000222', 'EFO_0000221', 'EFO_1001469', 'EFO_0005952',
       'EFO_1001830', 'EFO_0008522', 'EFO_0000565', 'MONDO_0004992',
       'EFO_0000224', 'EFO_0000339', 'EFO_0000095', 'MONDO_0008315',
       'MONDO_0008315', 'EFO_0001378', 'EFO_0000178', 'EFO_0000574',
       'EFO_0000403', 'EFO_0006859', 'MONDO_0007254', 'EFO_1000286',
       'MONDO_0001023', 'MONDO_0019460', 'MONDO_0000873', 'EFO_1001052',
       'EFO_0001663'], dtype=object), 'count': 41}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 5 approved and 36 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1418176,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,XWALNWXLMVGSFR-HLXURNFRSA-N,Small molecule,False,METHANDROSTENOLONE,,4.0,,True,True,['Dianabol'],"['Metandienone' 'Methandienone' 'Methandrostenolone' 'NSC-42722' 'Nerobol'
 'Perbolin']","[('PubChem', array(['144205200', '170466069', '29215353'], dtype=object)), ('Wikipedia', array(['Methandrostenolone'], dtype=object)), ('drugbank', array(['DB13586'], dtype=object))]",,,[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1654,O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+],DRFDPXKCEWYIAW-UHFFFAOYSA-M,Small molecule,False,RISEDRONATE SODIUM,1998.0,4.0,CHEMBL923,False,True,['Actonel' 'Atelvia' 'Risedronate sodium'],"['NE-58095' 'NE-58095 ANHYDROUS' 'NSC-722598' 'NSC-759280'
 'Risedronate monosodium' 'Risedronate sodium'
 'Risedronate sodium anhydrous' 'Risedronic acid monosodium salt']","[('DailyMed', array(['risedronate%20sodium'], dtype=object)), ('PubChem', array(['174006918'], dtype=object))]",,"{'rows': array(['MONDO_0005351', 'MONDO_0021165', 'EFO_0003854', 'EFO_0000574',
       'MONDO_0019019', 'EFO_0000565', 'EFO_0003882'], dtype=object), 'count': 7}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 4 investigational indications.
CHEMBL1671,CC(C)NCC(O)COc1cccc2ccccc12.Cl,ZMRUPTIKESYGQW-UHFFFAOYSA-N,Small molecule,True,PROPRANOLOL HYDROCHLORIDE,1967.0,4.0,CHEMBL27,False,True,"['Angilol' 'Apsolol' 'Avlocardyl' 'Bedranol' 'Bedranol s.r.' 'Berkolol'
 'Beta-prograne mr' 'Betadur cr' 'Cardinol' 'Dupromex'
 'Half beta-prograne mr' 'Half propanix la' 'Half propatard la'
 'Half-beprane cr' 'Half-betadur cr' 'Half-inderal la' 'Hemangeol'
 'Hemangiol' 'Inderal' 'Inderal la' 'Innopran xl' 'Lederpronol'
 'Lopranol la' 'Probeta la' 'Propanix la' 'Propanix-10' 'Propanix-160'
 'Propanix-160 sr' 'Propanix-40' 'Propanix-80' 'Propatard la'
 'Propranolol hydrochloride' 'Propranolol hydrochloride intensol'
 'Rapranol sr' 'Sagittol' 'Slo-blok' 'Slo-pro' 'Sloprolol' 'Syprol'
 'Tesnol']","['AY 64043' 'AY-64043' 'ICI 45520' 'ICI-45520' 'NSC-91523'
 'Propranolol hydrochloride']","[('DailyMed', array(['propranolol%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol'],
      dtype=object)), ('PubChem', array(['144209084', '144213222', '17389750', '26732618', '26747603',
       '26747604', '26751803', '46500341', '50106744', '50106745',
       '50106746'], dtype=object)), ('chEBI', array(['8500'], dtype=object))]",,"{'rows': array(['MONDO_0001187', 'EFO_0003913', 'EFO_1001968', 'HP_0001636',
       'MONDO_0021661', 'EFO_0000712', 'EFO_0004269', 'MONDO_0005277',
       'EFO_0001073', 'MONDO_0018089', 'EFO_0001663', 'MONDO_0005148',
       'EFO_1001450', 'EFO_0002610', 'EFO_0000389', 'EFO_0004142',
       'EFO_0009444', 'EFO_0009545', 'EFO_0001358', 'EFO_0004280',
       'EFO_1000635', 'EFO_0001422', 'EFO_0000537', 'EFO_0003860'],
      dtype=object), 'count': 24}","[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 8 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1708,Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,GELRVIPPMNMYGS-RVXRQPKJSA-N,Small molecule,True,PAROXETINE HYDROCHLORIDE,1992.0,4.0,CHEMBL490,False,True,['Paroxetine hydrochloride' 'Paxil' 'Paxil cr' 'Seroxat'],"['NSC-758654' 'Paroxetine HCl' 'Paroxetine hydrochloride'
 'Paroxetine hydrochloride anhydrous']","[('DailyMed', array(['paroxetine%20hydrochloride'], dtype=object)), ('PubChem', array(['26753519', '85273719'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0006788', 'EFO_0001358', 'EFO_0004262',
       'EFO_0803321', 'MONDO_0002009', 'EFO_0005230', 'MONDO_0002050',
       'EFO_1001917', 'EFO_0004242'], dtype=object), 'count': 10}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103739,CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O,FWLKKPKZQYVAFR-LVEZLNDCSA-N,Small molecule,False,EMEDASTINE DIFUMARATE,1997.0,4.0,CHEMBL594,False,True,['Emadine'],"['AL-3432A' 'Emedastine difumarate' 'Emedastine fumarate' 'KB-2413'
 'LY-188695' 'Ly188695' 'Rapimine']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emadine'],
      dtype=object)), ('PubChem', array(['144206353', '170465197'], dtype=object))]",,"{'rows': array(['EFO_0007141'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for allergic conjunctivitis.
CHEMBL2109327,,,Antibody,False,CSL-360,,1.0,,False,False,[],['CSL-360' 'Csl-360'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}","[ENSG00000292332,ENSG00000185291]",Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109498,,,Antibody,False,IPH-2101,,2.0,,False,False,[],['1-7F9' 'IHP-2101' 'IPH-2101' 'IPH2101' 'Iph-2101'],,,"{'rows': array(['EFO_0000222', 'EFO_0001378'], dtype=object), 'count': 2}","[ENSG00000278731,ENSG00000275546,ENSG00000276731,ENSG00000276011,ENSG00000275407,ENSG00000275914,ENSG00000125498,ENSG00000243772]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2110581,Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O,PRYZSLKPMFOUNL-MHIBGBBJSA-N,Oligonucleotide,False,BEVASIRANIB,,3.0,,False,False,[],['Bevasiranib'],,['CHEMBL2103797'],"{'rows': array(['EFO_0001365', 'EFO_0009606'], dtype=object), 'count': 2}","[ENSG00000164342,ENSG00000112715]",Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL315838,COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1,PJWPNDMDCLXCOM-UHFFFAOYSA-N,Small molecule,False,ENCAINIDE,1986.0,4.0,,True,True,[],['Encainide'],"[('drugbank', array(['DB01228'], dtype=object)), ('chEBI', array(['4788'], dtype=object))]",['CHEMBL2106155'],"{'rows': array(['EFO_0004269'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for cardiac arrhythmia.
CHEMBL3349607,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,VMZMNAABQBOLAK-DBILLSOUSA-N,Protein,False,PASIREOTIDE,2012.0,4.0,,False,True,['Signifor'],['Pasireotide' 'SOM 230' 'SOM-230' 'SOM230'],"[('drugbank', array(['DB06663'], dtype=object)), ('chEBI', array(['72312'], dtype=object))]",['CHEMBL5314380' 'CHEMBL5316227' 'CHEMBL5314382'],"{'rows': array(['MONDO_0016642', 'EFO_0000182', 'MONDO_0004992', 'EFO_0003843',
       'EFO_0001378', 'EFO_1001485', 'EFO_0007331', 'EFO_0004243',
       'EFO_0000673', 'HP_0003074', 'EFO_0000432', 'EFO_0001642',
       'EFO_1001110', 'EFO_1001471', 'EFO_1000581', 'EFO_0005323',
       'EFO_0008549', 'EFO_1001901', 'EFO_0000702', 'MONDO_0002108',
       'EFO_0002618', 'MONDO_0015277', 'MONDO_0007254', 'EFO_1001256',
       'EFO_0003086', 'EFO_1001485', 'MONDO_0024503', 'EFO_0000232',
       'EFO_0001071', 'EFO_0003099', 'EFO_1001307', 'MONDO_0008315'],
      dtype=object), 'count': 32}","[ENSG00000139874,ENSG00000162009,ENSG00000278195,ENSG00000180616]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for acromegaly and has 31 investigational indications.
CHEMBL3426621,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,QSKQVZWVLOIIEV-NSHDSACASA-N,Small molecule,False,RIPASUDIL,,3.0,,False,False,[],['Ripasudil'],"[('drugbank', array(['DB13165'], dtype=object))]",['CHEMBL4594454'],"{'rows': array(['MONDO_0005041', 'Orphanet_98974', 'MONDO_0005321', 'EFO_1000879',
       'EFO_1001158'], dtype=object), 'count': 5}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL3545111,,,Small molecule,False,HEMAY-022,,3.0,,False,False,[],['Hemay-022'],,,"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}",[ENSG00000141736],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3545148,,,Small molecule,False,PHE377,,1.0,,False,False,[],['Phe377'],,,,[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545351,Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O,HQLHZNDJQSRKDT-UHFFFAOYSA-N,Small molecule,False,AV-101,,3.0,,False,False,[],"['4-chlorokynurenine' '4-cl-kyn' 'Av-101' 'J578.071C'
 'L-4-chlorokynurenine' 'L-4-cl-kyn']",,,"{'rows': array(['MONDO_0002050', 'MONDO_0002009', 'EFO_0001361', 'EFO_0005762'],
      dtype=object), 'count': 4}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3707313,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1,MFBCDACCJCDGBA-UHFFFAOYSA-N,Small molecule,False,TRIFAROTENE,2019.0,4.0,,False,True,['Aklief'],['CD-5789' 'CD5789' 'Trifarotene'],"[('DailyMed', array(['trifarotene'], dtype=object)), ('drugbank', array(['DB12808'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'MONDO_0017778', 'EFO_0003894'], dtype=object), 'count': 3}",[ENSG00000172819],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for acne and has 2 investigational indications.
CHEMBL3833320,,,Antibody,False,EPTINEZUMAB,2020.0,4.0,,False,True,['Vyepti'],['ALD-403' 'ALD403' 'Eptinezumab'],"[('DailyMed', array(['eptinezumab-jjmr'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vyepti'],
      dtype=object))]",,"{'rows': array(['MONDO_0005277', 'EFO_0003843'], dtype=object), 'count': 2}","[ENSG00000110680,ENSG00000175868]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 1 investigational indication.
CHEMBL4298194,,,Gene,False,GIROCTOCOGENE FITELPARVOVEC,,3.0,,False,False,[],['Giroctocogene fitelparvovec' 'PF-07055480' 'SB-525'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GIROCTOCOGENE%20FITELPARVOVEC/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Gene drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4650274,,,Unknown,False,DASIGLUCAGON HYDROCHLORIDE,2021.0,4.0,,False,True,['Zegalogue' 'Zegalogue (autoinjector)'],[],,,"{'rows': array(['MONDO_0005147', 'HP_0001943'], dtype=object), 'count': 2}",[ENSG00000215644],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for type 1 diabetes mellitus and hypoglycemia.
CHEMBL4761468,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,DOEOECWDNSEFDN-UHFFFAOYSA-N,Small molecule,False,AUMOLERTINIB,,3.0,,False,False,['Ameile' 'Amerol'],"['Almonertinib' 'Ameile' 'Amerol' 'Aumolertinib' 'EQ-143' 'EQ143'
 'Egfr t790m inhibitor hs-10296' 'HS-10206' 'HS-10296' 'Hs 10296'
 'Hs-10296']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AUMOLERTINIB/relevant/1/'],
      dtype=object))]",['CHEMBL5095491'],"{'rows': array(['EFO_0001421', 'EFO_0000707', 'MONDO_0008903', 'EFO_0000313',
       'EFO_0000571', 'EFO_0000616', 'EFO_0003060', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 9}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL5095052,,,Oligonucleotide,False,INCLISIRAN SODIUM,2020.0,4.0,,False,True,['Leqvio'],['Leqvio sodium'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio'],
      dtype=object))]",,"{'rows': array(['EFO_0003914', 'EFO_0004911'], dtype=object), 'count': 2}",[ENSG00000169174],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for atherosclerosis and familial hypercholesterolemia.
CHEMBL552212,CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1,MTJHLONVHHPNSI-IBGZPJMESA-N,Small molecule,False,LEXIBULIN,,2.0,,False,False,[],['CYT 997' 'CYT-997' 'CYT997' 'Lexibulin'],,,"{'rows': array(['EFO_0001378', 'EFO_0000519'], dtype=object), 'count': 2}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL65375,Cl.N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl,KGHYQYACJRXCAT-UHFFFAOYSA-N,Small molecule,False,TIPIRACIL HYDROCHLORIDE,2015.0,4.0,CHEMBL235668,False,True,[],['TAS-1-462' 'TPI' 'Tipiracil hydrochloride'],"[('DailyMed', array(['tipiracil%20hydrochloride'], dtype=object))]",,"{'rows': array(['MONDO_0044937', 'EFO_1000657', 'EFO_0000365'], dtype=object), 'count': 3}",[ENSG00000025708],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 2 investigational indications.
CHEMBL675,NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.[Na+],CAKRAHQRJGUPIG-UHFFFAOYSA-M,Small molecule,False,ALENDRONATE SODIUM,1995.0,4.0,CHEMBL870,False,True,['Alendronate sodium' 'Binosto' 'Fosamax'],"['Adrovance' 'Alendronate (as sodium)' 'Alendronate sodium'
 'Alendronate sodium hydrate' 'Alendronate sodium trihydrate'
 'Alendronic acid monosodium salt trihydrate' 'Fosavance' 'G-704,650'
 'G-704650' 'MK-217' 'NSC-722597' 'NSC-758931' 'Sodium alendronate'
 'Sodium alendronate trihydrate' 'Vantavo']","[('DailyMed', array(['alendronate%20sodium'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0003762', 'EFO_0003854', 'EFO_0003882',
       'EFO_0000589', 'EFO_0004261'], dtype=object), 'count': 6}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 4 approved and 2 investigational indications.
CHEMBL696,CCC1(C)CC(=O)NC1=O,HAPOVYFOVVWLRS-UHFFFAOYSA-N,Small molecule,False,ETHOSUXIMIDE,1960.0,4.0,,False,True,['Emeside' 'Ethosuximide' 'Suxinutin' 'Zarontin'],"['CI-366' 'CN-10,395' 'CN-10395' 'Ethosuximide' 'Ethosuximidum'
 'NSC-64013' 'PM-671' 'Pyknolepsinum']","[('DailyMed', array(['ethosuximide'], dtype=object)), ('PubChem', array(['144203921', '170464802', '174006922', '26747515', '26747516',
       '50106318', '50106319', '85231037', '90340672'], dtype=object)), ('Wikipedia', array(['Ethosuximide'], dtype=object)), ('drugbank', array(['DB00593'], dtype=object)), ('chEBI', array(['4887'], dtype=object))]",,"{'rows': array(['EFO_0000474', 'MONDO_0002050', 'EFO_1001998', 'HP_0001250',
       'EFO_0000555', 'EFO_0005762', 'MONDO_0005277', 'MONDO_0010826'],
      dtype=object), 'count': 8}","[ENSG00000196557,ENSG00000006283,ENSG00000100346]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for epilepsy and has 7 investigational indications.
CHEMBL107,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,IAKHMKGGTNLKSZ-INIZCTEOSA-N,Small molecule,False,COLCHICINE,1961.0,4.0,,False,True,['Colchicine' 'Colcrys' 'Gloperba' 'Mitigare'],"['(-)-colchicine' 'Colchcine' 'Colchicine' 'Colchicinum' 'Colchineos'
 'Colchisol' 'Lodoco' 'NSC-757']","[('DailyMed', array(['colchicine'], dtype=object)), ('PubChem', array(['104219585', '11114044', '144204498', '144208745', '144210899',
       '170465011', '17389095', '17389096', '26752175', '26752176',
       '49718107', '50085974', '50104821', '50104822', '50113684',
       '50113685', '50113686', '67636', '90340644'], dtype=object)), ('TG-GATEs', array(['113'], dtype=object)), ('Wikipedia', array(['Colchicine'], dtype=object)), ('chEBI', array(['27882'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0007541', 'EFO_0003884', 'EFO_0004220',
       'EFO_0000401', 'EFO_0003818', 'EFO_0008586', 'EFO_0000551',
       'EFO_0000537', 'EFO_0007427', 'EFO_0005672', 'MONDO_0004976',
       'EFO_0004616', 'EFO_0003780', 'EFO_0000694', 'EFO_0001422',
       'EFO_0003777', 'EFO_0004274', 'EFO_0003144', 'EFO_1001486',
       'EFO_0005221', 'EFO_0006803', 'EFO_0007224', 'EFO_0000275',
       'MONDO_0004979', 'MONDO_0100096', 'EFO_0000319', 'MONDO_0018088',
       'EFO_0008585', 'EFO_0003863', 'EFO_0001645', 'EFO_0004264',
       'EFO_0003914', 'EFO_0003938', 'EFO_0000612', 'EFO_1001404',
       'EFO_0009609', 'EFO_0000616', 'EFO_1001129', 'EFO_0002687',
       'EFO_0004269', 'MONDO_0008315'], dtype=object), 'count': 42}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for gout and familial mediterranean fever and has 40 investigational indications.
CHEMBL113,Cn1c(=O)c2c(ncn2C)n(C)c1=O,RYYVLZVUVIJVGH-UHFFFAOYSA-N,Small molecule,False,CAFFEINE,1948.0,4.0,,False,True,['Nodoz' 'Pro-plus' 'Yeast-vite' 'Zanthine'],"['Anhydrous caffeine' 'Cafcit' 'Caffeine' 'Caffeine anhydrous'
 'Caffeine melting point standard' 'Caffeinum' 'Coffeine' 'Coffeinum'
 'Durvitan' 'FEMA NO. 2224' 'Guaranine' 'Methyltheobromine' 'NSC-5036'
 'Synalgos' 'Theine' 'Vivarin']","[('DailyMed', array(['caffeine'], dtype=object)), ('PubChem', array(['104171124', '11110908', '124879556', '144208883', '144210330',
       '17389997', '26732615', '26752751', '49718178', '50105397',
       '50105398', '90341215'], dtype=object)), ('TG-GATEs', array(['97'], dtype=object)), ('Wikipedia', array(['Caffeine', 'Caffeine_(data_page)'], dtype=object)), ('drugbank', array(['DB00201'], dtype=object)), ('chEBI', array(['27732'], dtype=object))]",['CHEMBL1200569'],"{'rows': array(['EFO_0005741', 'HP_0012228', 'MONDO_0007079', 'EFO_0002610',
       'EFO_0003843', 'EFO_0005252', 'MONDO_0100096', 'EFO_1001249',
       'EFO_0003929', 'EFO_0003888', 'EFO_0004714', 'EFO_0001421',
       'EFO_1001158', 'MONDO_0005299', 'MONDO_0005180', 'EFO_0004272',
       'EFO_0002617', 'EFO_0000685', 'MONDO_0100431', 'MONDO_0004938',
       'EFO_0000764', 'EFO_0004220', 'EFO_0000274', 'EFO_0009708',
       'HP_0002094', 'EFO_0009692', 'MONDO_0004976', 'MONDO_0021107',
       'MONDO_0001020', 'HP_0002315', 'EFO_0009444', 'EFO_0000384',
       'MONDO_0008315', 'EFO_0007214', 'MONDO_0004567', 'EFO_0000305',
       'HP_0002104', 'EFO_0001645', 'HP_0030833', 'EFO_0001072',
       'MONDO_0005475', 'EFO_0000756', 'EFO_0003917', 'MONDO_0044970',
       'EFO_0001073', 'MONDO_0005277', 'EFO_0000275', 'EFO_1001919',
       'EFO_0010072', 'EFO_0000676', 'EFO_0600064', 'MONDO_0019091',
       'HP_0002104', 'MONDO_0005148', 'HP_0001298', 'EFO_0000729',
       'EFO_0003843', 'HP_0100607', 'EFO_0000616', 'HP_0012532',
       'HP_0003418', 'EFO_0003876', 'HP_0003419', 'MONDO_0004975'],
      dtype=object), 'count': 64}","[ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 4 approved and 59 investigational indications.
CHEMBL1200449,CC(=O)OCC(=O)[C@@]1(O)[C@H](OC(C)=O)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,XGMPVBXKDAHORN-RBWIMXSLSA-N,Small molecule,False,TRIAMCINOLONE DIACETATE,1959.0,4.0,,False,True,['Aristocort' 'Kenacort' 'Triamcinolone diacetate'],"['Aristocort forte' 'NSC-757356' 'Orion' 'Polcortolon' 'Tedarol'
 'Triamcinolone 16,21-diacetate' 'Triamcinolone diacetate']","[('PubChem', array(['144206670', '170464837'], dtype=object)), ('chEBI', array(['9669'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959.
CHEMBL1200503,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O,NOJMTMIRQRDZMT-GSPXQYRGSA-N,Small molecule,False,BROMOCRIPTINE MESYLATE,1978.0,4.0,CHEMBL493,False,True,['Bromocriptine mesylate' 'Cycloset' 'Parlodel'],"['2-bromoergocryptine mesylate' 'Bromocriptine mesilate'
 'Bromocriptine mesylate' 'Bromocriptine methanesulfonate' 'CB-154'
 'CB-154 MESYLATE' 'Cb-154 mesilate' 'NSC-755915']","[('DailyMed', array(['bromocriptine%20mesylate'], dtype=object)), ('PubChem', array(['144213902', '442420', '50105911'], dtype=object)), ('chEBI', array(['3182'], dtype=object))]",,"{'rows': array(['EFO_0000232', 'MONDO_0005148', 'MONDO_0002146', 'EFO_0000545',
       'EFO_1001485', 'MONDO_0005180', 'EFO_0007319'], dtype=object), 'count': 7}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved indications.
CHEMBL1200545,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,Small molecule,False,DIFLORASONE DIACETATE,1977.0,4.0,,False,True,['Diflorasone diacetate' 'Florone' 'Florone e' 'Psorcon' 'Psorcon e'],"['Diflorasone' 'Diflorasone diacetate' 'Murode' 'U-34,865' 'U-34865']","[('DailyMed', array(['diflorasone%20diacetate'], dtype=object)), ('PubChem', array(['144204426', '170465294', '29215002', '56422226', '855657'],
      dtype=object)), ('chEBI', array(['31483'], dtype=object))]",,"{'rows': array(['EFO_0000701'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977 and is indicated for skin disease.
CHEMBL1201780,NC(=O)N[C@@H](CCC(=O)O)C(=O)O,LCQLHJZYVOQKHU-VKHMYHEASA-N,Small molecule,False,CARGLUMIC ACID,2010.0,4.0,,False,True,['Carbaglu' 'Ucedane'],"['Carglumic acid' 'N-carbamyl-l-glutamic acid' 'NSC-760124' 'OE 312'
 'OE 312 (LABORATORY CODE DESIGNATION)' 'OE-312']","[('DailyMed', array(['carglumic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ucedane'],
      dtype=object)), ('PubChem', array(['144206097', '170466164'], dtype=object)), ('Wikipedia', array(['Carglumic_acid'], dtype=object)), ('drugbank', array(['DB06775'], dtype=object)), ('chEBI', array(['71028'], dtype=object))]",,"{'rows': array(['MONDO_0011628', 'Orphanet_927', 'MONDO_0019052', 'HP_0001987',
       'MONDO_0004736'], dtype=object), 'count': 5}",[ENSG00000021826],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 2 investigational indications.
CHEMBL1213252,O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,XDDJGVMJFWAHJX-UHFFFAOYSA-N,Small molecule,True,CLORAZEPIC ACID,1972.0,4.0,,False,True,[],"['4306-CB FREE ACID' 'ABBOTT-35616 FREE ACID' 'Chlorazepate' 'Clorazepate'
 'Clorazepic acid']","[('drugbank', array(['DB00628'], dtype=object)), ('chEBI', array(['3761'], dtype=object))]",['CHEMBL2096631' 'CHEMBL2106085'],"{'rows': array(['HP_0001250', 'EFO_0006788', 'EFO_0005230'], dtype=object), 'count': 3}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for seizure and anxiety disorder and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1743039,,,Antibody,False,MAVRILIMUMAB,,2.0,,False,False,[],['CAM-3001' 'CAM3001' 'KPL-301' 'Mavrilimumab'],,,"{'rows': array(['EFO_0000685', 'MONDO_0100096', 'EFO_1001209'], dtype=object), 'count': 3}","[ENSG00000198223,ENSG00000292357,ENSG00000100368]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1908391,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,WJEOLQLKVOPQFV-UHFFFAOYSA-N,Small molecule,False,MASITINIB,2008.0,4.0,,False,True,['Kinavet' 'Masivet'],['AB-1010' 'AB1010' 'Ab-1010' 'Masican' 'Masitinib' 'Masiviera'],"[('PubChem', array(['124950163', '99460877'], dtype=object)), ('drugbank', array(['DB11526'], dtype=object)), ('chEBI', array(['63450'], dtype=object))]",['CHEMBL5315058'],"{'rows': array(['EFO_0002618', 'EFO_0002617', 'MONDO_0004975', 'MONDO_0004979',
       'MONDO_0100096', 'EFO_0000616', 'MONDO_0008315', 'MONDO_0008170',
       'EFO_0003840', 'EFO_0000685', 'EFO_0009001', 'EFO_0001378',
       'MONDO_0011719', 'MONDO_0004976', 'EFO_0000676', 'MONDO_0016586',
       'MONDO_0005301'], dtype=object), 'count': 17}","[ENSG00000068078,ENSG00000157404,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for neoplasm and has 16 investigational indications.
CHEMBL2103810,CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1.Cl,XJDYQYNYISTAMO-GFDYFVENSA-N,Small molecule,False,EZATIOSTAT HYDROCHLORIDE,,2.0,CHEMBL2110585,False,False,['Telintra'],"['Ezatiostat hcl' 'Ezatiostat hydrochloride' 'TER-199' 'TER199'
 'TLK-199 HYDROCHLORIDE' 'TLK199']",,,"{'rows': array(['MONDO_0001475', 'EFO_0000198'], dtype=object), 'count': 2}",[ENSG00000084207],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108985,,,Oligonucleotide,False,APRINOCARSEN SODIUM,,-1.0,,False,False,[],"['Aprinocarsen nonadecasodium salt' 'Aprinocarsen sodium' 'ISIS 5321'
 'ISIS-5321']",,,,[ENSG00000154229],Oligonucleotide drug.
CHEMBL2146110,Cl.Fc1ccc(-c2cncc(CNC[C@H]3CCc4ccccc4O3)c2)cc1,QDLVYMYXOLGZOD-ZMBIFBSDSA-N,Small molecule,False,SARIZOTAN HYDROCHLORIDE,,3.0,CHEMBL220808,False,False,[],"['EMD 128130' 'EMD-128130' 'Emd128130' 'Sarizotan hcl'
 'Sarizotan hydrochloride']",,,"{'rows': array(['MONDO_0005180', 'EFO_0004280'], dtype=object), 'count': 2}","[ENSG00000149295,ENSG00000069696,ENSG00000151577,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3301618,CCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1,QSPOQCXMGPDIHI-UHFFFAOYSA-N,Small molecule,False,MOTOLIMOD,,2.0,,False,False,[],['Motolimod' 'VTX-2337' 'VTX-378'],"[('drugbank', array(['DB12303'], dtype=object))]",,"{'rows': array(['EFO_0007535', 'EFO_0000707', 'MONDO_0044926', 'MONDO_0008170',
       'EFO_0002938', 'EFO_0006352', 'EFO_0000574', 'MONDO_0002158',
       'EFO_0000181', 'EFO_0003871'], dtype=object), 'count': 10}",[ENSG00000101916],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL3544968,,,Small molecule,False,GSK-610677,,1.0,,False,False,[],['Gsk-610677'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL44657,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,VJJPUSNTGOMMGY-MRVIYFEKSA-N,Small molecule,True,ETOPOSIDE,1983.0,4.0,,False,True,['Etoposide' 'Toposar' 'Vepesid'],"['Etoposide' 'Etoposide resolution mixture' 'Etoposidum' 'NSC-141540'
 'Sintopozid' 'VP-16-213']","[('DailyMed', array(['etoposide'], dtype=object)), ('PubChem', array(['164339423', '56463308'], dtype=object)), ('TG-GATEs', array(['131'], dtype=object)), ('Wikipedia', array(['Etoposide'], dtype=object)), ('drugbank', array(['DB00773'], dtype=object)), ('chEBI', array(['4911'], dtype=object))]",,"{'rows': array(['EFO_0008524', 'EFO_0005235', 'EFO_0000191', 'EFO_0000094',
       'EFO_0009441', 'EFO_0003811', 'MONDO_0002158', 'MONDO_0004992',
       'MONDO_0015760', 'MONDO_0001475', 'EFO_1000437', 'MONDO_0016717',
       'EFO_0000502', 'EFO_0000621', 'EFO_0003025', 'EFO_0000221',
       'EFO_1000564', 'MONDO_0002601', 'EFO_0005952', 'EFO_0004281',
       'MONDO_0013730', 'EFO_0000209', 'MONDO_0006058', 'EFO_0000637',
       'EFO_0000223', 'EFO_0003802', 'EFO_0000211', 'MONDO_0021657',
       'MONDO_0019472', 'EFO_0006475', 'EFO_0000180', 'EFO_0000616',
       'EFO_0004289', 'MONDO_0021193', 'MONDO_0001056', 'MONDO_0002367',
       'MONDO_0005575', 'EFO_1001052', 'EFO_0000558', 'EFO_0000174',
       'MONDO_0018906', 'MONDO_0008380', 'EFO_0004256', 'EFO_1000574',
       'EFO_0000702', 'MONDO_0008170', 'EFO_0000095', 'EFO_0000313',
       'EFO_0000632', 'MONDO_0020077', 'MONDO_0009348', 'EFO_0000248',
       'EFO_0000630', 'EFO_1001469', 'EFO_0000198', 'EFO_0000220',
       'EFO_1001365', 'MONDO_0003478', 'HP_0001871', 'MONDO_0003001',
       'EFO_0000519', 'EFO_1001465', 'EFO_0007362', 'EFO_0003032',
       'EFO_0003060', 'MONDO_0002087', 'EFO_1001383', 'EFO_1001968',
       'EFO_1000581', 'EFO_0003027', 'MONDO_0016691', 'EFO_0004251',
       'MONDO_0003751', 'EFO_0003028', 'EFO_0007416', 'MONDO_0015540',
       'EFO_0000437', 'MONDO_0024503', 'MONDO_0044917', 'EFO_0007498',
       'EFO_0000309', 'EFO_1000292', 'EFO_0000339', 'EFO_0003833',
       'MONDO_0002730', 'MONDO_0004095', 'MONDO_0019004', 'MONDO_0000870',
       'EFO_0000514', 'EFO_0000691', 'EFO_1000415', 'MONDO_0000873',
       'EFO_0002626', 'EFO_0001061', 'EFO_0004991', 'EFO_0002618',
       'MONDO_0015564', 'EFO_0000182', 'MONDO_0016700', 'EFO_0003029',
       'EFO_0009538', 'EFO_0004599', 'EFO_1001779', 'EFO_0000222',
       'MONDO_0002120', 'EFO_1000026', 'MONDO_0001657', 'MONDO_0100096',
       'MONDO_0044881', 'MONDO_0008903', 'EFO_0009254', 'MONDO_0007254',
       'EFO_1000796', 'EFO_0003929', 'EFO_0000565', 'EFO_0000218',
       'EFO_0000183', 'MONDO_0018944', 'EFO_1000028', 'MONDO_0021364',
       'EFO_0005088', 'EFO_1001471', 'EFO_0000574', 'EFO_0002939',
       'EFO_0001378', 'EFO_0005543', 'EFO_0002499', 'EFO_0002918',
       'EFO_0000571', 'EFO_0000403', 'MONDO_0019471', 'EFO_0002501',
       'EFO_0002428', 'EFO_0000765', 'EFO_0000708', 'MONDO_0008315',
       'EFO_1000158', 'EFO_0000096'], dtype=object), 'count': 138}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 133 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4594598,,,Unknown,False,EFTRENONACOG ALFA,2016.0,4.0,,False,True,['Alprolix'],['Alprolix' 'BIIB-029' 'Eftrenonacog alfa' 'Rfixfc'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alprolix'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604', 'MONDO_0018660'], dtype=object), 'count': 2}",[ENSG00000101981],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for hemophilia b and has 1 investigational indication.
CHEMBL5314551,,,Antibody,False,ADAKITUG,,2.0,,False,False,[],"['A33 124i' 'Adakitug' 'BMS-986253' 'BMS-986253-01' 'BMS986253'
 'Bms 986253' 'HuMax-IL8' 'Humax-il-8' 'Humax-il8' 'Humax-inflam'
 'MDX-018' 'aIL8']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ADAKITUG/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_1001950', 'MONDO_0004992', 'EFO_0002618',
       'EFO_0000181', 'EFO_0000756', 'EFO_0000198', 'EFO_0000673',
       'EFO_0000182', 'EFO_0000616'], dtype=object), 'count': 10}",[ENSG00000169429],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL544665,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl,SWZTYAVBMYWFGS-UHFFFAOYSA-N,Small molecule,False,FINGOLIMOD HYDROCHLORIDE,2010.0,4.0,CHEMBL314854,False,True,['Gilenya'],"['FTY-720 HYDROCHLORIDE' 'FTY720' 'FTY720 HYDROCHLORIDE'
 'Fingolimod (as hydrochloride)' 'Fingolimod hcl'
 'Fingolimod hydrochlorid' 'Fingolimod hydrochloride' 'Gilenia']","[('DailyMed', array(['fingolimod%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya'],
      dtype=object)), ('chEBI', array(['63112'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'MONDO_0004976', 'EFO_0000305', 'MONDO_0005301'],
      dtype=object), 'count': 4}","[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for multiple sclerosis and has 3 investigational indications.
CHEMBL648,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,UVKZSORBKUEBAZ-UHFFFAOYSA-N,Small molecule,False,CYCLIZINE,1982.0,4.0,,False,True,[],['Cyclizine' 'Marezine' 'NSC-26608'],"[('PubChem', array(['11112316', '124882239', '26747952'], dtype=object)), ('Wikipedia', array(['Cyclizine'], dtype=object)), ('drugbank', array(['DB01176'], dtype=object)), ('chEBI', array(['3994'], dtype=object))]",['CHEMBL1324714' 'CHEMBL3189137' 'CHEMBL1200497'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease.
CHEMBL989,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,FEBLZLNTKCEFIT-VSXGLTOVSA-N,Small molecule,False,FLUOCINOLONE ACETONIDE,1963.0,4.0,,False,True,"['Capex' 'Derma-smoothe/fs' 'Dermotic' 'Fluocet' 'Fluocinolone acetonide'
 'Fluonid' 'Fluotrex' 'Iluvien' 'Retisert' 'Synalar' 'Synalar fte'
 'Synalar-c' 'Synalar-hp' 'Synalar-n' 'Synandone' 'Yutiq']","['Flucinolone acetonide' 'Fluocinolide (acetate)' 'Fluocinolone'
 'Fluocinolone acetonide' 'NSC-92339' 'Oto-synalar']","[('DailyMed', array(['fluocinolone%20acetonide'], dtype=object)), ('PubChem', array(['144204420', '144212681', '170464630', '29214997', '398387',
       '56422130', '855535'], dtype=object)), ('Wikipedia', array(['Fluocinolone_acetonide'], dtype=object)), ('drugbank', array(['DB00591'], dtype=object)), ('chEBI', array(['31623'], dtype=object))]",,"{'rows': array(['EFO_1000764', 'EFO_0009560', 'EFO_0005741', 'EFO_0009552',
       'EFO_0000701', 'EFO_1000986', 'EFO_1000811', 'EFO_0000274',
       'EFO_1001119', 'EFO_0003963', 'EFO_0000676', 'EFO_1001231',
       'EFO_0005752', 'MONDO_0005041', 'MONDO_0003005', 'EFO_0009606',
       'EFO_0003839', 'EFO_0001365'], dtype=object), 'count': 18}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 10 approved and 8 investigational indications.
CHEMBL1200749,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl,SIEYLFHKZGLBNX-NTISSMGPSA-N,Small molecule,False,LEVOBUPIVACAINE HYDROCHLORIDE,1999.0,4.0,CHEMBL1201193,False,True,['Chirocaine' 'Levobupivac'],"['Bupivacaine (-)-form hydrochloride' 'CHIROCAINE' 'Levobupivacaine hcl'
 'Levobupivacaine hydrochloride']","[('PubChem', array(['144205259', '170465452'], dtype=object)), ('chEBI', array(['31772'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0002950'], dtype=object), 'count': 2}",[ENSG00000007314],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 2 investigational indications.
CHEMBL1201565,,,Protein,False,EPOETIN ALFA,1989.0,4.0,,False,True,['Abseamed' 'Binocrit' 'Epogen' 'Eprex' 'Procrit'],"['EPO' 'Epoetin' 'Epoetin alfa' 'Erythropoietin'
 'Erythropoietin for bioassays']","[('DailyMed', array(['epoetin%20alfa-epbx'], dtype=object)), ('DrugCentral', array(['4995'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/abseamed'],
      dtype=object)), ('Wikipedia', array(['Epoetin_alfa'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_0003884', 'EFO_0000764', 'HP_0012378',
       'EFO_0003047', 'EFO_0000612', 'MONDO_0007254', 'EFO_0009492',
       'EFO_0003917', 'EFO_1001459', 'EFO_0002618', 'EFO_0001645',
       'EFO_0004272', 'EFO_0003100', 'MONDO_0004992', 'EFO_0001663',
       'EFO_1001100', 'MONDO_0011382', 'EFO_0006859', 'EFO_1001779',
       'MONDO_0100339', 'MONDO_0043510', 'MONDO_0002280', 'EFO_0009909',
       'EFO_0001416', 'EFO_0000712', 'MONDO_0008903', 'MONDO_0001240',
       'EFO_0000198', 'Orphanet_848', 'EFO_0003890', 'EFO_0008585',
       'MONDO_0005299', 'EFO_0000222', 'EFO_0009446', 'HP_0004936'],
      dtype=object), 'count': 36}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 5 approved and 31 investigational indications.
CHEMBL1263,OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,GIIZNNXWQWCKIB-UHFFFAOYSA-N,Small molecule,True,SALMETEROL,1994.0,4.0,,False,True,['Beglan' 'Neovent' 'Serevent' 'Soltel' 'Vertine'],"['Cryogenine' 'GR 33343 X' 'GR-33343-X' 'GR-33343X' 'NSC-272693' 'SN408D'
 'Salmaterol' 'Salmeterol' 'Serevent']","[('PubChem', array(['144207133', '26719802'], dtype=object)), ('Wikipedia', array(['Salmeterol'], dtype=object)), ('drugbank', array(['DB00938'], dtype=object)), ('chEBI', array(['64064'], dtype=object))]",['CHEMBL3126379' 'CHEMBL1082607'],"{'rows': array(['MONDO_0004979', 'EFO_0001073', 'EFO_1001919', 'EFO_0006505',
       'HP_0006536', 'EFO_0000341', 'EFO_0000464', 'MONDO_0004979',
       'EFO_0006505', 'EFO_0007183', 'EFO_0000341', 'EFO_0000464'],
      dtype=object), 'count': 12}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1364551,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1.Cl.Cl,GNUCGROXDZMCJI-UHFFFAOYSA-N,Small molecule,False,MINAPRINE HYDROCHLORIDE,,4.0,CHEMBL278819,True,True,['Cantor'],"['30038-CB' '30038CB' 'Minaprine dihydrochloride' 'Minaprine hcl'
 'Minaprine hydrochloride' 'NSC-305742']","[('PubChem', array(['144204908', '170466172', '26748498'], dtype=object)), ('chEBI', array(['51040'], dtype=object))]",,,"[ENSG00000189221,ENSG00000149295,ENSG00000184845,ENSG00000168539,ENSG00000135914,ENSG00000102468,ENSG00000147246,ENSG00000087085]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1472,NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,XNSAINXGIQZQOO-SRVKXCTJSA-N,Protein,False,PROTIRELIN,1976.0,4.0,,False,True,['Thypinone' 'Thyrel trh' 'Trh-cambridge'],"['5-oxo-pro-his-pro-nh2' 'A-38579' 'ABBOTT-38579' 'Lopremone' 'NSC-760113'
 'Protirelin' 'Protirelin tartrate' 'Protirelin, synthetic' 'Relefact trh'
 'SYNTHETIC TRH' 'Synthetic TRH' 'Thyroid releasing hormone'
 'Thyroliberin' 'Thyrotropin releasing hormone'
 'Thyrotropin-releasing factor' 'Thyrotropin-releasing hormone']","[('PubChem', array(['144205492', '29216304'], dtype=object)), ('Wikipedia', array(['Thyrotropin-releasing_hormone'], dtype=object)), ('drugbank', array(['DB09421'], dtype=object)), ('chEBI', array(['35940'], dtype=object))]",,"{'rows': array(['EFO_1000637', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000174417],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 2 investigational indications.
CHEMBL1530428,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,AKUJBENLRBOFTD-RPRRAYFGSA-N,Small molecule,False,DEXAMETHASONE ACETATE,1973.0,4.0,,False,True,['Decadron-la' 'Dexamethasone acetate'],"['Dectancyl' 'Dexamethasone 21-acetate' 'Dexamethasone acetate'
 'Dexamethasone acetate anhydrous' 'Dexamethasone acetate monohydrate'
 'Dexamethasoni acetas' 'Dexamethasoni acetas monohydrate'
 'Fortecortin (crystal suspension)' 'NSC-39471']","[('PubChem', array(['144204050', '144206481', '170466872', '56423129', '855773'],
      dtype=object)), ('drugbank', array(['DB14649'], dtype=object)), ('chEBI', array(['4463'], dtype=object))]",,"{'rows': array(['EFO_0000565', 'EFO_0000574', 'EFO_0001378', 'EFO_1000652',
       'EFO_1001216'], dtype=object), 'count': 5}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 5 investigational indications.
CHEMBL1557,Cl.NCCc1ccc(O)c(O)c1,CTENFNNZBMHDDG-UHFFFAOYSA-N,Small molecule,False,DOPAMINE HYDROCHLORIDE,1974.0,4.0,CHEMBL59,False,True,"['Dopamin-Natterman' 'Dopamine hydrochloride' 'Dopmin' 'Dynatra'
 'Intropin' 'Sabax Dopamin' 'Selectajet']","['ASL-279' 'Cardiosteril' 'Dopamine hcl' 'Dopamine hydrochloride'
 'Dopamini hydrochloridum' 'Inotropin' 'NSC-169105' 'Tensamin']","[('DailyMed', array(['dopamine%20hydrochloride'], dtype=object)), ('PubChem', array(['11532883', '144208216', '26747527', '26747528', '50106387',
       '50106388', '56424030'], dtype=object))]",,"{'rows': array(['MONDO_0005180', 'EFO_0000612', 'EFO_0000373', 'EFO_1002048'],
      dtype=object), 'count': 4}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 3 approved and 1 investigational indication.
CHEMBL1795072,,,Protein,True,ZICONOTIDE ACETATE,2004.0,4.0,,False,True,['Prialt'],['Ziconotide acetate'],"[('DailyMed', array(['ziconotide%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/prialt'],
      dtype=object))]",,,[ENSG00000148408],Protein drug with a maximum clinical trial phase of IV that was first approved in 2004. This drug has a black box warning from the FDA.
CHEMBL2108672,,,Antibody drug conjugate,False,VORSETUZUMAB MAFODOTIN,,2.0,,False,False,['Sgn-75'],['SGN-75' 'Vorsetuzumab mafodotin'],,,"{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}",[ENSG00000125726],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109355,,,Antibody,False,DUSIGITUMAB,,2.0,,False,False,[],['Dusigitumab' 'MEDI-573' 'MEDI573'],,,"{'rows': array(['MONDO_0007254', 'MONDO_0004992', 'EFO_0000182'], dtype=object), 'count': 3}","[ENSG00000167244,ENSG00000017427]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2109447,,,Antibody,False,LYM-1,,3.0,,False,False,['Oncolym'],['LYM-1' 'Lym-1'],,,"{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}",[ENSG00000196126],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2109613,,,Antibody,False,PF-04236921,,2.0,,False,False,[],['PF 4236921' 'PF-04236921' 'PF-4236921' 'Pf-04236921'],,,"{'rows': array(['EFO_0000384', 'MONDO_0007915'], dtype=object), 'count': 2}",[ENSG00000136244],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109622,,,Antibody,False,PF-04605412,,1.0,,False,False,[],['PF-04605412' 'PF04605412' 'Pf 04605412' 'Pf-04605412'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000161638],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2110368,C/N=C(\NC)NCc1ccccc1.C/N=C(\NC)NCc1ccccc1.O=S(=O)(O)O,YTIJUXVIZLYQTB-UHFFFAOYSA-N,Small molecule,False,BETHANIDINE SULFATE,1982.0,4.0,CHEMBL1201260,False,True,['Bendogen' 'Esbatal' 'Tenathan'],"['BW-467-C-60' 'Betanidine sulfate' 'Betanidine sulphate'
 'Bethanidine sulfate' 'Bethanidine sulphate' 'NSC-106563']","[('chEBI', array(['31279'], dtype=object))]",,,[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL2151572,O=C(N[C@H]1CN2CCC1CC2)c1cc2cccc(Cl)c2s1,SSRDSYXGYPJKRR-ZDUSSCGKSA-N,Small molecule,False,ENCENICLINE,,3.0,,False,False,[],['EVP-6124' 'Encenicline' 'Evp-6124' 'MT-4666' 'MT4666'],"[('drugbank', array(['DB11726'], dtype=object))]",['CHEMBL3137323'],"{'rows': array(['HP_0000726', 'EFO_0005411', 'HP_0100543', 'EFO_0003086',
       'MONDO_0004975', 'MONDO_0005090', 'EFO_0001421', 'MONDO_0005090',
       'MONDO_0004975'], dtype=object), 'count': 9}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL240163,C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,XAGMUUZPGZWTRP-ZETCQYMHSA-N,Small molecule,False,PAZUFLOXACIN,,3.0,,False,False,[],['Pazufloxacin' 'T-3761'],"[('PubChem', array(['144206084', '170465985', '26719888', '49681761', '50112787'],
      dtype=object)), ('drugbank', array(['DB11774'], dtype=object))]",['CHEMBL3764913'],"{'rows': array(['EFO_0004992', 'EFO_0000771', 'EFO_1000829'], dtype=object), 'count': 3}","[ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3137352,,,Antibody,False,RALPANCIZUMAB,,2.0,,False,False,[],['PF-05335810' 'RN-317' 'RN317' 'Ralpancizumab'],,,"{'rows': array(['HP_0003124'], dtype=object), 'count': 1}",[ENSG00000169174],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3304485,CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1,DNHPDWGIXIMXSA-CXNSMIOJSA-N,Small molecule,True,TENAPANOR,2019.0,4.0,,False,True,[],['AZD-1722' 'KHK-7791' 'Khk7791' 'Tenapanor'],"[('drugbank', array(['DB11761'], dtype=object))]",['CHEMBL3301627'],"{'rows': array(['EFO_0003884', 'EFO_0000555', 'MONDO_0002203', 'HP_0002905',
       'EFO_0000555', 'HP_0002905', 'HP_0002019'], dtype=object), 'count': 7}",[ENSG00000066230],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL38380,O=S(=O)(c1cccc2cnccc12)N1CCCNCC1,NGOGFTYYXHNFQH-UHFFFAOYSA-N,Small molecule,False,FASUDIL,,3.0,,False,False,[],['AT 877' 'AT-877' 'Fasudil' 'HA 1077' 'HA-1077' 'NSC-759827' 'ZK-258594'],"[('PubChem', array(['103905389', '103905390', '104171358', '11113364', '124883255',
       '124883258', '124883259', '26751605', '92708292'], dtype=object)), ('Wikipedia', array(['Fasudil'], dtype=object)), ('drugbank', array(['DB08162'], dtype=object))]",['CHEMBL4459126' 'CHEMBL541388' 'CHEMBL4435188'],"{'rows': array(['MONDO_0004976', 'EFO_0000319', 'EFO_0000319', 'EFO_1001157',
       'EFO_0002615', 'EFO_1001158', 'HP_0000726'], dtype=object), 'count': 7}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL3989987,,,Oligonucleotide,False,PATISIRAN,,4.0,,False,True,[],['ALN-18328' 'ALN-TTR02' 'Genz-438027' 'Patisiran' 'SAR-438037'],,,"{'rows': array(['EFO_0004129', 'EFO_1000783', 'EFO_1001875'], dtype=object), 'count': 3}",[ENSG00000118271],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.
CHEMBL4594463,,,Antibody,False,AVDORALIMAB,,2.0,,False,False,[],"['Anti-c5ar-215' 'Avdoralimab' 'IPH-5401' 'Iph5401' 'NN-8210'
 'NNC-0215-0384']",,,"{'rows': array(['EFO_0000616', 'MONDO_0100096', 'EFO_0007187'], dtype=object), 'count': 3}",[ENSG00000197405],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL501,CC(N)Cc1ccccc1.O=S(=O)(O)O,SOFQDLYSFOWTJX-UHFFFAOYSA-N,Small molecule,True,AMPHETAMINE SULFATE,1960.0,4.0,CHEMBL405,False,True,['Amphetamine sulfate' 'Evekeo' 'Evekeo odt'],"['Amfetamine sulfate' 'Amfetamine sulphate' 'Amphetamine Sulfate'
 'Amphetamine sulfate' 'Astedin' 'Benzedrine' 'Dl-amphetamine sulfate'
 'Dl-amphetamine sulphate' 'NSC-170999']","[('DailyMed', array(['amphetamine%20sulfate'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'MONDO_0016158', 'EFO_0003888', 'EFO_0002610'],
      dtype=object), 'count': 4}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL5314386,Cc1c(O)ccc2c1OC[C@@H](c1ccc(O)cc1)[C@H]2c1ccc(O)cc1,QVCAATSEPLQVBX-FPOVZHCZSA-N,Small molecule,False,ME-344,,1.0,,False,False,[],['Me 344' 'Me-344'],,,"{'rows': array(['EFO_0000305', 'EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 3}","[ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL592445,CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,DWZAEMINVBZMHQ-UHFFFAOYSA-N,Small molecule,False,GEDATOLISIB,,3.0,,False,False,[],['Gedatolisib' 'PF-05212384' 'PKI-587'],"[('drugbank', array(['DB11896'], dtype=object))]",,"{'rows': array(['EFO_0000198', 'MONDO_0004992', 'EFO_0005537', 'EFO_0004230',
       'EFO_0003060', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000616'],
      dtype=object), 'count': 8}","[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL103,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,RJKFOVLPORLFTN-LEKSSAKUSA-N,Small molecule,True,PROGESTERONE,1976.0,4.0,,False,True,"['Crinone' 'Cyclogest' 'Endometrin' 'Gesterol' 'Lutigest' 'Milprosa'
 'Prochieve' 'Progesta-care' 'Progestasert' 'Progesterone' 'Progestin'
 'Prometrium' 'Regumate' 'Serenity for women' 'Syngestrone' 'Utrogestan']","['NSC-64377' 'NSC-9704' 'Progesterone' 'Progesterone, micronized'
 'Progesteronum' 'U 3672']","[('DailyMed', array(['progesterone'], dtype=object)), ('PubChem', array(['144206708', '144208990', '144210627', '17388760', '17389514',
       '26719639', '26751485', '26751486', '50104004', '50104005',
       '50104007', '56424141', '75083', '855688', '90340816'],
      dtype=object)), ('Wikipedia', array(['Progesterone'], dtype=object)), ('drugbank', array(['DB00396'], dtype=object)), ('chEBI', array(['17026'], dtype=object))]",,"{'rows': array(['HP_0000938', 'MONDO_0005351', 'MONDO_0005147', 'MONDO_0022394',
       'EFO_0010269', 'MP_0001914', 'EFO_1000623', 'EFO_0000731',
       'EFO_1000098', 'EFO_0000474', 'EFO_0005204', 'EFO_0002950',
       'EFO_0001645', 'EFO_0003869', 'EFO_0000400', 'EFO_0000180',
       'EFO_0007453', 'EFO_0000668', 'MONDO_0100096', 'MONDO_0007254',
       'EFO_0003917', 'MONDO_0004975', 'EFO_1000645', 'EFO_0004701',
       'EFO_0008560', 'EFO_0000537', 'MONDO_0011972', 'EFO_0007442',
       'EFO_0007191', 'EFO_1000985', 'EFO_0003768', 'EFO_0000660',
       'EFO_1001465', 'EFO_0000545', 'MONDO_0000831', 'MONDO_0043510',
       'MONDO_0011962', 'EFO_1001375', 'EFO_0003882', 'EFO_0001072',
       'GO_0042697', 'HP_0003124', 'EFO_0002610', 'EFO_0003893'],
      dtype=object), 'count': 44}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved and 41 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1189432,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,JBIMVDZLSHOPLA-LSCVHKIXSA-N,Small molecule,False,OLOPATADINE,1996.0,4.0,,False,True,['Opatanol'],['AL-4943A' 'Olopatadine'],"[('Wikipedia', array(['Olopatadine'], dtype=object)), ('drugbank', array(['DB00768'], dtype=object))]",['CHEMBL1719'],"{'rows': array(['EFO_0005854', 'EFO_1001417', 'EFO_0007141', 'EFO_0003956',
       'EFO_0005751', 'HP_0001742', 'HP_0000989', 'EFO_0003956',
       'EFO_0007141', 'EFO_0005854'], dtype=object), 'count': 10}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 4 investigational indications.
CHEMBL1200527,COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1,XXZSQOVSEBAPGS-UHFFFAOYSA-L,Small molecule,False,ATRACURIUM BESYLATE,1983.0,4.0,CHEMBL1360,False,True,"['Atracurium Besilate' 'Atracurium besylate'
 'Atracurium besylate preservative free' 'Tracrium'
 'Tracrium preservative free']","['Atracurium besilate' 'Atracurium besylate' 'Atracurium dibesylate'
 'BW 33A' 'BW-33A' 'NSC-760047']","[('DailyMed', array(['atracurium%20besylate'], dtype=object)), ('PubChem', array(['144204341', '174006843'], dtype=object)), ('drugbank', array(['DB00732'], dtype=object)), ('chEBI', array(['2915'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983.
CHEMBL1200775,CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,RGLRXNKKBLIBQS-XNHQSDQCSA-N,Protein,False,LEUPROLIDE ACETATE,1985.0,4.0,CHEMBL1201199,False,True,"['Carcinil' 'Eligard' 'Eligard kit' 'Fensolvi kit' 'Leuprolide acetate'
 'Leuprorelin' 'Lupron' 'Lupron Depot Ped' 'Lupron depot'
 'Lupron depot-ped' 'Lupron depot-ped kit' 'Lutrate depot kit' 'Viadur']","['A-43818' 'ABBOTT-43818' 'Carcinil' 'Enantone' 'Fensolvi' 'Leuplin'
 'Leuporelin acetate' 'Leuprolide acetate' 'Leuprolide monoacetate'
 'Leuprorelin acetate' 'Lucrin' 'Lupaneta' 'Lutrate depot' 'Prostap'
 'TAP-144' 'Tap-144-sr' 'Trenantone']","[('DailyMed', array(['leuprolide%20acetate'], dtype=object)), ('PubChem', array(['144207056'], dtype=object)), ('chEBI', array(['63597'], dtype=object))]",,"{'rows': array(['EFO_0009029', 'EFO_0001378', 'MONDO_0004975', 'EFO_0004248',
       'EFO_0005204', 'EFO_0000731', 'EFO_0000537', 'MONDO_0000088',
       'MONDO_0000521', 'EFO_0003869', 'EFO_1001469', 'MONDO_0007254',
       'MONDO_0008315', 'EFO_0000673', 'MONDO_0004992', 'EFO_0001073',
       'EFO_0000183', 'EFO_0001663', 'EFO_0001065', 'EFO_0000196',
       'HP_0100543', 'EFO_0007453'], dtype=object), 'count': 22}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 6 approved and 16 investigational indications.
CHEMBL1200975,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,SXYZQZLHAIHKKY-GSTUPEFVSA-N,Small molecule,False,CLOCORTOLONE PIVALATE,1977.0,4.0,,False,True,['Cloderm'],['Clocortolone 21-pivalate' 'Clocortolone pivalate' 'SH 863' 'SH-863'],"[('DailyMed', array(['clocortolone%20pivalate'], dtype=object)), ('PubChem', array(['144204183', '56463639'], dtype=object)), ('chEBI', array(['59583'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977.
CHEMBL1201655,,,Protein,False,INSULIN SUSP ISOPHANE PURIFIED BEEF,1980.0,4.0,,False,True,['Nph iletin ii'],['Insulin susp isophane purified beef'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1980.
CHEMBL18116,Cc1cccc(N2CC(CO)OC2=O)c1,MXUNKHLAEDCYJL-UHFFFAOYSA-N,Small molecule,False,TOLOXATONE,1984.0,4.0,,False,True,[],['Humoryl' 'Toloxatone'],"[('Wikipedia', array(['Toloxatone'], dtype=object)), ('drugbank', array(['DB09245'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}",[ENSG00000189221],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and has 1 investigational indication.
CHEMBL2105717,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,ONIQOQHATWINJY-UHFFFAOYSA-N,Small molecule,True,CABOZANTINIB,2012.0,4.0,,False,True,['Cabometyx' 'Cometriq'],"['BMS-907351' 'BMS-907351 FREE BASE' 'Cabozantinib' 'XL-184'
 'XL-184 FREE BASE' 'XL184']","[('PubChem', array(['137276008'], dtype=object)), ('drugbank', array(['DB08875'], dtype=object)), ('chEBI', array(['72317'], dtype=object))]",['CHEMBL2103868'],"{'rows': array(['EFO_0000519', 'EFO_0001075', 'MONDO_0004992', 'EFO_0000501',
       'EFO_1001949', 'EFO_0000640', 'EFO_0001421', 'EFO_0003968',
       'EFO_0000239', 'EFO_0000640', 'EFO_0000313', 'EFO_0000616',
       'EFO_1001512', 'EFO_0007532', 'EFO_0000681', 'EFO_0003060',
       'MONDO_0007254', 'EFO_1001968', 'MONDO_0002974', 'EFO_0003060',
       'EFO_0005220', 'EFO_1001951', 'EFO_0000326', 'EFO_0000272',
       'EFO_0000616', 'EFO_0000673', 'EFO_1000796', 'EFO_1001465',
       'EFO_0000389', 'MONDO_0002120', 'MONDO_0002108', 'EFO_0000182',
       'EFO_0004243', 'EFO_0002618', 'EFO_1000251', 'EFO_0000305',
       'EFO_1000657', 'MONDO_0011719', 'EFO_0004252', 'EFO_0008528',
       'EFO_0000349', 'EFO_0000641', 'EFO_0000222', 'EFO_0002617',
       'EFO_1000613', 'MONDO_0001187', 'MONDO_0004669', 'EFO_0000637',
       'EFO_0000519', 'EFO_1001465', 'EFO_0003016', 'EFO_0000756',
       'EFO_0000641', 'EFO_0000182', 'EFO_0002892', 'EFO_0001378',
       'MONDO_0008315', 'MONDO_0002108', 'EFO_0000637', 'MONDO_0004986',
       'EFO_0000707', 'EFO_0000349', 'MONDO_0002367', 'EFO_0000681',
       'MONDO_0016642', 'MONDO_0004992', 'EFO_0000501', 'EFO_0003863',
       'EFO_0000335', 'EFO_0008524', 'EFO_0000673', 'EFO_1001901',
       'EFO_0002499', 'MONDO_0015277', 'EFO_1001961'], dtype=object), 'count': 75}","[ENSG00000105976,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 9 approved and 61 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108713,,,Antibody,False,IODINE I 124 GIRENTUXIMAB,,3.0,,False,False,['Redectane'],"['124ICG250' 'Girentuximab i-124' 'Girentuximab iodine-124'
 'Iodine (124i) girentuximab' 'Iodine i 124 girentuximab' 'cG250 (124I)']",,,,[ENSG00000107159],Antibody drug with a maximum clinical trial phase of III.
CHEMBL2110732,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,LVXJQMNHJWSHET-AATRIKPKSA-N,Small molecule,False,DACOMITINIB ANHYDROUS,2018.0,4.0,,False,True,[],['Dacomitinib anhydrous' 'Pf-00299804'],"[('drugbank', array(['DB11963'], dtype=object))]",['CHEMBL2105719'],"{'rows': array(['MONDO_0008903', 'EFO_0000616', 'MONDO_0008903', 'EFO_0003060',
       'EFO_0004284', 'MONDO_0001657', 'EFO_1001951', 'EFO_0009708',
       'MONDO_0004992', 'EFO_0000707', 'EFO_0000181', 'EFO_0000519',
       'EFO_0000616', 'EFO_0003833', 'EFO_1001094', 'EFO_0000313',
       'EFO_0001421', 'EFO_0003060', 'EFO_0000181', 'EFO_0005570'],
      dtype=object), 'count': 20}","[ENSG00000146648,ENSG00000141736,ENSG00000178568]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 16 investigational indications.
CHEMBL2219418,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5,XNKCCCKFOQNXKV-ZRSCBOBOSA-N,Small molecule,False,NALOXEGOL,2014.0,4.0,,False,True,['Moventig'],['AZ-13337019' 'NKTR-118' 'Naloxegol'],"[('drugbank', array(['DB09049'], dtype=object)), ('chEBI', array(['82975'], dtype=object))]",['CHEMBL2219416'],"{'rows': array(['HP_0002019', 'MONDO_0002203', 'MONDO_0043510', 'EFO_0005611',
       'EFO_0003060', 'EFO_0005611', 'HP_0002019', 'MONDO_0004567',
       'EFO_0003843'], dtype=object), 'count': 9}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 4 investigational indications.
CHEMBL296419,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,GXDALQBWZGODGZ-UHFFFAOYSA-N,Small molecule,False,ASTEMIZOLE,1988.0,4.0,,True,True,['Hismanal' 'Pollon-eze'],"['Astemizole' 'GNF-Pf-2461' 'NSC-329963' 'NSC-759570' 'R 43,512']","[('PubChem', array(['104171329', '11112828', '124882660', '124882662', '144204231',
       '144207293', '170465888', '26746979', '26751496', '26751497',
       '56422418', '855746'], dtype=object)), ('Wikipedia', array(['Astemizole'], dtype=object)), ('drugbank', array(['DB00637'], dtype=object)), ('chEBI', array(['2896'], dtype=object))]",['CHEMBL1788122'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and is indicated for allergic disease. It was withdrawn in at least one region.
CHEMBL304087,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,JBPUGFODGPKTDW-SFHVURJKSA-N,Small molecule,False,MERIMEPODIB,,2.0,,False,False,[],"['Merimepodib' 'VI-21,497' 'VI-21497' 'VX-497']","[('drugbank', array(['DB04862'], dtype=object))]",,"{'rows': array(['MONDO_0100096'], dtype=object), 'count': 1}",[ENSG00000106348],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3087515,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1,ZFPZEYHRWGMJCV-ZHALLVOQSA-N,Small molecule,False,MAVOGLURANT,,2.0,,False,False,[],['AFQ-056' 'AFQ056' 'Mavoglurant'],"[('drugbank', array(['DB13004'], dtype=object))]",,"{'rows': array(['MONDO_0007739', 'EFO_0001421', 'EFO_0002610', 'EFO_0004329',
       'MONDO_0007079', 'EFO_0003086', 'MONDO_0010383', 'EFO_0004242',
       'EFO_0004152', 'MONDO_0005180', 'EFO_0003948'], dtype=object), 'count': 11}",[ENSG00000168959],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.
CHEMBL314854,CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,KKGQTZUTZRNORY-UHFFFAOYSA-N,Small molecule,False,FINGOLIMOD,2010.0,4.0,,False,True,['Gilenya'],['FTY-720' 'Fingolimod'],"[('Wikipedia', array(['Fingolimod'], dtype=object)), ('drugbank', array(['DB08868'], dtype=object)), ('chEBI', array(['63115'], dtype=object))]",['CHEMBL5095050' 'CHEMBL544665' 'CHEMBL3526818'],"{'rows': array(['EFO_0008520', 'EFO_0000540', 'EFO_0002499', 'EFO_1000868',
       'MONDO_0010726', 'HP_0000083', 'MONDO_0005090', 'EFO_1001231',
       'MONDO_0004979', 'EFO_0000712', 'EFO_0007405', 'MONDO_0100096',
       'EFO_0003840', 'EFO_0003929', 'EFO_0000519', 'MONDO_0004976',
       'MONDO_0005301', 'EFO_0000305', 'EFO_0003929', 'MONDO_0005301'],
      dtype=object), 'count': 20}","[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for immune system disease and multiple sclerosis and has 18 investigational indications.
CHEMBL3545262,,,Antibody drug conjugate,True,SACITUZUMAB GOVITECAN,2020.0,4.0,,False,True,['Trodelvy'],"['HRS7-SN38' 'HRS7-SN38-ANTIBODY-DRUG-CONJUGATE' 'IMMU-132'
 'Sacituzumab govitecan' 'Sacituzumab govitecan hziy']","[('DailyMed', array(['sacituzumab%20govitecan-hziy'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy'],
      dtype=object))]",,"{'rows': array(['EFO_0000519', 'EFO_0003863', 'MONDO_0004986', 'MONDO_0004992',
       'MONDO_0007254', 'EFO_0008528', 'EFO_1001512', 'EFO_0005537',
       'EFO_0003869', 'EFO_0000702', 'MONDO_0008315', 'EFO_0003060',
       'EFO_0000616', 'MONDO_0004669', 'MONDO_0001187', 'MONDO_0002974'],
      dtype=object), 'count': 16}","[ENSG00000184292,ENSG00000198900]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 5 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3597971,Cc1cc(C)nc(N2CC3CN(C(=O)c4c(F)cccc4-n4nccn4)CC3C2)n1,SQOCEMCKYDVLMM-UHFFFAOYSA-N,Small molecule,False,SELTOREXANT,,3.0,,False,False,[],['JNJ-42847922' 'MIN-202' 'Seltorexant'],,['CHEMBL4780973'],"{'rows': array(['EFO_0003086', 'EFO_0004698', 'MONDO_0004975', 'MONDO_0002009',
       'EFO_0003918', 'EFO_0001421'], dtype=object), 'count': 6}",[ENSG00000137252],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4297905,,,Antibody,False,OSOCIMAB,,2.0,,False,False,[],['BAY 1213790' 'BAY-1213790' 'Bay1213790' 'Osocimab'],,,,[ENSG00000088926],Antibody drug with a maximum clinical trial phase of II.
CHEMBL4594230,,,Protein,False,LIPEGFILGRASTIM,2013.0,4.0,,False,True,['Lonquex'],['Lipegfilgrastim' 'XM-22' 'XM22'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000174', 'EFO_0000574', 'MONDO_0001475'],
      dtype=object), 'count': 4}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for neoplasm and neutropenia and has 2 investigational indications.
CHEMBL4594287,COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2,CSOBIBXVIYAXFM-BYNJWEBRSA-N,Small molecule,False,ENSIFENTRINE,,3.0,,False,False,[],"['Ensifentrine' 'Ls-193,855' 'Ls-193855' 'RPL-554' 'RPL554']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENSIFENTRINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0000341', 'MONDO_0009061', 'MONDO_0004979'],
      dtype=object), 'count': 4}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4650470,,,Protein,False,EFPEGLENATIDE,,3.0,,False,False,[],"['Efpeglenatide' 'HM-11260C' 'HM11260C' 'Hm11260c' 'Langlenatide'
 'SAR-439977' 'SAR439977']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EFPEGLENATIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0001073', 'EFO_0000400'], dtype=object), 'count': 3}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL469,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,OZWKMVRBQXNZKK-UHFFFAOYSA-N,Small molecule,True,KETOROLAC,1989.0,4.0,,False,True,[],['Ketorolac'],"[('PubChem', array(['174007295', '90341692'], dtype=object)), ('Wikipedia', array(['Ketorolac'], dtype=object)), ('drugbank', array(['DB00465'], dtype=object)), ('chEBI', array(['76223'], dtype=object))]",['CHEMBL1201124'],"{'rows': array(['EFO_0003777', 'EFO_0005755', 'EFO_0003869', 'HP_0003418',
       'HP_0011110', 'EFO_1001178', 'EFO_0003843', 'EFO_0008571',
       'EFO_1001250', 'HP_0002315', 'EFO_0000649', 'MONDO_0003005',
       'EFO_0000668', 'EFO_0004616', 'EFO_1001158', 'MP_0001845',
       'HP_0200026', 'EFO_0000546', 'EFO_0009676', 'HP_0002015',
       'EFO_1001412', 'EFO_0004273', 'EFO_0003843', 'MONDO_0005277',
       'MONDO_0005129', 'HP_0002027', 'MONDO_0005184', 'EFO_1000859',
       'EFO_1001139', 'MONDO_0005277', 'EFO_1001412', 'EFO_1000652',
       'HP_0012532', 'MP_0001845', 'EFO_0009444', 'HP_0003418',
       'MONDO_0002087', 'EFO_0005752', 'MONDO_0005129', 'HP_0000616',
       'EFO_0005854', 'MONDO_0008170', 'EFO_0004253', 'EFO_0003770',
       'EFO_0004253', 'MONDO_0002158', 'MONDO_0002367'], dtype=object), 'count': 47}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 6 approved and 39 investigational indications. This drug has a black box warning from the FDA.
CHEMBL505,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,SOYKEARSMXGVTM-UHFFFAOYSA-N,Small molecule,False,CHLORPHENIRAMINE,1950.0,4.0,,False,True,[],"['Antagonate' 'Chlor-Trimeton' 'Chlorphenamine' 'Chlorpheniramine'
 'Isoclor' 'Kloromin' 'Phenetron' 'Teldrin']","[('PubChem', array(['174006626', '174007153', '50110994', '90340572'], dtype=object)), ('TG-GATEs', array(['90'], dtype=object)), ('Wikipedia', array(['Chlorphenamine'], dtype=object)), ('drugbank', array(['DB01114'], dtype=object)), ('chEBI', array(['52010'], dtype=object))]",['CHEMBL1201659' 'CHEMBL180454' 'CHEMBL1659'],"{'rows': array(['EFO_0007328', 'EFO_0005854', 'MONDO_0005271', 'HP_0003418',
       'EFO_0003843', 'HP_0012735', 'HP_0002315', 'MONDO_0005271',
       'EFO_0007214', 'HP_0001742', 'HP_0001945', 'EFO_0003956',
       'EFO_0003956', 'MONDO_0002258', 'EFO_0003958', 'EFO_0007486',
       'EFO_0004239'], dtype=object), 'count': 17}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 12 approved and 4 investigational indications.
CHEMBL5314363,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl.Cl.O,BOQNMOQMVACUOG-BXUUEFRQSA-N,Small molecule,False,APOMORPHINE HYDROCHLORIDE,2001.0,4.0,CHEMBL53,False,True,"['Apo-go' 'Apo-go pen' 'Apo-go pfs' 'Apokyn' 'Apomorph hcl' 'Britaject'
 'Dacepton' 'Diagesil' 'Diamorph hcl' 'Diamorph roche'
 'Diamorph,cocaine,chlorpromazine' 'Diaphine' 'Kynmobi' 'Uprima']","['Apokinon' 'Apomine' 'Apomorphine hcl' 'Apomorphine hydrochloride'
 'Apomorphine hydrochloride hemihydrate'
 'Apomorphine hydrochloride hydrate' 'Apomorphinum muriaticum'
 'Diamorphine hydrochloride ' 'Ixense' 'Kw-6500' 'NSC-11442' 'NSC-755875'
 'Taluvian']","[('DailyMed', array(['apomorphine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/uprima'],
      dtype=object))]",,"{'rows': array(['HP_0000802', 'MONDO_0005180', 'EFO_0000616', 'EFO_0003882'],
      dtype=object), 'count': 4}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for impotence and parkinson disease and has 2 investigational indications.
CHEMBL761,c1ccc2c(CC3=NCCN3)cccc2c1,CNIIGCLFLJGOGP-UHFFFAOYSA-N,Small molecule,False,NAPHAZOLINE,1971.0,4.0,,False,True,[],['Nafazair' 'Nafazolin' 'Naphazoline'],"[('PubChem', array(['11112411', '26751615'], dtype=object)), ('Wikipedia', array(['Naphazoline'], dtype=object)), ('drugbank', array(['DB06711'], dtype=object))]",['CHEMBL1706'],"{'rows': array(['EFO_0007214', 'EFO_0000678', 'MP_0001845', 'EFO_0007141',
       'EFO_0000616', 'HP_0001742', 'EFO_0007328', 'EFO_0003822',
       'EFO_0003956', 'EFO_0005751', 'EFO_0007214', 'EFO_0007486',
       'HP_0001742'], dtype=object), 'count': 13}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 7 investigational indications.
CHEMBL878,Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C,AQCHWTWZEMGIFD-UHFFFAOYSA-N,Small molecule,False,METOLAZONE,1973.0,4.0,,False,True,['Diulo' 'Metenix' 'Metolazone' 'Mykrox' 'Xuret' 'Zaroxolyn'],"['Metazoline' 'Metolazone' 'Metozalone' 'NSC-759581' 'Normelan' 'Oldren'
 'SR 720-22' 'SR-720-22']","[('DailyMed', array(['metolazone'], dtype=object)), ('PubChem', array(['144203737', '144207075', '170464665', '26747536', '26747537',
       '26753589', '26753590', '56463247'], dtype=object)), ('Wikipedia', array(['Metolazone'], dtype=object)), ('drugbank', array(['DB00524'], dtype=object)), ('chEBI', array(['64354'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0003144', 'EFO_0003884', 'EFO_0000373',
       'EFO_0000537', 'EFO_0000668'], dtype=object), 'count': 6}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 5 approved and 1 investigational indication.
CHEMBL969,O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1,MWQCHHACWWAQLJ-UHFFFAOYSA-N,Small molecule,False,PRAZEPAM,1982.0,4.0,,False,True,['Centrax' 'Demetrin' 'Prazepam'],['NSC-277179' 'Prazepam' 'Prazepam civ' 'W 4020' 'W-4020'],"[('PubChem', array(['144206168', '144207274', '50113069'], dtype=object)), ('Wikipedia', array(['Prazepam'], dtype=object)), ('drugbank', array(['DB01588'], dtype=object)), ('chEBI', array(['8362'], dtype=object))]",,"{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for anxiety.
CHEMBL119385,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl,VEPKQEUBKLEPRA-UHFFFAOYSA-N,Small molecule,False,NEFLAMAPIMOD,,2.0,,False,False,[],"['745' 'Neflamapimod' 'VD-31' 'VD-31,745' 'VD-31745' 'VRT-031745' 'VX-745'
 'Vx-745']","[('PubChem', array(['103905630', '124950172', '174006470', '50100122'], dtype=object)), ('drugbank', array(['DB07138'], dtype=object)), ('chEBI', array(['90528'], dtype=object))]",,"{'rows': array(['HP_0000726', 'MONDO_0007739', 'HP_0100543', 'MONDO_0004975'],
      dtype=object), 'count': 4}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1200848,CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,DOMWKUIIPQCAJU-LJHIYBGHSA-N,Small molecule,False,HYDROXYPROGESTERONE CAPROATE,1975.0,4.0,,False,True,"['Delalutin' 'Hydroxyprogesterone caproate' 'Makena'
 'Makena (autoinjector)' 'Makena preservative free' 'Proluton depot']","['17-ohpc' '17.alpha.-caproyloxy-p4' 'Depo-proluton' 'Hormofort'
 'Hydroxyprogesterone' 'Hydroxyprogesterone caproate'
 'Hydroxyprogesterone hexanoate' 'Hylutin' 'NSC-17592'
 'Oxiprogesterone caproate' 'Pharlon' 'Primolut depot' 'Procyte depo'
 'Proge' 'Syngynon' 'Teralutil']","[('DailyMed', array(['hydroxyprogesterone%20caproate'], dtype=object)), ('PubChem', array(['144207051', '144212650', '170465210', '56424128', '855528'],
      dtype=object)), ('drugbank', array(['DB06789'], dtype=object)), ('chEBI', array(['5812'], dtype=object))]",['CHEMBL3526451'],"{'rows': array(['EFO_0002950', 'EFO_0003917'], dtype=object), 'count': 2}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and is indicated for premature birth and has 1 investigational indication.
CHEMBL1201421,,,Unknown,False,PEGAPTANIB SODIUM,2004.0,4.0,,False,True,['Macugen'],"['EYE-001' 'EYE001' 'EYEOO1' 'NX-1838' 'NX1838' 'Pegaptanib na'
 'Pegaptanib sodium']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/macugen'],
      dtype=object))]",,"{'rows': array(['MONDO_0007935', 'MONDO_0003005', 'EFO_1001157', 'EFO_0001365',
       'EFO_0004683', 'MONDO_0008667', 'EFO_0009606'], dtype=object), 'count': 7}",[ENSG00000112715],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for wet macular degeneration and has 6 investigational indications.
CHEMBL1252,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,AIWRTTMUVOZGPW-HSPKUQOVSA-N,Protein,True,ABARELIX,2003.0,4.0,,False,True,['Plenaxis'],['Abarelix' 'PPI-149' 'Plenaxis' 'R-382' 'R-3827' 'R382' 'R3827'],"[('Wikipedia', array(['Abarelix'], dtype=object)), ('drugbank', array(['DB00106'], dtype=object)), ('chEBI', array(['337298'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 2}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for neoplasm and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1502,COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,IQPSEEYGBUAQFF-UHFFFAOYSA-N,Small molecule,False,PANTOPRAZOLE,2000.0,4.0,,False,True,['Pantoloc control' 'Protium' 'Protium i.v.'],"['Altopan' 'BY 1023' 'BY-1023' 'BY1023' 'NSC-759257' 'Pantocid' 'Pantoloc'
 'Pantoprazole' 'Pantozol' 'Protonix' 'SK&F 96022' 'SK&F-96022' 'SK-96022'
 'SKF-96022' 'Zovanta']","[('PubChem', array(['144205030', '170466337', '174007264', '26749082'], dtype=object)), ('Wikipedia', array(['Pantoprazole'], dtype=object)), ('drugbank', array(['DB00213'], dtype=object)), ('chEBI', array(['7915'], dtype=object))]",['CHEMBL5307366' 'CHEMBL3989559'],"{'rows': array(['EFO_0003948', 'EFO_0000771', 'HP_0002239', 'MONDO_0008315',
       'EFO_0007549', 'MONDO_0043839', 'EFO_0000616', 'HP_0100633',
       'EFO_0007549', 'EFO_0009454', 'HP_0004398', 'MONDO_0005301',
       'EFO_0000400', 'EFO_0003948', 'EFO_1000961', 'EFO_0005672',
       'EFO_0004607', 'MONDO_0003523', 'MONDO_0005090', 'MONDO_0005148',
       'EFO_0007157', 'HP_0100633', 'MONDO_0005147', 'EFO_1001355',
       'Orphanet_79292', 'MP_0001914', 'EFO_0000280', 'EFO_0009544',
       'EFO_0000373'], dtype=object), 'count': 29}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 26 investigational indications.
CHEMBL1631540,Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1,ANGUXJDGJCHGOG-UHFFFAOYSA-N,Small molecule,False,GSK163090,,2.0,,False,False,[],['GSK163090' 'Gsk163090'],,['CHEMBL3215829'],"{'rows': array(['MONDO_0002050', 'MONDO_0002009'], dtype=object), 'count': 2}","[ENSG00000178394,ENSG00000108576,ENSG00000135312,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1743015,,,Antibody,False,ETROLIZUMAB,,3.0,,False,False,[],"['Anti-.beta.7' 'Anti-Beta7' 'Anti-Beta7 Pro145223' 'Etrolizumab'
 'PRO-145223' 'PRO145223' 'RG-7413' 'RHUMAB-BETA7' 'Rhumab .beta.7'
 'rhuMAb beta7']",,,"{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}",[ENSG00000139626],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1889140,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl,NDNSIBYYUOEUSV-RSAXXLAASA-N,Small molecule,False,ROPIVACAINE HYDROCHLORIDE,1996.0,4.0,CHEMBL1077896,False,True,['Naropin' 'Ropivacaine hydrochloride'],"['Ropivacaine hcl' 'Ropivacaine hydrochloride'
 'Ropivacaine hydrochloride hydrate'
 'Ropivacaine hydrochloride monohydrate']","[('DailyMed', array(['ropivacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205774', '170465120', '49681555'], dtype=object)), ('chEBI', array(['60803'], dtype=object))]",,"{'rows': array(['EFO_0009676', 'EFO_0003931', 'EFO_0003843', 'EFO_0006859',
       'HP_0000023', 'MONDO_0005178', 'HP_0001822'], dtype=object), 'count': 7}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for pain and has 6 investigational indications.
CHEMBL1911882,CN(CCCNCc1ccc2c(c1)OCO2)c1nc(-n2ccnc2)ns1,ZJFFPGMGWOEQLF-UHFFFAOYSA-N,Small molecule,False,KD7040,,2.0,,False,False,[],['Kd7040'],,,,[ENSG00000007171],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108296,,,Oligonucleotide,False,AGANIRSEN,,2.0,,False,False,[],['Aganirsen' 'Gs-101'],,,,[ENSG00000169047],Oligonucleotide drug with a maximum clinical trial phase of II.
CHEMBL217092,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,OUKYUETWWIPKQR-UHFFFAOYSA-N,Small molecule,False,SARACATINIB,,3.0,,False,False,[],['AZ-10353926' 'AZD-0530' 'AZD0530' 'Azd-0530' 'Saracatinib'],"[('PubChem', array(['137275842', '164339484'], dtype=object)), ('drugbank', array(['DB11805'], dtype=object))]",['CHEMBL2105677'],"{'rows': array(['EFO_0006861', 'EFO_0000637', 'MONDO_0021063', 'MONDO_0011705',
       'EFO_0000616', 'MONDO_0007606', 'EFO_0000365', 'MONDO_0008315',
       'MONDO_0002158', 'EFO_1000581', 'EFO_0002618', 'MONDO_0007254',
       'EFO_0004329', 'MONDO_0008170', 'MONDO_0007079', 'EFO_0003060',
       'MONDO_0004992', 'EFO_0000756', 'EFO_1000657', 'MONDO_0004975'],
      dtype=object), 'count': 20}","[ENSG00000097007,ENSG00000197122]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.
CHEMBL253371,CCN(CCCc1ccccc1)CCCc1ccccc1,ZPFXAOWNKLFJDN-UHFFFAOYSA-N,Small molecule,False,ALVERINE,,4.0,,False,True,[],['Alverine' 'Phenpropamine'],"[('PubChem', array(['50103849', '50104229', '50104230'], dtype=object)), ('Wikipedia', array(['Alverine'], dtype=object)), ('drugbank', array(['DB01616'], dtype=object)), ('chEBI', array(['518413'], dtype=object))]",['CHEMBL1408594'],"{'rows': array(['EFO_0010282', 'EFO_0000666'], dtype=object), 'count': 2}","[ENSG00000101076,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and has 1 investigational indication.
CHEMBL3039558,,,Small molecule,False,ETIRINOTECAN PEGOL,,3.0,,False,False,[],['Etirinotecan pegol' 'NKTR-102'],,,"{'rows': array(['MONDO_0004992', 'EFO_0002499', 'EFO_0002501', 'EFO_0003060',
       'EFO_0000519', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001951',
       'EFO_0000616'], dtype=object), 'count': 9}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL3182621,Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O,RWEVIPRMPFNTLO-UHFFFAOYSA-N,Small molecule,False,AZD-8330,,1.0,,False,False,[],['ARRY-424704' 'ARRY-704' 'AZD-8330' 'Azd 8330' 'Azd-8330' 'Azd8330'],"[('PubChem', array(['174006482'], dtype=object)), ('drugbank', array(['DB06061'], dtype=object))]",,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3260505,CCc1cnc(N2CCC(c3nc(COc4ccc(-n5cnnn5)cc4)cs3)CC2)nc1,NFTMKHWBOINJGM-UHFFFAOYSA-N,Small molecule,False,MBX-2982,,2.0,,False,False,[],['Mbx-2982'],"[('drugbank', array(['DB12345'], dtype=object))]",,"{'rows': array(['MONDO_0005147', 'EFO_0000400'], dtype=object), 'count': 2}",[ENSG00000147262],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL329123,CCCc1c(OCCCOc2cc(O)c(-c3ccc(F)cc3)cc2CC)cccc1Oc1ccccc1C(=O)O,YFIZRWPXUYFCSN-UHFFFAOYSA-N,Small molecule,False,ETALOCIB,,2.0,,False,False,[],"['Etalocib' 'LY-193111' 'LY-293111' 'LY293111' 'Ly-293111' 'Ly293111'
 'VML 295']","[('Wikipedia', array(['Etalocib'], dtype=object)), ('drugbank', array(['DB12850'], dtype=object))]",,"{'rows': array(['EFO_0002618', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}","[ENSG00000213903,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3544943,Cl.O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12,UNDKJUKLBNARIZ-UHFFFAOYSA-N,Small molecule,False,BMS-863233,,2.0,CHEMBL3544944,False,False,[],['Bms-863233' 'XL-413'],,,,[ENSG00000097046],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545384,,,Small molecule,False,SB-85635,,1.0,,False,False,[],['Sb-85635'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3559672,,,Unknown,False,RAUWOLFIA SERPENTINA,1954.0,4.0,,False,True,"['Hiwolfia' 'Hyserpin' 'Koglucoid' 'Raudixin' 'Rauserpin' 'Rauval'
 'Rauwolfia serpentina' 'Wolfina']","['Rauvolfia serpentina root' 'Rauwolfia alkaloids'
 'Rauwolfia alkaloids, whole root' 'Rauwolfia serpentina'
 'Rauwolfia serpentina alseroxylon']",,,"{'rows': array(['EFO_0003777', 'EFO_0000537'], dtype=object), 'count': 2}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for hypertension and has 1 investigational indication.
CHEMBL4475463,O=C(O)c1ccc2c(c1)CCCC(c1ccc(Cl)cc1Cl)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1,KISZAGQTIXIVAR-VWLOTQADSA-N,Small molecule,False,AMCENESTRANT,,3.0,,False,False,[],['Amcenestrant' 'SAR-439859' 'SAR439859' 'Sar439859'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMCENESTRANT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0003968', 'EFO_0005537', 'EFO_0003869'],
      dtype=object), 'count': 4}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4650323,C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1,KOEUOFPEZFUWRF-LJQANCHMSA-N,Small molecule,False,TOLEBRUTINIB,,3.0,,False,False,[],['PRN-2246' 'PRN2246' 'SAR-442168' 'SAR442168' 'Sar442168' 'Tolebrutinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOLEBRUTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0003086', 'EFO_0008520', 'EFO_0008522', 'MONDO_0005301'],
      dtype=object), 'count': 4}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL5315048,,,Protein,True,ZILUCOPLAN SODIUM,2023.0,4.0,,False,True,['Zilbrysq'],[],,,"{'rows': array(['EFO_0004991'], dtype=object), 'count': 1}",[ENSG00000106804],Protein drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for myasthenia gravis. This drug has a black box warning from the FDA.
CHEMBL605846,COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1,COUYJEVMBVSIHV-SFHVURJKSA-N,Small molecule,False,OLODATEROL,2014.0,4.0,,False,True,['Striverdi respimat'],['BI 1744' 'Olodaterol'],"[('Wikipedia', array(['Olodaterol'], dtype=object)), ('drugbank', array(['DB09080'], dtype=object)), ('chEBI', array(['82700'], dtype=object))]",['CHEMBL2105743'],"{'rows': array(['EFO_0006505', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000464',
       'HP_0006536', 'EFO_0001421', 'EFO_0000341'], dtype=object), 'count': 7}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 3 investigational indications.
CHEMBL94657,C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1,QXRSDHAAWVKZLJ-PVYNADRNSA-N,Small molecule,False,PATUPILONE,,3.0,,False,False,[],"['(-)-epothilone b' 'EPO 906' 'EPO 906A' 'EPO-906' 'EPO-906A' 'EPO906'
 'EPO906A' 'Epithilone b' 'Epo b' 'Epothilone b' 'GNF-PF-193' 'Patupilone']","[('PubChem', array(['50125842', '520207'], dtype=object)), ('drugbank', array(['DB03010'], dtype=object)), ('chEBI', array(['31550'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_0000182', 'EFO_0003865', 'EFO_0004243',
       'EFO_0000673', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0007254',
       'EFO_0003060', 'EFO_0003869', 'EFO_0000616', 'MONDO_0002158',
       'MONDO_0008315', 'EFO_0000519', 'EFO_0004288', 'EFO_1001100',
       'MONDO_0021063'], dtype=object), 'count': 17}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications.
CHEMBL1200400,Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[n-]c12.[Na+],WISNYKIQFMKSDQ-UHFFFAOYSA-N,Small molecule,True,AZATHIOPRINE SODIUM,1974.0,4.0,CHEMBL1542,False,True,['Azathioprine sodium' 'Imuran'],['Azathioprine sodium' 'Azathioprine sodium salt'],"[('DailyMed', array(['azathioprine%20sodium'], dtype=object))]",,,[ENSG00000128059],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974. This drug has a black box warning from the FDA.
CHEMBL1201051,CN/C(=N\CCSCc1nc[nH]c1C)NC#N.Cl,QJHCNBWLPSXHBL-UHFFFAOYSA-N,Small molecule,False,CIMETIDINE HYDROCHLORIDE,1977.0,4.0,CHEMBL30,False,True,['Cimetidine hydrochloride' 'Tagamet'],['Cimetidine hcl' 'Cimetidine hydrochloride'],"[('chEBI', array(['50362'], dtype=object))]",,,[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977.
CHEMBL1201245,CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1,NUNIWXHYABYXKF-UHFFFAOYSA-N,Small molecule,False,BROMODIPHENHYDRAMINE,1954.0,4.0,,False,True,[],"['4-bromodiphen hydramine' 'Bromazine' 'Bromodiphenhydramine' 'Deserol'
 'Histabromamine' 'Neo-benadryl']","[('PubChem', array(['170465292'], dtype=object)), ('Wikipedia', array(['Bromazine'], dtype=object)), ('drugbank', array(['DB01237'], dtype=object)), ('chEBI', array(['59177'], dtype=object))]",['CHEMBL1200967'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954 and is indicated for allergic disease.
CHEMBL1201775,C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1.Cl.Cl,RKSUYBCOVNCALL-NTVURLEBSA-N,Small molecule,False,SAPROPTERIN DIHYDROCHLORIDE,2007.0,4.0,CHEMBL1201774,False,True,['Kuvan' 'Sapropterin dipharma'],"['Biopten' 'Dapropterin hydrochloride' 'Phenoptin' 'SUN-0588'
 'SUN-0588 (SHIRATORI)' 'Sapropterin dihydrochloride'
 'Sapropterin hydrochloride' 'T-1401' 'T1401' 'T1401 (BIOMARIN)']","[('DailyMed', array(['sapropterin%20dihydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sapropterin-dipharma'],
      dtype=object)), ('PubChem', array(['144205335'], dtype=object)), ('chEBI', array(['32120'], dtype=object))]",,"{'rows': array(['EFO_0003876', 'MONDO_0005090', 'EFO_0000537', 'EFO_0001361',
       'EFO_0005411', 'MONDO_0011382', 'Orphanet_238583', 'MONDO_0009861',
       'EFO_0000181', 'EFO_0003884', 'EFO_0001645'], dtype=object), 'count': 11}",[ENSG00000171759],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hyperphenylalaninemia and phenylketonuria and has 9 investigational indications.
CHEMBL1523964,CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O,CAVQBDOACNULDN-KHFUBBAMSA-N,Small molecule,False,EPHEDRINE SULFATE,2016.0,4.0,CHEMBL211456,False,True,['Akovaz' 'Corphedra' 'Emerphed' 'Expansyl' 'Franol plus' 'Franol-plus'],['Ephedrine sulfate' 'Ephedrine sulphate' 'Ephedrini sulfas'],"[('DailyMed', array(['ephedrine%20sulfate'], dtype=object)), ('PubChem', array(['50106282'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0005251'], dtype=object), 'count': 2}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for asthma and hypotension.
CHEMBL1730601,Oc1cc(O)c(Cl)cn1,ZPLQIPFOCGIIHV-UHFFFAOYSA-N,Small molecule,False,GIMERACIL,,3.0,,False,False,[],['Gimeracil' 'Gimestat'],"[('PubChem', array(['144206214', '170466048', '50125750'], dtype=object)), ('drugbank', array(['DB09257'], dtype=object))]",,"{'rows': array(['EFO_0000503', 'EFO_1001951', 'EFO_0000182', 'MONDO_0007254',
       'EFO_0006859', 'MONDO_0003060', 'EFO_0000228', 'MONDO_0002974',
       'EFO_0003860', 'MONDO_0002120', 'EFO_0003086', 'EFO_0001421',
       'MONDO_0005184', 'EFO_0000702', 'EFO_0000365', 'MONDO_0001056',
       'EFO_0005922', 'EFO_0004142', 'MONDO_0044937', 'MONDO_0007576',
       'EFO_0003060', 'EFO_0003897', 'EFO_0004252', 'EFO_0000181',
       'EFO_1000359', 'EFO_0000616', 'MONDO_0005575', 'EFO_0005221',
       'EFO_0000178', 'EFO_0003869', 'MONDO_0004992', 'EFO_1000657',
       'EFO_0002916', 'EFO_0002618'], dtype=object), 'count': 34}",[ENSG00000188641],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 34 investigational indications.
CHEMBL187927,c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3,SUPRUPHAEXPGPF-QWHCGFSZSA-N,Small molecule,False,DIANICLINE,,3.0,,False,False,[],['Dianicline' 'SSR-591813' 'SSR591813'],"[('drugbank', array(['DB12125'], dtype=object))]",,"{'rows': array(['EFO_0003768'], dtype=object), 'count': 1}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2105705,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O,RFQHCLMGLJGZNV-UXXOMSPDSA-N,Small molecule,False,LUNACALCIPOL,,2.0,,False,False,[],['CTA-018' 'CTA018' 'Lunacalcipol'],,,"{'rows': array(['EFO_0003884', 'EFO_0000676', 'EFO_0009909', 'EFO_1001173'],
      dtype=object), 'count': 4}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2108674,,,Protein,False,RAMATERCEPT,,2.0,,False,False,['Ace-031'],['ACE-031' 'Ramatercept'],,,"{'rows': array(['HP_0003202', 'MONDO_0010679'], dtype=object), 'count': 2}",[ENSG00000138379],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108968,,,Protein,False,"INSULIN [INJECTION], BIPHASIC",,4.0,,False,True,['Ins rapit mc'],"['Biphasic insulin injection' 'Insulin [injection], biphasic']",,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV.
CHEMBL2109391,,,Antibody,False,MDX-447,,2.0,,False,False,[],['EMD-82633' 'MDX-447' 'Mdx-447'],,,"{'rows': array(['EFO_1000158'], dtype=object), 'count': 1}","[ENSG00000150337,ENSG00000146648]",Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109530,,,Antibody,False,ASK-8007,,2.0,,False,False,[],['ASK-8007' 'Ask-8007'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000118785],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109559,,,Antibody,False,J591 177LU,,2.0,,False,False,[],['177 LU-J591' 'HUJ591-GS' 'J591 177lu'],,,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000086205],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2179529,O=C(c1ccc(Cl)o1)N1CC2CNCC2C1,GTUIQNHJSXQMKW-UHFFFAOYSA-N,Small molecule,False,AZD1446,,2.0,,False,False,[],"['AZD-1446' 'AZD1446 HCL' 'Azd 1446' 'Azd1446' 'Azd1446 free base'
 'TC-6683' 'TC6683' 'TC6683 HCL']",,,"{'rows': array(['HP_0100543', 'MONDO_0004975', 'EFO_0003888'], dtype=object), 'count': 3}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL220360,C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1,QLYKJCMUNUWAGO-GAJHUEQPSA-N,Small molecule,False,TARANABANT,,3.0,,False,False,[],['MK-0364' 'MK-0634' 'Mk-0364' 'Mk0364' 'Taranabant'],"[('drugbank', array(['DB06624'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0003768', 'HP_0000020', 'EFO_0001073'],
      dtype=object), 'count': 4}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL254219,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,WDJUZGPOPHTGOT-XUDUSOBPSA-N,Small molecule,False,DIGITOXIN,1982.0,4.0,,False,True,['Crystodigin' 'Digimerck' 'Nativelle digitaline'],"['CRYSTODIGIN' 'Cristapurat' 'Digitalin, crystalline' 'Digitophyllin'
 'Digitoxin' 'Digitoxinum' 'Digitoxoside' 'Glucodigin' 'Lanatoxin'
 'NSC-7529' 'Purpurid' 'Tradigal']","[('PubChem', array(['11533060', '144205212', '144212586', '170464713', '26754428',
       '26754429'], dtype=object)), ('Wikipedia', array(['Digitoxin'], dtype=object)), ('drugbank', array(['DB01396'], dtype=object)), ('chEBI', array(['28544'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'MONDO_0009061'], dtype=object), 'count': 2}","[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 1 investigational indication.
CHEMBL3545181,C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12.O.[Br-],MQLXPRBEAHBZTK-SEINRUQRSA-M,Small molecule,False,TIOTROPIUM BROMIDE,2004.0,4.0,CHEMBL1900528,False,True,['Spiriva' 'Spiriva respimat'],"['BA 679 BR' 'BA-679 BR' 'BA-679-BR' 'BA-679BR' 'Tiotropium bromide'
 'Tiotropium bromide anhydrous' 'Tiotropium bromide hydrate'
 'Tiotropium bromide monohydrate']","[('DailyMed', array(['tiotropium%20bromide'], dtype=object))]",,"{'rows': array(['EFO_1001919', 'HP_0006536', 'HP_0000083', 'MONDO_0009061',
       'EFO_0000616', 'MONDO_0004979', 'EFO_0006505', 'EFO_0000341',
       'EFO_0000464'], dtype=object), 'count': 9}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 4 investigational indications.
CHEMBL3545247,,,Small molecule,False,CAL-263,,1.0,,False,False,[],['Cal-263'],,,"{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}","[ENSG00000171608,ENSG00000105851]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545291,CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1,IURMHZBQEYNQOH-UHFFFAOYSA-N,Small molecule,False,JNJ-39393406,,2.0,,False,False,[],['Jnj-39393406'],"[('drugbank', array(['DB11867'], dtype=object))]",,"{'rows': array(['MONDO_0002050', 'EFO_0004319', 'MONDO_0005090'], dtype=object), 'count': 3}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3785909,COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(-c5cnn(C)c5)cn34)c(=O)c2c1,DWHXUGDWKAIASB-CQSZACIVSA-N,Small molecule,False,AMG-337,,2.0,,False,False,[],['AMG 337' 'Amg-337'],"[('drugbank', array(['DB15639'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003897', 'EFO_0008498', 'MONDO_0004992'],
      dtype=object), 'count': 4}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3989922,Cc1ccc(S(=O)(=O)O)cc1.NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12.O,ACNPUCQQZDAPJH-FMOMHUKBSA-N,Small molecule,False,NIRAPARIB TOSYLATE MONOHYDRATE,2017.0,4.0,CHEMBL1094636,False,True,['Zejula'],"['Niraparib tosilate hydrate' 'Niraparib tosylate'
 'Niraparib tosylate monohydrate']","[('DailyMed', array(['niraparib%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zejula'],
      dtype=object))]",,"{'rows': array(['EFO_0001075', 'EFO_0003893', 'EFO_0000564', 'EFO_1000251',
       'EFO_1001100'], dtype=object), 'count': 5}","[ENSG00000129484,ENSG00000143799]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 1 investigational indication.
CHEMBL4297589,CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1,FYXHWMQPCJOJCH-GMAHTHKFSA-N,Small molecule,False,SELATOGREL,,3.0,,False,False,[],['ACT-246475' 'Act-246475' 'Selatogrel'],"[('drugbank', array(['DB15163'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'EFO_0008583', 'EFO_0001645'], dtype=object), 'count': 3}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297871,,,Antibody drug conjugate,False,CAMIDANLUMAB TESIRINE,,2.0,,False,False,[],"['ADCT-301' 'ADCT-301 TESIRINE' 'ADCT301' 'Adct 301' 'Adct 502'
 'Adct-301 tesirine' 'Camidanlumab tesirine']",,,"{'rows': array(['EFO_0004251', 'EFO_0000183', 'EFO_0000220', 'EFO_0000198',
       'EFO_0000222', 'EFO_0005952'], dtype=object), 'count': 6}",[ENSG00000134460],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL43452,Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,UVSMNLNDYGZFPF-UHFFFAOYSA-N,Small molecule,True,POMALIDOMIDE,2013.0,4.0,,False,True,['Imnovid' 'Imnovid (previously pomalidomide celgene)' 'Pomalyst'],['Actimid' 'CC-4047' 'IMID 3' 'IMID-3' 'Pomalidomide'],"[('DailyMed', array(['pomalidomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid'],
      dtype=object)), ('PubChem', array(['174007398'], dtype=object)), ('Wikipedia', array(['Pomalidomide'], dtype=object)), ('drugbank', array(['DB08910'], dtype=object)), ('chEBI', array(['72690'], dtype=object))]",,"{'rows': array(['EFO_0003073', 'EFO_0009441', 'EFO_0005952', 'MONDO_0019180',
       'MONDO_0015564', 'MONDO_0017816', 'EFO_0002618', 'EFO_0002430',
       'EFO_0006475', 'EFO_0000717', 'EFO_0002939', 'EFO_0002429',
       'EFO_0004251', 'EFO_0000616', 'EFO_0000702', 'EFO_0001378',
       'EFO_0000403', 'EFO_0000540', 'EFO_0000558', 'EFO_0004244',
       'MONDO_0008315', 'EFO_1001968', 'EFO_0000183', 'EFO_0000309',
       'MONDO_0019438', 'MONDO_0013730', 'EFO_0009448', 'EFO_0006738',
       'MONDO_0044903', 'MONDO_0011382'], dtype=object), 'count': 30}","[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for multiple myeloma and immune system disease and has 28 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4594331,,,Protein,False,DAZODALIBEP,,2.0,,False,False,[],"['Dazodalibep' 'MEDI-4920' 'MEDI4920' 'Medi 4920' 'VIB-4920' 'VIB4920'
 'Vib4920']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DAZODALIBEP/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0007160', 'EFO_0005809', 'EFO_0000685', 'EFO_0000699',
       'EFO_0005761'], dtype=object), 'count': 5}",[ENSG00000102245],Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL686,Cc1cccc(Nc2ccccc2C(=O)O)c1C,HYYBABOKPJLUIN-UHFFFAOYSA-N,Small molecule,True,MEFENAMIC ACID,1967.0,4.0,,False,True,"['Contraflam' 'Dysman-250' 'Dysman-500' 'Mefenamic acid' 'Meflam 250'
 'Meflam 500' 'Mendys' 'Opustan 250' 'Opustan 500' 'Ponstan' 'Ponstan fte'
 'Ponstel']","['CI-473' 'CN-35355' 'Gardan' 'INF-3355' 'J2.344B' 'M01AG01' 'Mefenamate'
 'Mefenamic acid' 'Mefenaminic acid' 'Mephenamic acid' 'Mephenaminic acid'
 'NSC-94437']","[('DailyMed', array(['mefenamic%20acid'], dtype=object)), ('PubChem', array(['104171280', '11112163', '124882006', '144203895', '144212300',
       '170464813', '26746974', '26751493', '56422190', '855723'],
      dtype=object)), ('TG-GATEs', array(['84'], dtype=object)), ('Wikipedia', array(['Mefenamic_acid'], dtype=object)), ('drugbank', array(['DB00784'], dtype=object)), ('chEBI', array(['6717'], dtype=object))]",,"{'rows': array(['HP_0100607', 'EFO_0005755', 'EFO_0003843', 'EFO_0000400',
       'MP_0001914'], dtype=object), 'count': 5}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for dysmenorrhea and rheumatic disease and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1110,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O,JSWZEAMFRNKZNL-UHFFFAOYSA-N,Small molecule,True,ALOSETRON,2000.0,4.0,,False,True,[],['A03AE01' 'Alosetron' 'Lotronex'],"[('Wikipedia', array(['Alosetron'], dtype=object)), ('drugbank', array(['DB00969'], dtype=object)), ('chEBI', array(['253342'], dtype=object))]",['CHEMBL1200885'],"{'rows': array(['EFO_0010282', 'EFO_0000555', 'EFO_0000555'], dtype=object), 'count': 3}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for gastrointestinal disease and irritable bowel syndrome and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1194325,O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,ASMXXROZKSBQIH-VITNCHFBSA-N,Small molecule,False,ACLIDINIUM,2012.0,4.0,,False,True,[],['Aclidinium' 'Aclidinium cation' 'Aclidinium ion'],"[('drugbank', array(['DB08897'], dtype=object)), ('chEBI', array(['65346'], dtype=object))]",['CHEMBL551466'],"{'rows': array(['EFO_0000464', 'EFO_0000341', 'EFO_0006505', 'MONDO_0004979',
       'HP_0006536', 'EFO_0000341', 'EFO_0003768'], dtype=object), 'count': 7}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 approved and 2 investigational indications.
CHEMBL1201328,CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2,XZSMZRXAEFNJCU-UHFFFAOYSA-N,Small molecule,False,CARPHENAZINE,1982.0,4.0,,False,True,[],['Carfenazine' 'Carphenazine'],"[('PubChem', array(['50125832'], dtype=object)), ('Wikipedia', array(['Carfenazine'], dtype=object)), ('drugbank', array(['DB01038'], dtype=object))]",['CHEMBL2358147'],,"[ENSG00000149295,ENSG00000102468,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1342,O=C(O)CCCO,SJZRECIVHVDYJC-UHFFFAOYSA-N,Small molecule,True,OXYBATE,2002.0,4.0,,False,True,[],"['.gamma.-hydroxybutyrate' 'Gamma hydroxybutyrate' 'Gamma-hydroxybutyrate'
 'Oxybate' 'Xyrem']","[('Wikipedia', array(['Gamma-Hydroxybutyric_acid'], dtype=object)), ('drugbank', array(['DB01440'], dtype=object)), ('chEBI', array(['30830'], dtype=object))]",['CHEMBL1200682' 'CHEMBL4594393' 'CHEMBL4594395' 'CHEMBL4594394'],"{'rows': array(['MONDO_0018044', 'EFO_0003108', 'EFO_0008568', 'MONDO_0021107',
       'EFO_0005203', 'HP_0001337', 'EFO_0003843', 'MONDO_0016241',
       'MONDO_0000485', 'MONDO_0005180', 'EFO_0005687', 'MONDO_0016158'],
      dtype=object), 'count': 12}","[ENSG00000204681,ENSG00000136928]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for narcolepsy and narcolepsy-cataplexy syndrome and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1372,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O,YPZRWBKMTBYPTK-BJDJZHNGSA-N,Small molecule,False,OXIGLUTATIONE,2008.0,4.0,,False,True,[],['Glutathione disulfide' 'Oxiglutatione'],"[('DailyMed', array(['glutathione%20disulfide'], dtype=object)), ('PubChem', array(['144206973', '26754399', '29215201'], dtype=object)), ('Wikipedia', array(['Glutathione_disulfide'], dtype=object)), ('drugbank', array(['DB03310'], dtype=object)), ('chEBI', array(['17858'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000565', 'MONDO_0008170', 'MONDO_0007254',
       'EFO_0000198'], dtype=object), 'count': 5}",[ENSG00000104687],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 investigational indications.
CHEMBL1492500,CN(C)CC/C=C1\c2ccccc2CSc2ccccc21,PHTUQLWOUWZIMZ-GZTJUZNOSA-N,Small molecule,False,DOTHIEPIN,,4.0,,False,True,[],['Dosulepin' 'Dothiepin' 'Dothirpin'],"[('PubChem', array(['11112454'], dtype=object)), ('drugbank', array(['DB09167'], dtype=object)), ('chEBI', array(['36803'], dtype=object))]",['CHEMBL1711280'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder.
CHEMBL1950554,Nc1nc(N/N=C/C2CCCCC2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,XJFMHMFFBSOEPR-DNZQAUTHSA-N,Small molecule,False,BINODENOSON,,3.0,,False,False,['Corvue'],['Binodenoson' 'MRE-0470' 'MRE0470' 'Wrc0470'],"[('drugbank', array(['DB04853'], dtype=object))]",,,[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL2109138,,,Antibody,False,MOROLIMUMAB,,2.0,,False,False,[],['Morolimumab'],,,,[ENSG00000187010],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2443262,COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1,DMNOVGJWPASQDL-OAQYLSRUSA-N,Small molecule,True,OLICERIDINE,2020.0,4.0,,False,True,['Olinvyk' 'Olynvik'],['Oliceridine' 'TRV-130' 'TRV130'],"[('drugbank', array(['DB14881'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for pain. This drug has a black box warning from the FDA.
CHEMBL3301578,,,Antibody,False,EMIBETUZUMAB,,2.0,,False,False,[],['C-8H241' 'Emibetuzumab' 'LA480' 'LY-2875358' 'LY2875358' 'La-480'],,,"{'rows': array(['EFO_0003060', 'MONDO_0004992', 'MONDO_0001056'], dtype=object), 'count': 3}",[ENSG00000105976],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545327,,,Small molecule,False,TTP-607,,1.0,,False,False,[],['Ttp-607'],,,"{'rows': array(['MONDO_0004992', 'EFO_0000574'], dtype=object), 'count': 2}","[ENSG00000178999,ENSG00000105146,ENSG00000087586]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3707397,,,Small molecule,False,MR-1817,,1.0,,False,False,[],['Mr-1817'],,,,[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3764045,CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC,ORRNXRYWGDUDOG-UHFFFAOYSA-N,Small molecule,False,TAS-115,,1.0,,False,False,[],['Pamufetinib' 'Tas-115'],,,,"[ENSG00000128052,ENSG00000105976]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL382301,CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1,VWXRQYYUEIYXCZ-OBIMUBPZSA-N,Protein,False,ATOSIBAN,2000.0,4.0,,False,True,['Tractocile'],"['Antocile' 'Antocin' 'Antocin ii' 'Atosiban' 'CAP-449' 'CAP-476'
 'CAP-581' 'F-314' 'ORF 22164' 'ORF-22164' 'RW-22164' 'RWJ 22164'
 'RWJ-22164' 'Tractocil']","[('PubChem', array(['144207023', '29217473'], dtype=object)), ('drugbank', array(['DB09059'], dtype=object))]",['CHEMBL5315050'],"{'rows': array(['EFO_0003917', 'EFO_0003917', 'EFO_0001065'], dtype=object), 'count': 3}",[ENSG00000180914],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for premature birth and has 2 investigational indications.
CHEMBL415,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,GDLIGKIOYRNHDA-UHFFFAOYSA-N,Small molecule,True,CLOMIPRAMINE,1989.0,4.0,,False,True,[],"['3-chloro-iminodibenzyl' 'Anafranil' 'Anapramine' 'Chlorimipramine'
 'Clomicalm' 'Clomipramine' 'NSC-169865']","[('PubChem', array(['104171137', '11110978', '11110979', '11113368', '124879726',
       '144203668', '170464702', '26751616', '50100206', '50104278',
       '90340575'], dtype=object)), ('TG-GATEs', array(['121'], dtype=object)), ('Wikipedia', array(['Clomipramine'], dtype=object)), ('drugbank', array(['DB01242'], dtype=object)), ('chEBI', array(['47780'], dtype=object))]",['CHEMBL1200710'],"{'rows': array(['MONDO_0002050', 'EFO_0005230', 'HP_0000726', 'EFO_0004242',
       'EFO_0004242', 'MONDO_0002009', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0803321'], dtype=object), 'count': 9}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL483254,Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,FPOHNWQLNRZRFC-ZHACJKMWSA-N,Small molecule,True,PANOBINOSTAT,2015.0,4.0,,False,True,['Farydak'],['LBH-589' 'LBH589' 'Panobinostat' 'Panobinostat hydrate'],"[('drugbank', array(['DB06603'], dtype=object)), ('chEBI', array(['85990'], dtype=object))]",['CHEMBL3545368'],"{'rows': array(['EFO_0002892', 'EFO_0000349', 'EFO_0003060', 'EFO_0000673',
       'EFO_0004252', 'MONDO_0007254', 'EFO_1000026', 'EFO_0002617',
       'MONDO_0001056', 'EFO_0000519', 'EFO_0006475', 'EFO_0000403',
       'EFO_0000681', 'EFO_0000574', 'EFO_0000756', 'EFO_0002618',
       'EFO_1001469', 'EFO_0009441', 'EFO_0001378', 'EFO_0000220',
       'EFO_0002429', 'EFO_0002430', 'EFO_0000616', 'EFO_0000565',
       'EFO_0006738', 'MONDO_0020547', 'MONDO_0011382', 'MONDO_0002898',
       'MONDO_0044881', 'EFO_0001378', 'EFO_0000183', 'MONDO_0004992',
       'MONDO_0044903', 'EFO_0005952', 'EFO_1001901', 'EFO_0000339',
       'EFO_1001951', 'EFO_0000764', 'EFO_0000198', 'EFO_0000182',
       'MONDO_0100342', 'EFO_1000657', 'EFO_0005543', 'EFO_0000222',
       'MONDO_0008903', 'MONDO_0008315', 'MONDO_0002691', 'MONDO_0009348',
       'MONDO_0021063', 'EFO_1001779', 'EFO_0002913', 'MONDO_0013730'],
      dtype=object), 'count': 52}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 49 investigational indications. This drug has a black box warning from the FDA.
CHEMBL506981,COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12,DYLJVOXRWLXDIG-UHFFFAOYSA-N,Small molecule,False,REMINERTANT,,3.0,,False,False,[],['Meclinertant' 'Reminertant' 'SR-48692' 'Sr48692'],"[('PubChem', array(['124950704'], dtype=object)), ('drugbank', array(['DB06455'], dtype=object))]",,"{'rows': array(['EFO_0000702'], dtype=object), 'count': 1}",[ENSG00000101188],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL607400,CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1,MSYKRHVOOPPJKU-BDAKNGLRSA-N,Small molecule,False,BRIVARACETAM,2016.0,4.0,,False,True,['Briviact' 'Briviact (in italy:  nubriveo)'],['Brivaracetam' 'UCB 34714' 'UCB-34714'],"[('DailyMed', array(['brivaracetam'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo'],
      dtype=object)), ('Wikipedia', array(['Brivaracetam'], dtype=object)), ('drugbank', array(['DB05541'], dtype=object))]",,"{'rows': array(['Orphanet_308', 'EFO_1001919', 'EFO_0000474', 'EFO_0003833',
       'HP_0001250', 'MONDO_0041052', 'HP_0007359'], dtype=object), 'count': 7}",[ENSG00000159164],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 4 investigational indications.
CHEMBL77305,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1,VHXNKPBCCMUMSW-FQEVSTJZSA-N,Small molecule,False,RUBITECAN,,3.0,,False,False,[],"['9-nc' '9-nitro-20(s)-camptothecin' '9-nitro-20-(s)-camptothecin'
 '9-nitrocamptothecin' 'RFS 2000' 'RFS-2000' 'RFS2000' 'Rubitecan']","[('PubChem', array(['144206150', '50113013'], dtype=object)), ('Wikipedia', array(['Rubitecan'], dtype=object)), ('drugbank', array(['DB06159'], dtype=object)), ('chEBI', array(['90225'], dtype=object))]",,"{'rows': array(['MONDO_0001187', 'MONDO_0011962', 'MONDO_0004192', 'EFO_0000389',
       'MONDO_0008170', 'MONDO_0008903', 'EFO_0000616', 'MONDO_0002087',
       'EFO_0002618', 'MONDO_0007254', 'EFO_1001951', 'EFO_1000158'],
      dtype=object), 'count': 12}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications.
CHEMBL1008,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,UIEATEWHFDRYRU-UHFFFAOYSA-N,Small molecule,False,BEPRIDIL,1990.0,4.0,,False,True,[],['Bepadin' 'Bepridil' 'Vascor'],"[('PubChem', array(['104171114', '124879417', '124879419', '144203640', '170465240',
       '26755663', '26755664', '50110980', '90341574'], dtype=object)), ('Wikipedia', array(['Bepridil'], dtype=object)), ('drugbank', array(['DB01244'], dtype=object)), ('chEBI', array(['3061'], dtype=object))]",['CHEMBL1257078' 'CHEMBL1200382'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for cardiovascular disease.
CHEMBL119625,O=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21,SPXYHZRWPRQLNS-UHFFFAOYSA-N,Small molecule,False,ZONAMPANEL,,2.0,,False,False,[],"['YM 872 ANHYDROUS' 'YM-872' 'YM-872 ANHYDROUS' 'YM872' 'YM872 ANHYDROUS'
 'Ym 872' 'Zonampanel' 'Zonampanel anhydrous' 'Zonampanel monohydrate']",,,"{'rows': array(['HP_0002140', 'EFO_0000712'], dtype=object), 'count': 2}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1200494,Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,DGFYECXYGUIODH-UHFFFAOYSA-N,Small molecule,False,GUANFACINE HYDROCHLORIDE,1986.0,4.0,CHEMBL862,False,True,['Akfen' 'Estulic' 'Guanfacine hydrochloride' 'Intuniv' 'Tenex'],"['BS 100-141' 'BS-100-141' 'Guafacine hydrochloride' 'Guanfacine hcl'
 'Guanfacine hydrochloride' 'SPD503']","[('DailyMed', array(['guanfacine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv'],
      dtype=object)), ('PubChem', array(['11532959', '144203710', '170465381', '50106306', '56422899'],
      dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0003888'], dtype=object), 'count': 2}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for hypertension and attention deficit hyperactivity disorder.
CHEMBL1200538,CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,AKUJBENLRBOFTD-QZIXMDIESA-N,Small molecule,False,BETAMETHASONE ACETATE,1965.0,4.0,,False,True,[],['Betamethasone 21-acetate' 'Betamethasone acetate' 'NSC-759196'],"[('chEBI', array(['31275'], dtype=object))]",,"{'rows': array(['MONDO_0005178', 'MONDO_0002280', 'EFO_1001434', 'MONDO_0004979',
       'EFO_1001222', 'EFO_0000729', 'EFO_0004255', 'HP_0003419',
       'MONDO_0002406'], dtype=object), 'count': 9}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 6 approved and 3 investigational indications.
CHEMBL1201119,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+],SBXXSUDPJJJJLC-YDALLXLXSA-M,Small molecule,True,LIOTHYRONINE SODIUM,1956.0,4.0,CHEMBL1544,False,True,"['Cynomel' 'Cytomel' 'Liothyronine sodium' 'Tertroxin' 'Thybon'
 'Triiodothyronine' 'Triiodothyronine,evans' 'Triostat']","['Basoprocin' 'Cytobin' 'Ibiothyron' 'L-triiodothyronine hydrochloride'
 'L-triiodothyronine sodium salt' 'Liothyronine hydrochloride'
 'Liothyronine sodium' 'Liothyronine sodium salt' 'Liotrix (t3)'
 'Lyothyronin' 'NSC-758175' 'NSC-80774' 'Rathyronine hydrochloride, (s)-'
 'Rathyronine sodium, (s)-' 'T3 sodium salt'
 'Triiodothyronine sodium salt' 'Triiodothyronine sodium, levo']","[('DailyMed', array(['liothyronine%20sodium'], dtype=object)), ('PubChem', array(['144212831', '855617'], dtype=object)), ('Wikipedia', array(['Liothyronine'], dtype=object)), ('chEBI', array(['6484'], dtype=object))]",,"{'rows': array(['EFO_0003841', 'EFO_0006859', 'EFO_0004705', 'MONDO_0008315',
       'EFO_0005207', 'HP_0030680', 'EFO_1002017', 'MONDO_0005301',
       'EFO_1001055'], dtype=object), 'count': 9}","[ENSG00000126351,ENSG00000151090]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201540,,,Protein,False,INSULIN SUSP ISOPHANE RECOMBINANT HUMAN,1982.0,4.0,,False,True,['Humulin n' 'Novolin n'],['Insulin susp isophane recombinant human'],"[('DailyMed', array(['insulin%20susp%20isophane%20recombinant%20human'], dtype=object))]",,"{'rows': array(['EFO_0003914', 'MONDO_0005147', 'HP_0003074', 'MONDO_0005148',
       'EFO_0000537', 'EFO_0001645', 'HP_0003124', 'EFO_0000400'],
      dtype=object), 'count': 8}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 8 investigational indications.
CHEMBL1479,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,POZRVZJJTULAOH-LHZXLZLDSA-N,Small molecule,True,DANAZOL,1976.0,4.0,,False,True,['Danazol' 'Danocrine'],"['Danazol' 'NSC-270916' 'WIN 17,757' 'WIN-17757']","[('DailyMed', array(['danazol'], dtype=object)), ('PubChem', array(['144205667', '144212257', '170464884', '26757819', '49648394'],
      dtype=object)), ('TG-GATEs', array(['127'], dtype=object)), ('Wikipedia', array(['Danazol'], dtype=object)), ('drugbank', array(['DB01406'], dtype=object)), ('chEBI', array(['4315'], dtype=object))]",,"{'rows': array(['EFO_1001366', 'EFO_0007160', 'MONDO_0018896', 'EFO_0001065',
       'EFO_0000545', 'EFO_0000198', 'MONDO_0015780', 'MONDO_0011962',
       'MONDO_0019098', 'HP_0001915', 'EFO_0003014', 'MONDO_0019391'],
      dtype=object), 'count': 12}","[ENSG00000082175,ENSG00000169083]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for endometriosis and breast fibrocystic disease and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1501,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,WJOHZNCJWYWUJD-IUGZLZTKSA-N,Small molecule,True,FLUOCINONIDE,1971.0,4.0,,False,True,"['Fluocinonide' 'Fluocinonide emulsified base' 'Lidex' 'Lidex-e' 'Metosyn'
 'Metosyn fapg' 'Vanos']",['Fluocinolide' 'Fluocinonide' 'NSC-101791'],"[('DailyMed', array(['fluocinonide'], dtype=object)), ('PubChem', array(['144203989', '170464717', '855724'], dtype=object)), ('Wikipedia', array(['Fluocinonide'], dtype=object)), ('drugbank', array(['DB01047'], dtype=object))]",,"{'rows': array(['EFO_0000305', 'EFO_0000274', 'EFO_0009552', 'EFO_0000676',
       'EFO_0000701'], dtype=object), 'count': 5}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and is indicated for hemorrhoid and skin disease and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1761,Cl.OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1,ZFSPFXJSEHCTTR-UHFFFAOYSA-N,Small molecule,False,PROCYCLIDINE HYDROCHLORIDE,1955.0,4.0,CHEMBL86715,False,True,['Arpicolin' 'Kemadrin' 'Muscinil'],"['NSC-757293' 'Procyclidine HCl' 'Procyclidine hcl'
 'Procyclidine hydrochloride']","[('PubChem', array(['144204059', '170464805', '26748224', '26748225', '50107359',
       '50107360', '56424071', '856015'], dtype=object)), ('Wikipedia', array(['Procyclidine'], dtype=object)), ('chEBI', array(['8449'], dtype=object))]",,,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955.
CHEMBL1762621,COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,WPTTVJLTNAWYAO-KPOXMGGZSA-N,Small molecule,False,BARDOXOLONE METHYL,,3.0,,False,False,[],"['Bardoxolone methyl' 'Bardoxolone methyl ester' 'CDDO-METHYL ESTER'
 'CDDO-Me' 'NSC 713200' 'NSC-713200' 'RTA 402' 'RTA-402' 'RTA402'
 'Rta-402']","[('PubChem', array(['144206780', '532003'], dtype=object)), ('drugbank', array(['DB05983'], dtype=object))]",,"{'rows': array(['MONDO_0005149', 'EFO_0000756', 'MONDO_0100096', 'EFO_0000401',
       'EFO_0003884', 'EFO_0002618', 'MONDO_0018965', 'EFO_0001642',
       'EFO_0001421', 'EFO_0001361', 'EFO_1001496'], dtype=object), 'count': 11}","[ENSG00000132170,ENSG00000104365,ENSG00000116044,ENSG00000079999]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL2062257,Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,QZHBYNSSDLTCRG-UHFFFAOYSA-N,Small molecule,False,BRIMONIDINE TARTRATE,1996.0,4.0,CHEMBL844,False,True,"['Alphagan' 'Alphagan p' 'Brimonidine tartrate' 'Brymont' 'Lumify'
 'Mirvaso' 'Qoliana']","['AGN 190342-LF' 'AGN-190342-LF' 'AGN-190342LF' 'Brimonidine d-tartrate'
 'Brimonidine tartrate' 'Bromoxidine tartrate' 'Cd-07805' 'OCU-300'
 'OCU300' 'UK-14304-18' 'UK-1430418']","[('DailyMed', array(['brimonidine%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso'],
      dtype=object))]",,"{'rows': array(['EFO_1000906', 'EFO_0004190', 'MONDO_0021698', 'EFO_0000537',
       'EFO_1001893', 'MONDO_0001330', 'MONDO_0005041', 'EFO_0003822',
       'HP_0000951', 'EFO_1000879', 'HP_0010783', 'EFO_1000760',
       'HP_0031284', 'EFO_1001069', 'EFO_0007141'], dtype=object), 'count': 15}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 8 investigational indications.
CHEMBL2095211,C[C@H]1CNCCc2ccc(Cl)cc21.Cl,ITIHHRMYZPNGRC-QRPNPIFTSA-N,Small molecule,False,LORCASERIN HYDROCHLORIDE,2012.0,4.0,CHEMBL360328,False,True,['Belviq' 'Belviq xr'],['APD-356' 'APD356' 'Lorcaserin hcl' 'Lorcaserin hydrochloride' 'Lorqess'],"[('chEBI', array(['65350'], dtype=object))]",,"{'rows': array(['EFO_0004319', 'EFO_0001073'], dtype=object), 'count': 2}",[ENSG00000147246],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 2 investigational indications.
CHEMBL2108677,,,Protein,False,PEGINTERFERON BETA-1A,2014.0,4.0,,False,True,['Biib017' 'Plegridy'],['BIIB-017' 'BIIB017' 'Peginterferon beta' 'Peginterferon beta-1a'],"[('DailyMed', array(['peginterferon%20beta-1a'], dtype=object)), ('DrugCentral', array(['5137'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy'],
      dtype=object))]",,"{'rows': array(['HP_0000083', 'MONDO_0005301', 'EFO_0000616', 'EFO_0003929'],
      dtype=object), 'count': 4}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for multiple sclerosis and neoplasm and has 2 investigational indications.
CHEMBL2109095,,,Antibody,False,ERLIZUMAB,,2.0,,False,False,[],['Erlizumab' 'RHUMAB CD18' 'RHUMAB-CD18'],,,,[ENSG00000160255],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2134724,CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],KEWHKYJURDBRMN-XSAPEOHZSA-M,Small molecule,False,IPRATROPIUM BROMIDE,1986.0,4.0,CHEMBL1621597,False,True,"['Atrovent' 'Atrovent aerocaps' 'Atrovent fte' 'Atrovent hfa'
 'Atrovent udvs' 'Ipratrop' 'Ipratrop steripoule' 'Ipratropium bromide'
 'Respontin' 'Rinatec' 'Tropiovent']","['Ipratropium bromide' 'Ipratropium bromide anhydrous'
 'Ipratropium bromide hydrate' 'Ipratropium bromide monohydrate'
 'NSC-759613' 'SCH 1000-BR-MONOHYDRATE' 'SCH-1000-BR-']","[('DailyMed', array(['ipratropium%20bromide'], dtype=object)), ('PubChem', array(['56462997'], dtype=object))]",,"{'rows': array(['Orphanet_1764', 'MONDO_0005180', 'EFO_0003956', 'HP_0002307',
       'EFO_0001361', 'EFO_0000341', 'EFO_0006505', 'HP_0006536',
       'EFO_0007214', 'EFO_0000274', 'MONDO_0004979', 'EFO_0000464',
       'HP_0001742'], dtype=object), 'count': 13}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 9 approved and 4 investigational indications.
CHEMBL3109738,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3,JXDYOSVKVSQGJM-UHFFFAOYSA-N,Small molecule,False,JNJ-26483327,,1.0,,False,False,[],['JNJ 26483327' 'JNJ-26483327' 'Jnj-26483327'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000197122,ENSG00000178568,ENSG00000182866,ENSG00000254087,ENSG00000010810,ENSG00000037280,ENSG00000146648,ENSG00000176105,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3234681,CC(C)(C)NC(=O)c1nn(-c2ccc(F)cc2F)c2c1[C@H]1CC[C@@H]2C1,NTPZXHMTJGOMCJ-WDEREUQCSA-N,Small molecule,False,TEDALINAB,,2.0,,False,False,[],['GRC10693' 'Grc-10693' 'Tedalinab'],,,,[ENSG00000188822],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3673452,COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)cnc43)cc2OC)cc1,HVRWZFQFSQUILC-UHFFFAOYSA-N,Small molecule,False,GZ-389988,,2.0,,False,False,[],['GZ-389988' 'GZ389988' 'Gz-389988' 'Gz389988'],,,"{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}",[ENSG00000198400],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298126,,,Unknown,False,VON WILLEBRAND FACTOR HUMAN,,4.0,,False,True,[],"['Human von willebrand factor' 'Von willebrand factor'
 'Von willebrand factor (human)' 'Von willebrand factor human'
 'Von willebrand factor, human' ""Von willebrand's factor""]",,,"{'rows': array(['MONDO_0024574', 'Orphanet_903', 'MP_0001914', 'EFO_0009579'],
      dtype=object), 'count': 4}",[ENSG00000110799],Unknown drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 3 investigational indications.
CHEMBL4298211,,,Protein,True,PEGCETACOPLAN,2021.0,4.0,,False,True,['Aspaveli' 'Empaveli'],['APL-2' 'Pegcetacoplan' 'Syfovre'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEGCETACOPLAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0019737', 'MONDO_0100244', 'MONDO_0004976', 'EFO_0000540',
       'EFO_1001492', 'MONDO_0018922', 'MONDO_0019736', 'MONDO_0100244',
       'EFO_0001365'], dtype=object), 'count': 9}",[ENSG00000125730],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for paroxysmal nocturnal hemoglobinuria and immune system disease and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4299940,O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1,XAYGBKHKBBXDAK-UHFFFAOYSA-N,Small molecule,False,MITAPIVAT,2022.0,4.0,,False,True,[],['AG-348' 'Ag-348' 'Mitapivat' 'Pkr-in-1'],,['CHEMBL4297223'],"{'rows': array(['MONDO_0003689', 'MONDO_0002280', 'Orphanet_846', 'EFO_0000508',
       'EFO_0004272', 'MONDO_0011382', 'EFO_1001996', 'Orphanet_848',
       'EFO_0001421'], dtype=object), 'count': 9}",[ENSG00000143627],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 6 investigational indications.
CHEMBL4650276,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1,KRBMOYIWQCZVHA-INIZCTEOSA-N,Small molecule,False,SHR3680,,3.0,,False,False,[],['Rezvilutamide' 'SHR3680' 'Shr3680'],,,"{'rows': array(['MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0001421',
       'EFO_0005537'], dtype=object), 'count': 5}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4650989,C[C@@H](N)COc1ccc(-c2cnc3ccc(N[C@H](C)c4cccc(F)c4)nn23)cc1,HEVHTYMYEMEBPX-HZPDHXFCSA-N,Small molecule,False,TALETRECTINIB,,2.0,,False,False,[],['AB-106' 'Ab-106' 'DS-6051' 'DS-6051a' 'Taletrectinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TALETRECTINIB/relevant/1/'],
      dtype=object))]",['CHEMBL4650361'],"{'rows': array(['EFO_0003060', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000616'],
      dtype=object), 'count': 4}","[ENSG00000047936,ENSG00000198400,ENSG00000148053,ENSG00000140538]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL561132,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1,JTCAGRAKUAAYDY-OAHLLOKOSA-N,Small molecule,False,MK-7246,,1.0,,False,False,[],['MK-7246' 'MK7246'],,['CHEMBL2093879'],,[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1095097,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,JUKPWJGBANNWMW-VWBFHTRKSA-N,Small molecule,False,EPLERENONE,2002.0,4.0,,False,True,['Eplerenone' 'Inspra'],['Eplerenone' 'SC-66110' 'SC-6611O'],"[('DailyMed', array(['eplerenone'], dtype=object)), ('PubChem', array(['144205299', '170465283', '26754514'], dtype=object)), ('Wikipedia', array(['Eplerenone'], dtype=object)), ('drugbank', array(['DB00700'], dtype=object)), ('chEBI', array(['31547'], dtype=object))]",,"{'rows': array(['EFO_0000401', 'EFO_0003884', 'EFO_0000612', 'EFO_0008519',
       'EFO_0000275', 'MONDO_0010679', 'EFO_0009784', 'EFO_0003144',
       'MONDO_0005148', 'EFO_0000537', 'EFO_0000318', 'EFO_0000319',
       'MONDO_0007254', 'EFO_0000712', 'MONDO_0001134', 'EFO_0000373'],
      dtype=object), 'count': 16}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 10 investigational indications.
CHEMBL1200543,CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.O=P(O)(O)O,FLQCEKVTYABVSH-UHFFFAOYSA-N,Small molecule,False,ANILERIDINE PHOSPHATE,1982.0,4.0,CHEMBL1201347,False,True,['Leritine'],['Anileridine phosphate' 'Leritine phosphate'],,,,"[ENSG00000112038,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200853,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,JGMOKGBVKVMRFX-HQZYFCCVSA-N,Small molecule,False,DYDROGESTERONE,1982.0,4.0,,False,True,['Duphaston' 'Duphaston-hrt' 'Gynorest'],['Dydrogesterone' 'Isopregnenone' 'NSC-92336'],"[('PubChem', array(['144203980', '170465104', '56463092'], dtype=object)), ('drugbank', array(['DB00378'], dtype=object)), ('chEBI', array(['31527'], dtype=object))]",,"{'rows': array(['EFO_0008560', 'EFO_0000660', 'EFO_0003917', 'EFO_0002950',
       'HP_0000138', 'EFO_0000545', 'EFO_1000954', 'GO_0042697'],
      dtype=object), 'count': 8}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 8 investigational indications.
CHEMBL1201115,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl,GEKNCWBANDDJJL-UHFFFAOYSA-N,Small molecule,False,ESMOLOL HYDROCHLORIDE,1986.0,4.0,CHEMBL768,True,True,['Brevibloc' 'Esmolol hydrochloride'],['ASL-8052' 'Esmolol hcl' 'Esmolol hydrochloride'],"[('DailyMed', array(['esmolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144207045', '170465277', '49681641'], dtype=object)), ('chEBI', array(['4857'], dtype=object))]",,"{'rows': array(['HP_0100543', 'EFO_0000537', 'HP_0000138', 'EFO_1001459',
       'EFO_0006834'], dtype=object), 'count': 5}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for hypertension and has 4 investigational indications. It was withdrawn in at least one region.
CHEMBL1289926,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1,RITAVMQDGBJQJZ-FMIVXFBMSA-N,Small molecule,False,AXITINIB,2012.0,4.0,,False,True,['Inlyta'],['AG-013736' 'AG-13736' 'Axitinib' 'NSC-757441'],"[('DailyMed', array(['axitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta'],
      dtype=object)), ('PubChem', array(['124950168', '144207146', '170466656'], dtype=object)), ('Wikipedia', array(['Axitinib'], dtype=object)), ('drugbank', array(['DB06626'], dtype=object)), ('chEBI', array(['66910'], dtype=object))]",,"{'rows': array(['EFO_0004142', 'MONDO_0004669', 'EFO_0000673', 'EFO_0000198',
       'EFO_0000616', 'MONDO_0011719', 'MONDO_0011962', 'MONDO_0002367',
       'EFO_1001951', 'EFO_0009708', 'EFO_0003860', 'EFO_0003841',
       'EFO_1001465', 'EFO_0003060', 'EFO_0000231', 'EFO_1001968',
       'EFO_0003865', 'EFO_0000681', 'EFO_0004198', 'EFO_1000131',
       'EFO_0000222', 'EFO_1001513', 'EFO_0004252', 'EFO_0000640',
       'EFO_0000313', 'MONDO_0005184', 'EFO_0000181', 'EFO_0000349',
       'EFO_0000770', 'EFO_1000796', 'EFO_0002890', 'EFO_0003869',
       'EFO_0004243', 'EFO_0007143', 'EFO_0003891', 'MONDO_0008315',
       'EFO_0000756', 'EFO_0000519', 'MONDO_0016238', 'MONDO_0004992',
       'MONDO_0001056', 'EFO_0001065', 'EFO_0000182'], dtype=object), 'count': 43}","[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 37 investigational indications.
CHEMBL1616951,C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)O,PBKZPPIHUVSDNM-WNHSNXHDSA-N,Small molecule,False,CANRENOATE,,4.0,,False,True,[],['Canrenoic acid'],"[('drugbank', array(['DB09015'], dtype=object)), ('chEBI', array(['50156'], dtype=object))]",['CHEMBL1371200'],"{'rows': array(['EFO_0000319', 'EFO_0008585'], dtype=object), 'count': 2}",[ENSG00000151623],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.
CHEMBL1668,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,SZLZWPPUNLXJEA-QEGASFHISA-N,Small molecule,False,RESCINNAMINE,1956.0,4.0,,False,True,['Cinnasil' 'Moderil'],"['Apoterin s' 'Cartric' 'Cinnaloid' 'NSC-15628' 'Rescinnamine' 'Rescisan'
 'Resealoid' 'Reserpinine' 'Scinnamina' 'Tsuruselpi s']","[('PubChem', array(['56463114'], dtype=object)), ('Wikipedia', array(['Rescinnamine'], dtype=object)), ('chEBI', array(['28572'], dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}",[ENSG00000165646],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for hypertension.
CHEMBL1743026,,,Antibody,False,GEVOKIZUMAB,,3.0,,False,False,[],['Gevokizumab' 'VPM-087' 'VPM087' 'XOMA 052' 'XOMA-052'],,,"{'rows': array(['MONDO_0005148', 'HP_0000999', 'MONDO_0021063', 'EFO_0009672',
       'EFO_0003780', 'MONDO_0001718', 'MONDO_0005147', 'MONDO_0005178',
       'EFO_0003894', 'EFO_0000685', 'EFO_1001231'], dtype=object), 'count': 11}",[ENSG00000125538],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL2024517,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1.Cl,GPPJWWMREQHLQT-BHQIMSFRSA-N,Small molecule,True,CARIPRAZINE HYDROCHLORIDE,2015.0,4.0,CHEMBL2028019,False,True,['Reagila' 'Vraylar'],['Cariprazine hcl' 'Cariprazine hydrochloride' 'RGH-188 HCL'],"[('DailyMed', array(['cariprazine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/reagila'],
      dtype=object))]",,"{'rows': array(['MONDO_0004985', 'EFO_0009963', 'MONDO_0005090'], dtype=object), 'count': 3}","[ENSG00000151577,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL2107546,CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl,NCEAPFRHADKEHP-UHFFFAOYSA-N,Small molecule,False,BUCINDOLOL HYDROCHLORIDE,,2.0,CHEMBL321582,False,False,[],"['Bucindolol hcl' 'Bucindolol hydrochloride' 'Gencaro' 'MJ 13,105-1'
 'MJ-13105-1']",,,"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}","[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109478,,,Antibody,False,DAPIROLIZUMAB PEGOL,,3.0,,False,False,[],['CDP-7657' 'CDP7657' 'Cdp-7657' 'Dapirolizumab pegol'],,,"{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}",[ENSG00000102245],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL221959,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,UJLAWZDWDVHWOW-YPMHNXCESA-N,Small molecule,True,TOFACITINIB,2012.0,4.0,,False,True,[],"['550' 'CP 690550' 'CP- 690 550' 'CP-690' 'CP-690,550'
 'CP-690,550 FREE BASE' 'CP-690-550' 'CP-690550' 'CP-690550 FREE BASE'
 'CP690,550' 'CP690550' 'Cp-690 free base' 'Tofacitinib']","[('PubChem', array(['124939204', '50100095'], dtype=object)), ('Wikipedia', array(['Tofacitinib'], dtype=object)), ('drugbank', array(['DB08895'], dtype=object)), ('chEBI', array(['71200'], dtype=object))]",['CHEMBL2103743'],"{'rows': array(['MONDO_0019472', 'EFO_0003778', 'EFO_0000274', 'EFO_0003884',
       'EFO_0000398', 'MONDO_0018305', 'MONDO_0019338', 'EFO_0000274',
       'EFO_1001857', 'EFO_0000783', 'EFO_1000704', 'EFO_0000546',
       'EFO_0003921', 'MONDO_0007915', 'EFO_0008518', 'EFO_0003898',
       'EFO_0000699', 'EFO_0002609', 'EFO_1000906', 'EFO_0003778',
       'EFO_0000676', 'MONDO_0100096', 'EFO_0003834', 'EFO_0000729',
       'EFO_0003106', 'EFO_0000685', 'EFO_0004991', 'EFO_0001064',
       'MONDO_0019558', 'EFO_1001494', 'EFO_0000685', 'EFO_0000519',
       'EFO_0000384', 'EFO_0003872', 'MONDO_0007915', 'EFO_0004192',
       'EFO_0000717', 'EFO_0003898', 'EFO_0003086', 'EFO_0000540'],
      dtype=object), 'count': 40}","[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for psoriatic arthritis and rheumatoid arthritis and has 38 investigational indications. This drug has a black box warning from the FDA.
CHEMBL315985,NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21,BMPDWHIDQYTSHX-AWEZNQCLSA-N,Small molecule,False,ESLICARBAZEPINE,,4.0,,False,True,['Erelib' 'Pazzul' 'Stedesa'],"['(s)-licarbazepine' 'BIA 2-194' 'BIA-2-194' 'BIA-2194' 'CGP-13751'
 'Eslicarbazepine' 'Licarbazepine, (s)-']","[('drugbank', array(['DB14575'], dtype=object))]",,"{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for epilepsy.
CHEMBL3186492,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl.O.O,VRSLTNZJOUZKLX-UHFFFAOYSA-N,Small molecule,False,ONDANSETRON HYDROCHLORIDE,1991.0,4.0,CHEMBL46,False,True,"['Demorem' 'Ondansetron hydrochloride'
 'Ondansetron hydrochloride preservative free' 'Ondemet' 'Setofilm'
 'Zofran' 'Zofran preservative free']","['GR 38032F' 'GR-38032F' 'NSC-665799' 'Odansetron hydrochloride'
 'Ondansetron (as hydrochloride)' 'Ondansetron hcl'
 'Ondansetron hydrochloride' 'Ondansetron hydrochloride dihydrate'
 'Ondansetron hydrochloride hydrate' 'Ondansetron monohydrochloride'
 'SN 307' 'SN-307' 'Zophren']","[('DailyMed', array(['ondansetron%20hydrochloride'], dtype=object)), ('PubChem', array(['144206896'], dtype=object))]",,"{'rows': array(['EFO_0004888', 'EFO_0006911', 'EFO_0011023', 'MONDO_0004992',
       'HP_0002018', 'EFO_0003843', 'EFO_0007386', 'HP_0002013',
       'HP_0002017', 'Orphanet_79292'], dtype=object), 'count': 10}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 6 approved and 4 investigational indications.
CHEMBL3545013,,,Small molecule,False,APN1125,,1.0,,False,False,[],['Apn1125'],,,"{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3581693,CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,BURHGPHDEVGCEZ-KJGLQBJMSA-N,Small molecule,False,BRILANESTRANT,,2.0,,False,False,[],['ARN-810' 'Brilanestrant' 'GDC-0810' 'Gdc-0810' 'RG-6046' 'RG6046'],"[('drugbank', array(['DB12253'], dtype=object))]",,"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4071864,CN1C(=O)[C@@H](NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2ccccc21,LYPAFUINURXJSG-AWEZNQCLSA-N,Small molecule,False,GSK2982772,,2.0,,False,False,[],['Gsk2982772'],,,"{'rows': array(['EFO_0003767', 'EFO_0000540', 'EFO_0000729', 'EFO_0000676',
       'EFO_0000685'], dtype=object), 'count': 5}",[ENSG00000137275],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4297739,,,Oligonucleotide,False,DANVATIRSEN,,2.0,,False,False,[],"['AZD 9150' 'AZD-9150' 'AZD9150' 'Azd9150' 'Danvatirsen' 'ISIS-481464'
 'ISIS-STAT3RX']",,,"{'rows': array(['EFO_0000182', 'EFO_0000403', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0001187', 'EFO_0000181'], dtype=object), 'count': 7}",[ENSG00000168610],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4594260,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,UQRICAQPWZSJNF-UHFFFAOYSA-N,Small molecule,False,TAZEMETOSTAT HYDROBROMIDE,2020.0,4.0,CHEMBL3414621,False,True,['Tazverik'],"['E-7438 HYDROBROMIDE' 'EPZ-6438 HYDROBROMIDE' 'EPZ-6438 MONOHYDROBROMIDE'
 'EZ-438' 'EZ438' 'Tazemetostat hydrobromide'
 'Tazemetostat monohydrobromide']","[('DailyMed', array(['tazemetostat%20hydrobromide'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAZEMETOSTAT%20HYDROBROMIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000691', 'MONDO_0008315', 'EFO_0000702', 'EFO_0000616',
       'MONDO_0018906'], dtype=object), 'count': 5}",[ENSG00000106462],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sarcoma and follicular lymphoma and has 3 investigational indications.
CHEMBL4647810,C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1,YBXRSCXGRPSTMW-CYBMUJFWSA-N,Small molecule,False,ELIMUSERTIB,,1.0,,False,False,[],['BAY-1895344' 'Elimusertib'],,,"{'rows': array(['MONDO_0008170', 'EFO_1001469', 'EFO_0000616'], dtype=object), 'count': 3}",[ENSG00000175054],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL4650319,C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,AZSRSNUQCUDCGG-UHFFFAOYSA-N,Small molecule,True,MOBOCERTINIB,2021.0,4.0,,False,True,[],['AP-32788' 'AP32788' 'Mobocertinib' 'TAK-788' 'Tak-788'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOBOCERTINIB/relevant/1/'],
      dtype=object))]",['CHEMBL4802239'],"{'rows': array(['EFO_0003086', 'EFO_0001421', 'EFO_0003060', 'EFO_0000616',
       'EFO_0003060'], dtype=object), 'count': 5}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL485,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341,OROGSEYTTFOCAN-DNJOTXNNSA-N,Small molecule,True,CODEINE,1952.0,4.0,,False,True,[],"['Codeine' 'Codeine monohydrate' 'Codeinum' 'Codeinum monohydricum'
 'Dea no. 9050' 'IDS-NC-005(SECT.-2)']","[('PubChem', array(['144207280'], dtype=object)), ('Wikipedia', array(['Codeine'], dtype=object)), ('drugbank', array(['DB00318'], dtype=object)), ('chEBI', array(['16714'], dtype=object))]","['CHEMBL4297091' 'CHEMBL1257022' 'CHEMBL1159819' 'CHEMBL284671'
 'CHEMBL369475' 'CHEMBL1201463' 'CHEMBL1201099']","{'rows': array(['HP_0000545', 'HP_0002019', 'EFO_0003890', 'MONDO_0005277',
       'EFO_0003843', 'HP_0030833', 'HP_0003394', 'EFO_0003843',
       'EFO_0000764', 'EFO_0010072', 'MONDO_0011382', 'HP_0012735',
       'EFO_0003843', 'HP_0012735', 'EFO_0003890', 'HP_0011868',
       'MONDO_0005178'], dtype=object), 'count': 17}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 5 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL533,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1,ALOBUEHUHMBRLE-UHFFFAOYSA-N,Small molecule,True,IBUTILIDE,1995.0,4.0,,False,True,[],['Ibutilide'],"[('Wikipedia', array(['Ibutilide'], dtype=object)), ('drugbank', array(['DB00308'], dtype=object)), ('chEBI', array(['5856'], dtype=object))]",['CHEMBL3187455' 'CHEMBL2355456'],"{'rows': array(['EFO_0004269'], dtype=object), 'count': 1}",[ENSG00000055118],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for cardiac arrhythmia. This drug has a black box warning from the FDA.
CHEMBL548,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O,XEYBRNLFEZDVAW-ARSRFYASSA-N,Small molecule,False,DINOPROSTONE,1977.0,4.0,,False,True,['Cervidil' 'Prepidil' 'Propess' 'Prostin e2'],"['Dinoprostone' 'Dinoprostone beta-cyclodextrin clathrate' 'Enzaprost e'
 'Minprostin e2' 'NSC-165560' 'NSC-196514' 'Prostaglandin e2' 'U-12,062'
 'U-12062']","[('DailyMed', array(['dinoprostone'], dtype=object)), ('PubChem', array(['144204747', '170465000', '26753268', '26753269', '26753270',
       '50105679'], dtype=object)), ('Wikipedia', array(['Prostaglandin_E2'], dtype=object)), ('drugbank', array(['DB00917'], dtype=object)), ('chEBI', array(['15551'], dtype=object))]",,"{'rows': array(['EFO_1001799', 'EFO_0002950', 'MONDO_0003061', 'EFO_0003843',
       'EFO_0000495'], dtype=object), 'count': 5}","[ENSG00000160951,ENSG00000171522,ENSG00000125384,ENSG00000050628]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 investigational indications.
CHEMBL588,Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1,TVURRHSHRRELCG-UHFFFAOYSA-N,Small molecule,False,FENOLDOPAM,1997.0,4.0,,False,True,[],['Carlacor' 'Fenoldopam' 'SK&F-82526' 'SK-82526'],"[('PubChem', array(['104171160', '144203703', '170465321', '26752227', '50104923',
       '90340762'], dtype=object)), ('Wikipedia', array(['Fenoldopam'], dtype=object)), ('drugbank', array(['DB00800'], dtype=object)), ('chEBI', array(['5002'], dtype=object))]",['CHEMBL1256646' 'CHEMBL1026'],"{'rows': array(['EFO_0000537', 'HP_0001919', 'EFO_0000537', 'EFO_0000319',
       'EFO_1002048', 'HP_0001919'], dtype=object), 'count': 6}",[ENSG00000184845],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hypertension and cardiovascular disease and has 4 investigational indications.
CHEMBL605,CCN(CC)CCNC(=O)c1ccc(N)cc1.Cl,ABTXGJFUQRCPNH-UHFFFAOYSA-N,Small molecule,True,PROCAINAMIDE HYDROCHLORIDE,1950.0,4.0,CHEMBL640,False,True,"['Biocoryl' 'Novocainamid' 'Procainamide hydrochloride' 'Procan'
 'Procan sr' 'Procanbid' 'Procapan' 'Pronestyl' 'Pronestyl-sr']","['Amidoprocaine' 'Cardiorytmin' 'NSC-757279' 'Procainamide HCl'
 'Procainamide hcl' 'Procainamide hydrochloride'
 'Procainamidi hydrochloridum']","[('DailyMed', array(['procainamide%20hydrochloride'], dtype=object)), ('PubChem', array(['144210053', '26747643', '50106886', '56423113', '855728'],
      dtype=object)), ('chEBI', array(['8429'], dtype=object))]",,"{'rows': array(['HP_0004308', 'EFO_0004269', 'EFO_0003144', 'EFO_0000275'],
      dtype=object), 'count': 4}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL654,CN1CCN2c3ncccc3Cc3ccccc3C2C1,RONZAEMNMFQXRA-UHFFFAOYSA-N,Small molecule,True,MIRTAZAPINE,1996.0,4.0,,False,True,['Mirtazapine' 'Remeron' 'Remeron soltab' 'Zispin'],"['6-azamianserin' 'Avanza' 'Mirataz' 'Mirtazapin' 'Mirtazapine'
 'Mirtazapine anhydrous' 'Norset' 'ORG 3770' 'ORG-3770' 'Promyrtil'
 'Rexer']","[('DailyMed', array(['mirtazapine'], dtype=object)), ('PubChem', array(['144204516', '29215050', '49648465'], dtype=object)), ('Wikipedia', array(['Mirtazapine'], dtype=object)), ('drugbank', array(['DB00370'], dtype=object)), ('chEBI', array(['6950'], dtype=object))]",['CHEMBL5315116'],"{'rows': array(['HP_0004326', 'HP_0002039', 'EFO_0005687', 'EFO_0002610',
       'MONDO_0002050', 'EFO_0004240', 'EFO_0004888', 'MONDO_0005090',
       'HP_0000726', 'MONDO_0007079', 'EFO_0005230', 'MONDO_0002491',
       'MONDO_0005351', 'HP_0001824', 'EFO_0004698', 'MONDO_0002009',
       'EFO_0003890', 'EFO_0003918', 'EFO_0004701', 'EFO_0000326',
       'EFO_0006911', 'MONDO_0002009', 'EFO_0003756'], dtype=object), 'count': 23}","[ENSG00000102468,ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL738,CCCC(C)C1(CC)C(=O)[N-]C(=S)NC1=O.[Na+],AWLILQARPMWUHA-UHFFFAOYSA-M,Small molecule,False,THIOPENTAL SODIUM,1982.0,4.0,CHEMBL441,False,True,"['Intraval' 'Intraval sod' 'Penthiobarbital' 'Pentothal' 'Thiomebumal'
 'Thionembutal' 'Thiopentone' 'Trapanal']","['Farmotal' 'Hypnostan' 'Leopental' 'NSC-759557' 'Nesdonal'
 'Penthiobarbital sodium' 'Ravonal' 'Sodium pentothal' 'Sodium thiopental'
 'Thiomebumal sodium' 'Thiopental Sodium' 'Thiopental sodium'
 'Thiopentalum natricum' 'Thiopentobarbitone sodium' 'Thiopentone'
 'Thiopentone sodium' 'Trapanal']","[('PubChem', array(['144205294', '170464734', '26749790'], dtype=object)), ('Wikipedia', array(['Sodium_thiopental'], dtype=object)), ('chEBI', array(['9561'], dtype=object))]",,"{'rows': array(['EFO_1001454'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.
CHEMBL939,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,XGALLCVXEZPNRQ-UHFFFAOYSA-N,Small molecule,False,GEFITINIB,2003.0,4.0,,False,True,['Iressa'],['Gefitinib' 'Iressa' 'NSC-759856' 'ZD-1839' 'ZD1839'],"[('DailyMed', array(['gefitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/iressa'],
      dtype=object)), ('PubChem', array(['103905343', '103905344', '124892204', '124892206', '137275808',
       '144205236', '170464828', '29215403', '50100103'], dtype=object)), ('Wikipedia', array(['Gefitinib'], dtype=object)), ('drugbank', array(['DB00317'], dtype=object)), ('chEBI', array(['49668'], dtype=object))]",,"{'rows': array(['EFO_0000514', 'EFO_0000702', 'EFO_0000182', 'EFO_0003869',
       'EFO_0000222', 'MONDO_0001187', 'EFO_0003060', 'EFO_0000708',
       'MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0000616',
       'EFO_1000158', 'MONDO_0002367', 'EFO_0000313', 'MONDO_0004992',
       'EFO_0004252', 'EFO_0000681', 'EFO_0003859', 'EFO_0000588',
       'EFO_0002618', 'EFO_1001951', 'EFO_0000571', 'EFO_0000691',
       'EFO_0000181', 'MONDO_0004192', 'MONDO_0002158', 'EFO_0001071',
       'MONDO_0004669', 'EFO_0000308', 'EFO_0000707', 'EFO_0000519',
       'MONDO_0021117', 'EFO_0006861', 'EFO_0000621', 'MONDO_0002898',
       'MONDO_0002087', 'MONDO_0002974', 'MONDO_0007576', 'EFO_1000251',
       'MONDO_0008903', 'EFO_1001100', 'EFO_0006859', 'EFO_1001465',
       'EFO_0000178', 'EFO_0004284', 'MONDO_0008170', 'EFO_0003897'],
      dtype=object), 'count': 48}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 45 investigational indications.
CHEMBL1091644,C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1,PKCDDUHJAFVJJB-VLZXCDOPSA-N,Small molecule,False,LINSITINIB,,3.0,,False,False,[],['ASP-7487' 'Linsitinib' 'OSI-906' 'OSI-906AA'],"[('drugbank', array(['DB06075'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_1001951', 'EFO_0000702', 'EFO_0000174',
       'EFO_0006859', 'MONDO_0002898', 'EFO_0000181', 'EFO_0003060',
       'EFO_0000673', 'MONDO_0007254', 'EFO_0000182', 'EFO_1000796',
       'EFO_0000616'], dtype=object), 'count': 13}","[ENSG00000140443,ENSG00000171105]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL1200798,Cl.O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,OHHDIOKRWWOXMT-UHFFFAOYSA-N,Small molecule,True,TRAZODONE HYDROCHLORIDE,1981.0,4.0,CHEMBL621,False,True,"['Desyrel' 'Molipaxin' 'Molipaxin cr' 'Oleptro' 'Trazodone hydrochloride'
 'Trialodine']",['AF-1161' 'NSC-292811' 'Trazodone hcl' 'Trazodone hydrochloride'],"[('DailyMed', array(['trazodone%20hydrochloride'], dtype=object)), ('PubChem', array(['124891691', '144203837', '144213002', '170465234', '26747679',
       '50107085', '56423658', '855917'], dtype=object)), ('chEBI', array(['9655'], dtype=object))]",,"{'rows': array(['MONDO_0004976', 'MONDO_0002050', 'MONDO_0002009', 'MONDO_0002009'],
      dtype=object), 'count': 4}","[ENSG00000102468,ENSG00000147246,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for depressive disorder and major depressive disorder and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1200828,Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1,WBCWFMFZMRFRLT-UHFFFAOYSA-N,Small molecule,False,CYCRIMINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201227,False,True,['Pagitane'],['Cycrimine HCl' 'Cycrimine hcl' 'Cycrimine hydrochloride' 'NSC-169452'],"[('chEBI', array(['59693'], dtype=object))]",,,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201496,,,Protein,False,INSULIN ASPART,2000.0,4.0,,False,True,"['Fiasp' 'Fiasp flextouch' 'Fiasp penfill' 'Ins novorapid' 'Novolog'
 'Novolog flexpen' 'Novolog flextouch' 'Novolog innolet' 'Novolog penfill']",['B28-ASP-INSULIN' 'INA-X14' 'INSULIN X14' 'Insulin aspart'],"[('DailyMed', array(['insulin%20aspart', 'insulin%20aspart%20recombinant'], dtype=object)), ('DrugCentral', array(['4981'], dtype=object)), ('Wikipedia', array(['Insulin_aspart'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_0000565', 'EFO_0003914', 'EFO_0000400',
       'MONDO_0005148', 'EFO_0004593', 'MONDO_0004975', 'EFO_0000537',
       'EFO_0001645', 'MONDO_0005147', 'HP_0003124', 'MONDO_0009061'],
      dtype=object), 'count': 12}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for diabetes mellitus and has 11 investigational indications.
CHEMBL1201832,,,Protein,False,ROMIPLOSTIM,2008.0,4.0,,False,True,['Nplate'],['AMG 531' 'Romiplate' 'Romiplostim'],"[('DailyMed', array(['romiplostim'], dtype=object)), ('DrugCentral', array(['4996'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nplate'],
      dtype=object)), ('Wikipedia', array(['Romiplostim'], dtype=object))]",,"{'rows': array(['MONDO_0010518', 'MONDO_0018896', 'HP_0001873', 'EFO_0000198',
       'MP_0001914', 'MONDO_0008170', 'EFO_0000519', 'EFO_0000313',
       'HP_0001915', 'MONDO_0004992', 'EFO_0006927', 'EFO_0000574',
       'EFO_0007160', 'EFO_0005952', 'MONDO_0043768'], dtype=object), 'count': 15}",[ENSG00000117400],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 12 investigational indications.
CHEMBL1237123,COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC,GBLRQXKSCRCLBZ-UHFFFAOYSA-N,Small molecule,False,DOXACURIUM,1991.0,4.0,,False,True,[],['Doxacurium cation' 'Doxacurium ion'],"[('drugbank', array(['DB01135'], dtype=object)), ('chEBI', array(['4706'], dtype=object))]",['CHEMBL1237099'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991.
CHEMBL1271,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,XSBSKEQEUFOSDD-UHFFFAOYSA-N,Small molecule,False,PENTOLINIUM,1982.0,4.0,,False,True,[],"['Ansolysen' 'Pentolinium' 'Pentolinium cation' 'Pentolinium ion'
 'Pentolonium']","[('Wikipedia', array(['Pentolinium'], dtype=object)), ('drugbank', array(['DB01090'], dtype=object)), ('chEBI', array(['347401'], dtype=object))]",['CHEMBL118902' 'CHEMBL1356989' 'CHEMBL1318287'],,"[ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1487,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,XUKUURHRXDUEBC-KAYWLYCHSA-N,Small molecule,False,ATORVASTATIN,1996.0,4.0,,False,True,['Cardyl' 'Lipitor' 'Prevencor' 'Sortis' 'Tahor' 'Zarator'],['Atorvastatin'],"[('PubChem', array(['124892211', '144212734', '29215408'], dtype=object)), ('Wikipedia', array(['Atorvastatin'], dtype=object)), ('drugbank', array(['DB01076'], dtype=object)), ('chEBI', array(['39548'], dtype=object))]",['CHEMBL393220' 'CHEMBL1790017' 'CHEMBL3349878'],"{'rows': array(['MONDO_0011382', 'EFO_0003767', 'EFO_0009426', 'EFO_0004211',
       'EFO_0008568', 'EFO_0000612', 'EFO_0003086', 'MONDO_0019338',
       'MONDO_0005301', 'EFO_0008586', 'Orphanet_309005', 'EFO_1001771',
       'EFO_0000275', 'EFO_0000196', 'EFO_0001361', 'EFO_0000764',
       'EFO_0003914', 'MONDO_0018076', 'EFO_0004911', 'EFO_0003869',
       'EFO_0006818', 'EFO_0004616', 'EFO_0000616', 'EFO_0000685',
       'EFO_0009783', 'MONDO_0002492', 'HP_0100543', 'MONDO_0001444',
       'EFO_0000319', 'EFO_0000180', 'MONDO_0008315', 'EFO_0000519',
       'EFO_0000319', 'MONDO_0004782', 'EFO_0003913', 'EFO_0000660',
       'Orphanet_79211', 'EFO_0000538', 'EFO_0001645', 'EFO_0000373',
       'MONDO_0043510', 'EFO_0004211', 'MONDO_0011962', 'EFO_0000195',
       'EFO_0000673', 'EFO_1001249', 'EFO_0000384', 'EFO_0003047',
       'EFO_0000318', 'MONDO_0004992', 'EFO_1001466', 'EFO_0003870',
       'EFO_0000649', 'EFO_0000574', 'EFO_0004252', 'EFO_0001073',
       'EFO_0000681', 'EFO_0001378', 'Orphanet_309005', 'EFO_0003914',
       'EFO_0001365', 'EFO_0000668', 'EFO_0004911', 'EFO_0004194',
       'EFO_0003918', 'EFO_0000195', 'EFO_0000649', 'EFO_0000565',
       'MONDO_0021187', 'MONDO_0007915', 'EFO_0001645', 'MONDO_0018473',
       'EFO_0001422', 'EFO_0000198', 'EFO_0007328', 'EFO_0007129',
       'EFO_0005672', 'MONDO_0002679', 'HP_0003124', 'MONDO_0021661',
       'EFO_0003095', 'EFO_0000676', 'MONDO_0013730', 'MONDO_0018373',
       'MONDO_0021187', 'HP_0003119', 'MONDO_0005147', 'EFO_0000222',
       'EFO_0007160', 'EFO_0008583', 'EFO_0003884', 'MONDO_0007254',
       'EFO_0000712', 'EFO_0004208', 'HP_0003124', 'EFO_0004264',
       'EFO_1000984', 'EFO_1001993', 'EFO_0005952', 'Orphanet_413',
       'MONDO_0001134', 'MONDO_0007254', 'EFO_0000537', 'MONDO_0005148',
       'EFO_0008585', 'EFO_0003144', 'HP_0001258', 'EFO_0004255',
       'MONDO_0005835', 'EFO_0004246', 'EFO_0000400', 'EFO_0003929',
       'EFO_0000365', 'EFO_0004236', 'EFO_0007243', 'EFO_0004286',
       'EFO_0003047', 'HP_0100806', 'Orphanet_79211', 'EFO_1001801',
       'EFO_0000474', 'HP_0000083', 'MONDO_0004979', 'MONDO_0005148',
       'MONDO_0004975', 'MONDO_0100096', 'MONDO_0002050', 'HP_0001647',
       'EFO_0000400'], dtype=object), 'count': 129}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 14 approved and 106 investigational indications.
CHEMBL1651534,O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1,BATCTBJIJJEPHM-UHFFFAOYSA-N,Small molecule,False,REDAFAMDASTAT,,2.0,,False,False,[],['PF-04457845' 'PF-4457845' 'Pf-04457845' 'Redafamdastat'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object)), ('Wikipedia', array(['PF-04457845'], dtype=object)), ('drugbank', array(['DB12012'], dtype=object))]",,"{'rows': array(['EFO_0004616', 'EFO_0007191', 'HP_0012532', 'EFO_0001358',
       'EFO_0004895'], dtype=object), 'count': 5}",[ENSG00000117480],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1738699,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1,YVPGZQLRPAGKLA-UHFFFAOYSA-N,Small molecule,False,N6022,,3.0,,False,False,[],['N-6022' 'N6022'],"[('drugbank', array(['DB12206'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'MONDO_0009061'], dtype=object), 'count': 2}",[ENSG00000197894],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1922094,Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12,YOVVNQKCSKSHKT-HNNXBMFYSA-N,Small molecule,False,APITOLISIB,,2.0,,False,False,[],"['Apitolisib' 'G-038390' 'G-038390.1' 'GDC-0980' 'GDC-0980.1' 'Gne-390'
 'RG-7422' 'RG7422' 'Rg-7422']","[('drugbank', array(['DB12180'], dtype=object))]",['CHEMBL1922103' 'CHEMBL1922106'],"{'rows': array(['MONDO_0004992', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0007254',
       'EFO_0000681', 'EFO_1001512'], dtype=object), 'count': 6}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL2010872,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3,AEULIVPVIDOLIN-UHFFFAOYSA-N,Small molecule,False,CEP-11981,,2.0,,False,False,[],['BOL-303213X' 'CEP-11981' 'CEP11981' 'Cep 11981' 'Cep-11981'],,,"{'rows': array(['EFO_0000196', 'MONDO_0004992'], dtype=object), 'count': 2}","[ENSG00000120156,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2070241,CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O,FFHBJDQSGDNCIV-MFVUMRCOSA-N,Protein,False,BREMELANOTIDE,2019.0,4.0,,False,True,['Bremelanotide'],['Bremelanotide' 'PT-141' 'PT-141 FREE BASE'],"[('drugbank', array(['DB11653'], dtype=object))]",['CHEMBL4297533'],"{'rows': array(['EFO_0000677', 'EFO_0004714', 'EFO_0003086', 'EFO_0004714',
       'HP_0002018'], dtype=object), 'count': 5}",[ENSG00000166603],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for mental or behavioural disorder and sexual dysfunction and has 3 investigational indications.
CHEMBL2103839,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,BUROJSBIWGDYCN-GAUTUEMISA-N,Small molecule,False,RIDAFOROLIMUS,,3.0,,False,False,[],['AP 23573' 'AP-23573' 'AP23573' 'MK-8669' 'MK8669' 'Ridaforolimus'],"[('drugbank', array(['DB06233'], dtype=object)), ('chEBI', array(['79700'], dtype=object))]",,"{'rows': array(['EFO_0000569', 'MONDO_0008315', 'EFO_0003869', 'MONDO_0021054',
       'EFO_0001378', 'EFO_0002430', 'EFO_0000637', 'EFO_1001968',
       'EFO_1001465', 'EFO_0000574', 'MONDO_0011962', 'EFO_0003060',
       'EFO_0000198', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0000691', 'EFO_0000565', 'EFO_0000564'], dtype=object), 'count': 19}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications.
CHEMBL2105160,C[C@@H](N/C(=N\C#N)Nc1ccc(C#N)cc1)C(C)(C)C,PGYDRGZVXVVZQC-LLVKDONJSA-N,Small molecule,False,NAMINIDIL,,2.0,,False,False,[],"['BMS-234303' 'BMS-234303-01' 'Naminidil' 'Naminidil, (r)-']",,,,"[ENSG00000187486,ENSG00000069431,ENSG00000006071,ENSG00000121361]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108341,,,Antibody,False,SONTUZUMAB,,2.0,,False,False,[],['AS-1402' 'HUHMFG-1' 'Sontuzumab'],,,,[ENSG00000185499],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109428,,,Antibody,False,TRX-518,,1.0,,False,False,[],['TRX-518' 'Trx-518'],,,"{'rows': array(['MONDO_0008170', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0000756',
       'EFO_0000616'], dtype=object), 'count': 5}",[ENSG00000186891],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.
CHEMBL2109616,,,Antibody,False,ABX-IL8,,2.0,,False,False,[],['ABX-IL8' 'Abx-il8'],,,"{'rows': array(['EFO_0006505'], dtype=object), 'count': 1}",[ENSG00000169429],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2111051,C#CCO[C@H]1CN2CCC1CC2,XVFJONKUSLSKSW-JTQLQIEISA-N,Small molecule,False,TALSACLIDINE,,2.0,,False,False,[],['Talsaclidine'],"[('drugbank', array(['DB12287'], dtype=object))]",['CHEMBL2107204'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000168539,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL219410,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](n3cnnn3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CGTADGCBEXYWNE-JUKNQOCSSA-N,Small molecule,False,ZOTAROLIMUS,,3.0,,False,False,[],['ABT-578' 'Mdt-4107' 'Zotarolimus'],,,,[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of III.
CHEMBL282686,CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,CXGTZJYQWSUFET-IBGZPJMESA-N,Small molecule,False,TESAGLITAZAR,,3.0,,False,False,[],['AR-H-039242' 'AR-H039242XX' 'AZ-242' 'Az-242' 'BR-44608' 'Tesaglitazar'],"[('drugbank', array(['DB06536'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}","[ENSG00000186951,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3184437,OCc1ccc(Cl)cc1Cl,DBHODFSFBXJZNY-UHFFFAOYSA-N,Small molecule,False,DICHLOROBENZYL ALCOHOL,,4.0,,False,True,[],"['Dichlorobenzyl alcohol' 'Dybenal' 'NSC-15635'
 'Oxiconazole related compound d' 'Rapidosept']","[('PubChem', array(['144211212', '170465574'], dtype=object)), ('drugbank', array(['DB13269'], dtype=object)), ('chEBI', array(['48220'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL4105630,C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1,HARRKNSQXBRBGZ-GVKWWOCJSA-N,Small molecule,True,ZURANOLONE,2023.0,4.0,,False,True,['Zurzuvae'],['S-812217' 'SAGE-217' 'SGE-797' 'Sage-217' 'Zuranolone'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZURANOLONE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15490'], dtype=object))]",,"{'rows': array(['EFO_0007453', 'MONDO_0002009', 'EFO_0003108', 'MONDO_0005180',
       'MONDO_0002050', 'EFO_0004247'], dtype=object), 'count': 6}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for postpartum depression and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4298199,,,Gene,False,IDECABTAGENE VICLEUCEL,2021.0,4.0,,False,True,['Abecma'],"['Anti-bcma car t cell' 'BB-2121' 'Ide-cel' 'Idecabtagene vicleucel'
 'bb2121']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/abecma'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IDECABTAGENE%20VICLEUCEL/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0010283', 'HP_0001871', 'EFO_0000200', 'Orphanet_2442',
       'MONDO_0002243', 'MONDO_0021334', 'EFO_0004264', 'EFO_0001378',
       'EFO_0007326', 'MONDO_0003159', 'EFO_0000319', 'EFO_0000203',
       'EFO_0000616', 'EFO_0000540'], dtype=object), 'count': 14}",[ENSG00000048462],Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 14 approved indications.
CHEMBL435298,C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1,SYTBZMRGLBWNTM-JTQLQIEISA-N,Small molecule,False,ESFLURBIPROFEN,2015.0,4.0,,False,True,[],"['BTS 24332' 'BTS-24332' 'Esflurbiprofen' 'Flurbiprofen, (s)-']","[('PubChem', array(['47193727'], dtype=object)), ('chEBI', array(['42446'], dtype=object))]",,"{'rows': array(['HP_0002829', 'HP_0003326', 'EFO_0009582'], dtype=object), 'count': 3}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 investigational indications.
CHEMBL4594326,,,Antibody,False,APITEGROMAB,,3.0,,False,False,[],['Apitegromab' 'SRK-015' 'Srk-015'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/APITEGROMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0009673', 'MONDO_0009672', 'EFO_0008525', 'EFO_1000096',
       'HP_0003202'], dtype=object), 'count': 5}",[ENSG00000138379],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL5314408,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1,MVWATCATLSSVBH-UHFFFAOYSA-N,Small molecule,False,AZD-0424,,1.0,,False,False,[],['AZD0424' 'Azd-0424'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000197122,ENSG00000097007]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL544,COc1ccc(O)cc1,NWVVVBRKAWDGAB-UHFFFAOYSA-N,Small molecule,False,MEQUINOL,1999.0,4.0,,False,True,[],"['4-hydroxyanisole' '4-methoxyphenol' '4ha' 'BMS-181158'
 'Hqmme; hydroxyquinone methyl ether' 'Leucobasal' 'Leucodine b'
 'Mechinolum' 'Menthyl anthranilate' 'Mequinol' 'NSC-4960'
 'Novo-dermoquinona' 'P-guaiacol' 'P-hydroxyanisole']","[('PubChem', array(['144204676', '144209565', '144213193', '170464687', '17389832',
       '50105587', '71152', '85272557'], dtype=object)), ('Wikipedia', array(['Mequinol'], dtype=object)), ('drugbank', array(['DB09516'], dtype=object)), ('chEBI', array(['69441'], dtype=object))]",,,[ENSG00000077498],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999.
CHEMBL861,CCC1(c2ccccc2)NC(=O)N(C)C1=O,GMHKMTDVRCWUDX-UHFFFAOYSA-N,Small molecule,False,MEPHENYTOIN,1946.0,4.0,,False,True,['Mesantoin'],['Mephenytoin' 'Methoin' 'NSC-34652'],"[('PubChem', array(['56463168'], dtype=object)), ('Wikipedia', array(['Mephenytoin'], dtype=object)), ('drugbank', array(['DB00532'], dtype=object))]",,"{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for epilepsy.
CHEMBL1200329,Cl.Clc1ccc2nsnc2c1NC1=NCCN1,ZWUKMNZJRDGCTQ-UHFFFAOYSA-N,Small molecule,False,TIZANIDINE HYDROCHLORIDE,1996.0,4.0,CHEMBL1079,False,True,['Sirdalud' 'Sirdalud mr' 'Tizanidine hydrochloride' 'Zanaflex'],"['AN-021' 'AN021' 'DS 103-282' 'DS-103-282'
 'Tizanidine (as hydrochloride)' 'Tizanidine hcl'
 'Tizanidine hydrochloride']","[('DailyMed', array(['tizanidine%20hydrochloride'], dtype=object)), ('PubChem', array(['56320475'], dtype=object))]",,"{'rows': array(['MONDO_0043510', 'MONDO_0100431', 'HP_0001257', 'MONDO_0005475',
       'MONDO_0002959'], dtype=object), 'count': 5}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for spasticity and has 4 investigational indications.
CHEMBL1200500,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,KUVIULQEHSCUHY-XYWKZLDCSA-N,Small molecule,False,BECLOMETHASONE DIPROPIONATE,1976.0,4.0,,False,True,"['Aerobec 100' 'Aerobec 50' 'Aerobec fte 250' 'Asmabec clickhaler'
 'Asmabec spacehaler' 'Beclazone 100' 'Beclazone 100 e-breathe'
 'Beclazone 200' 'Beclazone 250' 'Beclazone 250 e-breathe' 'Beclazone 50'
 'Beclazone 50 e-breathe' 'Becloaqua 50' 'Becloforte'
 'Becloforte e-breathe' 'Becloforte integra' 'Becloforte-vm'
 'Beclomet diprop' 'Beclomet hayfever' 'Beclomist' 'Beclotaide'
 'Beclovent' 'Becodisks' 'Beconase' 'Beconase aq' 'Becotide'
 'Becotide 100' 'Becotide 100 e-breathe' 'Becotide 200' 'Becotide 50'
 'Becotide 50 e-breathe' 'Clenil modulite' 'Clipper' 'Filair 100'
 'Filair 50' 'Filair fte' 'Fostair' 'Fostair nexthaler' 'Nasobec aq'
 'Nasobec hayfever' 'Propaderm' 'Propaderm fte' 'Propaderm-a'
 'Propaderm-c' 'Pulvinal beclomet' 'Qnasl' 'Qvar 100' 'Qvar 100 e-breathe'
 'Qvar 40' 'Qvar 50' 'Qvar 50 e-breathe' 'Qvar 80' 'Qvar redihaler'
 'Rino clenil' 'Vancenase' 'Vancenase aq' 'Vancenase pockethaler'
 'Vanceril' 'Vanceril double strength' 'Ventide' 'Vivabec'
 'Zonivent aquanasal']","['Beclometasone' 'Beclometasone dipropionate' 'Beclomethasone'
 'Beclomethasone dipropionate' 'NSC-755901' 'SCH 18020W' 'SCH 8020W'
 'SCH-18020W' 'SGX-201' 'SGX-202' 'SGX-203']","[('DailyMed', array(['beclomethasone%20dipropionate',
       'beclomethasone%20dipropionate%20monohydrate'], dtype=object)), ('PubChem', array(['144206719', '56463541'], dtype=object)), ('Wikipedia', array(['Beclometasone_dipropionate'], dtype=object)), ('drugbank', array(['DB00394'], dtype=object)), ('chEBI', array(['3002'], dtype=object))]",,"{'rows': array(['HP_0006536', 'EFO_0000702', 'EFO_0003956', 'EFO_0005854',
       'MONDO_0004979', 'EFO_0007227', 'MONDO_0019091', 'HP_0002110',
       'MONDO_0043579', 'EFO_1000391', 'EFO_1001417', 'EFO_0004599',
       'EFO_1000702', 'EFO_1000644', 'EFO_0000768', 'HP_0001742',
       'MONDO_0013730', 'MONDO_0020547', 'EFO_0000544', 'EFO_0007486',
       'EFO_0004232', 'MONDO_0100096', 'EFO_0000341'], dtype=object), 'count': 23}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 6 approved and 17 investigational indications.
CHEMBL1201352,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1,HTIKWNNIPGXLGM-YLINKJIISA-N,Small molecule,False,RAPACURONIUM,1999.0,4.0,,True,True,[],['Rapacuronium' 'Rapacuronium cation' 'Rapacuronium ion'],"[('Wikipedia', array(['Rapacuronium'], dtype=object)), ('drugbank', array(['DB04834'], dtype=object))]",['CHEMBL1200549'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999.
CHEMBL1201607,,,Antibody,True,NATALIZUMAB,2004.0,4.0,,False,True,['Tysabri'],['AN100226M' 'ANTEGRAN' 'Antegren' 'Natalizumab'],"[('DailyMed', array(['natalizumab'], dtype=object)), ('DrugCentral', array(['4970'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri'],
      dtype=object)), ('Wikipedia', array(['Natalizumab'], dtype=object))]",,"{'rows': array(['MONDO_0013730', 'EFO_0008522', 'MONDO_0005090', 'EFO_0000637',
       'MONDO_0005301', 'MP_0001845', 'MONDO_0011382', 'EFO_0000685',
       'EFO_0000384', 'EFO_0004599', 'EFO_0000540', 'EFO_0003929',
       'EFO_0001378', 'EFO_0008520', 'EFO_0007323', 'HP_0002140'],
      dtype=object), 'count': 16}","[ENSG00000150093,ENSG00000115232,ENSG00000139626]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1648,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12,HMJIYCCIJYRONP-UHFFFAOYSA-N,Small molecule,False,ISRADIPINE,1990.0,4.0,,False,True,['Dynacirc' 'Dynacirc cr' 'Isradipine' 'Prescal'],['Isradipine' 'Isrodipine' 'NSC-759892' 'PN 200-110' 'PN-200-110'],"[('DailyMed', array(['isradipine'], dtype=object)), ('PubChem', array(['144204241', '170465070'], dtype=object)), ('Wikipedia', array(['Isradipine'], dtype=object)), ('drugbank', array(['DB00270'], dtype=object))]",,"{'rows': array(['EFO_0003890', 'EFO_0004319', 'EFO_0000537', 'EFO_0005611',
       'EFO_0000319', 'EFO_0003768', 'MONDO_0005180', 'MONDO_0004985'],
      dtype=object), 'count': 8}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for hypertension and cardiovascular disease and has 6 investigational indications.
CHEMBL1743023,,,Antibody,False,FULRANUMAB,,3.0,,False,False,[],['AMG 403' 'AMG-403' 'AMG403' 'Fulranumab' 'JNJ 42160443' 'JNJ-42160443'],,,"{'rows': array(['EFO_1000783', 'EFO_0003843', 'MONDO_0005178', 'HP_0012532',
       'EFO_1000869', 'HP_0003419'], dtype=object), 'count': 6}",[ENSG00000134259],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL1743051,,,Antibody,False,ONARTUZUMAB,,3.0,,False,False,[],"['METMA-B' 'Metmab' 'Onartuzumab' 'PRO-143966' 'PRO-143996' 'PRO143966'
 'RO-5490258' 'RO5490258']",,,"{'rows': array(['EFO_0000182', 'MONDO_0008903', 'MONDO_0004992', 'MONDO_0001056',
       'MONDO_0007254', 'EFO_0000519', 'EFO_0003060', 'EFO_0000616',
       'EFO_1001951'], dtype=object), 'count': 9}",[ENSG00000105976],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL19,CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C,FLOSMHQXBMRNHR-QPJJXVBHSA-N,Small molecule,False,METHAZOLAMIDE,1959.0,4.0,,False,True,['Methazolamide' 'Neptazane'],"['L-584601' 'Methazolamide' 'Methenamide' 'NSC-758426' 'Neptazaneat'
 'VVP-808' 'VVP808']","[('DailyMed', array(['methazolamide'], dtype=object)), ('PubChem', array(['11112413', '56422398', '855821'], dtype=object)), ('Wikipedia', array(['Methazolamide'], dtype=object)), ('chEBI', array(['6822'], dtype=object))]",,"{'rows': array(['MONDO_0005041', 'EFO_1000782', 'EFO_0004190', 'MONDO_0002974'],
      dtype=object), 'count': 4}","[ENSG00000168748,ENSG00000133742,ENSG00000104267,ENSG00000167434]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for glaucoma and open-angle glaucoma and has 2 investigational indications.
CHEMBL204021,CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2,WDPFJWLDPVQCAJ-UHFFFAOYSA-N,Small molecule,False,DARAPLADIB,,3.0,,False,False,[],['Darapladib' 'SB-480848'],"[('drugbank', array(['DB06311'], dtype=object))]",['CHEMBL3793364'],"{'rows': array(['EFO_0005672', 'EFO_0003914', 'EFO_0003770'], dtype=object), 'count': 3}",[ENSG00000146070],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2105682,CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1,ZLFZITWZOYXXAW-QXXZOGQOSA-N,Small molecule,True,EDOXABAN TOSYLATE,2015.0,4.0,CHEMBL1269025,False,True,['Roteas' 'Savaysa'],['DU-176B' 'Edoxaban tosilate' 'Edoxaban tosylate'],"[('DailyMed', array(['edoxaban%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/roteas'],
      dtype=object)), ('chEBI', array(['85975'], dtype=object))]",,"{'rows': array(['EFO_0003827', 'EFO_0003907', 'EFO_0000712', 'MONDO_0000831',
       'EFO_0004286', 'EFO_0000275'], dtype=object), 'count': 6}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2110814,CNCCC(c1cccc(F)c1)c1cccc(F)c1,MUGNLPWYHGOJEG-UHFFFAOYSA-N,Small molecule,False,DELUCEMINE,,2.0,,False,False,[],['Delucemine'],,['CHEMBL2106165'],,"[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2111110,C1CCC2(C1)[C@H]1CN(CC3CC3)C[C@@H]2CN(CC2CC2)C1,CTIRHWCPXYGDGF-HDICACEKSA-N,Small molecule,False,TEDISAMIL,,3.0,,False,False,[],['KC-8857' 'KC8857' 'Tedisamil'],,['CHEMBL2107378'],"{'rows': array(['EFO_0003911', 'EFO_0004269', 'EFO_0000275'], dtype=object), 'count': 3}","[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL344159,Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,GYHCTFXIZSNGJT-UHFFFAOYSA-N,Small molecule,True,TOLVAPTAN,2009.0,4.0,,False,True,['Jinarc' 'Jynarque' 'Samsca'],['OPC-41061' 'OPC-41061(TOLVAPTAN)' 'Tolvaptan'],"[('DailyMed', array(['tolvaptan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc'],
      dtype=object)), ('PubChem', array(['124894207', '144206807'], dtype=object)), ('Wikipedia', array(['Tolvaptan'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_1001496', 'EFO_0001422', 'EFO_1001771',
       'EFO_0000313', 'HP_0002094', 'EFO_0008620', 'EFO_1000982',
       'EFO_0003884', 'HP_0002902', 'EFO_0003086', 'EFO_0000373',
       'EFO_0003144', 'EFO_0004253'], dtype=object), 'count': 14}",[ENSG00000126895],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545299,,,Small molecule,False,BMS-698769,,1.0,,False,False,[],['Bms-698769'],,,,[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL395429,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,XNOPRXBHLZRZKH-DSZYJQQASA-N,Protein,True,OXYTOCIN,1980.0,4.0,,False,True,['Orasthin' 'Oxytocin' 'Pitocin' 'Syntocinon' 'Syntometrine'],"['Alpha-hypophamine' 'Endopituitrina' 'Intertocine s' 'Oxytocin'
 'Oxytocinum' 'TNX-1900' 'TNX1900' 'TTA-121']","[('DailyMed', array(['oxytocin'], dtype=object)), ('PubChem', array(['50112429'], dtype=object)), ('chEBI', array(['7872'], dtype=object))]",['CHEMBL3185709'],"{'rows': array(['EFO_0002610', 'EFO_1000948', 'MONDO_0007079', 'EFO_0001073',
       'EFO_0004242', 'MONDO_0100096', 'EFO_0003918', 'EFO_0003758',
       'MONDO_0005090', 'EFO_0000668', 'MONDO_0017276', 'EFO_0004714',
       'EFO_0004616', 'EFO_0010702', 'EFO_0003756', 'EFO_0005411',
       'EFO_0009579', 'HP_0000360', 'MONDO_0002009', 'MP_0001845',
       'EFO_0004566', 'MONDO_0008300', 'EFO_0003888', 'MONDO_0002025',
       'EFO_0004247', 'EFO_0000612', 'MONDO_0005351', 'EFO_0005611',
       'EFO_0004777', 'EFO_1001271', 'MONDO_0002050', 'HP_0012532',
       'EFO_1000911', 'EFO_1001863', 'EFO_0000432', 'EFO_0003877',
       'EFO_0003843', 'EFO_1000096', 'EFO_0001072', 'EFO_0005762',
       'EFO_1001917', 'EFO_0001358', 'EFO_0003890', 'MONDO_0004782',
       'EFO_0005203', 'MONDO_0002491', 'EFO_0010642', 'EFO_0004269',
       'MONDO_0010383', 'MP_0001914'], dtype=object), 'count': 50}",[ENSG00000180914],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for uterine inertia and hemorrhage and has 48 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4802152,O=C(c1cc(Cn2c(=O)[nH]c(=O)c3c(F)cccc32)ccc1F)N1CCN(c2ncccn2)CC1,VBTUJTGLLREMNW-UHFFFAOYSA-N,Small molecule,False,SENAPARIB,,2.0,,False,False,[],['IMP-4297' 'IMP4297' 'Imp4297' 'Senaparib'],,,"{'rows': array(['EFO_0000702', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0008170',
       'MONDO_0007254', 'MONDO_0008315'], dtype=object), 'count': 6}","[ENSG00000129484,ENSG00000143799]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL509,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,SBDNJUWAMKYJOX-UHFFFAOYSA-N,Small molecule,True,MECLOFENAMIC ACID,1980.0,4.0,,False,True,[],"['CI-583' 'CL-583' 'INF 4668' 'INF-4668' 'Meclodium' 'Meclofenamate'
 'Meclofenamic acid' 'Meclomen' 'NSC-95309']","[('PubChem', array(['24424562', '26751537', '90341585'], dtype=object)), ('Wikipedia', array(['Meclofenamic_acid'], dtype=object)), ('drugbank', array(['DB00939'], dtype=object)), ('chEBI', array(['6710'], dtype=object))]",['CHEMBL1562610' 'CHEMBL876'],"{'rows': array(['HP_0003326', 'MONDO_0005178', 'EFO_0005755', 'HP_0001945',
       'EFO_0000685', 'HP_0002829', 'EFO_0002609', 'HP_0100607'],
      dtype=object), 'count': 8}","[ENSG00000012779,ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 8 approved indications. This drug has a black box warning from the FDA.
CHEMBL518924,NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21,WVLHHLRVNDMIAR-IBGZPJMESA-N,Small molecule,False,MAVORIXAFOR,,3.0,,False,False,[],"['AMD-070' 'AMD-11070' 'AMD070' 'AMD11070' 'Amd 070'
 'Cxcr4 inhibitor x4p-001' 'Mavorixafor' 'X 4P-001' 'X4P-001' 'X4p001']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MAVORIXAFOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB05501'], dtype=object))]",['CHEMBL4203190'],"{'rows': array(['EFO_0009441', 'EFO_0000756', 'EFO_0000616', 'EFO_0000764',
       'MONDO_0007254', 'MONDO_0001475', 'EFO_0000349'], dtype=object), 'count': 7}",[ENSG00000121966],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL931,FC(F)(F)C(Cl)Br,BCQZXOMGPXTTIC-UHFFFAOYSA-N,Small molecule,False,HALOTHANE,1958.0,4.0,,False,True,['Fluothane' 'Halothane' 'Rhidialothan'],['FREON 123B1' 'Halothane' 'Halothanum' 'NSC-143490'],"[('PubChem', array(['144204584', '144208048', '170464645', '17388981'], dtype=object)), ('Wikipedia', array(['Halothane'], dtype=object)), ('drugbank', array(['DB01159'], dtype=object)), ('chEBI', array(['5615'], dtype=object))]",['CHEMBL3250431'],,"[ENSG00000169427,ENSG00000082482,ENSG00000186795,ENSG00000145888,ENSG00000109738,ENSG00000100433,ENSG00000171303,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958.
CHEMBL9967,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1,RMHMFHUVIITRHF-UHFFFAOYSA-N,Small molecule,False,PIRENZEPINE,,4.0,,False,True,['Gastri p' 'Gastrozepin'],['ACI-91' 'Pirenzepine'],"[('PubChem', array(['104171218', '11111661', '11111662', '11113363', '144203790',
       '170465793', '26751604', '90341394'], dtype=object)), ('Wikipedia', array(['Pirenzepine'], dtype=object)), ('drugbank', array(['DB00670'], dtype=object)), ('chEBI', array(['8247'], dtype=object))]",['CHEMBL1257024' 'CHEMBL1531864'],"{'rows': array(['EFO_0003948', 'HP_0004398'], dtype=object), 'count': 2}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastroesophageal reflux disease and peptic ulcer.
CHEMBL1200492,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl,DYCKFEBIOUQECE-UHFFFAOYSA-N,Small molecule,True,NEFAZODONE HYDROCHLORIDE,1994.0,4.0,CHEMBL623,True,True,['Dutonin' 'Nefazodone hydrochloride' 'Serzone'],"['BMY 13754' 'BMY-13754' 'MJ 13,754-1' 'MJ-13754-1' 'NSC-760344'
 'Nefazodone hcl' 'Nefazodone hydrochloride']","[('DailyMed', array(['nefazodone%20hydrochloride'], dtype=object)), ('PubChem', array(['144205288', '144207123', '170465078', '26719737', '49681554'],
      dtype=object)), ('chEBI', array(['7495'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000108576,ENSG00000147246,ENSG00000103546,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994 and is indicated for major depressive disorder. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1200666,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,LWQQLNNNIPYSNX-UROSTWAQSA-N,Small molecule,False,CALCIPOTRIENE,1993.0,4.0,,False,True,['Calcipotriene' 'Dovobet' 'Dovonex' 'Enstilar' 'Sorilux' 'Xamiol'],"['Calcipotriene' 'Calcipotriene hydrate' 'Calcipotriene monohydrate'
 'Calcipotriol' 'Calcipotriol anhydrous' 'Calcipotriol hydrate'
 'Calcipotriol monohydrate' 'Calciptriol' 'MC 903' 'MC-903' 'PRI-2201']","[('DailyMed', array(['calcipotriene', 'calcipotriene%20hydrate'], dtype=object)), ('PubChem', array(['144206022', '170464710', '49681738', '50112719'], dtype=object)), ('drugbank', array(['DB02300'], dtype=object)), ('chEBI', array(['50749'], dtype=object))]",,"{'rows': array(['EFO_0000707', 'MONDO_0043771', 'EFO_1001361', 'EFO_0003894',
       'EFO_1001993', 'EFO_0004208', 'EFO_1001494', 'EFO_0000701',
       'HP_0000964', 'EFO_0000274', 'EFO_0000676', 'EFO_0002496'],
      dtype=object), 'count': 12}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for psoriasis vulgaris and psoriasis and has 10 investigational indications.
CHEMBL1201271,CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1,MOYGZHXDRJNJEP-UHFFFAOYSA-N,Small molecule,False,BUCLIZINE,1982.0,4.0,,False,True,[],['Buclizine'],"[('Wikipedia', array(['Buclizine'], dtype=object)), ('drugbank', array(['DB00354'], dtype=object)), ('chEBI', array(['3205'], dtype=object))]",['CHEMBL2360580' 'CHEMBL1200403'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease.
CHEMBL1201477,,,Small molecule,False,POLYESTRADIOL PHOSPHATE,1957.0,4.0,,False,True,['Estradurin' 'Polyest phos'],"['Estradiol phosphate polymer' 'LEO 114' 'LEO-114'
 'Polyestradiol phos phosphate' 'Polyestradiol phosphate']","[('DrugCentral', array(['3482'], dtype=object)), ('Wikipedia', array(['Polyestradiol_phosphate'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for neoplasm.
CHEMBL1201536,,,Small molecule,False,NICOTINE POLACRILEX,1984.0,4.0,CHEMBL3,False,True,['Commit' 'Nicorette' 'Nicorette (mint)' 'Nicotine polacrilex' 'Thrive'],['Nicotine polacrilex'],"[('DailyMed', array(['nicotine%20polacrilex'], dtype=object))]",,"{'rows': array(['EFO_0004318', 'MONDO_0002050', 'EFO_0003768'], dtype=object), 'count': 3}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 investigational indications.
CHEMBL127516,CCCCOC(=O)c1ccc(N)cc1,IUWVALYLNVXWKX-UHFFFAOYSA-N,Small molecule,False,BUTAMBEN,,4.0,,True,True,[],"['Butamben' 'Butyl aminobenzoate' 'Butyl p-aminobenzoate' 'Butyl paba'
 'NSC-128464' 'P-aminobenzoic acid butyl ester']","[('PubChem', array(['104171291', '11112245', '11532999', '144203943', '144207576',
       '170465735', '17389507'], dtype=object)), ('Wikipedia', array(['Butamben'], dtype=object)), ('drugbank', array(['DB11148'], dtype=object)), ('chEBI', array(['3231'], dtype=object))]",['CHEMBL3142541'],,"[ENSG00000111199,ENSG00000104321]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL193240,O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,MNDBXUUTURYVHR-UHFFFAOYSA-N,Small molecule,False,ROFLUMILAST,2010.0,4.0,,False,True,['Daliresp' 'Daxas' 'Zoryve'],"['Arq-151' 'B-9302-107' 'B9302-107' 'BY-217' 'BY217' 'BYK-20869'
 'BYK20869' 'Roflumilast' 'Zoryve']","[('DailyMed', array(['roflumilast'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/daxas'],
      dtype=object)), ('PubChem', array(['165222658', '174007051'], dtype=object)), ('Wikipedia', array(['Roflumilast'], dtype=object)), ('drugbank', array(['DB01656'], dtype=object)), ('chEBI', array(['47657'], dtype=object))]",,"{'rows': array(['EFO_0006505', 'MONDO_0002009', 'HP_0006536', 'EFO_0000274',
       'EFO_1000760', 'EFO_0000401', 'EFO_0003095', 'HP_0000726',
       'MONDO_0010383', 'MONDO_0004979', 'EFO_0000676', 'MONDO_0002406',
       'EFO_0000341', 'MONDO_0005090', 'EFO_0000574', 'MONDO_0100130',
       'HP_0002110', 'EFO_0003100', 'MONDO_0004992', 'EFO_0001073',
       'EFO_0000618', 'MONDO_0005148'], dtype=object), 'count': 22}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 19 investigational indications.
CHEMBL2103873,CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,JGCMEBMXRHSZKX-UHFFFAOYSA-N,Small molecule,True,MACITENTAN,2010.0,4.0,,False,True,['Opsumit'],['ACT 064992' 'ACT-064992' 'Macitentan'],"[('DailyMed', array(['macitentan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit'],
      dtype=object)), ('drugbank', array(['DB08932'], dtype=object)), ('chEBI', array(['76607'], dtype=object))]",,"{'rows': array(['EFO_0005207', 'MONDO_0005149', 'EFO_0003144', 'EFO_0000537',
       'EFO_0000519', 'EFO_0000717', 'EFO_0000768', 'MONDO_0043839',
       'EFO_0001361'], dtype=object), 'count': 9}","[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108712,,,Small molecule,False,PLOVAMER ACETATE,,2.0,,False,False,[],['CO-14' 'PI-2301' 'Pi-2301 acetate' 'Plovamer acetate'],,,"{'rows': array(['EFO_0003929'], dtype=object), 'count': 1}",[ENSG00000196126],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL27759,Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,INVTYAOGFAGBOE-UHFFFAOYSA-N,Small molecule,False,ENTINOSTAT,,3.0,,False,False,[],['Entinostat' 'MS-27-275' 'MS-275' 'MS-275-27' 'SNDX-275'],"[('PubChem', array(['137275820', '29217590', '529250'], dtype=object)), ('Wikipedia', array(['Entinostat'], dtype=object)), ('drugbank', array(['DB11841'], dtype=object))]",['CHEMBL3093129'],"{'rows': array(['MONDO_0001879', 'MONDO_0001325', 'EFO_0000349', 'EFO_0000222',
       'EFO_0000756', 'EFO_0002618', 'EFO_0006861', 'MONDO_0008170',
       'EFO_0002916', 'EFO_1000657', 'EFO_0003086', 'EFO_0000681',
       'EFO_0000673', 'EFO_0000305', 'MONDO_0021063', 'MONDO_0002367',
       'MONDO_0002158', 'MONDO_0001528', 'EFO_0000198', 'EFO_1001951',
       'EFO_0005537', 'EFO_0003869', 'MONDO_0007254', 'MONDO_0004992',
       'MONDO_0002974', 'MONDO_0002087', 'EFO_0000326', 'EFO_0000183',
       'MONDO_0001187', 'EFO_1001901', 'EFO_0000616', 'MONDO_0001402',
       'EFO_0003060', 'EFO_0000574', 'EFO_1001931'], dtype=object), 'count': 35}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 35 investigational indications.
CHEMBL3114577,NCC(=O)Nc1cncc(-c2nn3c(=O)cc(N4CCNCC4)nc3s2)c1,LTVKZVGAALCRFW-UHFFFAOYSA-N,Small molecule,False,ZALUNFIBAN,,3.0,,False,False,[],['RUC-4' 'Zalunfiban'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZALUNFIBAN/relevant/1/'],
      dtype=object))]",['CHEMBL4802247'],"{'rows': array(['EFO_0001645', 'EFO_0008585', 'EFO_0008585'], dtype=object), 'count': 3}","[ENSG00000259207,ENSG00000005961]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL31965,C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1,OMZCMEYTWSXEPZ-UHFFFAOYSA-N,Small molecule,False,CANERTINIB,,3.0,,False,False,[],['CI-1033' 'Canertinib'],"[('PubChem', array(['124894124', '144206912', '174006548', '50100094'], dtype=object)), ('Wikipedia', array(['Canertinib'], dtype=object)), ('drugbank', array(['DB05424'], dtype=object)), ('chEBI', array(['61399'], dtype=object))]",['CHEMBL545315'],"{'rows': array(['EFO_0003869', 'MONDO_0021117', 'EFO_0003060'], dtype=object), 'count': 3}","[ENSG00000146648,ENSG00000178568,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL3301675,C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2,KXGCNMMJRFDFNR-WDRJZQOASA-N,Protein,True,LINACLOTIDE,2012.0,4.0,,False,True,['Constella' 'Linzess'],['ASP-0456' 'ASP0456' 'Linaclotide' 'MD-1100'],"[('DailyMed', array(['linaclotide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/constella'],
      dtype=object)), ('drugbank', array(['DB08890'], dtype=object)), ('chEBI', array(['68551'], dtype=object))]",['CHEMBL3301676'],"{'rows': array(['EFO_0000555', 'HP_0002019', 'MONDO_0002203', 'EFO_0005406',
       'EFO_0000555', 'HP_0002019', 'EFO_1001951'], dtype=object), 'count': 7}",[ENSG00000070019],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297576,,,Protein,False,EFINOPEGDUTIDE,,2.0,,False,False,[],['Efinopegdutide' 'HM-12525A' 'HM12525A' 'JNJ-64565111' 'Jnj-64565111'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EFINOPEGDUTIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0003884', 'EFO_1001249', 'EFO_0001073'],
      dtype=object), 'count': 4}","[ENSG00000215644,ENSG00000112164]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297627,C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(c3n2)C(=O)N1,OEBIHOVSAMBXIB-SJKOYZFVSA-N,Small molecule,False,SELITRECTINIB,,2.0,,False,False,[],['LOXO-195' 'Loxo-195' 'Selitrectinib'],"[('drugbank', array(['DB14896'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000198400,ENSG00000148053,ENSG00000140538]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297776,,,Unknown,False,LEFITOLIMOD,,2.0,,False,False,[],['Lefitolimod' 'MGN-1703' 'TLR9 AGONIST MGN1703'],,,"{'rows': array(['EFO_0000180'], dtype=object), 'count': 1}",[ENSG00000239732],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594535,,,Antibody,False,SUGEMALIMAB,,3.0,,False,False,[],['CS-1001' 'CS1001' 'Cs1001' 'Sugemalimab' 'WBP-315' 'WBP315'],,,"{'rows': array(['EFO_0000702', 'EFO_0000503', 'EFO_0000574', 'EFO_0003060',
       'MONDO_0004992', 'EFO_0000183', 'EFO_0000616', 'MONDO_0019472',
       'EFO_0000182'], dtype=object), 'count': 9}",[ENSG00000120217],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL4650279,C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1OCCN1CCOCC1,HIBPKFXWOPYJPZ-UHFFFAOYSA-N,Small molecule,False,TUXOBERTINIB,,1.0,,False,False,[],['BDTX-189' 'BDTX189' 'Bdtx-189' 'Bdtx189' 'Tuxobertinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TUXOBERTINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4650395,,,Antibody,False,GLENZOCIMAB,,2.0,,False,False,[],['ACT-017' 'ACT017' 'Glenzocimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GLENZOCIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0002140', 'EFO_0000712', 'MONDO_0005299'], dtype=object), 'count': 3}",[ENSG00000088053],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL52440,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,MKXZASYAUGDDCJ-NJAFHUGGSA-N,Small molecule,False,DEXTROMETHORPHAN,1982.0,4.0,,False,True,[],['Dextromethorphan' 'Dimetane-DX' 'NSC-751452'],"[('PubChem', array(['11111057', '50100218'], dtype=object)), ('Wikipedia', array(['Dextromethorphan'], dtype=object)), ('drugbank', array(['DB00514'], dtype=object))]","['CHEMBL1201461' 'CHEMBL3989946' 'CHEMBL3989940' 'CHEMBL1201004'
 'CHEMBL1256818']","{'rows': array(['MONDO_0002009', 'EFO_0007486', 'EFO_0000384', 'EFO_0005611',
       'EFO_0001068', 'MONDO_0004985', 'MONDO_0004976', 'HP_0012735',
       'EFO_0005772', 'EFO_0005762', 'EFO_0002460', 'EFO_0003843',
       'MONDO_0008315', 'EFO_0000764', 'EFO_0001062', 'EFO_0003100',
       'EFO_0003929', 'MONDO_0005180', 'MONDO_0010726', 'MONDO_0005148',
       'MONDO_0005277', 'EFO_0009854', 'HP_0000093', 'MONDO_0004976',
       'EFO_0000616', 'MONDO_0005148', 'HP_0100543', 'EFO_0003758',
       'EFO_0003890', 'EFO_0007214', 'EFO_0007214', 'EFO_0000756',
       'EFO_0002617', 'EFO_0009430', 'MONDO_0044970', 'MONDO_0005271',
       'EFO_1000783', 'MONDO_0002009', 'HP_0001945', 'EFO_0003756',
       'MONDO_0004975', 'EFO_0009692', 'MONDO_0005090', 'EFO_0000729',
       'EFO_0000616', 'EFO_0005687', 'EFO_0009708', 'MONDO_0002050',
       'EFO_0000555', 'HP_0002315', 'HP_0001742', 'HP_0012735',
       'EFO_0000676', 'EFO_0001663', 'MONDO_0005301'], dtype=object), 'count': 55}","[ENSG00000147955,ENSG00000183454]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 7 approved and 45 investigational indications.
CHEMBL5314342,,,Protein,False,GLUCAGON HYDROCHLORIDE,1960.0,4.0,,False,True,[],"['Glucagon chloride' 'Glucagon hcl' 'Glucagon hydrochloride'
 'Glucagon, monohydrochloride']","[('DailyMed', array(['glucagon%20hydrochloride'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'HP_0001943', 'EFO_0000400'],
      dtype=object), 'count': 4}",[ENSG00000215644],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 investigational indications.
CHEMBL549,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,WSEQXVZVJXJVFP-UHFFFAOYSA-N,Small molecule,True,CITALOPRAM,1998.0,4.0,,False,True,[],['Celexa' 'Citadur' 'Citalopram'],"[('PubChem', array(['174007166', '50104852', '90340852'], dtype=object)), ('Wikipedia', array(['Citalopram'], dtype=object)), ('drugbank', array(['DB00215'], dtype=object)), ('chEBI', array(['77397'], dtype=object))]",['CHEMBL1628605' 'CHEMBL1200781'],"{'rows': array(['MONDO_0002050', 'MONDO_0004985', 'HP_0000713', 'EFO_0005230',
       'MONDO_0002009', 'MONDO_0005180', 'MONDO_0002009', 'HP_0031217',
       'EFO_0004262', 'EFO_0005672', 'EFO_0003758', 'MONDO_0005090',
       'EFO_0000712', 'MONDO_0002009', 'EFO_0004242', 'EFO_0002610',
       'EFO_0003756', 'HP_0000726', 'MONDO_0002009', 'EFO_0000555',
       'MONDO_0007079', 'MONDO_0002046', 'EFO_0005611'], dtype=object), 'count': 23}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for depressive disorder and major depressive disorder and has 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL612,C[C@H](N)Cc1ccccc1,KWTSXDURSIMDCE-QMMMGPOBSA-N,Small molecule,True,DEXTROAMPHETAMINE,1955.0,4.0,,False,True,['Dexedrine' 'Dextrostat' 'Xelstrym'],"['Amfetamine, (s)-' 'Amphetamine, d-' 'D-amphetamine' 'Dexamfetamine'
 'Dexampex' 'Dexamphetamine' 'Dexedrine' 'Dexidrine' 'Dextroamphetamine'
 'Dextrostat' 'Ferndex' 'NSC-73713' 'Xelstrym']","[('PubChem', array(['50113060'], dtype=object)), ('Wikipedia', array(['Dextroamphetamine'], dtype=object)), ('drugbank', array(['DB01576'], dtype=object)), ('chEBI', array(['4469'], dtype=object))]","['CHEMBL1200782' 'CHEMBL287386' 'CHEMBL2106669' 'CHEMBL3544971'
 'CHEMBL3989844']","{'rows': array(['EFO_0005611', 'MONDO_0004985', 'EFO_0000712', 'EFO_0003888',
       'EFO_0005543', 'MONDO_0016158', 'MONDO_0016158', 'EFO_0002610',
       'EFO_0003888', 'MONDO_0005301', 'MONDO_0005090', 'EFO_0003888',
       'EFO_0003890', 'EFO_0004701', 'MONDO_0002277', 'EFO_0001358'],
      dtype=object), 'count': 16}","[ENSG00000103546,ENSG00000142319,ENSG00000165646]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL637,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,PNVNVHUZROJLTJ-UHFFFAOYSA-N,Small molecule,True,VENLAFAXINE,1993.0,4.0,,False,True,"['Alventa xl' 'Amphero xl' 'Bonilux xl' 'Depefex xl' 'Efexor' 'Efexor xl'
 'Foraven xl' 'Mentaven xl' 'Politid xl' 'Ranfaxine xl' 'Rodomel xl'
 'Sunveniz xl' 'Tardcaps xl' 'Tifaxin xl' 'Tonpular xl' 'Trixat xl'
 'Vaxalin xl' 'Venaxx xl' 'Venlablue xl' 'Venladex xl' 'Venlalic xl'
 'Venlaneo xl' 'Vensir xl' 'Vexarin xl' 'Viepax' 'Viepax xl' 'Winfex xl']","['Efectin' 'Effexor' 'Kanghong' 'NSC-758676' 'Trevilor' 'Velafax'
 'Venlafaxine' 'Venlor']","[('PubChem', array(['144204978', '170465123', '174007175', '26748923', '90341232'],
      dtype=object)), ('Wikipedia', array(['Venlafaxine'], dtype=object)), ('drugbank', array(['DB00285'], dtype=object)), ('chEBI', array(['9943'], dtype=object))]",['CHEMBL1201066' 'CHEMBL3133301' 'CHEMBL5095051'],"{'rows': array(['MONDO_0005180', 'EFO_0006788', 'MONDO_0002050', 'MONDO_0002009',
       'EFO_0006862', 'MONDO_0004985', 'EFO_0009854', 'HP_0000726',
       'HP_0031217', 'MONDO_0002009', 'EFO_0005687', 'MONDO_0004975',
       'EFO_0006788', 'EFO_1001892', 'EFO_1001917', 'EFO_0004242',
       'EFO_0004262', 'EFO_0000673', 'MONDO_0007254', 'MONDO_0005090',
       'MONDO_0002009', 'EFO_0003843', 'MONDO_0002050', 'EFO_1002014',
       'EFO_1001919', 'HP_0030833', 'EFO_0002610', 'EFO_0005230',
       'MONDO_0008315', 'EFO_0003918', 'EFO_0005762', 'MONDO_0002009',
       'MONDO_0002009'], dtype=object), 'count': 33}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1131,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,IHUNBGSDBOWDMA-AQFIFDHZSA-N,Small molecule,True,ACITRETIN,1996.0,4.0,,False,True,['Acitretin' 'Neotigason' 'Soriatane'],['Acitretin' 'Etretin' 'RO 10-1670' 'RO 10-1670/000' 'RO-101670000'],"[('DailyMed', array(['acitretin'], dtype=object)), ('PubChem', array(['144205565', '26756475', '29216416', '49640651'], dtype=object)), ('Wikipedia', array(['Acitretin'], dtype=object)), ('drugbank', array(['DB00459'], dtype=object)), ('chEBI', array(['50173'], dtype=object))]",,"{'rows': array(['EFO_1001494', 'EFO_0000676', 'MONDO_0002406', 'EFO_0000764',
       'EFO_0000756', 'MONDO_0004975'], dtype=object), 'count': 6}","[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for psoriasis vulgaris and psoriasis and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200446,CN(C)CCN(Cc1ccccc1)c1ccccn1.Cl,FSSICIQKZGUEAE-UHFFFAOYSA-N,Small molecule,False,TRIPELENNAMINE HYDROCHLORIDE,1948.0,4.0,CHEMBL1241,False,True,['Pbz-sr' 'Tripelennamine hydrochloride'],"['Azaron' 'Dehistin' 'NSC-409943' 'Pyribenzamine'
 'Tripelennamine chloride' 'Tripelennamine hcl'
 'Tripelennamine hydrochloride' 'Vetibenzamina']","[('PubChem', array(['26719674', '56424144', '855583'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1948.
CHEMBL1200635,CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C.Cl,AKQNAIYKSALPKV-OYHXESGYSA-N,Small molecule,False,HYDROCORTAMATE HYDROCHLORIDE,1956.0,4.0,CHEMBL1201263,False,True,['Magnacort'],"['Hydrocortamate chloride' 'Hydrocortamate hcl'
 'Hydrocortamate hydrochloride' 'NSC-12884']","[('chEBI', array(['50854'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL1200732,CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,ILKJAFIWWBXGDU-MOGDOJJUSA-N,Small molecule,False,AMCINONIDE,1979.0,4.0,,False,True,['Amcinonide' 'Cyclocort'],['Amcinonide' 'CL 34699' 'CL-34699' 'NSC-758620'],"[('DailyMed', array(['amcinonide'], dtype=object)), ('PubChem', array(['144204964', '56423154', '855515'], dtype=object)), ('Wikipedia', array(['Amcinonide'], dtype=object)), ('drugbank', array(['DB00288'], dtype=object)), ('chEBI', array(['31199'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979.
CHEMBL1269597,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](SCCN(C)C)C(=O)N(C)[C@@H](CC(C)(C)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,AQHMBDAHQGYLIU-XNFHFXFQSA-N,Protein,False,SCY 635,,2.0,,False,False,[],['SCY-635' 'Scy 635'],"[('drugbank', array(['DB12451'], dtype=object))]",,"{'rows': array(['EFO_0004220', 'EFO_0003047'], dtype=object), 'count': 2}",[ENSG00000196262],Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1367605,CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1.Cl,IDLSITKDRVDKRV-UHFFFAOYSA-N,Small molecule,False,RITODRINE HYDROCHLORIDE,1991.0,4.0,CHEMBL83063,False,True,['Ritodrine hydrochloride' 'Yutopar'],['Luteonin' 'NSC-291565' 'Ritodrine hcl' 'Ritodrine hydrochloride'],"[('PubChem', array(['26748517', '856010'], dtype=object))]",,,[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991.
CHEMBL1590,CN[C@@H](C)[C@@H](O)c1ccccc1,KWGRBVOPPLSCSI-WCBMZHEXSA-N,Small molecule,False,PSEUDOEPHEDRINE,1963.0,4.0,,False,True,[],"['Acunaso' 'Isoephedrine, d-' 'Neodurasina' 'Pseudoephedrine'
 'Pseudoephedrine polistirex']","[('PubChem', array(['11111142'], dtype=object)), ('Wikipedia', array(['Pseudoephedrine'], dtype=object)), ('drugbank', array(['DB00852'], dtype=object)), ('chEBI', array(['51209'], dtype=object))]",['CHEMBL1200724' 'CHEMBL1201483' 'CHEMBL3989855'],"{'rows': array(['EFO_0003843', 'EFO_0005854', 'EFO_1001417', 'EFO_0007533',
       'MONDO_0005271', 'EFO_0007328', 'MONDO_0005277', 'EFO_0003956',
       'MONDO_0024290', 'HP_0012735', 'HP_0001742', 'EFO_0005252',
       'EFO_0003956', 'EFO_1001050', 'EFO_0005854', 'EFO_0007214',
       'HP_0001742', 'EFO_0003956', 'MONDO_0024355', 'MP_0001845',
       'EFO_0008521', 'EFO_0007486', 'EFO_0005854', 'MONDO_0005271',
       'HP_0012735', 'EFO_0007214'], dtype=object), 'count': 26}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 10 approved and 10 investigational indications.
CHEMBL1743069,,,Antibody,False,SIFALIMUMAB,,2.0,,False,False,[],['MDX-1103' 'MEDI-545' 'Sifalimumab'],,,"{'rows': array(['EFO_0000676', 'EFO_0000398', 'MONDO_0007915'], dtype=object), 'count': 3}","[ENSG00000120235,ENSG00000120242,ENSG00000147873,ENSG00000186803,ENSG00000188379,ENSG00000197919,ENSG00000233816,ENSG00000214042,ENSG00000137080,ENSG00000147885,ENSG00000228083,ENSG00000234829,ENSG00000236637]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1743087,,,Antibody,False,VEDOLIZUMAB,2014.0,4.0,,False,True,['Entyvio'],['LDP-02' 'LDP02' 'MLN-0002' 'MLN-02' 'MLN0002' 'MLN02' 'Vedolizumab'],"[('DailyMed', array(['vedolizumab'], dtype=object)), ('DrugCentral', array(['4982'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio'],
      dtype=object))]",,"{'rows': array(['EFO_0000544', 'EFO_0000764', 'EFO_0000729', 'EFO_0000756',
       'EFO_0003767', 'EFO_0001060', 'EFO_0000180', 'EFO_0003872',
       'MONDO_0005147', 'EFO_0000384', 'EFO_0000540'], dtype=object), 'count': 11}","[ENSG00000115232,ENSG00000139626]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 8 investigational indications.
CHEMBL2028663,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,BFSMGDJOXZAERB-UHFFFAOYSA-N,Small molecule,False,DABRAFENIB,2013.0,4.0,,False,True,['Tafinlar'],['Dabrafenib' 'GSK-2118436' 'GSK-2118436A' 'GSK2118436A' 'Gsk2118436'],"[('drugbank', array(['DB08912'], dtype=object)), ('chEBI', array(['75045'], dtype=object))]",['CHEMBL2105729'],"{'rows': array(['EFO_0002892', 'EFO_1000926', 'EFO_0003833', 'EFO_0003086',
       'EFO_0002892', 'MONDO_0002108', 'EFO_0003060', 'MONDO_0008903',
       'MONDO_0002108', 'EFO_0002617', 'EFO_0002617', 'EFO_1000926',
       'EFO_0000389', 'MONDO_0100342', 'EFO_0000501', 'EFO_0000756',
       'EFO_0000641', 'MONDO_0017795', 'EFO_0000616', 'EFO_0001378',
       'MONDO_0004992', 'EFO_0001421', 'EFO_0001378', 'EFO_0006772',
       'EFO_0000389', 'EFO_0000756', 'EFO_1000209'], dtype=object), 'count': 27}",[ENSG00000157764],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 7 approved and 19 investigational indications.
CHEMBL2103772,CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1,ODUOJXZPIYUATO-UHFFFAOYSA-N,Small molecule,False,RACECADOTRIL,,4.0,,False,True,['Hidrasec'],['Acetorphan' 'NSC-759828' 'Racecadotril' 'Tiorfan' 'Tiorfix'],"[('PubChem', array(['174006909'], dtype=object)), ('drugbank', array(['DB11696'], dtype=object))]",,"{'rows': array(['HP_0002014', 'EFO_1001306'], dtype=object), 'count': 2}",[ENSG00000196549],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.
CHEMBL2106003,CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1.O=C(O)/C=C\C(=O)O,QIQWRCNAPQJQLL-COALEZEGSA-N,Small molecule,False,CIPRALISANT MALEATE,,1.0,CHEMBL278462,False,False,[],['Cipralisant maleate' 'GT-2331' 'Gt2331'],,,,[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2108585,,,Gene,False,CONTUSUGENE LADENOVEC,,2.0,,False,False,[],['AD5CMV-P53' 'Contusugene ladenovec' 'INGN 201' 'INGN-201'],,,"{'rows': array(['EFO_1000158', 'MONDO_0002691', 'MONDO_0008903', 'MONDO_0002087',
       'MONDO_0007254', 'EFO_0006859', 'MONDO_0004986', 'MONDO_0008170',
       'EFO_0003060'], dtype=object), 'count': 9}",[ENSG00000141510],Gene drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL2109263,,,Antibody,False,ING-1,,2.0,,False,False,[],['HEMAB' 'ING-1' 'Ing-1'],,,"{'rows': array(['EFO_0000228'], dtype=object), 'count': 1}",[ENSG00000119888],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109600,,,Antibody,False,RO-5458640,,1.0,,False,False,[],['RG-7212' 'RO-5458640' 'Ro-5458640'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000239697],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109629,,,Antibody drug conjugate,False,ANETUMAB RAVTANSINE,,2.0,,False,False,[],"['Anetumab ravtansine' 'BAY 94-9343' 'BAY-94-9343' 'BAY-949343'
 'BAY94-9343']",,,"{'rows': array(['EFO_0003060', 'EFO_0000770', 'EFO_0002618', 'MONDO_0004992',
       'EFO_0000616', 'EFO_0003893', 'MONDO_0021117', 'EFO_0000588'],
      dtype=object), 'count': 8}",[ENSG00000102854],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL2364626,CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21,XPPBBJCBDOEXDN-UHFFFAOYSA-N,Small molecule,False,RALIMETINIB,,2.0,,False,False,[],"['LSN-2322600 FREE BASE' 'LSN2322600 FREE BASE' 'LY-2228820' 'LY2228820'
 'LY22288220' 'Ly-2228820' 'Ralimetinib']","[('drugbank', array(['DB11787'], dtype=object))]",['CHEMBL2364627'],"{'rows': array(['MONDO_0008170', 'MONDO_0004992', 'MONDO_0002158', 'EFO_0000519',
       'MONDO_0007254'], dtype=object), 'count': 5}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2448613,CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1.CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1.O=C(O)C(O)C(O)C(=O)O,RGSULKHNAKTFIZ-UHFFFAOYSA-N,Small molecule,True,PIMAVANSERIN TARTRATE,2016.0,4.0,CHEMBL2111101,False,True,['Nuplazid'],['ACP-103' 'Pimavanserin tartrate'],"[('DailyMed', array(['pimavanserin%20tartrate'], dtype=object))]",,"{'rows': array(['EFO_0005407', 'HP_0000738', 'MONDO_0004975', 'MONDO_0005090',
       'MONDO_0005180'], dtype=object), 'count': 5}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3651966,C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1,VRQXRVAKPDCRCI-ZNMIVQPWSA-N,Small molecule,False,LGH-447,,1.0,,False,False,[],"['LGH-447' 'LGH447' 'Lgh-447' 'NVP-LGH477' 'PIM 447' 'PIM-447'
 'Pim kinase inhibitor lgh447']","[('drugbank', array(['DB14943'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'MONDO_0044903', 'EFO_0001378'], dtype=object), 'count': 3}","[ENSG00000137193,ENSG00000102096,ENSG00000198355]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3707396,,,Small molecule,False,EVT401,,-1.0,,False,False,[],['Evt401'],,,,[ENSG00000089041],Small molecule drug.
CHEMBL383824,CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,KUFRQPKVAWMTJO-LMZWQJSESA-N,Small molecule,False,ALVESPIMYCIN,,2.0,,False,False,[],['Alvespimycin' 'NSC-707545'],"[('Wikipedia', array(['17-Dimethylaminoethylamino-17-demethoxygeldanamycin'],
      dtype=object)), ('drugbank', array(['DB12442'], dtype=object)), ('chEBI', array(['65324'], dtype=object))]",['CHEMBL2105630'],"{'rows': array(['MONDO_0001023', 'EFO_0000095', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000080824,ENSG00000096384]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3989821,COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-],WMIZITXEJNQAQK-GGDSLZADSA-N,Small molecule,False,TUBOCURARINE CHLORIDE,1945.0,4.0,CHEMBL339427,False,True,['Jexin' 'Tubarine' 'Tubocurarine chloride'],"['Curare' 'NSC-757362' 'Tubaine' 'Tubarine pentahydrate'
 'Tubocurarine chloride' 'Tubocurarine chloride anhydrous'
 'Tubocurarine chloride, anhydrous' 'Tubocurarini chloridum']",,,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1945.
CHEMBL3990145,COCCCCn1c(C(=O)N(CC(C)C)[C@@H]2CNC[C@H](C(=O)N3CCOCC3)C2)nc2ccccc21,RHIBAIKQWJNESW-YADHBBJMSA-N,Small molecule,False,IMARIKIREN,,2.0,,False,False,[],['Imarikiren'],,['CHEMBL3969876'],,[ENSG00000143839],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297163,,,Oligosaccharide,False,MUPARFOSTAT,,3.0,,False,False,[],['Muparfostat' 'PI-88'],,['CHEMBL4297162'],"{'rows': array(['EFO_0003060', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000756',
       'EFO_0000182', 'MONDO_0008315'], dtype=object), 'count': 6}","[ENSG00000113578,ENSG00000138685,ENSG00000112715,ENSG00000173083]",Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4297185,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,BLIJXOOIHRSQRB-PXYINDEMSA-N,Small molecule,False,DAROLUTAMIDE,2019.0,4.0,,False,True,['Nubeqa'],"['BAY 1841788' 'BAY-1841788' 'BAY1841788' 'Darolutamide' 'ODM-201'
 'Odm-201']","[('DailyMed', array(['darolutamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa'],
      dtype=object)), ('drugbank', array(['DB12941'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0001663', 'MONDO_0007254', 'MONDO_0008315',
       'EFO_0000196', 'MONDO_0004992', 'EFO_0000673', 'MONDO_0021259',
       'MONDO_0004669', 'MONDO_0000521'], dtype=object), 'count': 10}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 7 approved and 3 investigational indications.
CHEMBL4297440,COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O,FSXLOWIFSZNIMV-UHFFFAOYSA-N,Small molecule,False,T-900607,,2.0,,False,False,[],['T 900607' 'T-900607' 'T900607'],"[('drugbank', array(['DB12068'], dtype=object))]",,"{'rows': array(['MONDO_0002691', 'EFO_0005952', 'EFO_0000182', 'MONDO_0001056',
       'EFO_0003893'], dtype=object), 'count': 5}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4592045,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1,CQOJHAJWCDJEAT-UHFFFAOYSA-N,Small molecule,False,NAVACAPRANT,,2.0,,False,False,[],['BTRX-335140' 'Btrx-335140' 'CYM-53093' 'Navacaprant'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]",['CHEMBL4455146'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}",[ENSG00000082556],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650282,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12,UPPAAWQBZQBNIE-USRGLUTNSA-N,Small molecule,False,DS-1001B,,2.0,CHEMBL4651002,False,False,[],['DS-1001b' 'Ds-1001b'],,,,[ENSG00000138413],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4650295,,,Cell,False,AMG553,,1.0,,False,False,[],['AMG553' 'Amg553'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000122025],Cell drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL489,CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,TXUZVZSFRXZGTL-QPLCGJKRSA-N,Small molecule,False,AFIMOXIFENE,,3.0,,False,False,[],['4-Hydroxytamoxifen' '4-OHT' 'Afimoxifene'],"[('PubChem', array(['11532960', '144208141', '26757818', '56422185'], dtype=object)), ('Wikipedia', array(['Afimoxifene'], dtype=object)), ('drugbank', array(['DB04468'], dtype=object)), ('chEBI', array(['44616'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000432', 'EFO_1001366'], dtype=object), 'count': 3}","[ENSG00000196482,ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL5314383,C[C@@H]1CN(C(=O)CN2CC(C)(C)OC[C@H]2C(=O)Nc2cc(Cl)cc3c2[nH]c2cnccc23)C[C@H](C)O1,BQBAVNBXWBYXIF-DMPWYTOCSA-N,Small molecule,False,MLN-0415,,1.0,,False,False,[],['Mln-0415'],,,,[ENSG00000104365],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL571948,C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1,JTVBXQAYBIJXRP-SNVBAGLBSA-N,Small molecule,False,Y-39983,,1.0,,False,False,[],['Y-39983'],,['CHEMBL3794409'],,"[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL681,CCOC(=O)c1cncn1[C@H](C)c1ccccc1,NPUKDXXFDDZOKR-LLVKDONJSA-N,Small molecule,False,ETOMIDATE,1982.0,4.0,,False,True,['Amidate' 'Etomidate'],['Etomidate' 'Hypnomidate' 'NSC-759160'],"[('DailyMed', array(['etomidate'], dtype=object)), ('PubChem', array(['11114097'], dtype=object)), ('drugbank', array(['DB00292'], dtype=object)), ('chEBI', array(['4910'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000712', 'EFO_0009686'], dtype=object), 'count': 3}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications.
CHEMBL914,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,RWTNPBWLLIMQHL-UHFFFAOYSA-N,Small molecule,False,FEXOFENADINE,,4.0,,False,True,[],['Allegra' 'Fexofenadine'],"[('PubChem', array(['50105687', '90341422'], dtype=object)), ('Wikipedia', array(['Fexofenadine'], dtype=object)), ('drugbank', array(['DB00950'], dtype=object)), ('chEBI', array(['5050'], dtype=object))]",['CHEMBL1200618'],"{'rows': array(['EFO_0000401', 'EFO_0003060', 'EFO_0004253', 'MONDO_0005271',
       'MONDO_0005271', 'EFO_0000274', 'HP_0000989', 'EFO_1001417',
       'EFO_0009373', 'EFO_0003956', 'EFO_0005531', 'EFO_0003956',
       'MONDO_0004979', 'EFO_0000685', 'EFO_0005854', 'EFO_0000673',
       'EFO_0003948', 'EFO_1001417'], dtype=object), 'count': 18}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 13 investigational indications.
CHEMBL118,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,RZEKVGVHFLEQIL-UHFFFAOYSA-N,Small molecule,True,CELECOXIB,1998.0,4.0,,False,True,['Celebra' 'Celebrex' 'Celecoxib' 'Elyxyb' 'Onsenal'],['Celecoxib' 'DFN-15' 'DFN15' 'NSC-719627' 'NSC-758624' 'SC-58635'],"[('DailyMed', array(['celecoxib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal'],
      dtype=object)), ('PubChem', array(['144204686', '144209162', '144210916', '170464693', '17389545',
       '26747363', '49665790', '49666478', '535138'], dtype=object)), ('Wikipedia', array(['Celecoxib'], dtype=object)), ('drugbank', array(['DB00482'], dtype=object)), ('chEBI', array(['41423'], dtype=object))]",['CHEMBL395268' 'CHEMBL1801594'],"{'rows': array(['EFO_0003843', 'HP_0012532', 'MONDO_0005090', 'EFO_1001893',
       'MP_0001914', 'MONDO_0001657', 'EFO_0005279', 'EFO_0009606',
       'EFO_0000546', 'EFO_0002496', 'EFO_0004239', 'EFO_0004251',
       'EFO_0000284', 'EFO_0003868', 'MONDO_0018975', 'EFO_0005252',
       'EFO_0005406', 'EFO_0004616', 'HP_0100607', 'MONDO_0042487',
       'EFO_0001075', 'MONDO_0018076', 'MONDO_0004976', 'MONDO_0011705',
       'MONDO_0004247', 'MONDO_0002087', 'HP_0004398', 'EFO_0000668',
       'EFO_0004142', 'EFO_0000616', 'MP_0001845', 'MONDO_0002363',
       'EFO_0000681', 'EFO_0001073', 'MONDO_0002974', 'EFO_0007328',
       'EFO_0000621', 'MONDO_0004985', 'EFO_0004242', 'EFO_0000685',
       'EFO_1001904', 'EFO_0002939', 'MONDO_0021056', 'EFO_0005543',
       'EFO_0004288', 'HP_0003418', 'EFO_0001416', 'MONDO_0008170',
       'EFO_0007453', 'MONDO_0021063', 'MONDO_0007254', 'EFO_0004252',
       'EFO_1001950', 'EFO_0008525', 'EFO_0000673', 'EFO_0010072',
       'MONDO_0002258', 'EFO_0003893', 'EFO_0000691', 'MONDO_0010200',
       'MONDO_0001187', 'EFO_0000305', 'EFO_0005537', 'EFO_0005669',
       'MONDO_0044937', 'EFO_0002609', 'MONDO_0002715', 'MONDO_0004975',
       'EFO_0005755', 'EFO_0000203', 'EFO_0002618', 'HP_0011110',
       'MONDO_0007576', 'EFO_1001250', 'MONDO_0005178', 'MONDO_0004992',
       'EFO_0003898', 'MONDO_0002050', 'MONDO_0003937', 'EFO_0004274',
       'EFO_0009625', 'EFO_0003931', 'EFO_0004142', 'EFO_0001072',
       'EFO_0000199', 'EFO_0000537', 'EFO_0000756', 'EFO_0003869',
       'EFO_0000365', 'MONDO_0002009', 'EFO_1001951', 'EFO_0005762',
       'Orphanet_733', 'MONDO_0008903', 'EFO_1000786', 'EFO_0003060',
       'MONDO_0100096', 'MONDO_0005277', 'EFO_0000712', 'MONDO_0002691',
       'EFO_1000158', 'EFO_1001466', 'EFO_0006859', 'MONDO_0024475',
       'MONDO_0008315', 'EFO_0000519', 'EFO_0001668', 'EFO_0003768',
       'HP_0003419', 'EFO_1000657', 'MONDO_0004658', 'EFO_0001378',
       'EFO_0000182'], dtype=object), 'count': 113}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 18 approved and 95 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200461,COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl,MGCQZNBCJBRZDT-UHFFFAOYSA-N,Small molecule,True,MIDODRINE HYDROCHLORIDE,1996.0,4.0,CHEMBL1201212,False,True,"['Bramox' 'Gutron' 'Midodrine hydrochloride' 'Midon' 'Orvaten'
 'Proamatine']","['A-4020 LINZ' 'Amatine' 'Hipertan' 'Metligine' 'Midodrine hcl'
 'Midodrine hydrochloride' 'Midodrine monohydrochloride' 'NSC-758429'
 'ST 1085 HYDROCHLORIDE' 'ST 1085 [AS THE BASE]' 'ST-1085' 'ST-1085 BASE'
 'ST-1085 HYDROCHLORIDE' 'ST-PETER-224' 'ST. PETER 224'
 'ST1085 HYDROCHLORIDE']","[('DailyMed', array(['midodrine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204080', '144213040', '170464672', '56320803'], dtype=object)), ('chEBI', array(['31847'], dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_0006834', 'HP_0100806', 'EFO_0005252'],
      dtype=object), 'count': 4}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200728,Cl.N=C(N)N,PJJJBBJSCAKJQF-UHFFFAOYSA-N,Small molecule,False,GUANIDINE HYDROCHLORIDE,1939.0,4.0,CHEMBL821,False,True,['Guanidine hydrochloride'],['Guanidine HCl' 'Guanidine hydrochloride'],"[('chEBI', array(['32735'], dtype=object))]",,"{'rows': array(['EFO_0008524', 'HP_0001324', 'EFO_0004991'], dtype=object), 'count': 3}","[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 3 approved indications.
CHEMBL1201216,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1,RFWZESUMWJKKRN-UHFFFAOYSA-N,Small molecule,False,DAPIPRAZOLE,1990.0,4.0,,False,True,[],['Dapiprazole'],"[('Wikipedia', array(['Dapiprazole'], dtype=object)), ('drugbank', array(['DB00298'], dtype=object)), ('chEBI', array(['51066'], dtype=object))]",['CHEMBL1201044'],"{'rows': array(['HP_0011499', 'EFO_0004190', 'MONDO_0005041'], dtype=object), 'count': 3}",[ENSG00000120907],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved indications.
CHEMBL1201563,,,Protein,False,INTERFERON BETA-1B,1993.0,4.0,,False,True,['Betaseron' 'Extavia'],['BAY 86-5046' 'BAY-86-5046' 'Interferon beta-1b'],"[('DailyMed', array(['interferon%20beta-1b'], dtype=object)), ('DrugCentral', array(['5140'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/extavia'],
      dtype=object)), ('Wikipedia', array(['Interferon_beta-1b'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000764', 'MONDO_0100096', 'MONDO_0005301',
       'MONDO_0100116', 'EFO_0000318', 'EFO_0003929'], dtype=object), 'count': 7}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for neoplasm and multiple sclerosis and has 5 investigational indications.
CHEMBL1201611,,,Protein,False,INSULIN LISPRO PROTAMINE RECOMBINANT,1999.0,4.0,,False,True,[],['Insulin lispro protamine recombinant'],,,"{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 2 investigational indications.
CHEMBL1201834,,,Antibody,False,CANAKINUMAB,2009.0,4.0,,False,True,['Ilaris'],['ACZ-885' 'ACZ885' 'Canakinumab'],"[('DailyMed', array(['canakinumab'], dtype=object)), ('DrugCentral', array(['4952'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris'],
      dtype=object)), ('Wikipedia', array(['Canakinumab'], dtype=object))]",,"{'rows': array(['EFO_0001365', 'EFO_0004616', 'MONDO_0011776', 'MONDO_0005178',
       'EFO_0001071', 'EFO_1000906', 'MONDO_0018088', 'EFO_0008518',
       'MONDO_0005184', 'EFO_0000756', 'MONDO_0017708', 'EFO_0000275',
       'EFO_0004274', 'EFO_0004265', 'EFO_0000341', 'EFO_0004274',
       'EFO_0004246', 'MONDO_0005148', 'EFO_1001345', 'MONDO_0005147',
       'EFO_0003914', 'EFO_0002609', 'MONDO_0007254', 'EFO_0000540',
       'EFO_0000681', 'EFO_0004214', 'MONDO_0008633', 'EFO_1001165',
       'HP_0000999', 'HP_0001945', 'EFO_1001478', 'MONDO_0016168',
       'EFO_0003106', 'MONDO_0008903', 'EFO_0003780', 'DOID_13406',
       'EFO_0000685', 'EFO_0003060', 'HP_0001943', 'MONDO_0011382',
       'MONDO_0100096', 'EFO_0007135', 'EFO_0000198'], dtype=object), 'count': 43}",[ENSG00000125538],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 8 approved and 35 investigational indications.
CHEMBL1592101,,,Small molecule,False,BISMUTH SUBGALLATE,,4.0,,False,True,[],"['Basic bismuth gallate' 'Bismuth subgallate'
 'Gallic acid bismuth basic salt']","[('PubChem', array(['144205941', '29218038'], dtype=object)), ('chEBI', array(['31292'], dtype=object))]",,"{'rows': array(['EFO_0009669'], dtype=object), 'count': 1}",[ENSG00000131187],Small molecule drug with a maximum clinical trial phase of IV and is indicated for flatulence.
CHEMBL1657,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1,OGQICQVSFDPSEI-UHFFFAOYSA-N,Small molecule,False,TAZAROTENE,1997.0,4.0,,False,True,['Arazlo' 'Avage' 'Fabior' 'Tazorac' 'Zorac'],['AGN 190168' 'AGN-190168' 'Idp-123' 'Tazarotene'],"[('DailyMed', array(['tazarotene'], dtype=object)), ('PubChem', array(['144206075', '170464671', '174006350', '50112778'], dtype=object)), ('Wikipedia', array(['Tazarotene'], dtype=object)), ('drugbank', array(['DB00799'], dtype=object)), ('chEBI', array(['32184'], dtype=object))]",,"{'rows': array(['EFO_0003894', 'EFO_0009259', 'Orphanet_183469', 'EFO_1001494',
       'EFO_0002913', 'EFO_0000701', 'EFO_0000676'], dtype=object), 'count': 7}","[ENSG00000172819,ENSG00000077092,ENSG00000131759]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 3 investigational indications.
CHEMBL2104955,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O,QSLUXQQUPXBIHH-YHSKWIAJSA-N,Small molecule,False,BECOCALCIDIOL,,2.0,,False,False,[],"['2MBisP' 'Becocalcidiol' 'DP-006' 'DP006' 'QRX 101' 'QRX-101' 'QRX101'
 'Qrx-101']","[('drugbank', array(['DB04891'], dtype=object))]",,"{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108151,,,Antibody drug conjugate,False,NACOLOMAB TAFENATOX,,2.0,,False,False,[],['Nacolomab tafenatox'],,,,[ENSG00000146242],Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2109556,,,Antibody drug conjugate,False,MLN-2704,,1.0,,False,False,[],['MLN-2704' 'MLN-591DM1' 'Mln-2704'],,,"{'rows': array(['MONDO_0008315', 'EFO_0000673'], dtype=object), 'count': 2}",[ENSG00000086205],Antibody drug conjugate drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL269732,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,QJJXYPPXXYFBGM-LFZNUXCKSA-N,Small molecule,True,TACROLIMUS ANHYDROUS,1994.0,4.0,,False,True,['Prograf' 'Protopic' 'Tacrolimus'],"['Anhydrous tacrolimus' 'FK-506' 'FR-900506' 'Fujimycin' 'Prograph'
 'Tacro' 'Tacrolimus anhydrous' 'Tacrolimus, anhydrous' 'Tsukubaenolide']","[('PubChem', array(['144205609', '50111459'], dtype=object)), ('drugbank', array(['DB00864'], dtype=object)), ('chEBI', array(['61049'], dtype=object))]",['CHEMBL3989887'],"{'rows': array(['EFO_0006344', 'EFO_1000794', 'EFO_0000274', 'EFO_1000309',
       'MONDO_0018906', 'MONDO_0019469', 'MONDO_0002334', 'EFO_0000274',
       'EFO_0004254', 'EFO_0000183', 'EFO_0002687', 'EFO_0004251',
       'HP_0001399', 'EFO_0003777', 'EFO_0000701', 'MONDO_0004979',
       'EFO_1000690', 'EFO_0000198', 'EFO_0001423', 'EFO_0000400',
       'EFO_0008517', 'MONDO_0100096', 'EFO_1002048', 'EFO_0003834',
       'EFO_0000255', 'EFO_0000403', 'EFO_0000211', 'MONDO_0004992',
       'EFO_1001993', 'MONDO_0021193', 'EFO_0004194', 'EFO_0003032',
       'HP_0012410', 'MONDO_0005147', 'EFO_0000574', 'EFO_0001378',
       'EFO_0006475', 'EFO_0003884', 'MONDO_0010518', 'EFO_0000729',
       'EFO_0000546', 'EFO_0000220', 'EFO_0003047', 'MONDO_0000873',
       'MONDO_0015253', 'EFO_0009441', 'MONDO_0009833', 'HP_0003124',
       'EFO_0006803', 'EFO_0000676', 'EFO_0002428', 'EFO_0005676',
       'MONDO_0004768', 'EFO_0004991', 'EFO_0004236', 'EFO_0000339',
       'EFO_0000544', 'EFO_0000685', 'EFO_0009510', 'EFO_0006927',
       'EFO_1001020', 'EFO_1001051', 'MONDO_0013730', 'EFO_1000131',
       'MONDO_0004976', 'EFO_0007183', 'Orphanet_848', 'EFO_0000621',
       'MONDO_0019471', 'EFO_0000191', 'EFO_0000309', 'EFO_0003818',
       'EFO_0001361', 'EFO_0000540', 'MONDO_0005301', 'EFO_0003086',
       'EFO_1000764', 'MONDO_0100244', 'MONDO_0044881', 'EFO_1001469',
       'MONDO_0008315', 'EFO_0000222', 'EFO_1000785', 'EFO_1001413',
       'EFO_0007141', 'EFO_0003872', 'MONDO_0044903', 'EFO_0009373',
       'MONDO_0000870', 'EFO_0004255', 'EFO_0000096', 'MONDO_0015760',
       'EFO_0000691', 'EFO_1001996', 'EFO_0000095', 'MONDO_0002898',
       'EFO_0004599', 'EFO_0002430', 'EFO_0000512', 'EFO_0005803',
       'EFO_0007157', 'MONDO_0004907', 'EFO_0004208', 'EFO_0002429',
       'EFO_0004220', 'EFO_0001365', 'EFO_0000717', 'MONDO_0000159',
       'MONDO_0015974', 'EFO_0005761', 'HP_0001915', 'EFO_1000956',
       'MONDO_0020077', 'EFO_0007160', 'EFO_0000616', 'MONDO_0019297',
       'EFO_0000565', 'EFO_1000318', 'MONDO_0020547', 'EFO_1000652',
       'MONDO_0019472', 'EFO_0000545', 'EFO_0004192', 'HP_0000964',
       'MONDO_0018923', 'EFO_0005952', 'EFO_0000384', 'EFO_0001642',
       'MONDO_0011382', 'EFO_0000182', 'EFO_0001421', 'HP_0002721',
       'EFO_0004286', 'EFO_1001779', 'EFO_1000623', 'EFO_0000699',
       'MONDO_0002367'], dtype=object), 'count': 137}",[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 134 investigational indications. This drug has a black box warning from the FDA.
CHEMBL278623,CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O,UJVDJAPJQWZRFR-DHIUTWEWSA-N,Small molecule,False,MACIMORELIN,2017.0,4.0,,False,True,['Macrilen' 'Solorel'],"['AEZS-130' 'ARD-07' 'ARD07' 'Ard-07' 'EP-01572' 'EP-1572' 'EP01572'
 'EP1572' 'JMV 1843' 'JMV-1843' 'Macimorelin']","[('drugbank', array(['DB13074'], dtype=object))]",['CHEMBL2364617'],"{'rows': array(['HP_0004326'], dtype=object), 'count': 1}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and has 1 investigational indication.
CHEMBL289351,COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+],VXNQMUVMEIGUJW-XNOMRPDFSA-L,Small molecule,False,FOSBRETABULIN DISODIUM,,2.0,CHEMBL1206232,False,False,[],"['CA 4P' 'CA-4DP' 'CA4DP' 'Fosbretabulin disodium'
 'Fosbretabulin disodium salt']",,,"{'rows': array(['EFO_0000616', 'EFO_0004683', 'MONDO_0004992', 'EFO_0006859'],
      dtype=object), 'count': 4}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3113974,CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1,VCFBPAOSTLMYIV-SANMLTNESA-N,Small molecule,False,TRANIMILAST,,2.0,,False,False,[],['CHF6001' 'Chf-6001' 'Chf6001' 'J3.309.618F' 'Tanimilast' 'Tranimilast'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRANIMILAST/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12800'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545213,N#CC(c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1)c1nc2ccccc2s1,XCPPIJCBCWUBNT-UHFFFAOYSA-N,Small molecule,False,BENTAMAPIMOD,,2.0,,False,False,[],['AS602801' 'As-602801' 'Bentamapimod' 'PGL-5001' 'PGL5001'],,,"{'rows': array(['EFO_0001065'], dtype=object), 'count': 1}","[ENSG00000107643,ENSG00000109339,ENSG00000050748]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989868,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,SDEAXTCZPQIFQM-UHFFFAOYSA-N,Small molecule,False,TUCATINIB,2020.0,4.0,,False,True,['Tukysa'],['ARRY-380' 'Irbinitinib' 'MK-7119' 'ONT-380' 'Ont-380' 'Tucatinib'],"[('DailyMed', array(['tucatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa'],
      dtype=object)), ('drugbank', array(['DB11652'], dtype=object))]",,"{'rows': array(['EFO_0009708', 'EFO_0000339', 'EFO_0001421', 'EFO_0004142',
       'EFO_0000305', 'EFO_1000294', 'EFO_0003060', 'EFO_0000616',
       'MONDO_0001056', 'EFO_0003869', 'MONDO_0004992', 'EFO_0000182',
       'EFO_0003968', 'EFO_0005537', 'MONDO_0007254', 'EFO_1001951'],
      dtype=object), 'count': 16}",[ENSG00000141736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 9 approved and 7 investigational indications.
CHEMBL4297579,,,Gene,False,VALOCTOCOGENE ROXAPARVOVEC,2022.0,4.0,,False,True,['Roctavian'],['BMN-270' 'BMN270' 'Valoctocogene roxaparvovec'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000101981],Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and has 1 investigational indication.
CHEMBL4297839,,,Protein,True,TIRZEPATIDE,2022.0,4.0,,False,True,['Mounjaro'],['LY-3298176' 'LY3298176' 'Ly3298176' 'Mounjaro' 'Tirzepatide'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro'],
      dtype=object))]",,"{'rows': array(['EFO_0003884', 'MONDO_0018105', 'MONDO_0005148', 'EFO_1001249',
       'EFO_0000400', 'EFO_0001073'], dtype=object), 'count': 6}","[ENSG00000010310,ENSG00000112164]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297850,,,Antibody,False,XENTUZUMAB,,2.0,,False,False,[],['BI 836845' 'BI-836845' 'Bi 836845' 'Xentuzumab'],,,"{'rows': array(['EFO_0000616', 'EFO_0000673', 'EFO_0003869', 'MONDO_0008315',
       'EFO_0003060'], dtype=object), 'count': 5}","[ENSG00000017427,ENSG00000167244]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4650349,O=C(c1ccc(F)cc1)c1ccccc1N[C@@H](Cc1ccc(OCCn2c3ccccc3c3ccccc32)cc1)C(=O)O,QNLWMPLUWMWDMQ-YTTGMZPUSA-N,Small molecule,False,CHIGLITAZAR,,3.0,,False,False,[],"['CS 038' 'CS-038' 'Carfloglitazar, (s)-' 'Chiglitazar']",,,"{'rows': array(['EFO_0003086', 'EFO_0001421', 'EFO_1001249', 'MONDO_0005148'],
      dtype=object), 'count': 4}","[ENSG00000132170,ENSG00000186951,ENSG00000112033]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4650402,,,Antibody,False,POSDINEMAB,,2.0,,False,False,[],['JNJ-63733657' 'Jnj-63733657' 'Posdinemab' 'Posdinemab '],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000186868],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL471897,Cc1cc(OCP2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)cc(C)c1Cc1ccc(O)c(C(C)C)c1,LGGPZDRLTDGYSQ-GYKKGXIBSA-N,Small molecule,False,MB07811,,2.0,,False,False,[],['MB-07811' 'MB07811' 'Mb-07811' 'Mb07811' 'VK2809' 'Vk-2809'],,['CHEMBL1162981'],"{'rows': array(['MONDO_0021187', 'HP_0003124', 'EFO_1001249'], dtype=object), 'count': 3}",[ENSG00000151090],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL90555,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,OGWKCGZFUXNPDA-XQKSVPLYSA-N,Small molecule,True,VINCRISTINE,1963.0,4.0,,False,True,[],"['22-oxovincaleukoblastine' 'Leucristine' 'Leurocristine' 'Oncotcs'
 'Tecnocris' 'Vincaleukoblastine, 22-oxo-' 'Vincristin' 'Vincristine'
 'Vinkristin']","[('PubChem', array(['124892473', '144205620', '170465186'], dtype=object)), ('chEBI', array(['28445'], dtype=object))]",['CHEMBL501867'],"{'rows': array(['EFO_0000174', 'MONDO_0009348', 'MONDO_0000870', 'EFO_0000248',
       'EFO_0000220', 'MONDO_0008380', 'EFO_1000292', 'EFO_0000183',
       'MONDO_0015760', 'EFO_0000094', 'MONDO_0016717', 'EFO_0000616',
       'EFO_1001469', 'EFO_0000183', 'EFO_0002939', 'EFO_0004289',
       'EFO_0000255', 'EFO_0000502', 'EFO_0003833', 'EFO_0000211',
       'EFO_0002918', 'EFO_0005952', 'EFO_0000096', 'MONDO_0008903',
       'EFO_1000131', 'EFO_0000180', 'EFO_0005235', 'EFO_0000502',
       'EFO_1000292', 'EFO_1000635', 'EFO_0002499', 'MONDO_0008380',
       'EFO_0000209', 'EFO_1001951', 'EFO_0000095', 'MONDO_0018906',
       'MONDO_0015540', 'EFO_0000095', 'MONDO_0044881', 'MONDO_0002974',
       'EFO_1000796', 'EFO_0007160', 'MONDO_0003478', 'HP_0001871',
       'EFO_0002939', 'MONDO_0000873', 'EFO_0000574', 'MONDO_0018271',
       'MONDO_0019004', 'EFO_0003833', 'EFO_0000309', 'EFO_0000222',
       'EFO_0000437', 'EFO_0000272', 'EFO_1001469', 'EFO_0000309',
       'EFO_0000211', 'EFO_0000094', 'MONDO_0000873', 'EFO_0009254',
       'EFO_0004289', 'MONDO_0044917', 'MONDO_0018975', 'MONDO_0000432',
       'EFO_0006859', 'EFO_1001365', 'EFO_0000198', 'EFO_0000558',
       'EFO_0000248', 'EFO_0000437', 'EFO_0000565', 'EFO_0001378',
       'EFO_0003032', 'MONDO_0004095', 'EFO_0000519', 'EFO_0000220',
       'EFO_1000158', 'EFO_0000756', 'EFO_0000565', 'EFO_1001042',
       'EFO_0009708', 'EFO_0000621', 'MONDO_0002367', 'EFO_0003032',
       'EFO_0000616', 'MONDO_0016700', 'EFO_0001378', 'MONDO_0019004',
       'EFO_0000621', 'MONDO_0001657', 'MONDO_0000430', 'EFO_0000403',
       'EFO_0000574', 'EFO_0000702', 'EFO_0000637', 'MONDO_0000870',
       'EFO_0000209', 'EFO_1000318', 'MONDO_0018944', 'MONDO_0015564',
       'EFO_0005952', 'EFO_0000313', 'EFO_0000691', 'EFO_1000158',
       'EFO_0000588', 'EFO_0000403', 'MONDO_0009348', 'MONDO_0006058',
       'EFO_0000222', 'EFO_1001830', 'EFO_1001365', 'EFO_0009441',
       'MONDO_0018906', 'EFO_0000691', 'MONDO_0019471', 'EFO_0000096',
       'EFO_0000765', 'EFO_0002918', 'EFO_0000174', 'MONDO_0044917'],
      dtype=object), 'count': 120}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for neoplasm and has 90 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1128,CC[N+](C)(C)c1cccc(O)c1.[Cl-],BXKDSDJJOVIHMX-UHFFFAOYSA-N,Small molecule,False,EDROPHONIUM CHLORIDE,1951.0,4.0,CHEMBL1104,False,True,"['Camsilon' 'Edrophonium chloride'
 'Edrophonium chloride preservative free' 'Enlon' 'Reversol' 'Tensilon'
 'Tensilon preservative free']","['Antirex' 'Edrophone chloride' 'Edrophonii chloridum'
 'Edrophonium Chloride' 'Edrophonium chloride' 'NSC-759577']","[('PubChem', array(['144203689', '170464801', '26747508', '26747509', '50106293',
       '50106294', '50106295', '56422101', '855983'], dtype=object)), ('Wikipedia', array(['Edrophonium'], dtype=object)), ('chEBI', array(['4759'], dtype=object))]",,,[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951.
CHEMBL1200636,CN(C)CCC=C1c2ccccc2C=Cc2ccccc21.Cl,VXEAYBOGHINOKW-UHFFFAOYSA-N,Small molecule,False,CYCLOBENZAPRINE HYDROCHLORIDE,1977.0,4.0,CHEMBL669,False,True,['Amrix' 'Cyclobenzaprine hydrochloride' 'Flexeril'],"['Cyclobenzaprine hcl' 'Cyclobenzaprine hydrochloride' 'MK-130'
 'MK-130 HYDROCHLORIDE' 'MK-130 [AS THE BASE]' 'NSC-169900' 'NSC-173379'
 'NSC-78206']","[('DailyMed', array(['cyclobenzaprine%20hydrochloride'], dtype=object)), ('PubChem', array(['124891634', '144203591', '170464953', '26748730', '26748731',
       '50106063', '50107452', '50107453', '551139', '56463037'],
      dtype=object)), ('chEBI', array(['3997'], dtype=object))]",,"{'rows': array(['MONDO_0005277', 'HP_0003394', 'EFO_1000632', 'EFO_0009488',
       'HP_0003326', 'HP_0001257'], dtype=object), 'count': 6}","[ENSG00000102468,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 1 investigational indication.
CHEMBL1200930,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[n-]2)c1C.[Na+],KRCQSTCYZUOBHN-UHFFFAOYSA-N,Small molecule,False,RABEPRAZOLE SODIUM,1999.0,4.0,CHEMBL1219,False,True,['Aciphex' 'Aciphex sprinkle' 'Pariet' 'Rabeprazole sodium'],"['E-3810' 'E-3810 SODIUM' 'Idiazole' 'LY-307640' 'LY-307640 SODIUM'
 'LY307640 SODIUM' 'NSC-759270' 'Rabeprazole na' 'Rabeprazole sodium'
 'Rabeprazole sodium salt' 'Sodium rabeprazole']","[('DailyMed', array(['rabeprazole%20sodium'], dtype=object)), ('PubChem', array(['144205289', '144212634', '170464736', '49666380'], dtype=object)), ('chEBI', array(['8769'], dtype=object))]",,"{'rows': array(['EFO_0004607', 'EFO_1001355', 'EFO_0003763', 'EFO_0007549',
       'EFO_0003948', 'EFO_1000961', 'EFO_1001095'], dtype=object), 'count': 7}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 4 investigational indications.
CHEMBL1373,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,YFGHCGITMMYXAQ-UHFFFAOYSA-N,Small molecule,False,MODAFINIL,1998.0,4.0,,False,True,['Modafinil' 'Provigil'],"['CEP 1538' 'CEP-1538' 'CRC-40476' 'CRL 40476' 'CRL-40476' 'DEP-1538'
 'Modafinil' 'Modafinil civ' 'Modaphonil' 'Modiodal' 'NSC-751178'
 'NSC-759110' 'THN-102 COMPONENT MODAFINIL' 'THN102 COMPONENT MODAFINIL']","[('DailyMed', array(['modafinil'], dtype=object)), ('PubChem', array(['144205023', '170465042', '26719679', '26749058', '26753746'],
      dtype=object)), ('Wikipedia', array(['Modafinil'], dtype=object)), ('drugbank', array(['DB00745'], dtype=object)), ('chEBI', array(['77585'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'EFO_0003925', 'EFO_0003768', 'HP_0100543',
       'EFO_0002610', 'EFO_0007454', 'MONDO_0002050', 'MONDO_0005180',
       'EFO_0008568', 'EFO_0005411', 'EFO_0005252', 'HP_0000360',
       'EFO_0003833', 'EFO_0004701', 'MONDO_0008170', 'HP_0003419',
       'EFO_0005611', 'EFO_0002617', 'MONDO_0004975', 'EFO_0003877',
       'EFO_0003918', 'MONDO_0002491', 'EFO_0001358', 'EFO_0000712',
       'MONDO_0016158', 'EFO_0000756', 'MONDO_0005090', 'HP_0002015',
       'EFO_0003890', 'MONDO_0021107', 'HP_0012378', 'MONDO_0007079',
       'MONDO_0005301', 'EFO_0003888', 'EFO_0000174', 'MONDO_0002009'],
      dtype=object), 'count': 36}",[ENSG00000142319],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 32 investigational indications.
CHEMBL1743027,,,Antibody,False,GIRENTUXIMAB,,3.0,,False,False,['Rencarex'],['CA9-SCAN CG250' 'CG-250' 'CG250' 'Girentuximab' 'WX-G250'],,,"{'rows': array(['EFO_0000681', 'MONDO_0002367', 'EFO_0000349'], dtype=object), 'count': 3}",[ENSG00000107159],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1743075,,,Antibody,False,TABALUMAB,,3.0,,False,False,[],['LY-2127399' 'LY2127399' 'Tabalumab'],,,"{'rows': array(['EFO_0001378', 'EFO_0000685', 'EFO_0003884', 'MONDO_0007915',
       'EFO_0003929'], dtype=object), 'count': 5}",[ENSG00000102524],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL2109509,,,Antibody,False,HCBE-11,,1.0,,False,False,[],['HCBE-11' 'Hcbe-11'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000111321],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2364574,C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2],GJPGCACMCURAKH-YQCFNCLSSA-L,Small molecule,False,DOXYCYCLINE CALCIUM,1974.0,4.0,CHEMBL1433,False,True,['Vibramycin'],['Doxycycline calcium'],,,"{'rows': array(['EFO_0003102'], dtype=object), 'count': 1}","[ENSG00000196611,ENSG00000118113,ENSG00000137745,ENSG00000137673]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and has 1 investigational indication.
CHEMBL3128043,Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1,AYCPARAPKDAOEN-LJQANCHMSA-N,Small molecule,False,PF-03758309,,1.0,,False,False,[],['PF-03758309' 'PF-3758309' 'Pf-03758309'],"[('drugbank', array(['DB11775'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000130669],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3301583,,,Unknown,False,ANDEXANET ALFA,2019.0,4.0,,False,True,['Ondexxya'],"['Andexanet alfa' 'Andexxa' 'PRT-064445' 'PRT-4445' 'PRT064445'
 'rfXa Inhibitor Antidote']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ondexxya'],
      dtype=object))]",,"{'rows': array(['EFO_0020003', 'MP_0001914'], dtype=object), 'count': 2}",[ENSG00000003436],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for drug toxicity and has 1 investigational indication.
CHEMBL3646221,O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,JGRXMPYUTJLTKT-UHFFFAOYSA-N,Small molecule,False,VADADUSTAT,,4.0,,False,True,[],['AKB-6548' 'B-506' 'B506' 'PG-1016548' 'PG1016548' 'Vadadustat'],"[('drugbank', array(['DB12255'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 3}","[ENSG00000129521,ENSG00000269858,ENSG00000135766]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for anemia (phenotype) and has 2 investigational indications.
CHEMBL422,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,ZEWQUBUPAILYHI-UHFFFAOYSA-N,Small molecule,True,TRIFLUOPERAZINE,1959.0,4.0,,False,True,['Amylozine' 'Stelazine' 'Stelazine fte'],"['Apo-trifluoperazine' 'Flurazine' 'NSC-17474' 'NSC-46061' 'RP-7623'
 'Trifluoperazine']","[('PubChem', array(['11110644', '11110645', '124877144', '124877145', '174006276',
       '26751598', '26751599', '4252673', '50100152', '50104251',
       '50104252', '50104253', '57287812', '90341087', '92763314'],
      dtype=object)), ('Wikipedia', array(['Trifluoperazine'], dtype=object)), ('drugbank', array(['DB00831'], dtype=object)), ('chEBI', array(['45951'], dtype=object))]",['CHEMBL1726794' 'CHEMBL1257040' 'CHEMBL1710'],"{'rows': array(['EFO_0005407', 'EFO_0006788', 'MONDO_0005090', 'EFO_0000677'],
      dtype=object), 'count': 4}","[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 4 approved indications. This drug has a black box warning from the FDA.
CHEMBL4297147,CC(O)C(=O)O.O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,BVUSNQJCSYDJJG-UHFFFAOYSA-N,Small molecule,True,HALOPERIDOL LACTATE,1967.0,4.0,CHEMBL54,False,True,['Haldol' 'Haloperidol intensol' 'Haloperidol lactate'],['Haloperidol lactate'],"[('DailyMed', array(['haloperidol%20lactate'], dtype=object))]",,"{'rows': array(['EFO_0005411', 'MONDO_0005090', 'HP_0000713'], dtype=object), 'count': 3}","[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for schizophrenia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297649,CC(C)COc1cc(F)cc(-c2ccc(C(=O)NS(=O)(=O)c3ccccc3)c(N3C[C@@H](C)CC3(C)C)n2)c1,NHOUNZMCSIHKHJ-FQEVSTJZSA-N,Small molecule,False,OLACAFTOR,,2.0,,False,False,[],['Olacaftor' 'VX-440' 'Vx-440'],,,"{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297966,,,Antibody,False,DEZAMIZUMAB,,2.0,,False,False,[],"['Anti - sap mab' 'Dezamizumab' 'GSK-2398852' 'GSK2398852' 'Gsk2398852'
 'anti-SAP mAb']",,,"{'rows': array(['MONDO_0017816', 'EFO_1001875'], dtype=object), 'count': 2}",[ENSG00000132703],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL440,C=CCC1(C(C)CCC)C(=O)NC(=S)NC1=O,XLOMZPUITCYLMJ-UHFFFAOYSA-N,Small molecule,False,THIAMYLAL,1982.0,4.0,,False,True,[],['NSC-120815' 'Thiamylal'],"[('Wikipedia', array(['Thiamylal'], dtype=object)), ('drugbank', array(['DB01154'], dtype=object)), ('chEBI', array(['9536'], dtype=object))]",['CHEMBL1201065'],,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL4594250,Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,OURRXQUGYQRVML-AREMUKBSSA-N,Small molecule,False,NETARSUDIL,2017.0,4.0,,False,True,[],['AR-11324 FREE BASE' 'AR-13324' 'Netarsudil'],,['CHEMBL4594251' 'CHEMBL4796289'],"{'rows': array(['MONDO_0005321', 'Orphanet_98974', 'EFO_0004190', 'EFO_0004190',
       'MONDO_0005041', 'EFO_1001069', 'EFO_1000879'], dtype=object), 'count': 7}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for open-angle glaucoma and ocular hypertension and has 5 investigational indications.
CHEMBL4594262,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=C(O)c1ccccc1,RVPCEXXEUXIPEO-UHFFFAOYSA-N,Small molecule,False,AMLODIPINE BENZOATE,2019.0,4.0,CHEMBL1491,False,True,['Katerzia'],[],"[('DailyMed', array(['amlodipine%20benzoate'], dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hypertension.
CHEMBL4594558,,,Antibody,False,RAGIFILIMAB,,2.0,,False,False,[],"['AGEN-1876' 'AGEN1876' 'CM-701' 'CM701' 'INCAGN-01876' 'INCAGN01876'
 'Incagn01876' 'Ragifilimab']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RAGIFILIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000707', 'EFO_0000519', 'EFO_0006859', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000186891],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL512351,COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1,XHOLNRLADUSQLD-UHFFFAOYSA-N,Small molecule,True,BETRIXABAN,2017.0,4.0,,False,True,['Bevyxxa'],['Betrixaban' 'Betrixaban maleate' 'PRT-054021' 'PRT054021'],"[('Wikipedia', array(['Betrixaban'], dtype=object)), ('drugbank', array(['DB12364'], dtype=object))]",,"{'rows': array(['EFO_0000275', 'EFO_0001421', 'EFO_0003911', 'HP_0001907',
       'EFO_0004286', 'EFO_0003086', 'MP_0001914', 'HP_0004419'],
      dtype=object), 'count': 8}",[ENSG00000126218],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for venous thromboembolism and recurrent thrombophlebitis and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1134,C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C.[Br-].[Br-],HLXQFVXURMXRPU-UHFFFAOYSA-L,Small molecule,False,DECAMETHONIUM BROMIDE,1982.0,4.0,CHEMBL1190,False,True,['Syncurine'],"['Decamethonium Bromide' 'Decamethonium bromide' 'Decamethonium diiodide'
 'Decamethonium iodide' 'NSC-23004']","[('PubChem', array(['144205588', '170465349', '50106154', '855712'], dtype=object)), ('Wikipedia', array(['Decamethonium'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200722,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1.[Br-].[Br-],TXWBOBJCRVVBJF-YTGGZNJNSA-L,Small molecule,False,PIPECURONIUM BROMIDE,1990.0,4.0,CHEMBL1201206,False,True,['Arduan'],"['Pipecurium bromide' 'Pipecuronium bromide'
 'Pipecuronium bromide anhydrous' 'Pipecuronium bromide dihydrate'
 'Pipecuronium bromide hydrate' 'RGH 1106' 'RGH-1106']","[('Wikipedia', array(['Pipecuronium_bromide'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990.
CHEMBL1201338,CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1,SKYSRIRYMSLOIN-UHFFFAOYSA-N,Small molecule,False,CYCLOPENTOLATE,1974.0,4.0,,False,True,[],['Bell pentolate' 'Cyclopentolate'],"[('drugbank', array(['DB00979'], dtype=object)), ('chEBI', array(['4024'], dtype=object))]",['CHEMBL1200473'],"{'rows': array(['HP_0000616', 'HP_0000545', 'HP_0011499'], dtype=object), 'count': 3}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for mydriasis and has 2 investigational indications.
CHEMBL1206,CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21,CDOZDBSBBXSXLB-UHFFFAOYSA-N,Small molecule,False,ETHOPROPAZINE,1982.0,4.0,,False,True,[],['Ethopropazine' 'Parsidol' 'Profenamine'],"[('PubChem', array(['90341779'], dtype=object)), ('Wikipedia', array(['Profenamine'], dtype=object)), ('drugbank', array(['DB00392'], dtype=object)), ('chEBI', array(['313639'], dtype=object))]",['CHEMBL1200970'],"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for parkinson disease.
CHEMBL12713,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,Small molecule,False,SERTINDOLE,1996.0,4.0,,True,True,[],['LU 23-174' 'LU-23-174' 'Serdolect' 'Sertindole' 'Zerdol'],"[('PubChem', array(['144206958', '144206971', '170465613'], dtype=object)), ('Wikipedia', array(['Sertindole'], dtype=object)), ('drugbank', array(['DB06144'], dtype=object)), ('chEBI', array(['9122'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0005407', 'HP_0100543'], dtype=object), 'count': 6}","[ENSG00000149295,ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000102468,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for psychosis and has 5 investigational indications. It was withdrawn in at least one region.
CHEMBL1680,C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,DEQANNDTNATYII-OULOTJBUSA-N,Protein,False,OCTREOTIDE,1988.0,4.0,,False,True,[],['Octreotide' 'SMS 201-995' 'SMS-201-995' 'SMS-995' 'SMS995'],"[('PubChem', array(['50126343'], dtype=object)), ('Wikipedia', array(['Octreotide'], dtype=object)), ('drugbank', array(['DB00104'], dtype=object))]",['CHEMBL3545066' 'CHEMBL1200480' 'CHEMBL2105834'],"{'rows': array(['EFO_0000544', 'EFO_0000182', 'EFO_1000852', 'MONDO_0005277',
       'EFO_1001496', 'MONDO_0004565', 'EFO_0000768', 'EFO_1000852',
       'EFO_1001951', 'EFO_0005252', 'MONDO_0017611', 'EFO_1000045',
       'MONDO_0019180', 'EFO_0002626', 'HP_0002014', 'EFO_0000616',
       'EFO_0007331', 'MONDO_0024503', 'MONDO_0016642', 'EFO_0001073',
       'MONDO_0007254', 'EFO_1001485', 'EFO_1001901', 'MONDO_0017182',
       'EFO_0000574', 'HP_0002239', 'EFO_0000555', 'HP_0002014',
       'MONDO_0002120', 'MONDO_0008300', 'EFO_1002048', 'EFO_1001901',
       'EFO_0004243', 'EFO_0009708', 'EFO_1000581', 'EFO_0000616',
       'MONDO_0043579', 'HP_0002019', 'MONDO_0007254', 'EFO_1001780',
       'EFO_0003770', 'EFO_1001485', 'EFO_0002618', 'EFO_1001485',
       'EFO_0004243', 'MONDO_0004992', 'MONDO_0024503', 'EFO_0001073',
       'MONDO_0008315', 'MONDO_0002691', 'MONDO_0008315', 'MONDO_0004565'],
      dtype=object), 'count': 52}","[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 41 investigational indications.
CHEMBL2109204,,,Oligosaccharide,False,NADROPARIN CALCIUM,,3.0,,False,False,[],"['CY 216' 'CY-216' 'Fraxiparin' 'Fraxiparina' 'Fraxiparine' 'Nadroparin'
 'Nadroparin calcium' 'Seleparina' 'Ultraparina']","[('DrugCentral', array(['5162'], dtype=object))]",,"{'rows': array(['HP_0004936', 'EFO_0004286', 'EFO_0009315', 'HP_0004419',
       'EFO_0003907', 'MONDO_0008903'], dtype=object), 'count': 6}",[ENSG00000117601],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2109500,,,Antibody,False,LIRILUMAB,,2.0,,False,False,[],"['Anti-KIR Antibody' 'BMS-986015' 'BMS-986015-01' 'BMS-98601501'
 'IPH-2102' 'IPH2102' 'Lirilumab']",,,"{'rows': array(['EFO_0000616', 'EFO_0000181', 'MONDO_0004992', 'MONDO_0001187',
       'EFO_0005952', 'EFO_0000095', 'EFO_0001378', 'EFO_0000183',
       'EFO_0000565', 'EFO_0000222'], dtype=object), 'count': 10}","[ENSG00000243772,ENSG00000125498,ENSG00000278731,ENSG00000275546,ENSG00000276731,ENSG00000276011,ENSG00000275407,ENSG00000275914]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL2109531,,,Antibody,False,MEDI-6469,,2.0,,False,False,[],"['9b12, a murine igg1 antibody' 'MEDI-6469' 'MEDI6469' 'Medi 6469'
 'Medi-6469']",,,"{'rows': array(['EFO_0002617', 'EFO_0006859', 'EFO_0004142', 'EFO_0000574',
       'EFO_0000196', 'MONDO_0007254'], dtype=object), 'count': 6}",[ENSG00000186827],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL2364605,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12,CSMVOZKEWSOFER-RQNOJGIXSA-N,Small molecule,False,CEBRANOPADOL,,3.0,,False,False,[],['Cebranopadol' 'GRT-6005' 'GRT6005'],"[('drugbank', array(['DB12830'], dtype=object))]",['CHEMBL3325957'],"{'rows': array(['MONDO_0001583', 'EFO_0004616', 'HP_0003419', 'EFO_0003890',
       'EFO_0003843'], dtype=object), 'count': 5}","[ENSG00000125510,ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL26,CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC,BGRJTUBHPOOWDU-UHFFFAOYSA-N,Small molecule,False,SULPIRIDE,,4.0,,False,True,['Dolmatil'],['N05AL01' 'NSC-757850' 'RD-1403' 'Sulpiride'],"[('PubChem', array(['144212522', '50104625'], dtype=object)), ('TG-GATEs', array(['115'], dtype=object)), ('Wikipedia', array(['Sulpiride'], dtype=object)), ('drugbank', array(['DB00391'], dtype=object)), ('chEBI', array(['32168'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0005407', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications.
CHEMBL284483,OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O,YOOVTUPUBVHMPG-LODYRLCVSA-N,Small molecule,False,COFORMYCIN,,2.0,,False,False,[],['Coformycin' 'NSC-277817'],"[('chEBI', array(['16213'], dtype=object))]",,"{'rows': array(['EFO_0000565'], dtype=object), 'count': 1}",[ENSG00000196839],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL325424,Cc1cccc(-c2ccc3c(c2)c(C(=O)C(=O)O)cn3Cc2ccc(C(C)(C)C)cc2)c1,HSXLMAFNWCSZGP-UHFFFAOYSA-N,Small molecule,False,ALEPLASININ,,2.0,,False,False,[],['Aleplasinin' 'PAZ-417'],"[('drugbank', array(['DB12635'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000106366],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3408248,C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12,LMJFJIDLEAWOQJ-CQSZACIVSA-N,Small molecule,False,AZD-8186,,1.0,,False,False,[],['AZD8186' 'Azd 8186' 'Azd-8186'],"[('drugbank', array(['DB15029'], dtype=object))]",,"{'rows': array(['EFO_0000196', 'MONDO_0008315', 'EFO_0005537', 'MONDO_0007254',
       'MONDO_0001056', 'EFO_0003060'], dtype=object), 'count': 6}","[ENSG00000171608,ENSG00000051382]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications.
CHEMBL3545017,O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,FBCQEUMZZNVQKD-UHFFFAOYSA-N,Small molecule,False,GTX-758,,2.0,,False,False,['Capesaris'],['Gtx 758' 'Gtx-758'],"[('drugbank', array(['DB14969'], dtype=object))]",,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707311,CCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@@]21C,AJAMXPWEAPICIM-XCAPYKEYSA-N,Small molecule,False,VAMOROLONE,2023.0,4.0,,False,True,['Agamree'],"['9,11-dehydro dexamethasone' '9,11-dehydrodexamethasone acetate' 'VBP-15'
 'Vamorolone' 'Vamorolone acetate' 'Vbp-15 free alcohol']",,,"{'rows': array(['EFO_0000729', 'MONDO_0010679', 'MONDO_0010311'], dtype=object), 'count': 3}","[ENSG00000151623,ENSG00000113580]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for duchenne muscular dystrophy and becker muscular dystrophy and has 1 investigational indication.
CHEMBL3989514,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,KLEAIHJJLUAXIQ-JDRGBKBRSA-N,Small molecule,True,IRINOTECAN HYDROCHLORIDE,1996.0,4.0,CHEMBL481,False,True,"['Campto' 'Camptosar' 'Irinotecan hydrochloride' 'Onivyde'
 'Onivyde pegylated liposomal (previously known as onivyde)']","['CPT-11' 'DQ-2805' 'Irinotecan hydrochloride'
 'Irinotecan hydrochloride anhydrous' 'Irinotecan hydrochloride hydrate'
 'Irinotecan hydrochloride trihydrate'
 'Irinotecan monohydrochloride trihydrate' 'NSC-759878' 'U-101,440E'
 'U-101440E']","[('DailyMed', array(['irinotecan%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal'],
      dtype=object))]",,"{'rows': array(['EFO_1000359', 'EFO_1001013', 'EFO_0001075', 'EFO_1000657',
       'MONDO_0002367', 'MONDO_0002158', 'EFO_0002618', 'EFO_1001512',
       'MONDO_0004669', 'EFO_0000313', 'EFO_1000292', 'EFO_0000681',
       'EFO_0002617', 'EFO_0000403', 'EFO_0000228', 'EFO_0000574',
       'EFO_0000707', 'EFO_0000365', 'EFO_1000407', 'MONDO_0008315',
       'MONDO_0002120', 'MONDO_0044926', 'EFO_0000309', 'MONDO_0000873',
       'EFO_0002938', 'MONDO_0001056', 'MONDO_0002537', 'MONDO_0018364',
       'EFO_0003860', 'EFO_1001051', 'EFO_0002501', 'MONDO_0008170',
       'MONDO_0021063', 'MONDO_0007576', 'MONDO_0002974', 'MONDO_0008903',
       'HP_0002014', 'EFO_0000621', 'EFO_0004193', 'EFO_0006352',
       'EFO_0002918', 'EFO_0000437', 'EFO_1000475', 'MONDO_0003060',
       'EFO_0000191', 'EFO_1001465', 'EFO_0004243', 'MONDO_0020634',
       'MONDO_0001475', 'EFO_1000251', 'EFO_0000702', 'EFO_0000519',
       'MONDO_0044937', 'EFO_0005537', 'MONDO_0100342', 'MONDO_0005411',
       'EFO_0000632', 'MONDO_0002087', 'MONDO_0001325', 'EFO_0000095',
       'EFO_1001951', 'MONDO_0019471', 'MONDO_0016717', 'EFO_0007535',
       'EFO_1000785', 'MONDO_0011719', 'EFO_1001469', 'MONDO_0001187',
       'MONDO_0003196', 'MONDO_0001879', 'EFO_0000183', 'EFO_0000389',
       'EFO_1001365', 'EFO_0000502', 'EFO_0000637', 'EFO_1001471',
       'EFO_0006859', 'MONDO_0002691', 'EFO_0002939', 'EFO_1000158',
       'EFO_0004142', 'MONDO_0005184', 'EFO_0000691', 'EFO_0000616',
       'EFO_0000503', 'EFO_0000174', 'EFO_0000248', 'EFO_0001071',
       'EFO_0003032', 'EFO_0002499', 'EFO_0000178', 'MONDO_0021633',
       'MONDO_0004192', 'MONDO_0004992', 'MONDO_0018271', 'MONDO_0018906',
       'MONDO_0007254', 'EFO_0000565', 'EFO_0003060', 'EFO_0000255'],
      dtype=object), 'count': 100}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 95 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297621,C[C@@H](N[C@H]1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12,RZNUIYPHQFXBAN-XLIONFOSSA-N,Small molecule,False,EVOCALCET,,3.0,,False,False,[],['Evocalcet' 'KHK-7580' 'KHK7580' 'Khk7580' 'MT-4580'],"[('drugbank', array(['DB12388'], dtype=object))]",['CHEMBL4128835'],"{'rows': array(['EFO_1001173', 'EFO_0008506'], dtype=object), 'count': 2}",[ENSG00000036828],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4297644,Cc1n[nH]cc1-c1cc2nc([C@@H]3CC4CCN3CC4)[nH]c(=O)c2s1,XGVXKJKTISMIOW-ZDUSSCGKSA-N,Small molecule,False,SIMUROSERTIB,,2.0,,False,False,[],['Simurosertib' 'TAK-931' 'TAK931F' 'Tak 931' 'Tak-931'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMUROSERTIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000097046],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL439849,N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,SGEGOXDYSFKCPT-UHFFFAOYSA-N,Small molecule,True,VILAZODONE,2011.0,4.0,,False,True,[],['EMD 515259' 'EMD-515259' 'EMD-68-843' 'Vilazodone'],"[('Wikipedia', array(['Vilazodone'], dtype=object)), ('drugbank', array(['DB06684'], dtype=object)), ('chEBI', array(['70707'], dtype=object))]",['CHEMBL1615374'],"{'rows': array(['EFO_0001358', 'EFO_1001892', 'MONDO_0002009', 'MONDO_0002009',
       'EFO_0001072', 'EFO_0007191', 'MONDO_0002009'], dtype=object), 'count': 7}","[ENSG00000178394,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for major depressive disorder and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4650283,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C,HJFSVYUFOXAVAA-YUAYGMJFSA-N,Small molecule,False,FF-10101,,1.0,,False,False,[],['FF-10101' 'FLT3-IN-1' 'Ff-10101'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000122025],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4650289,,,Unknown,False,KBP5209,,1.0,,False,False,[],['KBP5209' 'Kbp5209'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361]",Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL490,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,AHOUBRCZNHFOSL-YOEHRIQHSA-N,Small molecule,True,PAROXETINE,1992.0,4.0,,False,True,[],"['(-)3s,4r-paroxetine' 'Arketis' 'Arotin' 'BRL 29060' 'BRL-29060'
 'Besitram' 'Casbol' 'Daparox' 'Fg-7051' 'Frosinor' 'Motivan' 'Parogen'
 'Paroxetine' 'Paxil' 'Paxpar' 'Pexeva' 'Xetanor']","[('PubChem', array(['144206674', '170465075', '26752262', '29215051', '50104978',
       '50104979', '50104980', '50104981', '90341371'], dtype=object)), ('Wikipedia', array(['Paroxetine'], dtype=object)), ('drugbank', array(['DB00715'], dtype=object)), ('chEBI', array(['7936'], dtype=object))]","['CHEMBL1449490' 'CHEMBL1200609' 'CHEMBL1708' 'CHEMBL1256912'
 'CHEMBL3133300' 'CHEMBL1628650']","{'rows': array(['MONDO_0005180', 'EFO_0006788', 'EFO_0000612', 'EFO_1001917',
       'EFO_0004242', 'EFO_1001892', 'EFO_1001917', 'GO_0042697',
       'MONDO_0002050', 'EFO_0005762', 'HP_0000726', 'EFO_0005230',
       'HP_0031217', 'EFO_0004262', 'EFO_0005687', 'EFO_0004242',
       'EFO_0001358', 'MONDO_0002009', 'EFO_0803321', 'EFO_0005230',
       'EFO_0001358', 'MONDO_0002009', 'EFO_0803321', 'MONDO_0002009',
       'MONDO_0002009', 'MONDO_0004985', 'HP_0000360', 'MONDO_0005090',
       'EFO_0004220', 'MONDO_0007079', 'MONDO_0002050', 'EFO_1001917',
       'EFO_0006788', 'EFO_0004262', 'EFO_0004262', 'EFO_0004242',
       'EFO_1001872', 'MONDO_0002775', 'EFO_0001358', 'EFO_0000685',
       'EFO_0000768', 'MONDO_0002009'], dtype=object), 'count': 42}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 8 approved and 25 investigational indications. This drug has a black box warning from the FDA.
CHEMBL786,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,FQZYTYWMLGAPFJ-OQKDUQJOSA-N,Small molecule,True,TAMOXIFEN CITRATE,1977.0,4.0,CHEMBL83,False,True,"['Emblon' 'Fentamox 10' 'Fentamox 20' 'Kentadex' 'Kessar' 'Kessar 10'
 'Kessar 20' 'Noltam' 'Nolvadex' 'Nolvadex d' 'Nolvadex fte'
 'Oestrifen-10' 'Oestrifen-20' 'Oestrifen-40' 'Soltamox' 'Tamofen'
 'Tamoxifen citrate' 'Zynoplex']","['I.C.I.46474 CITRATE' 'ICI 46,474' 'ICI-46474' 'Kessar' 'NSC-180973'
 'NSC-757345' 'Nourytam' 'Tamofene' 'Tamoxifen citrate'
 'Tamoxifeni citras' 'Tomaxasta' 'Zemide' 'Zitazonium']","[('DailyMed', array(['tamoxifen%20citrate'], dtype=object)), ('PubChem', array(['11112087', '11112088', '124881893', '144204489', '144209268',
       '144210594', '170465425', '17389724', '26747686', '26747687',
       '26747688', '26752019', '447264', '49816809', '50107133',
       '85231332'], dtype=object)), ('chEBI', array(['9397'], dtype=object))]",,"{'rows': array(['MONDO_0001187', 'GO_0042697', 'MONDO_0010679', 'EFO_0003869',
       'EFO_0009907', 'MONDO_0002158', 'EFO_0003843', 'HP_0100543',
       'EFO_1000294', 'EFO_0000536', 'MONDO_0011962', 'EFO_0000294',
       'EFO_0000545', 'EFO_0004248', 'EFO_0000519', 'MONDO_0018364',
       'HP_0000771', 'EFO_0000305', 'EFO_0003833', 'EFO_0009708',
       'EFO_1000158', 'EFO_1001512', 'MONDO_0002087', 'EFO_0000389',
       'MONDO_0002691', 'EFO_0004220', 'MONDO_0004985', 'EFO_1001901',
       'EFO_0000232', 'MONDO_0008170', 'EFO_0000616', 'MONDO_0018848',
       'EFO_0000764', 'EFO_0005543', 'EFO_0006861', 'EFO_0000637',
       'EFO_0001075', 'MONDO_0008315', 'MONDO_0019180', 'EFO_1000251',
       'MONDO_0007254', 'EFO_1001375', 'EFO_0007532', 'MONDO_0004992',
       'MONDO_0100096', 'EFO_0000432', 'Orphanet_145', 'EFO_0000537',
       'MONDO_0004976', 'EFO_1000984', 'EFO_0001416'], dtype=object), 'count': 51}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 4 approved and 47 investigational indications. This drug has a black box warning from the FDA.
CHEMBL80,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,UZHSEJADLWPNLE-GRGSLBFTSA-N,Small molecule,False,NALOXONE,1971.0,4.0,,False,True,['Nalone' 'Narcan' 'Narcanti'],['Dbl naloxone' 'NSC-70413' 'Naloxone' 'Suboxone'],"[('PubChem', array(['144205559', '170465008'], dtype=object)), ('Wikipedia', array(['Naloxone'], dtype=object)), ('drugbank', array(['DB01183'], dtype=object)), ('chEBI', array(['7459'], dtype=object))]",['CHEMBL5315056' 'CHEMBL3186613' 'CHEMBL1718' 'CHEMBL1512507'],"{'rows': array(['MONDO_0018555', 'EFO_0003843', 'EFO_0003047', 'MONDO_0005147',
       'MONDO_0001583', 'HP_0000989', 'EFO_0005611', 'EFO_0010702',
       'EFO_0005203', 'EFO_0004270', 'EFO_1001051', 'EFO_0006834',
       'HP_0012532', 'EFO_1000785', 'EFO_0005611', 'MONDO_0004565',
       'EFO_0001073', 'EFO_0004699', 'HP_0003419', 'MONDO_0002009',
       'EFO_0005762', 'EFO_0005611', 'EFO_0004240', 'EFO_0000474',
       'HP_0002019', 'MONDO_0005178', 'HP_0002019', 'EFO_0003843',
       'EFO_0000555', 'EFO_0005800', 'MONDO_0004565', 'EFO_0003890',
       'MONDO_0005180', 'EFO_0005612'], dtype=object), 'count': 34}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 29 investigational indications.
CHEMBL1200940,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC.Cl.O,KJBLQGHJOCAOJP-UHFFFAOYSA-N,Small molecule,True,METOCLOPRAMIDE HYDROCHLORIDE,1979.0,4.0,CHEMBL86,False,True,"['""clopra-""""yellow""""""' 'Clopra' 'Clopra-""Yellow""' 'Gastrese l.a.'
 'Gastrobid continus' 'Gastroflux' 'Gastromax' 'Gimoti' 'Maxolon'
 'Maxolon sr' 'Metoclomex' 'Metoclopramide hydrochloride'
 'Metoclopramide intensol' 'Metox' 'Metozolv odt' 'Metramid' 'Mygdalon'
 'Parmid' 'Primperan' 'Reglan' 'Reglan odt']","['AHR-3070-C' 'Metipamid' 'Metoclopramide dihydrochloride monohydrate'
 'Metoclopramide hcl monohydrate' 'Metoclopramide hydrochloride'
 'Metoclopramide hydrochloride monohydrate'
 'Metoclopramide monohydrochloride monohydrate'
 'Metoclopramidi hydrochloridum' 'NSC-757117']","[('DailyMed', array(['metoclopramide%20hydrochloride'], dtype=object)), ('chEBI', array(['6899'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'HP_0002039', 'EFO_1002048', 'EFO_0004888',
       'EFO_1000948', 'HP_0002013', 'HP_0002017'], dtype=object), 'count': 7}","[ENSG00000149295,ENSG00000166736,ENSG00000164270]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 7 approved indications. This drug has a black box warning from the FDA.
CHEMBL1684984,CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21,JEGHXKRHKHPBJD-UHFFFAOYSA-N,Small molecule,False,IZORLISIB,,2.0,,False,False,[],"['CH-5132799' 'CH5132799' 'Ch 5132799' 'Izorlisib' 'PA-799' 'PA799'
 'Pa-799']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('drugbank', array(['DB13051'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1743008,,,Antibody,False,DROZITUMAB,,2.0,,False,False,[],"['ANTI-DR5' 'ANTI-DR5 RHUMAB-DR5' 'Drozitumab' 'PRO-95780' 'RHUMAB DR5'
 'RHUMAB-DR5' 'Usp mab 003, monoclonal igg1']",,,"{'rows': array(['EFO_0000333', 'EFO_0005952', 'EFO_0003060', 'EFO_1001951'],
      dtype=object), 'count': 4}",[ENSG00000120889],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1744447,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2],LALFOYNTGMUKGG-BGRFNVSISA-L,Small molecule,False,ROSUVASTATIN CALCIUM,2003.0,4.0,CHEMBL1496,False,True,['Crestor' 'Ezallor' 'Ezallor sprinkle' 'Rosuvastatin calcium'],"['Fortius' 'NSC-747274' 'NSC-758930' 'Rostar' 'Rosuvastatin (as calcium)'
 'Rosuvastatin calcium' 'Rosuvastatin calcium salt'
 'Rosuvastatin hemicalcium' 'Rozavel' 'S-4522' 'Suvikan' 'ZD-4522'
 'ZD-4522 (CALCIUM SALT)' 'ZD-4522 CALCIUM' 'ZD4522 (CALCIUM SALT)'
 'ZD4522 CALCIUM']","[('DailyMed', array(['rosuvastatin%20calcium'], dtype=object)), ('chEBI', array(['77249'], dtype=object))]",,"{'rows': array(['MONDO_0005147', 'EFO_0003144', 'Orphanet_79211', 'EFO_0003914',
       'EFO_0004911', 'EFO_0005672', 'EFO_0001645', 'EFO_0000400',
       'MONDO_0018473', 'Orphanet_309005', 'MONDO_0005148', 'EFO_0004211',
       'EFO_0000537', 'EFO_0000616', 'MONDO_0021187', 'HP_0003124',
       'EFO_0004239'], dtype=object), 'count': 17}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved and 11 investigational indications.
CHEMBL2109248,,,Antibody,False,APOMAB,,2.0,,False,False,['Apomab'],[],,,,[ENSG00000120889],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109326,,,Antibody,False,MIK-BETA-1,,1.0,,False,False,[],['MIK-BETA-1' 'Mik-beta-1'],,,"{'rows': array(['EFO_0000565'], dtype=object), 'count': 1}",[ENSG00000100385],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2364968,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,ZQLJWTRXKINMIN-BEJKIDSHSA-N,Unknown,False,ERGOLOID,1953.0,4.0,,False,True,[],[],,['CHEMBL2311030'],"{'rows': array(['EFO_0004718', 'EFO_0000319', 'MONDO_0010383'], dtype=object), 'count': 3}","[ENSG00000178394,ENSG00000135312,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL3545370,,,Antibody,False,EMACTUZUMAB,,3.0,,False,False,[],"['7i1955n5wx' 'CXD-301' 'CXD301' 'Emactuzumab' 'RG-7155' 'RG7155'
 'RO-5509554' 'RO5509554' 'RO5509554 (ANTI-CSF-R1)']",,,"{'rows': array(['EFO_0005952', 'MONDO_0004992', 'MONDO_0002171', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000182578],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3707393,N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1.O=P(O)(O)O,FMCPYRDGUZBOJZ-BTQNPOSSSA-N,Small molecule,False,OSILODROSTAT PHOSPHATE,2020.0,4.0,CHEMBL3099695,False,True,['Isturisa'],['LCI699-AZA' 'Osilodrostat phosphate'],"[('DailyMed', array(['osilodrostat%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/isturisa'],
      dtype=object))]",,"{'rows': array(['EFO_0003099', 'EFO_1001110'], dtype=object), 'count': 2}",[ENSG00000160882],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for cushing syndrome and pituitary-dependent cushing's disease.
CHEMBL4297422,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@@H]1C(=O)Nc2ccccc2-c2ccccc21,OJPLJFIFUQPSJR-INIZCTEOSA-N,Small molecule,False,RG-4733,,2.0,,False,False,[],['RO 4929097' 'RO-4929097' 'Rg 4733' 'Rg-4733' 'Ro4929097'],"[('drugbank', array(['DB11870'], dtype=object))]",,"{'rows': array(['EFO_0000365', 'EFO_1000251', 'MONDO_0021063', 'EFO_0000616',
       'EFO_0000756', 'EFO_0001378', 'EFO_0001075', 'EFO_0000673',
       'EFO_0002501', 'EFO_0000349', 'EFO_0005537', 'EFO_1001465',
       'EFO_0000389', 'EFO_1000657', 'EFO_0006861', 'EFO_0002499',
       'MONDO_0007254', 'EFO_0003060'], dtype=object), 'count': 18}","[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications.
CHEMBL4297508,CC(C)C[C@@H](C(=O)Nc1ccn(C[C@@H](O)CO)n1)N1CC(Oc2ccccc2Cl)=CC1=O,HMUMWSORCUWQJO-QAPCUYQASA-N,Small molecule,False,DORZAGLIATIN,,3.0,,False,False,[],"['Dorzagliatin' 'HMS-5552' 'HMS5552' 'Hms5552' 'RO-5305552' 'RO5305552'
 'Sinogliatin']","[('drugbank', array(['DB15123'], dtype=object))]",,"{'rows': array(['HP_0001952', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}",[ENSG00000106633],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1200406,CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O,NFLLKCVHYJRNRH-UHFFFAOYSA-N,Small molecule,False,DIMENHYDRINATE,1972.0,4.0,,False,True,['Antemin' 'Dimenhydrinate' 'Dramamine' 'Vertigo-vomex s'],['Chloranautine' 'Dimenhydrinate' 'NSC-117855'],"[('DailyMed', array(['dimenhydrinate'], dtype=object)), ('DrugCentral', array(['901'], dtype=object)), ('PubChem', array(['11112942', '144207521', '17389041', '26747407'], dtype=object)), ('Wikipedia', array(['Dimenhydrinate'], dtype=object)), ('drugbank', array(['DB00985'], dtype=object))]",,"{'rows': array(['HP_0002321', 'EFO_0004888', 'MONDO_0005271'], dtype=object), 'count': 3}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for allergic disease and has 2 investigational indications.
CHEMBL1201117,COc1ccccc1OCC(O)COC(N)=O,GNXFOGHNGIVQEH-UHFFFAOYSA-N,Small molecule,False,METHOCARBAMOL,1957.0,4.0,,False,True,"['Delaxin' 'Forbaxin' 'Methocarbamol' 'Miolaxin' 'Neuraxin' 'Robaxin'
 'Robaxin-750']",['Methocarbamol' 'NSC-170960'],"[('DailyMed', array(['methocarbamol'], dtype=object)), ('PubChem', array(['144204005', '170464808', '174006834', '26747217', '26747218',
       '56422407', '855587'], dtype=object)), ('Wikipedia', array(['Methocarbamol'], dtype=object)), ('drugbank', array(['DB00423'], dtype=object)), ('chEBI', array(['77498'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0001422'], dtype=object), 'count': 2}",[ENSG00000133742],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 2 investigational indications.
CHEMBL1201520,,,Unknown,False,UROFOLLITROPIN,1986.0,4.0,,False,True,"['Bravelle' 'Fertinex' 'Fostimon' 'Gonadotraphon fsh' 'Metrodin'
 'Metrodin high purity' 'Orgafol' 'Urofollitrophin']",['Fertinorm' 'Follitropin human' 'Urofollitrophin' 'Urofollitropin'],"[('Wikipedia', array(['Urofollitropin'], dtype=object))]",,"{'rows': array(['EFO_0008560', 'EFO_0000279', 'EFO_0004248', 'MONDO_0002775',
       'EFO_0000545'], dtype=object), 'count': 5}",[ENSG00000170820],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 5 investigational indications.
CHEMBL1314751,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O,DSKIOWHQLUWFLG-SPIKMXEPSA-N,Small molecule,True,PROCHLORPERAZINE MALEATE,1956.0,4.0,CHEMBL728,False,True,"['Buccastem' 'Buccastem m' 'Compazine' 'Prochlorperazine maleate'
 'Procomp' 'Proziere' 'Vertigon']",['Prochlorperazine dimaleate' 'Prochlorperazine maleate'],"[('DailyMed', array(['prochlorperazine%20maleate'], dtype=object)), ('PubChem', array(['144207071', '170464761', '50106935'], dtype=object)), ('chEBI', array(['8436'], dtype=object))]",,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956. This drug has a black box warning from the FDA.
CHEMBL1444,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,HPJKCIUCZWXJDR-UHFFFAOYSA-N,Small molecule,False,LETROZOLE,1997.0,4.0,,False,True,['Femara' 'Letrozole'],['CGS 20267' 'CGS-20267' 'Letrozole' 'NSC-759652'],"[('DailyMed', array(['letrozole'], dtype=object)), ('PubChem', array(['11112889', '124882709', '144204270', '144213877'], dtype=object)), ('Wikipedia', array(['Letrozole'], dtype=object)), ('drugbank', array(['DB01006'], dtype=object)), ('chEBI', array(['6413'], dtype=object))]",,"{'rows': array(['HP_0001510', 'EFO_0009708', 'EFO_0000279', 'MONDO_0011972',
       'GO_0042697', 'EFO_0000616', 'MONDO_0018555', 'EFO_1001346',
       'MONDO_0011962', 'EFO_0008509', 'EFO_0000305', 'MONDO_0002715',
       'MONDO_0002775', 'MONDO_0008170', 'EFO_0000466', 'EFO_0000313',
       'EFO_0001065', 'EFO_1001512', 'EFO_0001075', 'EFO_0003833',
       'EFO_0004248', 'EFO_0003060', 'EFO_0000660', 'EFO_0003859',
       'EFO_0005952', 'EFO_0000588', 'EFO_0000432', 'EFO_0000545',
       'EFO_1000251', 'EFO_1000984', 'EFO_0000731', 'EFO_0002950',
       'EFO_0003869', 'EFO_1001757', 'EFO_0000564', 'EFO_0004230',
       'MONDO_0011705', 'HP_0005268', 'Orphanet_145', 'MONDO_0002158',
       'EFO_0003968', 'EFO_0000553', 'MONDO_0007254', 'EFO_0005537',
       'MONDO_0002087', 'EFO_0003882', 'EFO_0001416'], dtype=object), 'count': 47}",[ENSG00000137869],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 43 investigational indications.
CHEMBL1742991,,,Antibody,False,BENRALIZUMAB,2017.0,4.0,,False,True,['Fasenra'],['BIW-8405' 'Benralizumab' 'MEDI-563'],"[('DailyMed', array(['benralizumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra'],
      dtype=object))]",,"{'rows': array(['EFO_0007187', 'HP_0002110', 'EFO_0004232', 'EFO_0007486',
       'MONDO_0021739', 'EFO_0000274', 'MONDO_0004979', 'HP_0001871',
       'EFO_1000391', 'EFO_0005531', 'EFO_0000341', 'EFO_1001467',
       'HP_0006536'], dtype=object), 'count': 13}",[ENSG00000091181],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for asthma and airway obstruction and has 11 investigational indications.
CHEMBL1766,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,VWVSBHGCDBMOOT-IIEHVVJPSA-N,Small molecule,False,DESOXIMETASONE,1977.0,4.0,,False,True,"['Desoximetasone' 'Stiedex' 'Stiedex lp' 'Stiedex lpn' 'Topicort'
 'Topicort lp']","['A-41-304' 'A-41304' 'Desoximetasone' 'Desoxymethasone' 'HOE 304'
 'HOE-304' 'J83.644C' 'NSC-759189' 'R 2113' 'R-2113']","[('DailyMed', array(['desoximetasone'], dtype=object)), ('PubChem', array(['144204440', '170464795', '29215017', '56423147', '855924'],
      dtype=object)), ('Wikipedia', array(['Desoximetasone'], dtype=object)), ('drugbank', array(['DB00547'], dtype=object)), ('chEBI', array(['691037'], dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_1001494', 'EFO_0000701'], dtype=object), 'count': 3}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 3 approved indications.
CHEMBL262747,CC(=O)Nc1ccc(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc2ccc(Cl)cc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(C)=O)C(=O)N[C@H](Cc2ccc(NC(C)=O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(N)=O)cc1,ZWNUQDJANZGVFO-YHSALVGYSA-N,Protein,False,ACYLINE,,2.0,,False,False,[],['Acyline' 'MER-104'],"[('drugbank', array(['DB11906'], dtype=object))]",,"{'rows': array(['MONDO_0002146'], dtype=object), 'count': 1}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL276520,c1ccc2c(CCC3CCNCC3)c[nH]c2c1,SADQVAVFGNTEOD-UHFFFAOYSA-N,Small molecule,False,INDALPINE,,4.0,,True,True,[],['Indalpine' 'LM-5008'],"[('Wikipedia', array(['Indalpine'], dtype=object)), ('drugbank', array(['DB08953'], dtype=object))]",['CHEMBL2362557'],,[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL3039518,COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,URWYQGVSPQJGGB-DHUJRADRSA-N,Small molecule,False,BATEFENTEROL,,2.0,,False,False,[],"['Batefenterol' 'GSK-961081' 'GSK-961081A' 'GSK961081' 'GSK961081A'
 'TD-5959']","[('drugbank', array(['DB12526'], dtype=object))]",['CHEMBL3039512'],"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}","[ENSG00000169252,ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545083,COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1,XLSYZSRXVVCHLS-UHFFFAOYSA-N,Small molecule,False,RGB-286638,,1.0,,False,False,[],['RGB 286638' 'Rgb-286638'],,,"{'rows': array(['EFO_0001642'], dtype=object), 'count': 1}","[ENSG00000134058,ENSG00000170312,ENSG00000136807,ENSG00000123374,ENSG00000164885,ENSG00000135446]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545368,CC(O)C(=O)O.Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,XVDWNSFFSMWXJJ-ASTDGNLGSA-N,Small molecule,True,PANOBINOSTAT LACTATE,2015.0,4.0,CHEMBL483254,False,True,['Farydak'],['Panobinostat lactate' 'Panobinostat lactate anhydrous'],"[('DailyMed', array(['panobinostat%20lactate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/farydak'],
      dtype=object)), ('chEBI', array(['85991'], dtype=object))]",,"{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for multiple myeloma. This drug has a black box warning from the FDA.
CHEMBL3545372,,,Antibody drug conjugate,False,SOFITUZUMAB VEDOTIN,,2.0,,False,False,[],['Anti-MUC16 ADC' 'DMUC-5754A' 'DMUC5754A' 'RG-7458' 'Sofituzumab vedotin'],,,"{'rows': array(['MONDO_0008170', 'EFO_0002618'], dtype=object), 'count': 2}","[ENSG00000181143,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3644252,Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)n1,JUPOTOIJLKDAPF-UHFFFAOYSA-N,Small molecule,False,ARRY-382,,2.0,,False,False,[],['Arry-382'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000182578],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3669417,N#Cc1ccc2c(c1)[C@H]1CCCN(C(=O)c3ccc4[nH]cnc4c3)[C@H]1C2,VVZNCSHIBODHMZ-UZLBHIALSA-N,Small molecule,False,BI-187004,,2.0,,False,False,[],['Bi 187004' 'Bi-187004'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000117594],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL369075,NC(=O)c1cnc2n1CCc1ccccc1C21CCNCC1,VQWGYPVNVICKFC-UHFFFAOYSA-N,Small molecule,False,VAPITADINE,,2.0,,False,False,[],['Vapitadine'],"[('drugbank', array(['DB05738'], dtype=object))]",['CHEMBL539843' 'CHEMBL1203919'],,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3912251,Cc1cc(C(=O)O)ccc1COc1cc2c(cc1N(CC(C)C)S(=O)(=O)c1nccs1)CCC2,ALLLQQUASFFEKP-UHFFFAOYSA-N,Small molecule,False,ONO-8539,,2.0,,False,False,[],['ONO-8539' 'Ono-8539'],"[('drugbank', array(['DB15325'], dtype=object))]",,"{'rows': array(['EFO_0003948', 'EFO_1000781'], dtype=object), 'count': 2}",[ENSG00000160951],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3989936,C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F,JUFWQQVHQFDUOD-ANRPBIDPSA-N,Small molecule,False,VILAPRISAN,,3.0,,False,False,[],['BAY-1002670' 'BAY1002670' 'Vilaprisan'],"[('drugbank', array(['DB11971'], dtype=object))]",,"{'rows': array(['EFO_0001065', 'MONDO_0001572', 'EFO_0000731'], dtype=object), 'count': 3}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4084119,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O,YSDQQAXHVYUZIW-QCIJIYAXSA-N,Protein,True,LIRAGLUTIDE,2010.0,4.0,,False,True,['Saxenda' 'Victoza'],"['Liraglutide' 'Liraglutide (rdna origin)' 'NN-2211' 'NN-9924' 'NN2211'
 'NN9924' 'NNC 90-1170' 'NNC-90-1170']","[('DailyMed', array(['liraglutide', 'liraglutide%20recombinant'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda'],
      dtype=object))]",,"{'rows': array(['MONDO_0015183', 'MONDO_0005148', 'EFO_0002546', 'EFO_0005935',
       'EFO_0001073', 'MONDO_0004975', 'EFO_0003921', 'MONDO_0002009',
       'EFO_0004319', 'EFO_0003144', 'HP_0003074', 'EFO_0000400',
       'EFO_0003877', 'HP_0001824', 'EFO_1001121', 'MONDO_0005180',
       'MONDO_0004985', 'EFO_0000401', 'EFO_0000195', 'EFO_1001249',
       'Orphanet_552', 'EFO_0005203', 'EFO_0005611', 'MONDO_0005147'],
      dtype=object), 'count': 24}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 5 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297631,CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21,RRTPWQXEERTRRK-UHFFFAOYSA-N,Small molecule,False,TELRATOLIMOD,,2.0,,False,False,[],['3M-052' 'MEDI9197' 'Medi 9197' 'Medi-9197' 'Medi9197' 'Telratolimod'],,,"{'rows': array(['EFO_0000764', 'EFO_0000180', 'EFO_0002913'], dtype=object), 'count': 3}","[ENSG00000196664,ENSG00000101916]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297684,,,Protein,False,ABICIPAR PEGOL,,3.0,,False,False,[],"['AGN-150998' 'Abicipar pegol' 'Agn-150998' 'MP-0112' 'MP-0260' 'MP0112'
 'Mp0112' 'P7FHD7AG35' 'Vegf-a binding darpin']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ABICIPAR%20PEGOL/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004683', 'MONDO_0003005', 'EFO_0009606', 'EFO_0005753',
       'EFO_0001365'], dtype=object), 'count': 5}",[ENSG00000112715],Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297717,,,Unknown,False,CD24FC,,3.0,,False,False,[],['Cd24fc' 'Cd24igg1fc' 'Efprezimod alfa' 'MK-7110' 'Saccovid'],,,"{'rows': array(['EFO_0000616', 'MONDO_0100096', 'EFO_0002617'], dtype=object), 'count': 3}","[ENSG00000204389,ENSG00000204388,ENSG00000142512,ENSG00000189403,ENSG00000080824,ENSG00000096384]",Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4650280,Cc1cnc(NC2CCOCC2)nc1-n1cnc(C(=O)N[C@H](CN)c2cc(F)cc(Cl)c2)c1,PWHIUQBBGPGFFV-GOSISDBHSA-N,Small molecule,False,ASN007,,1.0,,False,False,[],['ASN007' 'Asn007'],,,,"[ENSG00000102882,ENSG00000100030]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4802150,Nc1cc(S(=O)(=O)c2ccc(OC(F)(F)F)cc2)cnc1-c1nnc(CO)o1,WOXOLLSAICIZNO-UHFFFAOYSA-N,Small molecule,False,NAVOCAFTOR,,2.0,,False,False,[],['ABBV-3067' 'Abbv-3067' 'GLPG-3067' 'GLPG3067' 'Navocaftor'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NAVOCAFTOR/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL49642,O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12,SOLIIYNRSAWTSQ-UHFFFAOYSA-N,Small molecule,False,INDIBULIN,,2.0,,False,False,[],['D-24851' 'Indibulin' 'ZIO-301'],"[('PubChem', array(['174007308'], dtype=object)), ('drugbank', array(['DB06169'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0004992', 'MONDO_0007254'], dtype=object), 'count': 3}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL54,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,LNEPOXFFQSENCJ-UHFFFAOYSA-N,Small molecule,True,HALOPERIDOL,1967.0,4.0,,False,True,"['Dolpin' 'Dozic' 'Fortunan' 'Haldol' 'Haldol solutab' 'Haloperidol'
 'Kentace' 'Keselen' 'Serenace']","['Haloperidol' 'Haloperidol decanoate impurity, haloperidol-'
 'MCN-JR-1625' 'NSC-170973' 'NSC-615296' 'R-1625']","[('DailyMed', array(['haloperidol'], dtype=object)), ('PubChem', array(['104171168', '11111260', '11112116', '11113356', '124880286',
       '124880288', '124880291', '124880292', '144203713', '144210793',
       '170464841', '26747061', '26747062', '26751574', '26751575',
       '487337', '50100251', '50104201', '50104202', '56422397',
       '85231072', '855969', '90341418'], dtype=object)), ('TG-GATEs', array(['36'], dtype=object)), ('Wikipedia', array(['Haloperidol'], dtype=object)), ('drugbank', array(['DB00502'], dtype=object)), ('chEBI', array(['5613'], dtype=object))]","['CHEMBL2096643' 'CHEMBL4297147' 'CHEMBL1160253' 'CHEMBL545608'
 'CHEMBL2234294']","{'rows': array(['MONDO_0005090', 'EFO_0005407', 'EFO_0005411', 'EFO_0005230',
       'EFO_0009267', 'EFO_0005323', 'HP_0000713', 'EFO_0000677',
       'MONDO_0004985', 'EFO_0004895', 'MONDO_0007739', 'MONDO_0002050',
       'HP_0002018', 'EFO_0005411', 'EFO_0004701', 'EFO_0004247',
       'EFO_0004216', 'EFO_0003768', 'MONDO_0005090', 'HP_0000713',
       'HP_0000726', 'EFO_0009954', 'MONDO_0004975', 'HP_0100033',
       'EFO_0003015'], dtype=object), 'count': 25}","[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA.
CHEMBL727,Nc1nc2[nH]cnc2c(=S)[nH]1,WYWHKKSPHMUBEB-UHFFFAOYSA-N,Small molecule,False,THIOGUANINE,1966.0,4.0,,False,True,['Lanvis' 'Tabloid' 'Thioguanine'],"['NSC-752' 'NSC-76504' 'Thioguanine' 'Thioguanine anhydrous'
 'Thioguanine hemihydrate' 'Thioguanine, anhydrous' 'Tioguanine'
 'Tioguanine hemihydrate']","[('PubChem', array(['144204586', '144206735', '144209599', '144210595', '170464908',
       '174007001', '26748270', '538243', '57260104', '57264437'],
      dtype=object)), ('Wikipedia', array(['Tioguanine'], dtype=object)), ('drugbank', array(['DB00352'], dtype=object)), ('chEBI', array(['9555'], dtype=object))]",,"{'rows': array(['EFO_0000183', 'EFO_0003027', 'EFO_0000519', 'EFO_0000198',
       'EFO_0003811', 'MONDO_0001657', 'EFO_0000565', 'EFO_0000209',
       'EFO_0003025', 'MONDO_0000873', 'EFO_0003833', 'EFO_0004251',
       'EFO_0000574', 'EFO_1000318', 'EFO_0005952', 'EFO_0003029',
       'EFO_0000616', 'MONDO_0000870', 'EFO_0000220', 'EFO_0000222',
       'EFO_0000223', 'EFO_0000218', 'EFO_0004289', 'EFO_1001779',
       'EFO_0000221', 'EFO_0003802', 'MONDO_0044917'], dtype=object), 'count': 27}","[ENSG00000106348,ENSG00000178035]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and is indicated for neoplasm and has 26 investigational indications.
CHEMBL838,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,XPCFTKFZXHTYIP-PMACEKPBSA-N,Small molecule,True,BENAZEPRIL,1991.0,4.0,,False,True,[],"['Benazepril' 'Benazepril sandoz' 'Briem' 'C09AA07' 'CGS-14824A'
 'Cibacen ws' 'Cibacene' 'Forteekor' 'Lotensin' 'Lotrel']","[('Wikipedia', array(['Benazepril'], dtype=object)), ('drugbank', array(['DB00542'], dtype=object)), ('chEBI', array(['3011'], dtype=object))]",['CHEMBL1694'],"{'rows': array(['EFO_1002048', 'EFO_0000712', 'EFO_0000319', 'EFO_0001645',
       'HP_0003124', 'EFO_0003086', 'EFO_0000400', 'EFO_0003914',
       'MONDO_0010520', 'Orphanet_79292', 'MONDO_0007915', 'EFO_1000965',
       'MONDO_0005148', 'EFO_0000400', 'EFO_0000537', 'EFO_0000537',
       'MONDO_0018965'], dtype=object), 'count': 17}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1018,C/C=C(C(=C/C)/c1ccc(O)cc1)\c1ccc(O)cc1,NFDFQCUYFHCNBW-SCGPFSFSSA-N,Small molecule,False,DIENESTROL,1947.0,4.0,,False,True,['Dienestrol' 'Estraguard' 'Hormofemin'],"['.alpha.-dienestrol diacetate' 'Cycladiene' 'Dehydrostilbestrol'
 'Dienestrol' 'Dienestrol diacetate, .alpha.-' 'Dienestrol trans-form'
 'Dienestrol, .alpha.-' 'Dienoestrol' 'Dienol' 'Dinovex' 'Estragard'
 'Estroral' 'Follidiene' 'Gynefollin' 'NSC-59809' 'Oestrasid'
 'Oestrodiene' 'Oestroral' 'Restrol' 'Retalon']","[('PubChem', array(['124883370', '144203929', '170465362', '26746961', '56422141',
       '855694'], dtype=object)), ('Wikipedia', array(['Dienestrol'], dtype=object)), ('drugbank', array(['DB00890'], dtype=object))]",,,[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1947.
CHEMBL1021,NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,QEFAQIPZVLVERP-UHFFFAOYSA-N,Small molecule,False,NEPAFENAC,2005.0,4.0,,False,True,['Ilevro' 'Nepafenac' 'Nevanac'],['AHR-9434' 'AL-6515' 'Nepafenac'],"[('DailyMed', array(['nepafenac'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac'],
      dtype=object)), ('PubChem', array(['124896627', '144206538', '170465203'], dtype=object)), ('Wikipedia', array(['Nepafenac'], dtype=object)), ('drugbank', array(['DB06802'], dtype=object)), ('chEBI', array(['75922'], dtype=object))]",,"{'rows': array(['HP_0000616', 'MONDO_0005129', 'MONDO_0003005', 'EFO_0005752',
       'MP_0001845', 'EFO_0003843'], dtype=object), 'count': 6}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 approved and 2 investigational indications.
CHEMBL1200516,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O.Cl,UPRWQSQENCASAD-HBBGHHHDSA-N,Protein,False,GONADORELIN HYDROCHLORIDE,1982.0,4.0,CHEMBL1007,False,True,['Factrel'],"['AY-24,031' 'AY-24031' 'Gonadorelin hcl' 'Gonadorelin hydrochloride'
 'Luteinizing hormone-releasing factor dihydrochloride']",,,,[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200804,O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],KXZOIWWTXOCYKR-UHFFFAOYSA-M,Small molecule,True,DICLOFENAC POTASSIUM,1993.0,4.0,CHEMBL139,False,True,"['Cambia' 'Cataflam' 'Diclofenac potassium' 'Voltarol joint pain'
 'Voltarol pain-eze' 'Voltarol pain-eze extra strgh' 'Voltarol rapid'
 'Zipsor']","['CGP 45840B' 'CGP-45840B' 'Diclofenac potassium'
 'Diclofenac potassium salt' 'Potassium diclofenac']","[('DailyMed', array(['diclofenac%20potassium'], dtype=object)), ('chEBI', array(['4508'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_1001139', 'EFO_0003843', 'HP_0100607',
       'EFO_0010072', 'MONDO_0005178', 'EFO_0009454', 'MONDO_0005277'],
      dtype=object), 'count': 8}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 4 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201438,,,Protein,True,ALDESLEUKIN,1992.0,4.0,,False,True,['Proleukin'],"['Aldesleukin' 'Human interleukin-2' 'Human interleukin-2 125-serine'
 'ILT-101' 'Il2 (2-133) c125s' 'Ilt-101' 'Ilt-101 (low dose il-2)'
 'Interleukin 2' 'Interleukin-2' 'Interleukin-2 aldesleukin'
 'Interleukin-2(2-133),125-ser' 'Recombinant interleukin-2 human']","[('DailyMed', array(['aldesleukin'], dtype=object)), ('DrugCentral', array(['5011'], dtype=object))]",,"{'rows': array(['EFO_0000564', 'EFO_0000673', 'EFO_1000954', 'EFO_0005672',
       'EFO_0003780', 'EFO_0000565', 'EFO_0000616', 'EFO_0000389',
       'EFO_0000223', 'EFO_0009709', 'EFO_0009708', 'EFO_0004251',
       'EFO_0000222', 'EFO_0004599', 'EFO_0001062', 'EFO_0003811',
       'EFO_0004719', 'EFO_0000783', 'MONDO_0100096', 'EFO_0000691',
       'EFO_0002617', 'EFO_1000251', 'EFO_0003865', 'EFO_0000403',
       'MONDO_0020547', 'MONDO_0004975', 'EFO_0000313', 'MONDO_0001187',
       'EFO_0000681', 'EFO_0003025', 'EFO_0001378', 'MONDO_0002367',
       'EFO_0000220', 'EFO_1001375', 'EFO_0000729', 'MONDO_0007915',
       'EFO_1001051', 'EFO_0005531', 'EFO_0008518', 'EFO_0000339',
       'EFO_0000588', 'MONDO_0007254', 'MONDO_0002108', 'MONDO_0007576',
       'EFO_0000574', 'MONDO_0024475', 'EFO_0000182', 'MONDO_0002087',
       'MONDO_0019956', 'EFO_0000765', 'EFO_0000699', 'EFO_1001148',
       'EFO_0001061', 'EFO_0000180', 'EFO_1001806', 'EFO_1000984',
       'EFO_0000183', 'EFO_0001075', 'MONDO_0013730', 'MONDO_0002158',
       'MONDO_0018906', 'MONDO_0008170', 'EFO_1000158', 'EFO_0000398',
       'MONDO_0004992', 'EFO_0008528', 'EFO_0004255', 'EFO_1000131',
       'EFO_0000198', 'MONDO_0008903', 'MONDO_0020077', 'EFO_0003060',
       'EFO_0000095', 'EFO_1001471', 'MONDO_0008315', 'EFO_0000571',
       'MONDO_0044881', 'EFO_0003869', 'EFO_0006861', 'EFO_0005846',
       'EFO_1000785', 'EFO_0005952', 'EFO_0000756', 'EFO_0003029',
       'EFO_0007141', 'EFO_0000309', 'EFO_0000621', 'EFO_0000349',
       'EFO_0001668', 'MONDO_0002691', 'MONDO_0004976', 'EFO_0003027',
       'MONDO_0002898', 'EFO_0000764', 'HP_0001871', 'EFO_0004192',
       'EFO_0002428', 'EFO_0001376', 'EFO_0000218', 'EFO_0000384',
       'EFO_0000708', 'EFO_0006859', 'EFO_0003893', 'EFO_0003047',
       'EFO_1001951', 'EFO_1001264', 'EFO_1001779', 'EFO_0000096',
       'MONDO_0010518', 'EFO_0003802', 'EFO_1001465', 'MONDO_0005147',
       'EFO_0000221'], dtype=object), 'count': 113}","[ENSG00000134460,ENSG00000147168,ENSG00000100385]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 5 approved and 108 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1558,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl,WFXFYZULCQKPIP-UHFFFAOYSA-N,Small molecule,False,PRAZOSIN HYDROCHLORIDE,1976.0,4.0,CHEMBL2,False,True,"['Alphavase 0.5' 'Alphavase 1' 'Alphavase 2' 'Alphavase 5' 'Hypovase'
 'Hypovase b.d.' 'Kentovace' 'Minipress' 'Minipress xl'
 'Prazosin hydrochloride']","['CP-12,299-1' 'CP-12299-1' 'NSC-292810' 'Prazosin hcl'
 'Prazosin hydrochloride']","[('DailyMed', array(['prazosin%20hydrochloride'], dtype=object)), ('PubChem', array(['26747647', '26747648', '50106894', '50106895', '50106896',
       '56462999', '572084', '855727'], dtype=object)), ('chEBI', array(['8365'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000400'], dtype=object), 'count': 2}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for hypertension and diabetes mellitus.
CHEMBL1568057,CC(C)NCC(O)c1cc(O)cc(O)c1.CC(C)NCC(O)c1cc(O)cc(O)c1.O=S(=O)(O)O,MKFFGUZYVNDHIH-UHFFFAOYSA-N,Small molecule,False,METAPROTERENOL SULFATE,1973.0,4.0,CHEMBL776,True,True,['Alupent' 'Alupent obstetric' 'Metaproterenol sulfate' 'Prometa'],"['Metaproterenol sulfate' 'Metaproterenol sulphate'
 'Orciprenaline sulfate' 'Orciprenaline sulphate' 'TH-152']","[('PubChem', array(['170466142', '50106554'], dtype=object))]",,"{'rows': array(['EFO_0003890', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for asthma and has 1 investigational indication. It was withdrawn in at least one region.
CHEMBL1615779,N=C(N)NCc1cccc([131I])c1,PDWUPXJEEYOOTR-JRGAVVOBSA-N,Small molecule,False,IOBENGUANE I 131,2018.0,4.0,CHEMBL818,False,True,['Azedra'],"['(131i)-mibg' '131 i-mibg' '131i-mibg' '3-iodobenzylguanidine (131i)'
 '3-iodobenzylguanidine, i-131' 'I-131 metaiodobenzylguanidine'
 'Iobenguane (131 i)' 'Iobenguane (131i)' 'Iobenguane i 131'
 'Iobenguane, i-131' 'Iodine (131i) iobenguane' 'M131ibg'
 'Metaiodobenzylguanidine i-131' 'Mibg i-131']","[('DailyMed', array(['iobenguane%20i-131'], dtype=object))]",,"{'rows': array(['MONDO_0024503', 'EFO_1000453', 'EFO_0000621', 'EFO_0000239'],
      dtype=object), 'count': 4}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 1 investigational indication.
CHEMBL1743054,,,Antibody,False,OZORALIZUMAB,,2.0,,False,False,[],['ATN 103' 'ATN-103' 'Ozoralizumab'],,,"{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}",[ENSG00000232810],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1762,Cc1cccc(C)c1NC(=O)C(C)N,BUJAGSGYPOAWEI-UHFFFAOYSA-N,Small molecule,True,TOCAINIDE,1984.0,4.0,,False,True,[],['Tocainide' 'W-36095'],"[('PubChem', array(['90341559'], dtype=object)), ('Wikipedia', array(['Tocainide'], dtype=object)), ('drugbank', array(['DB01056'], dtype=object)), ('chEBI', array(['9611'], dtype=object))]",['CHEMBL1200773'],"{'rows': array(['EFO_0004269'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for cardiac arrhythmia. This drug has a black box warning from the FDA.
CHEMBL189676,CCc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1,HMXDWDSNPRNUKI-UHFFFAOYSA-N,Small molecule,False,SURINABANT,,2.0,,False,False,[],['SR-147778' 'Sr147778' 'Surinabant'],"[('PubChem', array(['144210559'], dtype=object)), ('Wikipedia', array(['Surinabant'], dtype=object)), ('drugbank', array(['DB13070'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'EFO_0004319'], dtype=object), 'count': 2}",[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2096631,O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-],QCHSEDTUUKDTIG-UHFFFAOYSA-L,Small molecule,True,CLORAZEPATE DIPOTASSIUM,1972.0,4.0,CHEMBL1213252,False,True,['Clorazepate dipotassium' 'Gen-xene' 'Tranxene' 'Tranxene sd'],"['4306 CB' '4306-CB' '4306CB' 'AB 35616' 'ABBOTT-35616' 'CB 4306'
 'CM 4306' 'Clorazepate dipotassium' 'Clorazepate dipotassium civ'
 'Clorazepic acid dipotassium salt' 'Dipotassium clorazepate'
 'Potassium Clorazepate' 'TR 19119']","[('DailyMed', array(['clorazepate%20dipotassium'], dtype=object)), ('chEBI', array(['3762'], dtype=object))]",,"{'rows': array(['HP_0001250', 'EFO_0006788'], dtype=object), 'count': 2}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for seizure and anxiety disorder. This drug has a black box warning from the FDA.
CHEMBL2108328,,,Protein,False,AMILOMOTIDE,,2.0,,False,False,[],['Amilomotide' 'CAD-106' 'CAD106' 'Cad106'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000142192],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108986,,,Protein,False,ARGIPRESSIN TANNATE,,4.0,,False,True,[],['Argipressin' 'Argipressin tannate' 'CI-107'],,,,"[ENSG00000126895,ENSG00000166148,ENSG00000198049]",Protein drug with a maximum clinical trial phase of IV.
CHEMBL2109434,,,Antibody,False,IMC-GP100,,-1.0,,False,False,[],['IMC-GP100'],,,,"[ENSG00000185664,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug.
CHEMBL2109475,,,Antibody,False,PG-102,,2.0,,False,False,[],['PG-102' 'Pg-102'],,,"{'rows': array(['EFO_0003778'], dtype=object), 'count': 1}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2355456,CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.O=C(O)/C=C/C(=O)O,PCIOHQNIRPWFMV-WXXKFALUSA-N,Small molecule,True,IBUTILIDE FUMARATE,1995.0,4.0,CHEMBL533,False,True,['Corvert' 'Ibutilide fumarate'],['Ibutilide fumarate' 'U-70226E'],"[('DailyMed', array(['ibutilide%20fumarate'], dtype=object)), ('PubChem', array(['144206557'], dtype=object))]",,,[ENSG00000055118],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995. This drug has a black box warning from the FDA.
CHEMBL317052,CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,LZPZPHGJDAGEJZ-AKAIJSEGSA-N,Small molecule,False,REGADENOSON ANHYDROUS,2008.0,4.0,,False,True,['Lexiscan'],['Regadenoson anhydrous'],"[('PubChem', array(['170465244'], dtype=object)), ('drugbank', array(['DB06213'], dtype=object))]",['CHEMBL3989695'],"{'rows': array(['EFO_0001645', 'EFO_1001154', 'EFO_0000319', 'MONDO_0011382'],
      dtype=object), 'count': 4}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for cardiovascular disease and has 3 investigational indications.
CHEMBL3360203,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1,QINPEPAQOBZPOF-UHFFFAOYSA-N,Small molecule,False,PILARALISIB,,2.0,,False,False,[],['Pilaralisib' 'SAR-245408' 'SAR245408' 'Sar-245408' 'XL-147' 'XL147'],"[('drugbank', array(['DB11772'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_0000519', 'EFO_0004230', 'EFO_0003060',
       'MONDO_0011962', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254'],
      dtype=object), 'count': 8}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications.
CHEMBL3545137,Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1,YFNWWNRZJGMDBR-UHFFFAOYSA-N,Small molecule,False,PF-00477736,,1.0,,False,False,[],['PF-00477736' 'PF-477736' 'PF477736' 'Pf 477736' 'Pf-00477736'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000149554],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545191,,,Antibody,False,EVINACUMAB,2021.0,4.0,,False,True,['Evkeeza'],['Evinacumab' 'Evinacumab dgnb' 'REGN-1500' 'REGN1500'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evkeeza'],
      dtype=object))]",,"{'rows': array(['HP_0003124', 'EFO_0000589', 'EFO_0000319', 'EFO_0004911',
       'EFO_0004211', 'MONDO_0018328'], dtype=object), 'count': 6}",[ENSG00000132855],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 2 investigational indications.
CHEMBL3545343,,,Small molecule,False,ADC3680,,2.0,,False,False,[],['ADC3680B' 'Adc3680'],,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707395,CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1,AFLFKFHDSCQHOL-IZZDOVSWSA-N,Small molecule,False,ELAFIBRANOR,,3.0,,False,False,[],['Elafibranor' 'GFT-505' 'GFT505' 'Gft505'],"[('drugbank', array(['DB05187'], dtype=object))]",,"{'rows': array(['EFO_1001486', 'EFO_0003095', 'EFO_0004268', 'MONDO_0005148',
       'EFO_1001248', 'EFO_0001421'], dtype=object), 'count': 6}","[ENSG00000186951,ENSG00000112033]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL400599,CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1,CJAVTWRYCDNHSM-UHFFFAOYSA-N,Small molecule,False,BENFLUOREX,1974.0,4.0,,True,True,[],['Benfluorex' 'Mediaxal' 'NSC-757396'],"[('PubChem', array(['56320700'], dtype=object)), ('Wikipedia', array(['Benfluorex'], dtype=object)), ('drugbank', array(['DB09022'], dtype=object))]",['CHEMBL1412305'],"{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000057252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for diabetes mellitus and has 1 investigational indication. It was withdrawn in at least one region.
CHEMBL4297213,CC(=O)O.CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C,LBIUKNXYUXOWFF-CRYSLBJVSA-N,Protein,False,AFAMELANOTIDE ACETATE,2014.0,4.0,CHEMBL441738,False,True,['Scenesse'],"['A-melanotropin, 4(nle)-7(d-phe)' 'Afamelanotide acetate'
 'Afamelanotide triacetate' 'CUV1647 ACETATE']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse'],
      dtype=object))]",,,[ENSG00000258839],Protein drug with a maximum clinical trial phase of IV that was first approved in 2014.
CHEMBL4297562,,,Unknown,False,DKN-01,,2.0,,False,False,[],['DKN-01' 'DKN01' 'Dkn 01' 'Dkn-01' 'LY-2812176' 'LY2812176' 'Sirexatamab'],,,"{'rows': array(['EFO_0001378', 'MONDO_0008315', 'EFO_0000182', 'MONDO_0011962',
       'MONDO_0003060'], dtype=object), 'count': 5}",[ENSG00000107984],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4594462,,,Protein,False,BATIRAXCEPT,,3.0,,False,False,[],"['AVB S6 500' 'AVB-500' 'AVB-S6-500' 'AVBS6500' 'Aravive-S6' 'Avb-s6-500'
 'Axl fc fusion protein avb-s6-500' 'Batiraxcept' 'Ruga-S6' 'S6-500c']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BATIRAXCEPT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0008528', 'EFO_0000616', 'MONDO_0002715', 'EFO_0003893',
       'EFO_0000349', 'MONDO_0008170', 'EFO_0004194'], dtype=object), 'count': 7}",[ENSG00000183087],Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4650478,,,Oligonucleotide,False,SAPABLURSEN,,2.0,,False,False,[],"['IONIS-TMPRSS6-LRx' 'ISIS 702843' 'ISIS-702843' 'Ionis tmprss6-lrx'
 'Sapablursen']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SAPABLURSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001996', 'Orphanet_848', 'MONDO_0016487', 'EFO_0002429'],
      dtype=object), 'count': 4}",[ENSG00000187045],Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL5314393,CC(C)(CN1CCN(C2=Nc3ccccc3Oc3ccccc32)CC1)C(=O)O,UEFWDVMEDFCHGW-UHFFFAOYSA-N,Small molecule,False,LY2624803,,2.0,,False,False,[],['DB-7' 'HY-10275' 'LY2624803' 'Ly-2624803' 'Ly2624803'],,,"{'rows': array(['EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1055,NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl,JIVPVXMEBJLZRO-UHFFFAOYSA-N,Small molecule,False,CHLORTHALIDONE,1960.0,4.0,,False,True,['Chlorthalidone' 'Hygroton' 'Thalitone'],"['Chlortalidone' 'Chlortalidonum' 'Chlorthalidone' 'G-33182' 'NSC-69200'
 'Natriuran' 'Phthalamudine']","[('DailyMed', array(['chlorthalidone'], dtype=object)), ('PubChem', array(['11532862', '170464745', '26747917'], dtype=object)), ('Wikipedia', array(['Chlortalidone'], dtype=object)), ('drugbank', array(['DB00310'], dtype=object)), ('chEBI', array(['3654'], dtype=object))]",,"{'rows': array(['EFO_0004255', 'EFO_0000537', 'HP_0003124', 'EFO_0003144',
       'EFO_0000400', 'EFO_0003777', 'EFO_0003763', 'EFO_0004278',
       'EFO_0001645', 'MONDO_0005147', 'MONDO_0001134', 'EFO_0003914',
       'EFO_1001375', 'EFO_0000319', 'EFO_0000612', 'MONDO_0005148',
       'MONDO_0002462', 'EFO_0000373', 'EFO_0003884', 'EFO_0000668',
       'EFO_0003913'], dtype=object), 'count': 21}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 9 approved and 12 investigational indications.
CHEMBL1200806,COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],CDBRNDSHEYLDJV-FVGYRXGTSA-M,Small molecule,True,NAPROXEN SODIUM,1980.0,4.0,CHEMBL154,False,True,['Aleve' 'Anaprox' 'Anaprox ds' 'Naprelan' 'Naproxen sodium' 'Synflex'],"['BAY-117031' 'BAY117031' 'BAYH6689' 'Naproxen sodium'
 'Naproxen sodium anhydrous' 'Naproxen sodium salt' 'RS-3650']","[('DailyMed', array(['naproxen%20sodium'], dtype=object)), ('PubChem', array(['11112047', '11113013', '144204325', '170465301', '50106619',
       '85231338', '855887'], dtype=object)), ('chEBI', array(['7477'], dtype=object))]",,"{'rows': array(['EFO_0003898', 'EFO_0009454', 'MONDO_0002258', 'EFO_0010072',
       'EFO_0003843', 'EFO_0004274', 'MONDO_0005178', 'EFO_0004616',
       'EFO_0002609', 'MONDO_0004975', 'HP_0002315', 'MONDO_0005277',
       'MONDO_0002471', 'MONDO_0003937', 'EFO_1001434', 'HP_0003418',
       'EFO_0000685', 'EFO_1000941', 'HP_0100607'], dtype=object), 'count': 19}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 14 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1256717,Cc1cc(C)c(NC(=O)C[C@H](CC(=O)O)c2cccc3ccccc23)c(C(=O)N2CCC3(CCCC3)CC2)c1,MFOOVZCXWVAWOV-RUZDIDTESA-N,Small molecule,False,ITRIGLUMIDE,,2.0,,False,False,[],['Cr-2945' 'Itriglumide'],"[('PubChem', array(['50111121'], dtype=object))]",['CHEMBL1335406'],,[ENSG00000110148],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL128748,COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC,ZMGUKFHHNQMKJI-CIOHCNBKSA-N,Small molecule,False,DIMETHYLCURCUMIN,,2.0,,False,False,[],['ASCJ-9' 'CHC-004' 'Dimethylcurcumin' 'GO-Y-025' 'Go-Y025'],"[('drugbank', array(['DB06133'], dtype=object))]",,"{'rows': array(['EFO_0003894'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1522,CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,GBBSUAFBMRNDJC-INIZCTEOSA-N,Small molecule,True,ESZOPICLONE,2004.0,4.0,,False,True,['Eszopiclone' 'Lunesta'],"['(S)-ZOPICLONE' '(S)-Zopiclone' 'Estorra' 'Eszopiclon' 'Eszopiclone'
 'Eszopiclone civ' 'GSK-1755165' 'Zopiclone s-form']","[('DailyMed', array(['eszopiclone'], dtype=object)), ('PubChem', array(['144205286', '170465445', '29215492', '49666409'], dtype=object)), ('Wikipedia', array(['Eszopiclone'], dtype=object)), ('drugbank', array(['DB00402'], dtype=object)), ('chEBI', array(['53760'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'EFO_1001892', 'EFO_0007191', 'EFO_0003918'],
      dtype=object), 'count': 4}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for insomnia and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL208427,O=C(O)c1cccc(-c2cccc(NCCNC[C@H](O)c3cccc(Cl)c3)c2)c1,LLDXOPKUNJTIRF-QFIPXVFZSA-N,Small molecule,False,SOLABEGRON,,2.0,,False,False,[],['Gw427353' 'Solabegron'],"[('drugbank', array(['DB06190'], dtype=object))]",['CHEMBL2107299'],"{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}",[ENSG00000188778],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108018,,,Antibody,False,ADECATUMUMAB,,2.0,,False,False,[],['Adecatumumab' 'MT-201'],,,"{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}",[ENSG00000119888],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2108309,,,Oligonucleotide,False,CUSTIRSEN,,3.0,,False,False,[],['Custirsen' 'ISIS-112989 FREE ACID' 'OGX-011 FREE ACID'],,,"{'rows': array(['EFO_0003060', 'MONDO_0008315', 'MONDO_0004992'], dtype=object), 'count': 3}",[ENSG00000120885],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2109582,,,Antibody,False,81C6 131I,,2.0,,False,False,[],['81C6' '81c6 131i'],,,,[ENSG00000041982],Antibody drug with a maximum clinical trial phase of II.
CHEMBL269864,O=c1[nH]cnc2c(CN3C[C@H](CO)[C@@H](O)C3)c[nH]c12,AFNHHLILYQEHKK-BDAKNGLRSA-N,Small molecule,False,ULODESINE,,2.0,,False,False,['Bcx-4208'],['BCX-3408' 'BCX4208' 'Dadme-immucillin h' 'R-3421' 'Ulodesine'],"[('drugbank', array(['DB12353'], dtype=object))]",['CHEMBL2107835' 'CHEMBL1213653'],"{'rows': array(['MONDO_0005178', 'EFO_0004274', 'EFO_0009104'], dtype=object), 'count': 3}",[ENSG00000198805],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL281764,CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N,WURGZWOTGMLDJP-ZCYANPAGSA-N,Small molecule,False,TABIMORELIN,,2.0,,False,False,[],['NN-703' 'NNC-26-0703' 'Nn703' 'Tabimorelin'],"[('PubChem', array(['26753275'], dtype=object))]",,,"[ENSG00000160868,ENSG00000121853]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3125702,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1,DRLCSJFKKILATL-YWCVFVGNSA-N,Small molecule,False,NAVTEMADLIN,,2.0,,False,False,[],"['AMG 232' 'AMG-232' 'Amg 232' 'KRT-232' 'Krt-232'
 'Mdm2 inhibitor amg-232' 'Navtemadlin']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NAVTEMADLIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15299'], dtype=object))]",,"{'rows': array(['EFO_0000339', 'EFO_1001471', 'EFO_0000222', 'EFO_0006738',
       'EFO_0002429', 'EFO_0000702', 'EFO_0004251', 'EFO_0003060',
       'MONDO_0004992', 'EFO_1001465', 'EFO_0001378', 'EFO_0000479',
       'MONDO_0011962', 'EFO_0000616', 'MONDO_0044903', 'EFO_1001968',
       'EFO_0000756', 'EFO_0002430'], dtype=object), 'count': 18}","[ENSG00000141510,ENSG00000135679]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications.
CHEMBL328190,Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1,GXESHMAMLJKROZ-IAPPQJPRSA-N,Small molecule,False,LASOFOXIFENE,2009.0,4.0,,False,True,[],['Lasofoxifene'],"[('Wikipedia', array(['Lasofoxifene'], dtype=object)), ('drugbank', array(['DB06202'], dtype=object))]",['CHEMBL5307767' 'CHEMBL2113354'],"{'rows': array(['EFO_0003882', 'EFO_0003968', 'MONDO_0007254', 'EFO_0005537'],
      dtype=object), 'count': 4}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 investigational indications.
CHEMBL3544914,CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO,MJUVRTYWUMPBTR-MRXNPFEDSA-N,Small molecule,False,TEZACAFTOR,2018.0,4.0,,False,True,[],['Tezacaftor' 'VX-661'],"[('drugbank', array(['DB11712'], dtype=object))]",,"{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for cystic fibrosis.
CHEMBL3545335,Cc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1,JXSVVZKPEDIRTN-DHZHZOJOSA-N,Small molecule,False,AG-13958,,2.0,,False,False,[],['AG 13958' 'Ag-13958'],,['CHEMBL3922529'],,"[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545383,,,Small molecule,False,RG-7167,,1.0,,False,False,[],['Rg-7167'],,,,"[ENSG00000126934,ENSG00000169032]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL386630,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,Small molecule,True,TESTOSTERONE,1972.0,4.0,,False,True,"['Androderm' 'Androgel' 'Androgel 1%' 'Andropatch' 'Axiron' 'Fortesta'
 'Intrinsa' 'Natesto' 'Striant' 'Striant sr' 'Testim' 'Testim 1%'
 'Testoderm' 'Testoderm tts' 'Testogel' 'Testopatch' 'Testopel' 'Testoral'
 'Testosterone' 'Tostran' 'Vogelxo']","['Android-t' 'Androlan' 'Delatestryl' 'Homosterone' 'Livensa' 'NSC-9700'
 'TESTIM' 'Testiculosterone' 'Testosterone' 'Testosterone ciii'
 'Virosterone']","[('DailyMed', array(['testosterone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/intrinsa'],
      dtype=object)), ('PubChem', array(['144207887', '17389513', '50085980', '56462804'], dtype=object)), ('Wikipedia', array(['Testosterone'], dtype=object)), ('drugbank', array(['DB00624'], dtype=object)), ('chEBI', array(['17347'], dtype=object))]",,"{'rows': array(['EFO_0000545', 'HP_0001510', 'EFO_0004234', 'EFO_1001919',
       'MONDO_0018555', 'MONDO_0005301', 'EFO_0000660', 'EFO_0003964',
       'EFO_0001073', 'EFO_0003884', 'EFO_0003843', 'EFO_0002970',
       'EFO_0000195', 'HP_0030016', 'EFO_0005088', 'MONDO_0004992',
       'Orphanet_325690', 'EFO_0000196', 'MONDO_0005351', 'EFO_1001006',
       'EFO_0003144', 'MONDO_0008315', 'EFO_1001078', 'EFO_1000859',
       'EFO_0001645', 'EFO_0001663', 'HP_0003549', 'Orphanet_145',
       'EFO_0004714', 'MONDO_0018800', 'GO_0042697', 'MONDO_0002146',
       'EFO_1000653', 'HP_0000044', 'EFO_0000765', 'EFO_0002614',
       'EFO_0000616'], dtype=object), 'count': 37}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 7 approved and 29 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3989948,CC#Cc1cncc(-c2ccc3c(c2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)c1,WKDNQONLGXOZRG-HRNNMHKYSA-N,Small molecule,False,LANABECESTAT,,3.0,,False,False,[],['AZD-3293' 'AZD3293' 'LY-3314814' 'LY3314814' 'Lanabecestat'],"[('drugbank', array(['DB14814'], dtype=object))]",['CHEMBL3989942'],"{'rows': array(['EFO_0001421', 'MONDO_0004975', 'HP_0000083'], dtype=object), 'count': 3}",[ENSG00000186318],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297296,C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1,XAYAKDZVINDZGB-BMVMHAJPSA-N,Small molecule,False,KOS-1584,,2.0,,False,False,[],"['(e)-9,10-dehydroepothilone d' '(e)-9,10-didehydroepothilone d'
 '9,10-trans-dehydroepothilone d' 'Dehydelone' 'Kos-1584' 'R-1645' 'R1645']","[('drugbank', array(['DB05903'], dtype=object))]",,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297622,C[C@@H]1OC(=O)N[C@@H]1C(=O)N[C@@H](Cc1cscn1)C(=O)N1CCC[C@H]1C,WTXWDXWZGJGIHV-URBCHYCLSA-N,Small molecule,False,ROVATIRELIN,,3.0,,False,False,[],['KPS-0373' 'Kps-0373' 'Rovatirelin' 'S-0373'],"[('drugbank', array(['DB15338'], dtype=object))]",,"{'rows': array(['MONDO_0000437'], dtype=object), 'count': 1}",[ENSG00000174417],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL499915,CC1(C)[C@@H](OC(=O)CCC(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12,OBZHEBDUNPOCJG-WBXJDKIVSA-N,Small molecule,False,CARBENOXOLONE,,4.0,,False,True,[],['Carbenoxolone'],"[('Wikipedia', array(['Carbenoxolone'], dtype=object)), ('drugbank', array(['DB02329'], dtype=object))]",['CHEMBL1697717'],"{'rows': array(['EFO_0003948', 'HP_0004398'], dtype=object), 'count': 2}","[ENSG00000176387,ENSG00000117594]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastroesophageal reflux disease and peptic ulcer.
CHEMBL645,CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,VHYCDWMUTMEGQY-UHFFFAOYSA-N,Small molecule,False,BISOPROLOL,1992.0,4.0,,False,True,[],"['Bisoprolol' 'CL 297,939' 'CL-297939' 'EMD 33 512' 'EMD-33-512' 'Zebeta'
 'Ziac']","[('PubChem', array(['174007419', '26751965', '29215032', '50104637', '90341096'],
      dtype=object)), ('Wikipedia', array(['Bisoprolol'], dtype=object)), ('drugbank', array(['DB00612'], dtype=object)), ('chEBI', array(['3127'], dtype=object))]",['CHEMBL1200708' 'CHEMBL1472989'],"{'rows': array(['Orphanet_79292', 'EFO_0000537', 'MONDO_0010679', 'MP_0001914',
       'EFO_0000319', 'MONDO_0017147', 'MONDO_0007254', 'EFO_0005672',
       'EFO_0000537', 'EFO_0001645', 'EFO_0000275'], dtype=object), 'count': 11}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for cardiovascular disease and hypertension and has 9 investigational indications.
CHEMBL75435,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,DKYWVDODHFEZIM-NSHDSACASA-N,Small molecule,False,DEXKETOPROFEN,1994.0,4.0,,False,True,['Keral'],"['(s)-ketoprofen' 'Arveles' 'Dexketoprofen' 'Ketoprofen, (s)-']","[('PubChem', array(['26754382', '26754383', '56320640'], dtype=object)), ('drugbank', array(['DB09214'], dtype=object)), ('chEBI', array(['76128'], dtype=object))]",,"{'rows': array(['HP_0002829', 'HP_0003419', 'EFO_0003843', 'HP_0003326',
       'EFO_0005755'], dtype=object), 'count': 5}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 2 investigational indications.
CHEMBL109648,COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO,LFWCJABOXHSRGC-UHFFFAOYSA-N,Small molecule,False,CLAZOSENTAN,,3.0,,False,False,['Pivlaz'],"['ACT-108475' 'AXV-034343' 'AXV-343434' 'Axv-034' 'Clazosentan'
 'RO-61-1790' 'Ro 61-1790' 'VML-588']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CLAZOSENTAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06677'], dtype=object))]",['CHEMBL5314590'],"{'rows': array(['EFO_0000713', 'EFO_0000713'], dtype=object), 'count': 2}",[ENSG00000151617],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1200517,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21.CS(=O)(=O)O,ADYPXRFPBQGGAH-UMYZUSPBSA-N,Small molecule,True,DIHYDROERGOTAMINE MESYLATE,1946.0,4.0,CHEMBL1732,False,True,"['D.h.e. 45' 'Diergo' 'Dihydergot' 'Dihydroergotamine mesylate' 'Tonopan'
 'Trudhesa']","['DHE-45' 'Dihydroergotamine Methanesulfonate'
 'Dihydroergotamine mesilate' 'Dihydroergotamine mesylate'
 'Dihydroergotamine methanesulfonate' 'Migranal' 'NSC-759848']","[('DailyMed', array(['dihydroergotamine%20mesylate'], dtype=object)), ('PubChem', array(['50106120'], dtype=object)), ('chEBI', array(['59756'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}",[ENSG00000179546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for migraine disorder. This drug has a black box warning from the FDA.
CHEMBL1200617,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,QTTRZHGPGKRAFB-OOKHYKNYSA-N,Small molecule,False,RIMEXOLONE,1994.0,4.0,,False,True,['Vexol'],['ORG 6216' 'ORG-6216' 'Rimexolon' 'Rimexolone'],"[('PubChem', array(['56463550'], dtype=object)), ('Wikipedia', array(['Rimexolone'], dtype=object)), ('drugbank', array(['DB00896'], dtype=object))]",,"{'rows': array(['EFO_1000906', 'EFO_0005752'], dtype=object), 'count': 2}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for eye inflammation and has 1 investigational indication.
CHEMBL1201567,,,Protein,False,FILGRASTIM,1991.0,4.0,,False,True,['Accofil' 'Neupogen' 'Neupogen 30' 'Neupogen 48' 'Nivestim' 'Zarzio'],"['Filgrastim' 'Filgrastim for bioassay'
 'Granulocyte colony-stimulating factor filgrastim' 'KRN-8601' 'MBRI-9901'
 'R-METHUG-CSF' 'TX-01' 'TX01' 'XM-02' 'XM02']","[('DailyMed', array(['filgrastim', 'filgrastim-aafi', 'filgrastim-sndz',
       'tbo-filgrastim'], dtype=object)), ('DrugCentral', array(['4987'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim'],
      dtype=object)), ('Wikipedia', array(['Filgrastim'], dtype=object))]",,"{'rows': array(['EFO_0007532', 'MONDO_0008867', 'MONDO_0004992', 'EFO_0001422',
       'EFO_0009708', 'EFO_0000565', 'EFO_0001421', 'EFO_0000223',
       'EFO_1001469', 'MONDO_0004643', 'EFO_0003833', 'EFO_0004272',
       'MONDO_0015760', 'EFO_0003811', 'MONDO_0007576', 'MONDO_0002334',
       'EFO_0002918', 'EFO_0000574', 'GO_0042697', 'EFO_0003060',
       'EFO_0000612', 'EFO_0003929', 'EFO_0000183', 'EFO_0000545',
       'EFO_0000239', 'EFO_0000637', 'MONDO_0008315', 'EFO_0005537',
       'EFO_0003869', 'EFO_0008583', 'EFO_0000621', 'EFO_1001779',
       'MONDO_0011382', 'EFO_0000221', 'EFO_0003802', 'MONDO_0002087',
       'EFO_0001642', 'EFO_0000095', 'MONDO_0004986', 'HP_0001871',
       'EFO_0003032', 'EFO_0000616', 'EFO_0004142', 'MONDO_0002974',
       'Orphanet_848', 'EFO_0005529', 'Orphanet_303', 'EFO_1001345',
       'MONDO_0003783', 'EFO_0000313', 'EFO_1001968', 'EFO_1001365',
       'MONDO_0002691', 'MONDO_0009348', 'EFO_0004991', 'EFO_0004251',
       'EFO_0000209', 'EFO_0000096', 'EFO_0000182', 'HP_0031217',
       'MONDO_0008903', 'MONDO_0019460', 'EFO_0000220', 'EFO_0000196',
       'EFO_1001465', 'HP_0008209', 'EFO_0001378', 'MONDO_0019391',
       'EFO_1000749', 'EFO_0006803', 'EFO_0000760', 'EFO_0007416',
       'EFO_0006927', 'EFO_0000717', 'EFO_0000702', 'EFO_0005952',
       'EFO_0003928', 'EFO_0003029', 'MONDO_0003751', 'EFO_0007362',
       'HP_0001399', 'HP_0001945', 'EFO_0000544', 'MONDO_0004192',
       'MONDO_0001475', 'MONDO_0005180', 'MONDO_0013730', 'EFO_1000131',
       'EFO_0000339', 'EFO_0000222', 'EFO_0001376', 'EFO_0000502',
       'MONDO_0018906', 'EFO_0006475', 'EFO_0009441', 'EFO_0000384',
       'MONDO_0002158', 'EFO_0000407', 'EFO_0000218', 'EFO_0000466',
       'EFO_0002428', 'EFO_1001951', 'EFO_0003875', 'MONDO_0007915',
       'MONDO_0005301', 'EFO_0000691', 'MONDO_0007254', 'EFO_1000796',
       'EFO_0003025', 'EFO_0002939', 'HP_0002721', 'MONDO_0001056',
       'MONDO_0001657', 'MONDO_0000870', 'EFO_0004145', 'MONDO_0008170',
       'EFO_1000984', 'EFO_0004256', 'EFO_0000211', 'MONDO_0019438',
       'EFO_0004281', 'EFO_0007498', 'EFO_1001042', 'MONDO_0005147',
       'EFO_0002618', 'MONDO_0008380', 'EFO_0004252', 'MONDO_0004975',
       'EFO_0000309', 'MONDO_0016700', 'EFO_0000712', 'EFO_0006859',
       'MONDO_0020077', 'HP_0002140', 'EFO_0000764', 'EFO_0000174',
       'EFO_0000191', 'EFO_0003968', 'EFO_0001645', 'EFO_0000094',
       'MONDO_0044903', 'HP_0012410', 'EFO_0008585', 'EFO_0000514',
       'EFO_0002430', 'EFO_1000318', 'EFO_0003893', 'MONDO_0011962',
       'EFO_0000198', 'MONDO_0015974', 'EFO_0000389', 'EFO_0005235',
       'EFO_0001065', 'EFO_0000403', 'MONDO_0008978', 'EFO_1000158',
       'EFO_0000756', 'EFO_0000181', 'MONDO_0006058', 'EFO_0004265',
       'MONDO_0002367', 'MONDO_0044881', 'EFO_0006861', 'EFO_0007359',
       'EFO_0003027', 'MONDO_0000873', 'MONDO_0019471', 'EFO_0000681',
       'EFO_0000224', 'HP_0001915', 'MONDO_0004976', 'EFO_1000043',
       'MONDO_0001187', 'EFO_1000632'], dtype=object), 'count': 174}",[ENSG00000119535],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 170 investigational indications.
CHEMBL1448187,Cl.Cl.OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,MBHNWCYEGXQEIT-UHFFFAOYSA-N,Small molecule,True,FLUPHENAZINE HYDROCHLORIDE,1959.0,4.0,CHEMBL726,False,True,['Fluphenazine hydrochloride' 'Moditen' 'Permitil' 'Prolixin'],"['Anatensol' 'Dapotum' 'Fluphenazine dihydrochloride' 'Fluphenazine hcl'
 'Fluphenazine hydrochloride' 'Fluphenazini hydrochloridum' 'NSC-179197'
 'SQUIBB 4918']","[('DailyMed', array(['fluphenazine%20hydrochloride'], dtype=object)), ('PubChem', array(['26747520', '26747521', '50106350'], dtype=object))]",,"{'rows': array(['EFO_0000677', 'EFO_0001378'], dtype=object), 'count': 2}",[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for mental or behavioural disorder and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1512,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,XSFJVAJPIHIPKU-XWCQMRHXSA-N,Small molecule,False,FLUNISOLIDE,1981.0,4.0,,False,True,"['Aerobid' 'Aerospan hfa' 'Flunisolide' 'Nasalide' 'Nasarel' 'Syntaris'
 'Syntaris hayfever']","['Flunisolide' 'Flunisolide anhydrous' 'Flunisolide hemihydrate'
 'NSC-757871' 'RS-3999']","[('DailyMed', array(['flunisolide'], dtype=object)), ('PubChem', array(['144204276', '170465331', '56463079'], dtype=object)), ('Wikipedia', array(['Flunisolide'], dtype=object)), ('drugbank', array(['DB00180'], dtype=object)), ('chEBI', array(['5106'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0008521', 'EFO_1001417', 'HP_0006536',
       'HP_0001742'], dtype=object), 'count': 5}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 1 investigational indication.
CHEMBL1743053,,,Antibody,False,OTELIXIZUMAB,,3.0,,False,False,[],"['CHAGLY CD3' 'CHAGLYCD-3' 'ChAglyCD' 'Chaglycd3' 'Otelixizumab' 'TRX-4'
 'TRX4']",,,"{'rows': array(['MONDO_0005147', 'EFO_1001466', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000198851],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2105743,COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,KCEHVJZZIGJAAW-FERBBOLQSA-N,Small molecule,False,OLODATEROL HYDROCHLORIDE,2014.0,4.0,CHEMBL605846,False,True,['Striverdi respimat'],['BI 1744 CL' 'BI-1744 CL' 'BI-1744-CL' 'Olodaterol hydrochloride'],"[('DailyMed', array(['olodaterol%20hydrochloride'], dtype=object)), ('chEBI', array(['83309'], dtype=object))]",,"{'rows': array(['EFO_0006505', 'EFO_0000341', 'EFO_0000464'], dtype=object), 'count': 3}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved indications.
CHEMBL2108569,,,Protein,False,INSULIN PEGLISPRO,,3.0,,False,False,[],['Insulin peglispro' 'LY-2605541' 'LY2605541'],,,"{'rows': array(['MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109385,,,Antibody,False,ENOTICUMAB,,2.0,,False,False,[],['Enoticumab' 'REGN-421' 'REGN421'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}",[ENSG00000128917],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2146102,CN[C@@H](C)[C@H](O)c1ccccc1.Cl,BALXUFOVQVENIU-GNAZCLTHSA-N,Small molecule,False,EPHEDRINE HYDROCHLORIDE,2021.0,4.0,CHEMBL211456,False,True,"['Amesec' 'Asmapax' 'Bronchipax' 'C.a.m.' 'Do-do' 'Ephed hcl'
 'Ephed in nor saline' 'Expurhin' 'Franol' 'Haymine' 'Rezipres' 'Secron'
 'Tabasan' 'Taumasthman' 'Tedral' 'Tedral sa']","['(-)-ephedrine hydrochloride' 'Ephedrine hcl' 'Ephedrine hydrochloride'
 'Ephedrini hydrochloridum' 'L-ephedrine hydrochloride' 'NSC-759611']","[('PubChem', array(['144204863', '170465509'], dtype=object))]",,"{'rows': array(['HP_0001742', 'EFO_0005251', 'EFO_0007214', 'EFO_0003956',
       'MONDO_0004979'], dtype=object), 'count': 5}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 5 approved indications.
CHEMBL278819,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1,LDMWSLGGVTVJPG-UHFFFAOYSA-N,Small molecule,False,MINAPRINE,,4.0,,True,True,[],['AGR-1240' 'Brantur' 'CB-30038' 'Cantor' 'Minaprine'],"[('PubChem', array(['11112706'], dtype=object)), ('Wikipedia', array(['Minaprine'], dtype=object)), ('drugbank', array(['DB00805'], dtype=object)), ('chEBI', array(['51038'], dtype=object))]",['CHEMBL536932' 'CHEMBL1364551'],"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000168539,ENSG00000087085,ENSG00000149295,ENSG00000184845,ENSG00000189221,ENSG00000135914,ENSG00000102468,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder. It was withdrawn in at least one region.
CHEMBL338604,CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23,CUNDRHORZHFPLY-UHFFFAOYSA-N,Small molecule,False,C-1311,,2.0,,False,False,[],['NSC-645809'],,['CHEMBL3545337' 'CHEMBL2002951'],,"[ENSG00000131747,ENSG00000077097,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545401,,,Small molecule,False,X-82,,2.0,,False,False,[],['X-82'],,,"{'rows': array(['EFO_0001365', 'EFO_0000228', 'EFO_0000616', 'EFO_0003860'],
      dtype=object), 'count': 4}","[ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3580737,CCS(=O)(=O)c1ccc(Oc2cc(O[C@@H](C)CO)cc(C(=O)Nc3ccn(C)n3)c2)cn1,KJSGTWFWVTYPFZ-AWEZNQCLSA-N,Small molecule,False,MK-0941,,2.0,,False,False,[],[],,['CHEMBL4297302'],"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000106633],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3692206,Cc1cc(Nc2nc(CC3(C(=O)O)CCN(C(=O)c4cccc(Cl)c4Cl)CC3)ccc2F)n[nH]1,PLAVWQHGBMTMFR-UHFFFAOYSA-N,Small molecule,False,TAS-119,,1.0,,False,False,[],['Tas 119' 'Tas-119'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000087586],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3916717,Cc1cc(F)c(C(=O)Nc2cccc(-c3nncn3C(C)C)n2)cc1-n1cnc(C2CC2)c1,YIDDLAAKOYYGJG-UHFFFAOYSA-N,Small molecule,False,SELONSERTIB,,3.0,,False,False,[],['GS-4997' 'Gs-4997' 'Selonsertib'],"[('drugbank', array(['DB14916'], dtype=object))]",,"{'rows': array(['EFO_0003095', 'EFO_1001249', 'EFO_0000401', 'EFO_1001345',
       'EFO_0001361'], dtype=object), 'count': 5}",[ENSG00000197442],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297066,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.O=C(O)C(O)C(O)C(=O)O,KUBARPMUNHKBIQ-ZBPSDVLKSA-N,Small molecule,False,ELIGLUSTAT TARTRATE,2014.0,4.0,CHEMBL2110588,False,True,['Cerdelga'],"['Eliglustat hemitartrate' 'Eliglustat tartrate' 'GENZ 112638'
 'GENZ-112638']","[('DailyMed', array(['eliglustat%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga'],
      dtype=object))]",,"{'rows': array(['MONDO_0018150'], dtype=object), 'count': 1}",[ENSG00000148154],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2014 and is indicated for gaucher disease.
CHEMBL4297593,CONC(=N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)c2cc(Cl)cc(OC(F)F)c2)cc1,XSNMGLZVFNDDPW-ZWKOTPCHSA-N,Small molecule,False,ATECEGATRAN METOXIL,,2.0,,False,False,[],"['AZD-0837' 'AZD0837' 'Atecegatran fexenetil' 'Atecegatran metoxil'
 'Azd 0837' 'Azd0837']","[('drugbank', array(['DB12507'], dtype=object))]",,"{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}",[ENSG00000180210],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297923,,,Protein,False,RASDEGAFUSP ALFA,,2.0,,False,False,[],['CDX-1401' 'Cdx-1401' 'Rasdegafusp alfa'],,,"{'rows': array(['MONDO_0004992', 'EFO_0000389', 'EFO_0003060'], dtype=object), 'count': 3}","[ENSG00000054219,ENSG00000184033,ENSG00000268651]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4650214,CN1CCC(c2ccccc2CC(C)(C)Nc2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1,WPFUFWIHMYZXSF-UHFFFAOYSA-N,Small molecule,False,ZANDELISIB,,3.0,,False,False,[],"['ACC-524' 'ME-401' 'Me-401' 'PW-143' 'PWT-143' 'PWT143' 'Pwt-143'
 'Zandelisib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANDELISIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000096', 'EFO_0000403', 'EFO_0004289', 'EFO_1001469',
       'MONDO_0004992', 'MONDO_0018906', 'EFO_0000095'], dtype=object), 'count': 7}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL573677,C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1,ZLJZDYOBXVOTSA-XMMPIXPASA-N,Small molecule,False,ABEQUOLIXRON,,1.0,,False,False,[],['Abequolixron' 'RGX-104' 'Rgx-104' 'SB-742881'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ABEQUOLIXRON/relevant/1/'],
      dtype=object))]",['CHEMBL5303417' 'CHEMBL5095408'],"{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_0003060', 'MONDO_0011962'],
      dtype=object), 'count': 4}","[ENSG00000025434,ENSG00000131408]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL640,CCN(CC)CCNC(=O)c1ccc(N)cc1,REQCZEXYDRLIBE-UHFFFAOYSA-N,Small molecule,True,PROCAINAMIDE,1950.0,4.0,,False,True,[],"['NSC-27461' 'Novocainamide' 'Procainamide' 'Procan' 'Procanbid'
 'Procapan' 'Pronestyl' 'Pronestyl-SR' 'Sp 100 (pharmaceutical)']","[('PubChem', array(['11111690', '11111691', '144203797', '170464952', '26751611',
       '90340905'], dtype=object)), ('Wikipedia', array(['Procainamide'], dtype=object)), ('drugbank', array(['DB01035'], dtype=object)), ('chEBI', array(['8428'], dtype=object))]",['CHEMBL605'],"{'rows': array(['EFO_0004278', 'HP_0004308', 'EFO_0000612', 'EFO_0004269',
       'EFO_0003144', 'EFO_0004287', 'EFO_0000275', 'EFO_0000275',
       'EFO_0004269'], dtype=object), 'count': 9}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1152,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,LRJOMUJRLNCICJ-JZYPGELDSA-N,Small molecule,False,PREDNISOLONE ACETATE,1955.0,4.0,,False,True,"['Econopred' 'Flo-pred' 'Meticortelone' 'Omnipred' 'Pred forte' 'Pred fte'
 'Pred mild' 'Prednisolone acetate' 'Sterane' 'Ultracortenol']","['NSC-10966' 'Prednisolone 21-acetate' 'Prednisolone Acetate'
 'Prednisolone acetate' 'Prednisoloni acetas']","[('DailyMed', array(['prednisolone%20acetate'], dtype=object)), ('PubChem', array(['144204881', '170464632', '56422451', '855649'], dtype=object)), ('drugbank', array(['DB15566'], dtype=object)), ('chEBI', array(['8380'], dtype=object))]",,"{'rows': array(['EFO_0007141', 'EFO_1000811', 'EFO_1001157', 'HP_0011868',
       'EFO_1001231', 'HP_0003419', 'MONDO_0005129', 'MONDO_0005301',
       'MP_0001845', 'EFO_1001888', 'EFO_1000997', 'MONDO_0003005',
       'HP_0000559', 'MONDO_0002280'], dtype=object), 'count': 14}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 5 approved and 9 investigational indications.
CHEMBL1197051,CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1,BMUKKTUHUDJSNZ-UHFFFAOYSA-N,Small molecule,False,ISOXSUPRINE,,4.0,,False,True,[],['Dilator' 'Isoxsuprine'],"[('Wikipedia', array(['Isoxsuprine'], dtype=object))]",['CHEMBL559180'],"{'rows': array(['EFO_0000319', 'MONDO_0005301'], dtype=object), 'count': 2}","[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.
CHEMBL1200772,CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[K+],WSHYKIAQCMIPTB-UHFFFAOYSA-M,Small molecule,False,WARFARIN POTASSIUM,1982.0,4.0,CHEMBL1464,False,True,['Athrombin-k'],['Potassium warfarin' 'Warfarin potassium' 'Warfarin-potassium'],"[('PubChem', array(['144205190', '170464790'], dtype=object))]",,"{'rows': array(['EFO_0000275', 'HP_0001907', 'HP_0004936'], dtype=object), 'count': 3}",[ENSG00000167397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications.
CHEMBL1201644,,,Protein,False,INSULIN ZINC SUSP RECOMBINANT HUMAN,1985.0,4.0,,False,True,['Humulin l' 'Novolin l'],['Insulin zinc susp recombinant human'],,,"{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1985 and has 1 investigational indication.
CHEMBL1201754,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,POGQSBRIGCQNEG-UHFFFAOYSA-N,Small molecule,False,RUFINAMIDE,2007.0,4.0,,False,True,['Banzel' 'Inovelon' 'Rufinamide'],"['60231/4' 'CGP 33101' 'CGP-33101' 'E-2080' 'E2080' 'RUF 331' 'RUF-331'
 'Rufinamide']","[('DailyMed', array(['rufinamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon'],
      dtype=object)), ('PubChem', array(['170465202', '29217641', '50111716', '56320687', '90341717'],
      dtype=object)), ('Wikipedia', array(['Rufinamide'], dtype=object)), ('drugbank', array(['DB06201'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'HP_0001250', 'EFO_0000474', 'MONDO_0016532'],
      dtype=object), 'count': 4}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 1 investigational indication.
CHEMBL1236962,COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F,CGBJSGAELGCMKE-UHFFFAOYSA-N,Small molecule,False,OMIPALISIB,,2.0,,False,False,[],['GSK-2126458' 'GSK2126458' 'Gsk-2126458' 'Omipalisib'],"[('drugbank', array(['DB12703'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000768', 'MONDO_0004992'], dtype=object), 'count': 3}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1420,C[n+]1ccccc1C=NO,JBKPUQTUERUYQE-UHFFFAOYSA-O,Small molecule,False,PRALIDOXIME,1964.0,4.0,,False,True,[],['Atnaa' 'Duodote' 'Pralidoxime' 'Pralidoxime cation' 'Pralidoxime ion'],"[('PubChem', array(['11112108'], dtype=object)), ('Wikipedia', array(['Pralidoxime'], dtype=object)), ('drugbank', array(['DB00733'], dtype=object)), ('chEBI', array(['8354'], dtype=object))]",['CHEMBL3335073' 'CHEMBL748' 'CHEMBL2104739' 'CHEMBL14577'],"{'rows': array(['EFO_0008546', 'EFO_0010581', 'EFO_0008546', 'EFO_0004991'],
      dtype=object), 'count': 4}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for poisoning and myasthenia gravis and has 2 investigational indications.
CHEMBL1694,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O.Cl,VPSRQEHTHIMDQM-FKLPMGAJSA-N,Small molecule,True,BENAZEPRIL HYDROCHLORIDE,1991.0,4.0,CHEMBL838,False,True,['Benazepril hydrochloride' 'Cibacen' 'Lotensin'],"['Benazepril hcl' 'Benazepril hydrochloride' 'CGS 14824A HCL' 'CGS-14824A'
 'CGS-14824A HCL' 'NSC-758920']","[('DailyMed', array(['benazepril%20hydrochloride'], dtype=object)), ('PubChem', array(['144204994', '170465003', '49648469'], dtype=object)), ('chEBI', array(['3012'], dtype=object))]",,"{'rows': array(['MONDO_0010520', 'Orphanet_79292', 'EFO_1002048', 'EFO_0000712',
       'EFO_1000965', 'EFO_0000400', 'EFO_0000537', 'EFO_0003086'],
      dtype=object), 'count': 8}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103881,CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C,IMYZQPCYWPFTAG-NGZCFLSTSA-N,Small molecule,False,DEXMECAMYLAMINE,,3.0,,False,False,[],['Dexmecamylamine' 'NIH-11008' 'TC-5214' 'Tc-5214'],"[('drugbank', array(['DB11807'], dtype=object))]",['CHEMBL2105753'],"{'rows': array(['MONDO_0002009', 'EFO_0003086', 'EFO_0000537', 'EFO_0003890',
       'HP_0000975', 'EFO_1000781'], dtype=object), 'count': 6}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL2105710,CCCCC[C@H](O)c1ccc(N2C(=O)CC[C@@H]2COCc2ccc(C(=O)OC(C)C)s2)cc1,MSIIJNOQQWRTFC-GGAORHGYSA-N,Small molecule,False,SIMENEPAG ISOPROPYL,,2.0,,False,False,[],['AGN-210669' 'Simenepag isopropyl'],"[('drugbank', array(['DB12977'], dtype=object))]",,,[ENSG00000125384],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2105747,COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,XNBRWUQWSKXMPW-UHFFFAOYSA-N,Small molecule,False,TOZADENANT,,3.0,,False,False,[],"['A-2A (3)' 'A2A (3)' 'A2A-(3)' 'RO-4494351' 'RO-4494351-000'
 'RO-4494351-002' 'RO-4494351000' 'RO4494351' 'RO4494351-000'
 'RO4494351-002' 'SYN-115' 'SYN115' 'Tozadenant']","[('drugbank', array(['DB12203'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'MONDO_0005180', 'EFO_0002610'], dtype=object), 'count': 3}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2108336,,,Protein,False,LIXISENATIDE,2013.0,4.0,,False,True,['Adlyxin' 'Lyxumia'],['AVE 010' 'AVE-0010' 'AVE-010' 'AVE0010' 'Lixisenatide' 'ZP 10' 'ZP-10'],"[('DailyMed', array(['lixisenatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia'],
      dtype=object))]",,"{'rows': array(['EFO_0000400', 'MONDO_0005147', 'EFO_0005672', 'MONDO_0005180',
       'MONDO_0005148'], dtype=object), 'count': 5}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 3 investigational indications.
CHEMBL225157,CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,LEEIJTHMHDMWLJ-CQSZACIVSA-N,Small molecule,False,RESATORVID,,3.0,,False,False,[],['Cli-095' 'Resatorvid' 'TAK-242' 'Tak-242'],"[('drugbank', array(['DB05943'], dtype=object))]",['CHEMBL3527013'],"{'rows': array(['EFO_0007949', 'HP_0100806'], dtype=object), 'count': 2}",[ENSG00000136869],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL38,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,SHGAZHPCJJPHSC-YCNIQYBTSA-N,Small molecule,True,TRETINOIN,1971.0,4.0,,False,True,"['Acticin' 'Altreno' 'Atralin' 'Avita' 'Renova' 'Retin-a' 'Retin-a micro'
 'Retin-a-micro' 'Tretin-X' 'Tretinoin' 'Vesanoid']","['Aberel' 'All-trans retinoic acid' 'All-trans-retinoic acid' 'Eudyna'
 'Kerlocal' 'NSC-122758' 'Oristar rna' 'Retin a' 'Retinoic acid'
 'Tretinoin']","[('DailyMed', array(['tretinoin'], dtype=object)), ('PubChem', array(['104171346', '124882949', '124882951', '124882956', '124882957',
       '144204363', '144209528', '144210625', '170465045', '26746936',
       '29214999', '416403', '50103969', '50103970', '50126361',
       '50126362', '56422209', '85231340', '855632', '90341365'],
      dtype=object)), ('Wikipedia', array(['Retinoic_acid', 'Tretinoin'], dtype=object)), ('drugbank', array(['DB00755'], dtype=object)), ('chEBI', array(['15367'], dtype=object))]",['CHEMBL2051965'],"{'rows': array(['EFO_0000621', 'EFO_0007160', 'EFO_0000231', 'EFO_0002618',
       'EFO_0000198', 'EFO_0000616', 'EFO_0003060', 'HP_0001065',
       'EFO_0000389', 'EFO_0000464', 'EFO_0004268', 'EFO_0000673',
       'EFO_0004193', 'MONDO_0002280', 'MONDO_0044881', 'EFO_0001378',
       'EFO_0000702', 'EFO_0000574', 'EFO_0004826', 'EFO_0003963',
       'EFO_0000222', 'EFO_1000760', 'EFO_0003758', 'MONDO_0004976',
       'MONDO_0019289', 'MONDO_0008903', 'EFO_0000224', 'EFO_0003869',
       'EFO_0002496', 'EFO_0000756', 'MONDO_0007254', 'EFO_0000707',
       'EFO_0000565', 'MONDO_0002367', 'EFO_0003894', 'MONDO_0019098',
       'EFO_0004251', 'HP_0003124', 'MONDO_0100096', 'MONDO_0020077'],
      dtype=object), 'count': 40}","[ENSG00000172819,ENSG00000077092,ENSG00000131759]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 35 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3833329,,,Antibody,False,ERENUMAB,2018.0,4.0,,False,True,['Aimovig'],['AMG 334' 'AMG-334' 'Erenumab' 'Erenumab aooe'],"[('DailyMed', array(['erenumab-aooe'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig'],
      dtype=object))]",,"{'rows': array(['EFO_0003913', 'EFO_1001219', 'MONDO_0005277', 'EFO_0004149',
       'EFO_0005279'], dtype=object), 'count': 5}",[ENSG00000064989],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 4 investigational indications.
CHEMBL3989690,CCOC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,VCVWXKKWDOJNIT-ZOMKSWQUSA-N,Small molecule,False,TESOFENSINE,,2.0,,False,False,[],['NS 2330' 'NS-2330' 'Ns2330' 'Tesofensine'],"[('drugbank', array(['DB06156'], dtype=object))]",,"{'rows': array(['EFO_0001073', 'MONDO_0005148', 'MONDO_0008300', 'MONDO_0005180',
       'MONDO_0004975'], dtype=object), 'count': 5}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3989914,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1,YRCHYHRCBXNYNU-UHFFFAOYSA-N,Small molecule,False,GLESATINIB,,2.0,,False,False,[],"['Glesatinib' 'MG-90265' 'MG-90265X' 'MG90265' 'MG90265H9' 'MG90265X'
 'MG90265gly' 'MGCD-265' 'MGCD265' 'Mgcd-265']","[('drugbank', array(['DB06302'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 2}","[ENSG00000120156,ENSG00000164078,ENSG00000105976,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4130229,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1,ZQOBVMHBVWNVBG-UHFFFAOYSA-N,Small molecule,False,VODOBATINIB,,2.0,,False,False,[],['K-0706' 'K0706' 'Sco-088' 'Vodobatinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VODOBATINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0005180', 'MONDO_0004643', 'HP_0000726', 'EFO_0000339',
       'EFO_0005772'], dtype=object), 'count': 5}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL4297385,COC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C,PGYDXVBZYKQYCS-VPWBDBDCSA-N,Small molecule,False,NS-2359,,2.0,,False,False,[],"['GSK-372,475' 'GSK-372475' 'GSK372475' 'Gsk372475' 'NS2359' 'Ns-2359'
 'Ns2359']","[('drugbank', array(['DB05805'], dtype=object))]",,"{'rows': array(['EFO_0002610', 'EFO_0003888', 'MONDO_0002050'], dtype=object), 'count': 3}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297441,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1,LRCZQSDQZJBHAF-PUBGEWHCSA-N,Small molecule,False,PACLITAXEL DOCOSAHEXAENOIC ACID,,3.0,,False,False,[],"['Dha paclitaxel' 'Dha-paclitaxel' 'Paclitaxel docosahexaenoic acid'
 'Paclitaxel-dha' 'Taxoprexin']","[('drugbank', array(['DB05297'], dtype=object))]",,"{'rows': array(['EFO_0003060', 'EFO_0000182', 'EFO_0002617'], dtype=object), 'count': 3}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297887,,,Unknown,False,GSK-2586881,,2.0,,False,False,[],"['APN-01' 'APN01' 'Alunacedase alfa' 'Apn01' 'GSK-2586881' 'Gsk-2586881'
 'Gsk2586881']",,,"{'rows': array(['EFO_0001361', 'EFO_0004610', 'MONDO_0100096'], dtype=object), 'count': 3}",[ENSG00000135744],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4594618,,,Gene,False,BREXUCABTAGENE AUTOLEUCEL,2020.0,4.0,,False,True,['Tecartus'],['Brexucabtagene autoleucel' 'KTE-X19'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BREXUCABTAGENE%20AUTOLEUCEL/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001642', 'EFO_0000095', 'EFO_0000220', 'EFO_0000616',
       'EFO_1001469'], dtype=object), 'count': 5}",[ENSG00000177455],Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for mantle cell lymphoma and has 4 investigational indications.
CHEMBL4594730,,,Small molecule,False,VIPIVOTIDE TETRAXETAN LUTETIUM,2022.0,4.0,,False,True,[],[],,['CHEMBL4594406'],"{'rows': array(['MONDO_0008315', 'MONDO_0008315', 'MONDO_0021259', 'EFO_0000616',
       'EFO_0001663', 'EFO_0003863', 'EFO_0000673'], dtype=object), 'count': 7}",[ENSG00000086205],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for prostate cancer and prostate neoplasm and has 5 investigational indications.
CHEMBL550781,CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1,QNQZBKQEIFTHFZ-GOSISDBHSA-N,Small molecule,False,DEXLOXIGLUMIDE,,3.0,,False,False,[],"['CR-2017' 'Dexloxiglumide' 'Loxiglumide (r)-form' 'Loxiglumide, (r)-']","[('Wikipedia', array(['Dexloxiglumide'], dtype=object)), ('drugbank', array(['DB04856'], dtype=object))]",,"{'rows': array(['EFO_0000555', 'EFO_0008533'], dtype=object), 'count': 2}",[ENSG00000163394],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1077,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,Small molecule,False,BROMFENAC,1997.0,4.0,,True,True,[],['Bromfenac' 'ISV-303'],"[('PubChem', array(['26757971'], dtype=object)), ('Wikipedia', array(['Bromfenac'], dtype=object)), ('drugbank', array(['DB00963'], dtype=object)), ('chEBI', array(['240107'], dtype=object))]",['CHEMBL751' 'CHEMBL3181947'],"{'rows': array(['EFO_0001365', 'HP_0200026', 'MONDO_0005129', 'MP_0001845',
       'MONDO_0001330', 'EFO_0003843', 'MONDO_0005129', 'EFO_0005752',
       'MP_0001845', 'MONDO_0007935', 'EFO_1000906', 'EFO_0007141'],
      dtype=object), 'count': 12}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 7 investigational indications.
CHEMBL1159650,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CBGUOGMQLZIXBE-XGQKBEPLSA-N,Small molecule,True,CLOBETASOL PROPIONATE,1985.0,4.0,,False,True,"['Clarelux' 'Clobaderm' 'Clobetasol propionate'
 'Clobetasol propionate (emollient)' 'Clobex' 'Cormax' 'Dermovate'
 'Dermovate nn' 'Embeline' 'Embeline e' 'Etrivex' 'Impeklo' 'Impoyz'
 'Olux' 'Olux e' 'Temovate' 'Temovate e']","['CCI 4725' 'CCI-4725' 'Clobecort amex' 'Clobetasol'
 'Clobetasol 17-propionate' 'Clobetasol propionate' 'Dovate' 'GR 2/925'
 'NSC-758634' 'Psorex']","[('DailyMed', array(['clobetasol%20propionate'], dtype=object)), ('PubChem', array(['144204967', '170465385', '56422175', '855884'], dtype=object)), ('Wikipedia', array(['Clobetasol_propionate'], dtype=object)), ('drugbank', array(['DB01013'], dtype=object)), ('chEBI', array(['31414'], dtype=object))]",,"{'rows': array(['EFO_0004192', 'EFO_1000657', 'EFO_1000726', 'EFO_1001347',
       'EFO_1000623', 'EFO_0000274', 'EFO_0004775', 'MONDO_0013730',
       'EFO_1001494', 'EFO_0000685', 'EFO_0007187', 'EFO_0000676',
       'EFO_1001993', 'MONDO_0020547', 'EFO_1001949', 'EFO_1000764',
       'EFO_0000701', 'MONDO_0005129', 'EFO_1000724', 'EFO_0008517',
       'EFO_1001395'], dtype=object), 'count': 21}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 18 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200721,C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)([O-])[O-].[Na+].[Na+],IIUMCNJTGSMNRO-VVSKJQCTSA-L,Small molecule,False,ESTRAMUSTINE PHOSPHATE SODIUM,1981.0,4.0,CHEMBL1756,False,True,['Emcyt'],"['Estramustine 17-(dihydrogenphosphate) disodium salt anhydrous'
 'Estramustine 17-(dihydrogenphosphate) disodium salt monohydrate'
 'Estramustine phosphate sodium' 'Estramustine phosphate sodium hydrate'
 'Estramustine phosphate sodium monohydrate'
 'Estramustine sodium phosphate' 'RO 21-8837/001' 'RO-218837-001']","[('DailyMed', array(['estramustine%20phosphate%20sodium'], dtype=object)), ('PubChem', array(['144206926'], dtype=object)), ('chEBI', array(['31562'], dtype=object))]",,"{'rows': array(['EFO_0000673', 'MONDO_0008315', 'EFO_0000574', 'MONDO_0002367',
       'MONDO_0007254', 'EFO_0000313'], dtype=object), 'count': 6}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for carcinoma and has 5 investigational indications.
CHEMBL1201148,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO,PIDANAQULIKBQS-RNUIGHNZSA-N,Small molecule,False,MEPREDNISONE,1982.0,4.0,,False,True,['Betapar'],['Meprednisone' 'NSC-527579' 'SCH 4358' 'SCH-4358'],"[('PubChem', array(['144207161', '170465165'], dtype=object)), ('Wikipedia', array(['Meprednisone'], dtype=object)), ('drugbank', array(['DB09383'], dtype=object))]",,"{'rows': array(['EFO_0000756'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication.
CHEMBL1256696,CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,AKJDEXBCRLOVTH-UHFFFAOYSA-N,Small molecule,False,CARBETAPENTANE CITRATE,,4.0,CHEMBL73234,True,True,[],"['Carbetapentane citrate' 'Loucarbate' 'NSC-757833' 'Pentoxyverine'
 'Pentoxyverine citrate' 'Pentoxyverine hydrogen citrate']","[('PubChem', array(['11112007', '11113006', '124881868', '26747484', '26747485',
       '46500452', '50106075', '85231297', '85273776'], dtype=object))]",,"{'rows': array(['EFO_0007486'], dtype=object), 'count': 1}",[ENSG00000147955],Small molecule drug with a maximum clinical trial phase of IV and is indicated for sinusitis. It was withdrawn in at least one region.
CHEMBL13376,COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1,DGMZLCLHHVYDIS-UHFFFAOYSA-N,Small molecule,False,CLOMETACIN,,4.0,,True,True,[],['C 1656' 'C-1656' 'Clometacin' 'Mindolic acid' 'R 3959' 'R-3959'],"[('PubChem', array(['144206860'], dtype=object))]",,,"[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL184412,CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1,ZQTNQVWKHCQYLQ-UHFFFAOYSA-N,Small molecule,True,DRONEDARONE,2009.0,4.0,,False,True,[],['Dronedarone' 'SR-33589' 'SR33589'],"[('PubChem', array(['144206559', '170465064'], dtype=object)), ('Wikipedia', array(['Dronedarone'], dtype=object)), ('drugbank', array(['DB04855'], dtype=object)), ('chEBI', array(['50659'], dtype=object))]",['CHEMBL1201729'],"{'rows': array(['EFO_0000275', 'EFO_0000373', 'EFO_0004269', 'EFO_0003911',
       'EFO_0000275'], dtype=object), 'count': 5}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000123700,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000138622]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for atrial fibrillation and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,IENZQIKPVFGBNW-UHFFFAOYSA-N,Small molecule,False,PRAZOSIN,1976.0,4.0,,False,True,[],['CP-12299' 'CP-122991' 'Prazosin'],"[('PubChem', array(['11112649', '11112650', '11113367', '124882482', '124882484',
       '124882486', '124882487', '144207195', '170465415', '26751613',
       '26751614', '50100502', '50104272', '50104273', '50104274',
       '50104275', '90340959'], dtype=object)), ('Wikipedia', array(['Prazosin'], dtype=object)), ('drugbank', array(['DB00457'], dtype=object)), ('chEBI', array(['8364'], dtype=object))]",['CHEMBL1558' 'CHEMBL1347191'],"{'rows': array(['EFO_0004777', 'EFO_0004701', 'EFO_0000537', 'EFO_0000537',
       'EFO_0003768', 'EFO_0000400', 'MONDO_0100096', 'EFO_0005230',
       'MONDO_0007079', 'HP_0000011', 'EFO_0001358', 'EFO_0004253'],
      dtype=object), 'count': 12}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for hypertension and diabetes mellitus and has 9 investigational indications.
CHEMBL2105661,CCNCCS(=O)(=O)NC[C@@]1(c2ccccc2)SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C,YVAFBXLHPINSIK-QHCPKHFHSA-N,Small molecule,False,LITRONESIB,,2.0,,False,False,[],"['KF 89617' 'KF-89617' 'KF89617' 'LY 2523355' 'LY-2523355' 'LY2523355'
 'Litronesib']","[('drugbank', array(['DB11861'], dtype=object))]",,"{'rows': array(['EFO_1001951', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000565',
       'EFO_0000702', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0008315',
       'EFO_0006859', 'MONDO_0007576', 'MONDO_0008170', 'MONDO_0004992'],
      dtype=object), 'count': 12}",[ENSG00000138160],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications.
CHEMBL2105683,COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1,JGBUBSOKFSVXKS-LBPRGKRZSA-N,Small molecule,False,NAPROXEN ETEMESIL,,2.0,,False,False,[],['LT-NS001' 'MX-1094' 'Naproxen etemesil'],"[('drugbank', array(['DB12398'], dtype=object))]",,"{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107360,CCCCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(CCN1CCC(c3noc4cc(F)ccc34)CC1)c2=O,VOMKSBFLAZZBOW-UHFFFAOYSA-N,Small molecule,True,PALIPERIDONE PALMITATE,2009.0,4.0,,False,True,"['Byannli (previously paliperidone janssen-cilag international)'
 'Invega sustenna' 'Invega trinza']","['JNS-010' 'JNS010' 'Paliperidone palmitate' 'Palperidone palmitate'
 'R-092670' 'R092670' 'RO-92670' 'RO92670']","[('DailyMed', array(['paliperidone%20palmitate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/byannli-previously-paliperidone-janssen-cilag-international'],
      dtype=object)), ('chEBI', array(['83808'], dtype=object))]",['CHEMBL4745890'],"{'rows': array(['MONDO_0005090', 'EFO_0005411'], dtype=object), 'count': 2}","[ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for schizophrenia and schizoaffective disorder. This drug has a black box warning from the FDA.
CHEMBL2108167,,,Antibody,False,VEPALIMOMAB,,2.0,,False,False,[],['Vapantix' 'Vepalimomab'],,,,[ENSG00000131471],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109325,,,Antibody,False,AMG-191,,1.0,,False,False,[],['AMG-191' 'Amg-191'],,,"{'rows': array(['MONDO_0015974'], dtype=object), 'count': 1}",[ENSG00000157404],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109486,,,Antibody,False,CDP-850,,1.0,,False,False,[],['CDP-850'],,,,[ENSG00000007908],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2338329,Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12,YOZBGTLTNGAVFU-UHFFFAOYSA-N,Small molecule,False,ROXADUSTAT,2021.0,4.0,,False,True,['Evrenzo'],['ASP-1517' 'ASP1517' 'FG-4592' 'FG4592' 'Roxadustat'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo'],
      dtype=object)), ('PubChem', array(['174006837'], dtype=object)), ('drugbank', array(['DB04847'], dtype=object))]",,"{'rows': array(['EFO_0000198', 'EFO_0004272', 'EFO_0003086', 'EFO_0008585',
       'EFO_0003884'], dtype=object), 'count': 5}","[ENSG00000269858,ENSG00000178467,ENSG00000135766,ENSG00000129521]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for anemia (phenotype) and chronic kidney disease and has 3 investigational indications.
CHEMBL2354773,,,Small molecule,False,AUROTHIOGLUCOSE,,4.0,,False,True,['Aureotan 100' 'Solganal'],"['(1-thio-d-glucopyranosato)gold' 'Aureotan' 'Aurothioglucose' 'Aurumine'
 'Authron' 'Brenol' 'Glysanol b' 'Gold thioglucose'
 'Gold, (1-thio-d-glucopyranosato)-' 'NSC-759601' 'Oronol' 'Solganal b']","[('DrugCentral', array(['4349'], dtype=object)), ('PubChem', array(['144205102'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}",[ENSG00000198431],Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease.
CHEMBL3421729,C[C@H]1c2cccc(CCC(C)(C)O)c2C[C@H](CO)N1C(=O)Cc1c(Cl)cccc1Cl,XHCSBQBBGNQINS-DOTOQJQBSA-N,Small molecule,False,MEVIDALEN,,2.0,,False,False,[],['LY-3154207' 'LY3154207' 'Ly3154207' 'Mevidalen'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MEVIDALEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0004975', 'MONDO_0005180', 'EFO_0006792'], dtype=object), 'count': 3}",[ENSG00000184845],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545323,,,Small molecule,False,PWT-33579,,1.0,,False,False,[],['Pwt-33579'],,,,"[ENSG00000198793,ENSG00000121879]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3666807,C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2,ZZWJKLGCDHYVMB-BWGXUDETSA-N,Small molecule,False,VELSECORAT,,2.0,,False,False,[],['AZD-7594' 'AZD7594' 'Azd 7594' 'Azd7594' 'Velsecorat'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VELSECORAT/relevant/1/'],
      dtype=object))]",['CHEMBL4093501'],"{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3707246,CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N.Cl,HAOOCAKHSFYDBU-BDQAORGHSA-N,Small molecule,False,OZANIMOD HYDROCHLORIDE,2020.0,4.0,CHEMBL3707247,False,True,['Zeposia'],['Ozanimod hydrochloride' 'RPC-1063 HCL' 'RPC1063 HCL'],"[('DailyMed', array(['ozanimod%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia'],
      dtype=object))]",,"{'rows': array(['MONDO_0005301', 'EFO_0000729', 'EFO_0003929'], dtype=object), 'count': 3}",[ENSG00000170989],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved indications.
CHEMBL3960488,Cn1cc(-c2ccc(=O)n(Cc3cccc(-c4ncc(OCCN5CCOCC5)cn4)c3)n2)cn1,CIUKPBWULKEZMF-UHFFFAOYSA-N,Small molecule,False,EMD-1204831,,1.0,,False,False,[],['Emd-1204831'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3989555,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1.Cl.Cl.O,KDLHYOMCWBWLMM-UHFFFAOYSA-N,Small molecule,False,MECLIZINE HYDROCHLORIDE,1957.0,4.0,CHEMBL1623,False,True,['Ancoloxin' 'Antivert' 'Meclizine hydrochloride' 'Sea-legs' 'Traveleeze'],"['Agyrax' 'Ancolan' 'Anhydrous meclozine hydrochloride' 'Bonamine'
 'Meclizine dihydrochloride monohydrate' 'Meclizine hcl'
 'Meclizine hydrochloride' 'Meclizine hydrochloride anhydrous'
 'Meclizine monohydrochloride' 'Meclozine dihydrochloride'
 'Meclozine hydrochloride' 'Meclozine hydrochloride monohydrate'
 'Meclozine monohydrochloride' 'NSC-28728' 'NSC-757094' 'Postafen'
 'UCB-5062']","[('DailyMed', array(['meclizine%20hydrochloride'], dtype=object))]",,"{'rows': array(['HP_0002013', 'EFO_0006928', 'HP_0002321', 'HP_0002018',
       'HP_0002017'], dtype=object), 'count': 5}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 5 approved indications.
CHEMBL3989767,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,BBBFJLBPOGFECG-VJVYQDLKSA-N,Protein,False,CALCITONIN SALMON,1978.0,4.0,,False,True,['Calcimar' 'Calcitonin-salmon' 'Forcaltonin' 'Fortical' 'Miacalcin'],"['Calcitonin (salmon synthetic)' 'Calcitonin salmon'
 'Calcitonin salmon recombinant']","[('DailyMed', array(['calcitonin%20salmon', 'calcitonin%20salmon%20recombinant'],
      dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/forcaltonin'],
      dtype=object))]",,"{'rows': array(['EFO_0004261', 'GO_0042697', 'EFO_0003854', 'EFO_0005754',
       'HP_0000938', 'HP_0003072', 'EFO_0003882'], dtype=object), 'count': 7}",[ENSG00000004948],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 3 investigational indications.
CHEMBL4298067,,,Antibody,False,TOMARALIMAB,,2.0,,False,False,[],['OPN-305' 'Opn 305' 'Opn-305' 'Tomaralimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOMARALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000198'], dtype=object), 'count': 1}",[ENSG00000137462],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL559478,O=C(Oc1ccc(Br)cc1)N1CCN2CCC1CC2,RXLOZRCLQMJJLC-UHFFFAOYSA-N,Small molecule,False,SSR180711,,2.0,,False,False,[],"['J2.849.107G' 'SSR-180,711' 'SSR-180711' 'SSR180711C' 'Ssr180711']","[('PubChem', array(['144210561'], dtype=object))]",['CHEMBL3235499'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1200323,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl,WQVZLXWQESQGIF-UHFFFAOYSA-N,Small molecule,False,LABETALOL HYDROCHLORIDE,1984.0,4.0,CHEMBL429,False,True,"['Labetalol Hydrocloride' 'Labetalol hydrochloride'
 'Labetalol hydrochloride in dextrose'
 'Labetalol hydrochloride in sodium chloride' 'Labrocol' 'Normodyne'
 'Trandate']","['AH 5158A' 'AH-5158A' 'AH-5158A HYDROCHLORIDE' 'Ibidomide hydrochloride'
 'Labetalol hcl' 'Labetalol hydrochloride' 'NSC-290312' 'SCH 15719W'
 'SCH-15719W' 'SCH-15719W HYDROCHLORIDE']","[('DailyMed', array(['labetalol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204174', '144213042', '26747550', '50106500', '56422413',
       '855542'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0005669', 'EFO_0000668'], dtype=object), 'count': 3}","[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for hypertension and has 2 investigational indications.
CHEMBL1200616,NS(=O)(=O)c1cc2c(cc1Cl)N=C[N-]S2(=O)=O.[Na+],CPIWHAFLBZQYLQ-UHFFFAOYSA-N,Small molecule,False,CHLOROTHIAZIDE SODIUM,1958.0,4.0,CHEMBL842,False,True,['Chlorothiazide sodium' 'Diuril'],['Chlorothiazide sodium' 'Chlorothiazide sodium salt'],"[('DailyMed', array(['chlorothiazide%20sodium'], dtype=object))]",,,[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958.
CHEMBL1200751,O.S=c1[nH]cnc2nc[nH]c12,WFFQYWAAEWLHJC-UHFFFAOYSA-N,Small molecule,False,MERCAPTOPURINE,1953.0,4.0,CHEMBL1425,False,True,"['Mercaptopurine' 'Puri-nethol' 'Purinethol' 'Purixan' 'Xaluprine'
 'Xaluprine (previously mercaptopurine nova laboratories)']","['6-mercaptopurine monohydrate' 'Mercaptopurine' 'Mercaptopurine hydrate'
 'Mercaptopurinum' 'NSC-755' 'NSC-759614']","[('DailyMed', array(['mercaptopurine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine'],
      dtype=object)), ('PubChem', array(['103804943', '57260342'], dtype=object)), ('chEBI', array(['31822'], dtype=object))]",,"{'rows': array(['MONDO_0000873', 'EFO_0000309', 'MONDO_0044917', 'MONDO_0019460',
       'EFO_0000574', 'EFO_0000565', 'EFO_0000224', 'EFO_0003833',
       'EFO_0004289', 'MONDO_0003268', 'EFO_0002501', 'EFO_0000729',
       'MONDO_0000870', 'EFO_0000616', 'EFO_0000209', 'EFO_0000222',
       'EFO_0000094', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872',
       'EFO_0002499', 'EFO_1000318', 'EFO_0000220'], dtype=object), 'count': 23}",[ENSG00000128059],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 5 approved and 18 investigational indications.
CHEMBL1201831,,,Antibody,True,CERTOLIZUMAB PEGOL,2008.0,4.0,,False,True,['Cimzia'],['CDP 870' 'CDP-870' 'CDP870' 'Certolizumab pegol' 'PHA-738144'],"[('DailyMed', array(['certolizumab%20pegol'], dtype=object)), ('DrugCentral', array(['4968'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia'],
      dtype=object)), ('Wikipedia', array(['Certolizumab_pegol'], dtype=object))]",,"{'rows': array(['EFO_0000540', 'EFO_0000384', 'MP_0001845', 'EFO_0000685',
       'EFO_0003898', 'EFO_0002609', 'EFO_0000676', 'EFO_0000729',
       'EFO_0003778', 'EFO_1000869'], dtype=object), 'count': 10}",[ENSG00000232810],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1472989,CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1.CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1.O=C(O)/C=C/C(=O)O,VMDFASMUILANOL-WXXKFALUSA-N,Small molecule,False,BISOPROLOL FUMARATE,1992.0,4.0,CHEMBL645,False,True,"['Bipranix' 'Bisoprolol fumarate' 'Cardicor' 'Concor' 'Congescor' 'Emcor'
 'Emcor ls' 'Isoten mitis' 'Monocor' 'Soloc' 'Soprol' 'Vivacor' 'Zebeta']","['Bisoprolol fumarate' 'Bisoprolol hemifumarate' 'CL 297,939' 'CL-297939'
 'Detensiel' 'EMD-33-512' 'EMD-33512' 'Emconcor' 'Euradal' 'Isoten'
 'Speridol']","[('DailyMed', array(['bisoprolol%20fumarate'], dtype=object)), ('PubChem', array(['144204814', '144206959', '170464815', '26753629'], dtype=object)), ('chEBI', array(['3128'], dtype=object))]",,"{'rows': array(['Orphanet_79292', 'MONDO_0010679', 'EFO_0005672', 'EFO_0000537'],
      dtype=object), 'count': 4}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for hypertension and has 3 investigational indications.
CHEMBL1726,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-],VKQFCGNPDRICFG-UHFFFAOYSA-N,Small molecule,False,NISOLDIPINE,1995.0,4.0,,False,True,['Nisoldipine' 'Sular' 'Syscor mr 10' 'Syscor mr 20' 'Syscor mr 30'],"['BAY K 5552' 'BAY-K-5552' 'Baymycard' 'Geomatrix 16e' 'NSC-759106'
 'Nisoldipin' 'Nisoldipine' 'Nisoldipine (stn)']","[('DailyMed', array(['nisoldipine'], dtype=object)), ('PubChem', array(['144205804', '144212682', '170465320', '26758055'], dtype=object)), ('Wikipedia', array(['Nisoldipine'], dtype=object)), ('drugbank', array(['DB00401'], dtype=object)), ('chEBI', array(['76917'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000319'], dtype=object), 'count': 2}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for hypertension and cardiovascular disease.
CHEMBL2107844,,,Protein,False,BRIOBACEPT,,2.0,,False,False,[],['BR-3-FC' 'BR3-FC' 'Briobacept' 'SS-79'],,,,[ENSG00000102524],Protein drug with a maximum clinical trial phase of II.
CHEMBL2108258,,,Antibody,False,ATOROLIMUMAB,,2.0,,False,False,[],['Atorolimumab'],,,,[ENSG00000187010],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108791,,,Enzyme,False,TENECTEPLASE,2000.0,4.0,,False,True,['Metalyse'],['Rhtnk-tpa' 'TNK-TPA' 'Tenecteplase'],"[('DailyMed', array(['tenecteplase'], dtype=object)), ('DrugCentral', array(['5066'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/metalyse'],
      dtype=object))]",,"{'rows': array(['EFO_0003827', 'EFO_0009637', 'MONDO_0002679', 'EFO_0000712',
       'EFO_0008585', 'HP_0002140', 'EFO_0008583', 'HP_0004419',
       'EFO_1000637', 'EFO_0000612', 'EFO_0000618', 'MONDO_0005299',
       'MONDO_0000831', 'EFO_0004278', 'EFO_1001154'], dtype=object), 'count': 15}",[ENSG00000104368],Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 11 investigational indications.
CHEMBL2109255,,,Antibody,False,HEFI-1,,1.0,,False,False,[],['HEFI-1' 'Hefi-1'],,,"{'rows': array(['EFO_0000574', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000120949],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2109282,,,Antibody drug conjugate,False,RG-7636,,1.0,,False,False,[],['DEDN-6526A' 'RG-7636'],,,,"[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000136160]",Antibody drug conjugate drug with a maximum clinical trial phase of I.
CHEMBL325109,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1,BVPWJMCABCPUQY-UHFFFAOYSA-N,Small molecule,False,CLEBOPRIDE,,4.0,,False,True,['Clanzoflat'],"['Amicos' 'Clanzol' 'Clast' 'Clebopride' 'Clebopride hydrogen malate'
 'Clebopride malate' 'Cleprid' 'LAS 9273' 'LAS-9273' 'Motilex']","[('PubChem', array(['11112867'], dtype=object)), ('Wikipedia', array(['Clebopride'], dtype=object)), ('drugbank', array(['DB13511'], dtype=object))]",['CHEMBL1599248'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000164270,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for gastrointestinal disease.
CHEMBL350775,COc1cc(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCc2cccnc2)CCCc2cccnc2)cc(OC)c1OC,CGVWPQOFHSAKRR-NDEPHWFRSA-N,Small molecule,False,BIRICODAR,,2.0,,False,False,[],['Biricodar'],"[('Wikipedia', array(['Biricodar'], dtype=object)), ('drugbank', array(['DB04851'], dtype=object))]",['CHEMBL2104406'],"{'rows': array(['MONDO_0008903'], dtype=object), 'count': 1}","[ENSG00000085563,ENSG00000103222]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL354077,Nc1ccncc1N,OYTKINVCDFNREN-UHFFFAOYSA-N,Small molecule,False,AMIFAMPRIDINE,2009.0,4.0,,False,True,['Ruzurgi'],"['3,4-DAP' '3,4-Diammoniopyridinium' '4-DAP' 'Amifampridine' 'DAP'
 'Dynamine' 'NSC-521760' 'Pyridine-3,4-Diamine']","[('PubChem', array(['144206108', '170466846', '50112814', '51088028', '56323425'],
      dtype=object)), ('Wikipedia', array(['3,4-Diaminopyridine'], dtype=object)), ('drugbank', array(['DB11640'], dtype=object))]",['CHEMBL3301611'],"{'rows': array(['EFO_0008525', 'EFO_0004991', 'MONDO_0005301', 'EFO_0005542',
       'EFO_0004991', 'EFO_0004991', 'MONDO_0015263', 'EFO_0020094',
       'EFO_0004991', 'EFO_0020094', 'EFO_0009851'], dtype=object), 'count': 11}","[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for myasthenia gravis and lambert-eaton myasthenic syndrome and has 6 investigational indications.
CHEMBL3544991,,,Antibody,False,DOMAGROZUMAB,,2.0,,False,False,[],['Domagrozumab' 'PF-06252616'],,,"{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}",[ENSG00000138379],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545074,,,Small molecule,False,LEO-15520,,1.0,,False,False,[],['Leo-15520'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707248,COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1,BXGKAGLZHGYAMW-TZYFFPFWSA-N,Small molecule,True,VALBENAZINE TOSYLATE,2017.0,4.0,CHEMBL2364639,False,True,['Ingrezza'],"['NBI-98854' 'Valbenazine ditosylate' 'Valbenazine tosilate'
 'Valbenazine tosylate']","[('DailyMed', array(['valbenazine%20tosylate'], dtype=object))]",,"{'rows': array(['EFO_0004280'], dtype=object), 'count': 1}",[ENSG00000165646],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for movement disorder. This drug has a black box warning from the FDA.
CHEMBL3707365,,,Oligosaccharide,False,BEMIPARIN,,3.0,,False,False,[],['Bemiparin'],"[('DrugCentral', array(['4840'], dtype=object))]",,"{'rows': array(['EFO_0001422', 'HP_0000083', 'EFO_0000702', 'EFO_1001459',
       'MONDO_0100096', 'HP_0004419'], dtype=object), 'count': 6}",[ENSG00000126218],Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4298123,,,Antibody,False,COBOLIMAB,,2.0,,False,False,[],['Cobolimab' 'TSR-022' 'Tsr 022' 'Tsr-022' 'WBP-296A'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/COBOLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0002691', 'EFO_0000616', 'EFO_0000756', 'EFO_0003060'],
      dtype=object), 'count': 4}",[ENSG00000135077],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4594424,CC(C)C[C@H]1NC(=O)[C@@H](C)N(C)C(=O)[C@H](C2CC2)NC[C@@H](C)Oc2ccccc2CC[C@H](C)NC1=O,HIIMPSTXUQUYOO-FPJBJBNZSA-N,Protein,False,TZP-102,,2.0,,False,False,[],['TZP-102' 'Tzp-102'],,,"{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}",[ENSG00000121853],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL482968,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1,BLQYVHBZHAISJM-CMDGGOBGSA-N,Small molecule,False,ENMD-2076,,2.0,,False,False,[],['ENMD-2076' 'Enmd 2076' 'Enmd-2076'],,['CHEMBL3237191'],"{'rows': array(['EFO_0001642', 'MONDO_0004992', 'EFO_0000348', 'MONDO_0002087',
       'EFO_1001968', 'EFO_1000251', 'MONDO_0008170', 'MONDO_0007254',
       'EFO_0001378', 'EFO_0000182'], dtype=object), 'count': 10}","[ENSG00000182578,ENSG00000178999,ENSG00000068078,ENSG00000157404,ENSG00000122025,ENSG00000087586,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL5095023,N#C/C(=C\C=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1,DTCCYSMPUUYHOF-LHQXNBGVSA-N,Small molecule,False,LS-104,,1.0,,False,False,[],['Ls-104' 'Tyrene cr-4'],,,,[ENSG00000096968],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL534,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,Small molecule,False,KETOTIFEN,1999.0,4.0,,False,True,[],['(R)-Ketotifen' 'Ketotifen'],"[('PubChem', array(['104171180', '11111350', '11111351', '11113338', '144203727',
       '170465378', '26751502', '50100258', '50104048', '90341121'],
      dtype=object)), ('Wikipedia', array(['Ketotifen'], dtype=object)), ('drugbank', array(['DB00920'], dtype=object))]",['CHEMBL1885671' 'CHEMBL1633'],"{'rows': array(['EFO_1001417', 'EFO_0005687', 'MONDO_0002406', 'MONDO_0005271',
       'EFO_0008533', 'EFO_0007141', 'HP_0012532', 'EFO_0004149',
       'EFO_1001417', 'EFO_0007141', 'EFO_0000274', 'MONDO_0100096',
       'HP_0001371', 'EFO_0003931', 'EFO_0007425', 'EFO_0005751'],
      dtype=object), 'count': 16}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for allergic disease and eye allergy and has 12 investigational indications.
CHEMBL647,Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1,IEJXVRYNEISIKR-UHFFFAOYSA-N,Small molecule,False,APRACLONIDINE,1987.0,4.0,,False,True,['Iopidine'],['Apraclonidine'],"[('PubChem', array(['11110712', '50110931', '90341674'], dtype=object)), ('Wikipedia', array(['Apraclonidine'], dtype=object)), ('drugbank', array(['DB00964'], dtype=object)), ('chEBI', array(['2788'], dtype=object))]",['CHEMBL1200379'],"{'rows': array(['MONDO_0005041', 'EFO_0004991'], dtype=object), 'count': 2}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for glaucoma and has 1 investigational indication.
CHEMBL1083385,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O,FDEODCTUSIWGLK-RSAXXLAASA-N,Small molecule,True,CLOPIDOGREL BISULFATE,1997.0,4.0,CHEMBL1771,False,True,['Clopidogrel bisulfate' 'Iscover' 'Plavix'],"['Clopidogrel (as bisulfate)' 'Clopidogrel (as hydrogen sulfate)'
 'Clopidogrel bisulfate' 'Clopidogrel bisulphate' 'Clopidogrel bms'
 'Clopidogrel hydrogen sulfate' 'Clopidogrel hydrogen sulphate'
 'Clopidogrel ratiopharm' 'Clopidogrel sulfate' 'Clopidogrel teva'
 'Clopidogrel zentiva' 'Clopidogrel-bgr' 'Clopidogrel-bms' 'Isocover'
 'Pidogrel' 'SR 25990C' 'SR-25990C']","[('DailyMed', array(['clopidogrel%20bisulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/iscover'],
      dtype=object)), ('PubChem', array(['144205123', '170465231'], dtype=object)), ('chEBI', array(['3759'], dtype=object))]",,"{'rows': array(['EFO_0005672', 'EFO_0004265', 'EFO_0000612', 'EFO_0001645',
       'EFO_0003869', 'HP_0002239', 'EFO_0000712', 'HP_0002140',
       'EFO_1000985', 'EFO_0000556'], dtype=object), 'count': 10}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1130,C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,Small molecule,False,DOXIFLURIDINE,,3.0,,False,False,[],"[""5'-Deoxy-5-Fluorouridine"" 'Capecitabine related compound b'
 'Doxifluridine' 'Flutron' 'Fulturon' 'Furtulon' 'NSC-758890' 'RO 219738'
 'RO-219738']","[('PubChem', array(['144204782', '170465861', '29215154', '50106323', '50106324',
       '56320807', '56322615', '90341388'], dtype=object)), ('drugbank', array(['DB12947'], dtype=object)), ('chEBI', array(['31521'], dtype=object))]",,"{'rows': array(['MONDO_0001056'], dtype=object), 'count': 1}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1200478,CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1.Cl,KNZADIMHVBBPOA-UHFFFAOYSA-N,Small molecule,False,DYCLONINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1201217,False,True,['Dyclone'],"['Dyclocaine' 'Dyclonine HCl' 'Dyclonine hcl' 'Dyclonine hydrochloride'
 'NSC-23018']","[('DailyMed', array(['dyclonine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204010', '170464776', '26748011', '26748012', '50107329',
       '50107330', '56422189', '855952'], dtype=object)), ('chEBI', array(['4725'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200976,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl,JVHPTYWUBOQMBP-RVFAQHLVSA-N,Small molecule,True,IDARUBICIN HYDROCHLORIDE,1990.0,4.0,CHEMBL1117,False,True,"['Idamycin' 'Idamycin pfs' 'Idarubicin hydrochloride'
 'Idarubicin hydrochloride pfs' 'Zavedos']","['IMI 30' 'IMI-30' 'Idarubicin hcl' 'Idarubicin hydrochloride'
 'NSC-256439']","[('DailyMed', array(['idarubicin%20hydrochloride'], dtype=object)), ('PubChem', array(['144204787', '170464627', '49681632'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_0000182', 'MONDO_0004643'], dtype=object), 'count': 3}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for acute myeloid leukemia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201613,,,Protein,False,INSULIN GLULISINE,2004.0,4.0,,False,True,"['Apidra' 'Apidra solostar' 'Ins apidra' 'Ins apidra opticlik'
 'Ins apidra optiset' 'Ins apidra solostar']","['Glulisine apidra' 'HMR 1964' 'HMR-1964' 'HMR1964'
 'Insulin Glulisine Recombinant' 'Insulin glulisine'
 'Insulin glulisine recombinant' 'Insulin, glulisine, human'
 'Insulin,glulisine,human']","[('DailyMed', array(['insulin%20glulisine%20recombinant'], dtype=object)), ('DrugCentral', array(['5057'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/apidra'],
      dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0001064', 'EFO_0000400', 'EFO_0008583',
       'MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 6}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for diabetes mellitus and has 5 investigational indications.
CHEMBL1607,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,DGHHQBMTXTWTJV-BQAIUKQQSA-N,Small molecule,True,TOPOTECAN HYDROCHLORIDE,1996.0,4.0,CHEMBL84,False,True,['Hycamptin' 'Hycamtin' 'Potactasol' 'Topotecan' 'Topotecan hydrochloride'],"['Evotopin' 'NSC-759263' 'Nogitecan hydrochloride' 'SK&F S-104864-A'
 'SK&F-S-104864A' 'SK-S-104864-A' 'Topotecan'
 'Topotecan (as hydrochloride)' 'Topotecan actavis' 'Topotecan hcl'
 'Topotecan hospira' 'Topotecan hydrochloride' 'Topotecan teva']","[('DailyMed', array(['topotecan%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin'],
      dtype=object)), ('PubChem', array(['144205031', '170465137', '26749084', '4254372', '49681835',
       '50107520', '580652'], dtype=object))]",,"{'rows': array(['EFO_0003833', 'EFO_0008498', 'MONDO_0002158', 'EFO_0002087',
       'MONDO_0100342', 'MONDO_0008903', 'EFO_0002918', 'EFO_0002617',
       'EFO_0000613', 'EFO_1000158', 'EFO_0000466', 'EFO_0000519',
       'EFO_0000621', 'MONDO_0008380', 'MONDO_0037745', 'EFO_0002939',
       'MONDO_0100096', 'EFO_0000630', 'EFO_1001465', 'EFO_0000702',
       'EFO_0001416', 'EFO_0003893', 'MONDO_0004992', 'EFO_0005543',
       'EFO_0001378', 'EFO_0000502', 'EFO_1001042', 'EFO_0000565',
       'EFO_1000251', 'EFO_0000681', 'EFO_0000220', 'EFO_0000691',
       'EFO_0008524', 'MONDO_0019004', 'EFO_0000198', 'EFO_1001100',
       'EFO_0002501', 'MONDO_0007576', 'EFO_1000823', 'EFO_0005561',
       'EFO_0005537', 'EFO_0002428', 'EFO_0002499', 'MONDO_0007254',
       'EFO_0000174', 'EFO_1000657', 'EFO_0000326', 'EFO_0001075',
       'EFO_0001061', 'EFO_0000616', 'EFO_0005952', 'EFO_0000389',
       'EFO_0000313', 'EFO_0003060', 'EFO_0003851', 'EFO_0003869',
       'MONDO_0021063', 'EFO_0000574', 'MONDO_0011962', 'MONDO_0006058',
       'EFO_0000222', 'EFO_1001331', 'MONDO_0018271', 'MONDO_0002974',
       'EFO_0007362', 'MONDO_0018364', 'EFO_1000895', 'MONDO_0008170',
       'MONDO_0008315', 'MONDO_0002380', 'MONDO_0002087', 'EFO_1000043'],
      dtype=object), 'count': 72}",[ENSG00000184428],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 65 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743045,,,Antibody drug conjugate,False,NAPTUMOMAB ESTAFENATOX,,2.0,,False,False,[],"['ABR-217620' 'ANYARA' 'ANYARA TTS CD3' 'Naptumomab estafenatox' 'TTS CD3'
 'TTS-CD3']",,,"{'rows': array(['EFO_0000681', 'EFO_0008528', 'EFO_0003060'], dtype=object), 'count': 3}",[ENSG00000146242],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL209821,CC(=O)Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2)c1,SPWZXWDPAWDKQE-UHFFFAOYSA-N,Small molecule,False,NALUZOTAN,,3.0,,False,False,[],['Naluzotan' 'PRX-00023'],"[('drugbank', array(['DB05562'], dtype=object))]",['CHEMBL2105647'],"{'rows': array(['MONDO_0002009', 'EFO_0000773', 'EFO_0005230'], dtype=object), 'count': 3}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2104984,Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3F)nc2C)ccc1OC(C)(C)C(=O)O,ZUGQWAYOWCBWGM-UHFFFAOYSA-N,Small molecule,False,SODELGLITAZAR,,2.0,,False,False,[],['GW-677954' 'GW677954' 'Sodelglitazar'],,,"{'rows': array(['MONDO_0005148', 'EFO_0000195'], dtype=object), 'count': 2}","[ENSG00000132170,ENSG00000186951,ENSG00000112033]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2356023,CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3\C[C@@H](O)CC[C@@H]3C)CCC[C@]12C,ILYCWAKSDCYMBB-OPCMSESCSA-N,Small molecule,False,DIHYDROTACHYSTEROL,,4.0,,False,True,['A.t. 10' 'Dihydral' 'Dygratyl' 'Tachyrol'],"['Dichysterol' 'Dihydrotachysterol' 'Dihydrotachysterol 2'
 'Dihydrotachysterol2' 'Tachysterol dihydro derivative' 'Vitamin d1']","[('PubChem', array(['144205894'], dtype=object)), ('drugbank', array(['DB01070'], dtype=object)), ('chEBI', array(['4591'], dtype=object))]",,,[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV.
CHEMBL238804,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,QXWZQTURMXZVHJ-UHFFFAOYSA-N,Small molecule,False,SELEXIPAG,2015.0,4.0,,False,True,['Uptravi'],['ACT-293987' 'NS-304' 'Selexipag'],"[('DailyMed', array(['selexipag'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi'],
      dtype=object)), ('drugbank', array(['DB11362'], dtype=object))]",,"{'rows': array(['MONDO_0017147', 'EFO_0001361', 'MONDO_0005149', 'HP_0004419'],
      dtype=object), 'count': 4}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved indications.
CHEMBL24072,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,IFFPICMESYHZPQ-UHFFFAOYSA-N,Small molecule,False,PRENYLAMINE,,4.0,,True,True,[],['B-436' 'Prenylamine' 'Prenylamine lactate'],"[('Wikipedia', array(['Prenylamine'], dtype=object)), ('drugbank', array(['DB04825'], dtype=object))]",['CHEMBL1367944'],"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}","[ENSG00000183873,ENSG00000198668]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region.
CHEMBL3545035,COCCCN1CC[C@@H](CNC(=O)c2cc(Cl)c(N)c3c2OC(C)(C)C3)[C@H](O)C1,FOUUNSGQVBGYQM-SUMWQHHRSA-N,Small molecule,False,REVEXEPRIDE,,2.0,,False,False,[],"['(-)-revexepride' 'R-149402' 'R149402' 'Revexepride' 'SPD-557' 'SPD557'
 'Ssp-002358']",,,"{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}",[ENSG00000164270],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3935857,Nc1nc2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1,BLGWHBSBBJNKJO-UHFFFAOYSA-N,Small molecule,False,SERABELISIB,,2.0,,False,False,[],"['AGN-PC-0DB6FL' 'INK1117' 'Ink-1117' 'MLN-1117' 'MLN1117' 'Mln-1117'
 'Serabelisib' 'TAK-117' 'Tak-117']","[('drugbank', array(['DB14935'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000681', 'EFO_0003060', 'EFO_0000616',
       'EFO_0004230'], dtype=object), 'count': 5}",[ENSG00000121879],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3963485,COCc1c(-c2cc3cc(C)cc(OC)c3s2)c2c(N)ncnn2c1CN1CCNC(=O)C1,HNLRRJSKGXOYNO-UHFFFAOYSA-N,Small molecule,False,ROGARATINIB,,2.0,,False,False,[],['BAY-1163877' 'Bay-1163877' 'Rogaratinib'],"[('drugbank', array(['DB15078'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'MONDO_0004992', 'EFO_0008528', 'EFO_0000616',
       'MONDO_0001187', 'EFO_0003060'], dtype=object), 'count': 6}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3989768,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13.O.O.O=C(O)C(O)C(O)C(=O)O,UMZNDVASJKIQCB-SODJFYQGSA-N,Small molecule,True,LEVORPHANOL TARTRATE,1991.0,4.0,CHEMBL592,False,True,['Dromoran' 'Levo-dromoran' 'Levorphanol tartrate'],"['Levorphanol tartrate' 'Levorphanol tartrate anhydrous'
 'Levorphanol tartrate dihydrate' 'NSC-91012']","[('DailyMed', array(['levorphanol%20tartrate'], dtype=object))]",,,[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991. This drug has a black box warning from the FDA.
CHEMBL4297294,O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1,YWGYNGCRVZLMCS-UHFFFAOYSA-N,Small molecule,False,JNJ-42165279,,2.0,,False,False,[],['Jnj-42165279'],"[('drugbank', array(['DB15173'], dtype=object))]",,"{'rows': array(['EFO_0003756', 'EFO_1001908'], dtype=object), 'count': 2}",[ENSG00000117480],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297604,O=C(O)c1ccc(CN2C[C@@H]3C[C@H]2CN3Cc2ccc(Oc3ccc(-c4ncco4)cc3)cc2)cc1,GERJIEKMNDGSCS-DQEYMECFSA-N,Small molecule,False,ACEBILUSTAT,,2.0,,False,False,[],['Acebilustat' 'CTX-4430' 'Ctx-4430' 'EP-501'],"[('drugbank', array(['DB15385'], dtype=object))]",,"{'rows': array(['MONDO_0009061', 'MONDO_0019297', 'EFO_0003894', 'MONDO_0100096'],
      dtype=object), 'count': 4}",[ENSG00000111144],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297809,,,Antibody,True,ELRANATAMAB,2023.0,4.0,,False,True,['Elrexfio'],['Elranatamab' 'PF-06863135' 'Pf-06863135' 'RN-613' 'RN613'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELRANATAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000048462,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for multiple myeloma and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL523299,OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-],PEJHHXHHNGORMP-UHFFFAOYSA-M,Small molecule,False,UMECLIDINIUM BROMIDE,2013.0,4.0,CHEMBL1187833,False,True,"['Incruse ellipta' 'Incruse ellipta (previously incruse)'
 'Rolufta ellipta (previously rolufta)']","['Anoro ellipta' 'GSK-573719A' 'GSK573719A' 'Umeclidinium brom'
 'Umeclidinium bromide']","[('DailyMed', array(['umeclidinium%20bromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta-previously-incruse',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/rolufta-ellipta'],
      dtype=object))]",,"{'rows': array(['EFO_0000464', 'HP_0006536', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0006505'], dtype=object), 'count': 5}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 1 investigational indication.
CHEMBL5314389,O=C(N[C@@H](Cc1ccc(OCc2ccc3ccc(F)cc3n2)cc1)C(=O)[O-])c1ccc2ccccc2n1.[Na+],KGZGMOFDZSCICN-YCBFMBTMSA-M,Small molecule,False,CR-3465,,1.0,CHEMBL5316169,False,False,[],['CR3465' 'Cr-3465'],,,,[ENSG00000173198],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL698,CCCCNc1ccc(C(=O)OCCN(C)C)cc1,GKCBAIGFKIBETG-UHFFFAOYSA-N,Small molecule,False,TETRACAINE,2005.0,4.0,,False,True,['Ametop' 'Dicaine' 'Pontocaine'],['Amethocaine' 'Tetracaine'],"[('DailyMed', array(['tetracaine'], dtype=object)), ('PubChem', array(['11111916', '11111917', '50111267', '90340576'], dtype=object)), ('Wikipedia', array(['Tetracaine'], dtype=object)), ('drugbank', array(['DB09085'], dtype=object)), ('chEBI', array(['9468'], dtype=object))]",['CHEMBL1255654'],"{'rows': array(['EFO_0000701', 'EFO_1001054', 'EFO_0004616', 'EFO_1001434',
       'HP_0000989', 'MONDO_0005129', 'EFO_0009552', 'EFO_1001178',
       'EFO_0003843', 'EFO_0004143', 'MONDO_0041052', 'EFO_0000546'],
      dtype=object), 'count': 12}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 9 investigational indications.
CHEMBL710,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,DBEPLOCGEIEOCV-WSBQPABSSA-N,Small molecule,False,FINASTERIDE,1992.0,4.0,,False,True,['Aindeem' 'Finasteride' 'Propecia' 'Proscar' 'Prostide'],['Finasteride' 'MK-906' 'NSC-741485' 'NSC-759318'],"[('DailyMed', array(['finasteride'], dtype=object)), ('PubChem', array(['144204268', '144208704', '144213061', '170464818', '26719811',
       '26753508', '26753509', '49666458'], dtype=object)), ('Wikipedia', array(['Finasteride'], dtype=object)), ('drugbank', array(['DB01216'], dtype=object)), ('chEBI', array(['5062'], dtype=object))]",,"{'rows': array(['EFO_0003839', 'EFO_0004191', 'EFO_0000673', 'EFO_0000284',
       'MONDO_0008315', 'EFO_0000536', 'MONDO_0004907', 'MONDO_0002146',
       'MONDO_0003037', 'EFO_0003894', 'EFO_0001663', 'EFO_0003060'],
      dtype=object), 'count': 12}",[ENSG00000277893],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 6 investigational indications.
CHEMBL741,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,PYZRQGJRPPTADH-UHFFFAOYSA-N,Small molecule,True,LAMOTRIGINE,1994.0,4.0,,False,True,['Lamictal' 'Lamictal cd' 'Lamictal odt' 'Lamictal xr' 'Lamotrigine'],['BW 430C' 'BW-430C' 'Lamotrigine' 'NSC-759171'],"[('DailyMed', array(['lamotrigine'], dtype=object)), ('PubChem', array(['11113342', '144203730', '170465024', '174006315', '26719658',
       '50104089', '56423136', '85231112', '855818', '90341162'],
      dtype=object)), ('Wikipedia', array(['Lamotrigine'], dtype=object)), ('drugbank', array(['DB00555'], dtype=object)), ('chEBI', array(['6367'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'HP_0001250', 'EFO_0003890', 'MONDO_0005090',
       'MONDO_0041052', 'EFO_0000474', 'MONDO_0016532', 'EFO_0009963',
       'MONDO_0007079', 'HP_0000726', 'EFO_0002610', 'MONDO_0010826',
       'EFO_0003843', 'MONDO_0002050', 'EFO_0000677', 'EFO_0003100',
       'HP_0002069', 'EFO_0005230', 'EFO_0001073', 'EFO_0005203',
       'HP_0100543', 'MONDO_0004985', 'EFO_0005611', 'EFO_0004263',
       'Orphanet_79292', 'EFO_0008522', 'MONDO_0018975', 'EFO_0007262',
       'EFO_0003929', 'EFO_0004247', 'MONDO_0002009'], dtype=object), 'count': 31}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 10 approved and 21 investigational indications. This drug has a black box warning from the FDA.
CHEMBL753,CC(COc1ccccc1)N(CCCl)Cc1ccccc1,QZVCTJOXCFMACW-UHFFFAOYSA-N,Small molecule,False,PHENOXYBENZAMINE,1953.0,4.0,,False,True,[],['Bensylyt' 'Benzylyt' 'Dibenylin' 'Phenoxybenzamine'],"[('PubChem', array(['104171113', '124879342', '124879343', '144203638', '170465147',
       '174007411', '26752309', '26752310', '90341231'], dtype=object)), ('Wikipedia', array(['Phenoxybenzamine'], dtype=object)), ('drugbank', array(['DB00925'], dtype=object)), ('chEBI', array(['8077'], dtype=object))]",['CHEMBL1200787'],"{'rows': array(['EFO_0005207', 'EFO_0000239', 'EFO_0000319'], dtype=object), 'count': 3}","[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for adrenal gland pheochromocytoma and cardiovascular disease and has 1 investigational indication.
CHEMBL1200549,C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1.[Br-],LVQTUXZKLGXYIU-GWSNJHLMSA-M,Small molecule,False,RAPACURONIUM BROMIDE,1999.0,4.0,CHEMBL1201352,True,True,['Raplon'],['ORG 9487' 'ORG-9487' 'Rapacuronium bromide'],"[('PubChem', array(['144206855'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999. It was withdrawn in at least one region.
CHEMBL1201490,,,Protein,False,SERMORELIN ACETATE,1990.0,4.0,,False,True,['Geref'],['Groliberin' 'Sermorelin' 'Sermorelin acetate'],"[('Wikipedia', array(['Sermorelin'], dtype=object))]",,,[ENSG00000106128],Protein drug with a maximum clinical trial phase of IV that was first approved in 1990.
CHEMBL1201539,,,Protein,False,INSULIN PORK,1966.0,4.0,,False,True,['Iletin i' 'Insulin' 'Regular insulin'],['Insulin porcine' 'Insulin porcine insulin' 'Insulin pork'],"[('DrugCentral', array(['5191'], dtype=object))]",,"{'rows': array(['EFO_0002614', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0003931',
       'EFO_0001645', 'EFO_0000400'], dtype=object), 'count': 6}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 6 investigational indications.
CHEMBL1245,CC1(C)C2CCC1(CS(=O)(=O)[O-])C(=O)C2.O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1,HALWUDBBYKMYPW-UHFFFAOYSA-M,Small molecule,False,TRIMETHAPHAN CAMSYLATE,1982.0,4.0,CHEMBL1201329,False,True,['Arfonad'],"['NU-2222' 'Trimetaphan camsilate' 'Trimetaphan camsylate'
 'Trimethaphan Camsylate' 'Trimethaphan camphorsulfonate'
 'Trimethaphan camsylate']","[('Wikipedia', array(['Trimetaphan_camsilate'], dtype=object))]",,,"[ENSG00000117971,ENSG00000080644]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1287853,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1,JOOXLOJCABQBSG-UHFFFAOYSA-N,Small molecule,True,FEDRATINIB,2019.0,4.0,,False,True,[],['Fedratinib' 'SAR-302503' 'SAR302503' 'Sar-302503' 'TG-101348' 'TG101348'],"[('drugbank', array(['DB12500'], dtype=object))]",['CHEMBL4297216'],"{'rows': array(['EFO_0004251', 'EFO_0000198', 'EFO_0000616', 'EFO_0001421',
       'EFO_1000179', 'EFO_0002430', 'EFO_0002430', 'HP_0011974',
       'MONDO_0044903', 'EFO_0003086', 'EFO_0004251'], dtype=object), 'count': 11}","[ENSG00000096968,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1370561,Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN,FQPFAHBPWDRTLU-UHFFFAOYSA-N,Small molecule,False,AMINOPHYLLINE,1940.0,4.0,CHEMBL190,False,True,"['Aminophyllin' 'Aminophylline' 'Aminophylline In Sodium Chloride'
 'Aminophylline dye free' 'Ammophyllin' 'Amnivent-225 sr'
 'Amnivent-350 sr' 'Peterphyllin' 'Phyllocontin' 'Somophyllin'
 'Somophyllin-df' 'Truphylline']","['Aminophylline' 'Aminophyllinum' 'Cardophyllin' 'Linampheta' 'NSC-7919'
 'Syntophyllin' 'Theophyllamine' 'Theophylline ethylenediamine'
 'Theophylline-ethylenediamine']","[('DailyMed', array(['aminophylline'], dtype=object)), ('PubChem', array(['11111990', '11111991', '50105733', '85231291'], dtype=object)), ('drugbank', array(['DB01223'], dtype=object))]",,"{'rows': array(['HP_0001919', 'HP_0002315', 'EFO_1000782', 'HP_0006536',
       'EFO_0009492', 'MONDO_0004979', 'EFO_0003917', 'EFO_0001361',
       'MONDO_0001187'], dtype=object), 'count': 9}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000172572,ENSG00000152270]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1940 and is indicated for airway obstruction and asthma and has 7 investigational indications.
CHEMBL1481,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,WIGIZIANZCJQQY-RUCARUNLSA-N,Small molecule,False,GLIMEPIRIDE,1995.0,4.0,,False,True,['Amaryl' 'Glimepiride' 'Niddaryl'],['Amaryl' 'Glimepiride' 'HOE 490' 'HOE-490' 'NSC-759809'],"[('DailyMed', array(['glimepiride'], dtype=object)), ('PubChem', array(['144204264', '170464966', '49648856'], dtype=object)), ('Wikipedia', array(['Glimepiride'], dtype=object)), ('drugbank', array(['DB00222'], dtype=object)), ('chEBI', array(['5383'], dtype=object))]",,"{'rows': array(['EFO_0003914', 'MONDO_0005148', 'EFO_0000400', 'Orphanet_552',
       'EFO_0000537', 'EFO_0001645', 'HP_0003124'], dtype=object), 'count': 7}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 4 investigational indications.
CHEMBL1742988,,,Protein,False,BAMINERCEPT,,2.0,,False,False,[],['BG 9924' 'BG-9924' 'BG9924' 'Baminercept' 'Baminercept alfa' 'TT-47'],,,"{'rows': array(['EFO_0000685', 'EFO_0008522', 'EFO_0000699', 'EFO_0004220'],
      dtype=object), 'count': 4}","[ENSG00000226979,ENSG00000227507,ENSG00000125735]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL194378,CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12,QVDSEJDULKLHCG-UHFFFAOYSA-N,Small molecule,False,PSILOCYBINE,,3.0,,False,False,[],['CY 39' 'CY-39' 'Indocybin' 'Psilocybin' 'Psilocybine' 'Teonanacatl'],"[('PubChem', array(['144206451'], dtype=object)), ('Wikipedia', array(['Psilocybin'], dtype=object)), ('drugbank', array(['DB11664'], dtype=object)), ('chEBI', array(['8614'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'HP_0002315', 'MONDO_0002334', 'EFO_0005230',
       'MONDO_0002050', 'EFO_0003843', 'EFO_0000546', 'EFO_0009854',
       'EFO_1001454', 'EFO_0005687', 'EFO_0003768', 'MONDO_0002009',
       'MONDO_0005351', 'EFO_0010702', 'MONDO_0044881', 'MONDO_0004985',
       'EFO_0008510', 'EFO_0004701', 'MONDO_0007079', 'EFO_0002610',
       'MONDO_0005277', 'EFO_0004242', 'EFO_0001358', 'HP_0003419'],
      dtype=object), 'count': 24}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications.
CHEMBL2087361,C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,QQLKULDARVNMAL-UHFFFAOYSA-N,Small molecule,False,ICOTINIB,,3.0,,False,False,[],['BPI-2009H' 'Bpi-2009' 'Icotinib'],"[('drugbank', array(['DB11737'], dtype=object))]",['CHEMBL4297665'],"{'rows': array(['EFO_0000708', 'MONDO_0008903', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0003060', 'EFO_0004252', 'EFO_0002618', 'EFO_1000849',
       'MONDO_0007576', 'EFO_0005922', 'EFO_0000313', 'EFO_0000676',
       'EFO_0000571'], dtype=object), 'count': 13}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL2103738,O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+],HXGWMCJZLNWEBC-UHFFFAOYSA-K,Small molecule,True,LITHIUM CITRATE,1980.0,4.0,CHEMBL1201170,False,True,['Li-liquid' 'Litarex' 'Lithium citrate'],['Lithium (as citrate)' 'Lithium citrate' 'Lithonate s' 'NSC-758700'],"[('DrugCentral', array(['4512'], dtype=object)), ('chEBI', array(['64754'], dtype=object))]",,"{'rows': array(['EFO_0009963'], dtype=object), 'count': 1}","[ENSG00000133731,ENSG00000105723,ENSG00000082701]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for bipolar i disorder. This drug has a black box warning from the FDA.
CHEMBL2109606,,,Antibody,False,GSK-1070806,,2.0,,False,False,[],['GSK-1070806' 'Gsk-1070806'],,,"{'rows': array(['EFO_0003767', 'EFO_0003780', 'EFO_0000400', 'EFO_0000384',
       'EFO_0000274'], dtype=object), 'count': 5}",[ENSG00000150782],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL232943,COC(=O)c1c(Cl)cccc1-c1ccc([C@@H](C)NC(=O)C2(NC(=O)C(F)(F)F)CC2)c(F)c1,WZZIQHIQMWJNLU-LLVKDONJSA-N,Small molecule,False,MK0686,,2.0,,False,False,[],['MK-0686' 'MK0686' 'Mk0686'],"[('drugbank', array(['DB12563'], dtype=object))]",,"{'rows': array(['MONDO_0041052', 'MONDO_0005178', 'EFO_0003843'], dtype=object), 'count': 3}",[ENSG00000100739],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3353541,C[C@]1(C(=O)N(CCCC(=O)O)Cc2cccc(Cl)c2)CCN1C(=O)c1csc2ccccc12,MPMKMQHJHDHPBE-RUZDIDTESA-N,Small molecule,False,GLPG-0974,,2.0,,False,False,[],['GLPG-0974' 'GLPG0974' 'Glpg-0974' 'Glpg0974'],"[('drugbank', array(['DB15406'], dtype=object))]",,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}",[ENSG00000126262],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545146,,,Small molecule,False,SRX251,,1.0,,False,False,[],['Srx251'],,,,[ENSG00000166148],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707318,,,Small molecule,False,GRC-17536,,2.0,,False,False,[],['Grc-17536'],,,"{'rows': array(['EFO_1000783'], dtype=object), 'count': 1}",[ENSG00000104321],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3945199,CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1,HNAJDMYOTDNOBK-UHFFFAOYSA-N,Small molecule,False,BMS-852927,,1.0,,False,False,[],['Bms-852927' 'EXEL-04541041' 'XL-041' 'XL-652'],,,"{'rows': array(['HP_0003124'], dtype=object), 'count': 1}","[ENSG00000131408,ENSG00000025434]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4297860,,,Antibody,False,TILAVONEMAB,,2.0,,False,False,[],['ABBV-8E12' 'Abbv-8e12' 'Tilavonemab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TILAVONEMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0019037', 'MONDO_0004975', 'EFO_0005772'], dtype=object), 'count': 3}",[ENSG00000186868],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL444172,O[C@@H](COc1cccc2ncccc12)CN1CCN([C@@H]2c3ccccc3[C@@H]3[C@H](c4ccccc42)C3(F)F)CC1,IHOVFYSQUDPMCN-DBEBIPAYSA-N,Small molecule,False,ZOSUQUIDAR,,3.0,,False,False,[],['Zosuquidar'],"[('Wikipedia', array(['Zosuquidar'], dtype=object)), ('drugbank', array(['DB06191'], dtype=object))]",['CHEMBL2074689'],"{'rows': array(['EFO_0000565', 'EFO_0000198', 'EFO_0000565'], dtype=object), 'count': 3}",[ENSG00000085563],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL487,CC/C(=C(/c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1,ZQZFYGIXNQKOAV-OCEACIFDSA-N,Small molecule,False,DROLOXIFENE,,3.0,,False,False,[],"['3-hydroxytamoxifen' 'Droloxifene' 'E-Droloxifene' 'FK-435' 'Fk-435'
 'K-060' 'K-21060E' 'K060' 'K060E']","[('chEBI', array(['34731'], dtype=object))]",['CHEMBL2105786'],,"[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of III.
CHEMBL5095026,C[C@@H](NCc1nc2ccc(Oc3cc(F)c(F)c(F)c3)nc2n1C1CCC1)C(N)=O,HHXCJIMPEJSJTG-SNVBAGLBSA-N,Small molecule,False,DSP-2230,,1.0,,False,False,[],['Dsp-2230'],,,,"[ENSG00000169432,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL519504,CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O,DAYKLWSKQJBGCS-NRFANRHFSA-N,Small molecule,False,ALEGLITAZAR,,3.0,,False,False,[],['Aleglitazar' 'R-1439' 'R1439' 'RO-0728804' 'RO0728804' 'Ro-0728804'],"[('Wikipedia', array(['Aleglitazar'], dtype=object)), ('drugbank', array(['DB08915'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}","[ENSG00000186951,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1200332,CNCCCC1c2ccccc2C=Cc2ccccc21.Cl,OGQDIIKRQRZXJH-UHFFFAOYSA-N,Small molecule,True,PROTRIPTYLINE HYDROCHLORIDE,1967.0,4.0,CHEMBL668,False,True,['Concordin-10' 'Concordin-5' 'Protriptyline hydrochloride' 'Vivactil'],['MK-240' 'NSC-169912' 'Protriptyline hcl' 'Protriptyline hydrochloride'],"[('DailyMed', array(['protriptyline%20hydrochloride'], dtype=object)), ('PubChem', array(['144203795', '170465077', '50106858', '50106859', '56422215',
       '855990'], dtype=object)), ('chEBI', array(['8598'], dtype=object))]",,"{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967 and is indicated for depressive disorder. This drug has a black box warning from the FDA.
CHEMBL1200609,CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,SHIJTGJXUHTGGZ-RVXRQPKJSA-N,Small molecule,True,PAROXETINE MESYLATE,2003.0,4.0,CHEMBL490,False,True,['Brisdelle' 'Pexeva'],"['Mesafem' 'PO-T.MES' 'POT.MES' 'Paroxetine mesilate'
 'Paroxetine mesylate' 'Paroxetine methanesulfonate'
 'Paroxetine methanesulphonate']","[('DailyMed', array(['paroxetine%20mesylate'], dtype=object))]",,"{'rows': array(['EFO_1001917', 'GO_0042697', 'EFO_0006788', 'MONDO_0002009',
       'EFO_0004242', 'HP_0031217', 'EFO_0001358', 'EFO_0004262'],
      dtype=object), 'count': 8}",[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201782,CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,VRQHBYGYXDWZDL-OOZCZQCLSA-N,Small molecule,False,FOSAPREPITANT DIMEGLUMINE,2008.0,4.0,CHEMBL1199324,False,True,['Emend' 'Fosaprepitant dimeglumine' 'Ivemend'],"['Fosaprepitant (as dimeglumine)' 'Fosaprepitant dimeglumine'
 'Fosaprepitant meglumine' 'MK-0517']","[('DailyMed', array(['fosaprepitant%20dimeglumine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend'],
      dtype=object)), ('chEBI', array(['64311'], dtype=object))]",,"{'rows': array(['EFO_0004888', 'HP_0002017', 'MONDO_0004992', 'EFO_0006911',
       'EFO_0000691'], dtype=object), 'count': 5}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 1 investigational indication.
CHEMBL1743018,,,Antibody,False,FICLATUZUMAB,,2.0,,False,False,[],['AV 299' 'AV-299' 'Ficlatuzumab' 'SCH 900105' 'SCH-900105'],,,"{'rows': array(['EFO_0000181', 'EFO_0000707', 'EFO_0001378', 'EFO_0000519',
       'EFO_0002618', 'EFO_0003060', 'EFO_0000222'], dtype=object), 'count': 7}",[ENSG00000019991],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL1963681,COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl,WEAJZXNPAWBCOA-INIZCTEOSA-N,Small molecule,False,AVANAFIL,2011.0,4.0,,False,True,['Spedra' 'Stendra'],['Avanafil' 'TA-1790'],"[('DailyMed', array(['avanafil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/spedra'],
      dtype=object)), ('PubChem', array(['165222624'], dtype=object)), ('Wikipedia', array(['Avanafil'], dtype=object)), ('drugbank', array(['DB06237'], dtype=object)), ('chEBI', array(['66876'], dtype=object))]",,"{'rows': array(['EFO_0004234', 'HP_0000802', 'EFO_0003086'], dtype=object), 'count': 3}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for erectile dysfunction and impotence and has 1 investigational indication.
CHEMBL2028661,CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,QJFSABGVXDWMIW-UHFFFAOYSA-N,Small molecule,True,AZILSARTAN MEDOXOMIL,2011.0,4.0,,False,True,['Edarbi'],['AR-14' 'Azilsartan medoxomil' 'Ipreziv' 'TAK 491' 'TAK-491'],"[('drugbank', array(['DB08822'], dtype=object)), ('chEBI', array(['68845'], dtype=object))]",['CHEMBL2103795'],"{'rows': array(['EFO_0000319', 'EFO_0000537', 'MONDO_0001134', 'EFO_0000712',
       'EFO_0000537'], dtype=object), 'count': 5}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hypertension and stroke and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2079130,CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1,BFDBKMOZYNOTPK-UHFFFAOYSA-N,Small molecule,False,VONOPRAZAN,2022.0,4.0,,False,True,['Takecab' 'Vocinti'],['TAK-438' 'Vonoprazan'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VONOPRAZAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11739'], dtype=object))]",['CHEMBL2064032'],"{'rows': array(['EFO_0009454', 'MONDO_0001409', 'HP_0004398', 'MONDO_0001409',
       'EFO_0003948', 'EFO_0003948', 'EFO_1000961', 'EFO_0004607',
       'EFO_1000961'], dtype=object), 'count': 9}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for peptic ulcer and gastroesophageal reflux disease and has 5 investigational indications.
CHEMBL2105740,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+],MDTNUYUCUYPIHE-UHFFFAOYSA-N,Small molecule,False,SITAXENTAN SODIUM,2006.0,4.0,CHEMBL282724,True,True,['Thelin'],"['Sitaxentan sodium' 'Sitaxsentan sodium salt' 'TBC-11251 SODIUM'
 'TBC-11251NA' 'TBC-11251Z']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thelin'],
      dtype=object))]",,"{'rows': array(['EFO_1000899', 'MONDO_0005149'], dtype=object), 'count': 2}","[ENSG00000136160,ENSG00000151617]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for pulmonary hypertension and has 1 investigational indication. It was withdrawn in at least one region.
CHEMBL2105857,CC[C@@]1(OC(=O)[C@@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=S)Nc2ccc(O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)[C@@H]3O)cc2)C(C)C)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1,SLOJCSGNHWIKIG-JNYZSSQASA-N,Small molecule,False,AFELETECAN,,2.0,,False,False,[],['Afeletecan'],,['CHEMBL4297664'],"{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2106483,CCOc1ccccc1OCC1CNCCO1.Cl,HJOCKFVCMLCPTP-UHFFFAOYSA-N,Small molecule,True,VILOXAZINE HYDROCHLORIDE,2021.0,4.0,CHEMBL306700,False,True,['Qelbree' 'Vivalan'],"['ICI 58,834' 'ICI-58834' 'SPN-812' 'Spn-812' 'Viloxazine hcl'
 'Viloxazine hydrochloride']","[('PubChem', array(['170466300'], dtype=object))]",,"{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA.
CHEMBL2108228,,,Antibody,False,BECTUMOMAB,,3.0,,False,False,['Lymphoscan'],['Bectumomab' 'IMMU-LL2' 'Technetium tc 99m bectumomab'],,,,[ENSG00000012124],Antibody drug with a maximum clinical trial phase of III.
CHEMBL2108401,,,Antibody,False,ENLIMOMAB PEGOL,,2.0,,False,False,[],['BIRR-1' 'Enlimomab pegol' 'R6.5'],,,,[ENSG00000090339],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109283,,,Antibody drug conjugate,False,BICIROMAB BRALLOBARBITAL,,1.0,,False,False,['Fibriscint'],['Biciromab brallobarbital' 'T2G1S'],,,,[ENSG00000171564],Antibody drug conjugate drug with a maximum clinical trial phase of I.
CHEMBL2109309,,,Antibody,False,RHIGM12B7,,1.0,,False,False,[],['RHIGM12B7' 'Rhigm12b7'],,,"{'rows': array(['EFO_0000389'], dtype=object), 'count': 1}",[ENSG00000197646],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109624,,,Antibody,False,CAPLACIZUMAB,2018.0,4.0,,False,True,['Cablivi'],['ALX-0081' 'Caplacizumab' 'Caplacizumab yhdp'],"[('DailyMed', array(['caplacizumab-yhdp'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cablivi'],
      dtype=object))]",,"{'rows': array(['MONDO_0019740', 'MONDO_0018896', 'HP_0004419'], dtype=object), 'count': 3}",[ENSG00000110799],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications.
CHEMBL2151437,c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,OCKIPDMKGPYYJS-ZDUSSCGKSA-N,Small molecule,False,AZD0328,,2.0,,False,False,[],['AZD-0328' 'AZD0328' 'Azd 0328' 'Azd-0328' 'Azd0328'],"[('drugbank', array(['DB12145'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL340978,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1,MITFXPHMIHQXPI-UHFFFAOYSA-N,Small molecule,False,BENOXAPROFEN,1982.0,4.0,,True,True,[],"['Benoxaprofen' 'COMPD 90459' 'COMPOUND 90459' 'Coxigon' 'NSC-299582'
 'Opren']","[('Wikipedia', array(['Benoxaprofen'], dtype=object)), ('drugbank', array(['DB04812'], dtype=object)), ('chEBI', array(['76114'], dtype=object))]",,"{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}",[ENSG00000108839],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for rheumatic disease. It was withdrawn in at least one region.
CHEMBL3545225,,,Small molecule,False,INCB-047986,,2.0,,False,False,[],['Incb-047986' 'Incb-47986'],,,"{'rows': array(['EFO_0000685', 'EFO_0000198', 'EFO_0000183', 'MONDO_0007254'],
      dtype=object), 'count': 4}",[ENSG00000162434],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3545341,Cl.O=c1[nH]ccc2cc(OC3CCNCC3)ccc12,KMNVOGVCCZNVNU-UHFFFAOYSA-N,Small molecule,False,SAR-407899,,2.0,CHEMBL1667969,False,False,[],['SAR-407899' 'SAR407899' 'Sar-407899'],,,"{'rows': array(['EFO_0003884', 'EFO_0004234', 'EFO_0001645'], dtype=object), 'count': 3}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545389,,,Small molecule,False,LY2245461,,2.0,,False,False,[],['Ly2245461'],,,,"[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3643413,CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1,MWKYMZXCGYXLPL-ZDUSSCGKSA-N,Small molecule,False,LENIOLISIB,2023.0,4.0,,False,True,[],"['CDZ-173-NX' 'CDZ173-NX' 'Cdz-173 free base' 'Cdz173 free base'
 'Leniolisib']",,['CHEMBL3989909'],"{'rows': array(['MONDO_0015517', 'EFO_0000699', 'MONDO_0003778'], dtype=object), 'count': 3}",[ENSG00000171608],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for inborn error of immunity and has 2 investigational indications.
CHEMBL3707228,,,Antibody,False,PLOZALIZUMAB,,2.0,,False,False,[],['HU-1D9' 'MLN-1202' 'MLN1202' 'Plozalizumab' 'hu1D9'],,,"{'rows': array(['EFO_0000756', 'EFO_0000401', 'MONDO_0005301', 'EFO_0003914',
       'EFO_0000319'], dtype=object), 'count': 5}",[ENSG00000121807],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3989872,C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O,DVBUEXCIEIAXPM-PJUQSVSOSA-N,Protein,False,APIMOSTINEL,,2.0,,False,False,[],['Apimostinel' 'NRX-1074' 'NRX1074' 'Nrx-1074'],"[('drugbank', array(['DB11784'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'MONDO_0005090'], dtype=object), 'count': 2}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297187,COCCNCCc1cccc(Nc2ncc3c(n2)-c2ccccc2[C@H](c2ccccc2F)C3)c1,KPJDVVCDVBFRMU-AREMUKBSSA-N,Small molecule,False,DERAZANTINIB,,2.0,,False,False,[],['ARQ 087' 'ARQ087' 'Arq-087' 'Derazantinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DERAZANTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14889'], dtype=object))]",['CHEMBL4298156'],"{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_1001961', 'EFO_0008528',
       'EFO_0000503'], dtype=object), 'count': 5}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297287,COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1,ABEJDMOBAFLQNJ-NHCUHLMSSA-N,Small molecule,False,HT-0712,,2.0,,False,False,[],['BLX-028914' 'Blx-028914' 'Ht-0712' 'IPL-455903' 'OX-914'],"[('drugbank', array(['DB11650'], dtype=object))]",,"{'rows': array(['EFO_0005854', 'EFO_0001072'], dtype=object), 'count': 2}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297311,COc1cc(Cl)ccc1[C@H]1c2[nH]c3cccc(F)c3c2C2(CC2)CN1C(C)=O,ZBQMTQGDBFZUBG-NRFANRHFSA-N,Small molecule,False,ONO-2952,,2.0,,False,False,[],['Ono-2952'],"[('drugbank', array(['DB14802'], dtype=object))]",,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}",[ENSG00000100300],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297462,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)n[nH]c3c1)C(=O)N2.O=C(O)/C=C/C(=O)O,AQCDFVLWUWJREO-WQVJSASDSA-N,Small molecule,False,CFI-400945,,2.0,CHEMBL3408947,False,False,[],"['CFI-400945' 'CFI-400945 FUMARATE' 'Cfi 400945' 'Cfi-400945'
 'Cfi-400945 fumarate' 'Ocifisertib fumarate']",,,"{'rows': array(['MONDO_0008315', 'MONDO_0004992', 'MONDO_0007254'], dtype=object), 'count': 3}",[ENSG00000142731],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297613,O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1,KZSKGLFYQAYZCO-UHFFFAOYSA-N,Small molecule,False,CILOFEXOR,,3.0,,False,False,[],['Cilofexor' 'GS 9674' 'GS-9674' 'Gs-9674' 'PX-104' 'PX104'],"[('drugbank', array(['DB15168'], dtype=object))]",,"{'rows': array(['EFO_1001249', 'EFO_0004268', 'EFO_1001486'], dtype=object), 'count': 3}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297640,NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O,QLRRJMOBVVGXEJ-XHSDSOJGSA-N,Small molecule,False,VECABRUTINIB,,2.0,,False,False,[],"['BIIB-062' 'BSK-4841' 'FP-0182' 'FP0182' 'SNS-062' 'Sns-062'
 'Vecabrutinib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VECABRUTINIB/relevant/1/'],
      dtype=object))]",['CHEMBL4298148'],"{'rows': array(['EFO_0000616', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication.
CHEMBL4303187,CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1,RGYQPQARIQKJKH-UHFFFAOYSA-N,Small molecule,False,SETANAXIB,,2.0,,False,False,[],['GKT-137831' 'GKT-831' 'Setanaxib'],,,"{'rows': array(['EFO_1001486', 'EFO_0000181', 'EFO_0000768'], dtype=object), 'count': 3}","[ENSG00000007952,ENSG00000086991]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL502182,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+],DQYGXRQUFSRDCH-UQIIZPHYSA-M,Small molecule,False,ELAGOLIX SODIUM,2018.0,4.0,CHEMBL1208155,False,True,['Orilissa'],"['Elagolix sodium' 'Elagolix sodium salt' 'NBI-56418 NA' 'NBI-56418-NA'
 'Orlissa']","[('DailyMed', array(['elagolix%20sodium'], dtype=object))]",,"{'rows': array(['EFO_0001065'], dtype=object), 'count': 1}",[ENSG00000109163],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for endometriosis.
CHEMBL1020,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1,UPSPUYADGBWSHF-UHFFFAOYSA-N,Small molecule,True,TOLMETIN,1976.0,4.0,,False,True,[],['MCN-2559' 'Tolectin' 'Tolmetin'],"[('Wikipedia', array(['Tolmetin'], dtype=object)), ('drugbank', array(['DB00500'], dtype=object)), ('chEBI', array(['71941'], dtype=object))]",['CHEMBL1556918' 'CHEMBL1200613' 'CHEMBL1437585'],"{'rows': array(['HP_0002829', 'HP_0003326', 'EFO_0005755', 'EFO_0000685',
       'MONDO_0005178'], dtype=object), 'count': 5}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 5 approved indications. This drug has a black box warning from the FDA.
CHEMBL1200987,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O,DJSLTDBPKHORNY-XMMWENQYSA-N,Small molecule,True,EPROSARTAN MESYLATE,1997.0,4.0,CHEMBL813,False,True,['Eprosartan mesylate' 'Teveten'],"['Eprosartan mesilate' 'Eprosartan mesylate'
 'Eprosartan monomethanesulfonate' 'SK&F 108566-J' 'SK&F-108566-J']","[('DailyMed', array(['eprosartan%20mesylate'], dtype=object)), ('PubChem', array(['144205739', '170465071'], dtype=object)), ('chEBI', array(['48409'], dtype=object))]",,"{'rows': array(['MONDO_0001134', 'EFO_0000537'], dtype=object), 'count': 2}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hypertension and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1201295,Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1,FZGVEKPRDOIXJY-UHFFFAOYSA-N,Small molecule,False,BITOLTEROL,1984.0,4.0,,False,True,[],['Bitolterol'],"[('PubChem', array(['170465239'], dtype=object)), ('Wikipedia', array(['Bitolterol'], dtype=object)), ('drugbank', array(['DB00901'], dtype=object)), ('chEBI', array(['3133'], dtype=object))]",['CHEMBL1200405'],"{'rows': array(['HP_0006536'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for airway obstruction.
CHEMBL1237044,COc1cccc(C2(O)CCCCC2CN(C)C)c1,TVYLLZQTGLZFBW-UHFFFAOYSA-N,Small molecule,True,TRAMADOL,1995.0,4.0,,False,True,[],"['Amanda' 'CG-315E' 'E-265' 'ETS-6103' 'ETS6103' 'Tramadol' 'U-26255A'
 'Ultracet' 'Ultram']","[('chEBI', array(['75722'], dtype=object))]",['CHEMBL1237065'],"{'rows': array(['HP_0012532', 'HP_0003419', 'EFO_1001250', 'HP_0002027',
       'EFO_0000181', 'EFO_0803321', 'EFO_0003964', 'EFO_0005762',
       'EFO_0005800', 'EFO_0003843', 'HP_0012532', 'MONDO_0002009',
       'MONDO_0005178', 'EFO_1000783', 'EFO_1000652', 'MONDO_0007254',
       'EFO_0010072', 'HP_0003419', 'EFO_0005611', 'EFO_0003843',
       'EFO_0005687', 'EFO_0004616', 'EFO_0003890', 'MONDO_0004992',
       'EFO_0000546'], dtype=object), 'count': 25}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1237099,COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-],APADFLLAXHIMFU-UHFFFAOYSA-L,Small molecule,False,DOXACURIUM CHLORIDE,1991.0,4.0,CHEMBL1237123,False,True,['Nuromax'],"['BW A938U DICHLORIDE' 'BW-A938U' 'Doxacurium chloride'
 'Doxacurium chloride, meso-' 'Meso doxacurium chloride']",,,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991.
CHEMBL1257040,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl,BXDAOUXDMHXPDI-UHFFFAOYSA-N,Small molecule,True,TRIFLUOPERAZINE HYDROCHLORIDE,1959.0,4.0,CHEMBL422,False,True,['Stelazine' 'Trifluoperazine hydrochloride'],"['NSC-757369' 'Trifluoperazine HCl' 'Trifluoperazine dihydrochloride'
 'Trifluoperazine hcl' 'Trifluoperazine hydrochloride'
 'Trifluoperazine maleate']","[('DailyMed', array(['trifluoperazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144203568', '170465265', '26747694', '26747695', '50107169'],
      dtype=object)), ('chEBI', array(['9710'], dtype=object))]",,"{'rows': array(['EFO_0006788', 'MONDO_0005090', 'EFO_0000677'], dtype=object), 'count': 3}","[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL1267,CC(O)c1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,OXVFDZYQLGRLCD-UHFFFAOYSA-N,Small molecule,False,LERIGLITAZONE,,3.0,,False,False,[],['Hydroxypioglitazone' 'Leriglitazone' 'MIN-102' 'Min-102'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LERIGLITAZONE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15021'], dtype=object)), ('chEBI', array(['82937'], dtype=object))]",['CHEMBL4298170'],"{'rows': array(['Orphanet_43', 'MONDO_0100339', 'Orphanet_43', 'MONDO_0018544'],
      dtype=object), 'count': 4}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL18442,c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,YIQPUIGJQJDJOS-UHFFFAOYSA-N,Small molecule,False,PLERIXAFOR,2008.0,4.0,,False,True,['Mozobil'],"['AMD 3100' 'AMD3100' 'JM 3100' 'Plerixafor' 'Plerixafor hydrochloride'
 'Plerixafor octahydrochloride' 'SID 791']","[('DailyMed', array(['plerixafor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil'],
      dtype=object)), ('PubChem', array(['174007494', '29217477'], dtype=object)), ('Wikipedia', array(['Plerixafor'], dtype=object)), ('drugbank', array(['DB06809'], dtype=object))]","['CHEMBL1788331' 'CHEMBL2311028' 'CHEMBL554014' 'CHEMBL2088494'
 'CHEMBL2373140' 'CHEMBL2311089']","{'rows': array(['MONDO_0003783', 'EFO_0001378', 'EFO_0000095', 'EFO_0000222',
       'MONDO_0000870', 'EFO_0000198', 'MONDO_0015760', 'EFO_1001311',
       'EFO_1001996', 'EFO_0000717', 'EFO_0000565', 'MONDO_0018305',
       'MONDO_0001475', 'MONDO_0011382', 'EFO_0000403', 'EFO_0000220',
       'EFO_0002618', 'EFO_0000691', 'EFO_1001465', 'EFO_0003086',
       'MONDO_0018906', 'MONDO_0019391', 'EFO_1001469', 'MONDO_0044881',
       'MONDO_0019460', 'EFO_0000574', 'EFO_0000220', 'EFO_0000616',
       'EFO_0006859', 'EFO_0005952', 'EFO_0000183', 'EFO_1001459',
       'MONDO_0005147', 'Orphanet_848', 'EFO_1000654', 'EFO_0004599'],
      dtype=object), 'count': 36}",[ENSG00000121966],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 30 investigational indications.
CHEMBL2104753,COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1,XMSXOLDPMGMWTH-UHFFFAOYSA-N,Small molecule,False,RIVOGLITAZONE,,3.0,,False,False,[],['CS-011' 'DE-101' 'R 106056' 'R-106056' 'Rivoglitazone'],"[('drugbank', array(['DB09200'], dtype=object))]",['CHEMBL3526906' 'CHEMBL3527103' 'CHEMBL3526905'],"{'rows': array(['EFO_1000906', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108621,,,Antibody,False,MAPATUMUMAB,,2.0,,False,False,[],"['HGS-1012' 'HGS-ETR1' 'HGS1012' 'Mapatumumab' 'TRAIL-R 1MAB'
 'TRAIL-R1 MAB' 'TRM-1' 'TRM-1 HGS-ETR1']",,,"{'rows': array(['EFO_0003060', 'MONDO_0002974', 'EFO_0005952', 'EFO_0001378',
       'EFO_0000182'], dtype=object), 'count': 5}",[ENSG00000104689],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2109496,,,Antibody,False,MLN-01,,1.0,,False,False,[],['MLN-01'],,,,[ENSG00000160255],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2397450,OC[C@H]1O[C@@H](c2cc(Cc3cc4cccccc-4c3)ccc2O)[C@H](O)[C@@H](O)[C@@H]1O,AGJJCLBOHJQGFA-ZQGJOIPISA-N,Small molecule,False,YM-543,,2.0,,False,False,[],[],,['CHEMBL4297452'],"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3187503,CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1,AYJRTVVIBJSSKN-UHFFFAOYSA-N,Small molecule,False,GSK-1292263,,2.0,,False,False,[],"['GSK-1292263' 'GSK-1292263A' 'GSK-263A' 'GSK1292263' 'Gsk 1292263'
 'Gsk-1292263' 'Gsk1292263']","[('PubChem', array(['174006808'], dtype=object)), ('drugbank', array(['DB12627'], dtype=object))]",,"{'rows': array(['Orphanet_309005', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000147262],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545316,,,Antibody,False,RINUCUMAB,,2.0,,False,False,[],['REGN-2176' 'REGN2176' 'Rinucumab'],,,"{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}",[ENSG00000113721],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4101487,O=C(O)c1ccc([C@H]2C[C@@H](NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c3ccc(OC(F)F)cc3O2)cc1,QVDYQHXNAQHIKH-TZIWHRDSSA-N,Small molecule,False,GALICAFTOR,,2.0,,False,False,[],['ABBV-2222' 'GLPG-2222' 'GLPG2222' 'Galicaftor' 'Glpg2222'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GALICAFTOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14894'], dtype=object))]",,"{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297756,,,Antibody,False,FREMANEZUMAB,2018.0,4.0,,False,True,['Ajovy'],"['Fremanezumab' 'Fremanezumab vfrm' 'LBR-101' 'LBR101' 'PF-04472429'
 'PF04472429' 'RN-307' 'RN307' 'TEV-48125' 'TEV48125' 'Tev-48125']","[('DailyMed', array(['fremanezumab-vfrm'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy'],
      dtype=object))]",,"{'rows': array(['MONDO_0005277', 'EFO_0005687', 'EFO_0008507', 'EFO_0003843'],
      dtype=object), 'count': 4}","[ENSG00000110680,ENSG00000175868]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 3 investigational indications.
CHEMBL4297792,,,Unknown,False,MYRCLUDEX B,,2.0,,False,False,[],['Hbvpres2-48myr' 'Myrcludex b'],,,"{'rows': array(['EFO_0007304', 'EFO_0004239', 'EFO_0004197'], dtype=object), 'count': 3}",[ENSG00000100652],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL447,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O,KQPKPCNLIDLUMF-UHFFFAOYSA-N,Small molecule,False,SECOBARBITAL,1950.0,4.0,,True,True,[],"['(rs)-secobarbital' 'Evronal' 'Hypotrol' 'Immenox' 'Meballymal'
 'Quinalbarbital' 'Secobarbital' 'Secobarbital cii'
 'Secobarbital sodium free acid' 'Secobarbitone' 'Somatarax']","[('Wikipedia', array(['Secobarbital'], dtype=object)), ('drugbank', array(['DB00418'], dtype=object)), ('chEBI', array(['9073'], dtype=object))]",['CHEMBL1200903'],,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950.
CHEMBL4594338,,,Oligonucleotide,False,NEDOSIRAN SODIUM,2023.0,4.0,,False,True,['Rivfloza'],['DCR-PHXC' 'Dcr-phxc' 'Nedosiran sodium'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NEDOSIRAN%20SODIUM/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0009823', 'MONDO_0002474'], dtype=object), 'count': 2}",[ENSG00000134333],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for primary hyperoxaluria type 1 and primary hyperoxaluria.
CHEMBL473417,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,BPQMGSKTAYIVFO-UHFFFAOYSA-N,Small molecule,True,VISMODEGIB,2012.0,4.0,,False,True,['Erivedge'],['GDC-0449' 'NSC-747691' 'NSC-755986' 'Vismodegib'],"[('DailyMed', array(['vismodegib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge'],
      dtype=object)), ('drugbank', array(['DB08828'], dtype=object)), ('chEBI', array(['66903'], dtype=object))]",['CHEMBL4129312' 'CHEMBL4125998' 'CHEMBL4127241'],"{'rows': array(['MONDO_0007254', 'EFO_0000702', 'MONDO_0008170', 'EFO_0002618',
       'EFO_0002939', 'MONDO_0008315', 'MONDO_0003684', 'EFO_0000222',
       'EFO_1001465', 'EFO_0005537', 'MONDO_0004992', 'MONDO_0005184',
       'EFO_0000768', 'EFO_0000673', 'EFO_0000616', 'EFO_0003897',
       'MONDO_0020547', 'EFO_0004193', 'MONDO_0044903', 'MONDO_0005341',
       'EFO_0000326', 'MONDO_0007187', 'EFO_0001378', 'EFO_0000519',
       'EFO_1001041', 'MONDO_0016642'], dtype=object), 'count': 26}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 4 approved and 22 investigational indications. This drug has a black box warning from the FDA.
CHEMBL497939,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1,ANJTVLIZGCUXLD-DTWKUNHWSA-N,Small molecule,False,CYTISINICLINE,,3.0,,False,False,['Tabex'],"['6039 Sopharma' 'Baptitoxine' 'Cytisine' 'Cytisinicline' 'Cytiton'
 'NSC-407282' 'Sophorine' 'Ulexine']","[('PubChem', array(['11112361', '11114058', '26752181', '477069', '56463106'],
      dtype=object)), ('Wikipedia', array(['Cytisine'], dtype=object)), ('drugbank', array(['DB09028'], dtype=object)), ('chEBI', array(['4055'], dtype=object))]",,"{'rows': array(['EFO_0004319', 'EFO_0003768', 'EFO_0003086'], dtype=object), 'count': 3}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL5095036,C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)[C@@](O)(CC)CC2,OXTSYWDBUVRXFF-GDLZYMKVSA-N,Small molecule,False,AZENOSERTIB,,2.0,,False,False,[],['Azenosertib' 'ZN-C3' 'Zn-c3'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_0000616', 'MONDO_0008170', 'MONDO_0002158',
       'EFO_0000637'], dtype=object), 'count': 5}",[ENSG00000166483],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL56337,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1,CHNUOJQWGUIOLD-NFZZJPOKSA-N,Small molecule,False,EPALRESTAT,1992.0,4.0,,False,True,[],['Aldonil' 'Aldorin' 'Epalrestat' 'Kinedak' 'Tanglin'],"[('PubChem', array(['26664249', '26758035'], dtype=object)), ('Wikipedia', array(['Epalrestat'], dtype=object)), ('drugbank', array(['DB15293'], dtype=object)), ('chEBI', array(['31539'], dtype=object))]",['CHEMBL4297277'],"{'rows': array(['EFO_1000783', 'MONDO_0007254', 'MONDO_0015626'], dtype=object), 'count': 3}",[ENSG00000085662],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 3 investigational indications.
CHEMBL812,CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],VNYBTNPBYXSMOO-UHFFFAOYSA-M,Small molecule,True,PYRIDOSTIGMINE BROMIDE,1955.0,4.0,CHEMBL1115,False,True,"['Kalymin' 'Mestinon' 'Mestinon 10' 'Mestinon ret'
 'Pyridostigmine bromide' 'Regonal' 'Regonol']","['Kalimin' 'Kalymin' 'NSC-679759' 'NSC-758435' 'Pyridostigmine Bromide'
 'Pyridostigmine bromide' 'Pyridostigmini bromidum' 'RO-1-5130']","[('DailyMed', array(['pyridostigmine%20bromide'], dtype=object)), ('PubChem', array(['144204818', '170464878', '26747656', '50106936', '518187',
       '56422100', '855974'], dtype=object))]",,"{'rows': array(['EFO_0003144', 'EFO_0005251', 'MONDO_0009672', 'MONDO_0100096',
       'MONDO_0004567', 'MONDO_0005180', 'Orphanet_365', 'EFO_0004991',
       'EFO_0005252'], dtype=object), 'count': 9}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for myasthenia gravis and has 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1070,COc1ccc2cc(CCC(C)=O)ccc2c1,BLXXJMDCKKHMKV-UHFFFAOYSA-N,Small molecule,True,NABUMETONE,1991.0,4.0,,False,True,['Nabumetone' 'Relafen' 'Relifex'],['BRL 14777' 'BRL-14777' 'NSC-758623' 'Nabumetone'],"[('DailyMed', array(['nabumetone'], dtype=object)), ('PubChem', array(['11112767', '124882597', '144204198', '170464970', '26748824',
       '8139968'], dtype=object)), ('Wikipedia', array(['Nabumetone'], dtype=object)), ('drugbank', array(['DB00461'], dtype=object)), ('chEBI', array(['7443'], dtype=object))]",,"{'rows': array(['MONDO_0005178', 'EFO_0005755', 'EFO_0000685'], dtype=object), 'count': 3}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved indications. This drug has a black box warning from the FDA.
CHEMBL1200865,CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,DMKSVUSAATWOCU-HROMYWEYSA-N,Small molecule,False,LOTEPREDNOL ETABONATE,1998.0,4.0,,False,True,['Alrex' 'Eysuvis' 'Inveltys' 'Lotemax' 'Lotemax sm'],"['CDDD 5604' 'CDDD-5604' 'CDDD5604' 'HGP-1' 'KPI-121' 'Loteprednol'
 'Loteprednol etabonate' 'P-5604']","[('DailyMed', array(['loteprednol%20etabonate'], dtype=object)), ('PubChem', array(['144205772', '170465195', '26758016'], dtype=object)), ('drugbank', array(['DB14596'], dtype=object)), ('chEBI', array(['31784'], dtype=object))]",,"{'rows': array(['EFO_1000811', 'EFO_0009536', 'MP_0001845', 'EFO_0007141',
       'EFO_0005752', 'EFO_1000906', 'MONDO_0005129', 'HP_0200026'],
      dtype=object), 'count': 8}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 3 investigational indications.
CHEMBL1200952,CN[C@@H](C)Cc1ccccc1.Cl,TWXDDNPPQUTEOV-FVGYRXGTSA-N,Small molecule,True,METHAMPHETAMINE HYDROCHLORIDE,1943.0,4.0,CHEMBL1201201,False,True,['Desoxyn' 'Methampex' 'Methamphetamine hydrochloride'],"['Desoxyephedrine hydrochloride' 'Metamfetamine hydrochloride'
 'Methamphetamine hcl' 'Methamphetamine hydrochloride'
 'Methamphetamine hydrochloride cii' 'Methylamfetamine hydrochloride'
 'NSC-169505']","[('DailyMed', array(['methamphetamine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206409'], dtype=object)), ('chEBI', array(['35340'], dtype=object))]",,"{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1943 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA.
CHEMBL1201575,,,Antibody,False,EFALIZUMAB,2003.0,4.0,,True,True,['Raptiva'],['ANTI-CD11A' 'Efalizumab' 'HU-1124' 'HU1124'],"[('DrugCentral', array(['4959'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/raptiva'],
      dtype=object)), ('Wikipedia', array(['Efalizumab'], dtype=object))]",,"{'rows': array(['EFO_0001365', 'EFO_1000710', 'EFO_0003778', 'MONDO_0019080',
       'EFO_0003884', 'EFO_0000699', 'EFO_0000274', 'MONDO_0005147',
       'EFO_0000540', 'EFO_0000676', 'EFO_0000685'], dtype=object), 'count': 11}","[ENSG00000005844,ENSG00000160255]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for immune system disease and psoriasis and has 9 investigational indications. It was withdrawn in at least one region.
CHEMBL1201638,,,Protein,False,INSULIN SUSP PROTAMINE ZINC PURIFIED PORK,1979.0,4.0,,False,True,['Protamine zinc and iletin ii (pork)'],['Insulin susp protamine zinc purified pork'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1979.
CHEMBL1230122,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21,KKKRKRMVJRHDMG-UHFFFAOYSA-N,Small molecule,False,R-1487,,1.0,,False,False,[],[],"[('PubChem', array(['103905625', '174007011'], dtype=object)), ('drugbank', array(['DB06518'], dtype=object))]",['CHEMBL1766582'],,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1358,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,VWUXBMIQPBEWFH-WCCTWKNTSA-N,Small molecule,False,FULVESTRANT,2002.0,4.0,,False,True,['Faslodex'],"['Faslodex' 'Fulvestrant' 'ICI 182,780' 'ICI-182780' 'NSC-759879'
 'ZD-9238' 'ZD9238']","[('DailyMed', array(['fulvestrant'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex'],
      dtype=object)), ('PubChem', array(['144204490', '144209802', '144213958', '170464917', '90341164'],
      dtype=object)), ('Wikipedia', array(['Fulvestrant'], dtype=object)), ('drugbank', array(['DB00947'], dtype=object)), ('chEBI', array(['31638'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0008528', 'MONDO_0011962', 'EFO_0003869',
       'EFO_0001075', 'MONDO_0007915', 'EFO_0007532', 'MONDO_0008903',
       'EFO_0000673', 'EFO_1001951', 'MONDO_0000088', 'EFO_0000432',
       'EFO_0002618', 'EFO_1000919', 'EFO_1000251', 'EFO_0000313',
       'EFO_0009708', 'MONDO_0018919', 'EFO_0000305', 'EFO_0000553',
       'EFO_0001361', 'Orphanet_145', 'EFO_0005952', 'EFO_0006318',
       'EFO_0000588', 'MONDO_0008315', 'EFO_0000616', 'EFO_1000294',
       'MONDO_0007254', 'EFO_1001512', 'MONDO_0008170', 'EFO_0000574',
       'EFO_0000181', 'EFO_0000702', 'EFO_1001331', 'EFO_0003060'],
      dtype=object), 'count': 36}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 30 investigational indications.
CHEMBL1770916,CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1,VFCRKLWBYMDAED-REWPJTCUSA-N,Small molecule,False,NIROGACESTAT,,3.0,,False,False,[],['Nirogacestat' 'PF 03084014' 'PF 3084014' 'PF-03084014' 'PF-3084014'],"[('drugbank', array(['DB12005'], dtype=object))]",['CHEMBL4298153'],"{'rows': array(['EFO_0001378', 'EFO_0003869', 'EFO_0000616', 'EFO_0002618',
       'EFO_0009907', 'EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 7}","[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL1879463,Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,JOGKUKXHTYWRGZ-UHFFFAOYSA-N,Small molecule,False,DACTOLISIB,,3.0,,False,False,[],"['BEZ-235' 'BEZ235' 'Bez-235' 'Dactolisib' 'NSC-751249' 'NVP-BEZ235'
 'NVP-BEZ235-NX' 'Nvp-bez-235' 'RTB-101' 'RTB101' 'Rtb101']","[('PubChem', array(['103905146', '124898663', '124898665', '99460876'], dtype=object)), ('drugbank', array(['DB11651'], dtype=object)), ('chEBI', array(['71952'], dtype=object))]",['CHEMBL3039506' 'CHEMBL1911126'],"{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0100096',
       'MONDO_0008315', 'EFO_1000045', 'EFO_0000544', 'MONDO_0002367',
       'MONDO_0011962', 'EFO_1000601'], dtype=object), 'count': 10}","[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL2062276,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13.O=C(O)C(O)C(O)C(=O)O,FWMLYVACGDQRFU-MBHUSPCXSA-N,Small molecule,False,LEVALLORPHAN TARTRATE,1982.0,4.0,CHEMBL1254682,False,True,['Lorfan'],['Levallorphan tartrate' 'Naloxiphane tartrate'],,,,"[ENSG00000112038,ENSG00000082556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL2105732,CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN.Cl,XNCDYJFPRPDERF-NQQJLSKUSA-N,Small molecule,True,LEVOMILNACIPRAN HYDROCHLORIDE,2013.0,4.0,CHEMBL99946,False,True,['Fetzima'],"['(1s,2r)-milnacipran hydrochloride' 'F 2695 HYDROCHLORIDE'
 'F-2695 HYDROCHLORIDE' 'F2695' 'F2695 HYDROCHLORIDE'
 'Levomilnacipran hydrochloride']","[('DailyMed', array(['levomilnacipran%20hydrochloride'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'EFO_0005687', 'HP_0002140', 'MONDO_0002009'],
      dtype=object), 'count': 4}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder and fibromyalgia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2108144,,,Antibody,False,TENELIXIMAB,,2.0,,False,False,[],['BMS-224819' 'Teneliximab'],,,,[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108324,,,Oligonucleotide,False,OBLIMERSEN,,2.0,,False,False,[],['Oblimersen'],"[('DrugCentral', array(['4792'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000171791],Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2364649,,,Antibody,True,MARGETUXIMAB,2020.0,4.0,,False,True,['Margenza'],['MGAH-22' 'MGAH22' 'Margetuximab' 'Margetuximab cmkb'],,,"{'rows': array(['EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 2}",[ENSG00000141736],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and breast cancer. This drug has a black box warning from the FDA.
CHEMBL238465,Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl,MBQYQLWSBRANKQ-IMTBSYHQSA-N,Small molecule,False,SOFINICLINE,,2.0,,False,False,[],['A-422894.0' 'ABT-894' 'Sofinicline'],"[('drugbank', array(['DB12527'], dtype=object))]",['CHEMBL2105654'],"{'rows': array(['EFO_0003888', 'EFO_0005762', 'EFO_0000401', 'MONDO_0001583'],
      dtype=object), 'count': 4}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL245019,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O,HZQDCMWJEBCWBR-UUOKFMHZSA-N,Small molecule,False,MIZORIBINE,,3.0,,False,False,[],['Bredinin' 'Mizoribine' 'NSC-289637'],"[('PubChem', array(['11532986', '170466027', '50106568', '50106569', '90340602'],
      dtype=object)), ('drugbank', array(['DB12617'], dtype=object))]",,"{'rows': array(['EFO_0000685', 'EFO_0005761', 'EFO_0004255'], dtype=object), 'count': 3}","[ENSG00000106348,ENSG00000178035,ENSG00000163655]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL316561,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1,DGMKFQYCZXERLX-UHFFFAOYSA-N,Small molecule,False,PROGLUMIDE,,4.0,,True,True,['Milid'],"['Binoside' 'CR-242' 'Dl-proglumide' 'Gastrotopic' 'Midelid' 'NSC-757841'
 'Proglumide' 'Promid' 'Ulcutin' 'W-5219' 'Xylamide']","[('PubChem', array(['144204108', '170465774', '26747589', '50106676', '56463359',
       '90341320'], dtype=object)), ('Wikipedia', array(['Proglumide'], dtype=object)), ('drugbank', array(['DB13431'], dtype=object)), ('chEBI', array(['32058'], dtype=object))]",['CHEMBL1345380'],"{'rows': array(['EFO_0002618', 'EFO_0003948', 'HP_0004398', 'EFO_0001422',
       'EFO_1001249'], dtype=object), 'count': 5}","[ENSG00000110148,ENSG00000163394]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastroesophageal reflux disease and peptic ulcer and has 3 investigational indications. It was withdrawn in at least one region.
CHEMBL3301621,c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1,HKHCSWPSUSWGLI-CABCVRRESA-N,Small molecule,False,CENTANAFADINE,,3.0,,False,False,[],"['Centanafadine' 'DOV 216,419' 'DOV 216,419 free base' 'DOV-216419'
 'EB-1020' 'EB-1020 free base']","[('drugbank', array(['DB14841'], dtype=object))]",['CHEMBL3301615'],"{'rows': array(['EFO_0004319', 'MONDO_0002009', 'EFO_0003888', 'EFO_0003888',
       'EFO_0005203'], dtype=object), 'count': 5}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3647536,CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21,PTTQXDBPTFOCMT-UHFFFAOYSA-N,Small molecule,False,DARIGABAT,,2.0,,False,False,[],['CVL-865' 'Cvl-865' 'Darigabat' 'PF-06372865' 'Pf-06372865'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DARIGABAT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004262', 'HP_0001250', 'HP_0001250', 'HP_0003419',
       'EFO_1001892', 'EFO_1001146'], dtype=object), 'count': 6}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL3989944,COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O,YIMYDTCOUQIDMT-SNAWJCMRSA-N,Small molecule,False,DIROXIMEL FUMARATE,2019.0,4.0,,False,True,['Vumerity'],"['ALKS 8700' 'ALKS-8700' 'ALKS8700' 'Alks 8700' 'BIIB-098' 'BIIB098'
 'Diroximel fumarate' 'RDC-5108' 'RDC5108']","[('DailyMed', array(['diroximel%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vumerity'],
      dtype=object)), ('drugbank', array(['DB14783'], dtype=object))]",,"{'rows': array(['EFO_0000540', 'EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 3}",[ENSG00000079999],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved indications.
CHEMBL4297601,COc1cc(F)c(C(C)C)cc1C1=C(CN2C(=O)O[C@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H]2C)CC(C)(C)CC1,GBHPDJQHZADVAA-SOKVYYICSA-N,Small molecule,False,ROCACETRAPIB,,2.0,,False,False,[],['CKD-519' 'Ckd-519' 'Rocacetrapib'],"[('drugbank', array(['DB15437'], dtype=object))]",,"{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}",[ENSG00000087237],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297686,,,Protein,False,IZOKIBEP,,3.0,,False,False,[],['ABY-035' 'Aby-035' 'Aby-035/afo2' 'Aby035' 'IMG-020' 'Izokibep'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IZOKIBEP/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001231', 'EFO_0000676', 'EFO_1000710', 'EFO_0003898',
       'EFO_0003778'], dtype=object), 'count': 5}",[ENSG00000112115],Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297995,,,Unknown,False,BAZLITORAN,,2.0,,False,False,[],['Bazlitoran' 'IMO-8400' 'Imo-8400'],,,"{'rows': array(['EFO_0009441', 'EFO_0000403', 'EFO_0000676', 'EFO_0000398'],
      dtype=object), 'count': 4}","[ENSG00000101916,ENSG00000196664,ENSG00000239732]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL429876,CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C,AMLYAMJWYAIXIA-VWNVYAMZSA-N,Protein,False,CILENGITIDE,,3.0,,False,False,[],['Cilengitide' 'EMD 121974' 'EMD-12192' 'EMD-121974'],"[('Wikipedia', array(['Cilengitide'], dtype=object)), ('drugbank', array(['DB11890'], dtype=object))]",,"{'rows': array(['EFO_0006861', 'MONDO_0008315', 'EFO_0000198', 'EFO_0000756',
       'EFO_1000026', 'MONDO_0021633', 'EFO_0000519', 'EFO_0002428',
       'EFO_1001465', 'EFO_0003086', 'EFO_0003060', 'EFO_0000326',
       'EFO_0001378', 'EFO_0002499', 'EFO_0000707', 'EFO_0002501',
       'EFO_0000565', 'EFO_1000158', 'EFO_0000691', 'EFO_0000616'],
      dtype=object), 'count': 20}","[ENSG00000259207,ENSG00000138448,ENSG00000082781]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications.
CHEMBL4650284,O=C1Nc2cc3[nH]nc(-c4ccncc4)c3cc2CN1Cc1ccccc1,ODIUJYZERXVGEI-UHFFFAOYSA-N,Small molecule,False,KO-947,,1.0,,False,False,[],['KO-947' 'Ko-947'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000102882,ENSG00000100030]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4802157,Cc1cc(F)ccc1-c1cc(N2C[C@H]3COCCN3C[C@H]2CO)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,DWRIJNIPBUFCQS-DQEYMECFSA-N,Small molecule,False,ELINZANETANT,,3.0,,False,False,[],['BAY-3427080' 'BAY3427080' 'Bay3427080' 'Elinzanetant' 'NT-814'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELINZANETANT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['GO_0042697', 'HP_0031217', 'EFO_0010702', 'MONDO_0007079'],
      dtype=object), 'count': 4}","[ENSG00000115353,ENSG00000169836]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL781,OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21,ZPXSCAKFGYXMGA-UHFFFAOYSA-N,Small molecule,False,MAZINDOL,1973.0,4.0,,False,True,['Mazanor' 'Sanorex' 'Teronac'],"['42-548' 'AN-448' 'Magrilon' 'Mazildene' 'Mazindol' 'Mazindol civ'
 'SAH-42548' 'Terenac']","[('Wikipedia', array(['Mazindol'], dtype=object)), ('drugbank', array(['DB00579'], dtype=object))]",,"{'rows': array(['EFO_0002610', 'MONDO_0016158', 'EFO_0003888', 'EFO_0001073'],
      dtype=object), 'count': 4}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for obesity and has 3 investigational indications.
CHEMBL1046,NCCCCCC(=O)O,SLXKOJJOQWFEFD-UHFFFAOYSA-N,Small molecule,False,AMINOCAPROIC ACID,1964.0,4.0,,False,True,['Amicar' 'Aminocaproic' 'Aminocaproic acid' 'Epsikapron'],"['.epsilon.-aminocaproic acid' '177 J.D' '177 J.D.' '177 JD' '177-JD'
 '6-aminocaproic acid' 'Aminocaproic acid' 'CL 10304' 'CL-10304' 'CY-116'
 'EACA' 'Epsilcapramin' 'Epsilon-aminocaproic acid'
 'Hexanoic acid, 6-amino-' 'NSC-26154' 'NSC-400230']","[('DailyMed', array(['aminocaproic%20acid'], dtype=object)), ('PubChem', array(['11110778', '11110779', '144203632', '170465057', '174007004',
       '26747439', '26747440', '50105811', '50105812', '57260392',
       '85230919', '90341441'], dtype=object)), ('Wikipedia', array(['Aminocaproic_acid'], dtype=object)), ('drugbank', array(['DB00513'], dtype=object)), ('chEBI', array(['16586'], dtype=object))]",,"{'rows': array(['EFO_0005775', 'MP_0001914', 'EFO_1000760', 'MONDO_0015469',
       'MP_0001845'], dtype=object), 'count': 5}","[ENSG00000104368,ENSG00000122194]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for hemorrhage and has 4 investigational indications.
CHEMBL1200440,Cc1cccc(C)c1NC(=O)C1CCCCN1C.Cl,RETIMRUQNCDCQB-UHFFFAOYSA-N,Small molecule,False,MEPIVACAINE HYDROCHLORIDE,1960.0,4.0,CHEMBL1087,False,True,"['Arestocaine hydrochloride' 'Carbocaine' 'Isocaine hydrochloride'
 'Mepivacaine hydrochloride' 'Polocaine' 'Polocaine-mpf' 'Scandicaine'
 'Scandonest' 'Scandonest plain']","['Mepivacaine hcl' 'Mepivacaine hydrochloride'
 'Mepivacaine monohydrochloride' 'NSC-758674' 'Optocain' 'Scandicain']","[('DailyMed', array(['mepivacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204977', '26748921', '56424124'], dtype=object)), ('chEBI', array(['6760'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1237122,CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O,DLJKPYFALUEJCK-IIELGFQLSA-N,Small molecule,True,CARBOPROST,1979.0,4.0,,False,True,['Hemabate'],"['(15s)-15-methyl-pgf2.alpha.' '15-methyl-pgf2.alpha.'
 '15-methylprostaglandin f2.alpha.' 'Carboprost' 'U-32,921' 'U-32921']",,['CHEMBL1237105'],"{'rows': array(['EFO_0000731', 'EFO_0009579', 'MP_0001914'], dtype=object), 'count': 3}",[ENSG00000122420],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for postpartum hemorrhage and hemorrhage and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1256,FC(F)OC(Cl)C(F)(F)F,PIWKPBJCKXDKJR-UHFFFAOYSA-N,Small molecule,False,ISOFLURANE,1979.0,4.0,,False,True,['Aerrane' 'Forane' 'Isoflurane'],['COMPOUND 469' 'COMPOUND-469' 'Isoflurane'],"[('DailyMed', array(['isoflurane'], dtype=object)), ('PubChem', array(['144206238', '144208029', '50125772'], dtype=object)), ('Wikipedia', array(['Isoflurane'], dtype=object)), ('drugbank', array(['DB00753'], dtype=object)), ('chEBI', array(['6015'], dtype=object))]",,"{'rows': array(['EFO_0005611', 'HP_0000023', 'EFO_0009686', 'MONDO_0100096',
       'EFO_0000713', 'EFO_0003777'], dtype=object), 'count': 6}","[ENSG00000100433,ENSG00000169427,ENSG00000082482,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000171303,ENSG00000145888,ENSG00000109738,ENSG00000186795]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 6 investigational indications.
CHEMBL1274,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,XWXYUMMDTVBTOU-UHFFFAOYSA-N,Small molecule,True,NILUTAMIDE,1996.0,4.0,,False,True,['Anadron' 'Nilandron' 'Nilutamide'],['NSC-758683' 'Nilutamide' 'RU 23908' 'RU-23908'],"[('DailyMed', array(['nilutamide'], dtype=object)), ('PubChem', array(['104171203', '11111555', '11111556', '11114201', '124880925',
       '124880926', '144203764', '144211906', '170465021', '174007285',
       '26747174', '26747175', '26752242', '50104947', '50104948',
       '50104949', '50104950', '56463082', '85231160', '90341288'],
      dtype=object)), ('Wikipedia', array(['Nilutamide'], dtype=object)), ('drugbank', array(['DB00665'], dtype=object)), ('chEBI', array(['7573'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'MONDO_0008315', 'EFO_0000196', 'EFO_0000673',
       'EFO_0000616'], dtype=object), 'count': 5}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1532,CCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1,AGMMTXLNIQSRCG-UHFFFAOYSA-N,Small molecule,False,QUINETHAZONE,1963.0,4.0,,False,True,['Hydromox'],['Chinethazone' 'NSC-759904' 'Quinethazone'],"[('PubChem', array(['144203917', '170465167', '56463176'], dtype=object)), ('Wikipedia', array(['Quinethazone'], dtype=object)), ('drugbank', array(['DB01325'], dtype=object)), ('chEBI', array(['8717'], dtype=object))]",,"{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}",[ENSG00000070915],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1963 and is indicated for cardiovascular disease.
CHEMBL1651956,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(CC)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,OLROWHGDTNFZBH-XEMWPYQTSA-N,Protein,False,ALISPORIVIR,,3.0,,False,False,[],"['(d-meala)3-(etval)4-csa' 'Alisporivir' 'DEB 025' 'DEB-025' 'DEB025'
 'DEBIO 025' 'DEBIO-025' 'DEBIO025' 'Debio 025' 'UNIL 025' 'UNIL-025'
 'UNIL025']","[('Wikipedia', array(['Alisporivir'], dtype=object)), ('drugbank', array(['DB12139'], dtype=object))]",,"{'rows': array(['EFO_0001421', 'EFO_0004220', 'MONDO_0100096', 'EFO_0003884',
       'EFO_0003047'], dtype=object), 'count': 5}",[ENSG00000196262],Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL1683590,C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C,UFNVPOGXISZXJD-JBQZKEIOSA-N,Small molecule,False,ERIBULIN,2010.0,4.0,,False,True,['Halaven'],['ER-086526' 'Eribulin'],"[('drugbank', array(['DB08871'], dtype=object)), ('chEBI', array(['63587'], dtype=object))]",['CHEMBL1683544' 'CHEMBL3526882'],"{'rows': array(['MONDO_0001187', 'EFO_0000569', 'MONDO_0004992', 'EFO_0008528',
       'MONDO_0004669', 'EFO_0006859', 'Orphanet_145', 'EFO_1001968',
       'EFO_0000681', 'EFO_0002617', 'MONDO_0004192', 'EFO_0000691',
       'EFO_1000251', 'MONDO_0015523', 'MONDO_0002974', 'EFO_0000389',
       'EFO_0000305', 'MONDO_0007254', 'EFO_0005537', 'MONDO_0007254',
       'EFO_0001075', 'MONDO_0004992', 'EFO_0003968', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000574', 'EFO_0000637', 'EFO_1000984',
       'EFO_0000616', 'EFO_0000673', 'EFO_0006861', 'MONDO_0021632',
       'MONDO_0016238', 'EFO_1000613', 'EFO_0000305', 'EFO_0003869',
       'EFO_0003060', 'EFO_0005537', 'MONDO_0008315'], dtype=object), 'count': 39}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 33 investigational indications.
CHEMBL1938400,CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,VGEXRDWWPSGZDH-UHFFFAOYSA-N,Small molecule,False,PF-03715455,,2.0,,False,False,[],['PF-03715455' 'Pf-03715455' 'Pf-3715455'],"[('drugbank', array(['DB12138'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1963684,,,Protein,True,PEGINESATIDE ACETATE,2012.0,4.0,,True,True,['Omontys' 'Omontys preservative free'],['AF37702' 'Hematide acetate' 'Peginesatide acetate'],,,,[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV that was first approved in 2012. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL2109300,,,Antibody,False,GSK933776,,2.0,,False,False,[],['GSK933776' 'Gsk933776'],,,"{'rows': array(['EFO_1001492', 'MONDO_0004975'], dtype=object), 'count': 2}",[ENSG00000142192],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3040440,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F,IGUBBWJDMLCRIK-UHFFFAOYSA-N,Small molecule,False,VS-4718,,1.0,,False,False,[],['PND-1186' 'SR-2516' 'VS-4718' 'Vs-4718'],"[('drugbank', array(['DB15273'], dtype=object))]",['CHEMBL2430358'],"{'rows': array(['EFO_0000094', 'EFO_0000222', 'EFO_0002618'], dtype=object), 'count': 3}",[ENSG00000169398],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3137309,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,LQBVNQSMGBZMKD-UHFFFAOYSA-N,Small molecule,False,VENETOCLAX,2016.0,4.0,,False,True,['Venclexta' 'Venclyxto'],['ABT-199' 'GDC-0199' 'RG-7601' 'RG7601' 'Venetoclax'],"[('DailyMed', array(['venetoclax'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto'],
      dtype=object)), ('drugbank', array(['DB11581'], dtype=object))]",,"{'rows': array(['MONDO_0001023', 'EFO_0000616', 'EFO_0000224', 'EFO_0000574',
       'EFO_1000560', 'MONDO_0015540', 'EFO_0000221', 'MONDO_0007254',
       'EFO_0000198', 'EFO_0003032', 'EFO_1001469', 'EFO_0002913',
       'EFO_0009441', 'EFO_0000095', 'EFO_0004251', 'EFO_0000096',
       'EFO_0000702', 'EFO_0000209', 'MONDO_0004992', 'EFO_0000196',
       'MONDO_0044881', 'EFO_0000222', 'EFO_0005952', 'EFO_0004289',
       'EFO_0000565', 'EFO_0000339', 'EFO_0001378', 'EFO_0000231',
       'MONDO_0019438', 'MONDO_0044917', 'EFO_0003086', 'EFO_0000094',
       'EFO_0003869', 'MONDO_0000870', 'MONDO_0000873', 'EFO_0000220',
       'EFO_0000180', 'MONDO_0018906', 'EFO_0003060', 'EFO_0000309',
       'EFO_1000131', 'MONDO_0019460', 'EFO_0000403'], dtype=object), 'count': 43}",[ENSG00000171791],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 40 investigational indications.
CHEMBL3137343,,,Antibody,False,PEMBROLIZUMAB,2014.0,4.0,,False,True,['Keytruda'],"['KEYLYNK-010 COMPONENT PEMBROLIZUMAB' 'Lambrolizumab' 'MK-3475'
 'PEMBROLIZUMAB COMPONENT OF KEYLYNK-010' 'Pembrolizumab' 'SCH-900475']","[('DailyMed', array(['pembrolizumab'], dtype=object)), ('DrugCentral', array(['4924'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda'],
      dtype=object))]",,"{'rows': array(['EFO_1001471', 'EFO_0000588', 'EFO_0009708', 'EFO_0000673',
       'EFO_0000707', 'MONDO_0003660', 'EFO_0000181', 'EFO_0005540',
       'EFO_1001951', 'EFO_1000251', 'EFO_0000519', 'MONDO_0018531',
       'MONDO_0005411', 'EFO_0000183', 'EFO_0000094', 'EFO_0003851',
       'MONDO_0002363', 'MONDO_0002108', 'MONDO_0002120', 'MONDO_0003659',
       'MONDO_0021148', 'EFO_0000305', 'EFO_1000613', 'MONDO_0021063',
       'EFO_1000601', 'EFO_1001469', 'EFO_0000681', 'EFO_0000571',
       'EFO_0000294', 'EFO_0000558', 'MONDO_0002367', 'MONDO_0011962',
       'EFO_0003893', 'EFO_0005543', 'EFO_0001416', 'EFO_0000182',
       'EFO_1000465', 'EFO_0000228', 'MONDO_0021117', 'EFO_1000581',
       'MONDO_0015277', 'EFO_0007541', 'EFO_0005537', 'EFO_0003968',
       'EFO_0000403', 'EFO_0003073', 'EFO_0000095', 'MONDO_0021310',
       'EFO_0000222', 'EFO_0000231', 'EFO_0000708', 'EFO_0000760',
       'EFO_0002913', 'MONDO_0002715', 'EFO_0000621', 'MONDO_0001528',
       'MONDO_0003199', 'EFO_1000785', 'EFO_0000574', 'EFO_0000764',
       'EFO_0003869', 'EFO_1000984', 'MONDO_0020634', 'MONDO_0004180',
       'EFO_0009259', 'MONDO_0001879', 'MONDO_0016642', 'MONDO_0002158',
       'EFO_0009441', 'Orphanet_145', 'EFO_0005952', 'MONDO_0002038',
       'EFO_0001061', 'EFO_1001968', 'EFO_0002617', 'MONDO_0004992',
       'EFO_0006859', 'MONDO_0002898', 'EFO_0000717', 'EFO_0000313',
       'EFO_1001931', 'MONDO_0100342', 'MONDO_0100096', 'MONDO_0024474',
       'EFO_0004284', 'EFO_0000096', 'EFO_0001378', 'EFO_0001663',
       'MONDO_0008315', 'EFO_0000691', 'EFO_0000365', 'EFO_0002921',
       'EFO_0000432', 'MONDO_0008170', 'EFO_1001513', 'HP_0002745',
       'MONDO_0017387', 'MONDO_0000521', 'MONDO_0018906', 'MONDO_0004658',
       'EFO_0001376', 'EFO_0000640', 'MONDO_0044881', 'EFO_0005950',
       'EFO_0002499', 'EFO_0003891', 'EFO_0000272', 'MONDO_0007576',
       'EFO_0007532', 'EFO_1001465', 'EFO_0000174', 'EFO_0001668',
       'MONDO_0004700', 'EFO_0003833', 'MONDO_0001657', 'EFO_0000565',
       'EFO_0003863', 'EFO_0000770', 'EFO_0003060', 'EFO_0002618',
       'MONDO_0000430', 'MONDO_0021251', 'EFO_0004230', 'MONDO_0011719',
       'MONDO_0004986', 'EFO_0000702', 'EFO_0006861', 'EFO_1001901',
       'EFO_0000196', 'EFO_0002918', 'EFO_0001642', 'EFO_1000576',
       'EFO_1000657', 'EFO_0000637', 'EFO_0004142', 'MONDO_0005184',
       'MONDO_0001056', 'EFO_1001512', 'EFO_0001071', 'EFO_0000220',
       'EFO_0000756', 'MONDO_0002974', 'EFO_0006352', 'EFO_0004252',
       'EFO_0000349', 'MONDO_0019472', 'EFO_0004198', 'EFO_0000616',
       'EFO_0002916', 'EFO_0003897', 'EFO_0004289', 'EFO_0005221',
       'MONDO_0009348', 'MONDO_0005341', 'EFO_0000389', 'EFO_0009709',
       'MONDO_0043243', 'EFO_0000503', 'EFO_1001100', 'MONDO_0018944',
       'EFO_0002892', 'EFO_0005922', 'EFO_1000796', 'EFO_1001051',
       'MONDO_0005575', 'EFO_0003868', 'MONDO_0003060', 'MONDO_0002087',
       'EFO_0000198', 'EFO_0008528', 'MONDO_0001187', 'MONDO_0021054',
       'EFO_0007143', 'EFO_0004243', 'MONDO_0002928', 'EFO_1000595',
       'MONDO_0007254', 'EFO_0001075', 'EFO_0003860', 'EFO_1001012',
       'MONDO_0044926', 'MONDO_0024503', 'MONDO_0008903'], dtype=object), 'count': 183}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 22 approved and 161 investigational indications.
CHEMBL3265032,c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,XSMSNFMDVXXHGJ-UHFFFAOYSA-N,Small molecule,False,ENTOSPLETINIB,,3.0,,False,False,[],['Entospletinib' 'GS-9973' 'SYK INHIBITOR GS-9973'],"[('drugbank', array(['DB12121'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'MONDO_0018906', 'EFO_1001469', 'EFO_0005952',
       'EFO_0000095', 'EFO_0000220', 'EFO_0000403', 'MONDO_0004992'],
      dtype=object), 'count': 8}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL3544960,NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1,IIRWNGPLJQXWFJ-KRWDZBQOSA-N,Small molecule,False,AT-13148,,1.0,,False,False,[],['AT13148' 'At-13148'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000162889,ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545091,,,Small molecule,False,XEN403,,1.0,,False,False,[],['Xen403'],,,,[ENSG00000169432],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545232,Cc1ccc(-c2ccc(OC3CN4CCC3CC4)cn2)cc1,NPDLTEZXGWRMLQ-UHFFFAOYSA-N,Small molecule,False,AQW051,,2.0,,False,False,[],['Aqw051'],,,"{'rows': array(['MONDO_0005090', 'HP_0100543', 'MONDO_0004975'], dtype=object), 'count': 3}",[ENSG00000175344],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545357,,,Small molecule,False,JTE-151,,1.0,,False,False,[],['Jte-151'],,,,[ENSG00000143365],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3694769,Nc1nc(-n2cccn2)nc(-n2cccn2)c1Br,ATFXVNUWQOXRRU-UHFFFAOYSA-N,Small molecule,False,PBF-509,,1.0,,False,False,[],['Pbf-509'],,,"{'rows': array(['MONDO_0005180', 'EFO_0003060'], dtype=object), 'count': 2}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3833307,,,Antibody,False,SATRALIZUMAB,2020.0,4.0,,False,True,['Enspryng'],"['RG6168' 'SA-237' 'SA237' 'Sapelizumab' 'Satralizumab'
 'Satralizumab mwge' 'Satralizumab-mwge']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/enspryng'],
      dtype=object))]",,"{'rows': array(['EFO_0000540', 'EFO_0004991', 'EFO_0004256', 'EFO_0001361',
       'EFO_0007332'], dtype=object), 'count': 5}","[ENSG00000160712,ENSG00000134352]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for immune system disease and neuromyelitis optica and has 3 investigational indications.
CHEMBL3990031,,,Antibody,False,ROSMANTUZUMAB,,3.0,,False,False,[],['OMP-131R10' 'Rosmantuzumab'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000146374,ENSG00000205213]",Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL4072833,C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,QUIWHXQETADMGN-UHFFFAOYSA-N,Small molecule,False,EVOBRUTINIB,,3.0,,False,False,[],['Evobrutinib' 'M-2951' 'M2951' 'Msc-2364447c' 'Msc2364447c'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EVOBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15170'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'EFO_0000685', 'MONDO_0005301', 'EFO_0003086',
       'MONDO_0007915'], dtype=object), 'count': 5}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL428690,CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,BIIVYFLTOXDAOV-YVEFUNNKSA-N,Small molecule,False,ALVOCIDIB,,3.0,,False,False,[],"['Alvocidib' 'Alvocidib freebase' 'Flavopiridol' 'HL 275' 'HL-275'
 'HMR 1275' 'HMR-1275' 'L 86 8275' 'L-868275' 'L86-8275' 'MDL 107,826A'
 'MDL-107826A' 'NSC-649890']","[('Wikipedia', array(['Alvocidib'], dtype=object)), ('drugbank', array(['DB03496'], dtype=object))]",['CHEMBL2105698'],"{'rows': array(['EFO_0001378', 'MONDO_0007254', 'EFO_1001469', 'EFO_0009441',
       'EFO_0000095', 'EFO_0000222', 'MONDO_0018906', 'EFO_0000616',
       'EFO_0000222', 'EFO_0000691', 'EFO_0000191', 'EFO_0000565',
       'EFO_0006861', 'MONDO_0008315', 'MONDO_0001023', 'EFO_0001642',
       'MONDO_0007576', 'MONDO_0002691', 'EFO_0000403', 'EFO_0000389',
       'EFO_0001378', 'EFO_0000095', 'EFO_0000574', 'MONDO_0001023',
       'MONDO_0002367', 'MONDO_0011962'], dtype=object), 'count': 26}","[ENSG00000123374,ENSG00000170312,ENSG00000136807,ENSG00000105810,ENSG00000135446,ENSG00000134058]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.
CHEMBL4297268,COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,AHXICHPPXIGCBN-GPWPDEGDSA-N,Small molecule,False,BMS-275183,,2.0,,False,False,[],['Bms 275183' 'Bms-275183'],"[('drugbank', array(['DB12144'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL589583,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1,WOUOLAUOZXOLJQ-MBSDFSHPSA-N,Small molecule,False,DELAPRIL,,3.0,,False,False,[],['Delapril'],"[('drugbank', array(['DB13312'], dtype=object))]",['CHEMBL2106126'],"{'rows': array(['EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 2}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL667,CC(=O)OCC[N+](C)(C)C,OIPILFWXSMYKGL-UHFFFAOYSA-N,Small molecule,False,ACETYLCHOLINE,1973.0,4.0,,False,True,[],['Acetylcholine'],"[('PubChem', array(['124883320', '26756572'], dtype=object)), ('Wikipedia', array(['Acetylcholine'], dtype=object)), ('drugbank', array(['DB03128'], dtype=object)), ('chEBI', array(['15355'], dtype=object))]",['CHEMBL1184' 'CHEMBL1736587' 'CHEMBL1427664' 'CHEMBL60457'],"{'rows': array(['EFO_0004272', 'EFO_0000764', 'MONDO_0005148', 'HP_0000616',
       'MONDO_0005041', 'MP_0001845', 'MONDO_0011382', 'EFO_0000668',
       'EFO_0000556', 'EFO_0001645', 'MONDO_0005129'], dtype=object), 'count': 11}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 8 investigational indications.
CHEMBL1096896,CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NCC(c4ccccc4)c4ccccc4)nc(C(=O)NCCNC(=O)NC4CCN(c5ccccn5)CC4)nc32)[C@H](O)[C@@H]1O,ZOTHAEBAWXWVID-HXEFRTELSA-N,Small molecule,False,UK432097,,2.0,,False,False,[],['Uk432097'],"[('drugbank', array(['DB12691'], dtype=object))]",,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1201190,Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,PGLIUCLTXOYQMV-GHVWMZMZSA-N,Small molecule,False,LEVOCETIRIZINE DIHYDROCHLORIDE,2007.0,4.0,CHEMBL1201191,False,True,"['Levocetirizine dihydrochloride' 'Xusal' 'Xyzal' 'Xyzal allergy 24hr'
 'Xyzall']","['Cetirizine (r)-form dihydrochloride' 'Cetirizine hydrochloride (r)-'
 'Levocetirizine dihydrochloride' 'Levocetirizine hydrochloride'
 'Levocetirizine monohydrochloride' 'NSC-758898' 'UCB 28556' 'UCB-28556']","[('DailyMed', array(['levocetirizine%20dihydrochloride'], dtype=object))]",,"{'rows': array(['EFO_1001417', 'EFO_0008521', 'EFO_0000701', 'EFO_0005531',
       'HP_0012735', 'EFO_0003956', 'Orphanet_79292'], dtype=object), 'count': 7}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 3 investigational indications.
CHEMBL1201263,CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,FWFVLWGEFDIZMJ-FOMYWIRZSA-N,Small molecule,False,HYDROCORTAMATE,1956.0,4.0,,False,True,[],['Hydrocortamate'],"[('PubChem', array(['170465314'], dtype=object)), ('drugbank', array(['DB00769'], dtype=object)), ('chEBI', array(['50851'], dtype=object))]",['CHEMBL1200635'],,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL1201550,,,Protein,True,DENILEUKIN DIFTITOX,1999.0,4.0,,False,True,['Ontak'],"['DAB(SUB 389)IL2' 'DAB-389IL2' 'DAB389 IL2' 'DAB389IL2' 'Denileukin'
 'Denileukin diftitox' 'E-7272' 'E-7777' 'E7272' 'E7777' 'LY-335348'
 'LY335348']","[('DrugCentral', array(['5087'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DENILEUKIN%20DIFTITOX/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Denileukin_diftitox', 'Resimmune'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'MONDO_0002367', 'EFO_0000756', 'EFO_0002913',
       'EFO_1000043', 'EFO_0000211', 'EFO_0000222', 'EFO_1000251',
       'EFO_0000389', 'EFO_0005952', 'EFO_0002618', 'EFO_0000095',
       'EFO_0000209', 'EFO_0000466', 'MONDO_0002087', 'EFO_0001378',
       'MONDO_0008170', 'EFO_0000565', 'EFO_0000616', 'MONDO_0013730',
       'MONDO_0002158', 'EFO_0006861'], dtype=object), 'count': 22}","[ENSG00000167658,ENSG00000134460,ENSG00000147168,ENSG00000100385]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for cutaneous t-cell lymphoma and neoplasm and has 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201621,,,Protein,False,SOMATROPIN,1976.0,4.0,,False,True,"['Accretropin' 'Asellacrin 10' 'Asellacrin 2' 'Bio-tropin' 'Crescormon'
 'Genotropin' 'Genotropin [Rdna Origin]' 'Genotropin goquick'
 'Genotropin kabipen' 'Genotropin kabiquick' 'Genotropin kabivial'
 'Genotropin miniquick' 'Genotropin preservative free' 'Humatrope'
 'Humatropen' 'Norditropin' 'Norditropin flexpro' 'Norditropin nordiflex'
 'Norditropin penset' 'Norditropin simplexx' 'Nutropin' 'Nutropin aq'
 'Nutropin aq nuspin' 'Nutropin aq pen' 'Nutropin depot' 'Nutropinaq'
 'Omnitrope' 'Omnitrope pen 10' 'Omnitrope pen 5' 'Omnitrope surepal 10'
 'Omnitrope surepal 15' 'Omnitrope surepal 5' 'Saizen' 'Saizen click.easy'
 'Saizen easyject' 'Serostim' 'Serostim lq' 'Tev-Tropin' 'Valtropin'
 'Zomacton' 'Zorbtive']","['CB-311' 'DA-3002' 'Genotonorm' 'Growth hormone' 'Growth hormone (human)'
 'Hsb-hgh' 'Human growth hormone' 'Hypertropin' 'LY-137998' 'LY137998'
 'R-hgh' 'Recombinant human growth hormone' 'Rh-polypeptide-7'
 'Somatotropin' 'Somatotropin (human)' 'Somatotropin human'
 'Somatotropin human growth hormone' 'Somatropin'
 'Somatropin (rdna origin)' 'Somatropin biopartners'
 'Somatropin for injection' 'Tev-tropin' 'Tevtropin' 'Vexxon-hgh']","[('DailyMed', array(['somatropin'], dtype=object)), ('DrugCentral', array(['4848'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope'],
      dtype=object))]",,"{'rows': array(['MONDO_0019019', 'Orphanet_665', 'EFO_0003944', 'EFO_0000319',
       'EFO_0001379', 'EFO_0001380', 'EFO_0000400', 'EFO_0000180',
       'HP_0100543', 'EFO_0700081', 'MONDO_0010674', 'MONDO_0009061',
       'EFO_0000495', 'Orphanet_269', 'MONDO_0015183', 'HP_0001510',
       'MONDO_0007078', 'EFO_0000545', 'MONDO_0008300', 'EFO_0001073',
       'EFO_0000764', 'EFO_0001379', 'MONDO_0043510', 'EFO_0003884',
       'EFO_1001434', 'MONDO_0007793', 'MONDO_0001967', 'EFO_0009607',
       'HP_0004326', 'MONDO_0015514', 'EFO_0008560', 'EFO_0007312',
       'EFO_1001919', 'MONDO_0019499', 'EFO_0001422', 'EFO_0009516',
       'MONDO_0009661', 'EFO_1000653', 'EFO_1001109', 'EFO_0003095',
       'EFO_0003144', 'MONDO_0004976', 'EFO_0000384', 'EFO_0004616',
       'MONDO_0018997', 'EFO_0008525'], dtype=object), 'count': 46}",[ENSG00000112964],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 14 approved and 32 investigational indications.
CHEMBL1201670,,,Protein,False,SARGRAMOSTIM,1991.0,4.0,,False,True,['Leukine'],"['B1 61.012' 'B1-61012'
 'Granulocyte-macrophage colony-stimulating factor sargramostim'
 'RHU GM-CSF' 'RHU-GM-CSF' 'Sargramostim' 'Sargramostim rdna']","[('DailyMed', array(['sargramostim'], dtype=object)), ('DrugCentral', array(['5025'], dtype=object)), ('Wikipedia', array(['Sargramostim'], dtype=object))]",,"{'rows': array(['EFO_1001469', 'EFO_0000199', 'EFO_0006475', 'EFO_1001465',
       'HP_0001945', 'EFO_0003869', 'EFO_0003060', 'MONDO_0008315',
       'EFO_0000673', 'EFO_0000756', 'MONDO_0018906', 'EFO_0004142',
       'EFO_0000681', 'EFO_0001378', 'EFO_1000657', 'MONDO_0005180',
       'EFO_0004239', 'EFO_0000198', 'MONDO_0002158', 'EFO_1000251',
       'EFO_0001075', 'EFO_0000313', 'MONDO_0015667', 'MONDO_0002087',
       'EFO_0002618', 'EFO_0005543', 'EFO_0000685', 'EFO_0000095',
       'EFO_0000389', 'MONDO_0004975', 'MONDO_0021063', 'MONDO_0001475',
       'EFO_1001042', 'EFO_0000649', 'EFO_0002428', 'MONDO_0004643',
       'MONDO_0044881', 'MONDO_0004992', 'EFO_0000502', 'EFO_0004265',
       'MONDO_0007254', 'EFO_0000565', 'EFO_0000574', 'EFO_1001951',
       'EFO_0000183', 'EFO_0003811', 'EFO_0000309', 'EFO_0001663',
       'EFO_0000339', 'MONDO_0007576', 'EFO_0000621', 'MONDO_0005411',
       'EFO_0003086', 'MONDO_0008170', 'MONDO_0005575', 'EFO_0000384',
       'EFO_0000180', 'EFO_0000544', 'EFO_1000043', 'HP_0100806',
       'EFO_0000220', 'EFO_0000616', 'EFO_0000403', 'EFO_0005046',
       'EFO_1000984', 'EFO_0003921', 'EFO_0002918', 'MONDO_0100096',
       'EFO_0000228', 'EFO_0004991', 'EFO_0005537', 'EFO_0002617',
       'EFO_0000519', 'MONDO_0001437', 'EFO_0000764', 'EFO_1001302',
       'EFO_0000637', 'EFO_0000694', 'EFO_0000691', 'MONDO_0001187',
       'MONDO_0002691', 'EFO_0009708', 'MONDO_0100130', 'Orphanet_264675',
       'MONDO_0013730', 'MONDO_0020077', 'MONDO_0100342', 'EFO_1000158',
       'MONDO_0008903', 'EFO_0000466', 'EFO_0003891', 'MONDO_0011962',
       'MONDO_0002367', 'EFO_0003893', 'EFO_0001064', 'EFO_0003833',
       'MONDO_0001056', 'HP_0001871', 'EFO_0000222', 'EFO_0005952',
       'EFO_0000181', 'EFO_0000432', 'EFO_0006861', 'EFO_0000182'],
      dtype=object), 'count': 104}","[ENSG00000198223,ENSG00000292357,ENSG00000100368]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 100 investigational indications.
CHEMBL1419,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,UNAANXDKBXWMLN-UHFFFAOYSA-N,Small molecule,False,SIBUTRAMINE,1997.0,4.0,,True,True,['Reductil'],['Butramin' 'Cf-alli' 'Medaria' 'Racemic sibutramine' 'Sibutramine'],"[('PubChem', array(['174007250', '49732001'], dtype=object)), ('Wikipedia', array(['Sibutramine'], dtype=object)), ('drugbank', array(['DB01105'], dtype=object)), ('chEBI', array(['9137'], dtype=object))]",['CHEMBL3989830' 'CHEMBL1200765'],"{'rows': array(['EFO_0001073', 'EFO_0001073'], dtype=object), 'count': 2}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for obesity and has 1 investigational indication. It was withdrawn in at least one region.
CHEMBL1633,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O,YNQQEYBLVYAWNX-WLHGVMLRSA-N,Small molecule,False,KETOTIFEN FUMARATE,1999.0,4.0,CHEMBL534,False,True,"['Acuvue theravision with ketotifen' 'Alaway' ""Children's alaway""
 'Ketotifen fumarate' 'Zaditen' 'Zaditor']","['HC 20,511 FUMARATE' 'HC-20511 FUMARATE' 'Ketotifen (as fumarate)'
 'Ketotifen fumarate' 'Ketotifen hydrogen fumarate' 'NSC-757415']","[('DailyMed', array(['ketotifen%20fumarate'], dtype=object)), ('PubChem', array(['26719657', '26747554', '26747555', '49731996', '50106521',
       '50106522', '50106523', '56424131', '855752'], dtype=object))]",,"{'rows': array(['MONDO_0002406', 'EFO_0000274', 'EFO_0007141', 'HP_0012532',
       'EFO_0003931', 'EFO_1001417'], dtype=object), 'count': 6}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 6 investigational indications.
CHEMBL2010601,CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O,PURKAOJPTOLRMP-UHFFFAOYSA-N,Small molecule,False,IVACAFTOR,2012.0,4.0,,False,True,['Kalydeco'],['Ivacaftor' 'VX-770'],"[('DailyMed', array(['ivacaftor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco'],
      dtype=object)), ('PubChem', array(['124950685'], dtype=object)), ('drugbank', array(['DB08820'], dtype=object)), ('chEBI', array(['66901'], dtype=object))]",['CHEMBL4297603'],"{'rows': array(['EFO_0007486', 'MONDO_0016575', 'EFO_0001421', 'EFO_0000341',
       'MONDO_0009061', 'EFO_0006505', 'EFO_0000684', 'MONDO_0009061'],
      dtype=object), 'count': 8}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for respiratory system disease and cystic fibrosis and has 6 investigational indications.
CHEMBL2064032,CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1.O=C(O)/C=C/C(=O)O,ROGSHYHKHPCCJW-WLHGVMLRSA-N,Small molecule,False,VONOPRAZAN FUMARATE,2022.0,4.0,CHEMBL2079130,False,True,[],"['TAK-438' 'TAK-438 monofumarate' 'Tak 438' 'Vonoprazan fumarate'
 'Vonoprazan monofumarate']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VONOPRAZAN%20FUMARATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0009454', 'MONDO_0001409', 'EFO_0003948', 'EFO_1000961',
       'EFO_0004607'], dtype=object), 'count': 5}","[ENSG00000105675,ENSG00000186009]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 5 investigational indications.
CHEMBL2108404,,,Antibody,False,EPRATUZUMAB,,3.0,,False,False,['Lymphocide'],['AMG-412' 'Epratuzumab' 'IMMU-HLL2' 'hLL2'],,,"{'rows': array(['MONDO_0000870', 'EFO_0009441', 'MONDO_0007915', 'EFO_0000403',
       'EFO_0005952', 'EFO_0000220', 'MONDO_0004992', 'EFO_0000094',
       'EFO_0000574', 'EFO_0000565'], dtype=object), 'count': 10}",[ENSG00000012124],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL2109398,,,Antibody,False,KB-004,,1.0,,False,False,[],['KB-004' 'Kb-004'],,,"{'rows': array(['EFO_0002430', 'EFO_0000198', 'EFO_0000519'], dtype=object), 'count': 3}",[ENSG00000044524],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL3301574,,,Cell,True,TISAGENLECLEUCEL,2018.0,4.0,,False,True,['Kymriah'],"['CART-19' 'CART19' 'CTL-019' 'CTL019' 'Car.cd19-redirected t cells'
 'Kymriah' 'Tisagenlecleucel' 'Tisagenlecleucel-t']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah'],
      dtype=object))]",,"{'rows': array(['EFO_0000094', 'EFO_0000403', 'EFO_0002618', 'EFO_0000183',
       'EFO_0000096', 'EFO_0001378', 'EFO_0005952', 'MONDO_0000873',
       'EFO_0000222', 'EFO_0000565', 'EFO_0000220', 'MONDO_0018906',
       'EFO_0000574', 'EFO_0000094', 'EFO_0000095'], dtype=object), 'count': 15}",[ENSG00000177455],Cell drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for b-cell acute lymphoblastic leukemia and diffuse large b-cell lymphoma and has 13 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3545204,,,Small molecule,False,QAF805,,1.0,,False,False,[],['Qaf805'],,,,"[ENSG00000170425,ENSG00000282608]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707401,,,Small molecule,False,MK-8777,,2.0,,False,False,[],['Mk-8777' 'Org-26576'],,,"{'rows': array(['EFO_0003888', 'MONDO_0002050'], dtype=object), 'count': 2}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3948730,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,IUVCFHHAEHNCFT-INIZCTEOSA-N,Small molecule,False,UMBRALISIB,2021.0,4.0,,False,True,[],"['RP-5264' 'RP5264' 'TGR-1202 FREE BASE' 'TGR-1202 base' 'Tgr 1202'
 'Umbralisib']","[('drugbank', array(['DB14989'], dtype=object))]",['CHEMBL3989869'],"{'rows': array(['EFO_0000095', 'EFO_0000183', 'MONDO_0044903', 'MONDO_0001056',
       'EFO_0000095', 'EFO_1000630', 'MONDO_0018906', 'MONDO_0007576',
       'EFO_1001469', 'EFO_1001469', 'EFO_1001951', 'EFO_0002618',
       'MONDO_0011719', 'EFO_0000183', 'EFO_0000616', 'EFO_0000403',
       'EFO_1000657', 'EFO_0002429', 'EFO_0000096', 'EFO_0000403',
       'EFO_0009441', 'EFO_0000211', 'MONDO_0018906'], dtype=object), 'count': 23}","[ENSG00000097007,ENSG00000213923,ENSG00000171608]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 19 investigational indications.
CHEMBL4297392,O=C(NCc1ccc(Oc2ccccc2)cc1)c1nc(-c2cc(Br)c(O)c(Br)c2)no1,DSFNLJXHXBIKDS-UHFFFAOYSA-N,Small molecule,False,IOWH-032,,2.0,,False,False,[],['Iowh-032' 'Iowh032'],"[('drugbank', array(['DB12959'], dtype=object))]",,"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}",[ENSG00000001626],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4650215,C[C@H](Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O,SGEUNORSOZVTOL-CABZTGNLSA-N,Small molecule,False,INAVOLISIB,,3.0,,False,False,[],"['GDC-0077' 'GDC0077' 'Gdc-0077' 'Inavolisib' 'RG-6114' 'RG6114'
 'RO-7113755' 'RO7113755']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/INAVOLISIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'MONDO_0011962', 'MONDO_0008170', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 5}",[ENSG00000121879],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4650368,COc1ncc(C)c(-c2ccc3c(c2)[nH]c(=O)c2cnn([C@H]4CCOC4)c23)c1C,CKJDCNZBABIEBZ-HNNXBMFYSA-N,Small molecule,False,IRSENONTRINE,,2.0,,False,False,[],['E-2027' 'E2027' 'ER-592221-00' 'Irsenontrine'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IRSENONTRINE/relevant/1/'],
      dtype=object))]",['CHEMBL4650224'],"{'rows': array(['HP_0000726', 'EFO_0006792', 'HP_0000726', 'MONDO_0005180',
       'EFO_0006792', 'MONDO_0005180'], dtype=object), 'count': 6}",[ENSG00000160191],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL477772,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,CUIHSIWYWATEQL-UHFFFAOYSA-N,Small molecule,True,PAZOPANIB,2009.0,4.0,,False,True,['Votrient'],['GW786034' 'NSC-752782' 'Pazopanib'],"[('PubChem', array(['103905642', '144206725', '170465625', '50100102'], dtype=object)), ('Wikipedia', array(['Pazopanib'], dtype=object)), ('drugbank', array(['DB06589'], dtype=object)), ('chEBI', array(['71219'], dtype=object))]",['CHEMBL1201733'],"{'rows': array(['EFO_1001465', 'EFO_0000182', 'MONDO_0004986', 'EFO_0005543',
       'MONDO_0002087', 'EFO_0003016', 'EFO_0000681', 'EFO_0007143',
       'MONDO_0011719', 'MONDO_0015277', 'EFO_1001465', 'EFO_0003869',
       'MONDO_0008903', 'EFO_1000613', 'MONDO_0004192', 'MONDO_0008170',
       'MONDO_0002158', 'MONDO_0019297', 'MONDO_0004986', 'MONDO_0000521',
       'EFO_0003893', 'EFO_1001968', 'EFO_0000637', 'EFO_0000691',
       'MONDO_0001056', 'MONDO_0008315', 'EFO_0000333', 'EFO_0002618',
       'EFO_0003968', 'MONDO_0008667', 'EFO_0000564', 'MONDO_0002367',
       'MONDO_0007254', 'EFO_1001100', 'EFO_0000616', 'EFO_0000519',
       'MONDO_0011934', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0019180',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000574', 'EFO_0000702',
       'EFO_0000222', 'EFO_0000501', 'EFO_0002892', 'MONDO_0001187',
       'MONDO_0001187', 'EFO_0000181', 'EFO_0000349', 'EFO_0003968',
       'MONDO_0002087', 'EFO_0000349', 'MONDO_0008315', 'EFO_0000588',
       'EFO_0001663', 'EFO_0009606', 'EFO_0000691', 'EFO_0000641',
       'MONDO_0002974', 'EFO_0000365', 'EFO_0000616', 'EFO_0000640',
       'MONDO_0002158', 'EFO_0000681', 'MONDO_0016238', 'EFO_1000880',
       'EFO_1001968', 'MONDO_0008903', 'EFO_0000756', 'EFO_0000569',
       'EFO_0000673', 'EFO_0000514', 'EFO_0000676', 'EFO_1001901',
       'EFO_0000335', 'EFO_0000389', 'MONDO_0008170'], dtype=object), 'count': 79}","[ENSG00000113721,ENSG00000134853,ENSG00000182866,ENSG00000068078,ENSG00000157404,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000077782,ENSG00000113263]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 66 investigational indications. This drug has a black box warning from the FDA.
CHEMBL5314390,CO[C@]1(COC(=O)CCNC(=O)C(N)CCCCN)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4.Cl.Cl,PBEVPBFDKPJIOM-RHIKYVLPSA-N,Small molecule,False,CEP-2563 DIHYDROCHLORIDE,,1.0,CHEMBL5316170,False,False,[],['Cep-2563' 'KT-8391'],,,,"[ENSG00000198400,ENSG00000148053,ENSG00000140538,ENSG00000122025,ENSG00000165731,ENSG00000113721,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL598797,C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1,PLIVFNIUGLLCEK-UHFFFAOYSA-N,Small molecule,False,CUDC-101,,1.0,,False,False,[],['CUDC-101' 'Cudc 101' 'Cudc-101'],"[('PubChem', array(['137276021'], dtype=object)), ('drugbank', array(['DB12174'], dtype=object))]",['CHEMBL3922781' 'CHEMBL3957601' 'CHEMBL3983283' 'CHEMBL3913031'],"{'rows': array(['EFO_0000616', 'EFO_0006859', 'EFO_0003060', 'MONDO_0002691',
       'MONDO_0001056', 'MONDO_0007254', 'MONDO_0004992'], dtype=object), 'count': 7}","[ENSG00000146648,ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications.
CHEMBL608533,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,BMGQWWVMWDBQGC-IIFHNQTCSA-N,Small molecule,False,MIDOSTAURIN,2017.0,4.0,,False,True,['Rydapt'],"['CGP 41251' 'CGP-41251' 'Midostaurin' 'NSC-656576' 'NVP-PKC412' 'PKC 412'
 'PKC-412' 'Pkc-412']","[('DailyMed', array(['midostaurin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt'],
      dtype=object)), ('PubChem', array(['124950161'], dtype=object)), ('Wikipedia', array(['Midostaurin'], dtype=object)), ('drugbank', array(['DB06595'], dtype=object)), ('chEBI', array(['63452'], dtype=object))]",,"{'rows': array(['EFO_1000131', 'EFO_0001421', 'EFO_0000220', 'EFO_0009001',
       'EFO_0000616', 'MONDO_0016586', 'EFO_0007359', 'EFO_0000198',
       'EFO_0000565', 'EFO_0000222', 'EFO_1000657'], dtype=object), 'count': 11}","[ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000122025,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 6 investigational indications.
CHEMBL652,O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F,DJBNUMBKLMJRSA-UHFFFAOYSA-N,Small molecule,True,FLECAINIDE,1985.0,4.0,,False,True,[],['Flecainide' 'NSC-719273' 'THN-102 COMPONENT FLECAINIDE'],"[('PubChem', array(['104171159', '124880129', '144203702', '170464874', '26752195'],
      dtype=object)), ('Wikipedia', array(['Flecainide'], dtype=object)), ('drugbank', array(['DB01195'], dtype=object)), ('chEBI', array(['75984'], dtype=object))]",['CHEMBL4591096' 'CHEMBL1200822'],"{'rows': array(['EFO_0004269', 'EFO_0000275', 'Orphanet_247', 'HP_0004308',
       'EFO_0003843', 'EFO_0000275'], dtype=object), 'count': 6}",[ENSG00000183873],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for cardiac arrhythmia and ventricular arrhythmia and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL673,C#CCN(C)Cc1ccccc1,DPWPWRLQFGFJFI-UHFFFAOYSA-N,Small molecule,False,PARGYLINE,1982.0,4.0,,False,True,[],['Eutonyl' 'Eutron' 'Pargyline'],"[('PubChem', array(['11111668', '11111669', '90340843'], dtype=object)), ('Wikipedia', array(['Pargyline'], dtype=object)), ('drugbank', array(['DB01626'], dtype=object)), ('chEBI', array(['7930'], dtype=object))]",['CHEMBL1200425'],"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000189221,ENSG00000069535]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for hypertension.
CHEMBL768,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,AQNDDEOPVVGCPG-UHFFFAOYSA-N,Small molecule,False,ESMOLOL,1986.0,4.0,,True,True,[],['ASL-8052-001' 'Esmolol'],"[('Wikipedia', array(['Esmolol'], dtype=object)), ('drugbank', array(['DB00187'], dtype=object)), ('chEBI', array(['88206'], dtype=object))]",['CHEMBL1201115'],"{'rows': array(['EFO_0000319', 'EFO_0003870', 'EFO_0000275', 'EFO_0002687',
       'HP_0100543', 'EFO_0003843', 'EFO_0000537', 'HP_0000138',
       'EFO_0003833', 'EFO_0006834', 'EFO_0001645', 'EFO_0007486',
       'EFO_1001459', 'EFO_0006834'], dtype=object), 'count': 14}","[ENSG00000169252,ENSG00000043591]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for cardiovascular disease and hypertension and has 12 investigational indications.
CHEMBL86715,OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1,WYDUSKDSKCASEF-UHFFFAOYSA-N,Small molecule,False,PROCYCLIDINE,1955.0,4.0,,False,True,[],"['Elorine' 'Kemadrine' 'Lergine' 'NSC-169103' 'Procyclidine' 'Tricoloid'
 'Vagosin']","[('drugbank', array(['DB00387'], dtype=object)), ('chEBI', array(['8448'], dtype=object))]",['CHEMBL1761'],"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and is indicated for parkinson disease.
CHEMBL973,C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,UTNUDOFZCWSZMS-YFHOEESVSA-N,Small molecule,True,TERIFLUNOMIDE,2012.0,4.0,,False,True,['Aubagio' 'Teriflunomide mylan'],"['A77 1726' 'HMR-1726' 'HMR1726' 'Leflunomide related compound b'
 'Leflunomide related compound b rs' 'Teriflunomide']","[('DailyMed', array(['teriflunomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/teriflunomide-mylan'],
      dtype=object)), ('Wikipedia', array(['Teriflunomide'], dtype=object)), ('drugbank', array(['DB08880'], dtype=object)), ('chEBI', array(['68540'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'MONDO_0005301', 'EFO_0001060', 'EFO_0007527',
       'EFO_0000540', 'EFO_0003086'], dtype=object), 'count': 6}",[ENSG00000102967],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1029,CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,UQRORFVVSGFNRO-UTINFBMNSA-N,Small molecule,False,MIGLUSTAT,2003.0,4.0,,False,True,['Miglustat dipharma' 'Zavesca'],"['Butyldeoxynojirimycin' 'Miglustat' 'N-butyldeoxynojirimycin' 'OGT 918'
 'OGT-918']","[('DailyMed', array(['miglustat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/miglustat-dipharma'],
      dtype=object)), ('PubChem', array(['144204381', '170464950'], dtype=object)), ('Wikipedia', array(['Miglustat'], dtype=object)), ('drugbank', array(['DB00419'], dtype=object)), ('chEBI', array(['50381'], dtype=object))]",['CHEMBL1329690'],"{'rows': array(['EFO_0000764', 'HP_0002014', 'Orphanet_365', 'Orphanet_77259',
       'MONDO_0019262', 'MONDO_0017720', 'MONDO_0018150', 'MONDO_0002412',
       'MONDO_0018982', 'MONDO_0010006', 'MONDO_0009061', 'MONDO_0019064'],
      dtype=object), 'count': 12}",[ENSG00000148154],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for gaucher disease type 1 and gaucher disease and has 10 investigational indications.
CHEMBL1104,CC[N+](C)(C)c1cccc(O)c1,VWLHWLSRQJQWRG-UHFFFAOYSA-O,Small molecule,False,EDROPHONIUM,1951.0,4.0,,False,True,[],"['ENLON-PLUS' 'Edrophonium' 'Edrophonium cation' 'Edrophonium ion' 'Enlon'
 'Reversol' 'Tensilon']","[('PubChem', array(['11111143', '11111144', '50100235', '50104222', '90341680'],
      dtype=object)), ('drugbank', array(['DB01010'], dtype=object)), ('chEBI', array(['251408'], dtype=object))]",['CHEMBL60745' 'CHEMBL1128'],"{'rows': array(['EFO_1000645', 'EFO_0005252'], dtype=object), 'count': 2}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 2 investigational indications.
CHEMBL1144,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,TUZYXOIXSAXUGO-PZAWKZKUSA-N,Small molecule,False,PRAVASTATIN,1991.0,4.0,,False,True,[],['C10AA03' 'Pravachol' 'Pravastatin' 'Pravator'],"[('Wikipedia', array(['Pravastatin'], dtype=object)), ('drugbank', array(['DB00175'], dtype=object)), ('chEBI', array(['63618'], dtype=object))]",['CHEMBL690'],"{'rows': array(['EFO_0000319', 'EFO_1001496', 'EFO_0004705', 'HP_0001919',
       'MONDO_0005147', 'EFO_0000668', 'MONDO_0008310', 'EFO_1000049',
       'EFO_0003929', 'EFO_0000685', 'EFO_0001645', 'EFO_0004911',
       'MONDO_0018473', 'HP_0003124', 'EFO_0000565', 'EFO_0000764',
       'MONDO_0007915', 'EFO_0000612', 'Orphanet_79211', 'EFO_0000182',
       'EFO_0000612', 'EFO_0000180', 'MONDO_0021187', 'EFO_0000319',
       'MONDO_0007254', 'MONDO_0021661', 'EFO_0000537', 'EFO_0000400',
       'EFO_1000727', 'HP_0003124', 'EFO_0004255', 'EFO_0000318',
       'EFO_0003884', 'EFO_0000400', 'EFO_0003914', 'Orphanet_79211',
       'MONDO_0020732', 'EFO_0003144', 'MONDO_0008903', 'EFO_0004246',
       'EFO_0006890', 'Orphanet_309005', 'MONDO_0018076', 'EFO_0000565',
       'EFO_0000764', 'EFO_0003106', 'EFO_0000313', 'MONDO_0002691',
       'HP_0002140', 'EFO_1001375'], dtype=object), 'count': 50}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 38 investigational indications.
CHEMBL1200330,CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C.Cl,RNAICSBVACLLGM-GNAZCLTHSA-N,Small molecule,False,PILOCARPINE HYDROCHLORIDE,1984.0,4.0,CHEMBL550,False,True,"['Isopto carpine' 'Ocusert' 'Piloc hcl' 'Pilocarpine hydrochloride'
 'Pilogel' 'Pilopine hs' 'Salagen' 'Sno pilo' 'Vuity']","['Pilocarpine hcl' 'Pilocarpine hydrochloride'
 'Pilocarpine monohydrochloride' 'Pilocarpini hydrochloridum'
 'Pilocarpinum muriaticum' 'Salagen' 'Vistacarpin n' 'Vuity']","[('DailyMed', array(['pilocarpine%20hydrochloride'], dtype=object)), ('PubChem', array(['26719685', '50106827', '539062', '855931'], dtype=object))]",,"{'rows': array(['MONDO_0001330', 'EFO_0006859'], dtype=object), 'count': 2}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 2 investigational indications.
CHEMBL1201466,,,Small molecule,True,"ESTROGENS, CONJUGATED SYNTHETIC A",1999.0,4.0,,False,True,['Cenestin' 'Synthetic conjugated estrogens a'],"['Estrogens, conjugated synthetic a' 'Estrogens,conjugated synthetic a'
 'Synthetic conjugated estrogens, a']","[('DailyMed', array(['estrogens,%20conjugated%20synthetic%20a'], dtype=object))]",,"{'rows': array(['GO_0042697', 'EFO_1000096'], dtype=object), 'count': 2}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for menopause and atrophy. This drug has a black box warning from the FDA.
CHEMBL1201605,,,Antibody,False,DACLIZUMAB,1997.0,4.0,,True,True,['Zenapax' 'Zinbryta'],['Daclizumab' 'Daclizumab beta' 'RO 24-7375' 'RO-24-7375'],"[('DrugCentral', array(['4953'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta'],
      dtype=object)), ('Wikipedia', array(['Daclizumab'], dtype=object))]",,"{'rows': array(['EFO_0000198', 'EFO_0001378', 'MONDO_0004979', 'EFO_0000574',
       'EFO_0000616', 'MONDO_0001705', 'EFO_0000676', 'HP_0012410',
       'EFO_0004683', 'EFO_0000764', 'MONDO_0013730', 'EFO_0000756',
       'EFO_0003929', 'MONDO_0018923', 'MONDO_0005301', 'EFO_0003086',
       'EFO_0000729', 'EFO_0003884', 'EFO_0000540', 'EFO_0000400',
       'HP_0001873', 'EFO_0005297', 'EFO_1001231', 'EFO_0000565',
       'HP_0001915', 'MONDO_0005147'], dtype=object), 'count': 26}","[ENSG00000134460,ENSG00000147168,ENSG00000100385]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 23 investigational indications. It was withdrawn in at least one region.
CHEMBL1201649,,,Unknown,True,"ESTROGENS, CONJUGATED",1942.0,4.0,,False,True,['Cenestin' 'Oestrogen' 'Premarin' 'Premarin Cream'],"['Conjugated estrogens' 'Estrogen, conjugated (class)'
 'Estrogens conjugated' 'Estrogens, conjugated' 'Estrogens,conjugated'
 'G03CA57' 'Oestrogens conjugated']","[('DailyMed', array(['estrogens,%20conjugated'], dtype=object)), ('DrugCentral', array(['4855'], dtype=object))]",,"{'rows': array(['HP_0000938', 'MONDO_0008315', 'EFO_0000612', 'MONDO_0007915',
       'EFO_0000712', 'MONDO_0004975', 'EFO_0004288', 'MONDO_0001410',
       'EFO_0000400', 'EFO_0001072', 'EFO_1000781', 'HP_0030016',
       'GO_0042697', 'MONDO_0002146', 'EFO_0000537', 'HP_0031217',
       'MONDO_0043510', 'HP_0031273', 'EFO_1000985', 'EFO_0001663',
       'EFO_1001375', 'EFO_0002687', 'EFO_1000096', 'MONDO_0011962',
       'EFO_0003869', 'EFO_0008507', 'MONDO_0000831', 'EFO_0001645',
       'EFO_0003882', 'HP_0003124', 'MONDO_0007254', 'MONDO_0019499',
       'EFO_0004266', 'MONDO_0005351', 'EFO_0003854'], dtype=object), 'count': 35}","[ENSG00000140009,ENSG00000091831]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and has 10 approved and 25 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2105613,CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+],MSRILKIQRXUYCT-UHFFFAOYSA-M,Small molecule,True,DIVALPROEX SODIUM,1983.0,4.0,CHEMBL109,False,True,['Depakote' 'Depakote cp' 'Depakote er' 'Divalproex sodium'],"['ABBOTT 50711' 'ABBOTT-50711' 'Divalproex' 'Divalproex sodium'
 'Semisodium valproate' 'Valproate semisodium'
 'Valproic acid sodium salt (2:1)']","[('DailyMed', array(['divalproex%20sodium'], dtype=object)), ('chEBI', array(['4667'], dtype=object))]",,"{'rows': array(['MONDO_0007079', 'EFO_0000474', 'HP_0000713', 'HP_0001250',
       'EFO_0000616', 'EFO_0000717', 'EFO_0001358', 'HP_0010865',
       'EFO_0004247', 'EFO_1000877', 'MONDO_0004975', 'HP_0002013',
       'MONDO_0002009', 'EFO_0003758', 'MONDO_0005090', 'EFO_0009963',
       'MONDO_0004985', 'HP_0000726', 'MONDO_0005277', 'HP_0007359',
       'HP_0002121', 'HP_0002039', 'MONDO_0007739'], dtype=object), 'count': 23}",[ENSG00000112294],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 11 approved and 12 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108570,,,Unknown,True,ABOBOTULINUMTOXINA,2009.0,4.0,,False,True,[],['Abobotulinumtoxina' 'RTI-150' 'RTI150'],"[('DailyMed', array(['abobotulinumtoxina'], dtype=object))]",,"{'rows': array(['EFO_0006346', 'EFO_1001896', 'HP_0003419'], dtype=object), 'count': 3}",[ENSG00000132639],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109437,,,Antibody,False,KHK-2866,,1.0,,False,False,[],['KHK-2866' 'KHK2866' 'Khk-2866'],,,"{'rows': array(['EFO_1001100', 'EFO_1000251', 'EFO_0003893'], dtype=object), 'count': 3}",[ENSG00000113070],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications.
CHEMBL2109602,,,Antibody,False,IMC-3C5,,1.0,,False,False,[],['IMC-3C5' 'Imc-3c5'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000037280],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2110824,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1,CUWODFFVMXJOKD-UVLQAERKSA-N,Protein,False,BUSERELIN,,4.0,,False,True,['Suprecur' 'Suprefact'],['Buserelin'],,['CHEMBL2106198'],"{'rows': array(['EFO_0000545', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000673',
       'EFO_0000196', 'EFO_0000545'], dtype=object), 'count': 6}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 5 investigational indications.
CHEMBL2219536,COCCO[C@@H]1[C@H](SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cnc4c(N)ncnc43)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2O)[C@@H](COP(=O)(O)S[C@H]2[C@@H](OCCOC)[C@H](n3cc(C)c(N)nc3=O)O[C@@H]2COP(=O)(O)S[C@H]2[C@@H](OCCOC)[C@H](n3cnc4c(=O)[nH]c(N)nc43)O[C@@H]2CO)O[C@H]1n1cc(C)c(N)nc1=O,TZRFSLHOCZEXCC-HIVFKXHNSA-N,Oligonucleotide,True,MIPOMERSEN,2013.0,4.0,,False,True,[],['Mipomersen'],"[('DrugCentral', array(['4747'], dtype=object))]",['CHEMBL502097'],"{'rows': array(['EFO_0000319', 'EFO_0004911', 'HP_0003124'], dtype=object), 'count': 3}",[ENSG00000084674],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for cardiovascular disease and familial hypercholesterolemia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2323775,Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1,VMJFTOSOFDEKTM-UHFFFAOYSA-N,Small molecule,False,MK-8033,,1.0,,False,False,[],['MK-8033' 'MK8033' 'Mk-8033'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000164078,ENSG00000105976]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3099695,N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1,USUZGMWDZDXMDG-CYBMUJFWSA-N,Small molecule,False,OSILODROSTAT,2020.0,4.0,,False,True,[],['LCI-699-NX' 'LCI699-NX' 'Lci-699' 'Lci699' 'Osilodrostat'],"[('drugbank', array(['DB11837'], dtype=object))]",['CHEMBL3707393'],"{'rows': array(['EFO_0003086', 'EFO_0000537', 'EFO_0005539', 'HP_0011736',
       'EFO_1001110', 'EFO_0001421', 'MONDO_0001134', 'EFO_0003099',
       'EFO_0003099', 'EFO_1001110'], dtype=object), 'count': 10}",[ENSG00000160882],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 7 investigational indications.
CHEMBL3353410,C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,DUYJMQONPNNFPI-UHFFFAOYSA-N,Small molecule,False,OSIMERTINIB,2015.0,4.0,,False,True,['Tagrisso'],"['AZD-9291' 'AZD-9291 FREE BASE' 'AZD9291' 'Azd-9291' 'Mereletinib'
 'Osimertinib']","[('drugbank', array(['DB09330'], dtype=object))]","['CHEMBL4741340' 'CHEMBL4754013' 'CHEMBL3545063' 'CHEMBL4472934'
 'CHEMBL4784911']","{'rows': array(['EFO_0000313', 'MONDO_0005575', 'MONDO_0004992', 'EFO_0000707',
       'MONDO_0021117', 'EFO_0000571', 'EFO_0000519', 'EFO_0003060',
       'MONDO_0008903', 'MONDO_0008903', 'EFO_0003833', 'EFO_0000228',
       'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 14}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 11 investigational indications.
CHEMBL3545331,,,Small molecule,False,RPR749,,1.0,,False,False,[],['Rpr749'],,,,[ENSG00000163485],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989931,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O,ORZHZQZYWXEDDL-UHFFFAOYSA-N,Small molecule,True,ENASIDENIB MESYLATE,2017.0,4.0,CHEMBL3989908,False,True,['Idhifa'],"['AG-221 mesylate' 'CC-90007' 'Enasidenib mesilate' 'Enasidenib mesylate'
 'Enasidenib methanesulfonate']","[('DailyMed', array(['enasidenib%20mesylate'], dtype=object))]",,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000182054],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA.
CHEMBL4298202,,,Oligonucleotide,False,PELACARSEN,,3.0,,False,False,[],"['AKCEA-APO(a)-LRx' 'ISIS 681257' 'ISIS-681257 FREE ACID'
 'Ionis-apo(a)-lrx' 'Pelacarsen']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PELACARSEN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0001645', 'MONDO_0037748', 'EFO_0003086',
       'EFO_0001421', 'EFO_0000266'], dtype=object), 'count': 6}",[ENSG00000198670],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL4650216,COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl,HJVGDXBEMFHGKI-BQAIUKQQSA-N,Small molecule,False,DARIDOREXANT HYDROCHLORIDE,2022.0,4.0,CHEMBL4297590,False,True,['Quviviq'],"['ACT-541468A' 'Daridorexant hydrochloride' 'Nemorexant hydrochloride'
 'Quviviq']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DARIDOREXANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}","[ENSG00000121764,ENSG00000137252]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for insomnia.
CHEMBL467,NC(=O)NO,VSNHCAURESNICA-UHFFFAOYSA-N,Small molecule,True,HYDROXYUREA,1967.0,4.0,,False,True,['Droxia' 'Hydrea' 'Hydroxyurea' 'Siklos'],['Hydroxycarbamide' 'Hydroxyurea' 'NSC-32065' 'SQ 1089' 'SQ-1089'],"[('DailyMed', array(['hydroxyurea'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/siklos'],
      dtype=object)), ('PubChem', array(['11111283', '144210638', '170465025', '174007362', '26747533',
       '50106399', '57260119', '85231078', '90341681', '90752'],
      dtype=object)), ('Wikipedia', array(['Hydroxycarbamide'], dtype=object)), ('drugbank', array(['DB01005'], dtype=object)), ('chEBI', array(['44423'], dtype=object))]",,"{'rows': array(['EFO_0000313', 'MONDO_0008903', 'EFO_0000198', 'EFO_0002430',
       'MONDO_0005301', 'EFO_0000616', 'EFO_0006859', 'EFO_1001465',
       'EFO_0000181', 'EFO_1000642', 'EFO_0000519', 'HP_0001871',
       'EFO_1000158', 'MONDO_0016487', 'EFO_0000764', 'EFO_0004251',
       'EFO_0005577', 'EFO_0000712', 'MONDO_0007576', 'EFO_0000707',
       'EFO_0002429', 'EFO_1001797', 'MONDO_0016642', 'EFO_0003866',
       'EFO_1001996', 'EFO_0000222', 'EFO_0000479', 'MONDO_0001056',
       'EFO_0000220', 'EFO_0000574', 'EFO_0003817', 'EFO_0008525',
       'EFO_0000339', 'Orphanet_848', 'EFO_0000756', 'EFO_0009907',
       'MONDO_0044903', 'EFO_0005570', 'MONDO_0005149', 'EFO_0000565',
       'EFO_0000224', 'MONDO_0011382'], dtype=object), 'count': 42}","[ENSG00000167325,ENSG00000048392,ENSG00000171848]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 6 approved and 36 investigational indications. This drug has a black box warning from the FDA.
CHEMBL515914,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O,QQOBRRFOVWGIMD-OJAKKHQRSA-N,Small molecule,False,AZARIBINE,,4.0,,True,True,[],['Azaribine' 'CB 304' 'CB-304' 'NSC-67239'],"[('PubChem', array(['144204429', '170466075', '29215005', '855722'], dtype=object))]",,,[ENSG00000114491],Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL5315122,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1O[C@H]([C@H](O)CO)[C@@H]([C@H](O)CO)O1,QDMRNLRJDHCHLB-DNNBANOASA-N,Small molecule,False,BORTEZOMIB D-MANNITOL,2015.0,4.0,,False,True,['Bortezomib accord'],['Bortezomib d-mannitol ester'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-accord'],
      dtype=object))]",,,"[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015.
CHEMBL550755,Cl.O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,WEIAMZKHBCLFOG-QPAIBFMUSA-N,Small molecule,False,FORODESINE HYDROCHLORIDE,,2.0,CHEMBL218291,False,False,[],['BCX-1777' 'Forodesine hcl' 'Forodesine hydrochloride'],,,"{'rows': array(['EFO_0000095', 'MONDO_0000430', 'EFO_0004289', 'EFO_0000574',
       'MONDO_0004992'], dtype=object), 'count': 5}",[ENSG00000198805],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL646,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2,JOFWLTCLBGQGBO-UHFFFAOYSA-N,Small molecule,True,TRIAZOLAM,1978.0,4.0,,True,True,['Halcion' 'Kention' 'Triazolam'],"['N05CD05' 'Triazolam' 'Triazolam civ' 'U-33,030' 'U-33030']","[('DailyMed', array(['triazolam'], dtype=object)), ('PubChem', array(['144206170', '50113071'], dtype=object)), ('TG-GATEs', array(['120'], dtype=object)), ('Wikipedia', array(['Triazolam'], dtype=object)), ('drugbank', array(['DB00897'], dtype=object)), ('chEBI', array(['9674'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'EFO_0003890',
       'MONDO_0005090', 'EFO_0004698'], dtype=object), 'count': 6}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for insomnia and has 5 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1200328,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl,BFFSMCNJSOPUAY-LMOVPXPDSA-N,Small molecule,True,DULOXETINE HYDROCHLORIDE,2004.0,4.0,CHEMBL1175,False,True,"['Ariclaim' 'Cymbalta' 'Drizalma sprinkle' 'Duciltia'
 'Duloxetine hydrochloride' 'Duloxetine zentiva' 'Yentreve']","['Ariclaim' 'Duloxetine (as hydrochloride)' 'Duloxetine hcl'
 'Duloxetine hydrochloride' 'Duloxetine mylan' 'LY-248686' 'LY-248686 HCL'
 'LY248686 HCL' 'NSC-759112' 'Xeristar']","[('DailyMed', array(['duloxetine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-zentiva'],
      dtype=object)), ('PubChem', array(['144205741', '170465319', '49681598'], dtype=object)), ('chEBI', array(['31526'], dtype=object))]",,"{'rows': array(['HP_0012532', 'EFO_0002970', 'HP_0000020', 'MONDO_0002009',
       'EFO_0005230', 'EFO_0005762', 'EFO_1001951', 'MONDO_0002009',
       'MONDO_0005301', 'EFO_0003843', 'MONDO_0002050', 'EFO_0001358',
       'MONDO_0005178', 'EFO_1000783', 'EFO_0005687', 'EFO_0006788'],
      dtype=object), 'count': 16}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200912,CC(C)(N)Cc1ccccc1.Cl,NCAIGTHBQTXTLR-UHFFFAOYSA-N,Small molecule,False,PHENTERMINE HYDROCHLORIDE,1973.0,4.0,CHEMBL1574,False,True,"['Adipex-p' 'Fastin' 'Lomaira' 'Obestin-30' 'Oby-trim' 'Ona-mast'
 'Phentermine hydrochloride' 'Suprenza' 'Tora' 'Wilpo']","['NSC-44090' 'Phentermine hcl' 'Phentermine hydrochloride'
 'Phentermine hydrochloride civ' 'Zantryl']","[('DailyMed', array(['phentermine%20hydrochloride'], dtype=object)), ('chEBI', array(['50506'], dtype=object))]",,"{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}",[ENSG00000103546],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973 and is indicated for obesity.
CHEMBL1201081,C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+],FQISKWAFAHGMGT-SGJOWKDISA-M,Small molecule,False,METHYLPREDNISOLONE SODIUM SUCCINATE,1959.0,4.0,CHEMBL1201265,False,True,"['A-methapred' 'Methylprednisolone sodium succinate' 'Min-i-mix'
 'Solu-medrol' 'Solu-medrone' 'Urbasone']","['Methylprednisolone 21-succinate sodium salt'
 'Methylprednisolone sodium succinate' 'NSC-48989']","[('DailyMed', array(['methylprednisolone%20sodium%20succinate'], dtype=object)), ('PubChem', array(['144207076'], dtype=object))]",,"{'rows': array(['EFO_0000694', 'EFO_0000768', 'MONDO_0007915', 'MONDO_0002280',
       'EFO_0008522', 'EFO_0000095', 'EFO_0000685', 'EFO_1001222',
       'EFO_0000540', 'MONDO_0002406', 'MONDO_0100096', 'MONDO_0013730',
       'EFO_0000220', 'MONDO_0005301', 'EFO_0003106', 'EFO_0003843',
       'MONDO_0002462', 'EFO_0003840', 'EFO_0000198', 'EFO_0004194',
       'EFO_1001272', 'EFO_0000574', 'MONDO_0004979', 'EFO_0004599',
       'EFO_0000565', 'EFO_0005952', 'EFO_0007359', 'EFO_0007332',
       'EFO_0007537', 'EFO_0004228', 'EFO_0001378', 'EFO_0000222',
       'EFO_0000474', 'EFO_0001063'], dtype=object), 'count': 34}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 8 approved and 26 investigational indications.
CHEMBL1201545,,,Protein,False,INSULIN SUSP ISOPHANE BEEF,1982.0,4.0,,False,True,['Nph insulin'],['Insulin susp isophane beef'],,,"{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'EFO_0004593'], dtype=object), 'count': 3}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications.
CHEMBL1201585,,,Antibody,True,TRASTUZUMAB,1998.0,4.0,,False,True,['Herceptin' 'Herzuma' 'Kadcyla'],"['4D5V8' 'ABP 980' 'ABP-980' 'ABP980' 'Abp-980 (trastuzumab biosimilar)'
 'Bmab-200' 'Canhera' 'DMB-3111 (TRASTUZUMAB BIOSIMILAR)' 'Dmb-3111'
 'EG-12014' 'EG12014' 'Eg-12014 (trastuzumab biosimilar)'
 'Eg12014 trastuzumab biosimilar' 'HLX-02' 'Herzuma' 'Hlx 02'
 'Hlx-02 trastuzumab biosimilar' 'Hlx02' 'Kanjinti' 'Ogivri' 'Ontruzant'
 'Pf-05280014' 'R-597' 'RO-0452317' 'RO0452317' 'Rhumab her2' 'SYD-977'
 'SYD977' 'Sb-3 (trastuzumab biosimilar)' 'Trastuzumab'
 'Trastuzumab (herceptin)' 'Trastuzumab anns' 'Trastuzumab beta'
 'Trastuzumab biosimilar (abp-980)' 'Trastuzumab biosimilar (amgen)'
 'Trastuzumab biosimilar (ct-p6)' 'Trastuzumab biosimilar (sb-3)'
 'Trastuzumab dkst' 'Trastuzumab dttb' 'Trastuzumab pkrb'
 'Trastuzumab qyyp' 'Trastuzumab-anns' 'Trastuzumab-dkst'
 'Trastuzumab-dttb' 'Trastuzumab-pfizer' 'Trastuzumab-pkrb'
 'Trastuzumab-qyyp' 'Trastuzumab-zzxf' 'Trazimera' 'Zercepac']","[('DailyMed', array(['trastuzumab', 'trastuzumab-anns', 'trastuzumab-dkst',
       'trastuzumab-pkrb'], dtype=object)), ('DrugCentral', array(['4979'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/herzuma'],
      dtype=object)), ('Wikipedia', array(['Trastuzumab'], dtype=object))]",,"{'rows': array(['MONDO_0018364', 'MONDO_0004192', 'EFO_1000796', 'EFO_0009637',
       'EFO_0005774', 'MONDO_0001056', 'MONDO_0002974', 'MONDO_0003060',
       'MONDO_0021311', 'EFO_0000691', 'MONDO_0004992', 'EFO_0005922',
       'MONDO_0003510', 'EFO_0000183', 'MONDO_0002158', 'EFO_0007532',
       'EFO_0000616', 'EFO_0003869', 'MONDO_0003196', 'MONDO_0005411',
       'EFO_0005537', 'MONDO_0001402', 'EFO_0000305', 'EFO_0000222',
       'EFO_1001187', 'EFO_0000641', 'EFO_1001951', 'EFO_1001512',
       'MONDO_0001528', 'EFO_0002916', 'MONDO_0008315', 'EFO_1001051',
       'EFO_0003968', 'MONDO_0021165', 'MONDO_0011962', 'EFO_0005221',
       'EFO_0000501', 'MONDO_0004669', 'MONDO_0004986', 'EFO_0000549',
       'EFO_0003863', 'MONDO_0000521', 'EFO_0000503', 'EFO_0000701',
       'EFO_0000637', 'EFO_1000028', 'EFO_0006861', 'MONDO_0001370',
       'EFO_0000228', 'MONDO_0001879', 'EFO_0009708', 'EFO_0000432',
       'EFO_0006859', 'EFO_1000984', 'EFO_0006352', 'EFO_0002618',
       'MONDO_0007254', 'MONDO_0007576', 'MONDO_0002087', 'EFO_0003060',
       'MONDO_0044926', 'MONDO_0001187', 'EFO_0003897', 'EFO_0008549',
       'EFO_0001642', 'EFO_0001663', 'EFO_1000294', 'EFO_0000313',
       'EFO_0004142', 'MONDO_0008903', 'MONDO_0008170', 'EFO_0000565',
       'EFO_0006318', 'EFO_0003891', 'EFO_0005952'], dtype=object), 'count': 75}",[ENSG00000141736],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 9 approved and 66 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1237021,O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,PQXKDMSYBGKCJA-CVTJIBDQSA-N,Small molecule,True,LURASIDONE,2010.0,4.0,,False,True,['Latuda'],['Lurasidone'],"[('Wikipedia', array(['Lurasidone'], dtype=object)), ('drugbank', array(['DB08815'], dtype=object)), ('chEBI', array(['70735'], dtype=object))]",['CHEMBL1615372'],"{'rows': array(['EFO_0009963', 'EFO_0005411', 'MONDO_0005090', 'MONDO_0004985',
       'MONDO_0002009', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0009963',
       'MONDO_0004985', 'EFO_0003758', 'EFO_0005407'], dtype=object), 'count': 11}","[ENSG00000149295,ENSG00000102468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1497,CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,SNHRLVCMMWUAJD-SUYDQAKGSA-N,Small molecule,True,BETAMETHASONE VALERATE,1967.0,4.0,,False,True,"['Audavate' 'Audavate rd' 'Beta-val' 'Betacap' 'Betaderm'
 'Betameth val in coal tar' 'Betamethasone valerate' 'Betatrex' 'Betesil'
 'Betnovate rd' 'Betnovate-c' 'Betnovate-n' 'Bettamousse' 'Bextasol'
 'Dermabet' 'Fucibet' 'Luxiq' 'Valisone' 'Valnac' 'Xemacort']","['Betamethasone (as valerate)' 'Betamethasone 17-valerate'
 'Betamethasone valerate' 'Betamethasoni valeras' 'NSC-755912'
 'Rinderon v' 'Stanoval' 'Tokuderm']","[('DailyMed', array(['betamethasone%20valerate'], dtype=object)), ('PubChem', array(['144212605'], dtype=object)), ('Wikipedia', array(['Betamethasone_17-valerate'], dtype=object)), ('chEBI', array(['31277'], dtype=object))]",,"{'rows': array(['EFO_1001818', 'EFO_0000274', 'EFO_0000701', 'EFO_1001494',
       'EFO_0000676'], dtype=object), 'count': 5}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for skin disease and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1615369,CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O,XETBXHPXHHOLOE-UHFFFAOYSA-N,Small molecule,True,DABIGATRAN ETEXILATE MESYLATE,2008.0,4.0,CHEMBL539697,False,True,['Pradaxa'],"['BIBR 1048 MS' 'BIBR-1048-MS' 'Dabigatran etexilate mesilate'
 'Dabigatran etexilate mesylate']","[('DailyMed', array(['dabigatran%20etexilate%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa'],
      dtype=object)), ('chEBI', array(['70743'], dtype=object))]",,"{'rows': array(['EFO_0010726', 'EFO_0000275', 'EFO_0003827', 'EFO_0000712',
       'EFO_0004286', 'EFO_1000652', 'EFO_0003907'], dtype=object), 'count': 7}",[ENSG00000180210],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL19449,CC(C)C(=O)c1c(C(C)C)nn2ccccc12,ZJVFLBOZORBYFE-UHFFFAOYSA-N,Small molecule,False,IBUDILAST,1989.0,4.0,,False,True,[],['AV-411' 'AV411' 'Ibudilast' 'Ketas' 'MN-166'],"[('PubChem', array(['11114182', '124880396', '124880398', '144207052', '170466049',
       '46500478', '50104937', '90341511'], dtype=object)), ('Wikipedia', array(['Ibudilast'], dtype=object)), ('drugbank', array(['DB05266'], dtype=object))]",,"{'rows': array(['HP_0006536', 'EFO_1000783', 'MONDO_0004976', 'MONDO_0007079',
       'EFO_0003843', 'EFO_0004701', 'EFO_0000519', 'EFO_0003840',
       'EFO_0007541', 'EFO_0005611', 'MONDO_0005277', 'HP_0002196',
       'MONDO_0002491'], dtype=object), 'count': 13}","[ENSG00000138735,ENSG00000112541,ENSG00000172572,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 13 investigational indications.
CHEMBL2036958,CC1(CCCc2cc(=O)oc3[nH]c(=O)[nH]c(=O)c23)CC1,ARJKMWXLIHZLQZ-UHFFFAOYSA-N,Small molecule,False,SCH-900271,,2.0,,False,False,[],['SCH 900271' 'Sch 900271' 'Sch-900271'],"[('drugbank', array(['DB12433'], dtype=object))]",,,[ENSG00000182782],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2103797,Cc1cn([C@H]2C[C@H](OP(=O)([O-])OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],JKXXLIACMWFHSH-FIIWBELYSA-A,Oligonucleotide,False,BEVASIRANIB SODIUM,,-1.0,CHEMBL2110581,False,False,[],['Bevasiranib sodium' 'CAND5'],,,,"[ENSG00000164342,ENSG00000112715]",Oligonucleotide drug.
CHEMBL2109367,,,Antibody drug conjugate,False,LMB-2,,2.0,,False,False,[],['LMB-2' 'Lmb-2'],,,"{'rows': array(['EFO_0000574', 'EFO_0000565', 'EFO_1000956', 'MONDO_0019471'],
      dtype=object), 'count': 4}",[ENSG00000134460],Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2158685,O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,CAOTVXGYTWCKQE-UHFFFAOYSA-N,Small molecule,False,ABC-294640,,2.0,,False,False,[],['ABC 294640' 'Abc-294640' 'Abc294640' 'Opaganib'],"[('PubChem', array(['174006706'], dtype=object)), ('drugbank', array(['DB12764'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'EFO_0002618', 'MONDO_0008315', 'EFO_0005221',
       'EFO_0000403', 'EFO_0001378', 'EFO_0007224'], dtype=object), 'count': 7}",[ENSG00000063176],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL256087,CC1CCC(C(C)C)C(O)C1,NOOLISFMXDJSKH-UHFFFAOYSA-N,Small molecule,False,MENTHOL,2008.0,4.0,,False,True,"['Aqua-cool' 'Aquasoothe' 'Arjun' 'Catarrh' 'Dermacool' 'Halls' 'Karvol'
 'Lockets' 'Meggezones' 'Muirs' 'Tixylix decongestant inh' 'Vocalzone']","['Dl-menthol' 'FEMA NO. 2665' 'Meggezone' 'Menthol' 'Menthol racemate'
 'Menthol, cis-1,3,trans-1,4-' 'Menthol, dl-' 'NSC-2603' 'Rac-menthol'
 'Racementhol']","[('PubChem', array(['144207208', '144213774', '26754473', '29215309'], dtype=object)), ('chEBI', array(['25187'], dtype=object))]",,"{'rows': array(['EFO_0005856', 'HP_0000989', 'MONDO_0004979', 'EFO_0003958',
       'EFO_1001347', 'HP_0002015', 'EFO_0009846', 'EFO_0003843',
       'EFO_0009552', 'MONDO_0002471', 'MONDO_0005178', 'HP_0003326',
       'EFO_0009516', 'EFO_0009582', 'EFO_1001434', 'HP_0003394',
       'HP_0001742', 'EFO_0003768', 'MONDO_0001056', 'HP_0012735',
       'HP_0003418', 'EFO_0000546', 'MONDO_0002258', 'HP_0000155',
       'MONDO_0004857', 'EFO_0000537', 'EFO_0009661', 'MONDO_0021201',
       'EFO_0007214', 'HP_0002315', 'EFO_1000941', 'HP_0002829',
       'EFO_1000783'], dtype=object), 'count': 33}","[ENSG00000104321,ENSG00000144481]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 28 approved and 5 investigational indications.
CHEMBL278462,CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1,CVKJAXCQPFOAIN-VXGBXAGGSA-N,Small molecule,False,CIPRALISANT,,2.0,,False,False,[],"['(-)-GT-2331' 'Cipralisant' 'Cipralisant, (-)-' 'GT-2331']","[('Wikipedia', array(['Cipralisant'], dtype=object))]",['CHEMBL2106003'],,[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL298406,CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccccc3CC[C@@H]21,DMJWENQHWZZWDF-PKOBYXMFSA-N,Small molecule,False,ECOPIPAM,,3.0,,False,False,[],['Ecopipam' 'SCH-39166'],"[('PubChem', array(['144204748', '170466462'], dtype=object)), ('drugbank', array(['DB12273'], dtype=object))]",['CHEMBL1535402' 'CHEMBL1822916'],"{'rows': array(['EFO_0004270', 'MONDO_0002182', 'MONDO_0010298', 'EFO_0004895',
       'EFO_0004895', 'EFO_0004699'], dtype=object), 'count': 6}",[ENSG00000184845],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL3287218,Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1,ZIUDADZJCKGWKR-AREMUKBSSA-N,Small molecule,False,PF-5190457,,2.0,,False,False,[],['PF-5190457' 'Pf-05190457' 'Pf-5190457'],"[('drugbank', array(['DB14870'], dtype=object))]",,"{'rows': array(['EFO_0004329', 'MONDO_0007079', 'MONDO_0005148'], dtype=object), 'count': 3}",[ENSG00000121853],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3544930,,,Small molecule,False,SC-80036,,1.0,,False,False,[],['Sc-80036'],,,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545132,,,Antibody drug conjugate,False,MIRVETUXIMAB SORAVTANSINE,2022.0,4.0,,False,True,['Elahere'],"['Elahere' 'IMGN-853' 'IMGN853' 'Mirvetuximab soravtansine'
 'Mirvetuximab soravtansine gynx' 'Mirvetuximab soravtansine-gynx']",,,"{'rows': array(['EFO_1001100', 'MONDO_0011962', 'MONDO_0018364', 'MONDO_0007254',
       'EFO_0000616', 'MONDO_0002158', 'MONDO_0008170', 'EFO_0005537',
       'MONDO_0021092'], dtype=object), 'count': 9}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000110195]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 4 approved and 5 investigational indications.
CHEMBL3545381,,,Small molecule,False,PLX-7486,,1.0,,False,False,[],['Plx-7486'],,,"{'rows': array(['MONDO_0002171'], dtype=object), 'count': 1}","[ENSG00000198400,ENSG00000140538,ENSG00000182578,ENSG00000148053]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL4297232,,,Unknown,False,DICLOFENAC ETALHYALURONATE SODIUM,,-1.0,,False,False,[],['Diclofenac etalhyaluronate sodium' 'SI-613 SODIUM'],,,,"[ENSG00000073756,ENSG00000095303]",Unknown drug.
CHEMBL4297632,COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5,RQHILGKAOIGUHU-BUCMUWKRSA-N,Small molecule,False,OXYCODEGOL,,3.0,,False,False,[],['Loxicodegol' 'NKTR-181' 'Nktr-181' 'Oxicodegol' 'Oxycodegol'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OXYCODEGOL/relevant/1/'],
      dtype=object))]",['CHEMBL4298154'],"{'rows': array(['HP_0012532', 'EFO_0004616', 'HP_0003419', 'HP_0003419'],
      dtype=object), 'count': 4}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297728,,,Antibody,False,CIRMTUZUMAB,,3.0,,False,False,[],['Cirmtuzumab' 'UC-961' 'Zilovertamab'],,,"{'rows': array(['MONDO_0001056', 'EFO_0002618', 'EFO_0003060', 'MONDO_0008170',
       'EFO_0008528', 'EFO_0000096', 'MONDO_0008315', 'EFO_0005537',
       'EFO_0000403', 'EFO_0000095'], dtype=object), 'count': 10}",[ENSG00000185483],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL4298212,,,Antibody,False,RAVAGALIMAB,,2.0,,False,False,[],['ABBV-323' 'PR-1629977' 'Ravagalimab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RAVAGALIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000729', 'EFO_0000699', 'EFO_0005809', 'MP_0001845'],
      dtype=object), 'count': 4}",[ENSG00000102245],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL45,COc1ccc2[nH]cc(CCNC(C)=O)c2c1,DRLFMBDRBRZALE-UHFFFAOYSA-N,Small molecule,False,MELATONIN,2022.0,4.0,,False,True,"['Circadin' 'General nutrit' 'Health aid' 'Heidadouppi' 'Icenia'
 'Life ext' 'Melapure' 'Melatonin neurim' 'Natrol' ""Nature's blend""
 'Natures bounty' 'Quality health' 'S.gard' 'Travelag' 'Vespro'
 'Vytalonin']","['5-methoxy n-acetyl-tryptamine' 'BCI-049' 'J5.258B' 'Melatol' 'Melatonin'
 'Melatonine' 'Melovine' 'N-(2-(5-Methoxy-1H-Indol-3-Yl)Ethyl)Acetamide'
 'N-Acetyl-5-Methoxytryptamine' 'NSC-113928' 'NSC-302012' 'NSC-56423'
 'Regulin' 'Tartrol']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/melatonin-neurim'],
      dtype=object)), ('PubChem', array(['104171188', '105815', '11111468', '124880734', '124880739',
       '144208725', '144213243', '170465589', '17388930', '17389536',
       '26747238', '26752764', '46500483', '50105414', '85231137',
       '90340716'], dtype=object)), ('Wikipedia', array(['Melatonin'], dtype=object)), ('drugbank', array(['DB01065'], dtype=object)), ('chEBI', array(['16796'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'EFO_0000195', 'EFO_0000555', 'MONDO_0001134',
       'HP_0001919', 'MONDO_0100096', 'EFO_0000589', 'MONDO_0005090',
       'EFO_0000616', 'EFO_0005800', 'EFO_0003888', 'EFO_0005687',
       'EFO_0000729', 'EFO_0002496', 'EFO_0000546', 'HP_0000303',
       'HP_0100806', 'EFO_0003758', 'EFO_1000824', 'EFO_0000275',
       'EFO_0000280', 'EFO_0003918', 'HP_0012378', 'MONDO_0002050',
       'EFO_0002687', 'HP_0040187', 'EFO_0000474', 'EFO_0003756',
       'EFO_0008583', 'MP_0001914', 'EFO_1001216', 'EFO_0000701',
       'MONDO_0002009', 'EFO_1001904', 'EFO_0008568', 'HP_0100543',
       'EFO_0000649', 'EFO_0009267', 'EFO_0006859', 'EFO_0003948',
       'EFO_0003928', 'EFO_1001121', 'EFO_0009516', 'EFO_0005230',
       'MONDO_0024290', 'HP_0000726', 'MONDO_0005277', 'MONDO_0043510',
       'EFO_0000756', 'EFO_0000274', 'HP_0031217', 'EFO_0003929',
       'EFO_0001666', 'MONDO_0005180', 'HP_0000938', 'EFO_0005547',
       'EFO_0004698', 'EFO_0000400', 'EFO_0000712', 'EFO_0003958',
       'MONDO_0021698', 'MONDO_0004992', 'MONDO_0005301', 'EFO_0009579',
       'EFO_0000199', 'EFO_0003060', 'MONDO_0007254', 'MONDO_0002635',
       'MONDO_0005299', 'EFO_0000537'], dtype=object), 'count': 70}","[ENSG00000168412,ENSG00000134640]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for insomnia and has 69 investigational indications.
CHEMBL4577523,COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1,CVCVOSPZEVINRM-MRXNPFEDSA-N,Small molecule,False,GOLIDOCITINIB,,2.0,,False,False,[],['AZD-4205' 'AZD4205' 'AZD4205 free base' 'Azd4205' 'Golidocitinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GOLIDOCITINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000211', 'EFO_0003060', 'EFO_0005809', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000162434],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4594311,,,Gene,False,BETIBEGLOGENE AUTOTEMCEL,2019.0,4.0,,False,True,['Zynteglo'],['BB-305' 'Betibeglogene autotemcel' 'LentiGlobin BB305' 'Zynteglo'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo'],
      dtype=object))]",,"{'rows': array(['MONDO_0011382', 'Orphanet_848', 'MONDO_0016486'], dtype=object), 'count': 3}",[ENSG00000244734],Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for beta-thalassemia and beta-thalassemia major and has 1 investigational indication.
CHEMBL4650230,CN1CCC2(CC1)NCC(=O)N2Cc1ccccc1,BSQPTZYKCAULBH-UHFFFAOYSA-N,Small molecule,False,SIMUFILAM,,3.0,,False,False,['Filora'],['C-0105' 'C0105' 'C0105M' 'PTI-125' 'PTI-910' 'Simufilam'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMUFILAM/relevant/1/'],
      dtype=object))]",['CHEMBL4650231'],"{'rows': array(['MONDO_0004975', 'MONDO_0004975', 'EFO_0000616', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000196924],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL522892,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,PIQCTGMSNWUMAF-UHFFFAOYSA-N,Small molecule,False,DOVITINIB,,3.0,,False,False,[],['CHIR-258' 'Dovitinib' 'GFKI-258' 'NVP-TKI258' 'TKI-258' 'Tki-258'],"[('PubChem', array(['103904684', '137275871', '50100092'], dtype=object)), ('drugbank', array(['DB05928'], dtype=object))]",['CHEMBL4297063'],"{'rows': array(['EFO_0000182', 'MONDO_0008667', 'EFO_0000222', 'MONDO_0008315',
       'EFO_1001465', 'MONDO_0011719', 'MONDO_0005184', 'EFO_0001378',
       'MONDO_0007254', 'MONDO_0001187', 'EFO_0003060', 'EFO_0000231',
       'EFO_1000796', 'EFO_0003060', 'MONDO_0002108', 'EFO_0000519',
       'EFO_0000756', 'MONDO_0001056', 'EFO_0000770', 'EFO_0000349',
       'MONDO_0011962', 'MONDO_0004992', 'EFO_0000681', 'EFO_0003863',
       'EFO_0000616'], dtype=object), 'count': 25}","[ENSG00000157404,ENSG00000122025,ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000068078]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 25 investigational indications.
CHEMBL5315056,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O,TXMZWEASFRBVKY-IOQDSZRYSA-N,Small molecule,False,NALOXONE HYDROCHLORIDE DIHYDRATE,2017.0,4.0,CHEMBL80,False,True,['Nyxoid'],['Naloxone chlorhydrate' 'Naloxoni hydrochloridum dihydrate'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid'],
      dtype=object))]",,"{'rows': array(['EFO_0005611'], dtype=object), 'count': 1}","[ENSG00000082556,ENSG00000116329,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for opioid dependence.
CHEMBL551813,CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)nc(N(C)C)c1CC(=O)O,XEOSTBFUCNZKGS-UHFFFAOYSA-N,Small molecule,False,BI-671800,,2.0,,False,False,[],['Actimis' 'BI 671800' 'BI671800' 'Bi 671800' 'Bi-671800'],"[('PubChem', array(['174006824'], dtype=object)), ('drugbank', array(['DB12524'], dtype=object))]",,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1098,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,LEBVLXFERQHONN-UHFFFAOYSA-N,Small molecule,True,BUPIVACAINE,1972.0,4.0,,False,True,"['Anekain' 'Exparel' 'Exparel liposomal' 'Marcaine' 'Posimir'
 'Sensorcaine']","['Bucaine' 'Bupivacaine' 'Bupivacaine liposome' 'LIQ-865' 'LIQ865'
 'Liposomal bupivacaine' 'Marcaine'
 'Ropivacaine hydrochloride impurity, bupivacaine-' 'SKY-0402' 'SKY0402'
 'Sensorcaine']","[('DailyMed', array(['bupivacaine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal'],
      dtype=object)), ('PubChem', array(['160644527'], dtype=object)), ('Wikipedia', array(['Bupivacaine'], dtype=object)), ('drugbank', array(['DB00297'], dtype=object)), ('chEBI', array(['77431'], dtype=object))]",['CHEMBL1200396'],"{'rows': array(['EFO_0003833', 'HP_0002315', 'HP_0001623', 'EFO_0000546',
       'EFO_1001866', 'EFO_0005251', 'MONDO_0000728', 'HP_0000175',
       'EFO_0007490', 'MONDO_0005277', 'EFO_0003060', 'MONDO_0007254',
       'EFO_0002950', 'HP_0000023', 'MONDO_0005178', 'EFO_1001792',
       'EFO_1000994', 'EFO_0004229', 'EFO_0009615', 'EFO_1000786',
       'EFO_1001250', 'EFO_0000342', 'EFO_1001267', 'HP_0001537',
       'EFO_1001909', 'EFO_0003869', 'EFO_0009676', 'EFO_0003964',
       'MONDO_0002087', 'EFO_0003931', 'HP_0012227', 'EFO_0010072',
       'EFO_0005762', 'MONDO_0041052', 'HP_0012532', 'HP_0000023',
       'EFO_0004888', 'EFO_1001331', 'HP_0009926', 'MONDO_0005277',
       'EFO_0004209', 'EFO_0002618', 'EFO_0003818', 'MONDO_0004992',
       'EFO_0001358', 'HP_0030834', 'MONDO_0021117', 'EFO_0000691',
       'EFO_1001139', 'MONDO_0008315', 'HP_0001822', 'HP_0002027',
       'EFO_0004616', 'EFO_0009620', 'EFO_0003843', 'MONDO_0004567',
       'EFO_0000764', 'HP_0000175', 'EFO_1001087', 'HP_0100790',
       'HP_0012735', 'EFO_0003843', 'EFO_0000275', 'HP_0012532',
       'MONDO_0007254', 'MONDO_0002959', 'EFO_0004616', 'HP_0001822',
       'EFO_0009314', 'HP_0031217', 'EFO_0001074', 'EFO_0001421',
       'MONDO_0004992', 'EFO_0007149', 'EFO_0009552', 'EFO_0000616',
       'MP_0001914', 'EFO_1001968', 'EFO_0009552', 'EFO_0000546',
       'EFO_0007486', 'HP_0003419', 'EFO_0000764', 'EFO_1001898'],
      dtype=object), 'count': 84}",[ENSG00000007314],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for pain and hernia and has 76 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200771,CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-],XJGONMZLEDGBRM-UHFFFAOYSA-M,Small molecule,False,TRIDIHEXETHYL CHLORIDE,1954.0,4.0,CHEMBL1201354,False,True,['Pathilon'],['Tridihexethyl chloride'],"[('PubChem', array(['144204284', '56463141'], dtype=object)), ('chEBI', array(['9703'], dtype=object))]",,,"[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954.
CHEMBL1201182,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CBPNZQVSJQDFBE-FUXHJELOSA-N,Small molecule,False,TEMSIROLIMUS,2007.0,4.0,,False,True,['Torisel'],['CCI-779' 'Temsirolimus'],"[('DailyMed', array(['temsirolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/torisel'],
      dtype=object)), ('PubChem', array(['144206068'], dtype=object)), ('Wikipedia', array(['Temsirolimus'], dtype=object)), ('drugbank', array(['DB06287'], dtype=object)), ('chEBI', array(['79699'], dtype=object))]",,"{'rows': array(['EFO_0000437', 'EFO_0000403', 'EFO_1000292', 'EFO_0000632',
       'EFO_0000702', 'EFO_0000181', 'EFO_0000685', 'EFO_1000026',
       'EFO_0000756', 'EFO_0003929', 'MONDO_0004992', 'MONDO_0004192',
       'EFO_0000565', 'EFO_0000222', 'EFO_0001378', 'MONDO_0002691',
       'EFO_0000616', 'EFO_0003869', 'EFO_0003833', 'MONDO_0001187',
       'MONDO_0002367', 'EFO_0003060', 'MONDO_0002974', 'EFO_0000313',
       'EFO_0007416', 'EFO_1000251', 'EFO_1001187', 'EFO_1001469',
       'EFO_0000182', 'EFO_0000305', 'MONDO_0003268', 'EFO_0000232',
       'EFO_0000248', 'EFO_0000681', 'EFO_0000228', 'MONDO_0016693',
       'EFO_0004265', 'EFO_1001512', 'EFO_1001968', 'EFO_0002501',
       'MONDO_0016691', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0002158',
       'MONDO_0024677', 'MONDO_0002108', 'EFO_0000183', 'EFO_0000574',
       'EFO_0000349', 'EFO_0000673', 'MONDO_0008315', 'EFO_0005952',
       'EFO_0000707', 'EFO_0000466', 'EFO_1000158', 'EFO_0000637',
       'EFO_0000502', 'EFO_0000621', 'EFO_1001465', 'EFO_0000556',
       'EFO_0009708', 'MONDO_0007254', 'EFO_0000519', 'EFO_0002499',
       'EFO_0007532', 'MONDO_0008170', 'EFO_0000339', 'EFO_1001331',
       'EFO_0000691', 'EFO_1000613', 'EFO_0000365', 'EFO_0006861',
       'EFO_0000389', 'MONDO_0021063', 'MONDO_0011962', 'EFO_0000198'],
      dtype=object), 'count': 76}",[ENSG00000088832],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 71 investigational indications.
CHEMBL1467,Oc1ncnc2[nH]ncc12,OFCNXPDARWKPPY-UHFFFAOYSA-N,Small molecule,False,ALLOPURINOL,1966.0,4.0,,False,True,"['Allopurinol' 'Aloral' 'Aluline 100' 'Aluline 300' 'Caplenal' 'Cosuric'
 'Hamarin 100' 'Hamarin 300' 'Ledopur' 'Lopurin' 'Uricto' 'Xanthomax-100'
 'Xanthomax-300' 'Zyloprim' 'Zyloric' 'Zyloric-300']","['Allopurinol' 'Allopurinolum' 'BW 56-158' 'BW-56-158' 'NSC-101655'
 'NSC-1390' 'Suspendol' 'Takanarumin']","[('DailyMed', array(['allopurinol'], dtype=object)), ('PubChem', array(['11110781', '144203633', '144208120', '170464935', '17389550',
       '174007214', '26747845', '50105533', '56424020', '8139898',
       '90341357'], dtype=object)), ('TG-GATEs', array(['28'], dtype=object)), ('Wikipedia', array(['Allopurinol'], dtype=object)), ('drugbank', array(['DB00437'], dtype=object)), ('chEBI', array(['40279'], dtype=object))]",['CHEMBL1200477'],"{'rows': array(['MONDO_0002087', 'EFO_0000319', 'EFO_0009104', 'EFO_1001893',
       'EFO_1001793', 'EFO_0005044', 'EFO_0003913', 'EFO_0000195',
       'MONDO_0005148', 'EFO_0000198', 'EFO_0000729', 'EFO_0005952',
       'EFO_0005207', 'EFO_0004274', 'EFO_0000565', 'EFO_0000574',
       'EFO_0000400', 'EFO_0000095', 'EFO_0004251', 'EFO_0000220',
       'EFO_0000702', 'EFO_0000537', 'EFO_0001422', 'MONDO_0001134',
       'EFO_0003777', 'MONDO_0004992', 'MONDO_0002158', 'EFO_0003884',
       'EFO_0000373', 'EFO_0003767', 'EFO_0001073', 'EFO_0001378',
       'EFO_0004253', 'MONDO_0005178', 'EFO_1001479', 'MONDO_0018076',
       'EFO_0000094', 'EFO_0003144', 'MONDO_0008170', 'MONDO_0004985',
       'EFO_0009582', 'EFO_0000222'], dtype=object), 'count': 42}",[ENSG00000158125],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 4 approved and 38 investigational indications.
CHEMBL1569487,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,WLHQHAUOOXYABV-UHFFFAOYSA-N,Small molecule,False,LORNOXICAM,,4.0,,False,True,['Xefo'],"['CTX' 'Lorcam' 'Lornoxicam' 'NSC-759620' 'RO 13-9297' 'RO-13-9297'
 'RO-139297']","[('PubChem', array(['49666507'], dtype=object)), ('drugbank', array(['DB06725'], dtype=object)), ('chEBI', array(['31783'], dtype=object))]",,"{'rows': array(['EFO_0005755', 'MONDO_0005277', 'EFO_0003843', 'MONDO_0004975'],
      dtype=object), 'count': 4}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 3 investigational indications.
CHEMBL1623,Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1,OCJYIGYOJCODJL-UHFFFAOYSA-N,Small molecule,False,MECLIZINE,1957.0,4.0,,False,True,[],['Meclizine' 'Meclozine' 'NSC-169189'],"[('Wikipedia', array(['Meclozine'], dtype=object)), ('drugbank', array(['DB00737'], dtype=object)), ('chEBI', array(['6709'], dtype=object))]",['CHEMBL1200590' 'CHEMBL1324020' 'CHEMBL3989555' 'CHEMBL1085765'],"{'rows': array(['MONDO_0005271', 'HP_0002013', 'EFO_0006928', 'HP_0002321',
       'HP_0002018', 'EFO_0004319', 'HP_0002321', 'EFO_0000182',
       'HP_0002017', 'EFO_0006928'], dtype=object), 'count': 10}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved and 4 investigational indications.
CHEMBL1670,Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1,JWBOIMRXGHLCPP-UHFFFAOYSA-N,Small molecule,True,MITOTANE,1970.0,4.0,,False,True,['Lysodren' 'Opddd'],"['CB 313' 'CB-313' 'Chloditan' 'Chlodithane' 'Mitotan' 'Mitotane'
 'NSC-38721' ""O,p'-ddd"" ""O,p'-ddd,o p'-tde"" ""O,p'-tde"" 'Opeprim']","[('DailyMed', array(['mitotane'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lysodren'],
      dtype=object)), ('PubChem', array(['104171128', '144203654', '144213121', '170464927', '17389949',
       '174007193', '26747348', '26752984', '50105583', '56462780',
       '85230966', '90341596', '94579'], dtype=object)), ('Wikipedia', array(['Mitotane'], dtype=object)), ('drugbank', array(['DB00648'], dtype=object))]",,"{'rows': array(['EFO_0000313', 'MONDO_0036591', 'EFO_1000796', 'MONDO_0008315',
       'EFO_0000616'], dtype=object), 'count': 5}","[ENSG00000140459,ENSG00000160882]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743082,,,Antibody drug conjugate,True,TRASTUZUMAB EMTANSINE,2013.0,4.0,,False,True,['Kadcyla'],"['PRO-132365' 'RG-3502' 'TRASTUZUMAB-MCC-DM1 T-DM1'
 'Trastuzumab emtansine']","[('DailyMed', array(['ado-trastuzumab%20emtansine'], dtype=object)), ('DrugCentral', array(['4990'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla'],
      dtype=object))]",,"{'rows': array(['EFO_1000294', 'EFO_1000984', 'MONDO_0000521', 'EFO_0001378',
       'EFO_0003869', 'EFO_0000305', 'MONDO_0008170', 'EFO_0009708',
       'EFO_0003060', 'MONDO_0004992', 'MONDO_0004669', 'MONDO_0001056',
       'MONDO_0011962', 'MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 15}","[ENSG00000141736,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103867,CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)O,NSPHQWLKCGGCQR-DLJDZFDSSA-N,Protein,True,PLECANATIDE,2017.0,4.0,,False,True,['Trulance'],['Guanilib' 'Plecanatide' 'SP-304' 'SP-304 (SYNERGY)'],"[('drugbank', array(['DB13170'], dtype=object))]",,"{'rows': array(['HP_0002019', 'EFO_0000555'], dtype=object), 'count': 2}",[ENSG00000070019],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for constipation and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL2108359,,,Antibody,False,NIMOTUZUMAB,,3.0,,False,False,['Theraloc theracim'],['HR3' 'Nimotuzumab' 'OSAG 101' 'THERACIM-HR3' 'THERALOC'],,,"{'rows': array(['EFO_0007331', 'EFO_0003060', 'MONDO_0002974', 'EFO_0002916',
       'MONDO_0001325', 'EFO_0000181', 'EFO_0000326', 'EFO_1001931',
       'MONDO_0005575', 'EFO_0003897', 'EFO_0000228', 'EFO_1000657',
       'MONDO_0007254', 'EFO_0000199', 'EFO_0000313', 'EFO_0006859',
       'EFO_0000616', 'EFO_1000026', 'EFO_0000707', 'EFO_0005922',
       'MONDO_0007576', 'EFO_0002618', 'MONDO_0001056', 'EFO_0002938',
       'EFO_1001951', 'MONDO_0004992', 'MONDO_0002914', 'EFO_0000519',
       'MONDO_0008903', 'EFO_0004252'], dtype=object), 'count': 30}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications.
CHEMBL2109072,,,Unknown,False,"FIBRINOGEN, HUMAN",,3.0,,False,False,[],"['Evarrest' 'Factor i (fibrinogen)' 'Factor i human' 'Fibrinogen'
 'Fibrinogen (human)' 'Fibrinogen concentrate (human)'
 'Fibrinogen concentrate human' 'Fibrinogen human'
 'Fibrinogen human plasma-derived' 'Fibrinogen, human' 'Haemocomplettan p'
 'Human fibrinogen' 'Parenogen' 'Raplixa']",,,"{'rows': array(['EFO_0001421', 'EFO_0005207', 'EFO_0009579', 'EFO_0010282',
       'EFO_0003777', 'MONDO_0008737', 'HP_0001871', 'HP_0031273',
       'EFO_0000546', 'MP_0001914', 'HP_0002647'], dtype=object), 'count': 11}","[ENSG00000171560,ENSG00000171564,ENSG00000171557]",Unknown drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications.
CHEMBL2170582,CNC(=O)COc1cccc(Nc2ncc(F)c(Nc3ccc4c(c3)NC(=O)C(F)(F)O4)n2)c1,MOXXQFNQDDSJHT-UHFFFAOYSA-N,Small molecule,False,R-343,,2.0,,False,False,[],['R-343'],,['CHEMBL3545340'],"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000165025],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL298734,NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,DHMTURDWPRKSOA-RUZDIDTESA-N,Small molecule,False,LONAFARNIB,2020.0,4.0,,False,True,['Zokinvy'],['Lonafarnib' 'SCH 66336' 'SCH-66336' 'SCH66336' 'Sarasar'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy'],
      dtype=object)), ('Wikipedia', array(['Lonafarnib'], dtype=object)), ('drugbank', array(['DB06448'], dtype=object))]",,"{'rows': array(['EFO_1001779', 'MONDO_0004192', 'EFO_0007304', 'MONDO_0007254',
       'EFO_0000339', 'EFO_0006859', 'EFO_0009708', 'EFO_0002499',
       'EFO_0000574', 'EFO_0000198', 'EFO_1000158', 'MONDO_0001187',
       'MONDO_0008310', 'MONDO_0002691', 'MONDO_0008170', 'EFO_0003060',
       'MONDO_0020732', 'EFO_1001951', 'EFO_1001465'], dtype=object), 'count': 19}","[ENSG00000168522,ENSG00000257365]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hutchinson-gilford progeria syndrome and progeria and has 17 investigational indications.
CHEMBL3182733,CCCN[C@H]1CCc2nc(N)sc2C1.Cl.Cl.O,APVQOOKHDZVJEX-QTPLPEIMSA-N,Small molecule,False,PRAMIPEXOLE DIHYDROCHLORIDE,1997.0,4.0,CHEMBL301265,False,True,"['Mirapex' 'Mirapex Extended Release' 'Mirapex er' 'Oprymea'
 'Pramipexole dihydrochloride']","['Daquiran' 'PNU-98528E' 'Pramipexole accord'
 'Pramipexole dihydrochloride' 'Pramipexole dihydrochloride anhydrous'
 'Pramipexole dihydrochloride monohydrate' 'Pramipexole hydrochloride'
 'Pramipexole hydrochloride hydrate' 'Pramipexole teva' 'SND-919CL2Y'
 'SND919CL2Y' 'Sifrol']","[('DailyMed', array(['pramipexole%20dihydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oprymea'],
      dtype=object)), ('PubChem', array(['144212633'], dtype=object)), ('chEBI', array(['51147'], dtype=object))]",,"{'rows': array(['EFO_0004270', 'MONDO_0004976', 'MONDO_0005180', 'MONDO_0004985'],
      dtype=object), 'count': 4}","[ENSG00000149295,ENSG00000151577,ENSG00000069696]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for restless legs syndrome and parkinson disease and has 2 investigational indications.
CHEMBL3304244,Cc1nn(-c2ncccc2CO)cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc12,NKQHBJNRBKHUQR-UHFFFAOYSA-N,Small molecule,False,LY-2940094,,2.0,,False,False,[],['BTRX-246040' 'Btrx-246040' 'J3.309.394B' 'Ly-2940094'],,['CHEMBL3236487'],"{'rows': array(['MONDO_0005180', 'MONDO_0002009'], dtype=object), 'count': 2}",[ENSG00000125510],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3545376,COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,OLAHOMJCDNXHFI-UHFFFAOYSA-N,Small molecule,False,ERDAFITINIB,2019.0,4.0,,False,True,['Balversa'],['Erdafitinib' 'JNJ-42756493' 'Jnj-42756493'],"[('DailyMed', array(['erdafitinib'], dtype=object)), ('drugbank', array(['DB12147'], dtype=object))]",['CHEMBL3918638' 'CHEMBL3919709' 'CHEMBL3975791' 'CHEMBL3948043'],"{'rows': array(['EFO_0000519', 'EFO_0003863', 'EFO_0008528', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0007254', 'EFO_0000574', 'EFO_0001421',
       'EFO_0001378', 'EFO_0000196', 'MONDO_0001187', 'EFO_0000294',
       'EFO_0000616', 'EFO_0000708', 'EFO_0000673', 'EFO_0000182'],
      dtype=object), 'count': 16}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 11 investigational indications.
CHEMBL359164,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,RXRGZNYSEHTMHC-BQBZGAKWSA-N,Small molecule,False,TROXACITABINE,,2.0,,False,False,[],"['(-)-ODDC' 'BCH-4556' 'Lamivudine impurity i' 'Lamivudine impurity i rs'
 'Troxacitabine' 'Troxatyl']","[('Wikipedia', array(['Troxacitabine'], dtype=object)), ('drugbank', array(['DB04961'], dtype=object))]",,"{'rows': array(['EFO_0000565'], dtype=object), 'count': 1}","[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3707317,,,Small molecule,False,LOREDIPLON,,2.0,,False,False,[],['Gf-015535-00' 'Lorediplon'],,,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3707331,C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,FIVSJYGQAIEMOC-ZGNKEGEESA-N,Small molecule,False,ROLAPITANT,2015.0,4.0,,False,True,['Varuby'],['Rolapitant'],"[('drugbank', array(['DB09291'], dtype=object))]",['CHEMBL3707330'],"{'rows': array(['EFO_0006911', 'EFO_0004888', 'HP_0002018', 'EFO_0000691',
       'EFO_0006911'], dtype=object), 'count': 5}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for chemotherapy-induced nausea and vomiting and has 4 investigational indications.
CHEMBL3989521,CC(C)NCC(O)c1ccc(O)c(O)c1.CC(C)NCC(O)c1ccc(O)c(O)c1.O.O.O=S(=O)(O)O,CUQPTVCVZLUXJB-UHFFFAOYSA-N,Small molecule,False,ISOPROTERENOL SULFATE,1956.0,4.0,CHEMBL434,False,True,['Medihaler-iso' 'Norisodrine'],"['Aludrin' 'Isomist' 'Isoprenaline sulfate'
 'Isoprenaline sulfate dihydrate' 'Isoprenaline sulphate'
 'Isoprenalini sulfas' 'Isopropylarterenol sulfate'
 'Isoproterenol sulfate' 'Isoproterenol sulfate anhydrous'
 'Isoproterenol sulfate dihydrate' 'Isoproterenol sulphate' 'Propal']",,,,"[ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL4297480,O=C(Nc1ccc(F)cc1)c1cnc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1,SDUDZBCEHIZMFZ-UHFFFAOYSA-N,Small molecule,False,SX-682,,2.0,,False,False,[],['SX-682' 'SX682' 'Sx-682'],,,"{'rows': array(['MONDO_0005184', 'EFO_0000756', 'EFO_0002618', 'EFO_0000198',
       'EFO_1001949', 'EFO_1000657', 'EFO_0003060'], dtype=object), 'count': 7}","[ENSG00000163464,ENSG00000180871]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4297701,,,Unknown,False,BIO-11006,,2.0,,False,False,[],['BIO-11006' 'Bio-11006'],,,"{'rows': array(['EFO_0000341', 'EFO_0003060', 'MONDO_0100130'], dtype=object), 'count': 3}",[ENSG00000277443],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297842,,,Antibody,False,TOMUZOTUXIMAB,,2.0,,False,False,[],['Tomuzotuximab'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298172,O=C(c1cccnc1-c1ccncc1)N1CCC(O)(Cc2ccccc2)CC1,XKUZMIUSBMCVPP-UHFFFAOYSA-N,Small molecule,False,SOTICLESTAT,,3.0,,False,False,[],['OV-935' 'OV935' 'Soticlestat' 'TAK-935' 'TAK935'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOTICLESTAT/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001998', 'MONDO_0016532', 'HP_0001250', 'EFO_0001421',
       'EFO_0000474'], dtype=object), 'count': 5}",[ENSG00000036530],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL490665,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl,DJSFYNINGIMKAG-FQJQBBMWSA-N,Small molecule,False,NALFURAFINE HYDROCHLORIDE,2009.0,4.0,CHEMBL267495,False,True,[],"['Nalfurafine hcl' 'Nalfurafine hydrochloride' 'Nopicor' 'Remitch'
 'TRK-820']",,,"{'rows': array(['EFO_0003884', 'EFO_0001421'], dtype=object), 'count': 2}",[ENSG00000082556],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 2 investigational indications.
CHEMBL5314407,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+],HXINDCTZKGGRDE-JPKZNVRTSA-L,Small molecule,False,ARQ-736,,1.0,CHEMBL5316167,False,False,[],['ARQ-736' 'Arq 736' 'Arq-736'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000132155,ENSG00000157764]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL563,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,SYTBZMRGLBWNTM-UHFFFAOYSA-N,Small molecule,True,FLURBIPROFEN,1986.0,4.0,,False,True,"['Ansaid' 'Cebutid' 'Flurbiprofen' 'Froben' 'Froben sr' 'Strefen'
 'Transact']","['BTS 18,322' 'BTS-18322' 'Flubiprofen' 'Flurbiprofen' 'NSC-757037'
 'Ocufen' 'U-27,182' 'U-27182']","[('DailyMed', array(['flurbiprofen'], dtype=object)), ('PubChem', array(['144204098', '144212670', '174007327', '26747178', '49732000',
       '520771', '855731', '860839'], dtype=object)), ('Wikipedia', array(['Flurbiprofen'], dtype=object)), ('drugbank', array(['DB00712'], dtype=object)), ('chEBI', array(['5130'], dtype=object))]",['CHEMBL3989754' 'CHEMBL1200990'],"{'rows': array(['HP_0003419', 'MONDO_0044970', 'EFO_0005752', 'EFO_0000649',
       'EFO_0000685', 'HP_0000616', 'EFO_0000764', 'MONDO_0002258',
       'EFO_0003843', 'HP_0003326', 'MONDO_0005148', 'HP_0002829',
       'EFO_0003931', 'EFO_0005755', 'EFO_0004272'], dtype=object), 'count': 15}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL691,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,BFPYWIDHMRZLRN-SLHNCBLASA-N,Small molecule,False,ETHINYL ESTRADIOL,2001.0,4.0,,False,True,['Estinyl' 'Etinestryl' 'Feminone' 'Follicoral' 'Lynoral'],"['17-ethinylestradiol' '17alpha-ethinylestradiol' 'Enovid' 'Enovid-E'
 'Ethinyl Estradiol' 'Ethinyl estradiol' 'Ethinylestradiol'
 'Ethinylestradiolum' 'Ethinyloestradiol' 'Ethynylestradiol' 'Ginestrene'
 'NSC-10973' 'Norinyl' 'Ovulen' 'Ovulen-21' 'Ovulen-28']","[('DailyMed', array(['ethinyl%20estradiol'], dtype=object)), ('PubChem', array(['144204698', '144208489', '144210731', '170464983', '26753042',
       '76025'], dtype=object)), ('TG-GATEs', array(['55'], dtype=object)), ('drugbank', array(['DB00977'], dtype=object)), ('chEBI', array(['4903'], dtype=object))]",,"{'rows': array(['EFO_0000660', 'EFO_0005924', 'MONDO_0005148', 'HP_0100608',
       'HP_0100607', 'MONDO_0009061', 'EFO_0000616', 'EFO_0010269',
       'MONDO_0004992', 'HP_0000938', 'MONDO_0002050', 'EFO_0008560',
       'EFO_1000710', 'EFO_0003047', 'MONDO_0019499', 'MONDO_0007254',
       'MONDO_0011962', 'EFO_0003882', 'EFO_0003894', 'MONDO_0004169',
       'EFO_0000764', 'MONDO_0005277', 'EFO_0004220', 'EFO_0009006',
       'MONDO_0018075', 'EFO_0000095', 'EFO_0004239', 'EFO_1001249',
       'EFO_0005204', 'EFO_0000180', 'EFO_0002950', 'MONDO_0005351'],
      dtype=object), 'count': 32}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 29 investigational indications.
CHEMBL81,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,GZUITABIAKMVPG-UHFFFAOYSA-N,Small molecule,True,RALOXIFENE,1997.0,4.0,,False,True,[],"['Eviden' 'Evista' 'J22.982B' 'Keoxifene' 'LY-139481' 'NSC-747974'
 'Raloxifene' 'Raloxiphene' 'Raxeto']","[('PubChem', array(['104171230', '11111733', '11111734', '144209801', '174007256',
       '26755239', '50105675', '90341181'], dtype=object)), ('Wikipedia', array(['Raloxifene'], dtype=object)), ('drugbank', array(['DB00481'], dtype=object)), ('chEBI', array(['8772'], dtype=object))]",['CHEMBL1116'],"{'rows': array(['GO_0042697', 'MONDO_0007254', 'EFO_0003854', 'HP_0100543',
       'MONDO_0004975', 'EFO_0000660', 'EFO_0000673', 'EFO_0003882',
       'EFO_0003882', 'EFO_0005411', 'EFO_0000673', 'MONDO_0011962',
       'EFO_0000694', 'MONDO_0007254', 'HP_0000938', 'MONDO_0005090',
       'EFO_0003854'], dtype=object), 'count': 17}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL827,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,DUGOZIWVEXMGBE-CHWSQXEVSA-N,Small molecule,False,DEXMETHYLPHENIDATE,,4.0,,False,True,[],['Dexmethylphenidate' 'Methylphenidate d-threo-form'],"[('Wikipedia', array(['Dexmethylphenidate'], dtype=object)), ('drugbank', array(['DB06701'], dtype=object)), ('chEBI', array(['51860'], dtype=object))]",['CHEMBL904'],"{'rows': array(['EFO_0003888', 'EFO_0003888'], dtype=object), 'count': 2}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for attention deficit hyperactivity disorder.
CHEMBL877,NC[C@H]1CC[C@H](C(=O)O)CC1,GYDJEQRTZSCIOI-LJGSYFOKSA-N,Small molecule,False,TRANEXAMIC ACID,1986.0,4.0,,False,True,"['Cyklo-f heavy period relief' 'Cyklokapron' 'Exacyl' 'Lysteda'
 'Menstralite' 'Tranexamic acid']","['Amcha' 'CL 65336' 'CL-65336' 'CL65336' 'Cyclo-f' 'Cyclocapron'
 'Cyclokapron' 'Espercil' 'Femstrual' 'Haematrix' 'LB-1148' 'LB1148'
 'NSC-291305' 'RP-18429' 'Rikavarin' 'TRANS AMCHA' 'TRANS-AMCHA'
 'Tranexamic acid' 'Trans AMCHA' 'Transamin']","[('DailyMed', array(['tranexamic%20acid'], dtype=object)), ('Wikipedia', array(['Tranexamic_acid'], dtype=object)), ('drugbank', array(['DB00302'], dtype=object)), ('chEBI', array(['48669'], dtype=object))]",,"{'rows': array(['HP_0003418', 'EFO_0004273', 'EFO_0009579', 'EFO_1000391',
       'EFO_0009516', 'MONDO_0007254', 'EFO_0006834', 'MONDO_0004992',
       'EFO_0005669', 'EFO_0000731', 'EFO_0000546', 'EFO_0004272',
       'HP_0100806', 'MONDO_0005178', 'EFO_0001645', 'EFO_0007440',
       'EFO_1000999', 'EFO_0004214', 'MONDO_0010602', 'MP_0001914',
       'MONDO_0021148', 'EFO_0001642', 'EFO_0003843', 'MONDO_0044881',
       'EFO_0000756', 'MONDO_0008315', 'MONDO_0043510', 'EFO_0003895',
       'EFO_0004710', 'EFO_1001792', 'EFO_1000350', 'EFO_0003833',
       'MONDO_0016642', 'MP_0001845', 'HP_0002239', 'EFO_0003931',
       'EFO_0003963', 'EFO_0004198', 'EFO_0007442', 'HP_0000132',
       'HP_0031273', 'EFO_0009314', 'MONDO_0004567', 'EFO_0004616',
       'EFO_0004284', 'EFO_0010680', 'EFO_0000713', 'EFO_0000326',
       'MONDO_0019623', 'MONDO_0001187', 'HP_0003040', 'EFO_0000272',
       'EFO_1001178', 'HP_0008419', 'HP_0002105', 'EFO_0005251',
       'EFO_0003964', 'MONDO_0019180', 'MONDO_0100096', 'EFO_1001801',
       'HP_0001873'], dtype=object), 'count': 61}",[ENSG00000122194],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 58 investigational indications.
CHEMBL1090771,NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(-c2ncon2)cc1F)S(=O)(=O)c1ccc(Cl)cc1,XEAOPVUAMONVLA-QGZVFWFLSA-N,Small molecule,False,AVAGACESTAT,,2.0,,False,False,[],"['Avagacestat' 'BMS 708163' 'BMS-708163' 'BMS-708163-01' 'BMS-70816301'
 'BMS708163']","[('drugbank', array(['DB11893'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL119549,O=C(Nc1ccc(-c2nnn[nH]2)cc1)c1ccc(-c2nnn[nH]2)cc1,VXEBMQZDPONDFB-UHFFFAOYSA-N,Small molecule,False,ANDOLAST,,2.0,,False,False,[],['Andolast' 'Cr2039'],,,,[ENSG00000156113],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1200845,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1,MUQNGPZZQDCDFT-JNQJZLCISA-N,Small molecule,False,HALCINONIDE,1974.0,4.0,,False,True,['Halog' 'Halog-e'],['Halcinonide' 'NSC-758413' 'SO 18566' 'SO-18566' 'SQ 18566' 'SQ-18566'],"[('DailyMed', array(['halcinonide'], dtype=object)), ('PubChem', array(['144204081', '170465389', '56463097'], dtype=object)), ('Wikipedia', array(['Halcinonide'], dtype=object)), ('drugbank', array(['DB06786'], dtype=object))]",,"{'rows': array(['EFO_0000701'], dtype=object), 'count': 1}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for skin disease.
CHEMBL1200914,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl,ZZIZZTHXZRDOFM-XFULWGLBSA-N,Small molecule,False,TAMSULOSIN HYDROCHLORIDE,1997.0,4.0,CHEMBL836,False,True,"['Alphacard mr' 'Bazetham mr' 'Contiflo xl' 'Cositam xl' 'Diffundox'
 'Faramsil' 'Flectone xl' 'Flomax' 'Flomax mr' 'Flomax relief mr'
 'Flomaxtra xl' 'Galebon' 'Losinate mr' 'Maxtron' 'Morvesin xl' 'Omnic mr'
 'Pamsvax xl' 'Petyme' 'Pinexel pr' 'Prosurin xl' 'Stronazon' 'Tabphyn mr'
 'Tamfrex xl' 'Tamsulosin hydrochloride' 'Tamurex']","['Harnal' 'LY-253351' 'LY253351' 'R-(-)-YM-12617' 'Tamsulosin hcl'
 'Tamsulosin hydrochloride' 'YM-12617-1' 'YM-617' 'YM617']","[('DailyMed', array(['tamsulosin%20hydrochloride'], dtype=object)), ('PubChem', array(['144205999', '170464826'], dtype=object)), ('chEBI', array(['9399'], dtype=object))]",,"{'rows': array(['HP_0000016', 'EFO_0000284', 'EFO_0005323', 'EFO_0000537',
       'HP_0000011', 'EFO_0003830', 'EFO_0001663'], dtype=object), 'count': 7}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for benign prostatic hyperplasia and prostate carcinoma and has 5 investigational indications.
CHEMBL1201528,,,Protein,False,VASOPRESSIN TANNATE,1982.0,4.0,,False,True,['Pitressin tannate'],['Vasopressin tannate'],,,,"[ENSG00000198049,ENSG00000166148,ENSG00000126895]",Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1208155,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,HEAUOKZIVMZVQL-VWLOTQADSA-N,Small molecule,False,ELAGOLIX,2018.0,4.0,,False,True,[],['Elagolix' 'NBI-56418'],"[('drugbank', array(['DB11979'], dtype=object))]",['CHEMBL502182'],"{'rows': array(['EFO_0000660', 'EFO_0001065', 'EFO_0001065'], dtype=object), 'count': 3}",[ENSG00000109163],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for endometriosis and has 2 investigational indications.
CHEMBL1756,C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,ADFOJJHRTBFFOF-RBRWEJTLSA-N,Small molecule,False,ESTRAMUSTINE PHOSPHATE,1981.0,4.0,,False,True,['Estracyt'],"['Estramustine 17-(dihydrogen phosphate)' 'Estramustine phosphate'
 'Ls 299' 'Ls-299' 'NSC-89199']","[('PubChem', array(['144206584'], dtype=object)), ('drugbank', array(['DB14674'], dtype=object)), ('chEBI', array(['68643'], dtype=object))]",['CHEMBL1200721'],"{'rows': array(['MONDO_0008315', 'EFO_0000673', 'MONDO_0008315', 'EFO_0000574',
       'MONDO_0002367', 'MONDO_0007254', 'EFO_0000313'], dtype=object), 'count': 7}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for carcinoma and has 6 investigational indications.
CHEMBL2017179,Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1,IHIUGIVXARLYHP-YBXDKENTSA-N,Small molecule,False,EVACETRAPIB,,3.0,,False,False,[],['Evacetrapib' 'LY-2484595' 'LY2484595'],"[('Wikipedia', array(['Evacetrapib'], dtype=object)), ('drugbank', array(['DB11655'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'HP_0003124', 'MONDO_0021187', 'Orphanet_309005'],
      dtype=object), 'count': 4}",[ENSG00000087237],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2079587,C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,Small molecule,False,STANOZOLOL,1962.0,4.0,,False,True,['Stromba' 'Tevabolin' 'Winstrol'],"['Androstanazol' 'Androstanazole' 'NSC-233046' 'NSC-43193' 'Stanozolol'
 'Stanozolol ciii' 'WIN 14833' 'WIN-14833' 'Winstrol' 'Winstrol Depot']","[('PubChem', array(['170465251'], dtype=object)), ('drugbank', array(['DB06718'], dtype=object)), ('chEBI', array(['9249'], dtype=object))]",,"{'rows': array(['EFO_0000198'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962 and has 1 investigational indication.
CHEMBL2104745,CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1,HIUPRQPBWVEQJJ-UHFFFAOYSA-N,Small molecule,False,PAGOCLONE,,2.0,,False,False,[],['CI-1043' 'IP 456' 'IP-456' 'Pagoclone' 'RP 62955' 'RP-62955'],"[('drugbank', array(['DB04903'], dtype=object))]",,"{'rows': array(['EFO_0803321', 'HP_0025268'], dtype=object), 'count': 2}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2106798,CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,CLUKHUGGXSIGRX-UHFFFAOYSA-N,Small molecule,False,NERAMEXANE MESYLATE,,3.0,CHEMBL2110954,False,False,[],['Neramexane mesilate' 'Neramexane mesylate'],,,"{'rows': array(['HP_0000360'], dtype=object), 'count': 1}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000174343,ENSG00000129749]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108035,,,Unknown,True,INCOBOTULINUMTOXINA,2010.0,4.0,,False,True,[],['Incobotulinumtoxina' 'RTI-150' 'RTI150'],,,"{'rows': array(['HP_0025267', 'EFO_0003108', 'HP_0012076', 'EFO_0003843',
       'MONDO_0005180', 'EFO_0004191', 'EFO_0003877', 'HP_0000473',
       'MONDO_0000396', 'MONDO_0003441', 'EFO_1001219', 'EFO_0000712',
       'MONDO_0011728', 'Orphanet_93955', 'HP_0001257', 'HP_0001337',
       'EFO_1000783', 'EFO_1000781', 'EFO_1000760'], dtype=object), 'count': 19}",[ENSG00000132639],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 18 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3707223,CCOC(=O)C[N+]1(C)CC[C@@H](OC(=O)[C@](O)(c2ccccc2)C2CCCC2)C1.[Br-],FIAFMTCUJCWADZ-JOFREBOKSA-M,Small molecule,False,SOFPIRONIUM BROMIDE,,3.0,CHEMBL3707224,False,False,[],['BBI-4000' 'Sofpironium bromide'],,,"{'rows': array(['HP_0000975'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3989682,CN(CP(=O)(O)O)c1cc([N+](=O)[O-])cc2[nH]c(=O)c(=O)[nH]c12,DDOAQMGXVXFNSH-UHFFFAOYSA-N,Small molecule,False,BECAMPANEL,,2.0,,False,False,[],['AMP-397' 'AMP397' 'Becampanel'],,,,"[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297333,CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)O,JGGNOCUEWOGWPL-MUUNZHRXSA-N,Small molecule,False,VB-201,,2.0,,False,False,[],['Vb 201' 'Vb-201'],"[('drugbank', array(['DB15259'], dtype=object))]",,"{'rows': array(['EFO_0000676', 'EFO_0000729', 'MONDO_0100096'], dtype=object), 'count': 3}","[ENSG00000137462,ENSG00000170458]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297951,,,Unknown,False,COAGULATION FACTOR X HUMAN,2016.0,4.0,,False,True,['Coagadex'],"['Coagulation factor x' 'Coagulation factor x human'
 'Coagulation factor x, human' 'Factor x' 'Human coagulation factor x'
 'Human factor x']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/coagadex'],
      dtype=object))]",,"{'rows': array(['MP_0001914', 'MONDO_0002247'], dtype=object), 'count': 2}",[ENSG00000126218],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for hemorrhage and factor x deficiency.
CHEMBL4297987,,,Antibody drug conjugate,False,ENAPOTAMAB VEDOTIN,,2.0,,False,False,[],['Axl-107-mmae' 'Enapotamab vedotin' 'Humax axl adc' 'Humax-axl-adc'],,,,"[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000167601]",Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL4594265,,,Oligonucleotide,False,GIVOSIRAN SODIUM,2019.0,4.0,,False,True,['Givlaari'],[],"[('DailyMed', array(['givosiran%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari'],
      dtype=object))]",,"{'rows': array(['Orphanet_95157', 'EFO_0001421'], dtype=object), 'count': 2}",[ENSG00000023330],Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for acute hepatic porphyria and liver disease.
CHEMBL513909,CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1,XQVVPGYIWAGRNI-JOCHJYFZSA-N,Small molecule,False,BI-2536,,2.0,,False,False,[],['BI-2536' 'BI2536' 'Bi 2536' 'Bi-2536'],,,"{'rows': array(['EFO_0000574', 'EFO_0000222', 'EFO_0000616', 'EFO_0003860',
       'EFO_0003060', 'EFO_0000673', 'EFO_0000702'], dtype=object), 'count': 7}",[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL571546,O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1,HUNGUWOZPQBXGX-UHFFFAOYSA-N,Small molecule,False,TIRBANIBULIN,2020.0,4.0,,False,True,['Klisyri'],['KX-01' 'KX-2-391' 'KX-2391' 'KX2-391' 'KX2391' 'Kx2-391' 'Tirbanibulin'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri'],
      dtype=object)), ('PubChem', array(['164339429'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIRBANIBULIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06137'], dtype=object))]",['CHEMBL4594279'],"{'rows': array(['EFO_0000574', 'EFO_0000222', 'EFO_0000616', 'EFO_0004193',
       'EFO_0002496', 'EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 7}",[ENSG00000197122],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for actinic keratosis and has 5 investigational indications.
CHEMBL576982,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1,CVWXJKQAOSCOAB-UHFFFAOYSA-N,Small molecule,True,QUIZARTINIB,2023.0,4.0,,False,True,[],['AC-010220' 'AC-220' 'AC010220' 'AC220' 'ASP-2689' 'Ac-220' 'Quizartinib'],"[('PubChem', array(['137275856'], dtype=object)), ('drugbank', array(['DB12874'], dtype=object)), ('chEBI', array(['90217'], dtype=object))]",['CHEMBL2105709'],"{'rows': array(['EFO_0001421', 'EFO_0000220', 'EFO_0000198', 'EFO_0000222',
       'EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 6}","[ENSG00000122025,ENSG00000157404,ENSG00000182578,ENSG00000165731,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for acute myeloid leukemia and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL783,CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1,OELFLUMRDSZNSF-BRWVUGGUSA-N,Small molecule,False,NATEGLINIDE,2000.0,4.0,,False,True,['Nateglinide' 'Starlix' 'Starsis'],"['A-4166' 'AY-4166' 'AY4166' 'D-nateglinide' 'DJN 608' 'DJN-608'
 'NSC-758695' 'Nateglinide' 'SDZ DJN 608' 'SDZ-DJN-608' 'Senaglinide']","[('DailyMed', array(['nateglinide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/starlix'],
      dtype=object)), ('PubChem', array(['144204985', '170464822', '26719880'], dtype=object)), ('drugbank', array(['DB00731'], dtype=object)), ('chEBI', array(['31897'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}","[ENSG00000187486,ENSG00000006071]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for type 2 diabetes mellitus and diabetes mellitus.
CHEMBL1200946,CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C,JKWKMORAXJQQSR-MOPIKTETSA-N,Small molecule,False,NANDROLONE DECANOATE,1983.0,4.0,,False,True,['Deca-durabolin' 'Nandrolone decanoate'],['Nandrolone decanoate' 'Nandrolone decanoate ciii'],"[('PubChem', array(['144205191', '170464711', '29215336'], dtype=object)), ('drugbank', array(['DB08804'], dtype=object)), ('chEBI', array(['7467'], dtype=object))]",,"{'rows': array(['EFO_0003964', 'EFO_0008572', 'EFO_0007312'], dtype=object), 'count': 3}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 3 investigational indications.
CHEMBL169896,Cc1nc2ccc3ccc(CNc4ccc5c(c4)CN([C@@H](CCC(=O)O)C(=O)O)C5=O)cc3c2c(=O)[nH]1,BRVFNEZMTRVUGW-QFIPXVFZSA-N,Small molecule,False,OSI-7904,,2.0,,False,False,[],"['Gw-1843' 'OSI-7904L' 'Osi 7904' 'Osi 7904l' 'Osi-7904' 'Osi-7904l'
 'TCMDC-131928']",,,"{'rows': array(['EFO_0006859', 'EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 3}",[ENSG00000176890],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1742987,,,Antibody,False,ATINUMAB,,2.0,,False,False,[],['ATI-355' 'Atinumab'],,,"{'rows': array(['EFO_1001919'], dtype=object), 'count': 1}",[ENSG00000115310],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL1743010,,,Antibody,False,ELOTUZUMAB,2015.0,4.0,,False,True,['Empliciti'],['BMS-901608' 'Elotuzumab' 'Empliciti' 'HULUC63' 'PDL-063' 'PDL063'],"[('DailyMed', array(['elotuzumab'], dtype=object)), ('DrugCentral', array(['5072'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/empliciti'],
      dtype=object))]",,"{'rows': array(['MONDO_0044881', 'EFO_0000616', 'EFO_0003073', 'MONDO_0017287',
       'EFO_0006475', 'MONDO_0019438', 'EFO_0001378'], dtype=object), 'count': 7}",[ENSG00000026751],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and multiple myeloma and has 5 investigational indications.
CHEMBL18901,Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1,BNFRJXLZYUTIII-UHFFFAOYSA-N,Small molecule,False,EFAPROXIRAL,,3.0,,False,False,[],['Efaproxiral' 'RSR-13' 'RSR13'],"[('Wikipedia', array(['Efaproxiral'], dtype=object)), ('drugbank', array(['DB08486'], dtype=object))]",['CHEMBL2107744'],"{'rows': array(['MONDO_0008903', 'EFO_0000616', 'EFO_1000158', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000206172,ENSG00000188536,ENSG00000244734]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL192,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BNRNXUUZRGQAQC-UHFFFAOYSA-N,Small molecule,False,SILDENAFIL,1998.0,4.0,,False,True,['Nipatra' 'Revatio' 'Viagra' 'Vizarsin'],"['Aphrodil' 'HIP-0908' 'HIP0908' 'Patrex' 'Sildenafil'
 'Sildenafil actavis' 'Sildenafil ratiopharm' 'Sildenafil teva' 'UK-92480']","[('PubChem', array(['26748898', '50085897'], dtype=object)), ('drugbank', array(['DB00203'], dtype=object)), ('chEBI', array(['9139'], dtype=object))]",['CHEMBL1737' 'CHEMBL5276310'],"{'rows': array(['HP_0000802', 'EFO_0000198', 'EFO_0002950', 'EFO_0004225',
       'EFO_1001893', 'MONDO_0004933', 'MONDO_0043510', 'EFO_0001422',
       'EFO_0009441', 'Orphanet_848', 'EFO_1001017', 'EFO_0004265',
       'EFO_1001145', 'HP_0001919', 'MONDO_0043510', 'EFO_0009085',
       'EFO_0803321', 'MONDO_0100096', 'EFO_0003144', 'EFO_0003917',
       'EFO_0008560', 'MONDO_0019091', 'EFO_0000545', 'HP_0200023',
       'EFO_1001134', 'EFO_0000537', 'MONDO_0100096', 'EFO_0000712',
       'HP_0001655', 'EFO_0001361', 'EFO_0004714', 'EFO_0000495',
       'EFO_0000284', 'HP_0200042', 'EFO_0000701', 'EFO_0003777',
       'EFO_1001134', 'MONDO_0005475', 'MONDO_0006058', 'EFO_0009429',
       'MONDO_0010679', 'EFO_0000341', 'EFO_1000824', 'EFO_0004234',
       'MONDO_0008315', 'EFO_0000668', 'EFO_1001103', 'MONDO_0005041',
       'EFO_0000400', 'EFO_1001145', 'MONDO_0005180', 'MONDO_0005149',
       'EFO_0003144', 'EFO_1001827', 'EFO_0003833', 'EFO_0000404',
       'EFO_0003060', 'HP_0001298', 'EFO_0000668', 'EFO_0000545',
       'EFO_0000519', 'EFO_0000717', 'EFO_0000373', 'MONDO_0005149',
       'EFO_0000768', 'EFO_0000464', 'EFO_1001986', 'EFO_0003047',
       'HP_0002140', 'EFO_1000824', 'HP_0100607', 'EFO_0001365',
       'EFO_0000537', 'MONDO_0011382', 'EFO_0011023', 'EFO_0008493',
       'HP_0000020', 'EFO_0009200', 'EFO_0000616', 'EFO_0004234',
       'EFO_0000495', 'MONDO_0010311', 'EFO_1001993', 'MONDO_0009061',
       'EFO_0003818', 'MONDO_0002013', 'EFO_0001361', 'EFO_1001103',
       'EFO_0001645', 'EFO_0003827'], dtype=object), 'count': 90}",[ENSG00000138735],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 79 investigational indications.
CHEMBL2095222,,,Protein,False,OCRIPLASMIN,2010.0,4.0,,False,True,['Jetrea'],"['Jetrea' 'MICROPLASMIN' 'Microplasmin (synthetic human)' 'Ocriplasmin'
 'Plasmin, micro- (synthetic human)' 'Recombinant human microplasmin']","[('DrugCentral', array(['5004'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea'],
      dtype=object))]",,"{'rows': array(['HP_0000479', 'EFO_0009606', 'EFO_1001028', 'EFO_0003966',
       'EFO_0003907', 'EFO_0000712', 'EFO_1001231', 'EFO_1001157'],
      dtype=object), 'count': 8}","[ENSG00000164692,ENSG00000108821,ENSG00000139219,ENSG00000168542,ENSG00000187498,ENSG00000130635,ENSG00000142156,ENSG00000060718,ENSG00000204291,ENSG00000182871,ENSG00000171502,ENSG00000196739,ENSG00000215018,ENSG00000134871,ENSG00000204262,ENSG00000142173,ENSG00000204248,ENSG00000169031,ENSG00000080573,ENSG00000163359,ENSG00000081052,ENSG00000188153,ENSG00000172752,ENSG00000197565,ENSG00000206384,ENSG00000101680,ENSG00000196569,ENSG00000053747,ENSG00000112769,ENSG00000130702,ENSG00000091136,ENSG00000172037,ENSG00000196878,ENSG00000091128,ENSG00000135862,ENSG00000058085,ENSG00000050555,ENSG00000115414]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for abnormal retinal morphology and eye disease and has 6 investigational indications.
CHEMBL2107884,,,Antibody,True,RESLIZUMAB,2016.0,4.0,,False,True,['Cinqaero' 'Cinqair' 'Cinquil'],"['CEP-38072' 'DCP 835' 'DCP-835' 'Reslizumab' 'SCH 55700' 'SCH-55700'
 'SCH55700']","[('DailyMed', array(['reslizumab'], dtype=object)), ('DrugCentral', array(['5093'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero'],
      dtype=object))]",,"{'rows': array(['EFO_1000729', 'MONDO_0004979', 'EFO_0007486', 'EFO_1001467',
       'EFO_0009661', 'EFO_0004232', 'MONDO_0004938', 'HP_0006536'],
      dtype=object), 'count': 8}",[ENSG00000113525],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for asthma and airway obstruction and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108499,,,Enzyme,False,LANOTEPLASE,,2.0,,False,False,[],"['7-l-glutamine-245-l-methionine' 'BMS-200980' 'Lanoteplase' 'SUN 9216'
 'SUN-9216']",,,,[ENSG00000104368],Enzyme drug with a maximum clinical trial phase of II.
CHEMBL2109229,,,Oligonucleotide,False,OBLIMERSEN SODIUM,,3.0,,False,False,[],['Augmerosen' 'D-G3139' 'G-3139' 'G3139' 'Oblimersen' 'Oblimersen sodium'],,,"{'rows': array(['EFO_0000403', 'MONDO_0008170', 'EFO_0000095', 'EFO_1001471',
       'MONDO_0008903', 'EFO_0003086', 'EFO_0000756', 'EFO_0000681',
       'MONDO_0002691', 'EFO_0001378', 'MONDO_0002367', 'EFO_0006861',
       'EFO_0000339', 'EFO_1001951', 'EFO_1001469', 'EFO_0000574',
       'EFO_0009441', 'MONDO_0008315', 'MONDO_0011719', 'MONDO_0018906',
       'EFO_0000389', 'MONDO_0007576', 'MONDO_0007254', 'EFO_0000702',
       'EFO_0006859', 'MONDO_0001187', 'EFO_0000616', 'EFO_0000565'],
      dtype=object), 'count': 28}",[ENSG00000171791],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications.
CHEMBL2109357,,,Antibody,False,VELIGROTUG,,2.0,,False,False,[],['AVE-1642' 'AVE1642' 'Ave 1642' 'Ave-1642' 'Veligrotug'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]",,"{'rows': array(['EFO_0003869', 'MONDO_0018531', 'EFO_0001378'], dtype=object), 'count': 3}",[ENSG00000140443],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2364652,,,Antibody,False,VANTICTUMAB,,2.0,,False,False,[],['OMP-18R5' 'Vantictumab'],,,"{'rows': array(['EFO_0000616', 'MONDO_0007254', 'EFO_0002618'], dtype=object), 'count': 3}","[ENSG00000163251,ENSG00000180340,ENSG00000155760,ENSG00000177283,ENSG00000157240]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545020,,,Small molecule,False,MBX-2044,,2.0,,False,False,[],['Mbx-2044'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545210,CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1.O=C(O)CC(O)(CC(=O)O)C(=O)O,VOHOCSJONOJOSD-RQIKCBEZSA-N,Small molecule,False,SR16234,,2.0,CHEMBL3545211,False,False,[],['HLX-801' 'SR-16234' 'Sr16234' 'TAS-108' 'TS-108'],,,"{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL363392,CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O,STPKWKPURVSAJF-LJEWAXOPSA-N,Small molecule,False,MARALIXIBAT,2021.0,4.0,,False,True,[],"['LUM-001 CATION' 'LUM001 CATION' 'Lopixibat' 'Maralixibat'
 'Maralixibat cation']",,['CHEMBL17879'],"{'rows': array(['EFO_0001421', 'MONDO_0007318', 'EFO_0004268', 'HP_0000989',
       'EFO_1001486', 'MONDO_0007318', 'MONDO_0008867'], dtype=object), 'count': 7}",[ENSG00000125255],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alagille syndrome and pruritus and has 5 investigational indications.
CHEMBL3918017,CC[C@@H](C(N)=O)N1C[C@H](C=C(F)F)CC1=O,ANWPENAPCIFDSZ-RQJHMYQMSA-N,Small molecule,False,SELETRACETAM,,3.0,,False,False,[],['Seletracetam' 'UCB 44212' 'UCB-44212'],"[('drugbank', array(['DB05885'], dtype=object))]",,"{'rows': array(['EFO_0000474', 'EFO_0004263'], dtype=object), 'count': 2}",[ENSG00000159164],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3989512,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,DZMVCVHATYROOS-ZBFGKEHZSA-N,Small molecule,False,SOBLIDOTIN,,2.0,,False,False,[],['Auristatin pe' 'Soblidotin' 'TZT-1027'],"[('drugbank', array(['DB12677'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0000691', 'MONDO_0008903'], dtype=object), 'count': 3}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4072756,COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1,FCNQMDSJHADDFT-WNSKOXEYSA-N,Small molecule,False,AZD-5423,,2.0,,False,False,[],['AZD5423' 'Azd 5423' 'Azd-5423' 'Azd5423'],"[('drugbank', array(['DB12280'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297630,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)C(C)C)C(=O)O,YEKUUBPJRPXMBM-PTCFZACGSA-N,Protein,False,COTADUTIDE,,2.0,,False,False,[],['Cotadutide' 'MEDI-0382' 'MEDI0382' 'Medi 0382' 'Medi0382'],"[('drugbank', array(['DB15194'], dtype=object))]",,"{'rows': array(['HP_0000083', 'EFO_0001421', 'EFO_0003095', 'EFO_0000400',
       'MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 6}","[ENSG00000215644,ENSG00000112164]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL5314400,FC(F)(F)c1cccnc1-c1ccc(-c2nc3ccc(Br)cc3[nH]2)nc1,WGAVAOCYBMNWID-UHFFFAOYSA-N,Small molecule,False,DWP05195,,2.0,,False,False,[],['DWP-05195' 'Dwp05195'],,,"{'rows': array(['MONDO_0041052'], dtype=object), 'count': 1}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL564829,CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2,RXZMYLDMFYNEIM-UHFFFAOYSA-N,Small molecule,False,MILCICLIB,,2.0,,False,False,[],['Milciclib' 'PHA 848125' 'PHA-848125' 'Pha-848125'],,['CHEMBL4297668' 'CHEMBL561564'],"{'rows': array(['EFO_1000576', 'EFO_1000581', 'EFO_0000616', 'EFO_0000182'],
      dtype=object), 'count': 4}","[ENSG00000135446,ENSG00000198400,ENSG00000123374,ENSG00000170312]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1200601,CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1.Cl,AWEZYKMQFAUBTD-UHFFFAOYSA-N,Small molecule,False,NARATRIPTAN HYDROCHLORIDE,1998.0,4.0,CHEMBL1278,False,True,['Amerge' 'Naramig' 'Naratriptan'],['GR 85548A' 'GR-85548A' 'Naratriptan hcl' 'Naratriptan hydrochloride'],"[('DailyMed', array(['naratriptan%20hydrochloride'], dtype=object)), ('PubChem', array(['144207166', '170465423'], dtype=object)), ('chEBI', array(['7479'], dtype=object))]",,"{'rows': array(['MONDO_0005277', 'HP_0002315'], dtype=object), 'count': 2}","[ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 1 investigational indication.
CHEMBL1200893,CC(Cc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(O)c1.Cl,LOVXREQUMZKFCM-UHFFFAOYSA-N,Small molecule,False,PROTOKYLOL HYDROCHLORIDE,1982.0,4.0,CHEMBL1201273,False,True,['Ventaire'],['NSC-113490' 'Protokylol HCl' 'Protokylol hcl' 'Protokylol hydrochloride'],,,,[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201543,,,Protein,False,INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN,1983.0,4.0,,False,True,['Novolin l'],['Insulin zinc susp semisynthetic purified human'],,,,[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV that was first approved in 1983.
CHEMBL1201627,,,Protein,False,INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN,1985.0,4.0,,False,True,['Insulatard nph human' 'Novolin n'],['Insulin susp isophane semisynthetic purified human'],,,"{'rows': array(['EFO_0003914', 'MONDO_0005148', 'HP_0003074', 'EFO_0000537',
       'EFO_0001645', 'HP_0003124'], dtype=object), 'count': 6}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 6 investigational indications.
CHEMBL1615374,Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,RPZBRGFNBNQSOP-UHFFFAOYSA-N,Small molecule,True,VILAZODONE HYDROCHLORIDE,2011.0,4.0,CHEMBL439849,False,True,['Viibryd'],"['EMD 68 843' 'EMD-68843' 'SB-659746-A' 'SB659746-A' 'Vilazodone hcl'
 'Vilazodone hydrochloride']","[('DailyMed', array(['vilazodone%20hydrochloride'], dtype=object)), ('chEBI', array(['70705'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000108576,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2011 and is indicated for major depressive disorder. This drug has a black box warning from the FDA.
CHEMBL1783282,CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,KYDURMHFWXCKMW-UHFFFAOYSA-N,Small molecule,False,AZD7325,,2.0,,False,False,[],['Azd7325'],"[('drugbank', array(['DB13994'], dtype=object))]",,"{'rows': array(['MONDO_0010383', 'EFO_0005230', 'EFO_0003756'], dtype=object), 'count': 3}","[ENSG00000011677,ENSG00000151834]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL1963502,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1,XRYJULCDUUATMC-CYBMUJFWSA-N,Small molecule,False,PKI-166,,1.0,,False,False,[],['CGP-75166' 'NVP-PKI166' 'PKI-166' 'Pki 166' 'Pki-166'],,['CHEMBL1914653'],,[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2107723,COc1cc(O)c(C(=O)Nc2nc(C(=O)NCCN(C(C)C)C(C)C)cs2)cc1OC,TWHZNAUBXFZMCA-UHFFFAOYSA-N,Small molecule,False,ACOTIAMIDE,,3.0,,False,False,[],['Acotiamide'],"[('drugbank', array(['DB12482'], dtype=object)), ('chEBI', array(['34523'], dtype=object))]",['CHEMBL2107308'],"{'rows': array(['EFO_0008533', 'EFO_0010282'], dtype=object), 'count': 2}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109370,,,Antibody,False,T84.66,,1.0,,False,False,[],['T84.66'],,,,[ENSG00000105388],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109456,,,Antibody,False,QUILIZUMAB,,2.0,,False,False,[],"['ANTI-M1' 'Anti-M1 prime' ""Anti-M1'"" 'MEMP-1972A' 'MEMP1972A' 'MEP-1972A'
 'MEP1972A' 'Quilizumab' 'RG-7449']",,,"{'rows': array(['EFO_0005854', 'EFO_0005531', 'MONDO_0004979'], dtype=object), 'count': 3}",[ENSG00000211891],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2364651,,,Antibody,False,TOVETUMAB,,2.0,,False,False,[],['MEDI-575' 'Tovetumab'],,,"{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000519'], dtype=object), 'count': 3}",[ENSG00000134853],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL279785,CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C,OCSMOTCMPXTDND-OUAUKWLOSA-N,Small molecule,False,MARIMASTAT,,3.0,,False,False,[],"['BB 2516' 'BB-2516' 'GI 5712' 'GI-5712' 'KB-R 8898' 'Marimastat'
 'NSC-719333' 'TA 2516' 'TA-2516']","[('PubChem', array(['136949642'], dtype=object)), ('Wikipedia', array(['Marimastat'], dtype=object)), ('drugbank', array(['DB00786'], dtype=object)), ('chEBI', array(['50662'], dtype=object))]",,"{'rows': array(['MONDO_0007254', 'MONDO_0008903'], dtype=object), 'count': 2}","[ENSG00000100985,ENSG00000149968,ENSG00000196611,ENSG00000087245,ENSG00000137673,ENSG00000262406]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3989780,O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O,WXOMTJVVIMOXJL-BOBFKVMVSA-A,Unknown,False,SUCRALFATE,1981.0,4.0,CHEMBL2367706,False,True,['Antepsin' 'Carafate' 'Sucralfate' 'Ulcerlmin'],"['Aluminum sucrose octasulfate' 'Citogel' 'Hexagastron' 'Succosa'
 'Sucralfate' 'Sucralfate hydrate' 'Sucralfin' 'Sucrate' 'Sugast'
 'Sulcrate' 'Ulcar' 'Ulcermin' 'Ulcogant' 'Ulsanic' 'Urbal' 'Venter']",,,"{'rows': array(['EFO_0004607', 'EFO_0003948', 'HP_0004398'], dtype=object), 'count': 3}",[ENSG00000256713],Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved indications.
CHEMBL3989861,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O,YETWCSLOYUZBLK-JITBQSAISA-N,Small molecule,True,DESVENLAFAXINE FUMARATE,2013.0,4.0,CHEMBL1118,False,True,[],['Desvenlafaxine fumarate anhydrous' 'O-desmethylvenlafaxine fumarate'],,,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for major depressive disorder. This drug has a black box warning from the FDA.
CHEMBL4297328,O=C(CN1CCOCC1)Nc1ccc(OC2CCN(C3CCC3)CC2)cc1,LNXDUSQEXVQFGP-UHFFFAOYSA-N,Small molecule,False,SUVN-G3031,,2.0,,False,False,[],['SUVN-G3031 FREE BASE' 'Samelisant' 'Suvn-g3031'],"[('drugbank', array(['DB14835'], dtype=object))]",['CHEMBL4593911'],"{'rows': array(['HP_0100543', 'MONDO_0021107'], dtype=object), 'count': 2}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594406,,,Small molecule,False,LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN,2022.0,4.0,CHEMBL4594730,False,True,['Pluvicto'],"['177LU-LABELED PSMA-617' '177Lu-PSMA-617' '177lu-psma-617'
 'Lutetium (177lu) vipivotide tetraxetan'
 'Lutetium lu 177 vipivotide tetraxetan' 'Pluvicto' 'Psma-617 lu-177'
 'Vipivotide tetraxetan lu-177' 'Vipivotide tetraxetan lutetium lu-177']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUTETIUM%20LU%20177%20VIPIVOTIDE%20TETRAXETAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0008315', 'MONDO_0008315', 'MONDO_0021259', 'EFO_0000616',
       'EFO_0001663', 'EFO_0003863', 'EFO_0000673'], dtype=object), 'count': 7}",[ENSG00000086205],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for prostate cancer and prostate neoplasm and has 5 investigational indications.
CHEMBL5315076,,,Protein,False,ALBUTREPENONACOG ALFA,2016.0,4.0,,False,True,['Idelvion'],['CSL-654' 'Csl654'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/idelvion'],
      dtype=object))]",,"{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}",[ENSG00000101981],Protein drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for hemophilia b.
CHEMBL571,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,DKYWVDODHFEZIM-UHFFFAOYSA-N,Small molecule,True,KETOPROFEN,1986.0,4.0,,False,True,"['Actron' 'Alrheumat' 'Axorid' 'Fenoket 200' 'Jomethid xl' 'Ketocid 200'
 'Ketonal' 'Ketoprofen' 'Ketotard 200 xl' 'Ketovail' 'Ketozip 200 xl'
 'Larafen' 'Larafen cr' 'Nexcede' 'Orudis' 'Orudis 100' 'Orudis kt'
 'Oruvail' 'Oruvail 100' 'Oruvail 150' 'Oruvail 200' 'Oruvail im'
 'Powergel' 'Tiloket' 'Tiloket cr' 'Valket 200 retard']","['(rs)-ketoprofen' '19583RP' 'Actron ketoprofen' 'Aneol' 'Capisten'
 'Hydratropic acid, m-benzoyl-' 'IDEA-033' 'Iso-k' 'Ketoprofen' 'Ketorin'
 'NSC-758144' 'R.P. 19,583' 'R.P. 19583' 'RP-19583' 'RU-4733' 'Sector']","[('DailyMed', array(['ketoprofen'], dtype=object)), ('PubChem', array(['11532908', '144204145', '144208045', '170465449', '26747548',
       '50086520', '50106498', '85231099', '857801', '90341309'],
      dtype=object)), ('Wikipedia', array(['Ketoprofen'], dtype=object)), ('drugbank', array(['DB01009'], dtype=object)), ('chEBI', array(['6128'], dtype=object))]",['CHEMBL4650345' 'CHEMBL341922'],"{'rows': array(['EFO_0000685', 'EFO_0000649', 'MONDO_0005178', 'HP_0003326',
       'EFO_0000546', 'EFO_0002970', 'EFO_1001412', 'HP_0003419',
       'MONDO_0005277', 'EFO_0000512', 'HP_0100607', 'MONDO_0002471',
       'HP_0002829', 'EFO_0005755', 'EFO_0003843', 'EFO_0009582',
       'EFO_0004888', 'MONDO_0004857', 'EFO_0004616', 'MP_0001845',
       'EFO_0004253'], dtype=object), 'count': 21}","[ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 approved and 14 investigational indications. This drug has a black box warning from the FDA.
CHEMBL601719,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,KTEIFNKAUNYNJU-GFCCVEGCSA-N,Small molecule,False,CRIZOTINIB,2011.0,4.0,,False,True,['Xalkori'],['Crizotinib' 'NSC-756645' 'PF-02341066' 'PF-2341066' 'Pf-2341066'],"[('DailyMed', array(['crizotinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori'],
      dtype=object)), ('Wikipedia', array(['Crizotinib'], dtype=object)), ('drugbank', array(['DB08865'], dtype=object)), ('chEBI', array(['64310'], dtype=object))]",,"{'rows': array(['EFO_1001951', 'EFO_1000026', 'EFO_0000707', 'MONDO_0008903',
       'MONDO_0011962', 'EFO_0000571', 'EFO_0000228', 'EFO_0000222',
       'MONDO_0007254', 'EFO_0001378', 'MONDO_0001056', 'EFO_0003060',
       'MONDO_0015798', 'MONDO_0004992', 'EFO_0000519', 'EFO_0003086',
       'MONDO_0007039', 'EFO_0003032', 'MONDO_0008315', 'EFO_0000616',
       'EFO_0000640', 'EFO_0000403'], dtype=object), 'count': 22}","[ENSG00000171094,ENSG00000181163,ENSG00000143924,ENSG00000105976]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 18 investigational indications.
CHEMBL870,NCCCC(O)(P(=O)(O)O)P(=O)(O)O,OGSPWJRAVKPPFI-UHFFFAOYSA-N,Small molecule,False,ALENDRONIC ACID,1995.0,4.0,,False,True,['Binosto' 'Fosamax'],['Alendronate' 'Alendronic Acid' 'Alendronic acid' 'Fosamax'],"[('Wikipedia', array(['Alendronic_acid'], dtype=object)), ('drugbank', array(['DB00630'], dtype=object)), ('chEBI', array(['2567'], dtype=object))]",['CHEMBL675' 'CHEMBL2367465'],"{'rows': array(['MONDO_0005178', 'EFO_0004260', 'EFO_0003882', 'EFO_0000649',
       'EFO_0004261', 'HP_0000938', 'EFO_0003762', 'EFO_0003854',
       'EFO_0000589', 'EFO_0000764', 'EFO_0004261', 'MONDO_0006715',
       'MONDO_0004979', 'EFO_0003854', 'EFO_0000266', 'MONDO_0007254',
       'EFO_0004197', 'EFO_0003882', 'EFO_0000673', 'EFO_0003869',
       'MONDO_0008170', 'MONDO_0008274'], dtype=object), 'count': 22}",[ENSG00000160752],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 17 investigational indications.
CHEMBL108,NC(=O)N1c2ccccc2C=Cc2ccccc21,FFGPTBGBLSHEPO-UHFFFAOYSA-N,Small molecule,True,CARBAMAZEPINE,1968.0,4.0,,False,True,"['Arbil mr' 'Carbagen sr' 'Carbamazepine' 'Carbatrol' 'Carnexiv' 'Epimaz'
 'Epimaz ret' 'Epitol' 'Equetro' 'Sirtal ret' 'Tegretol' 'Tegretol Xr'
 'Tegretol chewtab' 'Tegretol prolonged release' 'Tegretol-xr' 'Teril'
 'Teril ret' 'Timonil 200 ret' 'Timonil 400 ret']","['Biston' 'Carbamazepine' 'Carbamazepine anhydrous'
 'Carbamazepine extended release' 'Carbamazepinum' 'Finlepsin' 'G-32883'
 'GEIGY 32883' 'Karbamazepin' 'Karbelex' 'NSC-169864' 'Neurotol'
 'Neurotop' 'Sirtal' 'Stazepine' 'Tegretal' 'Telesmin' 'Timonil']","[('DailyMed', array(['carbamazepine'], dtype=object)), ('PubChem', array(['11110939', '11110940', '124879629', '144203655', '144209471',
       '144210515', '170464712', '17389547', '26751576', '50104203',
       '56314829', '56422193', '855967', '90341617'], dtype=object)), ('TG-GATEs', array(['18'], dtype=object)), ('Wikipedia', array(['Carbamazepine'], dtype=object)), ('drugbank', array(['DB00564'], dtype=object)), ('chEBI', array(['3387'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0015643',
       'MONDO_0005090', 'EFO_0009963', 'EFO_0006911', 'MONDO_0100096',
       'HP_0000726', 'HP_0001250', 'EFO_0004263', 'MONDO_0005180',
       'EFO_0002610', 'EFO_1001219', 'MONDO_0004985', 'EFO_0000474',
       'EFO_0004197'], dtype=object), 'count': 17}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201354,CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1,NPRHVSBSZMAEIN-UHFFFAOYSA-N,Small molecule,False,TRIDIHEXETHYL,1954.0,4.0,,False,True,[],['Tridihexethyl' 'Tridihexethyl cation' 'Tridihexethyl ion'],"[('Wikipedia', array(['Tridihexethyl'], dtype=object)), ('drugbank', array(['DB00505'], dtype=object)), ('chEBI', array(['9701'], dtype=object))]",['CHEMBL2107686' 'CHEMBL1200771'],"{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954 and is indicated for gastrointestinal disease.
CHEMBL1201604,,,Antibody,True,TOSITUMOMAB,2003.0,4.0,,False,True,['Bexxar'],['Tositumomab'],"[('Wikipedia', array(['Tositumomab'], dtype=object))]",,"{'rows': array(['EFO_0000574', 'EFO_0005952', 'MONDO_0018906', 'EFO_0000096',
       'EFO_1001469', 'EFO_0000095'], dtype=object), 'count': 6}",[ENSG00000156738],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201753,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,VGYFMXBACGZSIL-MCBHFWOFSA-N,Small molecule,False,PITAVASTATIN,2009.0,4.0,,False,True,[],['Itavastatin' 'NSC-760423' 'Pitavastatin'],"[('Wikipedia', array(['Pitavastatin'], dtype=object)), ('drugbank', array(['DB08860'], dtype=object)), ('chEBI', array(['32020'], dtype=object))]",['CHEMBL3989923' 'CHEMBL1237061' 'CHEMBL3989920'],"{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'Orphanet_309005',
       'MONDO_0021187', 'EFO_0001645', 'EFO_0007328', 'HP_0003119',
       'MONDO_0021187', 'HP_0000083', 'MONDO_0007254', 'HP_0003119',
       'EFO_0000195', 'Orphanet_309005', 'HP_0003119', 'HP_0003124',
       'EFO_0004911', 'MONDO_0021187', 'HP_0003124', 'MONDO_0021187',
       'EFO_0000319', 'HP_0003124'], dtype=object), 'count': 21}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 10 investigational indications.
CHEMBL1551724,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N,RTRQQBHATOEIAF-UUOKFMHZSA-N,Small molecule,False,ACADESINE,,3.0,,False,False,[],['Acadesine' 'GP-1-110' 'NSC-105823'],"[('PubChem', array(['124893186', '144205104', '170465608', '29217492'], dtype=object)), ('drugbank', array(['DB04944'], dtype=object)), ('chEBI', array(['28498'], dtype=object))]",,"{'rows': array(['EFO_0000319', 'EFO_0000095'], dtype=object), 'count': 2}","[ENSG00000162409,ENSG00000131791,ENSG00000181929,ENSG00000106617,ENSG00000111725,ENSG00000132356,ENSG00000115592]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2001019,OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1,PDMUGYOXRHVNMO-UHFFFAOYSA-N,Small molecule,False,PF-04217903,,1.0,,False,False,[],"['MET TYROSINE KINASE INHIBITOR PF-04217903' 'PF-04217903' 'PF-4217903'
 'Pf-04217903']","[('PubChem', array(['103905666', '137276005'], dtype=object)), ('drugbank', array(['DB12848'], dtype=object))]",['CHEMBL2170804'],"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2108882,,,Antibody,False,SIBROTUZUMAB,,2.0,,False,False,[],['Sibrotuzumab'],,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000078098],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2109323,,,Antibody,False,IMC-CS4,,1.0,,False,False,[],['IMC-CS4' 'Imc-cs4'],,,"{'rows': array(['EFO_0002618', 'EFO_0000616'], dtype=object), 'count': 2}",[ENSG00000182578],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL2219421,O=C(O)c1ccc(/C=C/S(=O)(=O)Cc2ccc(Cl)cc2)cc1,KBEKQQJUNVQLDZ-MDZDMXLPSA-N,Small molecule,False,RECILISIB,,2.0,,False,False,['Ex-rad'],['ON 01210' 'ON 01210.Na' 'ON01210' 'On-01210' 'Recilisib'],,['CHEMBL2219410'],,"[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL225411,O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F,TWQYWUXBZHPIIV-UHFFFAOYSA-N,Small molecule,False,GW842166X,,2.0,,False,False,[],"['GW 842166' 'GW 842166X' 'GW-842166' 'GW842166' 'GW842166X' 'Gw-842,166x'
 'Gw842166x']","[('PubChem', array(['174007169'], dtype=object)), ('Wikipedia', array(['GW-842,166X'], dtype=object)), ('drugbank', array(['DB11903'], dtype=object))]",,"{'rows': array(['EFO_0004616', 'MONDO_0005178', 'EFO_0003843'], dtype=object), 'count': 3}",[ENSG00000188822],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2368925,O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,UKTAZPQNNNJVKR-KJGYPYNMSA-N,Small molecule,False,DOLASETRON,1997.0,4.0,,False,True,[],['Dolasetron'],"[('drugbank', array(['DB00757'], dtype=object))]",['CHEMBL2373322' 'CHEMBL2368924'],"{'rows': array(['HP_0002018', 'MONDO_0004992', 'EFO_0004888', 'EFO_0005687',
       'EFO_0006911', 'HP_0002017'], dtype=object), 'count': 6}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 1 investigational indication.
CHEMBL281872,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1,YBTGTVGEKMZEQX-UHFFFAOYSA-N,Small molecule,False,ZD-4190,,1.0,,False,False,[],['ZD-4190'],,['CHEMBL3544937'],,[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545134,,,Small molecule,False,LY-2780301,,1.0,,False,False,[],['Ly-2780301'],,,"{'rows': array(['EFO_0000574', 'EFO_0009708'], dtype=object), 'count': 2}","[ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000175634,ENSG00000108443]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL3545289,C[C@@H](NC(=O)Cc1c(Cl)ccc(NCC(F)(F)c2cccc[n+]2O)[n+]1O)c1cccc(Cl)c1,GNYWBETUYIZBHL-CQSZACIVSA-P,Small molecule,False,AZD2207,,2.0,,False,False,[],['Azd2207'],,,,[ENSG00000118432],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3659497,CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1,AYOOGWWGECJQPI-NSHDSACASA-N,Small molecule,False,AZD-7451,,1.0,,False,False,[],['Azd-7451' 'Utatrectinib'],,,"{'rows': array(['EFO_0000519'], dtype=object), 'count': 1}","[ENSG00000140538,ENSG00000148053,ENSG00000198400]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3678958,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21,WSOHOUHPUOAXIN-UHFFFAOYSA-N,Small molecule,False,RUSERONTINIB,,3.0,,False,False,[],['Ruserontinib' 'SKLB-1028' 'Sklb 1028' 'Sklb1028'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000122025,ENSG00000146648,ENSG00000097007]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL370805,COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C,ZPUCINDJVBIVPJ-LJISPDSOSA-N,Small molecule,True,COCAINE,2017.0,4.0,,False,True,[],"['(r)-(-)-cocaine' 'Benzoylmethylecgonine' 'Cocaine' 'Cocainum'
 'IDS-NC-004' 'Neurocaine' 'RX-0041' 'RX0041']","[('drugbank', array(['DB00907'], dtype=object)), ('chEBI', array(['27958'], dtype=object))]",['CHEMBL529437'],"{'rows': array(['EFO_0005800', 'EFO_0005611', 'MONDO_0005271', 'EFO_0002610',
       'EFO_0002610'], dtype=object), 'count': 5}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3833330,,,Antibody,False,CINPANEMAB,,2.0,,False,False,[],['BIIB-054' 'BIIB054' 'Cinpanemab' 'Ni-202'],,,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000145335],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3989820,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O,VXRDAMSNTXUHFX-UHFFFAOYSA-N,Small molecule,True,ZOLPIDEM TARTRATE,1992.0,4.0,CHEMBL911,False,True,"['Ambien' 'Ambien cr' 'Edluar' 'Intermezzo' 'Stilnoct' 'Tovalt odt'
 'Zolpidem tartrate' 'Zolpimist']","['Ivadal' 'Myslee' 'Niotal' 'SL 80.0750-23N' 'SL-80.0750' 'SL-80.0750-23N'
 'Stilnox' 'Tovalt' 'Zolpidem hemitartrate' 'Zolpidem tartrate'
 'Zolpidem tartrate civ']","[('DailyMed', array(['zolpidem%20tartrate'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'EFO_0001073', 'EFO_0008568'], dtype=object), 'count': 3}","[ENSG00000022355,ENSG00000113327,ENSG00000163288]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for insomnia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL4297626,Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(C(=O)O)cc2)c2c1-c1cc(Cl)ccc1OC2,JYTIXGYXBIBOMN-UHFFFAOYSA-N,Small molecule,False,NIDUFEXOR,,2.0,,False,False,[],['LMB763' 'Lmb763' 'Nidufexor'],,,"{'rows': array(['EFO_0003095', 'EFO_0000401'], dtype=object), 'count': 2}",[ENSG00000012504],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL5095050,CCCCCCCCCCCCOS(=O)(=O)O.CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,XTLZVNMZICNQBB-UHFFFAOYSA-N,Small molecule,False,FINGOLIMOD LAURYL SULFATE,2021.0,4.0,CHEMBL314854,False,True,['Tascenso odt'],['Tascenso'],,,,"[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021.
CHEMBL5170587,N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F,OPSIVAKKLQRWKC-VXGBXAGGSA-N,Small molecule,False,VK5211,,2.0,,False,False,[],['LGD-4033' 'Ligandrol' 'Vk 5211' 'Vk-5211' 'Vk5211'],,,"{'rows': array(['EFO_0003964'], dtype=object), 'count': 1}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL837,CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,FJHBVJOVLFPMQE-QFIPXVFZSA-N,Small molecule,False,7-ETHYL-10-HYDROXYCAMPTOTHECIN,,2.0,,False,False,[],"['7-Ethyl-10-Hydroxy-Camptothecin' '7-ethyl-10-hydroxycamptothecin'
 'Camptothecin, 7-ethyl-10-hydroxy-' 'IT-141'
 'Irinotecan related compound b' 'It-141' 'NK 012' 'NK-012' 'NK012'
 'Nk012' 'SN 38' 'SN-38']","[('PubChem', array(['515301'], dtype=object)), ('Wikipedia', array(['SN-38'], dtype=object)), ('drugbank', array(['DB05482'], dtype=object)), ('chEBI', array(['8988'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0000702', 'MONDO_0008903', 'EFO_1001951',
       'MONDO_0007254'], dtype=object), 'count': 5}",[ENSG00000198900],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL844,Brc1c(NC2=NCCN2)ccc2nccnc12,XYLJNLCSTIOKRM-UHFFFAOYSA-N,Small molecule,False,BRIMONIDINE,1996.0,4.0,,False,True,[],"['AGN-190342 FREE BASE' 'Brimonidine' 'NSC-318825' 'UK-14304'
 'UK-1430418 FREE BASE']","[('PubChem', array(['104171261', '11111939', '11113354', '144203850', '170464941',
       '26751556', '50104157', '85231282', '855898', '90340645'],
      dtype=object)), ('Wikipedia', array(['Brimonidine'], dtype=object)), ('drugbank', array(['DB00484'], dtype=object)), ('chEBI', array(['3175'], dtype=object))]",['CHEMBL1200389' 'CHEMBL2062257'],"{'rows': array(['EFO_0003770', 'MONDO_0001330', 'EFO_1001069', 'EFO_0004190',
       'EFO_1000906', 'MONDO_0021698', 'EFO_0000537', 'EFO_1001893',
       'MONDO_0001330', 'MONDO_0005041', 'EFO_0003822', 'HP_0000951',
       'EFO_1000879', 'MONDO_0005041', 'HP_0010783', 'EFO_1000760',
       'EFO_1000906', 'HP_0031284', 'EFO_0005751', 'EFO_1001069',
       'EFO_0007141', 'EFO_1000760', 'EFO_0004190'], dtype=object), 'count': 23}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 14 investigational indications.
CHEMBL16476,CC(C)NCC(O)c1ccc2ccccc2c1,HRSANNODOVBCST-UHFFFAOYSA-N,Small molecule,False,PRONETALOL,,4.0,,True,True,[],"['AY 6204 [AS HYDROCHLORIDE]' 'AY-6204 HCL' 'Dl-pronethalol' 'GNF-PF-2670'
 'ICI 38174 [AS HYDROCHLORIDE]' 'Inetol' 'Naphthylisoproterenol'
 'Nethalide' 'Pronetalol' 'Pronethalol']","[('PubChem', array(['144204478', '170466606', '26751909'], dtype=object)), ('chEBI', array(['8463'], dtype=object))]",['CHEMBL1876082'],,"[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1743022,,,Antibody,False,FRESOLIMUMAB,,2.0,,False,False,[],['Fresolimumab' 'GC-1008' 'GC1008' 'GZ-402669' 'GZ402669'],,,"{'rows': array(['EFO_0003833', 'EFO_0003060', 'EFO_0004236', 'EFO_0000770',
       'EFO_0000768', 'EFO_0000404', 'MONDO_0019019', 'EFO_0000681',
       'MONDO_0007254'], dtype=object), 'count': 9}","[ENSG00000105329,ENSG00000119699,ENSG00000092969]",Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL1801204,COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,KVLFRAWTRWDEDF-IRXDYDNUSA-N,Small molecule,False,AZD-8055,,1.0,,False,False,[],['AZ-12600000' 'AZD 8055' 'AZD-8055' 'AZD8055' 'Azd-8055'],"[('drugbank', array(['DB12774'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_0002499', 'EFO_0002501',
       'EFO_0000182', 'EFO_0000574', 'EFO_0000519'], dtype=object), 'count': 7}",[ENSG00000198793],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications.
CHEMBL2109387,,,Antibody,False,PARSATUZUMAB,,2.0,,False,False,[],"['MEGF-0444A' 'MEGF0444A' 'Parsatuzumab' 'RG-741' 'RG-7414' 'RG7414'
 'anti-EGFL7 monoclonal antibody']",,,"{'rows': array(['EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 2}",[ENSG00000172889],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109548,,,Antibody,False,MK-4721,,2.0,,False,False,[],['AGS-1C4D4' 'AGS-PSCA' 'Ags 1c4d4' 'MK-4721' 'Mk-4721'],,,"{'rows': array(['MONDO_0005184', 'MONDO_0008315', 'EFO_0010282'], dtype=object), 'count': 3}",[ENSG00000167653],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2308782,C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c1ccccc1)c1ccccc1)C2.[Br-],CWRNUVNMUYSOFQ-ABHLOGGPSA-M,Small molecule,False,DAROTROPIUM BROMIDE,,2.0,CHEMBL2365940,False,False,[],['Darotropium bromide' 'GSK-233705' 'GSK-233705B' 'GSK233705' 'GSK233705B'],,,"{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}","[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2347655,CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1,LLXISKGBWFTGEI-FQEVSTJZSA-N,Small molecule,False,FILANESIB,,2.0,,False,False,[],['ARRY-520' 'Filanesib'],"[('drugbank', array(['DB06040'], dtype=object))]",['CHEMBL3544920'],"{'rows': array(['EFO_0000222', 'EFO_0001378', 'EFO_0000198', 'EFO_0006475',
       'EFO_0000616'], dtype=object), 'count': 5}",[ENSG00000138160],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL3545406,,,Small molecule,False,LY2940094,,2.0,,False,False,[],['Ly2940094'],,,"{'rows': array(['MONDO_0002050', 'MONDO_0007079', 'MONDO_0002009'], dtype=object), 'count': 3}",[ENSG00000125510],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3989871,Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F,PUKBOVABABRILL-YZNIXAGQSA-N,Small molecule,False,AVACOPAN,2021.0,4.0,,False,True,['Tavneos'],['Avacopan' 'CCX-168' 'CCX168' 'Ccx168'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos'],
      dtype=object)), ('drugbank', array(['DB15011'], dtype=object))]",,"{'rows': array(['EFO_1000784', 'EFO_0004826', 'EFO_0005297', 'EFO_0006803',
       'EFO_1000710', 'EFO_0000540', 'MONDO_0015492', 'EFO_0004194',
       'MONDO_0016244'], dtype=object), 'count': 9}",[ENSG00000197405],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 5 approved and 4 investigational indications.
CHEMBL4298045,,,Antibody drug conjugate,False,INDUSATUMAB VEDOTIN,,2.0,,False,False,[],['Indusatumab vedotin' 'MLN-0264' 'MLN0264' 'Mln0264' 'TAK-264'],,,"{'rows': array(['EFO_0000503', 'MONDO_0004992'], dtype=object), 'count': 2}","[ENSG00000070019,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4594503,,,Antibody,False,TALQUETAMAB,2023.0,4.0,,False,True,['Talvey'],['JNJ-63483043' 'JNJ-64407564' 'Talquetamab'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TALQUETAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0001642'], dtype=object), 'count': 2}","[ENSG00000111291,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for multiple myeloma and has 1 investigational indication.
CHEMBL467084,N[C@@H](Cc1ccccn1)c1ccccc1,FWUQWDCOOWEXRY-ZDUSSCGKSA-N,Small molecule,False,LANICEMINE,,2.0,,False,False,[],['AR-R15896AR' 'AZD-6765' 'AZD6765' 'Azd6765' 'Lanicemine'],"[('drugbank', array(['DB11889'], dtype=object))]",,"{'rows': array(['MONDO_0002009', 'MONDO_0002050'], dtype=object), 'count': 2}","[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL484785,N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,USZAGAREISWJDP-UHFFFAOYSA-N,Small molecule,False,CRISABOROLE,2016.0,4.0,,False,True,['Eucrisa' 'Staquis'],['AN-2728' 'AN2728' 'Crisaborole'],"[('DailyMed', array(['crisaborole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/staquis'],
      dtype=object)), ('PubChem', array(['174007043'], dtype=object)), ('drugbank', array(['DB05219'], dtype=object))]",,"{'rows': array(['EFO_0000676', 'MONDO_0002406', 'HP_0000964', 'EFO_0004208',
       'EFO_0000274', 'EFO_1001361', 'EFO_0004192'], dtype=object), 'count': 7}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for eczematoid dermatitis and atopic eczema and has 5 investigational indications.
CHEMBL502835,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,XZXHXSATPCNXJR-ZIADKAODSA-N,Small molecule,False,NINTEDANIB,2014.0,4.0,,False,True,['Ofev' 'Vargatef'],['BIBF 1120' 'BIBF-1120' 'BIBF1120' 'Bibf-1120' 'Intedanib' 'Nintedanib'],"[('drugbank', array(['DB09079'], dtype=object)), ('chEBI', array(['85164'], dtype=object))]",['CHEMBL3039504'],"{'rows': array(['MONDO_0019180', 'EFO_1001331', 'MONDO_0044937', 'EFO_0004244',
       'MONDO_0011705', 'EFO_1001949', 'EFO_0000222', 'EFO_0003893',
       'MONDO_0011962', 'EFO_0000691', 'EFO_0000503', 'EFO_0001378',
       'EFO_1001465', 'EFO_0000768', 'MONDO_0007254', 'EFO_0000681',
       'EFO_0000588', 'EFO_0007183', 'EFO_0009448', 'EFO_0000571',
       'MONDO_0100096', 'MONDO_0008903', 'EFO_0000616', 'EFO_0008528',
       'EFO_0000708', 'EFO_0004284', 'EFO_0000182', 'EFO_0002618',
       'EFO_0000717', 'EFO_0000770', 'EFO_0002499', 'EFO_0000519',
       'EFO_0001416', 'MONDO_0001235', 'EFO_0000702', 'MONDO_0015277',
       'MONDO_0004669', 'MONDO_0002158', 'EFO_0000717', 'EFO_0004142',
       'EFO_1001951', 'EFO_0000768', 'MONDO_0002087', 'MONDO_0008170',
       'EFO_0000673', 'EFO_0003060', 'EFO_0004243', 'EFO_0000389',
       'EFO_0002501'], dtype=object), 'count': 49}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for systemic scleroderma and idiopathic pulmonary fibrosis and has 47 investigational indications.
CHEMBL539423,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1,WRFHGDPIDHPWIQ-UHFFFAOYSA-N,Small molecule,True,SPARSENTAN,2023.0,4.0,,False,True,['Filspari'],['Filspari' 'PS-433540' 'PS433540' 'RE-021' 'Sparsentan'],"[('drugbank', array(['DB12548'], dtype=object))]",,"{'rows': array(['EFO_0004236', 'EFO_0000537', 'EFO_0004194'], dtype=object), 'count': 3}","[ENSG00000151617,ENSG00000144891]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for iga glomerulonephritis and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL79,CCN(CC)CC(=O)Nc1c(C)cccc1C,NNJVILVZKWQKPM-UHFFFAOYSA-N,Small molecule,True,LIDOCAINE,1948.0,4.0,,False,True,"['Alphacaine' 'Anestacon' 'Dentipatch' 'Lidocaine' 'Lidoderm'
 'Lignocaine Hcl' 'Lignostab' 'Lmx 4' 'Oraqix' 'Vagisil' 'Xylocaine'
 'Xylodase' 'Xylotox' 'Ztlido']","['ALGRX 3268' 'ALGRX-3268' 'Anestacon' 'Embolex' 'Iontocaine' 'Lidocaine'
 'Lidocainum' 'Lidocaton' 'Lidopen' 'Lignocaine' 'NSC-40030' 'Octocaine'
 'Solarcaine' 'Xylestesin']","[('DailyMed', array(['lidocaine'], dtype=object)), ('PubChem', array(['104171182', '11111384', '11111385', '144203734', '170464729',
       '26751483', '26751484', '56422194', '855682', '90340642'],
      dtype=object)), ('Wikipedia', array(['Lidocaine'], dtype=object)), ('drugbank', array(['DB00281'], dtype=object)), ('chEBI', array(['6456'], dtype=object))]",['CHEMBL3278065' 'CHEMBL541521' 'CHEMBL1200409'],"{'rows': array(['EFO_0003943', 'MONDO_0008903', 'EFO_0004273', 'EFO_0009364',
       'EFO_1001097', 'MONDO_0001572', 'EFO_0001074', 'Orphanet_365',
       'EFO_0002610', 'HP_0003418', 'EFO_0001663', 'EFO_1000941',
       'EFO_0003843', 'MONDO_0005178', 'EFO_0008507', 'EFO_0009688',
       'HP_0100543', 'HP_0000989', 'EFO_1001434', 'HP_0003419',
       'EFO_1001993', 'EFO_0000555', 'EFO_0005856', 'EFO_0009552',
       'EFO_0003878', 'EFO_1001896', 'EFO_0004616', 'HP_0002315',
       'EFO_0003958', 'EFO_0007214', 'EFO_1001250', 'EFO_1000249',
       'MONDO_0004992', 'EFO_0006346', 'EFO_0005230', 'EFO_0000668',
       'EFO_0009660', 'EFO_1001139', 'EFO_1001087', 'EFO_0002970',
       'EFO_1001178', 'HP_0003394', 'EFO_1001998', 'MONDO_0007254',
       'EFO_0000712', 'EFO_0002618', 'EFO_1001412', 'EFO_0009430',
       'EFO_0003917', 'MP_0001845', 'HP_0002315', 'EFO_0001073',
       'EFO_0004143', 'EFO_0000546', 'EFO_0009620', 'EFO_0007490',
       'MONDO_0004567', 'HP_0001907', 'EFO_1001951', 'EFO_0003888',
       'HP_0000360', 'EFO_0010582', 'MONDO_0100096', 'EFO_0000519',
       'EFO_0003902', 'EFO_1001898', 'EFO_0004142', 'EFO_0003833',
       'EFO_0000701', 'EFO_0009492', 'EFO_0009619', 'EFO_0000537',
       'EFO_0006834', 'EFO_0005762', 'EFO_0003100', 'HP_0030834',
       'EFO_1001492', 'HP_0000020', 'HP_0100607', 'EFO_0803321',
       'EFO_0005279', 'EFO_0003777', 'MP_0001914', 'MONDO_0002258',
       'EFO_0003957', 'EFO_1001996', 'EFO_0005687', 'EFO_0003103',
       'EFO_0009516', 'EFO_1001219', 'EFO_0000545', 'HP_0012532',
       'EFO_0005754', 'EFO_0009552', 'EFO_1001054', 'EFO_0801084',
       'HP_0003418', 'EFO_0009846', 'EFO_0000616', 'EFO_0000400',
       'EFO_0000546', 'MONDO_0005277', 'HP_0004308', 'EFO_0001069',
       'HP_0003326', 'EFO_1001255', 'EFO_1000910', 'EFO_1000781',
       'MONDO_0004992', 'MONDO_0002691', 'EFO_0003843', 'EFO_1001904',
       'EFO_0004198', 'EFO_1000783', 'EFO_0003901', 'EFO_0000707',
       'HP_0000989', 'EFO_0002950', 'EFO_0002950', 'EFO_0001361',
       'EFO_1000889', 'HP_0012532', 'EFO_0009582', 'EFO_0007486',
       'EFO_0000305', 'MONDO_0005277', 'HP_0012735', 'EFO_0004269',
       'EFO_0003854', 'EFO_0000313', 'EFO_1001887', 'EFO_0002496',
       'MONDO_0041052'], dtype=object), 'count': 133}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 23 approved and 105 investigational indications. This drug has a black box warning from the FDA.
CHEMBL964,CCN(CC)C(=S)SSC(=S)N(CC)CC,AUZONCFQVSMFAP-UHFFFAOYSA-N,Small molecule,True,DISULFIRAM,1951.0,4.0,,False,True,['Antabuse' 'Disulfiram' 'Esperal'],['Disulfiram' 'NSC-25953' 'ORA-102' 'ORA102'],"[('DailyMed', array(['disulfiram'], dtype=object)), ('PubChem', array(['104171249', '11111859', '11111860', '11533044', '123060006',
       '124881563', '124881565', '124881567', '124881570', '144203831',
       '144210721', '144214033', '170464767', '26747681', '26747682',
       '26753660', '26753661', '50107088', '50107089', '56422197',
       '85231246', '90340564'], dtype=object)), ('TG-GATEs', array(['109'], dtype=object)), ('Wikipedia', array(['Disulfiram'], dtype=object)), ('drugbank', array(['DB00822'], dtype=object)), ('chEBI', array(['4659'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0002610', 'EFO_0000519', 'EFO_0005611',
       'EFO_0001067', 'EFO_0001073', 'EFO_0002617', 'MONDO_0004992',
       'EFO_0003060', 'EFO_0004701', 'MONDO_0019118', 'EFO_0002618',
       'EFO_0000756', 'MONDO_0008315', 'HP_0012378', 'EFO_0000691',
       'EFO_0000764', 'MONDO_0021698', 'MONDO_0007254', 'MONDO_0007079',
       'MONDO_0100096', 'EFO_0000514'], dtype=object), 'count': 22}",[ENSG00000111275],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for parasitic infection and alcohol dependence and has 20 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1083659,Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1,JYTNQNCOQXFQPK-MRXNPFEDSA-N,Small molecule,False,SUVOREXANT,2014.0,4.0,,False,True,['Belsomra'],['MK-4305' 'MK4305' 'Suvorexant'],"[('DailyMed', array(['suvorexant'], dtype=object)), ('drugbank', array(['DB09034'], dtype=object)), ('chEBI', array(['82698'], dtype=object))]",,"{'rows': array(['EFO_0009267', 'EFO_0003768', 'MONDO_0004975', 'EFO_0003877',
       'EFO_0003758', 'EFO_0004698', 'EFO_0004319', 'EFO_0004270',
       'EFO_0008568', 'MONDO_0007079', 'EFO_0010702'], dtype=object), 'count': 11}","[ENSG00000137252,ENSG00000121764]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for insomnia and has 10 investigational indications.
CHEMBL1201231,C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,JDOZJEUDSLGTLU-VWUMJDOOSA-N,Small molecule,False,PREDNISOLONE PHOSPHORIC ACID,1973.0,4.0,,False,True,[],['Prednisolone phosphate' 'Prednisolone phosphoric acid'],"[('drugbank', array(['DB14631'], dtype=object))]",['CHEMBL1201014'],"{'rows': array(['MONDO_0005301', 'MONDO_0002280', 'EFO_1001231', 'EFO_0003929',
       'MP_0001845', 'EFO_0007126', 'MONDO_0004979', 'EFO_1001226',
       'EFO_0000768', 'EFO_0000341', 'HP_0000559', 'EFO_0009448',
       'EFO_0000565', 'EFO_0007308', 'EFO_0005854', 'EFO_0007141',
       'EFO_0004255', 'EFO_0007415'], dtype=object), 'count': 18}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 14 approved and 4 investigational indications.
CHEMBL1201747,CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,MWTBKTRZPHJQLH-UHFFFAOYSA-N,Small molecule,False,ALCAFTADINE,2010.0,4.0,,False,True,['Lastacaft'],['Alcaftadine' 'R 89674' 'R-89674'],"[('DailyMed', array(['alcaftadine'], dtype=object)), ('Wikipedia', array(['Alcaftadine'], dtype=object)), ('drugbank', array(['DB06766'], dtype=object)), ('chEBI', array(['71023'], dtype=object))]",,"{'rows': array(['EFO_0007141', 'EFO_0005751'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for allergic conjunctivitis and eye allergy.
CHEMBL1218,CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3,YLXDSYKOBKBWJQ-LBPRGKRZSA-N,Small molecule,False,RAMELTEON,2005.0,4.0,,False,True,['Ramelteon' 'Rozerem'],['Ramelteon' 'TAK-375' 'TAK375'],"[('DailyMed', array(['ramelteon'], dtype=object)), ('drugbank', array(['DB00980'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'MONDO_0004985', 'EFO_0004698', 'EFO_0003768',
       'EFO_0008568', 'MONDO_0005475', 'MONDO_0100096', 'EFO_0009516',
       'MONDO_0100431', 'EFO_0003890', 'MONDO_0002050', 'EFO_0007191',
       'EFO_0003918'], dtype=object), 'count': 13}","[ENSG00000168412,ENSG00000134640]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for insomnia and has 12 investigational indications.
CHEMBL1360,COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC,YXSLJKQTIDHPOT-UHFFFAOYSA-N,Small molecule,False,ATRACURIUM,1983.0,4.0,,False,True,[],['Atracurium' 'Atracurium cation' 'Atracurium ion' 'Tracrium'],"[('Wikipedia', array(['Atracurium_besilate'], dtype=object)), ('chEBI', array(['2914'], dtype=object))]",['CHEMBL4584552' 'CHEMBL1200527'],,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983.
CHEMBL1614725,CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21,ZYQXEVJIFYIBHZ-UHFFFAOYSA-N,Small molecule,False,TAK-285,,1.0,,False,False,[],['TAK-285' 'Tak 285' 'Tak-285' 'Tak285'],,,"{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}","[ENSG00000141736,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1754,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,XFDJYSQDBULQSI-UHFFFAOYSA-N,Small molecule,False,DOXAPRAM,1965.0,4.0,,False,True,[],['Docatone' 'Doxapram'],"[('PubChem', array(['50112713'], dtype=object)), ('Wikipedia', array(['Doxapram'], dtype=object)), ('drugbank', array(['DB00561'], dtype=object)), ('chEBI', array(['681848'], dtype=object))]",['CHEMBL1200876' 'CHEMBL3989519'],"{'rows': array(['EFO_0000684', 'EFO_0004262', 'EFO_0003818'], dtype=object), 'count': 3}","[ENSG00000171303,ENSG00000169427]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for respiratory system disease and lung disease and has 1 investigational indication.
CHEMBL17879,CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-],POMVPJBWDDJCMP-RUKDTIIFSA-M,Small molecule,False,MARALIXIBAT CHLORIDE,2021.0,4.0,CHEMBL363392,False,True,['Livmarli'],['LUM-001' 'LUM001' 'Lopixibat chloride' 'Maralixibat chloride'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/livmarli'],
      dtype=object))]",,"{'rows': array(['MONDO_0007318', 'EFO_0004268', 'HP_0000989', 'EFO_1001486'],
      dtype=object), 'count': 4}",[ENSG00000125255],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alagille syndrome and pruritus and has 2 investigational indications.
CHEMBL2107455,CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,ANMATWQYLIFGOK-UHFFFAOYSA-N,Small molecule,False,IGURATIMOD,,3.0,,False,False,[],['Careram' 'Iguratimod' 'Kolbet' 'T-614'],"[('PubChem', array(['144206972'], dtype=object)), ('drugbank', array(['DB12233'], dtype=object))]",,"{'rows': array(['EFO_0007160', 'EFO_0000699', 'EFO_0005761', 'EFO_0000685'],
      dtype=object), 'count': 4}","[ENSG00000240972,ENSG00000073756,ENSG00000056972]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2135460,NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,BENFXAYNYRLAIU-QSVFAHTRSA-N,Protein,True,TERLIPRESSIN,2022.0,4.0,,False,True,['Terlivaz' 'Variquel'],['Glycylpressin' 'Glypressin' 'Terlipressin' 'Terlipressin acetate'],"[('PubChem', array(['124896640', '144206925'], dtype=object)), ('drugbank', array(['DB02638'], dtype=object))]",['CHEMBL4088899'],"{'rows': array(['HP_0000083', 'EFO_0001422', 'MONDO_0001382', 'HP_0001399',
       'MP_0001914', 'HP_0002105', 'EFO_0006834', 'EFO_1002048'],
      dtype=object), 'count': 8}","[ENSG00000126895,ENSG00000166148,ENSG00000198049]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL272621,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C,DGABKXLVXPYZII-SIBKNCMHSA-N,Small molecule,False,HYODEOXYCHOLIC_ACID,,1.0,,False,False,[],"['.alpha.-hyodeoxycholic acid' 'AHRO-001' 'HDCA' 'Hyodeoxycholic acid'
 'Hyodeoxycholic_acid' 'Hyodesoxycholic acid' 'NSC-60672']","[('Wikipedia', array(['Hyodeoxycholic_acid'], dtype=object)), ('drugbank', array(['DB11789'], dtype=object)), ('chEBI', array(['52023'], dtype=object))]",,"{'rows': array(['HP_0003124'], dtype=object), 'count': 1}","[ENSG00000025434,ENSG00000131408]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL3545269,,,Small molecule,False,SAR425899,,2.0,,False,False,[],['Sar425899'],,,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000215644],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545313,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O,HYHMLYSLQUKXKP-UHFFFAOYSA-N,Small molecule,False,BEMPEDOIC ACID,2020.0,4.0,,False,True,['Nexletol' 'Nilemdo'],['Bempedoic acid' 'ESP-55016' 'ETC-1002' 'ETC1002'],"[('DailyMed', array(['bempedoic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nilemdo'],
      dtype=object)), ('drugbank', array(['DB11936'], dtype=object))]",,"{'rows': array(['HP_0003124', 'EFO_0000319', 'EFO_0004911', 'MONDO_0021187',
       'HP_0003119', 'Orphanet_309005', 'EFO_0001645', 'EFO_0003914',
       'MONDO_0005148'], dtype=object), 'count': 9}",[ENSG00000131473],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 6 approved and 3 investigational indications.
CHEMBL3647420,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C,SADXACCFNXBCFY-IYNHSRRRSA-N,Small molecule,False,PYROTINIB,,3.0,,False,False,[],['Pyrotinib' 'SHR-1258'],"[('drugbank', array(['DB14993'], dtype=object))]",,"{'rows': array(['EFO_0008549', 'MONDO_0001056', 'EFO_0000339', 'EFO_0003060',
       'EFO_1001951', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000182',
       'EFO_0003869', 'EFO_0005537'], dtype=object), 'count': 10}","[ENSG00000141736,ENSG00000146648]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL4297545,,,Protein,False,LUTETIUM OXODOTREOTIDE LU-177,2018.0,4.0,CHEMBL4302409,False,True,['Lutathera'],"['(177)lu-dotatate' '177lu-dota-tyr3-octreotate' '177lu-dotatate'
 'Dota-octreotate lutetium lu-177' 'Dotatate lutenium lu-177'
 'Dotatate lutetium lu-177' 'Lutetium (177lu) dotatate'
 'Lutetium (177lu) oxodotreotide' 'Lutetium dotatate lu-177'
 'Lutetium dotatate, lu-177' 'Lutetium lu 177 dotatate'
 'Lutetium lu-177 dotatate' 'Oxodotreotide lutetium lu-177'
 'Oxodotreotide lutetium, lu-177']","[('DailyMed', array(['lutetium%20lu%20177%20dotatate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera'],
      dtype=object))]",,"{'rows': array(['EFO_1000045', 'MONDO_0002120', 'EFO_0000305', 'MONDO_0020634',
       'EFO_0000621', 'MONDO_0016642', 'EFO_1001471', 'MONDO_0024503',
       'EFO_1001901', 'EFO_0007416'], dtype=object), 'count': 10}","[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for pancreatic neuroendocrine tumor and neuroendocrine neoplasm and has 8 investigational indications.
CHEMBL5314396,CNC1CN(c2cc(N)nc(CC(C)C)n2)C1,QRBVUFXEMHNIDB-UHFFFAOYSA-N,Small molecule,False,UR-63325,,2.0,,False,False,[],['Seliforant' 'UR-63325' 'Ur-63325'],,,"{'rows': array(['EFO_0003956'], dtype=object), 'count': 1}",[ENSG00000134489],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL813,CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,OROAFUQRIXKEMV-LDADJPATSA-N,Small molecule,True,EPROSARTAN,1997.0,4.0,,False,True,['Teveten'],['Eprosartan' 'SK&F 108566' 'SK&F-108566' 'SK-108566' 'Teveten'],"[('Wikipedia', array(['Eprosartan'], dtype=object)), ('drugbank', array(['DB00876'], dtype=object)), ('chEBI', array(['4814'], dtype=object))]",['CHEMBL1200987'],"{'rows': array(['EFO_0003086', 'MONDO_0100096', 'MONDO_0001134', 'EFO_0000694',
       'EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 6}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for cardiovascular disease and hypertension and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL865,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,LNPDTQAFDNKSHK-UHFFFAOYSA-N,Small molecule,True,VALDECOXIB,2001.0,4.0,,True,True,['Bextra'],['NSC-759846' 'SC-65872' 'Valdecoxib' 'Valdyn'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bextra'],
      dtype=object)), ('PubChem', array(['144204991', '170465163', '26748964', '49665731'], dtype=object)), ('Wikipedia', array(['Valdecoxib'], dtype=object)), ('drugbank', array(['DB00580'], dtype=object)), ('chEBI', array(['63634'], dtype=object))]",,"{'rows': array(['MONDO_0002258', 'MONDO_0005178', 'HP_0100607', 'EFO_0003843',
       'EFO_0004616', 'EFO_0000685', 'EFO_0000278', 'EFO_0005755'],
      dtype=object), 'count': 8}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 4 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL904,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1.Cl,JUMYIBMBTDDLNG-OJERSXHUSA-N,Small molecule,True,DEXMETHYLPHENIDATE HYDROCHLORIDE,2001.0,4.0,CHEMBL827,False,True,['Dexmethylphenidate hydrochloride' 'Focalin' 'Focalin xr'],"['Dex-methylphenidate hydrochloride' 'Dexmethylphenidate hcl'
 'Dexmethylphenidate hydrochloride'
 'Methylphenidate d-threo-form hydrochloride']","[('DailyMed', array(['dexmethylphenidate%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}","[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA.
CHEMBL1159,CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C,IVVNZDGDKPTYHK-UHFFFAOYSA-N,Small molecule,False,PINACIDIL ANHYDROUS,1989.0,4.0,,False,True,[],"['(r,s)-pinacidil' 'P-1134' 'Pinacidil anhydrous' 'S-1230']","[('PubChem', array(['11532877', '124881033', '26749106', '26752206', '50104869',
       '56463565', '90341497'], dtype=object)), ('Wikipedia', array(['Pinacidil'], dtype=object)), ('drugbank', array(['DB06762'], dtype=object))]",['CHEMBL1200338'],"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000187486,ENSG00000069431]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for hypertension.
CHEMBL1200335,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,VOCBWIIFXDYGNZ-IXKNJLPQSA-N,Small molecule,True,TESTOSTERONE ENANTHATE,1953.0,4.0,,False,True,"['Delatestryl' 'Primoteston depot' 'Testosterone enanthate'
 'Xyosted (autoinjector)']","['Androtardyl' 'NSC-17591' 'Testosterone enantate'
 'Testosterone enanthate' 'Testosterone enanthate ciii'
 'Testosterone heptanoate' 'Testosteroni enantas' 'Xyosted']","[('DailyMed', array(['testosterone%20enanthate'], dtype=object)), ('drugbank', array(['DB13944'], dtype=object)), ('chEBI', array(['9464'], dtype=object))]",,"{'rows': array(['EFO_0000341', 'EFO_0000673', 'EFO_1001078', 'HP_0000044',
       'MONDO_0008315', 'EFO_0000196', 'EFO_0000616', 'MONDO_0002146',
       'EFO_0007312', 'HP_0001824', 'Orphanet_269'], dtype=object), 'count': 11}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200432,CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1.Cl,QSRVZCCJDKYRRF-YDALLXLXSA-N,Small molecule,False,METHYLDOPATE HYDROCHLORIDE,1962.0,4.0,CHEMBL1201233,False,True,['Aldomet' 'Methyldopate hydrochloride'],"['Methyldopa l-form ethyl ester hydrochloride' 'Methyldopate hcl'
 'Methyldopate hydrochloride' 'NSC-760088']","[('PubChem', array(['144204076', '170466856'], dtype=object))]",,,"[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962.
CHEMBL1201208,CC1NCCOC1c1ccccc1,OOBHFESNSZDWIU-UHFFFAOYSA-N,Small molecule,False,PHENMETRAZINE,1982.0,4.0,,False,True,[],['Phenmetrazine' 'Preludin' 'Trans-phenmetrazine'],"[('Wikipedia', array(['Phenmetrazine'], dtype=object)), ('drugbank', array(['DB00830'], dtype=object)), ('chEBI', array(['8067'], dtype=object))]",['CHEMBL1200483'],,"[ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1230165,O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12,MUOKSQABCJCOPU-UHFFFAOYSA-N,Small molecule,False,SILMITASERTIB,,2.0,,False,False,[],"['CX 4945' 'CX-4945' 'CX4945' 'Cx-4945' 'Cx-4945 free acid'
 'Silmitasertib']","[('PubChem', array(['137276036'], dtype=object)), ('drugbank', array(['DB15408'], dtype=object))]",['CHEMBL5305652'],"{'rows': array(['EFO_0004193', 'EFO_0002939', 'EFO_0005221', 'MONDO_0100096',
       'EFO_0001378'], dtype=object), 'count': 5}",[ENSG00000101266],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2103741,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+],ANMYAHDLKVNJJO-LTCKWSDVSA-M,Small molecule,True,LEVOTHYROXINE SODIUM,2000.0,4.0,CHEMBL1624,False,True,"['Eltroxin' 'Ermeza' 'Euthyrox' 'Evotrox' 'L-thyroxine henning' 'Levo-t'
 'Levolet' 'Levothroid' 'Levothyroid' 'Levothyroxine sodium' 'Levoxine'
 'Levoxyl' 'Novothyrox' 'Soloxine' 'Synthroid' 'Thyquidity' 'Thyro-tabs'
 'Thyrol L' 'Thyroxine' 'Tirosint' 'Tirosint-sol' 'Unithroid']","['Eferox' 'Levaxin' 'Levothyrox' 'Levothyroxine sodium'
 'Levothyroxine sodium anhydrous' 'Levothyroxine sodium hydrate'
 'Levothyroxine sodium pentahydrate' 'Levothyroxinum natricum anhydrous'
 'Liotrix (t4)' 'Monosodium l-thyroxine hydrate' 'NSC-259940' 'Oroxine'
 'Sodium levothyroxine pentahydrate' 'Soloxine' 'T4' 'Thyroxine'
 'Thyroxine sodium' 'Thyroxine sodium salt']","[('DailyMed', array(['levothyroxine%20sodium'], dtype=object)), ('chEBI', array(['6447'], dtype=object))]",,"{'rows': array(['MONDO_0018612', 'EFO_0002892', 'EFO_0004705', 'EFO_0003843',
       'EFO_1002017', 'MONDO_0004985', 'MONDO_0002108'], dtype=object), 'count': 7}","[ENSG00000126351,ENSG00000151090]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103880,CN(C)CCCOc1ccc2[nH]nc(S(=O)(=O)c3cccc4ccccc34)c2c1,NXQGEDVQXVTCDA-UHFFFAOYSA-N,Small molecule,False,CERLAPIRDINE,,2.0,,False,False,[],"['Cerlapirdine' 'PF-05212365' 'SAM-531' 'SAM-531 FREE BASE' 'Sam-531'
 'WAY-262,531' 'WAY-262531']","[('drugbank', array(['DB12229'], dtype=object))]",['CHEMBL2105752'],"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000158748],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2104262,Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2,VTZPAJGVRWKMAG-UHFFFAOYSA-N,Small molecule,False,FADOLMIDINE,,2.0,,False,False,[],['Fadolmidine' 'Radolmidine'],,['CHEMBL2106710'],,"[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2107819,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,SJDDOCKBXFJEJB-MOKWFATOSA-N,Small molecule,False,BELNACASAN,,2.0,,False,False,['Vx-765'],['Belnacasan' 'VX-765' 'VX765'],,,"{'rows': array(['EFO_0000676', 'EFO_0000474', 'MONDO_0100096', 'EFO_0004263'],
      dtype=object), 'count': 4}",[ENSG00000137752],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2108119,,,Antibody,False,PASCOLIZUMAB,,2.0,,False,False,[],['ANTI-IL4' 'Anti-il-4 antibody' 'Pascolizumab' 'SB-240683'],,,"{'rows': array(['MONDO_0004979', 'MONDO_0018076'], dtype=object), 'count': 2}",[ENSG00000113520],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2109519,,,Antibody,False,ABX-MA1,,1.0,,False,False,[],['ABX-MA1'],,,,[ENSG00000076706],Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109575,,,Antibody drug conjugate,False,BIIB-015,,1.0,,False,False,[],['BIIB-015' 'Biib-015'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000241186],Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109591,,,Antibody,False,TOL-101,,2.0,,False,False,[],['TOL-101' 'TOL101' 'Tol-101'],,,"{'rows': array(['EFO_0003884'], dtype=object), 'count': 1}","[ENSG00000211810,ENSG00000277734,ENSG00000278030,ENSG00000211699]",Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545042,CC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C,MCECSFFXUPEPDB-UHFFFAOYSA-N,Small molecule,False,SELURAMPANEL,,2.0,,False,False,[],['BGG-492' 'BGG492' 'Bgg492' 'Selurampanel'],"[('drugbank', array(['DB12367'], dtype=object))]",,"{'rows': array(['MONDO_0015643', 'HP_0001250', 'HP_0001257', 'MONDO_0005277',
       'EFO_0000474', 'HP_0000360', 'MONDO_0005301'], dtype=object), 'count': 7}","[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL39541,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,OFDNQWIFNXBECV-VFSYNPLYSA-N,Small molecule,False,DOLASTATIN-10,,2.0,,False,False,[],['Dolastatin 10' 'Dolastatin-10' 'Dolostatin 10'],"[('drugbank', array(['DB12730'], dtype=object)), ('chEBI', array(['67357'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0002618', 'MONDO_0008170', 'EFO_0000574',
       'MONDO_0005411', 'EFO_0000198', 'EFO_0000565', 'MONDO_0002367',
       'EFO_0000691'], dtype=object), 'count': 9}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications.
CHEMBL4297763,,,Unknown,False,GTI-2040,,2.0,,False,False,[],['Gti 2040' 'Gti-2040'],,,"{'rows': array(['EFO_0000222', 'EFO_0000616', 'MONDO_0008315', 'EFO_0006861'],
      dtype=object), 'count': 4}",[ENSG00000171848],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297819,,,Unknown,False,ROPEGINTERFERON ALFA-2B,2019.0,4.0,,False,True,['Besremi'],"['Aop2014' 'Besremi' 'P-1101' 'P1101' 'Ropeginterferon alfa-2b'
 'Ropeginterferon alfa-2b njft' 'Ropeginterferon alfa-2b-njft']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/besremi'],
      dtype=object))]",,"{'rows': array(['EFO_0004239', 'EFO_0000616', 'MONDO_0044903', 'MONDO_0100096',
       'EFO_0000182', 'EFO_0000339', 'EFO_0002429', 'EFO_0007304',
       'EFO_0000479', 'EFO_0004220'], dtype=object), 'count': 10}","[ENSG00000142166,ENSG00000159110]",Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for neoplasm and polycythemia vera and has 8 investigational indications.
CHEMBL4297990,,,Protein,False,TEBENTAFUSP,2022.0,4.0,,False,True,['Kimmtrak'],"['IMCGP-100' 'IMCGP100' 'IMCgp 100' 'IMMTAC IMCGP100' 'Imcgp100'
 'ImmTAC IMCgpgp 100' 'Kimmtrak' 'Tebentafusp' 'Tebentafusp tebn'
 'Tebentafusp-tebn']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kimmtrak'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEBENTAFUSP/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001230', 'EFO_0000616', 'EFO_0000756'], dtype=object), 'count': 3}",[ENSG00000185664],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved indications.
CHEMBL4594614,,,Antibody,False,SIBEPRENLIMAB,,2.0,,False,False,[],['Sibeprenlimab' 'VIS-649' 'VIS649' 'Vis-649' 'Vis649'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIBEPRENLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004194'], dtype=object), 'count': 1}",[ENSG00000161955],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL460702,CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,VNBRGSXVFBYQNN-UHFFFAOYSA-N,Small molecule,False,BMS-777607,,2.0,,False,False,[],['ASLAN-002' 'ASLAN002' 'BMS-777607' 'Bms-777607'],"[('PubChem', array(['137276001'], dtype=object)), ('drugbank', array(['DB12064'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL46740,Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,UCJGJABZCDBEDK-UHFFFAOYSA-N,Small molecule,False,BAZEDOXIFENE,2009.0,4.0,,False,True,[],['Bazedoxifene'],"[('PubChem', array(['124893775'], dtype=object)), ('Wikipedia', array(['Bazedoxifene'], dtype=object)), ('drugbank', array(['DB06401'], dtype=object))]",['CHEMBL2106615'],"{'rows': array(['EFO_0000432', 'EFO_0003854', 'MONDO_0007254', 'GO_0042697',
       'EFO_0003929', 'EFO_0003882', 'EFO_0003882', 'EFO_0003854',
       'GO_0042697'], dtype=object), 'count': 9}","[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for postmenopausal osteoporosis and has 7 investigational indications.
CHEMBL5314379,C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,BICRTLVBTLFLRD-PTWUADNWSA-N,Protein,True,VOCLOSPORIN,2021.0,4.0,,False,True,['Lupkynis'],['ISA-247' 'ISA247' 'ISATX-247' 'ISATX247' 'LX-211' 'LX211' 'Voclosporin'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis'],
      dtype=object))]",,"{'rows': array(['EFO_1000986', 'EFO_0005761', 'EFO_1000811', 'EFO_1001082',
       'EFO_1001119', 'EFO_1000906', 'EFO_0003086', 'EFO_1001231',
       'MONDO_0007915', 'EFO_0004236', 'EFO_0000540', 'EFO_0000676'],
      dtype=object), 'count': 12}",[ENSG00000138814],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for lupus nephritis and immune system disease and has 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL5314380,NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O.N[C@@H](CC(=O)O)C(=O)O.N[C@@H](CC(=O)O)C(=O)O,NEEFMPSSNFRRNC-HQUONIRXSA-N,Protein,False,PASIREOTIDE DIASPARTATE,2012.0,4.0,CHEMBL3349607,False,True,['Signifor'],['Pasireotide (as diaspartate)'],"[('DailyMed', array(['pasireotide%20diaspartate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/signifor'],
      dtype=object))]",,,"[ENSG00000278195,ENSG00000139874,ENSG00000162009,ENSG00000180616]",Protein drug with a maximum clinical trial phase of IV that was first approved in 2012.
CHEMBL70418,CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21,CXOXHMZGEKVPMT-UHFFFAOYSA-N,Small molecule,True,CLOBAZAM,2005.0,4.0,,False,True,['Frisium' 'Onfi' 'Perizam' 'Sympazan' 'Tapclob' 'Urbanyl'],"['Clobazam' 'Colbazam' 'H 4723' 'H-4723' 'HR 376' 'HR-376' 'LM 2717'
 'LM-2717' 'Mystan' 'NSC-336279' 'Urbadan']","[('DailyMed', array(['clobazam'], dtype=object)), ('PubChem', array(['144206161'], dtype=object)), ('Wikipedia', array(['Clobazam'], dtype=object)), ('drugbank', array(['DB00349'], dtype=object)), ('chEBI', array(['31413'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'MONDO_0016532', 'HP_0001250', 'HP_0000726',
       'EFO_0000474', 'EFO_0005762', 'EFO_0005230', 'MONDO_0002050',
       'MONDO_0005090', 'EFO_1000924', 'HP_0003419'], dtype=object), 'count': 11}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL802,Nc1cc(N2CCCCC2)nc(N)[n+]1[O-],ZFMITUMMTDLWHR-UHFFFAOYSA-N,Small molecule,True,MINOXIDIL,1979.0,4.0,,False,True,"['Loniten' 'Lonolox' ""Men's rogaine"" 'Minodyl' 'Minoxidil'
 'Minoxidil (for men)' 'Minoxidil (for women)'
 'Minoxidil extra strength (for men)' 'Regaine for men'
 'Regaine for women' 'Rogaine (for men)' 'Rogaine (for women)'
 'Rogaine extra strength (for men)' 'Theroxidil' ""Women's rogaine""]","['Alopexil' 'Alostil' 'Minoxidil' 'Minoximen' 'Mintop' 'NSC-757106'
 'Normoxidil' 'Pierminox' 'Prexidil' 'Tricoxidil' 'U-10,858' 'U-10858']","[('DailyMed', array(['minoxidil'], dtype=object)), ('PubChem', array(['104171187', '11111457', '11111458', '11113580', '144203744',
       '170464704', '26751784', '26751785', '46500395', '50104471',
       '85231134', '90340717'], dtype=object)), ('Wikipedia', array(['Minoxidil'], dtype=object)), ('drugbank', array(['DB00350'], dtype=object)), ('chEBI', array(['6942'], dtype=object))]",,"{'rows': array(['MONDO_0008170', 'EFO_0004191', 'EFO_0000537', 'MONDO_0004907',
       'MONDO_0003037'], dtype=object), 'count': 5}","[ENSG00000187486,ENSG00000069431]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL862,N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,INJOMKTZOLKMBF-UHFFFAOYSA-N,Small molecule,False,GUANFACINE,1986.0,4.0,,False,True,['Intuniv'],['Guanfacine' 'NSC-759121' 'Tenex'],"[('PubChem', array(['104171166', '11111221', '11111222', '11113866', '124880211',
       '26752038', '90341397'], dtype=object)), ('Wikipedia', array(['Guanfacine'], dtype=object)), ('drugbank', array(['DB01018'], dtype=object)), ('chEBI', array(['5558'], dtype=object))]",['CHEMBL1200494'],"{'rows': array(['EFO_0004895', 'MONDO_0004975', 'EFO_0003890', 'EFO_0001358',
       'EFO_0002610', 'EFO_0004319', 'EFO_1001219', 'EFO_0003768',
       'EFO_0007191', 'EFO_0004329', 'EFO_0003888', 'MONDO_0007079',
       'EFO_0000712', 'EFO_0000537', 'EFO_0009267', 'MONDO_0001087',
       'EFO_0003888', 'EFO_0000537'], dtype=object), 'count': 18}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for attention deficit hyperactivity disorder and hypertension and has 15 investigational indications.
CHEMBL1085699,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1,ANEBWFXPVPTEET-UHFFFAOYSA-N,Small molecule,False,MANIDIPINE 6300,,3.0,,False,False,[],"['Artedil' 'Franidipine' 'Manidipine' 'Manidipine 6300'
 'Manidipine hydrochloride']","[('PubChem', array(['174006297', '50112746'], dtype=object)), ('drugbank', array(['DB09238'], dtype=object))]",['CHEMBL2362693'],"{'rows': array(['EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 2}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1200491,Cl.NC1=NCC2c3ccccc3Cc3ccccc3N12,VKXSGUIOOQPGAF-UHFFFAOYSA-N,Small molecule,False,EPINASTINE HYDROCHLORIDE,2003.0,4.0,CHEMBL1106,False,True,['Elestat' 'Epinastine hydrochloride' 'Relestat'],"['Alesion' 'DE-114' 'Epinastine HCl' 'Epinastine hcl'
 'Epinastine hydrochloride' 'WAL 801 CL' 'WAL-801CL' 'WAL-802-CL']","[('DailyMed', array(['epinastine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205816', '170465284'], dtype=object)), ('chEBI', array(['51037'], dtype=object))]",,"{'rows': array(['EFO_0007141'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003 and is indicated for allergic conjunctivitis.
CHEMBL1200885,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O.Cl,FNYQZOVOVDSGJH-UHFFFAOYSA-N,Small molecule,True,ALOSETRON HYDROCHLORIDE,2000.0,4.0,CHEMBL1110,False,True,['Alosetron hydrochloride' 'Lotronex'],"['Alosetron hcl' 'Alosetron hydrochloride' 'GR 68755C' 'GR-68755C'
 'Lotrpnex']","[('DailyMed', array(['alosetron%20hydrochloride'], dtype=object)), ('PubChem', array(['144206078', '170465416', '49681825'], dtype=object)), ('chEBI', array(['53783'], dtype=object))]",,"{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}",[ENSG00000166736],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for irritable bowel syndrome. This drug has a black box warning from the FDA.
CHEMBL1200968,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],RYJIRNNXCHOUTQ-OJJGEMKLSA-L,Small molecule,False,HYDROCORTISONE SODIUM PHOSPHATE,1960.0,4.0,CHEMBL1641,False,True,['Efcortesol' 'Hydrocortone'],['Cortisol 21-(disodium phosphate)' 'Hydrocortisone sodium phosphate'],"[('PubChem', array(['144206021'], dtype=object)), ('chEBI', array(['5781'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1201060,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.Cl,JSXBVMKACNEMKY-UHFFFAOYSA-N,Small molecule,False,LOXAPINE HYDROCHLORIDE,1976.0,4.0,CHEMBL831,False,True,['Loxitane c' 'Loxitane im'],['Loxapine hcl'],,,,"[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976.
CHEMBL1201156,CNCCC=C1c2ccccc2CCc2ccccc21.Cl,SHAYBENGXDALFF-UHFFFAOYSA-N,Small molecule,True,NORTRIPTYLINE HYDROCHLORIDE,1964.0,4.0,CHEMBL445,False,True,"['Aventyl' 'Aventyl hydrochloride' 'Nortriptyline hydrochloride' 'Pamelor'
 'Psychostyl']",['38489' 'NSC-169453' 'Nortriptyline hcl' 'Nortriptyline hydrochloride'],"[('DailyMed', array(['nortriptyline%20hydrochloride'], dtype=object)), ('PubChem', array(['144203599', '50106715', '50106716', '562776', '56423135',
       '855575'], dtype=object))]",,"{'rows': array(['EFO_0008524', 'EFO_0000676', 'EFO_1000948', 'MONDO_0002009',
       'EFO_0000274'], dtype=object), 'count': 5}","[ENSG00000103546,ENSG00000108576]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1206690,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,TZRHLKRLEZJVIJ-UHFFFAOYSA-N,Small molecule,False,PARECOXIB,2002.0,4.0,,False,True,[],['Parecoxib' 'Rayzon' 'SC-69124' 'Xapit'],"[('Wikipedia', array(['Parecoxib'], dtype=object)), ('drugbank', array(['DB08439'], dtype=object)), ('chEBI', array(['73038'], dtype=object))]",['CHEMBL296913'],"{'rows': array(['EFO_0003843', 'EFO_0009620', 'MONDO_0005178', 'EFO_1001412',
       'EFO_0003843', 'HP_0030834', 'EFO_0005755'], dtype=object), 'count': 7}",[ENSG00000073756],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for pain and rheumatic disease and has 5 investigational indications.
CHEMBL1236924,O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl,NMRWDFUZLLQSBN-UHFFFAOYSA-N,Small molecule,False,INT131,,2.0,,False,False,[],"['AMG-131' 'CHS-131' 'INT-131' 'Ibrigampar' 'Int131' 'T-0903131'
 'T0903131' 'T131']","[('drugbank', array(['DB05490'], dtype=object))]",,"{'rows': array(['EFO_0003929', 'MONDO_0005148'], dtype=object), 'count': 2}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1256818,Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O,STTADZBLEUMJRG-IKNOHUQMSA-N,Small molecule,False,DEXTROMETHORPHAN HYDROBROMIDE,1984.0,4.0,CHEMBL52440,False,True,"['Beecham coughcaps' 'Brontyl' 'Contac coughcaps' 'Delsym' 'Franolyn dry'
 'Franolyn sed' 'Tussabron' 'Tuxium']","['Dextromethorphan Hydrobromide Monohydrate'
 'Dextromethorphan hydrobromide' 'NSC-756723']","[('DailyMed', array(['dextromethorphan%20hydrobromide'], dtype=object)), ('PubChem', array(['11112982', '26732619', '49731998'], dtype=object))]",,"{'rows': array(['EFO_0007214', 'EFO_0007486', 'MONDO_0005271', 'MONDO_0004976',
       'MONDO_0002009', 'HP_0001945', 'EFO_0003843', 'EFO_0000616',
       'MONDO_0002050', 'HP_0002315', 'HP_0001742', 'HP_0012735',
       'MONDO_0005277', 'EFO_0001663', 'MONDO_0005148'], dtype=object), 'count': 15}","[ENSG00000183454,ENSG00000147955]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 7 approved and 8 investigational indications.
CHEMBL1473,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,WMWTYOKRWGGJOA-CENSZEJFSA-N,Small molecule,False,FLUTICASONE PROPIONATE,1990.0,4.0,,False,True,"['Aerivio spiromax' 'Airflusal forspiro' 'Armonair digihaler'
 'Armonair respiclick' 'Cutivate' 'Flixonase' 'Flixotide' 'Flonase'
 'Flonase allergy relief' 'Flovent' 'Flovent diskus 100'
 'Flovent diskus 250' 'Flovent diskus 50' 'Flovent hfa'
 'Fluticasone propionate' 'Flutiform' 'Nasofan' 'Pirinase' 'Sereflo'
 'Seretide 100' 'Seretide 125' 'Seretide 250' 'Seretide 50' 'Seretide 500'
 'Sirdupla' 'Xhance']","['CCI 18781' 'CCI-18781' 'CCI18781' 'FLOVENT' 'Fluticaps' 'Fluticasone'
 'Fluticasone propionate' 'Fluticasone propionate '
 'Fluticasone-17-propionate' 'NSC-759889' 'Opn-375' 'Optinose'
 'PF-00241939' 'R01AD08']","[('DailyMed', array(['fluticasone%20propionate'], dtype=object)), ('Wikipedia', array(['Fluticasone_propionate'], dtype=object)), ('drugbank', array(['DB00588'], dtype=object)), ('chEBI', array(['31441'], dtype=object))]",,"{'rows': array(['EFO_0004232', 'MONDO_0100096', 'EFO_1001942', 'EFO_0006505',
       'EFO_0000341', 'HP_0001742', 'EFO_0007486', 'EFO_1000024',
       'EFO_0005854', 'EFO_0000464', 'EFO_0003956', 'EFO_0007227',
       'HP_0011950', 'EFO_0000274', 'EFO_0000400', 'EFO_0000701',
       'EFO_0008521', 'EFO_1001417', 'HP_0100582', 'EFO_1000391',
       'EFO_0003918', 'HP_0010307', 'MONDO_0004979', 'EFO_0009536',
       'EFO_0000662', 'EFO_0007183', 'HP_0006536'], dtype=object), 'count': 27}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 12 approved and 15 investigational indications.
CHEMBL1641,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,BGSOJVFOEQLVMH-VWUMJDOOSA-N,Small molecule,False,HYDROCORTISONE PHOSPHORIC ACID,1960.0,4.0,,False,True,[],['Hydrocortisone phosphate'],"[('PubChem', array(['50112718'], dtype=object)), ('drugbank', array(['DB14542'], dtype=object)), ('chEBI', array(['68634'], dtype=object))]",['CHEMBL1200968'],,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960.
CHEMBL1768,CC(C[N+](C)(C)C)OC(N)=O.[Cl-],XXRMYXBSBOVVBH-UHFFFAOYSA-N,Small molecule,False,BETHANECHOL CHLORIDE,1948.0,4.0,CHEMBL1482,False,True,"['Bethanechol chloride' 'Duvoid' 'Myocholine' 'Myotonachol' 'Myotonine'
 'Urecholine']","['Bethanechol Chloride' 'Bethanechol chloride'
 'Carbamylmethylcholine chloride' 'NSC-30783']","[('DailyMed', array(['bethanechol%20chloride'], dtype=object)), ('PubChem', array(['144205581', '26747481', '50106064', '56422417', '855684'],
      dtype=object)), ('chEBI', array(['3085'], dtype=object))]",,"{'rows': array(['HP_0000016'], dtype=object), 'count': 1}","[ENSG00000181072,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1948 and is indicated for urinary retention.
CHEMBL1789843,,,Antibody,False,BELIMUMAB,2011.0,4.0,,False,True,['Benlysta' 'Lymphostat-b benlysta'],"['BEL-114333' 'BEL114333' 'Belimumab'
 'Belimumab (genetical recombination)' 'GSK-1550188' 'GSK1550188'
 'HGS-1006' 'HGS1006']","[('DailyMed', array(['belimumab'], dtype=object)), ('DrugCentral', array(['4949'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta'],
      dtype=object))]",,"{'rows': array(['MONDO_0013730', 'EFO_0000685', 'EFO_0006803', 'MONDO_0003783',
       'EFO_0002689', 'EFO_0000464', 'MONDO_0005301', 'EFO_0000783',
       'EFO_0000699', 'EFO_0005761', 'EFO_0004254', 'EFO_0007160',
       'EFO_0004256', 'MONDO_0007915', 'EFO_0000095', 'EFO_0000540',
       'EFO_0000717', 'EFO_0004255'], dtype=object), 'count': 18}",[ENSG00000102524],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 15 investigational indications.
CHEMBL2105804,Cc1cc(C)c2c3ccccc3n(Cc3cccc([C@@H](C(=O)N[C@@H](CO)c4ccccc4)C4CCCC4)c3)c2n1,AMNXBQPRODZJQR-DITALETJSA-N,Small molecule,False,IMPLITAPIDE,,2.0,,False,False,[],['BAY-13-9952' 'Implitapide'],"[('drugbank', array(['DB04852'], dtype=object))]",,"{'rows': array(['EFO_0004911', 'EFO_0004211'], dtype=object), 'count': 2}","[ENSG00000138823,ENSG00000185624]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2142592,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1,SZBGQDXLNMELTB-UHFFFAOYSA-N,Small molecule,False,TALADEGIB,,2.0,,False,False,[],['LY-2940680' 'LY2940680' 'Taladegib'],"[('PubChem', array(['137276014'], dtype=object)), ('drugbank', array(['DB12550'], dtype=object))]",,"{'rows': array(['EFO_0000768', 'EFO_0009708', 'EFO_0000702', 'MONDO_0004992',
       'EFO_0000616'], dtype=object), 'count': 5}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL2364607,O=C(O)/C=C/C(=O)O.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,RESIMIUSNACMNW-BXRWSSRYSA-N,Small molecule,False,COBIMETINIB FUMARATE,2015.0,4.0,CHEMBL2146883,False,True,['Cotellic'],"['Cobimetinib fumarate' 'Cobimetinib hemifumarate' 'Gdc-0973 hemifumarate'
 'Xl-518 hemifumarate']","[('DailyMed', array(['cobimetinib%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic'],
      dtype=object))]",,"{'rows': array(['EFO_0000756', 'EFO_0002617'], dtype=object), 'count': 2}","[ENSG00000169032,ENSG00000126934]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for melanoma and metastatic melanoma.
CHEMBL3301610,CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,UZWDCWONPYILKI-UHFFFAOYSA-N,Small molecule,False,ABEMACICLIB,2017.0,4.0,,False,True,['Verzenio' 'Verzenios'],['Abemaciclib' 'LY-2835219' 'LY2835219' 'Ly-2835219'],"[('DailyMed', array(['abemaciclib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios'],
      dtype=object)), ('drugbank', array(['DB12001'], dtype=object))]",['CHEMBL4290012' 'CHEMBL4560869' 'CHEMBL4534140' 'CHEMBL4474565'],"{'rows': array(['EFO_0000616', 'EFO_0000182', 'EFO_0003060', 'EFO_0004284',
       'EFO_0000588', 'MONDO_0008903', 'EFO_0002618', 'MONDO_0008170',
       'EFO_0009708', 'EFO_0000702', 'EFO_0000305', 'MONDO_0008315',
       'EFO_0000349', 'EFO_0000632', 'MONDO_0001187', 'EFO_0000181',
       'EFO_0003825', 'EFO_0005701', 'MONDO_0100342', 'EFO_0005543',
       'EFO_0001378', 'EFO_0003869', 'MONDO_0011962', 'EFO_1001951',
       'EFO_0005537', 'EFO_0000574', 'MONDO_0002108', 'EFO_0003085',
       'EFO_0006861', 'EFO_1001469', 'EFO_0000637', 'EFO_0005952',
       'EFO_0002918', 'EFO_0000196', 'EFO_0000174', 'EFO_0001075',
       'EFO_0000673', 'MONDO_0004992', 'MONDO_0005184', 'EFO_0000389',
       'MONDO_0003060', 'EFO_1000294', 'MONDO_0007254', 'EFO_0003833',
       'EFO_0000756', 'EFO_1000045', 'EFO_1000026', 'EFO_0000558',
       'EFO_0000621', 'EFO_0000519', 'EFO_0003968', 'EFO_1001331',
       'MONDO_0016642', 'MONDO_0018975'], dtype=object), 'count': 54}","[ENSG00000135446,ENSG00000105810]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 6 approved and 48 investigational indications.
CHEMBL3544984,O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1,CAVRKWRKTNINFF-UHFFFAOYSA-N,Small molecule,False,TRADIPITANT,,3.0,,False,False,[],['LY-686017' 'LY686017' 'Ly686017' 'Tradipitant' 'VLY-686'],"[('drugbank', array(['DB12580'], dtype=object))]",,"{'rows': array(['EFO_0000274', 'EFO_1000948', 'HP_0000989', 'MONDO_0007079',
       'EFO_1001917', 'MONDO_0100096', 'EFO_0008533', 'EFO_0006928'],
      dtype=object), 'count': 8}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications.
CHEMBL385517,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,QGJUIPDUBHWZPV-SGTAVMJGSA-N,Small molecule,False,SAXAGLIPTIN ANHYDROUS,2009.0,4.0,,False,True,[],['BMS-477118' 'SBMS-477118'],"[('PubChem', array(['144206461'], dtype=object)), ('Wikipedia', array(['Saxagliptin'], dtype=object)), ('drugbank', array(['DB06335'], dtype=object)), ('chEBI', array(['71272'], dtype=object))]",['CHEMBL2103745' 'CHEMBL1201743' 'CHEMBL3542376'],"{'rows': array(['MONDO_0005148', 'EFO_0008583', 'EFO_0000660', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0005147', 'EFO_0002546', 'EFO_0003940'],
      dtype=object), 'count': 8}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for type 2 diabetes mellitus and has 7 investigational indications.
CHEMBL4213970,CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1,KPQQGHGDBBJGFA-QNGWXLTQSA-N,Small molecule,False,MK-8353,,1.0,,False,False,[],['Mk-8353' 'SCH-900353'],,['CHEMBL4204280'],"{'rows': array(['EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 2}","[ENSG00000102882,ENSG00000100030]",Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications.
CHEMBL4297736,,,Antibody drug conjugate,False,PRALUZATAMAB RAVTANSINE,,2.0,,False,False,[],"['Anti-cd166-dm4 cx-2009' 'CX-2009' 'Cx 2009' 'Cx-2009'
 'Praluzatamab ravtansine']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PRALUZATAMAB%20RAVTANSINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000170017]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL457,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,HEMJJKBWTPKOJG-UHFFFAOYSA-N,Small molecule,False,GEMFIBROZIL,1981.0,4.0,,False,True,['Emfib' 'Gemfibrozil' 'Lopid'],['CI-719' 'Gemfibrozil' 'NSC-757024'],"[('DailyMed', array(['gemfibrozil'], dtype=object)), ('PubChem', array(['11112705', '144204164', '144209195', '144213101', '170464998',
       '17389870', '174007259', '26751515', '49718189', '855780'],
      dtype=object)), ('TG-GATEs', array(['31'], dtype=object)), ('Wikipedia', array(['Gemfibrozil'], dtype=object)), ('drugbank', array(['DB01241'], dtype=object)), ('chEBI', array(['5296'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'MONDO_0004975', 'EFO_0004319', 'EFO_0004211',
       'MONDO_0004992', 'EFO_0003768', 'MONDO_0007079', 'EFO_0000764',
       'HP_0002027', 'EFO_0001645', 'EFO_1001375', 'EFO_0004272',
       'EFO_0000319'], dtype=object), 'count': 13}",[ENSG00000186951],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 10 investigational indications.
CHEMBL4650405,,,Protein,False,LERODALCIBEP,,3.0,,False,False,[],['Lerodalcibep'],,,"{'rows': array(['MONDO_0018328', 'EFO_0004911', 'HP_0003124', 'EFO_0000319'],
      dtype=object), 'count': 4}",[ENSG00000169174],Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL467888,C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,HWLLYFXDDGGHOE-BCSUUIJWSA-N,Small molecule,False,LGD-2941,,1.0,,False,False,[],['LGD-122941' 'LGD122941' 'Lgd-2941'],"[('drugbank', array(['DB05234'], dtype=object))]",,,[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL830,NCCCC(N)(C(=O)O)C(F)F,VLCYCQAOQCDTCN-UHFFFAOYSA-N,Small molecule,False,EFLORNITHINE,1990.0,4.0,,False,True,[],['Eflornithine' 'Ornidyl' 'Vaniqa'],"[('PubChem', array(['174006789', '575150', '90341137'], dtype=object)), ('Wikipedia', array(['Eflornithine'], dtype=object)), ('drugbank', array(['DB06243'], dtype=object)), ('chEBI', array(['41948'], dtype=object))]",['CHEMBL536971' 'CHEMBL1201037'],"{'rows': array(['DOID_10113', 'MONDO_0007576', 'MONDO_0021074', 'EFO_0004142',
       'EFO_0000621', 'EFO_0000313', 'EFO_0002499', 'EFO_0000519',
       'Orphanet_733', 'MONDO_0001056', 'MONDO_0001187', 'Orphanet_733',
       'MONDO_0100342', 'EFO_0005225', 'EFO_0005044', 'EFO_1001951',
       'MONDO_0005147', 'EFO_0000621', 'MONDO_0002974', 'MONDO_0008315'],
      dtype=object), 'count': 20}",[ENSG00000115758],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 18 investigational indications.
CHEMBL1185,CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12,ULSDMUVEXKOYBU-ZDUSSCGKSA-N,Small molecule,False,ZOLMITRIPTAN,1997.0,4.0,,False,True,['Zolmitriptan' 'Zomig' 'Zomig-zmt'],['311-C-90' '311C90' 'Cvt-427' 'NSC-760383' 'Zolmitriptan'],"[('DailyMed', array(['zolmitriptan'], dtype=object)), ('PubChem', array(['144205008', '170464875'], dtype=object)), ('Wikipedia', array(['Zolmitriptan'], dtype=object)), ('drugbank', array(['DB00315'], dtype=object)), ('chEBI', array(['10124'], dtype=object))]",,"{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}","[ENSG00000135312,ENSG00000179546]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for migraine disorder.
CHEMBL1200384,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,CIWBQSYVNNPZIQ-XYWKZLDCSA-N,Small molecule,False,BETAMETHASONE DIPROPIONATE,1975.0,4.0,,False,True,"['Alphatrex' 'Betamethasone dipropionate' 'Diprolene' 'Diprolene af'
 'Diprosone' 'Sernivo']","['Betamethasone (as dipropionate)' 'Betamethasone 17,21-dipropionate'
 'Betamethasone dipropionate' 'Diprospan' 'Maxivate' 'NSC-758415'
 'Rinderon dp' 'SCH 11460' 'SCH-11460']","[('DailyMed', array(['betamethasone%20dipropionate'], dtype=object)), ('PubChem', array(['144206894', '29215385'], dtype=object)), ('Wikipedia', array(['Betamethasone_dipropionate'], dtype=object)), ('chEBI', array(['31276'], dtype=object))]",,"{'rows': array(['EFO_0000274', 'EFO_0000676', 'EFO_1001097', 'EFO_0000544',
       'EFO_0000701', 'EFO_0008517', 'EFO_0007486', 'EFO_1001494'],
      dtype=object), 'count': 8}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 4 investigational indications.
CHEMBL1201273,CC(Cc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(O)c1,LUMAEVHDZXIGEP-UHFFFAOYSA-N,Small molecule,False,PROTOKYLOL,1982.0,4.0,,False,True,[],['Asmeti' 'Caytine' 'Palisan' 'Protokylol' 'Ventaire'],"[('Wikipedia', array(['Protokylol'], dtype=object)), ('drugbank', array(['DB06814'], dtype=object))]",['CHEMBL1200893'],,[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201274,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,NWIUTZDMDHAVTP-KRWDZBQOSA-N,Small molecule,False,LEVOBETAXOLOL,2000.0,4.0,,False,True,[],"['Betaxolol, (s)-' 'Levobetaxolol']","[('Wikipedia', array(['Levobetaxolol'], dtype=object)), ('drugbank', array(['DB09351'], dtype=object)), ('chEBI', array(['59254'], dtype=object))]",['CHEMBL1200837'],"{'rows': array(['MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 2}",[ENSG00000043591],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 2 investigational indications.
CHEMBL1201569,,,Protein,True,RIMABOTULINUMTOXINB,2000.0,4.0,,False,True,['Myobloc' 'Neurobloc'],"['AN-0772' 'AN0772' 'BTX-8\t' 'BTX-B' 'Botulin b' 'Botulinum b toxin'
 'Botulinum neurotoxin type b' 'Botulinum toxin type b'
 'Rimabotulinumtoxinb']","[('DailyMed', array(['botulinum%20toxin%20type%20b'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/neurobloc'],
      dtype=object))]",,"{'rows': array(['EFO_0004143', 'HP_0000975', 'HP_0000473', 'HP_0000726',
       'EFO_1000632', 'EFO_0000275', 'HP_0001257', 'HP_0200042',
       'HP_0002307'], dtype=object), 'count': 9}",[ENSG00000220205],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for torticollis and has 8 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201731,Cl.OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,JWEXHQAEWHKGCW-UHFFFAOYSA-N,Small molecule,False,NEBIVOLOL HYDROCHLORIDE,2007.0,4.0,CHEMBL434394,False,True,['Bystolic' 'Nebivolol hydrochloride'],['Nebivolol hcl' 'Nebivolol hydrochloride' 'R-067555' 'R067555' 'RO67555'],"[('DailyMed', array(['nebivolol%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0000537', 'EFO_0000712'], dtype=object), 'count': 2}","[ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hypertension and stroke.
CHEMBL1732,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,LUZRJRNZXALNLM-JGRZULCMSA-N,Small molecule,True,DIHYDROERGOTAMINE,1946.0,4.0,,False,True,[],"['9,10-dihydroergotamine' 'Dihydroergotamine' 'MAP-0004' 'MAP0004'
 'Neomigran']","[('PubChem', array(['104171355', '124883195', '144204372', '170465012', '26751735',
       '50104427', '90341683'], dtype=object)), ('Wikipedia', array(['Dihydroergotamine'], dtype=object)), ('drugbank', array(['DB00320'], dtype=object)), ('chEBI', array(['4562'], dtype=object))]",['CHEMBL1200517'],"{'rows': array(['MONDO_0100431', 'MONDO_0005277', 'MONDO_0005277', 'MONDO_0005475'],
      dtype=object), 'count': 4}",[ENSG00000179546],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and is indicated for migraine disorder and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1743005,,,Antibody,False,DACETUZUMAB,,2.0,,False,False,[],['Dacetuzumab' 'HU-S2C6' 'HUS2C6' 'SGN-40'],,,"{'rows': array(['EFO_0000095', 'EFO_0005952', 'EFO_0001378', 'EFO_0000403'],
      dtype=object), 'count': 4}",[ENSG00000101017],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL1771,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,GKTWGGQPFAXNFI-HNNXBMFYSA-N,Small molecule,True,CLOPIDOGREL,1997.0,4.0,,False,True,['Grepid' 'Iscover' 'Plavix'],"['Clopidogrel' 'Clopidogrel 1a-pharma' 'Clopidogrel acino'
 'Clopidogrel apotex' 'Clopidogrel benzenesulfonate'
 'Clopidogrel besilate' 'Clopidogrel besylate' 'Clopidogrel hexal'
 'Clopidogrel sandoz' 'Clopidogrel-ratiopharm' 'NSC-758613' 'R 130964'
 'R-130964' 'SR 25990' 'SR-25990' 'Zyllt']","[('PubChem', array(['49666065', '49666423'], dtype=object)), ('Wikipedia', array(['Clopidogrel'], dtype=object)), ('drugbank', array(['DB00758'], dtype=object)), ('chEBI', array(['37941'], dtype=object))]",['CHEMBL1083385'],"{'rows': array(['EFO_0000712', 'MONDO_0000831', 'EFO_0003777', 'EFO_0003764',
       'HP_0002140', 'EFO_0000612', 'EFO_1000985', 'EFO_0000764',
       'EFO_0008583', 'EFO_0003106', 'EFO_0005672', 'EFO_0003144',
       'EFO_1000860', 'EFO_0001645', 'EFO_0007328', 'EFO_0006859',
       'EFO_0000275', 'EFO_0002615', 'EFO_0004265', 'EFO_0004264',
       'EFO_0002950', 'EFO_0000180', 'EFO_0000717', 'EFO_0000612',
       'EFO_0003914', 'EFO_0004277', 'EFO_0003869', 'MONDO_0004979',
       'EFO_0009315', 'HP_0030680', 'EFO_0004265', 'MONDO_0002009',
       'EFO_0003875', 'EFO_0008585', 'EFO_0001645', 'EFO_0000556',
       'EFO_0000712', 'EFO_0003870', 'EFO_0000266', 'EFO_0003913',
       'EFO_0002429', 'EFO_0004286', 'EFO_0000319', 'EFO_0009686',
       'MONDO_0007915', 'EFO_0005672', 'EFO_0009086', 'MONDO_0100096',
       'EFO_1001375', 'MP_0001914', 'EFO_0007541', 'HP_0002239',
       'EFO_0003876', 'EFO_0003884', 'EFO_0001361', 'EFO_0000556',
       'HP_0002140', 'HP_0004419', 'MONDO_0005148'], dtype=object), 'count': 59}",[ENSG00000169313],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 8 approved and 50 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1950553,Nc1nc(OCCc2ccc(Cl)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,WUCQGGOGHZRELS-LSCFUAHRSA-N,Small molecule,False,SONEDENOSON,,2.0,,False,False,[],['MRE-0094' 'MRE0094' 'Mre0094' 'Sonedenoson'],"[('drugbank', array(['DB12443'], dtype=object))]",,"{'rows': array(['EFO_1001459'], dtype=object), 'count': 1}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL206834,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1,ZGBAJMQHJDFTQJ-DEOSSOPVSA-N,Small molecule,False,BAFETINIB,,2.0,,False,False,[],['Bafetinib' 'CNS-9' 'INNO-406' 'NS-187'],"[('drugbank', array(['DB11851'], dtype=object))]",,"{'rows': array(['MONDO_0008315', 'EFO_0000095'], dtype=object), 'count': 2}","[ENSG00000097007,ENSG00000254087]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2107859,,,Unknown,False,ROZROLIMUPAB,,2.0,,False,False,[],['Rozrolimupab' 'SYM-001' 'SYM001'],,,"{'rows': array(['EFO_0007160'], dtype=object), 'count': 1}",[ENSG00000187010],Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2107885,,,Enzyme,False,RETEPLASE,1996.0,4.0,,False,True,['Rapilysin' 'Retavase'],"['BM 06.022' 'BM-06.022' 'BM-06022' 'Ecokinase' 'Retavase' 'Reteplase'
 'Reteplase, recombinant' 'Reteplase,recombinant' 'Retevase']","[('DailyMed', array(['reteplase'], dtype=object)), ('DrugCentral', array(['5044'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rapilysin'],
      dtype=object))]",,"{'rows': array(['EFO_0000712', 'EFO_0008585', 'EFO_0003144', 'EFO_0000612',
       'HP_0004419'], dtype=object), 'count': 5}",[ENSG00000104368],Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 1 investigational indication.
CHEMBL2108290,,,Protein,False,EPOETIN THETA,2009.0,4.0,,False,True,['Biopoin' 'Eporatio'],['Epoetin theta'],"[('DrugCentral', array(['5007'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/biopoin'],
      dtype=object))]",,"{'rows': array(['EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 2}",[ENSG00000187266],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for chronic kidney disease and anemia (phenotype).
CHEMBL2108594,,,Protein,False,EPTOTERMIN ALFA,2001.0,4.0,,False,True,['Osigraft'],"['Bmp-7' 'Bone morphogenetic protein 7' 'Eptotermin alfa' 'Hbmp7'
 'Opgenra' 'Osigraft' 'Osteogenic protein 1' 'Rh-polypeptide-52']","[('DrugCentral', array(['5175'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/osigraft'],
      dtype=object))]",,"{'rows': array(['EFO_0004260', 'EFO_0004616', 'EFO_0003944'], dtype=object), 'count': 3}","[ENSG00000138696,ENSG00000204217,ENSG00000115170,ENSG00000107779]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for bone disease and tibia fracture and has 1 investigational indication.
CHEMBL2108708,,,Antibody drug conjugate,False,YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN,,3.0,,False,False,['Hpam4-cide'],"['90HY-PAM4' '90Y-HPAM4' '90Y-HPAMA4' 'HPAM-4-DOTA' 'HPAM-DOTA HY-PAM4'
 'HPAM4-DOTA' 'IMMU-107' 'S9S0HY-PAM4'
 'Yttrium (90y) clivatuzumab tetraxetan'
 'Yttrium y 90 clivatuzumab tetraxetan']",,,"{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}",[ENSG00000215182],Antibody drug conjugate drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL214796,FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1,VTANGSDRFFLTSQ-UHFFFAOYSA-N,Small molecule,False,NGD-8243,,2.0,,False,False,[],['MK-2295' 'MK-2295-005' 'Ngd-8243'],,,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}",[ENSG00000196689],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2325741,NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1,JDUBGYFRJFOXQC-KRWDZBQOSA-N,Small molecule,False,CAPIVASERTIB,2023.0,4.0,,False,True,['Truqap'],['AZC5363' 'AZD-5363' 'AZD5363' 'Azd 5363' 'Azd-5363' 'Capivasertib'],"[('drugbank', array(['DB12218'], dtype=object))]",,"{'rows': array(['MONDO_0011962', 'EFO_0005537', 'EFO_0003060', 'EFO_0000707',
       'EFO_0000096', 'MONDO_0008170', 'MONDO_0008315', 'EFO_0000673',
       'MONDO_0001056', 'MONDO_0002974', 'MONDO_0007254', 'EFO_1000251',
       'EFO_0000616', 'EFO_0001378', 'MONDO_0004992', 'EFO_0000503',
       'EFO_0000228', 'EFO_0003869', 'EFO_0001642', 'EFO_0007532',
       'MONDO_0016642', 'Orphanet_145'], dtype=object), 'count': 22}","[ENSG00000105221,ENSG00000117020,ENSG00000142208]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 22 investigational indications.
CHEMBL317094,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O,KLZWOWYOHUKJIG-BPUTZDHNSA-N,Small molecule,False,IMIDAPRIL,1993.0,4.0,,False,True,['Tanatril'],"['Hipertene' 'Imidapril' 'Imidapril hcl' 'Imidapril hydrochloride'
 'Imidapril monohydrochloride' 'TA 6366' 'TA-6366']","[('Wikipedia', array(['Imidapril'], dtype=object)), ('drugbank', array(['DB11783'], dtype=object))]",['CHEMBL3183293'],"{'rows': array(['EFO_1001496', 'EFO_0000319', 'MONDO_0001134'], dtype=object), 'count': 3}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for cardiovascular disease and has 2 investigational indications.
CHEMBL361812,O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2,LDXDSHIEDAPSSA-OAHLLOKOSA-N,Small molecule,False,RAMATROBAN,2000.0,4.0,,False,True,[],['BAY U 3405' 'BAY-U-3405' 'Baynas' 'EN 137774' 'EN-137774' 'Ramatroban'],"[('PubChem', array(['144206069', '170465980'], dtype=object)), ('Wikipedia', array(['Ramatroban'], dtype=object)), ('drugbank', array(['DB13036'], dtype=object))]",,"{'rows': array(['MONDO_0004979', 'MONDO_0100096'], dtype=object), 'count': 2}","[ENSG00000006638,ENSG00000183134]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 2 investigational indications.
CHEMBL3707243,C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.Cc1ccc(S(=O)(=O)[O-])cc1.O,UOWOLENSDISMPG-UHFFFAOYSA-M,Small molecule,False,GLYCOPYRRONIUM TOSYLATE,2018.0,4.0,CHEMBL1201335,False,True,['Qbrexza'],"['DRM-04' 'DRM04' 'Glycopyrronium tosilate hydrate'
 'Glycopyrronium tosylate']",,,"{'rows': array(['EFO_1000632', 'HP_0000975', 'EFO_0004269', 'EFO_0000341',
       'MONDO_0004247'], dtype=object), 'count': 5}","[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved indications.
CHEMBL3707399,,,Small molecule,False,CX1739,,2.0,,False,False,[],['CX-1739' 'Cx1739'],,,,"[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3833368,CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)O)C(=O)C2.CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,INBJJAFXHQQSRW-STOWLHSFSA-N,Small molecule,False,RUCAPARIB CAMSYLATE,2016.0,4.0,CHEMBL1173055,False,True,['Rubraca'],['C0-338' 'CO-338' 'PF-1367338-BW' 'Rucaparib camsylate'],"[('DailyMed', array(['rucaparib%20camsylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003893', 'EFO_0000673', 'MONDO_0008170',
       'EFO_0001075'], dtype=object), 'count': 5}","[ENSG00000143799,ENSG00000041880,ENSG00000129484]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 2 investigational indications.
CHEMBL4297598,C[C@@H](C(=O)Nc1ccc(Cl)cc1)C1CCC(c2ccnc3ccc(F)cc23)CC1,KRTIYQIPSAGSBP-KLAILNCOSA-N,Small molecule,False,LINRODOSTAT,,3.0,,False,False,[],"['BMS 986205' 'BMS-986205' 'Bms-986205' 'F 001287' 'F-001287' 'F001287'
 'Linrodostat' 'ONO 7701' 'ONO-7701' 'ONO7701']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINRODOSTAT/relevant/1/'],
      dtype=object))]",['CHEMBL4298147'],"{'rows': array(['MONDO_0002334', 'EFO_0003060', 'MONDO_0001056', 'EFO_0000756',
       'MONDO_0002334', 'MONDO_0002898', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0000616', 'EFO_0006859', 'EFO_0000519', 'EFO_0000294',
       'EFO_0000199', 'EFO_0000182'], dtype=object), 'count': 14}",[ENSG00000131203],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications.
CHEMBL4298124,,,Antibody,False,DOSTARLIMAB,2021.0,4.0,,False,True,['Jemperli'],"['Dostarlimab' 'Dostarlimab gxly' 'GSK-4057190' 'GSK4057190' 'TSR-042'
 'Tsr 042' 'Tsr-042' 'WBP-285']","[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli'],
      dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0018944', 'EFO_1000465', 'EFO_0000181',
       'EFO_0006859', 'EFO_0002618', 'MONDO_0011962', 'EFO_1001951',
       'MONDO_0002165', 'EFO_0005537', 'MONDO_0004992', 'EFO_0001378',
       'MONDO_0002691', 'Orphanet_145', 'EFO_0000756', 'MONDO_0007254',
       'EFO_1000657', 'MONDO_0002974', 'EFO_0003893', 'MONDO_0005184',
       'EFO_0000691', 'EFO_0000702', 'EFO_0004288', 'MONDO_0008170',
       'MONDO_0021251', 'EFO_0003968', 'EFO_0001061', 'EFO_0003060',
       'MONDO_0021063', 'EFO_0000588'], dtype=object), 'count': 30}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 26 investigational indications.
CHEMBL517140,CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1,WROHEWWOCPRMIA-UHFFFAOYSA-N,Small molecule,False,GSK189254,,2.0,,False,False,[],['GSK189254' 'Gsk189254'],"[('Wikipedia', array(['GSK-189,254'], dtype=object))]",['CHEMBL2031739'],"{'rows': array(['MONDO_0021107'], dtype=object), 'count': 1}",[ENSG00000101180],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL656,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,BRUQQQPBMZOVGD-XFKAJCMBSA-N,Small molecule,True,OXYCODONE,1950.0,4.0,,True,True,['Proladone' 'Xtampza er'],"['(-)-14-hydroxydihydrocodeinone' '14-hydroxydihydrocodeinone' 'Dihydrone'
 'IDS-NO-002' 'N02AA05' 'NSC-19043' 'Oxicone' 'Oxycodone' 'Oxycodone cii'
 'Oxymorphone 3-methyl ether' 'PF-00345439' 'PTI-821' 'Pavinal' 'Pti 821'
 'Remoxy' 'Xtampza']","[('DailyMed', array(['oxycodone'], dtype=object)), ('Wikipedia', array(['Oxycodone'], dtype=object)), ('drugbank', array(['DB00497'], dtype=object)), ('chEBI', array(['7852'], dtype=object))]",['CHEMBL1200890' 'CHEMBL3989826'],"{'rows': array(['HP_0030833', 'EFO_0801084', 'EFO_0003890', 'EFO_0004253',
       'EFO_0004616', 'EFO_0003843', 'EFO_0004270', 'EFO_0010072',
       'MONDO_0002491', 'EFO_1000786', 'HP_0012532', 'HP_0003419',
       'EFO_0000668', 'HP_0012532', 'EFO_0010702', 'MONDO_0004992',
       'HP_0003418', 'MONDO_0005180', 'MONDO_0001583', 'EFO_0005611',
       'HP_0000989', 'HP_0003419', 'EFO_1001951', 'EFO_0005762',
       'EFO_0007486', 'EFO_1000999', 'EFO_1001919', 'EFO_0006859',
       'EFO_0003890', 'EFO_0001069', 'EFO_1000786', 'EFO_1001331',
       'HP_0008419', 'EFO_0004616', 'MONDO_0005178', 'EFO_0004209',
       'EFO_0003843', 'EFO_0009842', 'MONDO_0002367', 'EFO_0003843'],
      dtype=object), 'count': 40}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 4 approved and 29 investigational indications. This drug has a black box warning from the FDA.
CHEMBL704,Nc1ccc(O)c(C(=O)O)c1,KBOPZPXVLCULAV-UHFFFAOYSA-N,Small molecule,False,MESALAMINE,1987.0,4.0,,False,True,"['Apriso' 'Asacol' 'Asacol hd' 'Canasa' 'Coltec ec' 'Delzicol' 'Ipocol'
 'Lialda' 'Mesalamine' 'Mesren mr' 'Mezavant xl' 'Octasa' 'Pentasa'
 'Pentasa sr' 'Rowasa' 'Salofalk' 'Sfrowasa']","['Benzoic acid, 5-amino-2-hydroxy-' 'Fisalamine' 'Iialda' 'MAX-002'
 'Mesalamine' 'Mesalazine' 'Mesalazine ' 'NSC-38877']","[('DailyMed', array(['mesalamine'], dtype=object)), ('PubChem', array(['104171289', '11112235', '144203935', '144208808', '144213442',
       '170464840', '17389224', '26752847', '49681712'], dtype=object)), ('Wikipedia', array(['Mesalazine'], dtype=object)), ('drugbank', array(['DB00244'], dtype=object)), ('chEBI', array(['6775'], dtype=object))]",,"{'rows': array(['EFO_0005628', 'EFO_0007168', 'EFO_1001293', 'EFO_0003767',
       'MONDO_0005835', 'EFO_0008572', 'EFO_0009959', 'HP_0002253',
       'EFO_1001951', 'EFO_0000729', 'EFO_0000555', 'EFO_0004232',
       'EFO_0003872', 'EFO_0000384', 'EFO_0005406', 'EFO_1001294',
       'EFO_0000764', 'MONDO_0004235'], dtype=object), 'count': 18}","[ENSG00000132170,ENSG00000012779,ENSG00000073756,ENSG00000095303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for proctitis and ulcerative colitis and has 16 investigational indications.
CHEMBL1092,Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1,QDWJJTJNXAKQKD-UHFFFAOYSA-N,Small molecule,False,TRIHEXYPHENIDYL HYDROCHLORIDE,1949.0,4.0,CHEMBL1490,False,True,"['Agitane' 'Artane' 'Bentex' 'Broflex' 'Tremin'
 'Trihexyphenidyl hydrochloride']","['Aparkane' 'Benzhexol' 'Benzhexol hydrochloride' 'Cyclodol' 'Cyclodolum'
 'NSC-757357' 'Parcopane' 'Romparkin' 'Sedrina' 'Trihexyphenidyl HCl'
 'Trihexyphenidyl hcl' 'Trihexyphenidyl hydrochloride'
 'Trihexyphenidyli hydrochloridum' 'Triphedinon']","[('DailyMed', array(['trihexyphenidyl%20hydrochloride'], dtype=object)), ('PubChem', array(['144204826', '170464756', '26747667', '26747668', '50107036',
       '50107037', '50107038', '56422445', '855814'], dtype=object))]",,,[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1949.
CHEMBL1201020,CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C.O=P(O)(O)O,CGDDQFMPGMYYQP-UHFFFAOYSA-N,Small molecule,True,DISOPYRAMIDE PHOSPHATE,1977.0,4.0,CHEMBL517,False,True,"['Dirythmin' 'Dirythmin-sa' 'Disopyramide phosphate' 'Isomide cr'
 'Norpace' 'Norpace cr' 'Rythmodan ret']","['Dirythmin sa' 'Diso-duriles' 'Disopyramide phosphate' 'NSC-756744'
 'Rythmodan' 'SC-13957' 'SC-7031 PHOSPHATE']","[('DailyMed', array(['disopyramide%20phosphate'], dtype=object)), ('PubChem', array(['50106185', '855629'], dtype=object)), ('chEBI', array(['4658'], dtype=object))]",,"{'rows': array(['HP_0004308', 'EFO_0004269', 'EFO_0003144', 'EFO_0000275'],
      dtype=object), 'count': 4}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl,PGYPOBZJRVSMDS-UHFFFAOYSA-N,Small molecule,True,LOPERAMIDE HYDROCHLORIDE,1976.0,4.0,CHEMBL841,False,True,"['Arret' 'Diah-limit' 'Diaquitte' 'Diareze' 'Diarrhoea relief' 'Diasorb'
 'Diocalm' 'Diocaps' 'Dioraleze' 'Entrocalm' 'Gppe pack' 'Imodium'
 'Imodium Advanced' 'Imodium a-d' 'Imodium a-d ez chews' 'Imodium classic'
 'Imodium ibs relief' 'Imodium instant melts' 'Imodium instants'
 'Imodium liquicaps' 'Lodiar' 'Loperagen' 'Loperamide hydrochloride'
 'Norimode' 'Normaloe']","['Loperamide hcl' 'Loperamide hydrochloride' 'Loperamidi hydrochloridum'
 'NSC-696356' 'R 18,553' 'R-18553']","[('DailyMed', array(['loperamide%20hydrochloride'], dtype=object)), ('PubChem', array(['11533030', '26747556', '26747557', '50106525', '50125622',
       '56422888'], dtype=object)), ('chEBI', array(['6533'], dtype=object))]",,"{'rows': array(['HP_0002014'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for diarrhea. This drug has a black box warning from the FDA.
CHEMBL1738758,CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1,QHLVBNKYJGBCQJ-UHFFFAOYSA-N,Small molecule,False,ONVANSERTIB,,2.0,,False,False,[],['NMS-1286937' 'NMS-P937' 'Nms-1286937' 'Onvansertib' 'PCM-075'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ONVANSERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15110'], dtype=object))]",['CHEMBL4298158' 'CHEMBL1774489'],"{'rows': array(['EFO_0000616', 'EFO_1000984', 'EFO_0000702', 'EFO_0000222',
       'EFO_1001779', 'MONDO_0008315', 'EFO_0000616', 'MONDO_0005184'],
      dtype=object), 'count': 8}",[ENSG00000166851],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL2028987,CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(=O)O,AUTFSFUMNFDPLH-KYMMNHPFSA-N,Protein,False,DEGARELIX ACETATE,2008.0,4.0,CHEMBL415606,False,True,['Firmagon'],"['Degarelix (as acetate)' 'Degarelix acetate' 'Degarelix acetate hydrate'
 'FE-200486' 'FE200486' 'FE200486 (FREE BASE)']","[('DailyMed', array(['degarelix%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon'],
      dtype=object))]",,"{'rows': array(['EFO_0001663', 'MONDO_0008315', 'MONDO_0008315', 'EFO_0000673'],
      dtype=object), 'count': 4}",[ENSG00000109163],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 1 investigational indication.
CHEMBL2103883,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,OFZJKCQENFPZBH-UHFFFAOYSA-N,Small molecule,False,AVATROMBOPAG,2018.0,4.0,,False,True,[],['Akr-501' 'Avatrombopag' 'E-5501' 'E5501' 'YM-301477' 'YM-477'],"[('drugbank', array(['DB11995'], dtype=object))]",['CHEMBL2105758'],"{'rows': array(['HP_0001873', 'EFO_0006927', 'EFO_0007160', 'HP_0001915',
       'EFO_0001421', 'MP_0001914', 'HP_0001873', 'MONDO_0002245',
       'EFO_0001421'], dtype=object), 'count': 9}",[ENSG00000117400],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications.
CHEMBL2106710,Cl.Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2,OYKZVKWXOWICFI-UHFFFAOYSA-N,Small molecule,False,FADOLMIDINE HYDROCHLORIDE,,2.0,CHEMBL2104262,False,False,[],"['Fadolmidine hcl' 'Fadolmidine hydrochloride' 'MPV-2426'
 'Radolmidine hydrochloride']",,,,"[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108253,,,Antibody,False,ARCITUMOMAB,1996.0,4.0,,False,True,['Cea-scan'],['Arcitumomab' 'IMMU 4' 'IMMU-4'],"[('DrugCentral', array(['5127'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cea-scan'],
      dtype=object))]",,"{'rows': array(['EFO_0004142', 'EFO_0006887'], dtype=object), 'count': 2}",[ENSG00000105388],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for colorectal neoplasm and radiologic finding.
CHEMBL2109516,,,Antibody,False,SS1(DSFV)-PE38,,1.0,,False,False,[],['SS1(DSFV)-PE38' 'Ss1(dsfv)-pe38'],,,"{'rows': array(['EFO_0000616', 'EFO_0002618', 'MONDO_0002087', 'MONDO_0008903',
       'MONDO_0008170', 'MONDO_0002974', 'EFO_0006859', 'EFO_0000588',
       'MONDO_0002158'], dtype=object), 'count': 9}",[ENSG00000102854],Antibody drug with a maximum clinical trial phase of I (across all indications) and has 9 investigational indications.
CHEMBL2110774,CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1,KKHPNPMTPORSQE-UHFFFAOYSA-N,Small molecule,False,CHLORPHENOXAMINE,,4.0,,False,True,[],['Chlorphenoxamine'],"[('drugbank', array(['DB09007'], dtype=object))]",['CHEMBL2105980'],"{'rows': array(['HP_0000989', 'MONDO_0005271'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pruritus and allergic disease.
CHEMBL255863,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,HHZIURLSWUIHRB-UHFFFAOYSA-N,Small molecule,True,NILOTINIB,2007.0,4.0,,False,True,[],['AMN 107' 'AMN-107' 'AMN107' 'NSC-747599' 'Nilotinib'],"[('PubChem', array(['124894351', '124894352', '99460838'], dtype=object)), ('Wikipedia', array(['Nilotinib'], dtype=object)), ('drugbank', array(['DB04868'], dtype=object)), ('chEBI', array(['52172'], dtype=object))]",['CHEMBL1201740'],"{'rows': array(['MONDO_0005180', 'EFO_0002617', 'MONDO_0005180', 'EFO_0000565',
       'EFO_0001075', 'EFO_0000220', 'MONDO_0004992', 'EFO_0005543',
       'MONDO_0000437', 'EFO_0000756', 'MONDO_0004643', 'EFO_1000251',
       'MONDO_0007739', 'EFO_1001968', 'MONDO_0021063', 'MONDO_0004975',
       'MONDO_0013730', 'EFO_0000339', 'EFO_0001361', 'EFO_0000222',
       'MONDO_0007254', 'HP_0009588', 'EFO_0000717', 'EFO_0000616',
       'EFO_0000389', 'MONDO_0008978', 'EFO_1001106', 'EFO_1001512',
       'EFO_0000616', 'MONDO_0020547', 'EFO_0000339', 'MONDO_0002171',
       'MONDO_0011719'], dtype=object), 'count': 33}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic myelogenous leukemia and has 30 investigational indications. This drug has a black box warning from the FDA.
CHEMBL3301668,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,NSTRIRCPWQHTIA-DTRKZRJBSA-N,Protein,False,CARBETOCIN,,4.0,,False,True,['Duratocin' 'Duratocin long acting' 'Pabal'],['Carbetocin' 'FE 992097' 'FE-992097' 'LV-101'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CARBETOCIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB01282'], dtype=object)), ('chEBI', array(['59204'], dtype=object))]",,"{'rows': array(['EFO_0009579', 'MONDO_0008300', 'EFO_1001863'], dtype=object), 'count': 3}",[ENSG00000180914],Protein drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications.
CHEMBL343448,C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,OHRURASPPZQGQM-GCCNXGTGSA-N,Protein,False,ROMIDEPSIN,2009.0,4.0,,False,True,['Istodax'],"['Depsipeptide' 'FK-228' 'FK228' 'FR-901228' 'FR901228' 'NSC-630176'
 'Romidepsin']","[('DailyMed', array(['romidepsin'], dtype=object)), ('PubChem', array(['144206460'], dtype=object)), ('drugbank', array(['DB06176'], dtype=object)), ('chEBI', array(['61080'], dtype=object))]",,"{'rows': array(['EFO_0006861', 'EFO_0000183', 'EFO_1001951', 'EFO_0000224',
       'EFO_0000403', 'EFO_0002499', 'EFO_1001051', 'EFO_0000565',
       'EFO_1000785', 'MONDO_0004192', 'EFO_0003032', 'MONDO_0008170',
       'EFO_0000569', 'EFO_0000764', 'EFO_1001465', 'EFO_0000255',
       'EFO_0003060', 'EFO_1000984', 'EFO_1001469', 'EFO_0000641',
       'EFO_0005537', 'EFO_0000095', 'EFO_0000180', 'EFO_0002913',
       'EFO_0000574', 'EFO_0000211', 'EFO_0001378', 'EFO_0000616',
       'EFO_0002618', 'EFO_0000702', 'MONDO_0001187', 'MONDO_0018906',
       'EFO_0000503', 'MONDO_0004992', 'MONDO_0015760', 'EFO_0000756',
       'EFO_0000501', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0000430',
       'EFO_0002501', 'MONDO_0005184'], dtype=object), 'count': 42}","[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 36 investigational indications.
CHEMBL3707297,,,Antibody,False,CG250 177LU,,3.0,,False,False,[],['CG250' 'Cg250 (177lu)' 'Cg250 177lu'],,,"{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}",[ENSG00000107159],Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3707354,,,Small molecule,False,ABT-560,,-1.0,,False,False,[],['Abt-560'],,,,"[ENSG00000160716,ENSG00000101204]",Small molecule drug.
CHEMBL3989978,,,Oligonucleotide,False,PREXIGEBERSEN,,2.0,,False,False,[],['BP-100-1.01/L-Grb2' 'BP-1001' 'L-grb-2 antisense' 'Prexigebersen'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}",[ENSG00000177885],Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4297235,,,Unknown,False,OMBIPEPIMUT-S,,3.0,,False,False,[],['DSP-7888' 'Ombipepimut-s'],,,"{'rows': array(['EFO_0000222', 'EFO_0000198', 'EFO_0000519', 'EFO_1000026'],
      dtype=object), 'count': 4}",[ENSG00000184937],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297290,C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(C3CCOCC3)ncc2c(=O)[nH]1,GWGNPYYVGANHRJ-GDBMZVCRSA-N,Small molecule,False,TOVINONTRINE,,2.0,,False,False,[],"['68722' 'AF-68722' 'AF68722' 'CK-1598' 'CK1598' 'IMR-687' 'Imr-687'
 'Tovinontrine']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOVINONTRINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0011382', 'Orphanet_848', 'EFO_0003144'], dtype=object), 'count': 3}",[ENSG00000160191],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4303525,CC1(C)CC[C@]2(NC(=O)C(C)(F)F)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1,RJCWBNBKOKFWNY-IDPLTSGASA-N,Small molecule,False,OMAVELOXOLONE,2023.0,4.0,,False,True,['Skyclarys'],['Omaveloxolone' 'RTA 408' 'RTA-408' 'Skyclarys'],,,"{'rows': array(['EFO_0001421', 'MONDO_0007254', 'MONDO_0100339', 'EFO_0000756'],
      dtype=object), 'count': 4}",[ENSG00000116044],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for friedreich ataxia and has 3 investigational indications.
CHEMBL4650290,,,Antibody,False,GC1118,,2.0,,False,False,[],['GC1118' 'Gc1118'],,,"{'rows': array(['EFO_0000503', 'EFO_0000519'], dtype=object), 'count': 2}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL6318,CC/C(=C(\c1ccc(I)cc1)c1ccc(OCCN2CCCC2)cc1)c1ccccc1,JJKOTMDDZAJTGQ-DQSJHHFOSA-N,Small molecule,False,IDOXIFENE,,2.0,,False,False,[],['CB 7432' 'CB-7432' 'Idoxifene' 'SB-223030'],"[('Wikipedia', array(['Idoxifene'], dtype=object))]",,,"[ENSG00000140009,ENSG00000091831]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1168,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,HDACQVRGBOVJII-JBDAPHQKSA-N,Small molecule,True,RAMIPRIL,1991.0,4.0,,False,True,['Altace' 'Lopace' 'Ramipril' 'Ranace' 'Tritace'],"['C09AA05' 'Cardace' 'Corpril' 'Delix' 'Ecator' 'HOE 498' 'HOE-498'
 'Hopace' 'NSC-758933' 'Pramace' 'Ramace' 'Ramipres' 'Ramipril' 'Triatec'
 'Unipril' 'Vesdil']","[('DailyMed', array(['ramipril'], dtype=object)), ('PubChem', array(['144204259', '170464731', '49664947'], dtype=object)), ('Wikipedia', array(['Ramipril'], dtype=object)), ('drugbank', array(['DB00178'], dtype=object)), ('chEBI', array(['8774'], dtype=object))]",,"{'rows': array(['EFO_0003884', 'EFO_0000401', 'EFO_0000400', 'EFO_0004285',
       'EFO_0001645', 'EFO_0003914', 'EFO_0000319', 'EFO_0000195',
       'MONDO_0002462', 'EFO_0003911', 'EFO_0008583', 'EFO_0003777',
       'EFO_0003086', 'EFO_0000685', 'MONDO_0100096', 'EFO_0000712',
       'EFO_0000589', 'EFO_0000537', 'EFO_0000275', 'MONDO_0007915',
       'EFO_1001375', 'EFO_0000612', 'HP_0003124', 'EFO_0000373',
       'EFO_0002546', 'EFO_0003144', 'MONDO_0005147', 'MONDO_0005148'],
      dtype=object), 'count': 28}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 9 approved and 19 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1182833,COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2,ILVYCEVXHALBSC-OTBYEXOQSA-N,Small molecule,False,MIVACURIUM,1992.0,4.0,,False,True,[],['BW B109OU' 'BW-B109OU' 'Mivacurium' 'Mivacurium cation' 'Mivacurium ion'],"[('PubChem', array(['144206462', '50112723'], dtype=object)), ('drugbank', array(['DB01226'], dtype=object)), ('chEBI', array(['6958'], dtype=object))]",['CHEMBL984'],"{'rows': array(['HP_0001410'], dtype=object), 'count': 1}","[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and has 1 investigational indication.
CHEMBL1200376,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccccc1)C(=O)CO,SOQJPQZCPBDOMF-YCUXZELOSA-N,Small molecule,False,BETAMETHASONE BENZOATE,1982.0,4.0,,False,True,['Uticort'],['Betamethasone 17-benzoate' 'Betamethasone benzoate' 'W 5975' 'W-5975'],,,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200569,Cn1c(=O)c2c(ncn2C)n(C)c1=O.O=C(O)CC(O)(CC(=O)O)C(=O)O,RCQXSQPPHJPGOF-UHFFFAOYSA-N,Small molecule,False,CAFFEINE CITRATE,1999.0,4.0,CHEMBL113,False,True,"['Cafcit' 'Caffeine citrate' 'Gencebok' 'Peyona'
 'Peyona (previously nymusa)']","['Caffeine citrate' 'Caffeine mixture with citric acid'
 'Caffeine, citrated' 'Citrated caffeine']","[('DailyMed', array(['caffeine%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gencebok',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/peyona-previously-nymusa'],
      dtype=object)), ('PubChem', array(['144203650', '170464929'], dtype=object))]",,"{'rows': array(['HP_0001298', 'EFO_0003917', 'EFO_0003843', 'MONDO_0004567',
       'EFO_0001421', 'EFO_1001158', 'MONDO_0005299', 'HP_0002104'],
      dtype=object), 'count': 8}","[ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for apnea and has 7 investigational indications.
CHEMBL1275,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21.CS(=O)(=O)O,UWCVGPLTGZWHGS-ZORIOUSZSA-N,Small molecule,False,PERGOLIDE MESYLATE,1988.0,4.0,CHEMBL531,True,True,['Celance' 'Pergolide mesylate' 'Permax'],"['LY 127809' 'LY-127809' 'NSC-319773' 'NSC-758442' 'Pergolide mesilate'
 'Pergolide mesylate' 'Pergolide methanesulfonate']","[('PubChem', array(['11533039', '144204371', '170465250', '50106872', '56422469'],
      dtype=object)), ('chEBI', array(['8021'], dtype=object))]",,,"[ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988. It was withdrawn in at least one region.
CHEMBL128,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,KQKPFRSPSRPDEB-UHFFFAOYSA-N,Small molecule,False,SUMATRIPTAN,1992.0,4.0,,False,True,['Imitrex' 'Sumatriptan' 'Tosymra'],['Dfn-11' 'Dfn-11 (sumatriptan injection)' 'N02CC01' 'Sumatriptan'],"[('DailyMed', array(['sumatriptan'], dtype=object)), ('PubChem', array(['144205081', '170465377', '49679316'], dtype=object)), ('Wikipedia', array(['Sumatriptan'], dtype=object)), ('drugbank', array(['DB00669'], dtype=object)), ('chEBI', array(['10650'], dtype=object))]",['CHEMBL1201150'],"{'rows': array(['EFO_0001073', 'EFO_0003843', 'MONDO_0005475', 'MONDO_0005475',
       'MONDO_0005277', 'MONDO_0100431', 'MONDO_0005277'], dtype=object), 'count': 7}","[ENSG00000179546,ENSG00000135312]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for migraine disorder and has 4 investigational indications.
CHEMBL1743081,,,Antibody,False,TRALOKINUMAB,2021.0,4.0,,False,True,['Adbry' 'Adtralza'],['CAT-354' 'Tralokinumab'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza'],
      dtype=object))]",,"{'rows': array(['EFO_0000729', 'EFO_0000274', 'EFO_0000768', 'HP_0000964',
       'EFO_0002618', 'MONDO_0004979', 'EFO_0004192'], dtype=object), 'count': 7}",[ENSG00000169194],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for atopic eczema and eczematoid dermatitis and has 5 investigational indications.
CHEMBL1888176,O=C(O[C@H]1C[C@H]2CC[C@@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1,OYYDSUSKLWTMMQ-JKHIJQBDSA-N,Small molecule,False,TROSPIUM,2004.0,4.0,,False,True,[],['Trospium' 'Trospium cation' 'Trospium ion'],"[('PubChem', array(['50112692'], dtype=object)), ('drugbank', array(['DB00209'], dtype=object))]",['CHEMBL3084748'],"{'rows': array(['EFO_0006865', 'EFO_0000341', 'EFO_1000781', 'HP_0000103',
       'MONDO_0005090', 'HP_0000020', 'EFO_1000781'], dtype=object), 'count': 7}","[ENSG00000133019,ENSG00000181072]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 3 investigational indications.
CHEMBL1929396,Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,LDXYBEHACFJIEL-HNNXBMFYSA-N,Small molecule,False,ANAGLIPTIN,2012.0,4.0,,False,True,[],['Anagliptin' 'CWP-403' 'SK-0403' 'Sk-0403' 'Suiny'],"[('drugbank', array(['DB12417'], dtype=object))]",['CHEMBL1929387'],"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2012 and has 1 investigational indication.
CHEMBL2106195,Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,VPNGEIHDPSLNMU-MERQFXBCSA-N,Small molecule,False,DEXMEDETOMIDINE HYDROCHLORIDE,1999.0,4.0,CHEMBL778,False,True,"['Dexmedetomidine accord' 'Dexmedetomidine hydrochloride' 'Igalmi'
 'Precedex']","['Cepedex' 'Dexdomitor' 'Dexdor' 'Dexmedetomidine hcl'
 'Dexmedetomidine hydrochloride' 'Igalmi' 'Sedadex' 'Sileo']","[('DailyMed', array(['dexmedetomidine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dexmedetomidine-accord'],
      dtype=object)), ('chEBI', array(['31472'], dtype=object))]",,"{'rows': array(['HP_0000713', 'MONDO_0005090', 'MONDO_0003544', 'EFO_0005411',
       'EFO_0003843', 'MONDO_0043510', 'EFO_1001454', 'EFO_0009267'],
      dtype=object), 'count': 8}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 8 investigational indications.
CHEMBL2107830,OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,OBWASQILIWPZMG-QZMOQZSNSA-N,Small molecule,False,EMPAGLIFLOZIN,2014.0,4.0,,False,True,['Bi 10773' 'Jardiance'],['BI 10773' 'BI-10773' 'Bi10773' 'Empagliflozin'],"[('DailyMed', array(['empagliflozin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance'],
      dtype=object)), ('drugbank', array(['DB09038'], dtype=object)), ('chEBI', array(['82720'], dtype=object))]",,"{'rows': array(['EFO_1000982', 'EFO_0004593', 'HP_0002902', 'MONDO_0005147',
       'EFO_0000660', 'HP_0031273', 'EFO_0003144', 'EFO_0000474',
       'Orphanet_364', 'EFO_0000195', 'MONDO_0002009', 'EFO_0000694',
       'EFO_0000666', 'HP_0001919', 'EFO_1001121', 'EFO_0000400',
       'HP_0001943', 'EFO_0003086', 'EFO_0008583', 'EFO_0003095',
       'EFO_0000612', 'MONDO_0017147', 'EFO_1001482', 'EFO_0003884',
       'EFO_0000384', 'EFO_0000729', 'HP_0001541', 'EFO_0002614',
       'MONDO_0005148', 'EFO_0000401', 'EFO_0004253', 'EFO_1001496'],
      dtype=object), 'count': 32}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 30 investigational indications.
CHEMBL2107842,,,Protein,False,ALBINTERFERON ALFA-2B,,3.0,,False,False,['Albuferon'],['Albinterferon alfa-2b' 'Interferon-alfa-2b'],,,"{'rows': array(['EFO_0000616', 'EFO_0003047', 'EFO_0004239', 'EFO_0004220'],
      dtype=object), 'count': 4}","[ENSG00000142166,ENSG00000159110]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL2108724,,,Protein,True,SEMAGLUTIDE,2017.0,4.0,,False,True,['Ozempic' 'Rybelsus' 'Wegovy'],['NN-9535' 'NN9535' 'NNC 0113-0217' 'NNC-0113-0217' 'Nn9535' 'Semaglutide'],"[('DailyMed', array(['semaglutide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic'],
      dtype=object))]",,"{'rows': array(['EFO_0003095', 'EFO_0000660', 'MONDO_0004979', 'EFO_0000712',
       'MONDO_0005180', 'EFO_0000401', 'EFO_0001645', 'HP_0000938',
       'EFO_1001006', 'MONDO_0005147', 'MONDO_0002009', 'EFO_0003768',
       'MONDO_0005148', 'MONDO_0007079', 'HP_0002140', 'EFO_0000400',
       'MONDO_0004975', 'EFO_0001073', 'EFO_1001249'], dtype=object), 'count': 19}",[ENSG00000112164],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 17 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109604,,,Antibody,False,CAMOTESKIMAB,,2.0,,False,False,[],['AEVI-007' 'Aevi-007' 'CERC-007' 'Camoteskimab' 'MEDI-2338' 'MEDI2338'],"[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]",,"{'rows': array(['EFO_0007135', 'EFO_0000341', 'EFO_0001378', 'EFO_0000616'],
      dtype=object), 'count': 4}",[ENSG00000150782],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL290352,CCSCc1ccc2c(c1)c1c3c(c4c5cc(CSCC)ccc5n5c4c1n2[C@H]1C[C@](O)(C(=O)OC)[C@]5(C)O1)CNC3=O,SCMLRESZJCKCTC-KMYQRJGFSA-N,Small molecule,False,CEP-1347,,3.0,,False,False,[],['CEP-1347' 'Cep-1347' 'KT-1575' 'KT-7515' 'KT7515'],,,"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}","[ENSG00000073803,ENSG00000130758,ENSG00000139625,ENSG00000006432,ENSG00000173327]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL3039545,,,Protein,False,LUSPATERCEPT,2019.0,4.0,,False,True,['Reblozyl'],['ACE-536' 'Luspatercept' 'Luspatercept aamt'],"[('DailyMed', array(['luspatercept-aamt'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl'],
      dtype=object))]",,"{'rows': array(['EFO_0004272', 'Orphanet_848', 'EFO_1001996', 'HP_0001915',
       'EFO_0004251', 'EFO_0000198', 'MONDO_0002280', 'EFO_1001996'],
      dtype=object), 'count': 8}","[ENSG00000105329,ENSG00000092969,ENSG00000119699]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 3 investigational indications.
CHEMBL305660,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,MJJALKDDGIKVBE-UHFFFAOYSA-N,Small molecule,False,EBASTINE,1990.0,4.0,,False,True,[],['Ebastine' 'LAS W-090' 'LAS-W-090' 'RP 64305' 'RP-64305'],"[('PubChem', array(['144205778', '170465995', '26758025', '90340626'], dtype=object)), ('Wikipedia', array(['Ebastine'], dtype=object)), ('drugbank', array(['DB11742'], dtype=object))]",,"{'rows': array(['EFO_0000555', 'MONDO_0005271'], dtype=object), 'count': 2}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 2 investigational indications.
CHEMBL328560,NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1,HMHVCUVYZFYAJI-UHFFFAOYSA-N,Small molecule,False,SULTHIAME,,4.0,,False,True,['Ospolot'],['RIKER 594' 'RIKER-594' 'Sulthiame' 'Sultiame'],"[('PubChem', array(['170465788'], dtype=object)), ('Wikipedia', array(['Sultiame'], dtype=object)), ('drugbank', array(['DB08329'], dtype=object)), ('chEBI', array(['32171'], dtype=object))]",,"{'rows': array(['EFO_0003918', 'EFO_0000474'], dtype=object), 'count': 2}","[ENSG00000104267,ENSG00000168748,ENSG00000133742,ENSG00000164879,ENSG00000131686,ENSG00000074410,ENSG00000118298,ENSG00000107159,ENSG00000167434,ENSG00000185015,ENSG00000169239,ENSG00000174990]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for epilepsy and has 1 investigational indication.
CHEMBL3301585,,,Antibody drug conjugate,False,PINATUZUMAB VEDOTIN,,2.0,,False,False,[],"['ACD-22-VCMMAE' 'ACD-22VCMMAE' 'ACD22-VCMMAE' 'DCDT-2980S' 'DCDT2980S'
 'FCU-2703' 'FCU2703' 'Pinatuzumab vedotin' 'RG-7593' 'RO-5541072-000'
 'RO-5541072000' 'RO5541072-000']",,,"{'rows': array(['MONDO_0018906', 'EFO_0000095', 'EFO_0000403'], dtype=object), 'count': 3}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000012124]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3545388,CCN1CCC(c2cc(F)cc(S(C)(=O)=O)c2)CC1,PHRDGRSMZPOCAB-UHFFFAOYSA-N,Small molecule,False,SERIDOPIDINE,,2.0,,False,False,[],['Acr343' 'Seridopidine'],,,,[ENSG00000149295],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3707294,,,Antibody,False,DEPATUXIZUMAB,,2.0,,False,False,[],"['ABT-806' 'Anti-egfr mab abt-806' 'Anti-egfr moab abt-806'
 'Depatuxizumab']",,,"{'rows': array(['EFO_0000616', 'EFO_0000228'], dtype=object), 'count': 2}",[ENSG00000146648],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4068611,Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1,WANIDIGFXJFFEL-SANMLTNESA-N,Small molecule,False,RELACORILANT,,3.0,,False,False,[],['CORT125134' 'Cort 125134' 'Cort-125134' 'Relacorilant'],"[('drugbank', array(['DB14976'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_1000796', 'EFO_0000673', 'EFO_1000797',
       'MONDO_0008170', 'MONDO_0008315', 'EFO_1000251', 'EFO_0003099',
       'MONDO_0005184'], dtype=object), 'count': 9}",[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL4298085,,,Antibody,False,FIANLIMAB,,3.0,,False,False,[],['Fianlimab' 'REGN-3767' 'REGN3767' 'Regn3767'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FIANLIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0003060', 'EFO_0003968', 'EFO_0000616',
       'EFO_0000756', 'MONDO_0004992', 'EFO_0005537'], dtype=object), 'count': 7}",[ENSG00000089692],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL4594505,,,Antibody,True,TECLISTAMAB,2022.0,4.0,,False,True,['Tecvayli'],['BCMAxCD3' 'JNJ-64007957' 'Jnj 64007957' 'Teclistamab' 'Teclistamab cqyv'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TECLISTAMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0001642', 'MONDO_0004992', 'EFO_0001378'], dtype=object), 'count': 3}","[ENSG00000048462,ENSG00000198851,ENSG00000160654,ENSG00000167286]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for multiple myeloma and has 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL538867,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C,HZLFFNCLTRVYJG-WWGOJCOQSA-N,Small molecule,False,PATIDEGIB,,3.0,,False,False,[],"['FIN-5' 'IP-9' 'IP9 FREE BASE' 'IPI 926' 'IPI-926' 'IPI-926 FREE BASE'
 'Ipi-926' 'Patidegib' 'Saridegib']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PATIDEGIB/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['IPI-926'], dtype=object)), ('drugbank', array(['DB12655'], dtype=object))]",['CHEMBL2105764'],"{'rows': array(['EFO_0000616', 'EFO_0004193', 'EFO_0000333', 'MONDO_0007187',
       'EFO_0002618', 'EFO_0004193'], dtype=object), 'count': 6}",[ENSG00000128602],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL9194,CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,MOTJMGVDPWRKOC-QPVYNBJUSA-N,Small molecule,False,ATRASENTAN,,3.0,,False,False,[],['A-127722' 'Atrasentan'],"[('Wikipedia', array(['Atrasentan'], dtype=object)), ('drugbank', array(['DB06199'], dtype=object))]",['CHEMBL2106068'],"{'rows': array(['MONDO_0008315', 'EFO_0000673', 'MONDO_0002367', 'MONDO_0008315',
       'EFO_0000401', 'EFO_0004194', 'EFO_1000158', 'MONDO_0002087',
       'MONDO_0002158', 'MONDO_0008170'], dtype=object), 'count': 10}",[ENSG00000151617],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL932,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1,IZEKFCXSFNUWAM-UHFFFAOYSA-N,Small molecule,False,DIPYRIDAMOLE,1961.0,4.0,,False,True,"['Attia' 'Cerebrovase 100' 'Cerebrovase 25' 'Dipyridamole' 'Iv persantine'
 'Modaplate' 'Ofcram pr' 'Persantin' 'Persantin ret' 'Persantine'
 'Pyridantin' 'Vasyrol']",['B01AC07' 'Dipyridamole' 'NSC-515776' 'RA-8'],"[('DailyMed', array(['dipyridamole'], dtype=object)), ('PubChem', array(['104171148', '11111116', '11111117', '11113358', '124879978',
       '124879980', '124879984', '144203684', '170464694', '26747068',
       '26751580', '26751581', '489152', '50104213', '50104215',
       '56423153', '85231021', '855977', '90340971'], dtype=object)), ('Wikipedia', array(['Dipyridamole'], dtype=object)), ('drugbank', array(['DB00975'], dtype=object)), ('chEBI', array(['4653'], dtype=object))]",,"{'rows': array(['EFO_0001645', 'MONDO_0100096', 'EFO_1001375', 'EFO_1002000',
       'EFO_0000685', 'MONDO_0008170', 'MONDO_0011382', 'EFO_0000764',
       'EFO_0003777', 'EFO_0000712', 'EFO_0003913', 'EFO_0002615',
       'EFO_1000965', 'EFO_0000537', 'HP_0004419', 'EFO_0002618'],
      dtype=object), 'count': 16}","[ENSG00000138735,ENSG00000065989,ENSG00000172572,ENSG00000139053,ENSG00000185527,ENSG00000186642,ENSG00000205268,ENSG00000115252,ENSG00000160191,ENSG00000133256,ENSG00000113448,ENSG00000184588,ENSG00000156973,ENSG00000132915,ENSG00000152270,ENSG00000095464,ENSG00000113231,ENSG00000112541,ENSG00000123360,ENSG00000105650,ENSG00000154678,ENSG00000073417,ENSG00000171408,ENSG00000112759]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 13 investigational indications.
CHEMBL1090089,Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21,JYYLVUFNAHSSFE-UHFFFAOYSA-N,Small molecule,False,PAMAPIMOD,,2.0,,False,False,[],['Pamapimod' 'R-1503' 'R1503' 'RO 4402257' 'Ro-4402257'],"[('chEBI', array(['90685'], dtype=object))]",,,[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1200612,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1.Cl,IVHBBMHQKZBJEU-UHFFFAOYSA-N,Small molecule,False,DIBUCAINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1086,False,True,['Heavy solution nupercaine' 'Nupercainal' 'Nupercaine'],"['Cincaine chloride' 'Cinchocaine hydrochloride' 'Dibucaine hcl'
 'Dibucaine hydrochloride' 'NSC-756724']","[('PubChem', array(['26747981', '26747982', '50107328', '56422129', '855998'],
      dtype=object)), ('chEBI', array(['59735'], dtype=object))]",,,"[ENSG00000183873,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200757,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1.[Br-].[Br-],NPIJXCQZLFKBMV-YTGGZNJNSA-L,Small molecule,False,PANCURONIUM BROMIDE,1972.0,4.0,CHEMBL185073,False,True,['Mioblock' 'Pancuronium bromide' 'Pavulon'],"['Bromurex' 'Mioblock' 'NSC-293162' 'ORG NA 97' 'ORG-NA 97' 'ORG-NA-97'
 'Pancuronium bromide']","[('PubChem', array(['144205586', '50106734'], dtype=object)), ('chEBI', array(['7908'], dtype=object))]",,,"[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972.
CHEMBL1201506,,,Antibody drug conjugate,True,GEMTUZUMAB OZOGAMICIN,2000.0,4.0,,False,True,['Mylotarg'],"['CDP-771' 'CMA-676' 'CMC-676' 'Gemtuzumab ozogamicin'
 'Gemtuzumab ozogamicin recombinant' 'L01XC05' 'WAY-CMA-676']","[('DailyMed', array(['gemtuzumab%20ozogamicin'], dtype=object)), ('DrugCentral', array(['4980'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0'],
      dtype=object)), ('Wikipedia', array(['Gemtuzumab_ozogamicin'], dtype=object))]",,"{'rows': array(['EFO_1000309', 'EFO_0000095', 'EFO_0000222', 'EFO_0000565',
       'MONDO_0004643', 'EFO_0000224', 'EFO_0000616', 'EFO_0000198',
       'EFO_0000220'], dtype=object), 'count': 9}",[ENSG00000105383],Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1215,CNC[C@H](O)c1cccc(O)c1,SONNWYBIRXJNDC-VIFPVBQESA-N,Small molecule,False,PHENYLEPHRINE,1952.0,4.0,,False,True,[],"['(-)-phenylephrine' '(r)-phenylephrine' 'AB-101 (PHENYLEPHRINE)'
 'Cyclomydril' 'Duo-Medihaler' 'J8.601K' 'M-oxedrine' 'M-sympathol'
 'M-sympatol' 'M-synephrine' 'Meta-synephrine' 'Metasynephrine'
 'Phenylephrine' 'Phenylephrine minims' 'Phenylephrine, (r)-'
 'R(-)-mezaton']","[('PubChem', array(['11111644', '90340906'], dtype=object)), ('Wikipedia', array(['Phenylephrine'], dtype=object)), ('drugbank', array(['DB00388'], dtype=object)), ('chEBI', array(['8093'], dtype=object))]",['CHEMBL2062264' 'CHEMBL1200339'],"{'rows': array(['EFO_0009688', 'EFO_1001069', 'EFO_0007328', 'EFO_0007214',
       'HP_0000989', 'EFO_0007486', 'HP_0001742', 'EFO_0005751',
       'EFO_0000712', 'HP_0001742', 'EFO_0006834', 'EFO_0006834',
       'HP_0002315', 'EFO_0007214', 'EFO_0007533', 'EFO_0008521',
       'EFO_0000319', 'EFO_0001073', 'EFO_0000178', 'EFO_0005251',
       'HP_0011499', 'EFO_0005252', 'EFO_0005251', 'EFO_0000537',
       'EFO_0009552', 'MONDO_0005129', 'HP_0100543', 'MONDO_0005271',
       'EFO_0004269', 'EFO_0009523', 'EFO_0003843', 'EFO_0003966',
       'HP_0002140', 'EFO_0003956', 'EFO_0004610', 'HP_0011950',
       'HP_0000138', 'EFO_0000616', 'HP_0012735', 'HP_0001742',
       'EFO_1000645', 'MONDO_0024355', 'EFO_1001898', 'EFO_0007214',
       'EFO_0000544', 'EFO_0000319', 'EFO_0004264', 'MONDO_0024355',
       'EFO_0003956', 'EFO_0001358'], dtype=object), 'count': 50}","[ENSG00000120907,ENSG00000171873,ENSG00000170214]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 13 approved and 33 investigational indications.
CHEMBL1289601,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,WOSKHXYHFSIKNG-UHFFFAOYSA-N,Small molecule,False,LENVATINIB,2015.0,4.0,,False,True,['Kisplyx' 'Lenvima'],['E-7080' 'ER-203492-00' 'Lenvatinib'],"[('PubChem', array(['137276042'], dtype=object)), ('Wikipedia', array(['Lenvatinib'], dtype=object)), ('drugbank', array(['DB09078'], dtype=object)), ('chEBI', array(['85994'], dtype=object))]",['CHEMBL3527309' 'CHEMBL2105704'],"{'rows': array(['EFO_1001961', 'MONDO_0004992', 'EFO_1000158', 'MONDO_0002108',
       'MONDO_0002120', 'EFO_0000501', 'MONDO_0007576', 'EFO_0005221',
       'EFO_0000182', 'EFO_0000558', 'MONDO_0002367', 'EFO_0000231',
       'EFO_1000576', 'EFO_0001421', 'EFO_0000681', 'EFO_1001512',
       'EFO_0000349', 'EFO_0005922', 'EFO_0004142', 'EFO_0000228',
       'EFO_0000641', 'EFO_0000616', 'EFO_0000574', 'MONDO_0002974',
       'EFO_0001061', 'MONDO_0003060', 'EFO_1000796', 'MONDO_0008315',
       'EFO_0003891', 'MONDO_0001056', 'EFO_0000756', 'MONDO_0003060',
       'MONDO_0004992', 'MONDO_0024477', 'EFO_0002617', 'MONDO_0008170',
       'EFO_0003086', 'MONDO_0001528', 'EFO_0000702', 'MONDO_0002108',
       'EFO_1001471', 'EFO_0004230', 'EFO_0000637', 'EFO_0003060',
       'MONDO_0005184', 'EFO_0000178', 'EFO_0000691', 'EFO_1001961',
       'EFO_0000616', 'EFO_0003060', 'EFO_1001901', 'EFO_0000181',
       'EFO_0000681', 'EFO_0002892', 'EFO_0005543', 'EFO_0008528',
       'EFO_0000503', 'EFO_0000571', 'MONDO_0011962', 'MONDO_0005184',
       'EFO_0000588', 'EFO_1001012', 'EFO_1000657', 'MONDO_0007254',
       'EFO_1000613'], dtype=object), 'count': 65}","[ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 58 investigational indications.
CHEMBL142635,COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,HRRBJVNMSRJFHQ-UHFFFAOYSA-N,Small molecule,False,NAFTOPIDIL,1999.0,4.0,,False,True,[],['Flivas' 'NSC-759293' 'Naftopidil'],"[('PubChem', array(['104171197', '144203756', '170466026', '26719853', '26751791',
       '49681769', '50104483', '90340768'], dtype=object)), ('drugbank', array(['DB12092'], dtype=object))]",['CHEMBL1257069' 'CHEMBL1532139' 'CHEMBL1593765'],"{'rows': array(['EFO_0000536'], dtype=object), 'count': 1}",[ENSG00000171873],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999 and has 1 investigational indication.
CHEMBL1492,CN1CCC(OC(c2ccccc2)c2ccccc2)CC1,OWQUZNMMYNAXSL-UHFFFAOYSA-N,Small molecule,False,DIPHENYLPYRALINE,1982.0,4.0,,False,True,[],['Diphenylpyraline'],"[('PubChem', array(['11112289', '50123603', '50123604'], dtype=object)), ('Wikipedia', array(['Diphenylpyraline'], dtype=object)), ('drugbank', array(['DB01146'], dtype=object)), ('chEBI', array(['59788'], dtype=object))]",['CHEMBL1564'],"{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease.
CHEMBL27810,CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,JOATXPAWOHTVSZ-UHFFFAOYSA-N,Small molecule,False,CELIPROLOL,,4.0,,False,True,[],['Celiprolol' 'Celiprolol pch'],"[('Wikipedia', array(['Celiprolol'], dtype=object)), ('drugbank', array(['DB04846'], dtype=object))]",['CHEMBL1742424'],"{'rows': array(['EFO_0000319', 'MONDO_0020066'], dtype=object), 'count': 2}","[ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000043591,ENSG00000169252]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication.
CHEMBL3707276,,,Protein,False,VOSORITIDE,2021.0,4.0,,False,True,['Voxzogo'],['BMN 111' 'BMN-111' 'Bmn 111' 'Vosoritide' 'Voxzogo'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo'],
      dtype=object))]",,"{'rows': array(['MONDO_0009659', 'MONDO_0007037', 'EFO_0004260'], dtype=object), 'count': 3}",[ENSG00000159899],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for achondroplasia and bone disease and has 1 investigational indication.
CHEMBL403989,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12,JMGXJHWTVBGOKG-UHFFFAOYSA-N,Small molecule,False,TG100-801,,2.0,,False,False,[],['TG100-801' 'Tg100-801'],"[('drugbank', array(['DB05075'], dtype=object))]",,"{'rows': array(['EFO_0009606', 'EFO_0003770', 'EFO_0004683'], dtype=object), 'count': 3}","[ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000066468,ENSG00000128052,ENSG00000102755,ENSG00000113721,ENSG00000196411,ENSG00000077782]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4594288,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl.O=C(O)/C=C\C(=O)O,TZNOWAJJWCGILX-HNUXRKMMSA-N,Small molecule,False,LEVAMLODIPINE MALEATE,2019.0,4.0,CHEMBL2111097,False,True,['Conjupri'],"['Amlodipine maleate, s-' 'Levamlodipine maleate']","[('DailyMed', array(['levamlodipine%20maleate'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LEVAMLODIPINE%20MALEATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hypertension.
CHEMBL4650322,C[C@H]([C@H](C(=O)Nc1cc([C@@H](CC(=O)O)C2CC2)ccc1Cl)c1ccc(Cl)cc1)C(F)(F)F,NCRMKIWHFXSBGZ-CNBXIYLPSA-N,Small molecule,False,RUNCACIGUAT,,2.0,,False,False,[],['Runcaciguat'],,,"{'rows': array(['EFO_0003884', 'EFO_0003770'], dtype=object), 'count': 2}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4802154,Cn1ccc2c([C@H](Nc3cc(Cl)c4ncc(C#N)c(NCC(C)(C)C)c4c3)c3cn(C45CC(C4)C5)nn3)cccc2c1=O,VFGSKBLZRDRHOI-ZAGPDIDGSA-N,Small molecule,False,TILPISERTIB,,2.0,,False,False,[],['Tilpisertib'],,,"{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}",[ENSG00000107968],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL511099,Cc1ccc(C23CNCC2C3)cc1,OFYVIGTWSQPCLF-UHFFFAOYSA-N,Small molecule,False,BICIFADINE,,3.0,,False,False,[],['Bicifadine'],"[('drugbank', array(['DB04889'], dtype=object))]",['CHEMBL544862'],"{'rows': array(['HP_0003419', 'EFO_1000783'], dtype=object), 'count': 2}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL5315118,CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O.NC(CO)(CO)CO,KZSSWXACMCYLBM-RMWNCEGRSA-N,Small molecule,False,ILOPROST TROMETHAMINE,2003.0,4.0,CHEMBL494,False,True,['Ventavis'],['Ciloprost trometamol' 'Trometamol iloprost'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ventavis'],
      dtype=object))]",,,[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003.
CHEMBL551466,O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-],XLAKJQPTOJHYDR-QTQXQZBYSA-M,Small molecule,False,ACLIDINIUM BROMIDE,2012.0,4.0,CHEMBL1194325,False,True,['Eklira' 'Eklira genuair' 'Tudorza pressair'],"['14115700' 'Aclidinium bromide' 'Genuair' 'LAS 34273'
 'LAS 34273 MICRONIZED' 'LAS W-330' 'LAS-34273' 'LAS-34273 MICRONIZED'
 'LAS-W-330' 'LAS34273']","[('DailyMed', array(['aclidinium%20bromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair'],
      dtype=object)), ('Wikipedia', array(['Aclidinium_bromide'], dtype=object)), ('chEBI', array(['65344'], dtype=object))]",,"{'rows': array(['EFO_0000464', 'EFO_0000341', 'EFO_0006505', 'MONDO_0004979',
       'HP_0006536', 'EFO_0003768'], dtype=object), 'count': 6}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 approved and 1 investigational indication.
CHEMBL63,COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1,HJORMJIFDVBMOB-UHFFFAOYSA-N,Small molecule,False,ROLIPRAM,,2.0,,False,False,[],"['(r,s)-rolipram' 'NSC-760125' 'Rolipram' 'SB-95952' 'ZK 62 711'
 'ZK-62711' 'ZK-62771']","[('PubChem', array(['144204223', '170465962', '26719663', '26719664', '26752319',
       '26752320', '50105263', '56422401', '85231212', '855869',
       '90341367'], dtype=object)), ('Wikipedia', array(['Rolipram'], dtype=object)), ('drugbank', array(['DB01954'], dtype=object)), ('chEBI', array(['104872'], dtype=object))]",,"{'rows': array(['MONDO_0007739', 'MONDO_0005301', 'EFO_0000618', 'MONDO_0002009'],
      dtype=object), 'count': 4}","[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL954,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1,GKIRPKYJQBWNGO-OCEACIFDSA-N,Small molecule,False,ENCLOMIPHENE,,3.0,,False,False,[],"['Cisclomiphene' 'Clomiphene trans-form' 'Enclomifene' 'Enclomiphene'
 'ICI-46476' 'ISOMER B' 'ISOMER-B' 'Isomer B' 'Milophene' 'RMI 16,289'
 'RMI-16289' 'Rmi-16,289' 'Serophene']","[('PubChem', array(['50085975'], dtype=object)), ('drugbank', array(['DB06735'], dtype=object))]",['CHEMBL1200667'],"{'rows': array(['MONDO_0002146', 'MONDO_0018555', 'EFO_0001073', 'EFO_0000660',
       'MONDO_0002146', 'EFO_0000545'], dtype=object), 'count': 6}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications.
CHEMBL1196,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N,KCLANYCVBBTKTO-UHFFFAOYSA-N,Small molecule,False,PROPARACAINE,1953.0,4.0,,False,True,[],"['Alcaine' 'Kainair' 'Ophthaine' 'Ophthetic' 'Paracaine' 'Proparacaine'
 'Proxymetacaine']","[('PubChem', array(['11112907', '124882712', '174006303'], dtype=object)), ('Wikipedia', array(['Proxymetacaine'], dtype=object)), ('drugbank', array(['DB00807'], dtype=object)), ('chEBI', array(['8485'], dtype=object))]",['CHEMBL1200464'],"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and has 1 investigational indication.
CHEMBL1200814,CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+],MRSXAJAOWWFZJJ-UHFFFAOYSA-M,Small molecule,False,ACETAZOLAMIDE SODIUM,1990.0,4.0,CHEMBL20,False,True,['Acetazolamide sodium' 'Diamox'],"['Acetazolamide Sodium' 'Acetazolamide sodium' 'Acetazolamide sodium salt'
 'Sodium acetazolamide' 'Vetamox']","[('chEBI', array(['31163'], dtype=object))]",,"{'rows': array(['MONDO_0001744', 'EFO_0009373', 'MONDO_0005041', 'HP_0001250'],
      dtype=object), 'count': 4}","[ENSG00000074410,ENSG00000167434,ENSG00000133742,ENSG00000104267]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 4 approved indications.
CHEMBL1208829,COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O,UUROSJLZNDSXRF-UHFFFAOYSA-N,Small molecule,False,ITX-5061,,2.0,,False,False,[],[],"[('PubChem', array(['124360067'], dtype=object))]",['CHEMBL3402567'],"{'rows': array(['EFO_0004719', 'EFO_0003047'], dtype=object), 'count': 2}",[ENSG00000112062],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL121,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,YASAKCUCGLMORW-UHFFFAOYSA-N,Small molecule,True,ROSIGLITAZONE,1999.0,4.0,,True,True,['Avandia'],"['Avandamet' 'Avandaryl' 'Avandia' 'BRL-49653' 'Gaudil' 'NSC-758698'
 'Rezult' 'Rosiglitazone' 'Rosiglizole' 'Rosvel' 'TDZ-01']","[('PubChem', array(['144204987', '170465417', '174007204', '26748954'], dtype=object)), ('Wikipedia', array(['Rosiglitazone'], dtype=object)), ('drugbank', array(['DB00412'], dtype=object)), ('chEBI', array(['50122'], dtype=object))]",['CHEMBL843' 'CHEMBL1704605'],"{'rows': array(['MONDO_0004992', 'HP_0001952', 'EFO_1001373', 'MONDO_0004979',
       'EFO_0000400', 'MONDO_0007254', 'HP_0003124', 'MONDO_0005148',
       'EFO_0001068', 'EFO_1001051', 'EFO_0003914', 'EFO_0003914',
       'EFO_0000691', 'EFO_0000616', 'MONDO_0005148', 'EFO_0006911',
       'HP_0100543', 'EFO_0004236', 'Orphanet_309005', 'EFO_0000195',
       'EFO_0007444', 'EFO_0000764', 'EFO_1001110', 'EFO_0000373',
       'EFO_0000589', 'EFO_0002614', 'EFO_0004272', 'EFO_1000785',
       'HP_0002745', 'EFO_0000685', 'EFO_0004234', 'EFO_0000764',
       'EFO_1000158', 'EFO_0000729', 'EFO_0001065', 'EFO_0001645',
       'EFO_1001249', 'EFO_0000400', 'EFO_0002546', 'EFO_1001121',
       'EFO_1000783', 'EFO_0003095', 'MONDO_0004975', 'EFO_0000537',
       'EFO_0006859', 'EFO_0000673', 'EFO_0002614'], dtype=object), 'count': 47}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 43 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1578,CCCC(CCC)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C.[Br-],QSFKGMJOKUZAJM-CNKDKAJDSA-M,Small molecule,False,ANISOTROPINE METHYLBROMIDE,1962.0,4.0,CHEMBL1186610,False,True,['Anisotropine methylbromide' 'Valpin 50'],"['Anisotropine methylbromide' 'Methyloctatropine bromide'
 'Octatropine methylbromide' 'Octatropone bromide'
 'Octotropine methylbromide']","[('PubChem', array(['144204422', '144207024', '56422429', '855548'], dtype=object))]",,,"[ENSG00000168539,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962.
CHEMBL1697737,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,CHBRHODLKOZEPZ-UHFFFAOYSA-N,Small molecule,False,CLOTIAZEPAM,,4.0,,False,True,['Clozan'],['Clotiazepam'],"[('drugbank', array(['DB01559'], dtype=object))]",,"{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV and is indicated for anxiety.
CHEMBL188462,CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1,RPCVIAXDAUMJJP-PZBABLGHSA-N,Small molecule,False,ISPRONICLINE,,2.0,,False,False,[],['AZD-3480' 'Azd3480' 'Ispronicline' 'TC-01734' 'TC-1734'],,,"{'rows': array(['EFO_0001072', 'MONDO_0005090', 'MONDO_0004975', 'EFO_0003888'],
      dtype=object), 'count': 4}","[ENSG00000160716,ENSG00000101204]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2062154,C[C@](Cc1c[nH]c2ccccc12)(NC(=O)OC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2)C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1,FVQSSYMRZKLFDR-QRCSZXLUSA-N,Small molecule,False,CI-988,,1.0,,False,False,[],['Ci-988' 'PD-134308'],,,,[ENSG00000110148],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2105708,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl,BWTNNZPNKQIADY-UHFFFAOYSA-N,Small molecule,True,PONATINIB HYDROCHLORIDE,2012.0,4.0,CHEMBL1171837,False,True,['Iclusig'],['AP-24534 HCL' 'AP24534 HCL' 'Ponatinib hydrochloride'],"[('DailyMed', array(['ponatinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig'],
      dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_1000131', 'EFO_0000220', 'EFO_0000339',
       'MONDO_0004992'], dtype=object), 'count': 5}","[ENSG00000097007,ENSG00000186716]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for acute lymphoblastic leukemia and chronic myelogenous leukemia and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2105755,CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1,AXQACEQYCPKDMV-RZAWKFBISA-N,Small molecule,False,NALDEMEDINE,2017.0,4.0,,False,True,[],['Naldemedine' 'S-297995'],"[('drugbank', array(['DB11691'], dtype=object))]",['CHEMBL3039508'],"{'rows': array(['EFO_0003843', 'EFO_0000278', 'HP_0002019', 'HP_0002019',
       'MONDO_0002203'], dtype=object), 'count': 5}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 1 investigational indication.
CHEMBL2107349,C[C@H](CN(C(=O)c1ccc(C#N)cc1)c1ccccn1)N1CCN(c2cccc3c2OCCO3)CC1.Cl,GXYZREDEYDFJPT-ZMBIFBSDSA-N,Small molecule,False,LECOZOTAN HYDROCHLORIDE,,3.0,CHEMBL372205,False,False,[],['Lecozotan hcl' 'Lecozotan hydrochloride' 'SRA-333'],,,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}",[ENSG00000178394],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2108361,,,Enzyme,False,AMEDIPLASE,,2.0,,False,False,[],['Amediplase'],,,,[ENSG00000122194],Enzyme drug with a maximum clinical trial phase of II.
CHEMBL2108723,,,Protein,False,PEGINTERFERON LAMBDA-1A,,3.0,,False,False,[],"['BMS-914143' 'BMS914143' 'PEG-IL-29' 'PEG-RIL-29' 'PEG-RLL-29'
 'Peginterferon lambda-1a' 'Pegylated interferon lambda']",,,"{'rows': array(['EFO_0000694', 'EFO_0004220', 'EFO_0007304', 'MONDO_0100096',
       'EFO_0004197', 'EFO_0004239', 'EFO_0003047'], dtype=object), 'count': 7}","[ENSG00000243646,ENSG00000185436]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications.
CHEMBL2109526,,,Antibody,False,PG-110,,1.0,,False,False,[],['PG-110' 'Pg-110'],,,"{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}",[ENSG00000134259],Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL218427,Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)NC4(C(=O)N5CCN(C(=O)[C@@H](N)CCC[N+](C)(C)C)CC5)CCOCC4)c3Cl)c2n1,FQVSDHOWSLEEKJ-LJAQVGFWSA-N,Small molecule,False,FASITIBANT,,2.0,,False,False,[],"['Fasitibant' 'Fasitibant cation' 'Fasitibant ion' 'MEN-16132'
 'MEN-16132 FREE BASE']","[('drugbank', array(['DB15646'], dtype=object))]",['CHEMBL541758'],"{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}",[ENSG00000168398],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL221326,O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1,NMLMACJWHPHKGR-NCOIDOBVSA-N,Small molecule,False,DIQUAFOSOL,,3.0,,False,False,[],['Diquafosol' 'INS-365'],"[('Wikipedia', array(['Diquafosol'], dtype=object)), ('chEBI', array(['27791'], dtype=object))]",['CHEMBL1767408'],"{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}","[ENSG00000171631,ENSG00000186912,ENSG00000175591,ENSG00000169860]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL24441,CNCCc1ccccn1,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,Small molecule,False,BETAHISTINE,,4.0,,False,True,[],['Betahistine'],"[('Wikipedia', array(['Betahistine'], dtype=object)), ('drugbank', array(['DB06698'], dtype=object)), ('chEBI', array(['35677'], dtype=object))]",['CHEMBL4303472' 'CHEMBL1451277' 'CHEMBL1446813' 'CHEMBL1464589'],"{'rows': array(['HP_0003124', 'EFO_0001073', 'EFO_0001073', 'HP_0002321',
       'EFO_0003888', 'EFO_0004566', 'MONDO_0002009'], dtype=object), 'count': 7}","[ENSG00000101180,ENSG00000196639]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for vertigo and has 6 investigational indications.
CHEMBL3183409,CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,HJBWBFZLDZWPHF-UHFFFAOYSA-N,Small molecule,False,APALUTAMIDE,2018.0,4.0,,False,True,['Erleada'],['ARN-509' 'Apalutamide' 'Arn-509' 'JNJ-56021927'],"[('DailyMed', array(['apalutamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/erleada'],
      dtype=object)), ('PubChem', array(['174007290'], dtype=object)), ('drugbank', array(['DB11901'], dtype=object))]",['CHEMBL4082191' 'CHEMBL4105484' 'CHEMBL4100200' 'CHEMBL4062002'],"{'rows': array(['EFO_0000196', 'EFO_0000616', 'EFO_0000673', 'MONDO_0004992',
       'EFO_0001421', 'EFO_0001663', 'MONDO_0008315', 'EFO_0003826'],
      dtype=object), 'count': 8}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 2 investigational indications.
CHEMBL3545221,,,Small molecule,False,AZD2423,,2.0,,False,False,[],['Azd2423'],,,"{'rows': array(['EFO_0003843', 'EFO_0000341', 'EFO_0005762'], dtype=object), 'count': 3}",[ENSG00000121807],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3989519,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O,ZOMBFZRWMLIDPX-UHFFFAOYSA-N,Small molecule,False,DOXAPRAM HYDROCHLORIDE,1965.0,4.0,CHEMBL1754,False,True,['Dopram' 'Doxapram hydrochloride' 'Stimulexin'],"['AHR-619' 'Doxapram hcl' 'Doxapram hydrochloride'
 'Doxapram hydrochloride hydrate' 'Doxapram hydrochloride monohydrate'
 'NSC-170958' 'NSC-760347' 'Stimulexin']","[('DailyMed', array(['doxapram%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0004262', 'EFO_0003818'], dtype=object), 'count': 2}","[ENSG00000169427,ENSG00000171303]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for lung disease and has 1 investigational indication.
CHEMBL3989970,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F,JYIUNVOCEFIUIU-GHMZBOCLSA-N,Small molecule,False,MAVELERTINIB,,2.0,,False,False,[],['Egfr t790m inhibitor pf-06747775' 'Mavelertinib' 'PF-06747775'],,,"{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4298079,,,Unknown,False,SEPHB4-HSA,,2.0,,False,False,[],['Recombinant ephb4-hsa fusion protein' 'Sephb4-hsa'],,,"{'rows': array(['EFO_0000196', 'EFO_0000616', 'EFO_0008528', 'EFO_0000181',
       'MONDO_0004986', 'MONDO_0008315', 'EFO_0000558'], dtype=object), 'count': 7}",[ENSG00000125266],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4298171,COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)[O-])c3c2=O)cc1OCc1c(OC)ccc(F)c1F.C[N+](C)(C)CCO,IAIVRTFCYOGNBW-UHFFFAOYSA-M,Small molecule,False,LINZAGOLIX CHOLINE,2022.0,4.0,CHEMBL3668014,False,True,['Yselty'],['KLH-2109 choline' 'Linzagolix choline' 'OBE2109 choline'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yselty'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINZAGOLIX%20CHOLINE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['HP_0000131', 'EFO_0001065'], dtype=object), 'count': 2}",[ENSG00000109163],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for uterine leiomyoma and has 1 investigational indication.
CHEMBL4594351,Cc1c(Cc2ccc(-n3cccn3)cc2)cc2c(c1F)CN([C@H]1COCC[C@@H]1O)C2=O,WFSARWQASFQZMG-VXKWHMMOSA-N,Small molecule,False,TAK-071,,2.0,,False,False,[],['Tak-071'],,,"{'rows': array(['MONDO_0005180', 'MONDO_0004975'], dtype=object), 'count': 2}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4742157,CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl,BVAHPPKGOOJSPU-UHFFFAOYSA-N,Small molecule,False,GSK-2256098,,2.0,,False,False,[],['Gsk-2256098' 'Gsk2256098'],,,"{'rows': array(['EFO_0001361', 'MONDO_0004992', 'MONDO_0016642'], dtype=object), 'count': 3}",[ENSG00000169398],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL52939,COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,FFYNAVGJSYHHFO-UHFFFAOYSA-N,Small molecule,False,SARPOGRELATE,,3.0,,False,False,[],['Sarpogrelate' 'Sarpogrelate hydrochloride'],"[('PubChem', array(['124893325', '174006666', '50112742'], dtype=object)), ('drugbank', array(['DB12163'], dtype=object))]",['CHEMBL541829'],"{'rows': array(['EFO_0004265', 'MONDO_0002679'], dtype=object), 'count': 2}",[ENSG00000102468],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL5315064,,,Protein,False,FOLLITROPIN DELTA,2016.0,4.0,,False,True,['Rekovelle'],['FE 999049' 'FE-999049' 'Follitropin delta'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FOLLITROPIN%20DELTA/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0002775'], dtype=object), 'count': 1}",[ENSG00000170820],Protein drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for anovulation.
CHEMBL605525,C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O,UHMPCVGLSKFXHR-NAQZCRMNSA-N,Small molecule,False,DP001,,2.0,,False,False,[],['2MD' 'Dp001'],,,"{'rows': array(['EFO_0003854', 'EFO_1001173', 'EFO_0003882'], dtype=object), 'count': 3}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL6966,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,SGTNSNPWRIOYBX-UHFFFAOYSA-N,Small molecule,False,VERAPAMIL,1981.0,4.0,,False,True,[],"['CP-16,533-1' 'CP-16533-1' 'CP-165331' 'Calan' 'Covera-HS' 'D-365'
 'Iproveratril' 'Isoptin' 'NSC-272306NA' 'Tarka' 'Verapamil'
 'Verapamil slow release' 'Verelan']","[('PubChem', array(['104171262', '124881789', '124881790', '124881792', '124881795',
       '144203851', '170464904', '174316170', '26751825', '50104518',
       '50104519', '50104520', '90340771'], dtype=object)), ('Wikipedia', array(['Verapamil'], dtype=object)), ('drugbank', array(['DB00661'], dtype=object)), ('chEBI', array(['77733'], dtype=object))]",['CHEMBL1280' 'CHEMBL1707604' 'CHEMBL483787'],"{'rows': array(['HP_0004308', 'EFO_0004616', 'MONDO_0005148', 'MP_0001914',
       'EFO_0000384', 'EFO_0000275', 'MONDO_0100096', 'EFO_0003843',
       'EFO_0003890', 'EFO_0000319', 'EFO_0004269', 'EFO_0000319',
       'EFO_1001413', 'EFO_0000400', 'EFO_0003144', 'EFO_0000183',
       'EFO_0000275', 'HP_0002140', 'MONDO_0005147', 'MONDO_0004985',
       'EFO_0000537'], dtype=object), 'count': 21}","[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 16 investigational indications.
CHEMBL1094966,CC(C)(C)NCC(O)c1ccc(O)c(CO)n1,VQDBNKDJNJQRDG-UHFFFAOYSA-N,Small molecule,False,PIRBUTEROL,1986.0,4.0,,False,True,[],['ARA-211' 'Pirbuterol'],"[('Wikipedia', array(['Pirbuterol'], dtype=object)), ('drugbank', array(['DB01291'], dtype=object)), ('chEBI', array(['8245'], dtype=object))]",['CHEMBL1997417' 'CHEMBL3989646' 'CHEMBL1200444'],"{'rows': array(['MONDO_0004979', 'HP_0006536'], dtype=object), 'count': 2}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for asthma and airway obstruction.
CHEMBL1096885,CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O,ZOCKGBMQLCSHFP-KQRAQHLDSA-N,Small molecule,False,VALRUBICIN,1998.0,4.0,,False,True,['Valstar' 'Valstar preservative free'],['AD 32' 'AD-32' 'NSC-246131' 'Valrubicin'],"[('PubChem', array(['144205810'], dtype=object)), ('Wikipedia', array(['Valrubicin'], dtype=object)), ('drugbank', array(['DB00385'], dtype=object))]",,"{'rows': array(['EFO_0008528', 'EFO_0000616', 'EFO_0000313', 'MONDO_0001187',
       'MONDO_0004647'], dtype=object), 'count': 5}",[ENSG00000131747],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for neoplasm and carcinoma and has 3 investigational indications.
CHEMBL1201222,C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,VOBHXZCDAVEXEY-JSGCOSHPSA-N,Small molecule,True,LISDEXAMFETAMINE,2007.0,4.0,,False,True,[],['L-lysine-dextroamphetamine' 'Lisdexamfetamine' 'Lisdexamphetamine'],"[('Wikipedia', array(['Lisdexamfetamine'], dtype=object)), ('drugbank', array(['DB01255'], dtype=object))]",['CHEMBL1201178'],"{'rows': array(['EFO_0004701', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0005924',
       'EFO_0003888', 'EFO_0002610', 'MONDO_0005301', 'MONDO_0004985',
       'EFO_0001073', 'MONDO_0002009', 'MONDO_0002277', 'EFO_0005203',
       'EFO_0005203', 'EFO_0004698', 'EFO_0003890', 'EFO_0005204',
       'MONDO_0005041', 'EFO_0003888'], dtype=object), 'count': 18}","[ENSG00000103546,ENSG00000165646,ENSG00000142319]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 11 investigational indications. This drug has a black box warning from the FDA.
CHEMBL135400,CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,GBBSUAFBMRNDJC-UHFFFAOYSA-N,Small molecule,False,ZOPICLONE,,4.0,,False,True,['Zileze 3.75' 'Zileze 7.5' 'Zimovane' 'Zimovane ls'],['Amoban' 'Imovane' 'NSC-758463' 'RP 27267' 'RP-27267' 'Zopiclone'],"[('PubChem', array(['124881861', '26747152', '866104'], dtype=object)), ('Wikipedia', array(['Zopiclone'], dtype=object)), ('drugbank', array(['DB01198'], dtype=object)), ('chEBI', array(['32315'], dtype=object))]",,"{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0003918', 'EFO_0008568',
       'MONDO_0002009', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0004698',
       'EFO_0004329'], dtype=object), 'count': 9}","[ENSG00000022355,ENSG00000145864,ENSG00000166206,ENSG00000109158,ENSG00000011677,ENSG00000163288,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 9 investigational indications.
CHEMBL1531,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC,GCKFUYQCUCGESZ-BPIQYHPVSA-N,Small molecule,False,ETONOGESTREL,2001.0,4.0,,False,True,['Implanon' 'Nexplanon'],['Etonogestrel' 'Implanon' 'ORG 3236' 'ORG-3236'],"[('DailyMed', array(['etonogestrel'], dtype=object)), ('PubChem', array(['144206191', '50113279'], dtype=object)), ('Wikipedia', array(['Etonogestrel'], dtype=object)), ('drugbank', array(['DB00294'], dtype=object)), ('chEBI', array(['50777'], dtype=object))]",,"{'rows': array(['EFO_0000764', 'MONDO_0007915', 'EFO_0000765', 'EFO_0002950',
       'EFO_0000284', 'HP_0100607'], dtype=object), 'count': 6}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 investigational indications.
CHEMBL160519,CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,FKNXQNWAXFXVNW-UHFFFAOYSA-N,Small molecule,False,PROCATEROL,,3.0,,False,False,[],['Meptin' 'Procaterol'],,['CHEMBL1322218'],"{'rows': array(['MONDO_0004979', 'HP_0006536'], dtype=object), 'count': 2}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL1626,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,YNNUSGIPVFPVBX-NHCUHLMSSA-N,Small molecule,False,CLEMASTINE,1977.0,4.0,,False,True,[],['Clemastin' 'Clemastine' 'HS-592' 'NSC-756685'],"[('PubChem', array(['11111002', '11112618', '11114089', '124882478', '152146162'],
      dtype=object)), ('Wikipedia', array(['Clemastine'], dtype=object)), ('drugbank', array(['DB00283'], dtype=object)), ('chEBI', array(['3738'], dtype=object))]",['CHEMBL1200795'],"{'rows': array(['MONDO_0005271', 'EFO_0005532', 'EFO_0005854', 'EFO_0005531',
       'EFO_0003956', 'HP_0000989', 'MONDO_0002406', 'EFO_0005531',
       'EFO_0003840', 'MONDO_0005271', 'EFO_0007405', 'EFO_0007214',
       'EFO_0003929', 'EFO_0003929', 'MONDO_0005301', 'MONDO_0005301'],
      dtype=object), 'count': 16}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 6 approved and 10 investigational indications.
CHEMBL1719,CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,HVRLZEKDTUEKQH-NOILCQHBSA-N,Small molecule,False,OLOPATADINE HYDROCHLORIDE,1996.0,4.0,CHEMBL1189432,False,True,"['Olopatadine hydrochloride' 'Opatanol' 'Pataday'
 'Pataday once daily relief' 'Pataday twice daily relief' 'Patanase'
 'Patanol' 'Pazeo']","['ALO-4943A' 'ALO4943A' 'Allelock' 'KW-4679' 'KW4679'
 'Olopatadine (as hydrochloride)' 'Olopatadine hcl'
 'Olopatadine hydrochloride']","[('DailyMed', array(['olopatadine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/opatanol'],
      dtype=object)), ('PubChem', array(['144205795', '170465181', '49681604'], dtype=object))]",,"{'rows': array(['EFO_0005854', 'HP_0000989', 'EFO_0003956', 'EFO_0007141'],
      dtype=object), 'count': 4}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved indications.
CHEMBL2103822,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2,PTOIAAWZLUQTIO-GXFFZTMASA-N,Small molecule,False,TASIMELTEON,2014.0,4.0,,False,True,['Hetlioz' 'Hetlioz lq'],"['BMS-214,778' 'BMS-214778' 'Tasimelteon' 'VEC-162']","[('DailyMed', array(['tasimelteon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hetlioz'],
      dtype=object)), ('drugbank', array(['DB09071'], dtype=object)), ('chEBI', array(['79042'], dtype=object))]",,"{'rows': array(['MONDO_0003406', 'MONDO_0024361', 'MONDO_0008434', 'EFO_0001421',
       'EFO_0004698', 'Orphanet_68335', 'EFO_0003086', 'MONDO_0002009',
       'EFO_0007462'], dtype=object), 'count': 9}","[ENSG00000168412,ENSG00000134640]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 5 investigational indications.
CHEMBL2107313,CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,JSKFWUPVIZYJMR-UDOAKELVSA-N,Small molecule,False,BECATECARIN,,3.0,,False,False,[],"['BMS-181176' 'BMY-27557' 'Becatecarin' 'Deae-rebeccamycin' 'NSC-655649'
 'XL-119' 'XL119 ']","[('drugbank', array(['DB06362'], dtype=object))]",,"{'rows': array(['MONDO_0002367', 'EFO_0000574', 'EFO_0006861', 'EFO_1001951',
       'MONDO_0008170', 'MONDO_0003060', 'MONDO_0008903', 'EFO_0000616',
       'EFO_0000702', 'EFO_0000621'], dtype=object), 'count': 10}","[ENSG00000198900,ENSG00000131747,ENSG00000077097]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL2107797,C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,WWYNJERNGUHSAO-CULCCENASA-N,Small molecule,False,NORGESTREL,1968.0,4.0,,False,True,['Opill' 'Ovrette'],"['Dl-norgestrel' 'FH-122A' 'NSC-757251' 'Norgestrel' 'Prefest' 'Previfem'
 'SH-70850' 'SH-850' 'Sprintec' 'Tri-Previfem' 'Tri-Sprintec' 'WY-3707']","[('DailyMed', array(['norgestrel'], dtype=object)), ('PubChem', array(['144213928'], dtype=object))]",,"{'rows': array(['MP_0001914', 'MONDO_0011962'], dtype=object), 'count': 2}",[ENSG00000082175],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and is indicated for hemorrhage and has 1 investigational indication.
CHEMBL2107822,Cc1ccc(-c2ncccn2)c(C(=O)N2C[C@H](COc3ccc(F)cn3)CC[C@H]2C)c1,NPFDWHQSDBWQLH-QZTJIDSGSA-N,Small molecule,False,FILOREXANT,,2.0,,False,False,[],['Filorexant' 'MK-6096'],"[('drugbank', array(['DB12158'], dtype=object))]",,"{'rows': array(['EFO_0004698', 'EFO_1000783', 'MONDO_0002009'], dtype=object), 'count': 3}","[ENSG00000137252,ENSG00000121764]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL2107874,,,Antibody,True,ROMOSOZUMAB,2019.0,4.0,,False,True,['Evenity'],['AMG 785' 'AMG-785' 'CDP-7851' 'CDP7851' 'Romosozumab' 'Romosozumab aqqg'],"[('DailyMed', array(['romosozumab-aqqg'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evenity'],
      dtype=object))]",,"{'rows': array(['HP_0000938', 'MONDO_0019019', 'EFO_0003931', 'EFO_0003882',
       'EFO_0004260', 'EFO_0003854'], dtype=object), 'count': 6}",[ENSG00000167941],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108747,,,Antibody,False,TORALIZUMAB,,2.0,,False,False,[],['ANTI-CD154' 'ANTI-CD40L' 'ANTI-GP39' 'E-6040' 'IDEC-131' 'Toralizumab'],,,,[ENSG00000102245],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108964,,,Protein,False,"INSULIN, ISOPHANE",,4.0,,False,True,"['Ins hum insulat' 'Ins hum protaphane' 'Ins humulin i'
 'Ins hypurin bov isop' 'Ins hypurin pore isop' 'Ins innolet insulat'
 'Ins insulat' 'Ins insulat novolet' 'Ins insuman basal'
 'Ins insuman basal optiset' 'Ins insuman basal solostar'
 'Ins novolet hum protaphane' 'Ins pork insulat' 'Ins pur-in hum isop'
 'Penfill']","['Insulin injection' 'Insulin, isophane' 'Isophane (aqueous suspension)'
 'Isophane insulin']",,,"{'rows': array(['MONDO_0005147', 'EFO_0000400', 'MONDO_0005148', 'HP_0003419'],
      dtype=object), 'count': 4}",[ENSG00000171105],Protein drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications.
CHEMBL2109267,,,Antibody,False,M195,,2.0,,False,False,[],['M195'],,,,[ENSG00000105383],Antibody drug with a maximum clinical trial phase of II.
CHEMBL3185958,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,PYTMYKVIJXPNBD-UHFFFAOYSA-N,Small molecule,False,CLOMIPHENE CITRATE,1967.0,4.0,CHEMBL2355051,False,True,['Clomid' 'Clomiphene citrate' 'Clophene' 'Milophene' 'Serophene'],"['Chloramiphene' 'Clomid' 'Clomifene citrate' 'Clomifeni citras'
 'Clomiphene citrate' 'Clomiphene citrate (1:1)' 'Clostilbegyt'
 'Ikaclomine' 'MER-41' 'MRL-41' 'NSC-35770' 'Pergotime']","[('DailyMed', array(['clomiphene%20citrate'], dtype=object)), ('PubChem', array(['144212192'], dtype=object)), ('chEBI', array(['3753'], dtype=object))]",,"{'rows': array(['EFO_0000660', 'EFO_0000545', 'MP_0001914', 'EFO_0008560'],
      dtype=object), 'count': 4}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 3 approved and 1 investigational indication.
CHEMBL3544909,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O,WRLFSJXJGJBFJQ-WPUCQFJDSA-N,Small molecule,False,CALCIFEDIOL,1980.0,4.0,CHEMBL1040,False,True,['Calderol' 'Rayaldee'],"['CTAP101' 'Calcidiol' 'Calcifediol' 'Calcifediol hydrate'
 'Calcifediol monohydrate' 'Ctap-101' 'Didrogyl' 'Hidroferol' 'Rayaldy'
 'U-32,070E' 'U-32070E']","[('DailyMed', array(['calcifediol'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0003884', 'HP_0001919', 'EFO_0000612',
       'EFO_0005754', 'EFO_0003918', 'EFO_1001173', 'EFO_0003762'],
      dtype=object), 'count': 8}",[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved and 5 investigational indications.
CHEMBL3545208,,,Small molecule,False,AZD3161,,1.0,,False,False,[],['Azd3161'],,,"{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}",[ENSG00000169432],Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL371064,CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1,LLCRBOWRJOUJAE-UHFFFAOYSA-N,Small molecule,False,BALICATIB,,2.0,,False,False,[],['AAE-581' 'AAE581' 'Balicatib'],"[('drugbank', array(['DB12239'], dtype=object))]",,"{'rows': array(['EFO_0003882', 'EFO_0004616'], dtype=object), 'count': 2}",[ENSG00000143387],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL3989921,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C.O=C(O)/C=C\C(=O)O,VXZCUHNJXSIJIM-MEBGWEOYSA-N,Small molecule,False,NERATINIB MALEATE,2017.0,4.0,CHEMBL180022,False,True,['Nerlynx'],['Neratinib maleate' 'Neratinib maleate anhydrous'],"[('DailyMed', array(['neratinib%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx'],
      dtype=object))]",,"{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0000305'], dtype=object), 'count': 3}","[ENSG00000178568,ENSG00000146648,ENSG00000141736]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for breast cancer and breast carcinoma and has 1 investigational indication.
CHEMBL3990039,,,Antibody,False,MARSTACIMAB,,3.0,,False,False,[],['Marstacimab' 'PF-06741086'],,,"{'rows': array(['MONDO_0010602', 'MONDO_0018660', 'MONDO_0010604'], dtype=object), 'count': 3}",[ENSG00000003436],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297404,COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,ORZMUVMQJPGFOM-UHFFFAOYSA-N,Small molecule,False,MK-0767,,3.0,,False,False,[],['MK 0767' 'Mk-0767' 'Mk0767'],"[('drugbank', array(['DB12055'], dtype=object))]",,"{'rows': array(['MONDO_0005148', 'EFO_0000400', 'EFO_0000195'], dtype=object), 'count': 3}","[ENSG00000186951,ENSG00000132170]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4298207,,,Protein,False,ZILUCOPLAN,,3.0,,False,False,[],['RA101495' 'Zilucoplan'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZILUCOPLAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0004991', 'MONDO_0100244', 'MONDO_0100096', 'MONDO_0004976',
       'MONDO_0100244'], dtype=object), 'count': 5}",[ENSG00000106804],Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4650343,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1,DADAEARVGOQWHV-OSYLJGHBSA-N,Small molecule,False,IZENCITINIB,,2.0,,False,False,[],['Izencitinib' 'TD-1473' 'TD1473' 'Td-1473'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IZENCITINIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000729', 'EFO_0003767', 'EFO_0000384'], dtype=object), 'count': 3}","[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL5315071,,,Protein,False,TUROCTOCOG ALFA PEGOL,2019.0,4.0,,False,True,['Esperoct'],['N8-gp'],"[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct'],
      dtype=object))]",,"{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}",[ENSG00000185010],Protein drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hemophilia a.
CHEMBL703,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,AXOIZCJOOAYSMI-UHFFFAOYSA-N,Small molecule,True,SUXAMETHONIUM,1952.0,4.0,,False,True,[],"['Anectine' 'Quelicin' 'Succinylcholine' 'Succinylcholine cation'
 'Succinylcholine ion' 'Sucostrin' 'Suxamethonium' 'Suxamethonium cation'
 'Suxamethonium ion']","[('PubChem', array(['11111825', '90341285'], dtype=object)), ('drugbank', array(['DB00202'], dtype=object)), ('chEBI', array(['45652'], dtype=object))]",['CHEMBL2104486' 'CHEMBL3391771' 'CHEMBL983'],"{'rows': array(['EFO_0000712', 'HP_0001662', 'HP_0003326'], dtype=object), 'count': 3}","[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 3 investigational indications. This drug has a black box warning from the FDA.
CHEMBL902,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,XUFQPHANEAPEMJ-UHFFFAOYSA-N,Small molecule,False,FAMOTIDINE,1986.0,4.0,,False,True,"['Famotidine' 'Famotidine preservative free'
 'Famotidine preservative free (pharmacy bulk)' 'Fluxid' 'Pepcid'
 'Pepcid ac' 'Pepcid preservative free' 'Pepcid rpd']","['Amfamox' 'Fadul' 'Famodil' 'Famosan' 'Famotidine' 'Famoxal' 'Ganor'
 'Gastridin' 'Gastropen' 'L 643341' 'Lecedil' 'MK-208' 'Motiax' 'Muclox'
 'NSC-757810' 'Pepcidac' 'Pepdine' 'Pepdul' 'YM-11170']","[('DailyMed', array(['famotidine'], dtype=object)), ('PubChem', array(['11111194', '11111195', '144203704', '144212144', '170464877',
       '26748463', '26753575', '49681730', '50106279', '85231052',
       '855518'], dtype=object)), ('TG-GATEs', array(['85'], dtype=object)), ('Wikipedia', array(['Famotidine'], dtype=object)), ('drugbank', array(['DB00927'], dtype=object)), ('chEBI', array(['4975'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'MONDO_0011382', 'EFO_0009454', 'HP_0002239',
       'EFO_1001951', 'MONDO_0004992', 'EFO_0000180', 'MONDO_0043839',
       'EFO_0000676', 'EFO_0000764', 'EFO_0004607', 'HP_0100633',
       'MONDO_0004658', 'EFO_0004232', 'EFO_0006890', 'EFO_0000641',
       'MONDO_0005178', 'HP_0004398', 'EFO_0000616', 'HP_0100749',
       'MONDO_0001056', 'MONDO_0009291', 'EFO_0000756', 'MONDO_0017287',
       'EFO_0004280', 'EFO_0000685', 'MONDO_0005090', 'EFO_0003060',
       'EFO_0003948'], dtype=object), 'count': 29}",[ENSG00000113749],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 9 approved and 20 investigational indications.
CHEMBL1159717,CC(C)(C)NCC(O)c1ccccc1Cl,YREYLAVBNPACJM-UHFFFAOYSA-N,Small molecule,False,TULOBUTEROL,,4.0,,False,True,['Brelomax' 'Respacal'],"['Atenos' 'Berachin' 'Bremax' 'Chlibamol' 'Hokunalin' 'Lobuterol'
 'NSC-758643' 'Tulobuterol' 'Tulobuterol hcl' 'Tulobuterol hydrochloride']","[('PubChem', array(['90340621'], dtype=object)), ('Wikipedia', array(['Tulobuterol'], dtype=object)), ('drugbank', array(['DB12248'], dtype=object))]",['CHEMBL1256478'],"{'rows': array(['HP_0006536'], dtype=object), 'count': 1}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV and is indicated for airway obstruction.
CHEMBL1200395,Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,MMMNTDFSPSQXJP-UHFFFAOYSA-N,Small molecule,False,ORPHENADRINE CITRATE,1959.0,4.0,CHEMBL900,False,True,['Norflex' 'Orphenadrine citrate'],"['NSC-757238' 'Orphenadine citrate' 'Orphenadrine (citrate)'
 'Orphenadrine Citrate' 'Orphenadrine citrate'
 'Orphenadrine dihydrogen citrate']","[('DailyMed', array(['orphenadrine%20citrate'], dtype=object)), ('PubChem', array(['11532864', '144204876', '144207092', '144211396', '170464910',
       '26748176'], dtype=object)), ('chEBI', array(['7790'], dtype=object))]",,"{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}","[ENSG00000103546,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000196639,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for pain.
CHEMBL1200927,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,DBAKFASWICGISY-DASCVMRKSA-N,Small molecule,False,DEXCHLORPHENIRAMINE MALEATE,1981.0,4.0,CHEMBL1201353,False,True,['Dexchlorpheniramine maleate' 'Polaramine'],"['Chlorpheniramine d-form maleate' 'Chlorpheniramine maleate, (s)-'
 'D-chlorpheniramine maleate' 'Dexchlorpheniramine maleate' 'NSC-759156']","[('DailyMed', array(['dexchlorpheniramine%20maleate'], dtype=object)), ('PubChem', array(['26747471', '26747472', '49681543', '50106017'], dtype=object)), ('drugbank', array(['DB09555'], dtype=object)), ('chEBI', array(['4465'], dtype=object))]",,"{'rows': array(['EFO_0005531', 'EFO_0007141', 'EFO_1001417', 'MONDO_0005271',
       'EFO_0005854', 'EFO_0003958', 'MONDO_0005301', 'EFO_0003956',
       'EFO_0005532', 'EFO_0007533'], dtype=object), 'count': 10}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 3 investigational indications.
CHEMBL1201067,CC(O)C(=O)O.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2,GLPUBCPQWZZFNJ-UHFFFAOYSA-N,Small molecule,False,BIPERIDEN LACTATE,1961.0,4.0,CHEMBL1101,False,True,['Akineton'],['Biperiden lactate'],,,"{'rows': array(['MONDO_0043510'], dtype=object), 'count': 1}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961 and has 1 investigational indication.
CHEMBL1201269,CC(C)(N)Cc1ccc(Cl)cc1,ZCKAMNXUHHNZLN-UHFFFAOYSA-N,Small molecule,False,CHLORPHENTERMINE,1982.0,4.0,,True,True,[],['Chlorphentermine'],"[('PubChem', array(['29216103'], dtype=object)), ('Wikipedia', array(['Chlorphentermine'], dtype=object)), ('drugbank', array(['DB01556'], dtype=object)), ('chEBI', array(['3646'], dtype=object))]",['CHEMBL1200595'],,[ENSG00000108576],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201589,,,Antibody,True,OMALIZUMAB,2003.0,4.0,,False,True,['Xolair'],"['CT-P39' 'Ct-p39' 'GBR 310' 'Gbr-310' 'Hs632' 'IGE25' 'OLIZUMAB'
 'Omalizumab' 'Omalizumab biosimilar - synermore' 'RG-3648' 'RHUMAB-E25'
 'SYN-008' 'Syn008']","[('DailyMed', array(['omalizumab'], dtype=object)), ('DrugCentral', array(['4972'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xolair'],
      dtype=object)), ('Wikipedia', array(['Omalizumab'], dtype=object))]",,"{'rows': array(['EFO_0007486', 'MONDO_0021063', 'EFO_0007187', 'EFO_0009482',
       'Orphanet_2314', 'MONDO_0001085', 'EFO_1001890', 'MONDO_0004979',
       'MONDO_0100096', 'EFO_1000685', 'EFO_0000540', 'EFO_0009661',
       'EFO_0000274', 'EFO_0005532', 'EFO_0007425', 'MONDO_0005271',
       'EFO_0007369', 'EFO_0008507', 'EFO_0005854', 'EFO_1001881',
       'MONDO_0007915', 'EFO_0003956', 'EFO_0005531', 'HP_0006536',
       'EFO_1001463', 'EFO_0000341', 'EFO_0004232'], dtype=object), 'count': 27}",[ENSG00000211891],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 24 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1490,OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1,HWHLPVGTWGOCJO-UHFFFAOYSA-N,Small molecule,False,TRIHEXYPHENIDYL,1949.0,4.0,,False,True,[],['Apo-trihex' 'NSC-12268' 'Trihexyphenidyl'],"[('PubChem', array(['50105266', '90341555'], dtype=object)), ('Wikipedia', array(['Trihexyphenidyl'], dtype=object)), ('drugbank', array(['DB00376'], dtype=object)), ('chEBI', array(['9720'], dtype=object))]",['CHEMBL1092'],"{'rows': array(['MONDO_0005180', 'MONDO_0003441'], dtype=object), 'count': 2}",[ENSG00000168539],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1949 and is indicated for parkinson disease and has 1 investigational indication.
CHEMBL2105646,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,ORFLZNAGUTZRLQ-ZMBVWFSWSA-N,Protein,False,LARAZOTIDE,,3.0,,False,False,[],['AT-2347' 'Larazotide'],"[('drugbank', array(['DB05645'], dtype=object))]",['CHEMBL2103815'],"{'rows': array(['EFO_0001060', 'EFO_0001060'], dtype=object), 'count': 2}","[ENSG00000117971,ENSG00000080644]",Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2106155,COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1.Cl,OJIIZIWOLTYOBS-UHFFFAOYSA-N,Small molecule,False,ENCAINIDE HYDROCHLORIDE,1986.0,4.0,CHEMBL315838,True,True,[],"['Encainide hcl' 'Encainide hydrochloride' 'MJ 9067-1' 'MJ-9067'
 'MJ-9067-1']","[('PubChem', array(['144207047'], dtype=object)), ('chEBI', array(['59880'], dtype=object))]",,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. It was withdrawn in at least one region.
CHEMBL2107862,,,Oligonucleotide,False,RINTATOLIMOD,,3.0,,False,False,['Ampligen'],['Atvogen' 'Poly i : poly c12u' 'Poly i: poly c12u' 'Rintatolimod'],,,"{'rows': array(['EFO_0000756', 'MONDO_0044881', 'MONDO_0100096', 'EFO_0005537',
       'EFO_0004540', 'EFO_0001423', 'EFO_0000673', 'MONDO_0007254',
       'EFO_0006861', 'EFO_0000764', 'MONDO_0002158', 'EFO_0002618',
       'MONDO_0008170', 'MONDO_0004658'], dtype=object), 'count': 14}",[ENSG00000164342],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications.
CHEMBL2108131,,,Unknown,False,PLASMINOGEN,,3.0,,False,False,[],['Human plasminogen' 'Plasma trypsinogen' 'Plasminogen' 'Profibrinolysin'],,,"{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}","[ENSG00000171560,ENSG00000171564,ENSG00000171557]",Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2109288,,,Antibody drug conjugate,False,BIVATUZUMAB MERTANSINE,,1.0,,False,False,[],['BIWA-1-DM1' 'Bivatuzumab mertansine' 'Biwa-4 mertansine'],,,,"[ENSG00000026508,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of I.
CHEMBL2109667,,,Antibody,False,SIMTUZUMAB,,2.0,,False,False,[],['AB-0024' 'AB0024' 'GS-6624' 'Simtuzumab'],,,"{'rows': array(['EFO_1001951', 'EFO_0001422', 'EFO_0002618', 'EFO_0004268',
       'MONDO_0044903', 'EFO_0000616', 'EFO_0000768'], dtype=object), 'count': 7}",[ENSG00000134013],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL2109678,,,Antibody,False,HUJ591 177LU,,2.0,,False,False,[],['HUJ591' 'Huj591 (177lu)' 'Huj591 177lu'],,,"{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}",[ENSG00000086205],Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL2110730,CSCC[C@H](N)C(=O)N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21,VOYCNOJFAJAILW-CAMHOICYSA-N,Small molecule,False,POMAGLUMETAD METHIONIL ANHYDROUS,,3.0,,False,False,[],['LY-2140023' 'LY2140023' 'Ly2140023' 'Pomaglumetad methionil anhydrous'],,['CHEMBL2105707'],"{'rows': array(['MONDO_0005090', 'EFO_0004701', 'EFO_0005407', 'EFO_0001358'],
      dtype=object), 'count': 4}","[ENSG00000198822,ENSG00000164082]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL278020,CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,ALWKGYPQUAPLQC-UHFFFAOYSA-N,Small molecule,False,NEOSTIGMINE,2013.0,4.0,,False,True,[],"['Miostin' 'Neostigmine' 'Neostigmine (cation)' 'Neostigmine cation'
 'Neostigmine hydroxide' 'Neostigmine ion']","[('PubChem', array(['11111527', '11111528', '26756597', '90340848'], dtype=object)), ('drugbank', array(['DB01400'], dtype=object)), ('chEBI', array(['7514'], dtype=object))]",['CHEMBL211471' 'CHEMBL54126'],"{'rows': array(['EFO_0004209', 'EFO_0004991', 'EFO_1000948', 'EFO_0005323',
       'MONDO_0007254', 'HP_0025267', 'EFO_0001074', 'EFO_0009516',
       'HP_0002315', 'MONDO_0005041', 'EFO_0004888', 'EFO_0003843'],
      dtype=object), 'count': 12}",[ENSG00000087085],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for myasthenia gravis and glaucoma and has 10 investigational indications.
CHEMBL4113131,C[C@@H]1CN(C(=O)c2ccc(NC(=O)c3cc(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c(N)nn3)cc2)C[C@H](C)N1,GLYMPHUVMRFTFV-QLFBSQMISA-N,Small molecule,False,ENSARTINIB,,3.0,,False,False,[],['Ensartinib' 'X-396'],"[('drugbank', array(['DB14860'], dtype=object))]",['CHEMBL4297219'],"{'rows': array(['MONDO_0008903', 'EFO_0003060', 'EFO_0003060', 'EFO_0000756'],
      dtype=object), 'count': 4}",[ENSG00000171094],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4297190,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1,TTZSNFLLYPYKIL-UHFFFAOYSA-N,Small molecule,False,SURUFATINIB,,3.0,,False,False,[],['HMPL-012' 'Hmpl-012' 'Sulfatinib' 'Surufatinib'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SURUFATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15106'], dtype=object))]",,"{'rows': array(['EFO_0000503', 'EFO_0001421', 'EFO_0003086', 'EFO_0003860',
       'EFO_0005537', 'EFO_0003060', 'EFO_0000702', 'EFO_0000616',
       'EFO_0002618', 'EFO_0000637', 'EFO_0006859', 'MONDO_0007254',
       'EFO_0004142', 'MONDO_0005184', 'EFO_1001901', 'EFO_0000691',
       'EFO_1001951', 'EFO_0002892', 'MONDO_0005575', 'EFO_1001968',
       'MONDO_0003060', 'MONDO_0002120', 'EFO_0000182', 'EFO_0004252',
       'MONDO_0008170', 'MONDO_0002108'], dtype=object), 'count': 26}","[ENSG00000077782,ENSG00000102755,ENSG00000037280,ENSG00000128052]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications.
CHEMBL4297509,CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1,SIFNOOUKXBRGGB-AREMUKBSSA-N,Small molecule,False,ELACESTRANT,2023.0,4.0,,False,True,[],['ER-306323' 'Elacestrant' 'RAD-1901' 'RAD1901' 'Rad1901'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELACESTRANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06374'], dtype=object))]",['CHEMBL4594273'],"{'rows': array(['HP_0031217', 'EFO_0006861', 'EFO_0003869', 'EFO_0000305',
       'EFO_0003869', 'MONDO_0007254'], dtype=object), 'count': 6}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for male breast carcinoma and breast neoplasm and has 4 investigational indications.
CHEMBL4594298,COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2,AHJUHHDDCJQACA-UHFFFAOYSA-N,Small molecule,False,ENCEQUIDAR,,3.0,,False,False,[],['Encequidar' 'HM-30181' 'HM30181' 'HM30181AK' 'Pgp inhibitor hm30181ak'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENCEQUIDAR/relevant/1/'],
      dtype=object))]",['CHEMBL4594299'],"{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0000616', 'EFO_0003968',
       'EFO_0005537', 'EFO_0003968'], dtype=object), 'count': 6}",[ENSG00000085563],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL716,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,URKOMYMAXPYINW-UHFFFAOYSA-N,Small molecule,True,QUETIAPINE,1997.0,4.0,,False,True,"['Atrolak xl' 'Biquelle xl' 'Brancico xl' 'Ebesque xl' 'Mintreleq xl'
 'Psyquet xl' 'Seotiapim xl' 'Seroquel' 'Seroquel xl' 'Sondate xl'
 'Tenprolide xl' 'Zaluron xl']",['NSC-758918' 'Norsic' 'Quetiapine' 'Quetiapine extended release'],"[('PubChem', array(['144205090', '170465146', '26749928', '29215183', '49666155'],
      dtype=object)), ('Wikipedia', array(['Quetiapine'], dtype=object)), ('drugbank', array(['DB01224'], dtype=object)), ('chEBI', array(['8707'], dtype=object))]",['CHEMBL1200911' 'CHEMBL3188993'],"{'rows': array(['MONDO_0002009', 'MONDO_0005301', 'EFO_0004242', 'EFO_0002610',
       'EFO_0004698', 'EFO_0005411', 'EFO_0009963', 'EFO_0007191',
       'EFO_0003918', 'EFO_0009854', 'MONDO_0005351', 'EFO_0009963',
       'HP_0000726', 'MONDO_0005180', 'MONDO_0002009', 'MONDO_0002050',
       'EFO_0005407', 'Orphanet_79292', 'EFO_0004247', 'EFO_0003888',
       'MONDO_0002050', 'MONDO_0007079', 'EFO_0000677', 'MONDO_0004985',
       'EFO_1001892', 'MONDO_0005090', 'EFO_0005230', 'EFO_0005411',
       'EFO_0003884', 'MONDO_0002046', 'EFO_0004242', 'HP_0012076',
       'EFO_1001917', 'HP_0000713', 'MONDO_0002009', 'EFO_1000904',
       'MONDO_0005090', 'EFO_0009267', 'EFO_0009964', 'EFO_0005230',
       'EFO_0005407', 'EFO_0004701', 'MONDO_0007079', 'HP_0000726',
       'MONDO_0004985', 'HP_0012076', 'EFO_1001917', 'EFO_0004257',
       'MONDO_0002009', 'EFO_0001358', 'EFO_0007453', 'HP_0100543'],
      dtype=object), 'count': 52}","[ENSG00000147246,ENSG00000102468,ENSG00000149295]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 7 approved and 38 investigational indications. This drug has a black box warning from the FDA.
CHEMBL109,CCCC(CCC)C(=O)O,NIJJYAXOARWZEE-UHFFFAOYSA-N,Small molecule,True,VALPROIC ACID,1978.0,4.0,,False,True,['Convulex' 'Depakene' 'Depakote' 'Stavzor' 'Valproic acid'],"['44089' 'NSC-93819' 'Pentanoic acid, 2-propyl' 'Valproate'
 'Valproic acid' 'Valproic acid extended release']","[('DailyMed', array(['valproic%20acid'], dtype=object)), ('PubChem', array(['144204642', '144209161', '144210920', '170465446', '17389523',
       '26752921', '399407', '90341449'], dtype=object)), ('TG-GATEs', array(['5'], dtype=object)), ('Wikipedia', array(['Valproic_acid'], dtype=object)), ('drugbank', array(['DB00313'], dtype=object)), ('chEBI', array(['39867'], dtype=object))]",['CHEMBL2315212' 'CHEMBL2105613' 'CHEMBL433'],"{'rows': array(['HP_0000713', 'EFO_0002939', 'HP_0001250', 'MONDO_0019200',
       'EFO_0004247', 'MONDO_0007254', 'MONDO_0019188', 'MONDO_0001187',
       'EFO_1000158', 'HP_0001250', 'EFO_0005762', 'MONDO_0002009',
       'MONDO_0004985', 'EFO_0004252', 'EFO_0005762', 'EFO_0000095',
       'EFO_0000181', 'MONDO_0019037', 'EFO_0005230', 'MONDO_0100342',
       'EFO_0000616', 'EFO_0000717', 'MONDO_0044970', 'EFO_0009430',
       'EFO_0000519', 'MONDO_0002050', 'EFO_0008526', 'MONDO_0004975',
       'EFO_0003833', 'EFO_0004263', 'EFO_0000095', 'EFO_0000691',
       'EFO_0008525', 'MONDO_0010604', 'EFO_0006859', 'MONDO_0004976',
       'EFO_0009267', 'MONDO_0010826', 'HP_0000713', 'MONDO_0005277',
       'EFO_1001951', 'MONDO_0005277', 'HP_0007359', 'HP_0002121',
       'HP_0001250', 'EFO_0000180', 'MONDO_0007079', 'EFO_0000546',
       'MONDO_0004975', 'EFO_0004191', 'EFO_0001358', 'EFO_1000877',
       'Orphanet_83419', 'EFO_0002618', 'EFO_0003758', 'EFO_0000198',
       'EFO_0002499', 'EFO_1000877', 'MONDO_0008170', 'MONDO_0005277',
       'EFO_0000616', 'EFO_1001968', 'EFO_0008526', 'MONDO_0043510',
       'MONDO_0008903', 'EFO_0000519', 'MONDO_0004992', 'EFO_0003758',
       'EFO_0008525', 'HP_0000726', 'EFO_0000574', 'MONDO_0002974',
       'EFO_0000403', 'MONDO_0018105', 'EFO_0000616', 'EFO_0000474',
       'MONDO_0007254', 'MONDO_0004975', 'HP_0002121', 'MONDO_0007739',
       'EFO_0000565', 'MONDO_0004985', 'EFO_0007527', 'MONDO_0007079',
       'EFO_0000474', 'EFO_0000474', 'EFO_0000198', 'EFO_0000756',
       'EFO_0009963', 'EFO_0000702', 'EFO_0000764', 'MONDO_0005090',
       'HP_0010865', 'EFO_0003841', 'EFO_0003060', 'MONDO_0003478',
       'HP_0002013', 'MONDO_0008315', 'EFO_0004192', 'MONDO_0009293',
       'MONDO_0005090', 'EFO_0009963', 'HP_0031273', 'EFO_0001075',
       'EFO_0000222', 'MONDO_0004985', 'EFO_0000339', 'HP_0000726',
       'EFO_0000309', 'HP_0002039', 'EFO_1001469', 'EFO_0000403'],
      dtype=object), 'count': 112}",[ENSG00000112294],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 13 approved and 84 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1186610,CCCC(CCC)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C,XGGHHHBGPSNXFE-ZSHCYNCHSA-N,Small molecule,False,ANISOTROPINE,1962.0,4.0,,False,True,[],['Anisotropine' 'Octatropine'],"[('PubChem', array(['50103910', '50103911'], dtype=object)), ('Wikipedia', array(['Octatropine_methylbromide'], dtype=object))]",['CHEMBL1578'],,"[ENSG00000133019,ENSG00000168539]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962.
CHEMBL1200532,CN1CCC(CN2c3ccccc3Sc3ccccc32)C1.Cl,IEISBKIVLDXSMZ-UHFFFAOYSA-N,Small molecule,False,METHDILAZINE HYDROCHLORIDE,1982.0,4.0,CHEMBL1200959,False,True,['Methdilazine hydrochloride' 'Tacaryl'],['Methdilazine hcl' 'Methdilazine hydrochloride' 'NSC-169091'],"[('PubChem', array(['144203598', '562732'], dtype=object))]",,,[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200825,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl,FJQXCDYVZAHXNS-UHFFFAOYSA-N,Small molecule,True,METHADONE HYDROCHLORIDE,1947.0,4.0,CHEMBL651,False,True,"['Dolophine hydrochloride' 'Eptadone' 'Martindale'
 'Methadone hydrochloride' 'Methadone hydrochloride intensol' 'Methadose'
 'Metharose' 'Methex' 'Physeptone' 'Pinadone' 'Synastone' 'Westadone']","['AN-148' 'Butalgin' 'Dolofin hydrochloride' 'Dolophine' 'Fenadone'
 'Heptadon' 'Ketalgin hydrochloride' 'Mecodin' 'Methadone hcl'
 'Methadone hydrochloride' 'Methadone hydrochloride cii'
 'Methadonium chloride' 'NSC-19600' 'Phenadone hydrochloride']","[('DailyMed', array(['methadone%20hydrochloride'], dtype=object)), ('PubChem', array(['144206448', '144209224', '144210950'], dtype=object)), ('chEBI', array(['50140'], dtype=object))]",,"{'rows': array(['HP_0008419', 'EFO_0005611', 'EFO_0003843', 'EFO_0000764',
       'EFO_0003890'], dtype=object), 'count': 5}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1232461,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21,AAAQFGUYHFJNHI-SFHVURJKSA-N,Small molecule,False,MOLIBRESIB,,2.0,,False,False,[],"['Bet inhibitor gsk525762' 'GSK-525762' 'GSK-525762A' 'GSK525762'
 'GSK525762A' 'I-BET 762' 'Molibresib']",,['CHEMBL4297217'],"{'rows': array(['EFO_0000616', 'EFO_0000313'], dtype=object), 'count': 2}","[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL1677,Cl.Nc1c2c(nc3ccccc13)CCCC2,ZUFVXZVXEJHHBN-UHFFFAOYSA-N,Small molecule,False,TACRINE HYDROCHLORIDE,1993.0,4.0,CHEMBL95,False,True,['Alzyme' 'Cognex'],['CI-970' 'NSC-72108' 'Tacrine hcl' 'Tacrine hydrochloride'],"[('PubChem', array(['11532943', '144207497', '17388697', '26747422', '49732004',
       '50105756'], dtype=object))]",,,"[ENSG00000114200,ENSG00000087085]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993.
CHEMBL2105659,CCc1c(C(=O)C(N)=O)c2c(OCC(=O)OC)cccc2n1Cc1ccccc1,VJYDOJXJUCJUHL-UHFFFAOYSA-N,Small molecule,False,VARESPLADIB METHYL,,3.0,,False,False,[],"['A-002' 'LY-333013' 'LY333013' 'S-3013' 'Varespladib methyl'
 'Varespladib methyl ester']","[('drugbank', array(['DB05737'], dtype=object))]",,"{'rows': array(['EFO_0003086', 'EFO_0005672', 'EFO_0001645'], dtype=object), 'count': 3}","[ENSG00000127472,ENSG00000188257,ENSG00000069764]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL2107870,,,Oligonucleotide,False,PEGNIVACOGIN,,3.0,,False,False,[],['Pegnivacogin' 'RB-006' 'RB006' 'REG-1' 'REG1'],,,"{'rows': array(['EFO_0005672', 'EFO_0001645'], dtype=object), 'count': 2}",[ENSG00000101981],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL2108431,,,Antibody,False,METELIMUMAB,,2.0,,False,False,[],['CAT-192' 'Metelimumab'],,,,[ENSG00000105329],Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108474,,,Antibody,False,MASLIMOMAB,,2.0,,False,False,[],['Maslimomab'],,,,"[ENSG00000211810,ENSG00000277734,ENSG00000278030,ENSG00000211699]",Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109351,,,Antibody,False,FBT-A05,,1.0,,False,False,[],['FBT-A05'],,,,"[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000156738]",Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109372,,,Antibody,False,MEDI-565,,1.0,,False,False,[],['MEDI-565' 'Medi-565'],,,"{'rows': array(['EFO_0000228'], dtype=object), 'count': 1}","[ENSG00000105388,ENSG00000198851]",Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL2109430,,,Antibody,False,GIMSILUMAB,,2.0,,False,False,[],['Gimsilumab' 'MORAb-022'],,,"{'rows': array(['EFO_0000685', 'MONDO_0100096'], dtype=object), 'count': 2}",[ENSG00000164400],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2159122,COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O,QFNHIDANIVGXPE-FNZWTVRRSA-N,Small molecule,False,ELUXADOLINE,2015.0,4.0,,False,True,['Truberzi' 'Viberzi'],['Eluxadoline' 'JNJ-27018966'],"[('DailyMed', array(['eluxadoline'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi'],
      dtype=object)), ('drugbank', array(['DB09272'], dtype=object)), ('chEBI', array(['85980'], dtype=object))]",,"{'rows': array(['MONDO_0001673', 'EFO_0000555'], dtype=object), 'count': 2}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for diarrheal disease and irritable bowel syndrome.
CHEMBL2364619,C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13,ATCVVCBJNHXIEX-ZAHKBLQYSA-O,Small molecule,False,METHYLSAMIDORPHAN,,2.0,,False,False,[],"['ALKS 37' 'ALKS-37 CATION' 'ALKS37' 'Methylsamidorphan'
 'Methylsamidorphan cation' 'Methylsamidorphan ion' 'RDC-1036 CATION'
 'RDC-1036-00' 'RDC-103600' 'RDC-103603' 'Rdc-1036']","[('drugbank', array(['DB15241'], dtype=object))]",['CHEMBL2364620'],"{'rows': array(['HP_0002019'], dtype=object), 'count': 1}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3301577,,,Protein,False,IPAFRICEPT,,2.0,,False,False,[],['Ipafricept' 'OMP-54F28'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000177283],Protein drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545173,,,Small molecule,False,IRX4310,,1.0,,False,False,[],['Irx4310'],,,,"[ENSG00000172819,ENSG00000077092,ENSG00000131759]",Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707222,CCCC[C@]1(CC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2cccc(NC(=O)N[C@@H]3O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](OCc4ccccc4)[C@H]3O)c2)[C@H]1O,ULVBLFBUTQMAGZ-RTNCXNSASA-N,Small molecule,False,VOLIXIBAT,,2.0,,False,False,[],['SAR-548304 FREE ACID' 'Volixibat'],"[('drugbank', array(['DB13914'], dtype=object))]",['CHEMBL3956446' 'CHEMBL3707221'],"{'rows': array(['EFO_0004268', 'MONDO_0019072', 'EFO_1001486'], dtype=object), 'count': 3}",[ENSG00000125255],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL378544,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,KDQAABAKXDWYSZ-PNYVAJAMSA-N,Small molecule,False,VINBLASTINE SULFATE,1965.0,4.0,CHEMBL159,False,True,"['Velban' 'Velbe' 'Vinblast,lederle' 'Vinblastine sulfate']","['29060-LE' '29060LE' 'Alkaban-aq' 'NSC-49842' 'Vinblastine sulfate'
 'Vinblastine sulphate' 'Vinblastini sulfas' 'Vincaleukoblastine sulfate'
 'Vlb monosulfate']","[('DailyMed', array(['vinblastine%20sulfate'], dtype=object)), ('PubChem', array(['144205051', '144206288', '170464976', '170464977', '26663016',
       '56462989', '855758'], dtype=object))]",,"{'rows': array(['EFO_0000588', 'MONDO_0002041', 'MONDO_0008170', 'EFO_0000691',
       'EFO_0000574', 'MONDO_0008903', 'MONDO_0002367', 'MONDO_0004986',
       'EFO_0000756', 'MONDO_0001187', 'EFO_0004281', 'MONDO_0003751',
       'MONDO_0008315', 'EFO_0009907', 'EFO_0001642', 'MONDO_0009348',
       'EFO_0000183', 'MONDO_0004192', 'MONDO_0002974', 'EFO_0000389'],
      dtype=object), 'count': 20}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 5 approved and 15 investigational indications.
CHEMBL3809489,Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2,KXMZDGSRSGHMMK-VWLOTQADSA-N,Small molecule,False,BEMCENTINIB,,2.0,,False,False,[],"['BGB 324' 'BGB-324' 'BGB324' 'Bemcentinib' 'CS-1046' 'HY-15150'
 'KB-80319' 'QC-11751' 'R 428' 'R-428' 'R428' 'SYN-1131' 'SYN1131'
 'W-5845']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BEMCENTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12411'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_0000571', 'EFO_0002618', 'EFO_1000984',
       'EFO_0000756', 'EFO_0003060', 'EFO_0000222', 'EFO_0000198',
       'EFO_0000616', 'EFO_0000588', 'EFO_1000158'], dtype=object), 'count': 11}",[ENSG00000167601],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications.
CHEMBL4297455,O=C(O)Cc1nn(Cc2nc3cc(C(F)(F)F)ccc3s2)c(=O)c2nccnc12,YRGPAXAVTDMKDK-UHFFFAOYSA-N,Small molecule,False,CAFICRESTAT,,3.0,,False,False,[],['AT-001' 'Aldose reductase-in-1' 'At-001' 'Caficrestat'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CAFICRESTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15121'], dtype=object))]",,"{'rows': array(['MONDO_0100096', 'EFO_1001458'], dtype=object), 'count': 2}",[ENSG00000085662],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL4297573,,,Protein,True,TAGRAXOFUSP,2018.0,4.0,,False,True,['Elzonris'],"['DT-3881L3' 'DT388IL3' 'MOLECULE-129' 'Molecule 129' 'SL-401' 'Sl-401'
 'Tagraxofusp' 'Tagraxofusp erzs']","[('DailyMed', array(['tagraxofusp-erzs'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/elzonris'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAGRAXOFUSP/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001779', 'EFO_0000222', 'EFO_0000616', 'EFO_0000574',
       'EFO_0000198'], dtype=object), 'count': 5}","[ENSG00000292332,ENSG00000185291,ENSG00000167658]",Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.
CHEMBL441738,CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C,UAHFGYDRQSXQEB-LEBBXHLNSA-N,Protein,False,AFAMELANOTIDE,2014.0,4.0,,False,True,['Scenesse'],"['(nle4,d-phe7)-.alpha.-msh' 'Afamelanotide' 'CUV-1647' 'CUV1647'
 'Melanotan' 'Melanotan i' 'Melanotan-1' 'Ndp-alpha-msh']","[('DailyMed', array(['afamelanotide'], dtype=object)), ('Wikipedia', array(['Afamelanotide'], dtype=object)), ('drugbank', array(['DB04931'], dtype=object))]",['CHEMBL4297213'],"{'rows': array(['EFO_0005531', 'EFO_0004208', 'MONDO_0019600', 'MONDO_0001676',
       'EFO_0003894', 'MONDO_0008297', 'HP_0002140'], dtype=object), 'count': 7}",[ENSG00000258839],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for erythropoietic protoporphyria and has 6 investigational indications.
CHEMBL4461070,O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5ccc(F)cc5)nn34)cc2s1,ODIUNTQOXRXOIV-UHFFFAOYSA-N,Small molecule,False,SAR-125844,,2.0,,False,False,[],['SAR 125844' 'SAR-125844' 'SAR125844' 'Sar-125844'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000105976],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4594542,,,Protein,False,EFLEPEDOCOKIN ALFA,,2.0,,False,False,[],['Eflepedocokin alfa' 'F 652' 'F-652' 'Il-22 dimer f-652' 'Promenakin'],,,"{'rows': array(['MONDO_0100096', 'EFO_1001345', 'MONDO_0013730'], dtype=object), 'count': 3}","[ENSG00000243646,ENSG00000142677]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4596392,CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC,BZZKEPGENYLQSC-UHFFFAOYSA-N,Small molecule,False,CRAVACITINIB,2022.0,4.0,,False,True,[],[],,['CHEMBL4435170'],"{'rows': array(['EFO_0003778', 'EFO_0003834', 'EFO_0000729', 'EFO_0000540',
       'EFO_0003086', 'HP_0000999', 'EFO_0000676', 'MONDO_0007915',
       'EFO_0004192', 'EFO_0005761', 'HP_0001410', 'MP_0001845'],
      dtype=object), 'count': 12}",[ENSG00000105397],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 11 investigational indications.
CHEMBL463981,O=S(=O)(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)c1ccc(Cl)s1,PSXOKXJMVRSARX-SCSAIBSYSA-N,Small molecule,False,BEGACESTAT,,2.0,,False,False,[],['Begacestat' 'GSI-953'],"[('drugbank', array(['DB12263'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL478858,CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21,TXIIZHHIOHVWJD-UHFFFAOYSA-N,Small molecule,False,PACTIMIBE,,2.0,,False,False,[],['Pactimibe'],"[('drugbank', array(['DB12971'], dtype=object))]",['CHEMBL564483' 'CHEMBL447977'],"{'rows': array(['EFO_0003914', 'EFO_0001645'], dtype=object), 'count': 2}","[ENSG00000057252,ENSG00000167780]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL918,NC(=O)NC(=O)Cc1ccccc1,XPFRXWCVYUEORT-UHFFFAOYSA-N,Small molecule,False,PHENACEMIDE,1951.0,4.0,,False,True,['Phenurone'],['NSC-39458' 'Phenacemide'],"[('PubChem', array(['144204878', '170465322', '26748194'], dtype=object)), ('Wikipedia', array(['Phenacemide'], dtype=object)), ('drugbank', array(['DB01121'], dtype=object)), ('chEBI', array(['8049'], dtype=object))]",,"{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}","[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for epilepsy.
CHEMBL1200659,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O,OYFJQPXVCSSHAI-QFPUQLAESA-N,Small molecule,True,ENALAPRIL MALEATE,1985.0,4.0,CHEMBL578,False,True,"['Ednyt' 'Enalapril maleate' 'Enapren' 'Epaned' 'Epaned kit' 'Innovace'
 'Pralenal 10' 'Pralenal 2.5' 'Pralenal 20' 'Pralenal 5' 'Renitec'
 'Vasotec' 'Xanef']","['Amprace' 'Cardiovet' 'Enacard' 'Enalapril maleate' 'Glioten' 'Hipoartel'
 'MK-421' 'NSC-758143' 'Naprilene' 'Reniten' 'Renivace' 'Xanef']","[('DailyMed', array(['enalapril%20maleate'], dtype=object)), ('PubChem', array(['56424090', '855584'], dtype=object)), ('chEBI', array(['4785'], dtype=object))]",,"{'rows': array(['HP_0000093', 'EFO_0005669', 'EFO_0003144', 'EFO_0000373',
       'EFO_0000537', 'EFO_0000668', 'EFO_0000685'], dtype=object), 'count': 7}",[ENSG00000159640],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1201581,,,Antibody,True,INFLIXIMAB,1998.0,4.0,,False,True,['Inflectra' 'Remicade' 'Remsima'],"['ABP 710' 'Abp-710' 'Avsola' 'BOW015' 'Bow-015' 'Ct p13' 'Ct-p-13'
 'Ct-p13' 'Infimab' 'Infliximab' 'Infliximab (janssen)'
 'Infliximab (remicade)' 'Infliximab abda' 'Infliximab axxq'
 'Infliximab biosimilar (amgen)' 'Infliximab biosimilar (celltrion)'
 'Infliximab biosimilar (pfizer)' 'Infliximab biosimilar (sb-2)'
 'Infliximab dyyb' 'Infliximab qbtx' 'Infliximab-abda' 'Infliximab-axxq'
 'Infliximab-dyyb' 'Infliximab-hjmt' 'Infliximab-pfizer' 'Infliximab-qbtx'
 'Ixifi' 'NI-071' 'Pf-06438179' 'TA-650' 'Zessly' 'cA2']","[('DailyMed', array(['infliximab', 'infliximab-abda', 'infliximab-axxq',
       'infliximab-dyyb'], dtype=object)), ('DrugCentral', array(['4974'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/remsima'],
      dtype=object)), ('Wikipedia', array(['Infliximab'], dtype=object))]",,"{'rows': array(['HP_0012378', 'EFO_0007527', 'EFO_0003767', 'HP_0002039',
       'EFO_1001209', 'MONDO_0005041', 'EFO_0003047', 'EFO_0007168',
       'EFO_0000706', 'MONDO_0013730', 'EFO_1000784', 'EFO_0000685',
       'EFO_0000198', 'MONDO_0005178', 'EFO_0007460', 'EFO_0003780',
       'EFO_0000676', 'EFO_0003778', 'EFO_0002617', 'HP_0003419',
       'EFO_0005297', 'EFO_0003872', 'MONDO_0008903', 'MONDO_0001718',
       'EFO_0008518', 'EFO_0001065', 'EFO_0000398', 'EFO_0000341',
       'MONDO_0019338', 'EFO_0004232', 'MONDO_0005147', 'HP_0004326',
       'EFO_1000710', 'EFO_0004683', 'EFO_0000540', 'EFO_0000783',
       'EFO_0002687', 'EFO_0000384', 'EFO_0004599', 'EFO_0004246',
       'EFO_0002609', 'EFO_0003898', 'MONDO_0004985', 'MONDO_0100096',
       'MONDO_0018305', 'EFO_1000747', 'EFO_1001857', 'EFO_0004276',
       'EFO_0004775', 'EFO_0004220', 'EFO_0000729', 'EFO_1000749'],
      dtype=object), 'count': 52}",[ENSG00000232810],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 7 approved and 45 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1236936,O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1,WPYWMXNXEZFMAK-UHFFFAOYSA-N,Small molecule,False,CINACIGUAT,,2.0,,False,False,[],['BAY 58-2667' 'Cinaciguat'],,,"{'rows': array(['EFO_0000373', 'EFO_0003144'], dtype=object), 'count': 2}","[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL135,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,VOXZDWNPVJITMN-ZBRFXRBCSA-N,Small molecule,True,ESTRADIOL,1975.0,4.0,,False,True,"['Adgyn estro' 'Alora' 'Aquagen' 'Bedol' 'Climara' 'Climara Pro'
 'Dermestril 100' 'Dermestril 25' 'Dermestril 50' 'Dermestril septem 25'
 'Dermestril septem 50' 'Dermestril septem 75' 'Divigel' 'E-Cypionate'
 'Elestrin' 'Elleste solo' 'Elleste solo mx 40' 'Elleste solo mx 80'
 'Esclim' 'Estrace' 'Estraderm' 'Estraderm mx 100' 'Estraderm mx 25'
 'Estraderm mx 50' 'Estraderm mx 75' 'Estraderm tts 100'
 'Estraderm tts 25' 'Estraderm tts 50' 'Estradiol' 'Estrasorb' 'Estring'
 'Estrogel' 'Evamist' 'Evorel 100' 'Evorel 25' 'Evorel 50' 'Evorel 75'
 'Fematrix 40' 'Fematrix 80' 'Fempatch' 'Femseven 100' 'Femseven 50'
 'Femseven 75' 'Gynodiol' 'Gynogen' 'Imvexxy' 'Innofem' 'Menorest 37.5'
 'Menorest 50' 'Menorest 75' 'Menoring 50' 'Menostar' 'Minivelle'
 'Oestradiol' 'Progynova ts' 'Sandrena' 'Vagifem' 'Vagifem 18' 'Vagifem 8'
 'Vivelle' 'Vivelle-dot' 'Zumenon']","['17-.beta.-oestradiol' '17-beta-oestradiol' '17.beta.-estradiol'
 '17beta-estradiol' 'Agofollin' 'Alfatradiol' 'Depo-Estradiol'
 'Destradiol' 'Dihydrotheelin' 'Dihydroxyestrin' 'Estradiol'
 'Estradiol 17-beta' 'Estradiol anhydrous' 'Estradiol hemihydrate'
 'Estradiol valerate metabolite e2' 'Estrasorb' 'Gynergon' 'Gynoestryl'
 'NSC-20293' 'NSC-9895' 'Oestradiol' 'WC-3011' 'WC3011']","[('DailyMed', array(['estradiol'], dtype=object)), ('PubChem', array(['144204699', '144209255', '144210608', '17389898', '26753050',
       '26753051', '26753052', '29215115', '29215116', '29215117',
       '50105619', '50105620', '50124031', '56422158', '8139865',
       '90341590'], dtype=object)), ('Wikipedia', array(['Estradiol'], dtype=object)), ('drugbank', array(['DB00783'], dtype=object)), ('chEBI', array(['16469'], dtype=object))]",,"{'rows': array(['EFO_0003103', 'EFO_0009314', 'MONDO_0005147', 'MONDO_0005148',
       'EFO_0001358', 'MONDO_0005301', 'HP_0031217', 'EFO_0005204',
       'EFO_0000731', 'EFO_1000906', 'EFO_0000545', 'MONDO_0007254',
       'EFO_0003843', 'HP_0008209', 'EFO_0004714', 'GO_0042697',
       'EFO_0010269', 'HP_0030016', 'EFO_0003869', 'EFO_1001271',
       'MONDO_0005351', 'EFO_0005411', 'EFO_0004243', 'EFO_0004266',
       'EFO_1001249', 'EFO_1000859', 'EFO_0003854', 'EFO_1001375',
       'HP_0100607', 'MONDO_0002146', 'EFO_1000096', 'EFO_0000764',
       'MONDO_0002050', 'Orphanet_145', 'EFO_0001663', 'MONDO_0005090',
       'MONDO_0008315', 'MONDO_0005277', 'EFO_0000305', 'MONDO_0100096',
       'EFO_0001065', 'EFO_0005537', 'EFO_0000180', 'EFO_0001073',
       'EFO_0003914', 'EFO_0000660', 'MONDO_0001410', 'HP_0000938',
       'MONDO_0004975', 'EFO_0003882', 'EFO_0007453', 'MONDO_0019499'],
      dtype=object), 'count': 52}",[ENSG00000091831],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 13 approved and 39 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1441059,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,BNPSSFBOAGDEEL-UHFFFAOYSA-N,Small molecule,True,ALBUTEROL SULFATE,1982.0,4.0,CHEMBL714,False,True,"['Accuneb' 'Albuterol sulfate' 'Proair digihaler' 'Proair hfa'
 'Proair respiclick' 'Proventil' 'Proventil-hfa' 'Ventolin' 'Ventolin hfa'
 'Ventolin rotacaps' 'Volmax' 'Vospire er']","['Albuterol sulfate' 'Albuterol sulphate' 'Buventol' 'Ecovent' 'Hexotonal'
 'Loftan' 'NSC-289928' 'R03AC02' 'R03CC02' 'SCH 13949W SULFATE'
 'SCH-13949W SULFATE' 'Salamol' 'Salbumol' 'Salbutamol (as sulfate)'
 'Salbutamol sulfate' 'Salbutamol sulphate' 'Salbutamoli sulfas'
 'Sch 13949w sulphate' 'Sch-13949w sulphate' 'Sulbutamol (as sulphate)'
 'Sultanol' 'Torpex' 'Venetlin' 'Ventilastin' 'Vospire']","[('DailyMed', array(['albuterol%20sulfate'], dtype=object)), ('PubChem', array(['50107002'], dtype=object))]",,"{'rows': array(['EFO_0003818', 'MONDO_0100130', 'EFO_0000319', 'EFO_0000341',
       'MONDO_0004979', 'EFO_0008590'], dtype=object), 'count': 6}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for chronic obstructive pulmonary disease and asthma and has 4 investigational indications. This drug has a black box warning from the FDA.
CHEMBL146506,C/C(=C\c1ccc(OCCN2CCOCC2)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C,OUQPTBCOEKUHBH-LSDHQDQOSA-N,Small molecule,False,MOFAROTENE,,2.0,,False,False,[],['Mofarotene' 'RO 40-8757' 'Ro-408757'],,,,"[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]",Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1496,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,BPRHUIZQVSMCRT-VEUZHWNKSA-N,Small molecule,False,ROSUVASTATIN,2003.0,4.0,,False,True,[],['Creston' 'Rosuvastatin' 'X-plended' 'ZD-4522' 'ZD4522'],"[('Wikipedia', array(['Rosuvastatin'], dtype=object)), ('drugbank', array(['DB01098'], dtype=object)), ('chEBI', array(['38545'], dtype=object))]",['CHEMBL1744447'],"{'rows': array(['EFO_0003060', 'EFO_1001512', 'MONDO_0005147', 'EFO_1002048',
       'EFO_0009516', 'EFO_0009426', 'EFO_0000384', 'MONDO_0008170',
       'EFO_0000400', 'MONDO_0001583', 'EFO_0000668', 'EFO_0000319',
       'EFO_0001645', 'EFO_0001645', 'EFO_0000195', 'HP_0003124',
       'EFO_1001454', 'EFO_1001413', 'MONDO_0008315', 'EFO_0000537',
       'EFO_0003914', 'EFO_0000373', 'EFO_0000556', 'EFO_0002617',
       'MONDO_0005148', 'EFO_1000657', 'EFO_0000764', 'EFO_0003144',
       'EFO_1001150', 'MONDO_0100339', 'EFO_0000712', 'EFO_0003047',
       'EFO_0005672', 'EFO_0000729', 'EFO_0000540', 'EFO_0000589',
       'EFO_0004211', 'EFO_0000400', 'MONDO_0018473', 'MONDO_0004979',
       'MONDO_0004992', 'MONDO_0005180', 'MONDO_0019623', 'EFO_0000616',
       'EFO_1001951', 'MONDO_0021187', 'MONDO_0007915', 'EFO_0004272',
       'EFO_0004239', 'MONDO_0002050', 'MONDO_0021187', 'MONDO_0018328',
       'EFO_0600064', 'EFO_0003144', 'EFO_0000180', 'EFO_0008583',
       'EFO_0000649', 'EFO_0001068', 'MONDO_0018473', 'Orphanet_309005',
       'EFO_0000266', 'EFO_0000685', 'HP_0000083', 'EFO_1000049',
       'Orphanet_309005', 'EFO_0000537', 'EFO_0001073', 'EFO_0000701',
       'EFO_0003964', 'EFO_0004211', 'EFO_0005226', 'EFO_0000673',
       'EFO_0005669', 'HP_0003124', 'EFO_0005672', 'EFO_0004286',
       'Orphanet_79211', 'EFO_0003914', 'MONDO_0100096', 'EFO_0004911',
       'HP_0100806', 'MONDO_0021661', 'EFO_0000717', 'EFO_0009505',
       'EFO_0004911', 'EFO_0000612', 'EFO_0004826', 'EFO_1001249',
       'EFO_0000407', 'MONDO_0005148', 'MONDO_0007254', 'EFO_0000616',
       'EFO_0000341'], dtype=object), 'count': 93}",[ENSG00000113161],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved and 81 investigational indications.
CHEMBL1738757,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1,WVXNSAVVKYZVOE-UHFFFAOYSA-N,Small molecule,False,REBASTINIB,,2.0,,False,False,['Dp-1919'],['DCC-2036' 'DCC-2036 FREE BASE' 'DP-1919' 'Dcc-2036' 'Rebastinib'],"[('PubChem', array(['137276016'], dtype=object)), ('drugbank', array(['DB13005'], dtype=object)), ('chEBI', array(['62166'], dtype=object))]",['CHEMBL2107833'],"{'rows': array(['EFO_0000616', 'EFO_0000339'], dtype=object), 'count': 2}",[ENSG00000097007],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL285674,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,CDCHDCWJMGXXRH-UHFFFAOYSA-N,Small molecule,True,ESTAZOLAM,1990.0,4.0,,False,True,['Estazolam' 'Eurodin' 'Prosom'],['ABBOTT-47631' 'Estazolam' 'Estazolam civ' 'NSC-290818'],"[('DailyMed', array(['estazolam'], dtype=object)), ('PubChem', array(['144206162', '50113063'], dtype=object)), ('Wikipedia', array(['Estazolam'], dtype=object)), ('drugbank', array(['DB01215'], dtype=object)), ('chEBI', array(['4858'], dtype=object))]",,"{'rows': array(['EFO_0008568', 'EFO_0004698'], dtype=object), 'count': 2}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for insomnia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL3039529,C#Cc1cnc2nc(O)n(C(CC)CC)c2n1,RSQGZEAXODVTOL-UHFFFAOYSA-N,Small molecule,False,TIRASEMTIV,,3.0,,False,False,[],['CK-2017357' 'CK2017357' 'Tirasemtiv'],"[('drugbank', array(['DB12209'], dtype=object))]",,"{'rows': array(['EFO_0003876', 'EFO_0004265', 'EFO_0004991', 'MONDO_0004976'],
      dtype=object), 'count': 4}","[ENSG00000130598,ENSG00000130595,ENSG00000101470]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL3039531,Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O,NGYNBSHYFOFVLS-LBPRGKRZSA-N,Small molecule,False,DANIRIXIN,,2.0,,False,False,[],['Danirixin' 'GSK-1325756B' 'GSK1325756' 'GSK1325756B' 'Gsk1325756'],"[('drugbank', array(['DB11922'], dtype=object))]",['CHEMBL4560026'],"{'rows': array(['MONDO_0024355', 'EFO_0000341', 'EFO_1001413', 'EFO_0000763'],
      dtype=object), 'count': 4}",[ENSG00000180871],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3301586,,,Antibody drug conjugate,False,CLIVATUZUMAB TETRAXETAN,,2.0,,False,False,['Clivatucyn'],['Clivatuzumab tetraxetan' 'HPAM-4' 'IMMU-107' 'IgG-DOTA' 'hPAM4'],,,"{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}",[ENSG00000215182],Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3301593,Nc1ccc(C#Cc2cnn3c(C(F)(F)F)cc(-c4ccc(C(F)(F)F)cc4)nc23)cn1,DMJHZVARRXJSEG-UHFFFAOYSA-N,Small molecule,False,DECOGLURANT,,2.0,,False,False,[],['Decoglurant' 'RO-4995819' 'RO4995819' 'Rg1578'],"[('drugbank', array(['DB11923'], dtype=object))]",,"{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}","[ENSG00000164082,ENSG00000198822]",Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3544937,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1.Cl,IOFHDGSCWJNVRZ-UHFFFAOYSA-N,Small molecule,False,ZD-4190,,1.0,CHEMBL281872,False,False,[],['Zd-4190'],,,,[ENSG00000128052],Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545031,,,Small molecule,False,MK-1029,,2.0,,False,False,[],['Mk-1029'],,,"{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}",[ENSG00000183134],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL3545076,Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1,FYXRSVDHGLUMHB-UHFFFAOYSA-N,Small molecule,False,LY-2584702,,1.0,,False,False,[],['LY 2584702' 'LY2584702' 'Ly-2584702'],"[('drugbank', array(['DB12690'], dtype=object))]",['CHEMBL3911801' 'CHEMBL3909070'],"{'rows': array(['EFO_0000681', 'MONDO_0004992', 'EFO_0003060', 'EFO_1001901',
       'EFO_0009708'], dtype=object), 'count': 5}",[ENSG00000108443],Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications.
CHEMBL363295,CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C,UISARWKNNNHPGI-UHFFFAOYSA-N,Small molecule,False,TERODILINE,1986.0,4.0,,True,True,[],['Terodiline'],"[('Wikipedia', array(['Terodiline'], dtype=object)), ('drugbank', array(['DB13725'], dtype=object))]",['CHEMBL539770'],"{'rows': array(['HP_0000020', 'HP_0000103'], dtype=object), 'count': 2}","[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984,ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for urinary incontinence and polyuria.
CHEMBL4297904,,,Unknown,False,BAY-1093884,,2.0,,False,False,[],['BAY-1093884' 'BAY1093884' 'Bay-1093884' 'Bay1093884' 'Befovacimab'],,,"{'rows': array(['MONDO_0010604', 'MONDO_0010602', 'MONDO_0018660'], dtype=object), 'count': 3}",[ENSG00000003436],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4298001,,,Antibody,False,CETRELIMAB,,3.0,,False,False,[],['Cetrelimab' 'JNJ-63723283' 'JNJ63723283' 'Jnj 63723283' 'Jnj-63723283'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CETRELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0008528', 'EFO_0003060', 'EFO_0000616', 'EFO_0000673',
       'MONDO_0001187', 'EFO_0004239', 'EFO_0000294', 'EFO_0001378',
       'EFO_0001663'], dtype=object), 'count': 9}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications.
CHEMBL447664,Cc1cc(Cn2nnc3c(-c4ccco4)nc(N)nc32)ccc1N,HQSBCDPYXDGTCL-UHFFFAOYSA-N,Small molecule,False,VIPADENANT,,2.0,,False,False,[],"['BIIB-014' 'BIIB014' 'Biib014' 'CEB-4520' 'V-2006' 'V2006' 'VER-11135'
 'VER-A-00-11' 'VER-A-00049' 'VER-A00-11' 'VER-A00049' 'VER-ADO-49'
 'Vipadenant']","[('drugbank', array(['DB06625'], dtype=object))]",['CHEMBL3216899' 'CHEMBL461006'],"{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL459,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,CJCSPKMFHVPWAR-JTQLQIEISA-N,Small molecule,False,METHYLDOPA,1962.0,4.0,,False,True,"['Aldomet' 'Dopamet' 'Lederdopa' 'Medomet' 'Metalpha 250' 'Metalpha 500'
 'Methyldopa']","['(-)-.alpha.-methyldopa' '(s)-(-)-.alpha.-methyldopa'
 '.alpha.-methyl-l-dopa' 'Alpha-methyldopa' 'Anhydrous methyldopa'
 'BAYER-1440L' 'J9.247I' 'L-.alpha.-methyldopa' 'MK-351' 'Methyldopa'
 'Methyldopa (levorotatory)' 'Methyldopa anhydrous' 'Methyldopa hydrate'
 'Methyldopa sesquihydrate' 'Methyldopa, anhydrous' 'NSC-169916'
 'NSC-760080']","[('DailyMed', array(['methyldopa'], dtype=object)), ('PubChem', array(['11113581', '124886927', '144209808', '50104474', '8139902',
       '90341702'], dtype=object)), ('TG-GATEs', array(['56'], dtype=object)), ('Wikipedia', array(['Methyldopa'], dtype=object)), ('drugbank', array(['DB00968'], dtype=object)), ('chEBI', array(['61058'], dtype=object))]",['CHEMBL4063475' 'CHEMBL1591707'],"{'rows': array(['EFO_0000668', 'EFO_0000537', 'MONDO_0005147'], dtype=object), 'count': 3}","[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and is indicated for hypertension and has 2 investigational indications.
CHEMBL4594293,CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O,JWEQLWMZHJSMEC-AFJTUFCWSA-N,Small molecule,False,ACALABRUTINIB MALEATE,2022.0,4.0,CHEMBL3707348,False,True,['Calquence'],"['Acalabrutinib maleate' 'Acalabrutinib maleate anhydrous'
 'Calquence maleate']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ACALABRUTINIB%20MALEATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000095', 'EFO_1001469'], dtype=object), 'count': 2}",[ENSG00000010671],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for chronic lymphocytic leukemia and mantle cell lymphoma.
CHEMBL4594417,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1,KCBJGVDOSBKVKP-UHFFFAOYSA-N,Small molecule,False,PRUXELUTAMIDE,,3.0,,False,False,[],['Gt-0918' 'Gt0918' 'Proxalutamide' 'Pruxelutamide'],,,"{'rows': array(['MONDO_0100096', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000694'],
      dtype=object), 'count': 4}",[ENSG00000169083],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL4650398,,,Protein,False,HEPALATIDE,,2.0,,False,False,[],['Hepalatide'],,,"{'rows': array(['EFO_0007304', 'MONDO_0005148', 'EFO_0004239'], dtype=object), 'count': 3}",[ENSG00000100652],Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL470888,COc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,AJACDNCVEGIBNA-KQYNXXCUSA-N,Small molecule,False,BVT.115959,,2.0,,False,False,[],['Bvt.115959' 'Spongosine'],,,"{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}",[ENSG00000128271],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL4802130,CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1.CS(=O)(=O)O,ILQJXEIRBCHLOM-UHFFFAOYSA-N,Small molecule,False,BELUMOSUDIL MESYLATE,2021.0,4.0,CHEMBL2005186,False,True,['Rezurock'],['Belumosudil mesylate' 'KD025 mesylate'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELUMOSUDIL%20MESYLATE/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0013730', 'EFO_0005809'], dtype=object), 'count': 2}","[ENSG00000134318,ENSG00000067900]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for graft versus host disease and has 1 investigational indication.
CHEMBL522987,Cc1cc(F)ccc1[C@H]1CNCCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,SBBYBXSFWOLDDG-JLTOFOAXSA-N,Small molecule,False,VESTIPITANT,,2.0,,False,False,[],['GW-597599' 'Gw597599' 'Vestipitant'],"[('Wikipedia', array(['Vestipitant'], dtype=object)), ('drugbank', array(['DB11949'], dtype=object))]",['CHEMBL2104992'],"{'rows': array(['EFO_0004888', 'MONDO_0002050', 'HP_0000360', 'MONDO_0002009',
       'EFO_1001917', 'EFO_0008568'], dtype=object), 'count': 6}",[ENSG00000115353],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL5314406,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1,MAFACRSJGNJHCF-UHFFFAOYSA-N,Small molecule,False,4SC-203,,1.0,,False,False,[],['4sc 203' '4sc-203'],,,"{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}","[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL596,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,PJMPHNIQZUBGLI-UHFFFAOYSA-N,Small molecule,True,FENTANYL,1968.0,4.0,,False,True,"['Abstral' 'Actiq' 'Breakyl' 'Duragesic-100' 'Duragesic-12' 'Duragesic-25'
 'Duragesic-37' 'Duragesic-50' 'Duragesic-75' 'Durogesic'
 'Durogesic dtrans' 'Effentora' 'Fencino' 'Fentalis reservoir'
 'Fentanyl-100' 'Fentanyl-12' 'Fentanyl-25' 'Fentanyl-37' 'Fentanyl-50'
 'Fentanyl-62' 'Fentanyl-75' 'Fentanyl-87' 'Fentora' 'Ionsys' 'Leptanal'
 'Matrifen' 'Mezolar matrix' 'Mylafent' 'Opiodur' 'Oralet' 'Osmach'
 'Osmanil' 'Pecfent' 'Recivit' 'Sublimaze' 'Subsys' 'Tilofyl' 'Victanyl'
 'Yemex']","['AD 923' 'AD-923' 'Abstral-' 'Durogesic d-trans' 'EN-3267' 'En3267'
 'Fendrop' 'Fentanest' 'Fentanyl' 'Fentanyl cii' 'Fentora' 'IDS-NF-001'
 'Innovar' 'Ionsys' 'N02AB03' 'Phentanyl' 'R 4263' 'Recuvyra' 'Sublimase']","[('DailyMed', array(['fentanyl'], dtype=object)), ('PubChem', array(['144206164', '50113065'], dtype=object)), ('Wikipedia', array(['Fentanyl'], dtype=object)), ('drugbank', array(['DB00813'], dtype=object)), ('chEBI', array(['119915'], dtype=object))]",['CHEMBL688' 'CHEMBL1201159'],"{'rows': array(['EFO_0005251', 'EFO_0009870', 'HP_0003419', 'MONDO_0007254',
       'HP_0012532', 'EFO_0005762', 'EFO_0801084', 'EFO_0005611',
       'EFO_0000713', 'EFO_0003843', 'EFO_0009267', 'EFO_0003931',
       'EFO_0002618', 'EFO_0004209', 'EFO_0003843', 'MONDO_0005277',
       'HP_0003419', 'EFO_0000232', 'EFO_0003843', 'EFO_0003884',
       'EFO_0002950', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0001056',
       'MONDO_0004992', 'MONDO_0005277', 'EFO_0004273', 'EFO_1000637',
       'EFO_0003030', 'EFO_0801084', 'EFO_0001421', 'EFO_0001074',
       'EFO_0003918', 'MONDO_0100096', 'HP_0012532', 'EFO_1001139',
       'MONDO_0043510', 'MONDO_0005178', 'EFO_1000783', 'EFO_0009842',
       'HP_0002093', 'EFO_0004244', 'EFO_0000555', 'EFO_0001073',
       'HP_0002094', 'EFO_1001267', 'EFO_0009727', 'EFO_0000546'],
      dtype=object), 'count': 48}",[ENSG00000112038],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 6 approved and 38 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200909,CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,HUMXXHTVHHLNRO-KAJVQRHHSA-N,Small molecule,False,PREDNISOLONE TEBUTATE,1956.0,4.0,,False,True,['Hydeltra-tba' 'Prednisolone tebutate'],"['Anhydrous prednisolone tebutate' 'Prednisolone 21-tert-butylacetate'
 'Prednisolone butylacetate' 'Prednisolone tebutate']","[('PubChem', array(['170465430'], dtype=object)), ('drugbank', array(['DB14632'], dtype=object)), ('chEBI', array(['8381'], dtype=object))]",,,[ENSG00000113580],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956.
CHEMBL1200916,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2.Cl,NZFNXWQNBYZDAQ-UHFFFAOYSA-N,Small molecule,True,THIORIDAZINE HYDROCHLORIDE,1962.0,4.0,CHEMBL479,True,True,"['Mellaril' 'Thioridazine hydrochloride'
 'Thioridazine hydrochloride intensol']",['NSC-186060' 'Thioridazine hcl' 'Thioridazine hydrochloride'],"[('DailyMed', array(['thioridazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144209999', '26747699', '26747700', '50107199', '50107200',
       '50107201', '56422406', '855568'], dtype=object)), ('chEBI', array(['48566'], dtype=object))]",,,"[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL1201233,CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1,SVEBYYWCXTVYCR-LBPRGKRZSA-N,Small molecule,False,METHYLDOPATE,1962.0,4.0,,False,True,[],['Methyldopate'],,['CHEMBL1200432'],,"[ENSG00000150594,ENSG00000184160,ENSG00000274286]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962.
CHEMBL1363,COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,BPZSYCZIITTYBL-YJYMSZOUSA-N,Small molecule,False,ARFORMOTEROL,2006.0,4.0,,False,True,[],"['(-)-formoterol' '(r,r)-formoterol' 'Arformoterol' 'Formoterol r,r-form']","[('Wikipedia', array(['Formoterol'], dtype=object)), ('drugbank', array(['DB01274'], dtype=object)), ('chEBI', array(['408174'], dtype=object))]",['CHEMBL3184383' 'CHEMBL605993' 'CHEMBL1200811' 'CHEMBL1951071'],"{'rows': array(['EFO_0009661', 'EFO_0006505', 'EFO_0000341', 'EFO_0000341',
       'EFO_0006505', 'EFO_0000464', 'MONDO_0004979', 'EFO_0000464'],
      dtype=object), 'count': 8}",[ENSG00000169252],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 5 investigational indications.
CHEMBL14762,CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,BTIHMVBBUGXLCJ-OAHLLOKOSA-N,Small molecule,False,SELICICLIB,,2.0,,False,False,[],"['AL-39256' 'CYC-202' 'Cyc-202' 'NSC-701554' 'R-roscovitine' 'Roscovitin'
 'Roscovitine' 'Seliciclib']","[('PubChem', array(['124891685', '26753649', '26753650', '50100113', '50107006',
       '527377'], dtype=object)), ('Wikipedia', array(['Seliciclib'], dtype=object)), ('drugbank', array(['DB06195'], dtype=object)), ('chEBI', array(['45307'], dtype=object))]",,"{'rows': array(['MONDO_0009061', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000616',
       'EFO_1001110'], dtype=object), 'count': 5}","[ENSG00000134058,ENSG00000164885,ENSG00000136807,ENSG00000123374,ENSG00000170312]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications.
CHEMBL1743028,,,Antibody drug conjugate,False,GLEMBATUMUMAB VEDOTIN,,2.0,,False,False,[],['CDX-011' 'CR-011-VCMMAE' 'Glembatumumab vedotin'],,,"{'rows': array(['EFO_0000637', 'EFO_0000756', 'EFO_0000708', 'MONDO_0007254'],
      dtype=object), 'count': 4}","[ENSG00000136235,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL198877,Oc1ccc([C@H]2COc3cc(O)ccc3C2)cc1,ADFCQWZHKCXPAJ-GFCCVEGCSA-N,Small molecule,False,AUS-131,,2.0,,False,False,[],['(S)-Equol' 'Aus-131'],"[('Wikipedia', array(['Equol'], dtype=object)), ('drugbank', array(['DB11674'], dtype=object)), ('chEBI', array(['34741'], dtype=object))]",,"{'rows': array(['MONDO_0004975', 'EFO_0000284', 'GO_0042697', 'MONDO_0007254'],
      dtype=object), 'count': 4}",[ENSG00000140009],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL2105758,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1.O=C(O)/C=C\C(=O)O,MISPBGHDNZYFNM-BTJKTKAUSA-N,Small molecule,False,AVATROMBOPAG MALEATE,2018.0,4.0,CHEMBL2103883,False,True,['Doptelet'],['Avatrombopag maleate' 'E-5501 MALEATE' 'E5501 MALEATE'],"[('DailyMed', array(['avatrombopag%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet'],
      dtype=object))]",,"{'rows': array(['HP_0001873', 'EFO_0001421'], dtype=object), 'count': 2}",[ENSG00000117400],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for thrombocytopenia and liver disease.
CHEMBL2108611,,,Antibody drug conjugate,True,INOTUZUMAB OZOGAMICIN,2017.0,4.0,,False,True,['Besponsa'],"['CMC-544' 'Inotuzumab ozogamicin' 'PF-05208773' 'WAY-207294'
 'WAY-207294 CMC-544']","[('DailyMed', array(['inotuzumab%20ozogamicin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa'],
      dtype=object))]",,"{'rows': array(['EFO_0000565', 'EFO_0000616', 'EFO_0000094', 'MONDO_0044881',
       'EFO_0000220', 'EFO_0000094', 'EFO_0000403', 'MONDO_0000873',
       'EFO_1000131', 'EFO_0004289', 'EFO_0000096', 'EFO_0005952',
       'MONDO_0018906', 'EFO_0000574', 'EFO_0000309'], dtype=object), 'count': 15}",[ENSG00000012124],Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2108679,,,Antibody,False,OZANEZUMAB,,2.0,,False,False,['Gsk1223249'],['GSK-1223249' 'GSK1223249' 'Ozanezumab'],,,"{'rows': array(['MONDO_0005301', 'MONDO_0004976', 'EFO_0003929'], dtype=object), 'count': 3}",[ENSG00000115310],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL254328,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12,GZOSMCIZMLWJML-VJLLXTKPSA-N,Small molecule,False,ABIRATERONE,,4.0,,False,True,['Zytiga'],['Abiraterone' 'CB 7598' 'CB-7598' 'NSC-741232'],"[('Wikipedia', array(['Abiraterone'], dtype=object)), ('drugbank', array(['DB05812'], dtype=object)), ('chEBI', array(['68642'], dtype=object))]",,"{'rows': array(['MONDO_0004992', 'EFO_0001663', 'EFO_0000616', 'MONDO_0008315',
       'EFO_0000673', 'EFO_0000196'], dtype=object), 'count': 6}","[ENSG00000145545,ENSG00000277893,ENSG00000128039,ENSG00000148795,ENSG00000169083]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 4 investigational indications.
CHEMBL3137314,CC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O,CTPOHARTNNSRSR-NOQAJONNSA-N,Small molecule,False,ESUBERAPROST,,3.0,,False,False,[],['APS-314d' 'Aps-314d' 'Aps-314d free acid' 'BPS-314d' 'Esuberaprost'],,['CHEMBL3137337' 'CHEMBL4298145'],"{'rows': array(['EFO_0001361', 'MONDO_0005149'], dtype=object), 'count': 2}",[ENSG00000160013],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3545224,Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NCC2CCC(CNCCCNC3CCCCC3)CC2)n1,QLVSJMZJSABWRX-UHFFFAOYSA-N,Small molecule,False,BURIXAFOR,,2.0,,False,False,[],['Burixafor' 'Tg-0054'],,,"{'rows': array(['EFO_0000183', 'EFO_0005952', 'MONDO_0008315', 'EFO_0001378'],
      dtype=object), 'count': 4}",[ENSG00000121966],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL3701238,C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1,KEIPNCCJPRMIAX-HNNXBMFYSA-N,Small molecule,False,FUTIBATINIB,2022.0,4.0,,False,True,['Lytgobi'],['Fgfr-in-1' 'Futibatinib' 'TAS-120' 'Tas 120' 'Tas-120'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FUTIBATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15149'], dtype=object))]",,"{'rows': array(['EFO_0000182', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0003891',
       'EFO_1001968', 'EFO_0005221', 'EFO_0000616', 'EFO_0003060'],
      dtype=object), 'count': 8}","[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 5 investigational indications.
CHEMBL3833342,,,Oligonucleotide,False,NUSINERSEN SODIUM,2016.0,4.0,,False,True,['Spinraza'],[],"[('DailyMed', array(['nusinersen%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza'],
      dtype=object))]",,"{'rows': array(['EFO_0008525'], dtype=object), 'count': 1}",[ENSG00000205571],Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for spinal muscular atrophy.
CHEMBL3989689,CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O.C[C@H](O)C(=O)O.O,ZPYIELFRIYUVQP-BHBJEIPNSA-N,Small molecule,False,SQUALAMINE LACTATE,,3.0,CHEMBL444929,False,False,[],['MSI-1256F' 'Squalamine lactate' 'Squalamine lactate hydrate'],,,"{'rows': array(['MONDO_0008315', 'MONDO_0008170', 'EFO_0009606', 'EFO_0001365',
       'EFO_0003770'], dtype=object), 'count': 5}",[ENSG00000066230],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications.
CHEMBL4297578,,,Protein,False,PEGBELFERMIN,,2.0,,False,False,[],['ARX-618' 'BMS-986036' 'Bms-986036' 'Peg-fgf21' 'Pegbelfermin'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEGBELFERMIN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_1001249', 'MONDO_0005148', 'HP_0001395', 'EFO_0003095'],
      dtype=object), 'count': 4}","[ENSG00000113578,ENSG00000134962]",Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications.
CHEMBL4297610,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O,NEQYWYXGTJDAKR-JTQLQIEISA-N,Small molecule,True,OLUTASIDENIB,2022.0,4.0,,False,True,['Rezlidhia'],['FT-2102' 'Ft-2102' 'Olutasidenib' 'Rezlidhia'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLUTASIDENIB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000222', 'EFO_0000198'], dtype=object), 'count': 2}",[ENSG00000138413],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for acute myeloid leukemia and has 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL4297760,,,Oligonucleotide,False,GIVOSIRAN,,3.0,,False,False,[],['ALN-AS1' 'Givosiran'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GIVOSIRAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0008294', 'MONDO_0007369', 'Orphanet_95157'], dtype=object), 'count': 3}",[ENSG00000023330],Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297858,,,Antibody,False,BUDIGALIMAB,,2.0,,False,False,[],['ABBV-181' 'ABBV181' 'Abbv-181' 'Budigalimab' 'PR-1648817'],,,"{'rows': array(['EFO_0000182', 'EFO_1001951', 'EFO_0000764', 'EFO_0000180',
       'EFO_0000702', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0008170',
       'MONDO_0004992', 'EFO_0006859'], dtype=object), 'count': 10}",[ENSG00000188389],Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications.
CHEMBL436,COc1ccc2c(C(=S)N(C)CC(=O)O)cccc2c1C(F)(F)F,LUBHDINQXIHVLS-UHFFFAOYSA-N,Small molecule,False,TOLRESTAT,1989.0,4.0,,True,True,['Alderase' 'Alredase'],"['AY-27,773' 'AY-27773' 'Tolrestat']","[('PubChem', array(['144206867'], dtype=object)), ('Wikipedia', array(['Tolrestat'], dtype=object)), ('drugbank', array(['DB02383'], dtype=object)), ('chEBI', array(['48549'], dtype=object))]",,"{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}",[ENSG00000085662],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for diabetes mellitus. It was withdrawn in at least one region.
CHEMBL520733,CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21,PKXWXXPNHIWQHW-RCBQFDQVSA-N,Small molecule,False,SEMAGACESTAT,,3.0,,False,False,[],['LY-450139' 'LY450139' 'Semagacestat'],"[('Wikipedia', array(['Semagacestat'], dtype=object)), ('drugbank', array(['DB12463'], dtype=object))]",,"{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}","[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]",Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL968,CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21,SAADBVWGJQAEFS-UHFFFAOYSA-N,Small molecule,True,FLURAZEPAM,1970.0,4.0,,False,True,[],['Dalmane' 'Flurazepam' 'Insumin'],"[('PubChem', array(['144205754', '170465018', '26757995'], dtype=object)), ('Wikipedia', array(['Flurazepam'], dtype=object)), ('drugbank', array(['DB00690'], dtype=object))]",['CHEMBL3989724'],"{'rows': array(['EFO_0004698', 'EFO_0005230', 'EFO_0004698', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090'], dtype=object), 'count': 6}","[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for insomnia and has 5 investigational indications. This drug has a black box warning from the FDA.
CHEMBL1200341,CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21.Cl,NXNSCUZKMVYAJQ-UHFFFAOYSA-N,Small molecule,False,INDECAINIDE HYDROCHLORIDE,1989.0,4.0,CHEMBL1201242,False,True,['Decabid'],"['Indecainide hcl' 'Indecainide hydrochloride' 'LY 135837' 'LY-135837'
 'LY-135857' 'Ricainide']",,,,"[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989.
CHEMBL1200473,CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1.Cl,RHKZVMUBMXGOLL-UHFFFAOYSA-N,Small molecule,False,CYCLOPENTOLATE HYDROCHLORIDE,1974.0,4.0,CHEMBL1201338,False,True,"['Ak-pentolate' 'Akpentolate' 'Alnide' 'Cyclogyl'
 'Cyclopentolate hydrochloride' 'Mydrilate' 'Pentolair']","['Cyclopentolate hcl' 'Cyclopentolate hydrochloride' 'Cylate' 'Cyplegin'
 'NSC-756706']","[('DailyMed', array(['cyclopentolate%20hydrochloride'], dtype=object)), ('PubChem', array(['170464720', '26747954', '56320713', '855558'], dtype=object)), ('Wikipedia', array(['Cyclopentolate'], dtype=object)), ('chEBI', array(['4025'], dtype=object))]",,"{'rows': array(['HP_0011499'], dtype=object), 'count': 1}",[ENSG00000133019],Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for mydriasis.
CHEMBL1201758,O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1,YWGDOWXRIALTES-NRFANRHFSA-N,Small molecule,False,BEPOTASTINE,2009.0,4.0,,False,True,['Bepreve'],['Bepotastine' 'Betotastine'],"[('Wikipedia', array(['Bepotastine'], dtype=object)), ('chEBI', array(['71204'], dtype=object))]",['CHEMBL1201759'],"{'rows': array(['EFO_1001417', 'EFO_0007141', 'HP_0000989', 'MONDO_0002406',
       'EFO_1001417', 'EFO_0003956', 'EFO_0007141'], dtype=object), 'count': 7}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for allergic conjunctivitis and pruritus and has 4 investigational indications.
CHEMBL1404,COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,XKLMZUWKNUAPSZ-UHFFFAOYSA-N,Small molecule,False,RANOLAZINE,2006.0,4.0,,False,True,['Aspruzyo sprinkle' 'Ranexa' 'Ranexa (previously latixa)' 'Ranolazine'],['Aspruzyo' 'CVT-303' 'NSC-759100' 'RS-43285-003' 'Ran d' 'Ranolazine'],"[('DailyMed', array(['ranolazine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ranexa-previously-latixa'],
      dtype=object)), ('PubChem', array(['104171232', '170465435', '174006299', '26749060', '26749061',
       '50107515', '56463697', '90340842'], dtype=object)), ('Wikipedia', array(['Ranolazine'], dtype=object)), ('drugbank', array(['DB00243'], dtype=object)), ('chEBI', array(['87690'], dtype=object))]",['CHEMBL1526084' 'CHEMBL537649'],"{'rows': array(['EFO_0000319', 'MONDO_0004976', 'EFO_0000384', 'EFO_1001375',
       'MONDO_0005148', 'EFO_0001361', 'EFO_1000899', 'EFO_0003913',
       'EFO_0004264', 'EFO_0000275', 'EFO_0005672', 'MONDO_0008195',
       'EFO_0000407', 'EFO_0001645', 'EFO_0000555', 'EFO_0003086',
       'HP_0001657'], dtype=object), 'count': 17}","[ENSG00000007314,ENSG00000183873]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for cardiovascular disease and angina pectoris and has 15 investigational indications.
CHEMBL186179,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,IRLWJILLXJGJTD-UHFFFAOYSA-N,Small molecule,False,MURAGLITAZAR,,3.0,,False,False,[],['BMS-298585' 'BMS-298585-01' 'MK-0478' 'MK0478' 'Muraglitazar'],"[('PubChem', array(['170466259'], dtype=object)), ('drugbank', array(['DB06510'], dtype=object))]",['CHEMBL3527055' 'CHEMBL557580'],"{'rows': array(['Orphanet_309005', 'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 3}","[ENSG00000132170,ENSG00000186951]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL1909285,Cc1nc([N+](=O)[O-])cn1-c1ccc([N+](=O)[O-])cc1,NMTBSNPBIGRZBL-UHFFFAOYSA-N,Small molecule,False,NITREFAZOLE,,4.0,,True,True,[],['EMD 15 700' 'EMD-15-700' 'Nitrefazole'],"[('PubChem', array(['144206859'], dtype=object))]",,,"[ENSG00000187758,ENSG00000198099,ENSG00000196616,ENSG00000248144,ENSG00000196344,ENSG00000197894,ENSG00000172955]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL191,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Small molecule,True,LOSARTAN,1995.0,4.0,,False,True,[],"['Allisartan' 'Angizaar' 'Dup-89' 'E-3174' 'EXP3174' 'Exp-3174' 'HGP-1405'
 'HGP1405' 'Losartan' 'Losartan carboxylic acid' 'Losartic' 'Lozap'
 'NSC-758699']","[('PubChem', array(['144204988', '170465135', '26748956'], dtype=object)), ('Wikipedia', array(['Losartan'], dtype=object)), ('drugbank', array(['DB00678'], dtype=object)), ('chEBI', array(['6541'], dtype=object))]",['CHEMBL367465' 'CHEMBL995'],"{'rows': array(['MP_0001845', 'EFO_0004265', 'EFO_0000319', 'EFO_1000637',
       'EFO_0006818', 'MONDO_0007254', 'EFO_0000693', 'EFO_0000546',
       'EFO_0002618', 'HP_0009588', 'EFO_0007148', 'MONDO_0002474',
       'MONDO_0005149', 'EFO_0003086', 'EFO_0002618', 'EFO_0003144',
       'MONDO_0005147', 'EFO_0004194', 'EFO_0004236', 'MONDO_0005148',
       'MONDO_0009061', 'MONDO_0001134', 'EFO_0003095', 'EFO_0000637',
       'EFO_0000401', 'EFO_1001249', 'EFO_0002617', 'MONDO_0007947',
       'HP_0000093', 'EFO_0004232', 'MONDO_0011382', 'EFO_0004212',
       'EFO_0000537', 'EFO_0000537', 'EFO_0000668', 'EFO_0000694',
       'MONDO_0007947', 'EFO_0000712', 'EFO_0003884', 'EFO_0003884',
       'EFO_0000538', 'EFO_0003086', 'EFO_0000519', 'EFO_1000653',
       'MONDO_0100096', 'EFO_0000764', 'MONDO_0005184', 'EFO_0000768',
       'MONDO_0001134', 'EFO_0006890', 'HP_0000093', 'EFO_0004616',
       'EFO_0003896', 'EFO_0001358'], dtype=object), 'count': 54}",[ENSG00000144891],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 6 approved and 46 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2048484,Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,XTNGUQKDFGDXSJ-ZXGKGEBGSA-N,Small molecule,True,CANAGLIFLOZIN ANHYDROUS,2011.0,4.0,,False,True,[],['JNJ-28431754' 'TA-7284'],"[('drugbank', array(['DB08907'], dtype=object)), ('chEBI', array(['73274'], dtype=object))]",['CHEMBL4594217' 'CHEMBL2103841'],"{'rows': array(['EFO_0000401', 'MONDO_0005147', 'HP_0000083', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0007254', 'EFO_0003144', 'EFO_0001073',
       'EFO_0000660'], dtype=object), 'count': 9}",[ENSG00000140675],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2103991,Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O,IETKPTYAGKZLKY-UHFFFAOYSA-N,Small molecule,False,BALAGLITAZONE,,3.0,,False,False,[],['Balaglitazone' 'DRF-2593' 'Drf-2593' 'NN-2344'],"[('drugbank', array(['DB12781'], dtype=object))]",,"{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}",[ENSG00000132170],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL2105760,O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1,ZKIAIYBUSXZPLP-UHFFFAOYSA-N,Small molecule,True,BREXPIPRAZOLE,2015.0,4.0,,False,True,['Rexulti' 'Rxulti'],['Brexpiprazole' 'OPC-34712'],"[('DailyMed', array(['brexpiprazole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti'],
      dtype=object)), ('drugbank', array(['DB09128'], dtype=object))]",,"{'rows': array(['MONDO_0002050', 'MONDO_0004985', 'MONDO_0005090', 'HP_0000713',
       'EFO_0009963', 'EFO_0008568', 'MONDO_0002009', 'HP_0012076',
       'MONDO_0004975', 'EFO_0005411', 'MONDO_0002009', 'EFO_0005407',
       'MONDO_0007079', 'EFO_0001358'], dtype=object), 'count': 14}","[ENSG00000149295,ENSG00000102468,ENSG00000178394]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA.
CHEMBL2109508,,,Antibody,False,IMMURAIT-LL2,,-1.0,,False,False,[],['IMMURAIT-LL2'],,,,[ENSG00000012124],Antibody drug.
CHEMBL2364614,CN1Cc2cc(-c3ccc(N)nn3)ccc2[C@H](c2ccc3ccccc3c2)C1,VCIBGDSRPUOBOG-QFIPXVFZSA-N,Small molecule,False,LIAFENSINE,,2.0,,False,False,[],['BMS-820836' 'Liafensine'],"[('drugbank', array(['DB14878'], dtype=object))]",,"{'rows': array(['EFO_0009854', 'MONDO_0002050'], dtype=object), 'count': 2}","[ENSG00000108576,ENSG00000142319,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2364628,O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1)NO,QGZYDVAGYRLSKP-UHFFFAOYSA-N,Small molecule,False,RICOLINOSTAT,,2.0,,False,False,[],['ACY-1215' 'ACY-63' 'Ricolinostat'],"[('drugbank', array(['DB12376'], dtype=object))]",,"{'rows': array(['EFO_0001378', 'EFO_0000095', 'EFO_1000783', 'EFO_0000305',
       'EFO_0000574', 'EFO_1001959', 'EFO_0009387'], dtype=object), 'count': 7}",[ENSG00000094631],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL27193,C[C@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1,SGUAFYQXFOLMHL-ACJLOTCBSA-N,Small molecule,False,DILEVALOL,1990.0,4.0,,True,True,[],"['(r,r)-labetalol' 'Dilevalol' 'Labetalol (r,r)-form']",,['CHEMBL1204165'],,"[ENSG00000043591,ENSG00000169252,ENSG00000188778]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990.
CHEMBL3545308,C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,HUFOZJXAKZVRNJ-UHFFFAOYSA-N,Small molecule,False,ROCILETINIB,,3.0,,False,False,[],['AVL-301' 'CNX-419' 'CO-1686' 'CS-1631' 'Rociletinib'],"[('drugbank', array(['DB11907'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}",[ENSG00000146648],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications.
CHEMBL3707351,Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,FASLTMSUPQDLIB-MHZLTWQESA-N,Small molecule,False,ADOMEGLIVANT,,2.0,,False,False,[],"['Adomeglivant' 'Adomeglivant, (-)-' 'LY-2409021' 'LY2409021' 'Ly2409021']","[('drugbank', array(['DB11704'], dtype=object))]",,"{'rows': array(['EFO_0003884', 'MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 3}",[ENSG00000215644],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL3990029,,,Antibody,False,RISANKIZUMAB,2019.0,4.0,,False,True,['Skyrizi'],"['655066-01' 'ABBV-066' 'BI655066' 'Bi-655066' 'Risankizumab'
 'Risankizumab rzaa']","[('DailyMed', array(['risankizumab-rzaa'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi'],
      dtype=object))]",,"{'rows': array(['MONDO_0004979', 'MONDO_0002406', 'EFO_0000384', 'EFO_1000710',
       'EFO_0000676', 'EFO_0003778', 'EFO_0000729', 'EFO_0003898',
       'MONDO_0100096', 'MONDO_0015597', 'EFO_0000540'], dtype=object), 'count': 11}","[ENSG00000113302,ENSG00000110944]",Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 7 investigational indications.
CHEMBL4297960,,,Unknown,False,DAVANAT,,2.0,,False,False,[],['Davanat' 'GM-CT-01' 'Galactomannan c' 'Gm-ct-01'],,,"{'rows': array(['EFO_1001951', 'EFO_0002617'], dtype=object), 'count': 2}","[ENSG00000100097,ENSG00000131981]",Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL4297994,,,Unknown,False,TILSOTOLIMOD SODIUM,,3.0,,False,False,[],['IMO-2125 sodium' 'TLR9 AGONIST IMO-2125' 'Tilsotolimod sodium'],,,"{'rows': array(['EFO_0002617', 'EFO_0003047', 'EFO_0000756'], dtype=object), 'count': 3}",[ENSG00000239732],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4298086,,,Antibody,False,POZELIMAB,2023.0,4.0,,False,True,['Veopoz'],['Pozelimab' 'REGN-3918' 'REGN3918' 'Regn3918'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/POZELIMAB/relevant/1/'],
      dtype=object))]",,"{'rows': array(['MONDO_0100244', 'HP_0002243', 'MONDO_0100244', 'EFO_0004991'],
      dtype=object), 'count': 4}",[ENSG00000106804],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for protein-losing enteropathy and has 3 investigational indications.
CHEMBL4650521,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N,UCJZOKGUEJUNIO-IINYFYTJSA-N,Small molecule,False,BATOPROTAFIB,,2.0,,False,False,[],"['Batoprotafib' 'Ptpn11 inhibitor tno155' 'Shp2 inhibitor tno155'
 'TNO-155' 'TNO155' 'Tno 155' 'Tno-155' 'Tno155']","[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]",,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}",[ENSG00000179295],Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication.
CHEMBL5315126,,,Protein,False,FOLLITROPIN BETA,1996.0,4.0,,False,True,['Follistim' 'Follistim aq' 'Puregon'],['Fertavid' 'Follitropin beta'],"[('DailyMed', array(['follitropin%20alfa/beta'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/puregon'],
      dtype=object))]",,"{'rows': array(['EFO_0000545', 'HP_0000044'], dtype=object), 'count': 2}",[ENSG00000170820],Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for infertility and hypogonadotropic hypogonadism.
CHEMBL538943,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,CILBMBUYJCWATM-UDRBCWGGSA-N,Small molecule,True,VINORELBINE TARTRATE,1994.0,4.0,CHEMBL553025,False,True,['Navelbine' 'Vinorelbine tartrate'],"['Liposomal vinorelbine tartrate' 'TLC-178' 'TLC178'
 'Vinorelbine (as tartrate)' 'Vinorelbine Ditartarate'
 'Vinorelbine ditartrate' 'Vinorelbine liposomal' 'Vinorelbine tartrate'
 'Vinorelbine tartrate (1:2)']","[('PubChem', array(['144205824', '170465330'], dtype=object))]",,"{'rows': array(['EFO_0000571', 'EFO_0003060', 'EFO_0000211', 'EFO_0000691',
       'EFO_0006861', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0000588',
       'EFO_0000183', 'MONDO_0021063', 'EFO_0000313', 'MONDO_0008315',
       'EFO_0000437', 'MONDO_0007254', 'MONDO_0002367', 'EFO_0000616',
       'EFO_0000621', 'EFO_0000248', 'EFO_1000158', 'MONDO_0001187',
       'EFO_0003869', 'EFO_0000565', 'MONDO_0008903', 'EFO_0001416',
       'MONDO_0001402', 'MONDO_0011962', 'EFO_0005952', 'EFO_0000574'],
      dtype=object), 'count': 28}","[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 28 investigational indications. This drug has a black box warning from the FDA.
CHEMBL668,CNCCCC1c2ccccc2C=Cc2ccccc21,BWPIARFWQZKAIA-UHFFFAOYSA-N,Small molecule,True,PROTRIPTYLINE,1967.0,4.0,,False,True,[],['Protriptyline'],"[('PubChem', array(['11111679', '11111680', '50100330', '50104299', '90341254'],
      dtype=object)), ('Wikipedia', array(['Protriptyline'], dtype=object)), ('drugbank', array(['DB00344'], dtype=object)), ('chEBI', array(['8597'], dtype=object))]",['CHEMBL1200332'],"{'rows': array(['MONDO_0002009', 'MONDO_0002050'], dtype=object), 'count': 2}","[ENSG00000108576,ENSG00000103546]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for major depressive disorder and depressive disorder. This drug has a black box warning from the FDA.
CHEMBL811,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1,ZDIGNSYAACHWNL-UHFFFAOYSA-N,Small molecule,False,BROMPHENIRAMINE,1957.0,4.0,,False,True,[],"['BPN' 'Bromfed' 'Bromfenex' 'Brompheniramine' 'Brotane' 'Dimetane'
 'Dimetapp' 'Lodrane']","[('PubChem', array(['90341200'], dtype=object)), ('Wikipedia', array(['Brompheniramine'], dtype=object)), ('drugbank', array(['DB00835'], dtype=object)), ('chEBI', array(['3183'], dtype=object))]",['CHEMBL1200961'],"{'rows': array(['MONDO_0005271', 'HP_0001742', 'EFO_0007214', 'MONDO_0005271',
       'EFO_0003956', 'EFO_0007486', 'HP_0012735'], dtype=object), 'count': 7}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved indications.
CHEMBL859,Oc1nc(O)c2cn[nH]c2n1,HXNFUBHNUDHIGC-UHFFFAOYSA-N,Small molecule,False,OXYPURINOL,,4.0,,False,True,[],['NSC-76239' 'Oxipurinol' 'Oxypurinol'],"[('PubChem', array(['144211537', '57264357'], dtype=object)), ('Wikipedia', array(['Oxypurinol'], dtype=object)), ('drugbank', array(['DB05262'], dtype=object)), ('chEBI', array(['28315'], dtype=object))]",,"{'rows': array(['MONDO_0011382', 'EFO_0000373'], dtype=object), 'count': 2}",[ENSG00000158125],Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications.
CHEMBL86304,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1,YHXISWVBGDMDLQ-UHFFFAOYSA-N,Small molecule,False,MOCLOBEMIDE,1990.0,4.0,,False,True,['Manerix'],['Aurorix' 'GNF-PF-695' 'Moclobemide' 'RO 11-1163/000' 'RO-111163000'],"[('PubChem', array(['104171398', '144204522', '144207163', '170465663', '50086440',
       '50105006', '50105007', '846440', '90340853'], dtype=object)), ('Wikipedia', array(['Moclobemide'], dtype=object)), ('drugbank', array(['DB01171'], dtype=object)), ('chEBI', array(['83531'], dtype=object))]",,"{'rows': array(['EFO_0003768', 'EFO_0005230', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0003890'], dtype=object), 'count': 7}",[ENSG00000189221],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for major depressive disorder and depressive disorder and has 5 investigational indications.
CHEMBL1086997,CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO,UQRORFVVSGFNRO-XFWSIPNHSA-N,Small molecule,False,LUCERASTAT,,3.0,,False,False,[],['ACT-434964' 'Lucerastat' 'N-N-Butyl Deoxygalactonojirimycin'],"[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUCERASTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14872'], dtype=object))]",,"{'rows': array(['MONDO_0010526'], dtype=object), 'count': 1}",[ENSG00000148154],Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication.
CHEMBL1200903,C=CCC1(C(C)CCC)C(=O)[N-]C(=O)NC1=O.[Na+],AXXJTNXVUHVOJW-UHFFFAOYSA-M,Small molecule,False,SECOBARBITAL SODIUM,1950.0,4.0,CHEMBL447,True,True,['Secobarbital sodium' 'Seconal sodium' 'Seconesin' 'Tuinal'],"['(rs)-secobarbital sodium' 'Barbosec' 'Evronal sodium' 'Immenoctal'
 'NSC-10818' 'Pramil' 'Quinalbarbitone sodium' 'Sebar'
 'Secobarbital sodium' 'Synate']",,,,"[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]",Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950. It was withdrawn in at least one region.
CHEMBL1201777,CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl,ZELFLGGRLLOERW-YECZQDJWSA-N,Small molecule,True,TAPENTADOL HYDROCHLORIDE,2008.0,4.0,CHEMBL1201776,False,True,['Nucynta' 'Nucynta er' 'Palexia'],"['BN-200 HYDROCHLORIDE' 'CG-5503 HYDROCHLORIDE' 'CG5503 HYDROCHLORIDE'
 'Tapentadol hcl' 'Tapentadol hydrochloride']","[('DailyMed', array(['tapentadol%20hydrochloride'], dtype=object))]",,"{'rows': array(['EFO_0003843', 'HP_0003419', 'HP_0012532', 'EFO_0005762'],
      dtype=object), 'count': 4}","[ENSG00000103546,ENSG00000112038]",Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA.
CHEMBL1254771,COc1cc(C)c(S(=O)(=O)N(C)CCOCC(=O)N(C)Cc2ccc(C3=NCCN3)cc2)c(C)c1,AMTQCENHQIDBHQ-UHFFFAOYSA-N,Small molecule,False,SAFOTIBANT,,2.0,,False,False,[],"['FOV-2304' 'Fov2304' 'Fov2304 free base' 'LF22-0542' 'Lf 22-0542'
 'Lf-22-0542' 'Safotibant' 'Safotibant phosphate']",,,,[ENSG00000100739],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1258517,O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1,WXUUCRLKXQMWRY-UHFFFAOYSA-N,Small molecule,False,PKI-179,,1.0,,False,False,[],['PKI-179' 'Pki-179'],,,"{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}","[ENSG00000198793,ENSG00000121879]",Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication.
CHEMBL1607273,Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,PGLIUCLTXOYQMV-UHFFFAOYSA-N,Small molecule,False,CETIRIZINE HYDROCHLORIDE,1995.0,4.0,CHEMBL1000,False,True,"['Allacan' 'Allertek' 'Becoallergy' 'Cetec' 'Cetirizine hydrochloride'
 'Cetirizine hydrochloride allergy' 'Cetirizine hydrochloride hives'
 'Cetirizine hydrochloride hives relief' 'Cetirocol'
 ""Children's cetirizine hydrochloride allergy""
 ""Children's cetirizine hydrochloride hives relief""
 ""Children's zyrtec allergy"" ""Children's zyrtec hives relief"" 'Piriteze'
 'Pollenshield' 'Quzyttir' 'Zerviate' 'Ziralton' 'Zirtek' 'Zynor' 'Zyrtec'
 'Zyrtec allergy' 'Zyrtec hives relief']","['Cetirizine' 'Cetirizine dihydrochloride' 'Cetirizine hcl'
 'Cetirizine hydrochloride' 'Cetrine' 'NSC-759102' 'P 071' 'P-071'
 'Zyrtec']","[('DailyMed', array(['cetirizine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204255', '144212578', '170465442', '26749066'], dtype=object))]",,"{'rows': array(['EFO_0003830', 'HP_0001742', 'HP_0000989', 'EFO_0007141',
       'MONDO_0005271', 'EFO_0005531', 'EFO_0005854', 'EFO_1001417',
       'EFO_0003956'], dtype=object), 'count': 9}",[ENSG00000196639],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 7 approved and 2 investigational indications.
CHEMBL1789844,,,Antibody,False,IPILIMUMAB,2011.0,4.0,,False,True,['Yervoy'],"['BMS-734016' 'BMS734016' 'Ipilimumab' 'MDX-010' 'MDX-010 MDX-CTLA4'
 'MDX-101' 'MDX-CTLA-4' 'MDX010']","[('DailyMed', array(['ipilimumab'], dtype=object)), ('DrugCentral', array(['4958'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy'],
      dtype=object))]",,"{'rows': array(['MONDO_0001056', 'EFO_0007466', 'EFO_0000708', 'EFO_1000984',
       'EFO_1001950', 'EFO_0001416', 'EFO_0000365', 'EFO_0004251',
       'EFO_0001376', 'EFO_1001972', 'EFO_0005952', 'EFO_0001378',
       'MONDO_0002120', 'EFO_0004288', 'MONDO_0008315', 'MONDO_0002087',
       'MONDO_0007187', 'EFO_0000339', 'EFO_0009709', 'EFO_0008528',
       'EFO_0000096', 'EFO_0006859', 'EFO_0000403', 'EFO_0000389',
       'MONDO_0009348', 'MONDO_0002367', 'EFO_1001968', 'EFO_1000355',
       'EFO_0003085', 'EFO_1001471', 'EFO_0000621', 'EFO_0000181',
       'EFO_0004243', 'MONDO_0011719', 'EFO_1000359', 'EFO_0004284',
       'EFO_0003891', 'EFO_0002618', 'EFO_0000198', 'EFO_0000220',
       'EFO_1001951', 'EFO_0000228', 'EFO_0000702', 'EFO_0000616',
       'EFO_0001075', 'MONDO_0004992', 'MONDO_0001187', 'EFO_0000756',
       'EFO_0000519', 'EFO_1000657', 'EFO_0005543', 'EFO_0004142',
       'EFO_1001512', 'EFO_0000503', 'EFO_0000588', 'EFO_0001061',
       'EFO_0004193', 'EFO_0000196', 'MONDO_0011962', 'MONDO_0008903',
       'EFO_1000613', 'EFO_0005537', 'MONDO_0024503', 'EFO_0000673',
       'EFO_0004252', 'MONDO_0020634', 'EFO_0000707', 'MONDO_0005184',
       'EFO_0000222', 'MONDO_0008170', 'EFO_0000571', 'MONDO_0007254',
       'EFO_0000182', 'MONDO_0016642', 'MONDO_0004669', 'EFO_0000558',
       'MONDO_0002547', 'EFO_0000349', 'EFO_0000095', 'EFO_0003060',
       'EFO_1000251', 'MONDO_0007576', 'EFO_0000681', 'MONDO_0002898',
       'EFO_0002916', 'MONDO_0100342', 'MONDO_0017582', 'EFO_0001663',
       'EFO_0000313', 'EFO_0002617', 'MONDO_0021063', 'EFO_0000574',
       'EFO_0003863', 'EFO_0000770', 'MONDO_0002108', 'EFO_0000691',
       'EFO_0008524', 'EFO_0000305', 'EFO_1001465', 'EFO_0000764',
       'EFO_0000183', 'EFO_0005221'], dtype=object), 'count': 102}",[ENSG00000163599],Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 12 approved and 90 investigational indications.
CHEMBL2103856,CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCOCC3)c(OC)c(C(C)(C)C)c1)C2,QWKAUGRRIXBIPO-UHFFFAOYSA-N,Small molecule,False,ATOPAXAR,,2.0,,False,False,[],['Atopaxar' 'E-5555' 'E5555' 'ER-172594-00'],"[('drugbank', array(['DB12046'], dtype=object))]",['CHEMBL2105699'],"{'rows': array(['EFO_0005672', 'EFO_0001645'], dtype=object), 'count': 2}",[ENSG00000181104],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
CHEMBL2108285,,,Antibody,False,CAPROMAB,,2.0,,False,False,[],['Capromab'],,,,[ENSG00000142515],Antibody drug with a maximum clinical trial phase of II.
CHEMBL231616,NC(=S)N/N=C/c1ncccc1N,XMYKNCNAZKMVQN-NYYWCZLTSA-N,Small molecule,False,TRIAPINE,,3.0,,False,False,[],['3-AP' 'NSC-663249' 'OCX-0191' 'OCX-191' 'Ocx 191' 'PAN-811' 'Triapine'],"[('PubChem', array(['510133'], dtype=object)), ('Wikipedia', array(['3-Aminopyridine-2-carboxaldehyde_thiosemicarbazone'], dtype=object)), ('drugbank', array(['DB11940'], dtype=object))]",,"{'rows': array(['EFO_0000616', 'MONDO_0005411', 'EFO_1001901', 'MONDO_0008903',
       'MONDO_0024503', 'MONDO_0002367', 'EFO_0002618', 'MONDO_0008315',
       'EFO_0006861', 'EFO_0003060'], dtype=object), 'count': 10}","[ENSG00000167325,ENSG00000048392]",Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications.
CHEMBL2355333,CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1.Cl.Cl.O,WFUAVXYXJOQWAZ-GVKRCPFFSA-N,Small molecule,False,ZIMELDINE HYDROCHLORIDE,,4.0,CHEMBL37744,True,True,[],"['H 102/09 HYDROCHLORIDE' 'Zimeldine hcl' 'Zimeldine hydrochloride'
 'Zimelidine hydrochloride']","[('PubChem', array(['144204841', '170466366'], dtype=object))]",,,"[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]",Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL3545094,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@@H](C)C/C=C/C(O)(CC)CC)=CCC23)C[C@@H](O)C[C@@H]1O,XDBOQJCMEXOPMU-BAHYQGKPSA-N,Small molecule,False,ELOCALCITOL,,2.0,,False,False,[],['Bxl-628' 'Elocalcitol' 'Ro-26-9228'],,,,[ENSG00000111424],Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3707374,CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F.Cl,GEDVJGOVRLHFQG-UHFFFAOYSA-N,Small molecule,False,AMISELIMOD HYDROCHLORIDE,,2.0,CHEMBL3707375,False,False,[],['Amiselimod hydrochloride' 'MT-1303'],,,"{'rows': array(['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000384',
       'MONDO_0007915', 'EFO_0000729'], dtype=object), 'count': 6}","[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications.
CHEMBL376359,Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,ZSBOMTDTBDDKMP-OAHLLOKOSA-N,Small molecule,False,ALOGLIPTIN,2013.0,4.0,,False,True,['Vipidia'],['Alogliptin'],"[('Wikipedia', array(['Alogliptin'], dtype=object)), ('drugbank', array(['DB06203'], dtype=object)), ('chEBI', array(['72323'], dtype=object))]",['CHEMBL227529' 'CHEMBL458537' 'CHEMBL459806'],"{'rows': array(['EFO_0000400', 'MONDO_0005148', 'MONDO_0005148'], dtype=object), 'count': 3}",[ENSG00000197635],Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for type 2 diabetes mellitus and has 2 investigational indications.
CHEMBL4112929,C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O,FSWFYCYPTDLKON-CMJOXMDJSA-N,Small molecule,False,MILVEXIAN,,3.0,,False,False,[],"['BMS 986177' 'BMS-986177' 'Bms-986177' 'JNJ-70033093' 'Jnj-70033093'
 'Milvexian']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MILVEXIAN/relevant/1/'],
      dtype=object))]",,"{'rows': array(['EFO_0000275', 'MONDO_0000831', 'EFO_0005672'], dtype=object), 'count': 3}",[ENSG00000088926],Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications.
CHEMBL4297483,CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1,ZNKWRAKPQQZLNX-ZDQHWEPJSA-N,Small molecule,False,NAVAFENTEROL,,2.0,,False,False,[],"['AZD-8871' 'AZD8871' 'Azd 8871' 'Azd8871' 'LAS-191351' 'LAS191351'
 'Navafenterol']","[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NAVAFENTEROL/relevant/1/'],
      dtype=object))]",['CHEMBL4650222'],"{'rows': array(['EFO_0000341', 'EFO_0000341', 'MONDO_0004979', 'MONDO_0004979'],
      dtype=object), 'count': 4}","[ENSG00000169252,ENSG00000133019]",Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications.
CHEMBL4297577,,,Unknown,False,BELAPECTIN,,2.0,,False,False,[],['Belapectin' 'GR-MD-02' 'Gr-md-02'],,,"{'rows': array(['EFO_0003095', 'EFO_0000756', 'EFO_1001249', 'EFO_0001421',
       'EFO_0002617', 'EFO_0000666', 'EFO_0000676'], dtype=object), 'count': 7}",[ENSG00000131981],Unknown drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
CHEMBL4594536,,,Unknown,False,CS-1003,,3.0,,False,False,[],"['Antibody cs1003' 'CS 1003' 'CS-1003' 'CS1003' 'Cs-1003' 'Cs1003'
 'Nofazinlimab' 'Recombinant pd-1 mab cs1003']",,,"{'rows': array(['EFO_0000574', 'EFO_0000182', 'EFO_0000616', 'MONDO_0004992'],
      dtype=object), 'count': 4}",[ENSG00000188389],Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
CHEMBL5314421,CCOc1cc(CN2CCOCC2)cc2[nH]c(=O)c3c(c12)NCCC3.Cl.Cl.O.O,RYWIWBIJBCNLMR-UHFFFAOYSA-N,Small molecule,False,AMELPARIB DIHYDROCHLORIDE DIHYDRATE,,2.0,CHEMBL3649803,False,False,[],['Amelparib dihydrochloride dihydrate' 'JPI-289' 'Jpi-289'],,,"{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}",[ENSG00000143799],Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications.
